cancer_type qtl_type tag_SNP LD SNP_id gene_id gene_symbol t-stat p-value FDR beta r Traits SNP_position Gene_position CESC cis rs916888 0.773 rs199448 ENSG00000262539.1 RP11-259G18.3 20.91 5.18e-54 2.85e-48 1.22 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46259551~46260606:- CESC cis rs916888 0.773 rs199457 ENSG00000262539.1 RP11-259G18.3 20.79 1.25e-53 5.11e-48 1.26 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46259551~46260606:- CESC cis rs916888 0.687 rs199456 ENSG00000262539.1 RP11-259G18.3 20.79 1.25e-53 5.11e-48 1.26 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46259551~46260606:- CESC cis rs916888 0.773 rs199439 ENSG00000262539.1 RP11-259G18.3 20.52 8.27e-53 3.15e-47 1.24 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46259551~46260606:- CESC cis rs916888 0.773 rs199451 ENSG00000262539.1 RP11-259G18.3 20.41 1.8e-52 6.05e-47 1.25 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46259551~46260606:- CESC cis rs916888 0.773 rs1378358 ENSG00000262539.1 RP11-259G18.3 20.39 1.98e-52 6.52e-47 1.25 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46259551~46260606:- CESC cis rs916888 0.773 rs169201 ENSG00000262539.1 RP11-259G18.3 20.39 1.98e-52 6.52e-47 1.25 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46259551~46260606:- CESC cis rs2739330 0.892 rs4822455 ENSG00000273295.1 AP000350.5 20.28 4.42e-52 1.39e-46 0.91 0.81 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23901432~23907068:- CESC cis rs916888 0.773 rs538628 ENSG00000262539.1 RP11-259G18.3 20.14 1.17e-51 3.61e-46 1.24 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46259551~46260606:- CESC cis rs916888 0.773 rs199535 ENSG00000262539.1 RP11-259G18.3 19.98 3.63e-51 1.09e-45 1.2 0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46259551~46260606:- CESC cis rs858239 0.6 rs1468592 ENSG00000230658.1 KLHL7-AS1 -19.93 5.01e-51 1.49e-45 -0.97 -0.8 Cerebrospinal fluid biomarker levels; chr7:23101028 chr7:23101228~23105703:- CESC cis rs2739330 0.892 rs5751776 ENSG00000273295.1 AP000350.5 19.83 1.07e-50 3.1e-45 0.9 0.8 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23901432~23907068:- CESC cis rs858239 0.6 rs7799422 ENSG00000230658.1 KLHL7-AS1 19.62 4.67e-50 1.27e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23088794 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs28483572 ENSG00000230658.1 KLHL7-AS1 19.62 4.67e-50 1.27e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23092166 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs6961406 ENSG00000230658.1 KLHL7-AS1 19.62 4.67e-50 1.27e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23095272 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs6461690 ENSG00000230658.1 KLHL7-AS1 19.62 4.67e-50 1.27e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23095915 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs6967419 ENSG00000230658.1 KLHL7-AS1 19.62 4.67e-50 1.27e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23096691 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs2003555 ENSG00000230658.1 KLHL7-AS1 19.61 4.89e-50 1.3e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23083296 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs10256359 ENSG00000230658.1 KLHL7-AS1 19.61 4.89e-50 1.3e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23084258 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7784929 ENSG00000230658.1 KLHL7-AS1 19.61 4.89e-50 1.3e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23084658 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs10256524 ENSG00000230658.1 KLHL7-AS1 19.57 6.83e-50 1.8e-44 0.97 0.8 Cerebrospinal fluid biomarker levels; chr7:23105328 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7790157 ENSG00000230658.1 KLHL7-AS1 19.55 7.72e-50 1.95e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23087379 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs6960001 ENSG00000230658.1 KLHL7-AS1 19.55 7.72e-50 1.95e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23091257 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs10237755 ENSG00000230658.1 KLHL7-AS1 19.55 7.72e-50 1.95e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23091945 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs6961131 ENSG00000230658.1 KLHL7-AS1 19.55 7.72e-50 1.95e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23095171 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs2014768 ENSG00000230658.1 KLHL7-AS1 19.54 8.03e-50 1.98e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23082821 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs10256361 ENSG00000230658.1 KLHL7-AS1 19.54 8.03e-50 1.98e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23084266 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs6978827 ENSG00000230658.1 KLHL7-AS1 19.54 8.03e-50 1.98e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23085925 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs28646184 ENSG00000230658.1 KLHL7-AS1 19.51 1.03e-49 2.49e-44 0.97 0.8 Cerebrospinal fluid biomarker levels; chr7:23099976 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs4140959 ENSG00000230658.1 KLHL7-AS1 19.48 1.26e-49 3.03e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23131157 chr7:23101228~23105703:- CESC cis rs858239 0.632 rs1985769 ENSG00000230658.1 KLHL7-AS1 19.46 1.48e-49 3.49e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23082887 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs28499396 ENSG00000230658.1 KLHL7-AS1 19.46 1.48e-49 3.49e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23084479 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7789237 ENSG00000230658.1 KLHL7-AS1 19.46 1.48e-49 3.49e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23085094 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs1115941 ENSG00000230658.1 KLHL7-AS1 19.42 1.95e-49 4.53e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23097569 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7776644 ENSG00000230658.1 KLHL7-AS1 19.39 2.33e-49 5.26e-44 0.98 0.8 Cerebrospinal fluid biomarker levels; chr7:23079688 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7785842 ENSG00000230658.1 KLHL7-AS1 19.39 2.34e-49 5.26e-44 0.96 0.8 Cerebrospinal fluid biomarker levels; chr7:23102087 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7456915 ENSG00000230658.1 KLHL7-AS1 19.39 2.34e-49 5.26e-44 0.96 0.8 Cerebrospinal fluid biomarker levels; chr7:23103430 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs13438179 ENSG00000230658.1 KLHL7-AS1 19.39 2.34e-49 5.26e-44 0.96 0.8 Cerebrospinal fluid biomarker levels; chr7:23104232 chr7:23101228~23105703:- CESC cis rs916888 0.773 rs199445 ENSG00000262539.1 RP11-259G18.3 19.27 5.73e-49 1.27e-43 1.22 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46259551~46260606:- CESC cis rs858239 0.632 rs7811903 ENSG00000230658.1 KLHL7-AS1 19.26 6e-49 1.32e-43 0.98 0.79 Cerebrospinal fluid biomarker levels; chr7:23079437 chr7:23101228~23105703:- CESC cis rs858239 0.632 rs6952947 ENSG00000230658.1 KLHL7-AS1 -19.21 8.51e-49 1.85e-43 -0.95 -0.79 Cerebrospinal fluid biomarker levels; chr7:23081423 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs73272048 ENSG00000230658.1 KLHL7-AS1 19.21 8.77e-49 1.88e-43 0.97 0.79 Cerebrospinal fluid biomarker levels; chr7:23113034 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs10255228 ENSG00000230658.1 KLHL7-AS1 19.21 8.77e-49 1.88e-43 0.97 0.79 Cerebrospinal fluid biomarker levels; chr7:23119244 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7341483 ENSG00000230658.1 KLHL7-AS1 -19.15 1.33e-48 2.76e-43 -0.97 -0.79 Cerebrospinal fluid biomarker levels; chr7:23088038 chr7:23101228~23105703:- CESC cis rs916888 0.773 rs199533 ENSG00000262539.1 RP11-259G18.3 19.12 1.64e-48 3.38e-43 1.21 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46259551~46260606:- CESC cis rs858239 0.6 rs7776649 ENSG00000230658.1 KLHL7-AS1 19.11 1.84e-48 3.76e-43 0.97 0.79 Cerebrospinal fluid biomarker levels; chr7:23079698 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7787110 ENSG00000230658.1 KLHL7-AS1 19.09 2.03e-48 4.13e-43 0.95 0.79 Cerebrospinal fluid biomarker levels; chr7:23098855 chr7:23101228~23105703:- CESC cis rs916888 0.779 rs199528 ENSG00000262539.1 RP11-259G18.3 19.08 2.14e-48 4.29e-43 1.23 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46259551~46260606:- CESC cis rs916888 0.821 rs199525 ENSG00000262539.1 RP11-259G18.3 19.08 2.14e-48 4.29e-43 1.23 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46259551~46260606:- CESC cis rs858239 0.6 rs9691762 ENSG00000230658.1 KLHL7-AS1 19.04 2.84e-48 5.68e-43 0.98 0.79 Cerebrospinal fluid biomarker levels; chr7:23086303 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs1039788 ENSG00000253404.1 AC034243.1 -19.02 3.46e-48 6.66e-43 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138835812 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1828188 ENSG00000253404.1 AC034243.1 -19.02 3.46e-48 6.66e-43 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138836307 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs4835707 ENSG00000253404.1 AC034243.1 -19.02 3.46e-48 6.66e-43 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138838831 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs12656942 ENSG00000253404.1 AC034243.1 -19.02 3.46e-48 6.66e-43 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138840769 chr5:138744434~138753309:- CESC cis rs2882667 0.686 rs62381196 ENSG00000253404.1 AC034243.1 -19.02 3.46e-48 6.66e-43 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138841000 chr5:138744434~138753309:- CESC cis rs858239 0.57 rs10271613 ENSG00000230658.1 KLHL7-AS1 19.01 3.65e-48 6.94e-43 0.96 0.79 Cerebrospinal fluid biomarker levels; chr7:23122967 chr7:23101228~23105703:- CESC cis rs858239 0.57 rs10242166 ENSG00000230658.1 KLHL7-AS1 19.01 3.65e-48 6.94e-43 0.96 0.79 Cerebrospinal fluid biomarker levels; chr7:23123180 chr7:23101228~23105703:- CESC cis rs2882667 0.654 rs160406 ENSG00000253404.1 AC034243.1 -18.99 4.29e-48 8.06e-43 -1.05 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138748032 chr5:138744434~138753309:- CESC cis rs858239 0.601 rs15775 ENSG00000230658.1 KLHL7-AS1 18.98 4.62e-48 8.39e-43 0.96 0.79 Cerebrospinal fluid biomarker levels; chr7:23125082 chr7:23101228~23105703:- CESC cis rs858239 0.57 rs6968242 ENSG00000230658.1 KLHL7-AS1 18.98 4.62e-48 8.39e-43 0.96 0.79 Cerebrospinal fluid biomarker levels; chr7:23127792 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs1981665 ENSG00000230658.1 KLHL7-AS1 18.98 4.62e-48 8.39e-43 0.96 0.79 Cerebrospinal fluid biomarker levels; chr7:23128350 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs4599714 ENSG00000230658.1 KLHL7-AS1 18.98 4.62e-48 8.39e-43 0.96 0.79 Cerebrospinal fluid biomarker levels; chr7:23129182 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs10278776 ENSG00000230658.1 KLHL7-AS1 18.98 4.62e-48 8.39e-43 0.96 0.79 Cerebrospinal fluid biomarker levels; chr7:23130140 chr7:23101228~23105703:- CESC cis rs858239 0.632 rs13438452 ENSG00000230658.1 KLHL7-AS1 18.98 4.62e-48 8.39e-43 0.96 0.79 Cerebrospinal fluid biomarker levels; chr7:23134563 chr7:23101228~23105703:- CESC cis rs2882667 0.654 rs1972072 ENSG00000253404.1 AC034243.1 -18.93 6.27e-48 1.13e-42 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138849604 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6880786 ENSG00000253404.1 AC034243.1 -18.91 7.61e-48 1.36e-42 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138845874 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs9327826 ENSG00000253404.1 AC034243.1 -18.91 7.61e-48 1.36e-42 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138846318 chr5:138744434~138753309:- CESC cis rs858239 0.6 rs10235786 ENSG00000230658.1 KLHL7-AS1 18.88 9.09e-48 1.61e-42 0.98 0.79 Cerebrospinal fluid biomarker levels; chr7:23100321 chr7:23101228~23105703:- CESC cis rs916888 0.773 rs199443 ENSG00000262539.1 RP11-259G18.3 18.86 1.08e-47 1.89e-42 1.2 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46259551~46260606:- CESC cis rs2882667 0.69 rs1627698 ENSG00000253404.1 AC034243.1 -18.85 1.11e-47 1.93e-42 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138741777 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1976568 ENSG00000253404.1 AC034243.1 -18.82 1.38e-47 2.39e-42 -1.04 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138844627 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs495638 ENSG00000253404.1 AC034243.1 -18.82 1.42e-47 2.43e-42 -1.02 -0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138865253 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288042 ENSG00000253404.1 AC034243.1 18.82 1.42e-47 2.43e-42 1.02 0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138867345 chr5:138744434~138753309:- CESC cis rs858239 0.601 rs1034963 ENSG00000230658.1 KLHL7-AS1 18.82 1.45e-47 2.48e-42 0.95 0.79 Cerebrospinal fluid biomarker levels; chr7:23108854 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs2072369 ENSG00000230658.1 KLHL7-AS1 18.67 4.13e-47 6.91e-42 0.96 0.78 Cerebrospinal fluid biomarker levels; chr7:23106570 chr7:23101228~23105703:- CESC cis rs2882667 0.587 rs288015 ENSG00000253404.1 AC034243.1 -18.65 4.82e-47 8.03e-42 -1.02 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138859528 chr5:138744434~138753309:- CESC cis rs2882667 0.621 rs55901834 ENSG00000253404.1 AC034243.1 -18.59 7.6e-47 1.25e-41 -1.04 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138844094 chr5:138744434~138753309:- CESC cis rs916888 0.773 rs199534 ENSG00000262539.1 RP11-259G18.3 18.59 7.71e-47 1.26e-41 1.2 0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46259551~46260606:- CESC cis rs2882667 0.591 rs56322405 ENSG00000253404.1 AC034243.1 -18.58 8.26e-47 1.34e-41 -1.04 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138837693 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288030 ENSG00000253404.1 AC034243.1 18.55 9.78e-47 1.58e-41 1.02 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138880594 chr5:138744434~138753309:- CESC cis rs858239 0.6 rs10233039 ENSG00000230658.1 KLHL7-AS1 18.52 1.27e-46 2.05e-41 0.98 0.78 Cerebrospinal fluid biomarker levels; chr7:23103494 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs929507 ENSG00000230658.1 KLHL7-AS1 18.51 1.3e-46 2.07e-41 0.95 0.78 Cerebrospinal fluid biomarker levels; chr7:23127045 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs929508 ENSG00000230658.1 KLHL7-AS1 18.51 1.3e-46 2.07e-41 0.95 0.78 Cerebrospinal fluid biomarker levels; chr7:23127090 chr7:23101228~23105703:- CESC cis rs916888 0.821 rs199505 ENSG00000262539.1 RP11-259G18.3 -18.5 1.39e-46 2.2e-41 -1.19 -0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46259551~46260606:- CESC cis rs916888 0.821 rs70602 ENSG00000262539.1 RP11-259G18.3 -18.5 1.39e-46 2.2e-41 -1.19 -0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46259551~46260606:- CESC cis rs2882667 0.654 rs6863054 ENSG00000253404.1 AC034243.1 -18.49 1.59e-46 2.5e-41 -1.03 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138853166 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6421921 ENSG00000253404.1 AC034243.1 -18.44 2.21e-46 3.4e-41 -1.03 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138831581 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1039789 ENSG00000253404.1 AC034243.1 -18.44 2.21e-46 3.4e-41 -1.03 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138835734 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6887841 ENSG00000253404.1 AC034243.1 -18.44 2.21e-46 3.4e-41 -1.03 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138840221 chr5:138744434~138753309:- CESC cis rs2882667 0.72 rs56044552 ENSG00000253404.1 AC034243.1 -18.44 2.21e-46 3.4e-41 -1.03 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138841265 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs700616 ENSG00000253404.1 AC034243.1 -18.41 2.74e-46 4.16e-41 -1.06 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138752184 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs700617 ENSG00000253404.1 AC034243.1 -18.41 2.74e-46 4.16e-41 -1.06 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138752290 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs700618 ENSG00000253404.1 AC034243.1 -18.41 2.74e-46 4.16e-41 -1.06 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138752429 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs160405 ENSG00000253404.1 AC034243.1 18.4 2.99e-46 4.52e-41 1.11 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138748387 chr5:138744434~138753309:- CESC cis rs916888 0.821 rs199504 ENSG00000262539.1 RP11-259G18.3 -18.4 3.03e-46 4.56e-41 -1.19 -0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46259551~46260606:- CESC cis rs858239 0.601 rs3735228 ENSG00000230658.1 KLHL7-AS1 18.38 3.49e-46 5e-41 0.95 0.78 Cerebrospinal fluid biomarker levels; chr7:23130808 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs700625 ENSG00000253404.1 AC034243.1 -18.37 3.54e-46 5e-41 -1.05 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138763908 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs2940595 ENSG00000253404.1 AC034243.1 -18.37 3.54e-46 5e-41 -1.05 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138765348 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs851278 ENSG00000253404.1 AC034243.1 -18.37 3.54e-46 5e-41 -1.05 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138767577 chr5:138744434~138753309:- CESC cis rs2882667 0.589 rs825770 ENSG00000253404.1 AC034243.1 -18.37 3.54e-46 5e-41 -1.05 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138779530 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825769 ENSG00000253404.1 AC034243.1 -18.37 3.54e-46 5e-41 -1.05 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138779666 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs700627 ENSG00000253404.1 AC034243.1 -18.37 3.54e-46 5e-41 -1.05 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138783711 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825758 ENSG00000253404.1 AC034243.1 -18.37 3.54e-46 5e-41 -1.05 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138791288 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825754 ENSG00000253404.1 AC034243.1 -18.37 3.54e-46 5e-41 -1.05 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138796200 chr5:138744434~138753309:- CESC cis rs916888 0.697 rs199516 ENSG00000262539.1 RP11-259G18.3 -18.37 3.68e-46 5.17e-41 -1.18 -0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46259551~46260606:- CESC cis rs2882667 0.654 rs288019 ENSG00000253404.1 AC034243.1 -18.34 4.6e-46 6.41e-41 -1.03 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138855704 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs7710288 ENSG00000253404.1 AC034243.1 -18.25 8.75e-46 1.2e-40 -1.03 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138844049 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288011 ENSG00000253404.1 AC034243.1 -18.16 1.68e-45 2.27e-40 -1.02 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138864250 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288010 ENSG00000253404.1 AC034243.1 -18.16 1.68e-45 2.27e-40 -1.02 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138864340 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288039 ENSG00000253404.1 AC034243.1 18.16 1.68e-45 2.27e-40 1.02 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138870511 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288038 ENSG00000253404.1 AC034243.1 18.16 1.68e-45 2.27e-40 1.02 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138871844 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs10043478 ENSG00000253404.1 AC034243.1 18.15 1.79e-45 2.41e-40 0.99 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138853022 chr5:138744434~138753309:- CESC cis rs916888 0.773 rs199447 ENSG00000262539.1 RP11-259G18.3 18.12 2.22e-45 2.96e-40 1.2 0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46259551~46260606:- CESC cis rs2882667 0.69 rs288041 ENSG00000253404.1 AC034243.1 18.05 3.85e-45 4.98e-40 1.02 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138868322 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1828187 ENSG00000253404.1 AC034243.1 18.01 4.93e-45 6.34e-40 1 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138836531 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288013 ENSG00000253404.1 AC034243.1 -18 5.41e-45 6.91e-40 -1.01 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138860128 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs176381 ENSG00000253404.1 AC034243.1 -18 5.41e-45 6.91e-40 -1.01 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138861042 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288031 ENSG00000253404.1 AC034243.1 17.94 8.28e-45 1.04e-39 1.01 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138880377 chr5:138744434~138753309:- CESC cis rs916888 0.821 rs70600 ENSG00000262539.1 RP11-259G18.3 17.92 9.54e-45 1.19e-39 1.22 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46259551~46260606:- CESC cis rs2882667 0.722 rs825751 ENSG00000253404.1 AC034243.1 -17.9 1.13e-44 1.36e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138798180 chr5:138744434~138753309:- CESC cis rs2882667 0.722 rs4835649 ENSG00000253404.1 AC034243.1 -17.9 1.13e-44 1.36e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138810534 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs700624 ENSG00000253404.1 AC034243.1 -17.9 1.13e-44 1.36e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138763332 chr5:138744434~138753309:- CESC cis rs2882667 0.587 rs2174972 ENSG00000253404.1 AC034243.1 -17.9 1.13e-44 1.36e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138766229 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs2693963 ENSG00000253404.1 AC034243.1 -17.9 1.13e-44 1.36e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138770637 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1567313 ENSG00000253404.1 AC034243.1 -17.9 1.13e-44 1.36e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138775013 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1725335 ENSG00000253404.1 AC034243.1 -17.89 1.17e-44 1.4e-39 -1.03 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138745541 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288016 ENSG00000253404.1 AC034243.1 -17.89 1.22e-44 1.45e-39 -1 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138859299 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs1703211 ENSG00000253404.1 AC034243.1 -17.88 1.31e-44 1.56e-39 -1.01 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138740587 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6860780 ENSG00000253404.1 AC034243.1 -17.84 1.75e-44 2.04e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138824367 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6884198 ENSG00000253404.1 AC034243.1 -17.84 1.75e-44 2.04e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138828618 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs4835706 ENSG00000253404.1 AC034243.1 -17.84 1.75e-44 2.04e-39 -1.04 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138829037 chr5:138744434~138753309:- CESC cis rs916888 0.821 rs199512 ENSG00000262539.1 RP11-259G18.3 -17.82 1.98e-44 2.28e-39 -1.17 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46259551~46260606:- CESC cis rs916888 0.821 rs199509 ENSG00000262539.1 RP11-259G18.3 -17.82 1.98e-44 2.28e-39 -1.17 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46259551~46260606:- CESC cis rs916888 0.821 rs199507 ENSG00000262539.1 RP11-259G18.3 -17.82 1.98e-44 2.28e-39 -1.17 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46259551~46260606:- CESC cis rs2882667 0.69 rs825748 ENSG00000253404.1 AC034243.1 -17.81 2.16e-44 2.44e-39 -1.03 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138800378 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825746 ENSG00000253404.1 AC034243.1 -17.81 2.16e-44 2.44e-39 -1.03 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138800930 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825762 ENSG00000253404.1 AC034243.1 -17.81 2.16e-44 2.44e-39 -1.03 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138801981 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825761 ENSG00000253404.1 AC034243.1 -17.81 2.16e-44 2.44e-39 -1.03 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138802318 chr5:138744434~138753309:- CESC cis rs916888 0.821 rs415430 ENSG00000262539.1 RP11-259G18.3 -17.8 2.35e-44 2.63e-39 -1.18 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:46259551~46260606:- CESC cis rs916888 0.779 rs430685 ENSG00000262539.1 RP11-259G18.3 -17.8 2.35e-44 2.63e-39 -1.18 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:46259551~46260606:- CESC cis rs2882667 0.654 rs700626 ENSG00000253404.1 AC034243.1 -17.79 2.5e-44 2.8e-39 -1.07 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138782249 chr5:138744434~138753309:- CESC cis rs858239 0.6 rs4321896 ENSG00000230658.1 KLHL7-AS1 17.76 2.98e-44 3.25e-39 0.95 0.77 Cerebrospinal fluid biomarker levels; chr7:23088437 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs61292332 ENSG00000230658.1 KLHL7-AS1 17.76 2.98e-44 3.25e-39 0.95 0.77 Cerebrospinal fluid biomarker levels; chr7:23092243 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs59073109 ENSG00000230658.1 KLHL7-AS1 17.76 2.98e-44 3.25e-39 0.95 0.77 Cerebrospinal fluid biomarker levels; chr7:23093607 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs7788821 ENSG00000230658.1 KLHL7-AS1 17.76 2.98e-44 3.25e-39 0.95 0.77 Cerebrospinal fluid biomarker levels; chr7:23094026 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs6956595 ENSG00000230658.1 KLHL7-AS1 17.76 2.98e-44 3.25e-39 0.95 0.77 Cerebrospinal fluid biomarker levels; chr7:23094637 chr7:23101228~23105703:- CESC cis rs916888 0.821 rs199506 ENSG00000262539.1 RP11-259G18.3 -17.68 5.65e-44 6.13e-39 -1.17 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46259551~46260606:- CESC cis rs2882667 0.587 rs6596450 ENSG00000253404.1 AC034243.1 -17.61 9.15e-44 9.76e-39 -1.03 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138810831 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs10038162 ENSG00000253404.1 AC034243.1 -17.59 1.08e-43 1.14e-38 -0.97 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138901066 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs311596 ENSG00000253404.1 AC034243.1 -17.54 1.48e-43 1.55e-38 -1 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138736393 chr5:138744434~138753309:- CESC cis rs858239 0.6 rs6461692 ENSG00000230658.1 KLHL7-AS1 17.53 1.68e-43 1.75e-38 0.94 0.76 Cerebrospinal fluid biomarker levels; chr7:23100076 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs2662543 ENSG00000253404.1 AC034243.1 17.52 1.75e-43 1.82e-38 0.98 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138898441 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825669 ENSG00000253404.1 AC034243.1 -17.52 1.79e-43 1.86e-38 -1 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138731258 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs17207772 ENSG00000253404.1 AC034243.1 17.52 1.82e-43 1.88e-38 0.98 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138906131 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs3805753 ENSG00000231760.4 RP11-350J20.5 17.51 1.89e-43 1.94e-38 0.98 0.76 Lung cancer; chr6:149795662 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs4835705 ENSG00000253404.1 AC034243.1 -17.5 2.07e-43 2.11e-38 -1.04 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138827887 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs160398 ENSG00000253404.1 AC034243.1 17.49 2.14e-43 2.18e-38 1.02 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138727750 chr5:138744434~138753309:- CESC cis rs2882667 0.62 rs3789151 ENSG00000253404.1 AC034243.1 -17.45 2.98e-43 3.02e-38 -1.03 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138809771 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288025 ENSG00000253404.1 AC034243.1 17.43 3.33e-43 3.36e-38 0.98 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138887944 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs12517514 ENSG00000253404.1 AC034243.1 -17.38 4.8e-43 4.81e-38 -1.02 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138814430 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6873425 ENSG00000253404.1 AC034243.1 -17.38 4.8e-43 4.81e-38 -1.02 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138819556 chr5:138744434~138753309:- CESC cis rs916888 0.738 rs199515 ENSG00000262539.1 RP11-259G18.3 -17.35 5.98e-43 5.93e-38 -1.13 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46259551~46260606:- CESC cis rs858239 0.6 rs6461691 ENSG00000230658.1 KLHL7-AS1 17.32 7.33e-43 7.23e-38 0.97 0.76 Cerebrospinal fluid biomarker levels; chr7:23099726 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs10241208 ENSG00000230658.1 KLHL7-AS1 17.32 7.33e-43 7.23e-38 0.97 0.76 Cerebrospinal fluid biomarker levels; chr7:23105295 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs10266123 ENSG00000230658.1 KLHL7-AS1 17.32 7.36e-43 7.23e-38 0.99 0.76 Cerebrospinal fluid biomarker levels; chr7:23096868 chr7:23101228~23105703:- CESC cis rs9322193 0.683 rs113281309 ENSG00000231760.4 RP11-350J20.5 17.29 9.66e-43 9.38e-38 0.98 0.76 Lung cancer; chr6:149787289 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs2342861 ENSG00000231760.4 RP11-350J20.5 17.27 1.07e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149777561 chr6:149796151~149826294:- CESC cis rs9322193 0.926 rs2342860 ENSG00000231760.4 RP11-350J20.5 17.27 1.07e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149777641 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs10872653 ENSG00000231760.4 RP11-350J20.5 17.27 1.07e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149778907 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs11155683 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149779341 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9372044 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149780867 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs11155685 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149781649 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9322220 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149782897 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs10214845 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149783124 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9767122 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149783553 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs1413654 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149783956 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9688809 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149787920 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9689242 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149787970 chr6:149796151~149826294:- CESC cis rs9322193 1 rs9767077 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149788479 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9688938 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149788941 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9688940 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149788977 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9689447 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149789350 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9689269 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149791861 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs62441335 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149792658 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs4816 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149793609 chr6:149796151~149826294:- CESC cis rs9322193 0.926 rs952166 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149798774 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs952165 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149798900 chr6:149796151~149826294:- CESC cis rs9322193 0.926 rs9285525 ENSG00000231760.4 RP11-350J20.5 17.27 1.09e-42 9.69e-38 0.97 0.76 Lung cancer; chr6:149801253 chr6:149796151~149826294:- CESC cis rs858239 0.601 rs11984129 ENSG00000230658.1 KLHL7-AS1 17.27 1.14e-42 1.01e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23113058 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs764533 ENSG00000230658.1 KLHL7-AS1 17.27 1.14e-42 1.01e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23114256 chr7:23101228~23105703:- CESC cis rs1577917 0.655 rs1059307 ENSG00000203875.9 SNHG5 17.26 1.15e-42 1.02e-37 0.84 0.76 Response to antipsychotic treatment; chr6:85678170 chr6:85660950~85678736:- CESC cis rs858239 0.601 rs1558313 ENSG00000230658.1 KLHL7-AS1 17.26 1.22e-42 1.07e-37 0.94 0.76 Cerebrospinal fluid biomarker levels; chr7:23116460 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs6962526 ENSG00000230658.1 KLHL7-AS1 17.26 1.22e-42 1.07e-37 0.94 0.76 Cerebrospinal fluid biomarker levels; chr7:23118614 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs6971673 ENSG00000230658.1 KLHL7-AS1 17.26 1.22e-42 1.07e-37 0.94 0.76 Cerebrospinal fluid biomarker levels; chr7:23119904 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs7714455 ENSG00000253404.1 AC034243.1 -17.22 1.54e-42 1.34e-37 -1.02 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138818281 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1651032 ENSG00000253404.1 AC034243.1 -17.21 1.76e-42 1.52e-37 -0.99 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138743151 chr5:138744434~138753309:- CESC cis rs858239 0.6 rs10488077 ENSG00000230658.1 KLHL7-AS1 17.2 1.77e-42 1.52e-37 0.97 0.76 Cerebrospinal fluid biomarker levels; chr7:23104563 chr7:23101228~23105703:- CESC cis rs9322193 0.884 rs2342858 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149805967 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs2095375 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149807037 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs4869730 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149808187 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs11155689 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149808470 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs2151913 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149809506 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs2342857 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149809537 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs933055 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149809701 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs4869731 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149810072 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs4552 ENSG00000231760.4 RP11-350J20.5 17.16 2.39e-42 2.01e-37 0.97 0.76 Lung cancer; chr6:149811183 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs6899661 ENSG00000231760.4 RP11-350J20.5 17.16 2.51e-42 2.1e-37 0.98 0.76 Lung cancer; chr6:149818093 chr6:149796151~149826294:- CESC cis rs9322193 0.632 rs3828700 ENSG00000231760.4 RP11-350J20.5 17.15 2.63e-42 2.18e-37 0.98 0.76 Lung cancer; chr6:149791033 chr6:149796151~149826294:- CESC cis rs858239 0.601 rs10278700 ENSG00000230658.1 KLHL7-AS1 17.14 2.77e-42 2.27e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23120910 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs10263110 ENSG00000230658.1 KLHL7-AS1 17.14 2.77e-42 2.27e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23120932 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs11982002 ENSG00000230658.1 KLHL7-AS1 17.12 3.34e-42 2.72e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23123651 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs6969733 ENSG00000230658.1 KLHL7-AS1 17.12 3.4e-42 2.75e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23128758 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs4440529 ENSG00000230658.1 KLHL7-AS1 17.12 3.4e-42 2.75e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23129132 chr7:23101228~23105703:- CESC cis rs858239 0.571 rs6953020 ENSG00000230658.1 KLHL7-AS1 17.12 3.4e-42 2.75e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23132513 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs2072368 ENSG00000230658.1 KLHL7-AS1 17.11 3.55e-42 2.87e-37 0.94 0.76 Cerebrospinal fluid biomarker levels; chr7:23106493 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs160402 ENSG00000253404.1 AC034243.1 17.1 3.77e-42 3.04e-37 1.03 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138723599 chr5:138744434~138753309:- CESC cis rs858239 0.541 rs4624924 ENSG00000230658.1 KLHL7-AS1 17.1 3.92e-42 3.15e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23129224 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs6948469 ENSG00000230658.1 KLHL7-AS1 17.1 3.92e-42 3.15e-37 0.93 0.76 Cerebrospinal fluid biomarker levels; chr7:23135147 chr7:23101228~23105703:- CESC cis rs858239 0.6 rs4628176 ENSG00000230658.1 KLHL7-AS1 17.07 4.6e-42 3.68e-37 0.97 0.76 Cerebrospinal fluid biomarker levels; chr7:23102947 chr7:23101228~23105703:- CESC cis rs2882667 0.654 rs884470 ENSG00000253404.1 AC034243.1 -17.06 4.92e-42 3.89e-37 -1.02 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138820236 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs274118 ENSG00000253404.1 AC034243.1 17.04 5.88e-42 4.61e-37 0.98 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138729198 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs274117 ENSG00000253404.1 AC034243.1 17.04 5.88e-42 4.61e-37 0.98 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138729359 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs6914319 ENSG00000231760.4 RP11-350J20.5 17.03 6.38e-42 4.98e-37 0.97 0.76 Lung cancer; chr6:149806304 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs274119 ENSG00000253404.1 AC034243.1 17.01 7.27e-42 5.65e-37 0.98 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138728530 chr5:138744434~138753309:- CESC cis rs916888 0.821 rs199514 ENSG00000262539.1 RP11-259G18.3 -17.01 7.46e-42 5.79e-37 -1.19 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46259551~46260606:- CESC cis rs9322193 0.962 rs7818 ENSG00000231760.4 RP11-350J20.5 16.99 8.26e-42 6.39e-37 0.95 0.75 Lung cancer; chr6:149810956 chr6:149796151~149826294:- CESC cis rs858239 0.6 rs4409314 ENSG00000230658.1 KLHL7-AS1 16.99 8.4e-42 6.46e-37 0.96 0.75 Cerebrospinal fluid biomarker levels; chr7:23088333 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs6971002 ENSG00000230658.1 KLHL7-AS1 16.99 8.6e-42 6.61e-37 0.93 0.75 Cerebrospinal fluid biomarker levels; chr7:23132685 chr7:23101228~23105703:- CESC cis rs9322193 0.923 rs12175504 ENSG00000231760.4 RP11-350J20.5 16.98 8.89e-42 6.76e-37 0.98 0.75 Lung cancer; chr6:149664079 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs35443312 ENSG00000231760.4 RP11-350J20.5 16.98 8.89e-42 6.76e-37 0.98 0.75 Lung cancer; chr6:149670625 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs62439843 ENSG00000231760.4 RP11-350J20.5 16.98 8.89e-42 6.76e-37 0.98 0.75 Lung cancer; chr6:149676521 chr6:149796151~149826294:- CESC cis rs2882667 0.658 rs311592 ENSG00000253404.1 AC034243.1 16.98 8.91e-42 6.76e-37 1.01 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138734506 chr5:138744434~138753309:- CESC cis rs858239 0.601 rs6980224 ENSG00000230658.1 KLHL7-AS1 16.96 1.03e-41 7.77e-37 0.92 0.75 Cerebrospinal fluid biomarker levels; chr7:23109518 chr7:23101228~23105703:- CESC cis rs2882667 0.599 rs288008 ENSG00000253404.1 AC034243.1 16.93 1.35e-41 1.01e-36 0.98 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138893632 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288004 ENSG00000253404.1 AC034243.1 16.93 1.35e-41 1.01e-36 0.98 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138895956 chr5:138744434~138753309:- CESC cis rs2739330 0.892 rs5751776 ENSG00000218537.1 MIF-AS1 16.92 1.38e-41 1.04e-36 0.97 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23894426~23898930:- CESC cis rs9322193 0.926 rs9766562 ENSG00000231760.4 RP11-350J20.5 16.92 1.44e-41 1.07e-36 0.97 0.75 Lung cancer; chr6:149788709 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs13172507 ENSG00000253404.1 AC034243.1 16.91 1.5e-41 1.11e-36 0.98 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138907409 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825749 ENSG00000253404.1 AC034243.1 -16.9 1.6e-41 1.18e-36 -0.98 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138800232 chr5:138744434~138753309:- CESC cis rs858239 0.57 rs10235467 ENSG00000230658.1 KLHL7-AS1 16.88 1.89e-41 1.39e-36 0.92 0.75 Cerebrospinal fluid biomarker levels; chr7:23109189 chr7:23101228~23105703:- CESC cis rs9322193 0.962 rs35031906 ENSG00000231760.4 RP11-350J20.5 16.86 2.25e-41 1.65e-36 0.97 0.75 Lung cancer; chr6:149677438 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs288023 ENSG00000253404.1 AC034243.1 16.86 2.29e-41 1.67e-36 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138888359 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs9765929 ENSG00000231760.4 RP11-350J20.5 16.83 2.67e-41 1.88e-36 0.97 0.75 Lung cancer; chr6:149769680 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs3805748 ENSG00000231760.4 RP11-350J20.5 16.83 2.67e-41 1.88e-36 0.97 0.75 Lung cancer; chr6:149772542 chr6:149796151~149826294:- CESC cis rs9322193 0.736 rs10457851 ENSG00000231760.4 RP11-350J20.5 16.83 2.67e-41 1.88e-36 0.97 0.75 Lung cancer; chr6:149775216 chr6:149796151~149826294:- CESC cis rs9322193 0.886 rs10872652 ENSG00000231760.4 RP11-350J20.5 16.83 2.67e-41 1.88e-36 0.97 0.75 Lung cancer; chr6:149775303 chr6:149796151~149826294:- CESC cis rs9322193 0.886 rs12525871 ENSG00000231760.4 RP11-350J20.5 16.83 2.67e-41 1.88e-36 0.97 0.75 Lung cancer; chr6:149775882 chr6:149796151~149826294:- CESC cis rs9322193 0.886 rs17672976 ENSG00000231760.4 RP11-350J20.5 16.83 2.67e-41 1.88e-36 0.97 0.75 Lung cancer; chr6:149776207 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs2184369 ENSG00000231760.4 RP11-350J20.5 16.83 2.67e-41 1.88e-36 0.97 0.75 Lung cancer; chr6:149776681 chr6:149796151~149826294:- CESC cis rs858239 0.601 rs987257 ENSG00000230658.1 KLHL7-AS1 16.83 2.77e-41 1.95e-36 0.92 0.75 Cerebrospinal fluid biomarker levels; chr7:23108221 chr7:23101228~23105703:- CESC cis rs1577917 0.655 rs9444354 ENSG00000203875.9 SNHG5 16.79 3.63e-41 2.53e-36 0.81 0.75 Response to antipsychotic treatment; chr6:85582217 chr6:85660950~85678736:- CESC cis rs9322193 0.923 rs10872645 ENSG00000231760.4 RP11-350J20.5 16.79 3.82e-41 2.64e-36 0.96 0.75 Lung cancer; chr6:149742840 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs12211511 ENSG00000231760.4 RP11-350J20.5 16.79 3.82e-41 2.64e-36 0.96 0.75 Lung cancer; chr6:149745206 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9479810 ENSG00000231760.4 RP11-350J20.5 16.79 3.82e-41 2.64e-36 0.96 0.75 Lung cancer; chr6:149751359 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs10515504 ENSG00000253404.1 AC034243.1 -16.76 4.71e-41 3.24e-36 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138887305 chr5:138744434~138753309:- CESC cis rs858239 0.601 rs6461693 ENSG00000230658.1 KLHL7-AS1 -16.72 6.08e-41 4.17e-36 -0.92 -0.75 Cerebrospinal fluid biomarker levels; chr7:23120514 chr7:23101228~23105703:- CESC cis rs2739330 0.892 rs4822455 ENSG00000218537.1 MIF-AS1 16.72 6.17e-41 4.22e-36 0.97 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23894426~23898930:- CESC cis rs2882667 0.654 rs1095374 ENSG00000253404.1 AC034243.1 -16.66 9.77e-41 6.47e-36 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138759517 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs700620 ENSG00000253404.1 AC034243.1 -16.66 9.77e-41 6.47e-36 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138762247 chr5:138744434~138753309:- CESC cis rs2882667 0.659 rs700621 ENSG00000253404.1 AC034243.1 -16.66 9.77e-41 6.47e-36 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138762741 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs700623 ENSG00000253404.1 AC034243.1 -16.66 9.77e-41 6.47e-36 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138762993 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs700629 ENSG00000253404.1 AC034243.1 -16.66 9.77e-41 6.47e-36 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138788305 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs9688412 ENSG00000231760.4 RP11-350J20.5 -16.65 1.01e-40 6.68e-36 -0.96 -0.75 Lung cancer; chr6:149803147 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs6872423 ENSG00000253404.1 AC034243.1 16.65 1.07e-40 7.03e-36 0.96 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138911089 chr5:138744434~138753309:- CESC cis rs1577917 0.56 rs12193777 ENSG00000203875.9 SNHG5 16.63 1.16e-40 7.48e-36 0.81 0.75 Response to antipsychotic treatment; chr6:85536991 chr6:85660950~85678736:- CESC cis rs1577917 0.655 rs9444351 ENSG00000203875.9 SNHG5 16.63 1.16e-40 7.48e-36 0.81 0.75 Response to antipsychotic treatment; chr6:85538081 chr6:85660950~85678736:- CESC cis rs1577917 0.655 rs7766485 ENSG00000203875.9 SNHG5 16.63 1.16e-40 7.48e-36 0.81 0.75 Response to antipsychotic treatment; chr6:85553837 chr6:85660950~85678736:- CESC cis rs1577917 0.655 rs9450311 ENSG00000203875.9 SNHG5 16.61 1.39e-40 8.98e-36 0.81 0.75 Response to antipsychotic treatment; chr6:85666868 chr6:85660950~85678736:- CESC cis rs858239 0.6 rs13438188 ENSG00000230658.1 KLHL7-AS1 -16.58 1.78e-40 1.14e-35 -0.91 -0.75 Cerebrospinal fluid biomarker levels; chr7:23104578 chr7:23101228~23105703:- CESC cis rs9322193 0.962 rs12175575 ENSG00000231760.4 RP11-350J20.5 16.57 1.83e-40 1.15e-35 0.96 0.75 Lung cancer; chr6:149763351 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs4869966 ENSG00000231760.4 RP11-350J20.5 16.57 1.83e-40 1.15e-35 0.96 0.75 Lung cancer; chr6:149763714 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs1112730 ENSG00000231760.4 RP11-350J20.5 16.57 1.83e-40 1.15e-35 0.96 0.75 Lung cancer; chr6:149766383 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs1112729 ENSG00000231760.4 RP11-350J20.5 16.57 1.83e-40 1.15e-35 0.96 0.75 Lung cancer; chr6:149766491 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs10452626 ENSG00000231760.4 RP11-350J20.5 16.57 1.83e-40 1.15e-35 0.96 0.75 Lung cancer; chr6:149767481 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs62441303 ENSG00000231760.4 RP11-350J20.5 16.57 1.83e-40 1.15e-35 0.96 0.75 Lung cancer; chr6:149767547 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs1703212 ENSG00000253404.1 AC034243.1 -16.54 2.27e-40 1.42e-35 -0.96 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138742863 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs7753812 ENSG00000231760.4 RP11-350J20.5 16.54 2.34e-40 1.46e-35 0.95 0.75 Lung cancer; chr6:149690150 chr6:149796151~149826294:- CESC cis rs1577917 0.655 rs2842605 ENSG00000203875.9 SNHG5 -16.54 2.38e-40 1.48e-35 -0.81 -0.75 Response to antipsychotic treatment; chr6:85625432 chr6:85660950~85678736:- CESC cis rs9322193 0.923 rs12195866 ENSG00000231760.4 RP11-350J20.5 16.54 2.41e-40 1.49e-35 0.95 0.75 Lung cancer; chr6:149693334 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9285524 ENSG00000231760.4 RP11-350J20.5 16.54 2.41e-40 1.49e-35 0.95 0.75 Lung cancer; chr6:149694122 chr6:149796151~149826294:- CESC cis rs2882667 0.587 rs1848506 ENSG00000253404.1 AC034243.1 -16.53 2.42e-40 1.49e-35 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138846768 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1848505 ENSG00000253404.1 AC034243.1 -16.53 2.42e-40 1.49e-35 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138846841 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs176382 ENSG00000253404.1 AC034243.1 16.53 2.44e-40 1.5e-35 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138891078 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1651358 ENSG00000253404.1 AC034243.1 -16.53 2.47e-40 1.52e-35 -1.01 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138745318 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6596456 ENSG00000253404.1 AC034243.1 -16.52 2.72e-40 1.66e-35 -0.96 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138831808 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6877187 ENSG00000253404.1 AC034243.1 -16.51 2.88e-40 1.74e-35 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138823655 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs3804199 ENSG00000253404.1 AC034243.1 -16.51 2.88e-40 1.74e-35 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138826440 chr5:138744434~138753309:- CESC cis rs2882667 0.722 rs2011462 ENSG00000253404.1 AC034243.1 -16.51 2.88e-40 1.74e-35 -0.99 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138827083 chr5:138744434~138753309:- CESC cis rs2739330 0.828 rs5751770 ENSG00000273295.1 AP000350.5 16.5 3.13e-40 1.89e-35 0.82 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23901432~23907068:- CESC cis rs2739330 0.892 rs5751776 ENSG00000225282.1 AP000350.6 16.49 3.4e-40 2.04e-35 0.89 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23926900~23929574:+ CESC cis rs2882667 0.69 rs4835708 ENSG00000253404.1 AC034243.1 -16.47 3.97e-40 2.37e-35 -0.97 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138844204 chr5:138744434~138753309:- CESC cis rs1577917 0.561 rs3087978 ENSG00000203875.9 SNHG5 16.47 4e-40 2.38e-35 0.81 0.74 Response to antipsychotic treatment; chr6:85678505 chr6:85660950~85678736:- CESC cis rs2882667 0.69 rs9327829 ENSG00000253404.1 AC034243.1 -16.46 4.08e-40 2.42e-35 -0.97 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138925982 chr5:138744434~138753309:- CESC cis rs1577917 0.559 rs1173418 ENSG00000203875.9 SNHG5 16.45 4.6e-40 2.73e-35 0.81 0.74 Response to antipsychotic treatment; chr6:85693198 chr6:85660950~85678736:- CESC cis rs1577917 0.655 rs2758848 ENSG00000203875.9 SNHG5 -16.44 4.96e-40 2.92e-35 -0.81 -0.74 Response to antipsychotic treatment; chr6:85637887 chr6:85660950~85678736:- CESC cis rs858239 0.669 rs12539467 ENSG00000230658.1 KLHL7-AS1 16.41 5.91e-40 3.46e-35 0.98 0.74 Cerebrospinal fluid biomarker levels; chr7:23076240 chr7:23101228~23105703:- CESC cis rs1577917 0.61 rs11752795 ENSG00000203875.9 SNHG5 16.4 6.42e-40 3.71e-35 0.81 0.74 Response to antipsychotic treatment; chr6:85577411 chr6:85660950~85678736:- CESC cis rs1577917 0.566 rs2842611 ENSG00000203875.9 SNHG5 -16.4 6.42e-40 3.71e-35 -0.81 -0.74 Response to antipsychotic treatment; chr6:85592316 chr6:85660950~85678736:- CESC cis rs1577917 0.655 rs12203963 ENSG00000203875.9 SNHG5 16.35 9.22e-40 5.32e-35 0.8 0.74 Response to antipsychotic treatment; chr6:85513598 chr6:85660950~85678736:- CESC cis rs1577917 0.681 rs4707211 ENSG00000203875.9 SNHG5 16.34 1.04e-39 5.99e-35 0.81 0.74 Response to antipsychotic treatment; chr6:85522992 chr6:85660950~85678736:- CESC cis rs2882667 0.69 rs311597 ENSG00000253404.1 AC034243.1 16.33 1.12e-39 6.45e-35 1 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138720212 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs14314 ENSG00000231760.4 RP11-350J20.5 16.32 1.14e-39 6.55e-35 0.97 0.74 Lung cancer; chr6:149820395 chr6:149796151~149826294:- CESC cis rs858239 0.571 rs2390755 ENSG00000230658.1 KLHL7-AS1 16.32 1.18e-39 6.62e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23151097 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs4365988 ENSG00000230658.1 KLHL7-AS1 16.32 1.18e-39 6.62e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23151252 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs10279194 ENSG00000230658.1 KLHL7-AS1 16.32 1.18e-39 6.62e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23151464 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs3950345 ENSG00000230658.1 KLHL7-AS1 16.32 1.18e-39 6.62e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23151495 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs2178140 ENSG00000230658.1 KLHL7-AS1 16.32 1.18e-39 6.62e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23152006 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs2178139 ENSG00000230658.1 KLHL7-AS1 16.32 1.18e-39 6.62e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23152017 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs2141306 ENSG00000230658.1 KLHL7-AS1 16.32 1.18e-39 6.62e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23152045 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs2141305 ENSG00000230658.1 KLHL7-AS1 16.32 1.18e-39 6.62e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23152280 chr7:23101228~23105703:- CESC cis rs1577917 0.727 rs9344539 ENSG00000203875.9 SNHG5 -16.31 1.28e-39 7.14e-35 -0.81 -0.74 Response to antipsychotic treatment; chr6:85643903 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs9362232 ENSG00000203875.9 SNHG5 -16.31 1.28e-39 7.14e-35 -0.81 -0.74 Response to antipsychotic treatment; chr6:85643904 chr6:85660950~85678736:- CESC cis rs858239 0.6 rs6967475 ENSG00000230658.1 KLHL7-AS1 16.3 1.4e-39 7.77e-35 0.94 0.74 Cerebrospinal fluid biomarker levels; chr7:23089363 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs6965833 ENSG00000230658.1 KLHL7-AS1 16.28 1.54e-39 8.51e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23152747 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs6949363 ENSG00000230658.1 KLHL7-AS1 16.28 1.54e-39 8.51e-35 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23152775 chr7:23101228~23105703:- CESC cis rs2739330 0.892 rs4822455 ENSG00000225282.1 AP000350.6 16.27 1.65e-39 9.08e-35 0.89 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23926900~23929574:+ CESC cis rs9322193 0.926 rs3805751 ENSG00000231760.4 RP11-350J20.5 16.27 1.66e-39 9.14e-35 0.95 0.74 Lung cancer; chr6:149791193 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs10872656 ENSG00000231760.4 RP11-350J20.5 16.27 1.66e-39 9.14e-35 0.95 0.74 Lung cancer; chr6:149799444 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs311599 ENSG00000253404.1 AC034243.1 16.27 1.7e-39 9.28e-35 1.01 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138718994 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs906695 ENSG00000253404.1 AC034243.1 16.26 1.87e-39 1.02e-34 1 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138803588 chr5:138744434~138753309:- CESC cis rs2882667 0.659 rs311595 ENSG00000253404.1 AC034243.1 16.25 1.95e-39 1.06e-34 0.94 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138736183 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs884469 ENSG00000253404.1 AC034243.1 -16.25 2.02e-39 1.1e-34 -0.96 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138820270 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs3763162 ENSG00000231760.4 RP11-350J20.5 -16.23 2.37e-39 1.28e-34 -0.96 -0.74 Lung cancer; chr6:149819674 chr6:149796151~149826294:- CESC cis rs1577917 0.655 rs6454472 ENSG00000203875.9 SNHG5 16.21 2.71e-39 1.46e-34 0.8 0.74 Response to antipsychotic treatment; chr6:85514335 chr6:85660950~85678736:- CESC cis rs2882667 0.69 rs9327827 ENSG00000253404.1 AC034243.1 16.19 3.16e-39 1.7e-34 1 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138846639 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs17673294 ENSG00000231760.4 RP11-350J20.5 16.17 3.64e-39 1.95e-34 0.95 0.74 Lung cancer; chr6:149813857 chr6:149796151~149826294:- CESC cis rs1577917 0.655 rs9444352 ENSG00000203875.9 SNHG5 16.14 4.51e-39 2.41e-34 0.8 0.74 Response to antipsychotic treatment; chr6:85547817 chr6:85660950~85678736:- CESC cis rs858239 0.539 rs10280815 ENSG00000230658.1 KLHL7-AS1 16.11 5.69e-39 2.99e-34 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23148751 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs10225608 ENSG00000230658.1 KLHL7-AS1 16.11 5.69e-39 2.99e-34 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23149289 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs28624974 ENSG00000230658.1 KLHL7-AS1 16.11 5.69e-39 2.99e-34 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23149317 chr7:23101228~23105703:- CESC cis rs5850 0.557 rs10270788 ENSG00000230658.1 KLHL7-AS1 16.11 5.69e-39 2.99e-34 0.92 0.74 Blood protein levels; chr7:23149381 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs28716381 ENSG00000230658.1 KLHL7-AS1 16.11 5.69e-39 2.99e-34 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23149396 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs1358442 ENSG00000230658.1 KLHL7-AS1 16.11 5.69e-39 2.99e-34 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23150120 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs2351463 ENSG00000253404.1 AC034243.1 16.11 5.7e-39 2.99e-34 0.96 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138923113 chr5:138744434~138753309:- CESC cis rs858239 0.539 rs6945510 ENSG00000230658.1 KLHL7-AS1 16.1 5.81e-39 3.05e-34 0.92 0.74 Cerebrospinal fluid biomarker levels; chr7:23152621 chr7:23101228~23105703:- CESC cis rs2739330 0.731 rs4822450 ENSG00000273295.1 AP000350.5 16.1 6.11e-39 3.2e-34 0.84 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23901432~23907068:- CESC cis rs858239 0.602 rs6953996 ENSG00000230658.1 KLHL7-AS1 16.08 6.76e-39 3.53e-34 0.97 0.74 Cerebrospinal fluid biomarker levels; chr7:23136327 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs764534 ENSG00000230658.1 KLHL7-AS1 16.06 8.04e-39 4.18e-34 0.95 0.74 Cerebrospinal fluid biomarker levels; chr7:23114316 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs2068459 ENSG00000230658.1 KLHL7-AS1 16.06 8.04e-39 4.18e-34 0.95 0.74 Cerebrospinal fluid biomarker levels; chr7:23114694 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs160401 ENSG00000253404.1 AC034243.1 -16.06 8.08e-39 4.19e-34 -0.95 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138725652 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs13177415 ENSG00000253404.1 AC034243.1 16.03 1.01e-38 5.21e-34 0.96 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138914251 chr5:138744434~138753309:- CESC cis rs2739330 0.731 rs2000468 ENSG00000273295.1 AP000350.5 15.98 1.49e-38 7.71e-34 0.83 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23901432~23907068:- CESC cis rs9322193 0.962 rs9322206 ENSG00000231760.4 RP11-350J20.5 15.97 1.51e-38 7.75e-34 0.92 0.73 Lung cancer; chr6:149641481 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9322197 ENSG00000231760.4 RP11-350J20.5 15.97 1.52e-38 7.83e-34 0.91 0.73 Lung cancer; chr6:149622577 chr6:149796151~149826294:- CESC cis rs1577917 0.629 rs9450285 ENSG00000203875.9 SNHG5 15.97 1.53e-38 7.85e-34 0.81 0.73 Response to antipsychotic treatment; chr6:85498378 chr6:85660950~85678736:- CESC cis rs9322193 0.962 rs9688750 ENSG00000231760.4 RP11-350J20.5 15.97 1.61e-38 8.21e-34 0.92 0.73 Lung cancer; chr6:149657633 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs2151912 ENSG00000231760.4 RP11-350J20.5 15.96 1.68e-38 8.56e-34 0.95 0.73 Lung cancer; chr6:149831772 chr6:149796151~149826294:- CESC cis rs1577917 0.681 rs4348284 ENSG00000203875.9 SNHG5 -15.95 1.74e-38 8.86e-34 -0.81 -0.73 Response to antipsychotic treatment; chr6:85640676 chr6:85660950~85678736:- CESC cis rs1577917 0.655 rs2758849 ENSG00000203875.9 SNHG5 -15.95 1.75e-38 8.89e-34 -0.81 -0.73 Response to antipsychotic treatment; chr6:85634578 chr6:85660950~85678736:- CESC cis rs9322193 0.962 rs2275046 ENSG00000231760.4 RP11-350J20.5 15.93 2.16e-38 1.09e-33 0.96 0.73 Lung cancer; chr6:149835865 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs13181762 ENSG00000253404.1 AC034243.1 15.88 2.96e-38 1.48e-33 0.95 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138914417 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288012 ENSG00000253404.1 AC034243.1 -15.87 3.38e-38 1.68e-33 -0.93 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138860584 chr5:138744434~138753309:- CESC cis rs1577917 0.629 rs6927475 ENSG00000203875.9 SNHG5 15.85 3.67e-38 1.82e-33 0.8 0.73 Response to antipsychotic treatment; chr6:85497055 chr6:85660950~85678736:- CESC cis rs2882667 0.69 rs288014 ENSG00000253404.1 AC034243.1 -15.85 3.74e-38 1.86e-33 -0.93 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138860104 chr5:138744434~138753309:- CESC cis rs858239 0.601 rs10224327 ENSG00000230658.1 KLHL7-AS1 15.84 3.98e-38 1.97e-33 0.94 0.73 Cerebrospinal fluid biomarker levels; chr7:23122201 chr7:23101228~23105703:- CESC cis rs2739330 0.828 rs5760108 ENSG00000273295.1 AP000350.5 15.84 3.99e-38 1.97e-33 0.8 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23901432~23907068:- CESC cis rs1577917 0.655 rs2842600 ENSG00000203875.9 SNHG5 -15.84 4.06e-38 2e-33 -0.8 -0.73 Response to antipsychotic treatment; chr6:85615914 chr6:85660950~85678736:- CESC cis rs2882667 0.69 rs160404 ENSG00000253404.1 AC034243.1 15.83 4.36e-38 2.14e-33 0.98 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138748580 chr5:138744434~138753309:- CESC cis rs858239 0.539 rs57864591 ENSG00000230658.1 KLHL7-AS1 15.82 4.66e-38 2.29e-33 0.92 0.73 Cerebrospinal fluid biomarker levels; chr7:23144805 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs7791200 ENSG00000230658.1 KLHL7-AS1 15.82 4.67e-38 2.29e-33 0.92 0.73 Cerebrospinal fluid biomarker levels; chr7:23142502 chr7:23101228~23105703:- CESC cis rs9322193 0.961 rs9027 ENSG00000231760.4 RP11-350J20.5 15.82 4.89e-38 2.39e-33 0.91 0.73 Lung cancer; chr6:149594921 chr6:149796151~149826294:- CESC cis rs9322193 1 rs9322193 ENSG00000231760.4 RP11-350J20.5 15.82 4.89e-38 2.39e-33 0.91 0.73 Lung cancer; chr6:149598007 chr6:149796151~149826294:- CESC cis rs858239 0.601 rs7805206 ENSG00000230658.1 KLHL7-AS1 15.8 5.63e-38 2.75e-33 0.93 0.73 Cerebrospinal fluid biomarker levels; chr7:23120591 chr7:23101228~23105703:- CESC cis rs9322193 0.926 rs9383546 ENSG00000231760.4 RP11-350J20.5 15.78 6.52e-38 3.18e-33 0.94 0.73 Lung cancer; chr6:149822743 chr6:149796151~149826294:- CESC cis rs2739330 0.753 rs4822452 ENSG00000273295.1 AP000350.5 15.74 8.28e-38 4.03e-33 0.8 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23901432~23907068:- CESC cis rs9322193 0.962 rs7745915 ENSG00000231760.4 RP11-350J20.5 15.74 8.41e-38 4.08e-33 0.95 0.73 Lung cancer; chr6:149834111 chr6:149796151~149826294:- CESC cis rs858239 0.601 rs73272053 ENSG00000230658.1 KLHL7-AS1 15.74 8.78e-38 4.26e-33 0.95 0.73 Cerebrospinal fluid biomarker levels; chr7:23115906 chr7:23101228~23105703:- CESC cis rs9322193 0.884 rs9688858 ENSG00000231760.4 RP11-350J20.5 15.72 9.8e-38 4.74e-33 0.91 0.73 Lung cancer; chr6:149637911 chr6:149796151~149826294:- CESC cis rs2882667 0.658 rs172664 ENSG00000253404.1 AC034243.1 15.7 1.13e-37 5.44e-33 0.96 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138720617 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs160399 ENSG00000253404.1 AC034243.1 15.67 1.44e-37 6.95e-33 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138727552 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs2065664 ENSG00000231760.4 RP11-350J20.5 15.65 1.7e-37 8.19e-33 0.96 0.73 Lung cancer; chr6:149762485 chr6:149796151~149826294:- CESC cis rs858239 0.539 rs870476 ENSG00000230658.1 KLHL7-AS1 15.63 1.93e-37 9.23e-33 0.91 0.73 Cerebrospinal fluid biomarker levels; chr7:23153652 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs10239760 ENSG00000230658.1 KLHL7-AS1 15.62 2e-37 9.54e-33 0.95 0.73 Cerebrospinal fluid biomarker levels; chr7:23110331 chr7:23101228~23105703:- CESC cis rs858239 0.601 rs12539331 ENSG00000230658.1 KLHL7-AS1 15.62 2e-37 9.54e-33 0.95 0.73 Cerebrospinal fluid biomarker levels; chr7:23111711 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs891996 ENSG00000253404.1 AC034243.1 15.62 2.1e-37 1e-32 0.94 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138932127 chr5:138744434~138753309:- CESC cis rs9322193 0.736 rs3828701 ENSG00000231760.4 RP11-350J20.5 15.62 2.13e-37 1.01e-32 0.94 0.73 Lung cancer; chr6:149791063 chr6:149796151~149826294:- CESC cis rs9322193 0.736 rs3805750 ENSG00000231760.4 RP11-350J20.5 15.62 2.13e-37 1.01e-32 0.94 0.73 Lung cancer; chr6:149791065 chr6:149796151~149826294:- CESC cis rs916888 0.821 rs199513 ENSG00000262539.1 RP11-259G18.3 -15.61 2.3e-37 1.09e-32 -1.1 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46259551~46260606:- CESC cis rs2882667 0.69 rs288033 ENSG00000253404.1 AC034243.1 15.54 3.8e-37 1.79e-32 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138878405 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs160400 ENSG00000253404.1 AC034243.1 -15.52 4.23e-37 1.99e-32 -0.95 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138727330 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs2016720 ENSG00000253404.1 AC034243.1 15.51 4.64e-37 2.18e-32 0.93 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138928369 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs311602 ENSG00000253404.1 AC034243.1 15.51 4.82e-37 2.25e-32 0.98 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138717370 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs930063 ENSG00000253404.1 AC034243.1 15.51 4.82e-37 2.25e-32 0.98 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138717929 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs930062 ENSG00000253404.1 AC034243.1 15.51 4.82e-37 2.25e-32 0.98 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138717934 chr5:138744434~138753309:- CESC cis rs1577917 0.655 rs9342045 ENSG00000203875.9 SNHG5 15.47 6.07e-37 2.83e-32 0.79 0.72 Response to antipsychotic treatment; chr6:85715430 chr6:85660950~85678736:- CESC cis rs2739330 0.76 rs1007888 ENSG00000273295.1 AP000350.5 15.44 8.05e-37 3.73e-32 0.82 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23901432~23907068:- CESC cis rs2882667 0.69 rs10068280 ENSG00000253404.1 AC034243.1 15.39 1.12e-36 5.15e-32 0.96 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138931394 chr5:138744434~138753309:- CESC cis rs858239 0.539 rs6976957 ENSG00000230658.1 KLHL7-AS1 15.38 1.19e-36 5.46e-32 0.91 0.72 Cerebrospinal fluid biomarker levels; chr7:23147714 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs4294098 ENSG00000230658.1 KLHL7-AS1 15.38 1.25e-36 5.68e-32 0.91 0.72 Cerebrospinal fluid biomarker levels; chr7:23146376 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs4504540 ENSG00000230658.1 KLHL7-AS1 15.38 1.25e-36 5.68e-32 0.91 0.72 Cerebrospinal fluid biomarker levels; chr7:23146579 chr7:23101228~23105703:- CESC cis rs858239 0.509 rs6975524 ENSG00000230658.1 KLHL7-AS1 15.38 1.25e-36 5.68e-32 0.91 0.72 Cerebrospinal fluid biomarker levels; chr7:23146833 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs6955726 ENSG00000230658.1 KLHL7-AS1 15.38 1.25e-36 5.68e-32 0.91 0.72 Cerebrospinal fluid biomarker levels; chr7:23147072 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs6956828 ENSG00000230658.1 KLHL7-AS1 15.38 1.25e-36 5.68e-32 0.91 0.72 Cerebrospinal fluid biomarker levels; chr7:23147728 chr7:23101228~23105703:- CESC cis rs2882667 0.628 rs311606 ENSG00000253404.1 AC034243.1 15.38 1.25e-36 5.68e-32 0.97 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138709551 chr5:138744434~138753309:- CESC cis rs9326248 0.817 rs1242127 ENSG00000254851.1 RP11-109L13.1 15.33 1.75e-36 7.93e-32 0.91 0.72 Blood protein levels; chr11:117205848 chr11:117135528~117138582:+ CESC cis rs2882667 0.69 rs13178601 ENSG00000253404.1 AC034243.1 15.33 1.76e-36 7.97e-32 0.96 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138931688 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs3749664 ENSG00000253404.1 AC034243.1 15.31 2.12e-36 9.54e-32 0.94 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138935732 chr5:138744434~138753309:- CESC cis rs2882667 0.628 rs3749663 ENSG00000253404.1 AC034243.1 15.3 2.22e-36 9.97e-32 0.93 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138935498 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs423469 ENSG00000253404.1 AC034243.1 15.29 2.43e-36 1.09e-31 0.9 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138898427 chr5:138744434~138753309:- CESC cis rs858239 0.509 rs6962213 ENSG00000230658.1 KLHL7-AS1 15.28 2.56e-36 1.15e-31 0.9 0.72 Cerebrospinal fluid biomarker levels; chr7:23148490 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs4295546 ENSG00000230658.1 KLHL7-AS1 15.27 2.77e-36 1.23e-31 0.9 0.72 Cerebrospinal fluid biomarker levels; chr7:23151402 chr7:23101228~23105703:- CESC cis rs2882667 0.598 rs10078179 ENSG00000253404.1 AC034243.1 15.27 2.83e-36 1.26e-31 0.92 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138920410 chr5:138744434~138753309:- CESC cis rs858239 0.539 rs6955969 ENSG00000230658.1 KLHL7-AS1 15.26 3.01e-36 1.34e-31 0.9 0.72 Cerebrospinal fluid biomarker levels; chr7:23147080 chr7:23101228~23105703:- CESC cis rs9322193 0.962 rs4380763 ENSG00000231760.4 RP11-350J20.5 15.25 3.23e-36 1.43e-31 0.93 0.72 Lung cancer; chr6:149678086 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs62439836 ENSG00000231760.4 RP11-350J20.5 15.25 3.29e-36 1.45e-31 0.93 0.72 Lung cancer; chr6:149669173 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs4869812 ENSG00000231760.4 RP11-350J20.5 15.25 3.29e-36 1.45e-31 0.93 0.72 Lung cancer; chr6:149669447 chr6:149796151~149826294:- CESC cis rs2739330 0.627 rs9608219 ENSG00000273295.1 AP000350.5 15.21 4.22e-36 1.86e-31 0.81 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23901432~23907068:- CESC cis rs2882667 0.619 rs6861556 ENSG00000253404.1 AC034243.1 -15.2 4.62e-36 2.02e-31 -0.97 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138852351 chr5:138744434~138753309:- CESC cis rs2739330 0.76 rs1002286 ENSG00000273295.1 AP000350.5 -15.2 4.64e-36 2.03e-31 -0.8 -0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23901432~23907068:- CESC cis rs916888 0.773 rs199457 ENSG00000214401.4 KANSL1-AS1 15.16 6.4e-36 2.78e-31 1.06 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46193576~46196723:+ CESC cis rs916888 0.687 rs199456 ENSG00000214401.4 KANSL1-AS1 15.16 6.4e-36 2.78e-31 1.06 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46193576~46196723:+ CESC cis rs2882667 0.69 rs167009 ENSG00000253404.1 AC034243.1 -15.13 7.65e-36 3.3e-31 -0.96 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138864768 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288040 ENSG00000253404.1 AC034243.1 15.13 7.65e-36 3.3e-31 0.96 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138869205 chr5:138744434~138753309:- CESC cis rs2882667 0.659 rs288037 ENSG00000253404.1 AC034243.1 15.13 7.65e-36 3.3e-31 0.96 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138872752 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288036 ENSG00000253404.1 AC034243.1 15.13 7.65e-36 3.3e-31 0.96 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138875206 chr5:138744434~138753309:- CESC cis rs916888 0.773 rs1378358 ENSG00000214401.4 KANSL1-AS1 15.12 8.29e-36 3.57e-31 1.06 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46193576~46196723:+ CESC cis rs916888 0.773 rs169201 ENSG00000214401.4 KANSL1-AS1 15.12 8.29e-36 3.57e-31 1.06 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46193576~46196723:+ CESC cis rs2882667 0.69 rs6596455 ENSG00000253404.1 AC034243.1 -15.12 8.65e-36 3.7e-31 -0.97 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138831416 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs995177 ENSG00000253404.1 AC034243.1 -15.12 8.65e-36 3.7e-31 -0.97 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138833874 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs7710300 ENSG00000253404.1 AC034243.1 -15.12 8.65e-36 3.7e-31 -0.97 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138834793 chr5:138744434~138753309:- CESC cis rs2739330 0.791 rs9612520 ENSG00000273295.1 AP000350.5 15.11 9.04e-36 3.87e-31 0.8 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23901432~23907068:- CESC cis rs2882667 0.654 rs2351247 ENSG00000253404.1 AC034243.1 -15.1 9.84e-36 4.19e-31 -0.97 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138849456 chr5:138744434~138753309:- CESC cis rs916888 0.773 rs199439 ENSG00000214401.4 KANSL1-AS1 15.1 1.01e-35 4.29e-31 1.05 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46193576~46196723:+ CESC cis rs2882667 0.69 rs288035 ENSG00000253404.1 AC034243.1 15.07 1.18e-35 5.01e-31 0.96 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138876728 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs1413655 ENSG00000231760.4 RP11-350J20.5 15.07 1.22e-35 5.2e-31 0.92 0.71 Lung cancer; chr6:149821815 chr6:149796151~149826294:- CESC cis rs916888 0.773 rs538628 ENSG00000214401.4 KANSL1-AS1 15.06 1.29e-35 5.45e-31 1.05 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46193576~46196723:+ CESC cis rs2882667 0.69 rs1059110 ENSG00000253404.1 AC034243.1 15.06 1.34e-35 5.68e-31 0.96 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138930857 chr5:138744434~138753309:- CESC cis rs2882667 0.659 rs12719515 ENSG00000253404.1 AC034243.1 15.05 1.39e-35 5.88e-31 0.9 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138905629 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs4870529 ENSG00000231760.4 RP11-350J20.5 15.04 1.49e-35 6.27e-31 0.91 0.71 Lung cancer; chr6:149716436 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9767309 ENSG00000231760.4 RP11-350J20.5 15.04 1.49e-35 6.27e-31 0.91 0.71 Lung cancer; chr6:149716807 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs62441279 ENSG00000231760.4 RP11-350J20.5 15.04 1.49e-35 6.27e-31 0.91 0.71 Lung cancer; chr6:149721194 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs17745062 ENSG00000231760.4 RP11-350J20.5 15.04 1.58e-35 6.62e-31 0.91 0.71 Lung cancer; chr6:149721079 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs288022 ENSG00000253404.1 AC034243.1 15.02 1.8e-35 7.55e-31 0.9 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138888586 chr5:138744434~138753309:- CESC cis rs2882667 0.598 rs288020 ENSG00000253404.1 AC034243.1 15.02 1.8e-35 7.55e-31 0.9 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138888609 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs7446631 ENSG00000253404.1 AC034243.1 15.01 1.89e-35 7.92e-31 0.9 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138891376 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288018 ENSG00000253404.1 AC034243.1 -15.01 1.91e-35 7.96e-31 -0.95 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138856727 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288017 ENSG00000253404.1 AC034243.1 -15.01 1.91e-35 7.96e-31 -0.95 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138857826 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs4870267 ENSG00000231760.4 RP11-350J20.5 14.98 2.43e-35 1.01e-30 0.92 0.71 Lung cancer; chr6:149671572 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs288032 ENSG00000253404.1 AC034243.1 14.97 2.54e-35 1.05e-30 0.95 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138879639 chr5:138744434~138753309:- CESC cis rs9322193 1 rs9399693 ENSG00000231760.4 RP11-350J20.5 14.96 2.67e-35 1.1e-30 0.89 0.71 Lung cancer; chr6:149612718 chr6:149796151~149826294:- CESC cis rs916888 0.773 rs199451 ENSG00000214401.4 KANSL1-AS1 14.96 2.86e-35 1.18e-30 1.05 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46193576~46196723:+ CESC cis rs916888 0.773 rs199448 ENSG00000214401.4 KANSL1-AS1 14.95 2.88e-35 1.19e-30 1.02 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46193576~46196723:+ CESC cis rs2739330 0.76 rs5751760 ENSG00000273295.1 AP000350.5 14.95 2.93e-35 1.2e-30 0.81 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23901432~23907068:- CESC cis rs2882667 0.69 rs160403 ENSG00000253404.1 AC034243.1 14.94 3.23e-35 1.33e-30 0.92 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138722793 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs9767123 ENSG00000231760.4 RP11-350J20.5 14.93 3.33e-35 1.37e-30 0.91 0.71 Lung cancer; chr6:149660323 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs288029 ENSG00000253404.1 AC034243.1 14.91 4.1e-35 1.68e-30 0.95 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138881616 chr5:138744434~138753309:- CESC cis rs2739330 0.703 rs5760112 ENSG00000273295.1 AP000350.5 14.9 4.34e-35 1.77e-30 0.8 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23901432~23907068:- CESC cis rs9322193 0.923 rs9800871 ENSG00000231760.4 RP11-350J20.5 14.89 4.57e-35 1.86e-30 0.89 0.71 Lung cancer; chr6:149644540 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs1934534 ENSG00000231760.4 RP11-350J20.5 14.88 4.89e-35 1.98e-30 0.91 0.71 Lung cancer; chr6:149711896 chr6:149796151~149826294:- CESC cis rs9326248 1 rs664971 ENSG00000254851.1 RP11-109L13.1 14.88 5.09e-35 2.06e-30 0.88 0.71 Blood protein levels; chr11:117200141 chr11:117135528~117138582:+ CESC cis rs2882667 0.628 rs13171173 ENSG00000253404.1 AC034243.1 -14.81 8.15e-35 3.3e-30 -0.97 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138706775 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs4354168 ENSG00000231760.4 RP11-350J20.5 14.8 8.89e-35 3.59e-30 0.91 0.71 Lung cancer; chr6:149696642 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs4455682 ENSG00000231760.4 RP11-350J20.5 14.8 8.97e-35 3.61e-30 0.91 0.71 Lung cancer; chr6:149700161 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9766037 ENSG00000231760.4 RP11-350J20.5 14.78 1.01e-34 4.07e-30 0.9 0.71 Lung cancer; chr6:149616921 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs4870048 ENSG00000231760.4 RP11-350J20.5 14.77 1.09e-34 4.37e-30 0.92 0.71 Lung cancer; chr6:149834324 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs825672 ENSG00000253404.1 AC034243.1 -14.75 1.3e-34 5.23e-30 -0.96 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138759954 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs9404048 ENSG00000231760.4 RP11-350J20.5 14.74 1.39e-34 5.56e-30 0.89 0.71 Lung cancer; chr6:149616188 chr6:149796151~149826294:- CESC cis rs2882667 0.587 rs825674 ENSG00000253404.1 AC034243.1 -14.74 1.46e-34 5.82e-30 -1 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138767031 chr5:138744434~138753309:- CESC cis rs9322193 0.924 rs9498382 ENSG00000231760.4 RP11-350J20.5 14.72 1.65e-34 6.58e-30 0.88 0.71 Lung cancer; chr6:149610982 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs2186366 ENSG00000273295.1 AP000350.5 -14.69 2.09e-34 8.3e-30 -0.78 -0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23901432~23907068:- CESC cis rs916888 0.773 rs199535 ENSG00000214401.4 KANSL1-AS1 14.68 2.23e-34 8.83e-30 1.01 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46193576~46196723:+ CESC cis rs2739330 0.828 rs5760107 ENSG00000273295.1 AP000350.5 14.68 2.23e-34 8.83e-30 0.79 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23901432~23907068:- CESC cis rs2739330 0.789 rs5760109 ENSG00000273295.1 AP000350.5 14.68 2.23e-34 8.83e-30 0.79 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23901432~23907068:- CESC cis rs2739330 0.828 rs2154593 ENSG00000273295.1 AP000350.5 14.67 2.35e-34 9.28e-30 0.79 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23901432~23907068:- CESC cis rs858239 0.669 rs1006709 ENSG00000230658.1 KLHL7-AS1 14.65 2.81e-34 1.11e-29 0.86 0.7 Cerebrospinal fluid biomarker levels; chr7:23100480 chr7:23101228~23105703:- CESC cis rs9322193 0.923 rs9767554 ENSG00000231760.4 RP11-350J20.5 14.64 2.98e-34 1.17e-29 0.88 0.7 Lung cancer; chr6:149616860 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9800614 ENSG00000231760.4 RP11-350J20.5 14.64 3e-34 1.18e-29 0.89 0.7 Lung cancer; chr6:149644604 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs13215691 ENSG00000231760.4 RP11-350J20.5 14.63 3.11e-34 1.22e-29 0.9 0.7 Lung cancer; chr6:149792666 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10782317 ENSG00000231760.4 RP11-350J20.5 -14.63 3.21e-34 1.26e-29 -0.9 -0.7 Lung cancer; chr6:149753911 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs2877178 ENSG00000273295.1 AP000350.5 14.63 3.23e-34 1.26e-29 0.8 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23901432~23907068:- CESC cis rs9322193 0.923 rs35961297 ENSG00000231760.4 RP11-350J20.5 14.61 3.61e-34 1.4e-29 0.9 0.7 Lung cancer; chr6:149667929 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs35967444 ENSG00000231760.4 RP11-350J20.5 14.61 3.61e-34 1.4e-29 0.9 0.7 Lung cancer; chr6:149675588 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs62439842 ENSG00000231760.4 RP11-350J20.5 14.61 3.61e-34 1.4e-29 0.9 0.7 Lung cancer; chr6:149675847 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9377230 ENSG00000231760.4 RP11-350J20.5 14.61 3.62e-34 1.41e-29 0.88 0.7 Lung cancer; chr6:149613607 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs35830138 ENSG00000231760.4 RP11-350J20.5 14.61 3.69e-34 1.43e-29 0.9 0.7 Lung cancer; chr6:149668635 chr6:149796151~149826294:- CESC cis rs4853012 0.838 rs4563249 ENSG00000217702.2 RP11-287D1.4 14.6 3.95e-34 1.53e-29 1 0.7 Gestational age at birth (maternal effect); chr2:74126889 chr2:74130583~74135395:+ CESC cis rs858239 0.511 rs10256996 ENSG00000230658.1 KLHL7-AS1 -14.58 4.52e-34 1.74e-29 -0.9 -0.7 Cerebrospinal fluid biomarker levels; chr7:23105676 chr7:23101228~23105703:- CESC cis rs2739330 0.731 rs4822450 ENSG00000225282.1 AP000350.6 14.58 4.71e-34 1.81e-29 0.86 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23926900~23929574:+ CESC cis rs2739330 0.828 rs4822454 ENSG00000273295.1 AP000350.5 14.54 6e-34 2.3e-29 0.78 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23901432~23907068:- CESC cis rs916888 0.773 rs199534 ENSG00000214401.4 KANSL1-AS1 14.54 6.29e-34 2.4e-29 1.03 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46193576~46196723:+ CESC cis rs916888 0.779 rs199528 ENSG00000214401.4 KANSL1-AS1 14.54 6.34e-34 2.41e-29 1.04 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46193576~46196723:+ CESC cis rs916888 0.821 rs199525 ENSG00000214401.4 KANSL1-AS1 14.54 6.34e-34 2.41e-29 1.04 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46193576~46196723:+ CESC cis rs9322193 1 rs9377228 ENSG00000231760.4 RP11-350J20.5 14.49 8.77e-34 3.31e-29 0.88 0.7 Lung cancer; chr6:149600862 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9689084 ENSG00000231760.4 RP11-350J20.5 14.49 9.02e-34 3.41e-29 0.88 0.7 Lung cancer; chr6:149639648 chr6:149796151~149826294:- CESC cis rs9322193 0.886 rs9485408 ENSG00000231760.4 RP11-350J20.5 14.49 9.12e-34 3.42e-29 0.87 0.7 Lung cancer; chr6:149618888 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs1080670 ENSG00000231760.4 RP11-350J20.5 14.49 9.12e-34 3.42e-29 0.87 0.7 Lung cancer; chr6:149620161 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs10782312 ENSG00000231760.4 RP11-350J20.5 14.49 9.12e-34 3.42e-29 0.87 0.7 Lung cancer; chr6:149622669 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9505823 ENSG00000231760.4 RP11-350J20.5 14.49 9.12e-34 3.42e-29 0.87 0.7 Lung cancer; chr6:149628899 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9689599 ENSG00000231760.4 RP11-350J20.5 14.49 9.12e-34 3.42e-29 0.87 0.7 Lung cancer; chr6:149631973 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9800580 ENSG00000231760.4 RP11-350J20.5 14.49 9.12e-34 3.42e-29 0.87 0.7 Lung cancer; chr6:149632845 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs12174716 ENSG00000231760.4 RP11-350J20.5 14.49 9.16e-34 3.43e-29 0.88 0.7 Lung cancer; chr6:149644487 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9505982 ENSG00000231760.4 RP11-350J20.5 14.48 9.86e-34 3.62e-29 0.88 0.7 Lung cancer; chr6:149618465 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9322196 ENSG00000231760.4 RP11-350J20.5 14.48 9.86e-34 3.62e-29 0.88 0.7 Lung cancer; chr6:149619645 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10782310 ENSG00000231760.4 RP11-350J20.5 14.48 9.86e-34 3.62e-29 0.88 0.7 Lung cancer; chr6:149622458 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10782311 ENSG00000231760.4 RP11-350J20.5 14.48 9.86e-34 3.62e-29 0.88 0.7 Lung cancer; chr6:149622592 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10747275 ENSG00000231760.4 RP11-350J20.5 14.48 9.86e-34 3.62e-29 0.88 0.7 Lung cancer; chr6:149622782 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9322200 ENSG00000231760.4 RP11-350J20.5 14.48 9.86e-34 3.62e-29 0.88 0.7 Lung cancer; chr6:149630078 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs9688794 ENSG00000231760.4 RP11-350J20.5 14.48 9.86e-34 3.62e-29 0.88 0.7 Lung cancer; chr6:149632121 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9322204 ENSG00000231760.4 RP11-350J20.5 14.47 1.06e-33 3.88e-29 0.88 0.7 Lung cancer; chr6:149636047 chr6:149796151~149826294:- CESC cis rs9322193 0.847 rs62439808 ENSG00000231760.4 RP11-350J20.5 14.47 1.07e-33 3.9e-29 0.88 0.7 Lung cancer; chr6:149629690 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs11155671 ENSG00000231760.4 RP11-350J20.5 14.46 1.09e-33 3.96e-29 0.88 0.7 Lung cancer; chr6:149650996 chr6:149796151~149826294:- CESC cis rs2882667 0.652 rs700622 ENSG00000253404.1 AC034243.1 -14.45 1.19e-33 4.29e-29 -0.98 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138762862 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs7722965 ENSG00000253404.1 AC034243.1 -14.45 1.19e-33 4.29e-29 -0.98 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138764766 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825677 ENSG00000253404.1 AC034243.1 -14.45 1.19e-33 4.29e-29 -0.98 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138769081 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs1976562 ENSG00000253404.1 AC034243.1 -14.45 1.19e-33 4.29e-29 -0.98 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138774905 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs825759 ENSG00000253404.1 AC034243.1 -14.45 1.19e-33 4.29e-29 -0.98 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138790250 chr5:138744434~138753309:- CESC cis rs4853012 0.838 rs72915068 ENSG00000217702.2 RP11-287D1.4 14.44 1.27e-33 4.55e-29 1.03 0.7 Gestational age at birth (maternal effect); chr2:74129058 chr2:74130583~74135395:+ CESC cis rs9322193 0.923 rs2297930 ENSG00000231760.4 RP11-350J20.5 14.44 1.28e-33 4.6e-29 0.89 0.7 Lung cancer; chr6:149718360 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9478848 ENSG00000231760.4 RP11-350J20.5 14.43 1.39e-33 4.97e-29 0.88 0.7 Lung cancer; chr6:149825080 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9689723 ENSG00000231760.4 RP11-350J20.5 14.43 1.44e-33 5.14e-29 0.88 0.7 Lung cancer; chr6:149655935 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9968911 ENSG00000231760.4 RP11-350J20.5 14.43 1.44e-33 5.14e-29 0.88 0.7 Lung cancer; chr6:149657419 chr6:149796151~149826294:- CESC cis rs2739330 0.791 rs4822458 ENSG00000273295.1 AP000350.5 14.43 1.45e-33 5.16e-29 0.78 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23901432~23907068:- CESC cis rs9322193 0.847 rs12234128 ENSG00000231760.4 RP11-350J20.5 14.41 1.6e-33 5.71e-29 0.88 0.7 Lung cancer; chr6:149627553 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs10078079 ENSG00000253404.1 AC034243.1 14.39 1.86e-33 6.63e-29 0.93 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138920450 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs700619 ENSG00000253404.1 AC034243.1 -14.39 1.93e-33 6.87e-29 -0.99 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138753060 chr5:138744434~138753309:- CESC cis rs9322193 0.962 rs9505974 ENSG00000231760.4 RP11-350J20.5 14.37 2.12e-33 7.43e-29 0.88 0.7 Lung cancer; chr6:149779294 chr6:149796151~149826294:- CESC cis rs9322193 0.926 rs9689036 ENSG00000231760.4 RP11-350J20.5 14.37 2.12e-33 7.43e-29 0.88 0.7 Lung cancer; chr6:149780563 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9322218 ENSG00000231760.4 RP11-350J20.5 14.37 2.12e-33 7.43e-29 0.88 0.7 Lung cancer; chr6:149782183 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9322219 ENSG00000231760.4 RP11-350J20.5 14.37 2.12e-33 7.43e-29 0.88 0.7 Lung cancer; chr6:149782263 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9322223 ENSG00000231760.4 RP11-350J20.5 14.37 2.12e-33 7.43e-29 0.88 0.7 Lung cancer; chr6:149801509 chr6:149796151~149826294:- CESC cis rs2739330 0.76 rs1007888 ENSG00000225282.1 AP000350.6 14.37 2.2e-33 7.72e-29 0.85 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23926900~23929574:+ CESC cis rs9322193 0.923 rs3924871 ENSG00000231760.4 RP11-350J20.5 14.37 2.26e-33 7.91e-29 0.89 0.7 Lung cancer; chr6:149662080 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs13174008 ENSG00000253404.1 AC034243.1 14.36 2.3e-33 8.04e-29 0.87 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138922220 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288028 ENSG00000253404.1 AC034243.1 14.36 2.38e-33 8.33e-29 0.92 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138886300 chr5:138744434~138753309:- CESC cis rs858239 0.509 rs57611130 ENSG00000230658.1 KLHL7-AS1 14.34 2.64e-33 9.2e-29 0.88 0.7 Cerebrospinal fluid biomarker levels; chr7:23144933 chr7:23101228~23105703:- CESC cis rs9322193 0.886 rs9718079 ENSG00000231760.4 RP11-350J20.5 14.33 2.91e-33 1.01e-28 0.88 0.7 Lung cancer; chr6:149645947 chr6:149796151~149826294:- CESC cis rs916888 0.773 rs199443 ENSG00000214401.4 KANSL1-AS1 14.33 2.98e-33 1.03e-28 1.02 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46193576~46196723:+ CESC cis rs9322193 0.962 rs6903998 ENSG00000231760.4 RP11-350J20.5 14.33 2.98e-33 1.04e-28 0.88 0.7 Lung cancer; chr6:149831357 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs1984111 ENSG00000231760.4 RP11-350J20.5 14.33 2.98e-33 1.04e-28 0.88 0.7 Lung cancer; chr6:149831720 chr6:149796151~149826294:- CESC cis rs4853012 0.838 rs12619982 ENSG00000217702.2 RP11-287D1.4 14.33 3e-33 1.04e-28 1.04 0.7 Gestational age at birth (maternal effect); chr2:74128895 chr2:74130583~74135395:+ CESC cis rs9322193 0.962 rs3763163 ENSG00000231760.4 RP11-350J20.5 14.32 3.18e-33 1.1e-28 0.88 0.7 Lung cancer; chr6:149819770 chr6:149796151~149826294:- CESC cis rs916888 0.773 rs199533 ENSG00000214401.4 KANSL1-AS1 14.31 3.34e-33 1.15e-28 1.02 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46193576~46196723:+ CESC cis rs858239 0.67 rs6967526 ENSG00000230658.1 KLHL7-AS1 14.31 3.38e-33 1.17e-28 0.85 0.7 Cerebrospinal fluid biomarker levels; chr7:23119622 chr7:23101228~23105703:- CESC cis rs4853012 0.838 rs60705299 ENSG00000217702.2 RP11-287D1.4 14.31 3.46e-33 1.19e-28 0.99 0.7 Gestational age at birth (maternal effect); chr2:74118243 chr2:74130583~74135395:+ CESC cis rs9322193 0.923 rs2185352 ENSG00000231760.4 RP11-350J20.5 14.31 3.52e-33 1.21e-28 0.89 0.7 Lung cancer; chr6:149714640 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs6890932 ENSG00000253404.1 AC034243.1 14.31 3.54e-33 1.21e-28 0.88 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138910639 chr5:138744434~138753309:- CESC cis rs4853012 0.838 rs6715351 ENSG00000217702.2 RP11-287D1.4 14.31 3.54e-33 1.21e-28 0.99 0.7 Gestational age at birth (maternal effect); chr2:74118992 chr2:74130583~74135395:+ CESC cis rs4853012 0.838 rs61521879 ENSG00000217702.2 RP11-287D1.4 14.31 3.54e-33 1.21e-28 0.99 0.7 Gestational age at birth (maternal effect); chr2:74119081 chr2:74130583~74135395:+ CESC cis rs9322193 0.923 rs11155677 ENSG00000231760.4 RP11-350J20.5 14.3 3.7e-33 1.26e-28 0.9 0.7 Lung cancer; chr6:149756953 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs9480009 ENSG00000231760.4 RP11-350J20.5 14.3 3.7e-33 1.26e-28 0.9 0.7 Lung cancer; chr6:149758502 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9480031 ENSG00000231760.4 RP11-350J20.5 14.3 3.7e-33 1.26e-28 0.9 0.7 Lung cancer; chr6:149758875 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10872649 ENSG00000231760.4 RP11-350J20.5 14.3 3.7e-33 1.26e-28 0.9 0.7 Lung cancer; chr6:149759454 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9322209 ENSG00000231760.4 RP11-350J20.5 14.29 3.86e-33 1.31e-28 0.89 0.7 Lung cancer; chr6:149691226 chr6:149796151~149826294:- CESC cis rs9322193 0.887 rs3777949 ENSG00000231760.4 RP11-350J20.5 14.29 3.87e-33 1.31e-28 0.87 0.7 Lung cancer; chr6:149596021 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10782316 ENSG00000231760.4 RP11-350J20.5 14.29 4e-33 1.35e-28 0.9 0.7 Lung cancer; chr6:149752755 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs5760108 ENSG00000225282.1 AP000350.6 14.26 4.87e-33 1.64e-28 0.82 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23926900~23929574:+ CESC cis rs916888 0.773 rs199445 ENSG00000214401.4 KANSL1-AS1 14.26 4.94e-33 1.66e-28 1.02 0.69 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46193576~46196723:+ CESC cis rs62445005 1 rs62445005 ENSG00000211697.3 TRGV5 14.26 5.07e-33 1.7e-28 0.81 0.69 Shingles; chr7:38346957 chr7:38343894~38350022:- CESC cis rs9322193 0.962 rs9397022 ENSG00000231760.4 RP11-350J20.5 14.25 5.17e-33 1.73e-28 0.88 0.69 Lung cancer; chr6:149812052 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9397357 ENSG00000231760.4 RP11-350J20.5 14.25 5.17e-33 1.73e-28 0.88 0.69 Lung cancer; chr6:149812465 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs5751770 ENSG00000225282.1 AP000350.6 14.25 5.18e-33 1.73e-28 0.82 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23926900~23929574:+ CESC cis rs9322193 0.923 rs9688861 ENSG00000231760.4 RP11-350J20.5 14.25 5.3e-33 1.77e-28 0.87 0.69 Lung cancer; chr6:149637924 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs7740278 ENSG00000231760.4 RP11-350J20.5 14.25 5.3e-33 1.77e-28 0.87 0.69 Lung cancer; chr6:149640116 chr6:149796151~149826294:- CESC cis rs4853012 0.838 rs59570457 ENSG00000217702.2 RP11-287D1.4 14.24 5.85e-33 1.94e-28 0.99 0.69 Gestational age at birth (maternal effect); chr2:74117155 chr2:74130583~74135395:+ CESC cis rs858239 0.636 rs28706766 ENSG00000230658.1 KLHL7-AS1 14.24 5.93e-33 1.97e-28 0.85 0.69 Cerebrospinal fluid biomarker levels; chr7:23130215 chr7:23101228~23105703:- CESC cis rs9322193 0.886 rs9322198 ENSG00000231760.4 RP11-350J20.5 14.23 6.18e-33 2.04e-28 0.87 0.69 Lung cancer; chr6:149623772 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs11155669 ENSG00000231760.4 RP11-350J20.5 14.23 6.18e-33 2.04e-28 0.87 0.69 Lung cancer; chr6:149633501 chr6:149796151~149826294:- CESC cis rs9322193 0.887 rs9505824 ENSG00000231760.4 RP11-350J20.5 14.23 6.18e-33 2.04e-28 0.87 0.69 Lung cancer; chr6:149633663 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9505826 ENSG00000231760.4 RP11-350J20.5 14.23 6.18e-33 2.04e-28 0.87 0.69 Lung cancer; chr6:149633912 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9766886 ENSG00000231760.4 RP11-350J20.5 14.23 6.18e-33 2.04e-28 0.87 0.69 Lung cancer; chr6:149637048 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs57012784 ENSG00000231760.4 RP11-350J20.5 14.23 6.19e-33 2.04e-28 0.87 0.69 Lung cancer; chr6:149627691 chr6:149796151~149826294:- CESC cis rs916888 0.773 rs199447 ENSG00000214401.4 KANSL1-AS1 14.22 6.46e-33 2.13e-28 1.02 0.69 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46193576~46196723:+ CESC cis rs2882667 0.69 rs11750163 ENSG00000253404.1 AC034243.1 14.22 6.75e-33 2.22e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138705920 chr5:138744434~138753309:- CESC cis rs2739330 0.685 rs4822453 ENSG00000273295.1 AP000350.5 14.21 7.07e-33 2.32e-28 0.78 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23901432~23907068:- CESC cis rs9322193 0.923 rs3798761 ENSG00000231760.4 RP11-350J20.5 14.2 7.65e-33 2.5e-28 0.88 0.69 Lung cancer; chr6:149683643 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs288007 ENSG00000253404.1 AC034243.1 14.19 8.14e-33 2.66e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138894939 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288026 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138886905 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288024 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138888103 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288009 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138892973 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs185956 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138894574 chr5:138744434~138753309:- CESC cis rs2882667 0.658 rs288003 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138896266 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288002 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138896398 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs10044401 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138901868 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs10067361 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138905185 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs12186373 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138912885 chr5:138744434~138753309:- CESC cis rs2882667 0.628 rs10076629 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138920272 chr5:138744434~138753309:- CESC cis rs2882667 0.659 rs11750067 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138920589 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs10054682 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138923754 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs11953339 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138923853 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs9327828 ENSG00000253404.1 AC034243.1 14.18 9.11e-33 2.92e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138925859 chr5:138744434~138753309:- CESC cis rs4853012 0.838 rs6707729 ENSG00000217702.2 RP11-287D1.4 14.17 9.4e-33 3.01e-28 0.98 0.69 Gestational age at birth (maternal effect); chr2:74117558 chr2:74130583~74135395:+ CESC cis rs9322193 0.961 rs2064520 ENSG00000231760.4 RP11-350J20.5 14.17 9.57e-33 3.06e-28 0.87 0.69 Lung cancer; chr6:149603650 chr6:149796151~149826294:- CESC cis rs2882667 0.628 rs311605 ENSG00000253404.1 AC034243.1 14.17 9.67e-33 3.08e-28 0.95 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138710150 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs288021 ENSG00000253404.1 AC034243.1 14.16 1.04e-32 3.32e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138888594 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs311608 ENSG00000253404.1 AC034243.1 14.16 1.04e-32 3.32e-28 0.94 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138708000 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs9766004 ENSG00000231760.4 RP11-350J20.5 14.15 1.13e-32 3.57e-28 0.89 0.69 Lung cancer; chr6:149754363 chr6:149796151~149826294:- CESC cis rs2882667 0.659 rs10056014 ENSG00000253404.1 AC034243.1 14.14 1.16e-32 3.68e-28 0.87 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138920329 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs13158360 ENSG00000253404.1 AC034243.1 14.14 1.16e-32 3.68e-28 0.87 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138922488 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs10463975 ENSG00000253404.1 AC034243.1 14.14 1.18e-32 3.72e-28 0.92 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138927560 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs825760 ENSG00000253404.1 AC034243.1 -14.14 1.19e-32 3.75e-28 -0.96 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138804285 chr5:138744434~138753309:- CESC cis rs2739330 0.828 rs2154593 ENSG00000225282.1 AP000350.6 14.12 1.38e-32 4.35e-28 0.83 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23926900~23929574:+ CESC cis rs4853012 0.838 rs72911122 ENSG00000217702.2 RP11-287D1.4 14.1 1.66e-32 5.22e-28 0.98 0.69 Gestational age at birth (maternal effect); chr2:74116992 chr2:74130583~74135395:+ CESC cis rs4853012 0.838 rs4452177 ENSG00000217702.2 RP11-287D1.4 14.1 1.68e-32 5.26e-28 0.98 0.69 Gestational age at birth (maternal effect); chr2:74118079 chr2:74130583~74135395:+ CESC cis rs858239 0.539 rs4559148 ENSG00000230658.1 KLHL7-AS1 14.09 1.76e-32 5.5e-28 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23146348 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs6975852 ENSG00000230658.1 KLHL7-AS1 14.09 1.76e-32 5.5e-28 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23147035 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs10247268 ENSG00000230658.1 KLHL7-AS1 14.09 1.76e-32 5.5e-28 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23147560 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs6461694 ENSG00000230658.1 KLHL7-AS1 14.09 1.76e-32 5.5e-28 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23148160 chr7:23101228~23105703:- CESC cis rs858239 0.508 rs7805071 ENSG00000230658.1 KLHL7-AS1 14.09 1.76e-32 5.5e-28 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23150593 chr7:23101228~23105703:- CESC cis rs858239 0.508 rs7805085 ENSG00000230658.1 KLHL7-AS1 14.09 1.76e-32 5.5e-28 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23150624 chr7:23101228~23105703:- CESC cis rs2739330 0.731 rs2000468 ENSG00000225282.1 AP000350.6 14.08 1.92e-32 5.97e-28 0.83 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23926900~23929574:+ CESC cis rs9322193 0.923 rs1572229 ENSG00000231760.4 RP11-350J20.5 14.07 2.03e-32 6.3e-28 0.9 0.69 Lung cancer; chr6:149743841 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs10872646 ENSG00000231760.4 RP11-350J20.5 14.05 2.28e-32 7.07e-28 0.89 0.69 Lung cancer; chr6:149746539 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs12528279 ENSG00000231760.4 RP11-350J20.5 14.05 2.28e-32 7.07e-28 0.89 0.69 Lung cancer; chr6:149750892 chr6:149796151~149826294:- CESC cis rs9322193 0.809 rs9479808 ENSG00000231760.4 RP11-350J20.5 14.05 2.28e-32 7.07e-28 0.89 0.69 Lung cancer; chr6:149751328 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10872644 ENSG00000231760.4 RP11-350J20.5 14.05 2.34e-32 7.24e-28 0.89 0.69 Lung cancer; chr6:149741819 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs1889473 ENSG00000231760.4 RP11-350J20.5 14.03 2.67e-32 8.23e-28 0.87 0.69 Lung cancer; chr6:149825485 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9688517 ENSG00000231760.4 RP11-350J20.5 13.99 3.59e-32 1.1e-27 0.89 0.69 Lung cancer; chr6:149740655 chr6:149796151~149826294:- CESC cis rs916888 0.773 rs9896243 ENSG00000262539.1 RP11-259G18.3 13.99 3.78e-32 1.16e-27 1 0.69 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:46259551~46260606:- CESC cis rs9322193 0.923 rs9800806 ENSG00000231760.4 RP11-350J20.5 13.98 3.87e-32 1.19e-27 0.89 0.69 Lung cancer; chr6:149740350 chr6:149796151~149826294:- CESC cis rs2882667 0.69 rs311601 ENSG00000253404.1 AC034243.1 13.98 3.94e-32 1.2e-27 0.99 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138717697 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs11155674 ENSG00000231760.4 RP11-350J20.5 13.97 4.28e-32 1.3e-27 0.87 0.69 Lung cancer; chr6:149711111 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs12174349 ENSG00000231760.4 RP11-350J20.5 13.97 4.28e-32 1.3e-27 0.87 0.69 Lung cancer; chr6:149718012 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs2297932 ENSG00000231760.4 RP11-350J20.5 13.97 4.28e-32 1.3e-27 0.87 0.69 Lung cancer; chr6:149718225 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs2297928 ENSG00000231760.4 RP11-350J20.5 13.97 4.28e-32 1.3e-27 0.87 0.69 Lung cancer; chr6:149718584 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9479094 ENSG00000231760.4 RP11-350J20.5 13.97 4.28e-32 1.3e-27 0.87 0.69 Lung cancer; chr6:149725083 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10872650 ENSG00000231760.4 RP11-350J20.5 13.94 5.38e-32 1.63e-27 0.89 0.69 Lung cancer; chr6:149760959 chr6:149796151~149826294:- CESC cis rs858239 0.601 rs2141307 ENSG00000230658.1 KLHL7-AS1 13.93 5.71e-32 1.73e-27 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23151805 chr7:23101228~23105703:- CESC cis rs2739330 0.753 rs4822452 ENSG00000225282.1 AP000350.6 13.93 5.74e-32 1.74e-27 0.81 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23926900~23929574:+ CESC cis rs4853012 0.793 rs6723185 ENSG00000217702.2 RP11-287D1.4 13.93 5.85e-32 1.77e-27 0.98 0.69 Gestational age at birth (maternal effect); chr2:74117757 chr2:74130583~74135395:+ CESC cis rs2882667 0.654 rs7709770 ENSG00000253404.1 AC034243.1 -13.92 6.12e-32 1.84e-27 -0.95 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138813650 chr5:138744434~138753309:- CESC cis rs2882667 0.622 rs34645817 ENSG00000253404.1 AC034243.1 -13.92 6.12e-32 1.84e-27 -0.95 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138816944 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs7736925 ENSG00000253404.1 AC034243.1 -13.92 6.12e-32 1.84e-27 -0.95 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138818841 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs883333 ENSG00000253404.1 AC034243.1 -13.92 6.12e-32 1.84e-27 -0.95 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138819781 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs9479494 ENSG00000231760.4 RP11-350J20.5 13.91 6.85e-32 2.06e-27 0.88 0.69 Lung cancer; chr6:149739108 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs2877178 ENSG00000225282.1 AP000350.6 13.9 7.18e-32 2.15e-27 0.83 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23926900~23929574:+ CESC cis rs858239 0.699 rs858260 ENSG00000230658.1 KLHL7-AS1 13.88 8.01e-32 2.4e-27 0.91 0.69 Cerebrospinal fluid biomarker levels; chr7:23173315 chr7:23101228~23105703:- CESC cis rs9322193 0.884 rs9322210 ENSG00000231760.4 RP11-350J20.5 13.88 8.51e-32 2.54e-27 0.87 0.68 Lung cancer; chr6:149695440 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9689716 ENSG00000231760.4 RP11-350J20.5 13.87 9.18e-32 2.73e-27 0.85 0.68 Lung cancer; chr6:149655662 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9322207 ENSG00000231760.4 RP11-350J20.5 13.87 9.18e-32 2.73e-27 0.85 0.68 Lung cancer; chr6:149657185 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9322208 ENSG00000231760.4 RP11-350J20.5 13.87 9.18e-32 2.73e-27 0.85 0.68 Lung cancer; chr6:149658547 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs2342765 ENSG00000231760.4 RP11-350J20.5 13.86 9.29e-32 2.76e-27 0.89 0.68 Lung cancer; chr6:149858873 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs7767622 ENSG00000231760.4 RP11-350J20.5 13.86 9.31e-32 2.76e-27 0.87 0.68 Lung cancer; chr6:149681766 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs4421206 ENSG00000231760.4 RP11-350J20.5 13.86 9.31e-32 2.76e-27 0.87 0.68 Lung cancer; chr6:149682891 chr6:149796151~149826294:- CESC cis rs4853012 0.941 rs60291089 ENSG00000217702.2 RP11-287D1.4 13.86 9.74e-32 2.88e-27 0.97 0.68 Gestational age at birth (maternal effect); chr2:74117763 chr2:74130583~74135395:+ CESC cis rs4853012 0.838 rs58759652 ENSG00000217702.2 RP11-287D1.4 13.86 9.74e-32 2.88e-27 0.97 0.68 Gestational age at birth (maternal effect); chr2:74117775 chr2:74130583~74135395:+ CESC cis rs858239 0.669 rs1990365 ENSG00000230658.1 KLHL7-AS1 13.85 1.01e-31 2.97e-27 0.84 0.68 Cerebrospinal fluid biomarker levels; chr7:23076347 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs10071381 ENSG00000253404.1 AC034243.1 13.83 1.22e-31 3.59e-27 0.92 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138937159 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs3763016 ENSG00000253404.1 AC034243.1 13.81 1.37e-31 4.01e-27 0.89 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138935043 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs9942422 ENSG00000253404.1 AC034243.1 13.81 1.38e-31 4.06e-27 0.92 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138936847 chr5:138744434~138753309:- CESC cis rs858239 0.539 rs10254544 ENSG00000230658.1 KLHL7-AS1 13.8 1.47e-31 4.3e-27 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23180616 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs4835703 ENSG00000253404.1 AC034243.1 -13.78 1.69e-31 4.92e-27 -0.95 -0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138815048 chr5:138744434~138753309:- CESC cis rs2882667 0.654 rs4835704 ENSG00000253404.1 AC034243.1 -13.78 1.69e-31 4.92e-27 -0.95 -0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138815636 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs6596453 ENSG00000253404.1 AC034243.1 -13.78 1.69e-31 4.92e-27 -0.95 -0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138816202 chr5:138744434~138753309:- CESC cis rs858239 0.539 rs4377861 ENSG00000230658.1 KLHL7-AS1 13.77 1.83e-31 5.34e-27 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23146350 chr7:23101228~23105703:- CESC cis rs858239 0.508 rs2390754 ENSG00000230658.1 KLHL7-AS1 13.77 1.89e-31 5.49e-27 0.89 0.68 Cerebrospinal fluid biomarker levels; chr7:23150875 chr7:23101228~23105703:- CESC cis rs2739330 0.828 rs5760107 ENSG00000225282.1 AP000350.6 13.76 1.96e-31 5.71e-27 0.81 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23926900~23929574:+ CESC cis rs2739330 0.789 rs5760109 ENSG00000225282.1 AP000350.6 13.76 1.96e-31 5.71e-27 0.81 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23926900~23929574:+ CESC cis rs858239 0.665 rs6964665 ENSG00000230658.1 KLHL7-AS1 13.76 1.98e-31 5.74e-27 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23171733 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs7709789 ENSG00000253404.1 AC034243.1 13.74 2.3e-31 6.64e-27 0.92 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138938762 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs10155636 ENSG00000253404.1 AC034243.1 13.73 2.42e-31 7e-27 0.89 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138926301 chr5:138744434~138753309:- CESC cis rs858239 0.67 rs3807452 ENSG00000230658.1 KLHL7-AS1 -13.73 2.56e-31 7.39e-27 -0.82 -0.68 Cerebrospinal fluid biomarker levels; chr7:23122462 chr7:23101228~23105703:- CESC cis rs2739330 0.828 rs2186366 ENSG00000225282.1 AP000350.6 -13.69 3.49e-31 1e-26 -0.8 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23926900~23929574:+ CESC cis rs858239 0.537 rs2286272 ENSG00000230658.1 KLHL7-AS1 13.67 3.85e-31 1.1e-26 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23184748 chr7:23101228~23105703:- CESC cis rs858239 0.537 rs6955115 ENSG00000230658.1 KLHL7-AS1 13.67 3.85e-31 1.1e-26 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23187525 chr7:23101228~23105703:- CESC cis rs858239 0.537 rs10279691 ENSG00000230658.1 KLHL7-AS1 13.67 3.85e-31 1.1e-26 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23188768 chr7:23101228~23105703:- CESC cis rs858239 0.539 rs2390757 ENSG00000230658.1 KLHL7-AS1 13.66 4.26e-31 1.21e-26 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23151873 chr7:23101228~23105703:- CESC cis rs2882667 0.654 rs6862845 ENSG00000253404.1 AC034243.1 13.65 4.55e-31 1.3e-26 0.88 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138937456 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs9478291 ENSG00000231760.4 RP11-350J20.5 13.65 4.68e-31 1.33e-26 0.88 0.68 Lung cancer; chr6:149729434 chr6:149796151~149826294:- CESC cis rs2739330 0.76 rs5760095 ENSG00000273295.1 AP000350.5 13.65 4.7e-31 1.33e-26 0.78 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23901432~23907068:- CESC cis rs858239 0.539 rs2103281 ENSG00000230658.1 KLHL7-AS1 13.62 5.64e-31 1.6e-26 0.9 0.68 Cerebrospinal fluid biomarker levels; chr7:23154612 chr7:23101228~23105703:- CESC cis rs916888 0.61 rs199529 ENSG00000262539.1 RP11-259G18.3 13.59 7.12e-31 2.01e-26 0.92 0.68 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:46259551~46260606:- CESC cis rs2882667 0.69 rs9327831 ENSG00000253404.1 AC034243.1 13.58 7.42e-31 2.09e-26 0.88 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138936597 chr5:138744434~138753309:- CESC cis rs2739330 0.828 rs4822454 ENSG00000225282.1 AP000350.6 13.58 7.53e-31 2.12e-26 0.81 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23926900~23929574:+ CESC cis rs9322193 0.924 rs9322189 ENSG00000231760.4 RP11-350J20.5 13.56 8.62e-31 2.41e-26 0.87 0.68 Lung cancer; chr6:149588797 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs2330635 ENSG00000273295.1 AP000350.5 13.54 1.01e-30 2.83e-26 0.77 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23901432~23907068:- CESC cis rs2882667 0.69 rs825747 ENSG00000253404.1 AC034243.1 -13.54 1.04e-30 2.9e-26 -0.96 -0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138800896 chr5:138744434~138753309:- CESC cis rs858239 0.539 rs6461695 ENSG00000230658.1 KLHL7-AS1 13.51 1.26e-30 3.49e-26 0.89 0.68 Cerebrospinal fluid biomarker levels; chr7:23158165 chr7:23101228~23105703:- CESC cis rs858239 0.568 rs6970694 ENSG00000230658.1 KLHL7-AS1 13.5 1.33e-30 3.69e-26 0.9 0.67 Cerebrospinal fluid biomarker levels; chr7:23211209 chr7:23101228~23105703:- CESC cis rs1577917 0.56 rs9450288 ENSG00000203875.9 SNHG5 13.5 1.34e-30 3.71e-26 0.73 0.67 Response to antipsychotic treatment; chr6:85511868 chr6:85660950~85678736:- CESC cis rs858239 0.669 rs10950940 ENSG00000230658.1 KLHL7-AS1 -13.5 1.4e-30 3.88e-26 -0.85 -0.67 Cerebrospinal fluid biomarker levels; chr7:23157197 chr7:23101228~23105703:- CESC cis rs916888 0.697 rs199516 ENSG00000214401.4 KANSL1-AS1 -13.46 1.78e-30 4.9e-26 -0.98 -0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46193576~46196723:+ CESC cis rs2739330 0.731 rs4822450 ENSG00000218537.1 MIF-AS1 13.44 2.11e-30 5.77e-26 0.88 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23894426~23898930:- CESC cis rs2739330 0.828 rs4820572 ENSG00000273295.1 AP000350.5 13.44 2.12e-30 5.79e-26 0.77 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23901432~23907068:- CESC cis rs2739330 0.796 rs2154594 ENSG00000273295.1 AP000350.5 -13.4 2.88e-30 7.81e-26 -0.76 -0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23901432~23907068:- CESC cis rs2739330 0.796 rs1006771 ENSG00000273295.1 AP000350.5 13.38 3.46e-30 9.33e-26 0.72 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23901432~23907068:- CESC cis rs4853012 0.838 rs4429500 ENSG00000217702.2 RP11-287D1.4 13.37 3.57e-30 9.57e-26 0.97 0.67 Gestational age at birth (maternal effect); chr2:74118209 chr2:74130583~74135395:+ CESC cis rs4853012 0.793 rs6707619 ENSG00000217702.2 RP11-287D1.4 13.37 3.61e-30 9.62e-26 0.96 0.67 Gestational age at birth (maternal effect); chr2:74117529 chr2:74130583~74135395:+ CESC cis rs2882667 0.728 rs10068766 ENSG00000253404.1 AC034243.1 13.33 4.81e-30 1.27e-25 0.89 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138941095 chr5:138744434~138753309:- CESC cis rs2739330 0.731 rs2000468 ENSG00000218537.1 MIF-AS1 13.31 5.55e-30 1.47e-25 0.86 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23894426~23898930:- CESC cis rs2739330 0.76 rs5751760 ENSG00000225282.1 AP000350.6 13.31 5.69e-30 1.5e-25 0.81 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23926900~23929574:+ CESC cis rs9322193 0.923 rs62441284 ENSG00000231760.4 RP11-350J20.5 13.3 5.86e-30 1.55e-25 0.87 0.67 Lung cancer; chr6:149751542 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs2330635 ENSG00000225282.1 AP000350.6 13.29 6.26e-30 1.65e-25 0.82 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23926900~23929574:+ CESC cis rs2882667 0.69 rs9327830 ENSG00000253404.1 AC034243.1 13.25 8.5e-30 2.23e-25 0.88 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138936560 chr5:138744434~138753309:- CESC cis rs916888 0.821 rs70600 ENSG00000214401.4 KANSL1-AS1 13.24 9.3e-30 2.43e-25 1.01 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46193576~46196723:+ CESC cis rs2739330 0.828 rs5751770 ENSG00000218537.1 MIF-AS1 13.23 9.95e-30 2.6e-25 0.84 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23894426~23898930:- CESC cis rs2882667 0.658 rs10076442 ENSG00000253404.1 AC034243.1 13.21 1.15e-29 2.92e-25 0.86 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138941090 chr5:138744434~138753309:- CESC cis rs9322193 0.887 rs3734295 ENSG00000231760.4 RP11-350J20.5 13.19 1.36e-29 3.44e-25 0.84 0.67 Lung cancer; chr6:149593917 chr6:149796151~149826294:- CESC cis rs9322193 0.851 rs9322194 ENSG00000231760.4 RP11-350J20.5 13.19 1.36e-29 3.44e-25 0.84 0.67 Lung cancer; chr6:149599113 chr6:149796151~149826294:- CESC cis rs9326248 1 rs9326248 ENSG00000254851.1 RP11-109L13.1 -13.18 1.43e-29 3.61e-25 -0.88 -0.67 Blood protein levels; chr11:117128509 chr11:117135528~117138582:+ CESC cis rs858239 0.669 rs1618339 ENSG00000230658.1 KLHL7-AS1 13.16 1.65e-29 4.15e-25 0.82 0.67 Cerebrospinal fluid biomarker levels; chr7:23190155 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs10045605 ENSG00000253404.1 AC034243.1 13.15 1.78e-29 4.47e-25 0.91 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138936458 chr5:138744434~138753309:- CESC cis rs2739330 0.76 rs1002286 ENSG00000225282.1 AP000350.6 -13.14 1.96e-29 4.91e-25 -0.8 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23926900~23929574:+ CESC cis rs2739330 0.796 rs2154594 ENSG00000225282.1 AP000350.6 -13.1 2.62e-29 6.54e-25 -0.81 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23926900~23929574:+ CESC cis rs2739330 0.796 rs5760106 ENSG00000273295.1 AP000350.5 -13.09 2.94e-29 7.3e-25 -0.75 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23901432~23907068:- CESC cis rs2739330 0.685 rs4822453 ENSG00000225282.1 AP000350.6 13.08 2.95e-29 7.32e-25 0.8 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23926900~23929574:+ CESC cis rs4853012 0.941 rs78128123 ENSG00000217702.2 RP11-287D1.4 13.08 3.03e-29 7.53e-25 1.04 0.66 Gestational age at birth (maternal effect); chr2:74120398 chr2:74130583~74135395:+ CESC cis rs1930961 1 rs5996946 ENSG00000272977.1 CTA-390C10.10 -12.99 6.02e-29 1.48e-24 -0.98 -0.66 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25476218~25479971:+ CESC cis rs858239 0.508 rs10242104 ENSG00000230658.1 KLHL7-AS1 12.98 6.37e-29 1.56e-24 0.88 0.66 Cerebrospinal fluid biomarker levels; chr7:23180831 chr7:23101228~23105703:- CESC cis rs2882667 0.69 rs11954103 ENSG00000253404.1 AC034243.1 12.93 9.15e-29 2.24e-24 0.9 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138933459 chr5:138744434~138753309:- CESC cis rs2739330 0.791 rs9612520 ENSG00000225282.1 AP000350.6 12.92 9.9e-29 2.41e-24 0.79 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23926900~23929574:+ CESC cis rs916888 0.821 rs199505 ENSG00000214401.4 KANSL1-AS1 -12.92 1e-28 2.45e-24 -0.96 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46193576~46196723:+ CESC cis rs916888 0.821 rs70602 ENSG00000214401.4 KANSL1-AS1 -12.92 1e-28 2.45e-24 -0.96 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46193576~46196723:+ CESC cis rs2739330 0.703 rs5760112 ENSG00000225282.1 AP000350.6 12.89 1.27e-28 3.08e-24 0.8 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23926900~23929574:+ CESC cis rs2739330 0.828 rs4820572 ENSG00000225282.1 AP000350.6 12.88 1.38e-28 3.34e-24 0.8 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23926900~23929574:+ CESC cis rs2739330 0.627 rs9608219 ENSG00000225282.1 AP000350.6 12.85 1.67e-28 4.04e-24 0.79 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23926900~23929574:+ CESC cis rs9322193 0.884 rs2064521 ENSG00000231760.4 RP11-350J20.5 -12.85 1.71e-28 4.14e-24 -0.85 -0.66 Lung cancer; chr6:149625336 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs5760108 ENSG00000218537.1 MIF-AS1 12.84 1.84e-28 4.43e-24 0.83 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23894426~23898930:- CESC cis rs2739330 0.753 rs4822452 ENSG00000218537.1 MIF-AS1 12.82 2e-28 4.8e-24 0.82 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23894426~23898930:- CESC cis rs916888 0.821 rs199512 ENSG00000214401.4 KANSL1-AS1 -12.81 2.2e-28 5.21e-24 -0.96 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46193576~46196723:+ CESC cis rs916888 0.821 rs199509 ENSG00000214401.4 KANSL1-AS1 -12.81 2.2e-28 5.21e-24 -0.96 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46193576~46196723:+ CESC cis rs916888 0.821 rs199507 ENSG00000214401.4 KANSL1-AS1 -12.81 2.2e-28 5.21e-24 -0.96 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46193576~46196723:+ CESC cis rs858239 0.537 rs6942981 ENSG00000230658.1 KLHL7-AS1 12.8 2.41e-28 5.7e-24 0.87 0.66 Cerebrospinal fluid biomarker levels; chr7:23191929 chr7:23101228~23105703:- CESC cis rs916888 0.821 rs199514 ENSG00000214401.4 KANSL1-AS1 -12.79 2.53e-28 5.98e-24 -0.98 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46193576~46196723:+ CESC cis rs916888 0.821 rs199506 ENSG00000214401.4 KANSL1-AS1 -12.78 2.85e-28 6.7e-24 -0.96 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46193576~46196723:+ CESC cis rs9322193 0.651 rs9322188 ENSG00000231760.4 RP11-350J20.5 -12.76 3.12e-28 7.32e-24 -0.83 -0.65 Lung cancer; chr6:149588355 chr6:149796151~149826294:- CESC cis rs916888 0.821 rs199504 ENSG00000214401.4 KANSL1-AS1 -12.76 3.12e-28 7.32e-24 -0.96 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46193576~46196723:+ CESC cis rs1577917 0.74 rs7771612 ENSG00000203875.9 SNHG5 12.76 3.14e-28 7.35e-24 0.71 0.65 Response to antipsychotic treatment; chr6:85554656 chr6:85660950~85678736:- CESC cis rs4853012 1 rs2280643 ENSG00000217702.2 RP11-287D1.4 12.76 3.15e-28 7.37e-24 0.96 0.65 Gestational age at birth (maternal effect); chr2:74131159 chr2:74130583~74135395:+ CESC cis rs4853012 0.887 rs2280644 ENSG00000217702.2 RP11-287D1.4 12.76 3.15e-28 7.37e-24 0.96 0.65 Gestational age at birth (maternal effect); chr2:74131284 chr2:74130583~74135395:+ CESC cis rs1577917 0.74 rs9344533 ENSG00000203875.9 SNHG5 12.75 3.36e-28 7.83e-24 0.71 0.65 Response to antipsychotic treatment; chr6:85526470 chr6:85660950~85678736:- CESC cis rs1577917 0.74 rs9353320 ENSG00000203875.9 SNHG5 12.75 3.36e-28 7.83e-24 0.71 0.65 Response to antipsychotic treatment; chr6:85535130 chr6:85660950~85678736:- CESC cis rs1577917 0.74 rs7775864 ENSG00000203875.9 SNHG5 12.75 3.36e-28 7.83e-24 0.71 0.65 Response to antipsychotic treatment; chr6:85538041 chr6:85660950~85678736:- CESC cis rs2882667 0.654 rs10044432 ENSG00000253404.1 AC034243.1 12.75 3.4e-28 7.91e-24 0.92 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138939207 chr5:138744434~138753309:- CESC cis rs2882667 0.69 rs17031 ENSG00000253404.1 AC034243.1 12.75 3.57e-28 8.29e-24 0.85 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138934853 chr5:138744434~138753309:- CESC cis rs1577917 0.74 rs9353327 ENSG00000203875.9 SNHG5 -12.75 3.59e-28 8.34e-24 -0.72 -0.65 Response to antipsychotic treatment; chr6:85684348 chr6:85660950~85678736:- CESC cis rs9322193 0.886 rs4870055 ENSG00000231760.4 RP11-350J20.5 12.71 4.68e-28 1.08e-23 0.89 0.65 Lung cancer; chr6:149848433 chr6:149796151~149826294:- CESC cis rs4853012 0.838 rs2177707 ENSG00000217702.2 RP11-287D1.4 12.71 4.8e-28 1.11e-23 0.99 0.65 Gestational age at birth (maternal effect); chr2:74129723 chr2:74130583~74135395:+ CESC cis rs4853012 0.887 rs2280642 ENSG00000217702.2 RP11-287D1.4 12.71 4.8e-28 1.11e-23 0.99 0.65 Gestational age at birth (maternal effect); chr2:74131125 chr2:74130583~74135395:+ CESC cis rs858239 0.601 rs6461702 ENSG00000230658.1 KLHL7-AS1 12.68 5.92e-28 1.36e-23 0.87 0.65 Cerebrospinal fluid biomarker levels; chr7:23209654 chr7:23101228~23105703:- CESC cis rs9322193 0.923 rs9800736 ENSG00000231760.4 RP11-350J20.5 12.67 6.1e-28 1.4e-23 0.83 0.65 Lung cancer; chr6:149661281 chr6:149796151~149826294:- CESC cis rs2739330 0.796 rs5760106 ENSG00000225282.1 AP000350.6 -12.67 6.23e-28 1.43e-23 -0.79 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23926900~23929574:+ CESC cis rs858239 0.539 rs10270695 ENSG00000230658.1 KLHL7-AS1 -12.66 6.57e-28 1.5e-23 -0.85 -0.65 Cerebrospinal fluid biomarker levels; chr7:23149369 chr7:23101228~23105703:- CESC cis rs2739330 0.76 rs1007888 ENSG00000218537.1 MIF-AS1 12.66 6.62e-28 1.51e-23 0.85 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23894426~23898930:- CESC cis rs858239 0.669 rs6461688 ENSG00000230658.1 KLHL7-AS1 12.65 7.44e-28 1.69e-23 0.82 0.65 Cerebrospinal fluid biomarker levels; chr7:23076996 chr7:23101228~23105703:- CESC cis rs2882667 0.628 rs13173618 ENSG00000253404.1 AC034243.1 12.64 7.68e-28 1.74e-23 0.98 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138804091 chr5:138744434~138753309:- CESC cis rs2739330 0.627 rs9608219 ENSG00000218537.1 MIF-AS1 12.64 7.82e-28 1.77e-23 0.84 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23894426~23898930:- CESC cis rs2882667 0.728 rs10037071 ENSG00000253404.1 AC034243.1 12.63 8.46e-28 1.91e-23 0.85 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138942158 chr5:138744434~138753309:- CESC cis rs2882667 0.728 rs7722413 ENSG00000253404.1 AC034243.1 12.63 8.46e-28 1.91e-23 0.85 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138942562 chr5:138744434~138753309:- CESC cis rs9322193 0.923 rs11155670 ENSG00000231760.4 RP11-350J20.5 12.61 9.39e-28 2.11e-23 0.81 0.65 Lung cancer; chr6:149644992 chr6:149796151~149826294:- CESC cis rs858239 0.699 rs955187 ENSG00000230658.1 KLHL7-AS1 -12.6 1.02e-27 2.29e-23 -0.81 -0.65 Cerebrospinal fluid biomarker levels; chr7:23154986 chr7:23101228~23105703:- CESC cis rs5850 0.602 rs1005786 ENSG00000230658.1 KLHL7-AS1 12.6 1.08e-27 2.41e-23 0.81 0.65 Blood protein levels; chr7:23106218 chr7:23101228~23105703:- CESC cis rs916888 0.821 rs415430 ENSG00000214401.4 KANSL1-AS1 -12.59 1.15e-27 2.56e-23 -0.95 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:46193576~46196723:+ CESC cis rs916888 0.779 rs430685 ENSG00000214401.4 KANSL1-AS1 -12.59 1.15e-27 2.56e-23 -0.95 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:46193576~46196723:+ CESC cis rs2882667 0.728 rs10068786 ENSG00000253404.1 AC034243.1 12.58 1.23e-27 2.74e-23 0.91 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138941255 chr5:138744434~138753309:- CESC cis rs2739330 0.828 rs2877178 ENSG00000218537.1 MIF-AS1 12.56 1.37e-27 3.02e-23 0.84 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23894426~23898930:- CESC cis rs1577917 0.655 rs7742691 ENSG00000203875.9 SNHG5 12.55 1.51e-27 3.34e-23 0.71 0.65 Response to antipsychotic treatment; chr6:85568973 chr6:85660950~85678736:- CESC cis rs1930961 1 rs997873 ENSG00000272977.1 CTA-390C10.10 -12.53 1.71e-27 3.77e-23 -0.99 -0.65 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25476218~25479971:+ CESC cis rs858239 0.669 rs6461687 ENSG00000230658.1 KLHL7-AS1 12.5 2.1e-27 4.61e-23 0.81 0.65 Cerebrospinal fluid biomarker levels; chr7:23076961 chr7:23101228~23105703:- CESC cis rs2739330 0.76 rs1002286 ENSG00000218537.1 MIF-AS1 -12.5 2.11e-27 4.63e-23 -0.83 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23894426~23898930:- CESC cis rs1577917 0.74 rs2758842 ENSG00000203875.9 SNHG5 -12.5 2.12e-27 4.65e-23 -0.71 -0.65 Response to antipsychotic treatment; chr6:85599013 chr6:85660950~85678736:- CESC cis rs1577917 0.572 rs911927 ENSG00000203875.9 SNHG5 -12.5 2.12e-27 4.65e-23 -0.71 -0.65 Response to antipsychotic treatment; chr6:85618142 chr6:85660950~85678736:- CESC cis rs2882667 0.728 rs13181830 ENSG00000253404.1 AC034243.1 -12.5 2.17e-27 4.77e-23 -0.83 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138944727 chr5:138744434~138753309:- CESC cis rs1577917 0.74 rs7752502 ENSG00000203875.9 SNHG5 12.49 2.28e-27 4.97e-23 0.71 0.65 Response to antipsychotic treatment; chr6:85700933 chr6:85660950~85678736:- CESC cis rs858239 0.601 rs28673077 ENSG00000230658.1 KLHL7-AS1 12.49 2.4e-27 5.23e-23 0.87 0.65 Cerebrospinal fluid biomarker levels; chr7:23211235 chr7:23101228~23105703:- CESC cis rs9322193 0.923 rs12529698 ENSG00000231760.4 RP11-350J20.5 12.47 2.66e-27 5.75e-23 0.8 0.65 Lung cancer; chr6:149650951 chr6:149796151~149826294:- CESC cis rs2739330 0.791 rs9612520 ENSG00000218537.1 MIF-AS1 12.47 2.71e-27 5.85e-23 0.83 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23894426~23898930:- CESC cis rs4853012 0.941 rs4852329 ENSG00000217702.2 RP11-287D1.4 12.47 2.74e-27 5.91e-23 1.02 0.65 Gestational age at birth (maternal effect); chr2:74127417 chr2:74130583~74135395:+ CESC cis rs1577917 0.883 rs2166664 ENSG00000203875.9 SNHG5 -12.46 2.87e-27 6.18e-23 -0.69 -0.64 Response to antipsychotic treatment; chr6:85886904 chr6:85660950~85678736:- CESC cis rs1577917 0.883 rs9450348 ENSG00000203875.9 SNHG5 -12.46 2.87e-27 6.18e-23 -0.69 -0.64 Response to antipsychotic treatment; chr6:85888318 chr6:85660950~85678736:- CESC cis rs858239 0.665 rs858306 ENSG00000230658.1 KLHL7-AS1 12.46 2.93e-27 6.29e-23 0.81 0.64 Cerebrospinal fluid biomarker levels; chr7:23203135 chr7:23101228~23105703:- CESC cis rs2739330 0.796 rs1006771 ENSG00000225282.1 AP000350.6 12.45 3.14e-27 6.72e-23 0.74 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23926900~23929574:+ CESC cis rs916888 0.821 rs199513 ENSG00000214401.4 KANSL1-AS1 -12.45 3.16e-27 6.76e-23 -0.94 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46193576~46196723:+ CESC cis rs916888 0.738 rs199515 ENSG00000214401.4 KANSL1-AS1 -12.42 3.92e-27 8.31e-23 -0.91 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46193576~46196723:+ CESC cis rs4853012 0.838 rs60964317 ENSG00000217702.2 RP11-287D1.4 12.41 4.12e-27 8.73e-23 0.92 0.64 Gestational age at birth (maternal effect); chr2:74116296 chr2:74130583~74135395:+ CESC cis rs1577917 0.883 rs13212415 ENSG00000203875.9 SNHG5 -12.41 4.19e-27 8.87e-23 -0.68 -0.64 Response to antipsychotic treatment; chr6:85898365 chr6:85660950~85678736:- CESC cis rs1577917 0.839 rs1447159 ENSG00000203875.9 SNHG5 -12.41 4.19e-27 8.87e-23 -0.68 -0.64 Response to antipsychotic treatment; chr6:85899531 chr6:85660950~85678736:- CESC cis rs9322193 0.923 rs9688350 ENSG00000231760.4 RP11-350J20.5 12.39 4.87e-27 1.03e-22 0.84 0.64 Lung cancer; chr6:149730977 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9767652 ENSG00000231760.4 RP11-350J20.5 12.39 4.87e-27 1.03e-22 0.84 0.64 Lung cancer; chr6:149734502 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs10782314 ENSG00000231760.4 RP11-350J20.5 12.39 4.87e-27 1.03e-22 0.84 0.64 Lung cancer; chr6:149735527 chr6:149796151~149826294:- CESC cis rs2882667 0.628 rs13154573 ENSG00000253404.1 AC034243.1 12.38 5.28e-27 1.11e-22 0.97 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138812375 chr5:138744434~138753309:- CESC cis rs1930961 0.85 rs5996945 ENSG00000272977.1 CTA-390C10.10 12.37 5.71e-27 1.2e-22 0.94 0.64 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25476218~25479971:+ CESC cis rs12594515 0.967 rs11070465 ENSG00000273972.1 CTD-2306A12.1 -12.36 5.99e-27 1.26e-22 -0.71 -0.64 Weight;Waist circumference; chr15:45692701 chr15:45702640~45703183:+ CESC cis rs2739330 0.828 rs4822454 ENSG00000218537.1 MIF-AS1 12.36 6e-27 1.26e-22 0.82 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23894426~23898930:- CESC cis rs1577917 0.682 rs6909767 ENSG00000203875.9 SNHG5 12.35 6.38e-27 1.34e-22 0.7 0.64 Response to antipsychotic treatment; chr6:85518391 chr6:85660950~85678736:- CESC cis rs2739330 0.76 rs5751760 ENSG00000218537.1 MIF-AS1 12.33 7.45e-27 1.56e-22 0.83 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23894426~23898930:- CESC cis rs1577917 0.793 rs9362245 ENSG00000203875.9 SNHG5 -12.32 8.01e-27 1.67e-22 -0.67 -0.64 Response to antipsychotic treatment; chr6:85786602 chr6:85660950~85678736:- CESC cis rs1577917 0.74 rs2842614 ENSG00000203875.9 SNHG5 -12.32 8.27e-27 1.72e-22 -0.71 -0.64 Response to antipsychotic treatment; chr6:85596351 chr6:85660950~85678736:- CESC cis rs2739330 0.828 rs2154593 ENSG00000218537.1 MIF-AS1 12.31 8.88e-27 1.85e-22 0.82 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23894426~23898930:- CESC cis rs1577917 0.696 rs2842603 ENSG00000203875.9 SNHG5 -12.3 9.27e-27 1.92e-22 -0.71 -0.64 Response to antipsychotic treatment; chr6:85626619 chr6:85660950~85678736:- CESC cis rs12594515 1 rs12594515 ENSG00000273972.1 CTD-2306A12.1 12.3 9.39e-27 1.94e-22 0.72 0.64 Weight;Waist circumference; chr15:45692873 chr15:45702640~45703183:+ CESC cis rs1577917 0.696 rs2842617 ENSG00000203875.9 SNHG5 -12.3 9.39e-27 1.94e-22 -0.69 -0.64 Response to antipsychotic treatment; chr6:85599980 chr6:85660950~85678736:- CESC cis rs2882667 0.69 rs11749163 ENSG00000253404.1 AC034243.1 12.29 9.88e-27 2.04e-22 0.83 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138926981 chr5:138744434~138753309:- CESC cis rs1930961 1 rs7285549 ENSG00000272977.1 CTA-390C10.10 -12.28 1.05e-26 2.16e-22 -0.95 -0.64 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25476218~25479971:+ CESC cis rs2739330 0.828 rs2186366 ENSG00000218537.1 MIF-AS1 -12.28 1.12e-26 2.29e-22 -0.81 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23894426~23898930:- CESC cis rs1577917 0.816 rs1838952 ENSG00000203875.9 SNHG5 -12.27 1.18e-26 2.42e-22 -0.69 -0.64 Response to antipsychotic treatment; chr6:85891426 chr6:85660950~85678736:- CESC cis rs1930961 1 rs1930961 ENSG00000272977.1 CTA-390C10.10 -12.27 1.19e-26 2.44e-22 -0.91 -0.64 Bipolar disorder with mood-incongruent psychosis; chr22:25479298 chr22:25476218~25479971:+ CESC cis rs2739330 0.76 rs5751761 ENSG00000273295.1 AP000350.5 -12.26 1.22e-26 2.5e-22 -0.71 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23901432~23907068:- CESC cis rs1577917 0.959 rs2816822 ENSG00000203875.9 SNHG5 -12.26 1.28e-26 2.61e-22 -0.68 -0.64 Response to antipsychotic treatment; chr6:85948574 chr6:85660950~85678736:- CESC cis rs1577917 0.804 rs2786854 ENSG00000203875.9 SNHG5 -12.26 1.28e-26 2.61e-22 -0.68 -0.64 Response to antipsychotic treatment; chr6:85959022 chr6:85660950~85678736:- CESC cis rs1577917 0.92 rs1337842 ENSG00000203875.9 SNHG5 -12.26 1.28e-26 2.61e-22 -0.68 -0.64 Response to antipsychotic treatment; chr6:85965379 chr6:85660950~85678736:- CESC cis rs1577917 0.883 rs2660575 ENSG00000203875.9 SNHG5 -12.26 1.28e-26 2.61e-22 -0.68 -0.64 Response to antipsychotic treatment; chr6:85975277 chr6:85660950~85678736:- CESC cis rs2739330 0.791 rs4822458 ENSG00000218537.1 MIF-AS1 12.26 1.28e-26 2.61e-22 0.82 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23894426~23898930:- CESC cis rs2882667 0.628 rs13162420 ENSG00000253404.1 AC034243.1 12.24 1.42e-26 2.88e-22 0.98 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138839070 chr5:138744434~138753309:- CESC cis rs2882667 0.628 rs13167462 ENSG00000253404.1 AC034243.1 12.24 1.42e-26 2.88e-22 0.98 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138841572 chr5:138744434~138753309:- CESC cis rs1930961 1 rs6004672 ENSG00000272977.1 CTA-390C10.10 -12.24 1.47e-26 2.99e-22 -0.97 -0.64 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25476218~25479971:+ CESC cis rs12594515 0.967 rs11854477 ENSG00000273972.1 CTD-2306A12.1 -12.24 1.49e-26 3.02e-22 -0.7 -0.64 Weight;Waist circumference; chr15:45706147 chr15:45702640~45703183:+ CESC cis rs2739330 0.703 rs5760112 ENSG00000218537.1 MIF-AS1 12.23 1.58e-26 3.2e-22 0.83 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23894426~23898930:- CESC cis rs9322193 0.923 rs66516768 ENSG00000231760.4 RP11-350J20.5 12.22 1.63e-26 3.31e-22 0.82 0.64 Lung cancer; chr6:149671999 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs7769101 ENSG00000231760.4 RP11-350J20.5 12.22 1.66e-26 3.37e-22 0.87 0.64 Lung cancer; chr6:149848768 chr6:149796151~149826294:- CESC cis rs2739330 0.828 rs5760107 ENSG00000218537.1 MIF-AS1 12.21 1.8e-26 3.65e-22 0.81 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23894426~23898930:- CESC cis rs2739330 0.789 rs5760109 ENSG00000218537.1 MIF-AS1 12.21 1.8e-26 3.65e-22 0.81 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23894426~23898930:- CESC cis rs1577917 0.816 rs12664099 ENSG00000203875.9 SNHG5 -12.19 2.04e-26 4.12e-22 -0.68 -0.64 Response to antipsychotic treatment; chr6:85938854 chr6:85660950~85678736:- CESC cis rs1577917 0.839 rs9450333 ENSG00000203875.9 SNHG5 -12.19 2.06e-26 4.16e-22 -0.67 -0.64 Response to antipsychotic treatment; chr6:85810037 chr6:85660950~85678736:- CESC cis rs1577917 0.633 rs7770835 ENSG00000203875.9 SNHG5 -12.15 2.76e-26 5.54e-22 -0.68 -0.64 Response to antipsychotic treatment; chr6:85899189 chr6:85660950~85678736:- CESC cis rs9322193 0.923 rs55993747 ENSG00000231760.4 RP11-350J20.5 12.15 2.83e-26 5.66e-22 0.79 0.64 Lung cancer; chr6:149622016 chr6:149796151~149826294:- CESC cis rs9322193 0.847 rs12191643 ENSG00000231760.4 RP11-350J20.5 12.15 2.83e-26 5.66e-22 0.79 0.64 Lung cancer; chr6:149628912 chr6:149796151~149826294:- CESC cis rs1577917 0.839 rs6454492 ENSG00000203875.9 SNHG5 -12.13 3.25e-26 6.49e-22 -0.66 -0.63 Response to antipsychotic treatment; chr6:85773496 chr6:85660950~85678736:- CESC cis rs12594515 1 rs11070464 ENSG00000273972.1 CTD-2306A12.1 -12.12 3.5e-26 6.98e-22 -0.71 -0.63 Weight;Waist circumference; chr15:45692578 chr15:45702640~45703183:+ CESC cis rs12594515 0.967 rs11070466 ENSG00000273972.1 CTD-2306A12.1 -12.12 3.5e-26 6.98e-22 -0.71 -0.63 Weight;Waist circumference; chr15:45692757 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs7162201 ENSG00000273972.1 CTD-2306A12.1 -12.1 3.98e-26 7.91e-22 -0.7 -0.63 Weight;Waist circumference; chr15:45700460 chr15:45702640~45703183:+ CESC cis rs1577917 0.74 rs2758843 ENSG00000203875.9 SNHG5 -12.09 4.31e-26 8.55e-22 -0.7 -0.63 Response to antipsychotic treatment; chr6:85618713 chr6:85660950~85678736:- CESC cis rs858239 0.698 rs858295 ENSG00000230658.1 KLHL7-AS1 12.08 4.76e-26 9.41e-22 0.8 0.63 Cerebrospinal fluid biomarker levels; chr7:23205950 chr7:23101228~23105703:- CESC cis rs1577917 0.74 rs2475792 ENSG00000203875.9 SNHG5 12.07 4.91e-26 9.72e-22 0.7 0.63 Response to antipsychotic treatment; chr6:85682384 chr6:85660950~85678736:- CESC cis rs9322193 0.923 rs9383812 ENSG00000231760.4 RP11-350J20.5 12.06 5.32e-26 1.05e-21 0.8 0.63 Lung cancer; chr6:149712355 chr6:149796151~149826294:- CESC cis rs9322193 0.847 rs9383844 ENSG00000231760.4 RP11-350J20.5 12.06 5.32e-26 1.05e-21 0.8 0.63 Lung cancer; chr6:149716268 chr6:149796151~149826294:- CESC cis rs12594515 1 rs8029209 ENSG00000273972.1 CTD-2306A12.1 -12.06 5.5e-26 1.08e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45701291 chr15:45702640~45703183:+ CESC cis rs3814244 0.528 rs7306466 ENSG00000255733.4 IFNG-AS1 12.06 5.53e-26 1.09e-21 0.57 0.63 Itch intensity from mosquito bite adjusted by bite size; chr12:68014942 chr12:67989445~68234686:+ CESC cis rs12594515 1 rs8033148 ENSG00000273972.1 CTD-2306A12.1 -12.05 5.66e-26 1.11e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45705731 chr15:45702640~45703183:+ CESC cis rs12594515 0.904 rs8032875 ENSG00000273972.1 CTD-2306A12.1 -12.05 5.66e-26 1.11e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45705812 chr15:45702640~45703183:+ CESC cis rs12594515 0.874 rs8032878 ENSG00000273972.1 CTD-2306A12.1 -12.05 5.66e-26 1.11e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45705817 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs6493169 ENSG00000273972.1 CTD-2306A12.1 12.05 5.73e-26 1.12e-21 0.7 0.63 Weight;Waist circumference; chr15:45694796 chr15:45702640~45703183:+ CESC cis rs916888 0.773 rs9896243 ENSG00000214401.4 KANSL1-AS1 12.01 7.55e-26 1.47e-21 0.88 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:46193576~46196723:+ CESC cis rs1577917 0.71 rs9342041 ENSG00000203875.9 SNHG5 11.99 8.97e-26 1.74e-21 0.69 0.63 Response to antipsychotic treatment; chr6:85571157 chr6:85660950~85678736:- CESC cis rs1577917 0.682 rs6935918 ENSG00000203875.9 SNHG5 11.99 8.97e-26 1.74e-21 0.69 0.63 Response to antipsychotic treatment; chr6:85573857 chr6:85660950~85678736:- CESC cis rs1577917 0.883 rs1337854 ENSG00000203875.9 SNHG5 11.98 9.58e-26 1.85e-21 0.68 0.63 Response to antipsychotic treatment; chr6:86014297 chr6:85660950~85678736:- CESC cis rs9322193 0.884 rs7450246 ENSG00000231760.4 RP11-350J20.5 11.97 1.03e-25 1.99e-21 0.8 0.63 Lung cancer; chr6:149702517 chr6:149796151~149826294:- CESC cis rs875971 0.54 rs35510581 ENSG00000226824.5 RP4-756H11.3 11.97 1.06e-25 2.03e-21 0.8 0.63 Aortic root size; chr7:66113790 chr7:66654538~66669855:+ CESC cis rs12594515 1 rs8039974 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45694467 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs6493167 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45694611 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs6493168 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45694613 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs6493170 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45694821 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs8025258 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45695356 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs8027000 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45695597 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs8026221 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45695712 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs8031128 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45696330 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs8032361 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45696355 chr15:45702640~45703183:+ CESC cis rs12594515 0.967 rs71405295 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45696723 chr15:45702640~45703183:+ CESC cis rs12594515 0.506 rs74199860 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45696992 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs6493175 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45697700 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs6493176 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45697828 chr15:45702640~45703183:+ CESC cis rs12594515 0.967 rs8039088 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45697980 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs8038320 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45698069 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs8038058 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45698074 chr15:45702640~45703183:+ CESC cis rs12594515 0.967 rs67854274 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45698320 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs58368732 ENSG00000273972.1 CTD-2306A12.1 -11.97 1.07e-25 2.03e-21 -0.7 -0.63 Weight;Waist circumference; chr15:45698333 chr15:45702640~45703183:+ CESC cis rs858239 0.806 rs10268610 ENSG00000230658.1 KLHL7-AS1 11.96 1.1e-25 2.1e-21 0.83 0.63 Cerebrospinal fluid biomarker levels; chr7:23235145 chr7:23101228~23105703:- CESC cis rs858239 0.899 rs7794684 ENSG00000230658.1 KLHL7-AS1 11.95 1.22e-25 2.31e-21 0.84 0.63 Cerebrospinal fluid biomarker levels; chr7:23271186 chr7:23101228~23105703:- CESC cis rs1577917 0.883 rs6454505 ENSG00000203875.9 SNHG5 -11.94 1.27e-25 2.4e-21 -0.71 -0.63 Response to antipsychotic treatment; chr6:85882644 chr6:85660950~85678736:- CESC cis rs9322193 0.923 rs10747276 ENSG00000231760.4 RP11-350J20.5 11.94 1.3e-25 2.45e-21 0.8 0.63 Lung cancer; chr6:149758739 chr6:149796151~149826294:- CESC cis rs4423214 1 rs4944958 ENSG00000254682.1 RP11-660L16.2 11.94 1.31e-25 2.47e-21 0.8 0.63 Vitamin D levels; chr11:71457027 chr11:71448674~71452157:+ CESC cis rs4423214 0.959 rs12793224 ENSG00000254682.1 RP11-660L16.2 11.94 1.31e-25 2.47e-21 0.8 0.63 Vitamin D levels; chr11:71457664 chr11:71448674~71452157:+ CESC cis rs4423214 0.959 rs12794668 ENSG00000254682.1 RP11-660L16.2 11.94 1.31e-25 2.47e-21 0.8 0.63 Vitamin D levels; chr11:71457669 chr11:71448674~71452157:+ CESC cis rs10256972 0.552 rs2960830 ENSG00000229043.2 AC091729.9 -11.93 1.38e-25 2.59e-21 -0.69 -0.63 Endometriosis;Longevity; chr7:1161005 chr7:1160374~1165267:+ CESC cis rs10256972 0.552 rs6978842 ENSG00000229043.2 AC091729.9 -11.93 1.41e-25 2.64e-21 -0.69 -0.63 Endometriosis;Longevity; chr7:1164963 chr7:1160374~1165267:+ CESC cis rs10256972 0.552 rs2960831 ENSG00000229043.2 AC091729.9 -11.93 1.42e-25 2.66e-21 -0.69 -0.63 Endometriosis;Longevity; chr7:1161556 chr7:1160374~1165267:+ CESC cis rs12594515 1 rs7172161 ENSG00000273972.1 CTD-2306A12.1 -11.92 1.52e-25 2.83e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45698582 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs7173144 ENSG00000273972.1 CTD-2306A12.1 -11.92 1.52e-25 2.83e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45698998 chr15:45702640~45703183:+ CESC cis rs2739330 0.732 rs5760175 ENSG00000250470.1 AP000351.3 11.91 1.64e-25 3.06e-21 0.79 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23976904~23977585:- CESC cis rs12594515 1 rs12906442 ENSG00000273972.1 CTD-2306A12.1 -11.91 1.66e-25 3.09e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45693056 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs12911309 ENSG00000273972.1 CTD-2306A12.1 -11.91 1.66e-25 3.09e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45693521 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs12595137 ENSG00000273972.1 CTD-2306A12.1 -11.91 1.66e-25 3.09e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45693907 chr15:45702640~45703183:+ CESC cis rs12594515 0.967 rs12595138 ENSG00000273972.1 CTD-2306A12.1 -11.91 1.66e-25 3.09e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45693910 chr15:45702640~45703183:+ CESC cis rs1930961 1 rs6004669 ENSG00000272977.1 CTA-390C10.10 -11.9 1.7e-25 3.16e-21 -0.94 -0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25476218~25479971:+ CESC cis rs1930961 1 rs6004673 ENSG00000272977.1 CTA-390C10.10 -11.9 1.76e-25 3.26e-21 -0.98 -0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25476218~25479971:+ CESC cis rs1577917 0.771 rs7762321 ENSG00000203875.9 SNHG5 11.9 1.76e-25 3.27e-21 0.7 0.63 Response to antipsychotic treatment; chr6:85702428 chr6:85660950~85678736:- CESC cis rs2486288 0.656 rs11637364 ENSG00000259520.4 CTD-2651B20.3 11.89 1.8e-25 3.34e-21 0.84 0.63 Glomerular filtration rate; chr15:45287040 chr15:45251580~45279251:- CESC cis rs3814244 0.569 rs2051993 ENSG00000255733.4 IFNG-AS1 11.89 1.88e-25 3.47e-21 0.57 0.63 Itch intensity from mosquito bite adjusted by bite size; chr12:68019898 chr12:67989445~68234686:+ CESC cis rs1577917 0.883 rs9450375 ENSG00000203875.9 SNHG5 11.88 1.95e-25 3.59e-21 0.67 0.63 Response to antipsychotic treatment; chr6:86046911 chr6:85660950~85678736:- CESC cis rs3814244 0.528 rs7952790 ENSG00000255733.4 IFNG-AS1 11.87 2.18e-25 3.99e-21 0.57 0.63 Itch intensity from mosquito bite adjusted by bite size; chr12:68012672 chr12:67989445~68234686:+ CESC cis rs12594515 1 rs11070467 ENSG00000273972.1 CTD-2306A12.1 11.87 2.19e-25 4.01e-21 0.69 0.63 Weight;Waist circumference; chr15:45692803 chr15:45702640~45703183:+ CESC cis rs1577917 0.839 rs6929514 ENSG00000203875.9 SNHG5 -11.87 2.2e-25 4.03e-21 -0.67 -0.63 Response to antipsychotic treatment; chr6:85816050 chr6:85660950~85678736:- CESC cis rs3814244 0.528 rs17104682 ENSG00000255733.4 IFNG-AS1 -11.87 2.23e-25 4.07e-21 -0.56 -0.63 Itch intensity from mosquito bite adjusted by bite size; chr12:68033256 chr12:67989445~68234686:+ CESC cis rs1577917 0.682 rs1173417 ENSG00000203875.9 SNHG5 11.86 2.24e-25 4.08e-21 0.69 0.63 Response to antipsychotic treatment; chr6:85694223 chr6:85660950~85678736:- CESC cis rs2739330 0.761 rs5760176 ENSG00000250470.1 AP000351.3 -11.86 2.35e-25 4.24e-21 -0.79 -0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23976904~23977585:- CESC cis rs801193 1 rs2659909 ENSG00000226824.5 RP4-756H11.3 -11.86 2.39e-25 4.3e-21 -0.8 -0.63 Aortic root size; chr7:66695292 chr7:66654538~66669855:+ CESC cis rs12594515 0.967 rs11856523 ENSG00000273972.1 CTD-2306A12.1 -11.86 2.39e-25 4.3e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45697297 chr15:45702640~45703183:+ CESC cis rs858239 0.636 rs7808488 ENSG00000230658.1 KLHL7-AS1 11.85 2.45e-25 4.38e-21 0.79 0.63 Cerebrospinal fluid biomarker levels; chr7:23182251 chr7:23101228~23105703:- CESC cis rs9322193 0.923 rs12660304 ENSG00000231760.4 RP11-350J20.5 11.85 2.45e-25 4.39e-21 0.79 0.63 Lung cancer; chr6:149739647 chr6:149796151~149826294:- CESC cis rs4853012 0.941 rs2421752 ENSG00000217702.2 RP11-287D1.4 11.84 2.63e-25 4.69e-21 0.96 0.63 Gestational age at birth (maternal effect); chr2:74114488 chr2:74130583~74135395:+ CESC cis rs12594515 1 rs6493172 ENSG00000273972.1 CTD-2306A12.1 -11.83 2.77e-25 4.94e-21 -0.69 -0.63 Weight;Waist circumference; chr15:45695015 chr15:45702640~45703183:+ CESC cis rs1577917 0.74 rs2758845 ENSG00000203875.9 SNHG5 -11.82 3.02e-25 5.31e-21 -0.69 -0.63 Response to antipsychotic treatment; chr6:85625130 chr6:85660950~85678736:- CESC cis rs2739330 0.731 rs5751792 ENSG00000250470.1 AP000351.3 11.81 3.24e-25 5.7e-21 0.79 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23976904~23977585:- CESC cis rs3814244 0.528 rs2870960 ENSG00000255733.4 IFNG-AS1 11.81 3.24e-25 5.7e-21 0.57 0.62 Itch intensity from mosquito bite adjusted by bite size; chr12:68032848 chr12:67989445~68234686:+ CESC cis rs1577917 0.796 rs12661231 ENSG00000203875.9 SNHG5 -11.8 3.49e-25 6.09e-21 -0.68 -0.62 Response to antipsychotic treatment; chr6:85834753 chr6:85660950~85678736:- CESC cis rs1577917 0.839 rs12055653 ENSG00000203875.9 SNHG5 -11.8 3.54e-25 6.16e-21 -0.68 -0.62 Response to antipsychotic treatment; chr6:85836945 chr6:85660950~85678736:- CESC cis rs1930961 1 rs997872 ENSG00000272977.1 CTA-390C10.10 -11.77 4.31e-25 7.42e-21 -0.97 -0.62 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25476218~25479971:+ CESC cis rs12594515 1 rs8039622 ENSG00000273972.1 CTD-2306A12.1 -11.77 4.56e-25 7.83e-21 -0.69 -0.62 Weight;Waist circumference; chr15:45694233 chr15:45702640~45703183:+ CESC cis rs2486288 0.656 rs8039153 ENSG00000259520.4 CTD-2651B20.3 11.76 4.65e-25 7.96e-21 0.83 0.62 Glomerular filtration rate; chr15:45287615 chr15:45251580~45279251:- CESC cis rs1577917 0.839 rs1596990 ENSG00000203875.9 SNHG5 -11.76 4.67e-25 7.96e-21 -0.67 -0.62 Response to antipsychotic treatment; chr6:85840974 chr6:85660950~85678736:- CESC cis rs1577917 0.916 rs12661611 ENSG00000203875.9 SNHG5 -11.76 4.67e-25 7.96e-21 -0.67 -0.62 Response to antipsychotic treatment; chr6:85844117 chr6:85660950~85678736:- CESC cis rs1577917 0.637 rs1838957 ENSG00000203875.9 SNHG5 -11.76 4.67e-25 7.96e-21 -0.67 -0.62 Response to antipsychotic treatment; chr6:85855338 chr6:85660950~85678736:- CESC cis rs1577917 0.839 rs1838956 ENSG00000203875.9 SNHG5 -11.76 4.67e-25 7.96e-21 -0.67 -0.62 Response to antipsychotic treatment; chr6:85855545 chr6:85660950~85678736:- CESC cis rs1577917 0.839 rs12216103 ENSG00000203875.9 SNHG5 -11.76 4.67e-25 7.96e-21 -0.67 -0.62 Response to antipsychotic treatment; chr6:85861410 chr6:85660950~85678736:- CESC cis rs2486288 0.656 rs6493144 ENSG00000259520.4 CTD-2651B20.3 -11.76 4.76e-25 8.11e-21 -0.82 -0.62 Glomerular filtration rate; chr15:45281291 chr15:45251580~45279251:- CESC cis rs801193 1 rs17566701 ENSG00000226824.5 RP4-756H11.3 -11.76 4.94e-25 8.42e-21 -0.78 -0.62 Aortic root size; chr7:66728196 chr7:66654538~66669855:+ CESC cis rs9322193 0.923 rs10782315 ENSG00000231760.4 RP11-350J20.5 11.75 5.26e-25 8.94e-21 0.79 0.62 Lung cancer; chr6:149743093 chr6:149796151~149826294:- CESC cis rs12594515 1 rs8032835 ENSG00000273972.1 CTD-2306A12.1 -11.75 5.27e-25 8.96e-21 -0.69 -0.62 Weight;Waist circumference; chr15:45705699 chr15:45702640~45703183:+ CESC cis rs2739330 0.828 rs2330635 ENSG00000218537.1 MIF-AS1 11.75 5.3e-25 9.01e-21 0.81 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23894426~23898930:- CESC cis rs12594515 0.967 rs11857628 ENSG00000273972.1 CTD-2306A12.1 -11.74 5.42e-25 9.2e-21 -0.68 -0.62 Weight;Waist circumference; chr15:45706008 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs12592190 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45701830 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs11854554 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45702348 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs35182335 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45702986 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs11855509 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45703276 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs11855562 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45703461 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs8043291 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45704049 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs56412446 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45704226 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs57299255 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45704334 chr15:45702640~45703183:+ CESC cis rs12594515 1 rs56220882 ENSG00000273972.1 CTD-2306A12.1 -11.73 6.15e-25 1.03e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45704877 chr15:45702640~45703183:+ CESC cis rs9322193 0.884 rs9689702 ENSG00000231760.4 RP11-350J20.5 11.72 6.28e-25 1.05e-20 0.79 0.62 Lung cancer; chr6:149740720 chr6:149796151~149826294:- CESC cis rs3814244 0.528 rs12228471 ENSG00000255733.4 IFNG-AS1 11.72 6.43e-25 1.08e-20 0.57 0.62 Itch intensity from mosquito bite adjusted by bite size; chr12:68027842 chr12:67989445~68234686:+ CESC cis rs1577917 0.839 rs12664634 ENSG00000203875.9 SNHG5 -11.72 6.5e-25 1.09e-20 -0.68 -0.62 Response to antipsychotic treatment; chr6:85869696 chr6:85660950~85678736:- CESC cis rs3814244 0.528 rs12582272 ENSG00000255733.4 IFNG-AS1 11.72 6.56e-25 1.1e-20 0.58 0.62 Itch intensity from mosquito bite adjusted by bite size; chr12:68006298 chr12:67989445~68234686:+ CESC cis rs1577917 0.883 rs2782263 ENSG00000203875.9 SNHG5 -11.71 6.98e-25 1.17e-20 -0.65 -0.62 Response to antipsychotic treatment; chr6:86081589 chr6:85660950~85678736:- CESC cis rs875971 0.577 rs35072105 ENSG00000226824.5 RP4-756H11.3 11.71 7.08e-25 1.18e-20 0.78 0.62 Aortic root size; chr7:66144830 chr7:66654538~66669855:+ CESC cis rs916888 0.61 rs199436 ENSG00000262539.1 RP11-259G18.3 -11.7 7.2e-25 1.2e-20 -0.79 -0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46259551~46260606:- CESC cis rs4853012 0.887 rs77148265 ENSG00000217702.2 RP11-287D1.4 11.7 7.37e-25 1.23e-20 0.95 0.62 Gestational age at birth (maternal effect); chr2:74112392 chr2:74130583~74135395:+ CESC cis rs7208859 0.673 rs9915139 ENSG00000263531.1 RP13-753N3.1 11.69 7.76e-25 1.29e-20 1.26 0.62 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831497 chr17:30863921~30864940:- CESC cis rs1577917 0.883 rs12214536 ENSG00000203875.9 SNHG5 -11.69 7.79e-25 1.3e-20 -0.66 -0.62 Response to antipsychotic treatment; chr6:86080592 chr6:85660950~85678736:- CESC cis rs2739330 0.828 rs4820572 ENSG00000218537.1 MIF-AS1 11.69 8e-25 1.33e-20 0.81 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23894426~23898930:- CESC cis rs858239 0.738 rs13225593 ENSG00000230658.1 KLHL7-AS1 11.69 8.04e-25 1.34e-20 0.83 0.62 Cerebrospinal fluid biomarker levels; chr7:23220688 chr7:23101228~23105703:- CESC cis rs916888 0.61 rs199438 ENSG00000262539.1 RP11-259G18.3 11.69 8.05e-25 1.34e-20 0.79 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46259551~46260606:- CESC cis rs858239 0.899 rs2268747 ENSG00000230658.1 KLHL7-AS1 11.68 8.31e-25 1.38e-20 0.83 0.62 Cerebrospinal fluid biomarker levels; chr7:23273843 chr7:23101228~23105703:- CESC cis rs4423214 1 rs2002063 ENSG00000254682.1 RP11-660L16.2 11.68 8.36e-25 1.38e-20 0.78 0.62 Vitamin D levels; chr11:71452430 chr11:71448674~71452157:+ CESC cis rs1577917 0.839 rs6454504 ENSG00000203875.9 SNHG5 -11.68 8.75e-25 1.45e-20 -0.67 -0.62 Response to antipsychotic treatment; chr6:85870612 chr6:85660950~85678736:- CESC cis rs916888 0.647 rs199449 ENSG00000262539.1 RP11-259G18.3 11.67 8.98e-25 1.48e-20 0.77 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46259551~46260606:- CESC cis rs12594515 1 rs12185095 ENSG00000273972.1 CTD-2306A12.1 -11.67 9.08e-25 1.5e-20 -0.69 -0.62 Weight;Waist circumference; chr15:45702437 chr15:45702640~45703183:+ CESC cis rs2739330 0.76 rs5760095 ENSG00000225282.1 AP000350.6 11.67 9.15e-25 1.51e-20 0.77 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23926900~23929574:+ CESC cis rs12594515 0.935 rs8042519 ENSG00000273972.1 CTD-2306A12.1 -11.67 9.34e-25 1.54e-20 -0.68 -0.62 Weight;Waist circumference; chr15:45704143 chr15:45702640~45703183:+ CESC cis rs9322193 0.923 rs56397000 ENSG00000231760.4 RP11-350J20.5 11.66 9.52e-25 1.57e-20 0.78 0.62 Lung cancer; chr6:149739347 chr6:149796151~149826294:- CESC cis rs916888 0.531 rs183211 ENSG00000262539.1 RP11-259G18.3 11.65 1.09e-24 1.75e-20 0.79 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46259551~46260606:- CESC cis rs858239 0.73 rs858279 ENSG00000230658.1 KLHL7-AS1 11.64 1.14e-24 1.83e-20 0.75 0.62 Cerebrospinal fluid biomarker levels; chr7:23211386 chr7:23101228~23105703:- CESC cis rs1577917 0.74 rs9344542 ENSG00000203875.9 SNHG5 11.64 1.16e-24 1.86e-20 0.69 0.62 Response to antipsychotic treatment; chr6:85684187 chr6:85660950~85678736:- CESC cis rs2486288 0.656 rs8024620 ENSG00000259520.4 CTD-2651B20.3 11.63 1.22e-24 1.95e-20 0.81 0.62 Glomerular filtration rate; chr15:45282131 chr15:45251580~45279251:- CESC cis rs3814244 0.528 rs56393928 ENSG00000255733.4 IFNG-AS1 11.63 1.22e-24 1.95e-20 0.56 0.62 Itch intensity from mosquito bite adjusted by bite size; chr12:68029927 chr12:67989445~68234686:+ CESC cis rs2486288 0.656 rs6493145 ENSG00000259520.4 CTD-2651B20.3 11.63 1.27e-24 2.02e-20 0.82 0.62 Glomerular filtration rate; chr15:45281664 chr15:45251580~45279251:- CESC cis rs2739330 0.791 rs4822458 ENSG00000225282.1 AP000350.6 11.62 1.29e-24 2.06e-20 0.74 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23926900~23929574:+ CESC cis rs875971 0.66 rs2013222 ENSG00000226824.5 RP4-756H11.3 11.62 1.32e-24 2.1e-20 0.78 0.62 Aortic root size; chr7:66570949 chr7:66654538~66669855:+ CESC cis rs4423214 1 rs11600569 ENSG00000254682.1 RP11-660L16.2 11.61 1.38e-24 2.2e-20 0.8 0.62 Vitamin D levels; chr11:71462701 chr11:71448674~71452157:+ CESC cis rs9326248 0.861 rs1871757 ENSG00000254851.1 RP11-109L13.1 -11.6 1.55e-24 2.45e-20 -0.89 -0.62 Blood protein levels; chr11:117159865 chr11:117135528~117138582:+ CESC cis rs4423214 1 rs12790010 ENSG00000254682.1 RP11-660L16.2 11.59 1.69e-24 2.66e-20 0.8 0.62 Vitamin D levels; chr11:71459607 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs12806844 ENSG00000254682.1 RP11-660L16.2 11.59 1.69e-24 2.66e-20 0.8 0.62 Vitamin D levels; chr11:71459724 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs12808368 ENSG00000254682.1 RP11-660L16.2 11.59 1.69e-24 2.66e-20 0.8 0.62 Vitamin D levels; chr11:71459771 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs12790558 ENSG00000254682.1 RP11-660L16.2 11.59 1.69e-24 2.66e-20 0.8 0.62 Vitamin D levels; chr11:71459859 chr11:71448674~71452157:+ CESC cis rs4423214 0.959 rs11233747 ENSG00000254682.1 RP11-660L16.2 11.59 1.69e-24 2.66e-20 0.8 0.62 Vitamin D levels; chr11:71460596 chr11:71448674~71452157:+ CESC cis rs1577917 0.74 rs12212560 ENSG00000203875.9 SNHG5 -11.57 1.95e-24 3.06e-20 -0.69 -0.62 Response to antipsychotic treatment; chr6:85632961 chr6:85660950~85678736:- CESC cis rs4423214 1 rs7935125 ENSG00000254682.1 RP11-660L16.2 11.56 2.04e-24 3.2e-20 0.8 0.62 Vitamin D levels; chr11:71473144 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs3794060 ENSG00000254682.1 RP11-660L16.2 11.56 2.04e-24 3.2e-20 0.8 0.62 Vitamin D levels; chr11:71476633 chr11:71448674~71452157:+ CESC cis rs2486288 0.656 rs12911861 ENSG00000259520.4 CTD-2651B20.3 11.54 2.27e-24 3.54e-20 0.82 0.62 Glomerular filtration rate; chr15:45274520 chr15:45251580~45279251:- CESC cis rs858239 0.738 rs7807879 ENSG00000230658.1 KLHL7-AS1 11.53 2.44e-24 3.79e-20 0.85 0.62 Cerebrospinal fluid biomarker levels; chr7:23220969 chr7:23101228~23105703:- CESC cis rs916888 0.61 rs199452 ENSG00000262539.1 RP11-259G18.3 11.53 2.56e-24 3.97e-20 0.77 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46259551~46260606:- CESC cis rs1930961 1 rs6004667 ENSG00000272977.1 CTA-390C10.10 11.53 2.57e-24 3.98e-20 0.96 0.62 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25476218~25479971:+ CESC cis rs3814244 0.569 rs11177008 ENSG00000255733.4 IFNG-AS1 11.52 2.64e-24 4.1e-20 0.56 0.62 Itch intensity from mosquito bite adjusted by bite size; chr12:68021024 chr12:67989445~68234686:+ CESC cis rs1577917 0.682 rs1173419 ENSG00000203875.9 SNHG5 -11.51 2.88e-24 4.45e-20 -0.69 -0.61 Response to antipsychotic treatment; chr6:85692445 chr6:85660950~85678736:- CESC cis rs858239 0.867 rs10250602 ENSG00000230658.1 KLHL7-AS1 11.51 2.89e-24 4.46e-20 0.82 0.61 Cerebrospinal fluid biomarker levels; chr7:23264082 chr7:23101228~23105703:- CESC cis rs2739330 0.76 rs5760095 ENSG00000218537.1 MIF-AS1 11.5 3.18e-24 4.9e-20 0.81 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23894426~23898930:- CESC cis rs916888 0.61 rs199453 ENSG00000262539.1 RP11-259G18.3 11.5 3.18e-24 4.9e-20 0.77 0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46259551~46260606:- CESC cis rs858239 1 rs156407 ENSG00000230658.1 KLHL7-AS1 11.5 3.2e-24 4.93e-20 0.77 0.61 Cerebrospinal fluid biomarker levels; chr7:23276020 chr7:23101228~23105703:- CESC cis rs1577917 0.655 rs9359658 ENSG00000203875.9 SNHG5 11.5 3.23e-24 4.97e-20 0.67 0.61 Response to antipsychotic treatment; chr6:85596051 chr6:85660950~85678736:- CESC cis rs2739330 0.796 rs5760106 ENSG00000218537.1 MIF-AS1 -11.48 3.57e-24 5.47e-20 -0.79 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23894426~23898930:- CESC cis rs801193 1 rs2420824 ENSG00000226824.5 RP4-756H11.3 11.48 3.58e-24 5.48e-20 0.79 0.61 Aortic root size; chr7:66666129 chr7:66654538~66669855:+ CESC cis rs858239 0.699 rs1881201 ENSG00000230658.1 KLHL7-AS1 -11.48 3.61e-24 5.53e-20 -0.78 -0.61 Cerebrospinal fluid biomarker levels; chr7:23154394 chr7:23101228~23105703:- CESC cis rs4423214 1 rs11600860 ENSG00000254682.1 RP11-660L16.2 11.47 3.77e-24 5.74e-20 0.78 0.61 Vitamin D levels; chr11:71452973 chr11:71448674~71452157:+ CESC cis rs4423214 0.959 rs11606611 ENSG00000254682.1 RP11-660L16.2 11.47 3.77e-24 5.74e-20 0.78 0.61 Vitamin D levels; chr11:71453000 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs11606612 ENSG00000254682.1 RP11-660L16.2 11.47 3.77e-24 5.74e-20 0.78 0.61 Vitamin D levels; chr11:71453001 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs11606631 ENSG00000254682.1 RP11-660L16.2 11.47 3.77e-24 5.74e-20 0.78 0.61 Vitamin D levels; chr11:71453075 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs12789751 ENSG00000254682.1 RP11-660L16.2 11.47 3.77e-24 5.74e-20 0.78 0.61 Vitamin D levels; chr11:71453425 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs12791871 ENSG00000254682.1 RP11-660L16.2 11.47 3.77e-24 5.74e-20 0.78 0.61 Vitamin D levels; chr11:71453498 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs7944926 ENSG00000254682.1 RP11-660L16.2 11.47 3.77e-24 5.74e-20 0.78 0.61 Vitamin D levels; chr11:71454579 chr11:71448674~71452157:+ CESC cis rs3814244 0.528 rs10878723 ENSG00000255733.4 IFNG-AS1 11.46 4.3e-24 6.53e-20 0.58 0.61 Itch intensity from mosquito bite adjusted by bite size; chr12:68005493 chr12:67989445~68234686:+ CESC cis rs10256972 0.577 rs2949179 ENSG00000229043.2 AC091729.9 -11.45 4.55e-24 6.9e-20 -0.68 -0.61 Endometriosis;Longevity; chr7:1170249 chr7:1160374~1165267:+ CESC cis rs10256972 0.504 rs2949178 ENSG00000229043.2 AC091729.9 -11.45 4.55e-24 6.9e-20 -0.68 -0.61 Endometriosis;Longevity; chr7:1170289 chr7:1160374~1165267:+ CESC cis rs916888 0.61 rs199444 ENSG00000262539.1 RP11-259G18.3 11.45 4.56e-24 6.9e-20 0.77 0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46259551~46260606:- CESC cis rs9322193 0.884 rs62439837 ENSG00000231760.4 RP11-350J20.5 11.44 4.92e-24 7.44e-20 0.81 0.61 Lung cancer; chr6:149670380 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs62439840 ENSG00000231760.4 RP11-350J20.5 11.44 4.96e-24 7.49e-20 0.81 0.61 Lung cancer; chr6:149674639 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs9393175 ENSG00000231760.4 RP11-350J20.5 11.44 4.96e-24 7.49e-20 0.81 0.61 Lung cancer; chr6:149677587 chr6:149796151~149826294:- CESC cis rs2739330 0.796 rs1006771 ENSG00000218537.1 MIF-AS1 11.43 5.14e-24 7.76e-20 0.75 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23894426~23898930:- CESC cis rs916888 0.61 rs142167 ENSG00000262539.1 RP11-259G18.3 -11.42 5.75e-24 8.67e-20 -0.78 -0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46259551~46260606:- CESC cis rs858239 1 rs199351 ENSG00000230658.1 KLHL7-AS1 11.42 5.76e-24 8.68e-20 0.76 0.61 Cerebrospinal fluid biomarker levels; chr7:23260430 chr7:23101228~23105703:- CESC cis rs10256972 0.552 rs2960837 ENSG00000229043.2 AC091729.9 -11.41 5.94e-24 8.92e-20 -0.68 -0.61 Endometriosis;Longevity; chr7:1164321 chr7:1160374~1165267:+ CESC cis rs801193 0.935 rs11772264 ENSG00000226824.5 RP4-756H11.3 -11.4 6.41e-24 9.6e-20 -0.75 -0.61 Aortic root size; chr7:66711400 chr7:66654538~66669855:+ CESC cis rs858239 0.932 rs858272 ENSG00000230658.1 KLHL7-AS1 11.4 6.56e-24 9.8e-20 0.75 0.61 Cerebrospinal fluid biomarker levels; chr7:23237166 chr7:23101228~23105703:- CESC cis rs1577917 0.883 rs1415749 ENSG00000203875.9 SNHG5 11.39 6.68e-24 9.98e-20 0.65 0.61 Response to antipsychotic treatment; chr6:86069366 chr6:85660950~85678736:- CESC cis rs3814244 0.528 rs61923060 ENSG00000255733.4 IFNG-AS1 11.39 6.74e-24 1.01e-19 0.56 0.61 Itch intensity from mosquito bite adjusted by bite size; chr12:67997341 chr12:67989445~68234686:+ CESC cis rs2739330 0.685 rs4822453 ENSG00000218537.1 MIF-AS1 11.39 6.81e-24 1.02e-19 0.78 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23894426~23898930:- CESC cis rs916888 0.61 rs199442 ENSG00000262539.1 RP11-259G18.3 11.39 6.82e-24 1.02e-19 0.76 0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46259551~46260606:- CESC cis rs2486288 0.656 rs62026703 ENSG00000259520.4 CTD-2651B20.3 11.39 7e-24 1.04e-19 0.81 0.61 Glomerular filtration rate; chr15:45277731 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs7171312 ENSG00000259520.4 CTD-2651B20.3 11.39 7e-24 1.04e-19 0.81 0.61 Glomerular filtration rate; chr15:45278027 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs7165039 ENSG00000259520.4 CTD-2651B20.3 11.39 7e-24 1.04e-19 0.81 0.61 Glomerular filtration rate; chr15:45278215 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs6493143 ENSG00000259520.4 CTD-2651B20.3 11.39 7e-24 1.04e-19 0.81 0.61 Glomerular filtration rate; chr15:45278583 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs7166580 ENSG00000259520.4 CTD-2651B20.3 11.39 7e-24 1.04e-19 0.81 0.61 Glomerular filtration rate; chr15:45279011 chr15:45251580~45279251:- CESC cis rs4853012 0.941 rs7571083 ENSG00000217702.2 RP11-287D1.4 11.38 7.29e-24 1.08e-19 0.9 0.61 Gestational age at birth (maternal effect); chr2:74115133 chr2:74130583~74135395:+ CESC cis rs9326248 0.727 rs4938347 ENSG00000254851.1 RP11-109L13.1 -11.37 7.84e-24 1.16e-19 -0.88 -0.61 Blood protein levels; chr11:117151043 chr11:117135528~117138582:+ CESC cis rs9326248 0.813 rs4938350 ENSG00000254851.1 RP11-109L13.1 -11.37 7.84e-24 1.16e-19 -0.88 -0.61 Blood protein levels; chr11:117151560 chr11:117135528~117138582:+ CESC cis rs9326248 0.768 rs4936366 ENSG00000254851.1 RP11-109L13.1 -11.37 7.84e-24 1.16e-19 -0.88 -0.61 Blood protein levels; chr11:117156169 chr11:117135528~117138582:+ CESC cis rs9326248 0.861 rs4938352 ENSG00000254851.1 RP11-109L13.1 -11.37 7.84e-24 1.16e-19 -0.88 -0.61 Blood protein levels; chr11:117156765 chr11:117135528~117138582:+ CESC cis rs10256972 0.552 rs2949195 ENSG00000229043.2 AC091729.9 -11.37 8.25e-24 1.21e-19 -0.67 -0.61 Endometriosis;Longevity; chr7:1163069 chr7:1160374~1165267:+ CESC cis rs9322193 0.923 rs9767105 ENSG00000231760.4 RP11-350J20.5 11.36 8.45e-24 1.24e-19 0.79 0.61 Lung cancer; chr6:149659591 chr6:149796151~149826294:- CESC cis rs801193 1 rs2659912 ENSG00000226824.5 RP4-756H11.3 -11.35 9.03e-24 1.32e-19 -0.75 -0.61 Aortic root size; chr7:66693012 chr7:66654538~66669855:+ CESC cis rs9322193 0.847 rs56103941 ENSG00000231760.4 RP11-350J20.5 11.35 9.25e-24 1.35e-19 0.8 0.61 Lung cancer; chr6:149816095 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs9688699 ENSG00000231760.4 RP11-350J20.5 11.34 9.58e-24 1.4e-19 0.79 0.61 Lung cancer; chr6:149733680 chr6:149796151~149826294:- CESC cis rs7208859 0.673 rs9911989 ENSG00000263531.1 RP13-753N3.1 -11.34 9.6e-24 1.4e-19 -1.25 -0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910684 chr17:30863921~30864940:- CESC cis rs858239 0.896 rs1637193 ENSG00000230658.1 KLHL7-AS1 11.34 9.64e-24 1.41e-19 0.76 0.61 Cerebrospinal fluid biomarker levels; chr7:23220632 chr7:23101228~23105703:- CESC cis rs801193 0.967 rs2707849 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66687725 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2707836 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66695448 chr7:66654538~66669855:+ CESC cis rs801193 0.844 rs7779971 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66696803 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2659906 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66700323 chr7:66654538~66669855:+ CESC cis rs801193 1 rs62466793 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66726530 chr7:66654538~66669855:+ CESC cis rs801193 1 rs1553610 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66732246 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2707845 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66733811 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2707850 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66738883 chr7:66654538~66669855:+ CESC cis rs801193 0.967 rs1110414 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66740595 chr7:66654538~66669855:+ CESC cis rs801193 1 rs7783924 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66744070 chr7:66654538~66669855:+ CESC cis rs801193 1 rs7789184 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66745208 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2707854 ENSG00000226824.5 RP4-756H11.3 -11.32 1.12e-23 1.62e-19 -0.75 -0.61 Aortic root size; chr7:66747610 chr7:66654538~66669855:+ CESC cis rs10256972 0.577 rs6962809 ENSG00000229043.2 AC091729.9 -11.32 1.18e-23 1.7e-19 -0.67 -0.61 Endometriosis;Longevity; chr7:1169253 chr7:1160374~1165267:+ CESC cis rs9322193 0.847 rs12210605 ENSG00000231760.4 RP11-350J20.5 11.31 1.18e-23 1.71e-19 0.8 0.61 Lung cancer; chr6:149817267 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs9371199 ENSG00000231760.4 RP11-350J20.5 11.31 1.18e-23 1.71e-19 0.8 0.61 Lung cancer; chr6:149817526 chr6:149796151~149826294:- CESC cis rs1799949 1 rs8176126 ENSG00000198496.9 NBR2 11.31 1.21e-23 1.74e-19 0.77 0.61 Menopause (age at onset); chr17:43107032 chr17:43125610~43153671:+ CESC cis rs858239 0.633 rs858300 ENSG00000230658.1 KLHL7-AS1 11.31 1.26e-23 1.81e-19 0.77 0.61 Cerebrospinal fluid biomarker levels; chr7:23205012 chr7:23101228~23105703:- CESC cis rs858239 0.665 rs858305 ENSG00000230658.1 KLHL7-AS1 -11.31 1.27e-23 1.82e-19 -0.76 -0.61 Cerebrospinal fluid biomarker levels; chr7:23203211 chr7:23101228~23105703:- CESC cis rs9322193 0.887 rs9767113 ENSG00000231760.4 RP11-350J20.5 11.3 1.36e-23 1.94e-19 0.8 0.61 Lung cancer; chr6:149718157 chr6:149796151~149826294:- CESC cis rs858239 0.536 rs6961109 ENSG00000230658.1 KLHL7-AS1 11.28 1.53e-23 2.18e-19 0.78 0.61 Cerebrospinal fluid biomarker levels; chr7:23212794 chr7:23101228~23105703:- CESC cis rs801193 0.904 rs4718405 ENSG00000226824.5 RP4-756H11.3 -11.26 1.82e-23 2.58e-19 -0.76 -0.61 Aortic root size; chr7:66789659 chr7:66654538~66669855:+ CESC cis rs7208859 0.623 rs9906957 ENSG00000263531.1 RP13-753N3.1 11.25 1.89e-23 2.68e-19 1.19 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30830737 chr17:30863921~30864940:- CESC cis rs916888 0.61 rs199454 ENSG00000262539.1 RP11-259G18.3 -11.25 1.94e-23 2.75e-19 -0.77 -0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46259551~46260606:- CESC cis rs1799949 0.965 rs8176161 ENSG00000198496.9 NBR2 -11.24 1.97e-23 2.77e-19 -0.76 -0.61 Menopause (age at onset); chr17:43089373 chr17:43125610~43153671:+ CESC cis rs1799949 0.894 rs8176160 ENSG00000198496.9 NBR2 -11.24 1.97e-23 2.77e-19 -0.76 -0.61 Menopause (age at onset); chr17:43089486 chr17:43125610~43153671:+ CESC cis rs1799949 0.896 rs35908185 ENSG00000198496.9 NBR2 -11.24 1.97e-23 2.77e-19 -0.76 -0.61 Menopause (age at onset); chr17:43103094 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs8176130 ENSG00000198496.9 NBR2 -11.24 1.97e-23 2.77e-19 -0.76 -0.61 Menopause (age at onset); chr17:43106026 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176120 ENSG00000198496.9 NBR2 -11.24 1.97e-23 2.77e-19 -0.76 -0.61 Menopause (age at onset); chr17:43109216 chr17:43125610~43153671:+ CESC cis rs858239 0.699 rs1881200 ENSG00000230658.1 KLHL7-AS1 -11.24 1.97e-23 2.77e-19 -0.77 -0.61 Cerebrospinal fluid biomarker levels; chr7:23162018 chr7:23101228~23105703:- CESC cis rs4853012 0.887 rs6737314 ENSG00000217702.2 RP11-287D1.4 11.24 1.98e-23 2.78e-19 0.89 0.61 Gestational age at birth (maternal effect); chr2:74112459 chr2:74130583~74135395:+ CESC cis rs858239 0.899 rs28635122 ENSG00000230658.1 KLHL7-AS1 11.24 1.99e-23 2.79e-19 0.81 0.61 Cerebrospinal fluid biomarker levels; chr7:23270562 chr7:23101228~23105703:- CESC cis rs4423214 1 rs12785878 ENSG00000254682.1 RP11-660L16.2 11.24 2e-23 2.81e-19 0.76 0.61 Vitamin D levels; chr11:71456403 chr11:71448674~71452157:+ CESC cis rs858239 0.899 rs2268745 ENSG00000230658.1 KLHL7-AS1 11.24 2.02e-23 2.83e-19 0.81 0.61 Cerebrospinal fluid biomarker levels; chr7:23277981 chr7:23101228~23105703:- CESC cis rs7208859 0.673 rs9889968 ENSG00000263531.1 RP13-753N3.1 11.23 2.22e-23 3.08e-19 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30893110 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs61348930 ENSG00000263531.1 RP13-753N3.1 11.23 2.22e-23 3.08e-19 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30894745 chr17:30863921~30864940:- CESC cis rs7208859 0.614 rs28758251 ENSG00000263531.1 RP13-753N3.1 11.23 2.22e-23 3.08e-19 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896294 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9899943 ENSG00000263531.1 RP13-753N3.1 11.23 2.22e-23 3.08e-19 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896907 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11080138 ENSG00000263531.1 RP13-753N3.1 11.23 2.22e-23 3.08e-19 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30897524 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73265612 ENSG00000263531.1 RP13-753N3.1 11.23 2.22e-23 3.08e-19 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30898965 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11658435 ENSG00000263531.1 RP13-753N3.1 11.23 2.22e-23 3.08e-19 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30901543 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73265624 ENSG00000263531.1 RP13-753N3.1 11.23 2.22e-23 3.08e-19 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905048 chr17:30863921~30864940:- CESC cis rs1799949 0.965 rs8176193 ENSG00000198496.9 NBR2 -11.21 2.51e-23 3.47e-19 -0.76 -0.6 Menopause (age at onset); chr17:43079499 chr17:43125610~43153671:+ CESC cis rs9322193 0.923 rs12526675 ENSG00000231760.4 RP11-350J20.5 -11.21 2.56e-23 3.54e-19 -0.79 -0.6 Lung cancer; chr6:149729540 chr6:149796151~149826294:- CESC cis rs1799949 1 rs2070834 ENSG00000198496.9 NBR2 -11.2 2.63e-23 3.63e-19 -0.76 -0.6 Menopause (age at onset); chr17:43090268 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs16942 ENSG00000198496.9 NBR2 -11.2 2.63e-23 3.63e-19 -0.76 -0.6 Menopause (age at onset); chr17:43091983 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176145 ENSG00000198496.9 NBR2 -11.2 2.63e-23 3.63e-19 -0.76 -0.6 Menopause (age at onset); chr17:43097077 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs8176140 ENSG00000198496.9 NBR2 -11.2 2.63e-23 3.63e-19 -0.76 -0.6 Menopause (age at onset); chr17:43099629 chr17:43125610~43153671:+ CESC cis rs9322193 0.962 rs3805752 ENSG00000231760.4 RP11-350J20.5 11.2 2.77e-23 3.8e-19 0.8 0.6 Lung cancer; chr6:149795490 chr6:149796151~149826294:- CESC cis rs875971 0.666 rs13242072 ENSG00000226824.5 RP4-756H11.3 11.19 2.84e-23 3.9e-19 0.76 0.6 Aortic root size; chr7:66301001 chr7:66654538~66669855:+ CESC cis rs3814244 0.528 rs7962511 ENSG00000255733.4 IFNG-AS1 11.19 3e-23 4.12e-19 0.56 0.6 Itch intensity from mosquito bite adjusted by bite size; chr12:68002854 chr12:67989445~68234686:+ CESC cis rs7208859 0.673 rs73263785 ENSG00000263531.1 RP13-753N3.1 11.18 3.02e-23 4.13e-19 1.23 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887790 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs55904046 ENSG00000263531.1 RP13-753N3.1 11.18 3.02e-23 4.13e-19 1.23 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888373 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73263776 ENSG00000263531.1 RP13-753N3.1 11.18 3.05e-23 4.15e-19 1.23 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30884313 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11650271 ENSG00000263531.1 RP13-753N3.1 11.18 3.05e-23 4.15e-19 1.23 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30886925 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11657270 ENSG00000263531.1 RP13-753N3.1 11.18 3.05e-23 4.15e-19 1.23 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887369 chr17:30863921~30864940:- CESC cis rs875971 0.558 rs4433015 ENSG00000226824.5 RP4-756H11.3 11.18 3.05e-23 4.16e-19 0.76 0.6 Aortic root size; chr7:66174736 chr7:66654538~66669855:+ CESC cis rs7208859 0.673 rs2433 ENSG00000263531.1 RP13-753N3.1 11.17 3.29e-23 4.47e-19 1.23 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30899210 chr17:30863921~30864940:- CESC cis rs1799949 1 rs3950989 ENSG00000198496.9 NBR2 -11.17 3.37e-23 4.58e-19 -0.76 -0.6 Menopause (age at onset); chr17:43085936 chr17:43125610~43153671:+ CESC cis rs801193 1 rs2707856 ENSG00000226824.5 RP4-756H11.3 -11.17 3.37e-23 4.59e-19 -0.75 -0.6 Aortic root size; chr7:66746023 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2055682 ENSG00000226824.5 RP4-756H11.3 -11.17 3.4e-23 4.62e-19 -0.75 -0.6 Aortic root size; chr7:66795302 chr7:66654538~66669855:+ CESC cis rs2486288 0.656 rs12908818 ENSG00000259520.4 CTD-2651B20.3 11.17 3.41e-23 4.62e-19 0.8 0.6 Glomerular filtration rate; chr15:45279470 chr15:45251580~45279251:- CESC cis rs2486288 0.586 rs12909625 ENSG00000259520.4 CTD-2651B20.3 11.17 3.41e-23 4.62e-19 0.8 0.6 Glomerular filtration rate; chr15:45279855 chr15:45251580~45279251:- CESC cis rs2486288 0.586 rs12909883 ENSG00000259520.4 CTD-2651B20.3 11.17 3.41e-23 4.62e-19 0.8 0.6 Glomerular filtration rate; chr15:45279856 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs12910009 ENSG00000259520.4 CTD-2651B20.3 11.17 3.41e-23 4.62e-19 0.8 0.6 Glomerular filtration rate; chr15:45280210 chr15:45251580~45279251:- CESC cis rs858239 0.899 rs10085838 ENSG00000230658.1 KLHL7-AS1 11.17 3.42e-23 4.64e-19 0.8 0.6 Cerebrospinal fluid biomarker levels; chr7:23258796 chr7:23101228~23105703:- CESC cis rs1799949 1 rs33926631 ENSG00000198496.9 NBR2 -11.16 3.56e-23 4.83e-19 -0.77 -0.6 Menopause (age at onset); chr17:43152446 chr17:43125610~43153671:+ CESC cis rs3814244 0.528 rs11177002 ENSG00000255733.4 IFNG-AS1 11.16 3.68e-23 4.98e-19 0.56 0.6 Itch intensity from mosquito bite adjusted by bite size; chr12:68003377 chr12:67989445~68234686:+ CESC cis rs2739330 0.76 rs5751761 ENSG00000225282.1 AP000350.6 -11.15 3.91e-23 5.28e-19 -0.72 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23926900~23929574:+ CESC cis rs858239 0.899 rs5850 ENSG00000230658.1 KLHL7-AS1 11.14 4.23e-23 5.7e-19 0.8 0.6 Cerebrospinal fluid biomarker levels; chr7:23274928 chr7:23101228~23105703:- CESC cis rs9322193 0.923 rs4870509 ENSG00000231760.4 RP11-350J20.5 11.14 4.24e-23 5.7e-19 0.79 0.6 Lung cancer; chr6:149702212 chr6:149796151~149826294:- CESC cis rs801193 0.935 rs2659916 ENSG00000226824.5 RP4-756H11.3 -11.12 4.73e-23 6.34e-19 -0.75 -0.6 Aortic root size; chr7:66686365 chr7:66654538~66669855:+ CESC cis rs801193 1 rs6958520 ENSG00000226824.5 RP4-756H11.3 -11.12 4.73e-23 6.34e-19 -0.75 -0.6 Aortic root size; chr7:66686466 chr7:66654538~66669855:+ CESC cis rs4423214 1 rs732934 ENSG00000254682.1 RP11-660L16.2 11.11 4.98e-23 6.67e-19 0.78 0.6 Vitamin D levels; chr11:71475430 chr11:71448674~71452157:+ CESC cis rs858239 0.899 rs1881203 ENSG00000230658.1 KLHL7-AS1 11.1 5.4e-23 7.22e-19 0.79 0.6 Cerebrospinal fluid biomarker levels; chr7:23253189 chr7:23101228~23105703:- CESC cis rs9326248 0.861 rs4938348 ENSG00000254851.1 RP11-109L13.1 -11.1 5.41e-23 7.24e-19 -0.87 -0.6 Blood protein levels; chr11:117151161 chr11:117135528~117138582:+ CESC cis rs858239 0.899 rs10262243 ENSG00000230658.1 KLHL7-AS1 11.1 5.48e-23 7.31e-19 0.79 0.6 Cerebrospinal fluid biomarker levels; chr7:23251368 chr7:23101228~23105703:- CESC cis rs10256972 0.577 rs4999286 ENSG00000229043.2 AC091729.9 -11.09 5.91e-23 7.86e-19 -0.67 -0.6 Endometriosis;Longevity; chr7:1159870 chr7:1160374~1165267:+ CESC cis rs858239 0.73 rs858290 ENSG00000230658.1 KLHL7-AS1 11.09 6.07e-23 8.07e-19 0.76 0.6 Cerebrospinal fluid biomarker levels; chr7:23208417 chr7:23101228~23105703:- CESC cis rs858239 0.73 rs858289 ENSG00000230658.1 KLHL7-AS1 11.09 6.07e-23 8.07e-19 0.76 0.6 Cerebrospinal fluid biomarker levels; chr7:23208539 chr7:23101228~23105703:- CESC cis rs7208859 0.623 rs3752019 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824687 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73271869 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825203 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73271872 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825210 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs56146117 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826307 chr17:30863921~30864940:- CESC cis rs17826219 0.568 rs9907834 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Body mass index; chr17:30826995 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73271887 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827917 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9898858 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829193 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs55658077 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829501 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9899692 ENSG00000263531.1 RP13-753N3.1 11.08 6.47e-23 8.54e-19 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829921 chr17:30863921~30864940:- CESC cis rs9322193 0.923 rs55849538 ENSG00000231760.4 RP11-350J20.5 11.07 6.83e-23 9.01e-19 0.77 0.6 Lung cancer; chr6:149635330 chr6:149796151~149826294:- CESC cis rs4423214 0.921 rs12807827 ENSG00000254682.1 RP11-660L16.2 11.07 6.91e-23 9.12e-19 0.79 0.6 Vitamin D levels; chr11:71492744 chr11:71448674~71452157:+ CESC cis rs7208859 0.673 rs12103759 ENSG00000263531.1 RP13-753N3.1 11.06 7.49e-23 9.83e-19 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908669 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs59029591 ENSG00000263531.1 RP13-753N3.1 11.06 7.49e-23 9.83e-19 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908728 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73265633 ENSG00000263531.1 RP13-753N3.1 11.06 7.49e-23 9.83e-19 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30909288 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9913782 ENSG00000263531.1 RP13-753N3.1 11.06 7.49e-23 9.83e-19 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910366 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9895684 ENSG00000263531.1 RP13-753N3.1 11.06 7.49e-23 9.83e-19 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30915582 chr17:30863921~30864940:- CESC cis rs858239 1 rs858239 ENSG00000230658.1 KLHL7-AS1 11.05 7.89e-23 1.03e-18 0.74 0.6 Cerebrospinal fluid biomarker levels; chr7:23246696 chr7:23101228~23105703:- CESC cis rs858239 0.899 rs28458177 ENSG00000230658.1 KLHL7-AS1 11.05 7.93e-23 1.04e-18 0.79 0.6 Cerebrospinal fluid biomarker levels; chr7:23255253 chr7:23101228~23105703:- CESC cis rs4423214 0.879 rs4945008 ENSG00000254682.1 RP11-660L16.2 11.05 7.95e-23 1.04e-18 0.76 0.6 Vitamin D levels; chr11:71510202 chr11:71448674~71452157:+ CESC cis rs801193 1 rs3778909 ENSG00000226824.5 RP4-756H11.3 -11.03 8.79e-23 1.15e-18 -0.74 -0.6 Aortic root size; chr7:66790659 chr7:66654538~66669855:+ CESC cis rs2739330 0.796 rs2154594 ENSG00000218537.1 MIF-AS1 -11.03 8.85e-23 1.16e-18 -0.78 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23894426~23898930:- CESC cis rs9322193 0.923 rs12176034 ENSG00000231760.4 RP11-350J20.5 11.03 9.29e-23 1.21e-18 0.79 0.6 Lung cancer; chr6:149800557 chr6:149796151~149826294:- CESC cis rs2739330 0.734 rs2000467 ENSG00000273295.1 AP000350.5 -11.02 9.61e-23 1.25e-18 -0.69 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23901432~23907068:- CESC cis rs801193 0.967 rs2420827 ENSG00000226824.5 RP4-756H11.3 11.02 9.78e-23 1.27e-18 0.76 0.6 Aortic root size; chr7:66682114 chr7:66654538~66669855:+ CESC cis rs4423214 1 rs4944946 ENSG00000254682.1 RP11-660L16.2 11 1.1e-22 1.42e-18 0.77 0.6 Vitamin D levels; chr11:71448383 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs28364617 ENSG00000254682.1 RP11-660L16.2 11 1.1e-22 1.42e-18 0.77 0.6 Vitamin D levels; chr11:71448718 chr11:71448674~71452157:+ CESC cis rs801193 1 rs4717319 ENSG00000226824.5 RP4-756H11.3 -11 1.11e-22 1.44e-18 -0.73 -0.6 Aortic root size; chr7:66777606 chr7:66654538~66669855:+ CESC cis rs2486288 0.656 rs2413771 ENSG00000259520.4 CTD-2651B20.3 11 1.12e-22 1.45e-18 0.78 0.6 Glomerular filtration rate; chr15:45260942 chr15:45251580~45279251:- CESC cis rs801193 0.904 rs4718403 ENSG00000226824.5 RP4-756H11.3 -10.99 1.18e-22 1.52e-18 -0.73 -0.6 Aortic root size; chr7:66777742 chr7:66654538~66669855:+ CESC cis rs9322193 0.962 rs2342764 ENSG00000231760.4 RP11-350J20.5 10.99 1.2e-22 1.55e-18 0.8 0.6 Lung cancer; chr6:149835068 chr6:149796151~149826294:- CESC cis rs1799949 0.896 rs8176086 ENSG00000198496.9 NBR2 -10.99 1.22e-22 1.57e-18 -0.76 -0.6 Menopause (age at onset); chr17:43122761 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs3765640 ENSG00000198496.9 NBR2 -10.99 1.22e-22 1.57e-18 -0.76 -0.6 Menopause (age at onset); chr17:43124230 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176077 ENSG00000198496.9 NBR2 -10.99 1.22e-22 1.57e-18 -0.76 -0.6 Menopause (age at onset); chr17:43124331 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs11655505 ENSG00000198496.9 NBR2 -10.99 1.22e-22 1.57e-18 -0.76 -0.6 Menopause (age at onset); chr17:43126360 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs4793204 ENSG00000198496.9 NBR2 -10.99 1.22e-22 1.57e-18 -0.76 -0.6 Menopause (age at onset); chr17:43127281 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs12947782 ENSG00000198496.9 NBR2 -10.99 1.22e-22 1.57e-18 -0.76 -0.6 Menopause (age at onset); chr17:43127865 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs33945274 ENSG00000198496.9 NBR2 -10.99 1.22e-22 1.57e-18 -0.76 -0.6 Menopause (age at onset); chr17:43128056 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs33925201 ENSG00000198496.9 NBR2 -10.99 1.22e-22 1.57e-18 -0.76 -0.6 Menopause (age at onset); chr17:43128665 chr17:43125610~43153671:+ CESC cis rs801193 1 rs7782320 ENSG00000226824.5 RP4-756H11.3 -10.99 1.22e-22 1.57e-18 -0.74 -0.6 Aortic root size; chr7:66712111 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs35668327 ENSG00000198496.9 NBR2 -10.98 1.31e-22 1.68e-18 -0.76 -0.6 Menopause (age at onset); chr17:43121078 chr17:43125610~43153671:+ CESC cis rs916888 0.61 rs199446 ENSG00000262539.1 RP11-259G18.3 -10.97 1.35e-22 1.73e-18 -0.74 -0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46259551~46260606:- CESC cis rs7208859 0.673 rs2269915 ENSG00000263531.1 RP13-753N3.1 10.97 1.38e-22 1.76e-18 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906326 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs2269916 ENSG00000263531.1 RP13-753N3.1 10.97 1.38e-22 1.76e-18 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906745 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11649765 ENSG00000263531.1 RP13-753N3.1 10.97 1.38e-22 1.76e-18 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906870 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs79541516 ENSG00000263531.1 RP13-753N3.1 10.97 1.38e-22 1.76e-18 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913565 chr17:30863921~30864940:- CESC cis rs9322193 0.923 rs12205092 ENSG00000231760.4 RP11-350J20.5 10.97 1.41e-22 1.8e-18 0.79 0.6 Lung cancer; chr6:149761375 chr6:149796151~149826294:- CESC cis rs1799949 1 rs1960605 ENSG00000198496.9 NBR2 -10.97 1.44e-22 1.84e-18 -0.76 -0.6 Menopause (age at onset); chr17:43153380 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs2037076 ENSG00000198496.9 NBR2 -10.97 1.44e-22 1.84e-18 -0.76 -0.6 Menopause (age at onset); chr17:43153866 chr17:43125610~43153671:+ CESC cis rs2739330 0.76 rs5751761 ENSG00000218537.1 MIF-AS1 -10.96 1.49e-22 1.9e-18 -0.76 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23894426~23898930:- CESC cis rs9322193 0.923 rs9800686 ENSG00000231760.4 RP11-350J20.5 10.96 1.51e-22 1.92e-18 0.76 0.6 Lung cancer; chr6:149634464 chr6:149796151~149826294:- CESC cis rs9322193 0.923 rs57938011 ENSG00000231760.4 RP11-350J20.5 10.96 1.51e-22 1.92e-18 0.76 0.6 Lung cancer; chr6:149642969 chr6:149796151~149826294:- CESC cis rs858239 1 rs199347 ENSG00000230658.1 KLHL7-AS1 10.96 1.52e-22 1.93e-18 0.73 0.6 Cerebrospinal fluid biomarker levels; chr7:23254127 chr7:23101228~23105703:- CESC cis rs9322193 0.923 rs6913486 ENSG00000231760.4 RP11-350J20.5 -10.96 1.53e-22 1.94e-18 -0.79 -0.6 Lung cancer; chr6:149705060 chr6:149796151~149826294:- CESC cis rs1799949 1 rs11653069 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43131360 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs33988650 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43135863 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs11656097 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43138596 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs2292595 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43138657 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs11658754 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43140722 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs33968979 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43145975 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs12952790 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43147590 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs12950607 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43147911 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs11079056 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43148782 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs12936816 ENSG00000198496.9 NBR2 -10.96 1.55e-22 1.96e-18 -0.76 -0.6 Menopause (age at onset); chr17:43149692 chr17:43125610~43153671:+ CESC cis rs9322193 0.886 rs2065663 ENSG00000231760.4 RP11-350J20.5 10.95 1.61e-22 2.02e-18 0.79 0.6 Lung cancer; chr6:149760331 chr6:149796151~149826294:- CESC cis rs1799949 1 rs2175957 ENSG00000198496.9 NBR2 -10.95 1.61e-22 2.03e-18 -0.76 -0.6 Menopause (age at onset); chr17:43134805 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs12950779 ENSG00000198496.9 NBR2 -10.94 1.7e-22 2.14e-18 -0.76 -0.6 Menopause (age at onset); chr17:43154506 chr17:43125610~43153671:+ CESC cis rs801193 0.967 rs3800823 ENSG00000226824.5 RP4-756H11.3 10.94 1.76e-22 2.21e-18 0.75 0.6 Aortic root size; chr7:66682123 chr7:66654538~66669855:+ CESC cis rs1799949 0.965 rs4793234 ENSG00000198496.9 NBR2 -10.93 1.83e-22 2.3e-18 -0.76 -0.6 Menopause (age at onset); chr17:43358815 chr17:43125610~43153671:+ CESC cis rs9322193 0.923 rs9322214 ENSG00000231760.4 RP11-350J20.5 10.93 1.84e-22 2.31e-18 0.79 0.6 Lung cancer; chr6:149703986 chr6:149796151~149826294:- CESC cis rs7208859 0.673 rs78799101 ENSG00000263531.1 RP13-753N3.1 10.93 1.91e-22 2.4e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888142 chr17:30863921~30864940:- CESC cis rs9322193 0.81 rs62439811 ENSG00000231760.4 RP11-350J20.5 10.92 1.96e-22 2.45e-18 0.76 0.59 Lung cancer; chr6:149640416 chr6:149796151~149826294:- CESC cis rs875971 0.577 rs34888281 ENSG00000226824.5 RP4-756H11.3 10.92 2.03e-22 2.54e-18 0.75 0.59 Aortic root size; chr7:66120784 chr7:66654538~66669855:+ CESC cis rs801193 0.967 rs2707841 ENSG00000226824.5 RP4-756H11.3 -10.91 2.11e-22 2.63e-18 -0.74 -0.59 Aortic root size; chr7:66692033 chr7:66654538~66669855:+ CESC cis rs801193 1 rs4717310 ENSG00000226824.5 RP4-756H11.3 -10.91 2.11e-22 2.63e-18 -0.74 -0.59 Aortic root size; chr7:66696020 chr7:66654538~66669855:+ CESC cis rs801193 0.935 rs2659899 ENSG00000226824.5 RP4-756H11.3 -10.91 2.11e-22 2.63e-18 -0.74 -0.59 Aortic root size; chr7:66721734 chr7:66654538~66669855:+ CESC cis rs801193 1 rs62466794 ENSG00000226824.5 RP4-756H11.3 -10.91 2.11e-22 2.63e-18 -0.74 -0.59 Aortic root size; chr7:66726592 chr7:66654538~66669855:+ CESC cis rs801193 1 rs1553609 ENSG00000226824.5 RP4-756H11.3 -10.91 2.11e-22 2.63e-18 -0.74 -0.59 Aortic root size; chr7:66732152 chr7:66654538~66669855:+ CESC cis rs12594515 0.694 rs2068295 ENSG00000273972.1 CTD-2306A12.1 -10.91 2.16e-22 2.69e-18 -0.65 -0.59 Weight;Waist circumference; chr15:45693348 chr15:45702640~45703183:+ CESC cis rs12594515 0.694 rs2068294 ENSG00000273972.1 CTD-2306A12.1 -10.91 2.16e-22 2.69e-18 -0.65 -0.59 Weight;Waist circumference; chr15:45693350 chr15:45702640~45703183:+ CESC cis rs9322193 0.772 rs7738696 ENSG00000231760.4 RP11-350J20.5 10.91 2.2e-22 2.73e-18 0.8 0.59 Lung cancer; chr6:149848985 chr6:149796151~149826294:- CESC cis rs10256972 0.567 rs2960835 ENSG00000229043.2 AC091729.9 -10.89 2.45e-22 3.04e-18 -0.66 -0.59 Endometriosis;Longevity; chr7:1163327 chr7:1160374~1165267:+ CESC cis rs801193 1 rs7788576 ENSG00000226824.5 RP4-756H11.3 10.89 2.54e-22 3.14e-18 0.74 0.59 Aortic root size; chr7:66683315 chr7:66654538~66669855:+ CESC cis rs1799949 0.929 rs12937015 ENSG00000198496.9 NBR2 -10.86 2.98e-22 3.68e-18 -0.75 -0.59 Menopause (age at onset); chr17:43155456 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs4340367 ENSG00000198496.9 NBR2 -10.86 2.98e-22 3.68e-18 -0.75 -0.59 Menopause (age at onset); chr17:43155755 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs4792981 ENSG00000198496.9 NBR2 -10.86 2.98e-22 3.68e-18 -0.75 -0.59 Menopause (age at onset); chr17:43156257 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176109 ENSG00000198496.9 NBR2 -10.86 3e-22 3.69e-18 -0.75 -0.59 Menopause (age at onset); chr17:43113759 chr17:43125610~43153671:+ CESC cis rs1799949 0.896 rs8176098 ENSG00000198496.9 NBR2 -10.86 3e-22 3.69e-18 -0.75 -0.59 Menopause (age at onset); chr17:43116189 chr17:43125610~43153671:+ CESC cis rs7208859 0.623 rs55724095 ENSG00000263531.1 RP13-753N3.1 10.86 3.02e-22 3.71e-18 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826040 chr17:30863921~30864940:- CESC cis rs17826219 0.568 rs9903854 ENSG00000263531.1 RP13-753N3.1 10.86 3.02e-22 3.71e-18 1.18 0.59 Body mass index; chr17:30826980 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs80355557 ENSG00000263531.1 RP13-753N3.1 10.86 3.02e-22 3.71e-18 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827403 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9911173 ENSG00000263531.1 RP13-753N3.1 10.86 3.02e-22 3.71e-18 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827732 chr17:30863921~30864940:- CESC cis rs9322193 0.962 rs7740784 ENSG00000231760.4 RP11-350J20.5 10.86 3.09e-22 3.79e-18 0.78 0.59 Lung cancer; chr6:149833364 chr6:149796151~149826294:- CESC cis rs916888 0.61 rs199536 ENSG00000262539.1 RP11-259G18.3 -10.85 3.33e-22 4.07e-18 -0.73 -0.59 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46259551~46260606:- CESC cis rs6597981 0.592 rs10902218 ENSG00000279672.1 CMB9-55F22.1 -10.84 3.55e-22 4.33e-18 -0.57 -0.59 Breast cancer; chr11:743813 chr11:779617~780755:+ CESC cis rs17826219 0.706 rs9905827 ENSG00000263531.1 RP13-753N3.1 10.83 3.85e-22 4.69e-18 1.21 0.59 Body mass index; chr17:30865150 chr17:30863921~30864940:- CESC cis rs1799949 1 rs8176103 ENSG00000198496.9 NBR2 -10.83 3.91e-22 4.76e-18 -0.75 -0.59 Menopause (age at onset); chr17:43115033 chr17:43125610~43153671:+ CESC cis rs1577917 0.74 rs9450302 ENSG00000203875.9 SNHG5 10.82 3.97e-22 4.83e-18 0.64 0.59 Response to antipsychotic treatment; chr6:85579955 chr6:85660950~85678736:- CESC cis rs7208859 0.623 rs11651858 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843700 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs36056619 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30845266 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9909497 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846210 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11080135 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30849463 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9894876 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855002 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73277967 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30857148 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs60020217 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30858036 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs73277974 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862851 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73277978 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864431 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11657391 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30867269 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs58089675 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869746 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73263755 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30871954 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9899349 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30873104 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11652358 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30878462 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9891179 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881142 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9891413 ENSG00000263531.1 RP13-753N3.1 10.82 4.09e-22 4.91e-18 1.21 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881191 chr17:30863921~30864940:- CESC cis rs7847628 0.551 rs10818476 ENSG00000226752.6 PSMD5-AS1 -10.82 4.2e-22 5.04e-18 -0.65 -0.59 Birth weight; chr9:120809760 chr9:120824828~120854385:+ CESC cis rs9322193 0.923 rs10872651 ENSG00000231760.4 RP11-350J20.5 10.81 4.32e-22 5.17e-18 0.78 0.59 Lung cancer; chr6:149768273 chr6:149796151~149826294:- CESC cis rs9322193 0.962 rs3805749 ENSG00000231760.4 RP11-350J20.5 10.81 4.32e-22 5.17e-18 0.78 0.59 Lung cancer; chr6:149772546 chr6:149796151~149826294:- CESC cis rs9322193 0.847 rs9505972 ENSG00000231760.4 RP11-350J20.5 10.81 4.32e-22 5.17e-18 0.78 0.59 Lung cancer; chr6:149775255 chr6:149796151~149826294:- CESC cis rs7208859 0.673 rs11656845 ENSG00000263531.1 RP13-753N3.1 10.8 4.73e-22 5.64e-18 1.22 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879146 chr17:30863921~30864940:- CESC cis rs2486288 0.554 rs1719235 ENSG00000259520.4 CTD-2651B20.3 10.79 4.9e-22 5.84e-18 0.76 0.59 Glomerular filtration rate; chr15:45283910 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11631021 ENSG00000259520.4 CTD-2651B20.3 10.78 5.21e-22 6.2e-18 0.77 0.59 Glomerular filtration rate; chr15:45264631 chr15:45251580~45279251:- CESC cis rs858239 0.536 rs6956974 ENSG00000230658.1 KLHL7-AS1 -10.78 5.33e-22 6.33e-18 -0.77 -0.59 Cerebrospinal fluid biomarker levels; chr7:23212699 chr7:23101228~23105703:- CESC cis rs875971 0.619 rs12533585 ENSG00000226824.5 RP4-756H11.3 -10.77 5.63e-22 6.67e-18 -0.73 -0.59 Aortic root size; chr7:66519618 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs28698552 ENSG00000226824.5 RP4-756H11.3 -10.77 5.63e-22 6.67e-18 -0.73 -0.59 Aortic root size; chr7:66540031 chr7:66654538~66669855:+ CESC cis rs9322193 0.887 rs11155662 ENSG00000231760.4 RP11-350J20.5 10.77 5.73e-22 6.79e-18 0.76 0.59 Lung cancer; chr6:149592731 chr6:149796151~149826294:- CESC cis rs7208859 0.623 rs58908911 ENSG00000263531.1 RP13-753N3.1 10.77 5.86e-22 6.93e-18 1.19 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917540 chr17:30863921~30864940:- CESC cis rs1799949 1 rs8176202 ENSG00000198496.9 NBR2 -10.76 6.12e-22 7.23e-18 -0.76 -0.59 Menopause (age at onset); chr17:43078211 chr17:43125610~43153671:+ CESC cis rs2486288 0.656 rs11639420 ENSG00000259520.4 CTD-2651B20.3 10.75 6.47e-22 7.61e-18 0.76 0.59 Glomerular filtration rate; chr15:45267070 chr15:45251580~45279251:- CESC cis rs10256972 0.552 rs2949192 ENSG00000229043.2 AC091729.9 -10.75 6.75e-22 7.95e-18 -0.65 -0.59 Endometriosis;Longevity; chr7:1164205 chr7:1160374~1165267:+ CESC cis rs2486288 0.656 rs1706770 ENSG00000259520.4 CTD-2651B20.3 10.75 6.87e-22 8.08e-18 0.76 0.59 Glomerular filtration rate; chr15:45282864 chr15:45251580~45279251:- CESC cis rs4423214 1 rs909217 ENSG00000254682.1 RP11-660L16.2 10.73 7.43e-22 8.7e-18 0.76 0.59 Vitamin D levels; chr11:71435531 chr11:71448674~71452157:+ CESC cis rs858239 0.899 rs858271 ENSG00000230658.1 KLHL7-AS1 10.73 7.76e-22 9.06e-18 0.73 0.59 Cerebrospinal fluid biomarker levels; chr7:23238664 chr7:23101228~23105703:- CESC cis rs950027 0.549 rs11070452 ENSG00000259520.4 CTD-2651B20.3 10.72 8.09e-22 9.44e-18 0.77 0.59 Response to fenofibrate (adiponectin levels); chr15:45302638 chr15:45251580~45279251:- CESC cis rs7847628 0.587 rs1060817 ENSG00000226752.6 PSMD5-AS1 -10.71 8.66e-22 1.01e-17 -0.64 -0.59 Birth weight; chr9:120820914 chr9:120824828~120854385:+ CESC cis rs7847628 0.587 rs10760117 ENSG00000226752.6 PSMD5-AS1 -10.71 8.66e-22 1.01e-17 -0.64 -0.59 Birth weight; chr9:120824459 chr9:120824828~120854385:+ CESC cis rs2486288 0.656 rs2461705 ENSG00000259520.4 CTD-2651B20.3 10.71 8.66e-22 1.01e-17 0.77 0.59 Glomerular filtration rate; chr15:45278043 chr15:45251580~45279251:- CESC cis rs1799949 1 rs16941 ENSG00000198496.9 NBR2 -10.71 8.92e-22 1.04e-17 -0.75 -0.59 Menopause (age at onset); chr17:43092418 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs67060599 ENSG00000198496.9 NBR2 -10.71 8.92e-22 1.04e-17 -0.75 -0.59 Menopause (age at onset); chr17:43103085 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176133 ENSG00000198496.9 NBR2 -10.71 8.92e-22 1.04e-17 -0.75 -0.59 Menopause (age at onset); chr17:43105441 chr17:43125610~43153671:+ CESC cis rs2486288 0.656 rs12440356 ENSG00000259520.4 CTD-2651B20.3 -10.7 9.57e-22 1.1e-17 -0.77 -0.59 Glomerular filtration rate; chr15:45275331 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11639349 ENSG00000259520.4 CTD-2651B20.3 10.7 9.57e-22 1.1e-17 0.77 0.59 Glomerular filtration rate; chr15:45276062 chr15:45251580~45279251:- CESC cis rs10256972 0.567 rs2949185 ENSG00000229043.2 AC091729.9 -10.7 9.62e-22 1.11e-17 -0.65 -0.59 Endometriosis;Longevity; chr7:1169377 chr7:1160374~1165267:+ CESC cis rs10256972 0.552 rs7805591 ENSG00000229043.2 AC091729.9 -10.7 9.65e-22 1.11e-17 -0.65 -0.59 Endometriosis;Longevity; chr7:1171109 chr7:1160374~1165267:+ CESC cis rs875971 0.66 rs801192 ENSG00000226824.5 RP4-756H11.3 10.69 1.01e-21 1.16e-17 0.73 0.59 Aortic root size; chr7:66566965 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs801190 ENSG00000226824.5 RP4-756H11.3 10.69 1.01e-21 1.16e-17 0.73 0.59 Aortic root size; chr7:66568046 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs3857686 ENSG00000226824.5 RP4-756H11.3 10.69 1.01e-21 1.16e-17 0.73 0.59 Aortic root size; chr7:66571204 chr7:66654538~66669855:+ CESC cis rs858239 1 rs166663 ENSG00000230658.1 KLHL7-AS1 10.69 1.03e-21 1.19e-17 0.75 0.59 Cerebrospinal fluid biomarker levels; chr7:23277123 chr7:23101228~23105703:- CESC cis rs858239 1 rs858240 ENSG00000230658.1 KLHL7-AS1 10.69 1.04e-21 1.19e-17 0.73 0.59 Cerebrospinal fluid biomarker levels; chr7:23244618 chr7:23101228~23105703:- CESC cis rs1930961 1 rs6004668 ENSG00000272977.1 CTA-390C10.10 10.68 1.08e-21 1.24e-17 0.9 0.59 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25476218~25479971:+ CESC cis rs7208859 0.614 rs73265646 ENSG00000263531.1 RP13-753N3.1 10.68 1.11e-21 1.26e-17 1.19 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917005 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11651802 ENSG00000263531.1 RP13-753N3.1 10.68 1.11e-21 1.27e-17 1.2 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832642 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs17826219 ENSG00000263531.1 RP13-753N3.1 10.68 1.11e-21 1.27e-17 1.2 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834827 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs61223749 ENSG00000263531.1 RP13-753N3.1 10.68 1.11e-21 1.27e-17 1.2 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30836729 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs3764420 ENSG00000263531.1 RP13-753N3.1 10.68 1.11e-21 1.27e-17 1.2 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837136 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs3764421 ENSG00000263531.1 RP13-753N3.1 10.68 1.11e-21 1.27e-17 1.2 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30840635 chr17:30863921~30864940:- CESC cis rs1799949 0.93 rs66499067 ENSG00000198496.9 NBR2 -10.67 1.15e-21 1.3e-17 -0.74 -0.59 Menopause (age at onset); chr17:43096467 chr17:43125610~43153671:+ CESC cis rs9322193 0.886 rs9767555 ENSG00000231760.4 RP11-350J20.5 10.66 1.28e-21 1.44e-17 0.74 0.59 Lung cancer; chr6:149647022 chr6:149796151~149826294:- CESC cis rs7847628 0.587 rs4837796 ENSG00000226752.6 PSMD5-AS1 10.64 1.44e-21 1.62e-17 0.62 0.58 Birth weight; chr9:120848010 chr9:120824828~120854385:+ CESC cis rs9322193 0.923 rs4869750 ENSG00000231760.4 RP11-350J20.5 10.64 1.49e-21 1.67e-17 0.83 0.58 Lung cancer; chr6:149855996 chr6:149796151~149826294:- CESC cis rs1799949 1 rs34942571 ENSG00000198496.9 NBR2 -10.63 1.6e-21 1.78e-17 -0.76 -0.58 Menopause (age at onset); chr17:43121362 chr17:43125610~43153671:+ CESC cis rs875971 0.638 rs7793569 ENSG00000226824.5 RP4-756H11.3 10.62 1.64e-21 1.82e-17 0.73 0.58 Aortic root size; chr7:66651646 chr7:66654538~66669855:+ CESC cis rs801193 1 rs6975195 ENSG00000226824.5 RP4-756H11.3 10.62 1.64e-21 1.82e-17 0.73 0.58 Aortic root size; chr7:66659787 chr7:66654538~66669855:+ CESC cis rs801193 1 rs3857688 ENSG00000226824.5 RP4-756H11.3 10.62 1.64e-21 1.82e-17 0.73 0.58 Aortic root size; chr7:66662819 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2286684 ENSG00000226824.5 RP4-756H11.3 10.62 1.64e-21 1.82e-17 0.73 0.58 Aortic root size; chr7:66664843 chr7:66654538~66669855:+ CESC cis rs801193 0.935 rs2286683 ENSG00000226824.5 RP4-756H11.3 10.62 1.64e-21 1.82e-17 0.73 0.58 Aortic root size; chr7:66664856 chr7:66654538~66669855:+ CESC cis rs801193 1 rs10274773 ENSG00000226824.5 RP4-756H11.3 10.62 1.64e-21 1.82e-17 0.73 0.58 Aortic root size; chr7:66668591 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs1060915 ENSG00000198496.9 NBR2 -10.61 1.75e-21 1.93e-17 -0.74 -0.58 Menopause (age at onset); chr17:43082453 chr17:43125610~43153671:+ CESC cis rs4423214 1 rs12797951 ENSG00000254682.1 RP11-660L16.2 -10.59 2.04e-21 2.24e-17 -0.74 -0.58 Vitamin D levels; chr11:71432220 chr11:71448674~71452157:+ CESC cis rs2486288 0.656 rs11632419 ENSG00000259520.4 CTD-2651B20.3 10.59 2.11e-21 2.32e-17 0.75 0.58 Glomerular filtration rate; chr15:45265258 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs2271438 ENSG00000259520.4 CTD-2651B20.3 10.59 2.11e-21 2.32e-17 0.75 0.58 Glomerular filtration rate; chr15:45265270 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11854365 ENSG00000259520.4 CTD-2651B20.3 10.59 2.11e-21 2.32e-17 0.75 0.58 Glomerular filtration rate; chr15:45265885 chr15:45251580~45279251:- CESC cis rs16828019 0.777 rs2300658 ENSG00000235358.1 RP11-399E6.1 10.58 2.21e-21 2.43e-17 0.92 0.58 Intelligence (multi-trait analysis); chr1:41039350 chr1:41242373~41284861:+ CESC cis rs2486288 0.656 rs1706768 ENSG00000259520.4 CTD-2651B20.3 10.57 2.35e-21 2.56e-17 0.76 0.58 Glomerular filtration rate; chr15:45277245 chr15:45251580~45279251:- CESC cis rs875971 0.638 rs6460305 ENSG00000226824.5 RP4-756H11.3 10.57 2.38e-21 2.59e-17 0.73 0.58 Aortic root size; chr7:66595421 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs10272357 ENSG00000226824.5 RP4-756H11.3 10.57 2.38e-21 2.59e-17 0.73 0.58 Aortic root size; chr7:66598087 chr7:66654538~66669855:+ CESC cis rs1799949 0.965 rs8176087 ENSG00000198496.9 NBR2 -10.55 2.68e-21 2.91e-17 -0.75 -0.58 Menopause (age at onset); chr17:43118649 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176083 ENSG00000198496.9 NBR2 -10.55 2.68e-21 2.91e-17 -0.75 -0.58 Menopause (age at onset); chr17:43123134 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs8176194 ENSG00000198496.9 NBR2 -10.55 2.69e-21 2.91e-17 -0.74 -0.58 Menopause (age at onset); chr17:43079204 chr17:43125610~43153671:+ CESC cis rs950027 0.549 rs9920634 ENSG00000259520.4 CTD-2651B20.3 10.55 2.76e-21 2.97e-17 0.76 0.58 Response to fenofibrate (adiponectin levels); chr15:45304348 chr15:45251580~45279251:- CESC cis rs950027 0.549 rs2899375 ENSG00000259520.4 CTD-2651B20.3 10.55 2.82e-21 3.04e-17 0.76 0.58 Response to fenofibrate (adiponectin levels); chr15:45306137 chr15:45251580~45279251:- CESC cis rs9322193 0.884 rs10872648 ENSG00000231760.4 RP11-350J20.5 10.54 3.04e-21 3.27e-17 0.76 0.58 Lung cancer; chr6:149758699 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs11155679 ENSG00000231760.4 RP11-350J20.5 10.54 3.04e-21 3.27e-17 0.76 0.58 Lung cancer; chr6:149758881 chr6:149796151~149826294:- CESC cis rs1799949 0.965 rs4793233 ENSG00000198496.9 NBR2 -10.54 3.04e-21 3.27e-17 -0.75 -0.58 Menopause (age at onset); chr17:43358069 chr17:43125610~43153671:+ CESC cis rs1799949 0.864 rs60309406 ENSG00000198496.9 NBR2 -10.54 3.04e-21 3.27e-17 -0.75 -0.58 Menopause (age at onset); chr17:43358297 chr17:43125610~43153671:+ CESC cis rs9322193 1 rs58189451 ENSG00000231760.4 RP11-350J20.5 10.53 3.11e-21 3.33e-17 0.77 0.58 Lung cancer; chr6:149600252 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs10872647 ENSG00000231760.4 RP11-350J20.5 10.53 3.23e-21 3.46e-17 0.76 0.58 Lung cancer; chr6:149758687 chr6:149796151~149826294:- CESC cis rs1799949 1 rs16940 ENSG00000198496.9 NBR2 -10.5 3.79e-21 4.04e-17 -0.73 -0.58 Menopause (age at onset); chr17:43093220 chr17:43125610~43153671:+ CESC cis rs858239 0.72 rs10227559 ENSG00000230658.1 KLHL7-AS1 10.5 4.01e-21 4.26e-17 0.79 0.58 Cerebrospinal fluid biomarker levels; chr7:23232525 chr7:23101228~23105703:- CESC cis rs4423214 0.879 rs12803256 ENSG00000254682.1 RP11-660L16.2 10.49 4.05e-21 4.3e-17 0.76 0.58 Vitamin D levels; chr11:71421822 chr11:71448674~71452157:+ CESC cis rs1577917 0.654 rs9450284 ENSG00000203875.9 SNHG5 10.49 4.09e-21 4.34e-17 0.65 0.58 Response to antipsychotic treatment; chr6:85489611 chr6:85660950~85678736:- CESC cis rs1799949 1 rs11649954 ENSG00000198496.9 NBR2 -10.49 4.19e-21 4.44e-17 -0.74 -0.58 Menopause (age at onset); chr17:43342667 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs1824889 ENSG00000198496.9 NBR2 -10.49 4.19e-21 4.44e-17 -0.74 -0.58 Menopause (age at onset); chr17:43344508 chr17:43125610~43153671:+ CESC cis rs858239 0.932 rs1624451 ENSG00000230658.1 KLHL7-AS1 -10.49 4.24e-21 4.49e-17 -0.75 -0.58 Cerebrospinal fluid biomarker levels; chr7:23222816 chr7:23101228~23105703:- CESC cis rs801193 0.935 rs3800820 ENSG00000226824.5 RP4-756H11.3 10.48 4.33e-21 4.58e-17 0.72 0.58 Aortic root size; chr7:66682191 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2003301 ENSG00000226824.5 RP4-756H11.3 10.48 4.33e-21 4.58e-17 0.72 0.58 Aortic root size; chr7:66682669 chr7:66654538~66669855:+ CESC cis rs4853012 1 rs4853012 ENSG00000217702.2 RP11-287D1.4 10.48 4.47e-21 4.72e-17 0.96 0.58 Gestational age at birth (maternal effect); chr2:74134163 chr2:74130583~74135395:+ CESC cis rs1799949 0.931 rs34410138 ENSG00000198496.9 NBR2 -10.47 4.97e-21 5.22e-17 -0.73 -0.58 Menopause (age at onset); chr17:43127753 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs33961729 ENSG00000198496.9 NBR2 -10.46 5.06e-21 5.3e-17 -0.74 -0.58 Menopause (age at onset); chr17:43135907 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs11652332 ENSG00000198496.9 NBR2 -10.46 5.06e-21 5.3e-17 -0.74 -0.58 Menopause (age at onset); chr17:43143472 chr17:43125610~43153671:+ CESC cis rs801193 1 rs11773829 ENSG00000226824.5 RP4-756H11.3 10.46 5.1e-21 5.33e-17 0.72 0.58 Aortic root size; chr7:66676087 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs11651341 ENSG00000198496.9 NBR2 -10.45 5.39e-21 5.6e-17 -0.74 -0.58 Menopause (age at onset); chr17:43350693 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs34572725 ENSG00000198496.9 NBR2 -10.45 5.39e-21 5.6e-17 -0.74 -0.58 Menopause (age at onset); chr17:43351298 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs4534897 ENSG00000198496.9 NBR2 -10.45 5.39e-21 5.6e-17 -0.74 -0.58 Menopause (age at onset); chr17:43354440 chr17:43125610~43153671:+ CESC cis rs2486288 0.656 rs11637838 ENSG00000259520.4 CTD-2651B20.3 10.45 5.4e-21 5.61e-17 0.76 0.58 Glomerular filtration rate; chr15:45258459 chr15:45251580~45279251:- CESC cis rs858239 0.863 rs274054 ENSG00000230658.1 KLHL7-AS1 10.45 5.59e-21 5.8e-17 0.72 0.58 Cerebrospinal fluid biomarker levels; chr7:23350848 chr7:23101228~23105703:- CESC cis rs875971 0.706 rs1643374 ENSG00000226824.5 RP4-756H11.3 -10.44 5.92e-21 6.11e-17 -0.74 -0.58 Aortic root size; chr7:66407695 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs35956818 ENSG00000198496.9 NBR2 -10.44 6.06e-21 6.25e-17 -0.74 -0.58 Menopause (age at onset); chr17:43345617 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs4584865 ENSG00000198496.9 NBR2 -10.44 6.06e-21 6.25e-17 -0.74 -0.58 Menopause (age at onset); chr17:43347551 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs35521261 ENSG00000198496.9 NBR2 -10.44 6.08e-21 6.26e-17 -0.74 -0.58 Menopause (age at onset); chr17:43161595 chr17:43125610~43153671:+ CESC cis rs2739330 0.734 rs2000467 ENSG00000225282.1 AP000350.6 -10.44 6.14e-21 6.31e-17 -0.71 -0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23926900~23929574:+ CESC cis rs2486288 0.656 rs2413768 ENSG00000259520.4 CTD-2651B20.3 10.43 6.51e-21 6.64e-17 0.75 0.58 Glomerular filtration rate; chr15:45269786 chr15:45251580~45279251:- CESC cis rs1799949 1 rs2037075 ENSG00000198496.9 NBR2 -10.42 6.65e-21 6.77e-17 -0.74 -0.58 Menopause (age at onset); chr17:43153809 chr17:43125610~43153671:+ CESC cis rs2486288 0.656 rs1719232 ENSG00000259520.4 CTD-2651B20.3 10.42 6.83e-21 6.94e-17 0.75 0.58 Glomerular filtration rate; chr15:45279874 chr15:45251580~45279251:- CESC cis rs1799949 1 rs4793194 ENSG00000198496.9 NBR2 -10.41 7.43e-21 7.52e-17 -0.75 -0.58 Menopause (age at onset); chr17:43066316 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176234 ENSG00000198496.9 NBR2 -10.41 7.43e-21 7.52e-17 -0.75 -0.58 Menopause (age at onset); chr17:43067763 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176233 ENSG00000198496.9 NBR2 -10.41 7.43e-21 7.52e-17 -0.75 -0.58 Menopause (age at onset); chr17:43067787 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176220 ENSG00000198496.9 NBR2 -10.41 7.43e-21 7.52e-17 -0.75 -0.58 Menopause (age at onset); chr17:43070445 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs1799966 ENSG00000198496.9 NBR2 -10.41 7.43e-21 7.52e-17 -0.75 -0.58 Menopause (age at onset); chr17:43071077 chr17:43125610~43153671:+ CESC cis rs12594515 0.6 rs12903858 ENSG00000273972.1 CTD-2306A12.1 -10.4 8.15e-21 8.23e-17 -0.67 -0.58 Weight;Waist circumference; chr15:45679968 chr15:45702640~45703183:+ CESC cis rs1799949 1 rs33946455 ENSG00000198496.9 NBR2 -10.39 8.45e-21 8.53e-17 -0.74 -0.58 Menopause (age at onset); chr17:43169829 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs4793229 ENSG00000198496.9 NBR2 10.38 8.79e-21 8.83e-17 0.74 0.58 Menopause (age at onset); chr17:43340966 chr17:43125610~43153671:+ CESC cis rs9322193 0.923 rs10782318 ENSG00000231760.4 RP11-350J20.5 10.38 9.16e-21 9.18e-17 0.76 0.58 Lung cancer; chr6:149754137 chr6:149796151~149826294:- CESC cis rs4423214 0.918 rs11233789 ENSG00000254682.1 RP11-660L16.2 10.38 9.19e-21 9.21e-17 0.76 0.58 Vitamin D levels; chr11:71470039 chr11:71448674~71452157:+ CESC cis rs875971 0.66 rs801217 ENSG00000226824.5 RP4-756H11.3 10.38 9.3e-21 9.3e-17 0.72 0.57 Aortic root size; chr7:66545590 chr7:66654538~66669855:+ CESC cis rs875971 0.638 rs801216 ENSG00000226824.5 RP4-756H11.3 10.38 9.3e-21 9.3e-17 0.72 0.57 Aortic root size; chr7:66546680 chr7:66654538~66669855:+ CESC cis rs801193 1 rs3800812 ENSG00000226824.5 RP4-756H11.3 -10.37 9.59e-21 9.58e-17 -0.72 -0.57 Aortic root size; chr7:66758474 chr7:66654538~66669855:+ CESC cis rs801193 1 rs4279493 ENSG00000226824.5 RP4-756H11.3 -10.37 9.59e-21 9.58e-17 -0.72 -0.57 Aortic root size; chr7:66761633 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs62465434 ENSG00000226824.5 RP4-756H11.3 -10.37 9.7e-21 9.68e-17 -0.72 -0.57 Aortic root size; chr7:66540165 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs13224319 ENSG00000226824.5 RP4-756H11.3 -10.37 9.7e-21 9.68e-17 -0.72 -0.57 Aortic root size; chr7:66542376 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs11657835 ENSG00000198496.9 NBR2 -10.37 9.73e-21 9.68e-17 -0.74 -0.57 Menopause (age at onset); chr17:43139936 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs1135214 ENSG00000198496.9 NBR2 -10.37 9.73e-21 9.68e-17 -0.74 -0.57 Menopause (age at onset); chr17:43140306 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs4793212 ENSG00000198496.9 NBR2 -10.37 9.73e-21 9.68e-17 -0.74 -0.57 Menopause (age at onset); chr17:43150733 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs34534709 ENSG00000198496.9 NBR2 -10.37 9.73e-21 9.68e-17 -0.74 -0.57 Menopause (age at onset); chr17:43150923 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs34059614 ENSG00000198496.9 NBR2 -10.37 9.73e-21 9.68e-17 -0.74 -0.57 Menopause (age at onset); chr17:43151054 chr17:43125610~43153671:+ CESC cis rs3814244 0.528 rs2906854 ENSG00000255733.4 IFNG-AS1 -10.36 1.01e-20 1e-16 -0.53 -0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:67993566 chr12:67989445~68234686:+ CESC cis rs2486288 0.656 rs7162022 ENSG00000259520.4 CTD-2651B20.3 10.35 1.13e-20 1.11e-16 0.75 0.57 Glomerular filtration rate; chr15:45273055 chr15:45251580~45279251:- CESC cis rs1799949 0.896 rs33933393 ENSG00000198496.9 NBR2 -10.35 1.15e-20 1.13e-16 -0.74 -0.57 Menopause (age at onset); chr17:43165415 chr17:43125610~43153671:+ CESC cis rs7208859 0.623 rs56325146 ENSG00000263531.1 RP13-753N3.1 10.34 1.22e-20 1.2e-16 1.11 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824006 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs999797 ENSG00000263531.1 RP13-753N3.1 10.33 1.27e-20 1.24e-16 1.18 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832311 chr17:30863921~30864940:- CESC cis rs1799949 0.501 rs2343819 ENSG00000198496.9 NBR2 -10.32 1.35e-20 1.32e-16 -0.74 -0.57 Menopause (age at onset); chr17:43332285 chr17:43125610~43153671:+ CESC cis rs1799949 0.501 rs35399157 ENSG00000198496.9 NBR2 -10.32 1.35e-20 1.32e-16 -0.74 -0.57 Menopause (age at onset); chr17:43334234 chr17:43125610~43153671:+ CESC cis rs1799949 0.602 rs4600503 ENSG00000198496.9 NBR2 -10.32 1.35e-20 1.32e-16 -0.74 -0.57 Menopause (age at onset); chr17:43336956 chr17:43125610~43153671:+ CESC cis rs1799949 0.501 rs9675035 ENSG00000198496.9 NBR2 -10.32 1.35e-20 1.32e-16 -0.74 -0.57 Menopause (age at onset); chr17:43337648 chr17:43125610~43153671:+ CESC cis rs2486288 0.656 rs11629807 ENSG00000259520.4 CTD-2651B20.3 10.32 1.42e-20 1.38e-16 0.73 0.57 Glomerular filtration rate; chr15:45254839 chr15:45251580~45279251:- CESC cis rs9322193 0.847 rs880246 ENSG00000231760.4 RP11-350J20.5 10.31 1.45e-20 1.41e-16 0.78 0.57 Lung cancer; chr6:149845972 chr6:149796151~149826294:- CESC cis rs801193 0.967 rs34356500 ENSG00000226824.5 RP4-756H11.3 -10.31 1.49e-20 1.45e-16 -0.72 -0.57 Aortic root size; chr7:66771620 chr7:66654538~66669855:+ CESC cis rs16828019 0.777 rs16911 ENSG00000235358.1 RP11-399E6.1 10.3 1.6e-20 1.55e-16 0.92 0.57 Intelligence (multi-trait analysis); chr1:41032349 chr1:41242373~41284861:+ CESC cis rs4423214 1 rs12278461 ENSG00000254682.1 RP11-660L16.2 10.3 1.62e-20 1.56e-16 0.76 0.57 Vitamin D levels; chr11:71471139 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs2282621 ENSG00000254682.1 RP11-660L16.2 10.3 1.62e-20 1.56e-16 0.76 0.57 Vitamin D levels; chr11:71472428 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs2282620 ENSG00000254682.1 RP11-660L16.2 10.3 1.62e-20 1.56e-16 0.76 0.57 Vitamin D levels; chr11:71472431 chr11:71448674~71452157:+ CESC cis rs9322193 0.961 rs9767713 ENSG00000231760.4 RP11-350J20.5 10.29 1.64e-20 1.59e-16 0.74 0.57 Lung cancer; chr6:149588241 chr6:149796151~149826294:- CESC cis rs1577917 0.696 rs10806334 ENSG00000203875.9 SNHG5 -10.29 1.64e-20 1.59e-16 -0.64 -0.57 Response to antipsychotic treatment; chr6:85729611 chr6:85660950~85678736:- CESC cis rs875971 0.66 rs801211 ENSG00000226824.5 RP4-756H11.3 10.29 1.7e-20 1.64e-16 0.71 0.57 Aortic root size; chr7:66550702 chr7:66654538~66669855:+ CESC cis rs875971 0.638 rs801205 ENSG00000226824.5 RP4-756H11.3 10.29 1.7e-20 1.64e-16 0.71 0.57 Aortic root size; chr7:66557157 chr7:66654538~66669855:+ CESC cis rs875971 0.617 rs810400 ENSG00000226824.5 RP4-756H11.3 10.29 1.7e-20 1.64e-16 0.71 0.57 Aortic root size; chr7:66557902 chr7:66654538~66669855:+ CESC cis rs875971 0.638 rs3898855 ENSG00000226824.5 RP4-756H11.3 10.29 1.7e-20 1.64e-16 0.71 0.57 Aortic root size; chr7:66571411 chr7:66654538~66669855:+ CESC cis rs2486288 0.656 rs8037583 ENSG00000259520.4 CTD-2651B20.3 10.28 1.78e-20 1.71e-16 0.73 0.57 Glomerular filtration rate; chr15:45254180 chr15:45251580~45279251:- CESC cis rs875971 0.66 rs12698534 ENSG00000226824.5 RP4-756H11.3 -10.28 1.82e-20 1.75e-16 -0.71 -0.57 Aortic root size; chr7:66521858 chr7:66654538~66669855:+ CESC cis rs875971 0.628 rs6974355 ENSG00000226824.5 RP4-756H11.3 -10.28 1.84e-20 1.77e-16 -0.73 -0.57 Aortic root size; chr7:66376994 chr7:66654538~66669855:+ CESC cis rs1153858 0.621 rs2413769 ENSG00000259520.4 CTD-2651B20.3 -10.26 2.13e-20 2.01e-16 -0.76 -0.57 Homoarginine levels; chr15:45269670 chr15:45251580~45279251:- CESC cis rs858239 0.932 rs1637190 ENSG00000230658.1 KLHL7-AS1 10.24 2.46e-20 2.3e-16 0.72 0.57 Cerebrospinal fluid biomarker levels; chr7:23229446 chr7:23101228~23105703:- CESC cis rs2486288 0.656 rs9921025 ENSG00000259520.4 CTD-2651B20.3 10.24 2.46e-20 2.3e-16 0.72 0.57 Glomerular filtration rate; chr15:45254404 chr15:45251580~45279251:- CESC cis rs916888 0.61 rs199529 ENSG00000214401.4 KANSL1-AS1 10.23 2.54e-20 2.38e-16 0.74 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:46193576~46196723:+ CESC cis rs2486288 0.656 rs8041702 ENSG00000259520.4 CTD-2651B20.3 10.22 2.86e-20 2.67e-16 0.74 0.57 Glomerular filtration rate; chr15:45254895 chr15:45251580~45279251:- CESC cis rs801193 0.967 rs2707853 ENSG00000226824.5 RP4-756H11.3 -10.21 2.99e-20 2.78e-16 -0.71 -0.57 Aortic root size; chr7:66749023 chr7:66654538~66669855:+ CESC cis rs801193 1 rs2659889 ENSG00000226824.5 RP4-756H11.3 -10.21 2.99e-20 2.78e-16 -0.71 -0.57 Aortic root size; chr7:66752125 chr7:66654538~66669855:+ CESC cis rs1153858 0.723 rs4580098 ENSG00000259520.4 CTD-2651B20.3 -10.2 3.27e-20 3.03e-16 -0.75 -0.57 Homoarginine levels; chr15:45304711 chr15:45251580~45279251:- CESC cis rs1153858 0.723 rs1719238 ENSG00000259520.4 CTD-2651B20.3 10.2 3.27e-20 3.03e-16 0.75 0.57 Homoarginine levels; chr15:45302568 chr15:45251580~45279251:- CESC cis rs1799949 1 rs2271574 ENSG00000198496.9 NBR2 -10.19 3.33e-20 3.09e-16 -0.73 -0.57 Menopause (age at onset); chr17:43175631 chr17:43125610~43153671:+ CESC cis rs875971 0.638 rs10278816 ENSG00000226824.5 RP4-756H11.3 10.19 3.42e-20 3.16e-16 0.71 0.57 Aortic root size; chr7:66572000 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs10281080 ENSG00000226824.5 RP4-756H11.3 10.19 3.42e-20 3.16e-16 0.71 0.57 Aortic root size; chr7:66577454 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs10950044 ENSG00000226824.5 RP4-756H11.3 10.19 3.42e-20 3.16e-16 0.71 0.57 Aortic root size; chr7:66577989 chr7:66654538~66669855:+ CESC cis rs2486288 0.656 rs11629858 ENSG00000259520.4 CTD-2651B20.3 10.19 3.49e-20 3.22e-16 0.73 0.57 Glomerular filtration rate; chr15:45254916 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11629859 ENSG00000259520.4 CTD-2651B20.3 10.19 3.49e-20 3.22e-16 0.73 0.57 Glomerular filtration rate; chr15:45254923 chr15:45251580~45279251:- CESC cis rs16828019 0.929 rs8179465 ENSG00000235358.1 RP11-399E6.1 10.18 3.72e-20 3.41e-16 0.93 0.57 Intelligence (multi-trait analysis); chr1:41236075 chr1:41242373~41284861:+ CESC cis rs9322193 0.884 rs1125 ENSG00000231760.4 RP11-350J20.5 10.17 3.92e-20 3.59e-16 0.72 0.57 Lung cancer; chr6:149658280 chr6:149796151~149826294:- CESC cis rs875971 0.522 rs1968127 ENSG00000226824.5 RP4-756H11.3 10.17 3.96e-20 3.62e-16 0.71 0.57 Aortic root size; chr7:66591816 chr7:66654538~66669855:+ CESC cis rs1153858 0.621 rs1706824 ENSG00000259520.4 CTD-2651B20.3 -10.17 3.99e-20 3.65e-16 -0.76 -0.57 Homoarginine levels; chr15:45287750 chr15:45251580~45279251:- CESC cis rs1577917 0.629 rs7761762 ENSG00000203875.9 SNHG5 10.16 4.08e-20 3.73e-16 0.64 0.57 Response to antipsychotic treatment; chr6:85496250 chr6:85660950~85678736:- CESC cis rs801193 0.761 rs2659888 ENSG00000226824.5 RP4-756H11.3 -10.16 4.11e-20 3.75e-16 -0.71 -0.57 Aortic root size; chr7:66765184 chr7:66654538~66669855:+ CESC cis rs3814244 0.528 rs1468487 ENSG00000255733.4 IFNG-AS1 -10.16 4.22e-20 3.85e-16 -0.53 -0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:67996602 chr12:67989445~68234686:+ CESC cis rs3814244 0.528 rs2860609 ENSG00000255733.4 IFNG-AS1 -10.16 4.22e-20 3.85e-16 -0.53 -0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:67997215 chr12:67989445~68234686:+ CESC cis rs875971 0.638 rs6960778 ENSG00000226824.5 RP4-756H11.3 10.15 4.39e-20 3.99e-16 0.72 0.57 Aortic root size; chr7:66606610 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs801193 ENSG00000226824.5 RP4-756H11.3 10.15 4.42e-20 4.02e-16 0.71 0.57 Aortic root size; chr7:66565625 chr7:66654538~66669855:+ CESC cis rs875971 0.638 rs10249404 ENSG00000226824.5 RP4-756H11.3 10.15 4.54e-20 4.13e-16 0.71 0.57 Aortic root size; chr7:66581737 chr7:66654538~66669855:+ CESC cis rs875971 0.66 rs10215132 ENSG00000226824.5 RP4-756H11.3 10.15 4.54e-20 4.13e-16 0.71 0.57 Aortic root size; chr7:66589419 chr7:66654538~66669855:+ CESC cis rs7301826 0.651 rs10848209 ENSG00000256250.1 RP11-989F5.1 -10.15 4.62e-20 4.19e-16 -0.68 -0.57 Plasma plasminogen activator levels; chr12:130826727 chr12:130810606~130812438:+ CESC cis rs2486288 0.656 rs1060896 ENSG00000259520.4 CTD-2651B20.3 10.12 5.47e-20 4.92e-16 0.72 0.57 Glomerular filtration rate; chr15:45262069 chr15:45251580~45279251:- CESC cis rs1799949 0.965 rs34633610 ENSG00000198496.9 NBR2 -10.12 5.62e-20 5.05e-16 -0.74 -0.57 Menopause (age at onset); chr17:43342017 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs11654051 ENSG00000198496.9 NBR2 -10.12 5.62e-20 5.05e-16 -0.74 -0.57 Menopause (age at onset); chr17:43342288 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs56729776 ENSG00000198496.9 NBR2 -10.12 5.62e-20 5.05e-16 -0.74 -0.57 Menopause (age at onset); chr17:43344763 chr17:43125610~43153671:+ CESC cis rs2486288 0.656 rs2413774 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45257225 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs2413773 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45257244 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11632724 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45258593 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11632651 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45258640 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11637920 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45258707 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11632777 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45258847 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11632778 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45258858 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11632752 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45258942 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs12911186 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45259225 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs12915314 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45259293 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs8039138 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45259394 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs8039540 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45259644 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs8040185 ENSG00000259520.4 CTD-2651B20.3 10.11 5.78e-20 5.16e-16 0.72 0.57 Glomerular filtration rate; chr15:45259883 chr15:45251580~45279251:- CESC cis rs16828019 0.789 rs36084778 ENSG00000235358.1 RP11-399E6.1 10.11 5.84e-20 5.22e-16 0.91 0.57 Intelligence (multi-trait analysis); chr1:41013866 chr1:41242373~41284861:+ CESC cis rs16828019 0.777 rs11209363 ENSG00000235358.1 RP11-399E6.1 10.11 5.84e-20 5.22e-16 0.91 0.57 Intelligence (multi-trait analysis); chr1:41019405 chr1:41242373~41284861:+ CESC cis rs4853012 0.775 rs12465641 ENSG00000217702.2 RP11-287D1.4 -10.11 6.16e-20 5.47e-16 -0.8 -0.56 Gestational age at birth (maternal effect); chr2:74110588 chr2:74130583~74135395:+ CESC cis rs2486288 0.587 rs12899942 ENSG00000259520.4 CTD-2651B20.3 10.1 6.23e-20 5.52e-16 0.72 0.56 Glomerular filtration rate; chr15:45255082 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs12899058 ENSG00000259520.4 CTD-2651B20.3 10.1 6.23e-20 5.52e-16 0.72 0.56 Glomerular filtration rate; chr15:45255126 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs12904150 ENSG00000259520.4 CTD-2651B20.3 10.1 6.23e-20 5.52e-16 0.72 0.56 Glomerular filtration rate; chr15:45255407 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs9920290 ENSG00000259520.4 CTD-2651B20.3 10.1 6.23e-20 5.52e-16 0.72 0.56 Glomerular filtration rate; chr15:45255837 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs11854325 ENSG00000259520.4 CTD-2651B20.3 10.1 6.23e-20 5.52e-16 0.72 0.56 Glomerular filtration rate; chr15:45256761 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs2413772 ENSG00000259520.4 CTD-2651B20.3 10.1 6.23e-20 5.52e-16 0.72 0.56 Glomerular filtration rate; chr15:45257664 chr15:45251580~45279251:- CESC cis rs1799949 1 rs33994002 ENSG00000198496.9 NBR2 -10.1 6.46e-20 5.72e-16 -0.73 -0.56 Menopause (age at onset); chr17:43176801 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs33920795 ENSG00000198496.9 NBR2 -10.1 6.46e-20 5.72e-16 -0.73 -0.56 Menopause (age at onset); chr17:43176993 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs33918839 ENSG00000198496.9 NBR2 -10.1 6.46e-20 5.72e-16 -0.73 -0.56 Menopause (age at onset); chr17:43177155 chr17:43125610~43153671:+ CESC cis rs16828019 0.64 rs1140227 ENSG00000235358.1 RP11-399E6.1 10.08 7.36e-20 6.5e-16 0.91 0.56 Intelligence (multi-trait analysis); chr1:41028139 chr1:41242373~41284861:+ CESC cis rs7301826 0.651 rs10744485 ENSG00000256250.1 RP11-989F5.1 -10.08 7.49e-20 6.61e-16 -0.69 -0.56 Plasma plasminogen activator levels; chr12:130814005 chr12:130810606~130812438:+ CESC cis rs1799949 1 rs4793231 ENSG00000198496.9 NBR2 -10.08 7.5e-20 6.62e-16 -0.73 -0.56 Menopause (age at onset); chr17:43350101 chr17:43125610~43153671:+ CESC cis rs6952407 1 rs6952407 ENSG00000226824.5 RP4-756H11.3 10.08 7.55e-20 6.66e-16 0.73 0.56 Cotinine glucuronidation; chr7:66580525 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs8074136 ENSG00000198496.9 NBR2 -10.07 7.72e-20 6.8e-16 -0.72 -0.56 Menopause (age at onset); chr17:43190296 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs9646417 ENSG00000198496.9 NBR2 -10.07 7.85e-20 6.9e-16 -0.74 -0.56 Menopause (age at onset); chr17:43346885 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs1545764 ENSG00000198496.9 NBR2 -10.07 7.85e-20 6.9e-16 -0.74 -0.56 Menopause (age at onset); chr17:43347197 chr17:43125610~43153671:+ CESC cis rs875971 0.619 rs10278371 ENSG00000226824.5 RP4-756H11.3 10.07 7.98e-20 7.01e-16 0.73 0.56 Aortic root size; chr7:66586553 chr7:66654538~66669855:+ CESC cis rs977987 0.705 rs4888377 ENSG00000261783.1 RP11-252K23.2 -10.07 7.98e-20 7.01e-16 -0.71 -0.56 Dupuytren's disease; chr16:75291788 chr16:75379818~75381260:- CESC cis rs801193 1 rs7785213 ENSG00000226824.5 RP4-756H11.3 10.06 8.39e-20 7.34e-16 0.71 0.56 Aortic root size; chr7:66673991 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs4793197 ENSG00000198496.9 NBR2 -10.06 8.44e-20 7.39e-16 -0.73 -0.56 Menopause (age at onset); chr17:43079885 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs3092994 ENSG00000198496.9 NBR2 -10.05 8.75e-20 7.61e-16 -0.73 -0.56 Menopause (age at onset); chr17:43063808 chr17:43125610~43153671:+ CESC cis rs2906856 0.848 rs3015001 ENSG00000255733.4 IFNG-AS1 -10.05 9.21e-20 7.99e-16 -0.53 -0.56 Mosquito bite size; chr12:68003593 chr12:67989445~68234686:+ CESC cis rs16828019 0.704 rs12024115 ENSG00000235358.1 RP11-399E6.1 10.05 9.31e-20 8.08e-16 0.93 0.56 Intelligence (multi-trait analysis); chr1:41068685 chr1:41242373~41284861:+ CESC cis rs1153858 0.621 rs1719237 ENSG00000259520.4 CTD-2651B20.3 -10.04 9.39e-20 8.15e-16 -0.76 -0.56 Homoarginine levels; chr15:45287624 chr15:45251580~45279251:- CESC cis rs858239 0.965 rs156429 ENSG00000230658.1 KLHL7-AS1 10.04 9.79e-20 8.45e-16 0.69 0.56 Cerebrospinal fluid biomarker levels; chr7:23266401 chr7:23101228~23105703:- CESC cis rs16828019 0.852 rs12742379 ENSG00000235358.1 RP11-399E6.1 10.03 1.04e-19 8.96e-16 0.92 0.56 Intelligence (multi-trait analysis); chr1:41060709 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs16827876 ENSG00000235358.1 RP11-399E6.1 10.03 1.04e-19 8.96e-16 0.92 0.56 Intelligence (multi-trait analysis); chr1:41073864 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs34979067 ENSG00000235358.1 RP11-399E6.1 10.03 1.04e-19 8.96e-16 0.92 0.56 Intelligence (multi-trait analysis); chr1:41077412 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs35190461 ENSG00000235358.1 RP11-399E6.1 10.03 1.04e-19 8.96e-16 0.92 0.56 Intelligence (multi-trait analysis); chr1:41077463 chr1:41242373~41284861:+ CESC cis rs4423214 0.921 rs11603330 ENSG00000254682.1 RP11-660L16.2 10.03 1.04e-19 8.98e-16 0.71 0.56 Vitamin D levels; chr11:71442413 chr11:71448674~71452157:+ CESC cis rs2486288 0.656 rs7167146 ENSG00000259520.4 CTD-2651B20.3 -10.03 1.06e-19 9.13e-16 -0.76 -0.56 Glomerular filtration rate; chr15:45279188 chr15:45251580~45279251:- CESC cis rs4423214 1 rs4944957 ENSG00000254682.1 RP11-660L16.2 -10.02 1.1e-19 9.43e-16 -0.71 -0.56 Vitamin D levels; chr11:71456989 chr11:71448674~71452157:+ CESC cis rs1153858 0.668 rs63603561 ENSG00000259520.4 CTD-2651B20.3 10.02 1.12e-19 9.62e-16 0.75 0.56 Homoarginine levels; chr15:45301125 chr15:45251580~45279251:- CESC cis rs16828019 0.852 rs12045171 ENSG00000235358.1 RP11-399E6.1 10.02 1.12e-19 9.64e-16 0.9 0.56 Intelligence (multi-trait analysis); chr1:41063133 chr1:41242373~41284861:+ CESC cis rs3814244 0.528 rs2906859 ENSG00000255733.4 IFNG-AS1 10.02 1.13e-19 9.7e-16 0.52 0.56 Itch intensity from mosquito bite adjusted by bite size; chr12:68002355 chr12:67989445~68234686:+ CESC cis rs7208859 0.673 rs28588622 ENSG00000263531.1 RP13-753N3.1 10.02 1.14e-19 9.76e-16 1.13 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30918681 chr17:30863921~30864940:- CESC cis rs1577917 0.559 rs2223788 ENSG00000203875.9 SNHG5 -10 1.24e-19 1.06e-15 -0.63 -0.56 Response to antipsychotic treatment; chr6:86102202 chr6:85660950~85678736:- CESC cis rs1577917 0.523 rs1413724 ENSG00000203875.9 SNHG5 -10 1.24e-19 1.06e-15 -0.63 -0.56 Response to antipsychotic treatment; chr6:86104831 chr6:85660950~85678736:- CESC cis rs9322193 0.543 rs9371533 ENSG00000231760.4 RP11-350J20.5 10 1.25e-19 1.06e-15 0.69 0.56 Lung cancer; chr6:149889545 chr6:149796151~149826294:- CESC cis rs1799949 0.965 rs8176323 ENSG00000198496.9 NBR2 -10 1.31e-19 1.12e-15 -0.73 -0.56 Menopause (age at onset); chr17:43043694 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs8176322 ENSG00000198496.9 NBR2 -10 1.31e-19 1.12e-15 -0.73 -0.56 Menopause (age at onset); chr17:43043756 chr17:43125610~43153671:+ CESC cis rs1577917 0.538 rs6454483 ENSG00000203875.9 SNHG5 9.99 1.33e-19 1.13e-15 0.61 0.56 Response to antipsychotic treatment; chr6:85708565 chr6:85660950~85678736:- CESC cis rs1799949 0.965 rs1842147 ENSG00000198496.9 NBR2 -9.99 1.35e-19 1.15e-15 -0.73 -0.56 Menopause (age at onset); chr17:43357824 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs9646412 ENSG00000198496.9 NBR2 -9.99 1.39e-19 1.18e-15 -0.73 -0.56 Menopause (age at onset); chr17:43348525 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs4793190 ENSG00000198496.9 NBR2 -9.98 1.42e-19 1.2e-15 -0.73 -0.56 Menopause (age at onset); chr17:43048092 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176297 ENSG00000198496.9 NBR2 -9.98 1.42e-19 1.2e-15 -0.73 -0.56 Menopause (age at onset); chr17:43051308 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176296 ENSG00000198496.9 NBR2 -9.98 1.42e-19 1.2e-15 -0.73 -0.56 Menopause (age at onset); chr17:43051574 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs4793191 ENSG00000198496.9 NBR2 -9.98 1.42e-19 1.2e-15 -0.73 -0.56 Menopause (age at onset); chr17:43052360 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs4793192 ENSG00000198496.9 NBR2 -9.98 1.42e-19 1.2e-15 -0.73 -0.56 Menopause (age at onset); chr17:43052373 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs8176289 ENSG00000198496.9 NBR2 -9.98 1.42e-19 1.2e-15 -0.73 -0.56 Menopause (age at onset); chr17:43054039 chr17:43125610~43153671:+ CESC cis rs16828019 0.852 rs12729448 ENSG00000235358.1 RP11-399E6.1 9.98 1.44e-19 1.22e-15 0.9 0.56 Intelligence (multi-trait analysis); chr1:41044162 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs2268678 ENSG00000235358.1 RP11-399E6.1 9.98 1.44e-19 1.22e-15 0.9 0.56 Intelligence (multi-trait analysis); chr1:41045381 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs10489520 ENSG00000235358.1 RP11-399E6.1 9.98 1.44e-19 1.22e-15 0.9 0.56 Intelligence (multi-trait analysis); chr1:41046083 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs12406620 ENSG00000235358.1 RP11-399E6.1 9.98 1.44e-19 1.22e-15 0.9 0.56 Intelligence (multi-trait analysis); chr1:41046992 chr1:41242373~41284861:+ CESC cis rs875971 0.66 rs7807930 ENSG00000226824.5 RP4-756H11.3 9.98 1.47e-19 1.24e-15 0.71 0.56 Aortic root size; chr7:66622178 chr7:66654538~66669855:+ CESC cis rs5760092 0.755 rs4585126 ENSG00000273295.1 AP000350.5 -9.98 1.48e-19 1.25e-15 -0.7 -0.56 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23901432~23907068:- CESC cis rs1799949 1 rs11653231 ENSG00000198496.9 NBR2 -9.97 1.55e-19 1.31e-15 -0.72 -0.56 Menopause (age at onset); chr17:43179443 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs1399323 ENSG00000198496.9 NBR2 -9.97 1.55e-19 1.31e-15 -0.72 -0.56 Menopause (age at onset); chr17:43180313 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs35954893 ENSG00000198496.9 NBR2 -9.97 1.55e-19 1.31e-15 -0.72 -0.56 Menopause (age at onset); chr17:43181769 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs4445938 ENSG00000198496.9 NBR2 -9.97 1.55e-19 1.31e-15 -0.72 -0.56 Menopause (age at onset); chr17:43185883 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs12516 ENSG00000198496.9 NBR2 -9.96 1.71e-19 1.43e-15 -0.73 -0.56 Menopause (age at onset); chr17:43044391 chr17:43125610~43153671:+ CESC cis rs997154 0.579 rs12889177 ENSG00000279656.1 RP11-298I3.6 -9.96 1.74e-19 1.46e-15 -0.83 -0.56 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:23022120 chr14:23023083~23024217:- CESC cis rs1799949 1 rs35330014 ENSG00000198496.9 NBR2 -9.95 1.86e-19 1.55e-15 -0.73 -0.56 Menopause (age at onset); chr17:43060530 chr17:43125610~43153671:+ CESC cis rs7301826 0.627 rs4334059 ENSG00000256250.1 RP11-989F5.1 -9.94 1.88e-19 1.57e-15 -0.68 -0.56 Plasma plasminogen activator levels; chr12:130829669 chr12:130810606~130812438:+ CESC cis rs2486288 0.656 rs10519018 ENSG00000259520.4 CTD-2651B20.3 9.94 1.93e-19 1.61e-15 0.71 0.56 Glomerular filtration rate; chr15:45257067 chr15:45251580~45279251:- CESC cis rs1799949 1 rs8176242 ENSG00000198496.9 NBR2 -9.94 1.96e-19 1.63e-15 -0.74 -0.56 Menopause (age at onset); chr17:43065857 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs3092987 ENSG00000198496.9 NBR2 -9.94 1.96e-19 1.63e-15 -0.74 -0.56 Menopause (age at onset); chr17:43070706 chr17:43125610~43153671:+ CESC cis rs7301826 0.61 rs9668291 ENSG00000256250.1 RP11-989F5.1 -9.93 2.12e-19 1.76e-15 -0.68 -0.56 Plasma plasminogen activator levels; chr12:130812363 chr12:130810606~130812438:+ CESC cis rs858239 1 rs156421 ENSG00000230658.1 KLHL7-AS1 9.92 2.16e-19 1.8e-15 0.7 0.56 Cerebrospinal fluid biomarker levels; chr7:23272868 chr7:23101228~23105703:- CESC cis rs1799949 1 rs1973646 ENSG00000198496.9 NBR2 -9.91 2.35e-19 1.95e-15 -0.72 -0.56 Menopause (age at onset); chr17:43158478 chr17:43125610~43153671:+ CESC cis rs7301826 0.627 rs1077317 ENSG00000256250.1 RP11-989F5.1 -9.91 2.36e-19 1.95e-15 -0.66 -0.56 Plasma plasminogen activator levels; chr12:130830432 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs4759525 ENSG00000256250.1 RP11-989F5.1 -9.91 2.36e-19 1.95e-15 -0.66 -0.56 Plasma plasminogen activator levels; chr12:130831736 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs1554807 ENSG00000256250.1 RP11-989F5.1 9.91 2.4e-19 1.98e-15 0.67 0.56 Plasma plasminogen activator levels; chr12:130795872 chr12:130810606~130812438:+ CESC cis rs4423214 1 rs2852853 ENSG00000254682.1 RP11-660L16.2 9.9 2.53e-19 2.09e-15 0.71 0.56 Vitamin D levels; chr11:71439171 chr11:71448674~71452157:+ CESC cis rs16828019 0.852 rs34386859 ENSG00000235358.1 RP11-399E6.1 9.9 2.54e-19 2.1e-15 0.92 0.56 Intelligence (multi-trait analysis); chr1:41098352 chr1:41242373~41284861:+ CESC cis rs858239 1 rs156425 ENSG00000230658.1 KLHL7-AS1 -9.89 2.76e-19 2.27e-15 -0.7 -0.56 Cerebrospinal fluid biomarker levels; chr7:23269500 chr7:23101228~23105703:- CESC cis rs1799949 0.526 rs4352088 ENSG00000198496.9 NBR2 -9.88 2.87e-19 2.36e-15 -0.73 -0.56 Menopause (age at onset); chr17:43337311 chr17:43125610~43153671:+ CESC cis rs7174755 1 rs7174755 ENSG00000260657.2 RP11-315D16.4 -9.88 2.94e-19 2.42e-15 -0.65 -0.56 Major depressive disorder; chr15:68304789 chr15:68267792~68277994:- CESC cis rs1799949 0.55 rs2343818 ENSG00000198496.9 NBR2 -9.88 2.97e-19 2.44e-15 -0.73 -0.56 Menopause (age at onset); chr17:43332406 chr17:43125610~43153671:+ CESC cis rs950027 0.549 rs1719250 ENSG00000259520.4 CTD-2651B20.3 -9.88 2.99e-19 2.46e-15 -0.71 -0.56 Response to fenofibrate (adiponectin levels); chr15:45317575 chr15:45251580~45279251:- CESC cis rs1153858 0.621 rs2687512 ENSG00000259520.4 CTD-2651B20.3 9.88 3.01e-19 2.47e-15 0.74 0.56 Homoarginine levels; chr15:45289297 chr15:45251580~45279251:- CESC cis rs858239 0.932 rs199355 ENSG00000230658.1 KLHL7-AS1 9.88 3.02e-19 2.47e-15 0.71 0.56 Cerebrospinal fluid biomarker levels; chr7:23256914 chr7:23101228~23105703:- CESC cis rs2739330 0.732 rs5760175 ENSG00000273295.1 AP000350.5 9.87 3.08e-19 2.52e-15 0.62 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23901432~23907068:- CESC cis rs9326248 0.648 rs11216257 ENSG00000254851.1 RP11-109L13.1 -9.87 3.23e-19 2.65e-15 -0.83 -0.56 Blood protein levels; chr11:117061845 chr11:117135528~117138582:+ CESC cis rs7301826 0.651 rs10848210 ENSG00000256250.1 RP11-989F5.1 -9.86 3.44e-19 2.81e-15 -0.66 -0.56 Plasma plasminogen activator levels; chr12:130827475 chr12:130810606~130812438:+ CESC cis rs7301826 0.627 rs4325342 ENSG00000256250.1 RP11-989F5.1 -9.86 3.44e-19 2.81e-15 -0.66 -0.56 Plasma plasminogen activator levels; chr12:130827937 chr12:130810606~130812438:+ CESC cis rs7208859 0.623 rs9914242 ENSG00000263531.1 RP13-753N3.1 9.84 3.77e-19 3.07e-15 1.04 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889227 chr17:30863921~30864940:- CESC cis rs2739330 0.734 rs2000467 ENSG00000218537.1 MIF-AS1 -9.84 3.81e-19 3.1e-15 -0.73 -0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23894426~23898930:- CESC cis rs1577917 0.771 rs9450319 ENSG00000203875.9 SNHG5 9.83 4.05e-19 3.29e-15 0.62 0.55 Response to antipsychotic treatment; chr6:85717607 chr6:85660950~85678736:- CESC cis rs875971 0.66 rs7807944 ENSG00000226824.5 RP4-756H11.3 9.83 4.05e-19 3.29e-15 0.7 0.55 Aortic root size; chr7:66622208 chr7:66654538~66669855:+ CESC cis rs1153858 0.621 rs12913645 ENSG00000259520.4 CTD-2651B20.3 9.83 4.2e-19 3.4e-15 0.76 0.55 Homoarginine levels; chr15:45262868 chr15:45251580~45279251:- CESC cis rs858239 0.799 rs10279941 ENSG00000230658.1 KLHL7-AS1 9.83 4.25e-19 3.43e-15 0.74 0.55 Cerebrospinal fluid biomarker levels; chr7:23330889 chr7:23101228~23105703:- CESC cis rs858239 1 rs199348 ENSG00000230658.1 KLHL7-AS1 9.81 4.68e-19 3.77e-15 0.71 0.55 Cerebrospinal fluid biomarker levels; chr7:23253479 chr7:23101228~23105703:- CESC cis rs16828019 0.852 rs3766324 ENSG00000235358.1 RP11-399E6.1 9.81 4.78e-19 3.85e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41122981 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs2300649 ENSG00000235358.1 RP11-399E6.1 9.81 4.88e-19 3.93e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41103531 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs3904243 ENSG00000235358.1 RP11-399E6.1 9.81 4.88e-19 3.93e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41109180 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs11209545 ENSG00000235358.1 RP11-399E6.1 9.81 4.88e-19 3.93e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41110685 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs11209576 ENSG00000235358.1 RP11-399E6.1 9.81 4.88e-19 3.93e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41120357 chr1:41242373~41284861:+ CESC cis rs875971 0.619 rs2302918 ENSG00000226824.5 RP4-756H11.3 -9.8 5.07e-19 4.07e-15 -0.7 -0.55 Aortic root size; chr7:66535945 chr7:66654538~66669855:+ CESC cis rs1577917 0.518 rs2475787 ENSG00000203875.9 SNHG5 9.8 5.11e-19 4.1e-15 0.61 0.55 Response to antipsychotic treatment; chr6:85705518 chr6:85660950~85678736:- CESC cis rs7301826 0.651 rs7968675 ENSG00000256250.1 RP11-989F5.1 -9.79 5.31e-19 4.26e-15 -0.65 -0.55 Plasma plasminogen activator levels; chr12:130818832 chr12:130810606~130812438:+ CESC cis rs858239 0.863 rs274058 ENSG00000230658.1 KLHL7-AS1 9.79 5.57e-19 4.46e-15 0.69 0.55 Cerebrospinal fluid biomarker levels; chr7:23351890 chr7:23101228~23105703:- CESC cis rs4423214 1 rs12422045 ENSG00000254682.1 RP11-660L16.2 9.78 5.67e-19 4.53e-15 0.7 0.55 Vitamin D levels; chr11:71443774 chr11:71448674~71452157:+ CESC cis rs950027 0.549 rs12909409 ENSG00000259520.4 CTD-2651B20.3 9.78 5.94e-19 4.73e-15 0.72 0.55 Response to fenofibrate (adiponectin levels); chr15:45316384 chr15:45251580~45279251:- CESC cis rs1799949 1 rs4793215 ENSG00000198496.9 NBR2 -9.78 5.96e-19 4.75e-15 -0.72 -0.55 Menopause (age at onset); chr17:43166915 chr17:43125610~43153671:+ CESC cis rs16828019 0.789 rs34216154 ENSG00000235358.1 RP11-399E6.1 9.78 6.03e-19 4.79e-15 0.93 0.55 Intelligence (multi-trait analysis); chr1:41205235 chr1:41242373~41284861:+ CESC cis rs950027 0.572 rs12910764 ENSG00000259520.4 CTD-2651B20.3 9.77 6.03e-19 4.8e-15 0.72 0.55 Response to fenofibrate (adiponectin levels); chr15:45317162 chr15:45251580~45279251:- CESC cis rs2486288 0.656 rs8039354 ENSG00000259520.4 CTD-2651B20.3 -9.77 6.13e-19 4.87e-15 -0.7 -0.55 Glomerular filtration rate; chr15:45259558 chr15:45251580~45279251:- CESC cis rs858239 0.676 rs274032 ENSG00000230658.1 KLHL7-AS1 9.77 6.22e-19 4.94e-15 0.7 0.55 Cerebrospinal fluid biomarker levels; chr7:23334940 chr7:23101228~23105703:- CESC cis rs5760092 0.618 rs4461358 ENSG00000273295.1 AP000350.5 -9.77 6.43e-19 5.09e-15 -0.69 -0.55 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23901432~23907068:- CESC cis rs7301826 0.571 rs4759788 ENSG00000256250.1 RP11-989F5.1 -9.76 6.86e-19 5.43e-15 -0.67 -0.55 Plasma plasminogen activator levels; chr12:130811769 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs4759794 ENSG00000256250.1 RP11-989F5.1 -9.76 6.86e-19 5.43e-15 -0.67 -0.55 Plasma plasminogen activator levels; chr12:130812803 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs10773824 ENSG00000256250.1 RP11-989F5.1 -9.76 6.86e-19 5.43e-15 -0.67 -0.55 Plasma plasminogen activator levels; chr12:130814306 chr12:130810606~130812438:+ CESC cis rs2739330 0.761 rs5760176 ENSG00000273295.1 AP000350.5 -9.75 7.03e-19 5.54e-15 -0.61 -0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23901432~23907068:- CESC cis rs2486288 0.656 rs8039352 ENSG00000259520.4 CTD-2651B20.3 9.75 7.12e-19 5.61e-15 0.71 0.55 Glomerular filtration rate; chr15:45259592 chr15:45251580~45279251:- CESC cis rs16828019 0.852 rs3820090 ENSG00000235358.1 RP11-399E6.1 9.74 7.83e-19 6.16e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41107980 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs11209531 ENSG00000235358.1 RP11-399E6.1 9.72 8.5e-19 6.62e-15 0.88 0.55 Intelligence (multi-trait analysis); chr1:41105349 chr1:41242373~41284861:+ CESC cis rs2739330 0.731 rs5751792 ENSG00000273295.1 AP000350.5 9.72 8.75e-19 6.81e-15 0.61 0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23901432~23907068:- CESC cis rs801193 1 rs10234018 ENSG00000226824.5 RP4-756H11.3 9.72 8.81e-19 6.85e-15 0.7 0.55 Aortic root size; chr7:66681297 chr7:66654538~66669855:+ CESC cis rs16828019 0.852 rs12759023 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41138306 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs34286980 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41142717 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs71648534 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41148075 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs71648535 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41148078 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs12048187 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41150511 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs71648536 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41166336 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs12742803 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41182459 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs12408956 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41186280 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs35992757 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41187190 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs12044539 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41196060 chr1:41242373~41284861:+ CESC cis rs16828019 0.852 rs12759050 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41198532 chr1:41242373~41284861:+ CESC cis rs16828019 0.929 rs1032728 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41213894 chr1:41242373~41284861:+ CESC cis rs16828019 0.929 rs12029321 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41216858 chr1:41242373~41284861:+ CESC cis rs16828019 0.929 rs35286837 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41217326 chr1:41242373~41284861:+ CESC cis rs16828019 0.929 rs11209734 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41232402 chr1:41242373~41284861:+ CESC cis rs16828019 0.929 rs12037037 ENSG00000235358.1 RP11-399E6.1 9.71 9.23e-19 7.12e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41232584 chr1:41242373~41284861:+ CESC cis rs858239 0.932 rs1728313 ENSG00000230658.1 KLHL7-AS1 9.71 9.23e-19 7.12e-15 0.69 0.55 Cerebrospinal fluid biomarker levels; chr7:23231412 chr7:23101228~23105703:- CESC cis rs16828019 0.852 rs12729586 ENSG00000235358.1 RP11-399E6.1 9.71 9.39e-19 7.24e-15 0.9 0.55 Intelligence (multi-trait analysis); chr1:41056705 chr1:41242373~41284861:+ CESC cis rs16828019 0.704 rs34486565 ENSG00000235358.1 RP11-399E6.1 9.71 9.39e-19 7.24e-15 0.9 0.55 Intelligence (multi-trait analysis); chr1:41056838 chr1:41242373~41284861:+ CESC cis rs1577917 1 rs7747824 ENSG00000203875.9 SNHG5 -9.71 9.56e-19 7.36e-15 -0.61 -0.55 Response to antipsychotic treatment; chr6:85937388 chr6:85660950~85678736:- CESC cis rs1577917 1 rs35385043 ENSG00000203875.9 SNHG5 -9.71 9.56e-19 7.36e-15 -0.61 -0.55 Response to antipsychotic treatment; chr6:85938828 chr6:85660950~85678736:- CESC cis rs7301826 0.585 rs6486600 ENSG00000256250.1 RP11-989F5.1 -9.71 9.58e-19 7.37e-15 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130808432 chr12:130810606~130812438:+ CESC cis rs16828019 0.704 rs12031277 ENSG00000235358.1 RP11-399E6.1 9.71 9.65e-19 7.42e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41026129 chr1:41242373~41284861:+ CESC cis rs1577917 1 rs16876529 ENSG00000203875.9 SNHG5 -9.7 1.02e-18 7.78e-15 -0.61 -0.55 Response to antipsychotic treatment; chr6:85881484 chr6:85660950~85678736:- CESC cis rs7847628 0.55 rs12343516 ENSG00000226752.6 PSMD5-AS1 -9.69 1.06e-18 8.11e-15 -0.59 -0.55 Birth weight; chr9:120841191 chr9:120824828~120854385:+ CESC cis rs7301826 0.651 rs7971046 ENSG00000256250.1 RP11-989F5.1 -9.69 1.07e-18 8.17e-15 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130802262 chr12:130810606~130812438:+ CESC cis rs16828019 0.852 rs12022978 ENSG00000235358.1 RP11-399E6.1 9.69 1.07e-18 8.19e-15 0.9 0.55 Intelligence (multi-trait analysis); chr1:41088416 chr1:41242373~41284861:+ CESC cis rs2486288 0.656 rs9921035 ENSG00000259520.4 CTD-2651B20.3 9.68 1.16e-18 8.83e-15 0.72 0.55 Glomerular filtration rate; chr15:45254462 chr15:45251580~45279251:- CESC cis rs5760092 0.618 rs5996631 ENSG00000273295.1 AP000350.5 -9.68 1.17e-18 8.87e-15 -0.68 -0.55 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23901432~23907068:- CESC cis rs875971 0.66 rs79009421 ENSG00000226824.5 RP4-756H11.3 9.68 1.17e-18 8.88e-15 0.69 0.55 Aortic root size; chr7:66603522 chr7:66654538~66669855:+ CESC cis rs2739330 0.587 rs4820571 ENSG00000225282.1 AP000350.6 9.67 1.21e-18 9.18e-15 0.67 0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23926900~23929574:+ CESC cis rs16828019 0.852 rs71648540 ENSG00000235358.1 RP11-399E6.1 9.67 1.26e-18 9.5e-15 0.89 0.55 Intelligence (multi-trait analysis); chr1:41256623 chr1:41242373~41284861:+ CESC cis rs11155671 0.53 rs4458704 ENSG00000231760.4 RP11-350J20.5 9.66 1.31e-18 9.89e-15 0.67 0.55 Testicular germ cell tumor; chr6:149911743 chr6:149796151~149826294:- CESC cis rs16828019 0.929 rs2363805 ENSG00000235358.1 RP11-399E6.1 9.66 1.36e-18 1.03e-14 0.89 0.55 Intelligence (multi-trait analysis); chr1:41253762 chr1:41242373~41284861:+ CESC cis rs1577917 0.958 rs6454487 ENSG00000203875.9 SNHG5 9.65 1.46e-18 1.09e-14 0.6 0.55 Response to antipsychotic treatment; chr6:85737150 chr6:85660950~85678736:- CESC cis rs875971 0.66 rs6460308 ENSG00000226824.5 RP4-756H11.3 9.64 1.48e-18 1.11e-14 0.69 0.55 Aortic root size; chr7:66619753 chr7:66654538~66669855:+ CESC cis rs7301826 0.651 rs10734979 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130804409 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs4759519 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130804963 chr12:130810606~130812438:+ CESC cis rs7301826 0.627 rs10773823 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130809956 chr12:130810606~130812438:+ CESC cis rs7301826 0.627 rs73162873 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130811468 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs12228957 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130811521 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs12228959 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130811523 chr12:130810606~130812438:+ CESC cis rs7301826 0.61 rs4759789 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130811835 chr12:130810606~130812438:+ CESC cis rs7301826 0.61 rs4759791 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130811950 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs4759521 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130812768 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs10734981 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130813350 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs10744483 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130813661 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs10744484 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130813961 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs10773825 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130814368 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs7295705 ENSG00000256250.1 RP11-989F5.1 -9.64 1.49e-18 1.11e-14 -0.66 -0.55 Plasma plasminogen activator levels; chr12:130817340 chr12:130810606~130812438:+ CESC cis rs1799949 1 rs11654731 ENSG00000198496.9 NBR2 -9.64 1.52e-18 1.13e-14 -0.71 -0.55 Menopause (age at onset); chr17:43174923 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs11651623 ENSG00000198496.9 NBR2 -9.64 1.52e-18 1.13e-14 -0.71 -0.55 Menopause (age at onset); chr17:43177830 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs11657883 ENSG00000198496.9 NBR2 -9.64 1.52e-18 1.13e-14 -0.71 -0.55 Menopause (age at onset); chr17:43178007 chr17:43125610~43153671:+ CESC cis rs7301826 0.651 rs2037789 ENSG00000256250.1 RP11-989F5.1 9.63 1.57e-18 1.17e-14 0.66 0.55 Plasma plasminogen activator levels; chr12:130803747 chr12:130810606~130812438:+ CESC cis rs16828019 0.777 rs35044078 ENSG00000235358.1 RP11-399E6.1 9.63 1.59e-18 1.18e-14 0.89 0.55 Intelligence (multi-trait analysis); chr1:41008728 chr1:41242373~41284861:+ CESC cis rs16828019 0.704 rs4996176 ENSG00000235358.1 RP11-399E6.1 9.63 1.59e-18 1.18e-14 0.89 0.55 Intelligence (multi-trait analysis); chr1:41022496 chr1:41242373~41284861:+ CESC cis rs16828019 0.777 rs35496942 ENSG00000235358.1 RP11-399E6.1 9.63 1.59e-18 1.18e-14 0.89 0.55 Intelligence (multi-trait analysis); chr1:41023232 chr1:41242373~41284861:+ CESC cis rs950027 0.62 rs1617634 ENSG00000259520.4 CTD-2651B20.3 -9.63 1.67e-18 1.24e-14 -0.7 -0.55 Response to fenofibrate (adiponectin levels); chr15:45323380 chr15:45251580~45279251:- CESC cis rs1799949 1 rs3092988 ENSG00000198496.9 NBR2 -9.63 1.68e-18 1.25e-14 -0.73 -0.55 Menopause (age at onset); chr17:43049685 chr17:43125610~43153671:+ CESC cis rs801193 1 rs2659915 ENSG00000226824.5 RP4-756H11.3 -9.62 1.77e-18 1.31e-14 -0.67 -0.55 Aortic root size; chr7:66688114 chr7:66654538~66669855:+ CESC cis rs1799949 0.965 rs11650132 ENSG00000198496.9 NBR2 -9.61 1.87e-18 1.38e-14 -0.71 -0.55 Menopause (age at onset); chr17:43174070 chr17:43125610~43153671:+ CESC cis rs7174755 0.962 rs4777034 ENSG00000260657.2 RP11-315D16.4 -9.61 1.88e-18 1.39e-14 -0.66 -0.55 Major depressive disorder; chr15:68309546 chr15:68267792~68277994:- CESC cis rs7174755 0.962 rs1020842 ENSG00000260657.2 RP11-315D16.4 -9.61 1.88e-18 1.39e-14 -0.66 -0.55 Major depressive disorder; chr15:68309840 chr15:68267792~68277994:- CESC cis rs2739330 0.587 rs4820571 ENSG00000273295.1 AP000350.5 9.61 1.93e-18 1.42e-14 0.62 0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23901432~23907068:- CESC cis rs1577917 0.958 rs6921315 ENSG00000203875.9 SNHG5 -9.6 1.98e-18 1.46e-14 -0.6 -0.55 Response to antipsychotic treatment; chr6:85761950 chr6:85660950~85678736:- CESC cis rs7208859 0.623 rs11657662 ENSG00000263531.1 RP13-753N3.1 -9.6 2.01e-18 1.48e-14 -1.13 -0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749329 chr17:30863921~30864940:- CESC cis rs7174755 1 rs68069953 ENSG00000260657.2 RP11-315D16.4 9.6 2.02e-18 1.49e-14 0.66 0.55 Major depressive disorder; chr15:68304235 chr15:68267792~68277994:- CESC cis rs1577917 0.816 rs9353349 ENSG00000203875.9 SNHG5 9.59 2.07e-18 1.52e-14 0.61 0.54 Response to antipsychotic treatment; chr6:85998007 chr6:85660950~85678736:- CESC cis rs1577917 0.739 rs9450318 ENSG00000203875.9 SNHG5 9.59 2.1e-18 1.54e-14 0.6 0.54 Response to antipsychotic treatment; chr6:85717459 chr6:85660950~85678736:- CESC cis rs7301826 0.651 rs7132657 ENSG00000256250.1 RP11-989F5.1 -9.59 2.16e-18 1.59e-14 -0.66 -0.54 Plasma plasminogen activator levels; chr12:130800642 chr12:130810606~130812438:+ CESC cis rs1577917 1 rs2166663 ENSG00000203875.9 SNHG5 -9.59 2.17e-18 1.59e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85884178 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs16876530 ENSG00000203875.9 SNHG5 -9.59 2.17e-18 1.59e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85885923 chr6:85660950~85678736:- CESC cis rs1577917 0.876 rs4618490 ENSG00000203875.9 SNHG5 -9.59 2.19e-18 1.61e-14 -0.62 -0.54 Response to antipsychotic treatment; chr6:85808685 chr6:85660950~85678736:- CESC cis rs950027 0.62 rs872192 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.27e-18 1.66e-14 -0.7 -0.54 Response to fenofibrate (adiponectin levels); chr15:45322304 chr15:45251580~45279251:- CESC cis rs9898641 1 rs9898641 ENSG00000266992.1 DHX40P1 9.58 2.28e-18 1.67e-14 0.6 0.54 Interleukin-1-beta levels; chr17:59493672 chr17:59976009~60002384:- CESC cis rs7301826 0.557 rs7953184 ENSG00000256250.1 RP11-989F5.1 9.57 2.46e-18 1.8e-14 0.68 0.54 Plasma plasminogen activator levels; chr12:130800307 chr12:130810606~130812438:+ CESC cis rs9828933 0.832 rs2292662 ENSG00000280620.1 SCAANT1 9.55 2.72e-18 1.98e-14 0.91 0.54 Type 2 diabetes; chr3:63911539 chr3:63911518~63911772:- CESC cis rs1799949 1 rs4793189 ENSG00000198496.9 NBR2 -9.55 2.75e-18 2e-14 -0.73 -0.54 Menopause (age at onset); chr17:43038698 chr17:43125610~43153671:+ CESC cis rs1577917 0.958 rs12190603 ENSG00000203875.9 SNHG5 -9.55 2.78e-18 2.02e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85766000 chr6:85660950~85678736:- CESC cis rs1799949 0.965 rs11656945 ENSG00000198496.9 NBR2 -9.55 2.82e-18 2.05e-14 -0.71 -0.54 Menopause (age at onset); chr17:43178248 chr17:43125610~43153671:+ CESC cis rs7208859 0.573 rs11654035 ENSG00000263531.1 RP13-753N3.1 9.55 2.85e-18 2.07e-14 1.12 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809408 chr17:30863921~30864940:- CESC cis rs1799949 1 rs8176269 ENSG00000198496.9 NBR2 -9.55 2.86e-18 2.08e-14 -0.72 -0.54 Menopause (age at onset); chr17:43061609 chr17:43125610~43153671:+ CESC cis rs875971 0.642 rs35526611 ENSG00000226824.5 RP4-756H11.3 9.54 2.91e-18 2.11e-14 0.69 0.54 Aortic root size; chr7:66629021 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs11657053 ENSG00000198496.9 NBR2 -9.54 2.92e-18 2.12e-14 -0.73 -0.54 Menopause (age at onset); chr17:43039112 chr17:43125610~43153671:+ CESC cis rs1577917 0.958 rs6454488 ENSG00000203875.9 SNHG5 -9.54 2.93e-18 2.12e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85741124 chr6:85660950~85678736:- CESC cis rs875971 0.638 rs35986979 ENSG00000226824.5 RP4-756H11.3 9.54 2.96e-18 2.14e-14 0.69 0.54 Aortic root size; chr7:66624003 chr7:66654538~66669855:+ CESC cis rs9322193 0.847 rs868375 ENSG00000231760.4 RP11-350J20.5 9.54 2.99e-18 2.16e-14 0.74 0.54 Lung cancer; chr6:149844905 chr6:149796151~149826294:- CESC cis rs1577917 0.958 rs2324817 ENSG00000203875.9 SNHG5 -9.54 3.07e-18 2.22e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85752936 chr6:85660950~85678736:- CESC cis rs1577917 0.837 rs806529 ENSG00000203875.9 SNHG5 -9.54 3.07e-18 2.22e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85757403 chr6:85660950~85678736:- CESC cis rs1799949 1 rs12944430 ENSG00000198496.9 NBR2 -9.53 3.15e-18 2.27e-14 -0.71 -0.54 Menopause (age at onset); chr17:43178803 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs11653460 ENSG00000198496.9 NBR2 -9.53 3.15e-18 2.27e-14 -0.71 -0.54 Menopause (age at onset); chr17:43179289 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs11650913 ENSG00000198496.9 NBR2 -9.53 3.15e-18 2.27e-14 -0.71 -0.54 Menopause (age at onset); chr17:43179580 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs12936831 ENSG00000198496.9 NBR2 -9.53 3.15e-18 2.27e-14 -0.71 -0.54 Menopause (age at onset); chr17:43179799 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs35292991 ENSG00000198496.9 NBR2 -9.53 3.15e-18 2.27e-14 -0.71 -0.54 Menopause (age at onset); chr17:43181999 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs11658499 ENSG00000198496.9 NBR2 -9.53 3.15e-18 2.27e-14 -0.71 -0.54 Menopause (age at onset); chr17:43182732 chr17:43125610~43153671:+ CESC cis rs3814244 0.515 rs2906856 ENSG00000255733.4 IFNG-AS1 -9.52 3.33e-18 2.39e-14 -0.49 -0.54 Itch intensity from mosquito bite adjusted by bite size; chr12:67996421 chr12:67989445~68234686:+ CESC cis rs1577917 0.916 rs7759727 ENSG00000203875.9 SNHG5 -9.52 3.39e-18 2.44e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85809160 chr6:85660950~85678736:- CESC cis rs6452524 0.618 rs255561 ENSG00000249664.1 CTD-2227C6.2 9.52 3.4e-18 2.44e-14 0.57 0.54 Hypertension (SNP x SNP interaction); chr5:83054991 chr5:83012285~83013109:- CESC cis rs858239 0.932 rs858275 ENSG00000230658.1 KLHL7-AS1 9.52 3.4e-18 2.44e-14 0.68 0.54 Cerebrospinal fluid biomarker levels; chr7:23254525 chr7:23101228~23105703:- CESC cis rs7208859 0.623 rs11658022 ENSG00000263531.1 RP13-753N3.1 9.51 3.61e-18 2.58e-14 1.11 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758341 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73269923 ENSG00000263531.1 RP13-753N3.1 9.51 3.61e-18 2.58e-14 1.11 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775553 chr17:30863921~30864940:- CESC cis rs1799949 1 rs8176273 ENSG00000198496.9 NBR2 -9.51 3.62e-18 2.59e-14 -0.72 -0.54 Menopause (age at onset); chr17:43059636 chr17:43125610~43153671:+ CESC cis rs977987 0.735 rs166013 ENSG00000261783.1 RP11-252K23.2 9.51 3.72e-18 2.65e-14 0.68 0.54 Dupuytren's disease; chr16:75400248 chr16:75379818~75381260:- CESC cis rs7301826 0.651 rs2277336 ENSG00000256250.1 RP11-989F5.1 9.51 3.79e-18 2.7e-14 0.67 0.54 Plasma plasminogen activator levels; chr12:130801574 chr12:130810606~130812438:+ CESC cis rs1577917 1 rs12204015 ENSG00000203875.9 SNHG5 -9.5 3.91e-18 2.78e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85888616 chr6:85660950~85678736:- CESC cis rs875971 0.505 rs2462573 ENSG00000226824.5 RP4-756H11.3 9.5 3.95e-18 2.81e-14 0.68 0.54 Aortic root size; chr7:66042405 chr7:66654538~66669855:+ CESC cis rs875971 0.505 rs1167385 ENSG00000226824.5 RP4-756H11.3 9.5 3.95e-18 2.81e-14 0.68 0.54 Aortic root size; chr7:66048321 chr7:66654538~66669855:+ CESC cis rs16828019 0.777 rs3738369 ENSG00000235358.1 RP11-399E6.1 9.5 4.07e-18 2.89e-14 0.86 0.54 Intelligence (multi-trait analysis); chr1:41020736 chr1:41242373~41284861:+ CESC cis rs1577917 1 rs7766645 ENSG00000203875.9 SNHG5 -9.49 4.28e-18 3.04e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85912520 chr6:85660950~85678736:- CESC cis rs1577917 1 rs1911552 ENSG00000203875.9 SNHG5 -9.49 4.28e-18 3.04e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85928306 chr6:85660950~85678736:- CESC cis rs1577917 1 rs9647603 ENSG00000203875.9 SNHG5 -9.49 4.28e-18 3.04e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85929623 chr6:85660950~85678736:- CESC cis rs1799949 1 rs11653253 ENSG00000198496.9 NBR2 -9.49 4.29e-18 3.04e-14 -0.73 -0.54 Menopause (age at onset); chr17:43030645 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs12951869 ENSG00000198496.9 NBR2 -9.49 4.29e-18 3.04e-14 -0.73 -0.54 Menopause (age at onset); chr17:43035550 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs11654452 ENSG00000198496.9 NBR2 -9.49 4.29e-18 3.04e-14 -0.73 -0.54 Menopause (age at onset); chr17:43037366 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs2298862 ENSG00000198496.9 NBR2 -9.49 4.33e-18 3.06e-14 -0.73 -0.54 Menopause (age at onset); chr17:43024671 chr17:43125610~43153671:+ CESC cis rs1799949 0.93 rs2298861 ENSG00000198496.9 NBR2 -9.49 4.33e-18 3.06e-14 -0.73 -0.54 Menopause (age at onset); chr17:43024814 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs36036395 ENSG00000198496.9 NBR2 -9.49 4.33e-18 3.06e-14 -0.73 -0.54 Menopause (age at onset); chr17:43029280 chr17:43125610~43153671:+ CESC cis rs875971 0.505 rs1167386 ENSG00000226824.5 RP4-756H11.3 9.48 4.55e-18 3.21e-14 0.68 0.54 Aortic root size; chr7:66048109 chr7:66654538~66669855:+ CESC cis rs1577917 0.518 rs6454482 ENSG00000203875.9 SNHG5 9.48 4.58e-18 3.24e-14 0.59 0.54 Response to antipsychotic treatment; chr6:85708470 chr6:85660950~85678736:- CESC cis rs977987 0.671 rs9922008 ENSG00000261783.1 RP11-252K23.2 -9.47 4.71e-18 3.32e-14 -0.7 -0.54 Dupuytren's disease; chr16:75301508 chr16:75379818~75381260:- CESC cis rs7301826 0.61 rs36051740 ENSG00000256250.1 RP11-989F5.1 9.47 4.87e-18 3.43e-14 0.65 0.54 Plasma plasminogen activator levels; chr12:130808177 chr12:130810606~130812438:+ CESC cis rs1577917 0.958 rs12192033 ENSG00000203875.9 SNHG5 -9.47 4.97e-18 3.5e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85762841 chr6:85660950~85678736:- CESC cis rs7208859 0.673 rs11650305 ENSG00000263531.1 RP13-753N3.1 9.46 5.12e-18 3.6e-14 1.02 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902343 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11654914 ENSG00000263531.1 RP13-753N3.1 9.46 5.12e-18 3.6e-14 1.02 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902406 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9914271 ENSG00000263531.1 RP13-753N3.1 9.46 5.12e-18 3.6e-14 1.02 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905607 chr17:30863921~30864940:- CESC cis rs2906856 0.921 rs1019076 ENSG00000255733.4 IFNG-AS1 -9.46 5.3e-18 3.72e-14 -0.49 -0.54 Mosquito bite size; chr12:68004338 chr12:67989445~68234686:+ CESC cis rs1577917 1 rs13199006 ENSG00000203875.9 SNHG5 -9.46 5.32e-18 3.73e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85898990 chr6:85660950~85678736:- CESC cis rs1577917 1 rs4707239 ENSG00000203875.9 SNHG5 -9.46 5.32e-18 3.73e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85900999 chr6:85660950~85678736:- CESC cis rs3814244 0.832 rs11177006 ENSG00000255733.4 IFNG-AS1 9.45 5.35e-18 3.75e-14 0.48 0.54 Itch intensity from mosquito bite adjusted by bite size; chr12:68019317 chr12:67989445~68234686:+ CESC cis rs858239 0.896 rs1637192 ENSG00000230658.1 KLHL7-AS1 9.45 5.4e-18 3.79e-14 0.7 0.54 Cerebrospinal fluid biomarker levels; chr7:23220895 chr7:23101228~23105703:- CESC cis rs1577917 0.771 rs4383777 ENSG00000203875.9 SNHG5 9.44 5.95e-18 4.15e-14 0.6 0.54 Response to antipsychotic treatment; chr6:85726242 chr6:85660950~85678736:- CESC cis rs7174755 0.924 rs8035431 ENSG00000260657.2 RP11-315D16.4 9.44 5.97e-18 4.16e-14 0.65 0.54 Major depressive disorder; chr15:68305012 chr15:68267792~68277994:- CESC cis rs1577917 1 rs4706254 ENSG00000203875.9 SNHG5 -9.44 6.05e-18 4.21e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85893095 chr6:85660950~85678736:- CESC cis rs1799949 1 rs12944458 ENSG00000198496.9 NBR2 -9.43 6.27e-18 4.35e-14 -0.73 -0.54 Menopause (age at onset); chr17:43028755 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs72829113 ENSG00000198496.9 NBR2 -9.43 6.27e-18 4.35e-14 -0.73 -0.54 Menopause (age at onset); chr17:43029818 chr17:43125610~43153671:+ CESC cis rs1577917 0.916 rs4142546 ENSG00000203875.9 SNHG5 -9.43 6.47e-18 4.48e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85795593 chr6:85660950~85678736:- CESC cis rs7208859 0.673 rs11653955 ENSG00000263531.1 RP13-753N3.1 9.42 6.69e-18 4.63e-14 1.1 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30706274 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs56085216 ENSG00000263531.1 RP13-753N3.1 9.42 6.71e-18 4.63e-14 1.02 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30890216 chr17:30863921~30864940:- CESC cis rs16828019 0.777 rs13376450 ENSG00000235358.1 RP11-399E6.1 9.42 6.78e-18 4.67e-14 0.88 0.54 Intelligence (multi-trait analysis); chr1:41003371 chr1:41242373~41284861:+ CESC cis rs1577917 0.771 rs9362239 ENSG00000203875.9 SNHG5 9.42 6.86e-18 4.73e-14 0.59 0.54 Response to antipsychotic treatment; chr6:85719545 chr6:85660950~85678736:- CESC cis rs7208859 0.573 rs11656121 ENSG00000263531.1 RP13-753N3.1 9.42 6.86e-18 4.73e-14 1.02 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887025 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11650973 ENSG00000263531.1 RP13-753N3.1 9.42 6.86e-18 4.73e-14 1.02 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887027 chr17:30863921~30864940:- CESC cis rs1577917 0.958 rs13207173 ENSG00000203875.9 SNHG5 -9.42 6.89e-18 4.74e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85747804 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs4098044 ENSG00000203875.9 SNHG5 -9.42 6.89e-18 4.74e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85752348 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12191340 ENSG00000203875.9 SNHG5 -9.42 6.9e-18 4.74e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85811682 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs1414199 ENSG00000203875.9 SNHG5 -9.42 6.9e-18 4.74e-14 -0.61 -0.54 Response to antipsychotic treatment; chr6:85812652 chr6:85660950~85678736:- CESC cis rs1577917 0.559 rs7763210 ENSG00000203875.9 SNHG5 -9.41 7.06e-18 4.86e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:86098900 chr6:85660950~85678736:- CESC cis rs3814244 0.515 rs2906862 ENSG00000255733.4 IFNG-AS1 -9.41 7.38e-18 5.07e-14 -0.49 -0.54 Itch intensity from mosquito bite adjusted by bite size; chr12:68005371 chr12:67989445~68234686:+ CESC cis rs10256972 0.527 rs2949170 ENSG00000229043.2 AC091729.9 -9.4 7.51e-18 5.16e-14 -0.61 -0.54 Endometriosis;Longevity; chr7:1176802 chr7:1160374~1165267:+ CESC cis rs7208859 0.673 rs12949860 ENSG00000263531.1 RP13-753N3.1 9.4 7.66e-18 5.25e-14 1.02 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896014 chr17:30863921~30864940:- CESC cis rs1799949 1 rs8176265 ENSG00000198496.9 NBR2 -9.4 7.66e-18 5.26e-14 -0.71 -0.54 Menopause (age at onset); chr17:43061979 chr17:43125610~43153671:+ CESC cis rs7301826 0.651 rs4514465 ENSG00000256250.1 RP11-989F5.1 -9.4 7.7e-18 5.28e-14 -0.63 -0.54 Plasma plasminogen activator levels; chr12:130829124 chr12:130810606~130812438:+ CESC cis rs7208859 0.623 rs3794796 ENSG00000263531.1 RP13-753N3.1 9.39 8.05e-18 5.51e-14 1.09 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30863921~30864940:- CESC cis rs7301826 0.934 rs10773826 ENSG00000256250.1 RP11-989F5.1 -9.39 8.52e-18 5.82e-14 -0.6 -0.54 Plasma plasminogen activator levels; chr12:130836629 chr12:130810606~130812438:+ CESC cis rs1577917 1 rs2812972 ENSG00000203875.9 SNHG5 -9.38 8.61e-18 5.88e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85960162 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs1337843 ENSG00000203875.9 SNHG5 -9.38 8.61e-18 5.88e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85965827 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs6900436 ENSG00000203875.9 SNHG5 -9.38 8.89e-18 6.06e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85796570 chr6:85660950~85678736:- CESC cis rs1577917 0.687 rs1470531 ENSG00000203875.9 SNHG5 -9.38 8.89e-18 6.06e-14 -0.6 -0.54 Response to antipsychotic treatment; chr6:85797651 chr6:85660950~85678736:- CESC cis rs7208859 0.673 rs75142521 ENSG00000263531.1 RP13-753N3.1 9.37 9.22e-18 6.28e-14 1.01 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913519 chr17:30863921~30864940:- CESC cis rs1577917 1 rs6454513 ENSG00000203875.9 SNHG5 9.36 9.89e-18 6.71e-14 0.6 0.54 Response to antipsychotic treatment; chr6:86010331 chr6:85660950~85678736:- CESC cis rs7208859 0.623 rs73263788 ENSG00000263531.1 RP13-753N3.1 9.36 9.93e-18 6.73e-14 1.01 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889472 chr17:30863921~30864940:- CESC cis rs1799949 1 rs11659028 ENSG00000198496.9 NBR2 -9.36 1.02e-17 6.88e-14 -0.72 -0.54 Menopause (age at onset); chr17:43043008 chr17:43125610~43153671:+ CESC cis rs1577917 0.958 rs34994386 ENSG00000203875.9 SNHG5 -9.36 1.04e-17 7.06e-14 -0.59 -0.54 Response to antipsychotic treatment; chr6:85814417 chr6:85660950~85678736:- CESC cis rs801193 0.901 rs4273746 ENSG00000226824.5 RP4-756H11.3 9.36 1.05e-17 7.06e-14 0.69 0.54 Aortic root size; chr7:66836124 chr7:66654538~66669855:+ CESC cis rs5760092 0.618 rs4461358 ENSG00000218537.1 MIF-AS1 -9.36 1.05e-17 7.07e-14 -0.76 -0.54 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23894426~23898930:- CESC cis rs1799949 1 rs915945 ENSG00000198496.9 NBR2 -9.35 1.09e-17 7.35e-14 -0.73 -0.54 Menopause (age at onset); chr17:43027847 chr17:43125610~43153671:+ CESC cis rs7301826 1 rs1609985 ENSG00000256250.1 RP11-989F5.1 -9.35 1.1e-17 7.4e-14 -0.61 -0.53 Plasma plasminogen activator levels; chr12:130835625 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs4759517 ENSG00000256250.1 RP11-989F5.1 -9.35 1.1e-17 7.42e-14 -0.65 -0.53 Plasma plasminogen activator levels; chr12:130799153 chr12:130810606~130812438:+ CESC cis rs3814244 0.868 rs11177007 ENSG00000255733.4 IFNG-AS1 9.35 1.12e-17 7.56e-14 0.47 0.53 Itch intensity from mosquito bite adjusted by bite size; chr12:68020964 chr12:67989445~68234686:+ CESC cis rs5760092 0.618 rs5996631 ENSG00000218537.1 MIF-AS1 -9.35 1.12e-17 7.57e-14 -0.76 -0.53 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23894426~23898930:- CESC cis rs7208859 0.623 rs60890550 ENSG00000263531.1 RP13-753N3.1 9.34 1.16e-17 7.78e-14 1.07 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30703843 chr17:30863921~30864940:- CESC cis rs4423214 1 rs4944959 ENSG00000254682.1 RP11-660L16.2 -9.34 1.2e-17 8.07e-14 -0.67 -0.53 Vitamin D levels; chr11:71457188 chr11:71448674~71452157:+ CESC cis rs7301826 0.651 rs7299281 ENSG00000256250.1 RP11-989F5.1 9.33 1.22e-17 8.19e-14 0.63 0.53 Plasma plasminogen activator levels; chr12:130818587 chr12:130810606~130812438:+ CESC cis rs950027 0.62 rs1719246 ENSG00000259520.4 CTD-2651B20.3 -9.33 1.24e-17 8.33e-14 -0.7 -0.53 Response to fenofibrate (adiponectin levels); chr15:45333281 chr15:45251580~45279251:- CESC cis rs916888 0.61 rs199530 ENSG00000262539.1 RP11-259G18.3 -9.33 1.27e-17 8.52e-14 -0.67 -0.53 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46259551~46260606:- CESC cis rs801193 1 rs13239306 ENSG00000226824.5 RP4-756H11.3 9.32 1.35e-17 9.03e-14 0.67 0.53 Aortic root size; chr7:66671030 chr7:66654538~66669855:+ CESC cis rs16828019 0.929 rs111309254 ENSG00000235358.1 RP11-399E6.1 9.32 1.35e-17 9.03e-14 0.87 0.53 Intelligence (multi-trait analysis); chr1:41270328 chr1:41242373~41284861:+ CESC cis rs16828019 0.929 rs4131949 ENSG00000235358.1 RP11-399E6.1 9.32 1.35e-17 9.03e-14 0.87 0.53 Intelligence (multi-trait analysis); chr1:41272965 chr1:41242373~41284861:+ CESC cis rs16828019 0.929 rs35813191 ENSG00000235358.1 RP11-399E6.1 9.32 1.35e-17 9.03e-14 0.87 0.53 Intelligence (multi-trait analysis); chr1:41277128 chr1:41242373~41284861:+ CESC cis rs4423214 1 rs2276362 ENSG00000254682.1 RP11-660L16.2 9.32 1.37e-17 9.13e-14 0.69 0.53 Vitamin D levels; chr11:71463406 chr11:71448674~71452157:+ CESC cis rs858239 0.712 rs199650 ENSG00000230658.1 KLHL7-AS1 -9.31 1.4e-17 9.32e-14 -0.68 -0.53 Cerebrospinal fluid biomarker levels; chr7:23327570 chr7:23101228~23105703:- CESC cis rs11155671 0.53 rs9371215 ENSG00000231760.4 RP11-350J20.5 9.31 1.41e-17 9.35e-14 0.68 0.53 Testicular germ cell tumor; chr6:149873162 chr6:149796151~149826294:- CESC cis rs950027 0.62 rs1719245 ENSG00000259520.4 CTD-2651B20.3 -9.31 1.41e-17 9.39e-14 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45331584 chr15:45251580~45279251:- CESC cis rs950027 0.549 rs11636114 ENSG00000259520.4 CTD-2651B20.3 -9.31 1.42e-17 9.4e-14 -0.71 -0.53 Response to fenofibrate (adiponectin levels); chr15:45309214 chr15:45251580~45279251:- CESC cis rs4423214 0.819 rs7938885 ENSG00000254682.1 RP11-660L16.2 9.31 1.43e-17 9.51e-14 0.69 0.53 Vitamin D levels; chr11:71458997 chr11:71448674~71452157:+ CESC cis rs4423214 0.959 rs12800438 ENSG00000254682.1 RP11-660L16.2 9.31 1.43e-17 9.51e-14 0.69 0.53 Vitamin D levels; chr11:71459957 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs12807718 ENSG00000254682.1 RP11-660L16.2 9.31 1.43e-17 9.51e-14 0.69 0.53 Vitamin D levels; chr11:71460124 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs4423214 ENSG00000254682.1 RP11-660L16.2 9.31 1.43e-17 9.51e-14 0.69 0.53 Vitamin D levels; chr11:71462208 chr11:71448674~71452157:+ CESC cis rs1577917 0.958 rs12216074 ENSG00000203875.9 SNHG5 -9.3 1.53e-17 1.01e-13 -0.61 -0.53 Response to antipsychotic treatment; chr6:85810284 chr6:85660950~85678736:- CESC cis rs1799949 1 rs12944597 ENSG00000198496.9 NBR2 -9.3 1.54e-17 1.02e-13 -0.72 -0.53 Menopause (age at onset); chr17:43035667 chr17:43125610~43153671:+ CESC cis rs1799949 1 rs12942277 ENSG00000198496.9 NBR2 -9.3 1.54e-17 1.02e-13 -0.72 -0.53 Menopause (age at onset); chr17:43035957 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs34616041 ENSG00000198496.9 NBR2 -9.3 1.54e-17 1.02e-13 -0.72 -0.53 Menopause (age at onset); chr17:43036769 chr17:43125610~43153671:+ CESC cis rs1577917 0.958 rs9647601 ENSG00000203875.9 SNHG5 -9.29 1.63e-17 1.08e-13 -0.6 -0.53 Response to antipsychotic treatment; chr6:85740109 chr6:85660950~85678736:- CESC cis rs9545047 0.967 rs9318627 ENSG00000227676.3 LINC01068 9.29 1.66e-17 1.09e-13 0.6 0.53 Schizophrenia; chr13:79355944 chr13:79566727~79571436:+ CESC cis rs875971 0.505 rs1723275 ENSG00000226824.5 RP4-756H11.3 9.28 1.69e-17 1.11e-13 0.68 0.53 Aortic root size; chr7:66039646 chr7:66654538~66669855:+ CESC cis rs1577917 0.958 rs2660576 ENSG00000203875.9 SNHG5 -9.28 1.7e-17 1.12e-13 -0.6 -0.53 Response to antipsychotic treatment; chr6:85941885 chr6:85660950~85678736:- CESC cis rs1577917 1 rs6914463 ENSG00000203875.9 SNHG5 -9.28 1.7e-17 1.12e-13 -0.6 -0.53 Response to antipsychotic treatment; chr6:85943697 chr6:85660950~85678736:- CESC cis rs1577917 1 rs2816821 ENSG00000203875.9 SNHG5 -9.28 1.7e-17 1.12e-13 -0.6 -0.53 Response to antipsychotic treatment; chr6:85947366 chr6:85660950~85678736:- CESC cis rs4423214 1 rs2040323 ENSG00000254682.1 RP11-660L16.2 9.28 1.71e-17 1.13e-13 0.7 0.53 Vitamin D levels; chr11:71461737 chr11:71448674~71452157:+ CESC cis rs7208859 0.623 rs56378576 ENSG00000263531.1 RP13-753N3.1 9.28 1.76e-17 1.16e-13 1.08 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30683102 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs35916850 ENSG00000263531.1 RP13-753N3.1 9.28 1.76e-17 1.16e-13 1.08 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30684155 chr17:30863921~30864940:- CESC cis rs950027 0.62 rs1617984 ENSG00000259520.4 CTD-2651B20.3 -9.28 1.77e-17 1.17e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45330464 chr15:45251580~45279251:- CESC cis rs7208859 0.573 rs55661352 ENSG00000263531.1 RP13-753N3.1 9.27 1.81e-17 1.19e-13 1.08 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30863921~30864940:- CESC cis rs7301826 0.651 rs10848206 ENSG00000256250.1 RP11-989F5.1 -9.27 1.82e-17 1.19e-13 -0.65 -0.53 Plasma plasminogen activator levels; chr12:130796926 chr12:130810606~130812438:+ CESC cis rs1577917 0.958 rs12196230 ENSG00000203875.9 SNHG5 -9.27 1.86e-17 1.22e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85810242 chr6:85660950~85678736:- CESC cis rs3814244 0.515 rs3015002 ENSG00000255733.4 IFNG-AS1 -9.27 1.88e-17 1.23e-13 -0.48 -0.53 Itch intensity from mosquito bite adjusted by bite size; chr12:68010853 chr12:67989445~68234686:+ CESC cis rs16828019 0.929 rs10524 ENSG00000235358.1 RP11-399E6.1 9.26 1.95e-17 1.28e-13 0.86 0.53 Intelligence (multi-trait analysis); chr1:41260801 chr1:41242373~41284861:+ CESC cis rs7174755 0.961 rs12148843 ENSG00000260657.2 RP11-315D16.4 9.24 2.21e-17 1.44e-13 0.63 0.53 Major depressive disorder; chr15:68302184 chr15:68267792~68277994:- CESC cis rs7174755 0.961 rs1122247 ENSG00000260657.2 RP11-315D16.4 9.24 2.21e-17 1.44e-13 0.63 0.53 Major depressive disorder; chr15:68302523 chr15:68267792~68277994:- CESC cis rs7174755 0.961 rs11631030 ENSG00000260657.2 RP11-315D16.4 9.24 2.21e-17 1.44e-13 0.63 0.53 Major depressive disorder; chr15:68303463 chr15:68267792~68277994:- CESC cis rs977987 0.654 rs8054194 ENSG00000261783.1 RP11-252K23.2 -9.22 2.65e-17 1.7e-13 -0.67 -0.53 Dupuytren's disease; chr16:75463262 chr16:75379818~75381260:- CESC cis rs977987 0.581 rs8056141 ENSG00000261783.1 RP11-252K23.2 -9.22 2.65e-17 1.7e-13 -0.67 -0.53 Dupuytren's disease; chr16:75463264 chr16:75379818~75381260:- CESC cis rs6452524 0.618 rs2306336 ENSG00000249664.1 CTD-2227C6.2 9.22 2.68e-17 1.72e-13 0.55 0.53 Hypertension (SNP x SNP interaction); chr5:83064964 chr5:83012285~83013109:- CESC cis rs7301826 0.58 rs61938969 ENSG00000256250.1 RP11-989F5.1 9.21 2.8e-17 1.79e-13 0.64 0.53 Plasma plasminogen activator levels; chr12:130831525 chr12:130810606~130812438:+ CESC cis rs950027 0.62 rs1153862 ENSG00000259520.4 CTD-2651B20.3 -9.21 2.88e-17 1.85e-13 -0.68 -0.53 Response to fenofibrate (adiponectin levels); chr15:45339670 chr15:45251580~45279251:- CESC cis rs1577917 0.958 rs4707223 ENSG00000203875.9 SNHG5 -9.2 2.9e-17 1.86e-13 -0.6 -0.53 Response to antipsychotic treatment; chr6:85800084 chr6:85660950~85678736:- CESC cis rs7301826 1 rs2001483 ENSG00000256250.1 RP11-989F5.1 -9.2 2.99e-17 1.91e-13 -0.59 -0.53 Plasma plasminogen activator levels; chr12:130834100 chr12:130810606~130812438:+ CESC cis rs6452524 0.618 rs10462394 ENSG00000249664.1 CTD-2227C6.2 9.2 3.02e-17 1.93e-13 0.56 0.53 Hypertension (SNP x SNP interaction); chr5:83058735 chr5:83012285~83013109:- CESC cis rs1577917 0.958 rs12195776 ENSG00000203875.9 SNHG5 -9.2 3.05e-17 1.95e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85778881 chr6:85660950~85678736:- CESC cis rs1577917 0.916 rs12206726 ENSG00000203875.9 SNHG5 -9.2 3.05e-17 1.95e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85789998 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs1414201 ENSG00000203875.9 SNHG5 -9.19 3.14e-17 2e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85790598 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs7453105 ENSG00000203875.9 SNHG5 -9.19 3.14e-17 2e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85791043 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12209259 ENSG00000203875.9 SNHG5 -9.19 3.14e-17 2e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85792630 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs4441928 ENSG00000203875.9 SNHG5 9.19 3.14e-17 2e-13 0.62 0.53 Response to antipsychotic treatment; chr6:85532176 chr6:85660950~85678736:- CESC cis rs7301826 0.61 rs7957899 ENSG00000256250.1 RP11-989F5.1 -9.18 3.35e-17 2.13e-13 -0.64 -0.53 Plasma plasminogen activator levels; chr12:130794531 chr12:130810606~130812438:+ CESC cis rs7301826 0.651 rs1973834 ENSG00000256250.1 RP11-989F5.1 -9.18 3.35e-17 2.13e-13 -0.64 -0.53 Plasma plasminogen activator levels; chr12:130795612 chr12:130810606~130812438:+ CESC cis rs858239 0.831 rs7796541 ENSG00000230658.1 KLHL7-AS1 9.18 3.47e-17 2.2e-13 0.71 0.53 Cerebrospinal fluid biomarker levels; chr7:23349454 chr7:23101228~23105703:- CESC cis rs10256972 0.527 rs28671326 ENSG00000229043.2 AC091729.9 -9.18 3.47e-17 2.2e-13 -0.59 -0.53 Endometriosis;Longevity; chr7:1135337 chr7:1160374~1165267:+ CESC cis rs1577917 1 rs35760725 ENSG00000203875.9 SNHG5 -9.15 4.09e-17 2.58e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85939267 chr6:85660950~85678736:- CESC cis rs7301826 0.61 rs7961690 ENSG00000256250.1 RP11-989F5.1 9.15 4.22e-17 2.66e-13 0.63 0.53 Plasma plasminogen activator levels; chr12:130812335 chr12:130810606~130812438:+ CESC cis rs7301826 0.627 rs61937256 ENSG00000256250.1 RP11-989F5.1 9.15 4.22e-17 2.66e-13 0.63 0.53 Plasma plasminogen activator levels; chr12:130818100 chr12:130810606~130812438:+ CESC cis rs7301826 0.56 rs12829294 ENSG00000256250.1 RP11-989F5.1 9.15 4.22e-17 2.66e-13 0.63 0.53 Plasma plasminogen activator levels; chr12:130825427 chr12:130810606~130812438:+ CESC cis rs1577917 0.958 rs4707236 ENSG00000203875.9 SNHG5 -9.15 4.27e-17 2.69e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85874249 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs34795473 ENSG00000203875.9 SNHG5 -9.14 4.37e-17 2.76e-13 -0.6 -0.53 Response to antipsychotic treatment; chr6:85752081 chr6:85660950~85678736:- CESC cis rs977987 0.832 rs37597 ENSG00000261783.1 RP11-252K23.2 9.14 4.49e-17 2.81e-13 0.66 0.53 Dupuytren's disease; chr16:75466377 chr16:75379818~75381260:- CESC cis rs1930961 1 rs6004667 ENSG00000100058.11 CRYBB2P1 -9.13 4.61e-17 2.89e-13 -0.82 -0.53 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25448105~25520854:+ CESC cis rs7301826 0.651 rs6486601 ENSG00000256250.1 RP11-989F5.1 9.13 4.8e-17 3e-13 0.63 0.53 Plasma plasminogen activator levels; chr12:130816692 chr12:130810606~130812438:+ CESC cis rs7208859 0.673 rs73277964 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30852183 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11652409 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855689 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9896095 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30860479 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs58920731 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864728 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73277984 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869115 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs73277986 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869179 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs12103588 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30870442 chr17:30863921~30864940:- CESC cis rs7208859 0.614 rs9914534 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30875646 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs4131618 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30877783 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs11658344 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30880727 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9900144 ENSG00000263531.1 RP13-753N3.1 9.13 4.81e-17 3e-13 1 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881371 chr17:30863921~30864940:- CESC cis rs950027 0.62 rs35861938 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.96e-17 3.09e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45345145 chr15:45251580~45279251:- CESC cis rs950027 0.596 rs2467865 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.96e-17 3.09e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45346109 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs2486274 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.96e-17 3.09e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45374030 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs1145084 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.96e-17 3.09e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45383242 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs1145080 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.96e-17 3.09e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45389140 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs2461700 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.98e-17 3.1e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45348429 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs2453533 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.98e-17 3.1e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45349027 chr15:45251580~45279251:- CESC cis rs950027 0.584 rs1145086 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.98e-17 3.1e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45362129 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs1153857 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.98e-17 3.1e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45366897 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs1153855 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.98e-17 3.1e-13 -0.69 -0.53 Response to fenofibrate (adiponectin levels); chr15:45368560 chr15:45251580~45279251:- CESC cis rs2486288 0.539 rs2433601 ENSG00000259520.4 CTD-2651B20.3 -9.12 4.98e-17 3.1e-13 -0.68 -0.53 Glomerular filtration rate; chr15:45424227 chr15:45251580~45279251:- CESC cis rs1799949 1 rs8070085 ENSG00000198496.9 NBR2 9.11 5.36e-17 3.33e-13 0.66 0.53 Menopause (age at onset); chr17:43189967 chr17:43125610~43153671:+ CESC cis rs1577917 0.958 rs36042496 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85814496 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs1584273 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85814859 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12198971 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85815727 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs34230196 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85816304 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs4707226 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85818110 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs10455448 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85823893 chr6:85660950~85678736:- CESC cis rs1577917 0.876 rs12212808 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85824254 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs13196576 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85824348 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs13213603 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85825040 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs3857480 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85825431 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs2324839 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85827224 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs3900313 ENSG00000203875.9 SNHG5 -9.11 5.48e-17 3.39e-13 -0.59 -0.53 Response to antipsychotic treatment; chr6:85827436 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12213431 ENSG00000203875.9 SNHG5 -9.11 5.57e-17 3.44e-13 -0.57 -0.52 Response to antipsychotic treatment; chr6:85791238 chr6:85660950~85678736:- CESC cis rs10256972 0.528 rs7784607 ENSG00000229043.2 AC091729.9 -9.11 5.62e-17 3.47e-13 -0.59 -0.52 Endometriosis;Longevity; chr7:1139058 chr7:1160374~1165267:+ CESC cis rs6452524 0.648 rs27364 ENSG00000249664.1 CTD-2227C6.2 9.1 5.97e-17 3.68e-13 0.55 0.52 Hypertension (SNP x SNP interaction); chr5:83052137 chr5:83012285~83013109:- CESC cis rs3814244 0.868 rs10878726 ENSG00000255733.4 IFNG-AS1 9.09 6.04e-17 3.72e-13 0.45 0.52 Itch intensity from mosquito bite adjusted by bite size; chr12:68022865 chr12:67989445~68234686:+ CESC cis rs1930961 1 rs6004673 ENSG00000100058.11 CRYBB2P1 9.09 6.1e-17 3.76e-13 0.82 0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25448105~25520854:+ CESC cis rs1799949 1 rs8176318 ENSG00000198496.9 NBR2 -9.09 6.39e-17 3.93e-13 -0.68 -0.52 Menopause (age at onset); chr17:43045257 chr17:43125610~43153671:+ CESC cis rs7208859 0.573 rs73277960 ENSG00000263531.1 RP13-753N3.1 9.08 6.67e-17 4.09e-13 1 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30850423 chr17:30863921~30864940:- CESC cis rs9322193 0.884 rs7743823 ENSG00000231760.4 RP11-350J20.5 9.07 6.91e-17 4.23e-13 0.69 0.52 Lung cancer; chr6:149849744 chr6:149796151~149826294:- CESC cis rs7174755 0.743 rs4777035 ENSG00000260657.2 RP11-315D16.4 -9.07 7.32e-17 4.47e-13 -0.63 -0.52 Major depressive disorder; chr15:68312831 chr15:68267792~68277994:- CESC cis rs1577917 0.958 rs10944136 ENSG00000203875.9 SNHG5 -9.06 7.4e-17 4.51e-13 -0.59 -0.52 Response to antipsychotic treatment; chr6:85738781 chr6:85660950~85678736:- CESC cis rs7301826 0.627 rs34103763 ENSG00000256250.1 RP11-989F5.1 9.06 7.54e-17 4.6e-13 0.63 0.52 Plasma plasminogen activator levels; chr12:130805604 chr12:130810606~130812438:+ CESC cis rs950027 0.62 rs1426932 ENSG00000259520.4 CTD-2651B20.3 -9.05 8.11e-17 4.92e-13 -0.68 -0.52 Response to fenofibrate (adiponectin levels); chr15:45395058 chr15:45251580~45279251:- CESC cis rs950027 0.596 rs2467853 ENSG00000259520.4 CTD-2651B20.3 -9.05 8.11e-17 4.92e-13 -0.68 -0.52 Response to fenofibrate (adiponectin levels); chr15:45406595 chr15:45251580~45279251:- CESC cis rs950027 0.595 rs2486288 ENSG00000259520.4 CTD-2651B20.3 -9.05 8.11e-17 4.92e-13 -0.68 -0.52 Response to fenofibrate (adiponectin levels); chr15:45420141 chr15:45251580~45279251:- CESC cis rs7301826 0.651 rs7956851 ENSG00000256250.1 RP11-989F5.1 -9.05 8.31e-17 5.05e-13 -0.62 -0.52 Plasma plasminogen activator levels; chr12:130834554 chr12:130810606~130812438:+ CESC cis rs950027 0.62 rs1145076 ENSG00000259520.4 CTD-2651B20.3 -9.04 8.41e-17 5.1e-13 -0.67 -0.52 Response to fenofibrate (adiponectin levels); chr15:45392310 chr15:45251580~45279251:- CESC cis rs6452524 0.618 rs10051445 ENSG00000249664.1 CTD-2227C6.2 9.04 8.46e-17 5.13e-13 0.56 0.52 Hypertension (SNP x SNP interaction); chr5:83060280 chr5:83012285~83013109:- CESC cis rs6452524 0.618 rs6867727 ENSG00000249664.1 CTD-2227C6.2 9.04 8.46e-17 5.13e-13 0.56 0.52 Hypertension (SNP x SNP interaction); chr5:83061333 chr5:83012285~83013109:- CESC cis rs6452524 0.618 rs7723639 ENSG00000249664.1 CTD-2227C6.2 9.04 8.46e-17 5.13e-13 0.56 0.52 Hypertension (SNP x SNP interaction); chr5:83062610 chr5:83012285~83013109:- CESC cis rs6452524 0.56 rs6895174 ENSG00000249664.1 CTD-2227C6.2 9.03 9.34e-17 5.63e-13 0.54 0.52 Hypertension (SNP x SNP interaction); chr5:83071606 chr5:83012285~83013109:- CESC cis rs916888 0.647 rs199523 ENSG00000262539.1 RP11-259G18.3 -9.03 9.53e-17 5.73e-13 -0.66 -0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46259551~46260606:- CESC cis rs6452524 0.618 rs1871203 ENSG00000249664.1 CTD-2227C6.2 9.02 1.01e-16 6.07e-13 0.55 0.52 Hypertension (SNP x SNP interaction); chr5:83059567 chr5:83012285~83013109:- CESC cis rs7208859 0.673 rs11654331 ENSG00000263531.1 RP13-753N3.1 9 1.12e-16 6.69e-13 0.99 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837999 chr17:30863921~30864940:- CESC cis rs977987 0.735 rs11149831 ENSG00000261783.1 RP11-252K23.2 -9 1.13e-16 6.75e-13 -0.67 -0.52 Dupuytren's disease; chr16:75417563 chr16:75379818~75381260:- CESC cis rs1930961 1 rs6004668 ENSG00000100058.11 CRYBB2P1 -9 1.16e-16 6.89e-13 -0.8 -0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25448105~25520854:+ CESC cis rs1153858 0.723 rs11855527 ENSG00000259520.4 CTD-2651B20.3 8.99 1.19e-16 7.09e-13 0.68 0.52 Homoarginine levels; chr15:45314487 chr15:45251580~45279251:- CESC cis rs875971 0.965 rs7794930 ENSG00000226824.5 RP4-756H11.3 8.98 1.26e-16 7.51e-13 0.63 0.52 Aortic root size; chr7:66313559 chr7:66654538~66669855:+ CESC cis rs7208859 0.673 rs11656462 ENSG00000263531.1 RP13-753N3.1 8.98 1.27e-16 7.54e-13 0.99 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30833682 chr17:30863921~30864940:- CESC cis rs17826219 0.706 rs57698184 ENSG00000263531.1 RP13-753N3.1 8.98 1.31e-16 7.78e-13 1.04 0.52 Body mass index; chr17:30737900 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs59923796 ENSG00000263531.1 RP13-753N3.1 8.98 1.31e-16 7.78e-13 1.04 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30863921~30864940:- CESC cis rs1577917 0.958 rs1545376 ENSG00000203875.9 SNHG5 8.98 1.31e-16 7.79e-13 0.59 0.52 Response to antipsychotic treatment; chr6:85794864 chr6:85660950~85678736:- CESC cis rs858239 1 rs199357 ENSG00000230658.1 KLHL7-AS1 -8.98 1.32e-16 7.8e-13 -0.64 -0.52 Cerebrospinal fluid biomarker levels; chr7:23248690 chr7:23101228~23105703:- CESC cis rs7617773 0.817 rs34225441 ENSG00000229759.1 MRPS18AP1 8.97 1.34e-16 7.94e-13 0.57 0.52 Coronary artery disease; chr3:48267401 chr3:48256350~48256938:- CESC cis rs7301826 1 rs4759523 ENSG00000256250.1 RP11-989F5.1 -8.97 1.36e-16 8.04e-13 -0.58 -0.52 Plasma plasminogen activator levels; chr12:130830867 chr12:130810606~130812438:+ CESC cis rs7301826 1 rs4759524 ENSG00000256250.1 RP11-989F5.1 -8.97 1.36e-16 8.04e-13 -0.58 -0.52 Plasma plasminogen activator levels; chr12:130831065 chr12:130810606~130812438:+ CESC cis rs7301826 0.603 rs7975825 ENSG00000256250.1 RP11-989F5.1 -8.96 1.47e-16 8.68e-13 -0.62 -0.52 Plasma plasminogen activator levels; chr12:130803899 chr12:130810606~130812438:+ CESC cis rs1577917 1 rs6923148 ENSG00000203875.9 SNHG5 8.95 1.57e-16 9.24e-13 0.58 0.52 Response to antipsychotic treatment; chr6:86058068 chr6:85660950~85678736:- CESC cis rs7208859 0.623 rs9912440 ENSG00000263531.1 RP13-753N3.1 8.95 1.61e-16 9.47e-13 0.98 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30821754 chr17:30863921~30864940:- CESC cis rs1577917 1 rs2816815 ENSG00000203875.9 SNHG5 -8.95 1.62e-16 9.54e-13 -0.59 -0.52 Response to antipsychotic treatment; chr6:85981938 chr6:85660950~85678736:- CESC cis rs6452524 0.618 rs3899556 ENSG00000249664.1 CTD-2227C6.2 8.94 1.66e-16 9.75e-13 0.54 0.52 Hypertension (SNP x SNP interaction); chr5:83067862 chr5:83012285~83013109:- CESC cis rs6452524 0.589 rs6882386 ENSG00000249664.1 CTD-2227C6.2 8.94 1.72e-16 1.01e-12 0.54 0.52 Hypertension (SNP x SNP interaction); chr5:83065555 chr5:83012285~83013109:- CESC cis rs6452524 0.618 rs6860752 ENSG00000249664.1 CTD-2227C6.2 8.94 1.72e-16 1.01e-12 0.54 0.52 Hypertension (SNP x SNP interaction); chr5:83065587 chr5:83012285~83013109:- CESC cis rs950027 0.62 rs1145093 ENSG00000259520.4 CTD-2651B20.3 -8.93 1.79e-16 1.05e-12 -0.67 -0.52 Response to fenofibrate (adiponectin levels); chr15:45357615 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs1145089 ENSG00000259520.4 CTD-2651B20.3 -8.93 1.79e-16 1.05e-12 -0.67 -0.52 Response to fenofibrate (adiponectin levels); chr15:45359856 chr15:45251580~45279251:- CESC cis rs950027 0.62 rs1049518 ENSG00000259520.4 CTD-2651B20.3 -8.93 1.79e-16 1.05e-12 -0.67 -0.52 Response to fenofibrate (adiponectin levels); chr15:45361169 chr15:45251580~45279251:- CESC cis rs875971 0.522 rs1880556 ENSG00000226824.5 RP4-756H11.3 -8.93 1.81e-16 1.06e-12 -0.68 -0.52 Aortic root size; chr7:65967557 chr7:66654538~66669855:+ CESC cis rs950027 0.62 rs1153860 ENSG00000259520.4 CTD-2651B20.3 8.93 1.82e-16 1.06e-12 0.68 0.52 Response to fenofibrate (adiponectin levels); chr15:45344386 chr15:45251580~45279251:- CESC cis rs875971 1 rs937495 ENSG00000226824.5 RP4-756H11.3 8.93 1.83e-16 1.07e-12 0.63 0.52 Aortic root size; chr7:66314811 chr7:66654538~66669855:+ CESC cis rs950027 0.62 rs2467862 ENSG00000259520.4 CTD-2651B20.3 -8.93 1.83e-16 1.07e-12 -0.67 -0.52 Response to fenofibrate (adiponectin levels); chr15:45351645 chr15:45251580~45279251:- CESC cis rs9545047 0.967 rs9574402 ENSG00000227676.3 LINC01068 8.92 1.88e-16 1.1e-12 0.59 0.52 Schizophrenia; chr13:79298392 chr13:79566727~79571436:+ CESC cis rs9322193 0.884 rs7769115 ENSG00000231760.4 RP11-350J20.5 8.91 2.11e-16 1.23e-12 0.68 0.52 Lung cancer; chr6:149848796 chr6:149796151~149826294:- CESC cis rs10256972 0.553 rs4236381 ENSG00000229043.2 AC091729.9 -8.89 2.28e-16 1.32e-12 -0.58 -0.52 Endometriosis;Longevity; chr7:1126087 chr7:1160374~1165267:+ CESC cis rs17826219 0.706 rs8075357 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Body mass index; chr17:30730179 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs59447372 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30730567 chr17:30863921~30864940:- CESC cis rs17826219 0.706 rs61643715 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Body mass index; chr17:30730744 chr17:30863921~30864940:- CESC cis rs17826219 0.636 rs8080829 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Body mass index; chr17:30731712 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs8079891 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30731845 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73267858 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732719 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs56018041 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732967 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs56095789 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733152 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11656844 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733579 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11652533 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733583 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11652631 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733748 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs79505916 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30735308 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs77498725 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs73267865 ENSG00000263531.1 RP13-753N3.1 8.89 2.33e-16 1.34e-12 1.03 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30863921~30864940:- CESC cis rs1577917 0.874 rs1838954 ENSG00000203875.9 SNHG5 -8.88 2.44e-16 1.4e-12 -0.58 -0.52 Response to antipsychotic treatment; chr6:85855760 chr6:85660950~85678736:- CESC cis rs875971 0.964 rs55748098 ENSG00000226824.5 RP4-756H11.3 8.88 2.45e-16 1.41e-12 0.63 0.52 Aortic root size; chr7:66298631 chr7:66654538~66669855:+ CESC cis rs11155671 0.53 rs9383940 ENSG00000231760.4 RP11-350J20.5 8.88 2.5e-16 1.43e-12 0.64 0.52 Testicular germ cell tumor; chr6:149904923 chr6:149796151~149826294:- CESC cis rs875971 0.965 rs10267430 ENSG00000226824.5 RP4-756H11.3 8.88 2.58e-16 1.48e-12 0.63 0.52 Aortic root size; chr7:66278036 chr7:66654538~66669855:+ CESC cis rs7208859 0.623 rs9899268 ENSG00000263531.1 RP13-753N3.1 8.88 2.59e-16 1.48e-12 1.02 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30863921~30864940:- CESC cis rs6452524 0.618 rs6452501 ENSG00000249664.1 CTD-2227C6.2 8.87 2.66e-16 1.52e-12 0.54 0.52 Hypertension (SNP x SNP interaction); chr5:83068681 chr5:83012285~83013109:- CESC cis rs6452524 0.618 rs6452502 ENSG00000249664.1 CTD-2227C6.2 8.87 2.69e-16 1.53e-12 0.55 0.51 Hypertension (SNP x SNP interaction); chr5:83074578 chr5:83012285~83013109:- CESC cis rs6452524 0.618 rs6452503 ENSG00000249664.1 CTD-2227C6.2 8.87 2.69e-16 1.53e-12 0.55 0.51 Hypertension (SNP x SNP interaction); chr5:83074596 chr5:83012285~83013109:- CESC cis rs6452524 0.618 rs6452504 ENSG00000249664.1 CTD-2227C6.2 8.87 2.69e-16 1.53e-12 0.55 0.51 Hypertension (SNP x SNP interaction); chr5:83074625 chr5:83012285~83013109:- CESC cis rs7208859 0.623 rs7220999 ENSG00000263531.1 RP13-753N3.1 8.87 2.75e-16 1.56e-12 1.02 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs55638872 ENSG00000263531.1 RP13-753N3.1 8.87 2.75e-16 1.56e-12 1.02 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30863921~30864940:- CESC cis rs9322193 0.884 rs7744105 ENSG00000231760.4 RP11-350J20.5 8.86 2.81e-16 1.59e-12 0.67 0.51 Lung cancer; chr6:149849308 chr6:149796151~149826294:- CESC cis rs4423214 1 rs2276360 ENSG00000254682.1 RP11-660L16.2 8.85 3.02e-16 1.71e-12 0.65 0.51 Vitamin D levels; chr11:71458501 chr11:71448674~71452157:+ CESC cis rs2739330 0.732 rs5760175 ENSG00000231271.1 AP000350.8 8.85 3.04e-16 1.72e-12 0.62 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23949918~23954042:+ CESC cis rs977987 0.8 rs3784935 ENSG00000261783.1 RP11-252K23.2 -8.85 3.1e-16 1.75e-12 -0.63 -0.51 Dupuytren's disease; chr16:75302532 chr16:75379818~75381260:- CESC cis rs977987 0.8 rs11645329 ENSG00000261783.1 RP11-252K23.2 -8.85 3.1e-16 1.75e-12 -0.63 -0.51 Dupuytren's disease; chr16:75302781 chr16:75379818~75381260:- CESC cis rs875971 1 rs10257427 ENSG00000226824.5 RP4-756H11.3 8.85 3.14e-16 1.78e-12 0.63 0.51 Aortic root size; chr7:66278221 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6956179 ENSG00000226824.5 RP4-756H11.3 8.85 3.16e-16 1.78e-12 0.64 0.51 Aortic root size; chr7:66341672 chr7:66654538~66669855:+ CESC cis rs6452524 0.618 rs7722924 ENSG00000249664.1 CTD-2227C6.2 8.84 3.27e-16 1.84e-12 0.55 0.51 Hypertension (SNP x SNP interaction); chr5:83060223 chr5:83012285~83013109:- CESC cis rs916888 0.647 rs199524 ENSG00000262539.1 RP11-259G18.3 -8.84 3.34e-16 1.88e-12 -0.65 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46259551~46260606:- CESC cis rs977987 0.806 rs4993969 ENSG00000261783.1 RP11-252K23.2 -8.84 3.37e-16 1.89e-12 -0.63 -0.51 Dupuytren's disease; chr16:75377623 chr16:75379818~75381260:- CESC cis rs2882667 0.931 rs10077796 ENSG00000253404.1 AC034243.1 -8.83 3.38e-16 1.9e-12 -0.61 -0.51 Age-related hearing impairment (SNP x SNP interaction); chr5:139021086 chr5:138744434~138753309:- CESC cis rs2486288 0.656 rs11632920 ENSG00000259520.4 CTD-2651B20.3 8.83 3.52e-16 1.97e-12 0.64 0.51 Glomerular filtration rate; chr15:45259066 chr15:45251580~45279251:- CESC cis rs875971 0.66 rs3764903 ENSG00000226824.5 RP4-756H11.3 8.83 3.55e-16 1.99e-12 0.63 0.51 Aortic root size; chr7:66633495 chr7:66654538~66669855:+ CESC cis rs6597981 0.675 rs4963120 ENSG00000279672.1 CMB9-55F22.1 -8.83 3.6e-16 2.01e-12 -0.52 -0.51 Breast cancer; chr11:825777 chr11:779617~780755:+ CESC cis rs1799949 0.931 rs9912203 ENSG00000198496.9 NBR2 8.82 3.82e-16 2.14e-12 0.61 0.51 Menopause (age at onset); chr17:43367777 chr17:43125610~43153671:+ CESC cis rs1799949 0.931 rs34474989 ENSG00000198496.9 NBR2 -8.82 3.82e-16 2.14e-12 -0.61 -0.51 Menopause (age at onset); chr17:43368042 chr17:43125610~43153671:+ CESC cis rs7208859 0.573 rs73267872 ENSG00000263531.1 RP13-753N3.1 8.82 3.83e-16 2.14e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30863921~30864940:- CESC cis rs1577917 0.958 rs12213343 ENSG00000203875.9 SNHG5 -8.81 3.87e-16 2.16e-12 -0.59 -0.51 Response to antipsychotic treatment; chr6:85733301 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12215265 ENSG00000203875.9 SNHG5 -8.81 3.87e-16 2.16e-12 -0.59 -0.51 Response to antipsychotic treatment; chr6:85734251 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12197463 ENSG00000203875.9 SNHG5 -8.81 3.87e-16 2.16e-12 -0.59 -0.51 Response to antipsychotic treatment; chr6:85735524 chr6:85660950~85678736:- CESC cis rs7617773 0.817 rs13068265 ENSG00000229759.1 MRPS18AP1 8.81 3.9e-16 2.18e-12 0.56 0.51 Coronary artery disease; chr3:48260124 chr3:48256350~48256938:- CESC cis rs7617773 0.817 rs11709691 ENSG00000229759.1 MRPS18AP1 8.81 3.9e-16 2.18e-12 0.56 0.51 Coronary artery disease; chr3:48262179 chr3:48256350~48256938:- CESC cis rs7208859 0.673 rs9903862 ENSG00000263531.1 RP13-753N3.1 8.81 3.99e-16 2.22e-12 1.33 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879415 chr17:30863921~30864940:- CESC cis rs858239 0.676 rs3807459 ENSG00000230658.1 KLHL7-AS1 8.81 3.99e-16 2.23e-12 0.68 0.51 Cerebrospinal fluid biomarker levels; chr7:23350132 chr7:23101228~23105703:- CESC cis rs6452524 0.618 rs6452506 ENSG00000249664.1 CTD-2227C6.2 8.81 4.08e-16 2.27e-12 0.54 0.51 Hypertension (SNP x SNP interaction); chr5:83075844 chr5:83012285~83013109:- CESC cis rs6452524 0.618 rs1993948 ENSG00000249664.1 CTD-2227C6.2 8.81 4.08e-16 2.27e-12 0.54 0.51 Hypertension (SNP x SNP interaction); chr5:83076461 chr5:83012285~83013109:- CESC cis rs2486288 0.656 rs1719236 ENSG00000259520.4 CTD-2651B20.3 8.8 4.15e-16 2.31e-12 0.68 0.51 Glomerular filtration rate; chr15:45285585 chr15:45251580~45279251:- CESC cis rs7208859 0.623 rs56812022 ENSG00000263531.1 RP13-753N3.1 8.79 4.44e-16 2.46e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30863921~30864940:- CESC cis rs4423214 1 rs12419334 ENSG00000254682.1 RP11-660L16.2 8.79 4.62e-16 2.55e-12 0.67 0.51 Vitamin D levels; chr11:71428426 chr11:71448674~71452157:+ CESC cis rs977987 0.864 rs37592 ENSG00000261783.1 RP11-252K23.2 8.78 4.86e-16 2.67e-12 0.64 0.51 Dupuytren's disease; chr16:75462893 chr16:75379818~75381260:- CESC cis rs977987 0.864 rs37595 ENSG00000261783.1 RP11-252K23.2 8.78 4.86e-16 2.67e-12 0.64 0.51 Dupuytren's disease; chr16:75463065 chr16:75379818~75381260:- CESC cis rs7208859 0.673 rs11655623 ENSG00000263531.1 RP13-753N3.1 8.78 4.94e-16 2.72e-12 0.97 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30835155 chr17:30863921~30864940:- CESC cis rs6452524 0.618 rs2075685 ENSG00000249664.1 CTD-2227C6.2 8.78 4.96e-16 2.73e-12 0.55 0.51 Hypertension (SNP x SNP interaction); chr5:83076846 chr5:83012285~83013109:- CESC cis rs4423214 1 rs1981412 ENSG00000254682.1 RP11-660L16.2 8.78 5e-16 2.75e-12 0.67 0.51 Vitamin D levels; chr11:71427664 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs12419279 ENSG00000254682.1 RP11-660L16.2 8.78 5e-16 2.75e-12 0.67 0.51 Vitamin D levels; chr11:71428015 chr11:71448674~71452157:+ CESC cis rs2739330 0.761 rs5760176 ENSG00000231271.1 AP000350.8 -8.78 5e-16 2.75e-12 -0.61 -0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23949918~23954042:+ CESC cis rs1577917 1 rs791856 ENSG00000203875.9 SNHG5 8.77 5.05e-16 2.77e-12 0.57 0.51 Response to antipsychotic treatment; chr6:85972123 chr6:85660950~85678736:- CESC cis rs10256972 0.591 rs6950319 ENSG00000229043.2 AC091729.9 -8.77 5.12e-16 2.81e-12 -0.58 -0.51 Endometriosis;Longevity; chr7:1121688 chr7:1160374~1165267:+ CESC cis rs7301826 1 rs7301826 ENSG00000256250.1 RP11-989F5.1 -8.77 5.13e-16 2.82e-12 -0.58 -0.51 Plasma plasminogen activator levels; chr12:130806556 chr12:130810606~130812438:+ CESC cis rs2882667 0.931 rs11955952 ENSG00000253404.1 AC034243.1 8.77 5.19e-16 2.85e-12 0.6 0.51 Age-related hearing impairment (SNP x SNP interaction); chr5:138993430 chr5:138744434~138753309:- CESC cis rs2739330 0.791 rs4822458 ENSG00000250470.1 AP000351.3 8.77 5.22e-16 2.86e-12 0.65 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23976904~23977585:- CESC cis rs950027 0.62 rs1346267 ENSG00000259520.4 CTD-2651B20.3 -8.76 5.57e-16 3.04e-12 -0.67 -0.51 Response to fenofibrate (adiponectin levels); chr15:45398791 chr15:45251580~45279251:- CESC cis rs2739330 0.731 rs5751792 ENSG00000231271.1 AP000350.8 8.75 5.82e-16 3.17e-12 0.61 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23949918~23954042:+ CESC cis rs7208859 0.623 rs11657990 ENSG00000263531.1 RP13-753N3.1 8.74 6.15e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30863921~30864940:- CESC cis rs17826219 0.636 rs79565452 ENSG00000263531.1 RP13-753N3.1 8.74 6.18e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30815823 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs1061342 ENSG00000263531.1 RP13-753N3.1 8.74 6.25e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30863921~30864940:- CESC cis rs17826219 0.5 rs57005940 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30739311 chr17:30863921~30864940:- CESC cis rs17826219 0.706 rs9893922 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30741407 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs57670615 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30863921~30864940:- CESC cis rs17826219 0.5 rs2874724 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30745415 chr17:30863921~30864940:- CESC cis rs17826219 0.568 rs9898097 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30745654 chr17:30863921~30864940:- CESC cis rs17826219 0.5 rs9891256 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30745674 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9911490 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7503542 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7503335 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs11656278 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs6505207 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs7223803 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30863921~30864940:- CESC cis rs17826219 0.568 rs2626985 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30750419 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs55814012 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs34756112 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs60724269 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs76633166 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs1061346 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs1061343 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs55938328 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73269988 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs55961983 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs7222803 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792879 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9899525 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30863921~30864940:- CESC cis rs17826219 0.568 rs7213925 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30794616 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs11653098 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11658945 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9911784 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9911997 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9890862 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs78071511 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11650982 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs2035494 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9915546 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9915566 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs8064686 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11657369 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs8075341 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73271842 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9895815 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs8077116 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs28760584 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30863921~30864940:- CESC cis rs17826219 0.706 rs73271850 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Body mass index; chr17:30815122 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7208088 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7212991 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs28627615 ENSG00000263531.1 RP13-753N3.1 8.74 6.27e-16 3.35e-12 1.01 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30863921~30864940:- CESC cis rs2882667 0.898 rs2351465 ENSG00000253404.1 AC034243.1 8.74 6.28e-16 3.35e-12 0.61 0.51 Age-related hearing impairment (SNP x SNP interaction); chr5:139028162 chr5:138744434~138753309:- CESC cis rs7208859 0.562 rs11650923 ENSG00000263531.1 RP13-753N3.1 8.74 6.34e-16 3.38e-12 1.04 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30681149 chr17:30863921~30864940:- CESC cis rs7617773 0.817 rs13072018 ENSG00000229759.1 MRPS18AP1 8.73 6.77e-16 3.6e-12 0.56 0.51 Coronary artery disease; chr3:48278842 chr3:48256350~48256938:- CESC cis rs1577917 0.958 rs7739241 ENSG00000203875.9 SNHG5 -8.73 6.87e-16 3.65e-12 -0.57 -0.51 Response to antipsychotic treatment; chr6:85866078 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12202712 ENSG00000203875.9 SNHG5 -8.73 6.87e-16 3.65e-12 -0.57 -0.51 Response to antipsychotic treatment; chr6:85868823 chr6:85660950~85678736:- CESC cis rs916888 0.779 rs199498 ENSG00000262539.1 RP11-259G18.3 8.73 6.91e-16 3.67e-12 0.69 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46259551~46260606:- CESC cis rs7208859 0.573 rs73267829 ENSG00000263531.1 RP13-753N3.1 8.72 7.06e-16 3.74e-12 1.04 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30676921 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7208441 ENSG00000263531.1 RP13-753N3.1 8.72 7.17e-16 3.79e-12 1 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30863921~30864940:- CESC cis rs1167827 1 rs1167827 ENSG00000127957.15 PMS2P3 -8.72 7.41e-16 3.9e-12 -0.53 -0.51 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75533848 chr7:75502930~75528148:- CESC cis rs875971 0.522 rs709604 ENSG00000226824.5 RP4-756H11.3 8.71 7.59e-16 4e-12 0.66 0.51 Aortic root size; chr7:66032447 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6945843 ENSG00000226824.5 RP4-756H11.3 8.71 7.68e-16 4.04e-12 0.62 0.51 Aortic root size; chr7:66269796 chr7:66654538~66669855:+ CESC cis rs7617773 0.817 rs13094727 ENSG00000229759.1 MRPS18AP1 8.7 7.94e-16 4.17e-12 0.56 0.51 Coronary artery disease; chr3:48281999 chr3:48256350~48256938:- CESC cis rs977987 0.806 rs4146809 ENSG00000261783.1 RP11-252K23.2 8.7 7.98e-16 4.19e-12 0.61 0.51 Dupuytren's disease; chr16:75381877 chr16:75379818~75381260:- CESC cis rs7208859 0.623 rs383436 ENSG00000263531.1 RP13-753N3.1 8.7 8.1e-16 4.25e-12 1.09 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30632161 chr17:30863921~30864940:- CESC cis rs17826219 0.714 rs11650821 ENSG00000263531.1 RP13-753N3.1 8.7 8.1e-16 4.25e-12 1.09 0.51 Body mass index; chr17:30641132 chr17:30863921~30864940:- CESC cis rs7617773 0.817 rs936427 ENSG00000229759.1 MRPS18AP1 -8.7 8.22e-16 4.31e-12 -0.58 -0.51 Coronary artery disease; chr3:48259584 chr3:48256350~48256938:- CESC cis rs7301826 1 rs10773822 ENSG00000256250.1 RP11-989F5.1 -8.69 8.65e-16 4.52e-12 -0.57 -0.51 Plasma plasminogen activator levels; chr12:130804562 chr12:130810606~130812438:+ CESC cis rs7301826 1 rs4759787 ENSG00000256250.1 RP11-989F5.1 -8.69 8.65e-16 4.52e-12 -0.57 -0.51 Plasma plasminogen activator levels; chr12:130805635 chr12:130810606~130812438:+ CESC cis rs7301826 0.966 rs10734980 ENSG00000256250.1 RP11-989F5.1 -8.69 8.65e-16 4.52e-12 -0.57 -0.51 Plasma plasminogen activator levels; chr12:130810081 chr12:130810606~130812438:+ CESC cis rs7301826 0.967 rs4759790 ENSG00000256250.1 RP11-989F5.1 -8.69 8.65e-16 4.52e-12 -0.57 -0.51 Plasma plasminogen activator levels; chr12:130811845 chr12:130810606~130812438:+ CESC cis rs7301826 0.967 rs4759792 ENSG00000256250.1 RP11-989F5.1 -8.69 8.65e-16 4.52e-12 -0.57 -0.51 Plasma plasminogen activator levels; chr12:130812086 chr12:130810606~130812438:+ CESC cis rs7301826 1 rs4759793 ENSG00000256250.1 RP11-989F5.1 -8.69 8.65e-16 4.52e-12 -0.57 -0.51 Plasma plasminogen activator levels; chr12:130812693 chr12:130810606~130812438:+ CESC cis rs7617773 0.78 rs11718350 ENSG00000229759.1 MRPS18AP1 8.69 8.88e-16 4.64e-12 0.55 0.51 Coronary artery disease; chr3:48319502 chr3:48256350~48256938:- CESC cis rs875971 0.838 rs2173570 ENSG00000226824.5 RP4-756H11.3 8.69 8.99e-16 4.7e-12 0.61 0.51 Aortic root size; chr7:66297976 chr7:66654538~66669855:+ CESC cis rs2006771 0.846 rs6518754 ENSG00000236132.1 CTA-440B3.1 -8.68 9.04e-16 4.72e-12 -0.57 -0.51 Nonsyndromic cleft lip with cleft palate; chr22:31701789 chr22:31816379~31817491:- CESC cis rs7617773 0.817 rs17647717 ENSG00000229759.1 MRPS18AP1 8.68 9.25e-16 4.83e-12 0.57 0.51 Coronary artery disease; chr3:48263966 chr3:48256350~48256938:- CESC cis rs10256972 0.641 rs12702017 ENSG00000229043.2 AC091729.9 -8.67 9.9e-16 5.16e-12 -0.56 -0.51 Endometriosis;Longevity; chr7:1089777 chr7:1160374~1165267:+ CESC cis rs858239 0.712 rs200717 ENSG00000230658.1 KLHL7-AS1 8.67 1.01e-15 5.24e-12 0.64 0.51 Cerebrospinal fluid biomarker levels; chr7:23352652 chr7:23101228~23105703:- CESC cis rs7301826 1 rs1106369 ENSG00000256250.1 RP11-989F5.1 -8.66 1.04e-15 5.39e-12 -0.56 -0.51 Plasma plasminogen activator levels; chr12:130815550 chr12:130810606~130812438:+ CESC cis rs1577917 0.771 rs2484355 ENSG00000203875.9 SNHG5 -8.66 1.06e-15 5.49e-12 -0.59 -0.51 Response to antipsychotic treatment; chr6:85684685 chr6:85660950~85678736:- CESC cis rs5760092 0.755 rs4585126 ENSG00000225282.1 AP000350.6 -8.66 1.09e-15 5.63e-12 -0.67 -0.51 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23926900~23929574:+ CESC cis rs1577917 0.958 rs11752180 ENSG00000203875.9 SNHG5 -8.66 1.09e-15 5.65e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85863447 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs12665464 ENSG00000203875.9 SNHG5 -8.66 1.09e-15 5.65e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85864415 chr6:85660950~85678736:- CESC cis rs1577917 0.57 rs114854865 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85844518 chr6:85660950~85678736:- CESC cis rs1577917 0.916 rs4706252 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85845462 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs1838959 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85847086 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs1579886 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85847473 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs1816937 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85847533 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs2324840 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85847902 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs7382798 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85850116 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12202188 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85852982 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs36035797 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85853162 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs1838958 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85854250 chr6:85660950~85678736:- CESC cis rs1577917 0.917 rs2084293 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85856284 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12209668 ENSG00000203875.9 SNHG5 -8.65 1.11e-15 5.73e-12 -0.58 -0.51 Response to antipsychotic treatment; chr6:85856799 chr6:85660950~85678736:- CESC cis rs9322193 0.884 rs880245 ENSG00000231760.4 RP11-350J20.5 -8.65 1.13e-15 5.81e-12 -0.68 -0.51 Lung cancer; chr6:149846262 chr6:149796151~149826294:- CESC cis rs17711722 0.565 rs73372653 ENSG00000164669.11 INTS4P1 -8.65 1.15e-15 5.9e-12 -0.68 -0.51 Calcium levels; chr7:65977808 chr7:65141225~65234216:+ CESC cis rs1577917 0.538 rs7755996 ENSG00000203875.9 SNHG5 8.65 1.16e-15 5.96e-12 0.55 0.51 Response to antipsychotic treatment; chr6:85714002 chr6:85660950~85678736:- CESC cis rs12439619 0.846 rs62012003 ENSG00000278603.1 RP13-608F4.5 8.65 1.16e-15 5.96e-12 0.84 0.51 Intelligence (multi-trait analysis); chr15:82183236 chr15:82472203~82472426:+ CESC cis rs12439619 0.768 rs28694364 ENSG00000278603.1 RP13-608F4.5 8.65 1.16e-15 5.96e-12 0.84 0.51 Intelligence (multi-trait analysis); chr15:82208119 chr15:82472203~82472426:+ CESC cis rs12439619 0.81 rs28876157 ENSG00000278603.1 RP13-608F4.5 8.65 1.16e-15 5.96e-12 0.84 0.51 Intelligence (multi-trait analysis); chr15:82216708 chr15:82472203~82472426:+ CESC cis rs10256972 0.681 rs12702016 ENSG00000229043.2 AC091729.9 -8.65 1.16e-15 5.97e-12 -0.57 -0.51 Endometriosis;Longevity; chr7:1089756 chr7:1160374~1165267:+ CESC cis rs9828933 0.882 rs3816156 ENSG00000280620.1 SCAANT1 8.64 1.18e-15 6.04e-12 0.84 0.51 Type 2 diabetes; chr3:64014036 chr3:63911518~63911772:- CESC cis rs1799949 0.859 rs11657004 ENSG00000198496.9 NBR2 -8.64 1.18e-15 6.04e-12 -0.6 -0.51 Menopause (age at onset); chr17:43365383 chr17:43125610~43153671:+ CESC cis rs7208859 0.524 rs73988172 ENSG00000263531.1 RP13-753N3.1 8.64 1.2e-15 6.15e-12 0.99 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30863921~30864940:- CESC cis rs2882667 0.898 rs3925110 ENSG00000253404.1 AC034243.1 8.63 1.26e-15 6.44e-12 0.61 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139035676 chr5:138744434~138753309:- CESC cis rs7301826 0.932 rs1007246 ENSG00000256250.1 RP11-989F5.1 -8.63 1.26e-15 6.44e-12 -0.57 -0.5 Plasma plasminogen activator levels; chr12:130795585 chr12:130810606~130812438:+ CESC cis rs7301826 0.627 rs7978987 ENSG00000256250.1 RP11-989F5.1 8.63 1.26e-15 6.46e-12 0.61 0.5 Plasma plasminogen activator levels; chr12:130796949 chr12:130810606~130812438:+ CESC cis rs977987 0.966 rs6564261 ENSG00000261783.1 RP11-252K23.2 -8.63 1.29e-15 6.61e-12 -0.62 -0.5 Dupuytren's disease; chr16:75458344 chr16:75379818~75381260:- CESC cis rs2882667 0.931 rs10070021 ENSG00000253404.1 AC034243.1 8.63 1.31e-15 6.7e-12 0.59 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:138989017 chr5:138744434~138753309:- CESC cis rs17711722 0.727 rs35850374 ENSG00000226824.5 RP4-756H11.3 -8.62 1.37e-15 6.99e-12 -0.65 -0.5 Calcium levels; chr7:65892789 chr7:66654538~66669855:+ CESC cis rs858239 0.796 rs433395 ENSG00000230658.1 KLHL7-AS1 8.62 1.41e-15 7.17e-12 0.61 0.5 Cerebrospinal fluid biomarker levels; chr7:23362336 chr7:23101228~23105703:- CESC cis rs2882667 0.898 rs10058347 ENSG00000253404.1 AC034243.1 8.61 1.43e-15 7.24e-12 0.61 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139025669 chr5:138744434~138753309:- CESC cis rs9322193 0.884 rs9397036 ENSG00000231760.4 RP11-350J20.5 8.61 1.43e-15 7.27e-12 0.67 0.5 Lung cancer; chr6:149851787 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs9383864 ENSG00000231760.4 RP11-350J20.5 8.61 1.43e-15 7.27e-12 0.67 0.5 Lung cancer; chr6:149851969 chr6:149796151~149826294:- CESC cis rs9322193 0.884 rs9383865 ENSG00000231760.4 RP11-350J20.5 8.61 1.43e-15 7.27e-12 0.67 0.5 Lung cancer; chr6:149852043 chr6:149796151~149826294:- CESC cis rs7208859 0.623 rs609063 ENSG00000263531.1 RP13-753N3.1 8.61 1.48e-15 7.5e-12 1.08 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624495 chr17:30863921~30864940:- CESC cis rs7301826 0.58 rs12821464 ENSG00000256250.1 RP11-989F5.1 8.61 1.49e-15 7.51e-12 0.6 0.5 Plasma plasminogen activator levels; chr12:130838174 chr12:130810606~130812438:+ CESC cis rs875971 0.867 rs1002053 ENSG00000226824.5 RP4-756H11.3 8.61 1.5e-15 7.58e-12 0.63 0.5 Aortic root size; chr7:66333558 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6460292 ENSG00000226824.5 RP4-756H11.3 8.61 1.5e-15 7.58e-12 0.63 0.5 Aortic root size; chr7:66345088 chr7:66654538~66669855:+ CESC cis rs17711722 0.727 rs1880555 ENSG00000226824.5 RP4-756H11.3 -8.61 1.51e-15 7.63e-12 -0.65 -0.5 Calcium levels; chr7:65967580 chr7:66654538~66669855:+ CESC cis rs2739330 0.627 rs9608219 ENSG00000250470.1 AP000351.3 8.6 1.52e-15 7.68e-12 0.64 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23976904~23977585:- CESC cis rs2739330 0.703 rs5760112 ENSG00000250470.1 AP000351.3 8.6 1.54e-15 7.75e-12 0.64 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23976904~23977585:- CESC cis rs2882667 0.898 rs6890272 ENSG00000253404.1 AC034243.1 8.6 1.59e-15 8e-12 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139035427 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs6882330 ENSG00000253404.1 AC034243.1 8.6 1.59e-15 8e-12 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139046493 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs6882526 ENSG00000253404.1 AC034243.1 8.6 1.59e-15 8e-12 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139046679 chr5:138744434~138753309:- CESC cis rs7617773 0.78 rs35411187 ENSG00000229759.1 MRPS18AP1 8.6 1.6e-15 8.02e-12 0.54 0.5 Coronary artery disease; chr3:48318527 chr3:48256350~48256938:- CESC cis rs7617773 0.78 rs11714176 ENSG00000229759.1 MRPS18AP1 8.6 1.6e-15 8.02e-12 0.54 0.5 Coronary artery disease; chr3:48319372 chr3:48256350~48256938:- CESC cis rs2882667 0.964 rs2288824 ENSG00000253404.1 AC034243.1 8.6 1.62e-15 8.14e-12 0.63 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:138962707 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs6862393 ENSG00000253404.1 AC034243.1 8.59 1.67e-15 8.39e-12 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139029009 chr5:138744434~138753309:- CESC cis rs7208859 0.623 rs1054397 ENSG00000263531.1 RP13-753N3.1 8.59 1.72e-15 8.61e-12 0.99 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs8069400 ENSG00000263531.1 RP13-753N3.1 8.59 1.73e-15 8.65e-12 1 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748949 chr17:30863921~30864940:- CESC cis rs1577917 0.771 rs2842602 ENSG00000203875.9 SNHG5 -8.58 1.77e-15 8.88e-12 -0.6 -0.5 Response to antipsychotic treatment; chr6:85622169 chr6:85660950~85678736:- CESC cis rs2882667 0.931 rs3749665 ENSG00000253404.1 AC034243.1 8.58 1.84e-15 9.18e-12 0.61 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139021522 chr5:138744434~138753309:- CESC cis rs5760092 0.755 rs4585126 ENSG00000218537.1 MIF-AS1 -8.58 1.85e-15 9.22e-12 -0.72 -0.5 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23894426~23898930:- CESC cis rs10256972 0.616 rs4585652 ENSG00000229043.2 AC091729.9 -8.58 1.85e-15 9.23e-12 -0.57 -0.5 Endometriosis;Longevity; chr7:1105760 chr7:1160374~1165267:+ CESC cis rs2882667 0.931 rs10038799 ENSG00000253404.1 AC034243.1 8.57 1.86e-15 9.28e-12 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139026594 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs6882583 ENSG00000253404.1 AC034243.1 8.57 1.86e-15 9.29e-12 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139050107 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs13182437 ENSG00000253404.1 AC034243.1 8.57 1.86e-15 9.29e-12 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139051460 chr5:138744434~138753309:- CESC cis rs7208859 0.573 rs56031503 ENSG00000263531.1 RP13-753N3.1 8.57 1.89e-15 9.42e-12 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30863921~30864940:- CESC cis rs7301826 0.651 rs12820597 ENSG00000256250.1 RP11-989F5.1 8.57 1.9e-15 9.47e-12 0.62 0.5 Plasma plasminogen activator levels; chr12:130795640 chr12:130810606~130812438:+ CESC cis rs35955747 0.601 rs5749302 ENSG00000236132.1 CTA-440B3.1 -8.57 1.9e-15 9.48e-12 -0.6 -0.5 Neutrophil count;Sum basophil neutrophil counts; chr22:31554632 chr22:31816379~31817491:- CESC cis rs4423214 1 rs4944955 ENSG00000254682.1 RP11-660L16.2 8.57 1.9e-15 9.49e-12 0.64 0.5 Vitamin D levels; chr11:71456631 chr11:71448674~71452157:+ CESC cis rs4423214 1 rs4944956 ENSG00000254682.1 RP11-660L16.2 8.57 1.9e-15 9.49e-12 0.64 0.5 Vitamin D levels; chr11:71456719 chr11:71448674~71452157:+ CESC cis rs1577917 0.958 rs2100109 ENSG00000203875.9 SNHG5 -8.57 1.94e-15 9.63e-12 -0.57 -0.5 Response to antipsychotic treatment; chr6:85835208 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs1447160 ENSG00000203875.9 SNHG5 -8.57 1.94e-15 9.63e-12 -0.57 -0.5 Response to antipsychotic treatment; chr6:85836405 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs4707229 ENSG00000203875.9 SNHG5 -8.57 1.94e-15 9.63e-12 -0.57 -0.5 Response to antipsychotic treatment; chr6:85836519 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12198061 ENSG00000203875.9 SNHG5 -8.57 1.94e-15 9.63e-12 -0.57 -0.5 Response to antipsychotic treatment; chr6:85841267 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs1838955 ENSG00000203875.9 SNHG5 -8.57 1.94e-15 9.63e-12 -0.57 -0.5 Response to antipsychotic treatment; chr6:85855731 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs2084294 ENSG00000203875.9 SNHG5 -8.57 1.94e-15 9.63e-12 -0.57 -0.5 Response to antipsychotic treatment; chr6:85856225 chr6:85660950~85678736:- CESC cis rs875971 0.522 rs2008188 ENSG00000226824.5 RP4-756H11.3 -8.57 1.94e-15 9.65e-12 -0.65 -0.5 Aortic root size; chr7:65964026 chr7:66654538~66669855:+ CESC cis rs2882667 0.858 rs7724108 ENSG00000253404.1 AC034243.1 -8.57 1.96e-15 9.77e-12 -0.64 -0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139075233 chr5:138744434~138753309:- CESC cis rs4423214 1 rs12792306 ENSG00000254682.1 RP11-660L16.2 8.56 2e-15 9.95e-12 0.64 0.5 Vitamin D levels; chr11:71455946 chr11:71448674~71452157:+ CESC cis rs9322193 0.884 rs1108889 ENSG00000231760.4 RP11-350J20.5 8.56 2.01e-15 9.96e-12 0.67 0.5 Lung cancer; chr6:149845433 chr6:149796151~149826294:- CESC cis rs875971 1 rs2036264 ENSG00000226824.5 RP4-756H11.3 8.56 2.06e-15 1.02e-11 0.62 0.5 Aortic root size; chr7:66334917 chr7:66654538~66669855:+ CESC cis rs875971 1 rs7783613 ENSG00000226824.5 RP4-756H11.3 8.56 2.06e-15 1.02e-11 0.62 0.5 Aortic root size; chr7:66340274 chr7:66654538~66669855:+ CESC cis rs1799949 0.894 rs71367985 ENSG00000198496.9 NBR2 -8.55 2.11e-15 1.04e-11 -0.62 -0.5 Menopause (age at onset); chr17:43222443 chr17:43125610~43153671:+ CESC cis rs875971 0.522 rs10807697 ENSG00000226824.5 RP4-756H11.3 -8.55 2.12e-15 1.05e-11 -0.65 -0.5 Aortic root size; chr7:65951183 chr7:66654538~66669855:+ CESC cis rs977987 0.742 rs34624768 ENSG00000261783.1 RP11-252K23.2 -8.55 2.17e-15 1.07e-11 -0.62 -0.5 Dupuytren's disease; chr16:75297674 chr16:75379818~75381260:- CESC cis rs977987 0.8 rs4888378 ENSG00000261783.1 RP11-252K23.2 -8.55 2.17e-15 1.07e-11 -0.62 -0.5 Dupuytren's disease; chr16:75298143 chr16:75379818~75381260:- CESC cis rs977987 0.8 rs12935787 ENSG00000261783.1 RP11-252K23.2 -8.55 2.17e-15 1.07e-11 -0.62 -0.5 Dupuytren's disease; chr16:75298437 chr16:75379818~75381260:- CESC cis rs1577917 0.958 rs66807489 ENSG00000203875.9 SNHG5 -8.55 2.19e-15 1.08e-11 -0.58 -0.5 Response to antipsychotic treatment; chr6:85730984 chr6:85660950~85678736:- CESC cis rs977987 0.836 rs4888376 ENSG00000261783.1 RP11-252K23.2 -8.55 2.2e-15 1.08e-11 -0.62 -0.5 Dupuytren's disease; chr16:75288675 chr16:75379818~75381260:- CESC cis rs9828933 0.938 rs9809432 ENSG00000280620.1 SCAANT1 8.54 2.26e-15 1.11e-11 0.85 0.5 Type 2 diabetes; chr3:64017277 chr3:63911518~63911772:- CESC cis rs875971 0.522 rs781144 ENSG00000226824.5 RP4-756H11.3 -8.54 2.28e-15 1.12e-11 -0.66 -0.5 Aortic root size; chr7:65975357 chr7:66654538~66669855:+ CESC cis rs1153858 1 rs1145074 ENSG00000259520.4 CTD-2651B20.3 -8.54 2.3e-15 1.13e-11 -0.65 -0.5 Homoarginine levels; chr15:45411626 chr15:45251580~45279251:- CESC cis rs17826219 0.706 rs28469200 ENSG00000263531.1 RP13-753N3.1 8.54 2.33e-15 1.15e-11 0.97 0.5 Body mass index; chr17:30806554 chr17:30863921~30864940:- CESC cis rs1799949 0.93 rs1554063 ENSG00000198496.9 NBR2 -8.54 2.34e-15 1.15e-11 -0.6 -0.5 Menopause (age at onset); chr17:43135128 chr17:43125610~43153671:+ CESC cis rs9828933 0.752 rs13434089 ENSG00000280620.1 SCAANT1 -8.54 2.36e-15 1.16e-11 -1 -0.5 Type 2 diabetes; chr3:63962890 chr3:63911518~63911772:- CESC cis rs977987 0.872 rs4887816 ENSG00000261783.1 RP11-252K23.2 -8.54 2.38e-15 1.16e-11 -0.62 -0.5 Dupuytren's disease; chr16:75285818 chr16:75379818~75381260:- CESC cis rs17826219 0.568 rs11658027 ENSG00000263531.1 RP13-753N3.1 -8.53 2.41e-15 1.16e-11 -0.98 -0.5 Body mass index; chr17:30767864 chr17:30863921~30864940:- CESC cis rs17826219 0.5 rs2449749 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Body mass index; chr17:30751280 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9894709 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9896603 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30863921~30864940:- CESC cis rs17826219 0.636 rs7221463 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Body mass index; chr17:30753533 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7219712 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs8078656 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs8080882 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9898084 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs28556733 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30863921~30864940:- CESC cis rs17826219 0.5 rs28452421 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Body mass index; chr17:30756962 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs28433704 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs28779471 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30863921~30864940:- CESC cis rs17826219 0.5 rs61685770 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Body mass index; chr17:30758695 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs57486336 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30863921~30864940:- CESC cis rs17826219 0.706 rs55764512 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Body mass index; chr17:30758740 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs12103440 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs12103508 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs11653605 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs11657777 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73269913 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7217984 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73269916 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs60114476 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs8065744 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30863921~30864940:- CESC cis rs17826219 0.706 rs8071236 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Body mass index; chr17:30772984 chr17:30863921~30864940:- CESC cis rs17826219 0.636 rs2449770 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Body mass index; chr17:30774046 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs59913838 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs56163556 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs8067338 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs4055105 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30863921~30864940:- CESC cis rs7208859 0.562 rs8078897 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs8075163 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30863921~30864940:- CESC cis rs17826219 0.706 rs8075107 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Body mass index; chr17:30779631 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7223209 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs7223404 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9916725 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9916727 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9914499 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73269945 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9897728 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs1054400 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9890558 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9912283 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs12006 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs3752021 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs3752020 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9890855 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9893422 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs9891166 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs73269974 ENSG00000263531.1 RP13-753N3.1 8.53 2.41e-15 1.16e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30863921~30864940:- CESC cis rs1577917 0.917 rs2218594 ENSG00000203875.9 SNHG5 -8.53 2.44e-15 1.18e-11 -0.57 -0.5 Response to antipsychotic treatment; chr6:85834048 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs2197648 ENSG00000203875.9 SNHG5 -8.53 2.44e-15 1.18e-11 -0.57 -0.5 Response to antipsychotic treatment; chr6:85834169 chr6:85660950~85678736:- CESC cis rs1577917 0.876 rs11752223 ENSG00000203875.9 SNHG5 -8.53 2.44e-15 1.18e-11 -0.57 -0.5 Response to antipsychotic treatment; chr6:85863676 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12660846 ENSG00000203875.9 SNHG5 -8.53 2.44e-15 1.18e-11 -0.57 -0.5 Response to antipsychotic treatment; chr6:85864091 chr6:85660950~85678736:- CESC cis rs875971 1 rs10215948 ENSG00000226824.5 RP4-756H11.3 8.53 2.46e-15 1.18e-11 0.61 0.5 Aortic root size; chr7:66282799 chr7:66654538~66669855:+ CESC cis rs12439619 0.846 rs28470877 ENSG00000278603.1 RP13-608F4.5 8.53 2.46e-15 1.19e-11 0.83 0.5 Intelligence (multi-trait analysis); chr15:82245797 chr15:82472203~82472426:+ CESC cis rs9828933 0.766 rs3774725 ENSG00000280620.1 SCAANT1 8.53 2.51e-15 1.21e-11 0.89 0.5 Type 2 diabetes; chr3:63988582 chr3:63911518~63911772:- CESC cis rs977987 0.771 rs8048527 ENSG00000261783.1 RP11-252K23.2 -8.53 2.53e-15 1.22e-11 -0.61 -0.5 Dupuytren's disease; chr16:75388156 chr16:75379818~75381260:- CESC cis rs2882667 0.898 rs13163536 ENSG00000253404.1 AC034243.1 8.53 2.53e-15 1.22e-11 0.61 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139041530 chr5:138744434~138753309:- CESC cis rs7301826 0.651 rs34749116 ENSG00000256250.1 RP11-989F5.1 8.52 2.62e-15 1.26e-11 0.6 0.5 Plasma plasminogen activator levels; chr12:130796207 chr12:130810606~130812438:+ CESC cis rs9545047 0.967 rs9593396 ENSG00000227676.3 LINC01068 8.52 2.64e-15 1.27e-11 0.58 0.5 Schizophrenia; chr13:79396164 chr13:79566727~79571436:+ CESC cis rs9545047 1 rs9545101 ENSG00000227676.3 LINC01068 8.52 2.64e-15 1.27e-11 0.58 0.5 Schizophrenia; chr13:79399806 chr13:79566727~79571436:+ CESC cis rs2739330 0.791 rs9612520 ENSG00000250470.1 AP000351.3 8.52 2.66e-15 1.27e-11 0.64 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23976904~23977585:- CESC cis rs875971 0.505 rs6955582 ENSG00000226824.5 RP4-756H11.3 -8.52 2.67e-15 1.28e-11 -0.64 -0.5 Aortic root size; chr7:65966699 chr7:66654538~66669855:+ CESC cis rs2882667 0.861 rs10037106 ENSG00000253404.1 AC034243.1 8.52 2.67e-15 1.28e-11 0.61 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139029801 chr5:138744434~138753309:- CESC cis rs10256972 0.567 rs7782651 ENSG00000229043.2 AC091729.9 -8.52 2.71e-15 1.3e-11 -0.57 -0.5 Endometriosis;Longevity; chr7:1120259 chr7:1160374~1165267:+ CESC cis rs1799949 0.929 rs799906 ENSG00000198496.9 NBR2 -8.52 2.72e-15 1.3e-11 -0.6 -0.5 Menopause (age at onset); chr17:43126099 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs799908 ENSG00000198496.9 NBR2 -8.52 2.72e-15 1.3e-11 -0.6 -0.5 Menopause (age at onset); chr17:43126899 chr17:43125610~43153671:+ CESC cis rs7208859 0.623 rs7219361 ENSG00000263531.1 RP13-753N3.1 8.52 2.73e-15 1.3e-11 0.98 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753375 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs7214313 ENSG00000263531.1 RP13-753N3.1 8.51 2.79e-15 1.33e-11 0.96 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30863921~30864940:- CESC cis rs9545047 1 rs9545078 ENSG00000227676.3 LINC01068 8.51 2.79e-15 1.33e-11 0.56 0.5 Schizophrenia; chr13:79339216 chr13:79566727~79571436:+ CESC cis rs2739330 0.732 rs5760175 ENSG00000225282.1 AP000350.6 8.51 2.81e-15 1.34e-11 0.59 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23926900~23929574:+ CESC cis rs977987 0.806 rs4888386 ENSG00000261783.1 RP11-252K23.2 -8.51 2.84e-15 1.35e-11 -0.6 -0.5 Dupuytren's disease; chr16:75355842 chr16:75379818~75381260:- CESC cis rs1799949 0.965 rs9897425 ENSG00000198496.9 NBR2 -8.51 2.84e-15 1.36e-11 -0.61 -0.5 Menopause (age at onset); chr17:43352811 chr17:43125610~43153671:+ CESC cis rs7617773 1 rs9832957 ENSG00000229759.1 MRPS18AP1 -8.51 2.86e-15 1.36e-11 -0.53 -0.5 Coronary artery disease; chr3:48143776 chr3:48256350~48256938:- CESC cis rs9545047 0.967 rs9545097 ENSG00000227676.3 LINC01068 8.51 2.87e-15 1.37e-11 0.58 0.5 Schizophrenia; chr13:79387352 chr13:79566727~79571436:+ CESC cis rs977987 0.778 rs4243112 ENSG00000261783.1 RP11-252K23.2 -8.51 2.9e-15 1.38e-11 -0.61 -0.5 Dupuytren's disease; chr16:75287133 chr16:75379818~75381260:- CESC cis rs977987 0.836 rs34673655 ENSG00000261783.1 RP11-252K23.2 -8.51 2.9e-15 1.38e-11 -0.61 -0.5 Dupuytren's disease; chr16:75289661 chr16:75379818~75381260:- CESC cis rs977987 0.836 rs17685540 ENSG00000261783.1 RP11-252K23.2 -8.51 2.9e-15 1.38e-11 -0.61 -0.5 Dupuytren's disease; chr16:75289942 chr16:75379818~75381260:- CESC cis rs977987 0.8 rs1011121 ENSG00000261783.1 RP11-252K23.2 -8.51 2.9e-15 1.38e-11 -0.61 -0.5 Dupuytren's disease; chr16:75292035 chr16:75379818~75381260:- CESC cis rs7617773 0.78 rs13081169 ENSG00000229759.1 MRPS18AP1 8.5 2.96e-15 1.41e-11 0.54 0.5 Coronary artery disease; chr3:48315307 chr3:48256350~48256938:- CESC cis rs2739330 0.587 rs4820571 ENSG00000218537.1 MIF-AS1 8.5 3.01e-15 1.43e-11 0.65 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23894426~23898930:- CESC cis rs2882667 0.898 rs12719519 ENSG00000253404.1 AC034243.1 8.5 3.07e-15 1.46e-11 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139039998 chr5:138744434~138753309:- CESC cis rs4423214 1 rs2276361 ENSG00000254682.1 RP11-660L16.2 8.49 3.2e-15 1.51e-11 0.65 0.5 Vitamin D levels; chr11:71458602 chr11:71448674~71452157:+ CESC cis rs2882667 0.858 rs4643949 ENSG00000253404.1 AC034243.1 8.49 3.2e-15 1.51e-11 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139036656 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs6867343 ENSG00000253404.1 AC034243.1 8.49 3.2e-15 1.51e-11 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139038739 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs2882792 ENSG00000253404.1 AC034243.1 8.49 3.2e-15 1.51e-11 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139044791 chr5:138744434~138753309:- CESC cis rs7617773 0.78 rs13079728 ENSG00000229759.1 MRPS18AP1 8.49 3.21e-15 1.52e-11 0.54 0.5 Coronary artery disease; chr3:48297870 chr3:48256350~48256938:- CESC cis rs2882667 0.898 rs11749944 ENSG00000253404.1 AC034243.1 8.49 3.3e-15 1.56e-11 0.59 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139077090 chr5:138744434~138753309:- CESC cis rs9828933 0.752 rs28675788 ENSG00000280620.1 SCAANT1 8.48 3.32e-15 1.57e-11 0.99 0.5 Type 2 diabetes; chr3:63956512 chr3:63911518~63911772:- CESC cis rs10256972 0.63 rs13235747 ENSG00000229043.2 AC091729.9 -8.48 3.33e-15 1.57e-11 -0.56 -0.5 Endometriosis;Longevity; chr7:1089487 chr7:1160374~1165267:+ CESC cis rs17826219 0.636 rs4055314 ENSG00000263531.1 RP13-753N3.1 8.48 3.36e-15 1.59e-11 0.98 0.5 Body mass index; chr17:30752751 chr17:30863921~30864940:- CESC cis rs1799949 0.965 rs9646418 ENSG00000198496.9 NBR2 -8.48 3.42e-15 1.61e-11 -0.59 -0.5 Menopause (age at onset); chr17:43348533 chr17:43125610~43153671:+ CESC cis rs977987 0.835 rs3851734 ENSG00000261783.1 RP11-252K23.2 -8.48 3.45e-15 1.63e-11 -0.62 -0.5 Dupuytren's disease; chr16:75338022 chr16:75379818~75381260:- CESC cis rs2006771 0.81 rs2006648 ENSG00000236132.1 CTA-440B3.1 8.48 3.46e-15 1.63e-11 0.57 0.5 Nonsyndromic cleft lip with cleft palate; chr22:31685943 chr22:31816379~31817491:- CESC cis rs875971 0.66 rs1860470 ENSG00000226824.5 RP4-756H11.3 8.48 3.46e-15 1.63e-11 0.62 0.5 Aortic root size; chr7:66638707 chr7:66654538~66669855:+ CESC cis rs977987 0.843 rs11860231 ENSG00000261783.1 RP11-252K23.2 -8.48 3.47e-15 1.63e-11 -0.6 -0.5 Dupuytren's disease; chr16:75351261 chr16:75379818~75381260:- CESC cis rs9545047 1 rs9545086 ENSG00000227676.3 LINC01068 8.47 3.64e-15 1.71e-11 0.57 0.5 Schizophrenia; chr13:79364233 chr13:79566727~79571436:+ CESC cis rs9545047 0.967 rs9545087 ENSG00000227676.3 LINC01068 8.47 3.64e-15 1.71e-11 0.57 0.5 Schizophrenia; chr13:79364440 chr13:79566727~79571436:+ CESC cis rs2882667 0.931 rs12719518 ENSG00000253404.1 AC034243.1 8.47 3.67e-15 1.72e-11 0.59 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139005287 chr5:138744434~138753309:- CESC cis rs9545047 1 rs9574418 ENSG00000227676.3 LINC01068 8.47 3.74e-15 1.75e-11 0.58 0.5 Schizophrenia; chr13:79393874 chr13:79566727~79571436:+ CESC cis rs9545047 1 rs9545047 ENSG00000227676.3 LINC01068 8.47 3.74e-15 1.76e-11 0.55 0.5 Schizophrenia; chr13:79285321 chr13:79566727~79571436:+ CESC cis rs4423214 1 rs11233746 ENSG00000254682.1 RP11-660L16.2 8.46 3.8e-15 1.78e-11 0.66 0.5 Vitamin D levels; chr11:71460394 chr11:71448674~71452157:+ CESC cis rs977987 0.835 rs8046109 ENSG00000261783.1 RP11-252K23.2 -8.46 3.81e-15 1.79e-11 -0.62 -0.5 Dupuytren's disease; chr16:75326198 chr16:75379818~75381260:- CESC cis rs17711722 0.727 rs2658585 ENSG00000226824.5 RP4-756H11.3 -8.46 3.82e-15 1.79e-11 -0.65 -0.5 Calcium levels; chr7:65996954 chr7:66654538~66669855:+ CESC cis rs11155671 0.53 rs7758033 ENSG00000231760.4 RP11-350J20.5 8.46 3.82e-15 1.79e-11 0.62 0.5 Testicular germ cell tumor; chr6:149886999 chr6:149796151~149826294:- CESC cis rs1930961 1 rs7285549 ENSG00000100058.11 CRYBB2P1 8.46 3.83e-15 1.79e-11 0.74 0.5 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25448105~25520854:+ CESC cis rs2882667 0.931 rs10068237 ENSG00000253404.1 AC034243.1 8.46 3.85e-15 1.8e-11 0.59 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139002271 chr5:138744434~138753309:- CESC cis rs950027 0.62 rs1145077 ENSG00000259520.4 CTD-2651B20.3 8.46 3.86e-15 1.81e-11 0.66 0.5 Response to fenofibrate (adiponectin levels); chr15:45391597 chr15:45251580~45279251:- CESC cis rs2882667 0.964 rs11958050 ENSG00000253404.1 AC034243.1 8.46 3.86e-15 1.81e-11 0.6 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:138966139 chr5:138744434~138753309:- CESC cis rs875971 0.54 rs736270 ENSG00000226824.5 RP4-756H11.3 -8.46 4e-15 1.87e-11 -0.65 -0.5 Aortic root size; chr7:65963835 chr7:66654538~66669855:+ CESC cis rs977987 0.806 rs4638613 ENSG00000261783.1 RP11-252K23.2 -8.45 4.12e-15 1.92e-11 -0.6 -0.5 Dupuytren's disease; chr16:75391655 chr16:75379818~75381260:- CESC cis rs977987 0.75 rs4888407 ENSG00000261783.1 RP11-252K23.2 -8.45 4.12e-15 1.92e-11 -0.6 -0.5 Dupuytren's disease; chr16:75398492 chr16:75379818~75381260:- CESC cis rs7208859 0.573 rs8070182 ENSG00000263531.1 RP13-753N3.1 8.45 4.13e-15 1.92e-11 0.96 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30863921~30864940:- CESC cis rs875971 0.522 rs9530 ENSG00000226824.5 RP4-756H11.3 -8.45 4.14e-15 1.93e-11 -0.65 -0.5 Aortic root size; chr7:65960907 chr7:66654538~66669855:+ CESC cis rs9545047 1 rs2484345 ENSG00000227676.3 LINC01068 -8.44 4.35e-15 2.02e-11 -0.56 -0.5 Schizophrenia; chr13:79427913 chr13:79566727~79571436:+ CESC cis rs977987 0.806 rs4888383 ENSG00000261783.1 RP11-252K23.2 -8.44 4.37e-15 2.03e-11 -0.6 -0.5 Dupuytren's disease; chr16:75352451 chr16:75379818~75381260:- CESC cis rs10256972 0.516 rs12702081 ENSG00000229043.2 AC091729.9 -8.44 4.49e-15 2.09e-11 -0.55 -0.5 Endometriosis;Longevity; chr7:1101892 chr7:1160374~1165267:+ CESC cis rs1799949 0.683 rs55737636 ENSG00000198496.9 NBR2 -8.44 4.49e-15 2.09e-11 -0.59 -0.5 Menopause (age at onset); chr17:43112722 chr17:43125610~43153671:+ CESC cis rs977987 0.806 rs2865531 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75356418 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs2113232 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75357287 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs7185640 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75360501 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs11640674 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75361046 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888389 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75361330 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs11865004 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75361879 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs56343285 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75375899 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs1544810 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75377265 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs11858992 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75377547 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4993970 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75377721 chr16:75379818~75381260:- CESC cis rs977987 0.736 rs4888392 ENSG00000261783.1 RP11-252K23.2 -8.43 4.65e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75378364 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs8050769 ENSG00000261783.1 RP11-252K23.2 -8.43 4.66e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75354536 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs6564252 ENSG00000261783.1 RP11-252K23.2 -8.43 4.66e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75355042 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs2903033 ENSG00000261783.1 RP11-252K23.2 -8.43 4.66e-15 2.15e-11 -0.6 -0.5 Dupuytren's disease; chr16:75355708 chr16:75379818~75381260:- CESC cis rs1153858 1 rs4775911 ENSG00000259520.4 CTD-2651B20.3 8.43 4.68e-15 2.16e-11 0.65 0.5 Homoarginine levels; chr15:45357589 chr15:45251580~45279251:- CESC cis rs1930961 1 rs6004669 ENSG00000100058.11 CRYBB2P1 8.43 4.87e-15 2.24e-11 0.75 0.5 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25448105~25520854:+ CESC cis rs977987 0.771 rs4888387 ENSG00000261783.1 RP11-252K23.2 -8.42 4.91e-15 2.26e-11 -0.6 -0.5 Dupuytren's disease; chr16:75355857 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs35552529 ENSG00000261783.1 RP11-252K23.2 -8.42 4.91e-15 2.26e-11 -0.6 -0.5 Dupuytren's disease; chr16:75371981 chr16:75379818~75381260:- CESC cis rs1577917 0.837 rs10944157 ENSG00000203875.9 SNHG5 -8.42 4.95e-15 2.28e-11 -0.56 -0.5 Response to antipsychotic treatment; chr6:85867481 chr6:85660950~85678736:- CESC cis rs2739330 0.761 rs5760176 ENSG00000225282.1 AP000350.6 -8.42 4.97e-15 2.29e-11 -0.59 -0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23926900~23929574:+ CESC cis rs7208859 0.623 rs11651857 ENSG00000263531.1 RP13-753N3.1 8.42 4.98e-15 2.29e-11 1.05 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30599344 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs216439 ENSG00000263531.1 RP13-753N3.1 8.42 4.98e-15 2.29e-11 1.05 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30600866 chr17:30863921~30864940:- CESC cis rs7208859 0.573 rs216442 ENSG00000263531.1 RP13-753N3.1 8.42 4.98e-15 2.29e-11 1.05 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604179 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs216445 ENSG00000263531.1 RP13-753N3.1 8.42 4.98e-15 2.29e-11 1.05 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606558 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs216446 ENSG00000263531.1 RP13-753N3.1 8.42 4.98e-15 2.29e-11 1.05 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606700 chr17:30863921~30864940:- CESC cis rs1930961 0.702 rs8141065 ENSG00000272977.1 CTA-390C10.10 8.42 4.98e-15 2.29e-11 0.82 0.5 Bipolar disorder with mood-incongruent psychosis; chr22:25489221 chr22:25476218~25479971:+ CESC cis rs2882667 0.931 rs10075951 ENSG00000253404.1 AC034243.1 8.42 5e-15 2.3e-11 0.59 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139020274 chr5:138744434~138753309:- CESC cis rs2882667 0.931 rs10069528 ENSG00000253404.1 AC034243.1 8.42 5.11e-15 2.35e-11 0.58 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:139018338 chr5:138744434~138753309:- CESC cis rs1153858 1 rs4775895 ENSG00000259520.4 CTD-2651B20.3 -8.41 5.33e-15 2.44e-11 -0.65 -0.49 Homoarginine levels; chr15:45325759 chr15:45251580~45279251:- CESC cis rs2006771 0.836 rs7285777 ENSG00000236132.1 CTA-440B3.1 8.41 5.36e-15 2.45e-11 0.59 0.49 Nonsyndromic cleft lip with cleft palate; chr22:31586255 chr22:31816379~31817491:- CESC cis rs5760092 0.755 rs915589 ENSG00000273295.1 AP000350.5 -8.41 5.38e-15 2.46e-11 -0.66 -0.49 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23901432~23907068:- CESC cis rs977987 0.806 rs1895490 ENSG00000261783.1 RP11-252K23.2 -8.4 5.57e-15 2.54e-11 -0.6 -0.49 Dupuytren's disease; chr16:75358908 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888388 ENSG00000261783.1 RP11-252K23.2 -8.4 5.57e-15 2.54e-11 -0.6 -0.49 Dupuytren's disease; chr16:75360250 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs1364077 ENSG00000261783.1 RP11-252K23.2 -8.4 5.57e-15 2.54e-11 -0.6 -0.49 Dupuytren's disease; chr16:75363093 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs4887820 ENSG00000261783.1 RP11-252K23.2 -8.4 5.57e-15 2.54e-11 -0.6 -0.49 Dupuytren's disease; chr16:75363389 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs34222958 ENSG00000261783.1 RP11-252K23.2 -8.4 5.57e-15 2.54e-11 -0.6 -0.49 Dupuytren's disease; chr16:75364354 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs4887821 ENSG00000261783.1 RP11-252K23.2 -8.4 5.57e-15 2.54e-11 -0.6 -0.49 Dupuytren's disease; chr16:75364676 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs8057203 ENSG00000261783.1 RP11-252K23.2 -8.4 5.57e-15 2.54e-11 -0.6 -0.49 Dupuytren's disease; chr16:75371076 chr16:75379818~75381260:- CESC cis rs1577917 0.739 rs2758846 ENSG00000203875.9 SNHG5 -8.4 5.58e-15 2.54e-11 -0.6 -0.49 Response to antipsychotic treatment; chr6:85639852 chr6:85660950~85678736:- CESC cis rs7617773 0.78 rs13067450 ENSG00000229759.1 MRPS18AP1 8.4 5.63e-15 2.56e-11 0.53 0.49 Coronary artery disease; chr3:48295716 chr3:48256350~48256938:- CESC cis rs7617773 0.78 rs4479622 ENSG00000229759.1 MRPS18AP1 8.4 5.63e-15 2.56e-11 0.53 0.49 Coronary artery disease; chr3:48296683 chr3:48256350~48256938:- CESC cis rs7617773 0.78 rs34946886 ENSG00000229759.1 MRPS18AP1 8.4 5.63e-15 2.56e-11 0.53 0.49 Coronary artery disease; chr3:48296997 chr3:48256350~48256938:- CESC cis rs7617773 0.78 rs34589064 ENSG00000229759.1 MRPS18AP1 8.4 5.63e-15 2.56e-11 0.53 0.49 Coronary artery disease; chr3:48298059 chr3:48256350~48256938:- CESC cis rs7617773 0.78 rs2541 ENSG00000229759.1 MRPS18AP1 8.4 5.63e-15 2.56e-11 0.53 0.49 Coronary artery disease; chr3:48298128 chr3:48256350~48256938:- CESC cis rs7617773 0.78 rs13085251 ENSG00000229759.1 MRPS18AP1 8.4 5.63e-15 2.56e-11 0.53 0.49 Coronary artery disease; chr3:48298555 chr3:48256350~48256938:- CESC cis rs7044106 0.791 rs10985004 ENSG00000226752.6 PSMD5-AS1 -8.4 5.63e-15 2.56e-11 -0.54 -0.49 Hip circumference adjusted for BMI; chr9:120722659 chr9:120824828~120854385:+ CESC cis rs10256972 0.568 rs1133043 ENSG00000229043.2 AC091729.9 -8.4 5.74e-15 2.61e-11 -0.55 -0.49 Endometriosis;Longevity; chr7:1093669 chr7:1160374~1165267:+ CESC cis rs977987 0.806 rs11862582 ENSG00000261783.1 RP11-252K23.2 -8.4 5.77e-15 2.62e-11 -0.6 -0.49 Dupuytren's disease; chr16:75397397 chr16:75379818~75381260:- CESC cis rs2739330 0.732 rs5760175 ENSG00000218537.1 MIF-AS1 8.4 5.77e-15 2.62e-11 0.63 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23894426~23898930:- CESC cis rs2882667 0.931 rs10077896 ENSG00000253404.1 AC034243.1 8.4 5.8e-15 2.63e-11 0.58 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:139021067 chr5:138744434~138753309:- CESC cis rs929843 1 rs929843 ENSG00000226232.7 RP11-419C5.2 -8.4 5.81e-15 2.64e-11 -0.61 -0.49 Menarche (age at onset); chr16:70011845 chr16:69976388~69996188:- CESC cis rs4423214 1 rs7928249 ENSG00000254682.1 RP11-660L16.2 8.4 5.87e-15 2.66e-11 0.62 0.49 Vitamin D levels; chr11:71450017 chr11:71448674~71452157:+ CESC cis rs977987 0.815 rs11149821 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75388919 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs4888400 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75391698 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888404 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75394199 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs2285225 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75395354 chr16:75379818~75381260:- CESC cis rs977987 0.527 rs62059844 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75395839 chr16:75379818~75381260:- CESC cis rs977987 0.585 rs62059845 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75396815 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs62059846 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75396911 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs11862719 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75397810 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs11149824 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75397932 chr16:75379818~75381260:- CESC cis rs977987 0.586 rs12920883 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75398783 chr16:75379818~75381260:- CESC cis rs977987 0.624 rs59867374 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75398784 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4887823 ENSG00000261783.1 RP11-252K23.2 -8.4 5.89e-15 2.66e-11 -0.6 -0.49 Dupuytren's disease; chr16:75399176 chr16:75379818~75381260:- CESC cis rs875971 0.54 rs781152 ENSG00000226824.5 RP4-756H11.3 -8.39 5.92e-15 2.68e-11 -0.63 -0.49 Aortic root size; chr7:66014585 chr7:66654538~66669855:+ CESC cis rs17711722 0.727 rs781151 ENSG00000226824.5 RP4-756H11.3 -8.39 5.92e-15 2.68e-11 -0.63 -0.49 Calcium levels; chr7:66014891 chr7:66654538~66669855:+ CESC cis rs977987 0.806 rs11860284 ENSG00000261783.1 RP11-252K23.2 -8.39 5.93e-15 2.68e-11 -0.6 -0.49 Dupuytren's disease; chr16:75379009 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs2865530 ENSG00000261783.1 RP11-252K23.2 -8.39 5.93e-15 2.68e-11 -0.6 -0.49 Dupuytren's disease; chr16:75380478 chr16:75379818~75381260:- CESC cis rs7617773 0.694 rs13099560 ENSG00000229759.1 MRPS18AP1 -8.39 5.95e-15 2.69e-11 -0.49 -0.49 Coronary artery disease; chr3:48163278 chr3:48256350~48256938:- CESC cis rs2739330 0.731 rs4822450 ENSG00000250470.1 AP000351.3 8.39 6.02e-15 2.72e-11 0.64 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23976904~23977585:- CESC cis rs1577917 0.771 rs2842613 ENSG00000203875.9 SNHG5 8.39 6.05e-15 2.73e-11 0.58 0.49 Response to antipsychotic treatment; chr6:85595984 chr6:85660950~85678736:- CESC cis rs858239 0.698 rs4265084 ENSG00000230658.1 KLHL7-AS1 8.39 6.11e-15 2.76e-11 0.67 0.49 Cerebrospinal fluid biomarker levels; chr7:23367621 chr7:23101228~23105703:- CESC cis rs1799949 0.536 rs4793227 ENSG00000198496.9 NBR2 -8.39 6.2e-15 2.79e-11 -0.61 -0.49 Menopause (age at onset); chr17:43334882 chr17:43125610~43153671:+ CESC cis rs916888 0.531 rs183211 ENSG00000214401.4 KANSL1-AS1 8.39 6.22e-15 2.8e-11 0.6 0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46193576~46196723:+ CESC cis rs7617773 0.817 rs3731497 ENSG00000229759.1 MRPS18AP1 8.38 6.34e-15 2.85e-11 0.53 0.49 Coronary artery disease; chr3:48185063 chr3:48256350~48256938:- CESC cis rs2739330 0.731 rs5751792 ENSG00000225282.1 AP000350.6 8.38 6.41e-15 2.88e-11 0.59 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23926900~23929574:+ CESC cis rs7617773 0.925 rs6442105 ENSG00000229759.1 MRPS18AP1 -8.38 6.42e-15 2.88e-11 -0.52 -0.49 Coronary artery disease; chr3:48140836 chr3:48256350~48256938:- CESC cis rs9545047 1 rs9318626 ENSG00000227676.3 LINC01068 8.38 6.53e-15 2.93e-11 0.57 0.49 Schizophrenia; chr13:79351820 chr13:79566727~79571436:+ CESC cis rs7044106 0.791 rs747819 ENSG00000226752.6 PSMD5-AS1 -8.38 6.66e-15 2.99e-11 -0.56 -0.49 Hip circumference adjusted for BMI; chr9:120726163 chr9:120824828~120854385:+ CESC cis rs977987 0.806 rs11643410 ENSG00000261783.1 RP11-252K23.2 -8.37 6.74e-15 3.02e-11 -0.6 -0.49 Dupuytren's disease; chr16:75394408 chr16:75379818~75381260:- CESC cis rs2882667 0.929 rs17207828 ENSG00000253404.1 AC034243.1 8.37 6.76e-15 3.03e-11 0.61 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138964146 chr5:138744434~138753309:- CESC cis rs150992 0.962 rs327811 ENSG00000248489.1 CTD-2007H13.3 8.37 6.85e-15 3.07e-11 0.57 0.49 Body mass index; chr5:98935471 chr5:98929171~98995013:+ CESC cis rs7208859 0.623 rs170051 ENSG00000263531.1 RP13-753N3.1 8.37 6.92e-15 3.1e-11 1.05 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587135 chr17:30863921~30864940:- CESC cis rs7208859 0.51 rs216402 ENSG00000263531.1 RP13-753N3.1 8.37 6.92e-15 3.1e-11 1.05 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30590108 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs216434 ENSG00000263531.1 RP13-753N3.1 8.37 6.92e-15 3.1e-11 1.05 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595317 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs216436 ENSG00000263531.1 RP13-753N3.1 8.37 6.92e-15 3.1e-11 1.05 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595882 chr17:30863921~30864940:- CESC cis rs526231 0.511 rs55896090 ENSG00000175749.11 EIF3KP1 8.36 7.19e-15 3.21e-11 0.55 0.49 Primary biliary cholangitis; chr5:103026300 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs55810112 ENSG00000175749.11 EIF3KP1 8.36 7.19e-15 3.21e-11 0.55 0.49 Primary biliary cholangitis; chr5:103026645 chr5:103032376~103033031:+ CESC cis rs2739330 0.76 rs1002286 ENSG00000250470.1 AP000351.3 -8.36 7.23e-15 3.22e-11 -0.63 -0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23976904~23977585:- CESC cis rs977987 0.778 rs35415181 ENSG00000261783.1 RP11-252K23.2 -8.36 7.25e-15 3.23e-11 -0.6 -0.49 Dupuytren's disease; chr16:75369226 chr16:75379818~75381260:- CESC cis rs1153858 1 rs1980288 ENSG00000259520.4 CTD-2651B20.3 -8.36 7.39e-15 3.29e-11 -0.65 -0.49 Homoarginine levels; chr15:45328414 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12909158 ENSG00000259520.4 CTD-2651B20.3 -8.36 7.39e-15 3.29e-11 -0.65 -0.49 Homoarginine levels; chr15:45328976 chr15:45251580~45279251:- CESC cis rs7208859 0.623 rs9895785 ENSG00000263531.1 RP13-753N3.1 -8.36 7.5e-15 3.34e-11 -0.96 -0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780690 chr17:30863921~30864940:- CESC cis rs977987 0.778 rs7203157 ENSG00000261783.1 RP11-252K23.2 -8.36 7.53e-15 3.35e-11 -0.6 -0.49 Dupuytren's disease; chr16:75384022 chr16:75379818~75381260:- CESC cis rs1153858 1 rs59889118 ENSG00000259520.4 CTD-2651B20.3 -8.35 7.8e-15 3.47e-11 -0.65 -0.49 Homoarginine levels; chr15:45326532 chr15:45251580~45279251:- CESC cis rs9545047 0.869 rs3742119 ENSG00000227676.3 LINC01068 8.35 7.95e-15 3.52e-11 0.56 0.49 Schizophrenia; chr13:79342859 chr13:79566727~79571436:+ CESC cis rs2882667 0.964 rs67296915 ENSG00000253404.1 AC034243.1 8.35 7.99e-15 3.54e-11 0.6 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138965910 chr5:138744434~138753309:- CESC cis rs9828933 0.678 rs704366 ENSG00000280620.1 SCAANT1 -8.35 8e-15 3.54e-11 -0.85 -0.49 Type 2 diabetes; chr3:63885972 chr3:63911518~63911772:- CESC cis rs875971 1 rs3981131 ENSG00000226824.5 RP4-756H11.3 -8.35 8.03e-15 3.55e-11 -0.63 -0.49 Aortic root size; chr7:66486690 chr7:66654538~66669855:+ CESC cis rs9545047 0.967 rs3903388 ENSG00000227676.3 LINC01068 8.35 8.07e-15 3.57e-11 0.55 0.49 Schizophrenia; chr13:79330686 chr13:79566727~79571436:+ CESC cis rs9545047 1 rs9545073 ENSG00000227676.3 LINC01068 8.35 8.07e-15 3.57e-11 0.55 0.49 Schizophrenia; chr13:79334872 chr13:79566727~79571436:+ CESC cis rs875971 0.965 rs9969301 ENSG00000226824.5 RP4-756H11.3 8.35 8.09e-15 3.58e-11 0.6 0.49 Aortic root size; chr7:66316668 chr7:66654538~66669855:+ CESC cis rs2882667 0.931 rs6596457 ENSG00000253404.1 AC034243.1 8.34 8.29e-15 3.66e-11 0.58 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138987690 chr5:138744434~138753309:- CESC cis rs3814244 0.54 rs2159064 ENSG00000255733.4 IFNG-AS1 -8.34 8.4e-15 3.71e-11 -0.43 -0.49 Itch intensity from mosquito bite adjusted by bite size; chr12:68017126 chr12:67989445~68234686:+ CESC cis rs7617773 0.817 rs3731534 ENSG00000229759.1 MRPS18AP1 8.34 8.5e-15 3.75e-11 0.56 0.49 Coronary artery disease; chr3:48170287 chr3:48256350~48256938:- CESC cis rs977987 0.806 rs4888390 ENSG00000261783.1 RP11-252K23.2 -8.33 8.76e-15 3.86e-11 -0.6 -0.49 Dupuytren's disease; chr16:75366422 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888391 ENSG00000261783.1 RP11-252K23.2 -8.33 8.76e-15 3.86e-11 -0.6 -0.49 Dupuytren's disease; chr16:75366848 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs8054769 ENSG00000261783.1 RP11-252K23.2 -8.33 8.76e-15 3.86e-11 -0.6 -0.49 Dupuytren's disease; chr16:75367215 chr16:75379818~75381260:- CESC cis rs7115242 0.514 rs4936367 ENSG00000254851.1 RP11-109L13.1 -8.33 8.93e-15 3.93e-11 -0.9 -0.49 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117171661 chr11:117135528~117138582:+ CESC cis rs9326248 0.53 rs4604928 ENSG00000254851.1 RP11-109L13.1 -8.33 8.93e-15 3.93e-11 -0.9 -0.49 Blood protein levels; chr11:117173487 chr11:117135528~117138582:+ CESC cis rs2882667 0.867 rs11749045 ENSG00000253404.1 AC034243.1 8.33 8.95e-15 3.93e-11 0.58 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:139085271 chr5:138744434~138753309:- CESC cis rs977987 0.806 rs1109342 ENSG00000261783.1 RP11-252K23.2 8.33 9.06e-15 3.98e-11 0.61 0.49 Dupuytren's disease; chr16:75411777 chr16:75379818~75381260:- CESC cis rs7617773 0.78 rs3731550 ENSG00000229759.1 MRPS18AP1 8.33 9.14e-15 4.02e-11 0.56 0.49 Coronary artery disease; chr3:48165093 chr3:48256350~48256938:- CESC cis rs1799949 1 rs35070007 ENSG00000198496.9 NBR2 8.33 9.24e-15 4.06e-11 0.6 0.49 Menopause (age at onset); chr17:43164730 chr17:43125610~43153671:+ CESC cis rs4853012 0.539 rs9789534 ENSG00000217702.2 RP11-287D1.4 8.32 9.28e-15 4.07e-11 0.72 0.49 Gestational age at birth (maternal effect); chr2:74135863 chr2:74130583~74135395:+ CESC cis rs1153858 0.945 rs2467854 ENSG00000259520.4 CTD-2651B20.3 -8.32 9.35e-15 4.1e-11 -0.63 -0.49 Homoarginine levels; chr15:45409399 chr15:45251580~45279251:- CESC cis rs1153858 1 rs2461701 ENSG00000259520.4 CTD-2651B20.3 -8.32 9.35e-15 4.1e-11 -0.63 -0.49 Homoarginine levels; chr15:45411193 chr15:45251580~45279251:- CESC cis rs1153858 1 rs2467858 ENSG00000259520.4 CTD-2651B20.3 -8.32 9.35e-15 4.1e-11 -0.63 -0.49 Homoarginine levels; chr15:45419294 chr15:45251580~45279251:- CESC cis rs9545047 1 rs9574422 ENSG00000227676.3 LINC01068 8.32 9.37e-15 4.11e-11 0.57 0.49 Schizophrenia; chr13:79415246 chr13:79566727~79571436:+ CESC cis rs858239 0.73 rs10255155 ENSG00000230658.1 KLHL7-AS1 -8.32 9.4e-15 4.12e-11 -0.64 -0.49 Cerebrospinal fluid biomarker levels; chr7:23362528 chr7:23101228~23105703:- CESC cis rs9545047 1 rs56911077 ENSG00000227676.3 LINC01068 8.32 9.57e-15 4.19e-11 0.56 0.49 Schizophrenia; chr13:79354126 chr13:79566727~79571436:+ CESC cis rs7208859 0.623 rs8067035 ENSG00000263531.1 RP13-753N3.1 8.32 9.65e-15 4.23e-11 0.94 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30863921~30864940:- CESC cis rs4718428 1 rs12534637 ENSG00000226824.5 RP4-756H11.3 -8.32 9.88e-15 4.31e-11 -0.64 -0.49 Corneal structure; chr7:66862667 chr7:66654538~66669855:+ CESC cis rs1577917 0.771 rs2842608 ENSG00000203875.9 SNHG5 -8.31 9.9e-15 4.32e-11 -0.58 -0.49 Response to antipsychotic treatment; chr6:85586140 chr6:85660950~85678736:- CESC cis rs9545047 0.613 rs79774056 ENSG00000227676.3 LINC01068 8.31 1e-14 4.38e-11 0.57 0.49 Schizophrenia; chr13:79421486 chr13:79566727~79571436:+ CESC cis rs1153858 1 rs9783731 ENSG00000259520.4 CTD-2651B20.3 8.31 1.02e-14 4.43e-11 0.63 0.49 Homoarginine levels; chr15:45350686 chr15:45251580~45279251:- CESC cis rs1153858 1 rs7171577 ENSG00000259520.4 CTD-2651B20.3 -8.31 1.02e-14 4.46e-11 -0.65 -0.49 Homoarginine levels; chr15:45335781 chr15:45251580~45279251:- CESC cis rs1153858 1 rs10519021 ENSG00000259520.4 CTD-2651B20.3 -8.31 1.02e-14 4.46e-11 -0.65 -0.49 Homoarginine levels; chr15:45339597 chr15:45251580~45279251:- CESC cis rs7617773 0.779 rs77957078 ENSG00000229759.1 MRPS18AP1 8.31 1.03e-14 4.49e-11 0.53 0.49 Coronary artery disease; chr3:48289796 chr3:48256350~48256938:- CESC cis rs1153858 1 rs1153849 ENSG00000259520.4 CTD-2651B20.3 -8.31 1.05e-14 4.55e-11 -0.64 -0.49 Homoarginine levels; chr15:45403497 chr15:45251580~45279251:- CESC cis rs875971 0.522 rs7784623 ENSG00000226824.5 RP4-756H11.3 -8.31 1.05e-14 4.55e-11 -0.63 -0.49 Aortic root size; chr7:65930047 chr7:66654538~66669855:+ CESC cis rs977987 0.806 rs4888405 ENSG00000261783.1 RP11-252K23.2 -8.3 1.08e-14 4.68e-11 -0.59 -0.49 Dupuytren's disease; chr16:75394298 chr16:75379818~75381260:- CESC cis rs2882667 1 rs2882667 ENSG00000253404.1 AC034243.1 8.3 1.08e-14 4.7e-11 0.61 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138978417 chr5:138744434~138753309:- CESC cis rs2882667 0.931 rs10075039 ENSG00000253404.1 AC034243.1 8.3 1.09e-14 4.74e-11 0.57 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:139002165 chr5:138744434~138753309:- CESC cis rs977987 0.806 rs1549306 ENSG00000261783.1 RP11-252K23.2 -8.3 1.1e-14 4.76e-11 -0.6 -0.49 Dupuytren's disease; chr16:75381443 chr16:75379818~75381260:- CESC cis rs10256972 0.591 rs10229680 ENSG00000229043.2 AC091729.9 -8.3 1.11e-14 4.82e-11 -0.56 -0.49 Endometriosis;Longevity; chr7:1118929 chr7:1160374~1165267:+ CESC cis rs7301826 1 rs10773819 ENSG00000256250.1 RP11-989F5.1 -8.3 1.12e-14 4.84e-11 -0.55 -0.49 Plasma plasminogen activator levels; chr12:130794477 chr12:130810606~130812438:+ CESC cis rs9326248 0.53 rs7112513 ENSG00000254851.1 RP11-109L13.1 -8.3 1.12e-14 4.86e-11 -0.89 -0.49 Blood protein levels; chr11:117166645 chr11:117135528~117138582:+ CESC cis rs977987 0.866 rs17696831 ENSG00000261783.1 RP11-252K23.2 -8.29 1.14e-14 4.93e-11 -0.61 -0.49 Dupuytren's disease; chr16:75459400 chr16:75379818~75381260:- CESC cis rs977987 0.902 rs34539062 ENSG00000261783.1 RP11-252K23.2 -8.29 1.15e-14 4.97e-11 -0.61 -0.49 Dupuytren's disease; chr16:75459381 chr16:75379818~75381260:- CESC cis rs977987 0.898 rs12918797 ENSG00000261783.1 RP11-252K23.2 -8.29 1.15e-14 4.97e-11 -0.61 -0.49 Dupuytren's disease; chr16:75459912 chr16:75379818~75381260:- CESC cis rs977987 0.931 rs11641430 ENSG00000261783.1 RP11-252K23.2 -8.29 1.15e-14 4.97e-11 -0.61 -0.49 Dupuytren's disease; chr16:75461378 chr16:75379818~75381260:- CESC cis rs977987 0.931 rs7195161 ENSG00000261783.1 RP11-252K23.2 -8.29 1.15e-14 4.97e-11 -0.61 -0.49 Dupuytren's disease; chr16:75461674 chr16:75379818~75381260:- CESC cis rs977987 0.931 rs1424013 ENSG00000261783.1 RP11-252K23.2 -8.29 1.15e-14 4.97e-11 -0.61 -0.49 Dupuytren's disease; chr16:75462088 chr16:75379818~75381260:- CESC cis rs12439619 0.846 rs62013464 ENSG00000278603.1 RP13-608F4.5 8.29 1.16e-14 5.01e-11 0.82 0.49 Intelligence (multi-trait analysis); chr15:82288250 chr15:82472203~82472426:+ CESC cis rs17826219 0.636 rs12946563 ENSG00000263531.1 RP13-753N3.1 8.29 1.17e-14 5.05e-11 0.96 0.49 Body mass index; chr17:30776148 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs8068645 ENSG00000263531.1 RP13-753N3.1 8.29 1.17e-14 5.05e-11 0.96 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs55811708 ENSG00000263531.1 RP13-753N3.1 8.29 1.17e-14 5.05e-11 0.96 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30863921~30864940:- CESC cis rs1799949 0.894 rs36062488 ENSG00000198496.9 NBR2 8.29 1.17e-14 5.07e-11 0.6 0.49 Menopause (age at onset); chr17:43185455 chr17:43125610~43153671:+ CESC cis rs9326248 0.53 rs7940310 ENSG00000254851.1 RP11-109L13.1 -8.29 1.19e-14 5.15e-11 -0.88 -0.49 Blood protein levels; chr11:117153765 chr11:117135528~117138582:+ CESC cis rs9326248 0.53 rs7123517 ENSG00000254851.1 RP11-109L13.1 -8.29 1.19e-14 5.15e-11 -0.88 -0.49 Blood protein levels; chr11:117157039 chr11:117135528~117138582:+ CESC cis rs2739330 0.761 rs5760176 ENSG00000218537.1 MIF-AS1 -8.28 1.24e-14 5.35e-11 -0.62 -0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23894426~23898930:- CESC cis rs12439619 0.774 rs2867649 ENSG00000278603.1 RP13-608F4.5 8.27 1.3e-14 5.57e-11 0.82 0.49 Intelligence (multi-trait analysis); chr15:82262331 chr15:82472203~82472426:+ CESC cis rs875971 0.522 rs2949690 ENSG00000226824.5 RP4-756H11.3 8.27 1.3e-14 5.57e-11 0.62 0.49 Aortic root size; chr7:66018255 chr7:66654538~66669855:+ CESC cis rs17711722 0.701 rs781145 ENSG00000226824.5 RP4-756H11.3 -8.27 1.35e-14 5.8e-11 -0.63 -0.49 Calcium levels; chr7:65975383 chr7:66654538~66669855:+ CESC cis rs1799949 0.965 rs2236762 ENSG00000198496.9 NBR2 -8.27 1.36e-14 5.81e-11 -0.59 -0.49 Menopause (age at onset); chr17:43074658 chr17:43125610~43153671:+ CESC cis rs7208859 0.623 rs7220289 ENSG00000263531.1 RP13-753N3.1 8.26 1.39e-14 5.93e-11 0.96 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30776744 chr17:30863921~30864940:- CESC cis rs2882667 0.861 rs11242445 ENSG00000253404.1 AC034243.1 8.26 1.44e-14 6.17e-11 0.57 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:139081365 chr5:138744434~138753309:- CESC cis rs1153858 1 rs28679834 ENSG00000259520.4 CTD-2651B20.3 -8.25 1.47e-14 6.27e-11 -0.65 -0.49 Homoarginine levels; chr15:45324008 chr15:45251580~45279251:- CESC cis rs150992 1 rs150992 ENSG00000248489.1 CTD-2007H13.3 8.25 1.48e-14 6.32e-11 0.57 0.49 Body mass index; chr5:98939493 chr5:98929171~98995013:+ CESC cis rs4423214 1 rs3750997 ENSG00000254682.1 RP11-660L16.2 8.25 1.49e-14 6.36e-11 0.63 0.49 Vitamin D levels; chr11:71447795 chr11:71448674~71452157:+ CESC cis rs7617773 0.78 rs3197223 ENSG00000229759.1 MRPS18AP1 8.25 1.52e-14 6.49e-11 0.53 0.49 Coronary artery disease; chr3:48294367 chr3:48256350~48256938:- CESC cis rs2882667 1 rs10064130 ENSG00000253404.1 AC034243.1 8.24 1.57e-14 6.7e-11 0.61 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138973618 chr5:138744434~138753309:- CESC cis rs7617773 1 rs7617773 ENSG00000229759.1 MRPS18AP1 -8.24 1.57e-14 6.7e-11 -0.51 -0.49 Coronary artery disease; chr3:48152025 chr3:48256350~48256938:- CESC cis rs1707322 0.662 rs11211160 ENSG00000280836.1 AL355480.1 -8.24 1.59e-14 6.75e-11 -0.58 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680557 chr1:45581219~45581321:- CESC cis rs875971 0.66 rs1860468 ENSG00000226824.5 RP4-756H11.3 8.24 1.61e-14 6.84e-11 0.59 0.49 Aortic root size; chr7:66642265 chr7:66654538~66669855:+ CESC cis rs2739330 0.731 rs5751792 ENSG00000218537.1 MIF-AS1 8.23 1.66e-14 7.04e-11 0.62 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23894426~23898930:- CESC cis rs9828933 0.938 rs2578011 ENSG00000280620.1 SCAANT1 8.23 1.66e-14 7.04e-11 0.83 0.49 Type 2 diabetes; chr3:64019143 chr3:63911518~63911772:- CESC cis rs26232 0.583 rs154258 ENSG00000175749.11 EIF3KP1 -8.23 1.66e-14 7.07e-11 -0.53 -0.49 Rheumatoid arthritis; chr5:103027919 chr5:103032376~103033031:+ CESC cis rs7044106 0.791 rs735110 ENSG00000226752.6 PSMD5-AS1 -8.23 1.73e-14 7.32e-11 -0.55 -0.49 Hip circumference adjusted for BMI; chr9:120726662 chr9:120824828~120854385:+ CESC cis rs2882667 0.931 rs10044736 ENSG00000253404.1 AC034243.1 -8.22 1.76e-14 7.45e-11 -0.55 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138985120 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs3828600 ENSG00000253404.1 AC034243.1 8.22 1.77e-14 7.49e-11 0.56 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:139051170 chr5:138744434~138753309:- CESC cis rs9326248 0.53 rs7122944 ENSG00000254851.1 RP11-109L13.1 -8.22 1.8e-14 7.59e-11 -0.89 -0.49 Blood protein levels; chr11:117163903 chr11:117135528~117138582:+ CESC cis rs26232 0.551 rs26431 ENSG00000175749.11 EIF3KP1 -8.22 1.8e-14 7.63e-11 -0.53 -0.49 Rheumatoid arthritis; chr5:103030090 chr5:103032376~103033031:+ CESC cis rs1799949 0.773 rs2137990 ENSG00000198496.9 NBR2 8.22 1.82e-14 7.68e-11 0.58 0.49 Menopause (age at onset); chr17:43165879 chr17:43125610~43153671:+ CESC cis rs10256972 0.591 rs6968988 ENSG00000229043.2 AC091729.9 -8.22 1.82e-14 7.69e-11 -0.55 -0.49 Endometriosis;Longevity; chr7:1129983 chr7:1160374~1165267:+ CESC cis rs526231 0.511 rs17154965 ENSG00000175749.11 EIF3KP1 8.21 1.91e-14 8.07e-11 0.55 0.49 Primary biliary cholangitis; chr5:103023862 chr5:103032376~103033031:+ CESC cis rs9326248 0.53 rs2127905 ENSG00000254851.1 RP11-109L13.1 -8.21 1.99e-14 8.37e-11 -0.88 -0.49 Blood protein levels; chr11:117155658 chr11:117135528~117138582:+ CESC cis rs2739330 0.76 rs1007888 ENSG00000250470.1 AP000351.3 8.2 2.02e-14 8.48e-11 0.63 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23976904~23977585:- CESC cis rs875971 1 rs7781698 ENSG00000226824.5 RP4-756H11.3 -8.2 2.04e-14 8.58e-11 -0.61 -0.49 Aortic root size; chr7:66431325 chr7:66654538~66669855:+ CESC cis rs2882667 1 rs10515505 ENSG00000253404.1 AC034243.1 8.2 2.04e-14 8.59e-11 0.58 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138977457 chr5:138744434~138753309:- CESC cis rs7208859 0.725 rs9897673 ENSG00000263531.1 RP13-753N3.1 8.2 2.07e-14 8.69e-11 0.83 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916348 chr17:30863921~30864940:- CESC cis rs1799949 0.965 rs9646413 ENSG00000198496.9 NBR2 -8.2 2.07e-14 8.71e-11 -0.59 -0.49 Menopause (age at onset); chr17:43348789 chr17:43125610~43153671:+ CESC cis rs150992 0.886 rs161948 ENSG00000248489.1 CTD-2007H13.3 8.2 2.09e-14 8.77e-11 0.55 0.49 Body mass index; chr5:98932333 chr5:98929171~98995013:+ CESC cis rs1707322 0.752 rs6662164 ENSG00000280836.1 AL355480.1 -8.2 2.1e-14 8.82e-11 -0.57 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680558 chr1:45581219~45581321:- CESC cis rs1153858 1 rs2066090 ENSG00000259520.4 CTD-2651B20.3 -8.2 2.12e-14 8.91e-11 -0.63 -0.49 Homoarginine levels; chr15:45357820 chr15:45251580~45279251:- CESC cis rs1153858 1 rs61365925 ENSG00000259520.4 CTD-2651B20.3 -8.2 2.12e-14 8.91e-11 -0.63 -0.49 Homoarginine levels; chr15:45358113 chr15:45251580~45279251:- CESC cis rs1153858 1 rs16952714 ENSG00000259520.4 CTD-2651B20.3 -8.2 2.12e-14 8.91e-11 -0.63 -0.49 Homoarginine levels; chr15:45358160 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12101539 ENSG00000259520.4 CTD-2651B20.3 -8.2 2.12e-14 8.91e-11 -0.63 -0.49 Homoarginine levels; chr15:45358468 chr15:45251580~45279251:- CESC cis rs875971 1 rs709595 ENSG00000226824.5 RP4-756H11.3 -8.19 2.13e-14 8.95e-11 -0.61 -0.49 Aortic root size; chr7:66352346 chr7:66654538~66669855:+ CESC cis rs875971 1 rs811880 ENSG00000226824.5 RP4-756H11.3 -8.19 2.13e-14 8.95e-11 -0.61 -0.49 Aortic root size; chr7:66353659 chr7:66654538~66669855:+ CESC cis rs801193 0.844 rs2244022 ENSG00000226824.5 RP4-756H11.3 -8.19 2.14e-14 8.97e-11 -0.59 -0.49 Aortic root size; chr7:66737443 chr7:66654538~66669855:+ CESC cis rs858239 0.862 rs1728292 ENSG00000230658.1 KLHL7-AS1 8.19 2.15e-14 9.01e-11 0.59 0.49 Cerebrospinal fluid biomarker levels; chr7:23223855 chr7:23101228~23105703:- CESC cis rs9828933 0.752 rs73117082 ENSG00000280620.1 SCAANT1 8.19 2.15e-14 9.03e-11 0.97 0.49 Type 2 diabetes; chr3:63961889 chr3:63911518~63911772:- CESC cis rs1153858 1 rs1145091 ENSG00000259520.4 CTD-2651B20.3 -8.19 2.19e-14 9.18e-11 -0.62 -0.49 Homoarginine levels; chr15:45357798 chr15:45251580~45279251:- CESC cis rs977987 0.806 rs8050059 ENSG00000261783.1 RP11-252K23.2 -8.19 2.22e-14 9.32e-11 -0.59 -0.48 Dupuytren's disease; chr16:75354833 chr16:75379818~75381260:- CESC cis rs17711722 0.522 rs62469933 ENSG00000164669.11 INTS4P1 -8.19 2.24e-14 9.36e-11 -0.62 -0.48 Calcium levels; chr7:65800652 chr7:65141225~65234216:+ CESC cis rs992157 1 rs992157 ENSG00000261338.2 RP11-378A13.1 -8.18 2.27e-14 9.48e-11 -0.62 -0.48 Colorectal cancer; chr2:218290058 chr2:218255319~218257366:+ CESC cis rs801193 0.66 rs1962050 ENSG00000226824.5 RP4-756H11.3 8.18 2.27e-14 9.49e-11 0.59 0.48 Aortic root size; chr7:66775021 chr7:66654538~66669855:+ CESC cis rs9828933 0.766 rs704361 ENSG00000280620.1 SCAANT1 -8.18 2.32e-14 9.7e-11 -0.89 -0.48 Type 2 diabetes; chr3:63897995 chr3:63911518~63911772:- CESC cis rs977987 0.806 rs35263058 ENSG00000261783.1 RP11-252K23.2 -8.18 2.32e-14 9.71e-11 -0.59 -0.48 Dupuytren's disease; chr16:75358039 chr16:75379818~75381260:- CESC cis rs875971 0.522 rs34973832 ENSG00000226824.5 RP4-756H11.3 -8.18 2.36e-14 9.87e-11 -0.62 -0.48 Aortic root size; chr7:65931217 chr7:66654538~66669855:+ CESC cis rs17711722 0.74 rs7809991 ENSG00000226824.5 RP4-756H11.3 -8.18 2.36e-14 9.87e-11 -0.62 -0.48 Calcium levels; chr7:65941231 chr7:66654538~66669855:+ CESC cis rs916888 0.61 rs199438 ENSG00000214401.4 KANSL1-AS1 8.18 2.38e-14 9.92e-11 0.59 0.48 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46193576~46196723:+ CESC cis rs977987 0.898 rs12918974 ENSG00000261783.1 RP11-252K23.2 -8.18 2.4e-14 1e-10 -0.61 -0.48 Dupuytren's disease; chr16:75460045 chr16:75379818~75381260:- CESC cis rs977987 0.866 rs12932606 ENSG00000261783.1 RP11-252K23.2 -8.18 2.4e-14 1e-10 -0.61 -0.48 Dupuytren's disease; chr16:75460046 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs11862095 ENSG00000261783.1 RP11-252K23.2 -8.18 2.41e-14 1e-10 -0.59 -0.48 Dupuytren's disease; chr16:75351520 chr16:75379818~75381260:- CESC cis rs526231 0.511 rs3756582 ENSG00000175749.11 EIF3KP1 8.17 2.44e-14 1.01e-10 0.54 0.48 Primary biliary cholangitis; chr5:103003848 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs45518833 ENSG00000175749.11 EIF3KP1 8.17 2.44e-14 1.01e-10 0.54 0.48 Primary biliary cholangitis; chr5:103007286 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs1826673 ENSG00000175749.11 EIF3KP1 8.17 2.44e-14 1.01e-10 0.54 0.48 Primary biliary cholangitis; chr5:103010212 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs62362545 ENSG00000175749.11 EIF3KP1 8.17 2.44e-14 1.01e-10 0.54 0.48 Primary biliary cholangitis; chr5:103011748 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs3910557 ENSG00000175749.11 EIF3KP1 8.17 2.44e-14 1.01e-10 0.54 0.48 Primary biliary cholangitis; chr5:103014767 chr5:103032376~103033031:+ CESC cis rs7301826 1 rs10848205 ENSG00000256250.1 RP11-989F5.1 -8.17 2.45e-14 1.02e-10 -0.54 -0.48 Plasma plasminogen activator levels; chr12:130796169 chr12:130810606~130812438:+ CESC cis rs526231 0.543 rs4386712 ENSG00000175749.11 EIF3KP1 8.17 2.49e-14 1.03e-10 0.53 0.48 Primary biliary cholangitis; chr5:103033530 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs56235607 ENSG00000175749.11 EIF3KP1 8.17 2.49e-14 1.03e-10 0.53 0.48 Primary biliary cholangitis; chr5:103036902 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs55741939 ENSG00000175749.11 EIF3KP1 8.17 2.49e-14 1.03e-10 0.53 0.48 Primary biliary cholangitis; chr5:103036984 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs72785733 ENSG00000175749.11 EIF3KP1 8.17 2.49e-14 1.03e-10 0.53 0.48 Parkinson's disease; chr5:103038488 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs2288389 ENSG00000175749.11 EIF3KP1 8.17 2.52e-14 1.05e-10 0.53 0.48 Primary biliary cholangitis; chr5:103018104 chr5:103032376~103033031:+ CESC cis rs875971 0.522 rs6960048 ENSG00000226824.5 RP4-756H11.3 -8.17 2.53e-14 1.05e-10 -0.62 -0.48 Aortic root size; chr7:65943052 chr7:66654538~66669855:+ CESC cis rs2882667 0.894 rs1433008 ENSG00000253404.1 AC034243.1 8.17 2.55e-14 1.06e-10 0.57 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:138997975 chr5:138744434~138753309:- CESC cis rs875971 0.54 rs4717275 ENSG00000226824.5 RP4-756H11.3 8.17 2.55e-14 1.06e-10 0.62 0.48 Aortic root size; chr7:65800193 chr7:66654538~66669855:+ CESC cis rs875971 1 rs11974264 ENSG00000226824.5 RP4-756H11.3 8.17 2.56e-14 1.06e-10 0.59 0.48 Aortic root size; chr7:66182595 chr7:66654538~66669855:+ CESC cis rs875971 1 rs1540651 ENSG00000226824.5 RP4-756H11.3 8.17 2.56e-14 1.06e-10 0.59 0.48 Aortic root size; chr7:66185134 chr7:66654538~66669855:+ CESC cis rs2882667 0.964 rs12108892 ENSG00000253404.1 AC034243.1 8.16 2.6e-14 1.08e-10 0.6 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:138963941 chr5:138744434~138753309:- CESC cis rs1930961 1 rs6004672 ENSG00000100058.11 CRYBB2P1 8.16 2.64e-14 1.1e-10 0.74 0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25448105~25520854:+ CESC cis rs801193 0.66 rs2659897 ENSG00000226824.5 RP4-756H11.3 8.16 2.69e-14 1.12e-10 0.6 0.48 Aortic root size; chr7:66722728 chr7:66654538~66669855:+ CESC cis rs526231 0.511 rs6881612 ENSG00000175749.11 EIF3KP1 8.16 2.7e-14 1.12e-10 0.53 0.48 Primary biliary cholangitis; chr5:103041309 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs58344084 ENSG00000175749.11 EIF3KP1 8.16 2.7e-14 1.12e-10 0.53 0.48 Primary biliary cholangitis; chr5:103042508 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs10434792 ENSG00000175749.11 EIF3KP1 8.16 2.7e-14 1.12e-10 0.53 0.48 Primary biliary cholangitis; chr5:103053898 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs10434793 ENSG00000175749.11 EIF3KP1 8.16 2.7e-14 1.12e-10 0.53 0.48 Primary biliary cholangitis; chr5:103054111 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs12109860 ENSG00000175749.11 EIF3KP1 8.16 2.7e-14 1.12e-10 0.53 0.48 Primary biliary cholangitis; chr5:103057408 chr5:103032376~103033031:+ CESC cis rs7208859 0.623 rs79607958 ENSG00000263531.1 RP13-753N3.1 8.16 2.73e-14 1.13e-10 1.05 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607530 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs75136574 ENSG00000263531.1 RP13-753N3.1 8.16 2.73e-14 1.13e-10 1.05 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607531 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs77544470 ENSG00000263531.1 RP13-753N3.1 8.16 2.73e-14 1.13e-10 1.05 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607532 chr17:30863921~30864940:- CESC cis rs1153858 0.895 rs12593402 ENSG00000259520.4 CTD-2651B20.3 -8.15 2.77e-14 1.14e-10 -0.63 -0.48 Homoarginine levels; chr15:45325194 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12593370 ENSG00000259520.4 CTD-2651B20.3 -8.15 2.77e-14 1.14e-10 -0.63 -0.48 Homoarginine levels; chr15:45325219 chr15:45251580~45279251:- CESC cis rs17711722 0.701 rs55773927 ENSG00000226824.5 RP4-756H11.3 -8.15 2.8e-14 1.16e-10 -0.62 -0.48 Calcium levels; chr7:65872915 chr7:66654538~66669855:+ CESC cis rs875971 0.522 rs4718286 ENSG00000226824.5 RP4-756H11.3 -8.15 2.84e-14 1.17e-10 -0.62 -0.48 Aortic root size; chr7:65827777 chr7:66654538~66669855:+ CESC cis rs17711722 0.585 rs6942660 ENSG00000226824.5 RP4-756H11.3 -8.15 2.84e-14 1.17e-10 -0.62 -0.48 Calcium levels; chr7:65837419 chr7:66654538~66669855:+ CESC cis rs977987 0.806 rs11644306 ENSG00000261783.1 RP11-252K23.2 -8.15 2.88e-14 1.19e-10 -0.58 -0.48 Dupuytren's disease; chr16:75456155 chr16:75379818~75381260:- CESC cis rs977987 0.741 rs10514393 ENSG00000261783.1 RP11-252K23.2 -8.15 2.88e-14 1.19e-10 -0.59 -0.48 Dupuytren's disease; chr16:75310578 chr16:75379818~75381260:- CESC cis rs11155671 0.53 rs9397420 ENSG00000231760.4 RP11-350J20.5 -8.15 2.88e-14 1.19e-10 -0.6 -0.48 Testicular germ cell tumor; chr6:149885645 chr6:149796151~149826294:- CESC cis rs977987 0.843 rs28558946 ENSG00000261783.1 RP11-252K23.2 -8.15 2.89e-14 1.19e-10 -0.58 -0.48 Dupuytren's disease; chr16:75455424 chr16:75379818~75381260:- CESC cis rs1799949 0.965 rs4793237 ENSG00000198496.9 NBR2 -8.14 2.93e-14 1.2e-10 -0.58 -0.48 Menopause (age at onset); chr17:43359227 chr17:43125610~43153671:+ CESC cis rs4423214 0.61 rs12793607 ENSG00000254682.1 RP11-660L16.2 -8.14 2.94e-14 1.21e-10 -0.57 -0.48 Vitamin D levels; chr11:71418270 chr11:71448674~71452157:+ CESC cis rs1153858 1 rs1346266 ENSG00000259520.4 CTD-2651B20.3 -8.14 2.94e-14 1.21e-10 -0.63 -0.48 Homoarginine levels; chr15:45402318 chr15:45251580~45279251:- CESC cis rs875971 0.54 rs1723268 ENSG00000226824.5 RP4-756H11.3 -8.14 2.96e-14 1.22e-10 -0.61 -0.48 Aortic root size; chr7:66008093 chr7:66654538~66669855:+ CESC cis rs12439619 0.846 rs28697264 ENSG00000278603.1 RP13-608F4.5 8.14 3e-14 1.23e-10 0.81 0.48 Intelligence (multi-trait analysis); chr15:82265559 chr15:82472203~82472426:+ CESC cis rs17711722 0.701 rs781143 ENSG00000226824.5 RP4-756H11.3 -8.14 3.03e-14 1.24e-10 -0.63 -0.48 Calcium levels; chr7:65974892 chr7:66654538~66669855:+ CESC cis rs1930961 1 rs997873 ENSG00000100058.11 CRYBB2P1 8.14 3.07e-14 1.26e-10 0.74 0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25448105~25520854:+ CESC cis rs916888 0.61 rs199436 ENSG00000214401.4 KANSL1-AS1 -8.14 3.08e-14 1.27e-10 -0.59 -0.48 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46193576~46196723:+ CESC cis rs1153858 1 rs1145081 ENSG00000259520.4 CTD-2651B20.3 -8.14 3.1e-14 1.27e-10 -0.63 -0.48 Homoarginine levels; chr15:45387469 chr15:45251580~45279251:- CESC cis rs1153858 0.943 rs1145079 ENSG00000259520.4 CTD-2651B20.3 -8.14 3.1e-14 1.27e-10 -0.63 -0.48 Homoarginine levels; chr15:45389563 chr15:45251580~45279251:- CESC cis rs1153858 0.832 rs1145078 ENSG00000259520.4 CTD-2651B20.3 -8.14 3.1e-14 1.27e-10 -0.63 -0.48 Homoarginine levels; chr15:45390079 chr15:45251580~45279251:- CESC cis rs2882667 0.931 rs1433009 ENSG00000253404.1 AC034243.1 8.13 3.11e-14 1.28e-10 0.56 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:138998095 chr5:138744434~138753309:- CESC cis rs150992 0.742 rs34495 ENSG00000248489.1 CTD-2007H13.3 8.13 3.12e-14 1.28e-10 0.55 0.48 Body mass index; chr5:98930103 chr5:98929171~98995013:+ CESC cis rs875971 0.895 rs3857684 ENSG00000226824.5 RP4-756H11.3 -8.13 3.15e-14 1.29e-10 -0.6 -0.48 Aortic root size; chr7:66473171 chr7:66654538~66669855:+ CESC cis rs2882667 1 rs10064201 ENSG00000253404.1 AC034243.1 8.13 3.2e-14 1.31e-10 0.6 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:138973716 chr5:138744434~138753309:- CESC cis rs6142102 0.602 rs2268086 ENSG00000276073.1 RP5-1125A11.7 8.13 3.22e-14 1.32e-10 0.42 0.48 Skin pigmentation; chr20:34060932 chr20:33985617~33988989:- CESC cis rs977987 0.806 rs35683383 ENSG00000261783.1 RP11-252K23.2 -8.12 3.33e-14 1.36e-10 -0.58 -0.48 Dupuytren's disease; chr16:75445379 chr16:75379818~75381260:- CESC cis rs12439619 0.846 rs7496227 ENSG00000278603.1 RP13-608F4.5 8.12 3.39e-14 1.39e-10 0.81 0.48 Intelligence (multi-trait analysis); chr15:82275241 chr15:82472203~82472426:+ CESC cis rs11155671 0.53 rs9383577 ENSG00000231760.4 RP11-350J20.5 8.12 3.4e-14 1.39e-10 0.6 0.48 Testicular germ cell tumor; chr6:149886059 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs9383914 ENSG00000231760.4 RP11-350J20.5 8.12 3.4e-14 1.39e-10 0.6 0.48 Testicular germ cell tumor; chr6:149886098 chr6:149796151~149826294:- CESC cis rs11155671 0.517 rs9397058 ENSG00000231760.4 RP11-350J20.5 8.12 3.4e-14 1.39e-10 0.6 0.48 Testicular germ cell tumor; chr6:149886113 chr6:149796151~149826294:- CESC cis rs11722779 0.903 rs13130741 ENSG00000246560.2 RP11-10L12.4 8.12 3.44e-14 1.41e-10 0.6 0.48 Schizophrenia; chr4:103035799 chr4:102828055~102844075:+ CESC cis rs7208859 0.623 rs7214570 ENSG00000263531.1 RP13-753N3.1 8.12 3.47e-14 1.42e-10 0.91 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30863921~30864940:- CESC cis rs26232 0.521 rs3776856 ENSG00000175749.11 EIF3KP1 8.12 3.49e-14 1.43e-10 0.54 0.48 Rheumatoid arthritis; chr5:103023102 chr5:103032376~103033031:+ CESC cis rs1930961 1 rs997872 ENSG00000100058.11 CRYBB2P1 8.12 3.5e-14 1.43e-10 0.75 0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25448105~25520854:+ CESC cis rs875971 1 rs6460296 ENSG00000226824.5 RP4-756H11.3 -8.12 3.52e-14 1.44e-10 -0.6 -0.48 Aortic root size; chr7:66430152 chr7:66654538~66669855:+ CESC cis rs875971 1 rs2042133 ENSG00000226824.5 RP4-756H11.3 -8.12 3.52e-14 1.44e-10 -0.6 -0.48 Aortic root size; chr7:66466935 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs2161065 ENSG00000226824.5 RP4-756H11.3 -8.12 3.52e-14 1.44e-10 -0.6 -0.48 Aortic root size; chr7:66467918 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs12698521 ENSG00000226824.5 RP4-756H11.3 -8.12 3.52e-14 1.44e-10 -0.6 -0.48 Aortic root size; chr7:66474502 chr7:66654538~66669855:+ CESC cis rs875971 1 rs11971949 ENSG00000226824.5 RP4-756H11.3 8.11 3.56e-14 1.45e-10 0.59 0.48 Aortic root size; chr7:66161027 chr7:66654538~66669855:+ CESC cis rs1153858 1 rs1145085 ENSG00000259520.4 CTD-2651B20.3 -8.11 3.56e-14 1.45e-10 -0.63 -0.48 Homoarginine levels; chr15:45365606 chr15:45251580~45279251:- CESC cis rs1153858 1 rs1288775 ENSG00000259520.4 CTD-2651B20.3 -8.11 3.56e-14 1.45e-10 -0.63 -0.48 Homoarginine levels; chr15:45369480 chr15:45251580~45279251:- CESC cis rs7208859 0.623 rs8081299 ENSG00000263531.1 RP13-753N3.1 8.11 3.56e-14 1.45e-10 0.95 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777278 chr17:30863921~30864940:- CESC cis rs1930961 1 rs5996946 ENSG00000100058.11 CRYBB2P1 8.11 3.58e-14 1.46e-10 0.72 0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25448105~25520854:+ CESC cis rs875971 0.965 rs28682868 ENSG00000226824.5 RP4-756H11.3 8.11 3.63e-14 1.48e-10 0.59 0.48 Aortic root size; chr7:66224822 chr7:66654538~66669855:+ CESC cis rs7044106 0.791 rs12554440 ENSG00000226752.6 PSMD5-AS1 -8.11 3.68e-14 1.5e-10 -0.54 -0.48 Hip circumference adjusted for BMI; chr9:120723055 chr9:120824828~120854385:+ CESC cis rs977987 0.762 rs1364079 ENSG00000261783.1 RP11-252K23.2 -8.11 3.69e-14 1.5e-10 -0.58 -0.48 Dupuytren's disease; chr16:75359233 chr16:75379818~75381260:- CESC cis rs10256972 0.706 rs4285396 ENSG00000229043.2 AC091729.9 -8.11 3.71e-14 1.51e-10 -0.53 -0.48 Endometriosis;Longevity; chr7:1084102 chr7:1160374~1165267:+ CESC cis rs150992 0.678 rs161950 ENSG00000248489.1 CTD-2007H13.3 -8.11 3.71e-14 1.51e-10 -0.55 -0.48 Body mass index; chr5:98924533 chr5:98929171~98995013:+ CESC cis rs2882667 0.898 rs11950819 ENSG00000253404.1 AC034243.1 8.1 3.76e-14 1.53e-10 0.56 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139061411 chr5:138744434~138753309:- CESC cis rs858239 0.614 rs10229956 ENSG00000230658.1 KLHL7-AS1 -8.1 3.76e-14 1.53e-10 -0.64 -0.48 Cerebrospinal fluid biomarker levels; chr7:23363317 chr7:23101228~23105703:- CESC cis rs17826219 0.706 rs2322197 ENSG00000263531.1 RP13-753N3.1 8.1 3.77e-14 1.53e-10 0.92 0.48 Body mass index; chr17:30778787 chr17:30863921~30864940:- CESC cis rs526231 0.511 rs17155009 ENSG00000175749.11 EIF3KP1 8.1 3.89e-14 1.58e-10 0.53 0.48 Primary biliary cholangitis; chr5:103038440 chr5:103032376~103033031:+ CESC cis rs26232 0.521 rs67019105 ENSG00000175749.11 EIF3KP1 8.1 3.89e-14 1.58e-10 0.53 0.48 Rheumatoid arthritis; chr5:103038459 chr5:103032376~103033031:+ CESC cis rs916888 0.61 rs199452 ENSG00000214401.4 KANSL1-AS1 8.1 3.96e-14 1.61e-10 0.58 0.48 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46193576~46196723:+ CESC cis rs11763147 1 rs11763147 ENSG00000226824.5 RP4-756H11.3 8.1 3.98e-14 1.61e-10 0.62 0.48 Corneal structure; chr7:65861834 chr7:66654538~66669855:+ CESC cis rs8062405 1 rs8062405 ENSG00000259982.1 CDC37P1 -8.1 4e-14 1.62e-10 -0.6 -0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826585 chr16:28700294~28701540:- CESC cis rs1153858 1 rs67831559 ENSG00000259520.4 CTD-2651B20.3 -8.09 4.03e-14 1.63e-10 -0.63 -0.48 Homoarginine levels; chr15:45357109 chr15:45251580~45279251:- CESC cis rs9326248 0.569 rs10892082 ENSG00000254851.1 RP11-109L13.1 -8.09 4.05e-14 1.64e-10 -0.87 -0.48 Blood protein levels; chr11:117168609 chr11:117135528~117138582:+ CESC cis rs875971 1 rs778710 ENSG00000226824.5 RP4-756H11.3 -8.09 4.15e-14 1.67e-10 -0.61 -0.48 Aortic root size; chr7:66389847 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs778708 ENSG00000226824.5 RP4-756H11.3 -8.09 4.15e-14 1.67e-10 -0.61 -0.48 Aortic root size; chr7:66391332 chr7:66654538~66669855:+ CESC cis rs875971 1 rs778696 ENSG00000226824.5 RP4-756H11.3 -8.09 4.15e-14 1.67e-10 -0.61 -0.48 Aortic root size; chr7:66405826 chr7:66654538~66669855:+ CESC cis rs875971 1 rs778694 ENSG00000226824.5 RP4-756H11.3 -8.09 4.15e-14 1.67e-10 -0.61 -0.48 Aortic root size; chr7:66406571 chr7:66654538~66669855:+ CESC cis rs875971 1 rs4718344 ENSG00000226824.5 RP4-756H11.3 -8.09 4.15e-14 1.67e-10 -0.61 -0.48 Aortic root size; chr7:66409394 chr7:66654538~66669855:+ CESC cis rs875971 0.737 rs7803424 ENSG00000226824.5 RP4-756H11.3 -8.09 4.15e-14 1.67e-10 -0.61 -0.48 Aortic root size; chr7:66415618 chr7:66654538~66669855:+ CESC cis rs875971 0.83 rs7799834 ENSG00000226824.5 RP4-756H11.3 -8.09 4.15e-14 1.67e-10 -0.61 -0.48 Aortic root size; chr7:66415707 chr7:66654538~66669855:+ CESC cis rs2882667 0.898 rs10079634 ENSG00000253404.1 AC034243.1 8.09 4.2e-14 1.69e-10 0.57 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139077364 chr5:138744434~138753309:- CESC cis rs1707322 0.721 rs10430124 ENSG00000280836.1 AL355480.1 -8.09 4.23e-14 1.71e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755945 chr1:45581219~45581321:- CESC cis rs1577917 0.785 rs1885607 ENSG00000203875.9 SNHG5 8.08 4.33e-14 1.74e-10 0.57 0.48 Response to antipsychotic treatment; chr6:85685187 chr6:85660950~85678736:- CESC cis rs9322193 0.923 rs2880436 ENSG00000231760.4 RP11-350J20.5 8.08 4.36e-14 1.76e-10 0.64 0.48 Lung cancer; chr6:149859123 chr6:149796151~149826294:- CESC cis rs2882667 0.858 rs10900856 ENSG00000253404.1 AC034243.1 -8.08 4.38e-14 1.76e-10 -0.61 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139082057 chr5:138744434~138753309:- CESC cis rs1707322 0.717 rs1547925 ENSG00000280836.1 AL355480.1 8.08 4.4e-14 1.77e-10 0.56 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619684 chr1:45581219~45581321:- CESC cis rs113835537 0.529 rs2305535 ENSG00000255517.5 CTD-3074O7.5 8.08 4.49e-14 1.8e-10 0.57 0.48 Airway imaging phenotypes; chr11:66504766 chr11:66473490~66480233:- CESC cis rs7301826 1 rs10744482 ENSG00000256250.1 RP11-989F5.1 -8.08 4.5e-14 1.81e-10 -0.53 -0.48 Plasma plasminogen activator levels; chr12:130813650 chr12:130810606~130812438:+ CESC cis rs7301826 0.966 rs4759795 ENSG00000256250.1 RP11-989F5.1 -8.08 4.5e-14 1.81e-10 -0.53 -0.48 Plasma plasminogen activator levels; chr12:130816355 chr12:130810606~130812438:+ CESC cis rs977987 0.815 rs11149818 ENSG00000261783.1 RP11-252K23.2 -8.08 4.5e-14 1.81e-10 -0.58 -0.48 Dupuytren's disease; chr16:75385475 chr16:75379818~75381260:- CESC cis rs875971 1 rs11974219 ENSG00000226824.5 RP4-756H11.3 8.08 4.52e-14 1.81e-10 0.59 0.48 Aortic root size; chr7:66182423 chr7:66654538~66669855:+ CESC cis rs1153858 1 rs11852800 ENSG00000259520.4 CTD-2651B20.3 8.07 4.56e-14 1.83e-10 0.63 0.48 Homoarginine levels; chr15:45346933 chr15:45251580~45279251:- CESC cis rs150992 0.861 rs151102 ENSG00000248489.1 CTD-2007H13.3 -8.07 4.63e-14 1.86e-10 -0.57 -0.48 Body mass index; chr5:98947626 chr5:98929171~98995013:+ CESC cis rs1153858 1 rs7402650 ENSG00000259520.4 CTD-2651B20.3 -8.07 4.66e-14 1.87e-10 -0.63 -0.48 Homoarginine levels; chr15:45409697 chr15:45251580~45279251:- CESC cis rs1153858 1 rs8042786 ENSG00000259520.4 CTD-2651B20.3 -8.07 4.66e-14 1.87e-10 -0.63 -0.48 Homoarginine levels; chr15:45411341 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12440038 ENSG00000259520.4 CTD-2651B20.3 -8.07 4.66e-14 1.87e-10 -0.63 -0.48 Homoarginine levels; chr15:45414541 chr15:45251580~45279251:- CESC cis rs1153858 1 rs60476496 ENSG00000259520.4 CTD-2651B20.3 -8.07 4.66e-14 1.87e-10 -0.63 -0.48 Homoarginine levels; chr15:45421603 chr15:45251580~45279251:- CESC cis rs977987 0.806 rs11864102 ENSG00000261783.1 RP11-252K23.2 -8.07 4.71e-14 1.89e-10 -0.59 -0.48 Dupuytren's disease; chr16:75408462 chr16:75379818~75381260:- CESC cis rs875971 0.929 rs778712 ENSG00000226824.5 RP4-756H11.3 -8.06 4.84e-14 1.94e-10 -0.61 -0.48 Aortic root size; chr7:66384991 chr7:66654538~66669855:+ CESC cis rs1577917 1 rs11758849 ENSG00000203875.9 SNHG5 -8.06 4.85e-14 1.94e-10 -0.57 -0.48 Response to antipsychotic treatment; chr6:85998544 chr6:85660950~85678736:- CESC cis rs526231 0.543 rs34767 ENSG00000175749.11 EIF3KP1 8.06 4.89e-14 1.96e-10 0.54 0.48 Primary biliary cholangitis; chr5:103153807 chr5:103032376~103033031:+ CESC cis rs1707322 0.752 rs10430105 ENSG00000280836.1 AL355480.1 -8.06 4.96e-14 1.98e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45673204 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs10890341 ENSG00000280836.1 AL355480.1 -8.06 4.96e-14 1.98e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45681568 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs11211161 ENSG00000280836.1 AL355480.1 -8.06 4.96e-14 1.98e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45682466 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs61784793 ENSG00000280836.1 AL355480.1 -8.06 4.96e-14 1.98e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45683613 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs4586014 ENSG00000280836.1 AL355480.1 -8.06 4.96e-14 1.98e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684771 chr1:45581219~45581321:- CESC cis rs1707322 0.648 rs4439382 ENSG00000280836.1 AL355480.1 -8.06 4.96e-14 1.98e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45685133 chr1:45581219~45581321:- CESC cis rs3096299 0.685 rs12935112 ENSG00000274627.1 RP11-104N10.2 -8.06 4.99e-14 1.99e-10 -0.46 -0.48 Multiple myeloma (IgH translocation); chr16:89476450 chr16:89516797~89522217:+ CESC cis rs1577917 0.71 rs1059306 ENSG00000203875.9 SNHG5 8.06 5e-14 2e-10 0.57 0.48 Response to antipsychotic treatment; chr6:85678391 chr6:85660950~85678736:- CESC cis rs875971 0.929 rs34406470 ENSG00000226824.5 RP4-756H11.3 -8.06 5.12e-14 2.04e-10 -0.61 -0.48 Aortic root size; chr7:66464969 chr7:66654538~66669855:+ CESC cis rs11155671 0.53 rs7757984 ENSG00000231760.4 RP11-350J20.5 8.06 5.14e-14 2.05e-10 0.59 0.48 Testicular germ cell tumor; chr6:149887515 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs1334510 ENSG00000231760.4 RP11-350J20.5 8.05 5.21e-14 2.08e-10 0.62 0.48 Testicular germ cell tumor; chr6:149880043 chr6:149796151~149826294:- CESC cis rs875971 0.964 rs778735 ENSG00000226824.5 RP4-756H11.3 -8.05 5.23e-14 2.08e-10 -0.6 -0.48 Aortic root size; chr7:66349822 chr7:66654538~66669855:+ CESC cis rs2882667 0.931 rs7706391 ENSG00000253404.1 AC034243.1 8.05 5.25e-14 2.09e-10 0.56 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139013475 chr5:138744434~138753309:- CESC cis rs977987 0.806 rs11640473 ENSG00000261783.1 RP11-252K23.2 -8.05 5.32e-14 2.12e-10 -0.59 -0.48 Dupuytren's disease; chr16:75369391 chr16:75379818~75381260:- CESC cis rs9326248 0.53 rs6589589 ENSG00000254851.1 RP11-109L13.1 -8.05 5.35e-14 2.13e-10 -0.86 -0.48 Blood protein levels; chr11:117061712 chr11:117135528~117138582:+ CESC cis rs1153858 1 rs9788780 ENSG00000259520.4 CTD-2651B20.3 -8.05 5.46e-14 2.17e-10 -0.63 -0.48 Homoarginine levels; chr15:45393289 chr15:45251580~45279251:- CESC cis rs1153858 1 rs7181167 ENSG00000259520.4 CTD-2651B20.3 -8.05 5.46e-14 2.17e-10 -0.63 -0.48 Homoarginine levels; chr15:45394038 chr15:45251580~45279251:- CESC cis rs1153858 1 rs11070456 ENSG00000259520.4 CTD-2651B20.3 -8.05 5.46e-14 2.17e-10 -0.63 -0.48 Homoarginine levels; chr15:45394637 chr15:45251580~45279251:- CESC cis rs1153858 1 rs11070457 ENSG00000259520.4 CTD-2651B20.3 -8.05 5.46e-14 2.17e-10 -0.63 -0.48 Homoarginine levels; chr15:45394745 chr15:45251580~45279251:- CESC cis rs1153858 1 rs3809472 ENSG00000259520.4 CTD-2651B20.3 -8.05 5.46e-14 2.17e-10 -0.63 -0.48 Homoarginine levels; chr15:45402120 chr15:45251580~45279251:- CESC cis rs1153858 1 rs1820518 ENSG00000259520.4 CTD-2651B20.3 -8.05 5.46e-14 2.17e-10 -0.63 -0.48 Homoarginine levels; chr15:45402381 chr15:45251580~45279251:- CESC cis rs1153858 1 rs1365610 ENSG00000259520.4 CTD-2651B20.3 -8.05 5.46e-14 2.17e-10 -0.63 -0.48 Homoarginine levels; chr15:45402412 chr15:45251580~45279251:- CESC cis rs1707322 0.752 rs8179402 ENSG00000280836.1 AL355480.1 -8.05 5.47e-14 2.17e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45676794 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs8179296 ENSG00000280836.1 AL355480.1 -8.05 5.47e-14 2.17e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45678119 chr1:45581219~45581321:- CESC cis rs7044106 0.537 rs10739573 ENSG00000226752.6 PSMD5-AS1 -8.04 5.52e-14 2.19e-10 -0.57 -0.48 Hip circumference adjusted for BMI; chr9:120727540 chr9:120824828~120854385:+ CESC cis rs7208859 0.673 rs3816780 ENSG00000263531.1 RP13-753N3.1 8.04 5.53e-14 2.19e-10 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834340 chr17:30863921~30864940:- CESC cis rs1153858 1 rs1554521 ENSG00000259520.4 CTD-2651B20.3 8.04 5.53e-14 2.19e-10 0.63 0.48 Homoarginine levels; chr15:45371991 chr15:45251580~45279251:- CESC cis rs977987 0.806 rs34021527 ENSG00000261783.1 RP11-252K23.2 -8.04 5.59e-14 2.22e-10 -0.59 -0.48 Dupuytren's disease; chr16:75440192 chr16:75379818~75381260:- CESC cis rs977987 0.751 rs56004344 ENSG00000261783.1 RP11-252K23.2 -8.04 5.59e-14 2.22e-10 -0.59 -0.48 Dupuytren's disease; chr16:75440291 chr16:75379818~75381260:- CESC cis rs875971 0.964 rs778723 ENSG00000226824.5 RP4-756H11.3 -8.04 5.65e-14 2.24e-10 -0.6 -0.48 Aortic root size; chr7:66364510 chr7:66654538~66669855:+ CESC cis rs977987 0.788 rs7184525 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75403288 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs12051326 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75403989 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs12443834 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75404571 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs12924920 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75406235 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4887824 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75407715 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888411 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75409285 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs4888412 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75409298 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs4888413 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75409325 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs8057849 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75409918 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs72787160 ENSG00000261783.1 RP11-252K23.2 -8.04 5.75e-14 2.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75411264 chr16:75379818~75381260:- CESC cis rs1153858 1 rs1890565 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45371101 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12594857 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45374980 chr15:45251580~45279251:- CESC cis rs1153858 1 rs66528868 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45376349 chr15:45251580~45279251:- CESC cis rs1153858 1 rs7494956 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45376367 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12437840 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45376857 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12437887 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45376896 chr15:45251580~45279251:- CESC cis rs1153858 1 rs2114501 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45378118 chr15:45251580~45279251:- CESC cis rs1153858 0.887 rs7164139 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45378653 chr15:45251580~45279251:- CESC cis rs1153858 1 rs7164602 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45379127 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12441971 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45379759 chr15:45251580~45279251:- CESC cis rs1153858 1 rs1346268 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45380831 chr15:45251580~45279251:- CESC cis rs1153858 1 rs67461176 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45384621 chr15:45251580~45279251:- CESC cis rs1153858 1 rs66939267 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45384704 chr15:45251580~45279251:- CESC cis rs1153858 0.943 rs67045941 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45384813 chr15:45251580~45279251:- CESC cis rs1153858 1 rs67744121 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45385039 chr15:45251580~45279251:- CESC cis rs1153858 1 rs16942568 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45385192 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4775937 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45386416 chr15:45251580~45279251:- CESC cis rs1153858 0.943 rs11070454 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45388054 chr15:45251580~45279251:- CESC cis rs1153858 0.943 rs12439575 ENSG00000259520.4 CTD-2651B20.3 -8.04 5.79e-14 2.28e-10 -0.63 -0.48 Homoarginine levels; chr15:45392618 chr15:45251580~45279251:- CESC cis rs977987 0.843 rs17696749 ENSG00000261783.1 RP11-252K23.2 -8.03 5.88e-14 2.32e-10 -0.58 -0.48 Dupuytren's disease; chr16:75369164 chr16:75379818~75381260:- CESC cis rs977987 0.835 rs4888379 ENSG00000261783.1 RP11-252K23.2 -8.03 6.03e-14 2.37e-10 -0.58 -0.48 Dupuytren's disease; chr16:75306333 chr16:75379818~75381260:- CESC cis rs1153858 1 rs12439274 ENSG00000259520.4 CTD-2651B20.3 -8.03 6.1e-14 2.4e-10 -0.61 -0.48 Homoarginine levels; chr15:45344469 chr15:45251580~45279251:- CESC cis rs875971 0.895 rs4718349 ENSG00000226824.5 RP4-756H11.3 -8.03 6.11e-14 2.4e-10 -0.6 -0.48 Aortic root size; chr7:66444024 chr7:66654538~66669855:+ CESC cis rs977987 0.736 rs11865296 ENSG00000261783.1 RP11-252K23.2 -8.03 6.15e-14 2.42e-10 -0.59 -0.48 Dupuytren's disease; chr16:75439795 chr16:75379818~75381260:- CESC cis rs875971 0.516 rs6945322 ENSG00000226824.5 RP4-756H11.3 -8.03 6.22e-14 2.44e-10 -0.62 -0.48 Aortic root size; chr7:65871069 chr7:66654538~66669855:+ CESC cis rs977987 0.836 rs7200053 ENSG00000261783.1 RP11-252K23.2 -8.02 6.23e-14 2.45e-10 -0.59 -0.48 Dupuytren's disease; chr16:75440720 chr16:75379818~75381260:- CESC cis rs17711722 0.565 rs4717276 ENSG00000164669.11 INTS4P1 -8.02 6.26e-14 2.46e-10 -0.63 -0.48 Calcium levels; chr7:65829754 chr7:65141225~65234216:+ CESC cis rs875971 1 rs55962648 ENSG00000226824.5 RP4-756H11.3 8.02 6.28e-14 2.46e-10 0.59 0.48 Aortic root size; chr7:66160764 chr7:66654538~66669855:+ CESC cis rs875971 1 rs2420168 ENSG00000226824.5 RP4-756H11.3 8.02 6.28e-14 2.46e-10 0.59 0.48 Aortic root size; chr7:66165644 chr7:66654538~66669855:+ CESC cis rs875971 1 rs1565531 ENSG00000226824.5 RP4-756H11.3 8.02 6.28e-14 2.46e-10 0.59 0.48 Aortic root size; chr7:66198126 chr7:66654538~66669855:+ CESC cis rs875971 0.522 rs4718285 ENSG00000226824.5 RP4-756H11.3 -8.02 6.29e-14 2.46e-10 -0.62 -0.48 Aortic root size; chr7:65827018 chr7:66654538~66669855:+ CESC cis rs875971 0.522 rs4502988 ENSG00000226824.5 RP4-756H11.3 -8.02 6.29e-14 2.46e-10 -0.62 -0.48 Aortic root size; chr7:65832759 chr7:66654538~66669855:+ CESC cis rs17711722 0.64 rs13237956 ENSG00000226824.5 RP4-756H11.3 -8.02 6.29e-14 2.46e-10 -0.62 -0.48 Calcium levels; chr7:65853042 chr7:66654538~66669855:+ CESC cis rs526231 0.543 rs26523 ENSG00000175749.11 EIF3KP1 8.02 6.29e-14 2.46e-10 0.55 0.48 Primary biliary cholangitis; chr5:103120550 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34783 ENSG00000175749.11 EIF3KP1 8.02 6.29e-14 2.46e-10 0.55 0.48 Primary biliary cholangitis; chr5:103121337 chr5:103032376~103033031:+ CESC cis rs526231 0.512 rs28022 ENSG00000175749.11 EIF3KP1 8.02 6.29e-14 2.46e-10 0.55 0.48 Primary biliary cholangitis; chr5:103128663 chr5:103032376~103033031:+ CESC cis rs227275 0.525 rs17215211 ENSG00000246560.2 RP11-10L12.4 8.02 6.43e-14 2.51e-10 0.58 0.48 Allergic disease (asthma, hay fever or eczema); chr4:103025961 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs1080081 ENSG00000246560.2 RP11-10L12.4 8.02 6.43e-14 2.51e-10 0.58 0.48 Allergic disease (asthma, hay fever or eczema); chr4:103029268 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs4699049 ENSG00000246560.2 RP11-10L12.4 8.02 6.43e-14 2.51e-10 0.58 0.48 Allergic disease (asthma, hay fever or eczema); chr4:103030467 chr4:102828055~102844075:+ CESC cis rs1707322 0.752 rs28550303 ENSG00000280836.1 AL355480.1 -8.02 6.48e-14 2.53e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723242 chr1:45581219~45581321:- CESC cis rs875971 1 rs1981798 ENSG00000226824.5 RP4-756H11.3 -8.02 6.49e-14 2.54e-10 -0.61 -0.48 Aortic root size; chr7:66489916 chr7:66654538~66669855:+ CESC cis rs2882667 0.931 rs13153618 ENSG00000253404.1 AC034243.1 8.02 6.49e-14 2.54e-10 0.56 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139017087 chr5:138744434~138753309:- CESC cis rs7301826 1 rs4619189 ENSG00000256250.1 RP11-989F5.1 -8.02 6.55e-14 2.56e-10 -0.53 -0.48 Plasma plasminogen activator levels; chr12:130829252 chr12:130810606~130812438:+ CESC cis rs1799949 0.965 rs799910 ENSG00000198496.9 NBR2 -8.02 6.57e-14 2.56e-10 -0.56 -0.48 Menopause (age at onset); chr17:43127544 chr17:43125610~43153671:+ CESC cis rs875971 0.522 rs1617484 ENSG00000226824.5 RP4-756H11.3 -8.01 6.64e-14 2.59e-10 -0.62 -0.48 Aortic root size; chr7:65998108 chr7:66654538~66669855:+ CESC cis rs200367988 1 rs200367988 ENSG00000271670.1 RP11-95I16.4 -8.01 6.71e-14 2.62e-10 -0.46 -0.48 Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels; chr10:120915337 chr10:120879256~120880667:- CESC cis rs1153858 1 rs12595087 ENSG00000259520.4 CTD-2651B20.3 -8.01 6.73e-14 2.62e-10 -0.63 -0.48 Homoarginine levels; chr15:45363034 chr15:45251580~45279251:- CESC cis rs1153858 1 rs3759899 ENSG00000259520.4 CTD-2651B20.3 -8.01 6.73e-14 2.62e-10 -0.63 -0.48 Homoarginine levels; chr15:45363705 chr15:45251580~45279251:- CESC cis rs526231 0.511 rs73179850 ENSG00000175749.11 EIF3KP1 8.01 6.75e-14 2.63e-10 0.53 0.48 Primary biliary cholangitis; chr5:103012873 chr5:103032376~103033031:+ CESC cis rs875971 0.964 rs60193905 ENSG00000226824.5 RP4-756H11.3 -8.01 6.89e-14 2.68e-10 -0.6 -0.48 Aortic root size; chr7:66506273 chr7:66654538~66669855:+ CESC cis rs1799949 1 rs8077486 ENSG00000198496.9 NBR2 -8.01 6.95e-14 2.71e-10 -0.58 -0.48 Menopause (age at onset); chr17:43060788 chr17:43125610~43153671:+ CESC cis rs2882667 0.898 rs10045761 ENSG00000253404.1 AC034243.1 8.01 6.97e-14 2.71e-10 0.56 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139061600 chr5:138744434~138753309:- CESC cis rs9545047 0.904 rs2760105 ENSG00000227676.3 LINC01068 8.01 6.99e-14 2.72e-10 0.56 0.48 Schizophrenia; chr13:79535732 chr13:79566727~79571436:+ CESC cis rs2882667 0.861 rs10043676 ENSG00000253404.1 AC034243.1 8 7.07e-14 2.75e-10 0.55 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139053872 chr5:138744434~138753309:- CESC cis rs2882667 0.898 rs10038121 ENSG00000253404.1 AC034243.1 8 7.07e-14 2.75e-10 0.55 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139053913 chr5:138744434~138753309:- CESC cis rs2882667 0.861 rs10075541 ENSG00000253404.1 AC034243.1 8 7.07e-14 2.75e-10 0.55 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139054629 chr5:138744434~138753309:- CESC cis rs8062405 1 rs3888190 ENSG00000259982.1 CDC37P1 8 7.07e-14 2.75e-10 0.59 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878165 chr16:28700294~28701540:- CESC cis rs875971 1 rs6961717 ENSG00000226824.5 RP4-756H11.3 8 7.08e-14 2.75e-10 0.59 0.48 Aortic root size; chr7:66122550 chr7:66654538~66669855:+ CESC cis rs1707322 0.721 rs11211165 ENSG00000280836.1 AL355480.1 -8 7.23e-14 2.81e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692234 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs11211166 ENSG00000280836.1 AL355480.1 -8 7.23e-14 2.81e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692270 chr1:45581219~45581321:- CESC cis rs9326248 0.53 rs2155583 ENSG00000254851.1 RP11-109L13.1 -8 7.46e-14 2.89e-10 -0.86 -0.48 Blood protein levels; chr11:117044501 chr11:117135528~117138582:+ CESC cis rs9326248 0.53 rs2000615 ENSG00000254851.1 RP11-109L13.1 -8 7.46e-14 2.89e-10 -0.86 -0.48 Blood protein levels; chr11:117045103 chr11:117135528~117138582:+ CESC cis rs875971 1 rs2087647 ENSG00000226824.5 RP4-756H11.3 7.99 7.55e-14 2.93e-10 0.59 0.48 Aortic root size; chr7:66128201 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6958484 ENSG00000226824.5 RP4-756H11.3 7.99 7.55e-14 2.93e-10 0.59 0.48 Aortic root size; chr7:66134459 chr7:66654538~66669855:+ CESC cis rs526231 0.543 rs152123 ENSG00000175749.11 EIF3KP1 -7.99 7.59e-14 2.94e-10 -0.56 -0.48 Primary biliary cholangitis; chr5:103196218 chr5:103032376~103033031:+ CESC cis rs1707322 0.647 rs6686944 ENSG00000280836.1 AL355480.1 -7.99 7.63e-14 2.96e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690636 chr1:45581219~45581321:- CESC cis rs801193 0.66 rs2659914 ENSG00000226824.5 RP4-756H11.3 -7.99 7.67e-14 2.97e-10 -0.59 -0.48 Aortic root size; chr7:66691927 chr7:66654538~66669855:+ CESC cis rs7617773 0.817 rs6796490 ENSG00000229759.1 MRPS18AP1 7.99 7.75e-14 3e-10 0.47 0.48 Coronary artery disease; chr3:48195614 chr3:48256350~48256938:- CESC cis rs977987 0.835 rs3863445 ENSG00000261783.1 RP11-252K23.2 -7.99 7.84e-14 3.03e-10 -0.59 -0.48 Dupuytren's disease; chr16:75337846 chr16:75379818~75381260:- CESC cis rs875971 1 rs12533997 ENSG00000226824.5 RP4-756H11.3 -7.99 7.91e-14 3.06e-10 -0.6 -0.48 Aortic root size; chr7:66500390 chr7:66654538~66669855:+ CESC cis rs875971 0.929 rs10950041 ENSG00000226824.5 RP4-756H11.3 -7.99 7.91e-14 3.06e-10 -0.6 -0.48 Aortic root size; chr7:66508888 chr7:66654538~66669855:+ CESC cis rs1153858 1 rs2467863 ENSG00000259520.4 CTD-2651B20.3 -7.98 8.04e-14 3.11e-10 -0.63 -0.48 Homoarginine levels; chr15:45349682 chr15:45251580~45279251:- CESC cis rs2882667 0.931 rs10074461 ENSG00000253404.1 AC034243.1 7.98 8.07e-14 3.12e-10 0.54 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:138984126 chr5:138744434~138753309:- CESC cis rs977987 0.806 rs12599361 ENSG00000261783.1 RP11-252K23.2 -7.98 8.09e-14 3.12e-10 -0.59 -0.48 Dupuytren's disease; chr16:75401075 chr16:75379818~75381260:- CESC cis rs977987 0.835 rs7200616 ENSG00000261783.1 RP11-252K23.2 -7.98 8.1e-14 3.13e-10 -0.59 -0.48 Dupuytren's disease; chr16:75332191 chr16:75379818~75381260:- CESC cis rs977987 0.835 rs4888380 ENSG00000261783.1 RP11-252K23.2 -7.98 8.21e-14 3.17e-10 -0.59 -0.48 Dupuytren's disease; chr16:75313792 chr16:75379818~75381260:- CESC cis rs977987 0.835 rs8057535 ENSG00000261783.1 RP11-252K23.2 -7.98 8.21e-14 3.17e-10 -0.59 -0.48 Dupuytren's disease; chr16:75314043 chr16:75379818~75381260:- CESC cis rs977987 0.8 rs12922951 ENSG00000261783.1 RP11-252K23.2 -7.98 8.21e-14 3.17e-10 -0.59 -0.48 Dupuytren's disease; chr16:75321198 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4887818 ENSG00000261783.1 RP11-252K23.2 -7.98 8.21e-14 3.17e-10 -0.59 -0.48 Dupuytren's disease; chr16:75328097 chr16:75379818~75381260:- CESC cis rs7044106 0.791 rs10760116 ENSG00000226752.6 PSMD5-AS1 -7.98 8.23e-14 3.18e-10 -0.51 -0.48 Hip circumference adjusted for BMI; chr9:120732403 chr9:120824828~120854385:+ CESC cis rs17711722 1 rs17711722 ENSG00000226824.5 RP4-756H11.3 7.98 8.25e-14 3.18e-10 0.62 0.48 Calcium levels; chr7:65806210 chr7:66654538~66669855:+ CESC cis rs17711722 0.675 rs6947132 ENSG00000226824.5 RP4-756H11.3 7.98 8.25e-14 3.18e-10 0.62 0.48 Calcium levels; chr7:65808508 chr7:66654538~66669855:+ CESC cis rs1153858 1 rs1049508 ENSG00000259520.4 CTD-2651B20.3 -7.98 8.29e-14 3.2e-10 -0.62 -0.48 Homoarginine levels; chr15:45361394 chr15:45251580~45279251:- CESC cis rs1153858 1 rs1613559 ENSG00000259520.4 CTD-2651B20.3 -7.98 8.32e-14 3.21e-10 -0.62 -0.48 Homoarginine levels; chr15:45329918 chr15:45251580~45279251:- CESC cis rs1153858 1 rs1618874 ENSG00000259520.4 CTD-2651B20.3 -7.98 8.32e-14 3.21e-10 -0.62 -0.48 Homoarginine levels; chr15:45330588 chr15:45251580~45279251:- CESC cis rs977987 0.843 rs10871312 ENSG00000261783.1 RP11-252K23.2 -7.98 8.36e-14 3.22e-10 -0.58 -0.48 Dupuytren's disease; chr16:75452304 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs12051136 ENSG00000261783.1 RP11-252K23.2 -7.98 8.43e-14 3.24e-10 -0.58 -0.48 Dupuytren's disease; chr16:75401833 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs4888409 ENSG00000261783.1 RP11-252K23.2 -7.98 8.43e-14 3.24e-10 -0.58 -0.48 Dupuytren's disease; chr16:75402333 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs7206541 ENSG00000261783.1 RP11-252K23.2 -7.98 8.43e-14 3.24e-10 -0.58 -0.48 Dupuytren's disease; chr16:75402815 chr16:75379818~75381260:- CESC cis rs8062405 1 rs4788095 ENSG00000259982.1 CDC37P1 7.98 8.44e-14 3.24e-10 0.59 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28820038 chr16:28700294~28701540:- CESC cis rs8062405 0.964 rs72793809 ENSG00000259982.1 CDC37P1 7.98 8.44e-14 3.24e-10 0.59 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821061 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62036620 ENSG00000259982.1 CDC37P1 7.98 8.44e-14 3.24e-10 0.59 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821776 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62036621 ENSG00000259982.1 CDC37P1 7.98 8.44e-14 3.24e-10 0.59 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821978 chr16:28700294~28701540:- CESC cis rs8062405 1 rs4451951 ENSG00000259982.1 CDC37P1 7.98 8.44e-14 3.24e-10 0.59 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28824884 chr16:28700294~28701540:- CESC cis rs1707322 0.752 rs6678444 ENSG00000280836.1 AL355480.1 -7.98 8.47e-14 3.26e-10 -0.56 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764175 chr1:45581219~45581321:- CESC cis rs7174755 0.923 rs4777036 ENSG00000260657.2 RP11-315D16.4 -7.98 8.48e-14 3.26e-10 -0.58 -0.48 Major depressive disorder; chr15:68313230 chr15:68267792~68277994:- CESC cis rs9326248 0.53 rs2000614 ENSG00000254851.1 RP11-109L13.1 -7.98 8.5e-14 3.27e-10 -0.84 -0.48 Blood protein levels; chr11:117045026 chr11:117135528~117138582:+ CESC cis rs9326248 0.53 rs2000616 ENSG00000254851.1 RP11-109L13.1 -7.98 8.5e-14 3.27e-10 -0.84 -0.48 Blood protein levels; chr11:117045813 chr11:117135528~117138582:+ CESC cis rs9326248 0.53 rs10750100 ENSG00000254851.1 RP11-109L13.1 -7.98 8.5e-14 3.27e-10 -0.84 -0.48 Blood protein levels; chr11:117046528 chr11:117135528~117138582:+ CESC cis rs977987 0.836 rs7199062 ENSG00000261783.1 RP11-252K23.2 -7.97 8.53e-14 3.28e-10 -0.57 -0.48 Dupuytren's disease; chr16:75440929 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs10431974 ENSG00000261783.1 RP11-252K23.2 -7.97 8.55e-14 3.28e-10 -0.59 -0.48 Dupuytren's disease; chr16:75401563 chr16:75379818~75381260:- CESC cis rs1707322 0.65 rs4553239 ENSG00000280836.1 AL355480.1 -7.97 8.56e-14 3.29e-10 -0.57 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684814 chr1:45581219~45581321:- CESC cis rs875971 0.83 rs4718358 ENSG00000226824.5 RP4-756H11.3 -7.97 8.57e-14 3.29e-10 -0.6 -0.48 Aortic root size; chr7:66508681 chr7:66654538~66669855:+ CESC cis rs11155671 0.53 rs7768626 ENSG00000231760.4 RP11-350J20.5 7.97 8.59e-14 3.29e-10 0.59 0.48 Testicular germ cell tumor; chr6:149886826 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs7768665 ENSG00000231760.4 RP11-350J20.5 7.97 8.59e-14 3.29e-10 0.59 0.48 Testicular germ cell tumor; chr6:149886888 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs7758020 ENSG00000231760.4 RP11-350J20.5 7.97 8.59e-14 3.29e-10 0.59 0.48 Testicular germ cell tumor; chr6:149886975 chr6:149796151~149826294:- CESC cis rs875971 1 rs6979382 ENSG00000226824.5 RP4-756H11.3 -7.97 8.62e-14 3.3e-10 -0.6 -0.48 Aortic root size; chr7:66421388 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6961990 ENSG00000226824.5 RP4-756H11.3 -7.97 8.62e-14 3.3e-10 -0.6 -0.48 Aortic root size; chr7:66423583 chr7:66654538~66669855:+ CESC cis rs7301826 0.934 rs10848212 ENSG00000256250.1 RP11-989F5.1 7.97 8.73e-14 3.34e-10 0.53 0.48 Plasma plasminogen activator levels; chr12:130837455 chr12:130810606~130812438:+ CESC cis rs1707322 0.686 rs1547924 ENSG00000280836.1 AL355480.1 -7.97 8.8e-14 3.37e-10 -0.56 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619440 chr1:45581219~45581321:- CESC cis rs977987 0.806 rs766521 ENSG00000261783.1 RP11-252K23.2 7.97 8.88e-14 3.4e-10 0.57 0.47 Dupuytren's disease; chr16:75390256 chr16:75379818~75381260:- CESC cis rs11155671 0.53 rs9322228 ENSG00000231760.4 RP11-350J20.5 7.97 8.99e-14 3.44e-10 0.59 0.47 Testicular germ cell tumor; chr6:149888173 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs7774787 ENSG00000231760.4 RP11-350J20.5 7.97 8.99e-14 3.44e-10 0.59 0.47 Testicular germ cell tumor; chr6:149888296 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs2342767 ENSG00000231760.4 RP11-350J20.5 7.97 8.99e-14 3.44e-10 0.59 0.47 Testicular germ cell tumor; chr6:149888581 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs7764376 ENSG00000231760.4 RP11-350J20.5 7.97 8.99e-14 3.44e-10 0.59 0.47 Testicular germ cell tumor; chr6:149889208 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs6933882 ENSG00000231760.4 RP11-350J20.5 7.97 8.99e-14 3.44e-10 0.59 0.47 Testicular germ cell tumor; chr6:149889666 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs6939761 ENSG00000231760.4 RP11-350J20.5 7.97 8.99e-14 3.44e-10 0.59 0.47 Testicular germ cell tumor; chr6:149889858 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs3823021 ENSG00000231760.4 RP11-350J20.5 7.97 8.99e-14 3.44e-10 0.59 0.47 Testicular germ cell tumor; chr6:149889863 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs4869764 ENSG00000231760.4 RP11-350J20.5 7.97 8.99e-14 3.44e-10 0.59 0.47 Testicular germ cell tumor; chr6:149890692 chr6:149796151~149826294:- CESC cis rs1577917 0.958 rs7747897 ENSG00000203875.9 SNHG5 -7.97 9.01e-14 3.44e-10 -0.59 -0.47 Response to antipsychotic treatment; chr6:85937631 chr6:85660950~85678736:- CESC cis rs7617773 0.817 rs3731555 ENSG00000229759.1 MRPS18AP1 7.97 9.01e-14 3.44e-10 0.53 0.47 Coronary artery disease; chr3:48164612 chr3:48256350~48256938:- CESC cis rs10256972 0.591 rs11766651 ENSG00000229043.2 AC091729.9 -7.97 9.02e-14 3.45e-10 -0.54 -0.47 Endometriosis;Longevity; chr7:1122010 chr7:1160374~1165267:+ CESC cis rs1707322 0.752 rs11211152 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648485 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs4607935 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651489 chr1:45581219~45581321:- CESC cis rs1707322 0.681 rs12048866 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651820 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs3811436 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660208 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs12024590 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45661824 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs12027622 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664580 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs4415615 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45666437 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs7529699 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668962 chr1:45581219~45581321:- CESC cis rs1707322 0.716 rs6699444 ENSG00000280836.1 AL355480.1 -7.96 9.09e-14 3.47e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669448 chr1:45581219~45581321:- CESC cis rs17711722 0.701 rs4467826 ENSG00000226824.5 RP4-756H11.3 -7.96 9.11e-14 3.47e-10 -0.61 -0.47 Calcium levels; chr7:65903721 chr7:66654538~66669855:+ CESC cis rs977987 0.815 rs11646677 ENSG00000261783.1 RP11-252K23.2 -7.96 9.16e-14 3.49e-10 -0.58 -0.47 Dupuytren's disease; chr16:75375083 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs8056080 ENSG00000261783.1 RP11-252K23.2 -7.96 9.16e-14 3.49e-10 -0.58 -0.47 Dupuytren's disease; chr16:75376900 chr16:75379818~75381260:- CESC cis rs526231 0.543 rs34779 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103117064 chr5:103032376~103033031:+ CESC cis rs526231 0.547 rs34780 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103117853 chr5:103032376~103033031:+ CESC cis rs10463554 0.759 rs34781 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Parkinson's disease; chr5:103118735 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34784 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103121626 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34785 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103122399 chr5:103032376~103033031:+ CESC cis rs526231 0.578 rs34786 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103122409 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34787 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103123199 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34789 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103125035 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34791 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103126400 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs26525 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103129219 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs32851 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103132967 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs32849 ENSG00000175749.11 EIF3KP1 7.96 9.19e-14 3.49e-10 0.55 0.47 Primary biliary cholangitis; chr5:103134339 chr5:103032376~103033031:+ CESC cis rs875971 0.522 rs1917563 ENSG00000226824.5 RP4-756H11.3 7.96 9.27e-14 3.52e-10 0.6 0.47 Aortic root size; chr7:65950660 chr7:66654538~66669855:+ CESC cis rs1707322 0.716 rs10890342 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45691415 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs6658700 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45694588 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs12047629 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697130 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs11211169 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701037 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs11211171 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45702970 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs28623463 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45705086 chr1:45581219~45581321:- CESC cis rs1707322 0.716 rs28370457 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706390 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs28890893 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720904 chr1:45581219~45581321:- CESC cis rs1707322 0.716 rs28375469 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45729703 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs28545085 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736278 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs28812624 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45738064 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs28507722 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45740868 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs28568986 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45742071 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs28396194 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747555 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs28752166 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747637 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs10890345 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45748255 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs10789471 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45749947 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs11211173 ENSG00000280836.1 AL355480.1 -7.96 9.37e-14 3.55e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45753704 chr1:45581219~45581321:- CESC cis rs1707322 0.691 rs61784799 ENSG00000280836.1 AL355480.1 7.96 9.37e-14 3.55e-10 0.57 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712076 chr1:45581219~45581321:- CESC cis rs875971 1 rs6963646 ENSG00000226824.5 RP4-756H11.3 7.96 9.4e-14 3.56e-10 0.58 0.47 Aortic root size; chr7:66220780 chr7:66654538~66669855:+ CESC cis rs1707322 0.721 rs4660314 ENSG00000280836.1 AL355480.1 -7.96 9.43e-14 3.56e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764213 chr1:45581219~45581321:- CESC cis rs8062405 0.964 rs78613234 ENSG00000259982.1 CDC37P1 7.96 9.47e-14 3.58e-10 0.59 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828104 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62036624 ENSG00000259982.1 CDC37P1 7.96 9.47e-14 3.58e-10 0.59 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828609 chr16:28700294~28701540:- CESC cis rs1577917 1 rs1999852 ENSG00000203875.9 SNHG5 -7.96 9.53e-14 3.6e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85996020 chr6:85660950~85678736:- CESC cis rs1577917 1 rs35797755 ENSG00000203875.9 SNHG5 -7.96 9.53e-14 3.6e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85996836 chr6:85660950~85678736:- CESC cis rs12022452 0.591 rs11208315 ENSG00000238287.1 RP11-656D10.3 -7.95 9.68e-14 3.66e-10 -0.67 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40519730 chr1:40493157~40508661:- CESC cis rs977987 0.843 rs2059256 ENSG00000261783.1 RP11-252K23.2 -7.95 9.69e-14 3.66e-10 -0.58 -0.47 Dupuytren's disease; chr16:75361937 chr16:75379818~75381260:- CESC cis rs916888 0.61 rs199442 ENSG00000214401.4 KANSL1-AS1 7.95 9.74e-14 3.67e-10 0.57 0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46193576~46196723:+ CESC cis rs2882667 0.931 rs10075893 ENSG00000253404.1 AC034243.1 -7.95 9.79e-14 3.69e-10 -0.56 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139020182 chr5:138744434~138753309:- CESC cis rs1707322 0.752 rs28719889 ENSG00000280836.1 AL355480.1 -7.95 9.88e-14 3.73e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736611 chr1:45581219~45581321:- CESC cis rs12022452 0.591 rs61781641 ENSG00000238287.1 RP11-656D10.3 -7.95 9.91e-14 3.73e-10 -0.67 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40517412 chr1:40493157~40508661:- CESC cis rs12022452 0.591 rs12049435 ENSG00000238287.1 RP11-656D10.3 -7.95 9.91e-14 3.73e-10 -0.67 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40524888 chr1:40493157~40508661:- CESC cis rs1577917 0.958 rs11755048 ENSG00000203875.9 SNHG5 -7.95 1e-13 3.76e-10 -0.63 -0.47 Response to antipsychotic treatment; chr6:85804616 chr6:85660950~85678736:- CESC cis rs1707322 0.721 rs4559551 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701861 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs12045096 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648756 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs4609469 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651513 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs12049027 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45652512 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs10789467 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45653073 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs10890337 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658855 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs3811435 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660118 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs9793568 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664701 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs11211157 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667172 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs11211158 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667178 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs6429575 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668544 chr1:45581219~45581321:- CESC cis rs1707322 0.685 rs6690926 ENSG00000280836.1 AL355480.1 -7.95 1.01e-13 3.79e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669306 chr1:45581219~45581321:- CESC cis rs7044106 0.537 rs4434680 ENSG00000226752.6 PSMD5-AS1 -7.94 1.03e-13 3.87e-10 -0.57 -0.47 Hip circumference adjusted for BMI; chr9:120727410 chr9:120824828~120854385:+ CESC cis rs2882667 0.861 rs13176902 ENSG00000253404.1 AC034243.1 7.94 1.03e-13 3.87e-10 0.55 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139057640 chr5:138744434~138753309:- CESC cis rs977987 0.815 rs1364078 ENSG00000261783.1 RP11-252K23.2 -7.94 1.04e-13 3.88e-10 -0.58 -0.47 Dupuytren's disease; chr16:75362983 chr16:75379818~75381260:- CESC cis rs1707322 0.691 rs61784803 ENSG00000280836.1 AL355480.1 7.94 1.04e-13 3.88e-10 0.57 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45713599 chr1:45581219~45581321:- CESC cis rs1707322 0.663 rs3935296 ENSG00000280836.1 AL355480.1 7.94 1.04e-13 3.88e-10 0.57 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45714798 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs11211163 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45687876 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs12037803 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690820 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs10789470 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692659 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs61784796 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697584 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs10749856 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45699174 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs10890344 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45700418 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs4564187 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701189 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs28438704 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45704872 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs28442079 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706329 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs28817701 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720378 chr1:45581219~45581321:- CESC cis rs1707322 0.691 rs28495425 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45721648 chr1:45581219~45581321:- CESC cis rs1707322 0.685 rs28617418 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723854 chr1:45581219~45581321:- CESC cis rs1707322 0.682 rs28490344 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45732276 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs28501477 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45733412 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs28641748 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747164 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs6697821 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751050 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs4330955 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751813 chr1:45581219~45581321:- CESC cis rs1707322 0.691 rs11211174 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755144 chr1:45581219~45581321:- CESC cis rs1707322 0.691 rs12031182 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755327 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs10430123 ENSG00000280836.1 AL355480.1 -7.94 1.04e-13 3.88e-10 -0.57 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755768 chr1:45581219~45581321:- CESC cis rs1153858 1 rs11858495 ENSG00000259520.4 CTD-2651B20.3 7.94 1.05e-13 3.9e-10 0.62 0.47 Homoarginine levels; chr15:45345464 chr15:45251580~45279251:- CESC cis rs8062405 1 rs1987472 ENSG00000259982.1 CDC37P1 7.94 1.05e-13 3.9e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814456 chr16:28700294~28701540:- CESC cis rs8062405 0.895 rs56186137 ENSG00000259982.1 CDC37P1 7.94 1.05e-13 3.9e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814632 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62036617 ENSG00000259982.1 CDC37P1 7.94 1.05e-13 3.9e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28816177 chr16:28700294~28701540:- CESC cis rs17711722 0.522 rs6957759 ENSG00000164669.11 INTS4P1 -7.94 1.07e-13 3.97e-10 -0.6 -0.47 Calcium levels; chr7:65806798 chr7:65141225~65234216:+ CESC cis rs1815787 1 rs1815787 ENSG00000254851.1 RP11-109L13.1 -7.94 1.08e-13 4.02e-10 -0.84 -0.47 Subjective well-being; chr11:117050681 chr11:117135528~117138582:+ CESC cis rs977987 0.843 rs4146810 ENSG00000261783.1 RP11-252K23.2 -7.94 1.08e-13 4.03e-10 -0.57 -0.47 Dupuytren's disease; chr16:75381933 chr16:75379818~75381260:- CESC cis rs916888 0.61 rs199444 ENSG00000214401.4 KANSL1-AS1 7.94 1.09e-13 4.04e-10 0.57 0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46193576~46196723:+ CESC cis rs3931020 0.548 rs17618340 ENSG00000272864.1 RP11-17E13.2 -7.94 1.09e-13 4.06e-10 -0.5 -0.47 Resistin levels; chr1:74781933 chr1:74698769~74699333:- CESC cis rs977987 0.778 rs11149825 ENSG00000261783.1 RP11-252K23.2 -7.93 1.1e-13 4.09e-10 -0.58 -0.47 Dupuytren's disease; chr16:75400980 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs7202596 ENSG00000261783.1 RP11-252K23.2 -7.93 1.1e-13 4.11e-10 -0.58 -0.47 Dupuytren's disease; chr16:75457174 chr16:75379818~75381260:- CESC cis rs526231 0.543 rs8488 ENSG00000175749.11 EIF3KP1 7.93 1.11e-13 4.13e-10 0.54 0.47 Primary biliary cholangitis; chr5:103203051 chr5:103032376~103033031:+ CESC cis rs1799949 0.965 rs799912 ENSG00000198496.9 NBR2 -7.93 1.13e-13 4.18e-10 -0.56 -0.47 Menopause (age at onset); chr17:43105117 chr17:43125610~43153671:+ CESC cis rs3096299 0.509 rs4785691 ENSG00000274627.1 RP11-104N10.2 7.93 1.15e-13 4.27e-10 0.48 0.47 Multiple myeloma (IgH translocation); chr16:89530813 chr16:89516797~89522217:+ CESC cis rs977987 0.645 rs10871311 ENSG00000261783.1 RP11-252K23.2 -7.93 1.16e-13 4.31e-10 -0.58 -0.47 Dupuytren's disease; chr16:75417014 chr16:75379818~75381260:- CESC cis rs1577917 0.727 rs9444361 ENSG00000203875.9 SNHG5 7.93 1.16e-13 4.32e-10 0.57 0.47 Response to antipsychotic treatment; chr6:85691182 chr6:85660950~85678736:- CESC cis rs4718428 1 rs1830070 ENSG00000226824.5 RP4-756H11.3 -7.92 1.17e-13 4.32e-10 -0.61 -0.47 Corneal structure; chr7:66884684 chr7:66654538~66669855:+ CESC cis rs1153858 1 rs8032904 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45359111 chr15:45251580~45279251:- CESC cis rs1153858 0.943 rs8038342 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45359339 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4774579 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45359605 chr15:45251580~45279251:- CESC cis rs1153858 0.943 rs4774580 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45359888 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4271549 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45360532 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4627277 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45360570 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4625670 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45360728 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4534782 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45360735 chr15:45251580~45279251:- CESC cis rs1153858 1 rs1049503 ENSG00000259520.4 CTD-2651B20.3 -7.92 1.18e-13 4.35e-10 -0.62 -0.47 Homoarginine levels; chr15:45361509 chr15:45251580~45279251:- CESC cis rs10463554 0.963 rs1595553 ENSG00000175749.11 EIF3KP1 7.92 1.18e-13 4.36e-10 0.51 0.47 Parkinson's disease; chr5:103043164 chr5:103032376~103033031:+ CESC cis rs2882667 0.931 rs7720150 ENSG00000253404.1 AC034243.1 7.92 1.18e-13 4.38e-10 0.55 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:138998380 chr5:138744434~138753309:- CESC cis rs977987 0.806 rs12933281 ENSG00000261783.1 RP11-252K23.2 -7.92 1.2e-13 4.42e-10 -0.58 -0.47 Dupuytren's disease; chr16:75449166 chr16:75379818~75381260:- CESC cis rs7208859 0.573 rs73267873 ENSG00000263531.1 RP13-753N3.1 7.92 1.2e-13 4.44e-10 0.87 0.47 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741439 chr17:30863921~30864940:- CESC cis rs17826219 0.561 rs4085382 ENSG00000263531.1 RP13-753N3.1 7.92 1.2e-13 4.44e-10 0.87 0.47 Body mass index; chr17:30744184 chr17:30863921~30864940:- CESC cis rs1799949 0.965 rs6503726 ENSG00000198496.9 NBR2 -7.92 1.22e-13 4.51e-10 -0.55 -0.47 Menopause (age at onset); chr17:43132725 chr17:43125610~43153671:+ CESC cis rs977987 0.836 rs8055974 ENSG00000261783.1 RP11-252K23.2 -7.92 1.22e-13 4.51e-10 -0.57 -0.47 Dupuytren's disease; chr16:75437088 chr16:75379818~75381260:- CESC cis rs875971 0.965 rs6971509 ENSG00000226824.5 RP4-756H11.3 7.92 1.22e-13 4.51e-10 0.57 0.47 Aortic root size; chr7:66249983 chr7:66654538~66669855:+ CESC cis rs1799949 0.965 rs799917 ENSG00000198496.9 NBR2 -7.92 1.22e-13 4.51e-10 -0.55 -0.47 Menopause (age at onset); chr17:43092919 chr17:43125610~43153671:+ CESC cis rs875971 1 rs4718307 ENSG00000226824.5 RP4-756H11.3 7.92 1.23e-13 4.53e-10 0.58 0.47 Aortic root size; chr7:66146001 chr7:66654538~66669855:+ CESC cis rs875971 1 rs7801282 ENSG00000226824.5 RP4-756H11.3 7.92 1.23e-13 4.53e-10 0.58 0.47 Aortic root size; chr7:66148700 chr7:66654538~66669855:+ CESC cis rs17711722 0.523 rs313812 ENSG00000164669.11 INTS4P1 7.92 1.23e-13 4.53e-10 0.61 0.47 Calcium levels; chr7:66040056 chr7:65141225~65234216:+ CESC cis rs1153858 1 rs1719247 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.25e-13 4.58e-10 -0.62 -0.47 Homoarginine levels; chr15:45328787 chr15:45251580~45279251:- CESC cis rs977987 0.806 rs2161684 ENSG00000261783.1 RP11-252K23.2 -7.91 1.27e-13 4.68e-10 -0.58 -0.47 Dupuytren's disease; chr16:75445255 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs34996006 ENSG00000261783.1 RP11-252K23.2 -7.91 1.27e-13 4.68e-10 -0.58 -0.47 Dupuytren's disease; chr16:75445536 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs11149820 ENSG00000261783.1 RP11-252K23.2 -7.91 1.28e-13 4.68e-10 -0.57 -0.47 Dupuytren's disease; chr16:75388862 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs10514396 ENSG00000261783.1 RP11-252K23.2 -7.91 1.28e-13 4.68e-10 -0.57 -0.47 Dupuytren's disease; chr16:75389005 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs7499872 ENSG00000261783.1 RP11-252K23.2 -7.91 1.28e-13 4.68e-10 -0.57 -0.47 Dupuytren's disease; chr16:75392631 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs60730309 ENSG00000261783.1 RP11-252K23.2 -7.91 1.28e-13 4.68e-10 -0.57 -0.47 Dupuytren's disease; chr16:75397871 chr16:75379818~75381260:- CESC cis rs977987 0.75 rs4888406 ENSG00000261783.1 RP11-252K23.2 -7.91 1.28e-13 4.68e-10 -0.57 -0.47 Dupuytren's disease; chr16:75398436 chr16:75379818~75381260:- CESC cis rs1153858 1 rs16942000 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45340805 chr15:45251580~45279251:- CESC cis rs1153858 0.945 rs7182300 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45342730 chr15:45251580~45279251:- CESC cis rs1153858 0.887 rs7171163 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45344197 chr15:45251580~45279251:- CESC cis rs1153858 1 rs56669689 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45345531 chr15:45251580~45279251:- CESC cis rs1153858 1 rs56806728 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45345616 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4775906 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45346096 chr15:45251580~45279251:- CESC cis rs1153858 1 rs7179743 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45346133 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4775907 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45346449 chr15:45251580~45279251:- CESC cis rs1153858 1 rs7163720 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45347176 chr15:45251580~45279251:- CESC cis rs1153858 1 rs7167900 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45347273 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12591058 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45347974 chr15:45251580~45279251:- CESC cis rs1153858 1 rs7169587 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45348181 chr15:45251580~45279251:- CESC cis rs1153858 0.943 rs28605551 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45349522 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4775909 ENSG00000259520.4 CTD-2651B20.3 -7.91 1.29e-13 4.71e-10 -0.62 -0.47 Homoarginine levels; chr15:45350844 chr15:45251580~45279251:- CESC cis rs6700559 1 rs6656619 ENSG00000260088.1 RP11-92G12.3 7.91 1.29e-13 4.73e-10 0.58 0.47 Coronary artery disease; chr1:200671664 chr1:200669507~200694250:+ CESC cis rs1153858 1 rs1153858 ENSG00000259520.4 CTD-2651B20.3 7.91 1.31e-13 4.8e-10 0.62 0.47 Homoarginine levels; chr15:45360505 chr15:45251580~45279251:- CESC cis rs2882667 0.898 rs6863347 ENSG00000253404.1 AC034243.1 7.91 1.31e-13 4.8e-10 0.57 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139025446 chr5:138744434~138753309:- CESC cis rs8062405 1 rs62037364 ENSG00000259982.1 CDC37P1 7.9 1.33e-13 4.87e-10 0.59 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857374 chr16:28700294~28701540:- CESC cis rs916888 0.647 rs199449 ENSG00000214401.4 KANSL1-AS1 7.9 1.35e-13 4.92e-10 0.56 0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46193576~46196723:+ CESC cis rs1707322 0.691 rs11211175 ENSG00000280836.1 AL355480.1 -7.9 1.36e-13 4.96e-10 -0.55 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755212 chr1:45581219~45581321:- CESC cis rs1153858 1 rs2056493 ENSG00000259520.4 CTD-2651B20.3 -7.9 1.36e-13 4.96e-10 -0.59 -0.47 Homoarginine levels; chr15:45356074 chr15:45251580~45279251:- CESC cis rs12594515 0.591 rs35554150 ENSG00000273972.1 CTD-2306A12.1 -7.9 1.38e-13 5.01e-10 -0.64 -0.47 Weight;Waist circumference; chr15:45698100 chr15:45702640~45703183:+ CESC cis rs977987 0.843 rs11641801 ENSG00000261783.1 RP11-252K23.2 -7.9 1.39e-13 5.06e-10 -0.58 -0.47 Dupuytren's disease; chr16:75421550 chr16:75379818~75381260:- CESC cis rs526231 0.543 rs75913944 ENSG00000175749.11 EIF3KP1 7.9 1.4e-13 5.09e-10 0.55 0.47 Primary biliary cholangitis; chr5:103143799 chr5:103032376~103033031:+ CESC cis rs26232 0.521 rs3776855 ENSG00000175749.11 EIF3KP1 7.9 1.4e-13 5.11e-10 0.53 0.47 Rheumatoid arthritis; chr5:103023111 chr5:103032376~103033031:+ CESC cis rs7044106 0.537 rs10818474 ENSG00000226752.6 PSMD5-AS1 -7.89 1.41e-13 5.11e-10 -0.57 -0.47 Hip circumference adjusted for BMI; chr9:120727686 chr9:120824828~120854385:+ CESC cis rs10853057 0.541 rs77675516 ENSG00000214174.7 AMZ2P1 7.89 1.41e-13 5.11e-10 0.76 0.47 White matter microstructure (global fractional anisotropy); chr17:65050690 chr17:64966550~64975576:- CESC cis rs10853057 0.541 rs8076716 ENSG00000214174.7 AMZ2P1 7.89 1.41e-13 5.11e-10 0.76 0.47 White matter microstructure (global fractional anisotropy); chr17:65051891 chr17:64966550~64975576:- CESC cis rs2882667 1 rs2060222 ENSG00000253404.1 AC034243.1 7.89 1.41e-13 5.12e-10 0.59 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:138972777 chr5:138744434~138753309:- CESC cis rs8062405 0.679 rs72793818 ENSG00000259982.1 CDC37P1 7.89 1.41e-13 5.12e-10 0.59 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28881816 chr16:28700294~28701540:- CESC cis rs977987 0.843 rs59155720 ENSG00000261783.1 RP11-252K23.2 -7.89 1.41e-13 5.13e-10 -0.58 -0.47 Dupuytren's disease; chr16:75449908 chr16:75379818~75381260:- CESC cis rs2882667 0.898 rs2043272 ENSG00000253404.1 AC034243.1 7.89 1.42e-13 5.16e-10 0.55 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139054942 chr5:138744434~138753309:- CESC cis rs8062405 1 rs62036626 ENSG00000259982.1 CDC37P1 7.89 1.42e-13 5.17e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28832963 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62036657 ENSG00000259982.1 CDC37P1 7.89 1.42e-13 5.17e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833044 chr16:28700294~28701540:- CESC cis rs8062405 1 rs12444171 ENSG00000259982.1 CDC37P1 7.89 1.42e-13 5.17e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833930 chr16:28700294~28701540:- CESC cis rs977987 0.806 rs7204984 ENSG00000261783.1 RP11-252K23.2 -7.89 1.43e-13 5.2e-10 -0.58 -0.47 Dupuytren's disease; chr16:75441622 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs35214308 ENSG00000261783.1 RP11-252K23.2 -7.89 1.43e-13 5.2e-10 -0.58 -0.47 Dupuytren's disease; chr16:75442190 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888425 ENSG00000261783.1 RP11-252K23.2 -7.89 1.43e-13 5.2e-10 -0.58 -0.47 Dupuytren's disease; chr16:75442465 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs4888426 ENSG00000261783.1 RP11-252K23.2 -7.89 1.43e-13 5.2e-10 -0.58 -0.47 Dupuytren's disease; chr16:75442553 chr16:75379818~75381260:- CESC cis rs8062405 1 rs3088215 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28842675 chr16:28700294~28701540:- CESC cis rs8062405 1 rs28403629 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28843448 chr16:28700294~28701540:- CESC cis rs8062405 1 rs61737565 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844201 chr16:28700294~28701540:- CESC cis rs8062405 1 rs4788099 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844406 chr16:28700294~28701540:- CESC cis rs8062405 1 rs9972693 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28848481 chr16:28700294~28701540:- CESC cis rs8062405 0.964 rs9972768 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850413 chr16:28700294~28701540:- CESC cis rs8062405 0.965 rs56040780 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850560 chr16:28700294~28701540:- CESC cis rs8062405 0.965 rs62037363 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28853721 chr16:28700294~28701540:- CESC cis rs8062405 1 rs7205323 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854571 chr16:28700294~28701540:- CESC cis rs8062405 1 rs4788101 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28856483 chr16:28700294~28701540:- CESC cis rs8062405 0.929 rs11150609 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859275 chr16:28700294~28701540:- CESC cis rs8062405 0.737 rs11861132 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860539 chr16:28700294~28701540:- CESC cis rs8062405 1 rs11861174 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860668 chr16:28700294~28701540:- CESC cis rs8062405 1 rs4788102 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28862077 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62037367 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863226 chr16:28700294~28701540:- CESC cis rs8062405 1 rs7198606 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863801 chr16:28700294~28701540:- CESC cis rs8062405 0.929 rs11864750 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863883 chr16:28700294~28701540:- CESC cis rs8062405 0.964 rs7193733 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28864161 chr16:28700294~28701540:- CESC cis rs8062405 1 rs8055982 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28869881 chr16:28700294~28701540:- CESC cis rs8062405 1 rs7498665 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28871920 chr16:28700294~28701540:- CESC cis rs8062405 0.964 rs11864107 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874610 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62037371 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878810 chr16:28700294~28701540:- CESC cis rs8062405 1 rs8055138 ENSG00000259982.1 CDC37P1 7.89 1.44e-13 5.2e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28880144 chr16:28700294~28701540:- CESC cis rs875971 1 rs1167612 ENSG00000226824.5 RP4-756H11.3 7.89 1.44e-13 5.2e-10 0.6 0.47 Aortic root size; chr7:66102989 chr7:66654538~66669855:+ CESC cis rs977987 0.843 rs4888415 ENSG00000261783.1 RP11-252K23.2 -7.89 1.44e-13 5.21e-10 -0.58 -0.47 Dupuytren's disease; chr16:75415023 chr16:75379818~75381260:- CESC cis rs1707322 0.752 rs11488313 ENSG00000280836.1 AL355480.1 -7.89 1.45e-13 5.23e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45759108 chr1:45581219~45581321:- CESC cis rs6142102 0.602 rs10485503 ENSG00000276073.1 RP5-1125A11.7 -7.89 1.46e-13 5.28e-10 -0.42 -0.47 Skin pigmentation; chr20:33970036 chr20:33985617~33988989:- CESC cis rs1577917 0.771 rs4351223 ENSG00000203875.9 SNHG5 7.89 1.47e-13 5.29e-10 0.56 0.47 Response to antipsychotic treatment; chr6:85528079 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs7452605 ENSG00000203875.9 SNHG5 7.89 1.47e-13 5.29e-10 0.56 0.47 Response to antipsychotic treatment; chr6:85531233 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs9294337 ENSG00000203875.9 SNHG5 7.89 1.47e-13 5.29e-10 0.56 0.47 Response to antipsychotic treatment; chr6:85538742 chr6:85660950~85678736:- CESC cis rs977987 0.966 rs62060551 ENSG00000261783.1 RP11-252K23.2 -7.89 1.48e-13 5.33e-10 -0.58 -0.47 Dupuytren's disease; chr16:75468414 chr16:75379818~75381260:- CESC cis rs1153858 1 rs2668747 ENSG00000259520.4 CTD-2651B20.3 -7.89 1.48e-13 5.33e-10 -0.62 -0.47 Homoarginine levels; chr15:45325018 chr15:45251580~45279251:- CESC cis rs1707322 0.686 rs3014242 ENSG00000280836.1 AL355480.1 7.89 1.48e-13 5.34e-10 0.56 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621905 chr1:45581219~45581321:- CESC cis rs2739330 0.828 rs4820572 ENSG00000099984.9 GSTT2 -7.88 1.5e-13 5.39e-10 -0.58 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23980123~23983911:+ CESC cis rs1577917 0.771 rs2783171 ENSG00000203875.9 SNHG5 7.88 1.5e-13 5.4e-10 0.58 0.47 Response to antipsychotic treatment; chr6:85673047 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs2475791 ENSG00000203875.9 SNHG5 -7.88 1.5e-13 5.4e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85658446 chr6:85660950~85678736:- CESC cis rs977987 0.806 rs1030262 ENSG00000261783.1 RP11-252K23.2 -7.88 1.5e-13 5.41e-10 -0.57 -0.47 Dupuytren's disease; chr16:75457429 chr16:75379818~75381260:- CESC cis rs1799949 0.965 rs799916 ENSG00000198496.9 NBR2 7.88 1.5e-13 5.41e-10 0.57 0.47 Menopause (age at onset); chr17:43091173 chr17:43125610~43153671:+ CESC cis rs526231 0.543 rs26819 ENSG00000175749.11 EIF3KP1 7.88 1.51e-13 5.42e-10 0.53 0.47 Primary biliary cholangitis; chr5:103193700 chr5:103032376~103033031:+ CESC cis rs526231 0.615 rs26818 ENSG00000175749.11 EIF3KP1 7.88 1.51e-13 5.42e-10 0.53 0.47 Primary biliary cholangitis; chr5:103194018 chr5:103032376~103033031:+ CESC cis rs9828933 1 rs1060897 ENSG00000280620.1 SCAANT1 -7.88 1.52e-13 5.45e-10 -0.72 -0.47 Type 2 diabetes; chr3:64012196 chr3:63911518~63911772:- CESC cis rs1707322 0.721 rs61784800 ENSG00000280836.1 AL355480.1 7.88 1.52e-13 5.45e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712440 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs6665808 ENSG00000280836.1 AL355480.1 -7.88 1.52e-13 5.45e-10 -0.55 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45696611 chr1:45581219~45581321:- CESC cis rs1707322 0.682 rs28508523 ENSG00000280836.1 AL355480.1 -7.88 1.52e-13 5.45e-10 -0.55 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723953 chr1:45581219~45581321:- CESC cis rs3931020 0.772 rs11485555 ENSG00000272864.1 RP11-17E13.2 -7.88 1.54e-13 5.51e-10 -0.53 -0.47 Resistin levels; chr1:74720825 chr1:74698769~74699333:- CESC cis rs992157 0.965 rs13427681 ENSG00000261338.2 RP11-378A13.1 7.88 1.54e-13 5.54e-10 0.59 0.47 Colorectal cancer; chr2:218302840 chr2:218255319~218257366:+ CESC cis rs1799949 0.86 rs8176279 ENSG00000198496.9 NBR2 -7.88 1.55e-13 5.57e-10 -0.58 -0.47 Menopause (age at onset); chr17:43058379 chr17:43125610~43153671:+ CESC cis rs6991838 0.557 rs67685675 ENSG00000272010.1 CTD-3025N20.3 -7.88 1.55e-13 5.57e-10 -0.53 -0.47 Intelligence (multi-trait analysis); chr8:65574371 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs66486920 ENSG00000272010.1 CTD-3025N20.3 -7.88 1.55e-13 5.57e-10 -0.53 -0.47 Intelligence (multi-trait analysis); chr8:65574458 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs60023200 ENSG00000272010.1 CTD-3025N20.3 -7.88 1.55e-13 5.57e-10 -0.53 -0.47 Intelligence (multi-trait analysis); chr8:65574547 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs61083799 ENSG00000272010.1 CTD-3025N20.3 -7.88 1.55e-13 5.57e-10 -0.53 -0.47 Intelligence (multi-trait analysis); chr8:65574868 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs4449837 ENSG00000272010.1 CTD-3025N20.3 -7.88 1.55e-13 5.57e-10 -0.53 -0.47 Intelligence (multi-trait analysis); chr8:65575917 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs57042777 ENSG00000272010.1 CTD-3025N20.3 -7.88 1.55e-13 5.57e-10 -0.53 -0.47 Intelligence (multi-trait analysis); chr8:65576855 chr8:65591850~65592472:- CESC cis rs6991838 0.557 rs67046768 ENSG00000272010.1 CTD-3025N20.3 -7.88 1.55e-13 5.57e-10 -0.53 -0.47 Intelligence (multi-trait analysis); chr8:65577486 chr8:65591850~65592472:- CESC cis rs7044106 0.5 rs56725168 ENSG00000226752.6 PSMD5-AS1 -7.88 1.56e-13 5.6e-10 -0.52 -0.47 Hip circumference adjusted for BMI; chr9:120730298 chr9:120824828~120854385:+ CESC cis rs7044106 0.791 rs10985008 ENSG00000226752.6 PSMD5-AS1 -7.88 1.56e-13 5.6e-10 -0.52 -0.47 Hip circumference adjusted for BMI; chr9:120730682 chr9:120824828~120854385:+ CESC cis rs7044106 0.791 rs10985009 ENSG00000226752.6 PSMD5-AS1 7.88 1.56e-13 5.6e-10 0.52 0.47 Hip circumference adjusted for BMI; chr9:120730761 chr9:120824828~120854385:+ CESC cis rs9545047 0.935 rs9530925 ENSG00000227676.3 LINC01068 -7.88 1.57e-13 5.62e-10 -0.54 -0.47 Schizophrenia; chr13:79492641 chr13:79566727~79571436:+ CESC cis rs3931020 0.679 rs28671241 ENSG00000272864.1 RP11-17E13.2 -7.88 1.59e-13 5.68e-10 -0.52 -0.47 Resistin levels; chr1:74716197 chr1:74698769~74699333:- CESC cis rs977987 0.902 rs4888430 ENSG00000261783.1 RP11-252K23.2 -7.88 1.59e-13 5.69e-10 -0.58 -0.47 Dupuytren's disease; chr16:75460526 chr16:75379818~75381260:- CESC cis rs1707322 0.721 rs12069121 ENSG00000280836.1 AL355480.1 -7.87 1.59e-13 5.69e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45766312 chr1:45581219~45581321:- CESC cis rs1707322 0.686 rs61784833 ENSG00000280836.1 AL355480.1 -7.87 1.59e-13 5.69e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45768100 chr1:45581219~45581321:- CESC cis rs10256972 0.706 rs12701969 ENSG00000229043.2 AC091729.9 -7.87 1.6e-13 5.71e-10 -0.52 -0.47 Endometriosis;Longevity; chr7:1082213 chr7:1160374~1165267:+ CESC cis rs1577917 1 rs1018184 ENSG00000203875.9 SNHG5 7.87 1.6e-13 5.71e-10 0.56 0.47 Response to antipsychotic treatment; chr6:85938757 chr6:85660950~85678736:- CESC cis rs1707322 0.686 rs2275085 ENSG00000280836.1 AL355480.1 7.87 1.6e-13 5.72e-10 0.56 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620180 chr1:45581219~45581321:- CESC cis rs977987 0.778 rs2865528 ENSG00000261783.1 RP11-252K23.2 -7.87 1.6e-13 5.72e-10 -0.57 -0.47 Dupuytren's disease; chr16:75422044 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs67409275 ENSG00000261783.1 RP11-252K23.2 -7.87 1.6e-13 5.72e-10 -0.57 -0.47 Dupuytren's disease; chr16:75423314 chr16:75379818~75381260:- CESC cis rs1707322 0.682 rs3014241 ENSG00000280836.1 AL355480.1 7.87 1.6e-13 5.73e-10 0.57 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45622207 chr1:45581219~45581321:- CESC cis rs875971 0.522 rs1701760 ENSG00000226824.5 RP4-756H11.3 -7.87 1.61e-13 5.74e-10 -0.6 -0.47 Aortic root size; chr7:66008701 chr7:66654538~66669855:+ CESC cis rs8062405 1 rs55991577 ENSG00000259982.1 CDC37P1 7.87 1.61e-13 5.75e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831704 chr16:28700294~28701540:- CESC cis rs8062405 1 rs56358680 ENSG00000259982.1 CDC37P1 7.87 1.61e-13 5.75e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831797 chr16:28700294~28701540:- CESC cis rs1707322 0.685 rs56177313 ENSG00000280836.1 AL355480.1 -7.87 1.61e-13 5.75e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760134 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs11211178 ENSG00000280836.1 AL355480.1 -7.87 1.61e-13 5.75e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45761894 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs11211146 ENSG00000280836.1 AL355480.1 -7.87 1.64e-13 5.85e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644122 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs11211147 ENSG00000280836.1 AL355480.1 -7.87 1.64e-13 5.85e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644422 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs11211149 ENSG00000280836.1 AL355480.1 -7.87 1.64e-13 5.85e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45646546 chr1:45581219~45581321:- CESC cis rs1799949 0.965 rs11080034 ENSG00000198496.9 NBR2 -7.87 1.65e-13 5.86e-10 -0.57 -0.47 Menopause (age at onset); chr17:43365646 chr17:43125610~43153671:+ CESC cis rs977987 0.966 rs8055490 ENSG00000261783.1 RP11-252K23.2 -7.87 1.65e-13 5.86e-10 -0.58 -0.47 Dupuytren's disease; chr16:75463237 chr16:75379818~75381260:- CESC cis rs526231 0.543 rs34808 ENSG00000175749.11 EIF3KP1 7.87 1.65e-13 5.88e-10 0.53 0.47 Primary biliary cholangitis; chr5:103093484 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34809 ENSG00000175749.11 EIF3KP1 7.87 1.65e-13 5.88e-10 0.53 0.47 Primary biliary cholangitis; chr5:103094413 chr5:103032376~103033031:+ CESC cis rs17711722 0.523 rs365896 ENSG00000164669.11 INTS4P1 7.87 1.68e-13 5.97e-10 0.61 0.47 Calcium levels; chr7:66045710 chr7:65141225~65234216:+ CESC cis rs526231 0.511 rs34823 ENSG00000175749.11 EIF3KP1 -7.87 1.69e-13 6e-10 -0.54 -0.47 Primary biliary cholangitis; chr5:103102587 chr5:103032376~103033031:+ CESC cis rs9326248 0.53 rs7114963 ENSG00000254851.1 RP11-109L13.1 -7.87 1.69e-13 6.01e-10 -0.84 -0.47 Blood protein levels; chr11:117005267 chr11:117135528~117138582:+ CESC cis rs7115242 0.72 rs10790169 ENSG00000254851.1 RP11-109L13.1 -7.87 1.69e-13 6.01e-10 -0.84 -0.47 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117006443 chr11:117135528~117138582:+ CESC cis rs977987 0.75 rs4888414 ENSG00000261783.1 RP11-252K23.2 -7.87 1.69e-13 6.01e-10 -0.58 -0.47 Dupuytren's disease; chr16:75413335 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs6564258 ENSG00000261783.1 RP11-252K23.2 -7.87 1.69e-13 6.01e-10 -0.58 -0.47 Dupuytren's disease; chr16:75413465 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs6564259 ENSG00000261783.1 RP11-252K23.2 -7.87 1.69e-13 6.01e-10 -0.58 -0.47 Dupuytren's disease; chr16:75413495 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs6564260 ENSG00000261783.1 RP11-252K23.2 -7.87 1.69e-13 6.01e-10 -0.58 -0.47 Dupuytren's disease; chr16:75413528 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs11648176 ENSG00000261783.1 RP11-252K23.2 -7.86 1.73e-13 6.12e-10 -0.57 -0.47 Dupuytren's disease; chr16:75422525 chr16:75379818~75381260:- CESC cis rs1707322 0.752 rs12062535 ENSG00000280836.1 AL355480.1 -7.86 1.74e-13 6.17e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45757208 chr1:45581219~45581321:- CESC cis rs977987 0.771 rs12929673 ENSG00000261783.1 RP11-252K23.2 -7.86 1.74e-13 6.17e-10 -0.57 -0.47 Dupuytren's disease; chr16:75436397 chr16:75379818~75381260:- CESC cis rs977987 0.836 rs35209155 ENSG00000261783.1 RP11-252K23.2 -7.86 1.74e-13 6.17e-10 -0.57 -0.47 Dupuytren's disease; chr16:75436598 chr16:75379818~75381260:- CESC cis rs977987 0.872 rs4887825 ENSG00000261783.1 RP11-252K23.2 -7.86 1.74e-13 6.17e-10 -0.57 -0.47 Dupuytren's disease; chr16:75438524 chr16:75379818~75381260:- CESC cis rs7186831 1 rs7186831 ENSG00000261783.1 RP11-252K23.2 -7.86 1.74e-13 6.17e-10 -0.57 -0.47 Chronic obstructive pulmonary disease; chr16:75439257 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888418 ENSG00000261783.1 RP11-252K23.2 -7.86 1.77e-13 6.26e-10 -0.57 -0.47 Dupuytren's disease; chr16:75426408 chr16:75379818~75381260:- CESC cis rs9545047 0.935 rs6563113 ENSG00000227676.3 LINC01068 -7.86 1.79e-13 6.33e-10 -0.54 -0.47 Schizophrenia; chr13:79490000 chr13:79566727~79571436:+ CESC cis rs526231 0.543 rs28025 ENSG00000175749.11 EIF3KP1 7.86 1.8e-13 6.37e-10 0.53 0.47 Primary biliary cholangitis; chr5:103201678 chr5:103032376~103033031:+ CESC cis rs977987 0.843 rs4888427 ENSG00000261783.1 RP11-252K23.2 -7.85 1.8e-13 6.38e-10 -0.57 -0.47 Dupuytren's disease; chr16:75444549 chr16:75379818~75381260:- CESC cis rs1577917 0.771 rs12199873 ENSG00000203875.9 SNHG5 -7.85 1.81e-13 6.41e-10 -0.56 -0.47 Response to antipsychotic treatment; chr6:85585229 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs2842609 ENSG00000203875.9 SNHG5 -7.85 1.81e-13 6.41e-10 -0.56 -0.47 Response to antipsychotic treatment; chr6:85587070 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs2842612 ENSG00000203875.9 SNHG5 -7.85 1.81e-13 6.41e-10 -0.56 -0.47 Response to antipsychotic treatment; chr6:85593373 chr6:85660950~85678736:- CESC cis rs1577917 0.727 rs2758840 ENSG00000203875.9 SNHG5 -7.85 1.81e-13 6.41e-10 -0.56 -0.47 Response to antipsychotic treatment; chr6:85594907 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs9362230 ENSG00000203875.9 SNHG5 -7.85 1.81e-13 6.41e-10 -0.56 -0.47 Response to antipsychotic treatment; chr6:85595295 chr6:85660950~85678736:- CESC cis rs1707322 0.721 rs10890336 ENSG00000280836.1 AL355480.1 -7.85 1.82e-13 6.43e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645384 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs11211151 ENSG00000280836.1 AL355480.1 -7.85 1.82e-13 6.43e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45647080 chr1:45581219~45581321:- CESC cis rs801193 0.844 rs732465 ENSG00000226824.5 RP4-756H11.3 -7.85 1.83e-13 6.45e-10 -0.57 -0.47 Aortic root size; chr7:66533463 chr7:66654538~66669855:+ CESC cis rs801193 0.773 rs801207 ENSG00000226824.5 RP4-756H11.3 7.85 1.83e-13 6.45e-10 0.57 0.47 Aortic root size; chr7:66555603 chr7:66654538~66669855:+ CESC cis rs875971 0.543 rs801191 ENSG00000226824.5 RP4-756H11.3 7.85 1.83e-13 6.45e-10 0.57 0.47 Aortic root size; chr7:66567968 chr7:66654538~66669855:+ CESC cis rs875971 0.508 rs6947808 ENSG00000226824.5 RP4-756H11.3 7.85 1.83e-13 6.45e-10 0.57 0.47 Aortic root size; chr7:66580095 chr7:66654538~66669855:+ CESC cis rs6991838 0.584 rs7463649 ENSG00000272010.1 CTD-3025N20.3 -7.85 1.83e-13 6.46e-10 -0.52 -0.47 Intelligence (multi-trait analysis); chr8:65573760 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs7463740 ENSG00000272010.1 CTD-3025N20.3 -7.85 1.83e-13 6.46e-10 -0.52 -0.47 Intelligence (multi-trait analysis); chr8:65573950 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs66467166 ENSG00000272010.1 CTD-3025N20.3 -7.85 1.83e-13 6.46e-10 -0.52 -0.47 Intelligence (multi-trait analysis); chr8:65574165 chr8:65591850~65592472:- CESC cis rs875971 0.895 rs7788984 ENSG00000226824.5 RP4-756H11.3 -7.85 1.84e-13 6.48e-10 -0.59 -0.47 Aortic root size; chr7:66450629 chr7:66654538~66669855:+ CESC cis rs526231 0.543 rs34832 ENSG00000175749.11 EIF3KP1 7.85 1.84e-13 6.5e-10 0.54 0.47 Primary biliary cholangitis; chr5:103108891 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34770 ENSG00000175749.11 EIF3KP1 7.85 1.84e-13 6.5e-10 0.54 0.47 Primary biliary cholangitis; chr5:103111942 chr5:103032376~103033031:+ CESC cis rs2882667 0.638 rs6895690 ENSG00000253404.1 AC034243.1 7.85 1.85e-13 6.51e-10 0.55 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139130162 chr5:138744434~138753309:- CESC cis rs11155671 0.53 rs4869763 ENSG00000231760.4 RP11-350J20.5 7.85 1.85e-13 6.52e-10 0.58 0.47 Testicular germ cell tumor; chr6:149890548 chr6:149796151~149826294:- CESC cis rs916888 0.61 rs199453 ENSG00000214401.4 KANSL1-AS1 7.85 1.87e-13 6.58e-10 0.57 0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46193576~46196723:+ CESC cis rs12022452 0.591 rs1001400 ENSG00000238287.1 RP11-656D10.3 -7.85 1.9e-13 6.68e-10 -0.66 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40533230 chr1:40493157~40508661:- CESC cis rs977987 0.843 rs12928036 ENSG00000261783.1 RP11-252K23.2 -7.85 1.91e-13 6.71e-10 -0.57 -0.47 Dupuytren's disease; chr16:75449234 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs59465235 ENSG00000261783.1 RP11-252K23.2 -7.85 1.91e-13 6.71e-10 -0.57 -0.47 Dupuytren's disease; chr16:75449912 chr16:75379818~75381260:- CESC cis rs2882667 0.861 rs11959727 ENSG00000253404.1 AC034243.1 7.85 1.91e-13 6.71e-10 0.54 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139061276 chr5:138744434~138753309:- CESC cis rs526231 0.543 rs34765 ENSG00000175749.11 EIF3KP1 7.85 1.91e-13 6.72e-10 0.54 0.47 Primary biliary cholangitis; chr5:103171160 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs183752 ENSG00000175749.11 EIF3KP1 7.85 1.91e-13 6.72e-10 0.54 0.47 Primary biliary cholangitis; chr5:103172108 chr5:103032376~103033031:+ CESC cis rs977987 0.931 rs1834013 ENSG00000261783.1 RP11-252K23.2 -7.85 1.91e-13 6.72e-10 -0.58 -0.47 Dupuytren's disease; chr16:75462265 chr16:75379818~75381260:- CESC cis rs1153858 1 rs56850226 ENSG00000259520.4 CTD-2651B20.3 -7.85 1.91e-13 6.73e-10 -0.62 -0.47 Homoarginine levels; chr15:45340920 chr15:45251580~45279251:- CESC cis rs977987 0.872 rs1559339 ENSG00000261783.1 RP11-252K23.2 -7.84 1.93e-13 6.77e-10 -0.57 -0.47 Dupuytren's disease; chr16:75284748 chr16:75379818~75381260:- CESC cis rs526231 0.511 rs3776861 ENSG00000175749.11 EIF3KP1 7.84 1.94e-13 6.82e-10 0.5 0.47 Primary biliary cholangitis; chr5:103013958 chr5:103032376~103033031:+ CESC cis rs8062405 1 rs56404918 ENSG00000259982.1 CDC37P1 7.84 1.95e-13 6.83e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835519 chr16:28700294~28701540:- CESC cis rs8062405 1 rs55719896 ENSG00000259982.1 CDC37P1 7.84 1.95e-13 6.83e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835545 chr16:28700294~28701540:- CESC cis rs8062405 1 rs55830740 ENSG00000259982.1 CDC37P1 7.84 1.95e-13 6.83e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835828 chr16:28700294~28701540:- CESC cis rs11155671 0.53 rs9383912 ENSG00000231760.4 RP11-350J20.5 7.84 1.96e-13 6.88e-10 0.58 0.47 Testicular germ cell tumor; chr6:149885479 chr6:149796151~149826294:- CESC cis rs526231 0.511 rs11951374 ENSG00000175749.11 EIF3KP1 7.84 1.96e-13 6.89e-10 0.5 0.47 Primary biliary cholangitis; chr5:103020094 chr5:103032376~103033031:+ CESC cis rs150992 0.673 rs161953 ENSG00000248489.1 CTD-2007H13.3 7.84 1.98e-13 6.94e-10 0.54 0.47 Body mass index; chr5:98921201 chr5:98929171~98995013:+ CESC cis rs150992 0.673 rs161952 ENSG00000248489.1 CTD-2007H13.3 7.84 1.98e-13 6.94e-10 0.54 0.47 Body mass index; chr5:98921665 chr5:98929171~98995013:+ CESC cis rs977987 0.966 rs11643207 ENSG00000261783.1 RP11-252K23.2 -7.84 1.98e-13 6.94e-10 -0.58 -0.47 Dupuytren's disease; chr16:75464895 chr16:75379818~75381260:- CESC cis rs1707322 0.721 rs10890343 ENSG00000280836.1 AL355480.1 -7.84 2e-13 6.99e-10 -0.55 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692250 chr1:45581219~45581321:- CESC cis rs526231 0.543 rs158244 ENSG00000175749.11 EIF3KP1 7.84 2e-13 6.99e-10 0.52 0.47 Primary biliary cholangitis; chr5:103075062 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs257310 ENSG00000175749.11 EIF3KP1 7.84 2e-13 6.99e-10 0.52 0.47 Primary biliary cholangitis; chr5:103083149 chr5:103032376~103033031:+ CESC cis rs977987 0.872 rs4888422 ENSG00000261783.1 RP11-252K23.2 -7.84 2.01e-13 7.02e-10 -0.55 -0.47 Dupuytren's disease; chr16:75436678 chr16:75379818~75381260:- CESC cis rs2882667 0.894 rs10054478 ENSG00000253404.1 AC034243.1 7.84 2.03e-13 7.1e-10 0.55 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139018386 chr5:138744434~138753309:- CESC cis rs12022452 0.591 rs11208356 ENSG00000238287.1 RP11-656D10.3 -7.84 2.03e-13 7.11e-10 -0.65 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40541259 chr1:40493157~40508661:- CESC cis rs2882667 0.898 rs2116789 ENSG00000253404.1 AC034243.1 7.84 2.04e-13 7.12e-10 0.55 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139058573 chr5:138744434~138753309:- CESC cis rs2882667 0.964 rs12719517 ENSG00000253404.1 AC034243.1 7.83 2.05e-13 7.15e-10 0.59 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:138969813 chr5:138744434~138753309:- CESC cis rs2882667 0.964 rs11739351 ENSG00000253404.1 AC034243.1 7.83 2.07e-13 7.23e-10 0.59 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:138976053 chr5:138744434~138753309:- CESC cis rs2739330 0.828 rs5751770 ENSG00000099984.9 GSTT2 -7.83 2.08e-13 7.25e-10 -0.56 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23980123~23983911:+ CESC cis rs9545047 0.935 rs8002042 ENSG00000227676.3 LINC01068 -7.83 2.08e-13 7.27e-10 -0.54 -0.47 Schizophrenia; chr13:79486552 chr13:79566727~79571436:+ CESC cis rs1707322 0.752 rs11211168 ENSG00000280836.1 AL355480.1 -7.83 2.09e-13 7.3e-10 -0.56 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697975 chr1:45581219~45581321:- CESC cis rs526231 0.511 rs28062 ENSG00000175749.11 EIF3KP1 7.83 2.09e-13 7.31e-10 0.53 0.47 Primary biliary cholangitis; chr5:103204500 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs27361 ENSG00000175749.11 EIF3KP1 7.83 2.09e-13 7.31e-10 0.53 0.47 Primary biliary cholangitis; chr5:103213266 chr5:103032376~103033031:+ CESC cis rs977987 0.806 rs8056236 ENSG00000261783.1 RP11-252K23.2 -7.83 2.11e-13 7.36e-10 -0.58 -0.47 Dupuytren's disease; chr16:75414375 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs8051407 ENSG00000261783.1 RP11-252K23.2 -7.83 2.11e-13 7.36e-10 -0.58 -0.47 Dupuytren's disease; chr16:75414761 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888416 ENSG00000261783.1 RP11-252K23.2 -7.83 2.11e-13 7.36e-10 -0.58 -0.47 Dupuytren's disease; chr16:75415278 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs7199132 ENSG00000261783.1 RP11-252K23.2 -7.83 2.11e-13 7.36e-10 -0.58 -0.47 Dupuytren's disease; chr16:75416141 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs7188604 ENSG00000261783.1 RP11-252K23.2 -7.83 2.11e-13 7.36e-10 -0.58 -0.47 Dupuytren's disease; chr16:75417272 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs12149063 ENSG00000261783.1 RP11-252K23.2 -7.83 2.11e-13 7.36e-10 -0.58 -0.47 Dupuytren's disease; chr16:75417860 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs11642572 ENSG00000261783.1 RP11-252K23.2 -7.83 2.11e-13 7.36e-10 -0.58 -0.47 Dupuytren's disease; chr16:75418884 chr16:75379818~75381260:- CESC cis rs526231 0.543 rs26820 ENSG00000175749.11 EIF3KP1 7.83 2.12e-13 7.38e-10 0.53 0.47 Primary biliary cholangitis; chr5:103192391 chr5:103032376~103033031:+ CESC cis rs977987 0.843 rs35737321 ENSG00000261783.1 RP11-252K23.2 -7.83 2.12e-13 7.4e-10 -0.57 -0.47 Dupuytren's disease; chr16:75405287 chr16:75379818~75381260:- CESC cis rs8062405 0.964 rs11860513 ENSG00000259982.1 CDC37P1 7.83 2.13e-13 7.44e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814099 chr16:28700294~28701540:- CESC cis rs1153858 1 rs4774577 ENSG00000259520.4 CTD-2651B20.3 -7.83 2.14e-13 7.45e-10 -0.61 -0.47 Homoarginine levels; chr15:45352487 chr15:45251580~45279251:- CESC cis rs1153858 1 rs11070453 ENSG00000259520.4 CTD-2651B20.3 -7.83 2.14e-13 7.45e-10 -0.61 -0.47 Homoarginine levels; chr15:45352956 chr15:45251580~45279251:- CESC cis rs1153858 1 rs4774578 ENSG00000259520.4 CTD-2651B20.3 -7.83 2.14e-13 7.45e-10 -0.61 -0.47 Homoarginine levels; chr15:45353853 chr15:45251580~45279251:- CESC cis rs61524473 1 rs61524473 ENSG00000259520.4 CTD-2651B20.3 -7.83 2.14e-13 7.45e-10 -0.61 -0.47 Metabolite levels (small molecules and protein measures); chr15:45354085 chr15:45251580~45279251:- CESC cis rs1153858 1 rs12593230 ENSG00000259520.4 CTD-2651B20.3 -7.83 2.14e-13 7.45e-10 -0.61 -0.47 Homoarginine levels; chr15:45354770 chr15:45251580~45279251:- CESC cis rs1153858 1 rs10444821 ENSG00000259520.4 CTD-2651B20.3 -7.83 2.14e-13 7.45e-10 -0.61 -0.47 Homoarginine levels; chr15:45355038 chr15:45251580~45279251:- CESC cis rs1153858 1 rs72623915 ENSG00000259520.4 CTD-2651B20.3 -7.83 2.14e-13 7.45e-10 -0.61 -0.47 Homoarginine levels; chr15:45355235 chr15:45251580~45279251:- CESC cis rs1153858 1 rs66714503 ENSG00000259520.4 CTD-2651B20.3 -7.83 2.14e-13 7.45e-10 -0.61 -0.47 Homoarginine levels; chr15:45355840 chr15:45251580~45279251:- CESC cis rs977987 0.645 rs34904236 ENSG00000261783.1 RP11-252K23.2 -7.83 2.14e-13 7.45e-10 -0.57 -0.47 Dupuytren's disease; chr16:75464355 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs28655617 ENSG00000261783.1 RP11-252K23.2 -7.83 2.14e-13 7.46e-10 -0.56 -0.47 Dupuytren's disease; chr16:75455744 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs7188231 ENSG00000261783.1 RP11-252K23.2 -7.83 2.15e-13 7.48e-10 -0.57 -0.47 Dupuytren's disease; chr16:75402663 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs12443904 ENSG00000261783.1 RP11-252K23.2 -7.83 2.15e-13 7.48e-10 -0.57 -0.47 Dupuytren's disease; chr16:75404872 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs62062564 ENSG00000261783.1 RP11-252K23.2 -7.83 2.15e-13 7.48e-10 -0.57 -0.47 Dupuytren's disease; chr16:75408724 chr16:75379818~75381260:- CESC cis rs977987 0.843 rs62062568 ENSG00000261783.1 RP11-252K23.2 -7.83 2.15e-13 7.48e-10 -0.57 -0.47 Dupuytren's disease; chr16:75411426 chr16:75379818~75381260:- CESC cis rs12022452 0.506 rs6673386 ENSG00000238287.1 RP11-656D10.3 -7.83 2.16e-13 7.5e-10 -0.65 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40546207 chr1:40493157~40508661:- CESC cis rs875971 0.895 rs12698520 ENSG00000226824.5 RP4-756H11.3 -7.83 2.17e-13 7.53e-10 -0.59 -0.47 Aortic root size; chr7:66453720 chr7:66654538~66669855:+ CESC cis rs5769707 0.967 rs17182154 ENSG00000188511.11 C22orf34 7.83 2.17e-13 7.54e-10 0.49 0.47 Monocyte percentage of white cells;Monocyte count; chr22:49596822 chr22:49414524~49657542:- CESC cis rs1707322 0.721 rs56255771 ENSG00000280836.1 AL355480.1 -7.82 2.17e-13 7.55e-10 -0.54 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758647 chr1:45581219~45581321:- CESC cis rs1707322 0.686 rs11211179 ENSG00000280836.1 AL355480.1 -7.82 2.17e-13 7.55e-10 -0.54 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45762410 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs10157795 ENSG00000280836.1 AL355480.1 -7.82 2.17e-13 7.55e-10 -0.54 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45762520 chr1:45581219~45581321:- CESC cis rs977987 0.872 rs1542864 ENSG00000261783.1 RP11-252K23.2 -7.82 2.17e-13 7.55e-10 -0.56 -0.47 Dupuytren's disease; chr16:75437480 chr16:75379818~75381260:- CESC cis rs875971 1 rs2420591 ENSG00000226824.5 RP4-756H11.3 -7.82 2.18e-13 7.58e-10 -0.59 -0.47 Aortic root size; chr7:66447394 chr7:66654538~66669855:+ CESC cis rs2882667 0.858 rs11959851 ENSG00000253404.1 AC034243.1 7.82 2.2e-13 7.62e-10 0.6 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139085716 chr5:138744434~138753309:- CESC cis rs8062405 1 rs62037365 ENSG00000259982.1 CDC37P1 7.82 2.22e-13 7.69e-10 0.58 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857641 chr16:28700294~28701540:- CESC cis rs2739330 0.76 rs5751760 ENSG00000250470.1 AP000351.3 7.82 2.24e-13 7.75e-10 0.6 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23976904~23977585:- CESC cis rs977987 0.835 rs1010630 ENSG00000261783.1 RP11-252K23.2 -7.82 2.24e-13 7.77e-10 -0.57 -0.47 Dupuytren's disease; chr16:75294693 chr16:75379818~75381260:- CESC cis rs7617773 0.78 rs11706277 ENSG00000229759.1 MRPS18AP1 7.82 2.25e-13 7.8e-10 0.54 0.47 Coronary artery disease; chr3:48318943 chr3:48256350~48256938:- CESC cis rs227275 0.556 rs6842179 ENSG00000246560.2 RP11-10L12.4 7.82 2.25e-13 7.81e-10 0.57 0.47 Allergic disease (asthma, hay fever or eczema); chr4:103018363 chr4:102828055~102844075:+ CESC cis rs9322193 0.923 rs9371207 ENSG00000231760.4 RP11-350J20.5 7.82 2.27e-13 7.86e-10 0.63 0.47 Lung cancer; chr6:149858087 chr6:149796151~149826294:- CESC cis rs977987 0.843 rs11649638 ENSG00000261783.1 RP11-252K23.2 -7.82 2.28e-13 7.89e-10 -0.56 -0.47 Dupuytren's disease; chr16:75454387 chr16:75379818~75381260:- CESC cis rs977987 0.815 rs4887829 ENSG00000261783.1 RP11-252K23.2 -7.82 2.28e-13 7.89e-10 -0.56 -0.47 Dupuytren's disease; chr16:75455037 chr16:75379818~75381260:- CESC cis rs8062405 1 rs2008514 ENSG00000259982.1 CDC37P1 -7.82 2.28e-13 7.89e-10 -0.57 -0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814284 chr16:28700294~28701540:- CESC cis rs526231 0.543 rs34379 ENSG00000175749.11 EIF3KP1 -7.82 2.3e-13 7.97e-10 -0.52 -0.47 Primary biliary cholangitis; chr5:103062994 chr5:103032376~103033031:+ CESC cis rs1799949 0.628 rs4474733 ENSG00000198496.9 NBR2 -7.82 2.3e-13 7.97e-10 -0.67 -0.47 Menopause (age at onset); chr17:43356292 chr17:43125610~43153671:+ CESC cis rs2882667 0.858 rs6596460 ENSG00000253404.1 AC034243.1 7.81 2.33e-13 8.06e-10 0.59 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139078491 chr5:138744434~138753309:- CESC cis rs12439619 0.846 rs62011975 ENSG00000278603.1 RP13-608F4.5 7.81 2.33e-13 8.07e-10 0.8 0.47 Intelligence (multi-trait analysis); chr15:82159213 chr15:82472203~82472426:+ CESC cis rs12439619 0.846 rs62012004 ENSG00000278603.1 RP13-608F4.5 7.81 2.33e-13 8.07e-10 0.8 0.47 Intelligence (multi-trait analysis); chr15:82183924 chr15:82472203~82472426:+ CESC cis rs526231 0.543 rs3776863 ENSG00000175749.11 EIF3KP1 7.81 2.34e-13 8.09e-10 0.52 0.47 Primary biliary cholangitis; chr5:102992165 chr5:103032376~103033031:+ CESC cis rs113835537 0.529 rs78999944 ENSG00000255517.5 CTD-3074O7.5 -7.81 2.41e-13 8.3e-10 -0.54 -0.47 Airway imaging phenotypes; chr11:66483757 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs11550299 ENSG00000255517.5 CTD-3074O7.5 -7.81 2.41e-13 8.3e-10 -0.54 -0.47 Airway imaging phenotypes; chr11:66486614 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs4930379 ENSG00000255517.5 CTD-3074O7.5 -7.81 2.41e-13 8.3e-10 -0.54 -0.47 Airway imaging phenotypes; chr11:66488203 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs4930183 ENSG00000255517.5 CTD-3074O7.5 -7.81 2.41e-13 8.3e-10 -0.54 -0.47 Airway imaging phenotypes; chr11:66488261 chr11:66473490~66480233:- CESC cis rs875971 1 rs4717292 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66430611 chr7:66654538~66669855:+ CESC cis rs875971 0.895 rs10755833 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66448930 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs12668936 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66449417 chr7:66654538~66669855:+ CESC cis rs875971 0.895 rs1833495 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66456608 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs6945032 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66457499 chr7:66654538~66669855:+ CESC cis rs875971 0.929 rs12673810 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66458866 chr7:66654538~66669855:+ CESC cis rs875971 1 rs35149210 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66464938 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6961155 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66468308 chr7:66654538~66669855:+ CESC cis rs875971 1 rs7789768 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66473993 chr7:66654538~66669855:+ CESC cis rs875971 1 rs1363055 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66478288 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs9691480 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66479319 chr7:66654538~66669855:+ CESC cis rs875971 1 rs7789554 ENSG00000226824.5 RP4-756H11.3 -7.81 2.41e-13 8.3e-10 -0.59 -0.47 Aortic root size; chr7:66481051 chr7:66654538~66669855:+ CESC cis rs526231 0.512 rs34797 ENSG00000175749.11 EIF3KP1 7.81 2.43e-13 8.35e-10 0.53 0.47 Primary biliary cholangitis; chr5:103090023 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34801 ENSG00000175749.11 EIF3KP1 7.81 2.43e-13 8.35e-10 0.53 0.47 Primary biliary cholangitis; chr5:103090809 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs34807 ENSG00000175749.11 EIF3KP1 7.81 2.43e-13 8.35e-10 0.53 0.47 Primary biliary cholangitis; chr5:103092818 chr5:103032376~103033031:+ CESC cis rs2882667 0.929 rs34846849 ENSG00000253404.1 AC034243.1 7.81 2.43e-13 8.38e-10 0.6 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139024889 chr5:138744434~138753309:- CESC cis rs12022452 0.556 rs12037288 ENSG00000238287.1 RP11-656D10.3 -7.81 2.44e-13 8.4e-10 -0.66 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40530625 chr1:40493157~40508661:- CESC cis rs977987 0.806 rs35937717 ENSG00000261783.1 RP11-252K23.2 -7.8 2.46e-13 8.46e-10 -0.57 -0.47 Dupuytren's disease; chr16:75297669 chr16:75379818~75381260:- CESC cis rs1153858 1 rs10519022 ENSG00000259520.4 CTD-2651B20.3 7.8 2.5e-13 8.58e-10 0.62 0.47 Homoarginine levels; chr15:45371486 chr15:45251580~45279251:- CESC cis rs10463554 0.75 rs26257 ENSG00000175749.11 EIF3KP1 7.8 2.5e-13 8.59e-10 0.53 0.47 Parkinson's disease; chr5:103214830 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs246900 ENSG00000175749.11 EIF3KP1 7.8 2.5e-13 8.6e-10 0.52 0.47 Primary biliary cholangitis; chr5:103198928 chr5:103032376~103033031:+ CESC cis rs977987 0.778 rs1109341 ENSG00000261783.1 RP11-252K23.2 -7.8 2.52e-13 8.65e-10 -0.58 -0.47 Dupuytren's disease; chr16:75411707 chr16:75379818~75381260:- CESC cis rs10463554 0.727 rs34768 ENSG00000175749.11 EIF3KP1 7.8 2.53e-13 8.7e-10 0.54 0.47 Parkinson's disease; chr5:103155798 chr5:103032376~103033031:+ CESC cis rs2882667 0.838 rs11958529 ENSG00000253404.1 AC034243.1 7.8 2.55e-13 8.74e-10 0.54 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139059379 chr5:138744434~138753309:- CESC cis rs9545047 0.901 rs7982263 ENSG00000227676.3 LINC01068 -7.8 2.55e-13 8.74e-10 -0.55 -0.47 Schizophrenia; chr13:79486939 chr13:79566727~79571436:+ CESC cis rs875971 1 rs875971 ENSG00000226824.5 RP4-756H11.3 7.8 2.55e-13 8.76e-10 0.57 0.47 Aortic root size; chr7:66152608 chr7:66654538~66669855:+ CESC cis rs1707322 0.717 rs3014246 ENSG00000280836.1 AL355480.1 7.8 2.55e-13 8.77e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620405 chr1:45581219~45581321:- CESC cis rs10256972 0.706 rs12701970 ENSG00000229043.2 AC091729.9 -7.8 2.57e-13 8.82e-10 -0.51 -0.47 Endometriosis;Longevity; chr7:1082322 chr7:1160374~1165267:+ CESC cis rs10463554 0.759 rs34815 ENSG00000175749.11 EIF3KP1 7.8 2.59e-13 8.87e-10 0.54 0.47 Parkinson's disease; chr5:103098561 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs17154942 ENSG00000175749.11 EIF3KP1 -7.8 2.6e-13 8.9e-10 -0.53 -0.47 Primary biliary cholangitis; chr5:103017014 chr5:103032376~103033031:+ CESC cis rs7617773 0.78 rs13090538 ENSG00000229759.1 MRPS18AP1 7.8 2.6e-13 8.91e-10 0.51 0.47 Coronary artery disease; chr3:48329279 chr3:48256350~48256938:- CESC cis rs977987 0.835 rs3851733 ENSG00000261783.1 RP11-252K23.2 -7.8 2.61e-13 8.95e-10 -0.58 -0.47 Dupuytren's disease; chr16:75336365 chr16:75379818~75381260:- CESC cis rs7208859 0.673 rs999798 ENSG00000263531.1 RP13-753N3.1 7.8 2.61e-13 8.95e-10 0.73 0.47 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831822 chr17:30863921~30864940:- CESC cis rs12439619 0.846 rs62012059 ENSG00000278603.1 RP13-608F4.5 7.79 2.64e-13 9.04e-10 0.8 0.47 Intelligence (multi-trait analysis); chr15:82251669 chr15:82472203~82472426:+ CESC cis rs1707322 0.717 rs2253862 ENSG00000280836.1 AL355480.1 7.79 2.64e-13 9.04e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616288 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs2991988 ENSG00000280836.1 AL355480.1 7.79 2.64e-13 9.04e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616759 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs2991989 ENSG00000280836.1 AL355480.1 7.79 2.64e-13 9.04e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45617293 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs2275086 ENSG00000280836.1 AL355480.1 7.79 2.64e-13 9.04e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620207 chr1:45581219~45581321:- CESC cis rs1707322 0.655 rs3014240 ENSG00000280836.1 AL355480.1 7.79 2.64e-13 9.04e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45623553 chr1:45581219~45581321:- CESC cis rs1707322 0.686 rs3014235 ENSG00000280836.1 AL355480.1 7.79 2.64e-13 9.04e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625840 chr1:45581219~45581321:- CESC cis rs1707322 0.656 rs9429172 ENSG00000280836.1 AL355480.1 7.79 2.64e-13 9.04e-10 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45626804 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs1135850 ENSG00000280836.1 AL355480.1 -7.79 2.64e-13 9.04e-10 -0.55 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628020 chr1:45581219~45581321:- CESC cis rs526231 0.511 rs27896 ENSG00000175749.11 EIF3KP1 7.79 2.66e-13 9.09e-10 0.54 0.47 Primary biliary cholangitis; chr5:103152867 chr5:103032376~103033031:+ CESC cis rs10463554 0.526 rs114525197 ENSG00000175749.11 EIF3KP1 7.79 2.66e-13 9.1e-10 0.54 0.47 Parkinson's disease; chr5:103107341 chr5:103032376~103033031:+ CESC cis rs26232 0.521 rs40508 ENSG00000175749.11 EIF3KP1 7.79 2.66e-13 9.1e-10 0.54 0.47 Rheumatoid arthritis; chr5:103108234 chr5:103032376~103033031:+ CESC cis rs6142102 0.602 rs2300209 ENSG00000276073.1 RP5-1125A11.7 -7.79 2.71e-13 9.24e-10 -0.42 -0.47 Skin pigmentation; chr20:34055294 chr20:33985617~33988989:- CESC cis rs5769707 0.967 rs9616701 ENSG00000188511.11 C22orf34 7.79 2.72e-13 9.28e-10 0.48 0.47 Monocyte percentage of white cells;Monocyte count; chr22:49631898 chr22:49414524~49657542:- CESC cis rs1577917 1 rs12201880 ENSG00000203875.9 SNHG5 -7.79 2.72e-13 9.28e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85917289 chr6:85660950~85678736:- CESC cis rs1577917 1 rs7756203 ENSG00000203875.9 SNHG5 -7.79 2.72e-13 9.28e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85917989 chr6:85660950~85678736:- CESC cis rs1577917 1 rs10944161 ENSG00000203875.9 SNHG5 -7.79 2.72e-13 9.28e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85920658 chr6:85660950~85678736:- CESC cis rs1577917 1 rs1857965 ENSG00000203875.9 SNHG5 -7.79 2.72e-13 9.28e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85921058 chr6:85660950~85678736:- CESC cis rs1577917 1 rs7771342 ENSG00000203875.9 SNHG5 -7.79 2.72e-13 9.28e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85922218 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12154056 ENSG00000203875.9 SNHG5 -7.79 2.72e-13 9.28e-10 -0.58 -0.47 Response to antipsychotic treatment; chr6:85924376 chr6:85660950~85678736:- CESC cis rs977987 0.872 rs4243111 ENSG00000261783.1 RP11-252K23.2 -7.79 2.72e-13 9.29e-10 -0.57 -0.47 Dupuytren's disease; chr16:75286929 chr16:75379818~75381260:- CESC cis rs526231 0.543 rs27698 ENSG00000175749.11 EIF3KP1 -7.79 2.73e-13 9.31e-10 -0.53 -0.47 Primary biliary cholangitis; chr5:103190474 chr5:103032376~103033031:+ CESC cis rs1577917 0.771 rs9450290 ENSG00000203875.9 SNHG5 7.79 2.73e-13 9.31e-10 0.57 0.47 Response to antipsychotic treatment; chr6:85523679 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs9353318 ENSG00000203875.9 SNHG5 7.79 2.73e-13 9.31e-10 0.57 0.47 Response to antipsychotic treatment; chr6:85522003 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs7742201 ENSG00000203875.9 SNHG5 -7.79 2.76e-13 9.41e-10 -0.56 -0.47 Response to antipsychotic treatment; chr6:85723212 chr6:85660950~85678736:- CESC cis rs6991838 0.584 rs4737221 ENSG00000272010.1 CTD-3025N20.3 -7.79 2.77e-13 9.45e-10 -0.53 -0.47 Intelligence (multi-trait analysis); chr8:65569075 chr8:65591850~65592472:- CESC cis rs227275 0.525 rs13150426 ENSG00000246560.2 RP11-10L12.4 7.78 2.79e-13 9.51e-10 0.57 0.47 Allergic disease (asthma, hay fever or eczema); chr4:103013743 chr4:102828055~102844075:+ CESC cis rs526231 0.543 rs17154913 ENSG00000175749.11 EIF3KP1 7.78 2.8e-13 9.52e-10 0.52 0.47 Primary biliary cholangitis; chr5:102992786 chr5:103032376~103033031:+ CESC cis rs875971 1 rs778706 ENSG00000226824.5 RP4-756H11.3 -7.78 2.83e-13 9.62e-10 -0.59 -0.47 Aortic root size; chr7:66395437 chr7:66654538~66669855:+ CESC cis rs875971 0.895 rs778700 ENSG00000226824.5 RP4-756H11.3 -7.78 2.83e-13 9.62e-10 -0.59 -0.47 Aortic root size; chr7:66401463 chr7:66654538~66669855:+ CESC cis rs875971 1 rs778699 ENSG00000226824.5 RP4-756H11.3 -7.78 2.83e-13 9.62e-10 -0.59 -0.47 Aortic root size; chr7:66403303 chr7:66654538~66669855:+ CESC cis rs875971 0.929 rs778692 ENSG00000226824.5 RP4-756H11.3 -7.78 2.83e-13 9.62e-10 -0.59 -0.47 Aortic root size; chr7:66407462 chr7:66654538~66669855:+ CESC cis rs875971 1 rs4718343 ENSG00000226824.5 RP4-756H11.3 -7.78 2.83e-13 9.62e-10 -0.59 -0.47 Aortic root size; chr7:66409301 chr7:66654538~66669855:+ CESC cis rs875971 1 rs1968225 ENSG00000226824.5 RP4-756H11.3 -7.78 2.83e-13 9.62e-10 -0.59 -0.47 Aortic root size; chr7:66409786 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6460295 ENSG00000226824.5 RP4-756H11.3 -7.78 2.83e-13 9.62e-10 -0.59 -0.47 Aortic root size; chr7:66417741 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs6978721 ENSG00000226824.5 RP4-756H11.3 -7.78 2.83e-13 9.62e-10 -0.59 -0.47 Aortic root size; chr7:66418217 chr7:66654538~66669855:+ CESC cis rs12439619 0.846 rs62012056 ENSG00000278603.1 RP13-608F4.5 7.78 2.85e-13 9.67e-10 0.8 0.47 Intelligence (multi-trait analysis); chr15:82247278 chr15:82472203~82472426:+ CESC cis rs801193 0.613 rs2659900 ENSG00000226824.5 RP4-756H11.3 -7.78 2.85e-13 9.69e-10 -0.58 -0.47 Aortic root size; chr7:66719456 chr7:66654538~66669855:+ CESC cis rs801193 0.636 rs2659895 ENSG00000226824.5 RP4-756H11.3 -7.78 2.85e-13 9.69e-10 -0.58 -0.47 Aortic root size; chr7:66731484 chr7:66654538~66669855:+ CESC cis rs526231 0.543 rs7714539 ENSG00000175749.11 EIF3KP1 7.78 2.87e-13 9.73e-10 0.52 0.47 Primary biliary cholangitis; chr5:102993174 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs60633061 ENSG00000175749.11 EIF3KP1 7.78 2.87e-13 9.73e-10 0.52 0.47 Primary biliary cholangitis; chr5:102994345 chr5:103032376~103033031:+ CESC cis rs1799949 0.929 rs799905 ENSG00000198496.9 NBR2 -7.78 2.93e-13 9.93e-10 -0.55 -0.47 Menopause (age at onset); chr17:43125170 chr17:43125610~43153671:+ CESC cis rs526231 0.543 rs62362541 ENSG00000175749.11 EIF3KP1 7.78 2.93e-13 9.94e-10 0.52 0.47 Primary biliary cholangitis; chr5:102986744 chr5:103032376~103033031:+ CESC cis rs11722779 0.933 rs7695096 ENSG00000246560.2 RP11-10L12.4 7.78 2.94e-13 9.97e-10 0.57 0.47 Schizophrenia; chr4:103011399 chr4:102828055~102844075:+ CESC cis rs12022452 0.63 rs3795346 ENSG00000238287.1 RP11-656D10.3 -7.78 2.94e-13 9.98e-10 -0.67 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40508753 chr1:40493157~40508661:- CESC cis rs12022452 0.591 rs4660415 ENSG00000238287.1 RP11-656D10.3 -7.78 2.94e-13 9.98e-10 -0.67 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40512819 chr1:40493157~40508661:- CESC cis rs12022452 0.556 rs11208298 ENSG00000238287.1 RP11-656D10.3 -7.78 2.94e-13 9.98e-10 -0.67 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40513206 chr1:40493157~40508661:- CESC cis rs6700559 0.804 rs11588318 ENSG00000260088.1 RP11-92G12.3 -7.78 2.95e-13 9.98e-10 -0.58 -0.47 Coronary artery disease; chr1:200669534 chr1:200669507~200694250:+ CESC cis rs6700559 0.903 rs6661240 ENSG00000260088.1 RP11-92G12.3 -7.78 2.95e-13 9.98e-10 -0.58 -0.47 Coronary artery disease; chr1:200669719 chr1:200669507~200694250:+ CESC cis rs6700559 0.967 rs6688581 ENSG00000260088.1 RP11-92G12.3 -7.78 2.95e-13 9.98e-10 -0.58 -0.47 Coronary artery disease; chr1:200670028 chr1:200669507~200694250:+ CESC cis rs6700559 1 rs3806358 ENSG00000260088.1 RP11-92G12.3 -7.78 2.95e-13 9.98e-10 -0.58 -0.47 Coronary artery disease; chr1:200670555 chr1:200669507~200694250:+ CESC cis rs526231 0.543 rs158395 ENSG00000175749.11 EIF3KP1 7.78 2.95e-13 9.99e-10 0.52 0.47 Primary biliary cholangitis; chr5:103075685 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs158400 ENSG00000175749.11 EIF3KP1 7.78 2.95e-13 9.99e-10 0.52 0.47 Primary biliary cholangitis; chr5:103077628 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs257302 ENSG00000175749.11 EIF3KP1 7.78 2.95e-13 9.99e-10 0.52 0.47 Primary biliary cholangitis; chr5:103080426 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs257303 ENSG00000175749.11 EIF3KP1 7.78 2.95e-13 9.99e-10 0.52 0.47 Primary biliary cholangitis; chr5:103081023 chr5:103032376~103033031:+ CESC cis rs1707322 0.686 rs2991987 ENSG00000280836.1 AL355480.1 7.77 3e-13 1.01e-09 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615750 chr1:45581219~45581321:- CESC cis rs1707322 0.686 rs3014239 ENSG00000280836.1 AL355480.1 7.77 3e-13 1.01e-09 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624129 chr1:45581219~45581321:- CESC cis rs1707322 0.686 rs3014236 ENSG00000280836.1 AL355480.1 7.77 3e-13 1.01e-09 0.55 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625633 chr1:45581219~45581321:- CESC cis rs2404602 0.598 rs11634019 ENSG00000259422.1 RP11-593F23.1 -7.77 3.01e-13 1.02e-09 -0.6 -0.47 Blood metabolite levels; chr15:76342339 chr15:76174891~76181486:- CESC cis rs6700559 1 rs4265457 ENSG00000260088.1 RP11-92G12.3 -7.77 3.05e-13 1.03e-09 -0.58 -0.47 Coronary artery disease; chr1:200674326 chr1:200669507~200694250:+ CESC cis rs2882667 0.858 rs35812969 ENSG00000253404.1 AC034243.1 7.77 3.06e-13 1.03e-09 0.6 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139041861 chr5:138744434~138753309:- CESC cis rs2882667 0.858 rs11242442 ENSG00000253404.1 AC034243.1 7.77 3.06e-13 1.03e-09 0.6 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139044800 chr5:138744434~138753309:- CESC cis rs12594515 0.548 rs12912226 ENSG00000273972.1 CTD-2306A12.1 -7.77 3.08e-13 1.04e-09 -0.63 -0.47 Weight;Waist circumference; chr15:45693510 chr15:45702640~45703183:+ CESC cis rs875971 0.508 rs10242423 ENSG00000226824.5 RP4-756H11.3 7.77 3.1e-13 1.05e-09 0.56 0.47 Aortic root size; chr7:66594188 chr7:66654538~66669855:+ CESC cis rs875971 0.508 rs10253883 ENSG00000226824.5 RP4-756H11.3 7.77 3.1e-13 1.05e-09 0.56 0.47 Aortic root size; chr7:66596151 chr7:66654538~66669855:+ CESC cis rs12439619 0.739 rs62012046 ENSG00000278603.1 RP13-608F4.5 7.77 3.12e-13 1.05e-09 0.8 0.47 Intelligence (multi-trait analysis); chr15:82236824 chr15:82472203~82472426:+ CESC cis rs12439619 0.774 rs62012047 ENSG00000278603.1 RP13-608F4.5 7.77 3.12e-13 1.05e-09 0.8 0.47 Intelligence (multi-trait analysis); chr15:82236852 chr15:82472203~82472426:+ CESC cis rs12439619 0.81 rs62012049 ENSG00000278603.1 RP13-608F4.5 7.77 3.12e-13 1.05e-09 0.8 0.47 Intelligence (multi-trait analysis); chr15:82237722 chr15:82472203~82472426:+ CESC cis rs1577917 0.771 rs4419647 ENSG00000203875.9 SNHG5 7.77 3.13e-13 1.06e-09 0.56 0.47 Response to antipsychotic treatment; chr6:85516021 chr6:85660950~85678736:- CESC cis rs1930961 1 rs1930961 ENSG00000100058.11 CRYBB2P1 7.77 3.13e-13 1.06e-09 0.67 0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25479298 chr22:25448105~25520854:+ CESC cis rs6142102 0.581 rs4911148 ENSG00000276073.1 RP5-1125A11.7 -7.76 3.2e-13 1.08e-09 -0.43 -0.47 Skin pigmentation; chr20:34080438 chr20:33985617~33988989:- CESC cis rs1707322 0.686 rs1250 ENSG00000280836.1 AL355480.1 -7.76 3.2e-13 1.08e-09 -0.55 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628355 chr1:45581219~45581321:- CESC cis rs875971 0.508 rs10950045 ENSG00000226824.5 RP4-756H11.3 7.76 3.23e-13 1.09e-09 0.56 0.47 Aortic root size; chr7:66601386 chr7:66654538~66669855:+ CESC cis rs1707322 0.682 rs12037459 ENSG00000280836.1 AL355480.1 -7.76 3.23e-13 1.09e-09 -0.55 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629287 chr1:45581219~45581321:- CESC cis rs4718428 1 rs4718428 ENSG00000226824.5 RP4-756H11.3 -7.76 3.24e-13 1.09e-09 -0.6 -0.47 Corneal structure; chr7:66956459 chr7:66654538~66669855:+ CESC cis rs1577917 0.74 rs6926049 ENSG00000203875.9 SNHG5 7.76 3.26e-13 1.1e-09 0.55 0.47 Response to antipsychotic treatment; chr6:85556415 chr6:85660950~85678736:- CESC cis rs875971 0.964 rs1643388 ENSG00000226824.5 RP4-756H11.3 -7.76 3.3e-13 1.11e-09 -0.59 -0.47 Aortic root size; chr7:66379575 chr7:66654538~66669855:+ CESC cis rs875971 1 rs778722 ENSG00000226824.5 RP4-756H11.3 -7.76 3.3e-13 1.11e-09 -0.59 -0.47 Aortic root size; chr7:66379841 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs778721 ENSG00000226824.5 RP4-756H11.3 -7.76 3.3e-13 1.11e-09 -0.59 -0.47 Aortic root size; chr7:66380410 chr7:66654538~66669855:+ CESC cis rs150992 0.79 rs325220 ENSG00000248489.1 CTD-2007H13.3 7.76 3.3e-13 1.11e-09 0.55 0.47 Body mass index; chr5:98968860 chr5:98929171~98995013:+ CESC cis rs7849270 0.959 rs9408986 ENSG00000268707.1 RP11-247A12.7 7.76 3.32e-13 1.11e-09 0.62 0.47 Blood metabolite ratios; chr9:129126156 chr9:129170434~129170940:+ CESC cis rs7044106 0.734 rs12553070 ENSG00000226752.6 PSMD5-AS1 -7.76 3.33e-13 1.12e-09 -0.51 -0.47 Hip circumference adjusted for BMI; chr9:120722988 chr9:120824828~120854385:+ CESC cis rs7617773 0.963 rs12495221 ENSG00000229759.1 MRPS18AP1 -7.75 3.35e-13 1.12e-09 -0.47 -0.46 Coronary artery disease; chr3:48137688 chr3:48256350~48256938:- CESC cis rs526231 0.543 rs34766 ENSG00000175749.11 EIF3KP1 7.75 3.37e-13 1.13e-09 0.53 0.46 Primary biliary cholangitis; chr5:103175219 chr5:103032376~103033031:+ CESC cis rs1577917 1 rs955196 ENSG00000203875.9 SNHG5 7.75 3.42e-13 1.15e-09 0.59 0.46 Response to antipsychotic treatment; chr6:86020233 chr6:85660950~85678736:- CESC cis rs3096299 0.658 rs34590044 ENSG00000274627.1 RP11-104N10.2 7.75 3.49e-13 1.17e-09 0.45 0.46 Multiple myeloma (IgH translocation); chr16:89476749 chr16:89516797~89522217:+ CESC cis rs526231 0.543 rs34377 ENSG00000175749.11 EIF3KP1 7.75 3.51e-13 1.18e-09 0.52 0.46 Primary biliary cholangitis; chr5:103064852 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs40092 ENSG00000175749.11 EIF3KP1 7.75 3.54e-13 1.18e-09 0.53 0.46 Primary biliary cholangitis; chr5:103088509 chr5:103032376~103033031:+ CESC cis rs2739330 0.828 rs2877178 ENSG00000099984.9 GSTT2 -7.75 3.56e-13 1.19e-09 -0.57 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23980123~23983911:+ CESC cis rs977987 0.933 rs4888431 ENSG00000261783.1 RP11-252K23.2 -7.74 3.59e-13 1.2e-09 -0.57 -0.46 Dupuytren's disease; chr16:75466801 chr16:75379818~75381260:- CESC cis rs977987 1 rs62060550 ENSG00000261783.1 RP11-252K23.2 -7.74 3.59e-13 1.2e-09 -0.57 -0.46 Dupuytren's disease; chr16:75468354 chr16:75379818~75381260:- CESC cis rs1707322 0.717 rs3014245 ENSG00000280836.1 AL355480.1 7.74 3.6e-13 1.2e-09 0.56 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621241 chr1:45581219~45581321:- CESC cis rs526231 0.543 rs152134 ENSG00000175749.11 EIF3KP1 7.74 3.62e-13 1.21e-09 0.52 0.46 Primary biliary cholangitis; chr5:103176745 chr5:103032376~103033031:+ CESC cis rs113835537 0.529 rs11821155 ENSG00000255517.5 CTD-3074O7.5 7.74 3.64e-13 1.21e-09 0.52 0.46 Airway imaging phenotypes; chr11:66478866 chr11:66473490~66480233:- CESC cis rs1577917 0.771 rs9362233 ENSG00000203875.9 SNHG5 -7.74 3.64e-13 1.22e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85648529 chr6:85660950~85678736:- CESC cis rs7115242 0.8 rs10736487 ENSG00000254851.1 RP11-109L13.1 -7.74 3.67e-13 1.22e-09 -0.87 -0.46 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117079516 chr11:117135528~117138582:+ CESC cis rs2486288 0.656 rs12908581 ENSG00000259520.4 CTD-2651B20.3 7.74 3.67e-13 1.22e-09 0.59 0.46 Glomerular filtration rate; chr15:45256437 chr15:45251580~45279251:- CESC cis rs5760092 0.572 rs738806 ENSG00000273295.1 AP000350.5 7.74 3.68e-13 1.23e-09 0.58 0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23901432~23907068:- CESC cis rs11722779 0.935 rs11938650 ENSG00000246560.2 RP11-10L12.4 7.74 3.68e-13 1.23e-09 0.57 0.46 Schizophrenia; chr4:103021639 chr4:102828055~102844075:+ CESC cis rs1577917 0.727 rs9351065 ENSG00000203875.9 SNHG5 -7.74 3.75e-13 1.25e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85650710 chr6:85660950~85678736:- CESC cis rs1707322 0.717 rs3014237 ENSG00000280836.1 AL355480.1 7.73 3.81e-13 1.27e-09 0.56 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624580 chr1:45581219~45581321:- CESC cis rs6991838 0.584 rs1053088 ENSG00000272010.1 CTD-3025N20.3 7.73 3.84e-13 1.28e-09 0.52 0.46 Intelligence (multi-trait analysis); chr8:65603548 chr8:65591850~65592472:- CESC cis rs875971 1 rs778726 ENSG00000226824.5 RP4-756H11.3 -7.73 3.86e-13 1.28e-09 -0.59 -0.46 Aortic root size; chr7:66363744 chr7:66654538~66669855:+ CESC cis rs875971 0.767 rs1695815 ENSG00000226824.5 RP4-756H11.3 -7.73 3.86e-13 1.28e-09 -0.59 -0.46 Aortic root size; chr7:66366357 chr7:66654538~66669855:+ CESC cis rs875971 1 rs778685 ENSG00000226824.5 RP4-756H11.3 -7.73 3.86e-13 1.28e-09 -0.59 -0.46 Aortic root size; chr7:66371189 chr7:66654538~66669855:+ CESC cis rs875971 0.929 rs778682 ENSG00000226824.5 RP4-756H11.3 -7.73 3.86e-13 1.28e-09 -0.59 -0.46 Aortic root size; chr7:66372947 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs11765965 ENSG00000226824.5 RP4-756H11.3 -7.73 3.86e-13 1.28e-09 -0.59 -0.46 Aortic root size; chr7:66377234 chr7:66654538~66669855:+ CESC cis rs977987 0.843 rs12927562 ENSG00000261783.1 RP11-252K23.2 -7.73 3.88e-13 1.29e-09 -0.57 -0.46 Dupuytren's disease; chr16:75448962 chr16:75379818~75381260:- CESC cis rs6142102 0.602 rs932388 ENSG00000276073.1 RP5-1125A11.7 -7.73 3.9e-13 1.3e-09 -0.42 -0.46 Skin pigmentation; chr20:34069572 chr20:33985617~33988989:- CESC cis rs7617773 1 rs12496784 ENSG00000229759.1 MRPS18AP1 -7.73 3.92e-13 1.3e-09 -0.47 -0.46 Coronary artery disease; chr3:48144777 chr3:48256350~48256938:- CESC cis rs3096299 0.685 rs4329923 ENSG00000274627.1 RP11-104N10.2 7.73 3.93e-13 1.31e-09 0.45 0.46 Multiple myeloma (IgH translocation); chr16:89493770 chr16:89516797~89522217:+ CESC cis rs7208859 0.673 rs9907197 ENSG00000263531.1 RP13-753N3.1 7.73 3.95e-13 1.31e-09 0.82 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30691245 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9915963 ENSG00000263531.1 RP13-753N3.1 7.73 3.95e-13 1.31e-09 0.82 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30692625 chr17:30863921~30864940:- CESC cis rs1577917 1 rs12664335 ENSG00000203875.9 SNHG5 7.73 3.98e-13 1.32e-09 0.57 0.46 Response to antipsychotic treatment; chr6:85888056 chr6:85660950~85678736:- CESC cis rs526231 0.543 rs6880911 ENSG00000175749.11 EIF3KP1 7.73 4.01e-13 1.33e-09 0.52 0.46 Primary biliary cholangitis; chr5:102971767 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs6881225 ENSG00000175749.11 EIF3KP1 7.73 4.01e-13 1.33e-09 0.52 0.46 Primary biliary cholangitis; chr5:102971888 chr5:103032376~103033031:+ CESC cis rs875971 1 rs6946143 ENSG00000226824.5 RP4-756H11.3 -7.73 4.02e-13 1.33e-09 -0.59 -0.46 Aortic root size; chr7:66114735 chr7:66654538~66669855:+ CESC cis rs7104764 1 rs6598074 ENSG00000277290.1 RP11-326C3.16 -7.73 4.02e-13 1.33e-09 -0.46 -0.46 Menarche (age at onset); chr11:219398 chr11:243099~243483:- CESC cis rs875971 0.898 rs6977501 ENSG00000226824.5 RP4-756H11.3 7.73 4.02e-13 1.33e-09 0.56 0.46 Aortic root size; chr7:66228355 chr7:66654538~66669855:+ CESC cis rs5769707 0.837 rs5769709 ENSG00000188511.11 C22orf34 7.72 4.04e-13 1.34e-09 0.5 0.46 Monocyte percentage of white cells;Monocyte count; chr22:49628109 chr22:49414524~49657542:- CESC cis rs1707322 0.752 rs7541962 ENSG00000280836.1 AL355480.1 -7.72 4.05e-13 1.34e-09 -0.55 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769445 chr1:45581219~45581321:- CESC cis rs6991838 0.584 rs7459944 ENSG00000272010.1 CTD-3025N20.3 -7.72 4.06e-13 1.35e-09 -0.52 -0.46 Intelligence (multi-trait analysis); chr8:65566040 chr8:65591850~65592472:- CESC cis rs875971 0.862 rs7803416 ENSG00000226824.5 RP4-756H11.3 -7.72 4.07e-13 1.35e-09 -0.59 -0.46 Aortic root size; chr7:66489212 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs1981799 ENSG00000226824.5 RP4-756H11.3 -7.72 4.07e-13 1.35e-09 -0.59 -0.46 Aortic root size; chr7:66490572 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs2277911 ENSG00000226824.5 RP4-756H11.3 -7.72 4.07e-13 1.35e-09 -0.59 -0.46 Aortic root size; chr7:66493638 chr7:66654538~66669855:+ CESC cis rs977987 0.933 rs1834014 ENSG00000261783.1 RP11-252K23.2 -7.72 4.08e-13 1.35e-09 -0.57 -0.46 Dupuytren's disease; chr16:75467376 chr16:75379818~75381260:- CESC cis rs1707322 0.721 rs6429574 ENSG00000280836.1 AL355480.1 -7.72 4.09e-13 1.35e-09 -0.55 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668382 chr1:45581219~45581321:- CESC cis rs7849270 1 rs3118632 ENSG00000268707.1 RP11-247A12.7 7.72 4.09e-13 1.35e-09 0.56 0.46 Blood metabolite ratios; chr9:129139005 chr9:129170434~129170940:+ CESC cis rs977987 0.806 rs35787595 ENSG00000261783.1 RP11-252K23.2 -7.72 4.14e-13 1.37e-09 -0.57 -0.46 Dupuytren's disease; chr16:75432949 chr16:75379818~75381260:- CESC cis rs1707322 0.721 rs11211181 ENSG00000280836.1 AL355480.1 -7.72 4.19e-13 1.39e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45771128 chr1:45581219~45581321:- CESC cis rs1577917 1 rs13194429 ENSG00000203875.9 SNHG5 -7.71 4.3e-13 1.42e-09 -0.59 -0.46 Response to antipsychotic treatment; chr6:85936987 chr6:85660950~85678736:- CESC cis rs2739330 0.892 rs4822455 ENSG00000099984.9 GSTT2 -7.71 4.37e-13 1.44e-09 -0.56 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23980123~23983911:+ CESC cis rs2882667 0.755 rs55650316 ENSG00000253404.1 AC034243.1 7.71 4.41e-13 1.46e-09 0.58 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139131603 chr5:138744434~138753309:- CESC cis rs875971 1 rs3735148 ENSG00000226824.5 RP4-756H11.3 -7.71 4.49e-13 1.48e-09 -0.58 -0.46 Aortic root size; chr7:66506022 chr7:66654538~66669855:+ CESC cis rs6700559 1 rs7527499 ENSG00000260088.1 RP11-92G12.3 -7.71 4.54e-13 1.5e-09 -0.57 -0.46 Coronary artery disease; chr1:200676217 chr1:200669507~200694250:+ CESC cis rs6700559 1 rs6427838 ENSG00000260088.1 RP11-92G12.3 -7.71 4.54e-13 1.5e-09 -0.57 -0.46 Coronary artery disease; chr1:200676519 chr1:200669507~200694250:+ CESC cis rs6700559 1 rs12061346 ENSG00000260088.1 RP11-92G12.3 -7.71 4.54e-13 1.5e-09 -0.57 -0.46 Coronary artery disease; chr1:200677648 chr1:200669507~200694250:+ CESC cis rs6700559 1 rs7533971 ENSG00000260088.1 RP11-92G12.3 -7.71 4.54e-13 1.5e-09 -0.57 -0.46 Coronary artery disease; chr1:200678243 chr1:200669507~200694250:+ CESC cis rs6700559 1 rs10919998 ENSG00000260088.1 RP11-92G12.3 -7.71 4.54e-13 1.5e-09 -0.57 -0.46 Coronary artery disease; chr1:200679182 chr1:200669507~200694250:+ CESC cis rs6700559 0.967 rs4072552 ENSG00000260088.1 RP11-92G12.3 -7.71 4.54e-13 1.5e-09 -0.57 -0.46 Coronary artery disease; chr1:200680003 chr1:200669507~200694250:+ CESC cis rs1707322 0.721 rs7519900 ENSG00000280836.1 AL355480.1 -7.71 4.54e-13 1.5e-09 -0.55 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769275 chr1:45581219~45581321:- CESC cis rs2739330 0.731 rs2000468 ENSG00000250470.1 AP000351.3 7.71 4.55e-13 1.5e-09 0.59 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23976904~23977585:- CESC cis rs2882667 0.824 rs13189485 ENSG00000253404.1 AC034243.1 7.71 4.55e-13 1.5e-09 0.6 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139139712 chr5:138744434~138753309:- CESC cis rs526231 0.511 rs158402 ENSG00000175749.11 EIF3KP1 7.7 4.57e-13 1.5e-09 0.51 0.46 Primary biliary cholangitis; chr5:103079821 chr5:103032376~103033031:+ CESC cis rs1153858 1 rs2467864 ENSG00000259520.4 CTD-2651B20.3 7.7 4.6e-13 1.51e-09 0.61 0.46 Homoarginine levels; chr15:45348900 chr15:45251580~45279251:- CESC cis rs2882667 0.858 rs11957633 ENSG00000253404.1 AC034243.1 7.7 4.64e-13 1.53e-09 0.6 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139028705 chr5:138744434~138753309:- CESC cis rs977987 0.835 rs11641532 ENSG00000261783.1 RP11-252K23.2 -7.7 4.64e-13 1.53e-09 -0.57 -0.46 Dupuytren's disease; chr16:75295582 chr16:75379818~75381260:- CESC cis rs11722779 0.869 rs223350 ENSG00000246560.2 RP11-10L12.4 7.7 4.69e-13 1.54e-09 0.56 0.46 Schizophrenia; chr4:102856899 chr4:102828055~102844075:+ CESC cis rs1707322 0.721 rs10890346 ENSG00000280836.1 AL355480.1 7.7 4.69e-13 1.54e-09 0.54 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758220 chr1:45581219~45581321:- CESC cis rs6700559 1 rs6667172 ENSG00000260088.1 RP11-92G12.3 -7.7 4.69e-13 1.54e-09 -0.57 -0.46 Coronary artery disease; chr1:200674710 chr1:200669507~200694250:+ CESC cis rs6700559 1 rs10494821 ENSG00000260088.1 RP11-92G12.3 -7.7 4.76e-13 1.56e-09 -0.57 -0.46 Coronary artery disease; chr1:200673357 chr1:200669507~200694250:+ CESC cis rs1577917 0.771 rs9362237 ENSG00000203875.9 SNHG5 7.69 4.85e-13 1.59e-09 0.55 0.46 Response to antipsychotic treatment; chr6:85699346 chr6:85660950~85678736:- CESC cis rs1707322 0.506 rs2991983 ENSG00000280836.1 AL355480.1 7.69 4.89e-13 1.6e-09 0.55 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613719 chr1:45581219~45581321:- CESC cis rs526231 0.575 rs26822 ENSG00000175749.11 EIF3KP1 7.69 4.95e-13 1.62e-09 0.53 0.46 Primary biliary cholangitis; chr5:103183094 chr5:103032376~103033031:+ CESC cis rs150992 0.821 rs326480 ENSG00000248489.1 CTD-2007H13.3 7.69 5.01e-13 1.64e-09 0.55 0.46 Body mass index; chr5:98949263 chr5:98929171~98995013:+ CESC cis rs1577917 0.876 rs12201992 ENSG00000203875.9 SNHG5 -7.69 5.08e-13 1.66e-09 -0.58 -0.46 Response to antipsychotic treatment; chr6:85908501 chr6:85660950~85678736:- CESC cis rs977987 0.806 rs12917651 ENSG00000261783.1 RP11-252K23.2 -7.69 5.14e-13 1.68e-09 -0.56 -0.46 Dupuytren's disease; chr16:75432798 chr16:75379818~75381260:- CESC cis rs875971 0.964 rs6978429 ENSG00000226824.5 RP4-756H11.3 -7.68 5.16e-13 1.69e-09 -0.58 -0.46 Aortic root size; chr7:66494889 chr7:66654538~66669855:+ CESC cis rs875971 1 rs4718357 ENSG00000226824.5 RP4-756H11.3 -7.68 5.16e-13 1.69e-09 -0.58 -0.46 Aortic root size; chr7:66495891 chr7:66654538~66669855:+ CESC cis rs875971 0.929 rs12535036 ENSG00000226824.5 RP4-756H11.3 -7.68 5.16e-13 1.69e-09 -0.58 -0.46 Aortic root size; chr7:66499076 chr7:66654538~66669855:+ CESC cis rs875971 1 rs12698523 ENSG00000226824.5 RP4-756H11.3 -7.68 5.16e-13 1.69e-09 -0.58 -0.46 Aortic root size; chr7:66503126 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6970030 ENSG00000226824.5 RP4-756H11.3 -7.68 5.16e-13 1.69e-09 -0.58 -0.46 Aortic root size; chr7:66503692 chr7:66654538~66669855:+ CESC cis rs875971 0.928 rs6970357 ENSG00000226824.5 RP4-756H11.3 -7.68 5.16e-13 1.69e-09 -0.58 -0.46 Aortic root size; chr7:66503891 chr7:66654538~66669855:+ CESC cis rs875971 0.929 rs6970860 ENSG00000226824.5 RP4-756H11.3 -7.68 5.16e-13 1.69e-09 -0.58 -0.46 Aortic root size; chr7:66511647 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6957199 ENSG00000226824.5 RP4-756H11.3 -7.68 5.16e-13 1.69e-09 -0.58 -0.46 Aortic root size; chr7:66513532 chr7:66654538~66669855:+ CESC cis rs526231 0.578 rs34794 ENSG00000175749.11 EIF3KP1 7.68 5.19e-13 1.69e-09 0.53 0.46 Primary biliary cholangitis; chr5:103087664 chr5:103032376~103033031:+ CESC cis rs1577917 0.771 rs12205013 ENSG00000203875.9 SNHG5 -7.68 5.21e-13 1.7e-09 -0.56 -0.46 Response to antipsychotic treatment; chr6:85623311 chr6:85660950~85678736:- CESC cis rs1707322 0.721 rs10789468 ENSG00000280836.1 AL355480.1 -7.68 5.23e-13 1.71e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658886 chr1:45581219~45581321:- CESC cis rs977987 0.872 rs3743609 ENSG00000261783.1 RP11-252K23.2 -7.68 5.25e-13 1.71e-09 -0.55 -0.46 Dupuytren's disease; chr16:75433123 chr16:75379818~75381260:- CESC cis rs526231 0.511 rs1011453 ENSG00000175749.11 EIF3KP1 7.68 5.27e-13 1.72e-09 0.5 0.46 Primary biliary cholangitis; chr5:103032323 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs62362558 ENSG00000175749.11 EIF3KP1 7.68 5.27e-13 1.72e-09 0.5 0.46 Primary biliary cholangitis; chr5:103032789 chr5:103032376~103033031:+ CESC cis rs526231 0.511 rs4421079 ENSG00000175749.11 EIF3KP1 7.68 5.27e-13 1.72e-09 0.5 0.46 Primary biliary cholangitis; chr5:103033372 chr5:103032376~103033031:+ CESC cis rs977987 0.872 rs7206665 ENSG00000261783.1 RP11-252K23.2 -7.68 5.28e-13 1.72e-09 -0.56 -0.46 Dupuytren's disease; chr16:75441389 chr16:75379818~75381260:- CESC cis rs12022452 0.591 rs6672398 ENSG00000238287.1 RP11-656D10.3 -7.68 5.28e-13 1.72e-09 -0.65 -0.46 Age-related hearing impairment (SNP x SNP interaction); chr1:40536505 chr1:40493157~40508661:- CESC cis rs6700559 1 rs4311922 ENSG00000260088.1 RP11-92G12.3 -7.68 5.28e-13 1.72e-09 -0.57 -0.46 Coronary artery disease; chr1:200674257 chr1:200669507~200694250:+ CESC cis rs6700559 0.967 rs4447009 ENSG00000260088.1 RP11-92G12.3 -7.68 5.28e-13 1.72e-09 -0.57 -0.46 Coronary artery disease; chr1:200674278 chr1:200669507~200694250:+ CESC cis rs875971 1 rs12532998 ENSG00000226824.5 RP4-756H11.3 -7.68 5.31e-13 1.73e-09 -0.58 -0.46 Aortic root size; chr7:66502472 chr7:66654538~66669855:+ CESC cis rs5769707 1 rs5769707 ENSG00000188511.11 C22orf34 7.68 5.32e-13 1.73e-09 0.47 0.46 Monocyte percentage of white cells;Monocyte count; chr22:49619754 chr22:49414524~49657542:- CESC cis rs1799949 0.965 rs6503727 ENSG00000198496.9 NBR2 -7.68 5.34e-13 1.74e-09 -0.55 -0.46 Menopause (age at onset); chr17:43160842 chr17:43125610~43153671:+ CESC cis rs113835537 0.529 rs57634456 ENSG00000255517.5 CTD-3074O7.5 -7.68 5.38e-13 1.75e-09 -0.52 -0.46 Airway imaging phenotypes; chr11:66483367 chr11:66473490~66480233:- CESC cis rs9326248 0.53 rs10732856 ENSG00000254851.1 RP11-109L13.1 -7.68 5.4e-13 1.76e-09 -0.79 -0.46 Blood protein levels; chr11:117036397 chr11:117135528~117138582:+ CESC cis rs7044106 0.791 rs4836831 ENSG00000226752.6 PSMD5-AS1 -7.68 5.41e-13 1.76e-09 -0.5 -0.46 Hip circumference adjusted for BMI; chr9:120734292 chr9:120824828~120854385:+ CESC cis rs875971 0.895 rs1974769 ENSG00000226824.5 RP4-756H11.3 -7.68 5.43e-13 1.77e-09 -0.59 -0.46 Aortic root size; chr7:66485627 chr7:66654538~66669855:+ CESC cis rs875971 0.895 rs6460300 ENSG00000226824.5 RP4-756H11.3 -7.68 5.43e-13 1.77e-09 -0.59 -0.46 Aortic root size; chr7:66487937 chr7:66654538~66669855:+ CESC cis rs1577917 0.771 rs2842607 ENSG00000203875.9 SNHG5 -7.68 5.47e-13 1.78e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85635321 chr6:85660950~85678736:- CESC cis rs1577917 0.771 rs2758847 ENSG00000203875.9 SNHG5 -7.68 5.47e-13 1.78e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85639385 chr6:85660950~85678736:- CESC cis rs526231 0.511 rs7731395 ENSG00000175749.11 EIF3KP1 7.67 5.51e-13 1.79e-09 0.49 0.46 Primary biliary cholangitis; chr5:103026057 chr5:103032376~103033031:+ CESC cis rs7849270 0.959 rs3124509 ENSG00000268707.1 RP11-247A12.7 7.67 5.54e-13 1.8e-09 0.55 0.46 Blood metabolite ratios; chr9:129134720 chr9:129170434~129170940:+ CESC cis rs1577917 0.917 rs35738006 ENSG00000203875.9 SNHG5 -7.67 5.54e-13 1.8e-09 -0.58 -0.46 Response to antipsychotic treatment; chr6:85936591 chr6:85660950~85678736:- CESC cis rs9326248 0.53 rs10790172 ENSG00000254851.1 RP11-109L13.1 -7.67 5.56e-13 1.81e-09 -0.83 -0.46 Blood protein levels; chr11:117057024 chr11:117135528~117138582:+ CESC cis rs6142102 0.602 rs4911402 ENSG00000276073.1 RP5-1125A11.7 -7.67 5.57e-13 1.81e-09 -0.42 -0.46 Skin pigmentation; chr20:34079839 chr20:33985617~33988989:- CESC cis rs875971 0.508 rs10258739 ENSG00000226824.5 RP4-756H11.3 7.67 5.58e-13 1.81e-09 0.55 0.46 Aortic root size; chr7:66597948 chr7:66654538~66669855:+ CESC cis rs7626444 0.625 rs1104375 ENSG00000272359.1 U4 -7.67 5.58e-13 1.81e-09 -0.54 -0.46 Monocyte count; chr3:196749172 chr3:196747192~196747324:- CESC cis rs1799949 0.965 rs8067269 ENSG00000198496.9 NBR2 -7.67 5.61e-13 1.82e-09 -0.55 -0.46 Menopause (age at onset); chr17:43083782 chr17:43125610~43153671:+ CESC cis rs1577917 0.739 rs9344532 ENSG00000203875.9 SNHG5 7.67 5.64e-13 1.83e-09 0.56 0.46 Response to antipsychotic treatment; chr6:85524352 chr6:85660950~85678736:- CESC cis rs977987 0.843 rs10459859 ENSG00000261783.1 RP11-252K23.2 -7.67 5.64e-13 1.83e-09 -0.57 -0.46 Dupuytren's disease; chr16:75348052 chr16:75379818~75381260:- CESC cis rs2882667 0.858 rs11242444 ENSG00000253404.1 AC034243.1 7.67 5.68e-13 1.84e-09 0.58 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139070690 chr5:138744434~138753309:- CESC cis rs10853057 0.541 rs62065481 ENSG00000214174.7 AMZ2P1 7.67 5.69e-13 1.84e-09 0.81 0.46 White matter microstructure (global fractional anisotropy); chr17:65008273 chr17:64966550~64975576:- CESC cis rs26232 0.521 rs11958562 ENSG00000175749.11 EIF3KP1 7.67 5.69e-13 1.85e-09 0.49 0.46 Rheumatoid arthritis; chr5:103027357 chr5:103032376~103033031:+ CESC cis rs1799949 0.965 rs7212284 ENSG00000198496.9 NBR2 -7.67 5.7e-13 1.85e-09 -0.55 -0.46 Menopause (age at onset); chr17:43053924 chr17:43125610~43153671:+ CESC cis rs526231 0.543 rs62362544 ENSG00000175749.11 EIF3KP1 7.67 5.79e-13 1.88e-09 0.51 0.46 Primary biliary cholangitis; chr5:102998543 chr5:103032376~103033031:+ CESC cis rs7849270 0.959 rs3118628 ENSG00000268707.1 RP11-247A12.7 7.66 5.84e-13 1.89e-09 0.61 0.46 Blood metabolite ratios; chr9:129123000 chr9:129170434~129170940:+ CESC cis rs977987 0.836 rs7198873 ENSG00000261783.1 RP11-252K23.2 -7.66 5.86e-13 1.9e-09 -0.57 -0.46 Dupuytren's disease; chr16:75440856 chr16:75379818~75381260:- CESC cis rs875971 0.964 rs6945019 ENSG00000226824.5 RP4-756H11.3 -7.66 5.96e-13 1.93e-09 -0.59 -0.46 Aortic root size; chr7:66457471 chr7:66654538~66669855:+ CESC cis rs5760092 0.618 rs4461358 ENSG00000225282.1 AP000350.6 -7.66 5.97e-13 1.93e-09 -0.61 -0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23926900~23929574:+ CESC cis rs1577917 1 rs6940458 ENSG00000203875.9 SNHG5 -7.66 6.02e-13 1.95e-09 -0.56 -0.46 Response to antipsychotic treatment; chr6:85935274 chr6:85660950~85678736:- CESC cis rs7104764 0.879 rs6598072 ENSG00000277290.1 RP11-326C3.16 -7.66 6.03e-13 1.95e-09 -0.43 -0.46 Menarche (age at onset); chr11:219793 chr11:243099~243483:- CESC cis rs7104764 0.957 rs6598071 ENSG00000277290.1 RP11-326C3.16 -7.66 6.03e-13 1.95e-09 -0.43 -0.46 Menarche (age at onset); chr11:219800 chr11:243099~243483:- CESC cis rs7104764 0.957 rs10794301 ENSG00000277290.1 RP11-326C3.16 -7.66 6.03e-13 1.95e-09 -0.43 -0.46 Menarche (age at onset); chr11:220401 chr11:243099~243483:- CESC cis rs10463554 0.963 rs13340364 ENSG00000175749.11 EIF3KP1 7.66 6.03e-13 1.95e-09 0.49 0.46 Parkinson's disease; chr5:103003406 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs13340345 ENSG00000175749.11 EIF3KP1 7.66 6.03e-13 1.95e-09 0.49 0.46 Parkinson's disease; chr5:103003518 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs3776860 ENSG00000175749.11 EIF3KP1 7.66 6.03e-13 1.95e-09 0.49 0.46 Parkinson's disease; chr5:103014266 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs62362546 ENSG00000175749.11 EIF3KP1 7.66 6.03e-13 1.95e-09 0.49 0.46 Parkinson's disease; chr5:103015615 chr5:103032376~103033031:+ CESC cis rs977987 0.806 rs11862684 ENSG00000261783.1 RP11-252K23.2 -7.66 6.06e-13 1.96e-09 -0.56 -0.46 Dupuytren's disease; chr16:75427848 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs12930452 ENSG00000261783.1 RP11-252K23.2 -7.66 6.06e-13 1.96e-09 -0.56 -0.46 Dupuytren's disease; chr16:75428157 chr16:75379818~75381260:- CESC cis rs10463554 0.963 rs17154959 ENSG00000175749.11 EIF3KP1 7.66 6.08e-13 1.96e-09 0.49 0.46 Parkinson's disease; chr5:103020587 chr5:103032376~103033031:+ CESC cis rs10463554 0.926 rs3776858 ENSG00000175749.11 EIF3KP1 7.66 6.08e-13 1.96e-09 0.49 0.46 Parkinson's disease; chr5:103021790 chr5:103032376~103033031:+ CESC cis rs12439619 0.705 rs4778665 ENSG00000278603.1 RP13-608F4.5 7.66 6.1e-13 1.97e-09 0.8 0.46 Intelligence (multi-trait analysis); chr15:82144163 chr15:82472203~82472426:+ CESC cis rs1577917 1 rs13217384 ENSG00000203875.9 SNHG5 -7.66 6.14e-13 1.98e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:86010282 chr6:85660950~85678736:- CESC cis rs2882667 0.756 rs11957953 ENSG00000253404.1 AC034243.1 7.65 6.2e-13 2e-09 0.6 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139143688 chr5:138744434~138753309:- CESC cis rs9545047 0.935 rs2783119 ENSG00000227676.3 LINC01068 7.65 6.22e-13 2e-09 0.53 0.46 Schizophrenia; chr13:79524983 chr13:79566727~79571436:+ CESC cis rs9326248 0.731 rs90192 ENSG00000254851.1 RP11-109L13.1 -7.65 6.25e-13 2.01e-09 -0.72 -0.46 Blood protein levels; chr11:117188631 chr11:117135528~117138582:+ CESC cis rs875971 0.964 rs697969 ENSG00000226824.5 RP4-756H11.3 7.65 6.31e-13 2.03e-09 0.59 0.46 Aortic root size; chr7:66093491 chr7:66654538~66669855:+ CESC cis rs875971 1 rs1182882 ENSG00000226824.5 RP4-756H11.3 7.65 6.31e-13 2.03e-09 0.59 0.46 Aortic root size; chr7:66097076 chr7:66654538~66669855:+ CESC cis rs1577917 0.771 rs2475790 ENSG00000203875.9 SNHG5 -7.65 6.33e-13 2.04e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85658350 chr6:85660950~85678736:- CESC cis rs507080 0.697 rs656287 ENSG00000255422.1 AP002954.4 -7.65 6.39e-13 2.05e-09 -0.55 -0.46 Serum metabolite levels; chr11:118701081 chr11:118704607~118750263:+ CESC cis rs507080 0.733 rs570949 ENSG00000255422.1 AP002954.4 -7.65 6.39e-13 2.05e-09 -0.55 -0.46 Serum metabolite levels; chr11:118701202 chr11:118704607~118750263:+ CESC cis rs977987 0.843 rs11644741 ENSG00000261783.1 RP11-252K23.2 -7.65 6.44e-13 2.07e-09 -0.56 -0.46 Dupuytren's disease; chr16:75432535 chr16:75379818~75381260:- CESC cis rs5760092 0.618 rs5996631 ENSG00000225282.1 AP000350.6 -7.65 6.44e-13 2.07e-09 -0.61 -0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23926900~23929574:+ CESC cis rs7208859 0.623 rs8082537 ENSG00000263531.1 RP13-753N3.1 7.65 6.47e-13 2.08e-09 0.82 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30688914 chr17:30863921~30864940:- CESC cis rs17826219 0.561 rs11655876 ENSG00000263531.1 RP13-753N3.1 7.65 6.47e-13 2.08e-09 0.82 0.46 Body mass index; chr17:30690132 chr17:30863921~30864940:- CESC cis rs526231 0.543 rs246916 ENSG00000175749.11 EIF3KP1 7.65 6.48e-13 2.08e-09 0.52 0.46 Primary biliary cholangitis; chr5:103221814 chr5:103032376~103033031:+ CESC cis rs4423214 0.569 rs12806918 ENSG00000254682.1 RP11-660L16.2 7.65 6.49e-13 2.08e-09 0.55 0.46 Vitamin D levels; chr11:71407972 chr11:71448674~71452157:+ CESC cis rs9545047 0.905 rs9318644 ENSG00000227676.3 LINC01068 -7.65 6.51e-13 2.09e-09 -0.53 -0.46 Schizophrenia; chr13:79510042 chr13:79566727~79571436:+ CESC cis rs2739330 0.734 rs2000467 ENSG00000099984.9 GSTT2 7.65 6.54e-13 2.1e-09 0.57 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23980123~23983911:+ CESC cis rs9322193 0.567 rs7742692 ENSG00000231760.4 RP11-350J20.5 7.65 6.55e-13 2.1e-09 0.57 0.46 Lung cancer; chr6:149892363 chr6:149796151~149826294:- CESC cis rs227275 0.554 rs223339 ENSG00000246560.2 RP11-10L12.4 7.64 6.61e-13 2.12e-09 0.55 0.46 Allergic disease (asthma, hay fever or eczema); chr4:102864700 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223333 ENSG00000246560.2 RP11-10L12.4 7.64 6.61e-13 2.12e-09 0.55 0.46 Allergic disease (asthma, hay fever or eczema); chr4:102868653 chr4:102828055~102844075:+ CESC cis rs1577917 0.771 rs4145082 ENSG00000203875.9 SNHG5 -7.64 6.63e-13 2.12e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85642298 chr6:85660950~85678736:- CESC cis rs801193 0.839 rs12534943 ENSG00000226824.5 RP4-756H11.3 7.64 6.68e-13 2.14e-09 0.56 0.46 Aortic root size; chr7:66605533 chr7:66654538~66669855:+ CESC cis rs801193 0.591 rs2707839 ENSG00000226824.5 RP4-756H11.3 -7.64 6.69e-13 2.14e-09 -0.58 -0.46 Aortic root size; chr7:66728097 chr7:66654538~66669855:+ CESC cis rs801193 0.805 rs12532355 ENSG00000226824.5 RP4-756H11.3 7.64 6.69e-13 2.14e-09 0.56 0.46 Aortic root size; chr7:66605597 chr7:66654538~66669855:+ CESC cis rs2404602 0.735 rs11637490 ENSG00000259422.1 RP11-593F23.1 -7.64 6.76e-13 2.16e-09 -0.54 -0.46 Blood metabolite levels; chr15:76467224 chr15:76174891~76181486:- CESC cis rs801193 0.839 rs6968619 ENSG00000226824.5 RP4-756H11.3 7.64 6.77e-13 2.16e-09 0.56 0.46 Aortic root size; chr7:66603880 chr7:66654538~66669855:+ CESC cis rs875971 1 rs2077593 ENSG00000226824.5 RP4-756H11.3 -7.64 6.77e-13 2.16e-09 -0.58 -0.46 Aortic root size; chr7:66427543 chr7:66654538~66669855:+ CESC cis rs7044106 0.791 rs735109 ENSG00000226752.6 PSMD5-AS1 -7.64 6.78e-13 2.16e-09 -0.5 -0.46 Hip circumference adjusted for BMI; chr9:120726601 chr9:120824828~120854385:+ CESC cis rs150992 0.861 rs467728 ENSG00000248489.1 CTD-2007H13.3 7.64 6.79e-13 2.17e-09 0.55 0.46 Body mass index; chr5:98953863 chr5:98929171~98995013:+ CESC cis rs2404602 0.735 rs2957614 ENSG00000259422.1 RP11-593F23.1 7.64 6.8e-13 2.17e-09 0.53 0.46 Blood metabolite levels; chr15:76404294 chr15:76174891~76181486:- CESC cis rs228614 0.51 rs223328 ENSG00000246560.2 RP11-10L12.4 7.64 6.85e-13 2.18e-09 0.55 0.46 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873379 chr4:102828055~102844075:+ CESC cis rs228614 0.536 rs223325 ENSG00000246560.2 RP11-10L12.4 7.64 6.85e-13 2.18e-09 0.55 0.46 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102875751 chr4:102828055~102844075:+ CESC cis rs1799949 0.965 rs4793230 ENSG00000198496.9 NBR2 -7.64 6.88e-13 2.19e-09 -0.56 -0.46 Menopause (age at onset); chr17:43350035 chr17:43125610~43153671:+ CESC cis rs801193 0.613 rs2016325 ENSG00000226824.5 RP4-756H11.3 7.64 6.9e-13 2.2e-09 0.58 0.46 Aortic root size; chr7:66858513 chr7:66654538~66669855:+ CESC cis rs2882667 0.858 rs17207870 ENSG00000253404.1 AC034243.1 7.64 6.91e-13 2.2e-09 0.58 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139052048 chr5:138744434~138753309:- CESC cis rs7044106 0.791 rs7043969 ENSG00000226752.6 PSMD5-AS1 -7.64 6.93e-13 2.21e-09 -0.5 -0.46 Hip circumference adjusted for BMI; chr9:120731711 chr9:120824828~120854385:+ CESC cis rs9545047 0.935 rs7339303 ENSG00000227676.3 LINC01068 -7.63 7.04e-13 2.24e-09 -0.53 -0.46 Schizophrenia; chr13:79516730 chr13:79566727~79571436:+ CESC cis rs9545047 0.905 rs7321953 ENSG00000227676.3 LINC01068 -7.63 7.04e-13 2.24e-09 -0.53 -0.46 Schizophrenia; chr13:79517404 chr13:79566727~79571436:+ CESC cis rs1153858 1 rs7169818 ENSG00000259520.4 CTD-2651B20.3 -7.63 7.12e-13 2.27e-09 -0.6 -0.46 Homoarginine levels; chr15:45347993 chr15:45251580~45279251:- CESC cis rs1577917 0.771 rs2842601 ENSG00000203875.9 SNHG5 -7.63 7.17e-13 2.28e-09 -0.55 -0.46 Response to antipsychotic treatment; chr6:85620415 chr6:85660950~85678736:- CESC cis rs7849270 1 rs2541161 ENSG00000268707.1 RP11-247A12.7 7.63 7.19e-13 2.29e-09 0.56 0.46 Blood metabolite ratios; chr9:129122523 chr9:129170434~129170940:+ CESC cis rs10463554 0.759 rs461609 ENSG00000175749.11 EIF3KP1 7.63 7.19e-13 2.29e-09 0.53 0.46 Parkinson's disease; chr5:103111601 chr5:103032376~103033031:+ CESC cis rs801193 1 rs10252765 ENSG00000226824.5 RP4-756H11.3 -7.63 7.23e-13 2.3e-09 -0.59 -0.46 Aortic root size; chr7:66763745 chr7:66654538~66669855:+ CESC cis rs1707322 0.686 rs3014251 ENSG00000280836.1 AL355480.1 7.63 7.24e-13 2.3e-09 0.55 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45611756 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs1135812 ENSG00000280836.1 AL355480.1 -7.63 7.26e-13 2.31e-09 -0.55 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629600 chr1:45581219~45581321:- CESC cis rs1707322 0.752 rs6703748 ENSG00000280836.1 AL355480.1 -7.63 7.26e-13 2.31e-09 -0.55 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45630304 chr1:45581219~45581321:- CESC cis rs12022452 0.591 rs12042242 ENSG00000238287.1 RP11-656D10.3 7.63 7.28e-13 2.31e-09 0.64 0.46 Age-related hearing impairment (SNP x SNP interaction); chr1:40528201 chr1:40493157~40508661:- CESC cis rs6142102 0.625 rs4911137 ENSG00000276073.1 RP5-1125A11.7 -7.63 7.3e-13 2.32e-09 -0.41 -0.46 Skin pigmentation; chr20:33947657 chr20:33985617~33988989:- CESC cis rs7617773 0.963 rs6766754 ENSG00000229759.1 MRPS18AP1 -7.63 7.32e-13 2.33e-09 -0.46 -0.46 Coronary artery disease; chr3:48141099 chr3:48256350~48256938:- CESC cis rs7617773 0.832 rs6775114 ENSG00000229759.1 MRPS18AP1 -7.63 7.32e-13 2.33e-09 -0.46 -0.46 Coronary artery disease; chr3:48141130 chr3:48256350~48256938:- CESC cis rs1577917 0.74 rs2842604 ENSG00000203875.9 SNHG5 -7.63 7.33e-13 2.33e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85626582 chr6:85660950~85678736:- CESC cis rs7849270 0.879 rs10760587 ENSG00000268707.1 RP11-247A12.7 7.63 7.35e-13 2.33e-09 0.55 0.46 Blood metabolite ratios; chr9:129083737 chr9:129170434~129170940:+ CESC cis rs1707322 0.656 rs3014210 ENSG00000280836.1 AL355480.1 7.63 7.35e-13 2.33e-09 0.54 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45600936 chr1:45581219~45581321:- CESC cis rs6991838 0.584 rs34494846 ENSG00000272010.1 CTD-3025N20.3 -7.63 7.44e-13 2.36e-09 -0.52 -0.46 Intelligence (multi-trait analysis); chr8:65602397 chr8:65591850~65592472:- CESC cis rs2739330 0.828 rs2154593 ENSG00000099984.9 GSTT2 -7.62 7.46e-13 2.37e-09 -0.56 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23980123~23983911:+ CESC cis rs977987 0.815 rs11861810 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75427931 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs12929908 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75428173 chr16:75379818~75381260:- CESC cis rs977987 0.742 rs12928898 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75428183 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs11149832 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75428815 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs12448947 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75429056 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs4888420 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75429100 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs12449170 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75429114 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs11149833 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75430104 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs11641587 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75430521 chr16:75379818~75381260:- CESC cis rs977987 0.806 rs12930768 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75430602 chr16:75379818~75381260:- CESC cis rs977987 0.778 rs12445726 ENSG00000261783.1 RP11-252K23.2 -7.62 7.47e-13 2.37e-09 -0.56 -0.46 Dupuytren's disease; chr16:75431677 chr16:75379818~75381260:- CESC cis rs507080 0.733 rs7108144 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118698985 chr11:118704607~118750263:+ CESC cis rs507080 0.663 rs523793 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118699988 chr11:118704607~118750263:+ CESC cis rs507080 0.736 rs659564 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118700205 chr11:118704607~118750263:+ CESC cis rs507080 0.736 rs642224 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118700210 chr11:118704607~118750263:+ CESC cis rs507080 0.733 rs541631 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118700314 chr11:118704607~118750263:+ CESC cis rs507080 0.736 rs658676 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118700414 chr11:118704607~118750263:+ CESC cis rs507080 0.733 rs488141 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118700459 chr11:118704607~118750263:+ CESC cis rs507080 0.733 rs657769 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118700607 chr11:118704607~118750263:+ CESC cis rs507080 0.733 rs544452 ENSG00000255422.1 AP002954.4 -7.62 7.48e-13 2.37e-09 -0.54 -0.46 Serum metabolite levels; chr11:118700648 chr11:118704607~118750263:+ CESC cis rs113835537 0.529 rs80100524 ENSG00000255517.5 CTD-3074O7.5 -7.62 7.5e-13 2.37e-09 -0.53 -0.46 Airway imaging phenotypes; chr11:66478465 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs2279864 ENSG00000255517.5 CTD-3074O7.5 -7.62 7.5e-13 2.37e-09 -0.53 -0.46 Airway imaging phenotypes; chr11:66480373 chr11:66473490~66480233:- CESC cis rs1577917 0.771 rs10944133 ENSG00000203875.9 SNHG5 -7.62 7.59e-13 2.4e-09 -0.56 -0.46 Response to antipsychotic treatment; chr6:85649266 chr6:85660950~85678736:- CESC cis rs4423214 0.959 rs11606033 ENSG00000254682.1 RP11-660L16.2 7.62 7.6e-13 2.4e-09 0.59 0.46 Vitamin D levels; chr11:71443158 chr11:71448674~71452157:+ CESC cis rs2882667 0.788 rs11959691 ENSG00000253404.1 AC034243.1 7.62 7.67e-13 2.42e-09 0.61 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139145399 chr5:138744434~138753309:- CESC cis rs5769707 0.967 rs739248 ENSG00000188511.11 C22orf34 7.62 7.71e-13 2.44e-09 0.47 0.46 Monocyte percentage of white cells;Monocyte count; chr22:49631557 chr22:49414524~49657542:- CESC cis rs12022452 0.506 rs61779163 ENSG00000238287.1 RP11-656D10.3 -7.62 7.74e-13 2.45e-09 -0.64 -0.46 Age-related hearing impairment (SNP x SNP interaction); chr1:40549751 chr1:40493157~40508661:- CESC cis rs7044106 0.791 rs10739572 ENSG00000226752.6 PSMD5-AS1 -7.62 7.75e-13 2.45e-09 -0.5 -0.46 Hip circumference adjusted for BMI; chr9:120727537 chr9:120824828~120854385:+ CESC cis rs7847628 0.765 rs10985024 ENSG00000226752.6 PSMD5-AS1 -7.62 7.75e-13 2.45e-09 -0.55 -0.46 Birth weight; chr9:120754534 chr9:120824828~120854385:+ CESC cis rs113835537 0.529 rs4930378 ENSG00000255517.5 CTD-3074O7.5 -7.62 7.79e-13 2.46e-09 -0.5 -0.46 Airway imaging phenotypes; chr11:66488044 chr11:66473490~66480233:- CESC cis rs6142102 0.625 rs1883707 ENSG00000276073.1 RP5-1125A11.7 7.62 7.8e-13 2.46e-09 0.41 0.46 Skin pigmentation; chr20:33964781 chr20:33985617~33988989:- CESC cis rs5769707 0.935 rs5770594 ENSG00000188511.11 C22orf34 7.62 7.9e-13 2.49e-09 0.47 0.46 Monocyte percentage of white cells;Monocyte count; chr22:49624849 chr22:49414524~49657542:- CESC cis rs5769707 0.967 rs4524218 ENSG00000188511.11 C22orf34 7.62 7.9e-13 2.49e-09 0.47 0.46 Monocyte percentage of white cells;Monocyte count; chr22:49624991 chr22:49414524~49657542:- CESC cis rs526231 0.511 rs26255 ENSG00000175749.11 EIF3KP1 7.62 7.91e-13 2.49e-09 0.52 0.46 Primary biliary cholangitis; chr5:103218399 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs7717343 ENSG00000175749.11 EIF3KP1 7.61 7.94e-13 2.5e-09 0.49 0.46 Parkinson's disease; chr5:103026279 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs7721530 ENSG00000175749.11 EIF3KP1 7.61 7.94e-13 2.5e-09 0.49 0.46 Parkinson's disease; chr5:103026488 chr5:103032376~103033031:+ CESC cis rs1153858 1 rs2453541 ENSG00000259520.4 CTD-2651B20.3 -7.61 7.98e-13 2.51e-09 -0.6 -0.46 Homoarginine levels; chr15:45353180 chr15:45251580~45279251:- CESC cis rs1153858 1 rs2461702 ENSG00000259520.4 CTD-2651B20.3 -7.61 7.98e-13 2.51e-09 -0.6 -0.46 Homoarginine levels; chr15:45355229 chr15:45251580~45279251:- CESC cis rs10463554 0.963 rs3776857 ENSG00000175749.11 EIF3KP1 7.61 8.02e-13 2.52e-09 0.48 0.46 Parkinson's disease; chr5:103022456 chr5:103032376~103033031:+ CESC cis rs10256972 0.681 rs6979076 ENSG00000229043.2 AC091729.9 7.61 8.03e-13 2.53e-09 0.5 0.46 Endometriosis;Longevity; chr7:1076611 chr7:1160374~1165267:+ CESC cis rs1153858 0.943 rs7402632 ENSG00000259520.4 CTD-2651B20.3 -7.61 8.04e-13 2.53e-09 -0.61 -0.46 Homoarginine levels; chr15:45409715 chr15:45251580~45279251:- CESC cis rs10463554 1 rs3776864 ENSG00000175749.11 EIF3KP1 7.61 8.06e-13 2.53e-09 0.51 0.46 Parkinson's disease; chr5:102992164 chr5:103032376~103033031:+ CESC cis rs2882667 0.858 rs11956159 ENSG00000253404.1 AC034243.1 7.61 8.11e-13 2.54e-09 0.58 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139072879 chr5:138744434~138753309:- CESC cis rs6142102 0.625 rs4911384 ENSG00000276073.1 RP5-1125A11.7 -7.61 8.14e-13 2.56e-09 -0.41 -0.46 Skin pigmentation; chr20:33968001 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs6142051 ENSG00000276073.1 RP5-1125A11.7 -7.61 8.19e-13 2.57e-09 -0.41 -0.46 Skin pigmentation; chr20:33945212 chr20:33985617~33988989:- CESC cis rs1577917 1 rs12190598 ENSG00000203875.9 SNHG5 -7.61 8.19e-13 2.57e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85976356 chr6:85660950~85678736:- CESC cis rs2739330 0.828 rs2330635 ENSG00000099984.9 GSTT2 -7.61 8.22e-13 2.58e-09 -0.56 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23980123~23983911:+ CESC cis rs5769707 0.904 rs7288869 ENSG00000188511.11 C22orf34 7.61 8.28e-13 2.6e-09 0.47 0.46 Monocyte percentage of white cells;Monocyte count; chr22:49621679 chr22:49414524~49657542:- CESC cis rs6700559 0.683 rs4915450 ENSG00000260088.1 RP11-92G12.3 -7.61 8.28e-13 2.6e-09 -0.57 -0.46 Coronary artery disease; chr1:200672461 chr1:200669507~200694250:+ CESC cis rs1577917 1 rs12199516 ENSG00000203875.9 SNHG5 -7.61 8.29e-13 2.6e-09 -0.58 -0.46 Response to antipsychotic treatment; chr6:86016503 chr6:85660950~85678736:- CESC cis rs9326248 0.53 rs7121347 ENSG00000254851.1 RP11-109L13.1 -7.61 8.29e-13 2.6e-09 -0.81 -0.46 Blood protein levels; chr11:116996493 chr11:117135528~117138582:+ CESC cis rs9828933 0.938 rs3816157 ENSG00000280620.1 SCAANT1 7.61 8.34e-13 2.62e-09 0.82 0.46 Type 2 diabetes; chr3:64013646 chr3:63911518~63911772:- CESC cis rs875971 1 rs9986696 ENSG00000226824.5 RP4-756H11.3 7.61 8.37e-13 2.62e-09 0.56 0.46 Aortic root size; chr7:66239589 chr7:66654538~66669855:+ CESC cis rs11722779 0.935 rs7676736 ENSG00000246560.2 RP11-10L12.4 7.6 8.42e-13 2.64e-09 0.56 0.46 Schizophrenia; chr4:103016729 chr4:102828055~102844075:+ CESC cis rs5769707 0.837 rs5770599 ENSG00000188511.11 C22orf34 7.6 8.45e-13 2.64e-09 0.49 0.46 Monocyte percentage of white cells;Monocyte count; chr22:49626333 chr22:49414524~49657542:- CESC cis rs875971 1 rs2220626 ENSG00000226824.5 RP4-756H11.3 7.6 8.54e-13 2.67e-09 0.59 0.46 Aortic root size; chr7:66081075 chr7:66654538~66669855:+ CESC cis rs3931020 0.772 rs1409785 ENSG00000272864.1 RP11-17E13.2 -7.6 8.56e-13 2.68e-09 -0.53 -0.46 Resistin levels; chr1:74782438 chr1:74698769~74699333:- CESC cis rs10463554 0.553 rs72785712 ENSG00000175749.11 EIF3KP1 7.6 8.64e-13 2.7e-09 0.51 0.46 Parkinson's disease; chr5:102988693 chr5:103032376~103033031:+ CESC cis rs1799949 0.93 rs34210004 ENSG00000198496.9 NBR2 -7.6 8.75e-13 2.73e-09 -0.55 -0.46 Menopause (age at onset); chr17:43218318 chr17:43125610~43153671:+ CESC cis rs507080 0.733 rs4486664 ENSG00000255422.1 AP002954.4 -7.6 8.75e-13 2.73e-09 -0.53 -0.46 Serum metabolite levels; chr11:118698358 chr11:118704607~118750263:+ CESC cis rs7617773 0.963 rs9822496 ENSG00000229759.1 MRPS18AP1 7.6 8.88e-13 2.77e-09 0.47 0.46 Coronary artery disease; chr3:48139843 chr3:48256350~48256938:- CESC cis rs1577917 1 rs34622557 ENSG00000203875.9 SNHG5 -7.6 8.93e-13 2.79e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85921134 chr6:85660950~85678736:- CESC cis rs1577917 1 rs1911553 ENSG00000203875.9 SNHG5 -7.6 8.93e-13 2.79e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85921174 chr6:85660950~85678736:- CESC cis rs1577917 1 rs1995688 ENSG00000203875.9 SNHG5 -7.6 8.93e-13 2.79e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85922601 chr6:85660950~85678736:- CESC cis rs977987 0.806 rs12444589 ENSG00000261783.1 RP11-252K23.2 7.59 9.07e-13 2.83e-09 0.55 0.46 Dupuytren's disease; chr16:75420506 chr16:75379818~75381260:- CESC cis rs875971 1 rs4717300 ENSG00000226824.5 RP4-756H11.3 -7.59 9.1e-13 2.84e-09 -0.58 -0.46 Aortic root size; chr7:66482393 chr7:66654538~66669855:+ CESC cis rs1707322 0.752 rs4660313 ENSG00000280836.1 AL355480.1 7.59 9.16e-13 2.86e-09 0.54 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645169 chr1:45581219~45581321:- CESC cis rs977987 0.806 rs17696696 ENSG00000261783.1 RP11-252K23.2 7.59 9.21e-13 2.87e-09 0.56 0.46 Dupuytren's disease; chr16:75359454 chr16:75379818~75381260:- CESC cis rs227275 0.525 rs28445579 ENSG00000246560.2 RP11-10L12.4 7.59 9.35e-13 2.91e-09 0.56 0.46 Allergic disease (asthma, hay fever or eczema); chr4:103016438 chr4:102828055~102844075:+ CESC cis rs1577917 1 rs10455456 ENSG00000203875.9 SNHG5 -7.59 9.35e-13 2.91e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85960604 chr6:85660950~85678736:- CESC cis rs1577917 1 rs10455158 ENSG00000203875.9 SNHG5 -7.59 9.35e-13 2.91e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85963107 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12215903 ENSG00000203875.9 SNHG5 -7.59 9.35e-13 2.91e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85965310 chr6:85660950~85678736:- CESC cis rs1577917 0.959 rs34258068 ENSG00000203875.9 SNHG5 -7.59 9.35e-13 2.91e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85969731 chr6:85660950~85678736:- CESC cis rs1577917 1 rs10944170 ENSG00000203875.9 SNHG5 -7.59 9.35e-13 2.91e-09 -0.57 -0.46 Response to antipsychotic treatment; chr6:85975751 chr6:85660950~85678736:- CESC cis rs150992 0.711 rs161735 ENSG00000248489.1 CTD-2007H13.3 7.59 9.37e-13 2.92e-09 0.55 0.46 Body mass index; chr5:98862026 chr5:98929171~98995013:+ CESC cis rs1707322 0.721 rs7520123 ENSG00000280836.1 AL355480.1 -7.59 9.41e-13 2.93e-09 -0.53 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769547 chr1:45581219~45581321:- CESC cis rs7044106 0.791 rs4836830 ENSG00000226752.6 PSMD5-AS1 -7.59 9.43e-13 2.93e-09 -0.5 -0.46 Hip circumference adjusted for BMI; chr9:120721390 chr9:120824828~120854385:+ CESC cis rs1707322 0.752 rs11211145 ENSG00000280836.1 AL355480.1 -7.58 9.55e-13 2.97e-09 -0.58 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642819 chr1:45581219~45581321:- CESC cis rs2739330 0.828 rs5760108 ENSG00000099984.9 GSTT2 -7.58 9.71e-13 3.01e-09 -0.54 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23980123~23983911:+ CESC cis rs227275 0.556 rs7676765 ENSG00000246560.2 RP11-10L12.4 -7.58 9.78e-13 3.03e-09 -0.55 -0.46 Allergic disease (asthma, hay fever or eczema); chr4:103016776 chr4:102828055~102844075:+ CESC cis rs1799949 0.965 rs7223952 ENSG00000198496.9 NBR2 -7.58 9.85e-13 3.05e-09 -0.56 -0.46 Menopause (age at onset); chr17:43042868 chr17:43125610~43153671:+ CESC cis rs7044106 0.791 rs10818473 ENSG00000226752.6 PSMD5-AS1 -7.58 9.87e-13 3.06e-09 -0.5 -0.46 Hip circumference adjusted for BMI; chr9:120721877 chr9:120824828~120854385:+ CESC cis rs992157 1 rs13429408 ENSG00000261338.2 RP11-378A13.1 7.58 9.98e-13 3.09e-09 0.58 0.46 Colorectal cancer; chr2:218278137 chr2:218255319~218257366:+ CESC cis rs1707322 0.686 rs2991986 ENSG00000280836.1 AL355480.1 7.58 1.01e-12 3.12e-09 0.54 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615610 chr1:45581219~45581321:- CESC cis rs7044106 0.762 rs3903886 ENSG00000226752.6 PSMD5-AS1 7.57 1.01e-12 3.13e-09 0.49 0.46 Hip circumference adjusted for BMI; chr9:120621368 chr9:120824828~120854385:+ CESC cis rs1577917 0.958 rs12208227 ENSG00000203875.9 SNHG5 -7.57 1.03e-12 3.2e-09 -0.58 -0.46 Response to antipsychotic treatment; chr6:85961226 chr6:85660950~85678736:- CESC cis rs5760092 0.755 rs915589 ENSG00000218537.1 MIF-AS1 -7.57 1.04e-12 3.21e-09 -0.7 -0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23894426~23898930:- CESC cis rs875971 1 rs697970 ENSG00000226824.5 RP4-756H11.3 7.57 1.07e-12 3.29e-09 0.59 0.46 Aortic root size; chr7:66095065 chr7:66654538~66669855:+ CESC cis rs1799949 0.965 rs8176198 ENSG00000198496.9 NBR2 -7.57 1.07e-12 3.3e-09 -0.53 -0.46 Menopause (age at onset); chr17:43078520 chr17:43125610~43153671:+ CESC cis rs1707322 0.682 rs10890334 ENSG00000280836.1 AL355480.1 -7.56 1.08e-12 3.32e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634706 chr1:45581219~45581321:- CESC cis rs1707322 0.682 rs10890335 ENSG00000280836.1 AL355480.1 -7.56 1.08e-12 3.32e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634722 chr1:45581219~45581321:- CESC cis rs1707322 0.716 rs6694889 ENSG00000280836.1 AL355480.1 -7.56 1.08e-12 3.32e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45636134 chr1:45581219~45581321:- CESC cis rs1707322 0.682 rs12041197 ENSG00000280836.1 AL355480.1 -7.56 1.08e-12 3.32e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638792 chr1:45581219~45581321:- CESC cis rs1707322 0.717 rs12023439 ENSG00000280836.1 AL355480.1 -7.56 1.08e-12 3.32e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638964 chr1:45581219~45581321:- CESC cis rs8081395 0.836 rs2063353 ENSG00000266992.1 DHX40P1 -7.56 1.08e-12 3.32e-09 -0.49 -0.46 White blood cell count; chr17:59811831 chr17:59976009~60002384:- CESC cis rs10463554 0.963 rs1011454 ENSG00000175749.11 EIF3KP1 7.56 1.08e-12 3.33e-09 0.48 0.46 Parkinson's disease; chr5:103032551 chr5:103032376~103033031:+ CESC cis rs9545047 0.935 rs4885634 ENSG00000227676.3 LINC01068 -7.56 1.08e-12 3.33e-09 -0.53 -0.46 Schizophrenia; chr13:79482772 chr13:79566727~79571436:+ CESC cis rs875971 0.929 rs4122249 ENSG00000226824.5 RP4-756H11.3 -7.56 1.09e-12 3.34e-09 -0.57 -0.46 Aortic root size; chr7:66455949 chr7:66654538~66669855:+ CESC cis rs6991838 0.557 rs7012578 ENSG00000272010.1 CTD-3025N20.3 -7.56 1.11e-12 3.4e-09 -0.51 -0.46 Intelligence (multi-trait analysis); chr8:65592592 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs7812446 ENSG00000272010.1 CTD-3025N20.3 -7.56 1.11e-12 3.4e-09 -0.51 -0.46 Intelligence (multi-trait analysis); chr8:65593753 chr8:65591850~65592472:- CESC cis rs6991838 0.557 rs7812390 ENSG00000272010.1 CTD-3025N20.3 -7.56 1.11e-12 3.4e-09 -0.51 -0.46 Intelligence (multi-trait analysis); chr8:65593982 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs16932245 ENSG00000272010.1 CTD-3025N20.3 -7.56 1.11e-12 3.4e-09 -0.51 -0.46 Intelligence (multi-trait analysis); chr8:65597810 chr8:65591850~65592472:- CESC cis rs6991838 0.557 rs57419568 ENSG00000272010.1 CTD-3025N20.3 -7.56 1.11e-12 3.4e-09 -0.51 -0.46 Intelligence (multi-trait analysis); chr8:65598633 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs16932250 ENSG00000272010.1 CTD-3025N20.3 -7.56 1.11e-12 3.4e-09 -0.51 -0.46 Intelligence (multi-trait analysis); chr8:65598779 chr8:65591850~65592472:- CESC cis rs1062177 0.901 rs1549622 ENSG00000213433.5 RPLP1P6 -7.56 1.12e-12 3.43e-09 -0.56 -0.46 Preschool internalizing problems; chr5:151886488 chr5:151765859~151766378:- CESC cis rs113835537 0.529 rs57207756 ENSG00000255517.5 CTD-3074O7.5 -7.56 1.12e-12 3.44e-09 -0.54 -0.46 Airway imaging phenotypes; chr11:66502889 chr11:66473490~66480233:- CESC cis rs113835537 0.559 rs11227498 ENSG00000255517.5 CTD-3074O7.5 -7.56 1.12e-12 3.44e-09 -0.53 -0.46 Airway imaging phenotypes; chr11:66502243 chr11:66473490~66480233:- CESC cis rs7617773 0.925 rs34513961 ENSG00000229759.1 MRPS18AP1 7.56 1.13e-12 3.45e-09 0.53 0.46 Coronary artery disease; chr3:48132163 chr3:48256350~48256938:- CESC cis rs1577917 0.771 rs6454486 ENSG00000203875.9 SNHG5 7.56 1.13e-12 3.45e-09 0.5 0.46 Response to antipsychotic treatment; chr6:85723869 chr6:85660950~85678736:- CESC cis rs1577917 0.665 rs4304137 ENSG00000203875.9 SNHG5 7.56 1.13e-12 3.47e-09 0.56 0.46 Response to antipsychotic treatment; chr6:85507730 chr6:85660950~85678736:- CESC cis rs507080 0.733 rs4393358 ENSG00000255422.1 AP002954.4 -7.55 1.15e-12 3.51e-09 -0.52 -0.46 Serum metabolite levels; chr11:118698388 chr11:118704607~118750263:+ CESC cis rs7626444 0.625 rs7648479 ENSG00000272359.1 U4 -7.55 1.16e-12 3.54e-09 -0.52 -0.46 Monocyte count; chr3:196750342 chr3:196747192~196747324:- CESC cis rs2882667 0.858 rs11957527 ENSG00000253404.1 AC034243.1 7.55 1.18e-12 3.61e-09 0.57 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139069206 chr5:138744434~138753309:- CESC cis rs6142102 0.602 rs6141435 ENSG00000276073.1 RP5-1125A11.7 -7.55 1.2e-12 3.66e-09 -0.41 -0.46 Skin pigmentation; chr20:33963473 chr20:33985617~33988989:- CESC cis rs1707322 0.721 rs12043945 ENSG00000280836.1 AL355480.1 -7.55 1.2e-12 3.67e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45641250 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs12091503 ENSG00000280836.1 AL355480.1 -7.55 1.2e-12 3.67e-09 -0.54 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642196 chr1:45581219~45581321:- CESC cis rs10256972 0.524 rs6945202 ENSG00000229043.2 AC091729.9 -7.55 1.21e-12 3.69e-09 -0.51 -0.46 Endometriosis;Longevity; chr7:1076922 chr7:1160374~1165267:+ CESC cis rs1707322 0.686 rs2991977 ENSG00000280836.1 AL355480.1 7.54 1.22e-12 3.71e-09 0.54 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45588011 chr1:45581219~45581321:- CESC cis rs1707322 0.656 rs2991981 ENSG00000280836.1 AL355480.1 7.54 1.22e-12 3.71e-09 0.54 0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45591472 chr1:45581219~45581321:- CESC cis rs11722779 0.81 rs223417 ENSG00000246560.2 RP11-10L12.4 7.54 1.22e-12 3.73e-09 0.55 0.45 Schizophrenia; chr4:102810568 chr4:102828055~102844075:+ CESC cis rs11722779 0.805 rs223416 ENSG00000246560.2 RP11-10L12.4 7.54 1.22e-12 3.73e-09 0.55 0.45 Schizophrenia; chr4:102810580 chr4:102828055~102844075:+ CESC cis rs17826219 0.568 rs59858012 ENSG00000263531.1 RP13-753N3.1 7.54 1.23e-12 3.73e-09 1.01 0.45 Body mass index; chr17:30751564 chr17:30863921~30864940:- CESC cis rs7849270 0.84 rs12346996 ENSG00000268707.1 RP11-247A12.7 -7.54 1.23e-12 3.75e-09 -0.62 -0.45 Blood metabolite ratios; chr9:129078577 chr9:129170434~129170940:+ CESC cis rs5769707 0.967 rs763127 ENSG00000188511.11 C22orf34 7.54 1.24e-12 3.78e-09 0.46 0.45 Monocyte percentage of white cells;Monocyte count; chr22:49612430 chr22:49414524~49657542:- CESC cis rs7847628 0.666 rs2031974 ENSG00000226752.6 PSMD5-AS1 -7.54 1.25e-12 3.81e-09 -0.55 -0.45 Birth weight; chr9:120765243 chr9:120824828~120854385:+ CESC cis rs2739330 0.828 rs5760107 ENSG00000099984.9 GSTT2 -7.54 1.26e-12 3.83e-09 -0.55 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23980123~23983911:+ CESC cis rs2739330 0.789 rs5760109 ENSG00000099984.9 GSTT2 -7.54 1.26e-12 3.83e-09 -0.55 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23980123~23983911:+ CESC cis rs7849270 1 rs7023900 ENSG00000268707.1 RP11-247A12.7 -7.54 1.27e-12 3.86e-09 -0.55 -0.45 Blood metabolite ratios; chr9:129128873 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs7036114 ENSG00000268707.1 RP11-247A12.7 -7.54 1.27e-12 3.86e-09 -0.55 -0.45 Blood metabolite ratios; chr9:129131127 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs34055941 ENSG00000268707.1 RP11-247A12.7 -7.54 1.27e-12 3.86e-09 -0.55 -0.45 Blood metabolite ratios; chr9:129132797 chr9:129170434~129170940:+ CESC cis rs2882667 0.964 rs12055237 ENSG00000253404.1 AC034243.1 7.54 1.27e-12 3.86e-09 0.58 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:138971617 chr5:138744434~138753309:- CESC cis rs1707322 0.686 rs2230658 ENSG00000280836.1 AL355480.1 7.54 1.28e-12 3.88e-09 0.54 0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613182 chr1:45581219~45581321:- CESC cis rs1707322 0.686 rs2230659 ENSG00000280836.1 AL355480.1 7.54 1.28e-12 3.88e-09 0.54 0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613212 chr1:45581219~45581321:- CESC cis rs1577917 0.958 rs11758508 ENSG00000203875.9 SNHG5 7.53 1.34e-12 4.04e-09 0.57 0.45 Response to antipsychotic treatment; chr6:85797160 chr6:85660950~85678736:- CESC cis rs1577917 1 rs1857964 ENSG00000203875.9 SNHG5 -7.53 1.34e-12 4.04e-09 -0.58 -0.45 Response to antipsychotic treatment; chr6:85926276 chr6:85660950~85678736:- CESC cis rs1577917 0.798 rs7772384 ENSG00000203875.9 SNHG5 -7.53 1.34e-12 4.04e-09 -0.58 -0.45 Response to antipsychotic treatment; chr6:85929962 chr6:85660950~85678736:- CESC cis rs150992 0.673 rs692832 ENSG00000248489.1 CTD-2007H13.3 7.53 1.34e-12 4.04e-09 0.53 0.45 Body mass index; chr5:98856761 chr5:98929171~98995013:+ CESC cis rs150992 0.673 rs330419 ENSG00000248489.1 CTD-2007H13.3 -7.53 1.34e-12 4.04e-09 -0.53 -0.45 Body mass index; chr5:98857460 chr5:98929171~98995013:+ CESC cis rs875971 1 rs7792762 ENSG00000226824.5 RP4-756H11.3 -7.53 1.34e-12 4.04e-09 -0.57 -0.45 Aortic root size; chr7:66539151 chr7:66654538~66669855:+ CESC cis rs150992 0.861 rs428836 ENSG00000248489.1 CTD-2007H13.3 7.53 1.34e-12 4.04e-09 0.55 0.45 Body mass index; chr5:98951673 chr5:98929171~98995013:+ CESC cis rs150992 0.673 rs327792 ENSG00000248489.1 CTD-2007H13.3 7.53 1.36e-12 4.09e-09 0.53 0.45 Body mass index; chr5:98909802 chr5:98929171~98995013:+ CESC cis rs7044106 0.762 rs10984972 ENSG00000226752.6 PSMD5-AS1 -7.53 1.36e-12 4.1e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120647586 chr9:120824828~120854385:+ CESC cis rs2882667 0.858 rs6882112 ENSG00000253404.1 AC034243.1 -7.53 1.36e-12 4.11e-09 -0.56 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139078046 chr5:138744434~138753309:- CESC cis rs526231 0.575 rs55652053 ENSG00000175749.11 EIF3KP1 7.53 1.36e-12 4.11e-09 0.51 0.45 Primary biliary cholangitis; chr5:103001466 chr5:103032376~103033031:+ CESC cis rs875971 1 rs1144895 ENSG00000226824.5 RP4-756H11.3 7.53 1.37e-12 4.12e-09 0.59 0.45 Aortic root size; chr7:66076320 chr7:66654538~66669855:+ CESC cis rs9545047 0.935 rs1577416 ENSG00000227676.3 LINC01068 -7.52 1.38e-12 4.15e-09 -0.53 -0.45 Schizophrenia; chr13:79500646 chr13:79566727~79571436:+ CESC cis rs7104764 1 rs10794302 ENSG00000277290.1 RP11-326C3.16 -7.52 1.4e-12 4.22e-09 -0.43 -0.45 Menarche (age at onset); chr11:234102 chr11:243099~243483:- CESC cis rs1577917 1 rs34581302 ENSG00000203875.9 SNHG5 -7.52 1.42e-12 4.25e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85996230 chr6:85660950~85678736:- CESC cis rs1707322 0.721 rs4660883 ENSG00000280836.1 AL355480.1 -7.52 1.42e-12 4.25e-09 -0.54 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45770426 chr1:45581219~45581321:- CESC cis rs2404602 0.698 rs12909656 ENSG00000259422.1 RP11-593F23.1 -7.52 1.44e-12 4.31e-09 -0.54 -0.45 Blood metabolite levels; chr15:76372037 chr15:76174891~76181486:- CESC cis rs3096299 0.632 rs8051537 ENSG00000274627.1 RP11-104N10.2 7.52 1.44e-12 4.33e-09 0.44 0.45 Multiple myeloma (IgH translocation); chr16:89477976 chr16:89516797~89522217:+ CESC cis rs3096299 0.685 rs3803681 ENSG00000274627.1 RP11-104N10.2 7.52 1.44e-12 4.33e-09 0.44 0.45 Multiple myeloma (IgH translocation); chr16:89478348 chr16:89516797~89522217:+ CESC cis rs3096299 0.685 rs3803682 ENSG00000274627.1 RP11-104N10.2 7.52 1.45e-12 4.34e-09 0.44 0.45 Multiple myeloma (IgH translocation); chr16:89478228 chr16:89516797~89522217:+ CESC cis rs150992 0.711 rs2617507 ENSG00000248489.1 CTD-2007H13.3 7.51 1.46e-12 4.37e-09 0.55 0.45 Body mass index; chr5:98912548 chr5:98929171~98995013:+ CESC cis rs7849270 1 rs7021449 ENSG00000268707.1 RP11-247A12.7 -7.51 1.47e-12 4.4e-09 -0.54 -0.45 Blood metabolite ratios; chr9:129137033 chr9:129170434~129170940:+ CESC cis rs1707322 0.717 rs3014249 ENSG00000280836.1 AL355480.1 7.51 1.48e-12 4.43e-09 0.54 0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613821 chr1:45581219~45581321:- CESC cis rs7044106 0.762 rs7044226 ENSG00000226752.6 PSMD5-AS1 -7.51 1.48e-12 4.43e-09 -0.5 -0.45 Hip circumference adjusted for BMI; chr9:120704050 chr9:120824828~120854385:+ CESC cis rs7849270 1 rs713219 ENSG00000268707.1 RP11-247A12.7 -7.51 1.48e-12 4.43e-09 -0.54 -0.45 Blood metabolite ratios; chr9:129138641 chr9:129170434~129170940:+ CESC cis rs67383717 0.777 rs591486 ENSG00000175611.10 LINC00476 -7.51 1.48e-12 4.44e-09 -0.51 -0.45 Parkinson's disease (pesticide exposure interaction); chr9:95887764 chr9:95759231~95875977:- CESC cis rs2882667 0.858 rs11744972 ENSG00000253404.1 AC034243.1 7.51 1.49e-12 4.46e-09 0.59 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139093100 chr5:138744434~138753309:- CESC cis rs6142102 0.58 rs4911139 ENSG00000276073.1 RP5-1125A11.7 -7.51 1.49e-12 4.46e-09 -0.4 -0.45 Skin pigmentation; chr20:33963729 chr20:33985617~33988989:- CESC cis rs7104764 0.957 rs3829998 ENSG00000277290.1 RP11-326C3.16 -7.51 1.5e-12 4.5e-09 -0.44 -0.45 Menarche (age at onset); chr11:230751 chr11:243099~243483:- CESC cis rs1577917 0.771 rs2758844 ENSG00000203875.9 SNHG5 -7.51 1.51e-12 4.51e-09 -0.55 -0.45 Response to antipsychotic treatment; chr6:85620397 chr6:85660950~85678736:- CESC cis rs1707322 0.686 rs1084086 ENSG00000280836.1 AL355480.1 7.51 1.51e-12 4.53e-09 0.54 0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45575428 chr1:45581219~45581321:- CESC cis rs3096299 0.667 rs2965947 ENSG00000274627.1 RP11-104N10.2 7.51 1.52e-12 4.54e-09 0.44 0.45 Multiple myeloma (IgH translocation); chr16:89452262 chr16:89516797~89522217:+ CESC cis rs2882667 0.824 rs11748097 ENSG00000253404.1 AC034243.1 7.51 1.52e-12 4.54e-09 0.59 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139144198 chr5:138744434~138753309:- CESC cis rs2882667 0.824 rs12173085 ENSG00000253404.1 AC034243.1 7.51 1.52e-12 4.54e-09 0.59 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139144336 chr5:138744434~138753309:- CESC cis rs1577917 1 rs1962716 ENSG00000203875.9 SNHG5 -7.51 1.52e-12 4.55e-09 -0.55 -0.45 Response to antipsychotic treatment; chr6:85938718 chr6:85660950~85678736:- CESC cis rs9326248 0.53 rs1242229 ENSG00000254851.1 RP11-109L13.1 -7.51 1.53e-12 4.57e-09 -0.8 -0.45 Blood protein levels; chr11:117191654 chr11:117135528~117138582:+ CESC cis rs3931020 0.53 rs6668736 ENSG00000272864.1 RP11-17E13.2 -7.51 1.55e-12 4.62e-09 -0.46 -0.45 Resistin levels; chr1:74768866 chr1:74698769~74699333:- CESC cis rs5769707 0.967 rs9616327 ENSG00000188511.11 C22orf34 7.5 1.57e-12 4.68e-09 0.47 0.45 Monocyte percentage of white cells;Monocyte count; chr22:49617243 chr22:49414524~49657542:- CESC cis rs1577917 0.958 rs13213551 ENSG00000203875.9 SNHG5 -7.5 1.57e-12 4.7e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85898983 chr6:85660950~85678736:- CESC cis rs228614 0.51 rs150893 ENSG00000246560.2 RP11-10L12.4 -7.5 1.59e-12 4.74e-09 -0.55 -0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102817075 chr4:102828055~102844075:+ CESC cis rs12022452 0.591 rs16827359 ENSG00000238287.1 RP11-656D10.3 7.5 1.59e-12 4.75e-09 0.62 0.45 Age-related hearing impairment (SNP x SNP interaction); chr1:40535766 chr1:40493157~40508661:- CESC cis rs113835537 0.529 rs11227495 ENSG00000255517.5 CTD-3074O7.5 -7.5 1.61e-12 4.8e-09 -0.52 -0.45 Airway imaging phenotypes; chr11:66495772 chr11:66473490~66480233:- CESC cis rs227275 0.525 rs223332 ENSG00000246560.2 RP11-10L12.4 7.5 1.61e-12 4.81e-09 0.55 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102869029 chr4:102828055~102844075:+ CESC cis rs916888 0.61 rs142167 ENSG00000214401.4 KANSL1-AS1 -7.5 1.62e-12 4.82e-09 -0.55 -0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46193576~46196723:+ CESC cis rs7104764 1 rs6598060 ENSG00000277290.1 RP11-326C3.16 -7.5 1.62e-12 4.83e-09 -0.43 -0.45 Menarche (age at onset); chr11:243987 chr11:243099~243483:- CESC cis rs2882667 0.898 rs11952020 ENSG00000253404.1 AC034243.1 7.5 1.63e-12 4.85e-09 0.52 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139059467 chr5:138744434~138753309:- CESC cis rs7044106 0.762 rs1470307 ENSG00000226752.6 PSMD5-AS1 -7.49 1.67e-12 4.94e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120670761 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs10760112 ENSG00000226752.6 PSMD5-AS1 -7.49 1.67e-12 4.94e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120705292 chr9:120824828~120854385:+ CESC cis rs6991838 0.584 rs35790435 ENSG00000272010.1 CTD-3025N20.3 -7.49 1.69e-12 5e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65590288 chr8:65591850~65592472:- CESC cis rs228614 0.543 rs223330 ENSG00000246560.2 RP11-10L12.4 7.49 1.69e-12 5.01e-09 0.55 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102872502 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223329 ENSG00000246560.2 RP11-10L12.4 7.49 1.69e-12 5.01e-09 0.55 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873031 chr4:102828055~102844075:+ CESC cis rs228614 0.536 rs223327 ENSG00000246560.2 RP11-10L12.4 7.49 1.69e-12 5.01e-09 0.55 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873560 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223326 ENSG00000246560.2 RP11-10L12.4 7.49 1.69e-12 5.01e-09 0.55 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873770 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223324 ENSG00000246560.2 RP11-10L12.4 7.49 1.69e-12 5.01e-09 0.55 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102876177 chr4:102828055~102844075:+ CESC cis rs801193 0.66 rs1016265 ENSG00000226824.5 RP4-756H11.3 -7.49 1.7e-12 5.02e-09 -0.56 -0.45 Aortic root size; chr7:66749580 chr7:66654538~66669855:+ CESC cis rs3096299 0.719 rs2965945 ENSG00000274627.1 RP11-104N10.2 7.49 1.71e-12 5.05e-09 0.45 0.45 Multiple myeloma (IgH translocation); chr16:89447609 chr16:89516797~89522217:+ CESC cis rs3096299 0.719 rs2911265 ENSG00000274627.1 RP11-104N10.2 7.49 1.71e-12 5.05e-09 0.45 0.45 Multiple myeloma (IgH translocation); chr16:89444920 chr16:89516797~89522217:+ CESC cis rs801193 0.548 rs2659904 ENSG00000226824.5 RP4-756H11.3 -7.49 1.71e-12 5.06e-09 -0.57 -0.45 Aortic root size; chr7:66713615 chr7:66654538~66669855:+ CESC cis rs2882667 0.822 rs13187096 ENSG00000253404.1 AC034243.1 7.49 1.74e-12 5.14e-09 0.57 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139068399 chr5:138744434~138753309:- CESC cis rs113835537 0.529 rs17496250 ENSG00000255517.5 CTD-3074O7.5 -7.49 1.75e-12 5.16e-09 -0.53 -0.45 Airway imaging phenotypes; chr11:66503303 chr11:66473490~66480233:- CESC cis rs1799949 0.602 rs8176235 ENSG00000198496.9 NBR2 -7.48 1.75e-12 5.17e-09 -0.66 -0.45 Menopause (age at onset); chr17:43067543 chr17:43125610~43153671:+ CESC cis rs7044106 0.791 rs4837793 ENSG00000226752.6 PSMD5-AS1 -7.48 1.76e-12 5.2e-09 -0.5 -0.45 Hip circumference adjusted for BMI; chr9:120721343 chr9:120824828~120854385:+ CESC cis rs113835537 0.559 rs11227497 ENSG00000255517.5 CTD-3074O7.5 -7.48 1.78e-12 5.24e-09 -0.52 -0.45 Airway imaging phenotypes; chr11:66501993 chr11:66473490~66480233:- CESC cis rs6991838 0.584 rs1053087 ENSG00000272010.1 CTD-3025N20.3 -7.48 1.79e-12 5.27e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65603630 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs1053085 ENSG00000272010.1 CTD-3025N20.3 -7.48 1.79e-12 5.27e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65603753 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs4737747 ENSG00000272010.1 CTD-3025N20.3 -7.48 1.79e-12 5.27e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65607024 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs73236948 ENSG00000272010.1 CTD-3025N20.3 -7.48 1.79e-12 5.27e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65609176 chr8:65591850~65592472:- CESC cis rs1577917 0.917 rs35038582 ENSG00000203875.9 SNHG5 -7.48 1.82e-12 5.36e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:86011587 chr6:85660950~85678736:- CESC cis rs1577917 1 rs7760207 ENSG00000203875.9 SNHG5 -7.48 1.82e-12 5.36e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:86011982 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12207305 ENSG00000203875.9 SNHG5 -7.48 1.82e-12 5.36e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:86013784 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12199784 ENSG00000203875.9 SNHG5 -7.48 1.82e-12 5.36e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:86017090 chr6:85660950~85678736:- CESC cis rs6964833 1 rs4717907 ENSG00000123965.13 PMS2P5 7.48 1.82e-12 5.37e-09 0.7 0.45 Menarche (age at onset); chr7:74672169 chr7:74894116~74897835:+ CESC cis rs2739330 0.753 rs4822452 ENSG00000099984.9 GSTT2 -7.48 1.83e-12 5.38e-09 -0.54 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23980123~23983911:+ CESC cis rs1577917 0.666 rs6454471 ENSG00000203875.9 SNHG5 7.48 1.83e-12 5.38e-09 0.55 0.45 Response to antipsychotic treatment; chr6:85504738 chr6:85660950~85678736:- CESC cis rs12022452 0.506 rs11208363 ENSG00000238287.1 RP11-656D10.3 -7.48 1.83e-12 5.4e-09 -0.63 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr1:40544782 chr1:40493157~40508661:- CESC cis rs5769707 0.967 rs2071904 ENSG00000188511.11 C22orf34 7.48 1.84e-12 5.41e-09 0.47 0.45 Monocyte percentage of white cells;Monocyte count; chr22:49640829 chr22:49414524~49657542:- CESC cis rs5769707 0.846 rs5770610 ENSG00000188511.11 C22orf34 7.48 1.84e-12 5.41e-09 0.47 0.45 Monocyte percentage of white cells;Monocyte count; chr22:49643249 chr22:49414524~49657542:- CESC cis rs4423214 0.61 rs3763856 ENSG00000254682.1 RP11-660L16.2 7.48 1.84e-12 5.41e-09 0.54 0.45 Vitamin D levels; chr11:71414299 chr11:71448674~71452157:+ CESC cis rs6142102 0.517 rs8119076 ENSG00000276073.1 RP5-1125A11.7 -7.47 1.86e-12 5.46e-09 -0.41 -0.45 Skin pigmentation; chr20:33937909 chr20:33985617~33988989:- CESC cis rs6142102 0.517 rs6142050 ENSG00000276073.1 RP5-1125A11.7 -7.47 1.86e-12 5.46e-09 -0.41 -0.45 Skin pigmentation; chr20:33939322 chr20:33985617~33988989:- CESC cis rs6142102 0.517 rs6059577 ENSG00000276073.1 RP5-1125A11.7 -7.47 1.86e-12 5.46e-09 -0.41 -0.45 Skin pigmentation; chr20:33939880 chr20:33985617~33988989:- CESC cis rs227275 0.524 rs150894 ENSG00000246560.2 RP11-10L12.4 7.47 1.87e-12 5.49e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102811541 chr4:102828055~102844075:+ CESC cis rs11722779 0.692 rs223414 ENSG00000246560.2 RP11-10L12.4 7.47 1.87e-12 5.49e-09 0.54 0.45 Schizophrenia; chr4:102811688 chr4:102828055~102844075:+ CESC cis rs1577917 1 rs12201741 ENSG00000203875.9 SNHG5 -7.47 1.87e-12 5.5e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85892901 chr6:85660950~85678736:- CESC cis rs1577917 1 rs68171315 ENSG00000203875.9 SNHG5 -7.47 1.91e-12 5.61e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85997682 chr6:85660950~85678736:- CESC cis rs7044106 0.791 rs2416799 ENSG00000226752.6 PSMD5-AS1 -7.47 1.93e-12 5.66e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120718588 chr9:120824828~120854385:+ CESC cis rs5769707 0.967 rs1018812 ENSG00000188511.11 C22orf34 7.47 1.94e-12 5.68e-09 0.46 0.45 Monocyte percentage of white cells;Monocyte count; chr22:49616425 chr22:49414524~49657542:- CESC cis rs11155671 0.53 rs6557133 ENSG00000268592.3 RAET1E-AS1 7.47 1.96e-12 5.75e-09 0.57 0.45 Testicular germ cell tumor; chr6:149874248 chr6:149863494~149919507:+ CESC cis rs6504950 0.79 rs8076984 ENSG00000275710.1 RP11-257O5.4 7.47 1.97e-12 5.76e-09 0.55 0.45 Breast cancer; chr17:54958067 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs17745231 ENSG00000275710.1 RP11-257O5.4 7.47 1.97e-12 5.76e-09 0.55 0.45 Breast cancer; chr17:54959168 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs12938118 ENSG00000275710.1 RP11-257O5.4 7.47 1.97e-12 5.76e-09 0.55 0.45 Breast cancer; chr17:54959998 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs1802212 ENSG00000275710.1 RP11-257O5.4 7.47 1.97e-12 5.76e-09 0.55 0.45 Breast cancer; chr17:54961293 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs17817901 ENSG00000275710.1 RP11-257O5.4 7.47 1.97e-12 5.76e-09 0.55 0.45 Breast cancer; chr17:54961384 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs12150038 ENSG00000275710.1 RP11-257O5.4 7.47 1.97e-12 5.76e-09 0.55 0.45 Breast cancer; chr17:54964159 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs12951542 ENSG00000275710.1 RP11-257O5.4 7.47 1.97e-12 5.76e-09 0.55 0.45 Breast cancer; chr17:54964604 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs72831295 ENSG00000275710.1 RP11-257O5.4 7.47 1.97e-12 5.76e-09 0.55 0.45 Breast cancer; chr17:54966443 chr17:54964474~54964679:+ CESC cis rs10463554 0.963 rs6883113 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103042185 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs12655592 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103043715 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs12055075 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103044553 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs12054848 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103044736 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs11242484 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103046172 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs11242485 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103046330 chr5:103032376~103033031:+ CESC cis rs26232 0.526 rs61654927 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Rheumatoid arthritis; chr5:103047021 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs59292735 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103047047 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs10434791 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103053768 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs34382 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103060521 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs34380 ENSG00000175749.11 EIF3KP1 7.46 1.98e-12 5.77e-09 0.49 0.45 Parkinson's disease; chr5:103061245 chr5:103032376~103033031:+ CESC cis rs1577917 1 rs36096931 ENSG00000203875.9 SNHG5 -7.46 1.98e-12 5.78e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85983416 chr6:85660950~85678736:- CESC cis rs526231 0.543 rs246915 ENSG00000175749.11 EIF3KP1 7.46 1.99e-12 5.81e-09 0.52 0.45 Primary biliary cholangitis; chr5:103222343 chr5:103032376~103033031:+ CESC cis rs8081395 0.801 rs2665405 ENSG00000266992.1 DHX40P1 -7.46 2e-12 5.82e-09 -0.47 -0.45 White blood cell count; chr17:59797931 chr17:59976009~60002384:- CESC cis rs2739330 0.76 rs5760095 ENSG00000250470.1 AP000351.3 7.46 2e-12 5.84e-09 0.59 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23976904~23977585:- CESC cis rs7104764 1 rs10902112 ENSG00000277290.1 RP11-326C3.16 -7.46 2.02e-12 5.88e-09 -0.42 -0.45 Menarche (age at onset); chr11:244106 chr11:243099~243483:- CESC cis rs7104764 0.917 rs7107362 ENSG00000277290.1 RP11-326C3.16 -7.46 2.02e-12 5.88e-09 -0.42 -0.45 Menarche (age at onset); chr11:244108 chr11:243099~243483:- CESC cis rs7104764 1 rs7128044 ENSG00000277290.1 RP11-326C3.16 -7.46 2.02e-12 5.88e-09 -0.42 -0.45 Menarche (age at onset); chr11:244115 chr11:243099~243483:- CESC cis rs7104764 0.957 rs7116130 ENSG00000277290.1 RP11-326C3.16 -7.46 2.02e-12 5.88e-09 -0.42 -0.45 Menarche (age at onset); chr11:244129 chr11:243099~243483:- CESC cis rs7104764 1 rs7128029 ENSG00000277290.1 RP11-326C3.16 -7.46 2.02e-12 5.88e-09 -0.42 -0.45 Menarche (age at onset); chr11:244141 chr11:243099~243483:- CESC cis rs12022452 0.544 rs11208423 ENSG00000238287.1 RP11-656D10.3 -7.46 2.02e-12 5.9e-09 -0.63 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr1:40563942 chr1:40493157~40508661:- CESC cis rs507080 0.733 rs611733 ENSG00000255422.1 AP002954.4 -7.46 2.03e-12 5.9e-09 -0.54 -0.45 Serum metabolite levels; chr11:118702051 chr11:118704607~118750263:+ CESC cis rs507080 0.733 rs552079 ENSG00000255422.1 AP002954.4 -7.46 2.03e-12 5.9e-09 -0.54 -0.45 Serum metabolite levels; chr11:118702313 chr11:118704607~118750263:+ CESC cis rs507080 0.733 rs673547 ENSG00000255422.1 AP002954.4 -7.46 2.03e-12 5.9e-09 -0.54 -0.45 Serum metabolite levels; chr11:118702630 chr11:118704607~118750263:+ CESC cis rs227275 0.554 rs223404 ENSG00000246560.2 RP11-10L12.4 7.46 2.05e-12 5.97e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102816951 chr4:102828055~102844075:+ CESC cis rs526231 0.543 rs62362521 ENSG00000175749.11 EIF3KP1 7.46 2.06e-12 5.97e-09 0.51 0.45 Primary biliary cholangitis; chr5:102970357 chr5:103032376~103033031:+ CESC cis rs526231 0.575 rs12652973 ENSG00000175749.11 EIF3KP1 7.46 2.06e-12 5.97e-09 0.51 0.45 Primary biliary cholangitis; chr5:102970618 chr5:103032376~103033031:+ CESC cis rs526231 0.575 rs66730942 ENSG00000175749.11 EIF3KP1 7.46 2.06e-12 5.97e-09 0.51 0.45 Primary biliary cholangitis; chr5:102971075 chr5:103032376~103033031:+ CESC cis rs1577917 0.958 rs12199832 ENSG00000203875.9 SNHG5 -7.46 2.06e-12 5.99e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85943030 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12207374 ENSG00000203875.9 SNHG5 -7.46 2.06e-12 5.99e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85946927 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12201735 ENSG00000203875.9 SNHG5 -7.46 2.06e-12 5.99e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85947221 chr6:85660950~85678736:- CESC cis rs2882667 0.66 rs3088052 ENSG00000253404.1 AC034243.1 7.46 2.07e-12 5.99e-09 0.52 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139121126 chr5:138744434~138753309:- CESC cis rs1707322 0.627 rs3014213 ENSG00000280836.1 AL355480.1 7.46 2.07e-12 6e-09 0.54 0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45579850 chr1:45581219~45581321:- CESC cis rs1707322 0.686 rs2152078 ENSG00000280836.1 AL355480.1 7.46 2.07e-12 6e-09 0.54 0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45589928 chr1:45581219~45581321:- CESC cis rs1707322 0.686 rs2991979 ENSG00000280836.1 AL355480.1 7.46 2.07e-12 6e-09 0.54 0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45590186 chr1:45581219~45581321:- CESC cis rs10463554 0.963 rs67068617 ENSG00000175749.11 EIF3KP1 7.46 2.08e-12 6.03e-09 0.49 0.45 Parkinson's disease; chr5:103039977 chr5:103032376~103033031:+ CESC cis rs7617773 0.779 rs11718329 ENSG00000229759.1 MRPS18AP1 7.46 2.09e-12 6.06e-09 0.47 0.45 Coronary artery disease; chr3:48268338 chr3:48256350~48256938:- CESC cis rs227275 0.554 rs223409 ENSG00000246560.2 RP11-10L12.4 7.45 2.1e-12 6.09e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102815023 chr4:102828055~102844075:+ CESC cis rs6700559 1 rs6700559 ENSG00000260088.1 RP11-92G12.3 7.45 2.11e-12 6.11e-09 0.56 0.45 Coronary artery disease; chr1:200676945 chr1:200669507~200694250:+ CESC cis rs9545047 0.935 rs9530922 ENSG00000227676.3 LINC01068 -7.45 2.11e-12 6.12e-09 -0.51 -0.45 Schizophrenia; chr13:79469002 chr13:79566727~79571436:+ CESC cis rs6991838 0.584 rs35941313 ENSG00000272010.1 CTD-3025N20.3 -7.45 2.15e-12 6.22e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65587498 chr8:65591850~65592472:- CESC cis rs6142102 0.538 rs6142058 ENSG00000276073.1 RP5-1125A11.7 -7.45 2.15e-12 6.22e-09 -0.4 -0.45 Skin pigmentation; chr20:33954995 chr20:33985617~33988989:- CESC cis rs7104764 0.957 rs3817629 ENSG00000277290.1 RP11-326C3.16 -7.45 2.16e-12 6.25e-09 -0.42 -0.45 Menarche (age at onset); chr11:237312 chr11:243099~243483:- CESC cis rs7104764 1 rs10902110 ENSG00000277290.1 RP11-326C3.16 -7.45 2.16e-12 6.25e-09 -0.42 -0.45 Menarche (age at onset); chr11:237648 chr11:243099~243483:- CESC cis rs7104764 1 rs7481993 ENSG00000277290.1 RP11-326C3.16 -7.45 2.16e-12 6.25e-09 -0.42 -0.45 Menarche (age at onset); chr11:237875 chr11:243099~243483:- CESC cis rs10463554 0.927 rs34798 ENSG00000175749.11 EIF3KP1 7.45 2.2e-12 6.37e-09 0.58 0.45 Parkinson's disease; chr5:103090047 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs62364874 ENSG00000175749.11 EIF3KP1 7.44 2.26e-12 6.52e-09 0.49 0.45 Parkinson's disease; chr5:103056475 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs62364876 ENSG00000175749.11 EIF3KP1 7.44 2.26e-12 6.52e-09 0.49 0.45 Parkinson's disease; chr5:103058454 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs158254 ENSG00000175749.11 EIF3KP1 7.44 2.26e-12 6.52e-09 0.49 0.45 Parkinson's disease; chr5:103059179 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs34381 ENSG00000175749.11 EIF3KP1 7.44 2.26e-12 6.52e-09 0.49 0.45 Parkinson's disease; chr5:103060852 chr5:103032376~103033031:+ CESC cis rs6142102 0.625 rs1883706 ENSG00000276073.1 RP5-1125A11.7 -7.44 2.26e-12 6.52e-09 -0.4 -0.45 Skin pigmentation; chr20:33965071 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs1883705 ENSG00000276073.1 RP5-1125A11.7 -7.44 2.26e-12 6.52e-09 -0.4 -0.45 Skin pigmentation; chr20:33965072 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs4012234 ENSG00000276073.1 RP5-1125A11.7 -7.44 2.26e-12 6.52e-09 -0.4 -0.45 Skin pigmentation; chr20:33965241 chr20:33985617~33988989:- CESC cis rs6142102 0.649 rs4911382 ENSG00000276073.1 RP5-1125A11.7 -7.44 2.26e-12 6.52e-09 -0.4 -0.45 Skin pigmentation; chr20:33965289 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs6141436 ENSG00000276073.1 RP5-1125A11.7 -7.44 2.26e-12 6.52e-09 -0.4 -0.45 Skin pigmentation; chr20:33966765 chr20:33985617~33988989:- CESC cis rs7849270 1 rs3124513 ENSG00000268707.1 RP11-247A12.7 7.44 2.28e-12 6.58e-09 0.55 0.45 Blood metabolite ratios; chr9:129142314 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs3124514 ENSG00000268707.1 RP11-247A12.7 7.44 2.28e-12 6.58e-09 0.55 0.45 Blood metabolite ratios; chr9:129142329 chr9:129170434~129170940:+ CESC cis rs9601248 0.529 rs2783126 ENSG00000227676.3 LINC01068 7.44 2.3e-12 6.62e-09 0.52 0.45 Major depressive disorder; chr13:79584566 chr13:79566727~79571436:+ CESC cis rs7044106 0.791 rs10984998 ENSG00000226752.6 PSMD5-AS1 -7.44 2.3e-12 6.64e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120719238 chr9:120824828~120854385:+ CESC cis rs801193 0.66 rs4610622 ENSG00000226824.5 RP4-756H11.3 -7.44 2.31e-12 6.66e-09 -0.56 -0.45 Aortic root size; chr7:66759510 chr7:66654538~66669855:+ CESC cis rs6991838 0.556 rs7846527 ENSG00000272010.1 CTD-3025N20.3 -7.44 2.32e-12 6.68e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65586522 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs4320587 ENSG00000272010.1 CTD-3025N20.3 -7.44 2.32e-12 6.68e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65586991 chr8:65591850~65592472:- CESC cis rs6452524 0.935 rs7736296 ENSG00000249664.1 CTD-2227C6.2 -7.44 2.35e-12 6.76e-09 -0.48 -0.45 Hypertension (SNP x SNP interaction); chr5:83082421 chr5:83012285~83013109:- CESC cis rs6142102 0.625 rs9753690 ENSG00000276073.1 RP5-1125A11.7 -7.44 2.36e-12 6.78e-09 -0.4 -0.45 Skin pigmentation; chr20:33952995 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs7263727 ENSG00000276073.1 RP5-1125A11.7 -7.44 2.36e-12 6.78e-09 -0.4 -0.45 Skin pigmentation; chr20:33953133 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs6142056 ENSG00000276073.1 RP5-1125A11.7 -7.44 2.36e-12 6.78e-09 -0.4 -0.45 Skin pigmentation; chr20:33953349 chr20:33985617~33988989:- CESC cis rs6991838 0.584 rs4388482 ENSG00000272010.1 CTD-3025N20.3 -7.43 2.38e-12 6.84e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65583968 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs4637885 ENSG00000272010.1 CTD-3025N20.3 -7.43 2.38e-12 6.84e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65584849 chr8:65591850~65592472:- CESC cis rs7849270 1 rs932835 ENSG00000268707.1 RP11-247A12.7 -7.43 2.38e-12 6.85e-09 -0.55 -0.45 Blood metabolite ratios; chr9:129124792 chr9:129170434~129170940:+ CESC cis rs9322193 0.504 rs7771014 ENSG00000231760.4 RP11-350J20.5 7.43 2.41e-12 6.93e-09 0.57 0.45 Lung cancer; chr6:149884310 chr6:149796151~149826294:- CESC cis rs6142102 0.602 rs4911399 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.41e-12 6.93e-09 -0.4 -0.45 Skin pigmentation; chr20:34035612 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs2050208 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.42e-12 6.94e-09 -0.4 -0.45 Skin pigmentation; chr20:33955767 chr20:33985617~33988989:- CESC cis rs6142102 0.602 rs4911380 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.42e-12 6.94e-09 -0.4 -0.45 Skin pigmentation; chr20:33958418 chr20:33985617~33988989:- CESC cis rs1799949 0.965 rs9911630 ENSG00000198496.9 NBR2 -7.43 2.42e-12 6.95e-09 -0.56 -0.45 Menopause (age at onset); chr17:43036325 chr17:43125610~43153671:+ CESC cis rs2404602 0.735 rs2461870 ENSG00000259422.1 RP11-593F23.1 -7.43 2.45e-12 7.02e-09 -0.52 -0.45 Blood metabolite levels; chr15:76521579 chr15:76174891~76181486:- CESC cis rs2404602 0.735 rs2454454 ENSG00000259422.1 RP11-593F23.1 -7.43 2.45e-12 7.02e-09 -0.52 -0.45 Blood metabolite levels; chr15:76531306 chr15:76174891~76181486:- CESC cis rs2404602 0.709 rs11072591 ENSG00000259422.1 RP11-593F23.1 7.43 2.45e-12 7.02e-09 0.53 0.45 Blood metabolite levels; chr15:76357221 chr15:76174891~76181486:- CESC cis rs12439619 0.846 rs62010071 ENSG00000278603.1 RP13-608F4.5 7.43 2.45e-12 7.03e-09 0.78 0.45 Intelligence (multi-trait analysis); chr15:82289442 chr15:82472203~82472426:+ CESC cis rs227275 0.554 rs149576 ENSG00000246560.2 RP11-10L12.4 7.43 2.45e-12 7.04e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102811411 chr4:102828055~102844075:+ CESC cis rs7626444 0.625 rs9826214 ENSG00000272359.1 U4 -7.43 2.45e-12 7.04e-09 -0.52 -0.45 Monocyte count; chr3:196751342 chr3:196747192~196747324:- CESC cis rs9907295 0.688 rs2526327 ENSG00000270977.1 AC015849.16 7.43 2.46e-12 7.07e-09 0.54 0.45 Fibroblast growth factor basic levels; chr17:35929902 chr17:35893707~35911023:- CESC cis rs7044106 0.791 rs4617229 ENSG00000226752.6 PSMD5-AS1 -7.43 2.46e-12 7.07e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120718418 chr9:120824828~120854385:+ CESC cis rs6142102 0.625 rs4911138 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.47e-12 7.09e-09 -0.4 -0.45 Skin pigmentation; chr20:33959893 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs4243974 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.47e-12 7.09e-09 -0.4 -0.45 Skin pigmentation; chr20:33960062 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs6142062 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.47e-12 7.09e-09 -0.4 -0.45 Skin pigmentation; chr20:33960706 chr20:33985617~33988989:- CESC cis rs6142102 0.625 rs6141432 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.47e-12 7.09e-09 -0.4 -0.45 Skin pigmentation; chr20:33960791 chr20:33985617~33988989:- CESC cis rs6142102 0.602 rs6141433 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.47e-12 7.09e-09 -0.4 -0.45 Skin pigmentation; chr20:33961056 chr20:33985617~33988989:- CESC cis rs7208859 0.615 rs216462 ENSG00000263531.1 RP13-753N3.1 -7.43 2.48e-12 7.11e-09 -0.99 -0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30568879 chr17:30863921~30864940:- CESC cis rs6142102 0.625 rs6142061 ENSG00000276073.1 RP5-1125A11.7 -7.43 2.48e-12 7.11e-09 -0.4 -0.45 Skin pigmentation; chr20:33960529 chr20:33985617~33988989:- CESC cis rs6991838 0.557 rs4737222 ENSG00000272010.1 CTD-3025N20.3 -7.43 2.48e-12 7.11e-09 -0.51 -0.45 Intelligence (multi-trait analysis); chr8:65587878 chr8:65591850~65592472:- CESC cis rs227275 0.527 rs223338 ENSG00000246560.2 RP11-10L12.4 7.43 2.49e-12 7.13e-09 0.55 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102864959 chr4:102828055~102844075:+ CESC cis rs9601248 0.529 rs9545142 ENSG00000227676.3 LINC01068 7.42 2.51e-12 7.2e-09 0.52 0.45 Major depressive disorder; chr13:79588420 chr13:79566727~79571436:+ CESC cis rs1577917 1 rs12201571 ENSG00000203875.9 SNHG5 -7.42 2.52e-12 7.21e-09 -0.57 -0.45 Response to antipsychotic treatment; chr6:85900032 chr6:85660950~85678736:- CESC cis rs1577917 1 rs11759855 ENSG00000203875.9 SNHG5 -7.42 2.52e-12 7.21e-09 -0.57 -0.45 Response to antipsychotic treatment; chr6:85901123 chr6:85660950~85678736:- CESC cis rs9601248 0.508 rs9601240 ENSG00000227676.3 LINC01068 7.42 2.52e-12 7.22e-09 0.52 0.45 Major depressive disorder; chr13:79558238 chr13:79566727~79571436:+ CESC cis rs9545047 0.935 rs4885633 ENSG00000227676.3 LINC01068 -7.42 2.53e-12 7.23e-09 -0.51 -0.45 Schizophrenia; chr13:79469720 chr13:79566727~79571436:+ CESC cis rs4718428 0.96 rs6460317 ENSG00000226824.5 RP4-756H11.3 -7.42 2.54e-12 7.25e-09 -0.57 -0.45 Corneal structure; chr7:66925268 chr7:66654538~66669855:+ CESC cis rs1577917 1 rs10944169 ENSG00000203875.9 SNHG5 -7.42 2.54e-12 7.27e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85973318 chr6:85660950~85678736:- CESC cis rs1707322 0.752 rs4660880 ENSG00000280836.1 AL355480.1 -7.42 2.57e-12 7.36e-09 -0.53 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645368 chr1:45581219~45581321:- CESC cis rs228614 0.51 rs223362 ENSG00000246560.2 RP11-10L12.4 7.42 2.58e-12 7.38e-09 0.53 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102848077 chr4:102828055~102844075:+ CESC cis rs1140227 0.502 rs10789304 ENSG00000235358.1 RP11-399E6.1 7.42 2.6e-12 7.43e-09 0.63 0.45 Intelligence (multi-trait analysis); chr1:41121740 chr1:41242373~41284861:+ CESC cis rs228614 0.534 rs223387 ENSG00000246560.2 RP11-10L12.4 7.42 2.66e-12 7.6e-09 0.54 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102828359 chr4:102828055~102844075:+ CESC cis rs2739330 0.828 rs4822454 ENSG00000099984.9 GSTT2 -7.42 2.67e-12 7.6e-09 -0.54 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23980123~23983911:+ CESC cis rs2882667 0.898 rs4380651 ENSG00000253404.1 AC034243.1 7.41 2.71e-12 7.71e-09 0.54 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139055383 chr5:138744434~138753309:- CESC cis rs113835537 0.529 rs17147644 ENSG00000255517.5 CTD-3074O7.5 -7.41 2.72e-12 7.73e-09 -0.52 -0.45 Airway imaging phenotypes; chr11:66489189 chr11:66473490~66480233:- CESC cis rs7849270 1 rs3124510 ENSG00000268707.1 RP11-247A12.7 7.41 2.72e-12 7.73e-09 0.54 0.45 Blood metabolite ratios; chr9:129137411 chr9:129170434~129170940:+ CESC cis rs1577917 0.958 rs13207354 ENSG00000203875.9 SNHG5 -7.41 2.73e-12 7.75e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85990545 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12204365 ENSG00000203875.9 SNHG5 -7.41 2.73e-12 7.75e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85990814 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12663651 ENSG00000203875.9 SNHG5 -7.41 2.73e-12 7.75e-09 -0.56 -0.45 Response to antipsychotic treatment; chr6:85991937 chr6:85660950~85678736:- CESC cis rs227275 0.554 rs223367 ENSG00000246560.2 RP11-10L12.4 7.41 2.75e-12 7.81e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102843836 chr4:102828055~102844075:+ CESC cis rs875971 1 rs6958271 ENSG00000226824.5 RP4-756H11.3 -7.41 2.75e-12 7.82e-09 -0.57 -0.45 Aortic root size; chr7:66514344 chr7:66654538~66669855:+ CESC cis rs875971 1 rs6958277 ENSG00000226824.5 RP4-756H11.3 -7.41 2.75e-12 7.82e-09 -0.57 -0.45 Aortic root size; chr7:66514362 chr7:66654538~66669855:+ CESC cis rs227275 0.524 rs223337 ENSG00000246560.2 RP11-10L12.4 7.41 2.77e-12 7.87e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102865214 chr4:102828055~102844075:+ CESC cis rs113835537 0.529 rs7950790 ENSG00000255517.5 CTD-3074O7.5 -7.41 2.78e-12 7.89e-09 -0.51 -0.45 Airway imaging phenotypes; chr11:66490582 chr11:66473490~66480233:- CESC cis rs7104764 1 rs6598069 ENSG00000277290.1 RP11-326C3.16 -7.41 2.79e-12 7.92e-09 -0.42 -0.45 Menarche (age at onset); chr11:240664 chr11:243099~243483:- CESC cis rs7104764 1 rs1128320 ENSG00000277290.1 RP11-326C3.16 -7.41 2.81e-12 7.97e-09 -0.42 -0.45 Menarche (age at onset); chr11:244167 chr11:243099~243483:- CESC cis rs7104764 0.957 rs1128321 ENSG00000277290.1 RP11-326C3.16 -7.41 2.81e-12 7.97e-09 -0.42 -0.45 Menarche (age at onset); chr11:244171 chr11:243099~243483:- CESC cis rs801193 0.66 rs10950049 ENSG00000226824.5 RP4-756H11.3 -7.41 2.81e-12 7.99e-09 -0.56 -0.45 Aortic root size; chr7:66765873 chr7:66654538~66669855:+ CESC cis rs9481169 0.85 rs60962769 ENSG00000255389.1 C6orf3 -7.41 2.81e-12 7.99e-09 -0.93 -0.45 Inflammatory skin disease; chr6:111598221 chr6:111599875~111602295:+ CESC cis rs1577917 1 rs884841 ENSG00000203875.9 SNHG5 -7.4 2.83e-12 8.04e-09 -0.55 -0.45 Response to antipsychotic treatment; chr6:85970582 chr6:85660950~85678736:- CESC cis rs7044106 0.791 rs7036196 ENSG00000226752.6 PSMD5-AS1 -7.4 2.85e-12 8.07e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120717179 chr9:120824828~120854385:+ CESC cis rs7044106 0.791 rs7036766 ENSG00000226752.6 PSMD5-AS1 -7.4 2.85e-12 8.07e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120717343 chr9:120824828~120854385:+ CESC cis rs7044106 0.791 rs3904196 ENSG00000226752.6 PSMD5-AS1 -7.4 2.85e-12 8.07e-09 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120718091 chr9:120824828~120854385:+ CESC cis rs1707322 0.717 rs1972410 ENSG00000280836.1 AL355480.1 -7.4 2.85e-12 8.09e-09 -0.53 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615275 chr1:45581219~45581321:- CESC cis rs7849270 1 rs10819469 ENSG00000268707.1 RP11-247A12.7 -7.4 2.87e-12 8.14e-09 -0.54 -0.45 Blood metabolite ratios; chr9:129119788 chr9:129170434~129170940:+ CESC cis rs1577917 1 rs1337844 ENSG00000203875.9 SNHG5 -7.4 2.87e-12 8.14e-09 -0.55 -0.45 Response to antipsychotic treatment; chr6:85967555 chr6:85660950~85678736:- CESC cis rs5769707 0.967 rs5770585 ENSG00000188511.11 C22orf34 7.4 2.89e-12 8.18e-09 0.46 0.45 Monocyte percentage of white cells;Monocyte count; chr22:49614226 chr22:49414524~49657542:- CESC cis rs5769707 0.839 rs73176988 ENSG00000188511.11 C22orf34 7.4 2.92e-12 8.26e-09 0.47 0.45 Monocyte percentage of white cells;Monocyte count; chr22:49596001 chr22:49414524~49657542:- CESC cis rs916888 0.61 rs199454 ENSG00000214401.4 KANSL1-AS1 -7.4 2.92e-12 8.26e-09 -0.55 -0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46193576~46196723:+ CESC cis rs992157 1 rs2168704 ENSG00000261338.2 RP11-378A13.1 7.4 2.92e-12 8.26e-09 0.57 0.45 Colorectal cancer; chr2:218277769 chr2:218255319~218257366:+ CESC cis rs526231 0.575 rs62362523 ENSG00000175749.11 EIF3KP1 7.4 2.94e-12 8.3e-09 0.51 0.45 Primary biliary cholangitis; chr5:102977979 chr5:103032376~103033031:+ CESC cis rs526231 0.575 rs62362524 ENSG00000175749.11 EIF3KP1 7.4 2.94e-12 8.3e-09 0.51 0.45 Primary biliary cholangitis; chr5:102978523 chr5:103032376~103033031:+ CESC cis rs4853012 0.838 rs4563249 ENSG00000257800.1 FNBP1P1 7.4 2.95e-12 8.33e-09 0.46 0.45 Gestational age at birth (maternal effect); chr2:74126889 chr2:74120680~74123218:+ CESC cis rs6142102 0.602 rs11696338 ENSG00000276073.1 RP5-1125A11.7 -7.4 2.98e-12 8.4e-09 -0.41 -0.45 Skin pigmentation; chr20:34099805 chr20:33985617~33988989:- CESC cis rs6142102 0.58 rs6142101 ENSG00000276073.1 RP5-1125A11.7 -7.4 2.98e-12 8.4e-09 -0.41 -0.45 Skin pigmentation; chr20:34110039 chr20:33985617~33988989:- CESC cis rs12594515 0.548 rs55932467 ENSG00000273972.1 CTD-2306A12.1 -7.4 2.98e-12 8.4e-09 -0.61 -0.45 Weight;Waist circumference; chr15:45704926 chr15:45702640~45703183:+ CESC cis rs2404602 0.598 rs11855999 ENSG00000259422.1 RP11-593F23.1 -7.4 2.99e-12 8.43e-09 -0.57 -0.45 Blood metabolite levels; chr15:76334992 chr15:76174891~76181486:- CESC cis rs10463554 0.926 rs5855 ENSG00000175749.11 EIF3KP1 -7.4 3e-12 8.45e-09 -0.47 -0.45 Parkinson's disease; chr5:103029482 chr5:103032376~103033031:+ CESC cis rs528808 1 rs528808 ENSG00000219755.1 RP1-199J3.5 7.39 3.01e-12 8.47e-09 0.66 0.45 Age-related hearing impairment; chr6:99656413 chr6:99575712~99576456:+ CESC cis rs150992 0.711 rs326489 ENSG00000248489.1 CTD-2007H13.3 7.39 3.02e-12 8.51e-09 0.54 0.45 Body mass index; chr5:98841105 chr5:98929171~98995013:+ CESC cis rs7104764 1 rs6598066 ENSG00000277290.1 RP11-326C3.16 -7.39 3.04e-12 8.56e-09 -0.44 -0.45 Menarche (age at onset); chr11:243185 chr11:243099~243483:- CESC cis rs2739330 0.892 rs5751776 ENSG00000250470.1 AP000351.3 7.39 3.05e-12 8.58e-09 0.57 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23976904~23977585:- CESC cis rs2882667 0.858 rs11949916 ENSG00000253404.1 AC034243.1 7.39 3.07e-12 8.63e-09 0.56 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139060588 chr5:138744434~138753309:- CESC cis rs1577917 1 rs34106666 ENSG00000203875.9 SNHG5 -7.39 3.07e-12 8.64e-09 -0.55 -0.45 Response to antipsychotic treatment; chr6:85966540 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs884842 ENSG00000203875.9 SNHG5 -7.39 3.07e-12 8.64e-09 -0.55 -0.45 Response to antipsychotic treatment; chr6:85970679 chr6:85660950~85678736:- CESC cis rs227275 0.554 rs223381 ENSG00000246560.2 RP11-10L12.4 7.39 3.07e-12 8.64e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102832578 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223371 ENSG00000246560.2 RP11-10L12.4 7.39 3.07e-12 8.64e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102838032 chr4:102828055~102844075:+ CESC cis rs7617773 0.817 rs6800492 ENSG00000229759.1 MRPS18AP1 7.39 3.08e-12 8.66e-09 0.48 0.45 Coronary artery disease; chr3:48282400 chr3:48256350~48256938:- CESC cis rs801193 0.636 rs10233806 ENSG00000226824.5 RP4-756H11.3 7.39 3.1e-12 8.71e-09 0.56 0.45 Aortic root size; chr7:66653261 chr7:66654538~66669855:+ CESC cis rs1707322 0.685 rs11211177 ENSG00000280836.1 AL355480.1 -7.39 3.12e-12 8.75e-09 -0.52 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760677 chr1:45581219~45581321:- CESC cis rs7684253 0.565 rs13108570 ENSG00000269949.1 RP11-738E22.3 -7.39 3.12e-12 8.77e-09 -0.53 -0.45 Migraine; chr4:56940917 chr4:56960927~56961373:- CESC cis rs6142102 0.602 rs2268079 ENSG00000276073.1 RP5-1125A11.7 -7.39 3.13e-12 8.77e-09 -0.4 -0.45 Skin pigmentation; chr20:34008944 chr20:33985617~33988989:- CESC cis rs6142102 0.602 rs1054534 ENSG00000276073.1 RP5-1125A11.7 -7.39 3.13e-12 8.77e-09 -0.4 -0.45 Skin pigmentation; chr20:34017521 chr20:33985617~33988989:- CESC cis rs150992 0.678 rs327793 ENSG00000248489.1 CTD-2007H13.3 7.39 3.14e-12 8.82e-09 0.52 0.45 Body mass index; chr5:98913717 chr5:98929171~98995013:+ CESC cis rs227275 0.525 rs4698874 ENSG00000246560.2 RP11-10L12.4 7.39 3.16e-12 8.86e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:103009354 chr4:102828055~102844075:+ CESC cis rs1577917 0.652 rs75593931 ENSG00000203875.9 SNHG5 -7.39 3.16e-12 8.87e-09 -0.57 -0.45 Response to antipsychotic treatment; chr6:86009821 chr6:85660950~85678736:- CESC cis rs1577917 0.959 rs12201739 ENSG00000203875.9 SNHG5 -7.39 3.16e-12 8.87e-09 -0.57 -0.45 Response to antipsychotic treatment; chr6:86011021 chr6:85660950~85678736:- CESC cis rs26232 0.52 rs26432 ENSG00000175749.11 EIF3KP1 -7.39 3.17e-12 8.87e-09 -0.47 -0.45 Rheumatoid arthritis; chr5:103030006 chr5:103032376~103033031:+ CESC cis rs26232 0.583 rs26430 ENSG00000175749.11 EIF3KP1 -7.39 3.17e-12 8.87e-09 -0.47 -0.45 Rheumatoid arthritis; chr5:103030228 chr5:103032376~103033031:+ CESC cis rs10463554 0.89 rs26428 ENSG00000175749.11 EIF3KP1 -7.39 3.17e-12 8.87e-09 -0.47 -0.45 Parkinson's disease; chr5:103030780 chr5:103032376~103033031:+ CESC cis rs1577917 1 rs12192992 ENSG00000203875.9 SNHG5 -7.38 3.2e-12 8.96e-09 -0.57 -0.45 Response to antipsychotic treatment; chr6:85900197 chr6:85660950~85678736:- CESC cis rs507080 0.733 rs517445 ENSG00000255422.1 AP002954.4 -7.38 3.2e-12 8.97e-09 -0.53 -0.45 Serum metabolite levels; chr11:118702826 chr11:118704607~118750263:+ CESC cis rs1153858 0.725 rs74572151 ENSG00000259520.4 CTD-2651B20.3 -7.38 3.21e-12 9e-09 -0.58 -0.45 Homoarginine levels; chr15:45355328 chr15:45251580~45279251:- CESC cis rs526231 0.543 rs42431 ENSG00000175749.11 EIF3KP1 -7.38 3.21e-12 9e-09 -0.5 -0.45 Primary biliary cholangitis; chr5:103064359 chr5:103032376~103033031:+ CESC cis rs2882667 0.822 rs11738376 ENSG00000253404.1 AC034243.1 7.38 3.22e-12 9.02e-09 0.56 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139062483 chr5:138744434~138753309:- CESC cis rs3931020 0.745 rs1969111 ENSG00000272864.1 RP11-17E13.2 7.38 3.25e-12 9.1e-09 0.51 0.45 Resistin levels; chr1:74797801 chr1:74698769~74699333:- CESC cis rs4423214 0.61 rs12789253 ENSG00000254682.1 RP11-660L16.2 7.38 3.27e-12 9.14e-09 0.54 0.45 Vitamin D levels; chr11:71414719 chr11:71448674~71452157:+ CESC cis rs7849270 0.959 rs4836641 ENSG00000268707.1 RP11-247A12.7 7.38 3.34e-12 9.33e-09 0.6 0.45 Blood metabolite ratios; chr9:129149953 chr9:129170434~129170940:+ CESC cis rs1707322 0.721 rs6699418 ENSG00000280836.1 AL355480.1 -7.38 3.36e-12 9.38e-09 -0.53 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634509 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs4431884 ENSG00000280836.1 AL355480.1 -7.38 3.36e-12 9.38e-09 -0.53 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45635651 chr1:45581219~45581321:- CESC cis rs1707322 0.65 rs4660879 ENSG00000280836.1 AL355480.1 -7.38 3.36e-12 9.38e-09 -0.53 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45639729 chr1:45581219~45581321:- CESC cis rs6142102 0.517 rs6142046 ENSG00000276073.1 RP5-1125A11.7 -7.38 3.36e-12 9.39e-09 -0.4 -0.45 Skin pigmentation; chr20:33926255 chr20:33985617~33988989:- CESC cis rs7617773 0.744 rs2125482 ENSG00000229759.1 MRPS18AP1 7.37 3.43e-12 9.58e-09 0.48 0.45 Coronary artery disease; chr3:48281643 chr3:48256350~48256938:- CESC cis rs227275 0.554 rs223359 ENSG00000246560.2 RP11-10L12.4 7.37 3.44e-12 9.61e-09 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102849422 chr4:102828055~102844075:+ CESC cis rs35160687 0.862 rs13023154 ENSG00000273080.1 RP11-301O19.1 -7.37 3.45e-12 9.63e-09 -0.53 -0.45 Night sleep phenotypes; chr2:86289861 chr2:86195590~86196049:+ CESC cis rs9326248 0.53 rs6589576 ENSG00000254851.1 RP11-109L13.1 7.37 3.47e-12 9.68e-09 0.79 0.45 Blood protein levels; chr11:116865072 chr11:117135528~117138582:+ CESC cis rs7849270 1 rs10819464 ENSG00000268707.1 RP11-247A12.7 -7.37 3.47e-12 9.68e-09 -0.51 -0.45 Blood metabolite ratios; chr9:129113998 chr9:129170434~129170940:+ CESC cis rs9545047 0.935 rs1475797 ENSG00000227676.3 LINC01068 -7.37 3.47e-12 9.68e-09 -0.51 -0.45 Schizophrenia; chr13:79519690 chr13:79566727~79571436:+ CESC cis rs6142102 0.502 rs58393429 ENSG00000276073.1 RP5-1125A11.7 -7.37 3.48e-12 9.71e-09 -0.4 -0.45 Skin pigmentation; chr20:33957996 chr20:33985617~33988989:- CESC cis rs6142102 0.602 rs6142069 ENSG00000276073.1 RP5-1125A11.7 -7.37 3.5e-12 9.74e-09 -0.4 -0.45 Skin pigmentation; chr20:33972736 chr20:33985617~33988989:- CESC cis rs6142102 0.602 rs4911395 ENSG00000276073.1 RP5-1125A11.7 -7.37 3.5e-12 9.74e-09 -0.4 -0.45 Skin pigmentation; chr20:33992095 chr20:33985617~33988989:- CESC cis rs2882667 0.858 rs66839813 ENSG00000253404.1 AC034243.1 7.37 3.5e-12 9.75e-09 0.56 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139106633 chr5:138744434~138753309:- CESC cis rs7849270 0.959 rs1107329 ENSG00000268707.1 RP11-247A12.7 7.37 3.52e-12 9.81e-09 0.61 0.45 Blood metabolite ratios; chr9:129155435 chr9:129170434~129170940:+ CESC cis rs227275 0.554 rs223357 ENSG00000246560.2 RP11-10L12.4 7.37 3.55e-12 9.88e-09 0.53 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102851095 chr4:102828055~102844075:+ CESC cis rs150992 0.512 rs161954 ENSG00000248489.1 CTD-2007H13.3 7.37 3.55e-12 9.88e-09 0.51 0.45 Body mass index; chr5:98920833 chr5:98929171~98995013:+ CESC cis rs916888 0.61 rs199446 ENSG00000214401.4 KANSL1-AS1 -7.37 3.55e-12 9.88e-09 -0.53 -0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46193576~46196723:+ CESC cis rs9828933 0.766 rs864975 ENSG00000280620.1 SCAANT1 -7.37 3.57e-12 9.93e-09 -0.88 -0.45 Type 2 diabetes; chr3:63899939 chr3:63911518~63911772:- CESC cis rs7044106 0.762 rs10760107 ENSG00000226752.6 PSMD5-AS1 -7.37 3.58e-12 9.96e-09 -0.5 -0.45 Hip circumference adjusted for BMI; chr9:120621352 chr9:120824828~120854385:+ CESC cis rs9322193 0.847 rs4870054 ENSG00000231760.4 RP11-350J20.5 7.37 3.58e-12 9.96e-09 0.58 0.45 Lung cancer; chr6:149848402 chr6:149796151~149826294:- CESC cis rs6142102 0.602 rs4911396 ENSG00000276073.1 RP5-1125A11.7 -7.36 3.6e-12 1e-08 -0.4 -0.45 Skin pigmentation; chr20:33992139 chr20:33985617~33988989:- CESC cis rs9545047 0.935 rs7988601 ENSG00000227676.3 LINC01068 -7.36 3.62e-12 1.01e-08 -0.51 -0.45 Schizophrenia; chr13:79475648 chr13:79566727~79571436:+ CESC cis rs9545047 0.935 rs6563110 ENSG00000227676.3 LINC01068 -7.36 3.62e-12 1.01e-08 -0.51 -0.45 Schizophrenia; chr13:79477137 chr13:79566727~79571436:+ CESC cis rs7044106 0.791 rs4836829 ENSG00000226752.6 PSMD5-AS1 -7.36 3.63e-12 1.01e-08 -0.49 -0.45 Hip circumference adjusted for BMI; chr9:120720469 chr9:120824828~120854385:+ CESC cis rs1707322 0.721 rs10890333 ENSG00000280836.1 AL355480.1 -7.36 3.64e-12 1.01e-08 -0.54 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634650 chr1:45581219~45581321:- CESC cis rs7626444 0.584 rs844542 ENSG00000272359.1 U4 -7.36 3.68e-12 1.02e-08 -0.53 -0.45 Monocyte count; chr3:196752432 chr3:196747192~196747324:- CESC cis rs7626444 0.543 rs843528 ENSG00000272359.1 U4 -7.36 3.68e-12 1.02e-08 -0.53 -0.45 Monocyte count; chr3:196753464 chr3:196747192~196747324:- CESC cis rs977987 0.931 rs8057084 ENSG00000261783.1 RP11-252K23.2 7.36 3.72e-12 1.03e-08 0.55 0.45 Dupuytren's disease; chr16:75458808 chr16:75379818~75381260:- CESC cis rs227275 0.554 rs223399 ENSG00000246560.2 RP11-10L12.4 7.36 3.74e-12 1.04e-08 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102820800 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223388 ENSG00000246560.2 RP11-10L12.4 7.36 3.74e-12 1.04e-08 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102828287 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223386 ENSG00000246560.2 RP11-10L12.4 7.36 3.74e-12 1.04e-08 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102829111 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223385 ENSG00000246560.2 RP11-10L12.4 7.36 3.74e-12 1.04e-08 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102829159 chr4:102828055~102844075:+ CESC cis rs11722779 0.873 rs223384 ENSG00000246560.2 RP11-10L12.4 7.36 3.74e-12 1.04e-08 0.54 0.45 Schizophrenia; chr4:102829976 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223383 ENSG00000246560.2 RP11-10L12.4 7.36 3.74e-12 1.04e-08 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102830094 chr4:102828055~102844075:+ CESC cis rs5769707 0.935 rs1109320 ENSG00000188511.11 C22orf34 7.36 3.75e-12 1.04e-08 0.46 0.45 Monocyte percentage of white cells;Monocyte count; chr22:49595458 chr22:49414524~49657542:- CESC cis rs3931020 0.745 rs10874274 ENSG00000272864.1 RP11-17E13.2 -7.36 3.77e-12 1.05e-08 -0.51 -0.45 Resistin levels; chr1:74786450 chr1:74698769~74699333:- CESC cis rs150992 0.638 rs466340 ENSG00000248489.1 CTD-2007H13.3 7.36 3.78e-12 1.05e-08 0.52 0.45 Body mass index; chr5:98904318 chr5:98929171~98995013:+ CESC cis rs150992 0.673 rs326463 ENSG00000248489.1 CTD-2007H13.3 7.36 3.78e-12 1.05e-08 0.52 0.45 Body mass index; chr5:98905785 chr5:98929171~98995013:+ CESC cis rs3096299 0.685 rs12446145 ENSG00000274627.1 RP11-104N10.2 7.36 3.81e-12 1.06e-08 0.44 0.45 Multiple myeloma (IgH translocation); chr16:89476287 chr16:89516797~89522217:+ CESC cis rs1577917 0.739 rs6922 ENSG00000203875.9 SNHG5 7.36 3.82e-12 1.06e-08 0.55 0.45 Response to antipsychotic treatment; chr6:85495605 chr6:85660950~85678736:- CESC cis rs3096299 0.719 rs2965818 ENSG00000274627.1 RP11-104N10.2 7.36 3.82e-12 1.06e-08 0.44 0.45 Multiple myeloma (IgH translocation); chr16:89444086 chr16:89516797~89522217:+ CESC cis rs228614 0.51 rs223412 ENSG00000246560.2 RP11-10L12.4 7.35 3.83e-12 1.06e-08 0.54 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102812443 chr4:102828055~102844075:+ CESC cis rs7104764 1 rs7395328 ENSG00000277290.1 RP11-326C3.16 -7.35 3.83e-12 1.06e-08 -0.42 -0.45 Menarche (age at onset); chr11:242624 chr11:243099~243483:- CESC cis rs7104764 0.917 rs6598068 ENSG00000277290.1 RP11-326C3.16 -7.35 3.83e-12 1.06e-08 -0.42 -0.45 Menarche (age at onset); chr11:243092 chr11:243099~243483:- CESC cis rs7104764 0.917 rs6598067 ENSG00000277290.1 RP11-326C3.16 -7.35 3.83e-12 1.06e-08 -0.42 -0.45 Menarche (age at onset); chr11:243093 chr11:243099~243483:- CESC cis rs7104764 1 rs6598065 ENSG00000277290.1 RP11-326C3.16 -7.35 3.83e-12 1.06e-08 -0.42 -0.45 Menarche (age at onset); chr11:243211 chr11:243099~243483:- CESC cis rs7104764 0.957 rs6598064 ENSG00000277290.1 RP11-326C3.16 -7.35 3.83e-12 1.06e-08 -0.42 -0.45 Menarche (age at onset); chr11:243557 chr11:243099~243483:- CESC cis rs7104764 1 rs6598063 ENSG00000277290.1 RP11-326C3.16 -7.35 3.83e-12 1.06e-08 -0.42 -0.45 Menarche (age at onset); chr11:243672 chr11:243099~243483:- CESC cis rs7104764 1 rs6598062 ENSG00000277290.1 RP11-326C3.16 -7.35 3.83e-12 1.06e-08 -0.42 -0.45 Menarche (age at onset); chr11:243712 chr11:243099~243483:- CESC cis rs7104764 1 rs6598061 ENSG00000277290.1 RP11-326C3.16 -7.35 3.83e-12 1.06e-08 -0.42 -0.45 Menarche (age at onset); chr11:243853 chr11:243099~243483:- CESC cis rs1577917 0.958 rs2875456 ENSG00000203875.9 SNHG5 -7.35 3.84e-12 1.06e-08 -0.57 -0.45 Response to antipsychotic treatment; chr6:85892566 chr6:85660950~85678736:- CESC cis rs3096299 0.563 rs4600467 ENSG00000274627.1 RP11-104N10.2 7.35 3.85e-12 1.06e-08 0.43 0.45 Multiple myeloma (IgH translocation); chr16:89496108 chr16:89516797~89522217:+ CESC cis rs113835537 0.529 rs3179961 ENSG00000255517.5 CTD-3074O7.5 -7.35 3.9e-12 1.08e-08 -0.51 -0.45 Airway imaging phenotypes; chr11:66476983 chr11:66473490~66480233:- CESC cis rs7104764 0.879 rs6598070 ENSG00000277290.1 RP11-326C3.16 -7.35 3.92e-12 1.08e-08 -0.44 -0.45 Menarche (age at onset); chr11:225466 chr11:243099~243483:- CESC cis rs7044106 0.762 rs4837789 ENSG00000226752.6 PSMD5-AS1 -7.35 3.95e-12 1.09e-08 -0.5 -0.45 Hip circumference adjusted for BMI; chr9:120663978 chr9:120824828~120854385:+ CESC cis rs150992 0.547 rs325217 ENSG00000248489.1 CTD-2007H13.3 7.35 3.99e-12 1.1e-08 0.53 0.45 Body mass index; chr5:98844109 chr5:98929171~98995013:+ CESC cis rs6504950 0.705 rs17745123 ENSG00000275710.1 RP11-257O5.4 7.35 4.02e-12 1.11e-08 0.53 0.45 Breast cancer; chr17:54910871 chr17:54964474~54964679:+ CESC cis rs113835537 0.529 rs11824771 ENSG00000255517.5 CTD-3074O7.5 -7.34 4.06e-12 1.12e-08 -0.51 -0.45 Airway imaging phenotypes; chr11:66495079 chr11:66473490~66480233:- CESC cis rs6142102 0.625 rs6141431 ENSG00000276073.1 RP5-1125A11.7 -7.34 4.07e-12 1.12e-08 -0.4 -0.45 Skin pigmentation; chr20:33952508 chr20:33985617~33988989:- CESC cis rs1153858 1 rs4395020 ENSG00000259520.4 CTD-2651B20.3 -7.34 4.1e-12 1.13e-08 -0.59 -0.45 Homoarginine levels; chr15:45360691 chr15:45251580~45279251:- CESC cis rs10463554 0.963 rs6596530 ENSG00000175749.11 EIF3KP1 7.34 4.11e-12 1.13e-08 0.47 0.45 Parkinson's disease; chr5:103035736 chr5:103032376~103033031:+ CESC cis rs11155671 0.53 rs4870080 ENSG00000231760.4 RP11-350J20.5 7.34 4.11e-12 1.13e-08 0.57 0.45 Testicular germ cell tumor; chr6:149881508 chr6:149796151~149826294:- CESC cis rs1577917 1 rs12216203 ENSG00000203875.9 SNHG5 -7.34 4.13e-12 1.13e-08 -0.56 -0.45 Response to antipsychotic treatment; chr6:85965583 chr6:85660950~85678736:- CESC cis rs6991838 0.584 rs14213 ENSG00000272010.1 CTD-3025N20.3 7.34 4.16e-12 1.14e-08 0.5 0.45 Intelligence (multi-trait analysis); chr8:65602719 chr8:65591850~65592472:- CESC cis rs2404602 0.647 rs12910081 ENSG00000259422.1 RP11-593F23.1 -7.34 4.17e-12 1.14e-08 -0.52 -0.45 Blood metabolite levels; chr15:76730618 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs10851889 ENSG00000259422.1 RP11-593F23.1 -7.34 4.17e-12 1.14e-08 -0.52 -0.45 Blood metabolite levels; chr15:76730995 chr15:76174891~76181486:- CESC cis rs1707322 0.927 rs6690386 ENSG00000280836.1 AL355480.1 -7.34 4.19e-12 1.15e-08 -0.53 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45787339 chr1:45581219~45581321:- CESC cis rs2882667 0.858 rs11951899 ENSG00000253404.1 AC034243.1 7.34 4.22e-12 1.16e-08 0.59 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139038621 chr5:138744434~138753309:- CESC cis rs227275 0.554 rs223382 ENSG00000246560.2 RP11-10L12.4 7.34 4.23e-12 1.16e-08 0.54 0.45 Allergic disease (asthma, hay fever or eczema); chr4:102831145 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223377 ENSG00000246560.2 RP11-10L12.4 7.34 4.23e-12 1.16e-08 0.54 0.45 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102834919 chr4:102828055~102844075:+ CESC cis rs2882667 0.824 rs1560656 ENSG00000253404.1 AC034243.1 -7.34 4.24e-12 1.16e-08 -0.55 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139135100 chr5:138744434~138753309:- CESC cis rs7044106 0.762 rs7357638 ENSG00000226752.6 PSMD5-AS1 -7.33 4.35e-12 1.19e-08 -0.51 -0.44 Hip circumference adjusted for BMI; chr9:120626926 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs10818471 ENSG00000226752.6 PSMD5-AS1 -7.33 4.35e-12 1.19e-08 -0.51 -0.44 Hip circumference adjusted for BMI; chr9:120631767 chr9:120824828~120854385:+ CESC cis rs7044106 0.718 rs1960421 ENSG00000226752.6 PSMD5-AS1 -7.33 4.35e-12 1.19e-08 -0.51 -0.44 Hip circumference adjusted for BMI; chr9:120632616 chr9:120824828~120854385:+ CESC cis rs8062405 1 rs80275162 ENSG00000259982.1 CDC37P1 7.33 4.36e-12 1.19e-08 0.55 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28852196 chr16:28700294~28701540:- CESC cis rs227275 0.525 rs4699046 ENSG00000246560.2 RP11-10L12.4 7.33 4.37e-12 1.19e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103004514 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs4699047 ENSG00000246560.2 RP11-10L12.4 7.33 4.37e-12 1.19e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103005385 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs28778380 ENSG00000246560.2 RP11-10L12.4 7.33 4.37e-12 1.19e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103006416 chr4:102828055~102844075:+ CESC cis rs4718428 0.924 rs6971897 ENSG00000226824.5 RP4-756H11.3 -7.33 4.37e-12 1.19e-08 -0.57 -0.44 Corneal structure; chr7:66947787 chr7:66654538~66669855:+ CESC cis rs113835537 0.529 rs7943327 ENSG00000255517.5 CTD-3074O7.5 -7.33 4.38e-12 1.2e-08 -0.49 -0.44 Airway imaging phenotypes; chr11:66489110 chr11:66473490~66480233:- CESC cis rs2882667 0.898 rs11956089 ENSG00000253404.1 AC034243.1 -7.33 4.38e-12 1.2e-08 -0.52 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139058915 chr5:138744434~138753309:- CESC cis rs916888 0.61 rs199536 ENSG00000214401.4 KANSL1-AS1 -7.33 4.39e-12 1.2e-08 -0.53 -0.44 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46193576~46196723:+ CESC cis rs150992 0.72 rs469018 ENSG00000248489.1 CTD-2007H13.3 7.33 4.4e-12 1.2e-08 0.54 0.44 Body mass index; chr5:98953530 chr5:98929171~98995013:+ CESC cis rs10463554 0.963 rs61418746 ENSG00000175749.11 EIF3KP1 7.33 4.41e-12 1.2e-08 0.47 0.44 Parkinson's disease; chr5:103043914 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs62364875 ENSG00000175749.11 EIF3KP1 7.33 4.41e-12 1.2e-08 0.47 0.44 Parkinson's disease; chr5:103056486 chr5:103032376~103033031:+ CESC cis rs2404602 0.684 rs12437981 ENSG00000259422.1 RP11-593F23.1 -7.33 4.42e-12 1.21e-08 -0.52 -0.44 Blood metabolite levels; chr15:76550060 chr15:76174891~76181486:- CESC cis rs7849270 1 rs7849160 ENSG00000268707.1 RP11-247A12.7 -7.33 4.43e-12 1.21e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129112273 chr9:129170434~129170940:+ CESC cis rs2739330 0.796 rs5760106 ENSG00000099984.9 GSTT2 7.33 4.43e-12 1.21e-08 0.54 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23980123~23983911:+ CESC cis rs2404602 0.735 rs3765115 ENSG00000259422.1 RP11-593F23.1 -7.33 4.52e-12 1.23e-08 -0.53 -0.44 Blood metabolite levels; chr15:76381375 chr15:76174891~76181486:- CESC cis rs11155671 0.53 rs7742993 ENSG00000231760.4 RP11-350J20.5 7.32 4.58e-12 1.25e-08 0.55 0.44 Testicular germ cell tumor; chr6:149883959 chr6:149796151~149826294:- CESC cis rs35955747 0.659 rs11704494 ENSG00000236132.1 CTA-440B3.1 7.32 4.62e-12 1.26e-08 0.53 0.44 Neutrophil count;Sum basophil neutrophil counts; chr22:31517285 chr22:31816379~31817491:- CESC cis rs2404602 0.684 rs1011083 ENSG00000259422.1 RP11-593F23.1 -7.32 4.63e-12 1.26e-08 -0.52 -0.44 Blood metabolite levels; chr15:76715186 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs11631959 ENSG00000259422.1 RP11-593F23.1 -7.32 4.63e-12 1.26e-08 -0.52 -0.44 Blood metabolite levels; chr15:76747707 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs11072619 ENSG00000259422.1 RP11-593F23.1 -7.32 4.63e-12 1.26e-08 -0.52 -0.44 Blood metabolite levels; chr15:76750901 chr15:76174891~76181486:- CESC cis rs2404602 0.61 rs28823285 ENSG00000259422.1 RP11-593F23.1 -7.32 4.63e-12 1.26e-08 -0.52 -0.44 Blood metabolite levels; chr15:76758054 chr15:76174891~76181486:- CESC cis rs17711722 0.565 rs4275112 ENSG00000164669.11 INTS4P1 7.32 4.69e-12 1.27e-08 0.58 0.44 Calcium levels; chr7:65733651 chr7:65141225~65234216:+ CESC cis rs113835537 0.529 rs7950407 ENSG00000255517.5 CTD-3074O7.5 -7.32 4.73e-12 1.28e-08 -0.49 -0.44 Airway imaging phenotypes; chr11:66490535 chr11:66473490~66480233:- CESC cis rs1577917 0.958 rs1591438 ENSG00000203875.9 SNHG5 -7.32 4.74e-12 1.29e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85815496 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs1591437 ENSG00000203875.9 SNHG5 -7.32 4.74e-12 1.29e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85815587 chr6:85660950~85678736:- CESC cis rs2882667 0.66 rs11951084 ENSG00000253404.1 AC034243.1 7.32 4.75e-12 1.29e-08 0.53 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139125858 chr5:138744434~138753309:- CESC cis rs7104764 0.879 rs6421986 ENSG00000277290.1 RP11-326C3.16 -7.32 4.76e-12 1.29e-08 -0.42 -0.44 Menarche (age at onset); chr11:221659 chr11:243099~243483:- CESC cis rs7849270 1 rs10988214 ENSG00000268707.1 RP11-247A12.7 -7.32 4.77e-12 1.29e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129121473 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs932833 ENSG00000268707.1 RP11-247A12.7 -7.32 4.77e-12 1.29e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129121762 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs7020708 ENSG00000268707.1 RP11-247A12.7 -7.32 4.77e-12 1.29e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129122852 chr9:129170434~129170940:+ CESC cis rs1577917 0.958 rs12213331 ENSG00000203875.9 SNHG5 -7.32 4.81e-12 1.3e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85795079 chr6:85660950~85678736:- CESC cis rs7104764 1 rs9795476 ENSG00000277290.1 RP11-326C3.16 -7.32 4.82e-12 1.31e-08 -0.42 -0.44 Menarche (age at onset); chr11:235894 chr11:243099~243483:- CESC cis rs7104764 1 rs2272563 ENSG00000277290.1 RP11-326C3.16 -7.32 4.82e-12 1.31e-08 -0.42 -0.44 Menarche (age at onset); chr11:236871 chr11:243099~243483:- CESC cis rs7104764 0.917 rs1045288 ENSG00000277290.1 RP11-326C3.16 -7.32 4.82e-12 1.31e-08 -0.42 -0.44 Menarche (age at onset); chr11:237087 chr11:243099~243483:- CESC cis rs228614 0.51 rs223349 ENSG00000246560.2 RP11-10L12.4 7.32 4.83e-12 1.31e-08 0.54 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102857277 chr4:102828055~102844075:+ CESC cis rs1577917 0.916 rs12203358 ENSG00000203875.9 SNHG5 -7.31 4.88e-12 1.32e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85893506 chr6:85660950~85678736:- CESC cis rs7626444 0.625 rs2669637 ENSG00000272359.1 U4 -7.31 4.99e-12 1.35e-08 -0.52 -0.44 Monocyte count; chr3:196750498 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs1718410 ENSG00000272359.1 U4 -7.31 4.99e-12 1.35e-08 -0.52 -0.44 Monocyte count; chr3:196750789 chr3:196747192~196747324:- CESC cis rs977987 1 rs977985 ENSG00000261783.1 RP11-252K23.2 -7.31 5.01e-12 1.35e-08 -0.56 -0.44 Dupuytren's disease; chr16:75473049 chr16:75379818~75381260:- CESC cis rs2177312 0.53 rs7675353 ENSG00000251129.1 RP11-734I18.1 -7.31 5.06e-12 1.37e-08 -0.6 -0.44 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31999465 chr4:31997397~32155406:+ CESC cis rs7684253 0.565 rs7697176 ENSG00000269949.1 RP11-738E22.3 -7.31 5.08e-12 1.37e-08 -0.51 -0.44 Migraine; chr4:56956882 chr4:56960927~56961373:- CESC cis rs7684253 0.565 rs7680140 ENSG00000269949.1 RP11-738E22.3 -7.31 5.08e-12 1.37e-08 -0.51 -0.44 Migraine; chr4:56957291 chr4:56960927~56961373:- CESC cis rs7208859 0.623 rs426434 ENSG00000263531.1 RP13-753N3.1 7.31 5.1e-12 1.38e-08 0.84 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30598335 chr17:30863921~30864940:- CESC cis rs2404602 0.647 rs11072620 ENSG00000259422.1 RP11-593F23.1 -7.31 5.1e-12 1.38e-08 -0.52 -0.44 Blood metabolite levels; chr15:76756429 chr15:76174891~76181486:- CESC cis rs7208859 0.673 rs999796 ENSG00000263531.1 RP13-753N3.1 7.3 5.16e-12 1.39e-08 0.71 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832386 chr17:30863921~30864940:- CESC cis rs228614 0.51 rs223415 ENSG00000246560.2 RP11-10L12.4 7.3 5.2e-12 1.4e-08 0.53 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102811016 chr4:102828055~102844075:+ CESC cis rs5769707 0.967 rs2051626 ENSG00000188511.11 C22orf34 7.3 5.22e-12 1.41e-08 0.45 0.44 Monocyte percentage of white cells;Monocyte count; chr22:49615325 chr22:49414524~49657542:- CESC cis rs7849270 1 rs3124511 ENSG00000268707.1 RP11-247A12.7 7.3 5.23e-12 1.41e-08 0.55 0.44 Blood metabolite ratios; chr9:129139179 chr9:129170434~129170940:+ CESC cis rs17507216 0.718 rs4779033 ENSG00000278603.1 RP13-608F4.5 -7.3 5.24e-12 1.41e-08 -0.75 -0.44 Excessive daytime sleepiness; chr15:82576634 chr15:82472203~82472426:+ CESC cis rs35955747 0.714 rs4820048 ENSG00000236132.1 CTA-440B3.1 7.3 5.28e-12 1.42e-08 0.52 0.44 Neutrophil count;Sum basophil neutrophil counts; chr22:31458384 chr22:31816379~31817491:- CESC cis rs6504950 1 rs17818028 ENSG00000275710.1 RP11-257O5.4 -7.3 5.28e-12 1.42e-08 -0.57 -0.44 Breast cancer; chr17:54985394 chr17:54964474~54964679:+ CESC cis rs1577917 0.876 rs1582127 ENSG00000203875.9 SNHG5 -7.3 5.36e-12 1.44e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:85987486 chr6:85660950~85678736:- CESC cis rs6142102 0.58 rs761233 ENSG00000276073.1 RP5-1125A11.7 -7.3 5.41e-12 1.46e-08 -0.39 -0.44 Skin pigmentation; chr20:33981080 chr20:33985617~33988989:- CESC cis rs227275 0.555 rs223403 ENSG00000246560.2 RP11-10L12.4 7.3 5.46e-12 1.47e-08 0.54 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102817086 chr4:102828055~102844075:+ CESC cis rs227275 0.555 rs223402 ENSG00000246560.2 RP11-10L12.4 7.3 5.46e-12 1.47e-08 0.54 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102817198 chr4:102828055~102844075:+ CESC cis rs9660180 0.934 rs12729990 ENSG00000231050.1 RP1-140A9.1 7.3 5.47e-12 1.47e-08 0.52 0.44 Body mass index; chr1:1880596 chr1:1891471~1892658:+ CESC cis rs7044106 0.762 rs1867254 ENSG00000226752.6 PSMD5-AS1 -7.29 5.53e-12 1.48e-08 -0.5 -0.44 Hip circumference adjusted for BMI; chr9:120666800 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs966396 ENSG00000226752.6 PSMD5-AS1 -7.29 5.53e-12 1.48e-08 -0.5 -0.44 Hip circumference adjusted for BMI; chr9:120691003 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs7849566 ENSG00000226752.6 PSMD5-AS1 -7.29 5.53e-12 1.48e-08 -0.5 -0.44 Hip circumference adjusted for BMI; chr9:120698491 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs1324473 ENSG00000226752.6 PSMD5-AS1 7.29 5.54e-12 1.49e-08 0.48 0.44 Hip circumference adjusted for BMI; chr9:120642332 chr9:120824828~120854385:+ CESC cis rs1577917 1 rs12208493 ENSG00000203875.9 SNHG5 -7.29 5.58e-12 1.5e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85952549 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12213149 ENSG00000203875.9 SNHG5 -7.29 5.58e-12 1.5e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85958926 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs11756615 ENSG00000203875.9 SNHG5 -7.29 5.58e-12 1.5e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85970117 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs10944168 ENSG00000203875.9 SNHG5 -7.29 5.58e-12 1.5e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85970438 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs11755864 ENSG00000203875.9 SNHG5 -7.29 5.62e-12 1.51e-08 -0.54 -0.44 Response to antipsychotic treatment; chr6:85982073 chr6:85660950~85678736:- CESC cis rs228614 0.51 rs223405 ENSG00000246560.2 RP11-10L12.4 7.29 5.64e-12 1.51e-08 0.54 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102815894 chr4:102828055~102844075:+ CESC cis rs6452524 0.935 rs7703318 ENSG00000249664.1 CTD-2227C6.2 7.29 5.65e-12 1.52e-08 0.47 0.44 Hypertension (SNP x SNP interaction); chr5:83118234 chr5:83012285~83013109:- CESC cis rs1577917 1 rs34852683 ENSG00000203875.9 SNHG5 -7.29 5.66e-12 1.52e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:85992612 chr6:85660950~85678736:- CESC cis rs7044106 0.762 rs1158553 ENSG00000226752.6 PSMD5-AS1 -7.29 5.69e-12 1.52e-08 -0.5 -0.44 Hip circumference adjusted for BMI; chr9:120638696 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs1547268 ENSG00000226752.6 PSMD5-AS1 -7.29 5.69e-12 1.52e-08 -0.5 -0.44 Hip circumference adjusted for BMI; chr9:120646410 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs1547267 ENSG00000226752.6 PSMD5-AS1 -7.29 5.69e-12 1.52e-08 -0.5 -0.44 Hip circumference adjusted for BMI; chr9:120646458 chr9:120824828~120854385:+ CESC cis rs2404602 0.647 rs12910820 ENSG00000259422.1 RP11-593F23.1 -7.29 5.75e-12 1.54e-08 -0.52 -0.44 Blood metabolite levels; chr15:76730484 chr15:76174891~76181486:- CESC cis rs5769707 0.967 rs2187891 ENSG00000188511.11 C22orf34 7.29 5.79e-12 1.55e-08 0.47 0.44 Monocyte percentage of white cells;Monocyte count; chr22:49600446 chr22:49414524~49657542:- CESC cis rs7849270 0.921 rs6478864 ENSG00000268707.1 RP11-247A12.7 -7.29 5.8e-12 1.55e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129118351 chr9:129170434~129170940:+ CESC cis rs7849270 0.851 rs7861663 ENSG00000268707.1 RP11-247A12.7 -7.29 5.8e-12 1.55e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129118667 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs10819466 ENSG00000268707.1 RP11-247A12.7 -7.29 5.8e-12 1.55e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129119213 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs3739843 ENSG00000268707.1 RP11-247A12.7 -7.29 5.8e-12 1.55e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129120682 chr9:129170434~129170940:+ CESC cis rs507080 0.771 rs687664 ENSG00000255422.1 AP002954.4 -7.28 5.82e-12 1.55e-08 -0.54 -0.44 Serum metabolite levels; chr11:118703476 chr11:118704607~118750263:+ CESC cis rs507080 0.771 rs523715 ENSG00000255422.1 AP002954.4 -7.28 5.82e-12 1.55e-08 -0.54 -0.44 Serum metabolite levels; chr11:118703479 chr11:118704607~118750263:+ CESC cis rs7044106 0.708 rs10760113 ENSG00000226752.6 PSMD5-AS1 -7.28 5.84e-12 1.56e-08 -0.48 -0.44 Hip circumference adjusted for BMI; chr9:120711772 chr9:120824828~120854385:+ CESC cis rs2882667 0.858 rs13177503 ENSG00000253404.1 AC034243.1 7.28 5.85e-12 1.56e-08 0.58 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139097070 chr5:138744434~138753309:- CESC cis rs2882667 0.858 rs13170388 ENSG00000253404.1 AC034243.1 7.28 5.85e-12 1.56e-08 0.58 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139101176 chr5:138744434~138753309:- CESC cis rs35955747 0.714 rs5997989 ENSG00000236132.1 CTA-440B3.1 7.28 5.95e-12 1.59e-08 0.52 0.44 Neutrophil count;Sum basophil neutrophil counts; chr22:31443964 chr22:31816379~31817491:- CESC cis rs3931020 0.53 rs12125889 ENSG00000272864.1 RP11-17E13.2 -7.28 6.07e-12 1.62e-08 -0.46 -0.44 Resistin levels; chr1:74776287 chr1:74698769~74699333:- CESC cis rs113835537 0.529 rs3892818 ENSG00000255517.5 CTD-3074O7.5 -7.27 6.24e-12 1.66e-08 -0.48 -0.44 Airway imaging phenotypes; chr11:66472720 chr11:66473490~66480233:- CESC cis rs9828933 1 rs9828933 ENSG00000280620.1 SCAANT1 7.27 6.25e-12 1.67e-08 0.73 0.44 Type 2 diabetes; chr3:64017221 chr3:63911518~63911772:- CESC cis rs9828933 0.938 rs7617036 ENSG00000280620.1 SCAANT1 7.27 6.25e-12 1.67e-08 0.73 0.44 Type 2 diabetes; chr3:64017319 chr3:63911518~63911772:- CESC cis rs1577917 1 rs12213740 ENSG00000203875.9 SNHG5 -7.27 6.26e-12 1.67e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:85947015 chr6:85660950~85678736:- CESC cis rs10463554 0.926 rs26429 ENSG00000175749.11 EIF3KP1 -7.27 6.41e-12 1.71e-08 -0.46 -0.44 Parkinson's disease; chr5:103030349 chr5:103032376~103033031:+ CESC cis rs35955747 0.633 rs5998012 ENSG00000236132.1 CTA-440B3.1 7.27 6.45e-12 1.72e-08 0.53 0.44 Neutrophil count;Sum basophil neutrophil counts; chr22:31493858 chr22:31816379~31817491:- CESC cis rs11722779 0.935 rs3857200 ENSG00000246560.2 RP11-10L12.4 7.27 6.49e-12 1.73e-08 0.53 0.44 Schizophrenia; chr4:103001864 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs11731885 ENSG00000246560.2 RP11-10L12.4 7.27 6.49e-12 1.73e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103010913 chr4:102828055~102844075:+ CESC cis rs7849270 0.959 rs2900271 ENSG00000268707.1 RP11-247A12.7 7.27 6.52e-12 1.73e-08 0.55 0.44 Blood metabolite ratios; chr9:129132655 chr9:129170434~129170940:+ CESC cis rs2404602 0.684 rs28895952 ENSG00000259422.1 RP11-593F23.1 -7.26 6.59e-12 1.75e-08 -0.52 -0.44 Blood metabolite levels; chr15:76564435 chr15:76174891~76181486:- CESC cis rs526231 0.575 rs10463990 ENSG00000175749.11 EIF3KP1 7.26 6.66e-12 1.76e-08 0.5 0.44 Primary biliary cholangitis; chr5:102981714 chr5:103032376~103033031:+ CESC cis rs9660180 0.967 rs9660106 ENSG00000231050.1 RP1-140A9.1 7.26 6.68e-12 1.77e-08 0.52 0.44 Body mass index; chr1:1866508 chr1:1891471~1892658:+ CESC cis rs1707322 0.963 rs4630155 ENSG00000280836.1 AL355480.1 -7.26 6.69e-12 1.77e-08 -0.53 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45791438 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs4508055 ENSG00000280836.1 AL355480.1 -7.26 6.69e-12 1.77e-08 -0.53 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45792059 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs12076580 ENSG00000280836.1 AL355480.1 -7.26 6.69e-12 1.77e-08 -0.53 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45792487 chr1:45581219~45581321:- CESC cis rs8081395 0.836 rs2150879 ENSG00000266992.1 DHX40P1 -7.26 6.75e-12 1.79e-08 -0.46 -0.44 White blood cell count; chr17:59781849 chr17:59976009~60002384:- CESC cis rs6504950 0.751 rs12937760 ENSG00000275710.1 RP11-257O5.4 7.26 6.78e-12 1.79e-08 0.55 0.44 Breast cancer; chr17:54938769 chr17:54964474~54964679:+ CESC cis rs7104764 1 rs7104764 ENSG00000277290.1 RP11-326C3.16 -7.26 6.8e-12 1.8e-08 -0.42 -0.44 Menarche (age at onset); chr11:229977 chr11:243099~243483:- CESC cis rs7104764 1 rs7483951 ENSG00000277290.1 RP11-326C3.16 -7.26 6.8e-12 1.8e-08 -0.42 -0.44 Menarche (age at onset); chr11:231758 chr11:243099~243483:- CESC cis rs3096299 0.658 rs4291902 ENSG00000274627.1 RP11-104N10.2 7.26 6.8e-12 1.8e-08 0.43 0.44 Multiple myeloma (IgH translocation); chr16:89493907 chr16:89516797~89522217:+ CESC cis rs7044106 0.762 rs4142158 ENSG00000226752.6 PSMD5-AS1 -7.26 6.88e-12 1.82e-08 -0.5 -0.44 Hip circumference adjusted for BMI; chr9:120648541 chr9:120824828~120854385:+ CESC cis rs4423214 0.57 rs7118246 ENSG00000254682.1 RP11-660L16.2 7.26 6.89e-12 1.82e-08 0.61 0.44 Vitamin D levels; chr11:71520078 chr11:71448674~71452157:+ CESC cis rs11722779 0.844 rs223345 ENSG00000246560.2 RP11-10L12.4 7.26 6.92e-12 1.83e-08 0.53 0.44 Schizophrenia; chr4:102859366 chr4:102828055~102844075:+ CESC cis rs11722779 0.873 rs223344 ENSG00000246560.2 RP11-10L12.4 7.26 6.92e-12 1.83e-08 0.53 0.44 Schizophrenia; chr4:102859765 chr4:102828055~102844075:+ CESC cis rs11722779 0.775 rs223341 ENSG00000246560.2 RP11-10L12.4 7.26 6.92e-12 1.83e-08 0.53 0.44 Schizophrenia; chr4:102862343 chr4:102828055~102844075:+ CESC cis rs7208859 0.623 rs122898 ENSG00000263531.1 RP13-753N3.1 -7.26 6.93e-12 1.83e-08 -0.91 -0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30863921~30864940:- CESC cis rs7849270 1 rs1977447 ENSG00000268707.1 RP11-247A12.7 7.26 6.93e-12 1.83e-08 0.56 0.44 Blood metabolite ratios; chr9:129105917 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs3118625 ENSG00000268707.1 RP11-247A12.7 7.26 6.93e-12 1.83e-08 0.56 0.44 Blood metabolite ratios; chr9:129110977 chr9:129170434~129170940:+ CESC cis rs2404602 0.684 rs1603860 ENSG00000259422.1 RP11-593F23.1 -7.25 6.99e-12 1.84e-08 -0.52 -0.44 Blood metabolite levels; chr15:76557250 chr15:76174891~76181486:- CESC cis rs2404602 0.684 rs8037847 ENSG00000259422.1 RP11-593F23.1 -7.25 6.99e-12 1.84e-08 -0.52 -0.44 Blood metabolite levels; chr15:76564210 chr15:76174891~76181486:- CESC cis rs507080 0.961 rs34413584 ENSG00000255422.1 AP002954.4 -7.25 7.12e-12 1.87e-08 -0.53 -0.44 Serum metabolite levels; chr11:118675072 chr11:118704607~118750263:+ CESC cis rs1799949 0.965 rs4239149 ENSG00000198496.9 NBR2 7.25 7.23e-12 1.9e-08 0.53 0.44 Menopause (age at onset); chr17:43176078 chr17:43125610~43153671:+ CESC cis rs7849270 1 rs10819471 ENSG00000268707.1 RP11-247A12.7 -7.25 7.24e-12 1.9e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129134046 chr9:129170434~129170940:+ CESC cis rs3096299 0.728 rs1011749 ENSG00000274627.1 RP11-104N10.2 7.25 7.29e-12 1.92e-08 0.44 0.44 Multiple myeloma (IgH translocation); chr16:89444461 chr16:89516797~89522217:+ CESC cis rs3931020 0.72 rs1327090 ENSG00000272864.1 RP11-17E13.2 -7.24 7.38e-12 1.94e-08 -0.51 -0.44 Resistin levels; chr1:74800795 chr1:74698769~74699333:- CESC cis rs2882667 0.858 rs11750382 ENSG00000253404.1 AC034243.1 -7.24 7.39e-12 1.94e-08 -0.55 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139121305 chr5:138744434~138753309:- CESC cis rs2404602 0.583 rs12908334 ENSG00000259422.1 RP11-593F23.1 7.24 7.39e-12 1.94e-08 0.49 0.44 Blood metabolite levels; chr15:76289251 chr15:76174891~76181486:- CESC cis rs10463554 0.667 rs57714862 ENSG00000175749.11 EIF3KP1 7.24 7.46e-12 1.96e-08 0.47 0.44 Parkinson's disease; chr5:103047025 chr5:103032376~103033031:+ CESC cis rs12439619 0.705 rs17354185 ENSG00000278603.1 RP13-608F4.5 -7.24 7.47e-12 1.96e-08 -0.71 -0.44 Intelligence (multi-trait analysis); chr15:82133829 chr15:82472203~82472426:+ CESC cis rs26232 0.583 rs26434 ENSG00000175749.11 EIF3KP1 -7.24 7.51e-12 1.97e-08 -0.47 -0.44 Rheumatoid arthritis; chr5:103027698 chr5:103032376~103033031:+ CESC cis rs3096299 0.685 rs4785676 ENSG00000274627.1 RP11-104N10.2 7.24 7.54e-12 1.98e-08 0.44 0.44 Multiple myeloma (IgH translocation); chr16:89487216 chr16:89516797~89522217:+ CESC cis rs2739330 0.828 rs2186366 ENSG00000099984.9 GSTT2 7.24 7.6e-12 1.99e-08 0.53 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23980123~23983911:+ CESC cis rs7208859 0.673 rs1347360 ENSG00000263531.1 RP13-753N3.1 7.24 7.61e-12 2e-08 0.82 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587514 chr17:30863921~30864940:- CESC cis rs2882667 0.754 rs11746434 ENSG00000253404.1 AC034243.1 7.24 7.66e-12 2.01e-08 0.58 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139099614 chr5:138744434~138753309:- CESC cis rs3096299 0.658 rs4785679 ENSG00000274627.1 RP11-104N10.2 7.24 7.7e-12 2.02e-08 0.44 0.44 Multiple myeloma (IgH translocation); chr16:89499705 chr16:89516797~89522217:+ CESC cis rs7104764 1 rs1128322 ENSG00000277290.1 RP11-326C3.16 7.24 7.78e-12 2.04e-08 0.4 0.44 Menarche (age at onset); chr11:244197 chr11:243099~243483:- CESC cis rs2404602 0.735 rs283789 ENSG00000259422.1 RP11-593F23.1 7.24 7.8e-12 2.05e-08 0.5 0.44 Blood metabolite levels; chr15:76485236 chr15:76174891~76181486:- CESC cis rs5760092 0.755 rs915589 ENSG00000250470.1 AP000351.3 -7.24 7.8e-12 2.05e-08 -0.66 -0.44 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23976904~23977585:- CESC cis rs9545047 0.901 rs73235963 ENSG00000227676.3 LINC01068 7.23 7.85e-12 2.06e-08 0.51 0.44 Schizophrenia; chr13:79562805 chr13:79566727~79571436:+ CESC cis rs9545047 0.935 rs2484343 ENSG00000227676.3 LINC01068 7.23 7.85e-12 2.06e-08 0.51 0.44 Schizophrenia; chr13:79563587 chr13:79566727~79571436:+ CESC cis rs9545047 0.868 rs2476173 ENSG00000227676.3 LINC01068 7.23 7.85e-12 2.06e-08 0.51 0.44 Schizophrenia; chr13:79565740 chr13:79566727~79571436:+ CESC cis rs2882667 0.858 rs11948429 ENSG00000253404.1 AC034243.1 7.23 7.86e-12 2.06e-08 0.56 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139122895 chr5:138744434~138753309:- CESC cis rs2882667 0.858 rs2043271 ENSG00000253404.1 AC034243.1 7.23 7.86e-12 2.06e-08 0.56 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139123419 chr5:138744434~138753309:- CESC cis rs7849270 0.885 rs10760588 ENSG00000268707.1 RP11-247A12.7 -7.23 7.86e-12 2.06e-08 -0.5 -0.44 Blood metabolite ratios; chr9:129115195 chr9:129170434~129170940:+ CESC cis rs10256972 0.521 rs871019 ENSG00000229043.2 AC091729.9 -7.23 7.98e-12 2.09e-08 -0.49 -0.44 Endometriosis;Longevity; chr7:1065594 chr7:1160374~1165267:+ CESC cis rs150992 0.673 rs331929 ENSG00000248489.1 CTD-2007H13.3 7.23 8.03e-12 2.1e-08 0.53 0.44 Body mass index; chr5:98830528 chr5:98929171~98995013:+ CESC cis rs6452524 0.905 rs7736289 ENSG00000249664.1 CTD-2227C6.2 7.23 8.04e-12 2.11e-08 0.48 0.44 Hypertension (SNP x SNP interaction); chr5:83082401 chr5:83012285~83013109:- CESC cis rs1799949 0.602 rs8176257 ENSG00000198496.9 NBR2 -7.23 8.05e-12 2.11e-08 -0.64 -0.44 Menopause (age at onset); chr17:43064188 chr17:43125610~43153671:+ CESC cis rs10463554 0.889 rs34775 ENSG00000175749.11 EIF3KP1 7.23 8.06e-12 2.11e-08 0.5 0.44 Parkinson's disease; chr5:103115572 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34776 ENSG00000175749.11 EIF3KP1 7.23 8.06e-12 2.11e-08 0.5 0.44 Parkinson's disease; chr5:103116090 chr5:103032376~103033031:+ CESC cis rs10463554 0.667 rs34782 ENSG00000175749.11 EIF3KP1 7.23 8.06e-12 2.11e-08 0.5 0.44 Parkinson's disease; chr5:103118766 chr5:103032376~103033031:+ CESC cis rs1707322 0.686 rs1541131 ENSG00000280836.1 AL355480.1 7.23 8.08e-12 2.11e-08 0.52 0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619262 chr1:45581219~45581321:- CESC cis rs7044106 0.791 rs2416797 ENSG00000226752.6 PSMD5-AS1 -7.23 8.14e-12 2.13e-08 -0.49 -0.44 Hip circumference adjusted for BMI; chr9:120718322 chr9:120824828~120854385:+ CESC cis rs7044106 0.791 rs2416798 ENSG00000226752.6 PSMD5-AS1 -7.23 8.14e-12 2.13e-08 -0.49 -0.44 Hip circumference adjusted for BMI; chr9:120718325 chr9:120824828~120854385:+ CESC cis rs2404602 0.684 rs11072600 ENSG00000259422.1 RP11-593F23.1 -7.23 8.19e-12 2.14e-08 -0.52 -0.44 Blood metabolite levels; chr15:76575574 chr15:76174891~76181486:- CESC cis rs9660180 0.967 rs6603802 ENSG00000231050.1 RP1-140A9.1 7.23 8.25e-12 2.16e-08 0.51 0.44 Body mass index; chr1:1881082 chr1:1891471~1892658:+ CESC cis rs17608059 0.504 rs11656981 ENSG00000141028.6 CDRT15P1 -7.23 8.27e-12 2.16e-08 -0.46 -0.44 Temperament; chr17:14075460 chr17:14024514~14025488:+ CESC cis rs6142102 0.625 rs6142067 ENSG00000276073.1 RP5-1125A11.7 -7.22 8.34e-12 2.18e-08 -0.41 -0.44 Skin pigmentation; chr20:33968766 chr20:33985617~33988989:- CESC cis rs7849270 1 rs3814492 ENSG00000268707.1 RP11-247A12.7 -7.22 8.47e-12 2.21e-08 -0.52 -0.44 Blood metabolite ratios; chr9:129110943 chr9:129170434~129170940:+ CESC cis rs7044106 0.762 rs7024046 ENSG00000226752.6 PSMD5-AS1 -7.22 8.48e-12 2.21e-08 -0.49 -0.44 Hip circumference adjusted for BMI; chr9:120656900 chr9:120824828~120854385:+ CESC cis rs6452524 0.935 rs6868416 ENSG00000249664.1 CTD-2227C6.2 7.22 8.51e-12 2.22e-08 0.47 0.44 Hypertension (SNP x SNP interaction); chr5:83084320 chr5:83012285~83013109:- CESC cis rs9545047 0.901 rs7338530 ENSG00000227676.3 LINC01068 -7.22 8.53e-12 2.23e-08 -0.5 -0.44 Schizophrenia; chr13:79477715 chr13:79566727~79571436:+ CESC cis rs7626444 0.625 rs843530 ENSG00000272359.1 U4 -7.22 8.54e-12 2.23e-08 -0.5 -0.44 Monocyte count; chr3:196754153 chr3:196747192~196747324:- CESC cis rs1577917 0.958 rs34765423 ENSG00000203875.9 SNHG5 -7.22 8.54e-12 2.23e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:85774730 chr6:85660950~85678736:- CESC cis rs8081395 0.899 rs2777898 ENSG00000266992.1 DHX40P1 -7.22 8.55e-12 2.23e-08 -0.47 -0.44 White blood cell count; chr17:59738247 chr17:59976009~60002384:- CESC cis rs8081395 0.834 rs2665397 ENSG00000266992.1 DHX40P1 -7.22 8.55e-12 2.23e-08 -0.47 -0.44 White blood cell count; chr17:59749370 chr17:59976009~60002384:- CESC cis rs8081395 0.804 rs2777884 ENSG00000266992.1 DHX40P1 -7.22 8.55e-12 2.23e-08 -0.47 -0.44 White blood cell count; chr17:59753065 chr17:59976009~60002384:- CESC cis rs8081395 0.932 rs2777885 ENSG00000266992.1 DHX40P1 -7.22 8.55e-12 2.23e-08 -0.47 -0.44 White blood cell count; chr17:59753112 chr17:59976009~60002384:- CESC cis rs8081395 0.866 rs2777899 ENSG00000266992.1 DHX40P1 -7.22 8.55e-12 2.23e-08 -0.47 -0.44 White blood cell count; chr17:59755030 chr17:59976009~60002384:- CESC cis rs7044106 0.791 rs10984997 ENSG00000226752.6 PSMD5-AS1 -7.22 8.58e-12 2.24e-08 -0.5 -0.44 Hip circumference adjusted for BMI; chr9:120718928 chr9:120824828~120854385:+ CESC cis rs1577917 1 rs12190604 ENSG00000203875.9 SNHG5 -7.22 8.62e-12 2.25e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:86006497 chr6:85660950~85678736:- CESC cis rs8081395 0.899 rs2645477 ENSG00000266992.1 DHX40P1 -7.22 8.71e-12 2.27e-08 -0.47 -0.44 White blood cell count; chr17:59768263 chr17:59976009~60002384:- CESC cis rs875971 0.965 rs697968 ENSG00000226824.5 RP4-756H11.3 7.22 8.75e-12 2.28e-08 0.57 0.44 Aortic root size; chr7:66070046 chr7:66654538~66669855:+ CESC cis rs875971 1 rs1183245 ENSG00000226824.5 RP4-756H11.3 7.22 8.75e-12 2.28e-08 0.57 0.44 Aortic root size; chr7:66076198 chr7:66654538~66669855:+ CESC cis rs875971 1 rs1144894 ENSG00000226824.5 RP4-756H11.3 7.22 8.75e-12 2.28e-08 0.57 0.44 Aortic root size; chr7:66077907 chr7:66654538~66669855:+ CESC cis rs2404602 0.662 rs908817 ENSG00000259422.1 RP11-593F23.1 -7.22 8.76e-12 2.28e-08 -0.53 -0.44 Blood metabolite levels; chr15:76346850 chr15:76174891~76181486:- CESC cis rs227275 0.525 rs11097796 ENSG00000246560.2 RP11-10L12.4 7.22 8.8e-12 2.29e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103002401 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs11097797 ENSG00000246560.2 RP11-10L12.4 7.22 8.8e-12 2.29e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103002507 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs13117110 ENSG00000246560.2 RP11-10L12.4 7.22 8.8e-12 2.29e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103003981 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs13144033 ENSG00000246560.2 RP11-10L12.4 7.22 8.8e-12 2.29e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103004032 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs10029073 ENSG00000246560.2 RP11-10L12.4 7.22 8.8e-12 2.29e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103006991 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs724446 ENSG00000246560.2 RP11-10L12.4 7.22 8.8e-12 2.29e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103010206 chr4:102828055~102844075:+ CESC cis rs9545047 0.837 rs9601242 ENSG00000227676.3 LINC01068 7.21 8.88e-12 2.31e-08 0.51 0.44 Schizophrenia; chr13:79561543 chr13:79566727~79571436:+ CESC cis rs2404602 0.622 rs11632670 ENSG00000259422.1 RP11-593F23.1 -7.21 8.9e-12 2.31e-08 -0.52 -0.44 Blood metabolite levels; chr15:76681714 chr15:76174891~76181486:- CESC cis rs7849270 0.959 rs713218 ENSG00000268707.1 RP11-247A12.7 -7.21 8.9e-12 2.31e-08 -0.52 -0.44 Blood metabolite ratios; chr9:129138491 chr9:129170434~129170940:+ CESC cis rs9545047 0.901 rs1212082 ENSG00000227676.3 LINC01068 7.21 8.93e-12 2.32e-08 0.51 0.44 Schizophrenia; chr13:79552633 chr13:79566727~79571436:+ CESC cis rs7104764 1 rs2272565 ENSG00000277290.1 RP11-326C3.16 -7.21 8.93e-12 2.32e-08 -0.4 -0.44 Menarche (age at onset); chr11:244414 chr11:243099~243483:- CESC cis rs7104764 1 rs10902113 ENSG00000277290.1 RP11-326C3.16 -7.21 8.93e-12 2.32e-08 -0.4 -0.44 Menarche (age at onset); chr11:245523 chr11:243099~243483:- CESC cis rs7104764 1 rs7482591 ENSG00000277290.1 RP11-326C3.16 -7.21 8.93e-12 2.32e-08 -0.4 -0.44 Menarche (age at onset); chr11:245861 chr11:243099~243483:- CESC cis rs7849270 0.959 rs7032712 ENSG00000268707.1 RP11-247A12.7 -7.21 9.02e-12 2.34e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129130808 chr9:129170434~129170940:+ CESC cis rs6142102 0.602 rs4911145 ENSG00000276073.1 RP5-1125A11.7 7.21 9.03e-12 2.34e-08 0.39 0.44 Skin pigmentation; chr20:34027417 chr20:33985617~33988989:- CESC cis rs228614 0.51 rs223410 ENSG00000246560.2 RP11-10L12.4 7.21 9.06e-12 2.35e-08 0.54 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102813568 chr4:102828055~102844075:+ CESC cis rs7104764 0.957 rs519592 ENSG00000277290.1 RP11-326C3.16 -7.21 9.14e-12 2.37e-08 -0.41 -0.44 Menarche (age at onset); chr11:236811 chr11:243099~243483:- CESC cis rs7849270 1 rs10988223 ENSG00000268707.1 RP11-247A12.7 -7.21 9.16e-12 2.37e-08 -0.54 -0.44 Blood metabolite ratios; chr9:129140742 chr9:129170434~129170940:+ CESC cis rs6991838 0.584 rs7836349 ENSG00000272010.1 CTD-3025N20.3 -7.21 9.25e-12 2.4e-08 -0.49 -0.44 Intelligence (multi-trait analysis); chr8:65591328 chr8:65591850~65592472:- CESC cis rs801193 0.66 rs974239 ENSG00000226824.5 RP4-756H11.3 -7.21 9.3e-12 2.41e-08 -0.55 -0.44 Aortic root size; chr7:66748504 chr7:66654538~66669855:+ CESC cis rs1577917 1 rs12207610 ENSG00000203875.9 SNHG5 -7.21 9.33e-12 2.41e-08 -0.54 -0.44 Response to antipsychotic treatment; chr6:85978298 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12203457 ENSG00000203875.9 SNHG5 -7.21 9.33e-12 2.41e-08 -0.54 -0.44 Response to antipsychotic treatment; chr6:85979559 chr6:85660950~85678736:- CESC cis rs7626444 0.625 rs843531 ENSG00000272359.1 U4 -7.21 9.33e-12 2.41e-08 -0.51 -0.44 Monocyte count; chr3:196754900 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs9877495 ENSG00000272359.1 U4 -7.21 9.33e-12 2.41e-08 -0.51 -0.44 Monocyte count; chr3:196756409 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs2686599 ENSG00000272359.1 U4 -7.21 9.33e-12 2.41e-08 -0.51 -0.44 Monocyte count; chr3:196756923 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs1403101 ENSG00000272359.1 U4 -7.21 9.33e-12 2.41e-08 -0.51 -0.44 Monocyte count; chr3:196758203 chr3:196747192~196747324:- CESC cis rs7626444 0.628 rs1684464 ENSG00000272359.1 U4 -7.21 9.33e-12 2.41e-08 -0.51 -0.44 Monocyte count; chr3:196758643 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs1486358 ENSG00000272359.1 U4 -7.21 9.33e-12 2.41e-08 -0.51 -0.44 Monocyte count; chr3:196758719 chr3:196747192~196747324:- CESC cis rs7626444 0.563 rs2686598 ENSG00000272359.1 U4 -7.21 9.33e-12 2.41e-08 -0.51 -0.44 Monocyte count; chr3:196760848 chr3:196747192~196747324:- CESC cis rs227275 0.525 rs2086499 ENSG00000246560.2 RP11-10L12.4 7.2 9.37e-12 2.42e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103008672 chr4:102828055~102844075:+ CESC cis rs7849270 1 rs7037163 ENSG00000268707.1 RP11-247A12.7 -7.2 9.43e-12 2.44e-08 -0.54 -0.44 Blood metabolite ratios; chr9:129132061 chr9:129170434~129170940:+ CESC cis rs6452524 0.935 rs1478485 ENSG00000249664.1 CTD-2227C6.2 7.2 9.46e-12 2.44e-08 0.47 0.44 Hypertension (SNP x SNP interaction); chr5:83084708 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1017794 ENSG00000249664.1 CTD-2227C6.2 7.2 9.46e-12 2.44e-08 0.47 0.44 Hypertension (SNP x SNP interaction); chr5:83086236 chr5:83012285~83013109:- CESC cis rs7626444 0.625 rs843541 ENSG00000272359.1 U4 -7.2 9.54e-12 2.46e-08 -0.51 -0.44 Monocyte count; chr3:196748879 chr3:196747192~196747324:- CESC cis rs1577917 1 rs34281561 ENSG00000203875.9 SNHG5 -7.2 9.57e-12 2.47e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85992154 chr6:85660950~85678736:- CESC cis rs1577917 1 rs35419329 ENSG00000203875.9 SNHG5 -7.2 9.57e-12 2.47e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85992573 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12216328 ENSG00000203875.9 SNHG5 -7.2 9.57e-12 2.47e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85993700 chr6:85660950~85678736:- CESC cis rs7626444 0.627 rs5021326 ENSG00000272359.1 U4 -7.2 9.59e-12 2.47e-08 -0.52 -0.44 Monocyte count; chr3:196750757 chr3:196747192~196747324:- CESC cis rs2882667 0.858 rs11741150 ENSG00000253404.1 AC034243.1 7.2 9.67e-12 2.49e-08 0.58 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139095768 chr5:138744434~138753309:- CESC cis rs7104764 1 rs10400248 ENSG00000277290.1 RP11-326C3.16 -7.2 9.67e-12 2.49e-08 -0.41 -0.44 Menarche (age at onset); chr11:247029 chr11:243099~243483:- CESC cis rs9545047 0.935 rs2760102 ENSG00000227676.3 LINC01068 7.2 9.77e-12 2.52e-08 0.51 0.44 Schizophrenia; chr13:79555193 chr13:79566727~79571436:+ CESC cis rs3096299 0.658 rs12443705 ENSG00000274627.1 RP11-104N10.2 7.2 9.85e-12 2.54e-08 0.43 0.44 Multiple myeloma (IgH translocation); chr16:89480646 chr16:89516797~89522217:+ CESC cis rs227275 0.554 rs223395 ENSG00000246560.2 RP11-10L12.4 7.2 9.87e-12 2.54e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102823801 chr4:102828055~102844075:+ CESC cis rs2882667 0.858 rs11242447 ENSG00000253404.1 AC034243.1 7.2 9.87e-12 2.54e-08 0.58 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139090484 chr5:138744434~138753309:- CESC cis rs5769707 0.967 rs763126 ENSG00000188511.11 C22orf34 -7.2 9.89e-12 2.55e-08 -0.46 -0.44 Monocyte percentage of white cells;Monocyte count; chr22:49594926 chr22:49414524~49657542:- CESC cis rs2404602 0.647 rs62026889 ENSG00000259422.1 RP11-593F23.1 -7.2 9.91e-12 2.55e-08 -0.52 -0.44 Blood metabolite levels; chr15:76625544 chr15:76174891~76181486:- CESC cis rs228614 0.51 rs223356 ENSG00000246560.2 RP11-10L12.4 7.19 9.96e-12 2.56e-08 0.53 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102852344 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223353 ENSG00000246560.2 RP11-10L12.4 7.19 9.96e-12 2.56e-08 0.53 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102854547 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223352 ENSG00000246560.2 RP11-10L12.4 7.19 9.96e-12 2.56e-08 0.53 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102855710 chr4:102828055~102844075:+ CESC cis rs9326248 0.53 rs588918 ENSG00000254851.1 RP11-109L13.1 -7.19 1.01e-11 2.59e-08 -0.71 -0.44 Blood protein levels; chr11:116985926 chr11:117135528~117138582:+ CESC cis rs5760092 0.618 rs4461358 ENSG00000250470.1 AP000351.3 -7.19 1.01e-11 2.59e-08 -0.62 -0.44 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23976904~23977585:- CESC cis rs7208859 0.673 rs450585 ENSG00000263531.1 RP13-753N3.1 7.19 1.02e-11 2.62e-08 0.81 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624021 chr17:30863921~30864940:- CESC cis rs9545047 0.868 rs1208049 ENSG00000227676.3 LINC01068 7.19 1.02e-11 2.62e-08 0.51 0.44 Schizophrenia; chr13:79570220 chr13:79566727~79571436:+ CESC cis rs150992 0.711 rs170734 ENSG00000248489.1 CTD-2007H13.3 7.19 1.02e-11 2.62e-08 0.53 0.44 Body mass index; chr5:98811337 chr5:98929171~98995013:+ CESC cis rs9660180 0.837 rs915292 ENSG00000231050.1 RP1-140A9.1 7.19 1.03e-11 2.65e-08 0.52 0.44 Body mass index; chr1:1860718 chr1:1891471~1892658:+ CESC cis rs17711722 0.522 rs4642526 ENSG00000164669.11 INTS4P1 -7.19 1.03e-11 2.66e-08 -0.56 -0.44 Calcium levels; chr7:65751755 chr7:65141225~65234216:+ CESC cis rs7044106 0.762 rs1158554 ENSG00000226752.6 PSMD5-AS1 -7.19 1.04e-11 2.66e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120638620 chr9:120824828~120854385:+ CESC cis rs227275 0.554 rs223422 ENSG00000246560.2 RP11-10L12.4 7.19 1.04e-11 2.66e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102805616 chr4:102828055~102844075:+ CESC cis rs7044106 0.708 rs920745 ENSG00000226752.6 PSMD5-AS1 -7.19 1.04e-11 2.67e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120667665 chr9:120824828~120854385:+ CESC cis rs7044106 0.734 rs10491784 ENSG00000226752.6 PSMD5-AS1 -7.19 1.04e-11 2.67e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120670011 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs1886337 ENSG00000226752.6 PSMD5-AS1 -7.19 1.04e-11 2.67e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120681498 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs4837790 ENSG00000226752.6 PSMD5-AS1 -7.19 1.04e-11 2.67e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120684047 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs10491783 ENSG00000226752.6 PSMD5-AS1 -7.19 1.04e-11 2.67e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120687877 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs966397 ENSG00000226752.6 PSMD5-AS1 -7.19 1.04e-11 2.67e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120691034 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs1411158 ENSG00000226752.6 PSMD5-AS1 -7.19 1.04e-11 2.67e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120702526 chr9:120824828~120854385:+ CESC cis rs227275 0.556 rs223398 ENSG00000246560.2 RP11-10L12.4 7.19 1.04e-11 2.67e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102821256 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223392 ENSG00000246560.2 RP11-10L12.4 7.19 1.04e-11 2.67e-08 0.53 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102824599 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223390 ENSG00000246560.2 RP11-10L12.4 7.19 1.04e-11 2.67e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102827640 chr4:102828055~102844075:+ CESC cis rs2882667 0.858 rs13176497 ENSG00000253404.1 AC034243.1 7.19 1.04e-11 2.67e-08 0.56 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139110385 chr5:138744434~138753309:- CESC cis rs150992 0.711 rs331918 ENSG00000248489.1 CTD-2007H13.3 7.19 1.05e-11 2.69e-08 0.53 0.44 Body mass index; chr5:98823040 chr5:98929171~98995013:+ CESC cis rs11722779 0.873 rs223346 ENSG00000246560.2 RP11-10L12.4 7.18 1.06e-11 2.72e-08 0.53 0.44 Schizophrenia; chr4:102859339 chr4:102828055~102844075:+ CESC cis rs7195287 0.826 rs9925824 ENSG00000276791.1 CTD-2270P14.5 -7.18 1.06e-11 2.72e-08 -0.44 -0.44 Eosinophil counts; chr16:2777972 chr16:2777319~2780568:+ CESC cis rs7684253 0.565 rs12641030 ENSG00000269949.1 RP11-738E22.3 -7.18 1.07e-11 2.75e-08 -0.5 -0.44 Migraine; chr4:56937339 chr4:56960927~56961373:- CESC cis rs7626444 0.625 rs7638090 ENSG00000272359.1 U4 -7.18 1.08e-11 2.77e-08 -0.51 -0.44 Monocyte count; chr3:196749965 chr3:196747192~196747324:- CESC cis rs8081395 0.801 rs12938273 ENSG00000266992.1 DHX40P1 -7.18 1.09e-11 2.78e-08 -0.47 -0.44 White blood cell count; chr17:59824291 chr17:59976009~60002384:- CESC cis rs8081395 0.836 rs1292061 ENSG00000266992.1 DHX40P1 -7.18 1.09e-11 2.78e-08 -0.47 -0.44 White blood cell count; chr17:59833869 chr17:59976009~60002384:- CESC cis rs10256972 0.616 rs6463001 ENSG00000229043.2 AC091729.9 -7.18 1.09e-11 2.79e-08 -0.49 -0.44 Endometriosis;Longevity; chr7:1068636 chr7:1160374~1165267:+ CESC cis rs7626444 0.625 rs1798637 ENSG00000272359.1 U4 -7.18 1.09e-11 2.8e-08 -0.51 -0.44 Monocyte count; chr3:196749768 chr3:196747192~196747324:- CESC cis rs7849270 1 rs6478867 ENSG00000268707.1 RP11-247A12.7 7.18 1.1e-11 2.81e-08 0.54 0.44 Blood metabolite ratios; chr9:129141644 chr9:129170434~129170940:+ CESC cis rs6991838 0.584 rs6993876 ENSG00000272010.1 CTD-3025N20.3 7.18 1.1e-11 2.82e-08 0.49 0.44 Intelligence (multi-trait analysis); chr8:65601240 chr8:65591850~65592472:- CESC cis rs6142102 0.58 rs9753679 ENSG00000276073.1 RP5-1125A11.7 -7.18 1.1e-11 2.82e-08 -0.39 -0.44 Skin pigmentation; chr20:33953054 chr20:33985617~33988989:- CESC cis rs227275 0.554 rs223421 ENSG00000246560.2 RP11-10L12.4 7.18 1.11e-11 2.82e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102805861 chr4:102828055~102844075:+ CESC cis rs2404602 0.735 rs62028423 ENSG00000259422.1 RP11-593F23.1 -7.18 1.11e-11 2.83e-08 -0.52 -0.44 Blood metabolite levels; chr15:76462173 chr15:76174891~76181486:- CESC cis rs4718428 1 rs4718421 ENSG00000226824.5 RP4-756H11.3 -7.18 1.11e-11 2.84e-08 -0.56 -0.44 Corneal structure; chr7:66885313 chr7:66654538~66669855:+ CESC cis rs227275 0.554 rs223424 ENSG00000246560.2 RP11-10L12.4 7.18 1.11e-11 2.84e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102804177 chr4:102828055~102844075:+ CESC cis rs526231 0.511 rs10515341 ENSG00000175749.11 EIF3KP1 7.17 1.12e-11 2.85e-08 0.5 0.44 Primary biliary cholangitis; chr5:102981413 chr5:103032376~103033031:+ CESC cis rs2404602 0.735 rs4886493 ENSG00000259422.1 RP11-593F23.1 -7.17 1.12e-11 2.86e-08 -0.52 -0.44 Blood metabolite levels; chr15:76386685 chr15:76174891~76181486:- CESC cis rs11722779 0.901 rs28674656 ENSG00000246560.2 RP11-10L12.4 7.17 1.12e-11 2.86e-08 0.52 0.44 Schizophrenia; chr4:102944396 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs4699037 ENSG00000246560.2 RP11-10L12.4 7.17 1.12e-11 2.86e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102957010 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs3857198 ENSG00000246560.2 RP11-10L12.4 7.17 1.12e-11 2.86e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102957720 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs4699039 ENSG00000246560.2 RP11-10L12.4 7.17 1.12e-11 2.86e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102958354 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs6821173 ENSG00000246560.2 RP11-10L12.4 7.17 1.12e-11 2.86e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102966404 chr4:102828055~102844075:+ CESC cis rs7208859 0.725 rs9910051 ENSG00000263531.1 RP13-753N3.1 7.17 1.12e-11 2.87e-08 0.7 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834184 chr17:30863921~30864940:- CESC cis rs2882667 0.858 rs11242448 ENSG00000253404.1 AC034243.1 7.17 1.13e-11 2.87e-08 0.56 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139107465 chr5:138744434~138753309:- CESC cis rs14027 0.883 rs1469755 ENSG00000279347.1 RP11-85I17.2 -7.17 1.13e-11 2.89e-08 -0.43 -0.44 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119728107 chr8:119838736~119840385:- CESC cis rs11722779 0.903 rs6830193 ENSG00000246560.2 RP11-10L12.4 7.17 1.14e-11 2.9e-08 0.53 0.44 Schizophrenia; chr4:102955457 chr4:102828055~102844075:+ CESC cis rs7849270 1 rs7036236 ENSG00000268707.1 RP11-247A12.7 -7.17 1.14e-11 2.9e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129137020 chr9:129170434~129170940:+ CESC cis rs7849270 0.959 rs7039031 ENSG00000268707.1 RP11-247A12.7 -7.17 1.14e-11 2.9e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129137116 chr9:129170434~129170940:+ CESC cis rs1707322 0.821 rs10749857 ENSG00000280836.1 AL355480.1 -7.17 1.15e-11 2.92e-08 -0.52 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45782471 chr1:45581219~45581321:- CESC cis rs7849270 1 rs2297112 ENSG00000268707.1 RP11-247A12.7 -7.17 1.16e-11 2.94e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129137901 chr9:129170434~129170940:+ CESC cis rs1577917 1 rs12212733 ENSG00000203875.9 SNHG5 -7.17 1.16e-11 2.95e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:86016295 chr6:85660950~85678736:- CESC cis rs7849270 0.798 rs7865337 ENSG00000268707.1 RP11-247A12.7 -7.17 1.16e-11 2.96e-08 -0.55 -0.44 Blood metabolite ratios; chr9:129091799 chr9:129170434~129170940:+ CESC cis rs7849270 0.879 rs3124495 ENSG00000268707.1 RP11-247A12.7 7.17 1.16e-11 2.96e-08 0.55 0.44 Blood metabolite ratios; chr9:129093731 chr9:129170434~129170940:+ CESC cis rs7849270 0.879 rs3124496 ENSG00000268707.1 RP11-247A12.7 7.17 1.16e-11 2.96e-08 0.55 0.44 Blood metabolite ratios; chr9:129094583 chr9:129170434~129170940:+ CESC cis rs227275 0.554 rs223319 ENSG00000246560.2 RP11-10L12.4 7.17 1.17e-11 2.97e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102881157 chr4:102828055~102844075:+ CESC cis rs228614 0.509 rs223318 ENSG00000246560.2 RP11-10L12.4 7.17 1.17e-11 2.97e-08 0.53 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102881422 chr4:102828055~102844075:+ CESC cis rs8081395 0.834 rs11650106 ENSG00000266992.1 DHX40P1 -7.17 1.17e-11 2.98e-08 -0.46 -0.44 White blood cell count; chr17:59772890 chr17:59976009~60002384:- CESC cis rs7849270 0.921 rs7019373 ENSG00000268707.1 RP11-247A12.7 -7.17 1.17e-11 2.98e-08 -0.5 -0.44 Blood metabolite ratios; chr9:129134942 chr9:129170434~129170940:+ CESC cis rs1501911 0.509 rs330421 ENSG00000248489.1 CTD-2007H13.3 7.17 1.17e-11 2.98e-08 0.5 0.44 Lung function (FEV1/FVC); chr5:98859077 chr5:98929171~98995013:+ CESC cis rs6452524 0.905 rs1478482 ENSG00000249664.1 CTD-2227C6.2 7.17 1.17e-11 2.98e-08 0.47 0.44 Hypertension (SNP x SNP interaction); chr5:83111279 chr5:83012285~83013109:- CESC cis rs7044106 0.718 rs1981021 ENSG00000226752.6 PSMD5-AS1 -7.16 1.19e-11 3.02e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120626115 chr9:120824828~120854385:+ CESC cis rs7044106 0.734 rs1981020 ENSG00000226752.6 PSMD5-AS1 -7.16 1.19e-11 3.02e-08 -0.47 -0.44 Hip circumference adjusted for BMI; chr9:120626186 chr9:120824828~120854385:+ CESC cis rs7684253 0.565 rs13130605 ENSG00000269949.1 RP11-738E22.3 -7.16 1.19e-11 3.03e-08 -0.5 -0.44 Migraine; chr4:56943905 chr4:56960927~56961373:- CESC cis rs228614 0.51 rs65671 ENSG00000246560.2 RP11-10L12.4 7.16 1.2e-11 3.03e-08 0.52 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102801081 chr4:102828055~102844075:+ CESC cis rs875971 1 rs10244498 ENSG00000226824.5 RP4-756H11.3 -7.16 1.2e-11 3.05e-08 -0.54 -0.44 Aortic root size; chr7:66651069 chr7:66654538~66669855:+ CESC cis rs11317778 1 rs11317778 ENSG00000248489.1 CTD-2007H13.3 7.16 1.2e-11 3.06e-08 0.52 0.44 Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr5:98905525 chr5:98929171~98995013:+ CESC cis rs1707322 0.686 rs2050376 ENSG00000280836.1 AL355480.1 -7.16 1.21e-11 3.08e-08 -0.51 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45612958 chr1:45581219~45581321:- CESC cis rs227275 0.554 rs223439 ENSG00000246560.2 RP11-10L12.4 7.16 1.22e-11 3.1e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102798377 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223436 ENSG00000246560.2 RP11-10L12.4 7.16 1.22e-11 3.1e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102798749 chr4:102828055~102844075:+ CESC cis rs227275 0.524 rs223423 ENSG00000246560.2 RP11-10L12.4 7.16 1.22e-11 3.1e-08 0.52 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102804737 chr4:102828055~102844075:+ CESC cis rs7849270 1 rs7849270 ENSG00000268707.1 RP11-247A12.7 -7.16 1.23e-11 3.12e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129112362 chr9:129170434~129170940:+ CESC cis rs7208859 0.673 rs216420 ENSG00000263531.1 RP13-753N3.1 7.16 1.23e-11 3.12e-08 0.81 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30611490 chr17:30863921~30864940:- CESC cis rs875971 0.895 rs4145009 ENSG00000226824.5 RP4-756H11.3 7.16 1.24e-11 3.14e-08 0.54 0.44 Aortic root size; chr7:66261628 chr7:66654538~66669855:+ CESC cis rs875971 1 rs2420820 ENSG00000226824.5 RP4-756H11.3 7.16 1.24e-11 3.15e-08 0.56 0.44 Aortic root size; chr7:66626920 chr7:66654538~66669855:+ CESC cis rs1577917 1 rs12200330 ENSG00000203875.9 SNHG5 -7.16 1.25e-11 3.15e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85946935 chr6:85660950~85678736:- CESC cis rs2739330 0.892 rs4822455 ENSG00000250470.1 AP000351.3 7.16 1.25e-11 3.16e-08 0.56 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23976904~23977585:- CESC cis rs6142102 0.625 rs6142068 ENSG00000276073.1 RP5-1125A11.7 7.16 1.25e-11 3.16e-08 0.4 0.44 Skin pigmentation; chr20:33969366 chr20:33985617~33988989:- CESC cis rs228614 0.51 rs50034 ENSG00000246560.2 RP11-10L12.4 7.16 1.25e-11 3.17e-08 0.53 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102832214 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs223380 ENSG00000246560.2 RP11-10L12.4 7.16 1.25e-11 3.17e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102833343 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs223379 ENSG00000246560.2 RP11-10L12.4 7.16 1.25e-11 3.17e-08 0.53 0.44 Allergic disease (asthma, hay fever or eczema); chr4:102833434 chr4:102828055~102844075:+ CESC cis rs228614 0.536 rs223375 ENSG00000246560.2 RP11-10L12.4 7.16 1.25e-11 3.17e-08 0.53 0.44 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102836484 chr4:102828055~102844075:+ CESC cis rs9545047 0.901 rs314688 ENSG00000227676.3 LINC01068 7.15 1.26e-11 3.19e-08 0.49 0.44 Schizophrenia; chr13:79449171 chr13:79566727~79571436:+ CESC cis rs2404602 0.66 rs11852777 ENSG00000259422.1 RP11-593F23.1 -7.15 1.27e-11 3.2e-08 -0.52 -0.44 Blood metabolite levels; chr15:76637451 chr15:76174891~76181486:- CESC cis rs1891275 0.513 rs1539041 ENSG00000228701.1 TNKS2-AS1 -7.15 1.27e-11 3.21e-08 -0.58 -0.44 Intelligence (multi-trait analysis); chr10:91817384 chr10:91782839~91798291:- CESC cis rs7849270 0.725 rs59012667 ENSG00000268707.1 RP11-247A12.7 -7.15 1.28e-11 3.22e-08 -0.51 -0.44 Blood metabolite ratios; chr9:129088202 chr9:129170434~129170940:+ CESC cis rs1707322 0.827 rs12125508 ENSG00000280836.1 AL355480.1 -7.15 1.28e-11 3.22e-08 -0.52 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45780338 chr1:45581219~45581321:- CESC cis rs1707322 0.789 rs10789473 ENSG00000280836.1 AL355480.1 -7.15 1.28e-11 3.22e-08 -0.52 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45782459 chr1:45581219~45581321:- CESC cis rs7626444 0.625 rs2669638 ENSG00000272359.1 U4 -7.15 1.28e-11 3.23e-08 -0.51 -0.44 Monocyte count; chr3:196750527 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs2686593 ENSG00000272359.1 U4 -7.15 1.28e-11 3.23e-08 -0.51 -0.44 Monocyte count; chr3:196750530 chr3:196747192~196747324:- CESC cis rs2882667 0.858 rs11959803 ENSG00000253404.1 AC034243.1 7.15 1.29e-11 3.25e-08 0.55 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139115626 chr5:138744434~138753309:- CESC cis rs1577917 0.917 rs35283633 ENSG00000203875.9 SNHG5 -7.15 1.29e-11 3.25e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:85981069 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs11756510 ENSG00000203875.9 SNHG5 -7.15 1.3e-11 3.26e-08 -0.56 -0.44 Response to antipsychotic treatment; chr6:85990076 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12193904 ENSG00000203875.9 SNHG5 -7.15 1.3e-11 3.26e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:85742985 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs11754330 ENSG00000203875.9 SNHG5 -7.15 1.3e-11 3.26e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:85745352 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs34622605 ENSG00000203875.9 SNHG5 -7.15 1.3e-11 3.26e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:85746801 chr6:85660950~85678736:- CESC cis rs6452524 0.836 rs1478484 ENSG00000249664.1 CTD-2227C6.2 7.15 1.32e-11 3.3e-08 0.47 0.44 Hypertension (SNP x SNP interaction); chr5:83085055 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs7714710 ENSG00000249664.1 CTD-2227C6.2 7.15 1.32e-11 3.3e-08 0.47 0.44 Hypertension (SNP x SNP interaction); chr5:83085750 chr5:83012285~83013109:- CESC cis rs875971 0.867 rs13227219 ENSG00000226824.5 RP4-756H11.3 -7.15 1.32e-11 3.31e-08 -0.57 -0.44 Aortic root size; chr7:66379075 chr7:66654538~66669855:+ CESC cis rs150992 0.585 rs331931 ENSG00000248489.1 CTD-2007H13.3 7.15 1.33e-11 3.33e-08 0.53 0.44 Body mass index; chr5:98834012 chr5:98929171~98995013:+ CESC cis rs1577917 1 rs955197 ENSG00000203875.9 SNHG5 -7.15 1.33e-11 3.34e-08 -0.55 -0.44 Response to antipsychotic treatment; chr6:86019957 chr6:85660950~85678736:- CESC cis rs7849270 1 rs2541164 ENSG00000268707.1 RP11-247A12.7 -7.14 1.34e-11 3.36e-08 -0.54 -0.44 Blood metabolite ratios; chr9:129114629 chr9:129170434~129170940:+ CESC cis rs7727544 0.684 rs272889 ENSG00000233006.5 AC034220.3 7.14 1.36e-11 3.42e-08 0.48 0.44 Blood metabolite levels; chr5:132329685 chr5:132311285~132369916:- CESC cis rs875971 1 rs1544549 ENSG00000226824.5 RP4-756H11.3 7.14 1.36e-11 3.42e-08 0.56 0.44 Aortic root size; chr7:66625676 chr7:66654538~66669855:+ CESC cis rs150992 0.593 rs34497 ENSG00000248489.1 CTD-2007H13.3 7.14 1.37e-11 3.43e-08 0.53 0.44 Body mass index; chr5:98962885 chr5:98929171~98995013:+ CESC cis rs150992 0.593 rs34496 ENSG00000248489.1 CTD-2007H13.3 7.14 1.37e-11 3.43e-08 0.53 0.44 Body mass index; chr5:98963812 chr5:98929171~98995013:+ CESC cis rs6452524 0.935 rs6896953 ENSG00000249664.1 CTD-2227C6.2 -7.14 1.39e-11 3.49e-08 -0.47 -0.44 Hypertension (SNP x SNP interaction); chr5:83089284 chr5:83012285~83013109:- CESC cis rs7727544 0.735 rs273913 ENSG00000233006.5 AC034220.3 7.14 1.4e-11 3.5e-08 0.5 0.44 Blood metabolite levels; chr5:132325463 chr5:132311285~132369916:- CESC cis rs875971 1 rs709597 ENSG00000226824.5 RP4-756H11.3 7.13 1.42e-11 3.56e-08 0.54 0.44 Aortic root size; chr7:66360996 chr7:66654538~66669855:+ CESC cis rs9601248 0.529 rs2783125 ENSG00000227676.3 LINC01068 7.13 1.43e-11 3.57e-08 0.5 0.44 Major depressive disorder; chr13:79583755 chr13:79566727~79571436:+ CESC cis rs1707322 0.827 rs6694302 ENSG00000280836.1 AL355480.1 -7.13 1.44e-11 3.59e-08 -0.52 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45779973 chr1:45581219~45581321:- CESC cis rs1707322 0.826 rs10890349 ENSG00000280836.1 AL355480.1 -7.13 1.44e-11 3.59e-08 -0.52 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45784283 chr1:45581219~45581321:- CESC cis rs1707322 0.758 rs10789474 ENSG00000280836.1 AL355480.1 -7.13 1.44e-11 3.59e-08 -0.52 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45784368 chr1:45581219~45581321:- CESC cis rs7208859 0.725 rs9891656 ENSG00000263531.1 RP13-753N3.1 7.13 1.45e-11 3.61e-08 0.68 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30863921~30864940:- CESC cis rs2404602 0.684 rs8029283 ENSG00000259422.1 RP11-593F23.1 -7.13 1.46e-11 3.64e-08 -0.51 -0.43 Blood metabolite levels; chr15:76544799 chr15:76174891~76181486:- CESC cis rs6991838 0.584 rs4275254 ENSG00000272010.1 CTD-3025N20.3 -7.13 1.47e-11 3.66e-08 -0.49 -0.43 Intelligence (multi-trait analysis); chr8:65589129 chr8:65591850~65592472:- CESC cis rs2006771 0.618 rs470072 ENSG00000236132.1 CTA-440B3.1 -7.13 1.48e-11 3.69e-08 -0.49 -0.43 Nonsyndromic cleft lip with cleft palate; chr22:31867145 chr22:31816379~31817491:- CESC cis rs7849270 1 rs3739847 ENSG00000268707.1 RP11-247A12.7 7.13 1.49e-11 3.7e-08 0.53 0.43 Blood metabolite ratios; chr9:129149295 chr9:129170434~129170940:+ CESC cis rs228614 0.51 rs223378 ENSG00000246560.2 RP11-10L12.4 7.13 1.49e-11 3.7e-08 0.54 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102833488 chr4:102828055~102844075:+ CESC cis rs4423214 0.569 rs4944044 ENSG00000254682.1 RP11-660L16.2 7.13 1.49e-11 3.72e-08 0.51 0.43 Vitamin D levels; chr11:71409167 chr11:71448674~71452157:+ CESC cis rs7044106 0.791 rs10985000 ENSG00000226752.6 PSMD5-AS1 -7.13 1.5e-11 3.72e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120721837 chr9:120824828~120854385:+ CESC cis rs7044106 0.791 rs10985001 ENSG00000226752.6 PSMD5-AS1 -7.13 1.5e-11 3.72e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120721954 chr9:120824828~120854385:+ CESC cis rs977987 0.872 rs10781976 ENSG00000261783.1 RP11-252K23.2 -7.12 1.5e-11 3.73e-08 -0.54 -0.43 Dupuytren's disease; chr16:75280940 chr16:75379818~75381260:- CESC cis rs4423214 1 rs1044482 ENSG00000254682.1 RP11-660L16.2 7.12 1.5e-11 3.74e-08 0.55 0.43 Vitamin D levels; chr11:71444125 chr11:71448674~71452157:+ CESC cis rs228614 0.51 rs223358 ENSG00000246560.2 RP11-10L12.4 7.12 1.51e-11 3.75e-08 0.53 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102849637 chr4:102828055~102844075:+ CESC cis rs113835537 0.529 rs79798028 ENSG00000255517.5 CTD-3074O7.5 -7.12 1.51e-11 3.76e-08 -0.48 -0.43 Airway imaging phenotypes; chr11:66431891 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs2279865 ENSG00000255517.5 CTD-3074O7.5 -7.12 1.51e-11 3.76e-08 -0.48 -0.43 Airway imaging phenotypes; chr11:66435554 chr11:66473490~66480233:- CESC cis rs113835537 0.502 rs7104378 ENSG00000255517.5 CTD-3074O7.5 -7.12 1.51e-11 3.76e-08 -0.48 -0.43 Airway imaging phenotypes; chr11:66449204 chr11:66473490~66480233:- CESC cis rs7208859 0.673 rs423151 ENSG00000263531.1 RP13-753N3.1 7.12 1.51e-11 3.76e-08 0.8 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30625268 chr17:30863921~30864940:- CESC cis rs5769707 0.967 rs5769698 ENSG00000188511.11 C22orf34 7.12 1.52e-11 3.78e-08 0.44 0.43 Monocyte percentage of white cells;Monocyte count; chr22:49604058 chr22:49414524~49657542:- CESC cis rs11332131 1 rs11332131 ENSG00000266992.1 DHX40P1 7.12 1.52e-11 3.79e-08 0.47 0.43 Platelet distribution width; chr17:59849031 chr17:59976009~60002384:- CESC cis rs150992 0.673 rs331545 ENSG00000248489.1 CTD-2007H13.3 -7.12 1.52e-11 3.79e-08 -0.52 -0.43 Body mass index; chr5:98810402 chr5:98929171~98995013:+ CESC cis rs2404602 0.735 rs2454450 ENSG00000259422.1 RP11-593F23.1 -7.12 1.53e-11 3.79e-08 -0.52 -0.43 Blood metabolite levels; chr15:76538895 chr15:76174891~76181486:- CESC cis rs7617773 0.817 rs9818937 ENSG00000229759.1 MRPS18AP1 7.12 1.54e-11 3.83e-08 0.46 0.43 Coronary artery disease; chr3:48283791 chr3:48256350~48256938:- CESC cis rs10463554 0.963 rs34829 ENSG00000175749.11 EIF3KP1 7.12 1.54e-11 3.83e-08 0.46 0.43 Parkinson's disease; chr5:103108260 chr5:103032376~103033031:+ CESC cis rs7397814 0.558 rs4764447 ENSG00000278635.1 CTD-2318O12.1 7.12 1.55e-11 3.84e-08 0.43 0.43 IgG glycosylation; chr12:9426513 chr12:9415641~9416718:+ CESC cis rs2404602 0.684 rs4886819 ENSG00000259422.1 RP11-593F23.1 -7.12 1.55e-11 3.85e-08 -0.52 -0.43 Blood metabolite levels; chr15:76609357 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs11634266 ENSG00000259422.1 RP11-593F23.1 -7.12 1.57e-11 3.89e-08 -0.51 -0.43 Blood metabolite levels; chr15:76801120 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs12905181 ENSG00000259422.1 RP11-593F23.1 -7.12 1.57e-11 3.89e-08 -0.51 -0.43 Blood metabolite levels; chr15:76806090 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs7178250 ENSG00000259422.1 RP11-593F23.1 -7.12 1.57e-11 3.89e-08 -0.51 -0.43 Blood metabolite levels; chr15:76806766 chr15:76174891~76181486:- CESC cis rs2882667 0.858 rs13174479 ENSG00000253404.1 AC034243.1 7.12 1.58e-11 3.91e-08 0.55 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139108481 chr5:138744434~138753309:- CESC cis rs1577917 1 rs12205336 ENSG00000203875.9 SNHG5 -7.11 1.61e-11 3.98e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:86012649 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12209127 ENSG00000203875.9 SNHG5 -7.11 1.61e-11 3.98e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:86014709 chr6:85660950~85678736:- CESC cis rs1577917 1 rs1337850 ENSG00000203875.9 SNHG5 -7.11 1.61e-11 3.98e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:86019385 chr6:85660950~85678736:- CESC cis rs10463554 0.927 rs158403 ENSG00000175749.11 EIF3KP1 7.11 1.62e-11 4.01e-08 0.48 0.43 Parkinson's disease; chr5:103080064 chr5:103032376~103033031:+ CESC cis rs150992 0.64 rs326485 ENSG00000248489.1 CTD-2007H13.3 7.11 1.62e-11 4.01e-08 0.5 0.43 Body mass index; chr5:98845717 chr5:98929171~98995013:+ CESC cis rs1823913 0.927 rs13025919 ENSG00000280083.1 RP11-317J9.1 -7.11 1.62e-11 4.02e-08 -0.51 -0.43 Obesity-related traits; chr2:191260175 chr2:191154118~191156070:- CESC cis rs6991838 0.584 rs34226237 ENSG00000272010.1 CTD-3025N20.3 -7.11 1.62e-11 4.02e-08 -0.48 -0.43 Intelligence (multi-trait analysis); chr8:65600930 chr8:65591850~65592472:- CESC cis rs1062177 0.826 rs1549920 ENSG00000213433.5 RPLP1P6 -7.11 1.62e-11 4.02e-08 -0.5 -0.43 Preschool internalizing problems; chr5:151761283 chr5:151765859~151766378:- CESC cis rs10463554 1 rs12656131 ENSG00000175749.11 EIF3KP1 -7.11 1.63e-11 4.04e-08 -0.47 -0.43 Parkinson's disease; chr5:102990174 chr5:103032376~103033031:+ CESC cis rs227275 0.554 rs6810668 ENSG00000246560.2 RP11-10L12.4 7.11 1.63e-11 4.04e-08 0.53 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102987574 chr4:102828055~102844075:+ CESC cis rs7044106 0.762 rs10984974 ENSG00000226752.6 PSMD5-AS1 -7.11 1.64e-11 4.05e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120659278 chr9:120824828~120854385:+ CESC cis rs150992 0.79 rs40075 ENSG00000248489.1 CTD-2007H13.3 7.11 1.64e-11 4.05e-08 0.51 0.43 Body mass index; chr5:98976743 chr5:98929171~98995013:+ CESC cis rs2404602 0.735 rs12903874 ENSG00000259422.1 RP11-593F23.1 -7.11 1.64e-11 4.05e-08 -0.51 -0.43 Blood metabolite levels; chr15:76400977 chr15:76174891~76181486:- CESC cis rs1577917 1 rs6936048 ENSG00000203875.9 SNHG5 -7.11 1.64e-11 4.06e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85992890 chr6:85660950~85678736:- CESC cis rs7626444 0.647 rs844546 ENSG00000272359.1 U4 -7.11 1.64e-11 4.07e-08 -0.51 -0.43 Monocyte count; chr3:196748403 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs843540 ENSG00000272359.1 U4 -7.11 1.64e-11 4.07e-08 -0.51 -0.43 Monocyte count; chr3:196748442 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs1798636 ENSG00000272359.1 U4 -7.11 1.64e-11 4.07e-08 -0.51 -0.43 Monocyte count; chr3:196749733 chr3:196747192~196747324:- CESC cis rs7849270 0.879 rs10988197 ENSG00000268707.1 RP11-247A12.7 -7.11 1.65e-11 4.08e-08 -0.5 -0.43 Blood metabolite ratios; chr9:129078980 chr9:129170434~129170940:+ CESC cis rs113835537 0.529 rs75003264 ENSG00000255517.5 CTD-3074O7.5 -7.11 1.65e-11 4.09e-08 -0.52 -0.43 Airway imaging phenotypes; chr11:66488628 chr11:66473490~66480233:- CESC cis rs228614 0.51 rs223400 ENSG00000246560.2 RP11-10L12.4 7.11 1.66e-11 4.1e-08 0.53 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102820439 chr4:102828055~102844075:+ CESC cis rs1501911 0.53 rs751878 ENSG00000248489.1 CTD-2007H13.3 7.11 1.67e-11 4.11e-08 0.52 0.43 Lung function (FEV1/FVC); chr5:98827240 chr5:98929171~98995013:+ CESC cis rs8081395 0.769 rs12449331 ENSG00000266992.1 DHX40P1 -7.11 1.67e-11 4.13e-08 -0.46 -0.43 White blood cell count; chr17:59806285 chr17:59976009~60002384:- CESC cis rs7617773 0.784 rs9850672 ENSG00000229759.1 MRPS18AP1 7.11 1.68e-11 4.15e-08 0.46 0.43 Coronary artery disease; chr3:48259682 chr3:48256350~48256938:- CESC cis rs2404602 0.647 rs11632765 ENSG00000259422.1 RP11-593F23.1 7.11 1.69e-11 4.16e-08 0.51 0.43 Blood metabolite levels; chr15:76681920 chr15:76174891~76181486:- CESC cis rs1501911 0.53 rs161941 ENSG00000248489.1 CTD-2007H13.3 -7.1 1.7e-11 4.2e-08 -0.5 -0.43 Lung function (FEV1/FVC); chr5:98863500 chr5:98929171~98995013:+ CESC cis rs1707322 0.821 rs11211182 ENSG00000280836.1 AL355480.1 -7.1 1.73e-11 4.27e-08 -0.53 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45774498 chr1:45581219~45581321:- CESC cis rs7208859 0.673 rs56846352 ENSG00000263531.1 RP13-753N3.1 7.1 1.74e-11 4.29e-08 0.7 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792170 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs7211776 ENSG00000263531.1 RP13-753N3.1 7.1 1.74e-11 4.29e-08 0.7 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793178 chr17:30863921~30864940:- CESC cis rs7208859 0.673 rs9912122 ENSG00000263531.1 RP13-753N3.1 7.1 1.74e-11 4.29e-08 0.7 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813698 chr17:30863921~30864940:- CESC cis rs3814244 1 rs3814244 ENSG00000255733.4 IFNG-AS1 -7.1 1.74e-11 4.3e-08 -0.38 -0.43 Itch intensity from mosquito bite adjusted by bite size; chr12:68019691 chr12:67989445~68234686:+ CESC cis rs6452524 0.935 rs7718472 ENSG00000249664.1 CTD-2227C6.2 7.1 1.76e-11 4.33e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83082603 chr5:83012285~83013109:- CESC cis rs11722779 0.935 rs6533046 ENSG00000246560.2 RP11-10L12.4 7.1 1.77e-11 4.34e-08 0.52 0.43 Schizophrenia; chr4:102965917 chr4:102828055~102844075:+ CESC cis rs150992 0.673 rs331934 ENSG00000248489.1 CTD-2007H13.3 -7.1 1.78e-11 4.37e-08 -0.53 -0.43 Body mass index; chr5:98804016 chr5:98929171~98995013:+ CESC cis rs8062405 0.792 rs12446550 ENSG00000259982.1 CDC37P1 7.1 1.78e-11 4.39e-08 0.55 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28532060 chr16:28700294~28701540:- CESC cis rs1577917 0.917 rs2197651 ENSG00000203875.9 SNHG5 -7.09 1.79e-11 4.41e-08 -0.54 -0.43 Response to antipsychotic treatment; chr6:85785724 chr6:85660950~85678736:- CESC cis rs2404602 0.583 rs12592501 ENSG00000259422.1 RP11-593F23.1 7.09 1.81e-11 4.45e-08 0.49 0.43 Blood metabolite levels; chr15:76262449 chr15:76174891~76181486:- CESC cis rs2404602 0.583 rs2139190 ENSG00000259422.1 RP11-593F23.1 7.09 1.81e-11 4.45e-08 0.49 0.43 Blood metabolite levels; chr15:76263198 chr15:76174891~76181486:- CESC cis rs2404602 0.684 rs2047504 ENSG00000259422.1 RP11-593F23.1 -7.09 1.81e-11 4.46e-08 -0.51 -0.43 Blood metabolite levels; chr15:76591175 chr15:76174891~76181486:- CESC cis rs2404602 0.735 rs56246286 ENSG00000259422.1 RP11-593F23.1 -7.09 1.82e-11 4.46e-08 -0.51 -0.43 Blood metabolite levels; chr15:76398390 chr15:76174891~76181486:- CESC cis rs1577917 0.917 rs12202170 ENSG00000203875.9 SNHG5 -7.09 1.83e-11 4.49e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85880668 chr6:85660950~85678736:- CESC cis rs1577917 1 rs10455449 ENSG00000203875.9 SNHG5 -7.09 1.83e-11 4.49e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85882508 chr6:85660950~85678736:- CESC cis rs1707322 0.785 rs10890348 ENSG00000280836.1 AL355480.1 -7.09 1.84e-11 4.51e-08 -0.52 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776751 chr1:45581219~45581321:- CESC cis rs2404602 0.735 rs4886495 ENSG00000259422.1 RP11-593F23.1 7.09 1.84e-11 4.52e-08 0.51 0.43 Blood metabolite levels; chr15:76446618 chr15:76174891~76181486:- CESC cis rs14027 0.883 rs28486074 ENSG00000279347.1 RP11-85I17.2 -7.09 1.87e-11 4.59e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119720762 chr8:119838736~119840385:- CESC cis rs14027 0.842 rs28634937 ENSG00000279347.1 RP11-85I17.2 -7.09 1.87e-11 4.59e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119720877 chr8:119838736~119840385:- CESC cis rs14027 0.883 rs35449013 ENSG00000279347.1 RP11-85I17.2 -7.09 1.87e-11 4.59e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119729239 chr8:119838736~119840385:- CESC cis rs14027 0.705 rs13265683 ENSG00000279347.1 RP11-85I17.2 -7.09 1.87e-11 4.59e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119729926 chr8:119838736~119840385:- CESC cis rs7104764 1 rs10902114 ENSG00000277290.1 RP11-326C3.16 -7.09 1.89e-11 4.63e-08 -0.4 -0.43 Menarche (age at onset); chr11:246234 chr11:243099~243483:- CESC cis rs150992 0.632 rs34490 ENSG00000248489.1 CTD-2007H13.3 7.08 1.92e-11 4.69e-08 0.51 0.43 Body mass index; chr5:98974967 chr5:98929171~98995013:+ CESC cis rs7684253 0.565 rs6830774 ENSG00000269949.1 RP11-738E22.3 -7.08 1.93e-11 4.72e-08 -0.5 -0.43 Migraine; chr4:56950140 chr4:56960927~56961373:- CESC cis rs11722779 0.838 rs6821247 ENSG00000246560.2 RP11-10L12.4 7.08 1.93e-11 4.73e-08 0.52 0.43 Schizophrenia; chr4:102913483 chr4:102828055~102844075:+ CESC cis rs4888378 0.6 rs729109 ENSG00000261783.1 RP11-252K23.2 7.08 1.94e-11 4.74e-08 0.65 0.43 Coronary artery disease; chr16:75282176 chr16:75379818~75381260:- CESC cis rs113835537 0.529 rs75683511 ENSG00000255517.5 CTD-3074O7.5 -7.08 1.95e-11 4.76e-08 -0.5 -0.43 Airway imaging phenotypes; chr11:66507555 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs17065 ENSG00000255517.5 CTD-3074O7.5 -7.08 1.95e-11 4.76e-08 -0.5 -0.43 Airway imaging phenotypes; chr11:66509564 chr11:66473490~66480233:- CESC cis rs227275 0.554 rs223315 ENSG00000246560.2 RP11-10L12.4 7.08 1.95e-11 4.77e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102884286 chr4:102828055~102844075:+ CESC cis rs227275 0.527 rs223308 ENSG00000246560.2 RP11-10L12.4 7.08 1.95e-11 4.77e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102891342 chr4:102828055~102844075:+ CESC cis rs8062405 0.824 rs28698667 ENSG00000259982.1 CDC37P1 7.08 1.96e-11 4.79e-08 0.55 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28521750 chr16:28700294~28701540:- CESC cis rs8062405 0.754 rs62034323 ENSG00000259982.1 CDC37P1 7.08 1.96e-11 4.79e-08 0.55 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525152 chr16:28700294~28701540:- CESC cis rs8062405 0.824 rs62034324 ENSG00000259982.1 CDC37P1 7.08 1.96e-11 4.79e-08 0.55 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525441 chr16:28700294~28701540:- CESC cis rs8062405 0.824 rs62034326 ENSG00000259982.1 CDC37P1 7.08 1.96e-11 4.79e-08 0.55 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28527972 chr16:28700294~28701540:- CESC cis rs8062405 0.824 rs4788084 ENSG00000259982.1 CDC37P1 7.08 1.96e-11 4.79e-08 0.55 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28528527 chr16:28700294~28701540:- CESC cis rs10463554 0.927 rs34799 ENSG00000175749.11 EIF3KP1 7.08 1.96e-11 4.79e-08 0.48 0.43 Parkinson's disease; chr5:103090498 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34800 ENSG00000175749.11 EIF3KP1 7.08 1.96e-11 4.79e-08 0.48 0.43 Parkinson's disease; chr5:103090799 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34802 ENSG00000175749.11 EIF3KP1 7.08 1.96e-11 4.79e-08 0.48 0.43 Parkinson's disease; chr5:103091301 chr5:103032376~103033031:+ CESC cis rs526231 0.508 rs34805 ENSG00000175749.11 EIF3KP1 7.08 1.96e-11 4.79e-08 0.48 0.43 Primary biliary cholangitis; chr5:103092608 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34810 ENSG00000175749.11 EIF3KP1 7.08 1.96e-11 4.79e-08 0.48 0.43 Parkinson's disease; chr5:103095045 chr5:103032376~103033031:+ CESC cis rs11155671 0.53 rs6557133 ENSG00000231760.4 RP11-350J20.5 7.08 1.96e-11 4.8e-08 0.54 0.43 Testicular germ cell tumor; chr6:149874248 chr6:149796151~149826294:- CESC cis rs150992 0.673 rs331549 ENSG00000248489.1 CTD-2007H13.3 -7.08 1.97e-11 4.8e-08 -0.52 -0.43 Body mass index; chr5:98805731 chr5:98929171~98995013:+ CESC cis rs150992 0.673 rs992775 ENSG00000248489.1 CTD-2007H13.3 -7.08 1.97e-11 4.8e-08 -0.52 -0.43 Body mass index; chr5:98807754 chr5:98929171~98995013:+ CESC cis rs1577917 0.958 rs12192546 ENSG00000203875.9 SNHG5 7.08 1.98e-11 4.83e-08 0.57 0.43 Response to antipsychotic treatment; chr6:85766766 chr6:85660950~85678736:- CESC cis rs228614 0.51 rs4699032 ENSG00000246560.2 RP11-10L12.4 7.08 1.98e-11 4.83e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892724 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs6830407 ENSG00000246560.2 RP11-10L12.4 7.08 1.98e-11 4.83e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102895366 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs4235407 ENSG00000246560.2 RP11-10L12.4 7.08 1.98e-11 4.83e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102897427 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs4699033 ENSG00000246560.2 RP11-10L12.4 7.08 1.98e-11 4.83e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102897577 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs6815526 ENSG00000246560.2 RP11-10L12.4 7.08 1.98e-11 4.83e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102899729 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs6824070 ENSG00000246560.2 RP11-10L12.4 7.08 1.98e-11 4.83e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102901676 chr4:102828055~102844075:+ CESC cis rs11722779 0.935 rs6856176 ENSG00000246560.2 RP11-10L12.4 7.08 1.98e-11 4.83e-08 0.52 0.43 Schizophrenia; chr4:102902574 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs11722779 ENSG00000246560.2 RP11-10L12.4 7.08 1.98e-11 4.83e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102906331 chr4:102828055~102844075:+ CESC cis rs9326248 0.53 rs1351452 ENSG00000254851.1 RP11-109L13.1 7.08 2.01e-11 4.89e-08 0.77 0.43 Blood protein levels; chr11:117072638 chr11:117135528~117138582:+ CESC cis rs11722779 0.935 rs3974481 ENSG00000246560.2 RP11-10L12.4 7.07 2.03e-11 4.95e-08 0.52 0.43 Schizophrenia; chr4:102956834 chr4:102828055~102844075:+ CESC cis rs1501911 0.53 rs161933 ENSG00000248489.1 CTD-2007H13.3 7.07 2.05e-11 4.98e-08 0.5 0.43 Lung function (FEV1/FVC); chr5:98874643 chr5:98929171~98995013:+ CESC cis rs1501911 0.53 rs161938 ENSG00000248489.1 CTD-2007H13.3 7.07 2.05e-11 4.98e-08 0.5 0.43 Lung function (FEV1/FVC); chr5:98875501 chr5:98929171~98995013:+ CESC cis rs10463554 0.892 rs158246 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103073145 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs158245 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103073801 chr5:103032376~103033031:+ CESC cis rs10463554 0.857 rs158397 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103076497 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs158399 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103077564 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs158404 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103080206 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs257305 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103081533 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs257306 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103081770 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs257307 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103081805 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs257308 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103082557 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs257311 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103083394 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs257314 ENSG00000175749.11 EIF3KP1 7.07 2.05e-11 4.99e-08 0.47 0.43 Parkinson's disease; chr5:103085391 chr5:103032376~103033031:+ CESC cis rs113835537 0.529 rs12099041 ENSG00000255517.5 CTD-3074O7.5 -7.07 2.05e-11 4.99e-08 -0.5 -0.43 Airway imaging phenotypes; chr11:66465302 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs7928882 ENSG00000255517.5 CTD-3074O7.5 -7.07 2.05e-11 4.99e-08 -0.5 -0.43 Airway imaging phenotypes; chr11:66467294 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs57691879 ENSG00000255517.5 CTD-3074O7.5 -7.07 2.05e-11 4.99e-08 -0.5 -0.43 Airway imaging phenotypes; chr11:66469133 chr11:66473490~66480233:- CESC cis rs2404602 0.618 rs12442266 ENSG00000259422.1 RP11-593F23.1 7.07 2.06e-11 5.01e-08 0.48 0.43 Blood metabolite levels; chr15:76274801 chr15:76174891~76181486:- CESC cis rs2404602 0.684 rs157759 ENSG00000259422.1 RP11-593F23.1 7.07 2.07e-11 5.02e-08 0.49 0.43 Blood metabolite levels; chr15:76554649 chr15:76174891~76181486:- CESC cis rs7617773 0.817 rs745116 ENSG00000229759.1 MRPS18AP1 7.07 2.08e-11 5.05e-08 0.45 0.43 Coronary artery disease; chr3:48231046 chr3:48256350~48256938:- CESC cis rs1501911 0.53 rs161942 ENSG00000248489.1 CTD-2007H13.3 7.07 2.08e-11 5.06e-08 0.5 0.43 Lung function (FEV1/FVC); chr5:98868016 chr5:98929171~98995013:+ CESC cis rs7044106 0.791 rs10984995 ENSG00000226752.6 PSMD5-AS1 -7.07 2.1e-11 5.09e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120716932 chr9:120824828~120854385:+ CESC cis rs7849270 0.879 rs7859344 ENSG00000268707.1 RP11-247A12.7 -7.07 2.1e-11 5.1e-08 -0.5 -0.43 Blood metabolite ratios; chr9:129086103 chr9:129170434~129170940:+ CESC cis rs6142102 0.625 rs4911381 ENSG00000276073.1 RP5-1125A11.7 7.07 2.13e-11 5.16e-08 0.38 0.43 Skin pigmentation; chr20:33962539 chr20:33985617~33988989:- CESC cis rs7044106 0.708 rs10984992 ENSG00000226752.6 PSMD5-AS1 -7.06 2.13e-11 5.17e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120711138 chr9:120824828~120854385:+ CESC cis rs7044106 0.762 rs10760115 ENSG00000226752.6 PSMD5-AS1 -7.06 2.13e-11 5.17e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120714674 chr9:120824828~120854385:+ CESC cis rs1577917 0.958 rs28442244 ENSG00000203875.9 SNHG5 7.06 2.14e-11 5.19e-08 0.53 0.43 Response to antipsychotic treatment; chr6:85991518 chr6:85660950~85678736:- CESC cis rs7044106 0.762 rs10760110 ENSG00000226752.6 PSMD5-AS1 7.06 2.15e-11 5.22e-08 0.49 0.43 Hip circumference adjusted for BMI; chr9:120650285 chr9:120824828~120854385:+ CESC cis rs10463554 0.927 rs185387 ENSG00000175749.11 EIF3KP1 7.06 2.16e-11 5.22e-08 0.46 0.43 Parkinson's disease; chr5:103084315 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs257315 ENSG00000175749.11 EIF3KP1 7.06 2.16e-11 5.22e-08 0.46 0.43 Parkinson's disease; chr5:103085725 chr5:103032376~103033031:+ CESC cis rs1577917 0.958 rs12205492 ENSG00000203875.9 SNHG5 -7.06 2.16e-11 5.22e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85766258 chr6:85660950~85678736:- CESC cis rs35955747 0.633 rs4541328 ENSG00000236132.1 CTA-440B3.1 7.06 2.16e-11 5.22e-08 0.52 0.43 Neutrophil count;Sum basophil neutrophil counts; chr22:31500186 chr22:31816379~31817491:- CESC cis rs10463554 0.963 rs34772 ENSG00000175749.11 EIF3KP1 7.06 2.16e-11 5.23e-08 0.49 0.43 Parkinson's disease; chr5:103114808 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs34826 ENSG00000175749.11 EIF3KP1 7.06 2.17e-11 5.25e-08 0.49 0.43 Parkinson's disease; chr5:103106044 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs34830 ENSG00000175749.11 EIF3KP1 7.06 2.17e-11 5.25e-08 0.49 0.43 Parkinson's disease; chr5:103108349 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs257319 ENSG00000175749.11 EIF3KP1 7.06 2.17e-11 5.25e-08 0.49 0.43 Parkinson's disease; chr5:103110123 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs39666 ENSG00000175749.11 EIF3KP1 7.06 2.17e-11 5.25e-08 0.49 0.43 Parkinson's disease; chr5:103111423 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34769 ENSG00000175749.11 EIF3KP1 7.06 2.17e-11 5.25e-08 0.49 0.43 Parkinson's disease; chr5:103111523 chr5:103032376~103033031:+ CESC cis rs5760092 0.618 rs5996631 ENSG00000250470.1 AP000351.3 -7.06 2.18e-11 5.27e-08 -0.61 -0.43 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23976904~23977585:- CESC cis rs227275 0.554 rs9307281 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102934971 chr4:102828055~102844075:+ CESC cis rs11722779 0.903 rs6533037 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Schizophrenia; chr4:102935865 chr4:102828055~102844075:+ CESC cis rs11722779 0.903 rs4530634 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Schizophrenia; chr4:102937924 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs7676943 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102938135 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs6419160 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102938648 chr4:102828055~102844075:+ CESC cis rs11722779 0.838 rs3974494 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Schizophrenia; chr4:102945323 chr4:102828055~102844075:+ CESC cis rs11722779 0.873 rs6533041 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Schizophrenia; chr4:102951615 chr4:102828055~102844075:+ CESC cis rs11722779 0.935 rs3857199 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Schizophrenia; chr4:102957991 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs5028609 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102959294 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs6815540 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102959922 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs4698867 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102961049 chr4:102828055~102844075:+ CESC cis rs11722779 0.658 rs6533044 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Schizophrenia; chr4:102965261 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs7663876 ENSG00000246560.2 RP11-10L12.4 7.06 2.18e-11 5.27e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102966174 chr4:102828055~102844075:+ CESC cis rs35160687 0.862 rs13024964 ENSG00000273080.1 RP11-301O19.1 7.06 2.19e-11 5.28e-08 0.51 0.43 Night sleep phenotypes; chr2:86284745 chr2:86195590~86196049:+ CESC cis rs227275 0.525 rs9917919 ENSG00000246560.2 RP11-10L12.4 7.06 2.19e-11 5.29e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102918497 chr4:102828055~102844075:+ CESC cis rs526231 0.578 rs42860 ENSG00000175749.11 EIF3KP1 7.06 2.19e-11 5.29e-08 0.47 0.43 Primary biliary cholangitis; chr5:103092414 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34806 ENSG00000175749.11 EIF3KP1 7.06 2.19e-11 5.29e-08 0.47 0.43 Parkinson's disease; chr5:103092733 chr5:103032376~103033031:+ CESC cis rs14027 0.883 rs13255850 ENSG00000279347.1 RP11-85I17.2 -7.06 2.21e-11 5.33e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119705923 chr8:119838736~119840385:- CESC cis rs7044106 0.791 rs10984994 ENSG00000226752.6 PSMD5-AS1 7.06 2.22e-11 5.35e-08 0.48 0.43 Hip circumference adjusted for BMI; chr9:120716491 chr9:120824828~120854385:+ CESC cis rs6452524 0.901 rs10079680 ENSG00000249664.1 CTD-2227C6.2 7.06 2.22e-11 5.35e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83082746 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs11750799 ENSG00000249664.1 CTD-2227C6.2 7.06 2.22e-11 5.35e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83082983 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs10942321 ENSG00000249664.1 CTD-2227C6.2 7.06 2.22e-11 5.35e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83083200 chr5:83012285~83013109:- CESC cis rs9660180 0.967 rs6603803 ENSG00000231050.1 RP1-140A9.1 7.06 2.22e-11 5.36e-08 0.5 0.43 Body mass index; chr1:1881249 chr1:1891471~1892658:+ CESC cis rs7617773 0.817 rs6791930 ENSG00000229759.1 MRPS18AP1 7.06 2.23e-11 5.37e-08 0.46 0.43 Coronary artery disease; chr3:48288410 chr3:48256350~48256938:- CESC cis rs7617773 0.817 rs6794644 ENSG00000229759.1 MRPS18AP1 7.06 2.23e-11 5.37e-08 0.46 0.43 Coronary artery disease; chr3:48288547 chr3:48256350~48256938:- CESC cis rs10463554 0.927 rs34373 ENSG00000175749.11 EIF3KP1 7.06 2.24e-11 5.4e-08 0.47 0.43 Parkinson's disease; chr5:103068590 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs158253 ENSG00000175749.11 EIF3KP1 7.06 2.24e-11 5.4e-08 0.47 0.43 Parkinson's disease; chr5:103069502 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs158252 ENSG00000175749.11 EIF3KP1 7.06 2.24e-11 5.4e-08 0.47 0.43 Parkinson's disease; chr5:103070546 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs154369 ENSG00000175749.11 EIF3KP1 7.06 2.24e-11 5.4e-08 0.47 0.43 Parkinson's disease; chr5:103071140 chr5:103032376~103033031:+ CESC cis rs7044106 0.762 rs12003646 ENSG00000226752.6 PSMD5-AS1 -7.06 2.24e-11 5.4e-08 -0.49 -0.43 Hip circumference adjusted for BMI; chr9:120708343 chr9:120824828~120854385:+ CESC cis rs227275 0.525 rs7698608 ENSG00000246560.2 RP11-10L12.4 7.06 2.25e-11 5.41e-08 0.51 0.43 Allergic disease (asthma, hay fever or eczema); chr4:103016817 chr4:102828055~102844075:+ CESC cis rs1577917 1 rs12663690 ENSG00000203875.9 SNHG5 7.05 2.28e-11 5.47e-08 0.54 0.43 Response to antipsychotic treatment; chr6:85930444 chr6:85660950~85678736:- CESC cis rs7617773 0.779 rs9833309 ENSG00000229759.1 MRPS18AP1 7.05 2.28e-11 5.48e-08 0.46 0.43 Coronary artery disease; chr3:48285960 chr3:48256350~48256938:- CESC cis rs7617773 0.817 rs9853804 ENSG00000229759.1 MRPS18AP1 7.05 2.28e-11 5.48e-08 0.46 0.43 Coronary artery disease; chr3:48286239 chr3:48256350~48256938:- CESC cis rs7617773 0.817 rs9834095 ENSG00000229759.1 MRPS18AP1 7.05 2.28e-11 5.48e-08 0.46 0.43 Coronary artery disease; chr3:48286261 chr3:48256350~48256938:- CESC cis rs7617773 0.817 rs4131361 ENSG00000229759.1 MRPS18AP1 7.05 2.28e-11 5.48e-08 0.46 0.43 Coronary artery disease; chr3:48287322 chr3:48256350~48256938:- CESC cis rs7617773 0.817 rs4131362 ENSG00000229759.1 MRPS18AP1 7.05 2.28e-11 5.48e-08 0.46 0.43 Coronary artery disease; chr3:48287546 chr3:48256350~48256938:- CESC cis rs2404602 0.598 rs71405204 ENSG00000259422.1 RP11-593F23.1 -7.05 2.3e-11 5.53e-08 -0.56 -0.43 Blood metabolite levels; chr15:76342964 chr15:76174891~76181486:- CESC cis rs10463554 0.892 rs34816 ENSG00000175749.11 EIF3KP1 7.05 2.33e-11 5.6e-08 0.48 0.43 Parkinson's disease; chr5:103098941 chr5:103032376~103033031:+ CESC cis rs6991838 0.584 rs6994213 ENSG00000272010.1 CTD-3025N20.3 -7.05 2.38e-11 5.69e-08 -0.48 -0.43 Intelligence (multi-trait analysis); chr8:65601497 chr8:65591850~65592472:- CESC cis rs1577917 1 rs35761942 ENSG00000203875.9 SNHG5 -7.05 2.39e-11 5.72e-08 -0.56 -0.43 Response to antipsychotic treatment; chr6:85919786 chr6:85660950~85678736:- CESC cis rs11722779 0.844 rs10003326 ENSG00000246560.2 RP11-10L12.4 7.04 2.42e-11 5.79e-08 0.52 0.43 Schizophrenia; chr4:102948193 chr4:102828055~102844075:+ CESC cis rs11722779 0.787 rs6533040 ENSG00000246560.2 RP11-10L12.4 7.04 2.42e-11 5.79e-08 0.52 0.43 Schizophrenia; chr4:102951421 chr4:102828055~102844075:+ CESC cis rs7044106 0.762 rs3904197 ENSG00000226752.6 PSMD5-AS1 -7.04 2.42e-11 5.8e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120718100 chr9:120824828~120854385:+ CESC cis rs9545047 0.669 rs2095477 ENSG00000227676.3 LINC01068 -7.04 2.43e-11 5.81e-08 -0.49 -0.43 Schizophrenia; chr13:79427869 chr13:79566727~79571436:+ CESC cis rs228614 0.51 rs223434 ENSG00000246560.2 RP11-10L12.4 7.04 2.43e-11 5.82e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799902 chr4:102828055~102844075:+ CESC cis rs228614 0.536 rs223418 ENSG00000246560.2 RP11-10L12.4 7.04 2.43e-11 5.82e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102809336 chr4:102828055~102844075:+ CESC cis rs9828933 0.577 rs704374 ENSG00000280620.1 SCAANT1 -7.04 2.45e-11 5.87e-08 -0.79 -0.43 Type 2 diabetes; chr3:63880271 chr3:63911518~63911772:- CESC cis rs6504950 0.83 rs17817877 ENSG00000275710.1 RP11-257O5.4 7.04 2.46e-11 5.89e-08 0.55 0.43 Breast cancer; chr17:54957267 chr17:54964474~54964679:+ CESC cis rs4423214 0.84 rs1792233 ENSG00000254682.1 RP11-660L16.2 -7.04 2.47e-11 5.9e-08 -0.57 -0.43 Vitamin D levels; chr11:71471133 chr11:71448674~71452157:+ CESC cis rs3096299 0.685 rs4785571 ENSG00000274627.1 RP11-104N10.2 7.04 2.47e-11 5.91e-08 0.42 0.43 Multiple myeloma (IgH translocation); chr16:89498761 chr16:89516797~89522217:+ CESC cis rs1577917 1 rs12203924 ENSG00000203875.9 SNHG5 -7.04 2.48e-11 5.92e-08 -0.54 -0.43 Response to antipsychotic treatment; chr6:86066694 chr6:85660950~85678736:- CESC cis rs10463554 0.857 rs34376 ENSG00000175749.11 EIF3KP1 7.04 2.48e-11 5.92e-08 0.47 0.43 Parkinson's disease; chr5:103065409 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34375 ENSG00000175749.11 EIF3KP1 7.04 2.48e-11 5.92e-08 0.47 0.43 Parkinson's disease; chr5:103065419 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs40061 ENSG00000175749.11 EIF3KP1 7.04 2.48e-11 5.92e-08 0.47 0.43 Parkinson's disease; chr5:103067412 chr5:103032376~103033031:+ CESC cis rs1707322 0.789 rs7540578 ENSG00000280836.1 AL355480.1 -7.04 2.48e-11 5.93e-08 -0.51 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45786472 chr1:45581219~45581321:- CESC cis rs7044106 0.708 rs2416760 ENSG00000226752.6 PSMD5-AS1 -7.04 2.48e-11 5.94e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120612361 chr9:120824828~120854385:+ CESC cis rs8081395 0.836 rs1295926 ENSG00000266992.1 DHX40P1 -7.04 2.5e-11 5.97e-08 -0.46 -0.43 White blood cell count; chr17:59832012 chr17:59976009~60002384:- CESC cis rs1577917 1 rs2324843 ENSG00000203875.9 SNHG5 -7.04 2.5e-11 5.98e-08 -0.56 -0.43 Response to antipsychotic treatment; chr6:85907783 chr6:85660950~85678736:- CESC cis rs6452524 0.618 rs1478487 ENSG00000249664.1 CTD-2227C6.2 7.04 2.51e-11 5.99e-08 0.48 0.43 Hypertension (SNP x SNP interaction); chr5:83080900 chr5:83012285~83013109:- CESC cis rs6991838 0.584 rs3765205 ENSG00000272010.1 CTD-3025N20.3 -7.03 2.55e-11 6.04e-08 -0.48 -0.43 Intelligence (multi-trait analysis); chr8:65605251 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs7841652 ENSG00000272010.1 CTD-3025N20.3 -7.03 2.55e-11 6.04e-08 -0.48 -0.43 Intelligence (multi-trait analysis); chr8:65606392 chr8:65591850~65592472:- CESC cis rs6991838 0.53 rs35038843 ENSG00000272010.1 CTD-3025N20.3 -7.03 2.55e-11 6.04e-08 -0.48 -0.43 Intelligence (multi-trait analysis); chr8:65610263 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs4737748 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65613630 chr8:65591850~65592472:- CESC cis rs6991838 0.55 rs12335006 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65619394 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs10957361 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65619626 chr8:65591850~65592472:- CESC cis rs6991838 0.612 rs12335276 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65619668 chr8:65591850~65592472:- CESC cis rs6991838 0.612 rs7832407 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65621071 chr8:65591850~65592472:- CESC cis rs6991838 0.551 rs7007505 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65621719 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs7012856 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65622740 chr8:65591850~65592472:- CESC cis rs6991838 0.55 rs7817112 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65624885 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs2048650 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65625664 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs4737749 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65627672 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs10092109 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65627683 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs6997959 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65628247 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs7814841 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65629328 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs11985628 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65630504 chr8:65591850~65592472:- CESC cis rs6991838 0.557 rs13266834 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65631303 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs13268343 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65631742 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs7835313 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65633891 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs3812412 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65634857 chr8:65591850~65592472:- CESC cis rs6991838 0.53 rs6472217 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65635496 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs6472218 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65635502 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs1533285 ENSG00000272010.1 CTD-3025N20.3 7.03 2.55e-11 6.04e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65637129 chr8:65591850~65592472:- CESC cis rs2404602 0.647 rs920712 ENSG00000259422.1 RP11-593F23.1 -7.03 2.55e-11 6.05e-08 -0.5 -0.43 Blood metabolite levels; chr15:76741593 chr15:76174891~76181486:- CESC cis rs3931020 0.772 rs1475396 ENSG00000272864.1 RP11-17E13.2 -7.03 2.57e-11 6.09e-08 -0.49 -0.43 Resistin levels; chr1:74776712 chr1:74698769~74699333:- CESC cis rs6452524 0.935 rs6880566 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83086909 chr5:83012285~83013109:- CESC cis rs6452524 0.905 rs6884981 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83087339 chr5:83012285~83013109:- CESC cis rs6452524 0.905 rs6896548 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83089247 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1580311 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83091667 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1382376 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83095418 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs12109517 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83095947 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs12109514 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83095965 chr5:83012285~83013109:- CESC cis rs6452524 0.901 rs17284211 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83098706 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1382374 ENSG00000249664.1 CTD-2227C6.2 7.03 2.58e-11 6.1e-08 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83101010 chr5:83012285~83013109:- CESC cis rs7044106 0.762 rs13291660 ENSG00000226752.6 PSMD5-AS1 -7.03 2.58e-11 6.1e-08 -0.48 -0.43 Hip circumference adjusted for BMI; chr9:120630470 chr9:120824828~120854385:+ CESC cis rs228614 0.536 rs223437 ENSG00000246560.2 RP11-10L12.4 7.03 2.61e-11 6.16e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798736 chr4:102828055~102844075:+ CESC cis rs7044106 0.791 rs4837792 ENSG00000226752.6 PSMD5-AS1 -7.03 2.62e-11 6.19e-08 -0.47 -0.43 Hip circumference adjusted for BMI; chr9:120721281 chr9:120824828~120854385:+ CESC cis rs17507216 0.671 rs4779035 ENSG00000278603.1 RP13-608F4.5 7.03 2.62e-11 6.19e-08 0.74 0.43 Excessive daytime sleepiness; chr15:82591686 chr15:82472203~82472426:+ CESC cis rs8081395 0.801 rs2777895 ENSG00000266992.1 DHX40P1 -7.03 2.63e-11 6.21e-08 -0.45 -0.43 White blood cell count; chr17:59802249 chr17:59976009~60002384:- CESC cis rs227275 0.556 rs3886723 ENSG00000246560.2 RP11-10L12.4 7.03 2.64e-11 6.23e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102983013 chr4:102828055~102844075:+ CESC cis rs6452524 0.868 rs10071617 ENSG00000249664.1 CTD-2227C6.2 7.03 2.64e-11 6.23e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83103207 chr5:83012285~83013109:- CESC cis rs35160687 0.862 rs17737955 ENSG00000273080.1 RP11-301O19.1 7.03 2.64e-11 6.23e-08 0.51 0.43 Night sleep phenotypes; chr2:86280891 chr2:86195590~86196049:+ CESC cis rs9549367 0.713 rs1323315 ENSG00000269125.1 RP11-98F14.11 7.03 2.65e-11 6.26e-08 0.53 0.43 Platelet distribution width; chr13:113205344 chr13:113165002~113165183:- CESC cis rs228614 0.536 rs223419 ENSG00000246560.2 RP11-10L12.4 7.03 2.69e-11 6.35e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102808586 chr4:102828055~102844075:+ CESC cis rs2404602 0.684 rs2454451 ENSG00000259422.1 RP11-593F23.1 7.02 2.7e-11 6.38e-08 0.49 0.43 Blood metabolite levels; chr15:76569120 chr15:76174891~76181486:- CESC cis rs1577917 0.876 rs12190735 ENSG00000203875.9 SNHG5 -7.02 2.71e-11 6.39e-08 -0.53 -0.43 Response to antipsychotic treatment; chr6:85976749 chr6:85660950~85678736:- CESC cis rs35955747 0.633 rs5998002 ENSG00000236132.1 CTA-440B3.1 7.02 2.72e-11 6.42e-08 0.51 0.43 Neutrophil count;Sum basophil neutrophil counts; chr22:31485183 chr22:31816379~31817491:- CESC cis rs113835537 0.529 rs11227500 ENSG00000255517.5 CTD-3074O7.5 -7.02 2.73e-11 6.43e-08 -0.48 -0.43 Airway imaging phenotypes; chr11:66505762 chr11:66473490~66480233:- CESC cis rs3806843 0.676 rs778591 ENSG00000202111.1 VTRNA1-2 7.02 2.76e-11 6.49e-08 0.47 0.43 Depressive symptoms (multi-trait analysis); chr5:140645899 chr5:140718925~140719013:+ CESC cis rs1577917 0.958 rs1335442 ENSG00000203875.9 SNHG5 -7.02 2.77e-11 6.51e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85756974 chr6:85660950~85678736:- CESC cis rs228614 0.51 rs3774987 ENSG00000246560.2 RP11-10L12.4 7.02 2.78e-11 6.53e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799709 chr4:102828055~102844075:+ CESC cis rs875971 0.825 rs1129531 ENSG00000226824.5 RP4-756H11.3 7.02 2.78e-11 6.54e-08 0.52 0.43 Aortic root size; chr7:66154117 chr7:66654538~66669855:+ CESC cis rs228614 0.51 rs223397 ENSG00000246560.2 RP11-10L12.4 7.02 2.79e-11 6.57e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102821494 chr4:102828055~102844075:+ CESC cis rs6504950 1 rs7221223 ENSG00000275710.1 RP11-257O5.4 7.02 2.8e-11 6.57e-08 0.56 0.43 Breast cancer; chr17:54981646 chr17:54964474~54964679:+ CESC cis rs1707322 0.963 rs10789478 ENSG00000280836.1 AL355480.1 -7.02 2.83e-11 6.64e-08 -0.51 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45884834 chr1:45581219~45581321:- CESC cis rs6504950 0.83 rs56175787 ENSG00000275710.1 RP11-257O5.4 7.02 2.84e-11 6.66e-08 0.53 0.43 Breast cancer; chr17:54940386 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs17817847 ENSG00000275710.1 RP11-257O5.4 7.02 2.84e-11 6.66e-08 0.53 0.43 Breast cancer; chr17:54940920 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs35097996 ENSG00000275710.1 RP11-257O5.4 7.02 2.84e-11 6.66e-08 0.53 0.43 Breast cancer; chr17:54944562 chr17:54964474~54964679:+ CESC cis rs6504950 0.79 rs8066833 ENSG00000275710.1 RP11-257O5.4 7.02 2.84e-11 6.66e-08 0.53 0.43 Breast cancer; chr17:54948114 chr17:54964474~54964679:+ CESC cis rs6504950 0.821 rs8066588 ENSG00000275710.1 RP11-257O5.4 7.02 2.84e-11 6.66e-08 0.53 0.43 Breast cancer; chr17:54948328 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs3087650 ENSG00000275710.1 RP11-257O5.4 7.02 2.84e-11 6.66e-08 0.53 0.43 Breast cancer; chr17:54951967 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs12937006 ENSG00000275710.1 RP11-257O5.4 7.02 2.84e-11 6.66e-08 0.53 0.43 Breast cancer; chr17:54953100 chr17:54964474~54964679:+ CESC cis rs2404602 0.735 rs2280306 ENSG00000259422.1 RP11-593F23.1 -7.02 2.85e-11 6.69e-08 -0.52 -0.43 Blood metabolite levels; chr15:76359917 chr15:76174891~76181486:- CESC cis rs11155671 0.53 rs9371542 ENSG00000231760.4 RP11-350J20.5 7.01 2.86e-11 6.7e-08 0.53 0.43 Testicular germ cell tumor; chr6:149891949 chr6:149796151~149826294:- CESC cis rs9322193 0.567 rs7747457 ENSG00000231760.4 RP11-350J20.5 7.01 2.86e-11 6.7e-08 0.53 0.43 Lung cancer; chr6:149892366 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs9371223 ENSG00000231760.4 RP11-350J20.5 7.01 2.86e-11 6.7e-08 0.53 0.43 Testicular germ cell tumor; chr6:149893670 chr6:149796151~149826294:- CESC cis rs228614 0.51 rs223435 ENSG00000246560.2 RP11-10L12.4 7.01 2.87e-11 6.72e-08 0.52 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799826 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs223426 ENSG00000246560.2 RP11-10L12.4 7.01 2.87e-11 6.72e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102801330 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223425 ENSG00000246560.2 RP11-10L12.4 7.01 2.87e-11 6.72e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102802836 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223316 ENSG00000246560.2 RP11-10L12.4 7.01 2.88e-11 6.73e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102881949 chr4:102828055~102844075:+ CESC cis rs14027 0.883 rs10102038 ENSG00000279347.1 RP11-85I17.2 -7.01 2.89e-11 6.75e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119702544 chr8:119838736~119840385:- CESC cis rs14027 0.883 rs35660840 ENSG00000279347.1 RP11-85I17.2 -7.01 2.89e-11 6.75e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119704351 chr8:119838736~119840385:- CESC cis rs14027 0.883 rs1433953 ENSG00000279347.1 RP11-85I17.2 -7.01 2.89e-11 6.75e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119704754 chr8:119838736~119840385:- CESC cis rs11155671 0.53 rs9371544 ENSG00000231760.4 RP11-350J20.5 7.01 2.91e-11 6.8e-08 0.53 0.43 Testicular germ cell tumor; chr6:149896224 chr6:149796151~149826294:- CESC cis rs1501911 0.53 rs331926 ENSG00000248489.1 CTD-2007H13.3 7.01 2.92e-11 6.83e-08 0.51 0.43 Lung function (FEV1/FVC); chr5:98828697 chr5:98929171~98995013:+ CESC cis rs6991838 0.55 rs4737750 ENSG00000272010.1 CTD-3025N20.3 7.01 2.94e-11 6.86e-08 0.48 0.43 Intelligence (multi-trait analysis); chr8:65638724 chr8:65591850~65592472:- CESC cis rs8062405 0.691 rs11646653 ENSG00000259982.1 CDC37P1 -7.01 2.94e-11 6.87e-08 -0.53 -0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910828 chr16:28700294~28701540:- CESC cis rs227275 0.525 rs13113923 ENSG00000246560.2 RP11-10L12.4 7.01 2.96e-11 6.9e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102918936 chr4:102828055~102844075:+ CESC cis rs3096299 0.685 rs4238830 ENSG00000274627.1 RP11-104N10.2 7.01 2.96e-11 6.91e-08 0.42 0.43 Multiple myeloma (IgH translocation); chr16:89473833 chr16:89516797~89522217:+ CESC cis rs3096299 0.754 rs2965816 ENSG00000274627.1 RP11-104N10.2 -7.01 2.98e-11 6.96e-08 -0.41 -0.43 Multiple myeloma (IgH translocation); chr16:89447775 chr16:89516797~89522217:+ CESC cis rs150992 0.592 rs10038192 ENSG00000248489.1 CTD-2007H13.3 7.01 2.99e-11 6.97e-08 0.52 0.43 Body mass index; chr5:98989755 chr5:98929171~98995013:+ CESC cis rs150992 0.571 rs10045959 ENSG00000248489.1 CTD-2007H13.3 7.01 2.99e-11 6.97e-08 0.52 0.43 Body mass index; chr5:98989767 chr5:98929171~98995013:+ CESC cis rs150992 0.571 rs10037147 ENSG00000248489.1 CTD-2007H13.3 7.01 2.99e-11 6.97e-08 0.52 0.43 Body mass index; chr5:98989768 chr5:98929171~98995013:+ CESC cis rs977987 0.843 rs4888372 ENSG00000261783.1 RP11-252K23.2 -7.01 3e-11 6.99e-08 -0.53 -0.43 Dupuytren's disease; chr16:75279587 chr16:75379818~75381260:- CESC cis rs150992 0.711 rs1069182 ENSG00000248489.1 CTD-2007H13.3 -7.01 3.02e-11 7.03e-08 -0.52 -0.43 Body mass index; chr5:98806512 chr5:98929171~98995013:+ CESC cis rs150992 0.673 rs992773 ENSG00000248489.1 CTD-2007H13.3 -7.01 3.02e-11 7.03e-08 -0.52 -0.43 Body mass index; chr5:98808169 chr5:98929171~98995013:+ CESC cis rs113835537 0.529 rs2277302 ENSG00000255517.5 CTD-3074O7.5 -7 3.05e-11 7.1e-08 -0.47 -0.43 Airway imaging phenotypes; chr11:66473411 chr11:66473490~66480233:- CESC cis rs227275 0.554 rs223485 ENSG00000246560.2 RP11-10L12.4 7 3.06e-11 7.11e-08 0.52 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102764018 chr4:102828055~102844075:+ CESC cis rs7849270 1 rs7855278 ENSG00000268707.1 RP11-247A12.7 7 3.06e-11 7.11e-08 0.52 0.43 Blood metabolite ratios; chr9:129159086 chr9:129170434~129170940:+ CESC cis rs14027 0.883 rs10087723 ENSG00000279347.1 RP11-85I17.2 -7 3.07e-11 7.13e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119711014 chr8:119838736~119840385:- CESC cis rs2404602 0.647 rs907594 ENSG00000259422.1 RP11-593F23.1 -7 3.08e-11 7.15e-08 -0.5 -0.43 Blood metabolite levels; chr15:76905404 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs10152247 ENSG00000259422.1 RP11-593F23.1 -7 3.09e-11 7.17e-08 -0.51 -0.43 Blood metabolite levels; chr15:76649911 chr15:76174891~76181486:- CESC cis rs6452524 0.935 rs10076059 ENSG00000249664.1 CTD-2227C6.2 7 3.09e-11 7.18e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83105698 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs7736783 ENSG00000249664.1 CTD-2227C6.2 7 3.09e-11 7.18e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83107050 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs11951257 ENSG00000249664.1 CTD-2227C6.2 7 3.09e-11 7.18e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83107492 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs767771 ENSG00000249664.1 CTD-2227C6.2 7 3.09e-11 7.18e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83108117 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1542539 ENSG00000249664.1 CTD-2227C6.2 7 3.09e-11 7.18e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83116033 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1543847 ENSG00000249664.1 CTD-2227C6.2 7 3.09e-11 7.18e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83116044 chr5:83012285~83013109:- CESC cis rs6504950 0.705 rs9899545 ENSG00000275710.1 RP11-257O5.4 7 3.1e-11 7.18e-08 0.52 0.43 Breast cancer; chr17:54909484 chr17:54964474~54964679:+ CESC cis rs7849270 1 rs1107328 ENSG00000268707.1 RP11-247A12.7 7 3.1e-11 7.18e-08 0.55 0.43 Blood metabolite ratios; chr9:129155255 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs9697030 ENSG00000268707.1 RP11-247A12.7 -7 3.1e-11 7.19e-08 -0.53 -0.43 Blood metabolite ratios; chr9:129157902 chr9:129170434~129170940:+ CESC cis rs1707322 0.963 rs10890373 ENSG00000280836.1 AL355480.1 -7 3.1e-11 7.19e-08 -0.51 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45928083 chr1:45581219~45581321:- CESC cis rs7044106 0.664 rs7861679 ENSG00000226752.6 PSMD5-AS1 7 3.11e-11 7.2e-08 0.46 0.43 Hip circumference adjusted for BMI; chr9:120613311 chr9:120824828~120854385:+ CESC cis rs11722779 0.815 rs223347 ENSG00000246560.2 RP11-10L12.4 7 3.12e-11 7.23e-08 0.52 0.43 Schizophrenia; chr4:102858815 chr4:102828055~102844075:+ CESC cis rs2882667 0.66 rs6894907 ENSG00000253404.1 AC034243.1 7 3.12e-11 7.23e-08 0.48 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139106815 chr5:138744434~138753309:- CESC cis rs2284378 0.515 rs6059579 ENSG00000276073.1 RP5-1125A11.7 -7 3.12e-11 7.24e-08 -0.39 -0.43 Breast cancer; chr20:33940059 chr20:33985617~33988989:- CESC cis rs14027 0.883 rs13272852 ENSG00000279347.1 RP11-85I17.2 -7 3.14e-11 7.26e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119712921 chr8:119838736~119840385:- CESC cis rs7849270 0.959 rs2297111 ENSG00000268707.1 RP11-247A12.7 -7 3.14e-11 7.28e-08 -0.5 -0.43 Blood metabolite ratios; chr9:129142015 chr9:129170434~129170940:+ CESC cis rs2739330 0.791 rs4822458 ENSG00000231271.1 AP000350.8 7 3.16e-11 7.32e-08 0.52 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23949918~23954042:+ CESC cis rs10463554 0.927 rs158396 ENSG00000175749.11 EIF3KP1 7 3.17e-11 7.34e-08 0.46 0.43 Parkinson's disease; chr5:103076015 chr5:103032376~103033031:+ CESC cis rs7208859 0.673 rs216424 ENSG00000263531.1 RP13-753N3.1 7 3.18e-11 7.36e-08 0.79 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30616046 chr17:30863921~30864940:- CESC cis rs3096299 0.658 rs3934737 ENSG00000274627.1 RP11-104N10.2 7 3.19e-11 7.38e-08 0.43 0.43 Multiple myeloma (IgH translocation); chr16:89493801 chr16:89516797~89522217:+ CESC cis rs1799949 0.965 rs8176310 ENSG00000198496.9 NBR2 -6.99 3.21e-11 7.42e-08 -0.51 -0.43 Menopause (age at onset); chr17:43047896 chr17:43125610~43153671:+ CESC cis rs1799949 0.965 rs8070179 ENSG00000198496.9 NBR2 -6.99 3.21e-11 7.42e-08 -0.51 -0.43 Menopause (age at onset); chr17:43050671 chr17:43125610~43153671:+ CESC cis rs1577917 0.958 rs13213899 ENSG00000203875.9 SNHG5 -6.99 3.22e-11 7.42e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85763422 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs10806337 ENSG00000203875.9 SNHG5 -6.99 3.22e-11 7.42e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85764531 chr6:85660950~85678736:- CESC cis rs1577917 1 rs1577919 ENSG00000203875.9 SNHG5 -6.99 3.24e-11 7.48e-08 -0.54 -0.43 Response to antipsychotic treatment; chr6:86047578 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12203493 ENSG00000203875.9 SNHG5 -6.99 3.24e-11 7.48e-08 -0.54 -0.43 Response to antipsychotic treatment; chr6:86048924 chr6:85660950~85678736:- CESC cis rs14027 0.921 rs13261032 ENSG00000279347.1 RP11-85I17.2 -6.99 3.25e-11 7.49e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119733117 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs2048239 ENSG00000279347.1 RP11-85I17.2 -6.99 3.25e-11 7.49e-08 -0.42 -0.43 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119735701 chr8:119838736~119840385:- CESC cis rs10463554 0.927 rs34831 ENSG00000175749.11 EIF3KP1 6.99 3.32e-11 7.65e-08 0.48 0.43 Parkinson's disease; chr5:103108385 chr5:103032376~103033031:+ CESC cis rs3806843 0.9 rs2337984 ENSG00000202111.1 VTRNA1-2 6.99 3.33e-11 7.67e-08 0.44 0.43 Depressive symptoms (multi-trait analysis); chr5:140757226 chr5:140718925~140719013:+ CESC cis rs7617773 0.817 rs9847953 ENSG00000229759.1 MRPS18AP1 6.99 3.33e-11 7.68e-08 0.44 0.43 Coronary artery disease; chr3:48241205 chr3:48256350~48256938:- CESC cis rs7626444 0.626 rs5021325 ENSG00000272359.1 U4 -6.99 3.35e-11 7.72e-08 -0.5 -0.43 Monocyte count; chr3:196750758 chr3:196747192~196747324:- CESC cis rs1823913 0.927 rs13013390 ENSG00000280083.1 RP11-317J9.1 -6.99 3.37e-11 7.75e-08 -0.49 -0.43 Obesity-related traits; chr2:191262001 chr2:191154118~191156070:- CESC cis rs10129255 0.5 rs2027903 ENSG00000223648.3 IGHV3-64 6.99 3.37e-11 7.75e-08 0.35 0.43 Kawasaki disease; chr14:106807047 chr14:106643132~106658258:- CESC cis rs7674212 0.531 rs2866416 ENSG00000246560.2 RP11-10L12.4 6.99 3.39e-11 7.81e-08 0.55 0.43 Type 2 diabetes; chr4:102959554 chr4:102828055~102844075:+ CESC cis rs6991838 0.584 rs7823840 ENSG00000272010.1 CTD-3025N20.3 -6.99 3.4e-11 7.82e-08 -0.48 -0.43 Intelligence (multi-trait analysis); chr8:65606766 chr8:65591850~65592472:- CESC cis rs10463554 0.927 rs158250 ENSG00000175749.11 EIF3KP1 6.98 3.42e-11 7.85e-08 0.46 0.43 Parkinson's disease; chr5:103071075 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs464702 ENSG00000175749.11 EIF3KP1 6.98 3.42e-11 7.85e-08 0.46 0.43 Parkinson's disease; chr5:103071180 chr5:103032376~103033031:+ CESC cis rs227275 0.554 rs223363 ENSG00000246560.2 RP11-10L12.4 6.98 3.44e-11 7.91e-08 0.51 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102846182 chr4:102828055~102844075:+ CESC cis rs1062177 0.826 rs2915879 ENSG00000213433.5 RPLP1P6 -6.98 3.45e-11 7.92e-08 -0.5 -0.43 Preschool internalizing problems; chr5:151767881 chr5:151765859~151766378:- CESC cis rs7208859 0.673 rs2470251 ENSG00000263531.1 RP13-753N3.1 6.98 3.45e-11 7.93e-08 0.69 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30863921~30864940:- CESC cis rs1577917 0.876 rs66986937 ENSG00000203875.9 SNHG5 -6.98 3.46e-11 7.94e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85822473 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs10944144 ENSG00000203875.9 SNHG5 -6.98 3.46e-11 7.94e-08 -0.55 -0.43 Response to antipsychotic treatment; chr6:85828037 chr6:85660950~85678736:- CESC cis rs10463554 0.824 rs427430 ENSG00000175749.11 EIF3KP1 6.98 3.46e-11 7.94e-08 0.48 0.43 Parkinson's disease; chr5:103096320 chr5:103032376~103033031:+ CESC cis rs4423214 0.65 rs2186777 ENSG00000254682.1 RP11-660L16.2 6.98 3.47e-11 7.98e-08 0.59 0.43 Vitamin D levels; chr11:71508757 chr11:71448674~71452157:+ CESC cis rs7617773 0.78 rs6442111 ENSG00000229759.1 MRPS18AP1 6.98 3.48e-11 7.98e-08 0.46 0.43 Coronary artery disease; chr3:48270570 chr3:48256350~48256938:- CESC cis rs7617773 0.851 rs6775179 ENSG00000229759.1 MRPS18AP1 6.98 3.48e-11 7.98e-08 0.46 0.43 Coronary artery disease; chr3:48271928 chr3:48256350~48256938:- CESC cis rs35955747 0.633 rs7287937 ENSG00000236132.1 CTA-440B3.1 6.98 3.48e-11 8e-08 0.51 0.43 Neutrophil count;Sum basophil neutrophil counts; chr22:31624759 chr22:31816379~31817491:- CESC cis rs9549367 0.601 rs558869 ENSG00000269125.1 RP11-98F14.11 6.98 3.49e-11 8e-08 0.54 0.43 Platelet distribution width; chr13:113195618 chr13:113165002~113165183:- CESC cis rs7688014 1 rs7688014 ENSG00000246560.2 RP11-10L12.4 6.98 3.5e-11 8.04e-08 0.54 0.43 Schizophrenia; chr4:103053903 chr4:102828055~102844075:+ CESC cis rs113835537 0.529 rs11227503 ENSG00000255517.5 CTD-3074O7.5 -6.98 3.52e-11 8.06e-08 -0.48 -0.43 Airway imaging phenotypes; chr11:66507771 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs4542420 ENSG00000255517.5 CTD-3074O7.5 -6.98 3.52e-11 8.06e-08 -0.48 -0.43 Airway imaging phenotypes; chr11:66510139 chr11:66473490~66480233:- CESC cis rs1577917 0.958 rs2225754 ENSG00000203875.9 SNHG5 -6.98 3.53e-11 8.1e-08 -0.54 -0.43 Response to antipsychotic treatment; chr6:85739980 chr6:85660950~85678736:- CESC cis rs2177312 0.596 rs13108845 ENSG00000251129.1 RP11-734I18.1 -6.98 3.54e-11 8.1e-08 -0.57 -0.43 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31995660 chr4:31997397~32155406:+ CESC cis rs7674212 0.507 rs10516495 ENSG00000246560.2 RP11-10L12.4 6.98 3.54e-11 8.11e-08 0.54 0.43 Type 2 diabetes; chr4:102978933 chr4:102828055~102844075:+ CESC cis rs2404602 0.583 rs35707798 ENSG00000259422.1 RP11-593F23.1 6.98 3.56e-11 8.16e-08 0.47 0.43 Blood metabolite levels; chr15:76272685 chr15:76174891~76181486:- CESC cis rs8081395 0.801 rs2645479 ENSG00000266992.1 DHX40P1 6.98 3.58e-11 8.19e-08 0.46 0.43 White blood cell count; chr17:59843171 chr17:59976009~60002384:- CESC cis rs35955747 0.738 rs2012451 ENSG00000236132.1 CTA-440B3.1 6.97 3.62e-11 8.28e-08 0.5 0.43 Neutrophil count;Sum basophil neutrophil counts; chr22:31448387 chr22:31816379~31817491:- CESC cis rs875971 0.862 rs4149461 ENSG00000226824.5 RP4-756H11.3 6.97 3.65e-11 8.34e-08 0.52 0.43 Aortic root size; chr7:66279745 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs10261398 ENSG00000226824.5 RP4-756H11.3 6.97 3.65e-11 8.34e-08 0.52 0.43 Aortic root size; chr7:66285177 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs10224872 ENSG00000226824.5 RP4-756H11.3 6.97 3.65e-11 8.34e-08 0.52 0.43 Aortic root size; chr7:66294786 chr7:66654538~66669855:+ CESC cis rs10256972 0.521 rs7811577 ENSG00000229043.2 AC091729.9 -6.97 3.65e-11 8.35e-08 -0.48 -0.43 Endometriosis;Longevity; chr7:1063193 chr7:1160374~1165267:+ CESC cis rs2404602 0.583 rs12907668 ENSG00000259422.1 RP11-593F23.1 6.97 3.66e-11 8.37e-08 0.48 0.43 Blood metabolite levels; chr15:76297426 chr15:76174891~76181486:- CESC cis rs10463554 0.927 rs34821 ENSG00000175749.11 EIF3KP1 6.97 3.69e-11 8.42e-08 0.48 0.43 Parkinson's disease; chr5:103101913 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34824 ENSG00000175749.11 EIF3KP1 6.97 3.69e-11 8.42e-08 0.48 0.43 Parkinson's disease; chr5:103103227 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34825 ENSG00000175749.11 EIF3KP1 6.97 3.69e-11 8.42e-08 0.48 0.43 Parkinson's disease; chr5:103103614 chr5:103032376~103033031:+ CESC cis rs2739330 0.627 rs9608219 ENSG00000231271.1 AP000350.8 6.97 3.72e-11 8.5e-08 0.52 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23949918~23954042:+ CESC cis rs11722779 0.838 rs4533776 ENSG00000246560.2 RP11-10L12.4 6.97 3.72e-11 8.5e-08 0.51 0.43 Schizophrenia; chr4:102912732 chr4:102828055~102844075:+ CESC cis rs228614 0.514 rs59550147 ENSG00000246560.2 RP11-10L12.4 6.97 3.72e-11 8.5e-08 0.51 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102914239 chr4:102828055~102844075:+ CESC cis rs1577917 0.958 rs11755642 ENSG00000203875.9 SNHG5 -6.97 3.73e-11 8.52e-08 -0.54 -0.43 Response to antipsychotic treatment; chr6:85740348 chr6:85660950~85678736:- CESC cis rs113835537 0.529 rs11227509 ENSG00000255517.5 CTD-3074O7.5 -6.97 3.76e-11 8.57e-08 -0.49 -0.43 Airway imaging phenotypes; chr11:66513723 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs11227510 ENSG00000255517.5 CTD-3074O7.5 -6.97 3.76e-11 8.57e-08 -0.49 -0.43 Airway imaging phenotypes; chr11:66513749 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs11227512 ENSG00000255517.5 CTD-3074O7.5 -6.97 3.76e-11 8.57e-08 -0.49 -0.43 Airway imaging phenotypes; chr11:66513820 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs2298806 ENSG00000255517.5 CTD-3074O7.5 -6.97 3.76e-11 8.57e-08 -0.49 -0.43 Airway imaging phenotypes; chr11:66514624 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs2276406 ENSG00000255517.5 CTD-3074O7.5 -6.97 3.76e-11 8.57e-08 -0.49 -0.43 Airway imaging phenotypes; chr11:66515786 chr11:66473490~66480233:- CESC cis rs11155671 0.53 rs1334510 ENSG00000268592.3 RAET1E-AS1 6.97 3.77e-11 8.6e-08 0.55 0.43 Testicular germ cell tumor; chr6:149880043 chr6:149863494~149919507:+ CESC cis rs6504950 0.8 rs35647022 ENSG00000275710.1 RP11-257O5.4 6.97 3.77e-11 8.61e-08 0.55 0.43 Breast cancer; chr17:54930710 chr17:54964474~54964679:+ CESC cis rs6504950 0.83 rs8073158 ENSG00000275710.1 RP11-257O5.4 6.97 3.78e-11 8.63e-08 0.52 0.43 Breast cancer; chr17:54951254 chr17:54964474~54964679:+ CESC cis rs6452524 0.901 rs1600362 ENSG00000249664.1 CTD-2227C6.2 6.97 3.79e-11 8.65e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83091354 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1580310 ENSG00000249664.1 CTD-2227C6.2 6.97 3.79e-11 8.65e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83091792 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1011979 ENSG00000249664.1 CTD-2227C6.2 6.97 3.79e-11 8.65e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83097431 chr5:83012285~83013109:- CESC cis rs10463554 0.927 rs468844 ENSG00000175749.11 EIF3KP1 6.97 3.79e-11 8.65e-08 0.48 0.43 Parkinson's disease; chr5:103087872 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs469094 ENSG00000175749.11 EIF3KP1 6.97 3.79e-11 8.65e-08 0.48 0.43 Parkinson's disease; chr5:103087875 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34795 ENSG00000175749.11 EIF3KP1 6.97 3.79e-11 8.65e-08 0.48 0.43 Parkinson's disease; chr5:103088716 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs34796 ENSG00000175749.11 EIF3KP1 6.97 3.79e-11 8.65e-08 0.48 0.43 Parkinson's disease; chr5:103088725 chr5:103032376~103033031:+ CESC cis rs6504950 0.705 rs9899602 ENSG00000275710.1 RP11-257O5.4 -6.97 3.8e-11 8.66e-08 -0.51 -0.43 Breast cancer; chr17:54909547 chr17:54964474~54964679:+ CESC cis rs35160687 0.829 rs13017143 ENSG00000273080.1 RP11-301O19.1 -6.97 3.81e-11 8.69e-08 -0.5 -0.43 Night sleep phenotypes; chr2:86239426 chr2:86195590~86196049:+ CESC cis rs11155671 0.53 rs9371215 ENSG00000216906.2 RP11-350J20.9 6.97 3.81e-11 8.69e-08 0.47 0.43 Testicular germ cell tumor; chr6:149873162 chr6:149904243~149906418:+ CESC cis rs7849270 0.921 rs7868476 ENSG00000268707.1 RP11-247A12.7 -6.96 3.83e-11 8.71e-08 -0.53 -0.43 Blood metabolite ratios; chr9:129155854 chr9:129170434~129170940:+ CESC cis rs7849270 0.959 rs2094704 ENSG00000268707.1 RP11-247A12.7 -6.96 3.83e-11 8.71e-08 -0.53 -0.43 Blood metabolite ratios; chr9:129156015 chr9:129170434~129170940:+ CESC cis rs1707322 0.656 rs3014210 ENSG00000281133.1 AL355480.3 6.96 3.86e-11 8.78e-08 0.51 0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45600936 chr1:45580892~45580996:- CESC cis rs4853012 0.838 rs72915068 ENSG00000257800.1 FNBP1P1 6.96 3.87e-11 8.8e-08 0.45 0.43 Gestational age at birth (maternal effect); chr2:74129058 chr2:74120680~74123218:+ CESC cis rs7849270 1 rs10988224 ENSG00000268707.1 RP11-247A12.7 -6.96 3.88e-11 8.83e-08 -0.5 -0.43 Blood metabolite ratios; chr9:129141055 chr9:129170434~129170940:+ CESC cis rs1075265 0.633 rs7591431 ENSG00000233266.1 HMGB1P31 6.96 3.88e-11 8.83e-08 0.6 0.43 Chronotype;Morning vs. evening chronotype; chr2:53995028 chr2:54051334~54051760:+ CESC cis rs2404602 0.532 rs744336 ENSG00000259422.1 RP11-593F23.1 6.96 3.89e-11 8.85e-08 0.47 0.43 Blood metabolite levels; chr15:76382283 chr15:76174891~76181486:- CESC cis rs6504950 0.76 rs7214573 ENSG00000275710.1 RP11-257O5.4 6.96 3.89e-11 8.85e-08 0.54 0.43 Breast cancer; chr17:54929293 chr17:54964474~54964679:+ CESC cis rs1707322 0.963 rs6429581 ENSG00000280836.1 AL355480.1 -6.96 3.9e-11 8.87e-08 -0.51 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853424 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs12145287 ENSG00000280836.1 AL355480.1 -6.96 3.9e-11 8.87e-08 -0.51 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45859330 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10789479 ENSG00000280836.1 AL355480.1 -6.96 3.9e-11 8.87e-08 -0.51 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45886828 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs7512395 ENSG00000280836.1 AL355480.1 -6.96 3.9e-11 8.87e-08 -0.51 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45895505 chr1:45581219~45581321:- CESC cis rs6504950 0.76 rs17745189 ENSG00000275710.1 RP11-257O5.4 6.96 3.94e-11 8.96e-08 0.54 0.43 Breast cancer; chr17:54936619 chr17:54964474~54964679:+ CESC cis rs916888 0.61 rs199530 ENSG00000214401.4 KANSL1-AS1 -6.96 3.95e-11 8.97e-08 -0.51 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46193576~46196723:+ CESC cis rs1501911 0.509 rs330422 ENSG00000248489.1 CTD-2007H13.3 6.96 3.99e-11 9.06e-08 0.5 0.43 Lung function (FEV1/FVC); chr5:98859184 chr5:98929171~98995013:+ CESC cis rs2739330 0.703 rs5760112 ENSG00000231271.1 AP000350.8 6.96 4.03e-11 9.14e-08 0.52 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23949918~23954042:+ CESC cis rs3931020 0.745 rs1980851 ENSG00000272864.1 RP11-17E13.2 -6.95 4.05e-11 9.2e-08 -0.51 -0.43 Resistin levels; chr1:74803287 chr1:74698769~74699333:- CESC cis rs113835537 0.529 rs17580784 ENSG00000255517.5 CTD-3074O7.5 -6.95 4.06e-11 9.22e-08 -0.51 -0.43 Airway imaging phenotypes; chr11:66447388 chr11:66473490~66480233:- CESC cis rs228614 0.51 rs223470 ENSG00000246560.2 RP11-10L12.4 6.95 4.07e-11 9.24e-08 0.51 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102778004 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223468 ENSG00000246560.2 RP11-10L12.4 6.95 4.07e-11 9.24e-08 0.51 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102779265 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223465 ENSG00000246560.2 RP11-10L12.4 6.95 4.07e-11 9.24e-08 0.51 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780174 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223464 ENSG00000246560.2 RP11-10L12.4 6.95 4.07e-11 9.24e-08 0.51 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780603 chr4:102828055~102844075:+ CESC cis rs227275 0.531 rs223460 ENSG00000246560.2 RP11-10L12.4 6.95 4.07e-11 9.24e-08 0.51 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102782903 chr4:102828055~102844075:+ CESC cis rs7617773 0.817 rs11710861 ENSG00000229759.1 MRPS18AP1 6.95 4.11e-11 9.3e-08 0.45 0.43 Coronary artery disease; chr3:48256070 chr3:48256350~48256938:- CESC cis rs10256972 0.521 rs10280960 ENSG00000229043.2 AC091729.9 -6.95 4.14e-11 9.38e-08 -0.47 -0.43 Endometriosis;Longevity; chr7:1064061 chr7:1160374~1165267:+ CESC cis rs6452524 0.935 rs10045744 ENSG00000249664.1 CTD-2227C6.2 6.95 4.16e-11 9.41e-08 0.46 0.43 Hypertension (SNP x SNP interaction); chr5:83113688 chr5:83012285~83013109:- CESC cis rs228614 0.51 rs170565 ENSG00000246560.2 RP11-10L12.4 6.95 4.21e-11 9.52e-08 0.51 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798277 chr4:102828055~102844075:+ CESC cis rs113835537 0.529 rs10501397 ENSG00000255517.5 CTD-3074O7.5 -6.95 4.25e-11 9.6e-08 -0.47 -0.43 Airway imaging phenotypes; chr11:66505505 chr11:66473490~66480233:- CESC cis rs2739330 0.791 rs9612520 ENSG00000231271.1 AP000350.8 6.95 4.26e-11 9.61e-08 0.52 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23949918~23954042:+ CESC cis rs35160687 0.64 rs13015186 ENSG00000273080.1 RP11-301O19.1 6.94 4.31e-11 9.73e-08 0.51 0.43 Night sleep phenotypes; chr2:86258455 chr2:86195590~86196049:+ CESC cis rs227275 0.525 rs7685399 ENSG00000246560.2 RP11-10L12.4 6.94 4.34e-11 9.79e-08 0.51 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102991926 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs2866417 ENSG00000246560.2 RP11-10L12.4 6.94 4.34e-11 9.79e-08 0.51 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102993481 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs1383733 ENSG00000246560.2 RP11-10L12.4 6.94 4.34e-11 9.79e-08 0.51 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102995297 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs4623004 ENSG00000246560.2 RP11-10L12.4 6.94 4.34e-11 9.79e-08 0.51 0.43 Allergic disease (asthma, hay fever or eczema); chr4:103000141 chr4:102828055~102844075:+ CESC cis rs10463554 0.892 rs32842 ENSG00000175749.11 EIF3KP1 6.94 4.34e-11 9.8e-08 0.47 0.43 Parkinson's disease; chr5:103142298 chr5:103032376~103033031:+ CESC cis rs916888 0.779 rs199498 ENSG00000214401.4 KANSL1-AS1 6.94 4.45e-11 1e-07 0.55 0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46193576~46196723:+ CESC cis rs113835537 0.529 rs11227511 ENSG00000255517.5 CTD-3074O7.5 -6.94 4.45e-11 1e-07 -0.48 -0.43 Airway imaging phenotypes; chr11:66513773 chr11:66473490~66480233:- CESC cis rs1577917 0.959 rs16876540 ENSG00000203875.9 SNHG5 -6.94 4.45e-11 1e-07 -0.55 -0.43 Response to antipsychotic treatment; chr6:85902801 chr6:85660950~85678736:- CESC cis rs5769707 0.732 rs135865 ENSG00000188511.11 C22orf34 6.94 4.47e-11 1e-07 0.45 0.43 Monocyte percentage of white cells;Monocyte count; chr22:49611181 chr22:49414524~49657542:- CESC cis rs113835537 0.529 rs11227502 ENSG00000255517.5 CTD-3074O7.5 -6.94 4.47e-11 1.01e-07 -0.48 -0.43 Airway imaging phenotypes; chr11:66506677 chr11:66473490~66480233:- CESC cis rs11722779 0.869 rs223323 ENSG00000246560.2 RP11-10L12.4 6.94 4.48e-11 1.01e-07 0.52 0.43 Schizophrenia; chr4:102878412 chr4:102828055~102844075:+ CESC cis rs6964833 0.935 rs35735900 ENSG00000123965.13 PMS2P5 6.94 4.51e-11 1.01e-07 0.66 0.43 Menarche (age at onset); chr7:74651887 chr7:74894116~74897835:+ CESC cis rs6964833 0.872 rs4717903 ENSG00000123965.13 PMS2P5 6.94 4.51e-11 1.01e-07 0.66 0.43 Menarche (age at onset); chr7:74653827 chr7:74894116~74897835:+ CESC cis rs6964833 1 rs4717906 ENSG00000123965.13 PMS2P5 6.94 4.51e-11 1.01e-07 0.66 0.43 Menarche (age at onset); chr7:74671923 chr7:74894116~74897835:+ CESC cis rs3806843 0.676 rs778593 ENSG00000202111.1 VTRNA1-2 6.94 4.52e-11 1.01e-07 0.45 0.43 Depressive symptoms (multi-trait analysis); chr5:140647631 chr5:140718925~140719013:+ CESC cis rs7208859 0.673 rs11652370 ENSG00000263531.1 RP13-753N3.1 6.94 4.52e-11 1.01e-07 0.69 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770205 chr17:30863921~30864940:- CESC cis rs9322193 0.607 rs9322229 ENSG00000231760.4 RP11-350J20.5 6.93 4.56e-11 1.02e-07 0.61 0.43 Lung cancer; chr6:149908949 chr6:149796151~149826294:- CESC cis rs6452524 0.901 rs1580309 ENSG00000249664.1 CTD-2227C6.2 6.93 4.56e-11 1.02e-07 0.47 0.43 Hypertension (SNP x SNP interaction); chr5:83091948 chr5:83012285~83013109:- CESC cis rs10875746 0.855 rs10875731 ENSG00000240399.1 RP1-228P16.1 -6.93 4.57e-11 1.02e-07 -0.56 -0.43 Longevity (90 years and older); chr12:48038960 chr12:48054813~48055591:- CESC cis rs228614 0.51 rs223453 ENSG00000246560.2 RP11-10L12.4 6.93 4.58e-11 1.03e-07 0.51 0.43 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789895 chr4:102828055~102844075:+ CESC cis rs2404602 0.583 rs3759853 ENSG00000259422.1 RP11-593F23.1 6.93 4.61e-11 1.03e-07 0.48 0.43 Blood metabolite levels; chr15:76295436 chr15:76174891~76181486:- CESC cis rs35160687 0.862 rs12476706 ENSG00000273080.1 RP11-301O19.1 6.93 4.65e-11 1.04e-07 0.51 0.42 Night sleep phenotypes; chr2:86301247 chr2:86195590~86196049:+ CESC cis rs3096299 0.685 rs8050512 ENSG00000274627.1 RP11-104N10.2 6.93 4.65e-11 1.04e-07 0.41 0.42 Multiple myeloma (IgH translocation); chr16:89485912 chr16:89516797~89522217:+ CESC cis rs7044106 0.762 rs10739570 ENSG00000226752.6 PSMD5-AS1 -6.93 4.66e-11 1.04e-07 -0.47 -0.42 Hip circumference adjusted for BMI; chr9:120618944 chr9:120824828~120854385:+ CESC cis rs1577917 1 rs1415753 ENSG00000203875.9 SNHG5 -6.93 4.68e-11 1.05e-07 -0.54 -0.42 Response to antipsychotic treatment; chr6:86043356 chr6:85660950~85678736:- CESC cis rs227275 0.554 rs223314 ENSG00000246560.2 RP11-10L12.4 6.93 4.68e-11 1.05e-07 0.52 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102884642 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs7254 ENSG00000246560.2 RP11-10L12.4 6.93 4.68e-11 1.05e-07 0.52 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888488 chr4:102828055~102844075:+ CESC cis rs11722779 0.566 rs6822658 ENSG00000246560.2 RP11-10L12.4 6.93 4.68e-11 1.05e-07 0.52 0.42 Schizophrenia; chr4:102891964 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs6823625 ENSG00000246560.2 RP11-10L12.4 6.93 4.68e-11 1.05e-07 0.52 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892437 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs6846762 ENSG00000246560.2 RP11-10L12.4 6.93 4.68e-11 1.05e-07 0.52 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892577 chr4:102828055~102844075:+ CESC cis rs228614 0.536 rs223420 ENSG00000246560.2 RP11-10L12.4 6.93 4.68e-11 1.05e-07 0.52 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102806853 chr4:102828055~102844075:+ CESC cis rs10262624 0.504 rs4722255 ENSG00000234286.1 AC006026.13 -6.93 4.71e-11 1.05e-07 -0.43 -0.42 Schizophrenia; chr7:23706453 chr7:23680195~23680786:- CESC cis rs35955747 0.677 rs4820974 ENSG00000236132.1 CTA-440B3.1 6.93 4.72e-11 1.06e-07 0.51 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31473481 chr22:31816379~31817491:- CESC cis rs113835537 0.559 rs74933537 ENSG00000255517.5 CTD-3074O7.5 -6.93 4.72e-11 1.06e-07 -0.49 -0.42 Airway imaging phenotypes; chr11:66507487 chr11:66473490~66480233:- CESC cis rs4853012 0.838 rs12619982 ENSG00000257800.1 FNBP1P1 6.93 4.73e-11 1.06e-07 0.46 0.42 Gestational age at birth (maternal effect); chr2:74128895 chr2:74120680~74123218:+ CESC cis rs7727544 0.684 rs2631363 ENSG00000233006.5 AC034220.3 -6.93 4.77e-11 1.07e-07 -0.47 -0.42 Blood metabolite levels; chr5:132371403 chr5:132311285~132369916:- CESC cis rs7727544 0.66 rs2631361 ENSG00000233006.5 AC034220.3 -6.93 4.77e-11 1.07e-07 -0.47 -0.42 Blood metabolite levels; chr5:132371688 chr5:132311285~132369916:- CESC cis rs150992 0.751 rs172874 ENSG00000248489.1 CTD-2007H13.3 6.93 4.79e-11 1.07e-07 0.51 0.42 Body mass index; chr5:98969402 chr5:98929171~98995013:+ CESC cis rs6452524 0.934 rs12153440 ENSG00000249664.1 CTD-2227C6.2 6.93 4.82e-11 1.08e-07 0.48 0.42 Hypertension (SNP x SNP interaction); chr5:83125097 chr5:83012285~83013109:- CESC cis rs6452524 0.901 rs1842020 ENSG00000249664.1 CTD-2227C6.2 6.93 4.82e-11 1.08e-07 0.48 0.42 Hypertension (SNP x SNP interaction); chr5:83125814 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs7718278 ENSG00000249664.1 CTD-2227C6.2 6.93 4.82e-11 1.08e-07 0.48 0.42 Hypertension (SNP x SNP interaction); chr5:83126600 chr5:83012285~83013109:- CESC cis rs6452524 0.934 rs1120476 ENSG00000249664.1 CTD-2227C6.2 6.93 4.82e-11 1.08e-07 0.48 0.42 Hypertension (SNP x SNP interaction); chr5:83126824 chr5:83012285~83013109:- CESC cis rs8062405 0.824 rs4788083 ENSG00000259982.1 CDC37P1 6.92 4.83e-11 1.08e-07 0.53 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534128 chr16:28700294~28701540:- CESC cis rs2404602 0.647 rs11072625 ENSG00000259422.1 RP11-593F23.1 6.92 4.84e-11 1.08e-07 0.51 0.42 Blood metabolite levels; chr15:76792643 chr15:76174891~76181486:- CESC cis rs35955747 0.689 rs5997988 ENSG00000236132.1 CTA-440B3.1 6.92 4.85e-11 1.08e-07 0.51 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31442099 chr22:31816379~31817491:- CESC cis rs1707322 1 rs4606257 ENSG00000280836.1 AL355480.1 -6.92 4.88e-11 1.09e-07 -0.51 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45841596 chr1:45581219~45581321:- CESC cis rs150992 0.79 rs161731 ENSG00000248489.1 CTD-2007H13.3 6.92 4.88e-11 1.09e-07 0.51 0.42 Body mass index; chr5:98984339 chr5:98929171~98995013:+ CESC cis rs2404602 0.735 rs11638767 ENSG00000259422.1 RP11-593F23.1 -6.92 4.9e-11 1.09e-07 -0.51 -0.42 Blood metabolite levels; chr15:76363597 chr15:76174891~76181486:- CESC cis rs11722779 0.844 rs3974602 ENSG00000246560.2 RP11-10L12.4 6.92 4.92e-11 1.1e-07 0.51 0.42 Schizophrenia; chr4:102928840 chr4:102828055~102844075:+ CESC cis rs7104764 0.673 rs3782118 ENSG00000277290.1 RP11-326C3.16 -6.92 4.94e-11 1.1e-07 -0.38 -0.42 Menarche (age at onset); chr11:222620 chr11:243099~243483:- CESC cis rs10463554 0.927 rs257312 ENSG00000175749.11 EIF3KP1 6.92 4.97e-11 1.11e-07 0.46 0.42 Parkinson's disease; chr5:103083923 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs257313 ENSG00000175749.11 EIF3KP1 6.92 4.97e-11 1.11e-07 0.46 0.42 Parkinson's disease; chr5:103084943 chr5:103032376~103033031:+ CESC cis rs2404602 0.647 rs11072626 ENSG00000259422.1 RP11-593F23.1 -6.92 5.02e-11 1.12e-07 -0.51 -0.42 Blood metabolite levels; chr15:76798485 chr15:76174891~76181486:- CESC cis rs9545047 0.716 rs943710 ENSG00000227676.3 LINC01068 6.92 5.02e-11 1.12e-07 0.47 0.42 Schizophrenia; chr13:79282987 chr13:79566727~79571436:+ CESC cis rs1577917 0.958 rs72907388 ENSG00000203875.9 SNHG5 -6.92 5.06e-11 1.12e-07 -0.55 -0.42 Response to antipsychotic treatment; chr6:85730489 chr6:85660950~85678736:- CESC cis rs14027 0.843 rs1828238 ENSG00000279347.1 RP11-85I17.2 6.92 5.06e-11 1.13e-07 0.42 0.42 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119848105 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs1960438 ENSG00000279347.1 RP11-85I17.2 6.92 5.06e-11 1.13e-07 0.42 0.42 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119848193 chr8:119838736~119840385:- CESC cis rs10463554 0.927 rs34811 ENSG00000175749.11 EIF3KP1 6.92 5.07e-11 1.13e-07 0.47 0.42 Parkinson's disease; chr5:103096117 chr5:103032376~103033031:+ CESC cis rs1930961 0.702 rs6004684 ENSG00000272977.1 CTA-390C10.10 6.91 5.11e-11 1.14e-07 0.85 0.42 Bipolar disorder with mood-incongruent psychosis; chr22:25503972 chr22:25476218~25479971:+ CESC cis rs7674212 0.507 rs223331 ENSG00000246560.2 RP11-10L12.4 6.91 5.12e-11 1.14e-07 0.54 0.42 Type 2 diabetes; chr4:102872408 chr4:102828055~102844075:+ CESC cis rs17507216 1 rs17507216 ENSG00000278603.1 RP13-608F4.5 -6.91 5.12e-11 1.14e-07 -0.69 -0.42 Excessive daytime sleepiness; chr15:82558175 chr15:82472203~82472426:+ CESC cis rs2404602 0.684 rs62026898 ENSG00000259422.1 RP11-593F23.1 -6.91 5.13e-11 1.14e-07 -0.5 -0.42 Blood metabolite levels; chr15:76652030 chr15:76174891~76181486:- CESC cis rs2404602 0.684 rs965818 ENSG00000259422.1 RP11-593F23.1 -6.91 5.13e-11 1.14e-07 -0.51 -0.42 Blood metabolite levels; chr15:76574444 chr15:76174891~76181486:- CESC cis rs3806843 0.676 rs778594 ENSG00000202111.1 VTRNA1-2 6.91 5.13e-11 1.14e-07 0.45 0.42 Depressive symptoms (multi-trait analysis); chr5:140647719 chr5:140718925~140719013:+ CESC cis rs9549367 0.713 rs2480949 ENSG00000269125.1 RP11-98F14.11 6.91 5.14e-11 1.14e-07 0.54 0.42 Platelet distribution width; chr13:113198835 chr13:113165002~113165183:- CESC cis rs1707322 1 rs12124847 ENSG00000280836.1 AL355480.1 -6.91 5.14e-11 1.14e-07 -0.51 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45915178 chr1:45581219~45581321:- CESC cis rs1577917 0.958 rs10944137 ENSG00000203875.9 SNHG5 -6.91 5.16e-11 1.15e-07 -0.54 -0.42 Response to antipsychotic treatment; chr6:85744596 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12212480 ENSG00000203875.9 SNHG5 -6.91 5.16e-11 1.15e-07 -0.54 -0.42 Response to antipsychotic treatment; chr6:85749059 chr6:85660950~85678736:- CESC cis rs7849270 1 rs4713 ENSG00000268707.1 RP11-247A12.7 6.91 5.16e-11 1.15e-07 0.51 0.42 Blood metabolite ratios; chr9:129148526 chr9:129170434~129170940:+ CESC cis rs228614 0.517 rs3886722 ENSG00000246560.2 RP11-10L12.4 6.91 5.17e-11 1.15e-07 0.51 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102983084 chr4:102828055~102844075:+ CESC cis rs2404602 0.647 rs11072607 ENSG00000259422.1 RP11-593F23.1 -6.91 5.17e-11 1.15e-07 -0.5 -0.42 Blood metabolite levels; chr15:76616188 chr15:76174891~76181486:- CESC cis rs1062177 1 rs2964584 ENSG00000213433.5 RPLP1P6 -6.91 5.17e-11 1.15e-07 -0.52 -0.42 Preschool internalizing problems; chr5:151763317 chr5:151765859~151766378:- CESC cis rs1062177 1 rs2915878 ENSG00000213433.5 RPLP1P6 -6.91 5.17e-11 1.15e-07 -0.52 -0.42 Preschool internalizing problems; chr5:151770101 chr5:151765859~151766378:- CESC cis rs7208859 0.673 rs57432042 ENSG00000263531.1 RP13-753N3.1 6.91 5.17e-11 1.15e-07 0.91 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30914020 chr17:30863921~30864940:- CESC cis rs2404602 0.583 rs4381566 ENSG00000259422.1 RP11-593F23.1 6.91 5.2e-11 1.15e-07 0.47 0.42 Blood metabolite levels; chr15:76296921 chr15:76174891~76181486:- CESC cis rs1577917 1 rs10455455 ENSG00000203875.9 SNHG5 -6.91 5.2e-11 1.15e-07 -0.54 -0.42 Response to antipsychotic treatment; chr6:85960496 chr6:85660950~85678736:- CESC cis rs11155671 0.53 rs7756850 ENSG00000231760.4 RP11-350J20.5 6.91 5.21e-11 1.15e-07 0.52 0.42 Testicular germ cell tumor; chr6:149891460 chr6:149796151~149826294:- CESC cis rs7849270 1 rs2254230 ENSG00000268707.1 RP11-247A12.7 6.91 5.24e-11 1.16e-07 0.54 0.42 Blood metabolite ratios; chr9:129142898 chr9:129170434~129170940:+ CESC cis rs6504950 0.615 rs66898273 ENSG00000275710.1 RP11-257O5.4 6.91 5.3e-11 1.17e-07 0.52 0.42 Breast cancer; chr17:54916595 chr17:54964474~54964679:+ CESC cis rs6504950 0.745 rs1962045 ENSG00000275710.1 RP11-257O5.4 6.91 5.3e-11 1.17e-07 0.52 0.42 Breast cancer; chr17:54918789 chr17:54964474~54964679:+ CESC cis rs6504950 0.72 rs9914596 ENSG00000275710.1 RP11-257O5.4 6.91 5.3e-11 1.17e-07 0.52 0.42 Breast cancer; chr17:54919190 chr17:54964474~54964679:+ CESC cis rs8062405 0.72 rs9926245 ENSG00000259982.1 CDC37P1 6.91 5.31e-11 1.18e-07 0.53 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544385 chr16:28700294~28701540:- CESC cis rs228614 0.509 rs223486 ENSG00000246560.2 RP11-10L12.4 6.91 5.32e-11 1.18e-07 0.5 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102763796 chr4:102828055~102844075:+ CESC cis rs9907295 0.584 rs7215845 ENSG00000270977.1 AC015849.16 -6.91 5.34e-11 1.18e-07 -0.51 -0.42 Fibroblast growth factor basic levels; chr17:35894698 chr17:35893707~35911023:- CESC cis rs507080 0.922 rs12577485 ENSG00000255422.1 AP002954.4 -6.91 5.34e-11 1.18e-07 -0.49 -0.42 Serum metabolite levels; chr11:118676793 chr11:118704607~118750263:+ CESC cis rs150992 0.655 rs327807 ENSG00000248489.1 CTD-2007H13.3 -6.91 5.37e-11 1.19e-07 -0.52 -0.42 Body mass index; chr5:98942448 chr5:98929171~98995013:+ CESC cis rs9399135 0.933 rs28384512 ENSG00000232876.1 CTA-212D2.2 -6.9 5.44e-11 1.2e-07 -0.48 -0.42 Red blood cell count; chr6:135055094 chr6:135055033~135060550:+ CESC cis rs2739330 0.76 rs5760095 ENSG00000099984.9 GSTT2 -6.9 5.44e-11 1.2e-07 -0.53 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23980123~23983911:+ CESC cis rs7727544 0.684 rs272869 ENSG00000233006.5 AC034220.3 6.9 5.46e-11 1.21e-07 0.47 0.42 Blood metabolite levels; chr5:132342304 chr5:132311285~132369916:- CESC cis rs9322193 0.543 rs9371533 ENSG00000216906.2 RP11-350J20.9 6.9 5.5e-11 1.21e-07 0.46 0.42 Lung cancer; chr6:149889545 chr6:149904243~149906418:+ CESC cis rs10463554 0.892 rs464591 ENSG00000175749.11 EIF3KP1 6.9 5.51e-11 1.22e-07 0.48 0.42 Parkinson's disease; chr5:103111600 chr5:103032376~103033031:+ CESC cis rs2929278 0.546 rs686666 ENSG00000205771.5 CATSPER2P1 -6.9 5.57e-11 1.23e-07 -0.5 -0.42 Schizophrenia; chr15:43869352 chr15:43726918~43747094:- CESC cis rs3814244 0.751 rs12832728 ENSG00000255733.4 IFNG-AS1 -6.9 5.58e-11 1.23e-07 -0.36 -0.42 Itch intensity from mosquito bite adjusted by bite size; chr12:68026623 chr12:67989445~68234686:+ CESC cis rs3096299 0.719 rs2965817 ENSG00000274627.1 RP11-104N10.2 6.9 5.58e-11 1.23e-07 0.42 0.42 Multiple myeloma (IgH translocation); chr16:89446826 chr16:89516797~89522217:+ CESC cis rs150992 0.609 rs447044 ENSG00000248489.1 CTD-2007H13.3 6.9 5.59e-11 1.23e-07 0.49 0.42 Body mass index; chr5:98995572 chr5:98929171~98995013:+ CESC cis rs10875746 0.855 rs2269936 ENSG00000240399.1 RP1-228P16.1 -6.9 5.61e-11 1.24e-07 -0.56 -0.42 Longevity (90 years and older); chr12:48031452 chr12:48054813~48055591:- CESC cis rs10875746 0.855 rs10875730 ENSG00000240399.1 RP1-228P16.1 -6.9 5.61e-11 1.24e-07 -0.56 -0.42 Longevity (90 years and older); chr12:48034092 chr12:48054813~48055591:- CESC cis rs10875746 0.855 rs11168369 ENSG00000240399.1 RP1-228P16.1 -6.9 5.61e-11 1.24e-07 -0.56 -0.42 Longevity (90 years and older); chr12:48037385 chr12:48054813~48055591:- CESC cis rs227275 0.556 rs724447 ENSG00000246560.2 RP11-10L12.4 -6.9 5.65e-11 1.25e-07 -0.51 -0.42 Allergic disease (asthma, hay fever or eczema); chr4:103010149 chr4:102828055~102844075:+ CESC cis rs7849270 0.879 rs6478866 ENSG00000268707.1 RP11-247A12.7 -6.9 5.68e-11 1.25e-07 -0.49 -0.42 Blood metabolite ratios; chr9:129133585 chr9:129170434~129170940:+ CESC cis rs507080 0.961 rs673770 ENSG00000255422.1 AP002954.4 -6.9 5.69e-11 1.25e-07 -0.49 -0.42 Serum metabolite levels; chr11:118679892 chr11:118704607~118750263:+ CESC cis rs8062405 0.823 rs7202948 ENSG00000259982.1 CDC37P1 6.9 5.73e-11 1.26e-07 0.53 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546968 chr16:28700294~28701540:- CESC cis rs8062405 0.824 rs7191618 ENSG00000259982.1 CDC37P1 6.9 5.73e-11 1.26e-07 0.53 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554346 chr16:28700294~28701540:- CESC cis rs113835537 0.529 rs75685325 ENSG00000255517.5 CTD-3074O7.5 -6.89 5.76e-11 1.27e-07 -0.51 -0.42 Airway imaging phenotypes; chr11:66467771 chr11:66473490~66480233:- CESC cis rs150992 0.525 rs331930 ENSG00000248489.1 CTD-2007H13.3 6.89 5.79e-11 1.27e-07 0.5 0.42 Body mass index; chr5:98833559 chr5:98929171~98995013:+ CESC cis rs9549367 0.713 rs4907598 ENSG00000269125.1 RP11-98F14.11 6.89 5.81e-11 1.28e-07 0.52 0.42 Platelet distribution width; chr13:113207071 chr13:113165002~113165183:- CESC cis rs7727544 0.684 rs272893 ENSG00000233006.5 AC034220.3 6.89 5.88e-11 1.29e-07 0.47 0.42 Blood metabolite levels; chr5:132327369 chr5:132311285~132369916:- CESC cis rs113835537 0.529 rs61561111 ENSG00000255517.5 CTD-3074O7.5 -6.89 5.89e-11 1.3e-07 -0.48 -0.42 Airway imaging phenotypes; chr11:66508452 chr11:66473490~66480233:- CESC cis rs7899628 1 rs7899628 ENSG00000226864.1 ATE1-AS1 -6.89 5.91e-11 1.3e-07 -0.53 -0.42 Breast cancer; chr10:121904429 chr10:121928312~121951965:+ CESC cis rs9545047 0.716 rs314692 ENSG00000227676.3 LINC01068 -6.89 5.92e-11 1.3e-07 -0.48 -0.42 Schizophrenia; chr13:79433091 chr13:79566727~79571436:+ CESC cis rs7044106 0.615 rs10818470 ENSG00000226752.6 PSMD5-AS1 -6.89 5.98e-11 1.31e-07 -0.46 -0.42 Hip circumference adjusted for BMI; chr9:120596926 chr9:120824828~120854385:+ CESC cis rs8081395 0.801 rs2665404 ENSG00000266992.1 DHX40P1 6.89 5.98e-11 1.31e-07 0.44 0.42 White blood cell count; chr17:59798035 chr17:59976009~60002384:- CESC cis rs3806843 0.568 rs2530232 ENSG00000202111.1 VTRNA1-2 6.89 5.99e-11 1.32e-07 0.45 0.42 Depressive symptoms (multi-trait analysis); chr5:140703293 chr5:140718925~140719013:+ CESC cis rs7188445 0.592 rs4404082 ENSG00000261390.4 RP11-345M22.2 6.89 6e-11 1.32e-07 0.51 0.42 Urate levels; chr16:79716615 chr16:79715232~79770563:- CESC cis rs1707322 1 rs4660335 ENSG00000280836.1 AL355480.1 -6.89 6.07e-11 1.33e-07 -0.51 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46009046 chr1:45581219~45581321:- CESC cis rs227275 0.554 rs223467 ENSG00000246560.2 RP11-10L12.4 6.88 6.1e-11 1.34e-07 0.5 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102779721 chr4:102828055~102844075:+ CESC cis rs5769707 0.933 rs2157444 ENSG00000188511.11 C22orf34 6.88 6.11e-11 1.34e-07 0.45 0.42 Monocyte percentage of white cells;Monocyte count; chr22:49600644 chr22:49414524~49657542:- CESC cis rs2739330 0.796 rs2154594 ENSG00000099984.9 GSTT2 6.88 6.15e-11 1.35e-07 0.52 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23980123~23983911:+ CESC cis rs9399137 0.507 rs6904897 ENSG00000232876.1 CTA-212D2.2 -6.88 6.17e-11 1.35e-07 -0.52 -0.42 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135061842 chr6:135055033~135060550:+ CESC cis rs228614 0.51 rs223459 ENSG00000246560.2 RP11-10L12.4 6.88 6.19e-11 1.36e-07 0.51 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102788229 chr4:102828055~102844075:+ CESC cis rs2929278 0.617 rs12908467 ENSG00000249839.1 AC011330.5 6.88 6.24e-11 1.37e-07 0.44 0.42 Schizophrenia; chr15:43755232 chr15:43663654~43684339:- CESC cis rs526231 0.578 rs2112886 ENSG00000175749.11 EIF3KP1 -6.88 6.24e-11 1.37e-07 -0.47 -0.42 Primary biliary cholangitis; chr5:102915678 chr5:103032376~103033031:+ CESC cis rs67383717 0.689 rs62559007 ENSG00000175611.10 LINC00476 -6.88 6.26e-11 1.37e-07 -0.48 -0.42 Parkinson's disease (pesticide exposure interaction); chr9:95790981 chr9:95759231~95875977:- CESC cis rs227275 0.554 rs223466 ENSG00000246560.2 RP11-10L12.4 6.88 6.28e-11 1.38e-07 0.5 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102780039 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs223461 ENSG00000246560.2 RP11-10L12.4 6.88 6.28e-11 1.38e-07 0.5 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102782372 chr4:102828055~102844075:+ CESC cis rs1577917 0.958 rs12198876 ENSG00000203875.9 SNHG5 -6.88 6.29e-11 1.38e-07 -0.54 -0.42 Response to antipsychotic treatment; chr6:85815758 chr6:85660950~85678736:- CESC cis rs227275 0.525 rs3974608 ENSG00000246560.2 RP11-10L12.4 6.88 6.29e-11 1.38e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102925641 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs10028116 ENSG00000246560.2 RP11-10L12.4 6.88 6.29e-11 1.38e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102931421 chr4:102828055~102844075:+ CESC cis rs227275 0.588 rs223458 ENSG00000246560.2 RP11-10L12.4 6.88 6.29e-11 1.38e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102788414 chr4:102828055~102844075:+ CESC cis rs7626444 0.625 rs843539 ENSG00000272359.1 U4 -6.88 6.3e-11 1.38e-07 -0.5 -0.42 Monocyte count; chr3:196747985 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs2686596 ENSG00000272359.1 U4 -6.88 6.3e-11 1.38e-07 -0.5 -0.42 Monocyte count; chr3:196748248 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs2686595 ENSG00000272359.1 U4 -6.88 6.3e-11 1.38e-07 -0.5 -0.42 Monocyte count; chr3:196748271 chr3:196747192~196747324:- CESC cis rs9907295 0.818 rs7211393 ENSG00000270977.1 AC015849.16 -6.88 6.33e-11 1.38e-07 -0.51 -0.42 Fibroblast growth factor basic levels; chr17:35885124 chr17:35893707~35911023:- CESC cis rs7674212 0.507 rs223361 ENSG00000246560.2 RP11-10L12.4 6.88 6.35e-11 1.39e-07 0.54 0.42 Type 2 diabetes; chr4:102848147 chr4:102828055~102844075:+ CESC cis rs875971 0.83 rs427575 ENSG00000226824.5 RP4-756H11.3 -6.88 6.36e-11 1.39e-07 -0.54 -0.42 Aortic root size; chr7:66054232 chr7:66654538~66669855:+ CESC cis rs10256972 0.616 rs6957733 ENSG00000229043.2 AC091729.9 -6.88 6.42e-11 1.4e-07 -0.47 -0.42 Endometriosis;Longevity; chr7:1066691 chr7:1160374~1165267:+ CESC cis rs227275 0.554 rs223457 ENSG00000246560.2 RP11-10L12.4 6.87 6.54e-11 1.43e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102788506 chr4:102828055~102844075:+ CESC cis rs17507216 0.718 rs72751675 ENSG00000278603.1 RP13-608F4.5 6.87 6.56e-11 1.43e-07 0.73 0.42 Excessive daytime sleepiness; chr15:82630452 chr15:82472203~82472426:+ CESC cis rs2487048 0.761 rs1800976 ENSG00000226334.1 RP11-217B7.2 -6.87 6.61e-11 1.44e-07 -0.51 -0.42 Intraocular pressure; chr9:104928428 chr9:104927553~104928892:+ CESC cis rs9399135 0.935 rs4445070 ENSG00000232876.1 CTA-212D2.2 -6.87 6.64e-11 1.45e-07 -0.49 -0.42 Red blood cell count; chr6:134988074 chr6:135055033~135060550:+ CESC cis rs7626444 0.625 rs1798634 ENSG00000272359.1 U4 -6.87 6.67e-11 1.46e-07 -0.5 -0.42 Monocyte count; chr3:196747416 chr3:196747192~196747324:- CESC cis rs7626444 0.625 rs1798635 ENSG00000272359.1 U4 -6.87 6.67e-11 1.46e-07 -0.5 -0.42 Monocyte count; chr3:196747418 chr3:196747192~196747324:- CESC cis rs992157 0.798 rs1017698 ENSG00000261338.2 RP11-378A13.1 -6.87 6.68e-11 1.46e-07 -0.52 -0.42 Colorectal cancer; chr2:218305802 chr2:218255319~218257366:+ CESC cis rs507080 0.961 rs600969 ENSG00000255422.1 AP002954.4 -6.87 6.7e-11 1.46e-07 -0.49 -0.42 Serum metabolite levels; chr11:118675087 chr11:118704607~118750263:+ CESC cis rs7626444 0.625 rs1357287 ENSG00000272359.1 U4 -6.87 6.71e-11 1.46e-07 -0.49 -0.42 Monocyte count; chr3:196758096 chr3:196747192~196747324:- CESC cis rs9399137 0.507 rs4594969 ENSG00000232876.1 CTA-212D2.2 -6.87 6.72e-11 1.47e-07 -0.53 -0.42 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134964448 chr6:135055033~135060550:+ CESC cis rs2929278 0.588 rs1975364 ENSG00000205771.5 CATSPER2P1 -6.87 6.74e-11 1.47e-07 -0.5 -0.42 Schizophrenia; chr15:43857991 chr15:43726918~43747094:- CESC cis rs17826219 0.706 rs609472 ENSG00000263531.1 RP13-753N3.1 6.87 6.76e-11 1.47e-07 0.77 0.42 Body mass index; chr17:30624409 chr17:30863921~30864940:- CESC cis rs765787 0.53 rs2554454 ENSG00000259520.4 CTD-2651B20.3 6.87 6.8e-11 1.48e-07 0.54 0.42 Uric acid levels; chr15:45229338 chr15:45251580~45279251:- CESC cis rs2404602 0.583 rs12898415 ENSG00000259422.1 RP11-593F23.1 6.86 6.86e-11 1.49e-07 0.47 0.42 Blood metabolite levels; chr15:76281891 chr15:76174891~76181486:- CESC cis rs113835537 0.529 rs11227501 ENSG00000255517.5 CTD-3074O7.5 -6.86 6.87e-11 1.49e-07 -0.48 -0.42 Airway imaging phenotypes; chr11:66506601 chr11:66473490~66480233:- CESC cis rs227275 0.525 rs223462 ENSG00000246560.2 RP11-10L12.4 6.86 6.87e-11 1.5e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102780661 chr4:102828055~102844075:+ CESC cis rs14027 0.921 rs6469852 ENSG00000279347.1 RP11-85I17.2 6.86 6.92e-11 1.51e-07 0.41 0.42 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119848495 chr8:119838736~119840385:- CESC cis rs1707322 1 rs4074225 ENSG00000280836.1 AL355480.1 -6.86 6.94e-11 1.51e-07 -0.5 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45926692 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4134387 ENSG00000280836.1 AL355480.1 -6.86 6.94e-11 1.51e-07 -0.5 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45929486 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4660332 ENSG00000280836.1 AL355480.1 -6.86 6.94e-11 1.51e-07 -0.5 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45995746 chr1:45581219~45581321:- CESC cis rs2929278 0.589 rs2411284 ENSG00000249839.1 AC011330.5 6.86 7.02e-11 1.53e-07 0.44 0.42 Schizophrenia; chr15:43746701 chr15:43663654~43684339:- CESC cis rs10463554 0.963 rs257294 ENSG00000175749.11 EIF3KP1 6.86 7.03e-11 1.53e-07 0.47 0.42 Parkinson's disease; chr5:103131563 chr5:103032376~103033031:+ CESC cis rs7626444 0.625 rs2931210 ENSG00000272359.1 U4 -6.86 7.03e-11 1.53e-07 -0.49 -0.42 Monocyte count; chr3:196749805 chr3:196747192~196747324:- CESC cis rs150992 0.632 rs161936 ENSG00000248489.1 CTD-2007H13.3 6.86 7.09e-11 1.54e-07 0.5 0.42 Body mass index; chr5:98982953 chr5:98929171~98995013:+ CESC cis rs6452524 0.967 rs1564211 ENSG00000249664.1 CTD-2227C6.2 6.86 7.1e-11 1.54e-07 0.46 0.42 Hypertension (SNP x SNP interaction); chr5:83117014 chr5:83012285~83013109:- CESC cis rs2404602 0.684 rs11072602 ENSG00000259422.1 RP11-593F23.1 -6.86 7.11e-11 1.54e-07 -0.5 -0.42 Blood metabolite levels; chr15:76581126 chr15:76174891~76181486:- CESC cis rs11722779 0.935 rs7681629 ENSG00000246560.2 RP11-10L12.4 6.86 7.14e-11 1.55e-07 0.51 0.42 Schizophrenia; chr4:102974407 chr4:102828055~102844075:+ CESC cis rs11722779 0.844 rs17033381 ENSG00000246560.2 RP11-10L12.4 6.86 7.14e-11 1.55e-07 0.51 0.42 Schizophrenia; chr4:102974952 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs4699044 ENSG00000246560.2 RP11-10L12.4 6.86 7.14e-11 1.55e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102976939 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs4699045 ENSG00000246560.2 RP11-10L12.4 6.86 7.14e-11 1.55e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102977009 chr4:102828055~102844075:+ CESC cis rs7208859 0.573 rs8078182 ENSG00000263531.1 RP13-753N3.1 6.86 7.15e-11 1.55e-07 0.68 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822646 chr17:30863921~30864940:- CESC cis rs2404602 0.647 rs4886837 ENSG00000259422.1 RP11-593F23.1 -6.86 7.15e-11 1.55e-07 -0.49 -0.42 Blood metabolite levels; chr15:76864076 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs3812909 ENSG00000259422.1 RP11-593F23.1 -6.86 7.15e-11 1.55e-07 -0.49 -0.42 Blood metabolite levels; chr15:76883859 chr15:76174891~76181486:- CESC cis rs10463554 0.892 rs158401 ENSG00000175749.11 EIF3KP1 6.86 7.15e-11 1.55e-07 0.46 0.42 Parkinson's disease; chr5:103079764 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs257304 ENSG00000175749.11 EIF3KP1 6.86 7.15e-11 1.55e-07 0.46 0.42 Parkinson's disease; chr5:103081114 chr5:103032376~103033031:+ CESC cis rs2929278 0.617 rs693919 ENSG00000205771.5 CATSPER2P1 6.86 7.16e-11 1.55e-07 0.5 0.42 Schizophrenia; chr15:43810130 chr15:43726918~43747094:- CESC cis rs10262624 0.504 rs59865844 ENSG00000234286.1 AC006026.13 6.86 7.21e-11 1.56e-07 0.43 0.42 Schizophrenia; chr7:23693421 chr7:23680195~23680786:- CESC cis rs228614 0.51 rs223311 ENSG00000246560.2 RP11-10L12.4 6.85 7.26e-11 1.57e-07 0.52 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888757 chr4:102828055~102844075:+ CESC cis rs9326248 0.574 rs1263173 ENSG00000254851.1 RP11-109L13.1 -6.85 7.32e-11 1.59e-07 -0.5 -0.42 Blood protein levels; chr11:116810292 chr11:117135528~117138582:+ CESC cis rs1501911 0.53 rs193072 ENSG00000248489.1 CTD-2007H13.3 6.85 7.32e-11 1.59e-07 0.5 0.42 Lung function (FEV1/FVC); chr5:98822171 chr5:98929171~98995013:+ CESC cis rs9545047 0.716 rs7333904 ENSG00000227676.3 LINC01068 6.85 7.34e-11 1.59e-07 0.47 0.42 Schizophrenia; chr13:79281413 chr13:79566727~79571436:+ CESC cis rs150992 0.632 rs326493 ENSG00000248489.1 CTD-2007H13.3 6.85 7.36e-11 1.59e-07 0.5 0.42 Body mass index; chr5:98966251 chr5:98929171~98995013:+ CESC cis rs150992 0.632 rs162341 ENSG00000248489.1 CTD-2007H13.3 6.85 7.36e-11 1.59e-07 0.5 0.42 Body mass index; chr5:98967230 chr5:98929171~98995013:+ CESC cis rs9545047 0.692 rs314694 ENSG00000227676.3 LINC01068 -6.85 7.38e-11 1.6e-07 -0.48 -0.42 Schizophrenia; chr13:79432467 chr13:79566727~79571436:+ CESC cis rs4423214 0.515 rs4944042 ENSG00000254682.1 RP11-660L16.2 6.85 7.38e-11 1.6e-07 0.51 0.42 Vitamin D levels; chr11:71407742 chr11:71448674~71452157:+ CESC cis rs8081395 0.651 rs1292067 ENSG00000266992.1 DHX40P1 -6.85 7.38e-11 1.6e-07 -0.45 -0.42 White blood cell count; chr17:59853285 chr17:59976009~60002384:- CESC cis rs7188445 0.556 rs7203910 ENSG00000261390.4 RP11-345M22.2 -6.85 7.42e-11 1.6e-07 -0.5 -0.42 Urate levels; chr16:79711722 chr16:79715232~79770563:- CESC cis rs227275 0.554 rs150895 ENSG00000246560.2 RP11-10L12.4 6.85 7.42e-11 1.6e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102791432 chr4:102828055~102844075:+ CESC cis rs227275 0.586 rs223448 ENSG00000246560.2 RP11-10L12.4 6.85 7.42e-11 1.6e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102792189 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223442 ENSG00000246560.2 RP11-10L12.4 6.85 7.42e-11 1.6e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102793960 chr4:102828055~102844075:+ CESC cis rs227275 0.554 rs223441 ENSG00000246560.2 RP11-10L12.4 6.85 7.42e-11 1.6e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102794228 chr4:102828055~102844075:+ CESC cis rs7104764 0.778 rs7930823 ENSG00000277290.1 RP11-326C3.16 6.85 7.44e-11 1.61e-07 0.36 0.42 Menarche (age at onset); chr11:206767 chr11:243099~243483:- CESC cis rs1501911 0.53 rs162149 ENSG00000248489.1 CTD-2007H13.3 6.85 7.51e-11 1.62e-07 0.48 0.42 Lung function (FEV1/FVC); chr5:98913851 chr5:98929171~98995013:+ CESC cis rs1501911 0.53 rs162150 ENSG00000248489.1 CTD-2007H13.3 6.85 7.51e-11 1.62e-07 0.48 0.42 Lung function (FEV1/FVC); chr5:98913909 chr5:98929171~98995013:+ CESC cis rs7674212 0.507 rs223317 ENSG00000246560.2 RP11-10L12.4 6.85 7.53e-11 1.63e-07 0.53 0.42 Type 2 diabetes; chr4:102881667 chr4:102828055~102844075:+ CESC cis rs7674212 0.556 rs6533039 ENSG00000246560.2 RP11-10L12.4 6.85 7.59e-11 1.64e-07 0.53 0.42 Type 2 diabetes; chr4:102938381 chr4:102828055~102844075:+ CESC cis rs10463554 0.927 rs464720 ENSG00000175749.11 EIF3KP1 6.85 7.63e-11 1.65e-07 0.46 0.42 Parkinson's disease; chr5:103071183 chr5:103032376~103033031:+ CESC cis rs227275 0.556 rs10015289 ENSG00000246560.2 RP11-10L12.4 6.84 7.65e-11 1.65e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102984956 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs6852141 ENSG00000246560.2 RP11-10L12.4 6.84 7.65e-11 1.65e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102986439 chr4:102828055~102844075:+ CESC cis rs227275 0.556 rs9999303 ENSG00000246560.2 RP11-10L12.4 6.84 7.65e-11 1.65e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102986881 chr4:102828055~102844075:+ CESC cis rs228614 0.509 rs4455415 ENSG00000246560.2 RP11-10L12.4 6.84 7.65e-11 1.65e-07 0.51 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102993663 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs6853193 ENSG00000246560.2 RP11-10L12.4 6.84 7.65e-11 1.65e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102994888 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223313 ENSG00000246560.2 RP11-10L12.4 6.84 7.71e-11 1.66e-07 0.51 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102886563 chr4:102828055~102844075:+ CESC cis rs1062177 1 rs2915882 ENSG00000213433.5 RPLP1P6 -6.84 7.86e-11 1.69e-07 -0.52 -0.42 Preschool internalizing problems; chr5:151765875 chr5:151765859~151766378:- CESC cis rs1062177 1 rs2915880 ENSG00000213433.5 RPLP1P6 -6.84 7.86e-11 1.69e-07 -0.52 -0.42 Preschool internalizing problems; chr5:151767773 chr5:151765859~151766378:- CESC cis rs7849270 0.879 rs10819461 ENSG00000268707.1 RP11-247A12.7 -6.84 7.91e-11 1.7e-07 -0.53 -0.42 Blood metabolite ratios; chr9:129079608 chr9:129170434~129170940:+ CESC cis rs7044106 0.718 rs10616 ENSG00000226752.6 PSMD5-AS1 -6.84 7.96e-11 1.71e-07 -0.46 -0.42 Hip circumference adjusted for BMI; chr9:120601255 chr9:120824828~120854385:+ CESC cis rs150992 0.609 rs4703049 ENSG00000248489.1 CTD-2007H13.3 6.84 7.99e-11 1.72e-07 0.51 0.42 Body mass index; chr5:99004679 chr5:98929171~98995013:+ CESC cis rs227275 0.525 rs3974604 ENSG00000246560.2 RP11-10L12.4 6.83 8.11e-11 1.74e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102928601 chr4:102828055~102844075:+ CESC cis rs11155671 0.53 rs4458704 ENSG00000268592.3 RAET1E-AS1 6.83 8.25e-11 1.77e-07 0.52 0.42 Testicular germ cell tumor; chr6:149911743 chr6:149863494~149919507:+ CESC cis rs5760092 0.755 rs915589 ENSG00000225282.1 AP000350.6 -6.83 8.29e-11 1.78e-07 -0.6 -0.42 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23926900~23929574:+ CESC cis rs6452524 0.618 rs4266384 ENSG00000249664.1 CTD-2227C6.2 6.83 8.35e-11 1.79e-07 0.47 0.42 Hypertension (SNP x SNP interaction); chr5:83080872 chr5:83012285~83013109:- CESC cis rs1823913 0.892 rs35596292 ENSG00000280083.1 RP11-317J9.1 -6.83 8.37e-11 1.8e-07 -0.5 -0.42 Obesity-related traits; chr2:191246890 chr2:191154118~191156070:- CESC cis rs1823913 0.927 rs35530564 ENSG00000280083.1 RP11-317J9.1 -6.83 8.37e-11 1.8e-07 -0.5 -0.42 Obesity-related traits; chr2:191247324 chr2:191154118~191156070:- CESC cis rs2404602 0.647 rs12903586 ENSG00000259422.1 RP11-593F23.1 -6.83 8.38e-11 1.8e-07 -0.49 -0.42 Blood metabolite levels; chr15:76875899 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs12903331 ENSG00000259422.1 RP11-593F23.1 -6.83 8.38e-11 1.8e-07 -0.49 -0.42 Blood metabolite levels; chr15:76875927 chr15:76174891~76181486:- CESC cis rs4423214 0.84 rs1629220 ENSG00000254682.1 RP11-660L16.2 -6.83 8.39e-11 1.8e-07 -0.56 -0.42 Vitamin D levels; chr11:71463507 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1792224 ENSG00000254682.1 RP11-660L16.2 -6.83 8.39e-11 1.8e-07 -0.56 -0.42 Vitamin D levels; chr11:71465095 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1792226 ENSG00000254682.1 RP11-660L16.2 -6.83 8.39e-11 1.8e-07 -0.56 -0.42 Vitamin D levels; chr11:71465528 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1790344 ENSG00000254682.1 RP11-660L16.2 -6.83 8.39e-11 1.8e-07 -0.56 -0.42 Vitamin D levels; chr11:71465851 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1790343 ENSG00000254682.1 RP11-660L16.2 -6.83 8.39e-11 1.8e-07 -0.56 -0.42 Vitamin D levels; chr11:71466161 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1792227 ENSG00000254682.1 RP11-660L16.2 -6.83 8.39e-11 1.8e-07 -0.56 -0.42 Vitamin D levels; chr11:71466366 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1790341 ENSG00000254682.1 RP11-660L16.2 -6.83 8.39e-11 1.8e-07 -0.56 -0.42 Vitamin D levels; chr11:71466532 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1540127 ENSG00000254682.1 RP11-660L16.2 -6.83 8.39e-11 1.8e-07 -0.56 -0.42 Vitamin D levels; chr11:71467992 chr11:71448674~71452157:+ CESC cis rs228614 0.51 rs223438 ENSG00000246560.2 RP11-10L12.4 -6.83 8.41e-11 1.8e-07 -0.5 -0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798584 chr4:102828055~102844075:+ CESC cis rs2404602 0.583 rs12438741 ENSG00000259422.1 RP11-593F23.1 6.83 8.43e-11 1.81e-07 0.47 0.42 Blood metabolite levels; chr15:76249773 chr15:76174891~76181486:- CESC cis rs227275 0.554 rs223334 ENSG00000246560.2 RP11-10L12.4 -6.83 8.48e-11 1.81e-07 -0.52 -0.42 Allergic disease (asthma, hay fever or eczema); chr4:102867054 chr4:102828055~102844075:+ CESC cis rs150992 0.517 rs326464 ENSG00000248489.1 CTD-2007H13.3 6.83 8.5e-11 1.82e-07 0.48 0.42 Body mass index; chr5:98906499 chr5:98929171~98995013:+ CESC cis rs1707322 1 rs10890382 ENSG00000280836.1 AL355480.1 -6.83 8.52e-11 1.82e-07 -0.51 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46004002 chr1:45581219~45581321:- CESC cis rs7727544 0.684 rs270602 ENSG00000233006.5 AC034220.3 6.83 8.53e-11 1.82e-07 0.47 0.42 Blood metabolite levels; chr5:132321007 chr5:132311285~132369916:- CESC cis rs1062177 1 rs892006 ENSG00000213433.5 RPLP1P6 -6.83 8.55e-11 1.83e-07 -0.51 -0.42 Preschool internalizing problems; chr5:151801329 chr5:151765859~151766378:- CESC cis rs35955747 0.533 rs5998004 ENSG00000236132.1 CTA-440B3.1 6.83 8.57e-11 1.83e-07 0.5 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31485843 chr22:31816379~31817491:- CESC cis rs7674212 0.556 rs34475639 ENSG00000246560.2 RP11-10L12.4 6.82 8.58e-11 1.84e-07 0.54 0.42 Type 2 diabetes; chr4:103033694 chr4:102828055~102844075:+ CESC cis rs7626444 0.585 rs860050 ENSG00000272359.1 U4 -6.82 8.59e-11 1.84e-07 -0.49 -0.42 Monocyte count; chr3:196747576 chr3:196747192~196747324:- CESC cis rs2929278 0.561 rs62018952 ENSG00000249839.1 AC011330.5 6.82 8.62e-11 1.84e-07 0.44 0.42 Schizophrenia; chr15:43788539 chr15:43663654~43684339:- CESC cis rs526231 0.578 rs10515337 ENSG00000175749.11 EIF3KP1 -6.82 8.65e-11 1.85e-07 -0.48 -0.42 Primary biliary cholangitis; chr5:102965664 chr5:103032376~103033031:+ CESC cis rs1707322 0.964 rs12067716 ENSG00000280836.1 AL355480.1 -6.82 8.66e-11 1.85e-07 -0.5 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45968756 chr1:45581219~45581321:- CESC cis rs5769707 0.681 rs9616329 ENSG00000188511.11 C22orf34 6.82 8.73e-11 1.86e-07 0.48 0.42 Monocyte percentage of white cells;Monocyte count; chr22:49632666 chr22:49414524~49657542:- CESC cis rs227275 0.525 rs6533050 ENSG00000246560.2 RP11-10L12.4 6.82 8.74e-11 1.87e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102979044 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs10032234 ENSG00000246560.2 RP11-10L12.4 6.82 8.74e-11 1.87e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102980538 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs28845922 ENSG00000246560.2 RP11-10L12.4 6.82 8.74e-11 1.87e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102981959 chr4:102828055~102844075:+ CESC cis rs9545047 0.716 rs314693 ENSG00000227676.3 LINC01068 -6.82 8.74e-11 1.87e-07 -0.48 -0.42 Schizophrenia; chr13:79432792 chr13:79566727~79571436:+ CESC cis rs8062405 0.754 rs3859172 ENSG00000259982.1 CDC37P1 6.82 8.75e-11 1.87e-07 0.52 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554837 chr16:28700294~28701540:- CESC cis rs3806843 0.676 rs2245640 ENSG00000202111.1 VTRNA1-2 6.82 8.75e-11 1.87e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140650373 chr5:140718925~140719013:+ CESC cis rs14027 0.921 rs16893140 ENSG00000279347.1 RP11-85I17.2 -6.82 8.78e-11 1.87e-07 -0.41 -0.42 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119767007 chr8:119838736~119840385:- CESC cis rs9545047 0.735 rs314690 ENSG00000227676.3 LINC01068 6.82 8.8e-11 1.88e-07 0.47 0.42 Schizophrenia; chr13:79434822 chr13:79566727~79571436:+ CESC cis rs2929278 0.588 rs1975364 ENSG00000249839.1 AC011330.5 -6.82 8.81e-11 1.88e-07 -0.44 -0.42 Schizophrenia; chr15:43857991 chr15:43663654~43684339:- CESC cis rs11155671 0.53 rs6935829 ENSG00000231760.4 RP11-350J20.5 6.82 8.81e-11 1.88e-07 0.52 0.42 Testicular germ cell tumor; chr6:149896675 chr6:149796151~149826294:- CESC cis rs2581828 0.656 rs4687701 ENSG00000242142.1 SERBP1P3 -6.82 8.82e-11 1.88e-07 -0.46 -0.42 Crohn's disease; chr3:53087260 chr3:53064283~53065091:- CESC cis rs227275 0.525 rs11737544 ENSG00000246560.2 RP11-10L12.4 6.82 8.83e-11 1.88e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102983877 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs7672319 ENSG00000246560.2 RP11-10L12.4 6.82 8.83e-11 1.88e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102990002 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs6533051 ENSG00000246560.2 RP11-10L12.4 6.82 8.83e-11 1.88e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102990065 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs6533052 ENSG00000246560.2 RP11-10L12.4 6.82 8.83e-11 1.88e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102990624 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs3974485 ENSG00000246560.2 RP11-10L12.4 6.82 8.83e-11 1.88e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102993283 chr4:102828055~102844075:+ CESC cis rs227275 0.525 rs7688940 ENSG00000246560.2 RP11-10L12.4 6.82 8.83e-11 1.88e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102994153 chr4:102828055~102844075:+ CESC cis rs11155671 0.53 rs2342770 ENSG00000231760.4 RP11-350J20.5 6.82 8.92e-11 1.9e-07 0.52 0.42 Testicular germ cell tumor; chr6:149895549 chr6:149796151~149826294:- CESC cis rs3096299 0.685 rs4785675 ENSG00000274627.1 RP11-104N10.2 6.82 9.02e-11 1.92e-07 0.41 0.42 Multiple myeloma (IgH translocation); chr16:89473566 chr16:89516797~89522217:+ CESC cis rs113835537 0.529 rs11227499 ENSG00000255517.5 CTD-3074O7.5 -6.81 9.11e-11 1.94e-07 -0.44 -0.42 Airway imaging phenotypes; chr11:66505353 chr11:66473490~66480233:- CESC cis rs3096299 0.632 rs4399533 ENSG00000274627.1 RP11-104N10.2 6.81 9.16e-11 1.95e-07 0.41 0.42 Multiple myeloma (IgH translocation); chr16:89472974 chr16:89516797~89522217:+ CESC cis rs3806843 0.705 rs35614340 ENSG00000202111.1 VTRNA1-2 6.81 9.17e-11 1.95e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140664033 chr5:140718925~140719013:+ CESC cis rs875971 0.862 rs12537823 ENSG00000226824.5 RP4-756H11.3 -6.81 9.17e-11 1.95e-07 -0.51 -0.42 Aortic root size; chr7:66255897 chr7:66654538~66669855:+ CESC cis rs1577917 1 rs10944163 ENSG00000203875.9 SNHG5 -6.81 9.18e-11 1.95e-07 -0.53 -0.42 Response to antipsychotic treatment; chr6:85948975 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12661204 ENSG00000203875.9 SNHG5 -6.81 9.18e-11 1.95e-07 -0.53 -0.42 Response to antipsychotic treatment; chr6:85968868 chr6:85660950~85678736:- CESC cis rs11155671 0.53 rs7742993 ENSG00000268592.3 RAET1E-AS1 6.81 9.2e-11 1.95e-07 0.52 0.42 Testicular germ cell tumor; chr6:149883959 chr6:149863494~149919507:+ CESC cis rs2487048 0.725 rs2422493 ENSG00000226334.1 RP11-217B7.2 -6.81 9.22e-11 1.96e-07 -0.51 -0.42 Intraocular pressure; chr9:104928714 chr9:104927553~104928892:+ CESC cis rs35955747 0.633 rs2006771 ENSG00000236132.1 CTA-440B3.1 6.81 9.26e-11 1.97e-07 0.49 0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31602626 chr22:31816379~31817491:- CESC cis rs227275 0.525 rs4596243 ENSG00000246560.2 RP11-10L12.4 6.81 9.29e-11 1.97e-07 0.5 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102964411 chr4:102828055~102844075:+ CESC cis rs4853012 1 rs2280643 ENSG00000257800.1 FNBP1P1 6.81 9.29e-11 1.97e-07 0.45 0.42 Gestational age at birth (maternal effect); chr2:74131159 chr2:74120680~74123218:+ CESC cis rs4853012 0.887 rs2280644 ENSG00000257800.1 FNBP1P1 6.81 9.29e-11 1.97e-07 0.45 0.42 Gestational age at birth (maternal effect); chr2:74131284 chr2:74120680~74123218:+ CESC cis rs17507216 0.718 rs7161977 ENSG00000278603.1 RP13-608F4.5 6.81 9.51e-11 2.02e-07 0.72 0.42 Excessive daytime sleepiness; chr15:82646782 chr15:82472203~82472426:+ CESC cis rs1577917 1 rs13196930 ENSG00000203875.9 SNHG5 -6.81 9.53e-11 2.02e-07 -0.54 -0.42 Response to antipsychotic treatment; chr6:85942527 chr6:85660950~85678736:- CESC cis rs228614 0.536 rs223478 ENSG00000246560.2 RP11-10L12.4 6.81 9.58e-11 2.03e-07 0.5 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102768648 chr4:102828055~102844075:+ CESC cis rs228614 0.536 rs150898 ENSG00000246560.2 RP11-10L12.4 6.81 9.58e-11 2.03e-07 0.5 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769234 chr4:102828055~102844075:+ CESC cis rs228614 0.509 rs223476 ENSG00000246560.2 RP11-10L12.4 6.81 9.58e-11 2.03e-07 0.5 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771000 chr4:102828055~102844075:+ CESC cis rs228614 0.509 rs150896 ENSG00000246560.2 RP11-10L12.4 6.81 9.58e-11 2.03e-07 0.5 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771186 chr4:102828055~102844075:+ CESC cis rs7626444 0.625 rs843535 ENSG00000272359.1 U4 -6.81 9.59e-11 2.03e-07 -0.49 -0.42 Monocyte count; chr3:196746193 chr3:196747192~196747324:- CESC cis rs11155671 0.53 rs4870080 ENSG00000268592.3 RAET1E-AS1 6.8 9.63e-11 2.04e-07 0.54 0.42 Testicular germ cell tumor; chr6:149881508 chr6:149863494~149919507:+ CESC cis rs2929278 0.617 rs4617832 ENSG00000249839.1 AC011330.5 6.8 9.66e-11 2.05e-07 0.44 0.42 Schizophrenia; chr15:43738381 chr15:43663654~43684339:- CESC cis rs2404602 0.647 rs11072612 ENSG00000259422.1 RP11-593F23.1 -6.8 9.68e-11 2.05e-07 -0.49 -0.42 Blood metabolite levels; chr15:76668643 chr15:76174891~76181486:- CESC cis rs10129255 0.5 rs9324092 ENSG00000223648.3 IGHV3-64 -6.8 9.73e-11 2.06e-07 -0.34 -0.42 Kawasaki disease; chr14:106683806 chr14:106643132~106658258:- CESC cis rs9660180 0.967 rs12044597 ENSG00000231050.1 RP1-140A9.1 6.8 9.8e-11 2.07e-07 0.49 0.42 Body mass index; chr1:1777362 chr1:1891471~1892658:+ CESC cis rs6452524 0.935 rs7718284 ENSG00000249664.1 CTD-2227C6.2 -6.8 9.85e-11 2.08e-07 -0.47 -0.42 Hypertension (SNP x SNP interaction); chr5:83082488 chr5:83012285~83013109:- CESC cis rs6504950 0.72 rs9914836 ENSG00000275710.1 RP11-257O5.4 6.8 9.9e-11 2.09e-07 0.52 0.42 Breast cancer; chr17:54920514 chr17:54964474~54964679:+ CESC cis rs6964833 1 rs34324835 ENSG00000123965.13 PMS2P5 6.8 9.91e-11 2.1e-07 0.67 0.42 Menarche (age at onset); chr7:74717986 chr7:74894116~74897835:+ CESC cis rs3806843 0.735 rs801168 ENSG00000202111.1 VTRNA1-2 6.8 9.96e-11 2.11e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140700713 chr5:140718925~140719013:+ CESC cis rs1062177 1 rs2964585 ENSG00000213433.5 RPLP1P6 -6.8 1e-10 2.12e-07 -0.52 -0.42 Preschool internalizing problems; chr5:151762334 chr5:151765859~151766378:- CESC cis rs1062177 1 rs2964578 ENSG00000213433.5 RPLP1P6 -6.8 1e-10 2.12e-07 -0.52 -0.42 Preschool internalizing problems; chr5:151767637 chr5:151765859~151766378:- CESC cis rs6700559 0.935 rs4072553 ENSG00000260088.1 RP11-92G12.3 -6.8 1.01e-10 2.12e-07 -0.54 -0.42 Coronary artery disease; chr1:200680036 chr1:200669507~200694250:+ CESC cis rs9549367 0.789 rs2287253 ENSG00000269125.1 RP11-98F14.11 6.8 1.01e-10 2.13e-07 0.56 0.42 Platelet distribution width; chr13:113236761 chr13:113165002~113165183:- CESC cis rs9660180 0.967 rs2272908 ENSG00000231050.1 RP1-140A9.1 -6.8 1.01e-10 2.14e-07 -0.48 -0.42 Body mass index; chr1:1790040 chr1:1891471~1892658:+ CESC cis rs1707322 1 rs1622208 ENSG00000280836.1 AL355480.1 6.8 1.01e-10 2.14e-07 0.5 0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46032703 chr1:45581219~45581321:- CESC cis rs9549367 0.789 rs2287244 ENSG00000269125.1 RP11-98F14.11 6.79 1.02e-10 2.16e-07 0.54 0.42 Platelet distribution width; chr13:113232859 chr13:113165002~113165183:- CESC cis rs150992 0.632 rs1472622 ENSG00000248489.1 CTD-2007H13.3 -6.79 1.03e-10 2.16e-07 -0.49 -0.42 Body mass index; chr5:99000749 chr5:98929171~98995013:+ CESC cis rs2404602 0.622 rs4886506 ENSG00000259422.1 RP11-593F23.1 6.79 1.03e-10 2.17e-07 0.49 0.42 Blood metabolite levels; chr15:76914936 chr15:76174891~76181486:- CESC cis rs9399135 0.967 rs11755229 ENSG00000232876.1 CTA-212D2.2 -6.79 1.03e-10 2.17e-07 -0.47 -0.42 Red blood cell count; chr6:135048775 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs9389261 ENSG00000232876.1 CTA-212D2.2 -6.79 1.03e-10 2.17e-07 -0.47 -0.42 Red blood cell count; chr6:135050010 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs9376085 ENSG00000232876.1 CTA-212D2.2 -6.79 1.03e-10 2.17e-07 -0.47 -0.42 Red blood cell count; chr6:135050086 chr6:135055033~135060550:+ CESC cis rs3806843 0.966 rs6891559 ENSG00000202111.1 VTRNA1-2 -6.79 1.03e-10 2.17e-07 -0.43 -0.42 Depressive symptoms (multi-trait analysis); chr5:140765621 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs11741994 ENSG00000202111.1 VTRNA1-2 -6.79 1.03e-10 2.17e-07 -0.43 -0.42 Depressive symptoms (multi-trait analysis); chr5:140766364 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs2337516 ENSG00000202111.1 VTRNA1-2 6.79 1.03e-10 2.18e-07 0.43 0.42 Depressive symptoms (multi-trait analysis); chr5:140761268 chr5:140718925~140719013:+ CESC cis rs112721625 1 rs112721625 ENSG00000266992.1 DHX40P1 6.79 1.03e-10 2.18e-07 0.46 0.42 Monocyte count; chr17:59850066 chr17:59976009~60002384:- CESC cis rs9545047 0.716 rs6563096 ENSG00000227676.3 LINC01068 -6.79 1.03e-10 2.18e-07 -0.46 -0.42 Schizophrenia; chr13:79284100 chr13:79566727~79571436:+ CESC cis rs3806843 0.966 rs2563261 ENSG00000202111.1 VTRNA1-2 6.79 1.04e-10 2.18e-07 0.43 0.42 Depressive symptoms (multi-trait analysis); chr5:140758128 chr5:140718925~140719013:+ CESC cis rs10875746 0.81 rs10875732 ENSG00000240399.1 RP1-228P16.1 -6.79 1.05e-10 2.22e-07 -0.55 -0.42 Longevity (90 years and older); chr12:48048322 chr12:48054813~48055591:- CESC cis rs10875746 0.807 rs12297004 ENSG00000240399.1 RP1-228P16.1 -6.79 1.06e-10 2.22e-07 -0.55 -0.42 Longevity (90 years and older); chr12:48060037 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs58952582 ENSG00000240399.1 RP1-228P16.1 -6.79 1.06e-10 2.22e-07 -0.55 -0.42 Longevity (90 years and older); chr12:48064665 chr12:48054813~48055591:- CESC cis rs10853057 0.717 rs62062478 ENSG00000214174.7 AMZ2P1 6.79 1.06e-10 2.22e-07 0.72 0.42 White matter microstructure (global fractional anisotropy); chr17:65059458 chr17:64966550~64975576:- CESC cis rs10853057 0.717 rs58524282 ENSG00000214174.7 AMZ2P1 6.79 1.06e-10 2.22e-07 0.72 0.42 White matter microstructure (global fractional anisotropy); chr17:65060479 chr17:64966550~64975576:- CESC cis rs9545047 0.716 rs416660 ENSG00000227676.3 LINC01068 -6.79 1.06e-10 2.24e-07 -0.47 -0.42 Schizophrenia; chr13:79432726 chr13:79566727~79571436:+ CESC cis rs9545047 0.716 rs9545053 ENSG00000227676.3 LINC01068 6.79 1.07e-10 2.24e-07 0.46 0.42 Schizophrenia; chr13:79296079 chr13:79566727~79571436:+ CESC cis rs1823913 1 rs4853568 ENSG00000280083.1 RP11-317J9.1 6.79 1.07e-10 2.24e-07 0.47 0.42 Obesity-related traits; chr2:191261464 chr2:191154118~191156070:- CESC cis rs4888378 0.576 rs8050367 ENSG00000261783.1 RP11-252K23.2 6.79 1.07e-10 2.24e-07 0.65 0.42 Coronary artery disease; chr16:75279360 chr16:75379818~75381260:- CESC cis rs2404602 0.583 rs12913096 ENSG00000259422.1 RP11-593F23.1 6.79 1.07e-10 2.25e-07 0.46 0.42 Blood metabolite levels; chr15:76259511 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs35940181 ENSG00000259422.1 RP11-593F23.1 -6.79 1.07e-10 2.25e-07 -0.49 -0.42 Blood metabolite levels; chr15:76887678 chr15:76174891~76181486:- CESC cis rs2929278 0.589 rs7174732 ENSG00000249839.1 AC011330.5 6.79 1.07e-10 2.25e-07 0.44 0.42 Schizophrenia; chr15:43746265 chr15:43663654~43684339:- CESC cis rs7044106 0.512 rs7873848 ENSG00000226752.6 PSMD5-AS1 -6.79 1.07e-10 2.26e-07 -0.46 -0.42 Hip circumference adjusted for BMI; chr9:120591944 chr9:120824828~120854385:+ CESC cis rs3806843 1 rs3806845 ENSG00000202111.1 VTRNA1-2 -6.78 1.08e-10 2.27e-07 -0.43 -0.42 Depressive symptoms (multi-trait analysis); chr5:140801152 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs3733707 ENSG00000202111.1 VTRNA1-2 -6.78 1.08e-10 2.27e-07 -0.43 -0.42 Depressive symptoms (multi-trait analysis); chr5:140802307 chr5:140718925~140719013:+ CESC cis rs7849270 1 rs3124512 ENSG00000268707.1 RP11-247A12.7 6.78 1.08e-10 2.27e-07 0.53 0.42 Blood metabolite ratios; chr9:129141602 chr9:129170434~129170940:+ CESC cis rs3806843 0.735 rs801180 ENSG00000202111.1 VTRNA1-2 6.78 1.1e-10 2.31e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140713318 chr5:140718925~140719013:+ CESC cis rs9545047 0.645 rs9635027 ENSG00000227676.3 LINC01068 6.78 1.1e-10 2.32e-07 0.46 0.42 Schizophrenia; chr13:79295538 chr13:79566727~79571436:+ CESC cis rs875971 0.83 rs427973 ENSG00000226824.5 RP4-756H11.3 -6.78 1.11e-10 2.32e-07 -0.53 -0.42 Aortic root size; chr7:66061661 chr7:66654538~66669855:+ CESC cis rs35955747 0.902 rs7287402 ENSG00000236132.1 CTA-440B3.1 -6.78 1.11e-10 2.32e-07 -0.49 -0.42 Neutrophil count;Sum basophil neutrophil counts; chr22:31258837 chr22:31816379~31817491:- CESC cis rs1577917 0.958 rs12215232 ENSG00000203875.9 SNHG5 -6.78 1.12e-10 2.34e-07 -0.52 -0.42 Response to antipsychotic treatment; chr6:86075712 chr6:85660950~85678736:- CESC cis rs6991838 0.584 rs10089708 ENSG00000272010.1 CTD-3025N20.3 6.78 1.13e-10 2.36e-07 0.48 0.42 Intelligence (multi-trait analysis); chr8:65642927 chr8:65591850~65592472:- CESC cis rs6991838 0.584 rs6991731 ENSG00000272010.1 CTD-3025N20.3 6.78 1.13e-10 2.36e-07 0.48 0.42 Intelligence (multi-trait analysis); chr8:65643232 chr8:65591850~65592472:- CESC cis rs227275 0.556 rs4455413 ENSG00000246560.2 RP11-10L12.4 6.78 1.13e-10 2.36e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102971925 chr4:102828055~102844075:+ CESC cis rs1577917 0.876 rs1582126 ENSG00000203875.9 SNHG5 -6.78 1.13e-10 2.36e-07 -0.53 -0.42 Response to antipsychotic treatment; chr6:85987487 chr6:85660950~85678736:- CESC cis rs227275 0.556 rs12508069 ENSG00000246560.2 RP11-10L12.4 6.78 1.13e-10 2.36e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102983598 chr4:102828055~102844075:+ CESC cis rs227275 0.527 rs12500379 ENSG00000246560.2 RP11-10L12.4 6.78 1.13e-10 2.36e-07 0.51 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102983665 chr4:102828055~102844075:+ CESC cis rs2404602 0.647 rs3812908 ENSG00000259422.1 RP11-593F23.1 6.78 1.13e-10 2.37e-07 0.49 0.42 Blood metabolite levels; chr15:76883817 chr15:76174891~76181486:- CESC cis rs6700559 1 rs10800720 ENSG00000260088.1 RP11-92G12.3 -6.78 1.13e-10 2.38e-07 -0.54 -0.42 Coronary artery disease; chr1:200679441 chr1:200669507~200694250:+ CESC cis rs9399135 0.967 rs7741515 ENSG00000232876.1 CTA-212D2.2 6.78 1.14e-10 2.38e-07 0.48 0.42 Red blood cell count; chr6:135053230 chr6:135055033~135060550:+ CESC cis rs875971 0.862 rs10256544 ENSG00000226824.5 RP4-756H11.3 -6.78 1.14e-10 2.38e-07 -0.52 -0.42 Aortic root size; chr7:66210141 chr7:66654538~66669855:+ CESC cis rs3096299 0.642 rs12934829 ENSG00000274627.1 RP11-104N10.2 6.78 1.14e-10 2.38e-07 0.41 0.42 Multiple myeloma (IgH translocation); chr16:89456941 chr16:89516797~89522217:+ CESC cis rs3806843 0.735 rs702394 ENSG00000202111.1 VTRNA1-2 6.78 1.14e-10 2.39e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140707201 chr5:140718925~140719013:+ CESC cis rs9399135 0.967 rs9376082 ENSG00000232876.1 CTA-212D2.2 -6.78 1.14e-10 2.39e-07 -0.48 -0.42 Red blood cell count; chr6:135025251 chr6:135055033~135060550:+ CESC cis rs3806843 0.735 rs801183 ENSG00000202111.1 VTRNA1-2 -6.77 1.15e-10 2.4e-07 -0.43 -0.42 Depressive symptoms (multi-trait analysis); chr5:140711530 chr5:140718925~140719013:+ CESC cis rs150992 0.609 rs363929 ENSG00000248489.1 CTD-2007H13.3 6.77 1.15e-10 2.4e-07 0.5 0.42 Body mass index; chr5:98985933 chr5:98929171~98995013:+ CESC cis rs4423214 0.84 rs1792235 ENSG00000254682.1 RP11-660L16.2 -6.77 1.15e-10 2.41e-07 -0.55 -0.42 Vitamin D levels; chr11:71470427 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1619577 ENSG00000254682.1 RP11-660L16.2 -6.77 1.15e-10 2.41e-07 -0.55 -0.42 Vitamin D levels; chr11:71470439 chr11:71448674~71452157:+ CESC cis rs6991838 0.584 rs7842085 ENSG00000272010.1 CTD-3025N20.3 6.77 1.16e-10 2.42e-07 0.49 0.42 Intelligence (multi-trait analysis); chr8:65636787 chr8:65591850~65592472:- CESC cis rs2404602 0.735 rs11857015 ENSG00000259422.1 RP11-593F23.1 -6.77 1.16e-10 2.43e-07 -0.51 -0.42 Blood metabolite levels; chr15:76357049 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs11631394 ENSG00000259422.1 RP11-593F23.1 -6.77 1.16e-10 2.43e-07 -0.49 -0.42 Blood metabolite levels; chr15:76680868 chr15:76174891~76181486:- CESC cis rs150992 0.632 rs34489 ENSG00000248489.1 CTD-2007H13.3 -6.77 1.16e-10 2.43e-07 -0.5 -0.42 Body mass index; chr5:98977180 chr5:98929171~98995013:+ CESC cis rs2404602 0.647 rs4886840 ENSG00000259422.1 RP11-593F23.1 -6.77 1.17e-10 2.44e-07 -0.49 -0.42 Blood metabolite levels; chr15:76886661 chr15:76174891~76181486:- CESC cis rs1707322 1 rs10890376 ENSG00000280836.1 AL355480.1 -6.77 1.18e-10 2.47e-07 -0.5 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940910 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10890381 ENSG00000280836.1 AL355480.1 -6.77 1.18e-10 2.47e-07 -0.5 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45986099 chr1:45581219~45581321:- CESC cis rs1577917 1 rs955227 ENSG00000203875.9 SNHG5 -6.77 1.18e-10 2.47e-07 -0.54 -0.42 Response to antipsychotic treatment; chr6:85941314 chr6:85660950~85678736:- CESC cis rs1707322 1 rs12097761 ENSG00000280836.1 AL355480.1 -6.77 1.18e-10 2.47e-07 -0.5 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45825490 chr1:45581219~45581321:- CESC cis rs150992 0.632 rs34491 ENSG00000248489.1 CTD-2007H13.3 6.77 1.18e-10 2.47e-07 0.5 0.42 Body mass index; chr5:98974118 chr5:98929171~98995013:+ CESC cis rs1823913 0.599 rs67342262 ENSG00000280083.1 RP11-317J9.1 -6.77 1.19e-10 2.49e-07 -0.49 -0.42 Obesity-related traits; chr2:191295612 chr2:191154118~191156070:- CESC cis rs2404602 0.647 rs11072616 ENSG00000259422.1 RP11-593F23.1 -6.77 1.19e-10 2.49e-07 -0.49 -0.42 Blood metabolite levels; chr15:76692928 chr15:76174891~76181486:- CESC cis rs11155671 0.53 rs2342769 ENSG00000231760.4 RP11-350J20.5 6.77 1.2e-10 2.5e-07 0.51 0.42 Testicular germ cell tumor; chr6:149895371 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs7742993 ENSG00000216906.2 RP11-350J20.9 6.77 1.2e-10 2.51e-07 0.44 0.42 Testicular germ cell tumor; chr6:149883959 chr6:149904243~149906418:+ CESC cis rs3806843 0.705 rs2530230 ENSG00000202111.1 VTRNA1-2 6.76 1.21e-10 2.52e-07 0.43 0.42 Depressive symptoms (multi-trait analysis); chr5:140708546 chr5:140718925~140719013:+ CESC cis rs7208859 0.725 rs9915802 ENSG00000263531.1 RP13-753N3.1 6.76 1.23e-10 2.56e-07 0.65 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846040 chr17:30863921~30864940:- CESC cis rs7208859 0.725 rs7342938 ENSG00000263531.1 RP13-753N3.1 6.76 1.23e-10 2.56e-07 0.65 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862812 chr17:30863921~30864940:- CESC cis rs7208859 0.725 rs6505215 ENSG00000263531.1 RP13-753N3.1 6.76 1.23e-10 2.56e-07 0.65 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862885 chr17:30863921~30864940:- CESC cis rs9399137 0.507 rs7768278 ENSG00000232876.1 CTA-212D2.2 -6.76 1.23e-10 2.56e-07 -0.52 -0.42 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134953819 chr6:135055033~135060550:+ CESC cis rs150992 0.79 rs45931 ENSG00000248489.1 CTD-2007H13.3 6.76 1.23e-10 2.57e-07 0.5 0.42 Body mass index; chr5:98978344 chr5:98929171~98995013:+ CESC cis rs2739330 0.76 rs1002286 ENSG00000231271.1 AP000350.8 -6.76 1.24e-10 2.58e-07 -0.5 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23949918~23954042:+ CESC cis rs9660180 0.935 rs2180311 ENSG00000231050.1 RP1-140A9.1 6.76 1.24e-10 2.58e-07 0.48 0.42 Body mass index; chr1:1817295 chr1:1891471~1892658:+ CESC cis rs9660180 0.967 rs6664664 ENSG00000231050.1 RP1-140A9.1 6.76 1.24e-10 2.58e-07 0.48 0.42 Body mass index; chr1:1819825 chr1:1891471~1892658:+ CESC cis rs9545047 0.704 rs3742120 ENSG00000227676.3 LINC01068 6.76 1.24e-10 2.59e-07 0.48 0.42 Schizophrenia; chr13:79386700 chr13:79566727~79571436:+ CESC cis rs9545047 0.716 rs3742122 ENSG00000227676.3 LINC01068 6.76 1.24e-10 2.59e-07 0.48 0.42 Schizophrenia; chr13:79387061 chr13:79566727~79571436:+ CESC cis rs11155671 0.53 rs9383940 ENSG00000216906.2 RP11-350J20.9 6.76 1.25e-10 2.59e-07 0.45 0.42 Testicular germ cell tumor; chr6:149904923 chr6:149904243~149906418:+ CESC cis rs228614 0.51 rs223472 ENSG00000246560.2 RP11-10L12.4 6.76 1.25e-10 2.6e-07 0.51 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102774327 chr4:102828055~102844075:+ CESC cis rs3806843 0.676 rs2569159 ENSG00000202111.1 VTRNA1-2 6.76 1.25e-10 2.6e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140651125 chr5:140718925~140719013:+ CESC cis rs3806843 0.676 rs1583005 ENSG00000202111.1 VTRNA1-2 6.76 1.25e-10 2.6e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140651952 chr5:140718925~140719013:+ CESC cis rs7727544 0.735 rs2569266 ENSG00000233006.5 AC034220.3 -6.76 1.27e-10 2.63e-07 -0.46 -0.42 Blood metabolite levels; chr5:132371099 chr5:132311285~132369916:- CESC cis rs9399135 0.967 rs1854865 ENSG00000232876.1 CTA-212D2.2 -6.76 1.27e-10 2.64e-07 -0.47 -0.42 Red blood cell count; chr6:135039162 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs6569990 ENSG00000232876.1 CTA-212D2.2 -6.76 1.28e-10 2.65e-07 -0.47 -0.42 Red blood cell count; chr6:135044680 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs13191501 ENSG00000232876.1 CTA-212D2.2 -6.76 1.28e-10 2.65e-07 -0.47 -0.42 Red blood cell count; chr6:135045742 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs6908512 ENSG00000232876.1 CTA-212D2.2 -6.76 1.28e-10 2.65e-07 -0.47 -0.42 Red blood cell count; chr6:135046619 chr6:135055033~135060550:+ CESC cis rs10875746 0.855 rs12310999 ENSG00000240399.1 RP1-228P16.1 -6.76 1.28e-10 2.66e-07 -0.55 -0.42 Longevity (90 years and older); chr12:48053875 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs61918774 ENSG00000240399.1 RP1-228P16.1 -6.76 1.28e-10 2.66e-07 -0.55 -0.42 Longevity (90 years and older); chr12:48054351 chr12:48054813~48055591:- CESC cis rs2404602 0.647 rs8025991 ENSG00000259422.1 RP11-593F23.1 -6.75 1.28e-10 2.66e-07 -0.49 -0.42 Blood metabolite levels; chr15:76862927 chr15:76174891~76181486:- CESC cis rs1823913 0.599 rs2124095 ENSG00000280083.1 RP11-317J9.1 -6.75 1.29e-10 2.67e-07 -0.49 -0.42 Obesity-related traits; chr2:191301728 chr2:191154118~191156070:- CESC cis rs150992 0.721 rs2937706 ENSG00000248489.1 CTD-2007H13.3 6.75 1.31e-10 2.72e-07 0.5 0.42 Body mass index; chr5:98990434 chr5:98929171~98995013:+ CESC cis rs150992 0.714 rs76798907 ENSG00000248489.1 CTD-2007H13.3 6.75 1.31e-10 2.72e-07 0.5 0.42 Body mass index; chr5:98990780 chr5:98929171~98995013:+ CESC cis rs9549367 0.713 rs4907599 ENSG00000269125.1 RP11-98F14.11 6.75 1.31e-10 2.72e-07 0.52 0.42 Platelet distribution width; chr13:113207127 chr13:113165002~113165183:- CESC cis rs2404602 0.552 rs4886823 ENSG00000259422.1 RP11-593F23.1 -6.75 1.31e-10 2.73e-07 -0.51 -0.42 Blood metabolite levels; chr15:76673061 chr15:76174891~76181486:- CESC cis rs6452524 0.967 rs6897075 ENSG00000249664.1 CTD-2227C6.2 6.75 1.33e-10 2.75e-07 0.46 0.42 Hypertension (SNP x SNP interaction); chr5:83122959 chr5:83012285~83013109:- CESC cis rs7617773 0.78 rs34523942 ENSG00000229759.1 MRPS18AP1 6.75 1.33e-10 2.75e-07 0.44 0.42 Coronary artery disease; chr3:48301179 chr3:48256350~48256938:- CESC cis rs2404602 0.647 rs11072636 ENSG00000259422.1 RP11-593F23.1 -6.75 1.33e-10 2.75e-07 -0.49 -0.42 Blood metabolite levels; chr15:76893445 chr15:76174891~76181486:- CESC cis rs6991838 0.584 rs2175810 ENSG00000272010.1 CTD-3025N20.3 -6.75 1.33e-10 2.76e-07 -0.46 -0.42 Intelligence (multi-trait analysis); chr8:65643583 chr8:65591850~65592472:- CESC cis rs1823913 0.637 rs1378162 ENSG00000280083.1 RP11-317J9.1 -6.75 1.33e-10 2.76e-07 -0.49 -0.42 Obesity-related traits; chr2:191298523 chr2:191154118~191156070:- CESC cis rs7849270 1 rs746489 ENSG00000268707.1 RP11-247A12.7 -6.75 1.34e-10 2.78e-07 -0.49 -0.42 Blood metabolite ratios; chr9:129147814 chr9:129170434~129170940:+ CESC cis rs10875746 0.855 rs12296244 ENSG00000240399.1 RP1-228P16.1 -6.75 1.35e-10 2.8e-07 -0.55 -0.42 Longevity (90 years and older); chr12:48047696 chr12:48054813~48055591:- CESC cis rs2404602 0.647 rs7181506 ENSG00000259422.1 RP11-593F23.1 6.74 1.36e-10 2.82e-07 0.49 0.42 Blood metabolite levels; chr15:76643336 chr15:76174891~76181486:- CESC cis rs228614 0.509 rs223482 ENSG00000246560.2 RP11-10L12.4 6.74 1.38e-10 2.85e-07 0.5 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766051 chr4:102828055~102844075:+ CESC cis rs228614 0.509 rs223481 ENSG00000246560.2 RP11-10L12.4 6.74 1.38e-10 2.85e-07 0.5 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766860 chr4:102828055~102844075:+ CESC cis rs2581828 0.656 rs2336723 ENSG00000242142.1 SERBP1P3 6.74 1.38e-10 2.85e-07 0.47 0.42 Crohn's disease; chr3:53072031 chr3:53064283~53065091:- CESC cis rs2404602 0.608 rs12911035 ENSG00000259422.1 RP11-593F23.1 6.74 1.39e-10 2.86e-07 0.47 0.42 Blood metabolite levels; chr15:76314250 chr15:76174891~76181486:- CESC cis rs7727544 0.636 rs2631365 ENSG00000233006.5 AC034220.3 -6.74 1.39e-10 2.87e-07 -0.46 -0.42 Blood metabolite levels; chr5:132370257 chr5:132311285~132369916:- CESC cis rs3806843 0.676 rs2563304 ENSG00000202111.1 VTRNA1-2 6.74 1.39e-10 2.87e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140692472 chr5:140718925~140719013:+ CESC cis rs3806843 0.735 rs3776129 ENSG00000202111.1 VTRNA1-2 6.74 1.39e-10 2.87e-07 0.44 0.42 Depressive symptoms (multi-trait analysis); chr5:140692707 chr5:140718925~140719013:+ CESC cis rs9907295 0.591 rs2107538 ENSG00000270977.1 AC015849.16 -6.74 1.41e-10 2.91e-07 -0.51 -0.42 Fibroblast growth factor basic levels; chr17:35880776 chr17:35893707~35911023:- CESC cis rs150992 0.609 rs366353 ENSG00000248489.1 CTD-2007H13.3 -6.74 1.42e-10 2.92e-07 -0.49 -0.42 Body mass index; chr5:98995663 chr5:98929171~98995013:+ CESC cis rs1707322 0.691 rs11211175 ENSG00000281133.1 AL355480.3 -6.74 1.42e-10 2.92e-07 -0.49 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755212 chr1:45580892~45580996:- CESC cis rs6964833 0.786 rs35633336 ENSG00000123965.13 PMS2P5 6.74 1.42e-10 2.92e-07 0.65 0.42 Menarche (age at onset); chr7:74643961 chr7:74894116~74897835:+ CESC cis rs6964833 0.935 rs34630792 ENSG00000123965.13 PMS2P5 6.74 1.42e-10 2.92e-07 0.65 0.42 Menarche (age at onset); chr7:74646869 chr7:74894116~74897835:+ CESC cis rs1577917 1 rs12215037 ENSG00000203875.9 SNHG5 -6.74 1.42e-10 2.93e-07 -0.53 -0.42 Response to antipsychotic treatment; chr6:86017913 chr6:85660950~85678736:- CESC cis rs7849270 1 rs10760589 ENSG00000268707.1 RP11-247A12.7 -6.74 1.42e-10 2.93e-07 -0.49 -0.42 Blood metabolite ratios; chr9:129144014 chr9:129170434~129170940:+ CESC cis rs3096299 0.692 rs4785565 ENSG00000274627.1 RP11-104N10.2 6.74 1.43e-10 2.94e-07 0.41 0.42 Multiple myeloma (IgH translocation); chr16:89449351 chr16:89516797~89522217:+ CESC cis rs2404602 0.647 rs36114653 ENSG00000259422.1 RP11-593F23.1 -6.74 1.43e-10 2.95e-07 -0.5 -0.42 Blood metabolite levels; chr15:76733052 chr15:76174891~76181486:- CESC cis rs2739330 0.76 rs1007888 ENSG00000231271.1 AP000350.8 6.73 1.44e-10 2.97e-07 0.51 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23949918~23954042:+ CESC cis rs228614 0.51 rs223455 ENSG00000246560.2 RP11-10L12.4 6.73 1.45e-10 2.99e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789026 chr4:102828055~102844075:+ CESC cis rs5769707 0.749 rs7286706 ENSG00000188511.11 C22orf34 6.73 1.45e-10 2.99e-07 0.42 0.41 Monocyte percentage of white cells;Monocyte count; chr22:49664698 chr22:49414524~49657542:- CESC cis rs8062405 1 rs12446589 ENSG00000259982.1 CDC37P1 6.73 1.46e-10 3e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859641 chr16:28700294~28701540:- CESC cis rs150992 0.609 rs161935 ENSG00000248489.1 CTD-2007H13.3 6.73 1.47e-10 3.02e-07 0.5 0.41 Body mass index; chr5:98982733 chr5:98929171~98995013:+ CESC cis rs6964833 1 rs36044436 ENSG00000123965.13 PMS2P5 6.73 1.48e-10 3.03e-07 0.66 0.41 Menarche (age at onset); chr7:74675495 chr7:74894116~74897835:+ CESC cis rs2581828 0.656 rs1864367 ENSG00000242142.1 SERBP1P3 6.73 1.48e-10 3.03e-07 0.46 0.41 Crohn's disease; chr3:53077688 chr3:53064283~53065091:- CESC cis rs2882667 0.683 rs13188935 ENSG00000253404.1 AC034243.1 6.73 1.48e-10 3.04e-07 0.48 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139116536 chr5:138744434~138753309:- CESC cis rs875971 0.825 rs4587224 ENSG00000226824.5 RP4-756H11.3 6.73 1.48e-10 3.04e-07 0.5 0.41 Aortic root size; chr7:66271195 chr7:66654538~66669855:+ CESC cis rs875971 0.792 rs6971752 ENSG00000226824.5 RP4-756H11.3 6.73 1.48e-10 3.04e-07 0.5 0.41 Aortic root size; chr7:66272999 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs10950033 ENSG00000226824.5 RP4-756H11.3 6.73 1.48e-10 3.04e-07 0.5 0.41 Aortic root size; chr7:66274686 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs11760844 ENSG00000226824.5 RP4-756H11.3 6.73 1.48e-10 3.04e-07 0.5 0.41 Aortic root size; chr7:66274896 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs949930 ENSG00000226824.5 RP4-756H11.3 6.73 1.48e-10 3.04e-07 0.5 0.41 Aortic root size; chr7:66301835 chr7:66654538~66669855:+ CESC cis rs9326248 0.53 rs2075292 ENSG00000254851.1 RP11-109L13.1 -6.73 1.49e-10 3.05e-07 -0.76 -0.41 Blood protein levels; chr11:116861796 chr11:117135528~117138582:+ CESC cis rs9326248 0.53 rs6589575 ENSG00000254851.1 RP11-109L13.1 -6.73 1.49e-10 3.05e-07 -0.76 -0.41 Blood protein levels; chr11:116862594 chr11:117135528~117138582:+ CESC cis rs7626444 0.647 rs843537 ENSG00000272359.1 U4 -6.73 1.49e-10 3.06e-07 -0.49 -0.41 Monocyte count; chr3:196746532 chr3:196747192~196747324:- CESC cis rs7044106 0.708 rs959558 ENSG00000226752.6 PSMD5-AS1 -6.73 1.49e-10 3.06e-07 -0.46 -0.41 Hip circumference adjusted for BMI; chr9:120606633 chr9:120824828~120854385:+ CESC cis rs1707322 1 rs6672115 ENSG00000280836.1 AL355480.1 -6.73 1.49e-10 3.07e-07 -0.5 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45807207 chr1:45581219~45581321:- CESC cis rs1707322 1 rs7539800 ENSG00000280836.1 AL355480.1 6.73 1.49e-10 3.07e-07 0.5 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45796457 chr1:45581219~45581321:- CESC cis rs7617773 0.963 rs6800730 ENSG00000229759.1 MRPS18AP1 6.73 1.49e-10 3.07e-07 0.39 0.41 Coronary artery disease; chr3:48132720 chr3:48256350~48256938:- CESC cis rs526231 0.578 rs3776870 ENSG00000175749.11 EIF3KP1 6.73 1.5e-10 3.08e-07 0.46 0.41 Primary biliary cholangitis; chr5:102959366 chr5:103032376~103033031:+ CESC cis rs3806843 1 rs1030165 ENSG00000202111.1 VTRNA1-2 -6.73 1.5e-10 3.08e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140805863 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs1030166 ENSG00000202111.1 VTRNA1-2 -6.73 1.5e-10 3.08e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140805888 chr5:140718925~140719013:+ CESC cis rs1707322 1 rs11211232 ENSG00000280836.1 AL355480.1 -6.73 1.51e-10 3.1e-07 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45945474 chr1:45581219~45581321:- CESC cis rs10129255 0.5 rs10143242 ENSG00000223648.3 IGHV3-64 6.73 1.52e-10 3.1e-07 0.33 0.41 Kawasaki disease; chr14:106681814 chr14:106643132~106658258:- CESC cis rs10256972 0.732 rs12701856 ENSG00000229043.2 AC091729.9 -6.73 1.52e-10 3.11e-07 -0.47 -0.41 Endometriosis;Longevity; chr7:1068071 chr7:1160374~1165267:+ CESC cis rs6964833 0.935 rs13238996 ENSG00000123965.13 PMS2P5 6.73 1.52e-10 3.11e-07 0.66 0.41 Menarche (age at onset); chr7:74655318 chr7:74894116~74897835:+ CESC cis rs875971 0.825 rs1000464 ENSG00000226824.5 RP4-756H11.3 6.73 1.52e-10 3.11e-07 0.5 0.41 Aortic root size; chr7:66312922 chr7:66654538~66669855:+ CESC cis rs2404602 0.532 rs12591100 ENSG00000259422.1 RP11-593F23.1 -6.73 1.52e-10 3.11e-07 -0.47 -0.41 Blood metabolite levels; chr15:76408460 chr15:76174891~76181486:- CESC cis rs7208859 0.573 rs216443 ENSG00000263531.1 RP13-753N3.1 6.73 1.52e-10 3.11e-07 0.85 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604853 chr17:30863921~30864940:- CESC cis rs6504950 1 rs12940106 ENSG00000275710.1 RP11-257O5.4 6.73 1.52e-10 3.11e-07 0.55 0.41 Breast cancer; chr17:54990322 chr17:54964474~54964679:+ CESC cis rs875971 0.862 rs6460290 ENSG00000226824.5 RP4-756H11.3 6.72 1.52e-10 3.11e-07 0.51 0.41 Aortic root size; chr7:66344119 chr7:66654538~66669855:+ CESC cis rs9322193 0.504 rs7771014 ENSG00000268592.3 RAET1E-AS1 6.72 1.52e-10 3.11e-07 0.53 0.41 Lung cancer; chr6:149884310 chr6:149863494~149919507:+ CESC cis rs7727544 0.684 rs611084 ENSG00000233006.5 AC034220.3 -6.72 1.52e-10 3.12e-07 -0.46 -0.41 Blood metabolite levels; chr5:132374047 chr5:132311285~132369916:- CESC cis rs6700559 0.873 rs7542210 ENSG00000260088.1 RP11-92G12.3 -6.72 1.53e-10 3.13e-07 -0.54 -0.41 Coronary artery disease; chr1:200693087 chr1:200669507~200694250:+ CESC cis rs9399135 0.967 rs9376077 ENSG00000232876.1 CTA-212D2.2 -6.72 1.54e-10 3.15e-07 -0.48 -0.41 Red blood cell count; chr6:134978575 chr6:135055033~135060550:+ CESC cis rs2404602 0.647 rs11633869 ENSG00000259422.1 RP11-593F23.1 6.72 1.54e-10 3.16e-07 0.48 0.41 Blood metabolite levels; chr15:76840981 chr15:76174891~76181486:- CESC cis rs3096299 0.719 rs2353581 ENSG00000274627.1 RP11-104N10.2 6.72 1.55e-10 3.16e-07 0.41 0.41 Multiple myeloma (IgH translocation); chr16:89452500 chr16:89516797~89522217:+ CESC cis rs10129255 0.5 rs1024350 ENSG00000223648.3 IGHV3-64 6.72 1.55e-10 3.18e-07 0.33 0.41 Kawasaki disease; chr14:106685105 chr14:106643132~106658258:- CESC cis rs113835537 0.529 rs60358007 ENSG00000255517.5 CTD-3074O7.5 -6.72 1.56e-10 3.19e-07 -0.5 -0.41 Airway imaging phenotypes; chr11:66454882 chr11:66473490~66480233:- CESC cis rs507080 0.769 rs745663 ENSG00000255422.1 AP002954.4 -6.72 1.57e-10 3.21e-07 -0.49 -0.41 Serum metabolite levels; chr11:118658886 chr11:118704607~118750263:+ CESC cis rs6964833 0.935 rs34762099 ENSG00000123965.13 PMS2P5 6.72 1.58e-10 3.22e-07 0.65 0.41 Menarche (age at onset); chr7:74636378 chr7:74894116~74897835:+ CESC cis rs7849270 1 rs1360172 ENSG00000268707.1 RP11-247A12.7 -6.72 1.58e-10 3.22e-07 -0.49 -0.41 Blood metabolite ratios; chr9:129145701 chr9:129170434~129170940:+ CESC cis rs3806843 1 rs10053586 ENSG00000202111.1 VTRNA1-2 -6.72 1.59e-10 3.24e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140831175 chr5:140718925~140719013:+ CESC cis rs9549367 0.724 rs7985335 ENSG00000269125.1 RP11-98F14.11 6.72 1.59e-10 3.24e-07 0.53 0.41 Platelet distribution width; chr13:113214930 chr13:113165002~113165183:- CESC cis rs1823913 1 rs4853562 ENSG00000280083.1 RP11-317J9.1 6.72 1.59e-10 3.24e-07 0.47 0.41 Obesity-related traits; chr2:191253696 chr2:191154118~191156070:- CESC cis rs1823913 1 rs4853461 ENSG00000280083.1 RP11-317J9.1 6.72 1.59e-10 3.24e-07 0.47 0.41 Obesity-related traits; chr2:191254572 chr2:191154118~191156070:- CESC cis rs14027 0.921 rs2136374 ENSG00000279347.1 RP11-85I17.2 -6.72 1.59e-10 3.24e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119765046 chr8:119838736~119840385:- CESC cis rs14027 0.881 rs4871578 ENSG00000279347.1 RP11-85I17.2 -6.72 1.59e-10 3.24e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119767615 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs10110601 ENSG00000279347.1 RP11-85I17.2 -6.72 1.59e-10 3.24e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119774866 chr8:119838736~119840385:- CESC cis rs228614 0.51 rs223463 ENSG00000246560.2 RP11-10L12.4 6.72 1.59e-10 3.24e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780620 chr4:102828055~102844075:+ CESC cis rs8081395 0.805 rs1295927 ENSG00000266992.1 DHX40P1 6.72 1.6e-10 3.25e-07 0.43 0.41 White blood cell count; chr17:59852174 chr17:59976009~60002384:- CESC cis rs1062177 1 rs2915877 ENSG00000213433.5 RPLP1P6 -6.72 1.6e-10 3.26e-07 -0.52 -0.41 Preschool internalizing problems; chr5:151771040 chr5:151765859~151766378:- CESC cis rs1062177 1 rs2964576 ENSG00000213433.5 RPLP1P6 -6.72 1.6e-10 3.26e-07 -0.52 -0.41 Preschool internalizing problems; chr5:151771041 chr5:151765859~151766378:- CESC cis rs10853057 0.541 rs11656396 ENSG00000214174.7 AMZ2P1 6.72 1.6e-10 3.26e-07 0.54 0.41 White matter microstructure (global fractional anisotropy); chr17:65049958 chr17:64966550~64975576:- CESC cis rs3096299 0.582 rs12935119 ENSG00000274627.1 RP11-104N10.2 6.72 1.6e-10 3.27e-07 0.41 0.41 Multiple myeloma (IgH translocation); chr16:89476466 chr16:89516797~89522217:+ CESC cis rs1185460 0.967 rs1184902 ENSG00000271751.1 RP11-110I1.14 -6.72 1.61e-10 3.27e-07 -0.56 -0.41 Coronary artery disease; chr11:119074627 chr11:119065263~119065677:- CESC cis rs35955747 0.601 rs7289941 ENSG00000236132.1 CTA-440B3.1 -6.71 1.61e-10 3.28e-07 -0.47 -0.41 Neutrophil count;Sum basophil neutrophil counts; chr22:31488419 chr22:31816379~31817491:- CESC cis rs3806843 0.735 rs2563306 ENSG00000202111.1 VTRNA1-2 6.71 1.61e-10 3.28e-07 0.44 0.41 Depressive symptoms (multi-trait analysis); chr5:140690432 chr5:140718925~140719013:+ CESC cis rs3806843 0.735 rs813897 ENSG00000202111.1 VTRNA1-2 6.71 1.61e-10 3.28e-07 0.44 0.41 Depressive symptoms (multi-trait analysis); chr5:140690444 chr5:140718925~140719013:+ CESC cis rs1823913 0.526 rs36028476 ENSG00000280083.1 RP11-317J9.1 -6.71 1.61e-10 3.29e-07 -0.48 -0.41 Obesity-related traits; chr2:191300595 chr2:191154118~191156070:- CESC cis rs150992 0.593 rs326491 ENSG00000248489.1 CTD-2007H13.3 6.71 1.65e-10 3.36e-07 0.49 0.41 Body mass index; chr5:98972225 chr5:98929171~98995013:+ CESC cis rs1823913 0.599 rs67781530 ENSG00000280083.1 RP11-317J9.1 -6.71 1.66e-10 3.38e-07 -0.48 -0.41 Obesity-related traits; chr2:191295608 chr2:191154118~191156070:- CESC cis rs3806843 1 rs11167600 ENSG00000202111.1 VTRNA1-2 -6.71 1.67e-10 3.39e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140795280 chr5:140718925~140719013:+ CESC cis rs3806843 0.735 rs2563335 ENSG00000202111.1 VTRNA1-2 -6.71 1.69e-10 3.42e-07 -0.44 -0.41 Depressive symptoms (multi-trait analysis); chr5:140664707 chr5:140718925~140719013:+ CESC cis rs6504950 0.745 rs35079296 ENSG00000275710.1 RP11-257O5.4 6.7 1.71e-10 3.47e-07 0.5 0.41 Breast cancer; chr17:54916849 chr17:54964474~54964679:+ CESC cis rs9907295 0.591 rs4796128 ENSG00000270977.1 AC015849.16 -6.7 1.72e-10 3.48e-07 -0.5 -0.41 Fibroblast growth factor basic levels; chr17:35899268 chr17:35893707~35911023:- CESC cis rs3806843 0.735 rs2530235 ENSG00000202111.1 VTRNA1-2 6.7 1.72e-10 3.48e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140693062 chr5:140718925~140719013:+ CESC cis rs1577917 1 rs12205548 ENSG00000203875.9 SNHG5 -6.7 1.72e-10 3.49e-07 -0.52 -0.41 Response to antipsychotic treatment; chr6:86050052 chr6:85660950~85678736:- CESC cis rs1577917 1 rs12665321 ENSG00000203875.9 SNHG5 -6.7 1.72e-10 3.49e-07 -0.52 -0.41 Response to antipsychotic treatment; chr6:86059571 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12196175 ENSG00000203875.9 SNHG5 -6.7 1.72e-10 3.49e-07 -0.52 -0.41 Response to antipsychotic treatment; chr6:86069652 chr6:85660950~85678736:- CESC cis rs2581828 0.656 rs2253656 ENSG00000242142.1 SERBP1P3 6.7 1.73e-10 3.51e-07 0.46 0.41 Crohn's disease; chr3:53085083 chr3:53064283~53065091:- CESC cis rs2404602 0.684 rs11854850 ENSG00000259422.1 RP11-593F23.1 -6.7 1.74e-10 3.53e-07 -0.49 -0.41 Blood metabolite levels; chr15:76552230 chr15:76174891~76181486:- CESC cis rs1501911 0.53 rs326468 ENSG00000248489.1 CTD-2007H13.3 6.7 1.76e-10 3.56e-07 0.48 0.41 Lung function (FEV1/FVC); chr5:98897105 chr5:98929171~98995013:+ CESC cis rs875971 0.862 rs4236208 ENSG00000226824.5 RP4-756H11.3 6.7 1.76e-10 3.56e-07 0.5 0.41 Aortic root size; chr7:66284091 chr7:66654538~66669855:+ CESC cis rs150992 0.609 rs366000 ENSG00000248489.1 CTD-2007H13.3 -6.7 1.78e-10 3.6e-07 -0.49 -0.41 Body mass index; chr5:98991705 chr5:98929171~98995013:+ CESC cis rs7727544 0.684 rs274546 ENSG00000233006.5 AC034220.3 6.7 1.79e-10 3.61e-07 0.47 0.41 Blood metabolite levels; chr5:132364175 chr5:132311285~132369916:- CESC cis rs14027 0.921 rs16893101 ENSG00000279347.1 RP11-85I17.2 -6.7 1.8e-10 3.64e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119750669 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs13270831 ENSG00000279347.1 RP11-85I17.2 -6.7 1.8e-10 3.64e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119755071 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs16893113 ENSG00000279347.1 RP11-85I17.2 -6.7 1.8e-10 3.64e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119756447 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs2326377 ENSG00000279347.1 RP11-85I17.2 -6.7 1.8e-10 3.64e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119756696 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs13257002 ENSG00000279347.1 RP11-85I17.2 -6.7 1.8e-10 3.64e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119757489 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs62526565 ENSG00000279347.1 RP11-85I17.2 -6.7 1.8e-10 3.64e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119759301 chr8:119838736~119840385:- CESC cis rs2929278 0.562 rs8033846 ENSG00000249839.1 AC011330.5 6.69 1.8e-10 3.64e-07 0.43 0.41 Schizophrenia; chr15:43743165 chr15:43663654~43684339:- CESC cis rs35955747 0.87 rs7289189 ENSG00000236132.1 CTA-440B3.1 6.69 1.8e-10 3.64e-07 0.49 0.41 Neutrophil count;Sum basophil neutrophil counts; chr22:31261196 chr22:31816379~31817491:- CESC cis rs227275 0.556 rs223449 ENSG00000246560.2 RP11-10L12.4 6.69 1.8e-10 3.64e-07 0.5 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102791180 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223447 ENSG00000246560.2 RP11-10L12.4 6.69 1.8e-10 3.64e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102792202 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223446 ENSG00000246560.2 RP11-10L12.4 6.69 1.8e-10 3.64e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793025 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223445 ENSG00000246560.2 RP11-10L12.4 6.69 1.8e-10 3.64e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793337 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223443 ENSG00000246560.2 RP11-10L12.4 6.69 1.8e-10 3.64e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793629 chr4:102828055~102844075:+ CESC cis rs10129255 0.5 rs10142931 ENSG00000223648.3 IGHV3-64 6.69 1.81e-10 3.65e-07 0.34 0.41 Kawasaki disease; chr14:106782288 chr14:106643132~106658258:- CESC cis rs10256972 0.732 rs1574108 ENSG00000229043.2 AC091729.9 -6.69 1.82e-10 3.67e-07 -0.47 -0.41 Endometriosis;Longevity; chr7:1066169 chr7:1160374~1165267:+ CESC cis rs2739330 0.76 rs1002286 ENSG00000099984.9 GSTT2 6.69 1.83e-10 3.68e-07 0.5 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23980123~23983911:+ CESC cis rs1707322 0.721 rs61784800 ENSG00000281133.1 AL355480.3 6.69 1.83e-10 3.69e-07 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712440 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs6665808 ENSG00000281133.1 AL355480.3 -6.69 1.83e-10 3.69e-07 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45696611 chr1:45580892~45580996:- CESC cis rs1707322 0.682 rs28508523 ENSG00000281133.1 AL355480.3 -6.69 1.83e-10 3.69e-07 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723953 chr1:45580892~45580996:- CESC cis rs3806843 0.966 rs2240693 ENSG00000202111.1 VTRNA1-2 -6.69 1.84e-10 3.71e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140803740 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs2240692 ENSG00000202111.1 VTRNA1-2 -6.69 1.84e-10 3.71e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140804000 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs6579987 ENSG00000202111.1 VTRNA1-2 -6.69 1.84e-10 3.71e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140804074 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs1030163 ENSG00000202111.1 VTRNA1-2 -6.69 1.84e-10 3.71e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140805547 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs1030164 ENSG00000202111.1 VTRNA1-2 -6.69 1.84e-10 3.71e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140805687 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs4151680 ENSG00000202111.1 VTRNA1-2 -6.69 1.84e-10 3.71e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140807072 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs3822346 ENSG00000202111.1 VTRNA1-2 -6.69 1.84e-10 3.71e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140807737 chr5:140718925~140719013:+ CESC cis rs7208859 0.673 rs216418 ENSG00000263531.1 RP13-753N3.1 6.69 1.86e-10 3.73e-07 0.74 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30609519 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs216423 ENSG00000263531.1 RP13-753N3.1 6.69 1.86e-10 3.73e-07 0.74 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30615091 chr17:30863921~30864940:- CESC cis rs3806843 0.735 rs6849 ENSG00000202111.1 VTRNA1-2 6.69 1.86e-10 3.73e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140706606 chr5:140718925~140719013:+ CESC cis rs14027 0.921 rs1433951 ENSG00000279347.1 RP11-85I17.2 -6.69 1.87e-10 3.75e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119777362 chr8:119838736~119840385:- CESC cis rs875971 0.793 rs460678 ENSG00000226824.5 RP4-756H11.3 -6.69 1.87e-10 3.76e-07 -0.53 -0.41 Aortic root size; chr7:66062213 chr7:66654538~66669855:+ CESC cis rs1707322 0.721 rs56255771 ENSG00000281133.1 AL355480.3 -6.69 1.87e-10 3.76e-07 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758647 chr1:45580892~45580996:- CESC cis rs1707322 0.686 rs11211179 ENSG00000281133.1 AL355480.3 -6.69 1.87e-10 3.76e-07 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45762410 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs10157795 ENSG00000281133.1 AL355480.3 -6.69 1.87e-10 3.76e-07 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45762520 chr1:45580892~45580996:- CESC cis rs1577917 1 rs12196037 ENSG00000203875.9 SNHG5 -6.69 1.87e-10 3.76e-07 -0.53 -0.41 Response to antipsychotic treatment; chr6:85984913 chr6:85660950~85678736:- CESC cis rs10875746 0.903 rs10875735 ENSG00000240399.1 RP1-228P16.1 -6.69 1.89e-10 3.79e-07 -0.55 -0.41 Longevity (90 years and older); chr12:48070023 chr12:48054813~48055591:- CESC cis rs10875746 0.855 rs17122620 ENSG00000240399.1 RP1-228P16.1 -6.69 1.89e-10 3.79e-07 -0.55 -0.41 Longevity (90 years and older); chr12:48070692 chr12:48054813~48055591:- CESC cis rs10875746 0.859 rs4760680 ENSG00000240399.1 RP1-228P16.1 -6.69 1.89e-10 3.79e-07 -0.55 -0.41 Longevity (90 years and older); chr12:48072914 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs11168386 ENSG00000240399.1 RP1-228P16.1 -6.69 1.89e-10 3.79e-07 -0.55 -0.41 Longevity (90 years and older); chr12:48074194 chr12:48054813~48055591:- CESC cis rs10875746 0.807 rs12313300 ENSG00000240399.1 RP1-228P16.1 -6.69 1.89e-10 3.79e-07 -0.55 -0.41 Longevity (90 years and older); chr12:48076934 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs12315625 ENSG00000240399.1 RP1-228P16.1 -6.69 1.89e-10 3.79e-07 -0.55 -0.41 Longevity (90 years and older); chr12:48078670 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs12301339 ENSG00000240399.1 RP1-228P16.1 -6.69 1.89e-10 3.79e-07 -0.55 -0.41 Longevity (90 years and older); chr12:48081450 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs886588 ENSG00000240399.1 RP1-228P16.1 -6.69 1.89e-10 3.79e-07 -0.55 -0.41 Longevity (90 years and older); chr12:48083639 chr12:48054813~48055591:- CESC cis rs1707322 1 rs1707322 ENSG00000280836.1 AL355480.1 -6.69 1.89e-10 3.8e-07 -0.48 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46039475 chr1:45581219~45581321:- CESC cis rs875971 0.964 rs160635 ENSG00000226824.5 RP4-756H11.3 -6.69 1.9e-10 3.81e-07 -0.53 -0.41 Aortic root size; chr7:66063931 chr7:66654538~66669855:+ CESC cis rs3806843 0.648 rs702399 ENSG00000202111.1 VTRNA1-2 6.69 1.9e-10 3.82e-07 0.44 0.41 Depressive symptoms (multi-trait analysis); chr5:140644847 chr5:140718925~140719013:+ CESC cis rs6452524 0.967 rs10065973 ENSG00000249664.1 CTD-2227C6.2 6.69 1.91e-10 3.82e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83123181 chr5:83012285~83013109:- CESC cis rs227275 0.554 rs223454 ENSG00000246560.2 RP11-10L12.4 6.68 1.91e-10 3.84e-07 0.49 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102789773 chr4:102828055~102844075:+ CESC cis rs9549367 0.789 rs6577031 ENSG00000269125.1 RP11-98F14.11 6.68 1.93e-10 3.87e-07 0.53 0.41 Platelet distribution width; chr13:113223868 chr13:113165002~113165183:- CESC cis rs2404602 0.684 rs4886816 ENSG00000259422.1 RP11-593F23.1 -6.68 1.94e-10 3.88e-07 -0.49 -0.41 Blood metabolite levels; chr15:76582366 chr15:76174891~76181486:- CESC cis rs9326248 0.53 rs718847 ENSG00000254851.1 RP11-109L13.1 -6.68 1.94e-10 3.88e-07 -0.75 -0.41 Blood protein levels; chr11:116863430 chr11:117135528~117138582:+ CESC cis rs5769707 0.681 rs135879 ENSG00000188511.11 C22orf34 6.68 1.94e-10 3.89e-07 0.46 0.41 Monocyte percentage of white cells;Monocyte count; chr22:49625003 chr22:49414524~49657542:- CESC cis rs5769707 0.642 rs135880 ENSG00000188511.11 C22orf34 6.68 1.94e-10 3.89e-07 0.46 0.41 Monocyte percentage of white cells;Monocyte count; chr22:49625006 chr22:49414524~49657542:- CESC cis rs1707322 1 rs10789485 ENSG00000280836.1 AL355480.1 -6.68 1.94e-10 3.89e-07 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45941636 chr1:45581219~45581321:- CESC cis rs9549367 0.789 rs2287250 ENSG00000269125.1 RP11-98F14.11 6.68 1.95e-10 3.9e-07 0.53 0.41 Platelet distribution width; chr13:113235160 chr13:113165002~113165183:- CESC cis rs3814244 0.933 rs10878725 ENSG00000255733.4 IFNG-AS1 -6.68 1.96e-10 3.92e-07 -0.35 -0.41 Itch intensity from mosquito bite adjusted by bite size; chr12:68020930 chr12:67989445~68234686:+ CESC cis rs7617773 0.817 rs3937 ENSG00000229759.1 MRPS18AP1 6.68 1.96e-10 3.93e-07 0.44 0.41 Coronary artery disease; chr3:48270912 chr3:48256350~48256938:- CESC cis rs9549367 0.713 rs553316 ENSG00000269125.1 RP11-98F14.11 6.68 1.96e-10 3.93e-07 0.53 0.41 Platelet distribution width; chr13:113183701 chr13:113165002~113165183:- CESC cis rs9549367 0.713 rs556990 ENSG00000269125.1 RP11-98F14.11 6.68 1.96e-10 3.93e-07 0.53 0.41 Platelet distribution width; chr13:113190745 chr13:113165002~113165183:- CESC cis rs765787 0.53 rs4774542 ENSG00000259520.4 CTD-2651B20.3 -6.68 1.97e-10 3.93e-07 -0.52 -0.41 Uric acid levels; chr15:45233828 chr15:45251580~45279251:- CESC cis rs7727544 0.735 rs274559 ENSG00000233006.5 AC034220.3 -6.68 1.98e-10 3.95e-07 -0.46 -0.41 Blood metabolite levels; chr5:132384378 chr5:132311285~132369916:- CESC cis rs2581828 0.656 rs2253209 ENSG00000242142.1 SERBP1P3 6.68 1.98e-10 3.96e-07 0.46 0.41 Crohn's disease; chr3:53081144 chr3:53064283~53065091:- CESC cis rs7626444 0.565 rs7613010 ENSG00000272359.1 U4 -6.68 1.99e-10 3.98e-07 -0.49 -0.41 Monocyte count; chr3:196763350 chr3:196747192~196747324:- CESC cis rs2404602 0.532 rs284892 ENSG00000259422.1 RP11-593F23.1 6.68 2e-10 3.99e-07 0.46 0.41 Blood metabolite levels; chr15:76428696 chr15:76174891~76181486:- CESC cis rs4423214 0.798 rs12224205 ENSG00000254682.1 RP11-660L16.2 -6.67 2.03e-10 4.06e-07 -0.55 -0.41 Vitamin D levels; chr11:71469946 chr11:71448674~71452157:+ CESC cis rs916888 0.647 rs199523 ENSG00000214401.4 KANSL1-AS1 -6.67 2.04e-10 4.06e-07 -0.5 -0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46193576~46196723:+ CESC cis rs1062177 0.951 rs2915876 ENSG00000213433.5 RPLP1P6 -6.67 2.04e-10 4.07e-07 -0.52 -0.41 Preschool internalizing problems; chr5:151771184 chr5:151765859~151766378:- CESC cis rs9660180 0.967 rs61422524 ENSG00000231050.1 RP1-140A9.1 6.67 2.04e-10 4.07e-07 0.48 0.41 Body mass index; chr1:1836126 chr1:1891471~1892658:+ CESC cis rs3806843 0.735 rs809635 ENSG00000202111.1 VTRNA1-2 6.67 2.05e-10 4.09e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140702206 chr5:140718925~140719013:+ CESC cis rs3806843 0.648 rs2530233 ENSG00000202111.1 VTRNA1-2 6.67 2.05e-10 4.09e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140703291 chr5:140718925~140719013:+ CESC cis rs7849270 1 rs7869804 ENSG00000268707.1 RP11-247A12.7 -6.67 2.06e-10 4.1e-07 -0.49 -0.41 Blood metabolite ratios; chr9:129150865 chr9:129170434~129170940:+ CESC cis rs7849270 0.959 rs1410017 ENSG00000268707.1 RP11-247A12.7 -6.67 2.06e-10 4.1e-07 -0.49 -0.41 Blood metabolite ratios; chr9:129151151 chr9:129170434~129170940:+ CESC cis rs9549367 0.756 rs9603814 ENSG00000269125.1 RP11-98F14.11 6.67 2.06e-10 4.11e-07 0.53 0.41 Platelet distribution width; chr13:113246468 chr13:113165002~113165183:- CESC cis rs7115242 0.8 rs493134 ENSG00000254851.1 RP11-109L13.1 -6.67 2.06e-10 4.11e-07 -0.72 -0.41 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116962963 chr11:117135528~117138582:+ CESC cis rs6452524 0.935 rs9293330 ENSG00000249664.1 CTD-2227C6.2 6.67 2.06e-10 4.11e-07 0.44 0.41 Hypertension (SNP x SNP interaction); chr5:83102299 chr5:83012285~83013109:- CESC cis rs35955747 0.633 rs1916 ENSG00000236132.1 CTA-440B3.1 -6.67 2.07e-10 4.12e-07 -0.49 -0.41 Neutrophil count;Sum basophil neutrophil counts; chr22:31496135 chr22:31816379~31817491:- CESC cis rs228614 0.536 rs223484 ENSG00000246560.2 RP11-10L12.4 6.67 2.07e-10 4.12e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102764314 chr4:102828055~102844075:+ CESC cis rs35955747 0.902 rs739427 ENSG00000236132.1 CTA-440B3.1 -6.67 2.08e-10 4.14e-07 -0.49 -0.41 Neutrophil count;Sum basophil neutrophil counts; chr22:31263115 chr22:31816379~31817491:- CESC cis rs10463554 0.927 rs257316 ENSG00000175749.11 EIF3KP1 -6.67 2.11e-10 4.2e-07 -0.44 -0.41 Parkinson's disease; chr5:103086739 chr5:103032376~103033031:+ CESC cis rs6452524 0.934 rs12153179 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83125109 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs12153441 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83125181 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs12152891 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83125217 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs6452507 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83125537 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs6452508 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83125546 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs7717964 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83126323 chr5:83012285~83013109:- CESC cis rs6452524 0.934 rs1120477 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83127062 chr5:83012285~83013109:- CESC cis rs6452524 0.934 rs1120478 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83127072 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs6452514 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83127627 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs6884543 ENSG00000249664.1 CTD-2227C6.2 6.67 2.11e-10 4.2e-07 0.46 0.41 Hypertension (SNP x SNP interaction); chr5:83127939 chr5:83012285~83013109:- CESC cis rs507080 0.769 rs11603616 ENSG00000255422.1 AP002954.4 -6.67 2.12e-10 4.21e-07 -0.49 -0.41 Serum metabolite levels; chr11:118625350 chr11:118704607~118750263:+ CESC cis rs507080 0.769 rs483283 ENSG00000255422.1 AP002954.4 -6.67 2.12e-10 4.21e-07 -0.49 -0.41 Serum metabolite levels; chr11:118635684 chr11:118704607~118750263:+ CESC cis rs9399135 0.967 rs9389256 ENSG00000232876.1 CTA-212D2.2 -6.67 2.13e-10 4.23e-07 -0.48 -0.41 Red blood cell count; chr6:135010116 chr6:135055033~135060550:+ CESC cis rs10875746 0.855 rs10875729 ENSG00000240399.1 RP1-228P16.1 -6.67 2.13e-10 4.23e-07 -0.52 -0.41 Longevity (90 years and older); chr12:48032943 chr12:48054813~48055591:- CESC cis rs9545047 0.716 rs643778 ENSG00000227676.3 LINC01068 -6.66 2.14e-10 4.24e-07 -0.47 -0.41 Schizophrenia; chr13:79423937 chr13:79566727~79571436:+ CESC cis rs2929278 0.617 rs3087657 ENSG00000249839.1 AC011330.5 -6.66 2.15e-10 4.26e-07 -0.44 -0.41 Schizophrenia; chr15:43771661 chr15:43663654~43684339:- CESC cis rs2404602 0.684 rs1011084 ENSG00000259422.1 RP11-593F23.1 -6.66 2.16e-10 4.28e-07 -0.5 -0.41 Blood metabolite levels; chr15:76715139 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs11629727 ENSG00000259422.1 RP11-593F23.1 -6.66 2.16e-10 4.28e-07 -0.5 -0.41 Blood metabolite levels; chr15:76716697 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs11072618 ENSG00000259422.1 RP11-593F23.1 -6.66 2.16e-10 4.28e-07 -0.5 -0.41 Blood metabolite levels; chr15:76727001 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs1443115 ENSG00000259422.1 RP11-593F23.1 -6.66 2.16e-10 4.28e-07 -0.5 -0.41 Blood metabolite levels; chr15:76749488 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs12898416 ENSG00000259422.1 RP11-593F23.1 -6.66 2.16e-10 4.28e-07 -0.5 -0.41 Blood metabolite levels; chr15:76749951 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs12904149 ENSG00000259422.1 RP11-593F23.1 -6.66 2.16e-10 4.28e-07 -0.5 -0.41 Blood metabolite levels; chr15:76751311 chr15:76174891~76181486:- CESC cis rs3806843 1 rs3756340 ENSG00000202111.1 VTRNA1-2 -6.66 2.16e-10 4.28e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140800866 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs7701755 ENSG00000202111.1 VTRNA1-2 -6.66 2.16e-10 4.28e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140802516 chr5:140718925~140719013:+ CESC cis rs1707322 0.721 rs10890343 ENSG00000281133.1 AL355480.3 -6.66 2.17e-10 4.3e-07 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692250 chr1:45580892~45580996:- CESC cis rs3806843 0.735 rs778596 ENSG00000202111.1 VTRNA1-2 6.66 2.17e-10 4.3e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140657687 chr5:140718925~140719013:+ CESC cis rs17826219 0.5 rs117560728 ENSG00000263531.1 RP13-753N3.1 6.66 2.17e-10 4.31e-07 0.93 0.41 Body mass index; chr17:30743920 chr17:30863921~30864940:- CESC cis rs113835537 0.529 rs57724777 ENSG00000255517.5 CTD-3074O7.5 -6.66 2.18e-10 4.32e-07 -0.5 -0.41 Airway imaging phenotypes; chr11:66468960 chr11:66473490~66480233:- CESC cis rs1153858 0.945 rs1974981 ENSG00000259520.4 CTD-2651B20.3 6.66 2.2e-10 4.36e-07 0.55 0.41 Homoarginine levels; chr15:45436925 chr15:45251580~45279251:- CESC cis rs3806843 0.966 rs3756338 ENSG00000202111.1 VTRNA1-2 -6.66 2.2e-10 4.37e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140800976 chr5:140718925~140719013:+ CESC cis rs9549367 0.636 rs486407 ENSG00000269125.1 RP11-98F14.11 6.66 2.2e-10 4.37e-07 0.52 0.41 Platelet distribution width; chr13:113179185 chr13:113165002~113165183:- CESC cis rs9549367 0.713 rs2476319 ENSG00000269125.1 RP11-98F14.11 6.66 2.2e-10 4.37e-07 0.52 0.41 Platelet distribution width; chr13:113182205 chr13:113165002~113165183:- CESC cis rs1062177 1 rs41494545 ENSG00000213433.5 RPLP1P6 6.66 2.22e-10 4.39e-07 0.5 0.41 Preschool internalizing problems; chr5:151855533 chr5:151765859~151766378:- CESC cis rs875971 0.862 rs778734 ENSG00000226824.5 RP4-756H11.3 -6.66 2.23e-10 4.42e-07 -0.5 -0.41 Aortic root size; chr7:66349862 chr7:66654538~66669855:+ CESC cis rs12022452 0.506 rs12569328 ENSG00000238287.1 RP11-656D10.3 -6.66 2.23e-10 4.42e-07 -0.57 -0.41 Age-related hearing impairment (SNP x SNP interaction); chr1:40553549 chr1:40493157~40508661:- CESC cis rs7617773 0.817 rs9837228 ENSG00000229759.1 MRPS18AP1 -6.66 2.23e-10 4.42e-07 -0.44 -0.41 Coronary artery disease; chr3:48282976 chr3:48256350~48256938:- CESC cis rs12439619 0.693 rs17269819 ENSG00000278603.1 RP13-608F4.5 6.66 2.26e-10 4.47e-07 0.61 0.41 Intelligence (multi-trait analysis); chr15:82174660 chr15:82472203~82472426:+ CESC cis rs12439619 0.693 rs8034801 ENSG00000278603.1 RP13-608F4.5 6.66 2.26e-10 4.47e-07 0.61 0.41 Intelligence (multi-trait analysis); chr15:82183996 chr15:82472203~82472426:+ CESC cis rs2581828 0.694 rs2336725 ENSG00000242142.1 SERBP1P3 6.65 2.27e-10 4.48e-07 0.45 0.41 Crohn's disease; chr3:53084723 chr3:53064283~53065091:- CESC cis rs9660180 0.934 rs34849348 ENSG00000231050.1 RP1-140A9.1 6.65 2.27e-10 4.49e-07 0.47 0.41 Body mass index; chr1:1831318 chr1:1891471~1892658:+ CESC cis rs9660180 0.967 rs10907191 ENSG00000231050.1 RP1-140A9.1 6.65 2.27e-10 4.49e-07 0.47 0.41 Body mass index; chr1:1843381 chr1:1891471~1892658:+ CESC cis rs2581828 0.656 rs2253685 ENSG00000242142.1 SERBP1P3 6.65 2.28e-10 4.5e-07 0.46 0.41 Crohn's disease; chr3:53085687 chr3:53064283~53065091:- CESC cis rs2929278 0.561 rs3099045 ENSG00000249839.1 AC011330.5 -6.65 2.28e-10 4.51e-07 -0.44 -0.41 Schizophrenia; chr15:43631757 chr15:43663654~43684339:- CESC cis rs2404602 0.53 rs11072614 ENSG00000259422.1 RP11-593F23.1 -6.65 2.28e-10 4.52e-07 -0.5 -0.41 Blood metabolite levels; chr15:76674864 chr15:76174891~76181486:- CESC cis rs6700559 0.967 rs10919992 ENSG00000260088.1 RP11-92G12.3 -6.65 2.3e-10 4.55e-07 -0.53 -0.41 Coronary artery disease; chr1:200638338 chr1:200669507~200694250:+ CESC cis rs2581828 0.656 rs2253796 ENSG00000242142.1 SERBP1P3 6.65 2.3e-10 4.55e-07 0.46 0.41 Crohn's disease; chr3:53086082 chr3:53064283~53065091:- CESC cis rs14027 0.921 rs2289011 ENSG00000279347.1 RP11-85I17.2 6.65 2.3e-10 4.55e-07 0.39 0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119744768 chr8:119838736~119840385:- CESC cis rs2980436 1 rs2980436 ENSG00000173295.6 FAM86B3P -6.65 2.32e-10 4.59e-07 -0.57 -0.41 Schizophrenia; chr8:8234503 chr8:8228595~8244865:+ CESC cis rs2882667 0.505 rs7721110 ENSG00000253404.1 AC034243.1 6.65 2.33e-10 4.6e-07 0.48 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139146817 chr5:138744434~138753309:- CESC cis rs1707322 0.686 rs2050376 ENSG00000281133.1 AL355480.3 -6.65 2.34e-10 4.63e-07 -0.49 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45612958 chr1:45580892~45580996:- CESC cis rs3806843 0.741 rs4912597 ENSG00000202111.1 VTRNA1-2 6.65 2.35e-10 4.63e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140727272 chr5:140718925~140719013:+ CESC cis rs3806843 0.771 rs2563334 ENSG00000202111.1 VTRNA1-2 6.65 2.35e-10 4.63e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140727480 chr5:140718925~140719013:+ CESC cis rs17507216 0.958 rs72751643 ENSG00000278603.1 RP13-608F4.5 6.65 2.35e-10 4.64e-07 0.69 0.41 Excessive daytime sleepiness; chr15:82559444 chr15:82472203~82472426:+ CESC cis rs2929278 0.546 rs686666 ENSG00000249839.1 AC011330.5 -6.65 2.35e-10 4.64e-07 -0.43 -0.41 Schizophrenia; chr15:43869352 chr15:43663654~43684339:- CESC cis rs3806843 0.735 rs2563314 ENSG00000202111.1 VTRNA1-2 6.65 2.36e-10 4.65e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140667704 chr5:140718925~140719013:+ CESC cis rs3806843 0.735 rs2530240 ENSG00000202111.1 VTRNA1-2 6.65 2.36e-10 4.65e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140680962 chr5:140718925~140719013:+ CESC cis rs3806843 0.735 rs801189 ENSG00000202111.1 VTRNA1-2 6.65 2.36e-10 4.65e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140683506 chr5:140718925~140719013:+ CESC cis rs3806843 0.706 rs1089305 ENSG00000202111.1 VTRNA1-2 6.65 2.36e-10 4.65e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140686721 chr5:140718925~140719013:+ CESC cis rs3806843 0.735 rs801185 ENSG00000202111.1 VTRNA1-2 6.65 2.36e-10 4.65e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140689284 chr5:140718925~140719013:+ CESC cis rs11155671 0.53 rs4458704 ENSG00000216906.2 RP11-350J20.9 6.65 2.36e-10 4.66e-07 0.44 0.41 Testicular germ cell tumor; chr6:149911743 chr6:149904243~149906418:+ CESC cis rs12439619 0.693 rs28689861 ENSG00000278603.1 RP13-608F4.5 6.65 2.36e-10 4.66e-07 0.6 0.41 Intelligence (multi-trait analysis); chr15:82206369 chr15:82472203~82472426:+ CESC cis rs9660180 0.935 rs9786942 ENSG00000231050.1 RP1-140A9.1 6.65 2.36e-10 4.66e-07 0.47 0.41 Body mass index; chr1:1827774 chr1:1891471~1892658:+ CESC cis rs3806843 0.706 rs2563302 ENSG00000202111.1 VTRNA1-2 6.65 2.37e-10 4.67e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140699466 chr5:140718925~140719013:+ CESC cis rs10129255 0.5 rs8021941 ENSG00000223648.3 IGHV3-64 6.65 2.37e-10 4.67e-07 0.33 0.41 Kawasaki disease; chr14:106781490 chr14:106643132~106658258:- CESC cis rs10262624 0.528 rs722294 ENSG00000234286.1 AC006026.13 6.65 2.39e-10 4.7e-07 0.43 0.41 Schizophrenia; chr7:23706966 chr7:23680195~23680786:- CESC cis rs1061377 0.76 rs7678457 ENSG00000249207.1 RP11-360F5.1 -6.64 2.4e-10 4.72e-07 -0.46 -0.41 Uric acid levels; chr4:39136041 chr4:39112677~39126818:- CESC cis rs150992 0.673 rs161747 ENSG00000248489.1 CTD-2007H13.3 -6.64 2.4e-10 4.72e-07 -0.48 -0.41 Body mass index; chr5:98920433 chr5:98929171~98995013:+ CESC cis rs1823913 0.599 rs1454754 ENSG00000280083.1 RP11-317J9.1 -6.64 2.4e-10 4.73e-07 -0.48 -0.41 Obesity-related traits; chr2:191303562 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs13010441 ENSG00000280083.1 RP11-317J9.1 -6.64 2.4e-10 4.73e-07 -0.48 -0.41 Obesity-related traits; chr2:191303903 chr2:191154118~191156070:- CESC cis rs1707322 0.686 rs2991977 ENSG00000281133.1 AL355480.3 6.64 2.41e-10 4.74e-07 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45588011 chr1:45580892~45580996:- CESC cis rs1707322 0.656 rs2991981 ENSG00000281133.1 AL355480.3 6.64 2.41e-10 4.74e-07 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45591472 chr1:45580892~45580996:- CESC cis rs1823913 0.599 rs58106487 ENSG00000280083.1 RP11-317J9.1 -6.64 2.41e-10 4.74e-07 -0.48 -0.41 Obesity-related traits; chr2:191292404 chr2:191154118~191156070:- CESC cis rs9660180 0.839 rs12040826 ENSG00000231050.1 RP1-140A9.1 6.64 2.42e-10 4.76e-07 0.49 0.41 Body mass index; chr1:1773848 chr1:1891471~1892658:+ CESC cis rs3806843 1 rs4151682 ENSG00000202111.1 VTRNA1-2 -6.64 2.42e-10 4.76e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140821679 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs11958868 ENSG00000202111.1 VTRNA1-2 -6.64 2.42e-10 4.76e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140821835 chr5:140718925~140719013:+ CESC cis rs6700559 1 rs12076877 ENSG00000260088.1 RP11-92G12.3 -6.64 2.42e-10 4.77e-07 -0.54 -0.41 Coronary artery disease; chr1:200674277 chr1:200669507~200694250:+ CESC cis rs113835537 0.529 rs116867234 ENSG00000255517.5 CTD-3074O7.5 -6.64 2.43e-10 4.79e-07 -0.49 -0.41 Airway imaging phenotypes; chr11:66441553 chr11:66473490~66480233:- CESC cis rs1062177 1 rs17741826 ENSG00000213433.5 RPLP1P6 6.64 2.46e-10 4.84e-07 0.5 0.41 Preschool internalizing problems; chr5:151769701 chr5:151765859~151766378:- CESC cis rs9660180 0.967 rs11260623 ENSG00000231050.1 RP1-140A9.1 6.64 2.46e-10 4.84e-07 0.47 0.41 Body mass index; chr1:1850017 chr1:1891471~1892658:+ CESC cis rs1577917 0.958 rs10944147 ENSG00000203875.9 SNHG5 -6.64 2.47e-10 4.85e-07 -0.53 -0.41 Response to antipsychotic treatment; chr6:85841068 chr6:85660950~85678736:- CESC cis rs1577917 0.916 rs12198730 ENSG00000203875.9 SNHG5 -6.64 2.47e-10 4.85e-07 -0.53 -0.41 Response to antipsychotic treatment; chr6:85845420 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs13201730 ENSG00000203875.9 SNHG5 -6.64 2.47e-10 4.85e-07 -0.53 -0.41 Response to antipsychotic treatment; chr6:85846929 chr6:85660950~85678736:- CESC cis rs1577917 0.958 rs12196377 ENSG00000203875.9 SNHG5 -6.64 2.47e-10 4.85e-07 -0.53 -0.41 Response to antipsychotic treatment; chr6:85857057 chr6:85660950~85678736:- CESC cis rs7208859 0.725 rs7210904 ENSG00000263531.1 RP13-753N3.1 6.64 2.48e-10 4.87e-07 0.64 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843187 chr17:30863921~30864940:- CESC cis rs1823913 0.637 rs2067610 ENSG00000280083.1 RP11-317J9.1 -6.64 2.49e-10 4.89e-07 -0.48 -0.41 Obesity-related traits; chr2:191299251 chr2:191154118~191156070:- CESC cis rs7849270 0.851 rs1819381 ENSG00000268707.1 RP11-247A12.7 -6.64 2.5e-10 4.9e-07 -0.49 -0.41 Blood metabolite ratios; chr9:129145728 chr9:129170434~129170940:+ CESC cis rs1577917 0.958 rs12665542 ENSG00000203875.9 SNHG5 -6.64 2.5e-10 4.91e-07 -0.53 -0.41 Response to antipsychotic treatment; chr6:85834725 chr6:85660950~85678736:- CESC cis rs3806843 0.735 rs801188 ENSG00000202111.1 VTRNA1-2 6.64 2.51e-10 4.93e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140687331 chr5:140718925~140719013:+ CESC cis rs2404602 0.647 rs12904417 ENSG00000259422.1 RP11-593F23.1 6.64 2.53e-10 4.96e-07 0.47 0.41 Blood metabolite levels; chr15:76671811 chr15:76174891~76181486:- CESC cis rs2739330 0.796 rs1006771 ENSG00000099984.9 GSTT2 -6.64 2.53e-10 4.96e-07 -0.47 -0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23980123~23983911:+ CESC cis rs35160687 0.901 rs6713456 ENSG00000273080.1 RP11-301O19.1 6.63 2.53e-10 4.96e-07 0.47 0.41 Night sleep phenotypes; chr2:86280530 chr2:86195590~86196049:+ CESC cis rs950169 0.922 rs11635505 ENSG00000225151.9 GOLGA2P7 6.63 2.54e-10 4.99e-07 0.56 0.41 Schizophrenia; chr15:84553803 chr15:84199311~84230136:- CESC cis rs2404602 0.735 rs4886805 ENSG00000259422.1 RP11-593F23.1 6.63 2.55e-10 5.01e-07 0.5 0.41 Blood metabolite levels; chr15:76447043 chr15:76174891~76181486:- CESC cis rs875971 0.928 rs2036263 ENSG00000226824.5 RP4-756H11.3 6.63 2.57e-10 5.03e-07 0.5 0.41 Aortic root size; chr7:66335210 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs10240949 ENSG00000226824.5 RP4-756H11.3 6.63 2.57e-10 5.03e-07 0.5 0.41 Aortic root size; chr7:66339430 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs7782704 ENSG00000226824.5 RP4-756H11.3 6.63 2.57e-10 5.03e-07 0.5 0.41 Aortic root size; chr7:66340379 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6959268 ENSG00000226824.5 RP4-756H11.3 6.63 2.57e-10 5.03e-07 0.5 0.41 Aortic root size; chr7:66347979 chr7:66654538~66669855:+ CESC cis rs1062177 1 rs72802204 ENSG00000213433.5 RPLP1P6 -6.63 2.57e-10 5.03e-07 -0.5 -0.41 Preschool internalizing problems; chr5:151803622 chr5:151765859~151766378:- CESC cis rs1062177 1 rs1062177 ENSG00000213433.5 RPLP1P6 -6.63 2.57e-10 5.03e-07 -0.5 -0.41 Preschool internalizing problems; chr5:151805140 chr5:151765859~151766378:- CESC cis rs1062177 1 rs973529 ENSG00000213433.5 RPLP1P6 -6.63 2.57e-10 5.03e-07 -0.5 -0.41 Preschool internalizing problems; chr5:151808597 chr5:151765859~151766378:- CESC cis rs9399135 0.967 rs9399129 ENSG00000232876.1 CTA-212D2.2 -6.63 2.58e-10 5.04e-07 -0.48 -0.41 Red blood cell count; chr6:134964010 chr6:135055033~135060550:+ CESC cis rs6504950 0.83 rs12949538 ENSG00000275710.1 RP11-257O5.4 -6.63 2.58e-10 5.06e-07 -0.51 -0.41 Breast cancer; chr17:54933309 chr17:54964474~54964679:+ CESC cis rs4423214 0.765 rs2002064 ENSG00000254682.1 RP11-660L16.2 -6.63 2.6e-10 5.09e-07 -0.54 -0.41 Vitamin D levels; chr11:71452374 chr11:71448674~71452157:+ CESC cis rs2404602 0.684 rs3910756 ENSG00000259422.1 RP11-593F23.1 -6.63 2.62e-10 5.13e-07 -0.5 -0.41 Blood metabolite levels; chr15:76653028 chr15:76174891~76181486:- CESC cis rs7617773 0.817 rs9830016 ENSG00000229759.1 MRPS18AP1 6.63 2.63e-10 5.15e-07 0.41 0.41 Coronary artery disease; chr3:48241004 chr3:48256350~48256938:- CESC cis rs9545047 0.704 rs9530904 ENSG00000227676.3 LINC01068 6.63 2.64e-10 5.16e-07 0.47 0.41 Schizophrenia; chr13:79370157 chr13:79566727~79571436:+ CESC cis rs1185460 0.967 rs1784461 ENSG00000271751.1 RP11-110I1.14 -6.63 2.64e-10 5.16e-07 -0.53 -0.41 Coronary artery disease; chr11:119067274 chr11:119065263~119065677:- CESC cis rs7674212 0.581 rs13150953 ENSG00000246560.2 RP11-10L12.4 6.63 2.64e-10 5.17e-07 0.51 0.41 Type 2 diabetes; chr4:103021341 chr4:102828055~102844075:+ CESC cis rs7674212 0.556 rs13151569 ENSG00000246560.2 RP11-10L12.4 6.63 2.64e-10 5.17e-07 0.51 0.41 Type 2 diabetes; chr4:103021633 chr4:102828055~102844075:+ CESC cis rs113835537 0.529 rs2305532 ENSG00000255517.5 CTD-3074O7.5 -6.63 2.66e-10 5.19e-07 -0.49 -0.41 Airway imaging phenotypes; chr11:66531123 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs2305533 ENSG00000255517.5 CTD-3074O7.5 -6.63 2.66e-10 5.19e-07 -0.49 -0.41 Airway imaging phenotypes; chr11:66531152 chr11:66473490~66480233:- CESC cis rs7849270 0.959 rs913275 ENSG00000268707.1 RP11-247A12.7 -6.63 2.67e-10 5.21e-07 -0.48 -0.41 Blood metabolite ratios; chr9:129148365 chr9:129170434~129170940:+ CESC cis rs5760092 0.755 rs4585126 ENSG00000250470.1 AP000351.3 -6.63 2.67e-10 5.22e-07 -0.58 -0.41 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23976904~23977585:- CESC cis rs1155848 0.892 rs9574424 ENSG00000227354.5 RBM26-AS1 -6.62 2.68e-10 5.23e-07 -0.82 -0.41 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79448541 chr13:79406309~79424328:+ CESC cis rs3931020 0.548 rs969435 ENSG00000272864.1 RP11-17E13.2 6.62 2.68e-10 5.23e-07 0.43 0.41 Resistin levels; chr1:74808182 chr1:74698769~74699333:- CESC cis rs507080 0.961 rs1784298 ENSG00000255422.1 AP002954.4 -6.62 2.68e-10 5.24e-07 -0.47 -0.41 Serum metabolite levels; chr11:118677956 chr11:118704607~118750263:+ CESC cis rs507080 0.961 rs4938522 ENSG00000255422.1 AP002954.4 -6.62 2.68e-10 5.24e-07 -0.47 -0.41 Serum metabolite levels; chr11:118677962 chr11:118704607~118750263:+ CESC cis rs507080 0.961 rs4938523 ENSG00000255422.1 AP002954.4 -6.62 2.68e-10 5.24e-07 -0.47 -0.41 Serum metabolite levels; chr11:118678129 chr11:118704607~118750263:+ CESC cis rs507080 1 rs659969 ENSG00000255422.1 AP002954.4 -6.62 2.68e-10 5.24e-07 -0.47 -0.41 Serum metabolite levels; chr11:118679094 chr11:118704607~118750263:+ CESC cis rs6504950 0.83 rs12936860 ENSG00000275710.1 RP11-257O5.4 6.62 2.68e-10 5.24e-07 0.5 0.41 Breast cancer; chr17:54952865 chr17:54964474~54964679:+ CESC cis rs10256972 0.685 rs10263665 ENSG00000229043.2 AC091729.9 -6.62 2.69e-10 5.24e-07 -0.46 -0.41 Endometriosis;Longevity; chr7:1070992 chr7:1160374~1165267:+ CESC cis rs10129255 0.518 rs28378320 ENSG00000223648.3 IGHV3-64 6.62 2.69e-10 5.25e-07 0.33 0.41 Kawasaki disease; chr14:106808609 chr14:106643132~106658258:- CESC cis rs6504950 0.72 rs28564882 ENSG00000275710.1 RP11-257O5.4 6.62 2.7e-10 5.26e-07 0.51 0.41 Breast cancer; chr17:54912237 chr17:54964474~54964679:+ CESC cis rs9545047 0.716 rs586219 ENSG00000227676.3 LINC01068 -6.62 2.7e-10 5.26e-07 -0.47 -0.41 Schizophrenia; chr13:79425177 chr13:79566727~79571436:+ CESC cis rs9545047 0.716 rs2265377 ENSG00000227676.3 LINC01068 -6.62 2.7e-10 5.26e-07 -0.47 -0.41 Schizophrenia; chr13:79425485 chr13:79566727~79571436:+ CESC cis rs9545047 0.716 rs2265378 ENSG00000227676.3 LINC01068 -6.62 2.7e-10 5.26e-07 -0.47 -0.41 Schizophrenia; chr13:79425581 chr13:79566727~79571436:+ CESC cis rs9545047 0.716 rs8002838 ENSG00000227676.3 LINC01068 6.62 2.7e-10 5.26e-07 0.47 0.41 Schizophrenia; chr13:79421681 chr13:79566727~79571436:+ CESC cis rs9545047 0.669 rs9545113 ENSG00000227676.3 LINC01068 6.62 2.7e-10 5.26e-07 0.47 0.41 Schizophrenia; chr13:79422017 chr13:79566727~79571436:+ CESC cis rs9545047 0.68 rs9545114 ENSG00000227676.3 LINC01068 6.62 2.7e-10 5.26e-07 0.47 0.41 Schizophrenia; chr13:79423744 chr13:79566727~79571436:+ CESC cis rs7849270 0.959 rs10760591 ENSG00000268707.1 RP11-247A12.7 -6.62 2.71e-10 5.27e-07 -0.49 -0.41 Blood metabolite ratios; chr9:129152749 chr9:129170434~129170940:+ CESC cis rs10875746 0.903 rs3782911 ENSG00000240399.1 RP1-228P16.1 -6.62 2.72e-10 5.29e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48089709 chr12:48054813~48055591:- CESC cis rs10875746 0.859 rs3782910 ENSG00000240399.1 RP1-228P16.1 -6.62 2.72e-10 5.29e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48089724 chr12:48054813~48055591:- CESC cis rs2487048 0.725 rs2246293 ENSG00000226334.1 RP11-217B7.2 6.62 2.72e-10 5.29e-07 0.49 0.41 Intraocular pressure; chr9:104928557 chr9:104927553~104928892:+ CESC cis rs3806843 0.735 rs778595 ENSG00000202111.1 VTRNA1-2 6.62 2.72e-10 5.29e-07 0.42 0.41 Depressive symptoms (multi-trait analysis); chr5:140657096 chr5:140718925~140719013:+ CESC cis rs11155671 0.53 rs7763849 ENSG00000231760.4 RP11-350J20.5 6.62 2.72e-10 5.29e-07 0.51 0.41 Testicular germ cell tumor; chr6:149885244 chr6:149796151~149826294:- CESC cis rs8062405 1 rs62036616 ENSG00000259982.1 CDC37P1 6.62 2.74e-10 5.33e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814986 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62036622 ENSG00000259982.1 CDC37P1 6.62 2.74e-10 5.33e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28825882 chr16:28700294~28701540:- CESC cis rs10129255 0.5 rs1974468 ENSG00000223648.3 IGHV3-64 6.62 2.75e-10 5.35e-07 0.33 0.41 Kawasaki disease; chr14:106686149 chr14:106643132~106658258:- CESC cis rs2739330 0.892 rs5751776 ENSG00000099984.9 GSTT2 -6.62 2.76e-10 5.36e-07 -0.5 -0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23980123~23983911:+ CESC cis rs10129255 0.5 rs2105991 ENSG00000223648.3 IGHV3-64 6.62 2.76e-10 5.37e-07 0.33 0.41 Kawasaki disease; chr14:106682022 chr14:106643132~106658258:- CESC cis rs1707322 1 rs1707317 ENSG00000280836.1 AL355480.1 6.62 2.76e-10 5.37e-07 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46044970 chr1:45581219~45581321:- CESC cis rs3806843 0.619 rs2569160 ENSG00000202111.1 VTRNA1-2 6.62 2.8e-10 5.44e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140649189 chr5:140718925~140719013:+ CESC cis rs8072100 0.935 rs78551919 ENSG00000228782.6 CTD-2026D20.3 -6.62 2.81e-10 5.45e-07 -0.46 -0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47548636 chr17:47450568~47492492:- CESC cis rs977987 0.528 rs9926933 ENSG00000261783.1 RP11-252K23.2 6.62 2.81e-10 5.45e-07 0.61 0.41 Dupuytren's disease; chr16:75467669 chr16:75379818~75381260:- CESC cis rs1707322 0.827 rs6683274 ENSG00000280836.1 AL355480.1 -6.62 2.81e-10 5.46e-07 -0.5 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45775966 chr1:45581219~45581321:- CESC cis rs10463554 1 rs10463554 ENSG00000175749.11 EIF3KP1 6.62 2.83e-10 5.49e-07 0.43 0.41 Parkinson's disease; chr5:102983270 chr5:103032376~103033031:+ CESC cis rs1823913 1 rs4853563 ENSG00000280083.1 RP11-317J9.1 6.61 2.83e-10 5.5e-07 0.46 0.41 Obesity-related traits; chr2:191254808 chr2:191154118~191156070:- CESC cis rs9399137 0.507 rs7748708 ENSG00000232876.1 CTA-212D2.2 -6.61 2.85e-10 5.52e-07 -0.51 -0.41 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954004 chr6:135055033~135060550:+ CESC cis rs7044106 0.762 rs1530370 ENSG00000226752.6 PSMD5-AS1 -6.61 2.85e-10 5.53e-07 -0.47 -0.41 Hip circumference adjusted for BMI; chr9:120662274 chr9:120824828~120854385:+ CESC cis rs7727544 0.684 rs272849 ENSG00000233006.5 AC034220.3 6.61 2.86e-10 5.55e-07 0.46 0.41 Blood metabolite levels; chr5:132354548 chr5:132311285~132369916:- CESC cis rs7617773 0.817 rs6801801 ENSG00000229759.1 MRPS18AP1 6.61 2.86e-10 5.55e-07 0.43 0.41 Coronary artery disease; chr3:48284943 chr3:48256350~48256938:- CESC cis rs3096299 0.719 rs2911262 ENSG00000274627.1 RP11-104N10.2 6.61 2.88e-10 5.59e-07 0.4 0.41 Multiple myeloma (IgH translocation); chr16:89448633 chr16:89516797~89522217:+ CESC cis rs3806843 0.735 rs2530242 ENSG00000202111.1 VTRNA1-2 6.61 2.89e-10 5.59e-07 0.42 0.41 Depressive symptoms (multi-trait analysis); chr5:140673766 chr5:140718925~140719013:+ CESC cis rs3806843 0.735 rs2530241 ENSG00000202111.1 VTRNA1-2 6.61 2.89e-10 5.59e-07 0.42 0.41 Depressive symptoms (multi-trait analysis); chr5:140674900 chr5:140718925~140719013:+ CESC cis rs9545047 0.716 rs9530920 ENSG00000227676.3 LINC01068 6.61 2.89e-10 5.6e-07 0.47 0.41 Schizophrenia; chr13:79423254 chr13:79566727~79571436:+ CESC cis rs11155671 0.53 rs9371215 ENSG00000268592.3 RAET1E-AS1 6.61 2.89e-10 5.6e-07 0.52 0.41 Testicular germ cell tumor; chr6:149873162 chr6:149863494~149919507:+ CESC cis rs1185460 0.967 rs1784459 ENSG00000271751.1 RP11-110I1.14 -6.61 2.89e-10 5.61e-07 -0.53 -0.41 Coronary artery disease; chr11:119067677 chr11:119065263~119065677:- CESC cis rs1062177 1 rs2964571 ENSG00000213433.5 RPLP1P6 -6.61 2.9e-10 5.61e-07 -0.5 -0.41 Preschool internalizing problems; chr5:151791695 chr5:151765859~151766378:- CESC cis rs1062177 1 rs2915869 ENSG00000213433.5 RPLP1P6 -6.61 2.9e-10 5.61e-07 -0.5 -0.41 Preschool internalizing problems; chr5:151791948 chr5:151765859~151766378:- CESC cis rs1062177 1 rs2347596 ENSG00000213433.5 RPLP1P6 -6.61 2.9e-10 5.61e-07 -0.5 -0.41 Preschool internalizing problems; chr5:151799638 chr5:151765859~151766378:- CESC cis rs1062177 0.95 rs892005 ENSG00000213433.5 RPLP1P6 -6.61 2.9e-10 5.61e-07 -0.5 -0.41 Preschool internalizing problems; chr5:151801060 chr5:151765859~151766378:- CESC cis rs9545047 0.716 rs8001795 ENSG00000227676.3 LINC01068 6.61 2.91e-10 5.63e-07 0.47 0.41 Schizophrenia; chr13:79421402 chr13:79566727~79571436:+ CESC cis rs11690935 0.959 rs3770452 ENSG00000228389.1 AC068039.4 6.61 2.91e-10 5.64e-07 0.53 0.41 Schizophrenia; chr2:171812172 chr2:171773482~171775844:+ CESC cis rs7044106 0.708 rs991121 ENSG00000226752.6 PSMD5-AS1 -6.61 2.91e-10 5.64e-07 -0.45 -0.41 Hip circumference adjusted for BMI; chr9:120608067 chr9:120824828~120854385:+ CESC cis rs2882667 0.505 rs6596465 ENSG00000253404.1 AC034243.1 -6.61 2.92e-10 5.64e-07 -0.47 -0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139147337 chr5:138744434~138753309:- CESC cis rs14027 0.843 rs6469849 ENSG00000279347.1 RP11-85I17.2 -6.61 2.92e-10 5.65e-07 -0.39 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119844929 chr8:119838736~119840385:- CESC cis rs1185460 0.967 rs1784302 ENSG00000271751.1 RP11-110I1.14 -6.61 2.94e-10 5.68e-07 -0.55 -0.41 Coronary artery disease; chr11:119070247 chr11:119065263~119065677:- CESC cis rs11168854 0.656 rs7969963 ENSG00000258017.1 RP11-386G11.10 -6.61 2.94e-10 5.68e-07 -0.52 -0.41 Body mass index; chr12:49118222 chr12:49127782~49147869:+ CESC cis rs9545047 0.541 rs36152718 ENSG00000227676.3 LINC01068 6.61 2.95e-10 5.7e-07 0.46 0.41 Schizophrenia; chr13:79306069 chr13:79566727~79571436:+ CESC cis rs3806843 1 rs7710794 ENSG00000202111.1 VTRNA1-2 -6.61 2.95e-10 5.7e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140829882 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs10038174 ENSG00000202111.1 VTRNA1-2 -6.61 2.95e-10 5.7e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140831031 chr5:140718925~140719013:+ CESC cis rs7727544 0.684 rs274567 ENSG00000233006.5 AC034220.3 -6.61 2.95e-10 5.71e-07 -0.45 -0.41 Blood metabolite levels; chr5:132378717 chr5:132311285~132369916:- CESC cis rs6504950 1 rs17745344 ENSG00000275710.1 RP11-257O5.4 6.61 2.96e-10 5.72e-07 0.54 0.41 Breast cancer; chr17:54970958 chr17:54964474~54964679:+ CESC cis rs1577917 1 rs12196411 ENSG00000203875.9 SNHG5 -6.61 2.97e-10 5.73e-07 -0.51 -0.41 Response to antipsychotic treatment; chr6:86070044 chr6:85660950~85678736:- CESC cis rs1707322 0.827 rs10890347 ENSG00000280836.1 AL355480.1 6.61 2.99e-10 5.76e-07 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776660 chr1:45581219~45581321:- CESC cis rs3814244 0.966 rs10784666 ENSG00000255733.4 IFNG-AS1 -6.61 2.99e-10 5.76e-07 -0.35 -0.41 Itch intensity from mosquito bite adjusted by bite size; chr12:68021923 chr12:67989445~68234686:+ CESC cis rs3814244 0.966 rs10784667 ENSG00000255733.4 IFNG-AS1 -6.61 2.99e-10 5.76e-07 -0.35 -0.41 Itch intensity from mosquito bite adjusted by bite size; chr12:68021996 chr12:67989445~68234686:+ CESC cis rs1062177 0.826 rs2053063 ENSG00000213433.5 RPLP1P6 -6.6 3.01e-10 5.8e-07 -0.48 -0.41 Preschool internalizing problems; chr5:151787203 chr5:151765859~151766378:- CESC cis rs12931792 0.712 rs4787495 ENSG00000183604.13 SMG1P5 -6.6 3.02e-10 5.81e-07 -0.39 -0.41 Tonsillectomy; chr16:30154404 chr16:30267553~30335374:- CESC cis rs9309711 0.623 rs4641971 ENSG00000225234.1 TRAPPC12-AS1 6.6 3.02e-10 5.81e-07 0.4 0.41 Neurofibrillary tangles; chr2:3478086 chr2:3481242~3482409:- CESC cis rs2739330 0.731 rs4822450 ENSG00000099984.9 GSTT2 -6.6 3.02e-10 5.82e-07 -0.5 -0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23980123~23983911:+ CESC cis rs8062405 1 rs7498555 ENSG00000259982.1 CDC37P1 6.6 3.03e-10 5.83e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28882250 chr16:28700294~28701540:- CESC cis rs507080 1 rs507080 ENSG00000255422.1 AP002954.4 -6.6 3.05e-10 5.87e-07 -0.47 -0.41 Serum metabolite levels; chr11:118678873 chr11:118704607~118750263:+ CESC cis rs2581828 0.656 rs11130338 ENSG00000242142.1 SERBP1P3 6.6 3.07e-10 5.9e-07 0.46 0.41 Crohn's disease; chr3:53086908 chr3:53064283~53065091:- CESC cis rs3806843 0.657 rs2563283 ENSG00000202111.1 VTRNA1-2 6.6 3.1e-10 5.96e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140726393 chr5:140718925~140719013:+ CESC cis rs3806843 0.771 rs2563336 ENSG00000202111.1 VTRNA1-2 6.6 3.1e-10 5.96e-07 0.43 0.41 Depressive symptoms (multi-trait analysis); chr5:140727614 chr5:140718925~140719013:+ CESC cis rs10463554 0.963 rs32850 ENSG00000175749.11 EIF3KP1 6.6 3.12e-10 5.99e-07 0.44 0.41 Parkinson's disease; chr5:103134325 chr5:103032376~103033031:+ CESC cis rs2404602 0.647 rs11637096 ENSG00000259422.1 RP11-593F23.1 -6.6 3.15e-10 6.04e-07 -0.49 -0.41 Blood metabolite levels; chr15:76638761 chr15:76174891~76181486:- CESC cis rs1707322 0.686 rs2230658 ENSG00000281133.1 AL355480.3 6.6 3.15e-10 6.04e-07 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613182 chr1:45580892~45580996:- CESC cis rs1707322 0.686 rs2230659 ENSG00000281133.1 AL355480.3 6.6 3.15e-10 6.04e-07 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613212 chr1:45580892~45580996:- CESC cis rs9660180 1 rs9660180 ENSG00000231050.1 RP1-140A9.1 6.6 3.16e-10 6.06e-07 0.48 0.41 Body mass index; chr1:1791592 chr1:1891471~1892658:+ CESC cis rs8062405 1 rs72793811 ENSG00000259982.1 CDC37P1 6.6 3.16e-10 6.06e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828071 chr16:28700294~28701540:- CESC cis rs8062405 1 rs72793812 ENSG00000259982.1 CDC37P1 6.6 3.16e-10 6.06e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28829060 chr16:28700294~28701540:- CESC cis rs3096299 0.719 rs12934708 ENSG00000274627.1 RP11-104N10.2 6.6 3.16e-10 6.06e-07 0.4 0.41 Multiple myeloma (IgH translocation); chr16:89457382 chr16:89516797~89522217:+ CESC cis rs7626444 0.625 rs843529 ENSG00000272359.1 U4 6.6 3.17e-10 6.07e-07 0.47 0.41 Monocyte count; chr3:196753724 chr3:196747192~196747324:- CESC cis rs9660180 0.967 rs6687065 ENSG00000231050.1 RP1-140A9.1 6.59 3.19e-10 6.11e-07 0.47 0.41 Body mass index; chr1:1847030 chr1:1891471~1892658:+ CESC cis rs35955747 0.84 rs9621221 ENSG00000236132.1 CTA-440B3.1 6.59 3.2e-10 6.13e-07 0.48 0.41 Neutrophil count;Sum basophil neutrophil counts; chr22:31220183 chr22:31816379~31817491:- CESC cis rs228614 0.51 rs223451 ENSG00000246560.2 RP11-10L12.4 6.59 3.21e-10 6.15e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791032 chr4:102828055~102844075:+ CESC cis rs228614 0.51 rs223450 ENSG00000246560.2 RP11-10L12.4 6.59 3.21e-10 6.15e-07 0.5 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791052 chr4:102828055~102844075:+ CESC cis rs3806843 0.933 rs2337987 ENSG00000202111.1 VTRNA1-2 -6.59 3.21e-10 6.15e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140808798 chr5:140718925~140719013:+ CESC cis rs3806843 0.933 rs2879087 ENSG00000202111.1 VTRNA1-2 -6.59 3.21e-10 6.15e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140808990 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs2879089 ENSG00000202111.1 VTRNA1-2 -6.59 3.21e-10 6.15e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140812308 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs11167609 ENSG00000202111.1 VTRNA1-2 -6.59 3.21e-10 6.15e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140820841 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs6885319 ENSG00000202111.1 VTRNA1-2 -6.59 3.21e-10 6.15e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140821026 chr5:140718925~140719013:+ CESC cis rs3814244 0.788 rs11177014 ENSG00000255733.4 IFNG-AS1 -6.59 3.21e-10 6.15e-07 -0.35 -0.41 Itch intensity from mosquito bite adjusted by bite size; chr12:68031871 chr12:67989445~68234686:+ CESC cis rs897984 0.572 rs112906665 ENSG00000260911.2 RP11-196G11.2 6.59 3.22e-10 6.17e-07 0.42 0.41 Dementia with Lewy bodies; chr16:31028818 chr16:31043150~31049868:+ CESC cis rs897984 0.609 rs12445650 ENSG00000260911.2 RP11-196G11.2 6.59 3.22e-10 6.17e-07 0.42 0.41 Dementia with Lewy bodies; chr16:31033576 chr16:31043150~31049868:+ CESC cis rs875971 0.862 rs10282433 ENSG00000226824.5 RP4-756H11.3 6.59 3.22e-10 6.17e-07 0.49 0.41 Aortic root size; chr7:66256452 chr7:66654538~66669855:+ CESC cis rs9545047 0.716 rs9545067 ENSG00000227676.3 LINC01068 6.59 3.23e-10 6.19e-07 0.45 0.41 Schizophrenia; chr13:79323429 chr13:79566727~79571436:+ CESC cis rs9545047 0.68 rs9574405 ENSG00000227676.3 LINC01068 6.59 3.23e-10 6.19e-07 0.45 0.41 Schizophrenia; chr13:79328943 chr13:79566727~79571436:+ CESC cis rs2404602 0.647 rs7165053 ENSG00000259422.1 RP11-593F23.1 -6.59 3.23e-10 6.19e-07 -0.48 -0.41 Blood metabolite levels; chr15:76686577 chr15:76174891~76181486:- CESC cis rs897984 0.645 rs58726213 ENSG00000260911.2 RP11-196G11.2 6.59 3.23e-10 6.19e-07 0.42 0.41 Dementia with Lewy bodies; chr16:31033362 chr16:31043150~31049868:+ CESC cis rs10129255 0.518 rs10150460 ENSG00000223648.3 IGHV3-64 -6.59 3.24e-10 6.2e-07 -0.32 -0.41 Kawasaki disease; chr14:106677179 chr14:106643132~106658258:- CESC cis rs11690935 1 rs35549875 ENSG00000228389.1 AC068039.4 -6.59 3.25e-10 6.21e-07 -0.54 -0.41 Schizophrenia; chr2:171675882 chr2:171773482~171775844:+ CESC cis rs35955747 0.902 rs5997919 ENSG00000236132.1 CTA-440B3.1 6.59 3.26e-10 6.23e-07 0.48 0.41 Neutrophil count;Sum basophil neutrophil counts; chr22:31227456 chr22:31816379~31817491:- CESC cis rs1577917 1 rs10498958 ENSG00000203875.9 SNHG5 6.59 3.27e-10 6.26e-07 0.52 0.41 Response to antipsychotic treatment; chr6:85939987 chr6:85660950~85678736:- CESC cis rs14027 0.921 rs67905698 ENSG00000279347.1 RP11-85I17.2 -6.59 3.27e-10 6.26e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119792186 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs28756749 ENSG00000279347.1 RP11-85I17.2 -6.59 3.27e-10 6.26e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119803164 chr8:119838736~119840385:- CESC cis rs9545047 0.716 rs9545108 ENSG00000227676.3 LINC01068 6.59 3.28e-10 6.27e-07 0.47 0.41 Schizophrenia; chr13:79411175 chr13:79566727~79571436:+ CESC cis rs2117029 0.555 rs9788140 ENSG00000258017.1 RP11-386G11.10 -6.59 3.28e-10 6.27e-07 -0.52 -0.41 Intelligence (multi-trait analysis); chr12:49126738 chr12:49127782~49147869:+ CESC cis rs2117029 0.555 rs9788139 ENSG00000258017.1 RP11-386G11.10 -6.59 3.28e-10 6.27e-07 -0.52 -0.41 Intelligence (multi-trait analysis); chr12:49126886 chr12:49127782~49147869:+ CESC cis rs2117029 0.619 rs2241727 ENSG00000258017.1 RP11-386G11.10 -6.59 3.28e-10 6.27e-07 -0.52 -0.41 Intelligence (multi-trait analysis); chr12:49131225 chr12:49127782~49147869:+ CESC cis rs56163509 1 rs56163509 ENSG00000259982.1 CDC37P1 6.59 3.29e-10 6.29e-07 0.52 0.41 Tonsillectomy;Mean corpuscular volume; chr16:28853150 chr16:28700294~28701540:- CESC cis rs8062405 0.964 rs7187333 ENSG00000259982.1 CDC37P1 6.59 3.29e-10 6.29e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854595 chr16:28700294~28701540:- CESC cis rs8062405 1 rs62037369 ENSG00000259982.1 CDC37P1 6.59 3.29e-10 6.29e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28872520 chr16:28700294~28701540:- CESC cis rs8062405 0.965 rs7359397 ENSG00000259982.1 CDC37P1 6.59 3.29e-10 6.29e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874338 chr16:28700294~28701540:- CESC cis rs228614 0.536 rs150897 ENSG00000246560.2 RP11-10L12.4 6.59 3.29e-10 6.29e-07 0.49 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769309 chr4:102828055~102844075:+ CESC cis rs8062405 1 rs12325113 ENSG00000259982.1 CDC37P1 6.59 3.35e-10 6.39e-07 0.52 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28837347 chr16:28700294~28701540:- CESC cis rs9545047 0.716 rs9545061 ENSG00000227676.3 LINC01068 6.58 3.36e-10 6.42e-07 0.45 0.41 Schizophrenia; chr13:79310695 chr13:79566727~79571436:+ CESC cis rs1167827 0.68 rs1167796 ENSG00000127957.15 PMS2P3 6.58 3.39e-10 6.46e-07 0.46 0.41 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75543861 chr7:75502930~75528148:- CESC cis rs2404602 0.672 rs35374222 ENSG00000259422.1 RP11-593F23.1 -6.58 3.39e-10 6.47e-07 -0.5 -0.41 Blood metabolite levels; chr15:76779053 chr15:76174891~76181486:- CESC cis rs7617773 0.539 rs13087050 ENSG00000229759.1 MRPS18AP1 6.58 3.43e-10 6.54e-07 0.42 0.41 Coronary artery disease; chr3:48351310 chr3:48256350~48256938:- CESC cis rs150992 0.609 rs2927647 ENSG00000248489.1 CTD-2007H13.3 6.58 3.43e-10 6.54e-07 0.48 0.41 Body mass index; chr5:98990161 chr5:98929171~98995013:+ CESC cis rs875971 0.8 rs427557 ENSG00000226824.5 RP4-756H11.3 -6.58 3.44e-10 6.55e-07 -0.51 -0.41 Aortic root size; chr7:66054263 chr7:66654538~66669855:+ CESC cis rs875971 0.83 rs587360 ENSG00000226824.5 RP4-756H11.3 -6.58 3.44e-10 6.55e-07 -0.51 -0.41 Aortic root size; chr7:66057711 chr7:66654538~66669855:+ CESC cis rs3806843 1 rs4404730 ENSG00000202111.1 VTRNA1-2 -6.58 3.45e-10 6.57e-07 -0.41 -0.41 Depressive symptoms (multi-trait analysis); chr5:140783025 chr5:140718925~140719013:+ CESC cis rs2739330 0.828 rs5760107 ENSG00000250470.1 AP000351.3 6.58 3.46e-10 6.59e-07 0.51 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23976904~23977585:- CESC cis rs2739330 0.789 rs5760109 ENSG00000250470.1 AP000351.3 6.58 3.46e-10 6.59e-07 0.51 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23976904~23977585:- CESC cis rs10875746 0.903 rs11168401 ENSG00000240399.1 RP1-228P16.1 -6.58 3.46e-10 6.59e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48087736 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs12304476 ENSG00000240399.1 RP1-228P16.1 -6.58 3.46e-10 6.59e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48088370 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs12306451 ENSG00000240399.1 RP1-228P16.1 -6.58 3.46e-10 6.59e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48089458 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs989144 ENSG00000240399.1 RP1-228P16.1 -6.58 3.46e-10 6.59e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48090190 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs61918806 ENSG00000240399.1 RP1-228P16.1 -6.58 3.46e-10 6.59e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48090650 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs11168403 ENSG00000240399.1 RP1-228P16.1 -6.58 3.46e-10 6.59e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48091175 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs10875740 ENSG00000240399.1 RP1-228P16.1 -6.58 3.46e-10 6.59e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48095334 chr12:48054813~48055591:- CESC cis rs10875746 0.903 rs12313404 ENSG00000240399.1 RP1-228P16.1 -6.58 3.46e-10 6.59e-07 -0.54 -0.41 Longevity (90 years and older); chr12:48098265 chr12:48054813~48055591:- CESC cis rs875971 0.564 rs313804 ENSG00000226824.5 RP4-756H11.3 -6.58 3.47e-10 6.6e-07 -0.51 -0.41 Aortic root size; chr7:66049635 chr7:66654538~66669855:+ CESC cis rs875971 0.662 rs448725 ENSG00000226824.5 RP4-756H11.3 -6.58 3.47e-10 6.6e-07 -0.51 -0.41 Aortic root size; chr7:66049641 chr7:66654538~66669855:+ CESC cis rs875971 0.658 rs432667 ENSG00000226824.5 RP4-756H11.3 -6.58 3.47e-10 6.6e-07 -0.51 -0.41 Aortic root size; chr7:66049646 chr7:66654538~66669855:+ CESC cis rs3806843 0.676 rs2245643 ENSG00000202111.1 VTRNA1-2 6.58 3.5e-10 6.65e-07 0.42 0.41 Depressive symptoms (multi-trait analysis); chr5:140650195 chr5:140718925~140719013:+ CESC cis rs9595066 0.564 rs12869383 ENSG00000227258.4 SMIM2-AS1 -6.57 3.55e-10 6.74e-07 -0.54 -0.41 Schizophrenia; chr13:44131305 chr13:44110451~44240517:+ CESC cis rs8062405 0.824 rs4788085 ENSG00000259982.1 CDC37P1 6.57 3.56e-10 6.75e-07 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523682 chr16:28700294~28701540:- CESC cis rs8062405 0.824 rs28772958 ENSG00000259982.1 CDC37P1 6.57 3.56e-10 6.75e-07 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523984 chr16:28700294~28701540:- CESC cis rs8062405 0.789 rs2106480 ENSG00000259982.1 CDC37P1 6.57 3.56e-10 6.75e-07 0.51 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28526650 chr16:28700294~28701540:- CESC cis rs10853057 0.717 rs62062479 ENSG00000214174.7 AMZ2P1 6.57 3.57e-10 6.77e-07 0.72 0.41 White matter microstructure (global fractional anisotropy); chr17:65060017 chr17:64966550~64975576:- CESC cis rs1823913 0.895 rs10931491 ENSG00000280083.1 RP11-317J9.1 6.57 3.57e-10 6.77e-07 0.46 0.41 Obesity-related traits; chr2:191256087 chr2:191154118~191156070:- CESC cis rs1823913 1 rs11681777 ENSG00000280083.1 RP11-317J9.1 6.57 3.57e-10 6.77e-07 0.46 0.41 Obesity-related traits; chr2:191256741 chr2:191154118~191156070:- CESC cis rs1823913 1 rs1840377 ENSG00000280083.1 RP11-317J9.1 6.57 3.57e-10 6.77e-07 0.46 0.41 Obesity-related traits; chr2:191257992 chr2:191154118~191156070:- CESC cis rs1823913 1 rs4853564 ENSG00000280083.1 RP11-317J9.1 6.57 3.57e-10 6.77e-07 0.46 0.41 Obesity-related traits; chr2:191258939 chr2:191154118~191156070:- CESC cis rs1823913 1 rs4853565 ENSG00000280083.1 RP11-317J9.1 6.57 3.57e-10 6.77e-07 0.46 0.41 Obesity-related traits; chr2:191259020 chr2:191154118~191156070:- CESC cis rs1823913 1 rs4853462 ENSG00000280083.1 RP11-317J9.1 6.57 3.57e-10 6.77e-07 0.46 0.41 Obesity-related traits; chr2:191259078 chr2:191154118~191156070:- CESC cis rs2404602 0.647 rs11072610 ENSG00000259422.1 RP11-593F23.1 -6.57 3.57e-10 6.78e-07 -0.49 -0.41 Blood metabolite levels; chr15:76638464 chr15:76174891~76181486:- CESC cis rs10463554 0.963 rs17154953 ENSG00000175749.11 EIF3KP1 6.57 3.58e-10 6.8e-07 0.43 0.41 Parkinson's disease; chr5:103019557 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs3776859 ENSG00000175749.11 EIF3KP1 6.57 3.59e-10 6.82e-07 0.43 0.41 Parkinson's disease; chr5:103016330 chr5:103032376~103033031:+ CESC cis rs2882667 0.627 rs1549203 ENSG00000253404.1 AC034243.1 -6.57 3.63e-10 6.89e-07 -0.5 -0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139132655 chr5:138744434~138753309:- CESC cis rs4423214 0.84 rs1792315 ENSG00000254682.1 RP11-660L16.2 -6.57 3.64e-10 6.9e-07 -0.54 -0.41 Vitamin D levels; chr11:71454501 chr11:71448674~71452157:+ CESC cis rs113835537 0.529 rs11227514 ENSG00000255517.5 CTD-3074O7.5 -6.57 3.64e-10 6.9e-07 -0.45 -0.41 Airway imaging phenotypes; chr11:66519156 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs10896125 ENSG00000255517.5 CTD-3074O7.5 -6.57 3.64e-10 6.9e-07 -0.45 -0.41 Airway imaging phenotypes; chr11:66521262 chr11:66473490~66480233:- CESC cis rs7849270 1 rs10988232 ENSG00000268707.1 RP11-247A12.7 -6.57 3.65e-10 6.91e-07 -0.49 -0.41 Blood metabolite ratios; chr9:129153069 chr9:129170434~129170940:+ CESC cis rs7849270 0.959 rs10988233 ENSG00000268707.1 RP11-247A12.7 -6.57 3.65e-10 6.91e-07 -0.49 -0.41 Blood metabolite ratios; chr9:129153647 chr9:129170434~129170940:+ CESC cis rs9545047 0.68 rs7987769 ENSG00000227676.3 LINC01068 6.57 3.65e-10 6.91e-07 0.46 0.41 Schizophrenia; chr13:79343965 chr13:79566727~79571436:+ CESC cis rs9545047 0.716 rs7327386 ENSG00000227676.3 LINC01068 6.57 3.65e-10 6.91e-07 0.46 0.41 Schizophrenia; chr13:79347901 chr13:79566727~79571436:+ CESC cis rs9545047 0.644 rs9318624 ENSG00000227676.3 LINC01068 6.57 3.65e-10 6.91e-07 0.46 0.41 Schizophrenia; chr13:79350915 chr13:79566727~79571436:+ CESC cis rs1185460 0.967 rs1784460 ENSG00000271751.1 RP11-110I1.14 6.57 3.66e-10 6.93e-07 0.52 0.41 Coronary artery disease; chr11:119067660 chr11:119065263~119065677:- CESC cis rs2739330 0.703 rs5760112 ENSG00000099984.9 GSTT2 -6.57 3.66e-10 6.93e-07 -0.5 -0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23980123~23983911:+ CESC cis rs4888378 0.535 rs9319483 ENSG00000261783.1 RP11-252K23.2 6.57 3.67e-10 6.94e-07 0.59 0.41 Coronary artery disease; chr16:75311893 chr16:75379818~75381260:- CESC cis rs950169 0.922 rs12915832 ENSG00000225151.9 GOLGA2P7 -6.57 3.68e-10 6.96e-07 -0.54 -0.41 Schizophrenia; chr15:84568226 chr15:84199311~84230136:- CESC cis rs3806843 0.735 rs778597 ENSG00000202111.1 VTRNA1-2 -6.57 3.68e-10 6.96e-07 -0.42 -0.41 Depressive symptoms (multi-trait analysis); chr5:140661080 chr5:140718925~140719013:+ CESC cis rs10463554 0.963 rs187427 ENSG00000175749.11 EIF3KP1 6.57 3.69e-10 6.99e-07 0.44 0.41 Parkinson's disease; chr5:103177102 chr5:103032376~103033031:+ CESC cis rs14027 0.921 rs1567359 ENSG00000279347.1 RP11-85I17.2 -6.57 3.7e-10 6.99e-07 -0.39 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119778378 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs2043430 ENSG00000279347.1 RP11-85I17.2 -6.57 3.7e-10 6.99e-07 -0.39 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119779741 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs12543087 ENSG00000279347.1 RP11-85I17.2 -6.57 3.7e-10 6.99e-07 -0.39 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119784207 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs10101278 ENSG00000279347.1 RP11-85I17.2 -6.57 3.7e-10 6.99e-07 -0.39 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119784799 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs1976575 ENSG00000279347.1 RP11-85I17.2 -6.57 3.7e-10 6.99e-07 -0.39 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119788618 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs7837589 ENSG00000279347.1 RP11-85I17.2 -6.57 3.7e-10 6.99e-07 -0.39 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119789401 chr8:119838736~119840385:- CESC cis rs113835537 0.597 rs57288351 ENSG00000255517.5 CTD-3074O7.5 -6.57 3.7e-10 6.99e-07 -0.49 -0.41 Airway imaging phenotypes; chr11:66540018 chr11:66473490~66480233:- CESC cis rs113835537 0.529 rs11227525 ENSG00000255517.5 CTD-3074O7.5 -6.57 3.7e-10 6.99e-07 -0.49 -0.41 Airway imaging phenotypes; chr11:66540594 chr11:66473490~66480233:- CESC cis rs1061377 1 rs1061377 ENSG00000249207.1 RP11-360F5.1 -6.57 3.72e-10 7.02e-07 -0.45 -0.41 Uric acid levels; chr4:39123130 chr4:39112677~39126818:- CESC cis rs1061377 1 rs13109200 ENSG00000249207.1 RP11-360F5.1 -6.57 3.72e-10 7.02e-07 -0.45 -0.41 Uric acid levels; chr4:39124396 chr4:39112677~39126818:- CESC cis rs1061377 1 rs13144374 ENSG00000249207.1 RP11-360F5.1 -6.57 3.72e-10 7.02e-07 -0.45 -0.41 Uric acid levels; chr4:39128859 chr4:39112677~39126818:- CESC cis rs1061377 1 rs28607301 ENSG00000249207.1 RP11-360F5.1 -6.57 3.72e-10 7.02e-07 -0.45 -0.41 Uric acid levels; chr4:39136460 chr4:39112677~39126818:- CESC cis rs1061377 1 rs36090629 ENSG00000249207.1 RP11-360F5.1 -6.57 3.72e-10 7.02e-07 -0.45 -0.41 Uric acid levels; chr4:39137195 chr4:39112677~39126818:- CESC cis rs1061377 0.87 rs73238544 ENSG00000249207.1 RP11-360F5.1 -6.57 3.72e-10 7.02e-07 -0.45 -0.41 Uric acid levels; chr4:39137343 chr4:39112677~39126818:- CESC cis rs13230714 0.858 rs714429 ENSG00000204959.4 ARHGEF34P -6.57 3.72e-10 7.02e-07 -0.43 -0.41 Breast cancer; chr7:144456641 chr7:144272445~144286966:- CESC cis rs7626444 0.605 rs7642801 ENSG00000272359.1 U4 -6.57 3.72e-10 7.02e-07 -0.48 -0.41 Monocyte count; chr3:196763435 chr3:196747192~196747324:- CESC cis rs7626444 0.584 rs7633044 ENSG00000272359.1 U4 -6.57 3.72e-10 7.02e-07 -0.48 -0.41 Monocyte count; chr3:196763772 chr3:196747192~196747324:- CESC cis rs150992 0.609 rs1093794 ENSG00000248489.1 CTD-2007H13.3 -6.57 3.72e-10 7.03e-07 -0.49 -0.41 Body mass index; chr5:98993334 chr5:98929171~98995013:+ CESC cis rs7208859 0.673 rs216435 ENSG00000263531.1 RP13-753N3.1 6.56 3.77e-10 7.1e-07 0.76 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595719 chr17:30863921~30864940:- CESC cis rs6964833 1 rs17515241 ENSG00000123965.13 PMS2P5 -6.56 3.77e-10 7.1e-07 -0.63 -0.41 Menarche (age at onset); chr7:74717695 chr7:74894116~74897835:+ CESC cis rs14027 0.883 rs16893027 ENSG00000279347.1 RP11-85I17.2 -6.56 3.78e-10 7.12e-07 -0.38 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119701534 chr8:119838736~119840385:- CESC cis rs150992 0.609 rs78721487 ENSG00000248489.1 CTD-2007H13.3 6.56 3.8e-10 7.16e-07 0.48 0.41 Body mass index; chr5:98992926 chr5:98929171~98995013:+ CESC cis rs10463554 1 rs12659870 ENSG00000175749.11 EIF3KP1 6.56 3.81e-10 7.18e-07 0.43 0.41 Parkinson's disease; chr5:103000867 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs1552916 ENSG00000175749.11 EIF3KP1 6.56 3.81e-10 7.18e-07 0.43 0.41 Parkinson's disease; chr5:103002036 chr5:103032376~103033031:+ CESC cis rs9399135 0.967 rs12661423 ENSG00000232876.1 CTA-212D2.2 -6.56 3.84e-10 7.24e-07 -0.47 -0.41 Red blood cell count; chr6:135028432 chr6:135055033~135060550:+ CESC cis rs9399135 0.933 rs9389262 ENSG00000232876.1 CTA-212D2.2 -6.56 3.87e-10 7.29e-07 -0.47 -0.41 Red blood cell count; chr6:135055271 chr6:135055033~135060550:+ CESC cis rs1501911 0.53 rs162473 ENSG00000248489.1 CTD-2007H13.3 -6.56 3.87e-10 7.29e-07 -0.48 -0.41 Lung function (FEV1/FVC); chr5:98805276 chr5:98929171~98995013:+ CESC cis rs3806843 0.735 rs801167 ENSG00000202111.1 VTRNA1-2 -6.56 3.87e-10 7.29e-07 -0.43 -0.41 Depressive symptoms (multi-trait analysis); chr5:140701838 chr5:140718925~140719013:+ CESC cis rs10875746 0.855 rs10875728 ENSG00000240399.1 RP1-228P16.1 -6.56 3.91e-10 7.35e-07 -0.49 -0.41 Longevity (90 years and older); chr12:48032609 chr12:48054813~48055591:- CESC cis rs150992 0.587 rs1393210 ENSG00000248489.1 CTD-2007H13.3 -6.56 3.91e-10 7.36e-07 -0.49 -0.41 Body mass index; chr5:99025892 chr5:98929171~98995013:+ CESC cis rs150992 0.587 rs11242567 ENSG00000248489.1 CTD-2007H13.3 -6.56 3.91e-10 7.36e-07 -0.49 -0.41 Body mass index; chr5:99028686 chr5:98929171~98995013:+ CESC cis rs3806843 0.9 rs2261651 ENSG00000202111.1 VTRNA1-2 6.56 3.94e-10 7.4e-07 0.41 0.41 Depressive symptoms (multi-trait analysis); chr5:140757219 chr5:140718925~140719013:+ CESC cis rs3806843 0.9 rs2337983 ENSG00000202111.1 VTRNA1-2 6.56 3.94e-10 7.4e-07 0.41 0.41 Depressive symptoms (multi-trait analysis); chr5:140757223 chr5:140718925~140719013:+ CESC cis rs7727544 0.735 rs273914 ENSG00000233006.5 AC034220.3 6.56 3.94e-10 7.41e-07 0.46 0.41 Blood metabolite levels; chr5:132324738 chr5:132311285~132369916:- CESC cis rs9545047 0.74 rs9574409 ENSG00000227676.3 LINC01068 6.56 3.95e-10 7.43e-07 0.46 0.41 Schizophrenia; chr13:79341844 chr13:79566727~79571436:+ CESC cis rs992157 0.798 rs4996257 ENSG00000261338.2 RP11-378A13.1 6.56 3.95e-10 7.43e-07 0.52 0.41 Colorectal cancer; chr2:218298113 chr2:218255319~218257366:+ CESC cis rs875971 0.965 rs28682868 ENSG00000222364.1 RNU6-96P 6.56 3.95e-10 7.43e-07 0.47 0.41 Aortic root size; chr7:66224822 chr7:66395191~66395286:+ CESC cis rs3806843 0.741 rs2563293 ENSG00000202111.1 VTRNA1-2 6.56 3.96e-10 7.44e-07 0.42 0.41 Depressive symptoms (multi-trait analysis); chr5:140730951 chr5:140718925~140719013:+ CESC cis rs3806843 0.771 rs801174 ENSG00000202111.1 VTRNA1-2 6.56 3.96e-10 7.44e-07 0.42 0.41 Depressive symptoms (multi-trait analysis); chr5:140733127 chr5:140718925~140719013:+ CESC cis rs2929278 0.588 rs688009 ENSG00000249839.1 AC011330.5 -6.55 3.99e-10 7.49e-07 -0.42 -0.41 Schizophrenia; chr15:43864104 chr15:43663654~43684339:- CESC cis rs55894132 1 rs55894132 ENSG00000279656.1 RP11-298I3.6 6.55 4e-10 7.51e-07 0.5 0.41 Intelligence (multi-trait analysis); chr14:22939628 chr14:23023083~23024217:- CESC cis rs9399135 0.904 rs4895438 ENSG00000232876.1 CTA-212D2.2 -6.55 4.02e-10 7.55e-07 -0.47 -0.41 Red blood cell count; chr6:134996527 chr6:135055033~135060550:+ CESC cis rs11168854 0.656 rs7969967 ENSG00000258017.1 RP11-386G11.10 6.55 4.03e-10 7.57e-07 0.51 0.41 Body mass index; chr12:49118234 chr12:49127782~49147869:+ CESC cis rs11155671 0.53 rs9968871 ENSG00000268592.3 RAET1E-AS1 6.55 4.04e-10 7.59e-07 0.51 0.41 Testicular germ cell tumor; chr6:149888060 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs9969044 ENSG00000268592.3 RAET1E-AS1 6.55 4.04e-10 7.59e-07 0.51 0.41 Testicular germ cell tumor; chr6:149888068 chr6:149863494~149919507:+ CESC cis rs9399137 0.529 rs7739722 ENSG00000232876.1 CTA-212D2.2 -6.55 4.06e-10 7.63e-07 -0.51 -0.41 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134961087 chr6:135055033~135060550:+ CESC cis rs14027 0.921 rs10505374 ENSG00000279347.1 RP11-85I17.2 -6.55 4.07e-10 7.64e-07 -0.4 -0.41 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119832350 chr8:119838736~119840385:- CESC cis rs9907295 0.591 rs2291299 ENSG00000270977.1 AC015849.16 -6.55 4.08e-10 7.65e-07 -0.48 -0.41 Fibroblast growth factor basic levels; chr17:35864402 chr17:35893707~35911023:- CESC cis rs1707322 0.686 rs3014251 ENSG00000281133.1 AL355480.3 6.55 4.13e-10 7.74e-07 0.49 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45611756 chr1:45580892~45580996:- CESC cis rs7188445 0.592 rs17767281 ENSG00000261390.4 RP11-345M22.2 -6.55 4.14e-10 7.76e-07 -0.48 -0.41 Urate levels; chr16:79708544 chr16:79715232~79770563:- CESC cis rs7208859 0.673 rs73263981 ENSG00000263531.1 RP13-753N3.1 6.55 4.15e-10 7.77e-07 0.76 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593484 chr17:30863921~30864940:- CESC cis rs7208859 0.524 rs73263982 ENSG00000263531.1 RP13-753N3.1 6.55 4.15e-10 7.77e-07 0.76 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593606 chr17:30863921~30864940:- CESC cis rs7208859 0.623 rs216433 ENSG00000263531.1 RP13-753N3.1 6.55 4.15e-10 7.77e-07 0.76 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30594842 chr17:30863921~30864940:- CESC cis rs9326248 0.569 rs4938315 ENSG00000254851.1 RP11-109L13.1 -6.55 4.16e-10 7.79e-07 -0.68 -0.41 Blood protein levels; chr11:116860489 chr11:117135528~117138582:+ CESC cis rs2739330 0.685 rs4822453 ENSG00000099984.9 GSTT2 -6.55 4.18e-10 7.81e-07 -0.49 -0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23980123~23983911:+ CESC cis rs1823913 0.562 rs17347499 ENSG00000280083.1 RP11-317J9.1 -6.54 4.21e-10 7.88e-07 -0.48 -0.41 Obesity-related traits; chr2:191301116 chr2:191154118~191156070:- CESC cis rs2581828 0.656 rs2564940 ENSG00000242142.1 SERBP1P3 6.54 4.22e-10 7.89e-07 0.46 0.41 Crohn's disease; chr3:53073553 chr3:53064283~53065091:- CESC cis rs9399137 0.507 rs7772031 ENSG00000232876.1 CTA-212D2.2 6.54 4.24e-10 7.92e-07 0.5 0.41 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134938596 chr6:135055033~135060550:+ CESC cis rs4423214 0.84 rs1792234 ENSG00000254682.1 RP11-660L16.2 -6.54 4.26e-10 7.95e-07 -0.55 -0.41 Vitamin D levels; chr11:71470972 chr11:71448674~71452157:+ CESC cis rs6860806 0.507 rs272868 ENSG00000233006.5 AC034220.3 6.54 4.27e-10 7.97e-07 0.45 0.41 Breast cancer; chr5:132345058 chr5:132311285~132369916:- CESC cis rs11690935 1 rs11678984 ENSG00000228389.1 AC068039.4 -6.54 4.28e-10 8e-07 -0.53 -0.41 Schizophrenia; chr2:171679338 chr2:171773482~171775844:+ CESC cis rs12439619 0.693 rs9944185 ENSG00000278603.1 RP13-608F4.5 6.54 4.29e-10 8e-07 0.59 0.41 Intelligence (multi-trait analysis); chr15:82157927 chr15:82472203~82472426:+ CESC cis rs526231 0.578 rs59323174 ENSG00000175749.11 EIF3KP1 6.54 4.29e-10 8e-07 0.45 0.41 Primary biliary cholangitis; chr5:102932165 chr5:103032376~103033031:+ CESC cis rs9399135 0.967 rs2297338 ENSG00000232876.1 CTA-212D2.2 -6.54 4.3e-10 8.03e-07 -0.47 -0.41 Red blood cell count; chr6:135054624 chr6:135055033~135060550:+ CESC cis rs2404602 0.709 rs11072597 ENSG00000259422.1 RP11-593F23.1 -6.54 4.31e-10 8.04e-07 -0.49 -0.41 Blood metabolite levels; chr15:76471173 chr15:76174891~76181486:- CESC cis rs2404602 0.735 rs11857327 ENSG00000259422.1 RP11-593F23.1 -6.54 4.31e-10 8.04e-07 -0.49 -0.41 Blood metabolite levels; chr15:76471922 chr15:76174891~76181486:- CESC cis rs9399135 0.967 rs1590975 ENSG00000232876.1 CTA-212D2.2 -6.54 4.32e-10 8.07e-07 -0.46 -0.4 Red blood cell count; chr6:135030950 chr6:135055033~135060550:+ CESC cis rs7727544 0.735 rs4705933 ENSG00000233006.5 AC034220.3 6.54 4.33e-10 8.07e-07 0.45 0.4 Blood metabolite levels; chr5:132342719 chr5:132311285~132369916:- CESC cis rs7727544 0.735 rs272867 ENSG00000233006.5 AC034220.3 6.54 4.33e-10 8.07e-07 0.45 0.4 Blood metabolite levels; chr5:132345364 chr5:132311285~132369916:- CESC cis rs150992 0.631 rs112047336 ENSG00000248489.1 CTD-2007H13.3 6.54 4.33e-10 8.08e-07 0.48 0.4 Body mass index; chr5:98990041 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs112042355 ENSG00000248489.1 CTD-2007H13.3 6.54 4.33e-10 8.08e-07 0.48 0.4 Body mass index; chr5:98990046 chr5:98929171~98995013:+ CESC cis rs150992 0.587 rs75001231 ENSG00000248489.1 CTD-2007H13.3 6.54 4.33e-10 8.08e-07 0.48 0.4 Body mass index; chr5:98990085 chr5:98929171~98995013:+ CESC cis rs2739330 0.76 rs1007888 ENSG00000099984.9 GSTT2 -6.54 4.33e-10 8.08e-07 -0.5 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23980123~23983911:+ CESC cis rs507080 0.961 rs642530 ENSG00000255422.1 AP002954.4 -6.54 4.33e-10 8.08e-07 -0.46 -0.4 Serum metabolite levels; chr11:118680047 chr11:118704607~118750263:+ CESC cis rs7727544 0.735 rs272894 ENSG00000233006.5 AC034220.3 6.54 4.34e-10 8.09e-07 0.45 0.4 Blood metabolite levels; chr5:132326767 chr5:132311285~132369916:- CESC cis rs11155671 0.53 rs7758033 ENSG00000216906.2 RP11-350J20.9 6.54 4.34e-10 8.09e-07 0.44 0.4 Testicular germ cell tumor; chr6:149886999 chr6:149904243~149906418:+ CESC cis rs9584850 0.794 rs9630321 ENSG00000231194.1 FARP1-AS1 6.54 4.34e-10 8.1e-07 0.51 0.4 Neuroticism; chr13:98454725 chr13:98435405~98435840:- CESC cis rs9399135 0.967 rs2183709 ENSG00000232876.1 CTA-212D2.2 -6.54 4.36e-10 8.13e-07 -0.47 -0.4 Red blood cell count; chr6:135055953 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs4142299 ENSG00000232876.1 CTA-212D2.2 -6.54 4.36e-10 8.13e-07 -0.47 -0.4 Red blood cell count; chr6:135056048 chr6:135055033~135060550:+ CESC cis rs1823913 0.599 rs13027086 ENSG00000280083.1 RP11-317J9.1 -6.54 4.41e-10 8.21e-07 -0.47 -0.4 Obesity-related traits; chr2:191294058 chr2:191154118~191156070:- CESC cis rs916888 0.647 rs199524 ENSG00000214401.4 KANSL1-AS1 -6.53 4.45e-10 8.29e-07 -0.49 -0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46193576~46196723:+ CESC cis rs10463554 0.927 rs6862616 ENSG00000175749.11 EIF3KP1 6.53 4.49e-10 8.36e-07 0.43 0.4 Parkinson's disease; chr5:102910334 chr5:103032376~103033031:+ CESC cis rs1577917 1 rs1577917 ENSG00000203875.9 SNHG5 -6.53 4.53e-10 8.42e-07 -0.53 -0.4 Response to antipsychotic treatment; chr6:85982222 chr6:85660950~85678736:- CESC cis rs3814244 0.788 rs3741649 ENSG00000255733.4 IFNG-AS1 -6.53 4.54e-10 8.44e-07 -0.35 -0.4 Itch intensity from mosquito bite adjusted by bite size; chr12:68028351 chr12:67989445~68234686:+ CESC cis rs113835537 0.735 rs519380 ENSG00000255517.5 CTD-3074O7.5 -6.53 4.55e-10 8.46e-07 -0.51 -0.4 Airway imaging phenotypes; chr11:66641938 chr11:66473490~66480233:- CESC cis rs992157 0.731 rs1399132 ENSG00000261338.2 RP11-378A13.1 6.53 4.58e-10 8.52e-07 0.52 0.4 Colorectal cancer; chr2:218295047 chr2:218255319~218257366:+ CESC cis rs992157 0.796 rs55680399 ENSG00000261338.2 RP11-378A13.1 6.53 4.58e-10 8.52e-07 0.52 0.4 Colorectal cancer; chr2:218295898 chr2:218255319~218257366:+ CESC cis rs1185460 0.967 rs1786684 ENSG00000271751.1 RP11-110I1.14 -6.53 4.6e-10 8.54e-07 -0.53 -0.4 Coronary artery disease; chr11:119067724 chr11:119065263~119065677:- CESC cis rs2404602 0.647 rs11852395 ENSG00000259422.1 RP11-593F23.1 -6.53 4.66e-10 8.65e-07 -0.49 -0.4 Blood metabolite levels; chr15:76795444 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs12439141 ENSG00000259422.1 RP11-593F23.1 -6.53 4.66e-10 8.65e-07 -0.49 -0.4 Blood metabolite levels; chr15:76803082 chr15:76174891~76181486:- CESC cis rs7727544 0.735 rs272842 ENSG00000233006.5 AC034220.3 6.53 4.68e-10 8.68e-07 0.45 0.4 Blood metabolite levels; chr5:132320824 chr5:132311285~132369916:- CESC cis rs9545047 0.716 rs9565500 ENSG00000227676.3 LINC01068 -6.52 4.69e-10 8.7e-07 -0.47 -0.4 Schizophrenia; chr13:79433416 chr13:79566727~79571436:+ CESC cis rs526231 0.578 rs6860588 ENSG00000175749.11 EIF3KP1 -6.52 4.71e-10 8.72e-07 -0.45 -0.4 Primary biliary cholangitis; chr5:102944598 chr5:103032376~103033031:+ CESC cis rs3806843 1 rs3756339 ENSG00000202111.1 VTRNA1-2 -6.52 4.71e-10 8.73e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140800952 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs3733708 ENSG00000202111.1 VTRNA1-2 -6.52 4.71e-10 8.73e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140802149 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs2240694 ENSG00000202111.1 VTRNA1-2 -6.52 4.71e-10 8.73e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140803473 chr5:140718925~140719013:+ CESC cis rs7674212 0.531 rs6816370 ENSG00000246560.2 RP11-10L12.4 6.52 4.71e-10 8.73e-07 0.52 0.4 Type 2 diabetes; chr4:103018276 chr4:102828055~102844075:+ CESC cis rs1707322 1 rs6677777 ENSG00000280836.1 AL355480.1 -6.52 4.81e-10 8.92e-07 -0.5 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46010164 chr1:45581219~45581321:- CESC cis rs2404602 0.735 rs11635463 ENSG00000259422.1 RP11-593F23.1 -6.52 4.82e-10 8.93e-07 -0.49 -0.4 Blood metabolite levels; chr15:76470645 chr15:76174891~76181486:- CESC cis rs14027 0.921 rs7833112 ENSG00000279347.1 RP11-85I17.2 -6.52 4.83e-10 8.94e-07 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119835842 chr8:119838736~119840385:- CESC cis rs7849270 1 rs1009242 ENSG00000268707.1 RP11-247A12.7 -6.52 4.83e-10 8.95e-07 -0.49 -0.4 Blood metabolite ratios; chr9:129154553 chr9:129170434~129170940:+ CESC cis rs7849270 0.959 rs913276 ENSG00000268707.1 RP11-247A12.7 -6.52 4.83e-10 8.95e-07 -0.49 -0.4 Blood metabolite ratios; chr9:129154885 chr9:129170434~129170940:+ CESC cis rs7849270 1 rs7868408 ENSG00000268707.1 RP11-247A12.7 -6.52 4.83e-10 8.95e-07 -0.49 -0.4 Blood metabolite ratios; chr9:129155585 chr9:129170434~129170940:+ CESC cis rs1062177 0.826 rs1549920 ENSG00000253921.1 CTB-113P19.3 -6.52 4.86e-10 8.99e-07 -0.51 -0.4 Preschool internalizing problems; chr5:151761283 chr5:151753992~151767247:+ CESC cis rs1061377 1 rs7664078 ENSG00000249207.1 RP11-360F5.1 -6.52 4.91e-10 9.07e-07 -0.46 -0.4 Uric acid levels; chr4:39116583 chr4:39112677~39126818:- CESC cis rs7188445 0.556 rs7194711 ENSG00000261390.4 RP11-345M22.2 -6.52 4.94e-10 9.12e-07 -0.48 -0.4 Urate levels; chr16:79715134 chr16:79715232~79770563:- CESC cis rs7115242 0.8 rs6589597 ENSG00000254851.1 RP11-109L13.1 6.52 4.95e-10 9.14e-07 0.63 0.4 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117127082 chr11:117135528~117138582:+ CESC cis rs2929278 0.617 rs694461 ENSG00000249839.1 AC011330.5 6.52 4.96e-10 9.15e-07 0.42 0.4 Schizophrenia; chr15:43803865 chr15:43663654~43684339:- CESC cis rs3806843 0.931 rs13168670 ENSG00000202111.1 VTRNA1-2 -6.52 4.96e-10 9.15e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140767314 chr5:140718925~140719013:+ CESC cis rs12439619 0.921 rs4778672 ENSG00000278603.1 RP13-608F4.5 -6.51 4.96e-10 9.16e-07 -0.6 -0.4 Intelligence (multi-trait analysis); chr15:82245013 chr15:82472203~82472426:+ CESC cis rs10463554 0.963 rs10463555 ENSG00000175749.11 EIF3KP1 6.51 4.99e-10 9.21e-07 0.43 0.4 Parkinson's disease; chr5:102983333 chr5:103032376~103033031:+ CESC cis rs11155671 0.53 rs9383577 ENSG00000216906.2 RP11-350J20.9 6.51 5.03e-10 9.27e-07 0.43 0.4 Testicular germ cell tumor; chr6:149886059 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs9383914 ENSG00000216906.2 RP11-350J20.9 6.51 5.03e-10 9.27e-07 0.43 0.4 Testicular germ cell tumor; chr6:149886098 chr6:149904243~149906418:+ CESC cis rs11155671 0.517 rs9397058 ENSG00000216906.2 RP11-350J20.9 6.51 5.03e-10 9.27e-07 0.43 0.4 Testicular germ cell tumor; chr6:149886113 chr6:149904243~149906418:+ CESC cis rs526231 0.578 rs6867392 ENSG00000175749.11 EIF3KP1 6.51 5.03e-10 9.28e-07 0.44 0.4 Primary biliary cholangitis; chr5:102946183 chr5:103032376~103033031:+ CESC cis rs35955747 0.633 rs5998021 ENSG00000236132.1 CTA-440B3.1 6.51 5.07e-10 9.32e-07 0.48 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31511441 chr22:31816379~31817491:- CESC cis rs2404602 0.735 rs12906143 ENSG00000259422.1 RP11-593F23.1 -6.51 5.07e-10 9.32e-07 -0.49 -0.4 Blood metabolite levels; chr15:76417182 chr15:76174891~76181486:- CESC cis rs2404602 0.735 rs11632222 ENSG00000259422.1 RP11-593F23.1 -6.51 5.07e-10 9.32e-07 -0.49 -0.4 Blood metabolite levels; chr15:76420586 chr15:76174891~76181486:- CESC cis rs2929278 0.617 rs575082 ENSG00000249839.1 AC011330.5 6.51 5.08e-10 9.33e-07 0.42 0.4 Schizophrenia; chr15:43817944 chr15:43663654~43684339:- CESC cis rs2929278 0.617 rs2955969 ENSG00000249839.1 AC011330.5 6.51 5.08e-10 9.33e-07 0.42 0.4 Schizophrenia; chr15:43822329 chr15:43663654~43684339:- CESC cis rs897984 0.609 rs55979739 ENSG00000260911.2 RP11-196G11.2 6.51 5.09e-10 9.35e-07 0.42 0.4 Dementia with Lewy bodies; chr16:31037834 chr16:31043150~31049868:+ CESC cis rs14027 0.921 rs4871634 ENSG00000279347.1 RP11-85I17.2 -6.51 5.09e-10 9.35e-07 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119806243 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs12707880 ENSG00000279347.1 RP11-85I17.2 -6.51 5.09e-10 9.35e-07 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119829051 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs12542706 ENSG00000279347.1 RP11-85I17.2 -6.51 5.09e-10 9.35e-07 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119831539 chr8:119838736~119840385:- CESC cis rs2739330 0.731 rs4822450 ENSG00000231271.1 AP000350.8 6.51 5.09e-10 9.36e-07 0.49 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23949918~23954042:+ CESC cis rs150992 0.609 rs393697 ENSG00000248489.1 CTD-2007H13.3 6.51 5.1e-10 9.36e-07 0.49 0.4 Body mass index; chr5:98991357 chr5:98929171~98995013:+ CESC cis rs3806843 0.966 rs3756341 ENSG00000202111.1 VTRNA1-2 -6.51 5.12e-10 9.41e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140791609 chr5:140718925~140719013:+ CESC cis rs7727544 0.66 rs272886 ENSG00000233006.5 AC034220.3 6.51 5.21e-10 9.55e-07 0.45 0.4 Blood metabolite levels; chr5:132330147 chr5:132311285~132369916:- CESC cis rs7115242 0.748 rs1035237 ENSG00000254851.1 RP11-109L13.1 -6.51 5.21e-10 9.56e-07 -0.72 -0.4 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116857134 chr11:117135528~117138582:+ CESC cis rs6142102 0.602 rs10485503 ENSG00000275784.1 RP5-1125A11.6 -6.51 5.23e-10 9.59e-07 -0.4 -0.4 Skin pigmentation; chr20:33970036 chr20:33989480~33991818:- CESC cis rs507080 0.922 rs4589335 ENSG00000255422.1 AP002954.4 -6.5 5.27e-10 9.66e-07 -0.48 -0.4 Serum metabolite levels; chr11:118668431 chr11:118704607~118750263:+ CESC cis rs3806843 1 rs6870764 ENSG00000202111.1 VTRNA1-2 -6.5 5.27e-10 9.66e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140792205 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs6891995 ENSG00000202111.1 VTRNA1-2 -6.5 5.27e-10 9.66e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140792423 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs13184940 ENSG00000202111.1 VTRNA1-2 -6.5 5.27e-10 9.66e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140793333 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs1476768 ENSG00000202111.1 VTRNA1-2 -6.5 5.27e-10 9.66e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140794012 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs9686540 ENSG00000202111.1 VTRNA1-2 -6.5 5.27e-10 9.66e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140795037 chr5:140718925~140719013:+ CESC cis rs35955747 0.902 rs11703927 ENSG00000236132.1 CTA-440B3.1 6.5 5.28e-10 9.66e-07 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31248978 chr22:31816379~31817491:- CESC cis rs783540 0.5 rs7163840 ENSG00000276710.3 CSPG4P8 6.5 5.29e-10 9.69e-07 0.48 0.4 Schizophrenia; chr15:82729551 chr15:82459472~82477258:+ CESC cis rs2929278 0.617 rs693919 ENSG00000249839.1 AC011330.5 6.5 5.3e-10 9.69e-07 0.42 0.4 Schizophrenia; chr15:43810130 chr15:43663654~43684339:- CESC cis rs11155671 0.53 rs9383577 ENSG00000268592.3 RAET1E-AS1 6.5 5.3e-10 9.7e-07 0.5 0.4 Testicular germ cell tumor; chr6:149886059 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs9383914 ENSG00000268592.3 RAET1E-AS1 6.5 5.3e-10 9.7e-07 0.5 0.4 Testicular germ cell tumor; chr6:149886098 chr6:149863494~149919507:+ CESC cis rs11155671 0.517 rs9397058 ENSG00000268592.3 RAET1E-AS1 6.5 5.3e-10 9.7e-07 0.5 0.4 Testicular germ cell tumor; chr6:149886113 chr6:149863494~149919507:+ CESC cis rs2404602 0.735 rs11072598 ENSG00000259422.1 RP11-593F23.1 -6.5 5.34e-10 9.76e-07 -0.49 -0.4 Blood metabolite levels; chr15:76472447 chr15:76174891~76181486:- CESC cis rs3806843 1 rs13157397 ENSG00000202111.1 VTRNA1-2 -6.5 5.34e-10 9.77e-07 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140804857 chr5:140718925~140719013:+ CESC cis rs1707322 0.721 rs6429574 ENSG00000281133.1 AL355480.3 -6.5 5.34e-10 9.77e-07 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668382 chr1:45580892~45580996:- CESC cis rs3814244 0.788 rs3741647 ENSG00000255733.4 IFNG-AS1 -6.5 5.34e-10 9.77e-07 -0.35 -0.4 Itch intensity from mosquito bite adjusted by bite size; chr12:68028249 chr12:67989445~68234686:+ CESC cis rs1707322 1 rs7538978 ENSG00000280836.1 AL355480.1 6.5 5.37e-10 9.82e-07 0.47 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46039382 chr1:45581219~45581321:- CESC cis rs10256972 0.521 rs7457418 ENSG00000229043.2 AC091729.9 -6.5 5.41e-10 9.88e-07 -0.46 -0.4 Endometriosis;Longevity; chr7:1070619 chr7:1160374~1165267:+ CESC cis rs9399135 0.816 rs4134030 ENSG00000232876.1 CTA-212D2.2 -6.5 5.42e-10 9.91e-07 -0.45 -0.4 Red blood cell count; chr6:135032956 chr6:135055033~135060550:+ CESC cis rs1185460 0.967 rs1786685 ENSG00000271751.1 RP11-110I1.14 -6.5 5.42e-10 9.91e-07 -0.54 -0.4 Coronary artery disease; chr11:119068246 chr11:119065263~119065677:- CESC cis rs67383717 0.713 rs1369156 ENSG00000175611.10 LINC00476 -6.5 5.43e-10 9.91e-07 -0.45 -0.4 Parkinson's disease (pesticide exposure interaction); chr9:95794612 chr9:95759231~95875977:- CESC cis rs7044106 0.708 rs1324472 ENSG00000226752.6 PSMD5-AS1 -6.5 5.43e-10 9.93e-07 -0.46 -0.4 Hip circumference adjusted for BMI; chr9:120612832 chr9:120824828~120854385:+ CESC cis rs1185460 0.967 rs4454730 ENSG00000271751.1 RP11-110I1.14 -6.5 5.47e-10 9.99e-07 -0.53 -0.4 Coronary artery disease; chr11:119066733 chr11:119065263~119065677:- CESC cis rs1185460 0.967 rs4545564 ENSG00000271751.1 RP11-110I1.14 -6.5 5.47e-10 9.99e-07 -0.53 -0.4 Coronary artery disease; chr11:119066807 chr11:119065263~119065677:- CESC cis rs7849270 1 rs1571229 ENSG00000268707.1 RP11-247A12.7 -6.5 5.47e-10 9.99e-07 -0.48 -0.4 Blood metabolite ratios; chr9:129151432 chr9:129170434~129170940:+ CESC cis rs9584850 0.915 rs7983438 ENSG00000231194.1 FARP1-AS1 6.5 5.49e-10 1e-06 0.51 0.4 Neuroticism; chr13:98451063 chr13:98435405~98435840:- CESC cis rs3806843 0.966 rs10053945 ENSG00000202111.1 VTRNA1-2 -6.5 5.5e-10 1e-06 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140780542 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs1548700 ENSG00000202111.1 VTRNA1-2 -6.5 5.5e-10 1e-06 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140785304 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs1548699 ENSG00000202111.1 VTRNA1-2 -6.5 5.5e-10 1e-06 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140785333 chr5:140718925~140719013:+ CESC cis rs950169 0.8 rs34302901 ENSG00000225151.9 GOLGA2P7 -6.5 5.54e-10 1.01e-06 -0.53 -0.4 Schizophrenia; chr15:84567712 chr15:84199311~84230136:- CESC cis rs228614 0.536 rs223475 ENSG00000246560.2 RP11-10L12.4 6.49 5.55e-10 1.01e-06 0.49 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771986 chr4:102828055~102844075:+ CESC cis rs228614 0.536 rs223474 ENSG00000246560.2 RP11-10L12.4 6.49 5.55e-10 1.01e-06 0.49 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102772007 chr4:102828055~102844075:+ CESC cis rs9549367 0.713 rs2476328 ENSG00000269125.1 RP11-98F14.11 6.49 5.58e-10 1.02e-06 0.54 0.4 Platelet distribution width; chr13:113175036 chr13:113165002~113165183:- CESC cis rs150992 0.609 rs539024 ENSG00000248489.1 CTD-2007H13.3 6.49 5.59e-10 1.02e-06 0.49 0.4 Body mass index; chr5:98997103 chr5:98929171~98995013:+ CESC cis rs150992 0.532 rs416750 ENSG00000248489.1 CTD-2007H13.3 6.49 5.59e-10 1.02e-06 0.49 0.4 Body mass index; chr5:98999046 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs819232 ENSG00000248489.1 CTD-2007H13.3 6.49 5.59e-10 1.02e-06 0.49 0.4 Body mass index; chr5:98999416 chr5:98929171~98995013:+ CESC cis rs6504950 1 rs1990674 ENSG00000275710.1 RP11-257O5.4 6.49 5.61e-10 1.02e-06 0.49 0.4 Breast cancer; chr17:54983714 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs10468513 ENSG00000275710.1 RP11-257O5.4 6.49 5.61e-10 1.02e-06 0.49 0.4 Breast cancer; chr17:54985542 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs56348638 ENSG00000275710.1 RP11-257O5.4 6.49 5.61e-10 1.02e-06 0.49 0.4 Breast cancer; chr17:54987189 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs7219874 ENSG00000275710.1 RP11-257O5.4 6.49 5.66e-10 1.03e-06 0.49 0.4 Breast cancer; chr17:54988446 chr17:54964474~54964679:+ CESC cis rs7674212 0.507 rs223322 ENSG00000246560.2 RP11-10L12.4 6.49 5.66e-10 1.03e-06 0.5 0.4 Type 2 diabetes; chr4:102879037 chr4:102828055~102844075:+ CESC cis rs3806843 1 rs6898939 ENSG00000202111.1 VTRNA1-2 -6.49 5.66e-10 1.03e-06 -0.42 -0.4 Depressive symptoms (multi-trait analysis); chr5:140789770 chr5:140718925~140719013:+ CESC cis rs1062177 1 rs17804178 ENSG00000213433.5 RPLP1P6 -6.49 5.67e-10 1.03e-06 -0.5 -0.4 Preschool internalizing problems; chr5:151818168 chr5:151765859~151766378:- CESC cis rs2404602 0.735 rs2436996 ENSG00000259422.1 RP11-593F23.1 -6.49 5.68e-10 1.03e-06 -0.49 -0.4 Blood metabolite levels; chr15:76525079 chr15:76174891~76181486:- CESC cis rs10463554 0.963 rs11955683 ENSG00000175749.11 EIF3KP1 6.49 5.69e-10 1.04e-06 0.42 0.4 Parkinson's disease; chr5:102990992 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs62362489 ENSG00000175749.11 EIF3KP1 6.49 5.69e-10 1.04e-06 0.43 0.4 Parkinson's disease; chr5:102909841 chr5:103032376~103033031:+ CESC cis rs2404602 0.684 rs12591622 ENSG00000259422.1 RP11-593F23.1 -6.49 5.72e-10 1.04e-06 -0.49 -0.4 Blood metabolite levels; chr15:76638314 chr15:76174891~76181486:- CESC cis rs950169 0.81 rs2879976 ENSG00000225151.9 GOLGA2P7 -6.49 5.72e-10 1.04e-06 -0.55 -0.4 Schizophrenia; chr15:84566347 chr15:84199311~84230136:- CESC cis rs7617773 0.539 rs12486935 ENSG00000229759.1 MRPS18AP1 6.49 5.75e-10 1.04e-06 0.42 0.4 Coronary artery disease; chr3:48348674 chr3:48256350~48256938:- CESC cis rs116095464 0.558 rs113796397 ENSG00000250848.1 CTD-2083E4.5 -6.49 5.77e-10 1.05e-06 -0.54 -0.4 Breast cancer; chr5:246388 chr5:288833~290321:- CESC cis rs10129255 0.5 rs4774008 ENSG00000223648.3 IGHV3-64 6.49 5.77e-10 1.05e-06 0.33 0.4 Kawasaki disease; chr14:106681273 chr14:106643132~106658258:- CESC cis rs875971 0.862 rs2420174 ENSG00000226824.5 RP4-756H11.3 6.49 5.78e-10 1.05e-06 0.49 0.4 Aortic root size; chr7:66180374 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs2420173 ENSG00000226824.5 RP4-756H11.3 6.49 5.78e-10 1.05e-06 0.49 0.4 Aortic root size; chr7:66180412 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs4718319 ENSG00000226824.5 RP4-756H11.3 6.49 5.78e-10 1.05e-06 0.49 0.4 Aortic root size; chr7:66187797 chr7:66654538~66669855:+ CESC cis rs875971 0.723 rs28391294 ENSG00000226824.5 RP4-756H11.3 6.49 5.78e-10 1.05e-06 0.49 0.4 Aortic root size; chr7:66189328 chr7:66654538~66669855:+ CESC cis rs875971 0.83 rs6967708 ENSG00000226824.5 RP4-756H11.3 6.49 5.78e-10 1.05e-06 0.49 0.4 Aortic root size; chr7:66192326 chr7:66654538~66669855:+ CESC cis rs875971 0.895 rs7782806 ENSG00000226824.5 RP4-756H11.3 6.49 5.78e-10 1.05e-06 0.49 0.4 Aortic root size; chr7:66192910 chr7:66654538~66669855:+ CESC cis rs14027 0.921 rs2634 ENSG00000279347.1 RP11-85I17.2 -6.49 5.8e-10 1.05e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119819869 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs12542794 ENSG00000279347.1 RP11-85I17.2 -6.49 5.8e-10 1.05e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119826153 chr8:119838736~119840385:- CESC cis rs2929278 0.588 rs688009 ENSG00000205771.5 CATSPER2P1 -6.49 5.84e-10 1.06e-06 -0.47 -0.4 Schizophrenia; chr15:43864104 chr15:43726918~43747094:- CESC cis rs35955747 0.902 rs5997929 ENSG00000236132.1 CTA-440B3.1 6.49 5.85e-10 1.06e-06 0.48 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31268046 chr22:31816379~31817491:- CESC cis rs35955747 0.902 rs5997932 ENSG00000236132.1 CTA-440B3.1 6.49 5.85e-10 1.06e-06 0.48 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31272168 chr22:31816379~31817491:- CESC cis rs6991838 0.584 rs7463649 ENSG00000200714.1 Y_RNA -6.48 5.89e-10 1.07e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65573760 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs7463740 ENSG00000200714.1 Y_RNA -6.48 5.89e-10 1.07e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65573950 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs66467166 ENSG00000200714.1 Y_RNA -6.48 5.89e-10 1.07e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65574165 chr8:65592731~65592820:+ CESC cis rs1577917 0.958 rs2121594 ENSG00000203875.9 SNHG5 -6.48 5.89e-10 1.07e-06 -0.52 -0.4 Response to antipsychotic treatment; chr6:85867136 chr6:85660950~85678736:- CESC cis rs1062177 1 rs62377945 ENSG00000213433.5 RPLP1P6 -6.48 5.9e-10 1.07e-06 -0.5 -0.4 Preschool internalizing problems; chr5:151828443 chr5:151765859~151766378:- CESC cis rs1062177 1 rs12515762 ENSG00000213433.5 RPLP1P6 -6.48 5.9e-10 1.07e-06 -0.5 -0.4 Preschool internalizing problems; chr5:151830361 chr5:151765859~151766378:- CESC cis rs3806843 0.868 rs2563291 ENSG00000202111.1 VTRNA1-2 6.48 5.92e-10 1.07e-06 0.41 0.4 Depressive symptoms (multi-trait analysis); chr5:140740014 chr5:140718925~140719013:+ CESC cis rs10463554 1 rs11949145 ENSG00000175749.11 EIF3KP1 6.48 5.92e-10 1.07e-06 0.42 0.4 Parkinson's disease; chr5:102994552 chr5:103032376~103033031:+ CESC cis rs10256972 0.786 rs3735686 ENSG00000229043.2 AC091729.9 -6.48 5.93e-10 1.07e-06 -0.46 -0.4 Endometriosis;Longevity; chr7:1022891 chr7:1160374~1165267:+ CESC cis rs1061377 1 rs7675782 ENSG00000249207.1 RP11-360F5.1 -6.48 5.94e-10 1.08e-06 -0.45 -0.4 Uric acid levels; chr4:39120048 chr4:39112677~39126818:- CESC cis rs1075265 0.527 rs10167891 ENSG00000233266.1 HMGB1P31 6.48 5.95e-10 1.08e-06 0.54 0.4 Chronotype;Morning vs. evening chronotype; chr2:54003658 chr2:54051334~54051760:+ CESC cis rs1707322 1 rs10890370 ENSG00000280836.1 AL355480.1 -6.48 5.95e-10 1.08e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45923545 chr1:45581219~45581321:- CESC cis rs3806843 1 rs12055222 ENSG00000202111.1 VTRNA1-2 -6.48 5.95e-10 1.08e-06 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140785983 chr5:140718925~140719013:+ CESC cis rs2404602 0.503 rs284909 ENSG00000259422.1 RP11-593F23.1 6.48 5.96e-10 1.08e-06 0.44 0.4 Blood metabolite levels; chr15:76444287 chr15:76174891~76181486:- CESC cis rs1823913 0.599 rs17346475 ENSG00000280083.1 RP11-317J9.1 6.48 5.99e-10 1.08e-06 0.47 0.4 Obesity-related traits; chr2:191288488 chr2:191154118~191156070:- CESC cis rs6565180 0.507 rs4471699 ENSG00000183604.13 SMG1P5 -6.48 6.03e-10 1.09e-06 -0.39 -0.4 Tonsillectomy; chr16:30308986 chr16:30267553~30335374:- CESC cis rs1707322 1 rs3922887 ENSG00000280836.1 AL355480.1 -6.48 6.06e-10 1.1e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46008130 chr1:45581219~45581321:- CESC cis rs1707322 1 rs3922886 ENSG00000280836.1 AL355480.1 -6.48 6.06e-10 1.1e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46008230 chr1:45581219~45581321:- CESC cis rs1707322 0.721 rs6699418 ENSG00000281133.1 AL355480.3 -6.48 6.07e-10 1.1e-06 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634509 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs4431884 ENSG00000281133.1 AL355480.3 -6.48 6.07e-10 1.1e-06 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45635651 chr1:45580892~45580996:- CESC cis rs1707322 0.65 rs4660879 ENSG00000281133.1 AL355480.3 -6.48 6.07e-10 1.1e-06 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45639729 chr1:45580892~45580996:- CESC cis rs9399137 0.507 rs61738647 ENSG00000232876.1 CTA-212D2.2 -6.48 6.07e-10 1.1e-06 -0.5 -0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134961597 chr6:135055033~135060550:+ CESC cis rs9399135 0.527 rs61738492 ENSG00000232876.1 CTA-212D2.2 -6.48 6.07e-10 1.1e-06 -0.5 -0.4 Red blood cell count; chr6:134961633 chr6:135055033~135060550:+ CESC cis rs1155848 0.892 rs9565508 ENSG00000227354.5 RBM26-AS1 6.48 6.1e-10 1.1e-06 0.87 0.4 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79482451 chr13:79406309~79424328:+ CESC cis rs6504950 1 rs8082471 ENSG00000275710.1 RP11-257O5.4 6.48 6.11e-10 1.1e-06 0.49 0.4 Breast cancer; chr17:54990632 chr17:54964474~54964679:+ CESC cis rs875971 0.862 rs10276077 ENSG00000226824.5 RP4-756H11.3 6.48 6.13e-10 1.11e-06 0.48 0.4 Aortic root size; chr7:66263424 chr7:66654538~66669855:+ CESC cis rs1501911 0.53 rs162611 ENSG00000248489.1 CTD-2007H13.3 -6.48 6.15e-10 1.11e-06 -0.48 -0.4 Lung function (FEV1/FVC); chr5:98809801 chr5:98929171~98995013:+ CESC cis rs10463554 0.963 rs32840 ENSG00000175749.11 EIF3KP1 6.48 6.15e-10 1.11e-06 0.43 0.4 Parkinson's disease; chr5:103143446 chr5:103032376~103033031:+ CESC cis rs14027 0.921 rs35496588 ENSG00000279347.1 RP11-85I17.2 6.48 6.15e-10 1.11e-06 0.39 0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119842461 chr8:119838736~119840385:- CESC cis rs14027 0.883 rs16893025 ENSG00000279347.1 RP11-85I17.2 -6.48 6.16e-10 1.11e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119701440 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs3812463 ENSG00000279347.1 RP11-85I17.2 -6.48 6.16e-10 1.11e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119839860 chr8:119838736~119840385:- CESC cis rs4728142 0.604 rs2272347 ENSG00000275106.1 RP11-309L24.10 6.47 6.2e-10 1.12e-06 0.52 0.4 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128979361 chr7:128952527~128953316:- CESC cis rs1707322 0.964 rs6675259 ENSG00000280836.1 AL355480.1 6.47 6.21e-10 1.12e-06 0.49 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46036623 chr1:45581219~45581321:- CESC cis rs9399137 0.507 rs28384513 ENSG00000232876.1 CTA-212D2.2 -6.47 6.23e-10 1.12e-06 -0.49 -0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135055071 chr6:135055033~135060550:+ CESC cis rs2581828 0.656 rs11242 ENSG00000242142.1 SERBP1P3 -6.47 6.23e-10 1.12e-06 -0.43 -0.4 Crohn's disease; chr3:53091906 chr3:53064283~53065091:- CESC cis rs2739330 0.76 rs5751761 ENSG00000250470.1 AP000351.3 -6.47 6.25e-10 1.13e-06 -0.51 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23976904~23977585:- CESC cis rs1577917 0.874 rs11756621 ENSG00000203875.9 SNHG5 -6.47 6.3e-10 1.14e-06 -0.51 -0.4 Response to antipsychotic treatment; chr6:86030345 chr6:85660950~85678736:- CESC cis rs17507216 0.681 rs28877110 ENSG00000278603.1 RP13-608F4.5 6.47 6.3e-10 1.14e-06 0.7 0.4 Excessive daytime sleepiness; chr15:82672111 chr15:82472203~82472426:+ CESC cis rs8062405 0.964 rs62036614 ENSG00000259982.1 CDC37P1 6.47 6.31e-10 1.14e-06 0.52 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28813364 chr16:28700294~28701540:- CESC cis rs2404602 0.735 rs1607015 ENSG00000259422.1 RP11-593F23.1 -6.47 6.32e-10 1.14e-06 -0.49 -0.4 Blood metabolite levels; chr15:76410088 chr15:76174891~76181486:- CESC cis rs10129255 0.536 rs17113249 ENSG00000223648.3 IGHV3-64 6.47 6.33e-10 1.14e-06 0.32 0.4 Kawasaki disease; chr14:106678273 chr14:106643132~106658258:- CESC cis rs3096299 0.503 rs4785677 ENSG00000274627.1 RP11-104N10.2 6.47 6.34e-10 1.14e-06 0.41 0.4 Multiple myeloma (IgH translocation); chr16:89488693 chr16:89516797~89522217:+ CESC cis rs150992 0.609 rs77892628 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98990624 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs77231989 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98990650 chr5:98929171~98995013:+ CESC cis rs150992 0.631 rs79191251 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98990680 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs116183885 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98990735 chr5:98929171~98995013:+ CESC cis rs150992 0.534 rs115121903 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98990736 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs78254063 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98990803 chr5:98929171~98995013:+ CESC cis rs150992 0.592 rs2455423 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98990844 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs559574 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98991122 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs443726 ENSG00000248489.1 CTD-2007H13.3 6.47 6.35e-10 1.14e-06 0.48 0.4 Body mass index; chr5:98991163 chr5:98929171~98995013:+ CESC cis rs10256972 0.684 rs2363279 ENSG00000229043.2 AC091729.9 -6.47 6.35e-10 1.14e-06 -0.46 -0.4 Endometriosis;Longevity; chr7:1056507 chr7:1160374~1165267:+ CESC cis rs9545047 0.716 rs418150 ENSG00000227676.3 LINC01068 -6.47 6.36e-10 1.14e-06 -0.45 -0.4 Schizophrenia; chr13:79432675 chr13:79566727~79571436:+ CESC cis rs875971 1 rs9986696 ENSG00000222364.1 RNU6-96P 6.47 6.36e-10 1.14e-06 0.46 0.4 Aortic root size; chr7:66239589 chr7:66395191~66395286:+ CESC cis rs150992 0.609 rs709390 ENSG00000248489.1 CTD-2007H13.3 6.47 6.36e-10 1.15e-06 0.48 0.4 Body mass index; chr5:98993771 chr5:98929171~98995013:+ CESC cis rs10463554 0.963 rs34771 ENSG00000175749.11 EIF3KP1 6.47 6.37e-10 1.15e-06 0.43 0.4 Parkinson's disease; chr5:103114713 chr5:103032376~103033031:+ CESC cis rs3806843 0.801 rs2531358 ENSG00000202111.1 VTRNA1-2 6.47 6.39e-10 1.15e-06 0.42 0.4 Depressive symptoms (multi-trait analysis); chr5:140737852 chr5:140718925~140719013:+ CESC cis rs507080 0.922 rs525485 ENSG00000255422.1 AP002954.4 -6.47 6.39e-10 1.15e-06 -0.49 -0.4 Serum metabolite levels; chr11:118685045 chr11:118704607~118750263:+ CESC cis rs7617773 0.817 rs936426 ENSG00000229759.1 MRPS18AP1 6.47 6.41e-10 1.15e-06 0.43 0.4 Coronary artery disease; chr3:48173763 chr3:48256350~48256938:- CESC cis rs4239252 0.929 rs4251787 ENSG00000270977.1 AC015849.16 -6.47 6.42e-10 1.15e-06 -0.48 -0.4 Blood protein levels; chr17:35845577 chr17:35893707~35911023:- CESC cis rs1062177 1 rs6890099 ENSG00000213433.5 RPLP1P6 -6.47 6.46e-10 1.16e-06 -0.51 -0.4 Preschool internalizing problems; chr5:151772401 chr5:151765859~151766378:- CESC cis rs10129255 0.518 rs2006284 ENSG00000223648.3 IGHV3-64 6.47 6.46e-10 1.16e-06 0.32 0.4 Kawasaki disease; chr14:106676185 chr14:106643132~106658258:- CESC cis rs14027 0.921 rs10109901 ENSG00000279347.1 RP11-85I17.2 -6.47 6.49e-10 1.17e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119817287 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs10109951 ENSG00000279347.1 RP11-85I17.2 -6.47 6.49e-10 1.17e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119817519 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs4870955 ENSG00000279347.1 RP11-85I17.2 -6.47 6.49e-10 1.17e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119821929 chr8:119838736~119840385:- CESC cis rs14027 0.921 rs34718068 ENSG00000279347.1 RP11-85I17.2 -6.47 6.49e-10 1.17e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119822368 chr8:119838736~119840385:- CESC cis rs6991838 0.557 rs67685675 ENSG00000200714.1 Y_RNA -6.47 6.49e-10 1.17e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65574371 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs66486920 ENSG00000200714.1 Y_RNA -6.47 6.49e-10 1.17e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65574458 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs60023200 ENSG00000200714.1 Y_RNA -6.47 6.49e-10 1.17e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65574547 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs61083799 ENSG00000200714.1 Y_RNA -6.47 6.49e-10 1.17e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65574868 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs4449837 ENSG00000200714.1 Y_RNA -6.47 6.49e-10 1.17e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65575917 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs57042777 ENSG00000200714.1 Y_RNA -6.47 6.49e-10 1.17e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65576855 chr8:65592731~65592820:+ CESC cis rs6991838 0.557 rs67046768 ENSG00000200714.1 Y_RNA -6.47 6.49e-10 1.17e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65577486 chr8:65592731~65592820:+ CESC cis rs2929278 0.589 rs11638972 ENSG00000249839.1 AC011330.5 6.46 6.59e-10 1.18e-06 0.42 0.4 Schizophrenia; chr15:43782493 chr15:43663654~43684339:- CESC cis rs7727544 0.735 rs272875 ENSG00000233006.5 AC034220.3 6.46 6.6e-10 1.18e-06 0.45 0.4 Blood metabolite levels; chr5:132339195 chr5:132311285~132369916:- CESC cis rs1823913 1 rs1823913 ENSG00000280083.1 RP11-317J9.1 -6.46 6.7e-10 1.2e-06 -0.45 -0.4 Obesity-related traits; chr2:191253321 chr2:191154118~191156070:- CESC cis rs4728142 0.604 rs12155080 ENSG00000275106.1 RP11-309L24.10 -6.46 6.75e-10 1.21e-06 -0.52 -0.4 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129018685 chr7:128952527~128953316:- CESC cis rs1707322 1 rs6429588 ENSG00000280836.1 AL355480.1 -6.46 6.77e-10 1.21e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45988386 chr1:45581219~45581321:- CESC cis rs1707322 1 rs12097799 ENSG00000280836.1 AL355480.1 -6.46 6.77e-10 1.21e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45994214 chr1:45581219~45581321:- CESC cis rs3806843 0.966 rs4141841 ENSG00000202111.1 VTRNA1-2 -6.46 6.78e-10 1.21e-06 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140823847 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs10050455 ENSG00000202111.1 VTRNA1-2 -6.46 6.78e-10 1.21e-06 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140825065 chr5:140718925~140719013:+ CESC cis rs7188445 0.615 rs4340340 ENSG00000261390.4 RP11-345M22.2 -6.46 6.79e-10 1.21e-06 -0.49 -0.4 Urate levels; chr16:79716720 chr16:79715232~79770563:- CESC cis rs8062405 1 rs12443881 ENSG00000259982.1 CDC37P1 6.46 6.81e-10 1.22e-06 0.5 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28830456 chr16:28700294~28701540:- CESC cis rs875971 0.862 rs7786892 ENSG00000226824.5 RP4-756H11.3 6.46 6.83e-10 1.22e-06 0.49 0.4 Aortic root size; chr7:66163889 chr7:66654538~66669855:+ CESC cis rs7044106 0.69 rs10739569 ENSG00000226752.6 PSMD5-AS1 -6.46 6.84e-10 1.22e-06 -0.44 -0.4 Hip circumference adjusted for BMI; chr9:120598749 chr9:120824828~120854385:+ CESC cis rs10463554 1 rs1593842 ENSG00000175749.11 EIF3KP1 6.45 6.95e-10 1.24e-06 0.42 0.4 Parkinson's disease; chr5:102999018 chr5:103032376~103033031:+ CESC cis rs150992 0.632 rs395668 ENSG00000248489.1 CTD-2007H13.3 6.45 6.97e-10 1.24e-06 0.48 0.4 Body mass index; chr5:98991611 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs449204 ENSG00000248489.1 CTD-2007H13.3 6.45 6.97e-10 1.24e-06 0.48 0.4 Body mass index; chr5:98991775 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs378089 ENSG00000248489.1 CTD-2007H13.3 6.45 6.97e-10 1.24e-06 0.48 0.4 Body mass index; chr5:98991818 chr5:98929171~98995013:+ CESC cis rs150992 0.587 rs422127 ENSG00000248489.1 CTD-2007H13.3 6.45 6.97e-10 1.24e-06 0.48 0.4 Body mass index; chr5:98991984 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs113423144 ENSG00000248489.1 CTD-2007H13.3 6.45 6.97e-10 1.24e-06 0.48 0.4 Body mass index; chr5:98992055 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs380156 ENSG00000248489.1 CTD-2007H13.3 6.45 6.97e-10 1.24e-06 0.48 0.4 Body mass index; chr5:98992386 chr5:98929171~98995013:+ CESC cis rs11155671 0.53 rs9397420 ENSG00000268592.3 RAET1E-AS1 -6.45 6.97e-10 1.24e-06 -0.5 -0.4 Testicular germ cell tumor; chr6:149885645 chr6:149863494~149919507:+ CESC cis rs13230714 0.858 rs2888075 ENSG00000204959.4 ARHGEF34P 6.45 6.97e-10 1.24e-06 0.42 0.4 Breast cancer; chr7:144456786 chr7:144272445~144286966:- CESC cis rs7727544 0.709 rs272852 ENSG00000233006.5 AC034220.3 6.45 7.01e-10 1.25e-06 0.45 0.4 Blood metabolite levels; chr5:132353074 chr5:132311285~132369916:- CESC cis rs1153858 0.887 rs28569043 ENSG00000259520.4 CTD-2651B20.3 -6.45 7.03e-10 1.25e-06 -0.54 -0.4 Homoarginine levels; chr15:45438728 chr15:45251580~45279251:- CESC cis rs8005677 0.798 rs4982711 ENSG00000279656.1 RP11-298I3.6 6.45 7.03e-10 1.25e-06 0.49 0.4 Cognitive ability (multi-trait analysis); chr14:22929781 chr14:23023083~23024217:- CESC cis rs9399137 0.507 rs4896118 ENSG00000232876.1 CTA-212D2.2 6.45 7.05e-10 1.26e-06 0.48 0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954927 chr6:135055033~135060550:+ CESC cis rs11690935 0.959 rs7597387 ENSG00000228389.1 AC068039.4 6.45 7.1e-10 1.27e-06 0.53 0.4 Schizophrenia; chr2:171720606 chr2:171773482~171775844:+ CESC cis rs6504950 1 rs9902718 ENSG00000275710.1 RP11-257O5.4 6.45 7.11e-10 1.27e-06 0.49 0.4 Breast cancer; chr17:54984261 chr17:54964474~54964679:+ CESC cis rs1823913 1 rs12623832 ENSG00000280083.1 RP11-317J9.1 6.45 7.12e-10 1.27e-06 0.45 0.4 Obesity-related traits; chr2:191260918 chr2:191154118~191156070:- CESC cis rs3806843 1 rs7732179 ENSG00000202111.1 VTRNA1-2 -6.45 7.15e-10 1.27e-06 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140819454 chr5:140718925~140719013:+ CESC cis rs7727544 0.735 rs2631370 ENSG00000233006.5 AC034220.3 -6.45 7.15e-10 1.27e-06 -0.45 -0.4 Blood metabolite levels; chr5:132368084 chr5:132311285~132369916:- CESC cis rs10262624 0.528 rs5029444 ENSG00000234286.1 AC006026.13 6.45 7.16e-10 1.28e-06 0.41 0.4 Schizophrenia; chr7:23698176 chr7:23680195~23680786:- CESC cis rs7201929 1 rs11644151 ENSG00000259982.1 CDC37P1 -6.45 7.17e-10 1.28e-06 -0.53 -0.4 QT interval; chr16:28884339 chr16:28700294~28701540:- CESC cis rs10463554 0.926 rs34778 ENSG00000175749.11 EIF3KP1 6.45 7.24e-10 1.29e-06 0.43 0.4 Parkinson's disease; chr5:103116852 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs26524 ENSG00000175749.11 EIF3KP1 6.45 7.24e-10 1.29e-06 0.43 0.4 Parkinson's disease; chr5:103120600 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs34777 ENSG00000175749.11 EIF3KP1 6.45 7.27e-10 1.29e-06 0.44 0.4 Parkinson's disease; chr5:103116554 chr5:103032376~103033031:+ CESC cis rs10463554 1 rs56372231 ENSG00000175749.11 EIF3KP1 6.45 7.3e-10 1.3e-06 0.42 0.4 Parkinson's disease; chr5:102986201 chr5:103032376~103033031:+ CESC cis rs9549367 0.713 rs576463 ENSG00000269125.1 RP11-98F14.11 6.44 7.32e-10 1.3e-06 0.51 0.4 Platelet distribution width; chr13:113192300 chr13:113165002~113165183:- CESC cis rs1062177 1 rs2915887 ENSG00000213433.5 RPLP1P6 -6.44 7.33e-10 1.3e-06 -0.5 -0.4 Preschool internalizing problems; chr5:151825943 chr5:151765859~151766378:- CESC cis rs6700559 0.873 rs6427840 ENSG00000260088.1 RP11-92G12.3 -6.44 7.41e-10 1.32e-06 -0.52 -0.4 Coronary artery disease; chr1:200685659 chr1:200669507~200694250:+ CESC cis rs1707322 1 rs785478 ENSG00000280836.1 AL355480.1 6.44 7.41e-10 1.32e-06 0.46 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46025963 chr1:45581219~45581321:- CESC cis rs14027 0.883 rs4871642 ENSG00000279347.1 RP11-85I17.2 -6.44 7.43e-10 1.32e-06 -0.39 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119818813 chr8:119838736~119840385:- CESC cis rs2404602 0.684 rs10851888 ENSG00000259422.1 RP11-593F23.1 -6.44 7.45e-10 1.32e-06 -0.49 -0.4 Blood metabolite levels; chr15:76610165 chr15:76174891~76181486:- CESC cis rs7208859 0.673 rs1347359 ENSG00000263531.1 RP13-753N3.1 6.44 7.45e-10 1.32e-06 0.74 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587511 chr17:30863921~30864940:- CESC cis rs11155671 0.53 rs9383912 ENSG00000268592.3 RAET1E-AS1 6.44 7.48e-10 1.33e-06 0.5 0.4 Testicular germ cell tumor; chr6:149885479 chr6:149863494~149919507:+ CESC cis rs875971 1 rs10215948 ENSG00000222364.1 RNU6-96P 6.44 7.49e-10 1.33e-06 0.46 0.4 Aortic root size; chr7:66282799 chr7:66395191~66395286:+ CESC cis rs2404602 0.574 rs4886795 ENSG00000259422.1 RP11-593F23.1 -6.44 7.51e-10 1.33e-06 -0.51 -0.4 Blood metabolite levels; chr15:76349877 chr15:76174891~76181486:- CESC cis rs9584850 0.834 rs12463 ENSG00000231194.1 FARP1-AS1 6.44 7.54e-10 1.34e-06 0.51 0.4 Neuroticism; chr13:98453048 chr13:98435405~98435840:- CESC cis rs9584850 0.834 rs8481 ENSG00000231194.1 FARP1-AS1 6.44 7.54e-10 1.34e-06 0.51 0.4 Neuroticism; chr13:98453141 chr13:98435405~98435840:- CESC cis rs1062177 1 rs12518722 ENSG00000213433.5 RPLP1P6 -6.44 7.56e-10 1.34e-06 -0.5 -0.4 Preschool internalizing problems; chr5:151851899 chr5:151765859~151766378:- CESC cis rs6991838 0.584 rs4737221 ENSG00000200714.1 Y_RNA -6.44 7.56e-10 1.34e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65569075 chr8:65592731~65592820:+ CESC cis rs1707322 1 rs785467 ENSG00000280836.1 AL355480.1 6.44 7.56e-10 1.34e-06 0.48 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055887 chr1:45581219~45581321:- CESC cis rs10875746 0.903 rs17122666 ENSG00000240399.1 RP1-228P16.1 -6.44 7.6e-10 1.35e-06 -0.53 -0.4 Longevity (90 years and older); chr12:48108791 chr12:48054813~48055591:- CESC cis rs7727544 0.645 rs272857 ENSG00000233006.5 AC034220.3 6.44 7.61e-10 1.35e-06 0.45 0.4 Blood metabolite levels; chr5:132349604 chr5:132311285~132369916:- CESC cis rs35955747 0.902 rs7288735 ENSG00000236132.1 CTA-440B3.1 6.44 7.65e-10 1.35e-06 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31283560 chr22:31816379~31817491:- CESC cis rs10463554 0.892 rs11952337 ENSG00000175749.11 EIF3KP1 6.44 7.66e-10 1.35e-06 0.43 0.4 Parkinson's disease; chr5:102928043 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs6871715 ENSG00000175749.11 EIF3KP1 6.44 7.66e-10 1.35e-06 0.43 0.4 Parkinson's disease; chr5:102930398 chr5:103032376~103033031:+ CESC cis rs150992 0.57 rs398436 ENSG00000248489.1 CTD-2007H13.3 6.44 7.69e-10 1.36e-06 0.48 0.4 Body mass index; chr5:98991352 chr5:98929171~98995013:+ CESC cis rs113835537 0.529 rs11227515 ENSG00000255517.5 CTD-3074O7.5 -6.44 7.73e-10 1.37e-06 -0.45 -0.4 Airway imaging phenotypes; chr11:66519912 chr11:66473490~66480233:- CESC cis rs8005677 0.828 rs2295682 ENSG00000279656.1 RP11-298I3.6 6.43 7.75e-10 1.37e-06 0.48 0.4 Cognitive ability (multi-trait analysis); chr14:22905653 chr14:23023083~23024217:- CESC cis rs875971 1 rs6963646 ENSG00000222364.1 RNU6-96P 6.43 7.78e-10 1.37e-06 0.46 0.4 Aortic root size; chr7:66220780 chr7:66395191~66395286:+ CESC cis rs11690935 1 rs1554166 ENSG00000228389.1 AC068039.4 6.43 7.8e-10 1.38e-06 0.53 0.4 Schizophrenia; chr2:171685099 chr2:171773482~171775844:+ CESC cis rs875971 1 rs55962648 ENSG00000222364.1 RNU6-96P 6.43 7.83e-10 1.38e-06 0.46 0.4 Aortic root size; chr7:66160764 chr7:66395191~66395286:+ CESC cis rs875971 1 rs2420168 ENSG00000222364.1 RNU6-96P 6.43 7.83e-10 1.38e-06 0.46 0.4 Aortic root size; chr7:66165644 chr7:66395191~66395286:+ CESC cis rs875971 1 rs1565531 ENSG00000222364.1 RNU6-96P 6.43 7.83e-10 1.38e-06 0.46 0.4 Aortic root size; chr7:66198126 chr7:66395191~66395286:+ CESC cis rs9549367 0.673 rs575453 ENSG00000269125.1 RP11-98F14.11 6.43 7.84e-10 1.38e-06 0.52 0.4 Platelet distribution width; chr13:113183557 chr13:113165002~113165183:- CESC cis rs10463554 1 rs3776862 ENSG00000175749.11 EIF3KP1 6.43 7.85e-10 1.39e-06 0.42 0.4 Parkinson's disease; chr5:102996017 chr5:103032376~103033031:+ CESC cis rs7674212 0.531 rs10006474 ENSG00000246560.2 RP11-10L12.4 6.43 7.88e-10 1.39e-06 0.51 0.4 Type 2 diabetes; chr4:103006890 chr4:102828055~102844075:+ CESC cis rs9399137 0.507 rs6940258 ENSG00000232876.1 CTA-212D2.2 -6.43 7.88e-10 1.39e-06 -0.48 -0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135044994 chr6:135055033~135060550:+ CESC cis rs11690935 0.959 rs7562356 ENSG00000228389.1 AC068039.4 6.43 7.9e-10 1.39e-06 0.53 0.4 Schizophrenia; chr2:171770101 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs1113389 ENSG00000228389.1 AC068039.4 6.43 7.9e-10 1.39e-06 0.53 0.4 Schizophrenia; chr2:171778855 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs7355594 ENSG00000228389.1 AC068039.4 6.43 7.9e-10 1.39e-06 0.53 0.4 Schizophrenia; chr2:171782938 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs10497374 ENSG00000228389.1 AC068039.4 6.43 7.9e-10 1.39e-06 0.53 0.4 Schizophrenia; chr2:171784113 chr2:171773482~171775844:+ CESC cis rs9399137 0.507 rs4896129 ENSG00000232876.1 CTA-212D2.2 -6.43 7.91e-10 1.39e-06 -0.48 -0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135028707 chr6:135055033~135060550:+ CESC cis rs2487048 0.761 rs2980083 ENSG00000226334.1 RP11-217B7.2 -6.43 7.93e-10 1.4e-06 -0.49 -0.4 Intraocular pressure; chr9:104929081 chr9:104927553~104928892:+ CESC cis rs113835537 0.529 rs117112180 ENSG00000255517.5 CTD-3074O7.5 -6.43 7.96e-10 1.4e-06 -0.49 -0.4 Airway imaging phenotypes; chr11:66525802 chr11:66473490~66480233:- CESC cis rs6700559 0.815 rs7526365 ENSG00000260088.1 RP11-92G12.3 -6.43 7.98e-10 1.4e-06 -0.52 -0.4 Coronary artery disease; chr1:200688020 chr1:200669507~200694250:+ CESC cis rs950027 0.787 rs2433616 ENSG00000259520.4 CTD-2651B20.3 -6.43 7.99e-10 1.41e-06 -0.54 -0.4 Response to fenofibrate (adiponectin levels); chr15:45436401 chr15:45251580~45279251:- CESC cis rs1707322 1 rs7532204 ENSG00000280836.1 AL355480.1 6.43 8.01e-10 1.41e-06 0.46 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46019403 chr1:45581219~45581321:- CESC cis rs1707322 0.835 rs946525 ENSG00000280836.1 AL355480.1 6.43 8.01e-10 1.41e-06 0.46 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46021605 chr1:45581219~45581321:- CESC cis rs1707322 1 rs946524 ENSG00000280836.1 AL355480.1 6.43 8.01e-10 1.41e-06 0.46 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46021888 chr1:45581219~45581321:- CESC cis rs4423214 0.535 rs1540129 ENSG00000254682.1 RP11-660L16.2 6.43 8.03e-10 1.41e-06 0.51 0.4 Vitamin D levels; chr11:71418477 chr11:71448674~71452157:+ CESC cis rs228614 0.509 rs223480 ENSG00000246560.2 RP11-10L12.4 6.43 8.04e-10 1.41e-06 0.49 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766881 chr4:102828055~102844075:+ CESC cis rs17608059 1 rs17608059 ENSG00000141028.6 CDRT15P1 -6.43 8.06e-10 1.42e-06 -0.45 -0.4 Temperament; chr17:14007232 chr17:14024514~14025488:+ CESC cis rs3806843 0.966 rs3806844 ENSG00000202111.1 VTRNA1-2 -6.43 8.06e-10 1.42e-06 -0.41 -0.4 Depressive symptoms (multi-trait analysis); chr5:140826678 chr5:140718925~140719013:+ CESC cis rs2404602 0.735 rs4886798 ENSG00000259422.1 RP11-593F23.1 6.43 8.07e-10 1.42e-06 0.49 0.4 Blood metabolite levels; chr15:76380885 chr15:76174891~76181486:- CESC cis rs7727544 0.735 rs274568 ENSG00000233006.5 AC034220.3 -6.43 8.08e-10 1.42e-06 -0.44 -0.4 Blood metabolite levels; chr5:132377886 chr5:132311285~132369916:- CESC cis rs11690935 0.959 rs10184866 ENSG00000228389.1 AC068039.4 6.43 8.12e-10 1.43e-06 0.52 0.4 Schizophrenia; chr2:171752446 chr2:171773482~171775844:+ CESC cis rs1823913 0.599 rs13015653 ENSG00000280083.1 RP11-317J9.1 -6.43 8.14e-10 1.43e-06 -0.47 -0.4 Obesity-related traits; chr2:191306813 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs12994212 ENSG00000280083.1 RP11-317J9.1 -6.43 8.14e-10 1.43e-06 -0.47 -0.4 Obesity-related traits; chr2:191306910 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs12994236 ENSG00000280083.1 RP11-317J9.1 -6.43 8.14e-10 1.43e-06 -0.47 -0.4 Obesity-related traits; chr2:191306991 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs35495506 ENSG00000280083.1 RP11-317J9.1 -6.43 8.14e-10 1.43e-06 -0.47 -0.4 Obesity-related traits; chr2:191307551 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs34691559 ENSG00000280083.1 RP11-317J9.1 -6.43 8.14e-10 1.43e-06 -0.47 -0.4 Obesity-related traits; chr2:191307688 chr2:191154118~191156070:- CESC cis rs1823913 0.561 rs55790432 ENSG00000280083.1 RP11-317J9.1 -6.43 8.14e-10 1.43e-06 -0.47 -0.4 Obesity-related traits; chr2:191307722 chr2:191154118~191156070:- CESC cis rs7674212 0.531 rs4698875 ENSG00000246560.2 RP11-10L12.4 6.43 8.16e-10 1.43e-06 0.52 0.4 Type 2 diabetes; chr4:103012211 chr4:102828055~102844075:+ CESC cis rs1062177 1 rs2964612 ENSG00000213433.5 RPLP1P6 -6.42 8.17e-10 1.43e-06 -0.5 -0.4 Preschool internalizing problems; chr5:151819189 chr5:151765859~151766378:- CESC cis rs3806843 1 rs4451093 ENSG00000202111.1 VTRNA1-2 6.42 8.21e-10 1.44e-06 0.41 0.4 Depressive symptoms (multi-trait analysis); chr5:140778957 chr5:140718925~140719013:+ CESC cis rs2404602 0.622 rs9635380 ENSG00000259422.1 RP11-593F23.1 -6.42 8.21e-10 1.44e-06 -0.48 -0.4 Blood metabolite levels; chr15:76811138 chr15:76174891~76181486:- CESC cis rs875971 0.862 rs6960446 ENSG00000226824.5 RP4-756H11.3 6.42 8.22e-10 1.44e-06 0.49 0.4 Aortic root size; chr7:66268272 chr7:66654538~66669855:+ CESC cis rs875971 0.79 rs10257911 ENSG00000226824.5 RP4-756H11.3 6.42 8.22e-10 1.44e-06 0.49 0.4 Aortic root size; chr7:66278783 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs7796162 ENSG00000226824.5 RP4-756H11.3 6.42 8.22e-10 1.44e-06 0.49 0.4 Aortic root size; chr7:66280771 chr7:66654538~66669855:+ CESC cis rs1707322 1 rs6661500 ENSG00000280836.1 AL355480.1 -6.42 8.3e-10 1.46e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45999990 chr1:45581219~45581321:- CESC cis rs7617773 0.539 rs13094496 ENSG00000229759.1 MRPS18AP1 6.42 8.34e-10 1.46e-06 0.42 0.4 Coronary artery disease; chr3:48345560 chr3:48256350~48256938:- CESC cis rs897984 0.609 rs35468353 ENSG00000260911.2 RP11-196G11.2 6.42 8.36e-10 1.46e-06 0.41 0.4 Dementia with Lewy bodies; chr16:31045112 chr16:31043150~31049868:+ CESC cis rs897984 0.609 rs11862744 ENSG00000260911.2 RP11-196G11.2 6.42 8.36e-10 1.46e-06 0.41 0.4 Dementia with Lewy bodies; chr16:31046479 chr16:31043150~31049868:+ CESC cis rs6452524 0.934 rs10473870 ENSG00000249664.1 CTD-2227C6.2 6.42 8.36e-10 1.46e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83199768 chr5:83012285~83013109:- CESC cis rs2404602 0.735 rs2436994 ENSG00000259422.1 RP11-593F23.1 -6.42 8.36e-10 1.46e-06 -0.47 -0.4 Blood metabolite levels; chr15:76508722 chr15:76174891~76181486:- CESC cis rs7727544 0.684 rs274560 ENSG00000233006.5 AC034220.3 -6.42 8.36e-10 1.47e-06 -0.44 -0.4 Blood metabolite levels; chr5:132383758 chr5:132311285~132369916:- CESC cis rs8062405 0.721 rs151181 ENSG00000259982.1 CDC37P1 6.42 8.37e-10 1.47e-06 0.53 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28479196 chr16:28700294~28701540:- CESC cis rs11690935 0.959 rs6705200 ENSG00000228389.1 AC068039.4 6.42 8.37e-10 1.47e-06 0.52 0.4 Schizophrenia; chr2:171781090 chr2:171773482~171775844:+ CESC cis rs7617773 0.539 rs13069884 ENSG00000229759.1 MRPS18AP1 6.42 8.38e-10 1.47e-06 0.43 0.4 Coronary artery disease; chr3:48339658 chr3:48256350~48256938:- CESC cis rs7617773 0.539 rs2017859 ENSG00000229759.1 MRPS18AP1 6.42 8.38e-10 1.47e-06 0.43 0.4 Coronary artery disease; chr3:48340771 chr3:48256350~48256938:- CESC cis rs7617773 0.539 rs2017858 ENSG00000229759.1 MRPS18AP1 6.42 8.38e-10 1.47e-06 0.43 0.4 Coronary artery disease; chr3:48340792 chr3:48256350~48256938:- CESC cis rs7617773 0.501 rs12185901 ENSG00000229759.1 MRPS18AP1 6.42 8.38e-10 1.47e-06 0.43 0.4 Coronary artery disease; chr3:48341429 chr3:48256350~48256938:- CESC cis rs7617773 0.539 rs13082217 ENSG00000229759.1 MRPS18AP1 6.42 8.38e-10 1.47e-06 0.43 0.4 Coronary artery disease; chr3:48341774 chr3:48256350~48256938:- CESC cis rs7617773 0.539 rs11706939 ENSG00000229759.1 MRPS18AP1 6.42 8.38e-10 1.47e-06 0.43 0.4 Coronary artery disease; chr3:48342502 chr3:48256350~48256938:- CESC cis rs7617773 0.539 rs11130165 ENSG00000229759.1 MRPS18AP1 6.42 8.38e-10 1.47e-06 0.43 0.4 Coronary artery disease; chr3:48343231 chr3:48256350~48256938:- CESC cis rs7617773 0.539 rs1471217 ENSG00000229759.1 MRPS18AP1 6.42 8.38e-10 1.47e-06 0.43 0.4 Coronary artery disease; chr3:48343405 chr3:48256350~48256938:- CESC cis rs67383717 0.643 rs10759883 ENSG00000175611.10 LINC00476 -6.42 8.38e-10 1.47e-06 -0.45 -0.4 Parkinson's disease (pesticide exposure interaction); chr9:95790481 chr9:95759231~95875977:- CESC cis rs11155671 0.53 rs1334510 ENSG00000216906.2 RP11-350J20.9 6.42 8.4e-10 1.47e-06 0.44 0.4 Testicular germ cell tumor; chr6:149880043 chr6:149904243~149906418:+ CESC cis rs11690935 1 rs34542126 ENSG00000228389.1 AC068039.4 -6.42 8.4e-10 1.47e-06 -0.52 -0.4 Schizophrenia; chr2:171686195 chr2:171773482~171775844:+ CESC cis rs11690935 1 rs6721680 ENSG00000228389.1 AC068039.4 -6.42 8.4e-10 1.47e-06 -0.52 -0.4 Schizophrenia; chr2:171687403 chr2:171773482~171775844:+ CESC cis rs6991838 0.584 rs34494846 ENSG00000200714.1 Y_RNA -6.42 8.5e-10 1.49e-06 -0.48 -0.4 Intelligence (multi-trait analysis); chr8:65602397 chr8:65592731~65592820:+ CESC cis rs9584850 0.874 rs3742137 ENSG00000231194.1 FARP1-AS1 6.42 8.59e-10 1.5e-06 0.51 0.4 Neuroticism; chr13:98450195 chr13:98435405~98435840:- CESC cis rs1707322 0.721 rs10789468 ENSG00000281133.1 AL355480.3 -6.42 8.6e-10 1.5e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658886 chr1:45580892~45580996:- CESC cis rs150992 0.609 rs2927648 ENSG00000248489.1 CTD-2007H13.3 6.41 8.65e-10 1.51e-06 0.48 0.4 Body mass index; chr5:98990273 chr5:98929171~98995013:+ CESC cis rs3806843 1 rs991918 ENSG00000202111.1 VTRNA1-2 -6.41 8.7e-10 1.52e-06 -0.42 -0.4 Depressive symptoms (multi-trait analysis); chr5:140815273 chr5:140718925~140719013:+ CESC cis rs6700559 0.873 rs7526031 ENSG00000260088.1 RP11-92G12.3 -6.41 8.73e-10 1.52e-06 -0.52 -0.4 Coronary artery disease; chr1:200695174 chr1:200669507~200694250:+ CESC cis rs2929278 0.617 rs11070410 ENSG00000249839.1 AC011330.5 6.41 8.73e-10 1.52e-06 0.42 0.4 Schizophrenia; chr15:43764847 chr15:43663654~43684339:- CESC cis rs7617773 0.539 rs17593974 ENSG00000229759.1 MRPS18AP1 6.41 8.74e-10 1.52e-06 0.42 0.4 Coronary artery disease; chr3:48345844 chr3:48256350~48256938:- CESC cis rs7617773 0.514 rs11130166 ENSG00000229759.1 MRPS18AP1 6.41 8.74e-10 1.52e-06 0.42 0.4 Coronary artery disease; chr3:48346566 chr3:48256350~48256938:- CESC cis rs8005677 0.77 rs56180741 ENSG00000279656.1 RP11-298I3.6 6.41 8.77e-10 1.53e-06 0.48 0.4 Cognitive ability (multi-trait analysis); chr14:22908037 chr14:23023083~23024217:- CESC cis rs4853012 0.838 rs60705299 ENSG00000257800.1 FNBP1P1 6.41 8.79e-10 1.53e-06 0.41 0.4 Gestational age at birth (maternal effect); chr2:74118243 chr2:74120680~74123218:+ CESC cis rs2404602 0.735 rs1607017 ENSG00000259422.1 RP11-593F23.1 -6.41 8.79e-10 1.53e-06 -0.49 -0.4 Blood metabolite levels; chr15:76434124 chr15:76174891~76181486:- CESC cis rs3806843 0.966 rs2563265 ENSG00000202111.1 VTRNA1-2 6.41 8.82e-10 1.53e-06 0.41 0.4 Depressive symptoms (multi-trait analysis); chr5:140757420 chr5:140718925~140719013:+ CESC cis rs6504950 1 rs8078550 ENSG00000275710.1 RP11-257O5.4 6.41 8.85e-10 1.54e-06 0.49 0.4 Breast cancer; chr17:54976018 chr17:54964474~54964679:+ CESC cis rs35955747 0.902 rs5997938 ENSG00000236132.1 CTA-440B3.1 6.41 8.86e-10 1.54e-06 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31281006 chr22:31816379~31817491:- CESC cis rs783540 0.5 rs7163840 ENSG00000255769.6 GOLGA2P10 6.41 8.87e-10 1.54e-06 0.49 0.4 Schizophrenia; chr15:82729551 chr15:82472993~82513950:- CESC cis rs4423214 0.65 rs4245442 ENSG00000254682.1 RP11-660L16.2 6.41 8.87e-10 1.54e-06 0.56 0.4 Vitamin D levels; chr11:71509863 chr11:71448674~71452157:+ CESC cis rs950169 0.686 rs12906474 ENSG00000225151.9 GOLGA2P7 -6.41 8.88e-10 1.54e-06 -0.55 -0.4 Schizophrenia; chr15:84566006 chr15:84199311~84230136:- CESC cis rs46522 0.585 rs79049364 ENSG00000270781.1 RP11-501C14.9 -6.41 8.9e-10 1.55e-06 -0.46 -0.4 Coronary heart disease; chr17:48937629 chr17:48899131~48899748:+ CESC cis rs79349575 0.811 rs80032154 ENSG00000270781.1 RP11-501C14.9 -6.41 8.9e-10 1.55e-06 -0.46 -0.4 Type 2 diabetes; chr17:48937630 chr17:48899131~48899748:+ CESC cis rs11690935 0.959 rs10803863 ENSG00000228389.1 AC068039.4 -6.41 8.9e-10 1.55e-06 -0.52 -0.4 Schizophrenia; chr2:171678827 chr2:171773482~171775844:+ CESC cis rs1707322 0.964 rs10890358 ENSG00000280836.1 AL355480.1 -6.41 8.92e-10 1.55e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853353 chr1:45581219~45581321:- CESC cis rs7208859 0.673 rs216409 ENSG00000263531.1 RP13-753N3.1 -6.41 8.95e-10 1.55e-06 -0.72 -0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30579251 chr17:30863921~30864940:- CESC cis rs10463554 0.963 rs27970 ENSG00000175749.11 EIF3KP1 6.41 8.98e-10 1.56e-06 0.43 0.4 Parkinson's disease; chr5:103151019 chr5:103032376~103033031:+ CESC cis rs11690935 1 rs6433311 ENSG00000228389.1 AC068039.4 -6.41 8.99e-10 1.56e-06 -0.52 -0.4 Schizophrenia; chr2:171692738 chr2:171773482~171775844:+ CESC cis rs11690935 1 rs6757773 ENSG00000228389.1 AC068039.4 -6.41 8.99e-10 1.56e-06 -0.52 -0.4 Schizophrenia; chr2:171693120 chr2:171773482~171775844:+ CESC cis rs9399137 0.507 rs7771310 ENSG00000232876.1 CTA-212D2.2 -6.41 8.99e-10 1.56e-06 -0.5 -0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134951397 chr6:135055033~135060550:+ CESC cis rs875971 0.862 rs709596 ENSG00000226824.5 RP4-756H11.3 -6.41 9.01e-10 1.56e-06 -0.49 -0.4 Aortic root size; chr7:66360926 chr7:66654538~66669855:+ CESC cis rs1707322 1 rs946527 ENSG00000280836.1 AL355480.1 -6.41 9.01e-10 1.56e-06 -0.46 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46020298 chr1:45581219~45581321:- CESC cis rs11690935 1 rs12053003 ENSG00000228389.1 AC068039.4 -6.41 9.04e-10 1.57e-06 -0.52 -0.4 Schizophrenia; chr2:171680840 chr2:171773482~171775844:+ CESC cis rs6504950 1 rs9914732 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54977006 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9916642 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54977136 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9915832 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54977336 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9893306 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54977388 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs6504950 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54979110 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs6504951 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54979614 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9903146 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54980386 chr17:54964474~54964679:+ CESC cis rs6504950 0.962 rs9902950 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54980403 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9903220 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54980504 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9903444 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54980532 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9903825 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54980553 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs28558726 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54981315 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs16955471 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54981446 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9891865 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54982672 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9892173 ENSG00000275710.1 RP11-257O5.4 6.41 9.04e-10 1.57e-06 0.48 0.4 Breast cancer; chr17:54982853 chr17:54964474~54964679:+ CESC cis rs1707322 0.717 rs1972410 ENSG00000281133.1 AL355480.3 -6.41 9.06e-10 1.57e-06 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615275 chr1:45580892~45580996:- CESC cis rs4853012 0.838 rs2177707 ENSG00000257800.1 FNBP1P1 6.4 9.19e-10 1.59e-06 0.44 0.4 Gestational age at birth (maternal effect); chr2:74129723 chr2:74120680~74123218:+ CESC cis rs4853012 0.887 rs2280642 ENSG00000257800.1 FNBP1P1 6.4 9.19e-10 1.59e-06 0.44 0.4 Gestational age at birth (maternal effect); chr2:74131125 chr2:74120680~74123218:+ CESC cis rs79349575 0.749 rs12601672 ENSG00000270781.1 RP11-501C14.9 -6.4 9.25e-10 1.6e-06 -0.45 -0.4 Type 2 diabetes; chr17:48929131 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs17635252 ENSG00000270781.1 RP11-501C14.9 -6.4 9.25e-10 1.6e-06 -0.45 -0.4 Type 2 diabetes; chr17:48929588 chr17:48899131~48899748:+ CESC cis rs35955747 0.902 rs2413048 ENSG00000236132.1 CTA-440B3.1 6.4 9.29e-10 1.61e-06 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31290116 chr22:31816379~31817491:- CESC cis rs6860806 0.531 rs272887 ENSG00000233006.5 AC034220.3 6.4 9.3e-10 1.61e-06 0.44 0.4 Breast cancer; chr5:132330020 chr5:132311285~132369916:- CESC cis rs274567 0.55 rs272885 ENSG00000233006.5 AC034220.3 6.4 9.3e-10 1.61e-06 0.44 0.4 Blood metabolite levels; chr5:132332043 chr5:132311285~132369916:- CESC cis rs6452524 0.967 rs2974443 ENSG00000249664.1 CTD-2227C6.2 6.4 9.31e-10 1.61e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83184595 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs2974441 ENSG00000249664.1 CTD-2227C6.2 6.4 9.31e-10 1.61e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83193330 chr5:83012285~83013109:- CESC cis rs1707322 0.721 rs10430124 ENSG00000281133.1 AL355480.3 -6.4 9.31e-10 1.61e-06 -0.47 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755945 chr1:45580892~45580996:- CESC cis rs507080 0.883 rs692750 ENSG00000255422.1 AP002954.4 -6.4 9.31e-10 1.61e-06 -0.47 -0.4 Serum metabolite levels; chr11:118667599 chr11:118704607~118750263:+ CESC cis rs10129255 0.5 rs988132 ENSG00000223648.3 IGHV3-64 6.4 9.36e-10 1.62e-06 0.33 0.4 Kawasaki disease; chr14:106776758 chr14:106643132~106658258:- CESC cis rs6860806 0.531 rs272888 ENSG00000233006.5 AC034220.3 6.4 9.47e-10 1.63e-06 0.44 0.4 Breast cancer; chr5:132329730 chr5:132311285~132369916:- CESC cis rs507080 0.885 rs533144 ENSG00000255422.1 AP002954.4 -6.4 9.51e-10 1.64e-06 -0.48 -0.4 Serum metabolite levels; chr11:118688538 chr11:118704607~118750263:+ CESC cis rs228614 0.536 rs223477 ENSG00000246560.2 RP11-10L12.4 6.4 9.52e-10 1.64e-06 0.49 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769099 chr4:102828055~102844075:+ CESC cis rs2117029 0.653 rs1476137 ENSG00000258017.1 RP11-386G11.10 -6.4 9.53e-10 1.64e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49129930 chr12:49127782~49147869:+ CESC cis rs2117029 0.553 rs731350 ENSG00000258017.1 RP11-386G11.10 -6.4 9.53e-10 1.64e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49130804 chr12:49127782~49147869:+ CESC cis rs2117029 0.619 rs9325145 ENSG00000258017.1 RP11-386G11.10 -6.4 9.53e-10 1.64e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49132101 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs10783307 ENSG00000258017.1 RP11-386G11.10 -6.4 9.53e-10 1.64e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49135822 chr12:49127782~49147869:+ CESC cis rs2117029 0.554 rs12306494 ENSG00000258017.1 RP11-386G11.10 -6.4 9.53e-10 1.64e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49136998 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs11168884 ENSG00000258017.1 RP11-386G11.10 -6.4 9.53e-10 1.64e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49146109 chr12:49127782~49147869:+ CESC cis rs11168854 0.719 rs11168890 ENSG00000258017.1 RP11-386G11.10 -6.4 9.53e-10 1.64e-06 -0.51 -0.4 Body mass index; chr12:49150130 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs7954521 ENSG00000258017.1 RP11-386G11.10 -6.4 9.53e-10 1.64e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49151857 chr12:49127782~49147869:+ CESC cis rs1061377 1 rs1036036 ENSG00000249207.1 RP11-360F5.1 -6.4 9.53e-10 1.64e-06 -0.45 -0.4 Uric acid levels; chr4:39111104 chr4:39112677~39126818:- CESC cis rs8062405 1 rs7187776 ENSG00000259982.1 CDC37P1 6.4 9.61e-10 1.65e-06 0.47 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28846324 chr16:28700294~28701540:- CESC cis rs6700559 0.967 rs12041320 ENSG00000260088.1 RP11-92G12.3 -6.39 9.68e-10 1.67e-06 -0.51 -0.4 Coronary artery disease; chr1:200652107 chr1:200669507~200694250:+ CESC cis rs9399135 0.967 rs45544135 ENSG00000232876.1 CTA-212D2.2 -6.39 9.69e-10 1.67e-06 -0.46 -0.4 Red blood cell count; chr6:135002913 chr6:135055033~135060550:+ CESC cis rs7044106 0.648 rs2031369 ENSG00000226752.6 PSMD5-AS1 -6.39 9.73e-10 1.67e-06 -0.43 -0.4 Hip circumference adjusted for BMI; chr9:120598016 chr9:120824828~120854385:+ CESC cis rs9326248 0.59 rs2542063 ENSG00000254851.1 RP11-109L13.1 -6.39 9.74e-10 1.68e-06 -0.49 -0.4 Blood protein levels; chr11:116814051 chr11:117135528~117138582:+ CESC cis rs1823913 1 rs11691372 ENSG00000280083.1 RP11-317J9.1 6.39 9.75e-10 1.68e-06 0.45 0.4 Obesity-related traits; chr2:191249952 chr2:191154118~191156070:- CESC cis rs1707322 0.721 rs7520123 ENSG00000281133.1 AL355480.3 -6.39 9.77e-10 1.68e-06 -0.46 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769547 chr1:45580892~45580996:- CESC cis rs897984 0.609 rs4889609 ENSG00000260911.2 RP11-196G11.2 6.39 9.78e-10 1.68e-06 0.41 0.4 Dementia with Lewy bodies; chr16:31015106 chr16:31043150~31049868:+ CESC cis rs897984 0.572 rs4889526 ENSG00000260911.2 RP11-196G11.2 6.39 9.78e-10 1.68e-06 0.41 0.4 Dementia with Lewy bodies; chr16:31019023 chr16:31043150~31049868:+ CESC cis rs150992 0.592 rs407562 ENSG00000248489.1 CTD-2007H13.3 6.39 9.8e-10 1.69e-06 0.48 0.4 Body mass index; chr5:98991512 chr5:98929171~98995013:+ CESC cis rs2404602 0.647 rs34103231 ENSG00000259422.1 RP11-593F23.1 -6.39 9.86e-10 1.69e-06 -0.49 -0.4 Blood metabolite levels; chr15:76620349 chr15:76174891~76181486:- CESC cis rs897984 0.609 rs57576577 ENSG00000260911.2 RP11-196G11.2 6.39 9.89e-10 1.7e-06 0.41 0.4 Dementia with Lewy bodies; chr16:31025046 chr16:31043150~31049868:+ CESC cis rs9907295 0.591 rs3817655 ENSG00000270977.1 AC015849.16 6.39 9.89e-10 1.7e-06 0.48 0.4 Fibroblast growth factor basic levels; chr17:35872637 chr17:35893707~35911023:- CESC cis rs4972806 0.739 rs10834 ENSG00000226363.3 HAGLROS -6.39 9.96e-10 1.71e-06 -0.54 -0.4 IgG glycosylation; chr2:176177359 chr2:176177717~176179008:+ CESC cis rs875971 1 rs11974219 ENSG00000222364.1 RNU6-96P 6.39 9.97e-10 1.71e-06 0.46 0.4 Aortic root size; chr7:66182423 chr7:66395191~66395286:+ CESC cis rs1062177 1 rs12654573 ENSG00000213433.5 RPLP1P6 -6.39 9.98e-10 1.71e-06 -0.48 -0.4 Preschool internalizing problems; chr5:151827912 chr5:151765859~151766378:- CESC cis rs1823913 1 rs6749232 ENSG00000280083.1 RP11-317J9.1 6.39 1e-09 1.72e-06 0.45 0.4 Obesity-related traits; chr2:191250326 chr2:191154118~191156070:- CESC cis rs35955747 0.838 rs7285171 ENSG00000236132.1 CTA-440B3.1 6.39 1e-09 1.72e-06 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31202381 chr22:31816379~31817491:- CESC cis rs6860806 0.507 rs272883 ENSG00000233006.5 AC034220.3 6.39 1e-09 1.72e-06 0.44 0.4 Breast cancer; chr5:132333005 chr5:132311285~132369916:- CESC cis rs6860806 0.507 rs272882 ENSG00000233006.5 AC034220.3 6.39 1e-09 1.72e-06 0.44 0.4 Breast cancer; chr5:132333468 chr5:132311285~132369916:- CESC cis rs875971 1 rs4718307 ENSG00000222364.1 RNU6-96P 6.39 1e-09 1.72e-06 0.46 0.4 Aortic root size; chr7:66146001 chr7:66395191~66395286:+ CESC cis rs875971 1 rs7801282 ENSG00000222364.1 RNU6-96P 6.39 1e-09 1.72e-06 0.46 0.4 Aortic root size; chr7:66148700 chr7:66395191~66395286:+ CESC cis rs2487048 0.804 rs2472496 ENSG00000226334.1 RP11-217B7.2 -6.39 1e-09 1.72e-06 -0.5 -0.4 Intraocular pressure; chr9:104933072 chr9:104927553~104928892:+ CESC cis rs875971 1 rs6945843 ENSG00000222364.1 RNU6-96P 6.39 1.01e-09 1.74e-06 0.46 0.4 Aortic root size; chr7:66269796 chr7:66395191~66395286:+ CESC cis rs4853012 0.838 rs59570457 ENSG00000257800.1 FNBP1P1 6.39 1.02e-09 1.74e-06 0.41 0.4 Gestational age at birth (maternal effect); chr2:74117155 chr2:74120680~74123218:+ CESC cis rs17507216 0.609 rs1431716 ENSG00000278603.1 RP13-608F4.5 6.39 1.02e-09 1.74e-06 0.7 0.4 Excessive daytime sleepiness; chr15:82676180 chr15:82472203~82472426:+ CESC cis rs997154 0.655 rs8015121 ENSG00000279656.1 RP11-298I3.6 6.39 1.02e-09 1.74e-06 0.59 0.4 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22906042 chr14:23023083~23024217:- CESC cis rs35955747 0.902 rs7288643 ENSG00000236132.1 CTA-440B3.1 6.39 1.02e-09 1.74e-06 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31283683 chr22:31816379~31817491:- CESC cis rs150992 0.609 rs113868271 ENSG00000248489.1 CTD-2007H13.3 6.38 1.02e-09 1.75e-06 0.48 0.4 Body mass index; chr5:98992741 chr5:98929171~98995013:+ CESC cis rs150992 0.631 rs112393710 ENSG00000248489.1 CTD-2007H13.3 6.38 1.02e-09 1.75e-06 0.48 0.4 Body mass index; chr5:98992761 chr5:98929171~98995013:+ CESC cis rs150992 0.631 rs111871078 ENSG00000248489.1 CTD-2007H13.3 6.38 1.02e-09 1.75e-06 0.48 0.4 Body mass index; chr5:98992766 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs2937709 ENSG00000248489.1 CTD-2007H13.3 6.38 1.02e-09 1.75e-06 0.48 0.4 Body mass index; chr5:98993120 chr5:98929171~98995013:+ CESC cis rs150992 0.632 rs1104262 ENSG00000248489.1 CTD-2007H13.3 6.38 1.02e-09 1.75e-06 0.48 0.4 Body mass index; chr5:98993145 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs2927654 ENSG00000248489.1 CTD-2007H13.3 6.38 1.02e-09 1.75e-06 0.48 0.4 Body mass index; chr5:98993195 chr5:98929171~98995013:+ CESC cis rs9389248 0.708 rs7750574 ENSG00000232876.1 CTA-212D2.2 -6.38 1.03e-09 1.76e-06 -0.48 -0.4 High light scatter reticulocyte percentage of red cells; chr6:135029794 chr6:135055033~135060550:+ CESC cis rs9584850 1 rs9584850 ENSG00000231194.1 FARP1-AS1 6.38 1.03e-09 1.76e-06 0.5 0.4 Neuroticism; chr13:98449172 chr13:98435405~98435840:- CESC cis rs9399135 0.935 rs11759999 ENSG00000232876.1 CTA-212D2.2 -6.38 1.03e-09 1.77e-06 -0.46 -0.4 Red blood cell count; chr6:135049357 chr6:135055033~135060550:+ CESC cis rs9399135 0.935 rs11760000 ENSG00000232876.1 CTA-212D2.2 -6.38 1.03e-09 1.77e-06 -0.46 -0.4 Red blood cell count; chr6:135049358 chr6:135055033~135060550:+ CESC cis rs8072100 0.875 rs4794047 ENSG00000228782.6 CTD-2026D20.3 -6.38 1.03e-09 1.77e-06 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47685639 chr17:47450568~47492492:- CESC cis rs10875746 0.903 rs10875738 ENSG00000240399.1 RP1-228P16.1 -6.38 1.04e-09 1.78e-06 -0.52 -0.4 Longevity (90 years and older); chr12:48079956 chr12:48054813~48055591:- CESC cis rs507080 0.885 rs4938530 ENSG00000255422.1 AP002954.4 -6.38 1.04e-09 1.78e-06 -0.48 -0.4 Serum metabolite levels; chr11:118689861 chr11:118704607~118750263:+ CESC cis rs507080 0.769 rs2077173 ENSG00000255422.1 AP002954.4 -6.38 1.04e-09 1.78e-06 -0.47 -0.4 Serum metabolite levels; chr11:118621876 chr11:118704607~118750263:+ CESC cis rs6452524 0.967 rs4290995 ENSG00000249664.1 CTD-2227C6.2 6.38 1.05e-09 1.79e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83182177 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs965674 ENSG00000249664.1 CTD-2227C6.2 6.38 1.05e-09 1.79e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83186765 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs2662242 ENSG00000249664.1 CTD-2227C6.2 6.38 1.05e-09 1.79e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83189066 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs2731844 ENSG00000249664.1 CTD-2227C6.2 6.38 1.05e-09 1.79e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83192627 chr5:83012285~83013109:- CESC cis rs6452524 0.901 rs2940540 ENSG00000249664.1 CTD-2227C6.2 6.38 1.05e-09 1.79e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83193004 chr5:83012285~83013109:- CESC cis rs507080 0.922 rs592280 ENSG00000255422.1 AP002954.4 -6.38 1.05e-09 1.8e-06 -0.46 -0.4 Serum metabolite levels; chr11:118682509 chr11:118704607~118750263:+ CESC cis rs113835537 0.529 rs3816492 ENSG00000255517.5 CTD-3074O7.5 -6.38 1.06e-09 1.81e-06 -0.48 -0.4 Airway imaging phenotypes; chr11:66529892 chr11:66473490~66480233:- CESC cis rs6452524 0.967 rs4401555 ENSG00000249664.1 CTD-2227C6.2 6.38 1.06e-09 1.81e-06 0.43 0.4 Hypertension (SNP x SNP interaction); chr5:83175267 chr5:83012285~83013109:- CESC cis rs8005677 0.828 rs3794452 ENSG00000279656.1 RP11-298I3.6 6.38 1.06e-09 1.81e-06 0.48 0.4 Cognitive ability (multi-trait analysis); chr14:22917473 chr14:23023083~23024217:- CESC cis rs11690935 0.921 rs6710698 ENSG00000228389.1 AC068039.4 6.38 1.06e-09 1.81e-06 0.52 0.4 Schizophrenia; chr2:171739568 chr2:171773482~171775844:+ CESC cis rs1707322 1 rs11211223 ENSG00000280836.1 AL355480.1 -6.38 1.06e-09 1.81e-06 -0.46 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45914933 chr1:45581219~45581321:- CESC cis rs10463554 0.927 rs34820 ENSG00000175749.11 EIF3KP1 6.38 1.07e-09 1.82e-06 0.43 0.4 Parkinson's disease; chr5:103101164 chr5:103032376~103033031:+ CESC cis rs7617773 0.563 rs62263035 ENSG00000229759.1 MRPS18AP1 6.38 1.07e-09 1.82e-06 0.42 0.4 Coronary artery disease; chr3:48350079 chr3:48256350~48256938:- CESC cis rs12931792 0.712 rs56399904 ENSG00000183604.13 SMG1P5 6.38 1.07e-09 1.82e-06 0.38 0.4 Tonsillectomy; chr16:30154862 chr16:30267553~30335374:- CESC cis rs11155671 0.53 rs7768626 ENSG00000268592.3 RAET1E-AS1 6.37 1.08e-09 1.83e-06 0.49 0.4 Testicular germ cell tumor; chr6:149886826 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs7768665 ENSG00000268592.3 RAET1E-AS1 6.37 1.08e-09 1.83e-06 0.49 0.4 Testicular germ cell tumor; chr6:149886888 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs7758020 ENSG00000268592.3 RAET1E-AS1 6.37 1.08e-09 1.83e-06 0.49 0.4 Testicular germ cell tumor; chr6:149886975 chr6:149863494~149919507:+ CESC cis rs79349575 0.811 rs1057897 ENSG00000270781.1 RP11-501C14.9 -6.37 1.08e-09 1.84e-06 -0.45 -0.4 Type 2 diabetes; chr17:48928147 chr17:48899131~48899748:+ CESC cis rs6991838 0.612 rs7842162 ENSG00000272010.1 CTD-3025N20.3 6.37 1.08e-09 1.84e-06 0.45 0.4 Intelligence (multi-trait analysis); chr8:65644057 chr8:65591850~65592472:- CESC cis rs10129255 0.518 rs7143784 ENSG00000223648.3 IGHV3-64 6.37 1.08e-09 1.84e-06 0.32 0.4 Kawasaki disease; chr14:106687277 chr14:106643132~106658258:- CESC cis rs526231 0.578 rs17154821 ENSG00000175749.11 EIF3KP1 6.37 1.09e-09 1.84e-06 0.42 0.4 Primary biliary cholangitis; chr5:102905637 chr5:103032376~103033031:+ CESC cis rs11155671 0.53 rs9322228 ENSG00000268592.3 RAET1E-AS1 6.37 1.09e-09 1.85e-06 0.49 0.4 Testicular germ cell tumor; chr6:149888173 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs7774787 ENSG00000268592.3 RAET1E-AS1 6.37 1.09e-09 1.85e-06 0.49 0.4 Testicular germ cell tumor; chr6:149888296 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs2342767 ENSG00000268592.3 RAET1E-AS1 6.37 1.09e-09 1.85e-06 0.49 0.4 Testicular germ cell tumor; chr6:149888581 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs7764376 ENSG00000268592.3 RAET1E-AS1 6.37 1.09e-09 1.85e-06 0.49 0.4 Testicular germ cell tumor; chr6:149889208 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs6933882 ENSG00000268592.3 RAET1E-AS1 6.37 1.09e-09 1.85e-06 0.49 0.4 Testicular germ cell tumor; chr6:149889666 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs6939761 ENSG00000268592.3 RAET1E-AS1 6.37 1.09e-09 1.85e-06 0.49 0.4 Testicular germ cell tumor; chr6:149889858 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs3823021 ENSG00000268592.3 RAET1E-AS1 6.37 1.09e-09 1.85e-06 0.49 0.4 Testicular germ cell tumor; chr6:149889863 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs4869764 ENSG00000268592.3 RAET1E-AS1 6.37 1.09e-09 1.85e-06 0.49 0.4 Testicular germ cell tumor; chr6:149890692 chr6:149863494~149919507:+ CESC cis rs6504950 1 rs9892976 ENSG00000275710.1 RP11-257O5.4 6.37 1.09e-09 1.85e-06 0.48 0.4 Breast cancer; chr17:54982968 chr17:54964474~54964679:+ CESC cis rs875971 0.965 rs9969301 ENSG00000222364.1 RNU6-96P 6.37 1.09e-09 1.85e-06 0.45 0.4 Aortic root size; chr7:66316668 chr7:66395191~66395286:+ CESC cis rs1823913 0.599 rs13001899 ENSG00000280083.1 RP11-317J9.1 -6.37 1.09e-09 1.85e-06 -0.46 -0.4 Obesity-related traits; chr2:191285442 chr2:191154118~191156070:- CESC cis rs7617773 0.539 rs35460860 ENSG00000229759.1 MRPS18AP1 6.37 1.1e-09 1.86e-06 0.42 0.4 Coronary artery disease; chr3:48350595 chr3:48256350~48256938:- CESC cis rs7617773 0.563 rs13082269 ENSG00000229759.1 MRPS18AP1 6.37 1.1e-09 1.86e-06 0.42 0.4 Coronary artery disease; chr3:48350784 chr3:48256350~48256938:- CESC cis rs526231 0.578 rs1898672 ENSG00000175749.11 EIF3KP1 -6.37 1.1e-09 1.86e-06 -0.43 -0.4 Primary biliary cholangitis; chr5:102958149 chr5:103032376~103033031:+ CESC cis rs11155671 0.53 rs9968871 ENSG00000231760.4 RP11-350J20.5 6.37 1.1e-09 1.86e-06 0.49 0.4 Testicular germ cell tumor; chr6:149888060 chr6:149796151~149826294:- CESC cis rs11155671 0.53 rs9969044 ENSG00000231760.4 RP11-350J20.5 6.37 1.1e-09 1.86e-06 0.49 0.4 Testicular germ cell tumor; chr6:149888068 chr6:149796151~149826294:- CESC cis rs4853012 0.793 rs6723185 ENSG00000257800.1 FNBP1P1 6.37 1.1e-09 1.87e-06 0.41 0.4 Gestational age at birth (maternal effect); chr2:74117757 chr2:74120680~74123218:+ CESC cis rs526231 0.578 rs6876278 ENSG00000175749.11 EIF3KP1 6.37 1.11e-09 1.87e-06 0.43 0.4 Primary biliary cholangitis; chr5:102913842 chr5:103032376~103033031:+ CESC cis rs10463554 0.927 rs56361326 ENSG00000175749.11 EIF3KP1 6.37 1.11e-09 1.88e-06 0.41 0.4 Parkinson's disease; chr5:103054184 chr5:103032376~103033031:+ CESC cis rs875971 1 rs10257427 ENSG00000222364.1 RNU6-96P 6.37 1.11e-09 1.88e-06 0.46 0.4 Aortic root size; chr7:66278221 chr7:66395191~66395286:+ CESC cis rs8081395 0.741 rs1292051 ENSG00000266992.1 DHX40P1 6.37 1.11e-09 1.89e-06 0.43 0.4 White blood cell count; chr17:59886562 chr17:59976009~60002384:- CESC cis rs507080 0.697 rs653008 ENSG00000255422.1 AP002954.4 -6.37 1.12e-09 1.89e-06 -0.47 -0.4 Serum metabolite levels; chr11:118649775 chr11:118704607~118750263:+ CESC cis rs10256972 0.713 rs10435026 ENSG00000229043.2 AC091729.9 -6.37 1.12e-09 1.89e-06 -0.45 -0.4 Endometriosis;Longevity; chr7:1026312 chr7:1160374~1165267:+ CESC cis rs13230714 1 rs13230714 ENSG00000204959.4 ARHGEF34P -6.37 1.12e-09 1.9e-06 -0.43 -0.4 Breast cancer; chr7:144477198 chr7:144272445~144286966:- CESC cis rs4423214 0.879 rs1790330 ENSG00000254682.1 RP11-660L16.2 -6.37 1.13e-09 1.9e-06 -0.52 -0.4 Vitamin D levels; chr11:71436779 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1790328 ENSG00000254682.1 RP11-660L16.2 -6.37 1.13e-09 1.9e-06 -0.52 -0.4 Vitamin D levels; chr11:71436992 chr11:71448674~71452157:+ CESC cis rs35955747 0.871 rs2013254 ENSG00000236132.1 CTA-440B3.1 6.37 1.13e-09 1.91e-06 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31294817 chr22:31816379~31817491:- CESC cis rs6860806 0.507 rs272892 ENSG00000233006.5 AC034220.3 6.37 1.13e-09 1.91e-06 0.43 0.4 Breast cancer; chr5:132328656 chr5:132311285~132369916:- CESC cis rs8072100 0.905 rs8077106 ENSG00000228782.6 CTD-2026D20.3 -6.37 1.13e-09 1.92e-06 -0.44 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47575925 chr17:47450568~47492492:- CESC cis rs8072100 0.754 rs8081717 ENSG00000228782.6 CTD-2026D20.3 -6.37 1.13e-09 1.92e-06 -0.44 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47576555 chr17:47450568~47492492:- CESC cis rs875971 0.964 rs55748098 ENSG00000222364.1 RNU6-96P 6.37 1.13e-09 1.92e-06 0.46 0.4 Aortic root size; chr7:66298631 chr7:66395191~66395286:+ CESC cis rs7674212 0.507 rs6843738 ENSG00000246560.2 RP11-10L12.4 6.37 1.13e-09 1.92e-06 0.52 0.4 Type 2 diabetes; chr4:103014844 chr4:102828055~102844075:+ CESC cis rs7397814 0.558 rs4764447 ENSG00000256673.1 RP11-599J14.2 6.37 1.13e-09 1.92e-06 0.45 0.4 IgG glycosylation; chr12:9426513 chr12:9398355~9414851:- CESC cis rs2117029 0.586 rs11168874 ENSG00000258017.1 RP11-386G11.10 -6.37 1.13e-09 1.92e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49133753 chr12:49127782~49147869:+ CESC cis rs2117029 0.523 rs12227296 ENSG00000258017.1 RP11-386G11.10 -6.37 1.13e-09 1.92e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49136712 chr12:49127782~49147869:+ CESC cis rs2117029 0.521 rs10875925 ENSG00000258017.1 RP11-386G11.10 -6.37 1.13e-09 1.92e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49142575 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs11168882 ENSG00000258017.1 RP11-386G11.10 -6.37 1.13e-09 1.92e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49143560 chr12:49127782~49147869:+ CESC cis rs2117029 0.521 rs12227610 ENSG00000258017.1 RP11-386G11.10 -6.37 1.13e-09 1.92e-06 -0.51 -0.4 Intelligence (multi-trait analysis); chr12:49146153 chr12:49127782~49147869:+ CESC cis rs1823913 0.599 rs13002286 ENSG00000280083.1 RP11-317J9.1 6.37 1.14e-09 1.92e-06 0.46 0.4 Obesity-related traits; chr2:191285626 chr2:191154118~191156070:- CESC cis rs3931020 0.508 rs11485298 ENSG00000272864.1 RP11-17E13.2 -6.36 1.14e-09 1.92e-06 -0.46 -0.4 Resistin levels; chr1:74752068 chr1:74698769~74699333:- CESC cis rs3931020 0.508 rs4145871 ENSG00000272864.1 RP11-17E13.2 -6.36 1.14e-09 1.92e-06 -0.46 -0.4 Resistin levels; chr1:74753020 chr1:74698769~74699333:- CESC cis rs2404602 0.647 rs12914196 ENSG00000259422.1 RP11-593F23.1 -6.36 1.14e-09 1.92e-06 -0.48 -0.4 Blood metabolite levels; chr15:76649020 chr15:76174891~76181486:- CESC cis rs3806843 1 rs2098058 ENSG00000202111.1 VTRNA1-2 6.36 1.14e-09 1.93e-06 0.41 0.4 Depressive symptoms (multi-trait analysis); chr5:140777842 chr5:140718925~140719013:+ CESC cis rs11155671 0.53 rs7758033 ENSG00000268592.3 RAET1E-AS1 6.36 1.15e-09 1.94e-06 0.5 0.4 Testicular germ cell tumor; chr6:149886999 chr6:149863494~149919507:+ CESC cis rs1707322 1 rs10890380 ENSG00000280836.1 AL355480.1 -6.36 1.15e-09 1.94e-06 -0.46 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45983797 chr1:45581219~45581321:- CESC cis rs9595066 0.941 rs9533777 ENSG00000227258.4 SMIM2-AS1 -6.36 1.15e-09 1.95e-06 -0.56 -0.4 Schizophrenia; chr13:44134584 chr13:44110451~44240517:+ CESC cis rs2929278 0.617 rs663214 ENSG00000205771.5 CATSPER2P1 6.36 1.16e-09 1.96e-06 0.47 0.4 Schizophrenia; chr15:43821584 chr15:43726918~43747094:- CESC cis rs10463554 0.963 rs11242483 ENSG00000175749.11 EIF3KP1 6.36 1.16e-09 1.96e-06 0.42 0.4 Parkinson's disease; chr5:102988062 chr5:103032376~103033031:+ CESC cis rs2404602 0.611 rs2404734 ENSG00000259422.1 RP11-593F23.1 -6.36 1.16e-09 1.97e-06 -0.48 -0.4 Blood metabolite levels; chr15:76643824 chr15:76174891~76181486:- CESC cis rs10129255 0.5 rs8006888 ENSG00000223648.3 IGHV3-64 6.36 1.17e-09 1.97e-06 0.33 0.4 Kawasaki disease; chr14:106782219 chr14:106643132~106658258:- CESC cis rs2882667 0.638 rs2351905 ENSG00000253404.1 AC034243.1 6.36 1.17e-09 1.97e-06 0.49 0.4 Age-related hearing impairment (SNP x SNP interaction); chr5:139135641 chr5:138744434~138753309:- CESC cis rs507080 0.769 rs571001 ENSG00000255422.1 AP002954.4 -6.36 1.18e-09 1.99e-06 -0.47 -0.4 Serum metabolite levels; chr11:118629457 chr11:118704607~118750263:+ CESC cis rs507080 0.769 rs570952 ENSG00000255422.1 AP002954.4 -6.36 1.18e-09 1.99e-06 -0.47 -0.4 Serum metabolite levels; chr11:118629477 chr11:118704607~118750263:+ CESC cis rs507080 0.769 rs645637 ENSG00000255422.1 AP002954.4 -6.36 1.18e-09 1.99e-06 -0.47 -0.4 Serum metabolite levels; chr11:118634373 chr11:118704607~118750263:+ CESC cis rs1707322 0.721 rs4559551 ENSG00000281133.1 AL355480.3 -6.36 1.18e-09 1.99e-06 -0.48 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701861 chr1:45580892~45580996:- CESC cis rs10256972 0.684 rs4724039 ENSG00000229043.2 AC091729.9 -6.36 1.19e-09 2e-06 -0.45 -0.4 Endometriosis;Longevity; chr7:1071997 chr7:1160374~1165267:+ CESC cis rs2404602 0.552 rs11636612 ENSG00000259422.1 RP11-593F23.1 -6.36 1.19e-09 2e-06 -0.51 -0.4 Blood metabolite levels; chr15:76667189 chr15:76174891~76181486:- CESC cis rs9399137 0.507 rs7745289 ENSG00000232876.1 CTA-212D2.2 -6.36 1.19e-09 2e-06 -0.48 -0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135059189 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs11759062 ENSG00000232876.1 CTA-212D2.2 -6.36 1.19e-09 2e-06 -0.48 -0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135060110 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs11759077 ENSG00000232876.1 CTA-212D2.2 -6.36 1.19e-09 2e-06 -0.48 -0.4 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135060213 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs7750300 ENSG00000232876.1 CTA-212D2.2 -6.36 1.19e-09 2.01e-06 -0.45 -0.4 Red blood cell count; chr6:135029812 chr6:135055033~135060550:+ CESC cis rs6860806 0.507 rs273915 ENSG00000233006.5 AC034220.3 6.36 1.2e-09 2.01e-06 0.44 0.4 Breast cancer; chr5:132324426 chr5:132311285~132369916:- CESC cis rs507080 0.922 rs519848 ENSG00000255422.1 AP002954.4 -6.36 1.2e-09 2.02e-06 -0.46 -0.4 Serum metabolite levels; chr11:118682006 chr11:118704607~118750263:+ CESC cis rs2739330 0.76 rs5751760 ENSG00000099984.9 GSTT2 -6.36 1.2e-09 2.02e-06 -0.49 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23980123~23983911:+ CESC cis rs2117029 0.556 rs1057725 ENSG00000258017.1 RP11-386G11.10 -6.35 1.2e-09 2.02e-06 -0.5 -0.4 Intelligence (multi-trait analysis); chr12:49128795 chr12:49127782~49147869:+ CESC cis rs35955747 0.902 rs713947 ENSG00000236132.1 CTA-440B3.1 6.35 1.21e-09 2.03e-06 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts; chr22:31243523 chr22:31816379~31817491:- CESC cis rs1707322 1 rs4660331 ENSG00000280836.1 AL355480.1 -6.35 1.21e-09 2.04e-06 -0.46 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45993111 chr1:45581219~45581321:- CESC cis rs950169 0.922 rs11630760 ENSG00000225151.9 GOLGA2P7 -6.35 1.21e-09 2.04e-06 -0.54 -0.4 Schizophrenia; chr15:84570106 chr15:84199311~84230136:- CESC cis rs950169 0.887 rs71395453 ENSG00000225151.9 GOLGA2P7 -6.35 1.21e-09 2.04e-06 -0.54 -0.4 Schizophrenia; chr15:84570259 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs11633075 ENSG00000225151.9 GOLGA2P7 -6.35 1.21e-09 2.04e-06 -0.54 -0.4 Schizophrenia; chr15:84570741 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs12912934 ENSG00000225151.9 GOLGA2P7 -6.35 1.21e-09 2.04e-06 -0.54 -0.4 Schizophrenia; chr15:84571216 chr15:84199311~84230136:- CESC cis rs4423214 0.84 rs1792231 ENSG00000254682.1 RP11-660L16.2 -6.35 1.22e-09 2.04e-06 -0.54 -0.4 Vitamin D levels; chr11:71471635 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs1790339 ENSG00000254682.1 RP11-660L16.2 -6.35 1.22e-09 2.04e-06 -0.54 -0.4 Vitamin D levels; chr11:71471715 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs4435028 ENSG00000254682.1 RP11-660L16.2 -6.35 1.22e-09 2.04e-06 -0.54 -0.4 Vitamin D levels; chr11:71472644 chr11:71448674~71452157:+ CESC cis rs4423214 0.802 rs4616066 ENSG00000254682.1 RP11-660L16.2 -6.35 1.22e-09 2.04e-06 -0.54 -0.4 Vitamin D levels; chr11:71472800 chr11:71448674~71452157:+ CESC cis rs4423214 0.802 rs4402322 ENSG00000254682.1 RP11-660L16.2 -6.35 1.22e-09 2.04e-06 -0.54 -0.4 Vitamin D levels; chr11:71472969 chr11:71448674~71452157:+ CESC cis rs4423214 0.802 rs2276358 ENSG00000254682.1 RP11-660L16.2 -6.35 1.22e-09 2.04e-06 -0.54 -0.4 Vitamin D levels; chr11:71473452 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs3794057 ENSG00000254682.1 RP11-660L16.2 -6.35 1.22e-09 2.04e-06 -0.54 -0.4 Vitamin D levels; chr11:71475698 chr11:71448674~71452157:+ CESC cis rs4423214 0.84 rs2017686 ENSG00000254682.1 RP11-660L16.2 -6.35 1.22e-09 2.04e-06 -0.54 -0.4 Vitamin D levels; chr11:71476015 chr11:71448674~71452157:+ CESC cis rs10129255 0.536 rs10142951 ENSG00000223648.3 IGHV3-64 6.35 1.22e-09 2.04e-06 0.33 0.4 Kawasaki disease; chr14:106782337 chr14:106643132~106658258:- CESC cis rs1061377 0.965 rs7690465 ENSG00000249207.1 RP11-360F5.1 -6.35 1.22e-09 2.04e-06 -0.45 -0.4 Uric acid levels; chr4:39147015 chr4:39112677~39126818:- CESC cis rs10463554 0.856 rs26427 ENSG00000175749.11 EIF3KP1 -6.35 1.23e-09 2.06e-06 -0.41 -0.4 Parkinson's disease; chr5:103031079 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs26821 ENSG00000175749.11 EIF3KP1 6.35 1.23e-09 2.06e-06 0.42 0.4 Parkinson's disease; chr5:103184699 chr5:103032376~103033031:+ CESC cis rs4239252 0.929 rs4796116 ENSG00000270977.1 AC015849.16 -6.35 1.23e-09 2.07e-06 -0.46 -0.4 Blood protein levels; chr17:35841496 chr17:35893707~35911023:- CESC cis rs4239252 0.929 rs4251791 ENSG00000270977.1 AC015849.16 -6.35 1.23e-09 2.07e-06 -0.46 -0.4 Blood protein levels; chr17:35845711 chr17:35893707~35911023:- CESC cis rs9907295 0.591 rs78655848 ENSG00000270977.1 AC015849.16 -6.35 1.23e-09 2.07e-06 -0.46 -0.4 Fibroblast growth factor basic levels; chr17:35856952 chr17:35893707~35911023:- CESC cis rs1185460 0.967 rs1786141 ENSG00000271751.1 RP11-110I1.14 -6.35 1.23e-09 2.07e-06 -0.52 -0.4 Coronary artery disease; chr11:119067604 chr11:119065263~119065677:- CESC cis rs10463554 0.892 rs66505956 ENSG00000175749.11 EIF3KP1 6.35 1.23e-09 2.07e-06 0.42 0.4 Parkinson's disease; chr5:102943853 chr5:103032376~103033031:+ CESC cis rs6860806 0.507 rs272872 ENSG00000233006.5 AC034220.3 -6.35 1.24e-09 2.08e-06 -0.44 -0.4 Breast cancer; chr5:132340171 chr5:132311285~132369916:- CESC cis rs3806843 0.838 rs2563289 ENSG00000202111.1 VTRNA1-2 6.35 1.24e-09 2.08e-06 0.41 0.4 Depressive symptoms (multi-trait analysis); chr5:140743181 chr5:140718925~140719013:+ CESC cis rs3096299 0.503 rs9940093 ENSG00000274627.1 RP11-104N10.2 6.35 1.24e-09 2.08e-06 0.4 0.4 Multiple myeloma (IgH translocation); chr16:89492297 chr16:89516797~89522217:+ CESC cis rs35955747 0.869 rs34873968 ENSG00000236132.1 CTA-440B3.1 6.35 1.25e-09 2.1e-06 0.47 0.39 Neutrophil count;Sum basophil neutrophil counts; chr22:31185787 chr22:31816379~31817491:- CESC cis rs9399137 0.507 rs4580893 ENSG00000232876.1 CTA-212D2.2 -6.35 1.25e-09 2.1e-06 -0.49 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134976524 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs10484496 ENSG00000232876.1 CTA-212D2.2 -6.35 1.25e-09 2.1e-06 -0.49 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134978544 chr6:135055033~135060550:+ CESC cis rs9389248 0.737 rs56358308 ENSG00000232876.1 CTA-212D2.2 -6.35 1.25e-09 2.1e-06 -0.49 -0.39 High light scatter reticulocyte percentage of red cells; chr6:134985842 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs11754021 ENSG00000232876.1 CTA-212D2.2 -6.35 1.25e-09 2.1e-06 -0.49 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134987237 chr6:135055033~135060550:+ CESC cis rs6860806 0.507 rs270601 ENSG00000233006.5 AC034220.3 6.35 1.25e-09 2.1e-06 0.44 0.39 Breast cancer; chr5:132321304 chr5:132311285~132369916:- CESC cis rs1062177 0.906 rs2964573 ENSG00000213433.5 RPLP1P6 -6.35 1.26e-09 2.11e-06 -0.49 -0.39 Preschool internalizing problems; chr5:151780561 chr5:151765859~151766378:- CESC cis rs113835537 0.529 rs3741360 ENSG00000255517.5 CTD-3074O7.5 -6.35 1.26e-09 2.12e-06 -0.47 -0.39 Airway imaging phenotypes; chr11:66532877 chr11:66473490~66480233:- CESC cis rs3806843 0.966 rs2563267 ENSG00000202111.1 VTRNA1-2 6.35 1.26e-09 2.12e-06 0.4 0.39 Depressive symptoms (multi-trait analysis); chr5:140757328 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs2563266 ENSG00000202111.1 VTRNA1-2 6.35 1.26e-09 2.12e-06 0.4 0.39 Depressive symptoms (multi-trait analysis); chr5:140757330 chr5:140718925~140719013:+ CESC cis rs2564921 0.765 rs35333155 ENSG00000242142.1 SERBP1P3 6.35 1.26e-09 2.12e-06 0.43 0.39 Height; chr3:53073764 chr3:53064283~53065091:- CESC cis rs2404602 0.647 rs35710279 ENSG00000259422.1 RP11-593F23.1 -6.35 1.26e-09 2.12e-06 -0.48 -0.39 Blood metabolite levels; chr15:76789893 chr15:76174891~76181486:- CESC cis rs4853012 0.838 rs6707729 ENSG00000257800.1 FNBP1P1 6.34 1.27e-09 2.12e-06 0.41 0.39 Gestational age at birth (maternal effect); chr2:74117558 chr2:74120680~74123218:+ CESC cis rs3806843 0.966 rs2563260 ENSG00000202111.1 VTRNA1-2 6.34 1.27e-09 2.13e-06 0.4 0.39 Depressive symptoms (multi-trait analysis); chr5:140758282 chr5:140718925~140719013:+ CESC cis rs526231 0.578 rs10463553 ENSG00000175749.11 EIF3KP1 6.34 1.28e-09 2.14e-06 0.43 0.39 Primary biliary cholangitis; chr5:102913503 chr5:103032376~103033031:+ CESC cis rs2117029 0.587 rs57853986 ENSG00000258017.1 RP11-386G11.10 -6.34 1.28e-09 2.14e-06 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49124612 chr12:49127782~49147869:+ CESC cis rs507080 0.961 rs642497 ENSG00000255422.1 AP002954.4 -6.34 1.28e-09 2.14e-06 -0.45 -0.39 Serum metabolite levels; chr11:118680075 chr11:118704607~118750263:+ CESC cis rs35955747 0.869 rs8143002 ENSG00000236132.1 CTA-440B3.1 6.34 1.28e-09 2.14e-06 0.47 0.39 Neutrophil count;Sum basophil neutrophil counts; chr22:31191205 chr22:31816379~31817491:- CESC cis rs7674212 0.581 rs11946020 ENSG00000246560.2 RP11-10L12.4 6.34 1.28e-09 2.14e-06 0.51 0.39 Type 2 diabetes; chr4:103023585 chr4:102828055~102844075:+ CESC cis rs6504950 1 rs9894529 ENSG00000275710.1 RP11-257O5.4 6.34 1.29e-09 2.16e-06 0.48 0.39 Breast cancer; chr17:54977885 chr17:54964474~54964679:+ CESC cis rs8072100 0.935 rs12150231 ENSG00000228782.6 CTD-2026D20.3 -6.34 1.3e-09 2.17e-06 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47639725 chr17:47450568~47492492:- CESC cis rs6700559 0.873 rs7542840 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200686558 chr1:200669507~200694250:+ CESC cis rs6700559 0.873 rs7524025 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200687859 chr1:200669507~200694250:+ CESC cis rs6700559 0.683 rs7548530 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200687904 chr1:200669507~200694250:+ CESC cis rs6700559 0.683 rs7526136 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200687911 chr1:200669507~200694250:+ CESC cis rs6700559 0.733 rs7526265 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200687916 chr1:200669507~200694250:+ CESC cis rs6700559 0.873 rs7526482 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200688310 chr1:200669507~200694250:+ CESC cis rs6700559 0.873 rs7526853 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200688529 chr1:200669507~200694250:+ CESC cis rs6700559 0.844 rs61825137 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200689267 chr1:200669507~200694250:+ CESC cis rs6700559 0.873 rs7545177 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200690727 chr1:200669507~200694250:+ CESC cis rs6700559 0.873 rs7539646 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200692534 chr1:200669507~200694250:+ CESC cis rs6700559 0.873 rs7519383 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200692968 chr1:200669507~200694250:+ CESC cis rs6700559 0.815 rs12141497 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200693389 chr1:200669507~200694250:+ CESC cis rs6700559 0.873 rs12126708 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200693397 chr1:200669507~200694250:+ CESC cis rs6700559 0.873 rs10920008 ENSG00000260088.1 RP11-92G12.3 -6.34 1.3e-09 2.17e-06 -0.51 -0.39 Coronary artery disease; chr1:200694546 chr1:200669507~200694250:+ CESC cis rs10256972 0.758 rs11979275 ENSG00000229043.2 AC091729.9 -6.34 1.3e-09 2.18e-06 -0.45 -0.39 Endometriosis;Longevity; chr7:1029699 chr7:1160374~1165267:+ CESC cis rs10256972 0.758 rs11980081 ENSG00000229043.2 AC091729.9 -6.34 1.3e-09 2.18e-06 -0.45 -0.39 Endometriosis;Longevity; chr7:1029736 chr7:1160374~1165267:+ CESC cis rs2404602 0.647 rs11855296 ENSG00000259422.1 RP11-593F23.1 -6.34 1.31e-09 2.18e-06 -0.48 -0.39 Blood metabolite levels; chr15:76800621 chr15:76174891~76181486:- CESC cis rs897984 0.542 rs6565217 ENSG00000260911.2 RP11-196G11.2 6.34 1.32e-09 2.2e-06 0.4 0.39 Dementia with Lewy bodies; chr16:31072003 chr16:31043150~31049868:+ CESC cis rs6860806 0.507 rs156322 ENSG00000233006.5 AC034220.3 6.34 1.32e-09 2.2e-06 0.44 0.39 Breast cancer; chr5:132318232 chr5:132311285~132369916:- CESC cis rs12931792 0.712 rs2887799 ENSG00000183604.13 SMG1P5 6.34 1.32e-09 2.2e-06 0.39 0.39 Tonsillectomy; chr16:30152512 chr16:30267553~30335374:- CESC cis rs11155671 0.53 rs4869763 ENSG00000268592.3 RAET1E-AS1 6.34 1.32e-09 2.21e-06 0.49 0.39 Testicular germ cell tumor; chr6:149890548 chr6:149863494~149919507:+ CESC cis rs10463554 0.963 rs34773 ENSG00000175749.11 EIF3KP1 6.34 1.34e-09 2.23e-06 0.42 0.39 Parkinson's disease; chr5:103114872 chr5:103032376~103033031:+ CESC cis rs9399135 0.967 rs12526055 ENSG00000232876.1 CTA-212D2.2 -6.34 1.34e-09 2.23e-06 -0.46 -0.39 Red blood cell count; chr6:135004780 chr6:135055033~135060550:+ CESC cis rs10463554 0.963 rs40093 ENSG00000175749.11 EIF3KP1 6.34 1.34e-09 2.23e-06 0.42 0.39 Parkinson's disease; chr5:103104121 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs257318 ENSG00000175749.11 EIF3KP1 6.34 1.34e-09 2.23e-06 0.42 0.39 Parkinson's disease; chr5:103109766 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs40322 ENSG00000175749.11 EIF3KP1 6.34 1.34e-09 2.23e-06 0.42 0.39 Parkinson's disease; chr5:103111253 chr5:103032376~103033031:+ CESC cis rs4423214 0.879 rs1792264 ENSG00000254682.1 RP11-660L16.2 -6.34 1.34e-09 2.23e-06 -0.52 -0.39 Vitamin D levels; chr11:71439201 chr11:71448674~71452157:+ CESC cis rs2177312 0.574 rs1879999 ENSG00000251129.1 RP11-734I18.1 -6.33 1.34e-09 2.23e-06 -0.43 -0.39 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31986185 chr4:31997397~32155406:+ CESC cis rs3931020 0.72 rs927904 ENSG00000272864.1 RP11-17E13.2 -6.33 1.35e-09 2.24e-06 -0.46 -0.39 Resistin levels; chr1:74794644 chr1:74698769~74699333:- CESC cis rs14027 0.921 rs7813651 ENSG00000279347.1 RP11-85I17.2 -6.33 1.35e-09 2.25e-06 -0.39 -0.39 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119839119 chr8:119838736~119840385:- CESC cis rs12439619 0.693 rs7165536 ENSG00000278603.1 RP13-608F4.5 6.33 1.36e-09 2.26e-06 0.59 0.39 Intelligence (multi-trait analysis); chr15:82273743 chr15:82472203~82472426:+ CESC cis rs150992 0.609 rs7711061 ENSG00000248489.1 CTD-2007H13.3 -6.33 1.36e-09 2.26e-06 -0.49 -0.39 Body mass index; chr5:99003535 chr5:98929171~98995013:+ CESC cis rs10463554 0.963 rs34774 ENSG00000175749.11 EIF3KP1 6.33 1.36e-09 2.26e-06 0.43 0.39 Parkinson's disease; chr5:103115116 chr5:103032376~103033031:+ CESC cis rs10129255 0.5 rs8022547 ENSG00000223648.3 IGHV3-64 6.33 1.36e-09 2.27e-06 0.32 0.39 Kawasaki disease; chr14:106781985 chr14:106643132~106658258:- CESC cis rs10463554 0.927 rs257317 ENSG00000175749.11 EIF3KP1 6.33 1.37e-09 2.27e-06 0.41 0.39 Parkinson's disease; chr5:103086881 chr5:103032376~103033031:+ CESC cis rs4853012 0.838 rs72911122 ENSG00000257800.1 FNBP1P1 6.33 1.37e-09 2.28e-06 0.41 0.39 Gestational age at birth (maternal effect); chr2:74116992 chr2:74120680~74123218:+ CESC cis rs3931020 0.508 rs2345436 ENSG00000272864.1 RP11-17E13.2 -6.33 1.37e-09 2.28e-06 -0.48 -0.39 Resistin levels; chr1:74733056 chr1:74698769~74699333:- CESC cis rs3931020 0.508 rs28568334 ENSG00000272864.1 RP11-17E13.2 -6.33 1.37e-09 2.28e-06 -0.48 -0.39 Resistin levels; chr1:74733615 chr1:74698769~74699333:- CESC cis rs3806843 0.933 rs10069930 ENSG00000202111.1 VTRNA1-2 -6.33 1.37e-09 2.28e-06 -0.4 -0.39 Depressive symptoms (multi-trait analysis); chr5:140783743 chr5:140718925~140719013:+ CESC cis rs150992 0.587 rs10040066 ENSG00000248489.1 CTD-2007H13.3 -6.33 1.37e-09 2.28e-06 -0.5 -0.39 Body mass index; chr5:99001333 chr5:98929171~98995013:+ CESC cis rs150992 0.609 rs4565239 ENSG00000248489.1 CTD-2007H13.3 -6.33 1.37e-09 2.28e-06 -0.5 -0.39 Body mass index; chr5:99002144 chr5:98929171~98995013:+ CESC cis rs2929278 0.617 rs575082 ENSG00000205771.5 CATSPER2P1 6.33 1.37e-09 2.28e-06 0.47 0.39 Schizophrenia; chr15:43817944 chr15:43726918~43747094:- CESC cis rs2929278 0.617 rs2955969 ENSG00000205771.5 CATSPER2P1 6.33 1.37e-09 2.28e-06 0.47 0.39 Schizophrenia; chr15:43822329 chr15:43726918~43747094:- CESC cis rs2404602 0.647 rs4312276 ENSG00000259422.1 RP11-593F23.1 -6.33 1.38e-09 2.29e-06 -0.48 -0.39 Blood metabolite levels; chr15:76872020 chr15:76174891~76181486:- CESC cis rs6991838 0.557 rs7012578 ENSG00000200714.1 Y_RNA -6.33 1.38e-09 2.29e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65592592 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs7812446 ENSG00000200714.1 Y_RNA -6.33 1.38e-09 2.29e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65593753 chr8:65592731~65592820:+ CESC cis rs6991838 0.557 rs7812390 ENSG00000200714.1 Y_RNA -6.33 1.38e-09 2.29e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65593982 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs16932245 ENSG00000200714.1 Y_RNA -6.33 1.38e-09 2.29e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65597810 chr8:65592731~65592820:+ CESC cis rs6991838 0.557 rs57419568 ENSG00000200714.1 Y_RNA -6.33 1.38e-09 2.29e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65598633 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs16932250 ENSG00000200714.1 Y_RNA -6.33 1.38e-09 2.29e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65598779 chr8:65592731~65592820:+ CESC cis rs2739330 0.892 rs4822455 ENSG00000272787.1 KB-226F1.2 -6.33 1.38e-09 2.29e-06 -0.42 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23969211~23969873:+ CESC cis rs11690935 1 rs312918 ENSG00000228389.1 AC068039.4 6.33 1.38e-09 2.29e-06 0.51 0.39 Schizophrenia; chr2:171713077 chr2:171773482~171775844:+ CESC cis rs1707322 1 rs7531911 ENSG00000280836.1 AL355480.1 -6.33 1.39e-09 2.31e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45864751 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10890359 ENSG00000280836.1 AL355480.1 -6.33 1.39e-09 2.31e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45870963 chr1:45581219~45581321:- CESC cis rs1707322 0.928 rs7527244 ENSG00000280836.1 AL355480.1 -6.33 1.39e-09 2.31e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45903100 chr1:45581219~45581321:- CESC cis rs11676348 0.776 rs11690316 ENSG00000261338.2 RP11-378A13.1 -6.33 1.4e-09 2.32e-06 -0.46 -0.39 Ulcerative colitis; chr2:218152739 chr2:218255319~218257366:+ CESC cis rs7188445 0.614 rs62043313 ENSG00000261390.4 RP11-345M22.2 -6.33 1.4e-09 2.32e-06 -0.47 -0.39 Urate levels; chr16:79710237 chr16:79715232~79770563:- CESC cis rs9584850 0.874 rs3742136 ENSG00000231194.1 FARP1-AS1 6.33 1.4e-09 2.32e-06 0.5 0.39 Neuroticism; chr13:98450353 chr13:98435405~98435840:- CESC cis rs3806843 1 rs10066278 ENSG00000202111.1 VTRNA1-2 -6.33 1.4e-09 2.33e-06 -0.42 -0.39 Depressive symptoms (multi-trait analysis); chr5:140776733 chr5:140718925~140719013:+ CESC cis rs9399137 0.507 rs13214669 ENSG00000232876.1 CTA-212D2.2 -6.33 1.41e-09 2.33e-06 -0.49 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134978821 chr6:135055033~135060550:+ CESC cis rs2470135 1 rs2470135 ENSG00000249839.1 AC011330.5 -6.32 1.42e-09 2.35e-06 -0.42 -0.39 Diastolic blood pressure; chr15:43703591 chr15:43663654~43684339:- CESC cis rs875971 0.965 rs10267430 ENSG00000222364.1 RNU6-96P 6.32 1.42e-09 2.36e-06 0.45 0.39 Aortic root size; chr7:66278036 chr7:66395191~66395286:+ CESC cis rs2404602 0.647 rs11072628 ENSG00000259422.1 RP11-593F23.1 -6.32 1.42e-09 2.36e-06 -0.48 -0.39 Blood metabolite levels; chr15:76815420 chr15:76174891~76181486:- CESC cis rs10463554 0.927 rs11952361 ENSG00000175749.11 EIF3KP1 6.32 1.43e-09 2.37e-06 0.42 0.39 Parkinson's disease; chr5:102952216 chr5:103032376~103033031:+ CESC cis rs2739330 0.828 rs2186366 ENSG00000250470.1 AP000351.3 -6.32 1.43e-09 2.37e-06 -0.49 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23976904~23977585:- CESC cis rs9399135 1 rs35123050 ENSG00000232876.1 CTA-212D2.2 -6.32 1.43e-09 2.37e-06 -0.46 -0.39 Red blood cell count; chr6:134981602 chr6:135055033~135060550:+ CESC cis rs5769707 0.749 rs8137251 ENSG00000188511.11 C22orf34 6.32 1.43e-09 2.37e-06 0.42 0.39 Monocyte percentage of white cells;Monocyte count; chr22:49643021 chr22:49414524~49657542:- CESC cis rs875971 0.898 rs6977501 ENSG00000222364.1 RNU6-96P 6.32 1.44e-09 2.38e-06 0.45 0.39 Aortic root size; chr7:66228355 chr7:66395191~66395286:+ CESC cis rs9399135 0.967 rs6909975 ENSG00000232876.1 CTA-212D2.2 -6.32 1.44e-09 2.39e-06 -0.46 -0.39 Red blood cell count; chr6:134994432 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs7773126 ENSG00000232876.1 CTA-212D2.2 -6.32 1.44e-09 2.39e-06 -0.46 -0.39 Red blood cell count; chr6:134997252 chr6:135055033~135060550:+ CESC cis rs270601 0.913 rs273916 ENSG00000233006.5 AC034220.3 6.32 1.44e-09 2.39e-06 0.44 0.39 Acylcarnitine levels; chr5:132324137 chr5:132311285~132369916:- CESC cis rs34779708 0.868 rs2384352 ENSG00000230534.5 RP11-297A16.2 6.32 1.44e-09 2.39e-06 0.53 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35203904 chr10:35098006~35127020:- CESC cis rs7733403 1 rs7733403 ENSG00000202111.1 VTRNA1-2 -6.32 1.44e-09 2.39e-06 -0.4 -0.39 Schizophrenia; chr5:140774630 chr5:140718925~140719013:+ CESC cis rs507080 0.922 rs546890 ENSG00000255422.1 AP002954.4 -6.32 1.45e-09 2.39e-06 -0.48 -0.39 Serum metabolite levels; chr11:118686489 chr11:118704607~118750263:+ CESC cis rs507080 0.922 rs555356 ENSG00000255422.1 AP002954.4 -6.32 1.45e-09 2.39e-06 -0.48 -0.39 Serum metabolite levels; chr11:118687369 chr11:118704607~118750263:+ CESC cis rs507080 0.883 rs693306 ENSG00000255422.1 AP002954.4 -6.32 1.45e-09 2.39e-06 -0.48 -0.39 Serum metabolite levels; chr11:118687624 chr11:118704607~118750263:+ CESC cis rs507080 0.922 rs561845 ENSG00000255422.1 AP002954.4 -6.32 1.45e-09 2.39e-06 -0.48 -0.39 Serum metabolite levels; chr11:118688118 chr11:118704607~118750263:+ CESC cis rs507080 0.922 rs638805 ENSG00000255422.1 AP002954.4 -6.32 1.45e-09 2.39e-06 -0.48 -0.39 Serum metabolite levels; chr11:118688180 chr11:118704607~118750263:+ CESC cis rs507080 0.845 rs510408 ENSG00000255422.1 AP002954.4 -6.32 1.45e-09 2.39e-06 -0.48 -0.39 Serum metabolite levels; chr11:118688192 chr11:118704607~118750263:+ CESC cis rs507080 0.845 rs509641 ENSG00000255422.1 AP002954.4 -6.32 1.45e-09 2.39e-06 -0.48 -0.39 Serum metabolite levels; chr11:118688243 chr11:118704607~118750263:+ CESC cis rs507080 0.883 rs563549 ENSG00000255422.1 AP002954.4 -6.32 1.45e-09 2.39e-06 -0.48 -0.39 Serum metabolite levels; chr11:118688244 chr11:118704607~118750263:+ CESC cis rs1823913 0.599 rs2168166 ENSG00000280083.1 RP11-317J9.1 -6.32 1.45e-09 2.39e-06 -0.46 -0.39 Obesity-related traits; chr2:191288063 chr2:191154118~191156070:- CESC cis rs9907295 0.591 rs3760327 ENSG00000270977.1 AC015849.16 -6.32 1.46e-09 2.41e-06 -0.46 -0.39 Fibroblast growth factor basic levels; chr17:35836383 chr17:35893707~35911023:- CESC cis rs1707322 0.896 rs946528 ENSG00000280836.1 AL355480.1 6.32 1.46e-09 2.41e-06 0.46 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46019890 chr1:45581219~45581321:- CESC cis rs8072100 0.905 rs8078686 ENSG00000228782.6 CTD-2026D20.3 -6.32 1.46e-09 2.41e-06 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47658340 chr17:47450568~47492492:- CESC cis rs1707322 0.686 rs1084086 ENSG00000281133.1 AL355480.3 6.32 1.46e-09 2.41e-06 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45575428 chr1:45580892~45580996:- CESC cis rs2929278 0.617 rs663214 ENSG00000249839.1 AC011330.5 6.32 1.47e-09 2.43e-06 0.41 0.39 Schizophrenia; chr15:43821584 chr15:43663654~43684339:- CESC cis rs9399135 0.967 rs59329760 ENSG00000232876.1 CTA-212D2.2 -6.32 1.47e-09 2.43e-06 -0.45 -0.39 Red blood cell count; chr6:135021299 chr6:135055033~135060550:+ CESC cis rs897984 0.609 rs17839567 ENSG00000260911.2 RP11-196G11.2 6.32 1.47e-09 2.43e-06 0.4 0.39 Dementia with Lewy bodies; chr16:31046624 chr16:31043150~31049868:+ CESC cis rs897984 0.609 rs732173 ENSG00000260911.2 RP11-196G11.2 6.32 1.48e-09 2.44e-06 0.41 0.39 Dementia with Lewy bodies; chr16:31038702 chr16:31043150~31049868:+ CESC cis rs897984 0.609 rs1108431 ENSG00000260911.2 RP11-196G11.2 6.32 1.48e-09 2.44e-06 0.41 0.39 Dementia with Lewy bodies; chr16:31043286 chr16:31043150~31049868:+ CESC cis rs9399135 0.967 rs3756799 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135019873 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs4896125 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135021431 chr6:135055033~135060550:+ CESC cis rs9399135 0.838 rs4896126 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135021648 chr6:135055033~135060550:+ CESC cis rs9402673 0.517 rs978036 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 High light scatter reticulocyte count;Reticulocyte count; chr6:135021765 chr6:135055033~135060550:+ CESC cis rs9399135 0.935 rs949547 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135022361 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs1023179 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135022691 chr6:135055033~135060550:+ CESC cis rs9399135 0.935 rs2150680 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135025993 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs11756988 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135026457 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs11754783 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135026523 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs952674 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135028019 chr6:135055033~135060550:+ CESC cis rs9399135 0.935 rs987690 ENSG00000232876.1 CTA-212D2.2 -6.32 1.48e-09 2.44e-06 -0.45 -0.39 Red blood cell count; chr6:135029241 chr6:135055033~135060550:+ CESC cis rs2412819 0.599 rs2470120 ENSG00000249839.1 AC011330.5 -6.32 1.48e-09 2.44e-06 -0.42 -0.39 Lung cancer; chr15:43636872 chr15:43663654~43684339:- CESC cis rs11155671 0.53 rs6935829 ENSG00000216906.2 RP11-350J20.9 6.32 1.49e-09 2.45e-06 0.42 0.39 Testicular germ cell tumor; chr6:149896675 chr6:149904243~149906418:+ CESC cis rs526231 0.547 rs72783895 ENSG00000175749.11 EIF3KP1 6.32 1.49e-09 2.45e-06 0.45 0.39 Primary biliary cholangitis; chr5:102951792 chr5:103032376~103033031:+ CESC cis rs8072100 1 rs4794016 ENSG00000228782.6 CTD-2026D20.3 -6.32 1.49e-09 2.45e-06 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47648565 chr17:47450568~47492492:- CESC cis rs7727544 0.735 rs272884 ENSG00000233006.5 AC034220.3 6.32 1.49e-09 2.46e-06 0.44 0.39 Blood metabolite levels; chr5:132332961 chr5:132311285~132369916:- CESC cis rs7727544 0.735 rs272881 ENSG00000233006.5 AC034220.3 6.32 1.49e-09 2.46e-06 0.44 0.39 Blood metabolite levels; chr5:132333571 chr5:132311285~132369916:- CESC cis rs7727544 0.735 rs272879 ENSG00000233006.5 AC034220.3 6.32 1.49e-09 2.46e-06 0.44 0.39 Blood metabolite levels; chr5:132334853 chr5:132311285~132369916:- CESC cis rs2564921 0.765 rs2581799 ENSG00000242142.1 SERBP1P3 -6.32 1.49e-09 2.46e-06 -0.43 -0.39 Height; chr3:53074760 chr3:53064283~53065091:- CESC cis rs11155671 0.53 rs9383912 ENSG00000216906.2 RP11-350J20.9 6.32 1.49e-09 2.46e-06 0.42 0.39 Testicular germ cell tumor; chr6:149885479 chr6:149904243~149906418:+ CESC cis rs12439619 0.693 rs4778989 ENSG00000278603.1 RP13-608F4.5 6.31 1.5e-09 2.47e-06 0.59 0.39 Intelligence (multi-trait analysis); chr15:82276963 chr15:82472203~82472426:+ CESC cis rs2404602 0.647 rs12440511 ENSG00000259422.1 RP11-593F23.1 -6.31 1.5e-09 2.47e-06 -0.48 -0.39 Blood metabolite levels; chr15:76700794 chr15:76174891~76181486:- CESC cis rs6991838 0.584 rs7459944 ENSG00000200714.1 Y_RNA -6.31 1.5e-09 2.48e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65566040 chr8:65592731~65592820:+ CESC cis rs875971 1 rs2087647 ENSG00000222364.1 RNU6-96P 6.31 1.51e-09 2.48e-06 0.46 0.39 Aortic root size; chr7:66128201 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6958484 ENSG00000222364.1 RNU6-96P 6.31 1.51e-09 2.48e-06 0.46 0.39 Aortic root size; chr7:66134459 chr7:66395191~66395286:+ CESC cis rs897984 0.609 rs732172 ENSG00000260911.2 RP11-196G11.2 6.31 1.51e-09 2.49e-06 0.41 0.39 Dementia with Lewy bodies; chr16:31038712 chr16:31043150~31049868:+ CESC cis rs8072100 0.934 rs8067286 ENSG00000228782.6 CTD-2026D20.3 -6.31 1.51e-09 2.49e-06 -0.44 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47517224 chr17:47450568~47492492:- CESC cis rs10463554 0.963 rs28301 ENSG00000175749.11 EIF3KP1 6.31 1.51e-09 2.49e-06 0.43 0.39 Parkinson's disease; chr5:103105778 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs34828 ENSG00000175749.11 EIF3KP1 6.31 1.51e-09 2.49e-06 0.43 0.39 Parkinson's disease; chr5:103107209 chr5:103032376~103033031:+ CESC cis rs6452524 0.562 rs10474080 ENSG00000249664.1 CTD-2227C6.2 6.31 1.52e-09 2.5e-06 0.47 0.39 Hypertension (SNP x SNP interaction); chr5:83078300 chr5:83012285~83013109:- CESC cis rs1823913 0.599 rs17511410 ENSG00000280083.1 RP11-317J9.1 -6.31 1.52e-09 2.5e-06 -0.46 -0.39 Obesity-related traits; chr2:191278043 chr2:191154118~191156070:- CESC cis rs11155671 0.53 rs4870080 ENSG00000216906.2 RP11-350J20.9 6.31 1.52e-09 2.5e-06 0.44 0.39 Testicular germ cell tumor; chr6:149881508 chr6:149904243~149906418:+ CESC cis rs507080 0.922 rs558907 ENSG00000255422.1 AP002954.4 -6.31 1.52e-09 2.5e-06 -0.48 -0.39 Serum metabolite levels; chr11:118687746 chr11:118704607~118750263:+ CESC cis rs507080 0.885 rs7926959 ENSG00000255422.1 AP002954.4 -6.31 1.52e-09 2.5e-06 -0.48 -0.39 Serum metabolite levels; chr11:118689157 chr11:118704607~118750263:+ CESC cis rs507080 0.663 rs7926970 ENSG00000255422.1 AP002954.4 -6.31 1.52e-09 2.5e-06 -0.48 -0.39 Serum metabolite levels; chr11:118689172 chr11:118704607~118750263:+ CESC cis rs950169 0.922 rs62021167 ENSG00000225151.9 GOLGA2P7 -6.31 1.52e-09 2.5e-06 -0.53 -0.39 Schizophrenia; chr15:84574820 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs11633534 ENSG00000225151.9 GOLGA2P7 -6.31 1.52e-09 2.5e-06 -0.53 -0.39 Schizophrenia; chr15:84581411 chr15:84199311~84230136:- CESC cis rs950169 0.65 rs12902052 ENSG00000225151.9 GOLGA2P7 -6.31 1.52e-09 2.5e-06 -0.53 -0.39 Schizophrenia; chr15:84582607 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs17531523 ENSG00000225151.9 GOLGA2P7 -6.31 1.52e-09 2.5e-06 -0.53 -0.39 Schizophrenia; chr15:84589218 chr15:84199311~84230136:- CESC cis rs10256972 0.721 rs4720249 ENSG00000229043.2 AC091729.9 -6.31 1.52e-09 2.5e-06 -0.45 -0.39 Endometriosis;Longevity; chr7:1032927 chr7:1160374~1165267:+ CESC cis rs9399135 0.967 rs2297340 ENSG00000232876.1 CTA-212D2.2 -6.31 1.52e-09 2.5e-06 -0.45 -0.39 Red blood cell count; chr6:135054920 chr6:135055033~135060550:+ CESC cis rs10256972 0.758 rs4723649 ENSG00000229043.2 AC091729.9 -6.31 1.53e-09 2.51e-06 -0.45 -0.39 Endometriosis;Longevity; chr7:1032269 chr7:1160374~1165267:+ CESC cis rs9584850 0.874 rs9168 ENSG00000231194.1 FARP1-AS1 6.31 1.53e-09 2.51e-06 0.51 0.39 Neuroticism; chr13:98449329 chr13:98435405~98435840:- CESC cis rs150992 0.574 rs2927655 ENSG00000248489.1 CTD-2007H13.3 6.31 1.54e-09 2.53e-06 0.46 0.39 Body mass index; chr5:98839049 chr5:98929171~98995013:+ CESC cis rs2404602 0.647 rs907593 ENSG00000259422.1 RP11-593F23.1 -6.31 1.54e-09 2.53e-06 -0.48 -0.39 Blood metabolite levels; chr15:76904612 chr15:76174891~76181486:- CESC cis rs9399135 0.967 rs6915770 ENSG00000232876.1 CTA-212D2.2 -6.31 1.55e-09 2.55e-06 -0.45 -0.39 Red blood cell count; chr6:135048076 chr6:135055033~135060550:+ CESC cis rs9399135 0.935 rs9376086 ENSG00000232876.1 CTA-212D2.2 -6.31 1.55e-09 2.55e-06 -0.45 -0.39 Red blood cell count; chr6:135050191 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs1041480 ENSG00000232876.1 CTA-212D2.2 -6.31 1.55e-09 2.55e-06 -0.45 -0.39 Red blood cell count; chr6:135051938 chr6:135055033~135060550:+ CESC cis rs10875746 0.855 rs73102067 ENSG00000240399.1 RP1-228P16.1 -6.31 1.55e-09 2.55e-06 -0.52 -0.39 Longevity (90 years and older); chr12:48100643 chr12:48054813~48055591:- CESC cis rs6452524 0.967 rs11741420 ENSG00000249664.1 CTD-2227C6.2 6.31 1.56e-09 2.55e-06 0.43 0.39 Hypertension (SNP x SNP interaction); chr5:83174913 chr5:83012285~83013109:- CESC cis rs1061377 1 rs6829450 ENSG00000249207.1 RP11-360F5.1 -6.31 1.56e-09 2.56e-06 -0.45 -0.39 Uric acid levels; chr4:39114721 chr4:39112677~39126818:- CESC cis rs4853012 0.838 rs4452177 ENSG00000257800.1 FNBP1P1 6.31 1.56e-09 2.56e-06 0.4 0.39 Gestational age at birth (maternal effect); chr2:74118079 chr2:74120680~74123218:+ CESC cis rs3806843 1 rs10072015 ENSG00000202111.1 VTRNA1-2 6.31 1.58e-09 2.58e-06 0.4 0.39 Depressive symptoms (multi-trait analysis); chr5:140791070 chr5:140718925~140719013:+ CESC cis rs7727544 0.661 rs273900 ENSG00000233006.5 AC034220.3 6.31 1.58e-09 2.58e-06 0.44 0.39 Blood metabolite levels; chr5:132358913 chr5:132311285~132369916:- CESC cis rs9399137 0.507 rs11757723 ENSG00000232876.1 CTA-212D2.2 -6.31 1.58e-09 2.59e-06 -0.49 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134970155 chr6:135055033~135060550:+ CESC cis rs1707322 1 rs6675222 ENSG00000280836.1 AL355480.1 -6.3 1.58e-09 2.59e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45860904 chr1:45581219~45581321:- CESC cis rs42490 1 rs43134 ENSG00000251136.7 RP11-37B2.1 6.3 1.59e-09 2.6e-06 0.39 0.39 Leprosy; chr8:89775732 chr8:89609409~89757727:- CESC cis rs1061377 1 rs1982009 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39123253 chr4:39112677~39126818:- CESC cis rs1061377 0.965 rs1138494 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39123315 chr4:39112677~39126818:- CESC cis rs1061377 1 rs2890659 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39125401 chr4:39112677~39126818:- CESC cis rs1061377 0.965 rs1046655 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39126127 chr4:39112677~39126818:- CESC cis rs1061377 1 rs7694760 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39126481 chr4:39112677~39126818:- CESC cis rs1061377 1 rs35116118 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39127293 chr4:39112677~39126818:- CESC cis rs1061377 0.932 rs35464499 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39127670 chr4:39112677~39126818:- CESC cis rs1061377 0.965 rs11728058 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39128224 chr4:39112677~39126818:- CESC cis rs1061377 1 rs17508864 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39129025 chr4:39112677~39126818:- CESC cis rs1061377 1 rs1897136 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39131242 chr4:39112677~39126818:- CESC cis rs1061377 1 rs1897137 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39131387 chr4:39112677~39126818:- CESC cis rs1061377 1 rs35437629 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39131712 chr4:39112677~39126818:- CESC cis rs1061377 1 rs7657926 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39132443 chr4:39112677~39126818:- CESC cis rs1061377 1 rs7681116 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39133015 chr4:39112677~39126818:- CESC cis rs1061377 1 rs11096982 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39133247 chr4:39112677~39126818:- CESC cis rs1061377 1 rs11727875 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39133699 chr4:39112677~39126818:- CESC cis rs1061377 0.965 rs10018622 ENSG00000249207.1 RP11-360F5.1 -6.3 1.59e-09 2.6e-06 -0.44 -0.39 Uric acid levels; chr4:39133944 chr4:39112677~39126818:- CESC cis rs2117029 0.587 rs1865157 ENSG00000258017.1 RP11-386G11.10 -6.3 1.6e-09 2.61e-06 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49129003 chr12:49127782~49147869:+ CESC cis rs875971 1 rs6961717 ENSG00000222364.1 RNU6-96P 6.3 1.6e-09 2.62e-06 0.46 0.39 Aortic root size; chr7:66122550 chr7:66395191~66395286:+ CESC cis rs9399137 0.507 rs4520025 ENSG00000232876.1 CTA-212D2.2 -6.3 1.61e-09 2.64e-06 -0.49 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134957481 chr6:135055033~135060550:+ CESC cis rs1062177 0.826 rs2915879 ENSG00000253921.1 CTB-113P19.3 -6.3 1.62e-09 2.65e-06 -0.5 -0.39 Preschool internalizing problems; chr5:151767881 chr5:151753992~151767247:+ CESC cis rs9399137 0.507 rs11154791 ENSG00000232876.1 CTA-212D2.2 -6.3 1.63e-09 2.66e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135058010 chr6:135055033~135060550:+ CESC cis rs507080 0.922 rs4938524 ENSG00000255422.1 AP002954.4 -6.3 1.63e-09 2.66e-06 -0.48 -0.39 Serum metabolite levels; chr11:118681365 chr11:118704607~118750263:+ CESC cis rs10256972 0.721 rs2030959 ENSG00000229043.2 AC091729.9 -6.3 1.64e-09 2.68e-06 -0.44 -0.39 Endometriosis;Longevity; chr7:1036270 chr7:1160374~1165267:+ CESC cis rs875971 0.862 rs4718330 ENSG00000226824.5 RP4-756H11.3 6.3 1.65e-09 2.69e-06 0.47 0.39 Aortic root size; chr7:66250256 chr7:66654538~66669855:+ CESC cis rs11155671 0.53 rs9322228 ENSG00000216906.2 RP11-350J20.9 6.3 1.65e-09 2.69e-06 0.42 0.39 Testicular germ cell tumor; chr6:149888173 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs7774787 ENSG00000216906.2 RP11-350J20.9 6.3 1.65e-09 2.69e-06 0.42 0.39 Testicular germ cell tumor; chr6:149888296 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs2342767 ENSG00000216906.2 RP11-350J20.9 6.3 1.65e-09 2.69e-06 0.42 0.39 Testicular germ cell tumor; chr6:149888581 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs7764376 ENSG00000216906.2 RP11-350J20.9 6.3 1.65e-09 2.69e-06 0.42 0.39 Testicular germ cell tumor; chr6:149889208 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs6933882 ENSG00000216906.2 RP11-350J20.9 6.3 1.65e-09 2.69e-06 0.42 0.39 Testicular germ cell tumor; chr6:149889666 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs6939761 ENSG00000216906.2 RP11-350J20.9 6.3 1.65e-09 2.69e-06 0.42 0.39 Testicular germ cell tumor; chr6:149889858 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs3823021 ENSG00000216906.2 RP11-350J20.9 6.3 1.65e-09 2.69e-06 0.42 0.39 Testicular germ cell tumor; chr6:149889863 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs4869764 ENSG00000216906.2 RP11-350J20.9 6.3 1.65e-09 2.69e-06 0.42 0.39 Testicular germ cell tumor; chr6:149890692 chr6:149904243~149906418:+ CESC cis rs10256972 0.721 rs6975972 ENSG00000229043.2 AC091729.9 -6.3 1.65e-09 2.69e-06 -0.45 -0.39 Endometriosis;Longevity; chr7:1030832 chr7:1160374~1165267:+ CESC cis rs10463554 0.889 rs34822 ENSG00000175749.11 EIF3KP1 6.3 1.65e-09 2.69e-06 0.42 0.39 Parkinson's disease; chr5:103102007 chr5:103032376~103033031:+ CESC cis rs11168854 0.62 rs11168888 ENSG00000258017.1 RP11-386G11.10 -6.3 1.65e-09 2.7e-06 -0.52 -0.39 Body mass index; chr12:49149614 chr12:49127782~49147869:+ CESC cis rs1707322 1 rs4660336 ENSG00000280836.1 AL355480.1 6.3 1.66e-09 2.7e-06 0.46 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46022304 chr1:45581219~45581321:- CESC cis rs992157 0.835 rs34353396 ENSG00000261338.2 RP11-378A13.1 -6.3 1.66e-09 2.71e-06 -0.5 -0.39 Colorectal cancer; chr2:218289259 chr2:218255319~218257366:+ CESC cis rs11155671 0.53 rs7768626 ENSG00000216906.2 RP11-350J20.9 6.3 1.66e-09 2.71e-06 0.42 0.39 Testicular germ cell tumor; chr6:149886826 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs7768665 ENSG00000216906.2 RP11-350J20.9 6.3 1.66e-09 2.71e-06 0.42 0.39 Testicular germ cell tumor; chr6:149886888 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs7758020 ENSG00000216906.2 RP11-350J20.9 6.3 1.66e-09 2.71e-06 0.42 0.39 Testicular germ cell tumor; chr6:149886975 chr6:149904243~149906418:+ CESC cis rs10463554 0.963 rs154355 ENSG00000175749.11 EIF3KP1 6.3 1.66e-09 2.71e-06 0.42 0.39 Parkinson's disease; chr5:103163177 chr5:103032376~103033031:+ CESC cis rs26232 0.517 rs154356 ENSG00000175749.11 EIF3KP1 6.3 1.66e-09 2.71e-06 0.42 0.39 Rheumatoid arthritis; chr5:103163440 chr5:103032376~103033031:+ CESC cis rs9322193 0.567 rs7742692 ENSG00000268592.3 RAET1E-AS1 6.3 1.66e-09 2.71e-06 0.49 0.39 Lung cancer; chr6:149892363 chr6:149863494~149919507:+ CESC cis rs1577917 0.958 rs13219504 ENSG00000203875.9 SNHG5 -6.3 1.66e-09 2.71e-06 -0.51 -0.39 Response to antipsychotic treatment; chr6:85847199 chr6:85660950~85678736:- CESC cis rs1062177 0.901 rs1549622 ENSG00000253921.1 CTB-113P19.3 -6.29 1.67e-09 2.72e-06 -0.52 -0.39 Preschool internalizing problems; chr5:151886488 chr5:151753992~151767247:+ CESC cis rs875971 1 rs875971 ENSG00000222364.1 RNU6-96P 6.29 1.68e-09 2.74e-06 0.45 0.39 Aortic root size; chr7:66152608 chr7:66395191~66395286:+ CESC cis rs875971 1 rs937495 ENSG00000222364.1 RNU6-96P 6.29 1.69e-09 2.74e-06 0.45 0.39 Aortic root size; chr7:66314811 chr7:66395191~66395286:+ CESC cis rs1707322 1 rs12403666 ENSG00000280836.1 AL355480.1 -6.29 1.69e-09 2.76e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45965949 chr1:45581219~45581321:- CESC cis rs6452524 0.868 rs1564379 ENSG00000249664.1 CTD-2227C6.2 6.29 1.7e-09 2.77e-06 0.44 0.39 Hypertension (SNP x SNP interaction); chr5:83082143 chr5:83012285~83013109:- CESC cis rs2739330 0.76 rs5760095 ENSG00000231271.1 AP000350.8 6.29 1.71e-09 2.78e-06 0.49 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23949918~23954042:+ CESC cis rs9549367 0.713 rs510160 ENSG00000269125.1 RP11-98F14.11 6.29 1.71e-09 2.78e-06 0.5 0.39 Platelet distribution width; chr13:113168167 chr13:113165002~113165183:- CESC cis rs9399135 0.66 rs4472368 ENSG00000232876.1 CTA-212D2.2 -6.29 1.72e-09 2.79e-06 -0.45 -0.39 Red blood cell count; chr6:134953094 chr6:135055033~135060550:+ CESC cis rs6991838 0.584 rs4275254 ENSG00000200714.1 Y_RNA -6.29 1.72e-09 2.8e-06 -0.48 -0.39 Intelligence (multi-trait analysis); chr8:65589129 chr8:65592731~65592820:+ CESC cis rs3931020 1 rs12410060 ENSG00000272864.1 RP11-17E13.2 -6.29 1.73e-09 2.81e-06 -0.49 -0.39 Resistin levels; chr1:74780164 chr1:74698769~74699333:- CESC cis rs6142102 0.602 rs2268086 ENSG00000275784.1 RP5-1125A11.6 6.29 1.73e-09 2.81e-06 0.38 0.39 Skin pigmentation; chr20:34060932 chr20:33989480~33991818:- CESC cis rs1707322 0.717 rs1547925 ENSG00000281133.1 AL355480.3 6.29 1.73e-09 2.81e-06 0.46 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619684 chr1:45580892~45580996:- CESC cis rs950169 0.887 rs220333 ENSG00000225151.9 GOLGA2P7 -6.29 1.73e-09 2.82e-06 -0.54 -0.39 Schizophrenia; chr15:84547902 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs11630507 ENSG00000225151.9 GOLGA2P7 -6.29 1.73e-09 2.82e-06 -0.54 -0.39 Schizophrenia; chr15:84552494 chr15:84199311~84230136:- CESC cis rs8005677 0.828 rs712486 ENSG00000279656.1 RP11-298I3.6 6.29 1.74e-09 2.82e-06 0.47 0.39 Cognitive ability (multi-trait analysis); chr14:22955832 chr14:23023083~23024217:- CESC cis rs9399135 0.933 rs41294852 ENSG00000232876.1 CTA-212D2.2 -6.29 1.74e-09 2.82e-06 -0.45 -0.39 Red blood cell count; chr6:135055241 chr6:135055033~135060550:+ CESC cis rs2117029 0.521 rs58336603 ENSG00000258017.1 RP11-386G11.10 -6.29 1.74e-09 2.82e-06 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49163105 chr12:49127782~49147869:+ CESC cis rs2117029 0.553 rs1991427 ENSG00000258017.1 RP11-386G11.10 -6.29 1.74e-09 2.82e-06 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49164175 chr12:49127782~49147869:+ CESC cis rs2117029 0.521 rs2114845 ENSG00000258017.1 RP11-386G11.10 -6.29 1.74e-09 2.82e-06 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49164750 chr12:49127782~49147869:+ CESC cis rs875971 0.838 rs2173570 ENSG00000222364.1 RNU6-96P 6.29 1.74e-09 2.82e-06 0.44 0.39 Aortic root size; chr7:66297976 chr7:66395191~66395286:+ CESC cis rs6452524 0.967 rs62372752 ENSG00000249664.1 CTD-2227C6.2 6.29 1.74e-09 2.82e-06 0.45 0.39 Hypertension (SNP x SNP interaction); chr5:83134239 chr5:83012285~83013109:- CESC cis rs2739330 0.76 rs5751760 ENSG00000231271.1 AP000350.8 6.29 1.74e-09 2.83e-06 0.48 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23949918~23954042:+ CESC cis rs8072100 0.688 rs12602134 ENSG00000228782.6 CTD-2026D20.3 -6.29 1.75e-09 2.84e-06 -0.44 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47504770 chr17:47450568~47492492:- CESC cis rs8072100 0.875 rs62073966 ENSG00000228782.6 CTD-2026D20.3 -6.29 1.76e-09 2.85e-06 -0.44 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47522647 chr17:47450568~47492492:- CESC cis rs228614 0.51 rs223452 ENSG00000246560.2 RP11-10L12.4 6.29 1.76e-09 2.85e-06 0.48 0.39 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102790277 chr4:102828055~102844075:+ CESC cis rs9322193 0.504 rs7771014 ENSG00000216906.2 RP11-350J20.9 6.28 1.76e-09 2.86e-06 0.43 0.39 Lung cancer; chr6:149884310 chr6:149904243~149906418:+ CESC cis rs77505915 0.512 rs12921808 ENSG00000261783.1 RP11-252K23.2 6.28 1.77e-09 2.86e-06 0.56 0.39 Migraine; chr16:75350086 chr16:75379818~75381260:- CESC cis rs7727544 0.735 rs274558 ENSG00000233006.5 AC034220.3 -6.28 1.77e-09 2.87e-06 -0.43 -0.39 Blood metabolite levels; chr5:132385482 chr5:132311285~132369916:- CESC cis rs7727544 0.735 rs274557 ENSG00000233006.5 AC034220.3 -6.28 1.77e-09 2.87e-06 -0.43 -0.39 Blood metabolite levels; chr5:132385512 chr5:132311285~132369916:- CESC cis rs10463554 0.892 rs158408 ENSG00000175749.11 EIF3KP1 6.28 1.78e-09 2.88e-06 0.41 0.39 Parkinson's disease; chr5:103071670 chr5:103032376~103033031:+ CESC cis rs2404602 0.575 rs11633309 ENSG00000259422.1 RP11-593F23.1 -6.28 1.78e-09 2.88e-06 -0.49 -0.39 Blood metabolite levels; chr15:76670008 chr15:76174891~76181486:- CESC cis rs875971 1 rs11971949 ENSG00000222364.1 RNU6-96P 6.28 1.79e-09 2.89e-06 0.45 0.39 Aortic root size; chr7:66161027 chr7:66395191~66395286:+ CESC cis rs14027 0.921 rs13262434 ENSG00000279347.1 RP11-85I17.2 -6.28 1.8e-09 2.91e-06 -0.39 -0.39 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119733423 chr8:119838736~119840385:- CESC cis rs526231 0.543 rs7709726 ENSG00000175749.11 EIF3KP1 -6.28 1.8e-09 2.91e-06 -0.41 -0.39 Primary biliary cholangitis; chr5:102991759 chr5:103032376~103033031:+ CESC cis rs875971 0.867 rs13227219 ENSG00000222364.1 RNU6-96P -6.28 1.81e-09 2.92e-06 -0.48 -0.39 Aortic root size; chr7:66379075 chr7:66395191~66395286:+ CESC cis rs11155671 0.53 rs7757984 ENSG00000268592.3 RAET1E-AS1 6.28 1.81e-09 2.92e-06 0.49 0.39 Testicular germ cell tumor; chr6:149887515 chr6:149863494~149919507:+ CESC cis rs6860806 0.507 rs272878 ENSG00000233006.5 AC034220.3 -6.28 1.81e-09 2.93e-06 -0.43 -0.39 Breast cancer; chr5:132336076 chr5:132311285~132369916:- CESC cis rs10256972 0.758 rs2280724 ENSG00000229043.2 AC091729.9 -6.28 1.81e-09 2.93e-06 -0.45 -0.39 Endometriosis;Longevity; chr7:1025084 chr7:1160374~1165267:+ CESC cis rs7727544 0.735 rs270605 ENSG00000233006.5 AC034220.3 6.28 1.81e-09 2.93e-06 0.43 0.39 Blood metabolite levels; chr5:132316118 chr5:132311285~132369916:- CESC cis rs1707322 1 rs785507 ENSG00000280836.1 AL355480.1 6.28 1.82e-09 2.94e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46075886 chr1:45581219~45581321:- CESC cis rs10463554 0.824 rs34818 ENSG00000175749.11 EIF3KP1 6.28 1.82e-09 2.94e-06 0.42 0.39 Parkinson's disease; chr5:103100407 chr5:103032376~103033031:+ CESC cis rs7188445 0.592 rs7196490 ENSG00000261390.4 RP11-345M22.2 -6.28 1.82e-09 2.94e-06 -0.48 -0.39 Urate levels; chr16:79718572 chr16:79715232~79770563:- CESC cis rs2739330 0.828 rs4822454 ENSG00000250470.1 AP000351.3 6.28 1.83e-09 2.96e-06 0.49 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23976904~23977585:- CESC cis rs2404602 0.647 rs12913024 ENSG00000259422.1 RP11-593F23.1 -6.28 1.83e-09 2.96e-06 -0.48 -0.39 Blood metabolite levels; chr15:76852875 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs2404600 ENSG00000259422.1 RP11-593F23.1 -6.28 1.83e-09 2.96e-06 -0.48 -0.39 Blood metabolite levels; chr15:76881216 chr15:76174891~76181486:- CESC cis rs10875746 0.903 rs2158516 ENSG00000240399.1 RP1-228P16.1 -6.28 1.84e-09 2.97e-06 -0.51 -0.39 Longevity (90 years and older); chr12:48097051 chr12:48054813~48055591:- CESC cis rs10875746 0.855 rs73102065 ENSG00000240399.1 RP1-228P16.1 -6.28 1.84e-09 2.97e-06 -0.51 -0.39 Longevity (90 years and older); chr12:48098824 chr12:48054813~48055591:- CESC cis rs1707322 1 rs11211248 ENSG00000280836.1 AL355480.1 -6.28 1.84e-09 2.98e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46011172 chr1:45581219~45581321:- CESC cis rs6504950 1 rs9892848 ENSG00000275710.1 RP11-257O5.4 6.28 1.85e-09 2.98e-06 0.49 0.39 Breast cancer; chr17:54982414 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9890971 ENSG00000275710.1 RP11-257O5.4 6.28 1.85e-09 2.98e-06 0.49 0.39 Breast cancer; chr17:54982415 chr17:54964474~54964679:+ CESC cis rs6991838 0.584 rs1053087 ENSG00000200714.1 Y_RNA -6.28 1.86e-09 3e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65603630 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs1053085 ENSG00000200714.1 Y_RNA -6.28 1.86e-09 3e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65603753 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs4737747 ENSG00000200714.1 Y_RNA -6.28 1.86e-09 3e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65607024 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs73236948 ENSG00000200714.1 Y_RNA -6.28 1.86e-09 3e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65609176 chr8:65592731~65592820:+ CESC cis rs950169 0.84 rs12905223 ENSG00000225151.9 GOLGA2P7 -6.27 1.87e-09 3.01e-06 -0.53 -0.39 Schizophrenia; chr15:84571037 chr15:84199311~84230136:- CESC cis rs1707322 1 rs34694458 ENSG00000280836.1 AL355480.1 -6.27 1.87e-09 3.02e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45867024 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4660334 ENSG00000280836.1 AL355480.1 -6.27 1.87e-09 3.02e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45996454 chr1:45581219~45581321:- CESC cis rs2404602 0.647 rs2404604 ENSG00000259422.1 RP11-593F23.1 -6.27 1.89e-09 3.05e-06 -0.48 -0.39 Blood metabolite levels; chr15:76698764 chr15:76174891~76181486:- CESC cis rs875971 0.862 rs778724 ENSG00000226824.5 RP4-756H11.3 -6.27 1.9e-09 3.07e-06 -0.49 -0.39 Aortic root size; chr7:66364304 chr7:66654538~66669855:+ CESC cis rs8081395 0.741 rs1292055 ENSG00000266992.1 DHX40P1 6.27 1.91e-09 3.08e-06 0.43 0.39 White blood cell count; chr17:59881707 chr17:59976009~60002384:- CESC cis rs9399135 0.967 rs6919862 ENSG00000232876.1 CTA-212D2.2 -6.27 1.92e-09 3.09e-06 -0.45 -0.39 Red blood cell count; chr6:135031305 chr6:135055033~135060550:+ CESC cis rs507080 0.885 rs693037 ENSG00000255422.1 AP002954.4 -6.27 1.92e-09 3.09e-06 -0.48 -0.39 Serum metabolite levels; chr11:118682617 chr11:118704607~118750263:+ CESC cis rs2404602 0.647 rs10851892 ENSG00000259422.1 RP11-593F23.1 -6.27 1.92e-09 3.09e-06 -0.48 -0.39 Blood metabolite levels; chr15:76884150 chr15:76174891~76181486:- CESC cis rs10129255 0.556 rs8010005 ENSG00000223648.3 IGHV3-64 6.27 1.92e-09 3.09e-06 0.32 0.39 Kawasaki disease; chr14:106777987 chr14:106643132~106658258:- CESC cis rs10129255 0.556 rs6576224 ENSG00000223648.3 IGHV3-64 6.27 1.92e-09 3.09e-06 0.32 0.39 Kawasaki disease; chr14:106777997 chr14:106643132~106658258:- CESC cis rs10129255 0.518 rs8010020 ENSG00000223648.3 IGHV3-64 6.27 1.92e-09 3.09e-06 0.32 0.39 Kawasaki disease; chr14:106778016 chr14:106643132~106658258:- CESC cis rs8081395 0.805 rs2645485 ENSG00000266992.1 DHX40P1 6.27 1.92e-09 3.09e-06 0.43 0.39 White blood cell count; chr17:59866920 chr17:59976009~60002384:- CESC cis rs2404602 0.716 rs17460201 ENSG00000259422.1 RP11-593F23.1 -6.27 1.92e-09 3.1e-06 -0.43 -0.39 Blood metabolite levels; chr15:76381286 chr15:76174891~76181486:- CESC cis rs9399135 0.844 rs13209789 ENSG00000232876.1 CTA-212D2.2 -6.27 1.93e-09 3.1e-06 -0.45 -0.39 Red blood cell count; chr6:135046778 chr6:135055033~135060550:+ CESC cis rs997154 0.655 rs4981454 ENSG00000279656.1 RP11-298I3.6 6.27 1.93e-09 3.1e-06 0.59 0.39 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22952977 chr14:23023083~23024217:- CESC cis rs1707322 1 rs6687301 ENSG00000280836.1 AL355480.1 -6.27 1.93e-09 3.1e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45917180 chr1:45581219~45581321:- CESC cis rs4718428 0.705 rs10267335 ENSG00000226824.5 RP4-756H11.3 -6.27 1.93e-09 3.1e-06 -0.54 -0.39 Corneal structure; chr7:66938233 chr7:66654538~66669855:+ CESC cis rs11155671 0.53 rs9397420 ENSG00000216906.2 RP11-350J20.9 -6.27 1.93e-09 3.11e-06 -0.42 -0.39 Testicular germ cell tumor; chr6:149885645 chr6:149904243~149906418:+ CESC cis rs6860806 0.531 rs270607 ENSG00000233006.5 AC034220.3 6.27 1.93e-09 3.11e-06 0.43 0.39 Breast cancer; chr5:132313493 chr5:132311285~132369916:- CESC cis rs6504950 1 rs8080491 ENSG00000275710.1 RP11-257O5.4 6.27 1.94e-09 3.12e-06 0.48 0.39 Breast cancer; chr17:54972508 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs6504948 ENSG00000275710.1 RP11-257O5.4 6.27 1.94e-09 3.12e-06 0.48 0.39 Breast cancer; chr17:54972626 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs6504949 ENSG00000275710.1 RP11-257O5.4 6.27 1.94e-09 3.12e-06 0.48 0.39 Breast cancer; chr17:54972772 chr17:54964474~54964679:+ CESC cis rs10463554 0.963 rs257115 ENSG00000175749.11 EIF3KP1 6.27 1.94e-09 3.12e-06 0.41 0.39 Parkinson's disease; chr5:103196107 chr5:103032376~103033031:+ CESC cis rs875971 0.867 rs1002053 ENSG00000222364.1 RNU6-96P 6.27 1.94e-09 3.12e-06 0.46 0.39 Aortic root size; chr7:66333558 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6460292 ENSG00000222364.1 RNU6-96P 6.27 1.94e-09 3.12e-06 0.46 0.39 Aortic root size; chr7:66345088 chr7:66395191~66395286:+ CESC cis rs9399135 0.967 rs34546690 ENSG00000232876.1 CTA-212D2.2 -6.27 1.96e-09 3.15e-06 -0.45 -0.39 Red blood cell count; chr6:135048571 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs9373122 ENSG00000232876.1 CTA-212D2.2 -6.27 1.96e-09 3.15e-06 -0.45 -0.39 Red blood cell count; chr6:135052396 chr6:135055033~135060550:+ CESC cis rs4718428 0.607 rs66954441 ENSG00000226824.5 RP4-756H11.3 -6.27 1.96e-09 3.15e-06 -0.54 -0.39 Corneal structure; chr7:66904222 chr7:66654538~66669855:+ CESC cis rs3806843 0.966 rs2563263 ENSG00000202111.1 VTRNA1-2 -6.27 1.96e-09 3.15e-06 -0.41 -0.39 Depressive symptoms (multi-trait analysis); chr5:140758059 chr5:140718925~140719013:+ CESC cis rs526231 0.543 rs152137 ENSG00000175749.11 EIF3KP1 6.27 1.96e-09 3.15e-06 0.47 0.39 Primary biliary cholangitis; chr5:103224362 chr5:103032376~103033031:+ CESC cis rs14027 0.921 rs16893077 ENSG00000279347.1 RP11-85I17.2 -6.27 1.96e-09 3.15e-06 -0.37 -0.39 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119740332 chr8:119838736~119840385:- CESC cis rs7727544 0.735 rs274566 ENSG00000233006.5 AC034220.3 -6.26 1.97e-09 3.17e-06 -0.43 -0.39 Blood metabolite levels; chr5:132379319 chr5:132311285~132369916:- CESC cis rs11155671 0.53 rs9371544 ENSG00000268592.3 RAET1E-AS1 6.26 1.97e-09 3.17e-06 0.49 0.39 Testicular germ cell tumor; chr6:149896224 chr6:149863494~149919507:+ CESC cis rs1061377 1 rs34771104 ENSG00000249207.1 RP11-360F5.1 -6.26 1.97e-09 3.17e-06 -0.44 -0.39 Uric acid levels; chr4:39127432 chr4:39112677~39126818:- CESC cis rs2739330 0.828 rs2330635 ENSG00000250470.1 AP000351.3 6.26 1.98e-09 3.17e-06 0.5 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23976904~23977585:- CESC cis rs11155671 0.53 rs7757984 ENSG00000216906.2 RP11-350J20.9 6.26 1.98e-09 3.17e-06 0.42 0.39 Testicular germ cell tumor; chr6:149887515 chr6:149904243~149906418:+ CESC cis rs526231 0.578 rs35100629 ENSG00000175749.11 EIF3KP1 6.26 1.98e-09 3.18e-06 0.43 0.39 Primary biliary cholangitis; chr5:102910381 chr5:103032376~103033031:+ CESC cis rs2404602 0.71 rs2469541 ENSG00000259422.1 RP11-593F23.1 -6.26 1.98e-09 3.18e-06 -0.45 -0.39 Blood metabolite levels; chr15:76269777 chr15:76174891~76181486:- CESC cis rs9399137 0.507 rs13196486 ENSG00000232876.1 CTA-212D2.2 -6.26 1.99e-09 3.19e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134962736 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs6918512 ENSG00000232876.1 CTA-212D2.2 -6.26 1.99e-09 3.19e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134963701 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs13064 ENSG00000232876.1 CTA-212D2.2 -6.26 1.99e-09 3.19e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134966395 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs35571217 ENSG00000232876.1 CTA-212D2.2 -6.26 1.99e-09 3.19e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134969217 chr6:135055033~135060550:+ CESC cis rs1707322 1 rs1612419 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46081273 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs785516 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46099086 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785517 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46101863 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785484 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46108343 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785490 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46111452 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785493 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46119187 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs785496 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46122334 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785497 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126231 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs785499 ENSG00000280836.1 AL355480.1 6.26 2e-09 3.2e-06 0.48 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126748 chr1:45581219~45581321:- CESC cis rs2404602 0.735 rs2468130 ENSG00000259422.1 RP11-593F23.1 -6.26 2e-09 3.21e-06 -0.47 -0.39 Blood metabolite levels; chr15:76504155 chr15:76174891~76181486:- CESC cis rs2404602 0.735 rs2461871 ENSG00000259422.1 RP11-593F23.1 -6.26 2e-09 3.21e-06 -0.47 -0.39 Blood metabolite levels; chr15:76530077 chr15:76174891~76181486:- CESC cis rs3806843 0.966 rs7710380 ENSG00000202111.1 VTRNA1-2 -6.26 2e-09 3.21e-06 -0.4 -0.39 Depressive symptoms (multi-trait analysis); chr5:140776679 chr5:140718925~140719013:+ CESC cis rs1499614 1 rs1638731 ENSG00000232559.3 GS1-124K5.12 6.26 2.01e-09 3.22e-06 0.69 0.39 Gout; chr7:66679692 chr7:66554588~66576923:- CESC cis rs8072100 0.539 rs36043200 ENSG00000228782.6 CTD-2026D20.3 -6.26 2.01e-09 3.22e-06 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47552040 chr17:47450568~47492492:- CESC cis rs4718428 0.672 rs12530806 ENSG00000226824.5 RP4-756H11.3 -6.26 2.01e-09 3.22e-06 -0.54 -0.39 Corneal structure; chr7:66925737 chr7:66654538~66669855:+ CESC cis rs274567 0.602 rs272853 ENSG00000233006.5 AC034220.3 6.26 2.02e-09 3.23e-06 0.42 0.39 Blood metabolite levels; chr5:132352868 chr5:132311285~132369916:- CESC cis rs875971 0.825 rs6951503 ENSG00000226824.5 RP4-756H11.3 6.26 2.02e-09 3.24e-06 0.48 0.39 Aortic root size; chr7:66253949 chr7:66654538~66669855:+ CESC cis rs1499614 1 rs1882655 ENSG00000232559.3 GS1-124K5.12 -6.26 2.03e-09 3.25e-06 -0.69 -0.39 Gout; chr7:66682070 chr7:66554588~66576923:- CESC cis rs1499614 0.831 rs3800822 ENSG00000232559.3 GS1-124K5.12 -6.26 2.03e-09 3.25e-06 -0.69 -0.39 Gout; chr7:66682162 chr7:66554588~66576923:- CESC cis rs11690935 0.959 rs12692973 ENSG00000228389.1 AC068039.4 -6.26 2.04e-09 3.27e-06 -0.51 -0.39 Schizophrenia; chr2:171785547 chr2:171773482~171775844:+ CESC cis rs1062177 0.774 rs2964574 ENSG00000213433.5 RPLP1P6 -6.26 2.04e-09 3.27e-06 -0.47 -0.39 Preschool internalizing problems; chr5:151776150 chr5:151765859~151766378:- CESC cis rs1062177 0.826 rs2915873 ENSG00000213433.5 RPLP1P6 -6.26 2.04e-09 3.27e-06 -0.47 -0.39 Preschool internalizing problems; chr5:151777097 chr5:151765859~151766378:- CESC cis rs2980439 0.818 rs2948294 ENSG00000173295.6 FAM86B3P 6.26 2.05e-09 3.28e-06 0.51 0.39 Neuroticism; chr8:8237439 chr8:8228595~8244865:+ CESC cis rs10129255 0.5 rs6576225 ENSG00000223648.3 IGHV3-64 6.26 2.06e-09 3.29e-06 0.32 0.39 Kawasaki disease; chr14:106778120 chr14:106643132~106658258:- CESC cis rs10129255 0.5 rs6576226 ENSG00000223648.3 IGHV3-64 6.26 2.06e-09 3.29e-06 0.32 0.39 Kawasaki disease; chr14:106778135 chr14:106643132~106658258:- CESC cis rs9907295 0.688 rs2251660 ENSG00000270977.1 AC015849.16 -6.26 2.06e-09 3.29e-06 -0.46 -0.39 Fibroblast growth factor basic levels; chr17:35925533 chr17:35893707~35911023:- CESC cis rs1823913 0.599 rs1378156 ENSG00000280083.1 RP11-317J9.1 6.26 2.06e-09 3.29e-06 0.45 0.39 Obesity-related traits; chr2:191272466 chr2:191154118~191156070:- CESC cis rs10463554 1 rs6879788 ENSG00000175749.11 EIF3KP1 6.26 2.06e-09 3.29e-06 0.41 0.39 Parkinson's disease; chr5:102978353 chr5:103032376~103033031:+ CESC cis rs9399135 0.967 rs12527683 ENSG00000232876.1 CTA-212D2.2 -6.26 2.07e-09 3.31e-06 -0.46 -0.39 Red blood cell count; chr6:135003396 chr6:135055033~135060550:+ CESC cis rs6991838 0.584 rs35790435 ENSG00000200714.1 Y_RNA -6.26 2.07e-09 3.31e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65590288 chr8:65592731~65592820:+ CESC cis rs507080 0.961 rs520543 ENSG00000255422.1 AP002954.4 -6.25 2.07e-09 3.31e-06 -0.46 -0.39 Serum metabolite levels; chr11:118667448 chr11:118704607~118750263:+ CESC cis rs997154 0.655 rs2008345 ENSG00000279656.1 RP11-298I3.6 6.25 2.08e-09 3.32e-06 0.59 0.39 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22932233 chr14:23023083~23024217:- CESC cis rs5760092 0.755 rs4585126 ENSG00000231271.1 AP000350.8 -6.25 2.08e-09 3.33e-06 -0.52 -0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23949918~23954042:+ CESC cis rs9399137 0.507 rs13209780 ENSG00000232876.1 CTA-212D2.2 -6.25 2.09e-09 3.34e-06 -0.47 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135023657 chr6:135055033~135060550:+ CESC cis rs11155671 0.53 rs7763849 ENSG00000268592.3 RAET1E-AS1 6.25 2.09e-09 3.34e-06 0.49 0.39 Testicular germ cell tumor; chr6:149885244 chr6:149863494~149919507:+ CESC cis rs950169 0.881 rs72750843 ENSG00000225151.9 GOLGA2P7 -6.25 2.1e-09 3.34e-06 -0.52 -0.39 Schizophrenia; chr15:84592552 chr15:84199311~84230136:- CESC cis rs2117029 0.521 rs6580702 ENSG00000258017.1 RP11-386G11.10 -6.25 2.1e-09 3.35e-06 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49169483 chr12:49127782~49147869:+ CESC cis rs1707322 1 rs7547189 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853842 chr1:45581219~45581321:- CESC cis rs1707322 1 rs7547284 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853893 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211205 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45856202 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4660895 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45864067 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4660318 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45869204 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10890360 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45872772 chr1:45581219~45581321:- CESC cis rs1707322 1 rs6682683 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45876665 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211217 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45882557 chr1:45581219~45581321:- CESC cis rs1707322 1 rs7553924 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45886952 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4641257 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45887917 chr1:45581219~45581321:- CESC cis rs1707322 1 rs6693336 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45888923 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4539075 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45892338 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211219 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893806 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211222 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45902085 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4524994 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45904591 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs9787412 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45905924 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4660896 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45906744 chr1:45581219~45581321:- CESC cis rs1707322 0.928 rs10732844 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45907016 chr1:45581219~45581321:- CESC cis rs1707322 1 rs12133129 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45907676 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs4553121 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45909581 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs6690652 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45911020 chr1:45581219~45581321:- CESC cis rs1707322 1 rs6695421 ENSG00000280836.1 AL355480.1 -6.25 2.12e-09 3.38e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45914535 chr1:45581219~45581321:- CESC cis rs2404602 0.552 rs11634428 ENSG00000259422.1 RP11-593F23.1 -6.25 2.13e-09 3.39e-06 -0.49 -0.39 Blood metabolite levels; chr15:76792241 chr15:76174891~76181486:- CESC cis rs9399137 0.507 rs6940878 ENSG00000232876.1 CTA-212D2.2 -6.25 2.13e-09 3.39e-06 -0.47 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135045171 chr6:135055033~135060550:+ CESC cis rs7727544 0.684 rs274561 ENSG00000233006.5 AC034220.3 6.25 2.13e-09 3.39e-06 0.43 0.39 Blood metabolite levels; chr5:132383536 chr5:132311285~132369916:- CESC cis rs5760092 0.755 rs915589 ENSG00000231271.1 AP000350.8 -6.25 2.14e-09 3.4e-06 -0.56 -0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23949918~23954042:+ CESC cis rs2117029 0.554 rs12579015 ENSG00000258017.1 RP11-386G11.10 -6.25 2.15e-09 3.42e-06 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49162648 chr12:49127782~49147869:+ CESC cis rs147858478 1 rs147858478 ENSG00000233006.5 AC034220.3 6.25 2.15e-09 3.42e-06 0.44 0.39 High light scatter reticulocyte percentage of red cells; chr5:132347099 chr5:132311285~132369916:- CESC cis rs2117029 0.521 rs11168885 ENSG00000258017.1 RP11-386G11.10 -6.25 2.15e-09 3.42e-06 -0.5 -0.39 Intelligence (multi-trait analysis); chr12:49146204 chr12:49127782~49147869:+ CESC cis rs8062405 0.965 rs8049439 ENSG00000259982.1 CDC37P1 6.25 2.16e-09 3.43e-06 0.45 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826194 chr16:28700294~28701540:- CESC cis rs6452524 1 rs7710900 ENSG00000249664.1 CTD-2227C6.2 6.25 2.16e-09 3.43e-06 0.43 0.39 Hypertension (SNP x SNP interaction); chr5:83137201 chr5:83012285~83013109:- CESC cis rs113835537 0.597 rs3737525 ENSG00000255517.5 CTD-3074O7.5 -6.25 2.16e-09 3.43e-06 -0.47 -0.39 Airway imaging phenotypes; chr11:66538884 chr11:66473490~66480233:- CESC cis rs1185460 1 rs1784305 ENSG00000271751.1 RP11-110I1.14 -6.25 2.17e-09 3.44e-06 -0.52 -0.39 Coronary artery disease; chr11:119071338 chr11:119065263~119065677:- CESC cis rs79349575 0.749 rs1057902 ENSG00000270781.1 RP11-501C14.9 -6.25 2.17e-09 3.45e-06 -0.44 -0.39 Type 2 diabetes; chr17:48928226 chr17:48899131~48899748:+ CESC cis rs1499614 1 rs2659913 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66692349 chr7:66554588~66576923:- CESC cis rs1499614 1 rs2659911 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66693433 chr7:66554588~66576923:- CESC cis rs1499614 1 rs2707838 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66694214 chr7:66554588~66576923:- CESC cis rs1499614 1 rs60326618 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66701371 chr7:66554588~66576923:- CESC cis rs1499614 1 rs2707830 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66702658 chr7:66554588~66576923:- CESC cis rs1499614 1 rs2707828 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66706390 chr7:66554588~66576923:- CESC cis rs1499614 0.803 rs1922723 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66710076 chr7:66554588~66576923:- CESC cis rs1499614 1 rs2659903 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66715944 chr7:66554588~66576923:- CESC cis rs1499614 1 rs2141924 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66721259 chr7:66554588~66576923:- CESC cis rs1499614 0.901 rs2178742 ENSG00000232559.3 GS1-124K5.12 6.25 2.17e-09 3.45e-06 0.68 0.39 Gout; chr7:66732812 chr7:66554588~66576923:- CESC cis rs3806843 0.932 rs2563269 ENSG00000202111.1 VTRNA1-2 6.25 2.17e-09 3.45e-06 0.4 0.39 Depressive symptoms (multi-trait analysis); chr5:140756883 chr5:140718925~140719013:+ CESC cis rs35955747 0.838 rs5997900 ENSG00000236132.1 CTA-440B3.1 6.25 2.18e-09 3.46e-06 0.45 0.39 Neutrophil count;Sum basophil neutrophil counts; chr22:31184360 chr22:31816379~31817491:- CESC cis rs6142102 0.625 rs4911384 ENSG00000275784.1 RP5-1125A11.6 -6.25 2.19e-09 3.47e-06 -0.38 -0.39 Skin pigmentation; chr20:33968001 chr20:33989480~33991818:- CESC cis rs1061377 1 rs9998481 ENSG00000249207.1 RP11-360F5.1 -6.25 2.19e-09 3.47e-06 -0.44 -0.39 Uric acid levels; chr4:39117215 chr4:39112677~39126818:- CESC cis rs1061377 1 rs9998867 ENSG00000249207.1 RP11-360F5.1 -6.25 2.19e-09 3.47e-06 -0.44 -0.39 Uric acid levels; chr4:39117542 chr4:39112677~39126818:- CESC cis rs1707322 0.65 rs4553239 ENSG00000281133.1 AL355480.3 -6.24 2.19e-09 3.47e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684814 chr1:45580892~45580996:- CESC cis rs875971 0.83 rs4718358 ENSG00000222364.1 RNU6-96P -6.24 2.2e-09 3.49e-06 -0.46 -0.39 Aortic root size; chr7:66508681 chr7:66395191~66395286:+ CESC cis rs4660456 0.913 rs2744808 ENSG00000237899.1 RP4-739H11.3 -6.24 2.21e-09 3.5e-06 -0.52 -0.39 Platelet count; chr1:40712271 chr1:40669089~40687588:- CESC cis rs9399137 0.507 rs12663810 ENSG00000232876.1 CTA-212D2.2 -6.24 2.22e-09 3.51e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134968644 chr6:135055033~135060550:+ CESC cis rs7201929 0.801 rs9933198 ENSG00000259982.1 CDC37P1 -6.24 2.22e-09 3.52e-06 -0.52 -0.39 QT interval; chr16:28877088 chr16:28700294~28701540:- CESC cis rs9399135 0.933 rs7755680 ENSG00000232876.1 CTA-212D2.2 -6.24 2.22e-09 3.52e-06 -0.46 -0.39 Red blood cell count; chr6:134973121 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs4895436 ENSG00000232876.1 CTA-212D2.2 -6.24 2.22e-09 3.52e-06 -0.46 -0.39 Red blood cell count; chr6:134973863 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs4896122 ENSG00000232876.1 CTA-212D2.2 -6.24 2.22e-09 3.52e-06 -0.46 -0.39 Red blood cell count; chr6:134973943 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs9376075 ENSG00000232876.1 CTA-212D2.2 -6.24 2.22e-09 3.52e-06 -0.46 -0.39 Red blood cell count; chr6:134975825 chr6:135055033~135060550:+ CESC cis rs9399135 0.935 rs4273704 ENSG00000232876.1 CTA-212D2.2 -6.24 2.22e-09 3.52e-06 -0.46 -0.39 Red blood cell count; chr6:134976382 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs4637662 ENSG00000232876.1 CTA-212D2.2 -6.24 2.22e-09 3.52e-06 -0.46 -0.39 Red blood cell count; chr6:134977020 chr6:135055033~135060550:+ CESC cis rs79349575 0.715 rs55724082 ENSG00000270781.1 RP11-501C14.9 -6.24 2.22e-09 3.52e-06 -0.44 -0.39 Type 2 diabetes; chr17:48940517 chr17:48899131~48899748:+ CESC cis rs2404602 0.647 rs11072631 ENSG00000259422.1 RP11-593F23.1 -6.24 2.22e-09 3.52e-06 -0.47 -0.39 Blood metabolite levels; chr15:76840568 chr15:76174891~76181486:- CESC cis rs2404602 0.647 rs55778276 ENSG00000259422.1 RP11-593F23.1 -6.24 2.22e-09 3.52e-06 -0.47 -0.39 Blood metabolite levels; chr15:76844249 chr15:76174891~76181486:- CESC cis rs3806843 0.966 rs10060640 ENSG00000202111.1 VTRNA1-2 -6.24 2.23e-09 3.52e-06 -0.41 -0.39 Depressive symptoms (multi-trait analysis); chr5:140831641 chr5:140718925~140719013:+ CESC cis rs10129255 0.5 rs34326748 ENSG00000223648.3 IGHV3-64 6.24 2.24e-09 3.54e-06 0.32 0.39 Kawasaki disease; chr14:106782523 chr14:106643132~106658258:- CESC cis rs10129255 0.5 rs10143385 ENSG00000223648.3 IGHV3-64 6.24 2.24e-09 3.54e-06 0.32 0.39 Kawasaki disease; chr14:106782559 chr14:106643132~106658258:- CESC cis rs4718428 0.705 rs28648401 ENSG00000226824.5 RP4-756H11.3 -6.24 2.24e-09 3.54e-06 -0.54 -0.39 Corneal structure; chr7:66902145 chr7:66654538~66669855:+ CESC cis rs9399135 0.967 rs4376365 ENSG00000232876.1 CTA-212D2.2 -6.24 2.24e-09 3.54e-06 -0.46 -0.39 Red blood cell count; chr6:134986602 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs13218642 ENSG00000232876.1 CTA-212D2.2 -6.24 2.24e-09 3.54e-06 -0.46 -0.39 Red blood cell count; chr6:134988802 chr6:135055033~135060550:+ CESC cis rs3806843 1 rs10477034 ENSG00000202111.1 VTRNA1-2 -6.24 2.25e-09 3.56e-06 -0.4 -0.39 Depressive symptoms (multi-trait analysis); chr5:140790145 chr5:140718925~140719013:+ CESC cis rs79349575 0.783 rs4399576 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48932473 chr17:48899131~48899748:+ CESC cis rs79349575 0.687 rs12602179 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48932672 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs17708633 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48934258 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs9747646 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48939520 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs62075852 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48939814 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs12601858 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48940115 chr17:48899131~48899748:+ CESC cis rs79349575 0.749 rs8182364 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48940663 chr17:48899131~48899748:+ CESC cis rs79349575 0.681 rs56080003 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48941687 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs4793995 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48942037 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs4793996 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48942235 chr17:48899131~48899748:+ CESC cis rs79349575 0.715 rs4793997 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48942310 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs4793998 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48942537 chr17:48899131~48899748:+ CESC cis rs79349575 0.749 rs2270574 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48944908 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs4794000 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48945393 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs58591767 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48948714 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs59270107 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48948823 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs62078370 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48949474 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs11079844 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48950972 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs62078372 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48951627 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs12602933 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48951918 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs4794003 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48952542 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs12602746 ENSG00000270781.1 RP11-501C14.9 -6.24 2.26e-09 3.56e-06 -0.44 -0.39 Type 2 diabetes; chr17:48954379 chr17:48899131~48899748:+ CESC cis rs9549367 0.713 rs1755690 ENSG00000269125.1 RP11-98F14.11 6.24 2.26e-09 3.57e-06 0.49 0.39 Platelet distribution width; chr13:113169952 chr13:113165002~113165183:- CESC cis rs875971 0.862 rs908915 ENSG00000226824.5 RP4-756H11.3 6.24 2.27e-09 3.58e-06 0.48 0.39 Aortic root size; chr7:66149664 chr7:66654538~66669855:+ CESC cis rs997154 0.608 rs8007089 ENSG00000279656.1 RP11-298I3.6 6.24 2.27e-09 3.58e-06 0.58 0.39 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22922704 chr14:23023083~23024217:- CESC cis rs875971 1 rs11974264 ENSG00000222364.1 RNU6-96P 6.24 2.27e-09 3.58e-06 0.45 0.39 Aortic root size; chr7:66182595 chr7:66395191~66395286:+ CESC cis rs875971 1 rs1540651 ENSG00000222364.1 RNU6-96P 6.24 2.27e-09 3.58e-06 0.45 0.39 Aortic root size; chr7:66185134 chr7:66395191~66395286:+ CESC cis rs9309711 0.544 rs9309712 ENSG00000225234.1 TRAPPC12-AS1 -6.24 2.28e-09 3.59e-06 -0.35 -0.39 Neurofibrillary tangles; chr2:3487556 chr2:3481242~3482409:- CESC cis rs1061377 1 rs7685468 ENSG00000249207.1 RP11-360F5.1 -6.24 2.28e-09 3.59e-06 -0.44 -0.39 Uric acid levels; chr4:39116649 chr4:39112677~39126818:- CESC cis rs7727544 0.684 rs2516788 ENSG00000233006.5 AC034220.3 -6.24 2.29e-09 3.6e-06 -0.43 -0.39 Blood metabolite levels; chr5:132379873 chr5:132311285~132369916:- CESC cis rs7727544 0.66 rs274563 ENSG00000233006.5 AC034220.3 -6.24 2.29e-09 3.6e-06 -0.43 -0.39 Blood metabolite levels; chr5:132382167 chr5:132311285~132369916:- CESC cis rs526231 0.543 rs246913 ENSG00000175749.11 EIF3KP1 6.24 2.29e-09 3.61e-06 0.47 0.39 Primary biliary cholangitis; chr5:103224669 chr5:103032376~103033031:+ CESC cis rs8005677 0.828 rs8016027 ENSG00000279656.1 RP11-298I3.6 6.24 2.29e-09 3.62e-06 0.48 0.39 Cognitive ability (multi-trait analysis); chr14:22950944 chr14:23023083~23024217:- CESC cis rs79349575 0.783 rs56046215 ENSG00000270781.1 RP11-501C14.9 -6.24 2.3e-09 3.63e-06 -0.44 -0.39 Type 2 diabetes; chr17:48931395 chr17:48899131~48899748:+ CESC cis rs6452524 0.508 rs40214 ENSG00000249664.1 CTD-2227C6.2 -6.24 2.3e-09 3.63e-06 -0.44 -0.39 Hypertension (SNP x SNP interaction); chr5:83000359 chr5:83012285~83013109:- CESC cis rs992157 0.71 rs13026485 ENSG00000261338.2 RP11-378A13.1 -6.24 2.31e-09 3.63e-06 -0.49 -0.39 Colorectal cancer; chr2:218193261 chr2:218255319~218257366:+ CESC cis rs2117029 0.554 rs35884657 ENSG00000258017.1 RP11-386G11.10 -6.24 2.31e-09 3.63e-06 -0.52 -0.39 Intelligence (multi-trait analysis); chr12:49137317 chr12:49127782~49147869:+ CESC cis rs11690935 0.959 rs6722757 ENSG00000228389.1 AC068039.4 6.24 2.31e-09 3.63e-06 0.52 0.39 Schizophrenia; chr2:171735453 chr2:171773482~171775844:+ CESC cis rs1707322 1 rs4660905 ENSG00000280836.1 AL355480.1 6.23 2.31e-09 3.64e-06 0.45 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45995915 chr1:45581219~45581321:- CESC cis rs1707322 1 rs6657720 ENSG00000280836.1 AL355480.1 -6.23 2.31e-09 3.64e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45920597 chr1:45581219~45581321:- CESC cis rs1707322 1 rs7519181 ENSG00000280836.1 AL355480.1 -6.23 2.31e-09 3.64e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45922157 chr1:45581219~45581321:- CESC cis rs1707322 1 rs7526369 ENSG00000280836.1 AL355480.1 -6.23 2.31e-09 3.64e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45924888 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs10890371 ENSG00000280836.1 AL355480.1 -6.23 2.31e-09 3.64e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45925225 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10890372 ENSG00000280836.1 AL355480.1 -6.23 2.31e-09 3.64e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45925348 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211243 ENSG00000280836.1 AL355480.1 -6.23 2.31e-09 3.64e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45989761 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211244 ENSG00000280836.1 AL355480.1 -6.23 2.31e-09 3.64e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45991001 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4660903 ENSG00000280836.1 AL355480.1 -6.23 2.31e-09 3.64e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45991929 chr1:45581219~45581321:- CESC cis rs9399137 0.507 rs7754722 ENSG00000232876.1 CTA-212D2.2 6.23 2.32e-09 3.66e-06 0.48 0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134939165 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs6569986 ENSG00000232876.1 CTA-212D2.2 -6.23 2.33e-09 3.66e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134990503 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs13197750 ENSG00000232876.1 CTA-212D2.2 -6.23 2.33e-09 3.66e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134991242 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs7761964 ENSG00000232876.1 CTA-212D2.2 -6.23 2.33e-09 3.66e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134993127 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs11753673 ENSG00000232876.1 CTA-212D2.2 -6.23 2.33e-09 3.66e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134995338 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs12663447 ENSG00000232876.1 CTA-212D2.2 -6.23 2.33e-09 3.66e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134995888 chr6:135055033~135060550:+ CESC cis rs9399137 0.507 rs4895437 ENSG00000232876.1 CTA-212D2.2 -6.23 2.33e-09 3.66e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134996216 chr6:135055033~135060550:+ CESC cis rs79349575 0.783 rs4793992 ENSG00000270781.1 RP11-501C14.9 -6.23 2.34e-09 3.67e-06 -0.44 -0.39 Type 2 diabetes; chr17:48930845 chr17:48899131~48899748:+ CESC cis rs875971 1 rs3735148 ENSG00000222364.1 RNU6-96P -6.23 2.35e-09 3.69e-06 -0.46 -0.39 Aortic root size; chr7:66506022 chr7:66395191~66395286:+ CESC cis rs9399135 0.967 rs4388304 ENSG00000232876.1 CTA-212D2.2 -6.23 2.35e-09 3.69e-06 -0.46 -0.39 Red blood cell count; chr6:134988459 chr6:135055033~135060550:+ CESC cis rs1061377 0.965 rs7669376 ENSG00000249207.1 RP11-360F5.1 -6.23 2.36e-09 3.7e-06 -0.44 -0.39 Uric acid levels; chr4:39116717 chr4:39112677~39126818:- CESC cis rs8005677 0.828 rs35085068 ENSG00000279656.1 RP11-298I3.6 6.23 2.36e-09 3.7e-06 0.48 0.39 Cognitive ability (multi-trait analysis); chr14:22940700 chr14:23023083~23024217:- CESC cis rs8005677 0.828 rs57822749 ENSG00000279656.1 RP11-298I3.6 6.23 2.36e-09 3.7e-06 0.48 0.39 Cognitive ability (multi-trait analysis); chr14:22940758 chr14:23023083~23024217:- CESC cis rs8005677 0.828 rs4981451 ENSG00000279656.1 RP11-298I3.6 6.23 2.36e-09 3.7e-06 0.48 0.39 Cognitive ability (multi-trait analysis); chr14:22941072 chr14:23023083~23024217:- CESC cis rs8005677 0.798 rs4536383 ENSG00000279656.1 RP11-298I3.6 6.23 2.36e-09 3.7e-06 0.48 0.39 Cognitive ability (multi-trait analysis); chr14:22941717 chr14:23023083~23024217:- CESC cis rs8005677 0.828 rs34584578 ENSG00000279656.1 RP11-298I3.6 6.23 2.36e-09 3.7e-06 0.48 0.39 Cognitive ability (multi-trait analysis); chr14:22942481 chr14:23023083~23024217:- CESC cis rs1061377 1 rs2381284 ENSG00000249207.1 RP11-360F5.1 -6.23 2.36e-09 3.7e-06 -0.44 -0.39 Uric acid levels; chr4:39117976 chr4:39112677~39126818:- CESC cis rs1061377 0.803 rs6857761 ENSG00000249207.1 RP11-360F5.1 -6.23 2.36e-09 3.7e-06 -0.44 -0.39 Uric acid levels; chr4:39118353 chr4:39112677~39126818:- CESC cis rs1061377 1 rs9997089 ENSG00000249207.1 RP11-360F5.1 -6.23 2.36e-09 3.7e-06 -0.44 -0.39 Uric acid levels; chr4:39119263 chr4:39112677~39126818:- CESC cis rs875971 0.964 rs6978429 ENSG00000222364.1 RNU6-96P -6.23 2.36e-09 3.71e-06 -0.46 -0.39 Aortic root size; chr7:66494889 chr7:66395191~66395286:+ CESC cis rs875971 1 rs4718357 ENSG00000222364.1 RNU6-96P -6.23 2.36e-09 3.71e-06 -0.46 -0.39 Aortic root size; chr7:66495891 chr7:66395191~66395286:+ CESC cis rs875971 0.929 rs12535036 ENSG00000222364.1 RNU6-96P -6.23 2.36e-09 3.71e-06 -0.46 -0.39 Aortic root size; chr7:66499076 chr7:66395191~66395286:+ CESC cis rs875971 1 rs12698523 ENSG00000222364.1 RNU6-96P -6.23 2.36e-09 3.71e-06 -0.46 -0.39 Aortic root size; chr7:66503126 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6970030 ENSG00000222364.1 RNU6-96P -6.23 2.36e-09 3.71e-06 -0.46 -0.39 Aortic root size; chr7:66503692 chr7:66395191~66395286:+ CESC cis rs875971 0.928 rs6970357 ENSG00000222364.1 RNU6-96P -6.23 2.36e-09 3.71e-06 -0.46 -0.39 Aortic root size; chr7:66503891 chr7:66395191~66395286:+ CESC cis rs875971 0.929 rs6970860 ENSG00000222364.1 RNU6-96P -6.23 2.36e-09 3.71e-06 -0.46 -0.39 Aortic root size; chr7:66511647 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6957199 ENSG00000222364.1 RNU6-96P -6.23 2.36e-09 3.71e-06 -0.46 -0.39 Aortic root size; chr7:66513532 chr7:66395191~66395286:+ CESC cis rs9399135 0.967 rs7763836 ENSG00000232876.1 CTA-212D2.2 -6.23 2.37e-09 3.71e-06 -0.45 -0.39 Red blood cell count; chr6:135041240 chr6:135055033~135060550:+ CESC cis rs4718428 0.662 rs34577323 ENSG00000226824.5 RP4-756H11.3 -6.23 2.37e-09 3.71e-06 -0.53 -0.39 Corneal structure; chr7:66845054 chr7:66654538~66669855:+ CESC cis rs6504950 0.889 rs1484776 ENSG00000275710.1 RP11-257O5.4 -6.23 2.37e-09 3.72e-06 -0.48 -0.39 Breast cancer; chr17:55034022 chr17:54964474~54964679:+ CESC cis rs783540 0.5 rs7178459 ENSG00000276710.3 CSPG4P8 -6.23 2.37e-09 3.72e-06 -0.46 -0.39 Schizophrenia; chr15:82729632 chr15:82459472~82477258:+ CESC cis rs6452524 1 rs9293332 ENSG00000249664.1 CTD-2227C6.2 6.23 2.37e-09 3.72e-06 0.43 0.39 Hypertension (SNP x SNP interaction); chr5:83141546 chr5:83012285~83013109:- CESC cis rs1061377 1 rs12499266 ENSG00000249207.1 RP11-360F5.1 6.23 2.38e-09 3.73e-06 0.44 0.39 Uric acid levels; chr4:39118133 chr4:39112677~39126818:- CESC cis rs2177312 0.868 rs1523176 ENSG00000251129.1 RP11-734I18.1 6.23 2.38e-09 3.73e-06 0.5 0.39 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31950414 chr4:31997397~32155406:+ CESC cis rs17507216 1 rs17158413 ENSG00000278603.1 RP13-608F4.5 6.23 2.38e-09 3.73e-06 0.61 0.39 Excessive daytime sleepiness; chr15:82566658 chr15:82472203~82472426:+ CESC cis rs1075265 0.588 rs1477258 ENSG00000233266.1 HMGB1P31 6.23 2.39e-09 3.74e-06 0.52 0.39 Chronotype;Morning vs. evening chronotype; chr2:54000031 chr2:54051334~54051760:+ CESC cis rs1061377 0.722 rs34803689 ENSG00000249207.1 RP11-360F5.1 -6.23 2.4e-09 3.75e-06 -0.44 -0.39 Uric acid levels; chr4:39116665 chr4:39112677~39126818:- CESC cis rs4423214 0.879 rs1790345 ENSG00000254682.1 RP11-660L16.2 -6.23 2.4e-09 3.76e-06 -0.51 -0.39 Vitamin D levels; chr11:71434895 chr11:71448674~71452157:+ CESC cis rs875971 0.862 rs1695820 ENSG00000226824.5 RP4-756H11.3 -6.23 2.41e-09 3.77e-06 -0.48 -0.39 Aortic root size; chr7:66379576 chr7:66654538~66669855:+ CESC cis rs875971 0.83 rs778715 ENSG00000226824.5 RP4-756H11.3 -6.23 2.41e-09 3.77e-06 -0.48 -0.39 Aortic root size; chr7:66384222 chr7:66654538~66669855:+ CESC cis rs875971 0.83 rs809025 ENSG00000226824.5 RP4-756H11.3 -6.23 2.41e-09 3.77e-06 -0.48 -0.39 Aortic root size; chr7:66384832 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs778702 ENSG00000226824.5 RP4-756H11.3 -6.23 2.41e-09 3.77e-06 -0.48 -0.39 Aortic root size; chr7:66399848 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs1643375 ENSG00000226824.5 RP4-756H11.3 -6.23 2.41e-09 3.77e-06 -0.48 -0.39 Aortic root size; chr7:66407690 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6962717 ENSG00000226824.5 RP4-756H11.3 -6.23 2.41e-09 3.77e-06 -0.48 -0.39 Aortic root size; chr7:66418748 chr7:66654538~66669855:+ CESC cis rs1061377 1 rs28465556 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39119569 chr4:39112677~39126818:- CESC cis rs1061377 1 rs10027813 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39119818 chr4:39112677~39126818:- CESC cis rs1061377 1 rs9990755 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39119819 chr4:39112677~39126818:- CESC cis rs1061377 1 rs7676008 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39120154 chr4:39112677~39126818:- CESC cis rs1061377 0.965 rs7677729 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39120370 chr4:39112677~39126818:- CESC cis rs1061377 1 rs7655122 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39120396 chr4:39112677~39126818:- CESC cis rs1061377 1 rs3796511 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39120586 chr4:39112677~39126818:- CESC cis rs1061377 1 rs3733274 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39120957 chr4:39112677~39126818:- CESC cis rs1061377 0.965 rs3733275 ENSG00000249207.1 RP11-360F5.1 -6.23 2.41e-09 3.77e-06 -0.44 -0.39 Uric acid levels; chr4:39121077 chr4:39112677~39126818:- CESC cis rs1707322 1 rs4298677 ENSG00000280836.1 AL355480.1 -6.23 2.41e-09 3.77e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45840947 chr1:45581219~45581321:- CESC cis rs875971 0.965 rs6971509 ENSG00000222364.1 RNU6-96P 6.23 2.41e-09 3.77e-06 0.44 0.39 Aortic root size; chr7:66249983 chr7:66395191~66395286:+ CESC cis rs1707322 0.691 rs61784803 ENSG00000281133.1 AL355480.3 6.23 2.42e-09 3.78e-06 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45713599 chr1:45580892~45580996:- CESC cis rs1707322 0.663 rs3935296 ENSG00000281133.1 AL355480.3 6.23 2.42e-09 3.78e-06 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45714798 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs11211163 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45687876 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs12037803 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690820 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs10789470 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692659 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs61784796 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697584 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs10749856 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45699174 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs10890344 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45700418 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs4564187 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701189 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs28438704 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45704872 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs28442079 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706329 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs28817701 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720378 chr1:45580892~45580996:- CESC cis rs1707322 0.691 rs28495425 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45721648 chr1:45580892~45580996:- CESC cis rs1707322 0.685 rs28617418 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723854 chr1:45580892~45580996:- CESC cis rs1707322 0.682 rs28490344 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45732276 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs28501477 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45733412 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs28641748 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747164 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs6697821 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751050 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs4330955 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751813 chr1:45580892~45580996:- CESC cis rs1707322 0.691 rs11211174 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755144 chr1:45580892~45580996:- CESC cis rs1707322 0.691 rs12031182 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755327 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs10430123 ENSG00000281133.1 AL355480.3 -6.23 2.42e-09 3.78e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755768 chr1:45580892~45580996:- CESC cis rs1155848 0.892 rs953005 ENSG00000227354.5 RBM26-AS1 6.23 2.42e-09 3.78e-06 0.82 0.39 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79480544 chr13:79406309~79424328:+ CESC cis rs1823913 0.637 rs13382985 ENSG00000280083.1 RP11-317J9.1 6.23 2.42e-09 3.78e-06 0.45 0.39 Obesity-related traits; chr2:191306335 chr2:191154118~191156070:- CESC cis rs6452524 0.711 rs1478486 ENSG00000249664.1 CTD-2227C6.2 6.23 2.43e-09 3.79e-06 0.46 0.39 Hypertension (SNP x SNP interaction); chr5:83081185 chr5:83012285~83013109:- CESC cis rs765787 0.53 rs1706837 ENSG00000259520.4 CTD-2651B20.3 6.23 2.43e-09 3.79e-06 0.49 0.39 Uric acid levels; chr15:45226838 chr15:45251580~45279251:- CESC cis rs6504950 0.8 rs7209926 ENSG00000275710.1 RP11-257O5.4 -6.22 2.44e-09 3.81e-06 -0.45 -0.39 Breast cancer; chr17:54928963 chr17:54964474~54964679:+ CESC cis rs875971 1 rs1981798 ENSG00000222364.1 RNU6-96P -6.22 2.44e-09 3.81e-06 -0.47 -0.39 Aortic root size; chr7:66489916 chr7:66395191~66395286:+ CESC cis rs9907295 0.591 rs9908928 ENSG00000270977.1 AC015849.16 -6.22 2.45e-09 3.82e-06 -0.46 -0.39 Fibroblast growth factor basic levels; chr17:35862013 chr17:35893707~35911023:- CESC cis rs35955747 0.934 rs131200 ENSG00000236132.1 CTA-440B3.1 -6.22 2.45e-09 3.82e-06 -0.46 -0.39 Neutrophil count;Sum basophil neutrophil counts; chr22:31307286 chr22:31816379~31817491:- CESC cis rs8062405 0.755 rs62031607 ENSG00000259982.1 CDC37P1 6.22 2.45e-09 3.82e-06 0.52 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620209 chr16:28700294~28701540:- CESC cis rs765787 0.53 rs1706832 ENSG00000259520.4 CTD-2651B20.3 6.22 2.46e-09 3.83e-06 0.49 0.39 Uric acid levels; chr15:45224975 chr15:45251580~45279251:- CESC cis rs1823913 0.599 rs2124093 ENSG00000280083.1 RP11-317J9.1 -6.22 2.46e-09 3.84e-06 -0.46 -0.39 Obesity-related traits; chr2:191288280 chr2:191154118~191156070:- CESC cis rs875971 0.965 rs7794930 ENSG00000222364.1 RNU6-96P 6.22 2.46e-09 3.84e-06 0.44 0.39 Aortic root size; chr7:66313559 chr7:66395191~66395286:+ CESC cis rs7674212 0.581 rs10516496 ENSG00000246560.2 RP11-10L12.4 6.22 2.47e-09 3.85e-06 0.48 0.39 Type 2 diabetes; chr4:103021008 chr4:102828055~102844075:+ CESC cis rs11676348 0.811 rs13027120 ENSG00000261338.2 RP11-378A13.1 6.22 2.47e-09 3.85e-06 0.45 0.39 Ulcerative colitis; chr2:218156191 chr2:218255319~218257366:+ CESC cis rs6991838 0.557 rs4737222 ENSG00000200714.1 Y_RNA -6.22 2.47e-09 3.85e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65587878 chr8:65592731~65592820:+ CESC cis rs2842992 0.915 rs2842985 ENSG00000237927.1 RP3-393E18.2 -6.22 2.49e-09 3.87e-06 -0.52 -0.39 Age-related macular degeneration (geographic atrophy); chr6:159664402 chr6:159586955~159589169:- CESC cis rs10129255 0.5 rs59939897 ENSG00000223648.3 IGHV3-64 6.22 2.49e-09 3.88e-06 0.32 0.39 Kawasaki disease; chr14:106783414 chr14:106643132~106658258:- CESC cis rs992157 0.798 rs2382818 ENSG00000261338.2 RP11-378A13.1 -6.22 2.49e-09 3.88e-06 -0.5 -0.39 Colorectal cancer; chr2:218291184 chr2:218255319~218257366:+ CESC cis rs992157 0.798 rs2382819 ENSG00000261338.2 RP11-378A13.1 -6.22 2.49e-09 3.88e-06 -0.5 -0.39 Colorectal cancer; chr2:218291186 chr2:218255319~218257366:+ CESC cis rs4718428 0.705 rs4718424 ENSG00000226824.5 RP4-756H11.3 -6.22 2.49e-09 3.88e-06 -0.53 -0.39 Corneal structure; chr7:66911108 chr7:66654538~66669855:+ CESC cis rs1061377 1 rs7685082 ENSG00000249207.1 RP11-360F5.1 -6.22 2.5e-09 3.89e-06 -0.43 -0.39 Uric acid levels; chr4:39116472 chr4:39112677~39126818:- CESC cis rs6991838 0.584 rs4388482 ENSG00000200714.1 Y_RNA -6.22 2.51e-09 3.91e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65583968 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs4637885 ENSG00000200714.1 Y_RNA -6.22 2.51e-09 3.91e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65584849 chr8:65592731~65592820:+ CESC cis rs5760092 0.572 rs738806 ENSG00000218537.1 MIF-AS1 6.22 2.52e-09 3.91e-06 0.55 0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23894426~23898930:- CESC cis rs2935183 1 rs2935183 ENSG00000228782.6 CTD-2026D20.3 -6.22 2.52e-09 3.91e-06 -0.44 -0.39 Multiple sclerosis or amyotrophic lateral sclerosis; chr17:47530206 chr17:47450568~47492492:- CESC cis rs8062405 0.754 rs151179 ENSG00000259982.1 CDC37P1 6.22 2.53e-09 3.93e-06 0.52 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28475735 chr16:28700294~28701540:- CESC cis rs2404602 0.647 rs12440965 ENSG00000259422.1 RP11-593F23.1 -6.22 2.53e-09 3.93e-06 -0.47 -0.39 Blood metabolite levels; chr15:76666250 chr15:76174891~76181486:- CESC cis rs950169 0.881 rs150965 ENSG00000225151.9 GOLGA2P7 -6.22 2.53e-09 3.94e-06 -0.54 -0.39 Schizophrenia; chr15:84537296 chr15:84199311~84230136:- CESC cis rs875971 0.862 rs6460302 ENSG00000226824.5 RP4-756H11.3 -6.22 2.53e-09 3.94e-06 -0.49 -0.39 Aortic root size; chr7:66495270 chr7:66654538~66669855:+ CESC cis rs507080 0.922 rs514143 ENSG00000255422.1 AP002954.4 -6.22 2.55e-09 3.96e-06 -0.47 -0.39 Serum metabolite levels; chr11:118687740 chr11:118704607~118750263:+ CESC cis rs507080 0.769 rs7389 ENSG00000255422.1 AP002954.4 6.22 2.55e-09 3.97e-06 0.47 0.39 Serum metabolite levels; chr11:118657756 chr11:118704607~118750263:+ CESC cis rs4423214 0.879 rs10898144 ENSG00000254682.1 RP11-660L16.2 -6.22 2.57e-09 3.99e-06 -0.5 -0.39 Vitamin D levels; chr11:71440494 chr11:71448674~71452157:+ CESC cis rs35955747 0.902 rs12166373 ENSG00000236132.1 CTA-440B3.1 6.22 2.57e-09 3.99e-06 0.45 0.39 Neutrophil count;Sum basophil neutrophil counts; chr22:31304522 chr22:31816379~31817491:- CESC cis rs4423214 0.84 rs1123007 ENSG00000254682.1 RP11-660L16.2 -6.21 2.58e-09 4.01e-06 -0.54 -0.39 Vitamin D levels; chr11:71474311 chr11:71448674~71452157:+ CESC cis rs2404602 0.622 rs11632365 ENSG00000259422.1 RP11-593F23.1 -6.21 2.59e-09 4.01e-06 -0.49 -0.39 Blood metabolite levels; chr15:76846739 chr15:76174891~76181486:- CESC cis rs2404602 0.622 rs1567671 ENSG00000259422.1 RP11-593F23.1 -6.21 2.59e-09 4.01e-06 -0.46 -0.39 Blood metabolite levels; chr15:76916859 chr15:76174891~76181486:- CESC cis rs3806843 1 rs12717860 ENSG00000202111.1 VTRNA1-2 -6.21 2.59e-09 4.02e-06 -0.4 -0.39 Depressive symptoms (multi-trait analysis); chr5:140791857 chr5:140718925~140719013:+ CESC cis rs5760092 0.572 rs738806 ENSG00000250470.1 AP000351.3 6.21 2.59e-09 4.02e-06 0.55 0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23976904~23977585:- CESC cis rs8005677 0.798 rs4982713 ENSG00000279656.1 RP11-298I3.6 6.21 2.6e-09 4.03e-06 0.48 0.39 Cognitive ability (multi-trait analysis); chr14:22934893 chr14:23023083~23024217:- CESC cis rs8005677 0.798 rs35615180 ENSG00000279656.1 RP11-298I3.6 6.21 2.6e-09 4.03e-06 0.48 0.39 Cognitive ability (multi-trait analysis); chr14:22935180 chr14:23023083~23024217:- CESC cis rs4718428 0.705 rs4717328 ENSG00000226824.5 RP4-756H11.3 -6.21 2.6e-09 4.04e-06 -0.53 -0.39 Corneal structure; chr7:66887678 chr7:66654538~66669855:+ CESC cis rs4718428 0.705 rs4718422 ENSG00000226824.5 RP4-756H11.3 -6.21 2.6e-09 4.04e-06 -0.53 -0.39 Corneal structure; chr7:66894282 chr7:66654538~66669855:+ CESC cis rs4718428 0.705 rs13231140 ENSG00000226824.5 RP4-756H11.3 -6.21 2.6e-09 4.04e-06 -0.53 -0.39 Corneal structure; chr7:66896631 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs7803416 ENSG00000222364.1 RNU6-96P -6.21 2.61e-09 4.04e-06 -0.47 -0.39 Aortic root size; chr7:66489212 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs1981799 ENSG00000222364.1 RNU6-96P -6.21 2.61e-09 4.04e-06 -0.47 -0.39 Aortic root size; chr7:66490572 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs2277911 ENSG00000222364.1 RNU6-96P -6.21 2.61e-09 4.04e-06 -0.47 -0.39 Aortic root size; chr7:66493638 chr7:66395191~66395286:+ CESC cis rs875971 1 rs12532998 ENSG00000222364.1 RNU6-96P -6.21 2.61e-09 4.04e-06 -0.46 -0.39 Aortic root size; chr7:66502472 chr7:66395191~66395286:+ CESC cis rs2117029 0.586 rs10783308 ENSG00000258017.1 RP11-386G11.10 -6.21 2.61e-09 4.05e-06 -0.49 -0.39 Intelligence (multi-trait analysis); chr12:49137675 chr12:49127782~49147869:+ CESC cis rs9399137 0.507 rs56164974 ENSG00000232876.1 CTA-212D2.2 -6.21 2.61e-09 4.05e-06 -0.48 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134967578 chr6:135055033~135060550:+ CESC cis rs6991838 0.556 rs7846527 ENSG00000200714.1 Y_RNA -6.21 2.63e-09 4.07e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65586522 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs4320587 ENSG00000200714.1 Y_RNA -6.21 2.63e-09 4.07e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65586991 chr8:65592731~65592820:+ CESC cis rs11690935 1 rs2138348 ENSG00000228389.1 AC068039.4 -6.21 2.63e-09 4.07e-06 -0.51 -0.39 Schizophrenia; chr2:171701662 chr2:171773482~171775844:+ CESC cis rs9399135 1 rs1014021 ENSG00000232876.1 CTA-212D2.2 6.21 2.64e-09 4.08e-06 0.45 0.39 Red blood cell count; chr6:135013462 chr6:135055033~135060550:+ CESC cis rs875971 0.862 rs1875057 ENSG00000226824.5 RP4-756H11.3 6.21 2.64e-09 4.09e-06 0.48 0.39 Aortic root size; chr7:66266868 chr7:66654538~66669855:+ CESC cis rs2404602 0.608 rs12439484 ENSG00000259422.1 RP11-593F23.1 6.21 2.65e-09 4.1e-06 0.44 0.39 Blood metabolite levels; chr15:76310596 chr15:76174891~76181486:- CESC cis rs494459 0.964 rs576283 ENSG00000255422.1 AP002954.4 -6.21 2.66e-09 4.11e-06 -0.44 -0.39 Height; chr11:118703185 chr11:118704607~118750263:+ CESC cis rs494459 0.929 rs627391 ENSG00000255422.1 AP002954.4 -6.21 2.66e-09 4.11e-06 -0.44 -0.39 Height; chr11:118703207 chr11:118704607~118750263:+ CESC cis rs507080 0.524 rs524409 ENSG00000255422.1 AP002954.4 -6.21 2.66e-09 4.11e-06 -0.44 -0.39 Serum metabolite levels; chr11:118703602 chr11:118704607~118750263:+ CESC cis rs950169 0.881 rs34117475 ENSG00000225151.9 GOLGA2P7 -6.21 2.67e-09 4.13e-06 -0.54 -0.39 Schizophrenia; chr15:84565212 chr15:84199311~84230136:- CESC cis rs8062405 0.723 rs113208333 ENSG00000259982.1 CDC37P1 6.21 2.67e-09 4.14e-06 0.49 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28594839 chr16:28700294~28701540:- CESC cis rs2842992 0.915 rs2842958 ENSG00000237927.1 RP3-393E18.2 -6.21 2.68e-09 4.15e-06 -0.5 -0.39 Age-related macular degeneration (geographic atrophy); chr6:159687393 chr6:159586955~159589169:- CESC cis rs507080 0.961 rs607527 ENSG00000255422.1 AP002954.4 6.21 2.69e-09 4.15e-06 0.43 0.39 Serum metabolite levels; chr11:118667478 chr11:118704607~118750263:+ CESC cis rs875971 0.895 rs1974769 ENSG00000222364.1 RNU6-96P -6.21 2.69e-09 4.16e-06 -0.46 -0.39 Aortic root size; chr7:66485627 chr7:66395191~66395286:+ CESC cis rs875971 0.895 rs6460300 ENSG00000222364.1 RNU6-96P -6.21 2.69e-09 4.16e-06 -0.46 -0.39 Aortic root size; chr7:66487937 chr7:66395191~66395286:+ CESC cis rs1075265 0.633 rs7564912 ENSG00000233266.1 HMGB1P31 6.21 2.7e-09 4.17e-06 0.53 0.39 Chronotype;Morning vs. evening chronotype; chr2:53995048 chr2:54051334~54051760:+ CESC cis rs1075265 0.61 rs6746965 ENSG00000233266.1 HMGB1P31 6.21 2.7e-09 4.17e-06 0.53 0.39 Chronotype;Morning vs. evening chronotype; chr2:53996388 chr2:54051334~54051760:+ CESC cis rs42490 1 rs402886 ENSG00000251136.7 RP11-37B2.1 -6.21 2.7e-09 4.18e-06 -0.38 -0.39 Leprosy; chr8:89760272 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs39500 ENSG00000251136.7 RP11-37B2.1 -6.21 2.7e-09 4.18e-06 -0.38 -0.39 Leprosy; chr8:89760437 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs39761 ENSG00000251136.7 RP11-37B2.1 -6.21 2.7e-09 4.18e-06 -0.38 -0.39 Leprosy; chr8:89760692 chr8:89609409~89757727:- CESC cis rs42490 0.934 rs43225 ENSG00000251136.7 RP11-37B2.1 -6.21 2.7e-09 4.18e-06 -0.38 -0.39 Leprosy; chr8:89760776 chr8:89609409~89757727:- CESC cis rs42490 1 rs40452 ENSG00000251136.7 RP11-37B2.1 -6.21 2.7e-09 4.18e-06 -0.38 -0.39 Leprosy; chr8:89765931 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs39503 ENSG00000251136.7 RP11-37B2.1 -6.21 2.7e-09 4.18e-06 -0.38 -0.39 Leprosy; chr8:89767579 chr8:89609409~89757727:- CESC cis rs42490 1 rs447618 ENSG00000251136.7 RP11-37B2.1 -6.21 2.7e-09 4.18e-06 -0.38 -0.39 Leprosy; chr8:89773457 chr8:89609409~89757727:- CESC cis rs1707322 0.686 rs2991987 ENSG00000281133.1 AL355480.3 6.21 2.71e-09 4.19e-06 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615750 chr1:45580892~45580996:- CESC cis rs1707322 0.686 rs3014239 ENSG00000281133.1 AL355480.3 6.21 2.71e-09 4.19e-06 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624129 chr1:45580892~45580996:- CESC cis rs1707322 0.686 rs3014236 ENSG00000281133.1 AL355480.3 6.21 2.71e-09 4.19e-06 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625633 chr1:45580892~45580996:- CESC cis rs2729354 0.903 rs1846568 ENSG00000265566.2 RN7SL605P -6.21 2.71e-09 4.19e-06 -0.6 -0.39 Blood protein levels; chr11:57590241 chr11:57528085~57528365:- CESC cis rs6991838 0.584 rs35941313 ENSG00000200714.1 Y_RNA -6.2 2.73e-09 4.21e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65587498 chr8:65592731~65592820:+ CESC cis rs9402743 0.775 rs12196952 ENSG00000217482.2 HMGB1P17 6.2 2.75e-09 4.25e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135662235 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs9494323 ENSG00000217482.2 HMGB1P17 6.2 2.75e-09 4.25e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135663249 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs6917604 ENSG00000217482.2 HMGB1P17 6.2 2.75e-09 4.25e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135664161 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs7768645 ENSG00000217482.2 HMGB1P17 6.2 2.75e-09 4.25e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135664656 chr6:135636086~135636713:- CESC cis rs9545047 0.716 rs9545063 ENSG00000227676.3 LINC01068 6.2 2.78e-09 4.28e-06 0.44 0.39 Schizophrenia; chr13:79316989 chr13:79566727~79571436:+ CESC cis rs2404602 0.53 rs12915184 ENSG00000259422.1 RP11-593F23.1 -6.2 2.78e-09 4.28e-06 -0.49 -0.39 Blood metabolite levels; chr15:76673581 chr15:76174891~76181486:- CESC cis rs10463554 0.963 rs26816 ENSG00000175749.11 EIF3KP1 6.2 2.78e-09 4.28e-06 0.41 0.39 Parkinson's disease; chr5:103204821 chr5:103032376~103033031:+ CESC cis rs10463554 0.963 rs26261 ENSG00000175749.11 EIF3KP1 6.2 2.78e-09 4.28e-06 0.41 0.39 Parkinson's disease; chr5:103209992 chr5:103032376~103033031:+ CESC cis rs4728142 0.604 rs7783384 ENSG00000275106.1 RP11-309L24.10 -6.2 2.78e-09 4.28e-06 -0.5 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129041243 chr7:128952527~128953316:- CESC cis rs4853012 0.838 rs6715351 ENSG00000257800.1 FNBP1P1 6.2 2.78e-09 4.28e-06 0.4 0.39 Gestational age at birth (maternal effect); chr2:74118992 chr2:74120680~74123218:+ CESC cis rs4853012 0.838 rs61521879 ENSG00000257800.1 FNBP1P1 6.2 2.78e-09 4.28e-06 0.4 0.39 Gestational age at birth (maternal effect); chr2:74119081 chr2:74120680~74123218:+ CESC cis rs3806843 0.966 rs2337986 ENSG00000202111.1 VTRNA1-2 -6.2 2.78e-09 4.29e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140781037 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs1548701 ENSG00000202111.1 VTRNA1-2 -6.2 2.78e-09 4.29e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140784972 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs10073974 ENSG00000202111.1 VTRNA1-2 -6.2 2.78e-09 4.29e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140785646 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs3756342 ENSG00000202111.1 VTRNA1-2 -6.2 2.78e-09 4.29e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140786039 chr5:140718925~140719013:+ CESC cis rs1061377 1 rs10018049 ENSG00000249207.1 RP11-360F5.1 -6.2 2.79e-09 4.29e-06 -0.44 -0.39 Uric acid levels; chr4:39115781 chr4:39112677~39126818:- CESC cis rs3814244 0.933 rs12423194 ENSG00000255733.4 IFNG-AS1 6.2 2.79e-09 4.3e-06 0.33 0.39 Itch intensity from mosquito bite adjusted by bite size; chr12:68020387 chr12:67989445~68234686:+ CESC cis rs1823913 0.622 rs55787447 ENSG00000280083.1 RP11-317J9.1 -6.2 2.8e-09 4.32e-06 -0.45 -0.39 Obesity-related traits; chr2:191288596 chr2:191154118~191156070:- CESC cis rs2177312 0.794 rs1523161 ENSG00000251129.1 RP11-734I18.1 -6.2 2.81e-09 4.32e-06 -0.49 -0.39 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31953016 chr4:31997397~32155406:+ CESC cis rs1707322 1 rs10158032 ENSG00000280836.1 AL355480.1 -6.2 2.82e-09 4.33e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45867029 chr1:45581219~45581321:- CESC cis rs6452524 1 rs4590162 ENSG00000249664.1 CTD-2227C6.2 6.2 2.82e-09 4.33e-06 0.44 0.39 Hypertension (SNP x SNP interaction); chr5:83145621 chr5:83012285~83013109:- CESC cis rs12931792 0.682 rs12373113 ENSG00000183604.13 SMG1P5 6.2 2.82e-09 4.34e-06 0.38 0.39 Tonsillectomy; chr16:30176192 chr16:30267553~30335374:- CESC cis rs12931792 0.682 rs12373078 ENSG00000183604.13 SMG1P5 6.2 2.82e-09 4.34e-06 0.38 0.39 Tonsillectomy; chr16:30176355 chr16:30267553~30335374:- CESC cis rs42490 1 rs40545 ENSG00000251136.7 RP11-37B2.1 -6.2 2.83e-09 4.36e-06 -0.38 -0.39 Leprosy; chr8:89777483 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs39505 ENSG00000251136.7 RP11-37B2.1 -6.2 2.83e-09 4.36e-06 -0.38 -0.39 Leprosy; chr8:89779838 chr8:89609409~89757727:- CESC cis rs42490 1 rs39506 ENSG00000251136.7 RP11-37B2.1 -6.2 2.83e-09 4.36e-06 -0.38 -0.39 Leprosy; chr8:89779899 chr8:89609409~89757727:- CESC cis rs1062177 0.826 rs2915822 ENSG00000213433.5 RPLP1P6 6.2 2.84e-09 4.37e-06 0.46 0.39 Preschool internalizing problems; chr5:151751340 chr5:151765859~151766378:- CESC cis rs4728142 0.584 rs6965542 ENSG00000275106.1 RP11-309L24.10 -6.2 2.85e-09 4.38e-06 -0.51 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129015864 chr7:128952527~128953316:- CESC cis rs7572733 1 rs1583792 ENSG00000222017.1 AC011997.1 6.2 2.85e-09 4.38e-06 0.42 0.39 Dermatomyositis; chr2:198035564 chr2:197693106~197774823:+ CESC cis rs9399135 0.967 rs4451151 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:134989408 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs6925424 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:134992810 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs6902954 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:134992856 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs7741626 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:134993044 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs4895439 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:134997716 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs17638970 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:134998925 chr6:135055033~135060550:+ CESC cis rs9399135 0.935 rs11754504 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135000371 chr6:135055033~135060550:+ CESC cis rs9402673 0.558 rs9688342 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 High light scatter reticulocyte count;Reticulocyte count; chr6:135001888 chr6:135055033~135060550:+ CESC cis rs9399135 0.933 rs4559100 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135002947 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs12527707 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135003373 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs9389251 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135004579 chr6:135055033~135060550:+ CESC cis rs9399135 0.869 rs9402675 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135004656 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs6929661 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135007654 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs9389253 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135008617 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs2327578 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135008831 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs9389254 ENSG00000232876.1 CTA-212D2.2 -6.2 2.85e-09 4.38e-06 -0.45 -0.39 Red blood cell count; chr6:135009571 chr6:135055033~135060550:+ CESC cis rs765787 0.53 rs1706835 ENSG00000259520.4 CTD-2651B20.3 6.2 2.86e-09 4.39e-06 0.49 0.39 Uric acid levels; chr15:45225686 chr15:45251580~45279251:- CESC cis rs6860806 0.507 rs270606 ENSG00000233006.5 AC034220.3 6.2 2.87e-09 4.4e-06 0.43 0.39 Breast cancer; chr5:132315174 chr5:132311285~132369916:- CESC cis rs9389248 0.737 rs12664956 ENSG00000232876.1 CTA-212D2.2 -6.2 2.87e-09 4.4e-06 -0.48 -0.39 High light scatter reticulocyte percentage of red cells; chr6:135063050 chr6:135055033~135060550:+ CESC cis rs11690935 0.959 rs4668412 ENSG00000228389.1 AC068039.4 6.2 2.87e-09 4.4e-06 0.52 0.39 Schizophrenia; chr2:171763260 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs13419987 ENSG00000228389.1 AC068039.4 6.2 2.87e-09 4.4e-06 0.52 0.39 Schizophrenia; chr2:171767404 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs10194102 ENSG00000228389.1 AC068039.4 6.2 2.87e-09 4.4e-06 0.52 0.39 Schizophrenia; chr2:171769633 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs11904009 ENSG00000228389.1 AC068039.4 6.2 2.87e-09 4.4e-06 0.52 0.39 Schizophrenia; chr2:171770833 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs7572215 ENSG00000228389.1 AC068039.4 6.2 2.87e-09 4.4e-06 0.52 0.39 Schizophrenia; chr2:171777718 chr2:171773482~171775844:+ CESC cis rs11690935 0.918 rs11757 ENSG00000228389.1 AC068039.4 6.2 2.87e-09 4.4e-06 0.52 0.39 Schizophrenia; chr2:171784535 chr2:171773482~171775844:+ CESC cis rs6504950 1 rs7222197 ENSG00000275710.1 RP11-257O5.4 -6.19 2.87e-09 4.4e-06 -0.47 -0.39 Breast cancer; chr17:54970138 chr17:54964474~54964679:+ CESC cis rs2404602 1 rs12443137 ENSG00000259422.1 RP11-593F23.1 6.19 2.88e-09 4.41e-06 0.43 0.39 Blood metabolite levels; chr15:76548491 chr15:76174891~76181486:- CESC cis rs2842992 0.872 rs2758330 ENSG00000237927.1 RP3-393E18.2 -6.19 2.88e-09 4.42e-06 -0.51 -0.39 Age-related macular degeneration (geographic atrophy); chr6:159683812 chr6:159586955~159589169:- CESC cis rs875971 1 rs778706 ENSG00000222364.1 RNU6-96P -6.19 2.89e-09 4.43e-06 -0.46 -0.39 Aortic root size; chr7:66395437 chr7:66395191~66395286:+ CESC cis rs875971 0.895 rs778700 ENSG00000222364.1 RNU6-96P -6.19 2.89e-09 4.43e-06 -0.46 -0.39 Aortic root size; chr7:66401463 chr7:66395191~66395286:+ CESC cis rs875971 1 rs778699 ENSG00000222364.1 RNU6-96P -6.19 2.89e-09 4.43e-06 -0.46 -0.39 Aortic root size; chr7:66403303 chr7:66395191~66395286:+ CESC cis rs875971 0.929 rs778692 ENSG00000222364.1 RNU6-96P -6.19 2.89e-09 4.43e-06 -0.46 -0.39 Aortic root size; chr7:66407462 chr7:66395191~66395286:+ CESC cis rs875971 1 rs4718343 ENSG00000222364.1 RNU6-96P -6.19 2.89e-09 4.43e-06 -0.46 -0.39 Aortic root size; chr7:66409301 chr7:66395191~66395286:+ CESC cis rs875971 1 rs1968225 ENSG00000222364.1 RNU6-96P -6.19 2.89e-09 4.43e-06 -0.46 -0.39 Aortic root size; chr7:66409786 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6460295 ENSG00000222364.1 RNU6-96P -6.19 2.89e-09 4.43e-06 -0.46 -0.39 Aortic root size; chr7:66417741 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs6978721 ENSG00000222364.1 RNU6-96P -6.19 2.89e-09 4.43e-06 -0.46 -0.39 Aortic root size; chr7:66418217 chr7:66395191~66395286:+ CESC cis rs2404602 0.735 rs2048856 ENSG00000259422.1 RP11-593F23.1 -6.19 2.89e-09 4.43e-06 -0.47 -0.39 Blood metabolite levels; chr15:76507742 chr15:76174891~76181486:- CESC cis rs10463554 0.892 rs1837256 ENSG00000175749.11 EIF3KP1 6.19 2.9e-09 4.44e-06 0.44 0.39 Parkinson's disease; chr5:102968852 chr5:103032376~103033031:+ CESC cis rs1707322 0.721 rs11211165 ENSG00000281133.1 AL355480.3 -6.19 2.9e-09 4.44e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692234 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs11211166 ENSG00000281133.1 AL355480.3 -6.19 2.9e-09 4.44e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692270 chr1:45580892~45580996:- CESC cis rs10129255 0.518 rs12590732 ENSG00000223648.3 IGHV3-64 -6.19 2.9e-09 4.44e-06 -0.32 -0.39 Kawasaki disease; chr14:106779612 chr14:106643132~106658258:- CESC cis rs875971 0.767 rs1643394 ENSG00000226824.5 RP4-756H11.3 -6.19 2.9e-09 4.44e-06 -0.48 -0.39 Aortic root size; chr7:66371107 chr7:66654538~66669855:+ CESC cis rs4728142 0.604 rs10239340 ENSG00000275106.1 RP11-309L24.10 -6.19 2.91e-09 4.45e-06 -0.51 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129028456 chr7:128952527~128953316:- CESC cis rs4728142 0.604 rs6467222 ENSG00000275106.1 RP11-309L24.10 -6.19 2.91e-09 4.45e-06 -0.51 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129034365 chr7:128952527~128953316:- CESC cis rs875971 1 rs2420591 ENSG00000222364.1 RNU6-96P -6.19 2.92e-09 4.46e-06 -0.46 -0.39 Aortic root size; chr7:66447394 chr7:66395191~66395286:+ CESC cis rs4853012 0.793 rs6707619 ENSG00000257800.1 FNBP1P1 6.19 2.92e-09 4.47e-06 0.4 0.39 Gestational age at birth (maternal effect); chr2:74117529 chr2:74120680~74123218:+ CESC cis rs7572733 1 rs1541953 ENSG00000222017.1 AC011997.1 -6.19 2.93e-09 4.48e-06 -0.43 -0.39 Dermatomyositis; chr2:198033620 chr2:197693106~197774823:+ CESC cis rs8005677 0.798 rs61977741 ENSG00000279656.1 RP11-298I3.6 6.19 2.93e-09 4.49e-06 0.47 0.39 Cognitive ability (multi-trait analysis); chr14:22931770 chr14:23023083~23024217:- CESC cis rs2720460 0.502 rs223374 ENSG00000246560.2 RP11-10L12.4 6.19 2.95e-09 4.51e-06 0.51 0.39 Testicular germ cell tumor; chr4:102837144 chr4:102828055~102844075:+ CESC cis rs875971 1 rs778726 ENSG00000222364.1 RNU6-96P -6.19 2.95e-09 4.51e-06 -0.46 -0.39 Aortic root size; chr7:66363744 chr7:66395191~66395286:+ CESC cis rs875971 0.767 rs1695815 ENSG00000222364.1 RNU6-96P -6.19 2.95e-09 4.51e-06 -0.46 -0.39 Aortic root size; chr7:66366357 chr7:66395191~66395286:+ CESC cis rs875971 1 rs778685 ENSG00000222364.1 RNU6-96P -6.19 2.95e-09 4.51e-06 -0.46 -0.39 Aortic root size; chr7:66371189 chr7:66395191~66395286:+ CESC cis rs875971 0.929 rs778682 ENSG00000222364.1 RNU6-96P -6.19 2.95e-09 4.51e-06 -0.46 -0.39 Aortic root size; chr7:66372947 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs11765965 ENSG00000222364.1 RNU6-96P -6.19 2.95e-09 4.51e-06 -0.46 -0.39 Aortic root size; chr7:66377234 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs60193905 ENSG00000222364.1 RNU6-96P -6.19 2.96e-09 4.52e-06 -0.46 -0.39 Aortic root size; chr7:66506273 chr7:66395191~66395286:+ CESC cis rs992157 0.798 rs10932772 ENSG00000261338.2 RP11-378A13.1 6.19 2.96e-09 4.52e-06 0.49 0.39 Colorectal cancer; chr2:218312425 chr2:218255319~218257366:+ CESC cis rs10463554 0.926 rs26433 ENSG00000175749.11 EIF3KP1 6.19 2.96e-09 4.53e-06 0.4 0.39 Parkinson's disease; chr5:103028154 chr5:103032376~103033031:+ CESC cis rs875971 0.862 rs880166 ENSG00000226824.5 RP4-756H11.3 6.19 2.97e-09 4.54e-06 0.47 0.39 Aortic root size; chr7:66205775 chr7:66654538~66669855:+ CESC cis rs875971 1 rs12533997 ENSG00000222364.1 RNU6-96P -6.19 2.97e-09 4.55e-06 -0.46 -0.39 Aortic root size; chr7:66500390 chr7:66395191~66395286:+ CESC cis rs875971 0.929 rs10950041 ENSG00000222364.1 RNU6-96P -6.19 2.97e-09 4.55e-06 -0.46 -0.39 Aortic root size; chr7:66508888 chr7:66395191~66395286:+ CESC cis rs9402743 0.775 rs2876312 ENSG00000217482.2 HMGB1P17 6.19 2.98e-09 4.55e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135648714 chr6:135636086~135636713:- CESC cis rs1823913 0.599 rs13020656 ENSG00000280083.1 RP11-317J9.1 -6.19 2.98e-09 4.55e-06 -0.45 -0.39 Obesity-related traits; chr2:191314197 chr2:191154118~191156070:- CESC cis rs765787 0.53 rs1631533 ENSG00000259520.4 CTD-2651B20.3 6.19 2.98e-09 4.55e-06 0.49 0.39 Uric acid levels; chr15:45226430 chr15:45251580~45279251:- CESC cis rs875971 0.862 rs1983372 ENSG00000226824.5 RP4-756H11.3 6.19 2.99e-09 4.56e-06 0.48 0.39 Aortic root size; chr7:66146364 chr7:66654538~66669855:+ CESC cis rs10129255 0.556 rs9324093 ENSG00000223648.3 IGHV3-64 6.19 2.99e-09 4.56e-06 0.32 0.39 Kawasaki disease; chr14:106683893 chr14:106643132~106658258:- CESC cis rs6504950 0.889 rs2628305 ENSG00000275710.1 RP11-257O5.4 6.19 2.99e-09 4.57e-06 0.48 0.39 Breast cancer; chr17:55063066 chr17:54964474~54964679:+ CESC cis rs11690935 0.959 rs12692970 ENSG00000228389.1 AC068039.4 6.19 3e-09 4.58e-06 0.52 0.39 Schizophrenia; chr2:171737687 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs10166005 ENSG00000228389.1 AC068039.4 6.19 3e-09 4.58e-06 0.52 0.39 Schizophrenia; chr2:171750784 chr2:171773482~171775844:+ CESC cis rs6142102 0.602 rs6141435 ENSG00000275784.1 RP5-1125A11.6 -6.19 3e-09 4.59e-06 -0.38 -0.39 Skin pigmentation; chr20:33963473 chr20:33989480~33991818:- CESC cis rs113835537 0.529 rs17495838 ENSG00000255517.5 CTD-3074O7.5 -6.19 3e-09 4.59e-06 -0.47 -0.39 Airway imaging phenotypes; chr11:66428794 chr11:66473490~66480233:- CESC cis rs6860806 0.507 rs272880 ENSG00000233006.5 AC034220.3 6.19 3.02e-09 4.61e-06 0.42 0.39 Breast cancer; chr5:132334485 chr5:132311285~132369916:- CESC cis rs875971 0.862 rs778684 ENSG00000226824.5 RP4-756H11.3 -6.19 3.02e-09 4.61e-06 -0.48 -0.39 Aortic root size; chr7:66371416 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs778680 ENSG00000226824.5 RP4-756H11.3 -6.19 3.02e-09 4.61e-06 -0.48 -0.39 Aortic root size; chr7:66375427 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs11769079 ENSG00000226824.5 RP4-756H11.3 -6.19 3.02e-09 4.61e-06 -0.48 -0.39 Aortic root size; chr7:66377141 chr7:66654538~66669855:+ CESC cis rs3814244 0.933 rs10748093 ENSG00000255733.4 IFNG-AS1 -6.18 3.03e-09 4.63e-06 -0.33 -0.39 Itch intensity from mosquito bite adjusted by bite size; chr12:68024469 chr12:67989445~68234686:+ CESC cis rs1707322 0.686 rs3014242 ENSG00000281133.1 AL355480.3 6.18 3.04e-09 4.64e-06 0.47 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621905 chr1:45580892~45580996:- CESC cis rs875971 0.964 rs1643388 ENSG00000222364.1 RNU6-96P -6.18 3.05e-09 4.65e-06 -0.46 -0.39 Aortic root size; chr7:66379575 chr7:66395191~66395286:+ CESC cis rs875971 1 rs778722 ENSG00000222364.1 RNU6-96P -6.18 3.05e-09 4.65e-06 -0.46 -0.39 Aortic root size; chr7:66379841 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs778721 ENSG00000222364.1 RNU6-96P -6.18 3.05e-09 4.65e-06 -0.46 -0.39 Aortic root size; chr7:66380410 chr7:66395191~66395286:+ CESC cis rs875971 0.789 rs10260426 ENSG00000226824.5 RP4-756H11.3 6.18 3.05e-09 4.65e-06 0.47 0.39 Aortic root size; chr7:66271055 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs2901152 ENSG00000226824.5 RP4-756H11.3 6.18 3.05e-09 4.65e-06 0.47 0.39 Aortic root size; chr7:66300017 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs10263690 ENSG00000226824.5 RP4-756H11.3 6.18 3.05e-09 4.65e-06 0.47 0.39 Aortic root size; chr7:66301466 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs10250544 ENSG00000226824.5 RP4-756H11.3 6.18 3.05e-09 4.65e-06 0.47 0.39 Aortic root size; chr7:66301574 chr7:66654538~66669855:+ CESC cis rs6452524 0.967 rs62374400 ENSG00000249664.1 CTD-2227C6.2 6.18 3.05e-09 4.65e-06 0.42 0.39 Hypertension (SNP x SNP interaction); chr5:83177053 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs10040363 ENSG00000249664.1 CTD-2227C6.2 6.18 3.05e-09 4.65e-06 0.42 0.39 Hypertension (SNP x SNP interaction); chr5:83177826 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs10051542 ENSG00000249664.1 CTD-2227C6.2 6.18 3.05e-09 4.65e-06 0.42 0.39 Hypertension (SNP x SNP interaction); chr5:83178268 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs10051557 ENSG00000249664.1 CTD-2227C6.2 6.18 3.05e-09 4.65e-06 0.42 0.39 Hypertension (SNP x SNP interaction); chr5:83178307 chr5:83012285~83013109:- CESC cis rs875971 0.895 rs7788984 ENSG00000222364.1 RNU6-96P -6.18 3.06e-09 4.66e-06 -0.46 -0.39 Aortic root size; chr7:66450629 chr7:66395191~66395286:+ CESC cis rs2404602 0.608 rs17361504 ENSG00000259422.1 RP11-593F23.1 6.18 3.06e-09 4.66e-06 0.43 0.39 Blood metabolite levels; chr15:76309530 chr15:76174891~76181486:- CESC cis rs11690935 0.959 rs6709156 ENSG00000228389.1 AC068039.4 6.18 3.06e-09 4.67e-06 0.52 0.39 Schizophrenia; chr2:171735434 chr2:171773482~171775844:+ CESC cis rs2980439 0.818 rs2945249 ENSG00000173295.6 FAM86B3P 6.18 3.06e-09 4.67e-06 0.51 0.39 Neuroticism; chr8:8237204 chr8:8228595~8244865:+ CESC cis rs6142102 0.502 rs58393429 ENSG00000275784.1 RP5-1125A11.6 -6.18 3.07e-09 4.67e-06 -0.38 -0.39 Skin pigmentation; chr20:33957996 chr20:33989480~33991818:- CESC cis rs10875746 0.903 rs725454 ENSG00000240399.1 RP1-228P16.1 -6.18 3.07e-09 4.67e-06 -0.51 -0.39 Longevity (90 years and older); chr12:48108317 chr12:48054813~48055591:- CESC cis rs2442825 0.693 rs2728928 ENSG00000206573.7 THUMPD3-AS1 -6.18 3.07e-09 4.68e-06 -0.36 -0.39 Cerebrospinal fluid clusterin levels; chr3:9388275 chr3:9349689~9398579:- CESC cis rs1707322 0.685 rs56177313 ENSG00000281133.1 AL355480.3 -6.18 3.08e-09 4.69e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760134 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs11211178 ENSG00000281133.1 AL355480.3 -6.18 3.08e-09 4.69e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45761894 chr1:45580892~45580996:- CESC cis rs10129255 0.536 rs10139058 ENSG00000223648.3 IGHV3-64 6.18 3.09e-09 4.7e-06 0.31 0.39 Kawasaki disease; chr14:106685899 chr14:106643132~106658258:- CESC cis rs10129255 0.536 rs8004835 ENSG00000223648.3 IGHV3-64 6.18 3.09e-09 4.7e-06 0.31 0.39 Kawasaki disease; chr14:106686361 chr14:106643132~106658258:- CESC cis rs1930961 0.85 rs5996945 ENSG00000100058.11 CRYBB2P1 -6.18 3.11e-09 4.72e-06 -0.57 -0.39 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25448105~25520854:+ CESC cis rs9309711 0.737 rs9284795 ENSG00000225234.1 TRAPPC12-AS1 -6.18 3.11e-09 4.73e-06 -0.39 -0.39 Neurofibrillary tangles; chr2:3488294 chr2:3481242~3482409:- CESC cis rs2117029 0.619 rs2753 ENSG00000258017.1 RP11-386G11.10 -6.18 3.11e-09 4.73e-06 -0.49 -0.39 Intelligence (multi-trait analysis); chr12:49127889 chr12:49127782~49147869:+ CESC cis rs765787 0.53 rs2668751 ENSG00000259520.4 CTD-2651B20.3 6.18 3.11e-09 4.73e-06 0.49 0.39 Uric acid levels; chr15:45225095 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs1648286 ENSG00000259520.4 CTD-2651B20.3 6.18 3.11e-09 4.73e-06 0.49 0.39 Uric acid levels; chr15:45225188 chr15:45251580~45279251:- CESC cis rs1707322 0.752 rs11211168 ENSG00000281133.1 AL355480.3 -6.18 3.12e-09 4.74e-06 -0.47 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697975 chr1:45580892~45580996:- CESC cis rs875971 0.895 rs12698520 ENSG00000222364.1 RNU6-96P -6.18 3.12e-09 4.74e-06 -0.46 -0.39 Aortic root size; chr7:66453720 chr7:66395191~66395286:+ CESC cis rs7115242 0.858 rs6589592 ENSG00000254851.1 RP11-109L13.1 -6.18 3.13e-09 4.75e-06 -0.9 -0.39 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117087191 chr11:117135528~117138582:+ CESC cis rs6991838 0.584 rs7823840 ENSG00000200714.1 Y_RNA -6.18 3.15e-09 4.78e-06 -0.47 -0.39 Intelligence (multi-trait analysis); chr8:65606766 chr8:65592731~65592820:+ CESC cis rs875971 1 rs4717292 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66430611 chr7:66395191~66395286:+ CESC cis rs875971 0.895 rs10755833 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66448930 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs12668936 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66449417 chr7:66395191~66395286:+ CESC cis rs875971 0.895 rs1833495 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66456608 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs6945032 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66457499 chr7:66395191~66395286:+ CESC cis rs875971 0.929 rs12673810 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66458866 chr7:66395191~66395286:+ CESC cis rs875971 1 rs35149210 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66464938 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6961155 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66468308 chr7:66395191~66395286:+ CESC cis rs875971 1 rs7789768 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66473993 chr7:66395191~66395286:+ CESC cis rs875971 1 rs1363055 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66478288 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs9691480 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66479319 chr7:66395191~66395286:+ CESC cis rs875971 1 rs7789554 ENSG00000222364.1 RNU6-96P -6.18 3.15e-09 4.78e-06 -0.46 -0.39 Aortic root size; chr7:66481051 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6958271 ENSG00000222364.1 RNU6-96P -6.18 3.16e-09 4.8e-06 -0.46 -0.39 Aortic root size; chr7:66514344 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6958277 ENSG00000222364.1 RNU6-96P -6.18 3.16e-09 4.8e-06 -0.46 -0.39 Aortic root size; chr7:66514362 chr7:66395191~66395286:+ CESC cis rs10129255 0.53 rs11624912 ENSG00000223648.3 IGHV3-64 6.18 3.17e-09 4.81e-06 0.31 0.39 Kawasaki disease; chr14:106673891 chr14:106643132~106658258:- CESC cis rs9399137 0.507 rs4289677 ENSG00000232876.1 CTA-212D2.2 -6.18 3.17e-09 4.81e-06 -0.47 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954347 chr6:135055033~135060550:+ CESC cis rs1075265 0.633 rs28653587 ENSG00000233266.1 HMGB1P31 6.18 3.17e-09 4.81e-06 0.52 0.39 Chronotype;Morning vs. evening chronotype; chr2:53992435 chr2:54051334~54051760:+ CESC cis rs1707322 0.752 rs28719889 ENSG00000281133.1 AL355480.3 -6.18 3.18e-09 4.81e-06 -0.46 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736611 chr1:45580892~45580996:- CESC cis rs2404602 0.647 rs12898810 ENSG00000259422.1 RP11-593F23.1 -6.18 3.18e-09 4.82e-06 -0.48 -0.39 Blood metabolite levels; chr15:76612397 chr15:76174891~76181486:- CESC cis rs765787 0.53 rs2668737 ENSG00000259520.4 CTD-2651B20.3 6.18 3.18e-09 4.82e-06 0.49 0.39 Uric acid levels; chr15:45230601 chr15:45251580~45279251:- CESC cis rs2842992 0.915 rs2758335 ENSG00000237927.1 RP3-393E18.2 -6.18 3.19e-09 4.83e-06 -0.5 -0.39 Age-related macular degeneration (geographic atrophy); chr6:159689979 chr6:159586955~159589169:- CESC cis rs2842992 0.872 rs1570318 ENSG00000237927.1 RP3-393E18.2 -6.18 3.19e-09 4.83e-06 -0.5 -0.39 Age-related macular degeneration (geographic atrophy); chr6:159690441 chr6:159586955~159589169:- CESC cis rs2842992 0.915 rs2758350 ENSG00000237927.1 RP3-393E18.2 -6.18 3.19e-09 4.83e-06 -0.5 -0.39 Age-related macular degeneration (geographic atrophy); chr6:159697024 chr6:159586955~159589169:- CESC cis rs3806843 0.933 rs2240696 ENSG00000202111.1 VTRNA1-2 -6.18 3.19e-09 4.83e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140788485 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs2240695 ENSG00000202111.1 VTRNA1-2 -6.18 3.19e-09 4.83e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140788566 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs6579965 ENSG00000202111.1 VTRNA1-2 -6.18 3.19e-09 4.83e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140789226 chr5:140718925~140719013:+ CESC cis rs3806843 1 rs6898906 ENSG00000202111.1 VTRNA1-2 -6.18 3.19e-09 4.83e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140789714 chr5:140718925~140719013:+ CESC cis rs9402743 0.775 rs9483862 ENSG00000217482.2 HMGB1P17 6.18 3.19e-09 4.83e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135649541 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs9494315 ENSG00000217482.2 HMGB1P17 6.18 3.19e-09 4.83e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135649778 chr6:135636086~135636713:- CESC cis rs9402743 0.816 rs9402738 ENSG00000217482.2 HMGB1P17 6.18 3.19e-09 4.83e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135652112 chr6:135636086~135636713:- CESC cis rs9402743 0.74 rs9494318 ENSG00000217482.2 HMGB1P17 6.18 3.19e-09 4.83e-06 0.42 0.39 Systemic lupus erythematosus; chr6:135653519 chr6:135636086~135636713:- CESC cis rs507080 0.922 rs625513 ENSG00000255422.1 AP002954.4 -6.18 3.19e-09 4.83e-06 -0.47 -0.39 Serum metabolite levels; chr11:118685010 chr11:118704607~118750263:+ CESC cis rs4728142 0.604 rs10954215 ENSG00000275106.1 RP11-309L24.10 -6.17 3.21e-09 4.85e-06 -0.5 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129005459 chr7:128952527~128953316:- CESC cis rs3806843 1 rs2337985 ENSG00000202111.1 VTRNA1-2 -6.17 3.21e-09 4.86e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140778276 chr5:140718925~140719013:+ CESC cis rs1061377 1 rs3733277 ENSG00000249207.1 RP11-360F5.1 -6.17 3.22e-09 4.86e-06 -0.44 -0.39 Uric acid levels; chr4:39115483 chr4:39112677~39126818:- CESC cis rs1061377 1 rs3733278 ENSG00000249207.1 RP11-360F5.1 -6.17 3.22e-09 4.86e-06 -0.44 -0.39 Uric acid levels; chr4:39115615 chr4:39112677~39126818:- CESC cis rs1061377 1 rs3733279 ENSG00000249207.1 RP11-360F5.1 -6.17 3.22e-09 4.86e-06 -0.44 -0.39 Uric acid levels; chr4:39115625 chr4:39112677~39126818:- CESC cis rs6504950 0.85 rs2628309 ENSG00000275710.1 RP11-257O5.4 -6.17 3.23e-09 4.88e-06 -0.5 -0.39 Breast cancer; chr17:55038058 chr17:54964474~54964679:+ CESC cis rs4718428 0.705 rs4717331 ENSG00000226824.5 RP4-756H11.3 -6.17 3.23e-09 4.89e-06 -0.53 -0.39 Corneal structure; chr7:66913899 chr7:66654538~66669855:+ CESC cis rs3806843 1 rs10057161 ENSG00000202111.1 VTRNA1-2 -6.17 3.25e-09 4.91e-06 -0.39 -0.39 Depressive symptoms (multi-trait analysis); chr5:140777246 chr5:140718925~140719013:+ CESC cis rs12439619 0.883 rs62012045 ENSG00000278603.1 RP13-608F4.5 6.17 3.25e-09 4.91e-06 0.57 0.39 Intelligence (multi-trait analysis); chr15:82229366 chr15:82472203~82472426:+ CESC cis rs11690935 0.959 rs11897196 ENSG00000228389.1 AC068039.4 6.17 3.26e-09 4.91e-06 0.51 0.39 Schizophrenia; chr2:171729085 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs10207085 ENSG00000228389.1 AC068039.4 6.17 3.26e-09 4.91e-06 0.51 0.39 Schizophrenia; chr2:171729375 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs7604918 ENSG00000228389.1 AC068039.4 6.17 3.26e-09 4.91e-06 0.51 0.39 Schizophrenia; chr2:171731584 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs10204501 ENSG00000228389.1 AC068039.4 6.17 3.26e-09 4.91e-06 0.51 0.39 Schizophrenia; chr2:171732355 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs10204502 ENSG00000228389.1 AC068039.4 6.17 3.26e-09 4.91e-06 0.51 0.39 Schizophrenia; chr2:171732356 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs10204622 ENSG00000228389.1 AC068039.4 6.17 3.26e-09 4.91e-06 0.51 0.39 Schizophrenia; chr2:171732472 chr2:171773482~171775844:+ CESC cis rs1823913 0.599 rs12988037 ENSG00000280083.1 RP11-317J9.1 -6.17 3.26e-09 4.93e-06 -0.45 -0.39 Obesity-related traits; chr2:191306419 chr2:191154118~191156070:- CESC cis rs1707322 1 rs10890350 ENSG00000280836.1 AL355480.1 -6.17 3.28e-09 4.94e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45796706 chr1:45581219~45581321:- CESC cis rs9322193 0.607 rs6557165 ENSG00000231760.4 RP11-350J20.5 -6.17 3.3e-09 4.97e-06 -0.56 -0.39 Lung cancer; chr6:149906883 chr6:149796151~149826294:- CESC cis rs875971 0.862 rs7809814 ENSG00000226824.5 RP4-756H11.3 6.17 3.3e-09 4.98e-06 0.47 0.39 Aortic root size; chr7:66150410 chr7:66654538~66669855:+ CESC cis rs950169 0.922 rs11638445 ENSG00000225151.9 GOLGA2P7 -6.17 3.31e-09 4.99e-06 -0.52 -0.39 Schizophrenia; chr15:84594463 chr15:84199311~84230136:- CESC cis rs17711722 0.522 rs4642526 ENSG00000228409.4 CCT6P1 -6.17 3.32e-09 5.01e-06 -0.35 -0.39 Calcium levels; chr7:65751755 chr7:65751142~65763354:+ CESC cis rs2404602 0.622 rs11637296 ENSG00000259422.1 RP11-593F23.1 -6.17 3.34e-09 5.02e-06 -0.46 -0.39 Blood metabolite levels; chr15:76915544 chr15:76174891~76181486:- CESC cis rs6142102 0.625 rs1883707 ENSG00000275784.1 RP5-1125A11.6 6.17 3.34e-09 5.03e-06 0.37 0.39 Skin pigmentation; chr20:33964781 chr20:33989480~33991818:- CESC cis rs4728142 0.604 rs6969930 ENSG00000275106.1 RP11-309L24.10 -6.17 3.34e-09 5.03e-06 -0.5 -0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128990259 chr7:128952527~128953316:- CESC cis rs10463554 0.963 rs26253 ENSG00000175749.11 EIF3KP1 6.17 3.35e-09 5.04e-06 0.41 0.39 Parkinson's disease; chr5:103221266 chr5:103032376~103033031:+ CESC cis rs1707322 1 rs4660906 ENSG00000280836.1 AL355480.1 -6.17 3.36e-09 5.06e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46005188 chr1:45581219~45581321:- CESC cis rs720475 1 rs720475 ENSG00000204959.4 ARHGEF34P -6.17 3.36e-09 5.06e-06 -0.44 -0.39 Breast cancer; chr7:144377836 chr7:144272445~144286966:- CESC cis rs9399137 0.507 rs11758774 ENSG00000232876.1 CTA-212D2.2 -6.16 3.38e-09 5.08e-06 -0.47 -0.39 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135062651 chr6:135055033~135060550:+ CESC cis rs17507216 0.667 rs13379724 ENSG00000278603.1 RP13-608F4.5 6.16 3.38e-09 5.08e-06 0.59 0.39 Excessive daytime sleepiness; chr15:82619892 chr15:82472203~82472426:+ CESC cis rs875971 0.862 rs11773628 ENSG00000226824.5 RP4-756H11.3 6.16 3.39e-09 5.09e-06 0.49 0.39 Aortic root size; chr7:66517644 chr7:66654538~66669855:+ CESC cis rs11690935 0.959 rs973889 ENSG00000228389.1 AC068039.4 6.16 3.41e-09 5.13e-06 0.51 0.39 Schizophrenia; chr2:171723444 chr2:171773482~171775844:+ CESC cis rs950169 0.922 rs11631096 ENSG00000225151.9 GOLGA2P7 -6.16 3.42e-09 5.13e-06 -0.54 -0.39 Schizophrenia; chr15:84557698 chr15:84199311~84230136:- CESC cis rs950169 0.84 rs62019457 ENSG00000225151.9 GOLGA2P7 -6.16 3.42e-09 5.13e-06 -0.54 -0.39 Schizophrenia; chr15:84558911 chr15:84199311~84230136:- CESC cis rs35955747 0.902 rs12167361 ENSG00000236132.1 CTA-440B3.1 6.16 3.42e-09 5.14e-06 0.45 0.39 Neutrophil count;Sum basophil neutrophil counts; chr22:31300292 chr22:31816379~31817491:- CESC cis rs4853012 0.941 rs60291089 ENSG00000257800.1 FNBP1P1 6.16 3.42e-09 5.14e-06 0.4 0.39 Gestational age at birth (maternal effect); chr2:74117763 chr2:74120680~74123218:+ CESC cis rs4853012 0.838 rs58759652 ENSG00000257800.1 FNBP1P1 6.16 3.42e-09 5.14e-06 0.4 0.39 Gestational age at birth (maternal effect); chr2:74117775 chr2:74120680~74123218:+ CESC cis rs7208859 0.673 rs9889755 ENSG00000263531.1 RP13-753N3.1 -6.16 3.42e-09 5.14e-06 -0.64 -0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30907487 chr17:30863921~30864940:- CESC cis rs992157 0.735 rs13430006 ENSG00000261338.2 RP11-378A13.1 -6.16 3.43e-09 5.15e-06 -0.47 -0.39 Colorectal cancer; chr2:218248366 chr2:218255319~218257366:+ CESC cis rs1061377 1 rs13182 ENSG00000249207.1 RP11-360F5.1 -6.16 3.44e-09 5.16e-06 -0.43 -0.39 Uric acid levels; chr4:39121293 chr4:39112677~39126818:- CESC cis rs897984 0.571 rs7184567 ENSG00000260911.2 RP11-196G11.2 6.16 3.44e-09 5.16e-06 0.4 0.39 Dementia with Lewy bodies; chr16:31009757 chr16:31043150~31049868:+ CESC cis rs1707322 0.964 rs6697830 ENSG00000280836.1 AL355480.1 -6.16 3.44e-09 5.17e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45824805 chr1:45581219~45581321:- CESC cis rs1707322 1 rs12060274 ENSG00000280836.1 AL355480.1 -6.16 3.44e-09 5.17e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45825390 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10890353 ENSG00000280836.1 AL355480.1 -6.16 3.44e-09 5.17e-06 -0.45 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45832711 chr1:45581219~45581321:- CESC cis rs950169 0.922 rs67804993 ENSG00000225151.9 GOLGA2P7 -6.16 3.45e-09 5.18e-06 -0.54 -0.39 Schizophrenia; chr15:84560799 chr15:84199311~84230136:- CESC cis rs992157 0.732 rs10932771 ENSG00000261338.2 RP11-378A13.1 6.16 3.46e-09 5.19e-06 0.48 0.39 Colorectal cancer; chr2:218305513 chr2:218255319~218257366:+ CESC cis rs10463554 0.892 rs10463988 ENSG00000175749.11 EIF3KP1 6.16 3.46e-09 5.19e-06 0.41 0.39 Parkinson's disease; chr5:102913595 chr5:103032376~103033031:+ CESC cis rs1577917 0.958 rs67024565 ENSG00000203875.9 SNHG5 -6.16 3.46e-09 5.2e-06 -0.5 -0.39 Response to antipsychotic treatment; chr6:85844279 chr6:85660950~85678736:- CESC cis rs6452524 0.534 rs7727691 ENSG00000249664.1 CTD-2227C6.2 6.16 3.47e-09 5.2e-06 0.46 0.39 Hypertension (SNP x SNP interaction); chr5:83075876 chr5:83012285~83013109:- CESC cis rs875971 0.862 rs778686 ENSG00000226824.5 RP4-756H11.3 -6.16 3.48e-09 5.22e-06 -0.48 -0.39 Aortic root size; chr7:66370923 chr7:66654538~66669855:+ CESC cis rs150992 0.587 rs11949103 ENSG00000248489.1 CTD-2007H13.3 -6.16 3.5e-09 5.24e-06 -0.48 -0.38 Body mass index; chr5:99011939 chr5:98929171~98995013:+ CESC cis rs875971 0.893 rs62465470 ENSG00000226824.5 RP4-756H11.3 6.16 3.5e-09 5.24e-06 0.47 0.38 Aortic root size; chr7:66136231 chr7:66654538~66669855:+ CESC cis rs4728142 0.564 rs11767711 ENSG00000275106.1 RP11-309L24.10 -6.16 3.51e-09 5.25e-06 -0.5 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129011778 chr7:128952527~128953316:- CESC cis rs10129255 0.556 rs6576222 ENSG00000223648.3 IGHV3-64 6.16 3.52e-09 5.27e-06 0.32 0.38 Kawasaki disease; chr14:106776442 chr14:106643132~106658258:- CESC cis rs10129255 0.536 rs6576223 ENSG00000223648.3 IGHV3-64 6.16 3.52e-09 5.27e-06 0.32 0.38 Kawasaki disease; chr14:106776448 chr14:106643132~106658258:- CESC cis rs11690935 0.798 rs13018768 ENSG00000228389.1 AC068039.4 6.16 3.53e-09 5.28e-06 0.51 0.38 Schizophrenia; chr2:171742082 chr2:171773482~171775844:+ CESC cis rs8081395 0.741 rs2645462 ENSG00000266992.1 DHX40P1 6.16 3.54e-09 5.3e-06 0.42 0.38 White blood cell count; chr17:59906198 chr17:59976009~60002384:- CESC cis rs8081395 0.711 rs1292034 ENSG00000266992.1 DHX40P1 6.16 3.54e-09 5.3e-06 0.42 0.38 White blood cell count; chr17:59912499 chr17:59976009~60002384:- CESC cis rs8081395 0.741 rs180532 ENSG00000266992.1 DHX40P1 6.16 3.54e-09 5.3e-06 0.42 0.38 White blood cell count; chr17:59925936 chr17:59976009~60002384:- CESC cis rs8081395 0.741 rs180530 ENSG00000266992.1 DHX40P1 6.16 3.54e-09 5.3e-06 0.42 0.38 White blood cell count; chr17:59926233 chr17:59976009~60002384:- CESC cis rs8081395 0.741 rs180519 ENSG00000266992.1 DHX40P1 6.16 3.54e-09 5.3e-06 0.42 0.38 White blood cell count; chr17:59938910 chr17:59976009~60002384:- CESC cis rs507080 0.961 rs4457789 ENSG00000255422.1 AP002954.4 -6.16 3.55e-09 5.31e-06 -0.45 -0.38 Serum metabolite levels; chr11:118668461 chr11:118704607~118750263:+ CESC cis rs6860806 0.507 rs270608 ENSG00000233006.5 AC034220.3 6.16 3.56e-09 5.32e-06 0.43 0.38 Breast cancer; chr5:132312713 chr5:132311285~132369916:- CESC cis rs1707322 1 rs10890355 ENSG00000280836.1 AL355480.1 -6.15 3.57e-09 5.34e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45851676 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211204 ENSG00000280836.1 AL355480.1 -6.15 3.57e-09 5.34e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45852192 chr1:45581219~45581321:- CESC cis rs1707322 0.647 rs6686944 ENSG00000281133.1 AL355480.3 -6.15 3.57e-09 5.34e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690636 chr1:45580892~45580996:- CESC cis rs3806843 0.75 rs2563285 ENSG00000202111.1 VTRNA1-2 6.15 3.57e-09 5.34e-06 0.4 0.38 Depressive symptoms (multi-trait analysis); chr5:140746552 chr5:140718925~140719013:+ CESC cis rs6700559 0.873 rs7526367 ENSG00000260088.1 RP11-92G12.3 -6.15 3.57e-09 5.34e-06 -0.5 -0.38 Coronary artery disease; chr1:200688025 chr1:200669507~200694250:+ CESC cis rs34779708 0.771 rs12098283 ENSG00000230534.5 RP11-297A16.2 6.15 3.58e-09 5.34e-06 0.51 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35189187 chr10:35098006~35127020:- CESC cis rs7188445 0.592 rs7199794 ENSG00000261390.4 RP11-345M22.2 6.15 3.59e-09 5.36e-06 0.46 0.38 Urate levels; chr16:79708296 chr16:79715232~79770563:- CESC cis rs6860806 0.507 rs272891 ENSG00000233006.5 AC034220.3 6.15 3.59e-09 5.36e-06 0.42 0.38 Breast cancer; chr5:132328701 chr5:132311285~132369916:- CESC cis rs9399135 0.66 rs9376072 ENSG00000232876.1 CTA-212D2.2 -6.15 3.59e-09 5.37e-06 -0.44 -0.38 Red blood cell count; chr6:134959381 chr6:135055033~135060550:+ CESC cis rs1061377 1 rs6812540 ENSG00000249207.1 RP11-360F5.1 -6.15 3.61e-09 5.39e-06 -0.43 -0.38 Uric acid levels; chr4:39114803 chr4:39112677~39126818:- CESC cis rs1061377 1 rs10026775 ENSG00000249207.1 RP11-360F5.1 -6.15 3.61e-09 5.39e-06 -0.43 -0.38 Uric acid levels; chr4:39115155 chr4:39112677~39126818:- CESC cis rs1061377 1 rs3733276 ENSG00000249207.1 RP11-360F5.1 -6.15 3.61e-09 5.39e-06 -0.43 -0.38 Uric acid levels; chr4:39115291 chr4:39112677~39126818:- CESC cis rs6504950 1 rs9915183 ENSG00000275710.1 RP11-257O5.4 6.15 3.61e-09 5.39e-06 0.47 0.38 Breast cancer; chr17:54969776 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9895808 ENSG00000275710.1 RP11-257O5.4 6.15 3.61e-09 5.39e-06 0.47 0.38 Breast cancer; chr17:54971081 chr17:54964474~54964679:+ CESC cis rs6504950 1 rs9897447 ENSG00000275710.1 RP11-257O5.4 6.15 3.61e-09 5.39e-06 0.47 0.38 Breast cancer; chr17:54971108 chr17:54964474~54964679:+ CESC cis rs11690935 0.959 rs7608403 ENSG00000228389.1 AC068039.4 6.15 3.62e-09 5.4e-06 0.5 0.38 Schizophrenia; chr2:171790255 chr2:171773482~171775844:+ CESC cis rs875971 1 rs778710 ENSG00000222364.1 RNU6-96P -6.15 3.63e-09 5.41e-06 -0.46 -0.38 Aortic root size; chr7:66389847 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs778708 ENSG00000222364.1 RNU6-96P -6.15 3.63e-09 5.41e-06 -0.46 -0.38 Aortic root size; chr7:66391332 chr7:66395191~66395286:+ CESC cis rs875971 1 rs778696 ENSG00000222364.1 RNU6-96P -6.15 3.63e-09 5.41e-06 -0.46 -0.38 Aortic root size; chr7:66405826 chr7:66395191~66395286:+ CESC cis rs875971 1 rs778694 ENSG00000222364.1 RNU6-96P -6.15 3.63e-09 5.41e-06 -0.46 -0.38 Aortic root size; chr7:66406571 chr7:66395191~66395286:+ CESC cis rs875971 1 rs4718344 ENSG00000222364.1 RNU6-96P -6.15 3.63e-09 5.41e-06 -0.46 -0.38 Aortic root size; chr7:66409394 chr7:66395191~66395286:+ CESC cis rs875971 0.737 rs7803424 ENSG00000222364.1 RNU6-96P -6.15 3.63e-09 5.41e-06 -0.46 -0.38 Aortic root size; chr7:66415618 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs7799834 ENSG00000222364.1 RNU6-96P -6.15 3.63e-09 5.41e-06 -0.46 -0.38 Aortic root size; chr7:66415707 chr7:66395191~66395286:+ CESC cis rs1823913 0.599 rs55786000 ENSG00000280083.1 RP11-317J9.1 -6.15 3.63e-09 5.41e-06 -0.45 -0.38 Obesity-related traits; chr2:191284500 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs17346412 ENSG00000280083.1 RP11-317J9.1 -6.15 3.63e-09 5.41e-06 -0.45 -0.38 Obesity-related traits; chr2:191285902 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs17412239 ENSG00000280083.1 RP11-317J9.1 -6.15 3.63e-09 5.41e-06 -0.45 -0.38 Obesity-related traits; chr2:191285937 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs35098152 ENSG00000280083.1 RP11-317J9.1 -6.15 3.63e-09 5.41e-06 -0.45 -0.38 Obesity-related traits; chr2:191286658 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs35150635 ENSG00000280083.1 RP11-317J9.1 -6.15 3.63e-09 5.41e-06 -0.45 -0.38 Obesity-related traits; chr2:191287303 chr2:191154118~191156070:- CESC cis rs10129255 0.5 rs988134 ENSG00000223648.3 IGHV3-64 6.15 3.63e-09 5.42e-06 0.32 0.38 Kawasaki disease; chr14:106776698 chr14:106643132~106658258:- CESC cis rs10129255 0.5 rs988133 ENSG00000223648.3 IGHV3-64 6.15 3.63e-09 5.42e-06 0.32 0.38 Kawasaki disease; chr14:106776724 chr14:106643132~106658258:- CESC cis rs11690935 0.959 rs35391289 ENSG00000228389.1 AC068039.4 6.15 3.64e-09 5.42e-06 0.52 0.38 Schizophrenia; chr2:171778473 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs7586207 ENSG00000228389.1 AC068039.4 6.15 3.64e-09 5.43e-06 0.51 0.38 Schizophrenia; chr2:171814584 chr2:171773482~171775844:+ CESC cis rs9399135 0.967 rs4896119 ENSG00000232876.1 CTA-212D2.2 -6.15 3.67e-09 5.46e-06 -0.45 -0.38 Red blood cell count; chr6:134972253 chr6:135055033~135060550:+ CESC cis rs9399135 0.967 rs4896121 ENSG00000232876.1 CTA-212D2.2 -6.15 3.67e-09 5.46e-06 -0.45 -0.38 Red blood cell count; chr6:134972507 chr6:135055033~135060550:+ CESC cis rs1061377 0.965 rs12504238 ENSG00000249207.1 RP11-360F5.1 -6.15 3.69e-09 5.49e-06 -0.44 -0.38 Uric acid levels; chr4:39142824 chr4:39112677~39126818:- CESC cis rs875971 0.964 rs778723 ENSG00000222364.1 RNU6-96P -6.15 3.7e-09 5.51e-06 -0.46 -0.38 Aortic root size; chr7:66364510 chr7:66395191~66395286:+ CESC cis rs2739330 0.828 rs4820572 ENSG00000250470.1 AP000351.3 6.15 3.7e-09 5.52e-06 0.5 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23976904~23977585:- CESC cis rs6504950 0.889 rs1156287 ENSG00000275710.1 RP11-257O5.4 -6.15 3.71e-09 5.52e-06 -0.49 -0.38 Breast cancer; chr17:54999438 chr17:54964474~54964679:+ CESC cis rs7727544 0.709 rs441969 ENSG00000233006.5 AC034220.3 6.15 3.73e-09 5.55e-06 0.44 0.38 Blood metabolite levels; chr5:132366428 chr5:132311285~132369916:- CESC cis rs1707322 0.721 rs4660314 ENSG00000281133.1 AL355480.3 -6.15 3.74e-09 5.57e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764213 chr1:45580892~45580996:- CESC cis rs4728142 0.604 rs7807018 ENSG00000275106.1 RP11-309L24.10 -6.15 3.74e-09 5.57e-06 -0.5 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129000134 chr7:128952527~128953316:- CESC cis rs4728142 0.604 rs4731536 ENSG00000275106.1 RP11-309L24.10 -6.15 3.74e-09 5.57e-06 -0.5 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129000239 chr7:128952527~128953316:- CESC cis rs3814244 0.933 rs11610126 ENSG00000255733.4 IFNG-AS1 -6.15 3.75e-09 5.57e-06 -0.33 -0.38 Itch intensity from mosquito bite adjusted by bite size; chr12:68026493 chr12:67989445~68234686:+ CESC cis rs1061377 1 rs9999327 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39110111 chr4:39112677~39126818:- CESC cis rs1061377 0.965 rs6833654 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39110701 chr4:39112677~39126818:- CESC cis rs1061377 1 rs1036038 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39111383 chr4:39112677~39126818:- CESC cis rs1061377 1 rs1560396 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39112092 chr4:39112677~39126818:- CESC cis rs1061377 1 rs1560397 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39112265 chr4:39112677~39126818:- CESC cis rs1061377 1 rs2381285 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39112775 chr4:39112677~39126818:- CESC cis rs1061377 1 rs2163272 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39112790 chr4:39112677~39126818:- CESC cis rs1061377 1 rs2163273 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39112835 chr4:39112677~39126818:- CESC cis rs1061377 1 rs62310332 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39112939 chr4:39112677~39126818:- CESC cis rs1061377 0.965 rs3796510 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39113309 chr4:39112677~39126818:- CESC cis rs1061377 1 rs10030904 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39113603 chr4:39112677~39126818:- CESC cis rs1061377 0.932 rs6855118 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39114322 chr4:39112677~39126818:- CESC cis rs1061377 1 rs6829234 ENSG00000249207.1 RP11-360F5.1 -6.14 3.78e-09 5.62e-06 -0.43 -0.38 Uric acid levels; chr4:39114586 chr4:39112677~39126818:- CESC cis rs10875746 0.859 rs12305511 ENSG00000240399.1 RP1-228P16.1 6.14 3.78e-09 5.62e-06 0.49 0.38 Longevity (90 years and older); chr12:48188933 chr12:48054813~48055591:- CESC cis rs7617773 0.817 rs9819094 ENSG00000229759.1 MRPS18AP1 6.14 3.78e-09 5.62e-06 0.42 0.38 Coronary artery disease; chr3:48278068 chr3:48256350~48256938:- CESC cis rs10463554 0.824 rs3776868 ENSG00000175749.11 EIF3KP1 6.14 3.78e-09 5.62e-06 0.43 0.38 Parkinson's disease; chr5:102963012 chr5:103032376~103033031:+ CESC cis rs1707322 0.752 rs8179402 ENSG00000281133.1 AL355480.3 -6.14 3.79e-09 5.63e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45676794 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs8179296 ENSG00000281133.1 AL355480.3 -6.14 3.79e-09 5.63e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45678119 chr1:45580892~45580996:- CESC cis rs6142102 0.625 rs6142061 ENSG00000275784.1 RP5-1125A11.6 -6.14 3.81e-09 5.66e-06 -0.38 -0.38 Skin pigmentation; chr20:33960529 chr20:33989480~33991818:- CESC cis rs11690935 0.921 rs10200608 ENSG00000228389.1 AC068039.4 6.14 3.81e-09 5.66e-06 0.51 0.38 Schizophrenia; chr2:171741419 chr2:171773482~171775844:+ CESC cis rs6504950 1 rs9902687 ENSG00000275710.1 RP11-257O5.4 6.14 3.81e-09 5.66e-06 0.47 0.38 Breast cancer; chr17:54971563 chr17:54964474~54964679:+ CESC cis rs9660180 0.967 rs12034740 ENSG00000231050.1 RP1-140A9.1 6.14 3.82e-09 5.66e-06 0.45 0.38 Body mass index; chr1:1797530 chr1:1891471~1892658:+ CESC cis rs10463554 1 rs17154893 ENSG00000175749.11 EIF3KP1 6.14 3.82e-09 5.67e-06 0.41 0.38 Parkinson's disease; chr5:102980902 chr5:103032376~103033031:+ CESC cis rs10463554 1 rs6596529 ENSG00000175749.11 EIF3KP1 6.14 3.82e-09 5.67e-06 0.41 0.38 Parkinson's disease; chr5:102981338 chr5:103032376~103033031:+ CESC cis rs875971 0.929 rs778712 ENSG00000222364.1 RNU6-96P -6.14 3.82e-09 5.67e-06 -0.46 -0.38 Aortic root size; chr7:66384991 chr7:66395191~66395286:+ CESC cis rs11155671 0.53 rs4869763 ENSG00000216906.2 RP11-350J20.9 6.14 3.83e-09 5.68e-06 0.41 0.38 Testicular germ cell tumor; chr6:149890548 chr6:149904243~149906418:+ CESC cis rs2404602 0.552 rs11630185 ENSG00000259422.1 RP11-593F23.1 -6.14 3.85e-09 5.71e-06 -0.49 -0.38 Blood metabolite levels; chr15:76667442 chr15:76174891~76181486:- CESC cis rs10463554 0.963 rs26817 ENSG00000175749.11 EIF3KP1 -6.14 3.87e-09 5.73e-06 -0.4 -0.38 Parkinson's disease; chr5:103204665 chr5:103032376~103033031:+ CESC cis rs2581828 0.656 rs2581800 ENSG00000242142.1 SERBP1P3 6.14 3.87e-09 5.74e-06 0.43 0.38 Crohn's disease; chr3:53075336 chr3:53064283~53065091:- CESC cis rs1707322 1 rs785510 ENSG00000280836.1 AL355480.1 6.14 3.88e-09 5.75e-06 0.47 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46062946 chr1:45581219~45581321:- CESC cis rs875971 1 rs6460296 ENSG00000222364.1 RNU6-96P -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Aortic root size; chr7:66430152 chr7:66395191~66395286:+ CESC cis rs875971 1 rs2042133 ENSG00000222364.1 RNU6-96P -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Aortic root size; chr7:66466935 chr7:66395191~66395286:+ CESC cis rs875971 0.964 rs2161065 ENSG00000222364.1 RNU6-96P -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Aortic root size; chr7:66467918 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs12698521 ENSG00000222364.1 RNU6-96P -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Aortic root size; chr7:66474502 chr7:66395191~66395286:+ CESC cis rs1707322 0.928 rs6681068 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45932710 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211228 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45934168 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs11211229 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45934845 chr1:45581219~45581321:- CESC cis rs1707322 1 rs9803784 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45936235 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs12022335 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45937060 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10890375 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940909 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10890377 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940922 chr1:45581219~45581321:- CESC cis rs1707322 1 rs6671754 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45968318 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs6666763 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45970779 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4489497 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45973026 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211235 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45974703 chr1:45581219~45581321:- CESC cis rs1707322 0.893 rs9919275 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45975688 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211236 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45978095 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4660328 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45979159 chr1:45581219~45581321:- CESC cis rs1707322 0.928 rs61785614 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45980375 chr1:45581219~45581321:- CESC cis rs1707322 1 rs9793167 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45981128 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211237 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45981657 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs11211238 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45983743 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4460583 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45984246 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs4459051 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45985531 chr1:45581219~45581321:- CESC cis rs1707322 1 rs11211239 ENSG00000280836.1 AL355480.1 -6.14 3.89e-09 5.75e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45986275 chr1:45581219~45581321:- CESC cis rs1185460 1 rs1614264 ENSG00000271751.1 RP11-110I1.14 -6.14 3.91e-09 5.78e-06 -0.51 -0.38 Coronary artery disease; chr11:119071928 chr11:119065263~119065677:- CESC cis rs6991838 0.584 rs7836349 ENSG00000200714.1 Y_RNA -6.14 3.91e-09 5.78e-06 -0.46 -0.38 Intelligence (multi-trait analysis); chr8:65591328 chr8:65592731~65592820:+ CESC cis rs6452524 0.71 rs7708124 ENSG00000249664.1 CTD-2227C6.2 6.14 3.91e-09 5.78e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83132035 chr5:83012285~83013109:- CESC cis rs9402743 0.775 rs7742843 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135654681 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs9494319 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135655122 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs6916924 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135656563 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs6916825 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135656739 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs6917005 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135656842 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs9494320 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135657576 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs2068394 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135658279 chr6:135636086~135636713:- CESC cis rs9402743 0.775 rs9494321 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135658892 chr6:135636086~135636713:- CESC cis rs9402743 0.781 rs6935190 ENSG00000217482.2 HMGB1P17 6.14 3.91e-09 5.78e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135659553 chr6:135636086~135636713:- CESC cis rs6142102 0.625 rs4911138 ENSG00000275784.1 RP5-1125A11.6 -6.14 3.92e-09 5.79e-06 -0.38 -0.38 Skin pigmentation; chr20:33959893 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs4243974 ENSG00000275784.1 RP5-1125A11.6 -6.14 3.92e-09 5.79e-06 -0.38 -0.38 Skin pigmentation; chr20:33960062 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs6142062 ENSG00000275784.1 RP5-1125A11.6 -6.14 3.92e-09 5.79e-06 -0.38 -0.38 Skin pigmentation; chr20:33960706 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs6141432 ENSG00000275784.1 RP5-1125A11.6 -6.14 3.92e-09 5.79e-06 -0.38 -0.38 Skin pigmentation; chr20:33960791 chr20:33989480~33991818:- CESC cis rs6142102 0.602 rs6141433 ENSG00000275784.1 RP5-1125A11.6 -6.14 3.92e-09 5.79e-06 -0.38 -0.38 Skin pigmentation; chr20:33961056 chr20:33989480~33991818:- CESC cis rs1707322 0.963 rs34907901 ENSG00000280836.1 AL355480.1 -6.14 3.93e-09 5.81e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45939542 chr1:45581219~45581321:- CESC cis rs1075265 0.547 rs41385746 ENSG00000233266.1 HMGB1P31 -6.14 3.94e-09 5.82e-06 -0.53 -0.38 Chronotype;Morning vs. evening chronotype; chr2:54077893 chr2:54051334~54051760:+ CESC cis rs270601 0.955 rs273911 ENSG00000233006.5 AC034220.3 6.14 3.94e-09 5.82e-06 0.42 0.38 Acylcarnitine levels; chr5:132325833 chr5:132311285~132369916:- CESC cis rs875971 0.895 rs12531677 ENSG00000226824.5 RP4-756H11.3 6.13 3.97e-09 5.85e-06 0.47 0.38 Aortic root size; chr7:66304099 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs7798630 ENSG00000226824.5 RP4-756H11.3 6.13 3.97e-09 5.85e-06 0.47 0.38 Aortic root size; chr7:66306492 chr7:66654538~66669855:+ CESC cis rs8005677 0.828 rs4981450 ENSG00000279656.1 RP11-298I3.6 6.13 3.98e-09 5.87e-06 0.47 0.38 Cognitive ability (multi-trait analysis); chr14:22920095 chr14:23023083~23024217:- CESC cis rs11155671 0.53 rs2342769 ENSG00000216906.2 RP11-350J20.9 6.13 4.01e-09 5.92e-06 0.41 0.38 Testicular germ cell tumor; chr6:149895371 chr6:149904243~149906418:+ CESC cis rs1823913 0.599 rs55685315 ENSG00000280083.1 RP11-317J9.1 -6.13 4.02e-09 5.94e-06 -0.45 -0.38 Obesity-related traits; chr2:191306451 chr2:191154118~191156070:- CESC cis rs875971 0.862 rs1612452 ENSG00000226824.5 RP4-756H11.3 6.13 4.02e-09 5.94e-06 0.48 0.38 Aortic root size; chr7:66108909 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs1167390 ENSG00000226824.5 RP4-756H11.3 6.13 4.02e-09 5.94e-06 0.48 0.38 Aortic root size; chr7:66110906 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs35034167 ENSG00000226824.5 RP4-756H11.3 6.13 4.02e-09 5.94e-06 0.48 0.38 Aortic root size; chr7:66115179 chr7:66654538~66669855:+ CESC cis rs6142102 0.625 rs1883706 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.03e-09 5.94e-06 -0.38 -0.38 Skin pigmentation; chr20:33965071 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs1883705 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.03e-09 5.94e-06 -0.38 -0.38 Skin pigmentation; chr20:33965072 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs4012234 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.03e-09 5.94e-06 -0.38 -0.38 Skin pigmentation; chr20:33965241 chr20:33989480~33991818:- CESC cis rs6142102 0.649 rs4911382 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.03e-09 5.94e-06 -0.38 -0.38 Skin pigmentation; chr20:33965289 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs6141436 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.03e-09 5.94e-06 -0.38 -0.38 Skin pigmentation; chr20:33966765 chr20:33989480~33991818:- CESC cis rs35160687 0.901 rs10520415 ENSG00000273080.1 RP11-301O19.1 -6.13 4.03e-09 5.94e-06 -0.45 -0.38 Night sleep phenotypes; chr2:86271615 chr2:86195590~86196049:+ CESC cis rs1707322 1 rs785480 ENSG00000280836.1 AL355480.1 -6.13 4.04e-09 5.95e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46026492 chr1:45581219~45581321:- CESC cis rs11690935 0.959 rs76324055 ENSG00000228389.1 AC068039.4 6.13 4.05e-09 5.96e-06 0.51 0.38 Schizophrenia; chr2:171763640 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs77280952 ENSG00000228389.1 AC068039.4 6.13 4.05e-09 5.96e-06 0.51 0.38 Schizophrenia; chr2:171763641 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs75922913 ENSG00000228389.1 AC068039.4 6.13 4.05e-09 5.96e-06 0.51 0.38 Schizophrenia; chr2:171763642 chr2:171773482~171775844:+ CESC cis rs5769707 0.609 rs2071890 ENSG00000188511.11 C22orf34 6.13 4.05e-09 5.97e-06 0.44 0.38 Monocyte percentage of white cells;Monocyte count; chr22:49607643 chr22:49414524~49657542:- CESC cis rs7727544 0.735 rs272860 ENSG00000233006.5 AC034220.3 6.13 4.09e-09 6.03e-06 0.43 0.38 Blood metabolite levels; chr5:132348482 chr5:132311285~132369916:- CESC cis rs1823913 0.599 rs17412635 ENSG00000280083.1 RP11-317J9.1 6.13 4.09e-09 6.03e-06 0.44 0.38 Obesity-related traits; chr2:191294834 chr2:191154118~191156070:- CESC cis rs6142102 0.581 rs4911148 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.11e-09 6.05e-06 -0.39 -0.38 Skin pigmentation; chr20:34080438 chr20:33989480~33991818:- CESC cis rs7201929 1 rs7201929 ENSG00000259982.1 CDC37P1 6.13 4.11e-09 6.05e-06 0.48 0.38 QT interval; chr16:28860645 chr16:28700294~28701540:- CESC cis rs1061377 1 rs1036037 ENSG00000249207.1 RP11-360F5.1 -6.13 4.11e-09 6.06e-06 -0.43 -0.38 Uric acid levels; chr4:39111272 chr4:39112677~39126818:- CESC cis rs2404602 1 rs12594212 ENSG00000259422.1 RP11-593F23.1 6.13 4.13e-09 6.07e-06 0.43 0.38 Blood metabolite levels; chr15:76509673 chr15:76174891~76181486:- CESC cis rs6142102 0.538 rs6142058 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.13e-09 6.08e-06 -0.37 -0.38 Skin pigmentation; chr20:33954995 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs2050208 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.13e-09 6.08e-06 -0.37 -0.38 Skin pigmentation; chr20:33955767 chr20:33989480~33991818:- CESC cis rs6142102 0.602 rs4911380 ENSG00000275784.1 RP5-1125A11.6 -6.13 4.13e-09 6.08e-06 -0.37 -0.38 Skin pigmentation; chr20:33958418 chr20:33989480~33991818:- CESC cis rs116095464 0.867 rs7726582 ENSG00000250848.1 CTD-2083E4.5 -6.13 4.14e-09 6.1e-06 -0.48 -0.38 Breast cancer; chr5:215234 chr5:288833~290321:- CESC cis rs765787 0.53 rs2554457 ENSG00000259520.4 CTD-2651B20.3 6.13 4.16e-09 6.11e-06 0.49 0.38 Uric acid levels; chr15:45228728 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2554456 ENSG00000259520.4 CTD-2651B20.3 6.13 4.16e-09 6.11e-06 0.49 0.38 Uric acid levels; chr15:45228940 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs10467979 ENSG00000259520.4 CTD-2651B20.3 6.13 4.16e-09 6.11e-06 0.49 0.38 Uric acid levels; chr15:45229072 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2554455 ENSG00000259520.4 CTD-2651B20.3 6.13 4.16e-09 6.11e-06 0.49 0.38 Uric acid levels; chr15:45229106 chr15:45251580~45279251:- CESC cis rs11690935 0.959 rs2292815 ENSG00000228389.1 AC068039.4 6.13 4.16e-09 6.12e-06 0.52 0.38 Schizophrenia; chr2:171730141 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs4667694 ENSG00000228389.1 AC068039.4 6.13 4.16e-09 6.12e-06 0.52 0.38 Schizophrenia; chr2:171748889 chr2:171773482~171775844:+ CESC cis rs875971 0.964 rs6945019 ENSG00000222364.1 RNU6-96P -6.12 4.19e-09 6.16e-06 -0.46 -0.38 Aortic root size; chr7:66457471 chr7:66395191~66395286:+ CESC cis rs9584850 0.874 rs4584 ENSG00000231194.1 FARP1-AS1 6.12 4.19e-09 6.17e-06 0.49 0.38 Neuroticism; chr13:98449615 chr13:98435405~98435840:- CESC cis rs6142102 0.602 rs4911402 ENSG00000275784.1 RP5-1125A11.6 -6.12 4.2e-09 6.17e-06 -0.38 -0.38 Skin pigmentation; chr20:34079839 chr20:33989480~33991818:- CESC cis rs227275 0.53 rs3960788 ENSG00000246560.2 RP11-10L12.4 6.12 4.21e-09 6.18e-06 0.48 0.38 Allergic disease (asthma, hay fever or eczema); chr4:102994461 chr4:102828055~102844075:+ CESC cis rs875971 1 rs2077593 ENSG00000222364.1 RNU6-96P -6.12 4.23e-09 6.22e-06 -0.46 -0.38 Aortic root size; chr7:66427543 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs28470208 ENSG00000226824.5 RP4-756H11.3 6.12 4.24e-09 6.23e-06 0.48 0.38 Aortic root size; chr7:66119713 chr7:66654538~66669855:+ CESC cis rs8081395 0.775 rs2645482 ENSG00000266992.1 DHX40P1 6.12 4.25e-09 6.24e-06 0.42 0.38 White blood cell count; chr17:59865754 chr17:59976009~60002384:- CESC cis rs2739330 0.731 rs2000468 ENSG00000099984.9 GSTT2 -6.12 4.25e-09 6.25e-06 -0.47 -0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23980123~23983911:+ CESC cis rs9399135 0.967 rs2327580 ENSG00000232876.1 CTA-212D2.2 -6.12 4.28e-09 6.28e-06 -0.44 -0.38 Red blood cell count; chr6:135043279 chr6:135055033~135060550:+ CESC cis rs1707322 1 rs4073847 ENSG00000280836.1 AL355480.1 6.12 4.29e-09 6.3e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45997340 chr1:45581219~45581321:- CESC cis rs12439619 0.921 rs56042848 ENSG00000278603.1 RP13-608F4.5 6.12 4.29e-09 6.3e-06 0.57 0.38 Intelligence (multi-trait analysis); chr15:82235244 chr15:82472203~82472426:+ CESC cis rs1823913 0.599 rs17412094 ENSG00000280083.1 RP11-317J9.1 -6.12 4.3e-09 6.31e-06 -0.44 -0.38 Obesity-related traits; chr2:191284202 chr2:191154118~191156070:- CESC cis rs7201929 1 rs12920514 ENSG00000259982.1 CDC37P1 -6.12 4.3e-09 6.31e-06 -0.49 -0.38 QT interval; chr16:28824579 chr16:28700294~28701540:- CESC cis rs2117029 0.553 rs2162644 ENSG00000258017.1 RP11-386G11.10 -6.12 4.31e-09 6.32e-06 -0.49 -0.38 Intelligence (multi-trait analysis); chr12:49154407 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs6580701 ENSG00000258017.1 RP11-386G11.10 -6.12 4.31e-09 6.32e-06 -0.49 -0.38 Intelligence (multi-trait analysis); chr12:49163482 chr12:49127782~49147869:+ CESC cis rs2404602 0.655 rs10444809 ENSG00000259422.1 RP11-593F23.1 -6.12 4.31e-09 6.33e-06 -0.43 -0.38 Blood metabolite levels; chr15:76832195 chr15:76174891~76181486:- CESC cis rs6504950 0.889 rs2787505 ENSG00000275710.1 RP11-257O5.4 -6.12 4.33e-09 6.35e-06 -0.49 -0.38 Breast cancer; chr17:55030071 chr17:54964474~54964679:+ CESC cis rs3814244 0.902 rs2870961 ENSG00000255733.4 IFNG-AS1 -6.12 4.33e-09 6.35e-06 -0.33 -0.38 Itch intensity from mosquito bite adjusted by bite size; chr12:68024262 chr12:67989445~68234686:+ CESC cis rs8062405 0.895 rs62036658 ENSG00000259982.1 CDC37P1 6.12 4.33e-09 6.36e-06 0.48 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28839050 chr16:28700294~28701540:- CESC cis rs1577917 0.958 rs36053156 ENSG00000203875.9 SNHG5 -6.12 4.34e-09 6.36e-06 -0.5 -0.38 Response to antipsychotic treatment; chr6:85865791 chr6:85660950~85678736:- CESC cis rs9494142 0.592 rs1547247 ENSG00000232876.1 CTA-212D2.2 -6.12 4.34e-09 6.37e-06 -0.51 -0.38 Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts; chr6:135069698 chr6:135055033~135060550:+ CESC cis rs2117029 0.555 rs3741621 ENSG00000258017.1 RP11-386G11.10 -6.12 4.36e-09 6.4e-06 -0.49 -0.38 Intelligence (multi-trait analysis); chr12:49100242 chr12:49127782~49147869:+ CESC cis rs6452524 1 rs10067439 ENSG00000249664.1 CTD-2227C6.2 6.12 4.37e-09 6.41e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83136274 chr5:83012285~83013109:- CESC cis rs10875746 0.951 rs58865997 ENSG00000240399.1 RP1-228P16.1 -6.12 4.4e-09 6.45e-06 -0.49 -0.38 Longevity (90 years and older); chr12:48173090 chr12:48054813~48055591:- CESC cis rs7674212 0.865 rs13149311 ENSG00000246560.2 RP11-10L12.4 6.12 4.4e-09 6.45e-06 0.47 0.38 Type 2 diabetes; chr4:103056543 chr4:102828055~102844075:+ CESC cis rs1707322 1 rs11211190 ENSG00000280836.1 AL355480.1 -6.11 4.41e-09 6.46e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45800583 chr1:45581219~45581321:- CESC cis rs1707322 1 rs6429580 ENSG00000280836.1 AL355480.1 -6.11 4.41e-09 6.46e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45809976 chr1:45581219~45581321:- CESC cis rs11155671 0.53 rs9371542 ENSG00000216906.2 RP11-350J20.9 6.11 4.43e-09 6.48e-06 0.41 0.38 Testicular germ cell tumor; chr6:149891949 chr6:149904243~149906418:+ CESC cis rs9322193 0.567 rs7747457 ENSG00000216906.2 RP11-350J20.9 6.11 4.43e-09 6.48e-06 0.41 0.38 Lung cancer; chr6:149892366 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs9371223 ENSG00000216906.2 RP11-350J20.9 6.11 4.43e-09 6.48e-06 0.41 0.38 Testicular germ cell tumor; chr6:149893670 chr6:149904243~149906418:+ CESC cis rs507080 0.769 rs570836 ENSG00000255422.1 AP002954.4 -6.11 4.44e-09 6.49e-06 -0.46 -0.38 Serum metabolite levels; chr11:118641444 chr11:118704607~118750263:+ CESC cis rs875971 0.895 rs3857684 ENSG00000222364.1 RNU6-96P -6.11 4.44e-09 6.5e-06 -0.45 -0.38 Aortic root size; chr7:66473171 chr7:66395191~66395286:+ CESC cis rs10875746 0.904 rs11168422 ENSG00000240399.1 RP1-228P16.1 -6.11 4.45e-09 6.51e-06 -0.48 -0.38 Longevity (90 years and older); chr12:48125722 chr12:48054813~48055591:- CESC cis rs10875746 0.951 rs4760689 ENSG00000240399.1 RP1-228P16.1 -6.11 4.46e-09 6.52e-06 -0.48 -0.38 Longevity (90 years and older); chr12:48169861 chr12:48054813~48055591:- CESC cis rs10875746 0.951 rs4760690 ENSG00000240399.1 RP1-228P16.1 -6.11 4.46e-09 6.52e-06 -0.48 -0.38 Longevity (90 years and older); chr12:48169870 chr12:48054813~48055591:- CESC cis rs8005677 0.828 rs12589539 ENSG00000279656.1 RP11-298I3.6 6.11 4.46e-09 6.53e-06 0.47 0.38 Cognitive ability (multi-trait analysis); chr14:22927471 chr14:23023083~23024217:- CESC cis rs6452524 1 rs6452519 ENSG00000249664.1 CTD-2227C6.2 6.11 4.47e-09 6.55e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83133429 chr5:83012285~83013109:- CESC cis rs10853057 0.541 rs8082708 ENSG00000214174.7 AMZ2P1 -6.11 4.49e-09 6.56e-06 -0.48 -0.38 White matter microstructure (global fractional anisotropy); chr17:65046182 chr17:64966550~64975576:- CESC cis rs765787 0.53 rs2413785 ENSG00000259520.4 CTD-2651B20.3 6.11 4.49e-09 6.57e-06 0.49 0.38 Uric acid levels; chr15:45238183 chr15:45251580~45279251:- CESC cis rs875971 0.756 rs4718328 ENSG00000226824.5 RP4-756H11.3 6.11 4.5e-09 6.58e-06 0.46 0.38 Aortic root size; chr7:66228350 chr7:66654538~66669855:+ CESC cis rs2404602 1 rs2056544 ENSG00000259422.1 RP11-593F23.1 6.11 4.51e-09 6.59e-06 0.43 0.38 Blood metabolite levels; chr15:76533662 chr15:76174891~76181486:- CESC cis rs6860806 0.507 rs273917 ENSG00000233006.5 AC034220.3 6.11 4.53e-09 6.61e-06 0.43 0.38 Breast cancer; chr5:132323925 chr5:132311285~132369916:- CESC cis rs2842992 0.915 rs1967802 ENSG00000237927.1 RP3-393E18.2 -6.11 4.53e-09 6.61e-06 -0.51 -0.38 Age-related macular degeneration (geographic atrophy); chr6:159676759 chr6:159586955~159589169:- CESC cis rs2404602 0.684 rs57682236 ENSG00000259422.1 RP11-593F23.1 -6.11 4.53e-09 6.62e-06 -0.47 -0.38 Blood metabolite levels; chr15:76576137 chr15:76174891~76181486:- CESC cis rs7714584 1 rs79780973 ENSG00000197083.10 ZNF300P1 6.11 4.54e-09 6.63e-06 0.76 0.38 Crohn's disease; chr5:150795248 chr5:150930645~150946289:- CESC cis rs2729354 1 rs2511983 ENSG00000265566.2 RN7SL605P -6.11 4.54e-09 6.64e-06 -0.59 -0.38 Blood protein levels; chr11:57579401 chr11:57528085~57528365:- CESC cis rs2729354 0.953 rs2848625 ENSG00000265566.2 RN7SL605P -6.11 4.55e-09 6.65e-06 -0.6 -0.38 Blood protein levels; chr11:57563177 chr11:57528085~57528365:- CESC cis rs507080 0.501 rs494459 ENSG00000255422.1 AP002954.4 6.11 4.57e-09 6.67e-06 0.45 0.38 Serum metabolite levels; chr11:118703966 chr11:118704607~118750263:+ CESC cis rs8062405 0.755 rs2077031 ENSG00000259982.1 CDC37P1 6.11 4.57e-09 6.67e-06 0.48 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28591847 chr16:28700294~28701540:- CESC cis rs10463554 0.892 rs62362519 ENSG00000175749.11 EIF3KP1 6.11 4.58e-09 6.68e-06 0.43 0.38 Parkinson's disease; chr5:102965759 chr5:103032376~103033031:+ CESC cis rs10463554 0.853 rs2241565 ENSG00000175749.11 EIF3KP1 6.11 4.58e-09 6.68e-06 0.43 0.38 Parkinson's disease; chr5:102966233 chr5:103032376~103033031:+ CESC cis rs10463554 0.818 rs2241564 ENSG00000175749.11 EIF3KP1 6.11 4.58e-09 6.68e-06 0.43 0.38 Parkinson's disease; chr5:102966547 chr5:103032376~103033031:+ CESC cis rs7674212 0.531 rs4699048 ENSG00000246560.2 RP11-10L12.4 6.11 4.58e-09 6.68e-06 0.48 0.38 Type 2 diabetes; chr4:103005570 chr4:102828055~102844075:+ CESC cis rs9399135 0.967 rs9389258 ENSG00000232876.1 CTA-212D2.2 -6.11 4.6e-09 6.71e-06 -0.44 -0.38 Red blood cell count; chr6:135040002 chr6:135055033~135060550:+ CESC cis rs2117029 0.555 rs10783304 ENSG00000258017.1 RP11-386G11.10 -6.11 4.61e-09 6.72e-06 -0.48 -0.38 Intelligence (multi-trait analysis); chr12:49106615 chr12:49127782~49147869:+ CESC cis rs2243480 1 rs2707844 ENSG00000232559.3 GS1-124K5.12 6.11 4.61e-09 6.73e-06 0.66 0.38 Diabetic kidney disease; chr7:66594522 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1796220 ENSG00000232559.3 GS1-124K5.12 6.11 4.61e-09 6.73e-06 0.66 0.38 Diabetic kidney disease; chr7:66597113 chr7:66554588~66576923:- CESC cis rs2243480 1 rs2707831 ENSG00000232559.3 GS1-124K5.12 6.11 4.61e-09 6.73e-06 0.66 0.38 Diabetic kidney disease; chr7:66597524 chr7:66554588~66576923:- CESC cis rs6142102 0.602 rs932388 ENSG00000275784.1 RP5-1125A11.6 -6.11 4.62e-09 6.73e-06 -0.38 -0.38 Skin pigmentation; chr20:34069572 chr20:33989480~33991818:- CESC cis rs1707322 0.686 rs2275085 ENSG00000281133.1 AL355480.3 6.11 4.62e-09 6.74e-06 0.46 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620180 chr1:45580892~45580996:- CESC cis rs1823913 0.599 rs17414109 ENSG00000280083.1 RP11-317J9.1 -6.11 4.63e-09 6.75e-06 -0.45 -0.38 Obesity-related traits; chr2:191310675 chr2:191154118~191156070:- CESC cis rs11690935 0.694 rs312921 ENSG00000228389.1 AC068039.4 6.11 4.64e-09 6.76e-06 0.51 0.38 Schizophrenia; chr2:171710715 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs10206062 ENSG00000228389.1 AC068039.4 6.11 4.64e-09 6.76e-06 0.51 0.38 Schizophrenia; chr2:171720766 chr2:171773482~171775844:+ CESC cis rs6951245 0.58 rs77101766 ENSG00000229043.2 AC091729.9 -6.11 4.64e-09 6.76e-06 -0.51 -0.38 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1082802 chr7:1160374~1165267:+ CESC cis rs4728142 0.584 rs7796963 ENSG00000275106.1 RP11-309L24.10 -6.11 4.64e-09 6.76e-06 -0.5 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128988947 chr7:128952527~128953316:- CESC cis rs783540 0.521 rs28719490 ENSG00000276710.3 CSPG4P8 -6.11 4.65e-09 6.77e-06 -0.45 -0.38 Schizophrenia; chr15:82720688 chr15:82459472~82477258:+ CESC cis rs875971 0.862 rs4368860 ENSG00000226824.5 RP4-756H11.3 6.1 4.66e-09 6.78e-06 0.47 0.38 Aortic root size; chr7:66143495 chr7:66654538~66669855:+ CESC cis rs1062177 0.756 rs2964591 ENSG00000253921.1 CTB-113P19.3 6.1 4.67e-09 6.8e-06 0.51 0.38 Preschool internalizing problems; chr5:151737836 chr5:151753992~151767247:+ CESC cis rs11690935 1 rs312925 ENSG00000228389.1 AC068039.4 6.1 4.68e-09 6.82e-06 0.51 0.38 Schizophrenia; chr2:171707412 chr2:171773482~171775844:+ CESC cis rs875971 0.862 rs2088655 ENSG00000226824.5 RP4-756H11.3 6.1 4.69e-09 6.82e-06 0.48 0.38 Aortic root size; chr7:66330724 chr7:66654538~66669855:+ CESC cis rs875971 0.895 rs10447522 ENSG00000226824.5 RP4-756H11.3 6.1 4.69e-09 6.82e-06 0.48 0.38 Aortic root size; chr7:66331087 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs2088653 ENSG00000226824.5 RP4-756H11.3 6.1 4.69e-09 6.82e-06 0.48 0.38 Aortic root size; chr7:66343621 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6460293 ENSG00000226824.5 RP4-756H11.3 6.1 4.69e-09 6.82e-06 0.48 0.38 Aortic root size; chr7:66345205 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs778736 ENSG00000226824.5 RP4-756H11.3 -6.1 4.69e-09 6.82e-06 -0.48 -0.38 Aortic root size; chr7:66348861 chr7:66654538~66669855:+ CESC cis rs11096990 0.634 rs4975002 ENSG00000249207.1 RP11-360F5.1 6.1 4.69e-09 6.82e-06 0.41 0.38 Cognitive function; chr4:39286733 chr4:39112677~39126818:- CESC cis rs1707322 0.752 rs12062535 ENSG00000281133.1 AL355480.3 -6.1 4.69e-09 6.83e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45757208 chr1:45580892~45580996:- CESC cis rs875971 1 rs6979382 ENSG00000222364.1 RNU6-96P -6.1 4.71e-09 6.86e-06 -0.45 -0.38 Aortic root size; chr7:66421388 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6961990 ENSG00000222364.1 RNU6-96P -6.1 4.71e-09 6.86e-06 -0.45 -0.38 Aortic root size; chr7:66423583 chr7:66395191~66395286:+ CESC cis rs10129255 0.5 rs2105989 ENSG00000223648.3 IGHV3-64 6.1 4.72e-09 6.86e-06 0.31 0.38 Kawasaki disease; chr14:106682199 chr14:106643132~106658258:- CESC cis rs11690935 0.959 rs3770451 ENSG00000228389.1 AC068039.4 6.1 4.72e-09 6.87e-06 0.5 0.38 Schizophrenia; chr2:171812205 chr2:171773482~171775844:+ CESC cis rs2404602 0.591 rs11635162 ENSG00000259422.1 RP11-593F23.1 -6.1 4.73e-09 6.88e-06 -0.48 -0.38 Blood metabolite levels; chr15:76658764 chr15:76174891~76181486:- CESC cis rs1707322 0.721 rs11211181 ENSG00000281133.1 AL355480.3 -6.1 4.73e-09 6.88e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45771128 chr1:45580892~45580996:- CESC cis rs765787 0.53 rs1706764 ENSG00000259520.4 CTD-2651B20.3 6.1 4.76e-09 6.92e-06 0.48 0.38 Uric acid levels; chr15:45232058 chr15:45251580~45279251:- CESC cis rs6504950 0.85 rs2541242 ENSG00000275710.1 RP11-257O5.4 -6.1 4.77e-09 6.93e-06 -0.48 -0.38 Breast cancer; chr17:55012326 chr17:54964474~54964679:+ CESC cis rs6504950 0.889 rs2541245 ENSG00000275710.1 RP11-257O5.4 -6.1 4.77e-09 6.93e-06 -0.48 -0.38 Breast cancer; chr17:55023839 chr17:54964474~54964679:+ CESC cis rs2404602 1 rs12594541 ENSG00000259422.1 RP11-593F23.1 6.1 4.78e-09 6.95e-06 0.43 0.38 Blood metabolite levels; chr15:76542027 chr15:76174891~76181486:- CESC cis rs35160687 0.901 rs12999029 ENSG00000273080.1 RP11-301O19.1 6.1 4.78e-09 6.95e-06 0.44 0.38 Night sleep phenotypes; chr2:86275790 chr2:86195590~86196049:+ CESC cis rs35160687 0.901 rs12472676 ENSG00000273080.1 RP11-301O19.1 6.1 4.78e-09 6.95e-06 0.44 0.38 Night sleep phenotypes; chr2:86283692 chr2:86195590~86196049:+ CESC cis rs1707322 1 rs10890365 ENSG00000280836.1 AL355480.1 -6.1 4.78e-09 6.95e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893676 chr1:45581219~45581321:- CESC cis rs113835537 0.569 rs17496586 ENSG00000255517.5 CTD-3074O7.5 -6.1 4.8e-09 6.97e-06 -0.47 -0.38 Airway imaging phenotypes; chr11:66548041 chr11:66473490~66480233:- CESC cis rs1707322 0.682 rs3014241 ENSG00000281133.1 AL355480.3 6.1 4.82e-09 7e-06 0.46 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45622207 chr1:45580892~45580996:- CESC cis rs35955747 0.869 rs5753576 ENSG00000236132.1 CTA-440B3.1 -6.1 4.85e-09 7.04e-06 -0.43 -0.38 Neutrophil count;Sum basophil neutrophil counts; chr22:31361749 chr22:31816379~31817491:- CESC cis rs6452524 0.806 rs10078084 ENSG00000249664.1 CTD-2227C6.2 6.1 4.86e-09 7.05e-06 0.45 0.38 Hypertension (SNP x SNP interaction); chr5:83106588 chr5:83012285~83013109:- CESC cis rs6452524 0.868 rs11750836 ENSG00000249664.1 CTD-2227C6.2 6.1 4.86e-09 7.05e-06 0.45 0.38 Hypertension (SNP x SNP interaction); chr5:83107368 chr5:83012285~83013109:- CESC cis rs10129255 0.5 rs6576231 ENSG00000223648.3 IGHV3-64 6.1 4.87e-09 7.07e-06 0.32 0.38 Kawasaki disease; chr14:106783693 chr14:106643132~106658258:- CESC cis rs10129255 0.5 rs8014529 ENSG00000223648.3 IGHV3-64 6.1 4.87e-09 7.07e-06 0.32 0.38 Kawasaki disease; chr14:106784065 chr14:106643132~106658258:- CESC cis rs10129255 0.5 rs12101190 ENSG00000223648.3 IGHV3-64 6.1 4.87e-09 7.07e-06 0.32 0.38 Kawasaki disease; chr14:106784149 chr14:106643132~106658258:- CESC cis rs10129255 0.518 rs8004895 ENSG00000223648.3 IGHV3-64 6.1 4.87e-09 7.07e-06 0.32 0.38 Kawasaki disease; chr14:106785139 chr14:106643132~106658258:- CESC cis rs10129255 0.536 rs6576201 ENSG00000223648.3 IGHV3-64 -6.1 4.88e-09 7.08e-06 -0.31 -0.38 Kawasaki disease; chr14:106683696 chr14:106643132~106658258:- CESC cis rs10740039 0.548 rs9415607 ENSG00000254271.1 RP11-131N11.4 -6.1 4.88e-09 7.08e-06 -0.46 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60737616 chr10:60734342~60741828:+ CESC cis rs875971 0.798 rs6460304 ENSG00000226824.5 RP4-756H11.3 -6.1 4.9e-09 7.11e-06 -0.48 -0.38 Aortic root size; chr7:66499741 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6945775 ENSG00000226824.5 RP4-756H11.3 -6.1 4.9e-09 7.11e-06 -0.48 -0.38 Aortic root size; chr7:66503987 chr7:66654538~66669855:+ CESC cis rs875971 0.798 rs57739047 ENSG00000226824.5 RP4-756H11.3 -6.1 4.9e-09 7.11e-06 -0.48 -0.38 Aortic root size; chr7:66507579 chr7:66654538~66669855:+ CESC cis rs875971 0.83 rs6950137 ENSG00000226824.5 RP4-756H11.3 -6.1 4.9e-09 7.11e-06 -0.48 -0.38 Aortic root size; chr7:66511623 chr7:66654538~66669855:+ CESC cis rs3738443 0.52 rs6699577 ENSG00000259865.1 RP11-488L18.10 6.09 4.92e-09 7.12e-06 0.36 0.38 Alcohol dependence; chr1:247224152 chr1:247187281~247188526:- CESC cis rs3738443 0.545 rs12566906 ENSG00000259865.1 RP11-488L18.10 6.09 4.92e-09 7.12e-06 0.36 0.38 Alcohol dependence; chr1:247224904 chr1:247187281~247188526:- CESC cis rs11690935 0.959 rs2674484 ENSG00000228389.1 AC068039.4 6.09 4.92e-09 7.12e-06 0.51 0.38 Schizophrenia; chr2:171718102 chr2:171773482~171775844:+ CESC cis rs35160687 0.901 rs7571424 ENSG00000273080.1 RP11-301O19.1 6.09 4.95e-09 7.17e-06 0.43 0.38 Night sleep phenotypes; chr2:86312037 chr2:86195590~86196049:+ CESC cis rs2487048 0.773 rs2472494 ENSG00000226334.1 RP11-217B7.2 -6.09 4.96e-09 7.18e-06 -0.49 -0.38 Intraocular pressure; chr9:104933258 chr9:104927553~104928892:+ CESC cis rs17507216 0.718 rs72751657 ENSG00000278603.1 RP13-608F4.5 6.09 4.96e-09 7.18e-06 0.7 0.38 Excessive daytime sleepiness; chr15:82581259 chr15:82472203~82472426:+ CESC cis rs2739330 0.732 rs5760175 ENSG00000099984.9 GSTT2 -6.09 4.99e-09 7.22e-06 -0.46 -0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23980123~23983911:+ CESC cis rs7849270 0.801 rs10819475 ENSG00000268707.1 RP11-247A12.7 6.09 5.01e-09 7.25e-06 0.51 0.38 Blood metabolite ratios; chr9:129168561 chr9:129170434~129170940:+ CESC cis rs7849270 0.76 rs419636 ENSG00000268707.1 RP11-247A12.7 6.09 5.01e-09 7.25e-06 0.51 0.38 Blood metabolite ratios; chr9:129168998 chr9:129170434~129170940:+ CESC cis rs17608059 0.901 rs11078215 ENSG00000141028.6 CDRT15P1 -6.09 5.01e-09 7.25e-06 -0.43 -0.38 Temperament; chr17:14003617 chr17:14024514~14025488:+ CESC cis rs10256972 0.616 rs7806746 ENSG00000229043.2 AC091729.9 -6.09 5.02e-09 7.26e-06 -0.45 -0.38 Endometriosis;Longevity; chr7:1035937 chr7:1160374~1165267:+ CESC cis rs1707322 0.721 rs12069121 ENSG00000281133.1 AL355480.3 -6.09 5.02e-09 7.26e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45766312 chr1:45580892~45580996:- CESC cis rs1707322 0.686 rs61784833 ENSG00000281133.1 AL355480.3 -6.09 5.02e-09 7.26e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45768100 chr1:45580892~45580996:- CESC cis rs7674212 0.556 rs223401 ENSG00000246560.2 RP11-10L12.4 6.09 5.03e-09 7.27e-06 0.5 0.38 Type 2 diabetes; chr4:102817815 chr4:102828055~102844075:+ CESC cis rs62229266 0.773 rs878606 ENSG00000231106.2 LINC01436 6.09 5.05e-09 7.3e-06 0.54 0.38 Mitral valve prolapse; chr21:36034394 chr21:36005338~36007838:+ CESC cis rs42490 1 rs431264 ENSG00000251136.7 RP11-37B2.1 -6.09 5.06e-09 7.31e-06 -0.38 -0.38 Leprosy; chr8:89765282 chr8:89609409~89757727:- CESC cis rs6991838 0.584 rs1053088 ENSG00000200714.1 Y_RNA 6.09 5.06e-09 7.32e-06 0.46 0.38 Intelligence (multi-trait analysis); chr8:65603548 chr8:65592731~65592820:+ CESC cis rs1061377 1 rs9990742 ENSG00000249207.1 RP11-360F5.1 -6.09 5.08e-09 7.34e-06 -0.43 -0.38 Uric acid levels; chr4:39119794 chr4:39112677~39126818:- CESC cis rs3806843 1 rs3733710 ENSG00000202111.1 VTRNA1-2 -6.09 5.08e-09 7.34e-06 -0.39 -0.38 Depressive symptoms (multi-trait analysis); chr5:140787878 chr5:140718925~140719013:+ CESC cis rs4728142 0.604 rs4731541 ENSG00000275106.1 RP11-309L24.10 -6.09 5.08e-09 7.34e-06 -0.5 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129038182 chr7:128952527~128953316:- CESC cis rs8072100 1 rs3809868 ENSG00000228782.6 CTD-2026D20.3 -6.09 5.1e-09 7.36e-06 -0.43 -0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47673230 chr17:47450568~47492492:- CESC cis rs8072100 1 rs7210738 ENSG00000228782.6 CTD-2026D20.3 -6.09 5.1e-09 7.36e-06 -0.43 -0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47680232 chr17:47450568~47492492:- CESC cis rs4718428 0.672 rs36038499 ENSG00000226824.5 RP4-756H11.3 -6.09 5.1e-09 7.37e-06 -0.53 -0.38 Corneal structure; chr7:66824628 chr7:66654538~66669855:+ CESC cis rs4718428 0.705 rs62465692 ENSG00000226824.5 RP4-756H11.3 -6.09 5.1e-09 7.37e-06 -0.53 -0.38 Corneal structure; chr7:66830758 chr7:66654538~66669855:+ CESC cis rs9399137 0.507 rs4896128 ENSG00000232876.1 CTA-212D2.2 6.09 5.11e-09 7.38e-06 0.45 0.38 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135028618 chr6:135055033~135060550:+ CESC cis rs6504950 1 rs9896044 ENSG00000275710.1 RP11-257O5.4 6.09 5.11e-09 7.38e-06 0.47 0.38 Breast cancer; chr17:54971181 chr17:54964474~54964679:+ CESC cis rs7674212 0.531 rs4698876 ENSG00000246560.2 RP11-10L12.4 6.09 5.12e-09 7.39e-06 0.48 0.38 Type 2 diabetes; chr4:103012410 chr4:102828055~102844075:+ CESC cis rs7674212 0.531 rs7665026 ENSG00000246560.2 RP11-10L12.4 6.09 5.12e-09 7.39e-06 0.48 0.38 Type 2 diabetes; chr4:103015491 chr4:102828055~102844075:+ CESC cis rs897984 0.542 rs73530203 ENSG00000260911.2 RP11-196G11.2 6.09 5.12e-09 7.39e-06 0.41 0.38 Dementia with Lewy bodies; chr16:31088538 chr16:31043150~31049868:+ CESC cis rs9584850 0.834 rs3783005 ENSG00000231194.1 FARP1-AS1 -6.09 5.13e-09 7.41e-06 -0.48 -0.38 Neuroticism; chr13:98459083 chr13:98435405~98435840:- CESC cis rs11690935 0.959 rs1474074 ENSG00000228389.1 AC068039.4 6.09 5.14e-09 7.42e-06 0.51 0.38 Schizophrenia; chr2:171803342 chr2:171773482~171775844:+ CESC cis rs6452524 1 rs7716962 ENSG00000249664.1 CTD-2227C6.2 6.09 5.17e-09 7.46e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83138913 chr5:83012285~83013109:- CESC cis rs6452524 1 rs6882179 ENSG00000249664.1 CTD-2227C6.2 6.09 5.17e-09 7.46e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83139582 chr5:83012285~83013109:- CESC cis rs6452524 1 rs6863300 ENSG00000249664.1 CTD-2227C6.2 6.09 5.17e-09 7.46e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83139629 chr5:83012285~83013109:- CESC cis rs6452524 1 rs7732092 ENSG00000249664.1 CTD-2227C6.2 6.09 5.17e-09 7.46e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83141110 chr5:83012285~83013109:- CESC cis rs7849270 0.801 rs10819474 ENSG00000268707.1 RP11-247A12.7 -6.08 5.2e-09 7.5e-06 -0.5 -0.38 Blood metabolite ratios; chr9:129168215 chr9:129170434~129170940:+ CESC cis rs10875746 0.951 rs10875756 ENSG00000240399.1 RP1-228P16.1 -6.08 5.2e-09 7.51e-06 -0.48 -0.38 Longevity (90 years and older); chr12:48168521 chr12:48054813~48055591:- CESC cis rs270601 0.837 rs367805 ENSG00000233006.5 AC034220.3 6.08 5.21e-09 7.51e-06 0.43 0.38 Acylcarnitine levels; chr5:132365587 chr5:132311285~132369916:- CESC cis rs10463554 0.963 rs26262 ENSG00000175749.11 EIF3KP1 6.08 5.22e-09 7.53e-06 0.41 0.38 Parkinson's disease; chr5:103209462 chr5:103032376~103033031:+ CESC cis rs6860806 0.507 rs274570 ENSG00000233006.5 AC034220.3 -6.08 5.23e-09 7.54e-06 -0.43 -0.38 Breast cancer; chr5:132377534 chr5:132311285~132369916:- CESC cis rs35955747 0.87 rs5997986 ENSG00000236132.1 CTA-440B3.1 6.08 5.24e-09 7.55e-06 0.45 0.38 Neutrophil count;Sum basophil neutrophil counts; chr22:31438953 chr22:31816379~31817491:- CESC cis rs4423214 0.84 rs1792229 ENSG00000254682.1 RP11-660L16.2 -6.08 5.24e-09 7.56e-06 -0.51 -0.38 Vitamin D levels; chr11:71468349 chr11:71448674~71452157:+ CESC cis rs875971 1 rs709595 ENSG00000222364.1 RNU6-96P -6.08 5.25e-09 7.57e-06 -0.45 -0.38 Aortic root size; chr7:66352346 chr7:66395191~66395286:+ CESC cis rs875971 1 rs811880 ENSG00000222364.1 RNU6-96P -6.08 5.25e-09 7.57e-06 -0.45 -0.38 Aortic root size; chr7:66353659 chr7:66395191~66395286:+ CESC cis rs4853012 0.941 rs4852329 ENSG00000257800.1 FNBP1P1 6.08 5.25e-09 7.57e-06 0.44 0.38 Gestational age at birth (maternal effect); chr2:74127417 chr2:74120680~74123218:+ CESC cis rs17711722 0.523 rs313812 ENSG00000226824.5 RP4-756H11.3 6.08 5.26e-09 7.59e-06 0.46 0.38 Calcium levels; chr7:66040056 chr7:66654538~66669855:+ CESC cis rs35955747 0.838 rs28716 ENSG00000236132.1 CTA-440B3.1 -6.08 5.28e-09 7.61e-06 -0.44 -0.38 Neutrophil count;Sum basophil neutrophil counts; chr22:31334203 chr22:31816379~31817491:- CESC cis rs35955747 0.902 rs131209 ENSG00000236132.1 CTA-440B3.1 -6.08 5.28e-09 7.61e-06 -0.44 -0.38 Neutrophil count;Sum basophil neutrophil counts; chr22:31336475 chr22:31816379~31817491:- CESC cis rs150992 0.631 rs79399563 ENSG00000248489.1 CTD-2007H13.3 6.08 5.29e-09 7.62e-06 0.47 0.38 Body mass index; chr5:98993275 chr5:98929171~98995013:+ CESC cis rs9399135 0.967 rs9402676 ENSG00000232876.1 CTA-212D2.2 -6.08 5.29e-09 7.63e-06 -0.44 -0.38 Red blood cell count; chr6:135034369 chr6:135055033~135060550:+ CESC cis rs2581828 0.656 rs891368 ENSG00000242142.1 SERBP1P3 6.08 5.36e-09 7.72e-06 0.43 0.38 Crohn's disease; chr3:53089257 chr3:53064283~53065091:- CESC cis rs2581828 0.656 rs1078968 ENSG00000242142.1 SERBP1P3 6.08 5.36e-09 7.72e-06 0.43 0.38 Crohn's disease; chr3:53089470 chr3:53064283~53065091:- CESC cis rs9399137 0.507 rs12664898 ENSG00000232876.1 CTA-212D2.2 -6.08 5.39e-09 7.76e-06 -0.47 -0.38 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134967525 chr6:135055033~135060550:+ CESC cis rs8062405 0.573 rs6565300 ENSG00000259982.1 CDC37P1 6.08 5.41e-09 7.78e-06 0.49 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28981728 chr16:28700294~28701540:- CESC cis rs1707322 1 rs1707337 ENSG00000280836.1 AL355480.1 6.08 5.42e-09 7.79e-06 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46043097 chr1:45581219~45581321:- CESC cis rs1707322 1 rs1768807 ENSG00000280836.1 AL355480.1 6.08 5.42e-09 7.79e-06 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46044898 chr1:45581219~45581321:- CESC cis rs4853012 0.838 rs60964317 ENSG00000257800.1 FNBP1P1 6.08 5.42e-09 7.79e-06 0.39 0.38 Gestational age at birth (maternal effect); chr2:74116296 chr2:74120680~74123218:+ CESC cis rs11168854 0.595 rs11168857 ENSG00000258017.1 RP11-386G11.10 -6.08 5.44e-09 7.82e-06 -0.49 -0.38 Body mass index; chr12:49096526 chr12:49127782~49147869:+ CESC cis rs8072100 1 rs11870935 ENSG00000228782.6 CTD-2026D20.3 -6.07 5.46e-09 7.86e-06 -0.43 -0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47655239 chr17:47450568~47492492:- CESC cis rs875971 0.965 rs697968 ENSG00000222364.1 RNU6-96P 6.07 5.48e-09 7.87e-06 0.47 0.38 Aortic root size; chr7:66070046 chr7:66395191~66395286:+ CESC cis rs875971 1 rs1183245 ENSG00000222364.1 RNU6-96P 6.07 5.48e-09 7.87e-06 0.47 0.38 Aortic root size; chr7:66076198 chr7:66395191~66395286:+ CESC cis rs875971 1 rs1144894 ENSG00000222364.1 RNU6-96P 6.07 5.48e-09 7.87e-06 0.47 0.38 Aortic root size; chr7:66077907 chr7:66395191~66395286:+ CESC cis rs2404602 0.716 rs284895 ENSG00000259422.1 RP11-593F23.1 -6.07 5.48e-09 7.88e-06 -0.44 -0.38 Blood metabolite levels; chr15:76458884 chr15:76174891~76181486:- CESC cis rs11155671 0.53 rs9383940 ENSG00000268592.3 RAET1E-AS1 6.07 5.49e-09 7.89e-06 0.48 0.38 Testicular germ cell tumor; chr6:149904923 chr6:149863494~149919507:+ CESC cis rs2404602 1 rs2896954 ENSG00000259422.1 RP11-593F23.1 6.07 5.5e-09 7.9e-06 0.43 0.38 Blood metabolite levels; chr15:76559351 chr15:76174891~76181486:- CESC cis rs2404602 1 rs2404741 ENSG00000259422.1 RP11-593F23.1 6.07 5.5e-09 7.9e-06 0.43 0.38 Blood metabolite levels; chr15:76559394 chr15:76174891~76181486:- CESC cis rs2404602 1 rs2404740 ENSG00000259422.1 RP11-593F23.1 6.07 5.5e-09 7.9e-06 0.43 0.38 Blood metabolite levels; chr15:76559802 chr15:76174891~76181486:- CESC cis rs9322193 0.567 rs7742692 ENSG00000216906.2 RP11-350J20.9 6.07 5.5e-09 7.9e-06 0.41 0.38 Lung cancer; chr6:149892363 chr6:149904243~149906418:+ CESC cis rs1707322 0.686 rs1547924 ENSG00000281133.1 AL355480.3 -6.07 5.51e-09 7.92e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619440 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs10789484 ENSG00000280836.1 AL355480.1 -6.07 5.53e-09 7.94e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45941306 chr1:45581219~45581321:- CESC cis rs1707322 1 rs7527079 ENSG00000280836.1 AL355480.1 -6.07 5.53e-09 7.94e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45947778 chr1:45581219~45581321:- CESC cis rs1707322 1 rs34446427 ENSG00000280836.1 AL355480.1 -6.07 5.53e-09 7.94e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45951983 chr1:45581219~45581321:- CESC cis rs1707322 0.963 rs4660900 ENSG00000280836.1 AL355480.1 -6.07 5.53e-09 7.94e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45953933 chr1:45581219~45581321:- CESC cis rs1707322 1 rs4454479 ENSG00000280836.1 AL355480.1 -6.07 5.53e-09 7.94e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45957883 chr1:45581219~45581321:- CESC cis rs1707322 1 rs7517560 ENSG00000280836.1 AL355480.1 -6.07 5.53e-09 7.94e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45960271 chr1:45581219~45581321:- CESC cis rs1707322 1 rs12077546 ENSG00000280836.1 AL355480.1 -6.07 5.53e-09 7.94e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45966134 chr1:45581219~45581321:- CESC cis rs1707322 1 rs12124291 ENSG00000280836.1 AL355480.1 -6.07 5.53e-09 7.94e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45966460 chr1:45581219~45581321:- CESC cis rs1707322 1 rs10890378 ENSG00000280836.1 AL355480.1 6.07 5.53e-09 7.94e-06 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45944985 chr1:45581219~45581321:- CESC cis rs875971 0.929 rs34406470 ENSG00000222364.1 RNU6-96P -6.07 5.57e-09 7.99e-06 -0.45 -0.38 Aortic root size; chr7:66464969 chr7:66395191~66395286:+ CESC cis rs1707322 1 rs10789486 ENSG00000280836.1 AL355480.1 -6.07 5.58e-09 8.01e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45942995 chr1:45581219~45581321:- CESC cis rs1155848 0.892 rs1023293 ENSG00000227354.5 RBM26-AS1 6.07 5.6e-09 8.02e-06 0.79 0.38 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79480285 chr13:79406309~79424328:+ CESC cis rs9399135 0.967 rs1014020 ENSG00000232876.1 CTA-212D2.2 -6.07 5.6e-09 8.03e-06 -0.44 -0.38 Red blood cell count; chr6:135013288 chr6:135055033~135060550:+ CESC cis rs11690935 0.959 rs6745143 ENSG00000228389.1 AC068039.4 6.07 5.61e-09 8.03e-06 0.5 0.38 Schizophrenia; chr2:171793872 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs6758704 ENSG00000228389.1 AC068039.4 6.07 5.61e-09 8.03e-06 0.5 0.38 Schizophrenia; chr2:171798587 chr2:171773482~171775844:+ CESC cis rs6452524 1 rs10076271 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83133875 chr5:83012285~83013109:- CESC cis rs6452524 1 rs10076274 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83133908 chr5:83012285~83013109:- CESC cis rs6452524 1 rs10061521 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83133936 chr5:83012285~83013109:- CESC cis rs6452524 1 rs7733151 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83134655 chr5:83012285~83013109:- CESC cis rs6452524 1 rs7733330 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83134774 chr5:83012285~83013109:- CESC cis rs6452524 1 rs7733354 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83134859 chr5:83012285~83013109:- CESC cis rs6452524 1 rs4634330 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83134963 chr5:83012285~83013109:- CESC cis rs6452524 1 rs2386238 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83135266 chr5:83012285~83013109:- CESC cis rs6452524 1 rs2386239 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83135339 chr5:83012285~83013109:- CESC cis rs6452524 0.934 rs7700253 ENSG00000249664.1 CTD-2227C6.2 6.07 5.61e-09 8.04e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83135510 chr5:83012285~83013109:- CESC cis rs4718428 0.705 rs2901311 ENSG00000226824.5 RP4-756H11.3 -6.07 5.61e-09 8.04e-06 -0.53 -0.38 Corneal structure; chr7:66950082 chr7:66654538~66669855:+ CESC cis rs1075265 0.584 rs1559037 ENSG00000233266.1 HMGB1P31 6.07 5.62e-09 8.04e-06 0.54 0.38 Chronotype;Morning vs. evening chronotype; chr2:54051448 chr2:54051334~54051760:+ CESC cis rs1075265 0.584 rs7590846 ENSG00000233266.1 HMGB1P31 6.07 5.62e-09 8.04e-06 0.54 0.38 Chronotype;Morning vs. evening chronotype; chr2:54051530 chr2:54051334~54051760:+ CESC cis rs13056815 1 rs13056815 ENSG00000236132.1 CTA-440B3.1 6.07 5.65e-09 8.09e-06 0.46 0.38 Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr22:31272264 chr22:31816379~31817491:- CESC cis rs1075265 0.568 rs10865278 ENSG00000233266.1 HMGB1P31 6.07 5.67e-09 8.12e-06 0.53 0.38 Chronotype;Morning vs. evening chronotype; chr2:54074902 chr2:54051334~54051760:+ CESC cis rs1707322 0.506 rs2991983 ENSG00000281133.1 AL355480.3 6.07 5.69e-09 8.14e-06 0.46 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613719 chr1:45580892~45580996:- CESC cis rs1062177 1 rs2964584 ENSG00000253921.1 CTB-113P19.3 -6.07 5.69e-09 8.14e-06 -0.51 -0.38 Preschool internalizing problems; chr5:151763317 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs2915878 ENSG00000253921.1 CTB-113P19.3 -6.07 5.69e-09 8.14e-06 -0.51 -0.38 Preschool internalizing problems; chr5:151770101 chr5:151753992~151767247:+ CESC cis rs950169 0.84 rs62029595 ENSG00000225151.9 GOLGA2P7 -6.07 5.7e-09 8.15e-06 -0.54 -0.38 Schizophrenia; chr15:84400603 chr15:84199311~84230136:- CESC cis rs1707322 1 rs11211200 ENSG00000280836.1 AL355480.1 -6.07 5.7e-09 8.15e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45822680 chr1:45581219~45581321:- CESC cis rs1075265 0.584 rs1862122 ENSG00000233266.1 HMGB1P31 -6.07 5.73e-09 8.19e-06 -0.54 -0.38 Chronotype;Morning vs. evening chronotype; chr2:54052992 chr2:54051334~54051760:+ CESC cis rs6603134 0.502 rs10405582 ENSG00000267939.1 CTD-2325M2.1 -6.07 5.73e-09 8.19e-06 -0.47 -0.38 Blood protein levels; chr19:8038654 chr19:8008729~8016025:+ CESC cis rs6603134 0.502 rs10405588 ENSG00000267939.1 CTD-2325M2.1 -6.07 5.73e-09 8.19e-06 -0.47 -0.38 Blood protein levels; chr19:8038663 chr19:8008729~8016025:+ CESC cis rs6603134 0.502 rs6603133 ENSG00000267939.1 CTD-2325M2.1 -6.07 5.73e-09 8.19e-06 -0.47 -0.38 Blood protein levels; chr19:8038352 chr19:8008729~8016025:+ CESC cis rs9399135 0.967 rs10872427 ENSG00000232876.1 CTA-212D2.2 -6.07 5.74e-09 8.21e-06 -0.43 -0.38 Red blood cell count; chr6:135032314 chr6:135055033~135060550:+ CESC cis rs765787 0.53 rs11636367 ENSG00000259520.4 CTD-2651B20.3 6.06 5.78e-09 8.26e-06 0.48 0.38 Uric acid levels; chr15:45243664 chr15:45251580~45279251:- CESC cis rs6142102 0.58 rs4911139 ENSG00000275784.1 RP5-1125A11.6 -6.06 5.79e-09 8.27e-06 -0.37 -0.38 Skin pigmentation; chr20:33963729 chr20:33989480~33991818:- CESC cis rs6142102 0.602 rs2300209 ENSG00000275784.1 RP5-1125A11.6 -6.06 5.8e-09 8.29e-06 -0.37 -0.38 Skin pigmentation; chr20:34055294 chr20:33989480~33991818:- CESC cis rs8072100 0.744 rs34537623 ENSG00000228782.6 CTD-2026D20.3 6.06 5.82e-09 8.31e-06 0.45 0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47452837 chr17:47450568~47492492:- CESC cis rs8062405 0.573 rs7140 ENSG00000259982.1 CDC37P1 -6.06 5.83e-09 8.33e-06 -0.48 -0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28984436 chr16:28700294~28701540:- CESC cis rs2177312 0.767 rs1523174 ENSG00000251129.1 RP11-734I18.1 -6.06 5.84e-09 8.34e-06 -0.48 -0.38 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31949952 chr4:31997397~32155406:+ CESC cis rs875971 1 rs4717300 ENSG00000222364.1 RNU6-96P -6.06 5.84e-09 8.34e-06 -0.45 -0.38 Aortic root size; chr7:66482393 chr7:66395191~66395286:+ CESC cis rs6860806 0.507 rs200837 ENSG00000233006.5 AC034220.3 6.06 5.86e-09 8.36e-06 0.43 0.38 Breast cancer; chr5:132364266 chr5:132311285~132369916:- CESC cis rs7572733 1 rs962210 ENSG00000222017.1 AC011997.1 -6.06 5.86e-09 8.36e-06 -0.41 -0.38 Dermatomyositis; chr2:198037506 chr2:197693106~197774823:+ CESC cis rs8062405 0.721 rs151303 ENSG00000259982.1 CDC37P1 6.06 5.88e-09 8.39e-06 0.51 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28481189 chr16:28700294~28701540:- CESC cis rs1062177 1 rs892006 ENSG00000253921.1 CTB-113P19.3 -6.06 5.9e-09 8.42e-06 -0.51 -0.38 Preschool internalizing problems; chr5:151801329 chr5:151753992~151767247:+ CESC cis rs9402743 0.775 rs2179724 ENSG00000217482.2 HMGB1P17 6.06 5.96e-09 8.5e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135647928 chr6:135636086~135636713:- CESC cis rs1707322 0.682 rs12037459 ENSG00000281133.1 AL355480.3 -6.06 5.96e-09 8.51e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629287 chr1:45580892~45580996:- CESC cis rs6452524 0.534 rs10061690 ENSG00000249664.1 CTD-2227C6.2 6.06 5.97e-09 8.52e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83063226 chr5:83012285~83013109:- CESC cis rs17711722 0.522 rs6957759 ENSG00000226824.5 RP4-756H11.3 -6.06 6.01e-09 8.57e-06 -0.45 -0.38 Calcium levels; chr7:65806798 chr7:66654538~66669855:+ CESC cis rs6142102 0.625 rs9753690 ENSG00000275784.1 RP5-1125A11.6 -6.06 6.02e-09 8.58e-06 -0.37 -0.38 Skin pigmentation; chr20:33952995 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs7263727 ENSG00000275784.1 RP5-1125A11.6 -6.06 6.02e-09 8.58e-06 -0.37 -0.38 Skin pigmentation; chr20:33953133 chr20:33989480~33991818:- CESC cis rs6142102 0.625 rs6142056 ENSG00000275784.1 RP5-1125A11.6 -6.06 6.02e-09 8.58e-06 -0.37 -0.38 Skin pigmentation; chr20:33953349 chr20:33989480~33991818:- CESC cis rs9828933 0.808 rs3733125 ENSG00000280620.1 SCAANT1 6.06 6.07e-09 8.64e-06 0.94 0.38 Type 2 diabetes; chr3:63995959 chr3:63911518~63911772:- CESC cis rs1707322 0.716 rs10890342 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45691415 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs6658700 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45694588 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs12047629 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697130 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs11211169 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701037 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs11211171 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45702970 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs28623463 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45705086 chr1:45580892~45580996:- CESC cis rs1707322 0.716 rs28370457 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706390 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs28890893 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720904 chr1:45580892~45580996:- CESC cis rs1707322 0.716 rs28375469 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45729703 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs28545085 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736278 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs28812624 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45738064 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs28507722 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45740868 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs28568986 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45742071 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs28396194 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747555 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs28752166 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747637 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs10890345 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45748255 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs10789471 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45749947 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs11211173 ENSG00000281133.1 AL355480.3 -6.05 6.08e-09 8.64e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45753704 chr1:45580892~45580996:- CESC cis rs1707322 0.691 rs61784799 ENSG00000281133.1 AL355480.3 6.05 6.08e-09 8.64e-06 0.46 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712076 chr1:45580892~45580996:- CESC cis rs10463554 0.927 rs55641526 ENSG00000175749.11 EIF3KP1 6.05 6.09e-09 8.66e-06 0.41 0.38 Parkinson's disease; chr5:102915301 chr5:103032376~103033031:+ CESC cis rs34779708 0.966 rs2045918 ENSG00000230534.5 RP11-297A16.2 6.05 6.13e-09 8.71e-06 0.5 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35129589 chr10:35098006~35127020:- CESC cis rs783540 0.5 rs7178459 ENSG00000255769.6 GOLGA2P10 -6.05 6.13e-09 8.71e-06 -0.46 -0.38 Schizophrenia; chr15:82729632 chr15:82472993~82513950:- CESC cis rs34779708 0.966 rs35079558 ENSG00000230534.5 RP11-297A16.2 6.05 6.15e-09 8.73e-06 0.5 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35190958 chr10:35098006~35127020:- CESC cis rs9660180 1 rs3737628 ENSG00000231050.1 RP1-140A9.1 6.05 6.15e-09 8.74e-06 0.46 0.38 Body mass index; chr1:1791493 chr1:1891471~1892658:+ CESC cis rs35160687 0.865 rs10189492 ENSG00000273080.1 RP11-301O19.1 6.05 6.16e-09 8.75e-06 0.44 0.38 Night sleep phenotypes; chr2:86251779 chr2:86195590~86196049:+ CESC cis rs9545047 0.604 rs9318641 ENSG00000227676.3 LINC01068 -6.05 6.18e-09 8.77e-06 -0.43 -0.38 Schizophrenia; chr13:79426545 chr13:79566727~79571436:+ CESC cis rs1185460 0.967 rs1177563 ENSG00000271751.1 RP11-110I1.14 -6.05 6.18e-09 8.78e-06 -0.5 -0.38 Coronary artery disease; chr11:119078373 chr11:119065263~119065677:- CESC cis rs897984 0.609 rs72800847 ENSG00000260911.2 RP11-196G11.2 6.05 6.18e-09 8.78e-06 0.42 0.38 Dementia with Lewy bodies; chr16:31011318 chr16:31043150~31049868:+ CESC cis rs42490 1 rs405734 ENSG00000251136.7 RP11-37B2.1 -6.05 6.19e-09 8.79e-06 -0.38 -0.38 Leprosy; chr8:89756211 chr8:89609409~89757727:- CESC cis rs2117029 0.555 rs2047101 ENSG00000258017.1 RP11-386G11.10 -6.05 6.19e-09 8.79e-06 -0.49 -0.38 Intelligence (multi-trait analysis); chr12:49103860 chr12:49127782~49147869:+ CESC cis rs9399135 0.66 rs4267967 ENSG00000232876.1 CTA-212D2.2 -6.05 6.2e-09 8.8e-06 -0.44 -0.38 Red blood cell count; chr6:134951339 chr6:135055033~135060550:+ CESC cis rs35955747 0.838 rs5997887 ENSG00000236132.1 CTA-440B3.1 6.05 6.21e-09 8.81e-06 0.43 0.38 Neutrophil count;Sum basophil neutrophil counts; chr22:31147211 chr22:31816379~31817491:- CESC cis rs9399135 1 rs6569988 ENSG00000232876.1 CTA-212D2.2 -6.05 6.22e-09 8.82e-06 -0.43 -0.38 Red blood cell count; chr6:135031165 chr6:135055033~135060550:+ CESC cis rs1823913 0.599 rs56328712 ENSG00000280083.1 RP11-317J9.1 -6.05 6.23e-09 8.83e-06 -0.44 -0.38 Obesity-related traits; chr2:191273807 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs55862924 ENSG00000280083.1 RP11-317J9.1 -6.05 6.23e-09 8.83e-06 -0.44 -0.38 Obesity-related traits; chr2:191273809 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs12989203 ENSG00000280083.1 RP11-317J9.1 -6.05 6.23e-09 8.83e-06 -0.44 -0.38 Obesity-related traits; chr2:191276617 chr2:191154118~191156070:- CESC cis rs11690935 0.959 rs6433314 ENSG00000228389.1 AC068039.4 6.05 6.24e-09 8.84e-06 0.5 0.38 Schizophrenia; chr2:171804461 chr2:171773482~171775844:+ CESC cis rs11690935 0.959 rs12692974 ENSG00000228389.1 AC068039.4 6.05 6.24e-09 8.84e-06 0.5 0.38 Schizophrenia; chr2:171806746 chr2:171773482~171775844:+ CESC cis rs1707322 1 rs4660889 ENSG00000280836.1 AL355480.1 -6.05 6.24e-09 8.84e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45831659 chr1:45581219~45581321:- CESC cis rs150992 0.587 rs12189335 ENSG00000248489.1 CTD-2007H13.3 -6.05 6.24e-09 8.85e-06 -0.48 -0.38 Body mass index; chr5:99009311 chr5:98929171~98995013:+ CESC cis rs1707322 1 rs4390216 ENSG00000280836.1 AL355480.1 -6.05 6.26e-09 8.87e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45800784 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs10437063 ENSG00000280836.1 AL355480.1 -6.05 6.26e-09 8.87e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45807994 chr1:45581219~45581321:- CESC cis rs1707322 1 rs6676982 ENSG00000280836.1 AL355480.1 -6.05 6.26e-09 8.87e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45809729 chr1:45581219~45581321:- CESC cis rs1707322 0.927 rs11211194 ENSG00000280836.1 AL355480.1 -6.05 6.26e-09 8.87e-06 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45816412 chr1:45581219~45581321:- CESC cis rs11155671 0.53 rs9371544 ENSG00000216906.2 RP11-350J20.9 6.05 6.27e-09 8.89e-06 0.4 0.38 Testicular germ cell tumor; chr6:149896224 chr6:149904243~149906418:+ CESC cis rs875971 1 rs2036264 ENSG00000222364.1 RNU6-96P 6.05 6.31e-09 8.94e-06 0.44 0.38 Aortic root size; chr7:66334917 chr7:66395191~66395286:+ CESC cis rs875971 1 rs7783613 ENSG00000222364.1 RNU6-96P 6.05 6.31e-09 8.94e-06 0.44 0.38 Aortic root size; chr7:66340274 chr7:66395191~66395286:+ CESC cis rs1707322 0.929 rs785513 ENSG00000280836.1 AL355480.1 6.05 6.35e-09 8.98e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46072648 chr1:45581219~45581321:- CESC cis rs1075265 0.584 rs1833497 ENSG00000233266.1 HMGB1P31 6.05 6.35e-09 8.99e-06 0.53 0.38 Chronotype;Morning vs. evening chronotype; chr2:54052186 chr2:54051334~54051760:+ CESC cis rs34779708 0.966 rs2045917 ENSG00000230534.5 RP11-297A16.2 6.05 6.35e-09 8.99e-06 0.5 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35129598 chr10:35098006~35127020:- CESC cis rs950169 0.922 rs8037078 ENSG00000225151.9 GOLGA2P7 6.05 6.37e-09 9.01e-06 0.51 0.38 Schizophrenia; chr15:84150119 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs6603022 ENSG00000225151.9 GOLGA2P7 6.05 6.37e-09 9.01e-06 0.51 0.38 Schizophrenia; chr15:84161418 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs4842940 ENSG00000225151.9 GOLGA2P7 6.05 6.37e-09 9.01e-06 0.51 0.38 Schizophrenia; chr15:84162473 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs4842941 ENSG00000225151.9 GOLGA2P7 6.05 6.37e-09 9.01e-06 0.51 0.38 Schizophrenia; chr15:84162560 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs12911223 ENSG00000225151.9 GOLGA2P7 6.05 6.37e-09 9.01e-06 0.51 0.38 Schizophrenia; chr15:84162919 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs11639244 ENSG00000225151.9 GOLGA2P7 -6.05 6.37e-09 9.01e-06 -0.51 -0.38 Schizophrenia; chr15:84163898 chr15:84199311~84230136:- CESC cis rs950169 0.845 rs4106951 ENSG00000225151.9 GOLGA2P7 -6.05 6.37e-09 9.01e-06 -0.51 -0.38 Schizophrenia; chr15:84164642 chr15:84199311~84230136:- CESC cis rs4423214 0.65 rs7940244 ENSG00000254682.1 RP11-660L16.2 -6.05 6.38e-09 9.03e-06 -0.51 -0.38 Vitamin D levels; chr11:71510528 chr11:71448674~71452157:+ CESC cis rs3806843 0.518 rs2563310 ENSG00000202111.1 VTRNA1-2 6.05 6.39e-09 9.03e-06 0.4 0.38 Depressive symptoms (multi-trait analysis); chr5:140636156 chr5:140718925~140719013:+ CESC cis rs2404602 0.532 rs206205 ENSG00000259422.1 RP11-593F23.1 6.05 6.39e-09 9.03e-06 0.41 0.38 Blood metabolite levels; chr15:76443750 chr15:76174891~76181486:- CESC cis rs6452524 1 rs11958314 ENSG00000249664.1 CTD-2227C6.2 6.04 6.41e-09 9.06e-06 0.42 0.38 Hypertension (SNP x SNP interaction); chr5:83132929 chr5:83012285~83013109:- CESC cis rs6452524 0.686 rs6452517 ENSG00000249664.1 CTD-2227C6.2 6.04 6.41e-09 9.06e-06 0.42 0.38 Hypertension (SNP x SNP interaction); chr5:83133041 chr5:83012285~83013109:- CESC cis rs6452524 1 rs10069402 ENSG00000249664.1 CTD-2227C6.2 6.04 6.41e-09 9.06e-06 0.42 0.38 Hypertension (SNP x SNP interaction); chr5:83133776 chr5:83012285~83013109:- CESC cis rs9309711 0.643 rs4264589 ENSG00000225234.1 TRAPPC12-AS1 -6.04 6.43e-09 9.09e-06 -0.36 -0.38 Neurofibrillary tangles; chr2:3477327 chr2:3481242~3482409:- CESC cis rs1499614 1 rs2707840 ENSG00000232559.3 GS1-124K5.12 6.04 6.43e-09 9.09e-06 0.67 0.38 Gout; chr7:66693028 chr7:66554588~66576923:- CESC cis rs11690935 0.851 rs9808259 ENSG00000228389.1 AC068039.4 6.04 6.47e-09 9.14e-06 0.5 0.38 Schizophrenia; chr2:171792464 chr2:171773482~171775844:+ CESC cis rs11690935 0.879 rs13017585 ENSG00000228389.1 AC068039.4 6.04 6.54e-09 9.23e-06 0.52 0.38 Schizophrenia; chr2:171865298 chr2:171773482~171775844:+ CESC cis rs507080 0.845 rs613377 ENSG00000255422.1 AP002954.4 -6.04 6.56e-09 9.26e-06 -0.46 -0.38 Serum metabolite levels; chr11:118685375 chr11:118704607~118750263:+ CESC cis rs875971 0.862 rs3893216 ENSG00000226824.5 RP4-756H11.3 6.04 6.56e-09 9.26e-06 0.47 0.38 Aortic root size; chr7:66325720 chr7:66654538~66669855:+ CESC cis rs9402743 0.775 rs4504492 ENSG00000217482.2 HMGB1P17 6.04 6.6e-09 9.31e-06 0.41 0.38 Systemic lupus erythematosus; chr6:135648536 chr6:135636086~135636713:- CESC cis rs875971 1 rs1144895 ENSG00000222364.1 RNU6-96P 6.04 6.61e-09 9.33e-06 0.46 0.38 Aortic root size; chr7:66076320 chr7:66395191~66395286:+ CESC cis rs2739330 0.587 rs4820571 ENSG00000250470.1 AP000351.3 6.04 6.61e-09 9.33e-06 0.49 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23976904~23977585:- CESC cis rs10129255 0.5 rs2027902 ENSG00000223648.3 IGHV3-64 6.04 6.61e-09 9.33e-06 0.33 0.38 Kawasaki disease; chr14:106807157 chr14:106643132~106658258:- CESC cis rs17711722 0.503 rs453835 ENSG00000164669.11 INTS4P1 6.04 6.62e-09 9.34e-06 0.51 0.38 Calcium levels; chr7:66046172 chr7:65141225~65234216:+ CESC cis rs6452524 1 rs6452520 ENSG00000249664.1 CTD-2227C6.2 6.04 6.62e-09 9.34e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83133452 chr5:83012285~83013109:- CESC cis rs6452524 1 rs6452521 ENSG00000249664.1 CTD-2227C6.2 6.04 6.62e-09 9.34e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83133453 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs6452522 ENSG00000249664.1 CTD-2227C6.2 6.04 6.62e-09 9.34e-06 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83133471 chr5:83012285~83013109:- CESC cis rs1707322 0.717 rs1135850 ENSG00000281133.1 AL355480.3 -6.04 6.64e-09 9.36e-06 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628020 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs2253862 ENSG00000281133.1 AL355480.3 6.04 6.64e-09 9.36e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616288 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs2991988 ENSG00000281133.1 AL355480.3 6.04 6.64e-09 9.36e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616759 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs2991989 ENSG00000281133.1 AL355480.3 6.04 6.64e-09 9.36e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45617293 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs2275086 ENSG00000281133.1 AL355480.3 6.04 6.64e-09 9.36e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620207 chr1:45580892~45580996:- CESC cis rs1707322 0.655 rs3014240 ENSG00000281133.1 AL355480.3 6.04 6.64e-09 9.36e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45623553 chr1:45580892~45580996:- CESC cis rs1707322 0.686 rs3014235 ENSG00000281133.1 AL355480.3 6.04 6.64e-09 9.36e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625840 chr1:45580892~45580996:- CESC cis rs1707322 0.656 rs9429172 ENSG00000281133.1 AL355480.3 6.04 6.64e-09 9.36e-06 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45626804 chr1:45580892~45580996:- CESC cis rs2487048 0.773 rs2472493 ENSG00000226334.1 RP11-217B7.2 -6.04 6.64e-09 9.37e-06 -0.49 -0.38 Intraocular pressure; chr9:104933567 chr9:104927553~104928892:+ CESC cis rs1891275 0.515 rs7475294 ENSG00000228701.1 TNKS2-AS1 -6.04 6.65e-09 9.38e-06 -0.44 -0.38 Intelligence (multi-trait analysis); chr10:91748442 chr10:91782839~91798291:- CESC cis rs9389248 0.69 rs1028314 ENSG00000232876.1 CTA-212D2.2 6.04 6.66e-09 9.39e-06 0.44 0.38 High light scatter reticulocyte percentage of red cells; chr6:134934572 chr6:135055033~135060550:+ CESC cis rs7572733 0.967 rs1318867 ENSG00000222017.1 AC011997.1 -6.04 6.7e-09 9.45e-06 -0.41 -0.38 Dermatomyositis; chr2:198015757 chr2:197693106~197774823:+ CESC cis rs875971 0.83 rs6976714 ENSG00000226824.5 RP4-756H11.3 -6.04 6.73e-09 9.48e-06 -0.47 -0.38 Aortic root size; chr7:66426474 chr7:66654538~66669855:+ CESC cis rs875971 0.651 rs2420596 ENSG00000226824.5 RP4-756H11.3 -6.04 6.73e-09 9.48e-06 -0.47 -0.38 Aortic root size; chr7:66450996 chr7:66654538~66669855:+ CESC cis rs875971 0.52 rs2420597 ENSG00000226824.5 RP4-756H11.3 -6.04 6.73e-09 9.48e-06 -0.47 -0.38 Aortic root size; chr7:66450999 chr7:66654538~66669855:+ CESC cis rs507080 0.922 rs12788848 ENSG00000255422.1 AP002954.4 -6.04 6.74e-09 9.5e-06 -0.44 -0.38 Serum metabolite levels; chr11:118683079 chr11:118704607~118750263:+ CESC cis rs507080 0.922 rs4474473 ENSG00000255422.1 AP002954.4 -6.04 6.74e-09 9.5e-06 -0.44 -0.38 Serum metabolite levels; chr11:118683180 chr11:118704607~118750263:+ CESC cis rs507080 0.922 rs12796373 ENSG00000255422.1 AP002954.4 -6.04 6.74e-09 9.5e-06 -0.44 -0.38 Serum metabolite levels; chr11:118684230 chr11:118704607~118750263:+ CESC cis rs765787 0.53 rs2433228 ENSG00000259520.4 CTD-2651B20.3 6.03 6.77e-09 9.53e-06 0.47 0.38 Uric acid levels; chr15:45223173 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs11854690 ENSG00000259520.4 CTD-2651B20.3 6.03 6.77e-09 9.53e-06 0.47 0.38 Uric acid levels; chr15:45223818 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs28733848 ENSG00000259520.4 CTD-2651B20.3 6.03 6.77e-09 9.53e-06 0.47 0.38 Uric acid levels; chr15:45223849 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs11854689 ENSG00000259520.4 CTD-2651B20.3 6.03 6.77e-09 9.53e-06 0.47 0.38 Uric acid levels; chr15:45223854 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs1706830 ENSG00000259520.4 CTD-2651B20.3 6.03 6.77e-09 9.53e-06 0.47 0.38 Uric acid levels; chr15:45224031 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs1706831 ENSG00000259520.4 CTD-2651B20.3 6.03 6.77e-09 9.53e-06 0.47 0.38 Uric acid levels; chr15:45224032 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2433227 ENSG00000259520.4 CTD-2651B20.3 6.03 6.77e-09 9.53e-06 0.47 0.38 Uric acid levels; chr15:45224921 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2413775 ENSG00000259520.4 CTD-2651B20.3 6.03 6.78e-09 9.54e-06 0.48 0.38 Uric acid levels; chr15:45252090 chr15:45251580~45279251:- CESC cis rs7849270 0.679 rs10988217 ENSG00000268707.1 RP11-247A12.7 -6.03 6.79e-09 9.55e-06 -0.42 -0.38 Blood metabolite ratios; chr9:129125837 chr9:129170434~129170940:+ CESC cis rs6603134 0.502 rs10411185 ENSG00000267939.1 CTD-2325M2.1 -6.03 6.79e-09 9.56e-06 -0.46 -0.38 Blood protein levels; chr19:8038997 chr19:8008729~8016025:+ CESC cis rs10875746 1 rs10875746 ENSG00000240399.1 RP1-228P16.1 -6.03 6.81e-09 9.58e-06 -0.44 -0.38 Longevity (90 years and older); chr12:48124481 chr12:48054813~48055591:- CESC cis rs765787 0.53 rs2413786 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45233196 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs28815867 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45234607 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4775822 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45234929 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs11854294 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45235798 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2899381 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45237432 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2413784 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45238318 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs7165889 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45239442 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs11070451 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45241343 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4775831 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45242524 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4775832 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45242630 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4442750 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45243130 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4444275 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45243149 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4270107 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45243152 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4544188 ENSG00000259520.4 CTD-2651B20.3 6.03 6.82e-09 9.58e-06 0.48 0.38 Uric acid levels; chr15:45243195 chr15:45251580~45279251:- CESC cis rs79349575 0.783 rs2088139 ENSG00000270781.1 RP11-501C14.9 -6.03 6.83e-09 9.6e-06 -0.42 -0.38 Type 2 diabetes; chr17:48922748 chr17:48899131~48899748:+ CESC cis rs8072100 0.84 rs4968319 ENSG00000228782.6 CTD-2026D20.3 6.03 6.83e-09 9.6e-06 0.44 0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47387601 chr17:47450568~47492492:- CESC cis rs35160687 0.901 rs17738096 ENSG00000273080.1 RP11-301O19.1 6.03 6.85e-09 9.61e-06 0.44 0.38 Night sleep phenotypes; chr2:86286770 chr2:86195590~86196049:+ CESC cis rs35160687 0.901 rs6714362 ENSG00000273080.1 RP11-301O19.1 -6.03 6.85e-09 9.61e-06 -0.44 -0.38 Night sleep phenotypes; chr2:86249465 chr2:86195590~86196049:+ CESC cis rs950169 0.922 rs12910334 ENSG00000225151.9 GOLGA2P7 -6.03 6.85e-09 9.62e-06 -0.54 -0.38 Schizophrenia; chr15:84403620 chr15:84199311~84230136:- CESC cis rs6452524 0.686 rs6452518 ENSG00000249664.1 CTD-2227C6.2 6.03 6.88e-09 9.66e-06 0.42 0.38 Hypertension (SNP x SNP interaction); chr5:83133043 chr5:83012285~83013109:- CESC cis rs2243480 0.901 rs13237344 ENSG00000232559.3 GS1-124K5.12 6.03 6.89e-09 9.67e-06 0.66 0.38 Diabetic kidney disease; chr7:66557269 chr7:66554588~66576923:- CESC cis rs17711722 0.523 rs365896 ENSG00000226824.5 RP4-756H11.3 6.03 6.9e-09 9.69e-06 0.45 0.38 Calcium levels; chr7:66045710 chr7:66654538~66669855:+ CESC cis rs7115242 1 rs7115242 ENSG00000254851.1 RP11-109L13.1 6.03 6.92e-09 9.71e-06 0.8 0.38 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117037567 chr11:117135528~117138582:+ CESC cis rs2404602 0.583 rs11072580 ENSG00000259422.1 RP11-593F23.1 6.03 6.97e-09 9.77e-06 0.42 0.38 Blood metabolite levels; chr15:76247890 chr15:76174891~76181486:- CESC cis rs10740039 0.583 rs7917700 ENSG00000254271.1 RP11-131N11.4 -6.03 6.97e-09 9.78e-06 -0.46 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740596 chr10:60734342~60741828:+ CESC cis rs11690935 1 rs3795999 ENSG00000228389.1 AC068039.4 -6.03 7.01e-09 9.83e-06 -0.5 -0.38 Schizophrenia; chr2:171687973 chr2:171773482~171775844:+ CESC cis rs10256972 0.967 rs7799110 ENSG00000229043.2 AC091729.9 -6.03 7.02e-09 9.84e-06 -0.43 -0.38 Endometriosis;Longevity; chr7:999429 chr7:1160374~1165267:+ CESC cis rs1707322 0.721 rs12045096 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648756 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs4609469 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651513 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs12049027 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45652512 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs10789467 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45653073 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs10890337 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658855 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs3811435 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660118 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs9793568 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664701 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs11211157 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667172 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs11211158 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667178 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs6429575 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668544 chr1:45580892~45580996:- CESC cis rs1707322 0.685 rs6690926 ENSG00000281133.1 AL355480.3 -6.03 7.02e-09 9.84e-06 -0.46 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669306 chr1:45580892~45580996:- CESC cis rs10129255 0.518 rs10136903 ENSG00000223648.3 IGHV3-64 6.03 7.03e-09 9.86e-06 0.31 0.38 Kawasaki disease; chr14:106778866 chr14:106643132~106658258:- CESC cis rs9322193 0.962 rs6903998 ENSG00000268592.3 RAET1E-AS1 6.03 7.04e-09 9.87e-06 0.48 0.38 Lung cancer; chr6:149831357 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs1984111 ENSG00000268592.3 RAET1E-AS1 6.03 7.04e-09 9.87e-06 0.48 0.38 Lung cancer; chr6:149831720 chr6:149863494~149919507:+ CESC cis rs1823913 0.561 rs60479498 ENSG00000280083.1 RP11-317J9.1 -6.03 7.06e-09 9.9e-06 -0.44 -0.38 Obesity-related traits; chr2:191275197 chr2:191154118~191156070:- CESC cis rs2581828 0.607 rs2581784 ENSG00000242142.1 SERBP1P3 6.03 7.08e-09 9.91e-06 0.43 0.38 Crohn's disease; chr3:53088354 chr3:53064283~53065091:- CESC cis rs1062177 0.826 rs2053063 ENSG00000253921.1 CTB-113P19.3 -6.02 7.13e-09 9.99e-06 -0.48 -0.38 Preschool internalizing problems; chr5:151787203 chr5:151753992~151767247:+ CESC cis rs8081395 0.737 rs4968401 ENSG00000266992.1 DHX40P1 -6.02 7.15e-09 1e-05 -0.42 -0.38 White blood cell count; chr17:59963369 chr17:59976009~60002384:- CESC cis rs11155671 0.53 rs9968871 ENSG00000216906.2 RP11-350J20.9 6.02 7.16e-09 1e-05 0.4 0.38 Testicular germ cell tumor; chr6:149888060 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs9969044 ENSG00000216906.2 RP11-350J20.9 6.02 7.16e-09 1e-05 0.4 0.38 Testicular germ cell tumor; chr6:149888068 chr6:149904243~149906418:+ CESC cis rs17507216 0.588 rs4778687 ENSG00000278603.1 RP13-608F4.5 6.02 7.2e-09 1.01e-05 0.68 0.38 Excessive daytime sleepiness; chr15:82649085 chr15:82472203~82472426:+ CESC cis rs8081395 0.711 rs11368 ENSG00000266992.1 DHX40P1 6.02 7.21e-09 1.01e-05 0.42 0.38 White blood cell count; chr17:59954051 chr17:59976009~60002384:- CESC cis rs6860806 0.507 rs635620 ENSG00000233006.5 AC034220.3 -6.02 7.22e-09 1.01e-05 -0.41 -0.38 Breast cancer; chr5:132384571 chr5:132311285~132369916:- CESC cis rs6860806 0.507 rs635619 ENSG00000233006.5 AC034220.3 -6.02 7.22e-09 1.01e-05 -0.41 -0.38 Breast cancer; chr5:132384573 chr5:132311285~132369916:- CESC cis rs875971 0.964 rs778735 ENSG00000222364.1 RNU6-96P -6.02 7.23e-09 1.01e-05 -0.44 -0.38 Aortic root size; chr7:66349822 chr7:66395191~66395286:+ CESC cis rs10129255 0.5 rs6576230 ENSG00000223648.3 IGHV3-64 6.02 7.23e-09 1.01e-05 0.31 0.38 Kawasaki disease; chr14:106778539 chr14:106643132~106658258:- CESC cis rs10129255 0.518 rs11847766 ENSG00000223648.3 IGHV3-64 6.02 7.23e-09 1.01e-05 0.31 0.38 Kawasaki disease; chr14:106779186 chr14:106643132~106658258:- CESC cis rs2739330 0.761 rs5760176 ENSG00000099984.9 GSTT2 6.02 7.24e-09 1.01e-05 0.45 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23980123~23983911:+ CESC cis rs274567 0.501 rs272856 ENSG00000233006.5 AC034220.3 6.02 7.26e-09 1.01e-05 0.43 0.38 Blood metabolite levels; chr5:132351388 chr5:132311285~132369916:- CESC cis rs7572733 1 rs9973400 ENSG00000222017.1 AC011997.1 6.02 7.28e-09 1.02e-05 0.43 0.38 Dermatomyositis; chr2:198076854 chr2:197693106~197774823:+ CESC cis rs10740039 0.583 rs1904399 ENSG00000254271.1 RP11-131N11.4 -6.02 7.31e-09 1.02e-05 -0.45 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739240 chr10:60734342~60741828:+ CESC cis rs10740039 0.583 rs1904400 ENSG00000254271.1 RP11-131N11.4 -6.02 7.31e-09 1.02e-05 -0.45 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739361 chr10:60734342~60741828:+ CESC cis rs10740039 0.515 rs9414742 ENSG00000254271.1 RP11-131N11.4 -6.02 7.31e-09 1.02e-05 -0.45 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739769 chr10:60734342~60741828:+ CESC cis rs10740039 0.583 rs9415609 ENSG00000254271.1 RP11-131N11.4 -6.02 7.31e-09 1.02e-05 -0.45 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739832 chr10:60734342~60741828:+ CESC cis rs10740039 0.583 rs4948263 ENSG00000254271.1 RP11-131N11.4 -6.02 7.31e-09 1.02e-05 -0.45 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740132 chr10:60734342~60741828:+ CESC cis rs2739330 0.732 rs5760175 ENSG00000228039.3 KB-1125A3.10 6.02 7.37e-09 1.03e-05 0.45 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23963780~23964374:+ CESC cis rs34779708 0.966 rs4934540 ENSG00000230534.5 RP11-297A16.2 6.02 7.37e-09 1.03e-05 0.5 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35185771 chr10:35098006~35127020:- CESC cis rs875971 0.83 rs427575 ENSG00000222364.1 RNU6-96P -6.02 7.38e-09 1.03e-05 -0.45 -0.38 Aortic root size; chr7:66054232 chr7:66395191~66395286:+ CESC cis rs720475 0.732 rs7784282 ENSG00000204959.4 ARHGEF34P -6.02 7.39e-09 1.03e-05 -0.42 -0.38 Breast cancer; chr7:144431561 chr7:144272445~144286966:- CESC cis rs10078 0.898 rs2241598 ENSG00000221990.4 EXOC3-AS1 -6.02 7.44e-09 1.04e-05 -0.36 -0.38 Fat distribution (HIV); chr5:438449 chr5:441498~443160:- CESC cis rs35955747 0.869 rs131213 ENSG00000236132.1 CTA-440B3.1 -6.02 7.46e-09 1.04e-05 -0.43 -0.38 Neutrophil count;Sum basophil neutrophil counts; chr22:31357863 chr22:31816379~31817491:- CESC cis rs6452524 0.507 rs28592576 ENSG00000249664.1 CTD-2227C6.2 6.02 7.48e-09 1.04e-05 0.44 0.38 Hypertension (SNP x SNP interaction); chr5:83074772 chr5:83012285~83013109:- CESC cis rs8072100 1 rs8072100 ENSG00000228782.6 CTD-2026D20.3 -6.02 7.5e-09 1.04e-05 -0.43 -0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47597321 chr17:47450568~47492492:- CESC cis rs6860806 0.507 rs273901 ENSG00000233006.5 AC034220.3 6.02 7.5e-09 1.04e-05 0.43 0.38 Breast cancer; chr5:132358667 chr5:132311285~132369916:- CESC cis rs270601 0.913 rs273899 ENSG00000233006.5 AC034220.3 6.02 7.5e-09 1.04e-05 0.43 0.38 Acylcarnitine levels; chr5:132359485 chr5:132311285~132369916:- CESC cis rs9399137 0.507 rs6923512 ENSG00000232876.1 CTA-212D2.2 6.02 7.51e-09 1.05e-05 0.47 0.38 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135014130 chr6:135055033~135060550:+ CESC cis rs10463554 0.892 rs6872442 ENSG00000175749.11 EIF3KP1 6.02 7.51e-09 1.05e-05 0.41 0.38 Parkinson's disease; chr5:102930818 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs72783889 ENSG00000175749.11 EIF3KP1 6.02 7.51e-09 1.05e-05 0.41 0.38 Parkinson's disease; chr5:102938835 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs72783890 ENSG00000175749.11 EIF3KP1 6.02 7.51e-09 1.05e-05 0.41 0.38 Parkinson's disease; chr5:102938836 chr5:103032376~103033031:+ CESC cis rs1707322 0.686 rs1250 ENSG00000281133.1 AL355480.3 -6.01 7.51e-09 1.05e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628355 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs11488313 ENSG00000281133.1 AL355480.3 -6.01 7.55e-09 1.05e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45759108 chr1:45580892~45580996:- CESC cis rs2404602 0.575 rs11072611 ENSG00000259422.1 RP11-593F23.1 6.01 7.55e-09 1.05e-05 0.46 0.38 Blood metabolite levels; chr15:76655642 chr15:76174891~76181486:- CESC cis rs1707322 0.721 rs10890346 ENSG00000281133.1 AL355480.3 6.01 7.57e-09 1.05e-05 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758220 chr1:45580892~45580996:- CESC cis rs1501911 0.713 rs10479344 ENSG00000248489.1 CTD-2007H13.3 -6.01 7.58e-09 1.06e-05 -0.47 -0.38 Lung function (FEV1/FVC); chr5:99012676 chr5:98929171~98995013:+ CESC cis rs765787 0.53 rs7167389 ENSG00000259520.4 CTD-2651B20.3 6.01 7.6e-09 1.06e-05 0.48 0.38 Uric acid levels; chr15:45243485 chr15:45251580~45279251:- CESC cis rs7714584 0.826 rs12655654 ENSG00000197083.10 ZNF300P1 6.01 7.61e-09 1.06e-05 0.75 0.38 Crohn's disease; chr5:150794733 chr5:150930645~150946289:- CESC cis rs7714584 1 rs74955473 ENSG00000197083.10 ZNF300P1 6.01 7.61e-09 1.06e-05 0.75 0.38 Crohn's disease; chr5:150794996 chr5:150930645~150946289:- CESC cis rs35160687 0.901 rs12472390 ENSG00000273080.1 RP11-301O19.1 6.01 7.63e-09 1.06e-05 0.44 0.38 Night sleep phenotypes; chr2:86247960 chr2:86195590~86196049:+ CESC cis rs2117029 0.586 rs10875928 ENSG00000258017.1 RP11-386G11.10 -6.01 7.64e-09 1.06e-05 -0.48 -0.38 Intelligence (multi-trait analysis); chr12:49162520 chr12:49127782~49147869:+ CESC cis rs2739330 0.828 rs5751770 ENSG00000250470.1 AP000351.3 6.01 7.64e-09 1.06e-05 0.47 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23976904~23977585:- CESC cis rs1062177 1 rs2915882 ENSG00000253921.1 CTB-113P19.3 -6.01 7.65e-09 1.06e-05 -0.51 -0.38 Preschool internalizing problems; chr5:151765875 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs2915880 ENSG00000253921.1 CTB-113P19.3 -6.01 7.65e-09 1.06e-05 -0.51 -0.38 Preschool internalizing problems; chr5:151767773 chr5:151753992~151767247:+ CESC cis rs2117029 0.521 rs7953169 ENSG00000258017.1 RP11-386G11.10 -6.01 7.65e-09 1.06e-05 -0.49 -0.38 Intelligence (multi-trait analysis); chr12:49184389 chr12:49127782~49147869:+ CESC cis rs765787 0.53 rs2433229 ENSG00000259520.4 CTD-2651B20.3 6.01 7.66e-09 1.06e-05 0.47 0.38 Uric acid levels; chr15:45223037 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4331289 ENSG00000259520.4 CTD-2651B20.3 6.01 7.66e-09 1.06e-05 0.47 0.38 Uric acid levels; chr15:45223140 chr15:45251580~45279251:- CESC cis rs6452524 1 rs10037872 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83144101 chr5:83012285~83013109:- CESC cis rs6452524 1 rs62374374 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83144838 chr5:83012285~83013109:- CESC cis rs6452524 1 rs1382372 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83145237 chr5:83012285~83013109:- CESC cis rs6452524 1 rs1382371 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83145300 chr5:83012285~83013109:- CESC cis rs6452524 1 rs1382369 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83145610 chr5:83012285~83013109:- CESC cis rs6452524 1 rs2386240 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83147192 chr5:83012285~83013109:- CESC cis rs6452524 1 rs9986131 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83149037 chr5:83012285~83013109:- CESC cis rs6452524 1 rs11740478 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83150567 chr5:83012285~83013109:- CESC cis rs6452524 1 rs4591730 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83151983 chr5:83012285~83013109:- CESC cis rs6452524 1 rs1031902 ENSG00000249664.1 CTD-2227C6.2 6.01 7.67e-09 1.07e-05 0.41 0.38 Hypertension (SNP x SNP interaction); chr5:83152308 chr5:83012285~83013109:- CESC cis rs763121 0.524 rs760645 ENSG00000273076.1 RP3-508I15.22 6.01 7.68e-09 1.07e-05 0.45 0.38 Menopause (age at onset); chr22:38636265 chr22:38743495~38743910:+ CESC cis rs9399137 0.507 rs4451150 ENSG00000232876.1 CTA-212D2.2 -6.01 7.69e-09 1.07e-05 -0.47 -0.38 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134957925 chr6:135055033~135060550:+ CESC cis rs6452524 0.561 rs4331874 ENSG00000249664.1 CTD-2227C6.2 6.01 7.71e-09 1.07e-05 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83068253 chr5:83012285~83013109:- CESC cis rs9545047 0.547 rs1590465 ENSG00000227676.3 LINC01068 -6.01 7.73e-09 1.07e-05 -0.43 -0.38 Schizophrenia; chr13:79393998 chr13:79566727~79571436:+ CESC cis rs1061377 1 rs4974931 ENSG00000249207.1 RP11-360F5.1 -6.01 7.77e-09 1.08e-05 -0.43 -0.38 Uric acid levels; chr4:39108896 chr4:39112677~39126818:- CESC cis rs1061377 1 rs4974998 ENSG00000249207.1 RP11-360F5.1 -6.01 7.77e-09 1.08e-05 -0.43 -0.38 Uric acid levels; chr4:39109129 chr4:39112677~39126818:- CESC cis rs1061377 1 rs7673299 ENSG00000249207.1 RP11-360F5.1 -6.01 7.77e-09 1.08e-05 -0.43 -0.38 Uric acid levels; chr4:39109138 chr4:39112677~39126818:- CESC cis rs1061377 1 rs4974997 ENSG00000249207.1 RP11-360F5.1 -6.01 7.77e-09 1.08e-05 -0.43 -0.38 Uric acid levels; chr4:39109151 chr4:39112677~39126818:- CESC cis rs1707322 0.717 rs3014246 ENSG00000281133.1 AL355480.3 6.01 7.78e-09 1.08e-05 0.45 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620405 chr1:45580892~45580996:- CESC cis rs992157 0.798 rs7587220 ENSG00000261338.2 RP11-378A13.1 -6.01 7.79e-09 1.08e-05 -0.49 -0.38 Colorectal cancer; chr2:218296141 chr2:218255319~218257366:+ CESC cis rs992157 0.798 rs4674284 ENSG00000261338.2 RP11-378A13.1 -6.01 7.79e-09 1.08e-05 -0.49 -0.38 Colorectal cancer; chr2:218296518 chr2:218255319~218257366:+ CESC cis rs10129255 0.518 rs8009594 ENSG00000223648.3 IGHV3-64 6.01 7.83e-09 1.09e-05 0.31 0.38 Kawasaki disease; chr14:106777494 chr14:106643132~106658258:- CESC cis rs2980439 0.818 rs2945249 ENSG00000253893.2 FAM85B -6.01 7.84e-09 1.09e-05 -0.49 -0.38 Neuroticism; chr8:8237204 chr8:8167819~8226614:- CESC cis rs2739330 0.587 rs4820571 ENSG00000099984.9 GSTT2 -6.01 7.87e-09 1.09e-05 -0.46 -0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23980123~23983911:+ CESC cis rs4718428 0.705 rs3800817 ENSG00000226824.5 RP4-756H11.3 -6.01 7.88e-09 1.09e-05 -0.52 -0.38 Corneal structure; chr7:66798563 chr7:66654538~66669855:+ CESC cis rs2243480 0.908 rs1532573 ENSG00000232559.3 GS1-124K5.12 -6.01 7.89e-09 1.09e-05 -0.65 -0.38 Diabetic kidney disease; chr7:66333815 chr7:66554588~66576923:- CESC cis rs42490 1 rs42490 ENSG00000251136.7 RP11-37B2.1 -6 7.92e-09 1.1e-05 -0.37 -0.38 Leprosy; chr8:89766285 chr8:89609409~89757727:- CESC cis rs42490 1 rs40544 ENSG00000251136.7 RP11-37B2.1 -6 7.92e-09 1.1e-05 -0.37 -0.38 Leprosy; chr8:89768867 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs40377 ENSG00000251136.7 RP11-37B2.1 -6 7.92e-09 1.1e-05 -0.37 -0.38 Leprosy; chr8:89769725 chr8:89609409~89757727:- CESC cis rs1707322 1 rs34444543 ENSG00000280836.1 AL355480.1 -6 7.94e-09 1.1e-05 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893190 chr1:45581219~45581321:- CESC cis rs380904 0.926 rs7842979 ENSG00000254859.1 RP11-661A12.5 -6 7.94e-09 1.1e-05 -0.52 -0.38 Venous thromboembolism (SNP x SNP interaction); chr8:143519726 chr8:143541973~143549729:- CESC cis rs11155671 0.53 rs2342770 ENSG00000268592.3 RAET1E-AS1 6 7.96e-09 1.1e-05 0.47 0.38 Testicular germ cell tumor; chr6:149895549 chr6:149863494~149919507:+ CESC cis rs2739330 0.731 rs5751792 ENSG00000099984.9 GSTT2 -6 7.98e-09 1.1e-05 -0.45 -0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23980123~23983911:+ CESC cis rs10740039 0.583 rs4948264 ENSG00000254271.1 RP11-131N11.4 -6 7.99e-09 1.11e-05 -0.45 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740484 chr10:60734342~60741828:+ CESC cis rs10740039 0.583 rs4948265 ENSG00000254271.1 RP11-131N11.4 -6 7.99e-09 1.11e-05 -0.45 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740495 chr10:60734342~60741828:+ CESC cis rs6504950 0.925 rs244336 ENSG00000275710.1 RP11-257O5.4 6 8e-09 1.11e-05 0.46 0.38 Breast cancer; chr17:55124141 chr17:54964474~54964679:+ CESC cis rs9399135 0.967 rs6923765 ENSG00000232876.1 CTA-212D2.2 6 8.01e-09 1.11e-05 0.43 0.38 Red blood cell count; chr6:135014038 chr6:135055033~135060550:+ CESC cis rs7208859 0.562 rs216408 ENSG00000263531.1 RP13-753N3.1 -6 8.02e-09 1.11e-05 -0.66 -0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30580739 chr17:30863921~30864940:- CESC cis rs748404 0.56 rs572837 ENSG00000249839.1 AC011330.5 -6 8.04e-09 1.11e-05 -0.4 -0.38 Lung cancer; chr15:43531615 chr15:43663654~43684339:- CESC cis rs11676348 0.818 rs1126579 ENSG00000261338.2 RP11-378A13.1 -6 8.08e-09 1.12e-05 -0.44 -0.38 Ulcerative colitis; chr2:218136011 chr2:218255319~218257366:+ CESC cis rs11676348 0.846 rs4674260 ENSG00000261338.2 RP11-378A13.1 -6 8.15e-09 1.13e-05 -0.45 -0.38 Ulcerative colitis; chr2:218137653 chr2:218255319~218257366:+ CESC cis rs6504950 0.85 rs2787507 ENSG00000275710.1 RP11-257O5.4 -6 8.19e-09 1.13e-05 -0.49 -0.38 Breast cancer; chr17:55050563 chr17:54964474~54964679:+ CESC cis rs6504950 0.813 rs9889687 ENSG00000275710.1 RP11-257O5.4 -6 8.19e-09 1.13e-05 -0.49 -0.38 Breast cancer; chr17:55055050 chr17:54964474~54964679:+ CESC cis rs6504950 0.85 rs17745534 ENSG00000275710.1 RP11-257O5.4 -6 8.19e-09 1.13e-05 -0.49 -0.38 Breast cancer; chr17:55060145 chr17:54964474~54964679:+ CESC cis rs6504950 0.889 rs9303363 ENSG00000275710.1 RP11-257O5.4 -6 8.19e-09 1.13e-05 -0.49 -0.38 Breast cancer; chr17:55060613 chr17:54964474~54964679:+ CESC cis rs9389248 0.69 rs6939543 ENSG00000232876.1 CTA-212D2.2 6 8.21e-09 1.13e-05 0.44 0.38 High light scatter reticulocyte percentage of red cells; chr6:134934005 chr6:135055033~135060550:+ CESC cis rs8062405 0.755 rs62034358 ENSG00000259982.1 CDC37P1 6 8.27e-09 1.14e-05 0.48 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576276 chr16:28700294~28701540:- CESC cis rs8062405 0.755 rs12445823 ENSG00000259982.1 CDC37P1 6 8.27e-09 1.14e-05 0.48 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576728 chr16:28700294~28701540:- CESC cis rs8062405 0.723 rs12445744 ENSG00000259982.1 CDC37P1 6 8.27e-09 1.14e-05 0.48 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28577074 chr16:28700294~28701540:- CESC cis rs8062405 0.755 rs4787455 ENSG00000259982.1 CDC37P1 6 8.27e-09 1.14e-05 0.48 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28578134 chr16:28700294~28701540:- CESC cis rs6452524 0.534 rs10514246 ENSG00000249664.1 CTD-2227C6.2 6 8.27e-09 1.14e-05 0.43 0.38 Hypertension (SNP x SNP interaction); chr5:83069979 chr5:83012285~83013109:- CESC cis rs34779708 0.966 rs1057108 ENSG00000230534.5 RP11-297A16.2 6 8.32e-09 1.15e-05 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35196021 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs7070427 ENSG00000230534.5 RP11-297A16.2 6 8.32e-09 1.15e-05 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35196761 chr10:35098006~35127020:- CESC cis rs6142102 0.58 rs9753679 ENSG00000275784.1 RP5-1125A11.6 -6 8.33e-09 1.15e-05 -0.37 -0.38 Skin pigmentation; chr20:33953054 chr20:33989480~33991818:- CESC cis rs6452524 1 rs6887846 ENSG00000249664.1 CTD-2227C6.2 -6 8.35e-09 1.15e-05 -0.42 -0.38 Hypertension (SNP x SNP interaction); chr5:83140542 chr5:83012285~83013109:- CESC cis rs4853012 0.941 rs78128123 ENSG00000257800.1 FNBP1P1 6 8.35e-09 1.15e-05 0.43 0.38 Gestational age at birth (maternal effect); chr2:74120398 chr2:74120680~74123218:+ CESC cis rs2581828 0.656 rs2163167 ENSG00000242142.1 SERBP1P3 5.99 8.37e-09 1.15e-05 0.42 0.38 Crohn's disease; chr3:53097756 chr3:53064283~53065091:- CESC cis rs2581828 0.541 rs2115781 ENSG00000242142.1 SERBP1P3 5.99 8.37e-09 1.15e-05 0.42 0.38 Crohn's disease; chr3:53097813 chr3:53064283~53065091:- CESC cis rs10129255 0.509 rs756583 ENSG00000223648.3 IGHV3-64 5.99 8.37e-09 1.15e-05 0.31 0.38 Kawasaki disease; chr14:106680002 chr14:106643132~106658258:- CESC cis rs7714584 1 rs57406211 ENSG00000197083.10 ZNF300P1 5.99 8.39e-09 1.16e-05 0.74 0.38 Crohn's disease; chr5:150791404 chr5:150930645~150946289:- CESC cis rs7714584 1 rs79442859 ENSG00000197083.10 ZNF300P1 5.99 8.39e-09 1.16e-05 0.74 0.38 Crohn's disease; chr5:150791648 chr5:150930645~150946289:- CESC cis rs8062405 0.755 rs4788073 ENSG00000259982.1 CDC37P1 5.99 8.46e-09 1.17e-05 0.47 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28583228 chr16:28700294~28701540:- CESC cis rs8062405 0.755 rs55792032 ENSG00000259982.1 CDC37P1 5.99 8.46e-09 1.17e-05 0.47 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28588090 chr16:28700294~28701540:- CESC cis rs6951245 0.529 rs76001997 ENSG00000229043.2 AC091729.9 -5.99 8.48e-09 1.17e-05 -0.48 -0.38 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112979 chr7:1160374~1165267:+ CESC cis rs6951245 0.554 rs79367977 ENSG00000229043.2 AC091729.9 -5.99 8.48e-09 1.17e-05 -0.48 -0.38 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1113021 chr7:1160374~1165267:+ CESC cis rs10129255 0.518 rs8009612 ENSG00000223648.3 IGHV3-64 5.99 8.49e-09 1.17e-05 0.31 0.38 Kawasaki disease; chr14:106777510 chr14:106643132~106658258:- CESC cis rs2739330 0.761 rs5760176 ENSG00000228039.3 KB-1125A3.10 -5.99 8.5e-09 1.17e-05 -0.45 -0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23963780~23964374:+ CESC cis rs2739330 0.731 rs5751792 ENSG00000228039.3 KB-1125A3.10 5.99 8.53e-09 1.17e-05 0.45 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23963780~23964374:+ CESC cis rs62229266 0.654 rs62230787 ENSG00000231106.2 LINC01436 5.99 8.55e-09 1.18e-05 0.55 0.38 Mitral valve prolapse; chr21:36004182 chr21:36005338~36007838:+ CESC cis rs10463554 0.892 rs3776874 ENSG00000175749.11 EIF3KP1 5.99 8.65e-09 1.19e-05 0.4 0.38 Parkinson's disease; chr5:102946613 chr5:103032376~103033031:+ CESC cis rs10463554 0.857 rs3776873 ENSG00000175749.11 EIF3KP1 5.99 8.65e-09 1.19e-05 0.4 0.38 Parkinson's disease; chr5:102946768 chr5:103032376~103033031:+ CESC cis rs10129255 0.536 rs3944157 ENSG00000223648.3 IGHV3-64 5.99 8.66e-09 1.19e-05 0.31 0.38 Kawasaki disease; chr14:106682286 chr14:106643132~106658258:- CESC cis rs897984 0.542 rs35713203 ENSG00000260911.2 RP11-196G11.2 5.99 8.68e-09 1.19e-05 0.41 0.38 Dementia with Lewy bodies; chr16:31079086 chr16:31043150~31049868:+ CESC cis rs2243480 0.708 rs35825036 ENSG00000232559.3 GS1-124K5.12 5.99 8.68e-09 1.19e-05 0.65 0.38 Diabetic kidney disease; chr7:66521515 chr7:66554588~66576923:- CESC cis rs2243480 0.803 rs13224048 ENSG00000232559.3 GS1-124K5.12 5.99 8.68e-09 1.19e-05 0.65 0.38 Diabetic kidney disease; chr7:66528779 chr7:66554588~66576923:- CESC cis rs2243480 1 rs13237037 ENSG00000232559.3 GS1-124K5.12 5.99 8.68e-09 1.19e-05 0.65 0.38 Diabetic kidney disease; chr7:66532895 chr7:66554588~66576923:- CESC cis rs2404602 1 rs6495206 ENSG00000259422.1 RP11-593F23.1 5.99 8.69e-09 1.19e-05 0.42 0.38 Blood metabolite levels; chr15:76578622 chr15:76174891~76181486:- CESC cis rs2404602 1 rs1117367 ENSG00000259422.1 RP11-593F23.1 5.99 8.69e-09 1.19e-05 0.42 0.38 Blood metabolite levels; chr15:76579989 chr15:76174891~76181486:- CESC cis rs2243480 0.901 rs2900904 ENSG00000228409.4 CCT6P1 5.99 8.7e-09 1.2e-05 0.56 0.38 Diabetic kidney disease; chr7:65739282 chr7:65751142~65763354:+ CESC cis rs992157 0.735 rs13392177 ENSG00000261338.2 RP11-378A13.1 -5.99 8.71e-09 1.2e-05 -0.45 -0.38 Colorectal cancer; chr2:218248233 chr2:218255319~218257366:+ CESC cis rs10740039 0.549 rs9414741 ENSG00000254271.1 RP11-131N11.4 -5.99 8.72e-09 1.2e-05 -0.45 -0.38 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60738510 chr10:60734342~60741828:+ CESC cis rs1061377 1 rs12646251 ENSG00000249207.1 RP11-360F5.1 -5.99 8.73e-09 1.2e-05 -0.42 -0.38 Uric acid levels; chr4:39132751 chr4:39112677~39126818:- CESC cis rs875971 0.862 rs11984115 ENSG00000226824.5 RP4-756H11.3 5.99 8.73e-09 1.2e-05 0.46 0.38 Aortic root size; chr7:66308872 chr7:66654538~66669855:+ CESC cis rs9907295 0.688 rs2735475 ENSG00000270977.1 AC015849.16 -5.99 8.76e-09 1.2e-05 -0.48 -0.38 Fibroblast growth factor basic levels; chr17:35931003 chr17:35893707~35911023:- CESC cis rs8072100 0.846 rs4264433 ENSG00000228782.6 CTD-2026D20.3 -5.99 8.77e-09 1.2e-05 -0.43 -0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47659909 chr17:47450568~47492492:- CESC cis rs6860806 0.507 rs2631362 ENSG00000233006.5 AC034220.3 -5.99 8.77e-09 1.2e-05 -0.42 -0.38 Breast cancer; chr5:132371601 chr5:132311285~132369916:- CESC cis rs6860806 0.507 rs2631364 ENSG00000233006.5 AC034220.3 -5.99 8.78e-09 1.21e-05 -0.42 -0.38 Breast cancer; chr5:132371222 chr5:132311285~132369916:- CESC cis rs6860806 0.531 rs2631359 ENSG00000233006.5 AC034220.3 -5.99 8.78e-09 1.21e-05 -0.42 -0.38 Breast cancer; chr5:132372200 chr5:132311285~132369916:- CESC cis rs12022452 1 rs12022452 ENSG00000238287.1 RP11-656D10.3 -5.98 8.81e-09 1.21e-05 -0.6 -0.38 Age-related hearing impairment (SNP x SNP interaction); chr1:40487628 chr1:40493157~40508661:- CESC cis rs6504950 0.695 rs9904377 ENSG00000275710.1 RP11-257O5.4 5.98 8.87e-09 1.22e-05 0.43 0.38 Breast cancer; chr17:54908621 chr17:54964474~54964679:+ CESC cis rs1707322 0.89 rs2297883 ENSG00000280836.1 AL355480.1 5.98 8.89e-09 1.22e-05 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46045815 chr1:45581219~45581321:- CESC cis rs1707322 1 rs1707338 ENSG00000280836.1 AL355480.1 5.98 8.89e-09 1.22e-05 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46046309 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs1707339 ENSG00000280836.1 AL355480.1 5.98 8.89e-09 1.22e-05 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46047507 chr1:45581219~45581321:- CESC cis rs1707322 1 rs1768818 ENSG00000280836.1 AL355480.1 5.98 8.89e-09 1.22e-05 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46048614 chr1:45581219~45581321:- CESC cis rs1707322 1 rs1768817 ENSG00000280836.1 AL355480.1 5.98 8.89e-09 1.22e-05 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46048862 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785470 ENSG00000280836.1 AL355480.1 5.98 8.89e-09 1.22e-05 0.44 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46053950 chr1:45581219~45581321:- CESC cis rs8062405 0.755 rs17640009 ENSG00000259982.1 CDC37P1 5.98 8.97e-09 1.23e-05 0.48 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28584379 chr16:28700294~28701540:- CESC cis rs9584850 0.874 rs7988959 ENSG00000231194.1 FARP1-AS1 5.98 9.01e-09 1.24e-05 0.48 0.38 Neuroticism; chr13:98451750 chr13:98435405~98435840:- CESC cis rs6951245 0.554 rs11761322 ENSG00000229043.2 AC091729.9 -5.98 9.06e-09 1.24e-05 -0.48 -0.38 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112021 chr7:1160374~1165267:+ CESC cis rs9907295 1 rs11868244 ENSG00000270977.1 AC015849.16 -5.98 9.08e-09 1.24e-05 -0.53 -0.38 Fibroblast growth factor basic levels; chr17:35916339 chr17:35893707~35911023:- CESC cis rs1707322 0.752 rs6678444 ENSG00000281133.1 AL355480.3 -5.98 9.1e-09 1.25e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764175 chr1:45580892~45580996:- CESC cis rs9389248 0.5 rs116273677 ENSG00000232876.1 CTA-212D2.2 -5.98 9.13e-09 1.25e-05 -0.43 -0.38 High light scatter reticulocyte percentage of red cells; chr6:135017997 chr6:135055033~135060550:+ CESC cis rs35160687 0.901 rs12620833 ENSG00000273080.1 RP11-301O19.1 5.98 9.15e-09 1.25e-05 0.44 0.38 Night sleep phenotypes; chr2:86245747 chr2:86195590~86196049:+ CESC cis rs11155671 0.53 rs2342770 ENSG00000216906.2 RP11-350J20.9 5.98 9.17e-09 1.26e-05 0.4 0.38 Testicular germ cell tumor; chr6:149895549 chr6:149904243~149906418:+ CESC cis rs11690935 0.959 rs10167419 ENSG00000228389.1 AC068039.4 5.98 9.18e-09 1.26e-05 0.49 0.38 Schizophrenia; chr2:171793316 chr2:171773482~171775844:+ CESC cis rs2980439 0.846 rs2980437 ENSG00000173295.6 FAM86B3P -5.98 9.22e-09 1.26e-05 -0.49 -0.38 Neuroticism; chr8:8237241 chr8:8228595~8244865:+ CESC cis rs6860806 0.507 rs272854 ENSG00000233006.5 AC034220.3 5.98 9.24e-09 1.26e-05 0.42 0.38 Breast cancer; chr5:132352324 chr5:132311285~132369916:- CESC cis rs2243480 1 rs781150 ENSG00000228409.4 CCT6P1 5.97 9.28e-09 1.27e-05 0.55 0.38 Diabetic kidney disease; chr7:66015986 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs313798 ENSG00000228409.4 CCT6P1 5.97 9.28e-09 1.27e-05 0.55 0.38 Diabetic kidney disease; chr7:66028044 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs313809 ENSG00000228409.4 CCT6P1 5.97 9.28e-09 1.27e-05 0.55 0.38 Diabetic kidney disease; chr7:66034996 chr7:65751142~65763354:+ CESC cis rs42490 0.966 rs39499 ENSG00000251136.7 RP11-37B2.1 -5.97 9.29e-09 1.27e-05 -0.38 -0.38 Leprosy; chr8:89758381 chr8:89609409~89757727:- CESC cis rs10129255 0.5 rs7161740 ENSG00000223648.3 IGHV3-64 5.97 9.29e-09 1.27e-05 0.31 0.38 Kawasaki disease; chr14:106776119 chr14:106643132~106658258:- CESC cis rs2404602 0.716 rs17364076 ENSG00000259422.1 RP11-593F23.1 5.97 9.35e-09 1.28e-05 0.41 0.38 Blood metabolite levels; chr15:76468550 chr15:76174891~76181486:- CESC cis rs1707322 0.752 rs10430105 ENSG00000281133.1 AL355480.3 -5.97 9.36e-09 1.28e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45673204 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs10890341 ENSG00000281133.1 AL355480.3 -5.97 9.36e-09 1.28e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45681568 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs11211161 ENSG00000281133.1 AL355480.3 -5.97 9.36e-09 1.28e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45682466 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs61784793 ENSG00000281133.1 AL355480.3 -5.97 9.36e-09 1.28e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45683613 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs4586014 ENSG00000281133.1 AL355480.3 -5.97 9.36e-09 1.28e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684771 chr1:45580892~45580996:- CESC cis rs1707322 0.648 rs4439382 ENSG00000281133.1 AL355480.3 -5.97 9.36e-09 1.28e-05 -0.45 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45685133 chr1:45580892~45580996:- CESC cis rs1707322 1 rs12077974 ENSG00000280836.1 AL355480.1 -5.97 9.37e-09 1.28e-05 -0.44 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45918469 chr1:45581219~45581321:- CESC cis rs1062177 1 rs41494545 ENSG00000253921.1 CTB-113P19.3 5.97 9.38e-09 1.28e-05 0.49 0.38 Preschool internalizing problems; chr5:151855533 chr5:151753992~151767247:+ CESC cis rs3931020 0.962 rs2185695 ENSG00000272864.1 RP11-17E13.2 -5.97 9.38e-09 1.28e-05 -0.47 -0.38 Resistin levels; chr1:74792197 chr1:74698769~74699333:- CESC cis rs8081395 0.707 rs1024637 ENSG00000266992.1 DHX40P1 -5.97 9.43e-09 1.29e-05 -0.41 -0.37 White blood cell count; chr17:59961532 chr17:59976009~60002384:- CESC cis rs8072100 0.84 rs9893901 ENSG00000228782.6 CTD-2026D20.3 5.97 9.45e-09 1.29e-05 0.44 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47429316 chr17:47450568~47492492:- CESC cis rs62229266 0.804 rs880221 ENSG00000231106.2 LINC01436 5.97 9.45e-09 1.29e-05 0.51 0.37 Mitral valve prolapse; chr21:36048487 chr21:36005338~36007838:+ CESC cis rs62229266 0.804 rs11088331 ENSG00000231106.2 LINC01436 5.97 9.45e-09 1.29e-05 0.51 0.37 Mitral valve prolapse; chr21:36049574 chr21:36005338~36007838:+ CESC cis rs62229266 0.804 rs56279140 ENSG00000231106.2 LINC01436 5.97 9.45e-09 1.29e-05 0.51 0.37 Mitral valve prolapse; chr21:36052063 chr21:36005338~36007838:+ CESC cis rs9399135 0.967 rs2150681 ENSG00000232876.1 CTA-212D2.2 5.97 9.47e-09 1.29e-05 0.44 0.37 Red blood cell count; chr6:135054094 chr6:135055033~135060550:+ CESC cis rs62229266 0.804 rs2835259 ENSG00000231106.2 LINC01436 5.97 9.56e-09 1.3e-05 0.51 0.37 Mitral valve prolapse; chr21:36053004 chr21:36005338~36007838:+ CESC cis rs9399135 0.66 rs4646868 ENSG00000232876.1 CTA-212D2.2 -5.97 9.56e-09 1.3e-05 -0.44 -0.37 Red blood cell count; chr6:134950808 chr6:135055033~135060550:+ CESC cis rs2243480 1 rs1796228 ENSG00000232559.3 GS1-124K5.12 5.97 9.6e-09 1.31e-05 0.65 0.37 Diabetic kidney disease; chr7:66568097 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1267820 ENSG00000232559.3 GS1-124K5.12 5.97 9.6e-09 1.31e-05 0.65 0.37 Diabetic kidney disease; chr7:66585308 chr7:66554588~66576923:- CESC cis rs2243480 1 rs2533288 ENSG00000232559.3 GS1-124K5.12 5.97 9.6e-09 1.31e-05 0.65 0.37 Diabetic kidney disease; chr7:66591724 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs73148097 ENSG00000228409.4 CCT6P1 5.97 9.62e-09 1.31e-05 0.55 0.37 Diabetic kidney disease; chr7:65966800 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35820085 ENSG00000228409.4 CCT6P1 5.97 9.62e-09 1.31e-05 0.55 0.37 Diabetic kidney disease; chr7:65977771 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs906134 ENSG00000228409.4 CCT6P1 5.97 9.62e-09 1.31e-05 0.55 0.37 Diabetic kidney disease; chr7:65979301 chr7:65751142~65763354:+ CESC cis rs1707322 0.721 rs12043945 ENSG00000281133.1 AL355480.3 -5.97 9.63e-09 1.31e-05 -0.45 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45641250 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs12091503 ENSG00000281133.1 AL355480.3 -5.97 9.63e-09 1.31e-05 -0.45 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642196 chr1:45580892~45580996:- CESC cis rs35955747 1 rs35955747 ENSG00000236132.1 CTA-440B3.1 5.97 9.66e-09 1.31e-05 0.44 0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31417072 chr22:31816379~31817491:- CESC cis rs1891275 0.55 rs4933694 ENSG00000228701.1 TNKS2-AS1 -5.97 9.68e-09 1.32e-05 -0.44 -0.37 Intelligence (multi-trait analysis); chr10:91739456 chr10:91782839~91798291:- CESC cis rs1707322 0.717 rs3014249 ENSG00000281133.1 AL355480.3 5.97 9.69e-09 1.32e-05 0.45 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613821 chr1:45580892~45580996:- CESC cis rs1823913 0.538 rs35311234 ENSG00000280083.1 RP11-317J9.1 -5.97 9.7e-09 1.32e-05 -0.44 -0.37 Obesity-related traits; chr2:191316952 chr2:191154118~191156070:- CESC cis rs875971 0.83 rs778711 ENSG00000226824.5 RP4-756H11.3 -5.97 9.7e-09 1.32e-05 -0.47 -0.37 Aortic root size; chr7:66386670 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs1083554 ENSG00000226824.5 RP4-756H11.3 -5.97 9.7e-09 1.32e-05 -0.47 -0.37 Aortic root size; chr7:66387354 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs778707 ENSG00000226824.5 RP4-756H11.3 -5.97 9.7e-09 1.32e-05 -0.47 -0.37 Aortic root size; chr7:66392040 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs778705 ENSG00000226824.5 RP4-756H11.3 -5.97 9.7e-09 1.32e-05 -0.47 -0.37 Aortic root size; chr7:66396128 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs778697 ENSG00000226824.5 RP4-756H11.3 -5.97 9.7e-09 1.32e-05 -0.47 -0.37 Aortic root size; chr7:66405439 chr7:66654538~66669855:+ CESC cis rs875971 0.798 rs7789615 ENSG00000226824.5 RP4-756H11.3 -5.97 9.7e-09 1.32e-05 -0.47 -0.37 Aortic root size; chr7:66413674 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6978028 ENSG00000226824.5 RP4-756H11.3 -5.97 9.7e-09 1.32e-05 -0.47 -0.37 Aortic root size; chr7:66421313 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6947339 ENSG00000226824.5 RP4-756H11.3 -5.97 9.7e-09 1.32e-05 -0.47 -0.37 Aortic root size; chr7:66423483 chr7:66654538~66669855:+ CESC cis rs7714584 1 rs76872831 ENSG00000197083.10 ZNF300P1 5.97 9.71e-09 1.32e-05 0.74 0.37 Crohn's disease; chr5:150791997 chr5:150930645~150946289:- CESC cis rs10875746 0.859 rs11558768 ENSG00000240399.1 RP1-228P16.1 -5.97 9.73e-09 1.32e-05 -0.48 -0.37 Longevity (90 years and older); chr12:48184006 chr12:48054813~48055591:- CESC cis rs11155671 0.53 rs7756850 ENSG00000216906.2 RP11-350J20.9 5.97 9.73e-09 1.32e-05 0.4 0.37 Testicular germ cell tumor; chr6:149891460 chr6:149904243~149906418:+ CESC cis rs875971 0.755 rs76288834 ENSG00000226824.5 RP4-756H11.3 5.97 9.77e-09 1.33e-05 0.47 0.37 Aortic root size; chr7:66604815 chr7:66654538~66669855:+ CESC cis rs17711722 0.565 rs4275112 ENSG00000226824.5 RP4-756H11.3 5.96 9.84e-09 1.34e-05 0.46 0.37 Calcium levels; chr7:65733651 chr7:66654538~66669855:+ CESC cis rs79349575 0.811 rs12601072 ENSG00000270781.1 RP11-501C14.9 -5.96 9.86e-09 1.34e-05 -0.42 -0.37 Type 2 diabetes; chr17:48920636 chr17:48899131~48899748:+ CESC cis rs79349575 0.749 rs58838744 ENSG00000270781.1 RP11-501C14.9 -5.96 9.86e-09 1.34e-05 -0.42 -0.37 Type 2 diabetes; chr17:48921540 chr17:48899131~48899748:+ CESC cis rs79349575 0.811 rs60708039 ENSG00000270781.1 RP11-501C14.9 -5.96 9.86e-09 1.34e-05 -0.42 -0.37 Type 2 diabetes; chr17:48922011 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs55771415 ENSG00000270781.1 RP11-501C14.9 -5.96 9.86e-09 1.34e-05 -0.42 -0.37 Type 2 diabetes; chr17:48922575 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs4793991 ENSG00000270781.1 RP11-501C14.9 -5.96 9.86e-09 1.34e-05 -0.42 -0.37 Type 2 diabetes; chr17:48924439 chr17:48899131~48899748:+ CESC cis rs79349575 0.715 rs62075844 ENSG00000270781.1 RP11-501C14.9 -5.96 9.86e-09 1.34e-05 -0.42 -0.37 Type 2 diabetes; chr17:48925027 chr17:48899131~48899748:+ CESC cis rs79349575 0.749 rs957557 ENSG00000270781.1 RP11-501C14.9 -5.96 9.86e-09 1.34e-05 -0.42 -0.37 Type 2 diabetes; chr17:48925859 chr17:48899131~48899748:+ CESC cis rs6504950 0.85 rs11658717 ENSG00000275710.1 RP11-257O5.4 -5.96 9.9e-09 1.34e-05 -0.45 -0.37 Breast cancer; chr17:54999625 chr17:54964474~54964679:+ CESC cis rs6504950 0.85 rs11079143 ENSG00000275710.1 RP11-257O5.4 -5.96 9.9e-09 1.34e-05 -0.45 -0.37 Breast cancer; chr17:55005761 chr17:54964474~54964679:+ CESC cis rs10875746 0.859 rs11168371 ENSG00000240399.1 RP1-228P16.1 -5.96 9.91e-09 1.35e-05 -0.47 -0.37 Longevity (90 years and older); chr12:48043903 chr12:48054813~48055591:- CESC cis rs2404602 0.735 rs437131 ENSG00000259422.1 RP11-593F23.1 5.96 9.92e-09 1.35e-05 0.42 0.37 Blood metabolite levels; chr15:76488710 chr15:76174891~76181486:- CESC cis rs6452524 1 rs17284288 ENSG00000249664.1 CTD-2227C6.2 5.96 9.93e-09 1.35e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83148997 chr5:83012285~83013109:- CESC cis rs34779708 0.733 rs11597184 ENSG00000230534.5 RP11-297A16.2 5.96 9.95e-09 1.35e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35108468 chr10:35098006~35127020:- CESC cis rs10246939 0.544 rs6955562 ENSG00000228775.6 WEE2-AS1 5.96 9.96e-09 1.35e-05 0.44 0.37 Bitter taste perception; chr7:141886641 chr7:141704338~141738346:- CESC cis rs1707322 0.717 rs3014245 ENSG00000281133.1 AL355480.3 5.96 1e-08 1.36e-05 0.46 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621241 chr1:45580892~45580996:- CESC cis rs3738443 0.672 rs6691539 ENSG00000259865.1 RP11-488L18.10 5.96 1e-08 1.36e-05 0.35 0.37 Alcohol dependence; chr1:247209370 chr1:247187281~247188526:- CESC cis rs7201929 1 rs7499878 ENSG00000259982.1 CDC37P1 -5.96 1.01e-08 1.37e-05 -0.5 -0.37 QT interval; chr16:28857143 chr16:28700294~28701540:- CESC cis rs8040855 0.559 rs6496801 ENSG00000259295.5 CSPG4P12 -5.96 1.01e-08 1.37e-05 -0.45 -0.37 Bulimia nervosa; chr15:85185168 chr15:85191438~85213905:+ CESC cis rs8005677 0.828 rs12437151 ENSG00000279656.1 RP11-298I3.6 5.96 1.01e-08 1.37e-05 0.46 0.37 Cognitive ability (multi-trait analysis); chr14:22903704 chr14:23023083~23024217:- CESC cis rs5760092 0.755 rs915589 ENSG00000099984.9 GSTT2 5.96 1.01e-08 1.37e-05 0.54 0.37 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23980123~23983911:+ CESC cis rs6860806 0.507 rs582490 ENSG00000233006.5 AC034220.3 -5.96 1.02e-08 1.38e-05 -0.42 -0.37 Breast cancer; chr5:132374403 chr5:132311285~132369916:- CESC cis rs274567 0.501 rs581968 ENSG00000233006.5 AC034220.3 -5.96 1.02e-08 1.38e-05 -0.42 -0.37 Blood metabolite levels; chr5:132374510 chr5:132311285~132369916:- CESC cis rs6860806 0.507 rs274572 ENSG00000233006.5 AC034220.3 -5.96 1.02e-08 1.38e-05 -0.42 -0.37 Breast cancer; chr5:132375225 chr5:132311285~132369916:- CESC cis rs274567 0.501 rs274571 ENSG00000233006.5 AC034220.3 -5.96 1.02e-08 1.38e-05 -0.42 -0.37 Blood metabolite levels; chr5:132376433 chr5:132311285~132369916:- CESC cis rs10463554 0.963 rs26254 ENSG00000175749.11 EIF3KP1 5.96 1.02e-08 1.38e-05 0.4 0.37 Parkinson's disease; chr5:103221158 chr5:103032376~103033031:+ CESC cis rs10875746 0.951 rs8804 ENSG00000240399.1 RP1-228P16.1 -5.96 1.02e-08 1.38e-05 -0.48 -0.37 Longevity (90 years and older); chr12:48147974 chr12:48054813~48055591:- CESC cis rs897984 0.574 rs11647284 ENSG00000260911.2 RP11-196G11.2 5.96 1.02e-08 1.38e-05 0.4 0.37 Dementia with Lewy bodies; chr16:31066014 chr16:31043150~31049868:+ CESC cis rs2404602 1 rs12148786 ENSG00000259422.1 RP11-593F23.1 5.96 1.02e-08 1.38e-05 0.41 0.37 Blood metabolite levels; chr15:76508021 chr15:76174891~76181486:- CESC cis rs2177312 0.574 rs6553981 ENSG00000251129.1 RP11-734I18.1 -5.96 1.02e-08 1.39e-05 -0.42 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31976790 chr4:31997397~32155406:+ CESC cis rs2177312 0.574 rs1554554 ENSG00000251129.1 RP11-734I18.1 -5.96 1.02e-08 1.39e-05 -0.42 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31977641 chr4:31997397~32155406:+ CESC cis rs2177312 0.574 rs6850529 ENSG00000251129.1 RP11-734I18.1 -5.96 1.02e-08 1.39e-05 -0.42 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31979087 chr4:31997397~32155406:+ CESC cis rs150992 0.587 rs4703340 ENSG00000248489.1 CTD-2007H13.3 -5.96 1.02e-08 1.39e-05 -0.45 -0.37 Body mass index; chr5:99009083 chr5:98929171~98995013:+ CESC cis rs2117029 0.586 rs2114846 ENSG00000258017.1 RP11-386G11.10 -5.96 1.03e-08 1.39e-05 -0.47 -0.37 Intelligence (multi-trait analysis); chr12:49154493 chr12:49127782~49147869:+ CESC cis rs10463554 0.963 rs6889592 ENSG00000175749.11 EIF3KP1 5.95 1.03e-08 1.4e-05 0.4 0.37 Parkinson's disease; chr5:102978235 chr5:103032376~103033031:+ CESC cis rs1707322 0.662 rs11211160 ENSG00000281133.1 AL355480.3 -5.95 1.03e-08 1.4e-05 -0.45 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680557 chr1:45580892~45580996:- CESC cis rs6504950 0.745 rs12949718 ENSG00000275710.1 RP11-257O5.4 -5.95 1.03e-08 1.4e-05 -0.43 -0.37 Breast cancer; chr17:54904492 chr17:54964474~54964679:+ CESC cis rs783540 0.521 rs28719490 ENSG00000255769.6 GOLGA2P10 -5.95 1.04e-08 1.4e-05 -0.46 -0.37 Schizophrenia; chr15:82720688 chr15:82472993~82513950:- CESC cis rs1707322 0.721 rs7519900 ENSG00000281133.1 AL355480.3 -5.95 1.04e-08 1.4e-05 -0.45 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769275 chr1:45580892~45580996:- CESC cis rs6142102 0.602 rs6142069 ENSG00000275784.1 RP5-1125A11.6 -5.95 1.04e-08 1.4e-05 -0.37 -0.37 Skin pigmentation; chr20:33972736 chr20:33989480~33991818:- CESC cis rs6142102 0.602 rs4911395 ENSG00000275784.1 RP5-1125A11.6 -5.95 1.04e-08 1.4e-05 -0.37 -0.37 Skin pigmentation; chr20:33992095 chr20:33989480~33991818:- CESC cis rs11155671 0.53 rs9371542 ENSG00000268592.3 RAET1E-AS1 5.95 1.04e-08 1.41e-05 0.46 0.37 Testicular germ cell tumor; chr6:149891949 chr6:149863494~149919507:+ CESC cis rs9322193 0.567 rs7747457 ENSG00000268592.3 RAET1E-AS1 5.95 1.04e-08 1.41e-05 0.46 0.37 Lung cancer; chr6:149892366 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs9371223 ENSG00000268592.3 RAET1E-AS1 5.95 1.04e-08 1.41e-05 0.46 0.37 Testicular germ cell tumor; chr6:149893670 chr6:149863494~149919507:+ CESC cis rs35160687 1 rs35160687 ENSG00000273080.1 RP11-301O19.1 5.95 1.04e-08 1.41e-05 0.44 0.37 Night sleep phenotypes; chr2:86244991 chr2:86195590~86196049:+ CESC cis rs8072100 1 rs4375701 ENSG00000228782.6 CTD-2026D20.3 5.95 1.04e-08 1.41e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47634852 chr17:47450568~47492492:- CESC cis rs8072100 1 rs8065437 ENSG00000228782.6 CTD-2026D20.3 5.95 1.04e-08 1.41e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47644287 chr17:47450568~47492492:- CESC cis rs7500321 1 rs7500321 ENSG00000259982.1 CDC37P1 -5.95 1.05e-08 1.41e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr16:28965699 chr16:28700294~28701540:- CESC cis rs5769707 0.632 rs1476037 ENSG00000188511.11 C22orf34 5.95 1.05e-08 1.42e-05 0.44 0.37 Monocyte percentage of white cells;Monocyte count; chr22:49597729 chr22:49414524~49657542:- CESC cis rs2739330 0.76 rs5760095 ENSG00000272787.1 KB-226F1.2 -5.95 1.05e-08 1.42e-05 -0.41 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23969211~23969873:+ CESC cis rs9545047 0.604 rs7331872 ENSG00000227676.3 LINC01068 -5.95 1.05e-08 1.42e-05 -0.43 -0.37 Schizophrenia; chr13:79388717 chr13:79566727~79571436:+ CESC cis rs9322193 0.543 rs9371533 ENSG00000268592.3 RAET1E-AS1 5.95 1.05e-08 1.42e-05 0.47 0.37 Lung cancer; chr6:149889545 chr6:149863494~149919507:+ CESC cis rs801193 0.569 rs2659907 ENSG00000226824.5 RP4-756H11.3 -5.95 1.05e-08 1.42e-05 -0.47 -0.37 Aortic root size; chr7:66699045 chr7:66654538~66669855:+ CESC cis rs3931020 1 rs10874122 ENSG00000272864.1 RP11-17E13.2 -5.95 1.05e-08 1.42e-05 -0.44 -0.37 Resistin levels; chr1:74770182 chr1:74698769~74699333:- CESC cis rs992157 0.798 rs10193383 ENSG00000261338.2 RP11-378A13.1 5.95 1.06e-08 1.43e-05 0.49 0.37 Colorectal cancer; chr2:218292969 chr2:218255319~218257366:+ CESC cis rs992157 0.798 rs10206064 ENSG00000261338.2 RP11-378A13.1 5.95 1.06e-08 1.43e-05 0.49 0.37 Colorectal cancer; chr2:218293236 chr2:218255319~218257366:+ CESC cis rs992157 0.7 rs10165153 ENSG00000261338.2 RP11-378A13.1 5.95 1.06e-08 1.43e-05 0.49 0.37 Colorectal cancer; chr2:218294906 chr2:218255319~218257366:+ CESC cis rs2729354 0.953 rs2649650 ENSG00000265566.2 RN7SL605P -5.95 1.06e-08 1.44e-05 -0.57 -0.37 Blood protein levels; chr11:57560094 chr11:57528085~57528365:- CESC cis rs2404602 0.692 rs55729975 ENSG00000259422.1 RP11-593F23.1 5.95 1.07e-08 1.44e-05 0.43 0.37 Blood metabolite levels; chr15:76510885 chr15:76174891~76181486:- CESC cis rs2243480 1 rs2961102 ENSG00000228409.4 CCT6P1 5.95 1.07e-08 1.45e-05 0.55 0.37 Diabetic kidney disease; chr7:65959671 chr7:65751142~65763354:+ CESC cis rs6951245 0.554 rs10270249 ENSG00000229043.2 AC091729.9 -5.95 1.08e-08 1.45e-05 -0.48 -0.37 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112250 chr7:1160374~1165267:+ CESC cis rs4972806 0.849 rs1542180 ENSG00000226363.3 HAGLROS -5.95 1.08e-08 1.46e-05 -0.5 -0.37 IgG glycosylation; chr2:176164039 chr2:176177717~176179008:+ CESC cis rs1075265 0.554 rs10168293 ENSG00000233266.1 HMGB1P31 5.95 1.08e-08 1.46e-05 0.49 0.37 Chronotype;Morning vs. evening chronotype; chr2:53973793 chr2:54051334~54051760:+ CESC cis rs6504950 0.8 rs72829484 ENSG00000275710.1 RP11-257O5.4 5.95 1.08e-08 1.46e-05 0.45 0.37 Breast cancer; chr17:54931919 chr17:54964474~54964679:+ CESC cis rs6504950 0.8 rs17745183 ENSG00000275710.1 RP11-257O5.4 5.95 1.08e-08 1.46e-05 0.45 0.37 Breast cancer; chr17:54936234 chr17:54964474~54964679:+ CESC cis rs2581828 0.656 rs2581787 ENSG00000242142.1 SERBP1P3 5.95 1.08e-08 1.46e-05 0.42 0.37 Crohn's disease; chr3:53093661 chr3:53064283~53065091:- CESC cis rs12022452 1 rs12031278 ENSG00000238287.1 RP11-656D10.3 -5.94 1.09e-08 1.46e-05 -0.59 -0.37 Age-related hearing impairment (SNP x SNP interaction); chr1:40511246 chr1:40493157~40508661:- CESC cis rs10740039 0.583 rs9415608 ENSG00000254271.1 RP11-131N11.4 -5.94 1.09e-08 1.47e-05 -0.46 -0.37 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60737680 chr10:60734342~60741828:+ CESC cis rs9399135 0.967 rs6910530 ENSG00000232876.1 CTA-212D2.2 -5.94 1.1e-08 1.48e-05 -0.43 -0.37 Red blood cell count; chr6:135011632 chr6:135055033~135060550:+ CESC cis rs62229266 0.804 rs2255858 ENSG00000231106.2 LINC01436 5.94 1.1e-08 1.48e-05 0.51 0.37 Mitral valve prolapse; chr21:36040454 chr21:36005338~36007838:+ CESC cis rs1891275 0.515 rs10881957 ENSG00000228701.1 TNKS2-AS1 -5.94 1.1e-08 1.48e-05 -0.43 -0.37 Intelligence (multi-trait analysis); chr10:91742119 chr10:91782839~91798291:- CESC cis rs14027 0.961 rs7017279 ENSG00000279347.1 RP11-85I17.2 5.94 1.1e-08 1.48e-05 0.35 0.37 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119847580 chr8:119838736~119840385:- CESC cis rs17507216 0.718 rs72751662 ENSG00000278603.1 RP13-608F4.5 5.94 1.1e-08 1.48e-05 0.66 0.37 Excessive daytime sleepiness; chr15:82594705 chr15:82472203~82472426:+ CESC cis rs1707322 0.685 rs11211177 ENSG00000281133.1 AL355480.3 -5.94 1.1e-08 1.49e-05 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760677 chr1:45580892~45580996:- CESC cis rs897984 0.542 rs750952 ENSG00000260911.2 RP11-196G11.2 5.94 1.11e-08 1.49e-05 0.39 0.37 Dementia with Lewy bodies; chr16:31082633 chr16:31043150~31049868:+ CESC cis rs6142102 0.602 rs2268079 ENSG00000275784.1 RP5-1125A11.6 -5.94 1.11e-08 1.49e-05 -0.37 -0.37 Skin pigmentation; chr20:34008944 chr20:33989480~33991818:- CESC cis rs6142102 0.602 rs1054534 ENSG00000275784.1 RP5-1125A11.6 -5.94 1.11e-08 1.49e-05 -0.37 -0.37 Skin pigmentation; chr20:34017521 chr20:33989480~33991818:- CESC cis rs9399135 0.967 rs7766189 ENSG00000232876.1 CTA-212D2.2 -5.94 1.11e-08 1.49e-05 -0.43 -0.37 Red blood cell count; chr6:135032713 chr6:135055033~135060550:+ CESC cis rs2243480 1 rs1723269 ENSG00000228409.4 CCT6P1 5.94 1.11e-08 1.49e-05 0.54 0.37 Diabetic kidney disease; chr7:66007799 chr7:65751142~65763354:+ CESC cis rs9399135 0.967 rs6902438 ENSG00000232876.1 CTA-212D2.2 -5.94 1.11e-08 1.49e-05 -0.43 -0.37 Red blood cell count; chr6:135015449 chr6:135055033~135060550:+ CESC cis rs9399135 0.935 rs6908681 ENSG00000232876.1 CTA-212D2.2 -5.94 1.11e-08 1.49e-05 -0.43 -0.37 Red blood cell count; chr6:135016595 chr6:135055033~135060550:+ CESC cis rs9907295 0.591 rs11650668 ENSG00000270977.1 AC015849.16 -5.94 1.11e-08 1.49e-05 -0.46 -0.37 Fibroblast growth factor basic levels; chr17:35822045 chr17:35893707~35911023:- CESC cis rs7572733 1 rs11683222 ENSG00000222017.1 AC011997.1 5.94 1.11e-08 1.49e-05 0.41 0.37 Dermatomyositis; chr2:198019304 chr2:197693106~197774823:+ CESC cis rs7572733 1 rs2139049 ENSG00000222017.1 AC011997.1 5.94 1.11e-08 1.49e-05 0.41 0.37 Dermatomyositis; chr2:198022936 chr2:197693106~197774823:+ CESC cis rs7572733 1 rs2196172 ENSG00000222017.1 AC011997.1 5.94 1.11e-08 1.49e-05 0.41 0.37 Dermatomyositis; chr2:198025169 chr2:197693106~197774823:+ CESC cis rs7572733 1 rs1595823 ENSG00000222017.1 AC011997.1 5.94 1.11e-08 1.49e-05 0.41 0.37 Dermatomyositis; chr2:198027075 chr2:197693106~197774823:+ CESC cis rs11168854 0.651 rs12227770 ENSG00000258017.1 RP11-386G11.10 -5.94 1.11e-08 1.5e-05 -0.49 -0.37 Body mass index; chr12:49183065 chr12:49127782~49147869:+ CESC cis rs7572733 1 rs1866666 ENSG00000222017.1 AC011997.1 5.94 1.11e-08 1.5e-05 0.42 0.37 Dermatomyositis; chr2:198075883 chr2:197693106~197774823:+ CESC cis rs7572733 0.967 rs2196171 ENSG00000222017.1 AC011997.1 5.94 1.12e-08 1.5e-05 0.41 0.37 Dermatomyositis; chr2:198025083 chr2:197693106~197774823:+ CESC cis rs7572733 1 rs7587251 ENSG00000222017.1 AC011997.1 5.94 1.12e-08 1.5e-05 0.41 0.37 Dermatomyositis; chr2:198065473 chr2:197693106~197774823:+ CESC cis rs7572733 1 rs1025549 ENSG00000222017.1 AC011997.1 5.94 1.12e-08 1.5e-05 0.41 0.37 Dermatomyositis; chr2:198016459 chr2:197693106~197774823:+ CESC cis rs1823913 1 rs10445782 ENSG00000280083.1 RP11-317J9.1 5.94 1.13e-08 1.51e-05 0.42 0.37 Obesity-related traits; chr2:191236639 chr2:191154118~191156070:- CESC cis rs6860806 0.507 rs183898 ENSG00000233006.5 AC034220.3 -5.94 1.13e-08 1.52e-05 -0.41 -0.37 Breast cancer; chr5:132381210 chr5:132311285~132369916:- CESC cis rs6142102 0.602 rs4911396 ENSG00000275784.1 RP5-1125A11.6 -5.94 1.13e-08 1.52e-05 -0.37 -0.37 Skin pigmentation; chr20:33992139 chr20:33989480~33991818:- CESC cis rs1499614 1 rs2707832 ENSG00000232559.3 GS1-124K5.12 5.94 1.14e-08 1.53e-05 0.66 0.37 Gout; chr7:66671562 chr7:66554588~66576923:- CESC cis rs6860806 0.531 rs274556 ENSG00000233006.5 AC034220.3 -5.94 1.14e-08 1.53e-05 -0.41 -0.37 Breast cancer; chr5:132386383 chr5:132311285~132369916:- CESC cis rs11690935 0.959 rs12185567 ENSG00000228389.1 AC068039.4 -5.94 1.14e-08 1.53e-05 -0.5 -0.37 Schizophrenia; chr2:171704219 chr2:171773482~171775844:+ CESC cis rs2243480 1 rs6460260 ENSG00000228409.4 CCT6P1 -5.94 1.14e-08 1.53e-05 -0.56 -0.37 Diabetic kidney disease; chr7:65750468 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6460261 ENSG00000228409.4 CCT6P1 -5.94 1.14e-08 1.53e-05 -0.56 -0.37 Diabetic kidney disease; chr7:65750593 chr7:65751142~65763354:+ CESC cis rs9322193 0.962 rs9505974 ENSG00000268592.3 RAET1E-AS1 5.93 1.15e-08 1.54e-05 0.48 0.37 Lung cancer; chr6:149779294 chr6:149863494~149919507:+ CESC cis rs9322193 0.926 rs9689036 ENSG00000268592.3 RAET1E-AS1 5.93 1.15e-08 1.54e-05 0.48 0.37 Lung cancer; chr6:149780563 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9322218 ENSG00000268592.3 RAET1E-AS1 5.93 1.15e-08 1.54e-05 0.48 0.37 Lung cancer; chr6:149782183 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9322219 ENSG00000268592.3 RAET1E-AS1 5.93 1.15e-08 1.54e-05 0.48 0.37 Lung cancer; chr6:149782263 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9322223 ENSG00000268592.3 RAET1E-AS1 5.93 1.15e-08 1.54e-05 0.48 0.37 Lung cancer; chr6:149801509 chr6:149863494~149919507:+ CESC cis rs1823913 0.599 rs34100174 ENSG00000280083.1 RP11-317J9.1 -5.93 1.15e-08 1.54e-05 -0.44 -0.37 Obesity-related traits; chr2:191283579 chr2:191154118~191156070:- CESC cis rs1823913 1 rs4853561 ENSG00000280083.1 RP11-317J9.1 5.93 1.15e-08 1.54e-05 0.42 0.37 Obesity-related traits; chr2:191242980 chr2:191154118~191156070:- CESC cis rs1823913 1 rs6704784 ENSG00000280083.1 RP11-317J9.1 5.93 1.15e-08 1.54e-05 0.42 0.37 Obesity-related traits; chr2:191244832 chr2:191154118~191156070:- CESC cis rs8062405 0.756 rs151182 ENSG00000259982.1 CDC37P1 5.93 1.16e-08 1.55e-05 0.5 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28484431 chr16:28700294~28701540:- CESC cis rs6504950 0.889 rs1484769 ENSG00000275710.1 RP11-257O5.4 -5.93 1.16e-08 1.55e-05 -0.46 -0.37 Breast cancer; chr17:55089290 chr17:54964474~54964679:+ CESC cis rs6142102 0.58 rs761233 ENSG00000275784.1 RP5-1125A11.6 -5.93 1.16e-08 1.55e-05 -0.36 -0.37 Skin pigmentation; chr20:33981080 chr20:33989480~33991818:- CESC cis rs7674212 0.507 rs223413 ENSG00000246560.2 RP11-10L12.4 -5.93 1.16e-08 1.55e-05 -0.48 -0.37 Type 2 diabetes; chr4:102811709 chr4:102828055~102844075:+ CESC cis rs270601 0.909 rs2569265 ENSG00000233006.5 AC034220.3 -5.93 1.16e-08 1.55e-05 -0.42 -0.37 Acylcarnitine levels; chr5:132368827 chr5:132311285~132369916:- CESC cis rs9322193 0.962 rs1889473 ENSG00000268592.3 RAET1E-AS1 5.93 1.16e-08 1.55e-05 0.47 0.37 Lung cancer; chr6:149825485 chr6:149863494~149919507:+ CESC cis rs2404602 0.669 rs9788684 ENSG00000259422.1 RP11-593F23.1 5.93 1.16e-08 1.55e-05 0.42 0.37 Blood metabolite levels; chr15:76902497 chr15:76174891~76181486:- CESC cis rs1707322 0.627 rs3014213 ENSG00000281133.1 AL355480.3 5.93 1.16e-08 1.56e-05 0.45 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45579850 chr1:45580892~45580996:- CESC cis rs1707322 0.686 rs2152078 ENSG00000281133.1 AL355480.3 5.93 1.16e-08 1.56e-05 0.45 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45589928 chr1:45580892~45580996:- CESC cis rs1707322 0.686 rs2991979 ENSG00000281133.1 AL355480.3 5.93 1.16e-08 1.56e-05 0.45 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45590186 chr1:45580892~45580996:- CESC cis rs3806843 0.966 rs10036519 ENSG00000202111.1 VTRNA1-2 5.93 1.17e-08 1.56e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140772116 chr5:140718925~140719013:+ CESC cis rs35160687 0.901 rs67903513 ENSG00000273080.1 RP11-301O19.1 5.93 1.17e-08 1.56e-05 0.44 0.37 Night sleep phenotypes; chr2:86284976 chr2:86195590~86196049:+ CESC cis rs4423214 0.879 rs1792283 ENSG00000254682.1 RP11-660L16.2 -5.93 1.18e-08 1.57e-05 -0.51 -0.37 Vitamin D levels; chr11:71424090 chr11:71448674~71452157:+ CESC cis rs4423214 0.879 rs1792282 ENSG00000254682.1 RP11-660L16.2 -5.93 1.18e-08 1.57e-05 -0.51 -0.37 Vitamin D levels; chr11:71424120 chr11:71448674~71452157:+ CESC cis rs9595066 1 rs7981575 ENSG00000227258.4 SMIM2-AS1 5.93 1.18e-08 1.57e-05 0.6 0.37 Schizophrenia; chr13:44136811 chr13:44110451~44240517:+ CESC cis rs17711722 0.522 rs62469933 ENSG00000226824.5 RP4-756H11.3 -5.93 1.18e-08 1.58e-05 -0.45 -0.37 Calcium levels; chr7:65800652 chr7:66654538~66669855:+ CESC cis rs1891275 0.515 rs11186666 ENSG00000228701.1 TNKS2-AS1 -5.93 1.18e-08 1.58e-05 -0.42 -0.37 Intelligence (multi-trait analysis); chr10:91718162 chr10:91782839~91798291:- CESC cis rs1891275 0.515 rs7092745 ENSG00000228701.1 TNKS2-AS1 -5.93 1.18e-08 1.58e-05 -0.42 -0.37 Intelligence (multi-trait analysis); chr10:91724063 chr10:91782839~91798291:- CESC cis rs9402743 0.673 rs9483860 ENSG00000217482.2 HMGB1P17 -5.93 1.19e-08 1.59e-05 -0.41 -0.37 Systemic lupus erythematosus; chr6:135646872 chr6:135636086~135636713:- CESC cis rs2243480 1 rs410128 ENSG00000232559.3 GS1-124K5.12 5.93 1.19e-08 1.59e-05 0.65 0.37 Diabetic kidney disease; chr7:66138186 chr7:66554588~66576923:- CESC cis rs832187 0.629 rs6798742 ENSG00000280620.1 SCAANT1 5.93 1.19e-08 1.59e-05 0.5 0.37 Schizophrenia; chr3:63918083 chr3:63911518~63911772:- CESC cis rs748404 0.56 rs689797 ENSG00000249839.1 AC011330.5 -5.93 1.2e-08 1.6e-05 -0.39 -0.37 Lung cancer; chr15:43534359 chr15:43663654~43684339:- CESC cis rs34779708 0.966 rs4294520 ENSG00000230534.5 RP11-297A16.2 5.93 1.2e-08 1.6e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35133578 chr10:35098006~35127020:- CESC cis rs1707322 0.721 rs10890336 ENSG00000281133.1 AL355480.3 -5.93 1.2e-08 1.6e-05 -0.45 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645384 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs11211151 ENSG00000281133.1 AL355480.3 -5.93 1.2e-08 1.6e-05 -0.45 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45647080 chr1:45580892~45580996:- CESC cis rs1891275 0.515 rs4244930 ENSG00000228701.1 TNKS2-AS1 -5.93 1.2e-08 1.6e-05 -0.42 -0.37 Intelligence (multi-trait analysis); chr10:91707092 chr10:91782839~91798291:- CESC cis rs526231 0.543 rs246909 ENSG00000175749.11 EIF3KP1 5.93 1.2e-08 1.61e-05 0.45 0.37 Primary biliary cholangitis; chr5:103227976 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs246906 ENSG00000175749.11 EIF3KP1 5.93 1.2e-08 1.61e-05 0.45 0.37 Primary biliary cholangitis; chr5:103230770 chr5:103032376~103033031:+ CESC cis rs526231 0.543 rs62362884 ENSG00000175749.11 EIF3KP1 5.93 1.2e-08 1.61e-05 0.45 0.37 Primary biliary cholangitis; chr5:103231754 chr5:103032376~103033031:+ CESC cis rs9322193 0.962 rs1413655 ENSG00000268592.3 RAET1E-AS1 5.93 1.21e-08 1.61e-05 0.48 0.37 Lung cancer; chr6:149821815 chr6:149863494~149919507:+ CESC cis rs3806843 0.966 rs2563262 ENSG00000202111.1 VTRNA1-2 5.92 1.21e-08 1.61e-05 0.38 0.37 Depressive symptoms (multi-trait analysis); chr5:140758127 chr5:140718925~140719013:+ CESC cis rs6603134 0.502 rs10406511 ENSG00000267939.1 CTD-2325M2.1 -5.92 1.21e-08 1.62e-05 -0.46 -0.37 Blood protein levels; chr19:8039061 chr19:8008729~8016025:+ CESC cis rs10875746 0.951 rs11168433 ENSG00000240399.1 RP1-228P16.1 -5.92 1.21e-08 1.62e-05 -0.47 -0.37 Longevity (90 years and older); chr12:48164281 chr12:48054813~48055591:- CESC cis rs9402743 0.775 rs12210389 ENSG00000217482.2 HMGB1P17 5.92 1.21e-08 1.62e-05 0.4 0.37 Systemic lupus erythematosus; chr6:135661977 chr6:135636086~135636713:- CESC cis rs1823913 1 rs1454749 ENSG00000280083.1 RP11-317J9.1 -5.92 1.21e-08 1.62e-05 -0.42 -0.37 Obesity-related traits; chr2:191240909 chr2:191154118~191156070:- CESC cis rs1062177 0.756 rs2915817 ENSG00000213433.5 RPLP1P6 5.92 1.22e-08 1.62e-05 0.46 0.37 Preschool internalizing problems; chr5:151735956 chr5:151765859~151766378:- CESC cis rs11155671 0.53 rs7756850 ENSG00000268592.3 RAET1E-AS1 5.92 1.22e-08 1.62e-05 0.46 0.37 Testicular germ cell tumor; chr6:149891460 chr6:149863494~149919507:+ CESC cis rs3806843 0.966 rs7737424 ENSG00000202111.1 VTRNA1-2 -5.92 1.22e-08 1.62e-05 -0.38 -0.37 Depressive symptoms (multi-trait analysis); chr5:140766760 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs12659129 ENSG00000202111.1 VTRNA1-2 -5.92 1.22e-08 1.62e-05 -0.38 -0.37 Depressive symptoms (multi-trait analysis); chr5:140767663 chr5:140718925~140719013:+ CESC cis rs11690935 0.959 rs66835971 ENSG00000228389.1 AC068039.4 5.92 1.22e-08 1.63e-05 0.5 0.37 Schizophrenia; chr2:171820949 chr2:171773482~171775844:+ CESC cis rs11676348 0.755 rs13410318 ENSG00000261338.2 RP11-378A13.1 5.92 1.22e-08 1.63e-05 0.44 0.37 Ulcerative colitis; chr2:218158187 chr2:218255319~218257366:+ CESC cis rs6603134 0.502 rs10406540 ENSG00000267939.1 CTD-2325M2.1 -5.92 1.22e-08 1.63e-05 -0.45 -0.37 Blood protein levels; chr19:8039113 chr19:8008729~8016025:+ CESC cis rs2442825 0.693 rs2648535 ENSG00000206573.7 THUMPD3-AS1 5.92 1.23e-08 1.63e-05 0.36 0.37 Cerebrospinal fluid clusterin levels; chr3:9366759 chr3:9349689~9398579:- CESC cis rs3931020 1 rs3931020 ENSG00000272864.1 RP11-17E13.2 -5.92 1.23e-08 1.63e-05 -0.44 -0.37 Resistin levels; chr1:74769633 chr1:74698769~74699333:- CESC cis rs9545047 0.604 rs9574416 ENSG00000227676.3 LINC01068 -5.92 1.23e-08 1.64e-05 -0.42 -0.37 Schizophrenia; chr13:79388577 chr13:79566727~79571436:+ CESC cis rs11096990 0.613 rs6829660 ENSG00000249207.1 RP11-360F5.1 -5.92 1.23e-08 1.64e-05 -0.41 -0.37 Cognitive function; chr4:39280943 chr4:39112677~39126818:- CESC cis rs875971 0.862 rs7783779 ENSG00000226824.5 RP4-756H11.3 5.92 1.23e-08 1.64e-05 0.47 0.37 Aortic root size; chr7:66331639 chr7:66654538~66669855:+ CESC cis rs765787 0.53 rs28897155 ENSG00000259520.4 CTD-2651B20.3 5.92 1.23e-08 1.64e-05 0.47 0.37 Uric acid levels; chr15:45241776 chr15:45251580~45279251:- CESC cis rs6452524 0.967 rs6452509 ENSG00000249664.1 CTD-2227C6.2 5.92 1.23e-08 1.64e-05 0.44 0.37 Hypertension (SNP x SNP interaction); chr5:83125564 chr5:83012285~83013109:- CESC cis rs801193 0.569 rs2659908 ENSG00000226824.5 RP4-756H11.3 -5.92 1.23e-08 1.64e-05 -0.46 -0.37 Aortic root size; chr7:66695835 chr7:66654538~66669855:+ CESC cis rs801193 0.527 rs2707837 ENSG00000226824.5 RP4-756H11.3 -5.92 1.23e-08 1.64e-05 -0.46 -0.37 Aortic root size; chr7:66716086 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs2707824 ENSG00000226824.5 RP4-756H11.3 -5.92 1.23e-08 1.64e-05 -0.46 -0.37 Aortic root size; chr7:66724256 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs2659893 ENSG00000226824.5 RP4-756H11.3 -5.92 1.23e-08 1.64e-05 -0.46 -0.37 Aortic root size; chr7:66735006 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs2659892 ENSG00000226824.5 RP4-756H11.3 -5.92 1.23e-08 1.64e-05 -0.46 -0.37 Aortic root size; chr7:66735318 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs2707847 ENSG00000226824.5 RP4-756H11.3 -5.92 1.23e-08 1.64e-05 -0.46 -0.37 Aortic root size; chr7:66737884 chr7:66654538~66669855:+ CESC cis rs9399135 0.967 rs1041481 ENSG00000232876.1 CTA-212D2.2 -5.92 1.24e-08 1.64e-05 -0.43 -0.37 Red blood cell count; chr6:135013925 chr6:135055033~135060550:+ CESC cis rs6504950 0.8 rs12952253 ENSG00000275710.1 RP11-257O5.4 5.92 1.24e-08 1.64e-05 0.45 0.37 Breast cancer; chr17:54928355 chr17:54964474~54964679:+ CESC cis rs6504950 0.8 rs7208123 ENSG00000275710.1 RP11-257O5.4 5.92 1.24e-08 1.64e-05 0.45 0.37 Breast cancer; chr17:54928978 chr17:54964474~54964679:+ CESC cis rs2739330 0.796 rs5760106 ENSG00000250470.1 AP000351.3 -5.92 1.24e-08 1.65e-05 -0.47 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23976904~23977585:- CESC cis rs1185460 0.967 rs1786690 ENSG00000271751.1 RP11-110I1.14 -5.92 1.24e-08 1.65e-05 -0.5 -0.37 Coronary artery disease; chr11:119071357 chr11:119065263~119065677:- CESC cis rs34779708 0.966 rs12775799 ENSG00000230534.5 RP11-297A16.2 5.92 1.24e-08 1.65e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35199336 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs11010122 ENSG00000230534.5 RP11-297A16.2 5.92 1.24e-08 1.65e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35204590 chr10:35098006~35127020:- CESC cis rs950027 0.787 rs1547487 ENSG00000259520.4 CTD-2651B20.3 -5.92 1.24e-08 1.65e-05 -0.49 -0.37 Response to fenofibrate (adiponectin levels); chr15:45431785 chr15:45251580~45279251:- CESC cis rs9322193 0.962 rs9397022 ENSG00000268592.3 RAET1E-AS1 5.92 1.24e-08 1.65e-05 0.48 0.37 Lung cancer; chr6:149812052 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9397357 ENSG00000268592.3 RAET1E-AS1 5.92 1.24e-08 1.65e-05 0.48 0.37 Lung cancer; chr6:149812465 chr6:149863494~149919507:+ CESC cis rs1707322 0.964 rs7546237 ENSG00000280836.1 AL355480.1 -5.92 1.25e-08 1.66e-05 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45819938 chr1:45581219~45581321:- CESC cis rs2177312 0.868 rs6553978 ENSG00000251129.1 RP11-734I18.1 -5.92 1.25e-08 1.66e-05 -0.47 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31954999 chr4:31997397~32155406:+ CESC cis rs17711722 0.528 rs73138179 ENSG00000164669.11 INTS4P1 -5.92 1.25e-08 1.66e-05 -0.5 -0.37 Calcium levels; chr7:65829495 chr7:65141225~65234216:+ CESC cis rs6991838 0.584 rs6993876 ENSG00000200714.1 Y_RNA 5.92 1.25e-08 1.66e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65601240 chr8:65592731~65592820:+ CESC cis rs12022452 0.822 rs6600343 ENSG00000238287.1 RP11-656D10.3 -5.92 1.25e-08 1.66e-05 -0.54 -0.37 Age-related hearing impairment (SNP x SNP interaction); chr1:40562538 chr1:40493157~40508661:- CESC cis rs9322193 0.962 rs3763163 ENSG00000268592.3 RAET1E-AS1 5.92 1.25e-08 1.67e-05 0.48 0.37 Lung cancer; chr6:149819770 chr6:149863494~149919507:+ CESC cis rs7665090 0.51 rs223498 ENSG00000246560.2 RP11-10L12.4 -5.92 1.26e-08 1.67e-05 -0.48 -0.37 Primary biliary cholangitis; chr4:102730805 chr4:102828055~102844075:+ CESC cis rs6597981 0.592 rs10902218 ENSG00000255142.1 AP006621.6 -5.92 1.26e-08 1.67e-05 -0.32 -0.37 Breast cancer; chr11:743813 chr11:781645~782105:+ CESC cis rs1823913 0.599 rs13035132 ENSG00000280083.1 RP11-317J9.1 -5.92 1.26e-08 1.67e-05 -0.43 -0.37 Obesity-related traits; chr2:191265275 chr2:191154118~191156070:- CESC cis rs11690935 0.959 rs6754817 ENSG00000228389.1 AC068039.4 5.92 1.26e-08 1.67e-05 0.5 0.37 Schizophrenia; chr2:171806884 chr2:171773482~171775844:+ CESC cis rs11155671 0.53 rs6935829 ENSG00000268592.3 RAET1E-AS1 5.92 1.26e-08 1.68e-05 0.46 0.37 Testicular germ cell tumor; chr6:149896675 chr6:149863494~149919507:+ CESC cis rs1891275 0.515 rs1418161 ENSG00000228701.1 TNKS2-AS1 -5.92 1.27e-08 1.68e-05 -0.42 -0.37 Intelligence (multi-trait analysis); chr10:91724898 chr10:91782839~91798291:- CESC cis rs875971 0.862 rs2909688 ENSG00000226824.5 RP4-756H11.3 -5.92 1.27e-08 1.68e-05 -0.47 -0.37 Aortic root size; chr7:66376625 chr7:66654538~66669855:+ CESC cis rs17826219 0.561 rs562840 ENSG00000263531.1 RP13-753N3.1 5.92 1.27e-08 1.68e-05 0.61 0.37 Body mass index; chr17:30622372 chr17:30863921~30864940:- CESC cis rs950169 0.922 rs4586394 ENSG00000225151.9 GOLGA2P7 5.92 1.27e-08 1.68e-05 0.51 0.37 Schizophrenia; chr15:84153633 chr15:84199311~84230136:- CESC cis rs3806843 0.868 rs2531349 ENSG00000202111.1 VTRNA1-2 5.91 1.28e-08 1.7e-05 0.38 0.37 Depressive symptoms (multi-trait analysis); chr5:140741368 chr5:140718925~140719013:+ CESC cis rs1707322 1 rs785469 ENSG00000280836.1 AL355480.1 5.91 1.28e-08 1.7e-05 0.43 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055419 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785468 ENSG00000280836.1 AL355480.1 5.91 1.28e-08 1.7e-05 0.43 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055845 chr1:45581219~45581321:- CESC cis rs957448 0.554 rs12682601 ENSG00000253704.1 RP11-267M23.4 5.91 1.28e-08 1.7e-05 0.39 0.37 Nonsyndromic cleft lip with cleft palate; chr8:94582492 chr8:94553722~94569745:+ CESC cis rs62229266 0.804 rs12483151 ENSG00000231106.2 LINC01436 5.91 1.28e-08 1.7e-05 0.51 0.37 Mitral valve prolapse; chr21:36047280 chr21:36005338~36007838:+ CESC cis rs9322193 0.926 rs9383546 ENSG00000268592.3 RAET1E-AS1 5.91 1.29e-08 1.71e-05 0.48 0.37 Lung cancer; chr6:149822743 chr6:149863494~149919507:+ CESC cis rs1891275 0.508 rs2096079 ENSG00000228701.1 TNKS2-AS1 -5.91 1.29e-08 1.71e-05 -0.43 -0.37 Intelligence (multi-trait analysis); chr10:91736910 chr10:91782839~91798291:- CESC cis rs8062405 0.756 rs151301 ENSG00000259982.1 CDC37P1 5.91 1.29e-08 1.71e-05 0.5 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28485738 chr16:28700294~28701540:- CESC cis rs3738443 0.599 rs6693807 ENSG00000259865.1 RP11-488L18.10 -5.91 1.29e-08 1.71e-05 -0.38 -0.37 Alcohol dependence; chr1:247230353 chr1:247187281~247188526:- CESC cis rs1075265 0.597 rs11694711 ENSG00000233266.1 HMGB1P31 5.91 1.29e-08 1.71e-05 0.5 0.37 Chronotype;Morning vs. evening chronotype; chr2:53971924 chr2:54051334~54051760:+ CESC cis rs1707322 0.752 rs6662164 ENSG00000281133.1 AL355480.3 -5.91 1.29e-08 1.71e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680558 chr1:45580892~45580996:- CESC cis rs10463554 0.892 rs1561404 ENSG00000175749.11 EIF3KP1 5.91 1.3e-08 1.72e-05 0.42 0.37 Parkinson's disease; chr5:102963647 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs1560040 ENSG00000175749.11 EIF3KP1 5.91 1.3e-08 1.72e-05 0.42 0.37 Parkinson's disease; chr5:102964363 chr5:103032376~103033031:+ CESC cis rs17711722 0.51 rs11767457 ENSG00000164669.11 INTS4P1 -5.91 1.3e-08 1.72e-05 -0.5 -0.37 Calcium levels; chr7:65825628 chr7:65141225~65234216:+ CESC cis rs10463554 0.892 rs66759661 ENSG00000175749.11 EIF3KP1 5.91 1.3e-08 1.72e-05 0.4 0.37 Parkinson's disease; chr5:102925894 chr5:103032376~103033031:+ CESC cis rs17711722 0.522 rs4642526 ENSG00000226824.5 RP4-756H11.3 -5.91 1.3e-08 1.72e-05 -0.44 -0.37 Calcium levels; chr7:65751755 chr7:66654538~66669855:+ CESC cis rs3806843 0.9 rs2563287 ENSG00000202111.1 VTRNA1-2 -5.91 1.3e-08 1.72e-05 -0.38 -0.37 Depressive symptoms (multi-trait analysis); chr5:140745201 chr5:140718925~140719013:+ CESC cis rs10246939 0.579 rs58093678 ENSG00000228775.6 WEE2-AS1 5.91 1.31e-08 1.73e-05 0.44 0.37 Bitter taste perception; chr7:141856719 chr7:141704338~141738346:- CESC cis rs10246939 0.529 rs60165685 ENSG00000228775.6 WEE2-AS1 5.91 1.31e-08 1.73e-05 0.44 0.37 Bitter taste perception; chr7:141861190 chr7:141704338~141738346:- CESC cis rs9907295 0.688 rs2376287 ENSG00000270977.1 AC015849.16 -5.91 1.31e-08 1.73e-05 -0.5 -0.37 Fibroblast growth factor basic levels; chr17:35919865 chr17:35893707~35911023:- CESC cis rs9907295 0.688 rs4796133 ENSG00000270977.1 AC015849.16 -5.91 1.31e-08 1.73e-05 -0.5 -0.37 Fibroblast growth factor basic levels; chr17:35920505 chr17:35893707~35911023:- CESC cis rs9907295 0.688 rs7213636 ENSG00000270977.1 AC015849.16 -5.91 1.31e-08 1.73e-05 -0.5 -0.37 Fibroblast growth factor basic levels; chr17:35920944 chr17:35893707~35911023:- CESC cis rs9907295 0.688 rs28722787 ENSG00000270977.1 AC015849.16 -5.91 1.31e-08 1.73e-05 -0.5 -0.37 Fibroblast growth factor basic levels; chr17:35922795 chr17:35893707~35911023:- CESC cis rs897984 0.542 rs7197717 ENSG00000260911.2 RP11-196G11.2 5.91 1.31e-08 1.73e-05 0.38 0.37 Dementia with Lewy bodies; chr16:31071754 chr16:31043150~31049868:+ CESC cis rs2243480 1 rs422164 ENSG00000232559.3 GS1-124K5.12 5.91 1.31e-08 1.73e-05 0.63 0.37 Diabetic kidney disease; chr7:66121618 chr7:66554588~66576923:- CESC cis rs2177312 0.574 rs1523140 ENSG00000251129.1 RP11-734I18.1 -5.91 1.31e-08 1.74e-05 -0.42 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31982809 chr4:31997397~32155406:+ CESC cis rs9309711 0.772 rs9309714 ENSG00000225234.1 TRAPPC12-AS1 -5.91 1.32e-08 1.74e-05 -0.38 -0.37 Neurofibrillary tangles; chr2:3488059 chr2:3481242~3482409:- CESC cis rs4972806 0.849 rs2857541 ENSG00000226363.3 HAGLROS -5.91 1.32e-08 1.75e-05 -0.5 -0.37 IgG glycosylation; chr2:176164358 chr2:176177717~176179008:+ CESC cis rs3806843 0.897 rs2531338 ENSG00000202111.1 VTRNA1-2 5.91 1.32e-08 1.75e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140757372 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs2563264 ENSG00000202111.1 VTRNA1-2 5.91 1.32e-08 1.75e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140757918 chr5:140718925~140719013:+ CESC cis rs3806843 0.932 rs2563257 ENSG00000202111.1 VTRNA1-2 5.91 1.32e-08 1.75e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140760944 chr5:140718925~140719013:+ CESC cis rs3806843 0.932 rs2563256 ENSG00000202111.1 VTRNA1-2 5.91 1.32e-08 1.75e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140762194 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs2563255 ENSG00000202111.1 VTRNA1-2 5.91 1.32e-08 1.75e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140762962 chr5:140718925~140719013:+ CESC cis rs3806843 0.9 rs2563254 ENSG00000202111.1 VTRNA1-2 5.91 1.32e-08 1.75e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140763116 chr5:140718925~140719013:+ CESC cis rs3738443 0.594 rs6664697 ENSG00000259865.1 RP11-488L18.10 -5.91 1.33e-08 1.75e-05 -0.35 -0.37 Alcohol dependence; chr1:247217308 chr1:247187281~247188526:- CESC cis rs150992 0.587 rs4703052 ENSG00000248489.1 CTD-2007H13.3 -5.91 1.33e-08 1.76e-05 -0.44 -0.37 Body mass index; chr5:99008818 chr5:98929171~98995013:+ CESC cis rs7572733 1 rs10497811 ENSG00000222017.1 AC011997.1 5.91 1.33e-08 1.76e-05 0.41 0.37 Dermatomyositis; chr2:198038185 chr2:197693106~197774823:+ CESC cis rs8072100 0.84 rs9912311 ENSG00000228782.6 CTD-2026D20.3 5.91 1.34e-08 1.76e-05 0.44 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469766 chr17:47450568~47492492:- CESC cis rs6142102 0.625 rs6141431 ENSG00000275784.1 RP5-1125A11.6 -5.91 1.34e-08 1.76e-05 -0.36 -0.37 Skin pigmentation; chr20:33952508 chr20:33989480~33991818:- CESC cis rs9402743 0.673 rs9483858 ENSG00000217482.2 HMGB1P17 5.91 1.34e-08 1.76e-05 0.4 0.37 Systemic lupus erythematosus; chr6:135642670 chr6:135636086~135636713:- CESC cis rs9402743 0.577 rs111373814 ENSG00000217482.2 HMGB1P17 5.91 1.34e-08 1.76e-05 0.4 0.37 Systemic lupus erythematosus; chr6:135644459 chr6:135636086~135636713:- CESC cis rs9402743 0.608 rs6918917 ENSG00000217482.2 HMGB1P17 5.91 1.34e-08 1.76e-05 0.4 0.37 Systemic lupus erythematosus; chr6:135644473 chr6:135636086~135636713:- CESC cis rs9402743 0.673 rs56071012 ENSG00000217482.2 HMGB1P17 5.91 1.34e-08 1.76e-05 0.4 0.37 Systemic lupus erythematosus; chr6:135646213 chr6:135636086~135636713:- CESC cis rs9402743 0.673 rs56976899 ENSG00000217482.2 HMGB1P17 5.91 1.34e-08 1.76e-05 0.4 0.37 Systemic lupus erythematosus; chr6:135646262 chr6:135636086~135636713:- CESC cis rs9402743 0.673 rs9494312 ENSG00000217482.2 HMGB1P17 5.91 1.34e-08 1.76e-05 0.4 0.37 Systemic lupus erythematosus; chr6:135646826 chr6:135636086~135636713:- CESC cis rs72627509 1 rs72627509 ENSG00000269949.1 RP11-738E22.3 5.91 1.34e-08 1.77e-05 0.58 0.37 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56972885 chr4:56960927~56961373:- CESC cis rs1891275 0.515 rs7092884 ENSG00000228701.1 TNKS2-AS1 5.9 1.35e-08 1.78e-05 0.41 0.37 Intelligence (multi-trait analysis); chr10:91724115 chr10:91782839~91798291:- CESC cis rs950169 0.887 rs35986397 ENSG00000225151.9 GOLGA2P7 -5.9 1.35e-08 1.78e-05 -0.53 -0.37 Schizophrenia; chr15:84400409 chr15:84199311~84230136:- CESC cis rs6504950 0.925 rs244348 ENSG00000275710.1 RP11-257O5.4 5.9 1.35e-08 1.78e-05 0.46 0.37 Breast cancer; chr17:55118930 chr17:54964474~54964679:+ CESC cis rs9309711 0.643 rs10188449 ENSG00000225234.1 TRAPPC12-AS1 -5.9 1.35e-08 1.78e-05 -0.35 -0.37 Neurofibrillary tangles; chr2:3476595 chr2:3481242~3482409:- CESC cis rs897984 0.542 rs11865038 ENSG00000260911.2 RP11-196G11.2 5.9 1.36e-08 1.79e-05 0.39 0.37 Dementia with Lewy bodies; chr16:31083850 chr16:31043150~31049868:+ CESC cis rs897984 0.542 rs11864806 ENSG00000260911.2 RP11-196G11.2 5.9 1.36e-08 1.79e-05 0.39 0.37 Dementia with Lewy bodies; chr16:31083883 chr16:31043150~31049868:+ CESC cis rs897984 0.542 rs7199949 ENSG00000260911.2 RP11-196G11.2 5.9 1.36e-08 1.79e-05 0.39 0.37 Dementia with Lewy bodies; chr16:31084843 chr16:31043150~31049868:+ CESC cis rs897984 0.513 rs17839568 ENSG00000260911.2 RP11-196G11.2 5.9 1.36e-08 1.79e-05 0.39 0.37 Dementia with Lewy bodies; chr16:31088462 chr16:31043150~31049868:+ CESC cis rs801193 0.569 rs7782587 ENSG00000226824.5 RP4-756H11.3 -5.9 1.36e-08 1.8e-05 -0.46 -0.37 Aortic root size; chr7:66701485 chr7:66654538~66669855:+ CESC cis rs4718428 0.672 rs13241598 ENSG00000226824.5 RP4-756H11.3 -5.9 1.37e-08 1.8e-05 -0.51 -0.37 Corneal structure; chr7:66835665 chr7:66654538~66669855:+ CESC cis rs1707322 0.686 rs2991986 ENSG00000281133.1 AL355480.3 5.9 1.37e-08 1.8e-05 0.45 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615610 chr1:45580892~45580996:- CESC cis rs748404 0.518 rs480108 ENSG00000249839.1 AC011330.5 -5.9 1.37e-08 1.8e-05 -0.39 -0.37 Lung cancer; chr15:43525208 chr15:43663654~43684339:- CESC cis rs1707322 0.686 rs1541131 ENSG00000281133.1 AL355480.3 5.9 1.37e-08 1.81e-05 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619262 chr1:45580892~45580996:- CESC cis rs2404602 1 rs12898430 ENSG00000259422.1 RP11-593F23.1 5.9 1.37e-08 1.81e-05 0.42 0.37 Blood metabolite levels; chr15:76582582 chr15:76174891~76181486:- CESC cis rs2404602 1 rs4886818 ENSG00000259422.1 RP11-593F23.1 5.9 1.37e-08 1.81e-05 0.42 0.37 Blood metabolite levels; chr15:76588598 chr15:76174891~76181486:- CESC cis rs2404602 1 rs11072603 ENSG00000259422.1 RP11-593F23.1 5.9 1.37e-08 1.81e-05 0.42 0.37 Blood metabolite levels; chr15:76588797 chr15:76174891~76181486:- CESC cis rs507080 0.769 rs527290 ENSG00000255422.1 AP002954.4 -5.9 1.38e-08 1.81e-05 -0.45 -0.37 Serum metabolite levels; chr11:118644898 chr11:118704607~118750263:+ CESC cis rs8072100 0.905 rs9895274 ENSG00000228782.6 CTD-2026D20.3 5.9 1.38e-08 1.82e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47461751 chr17:47450568~47492492:- CESC cis rs10463554 0.892 rs17154860 ENSG00000175749.11 EIF3KP1 5.9 1.38e-08 1.82e-05 0.4 0.37 Parkinson's disease; chr5:102955441 chr5:103032376~103033031:+ CESC cis rs11096990 0.593 rs7662880 ENSG00000249207.1 RP11-360F5.1 5.9 1.38e-08 1.82e-05 0.4 0.37 Cognitive function; chr4:39283604 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs12648793 ENSG00000249207.1 RP11-360F5.1 5.9 1.38e-08 1.82e-05 0.4 0.37 Cognitive function; chr4:39284473 chr4:39112677~39126818:- CESC cis rs8062405 0.722 rs3785354 ENSG00000259982.1 CDC37P1 5.9 1.39e-08 1.82e-05 0.47 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28539346 chr16:28700294~28701540:- CESC cis rs6991838 0.584 rs14213 ENSG00000200714.1 Y_RNA 5.9 1.39e-08 1.83e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65602719 chr8:65592731~65592820:+ CESC cis rs8062405 0.755 rs4788076 ENSG00000259982.1 CDC37P1 5.9 1.4e-08 1.84e-05 0.47 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558684 chr16:28700294~28701540:- CESC cis rs6452524 1 rs6868817 ENSG00000249664.1 CTD-2227C6.2 5.9 1.4e-08 1.84e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83142287 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs10042018 ENSG00000249664.1 CTD-2227C6.2 5.9 1.4e-08 1.84e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83142490 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs10036418 ENSG00000249664.1 CTD-2227C6.2 5.9 1.4e-08 1.84e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83142493 chr5:83012285~83013109:- CESC cis rs6452524 1 rs10055948 ENSG00000249664.1 CTD-2227C6.2 5.9 1.4e-08 1.84e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83143437 chr5:83012285~83013109:- CESC cis rs9399137 0.561 rs11753985 ENSG00000232876.1 CTA-212D2.2 -5.9 1.4e-08 1.84e-05 -0.47 -0.37 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134959300 chr6:135055033~135060550:+ CESC cis rs67383717 0.527 rs12004422 ENSG00000175611.10 LINC00476 5.9 1.4e-08 1.84e-05 0.44 0.37 Parkinson's disease (pesticide exposure interaction); chr9:95873393 chr9:95759231~95875977:- CESC cis rs35955747 0.869 rs131219 ENSG00000236132.1 CTA-440B3.1 -5.9 1.4e-08 1.84e-05 -0.42 -0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31364264 chr22:31816379~31817491:- CESC cis rs1823913 0.599 rs35892286 ENSG00000280083.1 RP11-317J9.1 -5.9 1.41e-08 1.85e-05 -0.43 -0.37 Obesity-related traits; chr2:191269010 chr2:191154118~191156070:- CESC cis rs34779708 0.897 rs16935880 ENSG00000230534.5 RP11-297A16.2 5.9 1.41e-08 1.85e-05 0.48 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35126540 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs4934730 ENSG00000230534.5 RP11-297A16.2 5.9 1.41e-08 1.85e-05 0.48 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35126627 chr10:35098006~35127020:- CESC cis rs116095464 0.614 rs78905930 ENSG00000250848.1 CTD-2083E4.5 -5.9 1.41e-08 1.85e-05 -0.48 -0.37 Breast cancer; chr5:246445 chr5:288833~290321:- CESC cis rs2404602 0.967 rs12148805 ENSG00000259422.1 RP11-593F23.1 5.89 1.42e-08 1.86e-05 0.41 0.37 Blood metabolite levels; chr15:76508318 chr15:76174891~76181486:- CESC cis rs1707322 0.963 rs11211202 ENSG00000280836.1 AL355480.1 -5.89 1.42e-08 1.87e-05 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45826710 chr1:45581219~45581321:- CESC cis rs1862618 0.573 rs832532 ENSG00000271828.1 CTD-2310F14.1 5.89 1.43e-08 1.87e-05 0.5 0.37 Initial pursuit acceleration; chr5:56926111 chr5:56927874~56929573:+ CESC cis rs6452524 0.836 rs10041617 ENSG00000249664.1 CTD-2227C6.2 5.89 1.43e-08 1.88e-05 0.39 0.37 Hypertension (SNP x SNP interaction); chr5:83096535 chr5:83012285~83013109:- CESC cis rs11096990 0.634 rs2062229 ENSG00000249207.1 RP11-360F5.1 -5.89 1.44e-08 1.89e-05 -0.4 -0.37 Cognitive function; chr4:39285146 chr4:39112677~39126818:- CESC cis rs8062405 0.754 rs149299 ENSG00000259982.1 CDC37P1 5.89 1.44e-08 1.89e-05 0.5 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28473820 chr16:28700294~28701540:- CESC cis rs2243480 1 rs10247526 ENSG00000232559.3 GS1-124K5.12 -5.89 1.44e-08 1.89e-05 -0.64 -0.37 Diabetic kidney disease; chr7:66315709 chr7:66554588~66576923:- CESC cis rs34779708 0.966 rs12765038 ENSG00000230534.5 RP11-297A16.2 5.89 1.45e-08 1.9e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35127585 chr10:35098006~35127020:- CESC cis rs7572733 1 rs10196612 ENSG00000222017.1 AC011997.1 5.89 1.46e-08 1.91e-05 0.41 0.37 Dermatomyositis; chr2:198029415 chr2:197693106~197774823:+ CESC cis rs875971 0.895 rs4718349 ENSG00000222364.1 RNU6-96P -5.89 1.46e-08 1.91e-05 -0.44 -0.37 Aortic root size; chr7:66444024 chr7:66395191~66395286:+ CESC cis rs2404602 1 rs12441433 ENSG00000259422.1 RP11-593F23.1 5.89 1.46e-08 1.91e-05 0.41 0.37 Blood metabolite levels; chr15:76523674 chr15:76174891~76181486:- CESC cis rs7572733 1 rs10184227 ENSG00000222017.1 AC011997.1 5.89 1.46e-08 1.91e-05 0.41 0.37 Dermatomyositis; chr2:198029581 chr2:197693106~197774823:+ CESC cis rs7572733 0.967 rs10166845 ENSG00000222017.1 AC011997.1 5.89 1.46e-08 1.91e-05 0.41 0.37 Dermatomyositis; chr2:198031347 chr2:197693106~197774823:+ CESC cis rs34779708 0.9 rs73262807 ENSG00000230534.5 RP11-297A16.2 5.89 1.46e-08 1.91e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35207458 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs4934736 ENSG00000230534.5 RP11-297A16.2 5.89 1.46e-08 1.91e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35207940 chr10:35098006~35127020:- CESC cis rs9545047 0.584 rs12871015 ENSG00000227676.3 LINC01068 -5.89 1.47e-08 1.92e-05 -0.41 -0.37 Schizophrenia; chr13:79333564 chr13:79566727~79571436:+ CESC cis rs10256972 0.758 rs7799391 ENSG00000229043.2 AC091729.9 -5.89 1.47e-08 1.92e-05 -0.42 -0.37 Endometriosis;Longevity; chr7:1042930 chr7:1160374~1165267:+ CESC cis rs7572733 1 rs6738825 ENSG00000222017.1 AC011997.1 5.89 1.47e-08 1.93e-05 0.41 0.37 Dermatomyositis; chr2:198032171 chr2:197693106~197774823:+ CESC cis rs4972806 0.849 rs2071581 ENSG00000226363.3 HAGLROS -5.89 1.48e-08 1.93e-05 -0.5 -0.37 IgG glycosylation; chr2:176161420 chr2:176177717~176179008:+ CESC cis rs12931792 0.846 rs9924308 ENSG00000183604.13 SMG1P5 -5.89 1.48e-08 1.93e-05 -0.38 -0.37 Tonsillectomy; chr16:30143419 chr16:30267553~30335374:- CESC cis rs9402743 0.775 rs9494322 ENSG00000217482.2 HMGB1P17 -5.89 1.48e-08 1.94e-05 -0.39 -0.37 Systemic lupus erythematosus; chr6:135660922 chr6:135636086~135636713:- CESC cis rs2404602 0.716 rs12907805 ENSG00000259422.1 RP11-593F23.1 5.89 1.48e-08 1.94e-05 0.41 0.37 Blood metabolite levels; chr15:76398265 chr15:76174891~76181486:- CESC cis rs5769707 0.609 rs135861 ENSG00000188511.11 C22orf34 5.89 1.48e-08 1.94e-05 0.43 0.37 Monocyte percentage of white cells;Monocyte count; chr22:49604470 chr22:49414524~49657542:- CESC cis rs4728142 0.604 rs10229001 ENSG00000275106.1 RP11-309L24.10 -5.89 1.49e-08 1.94e-05 -0.49 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128959343 chr7:128952527~128953316:- CESC cis rs11096990 0.634 rs17754 ENSG00000249207.1 RP11-360F5.1 -5.88 1.49e-08 1.95e-05 -0.4 -0.37 Cognitive function; chr4:39287688 chr4:39112677~39126818:- CESC cis rs748404 0.631 rs7163288 ENSG00000249839.1 AC011330.5 -5.88 1.49e-08 1.95e-05 -0.39 -0.37 Lung cancer; chr15:43379157 chr15:43663654~43684339:- CESC cis rs6142102 0.625 rs6142051 ENSG00000275784.1 RP5-1125A11.6 -5.88 1.49e-08 1.95e-05 -0.36 -0.37 Skin pigmentation; chr20:33945212 chr20:33989480~33991818:- CESC cis rs6452524 1 rs10474093 ENSG00000249664.1 CTD-2227C6.2 5.88 1.5e-08 1.96e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83141612 chr5:83012285~83013109:- CESC cis rs11168854 0.93 rs10783302 ENSG00000258017.1 RP11-386G11.10 5.88 1.51e-08 1.98e-05 0.45 0.37 Body mass index; chr12:49104347 chr12:49127782~49147869:+ CESC cis rs6504950 0.72 rs9910653 ENSG00000275710.1 RP11-257O5.4 5.88 1.52e-08 1.98e-05 0.42 0.37 Breast cancer; chr17:54914907 chr17:54964474~54964679:+ CESC cis rs7617773 0.539 rs12486944 ENSG00000229759.1 MRPS18AP1 5.88 1.52e-08 1.98e-05 0.39 0.37 Coronary artery disease; chr3:48348526 chr3:48256350~48256938:- CESC cis rs11168854 0.719 rs11168902 ENSG00000258017.1 RP11-386G11.10 -5.88 1.52e-08 1.99e-05 -0.49 -0.37 Body mass index; chr12:49174483 chr12:49127782~49147869:+ CESC cis rs2117029 0.553 rs11168903 ENSG00000258017.1 RP11-386G11.10 -5.88 1.52e-08 1.99e-05 -0.49 -0.37 Intelligence (multi-trait analysis); chr12:49174883 chr12:49127782~49147869:+ CESC cis rs2404602 0.716 rs117129193 ENSG00000259422.1 RP11-593F23.1 5.88 1.52e-08 1.99e-05 0.42 0.37 Blood metabolite levels; chr15:76364462 chr15:76174891~76181486:- CESC cis rs2404602 0.583 rs2176623 ENSG00000259422.1 RP11-593F23.1 5.88 1.53e-08 1.99e-05 0.4 0.37 Blood metabolite levels; chr15:76276238 chr15:76174891~76181486:- CESC cis rs9907295 0.892 rs55950249 ENSG00000270977.1 AC015849.16 -5.88 1.54e-08 2.01e-05 -0.51 -0.37 Fibroblast growth factor basic levels; chr17:35903948 chr17:35893707~35911023:- CESC cis rs2243480 1 rs316329 ENSG00000232559.3 GS1-124K5.12 5.88 1.54e-08 2.01e-05 0.65 0.37 Diabetic kidney disease; chr7:66143429 chr7:66554588~66576923:- CESC cis rs8062405 0.755 rs7193402 ENSG00000259982.1 CDC37P1 5.88 1.55e-08 2.02e-05 0.47 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574806 chr16:28700294~28701540:- CESC cis rs11676348 0.846 rs7594532 ENSG00000261338.2 RP11-378A13.1 -5.88 1.55e-08 2.02e-05 -0.44 -0.37 Ulcerative colitis; chr2:218143277 chr2:218255319~218257366:+ CESC cis rs6142102 0.602 rs11696338 ENSG00000275784.1 RP5-1125A11.6 -5.88 1.55e-08 2.02e-05 -0.37 -0.37 Skin pigmentation; chr20:34099805 chr20:33989480~33991818:- CESC cis rs6142102 0.58 rs6142101 ENSG00000275784.1 RP5-1125A11.6 -5.88 1.55e-08 2.02e-05 -0.37 -0.37 Skin pigmentation; chr20:34110039 chr20:33989480~33991818:- CESC cis rs9322193 0.962 rs4870048 ENSG00000268592.3 RAET1E-AS1 5.88 1.55e-08 2.02e-05 0.48 0.37 Lung cancer; chr6:149834324 chr6:149863494~149919507:+ CESC cis rs765787 0.53 rs1648285 ENSG00000259520.4 CTD-2651B20.3 5.88 1.55e-08 2.02e-05 0.47 0.37 Uric acid levels; chr15:45225307 chr15:45251580~45279251:- CESC cis rs1062177 0.855 rs1346489 ENSG00000213433.5 RPLP1P6 -5.88 1.56e-08 2.03e-05 -0.42 -0.37 Preschool internalizing problems; chr5:151886973 chr5:151765859~151766378:- CESC cis rs10740039 0.583 rs2127348 ENSG00000254271.1 RP11-131N11.4 -5.88 1.56e-08 2.04e-05 -0.45 -0.37 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740945 chr10:60734342~60741828:+ CESC cis rs10740039 0.583 rs2127349 ENSG00000254271.1 RP11-131N11.4 -5.88 1.56e-08 2.04e-05 -0.45 -0.37 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740947 chr10:60734342~60741828:+ CESC cis rs113835537 0.597 rs7939759 ENSG00000255517.5 CTD-3074O7.5 -5.88 1.56e-08 2.04e-05 -0.44 -0.37 Airway imaging phenotypes; chr11:66570493 chr11:66473490~66480233:- CESC cis rs113835537 0.597 rs10896129 ENSG00000255517.5 CTD-3074O7.5 -5.88 1.56e-08 2.04e-05 -0.44 -0.37 Airway imaging phenotypes; chr11:66570829 chr11:66473490~66480233:- CESC cis rs113835537 0.559 rs57045447 ENSG00000255517.5 CTD-3074O7.5 -5.88 1.56e-08 2.04e-05 -0.44 -0.37 Airway imaging phenotypes; chr11:66572212 chr11:66473490~66480233:- CESC cis rs11096990 0.634 rs6531703 ENSG00000249207.1 RP11-360F5.1 5.88 1.56e-08 2.04e-05 0.4 0.37 Cognitive function; chr4:39281786 chr4:39112677~39126818:- CESC cis rs3814244 0.897 rs4141135 ENSG00000255733.4 IFNG-AS1 5.88 1.57e-08 2.04e-05 0.31 0.37 Itch intensity from mosquito bite adjusted by bite size; chr12:68025050 chr12:67989445~68234686:+ CESC cis rs2739330 0.731 rs2000468 ENSG00000231271.1 AP000350.8 5.87 1.57e-08 2.05e-05 0.45 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23949918~23954042:+ CESC cis rs6142102 0.625 rs4911137 ENSG00000275784.1 RP5-1125A11.6 -5.87 1.57e-08 2.05e-05 -0.36 -0.37 Skin pigmentation; chr20:33947657 chr20:33989480~33991818:- CESC cis rs227275 0.526 rs223497 ENSG00000246560.2 RP11-10L12.4 5.87 1.57e-08 2.05e-05 0.47 0.37 Allergic disease (asthma, hay fever or eczema); chr4:102732819 chr4:102828055~102844075:+ CESC cis rs1707322 1 rs785465 ENSG00000280836.1 AL355480.1 -5.87 1.58e-08 2.06e-05 -0.43 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46056905 chr1:45581219~45581321:- CESC cis rs9309711 0.698 rs9750503 ENSG00000225234.1 TRAPPC12-AS1 5.87 1.59e-08 2.06e-05 0.38 0.37 Neurofibrillary tangles; chr2:3488001 chr2:3481242~3482409:- CESC cis rs35160687 0.871 rs2278105 ENSG00000273080.1 RP11-301O19.1 5.87 1.59e-08 2.06e-05 0.43 0.37 Night sleep phenotypes; chr2:86239393 chr2:86195590~86196049:+ CESC cis rs4728142 0.564 rs10954213 ENSG00000275106.1 RP11-309L24.10 -5.87 1.59e-08 2.07e-05 -0.49 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128949373 chr7:128952527~128953316:- CESC cis rs4728142 0.604 rs13242262 ENSG00000275106.1 RP11-309L24.10 -5.87 1.59e-08 2.07e-05 -0.49 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128951310 chr7:128952527~128953316:- CESC cis rs6142102 0.602 rs4911399 ENSG00000275784.1 RP5-1125A11.6 -5.87 1.59e-08 2.07e-05 -0.36 -0.37 Skin pigmentation; chr20:34035612 chr20:33989480~33991818:- CESC cis rs11155671 0.53 rs2342769 ENSG00000268592.3 RAET1E-AS1 5.87 1.59e-08 2.07e-05 0.46 0.37 Testicular germ cell tumor; chr6:149895371 chr6:149863494~149919507:+ CESC cis rs897984 0.542 rs11864839 ENSG00000260911.2 RP11-196G11.2 5.87 1.59e-08 2.07e-05 0.38 0.37 Dementia with Lewy bodies; chr16:31083930 chr16:31043150~31049868:+ CESC cis rs9549367 0.713 rs3024769 ENSG00000269125.1 RP11-98F14.11 5.87 1.6e-08 2.07e-05 0.49 0.37 Platelet distribution width; chr13:113171287 chr13:113165002~113165183:- CESC cis rs9322193 0.566 rs9397070 ENSG00000231760.4 RP11-350J20.5 -5.87 1.6e-08 2.07e-05 -0.54 -0.37 Lung cancer; chr6:149922073 chr6:149796151~149826294:- CESC cis rs1499614 0.803 rs1796229 ENSG00000232559.3 GS1-124K5.12 5.87 1.6e-08 2.08e-05 0.65 0.37 Gout; chr7:66654674 chr7:66554588~66576923:- CESC cis rs1499614 0.901 rs3936 ENSG00000232559.3 GS1-124K5.12 5.87 1.6e-08 2.08e-05 0.65 0.37 Gout; chr7:66661502 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs11763189 ENSG00000226824.5 RP4-756H11.3 -5.87 1.6e-08 2.08e-05 -0.46 -0.37 Aortic root size; chr7:66518542 chr7:66654538~66669855:+ CESC cis rs765787 0.53 rs11636440 ENSG00000259520.4 CTD-2651B20.3 5.87 1.6e-08 2.08e-05 0.46 0.37 Uric acid levels; chr15:45243784 chr15:45251580~45279251:- CESC cis rs34779708 0.966 rs17591781 ENSG00000230534.5 RP11-297A16.2 5.87 1.6e-08 2.08e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35209610 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs17500582 ENSG00000230534.5 RP11-297A16.2 5.87 1.6e-08 2.08e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35209860 chr10:35098006~35127020:- CESC cis rs9389248 0.69 rs6569982 ENSG00000232876.1 CTA-212D2.2 -5.87 1.6e-08 2.08e-05 -0.44 -0.37 High light scatter reticulocyte percentage of red cells; chr6:134935357 chr6:135055033~135060550:+ CESC cis rs992157 0.71 rs10169718 ENSG00000261338.2 RP11-378A13.1 -5.87 1.6e-08 2.08e-05 -0.45 -0.37 Colorectal cancer; chr2:218238857 chr2:218255319~218257366:+ CESC cis rs8062405 0.755 rs7186573 ENSG00000259982.1 CDC37P1 5.87 1.61e-08 2.08e-05 0.46 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576068 chr16:28700294~28701540:- CESC cis rs116095464 0.558 rs10462754 ENSG00000250848.1 CTD-2083E4.5 -5.87 1.61e-08 2.09e-05 -0.47 -0.37 Breast cancer; chr5:246554 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10462755 ENSG00000250848.1 CTD-2083E4.5 -5.87 1.61e-08 2.09e-05 -0.47 -0.37 Breast cancer; chr5:246633 chr5:288833~290321:- CESC cis rs2404602 0.967 rs2083762 ENSG00000259422.1 RP11-593F23.1 5.87 1.61e-08 2.09e-05 0.41 0.37 Blood metabolite levels; chr15:76615035 chr15:76174891~76181486:- CESC cis rs2548724 0.588 rs17333350 ENSG00000250682.4 LINC00491 -5.87 1.61e-08 2.09e-05 -0.43 -0.37 Type 2 diabetes; chr5:102478905 chr5:102609156~102671559:- CESC cis rs3806843 0.518 rs2569191 ENSG00000202111.1 VTRNA1-2 5.87 1.61e-08 2.09e-05 0.39 0.37 Depressive symptoms (multi-trait analysis); chr5:140634318 chr5:140718925~140719013:+ CESC cis rs8072100 0.777 rs9914653 ENSG00000228782.6 CTD-2026D20.3 5.87 1.61e-08 2.09e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47460029 chr17:47450568~47492492:- CESC cis rs6452524 1 rs62374373 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83137389 chr5:83012285~83013109:- CESC cis rs6452524 1 rs10043018 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83138498 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs10037501 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83138722 chr5:83012285~83013109:- CESC cis rs6452524 0.904 rs6452525 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83138752 chr5:83012285~83013109:- CESC cis rs6452524 1 rs7716931 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83138856 chr5:83012285~83013109:- CESC cis rs6452524 1 rs7721416 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83139174 chr5:83012285~83013109:- CESC cis rs6452524 1 rs6882220 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83139715 chr5:83012285~83013109:- CESC cis rs6452524 1 rs6452526 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83140992 chr5:83012285~83013109:- CESC cis rs6452524 1 rs6452527 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83141021 chr5:83012285~83013109:- CESC cis rs6452524 1 rs10055844 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83141276 chr5:83012285~83013109:- CESC cis rs6452524 1 rs10077862 ENSG00000249664.1 CTD-2227C6.2 5.87 1.62e-08 2.1e-05 0.41 0.37 Hypertension (SNP x SNP interaction); chr5:83141322 chr5:83012285~83013109:- CESC cis rs875971 0.862 rs6958294 ENSG00000226824.5 RP4-756H11.3 5.87 1.62e-08 2.1e-05 0.46 0.37 Aortic root size; chr7:66329809 chr7:66654538~66669855:+ CESC cis rs1891275 0.515 rs6583784 ENSG00000228701.1 TNKS2-AS1 5.87 1.62e-08 2.11e-05 0.42 0.37 Intelligence (multi-trait analysis); chr10:91731819 chr10:91782839~91798291:- CESC cis rs2243480 1 rs316313 ENSG00000232559.3 GS1-124K5.12 5.87 1.63e-08 2.11e-05 0.63 0.37 Diabetic kidney disease; chr7:66128561 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316312 ENSG00000232559.3 GS1-124K5.12 5.87 1.63e-08 2.11e-05 0.63 0.37 Diabetic kidney disease; chr7:66131504 chr7:66554588~66576923:- CESC cis rs2243480 1 rs419603 ENSG00000232559.3 GS1-124K5.12 5.87 1.63e-08 2.11e-05 0.63 0.37 Diabetic kidney disease; chr7:66132354 chr7:66554588~66576923:- CESC cis rs2243480 1 rs387676 ENSG00000232559.3 GS1-124K5.12 5.87 1.63e-08 2.11e-05 0.63 0.37 Diabetic kidney disease; chr7:66133233 chr7:66554588~66576923:- CESC cis rs2243480 1 rs13310597 ENSG00000232559.3 GS1-124K5.12 5.87 1.63e-08 2.11e-05 0.63 0.37 Diabetic kidney disease; chr7:66133553 chr7:66554588~66576923:- CESC cis rs2117029 0.554 rs2334931 ENSG00000258017.1 RP11-386G11.10 -5.87 1.63e-08 2.11e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr12:49174130 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs10875929 ENSG00000258017.1 RP11-386G11.10 -5.87 1.63e-08 2.11e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr12:49174605 chr12:49127782~49147869:+ CESC cis rs2117029 0.554 rs2334930 ENSG00000258017.1 RP11-386G11.10 -5.87 1.63e-08 2.11e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr12:49175528 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs11168904 ENSG00000258017.1 RP11-386G11.10 -5.87 1.63e-08 2.11e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr12:49177234 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs10875931 ENSG00000258017.1 RP11-386G11.10 -5.87 1.63e-08 2.11e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr12:49179513 chr12:49127782~49147869:+ CESC cis rs2117029 0.554 rs7954530 ENSG00000258017.1 RP11-386G11.10 -5.87 1.63e-08 2.11e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr12:49179742 chr12:49127782~49147869:+ CESC cis rs2117029 0.586 rs7957998 ENSG00000258017.1 RP11-386G11.10 -5.87 1.63e-08 2.11e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr12:49180240 chr12:49127782~49147869:+ CESC cis rs2117029 0.553 rs11168909 ENSG00000258017.1 RP11-386G11.10 -5.87 1.63e-08 2.11e-05 -0.48 -0.37 Intelligence (multi-trait analysis); chr12:49183092 chr12:49127782~49147869:+ CESC cis rs765787 0.53 rs28414644 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45244523 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs28396110 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45244711 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4775834 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45245313 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4775835 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45245355 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4775836 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45245466 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4775837 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45245486 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs12917187 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45246099 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs11639403 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45246152 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2413782 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45246292 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2413780 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45246668 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs11636018 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45246939 chr15:45251580~45279251:- CESC cis rs765787 0.556 rs2413778 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45247199 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs28756676 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45248162 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs55771002 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45249368 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs55920042 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45249379 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4238376 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45249689 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4238377 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45249783 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs4775844 ENSG00000259520.4 CTD-2651B20.3 5.87 1.64e-08 2.12e-05 0.46 0.37 Uric acid levels; chr15:45249850 chr15:45251580~45279251:- CESC cis rs7208859 0.673 rs216440 ENSG00000263531.1 RP13-753N3.1 5.87 1.65e-08 2.13e-05 0.61 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30601291 chr17:30863921~30864940:- CESC cis rs748404 0.56 rs1060939 ENSG00000249839.1 AC011330.5 -5.86 1.66e-08 2.15e-05 -0.4 -0.37 Lung cancer; chr15:43524719 chr15:43663654~43684339:- CESC cis rs2548724 0.587 rs59399361 ENSG00000250682.4 LINC00491 5.86 1.66e-08 2.15e-05 0.44 0.37 Type 2 diabetes; chr5:102413414 chr5:102609156~102671559:- CESC cis rs11096990 0.634 rs1057807 ENSG00000249207.1 RP11-360F5.1 5.86 1.66e-08 2.15e-05 0.4 0.37 Cognitive function; chr4:39287853 chr4:39112677~39126818:- CESC cis rs9549367 0.789 rs9604040 ENSG00000269125.1 RP11-98F14.11 5.86 1.66e-08 2.15e-05 0.49 0.37 Platelet distribution width; chr13:113256297 chr13:113165002~113165183:- CESC cis rs3806843 0.868 rs2531342 ENSG00000202111.1 VTRNA1-2 5.86 1.67e-08 2.15e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140751027 chr5:140718925~140719013:+ CESC cis rs3806843 0.9 rs2563279 ENSG00000202111.1 VTRNA1-2 5.86 1.67e-08 2.15e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140751950 chr5:140718925~140719013:+ CESC cis rs4728142 0.625 rs4731533 ENSG00000275106.1 RP11-309L24.10 -5.86 1.67e-08 2.16e-05 -0.49 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128962088 chr7:128952527~128953316:- CESC cis rs4728142 0.525 rs4731534 ENSG00000275106.1 RP11-309L24.10 -5.86 1.67e-08 2.16e-05 -0.49 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128965540 chr7:128952527~128953316:- CESC cis rs2739330 0.828 rs4820572 ENSG00000272787.1 KB-226F1.2 -5.86 1.68e-08 2.16e-05 -0.4 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23969211~23969873:+ CESC cis rs116095464 0.558 rs7714335 ENSG00000250848.1 CTD-2083E4.5 -5.86 1.68e-08 2.17e-05 -0.51 -0.37 Breast cancer; chr5:263398 chr5:288833~290321:- CESC cis rs11155671 0.53 rs7763849 ENSG00000216906.2 RP11-350J20.9 5.86 1.68e-08 2.17e-05 0.4 0.37 Testicular germ cell tumor; chr6:149885244 chr6:149904243~149906418:+ CESC cis rs992157 0.798 rs12053514 ENSG00000261338.2 RP11-378A13.1 -5.86 1.69e-08 2.17e-05 -0.48 -0.37 Colorectal cancer; chr2:218303242 chr2:218255319~218257366:+ CESC cis rs1707322 0.752 rs11211152 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648485 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs4607935 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651489 chr1:45580892~45580996:- CESC cis rs1707322 0.681 rs12048866 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651820 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs3811436 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660208 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs12024590 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45661824 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs12027622 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664580 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs4415615 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45666437 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs7529699 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668962 chr1:45580892~45580996:- CESC cis rs1707322 0.716 rs6699444 ENSG00000281133.1 AL355480.3 -5.86 1.69e-08 2.18e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669448 chr1:45580892~45580996:- CESC cis rs8072100 0.84 rs9900360 ENSG00000228782.6 CTD-2026D20.3 5.86 1.7e-08 2.19e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47414613 chr17:47450568~47492492:- CESC cis rs8072100 0.84 rs56952963 ENSG00000228782.6 CTD-2026D20.3 5.86 1.7e-08 2.19e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47416460 chr17:47450568~47492492:- CESC cis rs9907295 0.591 rs8069014 ENSG00000270977.1 AC015849.16 -5.86 1.7e-08 2.19e-05 -0.44 -0.37 Fibroblast growth factor basic levels; chr17:35872994 chr17:35893707~35911023:- CESC cis rs75422866 0.867 rs73102166 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47653769 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102168 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47654010 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102171 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47656077 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102188 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47662993 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102195 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47666309 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102201 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47669269 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73104104 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47671986 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73104111 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47673994 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73104115 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47684843 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73104116 ENSG00000257433.4 RP1-197B17.3 5.86 1.71e-08 2.19e-05 0.85 0.37 Pneumonia; chr12:47685023 chr12:47706085~47742294:+ CESC cis rs992157 0.835 rs6707559 ENSG00000261338.2 RP11-378A13.1 5.86 1.71e-08 2.2e-05 0.48 0.37 Colorectal cancer; chr2:218278050 chr2:218255319~218257366:+ CESC cis rs1707322 0.752 rs28550303 ENSG00000281133.1 AL355480.3 -5.86 1.71e-08 2.2e-05 -0.45 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723242 chr1:45580892~45580996:- CESC cis rs9545047 0.604 rs9601227 ENSG00000227676.3 LINC01068 -5.86 1.71e-08 2.2e-05 -0.42 -0.37 Schizophrenia; chr13:79420805 chr13:79566727~79571436:+ CESC cis rs6452524 0.534 rs72765386 ENSG00000249664.1 CTD-2227C6.2 5.86 1.71e-08 2.2e-05 0.43 0.37 Hypertension (SNP x SNP interaction); chr5:83061502 chr5:83012285~83013109:- CESC cis rs8062405 0.688 rs3924376 ENSG00000259982.1 CDC37P1 -5.86 1.71e-08 2.2e-05 -0.48 -0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28914657 chr16:28700294~28701540:- CESC cis rs10256972 0.758 rs9801444 ENSG00000229043.2 AC091729.9 5.86 1.72e-08 2.21e-05 0.42 0.37 Endometriosis;Longevity; chr7:1040808 chr7:1160374~1165267:+ CESC cis rs35955747 0.669 rs878718 ENSG00000236132.1 CTA-440B3.1 -5.86 1.72e-08 2.21e-05 -0.43 -0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31156716 chr22:31816379~31817491:- CESC cis rs2243480 0.901 rs778730 ENSG00000232559.3 GS1-124K5.12 5.86 1.72e-08 2.21e-05 0.64 0.37 Diabetic kidney disease; chr7:66358338 chr7:66554588~66576923:- CESC cis rs6452524 0.534 rs10037377 ENSG00000249664.1 CTD-2227C6.2 5.86 1.72e-08 2.21e-05 0.42 0.37 Hypertension (SNP x SNP interaction); chr5:83071150 chr5:83012285~83013109:- CESC cis rs2729354 0.817 rs2848626 ENSG00000265566.2 RN7SL605P -5.86 1.72e-08 2.22e-05 -0.57 -0.37 Blood protein levels; chr11:57516515 chr11:57528085~57528365:- CESC cis rs1062177 1 rs6890099 ENSG00000253921.1 CTB-113P19.3 -5.86 1.73e-08 2.22e-05 -0.51 -0.37 Preschool internalizing problems; chr5:151772401 chr5:151753992~151767247:+ CESC cis rs75422866 0.867 rs73104138 ENSG00000257433.4 RP1-197B17.3 5.86 1.73e-08 2.22e-05 0.85 0.37 Pneumonia; chr12:47692302 chr12:47706085~47742294:+ CESC cis rs75422866 0.717 rs73104143 ENSG00000257433.4 RP1-197B17.3 5.86 1.73e-08 2.22e-05 0.85 0.37 Pneumonia; chr12:47693449 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73104144 ENSG00000257433.4 RP1-197B17.3 5.86 1.73e-08 2.22e-05 0.85 0.37 Pneumonia; chr12:47694390 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73104148 ENSG00000257433.4 RP1-197B17.3 5.86 1.73e-08 2.22e-05 0.85 0.37 Pneumonia; chr12:47696732 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73104152 ENSG00000257433.4 RP1-197B17.3 5.86 1.73e-08 2.22e-05 0.85 0.37 Pneumonia; chr12:47699091 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73104155 ENSG00000257433.4 RP1-197B17.3 5.86 1.73e-08 2.22e-05 0.85 0.37 Pneumonia; chr12:47700790 chr12:47706085~47742294:+ CESC cis rs9584850 0.834 rs2031239 ENSG00000231194.1 FARP1-AS1 5.86 1.73e-08 2.22e-05 0.47 0.37 Neuroticism; chr13:98459306 chr13:98435405~98435840:- CESC cis rs12022452 1 rs12034162 ENSG00000238287.1 RP11-656D10.3 -5.86 1.74e-08 2.23e-05 -0.6 -0.37 Age-related hearing impairment (SNP x SNP interaction); chr1:40498933 chr1:40493157~40508661:- CESC cis rs35955747 0.869 rs9621216 ENSG00000236132.1 CTA-440B3.1 5.85 1.74e-08 2.23e-05 0.44 0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31194222 chr22:31816379~31817491:- CESC cis rs9399135 0.967 rs9321481 ENSG00000232876.1 CTA-212D2.2 5.85 1.75e-08 2.24e-05 0.43 0.37 Red blood cell count; chr6:135031510 chr6:135055033~135060550:+ CESC cis rs3738443 0.569 rs6704060 ENSG00000259865.1 RP11-488L18.10 5.85 1.75e-08 2.24e-05 0.35 0.37 Alcohol dependence; chr1:247218222 chr1:247187281~247188526:- CESC cis rs3738443 0.52 rs1771932 ENSG00000259865.1 RP11-488L18.10 5.85 1.75e-08 2.24e-05 0.35 0.37 Alcohol dependence; chr1:247218747 chr1:247187281~247188526:- CESC cis rs8072100 0.807 rs2175290 ENSG00000228782.6 CTD-2026D20.3 5.85 1.76e-08 2.25e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402551 chr17:47450568~47492492:- CESC cis rs2581828 0.656 rs2581782 ENSG00000242142.1 SERBP1P3 5.85 1.76e-08 2.25e-05 0.42 0.37 Crohn's disease; chr3:53088241 chr3:53064283~53065091:- CESC cis rs2581828 0.656 rs2581783 ENSG00000242142.1 SERBP1P3 5.85 1.76e-08 2.25e-05 0.42 0.37 Crohn's disease; chr3:53088242 chr3:53064283~53065091:- CESC cis rs1062177 1 rs2915877 ENSG00000253921.1 CTB-113P19.3 -5.85 1.77e-08 2.26e-05 -0.5 -0.37 Preschool internalizing problems; chr5:151771040 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs2964576 ENSG00000253921.1 CTB-113P19.3 -5.85 1.77e-08 2.26e-05 -0.5 -0.37 Preschool internalizing problems; chr5:151771041 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs2964585 ENSG00000253921.1 CTB-113P19.3 -5.85 1.77e-08 2.27e-05 -0.5 -0.37 Preschool internalizing problems; chr5:151762334 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs2964578 ENSG00000253921.1 CTB-113P19.3 -5.85 1.77e-08 2.27e-05 -0.5 -0.37 Preschool internalizing problems; chr5:151767637 chr5:151753992~151767247:+ CESC cis rs875971 0.964 rs697969 ENSG00000222364.1 RNU6-96P 5.85 1.77e-08 2.27e-05 0.44 0.37 Aortic root size; chr7:66093491 chr7:66395191~66395286:+ CESC cis rs875971 1 rs1182882 ENSG00000222364.1 RNU6-96P 5.85 1.77e-08 2.27e-05 0.44 0.37 Aortic root size; chr7:66097076 chr7:66395191~66395286:+ CESC cis rs34779708 0.931 rs11010101 ENSG00000230534.5 RP11-297A16.2 5.85 1.77e-08 2.27e-05 0.48 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35122117 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs11010102 ENSG00000230534.5 RP11-297A16.2 5.85 1.77e-08 2.27e-05 0.48 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35122138 chr10:35098006~35127020:- CESC cis rs1062177 0.756 rs2915815 ENSG00000213433.5 RPLP1P6 5.85 1.78e-08 2.28e-05 0.47 0.37 Preschool internalizing problems; chr5:151736322 chr5:151765859~151766378:- CESC cis rs2280018 0.526 rs2966128 ENSG00000260735.1 RP11-72I8.1 -5.85 1.79e-08 2.29e-05 -0.41 -0.37 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059532 chr16:15094411~15109197:+ CESC cis rs2177312 0.868 rs1357466 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31948068 chr4:31997397~32155406:+ CESC cis rs2177312 0.83 rs1581454 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31948437 chr4:31997397~32155406:+ CESC cis rs2177312 0.767 rs1581455 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31948491 chr4:31997397~32155406:+ CESC cis rs2177312 0.794 rs1523169 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31948572 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1523170 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31948957 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1523171 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31948967 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1523172 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31949082 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1996882 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31949355 chr4:31997397~32155406:+ CESC cis rs2177312 0.83 rs1523173 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31949737 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1357464 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31951995 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1357463 ENSG00000251129.1 RP11-734I18.1 -5.85 1.8e-08 2.3e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31953425 chr4:31997397~32155406:+ CESC cis rs9309711 0.689 rs4535075 ENSG00000225234.1 TRAPPC12-AS1 -5.85 1.8e-08 2.3e-05 -0.35 -0.37 Neurofibrillary tangles; chr2:3477945 chr2:3481242~3482409:- CESC cis rs9309711 0.666 rs6767 ENSG00000225234.1 TRAPPC12-AS1 -5.85 1.8e-08 2.3e-05 -0.35 -0.37 Neurofibrillary tangles; chr2:3479434 chr2:3481242~3482409:- CESC cis rs9309711 0.623 rs7569694 ENSG00000225234.1 TRAPPC12-AS1 -5.85 1.8e-08 2.3e-05 -0.35 -0.37 Neurofibrillary tangles; chr2:3479619 chr2:3481242~3482409:- CESC cis rs34779708 0.966 rs34605125 ENSG00000230534.5 RP11-297A16.2 5.85 1.8e-08 2.3e-05 0.48 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35122318 chr10:35098006~35127020:- CESC cis rs6504950 0.72 rs9913784 ENSG00000275710.1 RP11-257O5.4 5.85 1.8e-08 2.3e-05 0.42 0.37 Breast cancer; chr17:54911710 chr17:54964474~54964679:+ CESC cis rs9399135 1 rs4896130 ENSG00000232876.1 CTA-212D2.2 -5.85 1.8e-08 2.3e-05 -0.42 -0.37 Red blood cell count; chr6:135033980 chr6:135055033~135060550:+ CESC cis rs10875746 0.903 rs11168370 ENSG00000240399.1 RP1-228P16.1 -5.85 1.81e-08 2.31e-05 -0.44 -0.37 Longevity (90 years and older); chr12:48041497 chr12:48054813~48055591:- CESC cis rs950169 0.96 rs35159785 ENSG00000225151.9 GOLGA2P7 -5.85 1.81e-08 2.31e-05 -0.52 -0.37 Schizophrenia; chr15:84135262 chr15:84199311~84230136:- CESC cis rs6951245 0.638 rs4720486 ENSG00000229043.2 AC091729.9 -5.85 1.82e-08 2.32e-05 -0.48 -0.37 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1107128 chr7:1160374~1165267:+ CESC cis rs9399135 1 rs9399135 ENSG00000232876.1 CTA-212D2.2 -5.85 1.82e-08 2.32e-05 -0.43 -0.37 Red blood cell count; chr6:135047176 chr6:135055033~135060550:+ CESC cis rs9545047 0.604 rs7336581 ENSG00000227676.3 LINC01068 5.85 1.82e-08 2.32e-05 0.41 0.37 Schizophrenia; chr13:79385739 chr13:79566727~79571436:+ CESC cis rs75422866 0.867 rs76100981 ENSG00000257433.4 RP1-197B17.3 5.85 1.82e-08 2.32e-05 0.85 0.37 Pneumonia; chr12:47660092 chr12:47706085~47742294:+ CESC cis rs12022452 1 rs12048678 ENSG00000238287.1 RP11-656D10.3 -5.85 1.82e-08 2.32e-05 -0.59 -0.37 Age-related hearing impairment (SNP x SNP interaction); chr1:40482096 chr1:40493157~40508661:- CESC cis rs113835537 0.597 rs4576 ENSG00000255517.5 CTD-3074O7.5 -5.85 1.82e-08 2.32e-05 -0.43 -0.37 Airway imaging phenotypes; chr11:66563529 chr11:66473490~66480233:- CESC cis rs9545047 0.584 rs1886494 ENSG00000227676.3 LINC01068 -5.85 1.83e-08 2.33e-05 -0.42 -0.37 Schizophrenia; chr13:79403005 chr13:79566727~79571436:+ CESC cis rs2404602 0.692 rs2117369 ENSG00000259422.1 RP11-593F23.1 5.84 1.84e-08 2.34e-05 0.41 0.37 Blood metabolite levels; chr15:76456520 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs2164101 ENSG00000259422.1 RP11-593F23.1 5.84 1.84e-08 2.34e-05 0.41 0.37 Blood metabolite levels; chr15:76456776 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs67888330 ENSG00000259422.1 RP11-593F23.1 5.84 1.84e-08 2.34e-05 0.41 0.37 Blood metabolite levels; chr15:76460142 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs1588961 ENSG00000259422.1 RP11-593F23.1 5.84 1.84e-08 2.34e-05 0.41 0.37 Blood metabolite levels; chr15:76460357 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs12592171 ENSG00000259422.1 RP11-593F23.1 5.84 1.84e-08 2.34e-05 0.41 0.37 Blood metabolite levels; chr15:76462792 chr15:76174891~76181486:- CESC cis rs2404602 0.679 rs12899871 ENSG00000259422.1 RP11-593F23.1 5.84 1.84e-08 2.34e-05 0.41 0.37 Blood metabolite levels; chr15:76465006 chr15:76174891~76181486:- CESC cis rs2842992 0.915 rs2758321 ENSG00000237927.1 RP3-393E18.2 -5.84 1.84e-08 2.34e-05 -0.49 -0.37 Age-related macular degeneration (geographic atrophy); chr6:159650579 chr6:159586955~159589169:- CESC cis rs801193 0.569 rs4717315 ENSG00000226824.5 RP4-756H11.3 -5.84 1.84e-08 2.34e-05 -0.46 -0.37 Aortic root size; chr7:66713338 chr7:66654538~66669855:+ CESC cis rs801193 0.548 rs2659891 ENSG00000226824.5 RP4-756H11.3 -5.84 1.84e-08 2.34e-05 -0.46 -0.37 Aortic root size; chr7:66736127 chr7:66654538~66669855:+ CESC cis rs801193 0.548 rs7805152 ENSG00000226824.5 RP4-756H11.3 -5.84 1.84e-08 2.34e-05 -0.46 -0.37 Aortic root size; chr7:66744266 chr7:66654538~66669855:+ CESC cis rs2117029 0.521 rs11168910 ENSG00000258017.1 RP11-386G11.10 -5.84 1.84e-08 2.34e-05 -0.49 -0.37 Intelligence (multi-trait analysis); chr12:49192707 chr12:49127782~49147869:+ CESC cis rs2929278 0.617 rs694461 ENSG00000205771.5 CATSPER2P1 5.84 1.84e-08 2.34e-05 0.43 0.37 Schizophrenia; chr15:43803865 chr15:43726918~43747094:- CESC cis rs7572733 1 rs2196175 ENSG00000222017.1 AC011997.1 5.84 1.85e-08 2.35e-05 0.4 0.37 Dermatomyositis; chr2:198040349 chr2:197693106~197774823:+ CESC cis rs7572733 0.967 rs2196174 ENSG00000222017.1 AC011997.1 5.84 1.85e-08 2.35e-05 0.4 0.37 Dermatomyositis; chr2:198040448 chr2:197693106~197774823:+ CESC cis rs10463554 0.857 rs3776871 ENSG00000175749.11 EIF3KP1 5.84 1.85e-08 2.35e-05 0.4 0.37 Parkinson's disease; chr5:102956507 chr5:103032376~103033031:+ CESC cis rs10463554 0.892 rs2195272 ENSG00000175749.11 EIF3KP1 5.84 1.85e-08 2.35e-05 0.4 0.37 Parkinson's disease; chr5:102959800 chr5:103032376~103033031:+ CESC cis rs6991838 0.584 rs34226237 ENSG00000200714.1 Y_RNA -5.84 1.85e-08 2.35e-05 -0.44 -0.37 Intelligence (multi-trait analysis); chr8:65600930 chr8:65592731~65592820:+ CESC cis rs2177312 0.553 rs9994107 ENSG00000251129.1 RP11-734I18.1 -5.84 1.86e-08 2.36e-05 -0.43 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31969061 chr4:31997397~32155406:+ CESC cis rs35955747 0.934 rs5994397 ENSG00000236132.1 CTA-440B3.1 5.84 1.86e-08 2.37e-05 0.43 0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31430164 chr22:31816379~31817491:- CESC cis rs2177312 0.794 rs7659098 ENSG00000251129.1 RP11-734I18.1 -5.84 1.86e-08 2.37e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31957567 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1608334 ENSG00000251129.1 RP11-734I18.1 -5.84 1.86e-08 2.37e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31957762 chr4:31997397~32155406:+ CESC cis rs2404602 0.716 rs12441247 ENSG00000259422.1 RP11-593F23.1 5.84 1.86e-08 2.37e-05 0.41 0.37 Blood metabolite levels; chr15:76519975 chr15:76174891~76181486:- CESC cis rs950169 0.881 rs34591918 ENSG00000225151.9 GOLGA2P7 -5.84 1.86e-08 2.37e-05 -0.52 -0.37 Schizophrenia; chr15:84396135 chr15:84199311~84230136:- CESC cis rs950169 0.887 rs12903946 ENSG00000225151.9 GOLGA2P7 -5.84 1.86e-08 2.37e-05 -0.52 -0.37 Schizophrenia; chr15:84399732 chr15:84199311~84230136:- CESC cis rs950169 0.887 rs62029593 ENSG00000225151.9 GOLGA2P7 -5.84 1.86e-08 2.37e-05 -0.52 -0.37 Schizophrenia; chr15:84400482 chr15:84199311~84230136:- CESC cis rs950169 0.81 rs62029594 ENSG00000225151.9 GOLGA2P7 -5.84 1.86e-08 2.37e-05 -0.52 -0.37 Schizophrenia; chr15:84400554 chr15:84199311~84230136:- CESC cis rs950169 0.881 rs62029596 ENSG00000225151.9 GOLGA2P7 -5.84 1.86e-08 2.37e-05 -0.52 -0.37 Schizophrenia; chr15:84400736 chr15:84199311~84230136:- CESC cis rs950169 0.881 rs4081123 ENSG00000225151.9 GOLGA2P7 -5.84 1.86e-08 2.37e-05 -0.52 -0.37 Schizophrenia; chr15:84401537 chr15:84199311~84230136:- CESC cis rs950169 0.881 rs62029599 ENSG00000225151.9 GOLGA2P7 -5.84 1.86e-08 2.37e-05 -0.52 -0.37 Schizophrenia; chr15:84401867 chr15:84199311~84230136:- CESC cis rs950169 0.8 rs4099846 ENSG00000225151.9 GOLGA2P7 -5.84 1.86e-08 2.37e-05 -0.52 -0.37 Schizophrenia; chr15:84402196 chr15:84199311~84230136:- CESC cis rs6452524 0.563 rs10473863 ENSG00000249664.1 CTD-2227C6.2 5.84 1.87e-08 2.37e-05 0.43 0.37 Hypertension (SNP x SNP interaction); chr5:83057500 chr5:83012285~83013109:- CESC cis rs11096990 0.634 rs7564 ENSG00000249207.1 RP11-360F5.1 5.84 1.87e-08 2.37e-05 0.4 0.37 Cognitive function; chr4:39285702 chr4:39112677~39126818:- CESC cis rs9549367 0.713 rs3024743 ENSG00000269125.1 RP11-98F14.11 -5.84 1.87e-08 2.38e-05 -0.51 -0.37 Platelet distribution width; chr13:113167116 chr13:113165002~113165183:- CESC cis rs2980439 0.818 rs2948294 ENSG00000253893.2 FAM85B -5.84 1.88e-08 2.38e-05 -0.48 -0.37 Neuroticism; chr8:8237439 chr8:8167819~8226614:- CESC cis rs748404 0.56 rs570933 ENSG00000249839.1 AC011330.5 -5.84 1.88e-08 2.39e-05 -0.39 -0.37 Lung cancer; chr15:43531832 chr15:43663654~43684339:- CESC cis rs8072100 0.84 rs12452796 ENSG00000228782.6 CTD-2026D20.3 -5.84 1.89e-08 2.39e-05 -0.43 -0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402367 chr17:47450568~47492492:- CESC cis rs6142102 0.625 rs4911381 ENSG00000275784.1 RP5-1125A11.6 5.84 1.89e-08 2.39e-05 0.36 0.37 Skin pigmentation; chr20:33962539 chr20:33989480~33991818:- CESC cis rs6504950 0.785 rs2628304 ENSG00000275710.1 RP11-257O5.4 -5.84 1.89e-08 2.4e-05 -0.45 -0.37 Breast cancer; chr17:55079828 chr17:54964474~54964679:+ CESC cis rs8062405 0.69 rs7187604 ENSG00000259982.1 CDC37P1 5.84 1.9e-08 2.41e-05 0.47 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554632 chr16:28700294~28701540:- CESC cis rs897984 0.683 rs729482 ENSG00000260911.2 RP11-196G11.2 5.84 1.9e-08 2.41e-05 0.4 0.37 Dementia with Lewy bodies; chr16:31005649 chr16:31043150~31049868:+ CESC cis rs2404602 0.692 rs58361452 ENSG00000259422.1 RP11-593F23.1 5.84 1.9e-08 2.41e-05 0.41 0.37 Blood metabolite levels; chr15:76681031 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs8043474 ENSG00000259422.1 RP11-593F23.1 5.84 1.9e-08 2.41e-05 0.41 0.37 Blood metabolite levels; chr15:76682382 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs35138393 ENSG00000259422.1 RP11-593F23.1 5.84 1.9e-08 2.41e-05 0.41 0.37 Blood metabolite levels; chr15:76685276 chr15:76174891~76181486:- CESC cis rs2404602 0.669 rs12595313 ENSG00000259422.1 RP11-593F23.1 5.84 1.9e-08 2.41e-05 0.41 0.37 Blood metabolite levels; chr15:76686029 chr15:76174891~76181486:- CESC cis rs9322193 0.607 rs6925151 ENSG00000231760.4 RP11-350J20.5 5.84 1.9e-08 2.41e-05 0.52 0.37 Lung cancer; chr6:149889587 chr6:149796151~149826294:- CESC cis rs1823913 0.576 rs13011608 ENSG00000280083.1 RP11-317J9.1 -5.84 1.91e-08 2.42e-05 -0.43 -0.37 Obesity-related traits; chr2:191267097 chr2:191154118~191156070:- CESC cis rs6504950 0.889 rs2541237 ENSG00000275710.1 RP11-257O5.4 -5.84 1.92e-08 2.43e-05 -0.48 -0.37 Breast cancer; chr17:55086676 chr17:54964474~54964679:+ CESC cis rs62229266 0.804 rs62230821 ENSG00000231106.2 LINC01436 5.84 1.92e-08 2.43e-05 0.5 0.37 Mitral valve prolapse; chr21:36052818 chr21:36005338~36007838:+ CESC cis rs2243480 0.831 rs57294491 ENSG00000232559.3 GS1-124K5.12 -5.84 1.92e-08 2.43e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66219914 chr7:66554588~66576923:- CESC cis rs8072100 0.967 rs12452315 ENSG00000228782.6 CTD-2026D20.3 -5.84 1.92e-08 2.43e-05 -0.42 -0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402080 chr17:47450568~47492492:- CESC cis rs2404602 1 rs2404602 ENSG00000259422.1 RP11-593F23.1 5.83 1.93e-08 2.44e-05 0.42 0.37 Blood metabolite levels; chr15:76738451 chr15:76174891~76181486:- CESC cis rs2243480 1 rs316304 ENSG00000232559.3 GS1-124K5.12 5.83 1.93e-08 2.44e-05 0.63 0.37 Diabetic kidney disease; chr7:66151907 chr7:66554588~66576923:- CESC cis rs9399135 0.684 rs1135205 ENSG00000232876.1 CTA-212D2.2 -5.83 1.94e-08 2.45e-05 -0.42 -0.37 Red blood cell count; chr6:134960657 chr6:135055033~135060550:+ CESC cis rs2739330 0.796 rs2154594 ENSG00000250470.1 AP000351.3 -5.83 1.94e-08 2.45e-05 -0.47 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23976904~23977585:- CESC cis rs875971 1 rs1167612 ENSG00000222364.1 RNU6-96P 5.83 1.94e-08 2.46e-05 0.44 0.37 Aortic root size; chr7:66102989 chr7:66395191~66395286:+ CESC cis rs35955747 0.869 rs5997909 ENSG00000236132.1 CTA-440B3.1 5.83 1.95e-08 2.46e-05 0.43 0.37 Neutrophil count;Sum basophil neutrophil counts; chr22:31195242 chr22:31816379~31817491:- CESC cis rs2882667 0.522 rs7731574 ENSG00000253404.1 AC034243.1 -5.83 1.96e-08 2.47e-05 -0.43 -0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139118503 chr5:138744434~138753309:- CESC cis rs897984 0.542 rs4468641 ENSG00000260911.2 RP11-196G11.2 5.83 1.96e-08 2.47e-05 0.38 0.37 Dementia with Lewy bodies; chr16:31085555 chr16:31043150~31049868:+ CESC cis rs6142102 0.517 rs6142046 ENSG00000275784.1 RP5-1125A11.6 -5.83 1.96e-08 2.47e-05 -0.36 -0.37 Skin pigmentation; chr20:33926255 chr20:33989480~33991818:- CESC cis rs1061377 0.748 rs12649085 ENSG00000249207.1 RP11-360F5.1 -5.83 1.97e-08 2.49e-05 -0.45 -0.37 Uric acid levels; chr4:39106459 chr4:39112677~39126818:- CESC cis rs7674212 1 rs7674212 ENSG00000246560.2 RP11-10L12.4 5.83 1.98e-08 2.5e-05 0.44 0.37 Type 2 diabetes; chr4:103067742 chr4:102828055~102844075:+ CESC cis rs9322193 0.923 rs12526675 ENSG00000268592.3 RAET1E-AS1 -5.83 1.98e-08 2.5e-05 -0.48 -0.37 Lung cancer; chr6:149729540 chr6:149863494~149919507:+ CESC cis rs34779708 0.966 rs12775548 ENSG00000230534.5 RP11-297A16.2 5.83 1.98e-08 2.5e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35190576 chr10:35098006~35127020:- CESC cis rs10875746 0.903 rs4760681 ENSG00000240399.1 RP1-228P16.1 -5.83 1.99e-08 2.51e-05 -0.48 -0.37 Longevity (90 years and older); chr12:48111447 chr12:48054813~48055591:- CESC cis rs6504950 0.72 rs9895901 ENSG00000275710.1 RP11-257O5.4 5.83 1.99e-08 2.51e-05 0.43 0.37 Breast cancer; chr17:54907524 chr17:54964474~54964679:+ CESC cis rs34779708 0.658 rs4934715 ENSG00000230534.5 RP11-297A16.2 5.83 1.99e-08 2.51e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35076064 chr10:35098006~35127020:- CESC cis rs9326248 1 rs664971 ENSG00000280143.1 AP000892.6 -5.83 1.99e-08 2.51e-05 -0.45 -0.37 Blood protein levels; chr11:117200141 chr11:117204967~117210292:+ CESC cis rs116095464 0.619 rs2303741 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:218241 chr5:288833~290321:- CESC cis rs116095464 0.614 rs10067482 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:219213 chr5:288833~290321:- CESC cis rs116095464 0.614 rs56299325 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:220479 chr5:288833~290321:- CESC cis rs116095464 0.558 rs62346526 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:220499 chr5:288833~290321:- CESC cis rs116095464 0.558 rs56043030 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:220802 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10067021 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:221375 chr5:288833~290321:- CESC cis rs116095464 0.558 rs9312977 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:221801 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6881920 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:222296 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6878061 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:222957 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6882584 ENSG00000250848.1 CTD-2083E4.5 -5.83 1.99e-08 2.51e-05 -0.46 -0.37 Breast cancer; chr5:223296 chr5:288833~290321:- CESC cis rs6452524 1 rs2126990 ENSG00000249664.1 CTD-2227C6.2 5.83 1.99e-08 2.51e-05 0.4 0.37 Hypertension (SNP x SNP interaction); chr5:83161351 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs1478480 ENSG00000249664.1 CTD-2227C6.2 5.83 2e-08 2.51e-05 0.39 0.37 Hypertension (SNP x SNP interaction); chr5:83112117 chr5:83012285~83013109:- CESC cis rs10129255 0.5 rs11628999 ENSG00000223648.3 IGHV3-64 5.83 2e-08 2.52e-05 0.31 0.37 Kawasaki disease; chr14:106800208 chr14:106643132~106658258:- CESC cis rs6452524 0.935 rs3901654 ENSG00000249664.1 CTD-2227C6.2 5.83 2e-08 2.52e-05 0.39 0.37 Hypertension (SNP x SNP interaction); chr5:83110519 chr5:83012285~83013109:- CESC cis rs2243480 0.901 rs34807232 ENSG00000232559.3 GS1-124K5.12 5.83 2e-08 2.52e-05 0.63 0.37 Diabetic kidney disease; chr7:66500146 chr7:66554588~66576923:- CESC cis rs1062177 1 rs72802204 ENSG00000253921.1 CTB-113P19.3 -5.83 2.01e-08 2.53e-05 -0.48 -0.37 Preschool internalizing problems; chr5:151803622 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs1062177 ENSG00000253921.1 CTB-113P19.3 -5.83 2.01e-08 2.53e-05 -0.48 -0.37 Preschool internalizing problems; chr5:151805140 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs973529 ENSG00000253921.1 CTB-113P19.3 -5.83 2.01e-08 2.53e-05 -0.48 -0.37 Preschool internalizing problems; chr5:151808597 chr5:151753992~151767247:+ CESC cis rs4660456 0.913 rs12743517 ENSG00000237899.1 RP4-739H11.3 5.83 2.01e-08 2.53e-05 0.47 0.37 Platelet count; chr1:40759682 chr1:40669089~40687588:- CESC cis rs2929278 0.617 rs12908467 ENSG00000205771.5 CATSPER2P1 5.83 2.01e-08 2.53e-05 0.44 0.37 Schizophrenia; chr15:43755232 chr15:43726918~43747094:- CESC cis rs10463554 0.892 rs1898673 ENSG00000175749.11 EIF3KP1 5.83 2.02e-08 2.54e-05 0.4 0.37 Parkinson's disease; chr5:102957676 chr5:103032376~103033031:+ CESC cis rs3806843 1 rs10477033 ENSG00000202111.1 VTRNA1-2 -5.83 2.02e-08 2.54e-05 -0.37 -0.37 Depressive symptoms (multi-trait analysis); chr5:140790018 chr5:140718925~140719013:+ CESC cis rs3806843 0.966 rs11953833 ENSG00000202111.1 VTRNA1-2 -5.83 2.03e-08 2.55e-05 -0.37 -0.37 Depressive symptoms (multi-trait analysis); chr5:140775538 chr5:140718925~140719013:+ CESC cis rs34779708 0.931 rs11010125 ENSG00000230534.5 RP11-297A16.2 5.83 2.03e-08 2.55e-05 0.48 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35214025 chr10:35098006~35127020:- CESC cis rs6452524 0.537 rs1583 ENSG00000249664.1 CTD-2227C6.2 5.82 2.05e-08 2.58e-05 0.43 0.37 Hypertension (SNP x SNP interaction); chr5:83052403 chr5:83012285~83013109:- CESC cis rs2404602 0.716 rs17363713 ENSG00000259422.1 RP11-593F23.1 5.82 2.05e-08 2.58e-05 0.41 0.37 Blood metabolite levels; chr15:76453787 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs8025134 ENSG00000259422.1 RP11-593F23.1 5.82 2.05e-08 2.58e-05 0.42 0.37 Blood metabolite levels; chr15:76489388 chr15:76174891~76181486:- CESC cis rs17507216 1 rs17356118 ENSG00000278603.1 RP13-608F4.5 5.82 2.06e-08 2.59e-05 0.58 0.37 Excessive daytime sleepiness; chr15:82569149 chr15:82472203~82472426:+ CESC cis rs1061377 1 rs3796509 ENSG00000249207.1 RP11-360F5.1 -5.82 2.06e-08 2.59e-05 -0.42 -0.37 Uric acid levels; chr4:39108566 chr4:39112677~39126818:- CESC cis rs2404602 0.716 rs56351018 ENSG00000259422.1 RP11-593F23.1 5.82 2.06e-08 2.59e-05 0.41 0.37 Blood metabolite levels; chr15:76532250 chr15:76174891~76181486:- CESC cis rs2243480 1 rs6964530 ENSG00000232559.3 GS1-124K5.12 -5.82 2.07e-08 2.59e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66253864 chr7:66554588~66576923:- CESC cis rs875971 0.861 rs801215 ENSG00000226824.5 RP4-756H11.3 5.82 2.07e-08 2.59e-05 0.46 0.37 Aortic root size; chr7:66546951 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs13232191 ENSG00000226824.5 RP4-756H11.3 -5.82 2.07e-08 2.59e-05 -0.46 -0.37 Aortic root size; chr7:66521661 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs35378740 ENSG00000226824.5 RP4-756H11.3 -5.82 2.07e-08 2.59e-05 -0.46 -0.37 Aortic root size; chr7:66522725 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs10950043 ENSG00000226824.5 RP4-756H11.3 -5.82 2.07e-08 2.59e-05 -0.46 -0.37 Aortic root size; chr7:66523623 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs17747530 ENSG00000226824.5 RP4-756H11.3 -5.82 2.07e-08 2.59e-05 -0.46 -0.37 Aortic root size; chr7:66529742 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs13226170 ENSG00000226824.5 RP4-756H11.3 -5.82 2.07e-08 2.59e-05 -0.46 -0.37 Aortic root size; chr7:66534311 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs2420611 ENSG00000226824.5 RP4-756H11.3 -5.82 2.07e-08 2.59e-05 -0.46 -0.37 Aortic root size; chr7:66534333 chr7:66654538~66669855:+ CESC cis rs875971 0.767 rs61348003 ENSG00000226824.5 RP4-756H11.3 -5.82 2.07e-08 2.59e-05 -0.46 -0.37 Aortic root size; chr7:66540947 chr7:66654538~66669855:+ CESC cis rs7396835 0.741 rs7396851 ENSG00000254851.1 RP11-109L13.1 5.82 2.07e-08 2.59e-05 0.57 0.37 Quantitative traits; chr11:116813448 chr11:117135528~117138582:+ CESC cis rs17711722 0.565 rs4717276 ENSG00000226824.5 RP4-756H11.3 -5.82 2.07e-08 2.6e-05 -0.45 -0.37 Calcium levels; chr7:65829754 chr7:66654538~66669855:+ CESC cis rs1707322 0.721 rs10890333 ENSG00000281133.1 AL355480.3 -5.82 2.08e-08 2.61e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634650 chr1:45580892~45580996:- CESC cis rs1062177 0.756 rs2964592 ENSG00000213433.5 RPLP1P6 5.82 2.08e-08 2.61e-05 0.45 0.37 Preschool internalizing problems; chr5:151736127 chr5:151765859~151766378:- CESC cis rs897984 0.511 rs7196726 ENSG00000260911.2 RP11-196G11.2 5.82 2.09e-08 2.62e-05 0.38 0.37 Dementia with Lewy bodies; chr16:31080754 chr16:31043150~31049868:+ CESC cis rs2177312 0.868 rs10029983 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31945451 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs10005394 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31945452 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs10007897 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31945840 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs7441108 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31946705 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs2177311 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31946793 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs2404292 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31946860 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1916300 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31947056 chr4:31997397~32155406:+ CESC cis rs2177312 1 rs2177312 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31947421 chr4:31997397~32155406:+ CESC cis rs2177312 0.83 rs1533925 ENSG00000251129.1 RP11-734I18.1 -5.82 2.1e-08 2.63e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31947689 chr4:31997397~32155406:+ CESC cis rs8072100 0.84 rs9895746 ENSG00000228782.6 CTD-2026D20.3 5.82 2.1e-08 2.63e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47401733 chr17:47450568~47492492:- CESC cis rs2739330 0.76 rs1002286 ENSG00000272787.1 KB-226F1.2 5.82 2.1e-08 2.63e-05 0.39 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23969211~23969873:+ CESC cis rs11096990 0.634 rs2839765 ENSG00000249207.1 RP11-360F5.1 5.82 2.1e-08 2.64e-05 0.39 0.37 Cognitive function; chr4:39293933 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs6531706 ENSG00000249207.1 RP11-360F5.1 5.82 2.1e-08 2.64e-05 0.39 0.37 Cognitive function; chr4:39294547 chr4:39112677~39126818:- CESC cis rs11096990 0.656 rs4580661 ENSG00000249207.1 RP11-360F5.1 5.82 2.1e-08 2.64e-05 0.39 0.37 Cognitive function; chr4:39294730 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs6815855 ENSG00000249207.1 RP11-360F5.1 5.82 2.1e-08 2.64e-05 0.39 0.37 Cognitive function; chr4:39294926 chr4:39112677~39126818:- CESC cis rs8072100 0.84 rs11079774 ENSG00000228782.6 CTD-2026D20.3 5.82 2.11e-08 2.64e-05 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402340 chr17:47450568~47492492:- CESC cis rs897984 0.542 rs59061704 ENSG00000260911.2 RP11-196G11.2 5.82 2.11e-08 2.64e-05 0.38 0.37 Dementia with Lewy bodies; chr16:31051383 chr16:31043150~31049868:+ CESC cis rs2404602 0.669 rs1875885 ENSG00000259422.1 RP11-593F23.1 5.82 2.11e-08 2.64e-05 0.42 0.37 Blood metabolite levels; chr15:76345740 chr15:76174891~76181486:- CESC cis rs2404602 0.669 rs1875884 ENSG00000259422.1 RP11-593F23.1 5.82 2.11e-08 2.64e-05 0.42 0.37 Blood metabolite levels; chr15:76345820 chr15:76174891~76181486:- CESC cis rs11690935 0.959 rs6724337 ENSG00000228389.1 AC068039.4 5.82 2.11e-08 2.64e-05 0.49 0.37 Schizophrenia; chr2:171878819 chr2:171773482~171775844:+ CESC cis rs274567 0.501 rs272855 ENSG00000233006.5 AC034220.3 5.82 2.11e-08 2.64e-05 0.41 0.37 Blood metabolite levels; chr5:132351482 chr5:132311285~132369916:- CESC cis rs116095464 0.558 rs13354585 ENSG00000250848.1 CTD-2083E4.5 -5.82 2.11e-08 2.65e-05 -0.47 -0.37 Breast cancer; chr5:242148 chr5:288833~290321:- CESC cis rs150992 0.587 rs10076291 ENSG00000248489.1 CTD-2007H13.3 -5.82 2.12e-08 2.65e-05 -0.46 -0.37 Body mass index; chr5:99012954 chr5:98929171~98995013:+ CESC cis rs9399135 0.66 rs4440481 ENSG00000232876.1 CTA-212D2.2 -5.82 2.12e-08 2.65e-05 -0.43 -0.37 Red blood cell count; chr6:134955558 chr6:135055033~135060550:+ CESC cis rs6504950 0.85 rs2628308 ENSG00000275710.1 RP11-257O5.4 -5.82 2.12e-08 2.66e-05 -0.45 -0.37 Breast cancer; chr17:55046212 chr17:54964474~54964679:+ CESC cis rs875971 0.522 rs1617484 ENSG00000164669.11 INTS4P1 -5.82 2.12e-08 2.66e-05 -0.51 -0.37 Aortic root size; chr7:65998108 chr7:65141225~65234216:+ CESC cis rs11096990 0.634 rs10019594 ENSG00000249207.1 RP11-360F5.1 5.82 2.12e-08 2.66e-05 0.39 0.37 Cognitive function; chr4:39287127 chr4:39112677~39126818:- CESC cis rs1891275 0.515 rs7911755 ENSG00000228701.1 TNKS2-AS1 -5.82 2.13e-08 2.66e-05 -0.42 -0.37 Intelligence (multi-trait analysis); chr10:91730060 chr10:91782839~91798291:- CESC cis rs2404602 0.669 rs17464903 ENSG00000259422.1 RP11-593F23.1 5.82 2.14e-08 2.67e-05 0.41 0.37 Blood metabolite levels; chr15:76903145 chr15:76174891~76181486:- CESC cis rs10740039 0.583 rs2170005 ENSG00000254271.1 RP11-131N11.4 5.82 2.14e-08 2.68e-05 0.43 0.37 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740842 chr10:60734342~60741828:+ CESC cis rs3806843 0.966 rs3806842 ENSG00000202111.1 VTRNA1-2 -5.81 2.14e-08 2.68e-05 -0.38 -0.37 Depressive symptoms (multi-trait analysis); chr5:140833091 chr5:140718925~140719013:+ CESC cis rs2108622 0.683 rs56228205 ENSG00000267453.5 AC004791.2 -5.81 2.14e-08 2.68e-05 -0.45 -0.37 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871163 chr19:15851993~15864904:- CESC cis rs9545047 0.716 rs9318638 ENSG00000227676.3 LINC01068 -5.81 2.15e-08 2.68e-05 -0.42 -0.37 Schizophrenia; chr13:79412018 chr13:79566727~79571436:+ CESC cis rs2404602 0.583 rs2456076 ENSG00000259422.1 RP11-593F23.1 -5.81 2.15e-08 2.68e-05 -0.4 -0.37 Blood metabolite levels; chr15:76265212 chr15:76174891~76181486:- CESC cis rs9545047 0.604 rs912639 ENSG00000227676.3 LINC01068 -5.81 2.15e-08 2.69e-05 -0.41 -0.37 Schizophrenia; chr13:79409788 chr13:79566727~79571436:+ CESC cis rs10875746 0.903 rs11168414 ENSG00000240399.1 RP1-228P16.1 -5.81 2.16e-08 2.69e-05 -0.48 -0.37 Longevity (90 years and older); chr12:48118548 chr12:48054813~48055591:- CESC cis rs6951245 0.554 rs58210047 ENSG00000229043.2 AC091729.9 -5.81 2.16e-08 2.7e-05 -0.48 -0.37 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1109745 chr7:1160374~1165267:+ CESC cis rs116095464 0.558 rs62347677 ENSG00000250848.1 CTD-2083E4.5 -5.81 2.16e-08 2.7e-05 -0.47 -0.37 Breast cancer; chr5:227338 chr5:288833~290321:- CESC cis rs10463554 0.892 rs17154859 ENSG00000175749.11 EIF3KP1 -5.81 2.16e-08 2.7e-05 -0.4 -0.37 Parkinson's disease; chr5:102955208 chr5:103032376~103033031:+ CESC cis rs2404602 0.692 rs1116535 ENSG00000259422.1 RP11-593F23.1 -5.81 2.16e-08 2.7e-05 -0.41 -0.37 Blood metabolite levels; chr15:76717173 chr15:76174891~76181486:- CESC cis rs3806843 0.868 rs2531352 ENSG00000202111.1 VTRNA1-2 5.81 2.16e-08 2.7e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140739949 chr5:140718925~140719013:+ CESC cis rs116095464 0.558 rs3213838 ENSG00000250848.1 CTD-2083E4.5 -5.81 2.17e-08 2.71e-05 -0.46 -0.37 Breast cancer; chr5:223775 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6555052 ENSG00000250848.1 CTD-2083E4.5 -5.81 2.17e-08 2.71e-05 -0.46 -0.37 Breast cancer; chr5:224153 chr5:288833~290321:- CESC cis rs116095464 0.558 rs61689490 ENSG00000250848.1 CTD-2083E4.5 -5.81 2.17e-08 2.71e-05 -0.46 -0.37 Breast cancer; chr5:224789 chr5:288833~290321:- CESC cis rs116095464 0.558 rs61492827 ENSG00000250848.1 CTD-2083E4.5 -5.81 2.17e-08 2.71e-05 -0.46 -0.37 Breast cancer; chr5:225659 chr5:288833~290321:- CESC cis rs116095464 0.558 rs56342538 ENSG00000250848.1 CTD-2083E4.5 -5.81 2.17e-08 2.71e-05 -0.46 -0.37 Breast cancer; chr5:225681 chr5:288833~290321:- CESC cis rs11096990 0.634 rs6829064 ENSG00000249207.1 RP11-360F5.1 5.81 2.17e-08 2.71e-05 0.39 0.37 Cognitive function; chr4:39290192 chr4:39112677~39126818:- CESC cis rs875971 0.755 rs76288834 ENSG00000237310.1 GS1-124K5.4 -5.81 2.18e-08 2.73e-05 -0.35 -0.37 Aortic root size; chr7:66604815 chr7:66493706~66495474:+ CESC cis rs12761761 0.739 rs11146471 ENSG00000279982.1 RP11-45A17.3 -5.81 2.21e-08 2.76e-05 -0.5 -0.37 Intelligence (multi-trait analysis);Educational attainment (years of education); chr10:131993114 chr10:131996738~131999846:+ CESC cis rs62229266 0.804 rs2835241 ENSG00000231106.2 LINC01436 -5.81 2.21e-08 2.76e-05 -0.5 -0.37 Mitral valve prolapse; chr21:36039082 chr21:36005338~36007838:+ CESC cis rs9545047 0.604 rs12875039 ENSG00000227676.3 LINC01068 -5.81 2.22e-08 2.76e-05 -0.41 -0.37 Schizophrenia; chr13:79327449 chr13:79566727~79571436:+ CESC cis rs875971 0.798 rs12698522 ENSG00000226824.5 RP4-756H11.3 -5.81 2.22e-08 2.77e-05 -0.46 -0.37 Aortic root size; chr7:66502354 chr7:66654538~66669855:+ CESC cis rs875971 0.83 rs28714531 ENSG00000226824.5 RP4-756H11.3 -5.81 2.22e-08 2.77e-05 -0.46 -0.37 Aortic root size; chr7:66503250 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs12698526 ENSG00000226824.5 RP4-756H11.3 -5.81 2.22e-08 2.77e-05 -0.46 -0.37 Aortic root size; chr7:66504118 chr7:66654538~66669855:+ CESC cis rs7572733 0.935 rs11690205 ENSG00000222017.1 AC011997.1 5.81 2.23e-08 2.78e-05 0.4 0.37 Dermatomyositis; chr2:198069224 chr2:197693106~197774823:+ CESC cis rs875971 0.895 rs6460278 ENSG00000226824.5 RP4-756H11.3 5.81 2.23e-08 2.78e-05 0.46 0.37 Aortic root size; chr7:66197749 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6460279 ENSG00000226824.5 RP4-756H11.3 5.81 2.23e-08 2.78e-05 0.46 0.37 Aortic root size; chr7:66197774 chr7:66654538~66669855:+ CESC cis rs8062405 0.755 rs4788074 ENSG00000259982.1 CDC37P1 -5.81 2.23e-08 2.78e-05 -0.46 -0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582276 chr16:28700294~28701540:- CESC cis rs875971 0.755 rs10228885 ENSG00000226824.5 RP4-756H11.3 5.81 2.23e-08 2.78e-05 0.45 0.37 Aortic root size; chr7:66315542 chr7:66654538~66669855:+ CESC cis rs9549367 0.713 rs3024744 ENSG00000269125.1 RP11-98F14.11 -5.81 2.24e-08 2.79e-05 -0.5 -0.37 Platelet distribution width; chr13:113167163 chr13:113165002~113165183:- CESC cis rs875971 0.862 rs6971059 ENSG00000237310.1 GS1-124K5.4 -5.81 2.25e-08 2.8e-05 -0.35 -0.37 Aortic root size; chr7:66602045 chr7:66493706~66495474:+ CESC cis rs875971 0.789 rs7808013 ENSG00000237310.1 GS1-124K5.4 -5.81 2.25e-08 2.8e-05 -0.35 -0.37 Aortic root size; chr7:66606209 chr7:66493706~66495474:+ CESC cis rs875971 0.825 rs7384021 ENSG00000237310.1 GS1-124K5.4 -5.81 2.25e-08 2.8e-05 -0.35 -0.37 Aortic root size; chr7:66612917 chr7:66493706~66495474:+ CESC cis rs875971 0.825 rs66981195 ENSG00000237310.1 GS1-124K5.4 -5.81 2.25e-08 2.8e-05 -0.35 -0.37 Aortic root size; chr7:66614048 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs3926380 ENSG00000237310.1 GS1-124K5.4 -5.81 2.25e-08 2.8e-05 -0.35 -0.37 Aortic root size; chr7:66615658 chr7:66493706~66495474:+ CESC cis rs6142102 0.923 rs6059586 ENSG00000276073.1 RP5-1125A11.7 -5.81 2.25e-08 2.8e-05 -0.35 -0.37 Skin pigmentation; chr20:33952695 chr20:33985617~33988989:- CESC cis rs2243480 1 rs313820 ENSG00000232559.3 GS1-124K5.12 5.8 2.26e-08 2.81e-05 0.63 0.37 Diabetic kidney disease; chr7:66109479 chr7:66554588~66576923:- CESC cis rs2243480 1 rs313824 ENSG00000232559.3 GS1-124K5.12 5.8 2.26e-08 2.81e-05 0.63 0.37 Diabetic kidney disease; chr7:66116220 chr7:66554588~66576923:- CESC cis rs2243480 1 rs186378 ENSG00000232559.3 GS1-124K5.12 5.8 2.26e-08 2.81e-05 0.63 0.37 Diabetic kidney disease; chr7:66117071 chr7:66554588~66576923:- CESC cis rs2243480 1 rs160637 ENSG00000232559.3 GS1-124K5.12 5.8 2.26e-08 2.81e-05 0.63 0.37 Diabetic kidney disease; chr7:66119331 chr7:66554588~66576923:- CESC cis rs1062177 1 rs2964571 ENSG00000253921.1 CTB-113P19.3 -5.8 2.26e-08 2.81e-05 -0.49 -0.37 Preschool internalizing problems; chr5:151791695 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs2915869 ENSG00000253921.1 CTB-113P19.3 -5.8 2.26e-08 2.81e-05 -0.49 -0.37 Preschool internalizing problems; chr5:151791948 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs2347596 ENSG00000253921.1 CTB-113P19.3 -5.8 2.26e-08 2.81e-05 -0.49 -0.37 Preschool internalizing problems; chr5:151799638 chr5:151753992~151767247:+ CESC cis rs1062177 0.95 rs892005 ENSG00000253921.1 CTB-113P19.3 -5.8 2.26e-08 2.81e-05 -0.49 -0.37 Preschool internalizing problems; chr5:151801060 chr5:151753992~151767247:+ CESC cis rs116095464 0.51 rs73016876 ENSG00000250848.1 CTD-2083E4.5 -5.8 2.26e-08 2.81e-05 -0.47 -0.37 Breast cancer; chr5:244360 chr5:288833~290321:- CESC cis rs11096990 0.656 rs3796513 ENSG00000249207.1 RP11-360F5.1 5.8 2.27e-08 2.82e-05 0.39 0.37 Cognitive function; chr4:39289462 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs10029074 ENSG00000249207.1 RP11-360F5.1 5.8 2.27e-08 2.82e-05 0.39 0.37 Cognitive function; chr4:39290882 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs1564710 ENSG00000249207.1 RP11-360F5.1 5.8 2.27e-08 2.82e-05 0.39 0.37 Cognitive function; chr4:39291178 chr4:39112677~39126818:- CESC cis rs2404602 0.631 rs9646213 ENSG00000259422.1 RP11-593F23.1 5.8 2.27e-08 2.83e-05 0.41 0.37 Blood metabolite levels; chr15:76515331 chr15:76174891~76181486:- CESC cis rs10129255 0.5 rs7157975 ENSG00000223648.3 IGHV3-64 5.8 2.27e-08 2.83e-05 0.31 0.37 Kawasaki disease; chr14:106804049 chr14:106643132~106658258:- CESC cis rs9322193 0.884 rs9688699 ENSG00000268592.3 RAET1E-AS1 5.8 2.29e-08 2.84e-05 0.48 0.37 Lung cancer; chr6:149733680 chr6:149863494~149919507:+ CESC cis rs7572733 1 rs2117339 ENSG00000222017.1 AC011997.1 5.8 2.29e-08 2.85e-05 0.4 0.37 Dermatomyositis; chr2:198051010 chr2:197693106~197774823:+ CESC cis rs1707322 0.682 rs10890334 ENSG00000281133.1 AL355480.3 -5.8 2.29e-08 2.85e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634706 chr1:45580892~45580996:- CESC cis rs1707322 0.682 rs10890335 ENSG00000281133.1 AL355480.3 -5.8 2.29e-08 2.85e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634722 chr1:45580892~45580996:- CESC cis rs1707322 0.716 rs6694889 ENSG00000281133.1 AL355480.3 -5.8 2.29e-08 2.85e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45636134 chr1:45580892~45580996:- CESC cis rs1707322 0.682 rs12041197 ENSG00000281133.1 AL355480.3 -5.8 2.29e-08 2.85e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638792 chr1:45580892~45580996:- CESC cis rs1707322 0.717 rs12023439 ENSG00000281133.1 AL355480.3 -5.8 2.29e-08 2.85e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638964 chr1:45580892~45580996:- CESC cis rs2177312 0.868 rs4280779 ENSG00000251129.1 RP11-734I18.1 -5.8 2.3e-08 2.85e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31959890 chr4:31997397~32155406:+ CESC cis rs2177312 0.761 rs13128834 ENSG00000251129.1 RP11-734I18.1 -5.8 2.3e-08 2.85e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31960440 chr4:31997397~32155406:+ CESC cis rs2177312 0.593 rs55818328 ENSG00000251129.1 RP11-734I18.1 -5.8 2.3e-08 2.85e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31960881 chr4:31997397~32155406:+ CESC cis rs2177312 0.514 rs11730254 ENSG00000251129.1 RP11-734I18.1 -5.8 2.3e-08 2.85e-05 -0.46 -0.37 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31961483 chr4:31997397~32155406:+ CESC cis rs2108622 1 rs62107762 ENSG00000267453.5 AC004791.2 -5.8 2.3e-08 2.85e-05 -0.49 -0.37 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871728 chr19:15851993~15864904:- CESC cis rs6504950 0.925 rs244358 ENSG00000275710.1 RP11-257O5.4 5.8 2.31e-08 2.87e-05 0.48 0.37 Breast cancer; chr17:55114870 chr17:54964474~54964679:+ CESC cis rs950169 0.763 rs35372971 ENSG00000225151.9 GOLGA2P7 -5.8 2.31e-08 2.87e-05 -0.52 -0.37 Schizophrenia; chr15:84387097 chr15:84199311~84230136:- CESC cis rs950169 0.881 rs4842852 ENSG00000225151.9 GOLGA2P7 -5.8 2.31e-08 2.87e-05 -0.52 -0.37 Schizophrenia; chr15:84387263 chr15:84199311~84230136:- CESC cis rs950169 0.84 rs4842853 ENSG00000225151.9 GOLGA2P7 -5.8 2.31e-08 2.87e-05 -0.52 -0.37 Schizophrenia; chr15:84387606 chr15:84199311~84230136:- CESC cis rs950169 0.922 rs4842946 ENSG00000225151.9 GOLGA2P7 -5.8 2.31e-08 2.87e-05 -0.52 -0.37 Schizophrenia; chr15:84387633 chr15:84199311~84230136:- CESC cis rs950169 0.84 rs4842854 ENSG00000225151.9 GOLGA2P7 -5.8 2.31e-08 2.87e-05 -0.52 -0.37 Schizophrenia; chr15:84387641 chr15:84199311~84230136:- CESC cis rs950169 0.887 rs3860265 ENSG00000225151.9 GOLGA2P7 -5.8 2.31e-08 2.87e-05 -0.52 -0.37 Schizophrenia; chr15:84390487 chr15:84199311~84230136:- CESC cis rs950169 0.724 rs11632668 ENSG00000225151.9 GOLGA2P7 -5.8 2.31e-08 2.87e-05 -0.52 -0.37 Schizophrenia; chr15:84393989 chr15:84199311~84230136:- CESC cis rs9399135 0.622 rs3817776 ENSG00000232876.1 CTA-212D2.2 5.8 2.31e-08 2.87e-05 0.41 0.37 Red blood cell count; chr6:134935618 chr6:135055033~135060550:+ CESC cis rs2243480 1 rs431076 ENSG00000232559.3 GS1-124K5.12 5.8 2.32e-08 2.88e-05 0.63 0.37 Diabetic kidney disease; chr7:66135333 chr7:66554588~66576923:- CESC cis rs2243480 1 rs2460422 ENSG00000232559.3 GS1-124K5.12 5.8 2.32e-08 2.88e-05 0.63 0.37 Diabetic kidney disease; chr7:66136518 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316334 ENSG00000232559.3 GS1-124K5.12 5.8 2.32e-08 2.88e-05 0.63 0.37 Diabetic kidney disease; chr7:66137139 chr7:66554588~66576923:- CESC cis rs6504622 0.755 rs34774205 ENSG00000262879.4 RP11-156P1.3 -5.8 2.32e-08 2.88e-05 -0.4 -0.37 Orofacial clefts; chr17:47083453 chr17:46984045~47100323:- CESC cis rs9322193 0.962 rs9478848 ENSG00000268592.3 RAET1E-AS1 5.8 2.32e-08 2.88e-05 0.46 0.37 Lung cancer; chr6:149825080 chr6:149863494~149919507:+ CESC cis rs2404602 0.692 rs35999717 ENSG00000259422.1 RP11-593F23.1 5.8 2.32e-08 2.88e-05 0.41 0.37 Blood metabolite levels; chr15:76901026 chr15:76174891~76181486:- CESC cis rs4423214 0.879 rs1792281 ENSG00000254682.1 RP11-660L16.2 -5.8 2.34e-08 2.9e-05 -0.49 -0.37 Vitamin D levels; chr11:71424450 chr11:71448674~71452157:+ CESC cis rs75422866 0.867 rs73104103 ENSG00000257433.4 RP1-197B17.3 5.8 2.34e-08 2.9e-05 0.84 0.37 Pneumonia; chr12:47669604 chr12:47706085~47742294:+ CESC cis rs2442825 0.693 rs1054975 ENSG00000206573.7 THUMPD3-AS1 5.8 2.34e-08 2.9e-05 0.35 0.37 Cerebrospinal fluid clusterin levels; chr3:9365152 chr3:9349689~9398579:- CESC cis rs2243480 0.901 rs12530490 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66226660 chr7:66554588~66576923:- CESC cis rs2243480 1 rs7778911 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66229519 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1979823 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66239626 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6964245 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66253730 chr7:66554588~66576923:- CESC cis rs2243480 1 rs10807701 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66259699 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1499613 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66265873 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1553174 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66266207 chr7:66554588~66576923:- CESC cis rs2243480 1 rs10950032 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66273604 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6958420 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66286184 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1392104 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66294120 chr7:66554588~66576923:- CESC cis rs2243480 1 rs4718333 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66307771 chr7:66554588~66576923:- CESC cis rs2243480 1 rs7792391 ENSG00000232559.3 GS1-124K5.12 -5.8 2.34e-08 2.9e-05 -0.63 -0.37 Diabetic kidney disease; chr7:66308442 chr7:66554588~66576923:- CESC cis rs950169 0.84 rs2896002 ENSG00000225151.9 GOLGA2P7 -5.8 2.35e-08 2.91e-05 -0.52 -0.37 Schizophrenia; chr15:84390423 chr15:84199311~84230136:- CESC cis rs897984 0.542 rs3751855 ENSG00000260911.2 RP11-196G11.2 5.8 2.35e-08 2.91e-05 0.38 0.37 Dementia with Lewy bodies; chr16:31079888 chr16:31043150~31049868:+ CESC cis rs2280018 0.526 rs2966129 ENSG00000260735.1 RP11-72I8.1 5.8 2.36e-08 2.92e-05 0.41 0.37 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059070 chr16:15094411~15109197:+ CESC cis rs2243480 1 rs778729 ENSG00000232559.3 GS1-124K5.12 5.8 2.36e-08 2.92e-05 0.63 0.37 Diabetic kidney disease; chr7:66359432 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs778687 ENSG00000232559.3 GS1-124K5.12 5.8 2.36e-08 2.92e-05 0.63 0.37 Diabetic kidney disease; chr7:66370832 chr7:66554588~66576923:- CESC cis rs2243480 1 rs778679 ENSG00000232559.3 GS1-124K5.12 5.8 2.36e-08 2.92e-05 0.63 0.37 Diabetic kidney disease; chr7:66375924 chr7:66554588~66576923:- CESC cis rs2243480 1 rs778704 ENSG00000232559.3 GS1-124K5.12 5.8 2.36e-08 2.92e-05 0.63 0.37 Diabetic kidney disease; chr7:66398480 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs778693 ENSG00000232559.3 GS1-124K5.12 5.8 2.36e-08 2.92e-05 0.63 0.37 Diabetic kidney disease; chr7:66407358 chr7:66554588~66576923:- CESC cis rs2243480 1 rs778691 ENSG00000232559.3 GS1-124K5.12 5.8 2.36e-08 2.92e-05 0.63 0.37 Diabetic kidney disease; chr7:66408105 chr7:66554588~66576923:- CESC cis rs2243480 1 rs13235972 ENSG00000232559.3 GS1-124K5.12 5.8 2.36e-08 2.92e-05 0.63 0.37 Diabetic kidney disease; chr7:66418618 chr7:66554588~66576923:- CESC cis rs2243480 1 rs34192067 ENSG00000232559.3 GS1-124K5.12 5.8 2.36e-08 2.92e-05 0.63 0.37 Diabetic kidney disease; chr7:66422670 chr7:66554588~66576923:- CESC cis rs2117029 0.555 rs7978448 ENSG00000258017.1 RP11-386G11.10 -5.8 2.36e-08 2.92e-05 -0.47 -0.37 Intelligence (multi-trait analysis); chr12:49113157 chr12:49127782~49147869:+ CESC cis rs6700559 0.81 rs10399615 ENSG00000260088.1 RP11-92G12.3 5.8 2.37e-08 2.93e-05 0.46 0.37 Coronary artery disease; chr1:200626145 chr1:200669507~200694250:+ CESC cis rs801193 0.548 rs6975044 ENSG00000226824.5 RP4-756H11.3 -5.8 2.37e-08 2.93e-05 -0.46 -0.37 Aortic root size; chr7:66762495 chr7:66654538~66669855:+ CESC cis rs6504950 0.925 rs8082622 ENSG00000275710.1 RP11-257O5.4 -5.79 2.37e-08 2.94e-05 -0.44 -0.37 Breast cancer; chr17:55100206 chr17:54964474~54964679:+ CESC cis rs6504950 0.925 rs244377 ENSG00000275710.1 RP11-257O5.4 -5.79 2.37e-08 2.94e-05 -0.44 -0.37 Breast cancer; chr17:55105718 chr17:54964474~54964679:+ CESC cis rs7684253 0.587 rs4339274 ENSG00000269949.1 RP11-738E22.3 5.79 2.37e-08 2.94e-05 0.42 0.37 Migraine; chr4:56881468 chr4:56960927~56961373:- CESC cis rs9545047 0.604 rs9318640 ENSG00000227676.3 LINC01068 -5.79 2.38e-08 2.95e-05 -0.41 -0.37 Schizophrenia; chr13:79426527 chr13:79566727~79571436:+ CESC cis rs116095464 0.558 rs10043002 ENSG00000250848.1 CTD-2083E4.5 -5.79 2.39e-08 2.95e-05 -0.47 -0.37 Breast cancer; chr5:226638 chr5:288833~290321:- CESC cis rs3738443 0.594 rs60050650 ENSG00000259865.1 RP11-488L18.10 5.79 2.39e-08 2.95e-05 0.34 0.37 Alcohol dependence; chr1:247213474 chr1:247187281~247188526:- CESC cis rs992157 0.71 rs6752254 ENSG00000261338.2 RP11-378A13.1 5.79 2.39e-08 2.95e-05 0.46 0.37 Colorectal cancer; chr2:218194020 chr2:218255319~218257366:+ CESC cis rs34779708 0.966 rs2045915 ENSG00000230534.5 RP11-297A16.2 5.79 2.39e-08 2.96e-05 0.49 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35129688 chr10:35098006~35127020:- CESC cis rs3806843 0.9 rs2563286 ENSG00000202111.1 VTRNA1-2 5.79 2.4e-08 2.96e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140745614 chr5:140718925~140719013:+ CESC cis rs950169 1 rs1818950 ENSG00000225151.9 GOLGA2P7 -5.79 2.4e-08 2.96e-05 -0.52 -0.37 Schizophrenia; chr15:84053769 chr15:84199311~84230136:- CESC cis rs3806843 0.868 rs2531345 ENSG00000202111.1 VTRNA1-2 5.79 2.4e-08 2.96e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140747196 chr5:140718925~140719013:+ CESC cis rs3806843 0.864 rs2531343 ENSG00000202111.1 VTRNA1-2 5.79 2.4e-08 2.96e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140749761 chr5:140718925~140719013:+ CESC cis rs3806843 0.9 rs2531341 ENSG00000202111.1 VTRNA1-2 5.79 2.4e-08 2.96e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140751309 chr5:140718925~140719013:+ CESC cis rs3806843 0.9 rs2531340 ENSG00000202111.1 VTRNA1-2 5.79 2.4e-08 2.96e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140751461 chr5:140718925~140719013:+ CESC cis rs3806843 0.868 rs2563281 ENSG00000202111.1 VTRNA1-2 5.79 2.4e-08 2.96e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140751634 chr5:140718925~140719013:+ CESC cis rs3806843 0.9 rs2563280 ENSG00000202111.1 VTRNA1-2 5.79 2.4e-08 2.96e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140751945 chr5:140718925~140719013:+ CESC cis rs3806843 0.838 rs2262567 ENSG00000202111.1 VTRNA1-2 5.79 2.4e-08 2.96e-05 0.37 0.37 Depressive symptoms (multi-trait analysis); chr5:140752549 chr5:140718925~140719013:+ CESC cis rs11096990 0.656 rs2123027 ENSG00000249207.1 RP11-360F5.1 5.79 2.4e-08 2.96e-05 0.39 0.37 Cognitive function; chr4:39289493 chr4:39112677~39126818:- CESC cis rs2243480 1 rs316322 ENSG00000232559.3 GS1-124K5.12 5.79 2.4e-08 2.96e-05 0.62 0.37 Diabetic kidney disease; chr7:66146246 chr7:66554588~66576923:- CESC cis rs34779708 1 rs12769189 ENSG00000230534.5 RP11-297A16.2 5.79 2.41e-08 2.97e-05 0.48 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35110740 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs11599606 ENSG00000230534.5 RP11-297A16.2 5.79 2.41e-08 2.97e-05 0.48 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35117698 chr10:35098006~35127020:- CESC cis rs1707322 0.717 rs1135812 ENSG00000281133.1 AL355480.3 -5.79 2.43e-08 2.99e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629600 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs6703748 ENSG00000281133.1 AL355480.3 -5.79 2.43e-08 2.99e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45630304 chr1:45580892~45580996:- CESC cis rs6452524 0.506 rs7891 ENSG00000249664.1 CTD-2227C6.2 5.79 2.43e-08 3e-05 0.42 0.37 Hypertension (SNP x SNP interaction); chr5:83053558 chr5:83012285~83013109:- CESC cis rs8062405 0.755 rs4787457 ENSG00000259982.1 CDC37P1 5.79 2.43e-08 3e-05 0.46 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544079 chr16:28700294~28701540:- CESC cis rs1823913 0.637 rs4853583 ENSG00000280083.1 RP11-317J9.1 5.79 2.43e-08 3e-05 0.42 0.37 Obesity-related traits; chr2:191304648 chr2:191154118~191156070:- CESC cis rs2404602 0.716 rs4886813 ENSG00000259422.1 RP11-593F23.1 -5.79 2.44e-08 3e-05 -0.4 -0.37 Blood metabolite levels; chr15:76545880 chr15:76174891~76181486:- CESC cis rs765787 0.53 rs3759893 ENSG00000259520.4 CTD-2651B20.3 5.79 2.44e-08 3.01e-05 0.45 0.37 Uric acid levels; chr15:45250752 chr15:45251580~45279251:- CESC cis rs2404602 0.967 rs7174096 ENSG00000259422.1 RP11-593F23.1 5.79 2.44e-08 3.01e-05 0.41 0.37 Blood metabolite levels; chr15:76780059 chr15:76174891~76181486:- CESC cis rs2929278 0.617 rs524908 ENSG00000205771.5 CATSPER2P1 5.79 2.44e-08 3.01e-05 0.41 0.37 Schizophrenia; chr15:43895793 chr15:43726918~43747094:- CESC cis rs6991838 0.584 rs3765205 ENSG00000200714.1 Y_RNA -5.79 2.44e-08 3.01e-05 -0.44 -0.37 Intelligence (multi-trait analysis); chr8:65605251 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs7841652 ENSG00000200714.1 Y_RNA -5.79 2.44e-08 3.01e-05 -0.44 -0.37 Intelligence (multi-trait analysis); chr8:65606392 chr8:65592731~65592820:+ CESC cis rs6991838 0.53 rs35038843 ENSG00000200714.1 Y_RNA -5.79 2.44e-08 3.01e-05 -0.44 -0.37 Intelligence (multi-trait analysis); chr8:65610263 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs4737748 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65613630 chr8:65592731~65592820:+ CESC cis rs6991838 0.55 rs12335006 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65619394 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs10957361 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65619626 chr8:65592731~65592820:+ CESC cis rs6991838 0.612 rs12335276 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65619668 chr8:65592731~65592820:+ CESC cis rs6991838 0.612 rs7832407 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65621071 chr8:65592731~65592820:+ CESC cis rs6991838 0.551 rs7007505 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65621719 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs7012856 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65622740 chr8:65592731~65592820:+ CESC cis rs6991838 0.55 rs7817112 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65624885 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs2048650 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65625664 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs4737749 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65627672 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs10092109 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65627683 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs6997959 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65628247 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs7814841 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65629328 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs11985628 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65630504 chr8:65592731~65592820:+ CESC cis rs6991838 0.557 rs13266834 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65631303 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs13268343 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65631742 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs7835313 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65633891 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs3812412 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65634857 chr8:65592731~65592820:+ CESC cis rs6991838 0.53 rs6472217 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65635496 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs6472218 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65635502 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs1533285 ENSG00000200714.1 Y_RNA 5.79 2.44e-08 3.01e-05 0.44 0.37 Intelligence (multi-trait analysis); chr8:65637129 chr8:65592731~65592820:+ CESC cis rs1062177 0.756 rs2964591 ENSG00000213433.5 RPLP1P6 5.79 2.45e-08 3.01e-05 0.45 0.37 Preschool internalizing problems; chr5:151737836 chr5:151765859~151766378:- CESC cis rs2404602 0.692 rs7169663 ENSG00000259422.1 RP11-593F23.1 5.79 2.45e-08 3.01e-05 0.41 0.37 Blood metabolite levels; chr15:76900502 chr15:76174891~76181486:- CESC cis rs1707322 0.752 rs7541962 ENSG00000281133.1 AL355480.3 -5.79 2.45e-08 3.01e-05 -0.44 -0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769445 chr1:45580892~45580996:- CESC cis rs9545047 0.604 rs9565487 ENSG00000227676.3 LINC01068 -5.79 2.45e-08 3.02e-05 -0.41 -0.37 Schizophrenia; chr13:79332742 chr13:79566727~79571436:+ CESC cis rs875971 1 rs2220626 ENSG00000222364.1 RNU6-96P 5.79 2.45e-08 3.02e-05 0.44 0.36 Aortic root size; chr7:66081075 chr7:66395191~66395286:+ CESC cis rs8072100 0.967 rs9894905 ENSG00000228782.6 CTD-2026D20.3 5.79 2.46e-08 3.02e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47408616 chr17:47450568~47492492:- CESC cis rs2442825 0.693 rs2648523 ENSG00000206573.7 THUMPD3-AS1 5.79 2.46e-08 3.03e-05 0.35 0.36 Cerebrospinal fluid clusterin levels; chr3:9370654 chr3:9349689~9398579:- CESC cis rs12022452 0.822 rs7545012 ENSG00000238287.1 RP11-656D10.3 5.79 2.46e-08 3.03e-05 0.52 0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40562178 chr1:40493157~40508661:- CESC cis rs116095464 0.558 rs6555055 ENSG00000250848.1 CTD-2083E4.5 -5.79 2.47e-08 3.04e-05 -0.46 -0.36 Breast cancer; chr5:226045 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6555056 ENSG00000250848.1 CTD-2083E4.5 -5.79 2.47e-08 3.04e-05 -0.46 -0.36 Breast cancer; chr5:226107 chr5:288833~290321:- CESC cis rs10129255 0.5 rs8011115 ENSG00000223648.3 IGHV3-64 5.79 2.48e-08 3.05e-05 0.31 0.36 Kawasaki disease; chr14:106786292 chr14:106643132~106658258:- CESC cis rs2404602 0.669 rs12916324 ENSG00000259422.1 RP11-593F23.1 5.79 2.48e-08 3.05e-05 0.41 0.36 Blood metabolite levels; chr15:76887262 chr15:76174891~76181486:- CESC cis rs720475 0.732 rs17172978 ENSG00000204959.4 ARHGEF34P -5.79 2.48e-08 3.05e-05 -0.41 -0.36 Breast cancer; chr7:144429551 chr7:144272445~144286966:- CESC cis rs2404602 0.967 rs7167613 ENSG00000259422.1 RP11-593F23.1 5.79 2.49e-08 3.06e-05 0.41 0.36 Blood metabolite levels; chr15:76748851 chr15:76174891~76181486:- CESC cis rs992157 0.835 rs2271543 ENSG00000261338.2 RP11-378A13.1 -5.79 2.49e-08 3.06e-05 -0.48 -0.36 Colorectal cancer; chr2:218277768 chr2:218255319~218257366:+ CESC cis rs992157 0.717 rs3817266 ENSG00000261338.2 RP11-378A13.1 -5.79 2.49e-08 3.06e-05 -0.48 -0.36 Colorectal cancer; chr2:218277871 chr2:218255319~218257366:+ CESC cis rs992157 0.835 rs2292551 ENSG00000261338.2 RP11-378A13.1 -5.79 2.49e-08 3.06e-05 -0.48 -0.36 Colorectal cancer; chr2:218278506 chr2:218255319~218257366:+ CESC cis rs992157 0.835 rs12987180 ENSG00000261338.2 RP11-378A13.1 -5.79 2.49e-08 3.06e-05 -0.48 -0.36 Colorectal cancer; chr2:218279366 chr2:218255319~218257366:+ CESC cis rs992157 0.835 rs12987219 ENSG00000261338.2 RP11-378A13.1 -5.79 2.49e-08 3.06e-05 -0.48 -0.36 Colorectal cancer; chr2:218279426 chr2:218255319~218257366:+ CESC cis rs992157 0.835 rs4674283 ENSG00000261338.2 RP11-378A13.1 -5.79 2.49e-08 3.06e-05 -0.48 -0.36 Colorectal cancer; chr2:218279531 chr2:218255319~218257366:+ CESC cis rs992157 0.835 rs2045434 ENSG00000261338.2 RP11-378A13.1 -5.79 2.49e-08 3.06e-05 -0.48 -0.36 Colorectal cancer; chr2:218279775 chr2:218255319~218257366:+ CESC cis rs6504950 0.72 rs12602751 ENSG00000275710.1 RP11-257O5.4 5.79 2.5e-08 3.07e-05 0.42 0.36 Breast cancer; chr17:54916813 chr17:54964474~54964679:+ CESC cis rs9907295 0.688 rs9890583 ENSG00000270977.1 AC015849.16 -5.79 2.5e-08 3.07e-05 -0.49 -0.36 Fibroblast growth factor basic levels; chr17:35919389 chr17:35893707~35911023:- CESC cis rs875971 0.862 rs11765791 ENSG00000226824.5 RP4-756H11.3 -5.78 2.5e-08 3.07e-05 -0.46 -0.36 Aortic root size; chr7:66471587 chr7:66654538~66669855:+ CESC cis rs11690935 0.918 rs12692978 ENSG00000228389.1 AC068039.4 5.78 2.5e-08 3.07e-05 0.51 0.36 Schizophrenia; chr2:171869471 chr2:171773482~171775844:+ CESC cis rs2404602 0.692 rs12904198 ENSG00000259422.1 RP11-593F23.1 5.78 2.51e-08 3.08e-05 0.41 0.36 Blood metabolite levels; chr15:76854637 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs2137307 ENSG00000259422.1 RP11-593F23.1 5.78 2.51e-08 3.08e-05 0.41 0.36 Blood metabolite levels; chr15:76856679 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs12594556 ENSG00000259422.1 RP11-593F23.1 5.78 2.51e-08 3.08e-05 0.41 0.36 Blood metabolite levels; chr15:76873022 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs12595586 ENSG00000259422.1 RP11-593F23.1 5.78 2.51e-08 3.08e-05 0.41 0.36 Blood metabolite levels; chr15:76879869 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs4360890 ENSG00000259422.1 RP11-593F23.1 5.78 2.51e-08 3.08e-05 0.41 0.36 Blood metabolite levels; chr15:76880954 chr15:76174891~76181486:- CESC cis rs2177312 0.83 rs2030586 ENSG00000251129.1 RP11-734I18.1 -5.78 2.51e-08 3.08e-05 -0.46 -0.36 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31936771 chr4:31997397~32155406:+ CESC cis rs7572733 0.765 rs2164068 ENSG00000222017.1 AC011997.1 5.78 2.51e-08 3.08e-05 0.4 0.36 Dermatomyositis; chr2:198079128 chr2:197693106~197774823:+ CESC cis rs992157 0.661 rs17653757 ENSG00000261338.2 RP11-378A13.1 5.78 2.51e-08 3.08e-05 0.44 0.36 Colorectal cancer; chr2:218244641 chr2:218255319~218257366:+ CESC cis rs8062405 0.755 rs12447461 ENSG00000259982.1 CDC37P1 5.78 2.51e-08 3.08e-05 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28571620 chr16:28700294~28701540:- CESC cis rs2442825 0.693 rs2648536 ENSG00000206573.7 THUMPD3-AS1 5.78 2.54e-08 3.11e-05 0.36 0.36 Cerebrospinal fluid clusterin levels; chr3:9365338 chr3:9349689~9398579:- CESC cis rs2581828 0.656 rs2581786 ENSG00000242142.1 SERBP1P3 5.78 2.54e-08 3.12e-05 0.4 0.36 Crohn's disease; chr3:53092127 chr3:53064283~53065091:- CESC cis rs950169 0.919 rs17300292 ENSG00000225151.9 GOLGA2P7 -5.78 2.54e-08 3.12e-05 -0.51 -0.36 Schizophrenia; chr15:84093816 chr15:84199311~84230136:- CESC cis rs950169 1 rs12916348 ENSG00000225151.9 GOLGA2P7 -5.78 2.54e-08 3.12e-05 -0.51 -0.36 Schizophrenia; chr15:84096775 chr15:84199311~84230136:- CESC cis rs6452524 1 rs10474094 ENSG00000249664.1 CTD-2227C6.2 5.78 2.54e-08 3.12e-05 0.4 0.36 Hypertension (SNP x SNP interaction); chr5:83154678 chr5:83012285~83013109:- CESC cis rs6991838 0.584 rs6994213 ENSG00000200714.1 Y_RNA -5.78 2.55e-08 3.12e-05 -0.44 -0.36 Intelligence (multi-trait analysis); chr8:65601497 chr8:65592731~65592820:+ CESC cis rs2739330 0.828 rs5760107 ENSG00000272787.1 KB-226F1.2 -5.78 2.56e-08 3.14e-05 -0.39 -0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23969211~23969873:+ CESC cis rs2739330 0.789 rs5760109 ENSG00000272787.1 KB-226F1.2 -5.78 2.56e-08 3.14e-05 -0.39 -0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23969211~23969873:+ CESC cis rs2404602 0.716 rs1125932 ENSG00000259422.1 RP11-593F23.1 5.78 2.56e-08 3.14e-05 0.41 0.36 Blood metabolite levels; chr15:76528199 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs66754747 ENSG00000259422.1 RP11-593F23.1 5.78 2.56e-08 3.14e-05 0.41 0.36 Blood metabolite levels; chr15:76536227 chr15:76174891~76181486:- CESC cis rs8072100 0.967 rs4338849 ENSG00000228782.6 CTD-2026D20.3 5.78 2.57e-08 3.14e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47435117 chr17:47450568~47492492:- CESC cis rs2243480 1 rs1638734 ENSG00000232559.3 GS1-124K5.12 5.78 2.57e-08 3.15e-05 0.63 0.36 Diabetic kidney disease; chr7:66632552 chr7:66554588~66576923:- CESC cis rs1499614 1 rs1267818 ENSG00000232559.3 GS1-124K5.12 5.78 2.57e-08 3.15e-05 0.63 0.36 Gout; chr7:66642037 chr7:66554588~66576923:- CESC cis rs1499614 1 rs1267817 ENSG00000232559.3 GS1-124K5.12 5.78 2.57e-08 3.15e-05 0.63 0.36 Gout; chr7:66645053 chr7:66554588~66576923:- CESC cis rs34779708 0.966 rs4934725 ENSG00000230534.5 RP11-297A16.2 5.78 2.57e-08 3.15e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35109308 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs12774834 ENSG00000230534.5 RP11-297A16.2 5.78 2.57e-08 3.15e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35111142 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs12775759 ENSG00000230534.5 RP11-297A16.2 5.78 2.57e-08 3.15e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35111255 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs34296409 ENSG00000230534.5 RP11-297A16.2 5.78 2.57e-08 3.15e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35115685 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs35777088 ENSG00000230534.5 RP11-297A16.2 5.78 2.57e-08 3.15e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35120120 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs11592567 ENSG00000230534.5 RP11-297A16.2 5.78 2.57e-08 3.15e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35120441 chr10:35098006~35127020:- CESC cis rs1062177 0.694 rs2915816 ENSG00000213433.5 RPLP1P6 5.78 2.58e-08 3.15e-05 0.43 0.36 Preschool internalizing problems; chr5:151736296 chr5:151765859~151766378:- CESC cis rs765787 0.53 rs2413776 ENSG00000259520.4 CTD-2651B20.3 5.78 2.58e-08 3.16e-05 0.45 0.36 Uric acid levels; chr15:45251972 chr15:45251580~45279251:- CESC cis rs34779708 0.966 rs10827487 ENSG00000230534.5 RP11-297A16.2 5.78 2.58e-08 3.16e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35117950 chr10:35098006~35127020:- CESC cis rs1891275 0.515 rs2421694 ENSG00000228701.1 TNKS2-AS1 -5.78 2.59e-08 3.17e-05 -0.43 -0.36 Intelligence (multi-trait analysis); chr10:91756347 chr10:91782839~91798291:- CESC cis rs12022452 0.822 rs7514623 ENSG00000238287.1 RP11-656D10.3 -5.78 2.59e-08 3.17e-05 -0.53 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40559330 chr1:40493157~40508661:- CESC cis rs6504950 0.925 rs2787497 ENSG00000275710.1 RP11-257O5.4 -5.78 2.6e-08 3.18e-05 -0.47 -0.36 Breast cancer; chr17:55098850 chr17:54964474~54964679:+ CESC cis rs6504950 0.925 rs181727 ENSG00000275710.1 RP11-257O5.4 5.78 2.6e-08 3.18e-05 0.47 0.36 Breast cancer; chr17:55113634 chr17:54964474~54964679:+ CESC cis rs116095464 0.558 rs2162870 ENSG00000250848.1 CTD-2083E4.5 -5.78 2.6e-08 3.18e-05 -0.46 -0.36 Breast cancer; chr5:228014 chr5:288833~290321:- CESC cis rs116095464 0.558 rs28729548 ENSG00000250848.1 CTD-2083E4.5 -5.78 2.6e-08 3.18e-05 -0.46 -0.36 Breast cancer; chr5:228910 chr5:288833~290321:- CESC cis rs116095464 0.558 rs9688136 ENSG00000250848.1 CTD-2083E4.5 -5.78 2.6e-08 3.18e-05 -0.46 -0.36 Breast cancer; chr5:229233 chr5:288833~290321:- CESC cis rs116095464 0.558 rs62347683 ENSG00000250848.1 CTD-2083E4.5 -5.78 2.6e-08 3.18e-05 -0.46 -0.36 Breast cancer; chr5:230216 chr5:288833~290321:- CESC cis rs116095464 0.51 rs55750776 ENSG00000250848.1 CTD-2083E4.5 -5.78 2.6e-08 3.18e-05 -0.46 -0.36 Breast cancer; chr5:230352 chr5:288833~290321:- CESC cis rs116095464 0.764 rs10069197 ENSG00000250848.1 CTD-2083E4.5 -5.78 2.6e-08 3.18e-05 -0.46 -0.36 Breast cancer; chr5:230707 chr5:288833~290321:- CESC cis rs6452524 1 rs9293334 ENSG00000249664.1 CTD-2227C6.2 5.78 2.6e-08 3.18e-05 0.4 0.36 Hypertension (SNP x SNP interaction); chr5:83156984 chr5:83012285~83013109:- CESC cis rs875971 1 rs697970 ENSG00000222364.1 RNU6-96P 5.78 2.6e-08 3.18e-05 0.44 0.36 Aortic root size; chr7:66095065 chr7:66395191~66395286:+ CESC cis rs1823913 0.599 rs1378155 ENSG00000280083.1 RP11-317J9.1 -5.78 2.61e-08 3.18e-05 -0.42 -0.36 Obesity-related traits; chr2:191266610 chr2:191154118~191156070:- CESC cis rs2929278 0.617 rs11070410 ENSG00000205771.5 CATSPER2P1 5.78 2.61e-08 3.18e-05 0.43 0.36 Schizophrenia; chr15:43764847 chr15:43726918~43747094:- CESC cis rs2729354 1 rs2729354 ENSG00000265566.2 RN7SL605P -5.78 2.61e-08 3.19e-05 -0.53 -0.36 Blood protein levels; chr11:57588497 chr11:57528085~57528365:- CESC cis rs2243480 1 rs316330 ENSG00000232559.3 GS1-124K5.12 5.78 2.62e-08 3.19e-05 0.62 0.36 Diabetic kidney disease; chr7:66140385 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316326 ENSG00000232559.3 GS1-124K5.12 5.78 2.62e-08 3.19e-05 0.62 0.36 Diabetic kidney disease; chr7:66144466 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316325 ENSG00000232559.3 GS1-124K5.12 5.78 2.62e-08 3.19e-05 0.62 0.36 Diabetic kidney disease; chr7:66144531 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316321 ENSG00000232559.3 GS1-124K5.12 5.78 2.62e-08 3.19e-05 0.62 0.36 Diabetic kidney disease; chr7:66146626 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316318 ENSG00000232559.3 GS1-124K5.12 5.78 2.62e-08 3.19e-05 0.62 0.36 Diabetic kidney disease; chr7:66147917 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316317 ENSG00000232559.3 GS1-124K5.12 5.78 2.62e-08 3.19e-05 0.62 0.36 Diabetic kidney disease; chr7:66148650 chr7:66554588~66576923:- CESC cis rs11096990 0.613 rs4974996 ENSG00000249207.1 RP11-360F5.1 -5.78 2.62e-08 3.19e-05 -0.4 -0.36 Cognitive function; chr4:39225928 chr4:39112677~39126818:- CESC cis rs11096990 0.593 rs1026235 ENSG00000249207.1 RP11-360F5.1 -5.78 2.62e-08 3.19e-05 -0.4 -0.36 Cognitive function; chr4:39226629 chr4:39112677~39126818:- CESC cis rs2404602 0.692 rs12910734 ENSG00000259422.1 RP11-593F23.1 5.78 2.62e-08 3.19e-05 0.41 0.36 Blood metabolite levels; chr15:76857590 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs12911174 ENSG00000259422.1 RP11-593F23.1 5.78 2.62e-08 3.19e-05 0.41 0.36 Blood metabolite levels; chr15:76857602 chr15:76174891~76181486:- CESC cis rs2177312 0.868 rs4600961 ENSG00000251129.1 RP11-734I18.1 5.78 2.62e-08 3.19e-05 0.46 0.36 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31947858 chr4:31997397~32155406:+ CESC cis rs950169 0.922 rs4338765 ENSG00000225151.9 GOLGA2P7 -5.78 2.62e-08 3.2e-05 -0.52 -0.36 Schizophrenia; chr15:84248084 chr15:84199311~84230136:- CESC cis rs34779708 0.931 rs4934724 ENSG00000230534.5 RP11-297A16.2 5.78 2.62e-08 3.2e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35104741 chr10:35098006~35127020:- CESC cis rs35955747 0.869 rs28715 ENSG00000236132.1 CTA-440B3.1 -5.78 2.63e-08 3.21e-05 -0.42 -0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31334183 chr22:31816379~31817491:- CESC cis rs1823913 0.637 rs1470962 ENSG00000280083.1 RP11-317J9.1 5.77 2.63e-08 3.21e-05 0.41 0.36 Obesity-related traits; chr2:191270271 chr2:191154118~191156070:- CESC cis rs765787 0.53 rs16941017 ENSG00000259520.4 CTD-2651B20.3 5.77 2.64e-08 3.23e-05 0.45 0.36 Uric acid levels; chr15:45251083 chr15:45251580~45279251:- CESC cis rs1707322 0.964 rs1768802 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46082196 chr1:45581219~45581321:- CESC cis rs1707322 1 rs1588663 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083153 chr1:45581219~45581321:- CESC cis rs1707322 1 rs1768801 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083465 chr1:45581219~45581321:- CESC cis rs1707322 1 rs1768800 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083516 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs785483 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46093499 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs796773 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46098803 chr1:45581219~45581321:- CESC cis rs1707322 0.896 rs785518 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46102750 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785519 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46102890 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785486 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46109476 chr1:45581219~45581321:- CESC cis rs1707322 0.865 rs785501 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46113939 chr1:45581219~45581321:- CESC cis rs1707322 0.929 rs785500 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46127372 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785504 ENSG00000280836.1 AL355480.1 5.77 2.65e-08 3.23e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46130024 chr1:45581219~45581321:- CESC cis rs35955747 0.869 rs7286648 ENSG00000236132.1 CTA-440B3.1 -5.77 2.65e-08 3.24e-05 -0.41 -0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31143628 chr22:31816379~31817491:- CESC cis rs5769707 0.632 rs135872 ENSG00000188511.11 C22orf34 5.77 2.67e-08 3.25e-05 0.43 0.36 Monocyte percentage of white cells;Monocyte count; chr22:49615652 chr22:49414524~49657542:- CESC cis rs3806843 0.801 rs801171 ENSG00000202111.1 VTRNA1-2 5.77 2.67e-08 3.26e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140735718 chr5:140718925~140719013:+ CESC cis rs875971 0.825 rs1860472 ENSG00000237310.1 GS1-124K5.4 -5.77 2.67e-08 3.26e-05 -0.35 -0.36 Aortic root size; chr7:66617736 chr7:66493706~66495474:+ CESC cis rs17507216 0.958 rs28648832 ENSG00000278603.1 RP13-608F4.5 5.77 2.67e-08 3.26e-05 0.58 0.36 Excessive daytime sleepiness; chr15:82567642 chr15:82472203~82472426:+ CESC cis rs12550612 0.614 rs4268128 ENSG00000253616.4 RP11-875O11.3 5.77 2.68e-08 3.26e-05 0.54 0.36 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23080343 chr8:23071377~23074488:- CESC cis rs2929278 0.589 rs2411284 ENSG00000205771.5 CATSPER2P1 5.77 2.71e-08 3.29e-05 0.43 0.36 Schizophrenia; chr15:43746701 chr15:43726918~43747094:- CESC cis rs35955747 0.902 rs131202 ENSG00000236132.1 CTA-440B3.1 -5.77 2.72e-08 3.31e-05 -0.43 -0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31313323 chr22:31816379~31817491:- CESC cis rs34779708 0.931 rs12776390 ENSG00000230534.5 RP11-297A16.2 5.77 2.73e-08 3.31e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35102607 chr10:35098006~35127020:- CESC cis rs2739330 0.685 rs4822453 ENSG00000250470.1 AP000351.3 5.77 2.73e-08 3.32e-05 0.46 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23976904~23977585:- CESC cis rs11676348 0.818 rs6436031 ENSG00000261338.2 RP11-378A13.1 -5.77 2.73e-08 3.32e-05 -0.43 -0.36 Ulcerative colitis; chr2:218114536 chr2:218255319~218257366:+ CESC cis rs4718428 0.705 rs11028 ENSG00000226824.5 RP4-756H11.3 -5.77 2.74e-08 3.33e-05 -0.5 -0.36 Corneal structure; chr7:66811230 chr7:66654538~66669855:+ CESC cis rs748404 0.588 rs2255410 ENSG00000249839.1 AC011330.5 -5.77 2.74e-08 3.33e-05 -0.38 -0.36 Lung cancer; chr15:43538899 chr15:43663654~43684339:- CESC cis rs2404602 0.716 rs12917430 ENSG00000259422.1 RP11-593F23.1 5.77 2.74e-08 3.34e-05 0.41 0.36 Blood metabolite levels; chr15:76382019 chr15:76174891~76181486:- CESC cis rs801193 0.548 rs6975044 ENSG00000237310.1 GS1-124K5.4 5.77 2.76e-08 3.36e-05 0.35 0.36 Aortic root size; chr7:66762495 chr7:66493706~66495474:+ CESC cis rs2117029 0.586 rs1874908 ENSG00000258017.1 RP11-386G11.10 -5.76 2.77e-08 3.37e-05 -0.46 -0.36 Intelligence (multi-trait analysis); chr12:49190247 chr12:49127782~49147869:+ CESC cis rs35955747 0.934 rs5997981 ENSG00000236132.1 CTA-440B3.1 5.76 2.77e-08 3.37e-05 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31412841 chr22:31816379~31817491:- CESC cis rs35955747 0.934 rs13053245 ENSG00000236132.1 CTA-440B3.1 5.76 2.77e-08 3.37e-05 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31420756 chr22:31816379~31817491:- CESC cis rs9545047 0.604 rs12865187 ENSG00000227676.3 LINC01068 -5.76 2.79e-08 3.38e-05 -0.41 -0.36 Schizophrenia; chr13:79316469 chr13:79566727~79571436:+ CESC cis rs57675369 1 rs57675369 ENSG00000251000.1 AC008592.3 5.76 2.79e-08 3.38e-05 0.65 0.36 Immature fraction of reticulocytes; chr5:95826714 chr5:95834424~95835046:- CESC cis rs35160687 0.901 rs12622200 ENSG00000273080.1 RP11-301O19.1 -5.76 2.79e-08 3.38e-05 -0.42 -0.36 Night sleep phenotypes; chr2:86271472 chr2:86195590~86196049:+ CESC cis rs6452524 0.534 rs7724935 ENSG00000249664.1 CTD-2227C6.2 5.76 2.79e-08 3.38e-05 0.42 0.36 Hypertension (SNP x SNP interaction); chr5:83057264 chr5:83012285~83013109:- CESC cis rs6452524 0.506 rs7707143 ENSG00000249664.1 CTD-2227C6.2 5.76 2.79e-08 3.38e-05 0.42 0.36 Hypertension (SNP x SNP interaction); chr5:83057268 chr5:83012285~83013109:- CESC cis rs11676348 0.818 rs7425447 ENSG00000261338.2 RP11-378A13.1 -5.76 2.79e-08 3.39e-05 -0.43 -0.36 Ulcerative colitis; chr2:218115460 chr2:218255319~218257366:+ CESC cis rs9545047 0.564 rs7336186 ENSG00000227676.3 LINC01068 -5.76 2.8e-08 3.39e-05 -0.41 -0.36 Schizophrenia; chr13:79385497 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2182009 ENSG00000227676.3 LINC01068 -5.76 2.8e-08 3.39e-05 -0.41 -0.36 Schizophrenia; chr13:79397781 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs4605023 ENSG00000227676.3 LINC01068 -5.76 2.8e-08 3.39e-05 -0.41 -0.36 Schizophrenia; chr13:79398700 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs12877507 ENSG00000227676.3 LINC01068 -5.76 2.8e-08 3.39e-05 -0.41 -0.36 Schizophrenia; chr13:79401822 chr13:79566727~79571436:+ CESC cis rs1707322 0.896 rs809774 ENSG00000280836.1 AL355480.1 5.76 2.8e-08 3.4e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46094572 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785498 ENSG00000280836.1 AL355480.1 5.76 2.8e-08 3.4e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126742 chr1:45581219~45581321:- CESC cis rs1823913 0.614 rs4853463 ENSG00000280083.1 RP11-317J9.1 5.76 2.81e-08 3.4e-05 0.42 0.36 Obesity-related traits; chr2:191278699 chr2:191154118~191156070:- CESC cis rs2404602 0.716 rs12594577 ENSG00000259422.1 RP11-593F23.1 5.76 2.81e-08 3.41e-05 0.41 0.36 Blood metabolite levels; chr15:76536452 chr15:76174891~76181486:- CESC cis rs4718428 0.705 rs13220977 ENSG00000226824.5 RP4-756H11.3 5.76 2.82e-08 3.41e-05 0.49 0.36 Corneal structure; chr7:66872661 chr7:66654538~66669855:+ CESC cis rs35955747 0.934 rs5997966 ENSG00000236132.1 CTA-440B3.1 5.76 2.82e-08 3.41e-05 0.42 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31380260 chr22:31816379~31817491:- CESC cis rs2243480 0.901 rs778732 ENSG00000232559.3 GS1-124K5.12 5.76 2.82e-08 3.42e-05 0.64 0.36 Diabetic kidney disease; chr7:66357373 chr7:66554588~66576923:- CESC cis rs35955747 0.87 rs4820969 ENSG00000236132.1 CTA-440B3.1 5.76 2.83e-08 3.42e-05 0.42 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31377587 chr22:31816379~31817491:- CESC cis rs8062405 0.755 rs4788080 ENSG00000259982.1 CDC37P1 5.76 2.83e-08 3.43e-05 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546760 chr16:28700294~28701540:- CESC cis rs8062405 0.723 rs4788079 ENSG00000259982.1 CDC37P1 5.76 2.83e-08 3.43e-05 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548042 chr16:28700294~28701540:- CESC cis rs8062405 0.755 rs4787456 ENSG00000259982.1 CDC37P1 5.76 2.83e-08 3.43e-05 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548252 chr16:28700294~28701540:- CESC cis rs8062405 0.755 rs4788078 ENSG00000259982.1 CDC37P1 5.76 2.83e-08 3.43e-05 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548660 chr16:28700294~28701540:- CESC cis rs9322193 0.884 rs880245 ENSG00000268592.3 RAET1E-AS1 -5.76 2.84e-08 3.44e-05 -0.49 -0.36 Lung cancer; chr6:149846262 chr6:149863494~149919507:+ CESC cis rs2404602 0.692 rs34181263 ENSG00000259422.1 RP11-593F23.1 5.76 2.84e-08 3.44e-05 0.41 0.36 Blood metabolite levels; chr15:76773047 chr15:76174891~76181486:- CESC cis rs1707322 0.752 rs11211146 ENSG00000281133.1 AL355480.3 -5.76 2.85e-08 3.45e-05 -0.44 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644122 chr1:45580892~45580996:- CESC cis rs1707322 0.752 rs11211147 ENSG00000281133.1 AL355480.3 -5.76 2.85e-08 3.45e-05 -0.44 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644422 chr1:45580892~45580996:- CESC cis rs1707322 0.721 rs11211149 ENSG00000281133.1 AL355480.3 -5.76 2.85e-08 3.45e-05 -0.44 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45646546 chr1:45580892~45580996:- CESC cis rs11096990 0.634 rs11947159 ENSG00000249207.1 RP11-360F5.1 5.76 2.86e-08 3.46e-05 0.39 0.36 Cognitive function; chr4:39286900 chr4:39112677~39126818:- CESC cis rs875971 1 rs3981131 ENSG00000222364.1 RNU6-96P -5.76 2.86e-08 3.46e-05 -0.44 -0.36 Aortic root size; chr7:66486690 chr7:66395191~66395286:+ CESC cis rs10078 0.848 rs890985 ENSG00000221990.4 EXOC3-AS1 5.76 2.87e-08 3.47e-05 0.33 0.36 Fat distribution (HIV); chr5:479631 chr5:441498~443160:- CESC cis rs9545047 0.604 rs2265381 ENSG00000227676.3 LINC01068 -5.76 2.89e-08 3.5e-05 -0.41 -0.36 Schizophrenia; chr13:79425903 chr13:79566727~79571436:+ CESC cis rs116095464 0.681 rs10060016 ENSG00000250848.1 CTD-2083E4.5 -5.76 2.9e-08 3.5e-05 -0.46 -0.36 Breast cancer; chr5:240985 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10057299 ENSG00000250848.1 CTD-2083E4.5 -5.76 2.9e-08 3.5e-05 -0.46 -0.36 Breast cancer; chr5:242020 chr5:288833~290321:- CESC cis rs116095464 0.558 rs13356367 ENSG00000250848.1 CTD-2083E4.5 -5.76 2.9e-08 3.5e-05 -0.46 -0.36 Breast cancer; chr5:242280 chr5:288833~290321:- CESC cis rs116095464 0.85 rs10055295 ENSG00000250848.1 CTD-2083E4.5 -5.76 2.9e-08 3.5e-05 -0.46 -0.36 Breast cancer; chr5:243634 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10055354 ENSG00000250848.1 CTD-2083E4.5 -5.76 2.9e-08 3.5e-05 -0.46 -0.36 Breast cancer; chr5:243679 chr5:288833~290321:- CESC cis rs116095464 0.614 rs62344292 ENSG00000250848.1 CTD-2083E4.5 -5.76 2.9e-08 3.5e-05 -0.46 -0.36 Breast cancer; chr5:244515 chr5:288833~290321:- CESC cis rs116095464 0.558 rs60251075 ENSG00000250848.1 CTD-2083E4.5 -5.76 2.9e-08 3.5e-05 -0.46 -0.36 Breast cancer; chr5:245177 chr5:288833~290321:- CESC cis rs116095464 0.558 rs62344300 ENSG00000250848.1 CTD-2083E4.5 -5.76 2.9e-08 3.5e-05 -0.46 -0.36 Breast cancer; chr5:246221 chr5:288833~290321:- CESC cis rs9545047 0.604 rs9565496 ENSG00000227676.3 LINC01068 -5.76 2.9e-08 3.5e-05 -0.41 -0.36 Schizophrenia; chr13:79398751 chr13:79566727~79571436:+ CESC cis rs10885396 0.967 rs7094463 ENSG00000233547.1 RP11-57H14.2 5.76 2.9e-08 3.5e-05 0.39 0.36 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112952224 chr10:112950646~112951875:- CESC cis rs8062405 0.755 rs17707300 ENSG00000259982.1 CDC37P1 5.76 2.91e-08 3.52e-05 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582026 chr16:28700294~28701540:- CESC cis rs1075265 0.568 rs10865277 ENSG00000233266.1 HMGB1P31 5.76 2.91e-08 3.52e-05 0.5 0.36 Chronotype;Morning vs. evening chronotype; chr2:54074865 chr2:54051334~54051760:+ CESC cis rs4660456 0.913 rs6661855 ENSG00000237899.1 RP4-739H11.3 5.75 2.92e-08 3.52e-05 0.49 0.36 Platelet count; chr1:40703245 chr1:40669089~40687588:- CESC cis rs1062177 1 rs12654573 ENSG00000253921.1 CTB-113P19.3 -5.75 2.92e-08 3.53e-05 -0.48 -0.36 Preschool internalizing problems; chr5:151827912 chr5:151753992~151767247:+ CESC cis rs8072100 0.902 rs12051716 ENSG00000228782.6 CTD-2026D20.3 -5.75 2.92e-08 3.53e-05 -0.42 -0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47505029 chr17:47450568~47492492:- CESC cis rs6504950 0.8 rs8065361 ENSG00000275710.1 RP11-257O5.4 5.75 2.92e-08 3.53e-05 0.42 0.36 Breast cancer; chr17:54931492 chr17:54964474~54964679:+ CESC cis rs6504950 0.745 rs12603899 ENSG00000275710.1 RP11-257O5.4 5.75 2.92e-08 3.53e-05 0.42 0.36 Breast cancer; chr17:54932737 chr17:54964474~54964679:+ CESC cis rs6504950 0.8 rs9891704 ENSG00000275710.1 RP11-257O5.4 5.75 2.92e-08 3.53e-05 0.42 0.36 Breast cancer; chr17:54933394 chr17:54964474~54964679:+ CESC cis rs6504950 0.8 rs9900816 ENSG00000275710.1 RP11-257O5.4 5.75 2.92e-08 3.53e-05 0.42 0.36 Breast cancer; chr17:54934696 chr17:54964474~54964679:+ CESC cis rs6504950 0.8 rs9907961 ENSG00000275710.1 RP11-257O5.4 5.75 2.92e-08 3.53e-05 0.42 0.36 Breast cancer; chr17:54935566 chr17:54964474~54964679:+ CESC cis rs6452524 0.935 rs10473868 ENSG00000249664.1 CTD-2227C6.2 5.75 2.93e-08 3.53e-05 0.4 0.36 Hypertension (SNP x SNP interaction); chr5:83141628 chr5:83012285~83013109:- CESC cis rs1823913 0.637 rs2356354 ENSG00000280083.1 RP11-317J9.1 5.75 2.93e-08 3.54e-05 0.42 0.36 Obesity-related traits; chr2:191270970 chr2:191154118~191156070:- CESC cis rs1707322 1 rs2458400 ENSG00000280836.1 AL355480.1 5.75 2.93e-08 3.54e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46065126 chr1:45581219~45581321:- CESC cis rs1707322 0.896 rs785512 ENSG00000280836.1 AL355480.1 5.75 2.93e-08 3.54e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46068871 chr1:45581219~45581321:- CESC cis rs1707322 1 rs9429186 ENSG00000280836.1 AL355480.1 5.75 2.93e-08 3.54e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46074015 chr1:45581219~45581321:- CESC cis rs1707322 1 rs785506 ENSG00000280836.1 AL355480.1 5.75 2.93e-08 3.54e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46074980 chr1:45581219~45581321:- CESC cis rs1062177 0.774 rs2964574 ENSG00000253921.1 CTB-113P19.3 -5.75 2.93e-08 3.54e-05 -0.47 -0.36 Preschool internalizing problems; chr5:151776150 chr5:151753992~151767247:+ CESC cis rs1062177 0.826 rs2915873 ENSG00000253921.1 CTB-113P19.3 -5.75 2.93e-08 3.54e-05 -0.47 -0.36 Preschool internalizing problems; chr5:151777097 chr5:151753992~151767247:+ CESC cis rs1862618 0.573 rs185220 ENSG00000271828.1 CTD-2310F14.1 5.75 2.94e-08 3.54e-05 0.49 0.36 Initial pursuit acceleration; chr5:56909530 chr5:56927874~56929573:+ CESC cis rs3806843 0.868 rs2262573 ENSG00000202111.1 VTRNA1-2 5.75 2.94e-08 3.54e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140744042 chr5:140718925~140719013:+ CESC cis rs34779708 0.931 rs12248333 ENSG00000230534.5 RP11-297A16.2 5.75 2.94e-08 3.55e-05 0.49 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35074049 chr10:35098006~35127020:- CESC cis rs10256972 0.933 rs35696159 ENSG00000229043.2 AC091729.9 -5.75 2.94e-08 3.55e-05 -0.41 -0.36 Endometriosis;Longevity; chr7:1007558 chr7:1160374~1165267:+ CESC cis rs2404602 0.716 rs67920045 ENSG00000259422.1 RP11-593F23.1 5.75 2.95e-08 3.56e-05 0.41 0.36 Blood metabolite levels; chr15:76507743 chr15:76174891~76181486:- CESC cis rs9545047 0.604 rs1324870 ENSG00000227676.3 LINC01068 -5.75 2.96e-08 3.56e-05 -0.41 -0.36 Schizophrenia; chr13:79297911 chr13:79566727~79571436:+ CESC cis rs2117029 0.521 rs1039225 ENSG00000258017.1 RP11-386G11.10 -5.75 2.97e-08 3.58e-05 -0.48 -0.36 Intelligence (multi-trait analysis); chr12:49188909 chr12:49127782~49147869:+ CESC cis rs11676348 0.811 rs4674255 ENSG00000261338.2 RP11-378A13.1 -5.75 2.97e-08 3.58e-05 -0.43 -0.36 Ulcerative colitis; chr2:218122602 chr2:218255319~218257366:+ CESC cis rs11676348 0.846 rs3890158 ENSG00000261338.2 RP11-378A13.1 -5.75 2.97e-08 3.58e-05 -0.43 -0.36 Ulcerative colitis; chr2:218125569 chr2:218255319~218257366:+ CESC cis rs11096990 0.679 rs6531707 ENSG00000249207.1 RP11-360F5.1 5.75 2.97e-08 3.58e-05 0.39 0.36 Cognitive function; chr4:39296064 chr4:39112677~39126818:- CESC cis rs8072100 0.764 rs4794371 ENSG00000228782.6 CTD-2026D20.3 -5.75 2.98e-08 3.59e-05 -0.42 -0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47550327 chr17:47450568~47492492:- CESC cis rs6452524 0.534 rs9293328 ENSG00000249664.1 CTD-2227C6.2 5.75 2.99e-08 3.6e-05 0.42 0.36 Hypertension (SNP x SNP interaction); chr5:83066855 chr5:83012285~83013109:- CESC cis rs1062177 0.724 rs2915828 ENSG00000213433.5 RPLP1P6 5.75 3e-08 3.61e-05 0.46 0.36 Preschool internalizing problems; chr5:151738560 chr5:151765859~151766378:- CESC cis rs1062177 0.724 rs2964590 ENSG00000213433.5 RPLP1P6 5.75 3e-08 3.61e-05 0.46 0.36 Preschool internalizing problems; chr5:151738585 chr5:151765859~151766378:- CESC cis rs720475 0.732 rs73159066 ENSG00000204959.4 ARHGEF34P -5.75 3.01e-08 3.62e-05 -0.41 -0.36 Breast cancer; chr7:144426495 chr7:144272445~144286966:- CESC cis rs9907295 0.591 rs4251749 ENSG00000270977.1 AC015849.16 -5.75 3.01e-08 3.62e-05 -0.44 -0.36 Fibroblast growth factor basic levels; chr17:35823421 chr17:35893707~35911023:- CESC cis rs9907295 0.591 rs4325615 ENSG00000270977.1 AC015849.16 -5.75 3.01e-08 3.62e-05 -0.44 -0.36 Fibroblast growth factor basic levels; chr17:35826379 chr17:35893707~35911023:- CESC cis rs9907295 0.551 rs28595279 ENSG00000270977.1 AC015849.16 -5.75 3.01e-08 3.62e-05 -0.44 -0.36 Fibroblast growth factor basic levels; chr17:35826416 chr17:35893707~35911023:- CESC cis rs2243480 0.901 rs35823062 ENSG00000232559.3 GS1-124K5.12 5.75 3.01e-08 3.63e-05 0.63 0.36 Diabetic kidney disease; chr7:66500834 chr7:66554588~66576923:- CESC cis rs2739330 0.892 rs5751776 ENSG00000231271.1 AP000350.8 5.75 3.01e-08 3.63e-05 0.44 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23949918~23954042:+ CESC cis rs2404602 0.716 rs12437627 ENSG00000259422.1 RP11-593F23.1 5.75 3.04e-08 3.66e-05 0.41 0.36 Blood metabolite levels; chr15:76552709 chr15:76174891~76181486:- CESC cis rs62229266 0.804 rs2835263 ENSG00000231106.2 LINC01436 -5.75 3.05e-08 3.67e-05 -0.49 -0.36 Mitral valve prolapse; chr21:36057947 chr21:36005338~36007838:+ CESC cis rs897984 0.542 rs8061047 ENSG00000260911.2 RP11-196G11.2 5.75 3.05e-08 3.67e-05 0.38 0.36 Dementia with Lewy bodies; chr16:31057639 chr16:31043150~31049868:+ CESC cis rs4889609 0.834 rs72785520 ENSG00000260911.2 RP11-196G11.2 5.75 3.05e-08 3.67e-05 0.38 0.36 Response to metformin (IC50); chr16:31059457 chr16:31043150~31049868:+ CESC cis rs801193 0.569 rs35070132 ENSG00000226824.5 RP4-756H11.3 -5.75 3.05e-08 3.67e-05 -0.46 -0.36 Aortic root size; chr7:66773096 chr7:66654538~66669855:+ CESC cis rs4423214 0.879 rs1790324 ENSG00000254682.1 RP11-660L16.2 -5.75 3.05e-08 3.67e-05 -0.47 -0.36 Vitamin D levels; chr11:71439474 chr11:71448674~71452157:+ CESC cis rs72627509 0.951 rs72627508 ENSG00000269949.1 RP11-738E22.3 5.75 3.06e-08 3.67e-05 0.56 0.36 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56965398 chr4:56960927~56961373:- CESC cis rs2404602 0.716 rs67204011 ENSG00000259422.1 RP11-593F23.1 5.74 3.07e-08 3.69e-05 0.41 0.36 Blood metabolite levels; chr15:76554214 chr15:76174891~76181486:- CESC cis rs2980439 0.846 rs2980437 ENSG00000253893.2 FAM85B 5.74 3.08e-08 3.7e-05 0.47 0.36 Neuroticism; chr8:8237241 chr8:8167819~8226614:- CESC cis rs2442825 0.693 rs2728949 ENSG00000206573.7 THUMPD3-AS1 5.74 3.09e-08 3.71e-05 0.35 0.36 Cerebrospinal fluid clusterin levels; chr3:9364977 chr3:9349689~9398579:- CESC cis rs3806843 0.733 rs801181 ENSG00000202111.1 VTRNA1-2 5.74 3.09e-08 3.71e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140713229 chr5:140718925~140719013:+ CESC cis rs9545047 0.604 rs9318634 ENSG00000227676.3 LINC01068 -5.74 3.09e-08 3.71e-05 -0.41 -0.36 Schizophrenia; chr13:79369303 chr13:79566727~79571436:+ CESC cis rs2006771 0.818 rs8142376 ENSG00000236132.1 CTA-440B3.1 5.74 3.11e-08 3.73e-05 0.42 0.36 Nonsyndromic cleft lip with cleft palate; chr22:31605051 chr22:31816379~31817491:- CESC cis rs950169 0.92 rs12915390 ENSG00000225151.9 GOLGA2P7 -5.74 3.12e-08 3.74e-05 -0.5 -0.36 Schizophrenia; chr15:84123317 chr15:84199311~84230136:- CESC cis rs189798 0.807 rs9949 ENSG00000254340.1 RP11-10A14.3 5.74 3.12e-08 3.74e-05 0.47 0.36 Myopia (pathological); chr8:9137002 chr8:9141424~9145435:+ CESC cis rs1823913 0.599 rs10497713 ENSG00000280083.1 RP11-317J9.1 -5.74 3.12e-08 3.74e-05 -0.42 -0.36 Obesity-related traits; chr2:191279312 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs34262638 ENSG00000280083.1 RP11-317J9.1 -5.74 3.12e-08 3.74e-05 -0.42 -0.36 Obesity-related traits; chr2:191279442 chr2:191154118~191156070:- CESC cis rs35955747 0.807 rs9619169 ENSG00000236132.1 CTA-440B3.1 5.74 3.13e-08 3.75e-05 0.41 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31141356 chr22:31816379~31817491:- CESC cis rs72627509 0.951 rs17087335 ENSG00000269949.1 RP11-738E22.3 5.74 3.13e-08 3.76e-05 0.54 0.36 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56972417 chr4:56960927~56961373:- CESC cis rs35160687 0.901 rs13017338 ENSG00000273080.1 RP11-301O19.1 5.74 3.14e-08 3.76e-05 0.42 0.36 Night sleep phenotypes; chr2:86274430 chr2:86195590~86196049:+ CESC cis rs7044106 1 rs7044106 ENSG00000226752.6 PSMD5-AS1 -5.74 3.17e-08 3.79e-05 -0.46 -0.36 Hip circumference adjusted for BMI; chr9:120731784 chr9:120824828~120854385:+ CESC cis rs2243480 1 rs4149468 ENSG00000232559.3 GS1-124K5.12 5.74 3.17e-08 3.8e-05 0.63 0.36 Diabetic kidney disease; chr7:66360703 chr7:66554588~66576923:- CESC cis rs4718428 0.705 rs12698547 ENSG00000226824.5 RP4-756H11.3 -5.74 3.2e-08 3.83e-05 -0.5 -0.36 Corneal structure; chr7:66813271 chr7:66654538~66669855:+ CESC cis rs2177312 0.62 rs6553980 ENSG00000251129.1 RP11-734I18.1 -5.74 3.21e-08 3.84e-05 -0.42 -0.36 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31975116 chr4:31997397~32155406:+ CESC cis rs832187 0.593 rs3774713 ENSG00000280620.1 SCAANT1 5.74 3.21e-08 3.84e-05 0.49 0.36 Schizophrenia; chr3:63932016 chr3:63911518~63911772:- CESC cis rs10875746 0.951 rs10875747 ENSG00000240399.1 RP1-228P16.1 -5.74 3.22e-08 3.85e-05 -0.47 -0.36 Longevity (90 years and older); chr12:48132078 chr12:48054813~48055591:- CESC cis rs1891275 0.515 rs2153653 ENSG00000228701.1 TNKS2-AS1 -5.73 3.23e-08 3.86e-05 -0.43 -0.36 Intelligence (multi-trait analysis); chr10:91736169 chr10:91782839~91798291:- CESC cis rs2882667 0.518 rs10041986 ENSG00000253404.1 AC034243.1 5.73 3.24e-08 3.87e-05 0.41 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139088748 chr5:138744434~138753309:- CESC cis rs9545047 0.604 rs2265382 ENSG00000227676.3 LINC01068 -5.73 3.24e-08 3.87e-05 -0.4 -0.36 Schizophrenia; chr13:79426196 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2477395 ENSG00000227676.3 LINC01068 -5.73 3.24e-08 3.87e-05 -0.4 -0.36 Schizophrenia; chr13:79427679 chr13:79566727~79571436:+ CESC cis rs8072100 1 rs8065669 ENSG00000228782.6 CTD-2026D20.3 5.73 3.24e-08 3.88e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47647630 chr17:47450568~47492492:- CESC cis rs1823913 0.637 rs4853465 ENSG00000280083.1 RP11-317J9.1 5.73 3.25e-08 3.88e-05 0.42 0.36 Obesity-related traits; chr2:191294768 chr2:191154118~191156070:- CESC cis rs6504950 0.925 rs2787481 ENSG00000275710.1 RP11-257O5.4 -5.73 3.25e-08 3.88e-05 -0.47 -0.36 Breast cancer; chr17:55133749 chr17:54964474~54964679:+ CESC cis rs6860806 0.507 rs2631371 ENSG00000233006.5 AC034220.3 -5.73 3.25e-08 3.89e-05 -0.41 -0.36 Breast cancer; chr5:132367999 chr5:132311285~132369916:- CESC cis rs950169 0.922 rs2033284 ENSG00000225151.9 GOLGA2P7 -5.73 3.25e-08 3.89e-05 -0.52 -0.36 Schizophrenia; chr15:84391575 chr15:84199311~84230136:- CESC cis rs1823913 0.637 rs4853573 ENSG00000280083.1 RP11-317J9.1 5.73 3.26e-08 3.89e-05 0.42 0.36 Obesity-related traits; chr2:191295866 chr2:191154118~191156070:- CESC cis rs1823913 0.614 rs4853466 ENSG00000280083.1 RP11-317J9.1 5.73 3.26e-08 3.89e-05 0.42 0.36 Obesity-related traits; chr2:191295943 chr2:191154118~191156070:- CESC cis rs12022452 0.818 rs11810978 ENSG00000238287.1 RP11-656D10.3 -5.73 3.26e-08 3.89e-05 -0.56 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40554175 chr1:40493157~40508661:- CESC cis rs9322193 0.962 rs13215691 ENSG00000268592.3 RAET1E-AS1 5.73 3.26e-08 3.89e-05 0.47 0.36 Lung cancer; chr6:149792666 chr6:149863494~149919507:+ CESC cis rs1891275 0.515 rs1361552 ENSG00000228701.1 TNKS2-AS1 -5.73 3.26e-08 3.9e-05 -0.42 -0.36 Intelligence (multi-trait analysis); chr10:91774867 chr10:91782839~91798291:- CESC cis rs1823913 0.637 rs4853574 ENSG00000280083.1 RP11-317J9.1 5.73 3.28e-08 3.91e-05 0.42 0.36 Obesity-related traits; chr2:191296113 chr2:191154118~191156070:- CESC cis rs14027 1 rs14027 ENSG00000279347.1 RP11-85I17.2 -5.73 3.28e-08 3.91e-05 -0.34 -0.36 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119834349 chr8:119838736~119840385:- CESC cis rs11690935 0.959 rs67204065 ENSG00000228389.1 AC068039.4 5.73 3.28e-08 3.92e-05 0.47 0.36 Schizophrenia; chr2:171816114 chr2:171773482~171775844:+ CESC cis rs875971 0.862 rs6944374 ENSG00000226824.5 RP4-756H11.3 5.73 3.3e-08 3.93e-05 0.46 0.36 Aortic root size; chr7:66221942 chr7:66654538~66669855:+ CESC cis rs2243480 0.764 rs2460423 ENSG00000232559.3 GS1-124K5.12 5.73 3.3e-08 3.94e-05 0.62 0.36 Diabetic kidney disease; chr7:66136229 chr7:66554588~66576923:- CESC cis rs1823913 0.614 rs11693878 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191299399 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs10931494 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191299442 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs10931495 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191299447 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs12623156 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191299661 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs1349938 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191299970 chr2:191154118~191156070:- CESC cis rs1823913 0.592 rs1349939 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191300079 chr2:191154118~191156070:- CESC cis rs1823913 0.614 rs6434459 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191300886 chr2:191154118~191156070:- CESC cis rs1823913 0.592 rs7588555 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191300912 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs4853581 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191301533 chr2:191154118~191156070:- CESC cis rs1823913 0.614 rs7565987 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191301815 chr2:191154118~191156070:- CESC cis rs1823913 0.614 rs1973067 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191302021 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs1973068 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191302227 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs7569231 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191302373 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs6434461 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191302661 chr2:191154118~191156070:- CESC cis rs1823913 0.614 rs6434462 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191302705 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs6750360 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191303089 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs11677694 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191303203 chr2:191154118~191156070:- CESC cis rs1823913 0.571 rs6737307 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191303247 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs4853582 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191303483 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs35200176 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191303534 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs17348013 ENSG00000280083.1 RP11-317J9.1 5.73 3.31e-08 3.94e-05 0.42 0.36 Obesity-related traits; chr2:191303726 chr2:191154118~191156070:- CESC cis rs7189233 0.531 rs9931702 ENSG00000279344.1 RP11-44F14.7 5.73 3.31e-08 3.95e-05 0.34 0.36 Intelligence (multi-trait analysis); chr16:53492639 chr16:53478957~53481550:- CESC cis rs4853012 0.941 rs2421752 ENSG00000257800.1 FNBP1P1 5.73 3.34e-08 3.97e-05 0.4 0.36 Gestational age at birth (maternal effect); chr2:74114488 chr2:74120680~74123218:+ CESC cis rs1823913 0.614 rs4853576 ENSG00000280083.1 RP11-317J9.1 5.73 3.34e-08 3.98e-05 0.42 0.36 Obesity-related traits; chr2:191296618 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs4853577 ENSG00000280083.1 RP11-317J9.1 5.73 3.34e-08 3.98e-05 0.42 0.36 Obesity-related traits; chr2:191297118 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs4853579 ENSG00000280083.1 RP11-317J9.1 5.73 3.34e-08 3.98e-05 0.42 0.36 Obesity-related traits; chr2:191297413 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs12622194 ENSG00000280083.1 RP11-317J9.1 5.73 3.34e-08 3.98e-05 0.42 0.36 Obesity-related traits; chr2:191298680 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs13019567 ENSG00000280083.1 RP11-317J9.1 5.73 3.34e-08 3.98e-05 0.42 0.36 Obesity-related traits; chr2:191298736 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs1947456 ENSG00000280083.1 RP11-317J9.1 5.73 3.34e-08 3.98e-05 0.42 0.36 Obesity-related traits; chr2:191298759 chr2:191154118~191156070:- CESC cis rs9309711 0.666 rs6723101 ENSG00000225234.1 TRAPPC12-AS1 -5.73 3.35e-08 3.98e-05 -0.34 -0.36 Neurofibrillary tangles; chr2:3480672 chr2:3481242~3482409:- CESC cis rs9309711 0.666 rs6723126 ENSG00000225234.1 TRAPPC12-AS1 -5.73 3.35e-08 3.98e-05 -0.34 -0.36 Neurofibrillary tangles; chr2:3480729 chr2:3481242~3482409:- CESC cis rs10129255 0.5 rs8004923 ENSG00000223648.3 IGHV3-64 5.73 3.35e-08 3.99e-05 0.31 0.36 Kawasaki disease; chr14:106785926 chr14:106643132~106658258:- CESC cis rs10129255 0.5 rs6576232 ENSG00000223648.3 IGHV3-64 5.73 3.35e-08 3.99e-05 0.31 0.36 Kawasaki disease; chr14:106787090 chr14:106643132~106658258:- CESC cis rs10129255 0.5 rs10131875 ENSG00000223648.3 IGHV3-64 5.73 3.35e-08 3.99e-05 0.31 0.36 Kawasaki disease; chr14:106792798 chr14:106643132~106658258:- CESC cis rs34779708 1 rs34779708 ENSG00000230534.5 RP11-297A16.2 5.73 3.35e-08 3.99e-05 0.47 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35177257 chr10:35098006~35127020:- CESC cis rs1823913 0.637 rs10931493 ENSG00000280083.1 RP11-317J9.1 -5.73 3.36e-08 4e-05 -0.42 -0.36 Obesity-related traits; chr2:191288142 chr2:191154118~191156070:- CESC cis rs6452524 1 rs10042854 ENSG00000249664.1 CTD-2227C6.2 -5.73 3.36e-08 4e-05 -0.4 -0.36 Hypertension (SNP x SNP interaction); chr5:83143876 chr5:83012285~83013109:- CESC cis rs3806843 0.801 rs801170 ENSG00000202111.1 VTRNA1-2 5.73 3.37e-08 4e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140735758 chr5:140718925~140719013:+ CESC cis rs7115242 0.8 rs6589597 ENSG00000280143.1 AP000892.6 -5.73 3.37e-08 4.01e-05 -0.56 -0.36 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117127082 chr11:117204967~117210292:+ CESC cis rs950169 0.84 rs72748702 ENSG00000225151.9 GOLGA2P7 -5.73 3.37e-08 4.01e-05 -0.51 -0.36 Schizophrenia; chr15:84246494 chr15:84199311~84230136:- CESC cis rs1823913 0.599 rs13427761 ENSG00000280083.1 RP11-317J9.1 5.73 3.37e-08 4.01e-05 0.42 0.36 Obesity-related traits; chr2:191269256 chr2:191154118~191156070:- CESC cis rs8062405 0.655 rs7184597 ENSG00000259982.1 CDC37P1 -5.73 3.38e-08 4.01e-05 -0.47 -0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910488 chr16:28700294~28701540:- CESC cis rs2739330 0.703 rs5760112 ENSG00000272787.1 KB-226F1.2 -5.73 3.38e-08 4.01e-05 -0.39 -0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23969211~23969873:+ CESC cis rs9907295 0.591 rs8080959 ENSG00000270977.1 AC015849.16 -5.73 3.39e-08 4.03e-05 -0.44 -0.36 Fibroblast growth factor basic levels; chr17:35813450 chr17:35893707~35911023:- CESC cis rs1075265 0.568 rs7604357 ENSG00000233266.1 HMGB1P31 5.73 3.39e-08 4.03e-05 0.51 0.36 Chronotype;Morning vs. evening chronotype; chr2:54074026 chr2:54051334~54051760:+ CESC cis rs6504950 0.72 rs7216138 ENSG00000275710.1 RP11-257O5.4 5.73 3.39e-08 4.03e-05 0.41 0.36 Breast cancer; chr17:54918303 chr17:54964474~54964679:+ CESC cis rs6504950 0.8 rs9916547 ENSG00000275710.1 RP11-257O5.4 5.72 3.4e-08 4.05e-05 0.42 0.36 Breast cancer; chr17:54929529 chr17:54964474~54964679:+ CESC cis rs10875746 0.903 rs11168427 ENSG00000240399.1 RP1-228P16.1 -5.72 3.41e-08 4.05e-05 -0.47 -0.36 Longevity (90 years and older); chr12:48145196 chr12:48054813~48055591:- CESC cis rs10875746 0.951 rs61918826 ENSG00000240399.1 RP1-228P16.1 -5.72 3.41e-08 4.05e-05 -0.47 -0.36 Longevity (90 years and older); chr12:48150195 chr12:48054813~48055591:- CESC cis rs10875746 0.904 rs10875750 ENSG00000240399.1 RP1-228P16.1 -5.72 3.41e-08 4.05e-05 -0.47 -0.36 Longevity (90 years and older); chr12:48151847 chr12:48054813~48055591:- CESC cis rs2177312 0.868 rs6821341 ENSG00000251129.1 RP11-734I18.1 -5.72 3.42e-08 4.06e-05 -0.46 -0.36 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31939414 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs4435785 ENSG00000251129.1 RP11-734I18.1 -5.72 3.42e-08 4.06e-05 -0.46 -0.36 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31940998 chr4:31997397~32155406:+ CESC cis rs2177312 0.868 rs1523164 ENSG00000251129.1 RP11-734I18.1 -5.72 3.42e-08 4.06e-05 -0.46 -0.36 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31943592 chr4:31997397~32155406:+ CESC cis rs2177312 0.794 rs1523165 ENSG00000251129.1 RP11-734I18.1 -5.72 3.42e-08 4.06e-05 -0.46 -0.36 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31943836 chr4:31997397~32155406:+ CESC cis rs7572733 0.875 rs11690149 ENSG00000222017.1 AC011997.1 5.72 3.42e-08 4.06e-05 0.4 0.36 Dermatomyositis; chr2:198069080 chr2:197693106~197774823:+ CESC cis rs9309711 0.506 rs9284794 ENSG00000225234.1 TRAPPC12-AS1 -5.72 3.42e-08 4.06e-05 -0.33 -0.36 Neurofibrillary tangles; chr2:3488281 chr2:3481242~3482409:- CESC cis rs2442825 0.693 rs2596916 ENSG00000206573.7 THUMPD3-AS1 5.72 3.42e-08 4.07e-05 0.35 0.36 Cerebrospinal fluid clusterin levels; chr3:9380526 chr3:9349689~9398579:- CESC cis rs34779708 0.931 rs67976880 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35083333 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs72789687 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35083561 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs35997236 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35087762 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934719 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35087841 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934720 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35087872 chr10:35098006~35127020:- CESC cis rs34779708 0.897 rs34481177 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35091985 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs11593858 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35092445 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934723 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35092835 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs72789690 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35093889 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs68039650 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35096571 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs35136660 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35097045 chr10:35098006~35127020:- CESC cis rs34779708 0.897 rs12764820 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35097393 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs67261877 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35097412 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs12768019 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35100915 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs34876468 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.47 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35135522 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs35814343 ENSG00000230534.5 RP11-297A16.2 5.72 3.44e-08 4.08e-05 0.47 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35138786 chr10:35098006~35127020:- CESC cis rs66486766 1 rs66486766 ENSG00000225151.9 GOLGA2P7 -5.72 3.45e-08 4.09e-05 -0.51 -0.36 Bipolar disorder lithium response (categorical) or schizophrenia; chr15:84137308 chr15:84199311~84230136:- CESC cis rs1075265 0.584 rs1862121 ENSG00000233266.1 HMGB1P31 5.72 3.46e-08 4.1e-05 0.52 0.36 Chronotype;Morning vs. evening chronotype; chr2:54058102 chr2:54051334~54051760:+ CESC cis rs765787 0.53 rs12905246 ENSG00000259520.4 CTD-2651B20.3 -5.72 3.47e-08 4.11e-05 -0.45 -0.36 Uric acid levels; chr15:45208643 chr15:45251580~45279251:- CESC cis rs950169 0.959 rs12902070 ENSG00000225151.9 GOLGA2P7 -5.72 3.47e-08 4.12e-05 -0.51 -0.36 Schizophrenia; chr15:84124806 chr15:84199311~84230136:- CESC cis rs13631 0.965 rs9411307 ENSG00000268996.3 MAN1B1-AS1 5.72 3.48e-08 4.12e-05 0.33 0.36 Cerebrospinal fluid biomarker levels; chr9:137100495 chr9:137084946~137086817:- CESC cis rs2929278 0.589 rs7174732 ENSG00000205771.5 CATSPER2P1 5.72 3.49e-08 4.13e-05 0.43 0.36 Schizophrenia; chr15:43746265 chr15:43726918~43747094:- CESC cis rs1823913 0.637 rs4853575 ENSG00000280083.1 RP11-317J9.1 5.72 3.5e-08 4.15e-05 0.42 0.36 Obesity-related traits; chr2:191296149 chr2:191154118~191156070:- CESC cis rs11096990 0.656 rs7693837 ENSG00000249207.1 RP11-360F5.1 -5.72 3.51e-08 4.15e-05 -0.4 -0.36 Cognitive function; chr4:39301481 chr4:39112677~39126818:- CESC cis rs116095464 0.681 rs9687745 ENSG00000250848.1 CTD-2083E4.5 -5.72 3.51e-08 4.16e-05 -0.46 -0.36 Breast cancer; chr5:229194 chr5:288833~290321:- CESC cis rs1185460 0.934 rs10892328 ENSG00000271751.1 RP11-110I1.14 -5.72 3.51e-08 4.16e-05 -0.51 -0.36 Coronary artery disease; chr11:119071944 chr11:119065263~119065677:- CESC cis rs875971 0.8 rs427557 ENSG00000222364.1 RNU6-96P -5.72 3.51e-08 4.16e-05 -0.43 -0.36 Aortic root size; chr7:66054263 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs587360 ENSG00000222364.1 RNU6-96P -5.72 3.51e-08 4.16e-05 -0.43 -0.36 Aortic root size; chr7:66057711 chr7:66395191~66395286:+ CESC cis rs2404602 0.716 rs7174953 ENSG00000259422.1 RP11-593F23.1 5.72 3.52e-08 4.17e-05 0.41 0.36 Blood metabolite levels; chr15:76614506 chr15:76174891~76181486:- CESC cis rs11096990 0.656 rs9993224 ENSG00000249207.1 RP11-360F5.1 5.72 3.53e-08 4.17e-05 0.39 0.36 Cognitive function; chr4:39298578 chr4:39112677~39126818:- CESC cis rs10256972 0.869 rs4720158 ENSG00000229043.2 AC091729.9 -5.72 3.53e-08 4.18e-05 -0.41 -0.36 Endometriosis;Longevity; chr7:1000689 chr7:1160374~1165267:+ CESC cis rs2117029 0.521 rs1056875 ENSG00000258017.1 RP11-386G11.10 -5.72 3.54e-08 4.18e-05 -0.46 -0.36 Intelligence (multi-trait analysis); chr12:49186397 chr12:49127782~49147869:+ CESC cis rs11690935 0.921 rs7355523 ENSG00000228389.1 AC068039.4 5.72 3.54e-08 4.18e-05 0.48 0.36 Schizophrenia; chr2:171887911 chr2:171773482~171775844:+ CESC cis rs2842992 0.915 rs2842980 ENSG00000237927.1 RP3-393E18.2 -5.72 3.55e-08 4.2e-05 -0.49 -0.36 Age-related macular degeneration (geographic atrophy); chr6:159679084 chr6:159586955~159589169:- CESC cis rs2117029 0.521 rs12229524 ENSG00000258017.1 RP11-386G11.10 -5.72 3.56e-08 4.21e-05 -0.47 -0.36 Intelligence (multi-trait analysis); chr12:49191570 chr12:49127782~49147869:+ CESC cis rs9322193 0.962 rs7740784 ENSG00000268592.3 RAET1E-AS1 5.72 3.56e-08 4.21e-05 0.48 0.36 Lung cancer; chr6:149833364 chr6:149863494~149919507:+ CESC cis rs875971 0.862 rs13536 ENSG00000226824.5 RP4-756H11.3 5.71 3.58e-08 4.24e-05 0.45 0.36 Aortic root size; chr7:66554203 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs801209 ENSG00000226824.5 RP4-756H11.3 5.71 3.58e-08 4.24e-05 0.45 0.36 Aortic root size; chr7:66554403 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs801206 ENSG00000226824.5 RP4-756H11.3 5.71 3.58e-08 4.24e-05 0.45 0.36 Aortic root size; chr7:66556979 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs801204 ENSG00000226824.5 RP4-756H11.3 5.71 3.58e-08 4.24e-05 0.45 0.36 Aortic root size; chr7:66557934 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs801203 ENSG00000226824.5 RP4-756H11.3 5.71 3.58e-08 4.24e-05 0.45 0.36 Aortic root size; chr7:66558025 chr7:66654538~66669855:+ CESC cis rs875971 0.825 rs801202 ENSG00000226824.5 RP4-756H11.3 5.71 3.58e-08 4.24e-05 0.45 0.36 Aortic root size; chr7:66558942 chr7:66654538~66669855:+ CESC cis rs1185460 0.967 rs3825061 ENSG00000271751.1 RP11-110I1.14 -5.71 3.59e-08 4.25e-05 -0.51 -0.36 Coronary artery disease; chr11:119073965 chr11:119065263~119065677:- CESC cis rs2117029 0.619 rs11168862 ENSG00000258017.1 RP11-386G11.10 -5.71 3.61e-08 4.26e-05 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49112175 chr12:49127782~49147869:+ CESC cis rs1577917 1 rs6933377 ENSG00000203875.9 SNHG5 5.71 3.62e-08 4.27e-05 0.39 0.36 Response to antipsychotic treatment; chr6:85995537 chr6:85660950~85678736:- CESC cis rs35955747 0.869 rs5997971 ENSG00000236132.1 CTA-440B3.1 5.71 3.62e-08 4.27e-05 0.42 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31396306 chr22:31816379~31817491:- CESC cis rs4423214 0.879 rs1790353 ENSG00000254682.1 RP11-660L16.2 -5.71 3.62e-08 4.27e-05 -0.49 -0.36 Vitamin D levels; chr11:71425684 chr11:71448674~71452157:+ CESC cis rs4423214 0.879 rs1792277 ENSG00000254682.1 RP11-660L16.2 -5.71 3.62e-08 4.27e-05 -0.49 -0.36 Vitamin D levels; chr11:71427872 chr11:71448674~71452157:+ CESC cis rs2117029 0.619 rs10747562 ENSG00000258017.1 RP11-386G11.10 -5.71 3.62e-08 4.28e-05 -0.45 -0.36 Intelligence (multi-trait analysis); chr12:49111401 chr12:49127782~49147869:+ CESC cis rs3806843 0.766 rs2530239 ENSG00000202111.1 VTRNA1-2 5.71 3.62e-08 4.28e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140682962 chr5:140718925~140719013:+ CESC cis rs6700559 0.81 rs10919991 ENSG00000260088.1 RP11-92G12.3 -5.71 3.62e-08 4.28e-05 -0.46 -0.36 Coronary artery disease; chr1:200627217 chr1:200669507~200694250:+ CESC cis rs2929278 0.617 rs4617832 ENSG00000205771.5 CATSPER2P1 5.71 3.63e-08 4.28e-05 0.43 0.36 Schizophrenia; chr15:43738381 chr15:43726918~43747094:- CESC cis rs6904897 0.563 rs4896117 ENSG00000232876.1 CTA-212D2.2 5.71 3.63e-08 4.28e-05 0.42 0.36 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134908262 chr6:135055033~135060550:+ CESC cis rs1061377 1 rs9996285 ENSG00000249207.1 RP11-360F5.1 -5.71 3.64e-08 4.29e-05 -0.4 -0.36 Uric acid levels; chr4:39130556 chr4:39112677~39126818:- CESC cis rs875971 0.505 rs1723275 ENSG00000164669.11 INTS4P1 5.71 3.64e-08 4.29e-05 0.49 0.36 Aortic root size; chr7:66039646 chr7:65141225~65234216:+ CESC cis rs12022452 0.73 rs2297755 ENSG00000238287.1 RP11-656D10.3 -5.71 3.65e-08 4.3e-05 -0.58 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40547343 chr1:40493157~40508661:- CESC cis rs4423214 0.625 rs78685409 ENSG00000254682.1 RP11-660L16.2 -5.71 3.66e-08 4.31e-05 -0.49 -0.36 Vitamin D levels; chr11:71426337 chr11:71448674~71452157:+ CESC cis rs8062405 0.573 rs8045689 ENSG00000259982.1 CDC37P1 -5.71 3.66e-08 4.31e-05 -0.48 -0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28976948 chr16:28700294~28701540:- CESC cis rs7572733 0.935 rs2217837 ENSG00000222017.1 AC011997.1 5.71 3.66e-08 4.32e-05 0.4 0.36 Dermatomyositis; chr2:197881535 chr2:197693106~197774823:+ CESC cis rs6951245 0.554 rs76243429 ENSG00000229043.2 AC091729.9 -5.71 3.67e-08 4.33e-05 -0.48 -0.36 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112907 chr7:1160374~1165267:+ CESC cis rs34779708 0.833 rs12777517 ENSG00000230534.5 RP11-297A16.2 5.71 3.68e-08 4.33e-05 0.47 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35184999 chr10:35098006~35127020:- CESC cis rs7104764 0.917 rs3825075 ENSG00000277290.1 RP11-326C3.16 5.71 3.69e-08 4.35e-05 0.3 0.36 Menarche (age at onset); chr11:217140 chr11:243099~243483:- CESC cis rs10875746 0.859 rs12305647 ENSG00000240399.1 RP1-228P16.1 -5.71 3.7e-08 4.35e-05 -0.46 -0.36 Longevity (90 years and older); chr12:48189178 chr12:48054813~48055591:- CESC cis rs75422866 0.867 rs73104163 ENSG00000257433.4 RP1-197B17.3 5.71 3.71e-08 4.37e-05 0.93 0.36 Pneumonia; chr12:47706187 chr12:47706085~47742294:+ CESC cis rs75422866 1 rs12423045 ENSG00000257433.4 RP1-197B17.3 5.71 3.71e-08 4.37e-05 0.93 0.36 Pneumonia; chr12:47706275 chr12:47706085~47742294:+ CESC cis rs34779708 0.931 rs11010130 ENSG00000230534.5 RP11-297A16.2 5.71 3.72e-08 4.38e-05 0.49 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35224379 chr10:35098006~35127020:- CESC cis rs34779708 0.897 rs11010131 ENSG00000230534.5 RP11-297A16.2 5.71 3.72e-08 4.38e-05 0.49 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35224388 chr10:35098006~35127020:- CESC cis rs1062177 0.756 rs2915827 ENSG00000213433.5 RPLP1P6 5.71 3.74e-08 4.4e-05 0.45 0.36 Preschool internalizing problems; chr5:151740144 chr5:151765859~151766378:- CESC cis rs1062177 0.756 rs2915826 ENSG00000213433.5 RPLP1P6 5.71 3.74e-08 4.4e-05 0.45 0.36 Preschool internalizing problems; chr5:151740402 chr5:151765859~151766378:- CESC cis rs1062177 0.756 rs2964587 ENSG00000213433.5 RPLP1P6 5.71 3.74e-08 4.4e-05 0.45 0.36 Preschool internalizing problems; chr5:151740411 chr5:151765859~151766378:- CESC cis rs2243480 1 rs1499614 ENSG00000232559.3 GS1-124K5.12 5.71 3.75e-08 4.41e-05 0.61 0.36 Diabetic kidney disease; chr7:66265811 chr7:66554588~66576923:- CESC cis rs875971 0.767 rs12668005 ENSG00000226824.5 RP4-756H11.3 -5.71 3.75e-08 4.41e-05 -0.46 -0.36 Aortic root size; chr7:66444034 chr7:66654538~66669855:+ CESC cis rs9322193 0.566 rs5024811 ENSG00000231760.4 RP11-350J20.5 -5.71 3.76e-08 4.42e-05 -0.52 -0.36 Lung cancer; chr6:149924898 chr6:149796151~149826294:- CESC cis rs2404602 1 rs2120107 ENSG00000259422.1 RP11-593F23.1 5.7 3.77e-08 4.43e-05 0.41 0.36 Blood metabolite levels; chr15:76577448 chr15:76174891~76181486:- CESC cis rs2404602 0.552 rs11072613 ENSG00000259422.1 RP11-593F23.1 -5.7 3.77e-08 4.43e-05 -0.45 -0.36 Blood metabolite levels; chr15:76669185 chr15:76174891~76181486:- CESC cis rs34779708 0.966 rs17591857 ENSG00000230534.5 RP11-297A16.2 -5.7 3.8e-08 4.46e-05 -0.47 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35210115 chr10:35098006~35127020:- CESC cis rs79349575 0.783 rs832410 ENSG00000270781.1 RP11-501C14.9 -5.7 3.8e-08 4.46e-05 -0.4 -0.36 Type 2 diabetes; chr17:48895503 chr17:48899131~48899748:+ CESC cis rs1075265 0.584 rs7558126 ENSG00000233266.1 HMGB1P31 5.7 3.8e-08 4.47e-05 0.51 0.36 Chronotype;Morning vs. evening chronotype; chr2:54053847 chr2:54051334~54051760:+ CESC cis rs1823913 0.614 rs12616167 ENSG00000280083.1 RP11-317J9.1 5.7 3.81e-08 4.48e-05 0.42 0.36 Obesity-related traits; chr2:191311274 chr2:191154118~191156070:- CESC cis rs2739330 0.828 rs5760108 ENSG00000250470.1 AP000351.3 5.7 3.81e-08 4.48e-05 0.45 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23976904~23977585:- CESC cis rs7572733 0.935 rs10189897 ENSG00000222017.1 AC011997.1 -5.7 3.82e-08 4.48e-05 -0.4 -0.36 Dermatomyositis; chr2:197948686 chr2:197693106~197774823:+ CESC cis rs765787 0.53 rs4774550 ENSG00000259520.4 CTD-2651B20.3 5.7 3.82e-08 4.48e-05 0.45 0.36 Uric acid levels; chr15:45250114 chr15:45251580~45279251:- CESC cis rs507080 0.501 rs637563 ENSG00000255422.1 AP002954.4 -5.7 3.82e-08 4.48e-05 -0.41 -0.36 Serum metabolite levels; chr11:118704770 chr11:118704607~118750263:+ CESC cis rs11096990 0.656 rs2066786 ENSG00000249207.1 RP11-360F5.1 -5.7 3.82e-08 4.49e-05 -0.4 -0.36 Cognitive function; chr4:39300409 chr4:39112677~39126818:- CESC cis rs2404602 0.716 rs1946650 ENSG00000259422.1 RP11-593F23.1 5.7 3.82e-08 4.49e-05 0.41 0.36 Blood metabolite levels; chr15:76556122 chr15:76174891~76181486:- CESC cis rs1062177 0.756 rs2964589 ENSG00000213433.5 RPLP1P6 5.7 3.83e-08 4.5e-05 0.45 0.36 Preschool internalizing problems; chr5:151738628 chr5:151765859~151766378:- CESC cis rs1062177 0.756 rs2964588 ENSG00000213433.5 RPLP1P6 5.7 3.83e-08 4.5e-05 0.45 0.36 Preschool internalizing problems; chr5:151738825 chr5:151765859~151766378:- CESC cis rs1707322 0.964 rs785508 ENSG00000280836.1 AL355480.1 5.7 3.84e-08 4.5e-05 0.42 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46061487 chr1:45581219~45581321:- CESC cis rs1707322 0.964 rs785509 ENSG00000280836.1 AL355480.1 5.7 3.84e-08 4.5e-05 0.42 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46061628 chr1:45581219~45581321:- CESC cis rs2404602 0.692 rs57178708 ENSG00000259422.1 RP11-593F23.1 5.7 3.85e-08 4.51e-05 0.41 0.36 Blood metabolite levels; chr15:76611728 chr15:76174891~76181486:- CESC cis rs950169 0.8 rs4842847 ENSG00000225151.9 GOLGA2P7 -5.7 3.85e-08 4.51e-05 -0.51 -0.36 Schizophrenia; chr15:84262447 chr15:84199311~84230136:- CESC cis rs1823913 0.637 rs11686185 ENSG00000280083.1 RP11-317J9.1 5.7 3.85e-08 4.51e-05 0.41 0.36 Obesity-related traits; chr2:191289282 chr2:191154118~191156070:- CESC cis rs875971 1 rs6956179 ENSG00000222364.1 RNU6-96P 5.7 3.86e-08 4.53e-05 0.42 0.36 Aortic root size; chr7:66341672 chr7:66395191~66395286:+ CESC cis rs1823913 0.637 rs12624271 ENSG00000280083.1 RP11-317J9.1 5.7 3.87e-08 4.53e-05 0.41 0.36 Obesity-related traits; chr2:191288586 chr2:191154118~191156070:- CESC cis rs2404602 0.692 rs4886503 ENSG00000259422.1 RP11-593F23.1 -5.7 3.87e-08 4.53e-05 -0.41 -0.36 Blood metabolite levels; chr15:76816533 chr15:76174891~76181486:- CESC cis rs1062177 0.855 rs6892117 ENSG00000213433.5 RPLP1P6 5.7 3.89e-08 4.56e-05 0.4 0.36 Preschool internalizing problems; chr5:151885424 chr5:151765859~151766378:- CESC cis rs3806843 0.832 rs2531360 ENSG00000202111.1 VTRNA1-2 5.7 3.9e-08 4.57e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140737079 chr5:140718925~140719013:+ CESC cis rs765787 0.53 rs4775819 ENSG00000259520.4 CTD-2651B20.3 5.7 3.91e-08 4.57e-05 0.46 0.36 Uric acid levels; chr15:45233768 chr15:45251580~45279251:- CESC cis rs2929278 0.617 rs524908 ENSG00000249839.1 AC011330.5 5.7 3.91e-08 4.58e-05 0.36 0.36 Schizophrenia; chr15:43895793 chr15:43663654~43684339:- CESC cis rs11155671 0.53 rs6557133 ENSG00000216906.2 RP11-350J20.9 5.7 3.91e-08 4.58e-05 0.39 0.36 Testicular germ cell tumor; chr6:149874248 chr6:149904243~149906418:+ CESC cis rs34779708 0.897 rs7897827 ENSG00000230534.5 RP11-297A16.2 5.7 3.92e-08 4.58e-05 0.47 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35097309 chr10:35098006~35127020:- CESC cis rs875971 0.564 rs313804 ENSG00000222364.1 RNU6-96P -5.7 3.92e-08 4.59e-05 -0.43 -0.36 Aortic root size; chr7:66049635 chr7:66395191~66395286:+ CESC cis rs875971 0.662 rs448725 ENSG00000222364.1 RNU6-96P -5.7 3.92e-08 4.59e-05 -0.43 -0.36 Aortic root size; chr7:66049641 chr7:66395191~66395286:+ CESC cis rs875971 0.658 rs432667 ENSG00000222364.1 RNU6-96P -5.7 3.92e-08 4.59e-05 -0.43 -0.36 Aortic root size; chr7:66049646 chr7:66395191~66395286:+ CESC cis rs6991838 0.8 rs28547533 ENSG00000272010.1 CTD-3025N20.3 5.7 3.94e-08 4.61e-05 0.39 0.36 Intelligence (multi-trait analysis); chr8:65559318 chr8:65591850~65592472:- CESC cis rs6991838 0.8 rs28626262 ENSG00000272010.1 CTD-3025N20.3 5.7 3.94e-08 4.61e-05 0.39 0.36 Intelligence (multi-trait analysis); chr8:65559335 chr8:65591850~65592472:- CESC cis rs6991838 0.8 rs28709439 ENSG00000272010.1 CTD-3025N20.3 5.7 3.94e-08 4.61e-05 0.39 0.36 Intelligence (multi-trait analysis); chr8:65559337 chr8:65591850~65592472:- CESC cis rs79349575 0.783 rs4255820 ENSG00000270781.1 RP11-501C14.9 -5.7 3.94e-08 4.61e-05 -0.4 -0.36 Type 2 diabetes; chr17:48919221 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs318095 ENSG00000270781.1 RP11-501C14.9 -5.7 3.95e-08 4.62e-05 -0.4 -0.36 Type 2 diabetes; chr17:48897372 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs318096 ENSG00000270781.1 RP11-501C14.9 -5.7 3.95e-08 4.62e-05 -0.4 -0.36 Type 2 diabetes; chr17:48898008 chr17:48899131~48899748:+ CESC cis rs79349575 0.777 rs28517720 ENSG00000270781.1 RP11-501C14.9 -5.7 3.95e-08 4.62e-05 -0.4 -0.36 Type 2 diabetes; chr17:48899394 chr17:48899131~48899748:+ CESC cis rs79349575 0.756 rs2643361 ENSG00000270781.1 RP11-501C14.9 -5.7 3.95e-08 4.62e-05 -0.4 -0.36 Type 2 diabetes; chr17:48900100 chr17:48899131~48899748:+ CESC cis rs79349575 0.749 rs2546491 ENSG00000270781.1 RP11-501C14.9 -5.7 3.95e-08 4.62e-05 -0.4 -0.36 Type 2 diabetes; chr17:48900554 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs962272 ENSG00000270781.1 RP11-501C14.9 -5.7 3.95e-08 4.62e-05 -0.4 -0.36 Type 2 diabetes; chr17:48900921 chr17:48899131~48899748:+ CESC cis rs2280018 0.526 rs2941257 ENSG00000260735.1 RP11-72I8.1 -5.7 3.95e-08 4.62e-05 -0.41 -0.36 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072588 chr16:15094411~15109197:+ CESC cis rs2280018 0.526 rs1510148 ENSG00000260735.1 RP11-72I8.1 -5.7 3.95e-08 4.62e-05 -0.41 -0.36 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15073522 chr16:15094411~15109197:+ CESC cis rs8072100 1 rs4794048 ENSG00000228782.6 CTD-2026D20.3 5.7 3.96e-08 4.63e-05 0.4 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47685707 chr17:47450568~47492492:- CESC cis rs9545047 0.604 rs11620233 ENSG00000227676.3 LINC01068 -5.69 3.98e-08 4.65e-05 -0.41 -0.36 Schizophrenia; chr13:79373871 chr13:79566727~79571436:+ CESC cis rs8062405 0.755 rs62034350 ENSG00000259982.1 CDC37P1 5.69 3.98e-08 4.65e-05 0.46 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28550935 chr16:28700294~28701540:- CESC cis rs1062177 0.855 rs919262 ENSG00000213433.5 RPLP1P6 5.69 3.99e-08 4.66e-05 0.41 0.36 Preschool internalizing problems; chr5:151886523 chr5:151765859~151766378:- CESC cis rs79349575 0.783 rs2112617 ENSG00000270781.1 RP11-501C14.9 -5.69 4e-08 4.68e-05 -0.41 -0.36 Type 2 diabetes; chr17:48899763 chr17:48899131~48899748:+ CESC cis rs9584850 0.834 rs17574378 ENSG00000231194.1 FARP1-AS1 5.69 4e-08 4.68e-05 0.45 0.36 Neuroticism; chr13:98464130 chr13:98435405~98435840:- CESC cis rs116095464 0.558 rs7710005 ENSG00000250848.1 CTD-2083E4.5 -5.69 4.01e-08 4.68e-05 -0.46 -0.36 Breast cancer; chr5:233457 chr5:288833~290321:- CESC cis rs9876781 0.56 rs2362451 ENSG00000229759.1 MRPS18AP1 -5.69 4.01e-08 4.68e-05 -0.34 -0.36 Longevity; chr3:48358338 chr3:48256350~48256938:- CESC cis rs2243480 0.901 rs3813708 ENSG00000228409.4 CCT6P1 5.69 4.01e-08 4.69e-05 0.52 0.36 Diabetic kidney disease; chr7:65840645 chr7:65751142~65763354:+ CESC cis rs2177312 0.868 rs11734946 ENSG00000251129.1 RP11-734I18.1 -5.69 4.02e-08 4.69e-05 -0.45 -0.36 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31942218 chr4:31997397~32155406:+ CESC cis rs12022452 1 rs3738471 ENSG00000238287.1 RP11-656D10.3 -5.69 4.02e-08 4.69e-05 -0.58 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40540873 chr1:40493157~40508661:- CESC cis rs62229266 0.804 rs62230822 ENSG00000231106.2 LINC01436 5.69 4.02e-08 4.69e-05 0.5 0.36 Mitral valve prolapse; chr21:36057647 chr21:36005338~36007838:+ CESC cis rs2243480 1 rs73142166 ENSG00000228409.4 CCT6P1 5.69 4.02e-08 4.69e-05 0.54 0.36 Diabetic kidney disease; chr7:65910845 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34193460 ENSG00000228409.4 CCT6P1 5.69 4.02e-08 4.69e-05 0.54 0.36 Diabetic kidney disease; chr7:65928123 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs57057549 ENSG00000228409.4 CCT6P1 5.69 4.02e-08 4.69e-05 0.54 0.36 Diabetic kidney disease; chr7:65940751 chr7:65751142~65763354:+ CESC cis rs4423214 0.879 rs1630498 ENSG00000254682.1 RP11-660L16.2 -5.69 4.02e-08 4.69e-05 -0.48 -0.36 Vitamin D levels; chr11:71439739 chr11:71448674~71452157:+ CESC cis rs875971 1 rs709597 ENSG00000222364.1 RNU6-96P 5.69 4.02e-08 4.69e-05 0.42 0.36 Aortic root size; chr7:66360996 chr7:66395191~66395286:+ CESC cis rs11096990 0.656 rs7686161 ENSG00000249207.1 RP11-360F5.1 5.69 4.02e-08 4.69e-05 0.39 0.36 Cognitive function; chr4:39283201 chr4:39112677~39126818:- CESC cis rs8062405 0.755 rs111693583 ENSG00000259982.1 CDC37P1 5.69 4.03e-08 4.7e-05 0.45 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28572289 chr16:28700294~28701540:- CESC cis rs2404602 0.716 rs56216512 ENSG00000259422.1 RP11-593F23.1 5.69 4.03e-08 4.7e-05 0.4 0.36 Blood metabolite levels; chr15:76394595 chr15:76174891~76181486:- CESC cis rs79349575 0.783 rs903567 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48902956 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs62075818 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48904965 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs9912829 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48905387 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs62075820 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48905809 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs4294857 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48906029 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs61576918 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48908231 chr17:48899131~48899748:+ CESC cis rs79349575 0.729 rs62075824 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48909317 chr17:48899131~48899748:+ CESC cis rs79349575 0.749 rs46521 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48911167 chr17:48899131~48899748:+ CESC cis rs79349575 0.749 rs318093 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48911992 chr17:48899131~48899748:+ CESC cis rs79349575 0.745 rs170319 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48914169 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs318090 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48914390 chr17:48899131~48899748:+ CESC cis rs79349575 0.721 rs3744608 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48915871 chr17:48899131~48899748:+ CESC cis rs79349575 0.651 rs4378658 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48916008 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs12453394 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48917608 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs62075838 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48919070 chr17:48899131~48899748:+ CESC cis rs79349575 0.783 rs62075839 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48919072 chr17:48899131~48899748:+ CESC cis rs2729354 0.953 rs1846567 ENSG00000265566.2 RN7SL605P -5.69 4.04e-08 4.71e-05 -0.55 -0.36 Blood protein levels; chr11:57590120 chr11:57528085~57528365:- CESC cis rs79349575 0.783 rs12453374 ENSG00000270781.1 RP11-501C14.9 -5.69 4.04e-08 4.71e-05 -0.4 -0.36 Type 2 diabetes; chr17:48917484 chr17:48899131~48899748:+ CESC cis rs2404602 0.692 rs4641709 ENSG00000259422.1 RP11-593F23.1 -5.69 4.05e-08 4.73e-05 -0.4 -0.36 Blood metabolite levels; chr15:76755395 chr15:76174891~76181486:- CESC cis rs1062177 0.951 rs2915876 ENSG00000253921.1 CTB-113P19.3 -5.69 4.06e-08 4.74e-05 -0.49 -0.36 Preschool internalizing problems; chr5:151771184 chr5:151753992~151767247:+ CESC cis rs9545047 0.716 rs7140027 ENSG00000227676.3 LINC01068 5.69 4.06e-08 4.74e-05 0.4 0.36 Schizophrenia; chr13:79281162 chr13:79566727~79571436:+ CESC cis rs116095464 0.558 rs12173244 ENSG00000250848.1 CTD-2083E4.5 -5.69 4.08e-08 4.76e-05 -0.47 -0.36 Breast cancer; chr5:269409 chr5:288833~290321:- CESC cis rs116095464 0.558 rs56127718 ENSG00000250848.1 CTD-2083E4.5 -5.69 4.08e-08 4.76e-05 -0.47 -0.36 Breast cancer; chr5:270158 chr5:288833~290321:- CESC cis rs34779708 0.931 rs7079498 ENSG00000230534.5 RP11-297A16.2 5.69 4.08e-08 4.76e-05 0.47 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35086416 chr10:35098006~35127020:- CESC cis rs17711722 0.522 rs6957759 ENSG00000228409.4 CCT6P1 -5.69 4.09e-08 4.76e-05 -0.33 -0.36 Calcium levels; chr7:65806798 chr7:65751142~65763354:+ CESC cis rs12022452 0.822 rs11811369 ENSG00000238287.1 RP11-656D10.3 -5.69 4.09e-08 4.76e-05 -0.52 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40560611 chr1:40493157~40508661:- CESC cis rs2442825 0.693 rs2596913 ENSG00000206573.7 THUMPD3-AS1 5.69 4.09e-08 4.77e-05 0.35 0.36 Cerebrospinal fluid clusterin levels; chr3:9394788 chr3:9349689~9398579:- CESC cis rs2404602 0.692 rs67010831 ENSG00000259422.1 RP11-593F23.1 5.69 4.1e-08 4.77e-05 0.41 0.36 Blood metabolite levels; chr15:76672967 chr15:76174891~76181486:- CESC cis rs2404602 0.655 rs4886824 ENSG00000259422.1 RP11-593F23.1 5.69 4.1e-08 4.77e-05 0.41 0.36 Blood metabolite levels; chr15:76676915 chr15:76174891~76181486:- CESC cis rs7572733 1 rs7572733 ENSG00000222017.1 AC011997.1 5.69 4.1e-08 4.77e-05 0.4 0.36 Dermatomyositis; chr2:198065082 chr2:197693106~197774823:+ CESC cis rs2243480 1 rs73142162 ENSG00000228409.4 CCT6P1 5.69 4.1e-08 4.78e-05 0.54 0.36 Diabetic kidney disease; chr7:65909309 chr7:65751142~65763354:+ CESC cis rs2243480 0.808 rs12698508 ENSG00000228409.4 CCT6P1 5.69 4.1e-08 4.78e-05 0.54 0.36 Diabetic kidney disease; chr7:65946971 chr7:65751142~65763354:+ CESC cis rs79349575 0.783 rs1994970 ENSG00000270781.1 RP11-501C14.9 5.69 4.12e-08 4.79e-05 0.4 0.36 Type 2 diabetes; chr17:48936765 chr17:48899131~48899748:+ CESC cis rs116095464 0.558 rs6872854 ENSG00000250848.1 CTD-2083E4.5 -5.69 4.13e-08 4.8e-05 -0.44 -0.36 Breast cancer; chr5:208923 chr5:288833~290321:- CESC cis rs10262624 0.935 rs6966641 ENSG00000234286.1 AC006026.13 -5.69 4.13e-08 4.8e-05 -0.38 -0.36 Schizophrenia; chr7:23866979 chr7:23680195~23680786:- CESC cis rs801193 0.569 rs10950050 ENSG00000237310.1 GS1-124K5.4 5.69 4.13e-08 4.81e-05 0.33 0.36 Aortic root size; chr7:66774601 chr7:66493706~66495474:+ CESC cis rs957448 1 rs12678305 ENSG00000253704.1 RP11-267M23.4 5.69 4.15e-08 4.83e-05 0.4 0.36 Nonsyndromic cleft lip with cleft palate; chr8:94508911 chr8:94553722~94569745:+ CESC cis rs957448 0.948 rs1470153 ENSG00000253704.1 RP11-267M23.4 5.69 4.15e-08 4.83e-05 0.4 0.36 Nonsyndromic cleft lip with cleft palate; chr8:94514587 chr8:94553722~94569745:+ CESC cis rs6504950 0.925 rs2787483 ENSG00000275710.1 RP11-257O5.4 5.69 4.17e-08 4.84e-05 0.47 0.36 Breast cancer; chr17:55132953 chr17:54964474~54964679:+ CESC cis rs6504950 0.925 rs2628317 ENSG00000275710.1 RP11-257O5.4 5.69 4.17e-08 4.84e-05 0.47 0.36 Breast cancer; chr17:55135212 chr17:54964474~54964679:+ CESC cis rs8072100 0.967 rs2317826 ENSG00000228782.6 CTD-2026D20.3 5.68 4.21e-08 4.89e-05 0.41 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47653533 chr17:47450568~47492492:- CESC cis rs8072100 0.967 rs4580230 ENSG00000228782.6 CTD-2026D20.3 5.68 4.21e-08 4.89e-05 0.41 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47661495 chr17:47450568~47492492:- CESC cis rs2243480 1 rs4718334 ENSG00000232559.3 GS1-124K5.12 -5.68 4.22e-08 4.9e-05 -0.59 -0.36 Diabetic kidney disease; chr7:66324467 chr7:66554588~66576923:- CESC cis rs12022452 0.822 rs11208390 ENSG00000238287.1 RP11-656D10.3 -5.68 4.23e-08 4.91e-05 -0.52 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40556342 chr1:40493157~40508661:- CESC cis rs3806843 0.9 rs2262576 ENSG00000202111.1 VTRNA1-2 5.68 4.23e-08 4.91e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140755951 chr5:140718925~140719013:+ CESC cis rs4660456 0.913 rs7542019 ENSG00000237899.1 RP4-739H11.3 5.68 4.25e-08 4.93e-05 0.49 0.36 Platelet count; chr1:40704039 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs1494 ENSG00000237899.1 RP4-739H11.3 5.68 4.25e-08 4.93e-05 0.49 0.36 Platelet count; chr1:40706176 chr1:40669089~40687588:- CESC cis rs4660456 0.869 rs7518344 ENSG00000237899.1 RP4-739H11.3 5.68 4.25e-08 4.93e-05 0.49 0.36 Platelet count; chr1:40708327 chr1:40669089~40687588:- CESC cis rs4660456 0.827 rs10736404 ENSG00000237899.1 RP4-739H11.3 5.68 4.25e-08 4.93e-05 0.49 0.36 Platelet count; chr1:40710331 chr1:40669089~40687588:- CESC cis rs875971 0.756 rs2901210 ENSG00000226824.5 RP4-756H11.3 5.68 4.25e-08 4.93e-05 0.45 0.36 Aortic root size; chr7:66552518 chr7:66654538~66669855:+ CESC cis rs7048146 0.966 rs4978401 ENSG00000213539.4 YBX1P6 -5.68 4.26e-08 4.94e-05 -0.42 -0.36 Vascular brain injury; chr9:109540631 chr9:109532830~109534332:- CESC cis rs6452524 1 rs2126988 ENSG00000249664.1 CTD-2227C6.2 5.68 4.26e-08 4.94e-05 0.39 0.36 Hypertension (SNP x SNP interaction); chr5:83146496 chr5:83012285~83013109:- CESC cis rs2404602 0.716 rs17362383 ENSG00000259422.1 RP11-593F23.1 5.68 4.27e-08 4.95e-05 0.4 0.36 Blood metabolite levels; chr15:76358361 chr15:76174891~76181486:- CESC cis rs6452524 0.905 rs10040244 ENSG00000249664.1 CTD-2227C6.2 5.68 4.27e-08 4.95e-05 0.41 0.36 Hypertension (SNP x SNP interaction); chr5:83089242 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs10474081 ENSG00000249664.1 CTD-2227C6.2 5.68 4.27e-08 4.95e-05 0.41 0.36 Hypertension (SNP x SNP interaction); chr5:83095064 chr5:83012285~83013109:- CESC cis rs4718428 0.672 rs4718412 ENSG00000226824.5 RP4-756H11.3 5.68 4.28e-08 4.97e-05 0.5 0.36 Corneal structure; chr7:66821880 chr7:66654538~66669855:+ CESC cis rs992157 0.71 rs12996912 ENSG00000261338.2 RP11-378A13.1 5.68 4.29e-08 4.97e-05 0.43 0.36 Colorectal cancer; chr2:218245832 chr2:218255319~218257366:+ CESC cis rs10875746 0.729 rs1990028 ENSG00000240399.1 RP1-228P16.1 -5.68 4.29e-08 4.97e-05 -0.45 -0.36 Longevity (90 years and older); chr12:48014230 chr12:48054813~48055591:- CESC cis rs8072100 0.934 rs9905583 ENSG00000228782.6 CTD-2026D20.3 5.68 4.29e-08 4.98e-05 0.41 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47663650 chr17:47450568~47492492:- CESC cis rs801193 0.591 rs4506088 ENSG00000226824.5 RP4-756H11.3 5.68 4.3e-08 4.98e-05 0.45 0.36 Aortic root size; chr7:66670470 chr7:66654538~66669855:+ CESC cis rs1823913 0.637 rs2883912 ENSG00000280083.1 RP11-317J9.1 5.68 4.31e-08 4.99e-05 0.41 0.36 Obesity-related traits; chr2:191284290 chr2:191154118~191156070:- CESC cis rs1823913 0.637 rs921737 ENSG00000280083.1 RP11-317J9.1 5.68 4.31e-08 4.99e-05 0.41 0.36 Obesity-related traits; chr2:191286097 chr2:191154118~191156070:- CESC cis rs1823913 0.599 rs6736071 ENSG00000280083.1 RP11-317J9.1 5.68 4.31e-08 4.99e-05 0.41 0.36 Obesity-related traits; chr2:191287265 chr2:191154118~191156070:- CESC cis rs11096990 0.572 rs35040563 ENSG00000249207.1 RP11-360F5.1 -5.68 4.32e-08 5e-05 -0.4 -0.36 Cognitive function; chr4:39154262 chr4:39112677~39126818:- CESC cis rs9545047 0.604 rs7329331 ENSG00000227676.3 LINC01068 5.68 4.32e-08 5e-05 0.4 0.36 Schizophrenia; chr13:79384986 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7330479 ENSG00000227676.3 LINC01068 5.68 4.32e-08 5e-05 0.4 0.36 Schizophrenia; chr13:79385058 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs6563104 ENSG00000227676.3 LINC01068 5.68 4.32e-08 5e-05 0.4 0.36 Schizophrenia; chr13:79389718 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7981500 ENSG00000227676.3 LINC01068 5.68 4.32e-08 5e-05 0.4 0.36 Schizophrenia; chr13:79391461 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs57821487 ENSG00000227676.3 LINC01068 5.68 4.32e-08 5e-05 0.4 0.36 Schizophrenia; chr13:79392810 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7323246 ENSG00000227676.3 LINC01068 5.68 4.32e-08 5e-05 0.4 0.36 Schizophrenia; chr13:79392903 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7331766 ENSG00000227676.3 LINC01068 5.68 4.32e-08 5e-05 0.4 0.36 Schizophrenia; chr13:79394076 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9530915 ENSG00000227676.3 LINC01068 5.68 4.32e-08 5e-05 0.4 0.36 Schizophrenia; chr13:79396512 chr13:79566727~79571436:+ CESC cis rs10875746 0.951 rs7485355 ENSG00000240399.1 RP1-228P16.1 -5.68 4.33e-08 5.01e-05 -0.46 -0.36 Longevity (90 years and older); chr12:48154559 chr12:48054813~48055591:- CESC cis rs13631 0.728 rs7466635 ENSG00000268996.3 MAN1B1-AS1 -5.68 4.33e-08 5.01e-05 -0.34 -0.36 Cerebrospinal fluid biomarker levels; chr9:137085965 chr9:137084946~137086817:- CESC cis rs9907295 0.636 rs4251724 ENSG00000270977.1 AC015849.16 -5.68 4.33e-08 5.01e-05 -0.43 -0.36 Fibroblast growth factor basic levels; chr17:35816641 chr17:35893707~35911023:- CESC cis rs9545047 0.604 rs2876740 ENSG00000227676.3 LINC01068 -5.68 4.34e-08 5.02e-05 -0.41 -0.36 Schizophrenia; chr13:79409829 chr13:79566727~79571436:+ CESC cis rs35955747 0.811 rs9606835 ENSG00000236132.1 CTA-440B3.1 -5.68 4.34e-08 5.03e-05 -0.42 -0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31370974 chr22:31816379~31817491:- CESC cis rs1707322 0.717 rs3014237 ENSG00000281133.1 AL355480.3 5.68 4.35e-08 5.03e-05 0.44 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624580 chr1:45580892~45580996:- CESC cis rs3806843 0.808 rs6893708 ENSG00000202111.1 VTRNA1-2 5.68 4.35e-08 5.03e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140746337 chr5:140718925~140719013:+ CESC cis rs3806843 0.778 rs2531346 ENSG00000202111.1 VTRNA1-2 5.68 4.35e-08 5.03e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140746554 chr5:140718925~140719013:+ CESC cis rs1062177 1 rs17741826 ENSG00000253921.1 CTB-113P19.3 5.68 4.36e-08 5.04e-05 0.47 0.36 Preschool internalizing problems; chr5:151769701 chr5:151753992~151767247:+ CESC cis rs1707322 0.963 rs1768815 ENSG00000280836.1 AL355480.1 5.68 4.36e-08 5.05e-05 0.42 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46062931 chr1:45581219~45581321:- CESC cis rs860295 0.58 rs11264361 ENSG00000225855.5 RUSC1-AS1 5.68 4.37e-08 5.05e-05 0.31 0.36 Body mass index; chr1:155319754 chr1:155316863~155324176:- CESC cis rs2404602 0.692 rs3110382 ENSG00000259422.1 RP11-593F23.1 -5.68 4.37e-08 5.06e-05 -0.41 -0.36 Blood metabolite levels; chr15:76856347 chr15:76174891~76181486:- CESC cis rs6860806 0.507 rs273912 ENSG00000233006.5 AC034220.3 -5.68 4.38e-08 5.07e-05 -0.4 -0.36 Breast cancer; chr5:132325656 chr5:132311285~132369916:- CESC cis rs2108622 1 rs55744319 ENSG00000267453.5 AC004791.2 -5.67 4.39e-08 5.07e-05 -0.49 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871011 chr19:15851993~15864904:- CESC cis rs2108622 0.958 rs56340170 ENSG00000267453.5 AC004791.2 -5.67 4.39e-08 5.07e-05 -0.49 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871067 chr19:15851993~15864904:- CESC cis rs9545047 0.604 rs7986306 ENSG00000227676.3 LINC01068 5.67 4.4e-08 5.08e-05 0.4 0.36 Schizophrenia; chr13:79392530 chr13:79566727~79571436:+ CESC cis rs6860806 0.507 rs2631372 ENSG00000233006.5 AC034220.3 5.67 4.41e-08 5.09e-05 0.46 0.36 Breast cancer; chr5:132367886 chr5:132311285~132369916:- CESC cis rs2404602 0.692 rs72738889 ENSG00000259422.1 RP11-593F23.1 5.67 4.41e-08 5.1e-05 0.41 0.36 Blood metabolite levels; chr15:76699722 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs3816266 ENSG00000259422.1 RP11-593F23.1 5.67 4.41e-08 5.1e-05 0.41 0.36 Blood metabolite levels; chr15:76701494 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs2304920 ENSG00000259422.1 RP11-593F23.1 5.67 4.41e-08 5.1e-05 0.41 0.36 Blood metabolite levels; chr15:76701526 chr15:76174891~76181486:- CESC cis rs10740039 0.583 rs2127350 ENSG00000254271.1 RP11-131N11.4 -5.67 4.42e-08 5.11e-05 -0.44 -0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741079 chr10:60734342~60741828:+ CESC cis rs10740039 0.583 rs2127351 ENSG00000254271.1 RP11-131N11.4 -5.67 4.42e-08 5.11e-05 -0.44 -0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741425 chr10:60734342~60741828:+ CESC cis rs2243480 1 rs4718270 ENSG00000228409.4 CCT6P1 5.67 4.43e-08 5.12e-05 0.54 0.36 Diabetic kidney disease; chr7:65737415 chr7:65751142~65763354:+ CESC cis rs34779708 0.931 rs34087268 ENSG00000230534.5 RP11-297A16.2 5.67 4.45e-08 5.14e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35057796 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs58159560 ENSG00000230534.5 RP11-297A16.2 5.67 4.45e-08 5.14e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35062321 chr10:35098006~35127020:- CESC cis rs79349575 0.783 rs28409394 ENSG00000270781.1 RP11-501C14.9 -5.67 4.45e-08 5.14e-05 -0.4 -0.36 Type 2 diabetes; chr17:48920756 chr17:48899131~48899748:+ CESC cis rs10885396 1 rs10885396 ENSG00000233547.1 RP11-57H14.2 -5.67 4.45e-08 5.14e-05 -0.39 -0.36 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112951996 chr10:112950646~112951875:- CESC cis rs6452524 0.967 rs12186460 ENSG00000249664.1 CTD-2227C6.2 5.67 4.46e-08 5.15e-05 0.39 0.36 Hypertension (SNP x SNP interaction); chr5:83123950 chr5:83012285~83013109:- CESC cis rs11096990 0.634 rs11736790 ENSG00000249207.1 RP11-360F5.1 -5.67 4.48e-08 5.17e-05 -0.4 -0.36 Cognitive function; chr4:39254704 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs1451818 ENSG00000249207.1 RP11-360F5.1 -5.67 4.48e-08 5.17e-05 -0.4 -0.36 Cognitive function; chr4:39257151 chr4:39112677~39126818:- CESC cis rs35160687 0.901 rs34048420 ENSG00000273080.1 RP11-301O19.1 5.67 4.48e-08 5.17e-05 0.42 0.36 Night sleep phenotypes; chr2:86302625 chr2:86195590~86196049:+ CESC cis rs35160687 0.901 rs34069316 ENSG00000273080.1 RP11-301O19.1 5.67 4.48e-08 5.17e-05 0.42 0.36 Night sleep phenotypes; chr2:86302669 chr2:86195590~86196049:+ CESC cis rs35160687 0.901 rs11127026 ENSG00000273080.1 RP11-301O19.1 5.67 4.48e-08 5.17e-05 0.42 0.36 Night sleep phenotypes; chr2:86304625 chr2:86195590~86196049:+ CESC cis rs8062405 0.573 rs7187575 ENSG00000259982.1 CDC37P1 -5.67 4.48e-08 5.17e-05 -0.47 -0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28978780 chr16:28700294~28701540:- CESC cis rs9309711 0.772 rs9309715 ENSG00000225234.1 TRAPPC12-AS1 5.67 4.49e-08 5.17e-05 0.37 0.36 Neurofibrillary tangles; chr2:3488547 chr2:3481242~3482409:- CESC cis rs2243480 1 rs73150014 ENSG00000228409.4 CCT6P1 5.67 4.5e-08 5.18e-05 0.52 0.36 Diabetic kidney disease; chr7:65985932 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1723270 ENSG00000228409.4 CCT6P1 5.67 4.5e-08 5.18e-05 0.52 0.36 Diabetic kidney disease; chr7:66004843 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35396113 ENSG00000228409.4 CCT6P1 5.67 4.5e-08 5.18e-05 0.52 0.36 Diabetic kidney disease; chr7:66030474 chr7:65751142~65763354:+ CESC cis rs748404 0.66 rs509306 ENSG00000249839.1 AC011330.5 -5.67 4.5e-08 5.19e-05 -0.37 -0.36 Lung cancer; chr15:43422973 chr15:43663654~43684339:- CESC cis rs17507216 1 rs3850610 ENSG00000255769.6 GOLGA2P10 5.67 4.5e-08 5.19e-05 0.48 0.36 Excessive daytime sleepiness; chr15:82552642 chr15:82472993~82513950:- CESC cis rs950169 0.919 rs12915589 ENSG00000225151.9 GOLGA2P7 -5.67 4.53e-08 5.22e-05 -0.51 -0.36 Schizophrenia; chr15:84065712 chr15:84199311~84230136:- CESC cis rs950169 0.959 rs66801143 ENSG00000225151.9 GOLGA2P7 -5.67 4.53e-08 5.22e-05 -0.51 -0.36 Schizophrenia; chr15:84067905 chr15:84199311~84230136:- CESC cis rs950169 1 rs35648189 ENSG00000225151.9 GOLGA2P7 -5.67 4.53e-08 5.22e-05 -0.51 -0.36 Schizophrenia; chr15:84071996 chr15:84199311~84230136:- CESC cis rs950169 0.92 rs17300048 ENSG00000225151.9 GOLGA2P7 -5.67 4.53e-08 5.22e-05 -0.51 -0.36 Schizophrenia; chr15:84080725 chr15:84199311~84230136:- CESC cis rs950169 1 rs1848093 ENSG00000225151.9 GOLGA2P7 -5.67 4.53e-08 5.22e-05 -0.51 -0.36 Schizophrenia; chr15:84086775 chr15:84199311~84230136:- CESC cis rs950169 1 rs34751999 ENSG00000225151.9 GOLGA2P7 -5.67 4.53e-08 5.22e-05 -0.51 -0.36 Schizophrenia; chr15:84089667 chr15:84199311~84230136:- CESC cis rs6991838 0.771 rs13282323 ENSG00000272010.1 CTD-3025N20.3 5.67 4.57e-08 5.26e-05 0.39 0.36 Intelligence (multi-trait analysis); chr8:65560557 chr8:65591850~65592472:- CESC cis rs12022452 1 rs2184877 ENSG00000238287.1 RP11-656D10.3 -5.67 4.58e-08 5.26e-05 -0.56 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40531260 chr1:40493157~40508661:- CESC cis rs35160687 0.901 rs12714180 ENSG00000273080.1 RP11-301O19.1 5.67 4.58e-08 5.27e-05 0.42 0.36 Night sleep phenotypes; chr2:86298200 chr2:86195590~86196049:+ CESC cis rs35160687 0.901 rs35281683 ENSG00000273080.1 RP11-301O19.1 5.67 4.58e-08 5.27e-05 0.42 0.36 Night sleep phenotypes; chr2:86299249 chr2:86195590~86196049:+ CESC cis rs35160687 0.901 rs10200186 ENSG00000273080.1 RP11-301O19.1 5.67 4.58e-08 5.27e-05 0.42 0.36 Night sleep phenotypes; chr2:86300300 chr2:86195590~86196049:+ CESC cis rs35160687 0.842 rs10200526 ENSG00000273080.1 RP11-301O19.1 5.67 4.58e-08 5.27e-05 0.42 0.36 Night sleep phenotypes; chr2:86300476 chr2:86195590~86196049:+ CESC cis rs6504950 0.925 rs244315 ENSG00000275710.1 RP11-257O5.4 5.67 4.61e-08 5.3e-05 0.44 0.36 Breast cancer; chr17:55137293 chr17:54964474~54964679:+ CESC cis rs2243480 1 rs34970380 ENSG00000228409.4 CCT6P1 5.66 4.62e-08 5.31e-05 0.52 0.36 Diabetic kidney disease; chr7:65966506 chr7:65751142~65763354:+ CESC cis rs1062177 0.855 rs6896664 ENSG00000213433.5 RPLP1P6 -5.66 4.64e-08 5.33e-05 -0.4 -0.36 Preschool internalizing problems; chr5:151885713 chr5:151765859~151766378:- CESC cis rs11690935 0.921 rs4668414 ENSG00000228389.1 AC068039.4 5.66 4.65e-08 5.34e-05 0.48 0.36 Schizophrenia; chr2:171847781 chr2:171773482~171775844:+ CESC cis rs720475 0.732 rs17195725 ENSG00000204959.4 ARHGEF34P 5.66 4.67e-08 5.36e-05 0.4 0.36 Breast cancer; chr7:144440044 chr7:144272445~144286966:- CESC cis rs3806843 0.712 rs2530244 ENSG00000202111.1 VTRNA1-2 5.66 4.67e-08 5.36e-05 0.37 0.36 Depressive symptoms (multi-trait analysis); chr5:140729570 chr5:140718925~140719013:+ CESC cis rs7572733 0.967 rs11889326 ENSG00000222017.1 AC011997.1 5.66 4.67e-08 5.37e-05 0.39 0.36 Dermatomyositis; chr2:198034551 chr2:197693106~197774823:+ CESC cis rs11096990 0.634 rs2276888 ENSG00000249207.1 RP11-360F5.1 5.66 4.68e-08 5.37e-05 0.39 0.36 Cognitive function; chr4:39278287 chr4:39112677~39126818:- CESC cis rs10740039 0.583 rs1904401 ENSG00000254271.1 RP11-131N11.4 -5.66 4.7e-08 5.39e-05 -0.44 -0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741809 chr10:60734342~60741828:+ CESC cis rs801193 0.569 rs13242290 ENSG00000226824.5 RP4-756H11.3 5.66 4.7e-08 5.4e-05 0.45 0.36 Aortic root size; chr7:66656898 chr7:66654538~66669855:+ CESC cis rs6860806 0.507 rs2631369 ENSG00000233006.5 AC034220.3 -5.66 4.7e-08 5.4e-05 -0.4 -0.36 Breast cancer; chr5:132369574 chr5:132311285~132369916:- CESC cis rs274567 0.501 rs2631368 ENSG00000233006.5 AC034220.3 -5.66 4.7e-08 5.4e-05 -0.4 -0.36 Blood metabolite levels; chr5:132369605 chr5:132311285~132369916:- CESC cis rs3806843 1 rs10223116 ENSG00000202111.1 VTRNA1-2 -5.66 4.71e-08 5.41e-05 -0.36 -0.36 Depressive symptoms (multi-trait analysis); chr5:140813058 chr5:140718925~140719013:+ CESC cis rs992157 0.835 rs4674282 ENSG00000261338.2 RP11-378A13.1 -5.66 4.71e-08 5.41e-05 -0.47 -0.36 Colorectal cancer; chr2:218279507 chr2:218255319~218257366:+ CESC cis rs2729354 1 rs2848630 ENSG00000265566.2 RN7SL605P -5.66 4.72e-08 5.41e-05 -0.54 -0.36 Blood protein levels; chr11:57589434 chr11:57528085~57528365:- CESC cis rs992157 0.767 rs2382822 ENSG00000261338.2 RP11-378A13.1 -5.66 4.72e-08 5.41e-05 -0.45 -0.36 Colorectal cancer; chr2:218308604 chr2:218255319~218257366:+ CESC cis rs10740039 0.583 rs2127352 ENSG00000254271.1 RP11-131N11.4 -5.66 4.73e-08 5.42e-05 -0.44 -0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60742129 chr10:60734342~60741828:+ CESC cis rs189798 0.807 rs330909 ENSG00000254340.1 RP11-10A14.3 5.66 4.73e-08 5.42e-05 0.46 0.36 Myopia (pathological); chr8:9137877 chr8:9141424~9145435:+ CESC cis rs10875746 0.903 rs11168418 ENSG00000240399.1 RP1-228P16.1 -5.66 4.73e-08 5.43e-05 -0.47 -0.36 Longevity (90 years and older); chr12:48121971 chr12:48054813~48055591:- CESC cis rs34779708 0.931 rs35126129 ENSG00000230534.5 RP11-297A16.2 5.66 4.74e-08 5.43e-05 0.47 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35163213 chr10:35098006~35127020:- CESC cis rs2404602 0.692 rs59088060 ENSG00000259422.1 RP11-593F23.1 5.66 4.74e-08 5.44e-05 0.41 0.36 Blood metabolite levels; chr15:76567633 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs12902174 ENSG00000259422.1 RP11-593F23.1 5.66 4.74e-08 5.44e-05 0.41 0.36 Blood metabolite levels; chr15:76571199 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs12438077 ENSG00000259422.1 RP11-593F23.1 5.66 4.74e-08 5.44e-05 0.41 0.36 Blood metabolite levels; chr15:76571260 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs12441550 ENSG00000259422.1 RP11-593F23.1 5.66 4.74e-08 5.44e-05 0.41 0.36 Blood metabolite levels; chr15:76571341 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs1874944 ENSG00000259422.1 RP11-593F23.1 5.66 4.74e-08 5.44e-05 0.41 0.36 Blood metabolite levels; chr15:76571587 chr15:76174891~76181486:- CESC cis rs17507216 0.718 rs72753931 ENSG00000278603.1 RP13-608F4.5 5.66 4.75e-08 5.44e-05 0.66 0.36 Excessive daytime sleepiness; chr15:82721485 chr15:82472203~82472426:+ CESC cis rs12022452 1 rs75936657 ENSG00000238287.1 RP11-656D10.3 -5.66 4.75e-08 5.44e-05 -0.58 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40536017 chr1:40493157~40508661:- CESC cis rs7572733 1 rs1579695 ENSG00000222017.1 AC011997.1 5.66 4.76e-08 5.46e-05 0.39 0.36 Dermatomyositis; chr2:198035639 chr2:197693106~197774823:+ CESC cis rs17507216 0.628 rs28737193 ENSG00000278603.1 RP13-608F4.5 5.66 4.77e-08 5.46e-05 0.58 0.36 Excessive daytime sleepiness; chr15:82701318 chr15:82472203~82472426:+ CESC cis rs9584850 0.834 rs745638 ENSG00000231194.1 FARP1-AS1 -5.66 4.79e-08 5.49e-05 -0.45 -0.36 Neuroticism; chr13:98467053 chr13:98435405~98435840:- CESC cis rs2404602 0.646 rs3764245 ENSG00000259422.1 RP11-593F23.1 5.66 4.79e-08 5.49e-05 0.41 0.36 Blood metabolite levels; chr15:76930835 chr15:76174891~76181486:- CESC cis rs950169 0.922 rs62029585 ENSG00000225151.9 GOLGA2P7 -5.66 4.81e-08 5.51e-05 -0.52 -0.36 Schizophrenia; chr15:84397176 chr15:84199311~84230136:- CESC cis rs9399135 1 rs11754265 ENSG00000232876.1 CTA-212D2.2 -5.66 4.81e-08 5.51e-05 -0.41 -0.36 Red blood cell count; chr6:135035078 chr6:135055033~135060550:+ CESC cis rs6452524 1 rs6452524 ENSG00000249664.1 CTD-2227C6.2 -5.66 4.82e-08 5.52e-05 -0.39 -0.36 Hypertension (SNP x SNP interaction); chr5:83137962 chr5:83012285~83013109:- CESC cis rs9322193 0.923 rs62439840 ENSG00000268592.3 RAET1E-AS1 5.66 4.83e-08 5.53e-05 0.48 0.36 Lung cancer; chr6:149674639 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9393175 ENSG00000268592.3 RAET1E-AS1 5.66 4.83e-08 5.53e-05 0.48 0.36 Lung cancer; chr6:149677587 chr6:149863494~149919507:+ CESC cis rs875971 0.825 rs28480509 ENSG00000237310.1 GS1-124K5.4 -5.66 4.83e-08 5.53e-05 -0.34 -0.36 Aortic root size; chr7:66634237 chr7:66493706~66495474:+ CESC cis rs1075265 0.567 rs66773232 ENSG00000233266.1 HMGB1P31 5.66 4.85e-08 5.55e-05 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:53973970 chr2:54051334~54051760:+ CESC cis rs1075265 0.633 rs3731967 ENSG00000233266.1 HMGB1P31 -5.66 4.85e-08 5.55e-05 -0.47 -0.36 Chronotype;Morning vs. evening chronotype; chr2:53975311 chr2:54051334~54051760:+ CESC cis rs2404602 0.692 rs34272342 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76719935 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs67570291 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76728161 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs1471780 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76734185 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs4442773 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76739292 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs60658665 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76750167 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs12910382 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76761101 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs12911902 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76761234 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs4383105 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76763169 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs7174673 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76779657 chr15:76174891~76181486:- CESC cis rs2404602 0.655 rs8028294 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76792536 chr15:76174891~76181486:- CESC cis rs2404602 0.669 rs12441484 ENSG00000259422.1 RP11-593F23.1 5.66 4.85e-08 5.55e-05 0.4 0.36 Blood metabolite levels; chr15:76817534 chr15:76174891~76181486:- CESC cis rs9481169 0.85 rs4947128 ENSG00000255389.1 C6orf3 -5.65 4.86e-08 5.56e-05 -0.66 -0.36 Inflammatory skin disease; chr6:111597665 chr6:111599875~111602295:+ CESC cis rs950169 0.92 rs2135551 ENSG00000225151.9 GOLGA2P7 -5.65 4.86e-08 5.56e-05 -0.51 -0.36 Schizophrenia; chr15:84039099 chr15:84199311~84230136:- CESC cis rs950169 1 rs12902672 ENSG00000225151.9 GOLGA2P7 -5.65 4.86e-08 5.56e-05 -0.51 -0.36 Schizophrenia; chr15:84048234 chr15:84199311~84230136:- CESC cis rs950169 1 rs12903820 ENSG00000225151.9 GOLGA2P7 -5.65 4.86e-08 5.56e-05 -0.51 -0.36 Schizophrenia; chr15:84055068 chr15:84199311~84230136:- CESC cis rs801193 0.569 rs35070132 ENSG00000237310.1 GS1-124K5.4 5.65 4.89e-08 5.59e-05 0.34 0.36 Aortic root size; chr7:66773096 chr7:66493706~66495474:+ CESC cis rs9322193 0.884 rs62439837 ENSG00000268592.3 RAET1E-AS1 5.65 4.9e-08 5.6e-05 0.48 0.36 Lung cancer; chr6:149670380 chr6:149863494~149919507:+ CESC cis rs6504950 0.889 rs2628296 ENSG00000275710.1 RP11-257O5.4 -5.65 4.9e-08 5.6e-05 -0.43 -0.36 Breast cancer; chr17:55089134 chr17:54964474~54964679:+ CESC cis rs9907295 0.688 rs2526327 ENSG00000271013.1 AC015849.15 5.65 4.91e-08 5.61e-05 0.4 0.36 Fibroblast growth factor basic levels; chr17:35929902 chr17:35912635~35918010:- CESC cis rs2729354 1 rs2649662 ENSG00000265566.2 RN7SL605P 5.65 4.92e-08 5.62e-05 0.53 0.36 Blood protein levels; chr11:57585089 chr11:57528085~57528365:- CESC cis rs801193 0.569 rs11772819 ENSG00000226824.5 RP4-756H11.3 -5.65 4.92e-08 5.62e-05 -0.44 -0.36 Aortic root size; chr7:66752983 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs7800620 ENSG00000226824.5 RP4-756H11.3 -5.65 4.92e-08 5.62e-05 -0.44 -0.36 Aortic root size; chr7:66758701 chr7:66654538~66669855:+ CESC cis rs7572733 0.935 rs9288281 ENSG00000222017.1 AC011997.1 5.65 4.93e-08 5.63e-05 0.39 0.36 Dermatomyositis; chr2:197879642 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1369511 ENSG00000222017.1 AC011997.1 5.65 4.93e-08 5.63e-05 0.39 0.36 Dermatomyositis; chr2:197881391 chr2:197693106~197774823:+ CESC cis rs10466239 0.73 rs2245413 ENSG00000230555.2 RP11-517P14.2 -5.65 4.94e-08 5.63e-05 -0.41 -0.36 Telomere length; chr10:43355120 chr10:43420738~43422100:+ CESC cis rs7684253 0.548 rs62308071 ENSG00000269949.1 RP11-738E22.3 -5.65 4.94e-08 5.64e-05 -0.43 -0.36 Migraine; chr4:56850720 chr4:56960927~56961373:- CESC cis rs75422866 0.764 rs73104188 ENSG00000257433.4 RP1-197B17.3 5.65 4.94e-08 5.64e-05 0.94 0.36 Pneumonia; chr12:47715885 chr12:47706085~47742294:+ CESC cis rs1707322 0.752 rs4660880 ENSG00000281133.1 AL355480.3 -5.65 4.96e-08 5.65e-05 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645368 chr1:45580892~45580996:- CESC cis rs35955747 0.934 rs926928 ENSG00000236132.1 CTA-440B3.1 5.65 4.96e-08 5.66e-05 0.42 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31425733 chr22:31816379~31817491:- CESC cis rs875971 0.862 rs6460282 ENSG00000226824.5 RP4-756H11.3 5.65 4.97e-08 5.67e-05 0.45 0.36 Aortic root size; chr7:66226259 chr7:66654538~66669855:+ CESC cis rs7572733 1 rs10497813 ENSG00000222017.1 AC011997.1 5.65 4.99e-08 5.68e-05 0.39 0.36 Dermatomyositis; chr2:198049348 chr2:197693106~197774823:+ CESC cis rs34779708 0.931 rs11010077 ENSG00000230534.5 RP11-297A16.2 -5.65 4.99e-08 5.68e-05 -0.46 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35039160 chr10:35098006~35127020:- CESC cis rs4718428 0.705 rs68168107 ENSG00000226824.5 RP4-756H11.3 -5.65 5e-08 5.69e-05 -0.5 -0.36 Corneal structure; chr7:66790251 chr7:66654538~66669855:+ CESC cis rs748404 0.56 rs1869258 ENSG00000249839.1 AC011330.5 -5.65 5e-08 5.69e-05 -0.38 -0.36 Lung cancer; chr15:43511423 chr15:43663654~43684339:- CESC cis rs748404 0.56 rs529611 ENSG00000249839.1 AC011330.5 -5.65 5e-08 5.69e-05 -0.38 -0.36 Lung cancer; chr15:43513790 chr15:43663654~43684339:- CESC cis rs3806843 0.838 rs2337514 ENSG00000202111.1 VTRNA1-2 5.65 5.01e-08 5.7e-05 0.36 0.36 Depressive symptoms (multi-trait analysis); chr5:140753147 chr5:140718925~140719013:+ CESC cis rs116095464 0.558 rs13357299 ENSG00000250848.1 CTD-2083E4.5 -5.65 5.01e-08 5.7e-05 -0.45 -0.36 Breast cancer; chr5:242096 chr5:288833~290321:- CESC cis rs2404602 0.716 rs17461634 ENSG00000259422.1 RP11-593F23.1 5.65 5.01e-08 5.71e-05 0.4 0.36 Blood metabolite levels; chr15:76471766 chr15:76174891~76181486:- CESC cis rs10510102 0.608 rs4077606 ENSG00000226864.1 ATE1-AS1 -5.65 5.01e-08 5.71e-05 -0.45 -0.36 Breast cancer; chr10:121849907 chr10:121928312~121951965:+ CESC cis rs116095464 0.558 rs62347678 ENSG00000250848.1 CTD-2083E4.5 -5.65 5.01e-08 5.71e-05 -0.45 -0.36 Breast cancer; chr5:227381 chr5:288833~290321:- CESC cis rs116095464 0.558 rs73031482 ENSG00000250848.1 CTD-2083E4.5 -5.65 5.01e-08 5.71e-05 -0.45 -0.36 Breast cancer; chr5:227479 chr5:288833~290321:- CESC cis rs75422866 0.764 rs73104177 ENSG00000257433.4 RP1-197B17.3 5.65 5.03e-08 5.73e-05 0.94 0.36 Pneumonia; chr12:47713550 chr12:47706085~47742294:+ CESC cis rs75422866 0.764 rs73104184 ENSG00000257433.4 RP1-197B17.3 5.65 5.03e-08 5.73e-05 0.94 0.36 Pneumonia; chr12:47715623 chr12:47706085~47742294:+ CESC cis rs9595066 1 rs9595066 ENSG00000227258.4 SMIM2-AS1 5.65 5.04e-08 5.74e-05 0.51 0.36 Schizophrenia; chr13:44132132 chr13:44110451~44240517:+ CESC cis rs10466239 0.73 rs2243492 ENSG00000230555.2 RP11-517P14.2 5.65 5.06e-08 5.76e-05 0.41 0.36 Telomere length; chr10:43353910 chr10:43420738~43422100:+ CESC cis rs875971 0.54 rs4717275 ENSG00000164669.11 INTS4P1 5.65 5.1e-08 5.8e-05 0.49 0.36 Aortic root size; chr7:65800193 chr7:65141225~65234216:+ CESC cis rs1062177 1 rs17804178 ENSG00000253921.1 CTB-113P19.3 -5.65 5.1e-08 5.8e-05 -0.49 -0.36 Preschool internalizing problems; chr5:151818168 chr5:151753992~151767247:+ CESC cis rs10256972 1 rs10256972 ENSG00000229043.2 AC091729.9 5.65 5.1e-08 5.8e-05 0.4 0.36 Endometriosis;Longevity; chr7:999367 chr7:1160374~1165267:+ CESC cis rs2404602 0.735 rs11629888 ENSG00000259422.1 RP11-593F23.1 -5.65 5.1e-08 5.81e-05 -0.45 -0.36 Blood metabolite levels; chr15:76427539 chr15:76174891~76181486:- CESC cis rs116095464 0.558 rs7713524 ENSG00000250848.1 CTD-2083E4.5 5.64 5.11e-08 5.82e-05 0.45 0.36 Breast cancer; chr5:276085 chr5:288833~290321:- CESC cis rs9322193 0.884 rs1108889 ENSG00000268592.3 RAET1E-AS1 5.64 5.11e-08 5.82e-05 0.49 0.36 Lung cancer; chr6:149845433 chr6:149863494~149919507:+ CESC cis rs950169 0.96 rs12905475 ENSG00000225151.9 GOLGA2P7 -5.64 5.12e-08 5.82e-05 -0.5 -0.36 Schizophrenia; chr15:84131743 chr15:84199311~84230136:- CESC cis rs2729354 0.817 rs2467327 ENSG00000265566.2 RN7SL605P -5.64 5.14e-08 5.84e-05 -0.56 -0.36 Blood protein levels; chr11:57511755 chr11:57528085~57528365:- CESC cis rs6142102 0.59 rs6059691 ENSG00000276073.1 RP5-1125A11.7 5.64 5.15e-08 5.85e-05 0.34 0.36 Skin pigmentation; chr20:34149161 chr20:33985617~33988989:- CESC cis rs75422866 0.867 rs73113117 ENSG00000257433.4 RP1-197B17.3 5.64 5.15e-08 5.85e-05 0.86 0.36 Pneumonia; chr12:47617299 chr12:47706085~47742294:+ CESC cis rs11651753 0.561 rs35336840 ENSG00000264920.1 RP11-6N17.4 -5.64 5.18e-08 5.89e-05 -0.42 -0.36 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47888742 chr17:47891255~47895812:- CESC cis rs6700559 0.81 rs7521550 ENSG00000260088.1 RP11-92G12.3 -5.64 5.2e-08 5.9e-05 -0.45 -0.36 Coronary artery disease; chr1:200623235 chr1:200669507~200694250:+ CESC cis rs881375 0.631 rs2416808 ENSG00000226752.6 PSMD5-AS1 -5.64 5.2e-08 5.91e-05 -0.38 -0.36 Rheumatoid arthritis; chr9:120944005 chr9:120824828~120854385:+ CESC cis rs11096990 0.634 rs745642 ENSG00000249207.1 RP11-360F5.1 5.64 5.21e-08 5.91e-05 0.38 0.36 Cognitive function; chr4:39279642 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs2086752 ENSG00000249207.1 RP11-360F5.1 5.64 5.21e-08 5.91e-05 0.38 0.36 Cognitive function; chr4:39280486 chr4:39112677~39126818:- CESC cis rs11096990 0.594 rs2381373 ENSG00000249207.1 RP11-360F5.1 5.64 5.21e-08 5.91e-05 0.38 0.36 Cognitive function; chr4:39280683 chr4:39112677~39126818:- CESC cis rs11096990 0.6 rs6835337 ENSG00000249207.1 RP11-360F5.1 5.64 5.21e-08 5.91e-05 0.38 0.36 Cognitive function; chr4:39281189 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs6531704 ENSG00000249207.1 RP11-360F5.1 5.64 5.21e-08 5.91e-05 0.38 0.36 Cognitive function; chr4:39282126 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs7654501 ENSG00000249207.1 RP11-360F5.1 5.64 5.21e-08 5.91e-05 0.38 0.36 Cognitive function; chr4:39282364 chr4:39112677~39126818:- CESC cis rs34779708 0.966 rs11010129 ENSG00000230534.5 RP11-297A16.2 5.64 5.23e-08 5.94e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35221894 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs4934737 ENSG00000230534.5 RP11-297A16.2 5.64 5.23e-08 5.94e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35223871 chr10:35098006~35127020:- CESC cis rs35160687 0.901 rs13020869 ENSG00000273080.1 RP11-301O19.1 5.64 5.24e-08 5.94e-05 0.42 0.36 Night sleep phenotypes; chr2:86296237 chr2:86195590~86196049:+ CESC cis rs2929278 0.562 rs8033846 ENSG00000205771.5 CATSPER2P1 5.64 5.25e-08 5.95e-05 0.42 0.36 Schizophrenia; chr15:43743165 chr15:43726918~43747094:- CESC cis rs9545047 0.604 rs9565483 ENSG00000227676.3 LINC01068 -5.64 5.26e-08 5.96e-05 -0.4 -0.36 Schizophrenia; chr13:79294001 chr13:79566727~79571436:+ CESC cis rs116095464 0.558 rs57335027 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:262792 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6869925 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:263921 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6875291 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:264077 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6866776 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:264380 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6874745 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:264412 chr5:288833~290321:- CESC cis rs116095464 0.558 rs7715108 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:264546 chr5:288833~290321:- CESC cis rs116095464 0.558 rs7730700 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:264598 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10057674 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:266698 chr5:288833~290321:- CESC cis rs116095464 0.558 rs1812843 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:267543 chr5:288833~290321:- CESC cis rs116095464 0.558 rs1971229 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.27e-08 5.97e-05 -0.46 -0.36 Breast cancer; chr5:268072 chr5:288833~290321:- CESC cis rs2108622 0.727 rs55954696 ENSG00000267453.5 AC004791.2 -5.64 5.27e-08 5.97e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870995 chr19:15851993~15864904:- CESC cis rs2404602 0.692 rs12437733 ENSG00000259422.1 RP11-593F23.1 5.64 5.3e-08 5.99e-05 0.4 0.36 Blood metabolite levels; chr15:76863221 chr15:76174891~76181486:- CESC cis rs2404602 0.669 rs17367297 ENSG00000259422.1 RP11-593F23.1 5.64 5.3e-08 5.99e-05 0.4 0.36 Blood metabolite levels; chr15:76865685 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs12913810 ENSG00000259422.1 RP11-593F23.1 5.64 5.3e-08 5.99e-05 0.4 0.36 Blood metabolite levels; chr15:76874334 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs58889902 ENSG00000259422.1 RP11-593F23.1 5.64 5.3e-08 5.99e-05 0.4 0.36 Blood metabolite levels; chr15:76880729 chr15:76174891~76181486:- CESC cis rs116095464 0.558 rs10036253 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.3e-08 5.99e-05 -0.45 -0.36 Breast cancer; chr5:238404 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10057492 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.3e-08 5.99e-05 -0.45 -0.36 Breast cancer; chr5:239388 chr5:288833~290321:- CESC cis rs116095464 0.558 rs28418643 ENSG00000250848.1 CTD-2083E4.5 -5.64 5.3e-08 5.99e-05 -0.45 -0.36 Breast cancer; chr5:240744 chr5:288833~290321:- CESC cis rs950169 0.922 rs12906983 ENSG00000225151.9 GOLGA2P7 -5.64 5.3e-08 5.99e-05 -0.51 -0.36 Schizophrenia; chr15:84262270 chr15:84199311~84230136:- CESC cis rs6991838 0.831 rs4394432 ENSG00000272010.1 CTD-3025N20.3 5.64 5.33e-08 6.02e-05 0.39 0.36 Intelligence (multi-trait analysis); chr8:65560939 chr8:65591850~65592472:- CESC cis rs8072100 0.84 rs2136751 ENSG00000228782.6 CTD-2026D20.3 5.64 5.33e-08 6.02e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47378727 chr17:47450568~47492492:- CESC cis rs5760092 0.618 rs4461358 ENSG00000099984.9 GSTT2 5.64 5.34e-08 6.03e-05 0.48 0.36 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23980123~23983911:+ CESC cis rs7048146 0.966 rs4978824 ENSG00000213539.4 YBX1P6 5.64 5.34e-08 6.03e-05 0.42 0.36 Vascular brain injury; chr9:109540112 chr9:109532830~109534332:- CESC cis rs7048146 0.966 rs4978826 ENSG00000213539.4 YBX1P6 5.64 5.34e-08 6.03e-05 0.42 0.36 Vascular brain injury; chr9:109540221 chr9:109532830~109534332:- CESC cis rs7048146 0.899 rs12550929 ENSG00000213539.4 YBX1P6 5.64 5.34e-08 6.03e-05 0.42 0.36 Vascular brain injury; chr9:109541072 chr9:109532830~109534332:- CESC cis rs9545047 0.625 rs7338170 ENSG00000227676.3 LINC01068 -5.64 5.35e-08 6.05e-05 -0.4 -0.36 Schizophrenia; chr13:79286030 chr13:79566727~79571436:+ CESC cis rs7572733 0.935 rs1595824 ENSG00000222017.1 AC011997.1 5.64 5.36e-08 6.06e-05 0.39 0.36 Dermatomyositis; chr2:198009282 chr2:197693106~197774823:+ CESC cis rs17507216 0.588 rs28864981 ENSG00000278603.1 RP13-608F4.5 5.64 5.36e-08 6.06e-05 0.57 0.36 Excessive daytime sleepiness; chr15:82695420 chr15:82472203~82472426:+ CESC cis rs17507216 0.628 rs8032321 ENSG00000278603.1 RP13-608F4.5 5.64 5.36e-08 6.06e-05 0.57 0.36 Excessive daytime sleepiness; chr15:82698956 chr15:82472203~82472426:+ CESC cis rs17507216 0.628 rs8040488 ENSG00000278603.1 RP13-608F4.5 5.64 5.36e-08 6.06e-05 0.57 0.36 Excessive daytime sleepiness; chr15:82699081 chr15:82472203~82472426:+ CESC cis rs8072100 1 rs11650372 ENSG00000228782.6 CTD-2026D20.3 5.64 5.36e-08 6.06e-05 0.41 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47644429 chr17:47450568~47492492:- CESC cis rs9545047 0.604 rs7988784 ENSG00000227676.3 LINC01068 -5.64 5.37e-08 6.06e-05 -0.4 -0.36 Schizophrenia; chr13:79335337 chr13:79566727~79571436:+ CESC cis rs3806843 0.569 rs753279 ENSG00000202111.1 VTRNA1-2 5.64 5.37e-08 6.06e-05 0.36 0.36 Depressive symptoms (multi-trait analysis); chr5:140644233 chr5:140718925~140719013:+ CESC cis rs4789693 0.518 rs6502117 ENSG00000265458.1 RP13-20L14.6 5.63 5.38e-08 6.07e-05 0.41 0.36 Glucocorticoid-induced osteonecrosis; chr17:82494716 chr17:82454273~82458521:- CESC cis rs8072100 0.84 rs12453233 ENSG00000228782.6 CTD-2026D20.3 5.63 5.38e-08 6.07e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47377204 chr17:47450568~47492492:- CESC cis rs8072100 0.84 rs1912482 ENSG00000228782.6 CTD-2026D20.3 5.63 5.38e-08 6.07e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47377517 chr17:47450568~47492492:- CESC cis rs72627509 1 rs57265257 ENSG00000269949.1 RP11-738E22.3 5.63 5.39e-08 6.09e-05 0.54 0.36 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56973114 chr4:56960927~56961373:- CESC cis rs765787 0.53 rs3759895 ENSG00000259520.4 CTD-2651B20.3 5.63 5.4e-08 6.1e-05 0.45 0.36 Uric acid levels; chr15:45251672 chr15:45251580~45279251:- CESC cis rs801193 0.569 rs881285 ENSG00000226824.5 RP4-756H11.3 5.63 5.43e-08 6.13e-05 0.44 0.36 Aortic root size; chr7:66654433 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs3846973 ENSG00000226824.5 RP4-756H11.3 5.63 5.43e-08 6.13e-05 0.44 0.36 Aortic root size; chr7:66655048 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs2013908 ENSG00000226824.5 RP4-756H11.3 5.63 5.43e-08 6.13e-05 0.44 0.36 Aortic root size; chr7:66656082 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs6951302 ENSG00000226824.5 RP4-756H11.3 5.63 5.43e-08 6.13e-05 0.44 0.36 Aortic root size; chr7:66667525 chr7:66654538~66669855:+ CESC cis rs765787 0.53 rs11636410 ENSG00000259520.4 CTD-2651B20.3 -5.63 5.44e-08 6.13e-05 -0.45 -0.36 Uric acid levels; chr15:45243715 chr15:45251580~45279251:- CESC cis rs7572733 1 rs1371664 ENSG00000222017.1 AC011997.1 5.63 5.44e-08 6.13e-05 0.39 0.36 Dermatomyositis; chr2:198039741 chr2:197693106~197774823:+ CESC cis rs7572733 1 rs745899 ENSG00000222017.1 AC011997.1 5.63 5.44e-08 6.14e-05 0.39 0.36 Dermatomyositis; chr2:198043316 chr2:197693106~197774823:+ CESC cis rs34779708 0.966 rs113170867 ENSG00000230534.5 RP11-297A16.2 5.63 5.45e-08 6.15e-05 0.46 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35161219 chr10:35098006~35127020:- CESC cis rs11676348 0.755 rs6436026 ENSG00000261338.2 RP11-378A13.1 -5.63 5.46e-08 6.15e-05 -0.41 -0.36 Ulcerative colitis; chr2:218087015 chr2:218255319~218257366:+ CESC cis rs2404602 0.619 rs7342603 ENSG00000259422.1 RP11-593F23.1 5.63 5.46e-08 6.15e-05 0.4 0.36 Blood metabolite levels; chr15:76690284 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs7350777 ENSG00000259422.1 RP11-593F23.1 5.63 5.46e-08 6.15e-05 0.4 0.36 Blood metabolite levels; chr15:76693100 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs35395069 ENSG00000259422.1 RP11-593F23.1 5.63 5.46e-08 6.15e-05 0.4 0.36 Blood metabolite levels; chr15:76693993 chr15:76174891~76181486:- CESC cis rs116095464 0.614 rs10061564 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:271214 chr5:288833~290321:- CESC cis rs116095464 0.558 rs55776650 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:273711 chr5:288833~290321:- CESC cis rs116095464 0.558 rs28635197 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:278956 chr5:288833~290321:- CESC cis rs116095464 0.558 rs59113266 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:279850 chr5:288833~290321:- CESC cis rs116095464 0.558 rs11959126 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:283765 chr5:288833~290321:- CESC cis rs116095464 0.558 rs7356696 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:284136 chr5:288833~290321:- CESC cis rs116095464 0.558 rs7356561 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:284266 chr5:288833~290321:- CESC cis rs116095464 0.558 rs59284383 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:284410 chr5:288833~290321:- CESC cis rs116095464 0.558 rs7731089 ENSG00000250848.1 CTD-2083E4.5 -5.63 5.46e-08 6.15e-05 -0.46 -0.36 Breast cancer; chr5:290307 chr5:288833~290321:- CESC cis rs1823913 0.637 rs4853578 ENSG00000280083.1 RP11-317J9.1 -5.63 5.46e-08 6.15e-05 -0.4 -0.36 Obesity-related traits; chr2:191297215 chr2:191154118~191156070:- CESC cis rs34779708 0.931 rs34375045 ENSG00000230534.5 RP11-297A16.2 5.63 5.46e-08 6.15e-05 0.48 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35073428 chr10:35098006~35127020:- CESC cis rs72627509 0.951 rs6554401 ENSG00000269949.1 RP11-738E22.3 5.63 5.47e-08 6.16e-05 0.53 0.36 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56959170 chr4:56960927~56961373:- CESC cis rs875971 0.862 rs801195 ENSG00000226824.5 RP4-756H11.3 5.63 5.47e-08 6.16e-05 0.45 0.36 Aortic root size; chr7:66561128 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs801194 ENSG00000226824.5 RP4-756H11.3 5.63 5.47e-08 6.16e-05 0.45 0.36 Aortic root size; chr7:66563508 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs2024192 ENSG00000226824.5 RP4-756H11.3 5.63 5.47e-08 6.16e-05 0.45 0.36 Aortic root size; chr7:66576460 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6955837 ENSG00000226824.5 RP4-756H11.3 5.63 5.47e-08 6.16e-05 0.45 0.36 Aortic root size; chr7:66578155 chr7:66654538~66669855:+ CESC cis rs875971 0.825 rs10281499 ENSG00000226824.5 RP4-756H11.3 5.63 5.47e-08 6.16e-05 0.45 0.36 Aortic root size; chr7:66583979 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs4718377 ENSG00000226824.5 RP4-756H11.3 5.63 5.47e-08 6.16e-05 0.45 0.36 Aortic root size; chr7:66584691 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs10278014 ENSG00000226824.5 RP4-756H11.3 5.63 5.47e-08 6.16e-05 0.45 0.36 Aortic root size; chr7:66586277 chr7:66654538~66669855:+ CESC cis rs2739330 0.796 rs2154594 ENSG00000272787.1 KB-226F1.2 5.63 5.48e-08 6.17e-05 0.39 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23969211~23969873:+ CESC cis rs9545047 0.604 rs7332367 ENSG00000227676.3 LINC01068 -5.63 5.48e-08 6.17e-05 -0.4 -0.36 Schizophrenia; chr13:79339816 chr13:79566727~79571436:+ CESC cis rs8072100 0.811 rs1912483 ENSG00000228782.6 CTD-2026D20.3 5.63 5.48e-08 6.17e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47366128 chr17:47450568~47492492:- CESC cis rs8072100 0.811 rs9889709 ENSG00000228782.6 CTD-2026D20.3 5.63 5.48e-08 6.17e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47367863 chr17:47450568~47492492:- CESC cis rs6142102 0.517 rs8119076 ENSG00000275784.1 RP5-1125A11.6 -5.63 5.49e-08 6.18e-05 -0.35 -0.36 Skin pigmentation; chr20:33937909 chr20:33989480~33991818:- CESC cis rs6142102 0.517 rs6142050 ENSG00000275784.1 RP5-1125A11.6 -5.63 5.49e-08 6.18e-05 -0.35 -0.36 Skin pigmentation; chr20:33939322 chr20:33989480~33991818:- CESC cis rs6142102 0.517 rs6059577 ENSG00000275784.1 RP5-1125A11.6 -5.63 5.49e-08 6.18e-05 -0.35 -0.36 Skin pigmentation; chr20:33939880 chr20:33989480~33991818:- CESC cis rs34779708 0.966 rs12782948 ENSG00000230534.5 RP11-297A16.2 5.63 5.51e-08 6.2e-05 0.46 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35161679 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs34630580 ENSG00000230534.5 RP11-297A16.2 5.63 5.51e-08 6.2e-05 0.47 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35160300 chr10:35098006~35127020:- CESC cis rs7572733 0.839 rs9712275 ENSG00000222017.1 AC011997.1 5.63 5.52e-08 6.2e-05 0.39 0.36 Dermatomyositis; chr2:198042419 chr2:197693106~197774823:+ CESC cis rs950169 1 rs12915234 ENSG00000225151.9 GOLGA2P7 -5.63 5.52e-08 6.21e-05 -0.51 -0.36 Schizophrenia; chr15:84089549 chr15:84199311~84230136:- CESC cis rs79349575 0.721 rs1008834 ENSG00000270781.1 RP11-501C14.9 -5.63 5.53e-08 6.22e-05 -0.4 -0.36 Type 2 diabetes; chr17:48890646 chr17:48899131~48899748:+ CESC cis rs35160687 0.901 rs35762338 ENSG00000273080.1 RP11-301O19.1 5.63 5.55e-08 6.24e-05 0.42 0.36 Night sleep phenotypes; chr2:86286430 chr2:86195590~86196049:+ CESC cis rs2243480 1 rs2465120 ENSG00000232559.3 GS1-124K5.12 5.63 5.56e-08 6.24e-05 0.61 0.36 Diabetic kidney disease; chr7:66155987 chr7:66554588~66576923:- CESC cis rs2243480 0.908 rs2460431 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66157859 chr7:66554588~66576923:- CESC cis rs2243480 0.711 rs2460426 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66158142 chr7:66554588~66576923:- CESC cis rs2243480 1 rs4718309 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66162777 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6460274 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66163497 chr7:66554588~66576923:- CESC cis rs2243480 1 rs7787230 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66164112 chr7:66554588~66576923:- CESC cis rs2243480 0.711 rs2420172 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66170354 chr7:66554588~66576923:- CESC cis rs2243480 1 rs2420171 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66172773 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6974723 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66172952 chr7:66554588~66576923:- CESC cis rs2243480 1 rs7804223 ENSG00000232559.3 GS1-124K5.12 -5.63 5.56e-08 6.24e-05 -0.61 -0.36 Diabetic kidney disease; chr7:66199572 chr7:66554588~66576923:- CESC cis rs992157 0.71 rs56364928 ENSG00000261338.2 RP11-378A13.1 5.63 5.57e-08 6.26e-05 0.44 0.36 Colorectal cancer; chr2:218194335 chr2:218255319~218257366:+ CESC cis rs10740039 0.583 rs9415611 ENSG00000254271.1 RP11-131N11.4 -5.63 5.58e-08 6.26e-05 -0.43 -0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60743440 chr10:60734342~60741828:+ CESC cis rs10246939 0.553 rs34894166 ENSG00000228775.6 WEE2-AS1 5.63 5.58e-08 6.26e-05 0.42 0.36 Bitter taste perception; chr7:141852158 chr7:141704338~141738346:- CESC cis rs10246939 0.579 rs17133534 ENSG00000228775.6 WEE2-AS1 5.63 5.58e-08 6.26e-05 0.42 0.36 Bitter taste perception; chr7:141860855 chr7:141704338~141738346:- CESC cis rs992157 0.687 rs35271699 ENSG00000261338.2 RP11-378A13.1 5.63 5.62e-08 6.3e-05 0.44 0.36 Colorectal cancer; chr2:218252759 chr2:218255319~218257366:+ CESC cis rs3806843 1 rs10037757 ENSG00000202111.1 VTRNA1-2 -5.62 5.66e-08 6.35e-05 -0.35 -0.36 Depressive symptoms (multi-trait analysis); chr5:140817637 chr5:140718925~140719013:+ CESC cis rs992157 0.798 rs7557709 ENSG00000261338.2 RP11-378A13.1 5.62 5.66e-08 6.35e-05 0.46 0.36 Colorectal cancer; chr2:218302806 chr2:218255319~218257366:+ CESC cis rs6603134 0.502 rs6603132 ENSG00000267939.1 CTD-2325M2.1 -5.62 5.66e-08 6.35e-05 -0.45 -0.36 Blood protein levels; chr19:8037908 chr19:8008729~8016025:+ CESC cis rs79349575 0.721 rs9904645 ENSG00000270781.1 RP11-501C14.9 -5.62 5.67e-08 6.36e-05 -0.4 -0.36 Type 2 diabetes; chr17:48892303 chr17:48899131~48899748:+ CESC cis rs1707322 0.721 rs4660883 ENSG00000281133.1 AL355480.3 -5.62 5.68e-08 6.37e-05 -0.43 -0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45770426 chr1:45580892~45580996:- CESC cis rs2243480 0.908 rs4718273 ENSG00000228409.4 CCT6P1 -5.62 5.69e-08 6.37e-05 -0.53 -0.36 Diabetic kidney disease; chr7:65751112 chr7:65751142~65763354:+ CESC cis rs1062177 1 rs12653926 ENSG00000213433.5 RPLP1P6 -5.62 5.69e-08 6.38e-05 -0.45 -0.36 Preschool internalizing problems; chr5:151870687 chr5:151765859~151766378:- CESC cis rs10875746 0.951 rs2228500 ENSG00000240399.1 RP1-228P16.1 5.62 5.69e-08 6.38e-05 0.46 0.36 Longevity (90 years and older); chr12:48132929 chr12:48054813~48055591:- CESC cis rs12022452 0.908 rs11811487 ENSG00000238287.1 RP11-656D10.3 -5.62 5.71e-08 6.39e-05 -0.57 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr1:40555398 chr1:40493157~40508661:- CESC cis rs4660456 0.913 rs2744799 ENSG00000237899.1 RP4-739H11.3 5.62 5.71e-08 6.4e-05 0.48 0.36 Platelet count; chr1:40719862 chr1:40669089~40687588:- CESC cis rs116095464 0.558 rs10052012 ENSG00000250848.1 CTD-2083E4.5 -5.62 5.72e-08 6.4e-05 -0.46 -0.36 Breast cancer; chr5:231793 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10077076 ENSG00000250848.1 CTD-2083E4.5 -5.62 5.72e-08 6.4e-05 -0.46 -0.36 Breast cancer; chr5:231825 chr5:288833~290321:- CESC cis rs6603134 0.502 rs6603131 ENSG00000267939.1 CTD-2325M2.1 -5.62 5.72e-08 6.4e-05 -0.45 -0.36 Blood protein levels; chr19:8037873 chr19:8008729~8016025:+ CESC cis rs7572733 0.967 rs12329164 ENSG00000222017.1 AC011997.1 5.62 5.73e-08 6.41e-05 0.39 0.36 Dermatomyositis; chr2:198040500 chr2:197693106~197774823:+ CESC cis rs1062177 1 rs62394155 ENSG00000213433.5 RPLP1P6 -5.62 5.74e-08 6.42e-05 -0.45 -0.36 Preschool internalizing problems; chr5:151868508 chr5:151765859~151766378:- CESC cis rs35160687 0.901 rs12714179 ENSG00000273080.1 RP11-301O19.1 5.62 5.74e-08 6.43e-05 0.42 0.36 Night sleep phenotypes; chr2:86287835 chr2:86195590~86196049:+ CESC cis rs7201929 1 rs8061877 ENSG00000259982.1 CDC37P1 -5.62 5.74e-08 6.43e-05 -0.49 -0.36 QT interval; chr16:28845498 chr16:28700294~28701540:- CESC cis rs5769707 0.609 rs739247 ENSG00000188511.11 C22orf34 5.62 5.77e-08 6.45e-05 0.42 0.36 Monocyte percentage of white cells;Monocyte count; chr22:49603009 chr22:49414524~49657542:- CESC cis rs1823913 0.637 rs897197 ENSG00000280083.1 RP11-317J9.1 5.62 5.79e-08 6.48e-05 0.41 0.36 Obesity-related traits; chr2:191281456 chr2:191154118~191156070:- CESC cis rs875971 0.83 rs427973 ENSG00000222364.1 RNU6-96P -5.62 5.8e-08 6.48e-05 -0.43 -0.36 Aortic root size; chr7:66061661 chr7:66395191~66395286:+ CESC cis rs957448 0.948 rs11992893 ENSG00000253704.1 RP11-267M23.4 5.62 5.81e-08 6.49e-05 0.4 0.36 Nonsyndromic cleft lip with cleft palate; chr8:94508473 chr8:94553722~94569745:+ CESC cis rs957448 1 rs1048029 ENSG00000253704.1 RP11-267M23.4 5.62 5.81e-08 6.49e-05 0.4 0.36 Nonsyndromic cleft lip with cleft palate; chr8:94510149 chr8:94553722~94569745:+ CESC cis rs10246939 0.579 rs12703413 ENSG00000228775.6 WEE2-AS1 -5.62 5.82e-08 6.51e-05 -0.42 -0.36 Bitter taste perception; chr7:141847047 chr7:141704338~141738346:- CESC cis rs116095464 0.51 rs10057501 ENSG00000250848.1 CTD-2083E4.5 -5.62 5.83e-08 6.51e-05 -0.45 -0.36 Breast cancer; chr5:239430 chr5:288833~290321:- CESC cis rs10875746 0.951 rs10875748 ENSG00000240399.1 RP1-228P16.1 -5.62 5.84e-08 6.52e-05 -0.46 -0.36 Longevity (90 years and older); chr12:48132577 chr12:48054813~48055591:- CESC cis rs10875746 0.951 rs2286021 ENSG00000240399.1 RP1-228P16.1 -5.62 5.84e-08 6.52e-05 -0.46 -0.36 Longevity (90 years and older); chr12:48134437 chr12:48054813~48055591:- CESC cis rs1707322 1 rs1707303 ENSG00000280836.1 AL355480.1 5.62 5.84e-08 6.52e-05 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46132601 chr1:45581219~45581321:- CESC cis rs11690935 0.921 rs7594711 ENSG00000228389.1 AC068039.4 5.62 5.85e-08 6.53e-05 0.49 0.36 Schizophrenia; chr2:172030734 chr2:171773482~171775844:+ CESC cis rs2404602 0.692 rs58973160 ENSG00000259422.1 RP11-593F23.1 5.62 5.86e-08 6.55e-05 0.41 0.36 Blood metabolite levels; chr15:76708001 chr15:76174891~76181486:- CESC cis rs2108622 0.727 rs62106155 ENSG00000267453.5 AC004791.2 -5.62 5.86e-08 6.55e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869550 chr19:15851993~15864904:- CESC cis rs8072100 0.935 rs8070759 ENSG00000228782.6 CTD-2026D20.3 -5.62 5.87e-08 6.55e-05 -0.42 -0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47561394 chr17:47450568~47492492:- CESC cis rs8072100 0.764 rs2644349 ENSG00000228782.6 CTD-2026D20.3 -5.62 5.87e-08 6.55e-05 -0.42 -0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47564377 chr17:47450568~47492492:- CESC cis rs17711722 0.565 rs4275112 ENSG00000228409.4 CCT6P1 5.62 5.88e-08 6.57e-05 0.33 0.36 Calcium levels; chr7:65733651 chr7:65751142~65763354:+ CESC cis rs2284378 0.506 rs6142059 ENSG00000276073.1 RP5-1125A11.7 -5.62 5.88e-08 6.57e-05 -0.32 -0.36 Breast cancer; chr20:33956521 chr20:33985617~33988989:- CESC cis rs1075265 0.568 rs959286 ENSG00000233266.1 HMGB1P31 5.62 5.89e-08 6.57e-05 0.49 0.36 Chronotype;Morning vs. evening chronotype; chr2:54078941 chr2:54051334~54051760:+ CESC cis rs35160687 0.901 rs12478575 ENSG00000273080.1 RP11-301O19.1 5.62 5.89e-08 6.57e-05 0.42 0.36 Night sleep phenotypes; chr2:86308191 chr2:86195590~86196049:+ CESC cis rs2108622 0.727 rs62106156 ENSG00000267453.5 AC004791.2 -5.62 5.9e-08 6.58e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869614 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs62106157 ENSG00000267453.5 AC004791.2 -5.62 5.9e-08 6.58e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869638 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs62106158 ENSG00000267453.5 AC004791.2 -5.62 5.9e-08 6.58e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869682 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs7256877 ENSG00000267453.5 AC004791.2 -5.62 5.9e-08 6.58e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869873 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs7253873 ENSG00000267453.5 AC004791.2 -5.62 5.9e-08 6.58e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870090 chr19:15851993~15864904:- CESC cis rs2108622 0.559 rs7252638 ENSG00000267453.5 AC004791.2 -5.62 5.9e-08 6.58e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870215 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs7253684 ENSG00000267453.5 AC004791.2 -5.62 5.9e-08 6.58e-05 -0.44 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870316 chr19:15851993~15864904:- CESC cis rs12439619 1 rs35152457 ENSG00000255769.6 GOLGA2P10 -5.62 5.9e-08 6.58e-05 -0.45 -0.36 Intelligence (multi-trait analysis); chr15:82254207 chr15:82472993~82513950:- CESC cis rs6452524 0.534 rs11746747 ENSG00000249664.1 CTD-2227C6.2 5.62 5.92e-08 6.6e-05 0.41 0.36 Hypertension (SNP x SNP interaction); chr5:83067666 chr5:83012285~83013109:- CESC cis rs748404 0.56 rs2255663 ENSG00000249839.1 AC011330.5 5.62 5.92e-08 6.61e-05 0.37 0.36 Lung cancer; chr15:43536810 chr15:43663654~43684339:- CESC cis rs2404602 0.583 rs2469542 ENSG00000259422.1 RP11-593F23.1 -5.62 5.93e-08 6.61e-05 -0.39 -0.36 Blood metabolite levels; chr15:76265135 chr15:76174891~76181486:- CESC cis rs7189233 0.531 rs9302648 ENSG00000279344.1 RP11-44F14.7 5.62 5.94e-08 6.62e-05 0.34 0.36 Intelligence (multi-trait analysis); chr16:53493869 chr16:53478957~53481550:- CESC cis rs897984 0.645 rs9938550 ENSG00000260911.2 RP11-196G11.2 -5.62 5.94e-08 6.62e-05 -0.39 -0.36 Dementia with Lewy bodies; chr16:30987821 chr16:31043150~31049868:+ CESC cis rs8072100 0.967 rs62076549 ENSG00000228782.6 CTD-2026D20.3 -5.62 5.95e-08 6.63e-05 -0.42 -0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47502189 chr17:47450568~47492492:- CESC cis rs34779708 0.966 rs10827492 ENSG00000230534.5 RP11-297A16.2 -5.61 5.95e-08 6.64e-05 -0.46 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35140897 chr10:35098006~35127020:- CESC cis rs8072100 0.745 rs7214410 ENSG00000228782.6 CTD-2026D20.3 5.61 5.96e-08 6.64e-05 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47345262 chr17:47450568~47492492:- CESC cis rs11096990 0.634 rs10010352 ENSG00000249207.1 RP11-360F5.1 -5.61 5.97e-08 6.65e-05 -0.4 -0.36 Cognitive function; chr4:39240657 chr4:39112677~39126818:- CESC cis rs6452524 1 rs6864479 ENSG00000249664.1 CTD-2227C6.2 5.61 5.98e-08 6.66e-05 0.39 0.36 Hypertension (SNP x SNP interaction); chr5:83166421 chr5:83012285~83013109:- CESC cis rs6452524 1 rs13436667 ENSG00000249664.1 CTD-2227C6.2 5.61 5.98e-08 6.66e-05 0.39 0.36 Hypertension (SNP x SNP interaction); chr5:83168948 chr5:83012285~83013109:- CESC cis rs6452524 1 rs7726564 ENSG00000249664.1 CTD-2227C6.2 5.61 5.98e-08 6.66e-05 0.39 0.36 Hypertension (SNP x SNP interaction); chr5:83170274 chr5:83012285~83013109:- CESC cis rs35955747 0.902 rs4820961 ENSG00000236132.1 CTA-440B3.1 5.61 5.99e-08 6.66e-05 0.41 0.36 Neutrophil count;Sum basophil neutrophil counts; chr22:31283463 chr22:31816379~31817491:- CESC cis rs1062177 1 rs2016409 ENSG00000213433.5 RPLP1P6 5.61 5.99e-08 6.67e-05 0.46 0.36 Preschool internalizing problems; chr5:151746763 chr5:151765859~151766378:- CESC cis rs42490 0.536 rs379015 ENSG00000251136.7 RP11-37B2.1 -5.61 6e-08 6.68e-05 -0.36 -0.36 Leprosy; chr8:89856245 chr8:89609409~89757727:- CESC cis rs2404602 0.679 rs12900494 ENSG00000259422.1 RP11-593F23.1 5.61 6e-08 6.68e-05 0.41 0.36 Blood metabolite levels; chr15:76620163 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs7169394 ENSG00000259422.1 RP11-593F23.1 5.61 6e-08 6.68e-05 0.41 0.36 Blood metabolite levels; chr15:76620933 chr15:76174891~76181486:- CESC cis rs34779708 0.966 rs7077242 ENSG00000230534.5 RP11-297A16.2 -5.61 6.02e-08 6.7e-05 -0.47 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35193037 chr10:35098006~35127020:- CESC cis rs9322193 0.576 rs7452592 ENSG00000231760.4 RP11-350J20.5 5.61 6.02e-08 6.7e-05 0.61 0.36 Lung cancer; chr6:149875445 chr6:149796151~149826294:- CESC cis rs1062177 0.906 rs2964573 ENSG00000253921.1 CTB-113P19.3 -5.61 6.03e-08 6.71e-05 -0.48 -0.36 Preschool internalizing problems; chr5:151780561 chr5:151753992~151767247:+ CESC cis rs801193 0.591 rs2707839 ENSG00000222364.1 RNU6-96P -5.61 6.06e-08 6.74e-05 -0.42 -0.36 Aortic root size; chr7:66728097 chr7:66395191~66395286:+ CESC cis rs62229266 0.682 rs2835224 ENSG00000231106.2 LINC01436 5.61 6.06e-08 6.74e-05 0.52 0.36 Mitral valve prolapse; chr21:35997732 chr21:36005338~36007838:+ CESC cis rs1075265 0.633 rs10183655 ENSG00000233266.1 HMGB1P31 5.61 6.07e-08 6.75e-05 0.48 0.36 Chronotype;Morning vs. evening chronotype; chr2:53983644 chr2:54051334~54051760:+ CESC cis rs11676348 0.818 rs6436033 ENSG00000261338.2 RP11-378A13.1 -5.61 6.09e-08 6.77e-05 -0.42 -0.36 Ulcerative colitis; chr2:218119040 chr2:218255319~218257366:+ CESC cis rs2404602 0.716 rs4886817 ENSG00000259422.1 RP11-593F23.1 5.61 6.1e-08 6.78e-05 0.41 0.36 Blood metabolite levels; chr15:76585361 chr15:76174891~76181486:- CESC cis rs1075265 0.547 rs11125520 ENSG00000233266.1 HMGB1P31 5.61 6.1e-08 6.78e-05 0.49 0.36 Chronotype;Morning vs. evening chronotype; chr2:54076696 chr2:54051334~54051760:+ CESC cis rs9545047 0.604 rs9545054 ENSG00000227676.3 LINC01068 5.61 6.1e-08 6.78e-05 0.39 0.36 Schizophrenia; chr13:79298833 chr13:79566727~79571436:+ CESC cis rs9545047 0.547 rs2876739 ENSG00000227676.3 LINC01068 5.61 6.1e-08 6.78e-05 0.39 0.36 Schizophrenia; chr13:79299057 chr13:79566727~79571436:+ CESC cis rs9545047 0.567 rs7988331 ENSG00000227676.3 LINC01068 5.61 6.1e-08 6.78e-05 0.39 0.36 Schizophrenia; chr13:79299745 chr13:79566727~79571436:+ CESC cis rs881375 0.678 rs10760125 ENSG00000226752.6 PSMD5-AS1 -5.61 6.14e-08 6.82e-05 -0.37 -0.36 Rheumatoid arthritis; chr9:120900312 chr9:120824828~120854385:+ CESC cis rs881375 0.678 rs9886724 ENSG00000226752.6 PSMD5-AS1 -5.61 6.14e-08 6.82e-05 -0.37 -0.36 Rheumatoid arthritis; chr9:120902741 chr9:120824828~120854385:+ CESC cis rs881375 0.631 rs10739577 ENSG00000226752.6 PSMD5-AS1 -5.61 6.14e-08 6.82e-05 -0.37 -0.36 Rheumatoid arthritis; chr9:120906576 chr9:120824828~120854385:+ CESC cis rs2739330 0.828 rs4822454 ENSG00000272787.1 KB-226F1.2 -5.61 6.14e-08 6.83e-05 -0.38 -0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23969211~23969873:+ CESC cis rs2404602 0.716 rs2404737 ENSG00000259422.1 RP11-593F23.1 5.61 6.15e-08 6.83e-05 0.4 0.36 Blood metabolite levels; chr15:76579876 chr15:76174891~76181486:- CESC cis rs6142102 0.527 rs1015362 ENSG00000276073.1 RP5-1125A11.7 5.61 6.16e-08 6.84e-05 0.34 0.36 Skin pigmentation; chr20:34150806 chr20:33985617~33988989:- CESC cis rs2404602 0.669 rs12148877 ENSG00000259422.1 RP11-593F23.1 5.61 6.17e-08 6.85e-05 0.41 0.36 Blood metabolite levels; chr15:76627618 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs12902452 ENSG00000259422.1 RP11-593F23.1 5.61 6.17e-08 6.85e-05 0.41 0.36 Blood metabolite levels; chr15:76629124 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs34478400 ENSG00000259422.1 RP11-593F23.1 5.61 6.17e-08 6.85e-05 0.41 0.36 Blood metabolite levels; chr15:76631169 chr15:76174891~76181486:- CESC cis rs1015362 0.869 rs6088411 ENSG00000276073.1 RP5-1125A11.7 5.61 6.2e-08 6.88e-05 0.34 0.36 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:34152101 chr20:33985617~33988989:- CESC cis rs997154 0.655 rs7147394 ENSG00000279656.1 RP11-298I3.6 5.61 6.2e-08 6.88e-05 0.53 0.36 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22941845 chr14:23023083~23024217:- CESC cis rs62229266 0.682 rs11700546 ENSG00000231106.2 LINC01436 5.61 6.21e-08 6.89e-05 0.51 0.35 Mitral valve prolapse; chr21:35998841 chr21:36005338~36007838:+ CESC cis rs9322193 0.607 rs9383941 ENSG00000231760.4 RP11-350J20.5 -5.61 6.22e-08 6.9e-05 -0.51 -0.35 Lung cancer; chr6:149912100 chr6:149796151~149826294:- CESC cis rs17507216 0.628 rs4627310 ENSG00000278603.1 RP13-608F4.5 5.61 6.23e-08 6.9e-05 0.58 0.35 Excessive daytime sleepiness; chr15:82708330 chr15:82472203~82472426:+ CESC cis rs17507216 0.628 rs4513065 ENSG00000278603.1 RP13-608F4.5 5.61 6.23e-08 6.9e-05 0.58 0.35 Excessive daytime sleepiness; chr15:82712096 chr15:82472203~82472426:+ CESC cis rs17507216 0.628 rs28371837 ENSG00000278603.1 RP13-608F4.5 5.61 6.23e-08 6.9e-05 0.58 0.35 Excessive daytime sleepiness; chr15:82714435 chr15:82472203~82472426:+ CESC cis rs7048146 0.966 rs10816829 ENSG00000213539.4 YBX1P6 5.61 6.23e-08 6.91e-05 0.42 0.35 Vascular brain injury; chr9:109536396 chr9:109532830~109534332:- CESC cis rs7048146 1 rs7048146 ENSG00000213539.4 YBX1P6 5.61 6.23e-08 6.91e-05 0.42 0.35 Vascular brain injury; chr9:109537042 chr9:109532830~109534332:- CESC cis rs7048146 1 rs12336499 ENSG00000213539.4 YBX1P6 5.61 6.23e-08 6.91e-05 0.42 0.35 Vascular brain injury; chr9:109537967 chr9:109532830~109534332:- CESC cis rs7048146 1 rs10979904 ENSG00000213539.4 YBX1P6 5.61 6.23e-08 6.91e-05 0.42 0.35 Vascular brain injury; chr9:109538136 chr9:109532830~109534332:- CESC cis rs7048146 1 rs7022179 ENSG00000213539.4 YBX1P6 5.61 6.23e-08 6.91e-05 0.42 0.35 Vascular brain injury; chr9:109538280 chr9:109532830~109534332:- CESC cis rs7048146 0.966 rs10816831 ENSG00000213539.4 YBX1P6 5.61 6.23e-08 6.91e-05 0.42 0.35 Vascular brain injury; chr9:109538337 chr9:109532830~109534332:- CESC cis rs7048146 0.966 rs10816833 ENSG00000213539.4 YBX1P6 5.61 6.23e-08 6.91e-05 0.42 0.35 Vascular brain injury; chr9:109538551 chr9:109532830~109534332:- CESC cis rs7048146 0.966 rs10816834 ENSG00000213539.4 YBX1P6 5.61 6.23e-08 6.91e-05 0.42 0.35 Vascular brain injury; chr9:109538626 chr9:109532830~109534332:- CESC cis rs950169 0.723 rs17589320 ENSG00000225151.9 GOLGA2P7 -5.6 6.27e-08 6.95e-05 -0.5 -0.35 Schizophrenia; chr15:84251244 chr15:84199311~84230136:- CESC cis rs7396835 1 rs7396835 ENSG00000254851.1 RP11-109L13.1 -5.6 6.28e-08 6.96e-05 -0.55 -0.35 Quantitative traits; chr11:116813312 chr11:117135528~117138582:+ CESC cis rs116095464 0.558 rs10079760 ENSG00000250848.1 CTD-2083E4.5 -5.6 6.29e-08 6.97e-05 -0.44 -0.35 Breast cancer; chr5:230663 chr5:288833~290321:- CESC cis rs17507216 0.718 rs28587782 ENSG00000278603.1 RP13-608F4.5 5.6 6.29e-08 6.97e-05 0.59 0.35 Excessive daytime sleepiness; chr15:82576881 chr15:82472203~82472426:+ CESC cis rs6452524 1 rs6452528 ENSG00000249664.1 CTD-2227C6.2 5.6 6.3e-08 6.98e-05 0.39 0.35 Hypertension (SNP x SNP interaction); chr5:83162560 chr5:83012285~83013109:- CESC cis rs1062177 1 rs62377945 ENSG00000253921.1 CTB-113P19.3 -5.6 6.32e-08 7e-05 -0.48 -0.35 Preschool internalizing problems; chr5:151828443 chr5:151753992~151767247:+ CESC cis rs1062177 1 rs12515762 ENSG00000253921.1 CTB-113P19.3 -5.6 6.32e-08 7e-05 -0.48 -0.35 Preschool internalizing problems; chr5:151830361 chr5:151753992~151767247:+ CESC cis rs11096990 0.634 rs11096988 ENSG00000249207.1 RP11-360F5.1 -5.6 6.33e-08 7.01e-05 -0.4 -0.35 Cognitive function; chr4:39264081 chr4:39112677~39126818:- CESC cis rs131777 0.575 rs131760 ENSG00000205559.3 CHKB-AS1 -5.6 6.34e-08 7.02e-05 -0.43 -0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50573507 chr22:50583026~50583877:+ CESC cis rs875971 1 rs7792762 ENSG00000222364.1 RNU6-96P -5.6 6.35e-08 7.03e-05 -0.42 -0.35 Aortic root size; chr7:66539151 chr7:66395191~66395286:+ CESC cis rs11096990 0.634 rs746678 ENSG00000249207.1 RP11-360F5.1 5.6 6.35e-08 7.03e-05 0.38 0.35 Cognitive function; chr4:39279035 chr4:39112677~39126818:- CESC cis rs2404602 0.679 rs12908421 ENSG00000259422.1 RP11-593F23.1 5.6 6.35e-08 7.03e-05 0.4 0.35 Blood metabolite levels; chr15:76589453 chr15:76174891~76181486:- CESC cis rs11676348 0.846 rs13009946 ENSG00000261338.2 RP11-378A13.1 -5.6 6.36e-08 7.03e-05 -0.42 -0.35 Ulcerative colitis; chr2:218143029 chr2:218255319~218257366:+ CESC cis rs2177312 0.868 rs3934117 ENSG00000251129.1 RP11-734I18.1 5.6 6.36e-08 7.03e-05 0.45 0.35 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31936498 chr4:31997397~32155406:+ CESC cis rs34779708 0.966 rs1545757 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35156660 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs12784482 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35157937 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs17499811 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35167287 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs35146199 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35172011 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs4934538 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35183222 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs10827493 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35166048 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs12260130 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35178743 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs4934539 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35183271 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs1478463 ENSG00000230534.5 RP11-297A16.2 5.6 6.37e-08 7.05e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35184107 chr10:35098006~35127020:- CESC cis rs11676348 0.791 rs6726126 ENSG00000261338.2 RP11-378A13.1 -5.6 6.38e-08 7.06e-05 -0.41 -0.35 Ulcerative colitis; chr2:218087510 chr2:218255319~218257366:+ CESC cis rs7615952 0.576 rs17523380 ENSG00000250012.1 RP11-124N2.1 -5.6 6.4e-08 7.08e-05 -0.34 -0.35 Blood pressure (smoking interaction); chr3:126084031 chr3:126084220~126095349:+ CESC cis rs3806843 0.766 rs2251860 ENSG00000202111.1 VTRNA1-2 5.6 6.46e-08 7.13e-05 0.36 0.35 Depressive symptoms (multi-trait analysis); chr5:140668624 chr5:140718925~140719013:+ CESC cis rs3806843 0.766 rs702397 ENSG00000202111.1 VTRNA1-2 5.6 6.46e-08 7.13e-05 0.36 0.35 Depressive symptoms (multi-trait analysis); chr5:140670680 chr5:140718925~140719013:+ CESC cis rs6700559 0.742 rs10399790 ENSG00000260088.1 RP11-92G12.3 -5.6 6.47e-08 7.15e-05 -0.45 -0.35 Coronary artery disease; chr1:200626241 chr1:200669507~200694250:+ CESC cis rs9907295 0.71 rs9894083 ENSG00000270977.1 AC015849.16 -5.6 6.48e-08 7.16e-05 -0.52 -0.35 Fibroblast growth factor basic levels; chr17:35842151 chr17:35893707~35911023:- CESC cis rs11096990 0.551 rs2060005 ENSG00000249207.1 RP11-360F5.1 -5.6 6.51e-08 7.18e-05 -0.39 -0.35 Cognitive function; chr4:39160901 chr4:39112677~39126818:- CESC cis rs1061377 0.501 rs62308278 ENSG00000249207.1 RP11-360F5.1 -5.6 6.51e-08 7.18e-05 -0.39 -0.35 Uric acid levels; chr4:39161038 chr4:39112677~39126818:- CESC cis rs763121 0.888 rs2235229 ENSG00000273076.1 RP3-508I15.22 5.6 6.51e-08 7.19e-05 0.38 0.35 Menopause (age at onset); chr22:38728907 chr22:38743495~38743910:+ CESC cis rs8072100 0.875 rs7208530 ENSG00000228782.6 CTD-2026D20.3 5.6 6.51e-08 7.19e-05 0.42 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47466741 chr17:47450568~47492492:- CESC cis rs8072100 0.875 rs12451409 ENSG00000228782.6 CTD-2026D20.3 5.6 6.51e-08 7.19e-05 0.42 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47467490 chr17:47450568~47492492:- CESC cis rs801193 0.569 rs11761542 ENSG00000237310.1 GS1-124K5.4 5.6 6.52e-08 7.19e-05 0.34 0.35 Aortic root size; chr7:66753209 chr7:66493706~66495474:+ CESC cis rs897984 0.762 rs2054213 ENSG00000260911.2 RP11-196G11.2 -5.6 6.54e-08 7.21e-05 -0.39 -0.35 Dementia with Lewy bodies; chr16:30960489 chr16:31043150~31049868:+ CESC cis rs10875746 0.768 rs4760676 ENSG00000240399.1 RP1-228P16.1 -5.6 6.54e-08 7.22e-05 -0.44 -0.35 Longevity (90 years and older); chr12:48027880 chr12:48054813~48055591:- CESC cis rs6452524 1 rs1382368 ENSG00000249664.1 CTD-2227C6.2 5.6 6.55e-08 7.23e-05 0.39 0.35 Hypertension (SNP x SNP interaction); chr5:83155256 chr5:83012285~83013109:- CESC cis rs6452524 1 rs1382366 ENSG00000249664.1 CTD-2227C6.2 5.6 6.55e-08 7.23e-05 0.39 0.35 Hypertension (SNP x SNP interaction); chr5:83156352 chr5:83012285~83013109:- CESC cis rs6452524 1 rs1382364 ENSG00000249664.1 CTD-2227C6.2 5.6 6.55e-08 7.23e-05 0.39 0.35 Hypertension (SNP x SNP interaction); chr5:83156677 chr5:83012285~83013109:- CESC cis rs6452524 1 rs1382363 ENSG00000249664.1 CTD-2227C6.2 5.6 6.55e-08 7.23e-05 0.39 0.35 Hypertension (SNP x SNP interaction); chr5:83156753 chr5:83012285~83013109:- CESC cis rs6452524 1 rs11741897 ENSG00000249664.1 CTD-2227C6.2 5.6 6.55e-08 7.23e-05 0.39 0.35 Hypertension (SNP x SNP interaction); chr5:83157246 chr5:83012285~83013109:- CESC cis rs6452524 1 rs13358361 ENSG00000249664.1 CTD-2227C6.2 5.6 6.55e-08 7.23e-05 0.39 0.35 Hypertension (SNP x SNP interaction); chr5:83160237 chr5:83012285~83013109:- CESC cis rs6452524 1 rs10076000 ENSG00000249664.1 CTD-2227C6.2 5.6 6.55e-08 7.23e-05 0.39 0.35 Hypertension (SNP x SNP interaction); chr5:83161629 chr5:83012285~83013109:- CESC cis rs3806843 0.766 rs801399 ENSG00000202111.1 VTRNA1-2 5.59 6.59e-08 7.26e-05 0.35 0.35 Depressive symptoms (multi-trait analysis); chr5:140655259 chr5:140718925~140719013:+ CESC cis rs875971 0.862 rs1167408 ENSG00000226824.5 RP4-756H11.3 5.59 6.59e-08 7.26e-05 0.45 0.35 Aortic root size; chr7:66091121 chr7:66654538~66669855:+ CESC cis rs875971 0.83 rs1167406 ENSG00000226824.5 RP4-756H11.3 5.59 6.59e-08 7.26e-05 0.45 0.35 Aortic root size; chr7:66091949 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs1167399 ENSG00000226824.5 RP4-756H11.3 5.59 6.59e-08 7.26e-05 0.45 0.35 Aortic root size; chr7:66096890 chr7:66654538~66669855:+ CESC cis rs875971 0.825 rs59466412 ENSG00000226824.5 RP4-756H11.3 5.59 6.59e-08 7.26e-05 0.45 0.35 Aortic root size; chr7:66100371 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs57866200 ENSG00000226824.5 RP4-756H11.3 5.59 6.59e-08 7.26e-05 0.45 0.35 Aortic root size; chr7:66100405 chr7:66654538~66669855:+ CESC cis rs950169 1 rs950169 ENSG00000225151.9 GOLGA2P7 -5.59 6.59e-08 7.26e-05 -0.51 -0.35 Schizophrenia; chr15:84037709 chr15:84199311~84230136:- CESC cis rs17507216 0.718 rs7165690 ENSG00000278603.1 RP13-608F4.5 5.59 6.6e-08 7.27e-05 0.6 0.35 Excessive daytime sleepiness; chr15:82654804 chr15:82472203~82472426:+ CESC cis rs4141404 0.582 rs5753630 ENSG00000236132.1 CTA-440B3.1 -5.59 6.61e-08 7.28e-05 -0.41 -0.35 Paclitaxel-induced neuropathy; chr22:31465964 chr22:31816379~31817491:- CESC cis rs35160687 0.871 rs11127028 ENSG00000273080.1 RP11-301O19.1 5.59 6.62e-08 7.29e-05 0.42 0.35 Night sleep phenotypes; chr2:86310386 chr2:86195590~86196049:+ CESC cis rs6991838 0.798 rs62507575 ENSG00000272010.1 CTD-3025N20.3 5.59 6.62e-08 7.29e-05 0.39 0.35 Intelligence (multi-trait analysis); chr8:65566486 chr8:65591850~65592472:- CESC cis rs2980439 0.87 rs2945230 ENSG00000253893.2 FAM85B -5.59 6.63e-08 7.3e-05 -0.47 -0.35 Neuroticism; chr8:8252414 chr8:8167819~8226614:- CESC cis rs7572733 0.84 rs4850808 ENSG00000222017.1 AC011997.1 5.59 6.64e-08 7.31e-05 0.39 0.35 Dermatomyositis; chr2:197711418 chr2:197693106~197774823:+ CESC cis rs34779708 0.931 rs55724039 ENSG00000230534.5 RP11-297A16.2 5.59 6.72e-08 7.39e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35176469 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs12769484 ENSG00000230534.5 RP11-297A16.2 5.59 6.72e-08 7.39e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35176818 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs11596502 ENSG00000230534.5 RP11-297A16.2 5.59 6.74e-08 7.41e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35098259 chr10:35098006~35127020:- CESC cis rs6700559 0.654 rs2809345 ENSG00000260088.1 RP11-92G12.3 5.59 6.74e-08 7.41e-05 0.43 0.35 Coronary artery disease; chr1:200627135 chr1:200669507~200694250:+ CESC cis rs1823913 0.599 rs4146103 ENSG00000280083.1 RP11-317J9.1 -5.59 6.74e-08 7.41e-05 -0.41 -0.35 Obesity-related traits; chr2:191272000 chr2:191154118~191156070:- CESC cis rs7572733 0.901 rs6734096 ENSG00000222017.1 AC011997.1 5.59 6.75e-08 7.42e-05 0.39 0.35 Dermatomyositis; chr2:197891735 chr2:197693106~197774823:+ CESC cis rs10885396 0.967 rs7094871 ENSG00000233547.1 RP11-57H14.2 -5.59 6.76e-08 7.43e-05 -0.39 -0.35 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112952395 chr10:112950646~112951875:- CESC cis rs6782228 0.675 rs6806687 ENSG00000242551.2 POU5F1P6 5.59 6.76e-08 7.44e-05 0.38 0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128672946 chr3:128674735~128677005:- CESC cis rs7572733 0.935 rs6434942 ENSG00000222017.1 AC011997.1 5.59 6.77e-08 7.44e-05 0.39 0.35 Dermatomyositis; chr2:197891964 chr2:197693106~197774823:+ CESC cis rs831571 0.519 rs13059603 ENSG00000280620.1 SCAANT1 -5.59 6.77e-08 7.44e-05 -0.51 -0.35 Type 2 diabetes; chr3:63841705 chr3:63911518~63911772:- CESC cis rs4660456 0.83 rs12742219 ENSG00000237899.1 RP4-739H11.3 -5.59 6.79e-08 7.46e-05 -0.48 -0.35 Platelet count; chr1:40728665 chr1:40669089~40687588:- CESC cis rs9545047 0.604 rs9574419 ENSG00000227676.3 LINC01068 -5.59 6.8e-08 7.47e-05 -0.4 -0.35 Schizophrenia; chr13:79402337 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9601226 ENSG00000227676.3 LINC01068 -5.59 6.8e-08 7.47e-05 -0.4 -0.35 Schizophrenia; chr13:79403400 chr13:79566727~79571436:+ CESC cis rs12022452 0.908 rs4660423 ENSG00000238287.1 RP11-656D10.3 -5.59 6.8e-08 7.48e-05 -0.58 -0.35 Age-related hearing impairment (SNP x SNP interaction); chr1:40554632 chr1:40493157~40508661:- CESC cis rs8072100 0.934 rs6504872 ENSG00000228782.6 CTD-2026D20.3 5.59 6.82e-08 7.49e-05 0.41 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47361586 chr17:47450568~47492492:- CESC cis rs9545047 0.604 rs943712 ENSG00000227676.3 LINC01068 5.59 6.83e-08 7.5e-05 0.39 0.35 Schizophrenia; chr13:79282671 chr13:79566727~79571436:+ CESC cis rs2404602 0.74 rs34924128 ENSG00000259422.1 RP11-593F23.1 5.59 6.85e-08 7.52e-05 0.4 0.35 Blood metabolite levels; chr15:76672828 chr15:76174891~76181486:- CESC cis rs11096990 0.593 rs35552004 ENSG00000249207.1 RP11-360F5.1 -5.59 6.87e-08 7.54e-05 -0.39 -0.35 Cognitive function; chr4:39170914 chr4:39112677~39126818:- CESC cis rs11096990 0.552 rs7655170 ENSG00000249207.1 RP11-360F5.1 -5.59 6.87e-08 7.54e-05 -0.39 -0.35 Cognitive function; chr4:39171984 chr4:39112677~39126818:- CESC cis rs2243480 1 rs3885839 ENSG00000228409.4 CCT6P1 5.59 6.88e-08 7.54e-05 0.51 0.35 Diabetic kidney disease; chr7:65825416 chr7:65751142~65763354:+ CESC cis rs6991838 0.55 rs4737750 ENSG00000200714.1 Y_RNA 5.59 6.9e-08 7.56e-05 0.43 0.35 Intelligence (multi-trait analysis); chr8:65638724 chr8:65592731~65592820:+ CESC cis rs11676348 0.755 rs1008562 ENSG00000261338.2 RP11-378A13.1 5.59 6.91e-08 7.56e-05 0.42 0.35 Ulcerative colitis; chr2:218162249 chr2:218255319~218257366:+ CESC cis rs11651753 0.561 rs11654010 ENSG00000264920.1 RP11-6N17.4 5.59 6.92e-08 7.58e-05 0.42 0.35 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47883499 chr17:47891255~47895812:- CESC cis rs1075265 0.527 rs959285 ENSG00000233266.1 HMGB1P31 5.59 6.92e-08 7.58e-05 0.5 0.35 Chronotype;Morning vs. evening chronotype; chr2:54078964 chr2:54051334~54051760:+ CESC cis rs9545047 0.604 rs943711 ENSG00000227676.3 LINC01068 5.58 6.94e-08 7.6e-05 0.39 0.35 Schizophrenia; chr13:79282886 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs943709 ENSG00000227676.3 LINC01068 5.58 6.94e-08 7.6e-05 0.39 0.35 Schizophrenia; chr13:79282990 chr13:79566727~79571436:+ CESC cis rs2243480 1 rs9769882 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66177938 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6966322 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66181767 chr7:66554588~66576923:- CESC cis rs2243480 1 rs4145008 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66182524 chr7:66554588~66576923:- CESC cis rs2243480 1 rs4718315 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66183554 chr7:66554588~66576923:- CESC cis rs2243480 1 rs4718316 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66183744 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1873494 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66184912 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6959002 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66185509 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1546059 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66189722 chr7:66554588~66576923:- CESC cis rs2243480 1 rs2420170 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66191066 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6958289 ENSG00000232559.3 GS1-124K5.12 -5.58 6.95e-08 7.6e-05 -0.6 -0.35 Diabetic kidney disease; chr7:66192124 chr7:66554588~66576923:- CESC cis rs9399135 0.636 rs7749106 ENSG00000232876.1 CTA-212D2.2 -5.58 6.97e-08 7.62e-05 -0.4 -0.35 Red blood cell count; chr6:134947004 chr6:135055033~135060550:+ CESC cis rs897984 0.721 rs28360557 ENSG00000260911.2 RP11-196G11.2 -5.58 6.98e-08 7.63e-05 -0.39 -0.35 Dementia with Lewy bodies; chr16:30971939 chr16:31043150~31049868:+ CESC cis rs897984 0.721 rs4889525 ENSG00000260911.2 RP11-196G11.2 -5.58 6.98e-08 7.63e-05 -0.39 -0.35 Dementia with Lewy bodies; chr16:30978537 chr16:31043150~31049868:+ CESC cis rs4853012 0.838 rs4429500 ENSG00000257800.1 FNBP1P1 5.58 6.98e-08 7.63e-05 0.37 0.35 Gestational age at birth (maternal effect); chr2:74118209 chr2:74120680~74123218:+ CESC cis rs17507216 1 rs17356118 ENSG00000255769.6 GOLGA2P10 -5.58 7.04e-08 7.69e-05 -0.5 -0.35 Excessive daytime sleepiness; chr15:82569149 chr15:82472993~82513950:- CESC cis rs2117029 0.561 rs7957983 ENSG00000258017.1 RP11-386G11.10 -5.58 7.04e-08 7.69e-05 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49115204 chr12:49127782~49147869:+ CESC cis rs2117029 0.587 rs7958572 ENSG00000258017.1 RP11-386G11.10 -5.58 7.04e-08 7.69e-05 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49115658 chr12:49127782~49147869:+ CESC cis rs507080 0.501 rs516503 ENSG00000255422.1 AP002954.4 -5.58 7.05e-08 7.69e-05 -0.41 -0.35 Serum metabolite levels; chr11:118709639 chr11:118704607~118750263:+ CESC cis rs11096990 0.593 rs35937374 ENSG00000249207.1 RP11-360F5.1 -5.58 7.05e-08 7.69e-05 -0.4 -0.35 Cognitive function; chr4:39184735 chr4:39112677~39126818:- CESC cis rs3806843 0.518 rs2569188 ENSG00000202111.1 VTRNA1-2 5.58 7.06e-08 7.7e-05 0.38 0.35 Depressive symptoms (multi-trait analysis); chr5:140628834 chr5:140718925~140719013:+ CESC cis rs875971 0.522 rs709604 ENSG00000164669.11 INTS4P1 5.58 7.06e-08 7.7e-05 0.49 0.35 Aortic root size; chr7:66032447 chr7:65141225~65234216:+ CESC cis rs9545047 0.604 rs9565497 ENSG00000227676.3 LINC01068 -5.58 7.07e-08 7.71e-05 -0.4 -0.35 Schizophrenia; chr13:79406330 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1853830 ENSG00000227676.3 LINC01068 -5.58 7.07e-08 7.71e-05 -0.4 -0.35 Schizophrenia; chr13:79406877 chr13:79566727~79571436:+ CESC cis rs116095464 0.614 rs4371799 ENSG00000250848.1 CTD-2083E4.5 -5.58 7.07e-08 7.71e-05 -0.45 -0.35 Breast cancer; chr5:268077 chr5:288833~290321:- CESC cis rs35160687 0.901 rs12478653 ENSG00000273080.1 RP11-301O19.1 -5.58 7.09e-08 7.73e-05 -0.41 -0.35 Night sleep phenotypes; chr2:86308271 chr2:86195590~86196049:+ CESC cis rs6142102 0.961 rs2284389 ENSG00000276073.1 RP5-1125A11.7 -5.58 7.09e-08 7.73e-05 -0.33 -0.35 Skin pigmentation; chr20:34069035 chr20:33985617~33988989:- CESC cis rs10262624 0.564 rs58051142 ENSG00000234286.1 AC006026.13 -5.58 7.11e-08 7.75e-05 -0.38 -0.35 Schizophrenia; chr7:23866047 chr7:23680195~23680786:- CESC cis rs7674212 0.507 rs223471 ENSG00000246560.2 RP11-10L12.4 5.58 7.11e-08 7.75e-05 0.47 0.35 Type 2 diabetes; chr4:102777629 chr4:102828055~102844075:+ CESC cis rs4423214 0.798 rs1894100 ENSG00000254682.1 RP11-660L16.2 -5.58 7.12e-08 7.75e-05 -0.49 -0.35 Vitamin D levels; chr11:71419297 chr11:71448674~71452157:+ CESC cis rs34779708 0.931 rs2001893 ENSG00000230534.5 RP11-297A16.2 5.58 7.13e-08 7.77e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35011695 chr10:35098006~35127020:- CESC cis rs8062405 0.508 rs9929088 ENSG00000259982.1 CDC37P1 -5.58 7.14e-08 7.78e-05 -0.47 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28990139 chr16:28700294~28701540:- CESC cis rs2404602 0.692 rs66866130 ENSG00000259422.1 RP11-593F23.1 5.58 7.18e-08 7.82e-05 0.4 0.35 Blood metabolite levels; chr15:76836233 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs35170561 ENSG00000259422.1 RP11-593F23.1 5.58 7.18e-08 7.82e-05 0.4 0.35 Blood metabolite levels; chr15:76838354 chr15:76174891~76181486:- CESC cis rs34779708 0.931 rs12771399 ENSG00000230534.5 RP11-297A16.2 5.58 7.2e-08 7.84e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35163449 chr10:35098006~35127020:- CESC cis rs11096990 0.613 rs12505690 ENSG00000249207.1 RP11-360F5.1 -5.58 7.2e-08 7.84e-05 -0.39 -0.35 Cognitive function; chr4:39167425 chr4:39112677~39126818:- CESC cis rs1823913 0.599 rs17511445 ENSG00000280083.1 RP11-317J9.1 5.58 7.23e-08 7.86e-05 0.41 0.35 Obesity-related traits; chr2:191279831 chr2:191154118~191156070:- CESC cis rs4266144 0.563 rs61124401 ENSG00000244515.1 KRT18P34 -5.58 7.24e-08 7.88e-05 -0.48 -0.35 Coronary artery disease; chr3:157123130 chr3:157162663~157163932:- CESC cis rs116095464 0.558 rs10076655 ENSG00000250848.1 CTD-2083E4.5 -5.58 7.25e-08 7.89e-05 -0.45 -0.35 Breast cancer; chr5:239349 chr5:288833~290321:- CESC cis rs34779708 0.931 rs12767414 ENSG00000230534.5 RP11-297A16.2 5.58 7.25e-08 7.89e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35101265 chr10:35098006~35127020:- CESC cis rs72627509 0.857 rs56155140 ENSG00000269949.1 RP11-738E22.3 5.57 7.28e-08 7.92e-05 0.52 0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56958285 chr4:56960927~56961373:- CESC cis rs897984 0.762 rs897986 ENSG00000260911.2 RP11-196G11.2 -5.57 7.3e-08 7.93e-05 -0.39 -0.35 Dementia with Lewy bodies; chr16:30969581 chr16:31043150~31049868:+ CESC cis rs520525 0.927 rs583006 ENSG00000271811.1 RP1-79C4.4 5.57 7.3e-08 7.94e-05 0.49 0.35 Atrial fibrillation; chr1:170659247 chr1:170667381~170669425:+ CESC cis rs9545047 0.604 rs2477397 ENSG00000227676.3 LINC01068 -5.57 7.33e-08 7.97e-05 -0.4 -0.35 Schizophrenia; chr13:79428211 chr13:79566727~79571436:+ CESC cis rs5758659 1 rs5751255 ENSG00000273366.1 CTA-989H11.1 -5.57 7.35e-08 7.99e-05 -0.43 -0.35 Cognitive function; chr22:42252402 chr22:42278188~42278846:+ CESC cis rs875971 0.929 rs4122249 ENSG00000222364.1 RNU6-96P -5.57 7.36e-08 8e-05 -0.42 -0.35 Aortic root size; chr7:66455949 chr7:66395191~66395286:+ CESC cis rs2729354 1 rs2729355 ENSG00000265566.2 RN7SL605P -5.57 7.41e-08 8.04e-05 -0.53 -0.35 Blood protein levels; chr11:57586510 chr11:57528085~57528365:- CESC cis rs2404602 0.692 rs55864032 ENSG00000259422.1 RP11-593F23.1 5.57 7.41e-08 8.05e-05 0.4 0.35 Blood metabolite levels; chr15:76830207 chr15:76174891~76181486:- CESC cis rs2108622 0.727 rs12609900 ENSG00000267453.5 AC004791.2 -5.57 7.43e-08 8.07e-05 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871604 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs62107763 ENSG00000267453.5 AC004791.2 -5.57 7.43e-08 8.07e-05 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871788 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs62107764 ENSG00000267453.5 AC004791.2 -5.57 7.43e-08 8.07e-05 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871848 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs76984410 ENSG00000267453.5 AC004791.2 -5.57 7.43e-08 8.07e-05 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871890 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs77780918 ENSG00000267453.5 AC004791.2 -5.57 7.43e-08 8.07e-05 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871897 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs8101038 ENSG00000267453.5 AC004791.2 -5.57 7.43e-08 8.07e-05 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872054 chr19:15851993~15864904:- CESC cis rs17507216 0.958 rs28648832 ENSG00000255769.6 GOLGA2P10 -5.57 7.44e-08 8.07e-05 -0.5 -0.35 Excessive daytime sleepiness; chr15:82567642 chr15:82472993~82513950:- CESC cis rs150992 0.57 rs10050423 ENSG00000248489.1 CTD-2007H13.3 -5.57 7.44e-08 8.07e-05 -0.45 -0.35 Body mass index; chr5:99006312 chr5:98929171~98995013:+ CESC cis rs2283792 0.812 rs240066 ENSG00000224086.5 LL22NC03-86G7.1 5.57 7.46e-08 8.09e-05 0.4 0.35 Multiple sclerosis; chr22:21938623 chr22:21938293~21977632:+ CESC cis rs875971 0.505 rs1167386 ENSG00000164669.11 INTS4P1 5.57 7.47e-08 8.1e-05 0.48 0.35 Aortic root size; chr7:66048109 chr7:65141225~65234216:+ CESC cis rs116095464 0.558 rs10075018 ENSG00000250848.1 CTD-2083E4.5 -5.57 7.48e-08 8.1e-05 -0.45 -0.35 Breast cancer; chr5:239060 chr5:288833~290321:- CESC cis rs2929278 0.561 rs2927071 ENSG00000249839.1 AC011330.5 -5.57 7.49e-08 8.11e-05 -0.38 -0.35 Schizophrenia; chr15:43626883 chr15:43663654~43684339:- CESC cis rs34779708 0.931 rs2148482 ENSG00000230534.5 RP11-297A16.2 5.57 7.5e-08 8.12e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35059982 chr10:35098006~35127020:- CESC cis rs2404602 0.692 rs8024476 ENSG00000259422.1 RP11-593F23.1 5.57 7.5e-08 8.13e-05 0.4 0.35 Blood metabolite levels; chr15:76691613 chr15:76174891~76181486:- CESC cis rs1155848 0.571 rs7983556 ENSG00000227354.5 RBM26-AS1 5.57 7.5e-08 8.13e-05 0.7 0.35 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79608777 chr13:79406309~79424328:+ CESC cis rs875971 0.66 rs10263935 ENSG00000226824.5 RP4-756H11.3 -5.57 7.51e-08 8.13e-05 -0.43 -0.35 Aortic root size; chr7:66631041 chr7:66654538~66669855:+ CESC cis rs2404602 0.716 rs4079681 ENSG00000259422.1 RP11-593F23.1 5.57 7.52e-08 8.14e-05 0.4 0.35 Blood metabolite levels; chr15:76402889 chr15:76174891~76181486:- CESC cis rs801193 0.66 rs1962050 ENSG00000222364.1 RNU6-96P 5.57 7.52e-08 8.15e-05 0.4 0.35 Aortic root size; chr7:66775021 chr7:66395191~66395286:+ CESC cis rs62229266 0.771 rs2835232 ENSG00000231106.2 LINC01436 5.57 7.53e-08 8.15e-05 0.48 0.35 Mitral valve prolapse; chr21:36021129 chr21:36005338~36007838:+ CESC cis rs62229266 0.74 rs2835233 ENSG00000231106.2 LINC01436 5.57 7.53e-08 8.15e-05 0.48 0.35 Mitral valve prolapse; chr21:36021284 chr21:36005338~36007838:+ CESC cis rs1891275 0.551 rs4933687 ENSG00000228701.1 TNKS2-AS1 -5.57 7.54e-08 8.16e-05 -0.44 -0.35 Intelligence (multi-trait analysis); chr10:91650642 chr10:91782839~91798291:- CESC cis rs34779708 0.931 rs17591135 ENSG00000230534.5 RP11-297A16.2 5.57 7.55e-08 8.17e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35176262 chr10:35098006~35127020:- CESC cis rs9545047 0.604 rs28579970 ENSG00000227676.3 LINC01068 -5.57 7.55e-08 8.17e-05 -0.39 -0.35 Schizophrenia; chr13:79308726 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9565486 ENSG00000227676.3 LINC01068 -5.57 7.55e-08 8.17e-05 -0.39 -0.35 Schizophrenia; chr13:79317469 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9285310 ENSG00000227676.3 LINC01068 -5.57 7.55e-08 8.17e-05 -0.39 -0.35 Schizophrenia; chr13:79328340 chr13:79566727~79571436:+ CESC cis rs9545047 0.625 rs9593391 ENSG00000227676.3 LINC01068 -5.57 7.55e-08 8.17e-05 -0.39 -0.35 Schizophrenia; chr13:79329168 chr13:79566727~79571436:+ CESC cis rs9322193 0.923 rs4870509 ENSG00000268592.3 RAET1E-AS1 5.57 7.55e-08 8.17e-05 0.47 0.35 Lung cancer; chr6:149702212 chr6:149863494~149919507:+ CESC cis rs2929278 0.561 rs62018952 ENSG00000205771.5 CATSPER2P1 5.57 7.55e-08 8.17e-05 0.42 0.35 Schizophrenia; chr15:43788539 chr15:43726918~43747094:- CESC cis rs9595066 0.715 rs9567366 ENSG00000227258.4 SMIM2-AS1 -5.57 7.58e-08 8.2e-05 -0.51 -0.35 Schizophrenia; chr13:44108837 chr13:44110451~44240517:+ CESC cis rs9907295 0.901 rs4796127 ENSG00000270977.1 AC015849.16 -5.57 7.6e-08 8.22e-05 -0.48 -0.35 Fibroblast growth factor basic levels; chr17:35899127 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs11868801 ENSG00000270977.1 AC015849.16 -5.57 7.6e-08 8.22e-05 -0.48 -0.35 Fibroblast growth factor basic levels; chr17:35900047 chr17:35893707~35911023:- CESC cis rs11976180 0.517 rs6949375 ENSG00000273234.1 OR2A13P -5.57 7.61e-08 8.23e-05 -0.56 -0.35 Obesity-related traits; chr7:144076758 chr7:144142009~144142938:+ CESC cis rs9545047 0.604 rs7987193 ENSG00000227676.3 LINC01068 -5.57 7.61e-08 8.23e-05 -0.4 -0.35 Schizophrenia; chr13:79408449 chr13:79566727~79571436:+ CESC cis rs8059260 0.668 rs74423828 ENSG00000274038.1 RP11-66H6.4 -5.57 7.63e-08 8.25e-05 -0.61 -0.35 Alcohol consumption over the past year; chr16:10975574 chr16:11056556~11057034:+ CESC cis rs11690935 0.921 rs3770445 ENSG00000228389.1 AC068039.4 5.57 7.64e-08 8.26e-05 0.47 0.35 Schizophrenia; chr2:171852409 chr2:171773482~171775844:+ CESC cis rs17711722 0.522 rs62469933 ENSG00000228409.4 CCT6P1 -5.57 7.64e-08 8.26e-05 -0.32 -0.35 Calcium levels; chr7:65800652 chr7:65751142~65763354:+ CESC cis rs11096990 0.574 rs34070258 ENSG00000249207.1 RP11-360F5.1 -5.57 7.65e-08 8.27e-05 -0.4 -0.35 Cognitive function; chr4:39188132 chr4:39112677~39126818:- CESC cis rs11096990 0.613 rs35391082 ENSG00000249207.1 RP11-360F5.1 -5.57 7.65e-08 8.27e-05 -0.4 -0.35 Cognitive function; chr4:39191033 chr4:39112677~39126818:- CESC cis rs1185460 0.934 rs1006195 ENSG00000271751.1 RP11-110I1.14 5.56 7.66e-08 8.28e-05 0.45 0.35 Coronary artery disease; chr11:119088159 chr11:119065263~119065677:- CESC cis rs9545047 0.604 rs7331867 ENSG00000227676.3 LINC01068 -5.56 7.67e-08 8.28e-05 -0.4 -0.35 Schizophrenia; chr13:79418791 chr13:79566727~79571436:+ CESC cis rs11690935 0.959 rs6759575 ENSG00000228389.1 AC068039.4 5.56 7.68e-08 8.3e-05 0.47 0.35 Schizophrenia; chr2:171832558 chr2:171773482~171775844:+ CESC cis rs5760092 0.618 rs5996631 ENSG00000099984.9 GSTT2 5.56 7.7e-08 8.32e-05 0.47 0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23980123~23983911:+ CESC cis rs3002131 0.736 rs2936027 ENSG00000225265.1 TAF1A-AS1 -5.56 7.71e-08 8.32e-05 -0.58 -0.35 Interleukin-10 levels; chr1:222588974 chr1:222589825~222593032:+ CESC cis rs6700559 0.81 rs10919990 ENSG00000260088.1 RP11-92G12.3 -5.56 7.71e-08 8.33e-05 -0.44 -0.35 Coronary artery disease; chr1:200627076 chr1:200669507~200694250:+ CESC cis rs720475 0.732 rs62483106 ENSG00000204959.4 ARHGEF34P -5.56 7.71e-08 8.33e-05 -0.4 -0.35 Breast cancer; chr7:144439533 chr7:144272445~144286966:- CESC cis rs7048146 0.899 rs10979957 ENSG00000213539.4 YBX1P6 5.56 7.73e-08 8.34e-05 0.41 0.35 Vascular brain injury; chr9:109594413 chr9:109532830~109534332:- CESC cis rs2842992 0.789 rs2277072 ENSG00000237927.1 RP3-393E18.2 -5.56 7.74e-08 8.35e-05 -0.46 -0.35 Age-related macular degeneration (geographic atrophy); chr6:159761813 chr6:159586955~159589169:- CESC cis rs2842992 0.83 rs2273819 ENSG00000237927.1 RP3-393E18.2 -5.56 7.74e-08 8.35e-05 -0.46 -0.35 Age-related macular degeneration (geographic atrophy); chr6:159762293 chr6:159586955~159589169:- CESC cis rs2404602 0.692 rs8037005 ENSG00000259422.1 RP11-593F23.1 5.56 7.79e-08 8.4e-05 0.4 0.35 Blood metabolite levels; chr15:76658768 chr15:76174891~76181486:- CESC cis rs950169 0.959 rs12911210 ENSG00000225151.9 GOLGA2P7 -5.56 7.8e-08 8.41e-05 -0.5 -0.35 Schizophrenia; chr15:84123331 chr15:84199311~84230136:- CESC cis rs3806843 0.766 rs6848 ENSG00000202111.1 VTRNA1-2 5.56 7.8e-08 8.41e-05 0.36 0.35 Depressive symptoms (multi-trait analysis); chr5:140706477 chr5:140718925~140719013:+ CESC cis rs1185460 0.967 rs1168568 ENSG00000271751.1 RP11-110I1.14 -5.56 7.81e-08 8.42e-05 -0.47 -0.35 Coronary artery disease; chr11:119079089 chr11:119065263~119065677:- CESC cis rs1185460 0.967 rs1307145 ENSG00000271751.1 RP11-110I1.14 -5.56 7.81e-08 8.42e-05 -0.47 -0.35 Coronary artery disease; chr11:119079507 chr11:119065263~119065677:- CESC cis rs748404 0.66 rs2439846 ENSG00000249839.1 AC011330.5 -5.56 7.81e-08 8.42e-05 -0.36 -0.35 Lung cancer; chr15:43448772 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs2467741 ENSG00000249839.1 AC011330.5 -5.56 7.81e-08 8.42e-05 -0.36 -0.35 Lung cancer; chr15:43450428 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs2439845 ENSG00000249839.1 AC011330.5 -5.56 7.81e-08 8.42e-05 -0.36 -0.35 Lung cancer; chr15:43430412 chr15:43663654~43684339:- CESC cis rs748404 0.631 rs2467745 ENSG00000249839.1 AC011330.5 -5.56 7.81e-08 8.42e-05 -0.36 -0.35 Lung cancer; chr15:43430544 chr15:43663654~43684339:- CESC cis rs875971 0.505 rs2462573 ENSG00000164669.11 INTS4P1 5.56 7.81e-08 8.42e-05 0.48 0.35 Aortic root size; chr7:66042405 chr7:65141225~65234216:+ CESC cis rs875971 0.505 rs1167385 ENSG00000164669.11 INTS4P1 5.56 7.81e-08 8.42e-05 0.48 0.35 Aortic root size; chr7:66048321 chr7:65141225~65234216:+ CESC cis rs7048146 0.966 rs10979906 ENSG00000213539.4 YBX1P6 5.56 7.82e-08 8.42e-05 0.41 0.35 Vascular brain injury; chr9:109541401 chr9:109532830~109534332:- CESC cis rs7048146 0.966 rs10979907 ENSG00000213539.4 YBX1P6 5.56 7.82e-08 8.42e-05 0.41 0.35 Vascular brain injury; chr9:109541739 chr9:109532830~109534332:- CESC cis rs8062405 0.573 rs11645306 ENSG00000259982.1 CDC37P1 -5.56 7.82e-08 8.43e-05 -0.46 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28972615 chr16:28700294~28701540:- CESC cis rs1062177 1 rs2964612 ENSG00000253921.1 CTB-113P19.3 -5.56 7.83e-08 8.43e-05 -0.48 -0.35 Preschool internalizing problems; chr5:151819189 chr5:151753992~151767247:+ CESC cis rs7684253 0.548 rs13106200 ENSG00000269949.1 RP11-738E22.3 -5.56 7.84e-08 8.44e-05 -0.41 -0.35 Migraine; chr4:56852029 chr4:56960927~56961373:- CESC cis rs11096990 0.613 rs9997015 ENSG00000249207.1 RP11-360F5.1 5.56 7.84e-08 8.45e-05 0.38 0.35 Cognitive function; chr4:39222677 chr4:39112677~39126818:- CESC cis rs748404 0.587 rs690276 ENSG00000249839.1 AC011330.5 -5.56 7.85e-08 8.46e-05 -0.36 -0.35 Lung cancer; chr15:43412360 chr15:43663654~43684339:- CESC cis rs42490 1 rs1003843 ENSG00000251136.7 RP11-37B2.1 -5.56 7.86e-08 8.46e-05 -0.34 -0.35 Leprosy; chr8:89727252 chr8:89609409~89757727:- CESC cis rs9545047 0.604 rs1980883 ENSG00000227676.3 LINC01068 -5.56 7.9e-08 8.5e-05 -0.39 -0.35 Schizophrenia; chr13:79310629 chr13:79566727~79571436:+ CESC cis rs67180937 0.922 rs1133220 ENSG00000272750.1 RP11-378J18.8 -5.56 7.9e-08 8.5e-05 -0.44 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222661461 chr1:222658867~222661512:- CESC cis rs1823913 0.637 rs6741454 ENSG00000280083.1 RP11-317J9.1 5.56 7.9e-08 8.5e-05 0.4 0.35 Obesity-related traits; chr2:191269520 chr2:191154118~191156070:- CESC cis rs7572733 0.935 rs7571869 ENSG00000222017.1 AC011997.1 5.56 7.91e-08 8.51e-05 0.39 0.35 Dermatomyositis; chr2:197976891 chr2:197693106~197774823:+ CESC cis rs2177312 0.761 rs1523157 ENSG00000251129.1 RP11-734I18.1 -5.56 7.92e-08 8.52e-05 -0.45 -0.35 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31970612 chr4:31997397~32155406:+ CESC cis rs875971 0.862 rs10274883 ENSG00000226824.5 RP4-756H11.3 5.56 7.92e-08 8.52e-05 0.44 0.35 Aortic root size; chr7:66651104 chr7:66654538~66669855:+ CESC cis rs801193 0.548 rs2109297 ENSG00000226824.5 RP4-756H11.3 5.56 7.92e-08 8.52e-05 0.44 0.35 Aortic root size; chr7:66657397 chr7:66654538~66669855:+ CESC cis rs801193 0.569 rs6978178 ENSG00000226824.5 RP4-756H11.3 5.56 7.92e-08 8.52e-05 0.44 0.35 Aortic root size; chr7:66658097 chr7:66654538~66669855:+ CESC cis rs801193 0.591 rs721717 ENSG00000226824.5 RP4-756H11.3 5.56 7.92e-08 8.52e-05 0.44 0.35 Aortic root size; chr7:66665305 chr7:66654538~66669855:+ CESC cis rs1891275 0.515 rs1592051 ENSG00000228701.1 TNKS2-AS1 5.56 7.93e-08 8.54e-05 0.4 0.35 Intelligence (multi-trait analysis); chr10:91782429 chr10:91782839~91798291:- CESC cis rs73086581 1 rs73086549 ENSG00000229539.1 RP11-119B16.2 5.56 7.93e-08 8.54e-05 0.6 0.35 Response to antidepressants in depression; chr20:3974015 chr20:3888239~3888868:- CESC cis rs5758659 1 rs134873 ENSG00000273366.1 CTA-989H11.1 -5.56 7.94e-08 8.54e-05 -0.43 -0.35 Cognitive function; chr22:42261560 chr22:42278188~42278846:+ CESC cis rs992157 0.767 rs2014615 ENSG00000261338.2 RP11-378A13.1 5.56 7.94e-08 8.54e-05 0.44 0.35 Colorectal cancer; chr2:218306468 chr2:218255319~218257366:+ CESC cis rs4853012 0.887 rs77148265 ENSG00000257800.1 FNBP1P1 5.56 7.94e-08 8.55e-05 0.39 0.35 Gestational age at birth (maternal effect); chr2:74112392 chr2:74120680~74123218:+ CESC cis rs10129255 0.5 rs4774189 ENSG00000223648.3 IGHV3-64 5.56 7.95e-08 8.55e-05 0.29 0.35 Kawasaki disease; chr14:106768275 chr14:106643132~106658258:- CESC cis rs4660456 0.913 rs12727412 ENSG00000237899.1 RP4-739H11.3 -5.56 7.95e-08 8.55e-05 -0.48 -0.35 Platelet count; chr1:40723243 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs4660448 ENSG00000237899.1 RP4-739H11.3 -5.56 7.95e-08 8.55e-05 -0.48 -0.35 Platelet count; chr1:40724682 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs7532802 ENSG00000237899.1 RP4-739H11.3 -5.56 7.95e-08 8.55e-05 -0.48 -0.35 Platelet count; chr1:40725528 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs2361648 ENSG00000237899.1 RP4-739H11.3 -5.56 7.95e-08 8.55e-05 -0.48 -0.35 Platelet count; chr1:40726825 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs6675886 ENSG00000237899.1 RP4-739H11.3 -5.56 7.95e-08 8.55e-05 -0.48 -0.35 Platelet count; chr1:40727955 chr1:40669089~40687588:- CESC cis rs897984 0.806 rs10782002 ENSG00000260911.2 RP11-196G11.2 -5.56 7.96e-08 8.56e-05 -0.39 -0.35 Dementia with Lewy bodies; chr16:30935185 chr16:31043150~31049868:+ CESC cis rs116095464 0.558 rs6555058 ENSG00000250848.1 CTD-2083E4.5 5.56 7.97e-08 8.57e-05 0.44 0.35 Breast cancer; chr5:226261 chr5:288833~290321:- CESC cis rs950169 0.922 rs62028133 ENSG00000225151.9 GOLGA2P7 -5.56 7.99e-08 8.59e-05 -0.5 -0.35 Schizophrenia; chr15:84250623 chr15:84199311~84230136:- CESC cis rs9322193 0.887 rs9767113 ENSG00000268592.3 RAET1E-AS1 5.56 7.99e-08 8.59e-05 0.47 0.35 Lung cancer; chr6:149718157 chr6:149863494~149919507:+ CESC cis rs2108622 0.727 rs8104311 ENSG00000267453.5 AC004791.2 -5.56 8.01e-08 8.61e-05 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871950 chr19:15851993~15864904:- CESC cis rs34779708 0.897 rs35784065 ENSG00000230534.5 RP11-297A16.2 5.56 8.03e-08 8.63e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35064646 chr10:35098006~35127020:- CESC cis rs8059260 0.736 rs16957836 ENSG00000274038.1 RP11-66H6.4 -5.55 8.05e-08 8.65e-05 -0.57 -0.35 Alcohol consumption over the past year; chr16:10959229 chr16:11056556~11057034:+ CESC cis rs8059260 0.736 rs3871209 ENSG00000274038.1 RP11-66H6.4 -5.55 8.05e-08 8.65e-05 -0.57 -0.35 Alcohol consumption over the past year; chr16:10962907 chr16:11056556~11057034:+ CESC cis rs2729354 0.953 rs2649663 ENSG00000265566.2 RN7SL605P -5.55 8.1e-08 8.7e-05 -0.51 -0.35 Blood protein levels; chr11:57589832 chr11:57528085~57528365:- CESC cis rs1891275 0.551 rs7908678 ENSG00000228701.1 TNKS2-AS1 5.55 8.1e-08 8.7e-05 0.42 0.35 Intelligence (multi-trait analysis); chr10:91659253 chr10:91782839~91798291:- CESC cis rs34779708 0.897 rs4934529 ENSG00000230534.5 RP11-297A16.2 5.55 8.12e-08 8.72e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35013448 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs7920095 ENSG00000230534.5 RP11-297A16.2 5.55 8.12e-08 8.72e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35014406 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934700 ENSG00000230534.5 RP11-297A16.2 5.55 8.12e-08 8.72e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35021914 chr10:35098006~35127020:- CESC cis rs10246939 0.579 rs13232651 ENSG00000228775.6 WEE2-AS1 5.55 8.14e-08 8.73e-05 0.41 0.35 Bitter taste perception; chr7:141862624 chr7:141704338~141738346:- CESC cis rs10740039 0.583 rs9415612 ENSG00000254271.1 RP11-131N11.4 -5.55 8.15e-08 8.75e-05 -0.43 -0.35 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60746638 chr10:60734342~60741828:+ CESC cis rs7572733 0.935 rs67031482 ENSG00000222017.1 AC011997.1 5.55 8.16e-08 8.75e-05 0.39 0.35 Dermatomyositis; chr2:198046442 chr2:197693106~197774823:+ CESC cis rs1823913 0.614 rs6755243 ENSG00000280083.1 RP11-317J9.1 5.55 8.16e-08 8.75e-05 0.4 0.35 Obesity-related traits; chr2:191269810 chr2:191154118~191156070:- CESC cis rs7188445 0.932 rs7203756 ENSG00000261390.4 RP11-345M22.2 5.55 8.17e-08 8.76e-05 0.44 0.35 Urate levels; chr16:79711709 chr16:79715232~79770563:- CESC cis rs2404602 0.692 rs35195096 ENSG00000259422.1 RP11-593F23.1 5.55 8.19e-08 8.78e-05 0.4 0.35 Blood metabolite levels; chr15:76646106 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs34287706 ENSG00000259422.1 RP11-593F23.1 5.55 8.19e-08 8.78e-05 0.4 0.35 Blood metabolite levels; chr15:76650061 chr15:76174891~76181486:- CESC cis rs2404602 0.669 rs12438540 ENSG00000259422.1 RP11-593F23.1 5.55 8.19e-08 8.78e-05 0.4 0.35 Blood metabolite levels; chr15:76650872 chr15:76174891~76181486:- CESC cis rs10510102 0.608 rs4486560 ENSG00000226864.1 ATE1-AS1 5.55 8.2e-08 8.79e-05 0.44 0.35 Breast cancer; chr10:121844840 chr10:121928312~121951965:+ CESC cis rs7048146 0.899 rs7032590 ENSG00000213539.4 YBX1P6 5.55 8.2e-08 8.79e-05 0.41 0.35 Vascular brain injury; chr9:109575480 chr9:109532830~109534332:- CESC cis rs6504622 0.693 rs12950276 ENSG00000262879.4 RP11-156P1.3 -5.55 8.21e-08 8.8e-05 -0.39 -0.35 Orofacial clefts; chr17:47095819 chr17:46984045~47100323:- CESC cis rs6504622 0.755 rs12950699 ENSG00000262879.4 RP11-156P1.3 -5.55 8.21e-08 8.8e-05 -0.39 -0.35 Orofacial clefts; chr17:47096296 chr17:46984045~47100323:- CESC cis rs6504622 0.748 rs7215573 ENSG00000262879.4 RP11-156P1.3 -5.55 8.21e-08 8.8e-05 -0.39 -0.35 Orofacial clefts; chr17:47096887 chr17:46984045~47100323:- CESC cis rs875971 0.862 rs28491091 ENSG00000226824.5 RP4-756H11.3 5.55 8.21e-08 8.8e-05 0.44 0.35 Aortic root size; chr7:66204077 chr7:66654538~66669855:+ CESC cis rs34779708 0.931 rs12240347 ENSG00000230534.5 RP11-297A16.2 5.55 8.22e-08 8.81e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35070547 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934533 ENSG00000230534.5 RP11-297A16.2 5.55 8.22e-08 8.81e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35070691 chr10:35098006~35127020:- CESC cis rs2404602 0.716 rs7179142 ENSG00000259422.1 RP11-593F23.1 5.55 8.22e-08 8.81e-05 0.4 0.35 Blood metabolite levels; chr15:76405927 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs8039545 ENSG00000259422.1 RP11-593F23.1 5.55 8.22e-08 8.81e-05 0.4 0.35 Blood metabolite levels; chr15:76414906 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs7164060 ENSG00000259422.1 RP11-593F23.1 5.55 8.22e-08 8.81e-05 0.4 0.35 Blood metabolite levels; chr15:76415353 chr15:76174891~76181486:- CESC cis rs2404602 0.716 rs7164813 ENSG00000259422.1 RP11-593F23.1 5.55 8.22e-08 8.81e-05 0.4 0.35 Blood metabolite levels; chr15:76415725 chr15:76174891~76181486:- CESC cis rs875971 0.862 rs6952182 ENSG00000226824.5 RP4-756H11.3 5.55 8.23e-08 8.82e-05 0.44 0.35 Aortic root size; chr7:66218330 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6964437 ENSG00000226824.5 RP4-756H11.3 5.55 8.23e-08 8.82e-05 0.44 0.35 Aortic root size; chr7:66221457 chr7:66654538~66669855:+ CESC cis rs6504622 0.721 rs7215903 ENSG00000262879.4 RP11-156P1.3 -5.55 8.24e-08 8.83e-05 -0.39 -0.35 Orofacial clefts; chr17:47097100 chr17:46984045~47100323:- CESC cis rs7048146 0.966 rs4978825 ENSG00000213539.4 YBX1P6 -5.55 8.26e-08 8.85e-05 -0.41 -0.35 Vascular brain injury; chr9:109540184 chr9:109532830~109534332:- CESC cis rs9545047 0.604 rs9318623 ENSG00000227676.3 LINC01068 -5.55 8.27e-08 8.85e-05 -0.4 -0.35 Schizophrenia; chr13:79346913 chr13:79566727~79571436:+ CESC cis rs9545047 0.564 rs7998837 ENSG00000227676.3 LINC01068 -5.55 8.27e-08 8.85e-05 -0.4 -0.35 Schizophrenia; chr13:79349190 chr13:79566727~79571436:+ CESC cis rs11676348 0.783 rs4674252 ENSG00000261338.2 RP11-378A13.1 -5.55 8.27e-08 8.85e-05 -0.42 -0.35 Ulcerative colitis; chr2:218119755 chr2:218255319~218257366:+ CESC cis rs11676348 0.818 rs7423433 ENSG00000261338.2 RP11-378A13.1 -5.55 8.27e-08 8.85e-05 -0.42 -0.35 Ulcerative colitis; chr2:218120361 chr2:218255319~218257366:+ CESC cis rs11676348 0.714 rs4674254 ENSG00000261338.2 RP11-378A13.1 -5.55 8.27e-08 8.85e-05 -0.42 -0.35 Ulcerative colitis; chr2:218121354 chr2:218255319~218257366:+ CESC cis rs8072100 0.748 rs9908016 ENSG00000228782.6 CTD-2026D20.3 5.55 8.27e-08 8.85e-05 0.42 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47473995 chr17:47450568~47492492:- CESC cis rs8072100 0.782 rs28507314 ENSG00000228782.6 CTD-2026D20.3 5.55 8.27e-08 8.85e-05 0.42 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47474036 chr17:47450568~47492492:- CESC cis rs2361701 0.636 rs1982244 ENSG00000279259.1 RP11-334C17.3 5.55 8.28e-08 8.86e-05 0.44 0.35 IgG glycosylation; chr17:80095149 chr17:80147250~80148596:+ CESC cis rs875971 0.825 rs1860472 ENSG00000226824.5 RP4-756H11.3 5.55 8.28e-08 8.87e-05 0.44 0.35 Aortic root size; chr7:66617736 chr7:66654538~66669855:+ CESC cis rs17711722 0.727 rs2658585 ENSG00000164669.11 INTS4P1 -5.55 8.29e-08 8.87e-05 -0.49 -0.35 Calcium levels; chr7:65996954 chr7:65141225~65234216:+ CESC cis rs950169 0.845 rs4502182 ENSG00000225151.9 GOLGA2P7 -5.55 8.29e-08 8.87e-05 -0.5 -0.35 Schizophrenia; chr15:84254768 chr15:84199311~84230136:- CESC cis rs4660456 0.711 rs12409109 ENSG00000237899.1 RP4-739H11.3 -5.55 8.32e-08 8.89e-05 -0.49 -0.35 Platelet count; chr1:40727216 chr1:40669089~40687588:- CESC cis rs897984 0.762 rs4889604 ENSG00000260911.2 RP11-196G11.2 -5.55 8.32e-08 8.9e-05 -0.39 -0.35 Dementia with Lewy bodies; chr16:30974673 chr16:31043150~31049868:+ CESC cis rs897984 0.762 rs12931046 ENSG00000260911.2 RP11-196G11.2 -5.55 8.32e-08 8.9e-05 -0.39 -0.35 Dementia with Lewy bodies; chr16:30975823 chr16:31043150~31049868:+ CESC cis rs9545047 0.604 rs7983344 ENSG00000227676.3 LINC01068 -5.55 8.32e-08 8.9e-05 -0.4 -0.35 Schizophrenia; chr13:79299295 chr13:79566727~79571436:+ CESC cis rs748404 0.66 rs2467742 ENSG00000249839.1 AC011330.5 -5.55 8.34e-08 8.92e-05 -0.36 -0.35 Lung cancer; chr15:43458039 chr15:43663654~43684339:- CESC cis rs8072100 0.748 rs9912592 ENSG00000228782.6 CTD-2026D20.3 5.55 8.34e-08 8.92e-05 0.42 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47479579 chr17:47450568~47492492:- CESC cis rs2404602 0.716 rs2404736 ENSG00000259422.1 RP11-593F23.1 5.55 8.36e-08 8.94e-05 0.4 0.35 Blood metabolite levels; chr15:76583602 chr15:76174891~76181486:- CESC cis rs11676348 0.818 rs4674256 ENSG00000261338.2 RP11-378A13.1 -5.55 8.37e-08 8.94e-05 -0.42 -0.35 Ulcerative colitis; chr2:218123170 chr2:218255319~218257366:+ CESC cis rs11676348 0.846 rs4674257 ENSG00000261338.2 RP11-378A13.1 -5.55 8.37e-08 8.94e-05 -0.42 -0.35 Ulcerative colitis; chr2:218124051 chr2:218255319~218257366:+ CESC cis rs1167827 1 rs1167827 ENSG00000278416.1 PMS2L2 5.55 8.45e-08 9.02e-05 0.4 0.35 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75533848 chr7:75344015~75359550:- CESC cis rs2243480 0.908 rs1532573 ENSG00000228409.4 CCT6P1 -5.54 8.48e-08 9.05e-05 -0.53 -0.35 Diabetic kidney disease; chr7:66333815 chr7:65751142~65763354:+ CESC cis rs8059260 0.673 rs74985998 ENSG00000274038.1 RP11-66H6.4 -5.54 8.48e-08 9.05e-05 -0.57 -0.35 Alcohol consumption over the past year; chr16:10967208 chr16:11056556~11057034:+ CESC cis rs34779708 0.966 rs11010095 ENSG00000230534.5 RP11-297A16.2 5.54 8.48e-08 9.05e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35107020 chr10:35098006~35127020:- CESC cis rs801193 0.569 rs13226966 ENSG00000226824.5 RP4-756H11.3 -5.54 8.48e-08 9.05e-05 -0.43 -0.35 Aortic root size; chr7:66768636 chr7:66654538~66669855:+ CESC cis rs875971 0.964 rs160635 ENSG00000222364.1 RNU6-96P -5.54 8.52e-08 9.1e-05 -0.42 -0.35 Aortic root size; chr7:66063931 chr7:66395191~66395286:+ CESC cis rs9545047 0.519 rs8001281 ENSG00000227676.3 LINC01068 5.54 8.54e-08 9.11e-05 0.39 0.35 Schizophrenia; chr13:79410707 chr13:79566727~79571436:+ CESC cis rs7847628 0.765 rs7026635 ENSG00000226752.6 PSMD5-AS1 5.54 8.55e-08 9.12e-05 0.44 0.35 Birth weight; chr9:120787749 chr9:120824828~120854385:+ CESC cis rs7829975 0.742 rs12547493 ENSG00000173295.6 FAM86B3P -5.54 8.56e-08 9.13e-05 -0.47 -0.35 Mood instability; chr8:8804024 chr8:8228595~8244865:+ CESC cis rs16928809 0.52 rs74050440 ENSG00000183562.3 CTC-343N3.1 5.54 8.59e-08 9.16e-05 0.53 0.35 Bilirubin levels; chr11:2941213 chr11:2989863~2991344:+ CESC cis rs7572733 1 rs67748055 ENSG00000222017.1 AC011997.1 5.54 8.62e-08 9.18e-05 0.38 0.35 Dermatomyositis; chr2:198046702 chr2:197693106~197774823:+ CESC cis rs67383717 0.672 rs589458 ENSG00000175611.10 LINC00476 5.54 8.64e-08 9.2e-05 0.4 0.35 Parkinson's disease (pesticide exposure interaction); chr9:95878389 chr9:95759231~95875977:- CESC cis rs875971 0.825 rs1000464 ENSG00000222364.1 RNU6-96P 5.54 8.66e-08 9.23e-05 0.4 0.35 Aortic root size; chr7:66312922 chr7:66395191~66395286:+ CESC cis rs4660456 0.913 rs6668453 ENSG00000237899.1 RP4-739H11.3 -5.54 8.68e-08 9.24e-05 -0.47 -0.35 Platelet count; chr1:40733299 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs35881320 ENSG00000237899.1 RP4-739H11.3 -5.54 8.68e-08 9.24e-05 -0.47 -0.35 Platelet count; chr1:40733893 chr1:40669089~40687588:- CESC cis rs4660456 0.871 rs34512220 ENSG00000237899.1 RP4-739H11.3 -5.54 8.68e-08 9.24e-05 -0.47 -0.35 Platelet count; chr1:40733912 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs6664044 ENSG00000237899.1 RP4-739H11.3 -5.54 8.68e-08 9.24e-05 -0.47 -0.35 Platelet count; chr1:40735089 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs6702983 ENSG00000237899.1 RP4-739H11.3 -5.54 8.68e-08 9.24e-05 -0.47 -0.35 Platelet count; chr1:40735585 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs12566733 ENSG00000237899.1 RP4-739H11.3 -5.54 8.68e-08 9.24e-05 -0.47 -0.35 Platelet count; chr1:40736067 chr1:40669089~40687588:- CESC cis rs881375 0.678 rs10760130 ENSG00000226752.6 PSMD5-AS1 -5.54 8.69e-08 9.25e-05 -0.37 -0.35 Rheumatoid arthritis; chr9:120939712 chr9:120824828~120854385:+ CESC cis rs116095464 0.867 rs10074958 ENSG00000250848.1 CTD-2083E4.5 -5.54 8.69e-08 9.25e-05 -0.45 -0.35 Breast cancer; chr5:230713 chr5:288833~290321:- CESC cis rs79349575 0.756 rs2291726 ENSG00000270781.1 RP11-501C14.9 5.54 8.7e-08 9.26e-05 0.39 0.35 Type 2 diabetes; chr17:48961892 chr17:48899131~48899748:+ CESC cis rs7188445 0.932 rs17767419 ENSG00000261390.4 RP11-345M22.2 -5.54 8.7e-08 9.26e-05 -0.45 -0.35 Urate levels; chr16:79710651 chr16:79715232~79770563:- CESC cis rs9399135 0.967 rs6923827 ENSG00000232876.1 CTA-212D2.2 -5.54 8.72e-08 9.27e-05 -0.4 -0.35 Red blood cell count; chr6:135014244 chr6:135055033~135060550:+ CESC cis rs34779708 0.931 rs6481935 ENSG00000230534.5 RP11-297A16.2 5.54 8.72e-08 9.27e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35054031 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs12242882 ENSG00000230534.5 RP11-297A16.2 5.54 8.72e-08 9.27e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35058932 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs2384287 ENSG00000230534.5 RP11-297A16.2 5.54 8.72e-08 9.28e-05 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35051631 chr10:35098006~35127020:- CESC cis rs116095464 0.51 rs60844864 ENSG00000250848.1 CTD-2083E4.5 -5.54 8.73e-08 9.29e-05 -0.46 -0.35 Breast cancer; chr5:266885 chr5:288833~290321:- CESC cis rs116095464 0.542 rs28650039 ENSG00000250848.1 CTD-2083E4.5 -5.54 8.73e-08 9.29e-05 -0.46 -0.35 Breast cancer; chr5:273839 chr5:288833~290321:- CESC cis rs116095464 0.558 rs6962 ENSG00000250848.1 CTD-2083E4.5 -5.54 8.74e-08 9.29e-05 -0.49 -0.35 Breast cancer; chr5:256394 chr5:288833~290321:- CESC cis rs35955747 0.902 rs140074 ENSG00000236132.1 CTA-440B3.1 -5.54 8.76e-08 9.31e-05 -0.4 -0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31329648 chr22:31816379~31817491:- CESC cis rs1062177 1 rs2915887 ENSG00000253921.1 CTB-113P19.3 -5.54 8.78e-08 9.32e-05 -0.48 -0.35 Preschool internalizing problems; chr5:151825943 chr5:151753992~151767247:+ CESC cis rs875971 0.793 rs460678 ENSG00000222364.1 RNU6-96P -5.54 8.8e-08 9.34e-05 -0.42 -0.35 Aortic root size; chr7:66062213 chr7:66395191~66395286:+ CESC cis rs8072100 0.817 rs12449647 ENSG00000228782.6 CTD-2026D20.3 5.54 8.82e-08 9.36e-05 0.42 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47471592 chr17:47450568~47492492:- CESC cis rs2108622 0.727 rs3093193 ENSG00000267453.5 AC004791.2 -5.54 8.82e-08 9.36e-05 -0.44 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15881104 chr19:15851993~15864904:- CESC cis rs34779708 0.931 rs11010067 ENSG00000230534.5 RP11-297A16.2 -5.54 8.87e-08 9.41e-05 -0.46 -0.35 Inflammatory bowel disease;Crohn's disease; chr10:35006503 chr10:35098006~35127020:- CESC cis rs2739330 0.828 rs2154593 ENSG00000250470.1 AP000351.3 5.54 8.89e-08 9.42e-05 0.45 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23976904~23977585:- CESC cis rs10875746 0.903 rs11168420 ENSG00000240399.1 RP1-228P16.1 -5.53 8.91e-08 9.45e-05 -0.45 -0.35 Longevity (90 years and older); chr12:48122113 chr12:48054813~48055591:- CESC cis rs9545047 0.584 rs9565485 ENSG00000227676.3 LINC01068 -5.53 8.92e-08 9.45e-05 -0.39 -0.35 Schizophrenia; chr13:79307428 chr13:79566727~79571436:+ CESC cis rs875971 0.862 rs6971059 ENSG00000226824.5 RP4-756H11.3 5.53 8.92e-08 9.45e-05 0.44 0.35 Aortic root size; chr7:66602045 chr7:66654538~66669855:+ CESC cis rs875971 0.789 rs7808013 ENSG00000226824.5 RP4-756H11.3 5.53 8.92e-08 9.45e-05 0.44 0.35 Aortic root size; chr7:66606209 chr7:66654538~66669855:+ CESC cis rs875971 0.825 rs7384021 ENSG00000226824.5 RP4-756H11.3 5.53 8.92e-08 9.45e-05 0.44 0.35 Aortic root size; chr7:66612917 chr7:66654538~66669855:+ CESC cis rs875971 0.825 rs66981195 ENSG00000226824.5 RP4-756H11.3 5.53 8.92e-08 9.45e-05 0.44 0.35 Aortic root size; chr7:66614048 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs3926380 ENSG00000226824.5 RP4-756H11.3 5.53 8.92e-08 9.45e-05 0.44 0.35 Aortic root size; chr7:66615658 chr7:66654538~66669855:+ CESC cis rs801193 0.613 rs2659900 ENSG00000222364.1 RNU6-96P -5.53 8.92e-08 9.45e-05 -0.41 -0.35 Aortic root size; chr7:66719456 chr7:66395191~66395286:+ CESC cis rs801193 0.636 rs2659895 ENSG00000222364.1 RNU6-96P -5.53 8.92e-08 9.45e-05 -0.41 -0.35 Aortic root size; chr7:66731484 chr7:66395191~66395286:+ CESC cis rs507080 0.501 rs625735 ENSG00000255422.1 AP002954.4 -5.53 8.94e-08 9.47e-05 -0.4 -0.35 Serum metabolite levels; chr11:118704710 chr11:118704607~118750263:+ CESC cis rs11096990 0.613 rs6840578 ENSG00000249207.1 RP11-360F5.1 -5.53 8.95e-08 9.48e-05 -0.4 -0.35 Cognitive function; chr4:39206996 chr4:39112677~39126818:- CESC cis rs10129255 0.646 rs55995061 ENSG00000211974.3 IGHV2-70 5.53 8.95e-08 9.48e-05 0.35 0.35 Kawasaki disease; chr14:106799309 chr14:106723574~106724093:- CESC cis rs7572733 0.935 rs11675025 ENSG00000222017.1 AC011997.1 5.53 8.95e-08 9.48e-05 0.39 0.35 Dermatomyositis; chr2:197973591 chr2:197693106~197774823:+ CESC cis rs875971 0.862 rs12537823 ENSG00000222364.1 RNU6-96P -5.53 8.96e-08 9.49e-05 -0.4 -0.35 Aortic root size; chr7:66255897 chr7:66395191~66395286:+ CESC cis rs6951245 0.529 rs10262070 ENSG00000229043.2 AC091729.9 -5.53 8.97e-08 9.5e-05 -0.45 -0.35 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1102102 chr7:1160374~1165267:+ CESC cis rs6700559 0.81 rs7529962 ENSG00000260088.1 RP11-92G12.3 -5.53 8.99e-08 9.52e-05 -0.42 -0.35 Coronary artery disease; chr1:200627849 chr1:200669507~200694250:+ CESC cis rs11096990 0.634 rs12648082 ENSG00000249207.1 RP11-360F5.1 5.53 8.99e-08 9.52e-05 0.38 0.35 Cognitive function; chr4:39278104 chr4:39112677~39126818:- CESC cis rs875971 1 rs7781698 ENSG00000222364.1 RNU6-96P -5.53 9e-08 9.53e-05 -0.41 -0.35 Aortic root size; chr7:66431325 chr7:66395191~66395286:+ CESC cis rs6951245 0.554 rs2070118 ENSG00000229043.2 AC091729.9 -5.53 9.01e-08 9.54e-05 -0.47 -0.35 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1092869 chr7:1160374~1165267:+ CESC cis rs9907295 0.892 rs4795100 ENSG00000270977.1 AC015849.16 -5.53 9.02e-08 9.54e-05 -0.51 -0.35 Fibroblast growth factor basic levels; chr17:35917470 chr17:35893707~35911023:- CESC cis rs7572733 1 rs6732340 ENSG00000222017.1 AC011997.1 5.53 9.04e-08 9.56e-05 0.38 0.35 Dermatomyositis; chr2:198048228 chr2:197693106~197774823:+ CESC cis rs7189233 0.531 rs9921587 ENSG00000279344.1 RP11-44F14.7 5.53 9.05e-08 9.57e-05 0.33 0.35 Intelligence (multi-trait analysis); chr16:53441738 chr16:53478957~53481550:- CESC cis rs9545047 0.604 rs314695 ENSG00000227676.3 LINC01068 -5.53 9.07e-08 9.6e-05 -0.39 -0.35 Schizophrenia; chr13:79432206 chr13:79566727~79571436:+ CESC cis rs34779708 0.931 rs4934535 ENSG00000230534.5 RP11-297A16.2 5.53 9.08e-08 9.6e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35143793 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs4934734 ENSG00000230534.5 RP11-297A16.2 5.53 9.08e-08 9.6e-05 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35145445 chr10:35098006~35127020:- CESC cis rs7572733 0.935 rs10931797 ENSG00000222017.1 AC011997.1 5.53 9.09e-08 9.61e-05 0.38 0.35 Dermatomyositis; chr2:197976069 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs13394871 ENSG00000222017.1 AC011997.1 5.53 9.12e-08 9.64e-05 0.38 0.35 Dermatomyositis; chr2:197981613 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs6742782 ENSG00000222017.1 AC011997.1 5.53 9.14e-08 9.66e-05 0.38 0.35 Dermatomyositis; chr2:197890297 chr2:197693106~197774823:+ CESC cis rs8072100 0.967 rs8074149 ENSG00000228782.6 CTD-2026D20.3 -5.53 9.14e-08 9.66e-05 -0.41 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47506009 chr17:47450568~47492492:- CESC cis rs875971 0.895 rs4145009 ENSG00000222364.1 RNU6-96P 5.53 9.16e-08 9.68e-05 0.4 0.35 Aortic root size; chr7:66261628 chr7:66395191~66395286:+ CESC cis rs748404 0.66 rs693510 ENSG00000249839.1 AC011330.5 -5.53 9.16e-08 9.68e-05 -0.36 -0.35 Lung cancer; chr15:43422427 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs690367 ENSG00000249839.1 AC011330.5 5.53 9.16e-08 9.68e-05 0.37 0.35 Lung cancer; chr15:43456106 chr15:43663654~43684339:- CESC cis rs8059260 0.668 rs16957839 ENSG00000274038.1 RP11-66H6.4 -5.53 9.2e-08 9.72e-05 -0.59 -0.35 Alcohol consumption over the past year; chr16:10962521 chr16:11056556~11057034:+ CESC cis rs73086581 1 rs113812453 ENSG00000229539.1 RP11-119B16.2 5.53 9.24e-08 9.76e-05 0.59 0.35 Response to antidepressants in depression; chr20:3982546 chr20:3888239~3888868:- CESC cis rs73086581 0.947 rs17287577 ENSG00000229539.1 RP11-119B16.2 5.53 9.24e-08 9.76e-05 0.59 0.35 Response to antidepressants in depression; chr20:3985607 chr20:3888239~3888868:- CESC cis rs2739330 0.828 rs5760107 ENSG00000231271.1 AP000350.8 5.53 9.25e-08 9.76e-05 0.42 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23949918~23954042:+ CESC cis rs2739330 0.789 rs5760109 ENSG00000231271.1 AP000350.8 5.53 9.25e-08 9.76e-05 0.42 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23949918~23954042:+ CESC cis rs62229266 0.659 rs2835243 ENSG00000231106.2 LINC01436 5.53 9.25e-08 9.77e-05 0.48 0.35 Mitral valve prolapse; chr21:36041648 chr21:36005338~36007838:+ CESC cis rs9545047 0.604 rs2765078 ENSG00000227676.3 LINC01068 5.53 9.27e-08 9.79e-05 0.39 0.35 Schizophrenia; chr13:79420604 chr13:79566727~79571436:+ CESC cis rs11651753 0.561 rs60580012 ENSG00000264920.1 RP11-6N17.4 -5.53 9.3e-08 9.81e-05 -0.41 -0.35 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47892442 chr17:47891255~47895812:- CESC cis rs11651753 0.561 rs61422354 ENSG00000264920.1 RP11-6N17.4 -5.53 9.3e-08 9.81e-05 -0.41 -0.35 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47892443 chr17:47891255~47895812:- CESC cis rs733592 0.507 rs7299704 ENSG00000240399.1 RP1-228P16.1 5.53 9.3e-08 9.81e-05 0.35 0.35 Plateletcrit; chr12:48050705 chr12:48054813~48055591:- CESC cis rs11096990 0.656 rs2123028 ENSG00000249207.1 RP11-360F5.1 5.53 9.32e-08 9.83e-05 0.37 0.35 Cognitive function; chr4:39301859 chr4:39112677~39126818:- CESC cis rs7572733 0.905 rs6718039 ENSG00000222017.1 AC011997.1 5.52 9.35e-08 9.86e-05 0.38 0.35 Dermatomyositis; chr2:197896918 chr2:197693106~197774823:+ CESC cis rs2117029 0.555 rs2279596 ENSG00000258017.1 RP11-386G11.10 -5.52 9.37e-08 9.88e-05 -0.44 -0.35 Intelligence (multi-trait analysis); chr12:49104968 chr12:49127782~49147869:+ CESC cis rs957448 1 rs2381882 ENSG00000253704.1 RP11-267M23.4 5.52 9.37e-08 9.88e-05 0.4 0.35 Nonsyndromic cleft lip with cleft palate; chr8:94535496 chr8:94553722~94569745:+ CESC cis rs116095464 0.558 rs55664502 ENSG00000250848.1 CTD-2083E4.5 -5.52 9.42e-08 9.92e-05 -0.45 -0.35 Breast cancer; chr5:270370 chr5:288833~290321:- CESC cis rs116095464 0.51 rs7723883 ENSG00000250848.1 CTD-2083E4.5 -5.52 9.42e-08 9.92e-05 -0.45 -0.35 Breast cancer; chr5:270683 chr5:288833~290321:- CESC cis rs116095464 0.558 rs28558836 ENSG00000250848.1 CTD-2083E4.5 -5.52 9.42e-08 9.92e-05 -0.45 -0.35 Breast cancer; chr5:285633 chr5:288833~290321:- CESC cis rs2243480 1 rs160639 ENSG00000232559.3 GS1-124K5.12 5.52 9.43e-08 9.93e-05 0.6 0.35 Diabetic kidney disease; chr7:66115000 chr7:66554588~66576923:- CESC cis rs1823913 0.637 rs4853584 ENSG00000280083.1 RP11-317J9.1 5.52 9.44e-08 9.94e-05 0.4 0.35 Obesity-related traits; chr2:191310596 chr2:191154118~191156070:- CESC cis rs7572733 0.905 rs6735214 ENSG00000222017.1 AC011997.1 5.52 9.44e-08 9.94e-05 0.39 0.35 Dermatomyositis; chr2:197895783 chr2:197693106~197774823:+ CESC cis rs9309711 0.621 rs7586472 ENSG00000225234.1 TRAPPC12-AS1 -5.52 9.45e-08 9.95e-05 -0.32 -0.35 Neurofibrillary tangles; chr2:3469899 chr2:3481242~3482409:- CESC cis rs6991838 0.831 rs11992528 ENSG00000272010.1 CTD-3025N20.3 5.52 9.46e-08 9.96e-05 0.37 0.35 Intelligence (multi-trait analysis); chr8:65561644 chr8:65591850~65592472:- CESC cis rs9322193 0.607 rs9371228 ENSG00000231760.4 RP11-350J20.5 -5.52 9.47e-08 9.96e-05 -0.52 -0.35 Lung cancer; chr6:149921977 chr6:149796151~149826294:- CESC cis rs34779708 0.966 rs17591163 ENSG00000230534.5 RP11-297A16.2 5.52 9.56e-08 0.000101 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35176351 chr10:35098006~35127020:- CESC cis rs2243480 1 rs160646 ENSG00000232559.3 GS1-124K5.12 5.52 9.6e-08 0.000101 0.6 0.35 Diabetic kidney disease; chr7:66091293 chr7:66554588~66576923:- CESC cis rs2243480 1 rs2257790 ENSG00000232559.3 GS1-124K5.12 5.52 9.61e-08 0.000101 0.6 0.35 Diabetic kidney disease; chr7:66135463 chr7:66554588~66576923:- CESC cis rs1823913 0.637 rs4613316 ENSG00000280083.1 RP11-317J9.1 -5.52 9.61e-08 0.000101 -0.4 -0.35 Obesity-related traits; chr2:191326074 chr2:191154118~191156070:- CESC cis rs2906856 0.524 rs56236103 ENSG00000255733.4 IFNG-AS1 5.52 9.62e-08 0.000101 0.42 0.35 Mosquito bite size; chr12:67937437 chr12:67989445~68234686:+ CESC cis rs9399135 0.636 rs4646871 ENSG00000232876.1 CTA-212D2.2 5.52 9.64e-08 0.000101 0.41 0.35 Red blood cell count; chr6:134944479 chr6:135055033~135060550:+ CESC cis rs2177312 0.83 rs1523156 ENSG00000251129.1 RP11-734I18.1 -5.52 9.64e-08 0.000101 -0.45 -0.35 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31970819 chr4:31997397~32155406:+ CESC cis rs875971 0.862 rs1968126 ENSG00000237310.1 GS1-124K5.4 -5.52 9.65e-08 0.000101 -0.33 -0.35 Aortic root size; chr7:66592017 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6460306 ENSG00000237310.1 GS1-124K5.4 -5.52 9.65e-08 0.000101 -0.33 -0.35 Aortic root size; chr7:66595806 chr7:66493706~66495474:+ CESC cis rs1062177 0.756 rs2915817 ENSG00000253921.1 CTB-113P19.3 5.52 9.66e-08 0.000102 0.47 0.35 Preschool internalizing problems; chr5:151735956 chr5:151753992~151767247:+ CESC cis rs1499614 1 rs2707840 ENSG00000228409.4 CCT6P1 5.52 9.67e-08 0.000102 0.54 0.35 Gout; chr7:66693028 chr7:65751142~65763354:+ CESC cis rs11096990 0.613 rs4974990 ENSG00000249207.1 RP11-360F5.1 -5.52 9.67e-08 0.000102 -0.4 -0.35 Cognitive function; chr4:39191645 chr4:39112677~39126818:- CESC cis rs7048146 0.832 rs10979945 ENSG00000213539.4 YBX1P6 5.52 9.68e-08 0.000102 0.4 0.35 Vascular brain injury; chr9:109582456 chr9:109532830~109534332:- CESC cis rs7048146 0.899 rs7861587 ENSG00000213539.4 YBX1P6 5.52 9.68e-08 0.000102 0.4 0.35 Vascular brain injury; chr9:109584316 chr9:109532830~109534332:- CESC cis rs7048146 0.899 rs884919 ENSG00000213539.4 YBX1P6 5.52 9.68e-08 0.000102 0.4 0.35 Vascular brain injury; chr9:109585693 chr9:109532830~109534332:- CESC cis rs7572733 0.935 rs10177758 ENSG00000222017.1 AC011997.1 5.52 9.69e-08 0.000102 0.38 0.35 Dermatomyositis; chr2:197994193 chr2:197693106~197774823:+ CESC cis rs10129255 0.536 rs6576201 ENSG00000211972.2 IGHV3-66 -5.52 9.71e-08 0.000102 -0.25 -0.35 Kawasaki disease; chr14:106683696 chr14:106675017~106675544:- CESC cis rs3806843 0.868 rs2262574 ENSG00000202111.1 VTRNA1-2 5.52 9.72e-08 0.000102 0.36 0.35 Depressive symptoms (multi-trait analysis); chr5:140744050 chr5:140718925~140719013:+ CESC cis rs1062177 0.855 rs919263 ENSG00000213433.5 RPLP1P6 -5.52 9.72e-08 0.000102 -0.41 -0.35 Preschool internalizing problems; chr5:151886292 chr5:151765859~151766378:- CESC cis rs113835537 0.627 rs11227534 ENSG00000255517.5 CTD-3074O7.5 -5.52 9.76e-08 0.000102 -0.42 -0.35 Airway imaging phenotypes; chr11:66568700 chr11:66473490~66480233:- CESC cis rs11690935 0.921 rs908670 ENSG00000228389.1 AC068039.4 5.51 9.84e-08 0.000103 0.47 0.35 Schizophrenia; chr2:171833670 chr2:171773482~171775844:+ CESC cis rs1823913 0.637 rs10931497 ENSG00000280083.1 RP11-317J9.1 5.51 9.85e-08 0.000103 0.4 0.35 Obesity-related traits; chr2:191306254 chr2:191154118~191156070:- CESC cis rs116095464 0.614 rs62344339 ENSG00000250848.1 CTD-2083E4.5 -5.51 9.87e-08 0.000103 -0.46 -0.35 Breast cancer; chr5:252880 chr5:288833~290321:- CESC cis rs116095464 0.558 rs9687898 ENSG00000250848.1 CTD-2083E4.5 -5.51 9.87e-08 0.000103 -0.46 -0.35 Breast cancer; chr5:253837 chr5:288833~290321:- CESC cis rs116095464 0.558 rs9688045 ENSG00000250848.1 CTD-2083E4.5 -5.51 9.87e-08 0.000103 -0.46 -0.35 Breast cancer; chr5:253920 chr5:288833~290321:- CESC cis rs116095464 0.558 rs112343653 ENSG00000250848.1 CTD-2083E4.5 -5.51 9.87e-08 0.000103 -0.46 -0.35 Breast cancer; chr5:257059 chr5:288833~290321:- CESC cis rs116095464 0.558 rs73024831 ENSG00000250848.1 CTD-2083E4.5 -5.51 9.87e-08 0.000103 -0.46 -0.35 Breast cancer; chr5:257077 chr5:288833~290321:- CESC cis rs116095464 0.558 rs62344345 ENSG00000250848.1 CTD-2083E4.5 -5.51 9.87e-08 0.000103 -0.46 -0.35 Breast cancer; chr5:257305 chr5:288833~290321:- CESC cis rs9549367 0.756 rs2302756 ENSG00000269125.1 RP11-98F14.11 5.51 9.87e-08 0.000103 0.48 0.35 Platelet distribution width; chr13:113245883 chr13:113165002~113165183:- CESC cis rs4423214 0.592 rs7120029 ENSG00000254682.1 RP11-660L16.2 -5.51 9.89e-08 0.000104 -0.51 -0.35 Vitamin D levels; chr11:71487911 chr11:71448674~71452157:+ CESC cis rs34779708 0.897 rs12830 ENSG00000230534.5 RP11-297A16.2 5.51 9.9e-08 0.000104 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35013777 chr10:35098006~35127020:- CESC cis rs9907295 0.818 rs4796115 ENSG00000270977.1 AC015849.16 -5.51 9.9e-08 0.000104 -0.52 -0.35 Fibroblast growth factor basic levels; chr17:35841315 chr17:35893707~35911023:- CESC cis rs17711722 0.523 rs313812 ENSG00000228409.4 CCT6P1 5.51 9.97e-08 0.000104 0.32 0.35 Calcium levels; chr7:66040056 chr7:65751142~65763354:+ CESC cis rs2177312 0.83 rs1357462 ENSG00000251129.1 RP11-734I18.1 -5.51 9.98e-08 0.000104 -0.45 -0.35 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31979347 chr4:31997397~32155406:+ CESC cis rs116095464 0.558 rs7708515 ENSG00000250848.1 CTD-2083E4.5 -5.51 9.99e-08 0.000105 -0.45 -0.35 Breast cancer; chr5:234874 chr5:288833~290321:- CESC cis rs1823913 0.637 rs6722183 ENSG00000280083.1 RP11-317J9.1 5.51 1e-07 0.000105 0.4 0.35 Obesity-related traits; chr2:191333203 chr2:191154118~191156070:- CESC cis rs2842992 0.83 rs2758320 ENSG00000237927.1 RP3-393E18.2 -5.51 1e-07 0.000105 -0.47 -0.35 Age-related macular degeneration (geographic atrophy); chr6:159649644 chr6:159586955~159589169:- CESC cis rs1499614 0.803 rs1796229 ENSG00000228409.4 CCT6P1 5.51 1e-07 0.000105 0.53 0.35 Gout; chr7:66654674 chr7:65751142~65763354:+ CESC cis rs1499614 0.901 rs3936 ENSG00000228409.4 CCT6P1 5.51 1e-07 0.000105 0.53 0.35 Gout; chr7:66661502 chr7:65751142~65763354:+ CESC cis rs9322193 0.566 rs6912330 ENSG00000231760.4 RP11-350J20.5 -5.51 1.01e-07 0.000105 -0.52 -0.35 Lung cancer; chr6:149908811 chr6:149796151~149826294:- CESC cis rs7189233 0.531 rs6499617 ENSG00000279344.1 RP11-44F14.7 5.51 1.01e-07 0.000105 0.33 0.35 Intelligence (multi-trait analysis); chr16:53433810 chr16:53478957~53481550:- CESC cis rs11723261 0.582 rs7679573 ENSG00000211553.1 AC253576.2 -5.51 1.01e-07 0.000105 -0.51 -0.35 Immune response to smallpox vaccine (IL-6); chr4:157810 chr4:136461~136568:+ CESC cis rs7208859 0.778 rs6505219 ENSG00000263531.1 RP13-753N3.1 5.51 1.01e-07 0.000106 0.49 0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30938603 chr17:30863921~30864940:- CESC cis rs9545047 0.604 rs7319212 ENSG00000227676.3 LINC01068 -5.51 1.01e-07 0.000106 -0.4 -0.35 Schizophrenia; chr13:79365404 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7319252 ENSG00000227676.3 LINC01068 -5.51 1.01e-07 0.000106 -0.4 -0.35 Schizophrenia; chr13:79365471 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9318633 ENSG00000227676.3 LINC01068 -5.51 1.01e-07 0.000106 -0.4 -0.35 Schizophrenia; chr13:79369113 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs12872328 ENSG00000227676.3 LINC01068 -5.51 1.01e-07 0.000106 -0.4 -0.35 Schizophrenia; chr13:79370489 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2182010 ENSG00000227676.3 LINC01068 -5.51 1.01e-07 0.000106 -0.4 -0.35 Schizophrenia; chr13:79370618 chr13:79566727~79571436:+ CESC cis rs116095464 0.558 rs7725227 ENSG00000250848.1 CTD-2083E4.5 -5.51 1.02e-07 0.000106 -0.44 -0.35 Breast cancer; chr5:233402 chr5:288833~290321:- CESC cis rs116095464 0.558 rs7708182 ENSG00000250848.1 CTD-2083E4.5 -5.51 1.02e-07 0.000106 -0.44 -0.35 Breast cancer; chr5:234673 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10058428 ENSG00000250848.1 CTD-2083E4.5 -5.51 1.02e-07 0.000106 -0.44 -0.35 Breast cancer; chr5:235493 chr5:288833~290321:- CESC cis rs801193 0.569 rs11772819 ENSG00000237310.1 GS1-124K5.4 5.51 1.02e-07 0.000106 0.33 0.35 Aortic root size; chr7:66752983 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs7800620 ENSG00000237310.1 GS1-124K5.4 5.51 1.02e-07 0.000106 0.33 0.35 Aortic root size; chr7:66758701 chr7:66493706~66495474:+ CESC cis rs801193 0.66 rs974239 ENSG00000222364.1 RNU6-96P -5.51 1.02e-07 0.000107 -0.41 -0.35 Aortic root size; chr7:66748504 chr7:66395191~66395286:+ CESC cis rs5760092 0.618 rs4461358 ENSG00000231271.1 AP000350.8 -5.51 1.02e-07 0.000107 -0.47 -0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23949918~23954042:+ CESC cis rs62229266 0.74 rs4817759 ENSG00000231106.2 LINC01436 5.51 1.03e-07 0.000107 0.48 0.35 Mitral valve prolapse; chr21:36017261 chr21:36005338~36007838:+ CESC cis rs9545047 0.604 rs9545104 ENSG00000227676.3 LINC01068 5.51 1.03e-07 0.000107 0.39 0.35 Schizophrenia; chr13:79404000 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9545106 ENSG00000227676.3 LINC01068 5.51 1.03e-07 0.000107 0.39 0.35 Schizophrenia; chr13:79404130 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2763810 ENSG00000227676.3 LINC01068 5.51 1.03e-07 0.000107 0.39 0.35 Schizophrenia; chr13:79405544 chr13:79566727~79571436:+ CESC cis rs34779708 0.931 rs34304999 ENSG00000230534.5 RP11-297A16.2 5.51 1.03e-07 0.000107 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35076777 chr10:35098006~35127020:- CESC cis rs2404602 0.692 rs1838048 ENSG00000259422.1 RP11-593F23.1 5.51 1.03e-07 0.000107 0.4 0.35 Blood metabolite levels; chr15:76639338 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs56193230 ENSG00000259422.1 RP11-593F23.1 5.51 1.03e-07 0.000107 0.4 0.35 Blood metabolite levels; chr15:76642131 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs35077207 ENSG00000259422.1 RP11-593F23.1 5.51 1.03e-07 0.000107 0.4 0.35 Blood metabolite levels; chr15:76642965 chr15:76174891~76181486:- CESC cis rs2404602 0.735 rs4886800 ENSG00000259422.1 RP11-593F23.1 -5.51 1.03e-07 0.000107 -0.42 -0.35 Blood metabolite levels; chr15:76386351 chr15:76174891~76181486:- CESC cis rs1862618 0.525 rs2662016 ENSG00000271828.1 CTD-2310F14.1 -5.51 1.03e-07 0.000107 -0.48 -0.35 Initial pursuit acceleration; chr5:56973220 chr5:56927874~56929573:+ CESC cis rs2177312 0.83 rs1523141 ENSG00000251129.1 RP11-734I18.1 -5.5 1.04e-07 0.000108 -0.45 -0.35 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31974255 chr4:31997397~32155406:+ CESC cis rs748404 0.69 rs2467737 ENSG00000249839.1 AC011330.5 -5.5 1.04e-07 0.000108 -0.36 -0.35 Lung cancer; chr15:43444990 chr15:43663654~43684339:- CESC cis rs116095464 0.558 rs10080225 ENSG00000250848.1 CTD-2083E4.5 -5.5 1.04e-07 0.000108 -0.45 -0.35 Breast cancer; chr5:232060 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10475136 ENSG00000250848.1 CTD-2083E4.5 -5.5 1.04e-07 0.000108 -0.45 -0.35 Breast cancer; chr5:232681 chr5:288833~290321:- CESC cis rs2882667 0.537 rs7701116 ENSG00000253404.1 AC034243.1 5.5 1.04e-07 0.000108 0.4 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139070389 chr5:138744434~138753309:- CESC cis rs7048146 0.899 rs1330846 ENSG00000213539.4 YBX1P6 -5.5 1.04e-07 0.000108 -0.41 -0.35 Vascular brain injury; chr9:109574668 chr9:109532830~109534332:- CESC cis rs67180937 0.884 rs2291832 ENSG00000272750.1 RP11-378J18.8 -5.5 1.04e-07 0.000109 -0.43 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222653139 chr1:222658867~222661512:- CESC cis rs3096299 0.967 rs2911255 ENSG00000274627.1 RP11-104N10.2 5.5 1.05e-07 0.000109 0.34 0.35 Multiple myeloma (IgH translocation); chr16:89420729 chr16:89516797~89522217:+ CESC cis rs116095464 0.558 rs2288459 ENSG00000250848.1 CTD-2083E4.5 -5.5 1.05e-07 0.000109 -0.45 -0.35 Breast cancer; chr5:231028 chr5:288833~290321:- CESC cis rs116095464 0.558 rs2288458 ENSG00000250848.1 CTD-2083E4.5 -5.5 1.05e-07 0.000109 -0.45 -0.35 Breast cancer; chr5:231145 chr5:288833~290321:- CESC cis rs116095464 0.558 rs2288457 ENSG00000250848.1 CTD-2083E4.5 -5.5 1.05e-07 0.000109 -0.45 -0.35 Breast cancer; chr5:231155 chr5:288833~290321:- CESC cis rs116095464 0.558 rs7736600 ENSG00000250848.1 CTD-2083E4.5 -5.5 1.05e-07 0.000109 -0.45 -0.35 Breast cancer; chr5:231222 chr5:288833~290321:- CESC cis rs11690935 0.879 rs908671 ENSG00000228389.1 AC068039.4 5.5 1.05e-07 0.000109 0.47 0.35 Schizophrenia; chr2:171833755 chr2:171773482~171775844:+ CESC cis rs8072100 0.871 rs7206971 ENSG00000228782.6 CTD-2026D20.3 -5.5 1.05e-07 0.000109 -0.41 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47347749 chr17:47450568~47492492:- CESC cis rs2404602 0.569 rs283793 ENSG00000259422.1 RP11-593F23.1 5.5 1.05e-07 0.000109 0.39 0.35 Blood metabolite levels; chr15:76482411 chr15:76174891~76181486:- CESC cis rs748404 0.56 rs2255663 ENSG00000205771.5 CATSPER2P1 5.5 1.06e-07 0.00011 0.41 0.35 Lung cancer; chr15:43536810 chr15:43726918~43747094:- CESC cis rs9545047 0.567 rs2296287 ENSG00000227676.3 LINC01068 5.5 1.06e-07 0.00011 0.39 0.35 Schizophrenia; chr13:79407045 chr13:79566727~79571436:+ CESC cis rs11676348 0.846 rs4674259 ENSG00000261338.2 RP11-378A13.1 -5.5 1.06e-07 0.00011 -0.42 -0.35 Ulcerative colitis; chr2:218126282 chr2:218255319~218257366:+ CESC cis rs1499614 1 rs1638731 ENSG00000228409.4 CCT6P1 5.5 1.06e-07 0.00011 0.54 0.35 Gout; chr7:66679692 chr7:65751142~65763354:+ CESC cis rs9309711 0.666 rs4321399 ENSG00000225234.1 TRAPPC12-AS1 -5.5 1.06e-07 0.00011 -0.32 -0.35 Neurofibrillary tangles; chr2:3477888 chr2:3481242~3482409:- CESC cis rs150992 0.507 rs377731 ENSG00000248489.1 CTD-2007H13.3 5.5 1.06e-07 0.00011 0.39 0.35 Body mass index; chr5:98996535 chr5:98929171~98995013:+ CESC cis rs10875746 0.768 rs12305182 ENSG00000240399.1 RP1-228P16.1 -5.5 1.06e-07 0.00011 -0.42 -0.35 Longevity (90 years and older); chr12:48027624 chr12:48054813~48055591:- CESC cis rs875971 0.862 rs10282433 ENSG00000222364.1 RNU6-96P 5.5 1.06e-07 0.00011 0.39 0.35 Aortic root size; chr7:66256452 chr7:66395191~66395286:+ CESC cis rs3096299 0.967 rs2911257 ENSG00000274627.1 RP11-104N10.2 5.5 1.06e-07 0.00011 0.34 0.35 Multiple myeloma (IgH translocation); chr16:89417726 chr16:89516797~89522217:+ CESC cis rs6504622 0.755 rs7216950 ENSG00000262879.4 RP11-156P1.3 -5.5 1.06e-07 0.00011 -0.38 -0.35 Orofacial clefts; chr17:47011089 chr17:46984045~47100323:- CESC cis rs9545047 0.567 rs9574420 ENSG00000227676.3 LINC01068 -5.5 1.06e-07 0.00011 -0.4 -0.35 Schizophrenia; chr13:79404342 chr13:79566727~79571436:+ CESC cis rs7048146 0.715 rs34983370 ENSG00000213539.4 YBX1P6 5.5 1.06e-07 0.00011 0.4 0.35 Vascular brain injury; chr9:109586983 chr9:109532830~109534332:- CESC cis rs748404 0.66 rs2602141 ENSG00000249839.1 AC011330.5 -5.5 1.07e-07 0.000111 -0.36 -0.35 Lung cancer; chr15:43432448 chr15:43663654~43684339:- CESC cis rs2243480 1 rs316332 ENSG00000232559.3 GS1-124K5.12 5.5 1.07e-07 0.000111 0.59 0.35 Diabetic kidney disease; chr7:66139312 chr7:66554588~66576923:- CESC cis rs992157 0.698 rs6746089 ENSG00000261338.2 RP11-378A13.1 5.5 1.07e-07 0.000111 0.44 0.35 Colorectal cancer; chr2:218305654 chr2:218255319~218257366:+ CESC cis rs10246939 0.579 rs9640205 ENSG00000228775.6 WEE2-AS1 5.5 1.07e-07 0.000112 0.41 0.35 Bitter taste perception; chr7:141844400 chr7:141704338~141738346:- CESC cis rs2404602 0.692 rs55676827 ENSG00000259422.1 RP11-593F23.1 5.5 1.08e-07 0.000112 0.39 0.35 Blood metabolite levels; chr15:76669375 chr15:76174891~76181486:- CESC cis rs2404602 0.692 rs10444858 ENSG00000259422.1 RP11-593F23.1 5.5 1.08e-07 0.000112 0.39 0.35 Blood metabolite levels; chr15:76670163 chr15:76174891~76181486:- CESC cis rs34779708 0.966 rs4934735 ENSG00000230534.5 RP11-297A16.2 -5.5 1.08e-07 0.000112 -0.46 -0.35 Inflammatory bowel disease;Crohn's disease; chr10:35207802 chr10:35098006~35127020:- CESC cis rs1891275 0.551 rs7908547 ENSG00000228701.1 TNKS2-AS1 -5.5 1.08e-07 0.000112 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91659230 chr10:91782839~91798291:- CESC cis rs7572733 0.84 rs10497807 ENSG00000222017.1 AC011997.1 -5.5 1.08e-07 0.000112 -0.39 -0.35 Dermatomyositis; chr2:197720363 chr2:197693106~197774823:+ CESC cis rs2404602 0.692 rs36070630 ENSG00000259422.1 RP11-593F23.1 5.5 1.08e-07 0.000112 0.4 0.35 Blood metabolite levels; chr15:76656918 chr15:76174891~76181486:- CESC cis rs62229266 0.771 rs11701590 ENSG00000231106.2 LINC01436 5.5 1.08e-07 0.000112 0.48 0.35 Mitral valve prolapse; chr21:36012432 chr21:36005338~36007838:+ CESC cis rs10246939 0.579 rs6969430 ENSG00000228775.6 WEE2-AS1 5.49 1.09e-07 0.000113 0.4 0.35 Bitter taste perception; chr7:141831340 chr7:141704338~141738346:- CESC cis rs2243480 0.901 rs34807232 ENSG00000228409.4 CCT6P1 5.49 1.09e-07 0.000113 0.53 0.35 Diabetic kidney disease; chr7:66500146 chr7:65751142~65763354:+ CESC cis rs10256972 0.967 rs4723338 ENSG00000229043.2 AC091729.9 -5.49 1.09e-07 0.000113 -0.4 -0.35 Endometriosis;Longevity; chr7:996605 chr7:1160374~1165267:+ CESC cis rs67383717 0.643 rs72756397 ENSG00000175611.10 LINC00476 -5.49 1.09e-07 0.000113 -0.39 -0.35 Parkinson's disease (pesticide exposure interaction); chr9:95790861 chr9:95759231~95875977:- CESC cis rs9545047 0.604 rs1927506 ENSG00000227676.3 LINC01068 5.49 1.09e-07 0.000113 0.39 0.35 Schizophrenia; chr13:79311350 chr13:79566727~79571436:+ CESC cis rs2243480 0.901 rs35823062 ENSG00000228409.4 CCT6P1 5.49 1.1e-07 0.000113 0.53 0.35 Diabetic kidney disease; chr7:66500834 chr7:65751142~65763354:+ CESC cis rs5769707 0.632 rs135871 ENSG00000235111.1 RP1-29C18.8 -5.49 1.1e-07 0.000113 -0.4 -0.35 Monocyte percentage of white cells;Monocyte count; chr22:49615321 chr22:49612657~49615716:- CESC cis rs1499614 1 rs1882655 ENSG00000228409.4 CCT6P1 -5.49 1.1e-07 0.000114 -0.54 -0.35 Gout; chr7:66682070 chr7:65751142~65763354:+ CESC cis rs1499614 0.831 rs3800822 ENSG00000228409.4 CCT6P1 -5.49 1.1e-07 0.000114 -0.54 -0.35 Gout; chr7:66682162 chr7:65751142~65763354:+ CESC cis rs2412819 0.571 rs56226333 ENSG00000249839.1 AC011330.5 -5.49 1.1e-07 0.000114 -0.49 -0.35 Lung cancer; chr15:43632410 chr15:43663654~43684339:- CESC cis rs34779708 0.931 rs7099593 ENSG00000230534.5 RP11-297A16.2 5.49 1.1e-07 0.000114 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35077950 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs7084196 ENSG00000230534.5 RP11-297A16.2 5.49 1.1e-07 0.000114 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35078233 chr10:35098006~35127020:- CESC cis rs34779708 0.897 rs4934716 ENSG00000230534.5 RP11-297A16.2 5.49 1.1e-07 0.000114 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35080371 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs13376801 ENSG00000230534.5 RP11-297A16.2 5.49 1.1e-07 0.000114 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35081515 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs7897457 ENSG00000230534.5 RP11-297A16.2 5.49 1.1e-07 0.000114 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35097112 chr10:35098006~35127020:- CESC cis rs4660456 0.83 rs12566786 ENSG00000237899.1 RP4-739H11.3 -5.49 1.1e-07 0.000114 -0.47 -0.35 Platelet count; chr1:40742709 chr1:40669089~40687588:- CESC cis rs11096990 0.613 rs2060805 ENSG00000249207.1 RP11-360F5.1 -5.49 1.1e-07 0.000114 -0.39 -0.35 Cognitive function; chr4:39232788 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs7666632 ENSG00000249207.1 RP11-360F5.1 -5.49 1.1e-07 0.000114 -0.39 -0.35 Cognitive function; chr4:39238568 chr4:39112677~39126818:- CESC cis rs2404602 0.669 rs8036703 ENSG00000259422.1 RP11-593F23.1 5.49 1.1e-07 0.000114 0.4 0.35 Blood metabolite levels; chr15:76658699 chr15:76174891~76181486:- CESC cis rs4853012 1 rs4853012 ENSG00000257800.1 FNBP1P1 5.49 1.1e-07 0.000114 0.42 0.35 Gestational age at birth (maternal effect); chr2:74134163 chr2:74120680~74123218:+ CESC cis rs2177312 0.83 rs1523160 ENSG00000251129.1 RP11-734I18.1 -5.49 1.1e-07 0.000114 -0.45 -0.35 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31966116 chr4:31997397~32155406:+ CESC cis rs748404 0.66 rs518288 ENSG00000249839.1 AC011330.5 -5.49 1.1e-07 0.000114 -0.36 -0.35 Lung cancer; chr15:43471801 chr15:43663654~43684339:- CESC cis rs9907295 0.818 rs2280789 ENSG00000270977.1 AC015849.16 -5.49 1.11e-07 0.000114 -0.48 -0.35 Fibroblast growth factor basic levels; chr17:35879999 chr17:35893707~35911023:- CESC cis rs8062405 0.755 rs62034325 ENSG00000259982.1 CDC37P1 5.49 1.11e-07 0.000115 0.45 0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28527319 chr16:28700294~28701540:- CESC cis rs4660456 0.826 rs3767952 ENSG00000237899.1 RP4-739H11.3 -5.49 1.11e-07 0.000115 -0.47 -0.35 Platelet count; chr1:40765360 chr1:40669089~40687588:- CESC cis rs9545047 0.604 rs3187338 ENSG00000227676.3 LINC01068 5.49 1.11e-07 0.000115 0.39 0.35 Schizophrenia; chr13:79320601 chr13:79566727~79571436:+ CESC cis rs881375 0.678 rs10118357 ENSG00000226752.6 PSMD5-AS1 -5.49 1.11e-07 0.000115 -0.36 -0.35 Rheumatoid arthritis; chr9:120917790 chr9:120824828~120854385:+ CESC cis rs6142102 0.961 rs2284386 ENSG00000276073.1 RP5-1125A11.7 -5.49 1.12e-07 0.000115 -0.33 -0.35 Skin pigmentation; chr20:34056590 chr20:33985617~33988989:- CESC cis rs34779708 0.966 rs12769575 ENSG00000230534.5 RP11-297A16.2 5.49 1.12e-07 0.000115 0.45 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35146999 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs4934536 ENSG00000230534.5 RP11-297A16.2 5.49 1.12e-07 0.000115 0.45 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35152241 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs4934537 ENSG00000230534.5 RP11-297A16.2 5.49 1.12e-07 0.000115 0.45 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35152584 chr10:35098006~35127020:- CESC cis rs67180937 0.885 rs2133187 ENSG00000272750.1 RP11-378J18.8 -5.49 1.12e-07 0.000115 -0.43 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222640383 chr1:222658867~222661512:- CESC cis rs9545047 0.625 rs9545109 ENSG00000227676.3 LINC01068 5.49 1.12e-07 0.000115 0.39 0.35 Schizophrenia; chr13:79413480 chr13:79566727~79571436:+ CESC cis rs9545047 0.518 rs7328494 ENSG00000227676.3 LINC01068 5.49 1.12e-07 0.000115 0.39 0.35 Schizophrenia; chr13:79414673 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2147568 ENSG00000227676.3 LINC01068 5.49 1.12e-07 0.000115 0.39 0.35 Schizophrenia; chr13:79417091 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9530917 ENSG00000227676.3 LINC01068 5.49 1.12e-07 0.000115 0.39 0.35 Schizophrenia; chr13:79417719 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7990321 ENSG00000227676.3 LINC01068 5.49 1.12e-07 0.000115 0.39 0.35 Schizophrenia; chr13:79418066 chr13:79566727~79571436:+ CESC cis rs1707322 0.752 rs4660313 ENSG00000281133.1 AL355480.3 5.49 1.12e-07 0.000116 0.42 0.35 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645169 chr1:45580892~45580996:- CESC cis rs957448 1 rs1055797 ENSG00000253704.1 RP11-267M23.4 5.49 1.12e-07 0.000116 0.39 0.35 Nonsyndromic cleft lip with cleft palate; chr8:94511005 chr8:94553722~94569745:+ CESC cis rs34779708 0.931 rs11010082 ENSG00000230534.5 RP11-297A16.2 5.49 1.12e-07 0.000116 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35062227 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs10508816 ENSG00000230534.5 RP11-297A16.2 5.49 1.12e-07 0.000116 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35171048 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs12762493 ENSG00000230534.5 RP11-297A16.2 5.49 1.12e-07 0.000116 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35182945 chr10:35098006~35127020:- CESC cis rs67180937 0.961 rs17465940 ENSG00000272750.1 RP11-378J18.8 -5.49 1.12e-07 0.000116 -0.44 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222663654 chr1:222658867~222661512:- CESC cis rs1185460 0.967 rs1177562 ENSG00000271751.1 RP11-110I1.14 -5.49 1.12e-07 0.000116 -0.49 -0.35 Coronary artery disease; chr11:119078621 chr11:119065263~119065677:- CESC cis rs992157 0.687 rs10206984 ENSG00000261338.2 RP11-378A13.1 5.49 1.12e-07 0.000116 0.43 0.35 Colorectal cancer; chr2:218202257 chr2:218255319~218257366:+ CESC cis rs992157 0.697 rs13384682 ENSG00000261338.2 RP11-378A13.1 5.49 1.12e-07 0.000116 0.43 0.35 Colorectal cancer; chr2:218204414 chr2:218255319~218257366:+ CESC cis rs992157 0.71 rs7569907 ENSG00000261338.2 RP11-378A13.1 5.49 1.12e-07 0.000116 0.43 0.35 Colorectal cancer; chr2:218205828 chr2:218255319~218257366:+ CESC cis rs10246939 0.579 rs10464444 ENSG00000228775.6 WEE2-AS1 -5.49 1.13e-07 0.000116 -0.4 -0.35 Bitter taste perception; chr7:141832387 chr7:141704338~141738346:- CESC cis rs3931020 0.671 rs1327088 ENSG00000272864.1 RP11-17E13.2 -5.49 1.13e-07 0.000116 -0.36 -0.35 Resistin levels; chr1:74789807 chr1:74698769~74699333:- CESC cis rs4718428 0.576 rs12698546 ENSG00000226824.5 RP4-756H11.3 -5.49 1.13e-07 0.000116 -0.49 -0.35 Corneal structure; chr7:66801919 chr7:66654538~66669855:+ CESC cis rs2842992 0.872 rs2758328 ENSG00000237927.1 RP3-393E18.2 -5.49 1.13e-07 0.000116 -0.46 -0.35 Age-related macular degeneration (geographic atrophy); chr6:159669699 chr6:159586955~159589169:- CESC cis rs9545047 0.604 rs1007569 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79306752 chr13:79566727~79571436:+ CESC cis rs9545047 0.584 rs4885626 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79309765 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs4885627 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79309786 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs4885628 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79309830 chr13:79566727~79571436:+ CESC cis rs9545047 0.554 rs4885629 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79309855 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1409019 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79312431 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7317343 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79312542 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs6563098 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79313102 chr13:79566727~79571436:+ CESC cis rs9545047 0.532 rs1748768 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79313276 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1748767 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79313381 chr13:79566727~79571436:+ CESC cis rs9545047 0.567 rs1409018 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79313403 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1410332 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79315171 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9545065 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79317034 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs3818563 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79318587 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9545068 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79324101 chr13:79566727~79571436:+ CESC cis rs9545047 0.625 rs9318621 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79325662 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7322167 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79325931 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9285309 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79326707 chr13:79566727~79571436:+ CESC cis rs9545047 0.584 rs9545069 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79328065 chr13:79566727~79571436:+ CESC cis rs9545047 0.647 rs7317416 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79328400 chr13:79566727~79571436:+ CESC cis rs9545047 0.588 rs1408658 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79329294 chr13:79566727~79571436:+ CESC cis rs9545047 0.625 rs1408657 ENSG00000227676.3 LINC01068 5.49 1.13e-07 0.000116 0.39 0.35 Schizophrenia; chr13:79329315 chr13:79566727~79571436:+ CESC cis rs7048146 0.899 rs4595205 ENSG00000213539.4 YBX1P6 5.49 1.13e-07 0.000117 0.4 0.35 Vascular brain injury; chr9:109575965 chr9:109532830~109534332:- CESC cis rs7048146 0.899 rs4978836 ENSG00000213539.4 YBX1P6 5.49 1.13e-07 0.000117 0.4 0.35 Vascular brain injury; chr9:109576701 chr9:109532830~109534332:- CESC cis rs2243480 1 rs465359 ENSG00000232559.3 GS1-124K5.12 5.49 1.14e-07 0.000117 0.6 0.35 Diabetic kidney disease; chr7:66093177 chr7:66554588~66576923:- CESC cis rs2243480 1 rs462853 ENSG00000232559.3 GS1-124K5.12 5.49 1.14e-07 0.000117 0.6 0.35 Diabetic kidney disease; chr7:66093180 chr7:66554588~66576923:- CESC cis rs2243480 1 rs160644 ENSG00000232559.3 GS1-124K5.12 5.49 1.14e-07 0.000117 0.6 0.35 Diabetic kidney disease; chr7:66093199 chr7:66554588~66576923:- CESC cis rs2243480 1 rs160642 ENSG00000232559.3 GS1-124K5.12 5.49 1.14e-07 0.000117 0.6 0.35 Diabetic kidney disease; chr7:66093386 chr7:66554588~66576923:- CESC cis rs2243480 0.614 rs34032527 ENSG00000232559.3 GS1-124K5.12 5.49 1.14e-07 0.000117 0.6 0.35 Diabetic kidney disease; chr7:66100154 chr7:66554588~66576923:- CESC cis rs2581828 0.656 rs2564921 ENSG00000242142.1 SERBP1P3 -5.49 1.14e-07 0.000117 -0.39 -0.35 Crohn's disease; chr3:53091569 chr3:53064283~53065091:- CESC cis rs3738443 0.645 rs11811599 ENSG00000259865.1 RP11-488L18.10 5.49 1.14e-07 0.000117 0.32 0.35 Alcohol dependence; chr1:247203133 chr1:247187281~247188526:- CESC cis rs113835537 0.597 rs2075792 ENSG00000255517.5 CTD-3074O7.5 -5.49 1.14e-07 0.000117 -0.42 -0.35 Airway imaging phenotypes; chr11:66567085 chr11:66473490~66480233:- CESC cis rs2729354 0.779 rs2454663 ENSG00000265566.2 RN7SL605P -5.49 1.14e-07 0.000117 -0.53 -0.35 Blood protein levels; chr11:57590610 chr11:57528085~57528365:- CESC cis rs992157 0.735 rs13393821 ENSG00000261338.2 RP11-378A13.1 5.49 1.14e-07 0.000117 0.43 0.35 Colorectal cancer; chr2:218212019 chr2:218255319~218257366:+ CESC cis rs2243480 0.708 rs13242216 ENSG00000228409.4 CCT6P1 5.49 1.14e-07 0.000117 0.53 0.35 Diabetic kidney disease; chr7:66433290 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs67536397 ENSG00000228409.4 CCT6P1 5.49 1.14e-07 0.000117 0.53 0.35 Diabetic kidney disease; chr7:66482930 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs58669269 ENSG00000228409.4 CCT6P1 5.49 1.14e-07 0.000117 0.53 0.35 Diabetic kidney disease; chr7:66486966 chr7:65751142~65763354:+ CESC cis rs2404602 0.692 rs7163397 ENSG00000259422.1 RP11-593F23.1 5.49 1.14e-07 0.000117 0.4 0.35 Blood metabolite levels; chr15:76647974 chr15:76174891~76181486:- CESC cis rs875971 0.522 rs1917563 ENSG00000164669.11 INTS4P1 5.48 1.15e-07 0.000118 0.47 0.35 Aortic root size; chr7:65950660 chr7:65141225~65234216:+ CESC cis rs9545047 0.604 rs1748761 ENSG00000227676.3 LINC01068 5.48 1.15e-07 0.000118 0.39 0.35 Schizophrenia; chr13:79407491 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2763809 ENSG00000227676.3 LINC01068 5.48 1.15e-07 0.000118 0.39 0.35 Schizophrenia; chr13:79407544 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1748762 ENSG00000227676.3 LINC01068 5.48 1.15e-07 0.000118 0.39 0.35 Schizophrenia; chr13:79407914 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1748763 ENSG00000227676.3 LINC01068 5.48 1.15e-07 0.000118 0.39 0.35 Schizophrenia; chr13:79407965 chr13:79566727~79571436:+ CESC cis rs9545047 0.511 rs1624537 ENSG00000227676.3 LINC01068 5.48 1.15e-07 0.000118 0.39 0.35 Schizophrenia; chr13:79411686 chr13:79566727~79571436:+ CESC cis rs1862618 0.525 rs2662021 ENSG00000271828.1 CTD-2310F14.1 -5.48 1.15e-07 0.000118 -0.45 -0.35 Initial pursuit acceleration; chr5:56965864 chr5:56927874~56929573:+ CESC cis rs7048146 1 rs7030085 ENSG00000213539.4 YBX1P6 5.48 1.15e-07 0.000118 0.41 0.35 Vascular brain injury; chr9:109539735 chr9:109532830~109534332:- CESC cis rs7048146 0.966 rs7046719 ENSG00000213539.4 YBX1P6 5.48 1.15e-07 0.000118 0.41 0.35 Vascular brain injury; chr9:109540085 chr9:109532830~109534332:- CESC cis rs79349575 0.756 rs3848460 ENSG00000270781.1 RP11-501C14.9 5.48 1.15e-07 0.000118 0.38 0.35 Type 2 diabetes; chr17:48969752 chr17:48899131~48899748:+ CESC cis rs1075265 0.68 rs6715488 ENSG00000233266.1 HMGB1P31 5.48 1.16e-07 0.000119 0.45 0.35 Chronotype;Morning vs. evening chronotype; chr2:54004130 chr2:54051334~54051760:+ CESC cis rs1075265 0.73 rs7597188 ENSG00000233266.1 HMGB1P31 5.48 1.16e-07 0.000119 0.45 0.35 Chronotype;Morning vs. evening chronotype; chr2:54014732 chr2:54051334~54051760:+ CESC cis rs11846409 0.86 rs1858692 ENSG00000211974.3 IGHV2-70 5.48 1.16e-07 0.000119 0.5 0.35 Rheumatic heart disease; chr14:106622776 chr14:106723574~106724093:- CESC cis rs116095464 0.614 rs28736753 ENSG00000250848.1 CTD-2083E4.5 -5.48 1.16e-07 0.000119 -0.46 -0.35 Breast cancer; chr5:273966 chr5:288833~290321:- CESC cis rs11096990 0.634 rs17431358 ENSG00000249207.1 RP11-360F5.1 5.48 1.16e-07 0.000119 0.38 0.35 Cognitive function; chr4:39275676 chr4:39112677~39126818:- CESC cis rs2842992 0.872 rs9456440 ENSG00000237927.1 RP3-393E18.2 -5.48 1.16e-07 0.000119 -0.46 -0.35 Age-related macular degeneration (geographic atrophy); chr6:159653431 chr6:159586955~159589169:- CESC cis rs4660456 0.871 rs2274957 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40747290 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs4660173 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40747876 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs4660452 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40748519 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs12567925 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40751428 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs12728776 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40751718 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs12567755 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40751813 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs16827532 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40755064 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs12729696 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40755099 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs16827552 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40758336 chr1:40669089~40687588:- CESC cis rs4660456 0.871 rs7549789 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40759362 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs16827569 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40761655 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs2361650 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40764678 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs954654 ENSG00000237899.1 RP4-739H11.3 -5.48 1.17e-07 0.00012 -0.47 -0.35 Platelet count; chr1:40764979 chr1:40669089~40687588:- CESC cis rs72627509 0.904 rs58408429 ENSG00000269949.1 RP11-738E22.3 5.48 1.17e-07 0.00012 0.53 0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56903658 chr4:56960927~56961373:- CESC cis rs1499614 1 rs2659913 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66692349 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs2659911 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66693433 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs2707838 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66694214 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs60326618 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66701371 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs2707830 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66702658 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs2707828 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66706390 chr7:65751142~65763354:+ CESC cis rs1499614 0.803 rs1922723 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66710076 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs2659903 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66715944 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs2141924 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66721259 chr7:65751142~65763354:+ CESC cis rs1499614 0.901 rs2178742 ENSG00000228409.4 CCT6P1 5.48 1.17e-07 0.00012 0.53 0.35 Gout; chr7:66732812 chr7:65751142~65763354:+ CESC cis rs9545047 0.604 rs1752649 ENSG00000227676.3 LINC01068 5.48 1.17e-07 0.00012 0.39 0.35 Schizophrenia; chr13:79331980 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1749983 ENSG00000227676.3 LINC01068 5.48 1.17e-07 0.00012 0.39 0.35 Schizophrenia; chr13:79332077 chr13:79566727~79571436:+ CESC cis rs9545047 0.567 rs1752648 ENSG00000227676.3 LINC01068 5.48 1.17e-07 0.00012 0.39 0.35 Schizophrenia; chr13:79332124 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1752647 ENSG00000227676.3 LINC01068 5.48 1.17e-07 0.00012 0.39 0.35 Schizophrenia; chr13:79332741 chr13:79566727~79571436:+ CESC cis rs9545047 0.532 rs1752646 ENSG00000227676.3 LINC01068 5.48 1.17e-07 0.00012 0.39 0.35 Schizophrenia; chr13:79332752 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1749988 ENSG00000227676.3 LINC01068 5.48 1.17e-07 0.00012 0.39 0.35 Schizophrenia; chr13:79333103 chr13:79566727~79571436:+ CESC cis rs9545047 0.588 rs9530894 ENSG00000227676.3 LINC01068 5.48 1.17e-07 0.00012 0.39 0.35 Schizophrenia; chr13:79334020 chr13:79566727~79571436:+ CESC cis rs67180937 0.849 rs4575092 ENSG00000272750.1 RP11-378J18.8 -5.48 1.17e-07 0.00012 -0.44 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222661161 chr1:222658867~222661512:- CESC cis rs2243480 0.908 rs313822 ENSG00000232559.3 GS1-124K5.12 5.48 1.17e-07 0.00012 0.6 0.35 Diabetic kidney disease; chr7:66108952 chr7:66554588~66576923:- CESC cis rs9481169 0.85 rs13210247 ENSG00000255389.1 C6orf3 -5.48 1.18e-07 0.00012 -0.56 -0.35 Inflammatory skin disease; chr6:111601517 chr6:111599875~111602295:+ CESC cis rs34779708 0.931 rs2384283 ENSG00000230534.5 RP11-297A16.2 5.48 1.18e-07 0.00012 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35037861 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs66887762 ENSG00000230534.5 RP11-297A16.2 5.48 1.18e-07 0.00012 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35041649 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs59418206 ENSG00000230534.5 RP11-297A16.2 5.48 1.18e-07 0.00012 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35042696 chr10:35098006~35127020:- CESC cis rs9309711 0.56 rs6548164 ENSG00000225234.1 TRAPPC12-AS1 5.48 1.18e-07 0.000121 0.32 0.35 Neurofibrillary tangles; chr2:3468894 chr2:3481242~3482409:- CESC cis rs4660456 0.913 rs3767951 ENSG00000237899.1 RP4-739H11.3 -5.48 1.18e-07 0.000121 -0.48 -0.35 Platelet count; chr1:40767359 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs3767950 ENSG00000237899.1 RP4-739H11.3 -5.48 1.18e-07 0.000121 -0.48 -0.35 Platelet count; chr1:40767541 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs3754179 ENSG00000237899.1 RP4-739H11.3 -5.48 1.18e-07 0.000121 -0.48 -0.35 Platelet count; chr1:40768464 chr1:40669089~40687588:- CESC cis rs2739330 0.587 rs4820571 ENSG00000231271.1 AP000350.8 5.48 1.19e-07 0.000121 0.43 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23949918~23954042:+ CESC cis rs10262624 0.935 rs4722283 ENSG00000234286.1 AC006026.13 5.48 1.19e-07 0.000121 0.37 0.35 Schizophrenia; chr7:23866595 chr7:23680195~23680786:- CESC cis rs875971 0.862 rs1968126 ENSG00000226824.5 RP4-756H11.3 5.48 1.19e-07 0.000122 0.43 0.35 Aortic root size; chr7:66592017 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs6460306 ENSG00000226824.5 RP4-756H11.3 5.48 1.19e-07 0.000122 0.43 0.35 Aortic root size; chr7:66595806 chr7:66654538~66669855:+ CESC cis rs881375 0.654 rs10760126 ENSG00000226752.6 PSMD5-AS1 -5.48 1.19e-07 0.000122 -0.36 -0.35 Rheumatoid arthritis; chr9:120900340 chr9:120824828~120854385:+ CESC cis rs881375 0.678 rs7031752 ENSG00000226752.6 PSMD5-AS1 -5.48 1.19e-07 0.000122 -0.36 -0.35 Rheumatoid arthritis; chr9:120901204 chr9:120824828~120854385:+ CESC cis rs881375 0.678 rs4836834 ENSG00000226752.6 PSMD5-AS1 -5.48 1.19e-07 0.000122 -0.36 -0.35 Rheumatoid arthritis; chr9:120903623 chr9:120824828~120854385:+ CESC cis rs9322193 0.962 rs6903998 ENSG00000216906.2 RP11-350J20.9 5.48 1.19e-07 0.000122 0.38 0.35 Lung cancer; chr6:149831357 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs1984111 ENSG00000216906.2 RP11-350J20.9 5.48 1.19e-07 0.000122 0.38 0.35 Lung cancer; chr6:149831720 chr6:149904243~149906418:+ CESC cis rs9907295 0.818 rs4796123 ENSG00000270977.1 AC015849.16 -5.48 1.19e-07 0.000122 -0.51 -0.35 Fibroblast growth factor basic levels; chr17:35884456 chr17:35893707~35911023:- CESC cis rs5758659 1 rs5758660 ENSG00000273366.1 CTA-989H11.1 -5.48 1.19e-07 0.000122 -0.43 -0.35 Cognitive function; chr22:42227712 chr22:42278188~42278846:+ CESC cis rs34779708 0.931 rs11010083 ENSG00000230534.5 RP11-297A16.2 5.48 1.19e-07 0.000122 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35062603 chr10:35098006~35127020:- CESC cis rs875971 0.651 rs313829 ENSG00000222364.1 RNU6-96P 5.48 1.19e-07 0.000122 0.43 0.35 Aortic root size; chr7:66087510 chr7:66395191~66395286:+ CESC cis rs881375 0.678 rs10760128 ENSG00000226752.6 PSMD5-AS1 -5.48 1.19e-07 0.000122 -0.37 -0.35 Rheumatoid arthritis; chr9:120934047 chr9:120824828~120854385:+ CESC cis rs765787 0.53 rs1706834 ENSG00000259520.4 CTD-2651B20.3 5.47 1.2e-07 0.000122 0.43 0.35 Uric acid levels; chr15:45225656 chr15:45251580~45279251:- CESC cis rs2243480 1 rs778729 ENSG00000228409.4 CCT6P1 5.47 1.2e-07 0.000122 0.52 0.35 Diabetic kidney disease; chr7:66359432 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs778687 ENSG00000228409.4 CCT6P1 5.47 1.2e-07 0.000122 0.52 0.35 Diabetic kidney disease; chr7:66370832 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs778679 ENSG00000228409.4 CCT6P1 5.47 1.2e-07 0.000122 0.52 0.35 Diabetic kidney disease; chr7:66375924 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs778704 ENSG00000228409.4 CCT6P1 5.47 1.2e-07 0.000122 0.52 0.35 Diabetic kidney disease; chr7:66398480 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs778693 ENSG00000228409.4 CCT6P1 5.47 1.2e-07 0.000122 0.52 0.35 Diabetic kidney disease; chr7:66407358 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs778691 ENSG00000228409.4 CCT6P1 5.47 1.2e-07 0.000122 0.52 0.35 Diabetic kidney disease; chr7:66408105 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs13235972 ENSG00000228409.4 CCT6P1 5.47 1.2e-07 0.000122 0.52 0.35 Diabetic kidney disease; chr7:66418618 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34192067 ENSG00000228409.4 CCT6P1 5.47 1.2e-07 0.000122 0.52 0.35 Diabetic kidney disease; chr7:66422670 chr7:65751142~65763354:+ CESC cis rs7714584 1 rs76433514 ENSG00000197083.10 ZNF300P1 5.47 1.2e-07 0.000123 0.72 0.35 Crohn's disease; chr5:150926970 chr5:150930645~150946289:- CESC cis rs2337406 1 rs10459466 ENSG00000211974.3 IGHV2-70 -5.47 1.2e-07 0.000123 -0.52 -0.35 Alzheimer's disease (late onset); chr14:106689255 chr14:106723574~106724093:- CESC cis rs11846409 0.872 rs74091715 ENSG00000211974.3 IGHV2-70 -5.47 1.21e-07 0.000123 -0.48 -0.35 Rheumatic heart disease; chr14:106637731 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs74091721 ENSG00000211974.3 IGHV2-70 -5.47 1.21e-07 0.000123 -0.48 -0.35 Rheumatic heart disease; chr14:106638262 chr14:106723574~106724093:- CESC cis rs9545047 0.588 rs9530913 ENSG00000227676.3 LINC01068 5.47 1.21e-07 0.000123 0.39 0.35 Schizophrenia; chr13:79384539 chr13:79566727~79571436:+ CESC cis rs831571 0.915 rs6797912 ENSG00000280620.1 SCAANT1 -5.47 1.21e-07 0.000123 -0.59 -0.35 Type 2 diabetes; chr3:64072564 chr3:63911518~63911772:- CESC cis rs6782228 0.628 rs7641584 ENSG00000242551.2 POU5F1P6 -5.47 1.21e-07 0.000123 -0.39 -0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128673787 chr3:128674735~128677005:- CESC cis rs34375054 0.738 rs10773145 ENSG00000279233.1 RP11-158L12.4 -5.47 1.21e-07 0.000123 -0.34 -0.35 Post bronchodilator FEV1/FVC ratio; chr12:125141057 chr12:125138245~125141711:+ CESC cis rs2739330 0.828 rs2186366 ENSG00000272787.1 KB-226F1.2 5.47 1.21e-07 0.000123 0.37 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23969211~23969873:+ CESC cis rs801193 0.66 rs4610622 ENSG00000222364.1 RNU6-96P -5.47 1.21e-07 0.000123 -0.41 -0.35 Aortic root size; chr7:66759510 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6460302 ENSG00000222364.1 RNU6-96P -5.47 1.21e-07 0.000123 -0.41 -0.35 Aortic root size; chr7:66495270 chr7:66395191~66395286:+ CESC cis rs9545047 0.604 rs9530891 ENSG00000227676.3 LINC01068 5.47 1.21e-07 0.000123 0.38 0.35 Schizophrenia; chr13:79284750 chr13:79566727~79571436:+ CESC cis rs35955747 0.934 rs4820045 ENSG00000236132.1 CTA-440B3.1 5.47 1.21e-07 0.000124 0.41 0.35 Neutrophil count;Sum basophil neutrophil counts; chr22:31389983 chr22:31816379~31817491:- CESC cis rs875971 0.825 rs4587224 ENSG00000222364.1 RNU6-96P 5.47 1.21e-07 0.000124 0.39 0.35 Aortic root size; chr7:66271195 chr7:66395191~66395286:+ CESC cis rs875971 0.792 rs6971752 ENSG00000222364.1 RNU6-96P 5.47 1.21e-07 0.000124 0.39 0.35 Aortic root size; chr7:66272999 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs10950033 ENSG00000222364.1 RNU6-96P 5.47 1.21e-07 0.000124 0.39 0.35 Aortic root size; chr7:66274686 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs11760844 ENSG00000222364.1 RNU6-96P 5.47 1.21e-07 0.000124 0.39 0.35 Aortic root size; chr7:66274896 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs949930 ENSG00000222364.1 RNU6-96P 5.47 1.21e-07 0.000124 0.39 0.35 Aortic root size; chr7:66301835 chr7:66395191~66395286:+ CESC cis rs67180937 0.921 rs17163360 ENSG00000272750.1 RP11-378J18.8 -5.47 1.22e-07 0.000124 -0.43 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647448 chr1:222658867~222661512:- CESC cis rs9907295 1 rs9901195 ENSG00000270977.1 AC015849.16 -5.47 1.22e-07 0.000125 -0.49 -0.35 Fibroblast growth factor basic levels; chr17:35915576 chr17:35893707~35911023:- CESC cis rs9907295 0.786 rs9901418 ENSG00000270977.1 AC015849.16 -5.47 1.22e-07 0.000125 -0.49 -0.35 Fibroblast growth factor basic levels; chr17:35915699 chr17:35893707~35911023:- CESC cis rs875971 0.862 rs10274883 ENSG00000237310.1 GS1-124K5.4 -5.47 1.22e-07 0.000125 -0.33 -0.35 Aortic root size; chr7:66651104 chr7:66493706~66495474:+ CESC cis rs801193 0.548 rs2109297 ENSG00000237310.1 GS1-124K5.4 -5.47 1.22e-07 0.000125 -0.33 -0.35 Aortic root size; chr7:66657397 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs6978178 ENSG00000237310.1 GS1-124K5.4 -5.47 1.22e-07 0.000125 -0.33 -0.35 Aortic root size; chr7:66658097 chr7:66493706~66495474:+ CESC cis rs801193 0.591 rs721717 ENSG00000237310.1 GS1-124K5.4 -5.47 1.22e-07 0.000125 -0.33 -0.35 Aortic root size; chr7:66665305 chr7:66493706~66495474:+ CESC cis rs8072100 0.967 rs7221548 ENSG00000228782.6 CTD-2026D20.3 -5.47 1.22e-07 0.000125 -0.4 -0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47505586 chr17:47450568~47492492:- CESC cis rs1823913 0.599 rs1823912 ENSG00000280083.1 RP11-317J9.1 -5.47 1.22e-07 0.000125 -0.4 -0.35 Obesity-related traits; chr2:191266388 chr2:191154118~191156070:- CESC cis rs131777 0.708 rs131749 ENSG00000205559.3 CHKB-AS1 5.47 1.23e-07 0.000125 0.42 0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586195 chr22:50583026~50583877:+ CESC cis rs1891275 0.551 rs7900863 ENSG00000228701.1 TNKS2-AS1 -5.47 1.23e-07 0.000125 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91665737 chr10:91782839~91798291:- CESC cis rs1891275 0.588 rs6583782 ENSG00000228701.1 TNKS2-AS1 -5.47 1.23e-07 0.000125 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91666022 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs1891271 ENSG00000228701.1 TNKS2-AS1 -5.47 1.23e-07 0.000125 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91666566 chr10:91782839~91798291:- CESC cis rs1972460 0.506 rs62012050 ENSG00000255769.6 GOLGA2P10 -5.47 1.23e-07 0.000125 -0.44 -0.35 Intelligence (multi-trait analysis); chr15:82239933 chr15:82472993~82513950:- CESC cis rs2739330 0.627 rs9608219 ENSG00000099984.9 GSTT2 -5.47 1.23e-07 0.000125 -0.42 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23980123~23983911:+ CESC cis rs6951245 0.554 rs10246354 ENSG00000229043.2 AC091729.9 -5.47 1.23e-07 0.000125 -0.46 -0.35 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1092820 chr7:1160374~1165267:+ CESC cis rs875971 0.522 rs9530 ENSG00000164669.11 INTS4P1 -5.47 1.23e-07 0.000125 -0.49 -0.35 Aortic root size; chr7:65960907 chr7:65141225~65234216:+ CESC cis rs9545047 0.604 rs4885625 ENSG00000227676.3 LINC01068 5.47 1.24e-07 0.000126 0.38 0.35 Schizophrenia; chr13:79290355 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1324873 ENSG00000227676.3 LINC01068 5.47 1.24e-07 0.000126 0.38 0.35 Schizophrenia; chr13:79292246 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs4573813 ENSG00000227676.3 LINC01068 5.47 1.24e-07 0.000126 0.38 0.35 Schizophrenia; chr13:79293357 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9545052 ENSG00000227676.3 LINC01068 5.47 1.24e-07 0.000126 0.38 0.35 Schizophrenia; chr13:79294875 chr13:79566727~79571436:+ CESC cis rs11096990 0.634 rs2381371 ENSG00000249207.1 RP11-360F5.1 -5.47 1.24e-07 0.000126 -0.38 -0.35 Cognitive function; chr4:39271414 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs2381372 ENSG00000249207.1 RP11-360F5.1 -5.47 1.24e-07 0.000126 -0.38 -0.35 Cognitive function; chr4:39271471 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs12651217 ENSG00000249207.1 RP11-360F5.1 -5.47 1.24e-07 0.000126 -0.38 -0.35 Cognitive function; chr4:39271964 chr4:39112677~39126818:- CESC cis rs72627509 0.904 rs56281640 ENSG00000269949.1 RP11-738E22.3 5.47 1.24e-07 0.000126 0.52 0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56899650 chr4:56960927~56961373:- CESC cis rs1062177 0.694 rs2915816 ENSG00000253921.1 CTB-113P19.3 5.47 1.24e-07 0.000126 0.45 0.35 Preschool internalizing problems; chr5:151736296 chr5:151753992~151767247:+ CESC cis rs2929278 0.617 rs533143 ENSG00000249839.1 AC011330.5 -5.47 1.24e-07 0.000126 -0.35 -0.35 Schizophrenia; chr15:43896656 chr15:43663654~43684339:- CESC cis rs2243480 1 rs2707844 ENSG00000275400.1 RP4-756H11.5 5.47 1.24e-07 0.000126 0.6 0.35 Diabetic kidney disease; chr7:66594522 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1796220 ENSG00000275400.1 RP4-756H11.5 5.47 1.24e-07 0.000126 0.6 0.35 Diabetic kidney disease; chr7:66597113 chr7:66553805~66554199:- CESC cis rs2243480 1 rs2707831 ENSG00000275400.1 RP4-756H11.5 5.47 1.24e-07 0.000126 0.6 0.35 Diabetic kidney disease; chr7:66597524 chr7:66553805~66554199:- CESC cis rs9545047 0.604 rs35476664 ENSG00000227676.3 LINC01068 -5.47 1.24e-07 0.000126 -0.4 -0.35 Schizophrenia; chr13:79375462 chr13:79566727~79571436:+ CESC cis rs9402743 0.816 rs9402737 ENSG00000217482.2 HMGB1P17 5.47 1.25e-07 0.000127 0.4 0.35 Systemic lupus erythematosus; chr6:135651778 chr6:135636086~135636713:- CESC cis rs875971 0.862 rs6460302 ENSG00000237310.1 GS1-124K5.4 5.47 1.25e-07 0.000127 0.33 0.35 Aortic root size; chr7:66495270 chr7:66493706~66495474:+ CESC cis rs801193 0.66 rs1016265 ENSG00000222364.1 RNU6-96P -5.47 1.25e-07 0.000127 -0.41 -0.35 Aortic root size; chr7:66749580 chr7:66395191~66395286:+ CESC cis rs5758659 1 rs5758659 ENSG00000273366.1 CTA-989H11.1 -5.47 1.25e-07 0.000127 -0.42 -0.35 Cognitive function; chr22:42225997 chr22:42278188~42278846:+ CESC cis rs9545047 0.604 rs9545048 ENSG00000227676.3 LINC01068 5.47 1.25e-07 0.000127 0.38 0.35 Schizophrenia; chr13:79285593 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs1626333 ENSG00000227676.3 LINC01068 5.47 1.25e-07 0.000127 0.38 0.35 Schizophrenia; chr13:79286932 chr13:79566727~79571436:+ CESC cis rs9545047 0.567 rs1856996 ENSG00000227676.3 LINC01068 5.47 1.25e-07 0.000127 0.38 0.35 Schizophrenia; chr13:79287453 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2147566 ENSG00000227676.3 LINC01068 5.47 1.25e-07 0.000127 0.38 0.35 Schizophrenia; chr13:79296580 chr13:79566727~79571436:+ CESC cis rs2882667 0.652 rs6596463 ENSG00000253404.1 AC034243.1 5.47 1.25e-07 0.000127 0.42 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139109237 chr5:138744434~138753309:- CESC cis rs801193 0.569 rs13242290 ENSG00000237310.1 GS1-124K5.4 -5.47 1.26e-07 0.000127 -0.33 -0.35 Aortic root size; chr7:66656898 chr7:66493706~66495474:+ CESC cis rs7048146 0.899 rs13284486 ENSG00000213539.4 YBX1P6 5.47 1.26e-07 0.000127 0.4 0.35 Vascular brain injury; chr9:109586658 chr9:109532830~109534332:- CESC cis rs79349575 0.594 rs1985785 ENSG00000270781.1 RP11-501C14.9 -5.47 1.26e-07 0.000128 -0.39 -0.35 Type 2 diabetes; chr17:48890426 chr17:48899131~48899748:+ CESC cis rs79349575 0.685 rs1124829 ENSG00000270781.1 RP11-501C14.9 -5.47 1.26e-07 0.000128 -0.39 -0.35 Type 2 diabetes; chr17:48890435 chr17:48899131~48899748:+ CESC cis rs34779708 0.931 rs2384289 ENSG00000230534.5 RP11-297A16.2 5.46 1.26e-07 0.000128 0.47 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35054597 chr10:35098006~35127020:- CESC cis rs1062177 1 rs12518722 ENSG00000253921.1 CTB-113P19.3 -5.46 1.27e-07 0.000128 -0.47 -0.35 Preschool internalizing problems; chr5:151851899 chr5:151753992~151767247:+ CESC cis rs7572733 0.935 rs10192466 ENSG00000222017.1 AC011997.1 5.46 1.27e-07 0.000128 0.38 0.35 Dermatomyositis; chr2:197873295 chr2:197693106~197774823:+ CESC cis rs2739330 0.892 rs5751776 ENSG00000272787.1 KB-226F1.2 -5.46 1.27e-07 0.000128 -0.37 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23969211~23969873:+ CESC cis rs10256972 0.869 rs13236369 ENSG00000229043.2 AC091729.9 -5.46 1.27e-07 0.000129 -0.4 -0.35 Endometriosis;Longevity; chr7:994163 chr7:1160374~1165267:+ CESC cis rs9549367 0.712 rs2316443 ENSG00000269125.1 RP11-98F14.11 -5.46 1.27e-07 0.000129 -0.46 -0.35 Platelet distribution width; chr13:113210523 chr13:113165002~113165183:- CESC cis rs7684253 0.548 rs922570 ENSG00000269949.1 RP11-738E22.3 -5.46 1.27e-07 0.000129 -0.41 -0.35 Migraine; chr4:56851192 chr4:56960927~56961373:- CESC cis rs5758659 0.967 rs5751250 ENSG00000273366.1 CTA-989H11.1 -5.46 1.27e-07 0.000129 -0.42 -0.35 Cognitive function; chr22:42243639 chr22:42278188~42278846:+ CESC cis rs73086581 1 rs17214949 ENSG00000229539.1 RP11-119B16.2 5.46 1.28e-07 0.000129 0.59 0.35 Response to antidepressants in depression; chr20:3960305 chr20:3888239~3888868:- CESC cis rs73086581 1 rs17215054 ENSG00000229539.1 RP11-119B16.2 5.46 1.28e-07 0.000129 0.59 0.35 Response to antidepressants in depression; chr20:3964132 chr20:3888239~3888868:- CESC cis rs73086581 1 rs17287486 ENSG00000229539.1 RP11-119B16.2 5.46 1.28e-07 0.000129 0.59 0.35 Response to antidepressants in depression; chr20:3965620 chr20:3888239~3888868:- CESC cis rs73086581 1 rs73086540 ENSG00000229539.1 RP11-119B16.2 5.46 1.28e-07 0.000129 0.59 0.35 Response to antidepressants in depression; chr20:3970203 chr20:3888239~3888868:- CESC cis rs73086581 1 rs73086544 ENSG00000229539.1 RP11-119B16.2 5.46 1.28e-07 0.000129 0.59 0.35 Response to antidepressants in depression; chr20:3970281 chr20:3888239~3888868:- CESC cis rs73086581 1 rs2326289 ENSG00000229539.1 RP11-119B16.2 5.46 1.28e-07 0.000129 0.59 0.35 Response to antidepressants in depression; chr20:3971653 chr20:3888239~3888868:- CESC cis rs9322193 0.923 rs10872651 ENSG00000268592.3 RAET1E-AS1 5.46 1.28e-07 0.000129 0.46 0.35 Lung cancer; chr6:149768273 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs3805749 ENSG00000268592.3 RAET1E-AS1 5.46 1.28e-07 0.000129 0.46 0.35 Lung cancer; chr6:149772546 chr6:149863494~149919507:+ CESC cis rs9322193 0.847 rs9505972 ENSG00000268592.3 RAET1E-AS1 5.46 1.28e-07 0.000129 0.46 0.35 Lung cancer; chr6:149775255 chr6:149863494~149919507:+ CESC cis rs957448 0.904 rs56302978 ENSG00000253704.1 RP11-267M23.4 5.46 1.28e-07 0.00013 0.39 0.35 Nonsyndromic cleft lip with cleft palate; chr8:94505883 chr8:94553722~94569745:+ CESC cis rs1075265 0.547 rs6741891 ENSG00000233266.1 HMGB1P31 5.46 1.29e-07 0.00013 0.49 0.35 Chronotype;Morning vs. evening chronotype; chr2:54088529 chr2:54051334~54051760:+ CESC cis rs9549367 0.713 rs3024746 ENSG00000269125.1 RP11-98F14.11 -5.46 1.29e-07 0.00013 -0.47 -0.35 Platelet distribution width; chr13:113167463 chr13:113165002~113165183:- CESC cis rs9549367 0.713 rs3024747 ENSG00000269125.1 RP11-98F14.11 -5.46 1.29e-07 0.00013 -0.47 -0.35 Platelet distribution width; chr13:113167473 chr13:113165002~113165183:- CESC cis rs2739330 0.828 rs2330635 ENSG00000272787.1 KB-226F1.2 -5.46 1.29e-07 0.00013 -0.38 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23969211~23969873:+ CESC cis rs801193 0.569 rs881285 ENSG00000237310.1 GS1-124K5.4 -5.46 1.29e-07 0.000131 -0.33 -0.35 Aortic root size; chr7:66654433 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs3846973 ENSG00000237310.1 GS1-124K5.4 -5.46 1.29e-07 0.000131 -0.33 -0.35 Aortic root size; chr7:66655048 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs2013908 ENSG00000237310.1 GS1-124K5.4 -5.46 1.29e-07 0.000131 -0.33 -0.35 Aortic root size; chr7:66656082 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs6951302 ENSG00000237310.1 GS1-124K5.4 -5.46 1.29e-07 0.000131 -0.33 -0.35 Aortic root size; chr7:66667525 chr7:66493706~66495474:+ CESC cis rs2729354 0.909 rs2729374 ENSG00000265566.2 RN7SL605P -5.46 1.3e-07 0.000131 -0.52 -0.35 Blood protein levels; chr11:57559454 chr11:57528085~57528365:- CESC cis rs7684253 0.548 rs13108002 ENSG00000269949.1 RP11-738E22.3 -5.46 1.3e-07 0.000131 -0.41 -0.35 Migraine; chr4:56852087 chr4:56960927~56961373:- CESC cis rs801193 0.569 rs4717315 ENSG00000232559.3 GS1-124K5.12 5.46 1.3e-07 0.000131 0.38 0.35 Aortic root size; chr7:66713338 chr7:66554588~66576923:- CESC cis rs801193 0.548 rs2659891 ENSG00000232559.3 GS1-124K5.12 5.46 1.3e-07 0.000131 0.38 0.35 Aortic root size; chr7:66736127 chr7:66554588~66576923:- CESC cis rs801193 0.548 rs7805152 ENSG00000232559.3 GS1-124K5.12 5.46 1.3e-07 0.000131 0.38 0.35 Aortic root size; chr7:66744266 chr7:66554588~66576923:- CESC cis rs748404 0.66 rs493377 ENSG00000249839.1 AC011330.5 -5.46 1.3e-07 0.000132 -0.36 -0.35 Lung cancer; chr15:43481269 chr15:43663654~43684339:- CESC cis rs6504622 0.755 rs12942936 ENSG00000262879.4 RP11-156P1.3 -5.46 1.3e-07 0.000132 -0.38 -0.35 Orofacial clefts; chr17:47075062 chr17:46984045~47100323:- CESC cis rs875971 0.522 rs781144 ENSG00000164669.11 INTS4P1 -5.46 1.31e-07 0.000132 -0.49 -0.35 Aortic root size; chr7:65975357 chr7:65141225~65234216:+ CESC cis rs2243480 0.708 rs13242216 ENSG00000232559.3 GS1-124K5.12 5.46 1.31e-07 0.000132 0.6 0.35 Diabetic kidney disease; chr7:66433290 chr7:66554588~66576923:- CESC cis rs2243480 1 rs67536397 ENSG00000232559.3 GS1-124K5.12 5.46 1.31e-07 0.000132 0.6 0.35 Diabetic kidney disease; chr7:66482930 chr7:66554588~66576923:- CESC cis rs2243480 1 rs58669269 ENSG00000232559.3 GS1-124K5.12 5.46 1.31e-07 0.000132 0.6 0.35 Diabetic kidney disease; chr7:66486966 chr7:66554588~66576923:- CESC cis rs2108622 0.958 rs79400241 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.48 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15873592 chr19:15851993~15864904:- CESC cis rs9322193 0.923 rs9688350 ENSG00000268592.3 RAET1E-AS1 5.46 1.31e-07 0.000132 0.46 0.35 Lung cancer; chr6:149730977 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9767652 ENSG00000268592.3 RAET1E-AS1 5.46 1.31e-07 0.000132 0.46 0.35 Lung cancer; chr6:149734502 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs10782314 ENSG00000268592.3 RAET1E-AS1 5.46 1.31e-07 0.000132 0.46 0.35 Lung cancer; chr6:149735527 chr6:149863494~149919507:+ CESC cis rs875971 0.862 rs10274883 ENSG00000232559.3 GS1-124K5.12 -5.46 1.31e-07 0.000132 -0.38 -0.35 Aortic root size; chr7:66651104 chr7:66554588~66576923:- CESC cis rs801193 0.548 rs2109297 ENSG00000232559.3 GS1-124K5.12 -5.46 1.31e-07 0.000132 -0.38 -0.35 Aortic root size; chr7:66657397 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs6978178 ENSG00000232559.3 GS1-124K5.12 -5.46 1.31e-07 0.000132 -0.38 -0.35 Aortic root size; chr7:66658097 chr7:66554588~66576923:- CESC cis rs801193 0.591 rs721717 ENSG00000232559.3 GS1-124K5.12 -5.46 1.31e-07 0.000132 -0.38 -0.35 Aortic root size; chr7:66665305 chr7:66554588~66576923:- CESC cis rs72627509 0.857 rs2227901 ENSG00000269949.1 RP11-738E22.3 -5.46 1.31e-07 0.000132 -0.49 -0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56932023 chr4:56960927~56961373:- CESC cis rs5758659 1 rs134869 ENSG00000273366.1 CTA-989H11.1 -5.46 1.31e-07 0.000132 -0.42 -0.35 Cognitive function; chr22:42256068 chr22:42278188~42278846:+ CESC cis rs2108622 0.683 rs111388185 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866604 chr19:15851993~15864904:- CESC cis rs2108622 0.683 rs112571591 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866635 chr19:15851993~15864904:- CESC cis rs2108622 0.647 rs111427692 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866669 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs12609468 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867004 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs12610967 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867119 chr19:15851993~15864904:- CESC cis rs2108622 0.711 rs12609820 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867247 chr19:15851993~15864904:- CESC cis rs2108622 0.668 rs62106153 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867697 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs12611242 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867754 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs12611308 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867776 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs12610189 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867831 chr19:15851993~15864904:- CESC cis rs2108622 0.711 rs113343664 ENSG00000267453.5 AC004791.2 -5.46 1.31e-07 0.000132 -0.43 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15868183 chr19:15851993~15864904:- CESC cis rs875971 0.862 rs778720 ENSG00000226824.5 RP4-756H11.3 5.46 1.31e-07 0.000132 0.43 0.35 Aortic root size; chr7:66381288 chr7:66654538~66669855:+ CESC cis rs10875746 0.951 rs2269935 ENSG00000240399.1 RP1-228P16.1 -5.46 1.32e-07 0.000133 -0.47 -0.35 Longevity (90 years and older); chr12:48122681 chr12:48054813~48055591:- CESC cis rs2739330 0.828 rs2877178 ENSG00000250470.1 AP000351.3 5.46 1.32e-07 0.000133 0.44 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23976904~23977585:- CESC cis rs10800713 0.866 rs6703783 ENSG00000260088.1 RP11-92G12.3 -5.46 1.32e-07 0.000133 -0.51 -0.35 Tandem gait; chr1:200544290 chr1:200669507~200694250:+ CESC cis rs5758659 1 rs5758677 ENSG00000273366.1 CTA-989H11.1 -5.46 1.32e-07 0.000133 -0.42 -0.35 Cognitive function; chr22:42247033 chr22:42278188~42278846:+ CESC cis rs4660456 0.913 rs34212676 ENSG00000237899.1 RP4-739H11.3 -5.46 1.32e-07 0.000133 -0.48 -0.35 Platelet count; chr1:40766522 chr1:40669089~40687588:- CESC cis rs2028299 0.92 rs4932265 ENSG00000259677.1 RP11-493E3.1 5.46 1.32e-07 0.000133 0.49 0.35 Type 2 diabetes; chr15:89880061 chr15:89876540~89877285:+ CESC cis rs14027 0.554 rs6998058 ENSG00000279347.1 RP11-85I17.2 -5.45 1.32e-07 0.000133 -0.33 -0.35 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119743079 chr8:119838736~119840385:- CESC cis rs1823913 0.637 rs12992372 ENSG00000280083.1 RP11-317J9.1 -5.45 1.33e-07 0.000134 -0.41 -0.35 Obesity-related traits; chr2:191289251 chr2:191154118~191156070:- CESC cis rs62229266 0.804 rs2835231 ENSG00000231106.2 LINC01436 5.45 1.33e-07 0.000134 0.47 0.35 Mitral valve prolapse; chr21:36018300 chr21:36005338~36007838:+ CESC cis rs1062177 0.826 rs2915822 ENSG00000253921.1 CTB-113P19.3 5.45 1.33e-07 0.000134 0.45 0.35 Preschool internalizing problems; chr5:151751340 chr5:151753992~151767247:+ CESC cis rs9322193 0.886 rs2065663 ENSG00000268592.3 RAET1E-AS1 5.45 1.33e-07 0.000134 0.46 0.35 Lung cancer; chr6:149760331 chr6:149863494~149919507:+ CESC cis rs1891275 0.516 rs10881935 ENSG00000228701.1 TNKS2-AS1 -5.45 1.33e-07 0.000134 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91637944 chr10:91782839~91798291:- CESC cis rs34779708 0.931 rs12773169 ENSG00000230534.5 RP11-297A16.2 5.45 1.33e-07 0.000134 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35077534 chr10:35098006~35127020:- CESC cis rs1862618 0.627 rs744023 ENSG00000271828.1 CTD-2310F14.1 5.45 1.33e-07 0.000134 0.49 0.35 Initial pursuit acceleration; chr5:56901251 chr5:56927874~56929573:+ CESC cis rs2243480 1 rs313831 ENSG00000232559.3 GS1-124K5.12 5.45 1.33e-07 0.000134 0.6 0.35 Diabetic kidney disease; chr7:66086239 chr7:66554588~66576923:- CESC cis rs2842992 0.714 rs2475564 ENSG00000237927.1 RP3-393E18.2 -5.45 1.33e-07 0.000134 -0.47 -0.35 Age-related macular degeneration (geographic atrophy); chr6:159702641 chr6:159586955~159589169:- CESC cis rs1075265 0.584 rs4671178 ENSG00000233266.1 HMGB1P31 -5.45 1.33e-07 0.000134 -0.49 -0.35 Chronotype;Morning vs. evening chronotype; chr2:54056356 chr2:54051334~54051760:+ CESC cis rs9322193 0.962 rs3805752 ENSG00000268592.3 RAET1E-AS1 5.45 1.34e-07 0.000134 0.47 0.35 Lung cancer; chr6:149795490 chr6:149863494~149919507:+ CESC cis rs1075265 0.547 rs10865279 ENSG00000233266.1 HMGB1P31 5.45 1.34e-07 0.000134 0.5 0.35 Chronotype;Morning vs. evening chronotype; chr2:54097564 chr2:54051334~54051760:+ CESC cis rs875971 0.862 rs778724 ENSG00000222364.1 RNU6-96P -5.45 1.34e-07 0.000135 -0.41 -0.35 Aortic root size; chr7:66364304 chr7:66395191~66395286:+ CESC cis rs11155671 0.53 rs7742993 ENSG00000223701.3 RAET1E-AS1 5.45 1.34e-07 0.000135 0.38 0.35 Testicular germ cell tumor; chr6:149883959 chr6:149884431~149919508:+ CESC cis rs9322193 0.543 rs9371533 ENSG00000223701.3 RAET1E-AS1 5.45 1.34e-07 0.000135 0.38 0.35 Lung cancer; chr6:149889545 chr6:149884431~149919508:+ CESC cis rs34779708 0.931 rs1926556 ENSG00000230534.5 RP11-297A16.2 5.45 1.34e-07 0.000135 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35055979 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs1926554 ENSG00000230534.5 RP11-297A16.2 5.45 1.34e-07 0.000135 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35056041 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934710 ENSG00000230534.5 RP11-297A16.2 5.45 1.34e-07 0.000135 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35061488 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs2505639 ENSG00000230534.5 RP11-297A16.2 -5.45 1.35e-07 0.000135 -0.45 -0.35 Inflammatory bowel disease;Crohn's disease; chr10:35185493 chr10:35098006~35127020:- CESC cis rs6504950 0.889 rs2628301 ENSG00000275710.1 RP11-257O5.4 -5.45 1.35e-07 0.000135 -0.45 -0.35 Breast cancer; chr17:55081912 chr17:54964474~54964679:+ CESC cis rs2739330 0.76 rs5751761 ENSG00000099984.9 GSTT2 5.45 1.35e-07 0.000136 0.42 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23980123~23983911:+ CESC cis rs10246939 0.579 rs35647444 ENSG00000228775.6 WEE2-AS1 5.45 1.35e-07 0.000136 0.4 0.35 Bitter taste perception; chr7:141833957 chr7:141704338~141738346:- CESC cis rs72627509 0.904 rs17081933 ENSG00000269949.1 RP11-738E22.3 5.45 1.35e-07 0.000136 0.51 0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56956703 chr4:56960927~56961373:- CESC cis rs7829975 0.511 rs1401390 ENSG00000253893.2 FAM85B -5.45 1.35e-07 0.000136 -0.46 -0.35 Mood instability; chr8:8278888 chr8:8167819~8226614:- CESC cis rs7048146 1 rs7021839 ENSG00000213539.4 YBX1P6 5.45 1.35e-07 0.000136 0.41 0.35 Vascular brain injury; chr9:109538257 chr9:109532830~109534332:- CESC cis rs7048146 0.966 rs10816832 ENSG00000213539.4 YBX1P6 5.45 1.35e-07 0.000136 0.41 0.35 Vascular brain injury; chr9:109538494 chr9:109532830~109534332:- CESC cis rs4423214 0.879 rs1792284 ENSG00000254682.1 RP11-660L16.2 5.45 1.35e-07 0.000136 0.48 0.35 Vitamin D levels; chr11:71423920 chr11:71448674~71452157:+ CESC cis rs1799949 1 rs8176126 ENSG00000267681.1 CTD-3199J23.6 5.45 1.35e-07 0.000136 0.44 0.35 Menopause (age at onset); chr17:43107032 chr17:43144956~43145255:+ CESC cis rs7048146 0.899 rs1541092 ENSG00000213539.4 YBX1P6 -5.45 1.36e-07 0.000136 -0.4 -0.35 Vascular brain injury; chr9:109580279 chr9:109532830~109534332:- CESC cis rs6904897 0.538 rs4639353 ENSG00000232876.1 CTA-212D2.2 5.45 1.36e-07 0.000136 0.4 0.35 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134903190 chr6:135055033~135060550:+ CESC cis rs8072100 0.817 rs9892497 ENSG00000228782.6 CTD-2026D20.3 5.45 1.36e-07 0.000136 0.41 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47468553 chr17:47450568~47492492:- CESC cis rs62229266 0.835 rs998384 ENSG00000231106.2 LINC01436 5.45 1.36e-07 0.000136 0.49 0.35 Mitral valve prolapse; chr21:36073228 chr21:36005338~36007838:+ CESC cis rs7829975 0.511 rs1543238 ENSG00000253893.2 FAM85B -5.45 1.36e-07 0.000136 -0.46 -0.35 Mood instability; chr8:8277287 chr8:8167819~8226614:- CESC cis rs950169 0.922 rs4842939 ENSG00000225151.9 GOLGA2P7 5.45 1.36e-07 0.000136 0.45 0.35 Schizophrenia; chr15:84159214 chr15:84199311~84230136:- CESC cis rs992157 0.764 rs2015863 ENSG00000261338.2 RP11-378A13.1 -5.45 1.36e-07 0.000136 -0.44 -0.35 Colorectal cancer; chr2:218320438 chr2:218255319~218257366:+ CESC cis rs150992 0.57 rs7710032 ENSG00000248489.1 CTD-2007H13.3 -5.45 1.36e-07 0.000137 -0.44 -0.35 Body mass index; chr5:99007501 chr5:98929171~98995013:+ CESC cis rs2919917 1 rs3808619 ENSG00000254352.1 RP11-578O24.2 5.45 1.36e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78665491 chr8:78723796~78724136:- CESC cis rs67180937 0.961 rs2133189 ENSG00000272750.1 RP11-378J18.8 -5.45 1.36e-07 0.000137 -0.43 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222641100 chr1:222658867~222661512:- CESC cis rs748404 0.66 rs690446 ENSG00000249839.1 AC011330.5 -5.45 1.36e-07 0.000137 -0.36 -0.35 Lung cancer; chr15:43469066 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs690472 ENSG00000249839.1 AC011330.5 -5.45 1.36e-07 0.000137 -0.36 -0.35 Lung cancer; chr15:43472170 chr15:43663654~43684339:- CESC cis rs748404 0.631 rs560191 ENSG00000249839.1 AC011330.5 -5.45 1.36e-07 0.000137 -0.36 -0.35 Lung cancer; chr15:43475576 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs2444251 ENSG00000249839.1 AC011330.5 -5.45 1.36e-07 0.000137 -0.36 -0.35 Lung cancer; chr15:43496397 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs548704 ENSG00000249839.1 AC011330.5 -5.45 1.36e-07 0.000137 -0.36 -0.35 Lung cancer; chr15:43499508 chr15:43663654~43684339:- CESC cis rs801193 0.636 rs10233806 ENSG00000222364.1 RNU6-96P 5.45 1.36e-07 0.000137 0.41 0.35 Aortic root size; chr7:66653261 chr7:66395191~66395286:+ CESC cis rs6452524 0.967 rs2662243 ENSG00000249664.1 CTD-2227C6.2 5.45 1.37e-07 0.000137 0.36 0.35 Hypertension (SNP x SNP interaction); chr5:83192630 chr5:83012285~83013109:- CESC cis rs507080 0.501 rs626645 ENSG00000255422.1 AP002954.4 -5.45 1.37e-07 0.000137 -0.39 -0.35 Serum metabolite levels; chr11:118704471 chr11:118704607~118750263:+ CESC cis rs6504950 0.886 rs4794551 ENSG00000275710.1 RP11-257O5.4 -5.45 1.37e-07 0.000137 -0.39 -0.35 Breast cancer; chr17:54998066 chr17:54964474~54964679:+ CESC cis rs2919917 1 rs13269243 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78669501 chr8:78723796~78724136:- CESC cis rs2919917 1 rs7839152 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78677777 chr8:78723796~78724136:- CESC cis rs2919917 1 rs28429528 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78678782 chr8:78723796~78724136:- CESC cis rs2919917 1 rs9298316 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78680191 chr8:78723796~78724136:- CESC cis rs2919917 1 rs7842142 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78681501 chr8:78723796~78724136:- CESC cis rs2919917 1 rs11785966 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78681851 chr8:78723796~78724136:- CESC cis rs2919917 1 rs10092335 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78686218 chr8:78723796~78724136:- CESC cis rs2919917 0.956 rs10112388 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78691512 chr8:78723796~78724136:- CESC cis rs2919917 1 rs7001074 ENSG00000254352.1 RP11-578O24.2 5.45 1.37e-07 0.000137 0.45 0.35 Lymphocyte counts; chr8:78691689 chr8:78723796~78724136:- CESC cis rs9322193 0.847 rs12210605 ENSG00000268592.3 RAET1E-AS1 5.45 1.37e-07 0.000137 0.46 0.35 Lung cancer; chr6:149817267 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9371199 ENSG00000268592.3 RAET1E-AS1 5.45 1.37e-07 0.000137 0.46 0.35 Lung cancer; chr6:149817526 chr6:149863494~149919507:+ CESC cis rs42490 0.7 rs40459 ENSG00000251136.7 RP11-37B2.1 5.45 1.37e-07 0.000137 0.34 0.35 Leprosy; chr8:89833998 chr8:89609409~89757727:- CESC cis rs9584850 0.834 rs3803253 ENSG00000231194.1 FARP1-AS1 5.45 1.38e-07 0.000138 0.44 0.35 Neuroticism; chr13:98464895 chr13:98435405~98435840:- CESC cis rs801193 0.591 rs9986881 ENSG00000226824.5 RP4-756H11.3 -5.45 1.38e-07 0.000138 -0.42 -0.35 Aortic root size; chr7:66708053 chr7:66654538~66669855:+ CESC cis rs10129255 0.642 rs11624918 ENSG00000211970.3 IGHV4-61 -5.45 1.38e-07 0.000138 -0.26 -0.35 Kawasaki disease; chr14:106664672 chr14:106639119~106639657:- CESC cis rs6452524 0.967 rs2974445 ENSG00000249664.1 CTD-2227C6.2 -5.45 1.38e-07 0.000138 -0.38 -0.35 Hypertension (SNP x SNP interaction); chr5:83185561 chr5:83012285~83013109:- CESC cis rs7572733 0.935 rs4410288 ENSG00000222017.1 AC011997.1 5.45 1.38e-07 0.000138 0.38 0.35 Dermatomyositis; chr2:197955100 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1607376 ENSG00000222017.1 AC011997.1 5.45 1.38e-07 0.000138 0.38 0.35 Dermatomyositis; chr2:197963190 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1850633 ENSG00000222017.1 AC011997.1 5.45 1.38e-07 0.000138 0.38 0.35 Dermatomyositis; chr2:197964858 chr2:197693106~197774823:+ CESC cis rs8059260 0.736 rs7195509 ENSG00000274038.1 RP11-66H6.4 -5.45 1.39e-07 0.000139 -0.56 -0.35 Alcohol consumption over the past year; chr16:10951572 chr16:11056556~11057034:+ CESC cis rs10262624 0.901 rs6977550 ENSG00000234286.1 AC006026.13 -5.45 1.39e-07 0.000139 -0.38 -0.35 Schizophrenia; chr7:23865825 chr7:23680195~23680786:- CESC cis rs9322193 0.884 rs7744105 ENSG00000268592.3 RAET1E-AS1 5.45 1.39e-07 0.000139 0.45 0.35 Lung cancer; chr6:149849308 chr6:149863494~149919507:+ CESC cis rs875971 0.522 rs1880556 ENSG00000164669.11 INTS4P1 -5.44 1.39e-07 0.000139 -0.49 -0.35 Aortic root size; chr7:65967557 chr7:65141225~65234216:+ CESC cis rs131777 0.547 rs131753 ENSG00000205559.3 CHKB-AS1 -5.44 1.39e-07 0.000139 -0.41 -0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50584433 chr22:50583026~50583877:+ CESC cis rs2243480 0.708 rs35825036 ENSG00000228409.4 CCT6P1 5.44 1.4e-07 0.00014 0.53 0.35 Diabetic kidney disease; chr7:66521515 chr7:65751142~65763354:+ CESC cis rs2243480 0.803 rs13224048 ENSG00000228409.4 CCT6P1 5.44 1.4e-07 0.00014 0.53 0.35 Diabetic kidney disease; chr7:66528779 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs13237037 ENSG00000228409.4 CCT6P1 5.44 1.4e-07 0.00014 0.53 0.35 Diabetic kidney disease; chr7:66532895 chr7:65751142~65763354:+ CESC cis rs11096990 0.634 rs6852967 ENSG00000249207.1 RP11-360F5.1 5.44 1.4e-07 0.00014 0.38 0.35 Cognitive function; chr4:39281526 chr4:39112677~39126818:- CESC cis rs1891275 0.551 rs7071844 ENSG00000228701.1 TNKS2-AS1 -5.44 1.4e-07 0.00014 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91644092 chr10:91782839~91798291:- CESC cis rs11651753 0.561 rs17616603 ENSG00000264920.1 RP11-6N17.4 -5.44 1.4e-07 0.00014 -0.41 -0.35 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47882254 chr17:47891255~47895812:- CESC cis rs9322193 0.847 rs56103941 ENSG00000268592.3 RAET1E-AS1 5.44 1.4e-07 0.00014 0.46 0.35 Lung cancer; chr6:149816095 chr6:149863494~149919507:+ CESC cis rs801193 0.66 rs2659914 ENSG00000222364.1 RNU6-96P -5.44 1.4e-07 0.00014 -0.4 -0.35 Aortic root size; chr7:66691927 chr7:66395191~66395286:+ CESC cis rs8072100 0.817 rs9912101 ENSG00000228782.6 CTD-2026D20.3 5.44 1.41e-07 0.000141 0.41 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469712 chr17:47450568~47492492:- CESC cis rs8072100 0.817 rs9905581 ENSG00000228782.6 CTD-2026D20.3 5.44 1.41e-07 0.000141 0.41 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469819 chr17:47450568~47492492:- CESC cis rs11846409 0.818 rs2516909 ENSG00000211974.3 IGHV2-70 5.44 1.41e-07 0.000141 0.46 0.35 Rheumatic heart disease; chr14:106630317 chr14:106723574~106724093:- CESC cis rs6700559 0.81 rs2809344 ENSG00000260088.1 RP11-92G12.3 5.44 1.41e-07 0.000141 0.43 0.35 Coronary artery disease; chr1:200627478 chr1:200669507~200694250:+ CESC cis rs875971 0.798 rs6460304 ENSG00000222364.1 RNU6-96P -5.44 1.41e-07 0.000141 -0.41 -0.35 Aortic root size; chr7:66499741 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6945775 ENSG00000222364.1 RNU6-96P -5.44 1.41e-07 0.000141 -0.41 -0.35 Aortic root size; chr7:66503987 chr7:66395191~66395286:+ CESC cis rs875971 0.798 rs57739047 ENSG00000222364.1 RNU6-96P -5.44 1.41e-07 0.000141 -0.41 -0.35 Aortic root size; chr7:66507579 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs6950137 ENSG00000222364.1 RNU6-96P -5.44 1.41e-07 0.000141 -0.41 -0.35 Aortic root size; chr7:66511623 chr7:66395191~66395286:+ CESC cis rs7572733 0.935 rs6753450 ENSG00000222017.1 AC011997.1 5.44 1.42e-07 0.000142 0.38 0.35 Dermatomyositis; chr2:197870307 chr2:197693106~197774823:+ CESC cis rs13631 0.928 rs9411308 ENSG00000268996.3 MAN1B1-AS1 5.44 1.42e-07 0.000142 0.32 0.35 Cerebrospinal fluid biomarker levels; chr9:137105663 chr9:137084946~137086817:- CESC cis rs42490 0.576 rs390536 ENSG00000251136.7 RP11-37B2.1 -5.44 1.42e-07 0.000142 -0.35 -0.35 Leprosy; chr8:89857122 chr8:89609409~89757727:- CESC cis rs1075265 0.73 rs11893270 ENSG00000233266.1 HMGB1P31 5.44 1.42e-07 0.000142 0.44 0.35 Chronotype;Morning vs. evening chronotype; chr2:54019828 chr2:54051334~54051760:+ CESC cis rs881375 0.692 rs2072438 ENSG00000226752.6 PSMD5-AS1 -5.44 1.43e-07 0.000142 -0.36 -0.35 Rheumatoid arthritis; chr9:120889023 chr9:120824828~120854385:+ CESC cis rs8059260 0.736 rs8059156 ENSG00000274038.1 RP11-66H6.4 -5.44 1.43e-07 0.000143 -0.56 -0.35 Alcohol consumption over the past year; chr16:10952135 chr16:11056556~11057034:+ CESC cis rs8059260 0.736 rs8044180 ENSG00000274038.1 RP11-66H6.4 -5.44 1.43e-07 0.000143 -0.56 -0.35 Alcohol consumption over the past year; chr16:10952531 chr16:11056556~11057034:+ CESC cis rs8059260 0.736 rs7192171 ENSG00000274038.1 RP11-66H6.4 -5.44 1.43e-07 0.000143 -0.56 -0.35 Alcohol consumption over the past year; chr16:10955262 chr16:11056556~11057034:+ CESC cis rs801193 0.569 rs2659907 ENSG00000232559.3 GS1-124K5.12 5.44 1.43e-07 0.000143 0.38 0.35 Aortic root size; chr7:66699045 chr7:66554588~66576923:- CESC cis rs526231 0.543 rs246901 ENSG00000175749.11 EIF3KP1 5.44 1.43e-07 0.000143 0.44 0.35 Primary biliary cholangitis; chr5:103248477 chr5:103032376~103033031:+ CESC cis rs5760092 0.618 rs5996631 ENSG00000231271.1 AP000350.8 -5.44 1.43e-07 0.000143 -0.46 -0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23949918~23954042:+ CESC cis rs2243480 1 rs1638734 ENSG00000228409.4 CCT6P1 5.44 1.43e-07 0.000143 0.53 0.35 Diabetic kidney disease; chr7:66632552 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs1267818 ENSG00000228409.4 CCT6P1 5.44 1.43e-07 0.000143 0.53 0.35 Gout; chr7:66642037 chr7:65751142~65763354:+ CESC cis rs1499614 1 rs1267817 ENSG00000228409.4 CCT6P1 5.44 1.43e-07 0.000143 0.53 0.35 Gout; chr7:66645053 chr7:65751142~65763354:+ CESC cis rs10262624 0.901 rs6966655 ENSG00000234286.1 AC006026.13 -5.44 1.43e-07 0.000143 -0.37 -0.35 Schizophrenia; chr7:23867010 chr7:23680195~23680786:- CESC cis rs9322193 0.607 rs7764677 ENSG00000231760.4 RP11-350J20.5 5.44 1.43e-07 0.000143 0.5 0.35 Lung cancer; chr6:149906197 chr6:149796151~149826294:- CESC cis rs34779708 0.931 rs7099036 ENSG00000230534.5 RP11-297A16.2 5.44 1.43e-07 0.000143 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35060646 chr10:35098006~35127020:- CESC cis rs801193 0.569 rs13242290 ENSG00000232559.3 GS1-124K5.12 -5.44 1.43e-07 0.000143 -0.38 -0.35 Aortic root size; chr7:66656898 chr7:66554588~66576923:- CESC cis rs2842992 0.83 rs2025190 ENSG00000237927.1 RP3-393E18.2 -5.44 1.44e-07 0.000143 -0.46 -0.35 Age-related macular degeneration (geographic atrophy); chr6:159717209 chr6:159586955~159589169:- CESC cis rs875971 0.862 rs9791712 ENSG00000237310.1 GS1-124K5.4 -5.44 1.44e-07 0.000143 -0.34 -0.35 Aortic root size; chr7:66640176 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs9791713 ENSG00000237310.1 GS1-124K5.4 -5.44 1.44e-07 0.000143 -0.34 -0.35 Aortic root size; chr7:66640211 chr7:66493706~66495474:+ CESC cis rs34779708 0.931 rs34954932 ENSG00000230534.5 RP11-297A16.2 5.44 1.44e-07 0.000143 0.45 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35121879 chr10:35098006~35127020:- CESC cis rs2919917 1 rs6980663 ENSG00000254352.1 RP11-578O24.2 5.44 1.44e-07 0.000143 0.45 0.35 Lymphocyte counts; chr8:78691589 chr8:78723796~78724136:- CESC cis rs79349575 0.756 rs937301 ENSG00000270781.1 RP11-501C14.9 5.44 1.44e-07 0.000144 0.38 0.35 Type 2 diabetes; chr17:48968914 chr17:48899131~48899748:+ CESC cis rs7189233 0.55 rs4783811 ENSG00000279344.1 RP11-44F14.7 5.44 1.44e-07 0.000144 0.32 0.35 Intelligence (multi-trait analysis); chr16:53449464 chr16:53478957~53481550:- CESC cis rs42490 0.576 rs386587 ENSG00000251136.7 RP11-37B2.1 -5.44 1.44e-07 0.000144 -0.36 -0.35 Leprosy; chr8:89862772 chr8:89609409~89757727:- CESC cis rs42490 0.576 rs381456 ENSG00000251136.7 RP11-37B2.1 -5.44 1.44e-07 0.000144 -0.36 -0.35 Leprosy; chr8:89865176 chr8:89609409~89757727:- CESC cis rs11690935 0.802 rs34636594 ENSG00000228389.1 AC068039.4 5.44 1.44e-07 0.000144 0.48 0.35 Schizophrenia; chr2:172046366 chr2:171773482~171775844:+ CESC cis rs34779708 0.931 rs10466072 ENSG00000230534.5 RP11-297A16.2 5.44 1.44e-07 0.000144 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35113828 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs998658 ENSG00000230534.5 RP11-297A16.2 5.44 1.44e-07 0.000144 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35119726 chr10:35098006~35127020:- CESC cis rs1891275 0.527 rs35812291 ENSG00000228701.1 TNKS2-AS1 -5.44 1.44e-07 0.000144 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91642584 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs4933681 ENSG00000228701.1 TNKS2-AS1 -5.44 1.44e-07 0.000144 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91643365 chr10:91782839~91798291:- CESC cis rs2739330 0.791 rs9612520 ENSG00000099984.9 GSTT2 -5.44 1.45e-07 0.000145 -0.42 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23980123~23983911:+ CESC cis rs1891275 0.551 rs2421621 ENSG00000228701.1 TNKS2-AS1 -5.44 1.45e-07 0.000145 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91640344 chr10:91782839~91798291:- CESC cis rs116095464 0.558 rs7703803 ENSG00000250848.1 CTD-2083E4.5 -5.44 1.46e-07 0.000145 -0.45 -0.35 Breast cancer; chr5:292196 chr5:288833~290321:- CESC cis rs116095464 0.558 rs9654452 ENSG00000250848.1 CTD-2083E4.5 -5.44 1.46e-07 0.000145 -0.45 -0.35 Breast cancer; chr5:299446 chr5:288833~290321:- CESC cis rs9322193 0.962 rs7818 ENSG00000268592.3 RAET1E-AS1 5.44 1.46e-07 0.000145 0.44 0.35 Lung cancer; chr6:149810956 chr6:149863494~149919507:+ CESC cis rs10256972 0.967 rs1881122 ENSG00000229043.2 AC091729.9 -5.44 1.46e-07 0.000145 -0.39 -0.35 Endometriosis;Longevity; chr7:1001310 chr7:1160374~1165267:+ CESC cis rs34779708 0.931 rs13376871 ENSG00000230534.5 RP11-297A16.2 5.43 1.46e-07 0.000146 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35080128 chr10:35098006~35127020:- CESC cis rs9545047 0.604 rs6563100 ENSG00000227676.3 LINC01068 5.43 1.46e-07 0.000146 0.39 0.35 Schizophrenia; chr13:79382978 chr13:79566727~79571436:+ CESC cis rs35158675 1 rs35158675 ENSG00000272750.1 RP11-378J18.8 -5.43 1.46e-07 0.000146 -0.43 -0.35 Coronary artery disease; chr1:222656208 chr1:222658867~222661512:- CESC cis rs9907295 1 rs9900236 ENSG00000270977.1 AC015849.16 -5.43 1.47e-07 0.000146 -0.5 -0.35 Fibroblast growth factor basic levels; chr17:35917049 chr17:35893707~35911023:- CESC cis rs875971 0.756 rs4718328 ENSG00000222364.1 RNU6-96P 5.43 1.47e-07 0.000146 0.39 0.35 Aortic root size; chr7:66228350 chr7:66395191~66395286:+ CESC cis rs7572733 0.792 rs1036333 ENSG00000222017.1 AC011997.1 5.43 1.47e-07 0.000146 0.39 0.35 Dermatomyositis; chr2:198079063 chr2:197693106~197774823:+ CESC cis rs7572733 0.755 rs6716898 ENSG00000222017.1 AC011997.1 5.43 1.47e-07 0.000146 0.39 0.35 Dermatomyositis; chr2:198079547 chr2:197693106~197774823:+ CESC cis rs7572733 0.792 rs1440089 ENSG00000222017.1 AC011997.1 5.43 1.47e-07 0.000146 0.39 0.35 Dermatomyositis; chr2:198080223 chr2:197693106~197774823:+ CESC cis rs62229266 0.804 rs998383 ENSG00000231106.2 LINC01436 5.43 1.47e-07 0.000146 0.48 0.35 Mitral valve prolapse; chr21:36073441 chr21:36005338~36007838:+ CESC cis rs875971 0.798 rs12698522 ENSG00000237310.1 GS1-124K5.4 5.43 1.47e-07 0.000147 0.33 0.35 Aortic root size; chr7:66502354 chr7:66493706~66495474:+ CESC cis rs875971 0.83 rs28714531 ENSG00000237310.1 GS1-124K5.4 5.43 1.47e-07 0.000147 0.33 0.35 Aortic root size; chr7:66503250 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs12698526 ENSG00000237310.1 GS1-124K5.4 5.43 1.47e-07 0.000147 0.33 0.35 Aortic root size; chr7:66504118 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs13226966 ENSG00000237310.1 GS1-124K5.4 5.43 1.48e-07 0.000147 0.32 0.35 Aortic root size; chr7:66768636 chr7:66493706~66495474:+ CESC cis rs3738443 0.678 rs6680707 ENSG00000259865.1 RP11-488L18.10 5.43 1.48e-07 0.000147 0.36 0.35 Alcohol dependence; chr1:247213648 chr1:247187281~247188526:- CESC cis rs4660456 0.564 rs34320811 ENSG00000237899.1 RP4-739H11.3 -5.43 1.48e-07 0.000147 -0.47 -0.35 Platelet count; chr1:40763288 chr1:40669089~40687588:- CESC cis rs875971 0.862 rs11763189 ENSG00000222364.1 RNU6-96P -5.43 1.48e-07 0.000147 -0.41 -0.35 Aortic root size; chr7:66518542 chr7:66395191~66395286:+ CESC cis rs7189233 0.531 rs1074182 ENSG00000279344.1 RP11-44F14.7 5.43 1.49e-07 0.000148 0.32 0.35 Intelligence (multi-trait analysis); chr16:53437445 chr16:53478957~53481550:- CESC cis rs2243480 1 rs1796228 ENSG00000275400.1 RP4-756H11.5 5.43 1.49e-07 0.000148 0.6 0.35 Diabetic kidney disease; chr7:66568097 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1267820 ENSG00000275400.1 RP4-756H11.5 5.43 1.49e-07 0.000148 0.6 0.35 Diabetic kidney disease; chr7:66585308 chr7:66553805~66554199:- CESC cis rs2243480 1 rs2533288 ENSG00000275400.1 RP4-756H11.5 5.43 1.49e-07 0.000148 0.6 0.35 Diabetic kidney disease; chr7:66591724 chr7:66553805~66554199:- CESC cis rs9549367 0.789 rs34448227 ENSG00000269125.1 RP11-98F14.11 -5.43 1.49e-07 0.000148 -0.48 -0.35 Platelet distribution width; chr13:113230440 chr13:113165002~113165183:- CESC cis rs875971 0.522 rs1701760 ENSG00000164669.11 INTS4P1 -5.43 1.49e-07 0.000148 -0.47 -0.35 Aortic root size; chr7:66008701 chr7:65141225~65234216:+ CESC cis rs12439619 1 rs12439619 ENSG00000255769.6 GOLGA2P10 -5.43 1.49e-07 0.000148 -0.44 -0.35 Intelligence (multi-trait analysis); chr15:82254605 chr15:82472993~82513950:- CESC cis rs62229266 0.771 rs62230790 ENSG00000231106.2 LINC01436 5.43 1.5e-07 0.000149 0.48 0.35 Mitral valve prolapse; chr21:36016613 chr21:36005338~36007838:+ CESC cis rs4660456 0.871 rs669072 ENSG00000237899.1 RP4-739H11.3 5.43 1.5e-07 0.000149 0.47 0.35 Platelet count; chr1:40679946 chr1:40669089~40687588:- CESC cis rs2919917 1 rs1384804 ENSG00000254352.1 RP11-578O24.2 5.43 1.5e-07 0.000149 0.45 0.35 Lymphocyte counts; chr8:78659987 chr8:78723796~78724136:- CESC cis rs2919917 1 rs10093654 ENSG00000254352.1 RP11-578O24.2 5.43 1.5e-07 0.000149 0.45 0.35 Lymphocyte counts; chr8:78660360 chr8:78723796~78724136:- CESC cis rs2919917 1 rs10093797 ENSG00000254352.1 RP11-578O24.2 5.43 1.5e-07 0.000149 0.45 0.35 Lymphocyte counts; chr8:78660478 chr8:78723796~78724136:- CESC cis rs34779708 0.966 rs7913615 ENSG00000230534.5 RP11-297A16.2 5.43 1.5e-07 0.000149 0.45 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35134029 chr10:35098006~35127020:- CESC cis rs11651753 0.636 rs12602494 ENSG00000264920.1 RP11-6N17.4 -5.43 1.5e-07 0.000149 -0.39 -0.35 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47960241 chr17:47891255~47895812:- CESC cis rs875971 0.862 rs10276077 ENSG00000222364.1 RNU6-96P 5.43 1.51e-07 0.000149 0.39 0.35 Aortic root size; chr7:66263424 chr7:66395191~66395286:+ CESC cis rs9545047 0.589 rs9545090 ENSG00000227676.3 LINC01068 5.43 1.51e-07 0.000149 0.39 0.35 Schizophrenia; chr13:79367276 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9530902 ENSG00000227676.3 LINC01068 5.43 1.51e-07 0.000149 0.39 0.35 Schizophrenia; chr13:79367748 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9545092 ENSG00000227676.3 LINC01068 5.43 1.51e-07 0.000149 0.39 0.35 Schizophrenia; chr13:79369809 chr13:79566727~79571436:+ CESC cis rs9545047 0.611 rs9545093 ENSG00000227676.3 LINC01068 5.43 1.51e-07 0.000149 0.39 0.35 Schizophrenia; chr13:79371969 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9530906 ENSG00000227676.3 LINC01068 5.43 1.51e-07 0.000149 0.39 0.35 Schizophrenia; chr13:79372401 chr13:79566727~79571436:+ CESC cis rs875971 0.862 rs1860469 ENSG00000237310.1 GS1-124K5.4 -5.43 1.51e-07 0.000149 -0.33 -0.35 Aortic root size; chr7:66641888 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs4718383 ENSG00000237310.1 GS1-124K5.4 -5.43 1.51e-07 0.000149 -0.33 -0.35 Aortic root size; chr7:66643422 chr7:66493706~66495474:+ CESC cis rs67180937 1 rs67180937 ENSG00000272750.1 RP11-378J18.8 -5.43 1.51e-07 0.00015 -0.43 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222650401 chr1:222658867~222661512:- CESC cis rs7189233 0.55 rs1861350 ENSG00000279344.1 RP11-44F14.7 5.43 1.51e-07 0.00015 0.33 0.35 Intelligence (multi-trait analysis); chr16:53499430 chr16:53478957~53481550:- CESC cis rs9549367 0.865 rs9549366 ENSG00000269125.1 RP11-98F14.11 -5.43 1.51e-07 0.00015 -0.46 -0.35 Platelet distribution width; chr13:113253330 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs9577220 ENSG00000269125.1 RP11-98F14.11 -5.43 1.51e-07 0.00015 -0.46 -0.35 Platelet distribution width; chr13:113253980 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs9549716 ENSG00000269125.1 RP11-98F14.11 -5.43 1.51e-07 0.00015 -0.46 -0.35 Platelet distribution width; chr13:113254164 chr13:113165002~113165183:- CESC cis rs9549367 0.773 rs9549717 ENSG00000269125.1 RP11-98F14.11 -5.43 1.51e-07 0.00015 -0.46 -0.35 Platelet distribution width; chr13:113254512 chr13:113165002~113165183:- CESC cis rs34779708 0.897 rs9665538 ENSG00000230534.5 RP11-297A16.2 5.43 1.51e-07 0.00015 0.45 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35172110 chr10:35098006~35127020:- CESC cis rs9545047 0.604 rs7327603 ENSG00000227676.3 LINC01068 5.43 1.51e-07 0.00015 0.39 0.35 Schizophrenia; chr13:79366676 chr13:79566727~79571436:+ CESC cis rs875971 0.862 rs13232191 ENSG00000237310.1 GS1-124K5.4 5.43 1.51e-07 0.00015 0.33 0.35 Aortic root size; chr7:66521661 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs35378740 ENSG00000237310.1 GS1-124K5.4 5.43 1.51e-07 0.00015 0.33 0.35 Aortic root size; chr7:66522725 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs10950043 ENSG00000237310.1 GS1-124K5.4 5.43 1.51e-07 0.00015 0.33 0.35 Aortic root size; chr7:66523623 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs17747530 ENSG00000237310.1 GS1-124K5.4 5.43 1.51e-07 0.00015 0.33 0.35 Aortic root size; chr7:66529742 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs13226170 ENSG00000237310.1 GS1-124K5.4 5.43 1.51e-07 0.00015 0.33 0.35 Aortic root size; chr7:66534311 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs2420611 ENSG00000237310.1 GS1-124K5.4 5.43 1.51e-07 0.00015 0.33 0.35 Aortic root size; chr7:66534333 chr7:66493706~66495474:+ CESC cis rs875971 0.767 rs61348003 ENSG00000237310.1 GS1-124K5.4 5.43 1.51e-07 0.00015 0.33 0.35 Aortic root size; chr7:66540947 chr7:66493706~66495474:+ CESC cis rs875971 0.861 rs801215 ENSG00000237310.1 GS1-124K5.4 -5.43 1.51e-07 0.00015 -0.33 -0.35 Aortic root size; chr7:66546951 chr7:66493706~66495474:+ CESC cis rs897984 0.684 rs6950 ENSG00000260911.2 RP11-196G11.2 -5.43 1.51e-07 0.00015 -0.38 -0.35 Dementia with Lewy bodies; chr16:30984348 chr16:31043150~31049868:+ CESC cis rs2243480 1 rs313832 ENSG00000232559.3 GS1-124K5.12 5.43 1.52e-07 0.00015 0.6 0.35 Diabetic kidney disease; chr7:66085904 chr7:66554588~66576923:- CESC cis rs7048146 0.966 rs1576591 ENSG00000213539.4 YBX1P6 5.43 1.52e-07 0.00015 0.41 0.35 Vascular brain injury; chr9:109542724 chr9:109532830~109534332:- CESC cis rs7048146 1 rs1411690 ENSG00000213539.4 YBX1P6 5.43 1.52e-07 0.00015 0.41 0.35 Vascular brain injury; chr9:109542827 chr9:109532830~109534332:- CESC cis rs9545047 0.604 rs7322901 ENSG00000227676.3 LINC01068 5.43 1.52e-07 0.00015 0.39 0.35 Schizophrenia; chr13:79383505 chr13:79566727~79571436:+ CESC cis rs9322193 0.962 rs2342764 ENSG00000268592.3 RAET1E-AS1 5.43 1.52e-07 0.00015 0.47 0.35 Lung cancer; chr6:149835068 chr6:149863494~149919507:+ CESC cis rs8040855 0.542 rs2342122 ENSG00000259295.5 CSPG4P12 -5.43 1.52e-07 0.000151 -0.4 -0.34 Bulimia nervosa; chr15:85185304 chr15:85191438~85213905:+ CESC cis rs8040855 0.644 rs2342120 ENSG00000259295.5 CSPG4P12 -5.43 1.52e-07 0.000151 -0.4 -0.34 Bulimia nervosa; chr15:85185589 chr15:85191438~85213905:+ CESC cis rs9322193 0.923 rs12176034 ENSG00000268592.3 RAET1E-AS1 5.43 1.52e-07 0.000151 0.46 0.34 Lung cancer; chr6:149800557 chr6:149863494~149919507:+ CESC cis rs1891275 0.576 rs1891272 ENSG00000228701.1 TNKS2-AS1 -5.43 1.53e-07 0.000151 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91666306 chr10:91782839~91798291:- CESC cis rs875971 0.862 rs4236208 ENSG00000222364.1 RNU6-96P 5.43 1.53e-07 0.000151 0.4 0.34 Aortic root size; chr7:66284091 chr7:66395191~66395286:+ CESC cis rs72627509 0.904 rs17081935 ENSG00000269949.1 RP11-738E22.3 5.43 1.53e-07 0.000151 0.53 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56957310 chr4:56960927~56961373:- CESC cis rs6452524 0.534 rs17284134 ENSG00000249664.1 CTD-2227C6.2 -5.43 1.53e-07 0.000151 -0.4 -0.34 Hypertension (SNP x SNP interaction); chr5:83068325 chr5:83012285~83013109:- CESC cis rs7684253 0.55 rs4566710 ENSG00000269949.1 RP11-738E22.3 -5.43 1.53e-07 0.000151 -0.4 -0.34 Migraine; chr4:56879297 chr4:56960927~56961373:- CESC cis rs6142102 0.625 rs6142067 ENSG00000275784.1 RP5-1125A11.6 -5.43 1.53e-07 0.000151 -0.35 -0.34 Skin pigmentation; chr20:33968766 chr20:33989480~33991818:- CESC cis rs992157 0.735 rs12990082 ENSG00000261338.2 RP11-378A13.1 5.43 1.53e-07 0.000151 0.42 0.34 Colorectal cancer; chr2:218237609 chr2:218255319~218257366:+ CESC cis rs9309711 0.643 rs4535074 ENSG00000225234.1 TRAPPC12-AS1 -5.43 1.53e-07 0.000152 -0.32 -0.34 Neurofibrillary tangles; chr2:3477866 chr2:3481242~3482409:- CESC cis rs957448 0.607 rs12680842 ENSG00000253704.1 RP11-267M23.4 5.43 1.54e-07 0.000152 0.35 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94570378 chr8:94553722~94569745:+ CESC cis rs897984 0.762 rs4889599 ENSG00000260911.2 RP11-196G11.2 -5.43 1.54e-07 0.000152 -0.38 -0.34 Dementia with Lewy bodies; chr16:30957268 chr16:31043150~31049868:+ CESC cis rs897984 0.721 rs2305884 ENSG00000260911.2 RP11-196G11.2 -5.43 1.54e-07 0.000152 -0.38 -0.34 Dementia with Lewy bodies; chr16:30959420 chr16:31043150~31049868:+ CESC cis rs897984 0.762 rs11150601 ENSG00000260911.2 RP11-196G11.2 -5.43 1.54e-07 0.000152 -0.38 -0.34 Dementia with Lewy bodies; chr16:30966478 chr16:31043150~31049868:+ CESC cis rs6951245 0.554 rs35126802 ENSG00000229043.2 AC091729.9 -5.42 1.54e-07 0.000152 -0.44 -0.34 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1095206 chr7:1160374~1165267:+ CESC cis rs2404602 0.692 rs35498563 ENSG00000259422.1 RP11-593F23.1 5.42 1.54e-07 0.000152 0.39 0.34 Blood metabolite levels; chr15:76666527 chr15:76174891~76181486:- CESC cis rs11096990 0.576 rs2008679 ENSG00000249207.1 RP11-360F5.1 5.42 1.54e-07 0.000152 0.38 0.34 Cognitive function; chr4:39266385 chr4:39112677~39126818:- CESC cis rs7189233 0.531 rs1362429 ENSG00000279344.1 RP11-44F14.7 5.42 1.54e-07 0.000152 0.32 0.34 Intelligence (multi-trait analysis); chr16:53445172 chr16:53478957~53481550:- CESC cis rs6504950 0.679 rs2628298 ENSG00000275710.1 RP11-257O5.4 -5.42 1.54e-07 0.000152 -0.46 -0.34 Breast cancer; chr17:55086117 chr17:54964474~54964679:+ CESC cis rs897984 0.806 rs8052245 ENSG00000260911.2 RP11-196G11.2 -5.42 1.54e-07 0.000153 -0.37 -0.34 Dementia with Lewy bodies; chr16:30905109 chr16:31043150~31049868:+ CESC cis rs7048146 0.932 rs1576590 ENSG00000213539.4 YBX1P6 5.42 1.55e-07 0.000153 0.41 0.34 Vascular brain injury; chr9:109542883 chr9:109532830~109534332:- CESC cis rs34779708 0.931 rs4934721 ENSG00000230534.5 RP11-297A16.2 5.42 1.55e-07 0.000153 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35088787 chr10:35098006~35127020:- CESC cis rs9545047 0.604 rs1028770 ENSG00000227676.3 LINC01068 -5.42 1.55e-07 0.000153 -0.38 -0.34 Schizophrenia; chr13:79297346 chr13:79566727~79571436:+ CESC cis rs62229266 0.659 rs2255734 ENSG00000231106.2 LINC01436 5.42 1.56e-07 0.000154 0.47 0.34 Mitral valve prolapse; chr21:36039611 chr21:36005338~36007838:+ CESC cis rs748404 0.66 rs690512 ENSG00000249839.1 AC011330.5 -5.42 1.56e-07 0.000154 -0.36 -0.34 Lung cancer; chr15:43425480 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs542898 ENSG00000249839.1 AC011330.5 -5.42 1.56e-07 0.000154 -0.36 -0.34 Lung cancer; chr15:43427194 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs2249952 ENSG00000249839.1 AC011330.5 -5.42 1.56e-07 0.000154 -0.36 -0.34 Lung cancer; chr15:43428335 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs689767 ENSG00000249839.1 AC011330.5 -5.42 1.56e-07 0.000154 -0.36 -0.34 Lung cancer; chr15:43429879 chr15:43663654~43684339:- CESC cis rs17608059 0.518 rs4792436 ENSG00000141028.6 CDRT15P1 5.42 1.56e-07 0.000154 0.36 0.34 Temperament; chr17:14068990 chr17:14024514~14025488:+ CESC cis rs35160687 0.798 rs6547674 ENSG00000273080.1 RP11-301O19.1 -5.42 1.56e-07 0.000154 -0.4 -0.34 Night sleep phenotypes; chr2:86325796 chr2:86195590~86196049:+ CESC cis rs35160687 0.798 rs11127029 ENSG00000273080.1 RP11-301O19.1 -5.42 1.56e-07 0.000154 -0.4 -0.34 Night sleep phenotypes; chr2:86327502 chr2:86195590~86196049:+ CESC cis rs6504622 0.755 rs7219544 ENSG00000262879.4 RP11-156P1.3 -5.42 1.56e-07 0.000154 -0.37 -0.34 Orofacial clefts; chr17:47089562 chr17:46984045~47100323:- CESC cis rs42490 0.576 rs376962 ENSG00000251136.7 RP11-37B2.1 -5.42 1.57e-07 0.000154 -0.35 -0.34 Leprosy; chr8:89862004 chr8:89609409~89757727:- CESC cis rs9322193 0.923 rs2342765 ENSG00000216906.2 RP11-350J20.9 5.42 1.57e-07 0.000155 0.39 0.34 Lung cancer; chr6:149858873 chr6:149904243~149906418:+ CESC cis rs11846409 0.86 rs61686131 ENSG00000211974.3 IGHV2-70 -5.42 1.57e-07 0.000155 -0.45 -0.34 Rheumatic heart disease; chr14:106631568 chr14:106723574~106724093:- CESC cis rs7396835 0.551 rs10750098 ENSG00000254851.1 RP11-109L13.1 -5.42 1.57e-07 0.000155 -0.56 -0.34 Quantitative traits; chr11:116834852 chr11:117135528~117138582:+ CESC cis rs9907295 1 rs11080361 ENSG00000270977.1 AC015849.16 -5.42 1.57e-07 0.000155 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35916184 chr17:35893707~35911023:- CESC cis rs9907295 1 rs11080362 ENSG00000270977.1 AC015849.16 -5.42 1.57e-07 0.000155 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35916224 chr17:35893707~35911023:- CESC cis rs9907295 1 rs16971670 ENSG00000270977.1 AC015849.16 -5.42 1.57e-07 0.000155 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35916548 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9896658 ENSG00000270977.1 AC015849.16 -5.42 1.57e-07 0.000155 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35916758 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9894314 ENSG00000270977.1 AC015849.16 -5.42 1.57e-07 0.000155 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35916822 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9897095 ENSG00000270977.1 AC015849.16 -5.42 1.57e-07 0.000155 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35916928 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9896265 ENSG00000270977.1 AC015849.16 -5.42 1.57e-07 0.000155 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35916930 chr17:35893707~35911023:- CESC cis rs143626010 1 rs143626010 ENSG00000259982.1 CDC37P1 5.42 1.57e-07 0.000155 0.44 0.34 Mosquito bite size; chr16:28528081 chr16:28700294~28701540:- CESC cis rs1862618 0.573 rs2034245 ENSG00000271828.1 CTD-2310F14.1 -5.42 1.57e-07 0.000155 -0.47 -0.34 Initial pursuit acceleration; chr5:56947858 chr5:56927874~56929573:+ CESC cis rs801193 0.569 rs2659908 ENSG00000232559.3 GS1-124K5.12 5.42 1.58e-07 0.000155 0.37 0.34 Aortic root size; chr7:66695835 chr7:66554588~66576923:- CESC cis rs801193 0.527 rs2707837 ENSG00000232559.3 GS1-124K5.12 5.42 1.58e-07 0.000155 0.37 0.34 Aortic root size; chr7:66716086 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs2707824 ENSG00000232559.3 GS1-124K5.12 5.42 1.58e-07 0.000155 0.37 0.34 Aortic root size; chr7:66724256 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs2659893 ENSG00000232559.3 GS1-124K5.12 5.42 1.58e-07 0.000155 0.37 0.34 Aortic root size; chr7:66735006 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs2659892 ENSG00000232559.3 GS1-124K5.12 5.42 1.58e-07 0.000155 0.37 0.34 Aortic root size; chr7:66735318 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs2707847 ENSG00000232559.3 GS1-124K5.12 5.42 1.58e-07 0.000155 0.37 0.34 Aortic root size; chr7:66737884 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs881285 ENSG00000232559.3 GS1-124K5.12 -5.42 1.58e-07 0.000155 -0.37 -0.34 Aortic root size; chr7:66654433 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs3846973 ENSG00000232559.3 GS1-124K5.12 -5.42 1.58e-07 0.000155 -0.37 -0.34 Aortic root size; chr7:66655048 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs2013908 ENSG00000232559.3 GS1-124K5.12 -5.42 1.58e-07 0.000155 -0.37 -0.34 Aortic root size; chr7:66656082 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs6951302 ENSG00000232559.3 GS1-124K5.12 -5.42 1.58e-07 0.000155 -0.37 -0.34 Aortic root size; chr7:66667525 chr7:66554588~66576923:- CESC cis rs1799949 0.965 rs8176161 ENSG00000267681.1 CTD-3199J23.6 -5.42 1.58e-07 0.000155 -0.44 -0.34 Menopause (age at onset); chr17:43089373 chr17:43144956~43145255:+ CESC cis rs1799949 0.894 rs8176160 ENSG00000267681.1 CTD-3199J23.6 -5.42 1.58e-07 0.000155 -0.44 -0.34 Menopause (age at onset); chr17:43089486 chr17:43144956~43145255:+ CESC cis rs1799949 0.896 rs35908185 ENSG00000267681.1 CTD-3199J23.6 -5.42 1.58e-07 0.000155 -0.44 -0.34 Menopause (age at onset); chr17:43103094 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs8176130 ENSG00000267681.1 CTD-3199J23.6 -5.42 1.58e-07 0.000155 -0.44 -0.34 Menopause (age at onset); chr17:43106026 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176120 ENSG00000267681.1 CTD-3199J23.6 -5.42 1.58e-07 0.000155 -0.44 -0.34 Menopause (age at onset); chr17:43109216 chr17:43144956~43145255:+ CESC cis rs897984 0.762 rs2305880 ENSG00000260911.2 RP11-196G11.2 -5.42 1.58e-07 0.000155 -0.38 -0.34 Dementia with Lewy bodies; chr16:30988141 chr16:31043150~31049868:+ CESC cis rs897984 0.759 rs13708 ENSG00000260911.2 RP11-196G11.2 -5.42 1.58e-07 0.000155 -0.38 -0.34 Dementia with Lewy bodies; chr16:30989488 chr16:31043150~31049868:+ CESC cis rs67180937 0.961 rs17163363 ENSG00000272750.1 RP11-378J18.8 -5.42 1.58e-07 0.000155 -0.43 -0.34 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222655362 chr1:222658867~222661512:- CESC cis rs875971 0.54 rs1723268 ENSG00000164669.11 INTS4P1 -5.42 1.58e-07 0.000156 -0.47 -0.34 Aortic root size; chr7:66008093 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs2707844 ENSG00000228409.4 CCT6P1 5.42 1.58e-07 0.000156 0.52 0.34 Diabetic kidney disease; chr7:66594522 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1796220 ENSG00000228409.4 CCT6P1 5.42 1.58e-07 0.000156 0.52 0.34 Diabetic kidney disease; chr7:66597113 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs2707831 ENSG00000228409.4 CCT6P1 5.42 1.58e-07 0.000156 0.52 0.34 Diabetic kidney disease; chr7:66597524 chr7:65751142~65763354:+ CESC cis rs453301 0.538 rs7830804 ENSG00000253893.2 FAM85B 5.42 1.58e-07 0.000156 0.43 0.34 Joint mobility (Beighton score); chr8:9113252 chr8:8167819~8226614:- CESC cis rs34779708 0.931 rs4934731 ENSG00000230534.5 RP11-297A16.2 5.42 1.59e-07 0.000156 0.46 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35142708 chr10:35098006~35127020:- CESC cis rs11096990 0.656 rs6531709 ENSG00000249207.1 RP11-360F5.1 5.42 1.59e-07 0.000156 0.37 0.34 Cognitive function; chr4:39300629 chr4:39112677~39126818:- CESC cis rs11096990 0.656 rs6531710 ENSG00000249207.1 RP11-360F5.1 5.42 1.59e-07 0.000156 0.37 0.34 Cognitive function; chr4:39300658 chr4:39112677~39126818:- CESC cis rs11096990 0.656 rs3733284 ENSG00000249207.1 RP11-360F5.1 5.42 1.59e-07 0.000156 0.36 0.34 Cognitive function; chr4:39299714 chr4:39112677~39126818:- CESC cis rs67180937 0.921 rs35700460 ENSG00000272750.1 RP11-378J18.8 -5.42 1.59e-07 0.000156 -0.43 -0.34 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222638065 chr1:222658867~222661512:- CESC cis rs2243480 1 rs316307 ENSG00000232559.3 GS1-124K5.12 5.42 1.59e-07 0.000156 0.59 0.34 Diabetic kidney disease; chr7:66105184 chr7:66554588~66576923:- CESC cis rs2739330 0.828 rs2186366 ENSG00000231271.1 AP000350.8 -5.42 1.59e-07 0.000156 -0.41 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23949918~23954042:+ CESC cis rs9322193 0.923 rs12660304 ENSG00000268592.3 RAET1E-AS1 5.42 1.59e-07 0.000156 0.44 0.34 Lung cancer; chr6:149739647 chr6:149863494~149919507:+ CESC cis rs67180937 0.961 rs17011681 ENSG00000272750.1 RP11-378J18.8 -5.42 1.59e-07 0.000156 -0.43 -0.34 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222651746 chr1:222658867~222661512:- CESC cis rs67180937 0.921 rs2291834 ENSG00000272750.1 RP11-378J18.8 -5.42 1.6e-07 0.000157 -0.43 -0.34 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222658953 chr1:222658867~222661512:- CESC cis rs801193 0.569 rs4717315 ENSG00000237310.1 GS1-124K5.4 5.42 1.6e-07 0.000157 0.33 0.34 Aortic root size; chr7:66713338 chr7:66493706~66495474:+ CESC cis rs801193 0.548 rs2659891 ENSG00000237310.1 GS1-124K5.4 5.42 1.6e-07 0.000157 0.33 0.34 Aortic root size; chr7:66736127 chr7:66493706~66495474:+ CESC cis rs801193 0.548 rs7805152 ENSG00000237310.1 GS1-124K5.4 5.42 1.6e-07 0.000157 0.33 0.34 Aortic root size; chr7:66744266 chr7:66493706~66495474:+ CESC cis rs1062177 0.855 rs6892117 ENSG00000253921.1 CTB-113P19.3 5.42 1.6e-07 0.000157 0.42 0.34 Preschool internalizing problems; chr5:151885424 chr5:151753992~151767247:+ CESC cis rs2243480 0.901 rs13237344 ENSG00000228409.4 CCT6P1 5.42 1.6e-07 0.000157 0.52 0.34 Diabetic kidney disease; chr7:66557269 chr7:65751142~65763354:+ CESC cis rs11676348 0.846 rs7607437 ENSG00000261338.2 RP11-378A13.1 -5.42 1.6e-07 0.000157 -0.41 -0.34 Ulcerative colitis; chr2:218143669 chr2:218255319~218257366:+ CESC cis rs801193 0.569 rs11761542 ENSG00000232559.3 GS1-124K5.12 5.42 1.61e-07 0.000158 0.38 0.34 Aortic root size; chr7:66753209 chr7:66554588~66576923:- CESC cis rs1891275 0.551 rs4933684 ENSG00000228701.1 TNKS2-AS1 -5.42 1.61e-07 0.000158 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91647805 chr10:91782839~91798291:- CESC cis rs11651753 0.636 rs4793731 ENSG00000264920.1 RP11-6N17.4 -5.42 1.61e-07 0.000158 -0.39 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47956327 chr17:47891255~47895812:- CESC cis rs11651753 0.636 rs4793733 ENSG00000264920.1 RP11-6N17.4 -5.42 1.61e-07 0.000158 -0.39 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47956616 chr17:47891255~47895812:- CESC cis rs11651753 0.636 rs35280206 ENSG00000264920.1 RP11-6N17.4 -5.42 1.61e-07 0.000158 -0.39 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47957645 chr17:47891255~47895812:- CESC cis rs748404 0.631 rs3809482 ENSG00000249839.1 AC011330.5 -5.42 1.61e-07 0.000158 -0.36 -0.34 Lung cancer; chr15:43369604 chr15:43663654~43684339:- CESC cis rs14027 0.64 rs6994604 ENSG00000279347.1 RP11-85I17.2 -5.42 1.61e-07 0.000158 -0.33 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119746463 chr8:119838736~119840385:- CESC cis rs14027 0.64 rs7837213 ENSG00000279347.1 RP11-85I17.2 -5.42 1.61e-07 0.000158 -0.33 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119750459 chr8:119838736~119840385:- CESC cis rs14027 0.596 rs28576821 ENSG00000279347.1 RP11-85I17.2 -5.42 1.61e-07 0.000158 -0.33 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119752777 chr8:119838736~119840385:- CESC cis rs14027 0.64 rs16893109 ENSG00000279347.1 RP11-85I17.2 -5.42 1.61e-07 0.000158 -0.33 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119756309 chr8:119838736~119840385:- CESC cis rs14027 0.64 rs7011974 ENSG00000279347.1 RP11-85I17.2 -5.42 1.61e-07 0.000158 -0.33 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119759623 chr8:119838736~119840385:- CESC cis rs14027 0.64 rs9693207 ENSG00000279347.1 RP11-85I17.2 -5.42 1.61e-07 0.000158 -0.33 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119759815 chr8:119838736~119840385:- CESC cis rs875971 0.756 rs2901210 ENSG00000237310.1 GS1-124K5.4 -5.41 1.61e-07 0.000158 -0.33 -0.34 Aortic root size; chr7:66552518 chr7:66493706~66495474:+ CESC cis rs1823913 0.637 rs979967 ENSG00000280083.1 RP11-317J9.1 -5.41 1.61e-07 0.000158 -0.4 -0.34 Obesity-related traits; chr2:191304695 chr2:191154118~191156070:- CESC cis rs9322193 0.566 rs4870118 ENSG00000231760.4 RP11-350J20.5 -5.41 1.62e-07 0.000158 -0.52 -0.34 Lung cancer; chr6:149923877 chr6:149796151~149826294:- CESC cis rs9322193 0.566 rs4869767 ENSG00000231760.4 RP11-350J20.5 -5.41 1.62e-07 0.000158 -0.52 -0.34 Lung cancer; chr6:149923974 chr6:149796151~149826294:- CESC cis rs9322193 0.566 rs4869768 ENSG00000231760.4 RP11-350J20.5 -5.41 1.62e-07 0.000158 -0.52 -0.34 Lung cancer; chr6:149924067 chr6:149796151~149826294:- CESC cis rs42490 0.576 rs432457 ENSG00000251136.7 RP11-37B2.1 -5.41 1.62e-07 0.000159 -0.35 -0.34 Leprosy; chr8:89853680 chr8:89609409~89757727:- CESC cis rs2906856 0.526 rs2906852 ENSG00000255733.4 IFNG-AS1 5.41 1.62e-07 0.000159 0.38 0.34 Mosquito bite size; chr12:67985701 chr12:67989445~68234686:+ CESC cis rs748404 0.646 rs2253268 ENSG00000249839.1 AC011330.5 -5.41 1.62e-07 0.000159 -0.37 -0.34 Lung cancer; chr15:43508770 chr15:43663654~43684339:- CESC cis rs9322193 0.923 rs12205092 ENSG00000268592.3 RAET1E-AS1 5.41 1.63e-07 0.000159 0.46 0.34 Lung cancer; chr6:149761375 chr6:149863494~149919507:+ CESC cis rs1823913 0.599 rs7598639 ENSG00000280083.1 RP11-317J9.1 -5.41 1.63e-07 0.000159 -0.4 -0.34 Obesity-related traits; chr2:191267958 chr2:191154118~191156070:- CESC cis rs10129255 0.536 rs10139058 ENSG00000211972.2 IGHV3-66 5.41 1.63e-07 0.000159 0.24 0.34 Kawasaki disease; chr14:106685899 chr14:106675017~106675544:- CESC cis rs10129255 0.536 rs8004835 ENSG00000211972.2 IGHV3-66 5.41 1.63e-07 0.000159 0.24 0.34 Kawasaki disease; chr14:106686361 chr14:106675017~106675544:- CESC cis rs11651753 0.598 rs4794286 ENSG00000264920.1 RP11-6N17.4 -5.41 1.63e-07 0.000159 -0.4 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47913231 chr17:47891255~47895812:- CESC cis rs7189233 0.531 rs11859538 ENSG00000279344.1 RP11-44F14.7 5.41 1.63e-07 0.00016 0.32 0.34 Intelligence (multi-trait analysis); chr16:53463133 chr16:53478957~53481550:- CESC cis rs6991838 0.798 rs6994889 ENSG00000200714.1 Y_RNA 5.41 1.63e-07 0.00016 0.4 0.34 Intelligence (multi-trait analysis); chr8:65562547 chr8:65592731~65592820:+ CESC cis rs10515750 0.643 rs10054755 ENSG00000251405.2 CTB-109A12.1 5.41 1.64e-07 0.00016 0.75 0.34 Lung function (FEV1/FVC); chr5:157384037 chr5:157362615~157460078:- CESC cis rs10515750 0.643 rs10063539 ENSG00000251405.2 CTB-109A12.1 5.41 1.64e-07 0.00016 0.75 0.34 Lung function (FEV1/FVC); chr5:157384666 chr5:157362615~157460078:- CESC cis rs748404 0.516 rs523156 ENSG00000249839.1 AC011330.5 5.41 1.64e-07 0.00016 0.38 0.34 Lung cancer; chr15:43519645 chr15:43663654~43684339:- CESC cis rs9545047 0.604 rs7996652 ENSG00000227676.3 LINC01068 5.41 1.64e-07 0.000161 0.39 0.34 Schizophrenia; chr13:79341474 chr13:79566727~79571436:+ CESC cis rs7572733 0.935 rs10048735 ENSG00000222017.1 AC011997.1 5.41 1.64e-07 0.000161 0.38 0.34 Dermatomyositis; chr2:197877801 chr2:197693106~197774823:+ CESC cis rs950169 1 rs11638394 ENSG00000225151.9 GOLGA2P7 -5.41 1.64e-07 0.000161 -0.49 -0.34 Schizophrenia; chr15:84110176 chr15:84199311~84230136:- CESC cis rs2108622 0.727 rs9305069 ENSG00000267453.5 AC004791.2 -5.41 1.64e-07 0.000161 -0.43 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872576 chr19:15851993~15864904:- CESC cis rs801193 0.569 rs2659907 ENSG00000237310.1 GS1-124K5.4 5.41 1.64e-07 0.000161 0.33 0.34 Aortic root size; chr7:66699045 chr7:66493706~66495474:+ CESC cis rs2842992 0.789 rs2475566 ENSG00000237927.1 RP3-393E18.2 -5.41 1.64e-07 0.000161 -0.46 -0.34 Age-related macular degeneration (geographic atrophy); chr6:159727709 chr6:159586955~159589169:- CESC cis rs875971 0.862 rs880166 ENSG00000222364.1 RNU6-96P 5.41 1.65e-07 0.000161 0.4 0.34 Aortic root size; chr7:66205775 chr7:66395191~66395286:+ CESC cis rs748404 0.69 rs2244981 ENSG00000249839.1 AC011330.5 -5.41 1.65e-07 0.000161 -0.35 -0.34 Lung cancer; chr15:43460553 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs694725 ENSG00000249839.1 AC011330.5 -5.41 1.65e-07 0.000161 -0.35 -0.34 Lung cancer; chr15:43464012 chr15:43663654~43684339:- CESC cis rs1023500 0.505 rs134885 ENSG00000273366.1 CTA-989H11.1 -5.41 1.66e-07 0.000162 -0.42 -0.34 Schizophrenia; chr22:42277805 chr22:42278188~42278846:+ CESC cis rs1823913 0.599 rs13399251 ENSG00000280083.1 RP11-317J9.1 -5.41 1.66e-07 0.000162 -0.4 -0.34 Obesity-related traits; chr2:191268758 chr2:191154118~191156070:- CESC cis rs9322193 0.923 rs6913486 ENSG00000268592.3 RAET1E-AS1 -5.41 1.66e-07 0.000162 -0.46 -0.34 Lung cancer; chr6:149705060 chr6:149863494~149919507:+ CESC cis rs62229266 0.659 rs2835242 ENSG00000231106.2 LINC01436 5.41 1.66e-07 0.000162 0.47 0.34 Mitral valve prolapse; chr21:36041234 chr21:36005338~36007838:+ CESC cis rs10256972 0.869 rs1007766 ENSG00000229043.2 AC091729.9 -5.41 1.66e-07 0.000162 -0.4 -0.34 Endometriosis;Longevity; chr7:995267 chr7:1160374~1165267:+ CESC cis rs1062177 0.756 rs2915815 ENSG00000253921.1 CTB-113P19.3 5.41 1.67e-07 0.000163 0.47 0.34 Preschool internalizing problems; chr5:151736322 chr5:151753992~151767247:+ CESC cis rs875971 0.862 rs801195 ENSG00000237310.1 GS1-124K5.4 -5.41 1.67e-07 0.000163 -0.33 -0.34 Aortic root size; chr7:66561128 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs801194 ENSG00000237310.1 GS1-124K5.4 -5.41 1.67e-07 0.000163 -0.33 -0.34 Aortic root size; chr7:66563508 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs2024192 ENSG00000237310.1 GS1-124K5.4 -5.41 1.67e-07 0.000163 -0.33 -0.34 Aortic root size; chr7:66576460 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6955837 ENSG00000237310.1 GS1-124K5.4 -5.41 1.67e-07 0.000163 -0.33 -0.34 Aortic root size; chr7:66578155 chr7:66493706~66495474:+ CESC cis rs875971 0.825 rs10281499 ENSG00000237310.1 GS1-124K5.4 -5.41 1.67e-07 0.000163 -0.33 -0.34 Aortic root size; chr7:66583979 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs4718377 ENSG00000237310.1 GS1-124K5.4 -5.41 1.67e-07 0.000163 -0.33 -0.34 Aortic root size; chr7:66584691 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs10278014 ENSG00000237310.1 GS1-124K5.4 -5.41 1.67e-07 0.000163 -0.33 -0.34 Aortic root size; chr7:66586277 chr7:66493706~66495474:+ CESC cis rs11651753 0.561 rs4794261 ENSG00000264920.1 RP11-6N17.4 -5.41 1.67e-07 0.000163 -0.4 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47904980 chr17:47891255~47895812:- CESC cis rs11651753 0.561 rs1108833 ENSG00000264920.1 RP11-6N17.4 -5.41 1.67e-07 0.000163 -0.4 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47905431 chr17:47891255~47895812:- CESC cis rs11651753 0.561 rs7211859 ENSG00000264920.1 RP11-6N17.4 -5.41 1.67e-07 0.000163 -0.4 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47908916 chr17:47891255~47895812:- CESC cis rs2108622 0.711 rs113059233 ENSG00000267453.5 AC004791.2 -5.41 1.67e-07 0.000163 -0.42 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866558 chr19:15851993~15864904:- CESC cis rs957448 1 rs10956915 ENSG00000253704.1 RP11-267M23.4 5.41 1.67e-07 0.000163 0.39 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94502362 chr8:94553722~94569745:+ CESC cis rs2243480 1 rs73142122 ENSG00000228409.4 CCT6P1 5.41 1.67e-07 0.000163 0.5 0.34 Diabetic kidney disease; chr7:65846311 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs73142137 ENSG00000228409.4 CCT6P1 5.41 1.67e-07 0.000163 0.5 0.34 Diabetic kidney disease; chr7:65878455 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs13247184 ENSG00000228409.4 CCT6P1 5.41 1.67e-07 0.000163 0.5 0.34 Diabetic kidney disease; chr7:65893941 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35283677 ENSG00000228409.4 CCT6P1 5.41 1.67e-07 0.000163 0.5 0.34 Diabetic kidney disease; chr7:65894246 chr7:65751142~65763354:+ CESC cis rs13108904 0.65 rs3796618 ENSG00000253399.1 AC078852.2 -5.41 1.67e-07 0.000163 -0.43 -0.34 Obesity-related traits; chr4:1355814 chr4:1358479~1359461:+ CESC cis rs6782228 0.675 rs9813845 ENSG00000242551.2 POU5F1P6 -5.41 1.68e-07 0.000163 -0.39 -0.34 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128680780 chr3:128674735~128677005:- CESC cis rs8059260 0.736 rs8049278 ENSG00000274038.1 RP11-66H6.4 -5.41 1.68e-07 0.000163 -0.56 -0.34 Alcohol consumption over the past year; chr16:10968766 chr16:11056556~11057034:+ CESC cis rs10256972 0.621 rs2280725 ENSG00000229043.2 AC091729.9 -5.41 1.68e-07 0.000163 -0.38 -0.34 Endometriosis;Longevity; chr7:1047790 chr7:1160374~1165267:+ CESC cis rs10256972 0.621 rs10951594 ENSG00000229043.2 AC091729.9 -5.41 1.68e-07 0.000163 -0.38 -0.34 Endometriosis;Longevity; chr7:1048971 chr7:1160374~1165267:+ CESC cis rs875971 0.862 rs1983372 ENSG00000222364.1 RNU6-96P 5.41 1.68e-07 0.000163 0.4 0.34 Aortic root size; chr7:66146364 chr7:66395191~66395286:+ CESC cis rs34779708 0.742 rs35912711 ENSG00000230534.5 RP11-297A16.2 5.41 1.68e-07 0.000164 0.46 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35024068 chr10:35098006~35127020:- CESC cis rs11723261 0.582 rs6830247 ENSG00000211553.1 AC253576.2 -5.41 1.68e-07 0.000164 -0.5 -0.34 Immune response to smallpox vaccine (IL-6); chr4:156885 chr4:136461~136568:+ CESC cis rs2177312 0.868 rs1523175 ENSG00000251129.1 RP11-734I18.1 -5.41 1.68e-07 0.000164 -0.42 -0.34 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31950071 chr4:31997397~32155406:+ CESC cis rs62229266 0.659 rs2835245 ENSG00000231106.2 LINC01436 5.41 1.69e-07 0.000164 0.46 0.34 Mitral valve prolapse; chr21:36044410 chr21:36005338~36007838:+ CESC cis rs62229266 0.659 rs7275820 ENSG00000231106.2 LINC01436 5.41 1.69e-07 0.000164 0.47 0.34 Mitral valve prolapse; chr21:36037116 chr21:36005338~36007838:+ CESC cis rs62229266 0.652 rs7280551 ENSG00000231106.2 LINC01436 5.41 1.69e-07 0.000164 0.47 0.34 Mitral valve prolapse; chr21:36037311 chr21:36005338~36007838:+ CESC cis rs62229266 0.659 rs2835258 ENSG00000231106.2 LINC01436 5.41 1.69e-07 0.000165 0.46 0.34 Mitral valve prolapse; chr21:36052067 chr21:36005338~36007838:+ CESC cis rs950169 1 rs35297609 ENSG00000225151.9 GOLGA2P7 -5.41 1.69e-07 0.000165 -0.49 -0.34 Schizophrenia; chr15:84104144 chr15:84199311~84230136:- CESC cis rs950169 1 rs62026530 ENSG00000225151.9 GOLGA2P7 -5.41 1.69e-07 0.000165 -0.49 -0.34 Schizophrenia; chr15:84107088 chr15:84199311~84230136:- CESC cis rs765787 0.53 rs12904331 ENSG00000259520.4 CTD-2651B20.3 -5.41 1.69e-07 0.000165 -0.44 -0.34 Uric acid levels; chr15:45226095 chr15:45251580~45279251:- CESC cis rs7048146 1 rs7046565 ENSG00000213539.4 YBX1P6 5.4 1.7e-07 0.000165 0.4 0.34 Vascular brain injury; chr9:109539940 chr9:109532830~109534332:- CESC cis rs801193 0.569 rs2659908 ENSG00000237310.1 GS1-124K5.4 5.4 1.7e-07 0.000165 0.33 0.34 Aortic root size; chr7:66695835 chr7:66493706~66495474:+ CESC cis rs801193 0.527 rs2707837 ENSG00000237310.1 GS1-124K5.4 5.4 1.7e-07 0.000165 0.33 0.34 Aortic root size; chr7:66716086 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs2707824 ENSG00000237310.1 GS1-124K5.4 5.4 1.7e-07 0.000165 0.33 0.34 Aortic root size; chr7:66724256 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs2659893 ENSG00000237310.1 GS1-124K5.4 5.4 1.7e-07 0.000165 0.33 0.34 Aortic root size; chr7:66735006 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs2659892 ENSG00000237310.1 GS1-124K5.4 5.4 1.7e-07 0.000165 0.33 0.34 Aortic root size; chr7:66735318 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs2707847 ENSG00000237310.1 GS1-124K5.4 5.4 1.7e-07 0.000165 0.33 0.34 Aortic root size; chr7:66737884 chr7:66493706~66495474:+ CESC cis rs6142102 0.923 rs3787230 ENSG00000276073.1 RP5-1125A11.7 -5.4 1.7e-07 0.000165 -0.32 -0.34 Skin pigmentation; chr20:34052466 chr20:33985617~33988989:- CESC cis rs9545047 0.604 rs7981067 ENSG00000227676.3 LINC01068 5.4 1.7e-07 0.000165 0.39 0.34 Schizophrenia; chr13:79341254 chr13:79566727~79571436:+ CESC cis rs6991838 0.798 rs6994889 ENSG00000272010.1 CTD-3025N20.3 5.4 1.71e-07 0.000166 0.37 0.34 Intelligence (multi-trait analysis); chr8:65562547 chr8:65591850~65592472:- CESC cis rs7048146 0.966 rs1411691 ENSG00000213539.4 YBX1P6 5.4 1.71e-07 0.000166 0.4 0.34 Vascular brain injury; chr9:109542444 chr9:109532830~109534332:- CESC cis rs801193 0.569 rs35070132 ENSG00000232559.3 GS1-124K5.12 5.4 1.71e-07 0.000166 0.38 0.34 Aortic root size; chr7:66773096 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs778730 ENSG00000228409.4 CCT6P1 5.4 1.72e-07 0.000167 0.52 0.34 Diabetic kidney disease; chr7:66358338 chr7:65751142~65763354:+ CESC cis rs8059260 0.668 rs74737820 ENSG00000274038.1 RP11-66H6.4 -5.4 1.72e-07 0.000167 -0.57 -0.34 Alcohol consumption over the past year; chr16:10972240 chr16:11056556~11057034:+ CESC cis rs875971 0.862 rs908915 ENSG00000222364.1 RNU6-96P 5.4 1.72e-07 0.000167 0.39 0.34 Aortic root size; chr7:66149664 chr7:66395191~66395286:+ CESC cis rs801193 0.591 rs4506088 ENSG00000237310.1 GS1-124K5.4 -5.4 1.73e-07 0.000168 -0.33 -0.34 Aortic root size; chr7:66670470 chr7:66493706~66495474:+ CESC cis rs2117029 1 rs11168827 ENSG00000258017.1 RP11-386G11.10 5.4 1.73e-07 0.000168 0.45 0.34 Intelligence (multi-trait analysis); chr12:49025894 chr12:49127782~49147869:+ CESC cis rs7189233 0.531 rs8056349 ENSG00000279344.1 RP11-44F14.7 5.4 1.73e-07 0.000168 0.32 0.34 Intelligence (multi-trait analysis); chr16:53434114 chr16:53478957~53481550:- CESC cis rs2243480 0.901 rs13237344 ENSG00000275400.1 RP4-756H11.5 5.4 1.74e-07 0.000168 0.6 0.34 Diabetic kidney disease; chr7:66557269 chr7:66553805~66554199:- CESC cis rs875971 0.862 rs13536 ENSG00000237310.1 GS1-124K5.4 -5.4 1.74e-07 0.000169 -0.33 -0.34 Aortic root size; chr7:66554203 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs801209 ENSG00000237310.1 GS1-124K5.4 -5.4 1.74e-07 0.000169 -0.33 -0.34 Aortic root size; chr7:66554403 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs801206 ENSG00000237310.1 GS1-124K5.4 -5.4 1.74e-07 0.000169 -0.33 -0.34 Aortic root size; chr7:66556979 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs801204 ENSG00000237310.1 GS1-124K5.4 -5.4 1.74e-07 0.000169 -0.33 -0.34 Aortic root size; chr7:66557934 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs801203 ENSG00000237310.1 GS1-124K5.4 -5.4 1.74e-07 0.000169 -0.33 -0.34 Aortic root size; chr7:66558025 chr7:66493706~66495474:+ CESC cis rs875971 0.825 rs801202 ENSG00000237310.1 GS1-124K5.4 -5.4 1.74e-07 0.000169 -0.33 -0.34 Aortic root size; chr7:66558942 chr7:66493706~66495474:+ CESC cis rs897984 0.76 rs11076 ENSG00000260911.2 RP11-196G11.2 -5.4 1.74e-07 0.000169 -0.38 -0.34 Dementia with Lewy bodies; chr16:30984207 chr16:31043150~31049868:+ CESC cis rs2028299 0.92 rs8027198 ENSG00000259677.1 RP11-493E3.1 5.4 1.74e-07 0.000169 0.48 0.34 Type 2 diabetes; chr15:89883457 chr15:89876540~89877285:+ CESC cis rs7714584 1 rs11739677 ENSG00000197083.10 ZNF300P1 5.4 1.75e-07 0.000169 0.71 0.34 Crohn's disease; chr5:150915321 chr5:150930645~150946289:- CESC cis rs9545047 0.604 rs9574406 ENSG00000227676.3 LINC01068 -5.4 1.75e-07 0.000169 -0.39 -0.34 Schizophrenia; chr13:79338982 chr13:79566727~79571436:+ CESC cis rs2243480 0.908 rs55876148 ENSG00000228409.4 CCT6P1 5.4 1.75e-07 0.000169 0.52 0.34 Diabetic kidney disease; chr7:65914813 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs56016656 ENSG00000228409.4 CCT6P1 5.4 1.75e-07 0.000169 0.52 0.34 Diabetic kidney disease; chr7:65918494 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs56291018 ENSG00000228409.4 CCT6P1 5.4 1.75e-07 0.000169 0.52 0.34 Diabetic kidney disease; chr7:65925352 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs36033484 ENSG00000228409.4 CCT6P1 5.4 1.75e-07 0.000169 0.52 0.34 Diabetic kidney disease; chr7:65925571 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34560516 ENSG00000228409.4 CCT6P1 5.4 1.75e-07 0.000169 0.52 0.34 Diabetic kidney disease; chr7:65939105 chr7:65751142~65763354:+ CESC cis rs9322193 0.566 rs3922947 ENSG00000231760.4 RP11-350J20.5 -5.4 1.75e-07 0.00017 -0.5 -0.34 Lung cancer; chr6:149924856 chr6:149796151~149826294:- CESC cis rs2439831 0.867 rs2614811 ENSG00000275601.1 AC011330.13 -5.4 1.76e-07 0.00017 -0.49 -0.34 Lung cancer in ever smokers; chr15:43621289 chr15:43642389~43643023:- CESC cis rs748404 0.578 rs4547312 ENSG00000249839.1 AC011330.5 -5.4 1.76e-07 0.00017 -0.36 -0.34 Lung cancer; chr15:43339940 chr15:43663654~43684339:- CESC cis rs957448 0.554 rs12680855 ENSG00000253704.1 RP11-267M23.4 5.4 1.76e-07 0.000171 0.35 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94570427 chr8:94553722~94569745:+ CESC cis rs6723162 0.965 rs7594319 ENSG00000237751.2 LINC01143 -5.4 1.77e-07 0.000171 -0.42 -0.34 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70891627 chr2:70887871~70889959:+ CESC cis rs1499614 1 rs1638731 ENSG00000275400.1 RP4-756H11.5 5.4 1.77e-07 0.000171 0.6 0.34 Gout; chr7:66679692 chr7:66553805~66554199:- CESC cis rs7727544 0.684 rs272874 ENSG00000233006.5 AC034220.3 -5.4 1.77e-07 0.000171 -0.44 -0.34 Blood metabolite levels; chr5:132339353 chr5:132311285~132369916:- CESC cis rs8072100 0.87 rs10432035 ENSG00000228782.6 CTD-2026D20.3 -5.4 1.77e-07 0.000171 -0.4 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47547547 chr17:47450568~47492492:- CESC cis rs34779708 0.966 rs34776628 ENSG00000230534.5 RP11-297A16.2 5.4 1.78e-07 0.000172 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35137396 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs17499247 ENSG00000230534.5 RP11-297A16.2 5.4 1.78e-07 0.000172 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35137827 chr10:35098006~35127020:- CESC cis rs34779708 0.966 rs10827491 ENSG00000230534.5 RP11-297A16.2 5.4 1.78e-07 0.000172 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35138467 chr10:35098006~35127020:- CESC cis rs4660456 0.826 rs2744802 ENSG00000237899.1 RP4-739H11.3 5.4 1.78e-07 0.000172 0.46 0.34 Platelet count; chr1:40687577 chr1:40669089~40687588:- CESC cis rs11676348 0.729 rs13013361 ENSG00000261338.2 RP11-378A13.1 -5.4 1.78e-07 0.000172 -0.4 -0.34 Ulcerative colitis; chr2:218082792 chr2:218255319~218257366:+ CESC cis rs2243480 0.615 rs34363376 ENSG00000232559.3 GS1-124K5.12 5.4 1.78e-07 0.000172 0.6 0.34 Diabetic kidney disease; chr7:66474549 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35421653 ENSG00000228409.4 CCT6P1 5.39 1.78e-07 0.000172 0.51 0.34 Diabetic kidney disease; chr7:65898442 chr7:65751142~65763354:+ CESC cis rs73086581 0.947 rs55794220 ENSG00000229539.1 RP11-119B16.2 5.39 1.78e-07 0.000172 0.55 0.34 Response to antidepressants in depression; chr20:3975755 chr20:3888239~3888868:- CESC cis rs2243480 1 rs410128 ENSG00000275400.1 RP4-756H11.5 5.39 1.78e-07 0.000172 0.6 0.34 Diabetic kidney disease; chr7:66138186 chr7:66553805~66554199:- CESC cis rs2739330 0.796 rs5760106 ENSG00000272787.1 KB-226F1.2 5.39 1.78e-07 0.000172 0.37 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23969211~23969873:+ CESC cis rs2842992 0.915 rs1322427 ENSG00000237927.1 RP3-393E18.2 -5.39 1.78e-07 0.000172 -0.46 -0.34 Age-related macular degeneration (geographic atrophy); chr6:159654422 chr6:159586955~159589169:- CESC cis rs4660456 1 rs4660456 ENSG00000237899.1 RP4-739H11.3 -5.39 1.78e-07 0.000172 -0.47 -0.34 Platelet count; chr1:40773839 chr1:40669089~40687588:- CESC cis rs957448 1 rs1992370 ENSG00000253704.1 RP11-267M23.4 5.39 1.78e-07 0.000172 0.39 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94546466 chr8:94553722~94569745:+ CESC cis rs5758659 0.845 rs5758645 ENSG00000273366.1 CTA-989H11.1 -5.39 1.79e-07 0.000173 -0.42 -0.34 Cognitive function; chr22:42202945 chr22:42278188~42278846:+ CESC cis rs6504950 0.886 rs2787501 ENSG00000275710.1 RP11-257O5.4 5.39 1.8e-07 0.000174 0.37 0.34 Breast cancer; chr17:55016604 chr17:54964474~54964679:+ CESC cis rs957448 0.554 rs10956919 ENSG00000253704.1 RP11-267M23.4 5.39 1.8e-07 0.000174 0.35 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94572945 chr8:94553722~94569745:+ CESC cis rs1891275 0.551 rs4933692 ENSG00000228701.1 TNKS2-AS1 -5.39 1.8e-07 0.000174 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91664876 chr10:91782839~91798291:- CESC cis rs9309711 0.922 rs13431788 ENSG00000225234.1 TRAPPC12-AS1 -5.39 1.81e-07 0.000174 -0.35 -0.34 Neurofibrillary tangles; chr2:3479141 chr2:3481242~3482409:- CESC cis rs801193 0.569 rs11761542 ENSG00000226824.5 RP4-756H11.3 -5.39 1.81e-07 0.000175 -0.43 -0.34 Aortic root size; chr7:66753209 chr7:66654538~66669855:+ CESC cis rs783540 0.609 rs803686 ENSG00000255769.6 GOLGA2P10 5.39 1.81e-07 0.000175 0.4 0.34 Schizophrenia; chr15:82550590 chr15:82472993~82513950:- CESC cis rs875971 0.862 rs4149461 ENSG00000222364.1 RNU6-96P 5.39 1.82e-07 0.000175 0.39 0.34 Aortic root size; chr7:66279745 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs10261398 ENSG00000222364.1 RNU6-96P 5.39 1.82e-07 0.000175 0.39 0.34 Aortic root size; chr7:66285177 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs10224872 ENSG00000222364.1 RNU6-96P 5.39 1.82e-07 0.000175 0.39 0.34 Aortic root size; chr7:66294786 chr7:66395191~66395286:+ CESC cis rs9907295 0.818 rs9889874 ENSG00000270977.1 AC015849.16 -5.39 1.82e-07 0.000175 -0.48 -0.34 Fibroblast growth factor basic levels; chr17:35875293 chr17:35893707~35911023:- CESC cis rs897984 0.762 rs7204459 ENSG00000260911.2 RP11-196G11.2 -5.39 1.82e-07 0.000175 -0.38 -0.34 Dementia with Lewy bodies; chr16:30972891 chr16:31043150~31049868:+ CESC cis rs7572733 0.935 rs12995110 ENSG00000222017.1 AC011997.1 -5.39 1.82e-07 0.000176 -0.38 -0.34 Dermatomyositis; chr2:197924289 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs4850816 ENSG00000222017.1 AC011997.1 -5.39 1.82e-07 0.000176 -0.38 -0.34 Dermatomyositis; chr2:197925041 chr2:197693106~197774823:+ CESC cis rs3096299 0.933 rs2965938 ENSG00000274627.1 RP11-104N10.2 5.39 1.82e-07 0.000176 0.34 0.34 Multiple myeloma (IgH translocation); chr16:89424928 chr16:89516797~89522217:+ CESC cis rs11096990 0.613 rs7690414 ENSG00000249207.1 RP11-360F5.1 -5.39 1.83e-07 0.000176 -0.39 -0.34 Cognitive function; chr4:39210669 chr4:39112677~39126818:- CESC cis rs9584850 0.834 rs7985565 ENSG00000231194.1 FARP1-AS1 5.39 1.83e-07 0.000177 0.42 0.34 Neuroticism; chr13:98461217 chr13:98435405~98435840:- CESC cis rs6142102 0.602 rs4911145 ENSG00000275784.1 RP5-1125A11.6 5.39 1.83e-07 0.000177 0.33 0.34 Skin pigmentation; chr20:34027417 chr20:33989480~33991818:- CESC cis rs875971 0.825 rs1129531 ENSG00000222364.1 RNU6-96P 5.39 1.84e-07 0.000177 0.39 0.34 Aortic root size; chr7:66154117 chr7:66395191~66395286:+ CESC cis rs2842992 0.83 rs2758313 ENSG00000237927.1 RP3-393E18.2 -5.39 1.84e-07 0.000177 -0.44 -0.34 Age-related macular degeneration (geographic atrophy); chr6:159733067 chr6:159586955~159589169:- CESC cis rs957448 1 rs12679345 ENSG00000253704.1 RP11-267M23.4 5.39 1.84e-07 0.000178 0.38 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94552305 chr8:94553722~94569745:+ CESC cis rs875971 0.862 rs7786892 ENSG00000222364.1 RNU6-96P 5.39 1.84e-07 0.000178 0.39 0.34 Aortic root size; chr7:66163889 chr7:66395191~66395286:+ CESC cis rs67180937 0.922 rs10495198 ENSG00000272750.1 RP11-378J18.8 -5.39 1.85e-07 0.000178 -0.43 -0.34 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222652375 chr1:222658867~222661512:- CESC cis rs950169 1 rs1911155 ENSG00000225151.9 GOLGA2P7 -5.39 1.85e-07 0.000178 -0.48 -0.34 Schizophrenia; chr15:84118883 chr15:84199311~84230136:- CESC cis rs72627509 0.904 rs781663 ENSG00000269949.1 RP11-738E22.3 5.39 1.85e-07 0.000178 0.5 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56915588 chr4:56960927~56961373:- CESC cis rs957448 0.554 rs72674877 ENSG00000253704.1 RP11-267M23.4 5.39 1.85e-07 0.000179 0.35 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94580479 chr8:94553722~94569745:+ CESC cis rs9545047 0.604 rs8001392 ENSG00000227676.3 LINC01068 5.39 1.86e-07 0.000179 0.39 0.34 Schizophrenia; chr13:79374211 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs4146473 ENSG00000227676.3 LINC01068 5.39 1.86e-07 0.000179 0.39 0.34 Schizophrenia; chr13:79374548 chr13:79566727~79571436:+ CESC cis rs9545047 0.584 rs1619669 ENSG00000227676.3 LINC01068 5.39 1.86e-07 0.000179 0.39 0.34 Schizophrenia; chr13:79378363 chr13:79566727~79571436:+ CESC cis rs1823913 0.892 rs35596292 ENSG00000227542.1 AC092614.2 5.39 1.86e-07 0.000179 0.37 0.34 Obesity-related traits; chr2:191246890 chr2:191229165~191246172:- CESC cis rs1823913 0.927 rs35530564 ENSG00000227542.1 AC092614.2 5.39 1.86e-07 0.000179 0.37 0.34 Obesity-related traits; chr2:191247324 chr2:191229165~191246172:- CESC cis rs5758659 0.935 rs134879 ENSG00000273366.1 CTA-989H11.1 -5.38 1.88e-07 0.00018 -0.41 -0.34 Cognitive function; chr22:42268195 chr22:42278188~42278846:+ CESC cis rs8059260 0.604 rs741177 ENSG00000274038.1 RP11-66H6.4 -5.38 1.88e-07 0.00018 -0.56 -0.34 Alcohol consumption over the past year; chr16:11051791 chr16:11056556~11057034:+ CESC cis rs2243480 0.803 rs423187 ENSG00000228409.4 CCT6P1 5.38 1.88e-07 0.00018 0.51 0.34 Diabetic kidney disease; chr7:66044512 chr7:65751142~65763354:+ CESC cis rs9322193 0.923 rs9322214 ENSG00000268592.3 RAET1E-AS1 5.38 1.88e-07 0.000181 0.46 0.34 Lung cancer; chr6:149703986 chr6:149863494~149919507:+ CESC cis rs2929278 0.589 rs11638972 ENSG00000205771.5 CATSPER2P1 5.38 1.88e-07 0.000181 0.41 0.34 Schizophrenia; chr15:43782493 chr15:43726918~43747094:- CESC cis rs957448 1 rs1055800 ENSG00000253704.1 RP11-267M23.4 -5.38 1.89e-07 0.000181 -0.38 -0.34 Nonsyndromic cleft lip with cleft palate; chr8:94510810 chr8:94553722~94569745:+ CESC cis rs11690935 0.885 rs6750058 ENSG00000228389.1 AC068039.4 5.38 1.89e-07 0.000181 0.44 0.34 Schizophrenia; chr2:171930399 chr2:171773482~171775844:+ CESC cis rs4660456 0.913 rs7551747 ENSG00000237899.1 RP4-739H11.3 5.38 1.89e-07 0.000181 0.48 0.34 Platelet count; chr1:40699407 chr1:40669089~40687588:- CESC cis rs875971 0.83 rs6976714 ENSG00000222364.1 RNU6-96P -5.38 1.89e-07 0.000181 -0.4 -0.34 Aortic root size; chr7:66426474 chr7:66395191~66395286:+ CESC cis rs875971 0.651 rs2420596 ENSG00000222364.1 RNU6-96P -5.38 1.89e-07 0.000181 -0.4 -0.34 Aortic root size; chr7:66450996 chr7:66395191~66395286:+ CESC cis rs875971 0.52 rs2420597 ENSG00000222364.1 RNU6-96P -5.38 1.89e-07 0.000181 -0.4 -0.34 Aortic root size; chr7:66450999 chr7:66395191~66395286:+ CESC cis rs2284378 0.515 rs6059579 ENSG00000275784.1 RP5-1125A11.6 -5.38 1.89e-07 0.000181 -0.34 -0.34 Breast cancer; chr20:33940059 chr20:33989480~33991818:- CESC cis rs950169 1 rs35658069 ENSG00000225151.9 GOLGA2P7 -5.38 1.89e-07 0.000182 -0.48 -0.34 Schizophrenia; chr15:84111394 chr15:84199311~84230136:- CESC cis rs6452524 0.967 rs62374399 ENSG00000249664.1 CTD-2227C6.2 5.38 1.89e-07 0.000182 0.39 0.34 Hypertension (SNP x SNP interaction); chr5:83176051 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs62374401 ENSG00000249664.1 CTD-2227C6.2 5.38 1.89e-07 0.000182 0.39 0.34 Hypertension (SNP x SNP interaction); chr5:83177159 chr5:83012285~83013109:- CESC cis rs8040855 0.644 rs7495437 ENSG00000259295.5 CSPG4P12 -5.38 1.89e-07 0.000182 -0.4 -0.34 Bulimia nervosa; chr15:85183059 chr15:85191438~85213905:+ CESC cis rs7572733 0.846 rs1518359 ENSG00000222017.1 AC011997.1 5.38 1.9e-07 0.000183 0.37 0.34 Dermatomyositis; chr2:197982659 chr2:197693106~197774823:+ CESC cis rs2919917 1 rs1545228 ENSG00000254352.1 RP11-578O24.2 -5.38 1.9e-07 0.000183 -0.45 -0.34 Lymphocyte counts; chr8:78732202 chr8:78723796~78724136:- CESC cis rs1062177 0.855 rs1346489 ENSG00000253921.1 CTB-113P19.3 -5.38 1.91e-07 0.000183 -0.42 -0.34 Preschool internalizing problems; chr5:151886973 chr5:151753992~151767247:+ CESC cis rs3762637 1 rs11932 ENSG00000272758.4 RP11-299J3.8 5.38 1.91e-07 0.000183 0.45 0.34 LDL cholesterol levels; chr3:122422288 chr3:122416207~122443180:+ CESC cis rs6951245 0.554 rs78999139 ENSG00000229043.2 AC091729.9 -5.38 1.92e-07 0.000184 -0.44 -0.34 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1098889 chr7:1160374~1165267:+ CESC cis rs6951245 0.554 rs4724294 ENSG00000229043.2 AC091729.9 -5.38 1.92e-07 0.000184 -0.44 -0.34 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1100059 chr7:1160374~1165267:+ CESC cis rs4660456 0.912 rs658806 ENSG00000237899.1 RP4-739H11.3 5.38 1.92e-07 0.000184 0.47 0.34 Platelet count; chr1:40683312 chr1:40669089~40687588:- CESC cis rs875971 0.862 rs709609 ENSG00000237310.1 GS1-124K5.4 -5.38 1.92e-07 0.000184 -0.34 -0.34 Aortic root size; chr7:66095574 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs778684 ENSG00000222364.1 RNU6-96P -5.38 1.93e-07 0.000185 -0.4 -0.34 Aortic root size; chr7:66371416 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs778680 ENSG00000222364.1 RNU6-96P -5.38 1.93e-07 0.000185 -0.4 -0.34 Aortic root size; chr7:66375427 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs11769079 ENSG00000222364.1 RNU6-96P -5.38 1.93e-07 0.000185 -0.4 -0.34 Aortic root size; chr7:66377141 chr7:66395191~66395286:+ CESC cis rs5758659 0.967 rs5758670 ENSG00000273366.1 CTA-989H11.1 -5.38 1.93e-07 0.000185 -0.42 -0.34 Cognitive function; chr22:42240681 chr22:42278188~42278846:+ CESC cis rs9322193 0.607 rs10457852 ENSG00000231760.4 RP11-350J20.5 5.38 1.93e-07 0.000185 0.51 0.34 Lung cancer; chr6:149880584 chr6:149796151~149826294:- CESC cis rs2243480 1 rs1796228 ENSG00000228409.4 CCT6P1 5.38 1.93e-07 0.000185 0.52 0.34 Diabetic kidney disease; chr7:66568097 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1267820 ENSG00000228409.4 CCT6P1 5.38 1.93e-07 0.000185 0.52 0.34 Diabetic kidney disease; chr7:66585308 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs2533288 ENSG00000228409.4 CCT6P1 5.38 1.93e-07 0.000185 0.52 0.34 Diabetic kidney disease; chr7:66591724 chr7:65751142~65763354:+ CESC cis rs1891275 0.551 rs7088831 ENSG00000228701.1 TNKS2-AS1 -5.38 1.94e-07 0.000186 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91652695 chr10:91782839~91798291:- CESC cis rs1891275 0.576 rs2000178 ENSG00000228701.1 TNKS2-AS1 -5.38 1.94e-07 0.000186 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91653287 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs2027486 ENSG00000228701.1 TNKS2-AS1 -5.38 1.94e-07 0.000186 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91654229 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs2421623 ENSG00000228701.1 TNKS2-AS1 -5.38 1.94e-07 0.000186 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91654700 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs10881941 ENSG00000228701.1 TNKS2-AS1 -5.38 1.94e-07 0.000186 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91655154 chr10:91782839~91798291:- CESC cis rs2929278 0.617 rs3087657 ENSG00000205771.5 CATSPER2P1 -5.38 1.95e-07 0.000186 -0.41 -0.34 Schizophrenia; chr15:43771661 chr15:43726918~43747094:- CESC cis rs3738443 0.645 rs55768801 ENSG00000259865.1 RP11-488L18.10 5.38 1.95e-07 0.000187 0.32 0.34 Alcohol dependence; chr1:247199688 chr1:247187281~247188526:- CESC cis rs2108622 0.727 rs8102532 ENSG00000267453.5 AC004791.2 -5.38 1.95e-07 0.000187 -0.43 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869250 chr19:15851993~15864904:- CESC cis rs801193 0.591 rs4506088 ENSG00000232559.3 GS1-124K5.12 -5.38 1.95e-07 0.000187 -0.37 -0.34 Aortic root size; chr7:66670470 chr7:66554588~66576923:- CESC cis rs957448 1 rs16916874 ENSG00000253704.1 RP11-267M23.4 5.38 1.96e-07 0.000188 0.39 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94537749 chr8:94553722~94569745:+ CESC cis rs79349575 0.87 rs12941262 ENSG00000270781.1 RP11-501C14.9 -5.37 1.96e-07 0.000188 -0.39 -0.34 Type 2 diabetes; chr17:48889675 chr17:48899131~48899748:+ CESC cis rs79349575 0.778 rs12950328 ENSG00000270781.1 RP11-501C14.9 -5.37 1.96e-07 0.000188 -0.39 -0.34 Type 2 diabetes; chr17:48889699 chr17:48899131~48899748:+ CESC cis rs10875746 0.859 rs4760695 ENSG00000240399.1 RP1-228P16.1 -5.37 1.97e-07 0.000188 -0.44 -0.34 Longevity (90 years and older); chr12:48198065 chr12:48054813~48055591:- CESC cis rs1891275 0.551 rs2000177 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91653237 chr10:91782839~91798291:- CESC cis rs1891275 0.54 rs10732773 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91656468 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs2421624 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91656659 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs2421625 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91656744 chr10:91782839~91798291:- CESC cis rs1891275 0.576 rs7900117 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91657530 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs4933213 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91657947 chr10:91782839~91798291:- CESC cis rs1891275 0.506 rs4933214 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91658004 chr10:91782839~91798291:- CESC cis rs1891275 0.515 rs7358148 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91658775 chr10:91782839~91798291:- CESC cis rs1891275 0.601 rs7358034 ENSG00000228701.1 TNKS2-AS1 -5.37 1.97e-07 0.000188 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91659007 chr10:91782839~91798291:- CESC cis rs73086581 0.891 rs55871214 ENSG00000229539.1 RP11-119B16.2 5.37 1.97e-07 0.000189 0.55 0.34 Response to antidepressants in depression; chr20:3985059 chr20:3888239~3888868:- CESC cis rs73086581 1 rs56069856 ENSG00000229539.1 RP11-119B16.2 5.37 1.97e-07 0.000189 0.55 0.34 Response to antidepressants in depression; chr20:3985062 chr20:3888239~3888868:- CESC cis rs783540 0.609 rs803686 ENSG00000276710.3 CSPG4P8 5.37 1.98e-07 0.000189 0.39 0.34 Schizophrenia; chr15:82550590 chr15:82459472~82477258:+ CESC cis rs2739330 0.828 rs5760108 ENSG00000272787.1 KB-226F1.2 -5.37 1.98e-07 0.000189 -0.36 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23969211~23969873:+ CESC cis rs801193 0.548 rs6975044 ENSG00000232559.3 GS1-124K5.12 5.37 1.99e-07 0.00019 0.38 0.34 Aortic root size; chr7:66762495 chr7:66554588~66576923:- CESC cis rs116095464 0.558 rs1541822 ENSG00000250848.1 CTD-2083E4.5 5.37 1.99e-07 0.00019 0.43 0.34 Breast cancer; chr5:269119 chr5:288833~290321:- CESC cis rs8059260 0.668 rs4781029 ENSG00000274038.1 RP11-66H6.4 -5.37 1.99e-07 0.00019 -0.56 -0.34 Alcohol consumption over the past year; chr16:10983717 chr16:11056556~11057034:+ CESC cis rs2739330 0.76 rs5751761 ENSG00000231271.1 AP000350.8 -5.37 2e-07 0.000191 -0.41 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23949918~23954042:+ CESC cis rs1891275 0.576 rs10881942 ENSG00000228701.1 TNKS2-AS1 -5.37 2e-07 0.000191 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91655263 chr10:91782839~91798291:- CESC cis rs2439831 0.867 rs2447208 ENSG00000275601.1 AC011330.13 -5.37 2.01e-07 0.000192 -0.49 -0.34 Lung cancer in ever smokers; chr15:43641697 chr15:43642389~43643023:- CESC cis rs11690935 0.885 rs10202823 ENSG00000228389.1 AC068039.4 5.37 2.02e-07 0.000192 0.43 0.34 Schizophrenia; chr2:171923622 chr2:171773482~171775844:+ CESC cis rs10875746 0.768 rs10875724 ENSG00000240399.1 RP1-228P16.1 -5.37 2.02e-07 0.000192 -0.43 -0.34 Longevity (90 years and older); chr12:48026470 chr12:48054813~48055591:- CESC cis rs6700559 0.81 rs2808248 ENSG00000260088.1 RP11-92G12.3 5.37 2.03e-07 0.000193 0.43 0.34 Coronary artery disease; chr1:200623147 chr1:200669507~200694250:+ CESC cis rs7174755 0.772 rs8025474 ENSG00000260657.2 RP11-315D16.4 5.37 2.03e-07 0.000193 0.43 0.34 Major depressive disorder; chr15:68094185 chr15:68267792~68277994:- CESC cis rs8177876 0.822 rs56166222 ENSG00000261838.4 RP11-303E16.6 5.37 2.03e-07 0.000193 0.74 0.34 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81067920 chr16:81069854~81076598:+ CESC cis rs6142102 0.961 rs2268089 ENSG00000276073.1 RP5-1125A11.7 -5.37 2.03e-07 0.000194 -0.33 -0.34 Skin pigmentation; chr20:34079492 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs6119447 ENSG00000276073.1 RP5-1125A11.7 -5.37 2.03e-07 0.000194 -0.33 -0.34 Skin pigmentation; chr20:34080770 chr20:33985617~33988989:- CESC cis rs763121 0.962 rs5757135 ENSG00000273076.1 RP3-508I15.22 5.37 2.04e-07 0.000194 0.38 0.34 Menopause (age at onset); chr22:38556568 chr22:38743495~38743910:+ CESC cis rs2243480 1 rs4718269 ENSG00000228409.4 CCT6P1 -5.37 2.04e-07 0.000194 -0.5 -0.34 Diabetic kidney disease; chr7:65735810 chr7:65751142~65763354:+ CESC cis rs9907295 0.901 rs3760326 ENSG00000270977.1 AC015849.16 -5.37 2.04e-07 0.000195 -0.51 -0.34 Fibroblast growth factor basic levels; chr17:35853493 chr17:35893707~35911023:- CESC cis rs875971 0.862 rs1695820 ENSG00000222364.1 RNU6-96P -5.37 2.04e-07 0.000195 -0.4 -0.34 Aortic root size; chr7:66379576 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs778715 ENSG00000222364.1 RNU6-96P -5.37 2.04e-07 0.000195 -0.4 -0.34 Aortic root size; chr7:66384222 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs809025 ENSG00000222364.1 RNU6-96P -5.37 2.04e-07 0.000195 -0.4 -0.34 Aortic root size; chr7:66384832 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs778702 ENSG00000222364.1 RNU6-96P -5.37 2.04e-07 0.000195 -0.4 -0.34 Aortic root size; chr7:66399848 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs1643375 ENSG00000222364.1 RNU6-96P -5.37 2.04e-07 0.000195 -0.4 -0.34 Aortic root size; chr7:66407690 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6962717 ENSG00000222364.1 RNU6-96P -5.37 2.04e-07 0.000195 -0.4 -0.34 Aortic root size; chr7:66418748 chr7:66395191~66395286:+ CESC cis rs1499614 1 rs1882655 ENSG00000275400.1 RP4-756H11.5 -5.37 2.05e-07 0.000195 -0.6 -0.34 Gout; chr7:66682070 chr7:66553805~66554199:- CESC cis rs1499614 0.831 rs3800822 ENSG00000275400.1 RP4-756H11.5 -5.37 2.05e-07 0.000195 -0.6 -0.34 Gout; chr7:66682162 chr7:66553805~66554199:- CESC cis rs748404 0.66 rs690012 ENSG00000249839.1 AC011330.5 -5.37 2.05e-07 0.000195 -0.35 -0.34 Lung cancer; chr15:43427557 chr15:43663654~43684339:- CESC cis rs8059260 0.604 rs76969865 ENSG00000274038.1 RP11-66H6.4 -5.37 2.05e-07 0.000195 -0.58 -0.34 Alcohol consumption over the past year; chr16:11050092 chr16:11056556~11057034:+ CESC cis rs2243480 1 rs160652 ENSG00000232559.3 GS1-124K5.12 5.37 2.05e-07 0.000195 0.6 0.34 Diabetic kidney disease; chr7:66073444 chr7:66554588~66576923:- CESC cis rs34779708 0.931 rs4934709 ENSG00000230534.5 RP11-297A16.2 -5.37 2.05e-07 0.000195 -0.46 -0.34 Inflammatory bowel disease;Crohn's disease; chr10:35050396 chr10:35098006~35127020:- CESC cis rs2108622 0.683 rs6512067 ENSG00000267453.5 AC004791.2 -5.36 2.06e-07 0.000196 -0.42 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872141 chr19:15851993~15864904:- CESC cis rs2739330 0.76 rs1007888 ENSG00000272787.1 KB-226F1.2 -5.36 2.07e-07 0.000196 -0.37 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23969211~23969873:+ CESC cis rs79349575 0.721 rs4794004 ENSG00000270781.1 RP11-501C14.9 -5.36 2.07e-07 0.000196 -0.38 -0.34 Type 2 diabetes; chr17:48961109 chr17:48899131~48899748:+ CESC cis rs9322193 0.884 rs10872647 ENSG00000268592.3 RAET1E-AS1 5.36 2.07e-07 0.000197 0.45 0.34 Lung cancer; chr6:149758687 chr6:149863494~149919507:+ CESC cis rs875971 0.522 rs2949690 ENSG00000164669.11 INTS4P1 5.36 2.07e-07 0.000197 0.46 0.34 Aortic root size; chr7:66018255 chr7:65141225~65234216:+ CESC cis rs7684253 0.526 rs34112167 ENSG00000269949.1 RP11-738E22.3 -5.36 2.08e-07 0.000197 -0.41 -0.34 Migraine; chr4:56853383 chr4:56960927~56961373:- CESC cis rs10515750 0.643 rs10063413 ENSG00000251405.2 CTB-109A12.1 -5.36 2.08e-07 0.000197 -0.74 -0.34 Lung function (FEV1/FVC); chr5:157384435 chr5:157362615~157460078:- CESC cis rs34779708 0.966 rs6481941 ENSG00000230534.5 RP11-297A16.2 5.36 2.08e-07 0.000197 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35151213 chr10:35098006~35127020:- CESC cis rs7951870 1 rs7108770 ENSG00000247675.5 LRP4-AS1 -5.36 2.08e-07 0.000198 -0.4 -0.34 Schizophrenia; chr11:46626882 chr11:46846412~46874396:+ CESC cis rs14027 0.512 rs7012791 ENSG00000279347.1 RP11-85I17.2 5.36 2.08e-07 0.000198 0.32 0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119707451 chr8:119838736~119840385:- CESC cis rs1075265 0.704 rs9631059 ENSG00000233266.1 HMGB1P31 5.36 2.09e-07 0.000198 0.43 0.34 Chronotype;Morning vs. evening chronotype; chr2:54015160 chr2:54051334~54051760:+ CESC cis rs9549367 0.713 rs3024756 ENSG00000269125.1 RP11-98F14.11 -5.36 2.09e-07 0.000198 -0.46 -0.34 Platelet distribution width; chr13:113168636 chr13:113165002~113165183:- CESC cis rs6452524 0.967 rs2974444 ENSG00000249664.1 CTD-2227C6.2 5.36 2.09e-07 0.000198 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83185174 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs2940542 ENSG00000249664.1 CTD-2227C6.2 5.36 2.09e-07 0.000198 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83185734 chr5:83012285~83013109:- CESC cis rs6452524 0.934 rs2940543 ENSG00000249664.1 CTD-2227C6.2 5.36 2.09e-07 0.000198 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83187297 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs2974450 ENSG00000249664.1 CTD-2227C6.2 5.36 2.09e-07 0.000198 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83187323 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs2974449 ENSG00000249664.1 CTD-2227C6.2 5.36 2.09e-07 0.000198 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83187465 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs2662241 ENSG00000249664.1 CTD-2227C6.2 5.36 2.09e-07 0.000198 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83188774 chr5:83012285~83013109:- CESC cis rs6452524 0.935 rs2940544 ENSG00000249664.1 CTD-2227C6.2 5.36 2.09e-07 0.000198 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83189785 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs2731865 ENSG00000249664.1 CTD-2227C6.2 5.36 2.09e-07 0.000198 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83190570 chr5:83012285~83013109:- CESC cis rs67517081 1 rs67517081 ENSG00000260911.2 RP11-196G11.2 -5.36 2.09e-07 0.000198 -0.38 -0.34 Mean corpuscular hemoglobin; chr16:30976060 chr16:31043150~31049868:+ CESC cis rs11976180 0.569 rs12703565 ENSG00000273234.1 OR2A13P -5.36 2.1e-07 0.000199 -0.55 -0.34 Obesity-related traits; chr7:144057308 chr7:144142009~144142938:+ CESC cis rs957448 0.554 rs12540967 ENSG00000253704.1 RP11-267M23.4 5.36 2.1e-07 0.000199 0.35 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94576862 chr8:94553722~94569745:+ CESC cis rs875971 0.767 rs1643394 ENSG00000222364.1 RNU6-96P -5.36 2.1e-07 0.000199 -0.4 -0.34 Aortic root size; chr7:66371107 chr7:66395191~66395286:+ CESC cis rs62229266 0.609 rs12482541 ENSG00000231106.2 LINC01436 5.36 2.1e-07 0.000199 0.46 0.34 Mitral valve prolapse; chr21:36047445 chr21:36005338~36007838:+ CESC cis rs62229266 0.609 rs2835253 ENSG00000231106.2 LINC01436 5.36 2.1e-07 0.000199 0.46 0.34 Mitral valve prolapse; chr21:36047447 chr21:36005338~36007838:+ CESC cis rs6504622 0.755 rs11653838 ENSG00000262879.4 RP11-156P1.3 -5.36 2.1e-07 0.000199 -0.37 -0.34 Orofacial clefts; chr17:47006317 chr17:46984045~47100323:- CESC cis rs2739330 0.753 rs4822452 ENSG00000250470.1 AP000351.3 5.36 2.11e-07 2e-04 0.42 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23976904~23977585:- CESC cis rs507080 0.922 rs4936433 ENSG00000255422.1 AP002954.4 5.36 2.11e-07 2e-04 0.43 0.34 Serum metabolite levels; chr11:118681711 chr11:118704607~118750263:+ CESC cis rs2243480 1 rs4149468 ENSG00000228409.4 CCT6P1 5.36 2.12e-07 0.000201 0.51 0.34 Diabetic kidney disease; chr7:66360703 chr7:65751142~65763354:+ CESC cis rs7188445 0.787 rs7189954 ENSG00000261390.4 RP11-345M22.2 5.36 2.13e-07 0.000202 0.41 0.34 Urate levels; chr16:79701150 chr16:79715232~79770563:- CESC cis rs34779708 0.931 rs7923217 ENSG00000230534.5 RP11-297A16.2 5.36 2.13e-07 0.000202 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35020661 chr10:35098006~35127020:- CESC cis rs3931020 0.657 rs10890142 ENSG00000272864.1 RP11-17E13.2 -5.36 2.13e-07 0.000202 -0.44 -0.34 Resistin levels; chr1:74713445 chr1:74698769~74699333:- CESC cis rs6782228 0.651 rs9852825 ENSG00000242551.2 POU5F1P6 -5.36 2.14e-07 0.000203 -0.39 -0.34 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128668514 chr3:128674735~128677005:- CESC cis rs6782228 0.651 rs9289332 ENSG00000242551.2 POU5F1P6 -5.36 2.14e-07 0.000203 -0.39 -0.34 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128669041 chr3:128674735~128677005:- CESC cis rs6782228 0.606 rs7613073 ENSG00000242551.2 POU5F1P6 -5.36 2.14e-07 0.000203 -0.39 -0.34 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128669660 chr3:128674735~128677005:- CESC cis rs1891275 0.515 rs7908980 ENSG00000228701.1 TNKS2-AS1 -5.36 2.14e-07 0.000203 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91659545 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs4933690 ENSG00000228701.1 TNKS2-AS1 -5.36 2.14e-07 0.000203 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91659810 chr10:91782839~91798291:- CESC cis rs1891275 0.576 rs4933216 ENSG00000228701.1 TNKS2-AS1 -5.36 2.14e-07 0.000203 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91659825 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs4933691 ENSG00000228701.1 TNKS2-AS1 -5.36 2.14e-07 0.000203 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91660200 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs2421628 ENSG00000228701.1 TNKS2-AS1 -5.36 2.14e-07 0.000203 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91662412 chr10:91782839~91798291:- CESC cis rs2882667 0.537 rs13181793 ENSG00000253404.1 AC034243.1 5.36 2.14e-07 0.000203 0.4 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139073267 chr5:138744434~138753309:- CESC cis rs1891275 0.551 rs7087959 ENSG00000228701.1 TNKS2-AS1 -5.36 2.14e-07 0.000203 -0.43 -0.34 Intelligence (multi-trait analysis); chr10:91656160 chr10:91782839~91798291:- CESC cis rs9389248 0.69 rs728030 ENSG00000232876.1 CTA-212D2.2 5.36 2.14e-07 0.000203 0.4 0.34 High light scatter reticulocyte percentage of red cells; chr6:134925156 chr6:135055033~135060550:+ CESC cis rs7829975 0.511 rs2980426 ENSG00000253893.2 FAM85B -5.36 2.14e-07 0.000203 -0.45 -0.34 Mood instability; chr8:8288087 chr8:8167819~8226614:- CESC cis rs189798 0.738 rs330908 ENSG00000254340.1 RP11-10A14.3 5.36 2.14e-07 0.000203 0.43 0.34 Myopia (pathological); chr8:9137656 chr8:9141424~9145435:+ CESC cis rs2739330 0.828 rs4822454 ENSG00000231271.1 AP000350.8 5.36 2.15e-07 0.000203 0.41 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23949918~23954042:+ CESC cis rs6951245 0.554 rs11544331 ENSG00000229043.2 AC091729.9 -5.36 2.15e-07 0.000203 -0.45 -0.34 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1091775 chr7:1160374~1165267:+ CESC cis rs992157 0.71 rs10167446 ENSG00000261338.2 RP11-378A13.1 5.36 2.15e-07 0.000203 0.42 0.34 Colorectal cancer; chr2:218192143 chr2:218255319~218257366:+ CESC cis rs10262624 0.935 rs6955884 ENSG00000234286.1 AC006026.13 -5.36 2.15e-07 0.000203 -0.37 -0.34 Schizophrenia; chr7:23865654 chr7:23680195~23680786:- CESC cis rs72627509 0.904 rs12645070 ENSG00000269949.1 RP11-738E22.3 5.36 2.15e-07 0.000204 0.52 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56903940 chr4:56960927~56961373:- CESC cis rs9549367 0.789 rs9549695 ENSG00000269125.1 RP11-98F14.11 5.36 2.16e-07 0.000204 0.46 0.34 Platelet distribution width; chr13:113220500 chr13:113165002~113165183:- CESC cis rs2337406 0.587 rs11624678 ENSG00000211974.3 IGHV2-70 5.36 2.16e-07 0.000204 0.49 0.34 Alzheimer's disease (late onset); chr14:106650408 chr14:106723574~106724093:- CESC cis rs11846409 0.587 rs1806881 ENSG00000211974.3 IGHV2-70 5.36 2.16e-07 0.000204 0.49 0.34 Rheumatic heart disease; chr14:106650770 chr14:106723574~106724093:- CESC cis rs2882667 0.537 rs7704790 ENSG00000253404.1 AC034243.1 5.36 2.16e-07 0.000204 0.39 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139074407 chr5:138744434~138753309:- CESC cis rs34779708 0.966 rs57081218 ENSG00000230534.5 RP11-297A16.2 5.35 2.17e-07 0.000205 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35145680 chr10:35098006~35127020:- CESC cis rs1075265 0.528 rs2018747 ENSG00000233266.1 HMGB1P31 5.35 2.17e-07 0.000205 0.48 0.34 Chronotype;Morning vs. evening chronotype; chr2:54082487 chr2:54051334~54051760:+ CESC cis rs2108622 0.727 rs62107770 ENSG00000267453.5 AC004791.2 -5.35 2.17e-07 0.000205 -0.43 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15874615 chr19:15851993~15864904:- CESC cis rs2108622 0.727 rs2158511 ENSG00000267453.5 AC004791.2 -5.35 2.17e-07 0.000205 -0.43 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15875837 chr19:15851993~15864904:- CESC cis rs9549367 0.756 rs9549702 ENSG00000269125.1 RP11-98F14.11 -5.35 2.18e-07 0.000206 -0.45 -0.34 Platelet distribution width; chr13:113227630 chr13:113165002~113165183:- CESC cis rs1263173 0.696 rs1263172 ENSG00000254851.1 RP11-109L13.1 -5.35 2.18e-07 0.000206 -0.42 -0.34 HDL cholesterol; chr11:116810202 chr11:117135528~117138582:+ CESC cis rs7396835 0.8 rs6589572 ENSG00000254851.1 RP11-109L13.1 -5.35 2.19e-07 0.000207 -0.55 -0.34 Quantitative traits; chr11:116810847 chr11:117135528~117138582:+ CESC cis rs34779708 0.931 rs4934711 ENSG00000230534.5 RP11-297A16.2 5.35 2.19e-07 0.000207 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35071382 chr10:35098006~35127020:- CESC cis rs34375054 0.738 rs3751181 ENSG00000279233.1 RP11-158L12.4 5.35 2.19e-07 0.000207 0.33 0.34 Post bronchodilator FEV1/FVC ratio; chr12:125141989 chr12:125138245~125141711:+ CESC cis rs9549367 0.789 rs9549365 ENSG00000269125.1 RP11-98F14.11 5.35 2.19e-07 0.000207 0.46 0.34 Platelet distribution width; chr13:113253077 chr13:113165002~113165183:- CESC cis rs875971 0.862 rs6460307 ENSG00000232559.3 GS1-124K5.12 5.35 2.19e-07 0.000207 0.37 0.34 Aortic root size; chr7:66595884 chr7:66554588~66576923:- CESC cis rs9322193 0.886 rs9767555 ENSG00000268592.3 RAET1E-AS1 5.35 2.2e-07 0.000207 0.44 0.34 Lung cancer; chr6:149647022 chr6:149863494~149919507:+ CESC cis rs2243480 0.708 rs35825036 ENSG00000275400.1 RP4-756H11.5 5.35 2.21e-07 0.000208 0.59 0.34 Diabetic kidney disease; chr7:66521515 chr7:66553805~66554199:- CESC cis rs2243480 0.803 rs13224048 ENSG00000275400.1 RP4-756H11.5 5.35 2.21e-07 0.000208 0.59 0.34 Diabetic kidney disease; chr7:66528779 chr7:66553805~66554199:- CESC cis rs2243480 1 rs13237037 ENSG00000275400.1 RP4-756H11.5 5.35 2.21e-07 0.000208 0.59 0.34 Diabetic kidney disease; chr7:66532895 chr7:66553805~66554199:- CESC cis rs34779708 0.931 rs4934702 ENSG00000230534.5 RP11-297A16.2 5.35 2.22e-07 0.000209 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35034146 chr10:35098006~35127020:- CESC cis rs17711722 1 rs17711722 ENSG00000164669.11 INTS4P1 5.35 2.22e-07 0.000209 0.47 0.34 Calcium levels; chr7:65806210 chr7:65141225~65234216:+ CESC cis rs17711722 0.675 rs6947132 ENSG00000164669.11 INTS4P1 5.35 2.22e-07 0.000209 0.47 0.34 Calcium levels; chr7:65808508 chr7:65141225~65234216:+ CESC cis rs17711722 0.523 rs365896 ENSG00000228409.4 CCT6P1 5.35 2.22e-07 0.000209 0.31 0.34 Calcium levels; chr7:66045710 chr7:65751142~65763354:+ CESC cis rs957448 1 rs72674861 ENSG00000253704.1 RP11-267M23.4 5.35 2.22e-07 0.00021 0.39 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94550051 chr8:94553722~94569745:+ CESC cis rs9545047 0.553 rs7332004 ENSG00000227676.3 LINC01068 -5.35 2.22e-07 0.00021 -0.39 -0.34 Schizophrenia; chr13:79364128 chr13:79566727~79571436:+ CESC cis rs1799949 1 rs2070834 ENSG00000267681.1 CTD-3199J23.6 -5.35 2.23e-07 0.00021 -0.43 -0.34 Menopause (age at onset); chr17:43090268 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs16942 ENSG00000267681.1 CTD-3199J23.6 -5.35 2.23e-07 0.00021 -0.43 -0.34 Menopause (age at onset); chr17:43091983 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176145 ENSG00000267681.1 CTD-3199J23.6 -5.35 2.23e-07 0.00021 -0.43 -0.34 Menopause (age at onset); chr17:43097077 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs8176140 ENSG00000267681.1 CTD-3199J23.6 -5.35 2.23e-07 0.00021 -0.43 -0.34 Menopause (age at onset); chr17:43099629 chr17:43144956~43145255:+ CESC cis rs4660456 0.913 rs489222 ENSG00000237899.1 RP4-739H11.3 5.35 2.23e-07 0.00021 0.46 0.34 Platelet count; chr1:40683422 chr1:40669089~40687588:- CESC cis rs4660456 0.871 rs671704 ENSG00000237899.1 RP4-739H11.3 5.35 2.23e-07 0.00021 0.46 0.34 Platelet count; chr1:40683974 chr1:40669089~40687588:- CESC cis rs4660456 0.826 rs507914 ENSG00000237899.1 RP4-739H11.3 5.35 2.23e-07 0.00021 0.46 0.34 Platelet count; chr1:40686529 chr1:40669089~40687588:- CESC cis rs4660456 0.913 rs2780950 ENSG00000237899.1 RP4-739H11.3 5.35 2.23e-07 0.00021 0.46 0.34 Platelet count; chr1:40686937 chr1:40669089~40687588:- CESC cis rs5758659 0.904 rs5758653 ENSG00000273366.1 CTA-989H11.1 -5.35 2.23e-07 0.00021 -0.42 -0.34 Cognitive function; chr22:42217479 chr22:42278188~42278846:+ CESC cis rs2739330 0.828 rs5751770 ENSG00000272787.1 KB-226F1.2 -5.35 2.23e-07 0.00021 -0.36 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23969211~23969873:+ CESC cis rs11096990 0.613 rs4974995 ENSG00000249207.1 RP11-360F5.1 5.35 2.23e-07 0.00021 0.39 0.34 Cognitive function; chr4:39216503 chr4:39112677~39126818:- CESC cis rs875971 0.862 rs11763189 ENSG00000237310.1 GS1-124K5.4 5.35 2.23e-07 0.00021 0.33 0.34 Aortic root size; chr7:66518542 chr7:66493706~66495474:+ CESC cis rs42490 0.664 rs39767 ENSG00000251136.7 RP11-37B2.1 -5.35 2.23e-07 0.00021 -0.34 -0.34 Leprosy; chr8:89807770 chr8:89609409~89757727:- CESC cis rs6991838 0.67 rs13275168 ENSG00000272010.1 CTD-3025N20.3 5.35 2.24e-07 0.000211 0.38 0.34 Intelligence (multi-trait analysis); chr8:65685107 chr8:65591850~65592472:- CESC cis rs2739330 0.828 rs4820572 ENSG00000231271.1 AP000350.8 5.35 2.24e-07 0.000211 0.42 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23949918~23954042:+ CESC cis rs1499614 1 rs2659913 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66692349 chr7:66553805~66554199:- CESC cis rs1499614 1 rs2659911 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66693433 chr7:66553805~66554199:- CESC cis rs1499614 1 rs2707838 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66694214 chr7:66553805~66554199:- CESC cis rs1499614 1 rs60326618 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66701371 chr7:66553805~66554199:- CESC cis rs1499614 1 rs2707830 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66702658 chr7:66553805~66554199:- CESC cis rs1499614 1 rs2707828 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66706390 chr7:66553805~66554199:- CESC cis rs1499614 0.803 rs1922723 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66710076 chr7:66553805~66554199:- CESC cis rs1499614 1 rs2659903 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66715944 chr7:66553805~66554199:- CESC cis rs1499614 1 rs2141924 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66721259 chr7:66553805~66554199:- CESC cis rs1499614 0.901 rs2178742 ENSG00000275400.1 RP4-756H11.5 5.35 2.25e-07 0.000211 0.59 0.34 Gout; chr7:66732812 chr7:66553805~66554199:- CESC cis rs765787 0.53 rs7167731 ENSG00000259520.4 CTD-2651B20.3 -5.35 2.25e-07 0.000211 -0.42 -0.34 Uric acid levels; chr15:45218702 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs12910270 ENSG00000259520.4 CTD-2651B20.3 -5.35 2.25e-07 0.000211 -0.42 -0.34 Uric acid levels; chr15:45219888 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs12915804 ENSG00000259520.4 CTD-2651B20.3 -5.35 2.25e-07 0.000211 -0.42 -0.34 Uric acid levels; chr15:45220364 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs12915027 ENSG00000259520.4 CTD-2651B20.3 -5.35 2.25e-07 0.000211 -0.42 -0.34 Uric acid levels; chr15:45220428 chr15:45251580~45279251:- CESC cis rs765787 0.556 rs12915965 ENSG00000259520.4 CTD-2651B20.3 -5.35 2.25e-07 0.000211 -0.42 -0.34 Uric acid levels; chr15:45220449 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs12440238 ENSG00000259520.4 CTD-2651B20.3 -5.35 2.25e-07 0.000211 -0.42 -0.34 Uric acid levels; chr15:45220707 chr15:45251580~45279251:- CESC cis rs1799949 0.965 rs8176193 ENSG00000267681.1 CTD-3199J23.6 -5.35 2.26e-07 0.000212 -0.44 -0.34 Menopause (age at onset); chr17:43079499 chr17:43144956~43145255:+ CESC cis rs2117029 0.555 rs10747561 ENSG00000258017.1 RP11-386G11.10 -5.35 2.26e-07 0.000213 -0.43 -0.34 Intelligence (multi-trait analysis); chr12:49106726 chr12:49127782~49147869:+ CESC cis rs12130219 0.5 rs4845743 ENSG00000237975.5 FLG-AS1 -5.35 2.26e-07 0.000213 -0.39 -0.34 Inflammatory skin disease; chr1:152211673 chr1:152168125~152445456:+ CESC cis rs2243480 1 rs466983 ENSG00000228409.4 CCT6P1 5.35 2.27e-07 0.000213 0.49 0.34 Diabetic kidney disease; chr7:66055509 chr7:65751142~65763354:+ CESC cis rs9549367 0.789 rs2287248 ENSG00000269125.1 RP11-98F14.11 -5.35 2.27e-07 0.000213 -0.47 -0.34 Platelet distribution width; chr13:113234912 chr13:113165002~113165183:- CESC cis rs9549367 0.826 rs2287249 ENSG00000269125.1 RP11-98F14.11 -5.35 2.27e-07 0.000213 -0.47 -0.34 Platelet distribution width; chr13:113235041 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs2287251 ENSG00000269125.1 RP11-98F14.11 -5.35 2.27e-07 0.000213 -0.47 -0.34 Platelet distribution width; chr13:113235185 chr13:113165002~113165183:- CESC cis rs3806843 0.766 rs801176 ENSG00000202111.1 VTRNA1-2 -5.35 2.27e-07 0.000213 -0.35 -0.34 Depressive symptoms (multi-trait analysis); chr5:140707425 chr5:140718925~140719013:+ CESC cis rs6142102 0.961 rs2377957 ENSG00000276073.1 RP5-1125A11.7 -5.35 2.27e-07 0.000213 -0.32 -0.34 Skin pigmentation; chr20:33966667 chr20:33985617~33988989:- CESC cis rs34779708 0.75 rs35032841 ENSG00000230534.5 RP11-297A16.2 5.34 2.28e-07 0.000214 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35023759 chr10:35098006~35127020:- CESC cis rs801193 0.548 rs2659904 ENSG00000222364.1 RNU6-96P -5.34 2.28e-07 0.000214 -0.4 -0.34 Aortic root size; chr7:66713615 chr7:66395191~66395286:+ CESC cis rs950169 1 rs11638297 ENSG00000225151.9 GOLGA2P7 -5.34 2.28e-07 0.000214 -0.47 -0.34 Schizophrenia; chr15:84113665 chr15:84199311~84230136:- CESC cis rs4423214 0.592 rs11233977 ENSG00000254682.1 RP11-660L16.2 -5.34 2.28e-07 0.000214 -0.49 -0.34 Vitamin D levels; chr11:71510559 chr11:71448674~71452157:+ CESC cis rs12680842 0.883 rs13265241 ENSG00000253704.1 RP11-267M23.4 5.34 2.29e-07 0.000215 0.35 0.34 Body mass index; chr8:94575129 chr8:94553722~94569745:+ CESC cis rs875971 0.545 rs1638735 ENSG00000237310.1 GS1-124K5.4 5.34 2.29e-07 0.000215 0.36 0.34 Aortic root size; chr7:66630751 chr7:66493706~66495474:+ CESC cis rs17711722 0.701 rs781143 ENSG00000164669.11 INTS4P1 -5.34 2.29e-07 0.000215 -0.47 -0.34 Calcium levels; chr7:65974892 chr7:65141225~65234216:+ CESC cis rs79349575 0.749 rs519537 ENSG00000270781.1 RP11-501C14.9 -5.34 2.29e-07 0.000215 -0.38 -0.34 Type 2 diabetes; chr17:48893778 chr17:48899131~48899748:+ CESC cis rs875971 0.862 rs2420174 ENSG00000222364.1 RNU6-96P 5.34 2.3e-07 0.000215 0.39 0.34 Aortic root size; chr7:66180374 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs2420173 ENSG00000222364.1 RNU6-96P 5.34 2.3e-07 0.000215 0.39 0.34 Aortic root size; chr7:66180412 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs4718319 ENSG00000222364.1 RNU6-96P 5.34 2.3e-07 0.000215 0.39 0.34 Aortic root size; chr7:66187797 chr7:66395191~66395286:+ CESC cis rs875971 0.723 rs28391294 ENSG00000222364.1 RNU6-96P 5.34 2.3e-07 0.000215 0.39 0.34 Aortic root size; chr7:66189328 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs6967708 ENSG00000222364.1 RNU6-96P 5.34 2.3e-07 0.000215 0.39 0.34 Aortic root size; chr7:66192326 chr7:66395191~66395286:+ CESC cis rs875971 0.895 rs7782806 ENSG00000222364.1 RNU6-96P 5.34 2.3e-07 0.000215 0.39 0.34 Aortic root size; chr7:66192910 chr7:66395191~66395286:+ CESC cis rs875971 1 rs6946143 ENSG00000222364.1 RNU6-96P -5.34 2.3e-07 0.000216 -0.41 -0.34 Aortic root size; chr7:66114735 chr7:66395191~66395286:+ CESC cis rs10800713 0.908 rs6686605 ENSG00000260088.1 RP11-92G12.3 -5.34 2.3e-07 0.000216 -0.5 -0.34 Tandem gait; chr1:200539440 chr1:200669507~200694250:+ CESC cis rs801193 0.66 rs10950049 ENSG00000222364.1 RNU6-96P -5.34 2.3e-07 0.000216 -0.4 -0.34 Aortic root size; chr7:66765873 chr7:66395191~66395286:+ CESC cis rs9549367 0.713 rs9577211 ENSG00000269125.1 RP11-98F14.11 -5.34 2.31e-07 0.000216 -0.47 -0.34 Platelet distribution width; chr13:113176404 chr13:113165002~113165183:- CESC cis rs1891275 0.516 rs10881943 ENSG00000228701.1 TNKS2-AS1 -5.34 2.31e-07 0.000217 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91655373 chr10:91782839~91798291:- CESC cis rs6452524 0.967 rs4541638 ENSG00000249664.1 CTD-2227C6.2 5.34 2.31e-07 0.000217 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83181325 chr5:83012285~83013109:- CESC cis rs2739330 0.892 rs4822455 ENSG00000231271.1 AP000350.8 5.34 2.32e-07 0.000217 0.41 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23949918~23954042:+ CESC cis rs875971 0.862 rs7809814 ENSG00000222364.1 RNU6-96P 5.34 2.32e-07 0.000217 0.39 0.34 Aortic root size; chr7:66150410 chr7:66395191~66395286:+ CESC cis rs17711722 0.727 rs1880555 ENSG00000164669.11 INTS4P1 -5.34 2.32e-07 0.000218 -0.47 -0.34 Calcium levels; chr7:65967580 chr7:65141225~65234216:+ CESC cis rs875971 0.862 rs4718330 ENSG00000222364.1 RNU6-96P 5.34 2.33e-07 0.000218 0.38 0.34 Aortic root size; chr7:66250256 chr7:66395191~66395286:+ CESC cis rs8040855 0.644 rs4635318 ENSG00000259295.5 CSPG4P12 -5.34 2.33e-07 0.000218 -0.39 -0.34 Bulimia nervosa; chr15:85183506 chr15:85191438~85213905:+ CESC cis rs897984 0.806 rs1458202 ENSG00000260911.2 RP11-196G11.2 5.34 2.33e-07 0.000218 0.37 0.34 Dementia with Lewy bodies; chr16:30941881 chr16:31043150~31049868:+ CESC cis rs34779708 0.931 rs10508815 ENSG00000230534.5 RP11-297A16.2 5.34 2.33e-07 0.000218 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35043693 chr10:35098006~35127020:- CESC cis rs801193 0.569 rs7782587 ENSG00000237310.1 GS1-124K5.4 5.34 2.34e-07 0.000219 0.32 0.34 Aortic root size; chr7:66701485 chr7:66493706~66495474:+ CESC cis rs9549367 0.789 rs2025247 ENSG00000269125.1 RP11-98F14.11 -5.34 2.34e-07 0.000219 -0.47 -0.34 Platelet distribution width; chr13:113228250 chr13:113165002~113165183:- CESC cis rs992157 0.764 rs4672886 ENSG00000261338.2 RP11-378A13.1 -5.34 2.35e-07 0.00022 -0.43 -0.34 Colorectal cancer; chr2:218320822 chr2:218255319~218257366:+ CESC cis rs62229266 0.659 rs2026259 ENSG00000231106.2 LINC01436 5.34 2.36e-07 0.00022 0.47 0.34 Mitral valve prolapse; chr21:36058329 chr21:36005338~36007838:+ CESC cis rs9876781 0.507 rs1824362 ENSG00000229759.1 MRPS18AP1 -5.34 2.36e-07 0.00022 -0.32 -0.34 Longevity; chr3:48360459 chr3:48256350~48256938:- CESC cis rs9584850 0.834 rs4294654 ENSG00000231194.1 FARP1-AS1 5.34 2.36e-07 0.000221 0.43 0.34 Neuroticism; chr13:98467353 chr13:98435405~98435840:- CESC cis rs763121 0.925 rs5757251 ENSG00000273076.1 RP3-508I15.22 5.34 2.36e-07 0.000221 0.37 0.34 Menopause (age at onset); chr22:38704123 chr22:38743495~38743910:+ CESC cis rs1823913 0.66 rs1454752 ENSG00000280083.1 RP11-317J9.1 5.34 2.36e-07 0.000221 0.4 0.34 Obesity-related traits; chr2:191298668 chr2:191154118~191156070:- CESC cis rs6951245 0.554 rs75075857 ENSG00000229043.2 AC091729.9 -5.34 2.36e-07 0.000221 -0.43 -0.34 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1100662 chr7:1160374~1165267:+ CESC cis rs2739330 0.734 rs2000467 ENSG00000250470.1 AP000351.3 -5.34 2.36e-07 0.000221 -0.44 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23976904~23977585:- CESC cis rs9907295 0.748 rs4251769 ENSG00000270977.1 AC015849.16 -5.34 2.37e-07 0.000221 -0.45 -0.34 Fibroblast growth factor basic levels; chr17:35837523 chr17:35893707~35911023:- CESC cis rs3096299 0.746 rs9931120 ENSG00000274627.1 RP11-104N10.2 5.34 2.37e-07 0.000221 0.34 0.34 Multiple myeloma (IgH translocation); chr16:89434949 chr16:89516797~89522217:+ CESC cis rs7684253 0.587 rs2002154 ENSG00000269949.1 RP11-738E22.3 -5.34 2.37e-07 0.000222 -0.4 -0.34 Migraine; chr4:56879851 chr4:56960927~56961373:- CESC cis rs992157 0.735 rs10932765 ENSG00000261338.2 RP11-378A13.1 5.34 2.38e-07 0.000222 0.41 0.34 Colorectal cancer; chr2:218234761 chr2:218255319~218257366:+ CESC cis rs6142102 0.961 rs6120519 ENSG00000276073.1 RP5-1125A11.7 -5.34 2.39e-07 0.000223 -0.32 -0.34 Skin pigmentation; chr20:34100307 chr20:33985617~33988989:- CESC cis rs2581828 0.965 rs2564961 ENSG00000242142.1 SERBP1P3 5.34 2.39e-07 0.000223 0.39 0.34 Crohn's disease; chr3:53102445 chr3:53064283~53065091:- CESC cis rs875971 0.862 rs2909688 ENSG00000237310.1 GS1-124K5.4 5.33 2.39e-07 0.000223 0.33 0.34 Aortic root size; chr7:66376625 chr7:66493706~66495474:+ CESC cis rs881375 0.678 rs10760129 ENSG00000226752.6 PSMD5-AS1 -5.33 2.39e-07 0.000223 -0.36 -0.34 Rheumatoid arthritis; chr9:120937905 chr9:120824828~120854385:+ CESC cis rs9549367 0.826 rs2302755 ENSG00000269125.1 RP11-98F14.11 -5.33 2.39e-07 0.000223 -0.46 -0.34 Platelet distribution width; chr13:113244104 chr13:113165002~113165183:- CESC cis rs992157 0.764 rs13020391 ENSG00000261338.2 RP11-378A13.1 -5.33 2.39e-07 0.000223 -0.44 -0.34 Colorectal cancer; chr2:218319713 chr2:218255319~218257366:+ CESC cis rs10129255 0.556 rs9324093 ENSG00000211972.2 IGHV3-66 5.33 2.4e-07 0.000224 0.24 0.34 Kawasaki disease; chr14:106683893 chr14:106675017~106675544:- CESC cis rs6504950 0.783 rs7211787 ENSG00000275710.1 RP11-257O5.4 5.33 2.4e-07 0.000224 0.44 0.34 Breast cancer; chr17:55157551 chr17:54964474~54964679:+ CESC cis rs8072100 0.817 rs11869940 ENSG00000228782.6 CTD-2026D20.3 -5.33 2.4e-07 0.000224 -0.39 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47501069 chr17:47450568~47492492:- CESC cis rs9549367 0.756 rs3861723 ENSG00000269125.1 RP11-98F14.11 -5.33 2.41e-07 0.000224 -0.46 -0.34 Platelet distribution width; chr13:113256612 chr13:113165002~113165183:- CESC cis rs875971 0.862 rs4368860 ENSG00000222364.1 RNU6-96P 5.33 2.41e-07 0.000225 0.39 0.34 Aortic root size; chr7:66143495 chr7:66395191~66395286:+ CESC cis rs8081395 0.741 rs1292056 ENSG00000266992.1 DHX40P1 5.33 2.41e-07 0.000225 0.37 0.34 White blood cell count; chr17:59881686 chr17:59976009~60002384:- CESC cis rs2243480 0.615 rs34363376 ENSG00000228409.4 CCT6P1 5.33 2.42e-07 0.000225 0.52 0.34 Diabetic kidney disease; chr7:66474549 chr7:65751142~65763354:+ CESC cis rs1823913 0.637 rs4853569 ENSG00000280083.1 RP11-317J9.1 5.33 2.42e-07 0.000226 0.39 0.34 Obesity-related traits; chr2:191266970 chr2:191154118~191156070:- CESC cis rs9322193 0.923 rs9322209 ENSG00000268592.3 RAET1E-AS1 5.33 2.42e-07 0.000226 0.44 0.34 Lung cancer; chr6:149691226 chr6:149863494~149919507:+ CESC cis rs2028299 0.919 rs7174878 ENSG00000259677.1 RP11-493E3.1 5.33 2.43e-07 0.000226 0.48 0.34 Type 2 diabetes; chr15:89891656 chr15:89876540~89877285:+ CESC cis rs6452524 0.967 rs28360104 ENSG00000249664.1 CTD-2227C6.2 5.33 2.43e-07 0.000226 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83181525 chr5:83012285~83013109:- CESC cis rs10740039 0.583 rs2127353 ENSG00000254271.1 RP11-131N11.4 -5.33 2.43e-07 0.000226 -0.42 -0.34 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60750206 chr10:60734342~60741828:+ CESC cis rs34779708 0.931 rs72789609 ENSG00000230534.5 RP11-297A16.2 5.33 2.43e-07 0.000226 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35017278 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs7908573 ENSG00000230534.5 RP11-297A16.2 5.33 2.43e-07 0.000226 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35020585 chr10:35098006~35127020:- CESC cis rs2243480 1 rs10247526 ENSG00000228409.4 CCT6P1 -5.33 2.43e-07 0.000227 -0.51 -0.34 Diabetic kidney disease; chr7:66315709 chr7:65751142~65763354:+ CESC cis rs4660456 0.913 rs2780953 ENSG00000237899.1 RP4-739H11.3 5.33 2.43e-07 0.000227 0.46 0.34 Platelet count; chr1:40694105 chr1:40669089~40687588:- CESC cis rs6504950 0.886 rs12449538 ENSG00000275710.1 RP11-257O5.4 -5.33 2.44e-07 0.000227 -0.37 -0.34 Breast cancer; chr17:55033760 chr17:54964474~54964679:+ CESC cis rs34779708 0.931 rs13377158 ENSG00000230534.5 RP11-297A16.2 -5.33 2.44e-07 0.000227 -0.44 -0.34 Inflammatory bowel disease;Crohn's disease; chr10:35081537 chr10:35098006~35127020:- CESC cis rs950169 1 rs79318564 ENSG00000225151.9 GOLGA2P7 -5.33 2.45e-07 0.000228 -0.48 -0.34 Schizophrenia; chr15:84117398 chr15:84199311~84230136:- CESC cis rs9907295 0.591 rs4239252 ENSG00000270977.1 AC015849.16 5.33 2.45e-07 0.000228 0.38 0.34 Fibroblast growth factor basic levels; chr17:35836561 chr17:35893707~35911023:- CESC cis rs17711722 0.701 rs781145 ENSG00000164669.11 INTS4P1 -5.33 2.45e-07 0.000228 -0.47 -0.34 Calcium levels; chr7:65975383 chr7:65141225~65234216:+ CESC cis rs897984 0.762 rs1870293 ENSG00000260911.2 RP11-196G11.2 -5.33 2.45e-07 0.000228 -0.38 -0.34 Dementia with Lewy bodies; chr16:30959620 chr16:31043150~31049868:+ CESC cis rs42490 0.609 rs367640 ENSG00000251136.7 RP11-37B2.1 -5.33 2.46e-07 0.000229 -0.34 -0.34 Leprosy; chr8:89852168 chr8:89609409~89757727:- CESC cis rs6951245 0.58 rs78894484 ENSG00000229043.2 AC091729.9 -5.33 2.46e-07 0.000229 -0.45 -0.34 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1099085 chr7:1160374~1165267:+ CESC cis rs992157 0.735 rs13388024 ENSG00000261338.2 RP11-378A13.1 5.33 2.47e-07 0.00023 0.41 0.34 Colorectal cancer; chr2:218233050 chr2:218255319~218257366:+ CESC cis rs6142102 0.961 rs2284387 ENSG00000276073.1 RP5-1125A11.7 -5.33 2.47e-07 0.00023 -0.34 -0.34 Skin pigmentation; chr20:34056782 chr20:33985617~33988989:- CESC cis rs34779708 0.966 rs4934732 ENSG00000230534.5 RP11-297A16.2 5.33 2.47e-07 0.00023 0.44 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35142756 chr10:35098006~35127020:- CESC cis rs9907295 1 rs9907295 ENSG00000270977.1 AC015849.16 -5.33 2.48e-07 0.00023 -0.53 -0.34 Fibroblast growth factor basic levels; chr17:35930309 chr17:35893707~35911023:- CESC cis rs9309711 0.922 rs13385119 ENSG00000225234.1 TRAPPC12-AS1 -5.33 2.48e-07 0.00023 -0.35 -0.34 Neurofibrillary tangles; chr2:3480750 chr2:3481242~3482409:- CESC cis rs1891275 0.551 rs2421626 ENSG00000228701.1 TNKS2-AS1 -5.33 2.48e-07 0.000231 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91661177 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs2421627 ENSG00000228701.1 TNKS2-AS1 -5.33 2.48e-07 0.000231 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91662226 chr10:91782839~91798291:- CESC cis rs1891275 0.515 rs10881945 ENSG00000228701.1 TNKS2-AS1 -5.33 2.48e-07 0.000231 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91663826 chr10:91782839~91798291:- CESC cis rs1891275 0.551 rs2421629 ENSG00000228701.1 TNKS2-AS1 -5.33 2.48e-07 0.000231 -0.42 -0.34 Intelligence (multi-trait analysis); chr10:91664018 chr10:91782839~91798291:- CESC cis rs1075265 0.73 rs7597189 ENSG00000233266.1 HMGB1P31 5.33 2.49e-07 0.000231 0.44 0.34 Chronotype;Morning vs. evening chronotype; chr2:54014733 chr2:54051334~54051760:+ CESC cis rs11096990 0.634 rs60016848 ENSG00000249207.1 RP11-360F5.1 5.33 2.49e-07 0.000232 0.37 0.34 Cognitive function; chr4:39281436 chr4:39112677~39126818:- CESC cis rs11096990 0.577 rs6830736 ENSG00000249207.1 RP11-360F5.1 5.33 2.49e-07 0.000232 0.37 0.34 Cognitive function; chr4:39281467 chr4:39112677~39126818:- CESC cis rs11096990 0.634 rs6854358 ENSG00000249207.1 RP11-360F5.1 5.33 2.49e-07 0.000232 0.37 0.34 Cognitive function; chr4:39281492 chr4:39112677~39126818:- CESC cis rs131777 0.575 rs963980 ENSG00000205559.3 CHKB-AS1 -5.33 2.5e-07 0.000232 -0.4 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50583688 chr22:50583026~50583877:+ CESC cis rs875971 0.862 rs6460290 ENSG00000222364.1 RNU6-96P 5.33 2.51e-07 0.000233 0.39 0.34 Aortic root size; chr7:66344119 chr7:66395191~66395286:+ CESC cis rs9549367 0.789 rs7338235 ENSG00000269125.1 RP11-98F14.11 -5.32 2.51e-07 0.000233 -0.47 -0.34 Platelet distribution width; chr13:113234373 chr13:113165002~113165183:- CESC cis rs62103177 0.525 rs4799116 ENSG00000261126.6 RP11-795F19.1 -5.32 2.51e-07 0.000233 -0.43 -0.34 Opioid sensitivity; chr18:79976735 chr18:80046900~80095482:+ CESC cis rs4722166 0.597 rs1554606 ENSG00000179428.2 AC073072.5 -5.32 2.52e-07 0.000234 -0.43 -0.34 Lung cancer; chr7:22729088 chr7:22725395~22727620:- CESC cis rs2729354 0.768 rs2848640 ENSG00000265566.2 RN7SL605P -5.32 2.52e-07 0.000234 -0.51 -0.34 Blood protein levels; chr11:57495207 chr11:57528085~57528365:- CESC cis rs2108622 0.727 rs7254940 ENSG00000267453.5 AC004791.2 -5.32 2.52e-07 0.000234 -0.42 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15873698 chr19:15851993~15864904:- CESC cis rs4660456 0.913 rs2223486 ENSG00000237899.1 RP4-739H11.3 -5.32 2.53e-07 0.000235 -0.45 -0.34 Platelet count; chr1:40693557 chr1:40669089~40687588:- CESC cis rs189798 0.807 rs12785 ENSG00000254340.1 RP11-10A14.3 5.32 2.53e-07 0.000235 0.44 0.34 Myopia (pathological); chr8:9137426 chr8:9141424~9145435:+ CESC cis rs6504950 0.886 rs2541236 ENSG00000275710.1 RP11-257O5.4 -5.32 2.53e-07 0.000235 -0.42 -0.34 Breast cancer; chr17:55082471 chr17:54964474~54964679:+ CESC cis rs6991838 0.584 rs10089708 ENSG00000200714.1 Y_RNA 5.32 2.53e-07 0.000235 0.42 0.34 Intelligence (multi-trait analysis); chr8:65642927 chr8:65592731~65592820:+ CESC cis rs6991838 0.584 rs6991731 ENSG00000200714.1 Y_RNA 5.32 2.53e-07 0.000235 0.42 0.34 Intelligence (multi-trait analysis); chr8:65643232 chr8:65592731~65592820:+ CESC cis rs2581828 1 rs2581828 ENSG00000242142.1 SERBP1P3 5.32 2.54e-07 0.000235 0.38 0.34 Crohn's disease; chr3:53099133 chr3:53064283~53065091:- CESC cis rs765787 0.505 rs11630884 ENSG00000259520.4 CTD-2651B20.3 5.32 2.54e-07 0.000235 0.42 0.34 Uric acid levels; chr15:45240048 chr15:45251580~45279251:- CESC cis rs4660456 0.913 rs12040422 ENSG00000237899.1 RP4-739H11.3 5.32 2.54e-07 0.000235 0.45 0.34 Platelet count; chr1:40669239 chr1:40669089~40687588:- CESC cis rs7621025 0.5 rs71630059 ENSG00000239213.4 NCK1-AS1 -5.32 2.54e-07 0.000236 -0.45 -0.34 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136862769 chr3:136841726~136862054:- CESC cis rs765787 0.53 rs11636404 ENSG00000259520.4 CTD-2651B20.3 5.32 2.55e-07 0.000236 0.42 0.34 Uric acid levels; chr15:45243663 chr15:45251580~45279251:- CESC cis rs748404 0.69 rs2924369 ENSG00000249839.1 AC011330.5 5.32 2.55e-07 0.000236 0.35 0.34 Lung cancer; chr15:43485787 chr15:43663654~43684339:- CESC cis rs748404 0.69 rs1079309 ENSG00000249839.1 AC011330.5 -5.32 2.55e-07 0.000236 -0.35 -0.34 Lung cancer; chr15:43490966 chr15:43663654~43684339:- CESC cis rs11690935 0.885 rs6752812 ENSG00000228389.1 AC068039.4 5.32 2.55e-07 0.000236 0.43 0.34 Schizophrenia; chr2:171986588 chr2:171773482~171775844:+ CESC cis rs9549367 0.789 rs9549361 ENSG00000269125.1 RP11-98F14.11 5.32 2.55e-07 0.000236 0.48 0.34 Platelet distribution width; chr13:113244015 chr13:113165002~113165183:- CESC cis rs2243480 0.803 rs55700941 ENSG00000228409.4 CCT6P1 5.32 2.56e-07 0.000237 0.51 0.34 Diabetic kidney disease; chr7:65924813 chr7:65751142~65763354:+ CESC cis rs9545047 0.604 rs9530895 ENSG00000227676.3 LINC01068 5.32 2.56e-07 0.000237 0.38 0.34 Schizophrenia; chr13:79334877 chr13:79566727~79571436:+ CESC cis rs9545047 0.567 rs9530896 ENSG00000227676.3 LINC01068 5.32 2.56e-07 0.000237 0.38 0.34 Schizophrenia; chr13:79335507 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9530897 ENSG00000227676.3 LINC01068 5.32 2.56e-07 0.000237 0.38 0.34 Schizophrenia; chr13:79336420 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9574411 ENSG00000227676.3 LINC01068 -5.32 2.56e-07 0.000237 -0.38 -0.34 Schizophrenia; chr13:79354342 chr13:79566727~79571436:+ CESC cis rs11723261 0.582 rs3747693 ENSG00000211553.1 AC253576.2 -5.32 2.57e-07 0.000238 -0.49 -0.34 Immune response to smallpox vaccine (IL-6); chr4:124493 chr4:136461~136568:+ CESC cis rs875971 0.862 rs11773628 ENSG00000222364.1 RNU6-96P 5.32 2.57e-07 0.000238 0.4 0.34 Aortic root size; chr7:66517644 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs778711 ENSG00000237310.1 GS1-124K5.4 5.32 2.57e-07 0.000238 0.32 0.34 Aortic root size; chr7:66386670 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs1083554 ENSG00000237310.1 GS1-124K5.4 5.32 2.57e-07 0.000238 0.32 0.34 Aortic root size; chr7:66387354 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs778707 ENSG00000237310.1 GS1-124K5.4 5.32 2.57e-07 0.000238 0.32 0.34 Aortic root size; chr7:66392040 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs778705 ENSG00000237310.1 GS1-124K5.4 5.32 2.57e-07 0.000238 0.32 0.34 Aortic root size; chr7:66396128 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs778697 ENSG00000237310.1 GS1-124K5.4 5.32 2.57e-07 0.000238 0.32 0.34 Aortic root size; chr7:66405439 chr7:66493706~66495474:+ CESC cis rs875971 0.798 rs7789615 ENSG00000237310.1 GS1-124K5.4 5.32 2.57e-07 0.000238 0.32 0.34 Aortic root size; chr7:66413674 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6978028 ENSG00000237310.1 GS1-124K5.4 5.32 2.57e-07 0.000238 0.32 0.34 Aortic root size; chr7:66421313 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6947339 ENSG00000237310.1 GS1-124K5.4 5.32 2.57e-07 0.000238 0.32 0.34 Aortic root size; chr7:66423483 chr7:66493706~66495474:+ CESC cis rs2739330 0.76 rs5751760 ENSG00000272787.1 KB-226F1.2 -5.32 2.57e-07 0.000238 -0.37 -0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23969211~23969873:+ CESC cis rs13631 0.697 rs1018330 ENSG00000268996.3 MAN1B1-AS1 5.32 2.59e-07 0.00024 0.32 0.34 Cerebrospinal fluid biomarker levels; chr9:137085933 chr9:137084946~137086817:- CESC cis rs875971 0.862 rs709609 ENSG00000226824.5 RP4-756H11.3 5.32 2.59e-07 0.00024 0.44 0.34 Aortic root size; chr7:66095574 chr7:66654538~66669855:+ CESC cis rs12761761 0.744 rs12769669 ENSG00000279982.1 RP11-45A17.3 -5.32 2.6e-07 0.00024 -0.45 -0.34 Intelligence (multi-trait analysis);Educational attainment (years of education); chr10:131992356 chr10:131996738~131999846:+ CESC cis rs875971 0.862 rs6971059 ENSG00000232559.3 GS1-124K5.12 -5.32 2.6e-07 0.000241 -0.37 -0.34 Aortic root size; chr7:66602045 chr7:66554588~66576923:- CESC cis rs875971 0.789 rs7808013 ENSG00000232559.3 GS1-124K5.12 -5.32 2.6e-07 0.000241 -0.37 -0.34 Aortic root size; chr7:66606209 chr7:66554588~66576923:- CESC cis rs875971 0.825 rs7384021 ENSG00000232559.3 GS1-124K5.12 -5.32 2.6e-07 0.000241 -0.37 -0.34 Aortic root size; chr7:66612917 chr7:66554588~66576923:- CESC cis rs875971 0.825 rs66981195 ENSG00000232559.3 GS1-124K5.12 -5.32 2.6e-07 0.000241 -0.37 -0.34 Aortic root size; chr7:66614048 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs3926380 ENSG00000232559.3 GS1-124K5.12 -5.32 2.6e-07 0.000241 -0.37 -0.34 Aortic root size; chr7:66615658 chr7:66554588~66576923:- CESC cis rs9545047 0.604 rs9574410 ENSG00000227676.3 LINC01068 -5.32 2.61e-07 0.000241 -0.38 -0.34 Schizophrenia; chr13:79343091 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2274555 ENSG00000227676.3 LINC01068 -5.32 2.61e-07 0.000241 -0.38 -0.34 Schizophrenia; chr13:79344188 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9565491 ENSG00000227676.3 LINC01068 -5.32 2.61e-07 0.000241 -0.38 -0.34 Schizophrenia; chr13:79346037 chr13:79566727~79571436:+ CESC cis rs765787 0.53 rs10851423 ENSG00000259520.4 CTD-2651B20.3 -5.32 2.62e-07 0.000242 -0.43 -0.34 Uric acid levels; chr15:45223752 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs12913123 ENSG00000259520.4 CTD-2651B20.3 -5.32 2.62e-07 0.000242 -0.43 -0.34 Uric acid levels; chr15:45224227 chr15:45251580~45279251:- CESC cis rs6452524 0.935 rs2731846 ENSG00000249664.1 CTD-2227C6.2 5.32 2.62e-07 0.000242 0.36 0.34 Hypertension (SNP x SNP interaction); chr5:83193781 chr5:83012285~83013109:- CESC cis rs34779708 0.931 rs12268745 ENSG00000230534.5 RP11-297A16.2 5.32 2.62e-07 0.000242 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35017061 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs7923172 ENSG00000230534.5 RP11-297A16.2 5.32 2.62e-07 0.000242 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35020439 chr10:35098006~35127020:- CESC cis rs875971 0.825 rs1860472 ENSG00000232559.3 GS1-124K5.12 -5.32 2.63e-07 0.000242 -0.37 -0.34 Aortic root size; chr7:66617736 chr7:66554588~66576923:- CESC cis rs1577917 0.545 rs9294338 ENSG00000203875.9 SNHG5 5.31 2.63e-07 0.000243 0.37 0.34 Response to antipsychotic treatment; chr6:85764650 chr6:85660950~85678736:- CESC cis rs831571 1 rs166230 ENSG00000280620.1 SCAANT1 -5.31 2.63e-07 0.000243 -0.57 -0.34 Type 2 diabetes; chr3:64067531 chr3:63911518~63911772:- CESC cis rs7665147 1 rs7665147 ENSG00000269949.1 RP11-738E22.3 5.31 2.64e-07 0.000244 0.5 0.34 Platelet count; chr4:56901161 chr4:56960927~56961373:- CESC cis rs6142102 0.625 rs6142068 ENSG00000275784.1 RP5-1125A11.6 5.31 2.64e-07 0.000244 0.34 0.34 Skin pigmentation; chr20:33969366 chr20:33989480~33991818:- CESC cis rs2108622 0.727 rs7251296 ENSG00000267453.5 AC004791.2 -5.31 2.65e-07 0.000244 -0.41 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872926 chr19:15851993~15864904:- CESC cis rs748404 0.631 rs7167882 ENSG00000249839.1 AC011330.5 -5.31 2.66e-07 0.000245 -0.36 -0.34 Lung cancer; chr15:43386465 chr15:43663654~43684339:- CESC cis rs8059260 0.604 rs16957984 ENSG00000274038.1 RP11-66H6.4 -5.31 2.66e-07 0.000245 -0.57 -0.34 Alcohol consumption over the past year; chr16:11051105 chr16:11056556~11057034:+ CESC cis rs875971 0.522 rs2008188 ENSG00000164669.11 INTS4P1 -5.31 2.66e-07 0.000245 -0.47 -0.34 Aortic root size; chr7:65964026 chr7:65141225~65234216:+ CESC cis rs1799949 1 rs8176109 ENSG00000267681.1 CTD-3199J23.6 -5.31 2.66e-07 0.000245 -0.44 -0.34 Menopause (age at onset); chr17:43113759 chr17:43144956~43145255:+ CESC cis rs1799949 0.896 rs8176098 ENSG00000267681.1 CTD-3199J23.6 -5.31 2.66e-07 0.000245 -0.44 -0.34 Menopause (age at onset); chr17:43116189 chr17:43144956~43145255:+ CESC cis rs9549367 0.789 rs7317558 ENSG00000269125.1 RP11-98F14.11 -5.31 2.67e-07 0.000245 -0.45 -0.34 Platelet distribution width; chr13:113239311 chr13:113165002~113165183:- CESC cis rs7572733 0.967 rs976179 ENSG00000222017.1 AC011997.1 -5.31 2.67e-07 0.000246 -0.37 -0.34 Dermatomyositis; chr2:198015654 chr2:197693106~197774823:+ CESC cis rs7188445 0.932 rs17767904 ENSG00000261390.4 RP11-345M22.2 -5.31 2.68e-07 0.000247 -0.44 -0.34 Urate levels; chr16:79716078 chr16:79715232~79770563:- CESC cis rs11651753 0.636 rs4794332 ENSG00000264920.1 RP11-6N17.4 -5.31 2.68e-07 0.000247 -0.39 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47963201 chr17:47891255~47895812:- CESC cis rs11096990 0.613 rs1451821 ENSG00000249207.1 RP11-360F5.1 5.31 2.68e-07 0.000247 0.38 0.34 Cognitive function; chr4:39178797 chr4:39112677~39126818:- CESC cis rs4718428 0.705 rs12536410 ENSG00000226824.5 RP4-756H11.3 -5.31 2.69e-07 0.000247 -0.47 -0.34 Corneal structure; chr7:66789303 chr7:66654538~66669855:+ CESC cis rs34779708 0.966 rs12257770 ENSG00000230534.5 RP11-297A16.2 5.31 2.69e-07 0.000247 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35228306 chr10:35098006~35127020:- CESC cis rs9545047 0.584 rs7995243 ENSG00000227676.3 LINC01068 -5.31 2.69e-07 0.000248 -0.38 -0.34 Schizophrenia; chr13:79358645 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9601217 ENSG00000227676.3 LINC01068 -5.31 2.69e-07 0.000248 -0.38 -0.34 Schizophrenia; chr13:79359797 chr13:79566727~79571436:+ CESC cis rs11096990 0.593 rs7685619 ENSG00000249207.1 RP11-360F5.1 -5.31 2.69e-07 0.000248 -0.38 -0.34 Cognitive function; chr4:39211779 chr4:39112677~39126818:- CESC cis rs131777 0.577 rs131748 ENSG00000205559.3 CHKB-AS1 5.31 2.7e-07 0.000248 0.38 0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586408 chr22:50583026~50583877:+ CESC cis rs7188445 0.932 rs73575095 ENSG00000261390.4 RP11-345M22.2 -5.31 2.7e-07 0.000248 -0.44 -0.34 Urate levels; chr16:79716435 chr16:79715232~79770563:- CESC cis rs2337406 0.866 rs74090151 ENSG00000274576.2 IGHV2-70 -5.31 2.7e-07 0.000248 -0.41 -0.34 Alzheimer's disease (late onset); chr14:106785377 chr14:106770577~106771020:- CESC cis rs7684253 0.587 rs7670313 ENSG00000269949.1 RP11-738E22.3 -5.31 2.71e-07 0.000249 -0.4 -0.34 Migraine; chr4:56880007 chr4:56960927~56961373:- CESC cis rs7684253 0.587 rs2170074 ENSG00000269949.1 RP11-738E22.3 -5.31 2.71e-07 0.000249 -0.4 -0.34 Migraine; chr4:56880190 chr4:56960927~56961373:- CESC cis rs7684253 0.587 rs2170073 ENSG00000269949.1 RP11-738E22.3 -5.31 2.71e-07 0.000249 -0.4 -0.34 Migraine; chr4:56880659 chr4:56960927~56961373:- CESC cis rs875971 0.522 rs10807697 ENSG00000164669.11 INTS4P1 -5.31 2.71e-07 0.000249 -0.47 -0.34 Aortic root size; chr7:65951183 chr7:65141225~65234216:+ CESC cis rs2581828 0.965 rs2581830 ENSG00000242142.1 SERBP1P3 5.31 2.71e-07 0.000249 0.38 0.34 Crohn's disease; chr3:53100082 chr3:53064283~53065091:- CESC cis rs9584850 0.794 rs72655609 ENSG00000231194.1 FARP1-AS1 5.31 2.71e-07 0.000249 0.44 0.34 Neuroticism; chr13:98476368 chr13:98435405~98435840:- CESC cis rs8062405 0.755 rs56209193 ENSG00000259982.1 CDC37P1 5.31 2.71e-07 0.000249 0.43 0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574315 chr16:28700294~28701540:- CESC cis rs1799949 1 rs35668327 ENSG00000267681.1 CTD-3199J23.6 -5.31 2.71e-07 0.000249 -0.44 -0.34 Menopause (age at onset); chr17:43121078 chr17:43144956~43145255:+ CESC cis rs4718428 0.705 rs10267335 ENSG00000273142.1 RP11-458F8.4 -5.31 2.72e-07 0.00025 -0.36 -0.34 Corneal structure; chr7:66938233 chr7:66902857~66906297:+ CESC cis rs957448 1 rs12543207 ENSG00000253704.1 RP11-267M23.4 5.31 2.72e-07 0.00025 0.39 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94485202 chr8:94553722~94569745:+ CESC cis rs2108622 0.628 rs11086005 ENSG00000267453.5 AC004791.2 -5.31 2.72e-07 0.00025 -0.4 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15864286 chr19:15851993~15864904:- CESC cis rs2108622 0.649 rs113055956 ENSG00000267453.5 AC004791.2 -5.31 2.72e-07 0.00025 -0.41 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866502 chr19:15851993~15864904:- CESC cis rs11690935 1 rs312924 ENSG00000228389.1 AC068039.4 -5.31 2.73e-07 0.00025 -0.45 -0.34 Schizophrenia; chr2:171707511 chr2:171773482~171775844:+ CESC cis rs4660456 0.956 rs4660457 ENSG00000237899.1 RP4-739H11.3 -5.31 2.73e-07 0.000251 -0.46 -0.34 Platelet count; chr1:40774121 chr1:40669089~40687588:- CESC cis rs6452524 0.967 rs2974448 ENSG00000249664.1 CTD-2227C6.2 5.31 2.73e-07 0.000251 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83190937 chr5:83012285~83013109:- CESC cis rs7572733 0.905 rs1866664 ENSG00000222017.1 AC011997.1 5.31 2.73e-07 0.000251 0.37 0.34 Dermatomyositis; chr2:197995704 chr2:197693106~197774823:+ CESC cis rs9549367 0.789 rs35569628 ENSG00000269125.1 RP11-98F14.11 -5.31 2.74e-07 0.000251 -0.45 -0.34 Platelet distribution width; chr13:113218398 chr13:113165002~113165183:- CESC cis rs10262624 0.935 rs6955725 ENSG00000234286.1 AC006026.13 -5.31 2.74e-07 0.000251 -0.37 -0.34 Schizophrenia; chr7:23865523 chr7:23680195~23680786:- CESC cis rs7189233 0.513 rs8044091 ENSG00000279344.1 RP11-44F14.7 5.31 2.74e-07 0.000252 0.32 0.34 Intelligence (multi-trait analysis); chr16:53487086 chr16:53478957~53481550:- CESC cis rs733592 0.507 rs56129148 ENSG00000240399.1 RP1-228P16.1 -5.31 2.75e-07 0.000253 -0.34 -0.34 Plateletcrit; chr12:48091747 chr12:48054813~48055591:- CESC cis rs9549367 0.673 rs3024735 ENSG00000269125.1 RP11-98F14.11 -5.3 2.76e-07 0.000253 -0.48 -0.34 Platelet distribution width; chr13:113165199 chr13:113165002~113165183:- CESC cis rs4974559 0.947 rs10018627 ENSG00000253399.1 AC078852.2 5.3 2.77e-07 0.000254 0.56 0.34 Systolic blood pressure; chr4:1362570 chr4:1358479~1359461:+ CESC cis rs875971 0.862 rs1167408 ENSG00000237310.1 GS1-124K5.4 -5.3 2.77e-07 0.000254 -0.33 -0.34 Aortic root size; chr7:66091121 chr7:66493706~66495474:+ CESC cis rs875971 0.83 rs1167406 ENSG00000237310.1 GS1-124K5.4 -5.3 2.77e-07 0.000254 -0.33 -0.34 Aortic root size; chr7:66091949 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs1167399 ENSG00000237310.1 GS1-124K5.4 -5.3 2.77e-07 0.000254 -0.33 -0.34 Aortic root size; chr7:66096890 chr7:66493706~66495474:+ CESC cis rs875971 0.825 rs59466412 ENSG00000237310.1 GS1-124K5.4 -5.3 2.77e-07 0.000254 -0.33 -0.34 Aortic root size; chr7:66100371 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs57866200 ENSG00000237310.1 GS1-124K5.4 -5.3 2.77e-07 0.000254 -0.33 -0.34 Aortic root size; chr7:66100405 chr7:66493706~66495474:+ CESC cis rs9549367 0.713 rs56002882 ENSG00000269125.1 RP11-98F14.11 -5.3 2.77e-07 0.000254 -0.48 -0.34 Platelet distribution width; chr13:113176380 chr13:113165002~113165183:- CESC cis rs7572733 0.773 rs16866970 ENSG00000222017.1 AC011997.1 5.3 2.78e-07 0.000255 0.38 0.34 Dermatomyositis; chr2:197646362 chr2:197693106~197774823:+ CESC cis rs7572733 0.773 rs11690491 ENSG00000222017.1 AC011997.1 5.3 2.78e-07 0.000255 0.38 0.34 Dermatomyositis; chr2:197650200 chr2:197693106~197774823:+ CESC cis rs10935480 0.904 rs13065271 ENSG00000239445.4 ST3GAL6-AS1 -5.3 2.79e-07 0.000256 -0.4 -0.34 Blood protein levels; chr3:98715649 chr3:98714330~98732651:- CESC cis rs2919917 1 rs2369440 ENSG00000254352.1 RP11-578O24.2 5.3 2.79e-07 0.000256 0.43 0.34 Lymphocyte counts; chr8:78709474 chr8:78723796~78724136:- CESC cis rs34779708 0.966 rs12773647 ENSG00000230534.5 RP11-297A16.2 5.3 2.8e-07 0.000257 0.44 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35151399 chr10:35098006~35127020:- CESC cis rs875971 0.798 rs6460304 ENSG00000237310.1 GS1-124K5.4 5.3 2.8e-07 0.000257 0.32 0.34 Aortic root size; chr7:66499741 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6945775 ENSG00000237310.1 GS1-124K5.4 5.3 2.8e-07 0.000257 0.32 0.34 Aortic root size; chr7:66503987 chr7:66493706~66495474:+ CESC cis rs875971 0.798 rs57739047 ENSG00000237310.1 GS1-124K5.4 5.3 2.8e-07 0.000257 0.32 0.34 Aortic root size; chr7:66507579 chr7:66493706~66495474:+ CESC cis rs875971 0.83 rs6950137 ENSG00000237310.1 GS1-124K5.4 5.3 2.8e-07 0.000257 0.32 0.34 Aortic root size; chr7:66511623 chr7:66493706~66495474:+ CESC cis rs6723162 0.965 rs11126308 ENSG00000237751.2 LINC01143 -5.3 2.8e-07 0.000257 -0.42 -0.34 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70887591 chr2:70887871~70889959:+ CESC cis rs11690935 0.843 rs9784123 ENSG00000228389.1 AC068039.4 5.3 2.81e-07 0.000257 0.43 0.34 Schizophrenia; chr2:171928495 chr2:171773482~171775844:+ CESC cis rs72627509 0.857 rs55762216 ENSG00000269949.1 RP11-738E22.3 5.3 2.81e-07 0.000257 0.52 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56899565 chr4:56960927~56961373:- CESC cis rs4660456 0.504 rs491619 ENSG00000237899.1 RP4-739H11.3 5.3 2.81e-07 0.000257 0.47 0.34 Platelet count; chr1:40641688 chr1:40669089~40687588:- CESC cis rs150992 0.603 rs161732 ENSG00000248489.1 CTD-2007H13.3 -5.3 2.81e-07 0.000257 -0.44 -0.34 Body mass index; chr5:98941418 chr5:98929171~98995013:+ CESC cis rs42490 0.966 rs218936 ENSG00000251136.7 RP11-37B2.1 5.3 2.81e-07 0.000258 0.34 0.34 Leprosy; chr8:89743186 chr8:89609409~89757727:- CESC cis rs9929218 0.559 rs55907909 ENSG00000260459.2 FTLP14 5.3 2.82e-07 0.000258 0.43 0.34 Colorectal cancer; chr16:68771902 chr16:68822587~68823070:+ CESC cis rs9929218 0.539 rs1125557 ENSG00000260459.2 FTLP14 5.3 2.82e-07 0.000258 0.43 0.34 Colorectal cancer; chr16:68775696 chr16:68822587~68823070:+ CESC cis rs7580658 0.864 rs3088374 ENSG00000236682.1 AC068282.3 -5.3 2.82e-07 0.000258 -0.4 -0.34 Protein C levels; chr2:127304472 chr2:127389130~127400580:+ CESC cis rs9907295 1 rs9908011 ENSG00000270977.1 AC015849.16 -5.3 2.82e-07 0.000258 -0.47 -0.34 Fibroblast growth factor basic levels; chr17:35908371 chr17:35893707~35911023:- CESC cis rs4718428 0.607 rs66954441 ENSG00000273142.1 RP11-458F8.4 -5.3 2.82e-07 0.000258 -0.36 -0.34 Corneal structure; chr7:66904222 chr7:66902857~66906297:+ CESC cis rs494459 0.838 rs555649 ENSG00000255422.1 AP002954.4 -5.3 2.82e-07 0.000258 -0.4 -0.34 Height; chr11:118781100 chr11:118704607~118750263:+ CESC cis rs2842992 0.83 rs1535475 ENSG00000237927.1 RP3-393E18.2 -5.3 2.83e-07 0.000259 -0.44 -0.34 Age-related macular degeneration (geographic atrophy); chr6:159727903 chr6:159586955~159589169:- CESC cis rs9549367 0.826 rs1885688 ENSG00000269125.1 RP11-98F14.11 -5.3 2.83e-07 0.000259 -0.45 -0.34 Platelet distribution width; chr13:113239922 chr13:113165002~113165183:- CESC cis rs7188445 0.836 rs3813580 ENSG00000261390.4 RP11-345M22.2 -5.3 2.83e-07 0.000259 -0.43 -0.34 Urate levels; chr16:79715383 chr16:79715232~79770563:- CESC cis rs11168351 0.591 rs4258439 ENSG00000240399.1 RP1-228P16.1 -5.3 2.84e-07 0.000259 -0.34 -0.34 Bipolar disorder and schizophrenia; chr12:48074869 chr12:48054813~48055591:- CESC cis rs733592 0.507 rs10747529 ENSG00000240399.1 RP1-228P16.1 -5.3 2.84e-07 0.000259 -0.34 -0.34 Plateletcrit; chr12:48079586 chr12:48054813~48055591:- CESC cis rs8072100 0.967 rs4794058 ENSG00000228782.6 CTD-2026D20.3 -5.3 2.84e-07 0.000259 -0.4 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47519732 chr17:47450568~47492492:- CESC cis rs10875746 0.68 rs4760610 ENSG00000240399.1 RP1-228P16.1 -5.3 2.84e-07 0.000259 -0.42 -0.34 Longevity (90 years and older); chr12:48024442 chr12:48054813~48055591:- CESC cis rs6142102 0.961 rs1319363 ENSG00000276073.1 RP5-1125A11.7 -5.3 2.84e-07 0.00026 -0.33 -0.34 Skin pigmentation; chr20:33954070 chr20:33985617~33988989:- CESC cis rs10829156 1 rs10829156 ENSG00000240291.1 RP11-499P20.2 5.3 2.84e-07 0.00026 0.36 0.34 Sudden cardiac arrest; chr10:18661626 chr10:18513115~18545651:- CESC cis rs875971 0.862 rs778720 ENSG00000237310.1 GS1-124K5.4 -5.3 2.85e-07 0.00026 -0.32 -0.34 Aortic root size; chr7:66381288 chr7:66493706~66495474:+ CESC cis rs73086581 1 rs73086535 ENSG00000229539.1 RP11-119B16.2 5.3 2.86e-07 0.000261 0.54 0.34 Response to antidepressants in depression; chr20:3963503 chr20:3888239~3888868:- CESC cis rs34779708 0.931 rs2384275 ENSG00000230534.5 RP11-297A16.2 5.3 2.86e-07 0.000261 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35008214 chr10:35098006~35127020:- CESC cis rs6504950 0.886 rs2787500 ENSG00000275710.1 RP11-257O5.4 -5.3 2.86e-07 0.000261 -0.38 -0.34 Breast cancer; chr17:55092445 chr17:54964474~54964679:+ CESC cis rs8177876 0.822 rs8177939 ENSG00000261838.4 RP11-303E16.6 5.3 2.86e-07 0.000261 0.74 0.34 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085591 chr16:81069854~81076598:+ CESC cis rs2284378 0.506 rs6142059 ENSG00000275784.1 RP5-1125A11.6 -5.3 2.87e-07 0.000262 -0.34 -0.34 Breast cancer; chr20:33956521 chr20:33989480~33991818:- CESC cis rs748404 0.56 rs570933 ENSG00000205771.5 CATSPER2P1 -5.3 2.87e-07 0.000262 -0.4 -0.34 Lung cancer; chr15:43531832 chr15:43726918~43747094:- CESC cis rs748404 0.631 rs7163288 ENSG00000205771.5 CATSPER2P1 -5.3 2.87e-07 0.000262 -0.41 -0.34 Lung cancer; chr15:43379157 chr15:43726918~43747094:- CESC cis rs42490 0.625 rs427854 ENSG00000251136.7 RP11-37B2.1 -5.3 2.87e-07 0.000262 -0.34 -0.34 Leprosy; chr8:89843518 chr8:89609409~89757727:- CESC cis rs1062177 0.855 rs919262 ENSG00000253921.1 CTB-113P19.3 5.3 2.89e-07 0.000263 0.42 0.34 Preschool internalizing problems; chr5:151886523 chr5:151753992~151767247:+ CESC cis rs4660456 0.913 rs2780952 ENSG00000237899.1 RP4-739H11.3 5.3 2.89e-07 0.000263 0.45 0.34 Platelet count; chr1:40689711 chr1:40669089~40687588:- CESC cis rs7572733 0.792 rs1064213 ENSG00000222017.1 AC011997.1 5.3 2.89e-07 0.000264 0.38 0.34 Dermatomyositis; chr2:198085516 chr2:197693106~197774823:+ CESC cis rs6904897 0.563 rs6569976 ENSG00000232876.1 CTA-212D2.2 -5.3 2.89e-07 0.000264 -0.38 -0.34 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134903615 chr6:135055033~135060550:+ CESC cis rs34779708 0.931 rs35388511 ENSG00000230534.5 RP11-297A16.2 5.3 2.89e-07 0.000264 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35007688 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs34815241 ENSG00000230534.5 RP11-297A16.2 5.3 2.89e-07 0.000264 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35007748 chr10:35098006~35127020:- CESC cis rs7572733 0.935 rs10931796 ENSG00000222017.1 AC011997.1 5.3 2.9e-07 0.000264 0.37 0.34 Dermatomyositis; chr2:197975937 chr2:197693106~197774823:+ CESC cis rs2581828 0.965 rs35783750 ENSG00000242142.1 SERBP1P3 5.3 2.9e-07 0.000264 0.38 0.34 Crohn's disease; chr3:53100847 chr3:53064283~53065091:- CESC cis rs2581828 0.965 rs34454739 ENSG00000242142.1 SERBP1P3 5.3 2.9e-07 0.000264 0.38 0.34 Crohn's disease; chr3:53100955 chr3:53064283~53065091:- CESC cis rs9322193 1 rs58189451 ENSG00000268592.3 RAET1E-AS1 5.3 2.9e-07 0.000264 0.45 0.34 Lung cancer; chr6:149600252 chr6:149863494~149919507:+ CESC cis rs9907295 0.901 rs9907121 ENSG00000270977.1 AC015849.16 -5.29 2.9e-07 0.000265 -0.46 -0.34 Fibroblast growth factor basic levels; chr17:35849074 chr17:35893707~35911023:- CESC cis rs9322193 0.923 rs10782318 ENSG00000268592.3 RAET1E-AS1 5.29 2.91e-07 0.000265 0.45 0.34 Lung cancer; chr6:149754137 chr6:149863494~149919507:+ CESC cis rs9907295 0.685 rs9909050 ENSG00000270977.1 AC015849.16 -5.29 2.91e-07 0.000266 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35887129 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs59338510 ENSG00000270977.1 AC015849.16 -5.29 2.91e-07 0.000266 -0.5 -0.34 Fibroblast growth factor basic levels; chr17:35888098 chr17:35893707~35911023:- CESC cis rs8059260 0.736 rs78121798 ENSG00000274038.1 RP11-66H6.4 -5.29 2.91e-07 0.000266 -0.55 -0.34 Alcohol consumption over the past year; chr16:10984224 chr16:11056556~11057034:+ CESC cis rs6782228 0.675 rs9841987 ENSG00000242551.2 POU5F1P6 -5.29 2.92e-07 0.000266 -0.38 -0.34 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128666299 chr3:128674735~128677005:- CESC cis rs7572733 0.84 rs700640 ENSG00000222017.1 AC011997.1 5.29 2.92e-07 0.000266 0.38 0.34 Dermatomyositis; chr2:197726162 chr2:197693106~197774823:+ CESC cis rs189798 0.592 rs10111263 ENSG00000253893.2 FAM85B 5.29 2.92e-07 0.000266 0.41 0.34 Myopia (pathological); chr8:9111923 chr8:8167819~8226614:- CESC cis rs6991838 0.584 rs2175810 ENSG00000200714.1 Y_RNA -5.29 2.94e-07 0.000268 -0.4 -0.34 Intelligence (multi-trait analysis); chr8:65643583 chr8:65592731~65592820:+ CESC cis rs7572733 0.773 rs7588831 ENSG00000222017.1 AC011997.1 5.29 2.95e-07 0.000269 0.38 0.34 Dermatomyositis; chr2:197643292 chr2:197693106~197774823:+ CESC cis rs7572733 0.773 rs10196961 ENSG00000222017.1 AC011997.1 5.29 2.95e-07 0.000269 0.38 0.34 Dermatomyositis; chr2:197649206 chr2:197693106~197774823:+ CESC cis rs7572733 0.773 rs56858593 ENSG00000222017.1 AC011997.1 5.29 2.96e-07 0.000269 0.38 0.34 Dermatomyositis; chr2:197629744 chr2:197693106~197774823:+ CESC cis rs7572733 0.742 rs3828317 ENSG00000222017.1 AC011997.1 5.29 2.96e-07 0.000269 0.38 0.34 Dermatomyositis; chr2:197630707 chr2:197693106~197774823:+ CESC cis rs11763147 1 rs11763147 ENSG00000164669.11 INTS4P1 5.29 2.96e-07 0.000269 0.47 0.34 Corneal structure; chr7:65861834 chr7:65141225~65234216:+ CESC cis rs7572733 0.773 rs970551 ENSG00000222017.1 AC011997.1 5.29 2.96e-07 0.000269 0.38 0.34 Dermatomyositis; chr2:197632985 chr2:197693106~197774823:+ CESC cis rs2729354 0.817 rs2649667 ENSG00000265566.2 RN7SL605P -5.29 2.96e-07 0.000269 -0.5 -0.34 Blood protein levels; chr11:57503036 chr11:57528085~57528365:- CESC cis rs10740039 0.583 rs1904404 ENSG00000254271.1 RP11-131N11.4 -5.29 2.96e-07 0.000269 -0.4 -0.34 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60742428 chr10:60734342~60741828:+ CESC cis rs7572733 0.84 rs12472359 ENSG00000222017.1 AC011997.1 -5.29 2.96e-07 0.000269 -0.37 -0.34 Dermatomyositis; chr2:197723141 chr2:197693106~197774823:+ CESC cis rs765787 0.53 rs1648289 ENSG00000259520.4 CTD-2651B20.3 5.29 2.97e-07 0.00027 0.41 0.34 Uric acid levels; chr15:45224296 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs1648287 ENSG00000259520.4 CTD-2651B20.3 5.29 2.97e-07 0.00027 0.41 0.34 Uric acid levels; chr15:45224758 chr15:45251580~45279251:- CESC cis rs7572733 0.773 rs970552 ENSG00000222017.1 AC011997.1 -5.29 2.97e-07 0.00027 -0.37 -0.34 Dermatomyositis; chr2:197632788 chr2:197693106~197774823:+ CESC cis rs3823536 0.583 rs11760442 ENSG00000275106.1 RP11-309L24.10 -5.29 2.97e-07 0.00027 -0.47 -0.34 Sjögren's syndrome; chr7:129016066 chr7:128952527~128953316:- CESC cis rs3823536 0.583 rs3847099 ENSG00000275106.1 RP11-309L24.10 -5.29 2.97e-07 0.00027 -0.47 -0.34 Sjögren's syndrome; chr7:129016777 chr7:128952527~128953316:- CESC cis rs3823536 0.604 rs3857852 ENSG00000275106.1 RP11-309L24.10 -5.29 2.97e-07 0.00027 -0.47 -0.34 Sjögren's syndrome; chr7:129017223 chr7:128952527~128953316:- CESC cis rs3823536 0.544 rs12532542 ENSG00000275106.1 RP11-309L24.10 -5.29 2.97e-07 0.00027 -0.47 -0.34 Sjögren's syndrome; chr7:129027358 chr7:128952527~128953316:- CESC cis rs3823536 0.583 rs4731540 ENSG00000275106.1 RP11-309L24.10 -5.29 2.97e-07 0.00027 -0.47 -0.34 Sjögren's syndrome; chr7:129028196 chr7:128952527~128953316:- CESC cis rs9322193 0.884 rs9689702 ENSG00000268592.3 RAET1E-AS1 5.29 2.97e-07 0.00027 0.43 0.34 Lung cancer; chr6:149740720 chr6:149863494~149919507:+ CESC cis rs1823913 0.637 rs11688994 ENSG00000280083.1 RP11-317J9.1 -5.29 2.97e-07 0.00027 -0.38 -0.34 Obesity-related traits; chr2:191266242 chr2:191154118~191156070:- CESC cis rs7572733 0.773 rs11690844 ENSG00000222017.1 AC011997.1 5.29 2.97e-07 0.00027 0.38 0.34 Dermatomyositis; chr2:197650812 chr2:197693106~197774823:+ CESC cis rs7572733 0.773 rs7601762 ENSG00000222017.1 AC011997.1 5.29 2.97e-07 0.00027 0.38 0.34 Dermatomyositis; chr2:197664513 chr2:197693106~197774823:+ CESC cis rs1707322 0.752 rs11211145 ENSG00000281133.1 AL355480.3 -5.29 2.98e-07 0.00027 -0.43 -0.34 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642819 chr1:45580892~45580996:- CESC cis rs801193 0.569 rs7782587 ENSG00000232559.3 GS1-124K5.12 5.29 2.98e-07 0.00027 0.37 0.34 Aortic root size; chr7:66701485 chr7:66554588~66576923:- CESC cis rs62229266 0.659 rs62230814 ENSG00000231106.2 LINC01436 5.29 2.98e-07 0.000271 0.45 0.34 Mitral valve prolapse; chr21:36031248 chr21:36005338~36007838:+ CESC cis rs62229266 0.633 rs34259635 ENSG00000231106.2 LINC01436 5.29 2.98e-07 0.000271 0.45 0.34 Mitral valve prolapse; chr21:36031272 chr21:36005338~36007838:+ CESC cis rs6991838 0.798 rs62507575 ENSG00000200714.1 Y_RNA 5.29 2.98e-07 0.000271 0.4 0.34 Intelligence (multi-trait analysis); chr8:65566486 chr8:65592731~65592820:+ CESC cis rs11690935 0.843 rs9784070 ENSG00000228389.1 AC068039.4 5.29 2.98e-07 0.000271 0.43 0.34 Schizophrenia; chr2:171928497 chr2:171773482~171775844:+ CESC cis rs4141404 0.604 rs5753625 ENSG00000236132.1 CTA-440B3.1 5.29 2.99e-07 0.000272 0.39 0.34 Paclitaxel-induced neuropathy; chr22:31458860 chr22:31816379~31817491:- CESC cis rs6504950 0.925 rs244317 ENSG00000275710.1 RP11-257O5.4 -5.29 3e-07 0.000272 -0.47 -0.34 Breast cancer; chr17:55139624 chr17:54964474~54964679:+ CESC cis rs8059260 0.736 rs16957872 ENSG00000274038.1 RP11-66H6.4 -5.29 3e-07 0.000273 -0.53 -0.34 Alcohol consumption over the past year; chr16:10988835 chr16:11056556~11057034:+ CESC cis rs9929218 0.559 rs11642362 ENSG00000260459.2 FTLP14 5.29 3.01e-07 0.000273 0.44 0.34 Colorectal cancer; chr16:68777404 chr16:68822587~68823070:+ CESC cis rs2882667 0.537 rs11743534 ENSG00000253404.1 AC034243.1 5.29 3.02e-07 0.000274 0.39 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139073318 chr5:138744434~138753309:- CESC cis rs42490 0.7 rs410663 ENSG00000251136.7 RP11-37B2.1 5.29 3.02e-07 0.000274 0.34 0.34 Leprosy; chr8:89859461 chr8:89609409~89757727:- CESC cis rs4660456 0.827 rs617413 ENSG00000237899.1 RP4-739H11.3 5.29 3.02e-07 0.000274 0.46 0.34 Platelet count; chr1:40669846 chr1:40669089~40687588:- CESC cis rs4660456 0.869 rs616954 ENSG00000237899.1 RP4-739H11.3 5.29 3.02e-07 0.000274 0.46 0.34 Platelet count; chr1:40669947 chr1:40669089~40687588:- CESC cis rs9545047 0.604 rs9545076 ENSG00000227676.3 LINC01068 -5.29 3.02e-07 0.000274 -0.37 -0.34 Schizophrenia; chr13:79335983 chr13:79566727~79571436:+ CESC cis rs875971 0.522 rs4718285 ENSG00000164669.11 INTS4P1 -5.29 3.03e-07 0.000274 -0.47 -0.34 Aortic root size; chr7:65827018 chr7:65141225~65234216:+ CESC cis rs875971 0.522 rs4502988 ENSG00000164669.11 INTS4P1 -5.29 3.03e-07 0.000274 -0.47 -0.34 Aortic root size; chr7:65832759 chr7:65141225~65234216:+ CESC cis rs17711722 0.64 rs13237956 ENSG00000164669.11 INTS4P1 -5.29 3.03e-07 0.000274 -0.47 -0.34 Calcium levels; chr7:65853042 chr7:65141225~65234216:+ CESC cis rs9322193 0.923 rs10782315 ENSG00000268592.3 RAET1E-AS1 5.29 3.03e-07 0.000274 0.43 0.34 Lung cancer; chr6:149743093 chr6:149863494~149919507:+ CESC cis rs2842992 0.83 rs1998365 ENSG00000237927.1 RP3-393E18.2 -5.29 3.03e-07 0.000275 -0.44 -0.34 Age-related macular degeneration (geographic atrophy); chr6:159758503 chr6:159586955~159589169:- CESC cis rs2337406 0.866 rs111881598 ENSG00000274576.2 IGHV2-70 -5.29 3.03e-07 0.000275 -0.41 -0.34 Alzheimer's disease (late onset); chr14:106783113 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs61164979 ENSG00000274576.2 IGHV2-70 -5.29 3.03e-07 0.000275 -0.41 -0.34 Alzheimer's disease (late onset); chr14:106783133 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs61419485 ENSG00000274576.2 IGHV2-70 -5.29 3.03e-07 0.000275 -0.41 -0.34 Alzheimer's disease (late onset); chr14:106783374 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs8015361 ENSG00000274576.2 IGHV2-70 -5.29 3.03e-07 0.000275 -0.41 -0.34 Alzheimer's disease (late onset); chr14:106783991 chr14:106770577~106771020:- CESC cis rs875971 0.862 rs6460307 ENSG00000237310.1 GS1-124K5.4 5.29 3.03e-07 0.000275 0.32 0.34 Aortic root size; chr7:66595884 chr7:66493706~66495474:+ CESC cis rs72627509 0.68 rs66790703 ENSG00000269949.1 RP11-738E22.3 5.29 3.04e-07 0.000275 0.49 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56907742 chr4:56960927~56961373:- CESC cis rs72627509 0.857 rs781658 ENSG00000269949.1 RP11-738E22.3 5.29 3.04e-07 0.000275 0.49 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56913401 chr4:56960927~56961373:- CESC cis rs11096990 0.634 rs7659894 ENSG00000249207.1 RP11-360F5.1 5.29 3.04e-07 0.000275 0.37 0.34 Cognitive function; chr4:39282815 chr4:39112677~39126818:- CESC cis rs7188445 0.932 rs73575086 ENSG00000261390.4 RP11-345M22.2 -5.28 3.05e-07 0.000276 -0.43 -0.34 Urate levels; chr16:79714588 chr16:79715232~79770563:- CESC cis rs13392177 0.672 rs1877715 ENSG00000261338.2 RP11-378A13.1 5.28 3.05e-07 0.000276 0.42 0.34 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218187823 chr2:218255319~218257366:+ CESC cis rs75422866 0.867 rs73113143 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47623060 chr12:47706085~47742294:+ CESC cis rs75422866 0.717 rs73113159 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47631318 chr12:47706085~47742294:+ CESC cis rs75422866 0.717 rs73113161 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47632361 chr12:47706085~47742294:+ CESC cis rs75422866 1 rs73102120 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47637280 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102125 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47637869 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs12426849 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47638975 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs117950951 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47639794 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs7954764 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47641136 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs12422974 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47644559 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102127 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47645341 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs75568526 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47649718 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs116302411 ENSG00000257433.4 RP1-197B17.3 5.28 3.05e-07 0.000276 0.83 0.34 Pneumonia; chr12:47649788 chr12:47706085~47742294:+ CESC cis rs2919917 1 rs7010897 ENSG00000254352.1 RP11-578O24.2 5.28 3.05e-07 0.000276 0.44 0.34 Lymphocyte counts; chr8:78708119 chr8:78723796~78724136:- CESC cis rs6142102 0.886 rs6142098 ENSG00000276073.1 RP5-1125A11.7 -5.28 3.05e-07 0.000276 -0.32 -0.34 Skin pigmentation; chr20:34100488 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs6087557 ENSG00000276073.1 RP5-1125A11.7 -5.28 3.05e-07 0.000276 -0.32 -0.34 Skin pigmentation; chr20:34110469 chr20:33985617~33988989:- CESC cis rs2548724 0.536 rs55912935 ENSG00000250682.4 LINC00491 5.28 3.06e-07 0.000277 0.4 0.34 Type 2 diabetes; chr5:102475250 chr5:102609156~102671559:- CESC cis rs42490 0.653 rs40247 ENSG00000251136.7 RP11-37B2.1 -5.28 3.06e-07 0.000277 -0.34 -0.34 Leprosy; chr8:89789744 chr8:89609409~89757727:- CESC cis rs17507216 0.628 rs28607761 ENSG00000278603.1 RP13-608F4.5 5.28 3.07e-07 0.000277 0.55 0.34 Excessive daytime sleepiness; chr15:82715317 chr15:82472203~82472426:+ CESC cis rs2015599 0.623 rs1006410 ENSG00000275476.1 RP11-996F15.4 5.28 3.07e-07 0.000277 0.38 0.34 Platelet count;Mean platelet volume; chr12:29282682 chr12:29277397~29277882:- CESC cis rs6700559 0.81 rs2808250 ENSG00000260088.1 RP11-92G12.3 -5.28 3.07e-07 0.000277 -0.42 -0.34 Coronary artery disease; chr1:200623419 chr1:200669507~200694250:+ CESC cis rs8040855 0.621 rs6496796 ENSG00000259295.5 CSPG4P12 -5.28 3.08e-07 0.000278 -0.39 -0.34 Bulimia nervosa; chr15:85183617 chr15:85191438~85213905:+ CESC cis rs8072100 0.967 rs8072644 ENSG00000228782.6 CTD-2026D20.3 -5.28 3.09e-07 0.000279 -0.38 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47575998 chr17:47450568~47492492:- CESC cis rs34779708 0.966 rs878264 ENSG00000230534.5 RP11-297A16.2 5.28 3.09e-07 0.000279 0.44 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35151653 chr10:35098006~35127020:- CESC cis rs35955747 0.869 rs8141987 ENSG00000236132.1 CTA-440B3.1 5.28 3.09e-07 0.000279 0.38 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31191169 chr22:31816379~31817491:- CESC cis rs35955747 0.869 rs8142988 ENSG00000236132.1 CTA-440B3.1 5.28 3.09e-07 0.000279 0.38 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31191172 chr22:31816379~31817491:- CESC cis rs10875746 0.551 rs11168536 ENSG00000240399.1 RP1-228P16.1 -5.28 3.1e-07 0.00028 -0.45 -0.34 Longevity (90 years and older); chr12:48351268 chr12:48054813~48055591:- CESC cis rs72627509 0.767 rs6853156 ENSG00000269949.1 RP11-738E22.3 5.28 3.11e-07 0.00028 0.51 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56908677 chr4:56960927~56961373:- CESC cis rs860295 0.557 rs10796941 ENSG00000225855.5 RUSC1-AS1 5.28 3.11e-07 0.00028 0.29 0.34 Body mass index; chr1:155314470 chr1:155316863~155324176:- CESC cis rs860295 0.58 rs10908463 ENSG00000225855.5 RUSC1-AS1 5.28 3.11e-07 0.00028 0.29 0.34 Body mass index; chr1:155316467 chr1:155316863~155324176:- CESC cis rs4660456 0.913 rs656230 ENSG00000237899.1 RP4-739H11.3 5.28 3.11e-07 0.000281 0.45 0.34 Platelet count; chr1:40692701 chr1:40669089~40687588:- CESC cis rs2739330 0.828 rs2330635 ENSG00000231271.1 AP000350.8 5.28 3.12e-07 0.000281 0.41 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23949918~23954042:+ CESC cis rs9549367 0.789 rs9577218 ENSG00000269125.1 RP11-98F14.11 -5.28 3.13e-07 0.000282 -0.45 -0.34 Platelet distribution width; chr13:113240597 chr13:113165002~113165183:- CESC cis rs2919917 1 rs1054283 ENSG00000254352.1 RP11-578O24.2 5.28 3.13e-07 0.000282 0.44 0.34 Lymphocyte counts; chr8:78698475 chr8:78723796~78724136:- CESC cis rs150992 0.688 rs161947 ENSG00000248489.1 CTD-2007H13.3 5.28 3.15e-07 0.000284 0.45 0.34 Body mass index; chr5:98932868 chr5:98929171~98995013:+ CESC cis rs765787 0.53 rs11636395 ENSG00000259520.4 CTD-2651B20.3 5.28 3.15e-07 0.000284 0.41 0.34 Uric acid levels; chr15:45243486 chr15:45251580~45279251:- CESC cis rs6142102 0.961 rs2235596 ENSG00000276073.1 RP5-1125A11.7 5.28 3.15e-07 0.000284 0.32 0.34 Skin pigmentation; chr20:34096503 chr20:33985617~33988989:- CESC cis rs748404 0.66 rs2467738 ENSG00000249839.1 AC011330.5 -5.28 3.15e-07 0.000284 -0.35 -0.34 Lung cancer; chr15:43447738 chr15:43663654~43684339:- CESC cis rs7674212 0.865 rs1481279 ENSG00000246560.2 RP11-10L12.4 -5.28 3.16e-07 0.000284 -0.4 -0.34 Type 2 diabetes; chr4:103056781 chr4:102828055~102844075:+ CESC cis rs35160687 0.798 rs2367233 ENSG00000273080.1 RP11-301O19.1 -5.28 3.16e-07 0.000284 -0.39 -0.34 Night sleep phenotypes; chr2:86314543 chr2:86195590~86196049:+ CESC cis rs2439831 0.867 rs3101443 ENSG00000275601.1 AC011330.13 -5.28 3.17e-07 0.000286 -0.48 -0.34 Lung cancer in ever smokers; chr15:43620174 chr15:43642389~43643023:- CESC cis rs1799949 1 rs3950989 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.17e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43085936 chr17:43144956~43145255:+ CESC cis rs9549367 0.713 rs9549357 ENSG00000269125.1 RP11-98F14.11 -5.28 3.18e-07 0.000286 -0.45 -0.34 Platelet distribution width; chr13:113205807 chr13:113165002~113165183:- CESC cis rs875971 0.516 rs6945322 ENSG00000164669.11 INTS4P1 -5.28 3.18e-07 0.000286 -0.47 -0.34 Aortic root size; chr7:65871069 chr7:65141225~65234216:+ CESC cis rs2581828 0.965 rs2581829 ENSG00000242142.1 SERBP1P3 -5.28 3.18e-07 0.000286 -0.38 -0.34 Crohn's disease; chr3:53099510 chr3:53064283~53065091:- CESC cis rs1799949 0.896 rs8176086 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43122761 chr17:43144956~43145255:+ CESC cis rs1799949 0.93 rs3765640 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43124230 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176077 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43124331 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs11655505 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43126360 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs4793204 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43127281 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs12947782 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43127865 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs33945274 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43128056 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs33925201 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000286 -0.43 -0.34 Menopause (age at onset); chr17:43128665 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs2175957 ENSG00000267681.1 CTD-3199J23.6 -5.28 3.18e-07 0.000287 -0.43 -0.34 Menopause (age at onset); chr17:43134805 chr17:43144956~43145255:+ CESC cis rs7572733 0.84 rs7340470 ENSG00000222017.1 AC011997.1 -5.28 3.19e-07 0.000287 -0.38 -0.34 Dermatomyositis; chr2:197680738 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs12622674 ENSG00000222017.1 AC011997.1 -5.28 3.19e-07 0.000287 -0.38 -0.34 Dermatomyositis; chr2:197687088 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs6743671 ENSG00000222017.1 AC011997.1 -5.28 3.19e-07 0.000287 -0.38 -0.34 Dermatomyositis; chr2:197698918 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs13034353 ENSG00000222017.1 AC011997.1 -5.28 3.19e-07 0.000287 -0.38 -0.34 Dermatomyositis; chr2:197701039 chr2:197693106~197774823:+ CESC cis rs8177876 0.658 rs77874075 ENSG00000261838.4 RP11-303E16.6 5.28 3.19e-07 0.000287 0.71 0.34 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81032734 chr16:81069854~81076598:+ CESC cis rs2919917 1 rs11986947 ENSG00000254352.1 RP11-578O24.2 5.28 3.19e-07 0.000287 0.44 0.34 Lymphocyte counts; chr8:78708957 chr8:78723796~78724136:- CESC cis rs2919917 1 rs2717539 ENSG00000254352.1 RP11-578O24.2 5.28 3.19e-07 0.000287 0.44 0.34 Lymphocyte counts; chr8:78716804 chr8:78723796~78724136:- CESC cis rs2919917 0.793 rs2625664 ENSG00000254352.1 RP11-578O24.2 5.28 3.19e-07 0.000287 0.44 0.34 Lymphocyte counts; chr8:78718373 chr8:78723796~78724136:- CESC cis rs2919917 1 rs1026920 ENSG00000254352.1 RP11-578O24.2 5.28 3.19e-07 0.000287 0.44 0.34 Lymphocyte counts; chr8:78719775 chr8:78723796~78724136:- CESC cis rs2919917 1 rs2717538 ENSG00000254352.1 RP11-578O24.2 5.28 3.19e-07 0.000287 0.44 0.34 Lymphocyte counts; chr8:78720914 chr8:78723796~78724136:- CESC cis rs11676348 1 rs11676348 ENSG00000261338.2 RP11-378A13.1 -5.27 3.2e-07 0.000288 -0.4 -0.34 Ulcerative colitis; chr2:218145423 chr2:218255319~218257366:+ CESC cis rs42490 0.576 rs388866 ENSG00000251136.7 RP11-37B2.1 -5.27 3.2e-07 0.000288 -0.34 -0.34 Leprosy; chr8:89856604 chr8:89609409~89757727:- CESC cis rs9549367 0.789 rs6577034 ENSG00000269125.1 RP11-98F14.11 -5.27 3.2e-07 0.000288 -0.44 -0.34 Platelet distribution width; chr13:113225586 chr13:113165002~113165183:- CESC cis rs7189233 0.531 rs3929 ENSG00000279344.1 RP11-44F14.7 -5.27 3.2e-07 0.000288 -0.32 -0.34 Intelligence (multi-trait analysis); chr16:53490396 chr16:53478957~53481550:- CESC cis rs11976020 1 rs11976020 ENSG00000205578.5 POM121B -5.27 3.2e-07 0.000288 -0.37 -0.34 Educational attainment (years of education); chr7:72782785 chr7:73293497~73301161:+ CESC cis rs9601248 0.845 rs1932197 ENSG00000227676.3 LINC01068 5.27 3.21e-07 0.000288 0.39 0.34 Major depressive disorder; chr13:79609218 chr13:79566727~79571436:+ CESC cis rs2015599 0.623 rs7313552 ENSG00000275476.1 RP11-996F15.4 5.27 3.21e-07 0.000288 0.38 0.34 Platelet count;Mean platelet volume; chr12:29277302 chr12:29277397~29277882:- CESC cis rs2015599 0.584 rs7299283 ENSG00000275476.1 RP11-996F15.4 5.27 3.21e-07 0.000288 0.38 0.34 Platelet count;Mean platelet volume; chr12:29277442 chr12:29277397~29277882:- CESC cis rs2337406 0.866 rs11488879 ENSG00000274576.2 IGHV2-70 -5.27 3.21e-07 0.000289 -0.41 -0.34 Alzheimer's disease (late onset); chr14:106786097 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs8012619 ENSG00000274576.2 IGHV2-70 -5.27 3.21e-07 0.000289 -0.41 -0.34 Alzheimer's disease (late onset); chr14:106793907 chr14:106770577~106771020:- CESC cis rs7572733 0.935 rs938929 ENSG00000222017.1 AC011997.1 -5.27 3.21e-07 0.000289 -0.37 -0.34 Dermatomyositis; chr2:197916136 chr2:197693106~197774823:+ CESC cis rs1061377 1 rs1982009 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39123253 chr4:39133913~39135608:+ CESC cis rs1061377 0.965 rs1138494 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39123315 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs2890659 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39125401 chr4:39133913~39135608:+ CESC cis rs1061377 0.965 rs1046655 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39126127 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs7694760 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39126481 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs35116118 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39127293 chr4:39133913~39135608:+ CESC cis rs1061377 0.932 rs35464499 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39127670 chr4:39133913~39135608:+ CESC cis rs1061377 0.965 rs11728058 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39128224 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs17508864 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39129025 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs1897136 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39131242 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs1897137 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39131387 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs35437629 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39131712 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs7657926 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39132443 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs7681116 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39133015 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs11096982 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39133247 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs11727875 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39133699 chr4:39133913~39135608:+ CESC cis rs1061377 0.965 rs10018622 ENSG00000249685.1 RP11-360F5.3 5.27 3.22e-07 0.000289 0.39 0.34 Uric acid levels; chr4:39133944 chr4:39133913~39135608:+ CESC cis rs7572733 0.84 rs2341510 ENSG00000222017.1 AC011997.1 -5.27 3.22e-07 0.000289 -0.38 -0.34 Dermatomyositis; chr2:197693955 chr2:197693106~197774823:+ CESC cis rs875971 0.522 rs4718286 ENSG00000164669.11 INTS4P1 -5.27 3.23e-07 0.000289 -0.47 -0.34 Aortic root size; chr7:65827777 chr7:65141225~65234216:+ CESC cis rs17711722 0.585 rs6942660 ENSG00000164669.11 INTS4P1 -5.27 3.23e-07 0.000289 -0.47 -0.34 Calcium levels; chr7:65837419 chr7:65141225~65234216:+ CESC cis rs17507216 0.718 rs17158403 ENSG00000278603.1 RP13-608F4.5 5.27 3.23e-07 0.000289 0.56 0.34 Excessive daytime sleepiness; chr15:82572478 chr15:82472203~82472426:+ CESC cis rs3823536 0.583 rs1072767 ENSG00000275106.1 RP11-309L24.10 -5.27 3.23e-07 0.00029 -0.47 -0.34 Sjögren's syndrome; chr7:129033151 chr7:128952527~128953316:- CESC cis rs4974559 0.947 rs28437782 ENSG00000253399.1 AC078852.2 5.27 3.23e-07 0.00029 0.56 0.34 Systolic blood pressure; chr4:1361274 chr4:1358479~1359461:+ CESC cis rs9322193 0.884 rs1125 ENSG00000268592.3 RAET1E-AS1 5.27 3.23e-07 0.00029 0.43 0.34 Lung cancer; chr6:149658280 chr6:149863494~149919507:+ CESC cis rs875971 0.825 rs28480509 ENSG00000226824.5 RP4-756H11.3 5.27 3.23e-07 0.00029 0.43 0.34 Aortic root size; chr7:66634237 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs778686 ENSG00000222364.1 RNU6-96P -5.27 3.25e-07 0.000291 -0.39 -0.34 Aortic root size; chr7:66370923 chr7:66395191~66395286:+ CESC cis rs17507216 1 rs17158413 ENSG00000255769.6 GOLGA2P10 -5.27 3.26e-07 0.000292 -0.47 -0.34 Excessive daytime sleepiness; chr15:82566658 chr15:82472993~82513950:- CESC cis rs881375 0.678 rs7021049 ENSG00000226752.6 PSMD5-AS1 -5.27 3.26e-07 0.000292 -0.35 -0.34 Rheumatoid arthritis; chr9:120921704 chr9:120824828~120854385:+ CESC cis rs5758659 1 rs134902 ENSG00000273366.1 CTA-989H11.1 -5.27 3.26e-07 0.000292 -0.4 -0.34 Cognitive function; chr22:42287991 chr22:42278188~42278846:+ CESC cis rs4974559 0.947 rs28540746 ENSG00000253399.1 AC078852.2 5.27 3.26e-07 0.000292 0.55 0.34 Systolic blood pressure; chr4:1359166 chr4:1358479~1359461:+ CESC cis rs3823536 0.583 rs3807302 ENSG00000275106.1 RP11-309L24.10 -5.27 3.27e-07 0.000293 -0.46 -0.34 Sjögren's syndrome; chr7:129004803 chr7:128952527~128953316:- CESC cis rs3823536 0.604 rs13221560 ENSG00000275106.1 RP11-309L24.10 -5.27 3.27e-07 0.000293 -0.46 -0.34 Sjögren's syndrome; chr7:129023121 chr7:128952527~128953316:- CESC cis rs765787 0.53 rs13329228 ENSG00000259520.4 CTD-2651B20.3 5.27 3.28e-07 0.000294 0.41 0.34 Uric acid levels; chr15:45240819 chr15:45251580~45279251:- CESC cis rs6452524 0.868 rs1011981 ENSG00000249664.1 CTD-2227C6.2 5.27 3.29e-07 0.000295 0.38 0.34 Hypertension (SNP x SNP interaction); chr5:83097869 chr5:83012285~83013109:- CESC cis rs6452524 0.868 rs17284218 ENSG00000249664.1 CTD-2227C6.2 5.27 3.29e-07 0.000295 0.38 0.34 Hypertension (SNP x SNP interaction); chr5:83099530 chr5:83012285~83013109:- CESC cis rs2442825 0.693 rs2255558 ENSG00000206573.7 THUMPD3-AS1 5.27 3.29e-07 0.000295 0.33 0.34 Cerebrospinal fluid clusterin levels; chr3:9375148 chr3:9349689~9398579:- CESC cis rs2442825 0.72 rs2648561 ENSG00000206573.7 THUMPD3-AS1 5.27 3.29e-07 0.000295 0.33 0.34 Cerebrospinal fluid clusterin levels; chr3:9376399 chr3:9349689~9398579:- CESC cis rs7188445 0.932 rs17689625 ENSG00000261390.4 RP11-345M22.2 -5.27 3.29e-07 0.000295 -0.43 -0.34 Urate levels; chr16:79715065 chr16:79715232~79770563:- CESC cis rs12550612 0.561 rs11784599 ENSG00000253616.4 RP11-875O11.3 5.27 3.3e-07 0.000296 0.53 0.34 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23074609 chr8:23071377~23074488:- CESC cis rs801193 0.569 rs13226966 ENSG00000232559.3 GS1-124K5.12 5.27 3.31e-07 0.000296 0.36 0.34 Aortic root size; chr7:66768636 chr7:66554588~66576923:- CESC cis rs11690935 0.885 rs7602037 ENSG00000228389.1 AC068039.4 5.27 3.31e-07 0.000297 0.42 0.34 Schizophrenia; chr2:171961268 chr2:171773482~171775844:+ CESC cis rs2842992 0.83 rs1853259 ENSG00000237927.1 RP3-393E18.2 5.27 3.32e-07 0.000297 0.44 0.34 Age-related macular degeneration (geographic atrophy); chr6:159726409 chr6:159586955~159589169:- CESC cis rs2842992 0.789 rs2842969 ENSG00000237927.1 RP3-393E18.2 -5.27 3.32e-07 0.000297 -0.44 -0.34 Age-related macular degeneration (geographic atrophy); chr6:159724332 chr6:159586955~159589169:- CESC cis rs875971 0.893 rs62465470 ENSG00000222364.1 RNU6-96P 5.27 3.32e-07 0.000297 0.39 0.34 Aortic root size; chr7:66136231 chr7:66395191~66395286:+ CESC cis rs7674212 1 rs7691873 ENSG00000246560.2 RP11-10L12.4 -5.27 3.34e-07 0.000298 -0.4 -0.34 Type 2 diabetes; chr4:103066742 chr4:102828055~102844075:+ CESC cis rs4718428 0.705 rs4718424 ENSG00000273142.1 RP11-458F8.4 -5.27 3.34e-07 0.000298 -0.36 -0.34 Corneal structure; chr7:66911108 chr7:66902857~66906297:+ CESC cis rs881375 0.715 rs10985073 ENSG00000226752.6 PSMD5-AS1 -5.27 3.34e-07 0.000299 -0.35 -0.34 Rheumatoid arthritis; chr9:120881577 chr9:120824828~120854385:+ CESC cis rs748404 0.631 rs6493084 ENSG00000249839.1 AC011330.5 -5.27 3.34e-07 0.000299 -0.36 -0.34 Lung cancer; chr15:43355429 chr15:43663654~43684339:- CESC cis rs748404 0.631 rs12905772 ENSG00000249839.1 AC011330.5 -5.27 3.34e-07 0.000299 -0.36 -0.34 Lung cancer; chr15:43356246 chr15:43663654~43684339:- CESC cis rs8081395 0.741 rs180520 ENSG00000266992.1 DHX40P1 5.27 3.34e-07 0.000299 0.37 0.34 White blood cell count; chr17:59937788 chr17:59976009~60002384:- CESC cis rs2882667 0.537 rs7701338 ENSG00000253404.1 AC034243.1 5.27 3.34e-07 0.000299 0.38 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139070305 chr5:138744434~138753309:- CESC cis rs42490 0.664 rs372981 ENSG00000251136.7 RP11-37B2.1 -5.27 3.35e-07 0.000299 -0.34 -0.34 Leprosy; chr8:89784740 chr8:89609409~89757727:- CESC cis rs42490 0.653 rs40453 ENSG00000251136.7 RP11-37B2.1 -5.27 3.35e-07 0.000299 -0.34 -0.34 Leprosy; chr8:89789817 chr8:89609409~89757727:- CESC cis rs42490 0.752 rs400411 ENSG00000251136.7 RP11-37B2.1 -5.27 3.35e-07 0.000299 -0.34 -0.34 Leprosy; chr8:89789871 chr8:89609409~89757727:- CESC cis rs42490 0.738 rs39509 ENSG00000251136.7 RP11-37B2.1 -5.27 3.35e-07 0.000299 -0.34 -0.34 Leprosy; chr8:89791937 chr8:89609409~89757727:- CESC cis rs9907295 0.901 rs4795096 ENSG00000270977.1 AC015849.16 -5.27 3.35e-07 0.000299 -0.46 -0.34 Fibroblast growth factor basic levels; chr17:35888821 chr17:35893707~35911023:- CESC cis rs7615952 0.641 rs12491577 ENSG00000250012.1 RP11-124N2.1 -5.27 3.35e-07 0.000299 -0.37 -0.34 Blood pressure (smoking interaction); chr3:126012288 chr3:126084220~126095349:+ CESC cis rs7188445 0.736 rs11642757 ENSG00000261390.4 RP11-345M22.2 -5.26 3.35e-07 3e-04 -0.42 -0.34 Urate levels; chr16:79719570 chr16:79715232~79770563:- CESC cis rs875971 0.522 rs34973832 ENSG00000164669.11 INTS4P1 -5.26 3.37e-07 0.000301 -0.46 -0.34 Aortic root size; chr7:65931217 chr7:65141225~65234216:+ CESC cis rs17711722 0.74 rs7809991 ENSG00000164669.11 INTS4P1 -5.26 3.37e-07 0.000301 -0.46 -0.34 Calcium levels; chr7:65941231 chr7:65141225~65234216:+ CESC cis rs2842992 0.83 rs2758352 ENSG00000237927.1 RP3-393E18.2 -5.26 3.37e-07 0.000301 -0.44 -0.34 Age-related macular degeneration (geographic atrophy); chr6:159701889 chr6:159586955~159589169:- CESC cis rs131777 0.526 rs86337 ENSG00000205559.3 CHKB-AS1 -5.26 3.37e-07 0.000301 -0.4 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50582239 chr22:50583026~50583877:+ CESC cis rs2243480 1 rs316329 ENSG00000228409.4 CCT6P1 5.26 3.38e-07 0.000302 0.52 0.34 Diabetic kidney disease; chr7:66143429 chr7:65751142~65763354:+ CESC cis rs11676348 0.846 rs6723449 ENSG00000261338.2 RP11-378A13.1 5.26 3.38e-07 0.000302 0.39 0.34 Ulcerative colitis; chr2:218132857 chr2:218255319~218257366:+ CESC cis rs17711722 0.701 rs55773927 ENSG00000164669.11 INTS4P1 -5.26 3.39e-07 0.000302 -0.46 -0.34 Calcium levels; chr7:65872915 chr7:65141225~65234216:+ CESC cis rs9549367 0.789 rs34568744 ENSG00000269125.1 RP11-98F14.11 -5.26 3.4e-07 0.000303 -0.47 -0.34 Platelet distribution width; chr13:113240250 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs57747440 ENSG00000269125.1 RP11-98F14.11 -5.26 3.4e-07 0.000303 -0.47 -0.34 Platelet distribution width; chr13:113240436 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs71446679 ENSG00000269125.1 RP11-98F14.11 -5.26 3.4e-07 0.000303 -0.47 -0.34 Platelet distribution width; chr13:113240507 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs71446682 ENSG00000269125.1 RP11-98F14.11 -5.26 3.4e-07 0.000303 -0.47 -0.34 Platelet distribution width; chr13:113240594 chr13:113165002~113165183:- CESC cis rs9907295 0.688 rs4795101 ENSG00000270977.1 AC015849.16 -5.26 3.4e-07 0.000303 -0.46 -0.34 Fibroblast growth factor basic levels; chr17:35932989 chr17:35893707~35911023:- CESC cis rs9907295 0.688 rs9754 ENSG00000270977.1 AC015849.16 -5.26 3.4e-07 0.000303 -0.46 -0.34 Fibroblast growth factor basic levels; chr17:35934827 chr17:35893707~35911023:- CESC cis rs7572733 0.935 rs11692344 ENSG00000222017.1 AC011997.1 5.26 3.41e-07 0.000304 0.37 0.34 Dermatomyositis; chr2:197931139 chr2:197693106~197774823:+ CESC cis rs17711722 0.727 rs35850374 ENSG00000164669.11 INTS4P1 -5.26 3.41e-07 0.000304 -0.46 -0.34 Calcium levels; chr7:65892789 chr7:65141225~65234216:+ CESC cis rs875971 0.54 rs736270 ENSG00000164669.11 INTS4P1 -5.26 3.41e-07 0.000304 -0.47 -0.34 Aortic root size; chr7:65963835 chr7:65141225~65234216:+ CESC cis rs34779708 0.931 rs17583009 ENSG00000230534.5 RP11-297A16.2 5.26 3.42e-07 0.000305 0.44 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35031987 chr10:35098006~35127020:- CESC cis rs34779708 0.898 rs11595898 ENSG00000230534.5 RP11-297A16.2 5.26 3.42e-07 0.000305 0.44 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35037335 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs35886556 ENSG00000230534.5 RP11-297A16.2 5.26 3.42e-07 0.000305 0.44 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35046057 chr10:35098006~35127020:- CESC cis rs2842992 0.789 rs4235925 ENSG00000237927.1 RP3-393E18.2 -5.26 3.43e-07 0.000305 -0.45 -0.34 Age-related macular degeneration (geographic atrophy); chr6:159781828 chr6:159586955~159589169:- CESC cis rs9907295 0.901 rs4796130 ENSG00000270977.1 AC015849.16 -5.26 3.43e-07 0.000306 -0.46 -0.34 Fibroblast growth factor basic levels; chr17:35904264 chr17:35893707~35911023:- CESC cis rs9907295 0.685 rs4796131 ENSG00000270977.1 AC015849.16 -5.26 3.43e-07 0.000306 -0.46 -0.34 Fibroblast growth factor basic levels; chr17:35904812 chr17:35893707~35911023:- CESC cis rs8059260 0.668 rs16957855 ENSG00000274038.1 RP11-66H6.4 -5.26 3.43e-07 0.000306 -0.54 -0.34 Alcohol consumption over the past year; chr16:10977116 chr16:11056556~11057034:+ CESC cis rs9549367 0.577 rs3024713 ENSG00000269125.1 RP11-98F14.11 -5.26 3.43e-07 0.000306 -0.49 -0.34 Platelet distribution width; chr13:113159007 chr13:113165002~113165183:- CESC cis rs875971 0.862 rs778734 ENSG00000222364.1 RNU6-96P -5.26 3.44e-07 0.000306 -0.39 -0.34 Aortic root size; chr7:66349862 chr7:66395191~66395286:+ CESC cis rs42490 0.966 rs2735871 ENSG00000251136.7 RP11-37B2.1 5.26 3.45e-07 0.000307 0.34 0.34 Leprosy; chr8:89731154 chr8:89609409~89757727:- CESC cis rs9322193 0.884 rs10872648 ENSG00000268592.3 RAET1E-AS1 5.26 3.46e-07 0.000308 0.44 0.34 Lung cancer; chr6:149758699 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs11155679 ENSG00000268592.3 RAET1E-AS1 5.26 3.46e-07 0.000308 0.44 0.34 Lung cancer; chr6:149758881 chr6:149863494~149919507:+ CESC cis rs897984 0.806 rs4889571 ENSG00000260911.2 RP11-196G11.2 -5.26 3.46e-07 0.000308 -0.37 -0.34 Dementia with Lewy bodies; chr16:30937726 chr16:31043150~31049868:+ CESC cis rs897984 0.762 rs7206511 ENSG00000260911.2 RP11-196G11.2 -5.26 3.46e-07 0.000308 -0.37 -0.34 Dementia with Lewy bodies; chr16:30939031 chr16:31043150~31049868:+ CESC cis rs3823536 0.583 rs6973975 ENSG00000275106.1 RP11-309L24.10 -5.26 3.46e-07 0.000308 -0.46 -0.34 Sjögren's syndrome; chr7:129035495 chr7:128952527~128953316:- CESC cis rs3823536 0.583 rs921403 ENSG00000275106.1 RP11-309L24.10 -5.26 3.46e-07 0.000308 -0.46 -0.34 Sjögren's syndrome; chr7:129036670 chr7:128952527~128953316:- CESC cis rs73086581 1 rs6052209 ENSG00000229539.1 RP11-119B16.2 5.26 3.46e-07 0.000308 0.53 0.34 Response to antidepressants in depression; chr20:3981100 chr20:3888239~3888868:- CESC cis rs7572733 0.935 rs7558450 ENSG00000222017.1 AC011997.1 5.26 3.47e-07 0.000309 0.37 0.34 Dermatomyositis; chr2:197973042 chr2:197693106~197774823:+ CESC cis rs2108622 0.701 rs118144071 ENSG00000267453.5 AC004791.2 -5.26 3.48e-07 0.000309 -0.42 -0.34 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15868384 chr19:15851993~15864904:- CESC cis rs5769707 0.609 rs2007024 ENSG00000188511.11 C22orf34 5.26 3.48e-07 0.000309 0.39 0.34 Monocyte percentage of white cells;Monocyte count; chr22:49595167 chr22:49414524~49657542:- CESC cis rs5769707 0.656 rs135875 ENSG00000235111.1 RP1-29C18.8 -5.26 3.49e-07 0.00031 -0.38 -0.34 Monocyte percentage of white cells;Monocyte count; chr22:49618771 chr22:49612657~49615716:- CESC cis rs11651753 0.636 rs4793737 ENSG00000264920.1 RP11-6N17.4 -5.26 3.5e-07 0.000311 -0.39 -0.34 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47964891 chr17:47891255~47895812:- CESC cis rs14027 0.64 rs7843304 ENSG00000279347.1 RP11-85I17.2 -5.26 3.51e-07 0.000311 -0.32 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119770796 chr8:119838736~119840385:- CESC cis rs35955747 0.871 rs5994392 ENSG00000236132.1 CTA-440B3.1 5.26 3.51e-07 0.000312 0.39 0.34 Neutrophil count;Sum basophil neutrophil counts; chr22:31387920 chr22:31816379~31817491:- CESC cis rs7572733 0.935 rs771010 ENSG00000222017.1 AC011997.1 -5.26 3.51e-07 0.000312 -0.37 -0.34 Dermatomyositis; chr2:197826282 chr2:197693106~197774823:+ CESC cis rs7615952 0.599 rs6766327 ENSG00000250012.1 RP11-124N2.1 -5.26 3.51e-07 0.000312 -0.36 -0.34 Blood pressure (smoking interaction); chr3:126004834 chr3:126084220~126095349:+ CESC cis rs10800713 0.954 rs10800710 ENSG00000260088.1 RP11-92G12.3 -5.26 3.51e-07 0.000312 -0.49 -0.34 Tandem gait; chr1:200569240 chr1:200669507~200694250:+ CESC cis rs10800713 0.954 rs10800711 ENSG00000260088.1 RP11-92G12.3 -5.26 3.51e-07 0.000312 -0.49 -0.34 Tandem gait; chr1:200569757 chr1:200669507~200694250:+ CESC cis rs10800713 0.954 rs12092148 ENSG00000260088.1 RP11-92G12.3 -5.26 3.51e-07 0.000312 -0.49 -0.34 Tandem gait; chr1:200570655 chr1:200669507~200694250:+ CESC cis rs10800713 0.826 rs11586257 ENSG00000260088.1 RP11-92G12.3 -5.26 3.51e-07 0.000312 -0.49 -0.34 Tandem gait; chr1:200572236 chr1:200669507~200694250:+ CESC cis rs10800713 0.954 rs10800712 ENSG00000260088.1 RP11-92G12.3 -5.26 3.51e-07 0.000312 -0.49 -0.34 Tandem gait; chr1:200576059 chr1:200669507~200694250:+ CESC cis rs10800713 0.908 rs10919978 ENSG00000260088.1 RP11-92G12.3 -5.26 3.51e-07 0.000312 -0.49 -0.34 Tandem gait; chr1:200576923 chr1:200669507~200694250:+ CESC cis rs10800713 0.954 rs4353125 ENSG00000260088.1 RP11-92G12.3 -5.26 3.51e-07 0.000312 -0.49 -0.34 Tandem gait; chr1:200582178 chr1:200669507~200694250:+ CESC cis rs10800713 0.908 rs6670625 ENSG00000260088.1 RP11-92G12.3 -5.26 3.51e-07 0.000312 -0.49 -0.34 Tandem gait; chr1:200587514 chr1:200669507~200694250:+ CESC cis rs7621025 0.5 rs16844241 ENSG00000239213.4 NCK1-AS1 -5.26 3.52e-07 0.000312 -0.44 -0.34 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136916329 chr3:136841726~136862054:- CESC cis rs4718428 0.662 rs34577323 ENSG00000273142.1 RP11-458F8.4 -5.25 3.53e-07 0.000313 -0.35 -0.34 Corneal structure; chr7:66845054 chr7:66902857~66906297:+ CESC cis rs6452524 0.967 rs2731861 ENSG00000249664.1 CTD-2227C6.2 5.25 3.53e-07 0.000314 0.37 0.34 Hypertension (SNP x SNP interaction); chr5:83189445 chr5:83012285~83013109:- CESC cis rs10800713 0.607 rs6682828 ENSG00000260088.1 RP11-92G12.3 -5.25 3.54e-07 0.000314 -0.41 -0.34 Tandem gait; chr1:200537968 chr1:200669507~200694250:+ CESC cis rs7615952 0.599 rs1875683 ENSG00000250012.1 RP11-124N2.1 -5.25 3.54e-07 0.000314 -0.36 -0.34 Blood pressure (smoking interaction); chr3:126013638 chr3:126084220~126095349:+ CESC cis rs957448 0.507 rs1984711 ENSG00000253704.1 RP11-267M23.4 5.25 3.55e-07 0.000315 0.35 0.34 Nonsyndromic cleft lip with cleft palate; chr8:94600276 chr8:94553722~94569745:+ CESC cis rs34779708 0.931 rs11010132 ENSG00000230534.5 RP11-297A16.2 5.25 3.55e-07 0.000315 0.45 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35228337 chr10:35098006~35127020:- CESC cis rs14027 0.577 rs12707876 ENSG00000279347.1 RP11-85I17.2 -5.25 3.56e-07 0.000316 -0.32 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119730143 chr8:119838736~119840385:- CESC cis rs1075265 0.633 rs4671190 ENSG00000233266.1 HMGB1P31 5.25 3.58e-07 0.000317 0.47 0.34 Chronotype;Morning vs. evening chronotype; chr2:54085604 chr2:54051334~54051760:+ CESC cis rs763121 1 rs138464 ENSG00000273076.1 RP3-508I15.22 -5.25 3.58e-07 0.000317 -0.37 -0.34 Menopause (age at onset); chr22:38510427 chr22:38743495~38743910:+ CESC cis rs748404 0.56 rs689797 ENSG00000205771.5 CATSPER2P1 -5.25 3.59e-07 0.000318 -0.4 -0.34 Lung cancer; chr15:43534359 chr15:43726918~43747094:- CESC cis rs2243480 1 rs316304 ENSG00000228409.4 CCT6P1 5.25 3.59e-07 0.000318 0.5 0.34 Diabetic kidney disease; chr7:66151907 chr7:65751142~65763354:+ CESC cis rs42490 0.789 rs51331 ENSG00000251136.7 RP11-37B2.1 -5.25 3.59e-07 0.000318 -0.34 -0.34 Leprosy; chr8:89801900 chr8:89609409~89757727:- CESC cis rs14027 0.64 rs2043431 ENSG00000279347.1 RP11-85I17.2 -5.25 3.6e-07 0.000319 -0.32 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119736214 chr8:119838736~119840385:- CESC cis rs875971 0.928 rs2036263 ENSG00000222364.1 RNU6-96P 5.25 3.6e-07 0.000319 0.38 0.34 Aortic root size; chr7:66335210 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs10240949 ENSG00000222364.1 RNU6-96P 5.25 3.6e-07 0.000319 0.38 0.34 Aortic root size; chr7:66339430 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs7782704 ENSG00000222364.1 RNU6-96P 5.25 3.6e-07 0.000319 0.38 0.34 Aortic root size; chr7:66340379 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6959268 ENSG00000222364.1 RNU6-96P 5.25 3.6e-07 0.000319 0.38 0.34 Aortic root size; chr7:66347979 chr7:66395191~66395286:+ CESC cis rs7572733 0.773 rs7603839 ENSG00000222017.1 AC011997.1 5.25 3.6e-07 0.000319 0.37 0.34 Dermatomyositis; chr2:197669984 chr2:197693106~197774823:+ CESC cis rs1155848 0.571 rs6563125 ENSG00000227354.5 RBM26-AS1 5.25 3.61e-07 0.00032 0.66 0.34 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79630618 chr13:79406309~79424328:+ CESC cis rs1155848 0.571 rs58739959 ENSG00000227354.5 RBM26-AS1 5.25 3.61e-07 0.00032 0.66 0.34 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79633468 chr13:79406309~79424328:+ CESC cis rs6782228 0.675 rs56141228 ENSG00000242551.2 POU5F1P6 -5.25 3.62e-07 0.00032 -0.38 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128667199 chr3:128674735~128677005:- CESC cis rs2842992 0.83 rs752779 ENSG00000237927.1 RP3-393E18.2 -5.25 3.62e-07 0.00032 -0.44 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159712925 chr6:159586955~159589169:- CESC cis rs2842992 0.83 rs2025189 ENSG00000237927.1 RP3-393E18.2 -5.25 3.62e-07 0.00032 -0.44 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159716486 chr6:159586955~159589169:- CESC cis rs2842992 0.83 rs2495279 ENSG00000237927.1 RP3-393E18.2 -5.25 3.62e-07 0.00032 -0.44 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159717764 chr6:159586955~159589169:- CESC cis rs875971 0.522 rs7784623 ENSG00000164669.11 INTS4P1 -5.25 3.62e-07 0.00032 -0.46 -0.33 Aortic root size; chr7:65930047 chr7:65141225~65234216:+ CESC cis rs1823913 0.599 rs34840299 ENSG00000280083.1 RP11-317J9.1 -5.25 3.62e-07 0.00032 -0.39 -0.33 Obesity-related traits; chr2:191280379 chr2:191154118~191156070:- CESC cis rs2929278 0.561 rs3099045 ENSG00000205771.5 CATSPER2P1 -5.25 3.63e-07 0.000321 -0.4 -0.33 Schizophrenia; chr15:43631757 chr15:43726918~43747094:- CESC cis rs875971 0.651 rs313829 ENSG00000226824.5 RP4-756H11.3 5.25 3.63e-07 0.000321 0.44 0.33 Aortic root size; chr7:66087510 chr7:66654538~66669855:+ CESC cis rs9907295 1 rs11653051 ENSG00000270977.1 AC015849.16 -5.25 3.63e-07 0.000321 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35909166 chr17:35893707~35911023:- CESC cis rs9907295 0.71 rs28912068 ENSG00000270977.1 AC015849.16 -5.25 3.64e-07 0.000322 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35881967 chr17:35893707~35911023:- CESC cis rs2337406 0.539 rs2583292 ENSG00000211974.3 IGHV2-70 -5.25 3.64e-07 0.000322 -0.48 -0.33 Alzheimer's disease (late onset); chr14:106649040 chr14:106723574~106724093:- CESC cis rs2919917 0.915 rs2046339 ENSG00000254352.1 RP11-578O24.2 5.25 3.64e-07 0.000322 0.43 0.33 Lymphocyte counts; chr8:78724283 chr8:78723796~78724136:- CESC cis rs6504950 0.783 rs12936639 ENSG00000275710.1 RP11-257O5.4 5.25 3.64e-07 0.000322 0.44 0.33 Breast cancer; chr17:55158621 chr17:54964474~54964679:+ CESC cis rs7572733 0.901 rs13011918 ENSG00000222017.1 AC011997.1 -5.25 3.64e-07 0.000322 -0.37 -0.33 Dermatomyositis; chr2:197914359 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1401093 ENSG00000222017.1 AC011997.1 -5.25 3.64e-07 0.000322 -0.37 -0.33 Dermatomyositis; chr2:197915115 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1401094 ENSG00000222017.1 AC011997.1 -5.25 3.64e-07 0.000322 -0.37 -0.33 Dermatomyositis; chr2:197915125 chr2:197693106~197774823:+ CESC cis rs2299587 0.58 rs2427739 ENSG00000253671.1 RP11-806O11.1 -5.25 3.64e-07 0.000322 -0.36 -0.33 Economic and political preferences; chr8:18014320 chr8:17808941~17820868:+ CESC cis rs8072100 0.935 rs12943464 ENSG00000228782.6 CTD-2026D20.3 -5.25 3.65e-07 0.000322 -0.39 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47612985 chr17:47450568~47492492:- CESC cis rs8072100 0.935 rs4793978 ENSG00000228782.6 CTD-2026D20.3 -5.25 3.65e-07 0.000322 -0.39 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47620809 chr17:47450568~47492492:- CESC cis rs2739330 0.753 rs4822452 ENSG00000272787.1 KB-226F1.2 -5.25 3.65e-07 0.000323 -0.35 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23969211~23969873:+ CESC cis rs34779708 0.931 rs35317849 ENSG00000230534.5 RP11-297A16.2 5.25 3.65e-07 0.000323 0.44 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34996793 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934697 ENSG00000230534.5 RP11-297A16.2 5.25 3.65e-07 0.000323 0.44 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34998264 chr10:35098006~35127020:- CESC cis rs17608059 0.524 rs9897978 ENSG00000141028.6 CDRT15P1 5.25 3.65e-07 0.000323 0.36 0.33 Temperament; chr17:13996939 chr17:14024514~14025488:+ CESC cis rs10256972 0.9 rs7812072 ENSG00000229043.2 AC091729.9 -5.25 3.65e-07 0.000323 -0.38 -0.33 Endometriosis;Longevity; chr7:1014226 chr7:1160374~1165267:+ CESC cis rs2108622 0.727 rs3093216 ENSG00000267453.5 AC004791.2 -5.25 3.66e-07 0.000323 -0.43 -0.33 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15876927 chr19:15851993~15864904:- CESC cis rs2108622 0.701 rs3093209 ENSG00000267453.5 AC004791.2 -5.25 3.66e-07 0.000323 -0.43 -0.33 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15877610 chr19:15851993~15864904:- CESC cis rs2243480 1 rs316322 ENSG00000228409.4 CCT6P1 5.25 3.67e-07 0.000324 0.5 0.33 Diabetic kidney disease; chr7:66146246 chr7:65751142~65763354:+ CESC cis rs42490 0.752 rs411279 ENSG00000251136.7 RP11-37B2.1 -5.25 3.68e-07 0.000325 -0.33 -0.33 Leprosy; chr8:89795929 chr8:89609409~89757727:- CESC cis rs3806843 0.735 rs2563333 ENSG00000202111.1 VTRNA1-2 5.25 3.68e-07 0.000325 0.34 0.33 Depressive symptoms (multi-trait analysis); chr5:140672686 chr5:140718925~140719013:+ CESC cis rs2919917 1 rs1441438 ENSG00000254352.1 RP11-578O24.2 -5.25 3.68e-07 0.000325 -0.43 -0.33 Lymphocyte counts; chr8:78729534 chr8:78723796~78724136:- CESC cis rs6452524 0.967 rs1031901 ENSG00000249664.1 CTD-2227C6.2 5.24 3.69e-07 0.000326 0.36 0.33 Hypertension (SNP x SNP interaction); chr5:83147904 chr5:83012285~83013109:- CESC cis rs11723261 0.621 rs7692530 ENSG00000211553.1 AC253576.2 -5.24 3.7e-07 0.000326 -0.47 -0.33 Immune response to smallpox vaccine (IL-6); chr4:123563 chr4:136461~136568:+ CESC cis rs9907295 1 rs11653016 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35909756 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9889977 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35910691 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9894799 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35911085 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9903590 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35911286 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9897665 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35911595 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9912049 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35912530 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9911016 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35913349 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9912894 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35913452 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9303693 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35913595 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9914468 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35913727 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9893004 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35913855 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9899215 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35914215 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9907145 ENSG00000270977.1 AC015849.16 -5.24 3.71e-07 0.000327 -0.47 -0.33 Fibroblast growth factor basic levels; chr17:35915237 chr17:35893707~35911023:- CESC cis rs8059260 0.604 rs78753859 ENSG00000274038.1 RP11-66H6.4 -5.24 3.71e-07 0.000327 -0.57 -0.33 Alcohol consumption over the past year; chr16:11052774 chr16:11056556~11057034:+ CESC cis rs957448 1 rs957447 ENSG00000253704.1 RP11-267M23.4 5.24 3.71e-07 0.000328 0.39 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94528995 chr8:94553722~94569745:+ CESC cis rs957448 1 rs72674852 ENSG00000253704.1 RP11-267M23.4 5.24 3.71e-07 0.000328 0.39 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94536523 chr8:94553722~94569745:+ CESC cis rs34779708 0.931 rs2505631 ENSG00000230534.5 RP11-297A16.2 -5.24 3.72e-07 0.000328 -0.43 -0.33 Inflammatory bowel disease;Crohn's disease; chr10:35079457 chr10:35098006~35127020:- CESC cis rs1799949 1 rs8176103 ENSG00000267681.1 CTD-3199J23.6 -5.24 3.72e-07 0.000328 -0.43 -0.33 Menopause (age at onset); chr17:43115033 chr17:43144956~43145255:+ CESC cis rs9549367 0.789 rs9549699 ENSG00000269125.1 RP11-98F14.11 -5.24 3.73e-07 0.000329 -0.46 -0.33 Platelet distribution width; chr13:113223949 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs7999579 ENSG00000269125.1 RP11-98F14.11 -5.24 3.73e-07 0.000329 -0.46 -0.33 Platelet distribution width; chr13:113225043 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs6577035 ENSG00000269125.1 RP11-98F14.11 -5.24 3.73e-07 0.000329 -0.46 -0.33 Platelet distribution width; chr13:113225683 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs12584981 ENSG00000269125.1 RP11-98F14.11 -5.24 3.73e-07 0.000329 -0.46 -0.33 Platelet distribution width; chr13:113226871 chr13:113165002~113165183:- CESC cis rs2243480 0.803 rs36127118 ENSG00000232559.3 GS1-124K5.12 5.24 3.73e-07 0.000329 0.57 0.33 Diabetic kidney disease; chr7:66100518 chr7:66554588~66576923:- CESC cis rs9584850 0.834 rs9584854 ENSG00000231194.1 FARP1-AS1 5.24 3.73e-07 0.000329 0.42 0.33 Neuroticism; chr13:98466336 chr13:98435405~98435840:- CESC cis rs2581828 0.965 rs4337632 ENSG00000242142.1 SERBP1P3 5.24 3.74e-07 0.000329 0.38 0.33 Crohn's disease; chr3:53103295 chr3:53064283~53065091:- CESC cis rs5769707 0.656 rs135875 ENSG00000188511.11 C22orf34 5.24 3.74e-07 0.000329 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49618771 chr22:49414524~49657542:- CESC cis rs34779708 0.931 rs3740083 ENSG00000230534.5 RP11-297A16.2 5.24 3.74e-07 0.00033 0.44 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35031455 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs12261654 ENSG00000230534.5 RP11-297A16.2 5.24 3.74e-07 0.00033 0.44 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35033096 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934704 ENSG00000230534.5 RP11-297A16.2 5.24 3.74e-07 0.00033 0.44 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35043236 chr10:35098006~35127020:- CESC cis rs765787 0.53 rs12592055 ENSG00000259520.4 CTD-2651B20.3 -5.24 3.75e-07 0.00033 -0.42 -0.33 Uric acid levels; chr15:45222279 chr15:45251580~45279251:- CESC cis rs75422866 0.867 rs78912815 ENSG00000257433.4 RP1-197B17.3 5.24 3.75e-07 0.00033 0.82 0.33 Pneumonia; chr12:47612065 chr12:47706085~47742294:+ CESC cis rs2548724 0.561 rs12658397 ENSG00000250682.4 LINC00491 5.24 3.76e-07 0.00033 0.39 0.33 Type 2 diabetes; chr5:102415949 chr5:102609156~102671559:- CESC cis rs2548724 0.561 rs6596486 ENSG00000250682.4 LINC00491 5.24 3.76e-07 0.00033 0.39 0.33 Type 2 diabetes; chr5:102420358 chr5:102609156~102671559:- CESC cis rs42490 0.674 rs447989 ENSG00000251136.7 RP11-37B2.1 -5.24 3.76e-07 0.00033 -0.34 -0.33 Leprosy; chr8:89848575 chr8:89609409~89757727:- CESC cis rs1075265 0.73 rs6711105 ENSG00000233266.1 HMGB1P31 5.24 3.76e-07 0.000331 0.42 0.33 Chronotype;Morning vs. evening chronotype; chr2:54017775 chr2:54051334~54051760:+ CESC cis rs1075265 0.704 rs6711217 ENSG00000233266.1 HMGB1P31 5.24 3.76e-07 0.000331 0.42 0.33 Chronotype;Morning vs. evening chronotype; chr2:54017892 chr2:54051334~54051760:+ CESC cis rs2283792 0.687 rs381849 ENSG00000224086.5 LL22NC03-86G7.1 -5.24 3.76e-07 0.000331 -0.38 -0.33 Multiple sclerosis; chr22:21951341 chr22:21938293~21977632:+ CESC cis rs10800713 0.954 rs6660637 ENSG00000260088.1 RP11-92G12.3 -5.24 3.76e-07 0.000331 -0.49 -0.33 Tandem gait; chr1:200550893 chr1:200669507~200694250:+ CESC cis rs10800713 0.954 rs10737572 ENSG00000260088.1 RP11-92G12.3 -5.24 3.76e-07 0.000331 -0.49 -0.33 Tandem gait; chr1:200552003 chr1:200669507~200694250:+ CESC cis rs10800713 0.862 rs7533417 ENSG00000260088.1 RP11-92G12.3 -5.24 3.76e-07 0.000331 -0.49 -0.33 Tandem gait; chr1:200558177 chr1:200669507~200694250:+ CESC cis rs9545047 0.604 rs9530900 ENSG00000227676.3 LINC01068 5.24 3.77e-07 0.000331 0.38 0.33 Schizophrenia; chr13:79355048 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9530901 ENSG00000227676.3 LINC01068 5.24 3.77e-07 0.000331 0.38 0.33 Schizophrenia; chr13:79355191 chr13:79566727~79571436:+ CESC cis rs9907295 0.901 rs28550999 ENSG00000270977.1 AC015849.16 -5.24 3.77e-07 0.000331 -0.5 -0.33 Fibroblast growth factor basic levels; chr17:35902887 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs74780070 ENSG00000270977.1 AC015849.16 -5.24 3.77e-07 0.000331 -0.5 -0.33 Fibroblast growth factor basic levels; chr17:35903521 chr17:35893707~35911023:- CESC cis rs9907295 0.786 rs56344830 ENSG00000270977.1 AC015849.16 -5.24 3.77e-07 0.000331 -0.5 -0.33 Fibroblast growth factor basic levels; chr17:35903951 chr17:35893707~35911023:- CESC cis rs10875746 0.729 rs11168355 ENSG00000240399.1 RP1-228P16.1 5.24 3.78e-07 0.000332 0.42 0.33 Longevity (90 years and older); chr12:48017195 chr12:48054813~48055591:- CESC cis rs42490 0.873 rs218903 ENSG00000251136.7 RP11-37B2.1 -5.24 3.78e-07 0.000332 -0.33 -0.33 Leprosy; chr8:89721458 chr8:89609409~89757727:- CESC cis rs875971 0.862 rs1612452 ENSG00000222364.1 RNU6-96P 5.24 3.79e-07 0.000333 0.4 0.33 Aortic root size; chr7:66108909 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs1167390 ENSG00000222364.1 RNU6-96P 5.24 3.79e-07 0.000333 0.4 0.33 Aortic root size; chr7:66110906 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs35034167 ENSG00000222364.1 RNU6-96P 5.24 3.79e-07 0.000333 0.4 0.33 Aortic root size; chr7:66115179 chr7:66395191~66395286:+ CESC cis rs11723261 0.582 rs4634177 ENSG00000211553.1 AC253576.2 -5.24 3.79e-07 0.000333 -0.48 -0.33 Immune response to smallpox vaccine (IL-6); chr4:143055 chr4:136461~136568:+ CESC cis rs4660456 0.913 rs552147 ENSG00000237899.1 RP4-739H11.3 -5.24 3.79e-07 0.000333 -0.45 -0.33 Platelet count; chr1:40689141 chr1:40669089~40687588:- CESC cis rs42490 0.664 rs389848 ENSG00000251136.7 RP11-37B2.1 -5.24 3.8e-07 0.000333 -0.33 -0.33 Leprosy; chr8:89784739 chr8:89609409~89757727:- CESC cis rs526231 0.543 rs171558 ENSG00000175749.11 EIF3KP1 5.24 3.8e-07 0.000333 0.39 0.33 Primary biliary cholangitis; chr5:103242193 chr5:103032376~103033031:+ CESC cis rs1075265 0.704 rs10084374 ENSG00000233266.1 HMGB1P31 5.24 3.81e-07 0.000335 0.42 0.33 Chronotype;Morning vs. evening chronotype; chr2:54022175 chr2:54051334~54051760:+ CESC cis rs9545047 0.604 rs9565488 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79341604 chr13:79566727~79571436:+ CESC cis rs9545047 0.625 rs9565489 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79342106 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs3742117 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79342498 chr13:79566727~79571436:+ CESC cis rs9545047 0.647 rs3742118 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79342838 chr13:79566727~79571436:+ CESC cis rs9545047 0.625 rs7319320 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79343072 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs3752994 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79345076 chr13:79566727~79571436:+ CESC cis rs9545047 0.532 rs9545079 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79346044 chr13:79566727~79571436:+ CESC cis rs9545047 0.567 rs4884129 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79346448 chr13:79566727~79571436:+ CESC cis rs9545047 0.567 rs1410336 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79347598 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9565492 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79348554 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9318625 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79351429 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9530899 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79352461 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7338677 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79352580 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7322744 ENSG00000227676.3 LINC01068 5.24 3.82e-07 0.000335 0.38 0.33 Schizophrenia; chr13:79354070 chr13:79566727~79571436:+ CESC cis rs67180937 0.961 rs17163358 ENSG00000272750.1 RP11-378J18.8 -5.24 3.82e-07 0.000335 -0.41 -0.33 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647297 chr1:222658867~222661512:- CESC cis rs1538970 0.504 rs3790585 ENSG00000280836.1 AL355480.1 -5.24 3.82e-07 0.000335 -0.45 -0.33 Platelet count; chr1:45557684 chr1:45581219~45581321:- CESC cis rs10078 1 rs10078 ENSG00000221990.4 EXOC3-AS1 5.24 3.82e-07 0.000335 0.32 0.33 Fat distribution (HIV); chr5:437987 chr5:441498~443160:- CESC cis rs957448 0.554 rs12541408 ENSG00000253704.1 RP11-267M23.4 5.24 3.82e-07 0.000335 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94573579 chr8:94553722~94569745:+ CESC cis rs14027 0.64 rs2326378 ENSG00000279347.1 RP11-85I17.2 -5.24 3.82e-07 0.000335 -0.32 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119764355 chr8:119838736~119840385:- CESC cis rs10754283 0.756 rs17441836 ENSG00000231613.1 RP5-943J3.1 5.24 3.82e-07 0.000335 0.43 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89669874 chr1:89788914~89790492:+ CESC cis rs1891275 0.601 rs1970506 ENSG00000228701.1 TNKS2-AS1 -5.24 3.82e-07 0.000335 -0.41 -0.33 Intelligence (multi-trait analysis); chr10:91668529 chr10:91782839~91798291:- CESC cis rs4718428 0.705 rs28648401 ENSG00000273142.1 RP11-458F8.4 -5.24 3.84e-07 0.000336 -0.35 -0.33 Corneal structure; chr7:66902145 chr7:66902857~66906297:+ CESC cis rs7572733 0.806 rs10169453 ENSG00000222017.1 AC011997.1 5.24 3.84e-07 0.000337 0.37 0.33 Dermatomyositis; chr2:197970488 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs10204166 ENSG00000222017.1 AC011997.1 5.24 3.84e-07 0.000337 0.37 0.33 Dermatomyositis; chr2:197970540 chr2:197693106~197774823:+ CESC cis rs875971 0.789 rs10260426 ENSG00000237310.1 GS1-124K5.4 -5.24 3.85e-07 0.000337 -0.31 -0.33 Aortic root size; chr7:66271055 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs2901152 ENSG00000237310.1 GS1-124K5.4 -5.24 3.85e-07 0.000337 -0.31 -0.33 Aortic root size; chr7:66300017 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs10263690 ENSG00000237310.1 GS1-124K5.4 -5.24 3.85e-07 0.000337 -0.31 -0.33 Aortic root size; chr7:66301466 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs10250544 ENSG00000237310.1 GS1-124K5.4 -5.24 3.85e-07 0.000337 -0.31 -0.33 Aortic root size; chr7:66301574 chr7:66493706~66495474:+ CESC cis rs10875746 0.859 rs4760622 ENSG00000240399.1 RP1-228P16.1 -5.24 3.85e-07 0.000337 -0.42 -0.33 Longevity (90 years and older); chr12:48198177 chr12:48054813~48055591:- CESC cis rs9322193 0.81 rs62439811 ENSG00000268592.3 RAET1E-AS1 5.24 3.86e-07 0.000338 0.43 0.33 Lung cancer; chr6:149640416 chr6:149863494~149919507:+ CESC cis rs7572733 0.935 rs1518366 ENSG00000222017.1 AC011997.1 5.24 3.86e-07 0.000338 0.37 0.33 Dermatomyositis; chr2:197944472 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1914690 ENSG00000222017.1 AC011997.1 5.24 3.86e-07 0.000338 0.37 0.33 Dermatomyositis; chr2:197944644 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1878732 ENSG00000222017.1 AC011997.1 5.24 3.86e-07 0.000338 0.37 0.33 Dermatomyositis; chr2:197944821 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1518364 ENSG00000222017.1 AC011997.1 5.24 3.86e-07 0.000338 0.37 0.33 Dermatomyositis; chr2:197945251 chr2:197693106~197774823:+ CESC cis rs875971 0.862 rs11765791 ENSG00000237310.1 GS1-124K5.4 5.24 3.87e-07 0.000339 0.32 0.33 Aortic root size; chr7:66471587 chr7:66493706~66495474:+ CESC cis rs763121 1 rs86796 ENSG00000273076.1 RP3-508I15.22 -5.24 3.87e-07 0.000339 -0.37 -0.33 Menopause (age at onset); chr22:38485449 chr22:38743495~38743910:+ CESC cis rs7572733 0.935 rs6434946 ENSG00000222017.1 AC011997.1 5.23 3.88e-07 0.000339 0.37 0.33 Dermatomyositis; chr2:197933773 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs1105078 ENSG00000222017.1 AC011997.1 5.23 3.88e-07 0.000339 0.37 0.33 Dermatomyositis; chr2:197943161 chr2:197693106~197774823:+ CESC cis rs1799949 1 rs33926631 ENSG00000267681.1 CTD-3199J23.6 -5.23 3.88e-07 0.000339 -0.43 -0.33 Menopause (age at onset); chr17:43152446 chr17:43144956~43145255:+ CESC cis rs1062177 0.855 rs6896664 ENSG00000253921.1 CTB-113P19.3 -5.23 3.88e-07 0.000339 -0.41 -0.33 Preschool internalizing problems; chr5:151885713 chr5:151753992~151767247:+ CESC cis rs1891275 0.515 rs7098763 ENSG00000228701.1 TNKS2-AS1 -5.23 3.89e-07 0.00034 -0.38 -0.33 Intelligence (multi-trait analysis); chr10:91685070 chr10:91782839~91798291:- CESC cis rs34779708 0.966 rs1148245 ENSG00000230534.5 RP11-297A16.2 5.23 3.9e-07 0.000341 0.45 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35222966 chr10:35098006~35127020:- CESC cis rs875971 0.862 rs778684 ENSG00000237310.1 GS1-124K5.4 5.23 3.9e-07 0.000341 0.32 0.33 Aortic root size; chr7:66371416 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs778680 ENSG00000237310.1 GS1-124K5.4 5.23 3.9e-07 0.000341 0.32 0.33 Aortic root size; chr7:66375427 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs11769079 ENSG00000237310.1 GS1-124K5.4 5.23 3.9e-07 0.000341 0.32 0.33 Aortic root size; chr7:66377141 chr7:66493706~66495474:+ CESC cis rs6504950 0.924 rs244338 ENSG00000275710.1 RP11-257O5.4 5.23 3.91e-07 0.000342 0.37 0.33 Breast cancer; chr17:55123057 chr17:54964474~54964679:+ CESC cis rs42490 1 rs218929 ENSG00000251136.7 RP11-37B2.1 -5.23 3.91e-07 0.000342 -0.34 -0.33 Leprosy; chr8:89739091 chr8:89609409~89757727:- CESC cis rs9545047 0.604 rs4328330 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79355503 chr13:79566727~79571436:+ CESC cis rs9545047 0.567 rs4497554 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79355651 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2182873 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79356846 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs2025913 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79357315 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9545082 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79358994 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7332913 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79359149 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs9545083 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79360695 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7322756 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79361120 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7324006 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79361225 chr13:79566727~79571436:+ CESC cis rs9545047 0.604 rs7322673 ENSG00000227676.3 LINC01068 5.23 3.92e-07 0.000342 0.38 0.33 Schizophrenia; chr13:79361266 chr13:79566727~79571436:+ CESC cis rs9322193 0.923 rs9800686 ENSG00000268592.3 RAET1E-AS1 5.23 3.92e-07 0.000342 0.43 0.33 Lung cancer; chr6:149634464 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs57938011 ENSG00000268592.3 RAET1E-AS1 5.23 3.92e-07 0.000342 0.43 0.33 Lung cancer; chr6:149642969 chr6:149863494~149919507:+ CESC cis rs2842992 0.714 rs2495278 ENSG00000237927.1 RP3-393E18.2 -5.23 3.93e-07 0.000342 -0.44 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159702642 chr6:159586955~159589169:- CESC cis rs8177876 0.822 rs79926943 ENSG00000261838.4 RP11-303E16.6 5.23 3.94e-07 0.000343 0.72 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81072005 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs77475047 ENSG00000261838.4 RP11-303E16.6 5.23 3.94e-07 0.000343 0.72 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81073355 chr16:81069854~81076598:+ CESC cis rs7115242 0.92 rs6589574 ENSG00000254851.1 RP11-109L13.1 -5.23 3.94e-07 0.000343 -0.7 -0.33 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116859922 chr11:117135528~117138582:+ CESC cis rs9907295 1 rs11653282 ENSG00000270977.1 AC015849.16 -5.23 3.94e-07 0.000344 -0.44 -0.33 Fibroblast growth factor basic levels; chr17:35909742 chr17:35893707~35911023:- CESC cis rs13631 0.965 rs7853589 ENSG00000268996.3 MAN1B1-AS1 -5.23 3.95e-07 0.000344 -0.31 -0.33 Cerebrospinal fluid biomarker levels; chr9:137109392 chr9:137084946~137086817:- CESC cis rs42490 0.536 rs366867 ENSG00000251136.7 RP11-37B2.1 -5.23 3.95e-07 0.000344 -0.34 -0.33 Leprosy; chr8:89851946 chr8:89609409~89757727:- CESC cis rs42490 0.576 rs425140 ENSG00000251136.7 RP11-37B2.1 -5.23 3.95e-07 0.000344 -0.34 -0.33 Leprosy; chr8:89852397 chr8:89609409~89757727:- CESC cis rs42490 0.576 rs377897 ENSG00000251136.7 RP11-37B2.1 -5.23 3.95e-07 0.000344 -0.34 -0.33 Leprosy; chr8:89852734 chr8:89609409~89757727:- CESC cis rs9907295 0.901 rs79730543 ENSG00000270977.1 AC015849.16 -5.23 3.95e-07 0.000344 -0.46 -0.33 Fibroblast growth factor basic levels; chr17:35896537 chr17:35893707~35911023:- CESC cis rs957448 1 rs12680965 ENSG00000253704.1 RP11-267M23.4 5.23 3.95e-07 0.000344 0.38 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94554069 chr8:94553722~94569745:+ CESC cis rs5769707 0.632 rs6009782 ENSG00000235111.1 RP1-29C18.8 -5.23 3.96e-07 0.000345 -0.38 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49617164 chr22:49612657~49615716:- CESC cis rs5769707 0.592 rs6009783 ENSG00000235111.1 RP1-29C18.8 -5.23 3.96e-07 0.000345 -0.38 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49617353 chr22:49612657~49615716:- CESC cis rs1862618 0.573 rs1550821 ENSG00000271828.1 CTD-2310F14.1 -5.23 3.96e-07 0.000345 -0.45 -0.33 Initial pursuit acceleration; chr5:56946496 chr5:56927874~56929573:+ CESC cis rs2842992 0.75 rs2758354 ENSG00000237927.1 RP3-393E18.2 -5.23 3.97e-07 0.000345 -0.44 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159704822 chr6:159586955~159589169:- CESC cis rs992157 0.735 rs2271541 ENSG00000261338.2 RP11-378A13.1 5.23 3.97e-07 0.000345 0.4 0.33 Colorectal cancer; chr2:218217396 chr2:218255319~218257366:+ CESC cis rs992157 0.71 rs12694432 ENSG00000261338.2 RP11-378A13.1 5.23 3.97e-07 0.000345 0.4 0.33 Colorectal cancer; chr2:218217607 chr2:218255319~218257366:+ CESC cis rs5769707 0.609 rs739247 ENSG00000235111.1 RP1-29C18.8 -5.23 3.97e-07 0.000346 -0.38 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49603009 chr22:49612657~49615716:- CESC cis rs875971 0.862 rs6958294 ENSG00000237310.1 GS1-124K5.4 -5.23 3.98e-07 0.000346 -0.31 -0.33 Aortic root size; chr7:66329809 chr7:66493706~66495474:+ CESC cis rs2243480 0.803 rs160649 ENSG00000232559.3 GS1-124K5.12 5.23 3.99e-07 0.000347 0.57 0.33 Diabetic kidney disease; chr7:66078212 chr7:66554588~66576923:- CESC cis rs2243480 1 rs160648 ENSG00000232559.3 GS1-124K5.12 5.23 3.99e-07 0.000347 0.57 0.33 Diabetic kidney disease; chr7:66078397 chr7:66554588~66576923:- CESC cis rs42490 0.553 rs380425 ENSG00000251136.7 RP11-37B2.1 -5.23 3.99e-07 0.000347 -0.35 -0.33 Leprosy; chr8:89849814 chr8:89609409~89757727:- CESC cis rs7572733 0.935 rs10497809 ENSG00000222017.1 AC011997.1 5.23 4e-07 0.000348 0.37 0.33 Dermatomyositis; chr2:197960944 chr2:197693106~197774823:+ CESC cis rs2739330 0.731 rs4822450 ENSG00000272787.1 KB-226F1.2 -5.23 4e-07 0.000348 -0.36 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23969211~23969873:+ CESC cis rs1062177 0.756 rs2964589 ENSG00000253921.1 CTB-113P19.3 5.23 4e-07 0.000348 0.46 0.33 Preschool internalizing problems; chr5:151738628 chr5:151753992~151767247:+ CESC cis rs1062177 0.756 rs2964588 ENSG00000253921.1 CTB-113P19.3 5.23 4e-07 0.000348 0.46 0.33 Preschool internalizing problems; chr5:151738825 chr5:151753992~151767247:+ CESC cis rs62229266 0.625 rs2051395 ENSG00000231106.2 LINC01436 -5.23 4.02e-07 0.000349 -0.45 -0.33 Mitral valve prolapse; chr21:36058967 chr21:36005338~36007838:+ CESC cis rs2337406 0.587 rs916547 ENSG00000211974.3 IGHV2-70 -5.23 4.04e-07 0.000351 -0.48 -0.33 Alzheimer's disease (late onset); chr14:106646735 chr14:106723574~106724093:- CESC cis rs875971 0.767 rs1643394 ENSG00000237310.1 GS1-124K5.4 5.23 4.05e-07 0.000351 0.32 0.33 Aortic root size; chr7:66371107 chr7:66493706~66495474:+ CESC cis rs9545047 0.604 rs9545085 ENSG00000227676.3 LINC01068 5.23 4.05e-07 0.000352 0.38 0.33 Schizophrenia; chr13:79363969 chr13:79566727~79571436:+ CESC cis rs12550612 0.614 rs11135696 ENSG00000253616.4 RP11-875O11.3 5.23 4.06e-07 0.000353 0.51 0.33 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23084410 chr8:23071377~23074488:- CESC cis rs875971 0.895 rs12531677 ENSG00000237310.1 GS1-124K5.4 -5.22 4.08e-07 0.000354 -0.31 -0.33 Aortic root size; chr7:66304099 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs7798630 ENSG00000237310.1 GS1-124K5.4 -5.22 4.08e-07 0.000354 -0.31 -0.33 Aortic root size; chr7:66306492 chr7:66493706~66495474:+ CESC cis rs801193 0.569 rs11772819 ENSG00000232559.3 GS1-124K5.12 5.22 4.08e-07 0.000354 0.36 0.33 Aortic root size; chr7:66752983 chr7:66554588~66576923:- CESC cis rs801193 0.569 rs7800620 ENSG00000232559.3 GS1-124K5.12 5.22 4.08e-07 0.000354 0.36 0.33 Aortic root size; chr7:66758701 chr7:66554588~66576923:- CESC cis rs9907295 0.748 rs4251719 ENSG00000270977.1 AC015849.16 -5.22 4.1e-07 0.000355 -0.44 -0.33 Fibroblast growth factor basic levels; chr17:35815358 chr17:35893707~35911023:- CESC cis rs2243480 1 rs1404147 ENSG00000228409.4 CCT6P1 5.22 4.11e-07 0.000356 0.46 0.33 Diabetic kidney disease; chr7:65799537 chr7:65751142~65763354:+ CESC cis rs748404 0.586 rs2584700 ENSG00000249839.1 AC011330.5 -5.22 4.12e-07 0.000357 -0.36 -0.33 Lung cancer; chr15:43393134 chr15:43663654~43684339:- CESC cis rs6991838 0.765 rs6472219 ENSG00000272010.1 CTD-3025N20.3 5.22 4.13e-07 0.000358 0.36 0.33 Intelligence (multi-trait analysis); chr8:65644487 chr8:65591850~65592472:- CESC cis rs8072100 0.967 rs8078880 ENSG00000228782.6 CTD-2026D20.3 -5.22 4.13e-07 0.000358 -0.38 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47599160 chr17:47450568~47492492:- CESC cis rs6142102 0.961 rs4911392 ENSG00000276073.1 RP5-1125A11.7 -5.22 4.13e-07 0.000358 -0.32 -0.33 Skin pigmentation; chr20:33982712 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs4911393 ENSG00000276073.1 RP5-1125A11.7 -5.22 4.13e-07 0.000358 -0.32 -0.33 Skin pigmentation; chr20:33983120 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs2300204 ENSG00000276073.1 RP5-1125A11.7 -5.22 4.13e-07 0.000358 -0.32 -0.33 Skin pigmentation; chr20:34000967 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs1055857 ENSG00000276073.1 RP5-1125A11.7 -5.22 4.13e-07 0.000358 -0.32 -0.33 Skin pigmentation; chr20:34026067 chr20:33985617~33988989:- CESC cis rs75422866 0.867 rs117388682 ENSG00000257433.4 RP1-197B17.3 5.22 4.14e-07 0.000359 0.82 0.33 Pneumonia; chr12:47599713 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs79113930 ENSG00000257433.4 RP1-197B17.3 5.22 4.14e-07 0.000359 0.82 0.33 Pneumonia; chr12:47600628 chr12:47706085~47742294:+ CESC cis rs10875746 0.587 rs9788082 ENSG00000240399.1 RP1-228P16.1 -5.22 4.14e-07 0.000359 -0.46 -0.33 Longevity (90 years and older); chr12:48358273 chr12:48054813~48055591:- CESC cis rs957448 0.554 rs4735297 ENSG00000253704.1 RP11-267M23.4 5.22 4.14e-07 0.000359 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94577112 chr8:94553722~94569745:+ CESC cis rs2006771 0.765 rs6518752 ENSG00000236132.1 CTA-440B3.1 -5.22 4.14e-07 0.000359 -0.38 -0.33 Nonsyndromic cleft lip with cleft palate; chr22:31603141 chr22:31816379~31817491:- CESC cis rs6504622 0.755 rs4968253 ENSG00000262879.4 RP11-156P1.3 -5.22 4.15e-07 0.000359 -0.36 -0.33 Orofacial clefts; chr17:47093553 chr17:46984045~47100323:- CESC cis rs3738443 0.678 rs61636449 ENSG00000259865.1 RP11-488L18.10 5.22 4.15e-07 0.00036 0.35 0.33 Alcohol dependence; chr1:247213758 chr1:247187281~247188526:- CESC cis rs3738443 0.678 rs57861883 ENSG00000259865.1 RP11-488L18.10 5.22 4.15e-07 0.00036 0.35 0.33 Alcohol dependence; chr1:247214089 chr1:247187281~247188526:- CESC cis rs7188445 0.899 rs57652769 ENSG00000261390.4 RP11-345M22.2 -5.22 4.16e-07 0.00036 -0.44 -0.33 Urate levels; chr16:79720079 chr16:79715232~79770563:- CESC cis rs7208859 0.614 rs216412 ENSG00000263531.1 RP13-753N3.1 -5.22 4.16e-07 0.00036 -0.56 -0.33 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576376 chr17:30863921~30864940:- CESC cis rs875971 0.862 rs1695820 ENSG00000237310.1 GS1-124K5.4 5.22 4.16e-07 0.00036 0.32 0.33 Aortic root size; chr7:66379576 chr7:66493706~66495474:+ CESC cis rs875971 0.83 rs778715 ENSG00000237310.1 GS1-124K5.4 5.22 4.16e-07 0.00036 0.32 0.33 Aortic root size; chr7:66384222 chr7:66493706~66495474:+ CESC cis rs875971 0.83 rs809025 ENSG00000237310.1 GS1-124K5.4 5.22 4.16e-07 0.00036 0.32 0.33 Aortic root size; chr7:66384832 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs778702 ENSG00000237310.1 GS1-124K5.4 5.22 4.16e-07 0.00036 0.32 0.33 Aortic root size; chr7:66399848 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs1643375 ENSG00000237310.1 GS1-124K5.4 5.22 4.16e-07 0.00036 0.32 0.33 Aortic root size; chr7:66407690 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6962717 ENSG00000237310.1 GS1-124K5.4 5.22 4.16e-07 0.00036 0.32 0.33 Aortic root size; chr7:66418748 chr7:66493706~66495474:+ CESC cis rs35955747 0.777 rs5997895 ENSG00000236132.1 CTA-440B3.1 5.22 4.16e-07 0.00036 0.38 0.33 Neutrophil count;Sum basophil neutrophil counts; chr22:31170187 chr22:31816379~31817491:- CESC cis rs2739330 0.734 rs2000467 ENSG00000272787.1 KB-226F1.2 5.22 4.16e-07 0.00036 0.37 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23969211~23969873:+ CESC cis rs6750795 0.765 rs6742387 ENSG00000181798.2 LINC00471 -5.22 4.16e-07 0.00036 -0.35 -0.33 Height; chr2:231490121 chr2:231508426~231514339:- CESC cis rs7598759 0.548 rs1823328 ENSG00000181798.2 LINC00471 -5.22 4.16e-07 0.00036 -0.35 -0.33 Noise-induced hearing loss; chr2:231490473 chr2:231508426~231514339:- CESC cis rs11096990 0.634 rs3733281 ENSG00000249207.1 RP11-360F5.1 5.22 4.16e-07 0.000361 0.36 0.33 Cognitive function; chr4:39270293 chr4:39112677~39126818:- CESC cis rs62229266 0.771 rs7280136 ENSG00000231106.2 LINC01436 -5.22 4.17e-07 0.000361 -0.47 -0.33 Mitral valve prolapse; chr21:36060612 chr21:36005338~36007838:+ CESC cis rs4718428 0.672 rs12530806 ENSG00000273142.1 RP11-458F8.4 -5.22 4.17e-07 0.000361 -0.35 -0.33 Corneal structure; chr7:66925737 chr7:66902857~66906297:+ CESC cis rs765787 0.505 rs1648302 ENSG00000259520.4 CTD-2651B20.3 5.22 4.18e-07 0.000361 0.4 0.33 Uric acid levels; chr15:45202040 chr15:45251580~45279251:- CESC cis rs5769707 0.616 rs6009786 ENSG00000188511.11 C22orf34 5.22 4.18e-07 0.000362 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49621497 chr22:49414524~49657542:- CESC cis rs9309711 0.736 rs9678647 ENSG00000225234.1 TRAPPC12-AS1 5.22 4.18e-07 0.000362 0.34 0.33 Neurofibrillary tangles; chr2:3493265 chr2:3481242~3482409:- CESC cis rs7927592 0.913 rs4316515 ENSG00000212093.1 AP000807.1 -5.22 4.18e-07 0.000362 -0.39 -0.33 Total body bone mineral density; chr11:68541372 chr11:68506083~68506166:- CESC cis rs7572733 0.935 rs700659 ENSG00000222017.1 AC011997.1 5.22 4.2e-07 0.000363 0.37 0.33 Dermatomyositis; chr2:197795199 chr2:197693106~197774823:+ CESC cis rs8059260 0.668 rs75637865 ENSG00000274038.1 RP11-66H6.4 -5.22 4.21e-07 0.000364 -0.55 -0.33 Alcohol consumption over the past year; chr16:10982439 chr16:11056556~11057034:+ CESC cis rs8059260 0.736 rs7202408 ENSG00000274038.1 RP11-66H6.4 -5.22 4.21e-07 0.000364 -0.55 -0.33 Alcohol consumption over the past year; chr16:10984758 chr16:11056556~11057034:+ CESC cis rs2243480 1 rs431076 ENSG00000228409.4 CCT6P1 5.22 4.21e-07 0.000364 0.5 0.33 Diabetic kidney disease; chr7:66135333 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs2460422 ENSG00000228409.4 CCT6P1 5.22 4.21e-07 0.000364 0.5 0.33 Diabetic kidney disease; chr7:66136518 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs316334 ENSG00000228409.4 CCT6P1 5.22 4.21e-07 0.000364 0.5 0.33 Diabetic kidney disease; chr7:66137139 chr7:65751142~65763354:+ CESC cis rs875971 0.862 rs778686 ENSG00000237310.1 GS1-124K5.4 5.22 4.22e-07 0.000364 0.32 0.33 Aortic root size; chr7:66370923 chr7:66493706~66495474:+ CESC cis rs2919917 0.688 rs3780003 ENSG00000254352.1 RP11-578O24.2 5.22 4.22e-07 0.000365 0.41 0.33 Lymphocyte counts; chr8:78696019 chr8:78723796~78724136:- CESC cis rs9584850 0.789 rs7988345 ENSG00000231194.1 FARP1-AS1 5.22 4.22e-07 0.000365 0.42 0.33 Neuroticism; chr13:98465431 chr13:98435405~98435840:- CESC cis rs875971 1 rs10244498 ENSG00000222364.1 RNU6-96P -5.22 4.22e-07 0.000365 -0.39 -0.33 Aortic root size; chr7:66651069 chr7:66395191~66395286:+ CESC cis rs7572733 0.935 rs1401090 ENSG00000222017.1 AC011997.1 5.22 4.23e-07 0.000365 0.38 0.33 Dermatomyositis; chr2:197943854 chr2:197693106~197774823:+ CESC cis rs7189233 0.531 rs17800577 ENSG00000279344.1 RP11-44F14.7 5.22 4.23e-07 0.000365 0.31 0.33 Intelligence (multi-trait analysis); chr16:53442892 chr16:53478957~53481550:- CESC cis rs12550612 0.614 rs6983885 ENSG00000253616.4 RP11-875O11.3 5.22 4.23e-07 0.000365 0.5 0.33 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23087574 chr8:23071377~23074488:- CESC cis rs3931020 0.688 rs405445 ENSG00000272864.1 RP11-17E13.2 5.22 4.24e-07 0.000366 0.42 0.33 Resistin levels; chr1:74755466 chr1:74698769~74699333:- CESC cis rs2117029 0.555 rs7958241 ENSG00000258017.1 RP11-386G11.10 5.22 4.25e-07 0.000367 0.42 0.33 Intelligence (multi-trait analysis); chr12:49115479 chr12:49127782~49147869:+ CESC cis rs2243480 1 rs316330 ENSG00000228409.4 CCT6P1 5.22 4.25e-07 0.000367 0.5 0.33 Diabetic kidney disease; chr7:66140385 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs316326 ENSG00000228409.4 CCT6P1 5.22 4.25e-07 0.000367 0.5 0.33 Diabetic kidney disease; chr7:66144466 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs316325 ENSG00000228409.4 CCT6P1 5.22 4.25e-07 0.000367 0.5 0.33 Diabetic kidney disease; chr7:66144531 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs316321 ENSG00000228409.4 CCT6P1 5.22 4.25e-07 0.000367 0.5 0.33 Diabetic kidney disease; chr7:66146626 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs316318 ENSG00000228409.4 CCT6P1 5.22 4.25e-07 0.000367 0.5 0.33 Diabetic kidney disease; chr7:66147917 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs316317 ENSG00000228409.4 CCT6P1 5.22 4.25e-07 0.000367 0.5 0.33 Diabetic kidney disease; chr7:66148650 chr7:65751142~65763354:+ CESC cis rs957448 1 rs2381885 ENSG00000253704.1 RP11-267M23.4 5.21 4.27e-07 0.000368 0.38 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94499974 chr8:94553722~94569745:+ CESC cis rs42490 0.727 rs42481 ENSG00000251136.7 RP11-37B2.1 5.21 4.27e-07 0.000369 0.32 0.33 Leprosy; chr8:89825486 chr8:89609409~89757727:- CESC cis rs10800713 0.954 rs6427835 ENSG00000260088.1 RP11-92G12.3 -5.21 4.28e-07 0.000369 -0.48 -0.33 Tandem gait; chr1:200591725 chr1:200669507~200694250:+ CESC cis rs10800713 0.954 rs6667081 ENSG00000260088.1 RP11-92G12.3 -5.21 4.28e-07 0.000369 -0.48 -0.33 Tandem gait; chr1:200593366 chr1:200669507~200694250:+ CESC cis rs10800713 0.954 rs6673474 ENSG00000260088.1 RP11-92G12.3 -5.21 4.28e-07 0.000369 -0.48 -0.33 Tandem gait; chr1:200594991 chr1:200669507~200694250:+ CESC cis rs9549367 0.713 rs3024764 ENSG00000269125.1 RP11-98F14.11 -5.21 4.29e-07 0.00037 -0.45 -0.33 Platelet distribution width; chr13:113170000 chr13:113165002~113165183:- CESC cis rs2842992 0.715 rs2277073 ENSG00000237927.1 RP3-393E18.2 -5.21 4.3e-07 0.000371 -0.43 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159761717 chr6:159586955~159589169:- CESC cis rs520525 0.963 rs524877 ENSG00000271811.1 RP1-79C4.4 5.21 4.31e-07 0.000371 0.44 0.33 Atrial fibrillation; chr1:170659294 chr1:170667381~170669425:+ CESC cis rs9322193 0.923 rs9800736 ENSG00000268592.3 RAET1E-AS1 5.21 4.31e-07 0.000371 0.43 0.33 Lung cancer; chr6:149661281 chr6:149863494~149919507:+ CESC cis rs2729354 0.768 rs2729384 ENSG00000265566.2 RN7SL605P -5.21 4.31e-07 0.000371 -0.48 -0.33 Blood protein levels; chr11:57491144 chr11:57528085~57528365:- CESC cis rs9549367 0.789 rs8001506 ENSG00000269125.1 RP11-98F14.11 -5.21 4.32e-07 0.000372 -0.45 -0.33 Platelet distribution width; chr13:113212839 chr13:113165002~113165183:- CESC cis rs3738443 0.678 rs4314914 ENSG00000259865.1 RP11-488L18.10 5.21 4.32e-07 0.000372 0.35 0.33 Alcohol dependence; chr1:247210326 chr1:247187281~247188526:- CESC cis rs7572733 0.935 rs771016 ENSG00000222017.1 AC011997.1 5.21 4.33e-07 0.000372 0.37 0.33 Dermatomyositis; chr2:197800796 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs771015 ENSG00000222017.1 AC011997.1 5.21 4.33e-07 0.000372 0.37 0.33 Dermatomyositis; chr2:197803570 chr2:197693106~197774823:+ CESC cis rs9545047 0.604 rs2057573 ENSG00000227676.3 LINC01068 -5.21 4.33e-07 0.000373 -0.37 -0.33 Schizophrenia; chr13:79357736 chr13:79566727~79571436:+ CESC cis rs9907295 1 rs9908525 ENSG00000270977.1 AC015849.16 -5.21 4.35e-07 0.000374 -0.46 -0.33 Fibroblast growth factor basic levels; chr17:35908605 chr17:35893707~35911023:- CESC cis rs765787 0.53 rs4514617 ENSG00000259520.4 CTD-2651B20.3 5.21 4.35e-07 0.000374 0.39 0.33 Uric acid levels; chr15:45243241 chr15:45251580~45279251:- CESC cis rs11723261 0.621 rs6599307 ENSG00000211553.1 AC253576.2 -5.21 4.35e-07 0.000374 -0.46 -0.33 Immune response to smallpox vaccine (IL-6); chr4:149993 chr4:136461~136568:+ CESC cis rs116095464 0.558 rs6866632 ENSG00000250848.1 CTD-2083E4.5 -5.21 4.35e-07 0.000374 -0.46 -0.33 Breast cancer; chr5:264314 chr5:288833~290321:- CESC cis rs875971 0.862 rs28470208 ENSG00000222364.1 RNU6-96P 5.21 4.35e-07 0.000375 0.39 0.33 Aortic root size; chr7:66119713 chr7:66395191~66395286:+ CESC cis rs2115630 0.653 rs61394864 ENSG00000225151.9 GOLGA2P7 5.21 4.36e-07 0.000375 0.37 0.33 P wave terminal force; chr15:84626943 chr15:84199311~84230136:- CESC cis rs950027 0.787 rs1153845 ENSG00000259520.4 CTD-2651B20.3 5.21 4.36e-07 0.000375 0.43 0.33 Response to fenofibrate (adiponectin levels); chr15:45432531 chr15:45251580~45279251:- CESC cis rs2108622 0.785 rs3093199 ENSG00000267453.5 AC004791.2 -5.21 4.37e-07 0.000376 -0.42 -0.33 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15879061 chr19:15851993~15864904:- CESC cis rs2564921 0.73 rs2564929 ENSG00000242142.1 SERBP1P3 -5.21 4.37e-07 0.000376 -0.39 -0.33 Height; chr3:53084188 chr3:53064283~53065091:- CESC cis rs897984 0.806 rs11640534 ENSG00000260911.2 RP11-196G11.2 -5.21 4.38e-07 0.000377 -0.36 -0.33 Dementia with Lewy bodies; chr16:30938194 chr16:31043150~31049868:+ CESC cis rs2243480 1 rs1964692 ENSG00000228409.4 CCT6P1 5.21 4.39e-07 0.000377 0.48 0.33 Diabetic kidney disease; chr7:65989196 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1723267 ENSG00000228409.4 CCT6P1 5.21 4.39e-07 0.000377 0.48 0.33 Diabetic kidney disease; chr7:66008327 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs781156 ENSG00000228409.4 CCT6P1 5.21 4.39e-07 0.000377 0.48 0.33 Diabetic kidney disease; chr7:66014154 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs451396 ENSG00000228409.4 CCT6P1 5.21 4.39e-07 0.000377 0.48 0.33 Diabetic kidney disease; chr7:66019087 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1715235 ENSG00000228409.4 CCT6P1 5.21 4.39e-07 0.000377 0.48 0.33 Diabetic kidney disease; chr7:66023407 chr7:65751142~65763354:+ CESC cis rs8177876 0.731 rs74882687 ENSG00000261838.4 RP11-303E16.6 5.21 4.4e-07 0.000378 0.72 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085315 chr16:81069854~81076598:+ CESC cis rs8177876 0.642 rs76909932 ENSG00000261838.4 RP11-303E16.6 5.21 4.4e-07 0.000378 0.72 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085449 chr16:81069854~81076598:+ CESC cis rs1387259 0.79 rs2732445 ENSG00000258273.1 RP11-370I10.4 -5.21 4.41e-07 0.000379 -0.41 -0.33 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48251750 chr12:48333755~48333901:- CESC cis rs520525 0.963 rs663887 ENSG00000271811.1 RP1-79C4.4 5.21 4.41e-07 0.000379 0.44 0.33 Atrial fibrillation; chr1:170657812 chr1:170667381~170669425:+ CESC cis rs11846409 0.799 rs2583330 ENSG00000211974.3 IGHV2-70 5.21 4.42e-07 0.00038 0.46 0.33 Rheumatic heart disease; chr14:106621051 chr14:106723574~106724093:- CESC cis rs2842992 0.789 rs7765490 ENSG00000237927.1 RP3-393E18.2 -5.21 4.42e-07 0.00038 -0.44 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159783294 chr6:159586955~159589169:- CESC cis rs9907295 0.901 rs2107540 ENSG00000270977.1 AC015849.16 -5.21 4.43e-07 0.00038 -0.49 -0.33 Fibroblast growth factor basic levels; chr17:35893516 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs28739295 ENSG00000270977.1 AC015849.16 -5.21 4.43e-07 0.00038 -0.49 -0.33 Fibroblast growth factor basic levels; chr17:35895812 chr17:35893707~35911023:- CESC cis rs34375054 0.735 rs34961756 ENSG00000279233.1 RP11-158L12.4 5.21 4.43e-07 0.00038 0.32 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125144052 chr12:125138245~125141711:+ CESC cis rs9322193 0.923 rs56397000 ENSG00000268592.3 RAET1E-AS1 5.21 4.44e-07 0.000381 0.42 0.33 Lung cancer; chr6:149739347 chr6:149863494~149919507:+ CESC cis rs2243480 1 rs160655 ENSG00000232559.3 GS1-124K5.12 5.21 4.44e-07 0.000381 0.57 0.33 Diabetic kidney disease; chr7:66068227 chr7:66554588~66576923:- CESC cis rs11723261 0.582 rs6599293 ENSG00000211553.1 AC253576.2 -5.21 4.44e-07 0.000381 -0.48 -0.33 Immune response to smallpox vaccine (IL-6); chr4:139246 chr4:136461~136568:+ CESC cis rs748404 0.631 rs1133395 ENSG00000249839.1 AC011330.5 -5.21 4.45e-07 0.000382 -0.36 -0.33 Lung cancer; chr15:43358186 chr15:43663654~43684339:- CESC cis rs4853012 0.775 rs12465641 ENSG00000257800.1 FNBP1P1 -5.21 4.45e-07 0.000382 -0.34 -0.33 Gestational age at birth (maternal effect); chr2:74110588 chr2:74120680~74123218:+ CESC cis rs4722166 0.508 rs1474347 ENSG00000179428.2 AC073072.5 5.21 4.45e-07 0.000382 0.43 0.33 Lung cancer; chr7:22728505 chr7:22725395~22727620:- CESC cis rs875971 0.862 rs1968126 ENSG00000232559.3 GS1-124K5.12 -5.2 4.48e-07 0.000384 -0.36 -0.33 Aortic root size; chr7:66592017 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6460306 ENSG00000232559.3 GS1-124K5.12 -5.2 4.48e-07 0.000384 -0.36 -0.33 Aortic root size; chr7:66595806 chr7:66554588~66576923:- CESC cis rs9549367 0.577 rs3024711 ENSG00000269125.1 RP11-98F14.11 -5.2 4.48e-07 0.000384 -0.48 -0.33 Platelet distribution width; chr13:113158954 chr13:113165002~113165183:- CESC cis rs1930961 0.702 rs6004684 ENSG00000100058.11 CRYBB2P1 -5.2 4.49e-07 0.000385 -0.67 -0.33 Bipolar disorder with mood-incongruent psychosis; chr22:25503972 chr22:25448105~25520854:+ CESC cis rs4718428 0.705 rs4717328 ENSG00000273142.1 RP11-458F8.4 -5.2 4.49e-07 0.000385 -0.35 -0.33 Corneal structure; chr7:66887678 chr7:66902857~66906297:+ CESC cis rs4718428 0.705 rs4718422 ENSG00000273142.1 RP11-458F8.4 -5.2 4.49e-07 0.000385 -0.35 -0.33 Corneal structure; chr7:66894282 chr7:66902857~66906297:+ CESC cis rs4718428 0.705 rs13231140 ENSG00000273142.1 RP11-458F8.4 -5.2 4.49e-07 0.000385 -0.35 -0.33 Corneal structure; chr7:66896631 chr7:66902857~66906297:+ CESC cis rs1823913 0.599 rs6732976 ENSG00000280083.1 RP11-317J9.1 5.2 4.49e-07 0.000385 0.39 0.33 Obesity-related traits; chr2:191281004 chr2:191154118~191156070:- CESC cis rs14027 0.512 rs13253139 ENSG00000279347.1 RP11-85I17.2 5.2 4.5e-07 0.000385 0.32 0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119718225 chr8:119838736~119840385:- CESC cis rs2028299 0.919 rs12440156 ENSG00000259677.1 RP11-493E3.1 5.2 4.51e-07 0.000386 0.47 0.33 Type 2 diabetes; chr15:89877441 chr15:89876540~89877285:+ CESC cis rs7714584 1 rs59321715 ENSG00000197083.10 ZNF300P1 5.2 4.51e-07 0.000386 0.76 0.33 Crohn's disease; chr5:150933918 chr5:150930645~150946289:- CESC cis rs1799949 1 rs11653069 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43131360 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs33988650 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43135863 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs11656097 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43138596 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs2292595 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43138657 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs11658754 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43140722 chr17:43144956~43145255:+ CESC cis rs1799949 0.93 rs33968979 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43145975 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs12952790 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43147590 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs12950607 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43147911 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs11079056 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43148782 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs12936816 ENSG00000267681.1 CTD-3199J23.6 -5.2 4.52e-07 0.000386 -0.43 -0.33 Menopause (age at onset); chr17:43149692 chr17:43144956~43145255:+ CESC cis rs1061377 1 rs34771104 ENSG00000249685.1 RP11-360F5.3 5.2 4.52e-07 0.000387 0.39 0.33 Uric acid levels; chr4:39127432 chr4:39133913~39135608:+ CESC cis rs6504950 0.924 rs244342 ENSG00000275710.1 RP11-257O5.4 5.2 4.53e-07 0.000388 0.37 0.33 Breast cancer; chr17:55121046 chr17:54964474~54964679:+ CESC cis rs6142102 0.923 rs6059635 ENSG00000276073.1 RP5-1125A11.7 -5.2 4.53e-07 0.000388 -0.32 -0.33 Skin pigmentation; chr20:34025687 chr20:33985617~33988989:- CESC cis rs9907295 0.688 rs2735475 ENSG00000271013.1 AC015849.15 -5.2 4.53e-07 0.000388 -0.39 -0.33 Fibroblast growth factor basic levels; chr17:35931003 chr17:35912635~35918010:- CESC cis rs11096990 0.593 rs6531700 ENSG00000249207.1 RP11-360F5.1 5.2 4.55e-07 0.000389 0.36 0.33 Cognitive function; chr4:39269265 chr4:39112677~39126818:- CESC cis rs6782228 0.606 rs6775270 ENSG00000242551.2 POU5F1P6 -5.2 4.55e-07 0.000389 -0.37 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128684655 chr3:128674735~128677005:- CESC cis rs7714584 1 rs6874560 ENSG00000197083.10 ZNF300P1 5.2 4.56e-07 0.000389 0.73 0.33 Crohn's disease; chr5:150803151 chr5:150930645~150946289:- CESC cis rs7714584 1 rs11748553 ENSG00000197083.10 ZNF300P1 5.2 4.56e-07 0.000389 0.73 0.33 Crohn's disease; chr5:150804991 chr5:150930645~150946289:- CESC cis rs7714584 1 rs11746560 ENSG00000197083.10 ZNF300P1 5.2 4.56e-07 0.000389 0.73 0.33 Crohn's disease; chr5:150806363 chr5:150930645~150946289:- CESC cis rs7714584 1 rs4958422 ENSG00000197083.10 ZNF300P1 5.2 4.56e-07 0.000389 0.73 0.33 Crohn's disease; chr5:150807172 chr5:150930645~150946289:- CESC cis rs7714584 1 rs59715748 ENSG00000197083.10 ZNF300P1 5.2 4.56e-07 0.000389 0.73 0.33 Crohn's disease; chr5:150809725 chr5:150930645~150946289:- CESC cis rs12439619 0.739 rs4778988 ENSG00000255769.6 GOLGA2P10 -5.2 4.56e-07 0.00039 -0.43 -0.33 Intelligence (multi-trait analysis); chr15:82247996 chr15:82472993~82513950:- CESC cis rs1062177 1 rs62394155 ENSG00000253921.1 CTB-113P19.3 -5.2 4.6e-07 0.000393 -0.46 -0.33 Preschool internalizing problems; chr5:151868508 chr5:151753992~151767247:+ CESC cis rs4660456 0.913 rs556875 ENSG00000237899.1 RP4-739H11.3 -5.2 4.61e-07 0.000394 -0.45 -0.33 Platelet count; chr1:40688571 chr1:40669089~40687588:- CESC cis rs42490 0.635 rs418634 ENSG00000251136.7 RP11-37B2.1 -5.2 4.62e-07 0.000394 -0.34 -0.33 Leprosy; chr8:89847469 chr8:89609409~89757727:- CESC cis rs7572733 0.84 rs4286272 ENSG00000222017.1 AC011997.1 -5.2 4.63e-07 0.000395 -0.38 -0.33 Dermatomyositis; chr2:197670954 chr2:197693106~197774823:+ CESC cis rs875971 0.862 rs778724 ENSG00000237310.1 GS1-124K5.4 5.2 4.65e-07 0.000397 0.32 0.33 Aortic root size; chr7:66364304 chr7:66493706~66495474:+ CESC cis rs748404 0.69 rs2924369 ENSG00000205771.5 CATSPER2P1 5.2 4.66e-07 0.000398 0.39 0.33 Lung cancer; chr15:43485787 chr15:43726918~43747094:- CESC cis rs748404 0.69 rs1079309 ENSG00000205771.5 CATSPER2P1 -5.2 4.66e-07 0.000398 -0.39 -0.33 Lung cancer; chr15:43490966 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs690012 ENSG00000205771.5 CATSPER2P1 -5.2 4.66e-07 0.000398 -0.39 -0.33 Lung cancer; chr15:43427557 chr15:43726918~43747094:- CESC cis rs9907295 0.901 rs56294660 ENSG00000270977.1 AC015849.16 -5.2 4.68e-07 0.000399 -0.49 -0.33 Fibroblast growth factor basic levels; chr17:35901470 chr17:35893707~35911023:- CESC cis rs2115630 0.691 rs61322921 ENSG00000225151.9 GOLGA2P7 5.2 4.68e-07 0.000399 0.37 0.33 P wave terminal force; chr15:84620407 chr15:84199311~84230136:- CESC cis rs763121 0.962 rs5757130 ENSG00000273076.1 RP3-508I15.22 5.2 4.69e-07 4e-04 0.38 0.33 Menopause (age at onset); chr22:38541789 chr22:38743495~38743910:+ CESC cis rs1499614 1 rs2707840 ENSG00000275400.1 RP4-756H11.5 5.2 4.69e-07 4e-04 0.58 0.33 Gout; chr7:66693028 chr7:66553805~66554199:- CESC cis rs4266144 1 rs4561781 ENSG00000244515.1 KRT18P34 5.19 4.7e-07 4e-04 0.38 0.33 Coronary artery disease; chr3:157135154 chr3:157162663~157163932:- CESC cis rs5769707 0.632 rs135876 ENSG00000188511.11 C22orf34 5.19 4.71e-07 0.000401 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49619925 chr22:49414524~49657542:- CESC cis rs11723261 0.546 rs57839456 ENSG00000211553.1 AC253576.2 -5.19 4.72e-07 0.000402 -0.48 -0.33 Immune response to smallpox vaccine (IL-6); chr4:154494 chr4:136461~136568:+ CESC cis rs34779708 0.966 rs1213392 ENSG00000230534.5 RP11-297A16.2 5.19 4.72e-07 0.000402 0.43 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35141357 chr10:35098006~35127020:- CESC cis rs10751647 0.804 rs3809112 ENSG00000251661.3 RP11-326C3.11 -5.19 4.72e-07 0.000402 -0.32 -0.33 Monocyte count; chr11:307036 chr11:318640~325631:+ CESC cis rs4713118 0.629 rs203887 ENSG00000219392.1 RP1-265C24.5 -5.19 4.73e-07 0.000403 -0.48 -0.33 Parkinson's disease; chr6:28053491 chr6:28115628~28116551:+ CESC cis rs11690935 0.885 rs6727017 ENSG00000228389.1 AC068039.4 5.19 4.73e-07 0.000403 0.42 0.33 Schizophrenia; chr2:171910337 chr2:171773482~171775844:+ CESC cis rs2548724 0.561 rs953280 ENSG00000250682.4 LINC00491 -5.19 4.75e-07 0.000404 -0.39 -0.33 Type 2 diabetes; chr5:102508055 chr5:102609156~102671559:- CESC cis rs14027 0.512 rs13252708 ENSG00000279347.1 RP11-85I17.2 -5.19 4.75e-07 0.000404 -0.32 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119718283 chr8:119838736~119840385:- CESC cis rs9322193 0.607 rs12210822 ENSG00000231760.4 RP11-350J20.5 5.19 4.76e-07 0.000405 0.49 0.33 Lung cancer; chr6:149905356 chr6:149796151~149826294:- CESC cis rs35160687 0.814 rs6547673 ENSG00000273080.1 RP11-301O19.1 5.19 4.76e-07 0.000405 0.36 0.33 Night sleep phenotypes; chr2:86301815 chr2:86195590~86196049:+ CESC cis rs34779708 0.931 rs4934524 ENSG00000230534.5 RP11-297A16.2 5.19 4.78e-07 0.000406 0.44 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34981993 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs4934693 ENSG00000230534.5 RP11-297A16.2 5.19 4.78e-07 0.000406 0.44 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34982916 chr10:35098006~35127020:- CESC cis rs6991838 0.765 rs4424306 ENSG00000272010.1 CTD-3025N20.3 5.19 4.78e-07 0.000407 0.37 0.33 Intelligence (multi-trait analysis); chr8:65618674 chr8:65591850~65592472:- CESC cis rs2028299 1 rs3960018 ENSG00000259677.1 RP11-493E3.1 5.19 4.79e-07 0.000407 0.46 0.33 Type 2 diabetes; chr15:89840075 chr15:89876540~89877285:+ CESC cis rs2028299 1 rs2351706 ENSG00000259677.1 RP11-493E3.1 5.19 4.79e-07 0.000407 0.46 0.33 Type 2 diabetes; chr15:89840883 chr15:89876540~89877285:+ CESC cis rs2412819 0.571 rs17727853 ENSG00000249839.1 AC011330.5 -5.19 4.79e-07 0.000407 -0.48 -0.33 Lung cancer; chr15:43630299 chr15:43663654~43684339:- CESC cis rs2412819 0.571 rs62018900 ENSG00000249839.1 AC011330.5 -5.19 4.79e-07 0.000407 -0.48 -0.33 Lung cancer; chr15:43633252 chr15:43663654~43684339:- CESC cis rs2412819 0.545 rs35333173 ENSG00000249839.1 AC011330.5 -5.19 4.79e-07 0.000407 -0.48 -0.33 Lung cancer; chr15:43640818 chr15:43663654~43684339:- CESC cis rs2412819 0.571 rs112667279 ENSG00000249839.1 AC011330.5 -5.19 4.79e-07 0.000407 -0.48 -0.33 Lung cancer; chr15:43649258 chr15:43663654~43684339:- CESC cis rs7188445 0.932 rs73575083 ENSG00000261390.4 RP11-345M22.2 -5.19 4.79e-07 0.000407 -0.42 -0.33 Urate levels; chr16:79713958 chr16:79715232~79770563:- CESC cis rs7188445 0.932 rs73575085 ENSG00000261390.4 RP11-345M22.2 -5.19 4.79e-07 0.000407 -0.42 -0.33 Urate levels; chr16:79714179 chr16:79715232~79770563:- CESC cis rs4718428 0.705 rs4717331 ENSG00000273142.1 RP11-458F8.4 -5.19 4.8e-07 0.000408 -0.35 -0.33 Corneal structure; chr7:66913899 chr7:66902857~66906297:+ CESC cis rs14027 0.512 rs7010808 ENSG00000279347.1 RP11-85I17.2 -5.19 4.8e-07 0.000408 -0.32 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119712216 chr8:119838736~119840385:- CESC cis rs9549367 0.662 rs3818334 ENSG00000269125.1 RP11-98F14.11 -5.19 4.81e-07 0.000408 -0.48 -0.33 Platelet distribution width; chr13:113170860 chr13:113165002~113165183:- CESC cis rs13108904 0.901 rs7695691 ENSG00000253399.1 AC078852.2 -5.19 4.82e-07 0.00041 -0.4 -0.33 Obesity-related traits; chr4:1310844 chr4:1358479~1359461:+ CESC cis rs1799949 1 rs1960605 ENSG00000267681.1 CTD-3199J23.6 -5.19 4.84e-07 0.000411 -0.43 -0.33 Menopause (age at onset); chr17:43153380 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs2037076 ENSG00000267681.1 CTD-3199J23.6 -5.19 4.84e-07 0.000411 -0.43 -0.33 Menopause (age at onset); chr17:43153866 chr17:43144956~43145255:+ CESC cis rs7714670 0.736 rs2962278 ENSG00000184084.7 CTD-2372A4.1 -5.19 4.85e-07 0.000411 -0.37 -0.33 Venous thromboembolism (SNP x SNP interaction); chr5:73798133 chr5:73803296~73803599:- CESC cis rs10800713 0.826 rs6427834 ENSG00000260088.1 RP11-92G12.3 -5.19 4.85e-07 0.000412 -0.48 -0.33 Tandem gait; chr1:200561936 chr1:200669507~200694250:+ CESC cis rs8177876 0.822 rs55939311 ENSG00000261838.4 RP11-303E16.6 5.19 4.86e-07 0.000412 0.72 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81075493 chr16:81069854~81076598:+ CESC cis rs10754283 0.967 rs4658302 ENSG00000231613.1 RP5-943J3.1 5.19 4.86e-07 0.000412 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89637777 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs7513928 ENSG00000231613.1 RP5-943J3.1 5.19 4.86e-07 0.000412 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89639275 chr1:89788914~89790492:+ CESC cis rs10754283 0.934 rs6428563 ENSG00000231613.1 RP5-943J3.1 5.19 4.86e-07 0.000412 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89646024 chr1:89788914~89790492:+ CESC cis rs9549367 0.789 rs12584813 ENSG00000269125.1 RP11-98F14.11 -5.19 4.89e-07 0.000414 -0.46 -0.33 Platelet distribution width; chr13:113241129 chr13:113165002~113165183:- CESC cis rs9549367 1 rs9549367 ENSG00000269125.1 RP11-98F14.11 -5.19 4.89e-07 0.000415 -0.45 -0.33 Platelet distribution width; chr13:113257218 chr13:113165002~113165183:- CESC cis rs156299 0.56 rs198317 ENSG00000226816.2 AC005082.12 -5.19 4.9e-07 0.000415 -0.41 -0.33 Vitamin D levels; chr7:24150702 chr7:23206013~23208045:+ CESC cis rs156299 0.519 rs198313 ENSG00000226816.2 AC005082.12 -5.19 4.9e-07 0.000415 -0.41 -0.33 Vitamin D levels; chr7:24151430 chr7:23206013~23208045:+ CESC cis rs9309711 0.883 rs13429373 ENSG00000225234.1 TRAPPC12-AS1 -5.19 4.9e-07 0.000415 -0.34 -0.33 Neurofibrillary tangles; chr2:3473243 chr2:3481242~3482409:- CESC cis rs14027 0.64 rs16893071 ENSG00000279347.1 RP11-85I17.2 -5.19 4.91e-07 0.000416 -0.31 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119738183 chr8:119838736~119840385:- CESC cis rs1800795 0.652 rs7802307 ENSG00000179428.2 AC073072.5 -5.18 4.93e-07 0.000417 -0.45 -0.33 Cerebrospinal fluid clusterin levels in APOEe4- carriers; chr7:22726814 chr7:22725395~22727620:- CESC cis rs7572733 1 rs10206714 ENSG00000222017.1 AC011997.1 5.18 4.94e-07 0.000418 0.36 0.33 Dermatomyositis; chr2:198041757 chr2:197693106~197774823:+ CESC cis rs10256972 0.9 rs4388364 ENSG00000229043.2 AC091729.9 -5.18 4.94e-07 0.000418 -0.38 -0.33 Endometriosis;Longevity; chr7:993409 chr7:1160374~1165267:+ CESC cis rs1061377 1 rs12646251 ENSG00000249685.1 RP11-360F5.3 5.18 4.95e-07 0.000419 0.39 0.33 Uric acid levels; chr4:39132751 chr4:39133913~39135608:+ CESC cis rs6142102 0.961 rs1883524 ENSG00000276073.1 RP5-1125A11.7 -5.18 4.95e-07 0.000419 -0.32 -0.33 Skin pigmentation; chr20:34038301 chr20:33985617~33988989:- CESC cis rs73086581 1 rs6037708 ENSG00000229539.1 RP11-119B16.2 5.18 4.95e-07 0.000419 0.53 0.33 Response to antidepressants in depression; chr20:3980606 chr20:3888239~3888868:- CESC cis rs7714584 1 rs58717741 ENSG00000197083.10 ZNF300P1 5.18 4.95e-07 0.000419 0.65 0.33 Crohn's disease; chr5:150905374 chr5:150930645~150946289:- CESC cis rs8100891 0.537 rs73034216 ENSG00000267213.4 AC007773.2 -5.18 4.96e-07 0.000419 -0.53 -0.33 Neuroticism; chr19:32392510 chr19:32390050~32405560:- CESC cis rs5769707 0.632 rs6009782 ENSG00000188511.11 C22orf34 5.18 4.97e-07 0.00042 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49617164 chr22:49414524~49657542:- CESC cis rs5769707 0.592 rs6009783 ENSG00000188511.11 C22orf34 5.18 4.97e-07 0.00042 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49617353 chr22:49414524~49657542:- CESC cis rs7189233 0.55 rs17193176 ENSG00000279344.1 RP11-44F14.7 5.18 4.97e-07 0.000421 0.31 0.33 Intelligence (multi-trait analysis); chr16:53484316 chr16:53478957~53481550:- CESC cis rs748404 0.66 rs690367 ENSG00000205771.5 CATSPER2P1 5.18 4.98e-07 0.000421 0.39 0.33 Lung cancer; chr15:43456106 chr15:43726918~43747094:- CESC cis rs5769707 0.681 rs2319346 ENSG00000188511.11 C22orf34 5.18 4.98e-07 0.000421 0.4 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49635992 chr22:49414524~49657542:- CESC cis rs875971 0.862 rs11984115 ENSG00000237310.1 GS1-124K5.4 -5.18 4.99e-07 0.000422 -0.31 -0.33 Aortic root size; chr7:66308872 chr7:66493706~66495474:+ CESC cis rs14027 0.512 rs6992632 ENSG00000279347.1 RP11-85I17.2 -5.18 4.99e-07 0.000422 -0.32 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119711969 chr8:119838736~119840385:- CESC cis rs14027 0.512 rs10095282 ENSG00000279347.1 RP11-85I17.2 -5.18 4.99e-07 0.000422 -0.32 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119712629 chr8:119838736~119840385:- CESC cis rs14027 0.512 rs28711081 ENSG00000279347.1 RP11-85I17.2 -5.18 4.99e-07 0.000422 -0.32 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119713469 chr8:119838736~119840385:- CESC cis rs14027 0.512 rs10103886 ENSG00000279347.1 RP11-85I17.2 -5.18 4.99e-07 0.000422 -0.32 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119715158 chr8:119838736~119840385:- CESC cis rs14027 0.512 rs7825803 ENSG00000279347.1 RP11-85I17.2 -5.18 4.99e-07 0.000422 -0.32 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119716558 chr8:119838736~119840385:- CESC cis rs5769707 0.632 rs135877 ENSG00000188511.11 C22orf34 5.18 4.99e-07 0.000422 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49620354 chr22:49414524~49657542:- CESC cis rs957448 0.561 rs12679785 ENSG00000253704.1 RP11-267M23.4 5.18 4.99e-07 0.000422 0.35 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94593349 chr8:94553722~94569745:+ CESC cis rs957448 0.561 rs13258635 ENSG00000253704.1 RP11-267M23.4 5.18 4.99e-07 0.000422 0.35 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94595629 chr8:94553722~94569745:+ CESC cis rs12680842 0.842 rs34691145 ENSG00000253704.1 RP11-267M23.4 5.18 4.99e-07 0.000422 0.35 0.33 Body mass index; chr8:94597715 chr8:94553722~94569745:+ CESC cis rs17711722 0.701 rs4467826 ENSG00000164669.11 INTS4P1 -5.18 5e-07 0.000422 -0.46 -0.33 Calcium levels; chr7:65903721 chr7:65141225~65234216:+ CESC cis rs9549367 0.789 rs9549698 ENSG00000269125.1 RP11-98F14.11 -5.18 5.01e-07 0.000423 -0.44 -0.33 Platelet distribution width; chr13:113223387 chr13:113165002~113165183:- CESC cis rs4718428 0.705 rs13220977 ENSG00000273142.1 RP11-458F8.4 5.18 5.01e-07 0.000423 0.34 0.33 Corneal structure; chr7:66872661 chr7:66902857~66906297:+ CESC cis rs7396835 0.866 rs7927820 ENSG00000254851.1 RP11-109L13.1 -5.18 5.01e-07 0.000424 -0.54 -0.33 Quantitative traits; chr11:116811440 chr11:117135528~117138582:+ CESC cis rs9584850 0.834 rs7334078 ENSG00000231194.1 FARP1-AS1 -5.18 5.01e-07 0.000424 -0.42 -0.33 Neuroticism; chr13:98468230 chr13:98435405~98435840:- CESC cis rs7189233 0.55 rs9927982 ENSG00000279344.1 RP11-44F14.7 5.18 5.04e-07 0.000426 0.31 0.33 Intelligence (multi-trait analysis); chr16:53440196 chr16:53478957~53481550:- CESC cis rs11638352 1 rs8038096 ENSG00000259479.5 SORD2P -5.18 5.04e-07 0.000426 -0.48 -0.33 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44075092 chr15:44826371~44884694:- CESC cis rs6991838 0.771 rs13282323 ENSG00000200714.1 Y_RNA 5.18 5.05e-07 0.000426 0.39 0.33 Intelligence (multi-trait analysis); chr8:65560557 chr8:65592731~65592820:+ CESC cis rs8100891 0.537 rs10417152 ENSG00000267213.4 AC007773.2 -5.18 5.06e-07 0.000427 -0.53 -0.33 Neuroticism; chr19:32397994 chr19:32390050~32405560:- CESC cis rs5769707 0.521 rs739244 ENSG00000188511.11 C22orf34 5.18 5.06e-07 0.000427 0.37 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49666510 chr22:49414524~49657542:- CESC cis rs2929278 0.736 rs2412823 ENSG00000249839.1 AC011330.5 5.18 5.08e-07 0.000429 0.33 0.33 Schizophrenia; chr15:43935072 chr15:43663654~43684339:- CESC cis rs75422866 0.867 rs117022227 ENSG00000257433.4 RP1-197B17.3 5.18 5.08e-07 0.000429 0.83 0.33 Pneumonia; chr12:47633282 chr12:47706085~47742294:+ CESC cis rs34779708 0.931 rs2244100 ENSG00000230534.5 RP11-297A16.2 -5.18 5.09e-07 0.00043 -0.43 -0.33 Inflammatory bowel disease;Crohn's disease; chr10:35034708 chr10:35098006~35127020:- CESC cis rs5769707 0.706 rs763128 ENSG00000188511.11 C22orf34 5.18 5.09e-07 0.00043 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49624397 chr22:49414524~49657542:- CESC cis rs4974559 0.793 rs10025954 ENSG00000253399.1 AC078852.2 5.18 5.09e-07 0.00043 0.53 0.33 Systolic blood pressure; chr4:1357594 chr4:1358479~1359461:+ CESC cis rs2882667 0.556 rs6873733 ENSG00000253404.1 AC034243.1 5.18 5.1e-07 0.00043 0.39 0.33 Age-related hearing impairment (SNP x SNP interaction); chr5:139067628 chr5:138744434~138753309:- CESC cis rs1062177 1 rs12653926 ENSG00000253921.1 CTB-113P19.3 -5.18 5.1e-07 0.00043 -0.46 -0.33 Preschool internalizing problems; chr5:151870687 chr5:151753992~151767247:+ CESC cis rs9322193 0.607 rs12209310 ENSG00000231760.4 RP11-350J20.5 5.18 5.11e-07 0.000431 0.49 0.33 Lung cancer; chr6:149904882 chr6:149796151~149826294:- CESC cis rs73086581 1 rs11906274 ENSG00000229539.1 RP11-119B16.2 5.18 5.11e-07 0.000431 0.53 0.33 Response to antidepressants in depression; chr20:3964889 chr20:3888239~3888868:- CESC cis rs73086581 1 rs6052196 ENSG00000229539.1 RP11-119B16.2 5.18 5.11e-07 0.000431 0.53 0.33 Response to antidepressants in depression; chr20:3965177 chr20:3888239~3888868:- CESC cis rs73086581 1 rs6116130 ENSG00000229539.1 RP11-119B16.2 5.18 5.11e-07 0.000431 0.53 0.33 Response to antidepressants in depression; chr20:3966379 chr20:3888239~3888868:- CESC cis rs5769707 0.609 rs2007024 ENSG00000235111.1 RP1-29C18.8 -5.18 5.13e-07 0.000432 -0.38 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49595167 chr22:49612657~49615716:- CESC cis rs11723261 0.582 rs11735742 ENSG00000211553.1 AC253576.2 5.18 5.13e-07 0.000432 0.47 0.33 Immune response to smallpox vaccine (IL-6); chr4:148766 chr4:136461~136568:+ CESC cis rs10754283 0.967 rs10922679 ENSG00000231613.1 RP5-943J3.1 5.18 5.13e-07 0.000433 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89635366 chr1:89788914~89790492:+ CESC cis rs10754283 0.935 rs10801756 ENSG00000231613.1 RP5-943J3.1 5.18 5.13e-07 0.000433 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89636273 chr1:89788914~89790492:+ CESC cis rs10754283 0.934 rs6684676 ENSG00000231613.1 RP5-943J3.1 5.18 5.13e-07 0.000433 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89636614 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs6428561 ENSG00000231613.1 RP5-943J3.1 5.18 5.13e-07 0.000433 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89637060 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs6428562 ENSG00000231613.1 RP5-943J3.1 5.18 5.13e-07 0.000433 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89637106 chr1:89788914~89790492:+ CESC cis rs7200543 0.848 rs62039480 ENSG00000260735.1 RP11-72I8.1 -5.18 5.14e-07 0.000433 -0.38 -0.33 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15043593 chr16:15094411~15109197:+ CESC cis rs1062177 0.756 rs2964592 ENSG00000253921.1 CTB-113P19.3 5.18 5.15e-07 0.000434 0.44 0.33 Preschool internalizing problems; chr5:151736127 chr5:151753992~151767247:+ CESC cis rs9309711 0.77 rs13409323 ENSG00000225234.1 TRAPPC12-AS1 -5.18 5.16e-07 0.000434 -0.33 -0.33 Neurofibrillary tangles; chr2:3484413 chr2:3481242~3482409:- CESC cis rs72627509 0.638 rs7658601 ENSG00000269949.1 RP11-738E22.3 5.17 5.17e-07 0.000436 0.5 0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56915181 chr4:56960927~56961373:- CESC cis rs2243480 0.901 rs12530490 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66226660 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs7778911 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66229519 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1979823 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66239626 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6964245 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66253730 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs10807701 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66259699 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1499613 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66265873 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1553174 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66266207 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs10950032 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66273604 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6958420 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66286184 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1392104 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66294120 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs4718333 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66307771 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs7792391 ENSG00000228409.4 CCT6P1 -5.17 5.17e-07 0.000436 -0.5 -0.33 Diabetic kidney disease; chr7:66308442 chr7:65751142~65763354:+ CESC cis rs42490 1 rs67143546 ENSG00000251136.7 RP11-37B2.1 -5.17 5.18e-07 0.000436 -0.34 -0.33 Leprosy; chr8:89753950 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs385524 ENSG00000251136.7 RP11-37B2.1 -5.17 5.18e-07 0.000436 -0.34 -0.33 Leprosy; chr8:89754242 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs419754 ENSG00000251136.7 RP11-37B2.1 -5.17 5.18e-07 0.000436 -0.34 -0.33 Leprosy; chr8:89755452 chr8:89609409~89757727:- CESC cis rs765787 0.53 rs11634794 ENSG00000259520.4 CTD-2651B20.3 5.17 5.2e-07 0.000437 0.41 0.33 Uric acid levels; chr15:45242294 chr15:45251580~45279251:- CESC cis rs494459 0.838 rs607125 ENSG00000255422.1 AP002954.4 -5.17 5.21e-07 0.000438 -0.38 -0.33 Height; chr11:118746590 chr11:118704607~118750263:+ CESC cis rs875971 0.862 rs709596 ENSG00000222364.1 RNU6-96P -5.17 5.21e-07 0.000438 -0.38 -0.33 Aortic root size; chr7:66360926 chr7:66395191~66395286:+ CESC cis rs8177876 0.749 rs75923695 ENSG00000261838.4 RP11-303E16.6 5.17 5.21e-07 0.000439 0.71 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81060289 chr16:81069854~81076598:+ CESC cis rs9601248 0.874 rs4141825 ENSG00000227676.3 LINC01068 5.17 5.22e-07 0.000439 0.38 0.33 Major depressive disorder; chr13:79616713 chr13:79566727~79571436:+ CESC cis rs3096299 0.933 rs2965939 ENSG00000274627.1 RP11-104N10.2 5.17 5.23e-07 0.00044 0.33 0.33 Multiple myeloma (IgH translocation); chr16:89426635 chr16:89516797~89522217:+ CESC cis rs5769707 0.616 rs135869 ENSG00000235111.1 RP1-29C18.8 -5.17 5.23e-07 0.00044 -0.38 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49614718 chr22:49612657~49615716:- CESC cis rs42490 0.966 rs2735878 ENSG00000251136.7 RP11-37B2.1 -5.17 5.23e-07 0.00044 -0.34 -0.33 Leprosy; chr8:89742720 chr8:89609409~89757727:- CESC cis rs9929218 0.508 rs1559366 ENSG00000260459.2 FTLP14 5.17 5.26e-07 0.000442 0.42 0.33 Colorectal cancer; chr16:68765708 chr16:68822587~68823070:+ CESC cis rs9929218 0.581 rs4783676 ENSG00000260459.2 FTLP14 5.17 5.26e-07 0.000442 0.42 0.33 Colorectal cancer; chr16:68767174 chr16:68822587~68823070:+ CESC cis rs10829156 0.947 rs7081435 ENSG00000240291.1 RP11-499P20.2 5.17 5.27e-07 0.000443 0.35 0.33 Sudden cardiac arrest; chr10:18667411 chr10:18513115~18545651:- CESC cis rs9907295 0.901 rs9898132 ENSG00000270977.1 AC015849.16 -5.17 5.27e-07 0.000443 -0.49 -0.33 Fibroblast growth factor basic levels; chr17:35869187 chr17:35893707~35911023:- CESC cis rs10754283 0.967 rs1934045 ENSG00000231613.1 RP5-943J3.1 -5.17 5.28e-07 0.000444 -0.42 -0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89642240 chr1:89788914~89790492:+ CESC cis rs9584850 0.718 rs6491427 ENSG00000231194.1 FARP1-AS1 5.17 5.3e-07 0.000445 0.42 0.33 Neuroticism; chr13:98460912 chr13:98435405~98435840:- CESC cis rs10129255 0.536 rs3944157 ENSG00000211972.2 IGHV3-66 5.17 5.32e-07 0.000446 0.24 0.33 Kawasaki disease; chr14:106682286 chr14:106675017~106675544:- CESC cis rs897984 0.806 rs8050588 ENSG00000260911.2 RP11-196G11.2 5.17 5.32e-07 0.000447 0.36 0.33 Dementia with Lewy bodies; chr16:30926478 chr16:31043150~31049868:+ CESC cis rs8059260 0.604 rs9940096 ENSG00000274038.1 RP11-66H6.4 -5.17 5.33e-07 0.000447 -0.55 -0.33 Alcohol consumption over the past year; chr16:11045737 chr16:11056556~11057034:+ CESC cis rs9907295 0.818 rs4795093 ENSG00000270977.1 AC015849.16 -5.17 5.33e-07 0.000447 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35853137 chr17:35893707~35911023:- CESC cis rs9907295 0.818 rs2306630 ENSG00000270977.1 AC015849.16 -5.17 5.33e-07 0.000447 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35855337 chr17:35893707~35911023:- CESC cis rs889512 0.731 rs3743614 ENSG00000280152.1 RP11-331F4.5 -5.17 5.34e-07 0.000448 -0.46 -0.33 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75247060 chr16:75245994~75250077:- CESC cis rs3762637 0.943 rs78429050 ENSG00000272758.4 RP11-299J3.8 -5.17 5.34e-07 0.000448 -0.46 -0.33 LDL cholesterol levels; chr3:122533581 chr3:122416207~122443180:+ CESC cis rs3762637 0.943 rs3817040 ENSG00000272758.4 RP11-299J3.8 -5.17 5.34e-07 0.000448 -0.46 -0.33 LDL cholesterol levels; chr3:122535922 chr3:122416207~122443180:+ CESC cis rs2564921 0.704 rs2336720 ENSG00000242142.1 SERBP1P3 -5.17 5.35e-07 0.000448 -0.39 -0.33 Height; chr3:52994045 chr3:53064283~53065091:- CESC cis rs2564921 0.73 rs56384586 ENSG00000242142.1 SERBP1P3 -5.17 5.35e-07 0.000448 -0.39 -0.33 Height; chr3:52994990 chr3:53064283~53065091:- CESC cis rs7572733 1 rs35062652 ENSG00000222017.1 AC011997.1 5.17 5.35e-07 0.000448 0.36 0.33 Dermatomyositis; chr2:198063203 chr2:197693106~197774823:+ CESC cis rs5769707 0.605 rs9616702 ENSG00000188511.11 C22orf34 5.17 5.36e-07 0.000449 0.4 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49632290 chr22:49414524~49657542:- CESC cis rs2015599 0.549 rs7134796 ENSG00000275476.1 RP11-996F15.4 5.17 5.36e-07 0.000449 0.37 0.33 Platelet count;Mean platelet volume; chr12:29294361 chr12:29277397~29277882:- CESC cis rs11846409 0.86 rs1974470 ENSG00000211974.3 IGHV2-70 -5.17 5.36e-07 0.000449 -0.45 -0.33 Rheumatic heart disease; chr14:106621300 chr14:106723574~106724093:- CESC cis rs748404 0.588 rs2255410 ENSG00000205771.5 CATSPER2P1 -5.17 5.37e-07 0.00045 -0.39 -0.33 Lung cancer; chr15:43538899 chr15:43726918~43747094:- CESC cis rs8059260 0.736 rs80079627 ENSG00000274038.1 RP11-66H6.4 -5.17 5.38e-07 0.000451 -0.57 -0.33 Alcohol consumption over the past year; chr16:10948741 chr16:11056556~11057034:+ CESC cis rs8059260 0.736 rs77920180 ENSG00000274038.1 RP11-66H6.4 -5.17 5.38e-07 0.000451 -0.57 -0.33 Alcohol consumption over the past year; chr16:10949041 chr16:11056556~11057034:+ CESC cis rs7714670 0.736 rs2973547 ENSG00000184084.7 CTD-2372A4.1 -5.17 5.39e-07 0.000451 -0.37 -0.33 Venous thromboembolism (SNP x SNP interaction); chr5:73796590 chr5:73803296~73803599:- CESC cis rs9907295 0.901 rs9914401 ENSG00000270977.1 AC015849.16 -5.17 5.4e-07 0.000452 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35861810 chr17:35893707~35911023:- CESC cis rs72627509 0.904 rs3796529 ENSG00000269949.1 RP11-738E22.3 5.17 5.41e-07 0.000453 0.48 0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56931248 chr4:56960927~56961373:- CESC cis rs42490 0.966 rs6992985 ENSG00000251136.7 RP11-37B2.1 -5.16 5.42e-07 0.000453 -0.34 -0.33 Leprosy; chr8:89746330 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs6993133 ENSG00000251136.7 RP11-37B2.1 -5.16 5.42e-07 0.000453 -0.34 -0.33 Leprosy; chr8:89746396 chr8:89609409~89757727:- CESC cis rs67180937 0.844 rs35626308 ENSG00000272750.1 RP11-378J18.8 -5.16 5.42e-07 0.000454 -0.42 -0.33 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222643014 chr1:222658867~222661512:- CESC cis rs1707322 0.827 rs6683274 ENSG00000281133.1 AL355480.3 -5.16 5.42e-07 0.000454 -0.41 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45775966 chr1:45580892~45580996:- CESC cis rs75422866 0.867 rs35044089 ENSG00000257433.4 RP1-197B17.3 5.16 5.43e-07 0.000454 0.81 0.33 Pneumonia; chr12:47610881 chr12:47706085~47742294:+ CESC cis rs7714584 1 rs75294883 ENSG00000197083.10 ZNF300P1 5.16 5.43e-07 0.000454 0.75 0.33 Crohn's disease; chr5:150816941 chr5:150930645~150946289:- CESC cis rs3762637 1 rs28497203 ENSG00000272758.4 RP11-299J3.8 -5.16 5.43e-07 0.000454 -0.46 -0.33 LDL cholesterol levels; chr3:122512972 chr3:122416207~122443180:+ CESC cis rs2243480 1 rs316313 ENSG00000275400.1 RP4-756H11.5 5.16 5.44e-07 0.000455 0.56 0.33 Diabetic kidney disease; chr7:66128561 chr7:66553805~66554199:- CESC cis rs2243480 1 rs316312 ENSG00000275400.1 RP4-756H11.5 5.16 5.44e-07 0.000455 0.56 0.33 Diabetic kidney disease; chr7:66131504 chr7:66553805~66554199:- CESC cis rs2243480 1 rs419603 ENSG00000275400.1 RP4-756H11.5 5.16 5.44e-07 0.000455 0.56 0.33 Diabetic kidney disease; chr7:66132354 chr7:66553805~66554199:- CESC cis rs2243480 1 rs387676 ENSG00000275400.1 RP4-756H11.5 5.16 5.44e-07 0.000455 0.56 0.33 Diabetic kidney disease; chr7:66133233 chr7:66553805~66554199:- CESC cis rs2243480 1 rs13310597 ENSG00000275400.1 RP4-756H11.5 5.16 5.44e-07 0.000455 0.56 0.33 Diabetic kidney disease; chr7:66133553 chr7:66553805~66554199:- CESC cis rs4974559 0.947 rs28509315 ENSG00000253399.1 AC078852.2 5.16 5.44e-07 0.000455 0.56 0.33 Systolic blood pressure; chr4:1364319 chr4:1358479~1359461:+ CESC cis rs3931020 0.688 rs1051122 ENSG00000272864.1 RP11-17E13.2 -5.16 5.44e-07 0.000455 -0.43 -0.33 Resistin levels; chr1:74724768 chr1:74698769~74699333:- CESC cis rs3931020 0.688 rs968358 ENSG00000272864.1 RP11-17E13.2 -5.16 5.44e-07 0.000455 -0.43 -0.33 Resistin levels; chr1:74728305 chr1:74698769~74699333:- CESC cis rs9549367 0.569 rs3024719 ENSG00000269125.1 RP11-98F14.11 -5.16 5.45e-07 0.000456 -0.49 -0.33 Platelet distribution width; chr13:113159911 chr13:113165002~113165183:- CESC cis rs897984 0.542 rs7294 ENSG00000260911.2 RP11-196G11.2 -5.16 5.46e-07 0.000456 -0.35 -0.33 Dementia with Lewy bodies; chr16:31091000 chr16:31043150~31049868:+ CESC cis rs7572733 0.905 rs6434945 ENSG00000222017.1 AC011997.1 5.16 5.46e-07 0.000456 0.37 0.33 Dermatomyositis; chr2:197933236 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs10207433 ENSG00000222017.1 AC011997.1 5.16 5.46e-07 0.000456 0.37 0.33 Dermatomyositis; chr2:197941206 chr2:197693106~197774823:+ CESC cis rs9907295 1 rs9904675 ENSG00000270977.1 AC015849.16 -5.16 5.46e-07 0.000456 -0.49 -0.33 Fibroblast growth factor basic levels; chr17:35921435 chr17:35893707~35911023:- CESC cis rs3762637 1 rs9867429 ENSG00000272758.4 RP11-299J3.8 -5.16 5.49e-07 0.000459 -0.46 -0.33 LDL cholesterol levels; chr3:122513821 chr3:122416207~122443180:+ CESC cis rs9847710 0.696 rs2581822 ENSG00000242142.1 SERBP1P3 5.16 5.49e-07 0.000459 0.39 0.33 Ulcerative colitis; chr3:52987733 chr3:53064283~53065091:- CESC cis rs9322193 0.962 rs3763163 ENSG00000216906.2 RP11-350J20.9 5.16 5.5e-07 0.000459 0.36 0.33 Lung cancer; chr6:149819770 chr6:149904243~149906418:+ CESC cis rs6142102 0.961 rs6120487 ENSG00000276073.1 RP5-1125A11.7 -5.16 5.5e-07 0.000459 -0.31 -0.33 Skin pigmentation; chr20:34034802 chr20:33985617~33988989:- CESC cis rs1061377 1 rs12499266 ENSG00000249685.1 RP11-360F5.3 -5.16 5.5e-07 0.00046 -0.39 -0.33 Uric acid levels; chr4:39118133 chr4:39133913~39135608:+ CESC cis rs9322193 0.884 rs7743823 ENSG00000268592.3 RAET1E-AS1 5.16 5.51e-07 0.00046 0.44 0.33 Lung cancer; chr6:149849744 chr6:149863494~149919507:+ CESC cis rs875971 0.8 rs427557 ENSG00000237310.1 GS1-124K5.4 5.16 5.51e-07 0.00046 0.32 0.33 Aortic root size; chr7:66054263 chr7:66493706~66495474:+ CESC cis rs875971 0.83 rs587360 ENSG00000237310.1 GS1-124K5.4 5.16 5.51e-07 0.00046 0.32 0.33 Aortic root size; chr7:66057711 chr7:66493706~66495474:+ CESC cis rs2243480 1 rs160652 ENSG00000228409.4 CCT6P1 5.16 5.51e-07 0.00046 0.5 0.33 Diabetic kidney disease; chr7:66073444 chr7:65751142~65763354:+ CESC cis rs73086581 0.891 rs11907503 ENSG00000229539.1 RP11-119B16.2 5.16 5.52e-07 0.000461 0.55 0.33 Response to antidepressants in depression; chr20:3906943 chr20:3888239~3888868:- CESC cis rs748404 0.69 rs2244981 ENSG00000205771.5 CATSPER2P1 -5.16 5.52e-07 0.000461 -0.38 -0.33 Lung cancer; chr15:43460553 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs694725 ENSG00000205771.5 CATSPER2P1 -5.16 5.52e-07 0.000461 -0.38 -0.33 Lung cancer; chr15:43464012 chr15:43726918~43747094:- CESC cis rs7714670 0.736 rs2973548 ENSG00000184084.7 CTD-2372A4.1 -5.16 5.54e-07 0.000463 -0.37 -0.33 Venous thromboembolism (SNP x SNP interaction); chr5:73795403 chr5:73803296~73803599:- CESC cis rs2108622 0.727 rs3093207 ENSG00000267453.5 AC004791.2 -5.16 5.56e-07 0.000464 -0.42 -0.33 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15877848 chr19:15851993~15864904:- CESC cis rs1799949 1 rs16941 ENSG00000267681.1 CTD-3199J23.6 -5.16 5.56e-07 0.000464 -0.43 -0.33 Menopause (age at onset); chr17:43092418 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs67060599 ENSG00000267681.1 CTD-3199J23.6 -5.16 5.56e-07 0.000464 -0.43 -0.33 Menopause (age at onset); chr17:43103085 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176133 ENSG00000267681.1 CTD-3199J23.6 -5.16 5.56e-07 0.000464 -0.43 -0.33 Menopause (age at onset); chr17:43105441 chr17:43144956~43145255:+ CESC cis rs1062177 0.855 rs919263 ENSG00000253921.1 CTB-113P19.3 -5.16 5.58e-07 0.000465 -0.42 -0.33 Preschool internalizing problems; chr5:151886292 chr5:151753992~151767247:+ CESC cis rs42490 0.966 rs218932 ENSG00000251136.7 RP11-37B2.1 -5.16 5.58e-07 0.000465 -0.34 -0.33 Leprosy; chr8:89740725 chr8:89609409~89757727:- CESC cis rs34779708 0.966 rs2126984 ENSG00000230534.5 RP11-297A16.2 5.16 5.59e-07 0.000466 0.45 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35121363 chr10:35098006~35127020:- CESC cis rs10129255 1 rs10129319 ENSG00000280411.1 IGHV1-69-2 -5.16 5.6e-07 0.000467 -0.26 -0.33 Kawasaki disease; chr14:106767996 chr14:106762092~106762588:- CESC cis rs6452524 0.967 rs4616871 ENSG00000249664.1 CTD-2227C6.2 5.16 5.61e-07 0.000467 0.36 0.33 Hypertension (SNP x SNP interaction); chr5:83175271 chr5:83012285~83013109:- CESC cis rs6452524 0.967 rs11949474 ENSG00000249664.1 CTD-2227C6.2 5.16 5.61e-07 0.000467 0.36 0.33 Hypertension (SNP x SNP interaction); chr5:83179759 chr5:83012285~83013109:- CESC cis rs9660180 0.967 rs6603803 ENSG00000268575.1 RP1-283E3.8 -5.16 5.62e-07 0.000468 -0.33 -0.33 Body mass index; chr1:1881249 chr1:1702736~1737688:- CESC cis rs957448 0.561 rs7459558 ENSG00000253704.1 RP11-267M23.4 5.16 5.63e-07 0.000468 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94598618 chr8:94553722~94569745:+ CESC cis rs957448 0.561 rs34471170 ENSG00000253704.1 RP11-267M23.4 5.16 5.63e-07 0.000468 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94601135 chr8:94553722~94569745:+ CESC cis rs957448 0.561 rs9642927 ENSG00000253704.1 RP11-267M23.4 5.16 5.63e-07 0.000468 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94601414 chr8:94553722~94569745:+ CESC cis rs957448 0.539 rs9643346 ENSG00000253704.1 RP11-267M23.4 5.16 5.63e-07 0.000468 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94601587 chr8:94553722~94569745:+ CESC cis rs957448 0.529 rs9642928 ENSG00000253704.1 RP11-267M23.4 5.16 5.63e-07 0.000468 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94601698 chr8:94553722~94569745:+ CESC cis rs957448 0.561 rs1808488 ENSG00000253704.1 RP11-267M23.4 5.16 5.63e-07 0.000468 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94602636 chr8:94553722~94569745:+ CESC cis rs957448 0.583 rs754275 ENSG00000253704.1 RP11-267M23.4 5.16 5.63e-07 0.000468 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94602741 chr8:94553722~94569745:+ CESC cis rs957448 0.561 rs1426172 ENSG00000253704.1 RP11-267M23.4 5.16 5.63e-07 0.000468 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94602988 chr8:94553722~94569745:+ CESC cis rs2243480 1 rs422164 ENSG00000275400.1 RP4-756H11.5 5.16 5.63e-07 0.000469 0.56 0.33 Diabetic kidney disease; chr7:66121618 chr7:66553805~66554199:- CESC cis rs7572733 0.935 rs696814 ENSG00000222017.1 AC011997.1 5.16 5.64e-07 0.000469 0.36 0.33 Dermatomyositis; chr2:197823175 chr2:197693106~197774823:+ CESC cis rs577676 0.564 rs619699 ENSG00000271811.1 RP1-79C4.4 5.16 5.64e-07 0.00047 0.43 0.33 Prevalent atrial fibrillation; chr1:170648238 chr1:170667381~170669425:+ CESC cis rs957448 0.948 rs72674867 ENSG00000253704.1 RP11-267M23.4 5.16 5.65e-07 0.000471 0.37 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94565973 chr8:94553722~94569745:+ CESC cis rs2283792 0.812 rs94194 ENSG00000224086.5 LL22NC03-86G7.1 -5.16 5.66e-07 0.000471 -0.37 -0.33 Multiple sclerosis; chr22:21933937 chr22:21938293~21977632:+ CESC cis rs2283792 0.812 rs5995269 ENSG00000224086.5 LL22NC03-86G7.1 -5.16 5.66e-07 0.000471 -0.37 -0.33 Multiple sclerosis; chr22:21935025 chr22:21938293~21977632:+ CESC cis rs748404 0.66 rs2467738 ENSG00000205771.5 CATSPER2P1 -5.16 5.67e-07 0.000472 -0.38 -0.33 Lung cancer; chr15:43447738 chr15:43726918~43747094:- CESC cis rs659580 1 rs659580 ENSG00000271811.1 RP1-79C4.4 -5.16 5.67e-07 0.000472 -0.4 -0.33 Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported); chr1:170664755 chr1:170667381~170669425:+ CESC cis rs7598759 0.527 rs7571691 ENSG00000181798.2 LINC00471 -5.15 5.68e-07 0.000473 -0.35 -0.33 Noise-induced hearing loss; chr2:231504690 chr2:231508426~231514339:- CESC cis rs2243480 0.764 rs2460423 ENSG00000228409.4 CCT6P1 5.15 5.69e-07 0.000473 0.49 0.33 Diabetic kidney disease; chr7:66136229 chr7:65751142~65763354:+ CESC cis rs733592 0.524 rs10875741 ENSG00000240399.1 RP1-228P16.1 -5.15 5.72e-07 0.000476 -0.34 -0.33 Plateletcrit; chr12:48099139 chr12:48054813~48055591:- CESC cis rs9322193 0.962 rs9397022 ENSG00000216906.2 RP11-350J20.9 5.15 5.73e-07 0.000477 0.36 0.33 Lung cancer; chr6:149812052 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9397357 ENSG00000216906.2 RP11-350J20.9 5.15 5.73e-07 0.000477 0.36 0.33 Lung cancer; chr6:149812465 chr6:149904243~149906418:+ CESC cis rs12439619 1 rs35152457 ENSG00000276710.3 CSPG4P8 -5.15 5.73e-07 0.000477 -0.4 -0.33 Intelligence (multi-trait analysis); chr15:82254207 chr15:82459472~82477258:+ CESC cis rs5769707 0.632 rs135871 ENSG00000188511.11 C22orf34 5.15 5.75e-07 0.000478 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49615321 chr22:49414524~49657542:- CESC cis rs9601248 0.874 rs2093621 ENSG00000227676.3 LINC01068 5.15 5.75e-07 0.000478 0.38 0.33 Major depressive disorder; chr13:79613953 chr13:79566727~79571436:+ CESC cis rs62229266 0.625 rs62230813 ENSG00000231106.2 LINC01436 5.15 5.77e-07 0.00048 0.44 0.33 Mitral valve prolapse; chr21:36031134 chr21:36005338~36007838:+ CESC cis rs9584850 0.54 rs61969457 ENSG00000231194.1 FARP1-AS1 5.15 5.78e-07 0.00048 0.48 0.33 Neuroticism; chr13:98524488 chr13:98435405~98435840:- CESC cis rs875971 0.505 rs6955582 ENSG00000164669.11 INTS4P1 -5.15 5.79e-07 0.000481 -0.45 -0.33 Aortic root size; chr7:65966699 chr7:65141225~65234216:+ CESC cis rs8100891 0.537 rs58591218 ENSG00000267213.4 AC007773.2 -5.15 5.8e-07 0.000482 -0.53 -0.33 Neuroticism; chr19:32399876 chr19:32390050~32405560:- CESC cis rs1062177 0.724 rs2915828 ENSG00000253921.1 CTB-113P19.3 5.15 5.8e-07 0.000482 0.45 0.33 Preschool internalizing problems; chr5:151738560 chr5:151753992~151767247:+ CESC cis rs1062177 0.724 rs2964590 ENSG00000253921.1 CTB-113P19.3 5.15 5.8e-07 0.000482 0.45 0.33 Preschool internalizing problems; chr5:151738585 chr5:151753992~151767247:+ CESC cis rs733592 0.894 rs886589 ENSG00000240399.1 RP1-228P16.1 -5.15 5.81e-07 0.000482 -0.35 -0.33 Plateletcrit; chr12:48083414 chr12:48054813~48055591:- CESC cis rs6504622 0.721 rs11079748 ENSG00000262879.4 RP11-156P1.3 -5.15 5.82e-07 0.000483 -0.37 -0.33 Orofacial clefts; chr17:47055097 chr17:46984045~47100323:- CESC cis rs62229266 0.633 rs743420 ENSG00000231106.2 LINC01436 5.15 5.82e-07 0.000483 0.45 0.33 Mitral valve prolapse; chr21:36015104 chr21:36005338~36007838:+ CESC cis rs1062177 0.756 rs2915827 ENSG00000253921.1 CTB-113P19.3 5.15 5.82e-07 0.000483 0.45 0.33 Preschool internalizing problems; chr5:151740144 chr5:151753992~151767247:+ CESC cis rs1062177 0.756 rs2915826 ENSG00000253921.1 CTB-113P19.3 5.15 5.82e-07 0.000483 0.45 0.33 Preschool internalizing problems; chr5:151740402 chr5:151753992~151767247:+ CESC cis rs1062177 0.756 rs2964587 ENSG00000253921.1 CTB-113P19.3 5.15 5.82e-07 0.000483 0.45 0.33 Preschool internalizing problems; chr5:151740411 chr5:151753992~151767247:+ CESC cis rs35160687 0.814 rs7563887 ENSG00000273080.1 RP11-301O19.1 5.15 5.82e-07 0.000483 0.36 0.33 Night sleep phenotypes; chr2:86288998 chr2:86195590~86196049:+ CESC cis rs9322193 0.884 rs7743823 ENSG00000216906.2 RP11-350J20.9 5.15 5.83e-07 0.000484 0.38 0.33 Lung cancer; chr6:149849744 chr6:149904243~149906418:+ CESC cis rs733592 0.524 rs10875726 ENSG00000240399.1 RP1-228P16.1 -5.15 5.84e-07 0.000484 -0.33 -0.33 Plateletcrit; chr12:48032209 chr12:48054813~48055591:- CESC cis rs733592 0.524 rs10875727 ENSG00000240399.1 RP1-228P16.1 -5.15 5.84e-07 0.000484 -0.33 -0.33 Plateletcrit; chr12:48032360 chr12:48054813~48055591:- CESC cis rs11096990 0.634 rs4975001 ENSG00000249207.1 RP11-360F5.1 5.15 5.84e-07 0.000484 0.36 0.33 Cognitive function; chr4:39264844 chr4:39112677~39126818:- CESC cis rs9322193 0.926 rs9383546 ENSG00000216906.2 RP11-350J20.9 5.15 5.84e-07 0.000484 0.37 0.33 Lung cancer; chr6:149822743 chr6:149904243~149906418:+ CESC cis rs860295 0.702 rs10908471 ENSG00000225855.5 RUSC1-AS1 5.15 5.84e-07 0.000485 0.28 0.33 Body mass index; chr1:155573151 chr1:155316863~155324176:- CESC cis rs860295 0.702 rs10908472 ENSG00000225855.5 RUSC1-AS1 5.15 5.84e-07 0.000485 0.28 0.33 Body mass index; chr1:155574465 chr1:155316863~155324176:- CESC cis rs860295 0.702 rs11264383 ENSG00000225855.5 RUSC1-AS1 5.15 5.84e-07 0.000485 0.28 0.33 Body mass index; chr1:155575555 chr1:155316863~155324176:- CESC cis rs860295 0.702 rs11264386 ENSG00000225855.5 RUSC1-AS1 5.15 5.84e-07 0.000485 0.28 0.33 Body mass index; chr1:155589379 chr1:155316863~155324176:- CESC cis rs14027 0.512 rs4871528 ENSG00000279347.1 RP11-85I17.2 5.15 5.84e-07 0.000485 0.32 0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119700371 chr8:119838736~119840385:- CESC cis rs9907295 0.901 rs4251729 ENSG00000270977.1 AC015849.16 -5.15 5.85e-07 0.000485 -0.48 -0.33 Fibroblast growth factor basic levels; chr17:35818348 chr17:35893707~35911023:- CESC cis rs875971 0.545 rs73378304 ENSG00000222364.1 RNU6-96P -5.15 5.85e-07 0.000485 -0.41 -0.33 Aortic root size; chr7:66175760 chr7:66395191~66395286:+ CESC cis rs7615952 0.599 rs6803160 ENSG00000250012.1 RP11-124N2.1 -5.15 5.86e-07 0.000486 -0.36 -0.33 Blood pressure (smoking interaction); chr3:125990711 chr3:126084220~126095349:+ CESC cis rs7615952 0.688 rs12485622 ENSG00000250012.1 RP11-124N2.1 -5.15 5.86e-07 0.000486 -0.36 -0.33 Blood pressure (smoking interaction); chr3:125991896 chr3:126084220~126095349:+ CESC cis rs7572733 0.773 rs13429970 ENSG00000222017.1 AC011997.1 5.15 5.87e-07 0.000486 0.37 0.33 Dermatomyositis; chr2:197657911 chr2:197693106~197774823:+ CESC cis rs7572733 0.773 rs6757852 ENSG00000222017.1 AC011997.1 5.15 5.87e-07 0.000486 0.37 0.33 Dermatomyositis; chr2:197665569 chr2:197693106~197774823:+ CESC cis rs11155671 0.53 rs9383577 ENSG00000223701.3 RAET1E-AS1 5.15 5.87e-07 0.000487 0.37 0.33 Testicular germ cell tumor; chr6:149886059 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs9383914 ENSG00000223701.3 RAET1E-AS1 5.15 5.87e-07 0.000487 0.37 0.33 Testicular germ cell tumor; chr6:149886098 chr6:149884431~149919508:+ CESC cis rs11155671 0.517 rs9397058 ENSG00000223701.3 RAET1E-AS1 5.15 5.87e-07 0.000487 0.37 0.33 Testicular germ cell tumor; chr6:149886113 chr6:149884431~149919508:+ CESC cis rs7572733 0.773 rs13413470 ENSG00000222017.1 AC011997.1 5.15 5.87e-07 0.000487 0.37 0.33 Dermatomyositis; chr2:197648125 chr2:197693106~197774823:+ CESC cis rs2919917 0.915 rs2953477 ENSG00000254352.1 RP11-578O24.2 5.15 5.89e-07 0.000488 0.43 0.33 Lymphocyte counts; chr8:78712370 chr8:78723796~78724136:- CESC cis rs6452524 0.868 rs10079372 ENSG00000249664.1 CTD-2227C6.2 5.15 5.9e-07 0.000488 0.39 0.33 Hypertension (SNP x SNP interaction); chr5:83117113 chr5:83012285~83013109:- CESC cis rs7572733 0.84 rs770666 ENSG00000222017.1 AC011997.1 5.15 5.91e-07 0.000489 0.37 0.33 Dermatomyositis; chr2:197747173 chr2:197693106~197774823:+ CESC cis rs1799949 0.965 rs8176087 ENSG00000267681.1 CTD-3199J23.6 -5.15 5.91e-07 0.000489 -0.43 -0.33 Menopause (age at onset); chr17:43118649 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176083 ENSG00000267681.1 CTD-3199J23.6 -5.15 5.91e-07 0.000489 -0.43 -0.33 Menopause (age at onset); chr17:43123134 chr17:43144956~43145255:+ CESC cis rs11846409 0.932 rs10151046 ENSG00000211974.3 IGHV2-70 -5.15 5.91e-07 0.00049 -0.42 -0.33 Rheumatic heart disease; chr14:106633095 chr14:106723574~106724093:- CESC cis rs7189233 0.531 rs17801498 ENSG00000279344.1 RP11-44F14.7 5.15 5.92e-07 0.00049 0.31 0.33 Intelligence (multi-trait analysis); chr16:53479540 chr16:53478957~53481550:- CESC cis rs62229266 0.693 rs2835264 ENSG00000231106.2 LINC01436 5.15 5.92e-07 0.00049 0.45 0.33 Mitral valve prolapse; chr21:36063667 chr21:36005338~36007838:+ CESC cis rs9322193 0.961 rs9767713 ENSG00000268592.3 RAET1E-AS1 5.15 5.92e-07 0.00049 0.43 0.33 Lung cancer; chr6:149588241 chr6:149863494~149919507:+ CESC cis rs17826219 0.568 rs59858012 ENSG00000266490.1 CTD-2349P21.9 5.15 5.94e-07 0.000492 0.56 0.33 Body mass index; chr17:30751564 chr17:30792372~30792833:+ CESC cis rs5769707 0.568 rs2011097 ENSG00000188511.11 C22orf34 5.15 5.94e-07 0.000492 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49624421 chr22:49414524~49657542:- CESC cis rs7572733 0.935 rs700665 ENSG00000222017.1 AC011997.1 5.15 5.94e-07 0.000492 0.37 0.33 Dermatomyositis; chr2:197808655 chr2:197693106~197774823:+ CESC cis rs9907295 1 rs11080360 ENSG00000270977.1 AC015849.16 -5.15 5.95e-07 0.000492 -0.5 -0.33 Fibroblast growth factor basic levels; chr17:35916086 chr17:35893707~35911023:- CESC cis rs9907295 1 rs11869976 ENSG00000270977.1 AC015849.16 -5.15 5.95e-07 0.000492 -0.5 -0.33 Fibroblast growth factor basic levels; chr17:35916492 chr17:35893707~35911023:- CESC cis rs1499614 1 rs2707832 ENSG00000228409.4 CCT6P1 5.15 5.95e-07 0.000493 0.51 0.33 Gout; chr7:66671562 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs778730 ENSG00000275400.1 RP4-756H11.5 5.15 5.95e-07 0.000493 0.57 0.33 Diabetic kidney disease; chr7:66358338 chr7:66553805~66554199:- CESC cis rs62388641 0.547 rs2745610 ENSG00000272279.1 RP11-157J24.2 -5.14 5.97e-07 0.000494 -0.43 -0.33 Daytime sleep phenotypes; chr6:1553741 chr6:1528364~1528911:- CESC cis rs4853012 0.941 rs7571083 ENSG00000257800.1 FNBP1P1 5.14 5.98e-07 0.000495 0.35 0.33 Gestational age at birth (maternal effect); chr2:74115133 chr2:74120680~74123218:+ CESC cis rs6991838 0.612 rs7842162 ENSG00000200714.1 Y_RNA 5.14 5.98e-07 0.000495 0.4 0.33 Intelligence (multi-trait analysis); chr8:65644057 chr8:65592731~65592820:+ CESC cis rs2286503 0.65 rs1990279 ENSG00000228649.7 AC005682.5 5.14 6e-07 0.000496 0.3 0.33 Fibrinogen; chr7:22851123 chr7:22854178~22861579:+ CESC cis rs2919917 0.955 rs1441850 ENSG00000254352.1 RP11-578O24.2 -5.14 6.01e-07 0.000497 -0.43 -0.33 Lymphocyte counts; chr8:78745431 chr8:78723796~78724136:- CESC cis rs801193 0.66 rs2659897 ENSG00000222364.1 RNU6-96P 5.14 6.02e-07 0.000498 0.38 0.33 Aortic root size; chr7:66722728 chr7:66395191~66395286:+ CESC cis rs6142102 0.812 rs761238 ENSG00000276073.1 RP5-1125A11.7 5.14 6.02e-07 0.000498 0.31 0.33 Skin pigmentation; chr20:33932182 chr20:33985617~33988989:- CESC cis rs7714584 1 rs12659118 ENSG00000197083.10 ZNF300P1 5.14 6.02e-07 0.000498 0.72 0.33 Crohn's disease; chr5:150945060 chr5:150930645~150946289:- CESC cis rs7615952 0.599 rs6779141 ENSG00000250012.1 RP11-124N2.1 -5.14 6.03e-07 0.000498 -0.36 -0.33 Blood pressure (smoking interaction); chr3:125991152 chr3:126084220~126095349:+ CESC cis rs6504622 0.599 rs197913 ENSG00000263142.4 LRRC37A17P 5.14 6.04e-07 0.000499 0.26 0.33 Orofacial clefts; chr17:46912680 chr17:46978481~47054569:+ CESC cis rs9907295 1 rs9913488 ENSG00000270977.1 AC015849.16 -5.14 6.05e-07 5e-04 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35906447 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9912571 ENSG00000270977.1 AC015849.16 -5.14 6.05e-07 5e-04 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35906782 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9912793 ENSG00000270977.1 AC015849.16 -5.14 6.05e-07 5e-04 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35906867 chr17:35893707~35911023:- CESC cis rs9907295 1 rs11655533 ENSG00000270977.1 AC015849.16 -5.14 6.05e-07 5e-04 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35908002 chr17:35893707~35911023:- CESC cis rs520525 0.963 rs552277 ENSG00000271811.1 RP1-79C4.4 5.14 6.06e-07 5e-04 0.43 0.33 Atrial fibrillation; chr1:170658653 chr1:170667381~170669425:+ CESC cis rs6142102 0.961 rs909884 ENSG00000276073.1 RP5-1125A11.7 -5.14 6.07e-07 0.000501 -0.32 -0.33 Skin pigmentation; chr20:34058257 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs2268088 ENSG00000276073.1 RP5-1125A11.7 -5.14 6.07e-07 0.000501 -0.32 -0.33 Skin pigmentation; chr20:34061258 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs4911401 ENSG00000276073.1 RP5-1125A11.7 -5.14 6.07e-07 0.000501 -0.32 -0.33 Skin pigmentation; chr20:34066756 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs2284388 ENSG00000276073.1 RP5-1125A11.7 -5.14 6.07e-07 0.000501 -0.32 -0.33 Skin pigmentation; chr20:34067935 chr20:33985617~33988989:- CESC cis rs9549367 0.789 rs9549701 ENSG00000269125.1 RP11-98F14.11 -5.14 6.1e-07 0.000503 -0.45 -0.33 Platelet distribution width; chr13:113227438 chr13:113165002~113165183:- CESC cis rs6723162 0.868 rs2215826 ENSG00000237751.2 LINC01143 -5.14 6.11e-07 0.000504 -0.4 -0.33 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70886266 chr2:70887871~70889959:+ CESC cis rs12130219 0.5 rs1552991 ENSG00000237975.5 FLG-AS1 -5.14 6.13e-07 0.000505 -0.38 -0.33 Inflammatory skin disease; chr1:152193402 chr1:152168125~152445456:+ CESC cis rs3823536 0.583 rs7789423 ENSG00000275106.1 RP11-309L24.10 -5.14 6.13e-07 0.000505 -0.46 -0.33 Sjögren's syndrome; chr7:128981150 chr7:128952527~128953316:- CESC cis rs9601248 0.874 rs2093620 ENSG00000227676.3 LINC01068 5.14 6.14e-07 0.000506 0.38 0.33 Major depressive disorder; chr13:79613954 chr13:79566727~79571436:+ CESC cis rs763121 0.962 rs1980455 ENSG00000273076.1 RP3-508I15.22 5.14 6.14e-07 0.000506 0.38 0.33 Menopause (age at onset); chr22:38529714 chr22:38743495~38743910:+ CESC cis rs957448 0.561 rs4734282 ENSG00000253704.1 RP11-267M23.4 5.14 6.15e-07 0.000506 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94603827 chr8:94553722~94569745:+ CESC cis rs6142102 0.923 rs2268078 ENSG00000276073.1 RP5-1125A11.7 -5.14 6.16e-07 0.000507 -0.33 -0.33 Skin pigmentation; chr20:34008898 chr20:33985617~33988989:- CESC cis rs4660456 0.913 rs569159 ENSG00000237899.1 RP4-739H11.3 -5.14 6.16e-07 0.000508 -0.44 -0.33 Platelet count; chr1:40701862 chr1:40669089~40687588:- CESC cis rs700641 1 rs700641 ENSG00000222017.1 AC011997.1 5.14 6.17e-07 0.000508 0.37 0.33 Morning vs. evening chronotype; chr2:197734509 chr2:197693106~197774823:+ CESC cis rs765787 0.53 rs11070444 ENSG00000259520.4 CTD-2651B20.3 -5.14 6.17e-07 0.000508 -0.41 -0.33 Uric acid levels; chr15:45220923 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs11070445 ENSG00000259520.4 CTD-2651B20.3 -5.14 6.17e-07 0.000508 -0.41 -0.33 Uric acid levels; chr15:45220965 chr15:45251580~45279251:- CESC cis rs748404 0.66 rs493377 ENSG00000205771.5 CATSPER2P1 -5.14 6.17e-07 0.000508 -0.38 -0.33 Lung cancer; chr15:43481269 chr15:43726918~43747094:- CESC cis rs10754283 0.967 rs10801757 ENSG00000231613.1 RP5-943J3.1 5.14 6.18e-07 0.000509 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89637521 chr1:89788914~89790492:+ CESC cis rs1799949 0.965 rs12950779 ENSG00000267681.1 CTD-3199J23.6 -5.14 6.18e-07 0.000509 -0.42 -0.33 Menopause (age at onset); chr17:43154506 chr17:43144956~43145255:+ CESC cis rs75422866 0.867 rs73111258 ENSG00000257433.4 RP1-197B17.3 5.14 6.19e-07 0.00051 0.81 0.33 Pneumonia; chr12:47597313 chr12:47706085~47742294:+ CESC cis rs42490 1 rs2735873 ENSG00000251136.7 RP11-37B2.1 5.14 6.19e-07 0.00051 0.33 0.33 Leprosy; chr8:89737748 chr8:89609409~89757727:- CESC cis rs748404 0.56 rs572837 ENSG00000205771.5 CATSPER2P1 -5.14 6.2e-07 0.00051 -0.39 -0.33 Lung cancer; chr15:43531615 chr15:43726918~43747094:- CESC cis rs10510102 0.608 rs4486560 ENSG00000276742.1 RP11-500G22.4 5.14 6.21e-07 0.000511 0.39 0.33 Breast cancer; chr10:121844840 chr10:121956782~121957098:+ CESC cis rs733592 0.965 rs1978161 ENSG00000240399.1 RP1-228P16.1 -5.14 6.21e-07 0.000511 -0.35 -0.33 Plateletcrit; chr12:48073938 chr12:48054813~48055591:- CESC cis rs2919917 1 rs894221 ENSG00000254352.1 RP11-578O24.2 -5.14 6.22e-07 0.000512 -0.42 -0.33 Lymphocyte counts; chr8:78736822 chr8:78723796~78724136:- CESC cis rs7572733 0.935 rs6734561 ENSG00000222017.1 AC011997.1 5.14 6.23e-07 0.000512 0.36 0.33 Dermatomyositis; chr2:197860352 chr2:197693106~197774823:+ CESC cis rs7572733 0.901 rs700689 ENSG00000222017.1 AC011997.1 5.14 6.23e-07 0.000512 0.36 0.33 Dermatomyositis; chr2:197861925 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs700691 ENSG00000222017.1 AC011997.1 5.14 6.23e-07 0.000512 0.36 0.33 Dermatomyositis; chr2:197863128 chr2:197693106~197774823:+ CESC cis rs7572733 0.905 rs700693 ENSG00000222017.1 AC011997.1 5.14 6.23e-07 0.000512 0.36 0.33 Dermatomyositis; chr2:197865291 chr2:197693106~197774823:+ CESC cis rs1075265 0.584 rs11896781 ENSG00000233266.1 HMGB1P31 5.14 6.24e-07 0.000513 0.46 0.33 Chronotype;Morning vs. evening chronotype; chr2:54096987 chr2:54051334~54051760:+ CESC cis rs765787 0.505 rs4439707 ENSG00000259520.4 CTD-2651B20.3 -5.13 6.26e-07 0.000515 -0.42 -0.33 Uric acid levels; chr15:45232018 chr15:45251580~45279251:- CESC cis rs67180937 0.922 rs17465982 ENSG00000272750.1 RP11-378J18.8 -5.13 6.26e-07 0.000515 -0.41 -0.33 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222664597 chr1:222658867~222661512:- CESC cis rs9907295 0.901 rs11652536 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35891043 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs9789051 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35892000 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs3809769 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35892484 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs76016589 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35892923 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs4796124 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35893280 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs11656556 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35894090 chr17:35893707~35911023:- CESC cis rs9907295 0.818 rs11653204 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35894538 chr17:35893707~35911023:- CESC cis rs9907295 0.792 rs4796125 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35894847 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs74622050 ENSG00000270977.1 AC015849.16 -5.13 6.28e-07 0.000517 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35895939 chr17:35893707~35911023:- CESC cis rs4718428 0.705 rs2901311 ENSG00000273142.1 RP11-458F8.4 -5.13 6.29e-07 0.000517 -0.35 -0.33 Corneal structure; chr7:66950082 chr7:66902857~66906297:+ CESC cis rs9438901 0.655 rs609320 ENSG00000261349.1 RP3-465N24.5 5.13 6.29e-07 0.000517 0.4 0.33 Red cell distribution width; chr1:25390874 chr1:25266102~25267136:- CESC cis rs748404 0.518 rs480108 ENSG00000205771.5 CATSPER2P1 -5.13 6.29e-07 0.000517 -0.39 -0.33 Lung cancer; chr15:43525208 chr15:43726918~43747094:- CESC cis rs42490 0.966 rs218914 ENSG00000251136.7 RP11-37B2.1 -5.13 6.3e-07 0.000518 -0.33 -0.33 Leprosy; chr8:89733130 chr8:89609409~89757727:- CESC cis rs17711722 0.565 rs4717276 ENSG00000228409.4 CCT6P1 -5.13 6.3e-07 0.000518 -0.31 -0.33 Calcium levels; chr7:65829754 chr7:65751142~65763354:+ CESC cis rs1061377 1 rs1061377 ENSG00000249685.1 RP11-360F5.3 5.13 6.31e-07 0.000518 0.38 0.33 Uric acid levels; chr4:39123130 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs13109200 ENSG00000249685.1 RP11-360F5.3 5.13 6.31e-07 0.000518 0.38 0.33 Uric acid levels; chr4:39124396 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs13144374 ENSG00000249685.1 RP11-360F5.3 5.13 6.31e-07 0.000518 0.38 0.33 Uric acid levels; chr4:39128859 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs28607301 ENSG00000249685.1 RP11-360F5.3 5.13 6.31e-07 0.000518 0.38 0.33 Uric acid levels; chr4:39136460 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs36090629 ENSG00000249685.1 RP11-360F5.3 5.13 6.31e-07 0.000518 0.38 0.33 Uric acid levels; chr4:39137195 chr4:39133913~39135608:+ CESC cis rs1061377 0.87 rs73238544 ENSG00000249685.1 RP11-360F5.3 5.13 6.31e-07 0.000518 0.38 0.33 Uric acid levels; chr4:39137343 chr4:39133913~39135608:+ CESC cis rs720475 0.695 rs62483108 ENSG00000204959.4 ARHGEF34P -5.13 6.32e-07 0.000519 -0.38 -0.33 Breast cancer; chr7:144442326 chr7:144272445~144286966:- CESC cis rs801193 0.569 rs10950050 ENSG00000226824.5 RP4-756H11.3 -5.13 6.32e-07 0.000519 -0.4 -0.33 Aortic root size; chr7:66774601 chr7:66654538~66669855:+ CESC cis rs7572733 0.773 rs6748788 ENSG00000222017.1 AC011997.1 -5.13 6.33e-07 0.00052 -0.37 -0.33 Dermatomyositis; chr2:197668882 chr2:197693106~197774823:+ CESC cis rs7826238 0.566 rs2945886 ENSG00000253893.2 FAM85B -5.13 6.34e-07 0.000521 -0.42 -0.33 Systolic blood pressure; chr8:8290748 chr8:8167819~8226614:- CESC cis rs17711722 0.653 rs2460421 ENSG00000226824.5 RP4-756H11.3 5.13 6.34e-07 0.000521 0.41 0.33 Calcium levels; chr7:66026136 chr7:66654538~66669855:+ CESC cis rs765787 0.556 rs10851422 ENSG00000259520.4 CTD-2651B20.3 -5.13 6.34e-07 0.000521 -0.41 -0.33 Uric acid levels; chr15:45221540 chr15:45251580~45279251:- CESC cis rs763121 0.962 rs138703 ENSG00000273076.1 RP3-508I15.22 5.13 6.36e-07 0.000522 0.36 0.33 Menopause (age at onset); chr22:38736743 chr22:38743495~38743910:+ CESC cis rs42490 0.966 rs218908 ENSG00000251136.7 RP11-37B2.1 -5.13 6.36e-07 0.000522 -0.33 -0.33 Leprosy; chr8:89728886 chr8:89609409~89757727:- CESC cis rs42490 1 rs2735870 ENSG00000251136.7 RP11-37B2.1 5.13 6.36e-07 0.000522 0.33 0.33 Leprosy; chr8:89730456 chr8:89609409~89757727:- CESC cis rs1891275 0.508 rs7099557 ENSG00000228701.1 TNKS2-AS1 -5.13 6.37e-07 0.000522 -0.38 -0.33 Intelligence (multi-trait analysis); chr10:91685607 chr10:91782839~91798291:- CESC cis rs9322193 0.962 rs1889473 ENSG00000216906.2 RP11-350J20.9 5.13 6.37e-07 0.000523 0.36 0.33 Lung cancer; chr6:149825485 chr6:149904243~149906418:+ CESC cis rs2836950 0.509 rs4816618 ENSG00000232608.1 TIMM9P2 5.13 6.37e-07 0.000523 0.37 0.33 Menarche (age at onset); chr21:39227603 chr21:39216624~39217506:+ CESC cis rs2836950 0.527 rs2836948 ENSG00000232608.1 TIMM9P2 5.13 6.37e-07 0.000523 0.37 0.33 Menarche (age at onset); chr21:39227751 chr21:39216624~39217506:+ CESC cis rs4718428 0.705 rs3800817 ENSG00000273142.1 RP11-458F8.4 -5.13 6.37e-07 0.000523 -0.35 -0.33 Corneal structure; chr7:66798563 chr7:66902857~66906297:+ CESC cis rs765787 0.53 rs12440321 ENSG00000259520.4 CTD-2651B20.3 -5.13 6.37e-07 0.000523 -0.41 -0.33 Uric acid levels; chr15:45237187 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs12442533 ENSG00000259520.4 CTD-2651B20.3 -5.13 6.37e-07 0.000523 -0.41 -0.33 Uric acid levels; chr15:45237433 chr15:45251580~45279251:- CESC cis rs34779708 0.931 rs11597392 ENSG00000230534.5 RP11-297A16.2 5.13 6.37e-07 0.000523 0.44 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34999647 chr10:35098006~35127020:- CESC cis rs7572733 0.84 rs13029495 ENSG00000222017.1 AC011997.1 -5.13 6.37e-07 0.000523 -0.37 -0.33 Dermatomyositis; chr2:197717877 chr2:197693106~197774823:+ CESC cis rs2919917 1 rs2953475 ENSG00000254352.1 RP11-578O24.2 -5.13 6.38e-07 0.000523 -0.43 -0.33 Lymphocyte counts; chr8:78725903 chr8:78723796~78724136:- CESC cis rs577676 0.586 rs549449 ENSG00000271811.1 RP1-79C4.4 5.13 6.38e-07 0.000523 0.45 0.33 Prevalent atrial fibrillation; chr1:170641569 chr1:170667381~170669425:+ CESC cis rs577676 0.586 rs639720 ENSG00000271811.1 RP1-79C4.4 5.13 6.38e-07 0.000523 0.45 0.33 Prevalent atrial fibrillation; chr1:170643785 chr1:170667381~170669425:+ CESC cis rs577676 0.586 rs593173 ENSG00000271811.1 RP1-79C4.4 5.13 6.38e-07 0.000523 0.45 0.33 Prevalent atrial fibrillation; chr1:170646719 chr1:170667381~170669425:+ CESC cis rs9549367 0.577 rs3024718 ENSG00000269125.1 RP11-98F14.11 5.13 6.39e-07 0.000524 0.45 0.33 Platelet distribution width; chr13:113159539 chr13:113165002~113165183:- CESC cis rs6142102 0.961 rs6059651 ENSG00000276073.1 RP5-1125A11.7 -5.13 6.39e-07 0.000524 -0.32 -0.33 Skin pigmentation; chr20:34057246 chr20:33985617~33988989:- CESC cis rs2243480 0.666 rs1880311 ENSG00000228409.4 CCT6P1 -5.13 6.39e-07 0.000524 -0.48 -0.33 Diabetic kidney disease; chr7:65811765 chr7:65751142~65763354:+ CESC cis rs9907295 0.901 rs9898152 ENSG00000270977.1 AC015849.16 -5.13 6.4e-07 0.000525 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35869211 chr17:35893707~35911023:- CESC cis rs9907295 0.901 rs4795095 ENSG00000270977.1 AC015849.16 -5.13 6.4e-07 0.000525 -0.45 -0.33 Fibroblast growth factor basic levels; chr17:35870296 chr17:35893707~35911023:- CESC cis rs7714584 1 rs17800886 ENSG00000197083.10 ZNF300P1 5.13 6.4e-07 0.000525 0.65 0.33 Crohn's disease; chr5:150929977 chr5:150930645~150946289:- CESC cis rs9322193 0.923 rs2880436 ENSG00000268592.3 RAET1E-AS1 5.13 6.42e-07 0.000526 0.44 0.33 Lung cancer; chr6:149859123 chr6:149863494~149919507:+ CESC cis rs2243480 1 rs464895 ENSG00000228409.4 CCT6P1 5.13 6.43e-07 0.000527 0.47 0.33 Diabetic kidney disease; chr7:66062119 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs160633 ENSG00000228409.4 CCT6P1 5.13 6.43e-07 0.000527 0.47 0.33 Diabetic kidney disease; chr7:66063241 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs431076 ENSG00000275400.1 RP4-756H11.5 5.13 6.45e-07 0.000529 0.56 0.33 Diabetic kidney disease; chr7:66135333 chr7:66553805~66554199:- CESC cis rs2243480 1 rs2460422 ENSG00000275400.1 RP4-756H11.5 5.13 6.45e-07 0.000529 0.56 0.33 Diabetic kidney disease; chr7:66136518 chr7:66553805~66554199:- CESC cis rs2243480 1 rs316334 ENSG00000275400.1 RP4-756H11.5 5.13 6.45e-07 0.000529 0.56 0.33 Diabetic kidney disease; chr7:66137139 chr7:66553805~66554199:- CESC cis rs720475 0.732 rs62483107 ENSG00000204959.4 ARHGEF34P -5.13 6.46e-07 0.000529 -0.38 -0.33 Breast cancer; chr7:144442144 chr7:144272445~144286966:- CESC cis rs2243480 1 rs316331 ENSG00000232559.3 GS1-124K5.12 -5.13 6.48e-07 0.000531 -0.55 -0.33 Diabetic kidney disease; chr7:66139635 chr7:66554588~66576923:- CESC cis rs10246939 0.543 rs12538701 ENSG00000228775.6 WEE2-AS1 5.13 6.48e-07 0.000531 0.41 0.33 Bitter taste perception; chr7:141893634 chr7:141704338~141738346:- CESC cis rs765787 0.53 rs12906537 ENSG00000259520.4 CTD-2651B20.3 -5.13 6.49e-07 0.000531 -0.42 -0.33 Uric acid levels; chr15:45227863 chr15:45251580~45279251:- CESC cis rs2439831 0.717 rs28495368 ENSG00000275601.1 AC011330.13 -5.13 6.49e-07 0.000531 -0.48 -0.33 Lung cancer in ever smokers; chr15:43603444 chr15:43642389~43643023:- CESC cis rs8177876 0.822 rs1563077 ENSG00000261838.4 RP11-303E16.6 5.13 6.49e-07 0.000532 0.71 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81073951 chr16:81069854~81076598:+ CESC cis rs9322193 0.923 rs10782317 ENSG00000268592.3 RAET1E-AS1 -5.13 6.54e-07 0.000536 -0.42 -0.33 Lung cancer; chr6:149753911 chr6:149863494~149919507:+ CESC cis rs2243480 1 rs160655 ENSG00000228409.4 CCT6P1 5.13 6.55e-07 0.000536 0.49 0.33 Diabetic kidney disease; chr7:66068227 chr7:65751142~65763354:+ CESC cis rs748404 0.676 rs4401024 ENSG00000249839.1 AC011330.5 -5.12 6.55e-07 0.000536 -0.35 -0.33 Lung cancer; chr15:43358137 chr15:43663654~43684339:- CESC cis rs1799949 1 rs11651341 ENSG00000267681.1 CTD-3199J23.6 -5.12 6.58e-07 0.000538 -0.43 -0.33 Menopause (age at onset); chr17:43350693 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs34572725 ENSG00000267681.1 CTD-3199J23.6 -5.12 6.58e-07 0.000538 -0.43 -0.33 Menopause (age at onset); chr17:43351298 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs4534897 ENSG00000267681.1 CTD-3199J23.6 -5.12 6.58e-07 0.000538 -0.43 -0.33 Menopause (age at onset); chr17:43354440 chr17:43144956~43145255:+ CESC cis rs765787 0.53 rs28526629 ENSG00000259520.4 CTD-2651B20.3 5.12 6.58e-07 0.000538 0.4 0.33 Uric acid levels; chr15:45248264 chr15:45251580~45279251:- CESC cis rs11779988 0.516 rs426498 ENSG00000253671.1 RP11-806O11.1 -5.12 6.58e-07 0.000538 -0.38 -0.33 Breast cancer; chr8:18039649 chr8:17808941~17820868:+ CESC cis rs2015599 0.525 rs7959145 ENSG00000275476.1 RP11-996F15.4 5.12 6.6e-07 0.000539 0.38 0.33 Platelet count;Mean platelet volume; chr12:29330850 chr12:29277397~29277882:- CESC cis rs2015599 0.525 rs7961943 ENSG00000275476.1 RP11-996F15.4 5.12 6.6e-07 0.000539 0.38 0.33 Platelet count;Mean platelet volume; chr12:29331146 chr12:29277397~29277882:- CESC cis rs2015599 0.525 rs10743656 ENSG00000275476.1 RP11-996F15.4 5.12 6.6e-07 0.000539 0.38 0.33 Platelet count;Mean platelet volume; chr12:29332516 chr12:29277397~29277882:- CESC cis rs7572733 0.935 rs1518360 ENSG00000222017.1 AC011997.1 -5.12 6.6e-07 0.000539 -0.36 -0.33 Dermatomyositis; chr2:197950579 chr2:197693106~197774823:+ CESC cis rs957448 1 rs72674843 ENSG00000253704.1 RP11-267M23.4 5.12 6.61e-07 0.00054 0.38 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94520772 chr8:94553722~94569745:+ CESC cis rs2243480 1 rs778729 ENSG00000275400.1 RP4-756H11.5 5.12 6.61e-07 0.00054 0.56 0.33 Diabetic kidney disease; chr7:66359432 chr7:66553805~66554199:- CESC cis rs2243480 0.901 rs778687 ENSG00000275400.1 RP4-756H11.5 5.12 6.61e-07 0.00054 0.56 0.33 Diabetic kidney disease; chr7:66370832 chr7:66553805~66554199:- CESC cis rs2243480 1 rs778679 ENSG00000275400.1 RP4-756H11.5 5.12 6.61e-07 0.00054 0.56 0.33 Diabetic kidney disease; chr7:66375924 chr7:66553805~66554199:- CESC cis rs2243480 1 rs778704 ENSG00000275400.1 RP4-756H11.5 5.12 6.61e-07 0.00054 0.56 0.33 Diabetic kidney disease; chr7:66398480 chr7:66553805~66554199:- CESC cis rs2243480 0.901 rs778693 ENSG00000275400.1 RP4-756H11.5 5.12 6.61e-07 0.00054 0.56 0.33 Diabetic kidney disease; chr7:66407358 chr7:66553805~66554199:- CESC cis rs2243480 1 rs778691 ENSG00000275400.1 RP4-756H11.5 5.12 6.61e-07 0.00054 0.56 0.33 Diabetic kidney disease; chr7:66408105 chr7:66553805~66554199:- CESC cis rs2243480 1 rs13235972 ENSG00000275400.1 RP4-756H11.5 5.12 6.61e-07 0.00054 0.56 0.33 Diabetic kidney disease; chr7:66418618 chr7:66553805~66554199:- CESC cis rs2243480 1 rs34192067 ENSG00000275400.1 RP4-756H11.5 5.12 6.61e-07 0.00054 0.56 0.33 Diabetic kidney disease; chr7:66422670 chr7:66553805~66554199:- CESC cis rs6991838 0.831 rs4394432 ENSG00000200714.1 Y_RNA 5.12 6.62e-07 0.000541 0.38 0.33 Intelligence (multi-trait analysis); chr8:65560939 chr8:65592731~65592820:+ CESC cis rs10246939 0.543 rs10952509 ENSG00000228775.6 WEE2-AS1 5.12 6.63e-07 0.000541 0.41 0.33 Bitter taste perception; chr7:141890884 chr7:141704338~141738346:- CESC cis rs4660456 0.913 rs6667368 ENSG00000237899.1 RP4-739H11.3 5.12 6.63e-07 0.000541 0.45 0.33 Platelet count; chr1:40694887 chr1:40669089~40687588:- CESC cis rs6142102 0.812 rs725478 ENSG00000276073.1 RP5-1125A11.7 5.12 6.63e-07 0.000541 0.32 0.33 Skin pigmentation; chr20:33930548 chr20:33985617~33988989:- CESC cis rs62388641 0.547 rs9391923 ENSG00000272279.1 RP11-157J24.2 -5.12 6.65e-07 0.000543 -0.39 -0.33 Daytime sleep phenotypes; chr6:1554089 chr6:1528364~1528911:- CESC cis rs62034325 0.697 rs710410 ENSG00000259982.1 CDC37P1 5.12 6.66e-07 0.000544 0.42 0.33 Body mass index; chr16:28592021 chr16:28700294~28701540:- CESC cis rs7188445 0.932 rs4575545 ENSG00000261390.4 RP11-345M22.2 -5.12 6.68e-07 0.000545 -0.43 -0.33 Urate levels; chr16:79721549 chr16:79715232~79770563:- CESC cis rs2842992 0.789 rs9365093 ENSG00000237927.1 RP3-393E18.2 -5.12 6.69e-07 0.000546 -0.43 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159754787 chr6:159586955~159589169:- CESC cis rs2243480 0.901 rs34807232 ENSG00000275400.1 RP4-756H11.5 5.12 6.7e-07 0.000547 0.56 0.33 Diabetic kidney disease; chr7:66500146 chr7:66553805~66554199:- CESC cis rs10262624 1 rs7792262 ENSG00000234286.1 AC006026.13 5.12 6.7e-07 0.000547 0.34 0.33 Schizophrenia; chr7:23876124 chr7:23680195~23680786:- CESC cis rs4660456 0.913 rs545218 ENSG00000237899.1 RP4-739H11.3 5.12 6.73e-07 0.000549 0.45 0.33 Platelet count; chr1:40675313 chr1:40669089~40687588:- CESC cis rs11118620 0.535 rs1389750 ENSG00000272823.1 RP11-295M18.6 5.12 6.73e-07 0.000549 0.36 0.33 Heart failure; chr1:220866829 chr1:220828676~220829211:- CESC cis rs12681963 0.688 rs67240919 ENSG00000272375.1 RP11-51J9.6 5.12 6.73e-07 0.000549 0.53 0.33 Migraine; chr8:30171039 chr8:30197404~30198048:+ CESC cis rs2439831 0.867 rs2447196 ENSG00000275601.1 AC011330.13 5.12 6.74e-07 0.00055 0.48 0.33 Lung cancer in ever smokers; chr15:43601620 chr15:43642389~43643023:- CESC cis rs2243480 1 rs313820 ENSG00000275400.1 RP4-756H11.5 5.12 6.75e-07 0.00055 0.56 0.33 Diabetic kidney disease; chr7:66109479 chr7:66553805~66554199:- CESC cis rs2243480 1 rs313824 ENSG00000275400.1 RP4-756H11.5 5.12 6.75e-07 0.00055 0.56 0.33 Diabetic kidney disease; chr7:66116220 chr7:66553805~66554199:- CESC cis rs2243480 1 rs186378 ENSG00000275400.1 RP4-756H11.5 5.12 6.75e-07 0.00055 0.56 0.33 Diabetic kidney disease; chr7:66117071 chr7:66553805~66554199:- CESC cis rs2243480 1 rs160637 ENSG00000275400.1 RP4-756H11.5 5.12 6.75e-07 0.00055 0.56 0.33 Diabetic kidney disease; chr7:66119331 chr7:66553805~66554199:- CESC cis rs10875746 0.669 rs11168499 ENSG00000240399.1 RP1-228P16.1 -5.12 6.76e-07 0.000551 -0.42 -0.33 Longevity (90 years and older); chr12:48268887 chr12:48054813~48055591:- CESC cis rs1862618 0.525 rs832403 ENSG00000271828.1 CTD-2310F14.1 -5.12 6.78e-07 0.000553 -0.45 -0.33 Initial pursuit acceleration; chr5:56970165 chr5:56927874~56929573:+ CESC cis rs2177312 0.83 rs6835697 ENSG00000251129.1 RP11-734I18.1 -5.12 6.79e-07 0.000553 -0.41 -0.33 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31981812 chr4:31997397~32155406:+ CESC cis rs2836950 0.545 rs2297256 ENSG00000232608.1 TIMM9P2 5.12 6.79e-07 0.000553 0.36 0.33 Menarche (age at onset); chr21:39186495 chr21:39216624~39217506:+ CESC cis rs577676 0.586 rs2022373 ENSG00000271811.1 RP1-79C4.4 5.12 6.79e-07 0.000554 0.44 0.33 Prevalent atrial fibrillation; chr1:170619453 chr1:170667381~170669425:+ CESC cis rs1799949 1 rs8176202 ENSG00000267681.1 CTD-3199J23.6 -5.12 6.81e-07 0.000555 -0.43 -0.33 Menopause (age at onset); chr17:43078211 chr17:43144956~43145255:+ CESC cis rs748404 0.586 rs2584700 ENSG00000205771.5 CATSPER2P1 -5.12 6.82e-07 0.000556 -0.4 -0.33 Lung cancer; chr15:43393134 chr15:43726918~43747094:- CESC cis rs765787 0.53 rs2899378 ENSG00000259520.4 CTD-2651B20.3 -5.12 6.83e-07 0.000556 -0.41 -0.33 Uric acid levels; chr15:45245386 chr15:45251580~45279251:- CESC cis rs8072100 0.967 rs11079784 ENSG00000228782.6 CTD-2026D20.3 -5.12 6.84e-07 0.000557 -0.37 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47624914 chr17:47450568~47492492:- CESC cis rs875971 0.564 rs313804 ENSG00000237310.1 GS1-124K5.4 5.12 6.85e-07 0.000558 0.32 0.33 Aortic root size; chr7:66049635 chr7:66493706~66495474:+ CESC cis rs875971 0.662 rs448725 ENSG00000237310.1 GS1-124K5.4 5.12 6.85e-07 0.000558 0.32 0.33 Aortic root size; chr7:66049641 chr7:66493706~66495474:+ CESC cis rs875971 0.658 rs432667 ENSG00000237310.1 GS1-124K5.4 5.12 6.85e-07 0.000558 0.32 0.33 Aortic root size; chr7:66049646 chr7:66493706~66495474:+ CESC cis rs7572733 0.84 rs770667 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197748584 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs1065953 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197749888 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs700648 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197757912 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs700649 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197758028 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs700650 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197759561 chr2:197693106~197774823:+ CESC cis rs7572733 0.811 rs771013 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197760513 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs1065949 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197762331 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs700653 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197772709 chr2:197693106~197774823:+ CESC cis rs7572733 0.84 rs700654 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197778697 chr2:197693106~197774823:+ CESC cis rs7572733 0.875 rs771018 ENSG00000222017.1 AC011997.1 5.12 6.85e-07 0.000558 0.37 0.33 Dermatomyositis; chr2:197785535 chr2:197693106~197774823:+ CESC cis rs1185460 1 rs1185460 ENSG00000271751.1 RP11-110I1.14 5.12 6.85e-07 0.000558 0.43 0.33 Coronary artery disease; chr11:119072723 chr11:119065263~119065677:- CESC cis rs4660456 0.542 rs850009 ENSG00000237899.1 RP4-739H11.3 5.11 6.87e-07 0.000559 0.46 0.33 Platelet count; chr1:40643593 chr1:40669089~40687588:- CESC cis rs34779708 0.931 rs11592404 ENSG00000230534.5 RP11-297A16.2 5.11 6.87e-07 0.000559 0.43 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34984548 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs79749947 ENSG00000230534.5 RP11-297A16.2 5.11 6.87e-07 0.000559 0.43 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34988153 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs9663401 ENSG00000230534.5 RP11-297A16.2 5.11 6.87e-07 0.000559 0.43 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34989921 chr10:35098006~35127020:- CESC cis rs34779708 0.897 rs9787566 ENSG00000230534.5 RP11-297A16.2 5.11 6.87e-07 0.000559 0.43 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34990527 chr10:35098006~35127020:- CESC cis rs3823536 0.583 rs6948928 ENSG00000275106.1 RP11-309L24.10 -5.11 6.89e-07 0.000561 -0.46 -0.33 Sjögren's syndrome; chr7:128983043 chr7:128952527~128953316:- CESC cis rs860295 0.541 rs11264359 ENSG00000225855.5 RUSC1-AS1 5.11 6.9e-07 0.000561 0.26 0.33 Body mass index; chr1:155313038 chr1:155316863~155324176:- CESC cis rs875971 0.862 rs9791712 ENSG00000226824.5 RP4-756H11.3 5.11 6.91e-07 0.000562 0.42 0.33 Aortic root size; chr7:66640176 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs9791713 ENSG00000226824.5 RP4-756H11.3 5.11 6.91e-07 0.000562 0.42 0.33 Aortic root size; chr7:66640211 chr7:66654538~66669855:+ CESC cis rs9584850 0.834 rs12869627 ENSG00000231194.1 FARP1-AS1 5.11 6.91e-07 0.000562 0.41 0.33 Neuroticism; chr13:98468198 chr13:98435405~98435840:- CESC cis rs875971 0.545 rs75840613 ENSG00000222364.1 RNU6-96P -5.11 6.92e-07 0.000563 -0.44 -0.33 Aortic root size; chr7:66376399 chr7:66395191~66395286:+ CESC cis rs1799949 1 rs4793194 ENSG00000267681.1 CTD-3199J23.6 -5.11 6.92e-07 0.000563 -0.43 -0.33 Menopause (age at onset); chr17:43066316 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176234 ENSG00000267681.1 CTD-3199J23.6 -5.11 6.92e-07 0.000563 -0.43 -0.33 Menopause (age at onset); chr17:43067763 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176233 ENSG00000267681.1 CTD-3199J23.6 -5.11 6.92e-07 0.000563 -0.43 -0.33 Menopause (age at onset); chr17:43067787 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176220 ENSG00000267681.1 CTD-3199J23.6 -5.11 6.92e-07 0.000563 -0.43 -0.33 Menopause (age at onset); chr17:43070445 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs1799966 ENSG00000267681.1 CTD-3199J23.6 -5.11 6.92e-07 0.000563 -0.43 -0.33 Menopause (age at onset); chr17:43071077 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs34942571 ENSG00000267681.1 CTD-3199J23.6 -5.11 6.92e-07 0.000563 -0.43 -0.33 Menopause (age at onset); chr17:43121362 chr17:43144956~43145255:+ CESC cis rs11159086 0.793 rs17100414 ENSG00000259005.1 RP3-449M8.6 5.11 6.94e-07 0.000564 0.48 0.33 Advanced glycation end-product levels; chr14:74467918 chr14:74474007~74474864:- CESC cis rs55879323 1 rs55879323 ENSG00000237975.5 FLG-AS1 -5.11 6.95e-07 0.000565 -0.38 -0.33 Inflammatory skin disease; chr1:152196264 chr1:152168125~152445456:+ CESC cis rs9322193 0.884 rs9397036 ENSG00000268592.3 RAET1E-AS1 5.11 6.95e-07 0.000565 0.44 0.33 Lung cancer; chr6:149851787 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs9383864 ENSG00000268592.3 RAET1E-AS1 5.11 6.95e-07 0.000565 0.44 0.33 Lung cancer; chr6:149851969 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs9383865 ENSG00000268592.3 RAET1E-AS1 5.11 6.95e-07 0.000565 0.44 0.33 Lung cancer; chr6:149852043 chr6:149863494~149919507:+ CESC cis rs4423214 0.592 rs10898186 ENSG00000254682.1 RP11-660L16.2 -5.11 6.96e-07 0.000565 -0.48 -0.33 Vitamin D levels; chr11:71477754 chr11:71448674~71452157:+ CESC cis rs875971 0.862 rs10256544 ENSG00000222364.1 RNU6-96P -5.11 6.96e-07 0.000565 -0.38 -0.33 Aortic root size; chr7:66210141 chr7:66395191~66395286:+ CESC cis rs2243480 1 rs313814 ENSG00000228409.4 CCT6P1 5.11 6.97e-07 0.000566 0.48 0.33 Diabetic kidney disease; chr7:66038306 chr7:65751142~65763354:+ CESC cis rs9549367 0.789 rs9549705 ENSG00000269125.1 RP11-98F14.11 -5.11 6.98e-07 0.000567 -0.46 -0.33 Platelet distribution width; chr13:113234111 chr13:113165002~113165183:- CESC cis rs3762637 0.823 rs9849013 ENSG00000272758.4 RP11-299J3.8 -5.11 7e-07 0.000568 -0.46 -0.33 LDL cholesterol levels; chr3:122531758 chr3:122416207~122443180:+ CESC cis rs5769707 0.632 rs135876 ENSG00000235111.1 RP1-29C18.8 -5.11 7.01e-07 0.000569 -0.37 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49619925 chr22:49612657~49615716:- CESC cis rs2858942 0.602 rs1211375 ENSG00000268836.1 LA16c-OS12.2 -5.11 7.02e-07 0.00057 -0.35 -0.33 Mean corpuscular hemoglobin; chr16:190281 chr16:185748~186294:- CESC cis rs9402743 0.775 rs12198378 ENSG00000217482.2 HMGB1P17 5.11 7.02e-07 0.00057 0.38 0.33 Systemic lupus erythematosus; chr6:135662479 chr6:135636086~135636713:- CESC cis rs992157 0.643 rs10191283 ENSG00000261338.2 RP11-378A13.1 5.11 7.03e-07 0.000571 0.4 0.33 Colorectal cancer; chr2:218192032 chr2:218255319~218257366:+ CESC cis rs875971 0.862 rs778720 ENSG00000222364.1 RNU6-96P 5.11 7.04e-07 0.000571 0.38 0.33 Aortic root size; chr7:66381288 chr7:66395191~66395286:+ CESC cis rs1862618 0.526 rs2591963 ENSG00000271828.1 CTD-2310F14.1 -5.11 7.05e-07 0.000572 -0.44 -0.33 Initial pursuit acceleration; chr5:56941308 chr5:56927874~56929573:+ CESC cis rs1862618 0.573 rs2591962 ENSG00000271828.1 CTD-2310F14.1 -5.11 7.05e-07 0.000572 -0.44 -0.33 Initial pursuit acceleration; chr5:56941328 chr5:56927874~56929573:+ CESC cis rs7621025 0.5 rs1965107 ENSG00000239213.4 NCK1-AS1 5.11 7.06e-07 0.000573 0.41 0.33 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136929801 chr3:136841726~136862054:- CESC cis rs2028299 0.84 rs17242083 ENSG00000259677.1 RP11-493E3.1 5.11 7.06e-07 0.000573 0.46 0.33 Type 2 diabetes; chr15:89906244 chr15:89876540~89877285:+ CESC cis rs116095464 0.558 rs6878087 ENSG00000250848.1 CTD-2083E4.5 5.11 7.06e-07 0.000573 0.39 0.33 Breast cancer; chr5:223002 chr5:288833~290321:- CESC cis rs748404 0.69 rs2467737 ENSG00000205771.5 CATSPER2P1 -5.11 7.07e-07 0.000573 -0.38 -0.33 Lung cancer; chr15:43444990 chr15:43726918~43747094:- CESC cis rs875971 0.545 rs13311962 ENSG00000237310.1 GS1-124K5.4 -5.11 7.07e-07 0.000573 -0.35 -0.33 Aortic root size; chr7:66603142 chr7:66493706~66495474:+ CESC cis rs2739330 0.731 rs2000468 ENSG00000272787.1 KB-226F1.2 -5.11 7.08e-07 0.000574 -0.35 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23969211~23969873:+ CESC cis rs520525 0.963 rs600093 ENSG00000271811.1 RP1-79C4.4 5.11 7.09e-07 0.000574 0.45 0.33 Atrial fibrillation; chr1:170660697 chr1:170667381~170669425:+ CESC cis rs12439619 0.508 rs8042665 ENSG00000255769.6 GOLGA2P10 -5.11 7.09e-07 0.000574 -0.36 -0.33 Intelligence (multi-trait analysis); chr15:82189008 chr15:82472993~82513950:- CESC cis rs5769707 0.554 rs10854876 ENSG00000235111.1 RP1-29C18.8 -5.11 7.09e-07 0.000574 -0.37 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49616922 chr22:49612657~49615716:- CESC cis rs950880 0.71 rs56043441 ENSG00000234389.1 AC007278.3 -5.11 7.1e-07 0.000575 -0.35 -0.33 Serum protein levels (sST2); chr2:102470923 chr2:102438713~102440475:+ CESC cis rs4266144 0.558 rs4680339 ENSG00000244515.1 KRT18P34 5.11 7.1e-07 0.000575 0.36 0.33 Coronary artery disease; chr3:157117630 chr3:157162663~157163932:- CESC cis rs5769707 0.632 rs135877 ENSG00000235111.1 RP1-29C18.8 -5.11 7.1e-07 0.000575 -0.38 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49620354 chr22:49612657~49615716:- CESC cis rs8177876 0.822 rs1563075 ENSG00000261838.4 RP11-303E16.6 5.11 7.11e-07 0.000576 0.7 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81074143 chr16:81069854~81076598:+ CESC cis rs4814920 0.818 rs4813376 ENSG00000275142.1 RP5-999L4.2 5.11 7.12e-07 0.000577 0.52 0.33 Bipolar disorder (body mass index interaction); chr20:19870811 chr20:19871891~19872284:+ CESC cis rs6504950 0.732 rs244373 ENSG00000275710.1 RP11-257O5.4 -5.11 7.13e-07 0.000577 -0.37 -0.33 Breast cancer; chr17:55107588 chr17:54964474~54964679:+ CESC cis rs6504950 0.924 rs187242 ENSG00000275710.1 RP11-257O5.4 5.11 7.13e-07 0.000577 0.37 0.33 Breast cancer; chr17:55115585 chr17:54964474~54964679:+ CESC cis rs2439831 0.867 rs2920781 ENSG00000275601.1 AC011330.13 -5.11 7.15e-07 0.000579 -0.48 -0.33 Lung cancer in ever smokers; chr15:43632484 chr15:43642389~43643023:- CESC cis rs2439831 0.764 rs2447193 ENSG00000275601.1 AC011330.13 -5.11 7.15e-07 0.000579 -0.48 -0.33 Lung cancer in ever smokers; chr15:43637535 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2447211 ENSG00000275601.1 AC011330.13 -5.11 7.15e-07 0.000579 -0.48 -0.33 Lung cancer in ever smokers; chr15:43644153 chr15:43642389~43643023:- CESC cis rs2439831 0.571 rs2470121 ENSG00000275601.1 AC011330.13 -5.11 7.15e-07 0.000579 -0.48 -0.33 Lung cancer in ever smokers; chr15:43645420 chr15:43642389~43643023:- CESC cis rs7429990 0.932 rs6803741 ENSG00000229759.1 MRPS18AP1 -5.11 7.15e-07 0.000579 -0.33 -0.33 Educational attainment (years of education); chr3:48082050 chr3:48256350~48256938:- CESC cis rs875971 0.83 rs6976714 ENSG00000237310.1 GS1-124K5.4 5.11 7.18e-07 0.00058 0.31 0.33 Aortic root size; chr7:66426474 chr7:66493706~66495474:+ CESC cis rs875971 0.651 rs2420596 ENSG00000237310.1 GS1-124K5.4 5.11 7.18e-07 0.00058 0.31 0.33 Aortic root size; chr7:66450996 chr7:66493706~66495474:+ CESC cis rs875971 0.52 rs2420597 ENSG00000237310.1 GS1-124K5.4 5.11 7.18e-07 0.00058 0.31 0.33 Aortic root size; chr7:66450999 chr7:66493706~66495474:+ CESC cis rs6504622 0.72 rs4968304 ENSG00000262879.4 RP11-156P1.3 -5.11 7.19e-07 0.000582 -0.36 -0.33 Orofacial clefts; chr17:47063235 chr17:46984045~47100323:- CESC cis rs765787 0.53 rs12904265 ENSG00000259520.4 CTD-2651B20.3 -5.11 7.2e-07 0.000582 -0.41 -0.33 Uric acid levels; chr15:45234515 chr15:45251580~45279251:- CESC cis rs765787 0.53 rs2899379 ENSG00000259520.4 CTD-2651B20.3 -5.11 7.2e-07 0.000582 -0.41 -0.33 Uric acid levels; chr15:45242601 chr15:45251580~45279251:- CESC cis rs10875746 0.768 rs4760609 ENSG00000240399.1 RP1-228P16.1 5.1 7.21e-07 0.000583 0.37 0.33 Longevity (90 years and older); chr12:48021974 chr12:48054813~48055591:- CESC cis rs748404 0.631 rs4296223 ENSG00000249839.1 AC011330.5 -5.1 7.21e-07 0.000583 -0.35 -0.33 Lung cancer; chr15:43353048 chr15:43663654~43684339:- CESC cis rs6142102 0.961 rs6059649 ENSG00000276073.1 RP5-1125A11.7 -5.1 7.22e-07 0.000584 -0.32 -0.33 Skin pigmentation; chr20:34056071 chr20:33985617~33988989:- CESC cis rs6686842 0.689 rs2885697 ENSG00000235358.1 RP11-399E6.1 -5.1 7.23e-07 0.000584 -0.4 -0.33 Height; chr1:41078607 chr1:41242373~41284861:+ CESC cis rs875971 0.862 rs11773628 ENSG00000237310.1 GS1-124K5.4 -5.1 7.23e-07 0.000584 -0.31 -0.33 Aortic root size; chr7:66517644 chr7:66493706~66495474:+ CESC cis rs9322193 0.923 rs10747276 ENSG00000268592.3 RAET1E-AS1 5.1 7.24e-07 0.000585 0.42 0.33 Lung cancer; chr6:149758739 chr6:149863494~149919507:+ CESC cis rs2412819 0.599 rs2470120 ENSG00000205771.5 CATSPER2P1 -5.1 7.26e-07 0.000586 -0.39 -0.33 Lung cancer; chr15:43636872 chr15:43726918~43747094:- CESC cis rs13108904 0.901 rs6851528 ENSG00000254094.1 AC078852.1 -5.1 7.26e-07 0.000586 -0.39 -0.33 Obesity-related traits; chr4:1302221 chr4:1356581~1358075:+ CESC cis rs116095464 0.51 rs7714944 ENSG00000250848.1 CTD-2083E4.5 -5.1 7.28e-07 0.000588 -0.42 -0.33 Breast cancer; chr5:231650 chr5:288833~290321:- CESC cis rs6782228 0.606 rs4857861 ENSG00000242551.2 POU5F1P6 -5.1 7.28e-07 0.000588 -0.37 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128687924 chr3:128674735~128677005:- CESC cis rs6782228 0.606 rs4857919 ENSG00000242551.2 POU5F1P6 -5.1 7.28e-07 0.000588 -0.37 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128688652 chr3:128674735~128677005:- CESC cis rs58873874 0.522 rs6875379 ENSG00000251405.2 CTB-109A12.1 5.1 7.29e-07 0.000588 0.78 0.33 Bipolar disorder (body mass index interaction); chr5:157391295 chr5:157362615~157460078:- CESC cis rs748404 0.66 rs2467742 ENSG00000205771.5 CATSPER2P1 -5.1 7.29e-07 0.000589 -0.38 -0.33 Lung cancer; chr15:43458039 chr15:43726918~43747094:- CESC cis rs3931020 0.657 rs7522428 ENSG00000272864.1 RP11-17E13.2 -5.1 7.29e-07 0.000589 -0.42 -0.33 Resistin levels; chr1:74712676 chr1:74698769~74699333:- CESC cis rs875971 0.767 rs12668005 ENSG00000237310.1 GS1-124K5.4 5.1 7.32e-07 0.000591 0.32 0.33 Aortic root size; chr7:66444034 chr7:66493706~66495474:+ CESC cis rs10461617 0.531 rs2662033 ENSG00000271828.1 CTD-2310F14.1 5.1 7.33e-07 0.000591 0.41 0.33 Type 2 diabetes; chr5:56917583 chr5:56927874~56929573:+ CESC cis rs6504950 0.924 rs244353 ENSG00000275710.1 RP11-257O5.4 -5.1 7.33e-07 0.000591 -0.36 -0.33 Breast cancer; chr17:55117408 chr17:54964474~54964679:+ CESC cis rs2015599 0.623 rs7964831 ENSG00000275476.1 RP11-996F15.4 -5.1 7.33e-07 0.000592 -0.37 -0.33 Platelet count;Mean platelet volume; chr12:29286655 chr12:29277397~29277882:- CESC cis rs9549367 0.789 rs912012 ENSG00000269125.1 RP11-98F14.11 -5.1 7.33e-07 0.000592 -0.46 -0.33 Platelet distribution width; chr13:113231838 chr13:113165002~113165183:- CESC cis rs733592 1 rs1859440 ENSG00000240399.1 RP1-228P16.1 -5.1 7.34e-07 0.000592 -0.34 -0.33 Plateletcrit; chr12:48033546 chr12:48054813~48055591:- CESC cis rs9322193 0.923 rs62441284 ENSG00000268592.3 RAET1E-AS1 5.1 7.35e-07 0.000593 0.43 0.33 Lung cancer; chr6:149751542 chr6:149863494~149919507:+ CESC cis rs2243480 0.901 rs778732 ENSG00000275400.1 RP4-756H11.5 5.1 7.37e-07 0.000595 0.57 0.33 Diabetic kidney disease; chr7:66357373 chr7:66553805~66554199:- CESC cis rs10829156 0.732 rs1917823 ENSG00000240291.1 RP11-499P20.2 5.1 7.37e-07 0.000595 0.38 0.33 Sudden cardiac arrest; chr10:18528184 chr10:18513115~18545651:- CESC cis rs10788972 0.873 rs11206283 ENSG00000225183.1 RP4-758J24.4 5.1 7.37e-07 0.000595 0.37 0.33 Parkinson disease and lewy body pathology; chr1:54110966 chr1:54089856~54090093:+ CESC cis rs14027 0.559 rs9297603 ENSG00000279347.1 RP11-85I17.2 -5.1 7.38e-07 0.000595 -0.31 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119707078 chr8:119838736~119840385:- CESC cis rs2243480 0.908 rs1532573 ENSG00000275400.1 RP4-756H11.5 -5.1 7.38e-07 0.000595 -0.56 -0.33 Diabetic kidney disease; chr7:66333815 chr7:66553805~66554199:- CESC cis rs3762637 0.823 rs59569049 ENSG00000272758.4 RP11-299J3.8 -5.1 7.38e-07 0.000595 -0.46 -0.33 LDL cholesterol levels; chr3:122519941 chr3:122416207~122443180:+ CESC cis rs3762637 0.943 rs9822345 ENSG00000272758.4 RP11-299J3.8 -5.1 7.38e-07 0.000595 -0.46 -0.33 LDL cholesterol levels; chr3:122526751 chr3:122416207~122443180:+ CESC cis rs7397814 0.558 rs4764447 ENSG00000255753.1 RP11-22B23.2 -5.1 7.4e-07 0.000596 -0.36 -0.33 IgG glycosylation; chr12:9426513 chr12:9314402~9316173:- CESC cis rs2243480 1 rs437889 ENSG00000228409.4 CCT6P1 5.1 7.4e-07 0.000597 0.48 0.33 Diabetic kidney disease; chr7:66044247 chr7:65751142~65763354:+ CESC cis rs6504622 0.702 rs11079747 ENSG00000262879.4 RP11-156P1.3 -5.1 7.41e-07 0.000597 -0.36 -0.33 Orofacial clefts; chr17:47001484 chr17:46984045~47100323:- CESC cis rs783540 0.5 rs783541 ENSG00000255769.6 GOLGA2P10 5.1 7.41e-07 0.000597 0.39 0.33 Schizophrenia; chr15:82586310 chr15:82472993~82513950:- CESC cis rs9549367 0.789 rs2302754 ENSG00000269125.1 RP11-98F14.11 5.1 7.42e-07 0.000598 0.45 0.33 Platelet distribution width; chr13:113244071 chr13:113165002~113165183:- CESC cis rs11096990 0.634 rs3733287 ENSG00000249207.1 RP11-360F5.1 -5.1 7.42e-07 0.000598 -0.38 -0.33 Cognitive function; chr4:39215732 chr4:39112677~39126818:- CESC cis rs6991838 0.733 rs7822627 ENSG00000272010.1 CTD-3025N20.3 5.1 7.43e-07 0.000598 0.36 0.33 Intelligence (multi-trait analysis); chr8:65714139 chr8:65591850~65592472:- CESC cis rs7189233 0.531 rs1072911 ENSG00000279344.1 RP11-44F14.7 5.1 7.43e-07 0.000599 0.31 0.33 Intelligence (multi-trait analysis); chr16:53465813 chr16:53478957~53481550:- CESC cis rs11690935 0.851 rs7573003 ENSG00000228389.1 AC068039.4 5.1 7.45e-07 6e-04 0.4 0.33 Schizophrenia; chr2:171884905 chr2:171773482~171775844:+ CESC cis rs2404602 0.569 rs2469249 ENSG00000259422.1 RP11-593F23.1 -5.1 7.48e-07 0.000602 -0.41 -0.33 Blood metabolite levels; chr15:76479721 chr15:76174891~76181486:- CESC cis rs9549367 0.789 rs9549708 ENSG00000269125.1 RP11-98F14.11 -5.1 7.5e-07 0.000604 -0.45 -0.33 Platelet distribution width; chr13:113237573 chr13:113165002~113165183:- CESC cis rs34779708 0.931 rs4351760 ENSG00000230534.5 RP11-297A16.2 5.1 7.5e-07 0.000604 0.43 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34991326 chr10:35098006~35127020:- CESC cis rs34779708 0.898 rs4934695 ENSG00000230534.5 RP11-297A16.2 5.1 7.5e-07 0.000604 0.43 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34991677 chr10:35098006~35127020:- CESC cis rs34779708 0.931 rs11597483 ENSG00000230534.5 RP11-297A16.2 5.1 7.5e-07 0.000604 0.43 0.33 Inflammatory bowel disease;Crohn's disease; chr10:34996189 chr10:35098006~35127020:- CESC cis rs765787 0.53 rs28524974 ENSG00000259520.4 CTD-2651B20.3 5.1 7.51e-07 0.000604 0.39 0.33 Uric acid levels; chr15:45251330 chr15:45251580~45279251:- CESC cis rs7598759 0.548 rs11686485 ENSG00000181798.2 LINC00471 -5.1 7.52e-07 0.000605 -0.34 -0.33 Noise-induced hearing loss; chr2:231495986 chr2:231508426~231514339:- CESC cis rs3762637 0.941 rs9837149 ENSG00000272758.4 RP11-299J3.8 -5.1 7.52e-07 0.000605 -0.46 -0.33 LDL cholesterol levels; chr3:122511998 chr3:122416207~122443180:+ CESC cis rs6452524 1 rs7738033 ENSG00000249664.1 CTD-2227C6.2 5.1 7.54e-07 0.000606 0.36 0.33 Hypertension (SNP x SNP interaction); chr5:83135470 chr5:83012285~83013109:- CESC cis rs6452524 1 rs6860239 ENSG00000249664.1 CTD-2227C6.2 5.1 7.54e-07 0.000606 0.36 0.33 Hypertension (SNP x SNP interaction); chr5:83136022 chr5:83012285~83013109:- CESC cis rs1823913 1 rs1454749 ENSG00000227542.1 AC092614.2 5.1 7.54e-07 0.000606 0.34 0.33 Obesity-related traits; chr2:191240909 chr2:191229165~191246172:- CESC cis rs17507216 1 rs17507216 ENSG00000255769.6 GOLGA2P10 5.1 7.54e-07 0.000607 0.47 0.33 Excessive daytime sleepiness; chr15:82558175 chr15:82472993~82513950:- CESC cis rs116095464 1 rs28416084 ENSG00000250848.1 CTD-2083E4.5 -5.09 7.55e-07 0.000607 -0.46 -0.33 Breast cancer; chr5:217525 chr5:288833~290321:- CESC cis rs116095464 0.558 rs9312978 ENSG00000250848.1 CTD-2083E4.5 -5.09 7.55e-07 0.000607 -0.46 -0.33 Breast cancer; chr5:221815 chr5:288833~290321:- CESC cis rs116095464 0.558 rs9312979 ENSG00000250848.1 CTD-2083E4.5 -5.09 7.55e-07 0.000607 -0.46 -0.33 Breast cancer; chr5:221942 chr5:288833~290321:- CESC cis rs62229266 0.804 rs62230788 ENSG00000231106.2 LINC01436 5.09 7.56e-07 0.000608 0.46 0.33 Mitral valve prolapse; chr21:36008039 chr21:36005338~36007838:+ CESC cis rs7674212 0.772 rs13113099 ENSG00000246560.2 RP11-10L12.4 5.09 7.57e-07 0.000608 0.4 0.33 Type 2 diabetes; chr4:103052965 chr4:102828055~102844075:+ CESC cis rs10754283 0.967 rs10801761 ENSG00000231613.1 RP5-943J3.1 5.09 7.57e-07 0.000609 0.42 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89649710 chr1:89788914~89790492:+ CESC cis rs42490 0.789 rs416324 ENSG00000251136.7 RP11-37B2.1 5.09 7.59e-07 0.00061 0.33 0.33 Leprosy; chr8:89803007 chr8:89609409~89757727:- CESC cis rs17711722 0.565 rs73372653 ENSG00000226824.5 RP4-756H11.3 -5.09 7.59e-07 0.00061 -0.41 -0.33 Calcium levels; chr7:65977808 chr7:66654538~66669855:+ CESC cis rs733592 0.507 rs3825403 ENSG00000240399.1 RP1-228P16.1 -5.09 7.61e-07 0.000612 -0.33 -0.33 Plateletcrit; chr12:48063376 chr12:48054813~48055591:- CESC cis rs2842992 0.672 rs7738253 ENSG00000237927.1 RP3-393E18.2 -5.09 7.63e-07 0.000613 -0.44 -0.33 Age-related macular degeneration (geographic atrophy); chr6:159772885 chr6:159586955~159589169:- CESC cis rs875971 0.755 rs10228885 ENSG00000237310.1 GS1-124K5.4 -5.09 7.63e-07 0.000613 -0.31 -0.33 Aortic root size; chr7:66315542 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs6460298 ENSG00000222364.1 RNU6-96P -5.09 7.65e-07 0.000615 -0.43 -0.33 Aortic root size; chr7:66442783 chr7:66395191~66395286:+ CESC cis rs7188445 0.932 rs17767491 ENSG00000261390.4 RP11-345M22.2 -5.09 7.66e-07 0.000615 -0.43 -0.33 Urate levels; chr16:79711590 chr16:79715232~79770563:- CESC cis rs2739330 0.828 rs2877178 ENSG00000272787.1 KB-226F1.2 -5.09 7.66e-07 0.000615 -0.35 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23969211~23969873:+ CESC cis rs875971 0.862 rs2909688 ENSG00000232559.3 GS1-124K5.12 5.09 7.67e-07 0.000616 0.36 0.33 Aortic root size; chr7:66376625 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs709596 ENSG00000237310.1 GS1-124K5.4 5.09 7.67e-07 0.000616 0.31 0.33 Aortic root size; chr7:66360926 chr7:66493706~66495474:+ CESC cis rs9907295 1 rs9889274 ENSG00000270977.1 AC015849.16 -5.09 7.68e-07 0.000617 -0.48 -0.33 Fibroblast growth factor basic levels; chr17:35910397 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9891064 ENSG00000270977.1 AC015849.16 -5.09 7.68e-07 0.000617 -0.48 -0.33 Fibroblast growth factor basic levels; chr17:35913045 chr17:35893707~35911023:- CESC cis rs9907295 1 rs9899870 ENSG00000270977.1 AC015849.16 -5.09 7.68e-07 0.000617 -0.48 -0.33 Fibroblast growth factor basic levels; chr17:35914438 chr17:35893707~35911023:- CESC cis rs1799949 0.93 rs66499067 ENSG00000267681.1 CTD-3199J23.6 -5.09 7.69e-07 0.000617 -0.42 -0.33 Menopause (age at onset); chr17:43096467 chr17:43144956~43145255:+ CESC cis rs2243480 0.803 rs160649 ENSG00000228409.4 CCT6P1 5.09 7.69e-07 0.000617 0.49 0.33 Diabetic kidney disease; chr7:66078212 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs160648 ENSG00000228409.4 CCT6P1 5.09 7.69e-07 0.000617 0.49 0.33 Diabetic kidney disease; chr7:66078397 chr7:65751142~65763354:+ CESC cis rs765787 0.53 rs12903149 ENSG00000259520.4 CTD-2651B20.3 -5.09 7.71e-07 0.000619 -0.41 -0.33 Uric acid levels; chr15:45246878 chr15:45251580~45279251:- CESC cis rs6782228 0.606 rs6807019 ENSG00000242551.2 POU5F1P6 -5.09 7.72e-07 0.00062 -0.37 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128687091 chr3:128674735~128677005:- CESC cis rs8059260 1 rs7205474 ENSG00000274038.1 RP11-66H6.4 -5.09 7.74e-07 0.000621 -0.49 -0.33 Alcohol consumption over the past year; chr16:10949556 chr16:11056556~11057034:+ CESC cis rs2439831 0.867 rs2260160 ENSG00000275601.1 AC011330.13 -5.09 7.75e-07 0.000621 -0.45 -0.33 Lung cancer in ever smokers; chr15:43603445 chr15:43642389~43643023:- CESC cis rs2732480 0.538 rs1387259 ENSG00000258273.1 RP11-370I10.4 5.09 7.76e-07 0.000622 0.4 0.33 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309739 chr12:48333755~48333901:- CESC cis rs7572733 0.935 rs700679 ENSG00000222017.1 AC011997.1 5.09 7.78e-07 0.000624 0.36 0.33 Dermatomyositis; chr2:197842192 chr2:197693106~197774823:+ CESC cis rs860295 0.702 rs1556488 ENSG00000225855.5 RUSC1-AS1 5.09 7.78e-07 0.000624 0.28 0.33 Body mass index; chr1:155570869 chr1:155316863~155324176:- CESC cis rs5769707 0.681 rs4824068 ENSG00000188511.11 C22orf34 5.09 7.79e-07 0.000625 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49631153 chr22:49414524~49657542:- CESC cis rs2243480 1 rs316322 ENSG00000275400.1 RP4-756H11.5 5.09 7.83e-07 0.000628 0.55 0.33 Diabetic kidney disease; chr7:66146246 chr7:66553805~66554199:- CESC cis rs875971 0.545 rs73152714 ENSG00000222364.1 RNU6-96P -5.09 7.85e-07 0.000628 -0.43 -0.33 Aortic root size; chr7:66534641 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs4718364 ENSG00000222364.1 RNU6-96P -5.09 7.85e-07 0.000628 -0.43 -0.33 Aortic root size; chr7:66536353 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs6961853 ENSG00000222364.1 RNU6-96P -5.09 7.85e-07 0.000628 -0.43 -0.33 Aortic root size; chr7:66537035 chr7:66395191~66395286:+ CESC cis rs116095464 0.558 rs10059907 ENSG00000250848.1 CTD-2083E4.5 -5.09 7.85e-07 0.000628 -0.46 -0.33 Breast cancer; chr5:205245 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10060089 ENSG00000250848.1 CTD-2083E4.5 -5.09 7.85e-07 0.000628 -0.46 -0.33 Breast cancer; chr5:205450 chr5:288833~290321:- CESC cis rs116095464 0.558 rs10068203 ENSG00000250848.1 CTD-2083E4.5 -5.09 7.85e-07 0.000628 -0.46 -0.33 Breast cancer; chr5:206503 chr5:288833~290321:- CESC cis rs116095464 0.558 rs73029475 ENSG00000250848.1 CTD-2083E4.5 -5.09 7.85e-07 0.000628 -0.46 -0.33 Breast cancer; chr5:206854 chr5:288833~290321:- CESC cis rs12458462 0.892 rs2242175 ENSG00000274828.1 RP11-567M16.6 5.09 7.85e-07 0.000628 0.31 0.33 Monocyte count; chr18:79704406 chr18:79677287~79679358:- CESC cis rs6452524 0.532 rs27363 ENSG00000249664.1 CTD-2227C6.2 5.09 7.86e-07 0.000629 0.37 0.33 Hypertension (SNP x SNP interaction); chr5:83040943 chr5:83012285~83013109:- CESC cis rs5769707 0.609 rs135861 ENSG00000235111.1 RP1-29C18.8 -5.09 7.86e-07 0.000629 -0.36 -0.33 Monocyte percentage of white cells;Monocyte count; chr22:49604470 chr22:49612657~49615716:- CESC cis rs11155671 0.53 rs7757984 ENSG00000223701.3 RAET1E-AS1 5.09 7.87e-07 0.00063 0.36 0.33 Testicular germ cell tumor; chr6:149887515 chr6:149884431~149919508:+ CESC cis rs2439831 0.717 rs2447198 ENSG00000275601.1 AC011330.13 -5.09 7.87e-07 0.00063 -0.46 -0.33 Lung cancer in ever smokers; chr15:43602920 chr15:43642389~43643023:- CESC cis rs748404 0.66 rs690512 ENSG00000205771.5 CATSPER2P1 -5.09 7.9e-07 0.000632 -0.38 -0.33 Lung cancer; chr15:43425480 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs542898 ENSG00000205771.5 CATSPER2P1 -5.09 7.9e-07 0.000632 -0.38 -0.33 Lung cancer; chr15:43427194 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs2249952 ENSG00000205771.5 CATSPER2P1 -5.09 7.9e-07 0.000632 -0.38 -0.33 Lung cancer; chr15:43428335 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs689767 ENSG00000205771.5 CATSPER2P1 -5.09 7.9e-07 0.000632 -0.38 -0.33 Lung cancer; chr15:43429879 chr15:43726918~43747094:- CESC cis rs2732480 0.5 rs12829841 ENSG00000258273.1 RP11-370I10.4 -5.09 7.9e-07 0.000632 -0.41 -0.33 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48234956 chr12:48333755~48333901:- CESC cis rs2732480 0.523 rs34286639 ENSG00000258273.1 RP11-370I10.4 -5.09 7.9e-07 0.000632 -0.41 -0.33 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48235261 chr12:48333755~48333901:- CESC cis rs1387259 0.929 rs11168484 ENSG00000258273.1 RP11-370I10.4 -5.09 7.9e-07 0.000632 -0.41 -0.33 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48239806 chr12:48333755~48333901:- CESC cis rs2739330 0.828 rs2154593 ENSG00000272787.1 KB-226F1.2 -5.09 7.9e-07 0.000632 -0.35 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23969211~23969873:+ CESC cis rs7598759 0.548 rs11693738 ENSG00000181798.2 LINC00471 -5.09 7.9e-07 0.000632 -0.34 -0.33 Noise-induced hearing loss; chr2:231495773 chr2:231508426~231514339:- CESC cis rs1799949 0.929 rs12937015 ENSG00000267681.1 CTD-3199J23.6 -5.08 7.92e-07 0.000633 -0.42 -0.33 Menopause (age at onset); chr17:43155456 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs4340367 ENSG00000267681.1 CTD-3199J23.6 -5.08 7.92e-07 0.000633 -0.42 -0.33 Menopause (age at onset); chr17:43155755 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs4792981 ENSG00000267681.1 CTD-3199J23.6 -5.08 7.92e-07 0.000633 -0.42 -0.33 Menopause (age at onset); chr17:43156257 chr17:43144956~43145255:+ CESC cis rs17507216 0.628 rs8028130 ENSG00000255769.6 GOLGA2P10 -5.08 7.92e-07 0.000634 -0.46 -0.33 Excessive daytime sleepiness; chr15:82734974 chr15:82472993~82513950:- CESC cis rs9309711 0.961 rs11692184 ENSG00000225234.1 TRAPPC12-AS1 -5.08 7.93e-07 0.000634 -0.32 -0.33 Neurofibrillary tangles; chr2:3476939 chr2:3481242~3482409:- CESC cis rs9876781 0.559 rs1841178 ENSG00000229759.1 MRPS18AP1 5.08 7.96e-07 0.000636 0.32 0.33 Longevity; chr3:48355556 chr3:48256350~48256938:- CESC cis rs1061377 0.76 rs7678457 ENSG00000249685.1 RP11-360F5.3 5.08 7.97e-07 0.000637 0.38 0.33 Uric acid levels; chr4:39136041 chr4:39133913~39135608:+ CESC cis rs1823913 1 rs10445782 ENSG00000227542.1 AC092614.2 -5.08 7.98e-07 0.000637 -0.34 -0.33 Obesity-related traits; chr2:191236639 chr2:191229165~191246172:- CESC cis rs9322193 0.772 rs7738696 ENSG00000216906.2 RP11-350J20.9 5.08 7.98e-07 0.000637 0.38 0.33 Lung cancer; chr6:149848985 chr6:149904243~149906418:+ CESC cis rs694739 0.734 rs663743 ENSG00000236935.1 AP003774.1 5.08 7.98e-07 0.000638 0.36 0.33 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64340263 chr11:64325050~64329504:- CESC cis rs10754283 0.967 rs1317864 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89639889 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs2390763 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89640129 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs2002883 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89640279 chr1:89788914~89790492:+ CESC cis rs10754283 0.934 rs1934043 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89641086 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs2185195 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89641138 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs6657988 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89641186 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs6698273 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89641232 chr1:89788914~89790492:+ CESC cis rs10754283 0.905 rs7519969 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89643162 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs7519971 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89643184 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs7546410 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89644256 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs7515375 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89644295 chr1:89788914~89790492:+ CESC cis rs10754283 0.901 rs6663526 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89645303 chr1:89788914~89790492:+ CESC cis rs10754283 0.934 rs7529653 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89646292 chr1:89788914~89790492:+ CESC cis rs10754283 0.87 rs2390764 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89647268 chr1:89788914~89790492:+ CESC cis rs10754283 0.901 rs4520403 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89647281 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs4658130 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89647888 chr1:89788914~89790492:+ CESC cis rs10754283 0.934 rs10754284 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89648143 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs10801759 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89648186 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs10801760 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89648265 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs7528433 ENSG00000231613.1 RP5-943J3.1 5.08 7.98e-07 0.000638 0.41 0.33 Amyotrophic lateral sclerosis (sporadic); chr1:89648512 chr1:89788914~89790492:+ CESC cis rs4366055 1 rs4366055 ENSG00000253704.1 RP11-267M23.4 5.08 7.99e-07 0.000638 0.36 0.33 Body mass index; chr8:94495100 chr8:94553722~94569745:+ CESC cis rs6991838 0.584 rs7842085 ENSG00000200714.1 Y_RNA 5.08 7.99e-07 0.000638 0.41 0.33 Intelligence (multi-trait analysis); chr8:65636787 chr8:65592731~65592820:+ CESC cis rs2548724 0.561 rs1584713 ENSG00000250682.4 LINC00491 5.08 8e-07 0.000639 0.38 0.33 Type 2 diabetes; chr5:102431585 chr5:102609156~102671559:- CESC cis rs5769707 0.604 rs1018814 ENSG00000188511.11 C22orf34 5.08 8.01e-07 0.000639 0.4 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49643252 chr22:49414524~49657542:- CESC cis rs10129255 0.509 rs756583 ENSG00000211972.2 IGHV3-66 5.08 8.01e-07 0.00064 0.23 0.33 Kawasaki disease; chr14:106680002 chr14:106675017~106675544:- CESC cis rs2337406 0.704 rs1858679 ENSG00000211974.3 IGHV2-70 -5.08 8.02e-07 0.00064 -0.52 -0.33 Alzheimer's disease (late onset); chr14:106706726 chr14:106723574~106724093:- CESC cis rs42490 1 rs218905 ENSG00000251136.7 RP11-37B2.1 -5.08 8.04e-07 0.000642 -0.33 -0.33 Leprosy; chr8:89723661 chr8:89609409~89757727:- CESC cis rs5769707 0.656 rs135878 ENSG00000188511.11 C22orf34 5.08 8.06e-07 0.000643 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49620721 chr22:49414524~49657542:- CESC cis rs11723261 0.582 rs6814287 ENSG00000211553.1 AC253576.2 -5.08 8.07e-07 0.000644 -0.47 -0.33 Immune response to smallpox vaccine (IL-6); chr4:122443 chr4:136461~136568:+ CESC cis rs2115630 0.691 rs8040066 ENSG00000225151.9 GOLGA2P7 5.08 8.09e-07 0.000645 0.36 0.33 P wave terminal force; chr15:84633234 chr15:84199311~84230136:- CESC cis rs4722166 0.508 rs1474348 ENSG00000179428.2 AC073072.5 -5.08 8.09e-07 0.000645 -0.45 -0.33 Lung cancer; chr7:22728289 chr7:22725395~22727620:- CESC cis rs2729354 0.729 rs2258835 ENSG00000265566.2 RN7SL605P -5.08 8.09e-07 0.000645 -0.48 -0.33 Blood protein levels; chr11:57476115 chr11:57528085~57528365:- CESC cis rs950880 0.71 rs4140785 ENSG00000234389.1 AC007278.3 -5.08 8.1e-07 0.000646 -0.36 -0.33 Serum protein levels (sST2); chr2:102472057 chr2:102438713~102440475:+ CESC cis rs9322193 0.884 rs7769115 ENSG00000268592.3 RAET1E-AS1 5.08 8.1e-07 0.000646 0.43 0.33 Lung cancer; chr6:149848796 chr6:149863494~149919507:+ CESC cis rs79349575 0.783 rs15563 ENSG00000270781.1 RP11-501C14.9 -5.08 8.13e-07 0.000648 -0.36 -0.33 Type 2 diabetes; chr17:48927831 chr17:48899131~48899748:+ CESC cis rs7572733 0.935 rs700669 ENSG00000222017.1 AC011997.1 5.08 8.13e-07 0.000648 0.36 0.33 Dermatomyositis; chr2:197819743 chr2:197693106~197774823:+ CESC cis rs733592 1 rs733592 ENSG00000240399.1 RP1-228P16.1 -5.08 8.13e-07 0.000648 -0.34 -0.33 Plateletcrit; chr12:48035993 chr12:48054813~48055591:- CESC cis rs733592 0.931 rs765260 ENSG00000240399.1 RP1-228P16.1 -5.08 8.13e-07 0.000648 -0.34 -0.33 Plateletcrit; chr12:48038153 chr12:48054813~48055591:- CESC cis rs9322193 0.607 rs915140 ENSG00000231760.4 RP11-350J20.5 5.08 8.14e-07 0.000648 0.49 0.33 Lung cancer; chr6:149899674 chr6:149796151~149826294:- CESC cis rs2243480 1 rs316330 ENSG00000275400.1 RP4-756H11.5 5.08 8.14e-07 0.000648 0.55 0.33 Diabetic kidney disease; chr7:66140385 chr7:66553805~66554199:- CESC cis rs2243480 1 rs316326 ENSG00000275400.1 RP4-756H11.5 5.08 8.14e-07 0.000648 0.55 0.33 Diabetic kidney disease; chr7:66144466 chr7:66553805~66554199:- CESC cis rs2243480 1 rs316325 ENSG00000275400.1 RP4-756H11.5 5.08 8.14e-07 0.000648 0.55 0.33 Diabetic kidney disease; chr7:66144531 chr7:66553805~66554199:- CESC cis rs2243480 1 rs316321 ENSG00000275400.1 RP4-756H11.5 5.08 8.14e-07 0.000648 0.55 0.33 Diabetic kidney disease; chr7:66146626 chr7:66553805~66554199:- CESC cis rs2243480 1 rs316318 ENSG00000275400.1 RP4-756H11.5 5.08 8.14e-07 0.000648 0.55 0.33 Diabetic kidney disease; chr7:66147917 chr7:66553805~66554199:- CESC cis rs2243480 1 rs316317 ENSG00000275400.1 RP4-756H11.5 5.08 8.14e-07 0.000648 0.55 0.33 Diabetic kidney disease; chr7:66148650 chr7:66553805~66554199:- CESC cis rs763121 1 rs1946990 ENSG00000273076.1 RP3-508I15.22 -5.08 8.14e-07 0.000649 -0.37 -0.33 Menopause (age at onset); chr22:38516766 chr22:38743495~38743910:+ CESC cis rs957448 1 rs7829886 ENSG00000253704.1 RP11-267M23.4 5.08 8.15e-07 0.000649 0.36 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94485160 chr8:94553722~94569745:+ CESC cis rs2243480 1 rs402418 ENSG00000228409.4 CCT6P1 5.08 8.17e-07 0.00065 0.48 0.33 Diabetic kidney disease; chr7:66044482 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs431318 ENSG00000228409.4 CCT6P1 5.08 8.17e-07 0.00065 0.48 0.33 Diabetic kidney disease; chr7:66046610 chr7:65751142~65763354:+ CESC cis rs34375054 0.558 rs67041765 ENSG00000279233.1 RP11-158L12.4 5.08 8.17e-07 0.00065 0.36 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125188367 chr12:125138245~125141711:+ CESC cis rs7188445 0.932 rs3813582 ENSG00000261390.4 RP11-345M22.2 -5.08 8.18e-07 0.000651 -0.42 -0.33 Urate levels; chr16:79715456 chr16:79715232~79770563:- CESC cis rs8059260 0.668 rs8055893 ENSG00000274038.1 RP11-66H6.4 -5.08 8.18e-07 0.000651 -0.53 -0.33 Alcohol consumption over the past year; chr16:10977938 chr16:11056556~11057034:+ CESC cis rs75422866 0.867 rs73113117 ENSG00000280054.1 RP1-197B17.7 5.08 8.19e-07 0.000652 0.81 0.33 Pneumonia; chr12:47617299 chr12:47728151~47730598:- CESC cis rs875971 0.756 rs2901210 ENSG00000232559.3 GS1-124K5.12 -5.08 8.22e-07 0.000654 -0.36 -0.33 Aortic root size; chr7:66552518 chr7:66554588~66576923:- CESC cis rs1823913 1 rs4853561 ENSG00000227542.1 AC092614.2 -5.08 8.23e-07 0.000654 -0.34 -0.33 Obesity-related traits; chr2:191242980 chr2:191229165~191246172:- CESC cis rs1823913 1 rs6704784 ENSG00000227542.1 AC092614.2 -5.08 8.23e-07 0.000654 -0.34 -0.33 Obesity-related traits; chr2:191244832 chr2:191229165~191246172:- CESC cis rs950027 0.967 rs2643718 ENSG00000259520.4 CTD-2651B20.3 -5.08 8.23e-07 0.000654 -0.42 -0.33 Response to fenofibrate (adiponectin levels); chr15:45502464 chr15:45251580~45279251:- CESC cis rs10262624 1 rs2106748 ENSG00000234286.1 AC006026.13 -5.08 8.23e-07 0.000654 -0.34 -0.33 Schizophrenia; chr7:23871694 chr7:23680195~23680786:- CESC cis rs10262624 1 rs2106747 ENSG00000234286.1 AC006026.13 -5.08 8.23e-07 0.000654 -0.34 -0.33 Schizophrenia; chr7:23871880 chr7:23680195~23680786:- CESC cis rs11155671 0.53 rs7758033 ENSG00000223701.3 RAET1E-AS1 5.08 8.23e-07 0.000655 0.36 0.33 Testicular germ cell tumor; chr6:149886999 chr6:149884431~149919508:+ CESC cis rs17837474 0.656 rs17273 ENSG00000276597.1 TRBV11-3 5.08 8.24e-07 0.000655 0.39 0.33 Cancer; chr7:142407435 chr7:142554836~142555318:+ CESC cis rs5769707 0.605 rs6009791 ENSG00000188511.11 C22orf34 5.08 8.24e-07 0.000655 0.39 0.33 Monocyte percentage of white cells;Monocyte count; chr22:49631617 chr22:49414524~49657542:- CESC cis rs9584850 0.834 rs745639 ENSG00000231194.1 FARP1-AS1 5.08 8.25e-07 0.000656 0.4 0.33 Neuroticism; chr13:98467025 chr13:98435405~98435840:- CESC cis rs7927592 0.913 rs7109294 ENSG00000212093.1 AP000807.1 5.08 8.26e-07 0.000656 0.39 0.33 Total body bone mineral density; chr11:68564625 chr11:68506083~68506166:- CESC cis rs3762637 0.943 rs28403550 ENSG00000272758.4 RP11-299J3.8 -5.08 8.27e-07 0.000657 -0.45 -0.33 LDL cholesterol levels; chr3:122532991 chr3:122416207~122443180:+ CESC cis rs9907295 0.818 rs4251737 ENSG00000270977.1 AC015849.16 -5.08 8.28e-07 0.000658 -0.44 -0.33 Fibroblast growth factor basic levels; chr17:35819814 chr17:35893707~35911023:- CESC cis rs2283792 0.718 rs239918 ENSG00000224086.5 LL22NC03-86G7.1 -5.08 8.28e-07 0.000658 -0.37 -0.33 Multiple sclerosis; chr22:21959457 chr22:21938293~21977632:+ CESC cis rs957448 0.561 rs4735302 ENSG00000253704.1 RP11-267M23.4 -5.07 8.3e-07 0.000659 -0.34 -0.33 Nonsyndromic cleft lip with cleft palate; chr8:94604752 chr8:94553722~94569745:+ CESC cis rs6969780 0.841 rs10246712 ENSG00000233429.8 HOTAIRM1 5.07 8.31e-07 0.000659 0.43 0.33 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27159241 chr7:27095647~27100265:+ CESC cis rs957448 0.561 rs58663902 ENSG00000253704.1 RP11-267M23.4 5.07 8.31e-07 0.000659 0.34 0.33 Nonsyndromic cleft lip with cleft palate; chr8:94610177 chr8:94553722~94569745:+ CESC cis rs9907295 0.681 rs9912284 ENSG00000270977.1 AC015849.16 -5.07 8.33e-07 0.000661 -0.45 -0.32 Fibroblast growth factor basic levels; chr17:35906638 chr17:35893707~35911023:- CESC cis rs9322193 0.962 rs13215691 ENSG00000216906.2 RP11-350J20.9 5.07 8.34e-07 0.000662 0.36 0.32 Lung cancer; chr6:149792666 chr6:149904243~149906418:+ CESC cis rs957448 1 rs60655325 ENSG00000253704.1 RP11-267M23.4 5.07 8.35e-07 0.000662 0.37 0.32 Nonsyndromic cleft lip with cleft palate; chr8:94552606 chr8:94553722~94569745:+ CESC cis rs957448 1 rs16916881 ENSG00000253704.1 RP11-267M23.4 5.07 8.35e-07 0.000662 0.37 0.32 Nonsyndromic cleft lip with cleft palate; chr8:94554042 chr8:94553722~94569745:+ CESC cis rs1023500 0.505 rs134891 ENSG00000273366.1 CTA-989H11.1 -5.07 8.35e-07 0.000662 -0.4 -0.32 Schizophrenia; chr22:42279876 chr22:42278188~42278846:+ CESC cis rs2919917 0.688 rs6993386 ENSG00000254352.1 RP11-578O24.2 -5.07 8.36e-07 0.000663 -0.39 -0.32 Lymphocyte counts; chr8:78741910 chr8:78723796~78724136:- CESC cis rs10246939 0.543 rs9640204 ENSG00000228775.6 WEE2-AS1 5.07 8.36e-07 0.000663 0.38 0.32 Bitter taste perception; chr7:141844300 chr7:141704338~141738346:- CESC cis rs10246939 0.543 rs9640359 ENSG00000228775.6 WEE2-AS1 5.07 8.36e-07 0.000663 0.38 0.32 Bitter taste perception; chr7:141844399 chr7:141704338~141738346:- CESC cis rs4722166 0.63 rs12700390 ENSG00000179428.2 AC073072.5 -5.07 8.36e-07 0.000663 -0.46 -0.32 Lung cancer; chr7:22737510 chr7:22725395~22727620:- CESC cis rs4722166 0.63 rs12700391 ENSG00000179428.2 AC073072.5 -5.07 8.36e-07 0.000663 -0.46 -0.32 Lung cancer; chr7:22737708 chr7:22725395~22727620:- CESC cis rs4722166 0.63 rs7781534 ENSG00000179428.2 AC073072.5 -5.07 8.36e-07 0.000663 -0.46 -0.32 Lung cancer; chr7:22738973 chr7:22725395~22727620:- CESC cis rs4722166 0.63 rs4722168 ENSG00000179428.2 AC073072.5 -5.07 8.36e-07 0.000663 -0.46 -0.32 Lung cancer; chr7:22739383 chr7:22725395~22727620:- CESC cis rs4722166 0.63 rs1581497 ENSG00000179428.2 AC073072.5 -5.07 8.36e-07 0.000663 -0.46 -0.32 Lung cancer; chr7:22739884 chr7:22725395~22727620:- CESC cis rs4722166 0.63 rs1829927 ENSG00000179428.2 AC073072.5 -5.07 8.36e-07 0.000663 -0.46 -0.32 Lung cancer; chr7:22740299 chr7:22725395~22727620:- CESC cis rs4722166 0.63 rs6969258 ENSG00000179428.2 AC073072.5 -5.07 8.36e-07 0.000663 -0.46 -0.32 Lung cancer; chr7:22742909 chr7:22725395~22727620:- CESC cis rs1061377 1 rs1036037 ENSG00000249685.1 RP11-360F5.3 5.07 8.39e-07 0.000665 0.39 0.32 Uric acid levels; chr4:39111272 chr4:39133913~39135608:+ CESC cis rs11428934 1 rs11428934 ENSG00000232871.7 SEC1P 5.07 8.41e-07 0.000666 0.39 0.32 Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts; chr19:48640988 chr19:48638071~48682245:+ CESC cis rs2470135 1 rs2470135 ENSG00000205771.5 CATSPER2P1 -5.07 8.43e-07 0.000668 -0.39 -0.32 Diastolic blood pressure; chr15:43703591 chr15:43726918~43747094:- CESC cis rs7951870 1 rs61882743 ENSG00000247675.5 LRP4-AS1 -5.07 8.44e-07 0.000668 -0.38 -0.32 Schizophrenia; chr11:46527204 chr11:46846412~46874396:+ CESC cis rs9549367 0.789 rs34989271 ENSG00000269125.1 RP11-98F14.11 -5.07 8.44e-07 0.000669 -0.45 -0.32 Platelet distribution width; chr13:113240452 chr13:113165002~113165183:- CESC cis rs9322193 0.923 rs12175504 ENSG00000268592.3 RAET1E-AS1 5.07 8.46e-07 0.00067 0.42 0.32 Lung cancer; chr6:149664079 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs35443312 ENSG00000268592.3 RAET1E-AS1 5.07 8.46e-07 0.00067 0.42 0.32 Lung cancer; chr6:149670625 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs62439843 ENSG00000268592.3 RAET1E-AS1 5.07 8.46e-07 0.00067 0.42 0.32 Lung cancer; chr6:149676521 chr6:149863494~149919507:+ CESC cis rs1075265 0.548 rs805448 ENSG00000233266.1 HMGB1P31 5.07 8.48e-07 0.000671 0.45 0.32 Chronotype;Morning vs. evening chronotype; chr2:53950055 chr2:54051334~54051760:+ CESC cis rs6504622 0.755 rs4074249 ENSG00000262879.4 RP11-156P1.3 -5.07 8.48e-07 0.000671 -0.35 -0.32 Orofacial clefts; chr17:47072043 chr17:46984045~47100323:- CESC cis rs116095464 0.558 rs9687621 ENSG00000250848.1 CTD-2083E4.5 -5.07 8.52e-07 0.000674 -0.47 -0.32 Breast cancer; chr5:229079 chr5:288833~290321:- CESC cis rs1930961 1 rs59226697 ENSG00000272977.1 CTA-390C10.10 -5.07 8.52e-07 0.000674 -0.67 -0.32 Bipolar disorder with mood-incongruent psychosis; chr22:25474070 chr22:25476218~25479971:+ CESC cis rs763121 0.925 rs17032 ENSG00000273076.1 RP3-508I15.22 5.07 8.55e-07 0.000676 0.36 0.32 Menopause (age at onset); chr22:38734838 chr22:38743495~38743910:+ CESC cis rs7615952 0.599 rs7652883 ENSG00000250012.1 RP11-124N2.1 -5.07 8.57e-07 0.000677 -0.35 -0.32 Blood pressure (smoking interaction); chr3:125989134 chr3:126084220~126095349:+ CESC cis rs2015599 0.623 rs3782505 ENSG00000275476.1 RP11-996F15.4 5.07 8.58e-07 0.000678 0.37 0.32 Platelet count;Mean platelet volume; chr12:29292236 chr12:29277397~29277882:- CESC cis rs875971 0.862 rs7783779 ENSG00000237310.1 GS1-124K5.4 -5.07 8.63e-07 0.000682 -0.31 -0.32 Aortic root size; chr7:66331639 chr7:66493706~66495474:+ CESC cis rs4660456 0.504 rs587963 ENSG00000237899.1 RP4-739H11.3 5.07 8.63e-07 0.000682 0.45 0.32 Platelet count; chr1:40640045 chr1:40669089~40687588:- CESC cis rs5742933 0.711 rs12693551 ENSG00000253559.1 OSGEPL1-AS1 5.07 8.64e-07 0.000682 0.41 0.32 Ferritin levels; chr2:189664505 chr2:189762704~189765556:+ CESC cis rs2739330 0.796 rs2154594 ENSG00000231271.1 AP000350.8 -5.07 8.65e-07 0.000683 -0.4 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23949918~23954042:+ CESC cis rs2019137 0.56 rs6707386 ENSG00000189223.12 PAX8-AS1 -5.07 8.65e-07 0.000683 -0.42 -0.32 Lymphocyte counts; chr2:113223445 chr2:113211522~113276581:+ CESC cis rs42490 0.716 rs40547 ENSG00000251136.7 RP11-37B2.1 -5.07 8.66e-07 0.000684 -0.32 -0.32 Leprosy; chr8:89817685 chr8:89609409~89757727:- CESC cis rs6597981 0.675 rs4963120 ENSG00000255142.1 AP006621.6 -5.07 8.66e-07 0.000684 -0.29 -0.32 Breast cancer; chr11:825777 chr11:781645~782105:+ CESC cis rs494459 0.838 rs1784543 ENSG00000255422.1 AP002954.4 -5.07 8.67e-07 0.000684 -0.37 -0.32 Height; chr11:118760944 chr11:118704607~118750263:+ CESC cis rs1061377 1 rs9996285 ENSG00000249685.1 RP11-360F5.3 5.07 8.69e-07 0.000686 0.38 0.32 Uric acid levels; chr4:39130556 chr4:39133913~39135608:+ CESC cis rs116095464 0.614 rs10059220 ENSG00000250848.1 CTD-2083E4.5 -5.06 8.7e-07 0.000687 -0.47 -0.32 Breast cancer; chr5:242698 chr5:288833~290321:- CESC cis rs1577917 0.771 rs3812133 ENSG00000203875.9 SNHG5 -5.06 8.7e-07 0.000687 -0.43 -0.32 Response to antipsychotic treatment; chr6:85644693 chr6:85660950~85678736:- CESC cis rs4722166 0.564 rs1800797 ENSG00000179428.2 AC073072.5 -5.06 8.71e-07 0.000687 -0.46 -0.32 Lung cancer; chr7:22726602 chr7:22725395~22727620:- CESC cis rs875971 0.545 rs221986 ENSG00000237310.1 GS1-124K5.4 -5.06 8.71e-07 0.000687 -0.36 -0.32 Aortic root size; chr7:66105323 chr7:66493706~66495474:+ CESC cis rs3762637 0.943 rs6762156 ENSG00000272758.4 RP11-299J3.8 -5.06 8.73e-07 0.000689 -0.45 -0.32 LDL cholesterol levels; chr3:122517178 chr3:122416207~122443180:+ CESC cis rs3762637 0.943 rs9872708 ENSG00000272758.4 RP11-299J3.8 -5.06 8.73e-07 0.000689 -0.45 -0.32 LDL cholesterol levels; chr3:122523960 chr3:122416207~122443180:+ CESC cis rs897984 0.647 rs8060857 ENSG00000260911.2 RP11-196G11.2 -5.06 8.74e-07 0.00069 -0.36 -0.32 Dementia with Lewy bodies; chr16:30991399 chr16:31043150~31049868:+ CESC cis rs9322193 0.847 rs868375 ENSG00000268592.3 RAET1E-AS1 5.06 8.78e-07 0.000692 0.44 0.32 Lung cancer; chr6:149844905 chr6:149863494~149919507:+ CESC cis rs4722166 0.63 rs4722169 ENSG00000179428.2 AC073072.5 -5.06 8.78e-07 0.000692 -0.46 -0.32 Lung cancer; chr7:22745800 chr7:22725395~22727620:- CESC cis rs4722166 0.598 rs4722171 ENSG00000179428.2 AC073072.5 -5.06 8.78e-07 0.000692 -0.46 -0.32 Lung cancer; chr7:22746098 chr7:22725395~22727620:- CESC cis rs2243480 1 rs316313 ENSG00000228409.4 CCT6P1 5.06 8.79e-07 0.000693 0.49 0.32 Diabetic kidney disease; chr7:66128561 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs316312 ENSG00000228409.4 CCT6P1 5.06 8.79e-07 0.000693 0.49 0.32 Diabetic kidney disease; chr7:66131504 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs419603 ENSG00000228409.4 CCT6P1 5.06 8.79e-07 0.000693 0.49 0.32 Diabetic kidney disease; chr7:66132354 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs387676 ENSG00000228409.4 CCT6P1 5.06 8.79e-07 0.000693 0.49 0.32 Diabetic kidney disease; chr7:66133233 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs13310597 ENSG00000228409.4 CCT6P1 5.06 8.79e-07 0.000693 0.49 0.32 Diabetic kidney disease; chr7:66133553 chr7:65751142~65763354:+ CESC cis rs1075265 0.584 rs34769118 ENSG00000233266.1 HMGB1P31 5.06 8.79e-07 0.000693 0.46 0.32 Chronotype;Morning vs. evening chronotype; chr2:54102173 chr2:54051334~54051760:+ CESC cis rs1799949 0.965 rs4793234 ENSG00000267681.1 CTD-3199J23.6 -5.06 8.79e-07 0.000693 -0.42 -0.32 Menopause (age at onset); chr17:43358815 chr17:43144956~43145255:+ CESC cis rs2919917 0.662 rs1483572 ENSG00000254352.1 RP11-578O24.2 5.06 8.81e-07 0.000694 0.39 0.32 Lymphocyte counts; chr8:78723008 chr8:78723796~78724136:- CESC cis rs4722166 0.603 rs7801406 ENSG00000179428.2 AC073072.5 -5.06 8.82e-07 0.000695 -0.46 -0.32 Lung cancer; chr7:22748655 chr7:22725395~22727620:- CESC cis rs2243480 0.764 rs2460423 ENSG00000275400.1 RP4-756H11.5 5.06 8.83e-07 0.000695 0.55 0.32 Diabetic kidney disease; chr7:66136229 chr7:66553805~66554199:- CESC cis rs17507216 1 rs17356118 ENSG00000276710.3 CSPG4P8 -5.06 8.83e-07 0.000696 -0.45 -0.32 Excessive daytime sleepiness; chr15:82569149 chr15:82459472~82477258:+ CESC cis rs765787 0.53 rs3759892 ENSG00000259520.4 CTD-2651B20.3 -5.06 8.84e-07 0.000696 -0.41 -0.32 Uric acid levels; chr15:45250511 chr15:45251580~45279251:- CESC cis rs12439619 0.693 rs9944185 ENSG00000255769.6 GOLGA2P10 -5.06 8.84e-07 0.000696 -0.42 -0.32 Intelligence (multi-trait analysis); chr15:82157927 chr15:82472993~82513950:- CESC cis rs42490 0.716 rs43135 ENSG00000251136.7 RP11-37B2.1 -5.06 8.85e-07 0.000697 -0.32 -0.32 Leprosy; chr8:89823722 chr8:89609409~89757727:- CESC cis rs9549367 0.756 rs2316463 ENSG00000269125.1 RP11-98F14.11 -5.06 8.88e-07 0.000699 -0.46 -0.32 Platelet distribution width; chr13:113247092 chr13:113165002~113165183:- CESC cis rs2729354 0.768 rs1001956 ENSG00000265566.2 RN7SL605P -5.06 8.88e-07 0.000699 -0.49 -0.32 Blood protein levels; chr11:57499476 chr11:57528085~57528365:- CESC cis rs5769707 0.554 rs10854876 ENSG00000188511.11 C22orf34 5.06 8.89e-07 7e-04 0.38 0.32 Monocyte percentage of white cells;Monocyte count; chr22:49616922 chr22:49414524~49657542:- CESC cis rs6504622 0.755 rs12938690 ENSG00000262879.4 RP11-156P1.3 -5.06 8.9e-07 7e-04 -0.35 -0.32 Orofacial clefts; chr17:46997999 chr17:46984045~47100323:- CESC cis rs6723162 1 rs6723162 ENSG00000237751.2 LINC01143 -5.06 8.9e-07 0.000701 -0.4 -0.32 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70875156 chr2:70887871~70889959:+ CESC cis rs62229266 0.563 rs6517325 ENSG00000231106.2 LINC01436 5.06 8.91e-07 0.000701 0.45 0.32 Mitral valve prolapse; chr21:36062680 chr21:36005338~36007838:+ CESC cis rs875971 0.862 rs13232191 ENSG00000232559.3 GS1-124K5.12 5.06 8.91e-07 0.000701 0.36 0.32 Aortic root size; chr7:66521661 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs35378740 ENSG00000232559.3 GS1-124K5.12 5.06 8.91e-07 0.000701 0.36 0.32 Aortic root size; chr7:66522725 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10950043 ENSG00000232559.3 GS1-124K5.12 5.06 8.91e-07 0.000701 0.36 0.32 Aortic root size; chr7:66523623 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs17747530 ENSG00000232559.3 GS1-124K5.12 5.06 8.91e-07 0.000701 0.36 0.32 Aortic root size; chr7:66529742 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs13226170 ENSG00000232559.3 GS1-124K5.12 5.06 8.91e-07 0.000701 0.36 0.32 Aortic root size; chr7:66534311 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs2420611 ENSG00000232559.3 GS1-124K5.12 5.06 8.91e-07 0.000701 0.36 0.32 Aortic root size; chr7:66534333 chr7:66554588~66576923:- CESC cis rs875971 0.767 rs61348003 ENSG00000232559.3 GS1-124K5.12 5.06 8.91e-07 0.000701 0.36 0.32 Aortic root size; chr7:66540947 chr7:66554588~66576923:- CESC cis rs875971 0.861 rs801215 ENSG00000232559.3 GS1-124K5.12 -5.06 8.91e-07 0.000701 -0.36 -0.32 Aortic root size; chr7:66546951 chr7:66554588~66576923:- CESC cis rs5758659 1 rs134882 ENSG00000273366.1 CTA-989H11.1 -5.06 8.95e-07 0.000703 -0.39 -0.32 Cognitive function; chr22:42274959 chr22:42278188~42278846:+ CESC cis rs4722166 0.573 rs35436671 ENSG00000179428.2 AC073072.5 -5.06 8.95e-07 0.000704 -0.46 -0.32 Lung cancer; chr7:22735889 chr7:22725395~22727620:- CESC cis rs9549367 0.789 rs3794422 ENSG00000269125.1 RP11-98F14.11 -5.06 8.96e-07 0.000704 -0.46 -0.32 Platelet distribution width; chr13:113239415 chr13:113165002~113165183:- CESC cis rs2028299 0.879 rs3803534 ENSG00000259677.1 RP11-493E3.1 5.06 8.97e-07 0.000705 0.46 0.32 Type 2 diabetes; chr15:89898638 chr15:89876540~89877285:+ CESC cis rs11723261 0.582 rs11732336 ENSG00000211553.1 AC253576.2 -5.06 8.97e-07 0.000705 -0.47 -0.32 Immune response to smallpox vaccine (IL-6); chr4:146728 chr4:136461~136568:+ CESC cis rs10875746 0.669 rs11168510 ENSG00000240399.1 RP1-228P16.1 -5.06 9e-07 0.000707 -0.42 -0.32 Longevity (90 years and older); chr12:48291772 chr12:48054813~48055591:- CESC cis rs72627509 0.904 rs7687767 ENSG00000269949.1 RP11-738E22.3 -5.06 9e-07 0.000707 -0.47 -0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56958766 chr4:56960927~56961373:- CESC cis rs10129255 0.642 rs11624918 ENSG00000223648.3 IGHV3-64 5.06 9e-07 0.000707 0.28 0.32 Kawasaki disease; chr14:106664672 chr14:106643132~106658258:- CESC cis rs2412819 0.571 rs7174260 ENSG00000249839.1 AC011330.5 -5.06 9.01e-07 0.000708 -0.47 -0.32 Lung cancer; chr15:43751988 chr15:43663654~43684339:- CESC cis rs5769707 0.616 rs6009786 ENSG00000235111.1 RP1-29C18.8 -5.06 9.03e-07 0.000709 -0.37 -0.32 Monocyte percentage of white cells;Monocyte count; chr22:49621497 chr22:49612657~49615716:- CESC cis rs875971 0.545 rs73136346 ENSG00000237310.1 GS1-124K5.4 -5.06 9.04e-07 0.00071 -0.36 -0.32 Aortic root size; chr7:66101095 chr7:66493706~66495474:+ CESC cis rs4718428 0.705 rs12698547 ENSG00000273142.1 RP11-458F8.4 -5.06 9.04e-07 0.00071 -0.35 -0.32 Corneal structure; chr7:66813271 chr7:66902857~66906297:+ CESC cis rs2015599 0.601 rs17715086 ENSG00000275476.1 RP11-996F15.4 -5.06 9.04e-07 0.00071 -0.37 -0.32 Platelet count;Mean platelet volume; chr12:29329073 chr12:29277397~29277882:- CESC cis rs8059260 0.877 rs111352543 ENSG00000274038.1 RP11-66H6.4 -5.06 9.05e-07 0.00071 -0.49 -0.32 Alcohol consumption over the past year; chr16:10949603 chr16:11056556~11057034:+ CESC cis rs17507216 1 rs3850610 ENSG00000276710.3 CSPG4P8 5.06 9.05e-07 0.00071 0.42 0.32 Excessive daytime sleepiness; chr15:82552642 chr15:82459472~82477258:+ CESC cis rs4141404 0.604 rs2103853 ENSG00000236132.1 CTA-440B3.1 -5.06 9.06e-07 0.000711 -0.38 -0.32 Paclitaxel-induced neuropathy; chr22:31459489 chr22:31816379~31817491:- CESC cis rs9322193 0.566 rs12528243 ENSG00000231760.4 RP11-350J20.5 5.06 9.06e-07 0.000711 0.49 0.32 Lung cancer; chr6:149898491 chr6:149796151~149826294:- CESC cis rs875971 0.545 rs35459055 ENSG00000222364.1 RNU6-96P -5.06 9.07e-07 0.000712 -0.43 -0.32 Aortic root size; chr7:66479399 chr7:66395191~66395286:+ CESC cis rs748404 0.631 rs8042688 ENSG00000249839.1 AC011330.5 -5.06 9.08e-07 0.000713 -0.34 -0.32 Lung cancer; chr15:43346327 chr15:43663654~43684339:- CESC cis rs875971 0.862 rs11984115 ENSG00000222364.1 RNU6-96P 5.06 9.08e-07 0.000713 0.37 0.32 Aortic root size; chr7:66308872 chr7:66395191~66395286:+ CESC cis rs2412819 0.545 rs17795279 ENSG00000249839.1 AC011330.5 5.06 9.1e-07 0.000714 0.46 0.32 Lung cancer; chr15:43637180 chr15:43663654~43684339:- CESC cis rs9322193 0.962 rs9505974 ENSG00000216906.2 RP11-350J20.9 5.05 9.13e-07 0.000716 0.35 0.32 Lung cancer; chr6:149779294 chr6:149904243~149906418:+ CESC cis rs9322193 0.926 rs9689036 ENSG00000216906.2 RP11-350J20.9 5.05 9.13e-07 0.000716 0.35 0.32 Lung cancer; chr6:149780563 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9322218 ENSG00000216906.2 RP11-350J20.9 5.05 9.13e-07 0.000716 0.35 0.32 Lung cancer; chr6:149782183 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9322219 ENSG00000216906.2 RP11-350J20.9 5.05 9.13e-07 0.000716 0.35 0.32 Lung cancer; chr6:149782263 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9322223 ENSG00000216906.2 RP11-350J20.9 5.05 9.13e-07 0.000716 0.35 0.32 Lung cancer; chr6:149801509 chr6:149904243~149906418:+ CESC cis rs860295 0.702 rs10908470 ENSG00000225855.5 RUSC1-AS1 5.05 9.13e-07 0.000716 0.28 0.32 Body mass index; chr1:155557222 chr1:155316863~155324176:- CESC cis rs875971 0.862 rs6952182 ENSG00000237310.1 GS1-124K5.4 -5.05 9.15e-07 0.000717 -0.31 -0.32 Aortic root size; chr7:66218330 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6964437 ENSG00000237310.1 GS1-124K5.4 -5.05 9.15e-07 0.000717 -0.31 -0.32 Aortic root size; chr7:66221457 chr7:66493706~66495474:+ CESC cis rs11155671 0.53 rs9371215 ENSG00000223701.3 RAET1E-AS1 5.05 9.16e-07 0.000717 0.37 0.32 Testicular germ cell tumor; chr6:149873162 chr6:149884431~149919508:+ CESC cis rs2337406 1 rs17113331 ENSG00000211974.3 IGHV2-70 -5.05 9.17e-07 0.000718 -0.51 -0.32 Alzheimer's disease (late onset); chr14:106703843 chr14:106723574~106724093:- CESC cis rs4423214 0.879 rs736894 ENSG00000254682.1 RP11-660L16.2 5.05 9.18e-07 0.000719 0.43 0.32 Vitamin D levels; chr11:71441212 chr11:71448674~71452157:+ CESC cis rs453301 0.682 rs2929451 ENSG00000173295.6 FAM86B3P 5.05 9.18e-07 0.000719 0.39 0.32 Joint mobility (Beighton score); chr8:9227785 chr8:8228595~8244865:+ CESC cis rs875971 0.862 rs13536 ENSG00000232559.3 GS1-124K5.12 -5.05 9.19e-07 0.000719 -0.35 -0.32 Aortic root size; chr7:66554203 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs801209 ENSG00000232559.3 GS1-124K5.12 -5.05 9.19e-07 0.000719 -0.35 -0.32 Aortic root size; chr7:66554403 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs801206 ENSG00000232559.3 GS1-124K5.12 -5.05 9.19e-07 0.000719 -0.35 -0.32 Aortic root size; chr7:66556979 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs801204 ENSG00000232559.3 GS1-124K5.12 -5.05 9.19e-07 0.000719 -0.35 -0.32 Aortic root size; chr7:66557934 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs801203 ENSG00000232559.3 GS1-124K5.12 -5.05 9.19e-07 0.000719 -0.35 -0.32 Aortic root size; chr7:66558025 chr7:66554588~66576923:- CESC cis rs875971 0.825 rs801202 ENSG00000232559.3 GS1-124K5.12 -5.05 9.19e-07 0.000719 -0.35 -0.32 Aortic root size; chr7:66558942 chr7:66554588~66576923:- CESC cis rs10875746 0.729 rs11168357 ENSG00000240399.1 RP1-228P16.1 -5.05 9.2e-07 0.00072 -0.4 -0.32 Longevity (90 years and older); chr12:48018355 chr12:48054813~48055591:- CESC cis rs11155671 0.53 rs4869763 ENSG00000223701.3 RAET1E-AS1 5.05 9.21e-07 0.00072 0.36 0.32 Testicular germ cell tumor; chr6:149890548 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs9968871 ENSG00000223701.3 RAET1E-AS1 5.05 9.21e-07 0.000721 0.36 0.32 Testicular germ cell tumor; chr6:149888060 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs9969044 ENSG00000223701.3 RAET1E-AS1 5.05 9.21e-07 0.000721 0.36 0.32 Testicular germ cell tumor; chr6:149888068 chr6:149884431~149919508:+ CESC cis rs748404 0.631 rs11070399 ENSG00000249839.1 AC011330.5 -5.05 9.21e-07 0.000721 -0.35 -0.32 Lung cancer; chr15:43354149 chr15:43663654~43684339:- CESC cis rs2433610 1 rs2433610 ENSG00000259479.5 SORD2P 5.05 9.22e-07 0.000721 0.76 0.32 Serum metabolite levels; chr15:45393893 chr15:44826371~44884694:- CESC cis rs2015599 0.549 rs7956305 ENSG00000275476.1 RP11-996F15.4 5.05 9.22e-07 0.000721 0.37 0.32 Platelet count;Mean platelet volume; chr12:29308639 chr12:29277397~29277882:- CESC cis rs2015599 0.543 rs6487807 ENSG00000275476.1 RP11-996F15.4 5.05 9.22e-07 0.000721 0.37 0.32 Platelet count;Mean platelet volume; chr12:29309291 chr12:29277397~29277882:- CESC cis rs11846409 0.789 rs34917868 ENSG00000211974.3 IGHV2-70 -5.05 9.22e-07 0.000721 -0.46 -0.32 Rheumatic heart disease; chr14:106618321 chr14:106723574~106724093:- CESC cis rs7951870 1 rs7951579 ENSG00000247675.5 LRP4-AS1 -5.05 9.22e-07 0.000721 -0.38 -0.32 Schizophrenia; chr11:46448350 chr11:46846412~46874396:+ CESC cis rs42490 1 rs13252917 ENSG00000251136.7 RP11-37B2.1 -5.05 9.23e-07 0.000722 -0.33 -0.32 Leprosy; chr8:89747202 chr8:89609409~89757727:- CESC cis rs42490 1 rs6470366 ENSG00000251136.7 RP11-37B2.1 -5.05 9.23e-07 0.000722 -0.33 -0.32 Leprosy; chr8:89747760 chr8:89609409~89757727:- CESC cis rs42490 1 rs10112852 ENSG00000251136.7 RP11-37B2.1 -5.05 9.23e-07 0.000722 -0.33 -0.32 Leprosy; chr8:89749257 chr8:89609409~89757727:- CESC cis rs42490 0.934 rs10095743 ENSG00000251136.7 RP11-37B2.1 -5.05 9.23e-07 0.000722 -0.33 -0.32 Leprosy; chr8:89749445 chr8:89609409~89757727:- CESC cis rs9322193 0.923 rs10872644 ENSG00000268592.3 RAET1E-AS1 5.05 9.24e-07 0.000722 0.42 0.32 Lung cancer; chr6:149741819 chr6:149863494~149919507:+ CESC cis rs2283792 0.745 rs5756306 ENSG00000224086.5 LL22NC03-86G7.1 5.05 9.27e-07 0.000725 0.36 0.32 Multiple sclerosis; chr22:21978846 chr22:21938293~21977632:+ CESC cis rs2243480 1 rs316329 ENSG00000275400.1 RP4-756H11.5 5.05 9.27e-07 0.000725 0.57 0.32 Diabetic kidney disease; chr7:66143429 chr7:66553805~66554199:- CESC cis rs950880 0.645 rs11679889 ENSG00000234389.1 AC007278.3 -5.05 9.3e-07 0.000727 -0.37 -0.32 Serum protein levels (sST2); chr2:102324549 chr2:102438713~102440475:+ CESC cis rs1799949 0.965 rs4793233 ENSG00000267681.1 CTD-3199J23.6 -5.05 9.31e-07 0.000727 -0.43 -0.32 Menopause (age at onset); chr17:43358069 chr17:43144956~43145255:+ CESC cis rs1799949 0.864 rs60309406 ENSG00000267681.1 CTD-3199J23.6 -5.05 9.31e-07 0.000727 -0.43 -0.32 Menopause (age at onset); chr17:43358297 chr17:43144956~43145255:+ CESC cis rs9322193 0.923 rs1572229 ENSG00000268592.3 RAET1E-AS1 5.05 9.32e-07 0.000728 0.42 0.32 Lung cancer; chr6:149743841 chr6:149863494~149919507:+ CESC cis rs860295 0.702 rs12067371 ENSG00000225855.5 RUSC1-AS1 5.05 9.32e-07 0.000728 0.26 0.32 Body mass index; chr1:155467878 chr1:155316863~155324176:- CESC cis rs17507216 1 rs17158413 ENSG00000276710.3 CSPG4P8 -5.05 9.33e-07 0.000729 -0.44 -0.32 Excessive daytime sleepiness; chr15:82566658 chr15:82459472~82477258:+ CESC cis rs2243480 1 rs10247526 ENSG00000275400.1 RP4-756H11.5 -5.05 9.33e-07 0.000729 -0.56 -0.32 Diabetic kidney disease; chr7:66315709 chr7:66553805~66554199:- CESC cis rs9987353 0.544 rs2929469 ENSG00000253893.2 FAM85B -5.05 9.34e-07 0.000729 -0.43 -0.32 Recombination measurement; chr8:9205146 chr8:8167819~8226614:- CESC cis rs6142102 0.962 rs2206448 ENSG00000276073.1 RP5-1125A11.7 -5.05 9.35e-07 0.000729 -0.31 -0.32 Skin pigmentation; chr20:34121719 chr20:33985617~33988989:- CESC cis rs875971 0.83 rs427575 ENSG00000237310.1 GS1-124K5.4 5.05 9.36e-07 0.000731 0.31 0.32 Aortic root size; chr7:66054232 chr7:66493706~66495474:+ CESC cis rs7188445 0.899 rs58722186 ENSG00000261390.4 RP11-345M22.2 -5.05 9.37e-07 0.000731 -0.43 -0.32 Urate levels; chr16:79717694 chr16:79715232~79770563:- CESC cis rs11779988 0.543 rs379066 ENSG00000253671.1 RP11-806O11.1 -5.05 9.38e-07 0.000732 -0.36 -0.32 Breast cancer; chr8:18024326 chr8:17808941~17820868:+ CESC cis rs6860806 0.507 rs169256 ENSG00000233006.5 AC034220.3 5.05 9.38e-07 0.000732 0.43 0.32 Breast cancer; chr5:132352840 chr5:132311285~132369916:- CESC cis rs9322193 0.923 rs66516768 ENSG00000268592.3 RAET1E-AS1 5.05 9.4e-07 0.000734 0.42 0.32 Lung cancer; chr6:149671999 chr6:149863494~149919507:+ CESC cis rs875971 0.862 rs801195 ENSG00000232559.3 GS1-124K5.12 -5.05 9.42e-07 0.000735 -0.35 -0.32 Aortic root size; chr7:66561128 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs801194 ENSG00000232559.3 GS1-124K5.12 -5.05 9.42e-07 0.000735 -0.35 -0.32 Aortic root size; chr7:66563508 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs2024192 ENSG00000232559.3 GS1-124K5.12 -5.05 9.42e-07 0.000735 -0.35 -0.32 Aortic root size; chr7:66576460 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6955837 ENSG00000232559.3 GS1-124K5.12 -5.05 9.42e-07 0.000735 -0.35 -0.32 Aortic root size; chr7:66578155 chr7:66554588~66576923:- CESC cis rs875971 0.825 rs10281499 ENSG00000232559.3 GS1-124K5.12 -5.05 9.42e-07 0.000735 -0.35 -0.32 Aortic root size; chr7:66583979 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs4718377 ENSG00000232559.3 GS1-124K5.12 -5.05 9.42e-07 0.000735 -0.35 -0.32 Aortic root size; chr7:66584691 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10278014 ENSG00000232559.3 GS1-124K5.12 -5.05 9.42e-07 0.000735 -0.35 -0.32 Aortic root size; chr7:66586277 chr7:66554588~66576923:- CESC cis rs875971 0.545 rs1796217 ENSG00000237310.1 GS1-124K5.4 -5.05 9.42e-07 0.000735 -0.35 -0.32 Aortic root size; chr7:66620931 chr7:66493706~66495474:+ CESC cis rs9907295 0.688 rs4796135 ENSG00000270977.1 AC015849.16 -5.05 9.44e-07 0.000736 -0.44 -0.32 Fibroblast growth factor basic levels; chr17:35924236 chr17:35893707~35911023:- CESC cis rs9907295 0.688 rs4796136 ENSG00000270977.1 AC015849.16 -5.05 9.44e-07 0.000736 -0.44 -0.32 Fibroblast growth factor basic levels; chr17:35924397 chr17:35893707~35911023:- CESC cis rs9907295 0.688 rs4796137 ENSG00000270977.1 AC015849.16 -5.05 9.44e-07 0.000736 -0.44 -0.32 Fibroblast growth factor basic levels; chr17:35924448 chr17:35893707~35911023:- CESC cis rs2833693 0.572 rs9982765 ENSG00000261610.1 AP000265.1 5.05 9.44e-07 0.000736 0.39 0.32 Temperament; chr21:32204315 chr21:32259804~32261585:- CESC cis rs7189233 0.55 rs9938788 ENSG00000279344.1 RP11-44F14.7 5.05 9.45e-07 0.000737 0.3 0.32 Intelligence (multi-trait analysis); chr16:53447510 chr16:53478957~53481550:- CESC cis rs875971 0.545 rs1638724 ENSG00000222364.1 RNU6-96P 5.05 9.46e-07 0.000738 0.43 0.32 Aortic root size; chr7:66575494 chr7:66395191~66395286:+ CESC cis rs2243480 1 rs313803 ENSG00000228409.4 CCT6P1 5.05 9.47e-07 0.000738 0.47 0.32 Diabetic kidney disease; chr7:66049744 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs313802 ENSG00000228409.4 CCT6P1 5.05 9.47e-07 0.000738 0.47 0.32 Diabetic kidney disease; chr7:66051386 chr7:65751142~65763354:+ CESC cis rs2243480 0.803 rs403089 ENSG00000228409.4 CCT6P1 5.05 9.47e-07 0.000738 0.47 0.32 Diabetic kidney disease; chr7:66052736 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs458291 ENSG00000228409.4 CCT6P1 5.05 9.47e-07 0.000738 0.47 0.32 Diabetic kidney disease; chr7:66055492 chr7:65751142~65763354:+ CESC cis rs875971 0.545 rs73148639 ENSG00000222364.1 RNU6-96P -5.05 9.48e-07 0.000739 -0.43 -0.32 Aortic root size; chr7:66390342 chr7:66395191~66395286:+ CESC cis rs13108904 0.901 rs2293634 ENSG00000254094.1 AC078852.1 -5.05 9.49e-07 0.00074 -0.39 -0.32 Obesity-related traits; chr4:1297923 chr4:1356581~1358075:+ CESC cis rs2842992 0.789 rs7758895 ENSG00000237927.1 RP3-393E18.2 -5.05 9.49e-07 0.00074 -0.43 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159772433 chr6:159586955~159589169:- CESC cis rs2842992 0.789 rs4276525 ENSG00000237927.1 RP3-393E18.2 -5.05 9.49e-07 0.00074 -0.43 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159772580 chr6:159586955~159589169:- CESC cis rs2836950 0.509 rs11088466 ENSG00000232608.1 TIMM9P2 5.05 9.5e-07 0.000741 0.36 0.32 Menarche (age at onset); chr21:39208091 chr21:39216624~39217506:+ CESC cis rs2243480 1 rs316304 ENSG00000275400.1 RP4-756H11.5 5.05 9.51e-07 0.000741 0.55 0.32 Diabetic kidney disease; chr7:66151907 chr7:66553805~66554199:- CESC cis rs9549367 0.789 rs12584008 ENSG00000269125.1 RP11-98F14.11 -5.05 9.52e-07 0.000741 -0.44 -0.32 Platelet distribution width; chr13:113226914 chr13:113165002~113165183:- CESC cis rs875971 0.83 rs778711 ENSG00000232559.3 GS1-124K5.12 5.05 9.52e-07 0.000741 0.35 0.32 Aortic root size; chr7:66386670 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs1083554 ENSG00000232559.3 GS1-124K5.12 5.05 9.52e-07 0.000741 0.35 0.32 Aortic root size; chr7:66387354 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs778707 ENSG00000232559.3 GS1-124K5.12 5.05 9.52e-07 0.000741 0.35 0.32 Aortic root size; chr7:66392040 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs778705 ENSG00000232559.3 GS1-124K5.12 5.05 9.52e-07 0.000741 0.35 0.32 Aortic root size; chr7:66396128 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs778697 ENSG00000232559.3 GS1-124K5.12 5.05 9.52e-07 0.000741 0.35 0.32 Aortic root size; chr7:66405439 chr7:66554588~66576923:- CESC cis rs875971 0.798 rs7789615 ENSG00000232559.3 GS1-124K5.12 5.05 9.52e-07 0.000741 0.35 0.32 Aortic root size; chr7:66413674 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6978028 ENSG00000232559.3 GS1-124K5.12 5.05 9.52e-07 0.000741 0.35 0.32 Aortic root size; chr7:66421313 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6947339 ENSG00000232559.3 GS1-124K5.12 5.05 9.52e-07 0.000741 0.35 0.32 Aortic root size; chr7:66423483 chr7:66554588~66576923:- CESC cis rs453301 0.686 rs3989373 ENSG00000173295.6 FAM86B3P -5.05 9.54e-07 0.000743 -0.4 -0.32 Joint mobility (Beighton score); chr8:9053798 chr8:8228595~8244865:+ CESC cis rs10129255 1 rs10129407 ENSG00000211970.3 IGHV4-61 -5.05 9.54e-07 0.000743 -0.26 -0.32 Kawasaki disease; chr14:106767956 chr14:106639119~106639657:- CESC cis rs748404 0.631 rs7166812 ENSG00000249839.1 AC011330.5 -5.04 9.55e-07 0.000743 -0.35 -0.32 Lung cancer; chr15:43352562 chr15:43663654~43684339:- CESC cis rs7188445 0.932 rs17767742 ENSG00000261390.4 RP11-345M22.2 -5.04 9.57e-07 0.000744 -0.41 -0.32 Urate levels; chr16:79715108 chr16:79715232~79770563:- CESC cis rs2404602 0.716 rs8030411 ENSG00000259422.1 RP11-593F23.1 5.04 9.57e-07 0.000745 0.36 0.32 Blood metabolite levels; chr15:76407514 chr15:76174891~76181486:- CESC cis rs9584850 0.794 rs17574433 ENSG00000231194.1 FARP1-AS1 -5.04 9.57e-07 0.000745 -0.41 -0.32 Neuroticism; chr13:98485803 chr13:98435405~98435840:- CESC cis rs4722166 0.508 rs2069832 ENSG00000179428.2 AC073072.5 -5.04 9.58e-07 0.000745 -0.45 -0.32 Lung cancer; chr7:22727814 chr7:22725395~22727620:- CESC cis rs1800795 0.901 rs2069833 ENSG00000179428.2 AC073072.5 -5.04 9.58e-07 0.000745 -0.45 -0.32 Cerebrospinal fluid clusterin levels in APOEe4- carriers; chr7:22728045 chr7:22725395~22727620:- CESC cis rs9549367 0.762 rs9549694 ENSG00000269125.1 RP11-98F14.11 -5.04 9.58e-07 0.000745 -0.43 -0.32 Platelet distribution width; chr13:113216196 chr13:113165002~113165183:- CESC cis rs13108904 0.65 rs3796618 ENSG00000254094.1 AC078852.1 -5.04 9.59e-07 0.000746 -0.4 -0.32 Obesity-related traits; chr4:1355814 chr4:1356581~1358075:+ CESC cis rs14027 0.512 rs6997976 ENSG00000279347.1 RP11-85I17.2 5.04 9.59e-07 0.000746 0.31 0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119722044 chr8:119838736~119840385:- CESC cis rs7572733 0.935 rs10198606 ENSG00000222017.1 AC011997.1 -5.04 9.6e-07 0.000747 -0.35 -0.32 Dermatomyositis; chr2:197905015 chr2:197693106~197774823:+ CESC cis rs4819052 0.851 rs914214 ENSG00000223768.1 LINC00205 -5.04 9.61e-07 0.000747 -0.38 -0.32 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45277905 chr21:45293285~45297354:+ CESC cis rs1061377 1 rs13182 ENSG00000249685.1 RP11-360F5.3 5.04 9.63e-07 0.000749 0.38 0.32 Uric acid levels; chr4:39121293 chr4:39133913~39135608:+ CESC cis rs860295 0.665 rs12079134 ENSG00000225855.5 RUSC1-AS1 5.04 9.63e-07 0.000749 0.26 0.32 Body mass index; chr1:155496993 chr1:155316863~155324176:- CESC cis rs860295 0.702 rs11264380 ENSG00000225855.5 RUSC1-AS1 5.04 9.63e-07 0.000749 0.26 0.32 Body mass index; chr1:155550353 chr1:155316863~155324176:- CESC cis rs9549367 0.713 rs9549682 ENSG00000269125.1 RP11-98F14.11 -5.04 9.66e-07 0.00075 -0.47 -0.32 Platelet distribution width; chr13:113175867 chr13:113165002~113165183:- CESC cis rs9322193 0.884 rs10872646 ENSG00000268592.3 RAET1E-AS1 5.04 9.67e-07 0.000751 0.42 0.32 Lung cancer; chr6:149746539 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs12528279 ENSG00000268592.3 RAET1E-AS1 5.04 9.67e-07 0.000751 0.42 0.32 Lung cancer; chr6:149750892 chr6:149863494~149919507:+ CESC cis rs9322193 0.809 rs9479808 ENSG00000268592.3 RAET1E-AS1 5.04 9.67e-07 0.000751 0.42 0.32 Lung cancer; chr6:149751328 chr6:149863494~149919507:+ CESC cis rs1799949 0.965 rs35521261 ENSG00000267681.1 CTD-3199J23.6 -5.04 9.67e-07 0.000751 -0.42 -0.32 Menopause (age at onset); chr17:43161595 chr17:43144956~43145255:+ CESC cis rs2028299 0.879 rs4932262 ENSG00000259677.1 RP11-493E3.1 5.04 9.67e-07 0.000751 0.45 0.32 Type 2 diabetes; chr15:89896365 chr15:89876540~89877285:+ CESC cis rs2028299 0.879 rs4932263 ENSG00000259677.1 RP11-493E3.1 5.04 9.67e-07 0.000751 0.45 0.32 Type 2 diabetes; chr15:89896395 chr15:89876540~89877285:+ CESC cis rs2015599 0.623 rs10843385 ENSG00000275476.1 RP11-996F15.4 -5.04 9.68e-07 0.000751 -0.37 -0.32 Platelet count;Mean platelet volume; chr12:29323100 chr12:29277397~29277882:- CESC cis rs783540 0.521 rs1259176 ENSG00000276710.3 CSPG4P8 5.04 9.7e-07 0.000753 0.36 0.32 Schizophrenia; chr15:82602149 chr15:82459472~82477258:+ CESC cis rs4266144 1 rs4266144 ENSG00000244515.1 KRT18P34 -5.04 9.7e-07 0.000753 -0.38 -0.32 Coronary artery disease; chr3:157134803 chr3:157162663~157163932:- CESC cis rs2404602 0.692 rs35557205 ENSG00000259422.1 RP11-593F23.1 5.04 9.71e-07 0.000754 0.37 0.32 Blood metabolite levels; chr15:76838370 chr15:76174891~76181486:- CESC cis rs950169 0.526 rs698620 ENSG00000225151.9 GOLGA2P7 5.04 9.73e-07 0.000755 0.36 0.32 Schizophrenia; chr15:84633977 chr15:84199311~84230136:- CESC cis rs4423214 0.592 rs10898211 ENSG00000254682.1 RP11-660L16.2 -5.04 9.76e-07 0.000757 -0.47 -0.32 Vitamin D levels; chr11:71499631 chr11:71448674~71452157:+ CESC cis rs10262624 1 rs2390847 ENSG00000234286.1 AC006026.13 -5.04 9.78e-07 0.000759 -0.34 -0.32 Schizophrenia; chr7:23872082 chr7:23680195~23680786:- CESC cis rs10262624 1 rs2023786 ENSG00000234286.1 AC006026.13 -5.04 9.78e-07 0.000759 -0.34 -0.32 Schizophrenia; chr7:23875534 chr7:23680195~23680786:- CESC cis rs2732480 0.538 rs1387260 ENSG00000258273.1 RP11-370I10.4 -5.04 9.79e-07 0.000759 -0.4 -0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309308 chr12:48333755~48333901:- CESC cis rs6782228 0.527 rs7426806 ENSG00000242551.2 POU5F1P6 -5.04 9.79e-07 0.000759 -0.36 -0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694087 chr3:128674735~128677005:- CESC cis rs9549367 0.707 rs9549353 ENSG00000269125.1 RP11-98F14.11 -5.04 9.8e-07 0.00076 -0.47 -0.32 Platelet distribution width; chr13:113189113 chr13:113165002~113165183:- CESC cis rs9549367 0.713 rs9549356 ENSG00000269125.1 RP11-98F14.11 -5.04 9.8e-07 0.00076 -0.47 -0.32 Platelet distribution width; chr13:113197319 chr13:113165002~113165183:- CESC cis rs11723261 0.582 rs11248005 ENSG00000211553.1 AC253576.2 -5.04 9.8e-07 0.00076 -0.48 -0.32 Immune response to smallpox vaccine (IL-6); chr4:172826 chr4:136461~136568:+ CESC cis rs11723261 0.582 rs11733927 ENSG00000211553.1 AC253576.2 -5.04 9.8e-07 0.00076 -0.48 -0.32 Immune response to smallpox vaccine (IL-6); chr4:173039 chr4:136461~136568:+ CESC cis rs34779708 0.897 rs7900480 ENSG00000230534.5 RP11-297A16.2 -5.04 9.82e-07 0.000761 -0.43 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35049771 chr10:35098006~35127020:- CESC cis rs875971 0.862 rs6960446 ENSG00000237310.1 GS1-124K5.4 -5.04 9.83e-07 0.000762 -0.3 -0.32 Aortic root size; chr7:66268272 chr7:66493706~66495474:+ CESC cis rs875971 0.79 rs10257911 ENSG00000237310.1 GS1-124K5.4 -5.04 9.83e-07 0.000762 -0.3 -0.32 Aortic root size; chr7:66278783 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs7796162 ENSG00000237310.1 GS1-124K5.4 -5.04 9.83e-07 0.000762 -0.3 -0.32 Aortic root size; chr7:66280771 chr7:66493706~66495474:+ CESC cis rs2243480 1 rs316327 ENSG00000232559.3 GS1-124K5.12 -5.04 9.84e-07 0.000763 -0.55 -0.32 Diabetic kidney disease; chr7:66144214 chr7:66554588~66576923:- CESC cis rs9584850 0.834 rs7339274 ENSG00000231194.1 FARP1-AS1 -5.04 9.85e-07 0.000763 -0.39 -0.32 Neuroticism; chr13:98468018 chr13:98435405~98435840:- CESC cis rs433852 0.718 rs550455 ENSG00000232871.7 SEC1P -5.04 9.85e-07 0.000763 -0.37 -0.32 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48633258 chr19:48638071~48682245:+ CESC cis rs875971 0.895 rs12531677 ENSG00000222364.1 RNU6-96P 5.04 9.86e-07 0.000763 0.37 0.32 Aortic root size; chr7:66304099 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs7798630 ENSG00000222364.1 RNU6-96P 5.04 9.86e-07 0.000763 0.37 0.32 Aortic root size; chr7:66306492 chr7:66395191~66395286:+ CESC cis rs944797 0.52 rs7028268 ENSG00000215221.2 UBA52P6 5.04 9.86e-07 0.000764 0.41 0.32 Coronary heart disease; chr9:22048415 chr9:22012155~22012536:+ CESC cis rs1061377 1 rs6812540 ENSG00000249685.1 RP11-360F5.3 5.04 9.86e-07 0.000764 0.38 0.32 Uric acid levels; chr4:39114803 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs10026775 ENSG00000249685.1 RP11-360F5.3 5.04 9.86e-07 0.000764 0.38 0.32 Uric acid levels; chr4:39115155 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs3733276 ENSG00000249685.1 RP11-360F5.3 5.04 9.86e-07 0.000764 0.38 0.32 Uric acid levels; chr4:39115291 chr4:39133913~39135608:+ CESC cis rs3096299 0.967 rs2911256 ENSG00000274627.1 RP11-104N10.2 5.04 9.87e-07 0.000764 0.32 0.32 Multiple myeloma (IgH translocation); chr16:89418688 chr16:89516797~89522217:+ CESC cis rs42490 0.716 rs40638 ENSG00000251136.7 RP11-37B2.1 -5.04 9.87e-07 0.000765 -0.32 -0.32 Leprosy; chr8:89815824 chr8:89609409~89757727:- CESC cis rs9601248 0.838 rs6563121 ENSG00000227676.3 LINC01068 -5.04 9.89e-07 0.000766 -0.38 -0.32 Major depressive disorder; chr13:79600865 chr13:79566727~79571436:+ CESC cis rs2337406 0.866 rs74092512 ENSG00000274576.2 IGHV2-70 -5.04 9.9e-07 0.000767 -0.38 -0.32 Alzheimer's disease (late onset); chr14:106779306 chr14:106770577~106771020:- CESC cis rs2337406 0.789 rs74092514 ENSG00000274576.2 IGHV2-70 -5.04 9.9e-07 0.000767 -0.38 -0.32 Alzheimer's disease (late onset); chr14:106779385 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs74092520 ENSG00000274576.2 IGHV2-70 -5.04 9.9e-07 0.000767 -0.38 -0.32 Alzheimer's disease (late onset); chr14:106779632 chr14:106770577~106771020:- CESC cis rs1861353 0.863 rs16952252 ENSG00000279344.1 RP11-44F14.7 5.04 9.91e-07 0.000767 0.3 0.32 Intelligence (multi-trait analysis); chr16:53450068 chr16:53478957~53481550:- CESC cis rs10129255 0.957 rs6576233 ENSG00000211974.3 IGHV2-70 5.04 9.91e-07 0.000767 0.34 0.32 Kawasaki disease; chr14:106787239 chr14:106723574~106724093:- CESC cis rs494459 0.756 rs570806 ENSG00000255422.1 AP002954.4 -5.04 9.92e-07 0.000768 -0.38 -0.32 Height; chr11:118786602 chr11:118704607~118750263:+ CESC cis rs5758659 0.714 rs5758578 ENSG00000227370.1 RP4-669P10.19 5.04 9.92e-07 0.000768 0.34 0.32 Cognitive function; chr22:42094288 chr22:42132543~42132998:+ CESC cis rs34779708 0.931 rs35848945 ENSG00000230534.5 RP11-297A16.2 5.04 9.96e-07 0.000769 0.42 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34998633 chr10:35098006~35127020:- CESC cis rs11676348 0.791 rs4133195 ENSG00000261338.2 RP11-378A13.1 5.04 9.96e-07 0.000769 0.37 0.32 Ulcerative colitis; chr2:218086522 chr2:218255319~218257366:+ CESC cis rs1061377 1 rs9999327 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39110111 chr4:39133913~39135608:+ CESC cis rs1061377 0.965 rs6833654 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39110701 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs1036038 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39111383 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs1560396 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39112092 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs1560397 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39112265 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs2381285 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39112775 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs2163272 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39112790 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs2163273 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39112835 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs62310332 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39112939 chr4:39133913~39135608:+ CESC cis rs1061377 0.965 rs3796510 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39113309 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs10030904 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39113603 chr4:39133913~39135608:+ CESC cis rs1061377 0.932 rs6855118 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39114322 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs6829234 ENSG00000249685.1 RP11-360F5.3 5.04 9.96e-07 0.000769 0.38 0.32 Uric acid levels; chr4:39114586 chr4:39133913~39135608:+ CESC cis rs17507216 0.667 rs72753916 ENSG00000278603.1 RP13-608F4.5 5.04 9.96e-07 0.000769 0.49 0.32 Excessive daytime sleepiness; chr15:82684001 chr15:82472203~82472426:+ CESC cis rs10875746 0.669 rs61941003 ENSG00000240399.1 RP1-228P16.1 -5.04 9.96e-07 0.00077 -0.43 -0.32 Longevity (90 years and older); chr12:48225842 chr12:48054813~48055591:- CESC cis rs2243480 1 rs6964530 ENSG00000228409.4 CCT6P1 -5.04 9.96e-07 0.00077 -0.48 -0.32 Diabetic kidney disease; chr7:66253864 chr7:65751142~65763354:+ CESC cis rs12468226 0.938 rs80315897 ENSG00000273456.1 RP11-686O6.2 5.04 9.97e-07 0.00077 0.46 0.32 Urate levels; chr2:202318044 chr2:202374932~202375604:- CESC cis rs7520050 0.645 rs1768809 ENSG00000280836.1 AL355480.1 5.04 1e-06 0.000772 0.36 0.32 Reticulocyte count;Red blood cell count; chr1:46037164 chr1:45581219~45581321:- CESC cis rs67180937 0.961 rs17465637 ENSG00000272750.1 RP11-378J18.8 5.03 1e-06 0.000773 0.4 0.32 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222650187 chr1:222658867~222661512:- CESC cis rs42490 1 rs454441 ENSG00000251136.7 RP11-37B2.1 -5.03 1e-06 0.000773 -0.33 -0.32 Leprosy; chr8:89750842 chr8:89609409~89757727:- CESC cis rs42490 1 rs40246 ENSG00000251136.7 RP11-37B2.1 -5.03 1e-06 0.000773 -0.33 -0.32 Leprosy; chr8:89752944 chr8:89609409~89757727:- CESC cis rs1799949 1 rs1060915 ENSG00000267681.1 CTD-3199J23.6 -5.03 1e-06 0.000774 -0.42 -0.32 Menopause (age at onset); chr17:43082453 chr17:43144956~43145255:+ CESC cis rs7188445 0.932 rs73575076 ENSG00000261390.4 RP11-345M22.2 -5.03 1e-06 0.000775 -0.41 -0.32 Urate levels; chr16:79710251 chr16:79715232~79770563:- CESC cis rs7188445 0.932 rs17767383 ENSG00000261390.4 RP11-345M22.2 -5.03 1e-06 0.000775 -0.41 -0.32 Urate levels; chr16:79710504 chr16:79715232~79770563:- CESC cis rs11155671 0.53 rs7768626 ENSG00000223701.3 RAET1E-AS1 5.03 1e-06 0.000775 0.36 0.32 Testicular germ cell tumor; chr6:149886826 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs7768665 ENSG00000223701.3 RAET1E-AS1 5.03 1e-06 0.000775 0.36 0.32 Testicular germ cell tumor; chr6:149886888 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs7758020 ENSG00000223701.3 RAET1E-AS1 5.03 1e-06 0.000775 0.36 0.32 Testicular germ cell tumor; chr6:149886975 chr6:149884431~149919508:+ CESC cis rs860295 0.639 rs10908469 ENSG00000225855.5 RUSC1-AS1 5.03 1.01e-06 0.000776 0.27 0.32 Body mass index; chr1:155498941 chr1:155316863~155324176:- CESC cis rs2842992 0.789 rs4709370 ENSG00000237927.1 RP3-393E18.2 -5.03 1.01e-06 0.000777 -0.43 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159789029 chr6:159586955~159589169:- CESC cis rs10262624 0.967 rs35988560 ENSG00000234286.1 AC006026.13 -5.03 1.01e-06 0.000777 -0.34 -0.32 Schizophrenia; chr7:23878561 chr7:23680195~23680786:- CESC cis rs11155671 0.53 rs9322228 ENSG00000223701.3 RAET1E-AS1 5.03 1.01e-06 0.000778 0.36 0.32 Testicular germ cell tumor; chr6:149888173 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs7774787 ENSG00000223701.3 RAET1E-AS1 5.03 1.01e-06 0.000778 0.36 0.32 Testicular germ cell tumor; chr6:149888296 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs2342767 ENSG00000223701.3 RAET1E-AS1 5.03 1.01e-06 0.000778 0.36 0.32 Testicular germ cell tumor; chr6:149888581 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs7764376 ENSG00000223701.3 RAET1E-AS1 5.03 1.01e-06 0.000778 0.36 0.32 Testicular germ cell tumor; chr6:149889208 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs6933882 ENSG00000223701.3 RAET1E-AS1 5.03 1.01e-06 0.000778 0.36 0.32 Testicular germ cell tumor; chr6:149889666 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs6939761 ENSG00000223701.3 RAET1E-AS1 5.03 1.01e-06 0.000778 0.36 0.32 Testicular germ cell tumor; chr6:149889858 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs3823021 ENSG00000223701.3 RAET1E-AS1 5.03 1.01e-06 0.000778 0.36 0.32 Testicular germ cell tumor; chr6:149889863 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs4869764 ENSG00000223701.3 RAET1E-AS1 5.03 1.01e-06 0.000778 0.36 0.32 Testicular germ cell tumor; chr6:149890692 chr6:149884431~149919508:+ CESC cis rs2842992 0.83 rs2758312 ENSG00000237927.1 RP3-393E18.2 -5.03 1.01e-06 0.000779 -0.42 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159732420 chr6:159586955~159589169:- CESC cis rs2842992 0.872 rs2758315 ENSG00000237927.1 RP3-393E18.2 -5.03 1.01e-06 0.000779 -0.42 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159737608 chr6:159586955~159589169:- CESC cis rs10129255 1 rs10129255 ENSG00000211970.3 IGHV4-61 5.03 1.01e-06 0.000779 0.26 0.32 Kawasaki disease; chr14:106767970 chr14:106639119~106639657:- CESC cis rs5769707 0.667 rs4824069 ENSG00000188511.11 C22orf34 5.03 1.01e-06 0.000779 0.39 0.32 Monocyte percentage of white cells;Monocyte count; chr22:49636677 chr22:49414524~49657542:- CESC cis rs9601248 0.838 rs2783130 ENSG00000227676.3 LINC01068 -5.03 1.01e-06 0.00078 -0.36 -0.32 Major depressive disorder; chr13:79596025 chr13:79566727~79571436:+ CESC cis rs6142102 0.812 rs6059554 ENSG00000276073.1 RP5-1125A11.7 -5.03 1.01e-06 0.000781 -0.32 -0.32 Skin pigmentation; chr20:33926286 chr20:33985617~33988989:- CESC cis rs4722166 0.604 rs2390715 ENSG00000179428.2 AC073072.5 -5.03 1.01e-06 0.000781 -0.45 -0.32 Lung cancer; chr7:22744259 chr7:22725395~22727620:- CESC cis rs875971 0.862 rs778720 ENSG00000232559.3 GS1-124K5.12 -5.03 1.01e-06 0.000781 -0.34 -0.32 Aortic root size; chr7:66381288 chr7:66554588~66576923:- CESC cis rs9847710 0.67 rs2564933 ENSG00000242142.1 SERBP1P3 5.03 1.01e-06 0.000781 0.38 0.32 Ulcerative colitis; chr3:52989357 chr3:53064283~53065091:- CESC cis rs12439619 0.53 rs7162177 ENSG00000255769.6 GOLGA2P10 -5.03 1.01e-06 0.000782 -0.35 -0.32 Intelligence (multi-trait analysis); chr15:82181728 chr15:82472993~82513950:- CESC cis rs2980436 1 rs2980436 ENSG00000253893.2 FAM85B 5.03 1.01e-06 0.000782 0.45 0.32 Schizophrenia; chr8:8234503 chr8:8167819~8226614:- CESC cis rs9322193 0.887 rs11155662 ENSG00000268592.3 RAET1E-AS1 5.03 1.02e-06 0.000782 0.42 0.32 Lung cancer; chr6:149592731 chr6:149863494~149919507:+ CESC cis rs4974559 0.947 rs28711287 ENSG00000253399.1 AC078852.2 5.03 1.02e-06 0.000782 0.53 0.32 Systolic blood pressure; chr4:1352894 chr4:1358479~1359461:+ CESC cis rs42490 1 rs13252013 ENSG00000251136.7 RP11-37B2.1 -5.03 1.02e-06 0.000783 -0.33 -0.32 Leprosy; chr8:89746881 chr8:89609409~89757727:- CESC cis rs42490 1 rs13279023 ENSG00000251136.7 RP11-37B2.1 -5.03 1.02e-06 0.000783 -0.33 -0.32 Leprosy; chr8:89748816 chr8:89609409~89757727:- CESC cis rs875971 0.522 rs6960048 ENSG00000164669.11 INTS4P1 -5.03 1.02e-06 0.000783 -0.45 -0.32 Aortic root size; chr7:65943052 chr7:65141225~65234216:+ CESC cis rs6142102 0.923 rs4911383 ENSG00000276073.1 RP5-1125A11.7 -5.03 1.02e-06 0.000783 -0.32 -0.32 Skin pigmentation; chr20:33967973 chr20:33985617~33988989:- CESC cis rs2732480 0.5 rs2450989 ENSG00000258273.1 RP11-370I10.4 5.03 1.02e-06 0.000784 0.39 0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48259625 chr12:48333755~48333901:- CESC cis rs8062405 0.69 rs762634 ENSG00000259982.1 CDC37P1 5.03 1.02e-06 0.000784 0.42 0.32 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28592014 chr16:28700294~28701540:- CESC cis rs9549367 0.737 rs71446680 ENSG00000269125.1 RP11-98F14.11 -5.03 1.02e-06 0.000785 -0.46 -0.32 Platelet distribution width; chr13:113240532 chr13:113165002~113165183:- CESC cis rs875971 0.862 rs778736 ENSG00000237310.1 GS1-124K5.4 5.03 1.02e-06 0.000785 0.31 0.32 Aortic root size; chr7:66348861 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs2088655 ENSG00000237310.1 GS1-124K5.4 -5.03 1.02e-06 0.000785 -0.31 -0.32 Aortic root size; chr7:66330724 chr7:66493706~66495474:+ CESC cis rs875971 0.895 rs10447522 ENSG00000237310.1 GS1-124K5.4 -5.03 1.02e-06 0.000785 -0.31 -0.32 Aortic root size; chr7:66331087 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs2088653 ENSG00000237310.1 GS1-124K5.4 -5.03 1.02e-06 0.000785 -0.31 -0.32 Aortic root size; chr7:66343621 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6460293 ENSG00000237310.1 GS1-124K5.4 -5.03 1.02e-06 0.000785 -0.31 -0.32 Aortic root size; chr7:66345205 chr7:66493706~66495474:+ CESC cis rs875971 0.651 rs313829 ENSG00000164669.11 INTS4P1 5.03 1.02e-06 0.000786 0.45 0.32 Aortic root size; chr7:66087510 chr7:65141225~65234216:+ CESC cis rs748404 0.578 rs507178 ENSG00000249839.1 AC011330.5 -5.03 1.02e-06 0.000787 -0.34 -0.32 Lung cancer; chr15:43317937 chr15:43663654~43684339:- CESC cis rs748404 0.578 rs478028 ENSG00000249839.1 AC011330.5 -5.03 1.02e-06 0.000787 -0.34 -0.32 Lung cancer; chr15:43318574 chr15:43663654~43684339:- CESC cis rs748404 0.578 rs552701 ENSG00000249839.1 AC011330.5 -5.03 1.02e-06 0.000787 -0.34 -0.32 Lung cancer; chr15:43321612 chr15:43663654~43684339:- CESC cis rs748404 0.578 rs573615 ENSG00000249839.1 AC011330.5 -5.03 1.02e-06 0.000787 -0.34 -0.32 Lung cancer; chr15:43322083 chr15:43663654~43684339:- CESC cis rs748404 0.66 rs2439845 ENSG00000205771.5 CATSPER2P1 -5.03 1.02e-06 0.000787 -0.37 -0.32 Lung cancer; chr15:43430412 chr15:43726918~43747094:- CESC cis rs748404 0.631 rs2467745 ENSG00000205771.5 CATSPER2P1 -5.03 1.02e-06 0.000787 -0.37 -0.32 Lung cancer; chr15:43430544 chr15:43726918~43747094:- CESC cis rs2006771 0.74 rs8140312 ENSG00000236132.1 CTA-440B3.1 -5.03 1.02e-06 0.000787 -0.37 -0.32 Nonsyndromic cleft lip with cleft palate; chr22:31609608 chr22:31816379~31817491:- CESC cis rs1062177 0.855 rs6884630 ENSG00000213433.5 RPLP1P6 -5.03 1.02e-06 0.000787 -0.38 -0.32 Preschool internalizing problems; chr5:151889436 chr5:151765859~151766378:- CESC cis rs10510102 0.608 rs4752607 ENSG00000226864.1 ATE1-AS1 -5.03 1.03e-06 0.000789 -0.41 -0.32 Breast cancer; chr10:121835426 chr10:121928312~121951965:+ CESC cis rs832187 0.665 rs7627690 ENSG00000280620.1 SCAANT1 5.03 1.03e-06 0.00079 0.45 0.32 Schizophrenia; chr3:63914801 chr3:63911518~63911772:- CESC cis rs748404 0.66 rs690446 ENSG00000205771.5 CATSPER2P1 -5.03 1.03e-06 0.00079 -0.37 -0.32 Lung cancer; chr15:43469066 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs690472 ENSG00000205771.5 CATSPER2P1 -5.03 1.03e-06 0.00079 -0.37 -0.32 Lung cancer; chr15:43472170 chr15:43726918~43747094:- CESC cis rs748404 0.631 rs560191 ENSG00000205771.5 CATSPER2P1 -5.03 1.03e-06 0.00079 -0.37 -0.32 Lung cancer; chr15:43475576 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs2444251 ENSG00000205771.5 CATSPER2P1 -5.03 1.03e-06 0.00079 -0.37 -0.32 Lung cancer; chr15:43496397 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs548704 ENSG00000205771.5 CATSPER2P1 -5.03 1.03e-06 0.00079 -0.37 -0.32 Lung cancer; chr15:43499508 chr15:43726918~43747094:- CESC cis rs1185460 0.546 rs549893 ENSG00000271751.1 RP11-110I1.14 5.03 1.03e-06 0.000791 0.39 0.32 Coronary artery disease; chr11:119089022 chr11:119065263~119065677:- CESC cis rs2028299 0.879 rs28678152 ENSG00000259677.1 RP11-493E3.1 5.03 1.03e-06 0.000791 0.45 0.32 Type 2 diabetes; chr15:89906291 chr15:89876540~89877285:+ CESC cis rs17507216 0.958 rs28648832 ENSG00000276710.3 CSPG4P8 -5.03 1.03e-06 0.000792 -0.45 -0.32 Excessive daytime sleepiness; chr15:82567642 chr15:82459472~82477258:+ CESC cis rs832187 0.629 rs59971314 ENSG00000280620.1 SCAANT1 5.03 1.03e-06 0.000793 0.45 0.32 Schizophrenia; chr3:63928942 chr3:63911518~63911772:- CESC cis rs9309711 0.922 rs11679058 ENSG00000225234.1 TRAPPC12-AS1 -5.03 1.03e-06 0.000794 -0.33 -0.32 Neurofibrillary tangles; chr2:3480042 chr2:3481242~3482409:- CESC cis rs3823536 0.583 rs10279821 ENSG00000275106.1 RP11-309L24.10 -5.03 1.04e-06 0.000795 -0.45 -0.32 Sjögren's syndrome; chr7:129043493 chr7:128952527~128953316:- CESC cis rs11155671 0.53 rs4458704 ENSG00000223701.3 RAET1E-AS1 5.03 1.04e-06 0.000795 0.35 0.32 Testicular germ cell tumor; chr6:149911743 chr6:149884431~149919508:+ CESC cis rs2919917 1 rs2919917 ENSG00000254352.1 RP11-578O24.2 -5.03 1.04e-06 0.000796 -0.42 -0.32 Lymphocyte counts; chr8:78745028 chr8:78723796~78724136:- CESC cis rs7188445 0.932 rs17689159 ENSG00000261390.4 RP11-345M22.2 -5.03 1.04e-06 0.000798 -0.42 -0.32 Urate levels; chr16:79708493 chr16:79715232~79770563:- CESC cis rs116095464 0.558 rs28636067 ENSG00000250848.1 CTD-2083E4.5 -5.03 1.04e-06 0.000798 -0.46 -0.32 Breast cancer; chr5:199300 chr5:288833~290321:- CESC cis rs3829251 0.786 rs7103591 ENSG00000254682.1 RP11-660L16.2 -5.03 1.04e-06 0.000798 -0.46 -0.32 Vitamin D levels; chr11:71526573 chr11:71448674~71452157:+ CESC cis rs4722166 0.597 rs2069845 ENSG00000179428.2 AC073072.5 -5.03 1.04e-06 0.000798 -0.4 -0.32 Lung cancer; chr7:22730530 chr7:22725395~22727620:- CESC cis rs748404 0.66 rs693510 ENSG00000205771.5 CATSPER2P1 -5.03 1.04e-06 0.000799 -0.37 -0.32 Lung cancer; chr15:43422427 chr15:43726918~43747094:- CESC cis rs8067354 0.645 rs28516945 ENSG00000266701.1 AC005702.4 5.03 1.04e-06 8e-04 0.44 0.32 Hemoglobin concentration; chr17:59739217 chr17:60042546~60042627:- CESC cis rs9549367 0.774 rs2287246 ENSG00000269125.1 RP11-98F14.11 -5.03 1.05e-06 0.000802 -0.45 -0.32 Platelet distribution width; chr13:113234813 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs2287247 ENSG00000269125.1 RP11-98F14.11 -5.03 1.05e-06 0.000802 -0.45 -0.32 Platelet distribution width; chr13:113234898 chr13:113165002~113165183:- CESC cis rs763121 0.925 rs9611008 ENSG00000273076.1 RP3-508I15.22 5.03 1.05e-06 0.000802 0.36 0.32 Menopause (age at onset); chr22:38702782 chr22:38743495~38743910:+ CESC cis rs42490 0.934 rs218925 ENSG00000251136.7 RP11-37B2.1 -5.03 1.05e-06 0.000802 -0.32 -0.32 Leprosy; chr8:89737352 chr8:89609409~89757727:- CESC cis rs42490 0.966 rs2644033 ENSG00000251136.7 RP11-37B2.1 5.03 1.05e-06 0.000802 0.32 0.32 Leprosy; chr8:89739196 chr8:89609409~89757727:- CESC cis rs9918079 0.506 rs10214 ENSG00000273133.1 RP11-799M12.2 5.02 1.05e-06 0.000804 0.41 0.32 Obesity-related traits; chr4:15604808 chr4:15563698~15564253:- CESC cis rs875971 0.83 rs427973 ENSG00000237310.1 GS1-124K5.4 5.02 1.05e-06 0.000804 0.31 0.32 Aortic root size; chr7:66061661 chr7:66493706~66495474:+ CESC cis rs75422866 0.867 rs76100981 ENSG00000280054.1 RP1-197B17.7 5.02 1.05e-06 0.000804 0.76 0.32 Pneumonia; chr12:47660092 chr12:47728151~47730598:- CESC cis rs14027 0.64 rs28421406 ENSG00000279347.1 RP11-85I17.2 -5.02 1.05e-06 0.000806 -0.3 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119752249 chr8:119838736~119840385:- CESC cis rs14027 0.64 rs16893104 ENSG00000279347.1 RP11-85I17.2 -5.02 1.05e-06 0.000806 -0.3 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119754778 chr8:119838736~119840385:- CESC cis rs1499614 0.803 rs1796229 ENSG00000275400.1 RP4-756H11.5 5.02 1.05e-06 0.000807 0.56 0.32 Gout; chr7:66654674 chr7:66553805~66554199:- CESC cis rs1499614 0.901 rs3936 ENSG00000275400.1 RP4-756H11.5 5.02 1.05e-06 0.000807 0.56 0.32 Gout; chr7:66661502 chr7:66553805~66554199:- CESC cis rs765787 0.53 rs12439643 ENSG00000259520.4 CTD-2651B20.3 -5.02 1.05e-06 0.000807 -0.41 -0.32 Uric acid levels; chr15:45237569 chr15:45251580~45279251:- CESC cis rs36229146 1 rs36229146 ENSG00000179428.2 AC073072.5 -5.02 1.06e-06 0.000809 -0.46 -0.32 Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells; chr7:22744893 chr7:22725395~22727620:- CESC cis rs42490 1 rs218913 ENSG00000251136.7 RP11-37B2.1 -5.02 1.06e-06 0.000814 -0.32 -0.32 Leprosy; chr8:89732206 chr8:89609409~89757727:- CESC cis rs783540 0.542 rs62009945 ENSG00000255769.6 GOLGA2P10 5.02 1.06e-06 0.000814 0.39 0.32 Schizophrenia; chr15:82631205 chr15:82472993~82513950:- CESC cis rs763567 0.605 rs619456 ENSG00000271811.1 RP1-79C4.4 -5.02 1.07e-06 0.000816 -0.37 -0.32 Tonsillectomy; chr1:170616691 chr1:170667381~170669425:+ CESC cis rs897984 0.806 rs9319588 ENSG00000260911.2 RP11-196G11.2 -5.02 1.07e-06 0.000816 -0.35 -0.32 Dementia with Lewy bodies; chr16:30919662 chr16:31043150~31049868:+ CESC cis rs897984 0.77 rs12930657 ENSG00000260911.2 RP11-196G11.2 -5.02 1.07e-06 0.000816 -0.35 -0.32 Dementia with Lewy bodies; chr16:30920647 chr16:31043150~31049868:+ CESC cis rs897984 0.77 rs3813020 ENSG00000260911.2 RP11-196G11.2 -5.02 1.07e-06 0.000816 -0.35 -0.32 Dementia with Lewy bodies; chr16:30922754 chr16:31043150~31049868:+ CESC cis rs42490 0.934 rs218947 ENSG00000251136.7 RP11-37B2.1 5.02 1.07e-06 0.000817 0.33 0.32 Leprosy; chr8:89705148 chr8:89609409~89757727:- CESC cis rs75422866 0.867 rs73102166 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47653769 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102168 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47654010 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102171 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47656077 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102188 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47662993 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102195 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47666309 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102201 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47669269 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73104104 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47671986 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73104111 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47673994 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73104115 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47684843 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73104116 ENSG00000280054.1 RP1-197B17.7 5.02 1.07e-06 0.000817 0.76 0.32 Pneumonia; chr12:47685023 chr12:47728151~47730598:- CESC cis rs748404 0.66 rs509306 ENSG00000205771.5 CATSPER2P1 -5.02 1.07e-06 0.000818 -0.38 -0.32 Lung cancer; chr15:43422973 chr15:43726918~43747094:- CESC cis rs116095464 0.558 rs62346508 ENSG00000250848.1 CTD-2083E4.5 -5.02 1.08e-06 0.000821 -0.46 -0.32 Breast cancer; chr5:203553 chr5:288833~290321:- CESC cis rs8072100 0.967 rs3760370 ENSG00000228782.6 CTD-2026D20.3 -5.02 1.08e-06 0.000822 -0.37 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47618466 chr17:47450568~47492492:- CESC cis rs34375054 0.526 rs4412800 ENSG00000279233.1 RP11-158L12.4 -5.02 1.08e-06 0.000825 -0.34 -0.32 Post bronchodilator FEV1/FVC ratio; chr12:125190196 chr12:125138245~125141711:+ CESC cis rs2439831 0.867 rs11856184 ENSG00000275601.1 AC011330.13 -5.02 1.08e-06 0.000825 -0.47 -0.32 Lung cancer in ever smokers; chr15:43626964 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2927072 ENSG00000275601.1 AC011330.13 -5.02 1.08e-06 0.000825 -0.47 -0.32 Lung cancer in ever smokers; chr15:43630200 chr15:43642389~43643023:- CESC cis rs42490 1 rs218907 ENSG00000251136.7 RP11-37B2.1 -5.02 1.08e-06 0.000825 -0.32 -0.32 Leprosy; chr8:89728164 chr8:89609409~89757727:- CESC cis rs5769707 0.616 rs135869 ENSG00000188511.11 C22orf34 5.02 1.08e-06 0.000826 0.39 0.32 Monocyte percentage of white cells;Monocyte count; chr22:49614718 chr22:49414524~49657542:- CESC cis rs2337406 1 rs75651733 ENSG00000211974.3 IGHV2-70 -5.02 1.09e-06 0.000828 -0.51 -0.32 Alzheimer's disease (late onset); chr14:106701309 chr14:106723574~106724093:- CESC cis rs42490 0.716 rs42346 ENSG00000251136.7 RP11-37B2.1 5.02 1.09e-06 0.000828 0.32 0.32 Leprosy; chr8:89816829 chr8:89609409~89757727:- CESC cis rs10800713 0.56 rs10919965 ENSG00000260088.1 RP11-92G12.3 -5.02 1.09e-06 0.00083 -0.5 -0.32 Tandem gait; chr1:200532134 chr1:200669507~200694250:+ CESC cis rs11155671 0.53 rs9383912 ENSG00000223701.3 RAET1E-AS1 5.02 1.09e-06 0.00083 0.36 0.32 Testicular germ cell tumor; chr6:149885479 chr6:149884431~149919508:+ CESC cis rs897984 0.762 rs12930545 ENSG00000260911.2 RP11-196G11.2 -5.02 1.09e-06 0.000831 -0.35 -0.32 Dementia with Lewy bodies; chr16:30927490 chr16:31043150~31049868:+ CESC cis rs897984 0.806 rs11150600 ENSG00000260911.2 RP11-196G11.2 -5.02 1.09e-06 0.000831 -0.35 -0.32 Dementia with Lewy bodies; chr16:30929010 chr16:31043150~31049868:+ CESC cis rs897984 0.806 rs10782001 ENSG00000260911.2 RP11-196G11.2 -5.02 1.09e-06 0.000831 -0.35 -0.32 Dementia with Lewy bodies; chr16:30931304 chr16:31043150~31049868:+ CESC cis rs897984 0.806 rs12928852 ENSG00000260911.2 RP11-196G11.2 -5.02 1.09e-06 0.000831 -0.35 -0.32 Dementia with Lewy bodies; chr16:30932667 chr16:31043150~31049868:+ CESC cis rs1862618 0.853 rs2432195 ENSG00000271828.1 CTD-2310F14.1 5.02 1.09e-06 0.000832 0.43 0.32 Initial pursuit acceleration; chr5:56824586 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs252916 ENSG00000271828.1 CTD-2310F14.1 5.02 1.09e-06 0.000832 0.43 0.32 Initial pursuit acceleration; chr5:56825961 chr5:56927874~56929573:+ CESC cis rs1862618 0.802 rs832560 ENSG00000271828.1 CTD-2310F14.1 5.02 1.09e-06 0.000832 0.43 0.32 Initial pursuit acceleration; chr5:56828596 chr5:56927874~56929573:+ CESC cis rs9326248 0.861 rs4938348 ENSG00000280143.1 AP000892.6 5.02 1.09e-06 0.000832 0.46 0.32 Blood protein levels; chr11:117151161 chr11:117204967~117210292:+ CESC cis rs4660456 0.504 rs2744805 ENSG00000237899.1 RP4-739H11.3 5.02 1.09e-06 0.000832 0.45 0.32 Platelet count; chr1:40654827 chr1:40669089~40687588:- CESC cis rs7927592 0.913 rs10896338 ENSG00000212093.1 AP000807.1 5.02 1.09e-06 0.000832 0.38 0.32 Total body bone mineral density; chr11:68531892 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs7115374 ENSG00000212093.1 AP000807.1 5.02 1.09e-06 0.000832 0.38 0.32 Total body bone mineral density; chr11:68532608 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs67605986 ENSG00000212093.1 AP000807.1 5.02 1.09e-06 0.000832 0.38 0.32 Total body bone mineral density; chr11:68533487 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs12285993 ENSG00000212093.1 AP000807.1 5.02 1.09e-06 0.000832 0.38 0.32 Total body bone mineral density; chr11:68535070 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs11228276 ENSG00000212093.1 AP000807.1 5.02 1.09e-06 0.000832 0.38 0.32 Total body bone mineral density; chr11:68540057 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs67005337 ENSG00000212093.1 AP000807.1 5.02 1.09e-06 0.000832 0.38 0.32 Total body bone mineral density; chr11:68540290 chr11:68506083~68506166:- CESC cis rs6700559 0.654 rs2809346 ENSG00000260088.1 RP11-92G12.3 5.02 1.09e-06 0.000833 0.39 0.32 Coronary artery disease; chr1:200627089 chr1:200669507~200694250:+ CESC cis rs1799949 0.965 rs33961729 ENSG00000267681.1 CTD-3199J23.6 -5.02 1.09e-06 0.000833 -0.42 -0.32 Menopause (age at onset); chr17:43135907 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs11652332 ENSG00000267681.1 CTD-3199J23.6 -5.02 1.09e-06 0.000833 -0.42 -0.32 Menopause (age at onset); chr17:43143472 chr17:43144956~43145255:+ CESC cis rs71403859 0.502 rs35394108 ENSG00000260886.1 TAT-AS1 5.02 1.09e-06 0.000834 0.5 0.32 Post bronchodilator FEV1; chr16:71506736 chr16:71565789~71578187:+ CESC cis rs7714584 1 rs11747065 ENSG00000197083.10 ZNF300P1 5.02 1.1e-06 0.000834 0.64 0.32 Crohn's disease; chr5:150915924 chr5:150930645~150946289:- CESC cis rs7714584 1 rs11740172 ENSG00000197083.10 ZNF300P1 5.02 1.1e-06 0.000834 0.64 0.32 Crohn's disease; chr5:150920716 chr5:150930645~150946289:- CESC cis rs7714584 1 rs11746807 ENSG00000197083.10 ZNF300P1 5.02 1.1e-06 0.000834 0.64 0.32 Crohn's disease; chr5:150920857 chr5:150930645~150946289:- CESC cis rs10262624 1 rs10257777 ENSG00000234286.1 AC006026.13 -5.02 1.1e-06 0.000834 -0.34 -0.32 Schizophrenia; chr7:23871362 chr7:23680195~23680786:- CESC cis rs131777 0.577 rs5770928 ENSG00000205559.3 CHKB-AS1 -5.01 1.1e-06 0.000838 -0.39 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50590662 chr22:50583026~50583877:+ CESC cis rs2028299 0.92 rs10852123 ENSG00000259677.1 RP11-493E3.1 5.01 1.1e-06 0.000838 0.48 0.32 Type 2 diabetes; chr15:89885662 chr15:89876540~89877285:+ CESC cis rs7429990 0.965 rs7642590 ENSG00000229759.1 MRPS18AP1 -5.01 1.1e-06 0.000838 -0.33 -0.32 Educational attainment (years of education); chr3:48058260 chr3:48256350~48256938:- CESC cis rs9584850 0.834 rs9584855 ENSG00000231194.1 FARP1-AS1 -5.01 1.1e-06 0.000838 -0.39 -0.32 Neuroticism; chr13:98466746 chr13:98435405~98435840:- CESC cis rs75422866 0.867 rs73104138 ENSG00000280054.1 RP1-197B17.7 5.01 1.1e-06 0.000838 0.76 0.32 Pneumonia; chr12:47692302 chr12:47728151~47730598:- CESC cis rs75422866 0.717 rs73104143 ENSG00000280054.1 RP1-197B17.7 5.01 1.1e-06 0.000838 0.76 0.32 Pneumonia; chr12:47693449 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73104144 ENSG00000280054.1 RP1-197B17.7 5.01 1.1e-06 0.000838 0.76 0.32 Pneumonia; chr12:47694390 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73104148 ENSG00000280054.1 RP1-197B17.7 5.01 1.1e-06 0.000838 0.76 0.32 Pneumonia; chr12:47696732 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73104152 ENSG00000280054.1 RP1-197B17.7 5.01 1.1e-06 0.000838 0.76 0.32 Pneumonia; chr12:47699091 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73104155 ENSG00000280054.1 RP1-197B17.7 5.01 1.1e-06 0.000838 0.76 0.32 Pneumonia; chr12:47700790 chr12:47728151~47730598:- CESC cis rs8177876 0.642 rs56032321 ENSG00000261838.4 RP11-303E16.6 5.01 1.1e-06 0.000838 0.69 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81084301 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs56119129 ENSG00000261838.4 RP11-303E16.6 5.01 1.1e-06 0.000838 0.69 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81084661 chr16:81069854~81076598:+ CESC cis rs748404 0.66 rs518288 ENSG00000205771.5 CATSPER2P1 -5.01 1.11e-06 0.000843 -0.37 -0.32 Lung cancer; chr15:43471801 chr15:43726918~43747094:- CESC cis rs3738443 1 rs74152976 ENSG00000259865.1 RP11-488L18.10 5.01 1.11e-06 0.000845 0.36 0.32 Alcohol dependence; chr1:247183504 chr1:247187281~247188526:- CESC cis rs6142102 0.961 rs761235 ENSG00000276073.1 RP5-1125A11.7 -5.01 1.11e-06 0.000845 -0.32 -0.32 Skin pigmentation; chr20:33946602 chr20:33985617~33988989:- CESC cis rs9601248 0.874 rs9545158 ENSG00000227676.3 LINC01068 5.01 1.11e-06 0.000845 0.38 0.32 Major depressive disorder; chr13:79618771 chr13:79566727~79571436:+ CESC cis rs7826238 0.72 rs12546760 ENSG00000253893.2 FAM85B 5.01 1.11e-06 0.000845 0.41 0.32 Systolic blood pressure; chr8:8517326 chr8:8167819~8226614:- CESC cis rs9987353 0.544 rs2929470 ENSG00000253893.2 FAM85B 5.01 1.12e-06 0.00085 0.43 0.32 Recombination measurement; chr8:9204980 chr8:8167819~8226614:- CESC cis rs34779708 0.966 rs12761675 ENSG00000230534.5 RP11-297A16.2 -5.01 1.12e-06 0.00085 -0.42 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35149409 chr10:35098006~35127020:- CESC cis rs10262624 1 rs10238070 ENSG00000234286.1 AC006026.13 -5.01 1.12e-06 0.000851 -0.34 -0.32 Schizophrenia; chr7:23870172 chr7:23680195~23680786:- CESC cis rs2564921 0.693 rs2336721 ENSG00000242142.1 SERBP1P3 -5.01 1.12e-06 0.000851 -0.38 -0.32 Height; chr3:52994359 chr3:53064283~53065091:- CESC cis rs875971 0.528 rs801213 ENSG00000222364.1 RNU6-96P 5.01 1.12e-06 0.000852 0.42 0.32 Aortic root size; chr7:66549931 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs801212 ENSG00000222364.1 RNU6-96P 5.01 1.12e-06 0.000852 0.42 0.32 Aortic root size; chr7:66550643 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs801199 ENSG00000222364.1 RNU6-96P 5.01 1.12e-06 0.000852 0.42 0.32 Aortic root size; chr7:66560286 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs1267814 ENSG00000222364.1 RNU6-96P 5.01 1.12e-06 0.000852 0.42 0.32 Aortic root size; chr7:66579422 chr7:66395191~66395286:+ CESC cis rs7714670 0.706 rs2973549 ENSG00000184084.7 CTD-2372A4.1 -5.01 1.12e-06 0.000852 -0.36 -0.32 Venous thromboembolism (SNP x SNP interaction); chr5:73795301 chr5:73803296~73803599:- CESC cis rs3762637 0.943 rs72960447 ENSG00000272758.4 RP11-299J3.8 -5.01 1.12e-06 0.000854 -0.45 -0.32 LDL cholesterol levels; chr3:122516258 chr3:122416207~122443180:+ CESC cis rs1891275 0.515 rs7093728 ENSG00000228701.1 TNKS2-AS1 -5.01 1.13e-06 0.000856 -0.37 -0.32 Intelligence (multi-trait analysis); chr10:91683860 chr10:91782839~91798291:- CESC cis rs1891275 0.515 rs10786010 ENSG00000228701.1 TNKS2-AS1 -5.01 1.13e-06 0.000856 -0.37 -0.32 Intelligence (multi-trait analysis); chr10:91684016 chr10:91782839~91798291:- CESC cis rs1891275 0.515 rs1986941 ENSG00000228701.1 TNKS2-AS1 -5.01 1.13e-06 0.000856 -0.37 -0.32 Intelligence (multi-trait analysis); chr10:91684586 chr10:91782839~91798291:- CESC cis rs763567 0.585 rs476810 ENSG00000271811.1 RP1-79C4.4 -5.01 1.13e-06 0.000858 -0.37 -0.32 Tonsillectomy; chr1:170604673 chr1:170667381~170669425:+ CESC cis rs763567 0.585 rs1234233 ENSG00000271811.1 RP1-79C4.4 -5.01 1.13e-06 0.000858 -0.37 -0.32 Tonsillectomy; chr1:170605787 chr1:170667381~170669425:+ CESC cis rs763567 0.546 rs566850 ENSG00000271811.1 RP1-79C4.4 -5.01 1.13e-06 0.000858 -0.37 -0.32 Tonsillectomy; chr1:170607597 chr1:170667381~170669425:+ CESC cis rs763567 0.565 rs546258 ENSG00000271811.1 RP1-79C4.4 -5.01 1.13e-06 0.000858 -0.37 -0.32 Tonsillectomy; chr1:170610453 chr1:170667381~170669425:+ CESC cis rs763567 0.585 rs553905 ENSG00000271811.1 RP1-79C4.4 -5.01 1.13e-06 0.000858 -0.37 -0.32 Tonsillectomy; chr1:170611336 chr1:170667381~170669425:+ CESC cis rs2243480 1 rs1638734 ENSG00000275400.1 RP4-756H11.5 5.01 1.13e-06 0.000859 0.56 0.32 Diabetic kidney disease; chr7:66632552 chr7:66553805~66554199:- CESC cis rs1499614 1 rs1267818 ENSG00000275400.1 RP4-756H11.5 5.01 1.13e-06 0.000859 0.56 0.32 Gout; chr7:66642037 chr7:66553805~66554199:- CESC cis rs1499614 1 rs1267817 ENSG00000275400.1 RP4-756H11.5 5.01 1.13e-06 0.000859 0.56 0.32 Gout; chr7:66645053 chr7:66553805~66554199:- CESC cis rs3931020 0.688 rs455032 ENSG00000272864.1 RP11-17E13.2 5.01 1.13e-06 0.00086 0.41 0.32 Resistin levels; chr1:74730804 chr1:74698769~74699333:- CESC cis rs1023500 0.505 rs134889 ENSG00000273366.1 CTA-989H11.1 -5.01 1.13e-06 0.00086 -0.4 -0.32 Schizophrenia; chr22:42278344 chr22:42278188~42278846:+ CESC cis rs9402743 0.748 rs11754958 ENSG00000217482.2 HMGB1P17 5.01 1.13e-06 0.000861 0.37 0.32 Systemic lupus erythematosus; chr6:135651462 chr6:135636086~135636713:- CESC cis rs950880 0.71 rs11678975 ENSG00000234389.1 AC007278.3 -5.01 1.14e-06 0.000861 -0.36 -0.32 Serum protein levels (sST2); chr2:102427279 chr2:102438713~102440475:+ CESC cis rs9549367 0.826 rs35306827 ENSG00000269125.1 RP11-98F14.11 -5.01 1.14e-06 0.000861 -0.44 -0.32 Platelet distribution width; chr13:113214731 chr13:113165002~113165183:- CESC cis rs3762637 1 rs28434553 ENSG00000272758.4 RP11-299J3.8 -5.01 1.14e-06 0.000861 -0.44 -0.32 LDL cholesterol levels; chr3:122510668 chr3:122416207~122443180:+ CESC cis rs116095464 0.558 rs6879656 ENSG00000250848.1 CTD-2083E4.5 -5.01 1.14e-06 0.000862 -0.45 -0.32 Breast cancer; chr5:264313 chr5:288833~290321:- CESC cis rs4718428 0.705 rs68168107 ENSG00000273142.1 RP11-458F8.4 -5.01 1.14e-06 0.000862 -0.35 -0.32 Corneal structure; chr7:66790251 chr7:66902857~66906297:+ CESC cis rs9322193 0.962 rs4870048 ENSG00000216906.2 RP11-350J20.9 5.01 1.14e-06 0.000862 0.36 0.32 Lung cancer; chr6:149834324 chr6:149904243~149906418:+ CESC cis rs860295 0.702 rs10796945 ENSG00000225855.5 RUSC1-AS1 5.01 1.14e-06 0.000864 0.26 0.32 Body mass index; chr1:155457897 chr1:155316863~155324176:- CESC cis rs10800713 0.954 rs6665951 ENSG00000260088.1 RP11-92G12.3 -5.01 1.14e-06 0.000864 -0.45 -0.32 Tandem gait; chr1:200589235 chr1:200669507~200694250:+ CESC cis rs67311347 1 rs9968170 ENSG00000223797.4 ENTPD3-AS1 -5.01 1.14e-06 0.000866 -0.33 -0.32 Renal cell carcinoma; chr3:40452783 chr3:40313802~40453329:- CESC cis rs2015599 0.623 rs1072724 ENSG00000275476.1 RP11-996F15.4 5.01 1.14e-06 0.000866 0.37 0.32 Platelet count;Mean platelet volume; chr12:29289205 chr12:29277397~29277882:- CESC cis rs2015599 0.623 rs7358667 ENSG00000275476.1 RP11-996F15.4 5.01 1.14e-06 0.000866 0.37 0.32 Platelet count;Mean platelet volume; chr12:29290236 chr12:29277397~29277882:- CESC cis rs694739 0.93 rs574087 ENSG00000236935.1 AP003774.1 5.01 1.14e-06 0.000866 0.33 0.32 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64335476 chr11:64325050~64329504:- CESC cis rs6700559 0.654 rs66717951 ENSG00000260088.1 RP11-92G12.3 5.01 1.14e-06 0.000867 0.39 0.32 Coronary artery disease; chr1:200626437 chr1:200669507~200694250:+ CESC cis rs75422866 0.867 rs117388682 ENSG00000280054.1 RP1-197B17.7 5.01 1.14e-06 0.000867 0.81 0.32 Pneumonia; chr12:47599713 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs79113930 ENSG00000280054.1 RP1-197B17.7 5.01 1.14e-06 0.000867 0.81 0.32 Pneumonia; chr12:47600628 chr12:47728151~47730598:- CESC cis rs3823536 0.505 rs3925323 ENSG00000275106.1 RP11-309L24.10 -5.01 1.15e-06 0.000868 -0.45 -0.32 Sjögren's syndrome; chr7:128952187 chr7:128952527~128953316:- CESC cis rs577676 0.586 rs10489231 ENSG00000271811.1 RP1-79C4.4 -5.01 1.15e-06 0.000868 -0.43 -0.32 Prevalent atrial fibrillation; chr1:170620296 chr1:170667381~170669425:+ CESC cis rs9322193 0.962 rs17673294 ENSG00000216906.2 RP11-350J20.9 5.01 1.15e-06 0.000869 0.36 0.32 Lung cancer; chr6:149813857 chr6:149904243~149906418:+ CESC cis rs10829156 1 rs10829157 ENSG00000240291.1 RP11-499P20.2 5.01 1.15e-06 0.00087 0.36 0.32 Sudden cardiac arrest; chr10:18662534 chr10:18513115~18545651:- CESC cis rs875971 1 rs2420820 ENSG00000222364.1 RNU6-96P 5.01 1.15e-06 0.00087 0.39 0.32 Aortic root size; chr7:66626920 chr7:66395191~66395286:+ CESC cis rs9322193 0.884 rs7769115 ENSG00000216906.2 RP11-350J20.9 5.01 1.15e-06 0.00087 0.37 0.32 Lung cancer; chr6:149848796 chr6:149904243~149906418:+ CESC cis rs13108904 0.901 rs12509700 ENSG00000254094.1 AC078852.1 -5.01 1.15e-06 0.00087 -0.37 -0.32 Obesity-related traits; chr4:1302533 chr4:1356581~1358075:+ CESC cis rs2337406 0.714 rs117798641 ENSG00000274576.2 IGHV2-70 -5 1.15e-06 0.000872 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106777984 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs7152038 ENSG00000274576.2 IGHV2-70 -5 1.15e-06 0.000872 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106778230 chr14:106770577~106771020:- CESC cis rs1023500 0.505 rs134899 ENSG00000273366.1 CTA-989H11.1 -5 1.15e-06 0.000873 -0.39 -0.32 Schizophrenia; chr22:42287024 chr22:42278188~42278846:+ CESC cis rs75422866 0.867 rs73104103 ENSG00000280054.1 RP1-197B17.7 5 1.15e-06 0.000873 0.76 0.32 Pneumonia; chr12:47669604 chr12:47728151~47730598:- CESC cis rs10246939 0.505 rs10952508 ENSG00000228775.6 WEE2-AS1 5 1.16e-06 0.000874 0.4 0.32 Bitter taste perception; chr7:141879415 chr7:141704338~141738346:- CESC cis rs9907295 0.688 rs2376287 ENSG00000271013.1 AC015849.15 -5 1.16e-06 0.000874 -0.4 -0.32 Fibroblast growth factor basic levels; chr17:35919865 chr17:35912635~35918010:- CESC cis rs9907295 0.688 rs4796133 ENSG00000271013.1 AC015849.15 -5 1.16e-06 0.000874 -0.4 -0.32 Fibroblast growth factor basic levels; chr17:35920505 chr17:35912635~35918010:- CESC cis rs9907295 0.688 rs7213636 ENSG00000271013.1 AC015849.15 -5 1.16e-06 0.000874 -0.4 -0.32 Fibroblast growth factor basic levels; chr17:35920944 chr17:35912635~35918010:- CESC cis rs9907295 0.688 rs28722787 ENSG00000271013.1 AC015849.15 -5 1.16e-06 0.000874 -0.4 -0.32 Fibroblast growth factor basic levels; chr17:35922795 chr17:35912635~35918010:- CESC cis rs2243480 0.901 rs35823062 ENSG00000275400.1 RP4-756H11.5 5 1.16e-06 0.000876 0.55 0.32 Diabetic kidney disease; chr7:66500834 chr7:66553805~66554199:- CESC cis rs2836950 0.545 rs8132424 ENSG00000232608.1 TIMM9P2 -5 1.16e-06 0.000876 -0.36 -0.32 Menarche (age at onset); chr21:39212486 chr21:39216624~39217506:+ CESC cis rs2564921 0.666 rs62253656 ENSG00000242142.1 SERBP1P3 -5 1.16e-06 0.000878 -0.39 -0.32 Height; chr3:52989412 chr3:53064283~53065091:- CESC cis rs7508 0.509 rs441764 ENSG00000253671.1 RP11-806O11.1 -5 1.16e-06 0.000878 -0.36 -0.32 Atrial fibrillation; chr8:18045648 chr8:17808941~17820868:+ CESC cis rs2842992 0.789 rs4709376 ENSG00000237927.1 RP3-393E18.2 -5 1.16e-06 0.000879 -0.43 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159805305 chr6:159586955~159589169:- CESC cis rs2283792 0.622 rs381523 ENSG00000224086.5 LL22NC03-86G7.1 -5 1.16e-06 0.00088 -0.37 -0.32 Multiple sclerosis; chr22:21951257 chr22:21938293~21977632:+ CESC cis rs950880 0.71 rs11681718 ENSG00000234389.1 AC007278.3 -5 1.17e-06 0.000882 -0.36 -0.32 Serum protein levels (sST2); chr2:102434684 chr2:102438713~102440475:+ CESC cis rs875971 0.862 rs6460282 ENSG00000222364.1 RNU6-96P 5 1.17e-06 0.000886 0.38 0.32 Aortic root size; chr7:66226259 chr7:66395191~66395286:+ CESC cis rs9549367 0.713 rs9549681 ENSG00000269125.1 RP11-98F14.11 -5 1.17e-06 0.000886 -0.46 -0.32 Platelet distribution width; chr13:113175559 chr13:113165002~113165183:- CESC cis rs748404 0.66 rs2439846 ENSG00000205771.5 CATSPER2P1 -5 1.17e-06 0.000886 -0.37 -0.32 Lung cancer; chr15:43448772 chr15:43726918~43747094:- CESC cis rs748404 0.66 rs2467741 ENSG00000205771.5 CATSPER2P1 -5 1.17e-06 0.000886 -0.37 -0.32 Lung cancer; chr15:43450428 chr15:43726918~43747094:- CESC cis rs7714670 0.736 rs2973545 ENSG00000184084.7 CTD-2372A4.1 -5 1.17e-06 0.000886 -0.35 -0.32 Venous thromboembolism (SNP x SNP interaction); chr5:73798384 chr5:73803296~73803599:- CESC cis rs10129255 1 rs10141557 ENSG00000211970.3 IGHV4-61 -5 1.17e-06 0.000887 -0.27 -0.32 Kawasaki disease; chr14:106767990 chr14:106639119~106639657:- CESC cis rs2015599 0.525 rs10771514 ENSG00000275476.1 RP11-996F15.4 5 1.18e-06 0.000887 0.37 0.32 Platelet count;Mean platelet volume; chr12:29315751 chr12:29277397~29277882:- CESC cis rs2015599 0.525 rs7298031 ENSG00000275476.1 RP11-996F15.4 5 1.18e-06 0.000887 0.37 0.32 Platelet count;Mean platelet volume; chr12:29317333 chr12:29277397~29277882:- CESC cis rs2015599 0.525 rs2016832 ENSG00000275476.1 RP11-996F15.4 5 1.18e-06 0.000887 0.37 0.32 Platelet count;Mean platelet volume; chr12:29318199 chr12:29277397~29277882:- CESC cis rs9322193 0.923 rs3924871 ENSG00000268592.3 RAET1E-AS1 5 1.18e-06 0.000888 0.41 0.32 Lung cancer; chr6:149662080 chr6:149863494~149919507:+ CESC cis rs2842992 0.747 rs733319 ENSG00000237927.1 RP3-393E18.2 -5 1.18e-06 0.000892 -0.43 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159800443 chr6:159586955~159589169:- CESC cis rs116095464 0.558 rs10055993 ENSG00000250848.1 CTD-2083E4.5 -5 1.18e-06 0.000892 -0.48 -0.32 Breast cancer; chr5:264181 chr5:288833~290321:- CESC cis rs7615952 0.641 rs6438951 ENSG00000250012.1 RP11-124N2.1 -5 1.18e-06 0.000892 -0.35 -0.32 Blood pressure (smoking interaction); chr3:125978156 chr3:126084220~126095349:+ CESC cis rs2337406 0.778 rs58113768 ENSG00000211974.3 IGHV2-70 -5 1.19e-06 0.000894 -0.51 -0.32 Alzheimer's disease (late onset); chr14:106700213 chr14:106723574~106724093:- CESC cis rs7189233 0.531 rs7204758 ENSG00000279344.1 RP11-44F14.7 5 1.19e-06 0.000898 0.3 0.32 Intelligence (multi-trait analysis); chr16:53448453 chr16:53478957~53481550:- CESC cis rs7189233 0.531 rs9921627 ENSG00000279344.1 RP11-44F14.7 5 1.19e-06 0.000898 0.3 0.32 Intelligence (multi-trait analysis); chr16:53448780 chr16:53478957~53481550:- CESC cis rs2337406 0.929 rs12050233 ENSG00000274576.2 IGHV2-70 -5 1.19e-06 0.000899 -0.38 -0.32 Alzheimer's disease (late onset); chr14:106781123 chr14:106770577~106771020:- CESC cis rs2337406 0.852 rs12050466 ENSG00000274576.2 IGHV2-70 -5 1.19e-06 0.000899 -0.38 -0.32 Alzheimer's disease (late onset); chr14:106781131 chr14:106770577~106771020:- CESC cis rs2337406 0.789 rs60000589 ENSG00000274576.2 IGHV2-70 -5 1.19e-06 0.000899 -0.38 -0.32 Alzheimer's disease (late onset); chr14:106782459 chr14:106770577~106771020:- CESC cis rs2243480 0.803 rs423187 ENSG00000232559.3 GS1-124K5.12 5 1.2e-06 0.000901 0.55 0.32 Diabetic kidney disease; chr7:66044512 chr7:66554588~66576923:- CESC cis rs783540 0.5 rs783541 ENSG00000276710.3 CSPG4P8 5 1.2e-06 0.000903 0.37 0.32 Schizophrenia; chr15:82586310 chr15:82459472~82477258:+ CESC cis rs10800713 0.56 rs10919967 ENSG00000260088.1 RP11-92G12.3 5 1.2e-06 0.000904 0.49 0.32 Tandem gait; chr1:200533543 chr1:200669507~200694250:+ CESC cis rs3931020 0.688 rs277375 ENSG00000272864.1 RP11-17E13.2 -5 1.2e-06 0.000904 -0.41 -0.32 Resistin levels; chr1:74738459 chr1:74698769~74699333:- CESC cis rs6991838 0.831 rs11992528 ENSG00000200714.1 Y_RNA 5 1.2e-06 0.000904 0.37 0.32 Intelligence (multi-trait analysis); chr8:65561644 chr8:65592731~65592820:+ CESC cis rs2243480 1 rs313832 ENSG00000228409.4 CCT6P1 5 1.2e-06 0.000905 0.49 0.32 Diabetic kidney disease; chr7:66085904 chr7:65751142~65763354:+ CESC cis rs7189233 0.55 rs4784312 ENSG00000279344.1 RP11-44F14.7 5 1.2e-06 0.000905 0.3 0.32 Intelligence (multi-trait analysis); chr16:53464490 chr16:53478957~53481550:- CESC cis rs2739330 0.791 rs4822458 ENSG00000099984.9 GSTT2 -5 1.2e-06 0.000905 -0.39 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23980123~23983911:+ CESC cis rs10510102 0.608 rs4077606 ENSG00000276742.1 RP11-500G22.4 -5 1.2e-06 0.000906 -0.39 -0.32 Breast cancer; chr10:121849907 chr10:121956782~121957098:+ CESC cis rs200895692 1 rs200895692 ENSG00000227533.4 SLC2A1-AS1 5 1.21e-06 0.000907 0.55 0.32 Monocyte count; chr1:42956299 chr1:42959049~42983358:+ CESC cis rs73086581 1 rs17286349 ENSG00000229539.1 RP11-119B16.2 4.99 1.21e-06 0.000908 0.51 0.32 Response to antidepressants in depression; chr20:3933655 chr20:3888239~3888868:- CESC cis rs12130219 0.5 rs4845737 ENSG00000237975.5 FLG-AS1 -4.99 1.21e-06 0.000909 -0.37 -0.32 Inflammatory skin disease; chr1:152205063 chr1:152168125~152445456:+ CESC cis rs9322193 0.923 rs10872645 ENSG00000268592.3 RAET1E-AS1 4.99 1.21e-06 0.000909 0.42 0.32 Lung cancer; chr6:149742840 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs12211511 ENSG00000268592.3 RAET1E-AS1 4.99 1.21e-06 0.000909 0.42 0.32 Lung cancer; chr6:149745206 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9479810 ENSG00000268592.3 RAET1E-AS1 4.99 1.21e-06 0.000909 0.42 0.32 Lung cancer; chr6:149751359 chr6:149863494~149919507:+ CESC cis rs875971 0.825 rs6951503 ENSG00000222364.1 RNU6-96P 4.99 1.21e-06 0.000909 0.37 0.32 Aortic root size; chr7:66253949 chr7:66395191~66395286:+ CESC cis rs1799949 0.93 rs8176194 ENSG00000267681.1 CTD-3199J23.6 -4.99 1.21e-06 0.00091 -0.42 -0.32 Menopause (age at onset); chr17:43079204 chr17:43144956~43145255:+ CESC cis rs75422866 0.867 rs117022227 ENSG00000280054.1 RP1-197B17.7 4.99 1.21e-06 0.00091 0.82 0.32 Pneumonia; chr12:47633282 chr12:47728151~47730598:- CESC cis rs748404 0.578 rs2278856 ENSG00000249839.1 AC011330.5 -4.99 1.21e-06 0.00091 -0.34 -0.32 Lung cancer; chr15:43339158 chr15:43663654~43684339:- CESC cis rs10754283 0.967 rs10737706 ENSG00000231613.1 RP5-943J3.1 4.99 1.21e-06 0.000911 0.41 0.32 Amyotrophic lateral sclerosis (sporadic); chr1:89647020 chr1:89788914~89790492:+ CESC cis rs10262624 1 rs11767124 ENSG00000234286.1 AC006026.13 -4.99 1.21e-06 0.000911 -0.34 -0.32 Schizophrenia; chr7:23879461 chr7:23680195~23680786:- CESC cis rs860295 0.702 rs12746592 ENSG00000225855.5 RUSC1-AS1 4.99 1.21e-06 0.000912 0.27 0.32 Body mass index; chr1:155536176 chr1:155316863~155324176:- CESC cis rs860295 0.702 rs10752611 ENSG00000225855.5 RUSC1-AS1 4.99 1.21e-06 0.000912 0.27 0.32 Body mass index; chr1:155539316 chr1:155316863~155324176:- CESC cis rs875971 0.895 rs6460278 ENSG00000237310.1 GS1-124K5.4 -4.99 1.21e-06 0.000913 -0.3 -0.32 Aortic root size; chr7:66197749 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6460279 ENSG00000237310.1 GS1-124K5.4 -4.99 1.21e-06 0.000913 -0.3 -0.32 Aortic root size; chr7:66197774 chr7:66493706~66495474:+ CESC cis rs8072100 0.875 rs9635762 ENSG00000228782.6 CTD-2026D20.3 -4.99 1.21e-06 0.000913 -0.37 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47571080 chr17:47450568~47492492:- CESC cis rs8072100 0.967 rs4793842 ENSG00000228782.6 CTD-2026D20.3 -4.99 1.21e-06 0.000913 -0.37 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47594140 chr17:47450568~47492492:- CESC cis rs8072100 0.967 rs8075411 ENSG00000228782.6 CTD-2026D20.3 -4.99 1.21e-06 0.000913 -0.37 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47599394 chr17:47450568~47492492:- CESC cis rs860295 0.702 rs10796943 ENSG00000225855.5 RUSC1-AS1 4.99 1.22e-06 0.000914 0.28 0.32 Body mass index; chr1:155444938 chr1:155316863~155324176:- CESC cis rs748404 0.66 rs2602141 ENSG00000205771.5 CATSPER2P1 -4.99 1.22e-06 0.000916 -0.37 -0.32 Lung cancer; chr15:43432448 chr15:43726918~43747094:- CESC cis rs831571 1 rs831571 ENSG00000280620.1 SCAANT1 -4.99 1.22e-06 0.000918 -0.52 -0.32 Type 2 diabetes; chr3:64062621 chr3:63911518~63911772:- CESC cis rs4853012 0.887 rs6737314 ENSG00000257800.1 FNBP1P1 4.99 1.22e-06 0.000919 0.34 0.32 Gestational age at birth (maternal effect); chr2:74112459 chr2:74120680~74123218:+ CESC cis rs7927592 0.913 rs948316 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68542202 chr11:68506083~68506166:- CESC cis rs7927592 0.956 rs10896341 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68545712 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs67947146 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68547512 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs7104345 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68549304 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs12284933 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68552021 chr11:68506083~68506166:- CESC cis rs7927592 0.871 rs11228284 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68555299 chr11:68506083~68506166:- CESC cis rs7927592 0.871 rs55953412 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68560815 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs7102898 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68561402 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs2282563 ENSG00000212093.1 AP000807.1 4.99 1.22e-06 0.000919 0.38 0.32 Total body bone mineral density; chr11:68565732 chr11:68506083~68506166:- CESC cis rs10788972 0.844 rs6588502 ENSG00000225183.1 RP4-758J24.4 -4.99 1.22e-06 0.00092 -0.37 -0.32 Parkinson disease and lewy body pathology; chr1:54097483 chr1:54089856~54090093:+ CESC cis rs6686842 0.582 rs12072990 ENSG00000235358.1 RP11-399E6.1 -4.99 1.23e-06 0.000923 -0.38 -0.32 Height; chr1:41034310 chr1:41242373~41284861:+ CESC cis rs9322193 0.683 rs113281309 ENSG00000268592.3 RAET1E-AS1 4.99 1.23e-06 0.000923 0.42 0.32 Lung cancer; chr6:149787289 chr6:149863494~149919507:+ CESC cis rs950880 0.71 rs11123929 ENSG00000234389.1 AC007278.3 -4.99 1.23e-06 0.000923 -0.35 -0.32 Serum protein levels (sST2); chr2:102450683 chr2:102438713~102440475:+ CESC cis rs9322193 0.923 rs3798761 ENSG00000268592.3 RAET1E-AS1 4.99 1.23e-06 0.000925 0.41 0.32 Lung cancer; chr6:149683643 chr6:149863494~149919507:+ CESC cis rs11155671 0.53 rs4870080 ENSG00000223701.3 RAET1E-AS1 4.99 1.24e-06 0.000929 0.37 0.32 Testicular germ cell tumor; chr6:149881508 chr6:149884431~149919508:+ CESC cis rs9907295 0.901 rs9909416 ENSG00000270977.1 AC015849.16 -4.99 1.24e-06 0.000929 -0.43 -0.32 Fibroblast growth factor basic levels; chr17:35870979 chr17:35893707~35911023:- CESC cis rs875971 0.964 rs160635 ENSG00000237310.1 GS1-124K5.4 4.99 1.24e-06 0.000929 0.31 0.32 Aortic root size; chr7:66063931 chr7:66493706~66495474:+ CESC cis rs8072100 0.575 rs1221385 ENSG00000228782.6 CTD-2026D20.3 4.99 1.24e-06 0.000929 0.39 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47450208 chr17:47450568~47492492:- CESC cis rs733592 0.507 rs7304428 ENSG00000240399.1 RP1-228P16.1 -4.99 1.24e-06 0.00093 -0.32 -0.32 Plateletcrit; chr12:48100492 chr12:48054813~48055591:- CESC cis rs12439619 1 rs12439619 ENSG00000276710.3 CSPG4P8 -4.99 1.24e-06 0.000933 -0.39 -0.32 Intelligence (multi-trait analysis); chr15:82254605 chr15:82459472~82477258:+ CESC cis rs42490 0.716 rs370282 ENSG00000251136.7 RP11-37B2.1 -4.99 1.25e-06 0.000934 -0.32 -0.32 Leprosy; chr8:89816117 chr8:89609409~89757727:- CESC cis rs875971 0.825 rs1000464 ENSG00000237310.1 GS1-124K5.4 -4.99 1.25e-06 0.000934 -0.29 -0.32 Aortic root size; chr7:66312922 chr7:66493706~66495474:+ CESC cis rs875971 0.767 rs12668005 ENSG00000232559.3 GS1-124K5.12 4.99 1.25e-06 0.000937 0.35 0.32 Aortic root size; chr7:66444034 chr7:66554588~66576923:- CESC cis rs2836950 0.545 rs2836940 ENSG00000232608.1 TIMM9P2 4.99 1.25e-06 0.000937 0.35 0.32 Menarche (age at onset); chr21:39216770 chr21:39216624~39217506:+ CESC cis rs3823536 0.583 rs7800687 ENSG00000275106.1 RP11-309L24.10 -4.99 1.25e-06 0.000939 -0.45 -0.32 Sjögren's syndrome; chr7:128953665 chr7:128952527~128953316:- CESC cis rs3823536 0.583 rs2280714 ENSG00000275106.1 RP11-309L24.10 -4.99 1.25e-06 0.000939 -0.45 -0.32 Sjögren's syndrome; chr7:128954671 chr7:128952527~128953316:- CESC cis rs3823536 0.583 rs10236569 ENSG00000275106.1 RP11-309L24.10 -4.99 1.25e-06 0.000939 -0.45 -0.32 Sjögren's syndrome; chr7:128957533 chr7:128952527~128953316:- CESC cis rs3931020 0.688 rs452242 ENSG00000272864.1 RP11-17E13.2 4.99 1.25e-06 0.000939 0.43 0.32 Resistin levels; chr1:74759941 chr1:74698769~74699333:- CESC cis rs875971 0.825 rs4587224 ENSG00000237310.1 GS1-124K5.4 -4.99 1.25e-06 0.000939 -0.29 -0.32 Aortic root size; chr7:66271195 chr7:66493706~66495474:+ CESC cis rs875971 0.792 rs6971752 ENSG00000237310.1 GS1-124K5.4 -4.99 1.25e-06 0.000939 -0.29 -0.32 Aortic root size; chr7:66272999 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs10950033 ENSG00000237310.1 GS1-124K5.4 -4.99 1.25e-06 0.000939 -0.29 -0.32 Aortic root size; chr7:66274686 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs11760844 ENSG00000237310.1 GS1-124K5.4 -4.99 1.25e-06 0.000939 -0.29 -0.32 Aortic root size; chr7:66274896 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs949930 ENSG00000237310.1 GS1-124K5.4 -4.99 1.25e-06 0.000939 -0.29 -0.32 Aortic root size; chr7:66301835 chr7:66493706~66495474:+ CESC cis rs5758659 0.714 rs133373 ENSG00000227370.1 RP4-669P10.19 -4.99 1.25e-06 0.000939 -0.34 -0.32 Cognitive function; chr22:42069784 chr22:42132543~42132998:+ CESC cis rs9322193 0.923 rs11155670 ENSG00000268592.3 RAET1E-AS1 4.99 1.26e-06 0.000941 0.4 0.32 Lung cancer; chr6:149644992 chr6:149863494~149919507:+ CESC cis rs733592 0.929 rs4760678 ENSG00000240399.1 RP1-228P16.1 -4.98 1.26e-06 0.000945 -0.34 -0.32 Plateletcrit; chr12:48067798 chr12:48054813~48055591:- CESC cis rs75422866 0.867 rs73113143 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47623060 chr12:47728151~47730598:- CESC cis rs75422866 0.717 rs73113159 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47631318 chr12:47728151~47730598:- CESC cis rs75422866 0.717 rs73113161 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47632361 chr12:47728151~47730598:- CESC cis rs75422866 1 rs73102120 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47637280 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102125 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47637869 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs12426849 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47638975 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs117950951 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47639794 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs7954764 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47641136 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs12422974 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47644559 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102127 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47645341 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs75568526 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47649718 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs116302411 ENSG00000280054.1 RP1-197B17.7 4.98 1.26e-06 0.000946 0.81 0.32 Pneumonia; chr12:47649788 chr12:47728151~47730598:- CESC cis rs10129255 0.642 rs11624918 ENSG00000224373.3 IGHV4-59 4.98 1.26e-06 0.000946 0.22 0.32 Kawasaki disease; chr14:106664672 chr14:106627249~106627825:- CESC cis rs9322193 0.504 rs7771014 ENSG00000223701.3 RAET1E-AS1 4.98 1.27e-06 0.000946 0.36 0.32 Lung cancer; chr6:149884310 chr6:149884431~149919508:+ CESC cis rs17507216 0.718 rs4779034 ENSG00000255769.6 GOLGA2P10 -4.98 1.27e-06 0.000948 -0.44 -0.32 Excessive daytime sleepiness; chr15:82576799 chr15:82472993~82513950:- CESC cis rs2243480 1 rs4718334 ENSG00000275400.1 RP4-756H11.5 -4.98 1.27e-06 0.00095 -0.53 -0.32 Diabetic kidney disease; chr7:66324467 chr7:66553805~66554199:- CESC cis rs4974559 0.947 rs10000797 ENSG00000253399.1 AC078852.2 4.98 1.27e-06 0.000951 0.53 0.32 Systolic blood pressure; chr4:1351859 chr4:1358479~1359461:+ CESC cis rs875971 1 rs1544549 ENSG00000222364.1 RNU6-96P 4.98 1.27e-06 0.000951 0.38 0.32 Aortic root size; chr7:66625676 chr7:66395191~66395286:+ CESC cis rs4718428 0.672 rs4718412 ENSG00000273142.1 RP11-458F8.4 4.98 1.27e-06 0.000951 0.35 0.32 Corneal structure; chr7:66821880 chr7:66902857~66906297:+ CESC cis rs3823536 0.583 rs3778750 ENSG00000275106.1 RP11-309L24.10 -4.98 1.27e-06 0.000952 -0.45 -0.32 Sjögren's syndrome; chr7:128977035 chr7:128952527~128953316:- CESC cis rs75422866 0.867 rs73113139 ENSG00000257433.4 RP1-197B17.3 4.98 1.27e-06 0.000952 0.8 0.32 Pneumonia; chr12:47622826 chr12:47706085~47742294:+ CESC cis rs748404 0.631 rs2412781 ENSG00000205771.5 CATSPER2P1 4.98 1.28e-06 0.000956 0.38 0.32 Lung cancer; chr15:43375702 chr15:43726918~43747094:- CESC cis rs8177876 0.749 rs58144189 ENSG00000261838.4 RP11-303E16.6 4.98 1.28e-06 0.000956 0.68 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81064478 chr16:81069854~81076598:+ CESC cis rs8177876 0.749 rs1035541 ENSG00000261838.4 RP11-303E16.6 4.98 1.28e-06 0.000956 0.68 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81065249 chr16:81069854~81076598:+ CESC cis rs42490 0.903 rs393891 ENSG00000251136.7 RP11-37B2.1 -4.98 1.28e-06 0.000957 -0.33 -0.32 Leprosy; chr8:89701556 chr8:89609409~89757727:- CESC cis rs7189233 0.571 rs4146344 ENSG00000279344.1 RP11-44F14.7 4.98 1.28e-06 0.000958 0.3 0.32 Intelligence (multi-trait analysis); chr16:53435050 chr16:53478957~53481550:- CESC cis rs7714584 1 rs17727568 ENSG00000197083.10 ZNF300P1 4.98 1.29e-06 0.00096 0.63 0.32 Crohn's disease; chr5:150865126 chr5:150930645~150946289:- CESC cis rs4266144 0.592 rs1545854 ENSG00000244515.1 KRT18P34 4.98 1.29e-06 0.000961 0.43 0.32 Coronary artery disease; chr3:157122349 chr3:157162663~157163932:- CESC cis rs9660180 0.62 rs3817856 ENSG00000268575.1 RP1-283E3.8 4.98 1.29e-06 0.000963 0.32 0.32 Body mass index; chr1:1732392 chr1:1702736~1737688:- CESC cis rs1799949 0.896 rs33933393 ENSG00000267681.1 CTD-3199J23.6 -4.98 1.29e-06 0.000963 -0.42 -0.32 Menopause (age at onset); chr17:43165415 chr17:43144956~43145255:+ CESC cis rs7189233 0.531 rs16952246 ENSG00000279344.1 RP11-44F14.7 4.98 1.29e-06 0.000963 0.3 0.32 Intelligence (multi-trait analysis); chr16:53446797 chr16:53478957~53481550:- CESC cis rs1799949 1 rs2037075 ENSG00000267681.1 CTD-3199J23.6 -4.98 1.29e-06 0.000963 -0.42 -0.32 Menopause (age at onset); chr17:43153809 chr17:43144956~43145255:+ CESC cis rs5769707 0.656 rs135878 ENSG00000235111.1 RP1-29C18.8 -4.98 1.29e-06 0.000963 -0.37 -0.32 Monocyte percentage of white cells;Monocyte count; chr22:49620721 chr22:49612657~49615716:- CESC cis rs10463554 0.889 rs246908 ENSG00000175749.11 EIF3KP1 4.98 1.29e-06 0.000965 0.36 0.32 Parkinson's disease; chr5:103228476 chr5:103032376~103033031:+ CESC cis rs10463554 0.853 rs246907 ENSG00000175749.11 EIF3KP1 4.98 1.29e-06 0.000965 0.36 0.32 Parkinson's disease; chr5:103230577 chr5:103032376~103033031:+ CESC cis rs7174755 0.608 rs10162905 ENSG00000260657.2 RP11-315D16.4 4.98 1.29e-06 0.000965 0.39 0.32 Major depressive disorder; chr15:68103709 chr15:68267792~68277994:- CESC cis rs2243480 0.831 rs57294491 ENSG00000228409.4 CCT6P1 -4.98 1.29e-06 0.000965 -0.48 -0.32 Diabetic kidney disease; chr7:66219914 chr7:65751142~65763354:+ CESC cis rs950880 0.71 rs55927292 ENSG00000234389.1 AC007278.3 -4.98 1.3e-06 0.000966 -0.35 -0.32 Serum protein levels (sST2); chr2:102348401 chr2:102438713~102440475:+ CESC cis rs748404 0.587 rs9920879 ENSG00000249839.1 AC011330.5 -4.98 1.3e-06 0.000967 -0.34 -0.32 Lung cancer; chr15:43347572 chr15:43663654~43684339:- CESC cis rs9322193 0.923 rs9767123 ENSG00000268592.3 RAET1E-AS1 4.98 1.3e-06 0.000967 0.42 0.32 Lung cancer; chr6:149660323 chr6:149863494~149919507:+ CESC cis rs2028299 0.959 rs748508 ENSG00000259677.1 RP11-493E3.1 4.98 1.3e-06 0.000969 0.43 0.32 Type 2 diabetes; chr15:89838026 chr15:89876540~89877285:+ CESC cis rs8100891 0.537 rs10409835 ENSG00000267213.4 AC007773.2 -4.98 1.3e-06 0.000969 -0.49 -0.32 Neuroticism; chr19:32397754 chr19:32390050~32405560:- CESC cis rs13108904 0.901 rs7695691 ENSG00000254094.1 AC078852.1 -4.98 1.3e-06 0.000969 -0.38 -0.32 Obesity-related traits; chr4:1310844 chr4:1356581~1358075:+ CESC cis rs3823536 0.583 rs10156169 ENSG00000275106.1 RP11-309L24.10 -4.98 1.3e-06 0.00097 -0.45 -0.32 Sjögren's syndrome; chr7:129044517 chr7:128952527~128953316:- CESC cis rs2243480 1 rs427044 ENSG00000228409.4 CCT6P1 4.98 1.3e-06 0.000971 0.47 0.32 Diabetic kidney disease; chr7:66043558 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6964530 ENSG00000275400.1 RP4-756H11.5 -4.98 1.3e-06 0.000971 -0.54 -0.32 Diabetic kidney disease; chr7:66253864 chr7:66553805~66554199:- CESC cis rs9907295 0.901 rs4796118 ENSG00000270977.1 AC015849.16 -4.98 1.3e-06 0.000971 -0.44 -0.32 Fibroblast growth factor basic levels; chr17:35858804 chr17:35893707~35911023:- CESC cis rs875971 0.862 rs6460282 ENSG00000237310.1 GS1-124K5.4 -4.98 1.31e-06 0.000972 -0.31 -0.32 Aortic root size; chr7:66226259 chr7:66493706~66495474:+ CESC cis rs9929218 0.501 rs12448999 ENSG00000260459.2 FTLP14 4.98 1.31e-06 0.000974 0.41 0.32 Colorectal cancer; chr16:68781646 chr16:68822587~68823070:+ CESC cis rs6504622 0.634 rs8068715 ENSG00000262879.4 RP11-156P1.3 -4.98 1.31e-06 0.000975 -0.35 -0.32 Orofacial clefts; chr17:46991022 chr17:46984045~47100323:- CESC cis rs6504622 0.514 rs60611133 ENSG00000262879.4 RP11-156P1.3 -4.98 1.31e-06 0.000975 -0.35 -0.32 Orofacial clefts; chr17:46993027 chr17:46984045~47100323:- CESC cis rs11715604 1 rs11715604 ENSG00000239213.4 NCK1-AS1 -4.98 1.31e-06 0.000975 -0.46 -0.32 B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy); chr3:136870707 chr3:136841726~136862054:- CESC cis rs2028299 0.919 rs8026131 ENSG00000259677.1 RP11-493E3.1 4.98 1.31e-06 0.000976 0.42 0.32 Type 2 diabetes; chr15:89874767 chr15:89876540~89877285:+ CESC cis rs2028299 0.879 rs986505 ENSG00000259677.1 RP11-493E3.1 4.98 1.31e-06 0.000976 0.42 0.32 Type 2 diabetes; chr15:89875181 chr15:89876540~89877285:+ CESC cis rs9907295 0.901 rs4796119 ENSG00000270977.1 AC015849.16 4.98 1.31e-06 0.000977 0.45 0.32 Fibroblast growth factor basic levels; chr17:35866084 chr17:35893707~35911023:- CESC cis rs9322193 0.923 rs10782316 ENSG00000268592.3 RAET1E-AS1 4.98 1.31e-06 0.000978 0.42 0.32 Lung cancer; chr6:149752755 chr6:149863494~149919507:+ CESC cis rs9322193 0.847 rs880246 ENSG00000268592.3 RAET1E-AS1 4.98 1.31e-06 0.000978 0.44 0.32 Lung cancer; chr6:149845972 chr6:149863494~149919507:+ CESC cis rs875971 0.545 rs4718348 ENSG00000222364.1 RNU6-96P -4.98 1.32e-06 0.00098 -0.42 -0.32 Aortic root size; chr7:66441589 chr7:66395191~66395286:+ CESC cis rs2739330 0.796 rs5760106 ENSG00000231271.1 AP000350.8 -4.98 1.32e-06 0.00098 -0.39 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23949918~23954042:+ CESC cis rs5769707 0.706 rs763128 ENSG00000235111.1 RP1-29C18.8 -4.98 1.32e-06 0.000981 -0.36 -0.32 Monocyte percentage of white cells;Monocyte count; chr22:49624397 chr22:49612657~49615716:- CESC cis rs6686842 0.866 rs2802550 ENSG00000235358.1 RP11-399E6.1 4.98 1.32e-06 0.000982 0.39 0.32 Height; chr1:41031956 chr1:41242373~41284861:+ CESC cis rs6686842 0.965 rs2802548 ENSG00000235358.1 RP11-399E6.1 -4.98 1.32e-06 0.000982 -0.39 -0.32 Height; chr1:41035441 chr1:41242373~41284861:+ CESC cis rs875971 0.789 rs10260426 ENSG00000222364.1 RNU6-96P 4.98 1.32e-06 0.000982 0.37 0.32 Aortic root size; chr7:66271055 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs2901152 ENSG00000222364.1 RNU6-96P 4.98 1.32e-06 0.000982 0.37 0.32 Aortic root size; chr7:66300017 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs10263690 ENSG00000222364.1 RNU6-96P 4.98 1.32e-06 0.000982 0.37 0.32 Aortic root size; chr7:66301466 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs10250544 ENSG00000222364.1 RNU6-96P 4.98 1.32e-06 0.000982 0.37 0.32 Aortic root size; chr7:66301574 chr7:66395191~66395286:+ CESC cis rs1799949 1 rs11649954 ENSG00000267681.1 CTD-3199J23.6 -4.98 1.32e-06 0.000982 -0.42 -0.32 Menopause (age at onset); chr17:43342667 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs1824889 ENSG00000267681.1 CTD-3199J23.6 -4.98 1.32e-06 0.000982 -0.42 -0.32 Menopause (age at onset); chr17:43344508 chr17:43144956~43145255:+ CESC cis rs2842992 0.789 rs2295901 ENSG00000237927.1 RP3-393E18.2 -4.97 1.32e-06 0.000983 -0.42 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159780263 chr6:159586955~159589169:- CESC cis rs9907295 0.901 rs78023535 ENSG00000270977.1 AC015849.16 -4.97 1.32e-06 0.000983 -0.43 -0.32 Fibroblast growth factor basic levels; chr17:35869598 chr17:35893707~35911023:- CESC cis rs73086581 0.786 rs6037705 ENSG00000229539.1 RP11-119B16.2 4.97 1.32e-06 0.000984 0.51 0.32 Response to antidepressants in depression; chr20:3972183 chr20:3888239~3888868:- CESC cis rs2842992 0.747 rs9365095 ENSG00000237927.1 RP3-393E18.2 -4.97 1.33e-06 0.000985 -0.42 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159771896 chr6:159586955~159589169:- CESC cis rs2842992 0.789 rs9355748 ENSG00000237927.1 RP3-393E18.2 -4.97 1.33e-06 0.000985 -0.42 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159773850 chr6:159586955~159589169:- CESC cis rs2732480 0.577 rs2634693 ENSG00000258273.1 RP11-370I10.4 -4.97 1.33e-06 0.000986 -0.39 -0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48312715 chr12:48333755~48333901:- CESC cis rs2732480 0.577 rs2634691 ENSG00000258273.1 RP11-370I10.4 -4.97 1.33e-06 0.000986 -0.39 -0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48314476 chr12:48333755~48333901:- CESC cis rs2732480 0.557 rs2732441 ENSG00000258273.1 RP11-370I10.4 -4.97 1.33e-06 0.000986 -0.39 -0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48329541 chr12:48333755~48333901:- CESC cis rs2732480 0.577 rs2732448 ENSG00000258273.1 RP11-370I10.4 -4.97 1.33e-06 0.000986 -0.39 -0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48336817 chr12:48333755~48333901:- CESC cis rs2732480 0.577 rs2732466 ENSG00000258273.1 RP11-370I10.4 -4.97 1.33e-06 0.000986 -0.39 -0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48338676 chr12:48333755~48333901:- CESC cis rs748404 0.631 rs6493086 ENSG00000249839.1 AC011330.5 -4.97 1.33e-06 0.000987 -0.34 -0.32 Lung cancer; chr15:43363196 chr15:43663654~43684339:- CESC cis rs2732480 0.538 rs2732462 ENSG00000258273.1 RP11-370I10.4 -4.97 1.33e-06 0.000987 -0.39 -0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48302601 chr12:48333755~48333901:- CESC cis rs12439619 0.846 rs28697264 ENSG00000255769.6 GOLGA2P10 -4.97 1.33e-06 0.000987 -0.48 -0.32 Intelligence (multi-trait analysis); chr15:82265559 chr15:82472993~82513950:- CESC cis rs6504622 0.667 rs11653589 ENSG00000262879.4 RP11-156P1.3 -4.97 1.33e-06 0.000988 -0.35 -0.32 Orofacial clefts; chr17:46990299 chr17:46984045~47100323:- CESC cis rs875971 0.793 rs460678 ENSG00000237310.1 GS1-124K5.4 4.97 1.33e-06 0.000988 0.31 0.32 Aortic root size; chr7:66062213 chr7:66493706~66495474:+ CESC cis rs748404 0.604 rs2278857 ENSG00000249839.1 AC011330.5 -4.97 1.33e-06 0.000988 -0.34 -0.32 Lung cancer; chr15:43340351 chr15:43663654~43684339:- CESC cis rs9907295 0.901 rs4796120 ENSG00000270977.1 AC015849.16 4.97 1.33e-06 0.000989 0.46 0.32 Fibroblast growth factor basic levels; chr17:35873887 chr17:35893707~35911023:- CESC cis rs42490 0.716 rs40636 ENSG00000251136.7 RP11-37B2.1 -4.97 1.33e-06 0.000989 -0.32 -0.32 Leprosy; chr8:89809079 chr8:89609409~89757727:- CESC cis rs2564921 0.73 rs56026870 ENSG00000242142.1 SERBP1P3 -4.97 1.33e-06 0.00099 -0.39 -0.32 Height; chr3:52998472 chr3:53064283~53065091:- CESC cis rs6504622 0.702 rs3851799 ENSG00000262879.4 RP11-156P1.3 -4.97 1.34e-06 0.000992 -0.35 -0.32 Orofacial clefts; chr17:46989122 chr17:46984045~47100323:- CESC cis rs10262624 0.967 rs10229233 ENSG00000234286.1 AC006026.13 -4.97 1.34e-06 0.000994 -0.33 -0.32 Schizophrenia; chr7:23867900 chr7:23680195~23680786:- CESC cis rs10262624 1 rs10245161 ENSG00000234286.1 AC006026.13 -4.97 1.34e-06 0.000994 -0.33 -0.32 Schizophrenia; chr7:23868073 chr7:23680195~23680786:- CESC cis rs783540 0.542 rs62009945 ENSG00000276710.3 CSPG4P8 4.97 1.34e-06 0.000994 0.37 0.32 Schizophrenia; chr15:82631205 chr15:82459472~82477258:+ CESC cis rs2243480 1 rs313831 ENSG00000228409.4 CCT6P1 4.97 1.34e-06 0.000994 0.49 0.32 Diabetic kidney disease; chr7:66086239 chr7:65751142~65763354:+ CESC cis rs1061377 0.965 rs12504238 ENSG00000249685.1 RP11-360F5.3 4.97 1.34e-06 0.000994 0.39 0.32 Uric acid levels; chr4:39142824 chr4:39133913~39135608:+ CESC cis rs1799949 1 rs4793231 ENSG00000267681.1 CTD-3199J23.6 -4.97 1.34e-06 0.000996 -0.42 -0.32 Menopause (age at onset); chr17:43350101 chr17:43144956~43145255:+ CESC cis rs8100891 0.537 rs10405382 ENSG00000267213.4 AC007773.2 -4.97 1.35e-06 0.000997 -0.49 -0.32 Neuroticism; chr19:32405810 chr19:32390050~32405560:- CESC cis rs875971 0.545 rs13311962 ENSG00000222364.1 RNU6-96P 4.97 1.35e-06 0.000998 0.42 0.32 Aortic root size; chr7:66603142 chr7:66395191~66395286:+ CESC cis rs9549367 0.789 rs9549711 ENSG00000269125.1 RP11-98F14.11 -4.97 1.35e-06 0.001 -0.45 -0.32 Platelet distribution width; chr13:113246243 chr13:113165002~113165183:- CESC cis rs9549367 0.737 rs9549712 ENSG00000269125.1 RP11-98F14.11 -4.97 1.35e-06 0.001 -0.45 -0.32 Platelet distribution width; chr13:113248041 chr13:113165002~113165183:- CESC cis rs9549367 0.774 rs9549364 ENSG00000269125.1 RP11-98F14.11 -4.97 1.35e-06 0.001 -0.45 -0.32 Platelet distribution width; chr13:113249431 chr13:113165002~113165183:- CESC cis rs9549367 0.737 rs11619691 ENSG00000269125.1 RP11-98F14.11 -4.97 1.35e-06 0.001 -0.45 -0.32 Platelet distribution width; chr13:113250322 chr13:113165002~113165183:- CESC cis rs9549367 0.826 rs9549713 ENSG00000269125.1 RP11-98F14.11 -4.97 1.35e-06 0.001 -0.45 -0.32 Platelet distribution width; chr13:113250994 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs3861720 ENSG00000269125.1 RP11-98F14.11 -4.97 1.35e-06 0.001 -0.45 -0.32 Platelet distribution width; chr13:113251783 chr13:113165002~113165183:- CESC cis rs9549367 0.865 rs3861721 ENSG00000269125.1 RP11-98F14.11 -4.97 1.35e-06 0.001 -0.45 -0.32 Platelet distribution width; chr13:113251994 chr13:113165002~113165183:- CESC cis rs8062405 0.754 rs28410083 ENSG00000259982.1 CDC37P1 -4.97 1.35e-06 0.001 -0.4 -0.32 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620039 chr16:28700294~28701540:- CESC cis rs8062405 0.789 rs1968751 ENSG00000259982.1 CDC37P1 -4.97 1.35e-06 0.001 -0.4 -0.32 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620438 chr16:28700294~28701540:- CESC cis rs2548724 0.561 rs10463981 ENSG00000250682.4 LINC00491 4.97 1.35e-06 0.001 0.38 0.32 Type 2 diabetes; chr5:102451358 chr5:102609156~102671559:- CESC cis rs9907295 0.688 rs4796138 ENSG00000270977.1 AC015849.16 -4.97 1.36e-06 0.001 -0.45 -0.32 Fibroblast growth factor basic levels; chr17:35932791 chr17:35893707~35911023:- CESC cis rs10800713 0.954 rs4623737 ENSG00000260088.1 RP11-92G12.3 -4.97 1.36e-06 0.00101 -0.38 -0.32 Tandem gait; chr1:200594578 chr1:200669507~200694250:+ CESC cis rs7714584 1 rs4958426 ENSG00000197083.10 ZNF300P1 4.97 1.36e-06 0.00101 0.66 0.32 Crohn's disease; chr5:150898784 chr5:150930645~150946289:- CESC cis rs3806843 0.521 rs192231 ENSG00000202111.1 VTRNA1-2 4.97 1.36e-06 0.00101 0.33 0.32 Depressive symptoms (multi-trait analysis); chr5:140868954 chr5:140718925~140719013:+ CESC cis rs6504622 0.755 rs11079750 ENSG00000262879.4 RP11-156P1.3 -4.97 1.36e-06 0.00101 -0.35 -0.32 Orofacial clefts; chr17:47072149 chr17:46984045~47100323:- CESC cis rs116095464 0.558 rs10065239 ENSG00000250848.1 CTD-2083E4.5 -4.97 1.36e-06 0.00101 -0.47 -0.32 Breast cancer; chr5:275173 chr5:288833~290321:- CESC cis rs9549367 0.789 rs7994324 ENSG00000269125.1 RP11-98F14.11 -4.97 1.36e-06 0.00101 -0.45 -0.32 Platelet distribution width; chr13:113252183 chr13:113165002~113165183:- CESC cis rs7927592 0.871 rs113020558 ENSG00000212093.1 AP000807.1 4.97 1.36e-06 0.00101 0.38 0.32 Total body bone mineral density; chr11:68529364 chr11:68506083~68506166:- CESC cis rs2337406 0.866 rs4583128 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106780669 chr14:106770577~106771020:- CESC cis rs2337406 0.852 rs12050239 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781132 chr14:106770577~106771020:- CESC cis rs2337406 0.929 rs59263250 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781183 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs58083017 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781256 chr14:106770577~106771020:- CESC cis rs2337406 0.789 rs60390024 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781327 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs74092532 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781363 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs74092534 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781364 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs74092535 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781722 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs74092537 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781883 chr14:106770577~106771020:- CESC cis rs2337406 0.81 rs74092538 ENSG00000274576.2 IGHV2-70 -4.97 1.37e-06 0.00101 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106781942 chr14:106770577~106771020:- CESC cis rs8067354 0.958 rs2777889 ENSG00000266701.1 AC005702.4 4.97 1.37e-06 0.00101 0.38 0.32 Hemoglobin concentration; chr17:59770645 chr17:60042546~60042627:- CESC cis rs875971 0.545 rs10950036 ENSG00000222364.1 RNU6-96P -4.97 1.37e-06 0.00101 -0.41 -0.32 Aortic root size; chr7:66353241 chr7:66395191~66395286:+ CESC cis rs1823913 0.927 rs13025919 ENSG00000227542.1 AC092614.2 4.97 1.37e-06 0.00101 0.34 0.32 Obesity-related traits; chr2:191260175 chr2:191229165~191246172:- CESC cis rs6686842 1 rs2749418 ENSG00000235358.1 RP11-399E6.1 -4.97 1.37e-06 0.00102 -0.39 -0.32 Height; chr1:41044002 chr1:41242373~41284861:+ CESC cis rs34779708 0.931 rs17582416 ENSG00000230534.5 RP11-297A16.2 4.97 1.37e-06 0.00102 0.43 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34998722 chr10:35098006~35127020:- CESC cis rs11089937 0.926 rs5750601 ENSG00000211639.2 IGLV4-60 4.97 1.37e-06 0.00102 0.27 0.32 Periodontitis (PAL4Q3); chr22:22144396 chr22:22162199~22162681:+ CESC cis rs875971 0.755 rs76288834 ENSG00000232559.3 GS1-124K5.12 -4.97 1.37e-06 0.00102 -0.35 -0.32 Aortic root size; chr7:66604815 chr7:66554588~66576923:- CESC cis rs10463554 0.889 rs246912 ENSG00000175749.11 EIF3KP1 4.97 1.38e-06 0.00102 0.36 0.32 Parkinson's disease; chr5:103225140 chr5:103032376~103033031:+ CESC cis rs9907295 0.818 rs7211393 ENSG00000271013.1 AC015849.15 -4.97 1.38e-06 0.00102 -0.36 -0.32 Fibroblast growth factor basic levels; chr17:35885124 chr17:35912635~35918010:- CESC cis rs13631 1 rs13631 ENSG00000268996.3 MAN1B1-AS1 4.97 1.38e-06 0.00102 0.3 0.32 Cerebrospinal fluid biomarker levels; chr9:137111750 chr9:137084946~137086817:- CESC cis rs12439619 0.846 rs62012003 ENSG00000255769.6 GOLGA2P10 -4.97 1.38e-06 0.00102 -0.47 -0.32 Intelligence (multi-trait analysis); chr15:82183236 chr15:82472993~82513950:- CESC cis rs12439619 0.768 rs28694364 ENSG00000255769.6 GOLGA2P10 -4.97 1.38e-06 0.00102 -0.47 -0.32 Intelligence (multi-trait analysis); chr15:82208119 chr15:82472993~82513950:- CESC cis rs12439619 0.81 rs28876157 ENSG00000255769.6 GOLGA2P10 -4.97 1.38e-06 0.00102 -0.47 -0.32 Intelligence (multi-trait analysis); chr15:82216708 chr15:82472993~82513950:- CESC cis rs9907295 0.688 rs9890583 ENSG00000271013.1 AC015849.15 -4.97 1.38e-06 0.00102 -0.4 -0.32 Fibroblast growth factor basic levels; chr17:35919389 chr17:35912635~35918010:- CESC cis rs2299587 0.552 rs433387 ENSG00000253671.1 RP11-806O11.1 -4.97 1.38e-06 0.00102 -0.33 -0.32 Economic and political preferences; chr8:18012326 chr8:17808941~17820868:+ CESC cis rs10853057 0.717 rs11079553 ENSG00000214174.7 AMZ2P1 -4.97 1.38e-06 0.00102 -0.41 -0.32 White matter microstructure (global fractional anisotropy); chr17:65061877 chr17:64966550~64975576:- CESC cis rs10262624 1 rs13244265 ENSG00000234286.1 AC006026.13 -4.96 1.39e-06 0.00103 -0.34 -0.32 Schizophrenia; chr7:23878284 chr7:23680195~23680786:- CESC cis rs7927592 0.913 rs12283755 ENSG00000212093.1 AP000807.1 4.96 1.39e-06 0.00103 0.38 0.32 Total body bone mineral density; chr11:68604190 chr11:68506083~68506166:- CESC cis rs7572733 0.875 rs7587043 ENSG00000222017.1 AC011997.1 4.96 1.39e-06 0.00103 0.35 0.32 Dermatomyositis; chr2:197977005 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs7587598 ENSG00000222017.1 AC011997.1 4.96 1.39e-06 0.00103 0.35 0.32 Dermatomyositis; chr2:197977520 chr2:197693106~197774823:+ CESC cis rs10518325 0.892 rs17642621 ENSG00000245958.5 RP11-33B1.1 4.96 1.39e-06 0.00103 0.54 0.32 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118487196 chr4:119454791~119552025:+ CESC cis rs783540 0.521 rs1259176 ENSG00000255769.6 GOLGA2P10 4.96 1.39e-06 0.00103 0.37 0.32 Schizophrenia; chr15:82602149 chr15:82472993~82513950:- CESC cis rs7208859 0.673 rs216410 ENSG00000263531.1 RP13-753N3.1 -4.96 1.4e-06 0.00103 -0.52 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576813 chr17:30863921~30864940:- CESC cis rs1061377 1 rs6829450 ENSG00000249685.1 RP11-360F5.3 4.96 1.4e-06 0.00103 0.38 0.32 Uric acid levels; chr4:39114721 chr4:39133913~39135608:+ CESC cis rs8059260 0.668 rs16957894 ENSG00000274038.1 RP11-66H6.4 -4.96 1.4e-06 0.00103 -0.52 -0.32 Alcohol consumption over the past year; chr16:10996501 chr16:11056556~11057034:+ CESC cis rs7927592 0.913 rs6591340 ENSG00000212093.1 AP000807.1 4.96 1.4e-06 0.00103 0.38 0.32 Total body bone mineral density; chr11:68530168 chr11:68506083~68506166:- CESC cis rs8067354 0.872 rs2645483 ENSG00000266701.1 AC005702.4 4.96 1.4e-06 0.00103 0.38 0.32 Hemoglobin concentration; chr17:59770823 chr17:60042546~60042627:- CESC cis rs2836950 0.565 rs7279497 ENSG00000232608.1 TIMM9P2 -4.96 1.4e-06 0.00103 -0.35 -0.32 Menarche (age at onset); chr21:39159380 chr21:39216624~39217506:+ CESC cis rs950880 0.645 rs56044378 ENSG00000234389.1 AC007278.3 -4.96 1.4e-06 0.00103 -0.35 -0.32 Serum protein levels (sST2); chr2:102448907 chr2:102438713~102440475:+ CESC cis rs992157 0.71 rs12612347 ENSG00000261338.2 RP11-378A13.1 -4.96 1.4e-06 0.00103 -0.39 -0.32 Colorectal cancer; chr2:218192615 chr2:218255319~218257366:+ CESC cis rs2729354 0.768 rs2584856 ENSG00000265566.2 RN7SL605P -4.96 1.4e-06 0.00103 -0.46 -0.32 Blood protein levels; chr11:57499839 chr11:57528085~57528365:- CESC cis rs1799949 1 rs16940 ENSG00000267681.1 CTD-3199J23.6 -4.96 1.4e-06 0.00103 -0.41 -0.32 Menopause (age at onset); chr17:43093220 chr17:43144956~43145255:+ CESC cis rs75422866 0.867 rs78912815 ENSG00000280054.1 RP1-197B17.7 4.96 1.41e-06 0.00104 0.8 0.32 Pneumonia; chr12:47612065 chr12:47728151~47730598:- CESC cis rs2028299 0.92 rs11638138 ENSG00000259677.1 RP11-493E3.1 -4.96 1.41e-06 0.00104 -0.42 -0.32 Type 2 diabetes; chr15:89885523 chr15:89876540~89877285:+ CESC cis rs957448 1 rs72674866 ENSG00000253704.1 RP11-267M23.4 4.96 1.41e-06 0.00104 0.37 0.32 Nonsyndromic cleft lip with cleft palate; chr8:94564619 chr8:94553722~94569745:+ CESC cis rs957448 1 rs55897841 ENSG00000253704.1 RP11-267M23.4 4.96 1.41e-06 0.00104 0.37 0.32 Nonsyndromic cleft lip with cleft palate; chr8:94565042 chr8:94553722~94569745:+ CESC cis rs2243480 1 rs4149468 ENSG00000275400.1 RP4-756H11.5 4.96 1.41e-06 0.00104 0.55 0.32 Diabetic kidney disease; chr7:66360703 chr7:66553805~66554199:- CESC cis rs9322193 0.923 rs2342765 ENSG00000268592.3 RAET1E-AS1 4.96 1.41e-06 0.00104 0.42 0.32 Lung cancer; chr6:149858873 chr6:149863494~149919507:+ CESC cis rs832187 0.594 rs832197 ENSG00000280620.1 SCAANT1 -4.96 1.41e-06 0.00104 -0.43 -0.32 Schizophrenia; chr3:63898616 chr3:63911518~63911772:- CESC cis rs3806843 0.676 rs753280 ENSG00000202111.1 VTRNA1-2 -4.96 1.41e-06 0.00104 -0.33 -0.32 Depressive symptoms (multi-trait analysis); chr5:140644457 chr5:140718925~140719013:+ CESC cis rs11157436 0.958 rs1041859 ENSG00000211813.2 TRAV34 4.96 1.41e-06 0.00104 0.36 0.32 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22204878 chr14:22207522~22208129:+ CESC cis rs11157436 0.958 rs1041860 ENSG00000211813.2 TRAV34 4.96 1.41e-06 0.00104 0.36 0.32 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22204897 chr14:22207522~22208129:+ CESC cis rs2108622 1 rs2108622 ENSG00000267453.5 AC004791.2 -4.96 1.41e-06 0.00104 -0.44 -0.32 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15879621 chr19:15851993~15864904:- CESC cis rs5769707 0.642 rs4824070 ENSG00000188511.11 C22orf34 4.96 1.41e-06 0.00104 0.39 0.32 Monocyte percentage of white cells;Monocyte count; chr22:49637873 chr22:49414524~49657542:- CESC cis rs11155671 0.53 rs9397420 ENSG00000223701.3 RAET1E-AS1 -4.96 1.42e-06 0.00104 -0.36 -0.32 Testicular germ cell tumor; chr6:149885645 chr6:149884431~149919508:+ CESC cis rs10754283 0.84 rs6428560 ENSG00000231613.1 RP5-943J3.1 4.96 1.42e-06 0.00104 0.41 0.32 Amyotrophic lateral sclerosis (sporadic); chr1:89636903 chr1:89788914~89790492:+ CESC cis rs9322193 0.847 rs880246 ENSG00000216906.2 RP11-350J20.9 4.96 1.42e-06 0.00104 0.37 0.32 Lung cancer; chr6:149845972 chr6:149904243~149906418:+ CESC cis rs875971 0.545 rs3735147 ENSG00000237310.1 GS1-124K5.4 4.96 1.42e-06 0.00104 0.35 0.32 Aortic root size; chr7:66505541 chr7:66493706~66495474:+ CESC cis rs34375054 0.526 rs7302475 ENSG00000279233.1 RP11-158L12.4 4.96 1.42e-06 0.00105 0.35 0.32 Post bronchodilator FEV1/FVC ratio; chr12:125193340 chr12:125138245~125141711:+ CESC cis rs10262624 1 rs9769098 ENSG00000234286.1 AC006026.13 -4.96 1.42e-06 0.00105 -0.33 -0.32 Schizophrenia; chr7:23877113 chr7:23680195~23680786:- CESC cis rs10262624 0.967 rs12333669 ENSG00000234286.1 AC006026.13 -4.96 1.42e-06 0.00105 -0.33 -0.32 Schizophrenia; chr7:23877267 chr7:23680195~23680786:- CESC cis rs10262624 0.935 rs10487596 ENSG00000234286.1 AC006026.13 -4.96 1.42e-06 0.00105 -0.33 -0.32 Schizophrenia; chr7:23877458 chr7:23680195~23680786:- CESC cis rs10262624 1 rs10950973 ENSG00000234286.1 AC006026.13 -4.96 1.42e-06 0.00105 -0.33 -0.32 Schizophrenia; chr7:23877658 chr7:23680195~23680786:- CESC cis rs10262624 1 rs10950974 ENSG00000234286.1 AC006026.13 -4.96 1.42e-06 0.00105 -0.33 -0.32 Schizophrenia; chr7:23877661 chr7:23680195~23680786:- CESC cis rs10262624 1 rs10950975 ENSG00000234286.1 AC006026.13 -4.96 1.42e-06 0.00105 -0.33 -0.32 Schizophrenia; chr7:23877861 chr7:23680195~23680786:- CESC cis rs10262624 0.967 rs13244145 ENSG00000234286.1 AC006026.13 -4.96 1.42e-06 0.00105 -0.33 -0.32 Schizophrenia; chr7:23878123 chr7:23680195~23680786:- CESC cis rs12458462 0.892 rs58675823 ENSG00000274828.1 RP11-567M16.6 4.96 1.43e-06 0.00105 0.3 0.32 Monocyte count; chr18:79703672 chr18:79677287~79679358:- CESC cis rs4423214 0.559 rs11234042 ENSG00000254682.1 RP11-660L16.2 -4.96 1.43e-06 0.00105 -0.46 -0.32 Vitamin D levels; chr11:71528040 chr11:71448674~71452157:+ CESC cis rs12439619 0.846 rs28470877 ENSG00000255769.6 GOLGA2P10 -4.96 1.43e-06 0.00105 -0.47 -0.32 Intelligence (multi-trait analysis); chr15:82245797 chr15:82472993~82513950:- CESC cis rs2028299 0.959 rs893617 ENSG00000259677.1 RP11-493E3.1 4.96 1.43e-06 0.00105 0.43 0.32 Type 2 diabetes; chr15:89838046 chr15:89876540~89877285:+ CESC cis rs9322193 0.884 rs1108889 ENSG00000216906.2 RP11-350J20.9 4.96 1.43e-06 0.00105 0.37 0.32 Lung cancer; chr6:149845433 chr6:149904243~149906418:+ CESC cis rs9907295 0.636 rs4251703 ENSG00000270977.1 AC015849.16 -4.96 1.43e-06 0.00105 -0.4 -0.32 Fibroblast growth factor basic levels; chr17:35807954 chr17:35893707~35911023:- CESC cis rs73086581 1 rs3746666 ENSG00000229539.1 RP11-119B16.2 4.96 1.44e-06 0.00106 0.52 0.32 Response to antidepressants in depression; chr20:3930214 chr20:3888239~3888868:- CESC cis rs7927592 0.913 rs11228262 ENSG00000212093.1 AP000807.1 4.96 1.44e-06 0.00106 0.38 0.32 Total body bone mineral density; chr11:68507439 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs55883802 ENSG00000212093.1 AP000807.1 4.96 1.44e-06 0.00106 0.38 0.32 Total body bone mineral density; chr11:68511361 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs11228268 ENSG00000212093.1 AP000807.1 4.96 1.44e-06 0.00106 0.38 0.32 Total body bone mineral density; chr11:68519979 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs4084149 ENSG00000212093.1 AP000807.1 4.96 1.44e-06 0.00106 0.38 0.32 Total body bone mineral density; chr11:68521099 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs7925275 ENSG00000212093.1 AP000807.1 4.96 1.44e-06 0.00106 0.38 0.32 Total body bone mineral density; chr11:68522965 chr11:68506083~68506166:- CESC cis rs860295 0.702 rs11264381 ENSG00000225855.5 RUSC1-AS1 -4.96 1.44e-06 0.00106 -0.27 -0.32 Body mass index; chr1:155552781 chr1:155316863~155324176:- CESC cis rs10129255 1 rs10129407 ENSG00000280411.1 IGHV1-69-2 -4.96 1.44e-06 0.00106 -0.25 -0.32 Kawasaki disease; chr14:106767956 chr14:106762092~106762588:- CESC cis rs889512 0.642 rs28595463 ENSG00000280152.1 RP11-331F4.5 -4.96 1.45e-06 0.00106 -0.46 -0.32 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75247337 chr16:75245994~75250077:- CESC cis rs889512 0.642 rs60879082 ENSG00000280152.1 RP11-331F4.5 -4.96 1.45e-06 0.00106 -0.46 -0.32 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75249167 chr16:75245994~75250077:- CESC cis rs2337406 0.866 rs79901786 ENSG00000274576.2 IGHV2-70 -4.95 1.45e-06 0.00106 -0.36 -0.32 Alzheimer's disease (late onset); chr14:106777623 chr14:106770577~106771020:- CESC cis rs748404 0.578 rs512628 ENSG00000249839.1 AC011330.5 -4.95 1.46e-06 0.00107 -0.34 -0.32 Lung cancer; chr15:43326536 chr15:43663654~43684339:- CESC cis rs9549367 0.826 rs9549710 ENSG00000269125.1 RP11-98F14.11 -4.95 1.46e-06 0.00107 -0.45 -0.32 Platelet distribution width; chr13:113243750 chr13:113165002~113165183:- CESC cis rs10262624 0.935 rs8180700 ENSG00000234286.1 AC006026.13 -4.95 1.46e-06 0.00107 -0.33 -0.32 Schizophrenia; chr7:23870323 chr7:23680195~23680786:- CESC cis rs950880 0.71 rs17027230 ENSG00000234389.1 AC007278.3 -4.95 1.46e-06 0.00107 -0.35 -0.32 Serum protein levels (sST2); chr2:102462870 chr2:102438713~102440475:+ CESC cis rs733592 0.56 rs2158515 ENSG00000240399.1 RP1-228P16.1 -4.95 1.46e-06 0.00107 -0.32 -0.32 Plateletcrit; chr12:48113885 chr12:48054813~48055591:- CESC cis rs5758659 0.714 rs2284087 ENSG00000227370.1 RP4-669P10.19 4.95 1.46e-06 0.00107 0.33 0.32 Cognitive function; chr22:42089667 chr22:42132543~42132998:+ CESC cis rs7598759 0.548 rs1584462 ENSG00000181798.2 LINC00471 -4.95 1.46e-06 0.00107 -0.34 -0.32 Noise-induced hearing loss; chr2:231505087 chr2:231508426~231514339:- CESC cis rs860295 0.702 rs4971095 ENSG00000225855.5 RUSC1-AS1 -4.95 1.46e-06 0.00107 -0.26 -0.32 Body mass index; chr1:155636433 chr1:155316863~155324176:- CESC cis rs72772090 0.539 rs11740375 ENSG00000248734.2 CTD-2260A17.1 -4.95 1.47e-06 0.00108 -0.48 -0.32 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777193 chr5:96784777~96785999:+ CESC cis rs950880 0.71 rs11694360 ENSG00000234389.1 AC007278.3 -4.95 1.47e-06 0.00108 -0.34 -0.32 Serum protein levels (sST2); chr2:102444687 chr2:102438713~102440475:+ CESC cis rs950880 0.677 rs4851585 ENSG00000234389.1 AC007278.3 -4.95 1.47e-06 0.00108 -0.34 -0.32 Serum protein levels (sST2); chr2:102446294 chr2:102438713~102440475:+ CESC cis rs34779708 0.931 rs4007289 ENSG00000230534.5 RP11-297A16.2 4.95 1.47e-06 0.00108 0.42 0.32 Inflammatory bowel disease;Crohn's disease; chr10:34980862 chr10:35098006~35127020:- CESC cis rs7714584 1 rs12656600 ENSG00000197083.10 ZNF300P1 4.95 1.47e-06 0.00108 0.63 0.32 Crohn's disease; chr5:150932310 chr5:150930645~150946289:- CESC cis rs6142102 0.961 rs4911407 ENSG00000276073.1 RP5-1125A11.7 -4.95 1.48e-06 0.00108 -0.31 -0.32 Skin pigmentation; chr20:34095759 chr20:33985617~33988989:- CESC cis rs2280018 0.538 rs7404526 ENSG00000260735.1 RP11-72I8.1 -4.95 1.48e-06 0.00109 -0.34 -0.32 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15035305 chr16:15094411~15109197:+ CESC cis rs2833693 0.615 rs9974274 ENSG00000261610.1 AP000265.1 4.95 1.48e-06 0.00109 0.38 0.32 Temperament; chr21:32196563 chr21:32259804~32261585:- CESC cis rs8177876 0.749 rs79834398 ENSG00000261838.4 RP11-303E16.6 4.95 1.49e-06 0.00109 0.67 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057033 chr16:81069854~81076598:+ CESC cis rs9322193 0.923 rs55849538 ENSG00000268592.3 RAET1E-AS1 4.95 1.49e-06 0.00109 0.41 0.32 Lung cancer; chr6:149635330 chr6:149863494~149919507:+ CESC cis rs9847710 0.696 rs2564932 ENSG00000242142.1 SERBP1P3 -4.95 1.49e-06 0.00109 -0.37 -0.32 Ulcerative colitis; chr3:52987994 chr3:53064283~53065091:- CESC cis rs2404602 0.692 rs2120108 ENSG00000259422.1 RP11-593F23.1 -4.95 1.49e-06 0.00109 -0.36 -0.32 Blood metabolite levels; chr15:76577588 chr15:76174891~76181486:- CESC cis rs2729354 0.768 rs2848635 ENSG00000265566.2 RN7SL605P -4.95 1.49e-06 0.00109 -0.46 -0.32 Blood protein levels; chr11:57486458 chr11:57528085~57528365:- CESC cis rs992157 0.764 rs10932774 ENSG00000261338.2 RP11-378A13.1 4.95 1.5e-06 0.00109 0.4 0.32 Colorectal cancer; chr2:218326846 chr2:218255319~218257366:+ CESC cis rs6142102 1 rs4911409 ENSG00000276073.1 RP5-1125A11.7 -4.95 1.5e-06 0.0011 -0.3 -0.32 Skin pigmentation; chr20:34122904 chr20:33985617~33988989:- CESC cis rs6142102 1 rs4911410 ENSG00000276073.1 RP5-1125A11.7 -4.95 1.5e-06 0.0011 -0.3 -0.32 Skin pigmentation; chr20:34123168 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs4911411 ENSG00000276073.1 RP5-1125A11.7 -4.95 1.5e-06 0.0011 -0.3 -0.32 Skin pigmentation; chr20:34128036 chr20:33985617~33988989:- CESC cis rs10262624 0.967 rs2390848 ENSG00000234286.1 AC006026.13 -4.95 1.5e-06 0.0011 -0.33 -0.32 Schizophrenia; chr7:23872755 chr7:23680195~23680786:- CESC cis rs10262624 1 rs2023787 ENSG00000234286.1 AC006026.13 -4.95 1.5e-06 0.0011 -0.33 -0.32 Schizophrenia; chr7:23875521 chr7:23680195~23680786:- CESC cis rs10262624 1 rs17347505 ENSG00000234286.1 AC006026.13 -4.95 1.5e-06 0.0011 -0.33 -0.32 Schizophrenia; chr7:23875664 chr7:23680195~23680786:- CESC cis rs10262624 1 rs12671624 ENSG00000234286.1 AC006026.13 -4.95 1.5e-06 0.0011 -0.33 -0.32 Schizophrenia; chr7:23875794 chr7:23680195~23680786:- CESC cis rs10262624 1 rs12671584 ENSG00000234286.1 AC006026.13 -4.95 1.5e-06 0.0011 -0.33 -0.32 Schizophrenia; chr7:23875803 chr7:23680195~23680786:- CESC cis rs10262624 1 rs10262624 ENSG00000234286.1 AC006026.13 -4.95 1.5e-06 0.0011 -0.33 -0.32 Schizophrenia; chr7:23876057 chr7:23680195~23680786:- CESC cis rs9549367 0.713 rs3024757 ENSG00000269125.1 RP11-98F14.11 -4.95 1.5e-06 0.0011 -0.46 -0.32 Platelet distribution width; chr13:113168872 chr13:113165002~113165183:- CESC cis rs12468226 1 rs16839077 ENSG00000273456.1 RP11-686O6.2 4.95 1.5e-06 0.0011 0.45 0.32 Urate levels; chr2:202343970 chr2:202374932~202375604:- CESC cis rs11907546 1 rs11907546 ENSG00000276073.1 RP5-1125A11.7 -4.95 1.5e-06 0.0011 -0.3 -0.32 Cancer (pleiotropy);Cancer; chr20:34131991 chr20:33985617~33988989:- CESC cis rs6142102 0.847 rs4911413 ENSG00000276073.1 RP5-1125A11.7 -4.95 1.5e-06 0.0011 -0.3 -0.32 Skin pigmentation; chr20:34133969 chr20:33985617~33988989:- CESC cis rs3806843 0.576 rs251376 ENSG00000202111.1 VTRNA1-2 4.95 1.5e-06 0.0011 0.33 0.32 Depressive symptoms (multi-trait analysis); chr5:140874104 chr5:140718925~140719013:+ CESC cis rs9322193 0.926 rs3805751 ENSG00000268592.3 RAET1E-AS1 4.95 1.5e-06 0.0011 0.41 0.32 Lung cancer; chr6:149791193 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs10872656 ENSG00000268592.3 RAET1E-AS1 4.95 1.5e-06 0.0011 0.41 0.32 Lung cancer; chr6:149799444 chr6:149863494~149919507:+ CESC cis rs9326248 0.727 rs4938347 ENSG00000280143.1 AP000892.6 4.95 1.51e-06 0.0011 0.45 0.32 Blood protein levels; chr11:117151043 chr11:117204967~117210292:+ CESC cis rs9326248 0.813 rs4938350 ENSG00000280143.1 AP000892.6 4.95 1.51e-06 0.0011 0.45 0.32 Blood protein levels; chr11:117151560 chr11:117204967~117210292:+ CESC cis rs9326248 0.768 rs4936366 ENSG00000280143.1 AP000892.6 4.95 1.51e-06 0.0011 0.45 0.32 Blood protein levels; chr11:117156169 chr11:117204967~117210292:+ CESC cis rs9326248 0.861 rs4938352 ENSG00000280143.1 AP000892.6 4.95 1.51e-06 0.0011 0.45 0.32 Blood protein levels; chr11:117156765 chr11:117204967~117210292:+ CESC cis rs11690935 0.885 rs6725388 ENSG00000228389.1 AC068039.4 4.95 1.51e-06 0.0011 0.4 0.32 Schizophrenia; chr2:171873505 chr2:171773482~171775844:+ CESC cis rs6964833 1 rs36044436 ENSG00000277053.3 GTF2IP1 -4.95 1.51e-06 0.0011 -0.39 -0.32 Menarche (age at onset); chr7:74675495 chr7:75185385~75237696:- CESC cis rs67180937 0.582 rs71524942 ENSG00000272750.1 RP11-378J18.8 -4.95 1.51e-06 0.00111 -0.39 -0.32 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222689650 chr1:222658867~222661512:- CESC cis rs4266144 0.562 rs56357317 ENSG00000244515.1 KRT18P34 -4.95 1.51e-06 0.00111 -0.42 -0.32 Coronary artery disease; chr3:157117385 chr3:157162663~157163932:- CESC cis rs34779708 0.931 rs2490663 ENSG00000230534.5 RP11-297A16.2 -4.95 1.52e-06 0.00111 -0.41 -0.32 Inflammatory bowel disease;Crohn's disease; chr10:35040807 chr10:35098006~35127020:- CESC cis rs494459 0.688 rs1048040 ENSG00000255422.1 AP002954.4 -4.94 1.52e-06 0.00111 -0.36 -0.32 Height; chr11:118747911 chr11:118704607~118750263:+ CESC cis rs13113518 0.595 rs13120635 ENSG00000273257.1 RP11-177J6.1 4.94 1.52e-06 0.00111 0.42 0.32 Height; chr4:55361200 chr4:55387949~55388271:+ CESC cis rs875971 0.862 rs6958294 ENSG00000232559.3 GS1-124K5.12 -4.94 1.53e-06 0.00111 -0.34 -0.32 Aortic root size; chr7:66329809 chr7:66554588~66576923:- CESC cis rs4718428 0.672 rs36038499 ENSG00000273142.1 RP11-458F8.4 -4.94 1.53e-06 0.00111 -0.34 -0.32 Corneal structure; chr7:66824628 chr7:66902857~66906297:+ CESC cis rs4718428 0.705 rs62465692 ENSG00000273142.1 RP11-458F8.4 -4.94 1.53e-06 0.00111 -0.34 -0.32 Corneal structure; chr7:66830758 chr7:66902857~66906297:+ CESC cis rs10466239 0.73 rs2460535 ENSG00000230555.2 RP11-517P14.2 4.94 1.53e-06 0.00111 0.36 0.32 Telomere length; chr10:43325932 chr10:43420738~43422100:+ CESC cis rs2919917 0.666 rs10957898 ENSG00000254352.1 RP11-578O24.2 -4.94 1.53e-06 0.00111 -0.46 -0.32 Lymphocyte counts; chr8:78705078 chr8:78723796~78724136:- CESC cis rs12134133 1 rs28371614 ENSG00000274245.1 RP11-357P18.2 4.94 1.53e-06 0.00111 0.41 0.32 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207331929 chr1:207372559~207373252:+ CESC cis rs9322193 0.962 rs2151912 ENSG00000268592.3 RAET1E-AS1 4.94 1.53e-06 0.00111 0.42 0.32 Lung cancer; chr6:149831772 chr6:149863494~149919507:+ CESC cis rs7189233 0.531 rs1131220 ENSG00000279344.1 RP11-44F14.7 4.94 1.53e-06 0.00112 0.3 0.32 Intelligence (multi-trait analysis); chr16:53470022 chr16:53478957~53481550:- CESC cis rs7189233 0.513 rs10748 ENSG00000279344.1 RP11-44F14.7 4.94 1.53e-06 0.00112 0.3 0.32 Intelligence (multi-trait analysis); chr16:53470809 chr16:53478957~53481550:- CESC cis rs7189233 0.531 rs8045674 ENSG00000279344.1 RP11-44F14.7 4.94 1.53e-06 0.00112 0.3 0.32 Intelligence (multi-trait analysis); chr16:53476024 chr16:53478957~53481550:- CESC cis rs2729354 0.729 rs2581923 ENSG00000265566.2 RN7SL605P -4.94 1.53e-06 0.00112 -0.45 -0.32 Blood protein levels; chr11:57482518 chr11:57528085~57528365:- CESC cis rs2243480 0.901 rs12530490 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66226660 chr7:66553805~66554199:- CESC cis rs2243480 1 rs7778911 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66229519 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1979823 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66239626 chr7:66553805~66554199:- CESC cis rs2243480 1 rs6964245 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66253730 chr7:66553805~66554199:- CESC cis rs2243480 1 rs10807701 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66259699 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1499613 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66265873 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1553174 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66266207 chr7:66553805~66554199:- CESC cis rs2243480 1 rs10950032 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66273604 chr7:66553805~66554199:- CESC cis rs2243480 1 rs6958420 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66286184 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1392104 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66294120 chr7:66553805~66554199:- CESC cis rs2243480 1 rs4718333 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66307771 chr7:66553805~66554199:- CESC cis rs2243480 1 rs7792391 ENSG00000275400.1 RP4-756H11.5 -4.94 1.53e-06 0.00112 -0.54 -0.32 Diabetic kidney disease; chr7:66308442 chr7:66553805~66554199:- CESC cis rs2243480 1 rs781150 ENSG00000232559.3 GS1-124K5.12 4.94 1.53e-06 0.00112 0.53 0.32 Diabetic kidney disease; chr7:66015986 chr7:66554588~66576923:- CESC cis rs2243480 1 rs313798 ENSG00000232559.3 GS1-124K5.12 4.94 1.53e-06 0.00112 0.53 0.32 Diabetic kidney disease; chr7:66028044 chr7:66554588~66576923:- CESC cis rs2243480 1 rs313809 ENSG00000232559.3 GS1-124K5.12 4.94 1.53e-06 0.00112 0.53 0.32 Diabetic kidney disease; chr7:66034996 chr7:66554588~66576923:- CESC cis rs748404 0.631 rs3809482 ENSG00000205771.5 CATSPER2P1 -4.94 1.54e-06 0.00112 -0.38 -0.32 Lung cancer; chr15:43369604 chr15:43726918~43747094:- CESC cis rs9322193 0.962 rs9765929 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149769680 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs3805748 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149772542 chr6:149863494~149919507:+ CESC cis rs9322193 0.736 rs10457851 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149775216 chr6:149863494~149919507:+ CESC cis rs9322193 0.886 rs10872652 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149775303 chr6:149863494~149919507:+ CESC cis rs9322193 0.886 rs12525871 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149775882 chr6:149863494~149919507:+ CESC cis rs9322193 0.886 rs17672976 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149776207 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs2184369 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149776681 chr6:149863494~149919507:+ CESC cis rs8067354 0.645 rs9910518 ENSG00000266701.1 AC005702.4 4.94 1.54e-06 0.00112 0.43 0.32 Hemoglobin concentration; chr17:59734706 chr17:60042546~60042627:- CESC cis rs8067354 0.645 rs56236317 ENSG00000266701.1 AC005702.4 4.94 1.54e-06 0.00112 0.43 0.32 Hemoglobin concentration; chr17:59744764 chr17:60042546~60042627:- CESC cis rs8067354 0.645 rs7215180 ENSG00000266701.1 AC005702.4 4.94 1.54e-06 0.00112 0.43 0.32 Hemoglobin concentration; chr17:59744993 chr17:60042546~60042627:- CESC cis rs8067354 0.645 rs72840522 ENSG00000266701.1 AC005702.4 4.94 1.54e-06 0.00112 0.43 0.32 Hemoglobin concentration; chr17:59752631 chr17:60042546~60042627:- CESC cis rs8177876 0.749 rs78707250 ENSG00000261838.4 RP11-303E16.6 4.94 1.54e-06 0.00112 0.66 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046757 chr16:81069854~81076598:+ CESC cis rs7189233 0.55 rs13330182 ENSG00000279344.1 RP11-44F14.7 4.94 1.54e-06 0.00112 0.3 0.32 Intelligence (multi-trait analysis); chr16:53438473 chr16:53478957~53481550:- CESC cis rs9322193 0.923 rs12195866 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149693334 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9285524 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149694122 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs7753812 ENSG00000268592.3 RAET1E-AS1 4.94 1.54e-06 0.00112 0.41 0.32 Lung cancer; chr6:149690150 chr6:149863494~149919507:+ CESC cis rs6782228 0.675 rs4443194 ENSG00000242551.2 POU5F1P6 -4.94 1.54e-06 0.00112 -0.36 -0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128664603 chr3:128674735~128677005:- CESC cis rs6782228 0.675 rs4857918 ENSG00000242551.2 POU5F1P6 -4.94 1.54e-06 0.00112 -0.36 -0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128665117 chr3:128674735~128677005:- CESC cis rs2408955 0.521 rs7301003 ENSG00000240399.1 RP1-228P16.1 4.94 1.54e-06 0.00112 0.35 0.32 Glycated hemoglobin levels; chr12:48156444 chr12:48054813~48055591:- CESC cis rs9549367 0.713 rs11620600 ENSG00000269125.1 RP11-98F14.11 -4.94 1.55e-06 0.00113 -0.46 -0.32 Platelet distribution width; chr13:113174776 chr13:113165002~113165183:- CESC cis rs1862618 0.853 rs190414 ENSG00000271828.1 CTD-2310F14.1 4.94 1.55e-06 0.00113 0.43 0.32 Initial pursuit acceleration; chr5:56820945 chr5:56927874~56929573:+ CESC cis rs150992 0.603 rs246251 ENSG00000248489.1 CTD-2007H13.3 4.94 1.55e-06 0.00113 0.43 0.32 Body mass index; chr5:98942362 chr5:98929171~98995013:+ CESC cis rs116095464 0.558 rs56298907 ENSG00000250848.1 CTD-2083E4.5 -4.94 1.55e-06 0.00113 -0.47 -0.32 Breast cancer; chr5:283165 chr5:288833~290321:- CESC cis rs116095464 0.558 rs7356535 ENSG00000250848.1 CTD-2083E4.5 -4.94 1.55e-06 0.00113 -0.47 -0.32 Breast cancer; chr5:284002 chr5:288833~290321:- CESC cis rs116095464 0.558 rs55833259 ENSG00000250848.1 CTD-2083E4.5 -4.94 1.55e-06 0.00113 -0.47 -0.32 Breast cancer; chr5:286613 chr5:288833~290321:- CESC cis rs11159086 0.793 rs8015894 ENSG00000270000.1 RP3-449M8.9 4.94 1.55e-06 0.00113 0.5 0.32 Advanced glycation end-product levels; chr14:74491917 chr14:74471930~74472360:- CESC cis rs1707322 0.827 rs10890347 ENSG00000281133.1 AL355480.3 4.94 1.55e-06 0.00113 0.39 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776660 chr1:45580892~45580996:- CESC cis rs1799949 1 rs33946455 ENSG00000267681.1 CTD-3199J23.6 -4.94 1.55e-06 0.00113 -0.42 -0.32 Menopause (age at onset); chr17:43169829 chr17:43144956~43145255:+ CESC cis rs2564921 0.73 rs930122 ENSG00000242142.1 SERBP1P3 4.94 1.55e-06 0.00113 0.37 0.32 Height; chr3:53085313 chr3:53064283~53065091:- CESC cis rs9322193 0.607 rs12527391 ENSG00000231760.4 RP11-350J20.5 4.94 1.56e-06 0.00113 0.48 0.32 Lung cancer; chr6:149882156 chr6:149796151~149826294:- CESC cis rs116095464 1 rs55671190 ENSG00000250848.1 CTD-2083E4.5 -4.94 1.56e-06 0.00113 -0.6 -0.32 Breast cancer; chr5:287307 chr5:288833~290321:- CESC cis rs1499614 1 rs2707832 ENSG00000275400.1 RP4-756H11.5 4.94 1.56e-06 0.00113 0.56 0.32 Gout; chr7:66671562 chr7:66553805~66554199:- CESC cis rs7189233 0.531 rs7199401 ENSG00000279344.1 RP11-44F14.7 4.94 1.56e-06 0.00114 0.3 0.32 Intelligence (multi-trait analysis); chr16:53483038 chr16:53478957~53481550:- CESC cis rs875971 0.862 rs1860469 ENSG00000226824.5 RP4-756H11.3 4.94 1.56e-06 0.00114 0.4 0.32 Aortic root size; chr7:66641888 chr7:66654538~66669855:+ CESC cis rs875971 0.862 rs4718383 ENSG00000226824.5 RP4-756H11.3 4.94 1.56e-06 0.00114 0.4 0.32 Aortic root size; chr7:66643422 chr7:66654538~66669855:+ CESC cis rs6782228 0.527 rs6767383 ENSG00000242551.2 POU5F1P6 -4.94 1.56e-06 0.00114 -0.36 -0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694744 chr3:128674735~128677005:- CESC cis rs875971 0.798 rs12698522 ENSG00000232559.3 GS1-124K5.12 4.94 1.57e-06 0.00114 0.35 0.32 Aortic root size; chr7:66502354 chr7:66554588~66576923:- CESC cis rs875971 0.83 rs28714531 ENSG00000232559.3 GS1-124K5.12 4.94 1.57e-06 0.00114 0.35 0.32 Aortic root size; chr7:66503250 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs12698526 ENSG00000232559.3 GS1-124K5.12 4.94 1.57e-06 0.00114 0.35 0.32 Aortic root size; chr7:66504118 chr7:66554588~66576923:- CESC cis rs748404 0.631 rs2412781 ENSG00000249839.1 AC011330.5 4.94 1.57e-06 0.00114 0.34 0.32 Lung cancer; chr15:43375702 chr15:43663654~43684339:- CESC cis rs9907295 0.591 rs4239252 ENSG00000271013.1 AC015849.15 4.94 1.57e-06 0.00114 0.33 0.32 Fibroblast growth factor basic levels; chr17:35836561 chr17:35912635~35918010:- CESC cis rs7714670 0.704 rs12653477 ENSG00000184084.7 CTD-2372A4.1 -4.94 1.57e-06 0.00114 -0.35 -0.32 Venous thromboembolism (SNP x SNP interaction); chr5:73794264 chr5:73803296~73803599:- CESC cis rs6686842 0.562 rs1618022 ENSG00000235358.1 RP11-399E6.1 -4.94 1.57e-06 0.00114 -0.37 -0.32 Height; chr1:41072721 chr1:41242373~41284861:+ CESC cis rs116095464 0.558 rs56081398 ENSG00000250848.1 CTD-2083E4.5 -4.94 1.57e-06 0.00114 -0.45 -0.32 Breast cancer; chr5:247203 chr5:288833~290321:- CESC cis rs9309711 0.736 rs9309717 ENSG00000225234.1 TRAPPC12-AS1 4.94 1.58e-06 0.00114 0.3 0.32 Neurofibrillary tangles; chr2:3491307 chr2:3481242~3482409:- CESC cis rs6142102 0.886 rs4911147 ENSG00000276073.1 RP5-1125A11.7 -4.94 1.58e-06 0.00114 -0.32 -0.32 Skin pigmentation; chr20:34079801 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs8123521 ENSG00000276073.1 RP5-1125A11.7 -4.94 1.58e-06 0.00114 -0.32 -0.32 Skin pigmentation; chr20:34081079 chr20:33985617~33988989:- CESC cis rs7927592 0.913 rs12363722 ENSG00000212093.1 AP000807.1 4.94 1.58e-06 0.00114 0.38 0.32 Total body bone mineral density; chr11:68468823 chr11:68506083~68506166:- CESC cis rs7927592 0.871 rs12360903 ENSG00000212093.1 AP000807.1 4.94 1.58e-06 0.00114 0.38 0.32 Total body bone mineral density; chr11:68468846 chr11:68506083~68506166:- CESC cis rs875971 0.545 rs3735147 ENSG00000222364.1 RNU6-96P -4.94 1.58e-06 0.00114 -0.43 -0.32 Aortic root size; chr7:66505541 chr7:66395191~66395286:+ CESC cis rs520525 0.963 rs501680 ENSG00000271811.1 RP1-79C4.4 4.94 1.58e-06 0.00115 0.41 0.32 Atrial fibrillation; chr1:170656726 chr1:170667381~170669425:+ CESC cis rs875971 0.545 rs75577046 ENSG00000237310.1 GS1-124K5.4 4.94 1.59e-06 0.00115 0.35 0.32 Aortic root size; chr7:66493729 chr7:66493706~66495474:+ CESC cis rs5758659 0.652 rs1063392 ENSG00000273366.1 CTA-989H11.1 4.93 1.59e-06 0.00115 0.38 0.32 Cognitive function; chr22:42058946 chr22:42278188~42278846:+ CESC cis rs1862618 1 rs1862618 ENSG00000271828.1 CTD-2310F14.1 4.93 1.59e-06 0.00115 0.41 0.32 Initial pursuit acceleration; chr5:56800488 chr5:56927874~56929573:+ CESC cis rs2833693 0.572 rs2833715 ENSG00000261610.1 AP000265.1 4.93 1.59e-06 0.00116 0.38 0.32 Temperament; chr21:32192268 chr21:32259804~32261585:- CESC cis rs6142102 0.961 rs4911408 ENSG00000276073.1 RP5-1125A11.7 -4.93 1.59e-06 0.00116 -0.32 -0.32 Skin pigmentation; chr20:34112760 chr20:33985617~33988989:- CESC cis rs2739330 0.828 rs5751770 ENSG00000231271.1 AP000350.8 4.93 1.6e-06 0.00116 0.38 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23949918~23954042:+ CESC cis rs11155671 0.53 rs1334510 ENSG00000223701.3 RAET1E-AS1 4.93 1.6e-06 0.00116 0.37 0.32 Testicular germ cell tumor; chr6:149880043 chr6:149884431~149919508:+ CESC cis rs2028299 0.919 rs3759831 ENSG00000259677.1 RP11-493E3.1 4.93 1.6e-06 0.00116 0.44 0.32 Type 2 diabetes; chr15:89871410 chr15:89876540~89877285:+ CESC cis rs1061377 1 rs7685082 ENSG00000249685.1 RP11-360F5.3 4.93 1.6e-06 0.00116 0.37 0.32 Uric acid levels; chr4:39116472 chr4:39133913~39135608:+ CESC cis rs7598759 0.527 rs12987949 ENSG00000181798.2 LINC00471 -4.93 1.6e-06 0.00116 -0.33 -0.32 Noise-induced hearing loss; chr2:231502800 chr2:231508426~231514339:- CESC cis rs1061377 1 rs3733277 ENSG00000249685.1 RP11-360F5.3 4.93 1.6e-06 0.00116 0.38 0.32 Uric acid levels; chr4:39115483 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs3733278 ENSG00000249685.1 RP11-360F5.3 4.93 1.6e-06 0.00116 0.38 0.32 Uric acid levels; chr4:39115615 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs3733279 ENSG00000249685.1 RP11-360F5.3 4.93 1.6e-06 0.00116 0.38 0.32 Uric acid levels; chr4:39115625 chr4:39133913~39135608:+ CESC cis rs7189233 0.531 rs7202621 ENSG00000279344.1 RP11-44F14.7 4.93 1.6e-06 0.00116 0.3 0.32 Intelligence (multi-trait analysis); chr16:53452125 chr16:53478957~53481550:- CESC cis rs950880 0.71 rs4851011 ENSG00000234389.1 AC007278.3 4.93 1.61e-06 0.00116 0.36 0.32 Serum protein levels (sST2); chr2:102473219 chr2:102438713~102440475:+ CESC cis rs42490 0.789 rs383592 ENSG00000251136.7 RP11-37B2.1 -4.93 1.61e-06 0.00116 -0.32 -0.32 Leprosy; chr8:89792100 chr8:89609409~89757727:- CESC cis rs950880 0.71 rs7597017 ENSG00000234389.1 AC007278.3 -4.93 1.61e-06 0.00116 -0.34 -0.32 Serum protein levels (sST2); chr2:102445656 chr2:102438713~102440475:+ CESC cis rs2015599 0.623 rs2288128 ENSG00000275476.1 RP11-996F15.4 4.93 1.61e-06 0.00116 0.36 0.32 Platelet count;Mean platelet volume; chr12:29316054 chr12:29277397~29277882:- CESC cis rs2015599 0.584 rs2288129 ENSG00000275476.1 RP11-996F15.4 4.93 1.61e-06 0.00116 0.36 0.32 Platelet count;Mean platelet volume; chr12:29316355 chr12:29277397~29277882:- CESC cis rs761746 0.739 rs5998086 ENSG00000236132.1 CTA-440B3.1 -4.93 1.61e-06 0.00117 -0.42 -0.32 Intelligence; chr22:31684258 chr22:31816379~31817491:- CESC cis rs10129255 1 rs10129255 ENSG00000280411.1 IGHV1-69-2 4.93 1.61e-06 0.00117 0.25 0.32 Kawasaki disease; chr14:106767970 chr14:106762092~106762588:- CESC cis rs9322193 0.962 rs17673294 ENSG00000268592.3 RAET1E-AS1 4.93 1.61e-06 0.00117 0.41 0.32 Lung cancer; chr6:149813857 chr6:149863494~149919507:+ CESC cis rs556990 0.57 rs5960 ENSG00000269125.1 RP11-98F14.11 4.93 1.61e-06 0.00117 0.42 0.32 Blood protein levels; chr13:113147423 chr13:113165002~113165183:- CESC cis rs8177876 0.749 rs12444969 ENSG00000261838.4 RP11-303E16.6 4.93 1.61e-06 0.00117 0.66 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81050211 chr16:81069854~81076598:+ CESC cis rs875971 0.545 rs11767262 ENSG00000222364.1 RNU6-96P -4.93 1.62e-06 0.00117 -0.4 -0.32 Aortic root size; chr7:66302237 chr7:66395191~66395286:+ CESC cis rs73086581 1 rs6052220 ENSG00000229539.1 RP11-119B16.2 4.93 1.62e-06 0.00117 0.48 0.32 Response to antidepressants in depression; chr20:3989947 chr20:3888239~3888868:- CESC cis rs1729407 0.647 rs2727791 ENSG00000254851.1 RP11-109L13.1 -4.93 1.62e-06 0.00117 -0.37 -0.32 Apolipoprotein A-IV levels; chr11:116813846 chr11:117135528~117138582:+ CESC cis rs8072100 0.817 rs6505049 ENSG00000228782.6 CTD-2026D20.3 -4.93 1.62e-06 0.00117 -0.38 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47598415 chr17:47450568~47492492:- CESC cis rs9907295 0.605 rs11652192 ENSG00000270977.1 AC015849.16 -4.93 1.62e-06 0.00117 -0.47 -0.32 Fibroblast growth factor basic levels; chr17:35833174 chr17:35893707~35911023:- CESC cis rs2243480 1 rs1723269 ENSG00000232559.3 GS1-124K5.12 4.93 1.62e-06 0.00117 0.53 0.32 Diabetic kidney disease; chr7:66007799 chr7:66554588~66576923:- CESC cis rs9549367 0.789 rs3850451 ENSG00000269125.1 RP11-98F14.11 -4.93 1.62e-06 0.00117 -0.45 -0.32 Platelet distribution width; chr13:113251498 chr13:113165002~113165183:- CESC cis rs6997458 0.606 rs1493302 ENSG00000253549.4 RP11-317J10.2 4.93 1.62e-06 0.00117 0.38 0.32 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85437051 chr8:85441851~85464915:- CESC cis rs8100891 0.537 rs3746016 ENSG00000267213.4 AC007773.2 -4.93 1.62e-06 0.00117 -0.5 -0.32 Neuroticism; chr19:32386353 chr19:32390050~32405560:- CESC cis rs75422866 0.867 rs35044089 ENSG00000280054.1 RP1-197B17.7 4.93 1.63e-06 0.00117 0.79 0.32 Pneumonia; chr12:47610881 chr12:47728151~47730598:- CESC cis rs6964833 0.935 rs13238996 ENSG00000277053.3 GTF2IP1 -4.93 1.63e-06 0.00118 -0.39 -0.32 Menarche (age at onset); chr7:74655318 chr7:75185385~75237696:- CESC cis rs6504622 0.677 rs12949446 ENSG00000262879.4 RP11-156P1.3 -4.93 1.63e-06 0.00118 -0.35 -0.32 Orofacial clefts; chr17:46994311 chr17:46984045~47100323:- CESC cis rs6504622 0.693 rs12952596 ENSG00000262879.4 RP11-156P1.3 -4.93 1.63e-06 0.00118 -0.35 -0.32 Orofacial clefts; chr17:46994319 chr17:46984045~47100323:- CESC cis rs9322193 0.962 rs35031906 ENSG00000268592.3 RAET1E-AS1 4.93 1.63e-06 0.00118 0.41 0.32 Lung cancer; chr6:149677438 chr6:149863494~149919507:+ CESC cis rs10262624 1 rs4722286 ENSG00000234286.1 AC006026.13 4.93 1.63e-06 0.00118 0.33 0.32 Schizophrenia; chr7:23874005 chr7:23680195~23680786:- CESC cis rs950880 0.71 rs66566526 ENSG00000234389.1 AC007278.3 -4.93 1.63e-06 0.00118 -0.35 -0.32 Serum protein levels (sST2); chr2:102431342 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs4851582 ENSG00000234389.1 AC007278.3 -4.93 1.63e-06 0.00118 -0.35 -0.32 Serum protein levels (sST2); chr2:102435098 chr2:102438713~102440475:+ CESC cis rs5758659 1 rs134900 ENSG00000273366.1 CTA-989H11.1 -4.93 1.63e-06 0.00118 -0.38 -0.32 Cognitive function; chr22:42287337 chr22:42278188~42278846:+ CESC cis rs7508 0.511 rs438818 ENSG00000253671.1 RP11-806O11.1 -4.93 1.63e-06 0.00118 -0.37 -0.32 Atrial fibrillation; chr8:18042052 chr8:17808941~17820868:+ CESC cis rs10129255 1 rs4612959 ENSG00000211970.3 IGHV4-61 -4.93 1.63e-06 0.00118 -0.25 -0.32 Kawasaki disease; chr14:106767055 chr14:106639119~106639657:- CESC cis rs9549367 0.789 rs9549715 ENSG00000269125.1 RP11-98F14.11 -4.93 1.63e-06 0.00118 -0.45 -0.32 Platelet distribution width; chr13:113253926 chr13:113165002~113165183:- CESC cis rs9549367 0.789 rs2302757 ENSG00000269125.1 RP11-98F14.11 -4.93 1.63e-06 0.00118 -0.45 -0.32 Platelet distribution width; chr13:113255025 chr13:113165002~113165183:- CESC cis rs783540 0.656 rs783524 ENSG00000276710.3 CSPG4P8 4.93 1.63e-06 0.00118 0.35 0.32 Schizophrenia; chr15:82615393 chr15:82459472~82477258:+ CESC cis rs783540 0.592 rs2567632 ENSG00000276710.3 CSPG4P8 4.93 1.63e-06 0.00118 0.35 0.32 Schizophrenia; chr15:82616053 chr15:82459472~82477258:+ CESC cis rs11159086 0.793 rs17100414 ENSG00000270000.1 RP3-449M8.9 4.93 1.63e-06 0.00118 0.52 0.32 Advanced glycation end-product levels; chr14:74467918 chr14:74471930~74472360:- CESC cis rs9907295 0.901 rs78905197 ENSG00000270977.1 AC015849.16 -4.93 1.64e-06 0.00118 -0.47 -0.32 Fibroblast growth factor basic levels; chr17:35850189 chr17:35893707~35911023:- CESC cis rs2337406 0.866 rs4773949 ENSG00000274576.2 IGHV2-70 4.93 1.64e-06 0.00118 0.35 0.32 Alzheimer's disease (late onset); chr14:106808070 chr14:106770577~106771020:- CESC cis rs6504622 0.577 rs197925 ENSG00000263142.4 LRRC37A17P 4.93 1.64e-06 0.00118 0.24 0.32 Orofacial clefts; chr17:46933355 chr17:46978481~47054569:+ CESC cis rs7809950 0.953 rs28687365 ENSG00000238832.1 snoU109 -4.93 1.64e-06 0.00119 -0.38 -0.32 Coronary artery disease; chr7:107466267 chr7:107603363~107603507:+ CESC cis rs7809950 0.954 rs12673675 ENSG00000238832.1 snoU109 -4.93 1.64e-06 0.00119 -0.38 -0.32 Coronary artery disease; chr7:107472775 chr7:107603363~107603507:+ CESC cis rs9543976 1 rs9543976 ENSG00000261553.4 RP11-29G8.3 4.93 1.65e-06 0.00119 0.44 0.32 Diabetic retinopathy; chr13:75562512 chr13:75549773~75807120:+ CESC cis rs75422866 0.867 rs73111258 ENSG00000280054.1 RP1-197B17.7 4.93 1.65e-06 0.00119 0.81 0.32 Pneumonia; chr12:47597313 chr12:47728151~47730598:- CESC cis rs6991838 0.806 rs11781358 ENSG00000272010.1 CTD-3025N20.3 4.93 1.65e-06 0.00119 0.35 0.32 Intelligence (multi-trait analysis); chr8:65557691 chr8:65591850~65592472:- CESC cis rs733592 0.524 rs10875744 ENSG00000240399.1 RP1-228P16.1 4.93 1.65e-06 0.00119 0.32 0.32 Plateletcrit; chr12:48104657 chr12:48054813~48055591:- CESC cis rs494459 0.838 rs488219 ENSG00000255422.1 AP002954.4 -4.93 1.65e-06 0.00119 -0.36 -0.32 Height; chr11:118749988 chr11:118704607~118750263:+ CESC cis rs7572733 0.935 rs2060489 ENSG00000222017.1 AC011997.1 4.93 1.65e-06 0.00119 0.35 0.32 Dermatomyositis; chr2:197887562 chr2:197693106~197774823:+ CESC cis rs14027 0.64 rs7009073 ENSG00000279347.1 RP11-85I17.2 -4.93 1.66e-06 0.00119 -0.3 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119769677 chr8:119838736~119840385:- CESC cis rs9907295 0.584 rs2280787 ENSG00000270977.1 AC015849.16 -4.93 1.66e-06 0.00119 -0.44 -0.32 Fibroblast growth factor basic levels; chr17:35930046 chr17:35893707~35911023:- CESC cis rs2243480 0.908 rs313822 ENSG00000275400.1 RP4-756H11.5 4.93 1.66e-06 0.00119 0.54 0.32 Diabetic kidney disease; chr7:66108952 chr7:66553805~66554199:- CESC cis rs12458462 0.859 rs2242177 ENSG00000274828.1 RP11-567M16.6 4.93 1.66e-06 0.00119 0.3 0.32 Monocyte count; chr18:79717379 chr18:79677287~79679358:- CESC cis rs2732480 0.5 rs2932093 ENSG00000258273.1 RP11-370I10.4 -4.93 1.66e-06 0.0012 -0.39 -0.32 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48254488 chr12:48333755~48333901:- CESC cis rs2243480 0.831 rs57294491 ENSG00000275400.1 RP4-756H11.5 -4.93 1.66e-06 0.0012 -0.54 -0.32 Diabetic kidney disease; chr7:66219914 chr7:66553805~66554199:- CESC cis rs875971 1 rs10244498 ENSG00000232559.3 GS1-124K5.12 4.92 1.67e-06 0.0012 0.34 0.32 Aortic root size; chr7:66651069 chr7:66554588~66576923:- CESC cis rs2929278 0.736 rs2412823 ENSG00000205771.5 CATSPER2P1 4.92 1.67e-06 0.0012 0.36 0.32 Schizophrenia; chr15:43935072 chr15:43726918~43747094:- CESC cis rs6452524 0.804 rs1478481 ENSG00000249664.1 CTD-2227C6.2 4.92 1.67e-06 0.0012 0.39 0.32 Hypertension (SNP x SNP interaction); chr5:83111286 chr5:83012285~83013109:- CESC cis rs8042680 0.637 rs4932182 ENSG00000214432.8 AC068831.10 4.92 1.68e-06 0.00121 0.38 0.32 Type 2 diabetes; chr15:90965573 chr15:91022619~91036611:+ CESC cis rs6142102 0.961 rs4911389 ENSG00000276073.1 RP5-1125A11.7 -4.92 1.68e-06 0.00121 -0.32 -0.32 Skin pigmentation; chr20:33977235 chr20:33985617~33988989:- CESC cis rs765787 0.505 rs12593605 ENSG00000259520.4 CTD-2651B20.3 -4.92 1.68e-06 0.00121 -0.4 -0.32 Uric acid levels; chr15:45205250 chr15:45251580~45279251:- CESC cis rs9532669 0.926 rs2183144 ENSG00000176268.5 CYCSP34 -4.92 1.69e-06 0.00121 -0.32 -0.32 Cervical cancer; chr13:40862129 chr13:40863599~40863902:- CESC cis rs950027 1 rs950027 ENSG00000259520.4 CTD-2651B20.3 4.92 1.69e-06 0.00121 0.4 0.32 Response to fenofibrate (adiponectin levels); chr15:45508837 chr15:45251580~45279251:- CESC cis rs2236295 0.814 rs1848797 ENSG00000238280.1 RP11-436D10.3 -4.92 1.69e-06 0.00121 -0.4 -0.32 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks); chr10:62793174 chr10:62793562~62805887:- CESC cis rs10754283 0.967 rs12058749 ENSG00000231613.1 RP5-943J3.1 4.92 1.69e-06 0.00121 0.39 0.32 Amyotrophic lateral sclerosis (sporadic); chr1:89640045 chr1:89788914~89790492:+ CESC cis rs7927592 0.871 rs17603185 ENSG00000212093.1 AP000807.1 4.92 1.69e-06 0.00121 0.38 0.32 Total body bone mineral density; chr11:68608773 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs2236708 ENSG00000212093.1 AP000807.1 4.92 1.69e-06 0.00121 0.38 0.32 Total body bone mineral density; chr11:68610577 chr11:68506083~68506166:- CESC cis rs1823913 0.503 rs34716486 ENSG00000280083.1 RP11-317J9.1 -4.92 1.7e-06 0.00122 -0.39 -0.32 Obesity-related traits; chr2:191343335 chr2:191154118~191156070:- CESC cis rs1823913 0.503 rs35672076 ENSG00000280083.1 RP11-317J9.1 -4.92 1.7e-06 0.00122 -0.39 -0.32 Obesity-related traits; chr2:191343907 chr2:191154118~191156070:- CESC cis rs1823913 0.503 rs35282329 ENSG00000280083.1 RP11-317J9.1 -4.92 1.7e-06 0.00122 -0.39 -0.32 Obesity-related traits; chr2:191343925 chr2:191154118~191156070:- CESC cis rs1823913 0.503 rs35868016 ENSG00000280083.1 RP11-317J9.1 -4.92 1.7e-06 0.00122 -0.39 -0.32 Obesity-related traits; chr2:191344082 chr2:191154118~191156070:- CESC cis rs11096990 0.634 rs6531702 ENSG00000249207.1 RP11-360F5.1 -4.92 1.7e-06 0.00122 -0.35 -0.32 Cognitive function; chr4:39273774 chr4:39112677~39126818:- CESC cis rs6991838 0.673 rs7462352 ENSG00000272010.1 CTD-3025N20.3 4.92 1.7e-06 0.00122 0.35 0.32 Intelligence (multi-trait analysis); chr8:65584378 chr8:65591850~65592472:- CESC cis rs7714584 1 rs11741861 ENSG00000197083.10 ZNF300P1 -4.92 1.71e-06 0.00122 -0.64 -0.32 Crohn's disease; chr5:150898347 chr5:150930645~150946289:- CESC cis rs9322193 0.884 rs880245 ENSG00000216906.2 RP11-350J20.9 -4.92 1.71e-06 0.00122 -0.37 -0.32 Lung cancer; chr6:149846262 chr6:149904243~149906418:+ CESC cis rs1823913 1 rs6749232 ENSG00000227542.1 AC092614.2 -4.92 1.71e-06 0.00123 -0.32 -0.32 Obesity-related traits; chr2:191250326 chr2:191229165~191246172:- CESC cis rs8062405 0.757 rs2411453 ENSG00000259982.1 CDC37P1 -4.92 1.71e-06 0.00123 -0.34 -0.32 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620700 chr16:28700294~28701540:- CESC cis rs1799949 1 rs35956818 ENSG00000267681.1 CTD-3199J23.6 -4.92 1.71e-06 0.00123 -0.41 -0.32 Menopause (age at onset); chr17:43345617 chr17:43144956~43145255:+ CESC cis rs1799949 0.93 rs4584865 ENSG00000267681.1 CTD-3199J23.6 -4.92 1.71e-06 0.00123 -0.41 -0.32 Menopause (age at onset); chr17:43347551 chr17:43144956~43145255:+ CESC cis rs12439619 0.739 rs62012046 ENSG00000255769.6 GOLGA2P10 -4.92 1.71e-06 0.00123 -0.49 -0.32 Intelligence (multi-trait analysis); chr15:82236824 chr15:82472993~82513950:- CESC cis rs12439619 0.774 rs62012047 ENSG00000255769.6 GOLGA2P10 -4.92 1.71e-06 0.00123 -0.49 -0.32 Intelligence (multi-trait analysis); chr15:82236852 chr15:82472993~82513950:- CESC cis rs12439619 0.81 rs62012049 ENSG00000255769.6 GOLGA2P10 -4.92 1.71e-06 0.00123 -0.49 -0.32 Intelligence (multi-trait analysis); chr15:82237722 chr15:82472993~82513950:- CESC cis rs9601248 0.874 rs9545154 ENSG00000227676.3 LINC01068 4.92 1.71e-06 0.00123 0.37 0.32 Major depressive disorder; chr13:79617682 chr13:79566727~79571436:+ CESC cis rs9601248 0.874 rs9545155 ENSG00000227676.3 LINC01068 4.92 1.71e-06 0.00123 0.37 0.32 Major depressive disorder; chr13:79617738 chr13:79566727~79571436:+ CESC cis rs889512 0.642 rs73605136 ENSG00000280152.1 RP11-331F4.5 -4.92 1.71e-06 0.00123 -0.46 -0.32 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75266069 chr16:75245994~75250077:- CESC cis rs889512 0.642 rs73605139 ENSG00000280152.1 RP11-331F4.5 -4.92 1.71e-06 0.00123 -0.46 -0.32 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75266140 chr16:75245994~75250077:- CESC cis rs9322193 0.962 rs2275046 ENSG00000268592.3 RAET1E-AS1 4.92 1.72e-06 0.00123 0.42 0.32 Lung cancer; chr6:149835865 chr6:149863494~149919507:+ CESC cis rs950880 0.71 rs56117144 ENSG00000234389.1 AC007278.3 -4.92 1.72e-06 0.00123 -0.36 -0.32 Serum protein levels (sST2); chr2:102458191 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs57081652 ENSG00000234389.1 AC007278.3 -4.92 1.72e-06 0.00123 -0.36 -0.32 Serum protein levels (sST2); chr2:102458921 chr2:102438713~102440475:+ CESC cis rs4974559 0.947 rs10000012 ENSG00000253399.1 AC078852.2 -4.92 1.72e-06 0.00123 -0.51 -0.32 Systolic blood pressure; chr4:1363537 chr4:1358479~1359461:+ CESC cis rs8100891 0.537 rs73034207 ENSG00000267213.4 AC007773.2 -4.92 1.72e-06 0.00123 -0.51 -0.32 Neuroticism; chr19:32384863 chr19:32390050~32405560:- CESC cis rs7811142 1 rs1000215 ENSG00000078319.8 PMS2P1 -4.92 1.72e-06 0.00123 -0.48 -0.32 Platelet count; chr7:100406920 chr7:100320992~100341908:- CESC cis rs10853057 0.717 rs4791242 ENSG00000214174.7 AMZ2P1 -4.92 1.72e-06 0.00124 -0.39 -0.32 White matter microstructure (global fractional anisotropy); chr17:65061533 chr17:64966550~64975576:- CESC cis rs42490 0.903 rs218944 ENSG00000251136.7 RP11-37B2.1 -4.92 1.72e-06 0.00124 -0.32 -0.32 Leprosy; chr8:89701839 chr8:89609409~89757727:- CESC cis rs8177876 0.822 rs12444137 ENSG00000261838.4 RP11-303E16.6 4.92 1.72e-06 0.00124 0.67 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81076746 chr16:81069854~81076598:+ CESC cis rs8177876 0.731 rs76093926 ENSG00000261838.4 RP11-303E16.6 4.92 1.72e-06 0.00124 0.67 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078920 chr16:81069854~81076598:+ CESC cis rs8177876 0.731 rs10514512 ENSG00000261838.4 RP11-303E16.6 4.92 1.72e-06 0.00124 0.67 0.32 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080350 chr16:81069854~81076598:+ CESC cis rs3733309 0.648 rs10016631 ENSG00000269949.1 RP11-738E22.3 4.92 1.73e-06 0.00124 0.44 0.32 Height; chr4:57019797 chr4:56960927~56961373:- CESC cis rs3931020 0.626 rs277402 ENSG00000272864.1 RP11-17E13.2 4.92 1.73e-06 0.00124 0.42 0.32 Resistin levels; chr1:74722637 chr1:74698769~74699333:- CESC cis rs10262624 1 rs17347692 ENSG00000234286.1 AC006026.13 -4.92 1.73e-06 0.00124 -0.33 -0.32 Schizophrenia; chr7:23878748 chr7:23680195~23680786:- CESC cis rs10262624 1 rs17347733 ENSG00000234286.1 AC006026.13 -4.92 1.73e-06 0.00124 -0.33 -0.32 Schizophrenia; chr7:23878891 chr7:23680195~23680786:- CESC cis rs7615952 0.599 rs2270986 ENSG00000250012.1 RP11-124N2.1 -4.92 1.73e-06 0.00124 -0.34 -0.32 Blood pressure (smoking interaction); chr3:125982256 chr3:126084220~126095349:+ CESC cis rs7615952 0.599 rs12496921 ENSG00000250012.1 RP11-124N2.1 -4.92 1.73e-06 0.00124 -0.34 -0.32 Blood pressure (smoking interaction); chr3:125983105 chr3:126084220~126095349:+ CESC cis rs2111504 0.945 rs1861780 ENSG00000267213.4 AC007773.2 -4.92 1.73e-06 0.00124 -0.49 -0.32 Bipolar disorder; chr19:32372138 chr19:32390050~32405560:- CESC cis rs875971 0.545 rs1796226 ENSG00000222364.1 RNU6-96P -4.92 1.73e-06 0.00124 -0.41 -0.32 Aortic root size; chr7:66622723 chr7:66395191~66395286:+ CESC cis rs8072100 0.701 rs10163469 ENSG00000228782.6 CTD-2026D20.3 -4.92 1.74e-06 0.00124 -0.37 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47610401 chr17:47450568~47492492:- CESC cis rs11155671 0.53 rs9383940 ENSG00000223701.3 RAET1E-AS1 4.92 1.74e-06 0.00124 0.35 0.32 Testicular germ cell tumor; chr6:149904923 chr6:149884431~149919508:+ CESC cis rs2028299 1 rs7111 ENSG00000259677.1 RP11-493E3.1 4.92 1.74e-06 0.00125 0.43 0.32 Type 2 diabetes; chr15:89830641 chr15:89876540~89877285:+ CESC cis rs950880 0.71 rs11123928 ENSG00000234389.1 AC007278.3 -4.92 1.74e-06 0.00125 -0.35 -0.32 Serum protein levels (sST2); chr2:102444826 chr2:102438713~102440475:+ CESC cis rs3931020 0.657 rs277368 ENSG00000272864.1 RP11-17E13.2 4.92 1.74e-06 0.00125 0.41 0.32 Resistin levels; chr1:74764922 chr1:74698769~74699333:- CESC cis rs3931020 0.657 rs277369 ENSG00000272864.1 RP11-17E13.2 4.92 1.74e-06 0.00125 0.41 0.32 Resistin levels; chr1:74768977 chr1:74698769~74699333:- CESC cis rs2243480 1 rs2465120 ENSG00000228409.4 CCT6P1 4.92 1.74e-06 0.00125 0.47 0.32 Diabetic kidney disease; chr7:66155987 chr7:65751142~65763354:+ CESC cis rs2243480 0.908 rs2460431 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66157859 chr7:65751142~65763354:+ CESC cis rs2243480 0.711 rs2460426 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66158142 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs4718309 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66162777 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6460274 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66163497 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs7787230 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66164112 chr7:65751142~65763354:+ CESC cis rs2243480 0.711 rs2420172 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66170354 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs2420171 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66172773 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6974723 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66172952 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs7804223 ENSG00000228409.4 CCT6P1 -4.92 1.74e-06 0.00125 -0.47 -0.32 Diabetic kidney disease; chr7:66199572 chr7:65751142~65763354:+ CESC cis rs10262624 0.967 rs2188845 ENSG00000234286.1 AC006026.13 -4.92 1.74e-06 0.00125 -0.34 -0.32 Schizophrenia; chr7:23882391 chr7:23680195~23680786:- CESC cis rs7048146 0.51 rs7859790 ENSG00000213539.4 YBX1P6 -4.91 1.75e-06 0.00125 -0.37 -0.32 Vascular brain injury; chr9:109528203 chr9:109532830~109534332:- CESC cis rs832187 0.64 rs3774729 ENSG00000280620.1 SCAANT1 4.91 1.75e-06 0.00125 0.49 0.32 Schizophrenia; chr3:63996406 chr3:63911518~63911772:- CESC cis rs6991838 0.67 rs13275168 ENSG00000200714.1 Y_RNA 4.91 1.75e-06 0.00125 0.37 0.32 Intelligence (multi-trait analysis); chr8:65685107 chr8:65592731~65592820:+ CESC cis rs9322193 0.962 rs3805753 ENSG00000268592.3 RAET1E-AS1 4.91 1.75e-06 0.00125 0.41 0.32 Lung cancer; chr6:149795662 chr6:149863494~149919507:+ CESC cis rs10463554 0.655 rs152138 ENSG00000175749.11 EIF3KP1 4.91 1.76e-06 0.00126 0.35 0.32 Parkinson's disease; chr5:103223727 chr5:103032376~103033031:+ CESC cis rs4141404 0.851 rs5749222 ENSG00000236132.1 CTA-440B3.1 4.91 1.76e-06 0.00126 0.37 0.32 Paclitaxel-induced neuropathy; chr22:31160773 chr22:31816379~31817491:- CESC cis rs1862618 0.853 rs863840 ENSG00000271828.1 CTD-2310F14.1 4.91 1.76e-06 0.00126 0.41 0.32 Initial pursuit acceleration; chr5:56833172 chr5:56927874~56929573:+ CESC cis rs875971 0.862 rs13232191 ENSG00000222364.1 RNU6-96P -4.91 1.77e-06 0.00126 -0.37 -0.32 Aortic root size; chr7:66521661 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs35378740 ENSG00000222364.1 RNU6-96P -4.91 1.77e-06 0.00126 -0.37 -0.32 Aortic root size; chr7:66522725 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs10950043 ENSG00000222364.1 RNU6-96P -4.91 1.77e-06 0.00126 -0.37 -0.32 Aortic root size; chr7:66523623 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs17747530 ENSG00000222364.1 RNU6-96P -4.91 1.77e-06 0.00126 -0.37 -0.32 Aortic root size; chr7:66529742 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs13226170 ENSG00000222364.1 RNU6-96P -4.91 1.77e-06 0.00126 -0.37 -0.32 Aortic root size; chr7:66534311 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs2420611 ENSG00000222364.1 RNU6-96P -4.91 1.77e-06 0.00126 -0.37 -0.32 Aortic root size; chr7:66534333 chr7:66395191~66395286:+ CESC cis rs875971 0.767 rs61348003 ENSG00000222364.1 RNU6-96P -4.91 1.77e-06 0.00126 -0.37 -0.32 Aortic root size; chr7:66540947 chr7:66395191~66395286:+ CESC cis rs875971 0.861 rs801215 ENSG00000222364.1 RNU6-96P 4.91 1.77e-06 0.00126 0.37 0.32 Aortic root size; chr7:66546951 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs1875057 ENSG00000237310.1 GS1-124K5.4 -4.91 1.77e-06 0.00126 -0.3 -0.32 Aortic root size; chr7:66266868 chr7:66493706~66495474:+ CESC cis rs5758659 0.904 rs134877 ENSG00000273366.1 CTA-989H11.1 -4.91 1.77e-06 0.00127 -0.38 -0.32 Cognitive function; chr22:42266365 chr22:42278188~42278846:+ CESC cis rs6951245 0.507 rs11976805 ENSG00000229043.2 AC091729.9 -4.91 1.77e-06 0.00127 -0.4 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1099080 chr7:1160374~1165267:+ CESC cis rs875971 0.545 rs66594357 ENSG00000222364.1 RNU6-96P -4.91 1.78e-06 0.00127 -0.41 -0.32 Aortic root size; chr7:66327797 chr7:66395191~66395286:+ CESC cis rs55665837 1 rs7121171 ENSG00000251991.1 RNU7-49P 4.91 1.78e-06 0.00127 0.35 0.32 Vitamin D levels; chr11:14424874 chr11:14478892~14478953:+ CESC cis rs12681963 0.688 rs12541087 ENSG00000272375.1 RP11-51J9.6 4.91 1.78e-06 0.00127 0.52 0.32 Migraine; chr8:30172398 chr8:30197404~30198048:+ CESC cis rs2337406 0.866 rs7152809 ENSG00000274576.2 IGHV2-70 -4.91 1.78e-06 0.00127 -0.36 -0.32 Alzheimer's disease (late onset); chr14:106778385 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs7152832 ENSG00000274576.2 IGHV2-70 -4.91 1.78e-06 0.00127 -0.36 -0.32 Alzheimer's disease (late onset); chr14:106778427 chr14:106770577~106771020:- CESC cis rs1862618 0.511 rs2591952 ENSG00000271828.1 CTD-2310F14.1 4.91 1.78e-06 0.00127 0.43 0.32 Initial pursuit acceleration; chr5:56824942 chr5:56927874~56929573:+ CESC cis rs2243480 0.901 rs778732 ENSG00000228409.4 CCT6P1 4.91 1.78e-06 0.00127 0.49 0.32 Diabetic kidney disease; chr7:66357373 chr7:65751142~65763354:+ CESC cis rs12439619 0.739 rs4778988 ENSG00000276710.3 CSPG4P8 -4.91 1.79e-06 0.00127 -0.39 -0.32 Intelligence (multi-trait analysis); chr15:82247996 chr15:82459472~82477258:+ CESC cis rs2243480 1 rs1039664 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:65984729 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs2456483 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:65996588 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs2949697 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:65999249 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1701750 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:66002158 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1701758 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:66005214 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs1701759 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:66005945 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs781149 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:66016297 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs58207111 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:66021736 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1167613 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:66022452 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs313799 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:66029343 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs313807 ENSG00000228409.4 CCT6P1 4.91 1.79e-06 0.00127 0.45 0.32 Diabetic kidney disease; chr7:66034494 chr7:65751142~65763354:+ CESC cis rs1030877 0.557 rs2278501 ENSG00000235319.1 AC012360.4 4.91 1.79e-06 0.00128 0.35 0.32 Obesity-related traits; chr2:105363049 chr2:105324210~105330529:+ CESC cis rs71403859 0.502 rs34015581 ENSG00000260886.1 TAT-AS1 4.91 1.79e-06 0.00128 0.46 0.32 Post bronchodilator FEV1; chr16:71474326 chr16:71565789~71578187:+ CESC cis rs10875746 0.669 rs10875792 ENSG00000240399.1 RP1-228P16.1 -4.91 1.79e-06 0.00128 -0.41 -0.32 Longevity (90 years and older); chr12:48303640 chr12:48054813~48055591:- CESC cis rs10875746 0.623 rs10875793 ENSG00000240399.1 RP1-228P16.1 -4.91 1.79e-06 0.00128 -0.41 -0.32 Longevity (90 years and older); chr12:48303647 chr12:48054813~48055591:- CESC cis rs2408955 0.5 rs12816820 ENSG00000240399.1 RP1-228P16.1 4.91 1.8e-06 0.00128 0.34 0.32 Glycated hemoglobin levels; chr12:48164542 chr12:48054813~48055591:- CESC cis rs9322193 0.962 rs7745915 ENSG00000268592.3 RAET1E-AS1 4.91 1.8e-06 0.00128 0.41 0.32 Lung cancer; chr6:149834111 chr6:149863494~149919507:+ CESC cis rs6142102 1 rs2143230 ENSG00000276073.1 RP5-1125A11.7 -4.91 1.8e-06 0.00128 -0.3 -0.32 Skin pigmentation; chr20:34136539 chr20:33985617~33988989:- CESC cis rs9318086 0.712 rs9318099 ENSG00000205861.10 C1QTNF9B-AS1 4.91 1.8e-06 0.00128 0.39 0.32 Myopia (pathological); chr13:23868323 chr13:23888889~23897263:+ CESC cis rs748404 0.631 rs28702649 ENSG00000249839.1 AC011330.5 -4.91 1.81e-06 0.00129 -0.34 -0.32 Lung cancer; chr15:43356431 chr15:43663654~43684339:- CESC cis rs2729354 0.817 rs2250673 ENSG00000265566.2 RN7SL605P -4.91 1.81e-06 0.00129 -0.47 -0.32 Blood protein levels; chr11:57500697 chr11:57528085~57528365:- CESC cis rs860295 0.729 rs11264369 ENSG00000225855.5 RUSC1-AS1 -4.91 1.81e-06 0.00129 -0.26 -0.32 Body mass index; chr1:155390039 chr1:155316863~155324176:- CESC cis rs6496044 0.507 rs8034676 ENSG00000202081.1 RNU6-1280P 4.91 1.81e-06 0.00129 0.33 0.32 Interstitial lung disease; chr15:85616031 chr15:85651522~85651628:- CESC cis rs9907295 1 rs11650409 ENSG00000270977.1 AC015849.16 4.91 1.81e-06 0.00129 0.43 0.32 Fibroblast growth factor basic levels; chr17:35907949 chr17:35893707~35911023:- CESC cis rs875971 0.545 rs75577046 ENSG00000222364.1 RNU6-96P -4.91 1.81e-06 0.00129 -0.43 -0.32 Aortic root size; chr7:66493729 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs709609 ENSG00000222364.1 RNU6-96P 4.91 1.81e-06 0.00129 0.38 0.32 Aortic root size; chr7:66095574 chr7:66395191~66395286:+ CESC cis rs2564921 0.679 rs2115779 ENSG00000242142.1 SERBP1P3 -4.91 1.81e-06 0.00129 -0.39 -0.32 Height; chr3:52992698 chr3:53064283~53065091:- CESC cis rs2836950 0.565 rs2836942 ENSG00000232608.1 TIMM9P2 4.91 1.81e-06 0.00129 0.35 0.32 Menarche (age at onset); chr21:39219455 chr21:39216624~39217506:+ CESC cis rs2842992 0.789 rs3818300 ENSG00000237927.1 RP3-393E18.2 -4.91 1.81e-06 0.00129 -0.42 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159780645 chr6:159586955~159589169:- CESC cis rs2842992 0.747 rs1547093 ENSG00000237927.1 RP3-393E18.2 -4.91 1.81e-06 0.00129 -0.42 -0.32 Age-related macular degeneration (geographic atrophy); chr6:159784959 chr6:159586955~159589169:- CESC cis rs4423214 0.547 rs11234030 ENSG00000254682.1 RP11-660L16.2 -4.91 1.82e-06 0.00129 -0.45 -0.32 Vitamin D levels; chr11:71525921 chr11:71448674~71452157:+ CESC cis rs4423214 0.592 rs7130829 ENSG00000254682.1 RP11-660L16.2 -4.91 1.82e-06 0.00129 -0.45 -0.32 Vitamin D levels; chr11:71526656 chr11:71448674~71452157:+ CESC cis rs1211375 0.607 rs1203978 ENSG00000268836.1 LA16c-OS12.2 -4.91 1.82e-06 0.0013 -0.31 -0.32 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:207212 chr16:185748~186294:- CESC cis rs6452524 0.775 rs10071579 ENSG00000249664.1 CTD-2227C6.2 4.91 1.82e-06 0.0013 0.38 0.32 Hypertension (SNP x SNP interaction); chr5:83113925 chr5:83012285~83013109:- CESC cis rs1061377 1 rs2381284 ENSG00000249685.1 RP11-360F5.3 4.91 1.82e-06 0.0013 0.37 0.32 Uric acid levels; chr4:39117976 chr4:39133913~39135608:+ CESC cis rs1061377 0.803 rs6857761 ENSG00000249685.1 RP11-360F5.3 4.91 1.82e-06 0.0013 0.37 0.32 Uric acid levels; chr4:39118353 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs9997089 ENSG00000249685.1 RP11-360F5.3 4.91 1.82e-06 0.0013 0.37 0.32 Uric acid levels; chr4:39119263 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs9998481 ENSG00000249685.1 RP11-360F5.3 4.91 1.82e-06 0.0013 0.37 0.32 Uric acid levels; chr4:39117215 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs9998867 ENSG00000249685.1 RP11-360F5.3 4.91 1.82e-06 0.0013 0.37 0.32 Uric acid levels; chr4:39117542 chr4:39133913~39135608:+ CESC cis rs2337406 0.929 rs12050200 ENSG00000274576.2 IGHV2-70 -4.9 1.83e-06 0.0013 -0.37 -0.32 Alzheimer's disease (late onset); chr14:106780983 chr14:106770577~106771020:- CESC cis rs9549367 0.713 rs3024745 ENSG00000269125.1 RP11-98F14.11 -4.9 1.83e-06 0.0013 -0.46 -0.32 Platelet distribution width; chr13:113167284 chr13:113165002~113165183:- CESC cis rs2337406 0.866 rs112089985 ENSG00000274576.2 IGHV2-70 -4.9 1.83e-06 0.0013 -0.38 -0.32 Alzheimer's disease (late onset); chr14:106780074 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs8003852 ENSG00000274576.2 IGHV2-70 -4.9 1.83e-06 0.0013 -0.36 -0.32 Alzheimer's disease (late onset); chr14:106776648 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs988131 ENSG00000274576.2 IGHV2-70 -4.9 1.83e-06 0.0013 -0.36 -0.32 Alzheimer's disease (late onset); chr14:106776833 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs8005518 ENSG00000274576.2 IGHV2-70 -4.9 1.83e-06 0.0013 -0.36 -0.32 Alzheimer's disease (late onset); chr14:106777009 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs57684263 ENSG00000274576.2 IGHV2-70 -4.9 1.83e-06 0.0013 -0.36 -0.32 Alzheimer's disease (late onset); chr14:106777263 chr14:106770577~106771020:- CESC cis rs116095464 0.558 rs10056628 ENSG00000250848.1 CTD-2083E4.5 -4.9 1.83e-06 0.0013 -0.46 -0.32 Breast cancer; chr5:279397 chr5:288833~290321:- CESC cis rs11159086 0.793 rs9285594 ENSG00000259005.1 RP3-449M8.6 4.9 1.83e-06 0.0013 0.44 0.32 Advanced glycation end-product levels; chr14:74489253 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs4903229 ENSG00000259005.1 RP3-449M8.6 4.9 1.83e-06 0.0013 0.44 0.32 Advanced glycation end-product levels; chr14:74489865 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs8016972 ENSG00000259005.1 RP3-449M8.6 4.9 1.83e-06 0.0013 0.44 0.32 Advanced glycation end-product levels; chr14:74491833 chr14:74474007~74474864:- CESC cis rs9322193 0.923 rs35961297 ENSG00000268592.3 RAET1E-AS1 4.9 1.84e-06 0.0013 0.41 0.32 Lung cancer; chr6:149667929 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs35967444 ENSG00000268592.3 RAET1E-AS1 4.9 1.84e-06 0.0013 0.41 0.32 Lung cancer; chr6:149675588 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs62439842 ENSG00000268592.3 RAET1E-AS1 4.9 1.84e-06 0.0013 0.41 0.32 Lung cancer; chr6:149675847 chr6:149863494~149919507:+ CESC cis rs13108904 0.967 rs62293658 ENSG00000254094.1 AC078852.1 4.9 1.84e-06 0.00131 0.37 0.32 Obesity-related traits; chr4:1282628 chr4:1356581~1358075:+ CESC cis rs8067354 0.958 rs8081468 ENSG00000266701.1 AC005702.4 4.9 1.84e-06 0.00131 0.38 0.32 Hemoglobin concentration; chr17:59759563 chr17:60042546~60042627:- CESC cis rs8067354 0.958 rs2333563 ENSG00000266701.1 AC005702.4 4.9 1.84e-06 0.00131 0.38 0.32 Hemoglobin concentration; chr17:59762207 chr17:60042546~60042627:- CESC cis rs9322193 0.962 rs9478848 ENSG00000216906.2 RP11-350J20.9 4.9 1.84e-06 0.00131 0.34 0.32 Lung cancer; chr6:149825080 chr6:149904243~149906418:+ CESC cis rs2929278 0.617 rs533143 ENSG00000205771.5 CATSPER2P1 -4.9 1.84e-06 0.00131 -0.36 -0.32 Schizophrenia; chr15:43896656 chr15:43726918~43747094:- CESC cis rs2243480 0.901 rs2900904 ENSG00000232559.3 GS1-124K5.12 4.9 1.84e-06 0.00131 0.54 0.32 Diabetic kidney disease; chr7:65739282 chr7:66554588~66576923:- CESC cis rs4660456 0.913 rs4660449 ENSG00000237899.1 RP4-739H11.3 4.9 1.85e-06 0.00131 0.41 0.32 Platelet count; chr1:40739780 chr1:40669089~40687588:- CESC cis rs763121 1 rs138457 ENSG00000273076.1 RP3-508I15.22 -4.9 1.85e-06 0.00131 -0.35 -0.32 Menopause (age at onset); chr22:38502046 chr22:38743495~38743910:+ CESC cis rs9322193 0.923 rs35830138 ENSG00000268592.3 RAET1E-AS1 4.9 1.85e-06 0.00131 0.41 0.32 Lung cancer; chr6:149668635 chr6:149863494~149919507:+ CESC cis rs1862618 0.853 rs252922 ENSG00000271828.1 CTD-2310F14.1 4.9 1.85e-06 0.00131 0.42 0.32 Initial pursuit acceleration; chr5:56840516 chr5:56927874~56929573:+ CESC cis rs9322193 0.632 rs3828700 ENSG00000268592.3 RAET1E-AS1 4.9 1.85e-06 0.00131 0.41 0.32 Lung cancer; chr6:149791033 chr6:149863494~149919507:+ CESC cis rs875971 0.545 rs6950988 ENSG00000222364.1 RNU6-96P -4.9 1.85e-06 0.00131 -0.42 -0.32 Aortic root size; chr7:66511428 chr7:66395191~66395286:+ CESC cis rs6969780 0.841 rs2301720 ENSG00000233429.8 HOTAIRM1 -4.9 1.86e-06 0.00132 -0.42 -0.32 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27156450 chr7:27095647~27100265:+ CESC cis rs2243480 1 rs9769882 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66177938 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6966322 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66181767 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs4145008 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66182524 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs4718315 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66183554 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs4718316 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66183744 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1873494 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66184912 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6959002 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66185509 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs1546059 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66189722 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs2420170 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66191066 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6958289 ENSG00000228409.4 CCT6P1 -4.9 1.86e-06 0.00132 -0.47 -0.32 Diabetic kidney disease; chr7:66192124 chr7:65751142~65763354:+ CESC cis rs1799949 1 rs3092994 ENSG00000267681.1 CTD-3199J23.6 -4.9 1.86e-06 0.00132 -0.42 -0.32 Menopause (age at onset); chr17:43063808 chr17:43144956~43145255:+ CESC cis rs9309711 0.736 rs13409102 ENSG00000225234.1 TRAPPC12-AS1 -4.9 1.86e-06 0.00132 -0.35 -0.32 Neurofibrillary tangles; chr2:3492550 chr2:3481242~3482409:- CESC cis rs2243480 0.901 rs73148097 ENSG00000232559.3 GS1-124K5.12 4.9 1.87e-06 0.00132 0.53 0.31 Diabetic kidney disease; chr7:65966800 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35820085 ENSG00000232559.3 GS1-124K5.12 4.9 1.87e-06 0.00132 0.53 0.31 Diabetic kidney disease; chr7:65977771 chr7:66554588~66576923:- CESC cis rs2243480 1 rs906134 ENSG00000232559.3 GS1-124K5.12 4.9 1.87e-06 0.00132 0.53 0.31 Diabetic kidney disease; chr7:65979301 chr7:66554588~66576923:- CESC cis rs950880 0.71 rs56331791 ENSG00000234389.1 AC007278.3 -4.9 1.87e-06 0.00132 -0.35 -0.31 Serum protein levels (sST2); chr2:102431697 chr2:102438713~102440475:+ CESC cis rs9322193 0.884 rs7450246 ENSG00000268592.3 RAET1E-AS1 4.9 1.87e-06 0.00132 0.4 0.31 Lung cancer; chr6:149702517 chr6:149863494~149919507:+ CESC cis rs7927592 0.956 rs7944870 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.36 0.31 Total body bone mineral density; chr11:68541640 chr11:68506083~68506166:- CESC cis rs8059260 0.736 rs7200623 ENSG00000274038.1 RP11-66H6.4 -4.9 1.87e-06 0.00132 -0.53 -0.31 Alcohol consumption over the past year; chr16:11001188 chr16:11056556~11057034:+ CESC cis rs7927592 0.913 rs3740631 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.38 0.31 Total body bone mineral density; chr11:68574254 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs3824850 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.38 0.31 Total body bone mineral density; chr11:68574405 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs3740629 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.38 0.31 Total body bone mineral density; chr11:68576125 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs11228287 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.38 0.31 Total body bone mineral density; chr11:68582286 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs10896346 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.38 0.31 Total body bone mineral density; chr11:68585203 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs10896347 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.38 0.31 Total body bone mineral density; chr11:68585659 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs6591344 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.38 0.31 Total body bone mineral density; chr11:68593405 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs7127948 ENSG00000212093.1 AP000807.1 4.9 1.87e-06 0.00132 0.38 0.31 Total body bone mineral density; chr11:68595594 chr11:68506083~68506166:- CESC cis rs875971 0.862 rs6952182 ENSG00000232559.3 GS1-124K5.12 -4.9 1.88e-06 0.00133 -0.34 -0.31 Aortic root size; chr7:66218330 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6964437 ENSG00000232559.3 GS1-124K5.12 -4.9 1.88e-06 0.00133 -0.34 -0.31 Aortic root size; chr7:66221457 chr7:66554588~66576923:- CESC cis rs7396835 0.866 rs6589570 ENSG00000254851.1 RP11-109L13.1 -4.9 1.88e-06 0.00133 -0.57 -0.31 Quantitative traits; chr11:116804578 chr11:117135528~117138582:+ CESC cis rs763121 0.815 rs9306328 ENSG00000273076.1 RP3-508I15.22 4.9 1.88e-06 0.00133 0.35 0.31 Menopause (age at onset); chr22:38632908 chr22:38743495~38743910:+ CESC cis rs9322193 0.923 rs9766004 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149754363 chr6:149863494~149919507:+ CESC cis rs748404 0.56 rs1060939 ENSG00000205771.5 CATSPER2P1 -4.9 1.88e-06 0.00133 -0.38 -0.31 Lung cancer; chr15:43524719 chr15:43726918~43747094:- CESC cis rs34375054 0.66 rs900411 ENSG00000279233.1 RP11-158L12.4 4.9 1.88e-06 0.00133 0.33 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125128293 chr12:125138245~125141711:+ CESC cis rs150992 0.603 rs326481 ENSG00000248489.1 CTD-2007H13.3 4.9 1.88e-06 0.00133 0.42 0.31 Body mass index; chr5:98949581 chr5:98929171~98995013:+ CESC cis rs9322193 0.962 rs2342861 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149777561 chr6:149863494~149919507:+ CESC cis rs9322193 0.926 rs2342860 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149777641 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs10872653 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149778907 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs11155683 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149779341 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9372044 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149780867 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs11155685 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149781649 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9322220 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149782897 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs10214845 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149783124 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9767122 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149783553 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs1413654 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149783956 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9688809 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149787920 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9689242 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149787970 chr6:149863494~149919507:+ CESC cis rs9322193 1 rs9767077 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149788479 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9688938 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149788941 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9688940 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149788977 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9689447 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149789350 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs9689269 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149791861 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs62441335 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149792658 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs4816 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149793609 chr6:149863494~149919507:+ CESC cis rs9322193 0.926 rs952166 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149798774 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs952165 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149798900 chr6:149863494~149919507:+ CESC cis rs9322193 0.926 rs9285525 ENSG00000268592.3 RAET1E-AS1 4.9 1.88e-06 0.00133 0.41 0.31 Lung cancer; chr6:149801253 chr6:149863494~149919507:+ CESC cis rs10875746 0.669 rs10875772 ENSG00000240399.1 RP1-228P16.1 -4.9 1.89e-06 0.00133 -0.43 -0.31 Longevity (90 years and older); chr12:48215770 chr12:48054813~48055591:- CESC cis rs763121 0.962 rs6001159 ENSG00000273076.1 RP3-508I15.22 4.9 1.89e-06 0.00134 0.36 0.31 Menopause (age at onset); chr22:38570482 chr22:38743495~38743910:+ CESC cis rs2732480 0.557 rs2634682 ENSG00000258273.1 RP11-370I10.4 -4.9 1.89e-06 0.00134 -0.39 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48339160 chr12:48333755~48333901:- CESC cis rs1061377 1 rs7685468 ENSG00000249685.1 RP11-360F5.3 4.9 1.89e-06 0.00134 0.38 0.31 Uric acid levels; chr4:39116649 chr4:39133913~39135608:+ CESC cis rs2337406 0.5 rs7152934 ENSG00000274576.2 IGHV2-70 -4.9 1.89e-06 0.00134 -0.36 -0.31 Alzheimer's disease (late onset); chr14:106778702 chr14:106770577~106771020:- CESC cis rs2337406 0.789 rs12050392 ENSG00000274576.2 IGHV2-70 -4.9 1.89e-06 0.00134 -0.36 -0.31 Alzheimer's disease (late onset); chr14:106779073 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs74092505 ENSG00000274576.2 IGHV2-70 -4.9 1.89e-06 0.00134 -0.36 -0.31 Alzheimer's disease (late onset); chr14:106779163 chr14:106770577~106771020:- CESC cis rs2337406 0.789 rs74092507 ENSG00000274576.2 IGHV2-70 -4.9 1.89e-06 0.00134 -0.36 -0.31 Alzheimer's disease (late onset); chr14:106779174 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs74092511 ENSG00000274576.2 IGHV2-70 -4.9 1.89e-06 0.00134 -0.36 -0.31 Alzheimer's disease (late onset); chr14:106779234 chr14:106770577~106771020:- CESC cis rs875971 0.862 rs28491091 ENSG00000237310.1 GS1-124K5.4 -4.9 1.9e-06 0.00134 -0.3 -0.31 Aortic root size; chr7:66204077 chr7:66493706~66495474:+ CESC cis rs9322193 0.923 rs9767105 ENSG00000268592.3 RAET1E-AS1 4.9 1.9e-06 0.00134 0.41 0.31 Lung cancer; chr6:149659591 chr6:149863494~149919507:+ CESC cis rs7560272 0.501 rs2421674 ENSG00000273245.1 RP11-434P11.2 -4.9 1.9e-06 0.00134 -0.39 -0.31 Schizophrenia; chr2:73728305 chr2:73750256~73750786:- CESC cis rs7560272 0.501 rs12713793 ENSG00000273245.1 RP11-434P11.2 -4.9 1.9e-06 0.00134 -0.39 -0.31 Schizophrenia; chr2:73728987 chr2:73750256~73750786:- CESC cis rs42490 0.903 rs218902 ENSG00000251136.7 RP11-37B2.1 4.9 1.9e-06 0.00134 0.32 0.31 Leprosy; chr8:89719986 chr8:89609409~89757727:- CESC cis rs17507216 0.591 rs7163848 ENSG00000255769.6 GOLGA2P10 -4.9 1.9e-06 0.00134 -0.46 -0.31 Excessive daytime sleepiness; chr15:82729563 chr15:82472993~82513950:- CESC cis rs12458462 0.892 rs2242174 ENSG00000274828.1 RP11-567M16.6 4.9 1.9e-06 0.00134 0.3 0.31 Monocyte count; chr18:79698037 chr18:79677287~79679358:- CESC cis rs2028299 1 rs2028299 ENSG00000259677.1 RP11-493E3.1 4.9 1.91e-06 0.00135 0.43 0.31 Type 2 diabetes; chr15:89831025 chr15:89876540~89877285:+ CESC cis rs7560272 0.501 rs7210 ENSG00000273245.1 RP11-434P11.2 -4.9 1.91e-06 0.00135 -0.39 -0.31 Schizophrenia; chr2:73729997 chr2:73750256~73750786:- CESC cis rs71335811 1 rs71335811 ENSG00000232871.7 SEC1P -4.9 1.91e-06 0.00135 -0.37 -0.31 Myeloid white cell count; chr19:48626814 chr19:48638071~48682245:+ CESC cis rs9907295 0.591 rs6505498 ENSG00000270977.1 AC015849.16 -4.9 1.91e-06 0.00135 -0.4 -0.31 Fibroblast growth factor basic levels; chr17:35803047 chr17:35893707~35911023:- CESC cis rs2028299 0.92 rs4932261 ENSG00000259677.1 RP11-493E3.1 4.9 1.91e-06 0.00135 0.42 0.31 Type 2 diabetes; chr15:89887164 chr15:89876540~89877285:+ CESC cis rs875971 0.862 rs6960446 ENSG00000222364.1 RNU6-96P 4.9 1.91e-06 0.00135 0.37 0.31 Aortic root size; chr7:66268272 chr7:66395191~66395286:+ CESC cis rs875971 0.79 rs10257911 ENSG00000222364.1 RNU6-96P 4.9 1.91e-06 0.00135 0.37 0.31 Aortic root size; chr7:66278783 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs7796162 ENSG00000222364.1 RNU6-96P 4.9 1.91e-06 0.00135 0.37 0.31 Aortic root size; chr7:66280771 chr7:66395191~66395286:+ CESC cis rs748404 0.587 rs690276 ENSG00000205771.5 CATSPER2P1 -4.9 1.91e-06 0.00135 -0.36 -0.31 Lung cancer; chr15:43412360 chr15:43726918~43747094:- CESC cis rs2439831 0.85 rs2957637 ENSG00000275601.1 AC011330.13 -4.9 1.91e-06 0.00135 -0.47 -0.31 Lung cancer in ever smokers; chr15:43658920 chr15:43642389~43643023:- CESC cis rs9487094 0.689 rs7754650 ENSG00000260273.1 RP11-425D10.10 4.9 1.91e-06 0.00135 0.38 0.31 Height; chr6:109405536 chr6:109382795~109383666:+ CESC cis rs7927592 0.913 rs10047412 ENSG00000212093.1 AP000807.1 4.9 1.91e-06 0.00135 0.38 0.31 Total body bone mineral density; chr11:68465444 chr11:68506083~68506166:- CESC cis rs7188445 0.932 rs17689455 ENSG00000261390.4 RP11-345M22.2 -4.89 1.91e-06 0.00135 -0.4 -0.31 Urate levels; chr16:79712438 chr16:79715232~79770563:- CESC cis rs801193 0.636 rs10233806 ENSG00000232559.3 GS1-124K5.12 -4.89 1.92e-06 0.00135 -0.34 -0.31 Aortic root size; chr7:66653261 chr7:66554588~66576923:- CESC cis rs2842992 0.789 rs9364536 ENSG00000237927.1 RP3-393E18.2 -4.89 1.92e-06 0.00135 -0.41 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159804527 chr6:159586955~159589169:- CESC cis rs7188445 0.932 rs73575079 ENSG00000261390.4 RP11-345M22.2 -4.89 1.92e-06 0.00135 -0.4 -0.31 Urate levels; chr16:79711344 chr16:79715232~79770563:- CESC cis rs10262624 0.967 rs13235406 ENSG00000234286.1 AC006026.13 -4.89 1.92e-06 0.00135 -0.33 -0.31 Schizophrenia; chr7:23879212 chr7:23680195~23680786:- CESC cis rs9322193 0.923 rs7767622 ENSG00000268592.3 RAET1E-AS1 4.89 1.92e-06 0.00136 0.4 0.31 Lung cancer; chr6:149681766 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs4421206 ENSG00000268592.3 RAET1E-AS1 4.89 1.92e-06 0.00136 0.4 0.31 Lung cancer; chr6:149682891 chr6:149863494~149919507:+ CESC cis rs1075265 0.704 rs10181999 ENSG00000233266.1 HMGB1P31 4.89 1.92e-06 0.00136 0.4 0.31 Chronotype;Morning vs. evening chronotype; chr2:54025360 chr2:54051334~54051760:+ CESC cis rs2028299 0.879 rs8034631 ENSG00000259677.1 RP11-493E3.1 4.89 1.93e-06 0.00136 0.42 0.31 Type 2 diabetes; chr15:89879433 chr15:89876540~89877285:+ CESC cis rs10829156 0.945 rs8181345 ENSG00000240291.1 RP11-499P20.2 4.89 1.93e-06 0.00136 0.34 0.31 Sudden cardiac arrest; chr10:18678689 chr10:18513115~18545651:- CESC cis rs11638352 0.661 rs2615278 ENSG00000259479.5 SORD2P -4.89 1.93e-06 0.00136 -0.45 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44166436 chr15:44826371~44884694:- CESC cis rs9322193 0.884 rs9322210 ENSG00000268592.3 RAET1E-AS1 4.89 1.93e-06 0.00136 0.4 0.31 Lung cancer; chr6:149695440 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9322197 ENSG00000216906.2 RP11-350J20.9 4.89 1.93e-06 0.00136 0.34 0.31 Lung cancer; chr6:149622577 chr6:149904243~149906418:+ CESC cis rs1061377 1 rs28465556 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39119569 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs10027813 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39119818 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs9990755 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39119819 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs7676008 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39120154 chr4:39133913~39135608:+ CESC cis rs1061377 0.965 rs7677729 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39120370 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs7655122 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39120396 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs3796511 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39120586 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs3733274 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39120957 chr4:39133913~39135608:+ CESC cis rs1061377 0.965 rs3733275 ENSG00000249685.1 RP11-360F5.3 4.89 1.93e-06 0.00136 0.37 0.31 Uric acid levels; chr4:39121077 chr4:39133913~39135608:+ CESC cis rs875971 0.862 rs3893216 ENSG00000237310.1 GS1-124K5.4 -4.89 1.94e-06 0.00136 -0.3 -0.31 Aortic root size; chr7:66325720 chr7:66493706~66495474:+ CESC cis rs6991838 0.8 rs28547533 ENSG00000200714.1 Y_RNA 4.89 1.94e-06 0.00136 0.36 0.31 Intelligence (multi-trait analysis); chr8:65559318 chr8:65592731~65592820:+ CESC cis rs6991838 0.8 rs28626262 ENSG00000200714.1 Y_RNA 4.89 1.94e-06 0.00136 0.36 0.31 Intelligence (multi-trait analysis); chr8:65559335 chr8:65592731~65592820:+ CESC cis rs6991838 0.8 rs28709439 ENSG00000200714.1 Y_RNA 4.89 1.94e-06 0.00136 0.36 0.31 Intelligence (multi-trait analysis); chr8:65559337 chr8:65592731~65592820:+ CESC cis rs1823913 0.525 rs7424440 ENSG00000280083.1 RP11-317J9.1 -4.89 1.94e-06 0.00136 -0.37 -0.31 Obesity-related traits; chr2:191337919 chr2:191154118~191156070:- CESC cis rs1823913 0.526 rs35340557 ENSG00000280083.1 RP11-317J9.1 -4.89 1.94e-06 0.00136 -0.37 -0.31 Obesity-related traits; chr2:191338688 chr2:191154118~191156070:- CESC cis rs1823913 0.503 rs35562914 ENSG00000280083.1 RP11-317J9.1 -4.89 1.94e-06 0.00136 -0.37 -0.31 Obesity-related traits; chr2:191338969 chr2:191154118~191156070:- CESC cis rs9322193 0.923 rs9371207 ENSG00000268592.3 RAET1E-AS1 4.89 1.94e-06 0.00136 0.43 0.31 Lung cancer; chr6:149858087 chr6:149863494~149919507:+ CESC cis rs1707322 0.789 rs7540578 ENSG00000281133.1 AL355480.3 -4.89 1.94e-06 0.00137 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45786472 chr1:45580892~45580996:- CESC cis rs1799949 1 rs11657835 ENSG00000267681.1 CTD-3199J23.6 -4.89 1.94e-06 0.00137 -0.41 -0.31 Menopause (age at onset); chr17:43139936 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs1135214 ENSG00000267681.1 CTD-3199J23.6 -4.89 1.94e-06 0.00137 -0.41 -0.31 Menopause (age at onset); chr17:43140306 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs4793212 ENSG00000267681.1 CTD-3199J23.6 -4.89 1.94e-06 0.00137 -0.41 -0.31 Menopause (age at onset); chr17:43150733 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs34534709 ENSG00000267681.1 CTD-3199J23.6 -4.89 1.94e-06 0.00137 -0.41 -0.31 Menopause (age at onset); chr17:43150923 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs34059614 ENSG00000267681.1 CTD-3199J23.6 -4.89 1.94e-06 0.00137 -0.41 -0.31 Menopause (age at onset); chr17:43151054 chr17:43144956~43145255:+ CESC cis rs651386 0.505 rs10919441 ENSG00000271811.1 RP1-79C4.4 4.89 1.94e-06 0.00137 0.42 0.31 Atrial fibrillation; chr1:170609948 chr1:170667381~170669425:+ CESC cis rs3931020 0.688 rs277374 ENSG00000272864.1 RP11-17E13.2 4.89 1.95e-06 0.00137 0.41 0.31 Resistin levels; chr1:74734802 chr1:74698769~74699333:- CESC cis rs897984 0.806 rs1046276 ENSG00000260911.2 RP11-196G11.2 -4.89 1.95e-06 0.00137 -0.35 -0.31 Dementia with Lewy bodies; chr16:30903305 chr16:31043150~31049868:+ CESC cis rs13108904 0.901 rs7673398 ENSG00000254094.1 AC078852.1 -4.89 1.95e-06 0.00137 -0.37 -0.31 Obesity-related traits; chr4:1306289 chr4:1356581~1358075:+ CESC cis rs13108904 0.901 rs7668661 ENSG00000254094.1 AC078852.1 -4.89 1.95e-06 0.00137 -0.37 -0.31 Obesity-related traits; chr4:1306384 chr4:1356581~1358075:+ CESC cis rs10754283 0.967 rs6663363 ENSG00000231613.1 RP5-943J3.1 4.89 1.95e-06 0.00137 0.4 0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89651295 chr1:89788914~89790492:+ CESC cis rs9322193 0.923 rs14314 ENSG00000216906.2 RP11-350J20.9 4.89 1.96e-06 0.00137 0.36 0.31 Lung cancer; chr6:149820395 chr6:149904243~149906418:+ CESC cis rs2836950 0.565 rs2836943 ENSG00000232608.1 TIMM9P2 4.89 1.96e-06 0.00137 0.35 0.31 Menarche (age at onset); chr21:39220685 chr21:39216624~39217506:+ CESC cis rs3096299 0.967 rs2965937 ENSG00000274627.1 RP11-104N10.2 4.89 1.96e-06 0.00137 0.31 0.31 Multiple myeloma (IgH translocation); chr16:89422371 chr16:89516797~89522217:+ CESC cis rs7927592 0.913 rs11228293 ENSG00000212093.1 AP000807.1 4.89 1.96e-06 0.00137 0.37 0.31 Total body bone mineral density; chr11:68617178 chr11:68506083~68506166:- CESC cis rs13108904 0.604 rs11946375 ENSG00000254094.1 AC078852.1 -4.89 1.96e-06 0.00137 -0.37 -0.31 Obesity-related traits; chr4:1319700 chr4:1356581~1358075:+ CESC cis rs116095464 0.558 rs9654453 ENSG00000250848.1 CTD-2083E4.5 -4.89 1.96e-06 0.00137 -0.46 -0.31 Breast cancer; chr5:299506 chr5:288833~290321:- CESC cis rs889512 0.642 rs7185352 ENSG00000280152.1 RP11-331F4.5 -4.89 1.96e-06 0.00138 -0.46 -0.31 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75266350 chr16:75245994~75250077:- CESC cis rs11651753 0.613 rs3096 ENSG00000264920.1 RP11-6N17.4 -4.89 1.96e-06 0.00138 -0.37 -0.31 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47952066 chr17:47891255~47895812:- CESC cis rs7560272 0.501 rs6755500 ENSG00000273245.1 RP11-434P11.2 -4.89 1.97e-06 0.00138 -0.38 -0.31 Schizophrenia; chr2:73715106 chr2:73750256~73750786:- CESC cis rs1061377 1 rs1036036 ENSG00000249685.1 RP11-360F5.3 4.89 1.97e-06 0.00138 0.37 0.31 Uric acid levels; chr4:39111104 chr4:39133913~39135608:+ CESC cis rs9322193 0.962 rs6899661 ENSG00000216906.2 RP11-350J20.9 4.89 1.97e-06 0.00138 0.35 0.31 Lung cancer; chr6:149818093 chr6:149904243~149906418:+ CESC cis rs9640161 0.75 rs11769348 ENSG00000261305.1 RP4-584D14.7 -4.89 1.97e-06 0.00138 -0.43 -0.31 Blood protein levels;Circulating chemerin levels; chr7:150329664 chr7:150341771~150342607:+ CESC cis rs9322193 0.926 rs3805751 ENSG00000216906.2 RP11-350J20.9 4.89 1.98e-06 0.00139 0.35 0.31 Lung cancer; chr6:149791193 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs10872656 ENSG00000216906.2 RP11-350J20.9 4.89 1.98e-06 0.00139 0.35 0.31 Lung cancer; chr6:149799444 chr6:149904243~149906418:+ CESC cis rs9322193 0.683 rs113281309 ENSG00000216906.2 RP11-350J20.9 4.89 1.98e-06 0.00139 0.35 0.31 Lung cancer; chr6:149787289 chr6:149904243~149906418:+ CESC cis rs875971 0.545 rs6950988 ENSG00000237310.1 GS1-124K5.4 4.89 1.98e-06 0.00139 0.34 0.31 Aortic root size; chr7:66511428 chr7:66493706~66495474:+ CESC cis rs2408955 0.501 rs8716 ENSG00000240399.1 RP1-228P16.1 4.89 1.99e-06 0.00139 0.34 0.31 Glycated hemoglobin levels; chr12:48145699 chr12:48054813~48055591:- CESC cis rs1862618 0.853 rs252909 ENSG00000271828.1 CTD-2310F14.1 4.89 1.99e-06 0.00139 0.43 0.31 Initial pursuit acceleration; chr5:56825304 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs252919 ENSG00000271828.1 CTD-2310F14.1 4.89 1.99e-06 0.00139 0.43 0.31 Initial pursuit acceleration; chr5:56828284 chr5:56927874~56929573:+ CESC cis rs1799949 0.931 rs34410138 ENSG00000267681.1 CTD-3199J23.6 -4.89 1.99e-06 0.00139 -0.41 -0.31 Menopause (age at onset); chr17:43127753 chr17:43144956~43145255:+ CESC cis rs9907295 0.748 rs4795091 ENSG00000270977.1 AC015849.16 -4.89 1.99e-06 0.00139 -0.46 -0.31 Fibroblast growth factor basic levels; chr17:35814874 chr17:35893707~35911023:- CESC cis rs9907295 0.71 rs4795092 ENSG00000270977.1 AC015849.16 -4.89 1.99e-06 0.00139 -0.46 -0.31 Fibroblast growth factor basic levels; chr17:35814967 chr17:35893707~35911023:- CESC cis rs875971 0.545 rs6460298 ENSG00000237310.1 GS1-124K5.4 4.89 1.99e-06 0.0014 0.34 0.31 Aortic root size; chr7:66442783 chr7:66493706~66495474:+ CESC cis rs9907295 0.748 rs78672421 ENSG00000270977.1 AC015849.16 -4.89 1.99e-06 0.0014 -0.46 -0.31 Fibroblast growth factor basic levels; chr17:35837325 chr17:35893707~35911023:- CESC cis rs2028299 1 rs8031576 ENSG00000259677.1 RP11-493E3.1 4.89 1.99e-06 0.0014 0.43 0.31 Type 2 diabetes; chr15:89836982 chr15:89876540~89877285:+ CESC cis rs7927592 0.913 rs7123564 ENSG00000212093.1 AP000807.1 4.89 2e-06 0.0014 0.37 0.31 Total body bone mineral density; chr11:68594696 chr11:68506083~68506166:- CESC cis rs8177876 0.731 rs77145371 ENSG00000261838.4 RP11-303E16.6 4.89 2e-06 0.0014 0.68 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085055 chr16:81069854~81076598:+ CESC cis rs8177876 0.908 rs80187824 ENSG00000261838.4 RP11-303E16.6 4.89 2e-06 0.0014 0.68 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81085075 chr16:81069854~81076598:+ CESC cis rs860295 0.58 rs6672284 ENSG00000225855.5 RUSC1-AS1 4.89 2e-06 0.0014 0.25 0.31 Body mass index; chr1:155308172 chr1:155316863~155324176:- CESC cis rs2564921 0.704 rs12053904 ENSG00000242142.1 SERBP1P3 -4.89 2e-06 0.0014 -0.39 -0.31 Height; chr3:52991821 chr3:53064283~53065091:- CESC cis rs9322193 0.926 rs9766562 ENSG00000268592.3 RAET1E-AS1 4.89 2e-06 0.0014 0.41 0.31 Lung cancer; chr6:149788709 chr6:149863494~149919507:+ CESC cis rs1061377 1 rs3796509 ENSG00000249685.1 RP11-360F5.3 4.89 2e-06 0.0014 0.37 0.31 Uric acid levels; chr4:39108566 chr4:39133913~39135608:+ CESC cis rs9322193 0.962 rs6899661 ENSG00000268592.3 RAET1E-AS1 4.89 2e-06 0.0014 0.41 0.31 Lung cancer; chr6:149818093 chr6:149863494~149919507:+ CESC cis rs7048146 0.51 rs1109477 ENSG00000213539.4 YBX1P6 -4.89 2e-06 0.0014 -0.37 -0.31 Vascular brain injury; chr9:109519571 chr9:109532830~109534332:- CESC cis rs7048146 0.51 rs1109478 ENSG00000213539.4 YBX1P6 -4.89 2e-06 0.0014 -0.37 -0.31 Vascular brain injury; chr9:109519583 chr9:109532830~109534332:- CESC cis rs7048146 0.51 rs10759347 ENSG00000213539.4 YBX1P6 -4.89 2e-06 0.0014 -0.37 -0.31 Vascular brain injury; chr9:109521455 chr9:109532830~109534332:- CESC cis rs4718428 0.672 rs13241598 ENSG00000273142.1 RP11-458F8.4 -4.88 2e-06 0.0014 -0.34 -0.31 Corneal structure; chr7:66835665 chr7:66902857~66906297:+ CESC cis rs9549367 0.577 rs776904 ENSG00000269125.1 RP11-98F14.11 -4.88 2.01e-06 0.0014 -0.47 -0.31 Platelet distribution width; chr13:113156228 chr13:113165002~113165183:- CESC cis rs2408955 0.541 rs11168428 ENSG00000240399.1 RP1-228P16.1 -4.88 2.01e-06 0.0014 -0.34 -0.31 Glycated hemoglobin levels; chr12:48153345 chr12:48054813~48055591:- CESC cis rs2564921 0.704 rs62253649 ENSG00000242142.1 SERBP1P3 -4.88 2.01e-06 0.0014 -0.38 -0.31 Height; chr3:52967831 chr3:53064283~53065091:- CESC cis rs10129255 1 rs10134517 ENSG00000280411.1 IGHV1-69-2 -4.88 2.01e-06 0.0014 -0.24 -0.31 Kawasaki disease; chr14:106718498 chr14:106762092~106762588:- CESC cis rs7560272 0.501 rs2006997 ENSG00000273245.1 RP11-434P11.2 -4.88 2.01e-06 0.0014 -0.39 -0.31 Schizophrenia; chr2:73720719 chr2:73750256~73750786:- CESC cis rs73086581 1 rs3746665 ENSG00000229539.1 RP11-119B16.2 -4.88 2.01e-06 0.0014 -0.48 -0.31 Response to antidepressants in depression; chr20:3929759 chr20:3888239~3888868:- CESC cis rs9549367 0.789 rs2316442 ENSG00000269125.1 RP11-98F14.11 -4.88 2.01e-06 0.0014 -0.44 -0.31 Platelet distribution width; chr13:113223173 chr13:113165002~113165183:- CESC cis rs14027 0.512 rs6469841 ENSG00000279347.1 RP11-85I17.2 -4.88 2.01e-06 0.0014 -0.3 -0.31 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119721889 chr8:119838736~119840385:- CESC cis rs9549367 0.664 rs9549689 ENSG00000269125.1 RP11-98F14.11 -4.88 2.01e-06 0.0014 -0.45 -0.31 Platelet distribution width; chr13:113194073 chr13:113165002~113165183:- CESC cis rs116095464 0.558 rs10065584 ENSG00000250848.1 CTD-2083E4.5 -4.88 2.01e-06 0.00141 -0.46 -0.31 Breast cancer; chr5:253882 chr5:288833~290321:- CESC cis rs1707322 1 rs1613296 ENSG00000280836.1 AL355480.1 4.88 2.01e-06 0.00141 0.4 0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46081180 chr1:45581219~45581321:- CESC cis rs1862618 0.853 rs9283717 ENSG00000271828.1 CTD-2310F14.1 4.88 2.01e-06 0.00141 0.42 0.31 Initial pursuit acceleration; chr5:56782832 chr5:56927874~56929573:+ CESC cis rs6997458 0.874 rs13252971 ENSG00000253549.4 RP11-317J10.2 4.88 2.01e-06 0.00141 0.38 0.31 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85357055 chr8:85441851~85464915:- CESC cis rs42490 0.903 rs218900 ENSG00000251136.7 RP11-37B2.1 -4.88 2.02e-06 0.00141 -0.32 -0.31 Leprosy; chr8:89718678 chr8:89609409~89757727:- CESC cis rs42490 0.903 rs218901 ENSG00000251136.7 RP11-37B2.1 -4.88 2.02e-06 0.00141 -0.32 -0.31 Leprosy; chr8:89719089 chr8:89609409~89757727:- CESC cis rs1862618 0.853 rs252921 ENSG00000271828.1 CTD-2310F14.1 4.88 2.02e-06 0.00141 0.42 0.31 Initial pursuit acceleration; chr5:56841960 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs33325 ENSG00000271828.1 CTD-2310F14.1 4.88 2.02e-06 0.00141 0.42 0.31 Initial pursuit acceleration; chr5:56846720 chr5:56927874~56929573:+ CESC cis rs1862618 0.802 rs42769 ENSG00000271828.1 CTD-2310F14.1 4.88 2.02e-06 0.00141 0.42 0.31 Initial pursuit acceleration; chr5:56848325 chr5:56927874~56929573:+ CESC cis rs453301 0.686 rs6601281 ENSG00000173295.6 FAM86B3P -4.88 2.02e-06 0.00141 -0.41 -0.31 Joint mobility (Beighton score); chr8:9053494 chr8:8228595~8244865:+ CESC cis rs748404 0.631 rs7167882 ENSG00000205771.5 CATSPER2P1 -4.88 2.02e-06 0.00141 -0.38 -0.31 Lung cancer; chr15:43386465 chr15:43726918~43747094:- CESC cis rs875971 0.862 rs11765791 ENSG00000232559.3 GS1-124K5.12 4.88 2.02e-06 0.00141 0.35 0.31 Aortic root size; chr7:66471587 chr7:66554588~66576923:- CESC cis rs13108904 0.901 rs6851528 ENSG00000253399.1 AC078852.2 -4.88 2.03e-06 0.00142 -0.38 -0.31 Obesity-related traits; chr4:1302221 chr4:1358479~1359461:+ CESC cis rs34375054 0.526 rs883315 ENSG00000279233.1 RP11-158L12.4 4.88 2.04e-06 0.00142 0.34 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125192343 chr12:125138245~125141711:+ CESC cis rs34375054 0.526 rs2343638 ENSG00000279233.1 RP11-158L12.4 4.88 2.04e-06 0.00142 0.34 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125192576 chr12:125138245~125141711:+ CESC cis rs7615952 0.576 rs2276726 ENSG00000250012.1 RP11-124N2.1 -4.88 2.04e-06 0.00142 -0.32 -0.31 Blood pressure (smoking interaction); chr3:126107444 chr3:126084220~126095349:+ CESC cis rs763121 0.853 rs138709 ENSG00000273076.1 RP3-508I15.22 4.88 2.04e-06 0.00142 0.35 0.31 Menopause (age at onset); chr22:38743211 chr22:38743495~38743910:+ CESC cis rs9322193 0.962 rs2065664 ENSG00000216906.2 RP11-350J20.9 4.88 2.04e-06 0.00142 0.36 0.31 Lung cancer; chr6:149762485 chr6:149904243~149906418:+ CESC cis rs3096299 0.781 rs2965819 ENSG00000274627.1 RP11-104N10.2 -4.88 2.04e-06 0.00143 -0.31 -0.31 Multiple myeloma (IgH translocation); chr16:89434622 chr16:89516797~89522217:+ CESC cis rs875971 1 rs1544549 ENSG00000237310.1 GS1-124K5.4 -4.88 2.05e-06 0.00143 -0.31 -0.31 Aortic root size; chr7:66625676 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs1167408 ENSG00000222364.1 RNU6-96P 4.88 2.05e-06 0.00143 0.38 0.31 Aortic root size; chr7:66091121 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs1167406 ENSG00000222364.1 RNU6-96P 4.88 2.05e-06 0.00143 0.38 0.31 Aortic root size; chr7:66091949 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs1167399 ENSG00000222364.1 RNU6-96P 4.88 2.05e-06 0.00143 0.38 0.31 Aortic root size; chr7:66096890 chr7:66395191~66395286:+ CESC cis rs875971 0.825 rs59466412 ENSG00000222364.1 RNU6-96P 4.88 2.05e-06 0.00143 0.38 0.31 Aortic root size; chr7:66100371 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs57866200 ENSG00000222364.1 RNU6-96P 4.88 2.05e-06 0.00143 0.38 0.31 Aortic root size; chr7:66100405 chr7:66395191~66395286:+ CESC cis rs950880 0.71 rs17027255 ENSG00000234389.1 AC007278.3 -4.88 2.05e-06 0.00143 -0.34 -0.31 Serum protein levels (sST2); chr2:102473668 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs1474309 ENSG00000234389.1 AC007278.3 -4.88 2.05e-06 0.00143 -0.34 -0.31 Serum protein levels (sST2); chr2:102474542 chr2:102438713~102440475:+ CESC cis rs10129255 1 rs10129319 ENSG00000211970.3 IGHV4-61 -4.88 2.05e-06 0.00143 -0.26 -0.31 Kawasaki disease; chr14:106767996 chr14:106639119~106639657:- CESC cis rs11159086 0.729 rs8015872 ENSG00000270000.1 RP3-449M8.9 4.88 2.06e-06 0.00143 0.5 0.31 Advanced glycation end-product levels; chr14:74475529 chr14:74471930~74472360:- CESC cis rs1823913 1 rs11691372 ENSG00000227542.1 AC092614.2 -4.88 2.06e-06 0.00143 -0.32 -0.31 Obesity-related traits; chr2:191249952 chr2:191229165~191246172:- CESC cis rs2243480 0.901 rs313808 ENSG00000228409.4 CCT6P1 4.88 2.06e-06 0.00144 0.45 0.31 Diabetic kidney disease; chr7:66034886 chr7:65751142~65763354:+ CESC cis rs2111504 0.583 rs1015839 ENSG00000267213.4 AC007773.2 4.88 2.06e-06 0.00144 0.38 0.31 Bipolar disorder; chr19:32390365 chr19:32390050~32405560:- CESC cis rs801193 0.569 rs10950050 ENSG00000232559.3 GS1-124K5.12 4.88 2.06e-06 0.00144 0.33 0.31 Aortic root size; chr7:66774601 chr7:66554588~66576923:- CESC cis rs75422866 0.558 rs73104190 ENSG00000257433.4 RP1-197B17.3 4.88 2.06e-06 0.00144 0.76 0.31 Pneumonia; chr12:47716040 chr12:47706085~47742294:+ CESC cis rs9813712 0.571 rs6795143 ENSG00000228252.7 COL6A4P2 -4.88 2.06e-06 0.00144 -0.37 -0.31 Response to amphetamines; chr3:130224355 chr3:130212823~130273806:+ CESC cis rs832187 0.704 rs704364 ENSG00000280620.1 SCAANT1 -4.88 2.07e-06 0.00144 -0.43 -0.31 Schizophrenia; chr3:63889058 chr3:63911518~63911772:- CESC cis rs748404 0.56 rs1869258 ENSG00000205771.5 CATSPER2P1 -4.88 2.07e-06 0.00144 -0.38 -0.31 Lung cancer; chr15:43511423 chr15:43726918~43747094:- CESC cis rs748404 0.56 rs529611 ENSG00000205771.5 CATSPER2P1 -4.88 2.07e-06 0.00144 -0.38 -0.31 Lung cancer; chr15:43513790 chr15:43726918~43747094:- CESC cis rs9322193 0.923 rs9383812 ENSG00000268592.3 RAET1E-AS1 4.88 2.07e-06 0.00144 0.4 0.31 Lung cancer; chr6:149712355 chr6:149863494~149919507:+ CESC cis rs9322193 0.847 rs9383844 ENSG00000268592.3 RAET1E-AS1 4.88 2.07e-06 0.00144 0.4 0.31 Lung cancer; chr6:149716268 chr6:149863494~149919507:+ CESC cis rs1799949 0.965 rs8176323 ENSG00000267681.1 CTD-3199J23.6 -4.88 2.07e-06 0.00144 -0.41 -0.31 Menopause (age at onset); chr17:43043694 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs8176322 ENSG00000267681.1 CTD-3199J23.6 -4.88 2.07e-06 0.00144 -0.41 -0.31 Menopause (age at onset); chr17:43043756 chr17:43144956~43145255:+ CESC cis rs6997458 0.742 rs13269441 ENSG00000253549.4 RP11-317J10.2 4.88 2.07e-06 0.00144 0.37 0.31 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85418406 chr8:85441851~85464915:- CESC cis rs875971 0.862 rs7783779 ENSG00000222364.1 RNU6-96P 4.88 2.07e-06 0.00144 0.37 0.31 Aortic root size; chr7:66331639 chr7:66395191~66395286:+ CESC cis rs7621025 0.5 rs12629000 ENSG00000239213.4 NCK1-AS1 4.88 2.07e-06 0.00144 0.4 0.31 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136924729 chr3:136841726~136862054:- CESC cis rs2028299 0.959 rs12912009 ENSG00000259677.1 RP11-493E3.1 4.88 2.08e-06 0.00144 0.42 0.31 Type 2 diabetes; chr15:89885916 chr15:89876540~89877285:+ CESC cis rs12439619 0.508 rs8032033 ENSG00000255769.6 GOLGA2P10 -4.88 2.08e-06 0.00145 -0.34 -0.31 Intelligence (multi-trait analysis); chr15:82165555 chr15:82472993~82513950:- CESC cis rs11723261 0.621 rs7440274 ENSG00000211553.1 AC253576.2 4.88 2.08e-06 0.00145 0.48 0.31 Immune response to smallpox vaccine (IL-6); chr4:161923 chr4:136461~136568:+ CESC cis rs748404 0.578 rs510108 ENSG00000249839.1 AC011330.5 -4.88 2.08e-06 0.00145 -0.33 -0.31 Lung cancer; chr15:43313241 chr15:43663654~43684339:- CESC cis rs7809950 1 rs2107713 ENSG00000238832.1 snoU109 -4.88 2.08e-06 0.00145 -0.39 -0.31 Coronary artery disease; chr7:107591924 chr7:107603363~107603507:+ CESC cis rs34779708 0.931 rs10437420 ENSG00000230534.5 RP11-297A16.2 -4.88 2.08e-06 0.00145 -0.42 -0.31 Inflammatory bowel disease;Crohn's disease; chr10:35046116 chr10:35098006~35127020:- CESC cis rs6504622 0.755 rs34038545 ENSG00000262879.4 RP11-156P1.3 -4.88 2.08e-06 0.00145 -0.34 -0.31 Orofacial clefts; chr17:47067541 chr17:46984045~47100323:- CESC cis rs2412819 0.559 rs8040336 ENSG00000249839.1 AC011330.5 -4.88 2.08e-06 0.00145 -0.34 -0.31 Lung cancer; chr15:43761419 chr15:43663654~43684339:- CESC cis rs10754283 0.967 rs10922680 ENSG00000231613.1 RP5-943J3.1 -4.88 2.08e-06 0.00145 -0.4 -0.31 Amyotrophic lateral sclerosis (sporadic); chr1:89635767 chr1:89788914~89790492:+ CESC cis rs14027 0.64 rs9297604 ENSG00000279347.1 RP11-85I17.2 4.88 2.09e-06 0.00145 0.3 0.31 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119738772 chr8:119838736~119840385:- CESC cis rs12439619 0.774 rs2867649 ENSG00000255769.6 GOLGA2P10 -4.88 2.09e-06 0.00145 -0.47 -0.31 Intelligence (multi-trait analysis); chr15:82262331 chr15:82472993~82513950:- CESC cis rs75422866 0.867 rs73102140 ENSG00000257433.4 RP1-197B17.3 4.87 2.1e-06 0.00146 0.8 0.31 Pneumonia; chr12:47647497 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102148 ENSG00000257433.4 RP1-197B17.3 4.87 2.1e-06 0.00146 0.8 0.31 Pneumonia; chr12:47648013 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs73102151 ENSG00000257433.4 RP1-197B17.3 4.87 2.1e-06 0.00146 0.8 0.31 Pneumonia; chr12:47648023 chr12:47706085~47742294:+ CESC cis rs950169 0.58 rs17532346 ENSG00000225151.9 GOLGA2P7 -4.87 2.1e-06 0.00146 -0.41 -0.31 Schizophrenia; chr15:84628264 chr15:84199311~84230136:- CESC cis rs763121 0.962 rs909564 ENSG00000273076.1 RP3-508I15.22 4.87 2.1e-06 0.00146 0.35 0.31 Menopause (age at onset); chr22:38730503 chr22:38743495~38743910:+ CESC cis rs2739330 0.627 rs9608219 ENSG00000272787.1 KB-226F1.2 -4.87 2.1e-06 0.00146 -0.34 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23969211~23969873:+ CESC cis rs12439619 0.508 rs8023960 ENSG00000255769.6 GOLGA2P10 -4.87 2.1e-06 0.00146 -0.35 -0.31 Intelligence (multi-trait analysis); chr15:82206704 chr15:82472993~82513950:- CESC cis rs13385 0.553 rs13179861 ENSG00000202111.1 VTRNA1-2 4.87 2.1e-06 0.00146 0.47 0.31 Atrial fibrillation; chr5:140148136 chr5:140718925~140719013:+ CESC cis rs34779708 0.897 rs4934527 ENSG00000230534.5 RP11-297A16.2 4.87 2.1e-06 0.00146 0.41 0.31 Inflammatory bowel disease;Crohn's disease; chr10:34992190 chr10:35098006~35127020:- CESC cis rs10246939 0.505 rs13236432 ENSG00000228775.6 WEE2-AS1 4.87 2.11e-06 0.00146 0.38 0.31 Bitter taste perception; chr7:141850980 chr7:141704338~141738346:- CESC cis rs12439619 0.846 rs62011975 ENSG00000255769.6 GOLGA2P10 -4.87 2.11e-06 0.00146 -0.48 -0.31 Intelligence (multi-trait analysis); chr15:82159213 chr15:82472993~82513950:- CESC cis rs12439619 0.846 rs62012004 ENSG00000255769.6 GOLGA2P10 -4.87 2.11e-06 0.00146 -0.48 -0.31 Intelligence (multi-trait analysis); chr15:82183924 chr15:82472993~82513950:- CESC cis rs2015599 0.514 rs10843376 ENSG00000275476.1 RP11-996F15.4 4.87 2.11e-06 0.00146 0.35 0.31 Platelet count;Mean platelet volume; chr12:29283651 chr12:29277397~29277882:- CESC cis rs9322193 0.962 rs7818 ENSG00000216906.2 RP11-350J20.9 4.87 2.11e-06 0.00146 0.34 0.31 Lung cancer; chr6:149810956 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs11155677 ENSG00000268592.3 RAET1E-AS1 4.87 2.12e-06 0.00147 0.41 0.31 Lung cancer; chr6:149756953 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs9480009 ENSG00000268592.3 RAET1E-AS1 4.87 2.12e-06 0.00147 0.41 0.31 Lung cancer; chr6:149758502 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9480031 ENSG00000268592.3 RAET1E-AS1 4.87 2.12e-06 0.00147 0.41 0.31 Lung cancer; chr6:149758875 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs10872649 ENSG00000268592.3 RAET1E-AS1 4.87 2.12e-06 0.00147 0.41 0.31 Lung cancer; chr6:149759454 chr6:149863494~149919507:+ CESC cis rs34375054 0.526 rs34764657 ENSG00000279233.1 RP11-158L12.4 4.87 2.12e-06 0.00147 0.34 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125195093 chr12:125138245~125141711:+ CESC cis rs801193 0.569 rs2659907 ENSG00000222364.1 RNU6-96P -4.87 2.12e-06 0.00147 -0.37 -0.31 Aortic root size; chr7:66699045 chr7:66395191~66395286:+ CESC cis rs6782228 0.509 rs6780447 ENSG00000242551.2 POU5F1P6 -4.87 2.12e-06 0.00147 -0.36 -0.31 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694965 chr3:128674735~128677005:- CESC cis rs6142102 0.961 rs6088355 ENSG00000276073.1 RP5-1125A11.7 -4.87 2.12e-06 0.00147 -0.31 -0.31 Skin pigmentation; chr20:33958081 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs6057957 ENSG00000276073.1 RP5-1125A11.7 -4.87 2.12e-06 0.00147 -0.31 -0.31 Skin pigmentation; chr20:33962052 chr20:33985617~33988989:- CESC cis rs11159086 0.793 rs28612392 ENSG00000259005.1 RP3-449M8.6 4.87 2.13e-06 0.00147 0.45 0.31 Advanced glycation end-product levels; chr14:74467894 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs11625502 ENSG00000259005.1 RP3-449M8.6 4.87 2.13e-06 0.00147 0.45 0.31 Advanced glycation end-product levels; chr14:74468309 chr14:74474007~74474864:- CESC cis rs2243480 1 rs2961102 ENSG00000232559.3 GS1-124K5.12 4.87 2.13e-06 0.00148 0.52 0.31 Diabetic kidney disease; chr7:65959671 chr7:66554588~66576923:- CESC cis rs4423214 0.592 rs10898191 ENSG00000254682.1 RP11-660L16.2 -4.87 2.13e-06 0.00148 -0.47 -0.31 Vitamin D levels; chr11:71483555 chr11:71448674~71452157:+ CESC cis rs8100891 0.537 rs10424665 ENSG00000267213.4 AC007773.2 -4.87 2.13e-06 0.00148 -0.47 -0.31 Neuroticism; chr19:32404725 chr19:32390050~32405560:- CESC cis rs9918079 0.542 rs6414765 ENSG00000273133.1 RP11-799M12.2 -4.87 2.14e-06 0.00148 -0.4 -0.31 Obesity-related traits; chr4:15624870 chr4:15563698~15564253:- CESC cis rs783540 0.656 rs783524 ENSG00000255769.6 GOLGA2P10 4.87 2.14e-06 0.00148 0.35 0.31 Schizophrenia; chr15:82615393 chr15:82472993~82513950:- CESC cis rs783540 0.592 rs2567632 ENSG00000255769.6 GOLGA2P10 4.87 2.14e-06 0.00148 0.35 0.31 Schizophrenia; chr15:82616053 chr15:82472993~82513950:- CESC cis rs9322193 0.923 rs55993747 ENSG00000268592.3 RAET1E-AS1 4.87 2.14e-06 0.00148 0.4 0.31 Lung cancer; chr6:149622016 chr6:149863494~149919507:+ CESC cis rs9322193 0.847 rs12191643 ENSG00000268592.3 RAET1E-AS1 4.87 2.14e-06 0.00148 0.4 0.31 Lung cancer; chr6:149628912 chr6:149863494~149919507:+ CESC cis rs2028299 0.959 rs12594808 ENSG00000259677.1 RP11-493E3.1 4.87 2.14e-06 0.00148 0.42 0.31 Type 2 diabetes; chr15:89857652 chr15:89876540~89877285:+ CESC cis rs7174755 0.608 rs62004789 ENSG00000260657.2 RP11-315D16.4 4.87 2.14e-06 0.00148 0.38 0.31 Major depressive disorder; chr15:68148268 chr15:68267792~68277994:- CESC cis rs11159086 0.793 rs8015894 ENSG00000259005.1 RP3-449M8.6 4.87 2.14e-06 0.00148 0.43 0.31 Advanced glycation end-product levels; chr14:74491917 chr14:74474007~74474864:- CESC cis rs9322193 0.962 rs1413655 ENSG00000216906.2 RP11-350J20.9 4.87 2.15e-06 0.00149 0.35 0.31 Lung cancer; chr6:149821815 chr6:149904243~149906418:+ CESC cis rs2337406 0.866 rs988130 ENSG00000274576.2 IGHV2-70 -4.87 2.15e-06 0.00149 -0.36 -0.31 Alzheimer's disease (late onset); chr14:106777154 chr14:106770577~106771020:- CESC cis rs42490 0.7 rs40250 ENSG00000251136.7 RP11-37B2.1 -4.87 2.15e-06 0.00149 -0.31 -0.31 Leprosy; chr8:89828779 chr8:89609409~89757727:- CESC cis rs42490 0.7 rs419890 ENSG00000251136.7 RP11-37B2.1 -4.87 2.15e-06 0.00149 -0.31 -0.31 Leprosy; chr8:89829012 chr8:89609409~89757727:- CESC cis rs9322193 0.923 rs9688517 ENSG00000268592.3 RAET1E-AS1 4.87 2.15e-06 0.00149 0.41 0.31 Lung cancer; chr6:149740655 chr6:149863494~149919507:+ CESC cis rs1862618 0.853 rs252915 ENSG00000271828.1 CTD-2310F14.1 -4.87 2.16e-06 0.00149 -0.42 -0.31 Initial pursuit acceleration; chr5:56825927 chr5:56927874~56929573:+ CESC cis rs8067354 0.645 rs9899611 ENSG00000266701.1 AC005702.4 4.87 2.16e-06 0.00149 0.42 0.31 Hemoglobin concentration; chr17:59754829 chr17:60042546~60042627:- CESC cis rs6991838 0.673 rs7462352 ENSG00000200714.1 Y_RNA 4.87 2.16e-06 0.00149 0.37 0.31 Intelligence (multi-trait analysis); chr8:65584378 chr8:65592731~65592820:+ CESC cis rs7208859 0.614 rs216474 ENSG00000263531.1 RP13-753N3.1 -4.87 2.16e-06 0.00149 -0.68 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30538073 chr17:30863921~30864940:- CESC cis rs7927592 0.913 rs12272917 ENSG00000212093.1 AP000807.1 4.87 2.16e-06 0.0015 0.37 0.31 Total body bone mineral density; chr11:68495902 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs59056571 ENSG00000212093.1 AP000807.1 4.87 2.16e-06 0.0015 0.37 0.31 Total body bone mineral density; chr11:68505505 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs66752716 ENSG00000212093.1 AP000807.1 4.87 2.16e-06 0.0015 0.37 0.31 Total body bone mineral density; chr11:68506158 chr11:68506083~68506166:- CESC cis rs10829156 0.945 rs10741131 ENSG00000240291.1 RP11-499P20.2 4.87 2.16e-06 0.0015 0.34 0.31 Sudden cardiac arrest; chr10:18683130 chr10:18513115~18545651:- CESC cis rs1862618 0.853 rs832553 ENSG00000271828.1 CTD-2310F14.1 4.87 2.16e-06 0.0015 0.42 0.31 Initial pursuit acceleration; chr5:56818959 chr5:56927874~56929573:+ CESC cis rs10788972 0.787 rs6674720 ENSG00000225183.1 RP4-758J24.4 -4.87 2.17e-06 0.0015 -0.36 -0.31 Parkinson disease and lewy body pathology; chr1:54073666 chr1:54089856~54090093:+ CESC cis rs10788972 0.779 rs7516791 ENSG00000225183.1 RP4-758J24.4 -4.87 2.17e-06 0.0015 -0.36 -0.31 Parkinson disease and lewy body pathology; chr1:54086202 chr1:54089856~54090093:+ CESC cis rs10788972 0.815 rs1981039 ENSG00000225183.1 RP4-758J24.4 -4.87 2.17e-06 0.0015 -0.36 -0.31 Parkinson disease and lewy body pathology; chr1:54089732 chr1:54089856~54090093:+ CESC cis rs763567 0.605 rs647438 ENSG00000271811.1 RP1-79C4.4 -4.87 2.17e-06 0.0015 -0.36 -0.31 Tonsillectomy; chr1:170608094 chr1:170667381~170669425:+ CESC cis rs7560272 0.538 rs2012574 ENSG00000273245.1 RP11-434P11.2 -4.87 2.17e-06 0.0015 -0.4 -0.31 Schizophrenia; chr2:73701239 chr2:73750256~73750786:- CESC cis rs875971 0.545 rs12670811 ENSG00000222364.1 RNU6-96P -4.87 2.17e-06 0.0015 -0.41 -0.31 Aortic root size; chr7:66358032 chr7:66395191~66395286:+ CESC cis rs2408955 0.521 rs10875753 ENSG00000240399.1 RP1-228P16.1 4.87 2.17e-06 0.0015 0.34 0.31 Glycated hemoglobin levels; chr12:48163358 chr12:48054813~48055591:- CESC cis rs801193 0.569 rs4717315 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66713338 chr7:66395191~66395286:+ CESC cis rs801193 0.548 rs2659891 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66736127 chr7:66395191~66395286:+ CESC cis rs801193 0.548 rs7805152 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66744266 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs2659908 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66695835 chr7:66395191~66395286:+ CESC cis rs801193 0.527 rs2707837 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66716086 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs2707824 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66724256 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs2659893 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66735006 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs2659892 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66735318 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs2707847 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.37 -0.31 Aortic root size; chr7:66737884 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs1909508 ENSG00000222364.1 RNU6-96P -4.87 2.18e-06 0.00151 -0.4 -0.31 Aortic root size; chr7:66301366 chr7:66395191~66395286:+ CESC cis rs8067354 0.645 rs9901606 ENSG00000266701.1 AC005702.4 4.87 2.18e-06 0.00151 0.42 0.31 Hemoglobin concentration; chr17:59734046 chr17:60042546~60042627:- CESC cis rs8067354 0.681 rs9907923 ENSG00000266701.1 AC005702.4 4.87 2.18e-06 0.00151 0.42 0.31 Hemoglobin concentration; chr17:59747566 chr17:60042546~60042627:- CESC cis rs7189233 0.531 rs9941254 ENSG00000279344.1 RP11-44F14.7 4.87 2.18e-06 0.00151 0.29 0.31 Intelligence (multi-trait analysis); chr16:53453306 chr16:53478957~53481550:- CESC cis rs7189233 0.531 rs7194730 ENSG00000279344.1 RP11-44F14.7 4.87 2.18e-06 0.00151 0.29 0.31 Intelligence (multi-trait analysis); chr16:53455278 chr16:53478957~53481550:- CESC cis rs7189233 0.531 rs13332406 ENSG00000279344.1 RP11-44F14.7 4.87 2.18e-06 0.00151 0.29 0.31 Intelligence (multi-trait analysis); chr16:53455793 chr16:53478957~53481550:- CESC cis rs9322193 0.962 rs2275046 ENSG00000216906.2 RP11-350J20.9 4.87 2.19e-06 0.00151 0.36 0.31 Lung cancer; chr6:149835865 chr6:149904243~149906418:+ CESC cis rs875971 0.756 rs2901210 ENSG00000222364.1 RNU6-96P 4.87 2.19e-06 0.00151 0.37 0.31 Aortic root size; chr7:66552518 chr7:66395191~66395286:+ CESC cis rs2243480 1 rs410128 ENSG00000228409.4 CCT6P1 4.87 2.19e-06 0.00151 0.48 0.31 Diabetic kidney disease; chr7:66138186 chr7:65751142~65763354:+ CESC cis rs853679 0.517 rs6932109 ENSG00000219392.1 RP1-265C24.5 4.87 2.19e-06 0.00151 0.4 0.31 Depression; chr6:28110525 chr6:28115628~28116551:+ CESC cis rs6452524 0.836 rs62372713 ENSG00000249664.1 CTD-2227C6.2 4.87 2.19e-06 0.00151 0.38 0.31 Hypertension (SNP x SNP interaction); chr5:83090635 chr5:83012285~83013109:- CESC cis rs6452524 0.868 rs62372714 ENSG00000249664.1 CTD-2227C6.2 4.87 2.19e-06 0.00151 0.38 0.31 Hypertension (SNP x SNP interaction); chr5:83095449 chr5:83012285~83013109:- CESC cis rs6452524 0.868 rs17205699 ENSG00000249664.1 CTD-2227C6.2 4.87 2.19e-06 0.00151 0.38 0.31 Hypertension (SNP x SNP interaction); chr5:83098479 chr5:83012285~83013109:- CESC cis rs9322193 0.923 rs9800806 ENSG00000268592.3 RAET1E-AS1 4.87 2.19e-06 0.00151 0.41 0.31 Lung cancer; chr6:149740350 chr6:149863494~149919507:+ CESC cis rs7048146 0.51 rs2210159 ENSG00000213539.4 YBX1P6 -4.87 2.19e-06 0.00151 -0.37 -0.31 Vascular brain injury; chr9:109526297 chr9:109532830~109534332:- CESC cis rs7048146 0.51 rs10816827 ENSG00000213539.4 YBX1P6 -4.87 2.19e-06 0.00151 -0.37 -0.31 Vascular brain injury; chr9:109529829 chr9:109532830~109534332:- CESC cis rs10262624 0.967 rs7792734 ENSG00000234286.1 AC006026.13 -4.87 2.19e-06 0.00151 -0.33 -0.31 Schizophrenia; chr7:23876429 chr7:23680195~23680786:- CESC cis rs1862618 0.853 rs252898 ENSG00000271828.1 CTD-2310F14.1 4.86 2.19e-06 0.00152 0.43 0.31 Initial pursuit acceleration; chr5:56893104 chr5:56927874~56929573:+ CESC cis rs1862618 0.802 rs194058 ENSG00000271828.1 CTD-2310F14.1 4.86 2.19e-06 0.00152 0.43 0.31 Initial pursuit acceleration; chr5:56893150 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs832584 ENSG00000271828.1 CTD-2310F14.1 -4.86 2.2e-06 0.00152 -0.42 -0.31 Initial pursuit acceleration; chr5:56883385 chr5:56927874~56929573:+ CESC cis rs8059260 0.736 rs16957835 ENSG00000274038.1 RP11-66H6.4 -4.86 2.2e-06 0.00152 -0.48 -0.31 Alcohol consumption over the past year; chr16:10958198 chr16:11056556~11057034:+ CESC cis rs73086581 0.838 rs56401022 ENSG00000229539.1 RP11-119B16.2 4.86 2.2e-06 0.00152 0.47 0.31 Response to antidepressants in depression; chr20:4043634 chr20:3888239~3888868:- CESC cis rs433852 0.718 rs386551 ENSG00000232871.7 SEC1P -4.86 2.21e-06 0.00152 -0.36 -0.31 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48635029 chr19:48638071~48682245:+ CESC cis rs4718428 0.705 rs11028 ENSG00000273142.1 RP11-458F8.4 -4.86 2.21e-06 0.00152 -0.33 -0.31 Corneal structure; chr7:66811230 chr7:66902857~66906297:+ CESC cis rs875971 0.545 rs75840613 ENSG00000237310.1 GS1-124K5.4 4.86 2.22e-06 0.00153 0.34 0.31 Aortic root size; chr7:66376399 chr7:66493706~66495474:+ CESC cis rs2243480 1 rs781157 ENSG00000228409.4 CCT6P1 4.86 2.22e-06 0.00153 0.45 0.31 Diabetic kidney disease; chr7:66013324 chr7:65751142~65763354:+ CESC cis rs2337406 0.929 rs11847182 ENSG00000211974.3 IGHV2-70 -4.86 2.22e-06 0.00153 -0.49 -0.31 Alzheimer's disease (late onset); chr14:106697724 chr14:106723574~106724093:- CESC cis rs4423214 0.592 rs10898234 ENSG00000254682.1 RP11-660L16.2 -4.86 2.22e-06 0.00153 -0.45 -0.31 Vitamin D levels; chr11:71525638 chr11:71448674~71452157:+ CESC cis rs733592 0.723 rs10875766 ENSG00000240399.1 RP1-228P16.1 4.86 2.23e-06 0.00153 0.33 0.31 Plateletcrit; chr12:48199797 chr12:48054813~48055591:- CESC cis rs12761761 1 rs12764703 ENSG00000279982.1 RP11-45A17.3 -4.86 2.23e-06 0.00153 -0.43 -0.31 Intelligence (multi-trait analysis);Educational attainment (years of education); chr10:131971832 chr10:131996738~131999846:+ CESC cis rs1799949 1 rs12516 ENSG00000267681.1 CTD-3199J23.6 -4.86 2.23e-06 0.00153 -0.41 -0.31 Menopause (age at onset); chr17:43044391 chr17:43144956~43145255:+ CESC cis rs4974559 0.895 rs12646130 ENSG00000253399.1 AC078852.2 4.86 2.23e-06 0.00154 0.52 0.31 Systolic blood pressure; chr4:1336742 chr4:1358479~1359461:+ CESC cis rs6928977 0.863 rs2614255 ENSG00000234084.1 RP3-388E23.2 4.86 2.23e-06 0.00154 0.28 0.31 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135342443 chr6:135301568~135307158:+ CESC cis rs763121 0.853 rs5750671 ENSG00000273076.1 RP3-508I15.22 4.86 2.23e-06 0.00154 0.35 0.31 Menopause (age at onset); chr22:38698614 chr22:38743495~38743910:+ CESC cis rs763121 0.853 rs926299 ENSG00000273076.1 RP3-508I15.22 4.86 2.23e-06 0.00154 0.35 0.31 Menopause (age at onset); chr22:38699693 chr22:38743495~38743910:+ CESC cis rs763121 0.785 rs6001203 ENSG00000273076.1 RP3-508I15.22 4.86 2.23e-06 0.00154 0.35 0.31 Menopause (age at onset); chr22:38703597 chr22:38743495~38743910:+ CESC cis rs6452524 1 rs10080123 ENSG00000249664.1 CTD-2227C6.2 -4.86 2.23e-06 0.00154 -0.36 -0.31 Hypertension (SNP x SNP interaction); chr5:83165447 chr5:83012285~83013109:- CESC cis rs5769707 0.706 rs2071903 ENSG00000188511.11 C22orf34 4.86 2.24e-06 0.00154 0.38 0.31 Monocyte percentage of white cells;Monocyte count; chr22:49640869 chr22:49414524~49657542:- CESC cis rs1056107 0.797 rs4979087 ENSG00000225513.1 RP11-165N19.2 -4.86 2.24e-06 0.00154 -0.38 -0.31 Colorectal cancer; chr9:112179920 chr9:112173522~112173971:- CESC cis rs3096299 0.967 rs2911253 ENSG00000274627.1 RP11-104N10.2 4.86 2.24e-06 0.00154 0.31 0.31 Multiple myeloma (IgH translocation); chr16:89422179 chr16:89516797~89522217:+ CESC cis rs6142102 0.961 rs973409 ENSG00000276073.1 RP5-1125A11.7 -4.86 2.24e-06 0.00155 -0.31 -0.31 Skin pigmentation; chr20:33948558 chr20:33985617~33988989:- CESC cis rs8100891 0.506 rs4804992 ENSG00000267213.4 AC007773.2 -4.86 2.24e-06 0.00155 -0.49 -0.31 Neuroticism; chr19:32367885 chr19:32390050~32405560:- CESC cis rs875971 0.862 rs4236208 ENSG00000237310.1 GS1-124K5.4 -4.86 2.24e-06 0.00155 -0.29 -0.31 Aortic root size; chr7:66284091 chr7:66493706~66495474:+ CESC cis rs12458462 0.892 rs12456692 ENSG00000274828.1 RP11-567M16.6 4.86 2.25e-06 0.00155 0.3 0.31 Monocyte count; chr18:79722189 chr18:79677287~79679358:- CESC cis rs7714584 1 rs17800987 ENSG00000197083.10 ZNF300P1 4.86 2.25e-06 0.00155 0.63 0.31 Crohn's disease; chr5:150943866 chr5:150930645~150946289:- CESC cis rs9549367 0.789 rs12869947 ENSG00000269125.1 RP11-98F14.11 -4.86 2.25e-06 0.00155 -0.44 -0.31 Platelet distribution width; chr13:113241842 chr13:113165002~113165183:- CESC cis rs2564921 0.704 rs62253606 ENSG00000242142.1 SERBP1P3 -4.86 2.25e-06 0.00155 -0.38 -0.31 Height; chr3:52949886 chr3:53064283~53065091:- CESC cis rs11089937 0.963 rs5757078 ENSG00000211639.2 IGLV4-60 4.86 2.25e-06 0.00155 0.27 0.31 Periodontitis (PAL4Q3); chr22:22145526 chr22:22162199~22162681:+ CESC cis rs7714584 1 rs11743488 ENSG00000197083.10 ZNF300P1 4.86 2.25e-06 0.00155 0.66 0.31 Crohn's disease; chr5:150899656 chr5:150930645~150946289:- CESC cis rs34779708 0.733 rs7081597 ENSG00000230534.5 RP11-297A16.2 4.86 2.26e-06 0.00155 0.43 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35257403 chr10:35098006~35127020:- CESC cis rs1799949 1 rs9646412 ENSG00000267681.1 CTD-3199J23.6 -4.86 2.26e-06 0.00156 -0.41 -0.31 Menopause (age at onset); chr17:43348525 chr17:43144956~43145255:+ CESC cis rs875971 0.862 rs10276077 ENSG00000237310.1 GS1-124K5.4 -4.86 2.26e-06 0.00156 -0.29 -0.31 Aortic root size; chr7:66263424 chr7:66493706~66495474:+ CESC cis rs881375 0.678 rs2269060 ENSG00000226752.6 PSMD5-AS1 -4.86 2.26e-06 0.00156 -0.32 -0.31 Rheumatoid arthritis; chr9:120921291 chr9:120824828~120854385:+ CESC cis rs7899628 1 rs7899628 ENSG00000276742.1 RP11-500G22.4 -4.86 2.27e-06 0.00156 -0.37 -0.31 Breast cancer; chr10:121904429 chr10:121956782~121957098:+ CESC cis rs9907295 0.591 rs2107538 ENSG00000271013.1 AC015849.15 -4.86 2.27e-06 0.00156 -0.35 -0.31 Fibroblast growth factor basic levels; chr17:35880776 chr17:35912635~35918010:- CESC cis rs5758659 0.819 rs134871 ENSG00000273366.1 CTA-989H11.1 -4.86 2.27e-06 0.00156 -0.38 -0.31 Cognitive function; chr22:42256710 chr22:42278188~42278846:+ CESC cis rs755249 1 rs2293476 ENSG00000228060.1 RP11-69E11.8 4.86 2.27e-06 0.00156 0.36 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39571175 chr1:39565160~39573203:+ CESC cis rs7508 0.509 rs441606 ENSG00000253671.1 RP11-806O11.1 4.86 2.27e-06 0.00156 0.35 0.31 Atrial fibrillation; chr8:18045537 chr8:17808941~17820868:+ CESC cis rs2243480 1 rs422164 ENSG00000228409.4 CCT6P1 4.86 2.27e-06 0.00156 0.46 0.31 Diabetic kidney disease; chr7:66121618 chr7:65751142~65763354:+ CESC cis rs556990 0.574 rs473598 ENSG00000269125.1 RP11-98F14.11 -4.86 2.27e-06 0.00156 -0.41 -0.31 Blood protein levels; chr13:113146875 chr13:113165002~113165183:- CESC cis rs9549367 0.713 rs9549352 ENSG00000269125.1 RP11-98F14.11 -4.86 2.27e-06 0.00156 -0.45 -0.31 Platelet distribution width; chr13:113178907 chr13:113165002~113165183:- CESC cis rs4660456 0.913 rs2361651 ENSG00000237899.1 RP4-739H11.3 4.86 2.28e-06 0.00157 0.42 0.31 Platelet count; chr1:40764542 chr1:40669089~40687588:- CESC cis rs2243480 0.708 rs13242216 ENSG00000275400.1 RP4-756H11.5 4.86 2.28e-06 0.00157 0.54 0.31 Diabetic kidney disease; chr7:66433290 chr7:66553805~66554199:- CESC cis rs2243480 1 rs67536397 ENSG00000275400.1 RP4-756H11.5 4.86 2.28e-06 0.00157 0.54 0.31 Diabetic kidney disease; chr7:66482930 chr7:66553805~66554199:- CESC cis rs2243480 1 rs58669269 ENSG00000275400.1 RP4-756H11.5 4.86 2.28e-06 0.00157 0.54 0.31 Diabetic kidney disease; chr7:66486966 chr7:66553805~66554199:- CESC cis rs7560272 0.538 rs11126415 ENSG00000273245.1 RP11-434P11.2 -4.86 2.28e-06 0.00157 -0.38 -0.31 Schizophrenia; chr2:73709373 chr2:73750256~73750786:- CESC cis rs7560272 0.538 rs12053242 ENSG00000273245.1 RP11-434P11.2 -4.86 2.28e-06 0.00157 -0.38 -0.31 Schizophrenia; chr2:73710041 chr2:73750256~73750786:- CESC cis rs2842992 0.789 rs10945635 ENSG00000237927.1 RP3-393E18.2 -4.86 2.28e-06 0.00157 -0.41 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159793455 chr6:159586955~159589169:- CESC cis rs763121 0.853 rs1056610 ENSG00000273076.1 RP3-508I15.22 -4.86 2.28e-06 0.00157 -0.35 -0.31 Menopause (age at onset); chr22:38684073 chr22:38743495~38743910:+ CESC cis rs7396835 0.866 rs6589571 ENSG00000254851.1 RP11-109L13.1 -4.86 2.29e-06 0.00157 -0.54 -0.31 Quantitative traits; chr11:116809702 chr11:117135528~117138582:+ CESC cis rs2028299 1 rs6496609 ENSG00000259677.1 RP11-493E3.1 4.86 2.29e-06 0.00157 0.42 0.31 Type 2 diabetes; chr15:89836400 chr15:89876540~89877285:+ CESC cis rs2028299 1 rs2351707 ENSG00000259677.1 RP11-493E3.1 4.86 2.29e-06 0.00157 0.42 0.31 Type 2 diabetes; chr15:89840813 chr15:89876540~89877285:+ CESC cis rs6142102 0.961 rs2235597 ENSG00000276073.1 RP5-1125A11.7 -4.86 2.29e-06 0.00157 -0.31 -0.31 Skin pigmentation; chr20:34077808 chr20:33985617~33988989:- CESC cis rs7429990 0.965 rs9854454 ENSG00000229759.1 MRPS18AP1 -4.86 2.29e-06 0.00157 -0.32 -0.31 Educational attainment (years of education); chr3:47971307 chr3:48256350~48256938:- CESC cis rs2412819 0.571 rs28410121 ENSG00000205771.5 CATSPER2P1 4.86 2.29e-06 0.00157 0.44 0.31 Lung cancer; chr15:43777831 chr15:43726918~43747094:- CESC cis rs2732480 0.577 rs2732479 ENSG00000258273.1 RP11-370I10.4 -4.86 2.29e-06 0.00157 -0.39 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342477 chr12:48333755~48333901:- CESC cis rs2732480 0.537 rs1061986 ENSG00000258273.1 RP11-370I10.4 -4.86 2.29e-06 0.00157 -0.39 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342656 chr12:48333755~48333901:- CESC cis rs2732480 0.577 rs2732481 ENSG00000258273.1 RP11-370I10.4 -4.86 2.29e-06 0.00157 -0.39 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343202 chr12:48333755~48333901:- CESC cis rs2732480 0.557 rs2732484 ENSG00000258273.1 RP11-370I10.4 -4.86 2.29e-06 0.00157 -0.39 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343462 chr12:48333755~48333901:- CESC cis rs9907295 0.584 rs7215845 ENSG00000271013.1 AC015849.15 -4.86 2.29e-06 0.00157 -0.35 -0.31 Fibroblast growth factor basic levels; chr17:35894698 chr17:35912635~35918010:- CESC cis rs6142102 0.961 rs4911390 ENSG00000276073.1 RP5-1125A11.7 -4.86 2.29e-06 0.00158 -0.31 -0.31 Skin pigmentation; chr20:33977401 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs1555075 ENSG00000276073.1 RP5-1125A11.7 -4.86 2.29e-06 0.00158 -0.31 -0.31 Skin pigmentation; chr20:34022595 chr20:33985617~33988989:- CESC cis rs1707322 0.963 rs4630155 ENSG00000281133.1 AL355480.3 -4.85 2.3e-06 0.00158 -0.38 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45791438 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs4508055 ENSG00000281133.1 AL355480.3 -4.85 2.3e-06 0.00158 -0.38 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45792059 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs12076580 ENSG00000281133.1 AL355480.3 -4.85 2.3e-06 0.00158 -0.38 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45792487 chr1:45580892~45580996:- CESC cis rs8062405 0.755 rs1074631 ENSG00000259982.1 CDC37P1 -4.85 2.3e-06 0.00158 -0.4 -0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28542787 chr16:28700294~28701540:- CESC cis rs10875746 0.624 rs11168498 ENSG00000240399.1 RP1-228P16.1 -4.85 2.31e-06 0.00158 -0.4 -0.31 Longevity (90 years and older); chr12:48261305 chr12:48054813~48055591:- CESC cis rs763121 0.925 rs1043312 ENSG00000273076.1 RP3-508I15.22 4.85 2.31e-06 0.00158 0.34 0.31 Menopause (age at onset); chr22:38735722 chr22:38743495~38743910:+ CESC cis rs5769707 0.568 rs2011097 ENSG00000235111.1 RP1-29C18.8 -4.85 2.31e-06 0.00159 -0.36 -0.31 Monocyte percentage of white cells;Monocyte count; chr22:49624421 chr22:49612657~49615716:- CESC cis rs7048146 0.51 rs4978821 ENSG00000213539.4 YBX1P6 -4.85 2.32e-06 0.00159 -0.37 -0.31 Vascular brain injury; chr9:109525661 chr9:109532830~109534332:- CESC cis rs801193 0.569 rs13242290 ENSG00000222364.1 RNU6-96P 4.85 2.32e-06 0.00159 0.37 0.31 Aortic root size; chr7:66656898 chr7:66395191~66395286:+ CESC cis rs42490 0.635 rs42186 ENSG00000251136.7 RP11-37B2.1 -4.85 2.32e-06 0.00159 -0.31 -0.31 Leprosy; chr8:89827257 chr8:89609409~89757727:- CESC cis rs42490 0.873 rs218895 ENSG00000251136.7 RP11-37B2.1 -4.85 2.32e-06 0.00159 -0.32 -0.31 Leprosy; chr8:89714320 chr8:89609409~89757727:- CESC cis rs2243480 1 rs316307 ENSG00000275400.1 RP4-756H11.5 4.85 2.32e-06 0.00159 0.54 0.31 Diabetic kidney disease; chr7:66105184 chr7:66553805~66554199:- CESC cis rs12439619 0.53 rs28883606 ENSG00000255769.6 GOLGA2P10 -4.85 2.33e-06 0.0016 -0.34 -0.31 Intelligence (multi-trait analysis); chr15:82216713 chr15:82472993~82513950:- CESC cis rs12439619 0.693 rs28665836 ENSG00000255769.6 GOLGA2P10 -4.85 2.33e-06 0.0016 -0.34 -0.31 Intelligence (multi-trait analysis); chr15:82218955 chr15:82472993~82513950:- CESC cis rs1862618 0.529 rs978406 ENSG00000271828.1 CTD-2310F14.1 -4.85 2.33e-06 0.0016 -0.41 -0.31 Initial pursuit acceleration; chr5:56963981 chr5:56927874~56929573:+ CESC cis rs4423214 0.524 rs4944046 ENSG00000254682.1 RP11-660L16.2 4.85 2.33e-06 0.0016 0.38 0.31 Vitamin D levels; chr11:71412748 chr11:71448674~71452157:+ CESC cis rs9987353 0.589 rs1053036 ENSG00000173295.6 FAM86B3P -4.85 2.33e-06 0.0016 -0.4 -0.31 Recombination measurement; chr8:9202567 chr8:8228595~8244865:+ CESC cis rs2280018 0.581 rs7404524 ENSG00000260735.1 RP11-72I8.1 -4.85 2.33e-06 0.0016 -0.34 -0.31 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15035301 chr16:15094411~15109197:+ CESC cis rs11690935 0.838 rs10432423 ENSG00000228389.1 AC068039.4 4.85 2.34e-06 0.0016 0.4 0.31 Schizophrenia; chr2:171896785 chr2:171773482~171775844:+ CESC cis rs1061377 1 rs4974931 ENSG00000249685.1 RP11-360F5.3 4.85 2.34e-06 0.0016 0.37 0.31 Uric acid levels; chr4:39108896 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs4974998 ENSG00000249685.1 RP11-360F5.3 4.85 2.34e-06 0.0016 0.37 0.31 Uric acid levels; chr4:39109129 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs7673299 ENSG00000249685.1 RP11-360F5.3 4.85 2.34e-06 0.0016 0.37 0.31 Uric acid levels; chr4:39109138 chr4:39133913~39135608:+ CESC cis rs1061377 1 rs4974997 ENSG00000249685.1 RP11-360F5.3 4.85 2.34e-06 0.0016 0.37 0.31 Uric acid levels; chr4:39109151 chr4:39133913~39135608:+ CESC cis rs4722166 0.541 rs1800795 ENSG00000179428.2 AC073072.5 -4.85 2.34e-06 0.0016 -0.43 -0.31 Lung cancer; chr7:22727026 chr7:22725395~22727620:- CESC cis rs8072100 0.512 rs3809863 ENSG00000228782.6 CTD-2026D20.3 4.85 2.35e-06 0.00161 0.37 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47307646 chr17:47450568~47492492:- CESC cis rs2015599 0.563 rs11050168 ENSG00000275476.1 RP11-996F15.4 4.85 2.35e-06 0.00161 0.36 0.31 Platelet count;Mean platelet volume; chr12:29273760 chr12:29277397~29277882:- CESC cis rs8177876 0.749 rs10459871 ENSG00000261838.4 RP11-303E16.6 4.85 2.35e-06 0.00161 0.65 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81059462 chr16:81069854~81076598:+ CESC cis rs6991838 0.733 rs7822627 ENSG00000200714.1 Y_RNA 4.85 2.36e-06 0.00161 0.37 0.31 Intelligence (multi-trait analysis); chr8:65714139 chr8:65592731~65592820:+ CESC cis rs2337406 1 rs78631692 ENSG00000211974.3 IGHV2-70 -4.85 2.36e-06 0.00161 -0.51 -0.31 Alzheimer's disease (late onset); chr14:106709371 chr14:106723574~106724093:- CESC cis rs783540 0.656 rs783538 ENSG00000276710.3 CSPG4P8 4.85 2.36e-06 0.00161 0.34 0.31 Schizophrenia; chr15:82584394 chr15:82459472~82477258:+ CESC cis rs875971 0.895 rs6460278 ENSG00000232559.3 GS1-124K5.12 -4.85 2.37e-06 0.00162 -0.34 -0.31 Aortic root size; chr7:66197749 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6460279 ENSG00000232559.3 GS1-124K5.12 -4.85 2.37e-06 0.00162 -0.34 -0.31 Aortic root size; chr7:66197774 chr7:66554588~66576923:- CESC cis rs875971 0.545 rs73136346 ENSG00000236529.1 RP13-254B10.1 -4.85 2.37e-06 0.00162 -0.4 -0.31 Aortic root size; chr7:66101095 chr7:65840212~65840596:+ CESC cis rs9907295 0.688 rs2251660 ENSG00000271013.1 AC015849.15 -4.85 2.37e-06 0.00162 -0.34 -0.31 Fibroblast growth factor basic levels; chr17:35925533 chr17:35912635~35918010:- CESC cis rs875971 0.545 rs1638735 ENSG00000236529.1 RP13-254B10.1 4.85 2.37e-06 0.00162 0.38 0.31 Aortic root size; chr7:66630751 chr7:65840212~65840596:+ CESC cis rs667920 0.573 rs9682783 ENSG00000239213.4 NCK1-AS1 4.85 2.38e-06 0.00162 0.39 0.31 Coronary artery disease; chr3:136820847 chr3:136841726~136862054:- CESC cis rs11723261 0.582 rs4582104 ENSG00000211553.1 AC253576.2 -4.85 2.38e-06 0.00162 -0.44 -0.31 Immune response to smallpox vaccine (IL-6); chr4:143160 chr4:136461~136568:+ CESC cis rs801193 0.569 rs881285 ENSG00000222364.1 RNU6-96P 4.85 2.38e-06 0.00163 0.37 0.31 Aortic root size; chr7:66654433 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs3846973 ENSG00000222364.1 RNU6-96P 4.85 2.38e-06 0.00163 0.37 0.31 Aortic root size; chr7:66655048 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs2013908 ENSG00000222364.1 RNU6-96P 4.85 2.38e-06 0.00163 0.37 0.31 Aortic root size; chr7:66656082 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs6951302 ENSG00000222364.1 RNU6-96P 4.85 2.38e-06 0.00163 0.37 0.31 Aortic root size; chr7:66667525 chr7:66395191~66395286:+ CESC cis rs875971 0.755 rs10228885 ENSG00000232559.3 GS1-124K5.12 -4.85 2.38e-06 0.00163 -0.34 -0.31 Aortic root size; chr7:66315542 chr7:66554588~66576923:- CESC cis rs11159086 0.793 rs1029703 ENSG00000270000.1 RP3-449M8.9 4.85 2.38e-06 0.00163 0.49 0.31 Advanced glycation end-product levels; chr14:74473899 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs12432412 ENSG00000270000.1 RP3-449M8.9 4.85 2.38e-06 0.00163 0.49 0.31 Advanced glycation end-product levels; chr14:74474294 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs1029700 ENSG00000270000.1 RP3-449M8.9 4.85 2.38e-06 0.00163 0.49 0.31 Advanced glycation end-product levels; chr14:74474309 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs1029699 ENSG00000270000.1 RP3-449M8.9 4.85 2.38e-06 0.00163 0.49 0.31 Advanced glycation end-product levels; chr14:74474790 chr14:74471930~74472360:- CESC cis rs875971 0.862 rs10274883 ENSG00000222364.1 RNU6-96P 4.85 2.38e-06 0.00163 0.37 0.31 Aortic root size; chr7:66651104 chr7:66395191~66395286:+ CESC cis rs801193 0.548 rs2109297 ENSG00000222364.1 RNU6-96P 4.85 2.38e-06 0.00163 0.37 0.31 Aortic root size; chr7:66657397 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs6978178 ENSG00000222364.1 RNU6-96P 4.85 2.38e-06 0.00163 0.37 0.31 Aortic root size; chr7:66658097 chr7:66395191~66395286:+ CESC cis rs801193 0.591 rs721717 ENSG00000222364.1 RNU6-96P 4.85 2.38e-06 0.00163 0.37 0.31 Aortic root size; chr7:66665305 chr7:66395191~66395286:+ CESC cis rs17507216 0.958 rs72751643 ENSG00000255769.6 GOLGA2P10 -4.85 2.38e-06 0.00163 -0.47 -0.31 Excessive daytime sleepiness; chr15:82559444 chr15:82472993~82513950:- CESC cis rs6142102 0.961 rs4911385 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:33970787 chr20:33985617~33988989:- CESC cis rs6142102 0.923 rs6057961 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:33986005 chr20:33985617~33988989:- CESC cis rs6142102 0.923 rs4911394 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:33989521 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs1007090 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:33995065 chr20:33985617~33988989:- CESC cis rs6142102 0.923 rs2284377 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:33998876 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs2284378 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:34000289 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs2284379 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:34006836 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs2268080 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:34009910 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs4911144 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:34026565 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs2056990 ENSG00000276073.1 RP5-1125A11.7 -4.85 2.39e-06 0.00163 -0.31 -0.31 Skin pigmentation; chr20:34035658 chr20:33985617~33988989:- CESC cis rs8177876 0.749 rs2287995 ENSG00000261838.4 RP11-303E16.6 4.85 2.39e-06 0.00163 0.65 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81061494 chr16:81069854~81076598:+ CESC cis rs8177876 0.749 rs754429 ENSG00000261838.4 RP11-303E16.6 4.85 2.39e-06 0.00163 0.65 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81062574 chr16:81069854~81076598:+ CESC cis rs763121 0.925 rs1056661 ENSG00000273076.1 RP3-508I15.22 4.85 2.39e-06 0.00163 0.34 0.31 Menopause (age at onset); chr22:38684240 chr22:38743495~38743910:+ CESC cis rs2028299 0.879 rs7163629 ENSG00000259677.1 RP11-493E3.1 4.85 2.39e-06 0.00163 0.4 0.31 Type 2 diabetes; chr15:89873508 chr15:89876540~89877285:+ CESC cis rs881375 0.678 rs10818488 ENSG00000226752.6 PSMD5-AS1 -4.85 2.4e-06 0.00164 -0.32 -0.31 Rheumatoid arthritis; chr9:120942809 chr9:120824828~120854385:+ CESC cis rs4722166 0.63 rs13311155 ENSG00000179428.2 AC073072.5 -4.85 2.4e-06 0.00164 -0.44 -0.31 Lung cancer; chr7:22750170 chr7:22725395~22727620:- CESC cis rs4722166 0.63 rs13311199 ENSG00000179428.2 AC073072.5 -4.85 2.4e-06 0.00164 -0.44 -0.31 Lung cancer; chr7:22750174 chr7:22725395~22727620:- CESC cis rs2733201 1 rs2733208 ENSG00000259479.5 SORD2P 4.84 2.4e-06 0.00164 0.46 0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44145494 chr15:44826371~44884694:- CESC cis rs875971 0.825 rs6951503 ENSG00000237310.1 GS1-124K5.4 -4.84 2.41e-06 0.00164 -0.29 -0.31 Aortic root size; chr7:66253949 chr7:66493706~66495474:+ CESC cis rs6504622 0.702 rs2316758 ENSG00000262879.4 RP11-156P1.3 -4.84 2.41e-06 0.00165 -0.34 -0.31 Orofacial clefts; chr17:46988999 chr17:46984045~47100323:- CESC cis rs875971 0.52 rs160645 ENSG00000237310.1 GS1-124K5.4 -4.84 2.42e-06 0.00165 -0.35 -0.31 Aortic root size; chr7:66091320 chr7:66493706~66495474:+ CESC cis rs875971 0.789 rs28815324 ENSG00000237310.1 GS1-124K5.4 -4.84 2.42e-06 0.00165 -0.35 -0.31 Aortic root size; chr7:66100789 chr7:66493706~66495474:+ CESC cis rs801193 0.548 rs2659904 ENSG00000232559.3 GS1-124K5.12 4.84 2.42e-06 0.00165 0.34 0.31 Aortic root size; chr7:66713615 chr7:66554588~66576923:- CESC cis rs12025262 0.546 rs10754539 ENSG00000259865.1 RP11-488L18.10 4.84 2.42e-06 0.00165 0.27 0.31 Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50); chr1:247202128 chr1:247187281~247188526:- CESC cis rs801193 0.591 rs2707839 ENSG00000232559.3 GS1-124K5.12 4.84 2.43e-06 0.00165 0.34 0.31 Aortic root size; chr7:66728097 chr7:66554588~66576923:- CESC cis rs556990 0.76 rs3024739 ENSG00000269125.1 RP11-98F14.11 -4.84 2.43e-06 0.00165 -0.47 -0.31 Blood protein levels; chr13:113165634 chr13:113165002~113165183:- CESC cis rs1707322 0.827 rs12125508 ENSG00000281133.1 AL355480.3 -4.84 2.43e-06 0.00166 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45780338 chr1:45580892~45580996:- CESC cis rs1707322 0.789 rs10789473 ENSG00000281133.1 AL355480.3 -4.84 2.43e-06 0.00166 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45782459 chr1:45580892~45580996:- CESC cis rs9318086 0.712 rs9318100 ENSG00000205861.10 C1QTNF9B-AS1 4.84 2.44e-06 0.00166 0.39 0.31 Myopia (pathological); chr13:23868343 chr13:23888889~23897263:+ CESC cis rs6693388 0.548 rs2999539 ENSG00000229021.2 AL591893.1 -4.84 2.44e-06 0.00166 -0.35 -0.31 Blood metabolite ratios; chr1:152014151 chr1:151994531~152042774:+ CESC cis rs7811142 0.83 rs6955367 ENSG00000078319.8 PMS2P1 -4.84 2.44e-06 0.00166 -0.46 -0.31 Platelet count; chr7:100363571 chr7:100320992~100341908:- CESC cis rs7560272 0.538 rs12619258 ENSG00000273245.1 RP11-434P11.2 -4.84 2.44e-06 0.00166 -0.39 -0.31 Schizophrenia; chr2:73708788 chr2:73750256~73750786:- CESC cis rs950880 0.614 rs60038017 ENSG00000234389.1 AC007278.3 -4.84 2.44e-06 0.00166 -0.34 -0.31 Serum protein levels (sST2); chr2:102459541 chr2:102438713~102440475:+ CESC cis rs3124314 1 rs2069258 ENSG00000229021.2 AL591893.1 4.84 2.44e-06 0.00166 0.34 0.31 Hair morphology; chr1:152073150 chr1:151994531~152042774:+ CESC cis rs8177876 0.658 rs2278022 ENSG00000261838.4 RP11-303E16.6 4.84 2.44e-06 0.00166 0.65 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81043216 chr16:81069854~81076598:+ CESC cis rs1862618 0.853 rs860580 ENSG00000271828.1 CTD-2310F14.1 -4.84 2.44e-06 0.00166 -0.4 -0.31 Initial pursuit acceleration; chr5:56853602 chr5:56927874~56929573:+ CESC cis rs875971 0.545 rs73152714 ENSG00000237310.1 GS1-124K5.4 4.84 2.45e-06 0.00167 0.33 0.31 Aortic root size; chr7:66534641 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs4718364 ENSG00000237310.1 GS1-124K5.4 4.84 2.45e-06 0.00167 0.33 0.31 Aortic root size; chr7:66536353 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs6961853 ENSG00000237310.1 GS1-124K5.4 4.84 2.45e-06 0.00167 0.33 0.31 Aortic root size; chr7:66537035 chr7:66493706~66495474:+ CESC cis rs6928977 0.863 rs2179780 ENSG00000234084.1 RP3-388E23.2 4.84 2.45e-06 0.00167 0.28 0.31 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135329128 chr6:135301568~135307158:+ CESC cis rs10829156 0.679 rs4747352 ENSG00000240291.1 RP11-499P20.2 4.84 2.45e-06 0.00167 0.34 0.31 Sudden cardiac arrest; chr10:18539734 chr10:18513115~18545651:- CESC cis rs860295 0.702 rs10796946 ENSG00000225855.5 RUSC1-AS1 4.84 2.45e-06 0.00167 0.26 0.31 Body mass index; chr1:155459699 chr1:155316863~155324176:- CESC cis rs860295 0.676 rs10908466 ENSG00000225855.5 RUSC1-AS1 4.84 2.45e-06 0.00167 0.26 0.31 Body mass index; chr1:155459934 chr1:155316863~155324176:- CESC cis rs1061377 0.722 rs34803689 ENSG00000249685.1 RP11-360F5.3 4.84 2.45e-06 0.00167 0.37 0.31 Uric acid levels; chr4:39116665 chr4:39133913~39135608:+ CESC cis rs860295 0.665 rs11264367 ENSG00000225855.5 RUSC1-AS1 4.84 2.46e-06 0.00167 0.27 0.31 Body mass index; chr1:155367547 chr1:155316863~155324176:- CESC cis rs875971 1 rs2420820 ENSG00000237310.1 GS1-124K5.4 -4.84 2.46e-06 0.00167 -0.3 -0.31 Aortic root size; chr7:66626920 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs778734 ENSG00000237310.1 GS1-124K5.4 4.84 2.46e-06 0.00167 0.29 0.31 Aortic root size; chr7:66349862 chr7:66493706~66495474:+ CESC cis rs2015599 0.549 rs7134796 ENSG00000257176.2 RP11-996F15.2 4.84 2.46e-06 0.00167 0.36 0.31 Platelet count;Mean platelet volume; chr12:29294361 chr12:29280418~29317848:- CESC cis rs2243480 1 rs6460260 ENSG00000232559.3 GS1-124K5.12 -4.84 2.46e-06 0.00167 -0.54 -0.31 Diabetic kidney disease; chr7:65750468 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6460261 ENSG00000232559.3 GS1-124K5.12 -4.84 2.46e-06 0.00167 -0.54 -0.31 Diabetic kidney disease; chr7:65750593 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6958294 ENSG00000222364.1 RNU6-96P 4.84 2.47e-06 0.00168 0.36 0.31 Aortic root size; chr7:66329809 chr7:66395191~66395286:+ CESC cis rs42490 0.934 rs218946 ENSG00000251136.7 RP11-37B2.1 -4.84 2.47e-06 0.00168 -0.32 -0.31 Leprosy; chr8:89704478 chr8:89609409~89757727:- CESC cis rs875971 0.545 rs313830 ENSG00000237310.1 GS1-124K5.4 -4.84 2.48e-06 0.00168 -0.35 -0.31 Aortic root size; chr7:66086944 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs313828 ENSG00000237310.1 GS1-124K5.4 -4.84 2.48e-06 0.00168 -0.35 -0.31 Aortic root size; chr7:66087627 chr7:66493706~66495474:+ CESC cis rs2836950 0.585 rs1029004 ENSG00000232608.1 TIMM9P2 4.84 2.48e-06 0.00168 0.34 0.31 Menarche (age at onset); chr21:39243417 chr21:39216624~39217506:+ CESC cis rs7508 0.511 rs2237853 ENSG00000253671.1 RP11-806O11.1 -4.84 2.48e-06 0.00168 -0.38 -0.31 Atrial fibrillation; chr8:18020371 chr8:17808941~17820868:+ CESC cis rs7809950 1 rs28714607 ENSG00000238832.1 snoU109 -4.84 2.48e-06 0.00168 -0.37 -0.31 Coronary artery disease; chr7:107465808 chr7:107603363~107603507:+ CESC cis rs42490 0.844 rs444078 ENSG00000251136.7 RP11-37B2.1 -4.84 2.48e-06 0.00169 -0.32 -0.31 Leprosy; chr8:89701558 chr8:89609409~89757727:- CESC cis rs950880 0.71 rs12905 ENSG00000234389.1 AC007278.3 -4.84 2.48e-06 0.00169 -0.35 -0.31 Serum protein levels (sST2); chr2:102343547 chr2:102438713~102440475:+ CESC cis rs1862618 0.853 rs10461617 ENSG00000271828.1 CTD-2310F14.1 4.84 2.48e-06 0.00169 0.41 0.31 Initial pursuit acceleration; chr5:56808481 chr5:56927874~56929573:+ CESC cis rs9322193 0.567 rs7742692 ENSG00000223701.3 RAET1E-AS1 4.84 2.49e-06 0.00169 0.34 0.31 Lung cancer; chr6:149892363 chr6:149884431~149919508:+ CESC cis rs7615952 0.599 rs12485717 ENSG00000250012.1 RP11-124N2.1 4.84 2.49e-06 0.00169 0.33 0.31 Blood pressure (smoking interaction); chr3:125988232 chr3:126084220~126095349:+ CESC cis rs150992 0.504 rs152036 ENSG00000248489.1 CTD-2007H13.3 4.84 2.49e-06 0.00169 0.43 0.31 Body mass index; chr5:98981729 chr5:98929171~98995013:+ CESC cis rs7684253 0.587 rs9685436 ENSG00000269949.1 RP11-738E22.3 -4.84 2.49e-06 0.00169 -0.37 -0.31 Migraine; chr4:56881195 chr4:56960927~56961373:- CESC cis rs783540 0.656 rs783538 ENSG00000255769.6 GOLGA2P10 4.84 2.5e-06 0.00169 0.35 0.31 Schizophrenia; chr15:82584394 chr15:82472993~82513950:- CESC cis rs9640161 0.702 rs11765692 ENSG00000261305.1 RP4-584D14.7 4.84 2.5e-06 0.0017 0.42 0.31 Blood protein levels;Circulating chemerin levels; chr7:150329478 chr7:150341771~150342607:+ CESC cis rs17507216 0.671 rs28582623 ENSG00000255769.6 GOLGA2P10 -4.84 2.5e-06 0.0017 -0.43 -0.31 Excessive daytime sleepiness; chr15:82577381 chr15:82472993~82513950:- CESC cis rs73086581 0.947 rs67356712 ENSG00000229539.1 RP11-119B16.2 4.84 2.5e-06 0.0017 0.53 0.31 Response to antidepressants in depression; chr20:3912239 chr20:3888239~3888868:- CESC cis rs4141404 0.561 rs5994376 ENSG00000236132.1 CTA-440B3.1 4.84 2.5e-06 0.0017 0.35 0.31 Paclitaxel-induced neuropathy; chr22:31167569 chr22:31816379~31817491:- CESC cis rs7927592 0.913 rs4988291 ENSG00000212093.1 AP000807.1 4.84 2.51e-06 0.0017 0.37 0.31 Total body bone mineral density; chr11:68614139 chr11:68506083~68506166:- CESC cis rs7927592 0.871 rs12941 ENSG00000212093.1 AP000807.1 4.84 2.51e-06 0.0017 0.37 0.31 Total body bone mineral density; chr11:68614725 chr11:68506083~68506166:- CESC cis rs9322193 0.962 rs3805753 ENSG00000216906.2 RP11-350J20.9 4.84 2.51e-06 0.0017 0.35 0.31 Lung cancer; chr6:149795662 chr6:149904243~149906418:+ CESC cis rs10463554 0.853 rs458598 ENSG00000175749.11 EIF3KP1 4.84 2.51e-06 0.0017 0.35 0.31 Parkinson's disease; chr5:103233677 chr5:103032376~103033031:+ CESC cis rs1061377 0.674 rs34506243 ENSG00000249207.1 RP11-360F5.1 -4.84 2.51e-06 0.00171 -0.37 -0.31 Uric acid levels; chr4:39082702 chr4:39112677~39126818:- CESC cis rs1972460 0.506 rs62012050 ENSG00000276710.3 CSPG4P8 -4.83 2.52e-06 0.00171 -0.38 -0.31 Intelligence (multi-trait analysis); chr15:82239933 chr15:82459472~82477258:+ CESC cis rs950880 0.71 rs3732123 ENSG00000234389.1 AC007278.3 -4.83 2.52e-06 0.00171 -0.34 -0.31 Serum protein levels (sST2); chr2:102401617 chr2:102438713~102440475:+ CESC cis rs6686842 0.965 rs4660184 ENSG00000235358.1 RP11-399E6.1 -4.83 2.52e-06 0.00171 -0.37 -0.31 Height; chr1:41058866 chr1:41242373~41284861:+ CESC cis rs8042680 0.688 rs4244883 ENSG00000214432.8 AC068831.10 -4.83 2.53e-06 0.00171 -0.38 -0.31 Type 2 diabetes; chr15:91003267 chr15:91022619~91036611:+ CESC cis rs494459 0.838 rs581045 ENSG00000255422.1 AP002954.4 -4.83 2.53e-06 0.00171 -0.35 -0.31 Height; chr11:118761813 chr11:118704607~118750263:+ CESC cis rs929843 1 rs929843 ENSG00000196696.11 PDXDC2P -4.83 2.53e-06 0.00172 -0.37 -0.31 Menarche (age at onset); chr16:70011845 chr16:69976297~70065948:- CESC cis rs8067354 1 rs8067354 ENSG00000266701.1 AC005702.4 4.83 2.55e-06 0.00173 0.38 0.31 Hemoglobin concentration; chr17:59744069 chr17:60042546~60042627:- CESC cis rs8067354 0.957 rs9896742 ENSG00000266701.1 AC005702.4 4.83 2.55e-06 0.00173 0.38 0.31 Hemoglobin concentration; chr17:59749169 chr17:60042546~60042627:- CESC cis rs875971 0.545 rs1638724 ENSG00000237310.1 GS1-124K5.4 -4.83 2.55e-06 0.00173 -0.33 -0.31 Aortic root size; chr7:66575494 chr7:66493706~66495474:+ CESC cis rs4660456 0.504 rs587064 ENSG00000237899.1 RP4-739H11.3 4.83 2.55e-06 0.00173 0.43 0.31 Platelet count; chr1:40640238 chr1:40669089~40687588:- CESC cis rs950880 0.71 rs55742125 ENSG00000234389.1 AC007278.3 -4.83 2.55e-06 0.00173 -0.34 -0.31 Serum protein levels (sST2); chr2:102403322 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs55883125 ENSG00000234389.1 AC007278.3 -4.83 2.55e-06 0.00173 -0.34 -0.31 Serum protein levels (sST2); chr2:102407871 chr2:102438713~102440475:+ CESC cis rs950880 0.645 rs4851006 ENSG00000234389.1 AC007278.3 -4.83 2.55e-06 0.00173 -0.34 -0.31 Serum protein levels (sST2); chr2:102408278 chr2:102438713~102440475:+ CESC cis rs6142102 0.961 rs4911405 ENSG00000276073.1 RP5-1125A11.7 -4.83 2.55e-06 0.00173 -0.31 -0.31 Skin pigmentation; chr20:34087161 chr20:33985617~33988989:- CESC cis rs5758659 0.652 rs133358 ENSG00000273366.1 CTA-989H11.1 -4.83 2.56e-06 0.00173 -0.38 -0.31 Cognitive function; chr22:42046535 chr22:42278188~42278846:+ CESC cis rs875971 0.895 rs12531677 ENSG00000232559.3 GS1-124K5.12 -4.83 2.56e-06 0.00173 -0.33 -0.31 Aortic root size; chr7:66304099 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs7798630 ENSG00000232559.3 GS1-124K5.12 -4.83 2.56e-06 0.00173 -0.33 -0.31 Aortic root size; chr7:66306492 chr7:66554588~66576923:- CESC cis rs4141404 0.851 rs8135417 ENSG00000236132.1 CTA-440B3.1 4.83 2.56e-06 0.00173 0.36 0.31 Paclitaxel-induced neuropathy; chr22:31163269 chr22:31816379~31817491:- CESC cis rs2842992 0.789 rs2146163 ENSG00000237927.1 RP3-393E18.2 -4.83 2.56e-06 0.00173 -0.41 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159803314 chr6:159586955~159589169:- CESC cis rs9907295 0.818 rs4796112 ENSG00000270977.1 AC015849.16 4.83 2.56e-06 0.00173 0.42 0.31 Fibroblast growth factor basic levels; chr17:35831722 chr17:35893707~35911023:- CESC cis rs9918079 0.56 rs7662032 ENSG00000273133.1 RP11-799M12.2 -4.83 2.57e-06 0.00174 -0.4 -0.31 Obesity-related traits; chr4:15633791 chr4:15563698~15564253:- CESC cis rs875971 0.862 rs13536 ENSG00000222364.1 RNU6-96P 4.83 2.57e-06 0.00174 0.37 0.31 Aortic root size; chr7:66554203 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs801209 ENSG00000222364.1 RNU6-96P 4.83 2.57e-06 0.00174 0.37 0.31 Aortic root size; chr7:66554403 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs801206 ENSG00000222364.1 RNU6-96P 4.83 2.57e-06 0.00174 0.37 0.31 Aortic root size; chr7:66556979 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs801204 ENSG00000222364.1 RNU6-96P 4.83 2.57e-06 0.00174 0.37 0.31 Aortic root size; chr7:66557934 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs801203 ENSG00000222364.1 RNU6-96P 4.83 2.57e-06 0.00174 0.37 0.31 Aortic root size; chr7:66558025 chr7:66395191~66395286:+ CESC cis rs875971 0.825 rs801202 ENSG00000222364.1 RNU6-96P 4.83 2.57e-06 0.00174 0.37 0.31 Aortic root size; chr7:66558942 chr7:66395191~66395286:+ CESC cis rs2836950 0.502 rs2150411 ENSG00000232608.1 TIMM9P2 4.83 2.57e-06 0.00174 0.34 0.31 Menarche (age at onset); chr21:39202626 chr21:39216624~39217506:+ CESC cis rs2836950 0.545 rs4818001 ENSG00000232608.1 TIMM9P2 4.83 2.57e-06 0.00174 0.34 0.31 Menarche (age at onset); chr21:39203162 chr21:39216624~39217506:+ CESC cis rs860295 0.665 rs11264393 ENSG00000225855.5 RUSC1-AS1 4.83 2.57e-06 0.00174 0.26 0.31 Body mass index; chr1:155604680 chr1:155316863~155324176:- CESC cis rs860295 0.702 rs3851912 ENSG00000225855.5 RUSC1-AS1 4.83 2.57e-06 0.00174 0.26 0.31 Body mass index; chr1:155616653 chr1:155316863~155324176:- CESC cis rs3808502 0.527 rs4410870 ENSG00000269918.1 AF131215.9 -4.83 2.57e-06 0.00174 -0.4 -0.31 Neuroticism; chr8:11298611 chr8:11104691~11106704:- CESC cis rs2243480 1 rs316332 ENSG00000228409.4 CCT6P1 4.83 2.57e-06 0.00174 0.46 0.31 Diabetic kidney disease; chr7:66139312 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs2257790 ENSG00000228409.4 CCT6P1 4.83 2.57e-06 0.00174 0.46 0.31 Diabetic kidney disease; chr7:66135463 chr7:65751142~65763354:+ CESC cis rs875971 0.545 rs7783889 ENSG00000222364.1 RNU6-96P -4.83 2.58e-06 0.00174 -0.4 -0.31 Aortic root size; chr7:66283366 chr7:66395191~66395286:+ CESC cis rs6893782 0.887 rs274552 ENSG00000233006.5 AC034220.3 4.83 2.58e-06 0.00175 0.42 0.31 Acylcarnitine levels; chr5:132391654 chr5:132311285~132369916:- CESC cis rs73086581 1 rs14047 ENSG00000229539.1 RP11-119B16.2 4.83 2.59e-06 0.00175 0.5 0.31 Response to antidepressants in depression; chr20:3933568 chr20:3888239~3888868:- CESC cis rs2243480 1 rs1499614 ENSG00000228409.4 CCT6P1 4.83 2.59e-06 0.00175 0.46 0.31 Diabetic kidney disease; chr7:66265811 chr7:65751142~65763354:+ CESC cis rs2337406 0.925 rs34064152 ENSG00000211974.3 IGHV2-70 -4.83 2.59e-06 0.00175 -0.51 -0.31 Alzheimer's disease (late onset); chr14:106700364 chr14:106723574~106724093:- CESC cis rs11638352 0.661 rs11857696 ENSG00000259479.5 SORD2P -4.83 2.59e-06 0.00175 -0.46 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44074060 chr15:44826371~44884694:- CESC cis rs1062177 1 rs2016409 ENSG00000253921.1 CTB-113P19.3 4.83 2.6e-06 0.00175 0.44 0.31 Preschool internalizing problems; chr5:151746763 chr5:151753992~151767247:+ CESC cis rs9907295 1 rs9900563 ENSG00000270977.1 AC015849.16 -4.83 2.6e-06 0.00176 -0.41 -0.31 Fibroblast growth factor basic levels; chr17:35908033 chr17:35893707~35911023:- CESC cis rs763121 0.853 rs6001204 ENSG00000273076.1 RP3-508I15.22 4.83 2.6e-06 0.00176 0.35 0.31 Menopause (age at onset); chr22:38704234 chr22:38743495~38743910:+ CESC cis rs11159086 0.793 rs11845370 ENSG00000270000.1 RP3-449M8.9 4.83 2.6e-06 0.00176 0.49 0.31 Advanced glycation end-product levels; chr14:74481587 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs3784035 ENSG00000270000.1 RP3-449M8.9 4.83 2.6e-06 0.00176 0.49 0.31 Advanced glycation end-product levels; chr14:74482221 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs12433382 ENSG00000270000.1 RP3-449M8.9 4.83 2.6e-06 0.00176 0.49 0.31 Advanced glycation end-product levels; chr14:74482940 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs10148268 ENSG00000270000.1 RP3-449M8.9 4.83 2.6e-06 0.00176 0.49 0.31 Advanced glycation end-product levels; chr14:74484261 chr14:74471930~74472360:- CESC cis rs2836950 0.565 rs7276046 ENSG00000232608.1 TIMM9P2 4.83 2.6e-06 0.00176 0.34 0.31 Menarche (age at onset); chr21:39209367 chr21:39216624~39217506:+ CESC cis rs2111504 0.583 rs8104714 ENSG00000267213.4 AC007773.2 4.83 2.6e-06 0.00176 0.38 0.31 Bipolar disorder; chr19:32381203 chr19:32390050~32405560:- CESC cis rs9322193 0.961 rs9027 ENSG00000216906.2 RP11-350J20.9 4.83 2.6e-06 0.00176 0.34 0.31 Lung cancer; chr6:149594921 chr6:149904243~149906418:+ CESC cis rs9322193 1 rs9322193 ENSG00000216906.2 RP11-350J20.9 4.83 2.6e-06 0.00176 0.34 0.31 Lung cancer; chr6:149598007 chr6:149904243~149906418:+ CESC cis rs1061377 0.965 rs7669376 ENSG00000249685.1 RP11-360F5.3 4.83 2.61e-06 0.00176 0.37 0.31 Uric acid levels; chr4:39116717 chr4:39133913~39135608:+ CESC cis rs2842992 0.83 rs2842966 ENSG00000237927.1 RP3-393E18.2 -4.83 2.61e-06 0.00176 -0.4 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159720560 chr6:159586955~159589169:- CESC cis rs1799949 1 rs2298862 ENSG00000267681.1 CTD-3199J23.6 -4.83 2.61e-06 0.00176 -0.43 -0.31 Menopause (age at onset); chr17:43024671 chr17:43144956~43145255:+ CESC cis rs1799949 0.93 rs2298861 ENSG00000267681.1 CTD-3199J23.6 -4.83 2.61e-06 0.00176 -0.43 -0.31 Menopause (age at onset); chr17:43024814 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs36036395 ENSG00000267681.1 CTD-3199J23.6 -4.83 2.61e-06 0.00176 -0.43 -0.31 Menopause (age at onset); chr17:43029280 chr17:43144956~43145255:+ CESC cis rs10246939 0.543 rs11765575 ENSG00000228775.6 WEE2-AS1 4.83 2.62e-06 0.00177 0.36 0.31 Bitter taste perception; chr7:141838168 chr7:141704338~141738346:- CESC cis rs9322193 0.923 rs14314 ENSG00000268592.3 RAET1E-AS1 4.83 2.62e-06 0.00177 0.41 0.31 Lung cancer; chr6:149820395 chr6:149863494~149919507:+ CESC cis rs1707322 0.827 rs6694302 ENSG00000281133.1 AL355480.3 -4.83 2.62e-06 0.00177 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45779973 chr1:45580892~45580996:- CESC cis rs1707322 0.826 rs10890349 ENSG00000281133.1 AL355480.3 -4.83 2.62e-06 0.00177 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45784283 chr1:45580892~45580996:- CESC cis rs1707322 0.758 rs10789474 ENSG00000281133.1 AL355480.3 -4.83 2.62e-06 0.00177 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45784368 chr1:45580892~45580996:- CESC cis rs6504622 0.755 rs36056466 ENSG00000262879.4 RP11-156P1.3 -4.83 2.62e-06 0.00177 -0.34 -0.31 Orofacial clefts; chr17:47006017 chr17:46984045~47100323:- CESC cis rs4974559 0.895 rs10018133 ENSG00000253399.1 AC078852.2 4.83 2.62e-06 0.00177 0.52 0.31 Systolic blood pressure; chr4:1344458 chr4:1358479~1359461:+ CESC cis rs2015599 0.623 rs1006410 ENSG00000257176.2 RP11-996F15.2 4.83 2.63e-06 0.00177 0.37 0.31 Platelet count;Mean platelet volume; chr12:29282682 chr12:29280418~29317848:- CESC cis rs875971 0.52 rs160645 ENSG00000236529.1 RP13-254B10.1 -4.82 2.63e-06 0.00178 -0.4 -0.31 Aortic root size; chr7:66091320 chr7:65840212~65840596:+ CESC cis rs875971 0.789 rs28815324 ENSG00000236529.1 RP13-254B10.1 -4.82 2.63e-06 0.00178 -0.4 -0.31 Aortic root size; chr7:66100789 chr7:65840212~65840596:+ CESC cis rs34375054 0.66 rs12578446 ENSG00000279233.1 RP11-158L12.4 4.82 2.63e-06 0.00178 0.33 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125121341 chr12:125138245~125141711:+ CESC cis rs875971 0.862 rs1612452 ENSG00000237310.1 GS1-124K5.4 -4.82 2.63e-06 0.00178 -0.3 -0.31 Aortic root size; chr7:66108909 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs1167390 ENSG00000237310.1 GS1-124K5.4 -4.82 2.63e-06 0.00178 -0.3 -0.31 Aortic root size; chr7:66110906 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs35034167 ENSG00000237310.1 GS1-124K5.4 -4.82 2.63e-06 0.00178 -0.3 -0.31 Aortic root size; chr7:66115179 chr7:66493706~66495474:+ CESC cis rs1799949 0.965 rs34633610 ENSG00000267681.1 CTD-3199J23.6 -4.82 2.64e-06 0.00178 -0.41 -0.31 Menopause (age at onset); chr17:43342017 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs11654051 ENSG00000267681.1 CTD-3199J23.6 -4.82 2.64e-06 0.00178 -0.41 -0.31 Menopause (age at onset); chr17:43342288 chr17:43144956~43145255:+ CESC cis rs1799949 0.93 rs56729776 ENSG00000267681.1 CTD-3199J23.6 -4.82 2.64e-06 0.00178 -0.41 -0.31 Menopause (age at onset); chr17:43344763 chr17:43144956~43145255:+ CESC cis rs7560272 0.501 rs6750494 ENSG00000273245.1 RP11-434P11.2 -4.82 2.64e-06 0.00178 -0.38 -0.31 Schizophrenia; chr2:73719369 chr2:73750256~73750786:- CESC cis rs1075265 0.568 rs3095756 ENSG00000233266.1 HMGB1P31 4.82 2.64e-06 0.00178 0.39 0.31 Chronotype;Morning vs. evening chronotype; chr2:53822332 chr2:54051334~54051760:+ CESC cis rs733592 0.507 rs7138917 ENSG00000240399.1 RP1-228P16.1 -4.82 2.65e-06 0.00178 -0.31 -0.31 Plateletcrit; chr12:48061472 chr12:48054813~48055591:- CESC cis rs2243480 1 rs937108 ENSG00000228409.4 CCT6P1 4.82 2.65e-06 0.00178 0.44 0.31 Diabetic kidney disease; chr7:65963465 chr7:65751142~65763354:+ CESC cis rs12429206 0.547 rs75419800 ENSG00000233672.5 RNASEH2B-AS1 -4.82 2.65e-06 0.00179 -0.43 -0.31 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50898897 chr13:50862172~50910764:- CESC cis rs1799949 1 rs2271574 ENSG00000267681.1 CTD-3199J23.6 -4.82 2.65e-06 0.00179 -0.41 -0.31 Menopause (age at onset); chr17:43175631 chr17:43144956~43145255:+ CESC cis rs17711722 0.528 rs73138179 ENSG00000234585.5 CCT6P3 4.82 2.65e-06 0.00179 0.34 0.31 Calcium levels; chr7:65829495 chr7:65038354~65074713:+ CESC cis rs6890270 1 rs6890270 ENSG00000271828.1 CTD-2310F14.1 4.82 2.65e-06 0.00179 0.42 0.31 Breast cancer; chr5:56964779 chr5:56927874~56929573:+ CESC cis rs13385 0.553 rs183869 ENSG00000202111.1 VTRNA1-2 4.82 2.65e-06 0.00179 0.42 0.31 Atrial fibrillation; chr5:140151433 chr5:140718925~140719013:+ CESC cis rs875971 0.545 rs313830 ENSG00000236529.1 RP13-254B10.1 -4.82 2.66e-06 0.00179 -0.4 -0.31 Aortic root size; chr7:66086944 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs313828 ENSG00000236529.1 RP13-254B10.1 -4.82 2.66e-06 0.00179 -0.4 -0.31 Aortic root size; chr7:66087627 chr7:65840212~65840596:+ CESC cis rs9549367 0.713 rs3024776 ENSG00000269125.1 RP11-98F14.11 4.82 2.66e-06 0.00179 0.45 0.31 Platelet distribution width; chr13:113172761 chr13:113165002~113165183:- CESC cis rs7189233 0.531 rs8049033 ENSG00000279344.1 RP11-44F14.7 4.82 2.66e-06 0.00179 0.29 0.31 Intelligence (multi-trait analysis); chr16:53479143 chr16:53478957~53481550:- CESC cis rs875971 0.862 rs28470208 ENSG00000237310.1 GS1-124K5.4 -4.82 2.67e-06 0.0018 -0.3 -0.31 Aortic root size; chr7:66119713 chr7:66493706~66495474:+ CESC cis rs4819052 0.851 rs914218 ENSG00000223768.1 LINC00205 -4.82 2.67e-06 0.0018 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45278530 chr21:45293285~45297354:+ CESC cis rs8059260 0.604 rs16957966 ENSG00000274038.1 RP11-66H6.4 -4.82 2.68e-06 0.0018 -0.5 -0.31 Alcohol consumption over the past year; chr16:11046280 chr16:11056556~11057034:+ CESC cis rs494459 0.838 rs632124 ENSG00000255422.1 AP002954.4 -4.82 2.68e-06 0.0018 -0.35 -0.31 Height; chr11:118742526 chr11:118704607~118750263:+ CESC cis rs2836950 0.565 rs2836945 ENSG00000232608.1 TIMM9P2 4.82 2.68e-06 0.0018 0.35 0.31 Menarche (age at onset); chr21:39224831 chr21:39216624~39217506:+ CESC cis rs2408955 0.504 rs11168441 ENSG00000240399.1 RP1-228P16.1 4.82 2.68e-06 0.00181 0.35 0.31 Glycated hemoglobin levels; chr12:48182271 chr12:48054813~48055591:- CESC cis rs2842992 0.673 rs6930904 ENSG00000237927.1 RP3-393E18.2 -4.82 2.68e-06 0.00181 -0.41 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159796401 chr6:159586955~159589169:- CESC cis rs2842992 0.789 rs6908680 ENSG00000237927.1 RP3-393E18.2 -4.82 2.68e-06 0.00181 -0.41 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159797177 chr6:159586955~159589169:- CESC cis rs2842992 0.672 rs4708845 ENSG00000237927.1 RP3-393E18.2 -4.82 2.68e-06 0.00181 -0.41 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159798569 chr6:159586955~159589169:- CESC cis rs2842992 0.789 rs2342446 ENSG00000237927.1 RP3-393E18.2 -4.82 2.68e-06 0.00181 -0.41 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159799655 chr6:159586955~159589169:- CESC cis rs5769707 0.632 rs5770601 ENSG00000188511.11 C22orf34 4.82 2.69e-06 0.00181 0.37 0.31 Monocyte percentage of white cells;Monocyte count; chr22:49628255 chr22:49414524~49657542:- CESC cis rs1799949 1 rs4793229 ENSG00000267681.1 CTD-3199J23.6 4.82 2.69e-06 0.00181 0.41 0.31 Menopause (age at onset); chr17:43340966 chr17:43144956~43145255:+ CESC cis rs875971 0.862 rs801195 ENSG00000222364.1 RNU6-96P 4.82 2.69e-06 0.00181 0.37 0.31 Aortic root size; chr7:66561128 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs801194 ENSG00000222364.1 RNU6-96P 4.82 2.69e-06 0.00181 0.37 0.31 Aortic root size; chr7:66563508 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs2024192 ENSG00000222364.1 RNU6-96P 4.82 2.69e-06 0.00181 0.37 0.31 Aortic root size; chr7:66576460 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6955837 ENSG00000222364.1 RNU6-96P 4.82 2.69e-06 0.00181 0.37 0.31 Aortic root size; chr7:66578155 chr7:66395191~66395286:+ CESC cis rs875971 0.825 rs10281499 ENSG00000222364.1 RNU6-96P 4.82 2.69e-06 0.00181 0.37 0.31 Aortic root size; chr7:66583979 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs4718377 ENSG00000222364.1 RNU6-96P 4.82 2.69e-06 0.00181 0.37 0.31 Aortic root size; chr7:66584691 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs10278014 ENSG00000222364.1 RNU6-96P 4.82 2.69e-06 0.00181 0.37 0.31 Aortic root size; chr7:66586277 chr7:66395191~66395286:+ CESC cis rs6142102 0.812 rs761236 ENSG00000276073.1 RP5-1125A11.7 -4.82 2.69e-06 0.00181 -0.31 -0.31 Skin pigmentation; chr20:33932245 chr20:33985617~33988989:- CESC cis rs75422866 0.867 rs73102166 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47653769 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102168 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47654010 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102171 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47656077 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102188 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47662993 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102195 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47666309 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102201 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47669269 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73104104 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47671986 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73104111 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47673994 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73104115 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47684843 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73104116 ENSG00000274902.1 RP1-197B17.4 4.82 2.69e-06 0.00181 0.72 0.31 Pneumonia; chr12:47685023 chr12:47731908~47732351:+ CESC cis rs2732480 0.577 rs1489109 ENSG00000258273.1 RP11-370I10.4 -4.82 2.7e-06 0.00181 -0.39 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344997 chr12:48333755~48333901:- CESC cis rs2732480 0.577 rs1489108 ENSG00000258273.1 RP11-370I10.4 -4.82 2.7e-06 0.00181 -0.39 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344998 chr12:48333755~48333901:- CESC cis rs9322193 0.923 rs4870267 ENSG00000268592.3 RAET1E-AS1 4.82 2.7e-06 0.00181 0.4 0.31 Lung cancer; chr6:149671572 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs2151912 ENSG00000216906.2 RP11-350J20.9 4.82 2.7e-06 0.00181 0.35 0.31 Lung cancer; chr6:149831772 chr6:149904243~149906418:+ CESC cis rs6991838 0.733 rs10111844 ENSG00000272010.1 CTD-3025N20.3 4.82 2.7e-06 0.00181 0.34 0.31 Intelligence (multi-trait analysis); chr8:65690374 chr8:65591850~65592472:- CESC cis rs801193 0.591 rs4506088 ENSG00000222364.1 RNU6-96P 4.82 2.7e-06 0.00181 0.36 0.31 Aortic root size; chr7:66670470 chr7:66395191~66395286:+ CESC cis rs9549367 0.713 rs9549691 ENSG00000269125.1 RP11-98F14.11 -4.82 2.71e-06 0.00182 -0.43 -0.31 Platelet distribution width; chr13:113207292 chr13:113165002~113165183:- CESC cis rs11159086 0.793 rs10147316 ENSG00000270000.1 RP3-449M8.9 4.82 2.71e-06 0.00182 0.49 0.31 Advanced glycation end-product levels; chr14:74475688 chr14:74471930~74472360:- CESC cis rs11159086 0.838 rs10147963 ENSG00000270000.1 RP3-449M8.9 4.82 2.71e-06 0.00182 0.49 0.31 Advanced glycation end-product levels; chr14:74476091 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs8021664 ENSG00000270000.1 RP3-449M8.9 4.82 2.71e-06 0.00182 0.49 0.31 Advanced glycation end-product levels; chr14:74476592 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs1860108 ENSG00000270000.1 RP3-449M8.9 4.82 2.71e-06 0.00182 0.49 0.31 Advanced glycation end-product levels; chr14:74478562 chr14:74471930~74472360:- CESC cis rs2412819 0.597 rs2412821 ENSG00000205771.5 CATSPER2P1 -4.82 2.71e-06 0.00182 -0.44 -0.31 Lung cancer; chr15:43864966 chr15:43726918~43747094:- CESC cis rs2739330 0.685 rs4822453 ENSG00000231271.1 AP000350.8 4.82 2.71e-06 0.00182 0.37 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23949918~23954042:+ CESC cis rs881375 0.9 rs2241003 ENSG00000226752.6 PSMD5-AS1 -4.82 2.71e-06 0.00182 -0.33 -0.31 Rheumatoid arthritis; chr9:120904499 chr9:120824828~120854385:+ CESC cis rs12429206 0.52 rs75594262 ENSG00000233672.5 RNASEH2B-AS1 -4.82 2.71e-06 0.00182 -0.43 -0.31 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50900249 chr13:50862172~50910764:- CESC cis rs4819052 0.851 rs2838857 ENSG00000223768.1 LINC00205 -4.82 2.72e-06 0.00182 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45261085 chr21:45293285~45297354:+ CESC cis rs6686842 0.965 rs2802551 ENSG00000235358.1 RP11-399E6.1 4.82 2.72e-06 0.00183 0.37 0.31 Height; chr1:41031771 chr1:41242373~41284861:+ CESC cis rs9660180 0.967 rs6603802 ENSG00000268575.1 RP1-283E3.8 -4.82 2.72e-06 0.00183 -0.31 -0.31 Body mass index; chr1:1881082 chr1:1702736~1737688:- CESC cis rs11651753 0.805 rs55822955 ENSG00000264920.1 RP11-6N17.4 -4.82 2.72e-06 0.00183 -0.35 -0.31 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47884447 chr17:47891255~47895812:- CESC cis rs4423214 0.559 rs10898228 ENSG00000254682.1 RP11-660L16.2 -4.82 2.72e-06 0.00183 -0.45 -0.31 Vitamin D levels; chr11:71517312 chr11:71448674~71452157:+ CESC cis rs2548724 0.588 rs62369342 ENSG00000250682.4 LINC00491 4.82 2.73e-06 0.00183 0.36 0.31 Type 2 diabetes; chr5:102402190 chr5:102609156~102671559:- CESC cis rs77972916 0.505 rs6719754 ENSG00000234936.1 AC010883.5 4.82 2.73e-06 0.00183 0.34 0.31 Granulocyte percentage of myeloid white cells; chr2:43299247 chr2:43229573~43233394:+ CESC cis rs763121 0.853 rs138706 ENSG00000273076.1 RP3-508I15.22 4.82 2.73e-06 0.00183 0.34 0.31 Menopause (age at onset); chr22:38741829 chr22:38743495~38743910:+ CESC cis rs2028299 0.92 rs12594774 ENSG00000259677.1 RP11-493E3.1 4.82 2.73e-06 0.00183 0.42 0.31 Type 2 diabetes; chr15:89863652 chr15:89876540~89877285:+ CESC cis rs875971 0.545 rs35459055 ENSG00000237310.1 GS1-124K5.4 4.82 2.74e-06 0.00184 0.33 0.31 Aortic root size; chr7:66479399 chr7:66493706~66495474:+ CESC cis rs71403859 0.502 rs12927006 ENSG00000260886.1 TAT-AS1 4.82 2.74e-06 0.00184 0.49 0.31 Post bronchodilator FEV1; chr16:71516008 chr16:71565789~71578187:+ CESC cis rs875971 0.928 rs2036263 ENSG00000237310.1 GS1-124K5.4 -4.82 2.74e-06 0.00184 -0.29 -0.31 Aortic root size; chr7:66335210 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs10240949 ENSG00000237310.1 GS1-124K5.4 -4.82 2.74e-06 0.00184 -0.29 -0.31 Aortic root size; chr7:66339430 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs7782704 ENSG00000237310.1 GS1-124K5.4 -4.82 2.74e-06 0.00184 -0.29 -0.31 Aortic root size; chr7:66340379 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs6959268 ENSG00000237310.1 GS1-124K5.4 -4.82 2.74e-06 0.00184 -0.29 -0.31 Aortic root size; chr7:66347979 chr7:66493706~66495474:+ CESC cis rs9322193 0.962 rs9322206 ENSG00000216906.2 RP11-350J20.9 4.82 2.74e-06 0.00184 0.34 0.31 Lung cancer; chr6:149641481 chr6:149904243~149906418:+ CESC cis rs75422866 0.867 rs73104103 ENSG00000274902.1 RP1-197B17.4 4.82 2.74e-06 0.00184 0.72 0.31 Pneumonia; chr12:47669604 chr12:47731908~47732351:+ CESC cis rs875971 0.545 rs2420456 ENSG00000222364.1 RNU6-96P -4.82 2.74e-06 0.00184 -0.4 -0.31 Aortic root size; chr7:66280619 chr7:66395191~66395286:+ CESC cis rs2177312 0.52 rs940090 ENSG00000251129.1 RP11-734I18.1 -4.82 2.74e-06 0.00184 -0.4 -0.31 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31917937 chr4:31997397~32155406:+ CESC cis rs801193 0.569 rs11761542 ENSG00000222364.1 RNU6-96P -4.82 2.74e-06 0.00184 -0.36 -0.31 Aortic root size; chr7:66753209 chr7:66395191~66395286:+ CESC cis rs577676 0.586 rs12068805 ENSG00000271811.1 RP1-79C4.4 4.82 2.74e-06 0.00184 0.41 0.31 Prevalent atrial fibrillation; chr1:170632172 chr1:170667381~170669425:+ CESC cis rs577676 0.586 rs12566725 ENSG00000271811.1 RP1-79C4.4 4.82 2.74e-06 0.00184 0.41 0.31 Prevalent atrial fibrillation; chr1:170632794 chr1:170667381~170669425:+ CESC cis rs577676 0.564 rs644784 ENSG00000271811.1 RP1-79C4.4 4.82 2.74e-06 0.00184 0.41 0.31 Prevalent atrial fibrillation; chr1:170636945 chr1:170667381~170669425:+ CESC cis rs11089937 0.963 rs2226943 ENSG00000211639.2 IGLV4-60 4.82 2.74e-06 0.00184 0.27 0.31 Periodontitis (PAL4Q3); chr22:22143100 chr22:22162199~22162681:+ CESC cis rs694739 1 rs1783521 ENSG00000236935.1 AP003774.1 4.82 2.74e-06 0.00184 0.31 0.31 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338819 chr11:64325050~64329504:- CESC cis rs8100891 0.537 rs113427979 ENSG00000267213.4 AC007773.2 -4.82 2.75e-06 0.00184 -0.49 -0.31 Neuroticism; chr19:32364502 chr19:32390050~32405560:- CESC cis rs8100891 0.537 rs4805758 ENSG00000267213.4 AC007773.2 -4.82 2.75e-06 0.00184 -0.49 -0.31 Neuroticism; chr19:32375518 chr19:32390050~32405560:- CESC cis rs950880 0.71 rs17027071 ENSG00000234389.1 AC007278.3 -4.82 2.75e-06 0.00184 -0.34 -0.31 Serum protein levels (sST2); chr2:102396214 chr2:102438713~102440475:+ CESC cis rs7809950 1 rs2520264 ENSG00000238832.1 snoU109 -4.82 2.75e-06 0.00184 -0.37 -0.31 Coronary artery disease; chr7:107538899 chr7:107603363~107603507:+ CESC cis rs7927592 0.913 rs7106010 ENSG00000212093.1 AP000807.1 4.82 2.75e-06 0.00184 0.37 0.31 Total body bone mineral density; chr11:68597744 chr11:68506083~68506166:- CESC cis rs7927592 0.913 rs3758643 ENSG00000212093.1 AP000807.1 4.82 2.75e-06 0.00184 0.37 0.31 Total body bone mineral density; chr11:68599725 chr11:68506083~68506166:- CESC cis rs6504622 0.702 rs3851796 ENSG00000262879.4 RP11-156P1.3 -4.82 2.75e-06 0.00184 -0.34 -0.31 Orofacial clefts; chr17:46983809 chr17:46984045~47100323:- CESC cis rs12439619 0.693 rs17269819 ENSG00000255769.6 GOLGA2P10 -4.81 2.75e-06 0.00184 -0.41 -0.31 Intelligence (multi-trait analysis); chr15:82174660 chr15:82472993~82513950:- CESC cis rs12439619 0.693 rs8034801 ENSG00000255769.6 GOLGA2P10 -4.81 2.75e-06 0.00184 -0.41 -0.31 Intelligence (multi-trait analysis); chr15:82183996 chr15:82472993~82513950:- CESC cis rs875971 0.862 rs1860469 ENSG00000232559.3 GS1-124K5.12 -4.81 2.75e-06 0.00184 -0.34 -0.31 Aortic root size; chr7:66641888 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs4718383 ENSG00000232559.3 GS1-124K5.12 -4.81 2.75e-06 0.00184 -0.34 -0.31 Aortic root size; chr7:66643422 chr7:66554588~66576923:- CESC cis rs2177312 0.52 rs9637713 ENSG00000251129.1 RP11-734I18.1 -4.81 2.75e-06 0.00184 -0.4 -0.31 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31925987 chr4:31997397~32155406:+ CESC cis rs150992 0.53 rs2927646 ENSG00000248489.1 CTD-2007H13.3 4.81 2.77e-06 0.00185 0.35 0.31 Body mass index; chr5:98989462 chr5:98929171~98995013:+ CESC cis rs763121 0.853 rs138713 ENSG00000273076.1 RP3-508I15.22 4.81 2.77e-06 0.00185 0.34 0.31 Menopause (age at onset); chr22:38746610 chr22:38743495~38743910:+ CESC cis rs2300206 1 rs2300206 ENSG00000276073.1 RP5-1125A11.7 -4.81 2.78e-06 0.00186 -0.31 -0.31 Cancer (pleiotropy);Cancer; chr20:34002002 chr20:33985617~33988989:- CESC cis rs34779708 0.766 rs16935949 ENSG00000230534.5 RP11-297A16.2 4.81 2.79e-06 0.00187 0.44 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35262887 chr10:35098006~35127020:- CESC cis rs4819052 0.851 rs35064782 ENSG00000223768.1 LINC00205 -4.81 2.79e-06 0.00187 -0.37 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45254445 chr21:45293285~45297354:+ CESC cis rs2243480 1 rs2257790 ENSG00000275400.1 RP4-756H11.5 4.81 2.79e-06 0.00187 0.53 0.31 Diabetic kidney disease; chr7:66135463 chr7:66553805~66554199:- CESC cis rs1799949 1 rs4793190 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.8e-06 0.00187 -0.41 -0.31 Menopause (age at onset); chr17:43048092 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176297 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.8e-06 0.00187 -0.41 -0.31 Menopause (age at onset); chr17:43051308 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176296 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.8e-06 0.00187 -0.41 -0.31 Menopause (age at onset); chr17:43051574 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs4793191 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.8e-06 0.00187 -0.41 -0.31 Menopause (age at onset); chr17:43052360 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs4793192 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.8e-06 0.00187 -0.41 -0.31 Menopause (age at onset); chr17:43052373 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs8176289 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.8e-06 0.00187 -0.41 -0.31 Menopause (age at onset); chr17:43054039 chr17:43144956~43145255:+ CESC cis rs2980436 1 rs2980436 ENSG00000253981.4 ALG1L13P -4.81 2.8e-06 0.00187 -0.39 -0.31 Schizophrenia; chr8:8234503 chr8:8236003~8244667:- CESC cis rs10875746 0.537 rs4760625 ENSG00000240399.1 RP1-228P16.1 -4.81 2.8e-06 0.00187 -0.4 -0.31 Longevity (90 years and older); chr12:48279960 chr12:48054813~48055591:- CESC cis rs1023500 0.505 rs134888 ENSG00000273366.1 CTA-989H11.1 -4.81 2.81e-06 0.00188 -0.38 -0.31 Schizophrenia; chr22:42278275 chr22:42278188~42278846:+ CESC cis rs77972916 0.561 rs4372955 ENSG00000234936.1 AC010883.5 4.81 2.81e-06 0.00188 0.39 0.31 Granulocyte percentage of myeloid white cells; chr2:43339007 chr2:43229573~43233394:+ CESC cis rs6928977 0.863 rs7772681 ENSG00000234084.1 RP3-388E23.2 -4.81 2.82e-06 0.00188 -0.28 -0.31 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135327875 chr6:135301568~135307158:+ CESC cis rs6686842 0.542 rs11209779 ENSG00000235358.1 RP11-399E6.1 4.81 2.82e-06 0.00188 0.37 0.31 Height; chr1:41271817 chr1:41242373~41284861:+ CESC cis rs6686842 0.562 rs10449765 ENSG00000235358.1 RP11-399E6.1 4.81 2.82e-06 0.00188 0.37 0.31 Height; chr1:41274113 chr1:41242373~41284861:+ CESC cis rs1799949 0.501 rs2343819 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.82e-06 0.00188 -0.4 -0.31 Menopause (age at onset); chr17:43332285 chr17:43144956~43145255:+ CESC cis rs1799949 0.501 rs35399157 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.82e-06 0.00188 -0.4 -0.31 Menopause (age at onset); chr17:43334234 chr17:43144956~43145255:+ CESC cis rs1799949 0.602 rs4600503 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.82e-06 0.00188 -0.4 -0.31 Menopause (age at onset); chr17:43336956 chr17:43144956~43145255:+ CESC cis rs1799949 0.501 rs9675035 ENSG00000267681.1 CTD-3199J23.6 -4.81 2.82e-06 0.00188 -0.4 -0.31 Menopause (age at onset); chr17:43337648 chr17:43144956~43145255:+ CESC cis rs9918079 0.56 rs4698402 ENSG00000273133.1 RP11-799M12.2 -4.81 2.82e-06 0.00188 -0.39 -0.31 Obesity-related traits; chr4:15628180 chr4:15563698~15564253:- CESC cis rs2243480 1 rs1499614 ENSG00000275400.1 RP4-756H11.5 4.81 2.82e-06 0.00188 0.52 0.31 Diabetic kidney disease; chr7:66265811 chr7:66553805~66554199:- CESC cis rs11651753 1 rs11651753 ENSG00000264920.1 RP11-6N17.4 -4.81 2.83e-06 0.00189 -0.35 -0.31 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47951723 chr17:47891255~47895812:- CESC cis rs2015599 0.623 rs7313552 ENSG00000257176.2 RP11-996F15.2 4.81 2.83e-06 0.00189 0.36 0.31 Platelet count;Mean platelet volume; chr12:29277302 chr12:29280418~29317848:- CESC cis rs2015599 0.584 rs7299283 ENSG00000257176.2 RP11-996F15.2 4.81 2.83e-06 0.00189 0.36 0.31 Platelet count;Mean platelet volume; chr12:29277442 chr12:29280418~29317848:- CESC cis rs875971 0.545 rs2707851 ENSG00000237310.1 GS1-124K5.4 -4.81 2.83e-06 0.00189 -0.34 -0.31 Aortic root size; chr7:66624178 chr7:66493706~66495474:+ CESC cis rs2564921 0.73 rs60579898 ENSG00000242142.1 SERBP1P3 -4.81 2.83e-06 0.00189 -0.37 -0.31 Height; chr3:53069965 chr3:53064283~53065091:- CESC cis rs1387259 0.57 rs12368659 ENSG00000240399.1 RP1-228P16.1 4.81 2.83e-06 0.00189 0.34 0.31 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48168516 chr12:48054813~48055591:- CESC cis rs6604026 0.503 rs4847311 ENSG00000223787.2 RP4-593M8.1 -4.81 2.83e-06 0.00189 -0.4 -0.31 Multiple sclerosis; chr1:92758297 chr1:92580476~92580821:- CESC cis rs1930961 1 rs59226697 ENSG00000100058.11 CRYBB2P1 4.81 2.83e-06 0.00189 0.64 0.31 Bipolar disorder with mood-incongruent psychosis; chr22:25474070 chr22:25448105~25520854:+ CESC cis rs957448 1 rs28817653 ENSG00000253704.1 RP11-267M23.4 4.81 2.84e-06 0.00189 0.35 0.31 Nonsyndromic cleft lip with cleft palate; chr8:94557822 chr8:94553722~94569745:+ CESC cis rs950880 0.668 rs3732126 ENSG00000234389.1 AC007278.3 -4.81 2.84e-06 0.00189 -0.34 -0.31 Serum protein levels (sST2); chr2:102397502 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs3732125 ENSG00000234389.1 AC007278.3 -4.81 2.84e-06 0.00189 -0.34 -0.31 Serum protein levels (sST2); chr2:102397503 chr2:102438713~102440475:+ CESC cis rs10875746 0.579 rs10875778 ENSG00000240399.1 RP1-228P16.1 -4.81 2.84e-06 0.00189 -0.41 -0.31 Longevity (90 years and older); chr12:48230872 chr12:48054813~48055591:- CESC cis rs10875746 0.669 rs10875779 ENSG00000240399.1 RP1-228P16.1 -4.81 2.84e-06 0.00189 -0.41 -0.31 Longevity (90 years and older); chr12:48236086 chr12:48054813~48055591:- CESC cis rs7560272 0.501 rs2421675 ENSG00000273245.1 RP11-434P11.2 -4.81 2.84e-06 0.00189 -0.38 -0.31 Schizophrenia; chr2:73728174 chr2:73750256~73750786:- CESC cis rs875971 0.789 rs10260426 ENSG00000232559.3 GS1-124K5.12 -4.81 2.84e-06 0.00189 -0.33 -0.31 Aortic root size; chr7:66271055 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs2901152 ENSG00000232559.3 GS1-124K5.12 -4.81 2.84e-06 0.00189 -0.33 -0.31 Aortic root size; chr7:66300017 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10263690 ENSG00000232559.3 GS1-124K5.12 -4.81 2.84e-06 0.00189 -0.33 -0.31 Aortic root size; chr7:66301466 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10250544 ENSG00000232559.3 GS1-124K5.12 -4.81 2.84e-06 0.00189 -0.33 -0.31 Aortic root size; chr7:66301574 chr7:66554588~66576923:- CESC cis rs860295 0.702 rs11264375 ENSG00000225855.5 RUSC1-AS1 -4.81 2.84e-06 0.00189 -0.26 -0.31 Body mass index; chr1:155454274 chr1:155316863~155324176:- CESC cis rs3823536 0.583 rs10954214 ENSG00000275106.1 RP11-309L24.10 -4.81 2.84e-06 0.00189 -0.43 -0.31 Sjögren's syndrome; chr7:128949579 chr7:128952527~128953316:- CESC cis rs8055167 1 rs8055167 ENSG00000280152.1 RP11-331F4.5 4.81 2.85e-06 0.0019 0.33 0.31 Alcoholic chronic pancreatitis; chr16:75220991 chr16:75245994~75250077:- CESC cis rs1862618 0.853 rs10051747 ENSG00000271828.1 CTD-2310F14.1 4.81 2.85e-06 0.0019 0.42 0.31 Initial pursuit acceleration; chr5:56787462 chr5:56927874~56929573:+ CESC cis rs7923609 0.578 rs10740138 ENSG00000232075.1 MRPL35P2 -4.81 2.85e-06 0.0019 -0.34 -0.31 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63635373 chr10:63634317~63634827:- CESC cis rs6597981 0.592 rs10902218 ENSG00000255284.1 AP006621.5 -4.81 2.85e-06 0.0019 -0.3 -0.31 Breast cancer; chr11:743813 chr11:777578~784297:+ CESC cis rs494459 0.657 rs614554 ENSG00000255422.1 AP002954.4 -4.81 2.85e-06 0.0019 -0.35 -0.31 Height; chr11:118764443 chr11:118704607~118750263:+ CESC cis rs5769707 0.706 rs2071903 ENSG00000235111.1 RP1-29C18.8 -4.81 2.85e-06 0.0019 -0.36 -0.31 Monocyte percentage of white cells;Monocyte count; chr22:49640869 chr22:49612657~49615716:- CESC cis rs17301013 0.507 rs72713537 ENSG00000227373.4 RP11-160H22.5 4.81 2.86e-06 0.0019 0.42 0.31 Systemic lupus erythematosus; chr1:174354189 chr1:174115300~174160004:- CESC cis rs7829975 0.623 rs10087493 ENSG00000173295.6 FAM86B3P -4.81 2.86e-06 0.00191 -0.38 -0.31 Mood instability; chr8:8516047 chr8:8228595~8244865:+ CESC cis rs9326248 0.53 rs588918 ENSG00000280143.1 AP000892.6 4.81 2.86e-06 0.00191 0.49 0.31 Blood protein levels; chr11:116985926 chr11:117204967~117210292:+ CESC cis rs9322193 0.923 rs9479494 ENSG00000268592.3 RAET1E-AS1 4.81 2.87e-06 0.00191 0.4 0.31 Lung cancer; chr6:149739108 chr6:149863494~149919507:+ CESC cis rs875971 0.862 rs778736 ENSG00000232559.3 GS1-124K5.12 4.81 2.87e-06 0.00191 0.34 0.31 Aortic root size; chr7:66348861 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs2088655 ENSG00000232559.3 GS1-124K5.12 -4.81 2.87e-06 0.00191 -0.34 -0.31 Aortic root size; chr7:66330724 chr7:66554588~66576923:- CESC cis rs875971 0.895 rs10447522 ENSG00000232559.3 GS1-124K5.12 -4.81 2.87e-06 0.00191 -0.34 -0.31 Aortic root size; chr7:66331087 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs2088653 ENSG00000232559.3 GS1-124K5.12 -4.81 2.87e-06 0.00191 -0.34 -0.31 Aortic root size; chr7:66343621 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6460293 ENSG00000232559.3 GS1-124K5.12 -4.81 2.87e-06 0.00191 -0.34 -0.31 Aortic root size; chr7:66345205 chr7:66554588~66576923:- CESC cis rs11723261 0.664 rs4627799 ENSG00000211553.1 AC253576.2 -4.81 2.87e-06 0.00191 -0.46 -0.31 Immune response to smallpox vaccine (IL-6); chr4:138608 chr4:136461~136568:+ CESC cis rs7560272 0.501 rs2272178 ENSG00000273245.1 RP11-434P11.2 -4.8 2.88e-06 0.00192 -0.39 -0.31 Schizophrenia; chr2:73750482 chr2:73750256~73750786:- CESC cis rs9322193 0.923 rs10872645 ENSG00000216906.2 RP11-350J20.9 4.8 2.88e-06 0.00192 0.35 0.31 Lung cancer; chr6:149742840 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs12211511 ENSG00000216906.2 RP11-350J20.9 4.8 2.88e-06 0.00192 0.35 0.31 Lung cancer; chr6:149745206 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9479810 ENSG00000216906.2 RP11-350J20.9 4.8 2.88e-06 0.00192 0.35 0.31 Lung cancer; chr6:149751359 chr6:149904243~149906418:+ CESC cis rs10829156 0.947 rs10764661 ENSG00000240291.1 RP11-499P20.2 4.8 2.88e-06 0.00192 0.34 0.31 Sudden cardiac arrest; chr10:18659018 chr10:18513115~18545651:- CESC cis rs10875746 0.669 rs11168496 ENSG00000240399.1 RP1-228P16.1 -4.8 2.88e-06 0.00192 -0.38 -0.31 Longevity (90 years and older); chr12:48257072 chr12:48054813~48055591:- CESC cis rs2177312 0.567 rs6837752 ENSG00000251129.1 RP11-734I18.1 -4.8 2.89e-06 0.00192 -0.41 -0.31 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31869266 chr4:31997397~32155406:+ CESC cis rs950880 0.71 rs10490204 ENSG00000234389.1 AC007278.3 -4.8 2.89e-06 0.00192 -0.35 -0.31 Serum protein levels (sST2); chr2:102440074 chr2:102438713~102440475:+ CESC cis rs7586673 0.893 rs889925 ENSG00000227403.1 AC009299.3 -4.8 2.89e-06 0.00192 -0.39 -0.31 Intelligence (multi-trait analysis); chr2:161115086 chr2:161244739~161249050:+ CESC cis rs7586673 0.93 rs2884364 ENSG00000227403.1 AC009299.3 -4.8 2.89e-06 0.00192 -0.39 -0.31 Intelligence (multi-trait analysis); chr2:161121136 chr2:161244739~161249050:+ CESC cis rs2299587 0.552 rs1978054 ENSG00000253671.1 RP11-806O11.1 -4.8 2.89e-06 0.00192 -0.32 -0.31 Economic and political preferences; chr8:18011012 chr8:17808941~17820868:+ CESC cis rs11638352 0.661 rs2706486 ENSG00000259479.5 SORD2P -4.8 2.89e-06 0.00192 -0.45 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44136784 chr15:44826371~44884694:- CESC cis rs10256972 0.621 rs2363285 ENSG00000229043.2 AC091729.9 -4.8 2.9e-06 0.00193 -0.34 -0.31 Endometriosis;Longevity; chr7:1052008 chr7:1160374~1165267:+ CESC cis rs950880 0.71 rs3821204 ENSG00000234389.1 AC007278.3 -4.8 2.9e-06 0.00193 -0.35 -0.31 Serum protein levels (sST2); chr2:102343821 chr2:102438713~102440475:+ CESC cis rs6504622 0.721 rs8077021 ENSG00000262879.4 RP11-156P1.3 -4.8 2.91e-06 0.00193 -0.33 -0.31 Orofacial clefts; chr17:47061937 chr17:46984045~47100323:- CESC cis rs875971 0.862 rs6460302 ENSG00000232559.3 GS1-124K5.12 4.8 2.91e-06 0.00193 0.34 0.31 Aortic root size; chr7:66495270 chr7:66554588~66576923:- CESC cis rs9322193 0.962 rs12175575 ENSG00000268592.3 RAET1E-AS1 4.8 2.91e-06 0.00193 0.4 0.31 Lung cancer; chr6:149763351 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs4869966 ENSG00000268592.3 RAET1E-AS1 4.8 2.91e-06 0.00193 0.4 0.31 Lung cancer; chr6:149763714 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs1112730 ENSG00000268592.3 RAET1E-AS1 4.8 2.91e-06 0.00193 0.4 0.31 Lung cancer; chr6:149766383 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs1112729 ENSG00000268592.3 RAET1E-AS1 4.8 2.91e-06 0.00193 0.4 0.31 Lung cancer; chr6:149766491 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs10452626 ENSG00000268592.3 RAET1E-AS1 4.8 2.91e-06 0.00193 0.4 0.31 Lung cancer; chr6:149767481 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs62441303 ENSG00000268592.3 RAET1E-AS1 4.8 2.91e-06 0.00193 0.4 0.31 Lung cancer; chr6:149767547 chr6:149863494~149919507:+ CESC cis rs1061377 1 rs10018049 ENSG00000249685.1 RP11-360F5.3 4.8 2.91e-06 0.00194 0.37 0.31 Uric acid levels; chr4:39115781 chr4:39133913~39135608:+ CESC cis rs9640161 0.711 rs55881542 ENSG00000261305.1 RP4-584D14.7 4.8 2.92e-06 0.00194 0.43 0.31 Blood protein levels;Circulating chemerin levels; chr7:150328645 chr7:150341771~150342607:+ CESC cis rs1799949 1 rs8176242 ENSG00000267681.1 CTD-3199J23.6 -4.8 2.92e-06 0.00194 -0.42 -0.31 Menopause (age at onset); chr17:43065857 chr17:43144956~43145255:+ CESC cis rs1799949 0.93 rs3092987 ENSG00000267681.1 CTD-3199J23.6 -4.8 2.92e-06 0.00194 -0.42 -0.31 Menopause (age at onset); chr17:43070706 chr17:43144956~43145255:+ CESC cis rs875971 0.862 rs778684 ENSG00000232559.3 GS1-124K5.12 4.8 2.92e-06 0.00194 0.33 0.31 Aortic root size; chr7:66371416 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs778680 ENSG00000232559.3 GS1-124K5.12 4.8 2.92e-06 0.00194 0.33 0.31 Aortic root size; chr7:66375427 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs11769079 ENSG00000232559.3 GS1-124K5.12 4.8 2.92e-06 0.00194 0.33 0.31 Aortic root size; chr7:66377141 chr7:66554588~66576923:- CESC cis rs9918079 0.56 rs13147590 ENSG00000273133.1 RP11-799M12.2 4.8 2.93e-06 0.00194 0.39 0.31 Obesity-related traits; chr4:15619565 chr4:15563698~15564253:- CESC cis rs2739330 0.587 rs4820571 ENSG00000228039.3 KB-1125A3.10 4.8 2.93e-06 0.00194 0.38 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23963780~23964374:+ CESC cis rs9660180 1 rs3737628 ENSG00000268575.1 RP1-283E3.8 -4.8 2.93e-06 0.00195 -0.32 -0.31 Body mass index; chr1:1791493 chr1:1702736~1737688:- CESC cis rs8042680 0.522 rs10775251 ENSG00000214432.8 AC068831.10 -4.8 2.94e-06 0.00195 -0.38 -0.31 Type 2 diabetes; chr15:91011195 chr15:91022619~91036611:+ CESC cis rs4266144 0.562 rs2086667 ENSG00000244515.1 KRT18P34 -4.8 2.94e-06 0.00195 -0.41 -0.31 Coronary artery disease; chr3:157118728 chr3:157162663~157163932:- CESC cis rs8072100 0.512 rs9674670 ENSG00000228782.6 CTD-2026D20.3 4.8 2.94e-06 0.00195 0.37 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47308791 chr17:47450568~47492492:- CESC cis rs2243480 1 rs160639 ENSG00000275400.1 RP4-756H11.5 4.8 2.94e-06 0.00195 0.53 0.31 Diabetic kidney disease; chr7:66115000 chr7:66553805~66554199:- CESC cis rs1799949 1 rs12944458 ENSG00000267681.1 CTD-3199J23.6 -4.8 2.94e-06 0.00195 -0.42 -0.31 Menopause (age at onset); chr17:43028755 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs72829113 ENSG00000267681.1 CTD-3199J23.6 -4.8 2.94e-06 0.00195 -0.42 -0.31 Menopause (age at onset); chr17:43029818 chr17:43144956~43145255:+ CESC cis rs8072100 0.967 rs11656855 ENSG00000228782.6 CTD-2026D20.3 -4.8 2.95e-06 0.00196 -0.36 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47637289 chr17:47450568~47492492:- CESC cis rs75422866 0.867 rs73104138 ENSG00000274902.1 RP1-197B17.4 4.8 2.95e-06 0.00196 0.72 0.31 Pneumonia; chr12:47692302 chr12:47731908~47732351:+ CESC cis rs75422866 0.717 rs73104143 ENSG00000274902.1 RP1-197B17.4 4.8 2.95e-06 0.00196 0.72 0.31 Pneumonia; chr12:47693449 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73104144 ENSG00000274902.1 RP1-197B17.4 4.8 2.95e-06 0.00196 0.72 0.31 Pneumonia; chr12:47694390 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73104148 ENSG00000274902.1 RP1-197B17.4 4.8 2.95e-06 0.00196 0.72 0.31 Pneumonia; chr12:47696732 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73104152 ENSG00000274902.1 RP1-197B17.4 4.8 2.95e-06 0.00196 0.72 0.31 Pneumonia; chr12:47699091 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73104155 ENSG00000274902.1 RP1-197B17.4 4.8 2.95e-06 0.00196 0.72 0.31 Pneumonia; chr12:47700790 chr12:47731908~47732351:+ CESC cis rs6452524 1 rs67683443 ENSG00000249664.1 CTD-2227C6.2 4.8 2.96e-06 0.00196 0.35 0.31 Hypertension (SNP x SNP interaction); chr5:83167884 chr5:83012285~83013109:- CESC cis rs9322193 0.884 rs2342858 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149805967 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs2095375 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149807037 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs4869730 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149808187 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs11155689 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149808470 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs2151913 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149809506 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs2342857 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149809537 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs933055 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149809701 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs4869731 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149810072 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs4552 ENSG00000268592.3 RAET1E-AS1 4.8 2.96e-06 0.00196 0.4 0.31 Lung cancer; chr6:149811183 chr6:149863494~149919507:+ CESC cis rs875971 0.545 rs221986 ENSG00000236529.1 RP13-254B10.1 -4.8 2.97e-06 0.00197 -0.39 -0.31 Aortic root size; chr7:66105323 chr7:65840212~65840596:+ CESC cis rs12439619 0.508 rs17354842 ENSG00000255769.6 GOLGA2P10 4.8 2.97e-06 0.00197 0.34 0.31 Intelligence (multi-trait analysis); chr15:82177259 chr15:82472993~82513950:- CESC cis rs2243480 1 rs437889 ENSG00000232559.3 GS1-124K5.12 4.8 2.97e-06 0.00197 0.52 0.31 Diabetic kidney disease; chr7:66044247 chr7:66554588~66576923:- CESC cis rs875971 0.767 rs1643394 ENSG00000232559.3 GS1-124K5.12 4.8 2.97e-06 0.00197 0.33 0.31 Aortic root size; chr7:66371107 chr7:66554588~66576923:- CESC cis rs2243480 1 rs465359 ENSG00000228409.4 CCT6P1 4.8 2.98e-06 0.00197 0.46 0.31 Diabetic kidney disease; chr7:66093177 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs462853 ENSG00000228409.4 CCT6P1 4.8 2.98e-06 0.00197 0.46 0.31 Diabetic kidney disease; chr7:66093180 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs160644 ENSG00000228409.4 CCT6P1 4.8 2.98e-06 0.00197 0.46 0.31 Diabetic kidney disease; chr7:66093199 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs160642 ENSG00000228409.4 CCT6P1 4.8 2.98e-06 0.00197 0.46 0.31 Diabetic kidney disease; chr7:66093386 chr7:65751142~65763354:+ CESC cis rs2243480 0.614 rs34032527 ENSG00000228409.4 CCT6P1 4.8 2.98e-06 0.00197 0.46 0.31 Diabetic kidney disease; chr7:66100154 chr7:65751142~65763354:+ CESC cis rs62229266 0.618 rs11088334 ENSG00000231106.2 LINC01436 4.8 2.98e-06 0.00197 0.45 0.31 Mitral valve prolapse; chr21:36094531 chr21:36005338~36007838:+ CESC cis rs7586673 0.93 rs7591506 ENSG00000227403.1 AC009299.3 -4.8 2.99e-06 0.00198 -0.39 -0.31 Intelligence (multi-trait analysis); chr2:161104414 chr2:161244739~161249050:+ CESC cis rs12761761 1 rs12411375 ENSG00000279982.1 RP11-45A17.3 -4.8 2.99e-06 0.00198 -0.43 -0.31 Intelligence (multi-trait analysis);Educational attainment (years of education); chr10:131962329 chr10:131996738~131999846:+ CESC cis rs4974559 0.895 rs10004411 ENSG00000253399.1 AC078852.2 4.8 2.99e-06 0.00198 0.48 0.31 Systolic blood pressure; chr4:1360518 chr4:1358479~1359461:+ CESC cis rs5758659 0.714 rs5758574 ENSG00000227370.1 RP4-669P10.19 4.8 2.99e-06 0.00198 0.33 0.31 Cognitive function; chr22:42085396 chr22:42132543~42132998:+ CESC cis rs1023500 0.505 rs134901 ENSG00000273366.1 CTA-989H11.1 -4.8 2.99e-06 0.00198 -0.38 -0.31 Schizophrenia; chr22:42287514 chr22:42278188~42278846:+ CESC cis rs8100891 0.537 rs28562777 ENSG00000267213.4 AC007773.2 -4.8 2.99e-06 0.00198 -0.48 -0.31 Neuroticism; chr19:32409913 chr19:32390050~32405560:- CESC cis rs875971 0.862 rs11984115 ENSG00000232559.3 GS1-124K5.12 -4.8 2.99e-06 0.00198 -0.33 -0.31 Aortic root size; chr7:66308872 chr7:66554588~66576923:- CESC cis rs2243480 0.803 rs160649 ENSG00000275400.1 RP4-756H11.5 4.8 2.99e-06 0.00198 0.52 0.31 Diabetic kidney disease; chr7:66078212 chr7:66553805~66554199:- CESC cis rs2243480 1 rs160648 ENSG00000275400.1 RP4-756H11.5 4.8 2.99e-06 0.00198 0.52 0.31 Diabetic kidney disease; chr7:66078397 chr7:66553805~66554199:- CESC cis rs1167827 0.68 rs1167796 ENSG00000278416.1 PMS2L2 -4.8 2.99e-06 0.00198 -0.38 -0.31 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75543861 chr7:75344015~75359550:- CESC cis rs11976180 1 rs1919950 ENSG00000273234.1 OR2A13P -4.8 3e-06 0.00199 -0.38 -0.31 Obesity-related traits; chr7:144070805 chr7:144142009~144142938:+ CESC cis rs957448 1 rs957448 ENSG00000253704.1 RP11-267M23.4 4.8 3.01e-06 0.00199 0.34 0.31 Nonsyndromic cleft lip with cleft palate; chr8:94529074 chr8:94553722~94569745:+ CESC cis rs957448 1 rs72674855 ENSG00000253704.1 RP11-267M23.4 4.8 3.01e-06 0.00199 0.34 0.31 Nonsyndromic cleft lip with cleft palate; chr8:94536706 chr8:94553722~94569745:+ CESC cis rs1799949 1 rs35330014 ENSG00000267681.1 CTD-3199J23.6 -4.8 3.01e-06 0.00199 -0.41 -0.31 Menopause (age at onset); chr17:43060530 chr17:43144956~43145255:+ CESC cis rs9813712 0.571 rs9836814 ENSG00000228252.7 COL6A4P2 4.8 3.01e-06 0.00199 0.36 0.31 Response to amphetamines; chr3:130216054 chr3:130212823~130273806:+ CESC cis rs2243480 1 rs4718317 ENSG00000232559.3 GS1-124K5.12 -4.79 3.01e-06 0.00199 -0.52 -0.31 Diabetic kidney disease; chr7:66183914 chr7:66554588~66576923:- CESC cis rs875971 0.545 rs1796217 ENSG00000222364.1 RNU6-96P 4.79 3.01e-06 0.00199 0.41 0.31 Aortic root size; chr7:66620931 chr7:66395191~66395286:+ CESC cis rs2111504 0.559 rs12460112 ENSG00000267213.4 AC007773.2 4.79 3.02e-06 0.002 0.38 0.31 Bipolar disorder; chr19:32363928 chr19:32390050~32405560:- CESC cis rs5760092 0.572 rs738806 ENSG00000225282.1 AP000350.6 4.79 3.02e-06 0.002 0.41 0.31 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23926900~23929574:+ CESC cis rs1799949 1 rs11657053 ENSG00000267681.1 CTD-3199J23.6 -4.79 3.03e-06 0.002 -0.42 -0.31 Menopause (age at onset); chr17:43039112 chr17:43144956~43145255:+ CESC cis rs5769707 0.681 rs2071902 ENSG00000188511.11 C22orf34 4.79 3.03e-06 0.002 0.37 0.31 Monocyte percentage of white cells;Monocyte count; chr22:49640890 chr22:49414524~49657542:- CESC cis rs2028299 0.959 rs2165069 ENSG00000259677.1 RP11-493E3.1 4.79 3.03e-06 0.002 0.42 0.31 Type 2 diabetes; chr15:89863887 chr15:89876540~89877285:+ CESC cis rs5758659 0.714 rs7245 ENSG00000273366.1 CTA-989H11.1 4.79 3.03e-06 0.002 0.38 0.31 Cognitive function; chr22:42085845 chr22:42278188~42278846:+ CESC cis rs860295 0.702 rs12239100 ENSG00000225855.5 RUSC1-AS1 4.79 3.03e-06 0.00201 0.26 0.31 Body mass index; chr1:155458685 chr1:155316863~155324176:- CESC cis rs2115630 0.645 rs2292463 ENSG00000225151.9 GOLGA2P7 4.79 3.03e-06 0.00201 0.34 0.31 P wave terminal force; chr15:84632519 chr15:84199311~84230136:- CESC cis rs7429990 0.965 rs34750113 ENSG00000229759.1 MRPS18AP1 4.79 3.04e-06 0.00201 0.33 0.31 Educational attainment (years of education); chr3:47944902 chr3:48256350~48256938:- CESC cis rs6686842 0.582 rs10889870 ENSG00000235358.1 RP11-399E6.1 4.79 3.04e-06 0.00201 0.36 0.31 Height; chr1:41172598 chr1:41242373~41284861:+ CESC cis rs6686842 0.582 rs6656085 ENSG00000235358.1 RP11-399E6.1 4.79 3.04e-06 0.00201 0.36 0.31 Height; chr1:41175655 chr1:41242373~41284861:+ CESC cis rs6686842 0.582 rs12026156 ENSG00000235358.1 RP11-399E6.1 4.79 3.04e-06 0.00201 0.36 0.31 Height; chr1:41195824 chr1:41242373~41284861:+ CESC cis rs950880 0.71 rs17027258 ENSG00000234389.1 AC007278.3 -4.79 3.04e-06 0.00201 -0.34 -0.31 Serum protein levels (sST2); chr2:102475081 chr2:102438713~102440475:+ CESC cis rs12458462 0.892 rs2007483 ENSG00000274828.1 RP11-567M16.6 4.79 3.04e-06 0.00201 0.29 0.31 Monocyte count; chr18:79716131 chr18:79677287~79679358:- CESC cis rs3096299 0.9 rs2911258 ENSG00000274627.1 RP11-104N10.2 4.79 3.04e-06 0.00201 0.31 0.31 Multiple myeloma (IgH translocation); chr16:89414352 chr16:89516797~89522217:+ CESC cis rs16982689 1 rs16982689 ENSG00000253239.1 IGLVI-70 -4.79 3.04e-06 0.00201 -0.45 -0.31 Attention function in attention deficit hyperactive disorder; chr22:22081907 chr22:22026076~22026593:+ CESC cis rs2732480 0.577 rs2732486 ENSG00000258273.1 RP11-370I10.4 -4.79 3.04e-06 0.00201 -0.38 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344051 chr12:48333755~48333901:- CESC cis rs2732480 0.517 rs2634676 ENSG00000258273.1 RP11-370I10.4 -4.79 3.04e-06 0.00201 -0.38 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344453 chr12:48333755~48333901:- CESC cis rs875971 0.755 rs10228885 ENSG00000222364.1 RNU6-96P 4.79 3.05e-06 0.00201 0.36 0.31 Aortic root size; chr7:66315542 chr7:66395191~66395286:+ CESC cis rs7176527 1 rs7176527 ENSG00000229212.6 RP11-561C5.4 4.79 3.05e-06 0.00201 0.4 0.31 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84597563 chr15:85205440~85234795:- CESC cis rs9318086 0.712 rs12875437 ENSG00000205861.10 C1QTNF9B-AS1 -4.79 3.05e-06 0.00201 -0.39 -0.31 Myopia (pathological); chr13:23879817 chr13:23888889~23897263:+ CESC cis rs860295 0.702 rs11264397 ENSG00000225855.5 RUSC1-AS1 4.79 3.05e-06 0.00202 0.26 0.31 Body mass index; chr1:155641694 chr1:155316863~155324176:- CESC cis rs9813712 0.571 rs9855426 ENSG00000228252.7 COL6A4P2 4.79 3.05e-06 0.00202 0.37 0.31 Response to amphetamines; chr3:130214475 chr3:130212823~130273806:+ CESC cis rs875971 0.597 rs11763224 ENSG00000237310.1 GS1-124K5.4 4.79 3.05e-06 0.00202 0.34 0.31 Aortic root size; chr7:66518628 chr7:66493706~66495474:+ CESC cis rs8100891 0.537 rs10415145 ENSG00000267213.4 AC007773.2 4.79 3.06e-06 0.00202 0.47 0.31 Neuroticism; chr19:32350147 chr19:32390050~32405560:- CESC cis rs441051 0.586 rs413826 ENSG00000236861.5 AC006378.2 4.79 3.07e-06 0.00203 0.34 0.31 Mean forced vital capacity from 2 exams; chr7:94426932 chr7:93969442~94011113:+ CESC cis rs6686842 0.582 rs4233487 ENSG00000235358.1 RP11-399E6.1 -4.79 3.07e-06 0.00203 -0.37 -0.31 Height; chr1:41086815 chr1:41242373~41284861:+ CESC cis rs9847710 0.696 rs2581821 ENSG00000242142.1 SERBP1P3 4.79 3.07e-06 0.00203 0.36 0.31 Ulcerative colitis; chr3:52987572 chr3:53064283~53065091:- CESC cis rs2015599 0.623 rs12581107 ENSG00000275476.1 RP11-996F15.4 -4.79 3.08e-06 0.00203 -0.36 -0.31 Platelet count;Mean platelet volume; chr12:29352358 chr12:29277397~29277882:- CESC cis rs2015599 0.645 rs12578931 ENSG00000275476.1 RP11-996F15.4 -4.79 3.08e-06 0.00203 -0.36 -0.31 Platelet count;Mean platelet volume; chr12:29358608 chr12:29277397~29277882:- CESC cis rs2015599 0.623 rs4931174 ENSG00000275476.1 RP11-996F15.4 -4.79 3.08e-06 0.00203 -0.36 -0.31 Platelet count;Mean platelet volume; chr12:29360545 chr12:29277397~29277882:- CESC cis rs11638352 0.661 rs2706462 ENSG00000259479.5 SORD2P -4.79 3.09e-06 0.00204 -0.48 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44183130 chr15:44826371~44884694:- CESC cis rs1799949 0.965 rs1842147 ENSG00000267681.1 CTD-3199J23.6 -4.79 3.09e-06 0.00204 -0.41 -0.31 Menopause (age at onset); chr17:43357824 chr17:43144956~43145255:+ CESC cis rs875971 0.862 rs4149461 ENSG00000237310.1 GS1-124K5.4 -4.79 3.1e-06 0.00204 -0.28 -0.31 Aortic root size; chr7:66279745 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs10261398 ENSG00000237310.1 GS1-124K5.4 -4.79 3.1e-06 0.00204 -0.28 -0.31 Aortic root size; chr7:66285177 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs10224872 ENSG00000237310.1 GS1-124K5.4 -4.79 3.1e-06 0.00204 -0.28 -0.31 Aortic root size; chr7:66294786 chr7:66493706~66495474:+ CESC cis rs9322193 0.962 rs9688412 ENSG00000268592.3 RAET1E-AS1 -4.79 3.1e-06 0.00205 -0.4 -0.31 Lung cancer; chr6:149803147 chr6:149863494~149919507:+ CESC cis rs1799949 1 rs1973646 ENSG00000267681.1 CTD-3199J23.6 -4.79 3.1e-06 0.00205 -0.41 -0.31 Menopause (age at onset); chr17:43158478 chr17:43144956~43145255:+ CESC cis rs10246939 0.543 rs9640357 ENSG00000228775.6 WEE2-AS1 4.79 3.1e-06 0.00205 0.36 0.31 Bitter taste perception; chr7:141843298 chr7:141704338~141738346:- CESC cis rs2842992 0.83 rs2842974 ENSG00000237927.1 RP3-393E18.2 -4.79 3.1e-06 0.00205 -0.4 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159738002 chr6:159586955~159589169:- CESC cis rs2255336 0.81 rs7956385 ENSG00000245648.1 RP11-277P12.20 4.79 3.11e-06 0.00205 0.55 0.31 Blood protein levels; chr12:10361398 chr12:10363769~10398506:+ CESC cis rs2564921 0.73 rs62253602 ENSG00000242142.1 SERBP1P3 -4.79 3.11e-06 0.00205 -0.38 -0.31 Height; chr3:52936861 chr3:53064283~53065091:- CESC cis rs2564921 0.704 rs62253603 ENSG00000242142.1 SERBP1P3 -4.79 3.11e-06 0.00205 -0.38 -0.31 Height; chr3:52938846 chr3:53064283~53065091:- CESC cis rs2564921 0.704 rs62253604 ENSG00000242142.1 SERBP1P3 -4.79 3.11e-06 0.00205 -0.38 -0.31 Height; chr3:52941053 chr3:53064283~53065091:- CESC cis rs9438901 0.592 rs1293259 ENSG00000261349.1 RP3-465N24.5 4.79 3.12e-06 0.00205 0.39 0.31 Red cell distribution width; chr1:25369344 chr1:25266102~25267136:- CESC cis rs6686842 0.562 rs213770 ENSG00000235358.1 RP11-399E6.1 -4.79 3.12e-06 0.00205 -0.36 -0.31 Height; chr1:41149153 chr1:41242373~41284861:+ CESC cis rs11159086 0.793 rs1029702 ENSG00000259005.1 RP3-449M8.6 4.79 3.12e-06 0.00206 0.43 0.31 Advanced glycation end-product levels; chr14:74473909 chr14:74474007~74474864:- CESC cis rs9322193 0.736 rs3828701 ENSG00000268592.3 RAET1E-AS1 4.79 3.12e-06 0.00206 0.4 0.31 Lung cancer; chr6:149791063 chr6:149863494~149919507:+ CESC cis rs9322193 0.736 rs3805750 ENSG00000268592.3 RAET1E-AS1 4.79 3.12e-06 0.00206 0.4 0.31 Lung cancer; chr6:149791065 chr6:149863494~149919507:+ CESC cis rs9813712 0.571 rs9289366 ENSG00000228252.7 COL6A4P2 -4.79 3.13e-06 0.00206 -0.37 -0.31 Response to amphetamines; chr3:130225267 chr3:130212823~130273806:+ CESC cis rs9813712 0.571 rs9289367 ENSG00000228252.7 COL6A4P2 -4.79 3.13e-06 0.00206 -0.37 -0.31 Response to amphetamines; chr3:130225286 chr3:130212823~130273806:+ CESC cis rs9813712 0.571 rs9289368 ENSG00000228252.7 COL6A4P2 -4.79 3.13e-06 0.00206 -0.37 -0.31 Response to amphetamines; chr3:130225562 chr3:130212823~130273806:+ CESC cis rs9813712 0.571 rs6774141 ENSG00000228252.7 COL6A4P2 -4.79 3.13e-06 0.00206 -0.37 -0.31 Response to amphetamines; chr3:130225599 chr3:130212823~130273806:+ CESC cis rs6142102 0.812 rs6059558 ENSG00000276073.1 RP5-1125A11.7 -4.79 3.13e-06 0.00206 -0.3 -0.31 Skin pigmentation; chr20:33929024 chr20:33985617~33988989:- CESC cis rs4423214 0.592 rs11234027 ENSG00000254682.1 RP11-660L16.2 -4.79 3.13e-06 0.00206 -0.45 -0.31 Vitamin D levels; chr11:71523061 chr11:71448674~71452157:+ CESC cis rs950880 0.71 rs12470867 ENSG00000234389.1 AC007278.3 -4.79 3.14e-06 0.00206 -0.35 -0.31 Serum protein levels (sST2); chr2:102309906 chr2:102438713~102440475:+ CESC cis rs8177876 0.658 rs75422577 ENSG00000261838.4 RP11-303E16.6 4.79 3.14e-06 0.00207 0.65 0.31 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81054561 chr16:81069854~81076598:+ CESC cis rs6964833 0.935 rs34762099 ENSG00000277053.3 GTF2IP1 -4.79 3.14e-06 0.00207 -0.38 -0.31 Menarche (age at onset); chr7:74636378 chr7:75185385~75237696:- CESC cis rs9322193 0.923 rs2185352 ENSG00000268592.3 RAET1E-AS1 4.79 3.14e-06 0.00207 0.4 0.31 Lung cancer; chr6:149714640 chr6:149863494~149919507:+ CESC cis rs763121 0.886 rs1013339 ENSG00000273076.1 RP3-508I15.22 4.79 3.14e-06 0.00207 0.36 0.31 Menopause (age at onset); chr22:38578675 chr22:38743495~38743910:+ CESC cis rs12439619 0.508 rs8042665 ENSG00000276710.3 CSPG4P8 -4.79 3.15e-06 0.00207 -0.33 -0.31 Intelligence (multi-trait analysis); chr15:82189008 chr15:82459472~82477258:+ CESC cis rs9876781 0.559 rs13073692 ENSG00000229759.1 MRPS18AP1 4.79 3.15e-06 0.00207 0.31 0.31 Longevity; chr3:48361812 chr3:48256350~48256938:- CESC cis rs950880 0.744 rs3771156 ENSG00000234389.1 AC007278.3 -4.79 3.15e-06 0.00207 -0.34 -0.31 Serum protein levels (sST2); chr2:102420217 chr2:102438713~102440475:+ CESC cis rs11159086 0.729 rs8015872 ENSG00000259005.1 RP3-449M8.6 4.78 3.16e-06 0.00208 0.43 0.31 Advanced glycation end-product levels; chr14:74475529 chr14:74474007~74474864:- CESC cis rs9322193 0.923 rs10872650 ENSG00000268592.3 RAET1E-AS1 4.78 3.16e-06 0.00208 0.41 0.31 Lung cancer; chr6:149760959 chr6:149863494~149919507:+ CESC cis rs7560272 0.538 rs2001436 ENSG00000273245.1 RP11-434P11.2 -4.78 3.16e-06 0.00208 -0.39 -0.31 Schizophrenia; chr2:73701838 chr2:73750256~73750786:- CESC cis rs7560272 0.512 rs12998980 ENSG00000273245.1 RP11-434P11.2 -4.78 3.16e-06 0.00208 -0.39 -0.31 Schizophrenia; chr2:73703599 chr2:73750256~73750786:- CESC cis rs2243480 1 rs316315 ENSG00000232559.3 GS1-124K5.12 -4.78 3.16e-06 0.00208 -0.44 -0.31 Diabetic kidney disease; chr7:66126218 chr7:66554588~66576923:- CESC cis rs6686842 0.582 rs213757 ENSG00000235358.1 RP11-399E6.1 -4.78 3.16e-06 0.00208 -0.37 -0.31 Height; chr1:41129126 chr1:41242373~41284861:+ CESC cis rs950880 0.71 rs3771150 ENSG00000234389.1 AC007278.3 -4.78 3.16e-06 0.00208 -0.35 -0.31 Serum protein levels (sST2); chr2:102444391 chr2:102438713~102440475:+ CESC cis rs9660180 0.934 rs12729990 ENSG00000268575.1 RP1-283E3.8 -4.78 3.17e-06 0.00208 -0.31 -0.31 Body mass index; chr1:1880596 chr1:1702736~1737688:- CESC cis rs7176527 0.784 rs62021162 ENSG00000229212.6 RP11-561C5.4 4.78 3.17e-06 0.00208 0.39 0.31 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84565602 chr15:85205440~85234795:- CESC cis rs10129255 0.646 rs55995061 ENSG00000223648.3 IGHV3-64 4.78 3.17e-06 0.00208 0.26 0.31 Kawasaki disease; chr14:106799309 chr14:106643132~106658258:- CESC cis rs6142102 0.812 rs6059574 ENSG00000276073.1 RP5-1125A11.7 4.78 3.17e-06 0.00208 0.29 0.31 Skin pigmentation; chr20:33935366 chr20:33985617~33988989:- CESC cis rs6142102 0.961 rs6059596 ENSG00000276073.1 RP5-1125A11.7 -4.78 3.17e-06 0.00209 -0.31 -0.31 Skin pigmentation; chr20:33969313 chr20:33985617~33988989:- CESC cis rs150992 0.569 rs326482 ENSG00000248489.1 CTD-2007H13.3 4.78 3.18e-06 0.00209 0.41 0.31 Body mass index; chr5:98951115 chr5:98929171~98995013:+ CESC cis rs860295 0.651 rs6677385 ENSG00000225855.5 RUSC1-AS1 4.78 3.18e-06 0.00209 0.26 0.31 Body mass index; chr1:155334790 chr1:155316863~155324176:- CESC cis rs860295 0.651 rs12239114 ENSG00000225855.5 RUSC1-AS1 4.78 3.18e-06 0.00209 0.27 0.31 Body mass index; chr1:155352351 chr1:155316863~155324176:- CESC cis rs10510102 0.608 rs4752607 ENSG00000276742.1 RP11-500G22.4 -4.78 3.18e-06 0.00209 -0.37 -0.31 Breast cancer; chr10:121835426 chr10:121956782~121957098:+ CESC cis rs801193 0.569 rs11772819 ENSG00000222364.1 RNU6-96P -4.78 3.2e-06 0.0021 -0.36 -0.31 Aortic root size; chr7:66752983 chr7:66395191~66395286:+ CESC cis rs801193 0.569 rs7800620 ENSG00000222364.1 RNU6-96P -4.78 3.2e-06 0.0021 -0.36 -0.31 Aortic root size; chr7:66758701 chr7:66395191~66395286:+ CESC cis rs9322193 0.884 rs2342858 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149805967 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs2095375 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149807037 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs4869730 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149808187 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs11155689 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149808470 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs2151913 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149809506 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs2342857 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149809537 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs933055 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149809701 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs4869731 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149810072 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs4552 ENSG00000216906.2 RP11-350J20.9 4.78 3.2e-06 0.0021 0.34 0.31 Lung cancer; chr6:149811183 chr6:149904243~149906418:+ CESC cis rs5758659 0.714 rs2413668 ENSG00000227370.1 RP4-669P10.19 4.78 3.2e-06 0.0021 0.32 0.31 Cognitive function; chr22:42109837 chr22:42132543~42132998:+ CESC cis rs5758659 0.657 rs5758587 ENSG00000227370.1 RP4-669P10.19 4.78 3.2e-06 0.0021 0.32 0.31 Cognitive function; chr22:42121632 chr22:42132543~42132998:+ CESC cis rs2919917 0.915 rs3899796 ENSG00000254352.1 RP11-578O24.2 4.78 3.21e-06 0.0021 0.39 0.31 Lymphocyte counts; chr8:78655847 chr8:78723796~78724136:- CESC cis rs2836950 0.565 rs2836926 ENSG00000232608.1 TIMM9P2 4.78 3.21e-06 0.00211 0.34 0.31 Menarche (age at onset); chr21:39164864 chr21:39216624~39217506:+ CESC cis rs2836950 0.565 rs8131132 ENSG00000232608.1 TIMM9P2 4.78 3.21e-06 0.00211 0.34 0.31 Menarche (age at onset); chr21:39166330 chr21:39216624~39217506:+ CESC cis rs577676 0.586 rs533603 ENSG00000271811.1 RP1-79C4.4 4.78 3.21e-06 0.00211 0.41 0.31 Prevalent atrial fibrillation; chr1:170639527 chr1:170667381~170669425:+ CESC cis rs577676 0.586 rs578928 ENSG00000271811.1 RP1-79C4.4 4.78 3.21e-06 0.00211 0.41 0.31 Prevalent atrial fibrillation; chr1:170640602 chr1:170667381~170669425:+ CESC cis rs6452524 1 rs10068099 ENSG00000249664.1 CTD-2227C6.2 4.78 3.21e-06 0.00211 0.35 0.31 Hypertension (SNP x SNP interaction); chr5:83161373 chr5:83012285~83013109:- CESC cis rs17507216 1 rs3850610 ENSG00000278603.1 RP13-608F4.5 -4.78 3.21e-06 0.00211 -0.45 -0.31 Excessive daytime sleepiness; chr15:82552642 chr15:82472203~82472426:+ CESC cis rs2243480 1 rs316331 ENSG00000228409.4 CCT6P1 -4.78 3.22e-06 0.00211 -0.45 -0.31 Diabetic kidney disease; chr7:66139635 chr7:65751142~65763354:+ CESC cis rs1930961 0.702 rs8141065 ENSG00000100058.11 CRYBB2P1 -4.78 3.22e-06 0.00211 -0.51 -0.31 Bipolar disorder with mood-incongruent psychosis; chr22:25489221 chr22:25448105~25520854:+ CESC cis rs2028299 1 rs1371135 ENSG00000259677.1 RP11-493E3.1 4.78 3.23e-06 0.00212 0.41 0.31 Type 2 diabetes; chr15:89848038 chr15:89876540~89877285:+ CESC cis rs2732480 0.577 rs2634680 ENSG00000258273.1 RP11-370I10.4 -4.78 3.23e-06 0.00212 -0.38 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48340781 chr12:48333755~48333901:- CESC cis rs2732480 0.577 rs2634678 ENSG00000258273.1 RP11-370I10.4 -4.78 3.23e-06 0.00212 -0.38 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48341755 chr12:48333755~48333901:- CESC cis rs12439619 0.846 rs62012059 ENSG00000255769.6 GOLGA2P10 -4.78 3.23e-06 0.00212 -0.47 -0.31 Intelligence (multi-trait analysis); chr15:82251669 chr15:82472993~82513950:- CESC cis rs860295 0.676 rs11264374 ENSG00000225855.5 RUSC1-AS1 4.78 3.23e-06 0.00212 0.26 0.31 Body mass index; chr1:155451721 chr1:155316863~155324176:- CESC cis rs2408955 0.521 rs10875749 ENSG00000240399.1 RP1-228P16.1 -4.78 3.24e-06 0.00212 -0.34 -0.31 Glycated hemoglobin levels; chr12:48138134 chr12:48054813~48055591:- CESC cis rs3124314 1 rs3124314 ENSG00000229021.2 AL591893.1 -4.78 3.24e-06 0.00212 -0.34 -0.31 Hair morphology; chr1:152065039 chr1:151994531~152042774:+ CESC cis rs12439619 0.693 rs28689861 ENSG00000255769.6 GOLGA2P10 -4.78 3.24e-06 0.00212 -0.4 -0.31 Intelligence (multi-trait analysis); chr15:82206369 chr15:82472993~82513950:- CESC cis rs875971 0.862 rs6460290 ENSG00000237310.1 GS1-124K5.4 -4.78 3.25e-06 0.00213 -0.29 -0.31 Aortic root size; chr7:66344119 chr7:66493706~66495474:+ CESC cis rs889512 0.731 rs8063014 ENSG00000280152.1 RP11-331F4.5 -4.78 3.25e-06 0.00213 -0.46 -0.31 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75263775 chr16:75245994~75250077:- CESC cis rs1799949 1 rs4793197 ENSG00000267681.1 CTD-3199J23.6 -4.78 3.25e-06 0.00213 -0.4 -0.31 Menopause (age at onset); chr17:43079885 chr17:43144956~43145255:+ CESC cis rs875971 0.545 rs4441996 ENSG00000222364.1 RNU6-96P 4.78 3.25e-06 0.00213 0.41 0.31 Aortic root size; chr7:66123233 chr7:66395191~66395286:+ CESC cis rs189798 1 rs189798 ENSG00000254340.1 RP11-10A14.3 -4.78 3.25e-06 0.00213 -0.37 -0.31 Myopia (pathological); chr8:9133067 chr8:9141424~9145435:+ CESC cis rs116175783 0.557 rs1146025 ENSG00000227403.1 AC009299.3 4.78 3.25e-06 0.00213 0.49 0.31 Intelligence (multi-trait analysis); chr2:161283301 chr2:161244739~161249050:+ CESC cis rs116175783 0.557 rs62197071 ENSG00000227403.1 AC009299.3 4.78 3.25e-06 0.00213 0.49 0.31 Intelligence (multi-trait analysis); chr2:161292703 chr2:161244739~161249050:+ CESC cis rs116175783 0.557 rs16845757 ENSG00000227403.1 AC009299.3 4.78 3.25e-06 0.00213 0.49 0.31 Intelligence (multi-trait analysis); chr2:161299749 chr2:161244739~161249050:+ CESC cis rs1799949 1 rs11653253 ENSG00000267681.1 CTD-3199J23.6 -4.78 3.25e-06 0.00213 -0.42 -0.31 Menopause (age at onset); chr17:43030645 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs12951869 ENSG00000267681.1 CTD-3199J23.6 -4.78 3.25e-06 0.00213 -0.42 -0.31 Menopause (age at onset); chr17:43035550 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs11654452 ENSG00000267681.1 CTD-3199J23.6 -4.78 3.25e-06 0.00213 -0.42 -0.31 Menopause (age at onset); chr17:43037366 chr17:43144956~43145255:+ CESC cis rs73086581 1 rs6052217 ENSG00000229539.1 RP11-119B16.2 4.78 3.26e-06 0.00213 0.47 0.31 Response to antidepressants in depression; chr20:3989564 chr20:3888239~3888868:- CESC cis rs73086581 1 rs6052218 ENSG00000229539.1 RP11-119B16.2 4.78 3.26e-06 0.00213 0.47 0.31 Response to antidepressants in depression; chr20:3989565 chr20:3888239~3888868:- CESC cis rs73086581 0.945 rs6052219 ENSG00000229539.1 RP11-119B16.2 4.78 3.26e-06 0.00213 0.47 0.31 Response to antidepressants in depression; chr20:3989660 chr20:3888239~3888868:- CESC cis rs9918079 0.56 rs4270584 ENSG00000273133.1 RP11-799M12.2 4.78 3.26e-06 0.00213 0.39 0.31 Obesity-related traits; chr4:15599176 chr4:15563698~15564253:- CESC cis rs1707322 0.927 rs6690386 ENSG00000281133.1 AL355480.3 -4.78 3.26e-06 0.00213 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45787339 chr1:45580892~45580996:- CESC cis rs75422866 0.867 rs76100981 ENSG00000274902.1 RP1-197B17.4 4.78 3.27e-06 0.00214 0.71 0.31 Pneumonia; chr12:47660092 chr12:47731908~47732351:+ CESC cis rs16863064 0.66 rs1007308 ENSG00000279891.1 FLJ42393 -4.78 3.27e-06 0.00214 -0.39 -0.31 Schizophrenia; chr3:188171935 chr3:188178543~188180812:+ CESC cis rs3096299 0.933 rs889576 ENSG00000274627.1 RP11-104N10.2 -4.78 3.28e-06 0.00214 -0.3 -0.31 Multiple myeloma (IgH translocation); chr16:89363245 chr16:89516797~89522217:+ CESC cis rs801193 0.613 rs2659900 ENSG00000232559.3 GS1-124K5.12 4.78 3.28e-06 0.00215 0.33 0.31 Aortic root size; chr7:66719456 chr7:66554588~66576923:- CESC cis rs801193 0.636 rs2659895 ENSG00000232559.3 GS1-124K5.12 4.78 3.28e-06 0.00215 0.33 0.31 Aortic root size; chr7:66731484 chr7:66554588~66576923:- CESC cis rs2243480 0.711 rs1626926 ENSG00000228409.4 CCT6P1 4.78 3.28e-06 0.00215 0.43 0.31 Diabetic kidney disease; chr7:65970805 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs781142 ENSG00000228409.4 CCT6P1 4.78 3.28e-06 0.00215 0.43 0.31 Diabetic kidney disease; chr7:65973791 chr7:65751142~65763354:+ CESC cis rs875971 0.862 rs1875057 ENSG00000222364.1 RNU6-96P 4.78 3.28e-06 0.00215 0.36 0.31 Aortic root size; chr7:66266868 chr7:66395191~66395286:+ CESC cis rs12439619 0.739 rs62012046 ENSG00000276710.3 CSPG4P8 -4.78 3.29e-06 0.00215 -0.46 -0.31 Intelligence (multi-trait analysis); chr15:82236824 chr15:82459472~82477258:+ CESC cis rs12439619 0.774 rs62012047 ENSG00000276710.3 CSPG4P8 -4.78 3.29e-06 0.00215 -0.46 -0.31 Intelligence (multi-trait analysis); chr15:82236852 chr15:82459472~82477258:+ CESC cis rs12439619 0.81 rs62012049 ENSG00000276710.3 CSPG4P8 -4.78 3.29e-06 0.00215 -0.46 -0.31 Intelligence (multi-trait analysis); chr15:82237722 chr15:82459472~82477258:+ CESC cis rs801193 0.66 rs974239 ENSG00000232559.3 GS1-124K5.12 4.78 3.29e-06 0.00215 0.34 0.31 Aortic root size; chr7:66748504 chr7:66554588~66576923:- CESC cis rs2732480 0.5 rs1552550 ENSG00000258273.1 RP11-370I10.4 -4.78 3.29e-06 0.00215 -0.38 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48249568 chr12:48333755~48333901:- CESC cis rs2732480 0.5 rs2450991 ENSG00000258273.1 RP11-370I10.4 -4.78 3.29e-06 0.00215 -0.38 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48257838 chr12:48333755~48333901:- CESC cis rs9847710 0.524 rs11712910 ENSG00000242142.1 SERBP1P3 4.78 3.29e-06 0.00215 0.37 0.31 Ulcerative colitis; chr3:53060178 chr3:53064283~53065091:- CESC cis rs17711722 0.51 rs11767457 ENSG00000234585.5 CCT6P3 4.78 3.29e-06 0.00215 0.34 0.31 Calcium levels; chr7:65825628 chr7:65038354~65074713:+ CESC cis rs17608059 0.679 rs9898056 ENSG00000141028.6 CDRT15P1 -4.78 3.29e-06 0.00215 -0.32 -0.31 Temperament; chr17:14048649 chr17:14024514~14025488:+ CESC cis rs6991838 0.733 rs10111844 ENSG00000200714.1 Y_RNA 4.78 3.29e-06 0.00215 0.36 0.31 Intelligence (multi-trait analysis); chr8:65690374 chr8:65592731~65592820:+ CESC cis rs4660456 0.913 rs657149 ENSG00000237899.1 RP4-739H11.3 4.78 3.3e-06 0.00215 0.41 0.31 Platelet count; chr1:40692486 chr1:40669089~40687588:- CESC cis rs6142102 0.961 rs6088360 ENSG00000276073.1 RP5-1125A11.7 -4.77 3.3e-06 0.00216 -0.31 -0.31 Skin pigmentation; chr20:33969383 chr20:33985617~33988989:- CESC cis rs577676 0.586 rs666419 ENSG00000271811.1 RP1-79C4.4 4.77 3.3e-06 0.00216 0.42 0.31 Prevalent atrial fibrillation; chr1:170645103 chr1:170667381~170669425:+ CESC cis rs7621025 0.5 rs9845460 ENSG00000239213.4 NCK1-AS1 4.77 3.31e-06 0.00216 0.38 0.31 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136868275 chr3:136841726~136862054:- CESC cis rs6782228 0.585 rs6774515 ENSG00000242551.2 POU5F1P6 -4.77 3.31e-06 0.00216 -0.35 -0.31 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128697035 chr3:128674735~128677005:- CESC cis rs875971 0.798 rs12698522 ENSG00000222364.1 RNU6-96P -4.77 3.31e-06 0.00216 -0.37 -0.31 Aortic root size; chr7:66502354 chr7:66395191~66395286:+ CESC cis rs875971 0.83 rs28714531 ENSG00000222364.1 RNU6-96P -4.77 3.31e-06 0.00216 -0.37 -0.31 Aortic root size; chr7:66503250 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs12698526 ENSG00000222364.1 RNU6-96P -4.77 3.31e-06 0.00216 -0.37 -0.31 Aortic root size; chr7:66504118 chr7:66395191~66395286:+ CESC cis rs9660180 0.967 rs12034740 ENSG00000268575.1 RP1-283E3.8 -4.77 3.32e-06 0.00217 -0.31 -0.31 Body mass index; chr1:1797530 chr1:1702736~1737688:- CESC cis rs9322193 0.923 rs9689716 ENSG00000268592.3 RAET1E-AS1 4.77 3.32e-06 0.00217 0.39 0.31 Lung cancer; chr6:149655662 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9322207 ENSG00000268592.3 RAET1E-AS1 4.77 3.32e-06 0.00217 0.39 0.31 Lung cancer; chr6:149657185 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9322208 ENSG00000268592.3 RAET1E-AS1 4.77 3.32e-06 0.00217 0.39 0.31 Lung cancer; chr6:149658547 chr6:149863494~149919507:+ CESC cis rs4819052 0.808 rs2246697 ENSG00000223768.1 LINC00205 -4.77 3.32e-06 0.00217 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45270084 chr21:45293285~45297354:+ CESC cis rs4819052 0.819 rs7279136 ENSG00000223768.1 LINC00205 -4.77 3.32e-06 0.00217 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45272372 chr21:45293285~45297354:+ CESC cis rs4819052 0.788 rs4819051 ENSG00000223768.1 LINC00205 -4.77 3.32e-06 0.00217 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45273213 chr21:45293285~45297354:+ CESC cis rs4819052 0.819 rs8134084 ENSG00000223768.1 LINC00205 -4.77 3.32e-06 0.00217 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45273380 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs7276828 ENSG00000223768.1 LINC00205 -4.77 3.32e-06 0.00217 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45275124 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs7281263 ENSG00000223768.1 LINC00205 -4.77 3.32e-06 0.00217 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45275691 chr21:45293285~45297354:+ CESC cis rs75422866 0.867 rs73102140 ENSG00000280054.1 RP1-197B17.7 4.77 3.33e-06 0.00217 0.8 0.31 Pneumonia; chr12:47647497 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102148 ENSG00000280054.1 RP1-197B17.7 4.77 3.33e-06 0.00217 0.8 0.31 Pneumonia; chr12:47648013 chr12:47728151~47730598:- CESC cis rs75422866 0.867 rs73102151 ENSG00000280054.1 RP1-197B17.7 4.77 3.33e-06 0.00217 0.8 0.31 Pneumonia; chr12:47648023 chr12:47728151~47730598:- CESC cis rs10875746 0.669 rs11168487 ENSG00000240399.1 RP1-228P16.1 -4.77 3.33e-06 0.00217 -0.4 -0.31 Longevity (90 years and older); chr12:48246926 chr12:48054813~48055591:- CESC cis rs11159086 1 rs4899516 ENSG00000259005.1 RP3-449M8.6 4.77 3.33e-06 0.00217 0.49 0.31 Advanced glycation end-product levels; chr14:74492825 chr14:74474007~74474864:- CESC cis rs6452524 0.868 rs2386235 ENSG00000249664.1 CTD-2227C6.2 4.77 3.33e-06 0.00217 0.37 0.31 Hypertension (SNP x SNP interaction); chr5:83101452 chr5:83012285~83013109:- CESC cis rs2177312 0.52 rs7688645 ENSG00000251129.1 RP11-734I18.1 -4.77 3.33e-06 0.00217 -0.4 -0.31 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31925432 chr4:31997397~32155406:+ CESC cis rs14027 0.64 rs10096846 ENSG00000279347.1 RP11-85I17.2 -4.77 3.34e-06 0.00218 -0.29 -0.31 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119760884 chr8:119838736~119840385:- CESC cis rs9322193 0.962 rs2342861 ENSG00000216906.2 RP11-350J20.9 4.77 3.35e-06 0.00218 0.34 0.31 Lung cancer; chr6:149777561 chr6:149904243~149906418:+ CESC cis rs9322193 0.926 rs2342860 ENSG00000216906.2 RP11-350J20.9 4.77 3.35e-06 0.00218 0.34 0.31 Lung cancer; chr6:149777641 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs10872653 ENSG00000216906.2 RP11-350J20.9 4.77 3.35e-06 0.00218 0.34 0.31 Lung cancer; chr6:149778907 chr6:149904243~149906418:+ CESC cis rs6142102 0.659 rs6057945 ENSG00000276073.1 RP5-1125A11.7 -4.77 3.35e-06 0.00218 -0.3 -0.31 Skin pigmentation; chr20:33929374 chr20:33985617~33988989:- CESC cis rs9918079 0.56 rs10008975 ENSG00000273133.1 RP11-799M12.2 -4.77 3.35e-06 0.00218 -0.39 -0.31 Obesity-related traits; chr4:15622948 chr4:15563698~15564253:- CESC cis rs1862618 0.853 rs2548665 ENSG00000271828.1 CTD-2310F14.1 4.77 3.35e-06 0.00218 0.42 0.31 Initial pursuit acceleration; chr5:56835978 chr5:56927874~56929573:+ CESC cis rs1862618 0.802 rs2591949 ENSG00000271828.1 CTD-2310F14.1 4.77 3.35e-06 0.00218 0.42 0.31 Initial pursuit acceleration; chr5:56836800 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs2548664 ENSG00000271828.1 CTD-2310F14.1 4.77 3.35e-06 0.00218 0.42 0.31 Initial pursuit acceleration; chr5:56837728 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs3099459 ENSG00000271828.1 CTD-2310F14.1 4.77 3.35e-06 0.00218 0.42 0.31 Initial pursuit acceleration; chr5:56841343 chr5:56927874~56929573:+ CESC cis rs9322193 0.923 rs11155683 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149779341 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9372044 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149780867 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs11155685 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149781649 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9322220 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149782897 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs10214845 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149783124 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9767122 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149783553 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs1413654 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149783956 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9688809 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149787920 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9689242 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149787970 chr6:149904243~149906418:+ CESC cis rs9322193 1 rs9767077 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149788479 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9688938 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149788941 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9688940 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149788977 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9689447 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149789350 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs9689269 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149791861 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs62441335 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149792658 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs4816 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149793609 chr6:149904243~149906418:+ CESC cis rs9322193 0.926 rs952166 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149798774 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs952165 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149798900 chr6:149904243~149906418:+ CESC cis rs9322193 0.926 rs9285525 ENSG00000216906.2 RP11-350J20.9 4.77 3.36e-06 0.00218 0.34 0.31 Lung cancer; chr6:149801253 chr6:149904243~149906418:+ CESC cis rs2732480 0.5 rs2450986 ENSG00000258273.1 RP11-370I10.4 -4.77 3.36e-06 0.00219 -0.38 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48267905 chr12:48333755~48333901:- CESC cis rs1387259 0.929 rs2634666 ENSG00000258273.1 RP11-370I10.4 -4.77 3.36e-06 0.00219 -0.38 -0.31 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48269887 chr12:48333755~48333901:- CESC cis rs8059260 0.542 rs11860851 ENSG00000274038.1 RP11-66H6.4 -4.77 3.36e-06 0.00219 -0.49 -0.31 Alcohol consumption over the past year; chr16:11033893 chr16:11056556~11057034:+ CESC cis rs11846409 0.932 rs60659763 ENSG00000211974.3 IGHV2-70 -4.77 3.36e-06 0.00219 -0.4 -0.31 Rheumatic heart disease; chr14:106634172 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs57080270 ENSG00000211974.3 IGHV2-70 -4.77 3.36e-06 0.00219 -0.4 -0.31 Rheumatic heart disease; chr14:106634215 chr14:106723574~106724093:- CESC cis rs9322193 0.962 rs9688750 ENSG00000268592.3 RAET1E-AS1 4.77 3.36e-06 0.00219 0.39 0.31 Lung cancer; chr6:149657633 chr6:149863494~149919507:+ CESC cis rs10875746 0.556 rs4760619 ENSG00000240399.1 RP1-228P16.1 -4.77 3.36e-06 0.00219 -0.46 -0.31 Longevity (90 years and older); chr12:48106148 chr12:48054813~48055591:- CESC cis rs2276314 0.857 rs6507158 ENSG00000278986.1 RP11-723J4.3 -4.77 3.37e-06 0.0022 -0.34 -0.31 Endometriosis;Drug-induced torsades de pointes; chr18:36056103 chr18:35972151~35973916:+ CESC cis rs9322193 0.962 rs3763162 ENSG00000216906.2 RP11-350J20.9 -4.77 3.37e-06 0.0022 -0.35 -0.31 Lung cancer; chr6:149819674 chr6:149904243~149906418:+ CESC cis rs875971 0.545 rs1547529 ENSG00000222364.1 RNU6-96P -4.77 3.38e-06 0.0022 -0.39 -0.31 Aortic root size; chr7:66258859 chr7:66395191~66395286:+ CESC cis rs9402743 0.816 rs9494327 ENSG00000217482.2 HMGB1P17 4.77 3.38e-06 0.0022 0.36 0.31 Systemic lupus erythematosus; chr6:135674898 chr6:135636086~135636713:- CESC cis rs17608059 0.71 rs8080167 ENSG00000141028.6 CDRT15P1 -4.77 3.38e-06 0.0022 -0.32 -0.31 Temperament; chr17:14046511 chr17:14024514~14025488:+ CESC cis rs7208859 0.623 rs9895785 ENSG00000266490.1 CTD-2349P21.9 -4.77 3.38e-06 0.0022 -0.46 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780690 chr17:30792372~30792833:+ CESC cis rs35160687 0.787 rs10186289 ENSG00000273080.1 RP11-301O19.1 4.77 3.38e-06 0.0022 0.33 0.31 Night sleep phenotypes; chr2:86285865 chr2:86195590~86196049:+ CESC cis rs860295 0.702 rs12040100 ENSG00000225855.5 RUSC1-AS1 4.77 3.38e-06 0.0022 0.26 0.31 Body mass index; chr1:155642056 chr1:155316863~155324176:- CESC cis rs73086581 0.947 rs11906612 ENSG00000229539.1 RP11-119B16.2 4.77 3.39e-06 0.0022 0.53 0.31 Response to antidepressants in depression; chr20:3922987 chr20:3888239~3888868:- CESC cis rs1707322 0.785 rs10890348 ENSG00000281133.1 AL355480.3 -4.77 3.4e-06 0.00221 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776751 chr1:45580892~45580996:- CESC cis rs4722166 0.645 rs1404006 ENSG00000179428.2 AC073072.5 -4.77 3.4e-06 0.00221 -0.39 -0.31 Lung cancer; chr7:22755458 chr7:22725395~22727620:- CESC cis rs113835537 0.877 rs57127845 ENSG00000255517.5 CTD-3074O7.5 -4.77 3.41e-06 0.00221 -0.49 -0.31 Airway imaging phenotypes; chr11:66550854 chr11:66473490~66480233:- CESC cis rs5769707 0.521 rs6009810 ENSG00000235111.1 RP1-29C18.8 -4.77 3.41e-06 0.00221 -0.34 -0.31 Monocyte percentage of white cells;Monocyte count; chr22:49665892 chr22:49612657~49615716:- CESC cis rs2732480 0.577 rs2634684 ENSG00000258273.1 RP11-370I10.4 4.77 3.41e-06 0.00221 0.38 0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48337092 chr12:48333755~48333901:- CESC cis rs6686842 1 rs6686842 ENSG00000235358.1 RP11-399E6.1 4.77 3.41e-06 0.00221 0.37 0.31 Height; chr1:41065199 chr1:41242373~41284861:+ CESC cis rs9322193 0.923 rs7769101 ENSG00000268592.3 RAET1E-AS1 4.77 3.41e-06 0.00221 0.42 0.31 Lung cancer; chr6:149848768 chr6:149863494~149919507:+ CESC cis rs1799949 1 rs9646417 ENSG00000267681.1 CTD-3199J23.6 -4.77 3.41e-06 0.00221 -0.41 -0.31 Menopause (age at onset); chr17:43346885 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs1545764 ENSG00000267681.1 CTD-3199J23.6 -4.77 3.41e-06 0.00221 -0.41 -0.31 Menopause (age at onset); chr17:43347197 chr17:43144956~43145255:+ CESC cis rs9640161 0.75 rs1983440 ENSG00000261305.1 RP4-584D14.7 4.77 3.41e-06 0.00221 0.42 0.31 Blood protein levels;Circulating chemerin levels; chr7:150326852 chr7:150341771~150342607:+ CESC cis rs1061377 0.71 rs12503506 ENSG00000249207.1 RP11-360F5.1 -4.77 3.42e-06 0.00222 -0.36 -0.31 Uric acid levels; chr4:39082553 chr4:39112677~39126818:- CESC cis rs3124314 1 rs2999563 ENSG00000229021.2 AL591893.1 -4.77 3.42e-06 0.00222 -0.33 -0.31 Hair morphology; chr1:152074519 chr1:151994531~152042774:+ CESC cis rs12439619 0.846 rs62012056 ENSG00000255769.6 GOLGA2P10 -4.77 3.42e-06 0.00222 -0.47 -0.31 Intelligence (multi-trait analysis); chr15:82247278 chr15:82472993~82513950:- CESC cis rs7615952 0.641 rs4490307 ENSG00000250012.1 RP11-124N2.1 -4.77 3.42e-06 0.00222 -0.32 -0.31 Blood pressure (smoking interaction); chr3:125993833 chr3:126084220~126095349:+ CESC cis rs2836950 0.545 rs8132143 ENSG00000232608.1 TIMM9P2 4.77 3.43e-06 0.00223 0.34 0.31 Menarche (age at onset); chr21:39212332 chr21:39216624~39217506:+ CESC cis rs12134133 1 rs28371583 ENSG00000274245.1 RP11-357P18.2 4.77 3.43e-06 0.00223 0.4 0.31 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207321334 chr1:207372559~207373252:+ CESC cis rs8042680 0.688 rs2386584 ENSG00000214432.8 AC068831.10 -4.77 3.43e-06 0.00223 -0.38 -0.31 Type 2 diabetes; chr15:90996342 chr15:91022619~91036611:+ CESC cis rs11157436 1 rs2293731 ENSG00000211813.2 TRAV34 4.77 3.43e-06 0.00223 0.34 0.31 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22148880 chr14:22207522~22208129:+ CESC cis rs763567 0.626 rs1234230 ENSG00000271811.1 RP1-79C4.4 -4.77 3.44e-06 0.00223 -0.36 -0.31 Tonsillectomy; chr1:170602702 chr1:170667381~170669425:+ CESC cis rs1862618 0.853 rs252902 ENSG00000271828.1 CTD-2310F14.1 4.77 3.44e-06 0.00223 0.41 0.31 Initial pursuit acceleration; chr5:56820258 chr5:56927874~56929573:+ CESC cis rs4819052 0.851 rs8127834 ENSG00000223768.1 LINC00205 -4.77 3.45e-06 0.00224 -0.36 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45276194 chr21:45293285~45297354:+ CESC cis rs8100891 0.537 rs10415744 ENSG00000267213.4 AC007773.2 -4.76 3.45e-06 0.00224 -0.48 -0.31 Neuroticism; chr19:32389674 chr19:32390050~32405560:- CESC cis rs2243480 1 rs958550 ENSG00000232559.3 GS1-124K5.12 -4.76 3.45e-06 0.00224 -0.53 -0.31 Diabetic kidney disease; chr7:66170692 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316332 ENSG00000275400.1 RP4-756H11.5 4.76 3.46e-06 0.00224 0.52 0.31 Diabetic kidney disease; chr7:66139312 chr7:66553805~66554199:- CESC cis rs1799949 1 rs4793189 ENSG00000267681.1 CTD-3199J23.6 -4.76 3.46e-06 0.00224 -0.42 -0.31 Menopause (age at onset); chr17:43038698 chr17:43144956~43145255:+ CESC cis rs13108904 0.901 rs2293634 ENSG00000253399.1 AC078852.2 -4.76 3.46e-06 0.00225 -0.37 -0.31 Obesity-related traits; chr4:1297923 chr4:1358479~1359461:+ CESC cis rs875971 0.862 rs1695820 ENSG00000232559.3 GS1-124K5.12 4.76 3.46e-06 0.00225 0.33 0.31 Aortic root size; chr7:66379576 chr7:66554588~66576923:- CESC cis rs875971 0.83 rs778715 ENSG00000232559.3 GS1-124K5.12 4.76 3.46e-06 0.00225 0.33 0.31 Aortic root size; chr7:66384222 chr7:66554588~66576923:- CESC cis rs875971 0.83 rs809025 ENSG00000232559.3 GS1-124K5.12 4.76 3.46e-06 0.00225 0.33 0.31 Aortic root size; chr7:66384832 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs778702 ENSG00000232559.3 GS1-124K5.12 4.76 3.46e-06 0.00225 0.33 0.31 Aortic root size; chr7:66399848 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs1643375 ENSG00000232559.3 GS1-124K5.12 4.76 3.46e-06 0.00225 0.33 0.31 Aortic root size; chr7:66407690 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6962717 ENSG00000232559.3 GS1-124K5.12 4.76 3.46e-06 0.00225 0.33 0.31 Aortic root size; chr7:66418748 chr7:66554588~66576923:- CESC cis rs2028299 0.959 rs4932144 ENSG00000259677.1 RP11-493E3.1 4.76 3.47e-06 0.00225 0.43 0.31 Type 2 diabetes; chr15:89828870 chr15:89876540~89877285:+ CESC cis rs12134133 1 rs2490261 ENSG00000274245.1 RP11-357P18.2 4.76 3.47e-06 0.00225 0.39 0.31 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207304124 chr1:207372559~207373252:+ CESC cis rs2299587 0.932 rs12547946 ENSG00000253671.1 RP11-806O11.1 -4.76 3.47e-06 0.00225 -0.32 -0.31 Economic and political preferences; chr8:18000928 chr8:17808941~17820868:+ CESC cis rs9532669 0.927 rs9532670 ENSG00000176268.5 CYCSP34 -4.76 3.47e-06 0.00225 -0.32 -0.31 Cervical cancer; chr13:40927691 chr13:40863599~40863902:- CESC cis rs9322193 0.632 rs3828700 ENSG00000216906.2 RP11-350J20.9 4.76 3.47e-06 0.00225 0.34 0.31 Lung cancer; chr6:149791033 chr6:149904243~149906418:+ CESC cis rs75422866 0.867 rs73113139 ENSG00000280054.1 RP1-197B17.7 4.76 3.47e-06 0.00225 0.79 0.31 Pneumonia; chr12:47622826 chr12:47728151~47730598:- CESC cis rs9876781 0.559 rs7630053 ENSG00000229759.1 MRPS18AP1 4.76 3.48e-06 0.00226 0.3 0.31 Longevity; chr3:48357096 chr3:48256350~48256938:- CESC cis rs6452524 0.868 rs10045104 ENSG00000249664.1 CTD-2227C6.2 4.76 3.48e-06 0.00226 0.37 0.31 Hypertension (SNP x SNP interaction); chr5:83116543 chr5:83012285~83013109:- CESC cis rs2243480 1 rs465359 ENSG00000275400.1 RP4-756H11.5 4.76 3.49e-06 0.00226 0.53 0.31 Diabetic kidney disease; chr7:66093177 chr7:66553805~66554199:- CESC cis rs2243480 1 rs462853 ENSG00000275400.1 RP4-756H11.5 4.76 3.49e-06 0.00226 0.53 0.31 Diabetic kidney disease; chr7:66093180 chr7:66553805~66554199:- CESC cis rs2243480 1 rs160644 ENSG00000275400.1 RP4-756H11.5 4.76 3.49e-06 0.00226 0.53 0.31 Diabetic kidney disease; chr7:66093199 chr7:66553805~66554199:- CESC cis rs2243480 1 rs160642 ENSG00000275400.1 RP4-756H11.5 4.76 3.49e-06 0.00226 0.53 0.31 Diabetic kidney disease; chr7:66093386 chr7:66553805~66554199:- CESC cis rs2243480 0.614 rs34032527 ENSG00000275400.1 RP4-756H11.5 4.76 3.49e-06 0.00226 0.53 0.31 Diabetic kidney disease; chr7:66100154 chr7:66553805~66554199:- CESC cis rs2243480 1 rs160646 ENSG00000275400.1 RP4-756H11.5 4.76 3.49e-06 0.00226 0.53 0.31 Diabetic kidney disease; chr7:66091293 chr7:66553805~66554199:- CESC cis rs42490 0.903 rs218948 ENSG00000251136.7 RP11-37B2.1 -4.76 3.49e-06 0.00226 -0.32 -0.31 Leprosy; chr8:89705617 chr8:89609409~89757727:- CESC cis rs7208859 0.524 rs8069400 ENSG00000266490.1 CTD-2349P21.9 4.76 3.49e-06 0.00226 0.47 0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748949 chr17:30792372~30792833:+ CESC cis rs1062177 0.855 rs62395861 ENSG00000213433.5 RPLP1P6 -4.76 3.49e-06 0.00226 -0.39 -0.31 Preschool internalizing problems; chr5:151889709 chr5:151765859~151766378:- CESC cis rs1062177 0.95 rs59580263 ENSG00000213433.5 RPLP1P6 -4.76 3.49e-06 0.00226 -0.39 -0.31 Preschool internalizing problems; chr5:151890016 chr5:151765859~151766378:- CESC cis rs875971 0.528 rs801213 ENSG00000237310.1 GS1-124K5.4 -4.76 3.49e-06 0.00226 -0.33 -0.31 Aortic root size; chr7:66549931 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs801212 ENSG00000237310.1 GS1-124K5.4 -4.76 3.49e-06 0.00226 -0.33 -0.31 Aortic root size; chr7:66550643 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs801199 ENSG00000237310.1 GS1-124K5.4 -4.76 3.49e-06 0.00226 -0.33 -0.31 Aortic root size; chr7:66560286 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs1267814 ENSG00000237310.1 GS1-124K5.4 -4.76 3.49e-06 0.00226 -0.33 -0.31 Aortic root size; chr7:66579422 chr7:66493706~66495474:+ CESC cis rs2564921 0.654 rs73087044 ENSG00000242142.1 SERBP1P3 -4.76 3.49e-06 0.00226 -0.37 -0.31 Height; chr3:52975027 chr3:53064283~53065091:- CESC cis rs11159086 0.793 rs28612392 ENSG00000270000.1 RP3-449M8.9 4.76 3.49e-06 0.00226 0.5 0.31 Advanced glycation end-product levels; chr14:74467894 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs11625502 ENSG00000270000.1 RP3-449M8.9 4.76 3.49e-06 0.00226 0.5 0.31 Advanced glycation end-product levels; chr14:74468309 chr14:74471930~74472360:- CESC cis rs9640161 0.75 rs11764936 ENSG00000261305.1 RP4-584D14.7 4.76 3.5e-06 0.00226 0.43 0.31 Blood protein levels;Circulating chemerin levels; chr7:150328826 chr7:150341771~150342607:+ CESC cis rs2946504 0.501 rs2977092 ENSG00000251468.2 RP11-369K16.1 -4.76 3.5e-06 0.00226 -0.38 -0.31 Type 2 diabetes; chr8:12949867 chr8:12958387~12962200:+ CESC cis rs2836950 0.565 rs4816617 ENSG00000232608.1 TIMM9P2 4.76 3.5e-06 0.00226 0.34 0.31 Menarche (age at onset); chr21:39168764 chr21:39216624~39217506:+ CESC cis rs7809950 0.954 rs2520243 ENSG00000238832.1 snoU109 -4.76 3.5e-06 0.00227 -0.36 -0.31 Coronary artery disease; chr7:107496528 chr7:107603363~107603507:+ CESC cis rs7809950 0.953 rs3094383 ENSG00000238832.1 snoU109 -4.76 3.5e-06 0.00227 -0.36 -0.31 Coronary artery disease; chr7:107502719 chr7:107603363~107603507:+ CESC cis rs7809950 0.954 rs2520247 ENSG00000238832.1 snoU109 -4.76 3.5e-06 0.00227 -0.36 -0.31 Coronary artery disease; chr7:107503501 chr7:107603363~107603507:+ CESC cis rs9322193 0.884 rs9688858 ENSG00000216906.2 RP11-350J20.9 4.76 3.51e-06 0.00227 0.33 0.31 Lung cancer; chr6:149637911 chr6:149904243~149906418:+ CESC cis rs6452524 0.868 rs10057303 ENSG00000249664.1 CTD-2227C6.2 4.76 3.51e-06 0.00227 0.37 0.31 Hypertension (SNP x SNP interaction); chr5:83098564 chr5:83012285~83013109:- CESC cis rs2243480 1 rs160655 ENSG00000275400.1 RP4-756H11.5 4.76 3.51e-06 0.00227 0.52 0.31 Diabetic kidney disease; chr7:66068227 chr7:66553805~66554199:- CESC cis rs2732480 0.5 rs12828309 ENSG00000258273.1 RP11-370I10.4 -4.76 3.51e-06 0.00227 -0.37 -0.31 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48247377 chr12:48333755~48333901:- CESC cis rs9322193 0.923 rs7769101 ENSG00000216906.2 RP11-350J20.9 4.76 3.52e-06 0.00228 0.36 0.31 Lung cancer; chr6:149848768 chr6:149904243~149906418:+ CESC cis rs12439619 0.846 rs7496227 ENSG00000255769.6 GOLGA2P10 -4.76 3.52e-06 0.00228 -0.46 -0.31 Intelligence (multi-trait analysis); chr15:82275241 chr15:82472993~82513950:- CESC cis rs3096299 0.933 rs28608022 ENSG00000274627.1 RP11-104N10.2 4.76 3.52e-06 0.00228 0.3 0.31 Multiple myeloma (IgH translocation); chr16:89387884 chr16:89516797~89522217:+ CESC cis rs889512 0.642 rs8046145 ENSG00000280152.1 RP11-331F4.5 -4.76 3.53e-06 0.00228 -0.44 -0.31 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75261123 chr16:75245994~75250077:- CESC cis rs10463554 0.895 rs12656561 ENSG00000175749.11 EIF3KP1 4.76 3.53e-06 0.00228 0.32 0.31 Parkinson's disease; chr5:102989988 chr5:103032376~103033031:+ CESC cis rs875971 0.545 rs73148639 ENSG00000237310.1 GS1-124K5.4 4.76 3.54e-06 0.00229 0.33 0.31 Aortic root size; chr7:66390342 chr7:66493706~66495474:+ CESC cis rs1012068 1 rs1012068 ENSG00000236132.1 CTA-440B3.1 -4.76 3.54e-06 0.00229 -0.36 -0.31 Chronic hepatitis C infection; chr22:31869917 chr22:31816379~31817491:- CESC cis rs875971 0.862 rs2088655 ENSG00000222364.1 RNU6-96P 4.76 3.54e-06 0.00229 0.36 0.31 Aortic root size; chr7:66330724 chr7:66395191~66395286:+ CESC cis rs875971 0.895 rs10447522 ENSG00000222364.1 RNU6-96P 4.76 3.54e-06 0.00229 0.36 0.31 Aortic root size; chr7:66331087 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs2088653 ENSG00000222364.1 RNU6-96P 4.76 3.54e-06 0.00229 0.36 0.31 Aortic root size; chr7:66343621 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6460293 ENSG00000222364.1 RNU6-96P 4.76 3.54e-06 0.00229 0.36 0.31 Aortic root size; chr7:66345205 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs778736 ENSG00000222364.1 RNU6-96P -4.76 3.54e-06 0.00229 -0.36 -0.31 Aortic root size; chr7:66348861 chr7:66395191~66395286:+ CESC cis rs2111504 0.583 rs1008425 ENSG00000267213.4 AC007773.2 4.76 3.55e-06 0.00229 0.37 0.31 Bipolar disorder; chr19:32361239 chr19:32390050~32405560:- CESC cis rs1538970 0.816 rs10789464 ENSG00000280836.1 AL355480.1 -4.76 3.55e-06 0.00229 -0.39 -0.31 Platelet count; chr1:45493430 chr1:45581219~45581321:- CESC cis rs42490 0.903 rs7824932 ENSG00000251136.7 RP11-37B2.1 4.76 3.55e-06 0.00229 0.31 0.31 Leprosy; chr8:89703848 chr8:89609409~89757727:- CESC cis rs2028299 1 rs4932148 ENSG00000259677.1 RP11-493E3.1 4.76 3.55e-06 0.0023 0.41 0.31 Type 2 diabetes; chr15:89851124 chr15:89876540~89877285:+ CESC cis rs77204473 1 rs17120157 ENSG00000254851.1 RP11-109L13.1 -4.76 3.55e-06 0.0023 -0.63 -0.31 Sum eosinophil basophil counts;Eosinophil counts; chr11:116941912 chr11:117135528~117138582:+ CESC cis rs9813712 0.571 rs11715351 ENSG00000228252.7 COL6A4P2 -4.76 3.55e-06 0.0023 -0.36 -0.31 Response to amphetamines; chr3:130214704 chr3:130212823~130273806:+ CESC cis rs6991838 0.671 rs13251307 ENSG00000272010.1 CTD-3025N20.3 4.76 3.56e-06 0.0023 0.33 0.31 Intelligence (multi-trait analysis); chr8:65664911 chr8:65591850~65592472:- CESC cis rs7777677 0.925 rs4726540 ENSG00000244273.1 PGBD4P1 -4.76 3.56e-06 0.0023 -0.33 -0.31 Alcoholic chronic pancreatitis; chr7:142658771 chr7:142722358~142722764:+ CESC cis rs2564921 0.666 rs11130335 ENSG00000242142.1 SERBP1P3 -4.76 3.56e-06 0.0023 -0.39 -0.31 Height; chr3:52989619 chr3:53064283~53065091:- CESC cis rs8100891 0.537 rs28672356 ENSG00000267213.4 AC007773.2 -4.76 3.57e-06 0.0023 -0.47 -0.31 Neuroticism; chr19:32416937 chr19:32390050~32405560:- CESC cis rs12439619 0.705 rs4778665 ENSG00000255769.6 GOLGA2P10 -4.76 3.57e-06 0.00231 -0.48 -0.31 Intelligence (multi-trait analysis); chr15:82144163 chr15:82472993~82513950:- CESC cis rs6964833 0.935 rs35735900 ENSG00000277053.3 GTF2IP1 -4.76 3.58e-06 0.00231 -0.37 -0.31 Menarche (age at onset); chr7:74651887 chr7:75185385~75237696:- CESC cis rs6964833 0.872 rs4717903 ENSG00000277053.3 GTF2IP1 -4.76 3.58e-06 0.00231 -0.37 -0.31 Menarche (age at onset); chr7:74653827 chr7:75185385~75237696:- CESC cis rs6964833 1 rs4717906 ENSG00000277053.3 GTF2IP1 -4.76 3.58e-06 0.00231 -0.37 -0.31 Menarche (age at onset); chr7:74671923 chr7:75185385~75237696:- CESC cis rs4423214 0.592 rs7114252 ENSG00000254682.1 RP11-660L16.2 -4.76 3.58e-06 0.00231 -0.45 -0.31 Vitamin D levels; chr11:71526560 chr11:71448674~71452157:+ CESC cis rs8042680 0.915 rs7166743 ENSG00000214432.8 AC068831.10 -4.76 3.59e-06 0.00231 -0.38 -0.31 Type 2 diabetes; chr15:90971584 chr15:91022619~91036611:+ CESC cis rs11638352 0.661 rs2114422 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44128046 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs2555384 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44128702 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs2706490 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44130040 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs2706491 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44131631 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs2706492 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44131648 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs2042738 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44134355 chr15:44826371~44884694:- CESC cis rs11638352 1 rs1820485 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44138134 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs2114415 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44140696 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs1426657 ENSG00000259479.5 SORD2P -4.76 3.59e-06 0.00231 -0.44 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44142331 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs2555382 ENSG00000259479.5 SORD2P 4.76 3.59e-06 0.00231 0.44 0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44132118 chr15:44826371~44884694:- CESC cis rs11638352 0.661 rs2615269 ENSG00000259479.5 SORD2P 4.76 3.59e-06 0.00231 0.44 0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44135758 chr15:44826371~44884694:- CESC cis rs875971 0.862 rs28491091 ENSG00000222364.1 RNU6-96P 4.76 3.59e-06 0.00232 0.36 0.31 Aortic root size; chr7:66204077 chr7:66395191~66395286:+ CESC cis rs6452524 0.78 rs2386237 ENSG00000249664.1 CTD-2227C6.2 4.76 3.6e-06 0.00232 0.37 0.31 Hypertension (SNP x SNP interaction); chr5:83101852 chr5:83012285~83013109:- CESC cis rs832187 0.64 rs56293138 ENSG00000280620.1 SCAANT1 4.76 3.6e-06 0.00232 0.42 0.31 Schizophrenia; chr3:63903259 chr3:63911518~63911772:- CESC cis rs6504950 0.85 rs2628321 ENSG00000275710.1 RP11-257O5.4 4.75 3.61e-06 0.00233 0.34 0.31 Breast cancer; chr17:55128556 chr17:54964474~54964679:+ CESC cis rs2787486 1 rs2787486 ENSG00000275710.1 RP11-257O5.4 4.75 3.61e-06 0.00233 0.34 0.31 Breast cancer; chr17:55132413 chr17:54964474~54964679:+ CESC cis rs2842992 1 rs2758322 ENSG00000237927.1 RP3-393E18.2 -4.75 3.61e-06 0.00233 -0.4 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159654156 chr6:159586955~159589169:- CESC cis rs11159086 0.793 rs1029703 ENSG00000259005.1 RP3-449M8.6 4.75 3.61e-06 0.00233 0.43 0.31 Advanced glycation end-product levels; chr14:74473899 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs12432412 ENSG00000259005.1 RP3-449M8.6 4.75 3.61e-06 0.00233 0.43 0.31 Advanced glycation end-product levels; chr14:74474294 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs1029700 ENSG00000259005.1 RP3-449M8.6 4.75 3.61e-06 0.00233 0.43 0.31 Advanced glycation end-product levels; chr14:74474309 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs1029699 ENSG00000259005.1 RP3-449M8.6 4.75 3.61e-06 0.00233 0.43 0.31 Advanced glycation end-product levels; chr14:74474790 chr14:74474007~74474864:- CESC cis rs7927592 0.913 rs11228292 ENSG00000212093.1 AP000807.1 4.75 3.61e-06 0.00233 0.36 0.31 Total body bone mineral density; chr11:68612304 chr11:68506083~68506166:- CESC cis rs9660180 0.967 rs9660106 ENSG00000268575.1 RP1-283E3.8 -4.75 3.61e-06 0.00233 -0.31 -0.31 Body mass index; chr1:1866508 chr1:1702736~1737688:- CESC cis rs1862618 0.853 rs43184 ENSG00000271828.1 CTD-2310F14.1 4.75 3.61e-06 0.00233 0.42 0.31 Initial pursuit acceleration; chr5:56845950 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs33326 ENSG00000271828.1 CTD-2310F14.1 4.75 3.61e-06 0.00233 0.42 0.31 Initial pursuit acceleration; chr5:56846774 chr5:56927874~56929573:+ CESC cis rs1862618 0.802 rs33327 ENSG00000271828.1 CTD-2310F14.1 4.75 3.61e-06 0.00233 0.42 0.31 Initial pursuit acceleration; chr5:56846866 chr5:56927874~56929573:+ CESC cis rs3096299 0.874 rs3102342 ENSG00000274627.1 RP11-104N10.2 4.75 3.62e-06 0.00233 0.3 0.31 Multiple myeloma (IgH translocation); chr16:89385167 chr16:89516797~89522217:+ CESC cis rs9660180 0.837 rs915292 ENSG00000268575.1 RP1-283E3.8 -4.75 3.62e-06 0.00233 -0.31 -0.31 Body mass index; chr1:1860718 chr1:1702736~1737688:- CESC cis rs950880 0.71 rs55645612 ENSG00000234389.1 AC007278.3 -4.75 3.62e-06 0.00233 -0.33 -0.31 Serum protein levels (sST2); chr2:102439201 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs17027179 ENSG00000234389.1 AC007278.3 -4.75 3.62e-06 0.00233 -0.33 -0.31 Serum protein levels (sST2); chr2:102440699 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs11123927 ENSG00000234389.1 AC007278.3 -4.75 3.62e-06 0.00233 -0.33 -0.31 Serum protein levels (sST2); chr2:102442343 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs10490203 ENSG00000234389.1 AC007278.3 -4.75 3.62e-06 0.00233 -0.33 -0.31 Serum protein levels (sST2); chr2:102442777 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs4851583 ENSG00000234389.1 AC007278.3 -4.75 3.62e-06 0.00233 -0.33 -0.31 Serum protein levels (sST2); chr2:102443840 chr2:102438713~102440475:+ CESC cis rs11976180 1 rs2961134 ENSG00000273234.1 OR2A13P -4.75 3.63e-06 0.00234 -0.37 -0.31 Obesity-related traits; chr7:144073969 chr7:144142009~144142938:+ CESC cis rs5769707 0.632 rs1476037 ENSG00000235111.1 RP1-29C18.8 -4.75 3.63e-06 0.00234 -0.35 -0.31 Monocyte percentage of white cells;Monocyte count; chr22:49597729 chr22:49612657~49615716:- CESC cis rs10875746 0.669 rs10783244 ENSG00000240399.1 RP1-228P16.1 -4.75 3.63e-06 0.00234 -0.38 -0.31 Longevity (90 years and older); chr12:48271206 chr12:48054813~48055591:- CESC cis rs4819052 0.851 rs3673 ENSG00000223768.1 LINC00205 -4.75 3.63e-06 0.00234 -0.35 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45261860 chr21:45293285~45297354:+ CESC cis rs35955747 0.749 rs2027982 ENSG00000236132.1 CTA-440B3.1 4.75 3.64e-06 0.00234 0.35 0.31 Neutrophil count;Sum basophil neutrophil counts; chr22:31197449 chr22:31816379~31817491:- CESC cis rs2243480 1 rs34703416 ENSG00000228409.4 CCT6P1 4.75 3.64e-06 0.00234 0.43 0.31 Diabetic kidney disease; chr7:65835655 chr7:65751142~65763354:+ CESC cis rs7429990 0.965 rs1060407 ENSG00000229759.1 MRPS18AP1 4.75 3.65e-06 0.00235 0.32 0.31 Educational attainment (years of education); chr3:47916547 chr3:48256350~48256938:- CESC cis rs2522056 1 rs10900807 ENSG00000233006.5 AC034220.3 -4.75 3.65e-06 0.00235 -0.41 -0.31 Fibrinogen;Lymphocyte counts; chr5:132421788 chr5:132311285~132369916:- CESC cis rs34779708 0.801 rs12246600 ENSG00000230534.5 RP11-297A16.2 4.75 3.65e-06 0.00235 0.43 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35249193 chr10:35098006~35127020:- CESC cis rs34779708 0.801 rs12098720 ENSG00000230534.5 RP11-297A16.2 4.75 3.65e-06 0.00235 0.43 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35249755 chr10:35098006~35127020:- CESC cis rs42490 0.903 rs184302 ENSG00000251136.7 RP11-37B2.1 -4.75 3.65e-06 0.00235 -0.31 -0.31 Leprosy; chr8:89704396 chr8:89609409~89757727:- CESC cis rs116095464 0.558 rs62346506 ENSG00000250848.1 CTD-2083E4.5 -4.75 3.65e-06 0.00235 -0.42 -0.31 Breast cancer; chr5:201479 chr5:288833~290321:- CESC cis rs116095464 0.558 rs9312956 ENSG00000250848.1 CTD-2083E4.5 -4.75 3.65e-06 0.00235 -0.42 -0.31 Breast cancer; chr5:201697 chr5:288833~290321:- CESC cis rs4819052 0.851 rs1056099 ENSG00000223768.1 LINC00205 -4.75 3.65e-06 0.00235 -0.35 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45258977 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2236446 ENSG00000223768.1 LINC00205 -4.75 3.65e-06 0.00235 -0.35 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45259070 chr21:45293285~45297354:+ CESC cis rs6928977 0.863 rs9389286 ENSG00000234084.1 RP3-388E23.2 4.75 3.65e-06 0.00235 0.27 0.31 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135319827 chr6:135301568~135307158:+ CESC cis rs9318086 0.648 rs7331047 ENSG00000205861.10 C1QTNF9B-AS1 -4.75 3.65e-06 0.00235 -0.38 -0.31 Myopia (pathological); chr13:23893203 chr13:23888889~23897263:+ CESC cis rs889512 0.642 rs3826110 ENSG00000280152.1 RP11-331F4.5 -4.75 3.65e-06 0.00235 -0.44 -0.31 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75243882 chr16:75245994~75250077:- CESC cis rs950880 0.71 rs1135354 ENSG00000234389.1 AC007278.3 -4.75 3.66e-06 0.00235 -0.33 -0.31 Serum protein levels (sST2); chr2:102397842 chr2:102438713~102440475:+ CESC cis rs10246939 0.543 rs35836873 ENSG00000228775.6 WEE2-AS1 4.75 3.66e-06 0.00235 0.36 0.31 Bitter taste perception; chr7:141844010 chr7:141704338~141738346:- CESC cis rs10246939 0.543 rs9640358 ENSG00000228775.6 WEE2-AS1 4.75 3.66e-06 0.00235 0.36 0.31 Bitter taste perception; chr7:141844082 chr7:141704338~141738346:- CESC cis rs11779988 0.528 rs376771 ENSG00000253671.1 RP11-806O11.1 -4.75 3.66e-06 0.00235 -0.37 -0.31 Breast cancer; chr8:18007476 chr8:17808941~17820868:+ CESC cis rs11690935 0.851 rs10174055 ENSG00000228389.1 AC068039.4 4.75 3.66e-06 0.00236 0.41 0.31 Schizophrenia; chr2:171993303 chr2:171773482~171775844:+ CESC cis rs1862618 0.715 rs6866779 ENSG00000271828.1 CTD-2310F14.1 4.75 3.67e-06 0.00236 0.42 0.31 Initial pursuit acceleration; chr5:56794173 chr5:56927874~56929573:+ CESC cis rs2243480 1 rs466983 ENSG00000232559.3 GS1-124K5.12 4.75 3.68e-06 0.00236 0.51 0.31 Diabetic kidney disease; chr7:66055509 chr7:66554588~66576923:- CESC cis rs12458462 0.859 rs35493271 ENSG00000274828.1 RP11-567M16.6 4.75 3.69e-06 0.00237 0.29 0.31 Monocyte count; chr18:79688793 chr18:79677287~79679358:- CESC cis rs875971 0.862 rs6952182 ENSG00000222364.1 RNU6-96P 4.75 3.69e-06 0.00237 0.36 0.31 Aortic root size; chr7:66218330 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6964437 ENSG00000222364.1 RNU6-96P 4.75 3.69e-06 0.00237 0.36 0.31 Aortic root size; chr7:66221457 chr7:66395191~66395286:+ CESC cis rs2243480 1 rs402418 ENSG00000232559.3 GS1-124K5.12 4.75 3.69e-06 0.00237 0.52 0.31 Diabetic kidney disease; chr7:66044482 chr7:66554588~66576923:- CESC cis rs2243480 1 rs431318 ENSG00000232559.3 GS1-124K5.12 4.75 3.69e-06 0.00237 0.52 0.31 Diabetic kidney disease; chr7:66046610 chr7:66554588~66576923:- CESC cis rs9640161 0.789 rs10952250 ENSG00000261305.1 RP4-584D14.7 4.75 3.7e-06 0.00238 0.4 0.31 Blood protein levels;Circulating chemerin levels; chr7:150328877 chr7:150341771~150342607:+ CESC cis rs10875746 0.669 rs11168516 ENSG00000240399.1 RP1-228P16.1 -4.75 3.71e-06 0.00238 -0.37 -0.31 Longevity (90 years and older); chr12:48308282 chr12:48054813~48055591:- CESC cis rs3738443 0.768 rs6668154 ENSG00000259865.1 RP11-488L18.10 4.75 3.71e-06 0.00238 0.35 0.31 Alcohol dependence; chr1:247187981 chr1:247187281~247188526:- CESC cis rs3738443 0.768 rs6665647 ENSG00000259865.1 RP11-488L18.10 4.75 3.71e-06 0.00238 0.35 0.31 Alcohol dependence; chr1:247188127 chr1:247187281~247188526:- CESC cis rs11159086 0.793 rs11850070 ENSG00000259005.1 RP3-449M8.6 4.75 3.71e-06 0.00238 0.44 0.31 Advanced glycation end-product levels; chr14:74487575 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs28378078 ENSG00000259005.1 RP3-449M8.6 4.75 3.71e-06 0.00238 0.44 0.31 Advanced glycation end-product levels; chr14:74487940 chr14:74474007~74474864:- CESC cis rs2111504 0.559 rs7250813 ENSG00000267213.4 AC007773.2 4.75 3.71e-06 0.00238 0.38 0.31 Bipolar disorder; chr19:32358815 chr19:32390050~32405560:- CESC cis rs2243480 1 rs160646 ENSG00000228409.4 CCT6P1 4.75 3.72e-06 0.00238 0.46 0.31 Diabetic kidney disease; chr7:66091293 chr7:65751142~65763354:+ CESC cis rs9322193 0.923 rs12529698 ENSG00000268592.3 RAET1E-AS1 4.75 3.72e-06 0.00239 0.38 0.31 Lung cancer; chr6:149650951 chr6:149863494~149919507:+ CESC cis rs9318086 0.687 rs9507182 ENSG00000205861.10 C1QTNF9B-AS1 -4.75 3.73e-06 0.00239 -0.38 -0.31 Myopia (pathological); chr13:23868226 chr13:23888889~23897263:+ CESC cis rs1707322 0.821 rs11211182 ENSG00000281133.1 AL355480.3 -4.75 3.73e-06 0.00239 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45774498 chr1:45580892~45580996:- CESC cis rs4974559 0.847 rs28477912 ENSG00000253399.1 AC078852.2 4.75 3.73e-06 0.00239 0.5 0.31 Systolic blood pressure; chr4:1337562 chr4:1358479~1359461:+ CESC cis rs9907295 0.688 rs4795101 ENSG00000271013.1 AC015849.15 -4.75 3.73e-06 0.00239 -0.39 -0.31 Fibroblast growth factor basic levels; chr17:35932989 chr17:35912635~35918010:- CESC cis rs9907295 0.688 rs9754 ENSG00000271013.1 AC015849.15 -4.75 3.73e-06 0.00239 -0.39 -0.31 Fibroblast growth factor basic levels; chr17:35934827 chr17:35912635~35918010:- CESC cis rs875971 0.545 rs316316 ENSG00000222364.1 RNU6-96P 4.75 3.73e-06 0.0024 0.4 0.31 Aortic root size; chr7:66149270 chr7:66395191~66395286:+ CESC cis rs2019137 0.539 rs11123170 ENSG00000189223.12 PAX8-AS1 -4.75 3.73e-06 0.0024 -0.4 -0.31 Lymphocyte counts; chr2:113221363 chr2:113211522~113276581:+ CESC cis rs1061377 1 rs7675782 ENSG00000249685.1 RP11-360F5.3 4.75 3.74e-06 0.0024 0.36 0.31 Uric acid levels; chr4:39120048 chr4:39133913~39135608:+ CESC cis rs2412819 0.571 rs12900924 ENSG00000249839.1 AC011330.5 -4.75 3.74e-06 0.0024 -0.45 -0.31 Lung cancer; chr15:43737329 chr15:43663654~43684339:- CESC cis rs6782228 0.565 rs12695509 ENSG00000242551.2 POU5F1P6 -4.75 3.74e-06 0.0024 -0.34 -0.31 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128698201 chr3:128674735~128677005:- CESC cis rs2337406 0.85 rs11849578 ENSG00000211974.3 IGHV2-70 -4.75 3.74e-06 0.0024 -0.47 -0.31 Alzheimer's disease (late onset); chr14:106670302 chr14:106723574~106724093:- CESC cis rs950880 0.71 rs11693204 ENSG00000234389.1 AC007278.3 -4.75 3.75e-06 0.0024 -0.35 -0.31 Serum protein levels (sST2); chr2:102319514 chr2:102438713~102440475:+ CESC cis rs9322193 0.962 rs9688750 ENSG00000216906.2 RP11-350J20.9 4.75 3.75e-06 0.00241 0.33 0.31 Lung cancer; chr6:149657633 chr6:149904243~149906418:+ CESC cis rs3806843 0.612 rs246075 ENSG00000202111.1 VTRNA1-2 -4.75 3.75e-06 0.00241 -0.32 -0.31 Depressive symptoms (multi-trait analysis); chr5:140920972 chr5:140718925~140719013:+ CESC cis rs6964833 1 rs4717907 ENSG00000277053.3 GTF2IP1 -4.75 3.75e-06 0.00241 -0.37 -0.31 Menarche (age at onset); chr7:74672169 chr7:75185385~75237696:- CESC cis rs875971 0.895 rs6460278 ENSG00000222364.1 RNU6-96P 4.75 3.76e-06 0.00241 0.36 0.31 Aortic root size; chr7:66197749 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6460279 ENSG00000222364.1 RNU6-96P 4.75 3.76e-06 0.00241 0.36 0.31 Aortic root size; chr7:66197774 chr7:66395191~66395286:+ CESC cis rs9322193 0.884 rs9397036 ENSG00000216906.2 RP11-350J20.9 4.75 3.76e-06 0.00241 0.35 0.31 Lung cancer; chr6:149851787 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs9383864 ENSG00000216906.2 RP11-350J20.9 4.75 3.76e-06 0.00241 0.35 0.31 Lung cancer; chr6:149851969 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs9383865 ENSG00000216906.2 RP11-350J20.9 4.75 3.76e-06 0.00241 0.35 0.31 Lung cancer; chr6:149852043 chr6:149904243~149906418:+ CESC cis rs11723261 0.582 rs11248006 ENSG00000211553.1 AC253576.2 -4.75 3.76e-06 0.00241 -0.49 -0.31 Immune response to smallpox vaccine (IL-6); chr4:172914 chr4:136461~136568:+ CESC cis rs950880 0.71 rs11693955 ENSG00000234389.1 AC007278.3 -4.75 3.76e-06 0.00241 -0.33 -0.31 Serum protein levels (sST2); chr2:102412705 chr2:102438713~102440475:+ CESC cis rs6142102 0.961 rs4911146 ENSG00000276073.1 RP5-1125A11.7 -4.74 3.78e-06 0.00242 -0.29 -0.31 Skin pigmentation; chr20:34052241 chr20:33985617~33988989:- CESC cis rs2739330 0.791 rs9612520 ENSG00000272787.1 KB-226F1.2 -4.74 3.78e-06 0.00242 -0.33 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23969211~23969873:+ CESC cis rs2283792 0.622 rs239917 ENSG00000224086.5 LL22NC03-86G7.1 -4.74 3.78e-06 0.00242 -0.35 -0.31 Multiple sclerosis; chr22:21960091 chr22:21938293~21977632:+ CESC cis rs733592 0.507 rs10875739 ENSG00000240399.1 RP1-228P16.1 4.74 3.78e-06 0.00242 0.32 0.31 Plateletcrit; chr12:48087136 chr12:48054813~48055591:- CESC cis rs34779708 0.801 rs34592588 ENSG00000230534.5 RP11-297A16.2 4.74 3.78e-06 0.00242 0.43 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35251206 chr10:35098006~35127020:- CESC cis rs6991838 0.671 rs13251307 ENSG00000200714.1 Y_RNA 4.74 3.78e-06 0.00242 0.36 0.31 Intelligence (multi-trait analysis); chr8:65664911 chr8:65592731~65592820:+ CESC cis rs7560272 0.501 rs12992607 ENSG00000273245.1 RP11-434P11.2 -4.74 3.79e-06 0.00242 -0.38 -0.31 Schizophrenia; chr2:73732833 chr2:73750256~73750786:- CESC cis rs2177312 0.521 rs61791995 ENSG00000251129.1 RP11-734I18.1 4.74 3.79e-06 0.00242 0.4 0.31 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31849287 chr4:31997397~32155406:+ CESC cis rs7614311 1 rs7614311 ENSG00000271843.1 RP11-245J9.5 -4.74 3.79e-06 0.00243 -0.41 -0.31 Lung function (FVC);Lung function (FEV1); chr3:63827978 chr3:64008082~64008692:- CESC cis rs1185460 0.904 rs1003081 ENSG00000271751.1 RP11-110I1.14 4.74 3.8e-06 0.00243 0.37 0.31 Coronary artery disease; chr11:119043282 chr11:119065263~119065677:- CESC cis rs801193 0.569 rs7782587 ENSG00000222364.1 RNU6-96P -4.74 3.8e-06 0.00243 -0.36 -0.31 Aortic root size; chr7:66701485 chr7:66395191~66395286:+ CESC cis rs755249 1 rs755249 ENSG00000228060.1 RP11-69E11.8 -4.74 3.8e-06 0.00243 -0.36 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39529402 chr1:39565160~39573203:+ CESC cis rs2919917 0.628 rs1384803 ENSG00000254352.1 RP11-578O24.2 -4.74 3.8e-06 0.00244 -0.42 -0.31 Lymphocyte counts; chr8:78669393 chr8:78723796~78724136:- CESC cis rs2058059 0.51 rs61567992 ENSG00000205578.5 POM121B -4.74 3.81e-06 0.00244 -0.4 -0.31 Subcutaneous adipose tissue; chr7:72576332 chr7:73293497~73301161:+ CESC cis rs9309711 0.736 rs13412581 ENSG00000225234.1 TRAPPC12-AS1 -4.74 3.82e-06 0.00244 -0.34 -0.31 Neurofibrillary tangles; chr2:3493416 chr2:3481242~3482409:- CESC cis rs4718428 0.705 rs12536410 ENSG00000273142.1 RP11-458F8.4 -4.74 3.82e-06 0.00244 -0.33 -0.31 Corneal structure; chr7:66789303 chr7:66902857~66906297:+ CESC cis rs8030379 0.967 rs2401171 ENSG00000230373.7 GOLGA6L5P -4.74 3.82e-06 0.00244 -0.3 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83888924 chr15:84507885~84516814:- CESC cis rs10129255 1 rs4612959 ENSG00000280411.1 IGHV1-69-2 -4.74 3.82e-06 0.00245 -0.23 -0.31 Kawasaki disease; chr14:106767055 chr14:106762092~106762588:- CESC cis rs4819052 0.851 rs2236443 ENSG00000223768.1 LINC00205 -4.74 3.82e-06 0.00245 -0.35 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45258259 chr21:45293285~45297354:+ CESC cis rs7508 0.546 rs382752 ENSG00000253671.1 RP11-806O11.1 4.74 3.82e-06 0.00245 0.34 0.31 Atrial fibrillation; chr8:18040874 chr8:17808941~17820868:+ CESC cis rs10129255 0.719 rs7156660 ENSG00000211970.3 IGHV4-61 -4.74 3.82e-06 0.00245 -0.23 -0.31 Kawasaki disease; chr14:106673171 chr14:106639119~106639657:- CESC cis rs11159086 0.793 rs10150696 ENSG00000259005.1 RP3-449M8.6 4.74 3.83e-06 0.00245 0.44 0.31 Advanced glycation end-product levels; chr14:74476723 chr14:74474007~74474864:- CESC cis rs5769707 0.521 rs5769719 ENSG00000188511.11 C22orf34 4.74 3.83e-06 0.00245 0.35 0.31 Monocyte percentage of white cells;Monocyte count; chr22:49668453 chr22:49414524~49657542:- CESC cis rs5769707 0.521 rs5769720 ENSG00000188511.11 C22orf34 4.74 3.83e-06 0.00245 0.35 0.31 Monocyte percentage of white cells;Monocyte count; chr22:49668485 chr22:49414524~49657542:- CESC cis rs5769707 0.521 rs5770633 ENSG00000188511.11 C22orf34 4.74 3.83e-06 0.00245 0.35 0.31 Monocyte percentage of white cells;Monocyte count; chr22:49668779 chr22:49414524~49657542:- CESC cis rs1609391 0.543 rs2117009 ENSG00000239213.4 NCK1-AS1 -4.74 3.84e-06 0.00245 -0.35 -0.31 Neuroticism; chr3:136914729 chr3:136841726~136862054:- CESC cis rs2111504 0.583 rs2868082 ENSG00000267213.4 AC007773.2 4.74 3.84e-06 0.00245 0.37 0.31 Bipolar disorder; chr19:32368475 chr19:32390050~32405560:- CESC cis rs2111504 0.583 rs2111503 ENSG00000267213.4 AC007773.2 4.74 3.84e-06 0.00245 0.37 0.31 Bipolar disorder; chr19:32383819 chr19:32390050~32405560:- CESC cis rs950027 0.815 rs1153835 ENSG00000259520.4 CTD-2651B20.3 -4.74 3.84e-06 0.00246 -0.4 -0.31 Response to fenofibrate (adiponectin levels); chr15:45456409 chr15:45251580~45279251:- CESC cis rs1876905 0.68 rs9384787 ENSG00000230177.1 RP5-1112D6.4 4.74 3.84e-06 0.00246 0.35 0.31 Mean corpuscular hemoglobin; chr6:111113707 chr6:111277932~111278742:+ CESC cis rs2243480 1 rs316331 ENSG00000275400.1 RP4-756H11.5 -4.74 3.85e-06 0.00246 -0.51 -0.31 Diabetic kidney disease; chr7:66139635 chr7:66553805~66554199:- CESC cis rs9322193 0.923 rs12175504 ENSG00000216906.2 RP11-350J20.9 4.74 3.86e-06 0.00246 0.34 0.31 Lung cancer; chr6:149664079 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs35443312 ENSG00000216906.2 RP11-350J20.9 4.74 3.86e-06 0.00246 0.34 0.31 Lung cancer; chr6:149670625 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs62439843 ENSG00000216906.2 RP11-350J20.9 4.74 3.86e-06 0.00246 0.34 0.31 Lung cancer; chr6:149676521 chr6:149904243~149906418:+ CESC cis rs520525 0.927 rs1234282 ENSG00000271811.1 RP1-79C4.4 4.74 3.86e-06 0.00247 0.4 0.31 Atrial fibrillation; chr1:170650183 chr1:170667381~170669425:+ CESC cis rs9813712 0.596 rs2587988 ENSG00000228252.7 COL6A4P2 -4.74 3.86e-06 0.00247 -0.34 -0.31 Response to amphetamines; chr3:130201415 chr3:130212823~130273806:+ CESC cis rs881375 0.678 rs1930782 ENSG00000226752.6 PSMD5-AS1 -4.74 3.86e-06 0.00247 -0.31 -0.31 Rheumatoid arthritis; chr9:120925627 chr9:120824828~120854385:+ CESC cis rs881375 0.678 rs10739581 ENSG00000226752.6 PSMD5-AS1 -4.74 3.86e-06 0.00247 -0.31 -0.31 Rheumatoid arthritis; chr9:120934593 chr9:120824828~120854385:+ CESC cis rs860295 0.651 rs6692183 ENSG00000225855.5 RUSC1-AS1 4.74 3.87e-06 0.00247 0.26 0.31 Body mass index; chr1:155334536 chr1:155316863~155324176:- CESC cis rs1862618 0.754 rs252899 ENSG00000271828.1 CTD-2310F14.1 4.74 3.87e-06 0.00247 0.42 0.31 Initial pursuit acceleration; chr5:56892742 chr5:56927874~56929573:+ CESC cis rs875971 0.862 rs6971059 ENSG00000222364.1 RNU6-96P 4.74 3.88e-06 0.00247 0.36 0.31 Aortic root size; chr7:66602045 chr7:66395191~66395286:+ CESC cis rs875971 0.789 rs7808013 ENSG00000222364.1 RNU6-96P 4.74 3.88e-06 0.00247 0.36 0.31 Aortic root size; chr7:66606209 chr7:66395191~66395286:+ CESC cis rs875971 0.825 rs7384021 ENSG00000222364.1 RNU6-96P 4.74 3.88e-06 0.00247 0.36 0.31 Aortic root size; chr7:66612917 chr7:66395191~66395286:+ CESC cis rs875971 0.825 rs66981195 ENSG00000222364.1 RNU6-96P 4.74 3.88e-06 0.00247 0.36 0.31 Aortic root size; chr7:66614048 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs3926380 ENSG00000222364.1 RNU6-96P 4.74 3.88e-06 0.00247 0.36 0.31 Aortic root size; chr7:66615658 chr7:66395191~66395286:+ CESC cis rs4819052 0.851 rs1006779 ENSG00000223768.1 LINC00205 -4.74 3.88e-06 0.00248 -0.35 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45250837 chr21:45293285~45297354:+ CESC cis rs5769707 0.681 rs2071902 ENSG00000235111.1 RP1-29C18.8 -4.74 3.89e-06 0.00248 -0.36 -0.31 Monocyte percentage of white cells;Monocyte count; chr22:49640890 chr22:49612657~49615716:- CESC cis rs763121 0.925 rs9835 ENSG00000273076.1 RP3-508I15.22 4.74 3.89e-06 0.00248 0.34 0.31 Menopause (age at onset); chr22:38734966 chr22:38743495~38743910:+ CESC cis rs77972916 0.505 rs6753197 ENSG00000234936.1 AC010883.5 4.74 3.89e-06 0.00248 0.36 0.31 Granulocyte percentage of myeloid white cells; chr2:43300823 chr2:43229573~43233394:+ CESC cis rs10129255 0.518 rs10150460 ENSG00000224373.3 IGHV4-59 -4.74 3.89e-06 0.00248 -0.19 -0.31 Kawasaki disease; chr14:106677179 chr14:106627249~106627825:- CESC cis rs875971 0.965 rs697968 ENSG00000237310.1 GS1-124K5.4 -4.74 3.9e-06 0.00249 -0.3 -0.31 Aortic root size; chr7:66070046 chr7:66493706~66495474:+ CESC cis rs875971 1 rs1183245 ENSG00000237310.1 GS1-124K5.4 -4.74 3.9e-06 0.00249 -0.3 -0.31 Aortic root size; chr7:66076198 chr7:66493706~66495474:+ CESC cis rs875971 1 rs1144894 ENSG00000237310.1 GS1-124K5.4 -4.74 3.9e-06 0.00249 -0.3 -0.31 Aortic root size; chr7:66077907 chr7:66493706~66495474:+ CESC cis rs881375 0.678 rs7037195 ENSG00000226752.6 PSMD5-AS1 -4.74 3.9e-06 0.00249 -0.31 -0.31 Rheumatoid arthritis; chr9:120921722 chr9:120824828~120854385:+ CESC cis rs881375 0.678 rs1014530 ENSG00000226752.6 PSMD5-AS1 -4.74 3.9e-06 0.00249 -0.31 -0.31 Rheumatoid arthritis; chr9:120922814 chr9:120824828~120854385:+ CESC cis rs4814920 0.818 rs4813377 ENSG00000275142.1 RP5-999L4.2 -4.74 3.91e-06 0.00249 -0.48 -0.31 Bipolar disorder (body mass index interaction); chr20:19870822 chr20:19871891~19872284:+ CESC cis rs860295 0.665 rs12028416 ENSG00000225855.5 RUSC1-AS1 4.74 3.91e-06 0.00249 0.26 0.31 Body mass index; chr1:155431370 chr1:155316863~155324176:- CESC cis rs860295 0.629 rs12026638 ENSG00000225855.5 RUSC1-AS1 4.74 3.91e-06 0.00249 0.26 0.31 Body mass index; chr1:155431469 chr1:155316863~155324176:- CESC cis rs860295 0.702 rs56675301 ENSG00000225855.5 RUSC1-AS1 4.74 3.91e-06 0.00249 0.26 0.31 Body mass index; chr1:155394536 chr1:155316863~155324176:- CESC cis rs4718428 0.576 rs12698546 ENSG00000273142.1 RP11-458F8.4 -4.74 3.91e-06 0.00249 -0.33 -0.31 Corneal structure; chr7:66801919 chr7:66902857~66906297:+ CESC cis rs3931020 0.688 rs277396 ENSG00000272864.1 RP11-17E13.2 4.74 3.91e-06 0.00249 0.4 0.31 Resistin levels; chr1:74747964 chr1:74698769~74699333:- CESC cis rs42490 0.903 rs218899 ENSG00000251136.7 RP11-37B2.1 -4.74 3.92e-06 0.0025 -0.32 -0.31 Leprosy; chr8:89717279 chr8:89609409~89757727:- CESC cis rs12922040 0.651 rs35288467 ENSG00000263335.1 AF001548.5 -4.74 3.93e-06 0.0025 -0.37 -0.31 Serum uric acid levels in response to allopurinol in gout; chr16:15773097 chr16:15726674~15732993:+ CESC cis rs11603023 0.874 rs483598 ENSG00000255422.1 AP002954.4 -4.74 3.93e-06 0.0025 -0.34 -0.31 Cholesterol, total; chr11:118638950 chr11:118704607~118750263:+ CESC cis rs4974559 0.947 rs12639938 ENSG00000253399.1 AC078852.2 4.74 3.93e-06 0.00251 0.5 0.31 Systolic blood pressure; chr4:1349347 chr4:1358479~1359461:+ CESC cis rs2337406 0.778 rs56965016 ENSG00000211974.3 IGHV2-70 -4.74 3.94e-06 0.00251 -0.46 -0.31 Alzheimer's disease (late onset); chr14:106656649 chr14:106723574~106724093:- CESC cis rs2337406 0.778 rs56658355 ENSG00000211974.3 IGHV2-70 -4.74 3.94e-06 0.00251 -0.46 -0.31 Alzheimer's disease (late onset); chr14:106662151 chr14:106723574~106724093:- CESC cis rs2337406 0.925 rs10131226 ENSG00000211974.3 IGHV2-70 -4.74 3.94e-06 0.00251 -0.46 -0.31 Alzheimer's disease (late onset); chr14:106665764 chr14:106723574~106724093:- CESC cis rs2733201 1 rs2114420 ENSG00000259479.5 SORD2P -4.74 3.94e-06 0.00251 -0.46 -0.31 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44020385 chr15:44826371~44884694:- CESC cis rs2729354 0.768 rs2581922 ENSG00000265566.2 RN7SL605P -4.74 3.94e-06 0.00251 -0.43 -0.31 Blood protein levels; chr11:57497927 chr11:57528085~57528365:- CESC cis rs55757919 1 rs55757919 ENSG00000231742.4 LINC01273 4.74 3.94e-06 0.00251 0.39 0.31 Monocyte percentage of white cells; chr20:50132011 chr20:50172550~50176671:+ CESC cis rs6565180 0.962 rs11642676 ENSG00000183604.13 SMG1P5 -4.73 3.94e-06 0.00251 -0.32 -0.31 Tonsillectomy; chr16:30360334 chr16:30267553~30335374:- CESC cis rs11976180 1 rs2961132 ENSG00000273234.1 OR2A13P -4.73 3.95e-06 0.00251 -0.38 -0.31 Obesity-related traits; chr7:144071035 chr7:144142009~144142938:+ CESC cis rs6991838 0.733 rs13281981 ENSG00000272010.1 CTD-3025N20.3 4.73 3.95e-06 0.00251 0.33 0.31 Intelligence (multi-trait analysis); chr8:65611649 chr8:65591850~65592472:- CESC cis rs9309473 1 rs7594511 ENSG00000163016.8 ALMS1P 4.73 3.95e-06 0.00252 0.41 0.31 Metabolite levels; chr2:73454512 chr2:73644919~73685576:+ CESC cis rs7874604 1 rs7874604 ENSG00000215221.2 UBA52P6 4.73 3.95e-06 0.00252 0.37 0.31 Basal cell carcinoma; chr9:22054691 chr9:22012155~22012536:+ CESC cis rs944801 0.631 rs2383204 ENSG00000215221.2 UBA52P6 4.73 3.95e-06 0.00252 0.37 0.31 Type 2 diabetes; chr9:22055049 chr9:22012155~22012536:+ CESC cis rs9813712 0.548 rs9880123 ENSG00000228252.7 COL6A4P2 -4.73 3.96e-06 0.00252 -0.36 -0.31 Response to amphetamines; chr3:130215275 chr3:130212823~130273806:+ CESC cis rs950880 0.71 rs17027006 ENSG00000234389.1 AC007278.3 4.73 3.96e-06 0.00252 0.34 0.31 Serum protein levels (sST2); chr2:102348872 chr2:102438713~102440475:+ CESC cis rs860295 0.702 rs11264366 ENSG00000225855.5 RUSC1-AS1 4.73 3.97e-06 0.00252 0.26 0.31 Body mass index; chr1:155365620 chr1:155316863~155324176:- CESC cis rs62344088 0.59 rs62345236 ENSG00000250848.1 CTD-2083E4.5 -4.73 3.97e-06 0.00252 -0.58 -0.31 Asthma (childhood onset); chr5:283404 chr5:288833~290321:- CESC cis rs763121 0.925 rs4821815 ENSG00000273076.1 RP3-508I15.22 4.73 3.97e-06 0.00252 0.34 0.31 Menopause (age at onset); chr22:38709702 chr22:38743495~38743910:+ CESC cis rs8072100 0.967 rs4794001 ENSG00000228782.6 CTD-2026D20.3 4.73 3.98e-06 0.00253 0.36 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47643483 chr17:47450568~47492492:- CESC cis rs17826219 0.636 rs4055314 ENSG00000266490.1 CTD-2349P21.9 4.73 3.99e-06 0.00253 0.47 0.31 Body mass index; chr17:30752751 chr17:30792372~30792833:+ CESC cis rs9907295 1 rs11657908 ENSG00000270977.1 AC015849.16 -4.73 3.99e-06 0.00254 -0.45 -0.31 Fibroblast growth factor basic levels; chr17:35908993 chr17:35893707~35911023:- CESC cis rs2564921 0.704 rs57916015 ENSG00000242142.1 SERBP1P3 -4.73 3.99e-06 0.00254 -0.37 -0.31 Height; chr3:52971094 chr3:53064283~53065091:- CESC cis rs11159086 0.793 rs1029702 ENSG00000270000.1 RP3-449M8.9 4.73 4e-06 0.00254 0.48 0.31 Advanced glycation end-product levels; chr14:74473909 chr14:74471930~74472360:- CESC cis rs763121 0.819 rs5757161 ENSG00000273076.1 RP3-508I15.22 4.73 4e-06 0.00254 0.35 0.31 Menopause (age at onset); chr22:38594657 chr22:38743495~38743910:+ CESC cis rs7429990 0.901 rs7431567 ENSG00000229759.1 MRPS18AP1 -4.73 4e-06 0.00254 -0.32 -0.31 Educational attainment (years of education); chr3:47986342 chr3:48256350~48256938:- CESC cis rs2243480 1 rs313832 ENSG00000275400.1 RP4-756H11.5 4.73 4.01e-06 0.00254 0.53 0.31 Diabetic kidney disease; chr7:66085904 chr7:66553805~66554199:- CESC cis rs881375 0.715 rs7858209 ENSG00000226752.6 PSMD5-AS1 -4.73 4.01e-06 0.00254 -0.31 -0.31 Rheumatoid arthritis; chr9:120883482 chr9:120824828~120854385:+ CESC cis rs881375 0.715 rs10760119 ENSG00000226752.6 PSMD5-AS1 -4.73 4.01e-06 0.00254 -0.31 -0.31 Rheumatoid arthritis; chr9:120883782 chr9:120824828~120854385:+ CESC cis rs12908161 0.959 rs2175567 ENSG00000225151.9 GOLGA2P7 -4.73 4.01e-06 0.00255 -0.41 -0.31 Schizophrenia; chr15:84657715 chr15:84199311~84230136:- CESC cis rs860295 0.702 rs12081067 ENSG00000225855.5 RUSC1-AS1 4.73 4.01e-06 0.00255 0.26 0.31 Body mass index; chr1:155389191 chr1:155316863~155324176:- CESC cis rs875971 0.862 rs778686 ENSG00000232559.3 GS1-124K5.12 4.73 4.02e-06 0.00255 0.33 0.31 Aortic root size; chr7:66370923 chr7:66554588~66576923:- CESC cis rs875971 0.502 rs2946580 ENSG00000236529.1 RP13-254B10.1 -4.73 4.04e-06 0.00256 -0.38 -0.31 Aortic root size; chr7:66066855 chr7:65840212~65840596:+ CESC cis rs875971 0.862 rs28491091 ENSG00000232559.3 GS1-124K5.12 -4.73 4.06e-06 0.00257 -0.33 -0.31 Aortic root size; chr7:66204077 chr7:66554588~66576923:- CESC cis rs71403859 0.502 rs36122765 ENSG00000260886.1 TAT-AS1 4.73 4.06e-06 0.00258 0.48 0.3 Post bronchodilator FEV1; chr16:71470280 chr16:71565789~71578187:+ CESC cis rs11779988 0.501 rs3760 ENSG00000253671.1 RP11-806O11.1 -4.73 4.07e-06 0.00258 -0.34 -0.3 Breast cancer; chr8:18028836 chr8:17808941~17820868:+ CESC cis rs11157436 0.958 rs61972231 ENSG00000211813.2 TRAV34 4.73 4.07e-06 0.00258 0.34 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22206508 chr14:22207522~22208129:+ CESC cis rs73086581 1 rs6107386 ENSG00000229539.1 RP11-119B16.2 4.73 4.07e-06 0.00258 0.51 0.3 Response to antidepressants in depression; chr20:3992109 chr20:3888239~3888868:- CESC cis rs7809950 0.953 rs2520263 ENSG00000238832.1 snoU109 -4.73 4.07e-06 0.00258 -0.36 -0.3 Coronary artery disease; chr7:107538674 chr7:107603363~107603507:+ CESC cis rs6565180 0.962 rs35480350 ENSG00000183604.13 SMG1P5 -4.73 4.08e-06 0.00258 -0.32 -0.3 Tonsillectomy; chr16:30354718 chr16:30267553~30335374:- CESC cis rs17507216 0.718 rs4779034 ENSG00000276710.3 CSPG4P8 -4.73 4.08e-06 0.00258 -0.4 -0.3 Excessive daytime sleepiness; chr15:82576799 chr15:82459472~82477258:+ CESC cis rs7429990 0.932 rs6442101 ENSG00000229759.1 MRPS18AP1 -4.73 4.08e-06 0.00258 -0.32 -0.3 Educational attainment (years of education); chr3:48089403 chr3:48256350~48256938:- CESC cis rs755249 0.958 rs17264866 ENSG00000228060.1 RP11-69E11.8 -4.73 4.08e-06 0.00258 -0.36 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557105 chr1:39565160~39573203:+ CESC cis rs71403859 0.73 rs12931191 ENSG00000260886.1 TAT-AS1 -4.73 4.08e-06 0.00258 -0.47 -0.3 Post bronchodilator FEV1; chr16:71587470 chr16:71565789~71578187:+ CESC cis rs1015362 0.869 rs6088411 ENSG00000275784.1 RP5-1125A11.6 4.73 4.08e-06 0.00259 0.32 0.3 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:34152101 chr20:33989480~33991818:- CESC cis rs2739330 0.796 rs1006771 ENSG00000250470.1 AP000351.3 4.73 4.09e-06 0.00259 0.37 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23976904~23977585:- CESC cis rs1012068 0.695 rs5998152 ENSG00000236132.1 CTA-440B3.1 -4.73 4.09e-06 0.00259 -0.36 -0.3 Chronic hepatitis C infection; chr22:31867176 chr22:31816379~31817491:- CESC cis rs950880 0.71 rs873022 ENSG00000234389.1 AC007278.3 -4.73 4.1e-06 0.00259 -0.35 -0.3 Serum protein levels (sST2); chr2:102339223 chr2:102438713~102440475:+ CESC cis rs944801 0.631 rs10757267 ENSG00000215221.2 UBA52P6 4.73 4.1e-06 0.0026 0.37 0.3 Type 2 diabetes; chr9:22052811 chr9:22012155~22012536:+ CESC cis rs9322193 0.651 rs9322188 ENSG00000268592.3 RAET1E-AS1 -4.73 4.1e-06 0.0026 -0.39 -0.3 Lung cancer; chr6:149588355 chr6:149863494~149919507:+ CESC cis rs2243480 1 rs313831 ENSG00000275400.1 RP4-756H11.5 4.73 4.11e-06 0.0026 0.53 0.3 Diabetic kidney disease; chr7:66086239 chr7:66553805~66554199:- CESC cis rs6565180 1 rs8049108 ENSG00000183604.13 SMG1P5 -4.73 4.11e-06 0.0026 -0.29 -0.3 Tonsillectomy; chr16:30365165 chr16:30267553~30335374:- CESC cis rs748404 0.578 rs576557 ENSG00000249839.1 AC011330.5 -4.73 4.12e-06 0.00261 -0.32 -0.3 Lung cancer; chr15:43305539 chr15:43663654~43684339:- CESC cis rs113835537 0.877 rs3867132 ENSG00000255517.5 CTD-3074O7.5 -4.72 4.13e-06 0.00261 -0.48 -0.3 Airway imaging phenotypes; chr11:66541798 chr11:66473490~66480233:- CESC cis rs17301013 0.507 rs4651008 ENSG00000227373.4 RP11-160H22.5 4.72 4.13e-06 0.00261 0.43 0.3 Systemic lupus erythematosus; chr1:174342681 chr1:174115300~174160004:- CESC cis rs875971 0.862 rs11765791 ENSG00000222364.1 RNU6-96P -4.72 4.14e-06 0.00262 -0.36 -0.3 Aortic root size; chr7:66471587 chr7:66395191~66395286:+ CESC cis rs6782228 0.606 rs10048945 ENSG00000242551.2 POU5F1P6 -4.72 4.14e-06 0.00262 -0.34 -0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128690837 chr3:128674735~128677005:- CESC cis rs9322193 0.962 rs4380763 ENSG00000268592.3 RAET1E-AS1 4.72 4.14e-06 0.00262 0.4 0.3 Lung cancer; chr6:149678086 chr6:149863494~149919507:+ CESC cis rs1387259 0.929 rs2956703 ENSG00000258273.1 RP11-370I10.4 -4.72 4.14e-06 0.00262 -0.38 -0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48276511 chr12:48333755~48333901:- CESC cis rs1387259 0.931 rs1107654 ENSG00000258273.1 RP11-370I10.4 -4.72 4.14e-06 0.00262 -0.38 -0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48287314 chr12:48333755~48333901:- CESC cis rs1387259 0.859 rs2054905 ENSG00000258273.1 RP11-370I10.4 -4.72 4.14e-06 0.00262 -0.38 -0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48294168 chr12:48333755~48333901:- CESC cis rs2732480 0.5 rs2732461 ENSG00000258273.1 RP11-370I10.4 -4.72 4.14e-06 0.00262 -0.38 -0.3 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48299019 chr12:48333755~48333901:- CESC cis rs17818399 0.781 rs4952837 ENSG00000279254.1 RP11-536C12.1 -4.72 4.14e-06 0.00262 -0.36 -0.3 Height; chr2:46638595 chr2:46668870~46670778:+ CESC cis rs17818399 0.781 rs6746598 ENSG00000279254.1 RP11-536C12.1 -4.72 4.14e-06 0.00262 -0.36 -0.3 Height; chr2:46638634 chr2:46668870~46670778:+ CESC cis rs7572733 0.935 rs1369512 ENSG00000222017.1 AC011997.1 4.72 4.15e-06 0.00262 0.34 0.3 Dermatomyositis; chr2:197902408 chr2:197693106~197774823:+ CESC cis rs860295 0.702 rs2025669 ENSG00000225855.5 RUSC1-AS1 4.72 4.16e-06 0.00263 0.26 0.3 Body mass index; chr1:155387818 chr1:155316863~155324176:- CESC cis rs860295 0.702 rs10908465 ENSG00000225855.5 RUSC1-AS1 4.72 4.16e-06 0.00263 0.26 0.3 Body mass index; chr1:155419897 chr1:155316863~155324176:- CESC cis rs9322193 0.884 rs62439836 ENSG00000268592.3 RAET1E-AS1 4.72 4.16e-06 0.00263 0.4 0.3 Lung cancer; chr6:149669173 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs4869812 ENSG00000268592.3 RAET1E-AS1 4.72 4.16e-06 0.00263 0.4 0.3 Lung cancer; chr6:149669447 chr6:149863494~149919507:+ CESC cis rs11159086 0.793 rs10136668 ENSG00000259005.1 RP3-449M8.6 4.72 4.16e-06 0.00263 0.43 0.3 Advanced glycation end-product levels; chr14:74492183 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs10139029 ENSG00000259005.1 RP3-449M8.6 4.72 4.16e-06 0.00263 0.43 0.3 Advanced glycation end-product levels; chr14:74492284 chr14:74474007~74474864:- CESC cis rs2243480 1 rs7456042 ENSG00000228409.4 CCT6P1 4.72 4.16e-06 0.00263 0.43 0.3 Diabetic kidney disease; chr7:65834791 chr7:65751142~65763354:+ CESC cis rs950880 0.71 rs12469506 ENSG00000234389.1 AC007278.3 -4.72 4.17e-06 0.00264 -0.34 -0.3 Serum protein levels (sST2); chr2:102349411 chr2:102438713~102440475:+ CESC cis rs5769707 0.632 rs135872 ENSG00000235111.1 RP1-29C18.8 -4.72 4.17e-06 0.00264 -0.35 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49615652 chr22:49612657~49615716:- CESC cis rs10463554 0.853 rs257309 ENSG00000175749.11 EIF3KP1 4.72 4.17e-06 0.00264 0.32 0.3 Parkinson's disease; chr5:103082900 chr5:103032376~103033031:+ CESC cis rs2842992 0.958 rs2758318 ENSG00000237927.1 RP3-393E18.2 -4.72 4.17e-06 0.00264 -0.4 -0.3 Age-related macular degeneration (geographic atrophy); chr6:159648605 chr6:159586955~159589169:- CESC cis rs1862618 0.853 rs6450408 ENSG00000271828.1 CTD-2310F14.1 4.72 4.18e-06 0.00264 0.41 0.3 Initial pursuit acceleration; chr5:56802319 chr5:56927874~56929573:+ CESC cis rs875971 0.964 rs697969 ENSG00000237310.1 GS1-124K5.4 -4.72 4.19e-06 0.00265 -0.3 -0.3 Aortic root size; chr7:66093491 chr7:66493706~66495474:+ CESC cis rs875971 1 rs1182882 ENSG00000237310.1 GS1-124K5.4 -4.72 4.19e-06 0.00265 -0.3 -0.3 Aortic root size; chr7:66097076 chr7:66493706~66495474:+ CESC cis rs6452524 0.868 rs11746977 ENSG00000249664.1 CTD-2227C6.2 4.72 4.19e-06 0.00265 0.37 0.3 Hypertension (SNP x SNP interaction); chr5:83085581 chr5:83012285~83013109:- CESC cis rs4819052 0.851 rs1056101 ENSG00000223768.1 LINC00205 -4.72 4.2e-06 0.00265 -0.36 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45258787 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs1056100 ENSG00000223768.1 LINC00205 -4.72 4.2e-06 0.00265 -0.36 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45258796 chr21:45293285~45297354:+ CESC cis rs2015599 0.623 rs3782505 ENSG00000257176.2 RP11-996F15.2 4.72 4.21e-06 0.00266 0.36 0.3 Platelet count;Mean platelet volume; chr12:29292236 chr12:29280418~29317848:- CESC cis rs853679 0.517 rs9380047 ENSG00000219392.1 RP1-265C24.5 -4.72 4.22e-06 0.00266 -0.4 -0.3 Depression; chr6:28070115 chr6:28115628~28116551:+ CESC cis rs10754283 0.871 rs72712569 ENSG00000231613.1 RP5-943J3.1 -4.72 4.22e-06 0.00267 -0.39 -0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89660098 chr1:89788914~89790492:+ CESC cis rs7829975 0.714 rs4841040 ENSG00000253893.2 FAM85B -4.72 4.22e-06 0.00267 -0.38 -0.3 Mood instability; chr8:8797017 chr8:8167819~8226614:- CESC cis rs875971 0.862 rs2909688 ENSG00000222364.1 RNU6-96P -4.72 4.23e-06 0.00267 -0.36 -0.3 Aortic root size; chr7:66376625 chr7:66395191~66395286:+ CESC cis rs889512 0.642 rs28439846 ENSG00000280152.1 RP11-331F4.5 -4.72 4.23e-06 0.00267 -0.44 -0.3 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75246480 chr16:75245994~75250077:- CESC cis rs7777677 0.925 rs4726546 ENSG00000244273.1 PGBD4P1 -4.72 4.23e-06 0.00267 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142660485 chr7:142722358~142722764:+ CESC cis rs7777677 0.925 rs6960743 ENSG00000244273.1 PGBD4P1 -4.72 4.23e-06 0.00267 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142661768 chr7:142722358~142722764:+ CESC cis rs7777677 0.925 rs6956756 ENSG00000244273.1 PGBD4P1 -4.72 4.23e-06 0.00267 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142661832 chr7:142722358~142722764:+ CESC cis rs7777677 0.889 rs6975391 ENSG00000244273.1 PGBD4P1 -4.72 4.23e-06 0.00267 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142662001 chr7:142722358~142722764:+ CESC cis rs7777677 0.925 rs9655661 ENSG00000244273.1 PGBD4P1 -4.72 4.23e-06 0.00267 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142662291 chr7:142722358~142722764:+ CESC cis rs7777677 0.888 rs9655574 ENSG00000244273.1 PGBD4P1 -4.72 4.23e-06 0.00267 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142662412 chr7:142722358~142722764:+ CESC cis rs7777677 0.963 rs4726550 ENSG00000244273.1 PGBD4P1 -4.72 4.23e-06 0.00267 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142662932 chr7:142722358~142722764:+ CESC cis rs7777677 0.963 rs7796324 ENSG00000244273.1 PGBD4P1 -4.72 4.23e-06 0.00267 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142663708 chr7:142722358~142722764:+ CESC cis rs7777677 0.925 rs73543808 ENSG00000244273.1 PGBD4P1 -4.72 4.24e-06 0.00268 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142660024 chr7:142722358~142722764:+ CESC cis rs12722605 0.54 rs36059985 ENSG00000232807.2 RP11-536K7.3 4.72 4.25e-06 0.00268 0.38 0.3 Inflammatory biomarkers; chr10:5996788 chr10:5934270~5945900:- CESC cis rs13113518 0.595 rs13120635 ENSG00000249700.7 SRD5A3-AS1 4.72 4.25e-06 0.00268 0.38 0.3 Height; chr4:55361200 chr4:55363971~55395847:- CESC cis rs4814920 0.756 rs6046400 ENSG00000275142.1 RP5-999L4.2 -4.72 4.26e-06 0.00268 -0.54 -0.3 Bipolar disorder (body mass index interaction); chr20:19878482 chr20:19871891~19872284:+ CESC cis rs10885122 0.602 rs4570512 ENSG00000278601.1 RP11-348N5.9 -4.72 4.26e-06 0.00268 -0.42 -0.3 Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;Fasting blood glucose; chr10:111279269 chr10:110907483~110908182:+ CESC cis rs9660180 0.935 rs9786942 ENSG00000268575.1 RP1-283E3.8 -4.72 4.27e-06 0.00269 -0.3 -0.3 Body mass index; chr1:1827774 chr1:1702736~1737688:- CESC cis rs11159086 0.793 rs11845370 ENSG00000259005.1 RP3-449M8.6 4.72 4.27e-06 0.00269 0.43 0.3 Advanced glycation end-product levels; chr14:74481587 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs3784035 ENSG00000259005.1 RP3-449M8.6 4.72 4.27e-06 0.00269 0.43 0.3 Advanced glycation end-product levels; chr14:74482221 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs12433382 ENSG00000259005.1 RP3-449M8.6 4.72 4.27e-06 0.00269 0.43 0.3 Advanced glycation end-product levels; chr14:74482940 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs10148268 ENSG00000259005.1 RP3-449M8.6 4.72 4.27e-06 0.00269 0.43 0.3 Advanced glycation end-product levels; chr14:74484261 chr14:74474007~74474864:- CESC cis rs10129255 0.957 rs28887506 ENSG00000211970.3 IGHV4-61 -4.72 4.27e-06 0.00269 -0.24 -0.3 Kawasaki disease; chr14:106785589 chr14:106639119~106639657:- CESC cis rs10788972 0.815 rs9651202 ENSG00000225183.1 RP4-758J24.4 -4.72 4.28e-06 0.00269 -0.35 -0.3 Parkinson disease and lewy body pathology; chr1:54087534 chr1:54089856~54090093:+ CESC cis rs9876781 0.559 rs11130167 ENSG00000229759.1 MRPS18AP1 4.72 4.29e-06 0.0027 0.3 0.3 Longevity; chr3:48358570 chr3:48256350~48256938:- CESC cis rs10875746 0.669 rs61941006 ENSG00000240399.1 RP1-228P16.1 -4.72 4.31e-06 0.00271 -0.39 -0.3 Longevity (90 years and older); chr12:48237350 chr12:48054813~48055591:- CESC cis rs4722166 0.63 rs7808457 ENSG00000179428.2 AC073072.5 4.72 4.31e-06 0.00271 0.46 0.3 Lung cancer; chr7:22758646 chr7:22725395~22727620:- CESC cis rs11638352 1 rs1808509 ENSG00000259479.5 SORD2P -4.71 4.31e-06 0.00271 -0.45 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44117341 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2555385 ENSG00000259479.5 SORD2P -4.71 4.31e-06 0.00271 -0.45 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44127261 chr15:44826371~44884694:- CESC cis rs9322193 0.923 rs9478291 ENSG00000268592.3 RAET1E-AS1 4.71 4.31e-06 0.00271 0.4 0.3 Lung cancer; chr6:149729434 chr6:149863494~149919507:+ CESC cis rs6991838 0.702 rs34496943 ENSG00000200714.1 Y_RNA 4.71 4.31e-06 0.00271 0.36 0.3 Intelligence (multi-trait analysis); chr8:65676978 chr8:65592731~65592820:+ CESC cis rs6991838 0.733 rs13281090 ENSG00000200714.1 Y_RNA 4.71 4.31e-06 0.00271 0.36 0.3 Intelligence (multi-trait analysis); chr8:65678244 chr8:65592731~65592820:+ CESC cis rs6991838 0.701 rs17395275 ENSG00000200714.1 Y_RNA 4.71 4.31e-06 0.00271 0.36 0.3 Intelligence (multi-trait analysis); chr8:65679003 chr8:65592731~65592820:+ CESC cis rs875971 0.756 rs4718328 ENSG00000237310.1 GS1-124K5.4 -4.71 4.32e-06 0.00272 -0.28 -0.3 Aortic root size; chr7:66228350 chr7:66493706~66495474:+ CESC cis rs34779708 0.766 rs7913451 ENSG00000230534.5 RP11-297A16.2 4.71 4.32e-06 0.00272 0.43 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35262597 chr10:35098006~35127020:- CESC cis rs34779708 0.766 rs7897088 ENSG00000230534.5 RP11-297A16.2 4.71 4.32e-06 0.00272 0.43 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35262639 chr10:35098006~35127020:- CESC cis rs9640161 0.789 rs1464752 ENSG00000261305.1 RP4-584D14.7 4.71 4.32e-06 0.00272 0.41 0.3 Blood protein levels;Circulating chemerin levels; chr7:150324195 chr7:150341771~150342607:+ CESC cis rs9640161 0.789 rs1464753 ENSG00000261305.1 RP4-584D14.7 4.71 4.32e-06 0.00272 0.41 0.3 Blood protein levels;Circulating chemerin levels; chr7:150324261 chr7:150341771~150342607:+ CESC cis rs11159086 1 rs12433848 ENSG00000259005.1 RP3-449M8.6 4.71 4.33e-06 0.00272 0.47 0.3 Advanced glycation end-product levels; chr14:74497570 chr14:74474007~74474864:- CESC cis rs1056107 0.763 rs60623018 ENSG00000225513.1 RP11-165N19.2 -4.71 4.33e-06 0.00272 -0.37 -0.3 Colorectal cancer; chr9:112175922 chr9:112173522~112173971:- CESC cis rs761746 0.542 rs7290856 ENSG00000236132.1 CTA-440B3.1 -4.71 4.34e-06 0.00273 -0.39 -0.3 Intelligence; chr22:31834930 chr22:31816379~31817491:- CESC cis rs67180937 0.774 rs3748626 ENSG00000272750.1 RP11-378J18.8 -4.71 4.34e-06 0.00273 -0.38 -0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222629461 chr1:222658867~222661512:- CESC cis rs6991838 0.8 rs11786598 ENSG00000272010.1 CTD-3025N20.3 -4.71 4.35e-06 0.00274 -0.34 -0.3 Intelligence (multi-trait analysis); chr8:65559944 chr8:65591850~65592472:- CESC cis rs55794721 0.543 rs1293260 ENSG00000261349.1 RP3-465N24.5 -4.71 4.36e-06 0.00274 -0.31 -0.3 Mean corpuscular volume;Plateletcrit; chr1:25382613 chr1:25266102~25267136:- CESC cis rs2243480 1 rs73150014 ENSG00000232559.3 GS1-124K5.12 4.71 4.36e-06 0.00274 0.5 0.3 Diabetic kidney disease; chr7:65985932 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1723270 ENSG00000232559.3 GS1-124K5.12 4.71 4.36e-06 0.00274 0.5 0.3 Diabetic kidney disease; chr7:66004843 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35396113 ENSG00000232559.3 GS1-124K5.12 4.71 4.36e-06 0.00274 0.5 0.3 Diabetic kidney disease; chr7:66030474 chr7:66554588~66576923:- CESC cis rs2439831 0.867 rs2255042 ENSG00000275601.1 AC011330.13 4.71 4.37e-06 0.00274 0.41 0.3 Lung cancer in ever smokers; chr15:43542120 chr15:43642389~43643023:- CESC cis rs2564921 0.704 rs35671032 ENSG00000242142.1 SERBP1P3 -4.71 4.37e-06 0.00274 -0.36 -0.3 Height; chr3:52972039 chr3:53064283~53065091:- CESC cis rs16885979 1 rs34142287 ENSG00000224984.1 RP11-524H19.2 4.71 4.37e-06 0.00274 0.72 0.3 Daytime sleep phenotypes; chr6:54831486 chr6:54840118~54840855:- CESC cis rs16885979 1 rs62412628 ENSG00000224984.1 RP11-524H19.2 4.71 4.37e-06 0.00274 0.72 0.3 Daytime sleep phenotypes; chr6:54831787 chr6:54840118~54840855:- CESC cis rs2836950 0.545 rs11700449 ENSG00000232608.1 TIMM9P2 4.71 4.37e-06 0.00274 0.34 0.3 Menarche (age at onset); chr21:39150493 chr21:39216624~39217506:+ CESC cis rs8177876 0.822 rs12443549 ENSG00000261838.4 RP11-303E16.6 -4.71 4.38e-06 0.00275 -0.65 -0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81070596 chr16:81069854~81076598:+ CESC cis rs6496044 0.507 rs2467096 ENSG00000202081.1 RNU6-1280P -4.71 4.38e-06 0.00275 -0.32 -0.3 Interstitial lung disease; chr15:85667447 chr15:85651522~85651628:- CESC cis rs9907295 0.688 rs4572457 ENSG00000270977.1 AC015849.16 -4.71 4.38e-06 0.00275 -0.45 -0.3 Fibroblast growth factor basic levels; chr17:35813645 chr17:35893707~35911023:- CESC cis rs875971 0.862 rs3893216 ENSG00000222364.1 RNU6-96P 4.71 4.38e-06 0.00275 0.36 0.3 Aortic root size; chr7:66325720 chr7:66395191~66395286:+ CESC cis rs494459 0.838 rs12796102 ENSG00000255422.1 AP002954.4 -4.71 4.39e-06 0.00275 -0.36 -0.3 Height; chr11:118791319 chr11:118704607~118750263:+ CESC cis rs2028299 1 rs4932143 ENSG00000259677.1 RP11-493E3.1 4.71 4.39e-06 0.00275 0.41 0.3 Type 2 diabetes; chr15:89828835 chr15:89876540~89877285:+ CESC cis rs7208859 0.623 rs9912440 ENSG00000266490.1 CTD-2349P21.9 4.71 4.39e-06 0.00275 0.45 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30821754 chr17:30792372~30792833:+ CESC cis rs6991838 0.778 rs11782837 ENSG00000272010.1 CTD-3025N20.3 4.71 4.39e-06 0.00275 0.34 0.3 Intelligence (multi-trait analysis); chr8:65550328 chr8:65591850~65592472:- CESC cis rs9322193 0.923 rs1934534 ENSG00000268592.3 RAET1E-AS1 4.71 4.39e-06 0.00276 0.39 0.3 Lung cancer; chr6:149711896 chr6:149863494~149919507:+ CESC cis rs7208859 0.623 rs1061342 ENSG00000266490.1 CTD-2349P21.9 4.71 4.4e-06 0.00276 0.47 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30792372~30792833:+ CESC cis rs57221529 0.654 rs77015126 ENSG00000225138.6 CTD-2228K2.7 4.71 4.41e-06 0.00276 0.48 0.3 Lung disease severity in cystic fibrosis; chr5:670794 chr5:473236~480884:+ CESC cis rs7189233 0.531 rs9929873 ENSG00000279344.1 RP11-44F14.7 4.71 4.41e-06 0.00276 0.28 0.3 Intelligence (multi-trait analysis); chr16:53456764 chr16:53478957~53481550:- CESC cis rs67180937 0.882 rs17163313 ENSG00000272750.1 RP11-378J18.8 -4.71 4.41e-06 0.00276 -0.38 -0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222626283 chr1:222658867~222661512:- CESC cis rs11159086 0.793 rs10147316 ENSG00000259005.1 RP3-449M8.6 4.71 4.42e-06 0.00277 0.43 0.3 Advanced glycation end-product levels; chr14:74475688 chr14:74474007~74474864:- CESC cis rs11159086 0.838 rs10147963 ENSG00000259005.1 RP3-449M8.6 4.71 4.42e-06 0.00277 0.43 0.3 Advanced glycation end-product levels; chr14:74476091 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs8021664 ENSG00000259005.1 RP3-449M8.6 4.71 4.42e-06 0.00277 0.43 0.3 Advanced glycation end-product levels; chr14:74476592 chr14:74474007~74474864:- CESC cis rs11159086 0.793 rs1860108 ENSG00000259005.1 RP3-449M8.6 4.71 4.42e-06 0.00277 0.43 0.3 Advanced glycation end-product levels; chr14:74478562 chr14:74474007~74474864:- CESC cis rs7508 0.595 rs383091 ENSG00000253671.1 RP11-806O11.1 -4.71 4.42e-06 0.00277 -0.31 -0.3 Atrial fibrillation; chr8:18027097 chr8:17808941~17820868:+ CESC cis rs9322193 0.886 rs4870055 ENSG00000216906.2 RP11-350J20.9 4.71 4.43e-06 0.00277 0.36 0.3 Lung cancer; chr6:149848433 chr6:149904243~149906418:+ CESC cis rs6142102 0.59 rs6059691 ENSG00000275784.1 RP5-1125A11.6 4.71 4.43e-06 0.00278 0.32 0.3 Skin pigmentation; chr20:34149161 chr20:33989480~33991818:- CESC cis rs3091242 0.866 rs11249249 ENSG00000261349.1 RP3-465N24.5 -4.71 4.44e-06 0.00278 -0.31 -0.3 Erythrocyte sedimentation rate; chr1:25431643 chr1:25266102~25267136:- CESC cis rs12439619 0.705 rs17354185 ENSG00000255769.6 GOLGA2P10 4.71 4.45e-06 0.00278 0.44 0.3 Intelligence (multi-trait analysis); chr15:82133829 chr15:82472993~82513950:- CESC cis rs6693388 0.548 rs2999561 ENSG00000229021.2 AL591893.1 4.71 4.45e-06 0.00278 0.35 0.3 Blood metabolite ratios; chr1:152012071 chr1:151994531~152042774:+ CESC cis rs8059260 0.736 rs12149904 ENSG00000274038.1 RP11-66H6.4 -4.71 4.45e-06 0.00278 -0.5 -0.3 Alcohol consumption over the past year; chr16:10991789 chr16:11056556~11057034:+ CESC cis rs875971 0.862 rs10282433 ENSG00000237310.1 GS1-124K5.4 -4.71 4.45e-06 0.00279 -0.28 -0.3 Aortic root size; chr7:66256452 chr7:66493706~66495474:+ CESC cis rs9907295 0.591 rs4796128 ENSG00000271013.1 AC015849.15 -4.71 4.45e-06 0.00279 -0.34 -0.3 Fibroblast growth factor basic levels; chr17:35899268 chr17:35912635~35918010:- CESC cis rs9640161 0.75 rs73170185 ENSG00000261305.1 RP4-584D14.7 4.71 4.45e-06 0.00279 0.43 0.3 Blood protein levels;Circulating chemerin levels; chr7:150333102 chr7:150341771~150342607:+ CESC cis rs17507216 0.588 rs28864981 ENSG00000255769.6 GOLGA2P10 -4.71 4.45e-06 0.00279 -0.44 -0.3 Excessive daytime sleepiness; chr15:82695420 chr15:82472993~82513950:- CESC cis rs17507216 0.628 rs8032321 ENSG00000255769.6 GOLGA2P10 -4.71 4.45e-06 0.00279 -0.44 -0.3 Excessive daytime sleepiness; chr15:82698956 chr15:82472993~82513950:- CESC cis rs17507216 0.628 rs8040488 ENSG00000255769.6 GOLGA2P10 -4.71 4.45e-06 0.00279 -0.44 -0.3 Excessive daytime sleepiness; chr15:82699081 chr15:82472993~82513950:- CESC cis rs3091242 0.933 rs35148262 ENSG00000261349.1 RP3-465N24.5 -4.71 4.45e-06 0.00279 -0.3 -0.3 Erythrocyte sedimentation rate; chr1:25440132 chr1:25266102~25267136:- CESC cis rs748404 0.697 rs555001 ENSG00000205771.5 CATSPER2P1 -4.71 4.46e-06 0.00279 -0.37 -0.3 Lung cancer; chr15:43253530 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs475261 ENSG00000205771.5 CATSPER2P1 -4.71 4.46e-06 0.00279 -0.37 -0.3 Lung cancer; chr15:43254258 chr15:43726918~43747094:- CESC cis rs8062405 0.723 rs4788077 ENSG00000259982.1 CDC37P1 4.71 4.46e-06 0.00279 0.4 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558443 chr16:28700294~28701540:- CESC cis rs8062405 0.755 rs56272201 ENSG00000259982.1 CDC37P1 4.71 4.46e-06 0.00279 0.4 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569364 chr16:28700294~28701540:- CESC cis rs8062405 0.755 rs62034355 ENSG00000259982.1 CDC37P1 4.71 4.46e-06 0.00279 0.4 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569717 chr16:28700294~28701540:- CESC cis rs875971 0.545 rs6969224 ENSG00000226824.5 RP4-756H11.3 -4.71 4.46e-06 0.00279 -0.45 -0.3 Aortic root size; chr7:66370011 chr7:66654538~66669855:+ CESC cis rs763121 0.925 rs4821797 ENSG00000273076.1 RP3-508I15.22 4.71 4.46e-06 0.00279 0.35 0.3 Menopause (age at onset); chr22:38620177 chr22:38743495~38743910:+ CESC cis rs875971 0.83 rs778711 ENSG00000222364.1 RNU6-96P -4.71 4.47e-06 0.0028 -0.36 -0.3 Aortic root size; chr7:66386670 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs1083554 ENSG00000222364.1 RNU6-96P -4.71 4.47e-06 0.0028 -0.36 -0.3 Aortic root size; chr7:66387354 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs778707 ENSG00000222364.1 RNU6-96P -4.71 4.47e-06 0.0028 -0.36 -0.3 Aortic root size; chr7:66392040 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs778705 ENSG00000222364.1 RNU6-96P -4.71 4.47e-06 0.0028 -0.36 -0.3 Aortic root size; chr7:66396128 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs778697 ENSG00000222364.1 RNU6-96P -4.71 4.47e-06 0.0028 -0.36 -0.3 Aortic root size; chr7:66405439 chr7:66395191~66395286:+ CESC cis rs875971 0.798 rs7789615 ENSG00000222364.1 RNU6-96P -4.71 4.47e-06 0.0028 -0.36 -0.3 Aortic root size; chr7:66413674 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6978028 ENSG00000222364.1 RNU6-96P -4.71 4.47e-06 0.0028 -0.36 -0.3 Aortic root size; chr7:66421313 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6947339 ENSG00000222364.1 RNU6-96P -4.71 4.47e-06 0.0028 -0.36 -0.3 Aortic root size; chr7:66423483 chr7:66395191~66395286:+ CESC cis rs7927592 0.956 rs2510384 ENSG00000212093.1 AP000807.1 4.71 4.47e-06 0.0028 0.35 0.3 Total body bone mineral density; chr11:68624369 chr11:68506083~68506166:- CESC cis rs761746 0.577 rs5994431 ENSG00000236132.1 CTA-440B3.1 4.71 4.48e-06 0.0028 0.39 0.3 Intelligence; chr22:31814314 chr22:31816379~31817491:- CESC cis rs875971 0.862 rs3893216 ENSG00000232559.3 GS1-124K5.12 -4.71 4.48e-06 0.0028 -0.33 -0.3 Aortic root size; chr7:66325720 chr7:66554588~66576923:- CESC cis rs6504622 0.577 rs197915 ENSG00000263142.4 LRRC37A17P 4.71 4.48e-06 0.0028 0.24 0.3 Orofacial clefts; chr17:46913156 chr17:46978481~47054569:+ CESC cis rs875971 0.825 rs1860472 ENSG00000222364.1 RNU6-96P 4.71 4.48e-06 0.0028 0.36 0.3 Aortic root size; chr7:66617736 chr7:66395191~66395286:+ CESC cis rs8042680 1 rs11853024 ENSG00000214432.8 AC068831.10 -4.71 4.49e-06 0.0028 -0.38 -0.3 Type 2 diabetes; chr15:90971567 chr15:91022619~91036611:+ CESC cis rs3091242 0.904 rs6661533 ENSG00000261349.1 RP3-465N24.5 -4.71 4.49e-06 0.00281 -0.3 -0.3 Erythrocyte sedimentation rate; chr1:25445224 chr1:25266102~25267136:- CESC cis rs8177876 0.822 rs9923732 ENSG00000261838.4 RP11-303E16.6 4.71 4.5e-06 0.00281 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077298 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs9933184 ENSG00000261838.4 RP11-303E16.6 4.71 4.5e-06 0.00281 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077571 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs9926174 ENSG00000261838.4 RP11-303E16.6 4.71 4.5e-06 0.00281 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077831 chr16:81069854~81076598:+ CESC cis rs8177876 0.642 rs8052490 ENSG00000261838.4 RP11-303E16.6 4.71 4.5e-06 0.00281 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078251 chr16:81069854~81076598:+ CESC cis rs763121 0.889 rs4820335 ENSG00000273076.1 RP3-508I15.22 -4.71 4.5e-06 0.00281 -0.35 -0.3 Menopause (age at onset); chr22:38539922 chr22:38743495~38743910:+ CESC cis rs7692995 0.844 rs16895971 ENSG00000235413.3 KRT18P63 4.71 4.5e-06 0.00281 0.4 0.3 Height; chr4:17883363 chr4:17911674~17912976:+ CESC cis rs2919917 0.617 rs4641056 ENSG00000254352.1 RP11-578O24.2 4.71 4.5e-06 0.00281 0.41 0.3 Lymphocyte counts; chr8:78670261 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs7823970 ENSG00000254352.1 RP11-578O24.2 4.71 4.5e-06 0.00281 0.41 0.3 Lymphocyte counts; chr8:78681364 chr8:78723796~78724136:- CESC cis rs2919917 0.616 rs7823723 ENSG00000254352.1 RP11-578O24.2 4.71 4.5e-06 0.00281 0.41 0.3 Lymphocyte counts; chr8:78681390 chr8:78723796~78724136:- CESC cis rs7250849 0.79 rs73052830 ENSG00000273837.1 LLNLR-470E3.1 -4.71 4.5e-06 0.00281 -0.59 -0.3 Blood protein levels; chr19:51657512 chr19:51639478~51639931:- CESC cis rs9322193 0.736 rs3828701 ENSG00000216906.2 RP11-350J20.9 4.7 4.51e-06 0.00282 0.34 0.3 Lung cancer; chr6:149791063 chr6:149904243~149906418:+ CESC cis rs9322193 0.736 rs3805750 ENSG00000216906.2 RP11-350J20.9 4.7 4.51e-06 0.00282 0.34 0.3 Lung cancer; chr6:149791065 chr6:149904243~149906418:+ CESC cis rs2243480 1 rs35542501 ENSG00000228409.4 CCT6P1 4.7 4.51e-06 0.00282 0.43 0.3 Diabetic kidney disease; chr7:65966228 chr7:65751142~65763354:+ CESC cis rs2243480 0.708 rs781141 ENSG00000228409.4 CCT6P1 4.7 4.51e-06 0.00282 0.43 0.3 Diabetic kidney disease; chr7:65973566 chr7:65751142~65763354:+ CESC cis rs748404 0.631 rs6493083 ENSG00000249839.1 AC011330.5 -4.7 4.51e-06 0.00282 -0.33 -0.3 Lung cancer; chr15:43345787 chr15:43663654~43684339:- CESC cis rs2243480 1 rs160652 ENSG00000275400.1 RP4-756H11.5 4.7 4.51e-06 0.00282 0.53 0.3 Diabetic kidney disease; chr7:66073444 chr7:66553805~66554199:- CESC cis rs6693388 0.52 rs2932570 ENSG00000229021.2 AL591893.1 4.7 4.51e-06 0.00282 0.34 0.3 Blood metabolite ratios; chr1:152014344 chr1:151994531~152042774:+ CESC cis rs2739330 0.761 rs5760176 ENSG00000272787.1 KB-226F1.2 4.7 4.53e-06 0.00283 0.32 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23969211~23969873:+ CESC cis rs11690935 0.851 rs7581072 ENSG00000228389.1 AC068039.4 4.7 4.53e-06 0.00283 0.4 0.3 Schizophrenia; chr2:171994938 chr2:171773482~171775844:+ CESC cis rs1799949 1 rs8074136 ENSG00000267681.1 CTD-3199J23.6 -4.7 4.54e-06 0.00283 -0.4 -0.3 Menopause (age at onset); chr17:43190296 chr17:43144956~43145255:+ CESC cis rs73086581 0.947 rs73084523 ENSG00000229539.1 RP11-119B16.2 4.7 4.54e-06 0.00283 0.52 0.3 Response to antidepressants in depression; chr20:3894979 chr20:3888239~3888868:- CESC cis rs748404 0.55 rs12912505 ENSG00000249839.1 AC011330.5 -4.7 4.55e-06 0.00284 -0.43 -0.3 Lung cancer; chr15:43525206 chr15:43663654~43684339:- CESC cis rs10875746 0.669 rs11168508 ENSG00000240399.1 RP1-228P16.1 -4.7 4.55e-06 0.00284 -0.38 -0.3 Longevity (90 years and older); chr12:48289728 chr12:48054813~48055591:- CESC cis rs9907295 0.71 rs4796113 ENSG00000270977.1 AC015849.16 -4.7 4.56e-06 0.00284 -0.45 -0.3 Fibroblast growth factor basic levels; chr17:35832562 chr17:35893707~35911023:- CESC cis rs9907295 0.818 rs4796114 ENSG00000270977.1 AC015849.16 -4.7 4.56e-06 0.00284 -0.45 -0.3 Fibroblast growth factor basic levels; chr17:35832653 chr17:35893707~35911023:- CESC cis rs9907295 0.818 rs3785764 ENSG00000270977.1 AC015849.16 -4.7 4.56e-06 0.00284 -0.45 -0.3 Fibroblast growth factor basic levels; chr17:35833760 chr17:35893707~35911023:- CESC cis rs12439619 0.846 rs62011975 ENSG00000276710.3 CSPG4P8 -4.7 4.56e-06 0.00284 -0.45 -0.3 Intelligence (multi-trait analysis); chr15:82159213 chr15:82459472~82477258:+ CESC cis rs12439619 0.846 rs62012004 ENSG00000276710.3 CSPG4P8 -4.7 4.56e-06 0.00284 -0.45 -0.3 Intelligence (multi-trait analysis); chr15:82183924 chr15:82459472~82477258:+ CESC cis rs9549367 0.789 rs12866090 ENSG00000269125.1 RP11-98F14.11 -4.7 4.56e-06 0.00285 -0.42 -0.3 Platelet distribution width; chr13:113215096 chr13:113165002~113165183:- CESC cis rs9813712 0.571 rs9855777 ENSG00000228252.7 COL6A4P2 4.7 4.57e-06 0.00285 0.35 0.3 Response to amphetamines; chr3:130214805 chr3:130212823~130273806:+ CESC cis rs950169 0.58 rs11635597 ENSG00000225151.9 GOLGA2P7 -4.7 4.57e-06 0.00285 -0.41 -0.3 Schizophrenia; chr15:84622468 chr15:84199311~84230136:- CESC cis rs6991838 0.778 rs13261559 ENSG00000272010.1 CTD-3025N20.3 4.7 4.58e-06 0.00285 0.32 0.3 Intelligence (multi-trait analysis); chr8:65549808 chr8:65591850~65592472:- CESC cis rs6991838 0.778 rs7843697 ENSG00000272010.1 CTD-3025N20.3 4.7 4.58e-06 0.00285 0.32 0.3 Intelligence (multi-trait analysis); chr8:65550533 chr8:65591850~65592472:- CESC cis rs6991838 0.778 rs7843724 ENSG00000272010.1 CTD-3025N20.3 4.7 4.58e-06 0.00285 0.32 0.3 Intelligence (multi-trait analysis); chr8:65550581 chr8:65591850~65592472:- CESC cis rs6991838 0.806 rs35284121 ENSG00000272010.1 CTD-3025N20.3 4.7 4.58e-06 0.00285 0.32 0.3 Intelligence (multi-trait analysis); chr8:65551230 chr8:65591850~65592472:- CESC cis rs763121 0.853 rs138704 ENSG00000273076.1 RP3-508I15.22 4.7 4.58e-06 0.00286 0.34 0.3 Menopause (age at onset); chr22:38737405 chr22:38743495~38743910:+ CESC cis rs9660180 0.934 rs34849348 ENSG00000268575.1 RP1-283E3.8 -4.7 4.58e-06 0.00286 -0.3 -0.3 Body mass index; chr1:1831318 chr1:1702736~1737688:- CESC cis rs9660180 0.967 rs10907191 ENSG00000268575.1 RP1-283E3.8 -4.7 4.58e-06 0.00286 -0.3 -0.3 Body mass index; chr1:1843381 chr1:1702736~1737688:- CESC cis rs3762637 1 rs72960431 ENSG00000272758.4 RP11-299J3.8 -4.7 4.59e-06 0.00286 -0.41 -0.3 LDL cholesterol levels; chr3:122509814 chr3:122416207~122443180:+ CESC cis rs9640161 0.75 rs11765644 ENSG00000261305.1 RP4-584D14.7 4.7 4.59e-06 0.00286 0.42 0.3 Blood protein levels;Circulating chemerin levels; chr7:150329250 chr7:150341771~150342607:+ CESC cis rs875971 0.545 rs2707851 ENSG00000222364.1 RNU6-96P 4.7 4.59e-06 0.00286 0.41 0.3 Aortic root size; chr7:66624178 chr7:66395191~66395286:+ CESC cis rs9549367 0.577 rs513479 ENSG00000269125.1 RP11-98F14.11 -4.7 4.59e-06 0.00286 -0.46 -0.3 Platelet distribution width; chr13:113160886 chr13:113165002~113165183:- CESC cis rs10129255 1 rs10134517 ENSG00000211970.3 IGHV4-61 -4.7 4.6e-06 0.00286 -0.24 -0.3 Kawasaki disease; chr14:106718498 chr14:106639119~106639657:- CESC cis rs5758659 0.714 rs5751216 ENSG00000227370.1 RP4-669P10.19 4.7 4.6e-06 0.00286 0.32 0.3 Cognitive function; chr22:42112933 chr22:42132543~42132998:+ CESC cis rs5758659 0.714 rs5758589 ENSG00000227370.1 RP4-669P10.19 4.7 4.6e-06 0.00286 0.32 0.3 Cognitive function; chr22:42122378 chr22:42132543~42132998:+ CESC cis rs1930961 0.85 rs5996945 ENSG00000272942.1 CTA-246H3.12 4.7 4.6e-06 0.00287 0.43 0.3 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25434324~25435070:- CESC cis rs8100891 0.537 rs2302773 ENSG00000267213.4 AC007773.2 -4.7 4.61e-06 0.00287 -0.46 -0.3 Neuroticism; chr19:32436405 chr19:32390050~32405560:- CESC cis rs10875746 0.624 rs10875777 ENSG00000240399.1 RP1-228P16.1 -4.7 4.62e-06 0.00287 -0.38 -0.3 Longevity (90 years and older); chr12:48228288 chr12:48054813~48055591:- CESC cis rs6142102 0.886 rs6059583 ENSG00000276073.1 RP5-1125A11.7 -4.7 4.62e-06 0.00288 -0.3 -0.3 Skin pigmentation; chr20:33944308 chr20:33985617~33988989:- CESC cis rs2842992 1 rs2842992 ENSG00000237927.1 RP3-393E18.2 -4.7 4.63e-06 0.00288 -0.4 -0.3 Age-related macular degeneration (geographic atrophy); chr6:159650127 chr6:159586955~159589169:- CESC cis rs9322193 0.923 rs9766037 ENSG00000216906.2 RP11-350J20.9 4.7 4.63e-06 0.00288 0.33 0.3 Lung cancer; chr6:149616921 chr6:149904243~149906418:+ CESC cis rs2337406 0.925 rs873534 ENSG00000211974.3 IGHV2-70 -4.7 4.63e-06 0.00288 -0.47 -0.3 Alzheimer's disease (late onset); chr14:106667423 chr14:106723574~106724093:- CESC cis rs7208859 0.573 rs73267872 ENSG00000266490.1 CTD-2349P21.9 4.7 4.63e-06 0.00288 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30792372~30792833:+ CESC cis rs6991838 0.733 rs13281981 ENSG00000200714.1 Y_RNA 4.7 4.63e-06 0.00288 0.36 0.3 Intelligence (multi-trait analysis); chr8:65611649 chr8:65592731~65592820:+ CESC cis rs2115630 0.691 rs2292462 ENSG00000225151.9 GOLGA2P7 4.7 4.63e-06 0.00288 0.34 0.3 P wave terminal force; chr15:84657523 chr15:84199311~84230136:- CESC cis rs2842992 0.709 rs1853257 ENSG00000237927.1 RP3-393E18.2 -4.7 4.63e-06 0.00288 -0.39 -0.3 Age-related macular degeneration (geographic atrophy); chr6:159791678 chr6:159586955~159589169:- CESC cis rs73086581 1 rs73086512 ENSG00000229539.1 RP11-119B16.2 4.7 4.63e-06 0.00288 0.48 0.3 Response to antidepressants in depression; chr20:3942125 chr20:3888239~3888868:- CESC cis rs1061377 1 rs7664078 ENSG00000249685.1 RP11-360F5.3 4.7 4.64e-06 0.00288 0.36 0.3 Uric acid levels; chr4:39116583 chr4:39133913~39135608:+ CESC cis rs950169 0.58 rs1061737 ENSG00000225151.9 GOLGA2P7 -4.7 4.64e-06 0.00288 -0.41 -0.3 Schizophrenia; chr15:84640559 chr15:84199311~84230136:- CESC cis rs761746 0.846 rs2295251 ENSG00000236132.1 CTA-440B3.1 4.7 4.64e-06 0.00289 0.38 0.3 Intelligence; chr22:31617279 chr22:31816379~31817491:- CESC cis rs875971 0.545 rs4718348 ENSG00000237310.1 GS1-124K5.4 4.7 4.64e-06 0.00289 0.33 0.3 Aortic root size; chr7:66441589 chr7:66493706~66495474:+ CESC cis rs2919917 0.628 rs10111658 ENSG00000254352.1 RP11-578O24.2 4.7 4.65e-06 0.00289 0.42 0.3 Lymphocyte counts; chr8:78652834 chr8:78723796~78724136:- CESC cis rs2919917 0.59 rs10098472 ENSG00000254352.1 RP11-578O24.2 4.7 4.65e-06 0.00289 0.42 0.3 Lymphocyte counts; chr8:78652955 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs13251931 ENSG00000254352.1 RP11-578O24.2 4.7 4.65e-06 0.00289 0.42 0.3 Lymphocyte counts; chr8:78653990 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs1351742 ENSG00000254352.1 RP11-578O24.2 4.7 4.65e-06 0.00289 0.42 0.3 Lymphocyte counts; chr8:78655823 chr8:78723796~78724136:- CESC cis rs2919917 0.666 rs982032 ENSG00000254352.1 RP11-578O24.2 4.7 4.65e-06 0.00289 0.42 0.3 Lymphocyte counts; chr8:78655825 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs13265305 ENSG00000254352.1 RP11-578O24.2 4.7 4.65e-06 0.00289 0.42 0.3 Lymphocyte counts; chr8:78656575 chr8:78723796~78724136:- CESC cis rs6964833 0.786 rs35633336 ENSG00000277053.3 GTF2IP1 -4.7 4.65e-06 0.00289 -0.37 -0.3 Menarche (age at onset); chr7:74643961 chr7:75185385~75237696:- CESC cis rs6964833 0.935 rs34630792 ENSG00000277053.3 GTF2IP1 -4.7 4.65e-06 0.00289 -0.37 -0.3 Menarche (age at onset); chr7:74646869 chr7:75185385~75237696:- CESC cis rs6686842 0.965 rs12731155 ENSG00000235358.1 RP11-399E6.1 4.7 4.66e-06 0.00289 0.37 0.3 Height; chr1:41000800 chr1:41242373~41284861:+ CESC cis rs9549367 0.713 rs3024761 ENSG00000269125.1 RP11-98F14.11 4.7 4.66e-06 0.00289 0.43 0.3 Platelet distribution width; chr13:113169776 chr13:113165002~113165183:- CESC cis rs7560272 0.501 rs4852978 ENSG00000273245.1 RP11-434P11.2 -4.7 4.66e-06 0.00289 -0.37 -0.3 Schizophrenia; chr2:73715983 chr2:73750256~73750786:- CESC cis rs7560272 0.501 rs11891140 ENSG00000273245.1 RP11-434P11.2 -4.7 4.66e-06 0.00289 -0.37 -0.3 Schizophrenia; chr2:73716957 chr2:73750256~73750786:- CESC cis rs7560272 0.501 rs12713789 ENSG00000273245.1 RP11-434P11.2 -4.7 4.66e-06 0.00289 -0.37 -0.3 Schizophrenia; chr2:73718473 chr2:73750256~73750786:- CESC cis rs7560272 0.501 rs12713790 ENSG00000273245.1 RP11-434P11.2 -4.7 4.66e-06 0.00289 -0.37 -0.3 Schizophrenia; chr2:73718484 chr2:73750256~73750786:- CESC cis rs875971 0.545 rs2279757 ENSG00000226824.5 RP4-756H11.3 -4.7 4.67e-06 0.0029 -0.45 -0.3 Aortic root size; chr7:66363676 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs11766183 ENSG00000226824.5 RP4-756H11.3 -4.7 4.67e-06 0.0029 -0.45 -0.3 Aortic root size; chr7:66374173 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs1065265 ENSG00000226824.5 RP4-756H11.3 -4.7 4.67e-06 0.0029 -0.45 -0.3 Aortic root size; chr7:66376216 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs7811204 ENSG00000226824.5 RP4-756H11.3 -4.7 4.67e-06 0.0029 -0.45 -0.3 Aortic root size; chr7:66387213 chr7:66654538~66669855:+ CESC cis rs7809950 1 rs4727680 ENSG00000238832.1 snoU109 -4.7 4.67e-06 0.0029 -0.35 -0.3 Coronary artery disease; chr7:107446962 chr7:107603363~107603507:+ CESC cis rs12439619 0.846 rs28470877 ENSG00000276710.3 CSPG4P8 -4.7 4.68e-06 0.0029 -0.44 -0.3 Intelligence (multi-trait analysis); chr15:82245797 chr15:82459472~82477258:+ CESC cis rs761746 0.577 rs5998136 ENSG00000236132.1 CTA-440B3.1 -4.7 4.68e-06 0.00291 -0.38 -0.3 Intelligence; chr22:31828687 chr22:31816379~31817491:- CESC cis rs875971 0.502 rs6460311 ENSG00000237310.1 GS1-124K5.4 -4.7 4.68e-06 0.00291 -0.35 -0.3 Aortic root size; chr7:66646886 chr7:66493706~66495474:+ CESC cis rs3931020 0.688 rs525487 ENSG00000272864.1 RP11-17E13.2 4.7 4.68e-06 0.00291 0.4 0.3 Resistin levels; chr1:74751736 chr1:74698769~74699333:- CESC cis rs2919917 0.628 rs2887482 ENSG00000254352.1 RP11-578O24.2 4.7 4.68e-06 0.00291 0.42 0.3 Lymphocyte counts; chr8:78659633 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs1905364 ENSG00000254352.1 RP11-578O24.2 4.7 4.68e-06 0.00291 0.42 0.3 Lymphocyte counts; chr8:78660244 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs1021157 ENSG00000254352.1 RP11-578O24.2 4.7 4.68e-06 0.00291 0.42 0.3 Lymphocyte counts; chr8:78662938 chr8:78723796~78724136:- CESC cis rs1538970 0.739 rs4660863 ENSG00000280836.1 AL355480.1 -4.7 4.68e-06 0.00291 -0.39 -0.3 Platelet count; chr1:45490196 chr1:45581219~45581321:- CESC cis rs1538970 0.816 rs3790583 ENSG00000280836.1 AL355480.1 -4.7 4.68e-06 0.00291 -0.39 -0.3 Platelet count; chr1:45491156 chr1:45581219~45581321:- CESC cis rs1538970 0.816 rs11211123 ENSG00000280836.1 AL355480.1 -4.7 4.68e-06 0.00291 -0.39 -0.3 Platelet count; chr1:45491937 chr1:45581219~45581321:- CESC cis rs1538970 0.816 rs11211124 ENSG00000280836.1 AL355480.1 -4.7 4.68e-06 0.00291 -0.39 -0.3 Platelet count; chr1:45496737 chr1:45581219~45581321:- CESC cis rs1538970 0.816 rs12029322 ENSG00000280836.1 AL355480.1 -4.7 4.68e-06 0.00291 -0.39 -0.3 Platelet count; chr1:45504774 chr1:45581219~45581321:- CESC cis rs1538970 0.774 rs67683090 ENSG00000280836.1 AL355480.1 -4.7 4.68e-06 0.00291 -0.39 -0.3 Platelet count; chr1:45512131 chr1:45581219~45581321:- CESC cis rs9907295 0.818 rs11658222 ENSG00000270977.1 AC015849.16 -4.7 4.69e-06 0.00291 -0.41 -0.3 Fibroblast growth factor basic levels; chr17:35825092 chr17:35893707~35911023:- CESC cis rs4722166 0.695 rs7787893 ENSG00000179428.2 AC073072.5 -4.7 4.69e-06 0.00291 -0.38 -0.3 Lung cancer; chr7:22734818 chr7:22725395~22727620:- CESC cis rs2739330 0.732 rs5760175 ENSG00000272787.1 KB-226F1.2 -4.7 4.69e-06 0.00291 -0.32 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23969211~23969873:+ CESC cis rs7208859 0.623 rs7219361 ENSG00000266490.1 CTD-2349P21.9 4.7 4.69e-06 0.00291 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753375 chr17:30792372~30792833:+ CESC cis rs6504950 0.924 rs2628316 ENSG00000275710.1 RP11-257O5.4 -4.7 4.69e-06 0.00291 -0.32 -0.3 Breast cancer; chr17:55142476 chr17:54964474~54964679:+ CESC cis rs1799949 1 rs33994002 ENSG00000267681.1 CTD-3199J23.6 -4.7 4.7e-06 0.00291 -0.4 -0.3 Menopause (age at onset); chr17:43176801 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs33920795 ENSG00000267681.1 CTD-3199J23.6 -4.7 4.7e-06 0.00291 -0.4 -0.3 Menopause (age at onset); chr17:43176993 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs33918839 ENSG00000267681.1 CTD-3199J23.6 -4.7 4.7e-06 0.00291 -0.4 -0.3 Menopause (age at onset); chr17:43177155 chr17:43144956~43145255:+ CESC cis rs9322193 0.962 rs3763162 ENSG00000268592.3 RAET1E-AS1 -4.7 4.7e-06 0.00292 -0.4 -0.3 Lung cancer; chr6:149819674 chr6:149863494~149919507:+ CESC cis rs3823536 0.583 rs1874327 ENSG00000275106.1 RP11-309L24.10 -4.7 4.71e-06 0.00292 -0.43 -0.3 Sjögren's syndrome; chr7:128945322 chr7:128952527~128953316:- CESC cis rs1023500 0.505 rs134886 ENSG00000273366.1 CTA-989H11.1 4.7 4.71e-06 0.00292 0.37 0.3 Schizophrenia; chr22:42277850 chr22:42278188~42278846:+ CESC cis rs763121 0.925 rs5757165 ENSG00000273076.1 RP3-508I15.22 4.69 4.71e-06 0.00293 0.35 0.3 Menopause (age at onset); chr22:38598572 chr22:38743495~38743910:+ CESC cis rs11846409 0.932 rs61233250 ENSG00000211974.3 IGHV2-70 -4.69 4.72e-06 0.00293 -0.39 -0.3 Rheumatic heart disease; chr14:106634072 chr14:106723574~106724093:- CESC cis rs944801 0.631 rs7027048 ENSG00000215221.2 UBA52P6 4.69 4.72e-06 0.00293 0.37 0.3 Type 2 diabetes; chr9:22053710 chr9:22012155~22012536:+ CESC cis rs950880 0.71 rs3771177 ENSG00000234389.1 AC007278.3 -4.69 4.72e-06 0.00293 -0.35 -0.3 Serum protein levels (sST2); chr2:102339400 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs3732129 ENSG00000234389.1 AC007278.3 -4.69 4.72e-06 0.00293 -0.35 -0.3 Serum protein levels (sST2); chr2:102341072 chr2:102438713~102440475:+ CESC cis rs17301013 0.507 rs12059307 ENSG00000227373.4 RP11-160H22.5 4.69 4.73e-06 0.00293 0.41 0.3 Systemic lupus erythematosus; chr1:174342105 chr1:174115300~174160004:- CESC cis rs7560272 0.538 rs12233112 ENSG00000273245.1 RP11-434P11.2 -4.69 4.73e-06 0.00293 -0.38 -0.3 Schizophrenia; chr2:73704637 chr2:73750256~73750786:- CESC cis rs875971 0.545 rs17138149 ENSG00000237310.1 GS1-124K5.4 4.69 4.73e-06 0.00293 0.31 0.3 Aortic root size; chr7:66228193 chr7:66493706~66495474:+ CESC cis rs6452524 0.746 rs28745311 ENSG00000249664.1 CTD-2227C6.2 4.69 4.73e-06 0.00294 0.37 0.3 Hypertension (SNP x SNP interaction); chr5:83123030 chr5:83012285~83013109:- CESC cis rs2836950 0.545 rs2836959 ENSG00000232608.1 TIMM9P2 4.69 4.74e-06 0.00294 0.33 0.3 Menarche (age at onset); chr21:39251742 chr21:39216624~39217506:+ CESC cis rs2283792 0.622 rs2266979 ENSG00000224086.5 LL22NC03-86G7.1 -4.69 4.74e-06 0.00294 -0.34 -0.3 Multiple sclerosis; chr22:21977447 chr22:21938293~21977632:+ CESC cis rs6452524 0.837 rs1479569 ENSG00000249664.1 CTD-2227C6.2 4.69 4.74e-06 0.00294 0.38 0.3 Hypertension (SNP x SNP interaction); chr5:83081747 chr5:83012285~83013109:- CESC cis rs875971 0.545 rs12670811 ENSG00000237310.1 GS1-124K5.4 4.69 4.74e-06 0.00294 0.32 0.3 Aortic root size; chr7:66358032 chr7:66493706~66495474:+ CESC cis rs875971 0.502 rs2946580 ENSG00000237310.1 GS1-124K5.4 -4.69 4.75e-06 0.00294 -0.34 -0.3 Aortic root size; chr7:66066855 chr7:66493706~66495474:+ CESC cis rs77972916 0.505 rs6756575 ENSG00000234936.1 AC010883.5 4.69 4.76e-06 0.00295 0.35 0.3 Granulocyte percentage of myeloid white cells; chr2:43301380 chr2:43229573~43233394:+ CESC cis rs7586673 1 rs7586673 ENSG00000227403.1 AC009299.3 -4.69 4.76e-06 0.00295 -0.39 -0.3 Intelligence (multi-trait analysis); chr2:161067009 chr2:161244739~161249050:+ CESC cis rs3738443 0.868 rs60698393 ENSG00000259865.1 RP11-488L18.10 4.69 4.76e-06 0.00295 0.34 0.3 Alcohol dependence; chr1:247198135 chr1:247187281~247188526:- CESC cis rs3738443 0.83 rs58405512 ENSG00000259865.1 RP11-488L18.10 4.69 4.76e-06 0.00295 0.34 0.3 Alcohol dependence; chr1:247198454 chr1:247187281~247188526:- CESC cis rs2243480 1 rs427044 ENSG00000232559.3 GS1-124K5.12 4.69 4.78e-06 0.00296 0.51 0.3 Diabetic kidney disease; chr7:66043558 chr7:66554588~66576923:- CESC cis rs4819052 0.851 rs2838856 ENSG00000223768.1 LINC00205 -4.69 4.78e-06 0.00296 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45260851 chr21:45293285~45297354:+ CESC cis rs7572733 0.935 rs2880389 ENSG00000222017.1 AC011997.1 4.69 4.79e-06 0.00296 0.34 0.3 Dermatomyositis; chr2:197936983 chr2:197693106~197774823:+ CESC cis rs7572733 0.935 rs11679040 ENSG00000222017.1 AC011997.1 4.69 4.79e-06 0.00296 0.34 0.3 Dermatomyositis; chr2:197942105 chr2:197693106~197774823:+ CESC cis rs9322193 0.923 rs11155674 ENSG00000268592.3 RAET1E-AS1 4.69 4.79e-06 0.00296 0.39 0.3 Lung cancer; chr6:149711111 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs12174349 ENSG00000268592.3 RAET1E-AS1 4.69 4.79e-06 0.00296 0.39 0.3 Lung cancer; chr6:149718012 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs2297932 ENSG00000268592.3 RAET1E-AS1 4.69 4.79e-06 0.00296 0.39 0.3 Lung cancer; chr6:149718225 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs2297928 ENSG00000268592.3 RAET1E-AS1 4.69 4.79e-06 0.00296 0.39 0.3 Lung cancer; chr6:149718584 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9479094 ENSG00000268592.3 RAET1E-AS1 4.69 4.79e-06 0.00296 0.39 0.3 Lung cancer; chr6:149725083 chr6:149863494~149919507:+ CESC cis rs6991838 0.765 rs10957358 ENSG00000272010.1 CTD-3025N20.3 4.69 4.79e-06 0.00297 0.33 0.3 Intelligence (multi-trait analysis); chr8:65590067 chr8:65591850~65592472:- CESC cis rs3762637 1 rs10049131 ENSG00000272758.4 RP11-299J3.8 -4.69 4.8e-06 0.00297 -0.42 -0.3 LDL cholesterol levels; chr3:122483255 chr3:122416207~122443180:+ CESC cis rs3762637 0.941 rs112768052 ENSG00000272758.4 RP11-299J3.8 -4.69 4.8e-06 0.00297 -0.42 -0.3 LDL cholesterol levels; chr3:122450537 chr3:122416207~122443180:+ CESC cis rs3762637 0.941 rs77599736 ENSG00000272758.4 RP11-299J3.8 -4.69 4.8e-06 0.00297 -0.42 -0.3 LDL cholesterol levels; chr3:122460662 chr3:122416207~122443180:+ CESC cis rs3762637 0.943 rs10439995 ENSG00000272758.4 RP11-299J3.8 -4.69 4.8e-06 0.00297 -0.42 -0.3 LDL cholesterol levels; chr3:122470313 chr3:122416207~122443180:+ CESC cis rs3762637 0.882 rs7630833 ENSG00000272758.4 RP11-299J3.8 -4.69 4.8e-06 0.00297 -0.42 -0.3 LDL cholesterol levels; chr3:122471577 chr3:122416207~122443180:+ CESC cis rs11157436 0.958 rs17255537 ENSG00000211813.2 TRAV34 4.69 4.81e-06 0.00297 0.34 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22208225 chr14:22207522~22208129:+ CESC cis rs453301 0.686 rs6601280 ENSG00000173295.6 FAM86B3P 4.69 4.81e-06 0.00297 0.41 0.3 Joint mobility (Beighton score); chr8:9051726 chr8:8228595~8244865:+ CESC cis rs8177876 0.822 rs9925940 ENSG00000261838.4 RP11-303E16.6 4.69 4.81e-06 0.00297 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077379 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs9925943 ENSG00000261838.4 RP11-303E16.6 4.69 4.81e-06 0.00297 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81077402 chr16:81069854~81076598:+ CESC cis rs1155848 0.571 rs6563127 ENSG00000227354.5 RBM26-AS1 4.69 4.81e-06 0.00297 0.58 0.3 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79642012 chr13:79406309~79424328:+ CESC cis rs7429990 0.901 rs6442091 ENSG00000229759.1 MRPS18AP1 -4.69 4.81e-06 0.00297 -0.32 -0.3 Educational attainment (years of education); chr3:48001568 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs4296617 ENSG00000229759.1 MRPS18AP1 -4.69 4.81e-06 0.00297 -0.32 -0.3 Educational attainment (years of education); chr3:48026818 chr3:48256350~48256938:- CESC cis rs5758659 0.714 rs6002607 ENSG00000273366.1 CTA-989H11.1 4.69 4.83e-06 0.00298 0.37 0.3 Cognitive function; chr22:42100502 chr22:42278188~42278846:+ CESC cis rs55794721 0.509 rs873308 ENSG00000261349.1 RP3-465N24.5 4.69 4.83e-06 0.00298 0.3 0.3 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25266102~25267136:- CESC cis rs8100891 0.537 rs738093 ENSG00000267213.4 AC007773.2 -4.69 4.83e-06 0.00298 -0.45 -0.3 Neuroticism; chr19:32439601 chr19:32390050~32405560:- CESC cis rs2548724 0.588 rs62369341 ENSG00000250682.4 LINC00491 4.69 4.83e-06 0.00298 0.36 0.3 Type 2 diabetes; chr5:102402034 chr5:102609156~102671559:- CESC cis rs950880 0.71 rs2287035 ENSG00000234389.1 AC007278.3 -4.69 4.83e-06 0.00299 -0.34 -0.3 Serum protein levels (sST2); chr2:102394070 chr2:102438713~102440475:+ CESC cis rs2243480 1 rs7794661 ENSG00000228409.4 CCT6P1 4.69 4.83e-06 0.00299 0.44 0.3 Diabetic kidney disease; chr7:65924743 chr7:65751142~65763354:+ CESC cis rs9309473 1 rs7598396 ENSG00000163016.8 ALMS1P 4.69 4.84e-06 0.00299 0.4 0.3 Metabolite levels; chr2:73425500 chr2:73644919~73685576:+ CESC cis rs4819052 0.851 rs9974891 ENSG00000223768.1 LINC00205 -4.69 4.84e-06 0.00299 -0.34 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45260852 chr21:45293285~45297354:+ CESC cis rs150992 0.504 rs11745405 ENSG00000248489.1 CTD-2007H13.3 -4.69 4.84e-06 0.00299 -0.4 -0.3 Body mass index; chr5:99047700 chr5:98929171~98995013:+ CESC cis rs2243480 1 rs313814 ENSG00000232559.3 GS1-124K5.12 4.69 4.84e-06 0.00299 0.51 0.3 Diabetic kidney disease; chr7:66038306 chr7:66554588~66576923:- CESC cis rs8100891 0.537 rs2012353 ENSG00000267213.4 AC007773.2 -4.69 4.84e-06 0.00299 -0.47 -0.3 Neuroticism; chr19:32408387 chr19:32390050~32405560:- CESC cis rs860295 0.702 rs12025532 ENSG00000225855.5 RUSC1-AS1 4.69 4.84e-06 0.00299 0.26 0.3 Body mass index; chr1:155399511 chr1:155316863~155324176:- CESC cis rs9813712 0.571 rs9824426 ENSG00000228252.7 COL6A4P2 -4.69 4.85e-06 0.00299 -0.36 -0.3 Response to amphetamines; chr3:130226115 chr3:130212823~130273806:+ CESC cis rs1707322 0.821 rs10749857 ENSG00000281133.1 AL355480.3 -4.69 4.85e-06 0.00299 -0.36 -0.3 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45782471 chr1:45580892~45580996:- CESC cis rs2919917 0.628 rs2717544 ENSG00000254352.1 RP11-578O24.2 -4.69 4.85e-06 0.00299 -0.42 -0.3 Lymphocyte counts; chr8:78724307 chr8:78723796~78724136:- CESC cis rs875971 0.545 rs6460281 ENSG00000222364.1 RNU6-96P -4.69 4.86e-06 0.003 -0.4 -0.3 Aortic root size; chr7:66216128 chr7:66395191~66395286:+ CESC cis rs1531343 0.73 rs2612056 ENSG00000276853.1 RP11-305O6.4 4.69 4.86e-06 0.003 0.6 0.3 Type 2 diabetes; chr12:65771691 chr12:65171262~65171917:+ CESC cis rs1531343 0.73 rs12303535 ENSG00000276853.1 RP11-305O6.4 4.69 4.86e-06 0.003 0.6 0.3 Type 2 diabetes; chr12:65772496 chr12:65171262~65171917:+ CESC cis rs7829975 0.582 rs11783950 ENSG00000253893.2 FAM85B 4.69 4.87e-06 0.003 0.38 0.3 Mood instability; chr8:8740321 chr8:8167819~8226614:- CESC cis rs62103177 0.525 rs10438902 ENSG00000261126.6 RP11-795F19.1 -4.69 4.87e-06 0.003 -0.37 -0.3 Opioid sensitivity; chr18:79985640 chr18:80046900~80095482:+ CESC cis rs6991838 0.751 rs35553155 ENSG00000272010.1 CTD-3025N20.3 4.69 4.88e-06 0.00301 0.32 0.3 Intelligence (multi-trait analysis); chr8:65551232 chr8:65591850~65592472:- CESC cis rs6991838 0.806 rs35024820 ENSG00000272010.1 CTD-3025N20.3 4.69 4.88e-06 0.00301 0.32 0.3 Intelligence (multi-trait analysis); chr8:65551296 chr8:65591850~65592472:- CESC cis rs763567 0.585 rs577827 ENSG00000271811.1 RP1-79C4.4 4.69 4.88e-06 0.00301 0.35 0.3 Tonsillectomy; chr1:170593942 chr1:170667381~170669425:+ CESC cis rs783540 0.632 rs17356528 ENSG00000276710.3 CSPG4P8 4.69 4.88e-06 0.00301 0.33 0.3 Schizophrenia; chr15:82636799 chr15:82459472~82477258:+ CESC cis rs9309473 0.948 rs11884776 ENSG00000163016.8 ALMS1P 4.69 4.88e-06 0.00301 0.39 0.3 Metabolite levels; chr2:73519796 chr2:73644919~73685576:+ CESC cis rs2243480 0.615 rs34363376 ENSG00000275400.1 RP4-756H11.5 4.69 4.89e-06 0.00301 0.53 0.3 Diabetic kidney disease; chr7:66474549 chr7:66553805~66554199:- CESC cis rs17826219 0.5 rs2449749 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Body mass index; chr17:30751280 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9894709 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9896603 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30792372~30792833:+ CESC cis rs17826219 0.636 rs7221463 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Body mass index; chr17:30753533 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs7219712 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs8078656 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs8080882 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9898084 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs28556733 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30792372~30792833:+ CESC cis rs17826219 0.5 rs28452421 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Body mass index; chr17:30756962 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs28433704 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs28779471 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30792372~30792833:+ CESC cis rs17826219 0.5 rs61685770 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Body mass index; chr17:30758695 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs57486336 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30792372~30792833:+ CESC cis rs17826219 0.706 rs55764512 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Body mass index; chr17:30758740 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs12103440 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs12103508 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs11653605 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs11657777 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs73269913 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs7217984 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30792372~30792833:+ CESC cis rs17826219 0.568 rs11658027 ENSG00000266490.1 CTD-2349P21.9 -4.69 4.9e-06 0.00301 -0.46 -0.3 Body mass index; chr17:30767864 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs73269916 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs60114476 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs8065744 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30792372~30792833:+ CESC cis rs17826219 0.706 rs8071236 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Body mass index; chr17:30772984 chr17:30792372~30792833:+ CESC cis rs17826219 0.636 rs2449770 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Body mass index; chr17:30774046 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs59913838 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs56163556 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs8067338 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs4055105 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30792372~30792833:+ CESC cis rs7208859 0.562 rs8078897 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs8075163 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30792372~30792833:+ CESC cis rs17826219 0.706 rs8075107 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Body mass index; chr17:30779631 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs7223209 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs7223404 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9916725 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9916727 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9914499 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs73269945 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9897728 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs1054400 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9890558 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9912283 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs12006 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs3752021 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs3752020 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9890855 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9893422 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9891166 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs73269974 ENSG00000266490.1 CTD-2349P21.9 4.69 4.9e-06 0.00301 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30792372~30792833:+ CESC cis rs5769707 0.632 rs5770601 ENSG00000235111.1 RP1-29C18.8 -4.69 4.9e-06 0.00302 -0.35 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49628255 chr22:49612657~49615716:- CESC cis rs4819052 0.765 rs2838852 ENSG00000223768.1 LINC00205 -4.69 4.93e-06 0.00303 -0.36 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45257122 chr21:45293285~45297354:+ CESC cis rs7809950 1 rs3801954 ENSG00000238832.1 snoU109 -4.68 4.93e-06 0.00303 -0.36 -0.3 Coronary artery disease; chr7:107476603 chr7:107603363~107603507:+ CESC cis rs7005380 0.785 rs7814294 ENSG00000279347.1 RP11-85I17.2 4.68 4.93e-06 0.00303 0.27 0.3 Interstitial lung disease; chr8:119927196 chr8:119838736~119840385:- CESC cis rs7005380 0.733 rs10808505 ENSG00000279347.1 RP11-85I17.2 4.68 4.93e-06 0.00303 0.27 0.3 Interstitial lung disease; chr8:119927966 chr8:119838736~119840385:- CESC cis rs9918079 0.542 rs12499412 ENSG00000273133.1 RP11-799M12.2 4.68 4.93e-06 0.00303 0.39 0.3 Obesity-related traits; chr4:15600629 chr4:15563698~15564253:- CESC cis rs1501911 0.509 rs34487 ENSG00000248489.1 CTD-2007H13.3 4.68 4.95e-06 0.00304 0.32 0.3 Lung function (FEV1/FVC); chr5:98872725 chr5:98929171~98995013:+ CESC cis rs1501911 0.509 rs327786 ENSG00000248489.1 CTD-2007H13.3 4.68 4.95e-06 0.00304 0.32 0.3 Lung function (FEV1/FVC); chr5:98878301 chr5:98929171~98995013:+ CESC cis rs7189233 0.531 rs8055279 ENSG00000279344.1 RP11-44F14.7 4.68 4.95e-06 0.00304 0.28 0.3 Intelligence (multi-trait analysis); chr16:53488837 chr16:53478957~53481550:- CESC cis rs10875746 0.669 rs9634261 ENSG00000240399.1 RP1-228P16.1 -4.68 4.96e-06 0.00305 -0.37 -0.3 Longevity (90 years and older); chr12:48293088 chr12:48054813~48055591:- CESC cis rs12439619 0.846 rs62013464 ENSG00000255769.6 GOLGA2P10 -4.68 4.96e-06 0.00305 -0.45 -0.3 Intelligence (multi-trait analysis); chr15:82288250 chr15:82472993~82513950:- CESC cis rs2243480 1 rs160634 ENSG00000228409.4 CCT6P1 -4.68 4.96e-06 0.00305 -0.39 -0.3 Diabetic kidney disease; chr7:66063677 chr7:65751142~65763354:+ CESC cis rs1061377 0.513 rs2566166 ENSG00000249207.1 RP11-360F5.1 4.68 4.98e-06 0.00306 0.4 0.3 Uric acid levels; chr4:39148404 chr4:39112677~39126818:- CESC cis rs7809950 0.834 rs2712199 ENSG00000238832.1 snoU109 -4.68 4.99e-06 0.00306 -0.36 -0.3 Coronary artery disease; chr7:107499794 chr7:107603363~107603507:+ CESC cis rs9907295 0.584 rs2280787 ENSG00000271013.1 AC015849.15 -4.68 4.99e-06 0.00307 -0.39 -0.3 Fibroblast growth factor basic levels; chr17:35930046 chr17:35912635~35918010:- CESC cis rs694739 1 rs11231757 ENSG00000236935.1 AP003774.1 4.68 5e-06 0.00307 0.3 0.3 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338845 chr11:64325050~64329504:- CESC cis rs6088580 0.634 rs4277599 ENSG00000126005.14 MMP24-AS1 4.68 5e-06 0.00307 0.33 0.3 Glomerular filtration rate (creatinine); chr20:34421099 chr20:35216462~35278131:- CESC cis rs523079 0.515 rs2590442 ENSG00000239093.1 snoU13 -4.68 5.01e-06 0.00307 -0.42 -0.3 Glucose homeostasis traits; chr3:187904019 chr3:187423315~187423419:+ CESC cis rs7777677 1 rs7777677 ENSG00000244273.1 PGBD4P1 -4.68 5.01e-06 0.00307 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142663616 chr7:142722358~142722764:+ CESC cis rs3806843 0.576 rs265316 ENSG00000202111.1 VTRNA1-2 -4.68 5.02e-06 0.00308 -0.31 -0.3 Depressive symptoms (multi-trait analysis); chr5:140911258 chr5:140718925~140719013:+ CESC cis rs853679 0.517 rs9380052 ENSG00000219392.1 RP1-265C24.5 -4.68 5.02e-06 0.00308 -0.4 -0.3 Depression; chr6:28096845 chr6:28115628~28116551:+ CESC cis rs4819052 0.819 rs13046807 ENSG00000223768.1 LINC00205 -4.68 5.02e-06 0.00308 -0.36 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45252371 chr21:45293285~45297354:+ CESC cis rs1012068 0.961 rs5994441 ENSG00000236132.1 CTA-440B3.1 -4.68 5.02e-06 0.00308 -0.36 -0.3 Chronic hepatitis C infection; chr22:31870560 chr22:31816379~31817491:- CESC cis rs13108904 0.901 rs7673398 ENSG00000253399.1 AC078852.2 -4.68 5.03e-06 0.00308 -0.36 -0.3 Obesity-related traits; chr4:1306289 chr4:1358479~1359461:+ CESC cis rs13108904 0.901 rs7668661 ENSG00000253399.1 AC078852.2 -4.68 5.03e-06 0.00308 -0.36 -0.3 Obesity-related traits; chr4:1306384 chr4:1358479~1359461:+ CESC cis rs11723261 0.621 rs11721745 ENSG00000211553.1 AC253576.2 -4.68 5.03e-06 0.00308 -0.46 -0.3 Immune response to smallpox vaccine (IL-6); chr4:115052 chr4:136461~136568:+ CESC cis rs7586673 0.866 rs747003 ENSG00000227403.1 AC009299.3 4.68 5.03e-06 0.00309 0.38 0.3 Intelligence (multi-trait analysis); chr2:161059898 chr2:161244739~161249050:+ CESC cis rs11846409 0.799 rs10467899 ENSG00000211974.3 IGHV2-70 -4.68 5.04e-06 0.00309 -0.4 -0.3 Rheumatic heart disease; chr14:106644012 chr14:106723574~106724093:- CESC cis rs8072100 0.967 rs11871606 ENSG00000228782.6 CTD-2026D20.3 -4.68 5.04e-06 0.00309 -0.35 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47655408 chr17:47450568~47492492:- CESC cis rs2919917 1 rs13280202 ENSG00000254352.1 RP11-578O24.2 -4.68 5.04e-06 0.00309 -0.39 -0.3 Lymphocyte counts; chr8:78700238 chr8:78723796~78724136:- CESC cis rs9640161 0.789 rs4554381 ENSG00000261305.1 RP4-584D14.7 4.68 5.04e-06 0.00309 0.4 0.3 Blood protein levels;Circulating chemerin levels; chr7:150328478 chr7:150341771~150342607:+ CESC cis rs2015599 0.623 rs3782510 ENSG00000275476.1 RP11-996F15.4 4.68 5.04e-06 0.00309 0.33 0.3 Platelet count;Mean platelet volume; chr12:29301176 chr12:29277397~29277882:- CESC cis rs761746 0.739 rs131225 ENSG00000236132.1 CTA-440B3.1 -4.68 5.05e-06 0.00309 -0.38 -0.3 Intelligence; chr22:31717863 chr22:31816379~31817491:- CESC cis rs875971 0.545 rs316316 ENSG00000237310.1 GS1-124K5.4 -4.68 5.05e-06 0.00309 -0.32 -0.3 Aortic root size; chr7:66149270 chr7:66493706~66495474:+ CESC cis rs35324223 1 rs35324223 ENSG00000247675.5 LRP4-AS1 -4.68 5.05e-06 0.00309 -0.36 -0.3 Autism spectrum disorder or schizophrenia; chr11:46381302 chr11:46846412~46874396:+ CESC cis rs7615952 0.599 rs66532274 ENSG00000250012.1 RP11-124N2.1 -4.68 5.06e-06 0.0031 -0.32 -0.3 Blood pressure (smoking interaction); chr3:126013002 chr3:126084220~126095349:+ CESC cis rs801193 0.569 rs13226966 ENSG00000222364.1 RNU6-96P -4.68 5.07e-06 0.0031 -0.35 -0.3 Aortic root size; chr7:66768636 chr7:66395191~66395286:+ CESC cis rs9660180 0.967 rs2272908 ENSG00000268575.1 RP1-283E3.8 4.68 5.07e-06 0.0031 0.3 0.3 Body mass index; chr1:1790040 chr1:1702736~1737688:- CESC cis rs1862618 0.853 rs832565 ENSG00000271828.1 CTD-2310F14.1 4.68 5.07e-06 0.0031 0.41 0.3 Initial pursuit acceleration; chr5:56854976 chr5:56927874~56929573:+ CESC cis rs8062405 0.69 rs62034351 ENSG00000259982.1 CDC37P1 4.68 5.07e-06 0.00311 0.39 0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554168 chr16:28700294~28701540:- CESC cis rs62103177 0.608 rs4799115 ENSG00000261126.6 RP11-795F19.1 -4.68 5.08e-06 0.00311 -0.41 -0.3 Opioid sensitivity; chr18:79976365 chr18:80046900~80095482:+ CESC cis rs2836950 0.565 rs2836934 ENSG00000232608.1 TIMM9P2 4.68 5.09e-06 0.00312 0.33 0.3 Menarche (age at onset); chr21:39192959 chr21:39216624~39217506:+ CESC cis rs75422866 0.764 rs67201012 ENSG00000257433.4 RP1-197B17.3 4.68 5.1e-06 0.00312 0.73 0.3 Pneumonia; chr12:47715881 chr12:47706085~47742294:+ CESC cis rs10754283 0.967 rs6428559 ENSG00000231613.1 RP5-943J3.1 4.68 5.1e-06 0.00312 0.38 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89633477 chr1:89788914~89790492:+ CESC cis rs9660180 0.783 rs1107910 ENSG00000231050.1 RP1-140A9.1 4.68 5.1e-06 0.00312 0.34 0.3 Body mass index; chr1:1760882 chr1:1891471~1892658:+ CESC cis rs860295 0.702 rs2048431 ENSG00000225855.5 RUSC1-AS1 4.68 5.1e-06 0.00312 0.26 0.3 Body mass index; chr1:155648839 chr1:155316863~155324176:- CESC cis rs7829975 0.902 rs485107 ENSG00000253893.2 FAM85B 4.68 5.1e-06 0.00312 0.37 0.3 Mood instability; chr8:8723898 chr8:8167819~8226614:- CESC cis rs9549367 0.789 rs3764124 ENSG00000269125.1 RP11-98F14.11 -4.68 5.11e-06 0.00312 -0.44 -0.3 Platelet distribution width; chr13:113243006 chr13:113165002~113165183:- CESC cis rs12922040 1 rs12922040 ENSG00000263335.1 AF001548.5 -4.68 5.11e-06 0.00312 -0.38 -0.3 Serum uric acid levels in response to allopurinol in gout; chr16:15775609 chr16:15726674~15732993:+ CESC cis rs6452524 0.87 rs12152892 ENSG00000249664.1 CTD-2227C6.2 4.68 5.11e-06 0.00312 0.37 0.3 Hypertension (SNP x SNP interaction); chr5:83125110 chr5:83012285~83013109:- CESC cis rs6452524 0.901 rs12188673 ENSG00000249664.1 CTD-2227C6.2 4.68 5.11e-06 0.00312 0.37 0.3 Hypertension (SNP x SNP interaction); chr5:83126268 chr5:83012285~83013109:- CESC cis rs1387259 0.839 rs7487682 ENSG00000240399.1 RP1-228P16.1 -4.68 5.11e-06 0.00313 -0.33 -0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48185882 chr12:48054813~48055591:- CESC cis rs1387259 0.929 rs11168460 ENSG00000258273.1 RP11-370I10.4 -4.68 5.11e-06 0.00313 -0.37 -0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48203582 chr12:48333755~48333901:- CESC cis rs2732480 0.5 rs7297824 ENSG00000258273.1 RP11-370I10.4 -4.68 5.11e-06 0.00313 -0.37 -0.3 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48204867 chr12:48333755~48333901:- CESC cis rs2732480 0.5 rs7315820 ENSG00000258273.1 RP11-370I10.4 -4.68 5.11e-06 0.00313 -0.37 -0.3 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48205155 chr12:48333755~48333901:- CESC cis rs2732480 0.5 rs11168464 ENSG00000258273.1 RP11-370I10.4 -4.68 5.11e-06 0.00313 -0.37 -0.3 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48208332 chr12:48333755~48333901:- CESC cis rs1387259 0.899 rs7307566 ENSG00000258273.1 RP11-370I10.4 -4.68 5.11e-06 0.00313 -0.37 -0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48210899 chr12:48333755~48333901:- CESC cis rs12908161 0.92 rs12904605 ENSG00000225151.9 GOLGA2P7 -4.68 5.11e-06 0.00313 -0.41 -0.3 Schizophrenia; chr15:84658188 chr15:84199311~84230136:- CESC cis rs4819052 0.851 rs12626188 ENSG00000223768.1 LINC00205 -4.68 5.12e-06 0.00313 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45249343 chr21:45293285~45297354:+ CESC cis rs3806843 0.576 rs251370 ENSG00000202111.1 VTRNA1-2 4.68 5.12e-06 0.00313 0.31 0.3 Depressive symptoms (multi-trait analysis); chr5:140866702 chr5:140718925~140719013:+ CESC cis rs150992 0.609 rs451141 ENSG00000248489.1 CTD-2007H13.3 -4.68 5.12e-06 0.00313 -0.38 -0.3 Body mass index; chr5:98991691 chr5:98929171~98995013:+ CESC cis rs2732480 0.5 rs11168468 ENSG00000258273.1 RP11-370I10.4 -4.68 5.13e-06 0.00313 -0.38 -0.3 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48218682 chr12:48333755~48333901:- CESC cis rs55794721 0.509 rs12027110 ENSG00000261349.1 RP3-465N24.5 -4.68 5.13e-06 0.00314 -0.3 -0.3 Mean corpuscular volume;Plateletcrit; chr1:25449191 chr1:25266102~25267136:- CESC cis rs8059260 0.551 rs7187539 ENSG00000274038.1 RP11-66H6.4 -4.68 5.14e-06 0.00314 -0.46 -0.3 Alcohol consumption over the past year; chr16:10964900 chr16:11056556~11057034:+ CESC cis rs1891275 0.515 rs1080496 ENSG00000228701.1 TNKS2-AS1 4.68 5.15e-06 0.00314 0.35 0.3 Intelligence (multi-trait analysis); chr10:91684505 chr10:91782839~91798291:- CESC cis rs9847710 0.566 rs2564951 ENSG00000242142.1 SERBP1P3 4.67 5.15e-06 0.00315 0.36 0.3 Ulcerative colitis; chr3:53026433 chr3:53064283~53065091:- CESC cis rs2729354 0.903 rs2729371 ENSG00000265566.2 RN7SL605P -4.67 5.15e-06 0.00315 -0.46 -0.3 Blood protein levels; chr11:57553849 chr11:57528085~57528365:- CESC cis rs875971 1 rs1144895 ENSG00000237310.1 GS1-124K5.4 -4.67 5.15e-06 0.00315 -0.3 -0.3 Aortic root size; chr7:66076320 chr7:66493706~66495474:+ CESC cis rs5769707 0.542 rs739242 ENSG00000188511.11 C22orf34 4.67 5.15e-06 0.00315 0.35 0.3 Monocyte percentage of white cells;Monocyte count; chr22:49663468 chr22:49414524~49657542:- CESC cis rs2243480 1 rs2462569 ENSG00000228409.4 CCT6P1 -4.67 5.16e-06 0.00315 -0.42 -0.3 Diabetic kidney disease; chr7:66009859 chr7:65751142~65763354:+ CESC cis rs2733201 1 rs2706472 ENSG00000259479.5 SORD2P -4.67 5.16e-06 0.00315 -0.43 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44141094 chr15:44826371~44884694:- CESC cis rs2243480 1 rs73142166 ENSG00000232559.3 GS1-124K5.12 4.67 5.17e-06 0.00316 0.52 0.3 Diabetic kidney disease; chr7:65910845 chr7:66554588~66576923:- CESC cis rs2243480 1 rs34193460 ENSG00000232559.3 GS1-124K5.12 4.67 5.17e-06 0.00316 0.52 0.3 Diabetic kidney disease; chr7:65928123 chr7:66554588~66576923:- CESC cis rs2243480 1 rs57057549 ENSG00000232559.3 GS1-124K5.12 4.67 5.17e-06 0.00316 0.52 0.3 Diabetic kidney disease; chr7:65940751 chr7:66554588~66576923:- CESC cis rs2243480 0.908 rs2460431 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66157859 chr7:66553805~66554199:- CESC cis rs2243480 0.711 rs2460426 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66158142 chr7:66553805~66554199:- CESC cis rs2243480 1 rs4718309 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66162777 chr7:66553805~66554199:- CESC cis rs2243480 1 rs6460274 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66163497 chr7:66553805~66554199:- CESC cis rs2243480 1 rs7787230 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66164112 chr7:66553805~66554199:- CESC cis rs2243480 0.711 rs2420172 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66170354 chr7:66553805~66554199:- CESC cis rs2243480 1 rs2420171 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66172773 chr7:66553805~66554199:- CESC cis rs2243480 1 rs6974723 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66172952 chr7:66553805~66554199:- CESC cis rs2243480 1 rs7804223 ENSG00000275400.1 RP4-756H11.5 -4.67 5.17e-06 0.00316 -0.51 -0.3 Diabetic kidney disease; chr7:66199572 chr7:66553805~66554199:- CESC cis rs2243480 1 rs2465120 ENSG00000275400.1 RP4-756H11.5 4.67 5.17e-06 0.00316 0.51 0.3 Diabetic kidney disease; chr7:66155987 chr7:66553805~66554199:- CESC cis rs875971 0.545 rs6460281 ENSG00000237310.1 GS1-124K5.4 4.67 5.18e-06 0.00316 0.33 0.3 Aortic root size; chr7:66216128 chr7:66493706~66495474:+ CESC cis rs12468226 0.938 rs80282360 ENSG00000273456.1 RP11-686O6.2 4.67 5.18e-06 0.00316 0.45 0.3 Urate levels; chr2:202275121 chr2:202374932~202375604:- CESC cis rs763121 0.853 rs1062687 ENSG00000273076.1 RP3-508I15.22 4.67 5.18e-06 0.00316 0.33 0.3 Menopause (age at onset); chr22:38738710 chr22:38743495~38743910:+ CESC cis rs75422866 0.764 rs67408202 ENSG00000257433.4 RP1-197B17.3 4.67 5.19e-06 0.00316 0.73 0.3 Pneumonia; chr12:47713564 chr12:47706085~47742294:+ CESC cis rs75422866 0.867 rs57848393 ENSG00000257433.4 RP1-197B17.3 4.67 5.19e-06 0.00316 0.73 0.3 Pneumonia; chr12:47714734 chr12:47706085~47742294:+ CESC cis rs7809950 0.954 rs2520245 ENSG00000238832.1 snoU109 -4.67 5.2e-06 0.00317 -0.36 -0.3 Coronary artery disease; chr7:107496983 chr7:107603363~107603507:+ CESC cis rs9640161 0.789 rs3735172 ENSG00000261305.1 RP4-584D14.7 -4.67 5.2e-06 0.00317 -0.4 -0.3 Blood protein levels;Circulating chemerin levels; chr7:150331869 chr7:150341771~150342607:+ CESC cis rs11976180 1 rs1919951 ENSG00000273234.1 OR2A13P -4.67 5.2e-06 0.00317 -0.38 -0.3 Obesity-related traits; chr7:144071798 chr7:144142009~144142938:+ CESC cis rs10129255 0.957 rs8009073 ENSG00000211970.3 IGHV4-61 -4.67 5.21e-06 0.00318 -0.24 -0.3 Kawasaki disease; chr14:106777278 chr14:106639119~106639657:- CESC cis rs7572733 0.935 rs4850817 ENSG00000222017.1 AC011997.1 -4.67 5.21e-06 0.00318 -0.34 -0.3 Dermatomyositis; chr2:197930480 chr2:197693106~197774823:+ CESC cis rs6142102 0.527 rs1015362 ENSG00000275784.1 RP5-1125A11.6 4.67 5.22e-06 0.00318 0.31 0.3 Skin pigmentation; chr20:34150806 chr20:33989480~33991818:- CESC cis rs2243480 1 rs34970380 ENSG00000232559.3 GS1-124K5.12 4.67 5.22e-06 0.00318 0.5 0.3 Diabetic kidney disease; chr7:65966506 chr7:66554588~66576923:- CESC cis rs2243480 1 rs9769882 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66177938 chr7:66553805~66554199:- CESC cis rs2243480 1 rs6966322 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66181767 chr7:66553805~66554199:- CESC cis rs2243480 1 rs4145008 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66182524 chr7:66553805~66554199:- CESC cis rs2243480 1 rs4718315 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66183554 chr7:66553805~66554199:- CESC cis rs2243480 1 rs4718316 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66183744 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1873494 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66184912 chr7:66553805~66554199:- CESC cis rs2243480 1 rs6959002 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66185509 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1546059 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66189722 chr7:66553805~66554199:- CESC cis rs2243480 1 rs2420170 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66191066 chr7:66553805~66554199:- CESC cis rs2243480 1 rs6958289 ENSG00000275400.1 RP4-756H11.5 -4.67 5.23e-06 0.00319 -0.51 -0.3 Diabetic kidney disease; chr7:66192124 chr7:66553805~66554199:- CESC cis rs1799949 1 rs11659028 ENSG00000267681.1 CTD-3199J23.6 -4.67 5.23e-06 0.00319 -0.41 -0.3 Menopause (age at onset); chr17:43043008 chr17:43144956~43145255:+ CESC cis rs6686842 0.601 rs4344323 ENSG00000235358.1 RP11-399E6.1 4.67 5.23e-06 0.00319 0.36 0.3 Height; chr1:41015123 chr1:41242373~41284861:+ CESC cis rs6893782 0.887 rs6596075 ENSG00000233006.5 AC034220.3 4.67 5.24e-06 0.00319 0.39 0.3 Acylcarnitine levels; chr5:132406536 chr5:132311285~132369916:- CESC cis rs77972916 0.517 rs17406126 ENSG00000234936.1 AC010883.5 4.67 5.25e-06 0.0032 0.43 0.3 Granulocyte percentage of myeloid white cells; chr2:43319493 chr2:43229573~43233394:+ CESC cis rs4974559 0.947 rs58750335 ENSG00000253399.1 AC078852.2 4.67 5.25e-06 0.0032 0.52 0.3 Systolic blood pressure; chr4:1370976 chr4:1358479~1359461:+ CESC cis rs7572733 0.555 rs7561950 ENSG00000222017.1 AC011997.1 4.67 5.25e-06 0.0032 0.38 0.3 Dermatomyositis; chr2:197889520 chr2:197693106~197774823:+ CESC cis rs11638352 1 rs4924727 ENSG00000259479.5 SORD2P -4.67 5.25e-06 0.0032 -0.47 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:43988411 chr15:44826371~44884694:- CESC cis rs73086581 0.735 rs6037730 ENSG00000229539.1 RP11-119B16.2 4.67 5.26e-06 0.00321 0.45 0.3 Response to antidepressants in depression; chr20:4046171 chr20:3888239~3888868:- CESC cis rs73086581 0.838 rs6052265 ENSG00000229539.1 RP11-119B16.2 4.67 5.26e-06 0.00321 0.45 0.3 Response to antidepressants in depression; chr20:4046188 chr20:3888239~3888868:- CESC cis rs875971 0.862 rs6960446 ENSG00000232559.3 GS1-124K5.12 -4.67 5.27e-06 0.00321 -0.32 -0.3 Aortic root size; chr7:66268272 chr7:66554588~66576923:- CESC cis rs875971 0.79 rs10257911 ENSG00000232559.3 GS1-124K5.12 -4.67 5.27e-06 0.00321 -0.32 -0.3 Aortic root size; chr7:66278783 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs7796162 ENSG00000232559.3 GS1-124K5.12 -4.67 5.27e-06 0.00321 -0.32 -0.3 Aortic root size; chr7:66280771 chr7:66554588~66576923:- CESC cis rs1853665 1 rs9383993 ENSG00000231760.4 RP11-350J20.5 -4.67 5.27e-06 0.00321 -0.51 -0.3 Radiation response; chr6:149978163 chr6:149796151~149826294:- CESC cis rs1862618 0.802 rs4389648 ENSG00000271828.1 CTD-2310F14.1 4.67 5.28e-06 0.00321 0.41 0.3 Initial pursuit acceleration; chr5:56807775 chr5:56927874~56929573:+ CESC cis rs1044826 0.642 rs295473 ENSG00000178631.7 ACTG1P1 4.67 5.28e-06 0.00321 0.38 0.3 Obesity-related traits; chr3:139496743 chr3:139493809~139494937:+ CESC cis rs1044826 0.642 rs7624321 ENSG00000178631.7 ACTG1P1 4.67 5.28e-06 0.00321 0.38 0.3 Obesity-related traits; chr3:139501317 chr3:139493809~139494937:+ CESC cis rs1044826 0.642 rs295478 ENSG00000178631.7 ACTG1P1 4.67 5.28e-06 0.00321 0.38 0.3 Obesity-related traits; chr3:139504293 chr3:139493809~139494937:+ CESC cis rs1044826 0.642 rs295479 ENSG00000178631.7 ACTG1P1 4.67 5.28e-06 0.00321 0.38 0.3 Obesity-related traits; chr3:139505023 chr3:139493809~139494937:+ CESC cis rs7615952 0.641 rs12488180 ENSG00000250012.1 RP11-124N2.1 -4.67 5.29e-06 0.00322 -0.32 -0.3 Blood pressure (smoking interaction); chr3:126063393 chr3:126084220~126095349:+ CESC cis rs7005380 0.733 rs56864850 ENSG00000279347.1 RP11-85I17.2 4.67 5.29e-06 0.00322 0.26 0.3 Interstitial lung disease; chr8:119931204 chr8:119838736~119840385:- CESC cis rs7005380 0.785 rs55892034 ENSG00000279347.1 RP11-85I17.2 4.67 5.29e-06 0.00322 0.26 0.3 Interstitial lung disease; chr8:119931267 chr8:119838736~119840385:- CESC cis rs4819052 0.851 rs2838843 ENSG00000223768.1 LINC00205 -4.67 5.29e-06 0.00322 -0.36 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45249369 chr21:45293285~45297354:+ CESC cis rs3762637 1 rs9836309 ENSG00000272758.4 RP11-299J3.8 -4.67 5.29e-06 0.00322 -0.41 -0.3 LDL cholesterol levels; chr3:122416348 chr3:122416207~122443180:+ CESC cis rs3762637 0.941 rs9873842 ENSG00000272758.4 RP11-299J3.8 -4.67 5.29e-06 0.00322 -0.41 -0.3 LDL cholesterol levels; chr3:122416484 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs12633461 ENSG00000272758.4 RP11-299J3.8 -4.67 5.29e-06 0.00322 -0.41 -0.3 LDL cholesterol levels; chr3:122417050 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs9879508 ENSG00000272758.4 RP11-299J3.8 -4.67 5.29e-06 0.00322 -0.41 -0.3 LDL cholesterol levels; chr3:122417633 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs9858558 ENSG00000272758.4 RP11-299J3.8 -4.67 5.29e-06 0.00322 -0.41 -0.3 LDL cholesterol levels; chr3:122420895 chr3:122416207~122443180:+ CESC cis rs875971 0.502 rs2946580 ENSG00000222364.1 RNU6-96P 4.67 5.3e-06 0.00322 0.41 0.3 Aortic root size; chr7:66066855 chr7:66395191~66395286:+ CESC cis rs10043775 1 rs10072051 ENSG00000251330.3 CTD-2283N19.1 -4.67 5.3e-06 0.00322 -0.39 -0.3 Periodontal microbiota; chr5:148395099 chr5:148430159~148430807:- CESC cis rs3091242 1 rs3091242 ENSG00000261349.1 RP3-465N24.5 -4.67 5.3e-06 0.00322 -0.31 -0.3 Erythrocyte sedimentation rate; chr1:25348294 chr1:25266102~25267136:- CESC cis rs3091242 0.967 rs3091240 ENSG00000261349.1 RP3-465N24.5 -4.67 5.3e-06 0.00322 -0.31 -0.3 Erythrocyte sedimentation rate; chr1:25350444 chr1:25266102~25267136:- CESC cis rs3091242 0.935 rs3093632 ENSG00000261349.1 RP3-465N24.5 -4.67 5.3e-06 0.00322 -0.31 -0.3 Erythrocyte sedimentation rate; chr1:25357521 chr1:25266102~25267136:- CESC cis rs4819052 0.851 rs2838834 ENSG00000223768.1 LINC00205 -4.67 5.3e-06 0.00322 -0.36 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45245293 chr21:45293285~45297354:+ CESC cis rs9322193 0.607 rs4869755 ENSG00000231760.4 RP11-350J20.5 4.67 5.3e-06 0.00322 0.45 0.3 Lung cancer; chr6:149886347 chr6:149796151~149826294:- CESC cis rs9322193 0.639 rs4869756 ENSG00000231760.4 RP11-350J20.5 4.67 5.3e-06 0.00322 0.45 0.3 Lung cancer; chr6:149886360 chr6:149796151~149826294:- CESC cis rs9322193 0.607 rs3798763 ENSG00000231760.4 RP11-350J20.5 4.67 5.3e-06 0.00322 0.45 0.3 Lung cancer; chr6:149889964 chr6:149796151~149826294:- CESC cis rs853679 0.517 rs9393891 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28111382 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9468286 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28111650 chr6:28115628~28116551:+ CESC cis rs4713118 0.516 rs7739216 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Parkinson's disease; chr6:28112168 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs35512245 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28112175 chr6:28115628~28116551:+ CESC cis rs853679 0.542 rs9393892 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28113616 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380055 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28113851 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9368553 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28114487 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9368554 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28114933 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs4713137 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28115743 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9348793 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Depression; chr6:28116411 chr6:28115628~28116551:+ CESC cis rs4713118 0.586 rs6905516 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Parkinson's disease; chr6:28118700 chr6:28115628~28116551:+ CESC cis rs4713118 0.586 rs6905522 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Parkinson's disease; chr6:28118701 chr6:28115628~28116551:+ CESC cis rs4713118 0.586 rs9468290 ENSG00000219392.1 RP1-265C24.5 -4.67 5.31e-06 0.00322 -0.39 -0.3 Parkinson's disease; chr6:28119896 chr6:28115628~28116551:+ CESC cis rs453301 0.606 rs6601279 ENSG00000173295.6 FAM86B3P -4.67 5.31e-06 0.00323 -0.39 -0.3 Joint mobility (Beighton score); chr8:9050721 chr8:8228595~8244865:+ CESC cis rs453301 0.606 rs6981060 ENSG00000173295.6 FAM86B3P -4.67 5.31e-06 0.00323 -0.39 -0.3 Joint mobility (Beighton score); chr8:9050725 chr8:8228595~8244865:+ CESC cis rs1609391 0.543 rs9881139 ENSG00000239213.4 NCK1-AS1 4.67 5.32e-06 0.00323 0.34 0.3 Neuroticism; chr3:136915198 chr3:136841726~136862054:- CESC cis rs7809950 1 rs2395883 ENSG00000238832.1 snoU109 -4.67 5.32e-06 0.00323 -0.35 -0.3 Coronary artery disease; chr7:107449225 chr7:107603363~107603507:+ CESC cis rs6686842 1 rs479493 ENSG00000235358.1 RP11-399E6.1 -4.67 5.32e-06 0.00323 -0.36 -0.3 Height; chr1:41101530 chr1:41242373~41284861:+ CESC cis rs6686842 1 rs656917 ENSG00000235358.1 RP11-399E6.1 -4.67 5.32e-06 0.00323 -0.36 -0.3 Height; chr1:41104036 chr1:41242373~41284861:+ CESC cis rs6686842 1 rs213734 ENSG00000235358.1 RP11-399E6.1 -4.67 5.32e-06 0.00323 -0.36 -0.3 Height; chr1:41110027 chr1:41242373~41284861:+ CESC cis rs6686842 1 rs213733 ENSG00000235358.1 RP11-399E6.1 -4.67 5.32e-06 0.00323 -0.36 -0.3 Height; chr1:41111317 chr1:41242373~41284861:+ CESC cis rs2058059 0.636 rs3132428 ENSG00000205578.5 POM121B -4.67 5.33e-06 0.00323 -0.37 -0.3 Subcutaneous adipose tissue; chr7:72717018 chr7:73293497~73301161:+ CESC cis rs1799949 1 rs4793215 ENSG00000267681.1 CTD-3199J23.6 -4.67 5.33e-06 0.00324 -0.4 -0.3 Menopause (age at onset); chr17:43166915 chr17:43144956~43145255:+ CESC cis rs2337406 0.81 rs7161739 ENSG00000211974.3 IGHV2-70 -4.67 5.33e-06 0.00324 -0.48 -0.3 Alzheimer's disease (late onset); chr14:106776118 chr14:106723574~106724093:- CESC cis rs8042680 0.621 rs12899811 ENSG00000214432.8 AC068831.10 -4.67 5.33e-06 0.00324 -0.39 -0.3 Type 2 diabetes; chr15:91000846 chr15:91022619~91036611:+ CESC cis rs6997458 0.742 rs20571 ENSG00000253549.4 RP11-317J10.2 4.67 5.33e-06 0.00324 0.36 0.3 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85439768 chr8:85441851~85464915:- CESC cis rs9660180 0.967 rs6687065 ENSG00000268575.1 RP1-283E3.8 -4.67 5.34e-06 0.00324 -0.3 -0.3 Body mass index; chr1:1847030 chr1:1702736~1737688:- CESC cis rs3762637 1 rs7626861 ENSG00000272758.4 RP11-299J3.8 -4.67 5.34e-06 0.00324 -0.42 -0.3 LDL cholesterol levels; chr3:122436349 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs9842736 ENSG00000272758.4 RP11-299J3.8 -4.67 5.34e-06 0.00324 -0.42 -0.3 LDL cholesterol levels; chr3:122442254 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs13321097 ENSG00000272758.4 RP11-299J3.8 -4.67 5.34e-06 0.00324 -0.42 -0.3 LDL cholesterol levels; chr3:122443160 chr3:122416207~122443180:+ CESC cis rs116095464 1 rs7723693 ENSG00000250848.1 CTD-2083E4.5 -4.67 5.35e-06 0.00325 -0.52 -0.3 Breast cancer; chr5:305917 chr5:288833~290321:- CESC cis rs73086581 1 rs17287822 ENSG00000229539.1 RP11-119B16.2 4.67 5.36e-06 0.00325 0.48 0.3 Response to antidepressants in depression; chr20:3997889 chr20:3888239~3888868:- CESC cis rs4819052 0.851 rs2877018 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45238391 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2330012 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45238677 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2877020 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45238827 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs10470245 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45238997 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs10470258 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45239074 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs4819038 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45239478 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs4819039 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45239543 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs4818768 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45239903 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs4819042 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45240157 chr21:45293285~45297354:+ CESC cis rs4819052 0.8 rs4819045 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45240223 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs13048789 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45240799 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs13047598 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45240862 chr21:45293285~45297354:+ CESC cis rs4819052 0.724 rs9753962 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45241469 chr21:45293285~45297354:+ CESC cis rs4819052 0.724 rs9753987 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45241474 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs9753963 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45241522 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs9754134 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45241836 chr21:45293285~45297354:+ CESC cis rs8177876 0.822 rs74437879 ENSG00000261838.4 RP11-303E16.6 4.67 5.36e-06 0.00325 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078987 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs76948085 ENSG00000261838.4 RP11-303E16.6 4.67 5.36e-06 0.00325 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079199 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs80315956 ENSG00000261838.4 RP11-303E16.6 4.67 5.36e-06 0.00325 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079254 chr16:81069854~81076598:+ CESC cis rs8177876 0.642 rs16954572 ENSG00000261838.4 RP11-303E16.6 4.67 5.36e-06 0.00325 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079299 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs9929586 ENSG00000261838.4 RP11-303E16.6 4.67 5.36e-06 0.00325 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079416 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs9938965 ENSG00000261838.4 RP11-303E16.6 4.67 5.36e-06 0.00325 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079558 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs7204040 ENSG00000261838.4 RP11-303E16.6 4.67 5.36e-06 0.00325 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81079888 chr16:81069854~81076598:+ CESC cis rs8177876 0.731 rs7188508 ENSG00000261838.4 RP11-303E16.6 4.67 5.36e-06 0.00325 0.63 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080097 chr16:81069854~81076598:+ CESC cis rs964611 0.816 rs1426722 ENSG00000259488.2 RP11-154J22.1 -4.67 5.36e-06 0.00325 -0.31 -0.3 Metabolite levels (Pyroglutamine); chr15:48277212 chr15:48312353~48331856:- CESC cis rs7429990 0.932 rs7630685 ENSG00000229759.1 MRPS18AP1 -4.67 5.36e-06 0.00325 -0.31 -0.3 Educational attainment (years of education); chr3:48089680 chr3:48256350~48256938:- CESC cis rs4819052 0.851 rs8133045 ENSG00000223768.1 LINC00205 -4.67 5.36e-06 0.00325 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45238222 chr21:45293285~45297354:+ CESC cis rs853679 0.517 rs7755442 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28071237 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs12174753 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28074687 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs55747925 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28076559 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs56310871 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28076704 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs34716816 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28078391 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393884 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28079011 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380049 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28080757 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380050 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28080760 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393885 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28082231 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393886 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28082261 chr6:28115628~28116551:+ CESC cis rs4713118 0.515 rs9368549 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Parkinson's disease; chr6:28082269 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs56364346 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28082984 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9357061 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28083994 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9368550 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28084025 chr6:28115628~28116551:+ CESC cis rs853679 0.542 rs2295594 ENSG00000219392.1 RP1-265C24.5 -4.67 5.37e-06 0.00326 -0.39 -0.3 Depression; chr6:28085319 chr6:28115628~28116551:+ CESC cis rs2243480 1 rs4718270 ENSG00000232559.3 GS1-124K5.12 4.67 5.37e-06 0.00326 0.51 0.3 Diabetic kidney disease; chr7:65737415 chr7:66554588~66576923:- CESC cis rs1823913 0.614 rs1947457 ENSG00000280083.1 RP11-317J9.1 -4.67 5.38e-06 0.00326 -0.57 -0.3 Obesity-related traits; chr2:191298970 chr2:191154118~191156070:- CESC cis rs9532669 0.926 rs7328139 ENSG00000176268.5 CYCSP34 4.67 5.38e-06 0.00326 0.31 0.3 Cervical cancer; chr13:40862295 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs7328145 ENSG00000176268.5 CYCSP34 4.67 5.38e-06 0.00326 0.31 0.3 Cervical cancer; chr13:40862307 chr13:40863599~40863902:- CESC cis rs8072100 0.738 rs9900123 ENSG00000228782.6 CTD-2026D20.3 4.66 5.39e-06 0.00326 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47471689 chr17:47450568~47492492:- CESC cis rs2408955 0.521 rs1476607 ENSG00000240399.1 RP1-228P16.1 -4.66 5.39e-06 0.00326 -0.33 -0.3 Glycated hemoglobin levels; chr12:48131021 chr12:48054813~48055591:- CESC cis rs10463554 0.889 rs246911 ENSG00000175749.11 EIF3KP1 4.66 5.39e-06 0.00327 0.34 0.3 Parkinson's disease; chr5:103227502 chr5:103032376~103033031:+ CESC cis rs7615952 0.599 rs2333408 ENSG00000250012.1 RP11-124N2.1 -4.66 5.39e-06 0.00327 -0.32 -0.3 Blood pressure (smoking interaction); chr3:126013255 chr3:126084220~126095349:+ CESC cis rs860295 0.702 rs11264387 ENSG00000225855.5 RUSC1-AS1 4.66 5.4e-06 0.00327 0.25 0.3 Body mass index; chr1:155593361 chr1:155316863~155324176:- CESC cis rs6504622 0.539 rs4968248 ENSG00000263142.4 LRRC37A17P -4.66 5.4e-06 0.00327 -0.23 -0.3 Orofacial clefts; chr17:46915762 chr17:46978481~47054569:+ CESC cis rs9487094 0.689 rs699700 ENSG00000260273.1 RP11-425D10.10 4.66 5.41e-06 0.00327 0.37 0.3 Height; chr6:109367528 chr6:109382795~109383666:+ CESC cis rs2337406 0.714 rs2337463 ENSG00000223648.3 IGHV3-64 4.66 5.41e-06 0.00328 0.32 0.3 Alzheimer's disease (late onset); chr14:106816066 chr14:106643132~106658258:- CESC cis rs9907295 0.688 rs4796138 ENSG00000271013.1 AC015849.15 -4.66 5.42e-06 0.00328 -0.39 -0.3 Fibroblast growth factor basic levels; chr17:35932791 chr17:35912635~35918010:- CESC cis rs1044826 0.642 rs295481 ENSG00000178631.7 ACTG1P1 4.66 5.42e-06 0.00328 0.38 0.3 Obesity-related traits; chr3:139509969 chr3:139493809~139494937:+ CESC cis rs7873102 0.654 rs7036516 ENSG00000230188.1 RP11-405L18.4 4.66 5.42e-06 0.00328 0.38 0.3 Brain structure; chr9:38009409 chr9:37490421~37490893:- CESC cis rs2108622 0.545 rs59140933 ENSG00000267453.5 AC004791.2 -4.66 5.43e-06 0.00328 -0.36 -0.3 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15864498 chr19:15851993~15864904:- CESC cis rs9322193 0.962 rs9765929 ENSG00000216906.2 RP11-350J20.9 4.66 5.43e-06 0.00328 0.34 0.3 Lung cancer; chr6:149769680 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs3805748 ENSG00000216906.2 RP11-350J20.9 4.66 5.43e-06 0.00328 0.34 0.3 Lung cancer; chr6:149772542 chr6:149904243~149906418:+ CESC cis rs9322193 0.736 rs10457851 ENSG00000216906.2 RP11-350J20.9 4.66 5.43e-06 0.00328 0.34 0.3 Lung cancer; chr6:149775216 chr6:149904243~149906418:+ CESC cis rs9322193 0.886 rs10872652 ENSG00000216906.2 RP11-350J20.9 4.66 5.43e-06 0.00328 0.34 0.3 Lung cancer; chr6:149775303 chr6:149904243~149906418:+ CESC cis rs9322193 0.886 rs12525871 ENSG00000216906.2 RP11-350J20.9 4.66 5.43e-06 0.00328 0.34 0.3 Lung cancer; chr6:149775882 chr6:149904243~149906418:+ CESC cis rs9322193 0.886 rs17672976 ENSG00000216906.2 RP11-350J20.9 4.66 5.43e-06 0.00328 0.34 0.3 Lung cancer; chr6:149776207 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs2184369 ENSG00000216906.2 RP11-350J20.9 4.66 5.43e-06 0.00328 0.34 0.3 Lung cancer; chr6:149776681 chr6:149904243~149906418:+ CESC cis rs6142102 0.961 rs6059587 ENSG00000276073.1 RP5-1125A11.7 -4.66 5.43e-06 0.00329 -0.29 -0.3 Skin pigmentation; chr20:33955120 chr20:33985617~33988989:- CESC cis rs694739 0.796 rs479777 ENSG00000236935.1 AP003774.1 4.66 5.43e-06 0.00329 0.31 0.3 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64340005 chr11:64325050~64329504:- CESC cis rs3762637 1 rs3762637 ENSG00000272758.4 RP11-299J3.8 -4.66 5.43e-06 0.00329 -0.42 -0.3 LDL cholesterol levels; chr3:122426477 chr3:122416207~122443180:+ CESC cis rs10246939 0.505 rs6967189 ENSG00000228775.6 WEE2-AS1 4.66 5.44e-06 0.00329 0.37 0.3 Bitter taste perception; chr7:141826220 chr7:141704338~141738346:- CESC cis rs9318086 0.663 rs2312295 ENSG00000205861.10 C1QTNF9B-AS1 -4.66 5.44e-06 0.00329 -0.38 -0.3 Myopia (pathological); chr13:23883605 chr13:23888889~23897263:+ CESC cis rs17826219 0.5 rs57005940 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Body mass index; chr17:30739311 chr17:30792372~30792833:+ CESC cis rs17826219 0.706 rs9893922 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Body mass index; chr17:30741407 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs57670615 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30792372~30792833:+ CESC cis rs17826219 0.5 rs2874724 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Body mass index; chr17:30745415 chr17:30792372~30792833:+ CESC cis rs17826219 0.568 rs9898097 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Body mass index; chr17:30745654 chr17:30792372~30792833:+ CESC cis rs17826219 0.5 rs9891256 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Body mass index; chr17:30745674 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9911490 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs7503542 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs7503335 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs11656278 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs6505207 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs7223803 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30792372~30792833:+ CESC cis rs17826219 0.568 rs2626985 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Body mass index; chr17:30750419 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs55814012 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs34756112 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs60724269 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs76633166 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs1061346 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs1061343 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs55938328 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs73269988 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs55961983 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs7222803 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792879 chr17:30792372~30792833:+ CESC cis rs7208859 0.673 rs9899525 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30792372~30792833:+ CESC cis rs17826219 0.568 rs7213925 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Body mass index; chr17:30794616 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs11653098 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs11658945 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9911784 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9911997 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9890862 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs78071511 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs11650982 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs2035494 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9915546 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs9915566 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs8064686 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs11657369 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs8075341 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs73271842 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30792372~30792833:+ CESC cis rs7208859 0.673 rs9895815 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30792372~30792833:+ CESC cis rs7208859 0.673 rs8077116 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs28760584 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30792372~30792833:+ CESC cis rs17826219 0.706 rs73271850 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Body mass index; chr17:30815122 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs7208088 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs7212991 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs28627615 ENSG00000266490.1 CTD-2349P21.9 4.66 5.44e-06 0.00329 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30792372~30792833:+ CESC cis rs3762637 1 rs55853677 ENSG00000272758.4 RP11-299J3.8 -4.66 5.46e-06 0.00329 -0.41 -0.3 LDL cholesterol levels; chr3:122421769 chr3:122416207~122443180:+ CESC cis rs10875746 0.669 rs4760701 ENSG00000240399.1 RP1-228P16.1 -4.66 5.46e-06 0.00329 -0.35 -0.3 Longevity (90 years and older); chr12:48304735 chr12:48054813~48055591:- CESC cis rs1799949 0.965 rs8176198 ENSG00000267681.1 CTD-3199J23.6 -4.66 5.47e-06 0.0033 -0.36 -0.3 Menopause (age at onset); chr17:43078520 chr17:43144956~43145255:+ CESC cis rs748404 0.697 rs574065 ENSG00000205771.5 CATSPER2P1 4.66 5.47e-06 0.0033 0.36 0.3 Lung cancer; chr15:43258457 chr15:43726918~43747094:- CESC cis rs4308124 0.708 rs28766030 ENSG00000227992.1 AC108463.2 -4.66 5.47e-06 0.0033 -0.4 -0.3 Vitiligo; chr2:111204852 chr2:111203964~111206215:- CESC cis rs4308124 0.708 rs28871990 ENSG00000227992.1 AC108463.2 -4.66 5.47e-06 0.0033 -0.4 -0.3 Vitiligo; chr2:111204864 chr2:111203964~111206215:- CESC cis rs4308124 0.708 rs67816163 ENSG00000227992.1 AC108463.2 -4.66 5.47e-06 0.0033 -0.4 -0.3 Vitiligo; chr2:111205733 chr2:111203964~111206215:- CESC cis rs8059260 0.542 rs6498148 ENSG00000274038.1 RP11-66H6.4 -4.66 5.48e-06 0.0033 -0.5 -0.3 Alcohol consumption over the past year; chr16:11018374 chr16:11056556~11057034:+ CESC cis rs9987353 0.522 rs2929466 ENSG00000173295.6 FAM86B3P -4.66 5.48e-06 0.00331 -0.39 -0.3 Recombination measurement; chr8:9206389 chr8:8228595~8244865:+ CESC cis rs2729354 0.693 rs2584862 ENSG00000265566.2 RN7SL605P -4.66 5.49e-06 0.00331 -0.43 -0.3 Blood protein levels; chr11:57474483 chr11:57528085~57528365:- CESC cis rs875971 0.862 rs11763189 ENSG00000232559.3 GS1-124K5.12 4.66 5.5e-06 0.00331 0.33 0.3 Aortic root size; chr7:66518542 chr7:66554588~66576923:- CESC cis rs11638352 1 rs958485 ENSG00000259479.5 SORD2P -4.66 5.51e-06 0.00332 -0.44 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44057867 chr15:44826371~44884694:- CESC cis rs875971 1 rs10244498 ENSG00000237310.1 GS1-124K5.4 4.66 5.51e-06 0.00332 0.29 0.3 Aortic root size; chr7:66651069 chr7:66493706~66495474:+ CESC cis rs875971 0.571 rs160641 ENSG00000222364.1 RNU6-96P 4.66 5.51e-06 0.00332 0.4 0.3 Aortic root size; chr7:66112359 chr7:66395191~66395286:+ CESC cis rs2919917 0.628 rs4739135 ENSG00000254352.1 RP11-578O24.2 4.66 5.51e-06 0.00332 0.41 0.3 Lymphocyte counts; chr8:78656057 chr8:78723796~78724136:- CESC cis rs9487094 0.517 rs3778474 ENSG00000260273.1 RP11-425D10.10 4.66 5.51e-06 0.00332 0.37 0.3 Height; chr6:109374782 chr6:109382795~109383666:+ CESC cis rs9322193 0.923 rs2297930 ENSG00000268592.3 RAET1E-AS1 4.66 5.52e-06 0.00332 0.39 0.3 Lung cancer; chr6:149718360 chr6:149863494~149919507:+ CESC cis rs8072100 0.905 rs11651766 ENSG00000228782.6 CTD-2026D20.3 4.66 5.52e-06 0.00332 0.35 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47497565 chr17:47450568~47492492:- CESC cis rs8072100 0.905 rs9901869 ENSG00000228782.6 CTD-2026D20.3 4.66 5.52e-06 0.00332 0.35 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47497840 chr17:47450568~47492492:- CESC cis rs11723261 0.621 rs61794960 ENSG00000211553.1 AC253576.2 -4.66 5.52e-06 0.00333 -0.47 -0.3 Immune response to smallpox vaccine (IL-6); chr4:156661 chr4:136461~136568:+ CESC cis rs751837 0.932 rs8021471 ENSG00000240624.1 RP11-45P15.2 -4.66 5.53e-06 0.00333 -0.47 -0.3 Large B-cell lymphoma; chr14:103020038 chr14:103282933~103283468:+ CESC cis rs8042680 0.522 rs1867225 ENSG00000214432.8 AC068831.10 -4.66 5.54e-06 0.00333 -0.36 -0.3 Type 2 diabetes; chr15:91020599 chr15:91022619~91036611:+ CESC cis rs7208859 0.623 rs7220999 ENSG00000266490.1 CTD-2349P21.9 4.66 5.54e-06 0.00334 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs55638872 ENSG00000266490.1 CTD-2349P21.9 4.66 5.54e-06 0.00334 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30792372~30792833:+ CESC cis rs875971 1 rs2220626 ENSG00000237310.1 GS1-124K5.4 -4.66 5.54e-06 0.00334 -0.29 -0.3 Aortic root size; chr7:66081075 chr7:66493706~66495474:+ CESC cis rs4819052 0.851 rs1999334 ENSG00000223768.1 LINC00205 -4.66 5.55e-06 0.00334 -0.34 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45250542 chr21:45293285~45297354:+ CESC cis rs6693388 0.548 rs2932574 ENSG00000229021.2 AL591893.1 -4.66 5.55e-06 0.00334 -0.33 -0.3 Blood metabolite ratios; chr1:152009544 chr1:151994531~152042774:+ CESC cis rs875971 0.825 rs6951503 ENSG00000232559.3 GS1-124K5.12 -4.66 5.56e-06 0.00334 -0.33 -0.3 Aortic root size; chr7:66253949 chr7:66554588~66576923:- CESC cis rs7896729 0.607 rs12771527 ENSG00000215267.7 AKR1C7P -4.66 5.56e-06 0.00334 -0.41 -0.3 Intelligence; chr10:5291183 chr10:5275173~5288470:- CESC cis rs950169 0.58 rs11634320 ENSG00000225151.9 GOLGA2P7 4.66 5.56e-06 0.00334 0.41 0.3 Schizophrenia; chr15:84628952 chr15:84199311~84230136:- CESC cis rs8072100 0.967 rs7219303 ENSG00000228782.6 CTD-2026D20.3 -4.66 5.57e-06 0.00335 -0.34 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47660335 chr17:47450568~47492492:- CESC cis rs2564921 0.704 rs11130333 ENSG00000242142.1 SERBP1P3 -4.66 5.57e-06 0.00335 -0.37 -0.3 Height; chr3:52977358 chr3:53064283~53065091:- CESC cis rs6504950 0.888 rs244294 ENSG00000275710.1 RP11-257O5.4 4.66 5.57e-06 0.00335 0.33 0.3 Breast cancer; chr17:55151182 chr17:54964474~54964679:+ CESC cis rs17301013 0.507 rs72713532 ENSG00000227373.4 RP11-160H22.5 4.66 5.58e-06 0.00335 0.41 0.3 Systemic lupus erythematosus; chr1:174337826 chr1:174115300~174160004:- CESC cis rs875971 0.798 rs6460304 ENSG00000232559.3 GS1-124K5.12 4.66 5.58e-06 0.00335 0.33 0.3 Aortic root size; chr7:66499741 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6945775 ENSG00000232559.3 GS1-124K5.12 4.66 5.58e-06 0.00335 0.33 0.3 Aortic root size; chr7:66503987 chr7:66554588~66576923:- CESC cis rs875971 0.798 rs57739047 ENSG00000232559.3 GS1-124K5.12 4.66 5.58e-06 0.00335 0.33 0.3 Aortic root size; chr7:66507579 chr7:66554588~66576923:- CESC cis rs875971 0.83 rs6950137 ENSG00000232559.3 GS1-124K5.12 4.66 5.58e-06 0.00335 0.33 0.3 Aortic root size; chr7:66511623 chr7:66554588~66576923:- CESC cis rs9660180 0.935 rs2180311 ENSG00000268575.1 RP1-283E3.8 -4.66 5.58e-06 0.00336 -0.29 -0.3 Body mass index; chr1:1817295 chr1:1702736~1737688:- CESC cis rs9660180 0.967 rs6664664 ENSG00000268575.1 RP1-283E3.8 -4.66 5.58e-06 0.00336 -0.29 -0.3 Body mass index; chr1:1819825 chr1:1702736~1737688:- CESC cis rs7809950 1 rs2520260 ENSG00000238832.1 snoU109 -4.66 5.59e-06 0.00336 -0.36 -0.3 Coronary artery disease; chr7:107532349 chr7:107603363~107603507:+ CESC cis rs7809950 1 rs12668402 ENSG00000238832.1 snoU109 -4.66 5.59e-06 0.00336 -0.36 -0.3 Coronary artery disease; chr7:107532575 chr7:107603363~107603507:+ CESC cis rs3762637 1 rs9882100 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122451061 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs9968189 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122456289 chr3:122416207~122443180:+ CESC cis rs3762637 0.941 rs60222267 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122460785 chr3:122416207~122443180:+ CESC cis rs3762637 0.882 rs56074178 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122461164 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs72958458 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122466702 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs7642869 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122471939 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs7617042 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122472138 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs6790051 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122473999 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs9878699 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122475384 chr3:122416207~122443180:+ CESC cis rs3762637 1 rs12638866 ENSG00000272758.4 RP11-299J3.8 -4.66 5.59e-06 0.00336 -0.41 -0.3 LDL cholesterol levels; chr3:122475535 chr3:122416207~122443180:+ CESC cis rs6782228 1 rs12495411 ENSG00000242551.2 POU5F1P6 4.66 5.6e-06 0.00337 0.37 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128676852 chr3:128674735~128677005:- CESC cis rs5769707 0.681 rs4824068 ENSG00000235111.1 RP1-29C18.8 -4.66 5.6e-06 0.00337 -0.35 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49631153 chr22:49612657~49615716:- CESC cis rs6782228 1 rs11711038 ENSG00000242551.2 POU5F1P6 4.66 5.61e-06 0.00337 0.37 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128675467 chr3:128674735~128677005:- CESC cis rs7174755 0.637 rs113002386 ENSG00000260657.2 RP11-315D16.4 4.66 5.61e-06 0.00337 0.37 0.3 Major depressive disorder; chr15:68172375 chr15:68267792~68277994:- CESC cis rs10463554 0.856 rs26260 ENSG00000175749.11 EIF3KP1 4.66 5.62e-06 0.00338 0.32 0.3 Parkinson's disease; chr5:103211493 chr5:103032376~103033031:+ CESC cis rs9322193 0.886 rs4870055 ENSG00000268592.3 RAET1E-AS1 4.66 5.63e-06 0.00338 0.42 0.3 Lung cancer; chr6:149848433 chr6:149863494~149919507:+ CESC cis rs9660180 1 rs9660180 ENSG00000268575.1 RP1-283E3.8 -4.65 5.63e-06 0.00338 -0.3 -0.3 Body mass index; chr1:1791592 chr1:1702736~1737688:- CESC cis rs2919917 0.628 rs10113703 ENSG00000254352.1 RP11-578O24.2 4.65 5.63e-06 0.00338 0.41 0.3 Lymphocyte counts; chr8:78688404 chr8:78723796~78724136:- CESC cis rs7777677 0.925 rs4726542 ENSG00000244273.1 PGBD4P1 -4.65 5.63e-06 0.00338 -0.32 -0.3 Alcoholic chronic pancreatitis; chr7:142659516 chr7:142722358~142722764:+ CESC cis rs875971 0.825 rs28480509 ENSG00000232559.3 GS1-124K5.12 -4.65 5.63e-06 0.00338 -0.33 -0.3 Aortic root size; chr7:66634237 chr7:66554588~66576923:- CESC cis rs950880 0.71 rs17027060 ENSG00000234389.1 AC007278.3 -4.65 5.63e-06 0.00338 -0.33 -0.3 Serum protein levels (sST2); chr2:102391107 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs66919607 ENSG00000234389.1 AC007278.3 -4.65 5.63e-06 0.00338 -0.33 -0.3 Serum protein levels (sST2); chr2:102392509 chr2:102438713~102440475:+ CESC cis rs6997458 0.712 rs9987281 ENSG00000253549.4 RP11-317J10.2 -4.65 5.63e-06 0.00338 -0.35 -0.3 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85436601 chr8:85441851~85464915:- CESC cis rs10754283 0.901 rs10922683 ENSG00000231613.1 RP5-943J3.1 4.65 5.64e-06 0.00338 0.38 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89650509 chr1:89788914~89790492:+ CESC cis rs748404 0.646 rs2253268 ENSG00000205771.5 CATSPER2P1 -4.65 5.65e-06 0.00339 -0.36 -0.3 Lung cancer; chr15:43508770 chr15:43726918~43747094:- CESC cis rs77972916 0.505 rs6727824 ENSG00000234936.1 AC010883.5 4.65 5.65e-06 0.00339 0.35 0.3 Granulocyte percentage of myeloid white cells; chr2:43301238 chr2:43229573~43233394:+ CESC cis rs875971 0.862 rs908915 ENSG00000237310.1 GS1-124K5.4 -4.65 5.66e-06 0.0034 -0.28 -0.3 Aortic root size; chr7:66149664 chr7:66493706~66495474:+ CESC cis rs453301 0.682 rs2929451 ENSG00000253981.4 ALG1L13P 4.65 5.66e-06 0.0034 0.33 0.3 Joint mobility (Beighton score); chr8:9227785 chr8:8236003~8244667:- CESC cis rs7580658 0.521 rs2404535 ENSG00000236682.1 AC068282.3 4.65 5.67e-06 0.0034 0.35 0.3 Protein C levels; chr2:127190133 chr2:127389130~127400580:+ CESC cis rs7208859 0.623 rs1054397 ENSG00000266490.1 CTD-2349P21.9 4.65 5.68e-06 0.00341 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30792372~30792833:+ CESC cis rs7873102 0.617 rs2381773 ENSG00000230188.1 RP11-405L18.4 4.65 5.68e-06 0.00341 0.39 0.3 Brain structure; chr9:38003665 chr9:37490421~37490893:- CESC cis rs9487094 0.666 rs7748669 ENSG00000260273.1 RP11-425D10.10 4.65 5.68e-06 0.00341 0.38 0.3 Height; chr6:109424139 chr6:109382795~109383666:+ CESC cis rs11159086 0.793 rs9285594 ENSG00000270000.1 RP3-449M8.9 4.65 5.68e-06 0.00341 0.48 0.3 Advanced glycation end-product levels; chr14:74489253 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs4903229 ENSG00000270000.1 RP3-449M8.9 4.65 5.68e-06 0.00341 0.48 0.3 Advanced glycation end-product levels; chr14:74489865 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs8016972 ENSG00000270000.1 RP3-449M8.9 4.65 5.68e-06 0.00341 0.48 0.3 Advanced glycation end-product levels; chr14:74491833 chr14:74471930~74472360:- CESC cis rs12439619 0.508 rs8023960 ENSG00000276710.3 CSPG4P8 -4.65 5.69e-06 0.00341 -0.32 -0.3 Intelligence (multi-trait analysis); chr15:82206704 chr15:82459472~82477258:+ CESC cis rs9487094 0.689 rs11251 ENSG00000260273.1 RP11-425D10.10 4.65 5.69e-06 0.00341 0.37 0.3 Height; chr6:109368704 chr6:109382795~109383666:+ CESC cis rs2408955 0.542 rs7975632 ENSG00000258273.1 RP11-370I10.4 -4.65 5.7e-06 0.00342 -0.35 -0.3 Glycated hemoglobin levels; chr12:48049265 chr12:48333755~48333901:- CESC cis rs4819052 0.851 rs2236445 ENSG00000223768.1 LINC00205 -4.65 5.71e-06 0.00342 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45258538 chr21:45293285~45297354:+ CESC cis rs2243480 0.908 rs313822 ENSG00000228409.4 CCT6P1 4.65 5.71e-06 0.00343 0.45 0.3 Diabetic kidney disease; chr7:66108952 chr7:65751142~65763354:+ CESC cis rs8020095 0.571 rs8022328 ENSG00000258561.1 RP11-72M17.1 4.65 5.72e-06 0.00343 0.43 0.3 Depression (quantitative trait); chr14:66786317 chr14:66212810~66509394:- CESC cis rs1862618 0.756 rs9292125 ENSG00000271828.1 CTD-2310F14.1 4.65 5.72e-06 0.00343 0.4 0.3 Initial pursuit acceleration; chr5:56811373 chr5:56927874~56929573:+ CESC cis rs1862618 0.802 rs986049 ENSG00000271828.1 CTD-2310F14.1 4.65 5.72e-06 0.00343 0.4 0.3 Initial pursuit acceleration; chr5:56814406 chr5:56927874~56929573:+ CESC cis rs8100891 0.537 rs28729153 ENSG00000267213.4 AC007773.2 -4.65 5.72e-06 0.00343 -0.47 -0.3 Neuroticism; chr19:32416672 chr19:32390050~32405560:- CESC cis rs9847710 0.733 rs2581808 ENSG00000242142.1 SERBP1P3 4.65 5.72e-06 0.00343 0.35 0.3 Ulcerative colitis; chr3:53055429 chr3:53064283~53065091:- CESC cis rs3762637 1 rs16845530 ENSG00000272758.4 RP11-299J3.8 -4.65 5.73e-06 0.00343 -0.41 -0.3 LDL cholesterol levels; chr3:122423600 chr3:122416207~122443180:+ CESC cis rs9322193 0.926 rs9766562 ENSG00000216906.2 RP11-350J20.9 4.65 5.74e-06 0.00344 0.34 0.3 Lung cancer; chr6:149788709 chr6:149904243~149906418:+ CESC cis rs2243480 1 rs4718334 ENSG00000228409.4 CCT6P1 -4.65 5.75e-06 0.00344 -0.43 -0.3 Diabetic kidney disease; chr7:66324467 chr7:65751142~65763354:+ CESC cis rs4423214 0.592 rs10898193 ENSG00000254682.1 RP11-660L16.2 4.65 5.75e-06 0.00344 0.44 0.3 Vitamin D levels; chr11:71486037 chr11:71448674~71452157:+ CESC cis rs875971 0.862 rs1968126 ENSG00000222364.1 RNU6-96P 4.65 5.75e-06 0.00345 0.35 0.3 Aortic root size; chr7:66592017 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs6460306 ENSG00000222364.1 RNU6-96P 4.65 5.75e-06 0.00345 0.35 0.3 Aortic root size; chr7:66595806 chr7:66395191~66395286:+ CESC cis rs11971779 0.715 rs10954646 ENSG00000273391.1 RP11-634H22.1 -4.65 5.77e-06 0.00345 -0.28 -0.3 Diisocyanate-induced asthma; chr7:139376323 chr7:139359032~139359566:- CESC cis rs875971 0.545 rs1796219 ENSG00000236529.1 RP13-254B10.1 -4.65 5.79e-06 0.00346 -0.4 -0.3 Aortic root size; chr7:66645977 chr7:65840212~65840596:+ CESC cis rs2833693 0.574 rs2211675 ENSG00000261610.1 AP000265.1 -4.65 5.79e-06 0.00346 -0.36 -0.3 Temperament; chr21:32180793 chr21:32259804~32261585:- CESC cis rs1862618 0.853 rs832578 ENSG00000271828.1 CTD-2310F14.1 4.65 5.79e-06 0.00346 0.4 0.3 Initial pursuit acceleration; chr5:56868396 chr5:56927874~56929573:+ CESC cis rs8031584 0.958 rs1043742 ENSG00000260382.1 RP11-540B6.2 4.65 5.79e-06 0.00346 0.41 0.3 Huntington's disease progression; chr15:30940378 chr15:30882267~30883231:- CESC cis rs7299940 0.967 rs10848243 ENSG00000256250.1 RP11-989F5.1 -4.65 5.79e-06 0.00346 -0.32 -0.3 Panic disorder; chr12:130894769 chr12:130810606~130812438:+ CESC cis rs6142102 0.812 rs6059578 ENSG00000276073.1 RP5-1125A11.7 -4.65 5.79e-06 0.00347 -0.3 -0.3 Skin pigmentation; chr20:33939900 chr20:33985617~33988989:- CESC cis rs17608059 0.545 rs736261 ENSG00000141028.6 CDRT15P1 -4.65 5.8e-06 0.00347 -0.31 -0.3 Temperament; chr17:14033087 chr17:14024514~14025488:+ CESC cis rs11159086 0.793 rs10139122 ENSG00000270000.1 RP3-449M8.9 4.65 5.81e-06 0.00347 0.48 0.3 Advanced glycation end-product levels; chr14:74492353 chr14:74471930~74472360:- CESC cis rs3806843 0.52 rs265312 ENSG00000202111.1 VTRNA1-2 -4.65 5.81e-06 0.00347 -0.31 -0.3 Depressive symptoms (multi-trait analysis); chr5:140916687 chr5:140718925~140719013:+ CESC cis rs494459 0.838 rs555639 ENSG00000255422.1 AP002954.4 4.65 5.82e-06 0.00348 0.34 0.3 Height; chr11:118758322 chr11:118704607~118750263:+ CESC cis rs10754283 0.967 rs7552896 ENSG00000231613.1 RP5-943J3.1 4.65 5.82e-06 0.00348 0.38 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89637635 chr1:89788914~89790492:+ CESC cis rs1075265 0.729 rs7571086 ENSG00000233266.1 HMGB1P31 4.65 5.82e-06 0.00348 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54007899 chr2:54051334~54051760:+ CESC cis rs7560272 0.501 rs17350188 ENSG00000273245.1 RP11-434P11.2 4.65 5.82e-06 0.00348 0.38 0.3 Schizophrenia; chr2:73737715 chr2:73750256~73750786:- CESC cis rs7819412 0.521 rs11777887 ENSG00000255046.1 RP11-297N6.4 -4.65 5.82e-06 0.00348 -0.35 -0.3 Triglycerides; chr8:11179290 chr8:11797928~11802568:- CESC cis rs1075265 0.87 rs1421617 ENSG00000233266.1 HMGB1P31 4.65 5.83e-06 0.00348 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54032995 chr2:54051334~54051760:+ CESC cis rs4977575 0.505 rs10811641 ENSG00000215221.2 UBA52P6 4.65 5.83e-06 0.00348 0.39 0.3 Pulse pressure; chr9:22014138 chr9:22012155~22012536:+ CESC cis rs5769707 0.967 rs9616327 ENSG00000235111.1 RP1-29C18.8 -4.65 5.83e-06 0.00348 -0.3 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49617243 chr22:49612657~49615716:- CESC cis rs6991838 0.765 rs4424306 ENSG00000200714.1 Y_RNA 4.65 5.83e-06 0.00349 0.36 0.3 Intelligence (multi-trait analysis); chr8:65618674 chr8:65592731~65592820:+ CESC cis rs832187 0.603 rs7615475 ENSG00000280620.1 SCAANT1 4.65 5.83e-06 0.00349 0.42 0.3 Schizophrenia; chr3:63940985 chr3:63911518~63911772:- CESC cis rs12458462 0.892 rs35928863 ENSG00000274828.1 RP11-567M16.6 4.65 5.85e-06 0.00349 0.28 0.3 Monocyte count; chr18:79678956 chr18:79677287~79679358:- CESC cis rs9322193 0.962 rs6914319 ENSG00000268592.3 RAET1E-AS1 4.65 5.85e-06 0.00349 0.39 0.3 Lung cancer; chr6:149806304 chr6:149863494~149919507:+ CESC cis rs8059260 0.736 rs113120936 ENSG00000274038.1 RP11-66H6.4 -4.65 5.86e-06 0.0035 -0.49 -0.3 Alcohol consumption over the past year; chr16:10989474 chr16:11056556~11057034:+ CESC cis rs950880 0.71 rs56166614 ENSG00000234389.1 AC007278.3 -4.65 5.86e-06 0.0035 -0.33 -0.3 Serum protein levels (sST2); chr2:102439636 chr2:102438713~102440475:+ CESC cis rs4819052 0.851 rs7275870 ENSG00000223768.1 LINC00205 -4.65 5.86e-06 0.0035 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251299 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs7275874 ENSG00000223768.1 LINC00205 -4.65 5.86e-06 0.0035 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251308 chr21:45293285~45297354:+ CESC cis rs4819052 0.819 rs34818688 ENSG00000223768.1 LINC00205 -4.65 5.86e-06 0.0035 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45252501 chr21:45293285~45297354:+ CESC cis rs1056107 0.763 rs7024998 ENSG00000225513.1 RP11-165N19.2 -4.65 5.86e-06 0.0035 -0.36 -0.3 Colorectal cancer; chr9:112175379 chr9:112173522~112173971:- CESC cis rs11976180 1 rs1540894 ENSG00000273234.1 OR2A13P -4.65 5.88e-06 0.00351 -0.37 -0.3 Obesity-related traits; chr7:144070583 chr7:144142009~144142938:+ CESC cis rs2739330 0.731 rs5751792 ENSG00000272787.1 KB-226F1.2 -4.64 5.88e-06 0.00351 -0.32 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23969211~23969873:+ CESC cis rs34375054 0.525 rs7133614 ENSG00000279233.1 RP11-158L12.4 4.64 5.88e-06 0.00351 0.31 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125121411 chr12:125138245~125141711:+ CESC cis rs7927592 0.956 rs60212556 ENSG00000212093.1 AP000807.1 4.64 5.89e-06 0.00352 0.35 0.3 Total body bone mineral density; chr11:68538026 chr11:68506083~68506166:- CESC cis rs881375 0.715 rs10818482 ENSG00000226752.6 PSMD5-AS1 4.64 5.89e-06 0.00352 0.31 0.3 Rheumatoid arthritis; chr9:120885807 chr9:120824828~120854385:+ CESC cis rs7809950 1 rs2066735 ENSG00000238832.1 snoU109 -4.64 5.9e-06 0.00352 -0.36 -0.3 Coronary artery disease; chr7:107548274 chr7:107603363~107603507:+ CESC cis rs11846409 0.932 rs60917084 ENSG00000211974.3 IGHV2-70 -4.64 5.9e-06 0.00352 -0.39 -0.3 Rheumatic heart disease; chr14:106634621 chr14:106723574~106724093:- CESC cis rs3762637 1 rs7609972 ENSG00000272758.4 RP11-299J3.8 -4.64 5.91e-06 0.00352 -0.41 -0.3 LDL cholesterol levels; chr3:122480579 chr3:122416207~122443180:+ CESC cis rs8030379 1 rs6603003 ENSG00000230373.7 GOLGA6L5P -4.64 5.93e-06 0.00353 -0.29 -0.3 Waist circumference;Waist circumference adjusted for body mass index; chr15:83896850 chr15:84507885~84516814:- CESC cis rs7208859 0.524 rs73988172 ENSG00000266490.1 CTD-2349P21.9 4.64 5.93e-06 0.00354 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30792372~30792833:+ CESC cis rs5758659 0.714 rs5751220 ENSG00000273366.1 CTA-989H11.1 4.64 5.94e-06 0.00354 0.37 0.3 Cognitive function; chr22:42120201 chr22:42278188~42278846:+ CESC cis rs5758659 0.714 rs6002626 ENSG00000273366.1 CTA-989H11.1 4.64 5.94e-06 0.00354 0.37 0.3 Cognitive function; chr22:42121985 chr22:42278188~42278846:+ CESC cis rs7777677 0.925 rs2156964 ENSG00000244273.1 PGBD4P1 -4.64 5.94e-06 0.00354 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142664755 chr7:142722358~142722764:+ CESC cis rs8059260 0.604 rs2160042 ENSG00000274038.1 RP11-66H6.4 -4.64 5.94e-06 0.00354 -0.53 -0.3 Alcohol consumption over the past year; chr16:11064375 chr16:11056556~11057034:+ CESC cis rs881375 0.678 rs3761846 ENSG00000226752.6 PSMD5-AS1 -4.64 5.95e-06 0.00355 -0.31 -0.3 Rheumatoid arthritis; chr9:120927319 chr9:120824828~120854385:+ CESC cis rs9907295 0.581 rs4251751 ENSG00000270977.1 AC015849.16 -4.64 5.95e-06 0.00355 -0.44 -0.3 Fibroblast growth factor basic levels; chr17:35823733 chr17:35893707~35911023:- CESC cis rs9907295 0.748 rs4251752 ENSG00000270977.1 AC015849.16 -4.64 5.95e-06 0.00355 -0.44 -0.3 Fibroblast growth factor basic levels; chr17:35823900 chr17:35893707~35911023:- CESC cis rs9640161 0.789 rs60283368 ENSG00000261305.1 RP4-584D14.7 4.64 5.95e-06 0.00355 0.4 0.3 Blood protein levels;Circulating chemerin levels; chr7:150326169 chr7:150341771~150342607:+ CESC cis rs7604827 0.841 rs7564279 ENSG00000230076.1 AC016708.2 -4.64 5.96e-06 0.00355 -0.43 -0.3 PR interval; chr2:214470483 chr2:214847128~214847445:+ CESC cis rs11155671 0.53 rs7756850 ENSG00000223701.3 RAET1E-AS1 4.64 5.96e-06 0.00355 0.33 0.3 Testicular germ cell tumor; chr6:149891460 chr6:149884431~149919508:+ CESC cis rs9322193 0.962 rs9688412 ENSG00000216906.2 RP11-350J20.9 -4.64 5.97e-06 0.00355 -0.33 -0.3 Lung cancer; chr6:149803147 chr6:149904243~149906418:+ CESC cis rs6142102 0.961 rs6088361 ENSG00000276073.1 RP5-1125A11.7 -4.64 5.97e-06 0.00355 -0.3 -0.3 Skin pigmentation; chr20:33969520 chr20:33985617~33988989:- CESC cis rs10246939 0.505 rs34726057 ENSG00000228775.6 WEE2-AS1 4.64 5.97e-06 0.00356 0.36 0.3 Bitter taste perception; chr7:141832117 chr7:141704338~141738346:- CESC cis rs5760092 0.572 rs738806 ENSG00000231271.1 AP000350.8 4.64 5.97e-06 0.00356 0.4 0.3 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23949918~23954042:+ CESC cis rs7714584 1 rs73282209 ENSG00000197083.10 ZNF300P1 4.64 5.97e-06 0.00356 0.53 0.3 Crohn's disease; chr5:150795397 chr5:150930645~150946289:- CESC cis rs2019137 0.56 rs7578633 ENSG00000189223.12 PAX8-AS1 -4.64 5.97e-06 0.00356 -0.4 -0.3 Lymphocyte counts; chr2:113221073 chr2:113211522~113276581:+ CESC cis rs1061377 0.513 rs2712000 ENSG00000249207.1 RP11-360F5.1 -4.64 5.97e-06 0.00356 -0.42 -0.3 Uric acid levels; chr4:39135462 chr4:39112677~39126818:- CESC cis rs5758659 0.714 rs133376 ENSG00000273366.1 CTA-989H11.1 -4.64 5.98e-06 0.00356 -0.37 -0.3 Cognitive function; chr22:42070901 chr22:42278188~42278846:+ CESC cis rs5758659 0.653 rs133383 ENSG00000273366.1 CTA-989H11.1 -4.64 5.98e-06 0.00356 -0.37 -0.3 Cognitive function; chr22:42077599 chr22:42278188~42278846:+ CESC cis rs9918079 0.56 rs7685083 ENSG00000273133.1 RP11-799M12.2 4.64 5.98e-06 0.00356 0.38 0.3 Obesity-related traits; chr4:15609148 chr4:15563698~15564253:- CESC cis rs6452524 0.508 rs256795 ENSG00000249664.1 CTD-2227C6.2 -4.64 5.98e-06 0.00356 -0.32 -0.3 Hypertension (SNP x SNP interaction); chr5:83001543 chr5:83012285~83013109:- CESC cis rs1930961 1 rs6004668 ENSG00000272942.1 CTA-246H3.12 4.64 5.98e-06 0.00356 0.45 0.3 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25434324~25435070:- CESC cis rs2733201 1 rs2412849 ENSG00000259479.5 SORD2P -4.64 5.98e-06 0.00356 -0.46 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:43984357 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2412850 ENSG00000259479.5 SORD2P -4.64 5.98e-06 0.00356 -0.46 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:43985963 chr15:44826371~44884694:- CESC cis rs11638352 1 rs11854312 ENSG00000259479.5 SORD2P -4.64 5.98e-06 0.00356 -0.46 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:43987511 chr15:44826371~44884694:- CESC cis rs11638352 1 rs11631340 ENSG00000259479.5 SORD2P -4.64 5.98e-06 0.00356 -0.46 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:43994127 chr15:44826371~44884694:- CESC cis rs2337406 1 rs11850600 ENSG00000211974.3 IGHV2-70 -4.64 5.99e-06 0.00357 -0.46 -0.3 Alzheimer's disease (late onset); chr14:106670765 chr14:106723574~106724093:- CESC cis rs6496044 0.507 rs410522 ENSG00000202081.1 RNU6-1280P -4.64 5.99e-06 0.00357 -0.32 -0.3 Interstitial lung disease; chr15:85663813 chr15:85651522~85651628:- CESC cis rs875971 1 rs1167612 ENSG00000237310.1 GS1-124K5.4 -4.64 6e-06 0.00357 -0.29 -0.3 Aortic root size; chr7:66102989 chr7:66493706~66495474:+ CESC cis rs10463554 0.895 rs3756583 ENSG00000175749.11 EIF3KP1 4.64 6e-06 0.00357 0.31 0.3 Parkinson's disease; chr5:102998340 chr5:103032376~103033031:+ CESC cis rs73086581 0.945 rs6052222 ENSG00000229539.1 RP11-119B16.2 4.64 6e-06 0.00357 0.48 0.3 Response to antidepressants in depression; chr20:3992146 chr20:3888239~3888868:- CESC cis rs7789940 1 rs7789940 ENSG00000230305.2 AC004980.9 4.64 6e-06 0.00357 0.43 0.3 Multiple sclerosis; chr7:76321913 chr7:76524515~76532692:+ CESC cis rs10875746 0.669 rs2279464 ENSG00000240399.1 RP1-228P16.1 -4.64 6.01e-06 0.00358 -0.39 -0.3 Longevity (90 years and older); chr12:48296626 chr12:48054813~48055591:- CESC cis rs2058059 0.636 rs3015897 ENSG00000205578.5 POM121B -4.64 6.03e-06 0.00359 -0.36 -0.3 Subcutaneous adipose tissue; chr7:72658854 chr7:73293497~73301161:+ CESC cis rs6565180 0.962 rs6565182 ENSG00000183604.13 SMG1P5 -4.64 6.03e-06 0.00359 -0.31 -0.3 Tonsillectomy; chr16:30363060 chr16:30267553~30335374:- CESC cis rs7586673 0.866 rs7579662 ENSG00000227403.1 AC009299.3 -4.64 6.03e-06 0.00359 -0.38 -0.3 Intelligence (multi-trait analysis); chr2:161059299 chr2:161244739~161249050:+ CESC cis rs5769707 0.967 rs763127 ENSG00000235111.1 RP1-29C18.8 -4.64 6.03e-06 0.00359 -0.29 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49612430 chr22:49612657~49615716:- CESC cis rs13108904 0.967 rs62293658 ENSG00000253399.1 AC078852.2 4.64 6.04e-06 0.00359 0.36 0.3 Obesity-related traits; chr4:1282628 chr4:1358479~1359461:+ CESC cis rs2980439 0.556 rs2921059 ENSG00000253893.2 FAM85B -4.64 6.04e-06 0.00359 -0.36 -0.3 Neuroticism; chr8:8460377 chr8:8167819~8226614:- CESC cis rs950880 0.71 rs4851570 ENSG00000234389.1 AC007278.3 -4.64 6.04e-06 0.00359 -0.33 -0.3 Serum protein levels (sST2); chr2:102389927 chr2:102438713~102440475:+ CESC cis rs755249 0.959 rs72663520 ENSG00000228060.1 RP11-69E11.8 -4.64 6.04e-06 0.00359 -0.35 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39537738 chr1:39565160~39573203:+ CESC cis rs1799949 1 rs3092988 ENSG00000267681.1 CTD-3199J23.6 -4.64 6.04e-06 0.00359 -0.41 -0.3 Menopause (age at onset); chr17:43049685 chr17:43144956~43145255:+ CESC cis rs4819052 0.765 rs2838854 ENSG00000223768.1 LINC00205 -4.64 6.05e-06 0.0036 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45260449 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2255766 ENSG00000223768.1 LINC00205 -4.64 6.05e-06 0.0036 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45263862 chr21:45293285~45297354:+ CESC cis rs7208859 0.623 rs9899268 ENSG00000266490.1 CTD-2349P21.9 4.64 6.06e-06 0.0036 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30792372~30792833:+ CESC cis rs7809950 1 rs2712200 ENSG00000238832.1 snoU109 -4.64 6.08e-06 0.00361 -0.36 -0.3 Coronary artery disease; chr7:107501990 chr7:107603363~107603507:+ CESC cis rs9322193 0.962 rs6914319 ENSG00000216906.2 RP11-350J20.9 4.64 6.09e-06 0.00362 0.34 0.3 Lung cancer; chr6:149806304 chr6:149904243~149906418:+ CESC cis rs7809950 1 rs10251808 ENSG00000238832.1 snoU109 -4.64 6.09e-06 0.00362 -0.35 -0.3 Coronary artery disease; chr7:107480008 chr7:107603363~107603507:+ CESC cis rs11846409 0.521 rs10143547 ENSG00000211974.3 IGHV2-70 -4.64 6.1e-06 0.00362 -0.4 -0.3 Rheumatic heart disease; chr14:106644638 chr14:106723574~106724093:- CESC cis rs755249 1 rs4660303 ENSG00000228060.1 RP11-69E11.8 -4.64 6.11e-06 0.00363 -0.35 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39594801 chr1:39565160~39573203:+ CESC cis rs763121 0.853 rs1569492 ENSG00000273076.1 RP3-508I15.22 -4.64 6.11e-06 0.00363 -0.33 -0.3 Menopause (age at onset); chr22:38579506 chr22:38743495~38743910:+ CESC cis rs5769707 0.521 rs6009810 ENSG00000188511.11 C22orf34 4.64 6.13e-06 0.00364 0.34 0.3 Monocyte percentage of white cells;Monocyte count; chr22:49665892 chr22:49414524~49657542:- CESC cis rs2108622 0.527 rs67617968 ENSG00000267453.5 AC004791.2 -4.64 6.13e-06 0.00364 -0.36 -0.3 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866755 chr19:15851993~15864904:- CESC cis rs9322193 0.923 rs7753812 ENSG00000216906.2 RP11-350J20.9 4.64 6.13e-06 0.00364 0.33 0.3 Lung cancer; chr6:149690150 chr6:149904243~149906418:+ CESC cis rs3762637 1 rs12630576 ENSG00000272758.4 RP11-299J3.8 -4.64 6.13e-06 0.00364 -0.41 -0.3 LDL cholesterol levels; chr3:122420670 chr3:122416207~122443180:+ CESC cis rs7429990 0.965 rs7649981 ENSG00000229759.1 MRPS18AP1 4.64 6.14e-06 0.00364 0.31 0.3 Educational attainment (years of education); chr3:47957847 chr3:48256350~48256938:- CESC cis rs4308124 0.708 rs7585313 ENSG00000227992.1 AC108463.2 -4.64 6.14e-06 0.00364 -0.4 -0.3 Vitiligo; chr2:111217626 chr2:111203964~111206215:- CESC cis rs6893782 0.887 rs274554 ENSG00000233006.5 AC034220.3 -4.64 6.14e-06 0.00364 -0.38 -0.3 Acylcarnitine levels; chr5:132389258 chr5:132311285~132369916:- CESC cis rs13108904 0.901 rs12509700 ENSG00000253399.1 AC078852.2 -4.64 6.14e-06 0.00365 -0.36 -0.3 Obesity-related traits; chr4:1302533 chr4:1358479~1359461:+ CESC cis rs9318086 0.6 rs9507185 ENSG00000205861.10 C1QTNF9B-AS1 -4.64 6.14e-06 0.00365 -0.37 -0.3 Myopia (pathological); chr13:23899595 chr13:23888889~23897263:+ CESC cis rs9322193 0.923 rs12174716 ENSG00000268592.3 RAET1E-AS1 4.63 6.15e-06 0.00365 0.38 0.3 Lung cancer; chr6:149644487 chr6:149863494~149919507:+ CESC cis rs9402743 0.781 rs9494326 ENSG00000217482.2 HMGB1P17 4.63 6.15e-06 0.00365 0.33 0.3 Systemic lupus erythematosus; chr6:135673400 chr6:135636086~135636713:- CESC cis rs875971 1 rs697970 ENSG00000237310.1 GS1-124K5.4 -4.63 6.16e-06 0.00365 -0.29 -0.3 Aortic root size; chr7:66095065 chr7:66493706~66495474:+ CESC cis rs9322193 0.923 rs12195866 ENSG00000216906.2 RP11-350J20.9 4.63 6.17e-06 0.00366 0.33 0.3 Lung cancer; chr6:149693334 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9285524 ENSG00000216906.2 RP11-350J20.9 4.63 6.17e-06 0.00366 0.33 0.3 Lung cancer; chr6:149694122 chr6:149904243~149906418:+ CESC cis rs875971 0.545 rs316324 ENSG00000222364.1 RNU6-96P 4.63 6.17e-06 0.00366 0.39 0.3 Aortic root size; chr7:66145627 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs316323 ENSG00000222364.1 RNU6-96P 4.63 6.17e-06 0.00366 0.39 0.3 Aortic root size; chr7:66146002 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs316305 ENSG00000222364.1 RNU6-96P 4.63 6.17e-06 0.00366 0.39 0.3 Aortic root size; chr7:66152984 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs316306 ENSG00000222364.1 RNU6-96P 4.63 6.17e-06 0.00366 0.39 0.3 Aortic root size; chr7:66153687 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs2460427 ENSG00000222364.1 RNU6-96P 4.63 6.17e-06 0.00366 0.39 0.3 Aortic root size; chr7:66154218 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs10950025 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66158946 chr7:66395191~66395286:+ CESC cis rs875971 0.52 rs12666485 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66160135 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs67688847 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66161064 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs7787063 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66164012 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs12673308 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66166374 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs67397473 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66168318 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs10950027 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66169164 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs6460276 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66182290 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs67775320 ENSG00000222364.1 RNU6-96P -4.63 6.17e-06 0.00366 -0.39 -0.3 Aortic root size; chr7:66193792 chr7:66395191~66395286:+ CESC cis rs4819052 0.851 rs2838837 ENSG00000223768.1 LINC00205 -4.63 6.18e-06 0.00366 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45246073 chr21:45293285~45297354:+ CESC cis rs1061377 0.513 rs2711994 ENSG00000249207.1 RP11-360F5.1 4.63 6.18e-06 0.00366 0.4 0.3 Uric acid levels; chr4:39148121 chr4:39112677~39126818:- CESC cis rs116095464 0.558 rs9312957 ENSG00000250848.1 CTD-2083E4.5 -4.63 6.18e-06 0.00367 -0.41 -0.3 Breast cancer; chr5:202079 chr5:288833~290321:- CESC cis rs1799949 0.526 rs4352088 ENSG00000267681.1 CTD-3199J23.6 -4.63 6.19e-06 0.00367 -0.4 -0.3 Menopause (age at onset); chr17:43337311 chr17:43144956~43145255:+ CESC cis rs10129255 0.957 rs8014696 ENSG00000280411.1 IGHV1-69-2 4.63 6.19e-06 0.00367 0.22 0.3 Kawasaki disease; chr14:106769752 chr14:106762092~106762588:- CESC cis rs9309473 1 rs10207220 ENSG00000163016.8 ALMS1P 4.63 6.19e-06 0.00367 0.39 0.3 Metabolite levels; chr2:73557919 chr2:73644919~73685576:+ CESC cis rs694739 0.894 rs887314 ENSG00000236935.1 AP003774.1 4.63 6.19e-06 0.00367 0.31 0.3 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64285685 chr11:64325050~64329504:- CESC cis rs7586673 0.93 rs6432667 ENSG00000227403.1 AC009299.3 -4.63 6.2e-06 0.00367 -0.4 -0.3 Intelligence (multi-trait analysis); chr2:161048490 chr2:161244739~161249050:+ CESC cis rs1061377 0.748 rs13117988 ENSG00000249207.1 RP11-360F5.1 -4.63 6.21e-06 0.00368 -0.36 -0.3 Uric acid levels; chr4:39092219 chr4:39112677~39126818:- CESC cis rs10829156 0.945 rs10829199 ENSG00000240291.1 RP11-499P20.2 4.63 6.21e-06 0.00368 0.32 0.3 Sudden cardiac arrest; chr10:18679012 chr10:18513115~18545651:- CESC cis rs12681963 0.688 rs12544416 ENSG00000272375.1 RP11-51J9.6 4.63 6.21e-06 0.00368 0.49 0.3 Migraine; chr8:30182057 chr8:30197404~30198048:+ CESC cis rs5769765 0.862 rs9616392 ENSG00000229409.1 RP11-494O16.3 4.63 6.22e-06 0.00368 0.46 0.3 Schizophrenia; chr22:49921057 chr22:49845929~49846090:+ CESC cis rs5769765 0.955 rs9616394 ENSG00000229409.1 RP11-494O16.3 4.63 6.22e-06 0.00368 0.46 0.3 Schizophrenia; chr22:49921279 chr22:49845929~49846090:+ CESC cis rs12134133 1 rs2802235 ENSG00000274245.1 RP11-357P18.2 4.63 6.22e-06 0.00368 0.38 0.3 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207298454 chr1:207372559~207373252:+ CESC cis rs34779708 0.766 rs35308730 ENSG00000230534.5 RP11-297A16.2 4.63 6.22e-06 0.00368 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260868 chr10:35098006~35127020:- CESC cis rs34779708 0.736 rs34195979 ENSG00000230534.5 RP11-297A16.2 4.63 6.22e-06 0.00368 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260889 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs12254018 ENSG00000230534.5 RP11-297A16.2 4.63 6.22e-06 0.00368 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35261713 chr10:35098006~35127020:- CESC cis rs875971 0.862 rs778724 ENSG00000232559.3 GS1-124K5.12 4.63 6.22e-06 0.00368 0.33 0.3 Aortic root size; chr7:66364304 chr7:66554588~66576923:- CESC cis rs860295 0.702 rs12043132 ENSG00000225855.5 RUSC1-AS1 4.63 6.23e-06 0.00369 0.25 0.3 Body mass index; chr1:155592576 chr1:155316863~155324176:- CESC cis rs3762637 1 rs9833415 ENSG00000272758.4 RP11-299J3.8 -4.63 6.23e-06 0.00369 -0.41 -0.3 LDL cholesterol levels; chr3:122440993 chr3:122416207~122443180:+ CESC cis rs755249 1 rs61779359 ENSG00000228060.1 RP11-69E11.8 -4.63 6.24e-06 0.00369 -0.36 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39544563 chr1:39565160~39573203:+ CESC cis rs755249 0.959 rs61781363 ENSG00000228060.1 RP11-69E11.8 -4.63 6.24e-06 0.00369 -0.36 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39546761 chr1:39565160~39573203:+ CESC cis rs755249 1 rs4660808 ENSG00000228060.1 RP11-69E11.8 -4.63 6.24e-06 0.00369 -0.36 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39552837 chr1:39565160~39573203:+ CESC cis rs755249 1 rs61781364 ENSG00000228060.1 RP11-69E11.8 -4.63 6.24e-06 0.00369 -0.36 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39553919 chr1:39565160~39573203:+ CESC cis rs9326248 1 rs9326248 ENSG00000280143.1 AP000892.6 4.63 6.24e-06 0.00369 0.39 0.3 Blood protein levels; chr11:117128509 chr11:117204967~117210292:+ CESC cis rs2243480 1 rs383402 ENSG00000232559.3 GS1-124K5.12 -4.63 6.26e-06 0.0037 -0.48 -0.3 Diabetic kidney disease; chr7:66121666 chr7:66554588~66576923:- CESC cis rs7777677 0.925 rs6969951 ENSG00000244273.1 PGBD4P1 4.63 6.26e-06 0.0037 0.32 0.3 Alcoholic chronic pancreatitis; chr7:142661753 chr7:142722358~142722764:+ CESC cis rs17826219 0.706 rs28469200 ENSG00000266490.1 CTD-2349P21.9 4.63 6.26e-06 0.0037 0.45 0.3 Body mass index; chr17:30806554 chr17:30792372~30792833:+ CESC cis rs7560272 0.538 rs7599453 ENSG00000273245.1 RP11-434P11.2 -4.63 6.26e-06 0.0037 -0.37 -0.3 Schizophrenia; chr2:73710774 chr2:73750256~73750786:- CESC cis rs3738443 0.599 rs1934986 ENSG00000259865.1 RP11-488L18.10 4.63 6.27e-06 0.00371 0.33 0.3 Alcohol dependence; chr1:247235696 chr1:247187281~247188526:- CESC cis rs3738443 0.644 rs2799177 ENSG00000259865.1 RP11-488L18.10 -4.63 6.27e-06 0.00371 -0.33 -0.3 Alcohol dependence; chr1:247235898 chr1:247187281~247188526:- CESC cis rs11089937 0.929 rs2236727 ENSG00000211639.2 IGLV4-60 4.63 6.27e-06 0.00371 0.26 0.3 Periodontitis (PAL4Q3); chr22:22156654 chr22:22162199~22162681:+ CESC cis rs1853665 1 rs1951931 ENSG00000231760.4 RP11-350J20.5 4.63 6.28e-06 0.00371 0.49 0.3 Radiation response; chr6:149975762 chr6:149796151~149826294:- CESC cis rs9326248 0.569 rs4938315 ENSG00000280143.1 AP000892.6 4.63 6.28e-06 0.00371 0.5 0.3 Blood protein levels; chr11:116860489 chr11:117204967~117210292:+ CESC cis rs875971 0.862 rs1875057 ENSG00000232559.3 GS1-124K5.12 -4.63 6.28e-06 0.00371 -0.32 -0.3 Aortic root size; chr7:66266868 chr7:66554588~66576923:- CESC cis rs7927592 0.913 rs10896329 ENSG00000212093.1 AP000807.1 4.63 6.29e-06 0.00372 0.35 0.3 Total body bone mineral density; chr11:68482561 chr11:68506083~68506166:- CESC cis rs12364620 1 rs12364620 ENSG00000212093.1 AP000807.1 4.63 6.29e-06 0.00372 0.35 0.3 Total body bone mineral density (age 0-15); chr11:68484655 chr11:68506083~68506166:- CESC cis rs34779708 0.733 rs4007271 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35257683 chr10:35098006~35127020:- CESC cis rs34779708 0.702 rs4007272 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35257931 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs4934740 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258213 chr10:35098006~35127020:- CESC cis rs34779708 0.702 rs4244995 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258247 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs4244997 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258326 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs4298846 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258452 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs4391768 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258667 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs7914468 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35259143 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs7914560 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35259171 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs4444023 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35259426 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs12243593 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260117 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs3936502 ENSG00000230534.5 RP11-297A16.2 4.63 6.29e-06 0.00372 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260290 chr10:35098006~35127020:- CESC cis rs11157436 0.958 rs764161 ENSG00000211813.2 TRAV34 4.63 6.29e-06 0.00372 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22231182 chr14:22207522~22208129:+ CESC cis rs11157436 0.958 rs12433649 ENSG00000211813.2 TRAV34 4.63 6.29e-06 0.00372 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22231828 chr14:22207522~22208129:+ CESC cis rs987724 0.592 rs9858861 ENSG00000240875.4 LINC00886 -4.63 6.29e-06 0.00372 -0.38 -0.3 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156824848 chr3:156747346~156817062:- CESC cis rs2243480 1 rs313820 ENSG00000228409.4 CCT6P1 4.63 6.3e-06 0.00372 0.45 0.3 Diabetic kidney disease; chr7:66109479 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs313824 ENSG00000228409.4 CCT6P1 4.63 6.3e-06 0.00372 0.45 0.3 Diabetic kidney disease; chr7:66116220 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs186378 ENSG00000228409.4 CCT6P1 4.63 6.3e-06 0.00372 0.45 0.3 Diabetic kidney disease; chr7:66117071 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs160637 ENSG00000228409.4 CCT6P1 4.63 6.3e-06 0.00372 0.45 0.3 Diabetic kidney disease; chr7:66119331 chr7:65751142~65763354:+ CESC cis rs7208859 0.623 rs56812022 ENSG00000266490.1 CTD-2349P21.9 4.63 6.31e-06 0.00373 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30792372~30792833:+ CESC cis rs1799949 0.55 rs2343818 ENSG00000267681.1 CTD-3199J23.6 -4.63 6.33e-06 0.00373 -0.4 -0.3 Menopause (age at onset); chr17:43332406 chr17:43144956~43145255:+ CESC cis rs3806843 0.576 rs251373 ENSG00000202111.1 VTRNA1-2 4.63 6.34e-06 0.00374 0.31 0.3 Depressive symptoms (multi-trait analysis); chr5:140873030 chr5:140718925~140719013:+ CESC cis rs3806843 0.545 rs251375 ENSG00000202111.1 VTRNA1-2 4.63 6.34e-06 0.00374 0.31 0.3 Depressive symptoms (multi-trait analysis); chr5:140873375 chr5:140718925~140719013:+ CESC cis rs3806843 0.606 rs251377 ENSG00000202111.1 VTRNA1-2 4.63 6.34e-06 0.00374 0.31 0.3 Depressive symptoms (multi-trait analysis); chr5:140876207 chr5:140718925~140719013:+ CESC cis rs8059260 0.604 rs11863415 ENSG00000274038.1 RP11-66H6.4 -4.63 6.34e-06 0.00374 -0.45 -0.3 Alcohol consumption over the past year; chr16:11053237 chr16:11056556~11057034:+ CESC cis rs17507216 0.671 rs28582623 ENSG00000278603.1 RP13-608F4.5 4.63 6.35e-06 0.00374 0.46 0.3 Excessive daytime sleepiness; chr15:82577381 chr15:82472203~82472426:+ CESC cis rs17608059 0.545 rs9915045 ENSG00000141028.6 CDRT15P1 -4.63 6.35e-06 0.00375 -0.31 -0.3 Temperament; chr17:13999319 chr17:14024514~14025488:+ CESC cis rs950169 0.544 rs2036949 ENSG00000225151.9 GOLGA2P7 -4.63 6.36e-06 0.00375 -0.41 -0.3 Schizophrenia; chr15:84620374 chr15:84199311~84230136:- CESC cis rs1056107 0.731 rs7047547 ENSG00000225513.1 RP11-165N19.2 -4.63 6.36e-06 0.00375 -0.36 -0.3 Colorectal cancer; chr9:112173568 chr9:112173522~112173971:- CESC cis rs6964833 1 rs34324835 ENSG00000277053.3 GTF2IP1 -4.63 6.36e-06 0.00375 -0.37 -0.3 Menarche (age at onset); chr7:74717986 chr7:75185385~75237696:- CESC cis rs2028299 0.839 rs3844575 ENSG00000259677.1 RP11-493E3.1 4.63 6.37e-06 0.00375 0.42 0.3 Type 2 diabetes; chr15:89900515 chr15:89876540~89877285:+ CESC cis rs2028299 0.839 rs2279848 ENSG00000259677.1 RP11-493E3.1 4.63 6.37e-06 0.00375 0.42 0.3 Type 2 diabetes; chr15:89901449 chr15:89876540~89877285:+ CESC cis rs6142102 0.778 rs4911374 ENSG00000276073.1 RP5-1125A11.7 -4.63 6.37e-06 0.00375 -0.3 -0.3 Skin pigmentation; chr20:33928195 chr20:33985617~33988989:- CESC cis rs71403859 0.502 rs17345863 ENSG00000260886.1 TAT-AS1 4.63 6.37e-06 0.00376 0.48 0.3 Post bronchodilator FEV1; chr16:71489358 chr16:71565789~71578187:+ CESC cis rs71403859 0.502 rs17280181 ENSG00000260886.1 TAT-AS1 4.63 6.37e-06 0.00376 0.48 0.3 Post bronchodilator FEV1; chr16:71489611 chr16:71565789~71578187:+ CESC cis rs7586673 1 rs16845584 ENSG00000227403.1 AC009299.3 4.63 6.38e-06 0.00376 0.38 0.3 Intelligence (multi-trait analysis); chr2:161067319 chr2:161244739~161249050:+ CESC cis rs172166 0.694 rs203876 ENSG00000219392.1 RP1-265C24.5 -4.63 6.38e-06 0.00376 -0.34 -0.3 Cardiac Troponin-T levels; chr6:28078895 chr6:28115628~28116551:+ CESC cis rs172166 0.694 rs203877 ENSG00000219392.1 RP1-265C24.5 -4.63 6.38e-06 0.00376 -0.34 -0.3 Cardiac Troponin-T levels; chr6:28080846 chr6:28115628~28116551:+ CESC cis rs6686842 1 rs6663565 ENSG00000235358.1 RP11-399E6.1 -4.63 6.39e-06 0.00376 -0.36 -0.3 Height; chr1:41098016 chr1:41242373~41284861:+ CESC cis rs2739330 0.791 rs4822458 ENSG00000272787.1 KB-226F1.2 -4.63 6.39e-06 0.00377 -0.32 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23969211~23969873:+ CESC cis rs7508 0.511 rs371922 ENSG00000253671.1 RP11-806O11.1 -4.63 6.4e-06 0.00377 -0.35 -0.3 Atrial fibrillation; chr8:18042494 chr8:17808941~17820868:+ CESC cis rs6452524 1 rs6452531 ENSG00000249664.1 CTD-2227C6.2 4.63 6.4e-06 0.00377 0.33 0.3 Hypertension (SNP x SNP interaction); chr5:83170355 chr5:83012285~83013109:- CESC cis rs1185460 1 rs7938944 ENSG00000271751.1 RP11-110I1.14 -4.63 6.4e-06 0.00377 -0.4 -0.3 Coronary artery disease; chr11:119083356 chr11:119065263~119065677:- CESC cis rs72627509 0.68 rs79641006 ENSG00000269949.1 RP11-738E22.3 4.63 6.4e-06 0.00377 0.5 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56981277 chr4:56960927~56961373:- CESC cis rs2058059 0.593 rs2960944 ENSG00000205578.5 POM121B -4.63 6.4e-06 0.00377 -0.37 -0.3 Subcutaneous adipose tissue; chr7:72680285 chr7:73293497~73301161:+ CESC cis rs875971 0.862 rs7783779 ENSG00000232559.3 GS1-124K5.12 -4.63 6.4e-06 0.00377 -0.33 -0.3 Aortic root size; chr7:66331639 chr7:66554588~66576923:- CESC cis rs875971 0.545 rs10950036 ENSG00000226824.5 RP4-756H11.3 -4.63 6.4e-06 0.00377 -0.41 -0.3 Aortic root size; chr7:66353241 chr7:66654538~66669855:+ CESC cis rs9309711 0.961 rs35067331 ENSG00000225234.1 TRAPPC12-AS1 -4.63 6.41e-06 0.00377 -0.3 -0.3 Neurofibrillary tangles; chr2:3470314 chr2:3481242~3482409:- CESC cis rs2019137 0.56 rs10206269 ENSG00000189223.12 PAX8-AS1 -4.63 6.41e-06 0.00378 -0.39 -0.3 Lymphocyte counts; chr2:113232816 chr2:113211522~113276581:+ CESC cis rs1061377 1 rs9990742 ENSG00000249685.1 RP11-360F5.3 4.63 6.41e-06 0.00378 0.35 0.3 Uric acid levels; chr4:39119794 chr4:39133913~39135608:+ CESC cis rs11779988 0.528 rs208029 ENSG00000253671.1 RP11-806O11.1 -4.63 6.41e-06 0.00378 -0.35 -0.3 Breast cancer; chr8:17983478 chr8:17808941~17820868:+ CESC cis rs875971 0.545 rs10950029 ENSG00000236529.1 RP13-254B10.1 4.63 6.42e-06 0.00378 0.37 0.3 Aortic root size; chr7:66169334 chr7:65840212~65840596:+ CESC cis rs9549367 0.713 rs2146750 ENSG00000269125.1 RP11-98F14.11 4.62 6.43e-06 0.00379 0.42 0.3 Platelet distribution width; chr13:113168216 chr13:113165002~113165183:- CESC cis rs9322193 0.962 rs6903998 ENSG00000223701.3 RAET1E-AS1 4.62 6.44e-06 0.00379 0.34 0.3 Lung cancer; chr6:149831357 chr6:149884431~149919508:+ CESC cis rs9322193 0.923 rs1984111 ENSG00000223701.3 RAET1E-AS1 4.62 6.44e-06 0.00379 0.34 0.3 Lung cancer; chr6:149831720 chr6:149884431~149919508:+ CESC cis rs9640161 0.663 rs1916932 ENSG00000261305.1 RP4-584D14.7 4.62 6.44e-06 0.00379 0.39 0.3 Blood protein levels;Circulating chemerin levels; chr7:150324555 chr7:150341771~150342607:+ CESC cis rs7560272 0.513 rs7558546 ENSG00000273245.1 RP11-434P11.2 -4.62 6.44e-06 0.00379 -0.37 -0.3 Schizophrenia; chr2:73710605 chr2:73750256~73750786:- CESC cis rs71403859 0.803 rs10500562 ENSG00000260886.1 TAT-AS1 4.62 6.45e-06 0.0038 0.47 0.3 Post bronchodilator FEV1; chr16:71593828 chr16:71565789~71578187:+ CESC cis rs71403859 0.803 rs17282500 ENSG00000260886.1 TAT-AS1 4.62 6.45e-06 0.0038 0.47 0.3 Post bronchodilator FEV1; chr16:71599750 chr16:71565789~71578187:+ CESC cis rs71403859 0.685 rs12444890 ENSG00000260886.1 TAT-AS1 4.62 6.45e-06 0.0038 0.47 0.3 Post bronchodilator FEV1; chr16:71602123 chr16:71565789~71578187:+ CESC cis rs12908161 0.959 rs11637728 ENSG00000225151.9 GOLGA2P7 -4.62 6.45e-06 0.0038 -0.41 -0.3 Schizophrenia; chr15:84660161 chr15:84199311~84230136:- CESC cis rs6782228 0.876 rs34198449 ENSG00000242551.2 POU5F1P6 4.62 6.46e-06 0.0038 0.37 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128662427 chr3:128674735~128677005:- CESC cis rs72772090 0.539 rs72773923 ENSG00000248734.2 CTD-2260A17.1 -4.62 6.46e-06 0.0038 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96781875 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs114006288 ENSG00000248734.2 CTD-2260A17.1 -4.62 6.46e-06 0.0038 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782300 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs72773932 ENSG00000248734.2 CTD-2260A17.1 -4.62 6.46e-06 0.0038 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782444 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs11750934 ENSG00000248734.2 CTD-2260A17.1 -4.62 6.46e-06 0.0038 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782783 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs11738810 ENSG00000248734.2 CTD-2260A17.1 -4.62 6.46e-06 0.0038 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96783351 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs11748519 ENSG00000248734.2 CTD-2260A17.1 -4.62 6.46e-06 0.0038 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96783624 chr5:96784777~96785999:+ CESC cis rs2337406 0.866 rs4280141 ENSG00000274576.2 IGHV2-70 4.62 6.47e-06 0.00381 0.33 0.3 Alzheimer's disease (late onset); chr14:106780476 chr14:106770577~106771020:- CESC cis rs9549367 0.774 rs9549696 ENSG00000269125.1 RP11-98F14.11 -4.62 6.47e-06 0.00381 -0.4 -0.3 Platelet distribution width; chr13:113220748 chr13:113165002~113165183:- CESC cis rs8100891 0.537 rs2302772 ENSG00000267213.4 AC007773.2 -4.62 6.47e-06 0.00381 -0.46 -0.3 Neuroticism; chr19:32411144 chr19:32390050~32405560:- CESC cis rs79243044 1 rs12294369 ENSG00000224295.2 AC087380.14 4.62 6.48e-06 0.00381 0.31 0.3 QRS duration in Tripanosoma cruzi seropositivity; chr11:5545838 chr11:5518441~5524955:- CESC cis rs765787 0.53 rs12909987 ENSG00000259520.4 CTD-2651B20.3 4.62 6.48e-06 0.00381 0.36 0.3 Uric acid levels; chr15:45220009 chr15:45251580~45279251:- CESC cis rs875971 0.651 rs313829 ENSG00000228409.4 CCT6P1 4.62 6.48e-06 0.00381 0.3 0.3 Aortic root size; chr7:66087510 chr7:65751142~65763354:+ CESC cis rs755249 0.958 rs2068663 ENSG00000228060.1 RP11-69E11.8 -4.62 6.51e-06 0.00383 -0.35 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572899 chr1:39565160~39573203:+ CESC cis rs75422866 0.867 rs73113117 ENSG00000274902.1 RP1-197B17.4 4.62 6.54e-06 0.00384 0.73 0.3 Pneumonia; chr12:47617299 chr12:47731908~47732351:+ CESC cis rs801193 0.66 rs4610622 ENSG00000232559.3 GS1-124K5.12 4.62 6.55e-06 0.00385 0.32 0.3 Aortic root size; chr7:66759510 chr7:66554588~66576923:- CESC cis rs11155671 0.53 rs9371542 ENSG00000223701.3 RAET1E-AS1 4.62 6.55e-06 0.00385 0.33 0.3 Testicular germ cell tumor; chr6:149891949 chr6:149884431~149919508:+ CESC cis rs9322193 0.567 rs7747457 ENSG00000223701.3 RAET1E-AS1 4.62 6.55e-06 0.00385 0.33 0.3 Lung cancer; chr6:149892366 chr6:149884431~149919508:+ CESC cis rs11155671 0.53 rs9371223 ENSG00000223701.3 RAET1E-AS1 4.62 6.55e-06 0.00385 0.33 0.3 Testicular germ cell tumor; chr6:149893670 chr6:149884431~149919508:+ CESC cis rs763121 0.853 rs5757253 ENSG00000273076.1 RP3-508I15.22 4.62 6.55e-06 0.00385 0.33 0.3 Menopause (age at onset); chr22:38708315 chr22:38743495~38743910:+ CESC cis rs9513627 0.573 rs7325697 ENSG00000228889.5 UBAC2-AS1 -4.62 6.56e-06 0.00385 -0.41 -0.3 Obesity-related traits; chr13:99465539 chr13:99196377~99200710:- CESC cis rs17507216 0.671 rs28582623 ENSG00000276710.3 CSPG4P8 -4.62 6.56e-06 0.00385 -0.4 -0.3 Excessive daytime sleepiness; chr15:82577381 chr15:82459472~82477258:+ CESC cis rs7560272 0.501 rs12615807 ENSG00000273245.1 RP11-434P11.2 -4.62 6.56e-06 0.00385 -0.37 -0.3 Schizophrenia; chr2:73720456 chr2:73750256~73750786:- CESC cis rs7250849 0.688 rs78019331 ENSG00000273837.1 LLNLR-470E3.1 -4.62 6.56e-06 0.00386 -0.41 -0.3 Blood protein levels; chr19:51658484 chr19:51639478~51639931:- CESC cis rs11168351 0.517 rs10875754 ENSG00000240399.1 RP1-228P16.1 4.62 6.57e-06 0.00386 0.3 0.3 Bipolar disorder and schizophrenia; chr12:48164139 chr12:48054813~48055591:- CESC cis rs7208859 0.623 rs7208441 ENSG00000266490.1 CTD-2349P21.9 4.62 6.57e-06 0.00386 0.46 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30792372~30792833:+ CESC cis rs73086581 0.838 rs73088426 ENSG00000229539.1 RP11-119B16.2 4.62 6.58e-06 0.00386 0.47 0.3 Response to antidepressants in depression; chr20:4022636 chr20:3888239~3888868:- CESC cis rs1823913 0.503 rs6434464 ENSG00000280083.1 RP11-317J9.1 4.62 6.58e-06 0.00386 0.35 0.3 Obesity-related traits; chr2:191341120 chr2:191154118~191156070:- CESC cis rs2919917 1 rs1021156 ENSG00000254352.1 RP11-578O24.2 4.62 6.6e-06 0.00387 0.38 0.3 Lymphocyte counts; chr8:78663569 chr8:78723796~78724136:- CESC cis rs2548724 0.588 rs62371034 ENSG00000250682.4 LINC00491 4.62 6.6e-06 0.00388 0.39 0.3 Type 2 diabetes; chr5:102489780 chr5:102609156~102671559:- CESC cis rs116095464 0.558 rs34629844 ENSG00000250848.1 CTD-2083E4.5 -4.62 6.61e-06 0.00388 -0.41 -0.3 Breast cancer; chr5:200714 chr5:288833~290321:- CESC cis rs875971 0.862 rs4718330 ENSG00000237310.1 GS1-124K5.4 -4.62 6.62e-06 0.00388 -0.27 -0.3 Aortic root size; chr7:66250256 chr7:66493706~66495474:+ CESC cis rs17826219 0.636 rs79565452 ENSG00000266490.1 CTD-2349P21.9 4.62 6.62e-06 0.00388 0.46 0.3 Body mass index; chr17:30815823 chr17:30792372~30792833:+ CESC cis rs2015599 0.623 rs1072724 ENSG00000257176.2 RP11-996F15.2 4.62 6.63e-06 0.00389 0.35 0.3 Platelet count;Mean platelet volume; chr12:29289205 chr12:29280418~29317848:- CESC cis rs2015599 0.623 rs7358667 ENSG00000257176.2 RP11-996F15.2 4.62 6.63e-06 0.00389 0.35 0.3 Platelet count;Mean platelet volume; chr12:29290236 chr12:29280418~29317848:- CESC cis rs3762637 0.882 rs72958418 ENSG00000272758.4 RP11-299J3.8 -4.62 6.63e-06 0.00389 -0.41 -0.3 LDL cholesterol levels; chr3:122441526 chr3:122416207~122443180:+ CESC cis rs8177876 0.822 rs28672349 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080768 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs4306521 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081288 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs4324142 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081298 chr16:81069854~81076598:+ CESC cis rs8177876 0.642 rs4324143 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081383 chr16:81069854~81076598:+ CESC cis rs8177876 0.818 rs59177227 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081524 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs59685942 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081534 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs10514515 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081717 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs1410 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81082228 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs1412 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81082237 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs1414 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81082252 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs8177950 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083290 chr16:81069854~81076598:+ CESC cis rs8177876 0.731 rs8177948 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083315 chr16:81069854~81076598:+ CESC cis rs8177876 0.822 rs8177940 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083789 chr16:81069854~81076598:+ CESC cis rs8177876 0.73 rs76656387 ENSG00000261838.4 RP11-303E16.6 4.62 6.63e-06 0.00389 0.61 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81083862 chr16:81069854~81076598:+ CESC cis rs9660180 0.62 rs34298494 ENSG00000268575.1 RP1-283E3.8 4.62 6.64e-06 0.00389 0.3 0.3 Body mass index; chr1:1731963 chr1:1702736~1737688:- CESC cis rs1862618 0.756 rs13356762 ENSG00000271828.1 CTD-2310F14.1 4.62 6.64e-06 0.00389 0.4 0.3 Initial pursuit acceleration; chr5:56815165 chr5:56927874~56929573:+ CESC cis rs755249 1 rs12037222 ENSG00000228060.1 RP11-69E11.8 -4.62 6.66e-06 0.0039 -0.35 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39599289 chr1:39565160~39573203:+ CESC cis rs2280018 0.526 rs2941257 ENSG00000188599.16 NPIPP1 -4.62 6.66e-06 0.0039 -0.3 -0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072588 chr16:15104312~15123498:- CESC cis rs2280018 0.526 rs1510148 ENSG00000188599.16 NPIPP1 -4.62 6.66e-06 0.0039 -0.3 -0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15073522 chr16:15104312~15123498:- CESC cis rs73086581 0.68 rs11908158 ENSG00000229539.1 RP11-119B16.2 4.62 6.66e-06 0.0039 0.46 0.3 Response to antidepressants in depression; chr20:3956025 chr20:3888239~3888868:- CESC cis rs34779708 0.643 rs4275563 ENSG00000230534.5 RP11-297A16.2 4.62 6.67e-06 0.00391 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35256358 chr10:35098006~35127020:- CESC cis rs6991838 0.701 rs7829434 ENSG00000200714.1 Y_RNA 4.62 6.68e-06 0.00391 0.34 0.3 Intelligence (multi-trait analysis); chr8:65716909 chr8:65592731~65592820:+ CESC cis rs9309711 0.961 rs11890651 ENSG00000225234.1 TRAPPC12-AS1 -4.62 6.69e-06 0.00392 -0.29 -0.3 Neurofibrillary tangles; chr2:3479025 chr2:3481242~3482409:- CESC cis rs453301 0.598 rs10104303 ENSG00000253893.2 FAM85B -4.62 6.69e-06 0.00392 -0.36 -0.3 Joint mobility (Beighton score); chr8:8977018 chr8:8167819~8226614:- CESC cis rs9318086 0.648 rs35449605 ENSG00000205861.10 C1QTNF9B-AS1 -4.62 6.7e-06 0.00392 -0.37 -0.3 Myopia (pathological); chr13:23898443 chr13:23888889~23897263:+ CESC cis rs7927592 0.956 rs10896343 ENSG00000212093.1 AP000807.1 4.62 6.7e-06 0.00392 0.34 0.3 Total body bone mineral density; chr11:68550392 chr11:68506083~68506166:- CESC cis rs1153858 0.848 rs9806699 ENSG00000259520.4 CTD-2651B20.3 -4.62 6.7e-06 0.00392 -0.39 -0.3 Homoarginine levels; chr15:45448194 chr15:45251580~45279251:- CESC cis rs11157436 1 rs3811278 ENSG00000211813.2 TRAV34 4.62 6.71e-06 0.00392 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22186227 chr14:22207522~22208129:+ CESC cis rs6496044 0.507 rs7175731 ENSG00000202081.1 RNU6-1280P -4.61 6.71e-06 0.00393 -0.32 -0.3 Interstitial lung disease; chr15:85611115 chr15:85651522~85651628:- CESC cis rs6496044 0.507 rs1471455 ENSG00000202081.1 RNU6-1280P -4.61 6.71e-06 0.00393 -0.32 -0.3 Interstitial lung disease; chr15:85611496 chr15:85651522~85651628:- CESC cis rs3096299 0.869 rs748941 ENSG00000274627.1 RP11-104N10.2 4.61 6.71e-06 0.00393 0.3 0.3 Multiple myeloma (IgH translocation); chr16:89374346 chr16:89516797~89522217:+ CESC cis rs7927592 0.913 rs7106339 ENSG00000212093.1 AP000807.1 4.61 6.73e-06 0.00394 0.36 0.3 Total body bone mineral density; chr11:68472773 chr11:68506083~68506166:- CESC cis rs7560272 0.501 rs13003035 ENSG00000273245.1 RP11-434P11.2 -4.61 6.73e-06 0.00394 -0.37 -0.3 Schizophrenia; chr2:73730100 chr2:73750256~73750786:- CESC cis rs13113518 0.683 rs9761521 ENSG00000273257.1 RP11-177J6.1 4.61 6.73e-06 0.00394 0.38 0.3 Height; chr4:55363436 chr4:55387949~55388271:+ CESC cis rs7873102 0.654 rs10814641 ENSG00000230188.1 RP11-405L18.4 4.61 6.73e-06 0.00394 0.38 0.3 Brain structure; chr9:38014698 chr9:37490421~37490893:- CESC cis rs7873102 0.63 rs2183130 ENSG00000230188.1 RP11-405L18.4 4.61 6.73e-06 0.00394 0.38 0.3 Brain structure; chr9:38015330 chr9:37490421~37490893:- CESC cis rs694739 0.964 rs2510066 ENSG00000236935.1 AP003774.1 4.61 6.74e-06 0.00394 0.31 0.3 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64284975 chr11:64325050~64329504:- CESC cis rs1012068 0.81 rs5998140 ENSG00000236132.1 CTA-440B3.1 -4.61 6.74e-06 0.00394 -0.35 -0.3 Chronic hepatitis C infection; chr22:31845961 chr22:31816379~31817491:- CESC cis rs2439831 0.85 rs10438303 ENSG00000275601.1 AC011330.13 -4.61 6.74e-06 0.00394 -0.46 -0.3 Lung cancer in ever smokers; chr15:43724219 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs12441127 ENSG00000275601.1 AC011330.13 -4.61 6.74e-06 0.00394 -0.46 -0.3 Lung cancer in ever smokers; chr15:43728977 chr15:43642389~43643023:- CESC cis rs9584850 0.708 rs4411372 ENSG00000231194.1 FARP1-AS1 4.61 6.75e-06 0.00394 0.39 0.3 Neuroticism; chr13:98478169 chr13:98435405~98435840:- CESC cis rs11155671 0.53 rs6557133 ENSG00000223701.3 RAET1E-AS1 4.61 6.75e-06 0.00395 0.34 0.3 Testicular germ cell tumor; chr6:149874248 chr6:149884431~149919508:+ CESC cis rs3124314 1 rs3001974 ENSG00000229021.2 AL591893.1 -4.61 6.75e-06 0.00395 -0.33 -0.3 Hair morphology; chr1:152105098 chr1:151994531~152042774:+ CESC cis rs3124314 0.964 rs1131471 ENSG00000229021.2 AL591893.1 -4.61 6.75e-06 0.00395 -0.33 -0.3 Hair morphology; chr1:152107513 chr1:151994531~152042774:+ CESC cis rs7429990 0.965 rs9811277 ENSG00000229759.1 MRPS18AP1 4.61 6.75e-06 0.00395 0.31 0.3 Educational attainment (years of education); chr3:47970148 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs9814961 ENSG00000229759.1 MRPS18AP1 4.61 6.75e-06 0.00395 0.31 0.3 Educational attainment (years of education); chr3:47976127 chr3:48256350~48256938:- CESC cis rs801193 0.66 rs10950049 ENSG00000232559.3 GS1-124K5.12 4.61 6.76e-06 0.00395 0.32 0.3 Aortic root size; chr7:66765873 chr7:66554588~66576923:- CESC cis rs11159086 0.793 rs11621693 ENSG00000270000.1 RP3-449M8.9 4.61 6.76e-06 0.00395 0.48 0.3 Advanced glycation end-product levels; chr14:74472631 chr14:74471930~74472360:- CESC cis rs3738443 0.868 rs6660351 ENSG00000259865.1 RP11-488L18.10 4.61 6.76e-06 0.00395 0.33 0.3 Alcohol dependence; chr1:247184526 chr1:247187281~247188526:- CESC cis rs6997458 0.742 rs10111039 ENSG00000253549.4 RP11-317J10.2 4.61 6.76e-06 0.00395 0.35 0.3 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85484427 chr8:85441851~85464915:- CESC cis rs6991838 0.765 rs10957358 ENSG00000200714.1 Y_RNA 4.61 6.76e-06 0.00395 0.35 0.3 Intelligence (multi-trait analysis); chr8:65590067 chr8:65592731~65592820:+ CESC cis rs7777677 0.925 rs6956269 ENSG00000244273.1 PGBD4P1 -4.61 6.77e-06 0.00395 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142661303 chr7:142722358~142722764:+ CESC cis rs7777677 0.925 rs4726547 ENSG00000244273.1 PGBD4P1 -4.61 6.77e-06 0.00395 -0.33 -0.3 Alcoholic chronic pancreatitis; chr7:142662750 chr7:142722358~142722764:+ CESC cis rs950880 0.71 rs11683700 ENSG00000234389.1 AC007278.3 -4.61 6.77e-06 0.00395 -0.33 -0.3 Serum protein levels (sST2); chr2:102380345 chr2:102438713~102440475:+ CESC cis rs6740322 0.895 rs6744746 ENSG00000234936.1 AC010883.5 -4.61 6.77e-06 0.00396 -0.31 -0.3 Coronary artery disease; chr2:43328666 chr2:43229573~43233394:+ CESC cis rs889512 0.642 rs13337397 ENSG00000280152.1 RP11-331F4.5 -4.61 6.79e-06 0.00396 -0.44 -0.3 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75261741 chr16:75245994~75250077:- CESC cis rs8100891 0.537 rs4805755 ENSG00000267213.4 AC007773.2 4.61 6.79e-06 0.00397 0.47 0.3 Neuroticism; chr19:32363564 chr19:32390050~32405560:- CESC cis rs9318086 0.624 rs9510909 ENSG00000205861.10 C1QTNF9B-AS1 -4.61 6.79e-06 0.00397 -0.38 -0.3 Myopia (pathological); chr13:23862621 chr13:23888889~23897263:+ CESC cis rs763121 0.925 rs5750654 ENSG00000273076.1 RP3-508I15.22 4.61 6.79e-06 0.00397 0.34 0.3 Menopause (age at onset); chr22:38655423 chr22:38743495~38743910:+ CESC cis rs2408955 0.521 rs11168437 ENSG00000240399.1 RP1-228P16.1 4.61 6.79e-06 0.00397 0.33 0.3 Glycated hemoglobin levels; chr12:48172373 chr12:48054813~48055591:- CESC cis rs4865169 0.595 rs9998008 ENSG00000269949.1 RP11-738E22.3 4.61 6.8e-06 0.00397 0.34 0.3 Breast cancer; chr4:56899886 chr4:56960927~56961373:- CESC cis rs2919917 1 rs3736169 ENSG00000254352.1 RP11-578O24.2 4.61 6.8e-06 0.00397 0.37 0.3 Lymphocyte counts; chr8:78675620 chr8:78723796~78724136:- CESC cis rs2919917 1 rs10093127 ENSG00000254352.1 RP11-578O24.2 4.61 6.8e-06 0.00397 0.37 0.3 Lymphocyte counts; chr8:78686869 chr8:78723796~78724136:- CESC cis rs2919917 1 rs1872072 ENSG00000254352.1 RP11-578O24.2 4.61 6.8e-06 0.00397 0.37 0.3 Lymphocyte counts; chr8:78689185 chr8:78723796~78724136:- CESC cis rs9487094 0.67 rs2024850 ENSG00000260273.1 RP11-425D10.10 -4.61 6.81e-06 0.00397 -0.37 -0.3 Height; chr6:109497253 chr6:109382795~109383666:+ CESC cis rs763121 0.853 rs2267393 ENSG00000273076.1 RP3-508I15.22 4.61 6.82e-06 0.00398 0.33 0.3 Menopause (age at onset); chr22:38705614 chr22:38743495~38743910:+ CESC cis rs763121 0.853 rs2267394 ENSG00000273076.1 RP3-508I15.22 4.61 6.82e-06 0.00398 0.33 0.3 Menopause (age at onset); chr22:38705628 chr22:38743495~38743910:+ CESC cis rs2919917 0.628 rs2717540 ENSG00000254352.1 RP11-578O24.2 4.61 6.82e-06 0.00398 0.44 0.3 Lymphocyte counts; chr8:78710128 chr8:78723796~78724136:- CESC cis rs8177876 0.822 rs8056972 ENSG00000261838.4 RP11-303E16.6 4.61 6.82e-06 0.00398 0.62 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078817 chr16:81069854~81076598:+ CESC cis rs12439619 0.53 rs28883606 ENSG00000276710.3 CSPG4P8 -4.61 6.82e-06 0.00398 -0.31 -0.3 Intelligence (multi-trait analysis); chr15:82216713 chr15:82459472~82477258:+ CESC cis rs12439619 0.693 rs28665836 ENSG00000276710.3 CSPG4P8 -4.61 6.82e-06 0.00398 -0.31 -0.3 Intelligence (multi-trait analysis); chr15:82218955 chr15:82459472~82477258:+ CESC cis rs9322193 0.923 rs4354168 ENSG00000268592.3 RAET1E-AS1 4.61 6.83e-06 0.00398 0.39 0.3 Lung cancer; chr6:149696642 chr6:149863494~149919507:+ CESC cis rs7615952 0.534 rs1503072 ENSG00000250012.1 RP11-124N2.1 -4.61 6.83e-06 0.00398 -0.33 -0.3 Blood pressure (smoking interaction); chr3:126035848 chr3:126084220~126095349:+ CESC cis rs7615952 0.599 rs7631268 ENSG00000250012.1 RP11-124N2.1 -4.61 6.83e-06 0.00398 -0.33 -0.3 Blood pressure (smoking interaction); chr3:126036821 chr3:126084220~126095349:+ CESC cis rs11159086 0.941 rs12434836 ENSG00000259005.1 RP3-449M8.6 4.61 6.84e-06 0.00399 0.51 0.3 Advanced glycation end-product levels; chr14:74468887 chr14:74474007~74474864:- CESC cis rs860295 0.702 rs12039893 ENSG00000225855.5 RUSC1-AS1 4.61 6.85e-06 0.00399 0.25 0.3 Body mass index; chr1:155645024 chr1:155316863~155324176:- CESC cis rs950169 0.614 rs12903883 ENSG00000225151.9 GOLGA2P7 -4.61 6.85e-06 0.004 -0.45 -0.3 Schizophrenia; chr15:84011801 chr15:84199311~84230136:- CESC cis rs889512 0.642 rs8048529 ENSG00000280152.1 RP11-331F4.5 -4.61 6.85e-06 0.004 -0.43 -0.3 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75241732 chr16:75245994~75250077:- CESC cis rs10129255 0.744 rs28517388 ENSG00000211974.3 IGHV2-70 4.61 6.86e-06 0.004 0.33 0.3 Kawasaki disease; chr14:106704323 chr14:106723574~106724093:- CESC cis rs7429990 0.965 rs2053767 ENSG00000229759.1 MRPS18AP1 4.61 6.87e-06 0.004 0.31 0.3 Educational attainment (years of education); chr3:47958184 chr3:48256350~48256938:- CESC cis rs4819052 0.851 rs8131143 ENSG00000223768.1 LINC00205 4.61 6.87e-06 0.004 0.35 0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251731 chr21:45293285~45297354:+ CESC cis rs8040855 0.825 rs4843021 ENSG00000259295.5 CSPG4P12 -4.61 6.87e-06 0.00401 -0.38 -0.3 Bulimia nervosa; chr15:85151317 chr15:85191438~85213905:+ CESC cis rs5769707 0.605 rs6009791 ENSG00000235111.1 RP1-29C18.8 -4.61 6.88e-06 0.00401 -0.34 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49631617 chr22:49612657~49615716:- CESC cis rs11638352 0.661 rs2706488 ENSG00000275601.1 AC011330.13 4.61 6.88e-06 0.00401 0.45 0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44097699 chr15:43642389~43643023:- CESC cis rs7809950 1 rs12667527 ENSG00000238832.1 snoU109 -4.61 6.88e-06 0.00401 -0.35 -0.3 Coronary artery disease; chr7:107446524 chr7:107603363~107603507:+ CESC cis rs2836950 0.545 rs11701805 ENSG00000232608.1 TIMM9P2 4.61 6.88e-06 0.00401 0.34 0.3 Menarche (age at onset); chr21:39246757 chr21:39216624~39217506:+ CESC cis rs9513627 1 rs7317126 ENSG00000228889.5 UBAC2-AS1 4.61 6.88e-06 0.00401 0.49 0.3 Obesity-related traits; chr13:99467485 chr13:99196377~99200710:- CESC cis rs2739330 0.828 rs5760108 ENSG00000231271.1 AP000350.8 4.61 6.88e-06 0.00401 0.35 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23949918~23954042:+ CESC cis rs1609391 0.543 rs6800690 ENSG00000239213.4 NCK1-AS1 4.61 6.89e-06 0.00401 0.34 0.3 Neuroticism; chr3:136904184 chr3:136841726~136862054:- CESC cis rs1609391 0.543 rs7651085 ENSG00000239213.4 NCK1-AS1 4.61 6.89e-06 0.00401 0.34 0.3 Neuroticism; chr3:136906497 chr3:136841726~136862054:- CESC cis rs1609391 0.543 rs6761993 ENSG00000239213.4 NCK1-AS1 4.61 6.89e-06 0.00401 0.34 0.3 Neuroticism; chr3:136907060 chr3:136841726~136862054:- CESC cis rs1609391 0.543 rs1347209 ENSG00000239213.4 NCK1-AS1 4.61 6.89e-06 0.00401 0.34 0.3 Neuroticism; chr3:136907855 chr3:136841726~136862054:- CESC cis rs1609391 0.561 rs9817967 ENSG00000239213.4 NCK1-AS1 4.61 6.89e-06 0.00401 0.34 0.3 Neuroticism; chr3:136910648 chr3:136841726~136862054:- CESC cis rs1609391 0.543 rs9859810 ENSG00000239213.4 NCK1-AS1 4.61 6.89e-06 0.00401 0.34 0.3 Neuroticism; chr3:136911144 chr3:136841726~136862054:- CESC cis rs1609391 0.543 rs9828009 ENSG00000239213.4 NCK1-AS1 4.61 6.89e-06 0.00401 0.34 0.3 Neuroticism; chr3:136912433 chr3:136841726~136862054:- CESC cis rs2836950 0.565 rs8130320 ENSG00000232608.1 TIMM9P2 4.61 6.89e-06 0.00401 0.33 0.3 Menarche (age at onset); chr21:39208332 chr21:39216624~39217506:+ CESC cis rs9532669 0.89 rs7333274 ENSG00000176268.5 CYCSP34 4.61 6.9e-06 0.00402 0.3 0.3 Cervical cancer; chr13:40862531 chr13:40863599~40863902:- CESC cis rs7809950 1 rs10234355 ENSG00000238832.1 snoU109 -4.61 6.9e-06 0.00402 -0.35 -0.3 Coronary artery disease; chr7:107446072 chr7:107603363~107603507:+ CESC cis rs11846409 0.932 rs28617526 ENSG00000211974.3 IGHV2-70 -4.61 6.9e-06 0.00402 -0.4 -0.3 Rheumatic heart disease; chr14:106637322 chr14:106723574~106724093:- CESC cis rs4722166 0.695 rs7808122 ENSG00000179428.2 AC073072.5 -4.61 6.91e-06 0.00403 -0.38 -0.3 Lung cancer; chr7:22758461 chr7:22725395~22727620:- CESC cis rs72772090 0.539 rs17481856 ENSG00000248734.2 CTD-2260A17.1 -4.61 6.92e-06 0.00403 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96781104 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs72773942 ENSG00000248734.2 CTD-2260A17.1 -4.61 6.92e-06 0.00403 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96787663 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs11743410 ENSG00000248734.2 CTD-2260A17.1 -4.61 6.92e-06 0.00403 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96788750 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs11746534 ENSG00000248734.2 CTD-2260A17.1 -4.61 6.92e-06 0.00403 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789104 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs55773007 ENSG00000248734.2 CTD-2260A17.1 -4.61 6.92e-06 0.00403 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789215 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs111886458 ENSG00000248734.2 CTD-2260A17.1 -4.61 6.92e-06 0.00403 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789344 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs10515249 ENSG00000248734.2 CTD-2260A17.1 -4.61 6.92e-06 0.00403 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789556 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs72773947 ENSG00000248734.2 CTD-2260A17.1 -4.61 6.92e-06 0.00403 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789830 chr5:96784777~96785999:+ CESC cis rs875971 0.862 rs6460307 ENSG00000226824.5 RP4-756H11.3 -4.61 6.92e-06 0.00403 -0.37 -0.3 Aortic root size; chr7:66595884 chr7:66654538~66669855:+ CESC cis rs9660180 0.967 rs11260623 ENSG00000268575.1 RP1-283E3.8 -4.61 6.93e-06 0.00403 -0.29 -0.3 Body mass index; chr1:1850017 chr1:1702736~1737688:- CESC cis rs6142102 0.778 rs6059581 ENSG00000276073.1 RP5-1125A11.7 -4.61 6.94e-06 0.00404 -0.3 -0.3 Skin pigmentation; chr20:33940582 chr20:33985617~33988989:- CESC cis rs1185460 0.565 rs540261 ENSG00000271751.1 RP11-110I1.14 4.61 6.94e-06 0.00404 0.37 0.3 Coronary artery disease; chr11:119076924 chr11:119065263~119065677:- CESC cis rs875971 0.862 rs6944374 ENSG00000237310.1 GS1-124K5.4 -4.61 6.95e-06 0.00404 -0.29 -0.3 Aortic root size; chr7:66221942 chr7:66493706~66495474:+ CESC cis rs1075265 0.589 rs2542571 ENSG00000233266.1 HMGB1P31 4.61 6.95e-06 0.00404 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:53814846 chr2:54051334~54051760:+ CESC cis rs2019137 0.56 rs7421852 ENSG00000189223.12 PAX8-AS1 -4.61 6.95e-06 0.00404 -0.38 -0.3 Lymphocyte counts; chr2:113232684 chr2:113211522~113276581:+ CESC cis rs12745968 0.586 rs2065915 ENSG00000223787.2 RP4-593M8.1 -4.61 6.95e-06 0.00404 -0.38 -0.3 Bipolar disorder and schizophrenia; chr1:92735925 chr1:92580476~92580821:- CESC cis rs12745968 0.718 rs10782941 ENSG00000223787.2 RP4-593M8.1 -4.61 6.95e-06 0.00404 -0.38 -0.3 Bipolar disorder and schizophrenia; chr1:92744283 chr1:92580476~92580821:- CESC cis rs7951870 0.945 rs10160701 ENSG00000247675.5 LRP4-AS1 -4.61 6.96e-06 0.00405 -0.37 -0.3 Schizophrenia; chr11:46530368 chr11:46846412~46874396:+ CESC cis rs7951870 1 rs11819869 ENSG00000247675.5 LRP4-AS1 -4.61 6.96e-06 0.00405 -0.37 -0.3 Schizophrenia; chr11:46539130 chr11:46846412~46874396:+ CESC cis rs9660180 0.967 rs61422524 ENSG00000268575.1 RP1-283E3.8 -4.61 6.97e-06 0.00405 -0.29 -0.3 Body mass index; chr1:1836126 chr1:1702736~1737688:- CESC cis rs9322193 0.923 rs4455682 ENSG00000268592.3 RAET1E-AS1 4.61 6.98e-06 0.00406 0.39 0.3 Lung cancer; chr6:149700161 chr6:149863494~149919507:+ CESC cis rs6686842 1 rs34454389 ENSG00000235358.1 RP11-399E6.1 4.61 6.98e-06 0.00406 0.36 0.3 Height; chr1:41197564 chr1:41242373~41284861:+ CESC cis rs6686842 1 rs11209718 ENSG00000235358.1 RP11-399E6.1 4.61 6.98e-06 0.00406 0.36 0.3 Height; chr1:41223266 chr1:41242373~41284861:+ CESC cis rs6686842 1 rs12134073 ENSG00000235358.1 RP11-399E6.1 4.61 6.98e-06 0.00406 0.36 0.3 Height; chr1:41223611 chr1:41242373~41284861:+ CESC cis rs3806843 0.576 rs155358 ENSG00000202111.1 VTRNA1-2 -4.61 6.99e-06 0.00406 -0.3 -0.3 Depressive symptoms (multi-trait analysis); chr5:140917447 chr5:140718925~140719013:+ CESC cis rs12439619 0.846 rs62012003 ENSG00000276710.3 CSPG4P8 -4.61 6.99e-06 0.00406 -0.43 -0.3 Intelligence (multi-trait analysis); chr15:82183236 chr15:82459472~82477258:+ CESC cis rs12439619 0.768 rs28694364 ENSG00000276710.3 CSPG4P8 -4.61 6.99e-06 0.00406 -0.43 -0.3 Intelligence (multi-trait analysis); chr15:82208119 chr15:82459472~82477258:+ CESC cis rs12439619 0.81 rs28876157 ENSG00000276710.3 CSPG4P8 -4.61 6.99e-06 0.00406 -0.43 -0.3 Intelligence (multi-trait analysis); chr15:82216708 chr15:82459472~82477258:+ CESC cis rs761746 0.577 rs131244 ENSG00000236132.1 CTA-440B3.1 -4.61 6.99e-06 0.00406 -0.41 -0.3 Intelligence; chr22:31730577 chr22:31816379~31817491:- CESC cis rs761746 0.614 rs131250 ENSG00000236132.1 CTA-440B3.1 -4.61 6.99e-06 0.00406 -0.41 -0.3 Intelligence; chr22:31733617 chr22:31816379~31817491:- CESC cis rs761746 0.579 rs131253 ENSG00000236132.1 CTA-440B3.1 -4.61 6.99e-06 0.00406 -0.41 -0.3 Intelligence; chr22:31734696 chr22:31816379~31817491:- CESC cis rs761746 0.614 rs5994427 ENSG00000236132.1 CTA-440B3.1 -4.61 6.99e-06 0.00406 -0.41 -0.3 Intelligence; chr22:31736590 chr22:31816379~31817491:- CESC cis rs3738443 0.868 rs61839994 ENSG00000259865.1 RP11-488L18.10 4.61 7e-06 0.00407 0.33 0.3 Alcohol dependence; chr1:247195479 chr1:247187281~247188526:- CESC cis rs3738443 0.868 rs7536883 ENSG00000259865.1 RP11-488L18.10 4.61 7e-06 0.00407 0.33 0.3 Alcohol dependence; chr1:247196266 chr1:247187281~247188526:- CESC cis rs3738443 0.817 rs61839996 ENSG00000259865.1 RP11-488L18.10 4.61 7e-06 0.00407 0.33 0.3 Alcohol dependence; chr1:247197571 chr1:247187281~247188526:- CESC cis rs17818399 0.815 rs17768018 ENSG00000279254.1 RP11-536C12.1 -4.6 7.01e-06 0.00407 -0.35 -0.3 Height; chr2:46634872 chr2:46668870~46670778:+ CESC cis rs7809950 1 rs2250414 ENSG00000238832.1 snoU109 -4.6 7.02e-06 0.00407 -0.35 -0.3 Coronary artery disease; chr7:107500542 chr7:107603363~107603507:+ CESC cis rs7809950 1 rs2520249 ENSG00000238832.1 snoU109 -4.6 7.02e-06 0.00407 -0.35 -0.3 Coronary artery disease; chr7:107506303 chr7:107603363~107603507:+ CESC cis rs2299587 0.573 rs6986123 ENSG00000253671.1 RP11-806O11.1 -4.6 7.02e-06 0.00408 -0.31 -0.3 Economic and political preferences; chr8:18030564 chr8:17808941~17820868:+ CESC cis rs12439619 0.508 rs17354842 ENSG00000276710.3 CSPG4P8 4.6 7.03e-06 0.00408 0.32 0.3 Intelligence (multi-trait analysis); chr15:82177259 chr15:82459472~82477258:+ CESC cis rs10754283 0.901 rs10047070 ENSG00000231613.1 RP5-943J3.1 4.6 7.03e-06 0.00408 0.38 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89633156 chr1:89788914~89790492:+ CESC cis rs2015599 0.623 rs10843385 ENSG00000257176.2 RP11-996F15.2 -4.6 7.04e-06 0.00408 -0.35 -0.3 Platelet count;Mean platelet volume; chr12:29323100 chr12:29280418~29317848:- CESC cis rs2243480 0.908 rs4718273 ENSG00000232559.3 GS1-124K5.12 -4.6 7.04e-06 0.00408 -0.51 -0.3 Diabetic kidney disease; chr7:65751112 chr7:66554588~66576923:- CESC cis rs7216064 0.589 rs7213585 ENSG00000267023.4 LRRC37A16P -4.6 7.05e-06 0.00409 -0.29 -0.3 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68066200 chr17:68125777~68152468:- CESC cis rs2243480 1 rs73142162 ENSG00000232559.3 GS1-124K5.12 4.6 7.05e-06 0.00409 0.51 0.3 Diabetic kidney disease; chr7:65909309 chr7:66554588~66576923:- CESC cis rs2243480 0.808 rs12698508 ENSG00000232559.3 GS1-124K5.12 4.6 7.05e-06 0.00409 0.51 0.3 Diabetic kidney disease; chr7:65946971 chr7:66554588~66576923:- CESC cis rs2337406 0.587 rs2516886 ENSG00000211974.3 IGHV2-70 4.6 7.05e-06 0.00409 0.41 0.3 Alzheimer's disease (late onset); chr14:106649674 chr14:106723574~106724093:- CESC cis rs950169 0.544 rs62021193 ENSG00000225151.9 GOLGA2P7 -4.6 7.06e-06 0.00409 -0.4 -0.3 Schizophrenia; chr15:84627352 chr15:84199311~84230136:- CESC cis rs950169 0.58 rs17598114 ENSG00000225151.9 GOLGA2P7 -4.6 7.06e-06 0.00409 -0.4 -0.3 Schizophrenia; chr15:84628086 chr15:84199311~84230136:- CESC cis rs950169 0.58 rs11634322 ENSG00000225151.9 GOLGA2P7 -4.6 7.06e-06 0.00409 -0.4 -0.3 Schizophrenia; chr15:84628978 chr15:84199311~84230136:- CESC cis rs950169 0.58 rs4603535 ENSG00000225151.9 GOLGA2P7 -4.6 7.06e-06 0.00409 -0.4 -0.3 Schizophrenia; chr15:84630641 chr15:84199311~84230136:- CESC cis rs950169 0.541 rs10795 ENSG00000225151.9 GOLGA2P7 -4.6 7.06e-06 0.00409 -0.4 -0.3 Schizophrenia; chr15:84634066 chr15:84199311~84230136:- CESC cis rs950169 0.58 rs36126054 ENSG00000225151.9 GOLGA2P7 -4.6 7.06e-06 0.00409 -0.4 -0.3 Schizophrenia; chr15:84634492 chr15:84199311~84230136:- CESC cis rs7572733 0.534 rs1607374 ENSG00000222017.1 AC011997.1 4.6 7.06e-06 0.00409 0.38 0.3 Dermatomyositis; chr2:197935716 chr2:197693106~197774823:+ CESC cis rs875971 0.545 rs1909508 ENSG00000237310.1 GS1-124K5.4 4.6 7.06e-06 0.00409 0.31 0.3 Aortic root size; chr7:66301366 chr7:66493706~66495474:+ CESC cis rs17301013 0.507 rs2860954 ENSG00000227373.4 RP11-160H22.5 4.6 7.06e-06 0.00409 0.46 0.3 Systemic lupus erythematosus; chr1:174344313 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs60864659 ENSG00000227373.4 RP11-160H22.5 4.6 7.06e-06 0.00409 0.46 0.3 Systemic lupus erythematosus; chr1:174344641 chr1:174115300~174160004:- CESC cis rs4819052 0.851 rs34101026 ENSG00000223768.1 LINC00205 -4.6 7.07e-06 0.0041 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45242285 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs13052312 ENSG00000223768.1 LINC00205 -4.6 7.07e-06 0.0041 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45242444 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2838828 ENSG00000223768.1 LINC00205 -4.6 7.07e-06 0.0041 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45243508 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs13049337 ENSG00000223768.1 LINC00205 -4.6 7.07e-06 0.0041 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45243545 chr21:45293285~45297354:+ CESC cis rs11157436 0.914 rs7142794 ENSG00000211813.2 TRAV34 4.6 7.07e-06 0.0041 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22238175 chr14:22207522~22208129:+ CESC cis rs11723261 0.564 rs61792258 ENSG00000211553.1 AC253576.2 -4.6 7.07e-06 0.0041 -0.45 -0.3 Immune response to smallpox vaccine (IL-6); chr4:143482 chr4:136461~136568:+ CESC cis rs73086581 0.838 rs11907416 ENSG00000229539.1 RP11-119B16.2 4.6 7.07e-06 0.0041 0.47 0.3 Response to antidepressants in depression; chr20:4024972 chr20:3888239~3888868:- CESC cis rs4819052 0.851 rs13047104 ENSG00000223768.1 LINC00205 -4.6 7.09e-06 0.00411 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45253647 chr21:45293285~45297354:+ CESC cis rs4819052 0.885 rs28576202 ENSG00000223768.1 LINC00205 -4.6 7.09e-06 0.00411 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45254769 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs28616694 ENSG00000223768.1 LINC00205 -4.6 7.09e-06 0.00411 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45254871 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs35871601 ENSG00000223768.1 LINC00205 -4.6 7.09e-06 0.00411 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45255299 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs28622522 ENSG00000223768.1 LINC00205 -4.6 7.09e-06 0.00411 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45256684 chr21:45293285~45297354:+ CESC cis rs5769707 0.521 rs5769719 ENSG00000235111.1 RP1-29C18.8 -4.6 7.11e-06 0.00412 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49668453 chr22:49612657~49615716:- CESC cis rs5769707 0.521 rs5769720 ENSG00000235111.1 RP1-29C18.8 -4.6 7.11e-06 0.00412 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49668485 chr22:49612657~49615716:- CESC cis rs5769707 0.521 rs5770633 ENSG00000235111.1 RP1-29C18.8 -4.6 7.11e-06 0.00412 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49668779 chr22:49612657~49615716:- CESC cis rs6782228 1 rs6775011 ENSG00000242551.2 POU5F1P6 4.6 7.11e-06 0.00412 0.37 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128677640 chr3:128674735~128677005:- CESC cis rs2919917 0.628 rs7010299 ENSG00000254352.1 RP11-578O24.2 4.6 7.12e-06 0.00412 0.41 0.3 Lymphocyte counts; chr8:78707786 chr8:78723796~78724136:- CESC cis rs4239252 0.725 rs1994182 ENSG00000270977.1 AC015849.16 4.6 7.12e-06 0.00412 0.33 0.3 Blood protein levels; chr17:35760685 chr17:35893707~35911023:- CESC cis rs4819052 0.851 rs2838836 ENSG00000223768.1 LINC00205 -4.6 7.12e-06 0.00412 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45245960 chr21:45293285~45297354:+ CESC cis rs2919917 0.578 rs11783804 ENSG00000254352.1 RP11-578O24.2 4.6 7.12e-06 0.00412 0.42 0.3 Lymphocyte counts; chr8:78652776 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs979564 ENSG00000254352.1 RP11-578O24.2 4.6 7.12e-06 0.00412 0.42 0.3 Lymphocyte counts; chr8:78663924 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs9643739 ENSG00000254352.1 RP11-578O24.2 4.6 7.12e-06 0.00412 0.42 0.3 Lymphocyte counts; chr8:78679535 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs2170732 ENSG00000254352.1 RP11-578O24.2 4.6 7.12e-06 0.00412 0.42 0.3 Lymphocyte counts; chr8:78684261 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs6990105 ENSG00000254352.1 RP11-578O24.2 4.6 7.12e-06 0.00412 0.42 0.3 Lymphocyte counts; chr8:78689652 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs6981103 ENSG00000254352.1 RP11-578O24.2 4.6 7.12e-06 0.00412 0.42 0.3 Lymphocyte counts; chr8:78691702 chr8:78723796~78724136:- CESC cis rs6686842 0.601 rs213736 ENSG00000235358.1 RP11-399E6.1 -4.6 7.12e-06 0.00412 -0.35 -0.3 Height; chr1:41158007 chr1:41242373~41284861:+ CESC cis rs6686842 0.562 rs18996 ENSG00000235358.1 RP11-399E6.1 -4.6 7.12e-06 0.00412 -0.35 -0.3 Height; chr1:41158848 chr1:41242373~41284861:+ CESC cis rs1061377 0.513 rs2566162 ENSG00000249207.1 RP11-360F5.1 -4.6 7.12e-06 0.00412 -0.42 -0.3 Uric acid levels; chr4:39126453 chr4:39112677~39126818:- CESC cis rs6928977 0.869 rs6912933 ENSG00000234084.1 RP3-388E23.2 4.6 7.13e-06 0.00412 0.26 0.3 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135306396 chr6:135301568~135307158:+ CESC cis rs12439619 0.508 rs8032033 ENSG00000276710.3 CSPG4P8 -4.6 7.13e-06 0.00413 -0.31 -0.3 Intelligence (multi-trait analysis); chr15:82165555 chr15:82459472~82477258:+ CESC cis rs3096299 0.606 rs8052103 ENSG00000274627.1 RP11-104N10.2 -4.6 7.13e-06 0.00413 -0.31 -0.3 Multiple myeloma (IgH translocation); chr16:89474835 chr16:89516797~89522217:+ CESC cis rs2919917 0.628 rs6997255 ENSG00000254352.1 RP11-578O24.2 4.6 7.14e-06 0.00413 0.41 0.3 Lymphocyte counts; chr8:78694850 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs7017898 ENSG00000254352.1 RP11-578O24.2 4.6 7.14e-06 0.00413 0.41 0.3 Lymphocyte counts; chr8:78697147 chr8:78723796~78724136:- CESC cis rs6142102 0.778 rs6059555 ENSG00000276073.1 RP5-1125A11.7 -4.6 7.14e-06 0.00413 -0.29 -0.3 Skin pigmentation; chr20:33926518 chr20:33985617~33988989:- CESC cis rs875971 0.545 rs2420612 ENSG00000226824.5 RP4-756H11.3 -4.6 7.14e-06 0.00413 -0.44 -0.3 Aortic root size; chr7:66536825 chr7:66654538~66669855:+ CESC cis rs11846409 0.86 rs73378154 ENSG00000211974.3 IGHV2-70 -4.6 7.15e-06 0.00413 -0.39 -0.3 Rheumatic heart disease; chr14:106637687 chr14:106723574~106724093:- CESC cis rs2739330 0.76 rs5751761 ENSG00000272787.1 KB-226F1.2 4.6 7.17e-06 0.00414 0.32 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23969211~23969873:+ CESC cis rs442309 0.583 rs10995307 ENSG00000238280.1 RP11-436D10.3 4.6 7.18e-06 0.00415 0.34 0.3 Vogt-Koyanagi-Harada syndrome; chr10:62792482 chr10:62793562~62805887:- CESC cis rs11695541 0.826 rs13412862 ENSG00000270820.4 RP11-355B11.2 4.6 7.18e-06 0.00415 0.68 0.3 Methadone dose in opioid dependence; chr2:60631728 chr2:61471188~61484130:+ CESC cis rs11695541 0.826 rs749296 ENSG00000270820.4 RP11-355B11.2 4.6 7.18e-06 0.00415 0.68 0.3 Methadone dose in opioid dependence; chr2:60640670 chr2:61471188~61484130:+ CESC cis rs1501911 0.509 rs692759 ENSG00000248489.1 CTD-2007H13.3 -4.6 7.19e-06 0.00415 -0.31 -0.3 Lung function (FEV1/FVC); chr5:98856841 chr5:98929171~98995013:+ CESC cis rs881375 0.702 rs3761847 ENSG00000226752.6 PSMD5-AS1 -4.6 7.19e-06 0.00416 -0.31 -0.3 Rheumatoid arthritis; chr9:120927961 chr9:120824828~120854385:+ CESC cis rs801193 0.66 rs1016265 ENSG00000232559.3 GS1-124K5.12 4.6 7.21e-06 0.00416 0.32 0.3 Aortic root size; chr7:66749580 chr7:66554588~66576923:- CESC cis rs7189233 0.531 rs4783813 ENSG00000279344.1 RP11-44F14.7 4.6 7.21e-06 0.00416 0.28 0.3 Intelligence (multi-trait analysis); chr16:53484458 chr16:53478957~53481550:- CESC cis rs7189233 0.531 rs8046307 ENSG00000279344.1 RP11-44F14.7 4.6 7.21e-06 0.00416 0.28 0.3 Intelligence (multi-trait analysis); chr16:53484774 chr16:53478957~53481550:- CESC cis rs9309473 0.898 rs10197755 ENSG00000163016.8 ALMS1P 4.6 7.21e-06 0.00416 0.39 0.3 Metabolite levels; chr2:73570496 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs7586463 ENSG00000163016.8 ALMS1P 4.6 7.21e-06 0.00416 0.39 0.3 Metabolite levels; chr2:73571349 chr2:73644919~73685576:+ CESC cis rs2836974 0.563 rs6517522 ENSG00000232608.1 TIMM9P2 -4.6 7.21e-06 0.00417 -0.33 -0.3 Cognitive function; chr21:39181919 chr21:39216624~39217506:+ CESC cis rs7873102 0.608 rs4342708 ENSG00000230188.1 RP11-405L18.4 4.6 7.22e-06 0.00417 0.38 0.3 Brain structure; chr9:38006760 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs55773241 ENSG00000230188.1 RP11-405L18.4 4.6 7.22e-06 0.00417 0.38 0.3 Brain structure; chr9:38008735 chr9:37490421~37490893:- CESC cis rs7873102 0.608 rs56100777 ENSG00000230188.1 RP11-405L18.4 4.6 7.22e-06 0.00417 0.38 0.3 Brain structure; chr9:38008849 chr9:37490421~37490893:- CESC cis rs4819052 0.851 rs2838865 ENSG00000223768.1 LINC00205 -4.6 7.24e-06 0.00418 -0.34 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45292384 chr21:45293285~45297354:+ CESC cis rs12439619 0.508 rs11856561 ENSG00000255769.6 GOLGA2P10 -4.6 7.24e-06 0.00418 -0.33 -0.3 Intelligence (multi-trait analysis); chr15:82161415 chr15:82472993~82513950:- CESC cis rs11723261 0.621 rs3829 ENSG00000211553.1 AC253576.2 -4.6 7.25e-06 0.00418 -0.45 -0.3 Immune response to smallpox vaccine (IL-6); chr4:141070 chr4:136461~136568:+ CESC cis rs11723261 0.621 rs57013142 ENSG00000211553.1 AC253576.2 -4.6 7.25e-06 0.00418 -0.45 -0.3 Immune response to smallpox vaccine (IL-6); chr4:141956 chr4:136461~136568:+ CESC cis rs11157436 0.918 rs1983519 ENSG00000211813.2 TRAV34 4.6 7.25e-06 0.00418 0.34 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150310 chr14:22207522~22208129:+ CESC cis rs8028182 0.537 rs4371118 ENSG00000260269.4 CTD-2323K18.1 -4.6 7.25e-06 0.00418 -0.5 -0.3 Sudden cardiac arrest; chr15:75606549 chr15:75527150~75601205:- CESC cis rs11846409 0.872 rs2516914 ENSG00000211974.3 IGHV2-70 4.6 7.26e-06 0.00419 0.38 0.3 Rheumatic heart disease; chr14:106629835 chr14:106723574~106724093:- CESC cis rs7586673 0.857 rs16845580 ENSG00000227403.1 AC009299.3 -4.6 7.26e-06 0.00419 -0.39 -0.3 Intelligence (multi-trait analysis); chr2:161064373 chr2:161244739~161249050:+ CESC cis rs7429990 0.965 rs4858810 ENSG00000229759.1 MRPS18AP1 -4.6 7.26e-06 0.00419 -0.31 -0.3 Educational attainment (years of education); chr3:48002247 chr3:48256350~48256938:- CESC cis rs116175783 0.557 rs72876083 ENSG00000227403.1 AC009299.3 4.6 7.27e-06 0.00419 0.48 0.3 Intelligence (multi-trait analysis); chr2:161327527 chr2:161244739~161249050:+ CESC cis rs1609391 0.561 rs9289523 ENSG00000239213.4 NCK1-AS1 4.6 7.28e-06 0.0042 0.34 0.3 Neuroticism; chr3:136916747 chr3:136841726~136862054:- CESC cis rs4319547 0.695 rs113841747 ENSG00000275265.1 RP11-15J22.8 4.6 7.28e-06 0.0042 0.42 0.3 Body mass index; chr12:122401541 chr12:122501187~122501641:+ CESC cis rs2028299 0.839 rs2279849 ENSG00000259677.1 RP11-493E3.1 4.6 7.28e-06 0.0042 0.42 0.3 Type 2 diabetes; chr15:89901407 chr15:89876540~89877285:+ CESC cis rs7005380 0.733 rs4871787 ENSG00000279347.1 RP11-85I17.2 4.6 7.28e-06 0.0042 0.26 0.3 Interstitial lung disease; chr8:119924178 chr8:119838736~119840385:- CESC cis rs7005380 0.746 rs1464276 ENSG00000279347.1 RP11-85I17.2 4.6 7.28e-06 0.0042 0.26 0.3 Interstitial lung disease; chr8:119924801 chr8:119838736~119840385:- CESC cis rs7005380 0.733 rs6469878 ENSG00000279347.1 RP11-85I17.2 4.6 7.28e-06 0.0042 0.26 0.3 Interstitial lung disease; chr8:119926208 chr8:119838736~119840385:- CESC cis rs875971 0.571 rs160641 ENSG00000236529.1 RP13-254B10.1 -4.6 7.29e-06 0.0042 -0.37 -0.3 Aortic root size; chr7:66112359 chr7:65840212~65840596:+ CESC cis rs4319547 0.656 rs7294559 ENSG00000275265.1 RP11-15J22.8 -4.6 7.29e-06 0.0042 -0.43 -0.3 Body mass index; chr12:122353017 chr12:122501187~122501641:+ CESC cis rs3096299 0.748 rs3102339 ENSG00000274627.1 RP11-104N10.2 4.6 7.29e-06 0.0042 0.29 0.3 Multiple myeloma (IgH translocation); chr16:89376303 chr16:89516797~89522217:+ CESC cis rs875971 0.83 rs6976714 ENSG00000232559.3 GS1-124K5.12 4.6 7.3e-06 0.00421 0.32 0.3 Aortic root size; chr7:66426474 chr7:66554588~66576923:- CESC cis rs875971 0.651 rs2420596 ENSG00000232559.3 GS1-124K5.12 4.6 7.3e-06 0.00421 0.32 0.3 Aortic root size; chr7:66450996 chr7:66554588~66576923:- CESC cis rs875971 0.52 rs2420597 ENSG00000232559.3 GS1-124K5.12 4.6 7.3e-06 0.00421 0.32 0.3 Aortic root size; chr7:66450999 chr7:66554588~66576923:- CESC cis rs71403859 1 rs71403859 ENSG00000260886.1 TAT-AS1 4.6 7.3e-06 0.00421 0.47 0.3 Post bronchodilator FEV1; chr16:71606304 chr16:71565789~71578187:+ CESC cis rs71403859 0.803 rs34381861 ENSG00000260886.1 TAT-AS1 4.6 7.3e-06 0.00421 0.47 0.3 Post bronchodilator FEV1; chr16:71606327 chr16:71565789~71578187:+ CESC cis rs2439831 1 rs2601014 ENSG00000205771.5 CATSPER2P1 -4.6 7.31e-06 0.00421 -0.47 -0.3 Lung cancer in ever smokers; chr15:43463815 chr15:43726918~43747094:- CESC cis rs9322193 0.923 rs9689723 ENSG00000268592.3 RAET1E-AS1 4.6 7.31e-06 0.00421 0.38 0.3 Lung cancer; chr6:149655935 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9968911 ENSG00000268592.3 RAET1E-AS1 4.6 7.31e-06 0.00421 0.38 0.3 Lung cancer; chr6:149657419 chr6:149863494~149919507:+ CESC cis rs34375054 0.738 rs10846834 ENSG00000279233.1 RP11-158L12.4 4.6 7.32e-06 0.00422 0.29 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125141024 chr12:125138245~125141711:+ CESC cis rs2015599 0.623 rs2288128 ENSG00000257176.2 RP11-996F15.2 4.6 7.32e-06 0.00422 0.35 0.3 Platelet count;Mean platelet volume; chr12:29316054 chr12:29280418~29317848:- CESC cis rs2015599 0.584 rs2288129 ENSG00000257176.2 RP11-996F15.2 4.6 7.32e-06 0.00422 0.35 0.3 Platelet count;Mean platelet volume; chr12:29316355 chr12:29280418~29317848:- CESC cis rs75422866 0.51 rs73104197 ENSG00000257433.4 RP1-197B17.3 4.59 7.32e-06 0.00422 0.71 0.3 Pneumonia; chr12:47717273 chr12:47706085~47742294:+ CESC cis rs7572733 0.935 rs1607373 ENSG00000222017.1 AC011997.1 4.59 7.33e-06 0.00422 0.33 0.3 Dermatomyositis; chr2:197935808 chr2:197693106~197774823:+ CESC cis rs2412819 0.571 rs2930529 ENSG00000205771.5 CATSPER2P1 4.59 7.33e-06 0.00422 0.43 0.3 Lung cancer; chr15:43819467 chr15:43726918~43747094:- CESC cis rs6782228 0.675 rs2253151 ENSG00000242551.2 POU5F1P6 -4.59 7.34e-06 0.00423 -0.33 -0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611294 chr3:128674735~128677005:- CESC cis rs11157436 0.958 rs2075494 ENSG00000211813.2 TRAV34 4.59 7.34e-06 0.00423 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22202564 chr14:22207522~22208129:+ CESC cis rs11157436 0.958 rs2242542 ENSG00000211813.2 TRAV34 4.59 7.34e-06 0.00423 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22203081 chr14:22207522~22208129:+ CESC cis rs2836950 0.52 rs8130240 ENSG00000232608.1 TIMM9P2 4.59 7.34e-06 0.00423 0.33 0.3 Menarche (age at onset); chr21:39166182 chr21:39216624~39217506:+ CESC cis rs4819052 0.851 rs2838840 ENSG00000223768.1 LINC00205 -4.59 7.35e-06 0.00423 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45248579 chr21:45293285~45297354:+ CESC cis rs72772090 0.539 rs35898772 ENSG00000248734.2 CTD-2260A17.1 -4.59 7.35e-06 0.00423 -0.45 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96843982 chr5:96784777~96785999:+ CESC cis rs7250849 0.688 rs16982907 ENSG00000273837.1 LLNLR-470E3.1 -4.59 7.35e-06 0.00423 -0.4 -0.3 Blood protein levels; chr19:51659782 chr19:51639478~51639931:- CESC cis rs9309473 0.95 rs6740766 ENSG00000163016.8 ALMS1P 4.59 7.37e-06 0.00424 0.39 0.3 Metabolite levels; chr2:73553786 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs13431267 ENSG00000163016.8 ALMS1P 4.59 7.37e-06 0.00424 0.39 0.3 Metabolite levels; chr2:73555073 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs10198549 ENSG00000163016.8 ALMS1P 4.59 7.37e-06 0.00424 0.39 0.3 Metabolite levels; chr2:73567277 chr2:73644919~73685576:+ CESC cis rs2919917 1 rs1483573 ENSG00000254352.1 RP11-578O24.2 4.59 7.37e-06 0.00425 0.38 0.3 Lymphocyte counts; chr8:78711382 chr8:78723796~78724136:- CESC cis rs5769707 0.521 rs7285764 ENSG00000235111.1 RP1-29C18.8 -4.59 7.38e-06 0.00425 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49664913 chr22:49612657~49615716:- CESC cis rs5769707 0.521 rs9616715 ENSG00000235111.1 RP1-29C18.8 -4.59 7.38e-06 0.00425 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49664934 chr22:49612657~49615716:- CESC cis rs5769707 0.521 rs6009805 ENSG00000235111.1 RP1-29C18.8 -4.59 7.38e-06 0.00425 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49665067 chr22:49612657~49615716:- CESC cis rs5769707 0.521 rs6009807 ENSG00000235111.1 RP1-29C18.8 -4.59 7.38e-06 0.00425 -0.33 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49665274 chr22:49612657~49615716:- CESC cis rs8042680 0.522 rs8026678 ENSG00000214432.8 AC068831.10 -4.59 7.38e-06 0.00425 -0.36 -0.3 Type 2 diabetes; chr15:91018775 chr15:91022619~91036611:+ CESC cis rs7615952 0.599 rs2279821 ENSG00000250012.1 RP11-124N2.1 -4.59 7.39e-06 0.00425 -0.33 -0.3 Blood pressure (smoking interaction); chr3:126015465 chr3:126084220~126095349:+ CESC cis rs9322193 0.923 rs2880436 ENSG00000216906.2 RP11-350J20.9 4.59 7.39e-06 0.00425 0.34 0.3 Lung cancer; chr6:149859123 chr6:149904243~149906418:+ CESC cis rs2028299 0.92 rs1866476 ENSG00000259677.1 RP11-493E3.1 4.59 7.39e-06 0.00425 0.4 0.3 Type 2 diabetes; chr15:89885311 chr15:89876540~89877285:+ CESC cis rs7189233 0.531 rs4281707 ENSG00000279344.1 RP11-44F14.7 4.59 7.4e-06 0.00425 0.28 0.3 Intelligence (multi-trait analysis); chr16:53468034 chr16:53478957~53481550:- CESC cis rs7873102 0.63 rs12347935 ENSG00000230188.1 RP11-405L18.4 4.59 7.41e-06 0.00426 0.38 0.3 Brain structure; chr9:38001076 chr9:37490421~37490893:- CESC cis rs7873102 0.63 rs12343426 ENSG00000230188.1 RP11-405L18.4 4.59 7.41e-06 0.00426 0.38 0.3 Brain structure; chr9:38001625 chr9:37490421~37490893:- CESC cis rs7873102 0.63 rs17438977 ENSG00000230188.1 RP11-405L18.4 4.59 7.41e-06 0.00426 0.38 0.3 Brain structure; chr9:38001837 chr9:37490421~37490893:- CESC cis rs7873102 0.63 rs60510358 ENSG00000230188.1 RP11-405L18.4 4.59 7.41e-06 0.00426 0.38 0.3 Brain structure; chr9:38001905 chr9:37490421~37490893:- CESC cis rs17711722 0.565 rs73372653 ENSG00000228409.4 CCT6P1 -4.59 7.41e-06 0.00426 -0.28 -0.3 Calcium levels; chr7:65977808 chr7:65751142~65763354:+ CESC cis rs2015599 0.601 rs17715086 ENSG00000257176.2 RP11-996F15.2 -4.59 7.42e-06 0.00426 -0.35 -0.3 Platelet count;Mean platelet volume; chr12:29329073 chr12:29280418~29317848:- CESC cis rs4819052 0.851 rs1999335 ENSG00000223768.1 LINC00205 -4.59 7.43e-06 0.00427 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45250698 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2838844 ENSG00000223768.1 LINC00205 -4.59 7.43e-06 0.00427 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45250818 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2838848 ENSG00000223768.1 LINC00205 -4.59 7.43e-06 0.00427 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251102 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2838849 ENSG00000223768.1 LINC00205 -4.59 7.43e-06 0.00427 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251112 chr21:45293285~45297354:+ CESC cis rs783540 0.632 rs17356528 ENSG00000255769.6 GOLGA2P10 4.59 7.43e-06 0.00427 0.34 0.3 Schizophrenia; chr15:82636799 chr15:82472993~82513950:- CESC cis rs944801 0.566 rs10965219 ENSG00000215221.2 UBA52P6 -4.59 7.45e-06 0.00428 -0.36 -0.3 Type 2 diabetes; chr9:22053688 chr9:22012155~22012536:+ CESC cis rs11723261 0.621 rs11733385 ENSG00000211553.1 AC253576.2 -4.59 7.45e-06 0.00428 -0.45 -0.3 Immune response to smallpox vaccine (IL-6); chr4:146677 chr4:136461~136568:+ CESC cis rs11723261 0.546 rs4315728 ENSG00000211553.1 AC253576.2 -4.59 7.45e-06 0.00428 -0.45 -0.3 Immune response to smallpox vaccine (IL-6); chr4:147237 chr4:136461~136568:+ CESC cis rs763121 0.853 rs2267395 ENSG00000273076.1 RP3-508I15.22 4.59 7.45e-06 0.00428 0.33 0.3 Menopause (age at onset); chr22:38717898 chr22:38743495~38743910:+ CESC cis rs11157436 1 rs12587166 ENSG00000211813.2 TRAV34 4.59 7.46e-06 0.00429 0.33 0.3 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22165492 chr14:22207522~22208129:+ CESC cis rs1862618 0.853 rs832568 ENSG00000271828.1 CTD-2310F14.1 4.59 7.47e-06 0.00429 0.4 0.3 Initial pursuit acceleration; chr5:56857949 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs832569 ENSG00000271828.1 CTD-2310F14.1 4.59 7.47e-06 0.00429 0.4 0.3 Initial pursuit acceleration; chr5:56858757 chr5:56927874~56929573:+ CESC cis rs4713118 0.587 rs61471148 ENSG00000219392.1 RP1-265C24.5 -4.59 7.48e-06 0.0043 -0.4 -0.3 Parkinson's disease; chr6:28069254 chr6:28115628~28116551:+ CESC cis rs8072100 0.713 rs11079776 ENSG00000228782.6 CTD-2026D20.3 4.59 7.49e-06 0.0043 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469527 chr17:47450568~47492492:- CESC cis rs875971 0.597 rs11763224 ENSG00000222364.1 RNU6-96P -4.59 7.5e-06 0.00431 -0.41 -0.3 Aortic root size; chr7:66518628 chr7:66395191~66395286:+ CESC cis rs2933343 0.951 rs789220 ENSG00000231305.3 RP11-723O4.2 -4.59 7.5e-06 0.00431 -0.29 -0.3 IgG glycosylation; chr3:128873292 chr3:128861313~128871540:- CESC cis rs8177876 0.749 rs76892049 ENSG00000261838.4 RP11-303E16.6 4.59 7.5e-06 0.00431 0.62 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81055736 chr16:81069854~81076598:+ CESC cis rs9322193 0.924 rs9322189 ENSG00000268592.3 RAET1E-AS1 4.59 7.51e-06 0.00431 0.39 0.3 Lung cancer; chr6:149588797 chr6:149863494~149919507:+ CESC cis rs9322193 1 rs58189451 ENSG00000216906.2 RP11-350J20.9 4.59 7.51e-06 0.00431 0.34 0.3 Lung cancer; chr6:149600252 chr6:149904243~149906418:+ CESC cis rs2439831 0.867 rs2278860 ENSG00000275601.1 AC011330.13 4.59 7.51e-06 0.00431 0.39 0.3 Lung cancer in ever smokers; chr15:43366848 chr15:43642389~43643023:- CESC cis rs11159086 0.793 rs11621693 ENSG00000259005.1 RP3-449M8.6 4.59 7.52e-06 0.00431 0.42 0.3 Advanced glycation end-product levels; chr14:74472631 chr14:74474007~74474864:- CESC cis rs1799949 1 rs8176269 ENSG00000267681.1 CTD-3199J23.6 -4.59 7.52e-06 0.00432 -0.4 -0.3 Menopause (age at onset); chr17:43061609 chr17:43144956~43145255:+ CESC cis rs34375054 0.525 rs1080910 ENSG00000279233.1 RP11-158L12.4 4.59 7.53e-06 0.00432 0.31 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125123946 chr12:125138245~125141711:+ CESC cis rs2833693 0.572 rs2833711 ENSG00000261610.1 AP000265.1 4.59 7.53e-06 0.00432 0.35 0.3 Temperament; chr21:32191022 chr21:32259804~32261585:- CESC cis rs10246939 0.505 rs12703409 ENSG00000228775.6 WEE2-AS1 4.59 7.53e-06 0.00432 0.36 0.3 Bitter taste perception; chr7:141812058 chr7:141704338~141738346:- CESC cis rs16953946 0.881 rs71400112 ENSG00000260896.4 RP11-314O13.1 -4.59 7.54e-06 0.00432 -0.83 -0.3 Inflammatory bowel disease; chr16:80749732 chr16:80828735~80892595:- CESC cis rs7178909 0.835 rs2174292 ENSG00000259677.1 RP11-493E3.1 4.59 7.54e-06 0.00432 0.33 0.3 Common traits (Other); chr15:89872349 chr15:89876540~89877285:+ CESC cis rs8031584 0.918 rs61997139 ENSG00000260382.1 RP11-540B6.2 4.59 7.56e-06 0.00433 0.41 0.3 Huntington's disease progression; chr15:30981399 chr15:30882267~30883231:- CESC cis rs875971 0.545 rs17138156 ENSG00000222364.1 RNU6-96P -4.59 7.56e-06 0.00434 -0.38 -0.3 Aortic root size; chr7:66249708 chr7:66395191~66395286:+ CESC cis rs2243480 1 rs316315 ENSG00000275400.1 RP4-756H11.5 -4.59 7.57e-06 0.00434 -0.42 -0.3 Diabetic kidney disease; chr7:66126218 chr7:66553805~66554199:- CESC cis rs9322193 0.961 rs9027 ENSG00000268592.3 RAET1E-AS1 4.59 7.57e-06 0.00434 0.38 0.3 Lung cancer; chr6:149594921 chr6:149863494~149919507:+ CESC cis rs9322193 1 rs9322193 ENSG00000268592.3 RAET1E-AS1 4.59 7.57e-06 0.00434 0.38 0.3 Lung cancer; chr6:149598007 chr6:149863494~149919507:+ CESC cis rs4819052 0.851 rs9974628 ENSG00000223768.1 LINC00205 -4.59 7.57e-06 0.00434 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45252732 chr21:45293285~45297354:+ CESC cis rs875971 0.893 rs62465470 ENSG00000237310.1 GS1-124K5.4 -4.59 7.57e-06 0.00434 -0.28 -0.3 Aortic root size; chr7:66136231 chr7:66493706~66495474:+ CESC cis rs72772090 0.539 rs116360011 ENSG00000248734.2 CTD-2260A17.1 -4.59 7.57e-06 0.00434 -0.44 -0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782093 chr5:96784777~96785999:+ CESC cis rs2243480 0.901 rs3813708 ENSG00000232559.3 GS1-124K5.12 4.59 7.58e-06 0.00435 0.49 0.3 Diabetic kidney disease; chr7:65840645 chr7:66554588~66576923:- CESC cis rs2980439 0.818 rs2945249 ENSG00000253981.4 ALG1L13P 4.59 7.59e-06 0.00435 0.36 0.3 Neuroticism; chr8:8237204 chr8:8236003~8244667:- CESC cis rs950169 0.61 rs34529571 ENSG00000225151.9 GOLGA2P7 -4.59 7.59e-06 0.00435 -0.44 -0.3 Schizophrenia; chr15:84023055 chr15:84199311~84230136:- CESC cis rs8072100 0.713 rs57427906 ENSG00000228782.6 CTD-2026D20.3 4.59 7.59e-06 0.00435 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47416648 chr17:47450568~47492492:- CESC cis rs8072100 0.713 rs4968228 ENSG00000228782.6 CTD-2026D20.3 4.59 7.59e-06 0.00435 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47420182 chr17:47450568~47492492:- CESC cis rs8072100 0.582 rs3826536 ENSG00000228782.6 CTD-2026D20.3 4.59 7.59e-06 0.00435 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47424601 chr17:47450568~47492492:- CESC cis rs8072100 0.676 rs9908049 ENSG00000228782.6 CTD-2026D20.3 4.59 7.59e-06 0.00435 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47424730 chr17:47450568~47492492:- CESC cis rs8072100 0.713 rs3871595 ENSG00000228782.6 CTD-2026D20.3 4.59 7.59e-06 0.00435 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47434022 chr17:47450568~47492492:- CESC cis rs8072100 0.713 rs9899859 ENSG00000228782.6 CTD-2026D20.3 4.59 7.59e-06 0.00435 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47435683 chr17:47450568~47492492:- CESC cis rs8072100 0.713 rs1912486 ENSG00000228782.6 CTD-2026D20.3 4.59 7.59e-06 0.00435 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47437801 chr17:47450568~47492492:- CESC cis rs8072100 0.667 rs1912485 ENSG00000228782.6 CTD-2026D20.3 4.59 7.59e-06 0.00435 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47438312 chr17:47450568~47492492:- CESC cis rs7615952 0.599 rs6438953 ENSG00000250012.1 RP11-124N2.1 -4.59 7.6e-06 0.00435 -0.31 -0.3 Blood pressure (smoking interaction); chr3:126006108 chr3:126084220~126095349:+ CESC cis rs7615952 0.599 rs1044215 ENSG00000250012.1 RP11-124N2.1 -4.59 7.6e-06 0.00435 -0.31 -0.3 Blood pressure (smoking interaction); chr3:126006716 chr3:126084220~126095349:+ CESC cis rs875971 0.862 rs709609 ENSG00000232559.3 GS1-124K5.12 -4.59 7.6e-06 0.00435 -0.33 -0.3 Aortic root size; chr7:66095574 chr7:66554588~66576923:- CESC cis rs11846409 0.655 rs79296226 ENSG00000211974.3 IGHV2-70 4.59 7.6e-06 0.00435 0.41 0.3 Rheumatic heart disease; chr14:106650436 chr14:106723574~106724093:- CESC cis rs2179367 0.959 rs9377212 ENSG00000231760.4 RP11-350J20.5 4.59 7.6e-06 0.00435 0.37 0.3 Dupuytren's disease; chr6:149383765 chr6:149796151~149826294:- CESC cis rs3096299 0.748 rs2965822 ENSG00000274627.1 RP11-104N10.2 4.59 7.61e-06 0.00436 0.3 0.3 Multiple myeloma (IgH translocation); chr16:89378269 chr16:89516797~89522217:+ CESC cis rs113835537 0.935 rs1127145 ENSG00000255517.5 CTD-3074O7.5 -4.59 7.62e-06 0.00436 -0.47 -0.3 Airway imaging phenotypes; chr11:66605834 chr11:66473490~66480233:- CESC cis rs113835537 0.935 rs11550057 ENSG00000255517.5 CTD-3074O7.5 -4.59 7.62e-06 0.00436 -0.47 -0.3 Airway imaging phenotypes; chr11:66625409 chr11:66473490~66480233:- CESC cis rs113835537 0.935 rs15969 ENSG00000255517.5 CTD-3074O7.5 -4.59 7.62e-06 0.00436 -0.47 -0.3 Airway imaging phenotypes; chr11:66626916 chr11:66473490~66480233:- CESC cis rs2919917 0.628 rs2625663 ENSG00000254352.1 RP11-578O24.2 4.59 7.63e-06 0.00437 0.41 0.3 Lymphocyte counts; chr8:78718106 chr8:78723796~78724136:- CESC cis rs2028299 0.92 rs2118847 ENSG00000259677.1 RP11-493E3.1 4.59 7.65e-06 0.00438 0.4 0.3 Type 2 diabetes; chr15:89865615 chr15:89876540~89877285:+ CESC cis rs4819052 0.851 rs2838858 ENSG00000223768.1 LINC00205 -4.59 7.65e-06 0.00438 -0.34 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45261178 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2838839 ENSG00000223768.1 LINC00205 4.58 7.66e-06 0.00438 0.35 0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45247943 chr21:45293285~45297354:+ CESC cis rs12458462 0.851 rs3859317 ENSG00000274828.1 RP11-567M16.6 4.58 7.67e-06 0.00438 0.28 0.3 Monocyte count; chr18:79683093 chr18:79677287~79679358:- CESC cis rs1185460 1 rs7127212 ENSG00000271751.1 RP11-110I1.14 4.58 7.67e-06 0.00439 0.4 0.3 Coronary artery disease; chr11:119082492 chr11:119065263~119065677:- CESC cis rs9601248 0.967 rs9545145 ENSG00000227676.3 LINC01068 -4.58 7.69e-06 0.00439 -0.34 -0.3 Major depressive disorder; chr13:79599625 chr13:79566727~79571436:+ CESC cis rs4141404 0.818 rs5997897 ENSG00000236132.1 CTA-440B3.1 4.58 7.69e-06 0.0044 0.33 0.3 Paclitaxel-induced neuropathy; chr22:31174450 chr22:31816379~31817491:- CESC cis rs9660180 0.875 rs4648727 ENSG00000231050.1 RP1-140A9.1 -4.58 7.69e-06 0.0044 -0.33 -0.3 Body mass index; chr1:1844830 chr1:1891471~1892658:+ CESC cis rs7829975 0.714 rs6994038 ENSG00000253893.2 FAM85B -4.58 7.69e-06 0.0044 -0.37 -0.3 Mood instability; chr8:8803028 chr8:8167819~8226614:- CESC cis rs10875746 0.551 rs10875799 ENSG00000240399.1 RP1-228P16.1 -4.58 7.69e-06 0.0044 -0.38 -0.3 Longevity (90 years and older); chr12:48347096 chr12:48054813~48055591:- CESC cis rs755249 0.958 rs61781370 ENSG00000228060.1 RP11-69E11.8 -4.58 7.7e-06 0.0044 -0.35 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39579628 chr1:39565160~39573203:+ CESC cis rs748404 0.589 rs62020612 ENSG00000249839.1 AC011330.5 -4.58 7.7e-06 0.0044 -0.41 -0.3 Lung cancer; chr15:43525881 chr15:43663654~43684339:- CESC cis rs6686842 0.965 rs10157966 ENSG00000235358.1 RP11-399E6.1 -4.58 7.7e-06 0.0044 -0.36 -0.3 Height; chr1:41256904 chr1:41242373~41284861:+ CESC cis rs73086581 1 rs73088416 ENSG00000229539.1 RP11-119B16.2 4.58 7.71e-06 0.0044 0.47 0.3 Response to antidepressants in depression; chr20:4014629 chr20:3888239~3888868:- CESC cis rs7189233 0.55 rs3803657 ENSG00000279344.1 RP11-44F14.7 4.58 7.72e-06 0.00441 0.28 0.3 Intelligence (multi-trait analysis); chr16:53482047 chr16:53478957~53481550:- CESC cis rs7189233 0.531 rs13337544 ENSG00000279344.1 RP11-44F14.7 4.58 7.72e-06 0.00441 0.28 0.3 Intelligence (multi-trait analysis); chr16:53485123 chr16:53478957~53481550:- CESC cis rs763121 0.853 rs10135 ENSG00000273076.1 RP3-508I15.22 -4.58 7.74e-06 0.00442 -0.33 -0.3 Menopause (age at onset); chr22:38686169 chr22:38743495~38743910:+ CESC cis rs6991838 0.806 rs11781358 ENSG00000200714.1 Y_RNA 4.58 7.74e-06 0.00442 0.35 0.3 Intelligence (multi-trait analysis); chr8:65557691 chr8:65592731~65592820:+ CESC cis rs494459 0.838 rs2510897 ENSG00000255422.1 AP002954.4 -4.58 7.74e-06 0.00442 -0.34 -0.3 Height; chr11:118773873 chr11:118704607~118750263:+ CESC cis rs9918079 0.56 rs12651550 ENSG00000273133.1 RP11-799M12.2 -4.58 7.75e-06 0.00442 -0.38 -0.3 Obesity-related traits; chr4:15639395 chr4:15563698~15564253:- CESC cis rs7591472 1 rs7591472 ENSG00000183308.6 AC005037.3 4.58 7.75e-06 0.00442 0.43 0.3 Triptolide cytotoxicity; chr2:201025028 chr2:200963263~201009102:+ CESC cis rs748404 0.723 rs573169 ENSG00000205771.5 CATSPER2P1 -4.58 7.77e-06 0.00443 -0.36 -0.3 Lung cancer; chr15:43258383 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs524547 ENSG00000205771.5 CATSPER2P1 -4.58 7.77e-06 0.00443 -0.36 -0.3 Lung cancer; chr15:43258825 chr15:43726918~43747094:- CESC cis rs2015599 0.56 rs3948497 ENSG00000275476.1 RP11-996F15.4 -4.58 7.77e-06 0.00443 -0.34 -0.3 Platelet count;Mean platelet volume; chr12:29247552 chr12:29277397~29277882:- CESC cis rs2179367 0.887 rs2789488 ENSG00000231760.4 RP11-350J20.5 -4.58 7.77e-06 0.00443 -0.36 -0.3 Dupuytren's disease; chr6:149404154 chr6:149796151~149826294:- CESC cis rs11089937 0.963 rs5757098 ENSG00000211639.2 IGLV4-60 -4.58 7.77e-06 0.00443 -0.26 -0.3 Periodontitis (PAL4Q3); chr22:22154322 chr22:22162199~22162681:+ CESC cis rs224090 0.54 rs11592442 ENSG00000238280.1 RP11-436D10.3 -4.58 7.78e-06 0.00444 -0.38 -0.3 Crohn's disease; chr10:62774144 chr10:62793562~62805887:- CESC cis rs6686842 1 rs213754 ENSG00000235358.1 RP11-399E6.1 -4.58 7.79e-06 0.00444 -0.36 -0.3 Height; chr1:41133176 chr1:41242373~41284861:+ CESC cis rs12439619 0.846 rs62010071 ENSG00000255769.6 GOLGA2P10 -4.58 7.79e-06 0.00444 -0.46 -0.3 Intelligence (multi-trait analysis); chr15:82289442 chr15:82472993~82513950:- CESC cis rs5769707 0.967 rs1018812 ENSG00000235111.1 RP1-29C18.8 -4.58 7.8e-06 0.00444 -0.29 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49616425 chr22:49612657~49615716:- CESC cis rs875971 0.545 rs73376401 ENSG00000222364.1 RNU6-96P -4.58 7.81e-06 0.00445 -0.39 -0.3 Aortic root size; chr7:66174841 chr7:66395191~66395286:+ CESC cis rs9318086 0.673 rs7981928 ENSG00000205861.10 C1QTNF9B-AS1 -4.58 7.82e-06 0.00445 -0.38 -0.3 Myopia (pathological); chr13:23861041 chr13:23888889~23897263:+ CESC cis rs12439619 0.53 rs7162177 ENSG00000276710.3 CSPG4P8 -4.58 7.83e-06 0.00446 -0.31 -0.3 Intelligence (multi-trait analysis); chr15:82181728 chr15:82459472~82477258:+ CESC cis rs5769707 0.605 rs9616702 ENSG00000235111.1 RP1-29C18.8 -4.58 7.83e-06 0.00446 -0.34 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49632290 chr22:49612657~49615716:- CESC cis rs11723261 0.621 rs6599306 ENSG00000211553.1 AC253576.2 4.58 7.84e-06 0.00446 0.45 0.3 Immune response to smallpox vaccine (IL-6); chr4:149655 chr4:136461~136568:+ CESC cis rs2408955 0.561 rs9971924 ENSG00000240399.1 RP1-228P16.1 -4.58 7.84e-06 0.00447 -0.33 -0.3 Glycated hemoglobin levels; chr12:48086049 chr12:48054813~48055591:- CESC cis rs2408955 0.522 rs7139330 ENSG00000240399.1 RP1-228P16.1 -4.58 7.84e-06 0.00447 -0.33 -0.3 Glycated hemoglobin levels; chr12:48089701 chr12:48054813~48055591:- CESC cis rs4814920 0.818 rs6035467 ENSG00000275142.1 RP5-999L4.2 -4.58 7.84e-06 0.00447 -0.53 -0.3 Bipolar disorder (body mass index interaction); chr20:19879602 chr20:19871891~19872284:+ CESC cis rs10754283 0.967 rs10754285 ENSG00000231613.1 RP5-943J3.1 4.58 7.85e-06 0.00447 0.37 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89651028 chr1:89788914~89790492:+ CESC cis rs748404 0.723 rs565658 ENSG00000205771.5 CATSPER2P1 -4.58 7.86e-06 0.00447 -0.36 -0.3 Lung cancer; chr15:43264109 chr15:43726918~43747094:- CESC cis rs2836950 0.565 rs8134214 ENSG00000232608.1 TIMM9P2 4.58 7.86e-06 0.00448 0.33 0.3 Menarche (age at onset); chr21:39170441 chr21:39216624~39217506:+ CESC cis rs2836950 0.52 rs1980407 ENSG00000232608.1 TIMM9P2 4.58 7.86e-06 0.00448 0.33 0.3 Menarche (age at onset); chr21:39172035 chr21:39216624~39217506:+ CESC cis rs2836950 0.565 rs2836930 ENSG00000232608.1 TIMM9P2 4.58 7.86e-06 0.00448 0.33 0.3 Menarche (age at onset); chr21:39173730 chr21:39216624~39217506:+ CESC cis rs2836950 0.565 rs2836931 ENSG00000232608.1 TIMM9P2 4.58 7.86e-06 0.00448 0.33 0.3 Menarche (age at onset); chr21:39174643 chr21:39216624~39217506:+ CESC cis rs12439619 0.705 rs4778665 ENSG00000276710.3 CSPG4P8 -4.58 7.87e-06 0.00448 -0.45 -0.3 Intelligence (multi-trait analysis); chr15:82144163 chr15:82459472~82477258:+ CESC cis rs7560272 0.538 rs2421575 ENSG00000273245.1 RP11-434P11.2 -4.58 7.88e-06 0.00449 -0.37 -0.3 Schizophrenia; chr2:73692395 chr2:73750256~73750786:- CESC cis rs7560272 0.538 rs13014700 ENSG00000273245.1 RP11-434P11.2 -4.58 7.88e-06 0.00449 -0.37 -0.3 Schizophrenia; chr2:73692994 chr2:73750256~73750786:- CESC cis rs9322193 0.962 rs9322206 ENSG00000268592.3 RAET1E-AS1 4.58 7.88e-06 0.00449 0.37 0.3 Lung cancer; chr6:149641481 chr6:149863494~149919507:+ CESC cis rs801193 0.66 rs974239 ENSG00000237310.1 GS1-124K5.4 4.58 7.89e-06 0.00449 0.28 0.3 Aortic root size; chr7:66748504 chr7:66493706~66495474:+ CESC cis rs4865169 0.791 rs11731868 ENSG00000269949.1 RP11-738E22.3 -4.58 7.89e-06 0.00449 -0.34 -0.3 Breast cancer; chr4:57029048 chr4:56960927~56961373:- CESC cis rs8072100 0.544 rs9284377 ENSG00000228782.6 CTD-2026D20.3 4.58 7.89e-06 0.00449 0.36 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309046 chr17:47450568~47492492:- CESC cis rs9309711 0.961 rs11678655 ENSG00000225234.1 TRAPPC12-AS1 -4.58 7.9e-06 0.0045 -0.29 -0.3 Neurofibrillary tangles; chr2:3472463 chr2:3481242~3482409:- CESC cis rs7560272 0.512 rs13015885 ENSG00000273245.1 RP11-434P11.2 -4.58 7.92e-06 0.00451 -0.37 -0.3 Schizophrenia; chr2:73693355 chr2:73750256~73750786:- CESC cis rs12458462 0.787 rs56006341 ENSG00000274828.1 RP11-567M16.6 4.58 7.92e-06 0.00451 0.28 0.3 Monocyte count; chr18:79679844 chr18:79677287~79679358:- CESC cis rs748404 0.697 rs564946 ENSG00000205771.5 CATSPER2P1 -4.58 7.94e-06 0.00452 -0.36 -0.3 Lung cancer; chr15:43264074 chr15:43726918~43747094:- CESC cis rs9532669 0.889 rs6560964 ENSG00000176268.5 CYCSP34 4.58 7.95e-06 0.00452 0.29 0.3 Cervical cancer; chr13:40871132 chr13:40863599~40863902:- CESC cis rs2337406 1 rs17095456 ENSG00000211974.3 IGHV2-70 -4.58 7.97e-06 0.00453 -0.44 -0.3 Alzheimer's disease (late onset); chr14:106676559 chr14:106723574~106724093:- CESC cis rs7208859 0.623 rs8067035 ENSG00000266490.1 CTD-2349P21.9 4.58 7.97e-06 0.00453 0.44 0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30792372~30792833:+ CESC cis rs10754283 0.935 rs1934046 ENSG00000231613.1 RP5-943J3.1 -4.58 7.98e-06 0.00454 -0.37 -0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89653731 chr1:89788914~89790492:+ CESC cis rs875971 0.545 rs73376401 ENSG00000237310.1 GS1-124K5.4 4.58 7.98e-06 0.00454 0.32 0.3 Aortic root size; chr7:66174841 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs4718335 ENSG00000226824.5 RP4-756H11.3 -4.57 7.99e-06 0.00454 -0.43 -0.3 Aortic root size; chr7:66339619 chr7:66654538~66669855:+ CESC cis rs6504622 0.702 rs3851798 ENSG00000262879.4 RP11-156P1.3 4.57 7.99e-06 0.00454 0.32 0.3 Orofacial clefts; chr17:46988901 chr17:46984045~47100323:- CESC cis rs4819052 0.851 rs4819049 ENSG00000223768.1 LINC00205 -4.57 7.99e-06 0.00454 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45253171 chr21:45293285~45297354:+ CESC cis rs5769707 0.967 rs5770585 ENSG00000235111.1 RP1-29C18.8 -4.57 8e-06 0.00455 -0.29 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49614226 chr22:49612657~49615716:- CESC cis rs7560272 0.538 rs4852972 ENSG00000273245.1 RP11-434P11.2 -4.57 8.01e-06 0.00455 -0.37 -0.3 Schizophrenia; chr2:73689545 chr2:73750256~73750786:- CESC cis rs875971 0.862 rs4368860 ENSG00000237310.1 GS1-124K5.4 -4.57 8.01e-06 0.00455 -0.28 -0.3 Aortic root size; chr7:66143495 chr7:66493706~66495474:+ CESC cis rs9545047 0.604 rs1856997 ENSG00000227676.3 LINC01068 4.57 8.01e-06 0.00455 0.33 0.3 Schizophrenia; chr13:79287487 chr13:79566727~79571436:+ CESC cis rs9929218 0.608 rs35158985 ENSG00000260459.2 FTLP14 -4.57 8.02e-06 0.00455 -0.39 -0.3 Colorectal cancer; chr16:68762843 chr16:68822587~68823070:+ CESC cis rs2177312 0.868 rs10024655 ENSG00000251129.1 RP11-734I18.1 -4.57 8.02e-06 0.00456 -0.41 -0.3 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31937322 chr4:31997397~32155406:+ CESC cis rs4141404 0.787 rs11913992 ENSG00000236132.1 CTA-440B3.1 4.57 8.04e-06 0.00457 0.33 0.3 Paclitaxel-induced neuropathy; chr22:31189234 chr22:31816379~31817491:- CESC cis rs1799949 1 rs8176265 ENSG00000267681.1 CTD-3199J23.6 -4.57 8.04e-06 0.00457 -0.4 -0.3 Menopause (age at onset); chr17:43061979 chr17:43144956~43145255:+ CESC cis rs7429990 0.965 rs6770467 ENSG00000229759.1 MRPS18AP1 -4.57 8.05e-06 0.00457 -0.3 -0.3 Educational attainment (years of education); chr3:47977742 chr3:48256350~48256938:- CESC cis rs7429990 0.932 rs6770477 ENSG00000229759.1 MRPS18AP1 -4.57 8.05e-06 0.00457 -0.3 -0.3 Educational attainment (years of education); chr3:47977768 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs28637561 ENSG00000229759.1 MRPS18AP1 -4.57 8.05e-06 0.00457 -0.3 -0.3 Educational attainment (years of education); chr3:47979528 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs7431572 ENSG00000229759.1 MRPS18AP1 -4.57 8.05e-06 0.00457 -0.3 -0.3 Educational attainment (years of education); chr3:47986361 chr3:48256350~48256938:- CESC cis rs10788972 1 rs10788972 ENSG00000225183.1 RP4-758J24.4 -4.57 8.05e-06 0.00457 -0.34 -0.3 Parkinson disease and lewy body pathology; chr1:54106570 chr1:54089856~54090093:+ CESC cis rs875971 0.545 rs221986 ENSG00000222364.1 RNU6-96P 4.57 8.07e-06 0.00458 0.41 0.3 Aortic root size; chr7:66105323 chr7:66395191~66395286:+ CESC cis rs748404 0.631 rs6493086 ENSG00000205771.5 CATSPER2P1 -4.57 8.07e-06 0.00458 -0.36 -0.3 Lung cancer; chr15:43363196 chr15:43726918~43747094:- CESC cis rs9309473 0.898 rs10185080 ENSG00000163016.8 ALMS1P 4.57 8.08e-06 0.00458 0.39 0.3 Metabolite levels; chr2:73570380 chr2:73644919~73685576:+ CESC cis rs9309473 0.848 rs17009159 ENSG00000163016.8 ALMS1P 4.57 8.08e-06 0.00458 0.39 0.3 Metabolite levels; chr2:73570635 chr2:73644919~73685576:+ CESC cis rs761746 0.739 rs140081 ENSG00000236132.1 CTA-440B3.1 -4.57 8.08e-06 0.00459 -0.38 -0.3 Intelligence; chr22:31716475 chr22:31816379~31817491:- CESC cis rs8072100 0.967 rs4289035 ENSG00000228782.6 CTD-2026D20.3 4.57 8.1e-06 0.0046 0.34 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47629845 chr17:47450568~47492492:- CESC cis rs801193 0.636 rs10233806 ENSG00000237310.1 GS1-124K5.4 -4.57 8.11e-06 0.0046 -0.28 -0.3 Aortic root size; chr7:66653261 chr7:66493706~66495474:+ CESC cis rs12681963 0.688 rs55810013 ENSG00000272375.1 RP11-51J9.6 4.57 8.12e-06 0.0046 0.48 0.3 Migraine; chr8:30181507 chr8:30197404~30198048:+ CESC cis rs12019361 0.541 rs2032588 ENSG00000224046.1 AC005076.5 4.57 8.12e-06 0.00461 0.48 0.3 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN); chr7:87550127 chr7:87151423~87152420:- CESC cis rs6991838 0.701 rs7829434 ENSG00000272010.1 CTD-3025N20.3 4.57 8.12e-06 0.00461 0.32 0.3 Intelligence (multi-trait analysis); chr8:65716909 chr8:65591850~65592472:- CESC cis rs4819052 0.807 rs4819047 ENSG00000223768.1 LINC00205 -4.57 8.12e-06 0.00461 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45245224 chr21:45293285~45297354:+ CESC cis rs7191700 0.712 rs7187741 ENSG00000262636.1 CTD-3088G3.4 -4.57 8.12e-06 0.00461 -0.38 -0.3 Multiple sclerosis; chr16:11339246 chr16:11380859~11381118:- CESC cis rs763121 0.962 rs6001193 ENSG00000273076.1 RP3-508I15.22 4.57 8.13e-06 0.00461 0.32 0.3 Menopause (age at onset); chr22:38678732 chr22:38743495~38743910:+ CESC cis rs9322193 0.884 rs9688858 ENSG00000268592.3 RAET1E-AS1 4.57 8.13e-06 0.00461 0.37 0.3 Lung cancer; chr6:149637911 chr6:149863494~149919507:+ CESC cis rs2412819 0.597 rs541871 ENSG00000205771.5 CATSPER2P1 -4.57 8.14e-06 0.00461 -0.43 -0.3 Lung cancer; chr15:43868656 chr15:43726918~43747094:- CESC cis rs6686842 1 rs6600365 ENSG00000235358.1 RP11-399E6.1 -4.57 8.14e-06 0.00461 -0.36 -0.3 Height; chr1:41090581 chr1:41242373~41284861:+ CESC cis rs4819052 0.851 rs2838842 ENSG00000223768.1 LINC00205 -4.57 8.15e-06 0.00462 -0.35 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45249302 chr21:45293285~45297354:+ CESC cis rs7615952 0.599 rs6438955 ENSG00000250012.1 RP11-124N2.1 -4.57 8.16e-06 0.00462 -0.31 -0.3 Blood pressure (smoking interaction); chr3:126011490 chr3:126084220~126095349:+ CESC cis rs10875746 0.669 rs1021313 ENSG00000240399.1 RP1-228P16.1 -4.57 8.17e-06 0.00463 -0.36 -0.3 Longevity (90 years and older); chr12:48244258 chr12:48054813~48055591:- CESC cis rs9322193 0.962 rs4870048 ENSG00000223701.3 RAET1E-AS1 4.57 8.18e-06 0.00463 0.34 0.3 Lung cancer; chr6:149834324 chr6:149884431~149919508:+ CESC cis rs875971 0.545 rs11767262 ENSG00000237310.1 GS1-124K5.4 4.57 8.18e-06 0.00463 0.3 0.3 Aortic root size; chr7:66302237 chr7:66493706~66495474:+ CESC cis rs7429990 0.965 rs7427418 ENSG00000229759.1 MRPS18AP1 -4.57 8.18e-06 0.00464 -0.3 -0.3 Educational attainment (years of education); chr3:47981217 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs13075795 ENSG00000229759.1 MRPS18AP1 -4.57 8.18e-06 0.00464 -0.3 -0.3 Educational attainment (years of education); chr3:47983139 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs13074973 ENSG00000229759.1 MRPS18AP1 -4.57 8.18e-06 0.00464 -0.3 -0.3 Educational attainment (years of education); chr3:47986654 chr3:48256350~48256938:- CESC cis rs42490 0.868 rs1605996 ENSG00000251136.7 RP11-37B2.1 4.57 8.19e-06 0.00464 0.3 0.3 Leprosy; chr8:89655674 chr8:89609409~89757727:- CESC cis rs9318086 0.648 rs7330140 ENSG00000205861.10 C1QTNF9B-AS1 -4.57 8.19e-06 0.00464 -0.37 -0.3 Myopia (pathological); chr13:23898935 chr13:23888889~23897263:+ CESC cis rs9318086 0.648 rs9507184 ENSG00000205861.10 C1QTNF9B-AS1 -4.57 8.19e-06 0.00464 -0.37 -0.3 Myopia (pathological); chr13:23899503 chr13:23888889~23897263:+ CESC cis rs9322193 0.923 rs4870529 ENSG00000268592.3 RAET1E-AS1 4.57 8.19e-06 0.00464 0.38 0.3 Lung cancer; chr6:149716436 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9767309 ENSG00000268592.3 RAET1E-AS1 4.57 8.19e-06 0.00464 0.38 0.3 Lung cancer; chr6:149716807 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs62441279 ENSG00000268592.3 RAET1E-AS1 4.57 8.19e-06 0.00464 0.38 0.3 Lung cancer; chr6:149721194 chr6:149863494~149919507:+ CESC cis rs9309473 1 rs62151652 ENSG00000163016.8 ALMS1P 4.57 8.2e-06 0.00464 0.4 0.3 Metabolite levels; chr2:73473004 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs13398956 ENSG00000163016.8 ALMS1P 4.57 8.2e-06 0.00464 0.4 0.3 Metabolite levels; chr2:73493131 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs56154726 ENSG00000163016.8 ALMS1P 4.57 8.2e-06 0.00464 0.4 0.3 Metabolite levels; chr2:73494640 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs7572722 ENSG00000163016.8 ALMS1P 4.57 8.2e-06 0.00464 0.4 0.3 Metabolite levels; chr2:73497548 chr2:73644919~73685576:+ CESC cis rs9640161 0.75 rs59211922 ENSG00000261305.1 RP4-584D14.7 4.57 8.2e-06 0.00464 0.39 0.3 Blood protein levels;Circulating chemerin levels; chr7:150326701 chr7:150341771~150342607:+ CESC cis rs9640161 0.711 rs60268791 ENSG00000261305.1 RP4-584D14.7 4.57 8.2e-06 0.00464 0.39 0.3 Blood protein levels;Circulating chemerin levels; chr7:150326711 chr7:150341771~150342607:+ CESC cis rs8005677 1 rs1956880 ENSG00000279656.1 RP11-298I3.6 4.57 8.2e-06 0.00464 0.36 0.3 Cognitive ability (multi-trait analysis); chr14:22924798 chr14:23023083~23024217:- CESC cis rs2408955 0.522 rs2051851 ENSG00000240399.1 RP1-228P16.1 -4.57 8.21e-06 0.00465 -0.33 -0.3 Glycated hemoglobin levels; chr12:48092157 chr12:48054813~48055591:- CESC cis rs2408955 0.522 rs973398 ENSG00000240399.1 RP1-228P16.1 -4.57 8.21e-06 0.00465 -0.33 -0.3 Glycated hemoglobin levels; chr12:48097265 chr12:48054813~48055591:- CESC cis rs17507216 0.628 rs8028130 ENSG00000278603.1 RP13-608F4.5 4.57 8.21e-06 0.00465 0.47 0.3 Excessive daytime sleepiness; chr15:82734974 chr15:82472203~82472426:+ CESC cis rs62103177 0.525 rs9949598 ENSG00000261126.6 RP11-795F19.1 -4.57 8.21e-06 0.00465 -0.35 -0.3 Opioid sensitivity; chr18:79993037 chr18:80046900~80095482:+ CESC cis rs860295 0.557 rs11264371 ENSG00000225855.5 RUSC1-AS1 4.57 8.21e-06 0.00465 0.26 0.3 Body mass index; chr1:155442246 chr1:155316863~155324176:- CESC cis rs9918079 0.56 rs7438356 ENSG00000273133.1 RP11-799M12.2 -4.57 8.22e-06 0.00465 -0.37 -0.3 Obesity-related traits; chr4:15623147 chr4:15563698~15564253:- CESC cis rs10463554 0.856 rs26522 ENSG00000175749.11 EIF3KP1 -4.57 8.22e-06 0.00465 -0.31 -0.3 Parkinson's disease; chr5:103148695 chr5:103032376~103033031:+ CESC cis rs612683 0.664 rs6702766 ENSG00000261254.2 RP4-714D9.5 4.57 8.22e-06 0.00465 0.27 0.3 Breast cancer; chr1:100532079 chr1:100030566~100035637:+ CESC cis rs17301013 0.507 rs6684688 ENSG00000227373.4 RP11-160H22.5 4.57 8.22e-06 0.00465 0.39 0.3 Systemic lupus erythematosus; chr1:174357180 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs926349 ENSG00000227373.4 RP11-160H22.5 4.57 8.22e-06 0.00465 0.39 0.3 Systemic lupus erythematosus; chr1:174368408 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs28628056 ENSG00000227373.4 RP11-160H22.5 4.57 8.22e-06 0.00465 0.39 0.3 Systemic lupus erythematosus; chr1:174369545 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10912772 ENSG00000227373.4 RP11-160H22.5 4.57 8.22e-06 0.00465 0.39 0.3 Systemic lupus erythematosus; chr1:174370832 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12073751 ENSG00000227373.4 RP11-160H22.5 4.57 8.22e-06 0.00465 0.39 0.3 Systemic lupus erythematosus; chr1:174373177 chr1:174115300~174160004:- CESC cis rs4308124 0.708 rs56693625 ENSG00000227992.1 AC108463.2 -4.57 8.23e-06 0.00465 -0.4 -0.3 Vitiligo; chr2:111207578 chr2:111203964~111206215:- CESC cis rs4308124 0.708 rs61358692 ENSG00000227992.1 AC108463.2 -4.57 8.23e-06 0.00465 -0.4 -0.3 Vitiligo; chr2:111207582 chr2:111203964~111206215:- CESC cis rs9640161 0.75 rs4395803 ENSG00000261305.1 RP4-584D14.7 4.57 8.23e-06 0.00465 0.42 0.3 Blood protein levels;Circulating chemerin levels; chr7:150328278 chr7:150341771~150342607:+ CESC cis rs4819052 0.851 rs8134392 ENSG00000223768.1 LINC00205 4.57 8.23e-06 0.00466 0.35 0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45243875 chr21:45293285~45297354:+ CESC cis rs11779988 0.5 rs208023 ENSG00000253671.1 RP11-806O11.1 -4.57 8.24e-06 0.00466 -0.33 -0.3 Breast cancer; chr8:18021373 chr8:17808941~17820868:+ CESC cis rs1862618 0.853 rs252904 ENSG00000271828.1 CTD-2310F14.1 4.57 8.24e-06 0.00466 0.4 0.3 Initial pursuit acceleration; chr5:56822906 chr5:56927874~56929573:+ CESC cis rs1538970 0.781 rs11211139 ENSG00000280836.1 AL355480.1 -4.57 8.24e-06 0.00466 -0.38 -0.3 Platelet count; chr1:45550079 chr1:45581219~45581321:- CESC cis rs950776 0.518 rs12902493 ENSG00000279373.1 RP11-650L12.4 4.57 8.24e-06 0.00466 0.35 0.3 Sudden cardiac arrest; chr15:78526933 chr15:78537681~78538946:+ CESC cis rs875971 0.862 rs7809814 ENSG00000237310.1 GS1-124K5.4 -4.57 8.25e-06 0.00466 -0.28 -0.3 Aortic root size; chr7:66150410 chr7:66493706~66495474:+ CESC cis rs875971 1 rs1544549 ENSG00000232559.3 GS1-124K5.12 -4.57 8.25e-06 0.00466 -0.33 -0.3 Aortic root size; chr7:66625676 chr7:66554588~66576923:- CESC cis rs7615952 0.576 rs2276727 ENSG00000250012.1 RP11-124N2.1 -4.57 8.26e-06 0.00467 -0.33 -0.3 Blood pressure (smoking interaction); chr3:126107400 chr3:126084220~126095349:+ CESC cis rs73086581 0.838 rs41398349 ENSG00000229539.1 RP11-119B16.2 -4.57 8.26e-06 0.00467 -0.45 -0.3 Response to antidepressants in depression; chr20:4043792 chr20:3888239~3888868:- CESC cis rs8031584 1 rs1474380 ENSG00000260382.1 RP11-540B6.2 4.57 8.26e-06 0.00467 0.41 0.3 Huntington's disease progression; chr15:30977032 chr15:30882267~30883231:- CESC cis rs8031584 0.918 rs34095794 ENSG00000260382.1 RP11-540B6.2 4.57 8.26e-06 0.00467 0.41 0.3 Huntington's disease progression; chr15:30977488 chr15:30882267~30883231:- CESC cis rs9322193 0.923 rs17745062 ENSG00000268592.3 RAET1E-AS1 4.57 8.27e-06 0.00467 0.38 0.3 Lung cancer; chr6:149721079 chr6:149863494~149919507:+ CESC cis rs10246939 0.505 rs9640203 ENSG00000228775.6 WEE2-AS1 4.57 8.27e-06 0.00467 0.36 0.3 Bitter taste perception; chr7:141844295 chr7:141704338~141738346:- CESC cis rs11089937 0.929 rs5757155 ENSG00000211639.2 IGLV4-60 4.57 8.27e-06 0.00467 0.26 0.3 Periodontitis (PAL4Q3); chr22:22165378 chr22:22162199~22162681:+ CESC cis rs5769707 0.521 rs7285764 ENSG00000188511.11 C22orf34 4.57 8.27e-06 0.00468 0.34 0.3 Monocyte percentage of white cells;Monocyte count; chr22:49664913 chr22:49414524~49657542:- CESC cis rs5769707 0.521 rs9616715 ENSG00000188511.11 C22orf34 4.57 8.27e-06 0.00468 0.34 0.3 Monocyte percentage of white cells;Monocyte count; chr22:49664934 chr22:49414524~49657542:- CESC cis rs5769707 0.521 rs6009805 ENSG00000188511.11 C22orf34 4.57 8.27e-06 0.00468 0.34 0.3 Monocyte percentage of white cells;Monocyte count; chr22:49665067 chr22:49414524~49657542:- CESC cis rs5769707 0.521 rs6009807 ENSG00000188511.11 C22orf34 4.57 8.27e-06 0.00468 0.34 0.3 Monocyte percentage of white cells;Monocyte count; chr22:49665274 chr22:49414524~49657542:- CESC cis rs1538970 0.851 rs2055145 ENSG00000280836.1 AL355480.1 -4.57 8.28e-06 0.00468 -0.37 -0.3 Platelet count; chr1:45460823 chr1:45581219~45581321:- CESC cis rs875971 0.862 rs6460282 ENSG00000232559.3 GS1-124K5.12 -4.57 8.29e-06 0.00468 -0.33 -0.3 Aortic root size; chr7:66226259 chr7:66554588~66576923:- CESC cis rs7829975 0.871 rs7829826 ENSG00000253893.2 FAM85B 4.57 8.29e-06 0.00468 0.36 0.3 Mood instability; chr8:8720610 chr8:8167819~8226614:- CESC cis rs7873102 0.654 rs56884355 ENSG00000230188.1 RP11-405L18.4 4.57 8.29e-06 0.00468 0.38 0.3 Brain structure; chr9:38004862 chr9:37490421~37490893:- CESC cis rs1799949 1 rs11653231 ENSG00000267681.1 CTD-3199J23.6 -4.57 8.3e-06 0.00469 -0.39 -0.3 Menopause (age at onset); chr17:43179443 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs1399323 ENSG00000267681.1 CTD-3199J23.6 -4.57 8.3e-06 0.00469 -0.39 -0.3 Menopause (age at onset); chr17:43180313 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs35954893 ENSG00000267681.1 CTD-3199J23.6 -4.57 8.3e-06 0.00469 -0.39 -0.3 Menopause (age at onset); chr17:43181769 chr17:43144956~43145255:+ CESC cis rs1799949 0.93 rs4445938 ENSG00000267681.1 CTD-3199J23.6 -4.57 8.3e-06 0.00469 -0.39 -0.3 Menopause (age at onset); chr17:43185883 chr17:43144956~43145255:+ CESC cis rs11638352 0.661 rs2615286 ENSG00000259479.5 SORD2P -4.57 8.3e-06 0.00469 -0.43 -0.3 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44124870 chr15:44826371~44884694:- CESC cis rs950880 0.71 rs2270298 ENSG00000234389.1 AC007278.3 -4.57 8.3e-06 0.00469 -0.32 -0.3 Serum protein levels (sST2); chr2:102375619 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs17027037 ENSG00000234389.1 AC007278.3 -4.57 8.3e-06 0.00469 -0.32 -0.3 Serum protein levels (sST2); chr2:102378424 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs2080289 ENSG00000234389.1 AC007278.3 -4.57 8.3e-06 0.00469 -0.32 -0.3 Serum protein levels (sST2); chr2:102378560 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs3821203 ENSG00000234389.1 AC007278.3 -4.57 8.3e-06 0.00469 -0.32 -0.3 Serum protein levels (sST2); chr2:102380412 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs3771162 ENSG00000234389.1 AC007278.3 -4.57 8.3e-06 0.00469 -0.32 -0.3 Serum protein levels (sST2); chr2:102380714 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs11465633 ENSG00000234389.1 AC007278.3 -4.57 8.3e-06 0.00469 -0.32 -0.3 Serum protein levels (sST2); chr2:102381273 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs1035130 ENSG00000234389.1 AC007278.3 -4.57 8.3e-06 0.00469 -0.32 -0.3 Serum protein levels (sST2); chr2:102384942 chr2:102438713~102440475:+ CESC cis rs11155671 0.53 rs2342769 ENSG00000223701.3 RAET1E-AS1 4.57 8.31e-06 0.00469 0.32 0.3 Testicular germ cell tumor; chr6:149895371 chr6:149884431~149919508:+ CESC cis rs74394007 0.92 rs439295 ENSG00000244515.1 KRT18P34 4.57 8.32e-06 0.0047 0.5 0.3 Total body bone mineral density; chr3:156854666 chr3:157162663~157163932:- CESC cis rs74394007 0.92 rs7639514 ENSG00000244515.1 KRT18P34 4.57 8.32e-06 0.0047 0.5 0.3 Total body bone mineral density; chr3:156858278 chr3:157162663~157163932:- CESC cis rs75422866 0.51 rs73105803 ENSG00000257433.4 RP1-197B17.3 4.57 8.32e-06 0.0047 0.7 0.3 Pneumonia; chr12:47722135 chr12:47706085~47742294:+ CESC cis rs75422866 0.51 rs73105812 ENSG00000257433.4 RP1-197B17.3 4.57 8.32e-06 0.0047 0.7 0.3 Pneumonia; chr12:47724404 chr12:47706085~47742294:+ CESC cis rs75422866 0.51 rs74733564 ENSG00000257433.4 RP1-197B17.3 4.57 8.32e-06 0.0047 0.7 0.3 Pneumonia; chr12:47724644 chr12:47706085~47742294:+ CESC cis rs75422866 0.51 rs73105814 ENSG00000257433.4 RP1-197B17.3 4.57 8.32e-06 0.0047 0.7 0.3 Pneumonia; chr12:47725817 chr12:47706085~47742294:+ CESC cis rs12908161 1 rs12905057 ENSG00000225151.9 GOLGA2P7 -4.57 8.33e-06 0.0047 -0.41 -0.3 Schizophrenia; chr15:84667534 chr15:84199311~84230136:- CESC cis rs860295 0.841 rs7556102 ENSG00000225855.5 RUSC1-AS1 -4.57 8.34e-06 0.00471 -0.24 -0.3 Body mass index; chr1:155398412 chr1:155316863~155324176:- CESC cis rs10829156 0.738 rs4748502 ENSG00000240291.1 RP11-499P20.2 4.57 8.34e-06 0.00471 0.32 0.3 Sudden cardiac arrest; chr10:18647032 chr10:18513115~18545651:- CESC cis rs2732480 0.5 rs1387257 ENSG00000258273.1 RP11-370I10.4 -4.56 8.35e-06 0.00471 -0.37 -0.3 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48242883 chr12:48333755~48333901:- CESC cis rs2243480 0.666 rs1880311 ENSG00000232559.3 GS1-124K5.12 -4.56 8.35e-06 0.00471 -0.5 -0.3 Diabetic kidney disease; chr7:65811765 chr7:66554588~66576923:- CESC cis rs7429990 0.965 rs9846062 ENSG00000229759.1 MRPS18AP1 4.56 8.37e-06 0.00472 0.31 0.3 Educational attainment (years of education); chr3:47957476 chr3:48256350~48256938:- CESC cis rs2739330 0.791 rs4822458 ENSG00000228039.3 KB-1125A3.10 4.56 8.37e-06 0.00473 0.36 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23963780~23964374:+ CESC cis rs6001482 0.778 rs1012819 ENSG00000236850.4 BMS1P20 -4.56 8.37e-06 0.00473 -0.31 -0.3 Diastolic blood pressure; chr22:22238997 chr22:22303224~22322847:+ CESC cis rs11159086 0.793 rs10139122 ENSG00000259005.1 RP3-449M8.6 4.56 8.39e-06 0.00473 0.42 0.3 Advanced glycation end-product levels; chr14:74492353 chr14:74474007~74474864:- CESC cis rs73086581 1 rs73086505 ENSG00000229539.1 RP11-119B16.2 4.56 8.39e-06 0.00473 0.48 0.3 Response to antidepressants in depression; chr20:3940924 chr20:3888239~3888868:- CESC cis rs73086581 1 rs73086508 ENSG00000229539.1 RP11-119B16.2 4.56 8.39e-06 0.00473 0.48 0.3 Response to antidepressants in depression; chr20:3941068 chr20:3888239~3888868:- CESC cis rs73086581 1 rs73086510 ENSG00000229539.1 RP11-119B16.2 4.56 8.39e-06 0.00473 0.48 0.3 Response to antidepressants in depression; chr20:3941484 chr20:3888239~3888868:- CESC cis rs73086581 1 rs17286768 ENSG00000229539.1 RP11-119B16.2 4.56 8.39e-06 0.00473 0.48 0.3 Response to antidepressants in depression; chr20:3943922 chr20:3888239~3888868:- CESC cis rs73086581 1 rs17214621 ENSG00000229539.1 RP11-119B16.2 4.56 8.39e-06 0.00473 0.48 0.3 Response to antidepressants in depression; chr20:3945277 chr20:3888239~3888868:- CESC cis rs8177876 0.642 rs10514513 ENSG00000261838.4 RP11-303E16.6 4.56 8.39e-06 0.00473 0.59 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080578 chr16:81069854~81076598:+ CESC cis rs875971 0.545 rs2420456 ENSG00000237310.1 GS1-124K5.4 4.56 8.39e-06 0.00473 0.31 0.3 Aortic root size; chr7:66280619 chr7:66493706~66495474:+ CESC cis rs9487094 0.67 rs10782163 ENSG00000260273.1 RP11-425D10.10 4.56 8.4e-06 0.00474 0.38 0.3 Height; chr6:109533040 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs10457195 ENSG00000260273.1 RP11-425D10.10 4.56 8.4e-06 0.00474 0.38 0.3 Height; chr6:109534269 chr6:109382795~109383666:+ CESC cis rs2015599 0.54 rs12301475 ENSG00000275476.1 RP11-996F15.4 4.56 8.4e-06 0.00474 0.34 0.3 Platelet count;Mean platelet volume; chr12:29253144 chr12:29277397~29277882:- CESC cis rs7873102 0.617 rs4323560 ENSG00000230188.1 RP11-405L18.4 4.56 8.41e-06 0.00474 0.38 0.3 Brain structure; chr9:38003806 chr9:37490421~37490893:- CESC cis rs10754283 0.967 rs7523046 ENSG00000231613.1 RP5-943J3.1 4.56 8.41e-06 0.00474 0.37 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89643940 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs7523518 ENSG00000231613.1 RP5-943J3.1 4.56 8.41e-06 0.00474 0.37 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89644451 chr1:89788914~89790492:+ CESC cis rs9876781 0.559 rs7611415 ENSG00000229759.1 MRPS18AP1 4.56 8.42e-06 0.00474 0.3 0.3 Longevity; chr3:48363659 chr3:48256350~48256938:- CESC cis rs897984 0.683 rs12447534 ENSG00000260911.2 RP11-196G11.2 -4.56 8.42e-06 0.00474 -0.3 -0.3 Dementia with Lewy bodies; chr16:30792936 chr16:31043150~31049868:+ CESC cis rs8100891 0.537 rs10410770 ENSG00000267213.4 AC007773.2 -4.56 8.42e-06 0.00475 -0.47 -0.3 Neuroticism; chr19:32411498 chr19:32390050~32405560:- CESC cis rs1023500 0.505 rs134887 ENSG00000273366.1 CTA-989H11.1 -4.56 8.42e-06 0.00475 -0.37 -0.3 Schizophrenia; chr22:42278233 chr22:42278188~42278846:+ CESC cis rs7560272 0.529 rs2421672 ENSG00000273245.1 RP11-434P11.2 -4.56 8.43e-06 0.00475 -0.37 -0.3 Schizophrenia; chr2:73728413 chr2:73750256~73750786:- CESC cis rs2058059 0.636 rs3015906 ENSG00000205578.5 POM121B -4.56 8.44e-06 0.00476 -0.36 -0.3 Subcutaneous adipose tissue; chr7:72670552 chr7:73293497~73301161:+ CESC cis rs10129255 0.642 rs11624918 ENSG00000211974.3 IGHV2-70 4.56 8.45e-06 0.00476 0.3 0.3 Kawasaki disease; chr14:106664672 chr14:106723574~106724093:- CESC cis rs2439831 0.85 rs7168158 ENSG00000275601.1 AC011330.13 -4.56 8.45e-06 0.00476 -0.46 -0.3 Lung cancer in ever smokers; chr15:43758178 chr15:43642389~43643023:- CESC cis rs8059260 0.736 rs80207136 ENSG00000274038.1 RP11-66H6.4 -4.56 8.45e-06 0.00476 -0.49 -0.3 Alcohol consumption over the past year; chr16:11015480 chr16:11056556~11057034:+ CESC cis rs7188445 0.932 rs56738967 ENSG00000261390.4 RP11-345M22.2 -4.56 8.47e-06 0.00477 -0.39 -0.3 Urate levels; chr16:79706644 chr16:79715232~79770563:- CESC cis rs9309473 1 rs9653557 ENSG00000163016.8 ALMS1P 4.56 8.48e-06 0.00477 0.39 0.3 Metabolite levels; chr2:73568835 chr2:73644919~73685576:+ CESC cis rs1538970 1 rs4660852 ENSG00000280836.1 AL355480.1 4.56 8.5e-06 0.00479 0.35 0.3 Platelet count; chr1:45383259 chr1:45581219~45581321:- CESC cis rs7873102 0.63 rs16934708 ENSG00000230188.1 RP11-405L18.4 4.56 8.51e-06 0.00479 0.37 0.3 Brain structure; chr9:38000650 chr9:37490421~37490893:- CESC cis rs34779708 0.649 rs34421369 ENSG00000230534.5 RP11-297A16.2 4.56 8.53e-06 0.0048 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35261347 chr10:35098006~35127020:- CESC cis rs34779708 0.677 rs112355105 ENSG00000230534.5 RP11-297A16.2 4.56 8.53e-06 0.0048 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35261366 chr10:35098006~35127020:- CESC cis rs34779708 0.706 rs36027395 ENSG00000230534.5 RP11-297A16.2 4.56 8.53e-06 0.0048 0.42 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35261395 chr10:35098006~35127020:- CESC cis rs12439619 0.846 rs28697264 ENSG00000276710.3 CSPG4P8 -4.56 8.53e-06 0.0048 -0.43 -0.3 Intelligence (multi-trait analysis); chr15:82265559 chr15:82459472~82477258:+ CESC cis rs10754283 0.967 rs7546518 ENSG00000231613.1 RP5-943J3.1 4.56 8.53e-06 0.0048 0.37 0.3 Amyotrophic lateral sclerosis (sporadic); chr1:89644397 chr1:89788914~89790492:+ CESC cis rs9640161 0.789 rs1464751 ENSG00000261305.1 RP4-584D14.7 4.56 8.54e-06 0.00481 0.39 0.3 Blood protein levels;Circulating chemerin levels; chr7:150324193 chr7:150341771~150342607:+ CESC cis rs9322193 0.962 rs12175575 ENSG00000216906.2 RP11-350J20.9 4.56 8.54e-06 0.00481 0.33 0.3 Lung cancer; chr6:149763351 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs4869966 ENSG00000216906.2 RP11-350J20.9 4.56 8.54e-06 0.00481 0.33 0.3 Lung cancer; chr6:149763714 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs1112730 ENSG00000216906.2 RP11-350J20.9 4.56 8.54e-06 0.00481 0.33 0.3 Lung cancer; chr6:149766383 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs1112729 ENSG00000216906.2 RP11-350J20.9 4.56 8.54e-06 0.00481 0.33 0.3 Lung cancer; chr6:149766491 chr6:149904243~149906418:+ CESC cis rs9322193 0.962 rs10452626 ENSG00000216906.2 RP11-350J20.9 4.56 8.54e-06 0.00481 0.33 0.3 Lung cancer; chr6:149767481 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs62441303 ENSG00000216906.2 RP11-350J20.9 4.56 8.54e-06 0.00481 0.33 0.3 Lung cancer; chr6:149767547 chr6:149904243~149906418:+ CESC cis rs7560272 0.538 rs4852976 ENSG00000273245.1 RP11-434P11.2 -4.56 8.55e-06 0.00481 -0.36 -0.3 Schizophrenia; chr2:73709195 chr2:73750256~73750786:- CESC cis rs17507216 0.718 rs4779034 ENSG00000278603.1 RP13-608F4.5 4.56 8.55e-06 0.00481 0.45 0.3 Excessive daytime sleepiness; chr15:82576799 chr15:82472203~82472426:+ CESC cis rs2439831 0.85 rs16965120 ENSG00000275601.1 AC011330.13 -4.56 8.56e-06 0.00481 -0.45 -0.3 Lung cancer in ever smokers; chr15:43808144 chr15:43642389~43643023:- CESC cis rs9532669 0.926 rs11147823 ENSG00000176268.5 CYCSP34 -4.56 8.56e-06 0.00482 -0.3 -0.3 Cervical cancer; chr13:40878138 chr13:40863599~40863902:- CESC cis rs62103177 0.564 rs7228971 ENSG00000261126.6 RP11-795F19.1 -4.56 8.57e-06 0.00482 -0.41 -0.3 Opioid sensitivity; chr18:79978025 chr18:80046900~80095482:+ CESC cis rs7809950 1 rs3801948 ENSG00000238832.1 snoU109 -4.56 8.57e-06 0.00482 -0.35 -0.3 Coronary artery disease; chr7:107598002 chr7:107603363~107603507:+ CESC cis rs7811142 0.943 rs67196635 ENSG00000078319.8 PMS2P1 -4.56 8.57e-06 0.00482 -0.47 -0.3 Platelet count; chr7:100427941 chr7:100320992~100341908:- CESC cis rs7811142 1 rs6962151 ENSG00000078319.8 PMS2P1 -4.56 8.57e-06 0.00482 -0.47 -0.3 Platelet count; chr7:100430861 chr7:100320992~100341908:- CESC cis rs7811142 0.943 rs67483801 ENSG00000078319.8 PMS2P1 -4.56 8.57e-06 0.00482 -0.47 -0.3 Platelet count; chr7:100434135 chr7:100320992~100341908:- CESC cis rs7811142 1 rs11761784 ENSG00000078319.8 PMS2P1 -4.56 8.57e-06 0.00482 -0.47 -0.3 Platelet count; chr7:100442347 chr7:100320992~100341908:- CESC cis rs11159086 0.793 rs10136668 ENSG00000270000.1 RP3-449M8.9 4.56 8.58e-06 0.00482 0.47 0.3 Advanced glycation end-product levels; chr14:74492183 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs10139029 ENSG00000270000.1 RP3-449M8.9 4.56 8.58e-06 0.00482 0.47 0.3 Advanced glycation end-product levels; chr14:74492284 chr14:74471930~74472360:- CESC cis rs950880 0.677 rs56224165 ENSG00000234389.1 AC007278.3 -4.56 8.59e-06 0.00483 -0.34 -0.29 Serum protein levels (sST2); chr2:102308763 chr2:102438713~102440475:+ CESC cis rs3892630 0.588 rs2112917 ENSG00000267475.1 CTD-2538C1.2 -4.56 8.59e-06 0.00483 -0.42 -0.29 Red blood cell traits; chr19:32826637 chr19:32687089~32691750:- CESC cis rs7208859 0.623 rs11657990 ENSG00000266490.1 CTD-2349P21.9 4.56 8.59e-06 0.00483 0.45 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30792372~30792833:+ CESC cis rs4660456 0.504 rs542214 ENSG00000237899.1 RP4-739H11.3 4.56 8.59e-06 0.00483 0.41 0.29 Platelet count; chr1:40632806 chr1:40669089~40687588:- CESC cis rs7572733 0.555 rs6434953 ENSG00000222017.1 AC011997.1 4.56 8.6e-06 0.00483 0.37 0.29 Dermatomyositis; chr2:198064969 chr2:197693106~197774823:+ CESC cis rs7572733 0.555 rs6745726 ENSG00000222017.1 AC011997.1 4.56 8.6e-06 0.00483 0.37 0.29 Dermatomyositis; chr2:198069356 chr2:197693106~197774823:+ CESC cis rs2058059 0.636 rs2961005 ENSG00000205578.5 POM121B 4.56 8.61e-06 0.00484 0.35 0.29 Subcutaneous adipose tissue; chr7:72675517 chr7:73293497~73301161:+ CESC cis rs7560272 0.538 rs35767294 ENSG00000273245.1 RP11-434P11.2 -4.56 8.62e-06 0.00484 -0.37 -0.29 Schizophrenia; chr2:73695707 chr2:73750256~73750786:- CESC cis rs2948294 0.588 rs12544596 ENSG00000253893.2 FAM85B -4.56 8.62e-06 0.00484 -0.39 -0.29 Red cell distribution width; chr8:8258824 chr8:8167819~8226614:- CESC cis rs72772090 0.539 rs11741100 ENSG00000248734.2 CTD-2260A17.1 -4.56 8.63e-06 0.00485 -0.46 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777541 chr5:96784777~96785999:+ CESC cis rs748404 0.697 rs579651 ENSG00000205771.5 CATSPER2P1 -4.56 8.64e-06 0.00485 -0.36 -0.29 Lung cancer; chr15:43266178 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs473016 ENSG00000205771.5 CATSPER2P1 -4.56 8.64e-06 0.00485 -0.36 -0.29 Lung cancer; chr15:43266625 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs531910 ENSG00000205771.5 CATSPER2P1 -4.56 8.64e-06 0.00485 -0.36 -0.29 Lung cancer; chr15:43268409 chr15:43726918~43747094:- CESC cis rs2732480 0.5 rs2450989 ENSG00000240399.1 RP1-228P16.1 -4.56 8.64e-06 0.00485 -0.34 -0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48259625 chr12:48054813~48055591:- CESC cis rs17818399 0.926 rs35350086 ENSG00000279254.1 RP11-536C12.1 -4.56 8.64e-06 0.00485 -0.38 -0.29 Height; chr2:46606897 chr2:46668870~46670778:+ CESC cis rs763121 0.853 rs2284073 ENSG00000273076.1 RP3-508I15.22 4.56 8.64e-06 0.00485 0.33 0.29 Menopause (age at onset); chr22:38709943 chr22:38743495~38743910:+ CESC cis rs7873102 0.617 rs2381772 ENSG00000230188.1 RP11-405L18.4 4.56 8.64e-06 0.00486 0.38 0.29 Brain structure; chr9:38003660 chr9:37490421~37490893:- CESC cis rs7811142 1 rs4472444 ENSG00000078319.8 PMS2P1 -4.56 8.65e-06 0.00486 -0.47 -0.29 Platelet count; chr7:100473135 chr7:100320992~100341908:- CESC cis rs7811142 1 rs7809801 ENSG00000078319.8 PMS2P1 -4.56 8.65e-06 0.00486 -0.47 -0.29 Platelet count; chr7:100474408 chr7:100320992~100341908:- CESC cis rs950169 0.58 rs2271431 ENSG00000225151.9 GOLGA2P7 -4.56 8.66e-06 0.00486 -0.4 -0.29 Schizophrenia; chr15:84646233 chr15:84199311~84230136:- CESC cis rs3762637 1 rs9843165 ENSG00000272758.4 RP11-299J3.8 -4.56 8.67e-06 0.00487 -0.4 -0.29 LDL cholesterol levels; chr3:122412264 chr3:122416207~122443180:+ CESC cis rs875971 0.545 rs1547529 ENSG00000237310.1 GS1-124K5.4 4.56 8.67e-06 0.00487 0.3 0.29 Aortic root size; chr7:66258859 chr7:66493706~66495474:+ CESC cis rs2243480 1 rs160643 ENSG00000232559.3 GS1-124K5.12 4.56 8.67e-06 0.00487 0.48 0.29 Diabetic kidney disease; chr7:66093235 chr7:66554588~66576923:- CESC cis rs9660180 0.967 rs12044597 ENSG00000268575.1 RP1-283E3.8 -4.56 8.67e-06 0.00487 -0.29 -0.29 Body mass index; chr1:1777362 chr1:1702736~1737688:- CESC cis rs9322193 0.962 rs35031906 ENSG00000216906.2 RP11-350J20.9 4.56 8.68e-06 0.00487 0.33 0.29 Lung cancer; chr6:149677438 chr6:149904243~149906418:+ CESC cis rs9907295 0.688 rs4796135 ENSG00000271013.1 AC015849.15 -4.56 8.68e-06 0.00487 -0.37 -0.29 Fibroblast growth factor basic levels; chr17:35924236 chr17:35912635~35918010:- CESC cis rs9907295 0.688 rs4796136 ENSG00000271013.1 AC015849.15 -4.56 8.68e-06 0.00487 -0.37 -0.29 Fibroblast growth factor basic levels; chr17:35924397 chr17:35912635~35918010:- CESC cis rs9907295 0.688 rs4796137 ENSG00000271013.1 AC015849.15 -4.56 8.68e-06 0.00487 -0.37 -0.29 Fibroblast growth factor basic levels; chr17:35924448 chr17:35912635~35918010:- CESC cis rs4722166 0.695 rs7793125 ENSG00000179428.2 AC073072.5 -4.56 8.68e-06 0.00487 -0.38 -0.29 Lung cancer; chr7:22769541 chr7:22725395~22727620:- CESC cis rs6740322 0.895 rs6544643 ENSG00000234936.1 AC010883.5 4.56 8.69e-06 0.00488 0.32 0.29 Coronary artery disease; chr2:43332933 chr2:43229573~43233394:+ CESC cis rs916888 0.773 rs199535 ENSG00000261575.2 RP11-259G18.1 4.56 8.7e-06 0.00488 0.42 0.29 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46267037~46268694:+ CESC cis rs9918079 0.58 rs13120905 ENSG00000273133.1 RP11-799M12.2 4.56 8.71e-06 0.00488 0.38 0.29 Obesity-related traits; chr4:15610665 chr4:15563698~15564253:- CESC cis rs9640161 0.75 rs3800780 ENSG00000261305.1 RP4-584D14.7 4.56 8.71e-06 0.00488 0.42 0.29 Blood protein levels;Circulating chemerin levels; chr7:150330195 chr7:150341771~150342607:+ CESC cis rs5769707 0.604 rs1018814 ENSG00000235111.1 RP1-29C18.8 -4.56 8.71e-06 0.00489 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49643252 chr22:49612657~49615716:- CESC cis rs761746 0.577 rs131245 ENSG00000236132.1 CTA-440B3.1 -4.56 8.71e-06 0.00489 -0.39 -0.29 Intelligence; chr22:31730777 chr22:31816379~31817491:- CESC cis rs5769707 0.967 rs2051626 ENSG00000235111.1 RP1-29C18.8 -4.56 8.71e-06 0.00489 -0.29 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49615325 chr22:49612657~49615716:- CESC cis rs4819052 0.885 rs9980676 ENSG00000223768.1 LINC00205 -4.55 8.72e-06 0.00489 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45245515 chr21:45293285~45297354:+ CESC cis rs12468226 1 rs16824599 ENSG00000273456.1 RP11-686O6.2 4.55 8.72e-06 0.00489 0.39 0.29 Urate levels; chr2:202358243 chr2:202374932~202375604:- CESC cis rs860295 0.557 rs11264372 ENSG00000225855.5 RUSC1-AS1 4.55 8.73e-06 0.0049 0.26 0.29 Body mass index; chr1:155443139 chr1:155316863~155324176:- CESC cis rs9918079 0.56 rs10008376 ENSG00000273133.1 RP11-799M12.2 4.55 8.73e-06 0.0049 0.37 0.29 Obesity-related traits; chr4:15622332 chr4:15563698~15564253:- CESC cis rs7005380 0.733 rs10107579 ENSG00000279347.1 RP11-85I17.2 4.55 8.74e-06 0.0049 0.26 0.29 Interstitial lung disease; chr8:119922329 chr8:119838736~119840385:- CESC cis rs6686842 1 rs213748 ENSG00000235358.1 RP11-399E6.1 -4.55 8.74e-06 0.0049 -0.36 -0.29 Height; chr1:41163058 chr1:41242373~41284861:+ CESC cis rs6686842 1 rs213747 ENSG00000235358.1 RP11-399E6.1 -4.55 8.74e-06 0.0049 -0.36 -0.29 Height; chr1:41163066 chr1:41242373~41284861:+ CESC cis rs6686842 1 rs2363803 ENSG00000235358.1 RP11-399E6.1 4.55 8.74e-06 0.0049 0.36 0.29 Height; chr1:41171857 chr1:41242373~41284861:+ CESC cis rs6686842 0.896 rs11209725 ENSG00000235358.1 RP11-399E6.1 4.55 8.74e-06 0.0049 0.36 0.29 Height; chr1:41228345 chr1:41242373~41284861:+ CESC cis rs4319547 0.697 rs7974262 ENSG00000275265.1 RP11-15J22.8 4.55 8.75e-06 0.0049 0.41 0.29 Body mass index; chr12:122411838 chr12:122501187~122501641:+ CESC cis rs875971 1 rs2420820 ENSG00000232559.3 GS1-124K5.12 -4.55 8.75e-06 0.00491 -0.33 -0.29 Aortic root size; chr7:66626920 chr7:66554588~66576923:- CESC cis rs73086581 0.947 rs56123574 ENSG00000229539.1 RP11-119B16.2 4.55 8.75e-06 0.00491 0.5 0.29 Response to antidepressants in depression; chr20:3897434 chr20:3888239~3888868:- CESC cis rs73086581 0.947 rs73084531 ENSG00000229539.1 RP11-119B16.2 4.55 8.75e-06 0.00491 0.5 0.29 Response to antidepressants in depression; chr20:3897782 chr20:3888239~3888868:- CESC cis rs6893782 0.83 rs274549 ENSG00000233006.5 AC034220.3 4.55 8.76e-06 0.00491 0.38 0.29 Acylcarnitine levels; chr5:132393426 chr5:132311285~132369916:- CESC cis rs453301 0.682 rs2929308 ENSG00000253893.2 FAM85B 4.55 8.76e-06 0.00491 0.36 0.29 Joint mobility (Beighton score); chr8:9226611 chr8:8167819~8226614:- CESC cis rs8020095 0.571 rs10142059 ENSG00000258561.1 RP11-72M17.1 -4.55 8.76e-06 0.00491 -0.43 -0.29 Depression (quantitative trait); chr14:67015912 chr14:66212810~66509394:- CESC cis rs7572733 0.555 rs11903129 ENSG00000222017.1 AC011997.1 4.55 8.77e-06 0.00491 0.37 0.29 Dermatomyositis; chr2:198053867 chr2:197693106~197774823:+ CESC cis rs763121 0.813 rs2179143 ENSG00000273076.1 RP3-508I15.22 4.55 8.77e-06 0.00492 0.33 0.29 Menopause (age at onset); chr22:38641979 chr22:38743495~38743910:+ CESC cis rs7189233 0.531 rs8043918 ENSG00000279344.1 RP11-44F14.7 4.55 8.79e-06 0.00492 0.28 0.29 Intelligence (multi-trait analysis); chr16:53479121 chr16:53478957~53481550:- CESC cis rs7587476 0.784 rs13026390 ENSG00000229267.2 AC072062.1 4.55 8.8e-06 0.00493 0.36 0.29 Neuroblastoma; chr2:214822351 chr2:214810229~214963274:+ CESC cis rs9640161 0.711 rs3800781 ENSG00000261305.1 RP4-584D14.7 4.55 8.8e-06 0.00493 0.42 0.29 Blood protein levels;Circulating chemerin levels; chr7:150330235 chr7:150341771~150342607:+ CESC cis rs28475163 0.958 rs7395116 ENSG00000254739.1 RP13-46H24.1 -4.55 8.81e-06 0.00493 -0.38 -0.29 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr11:324880 chr11:528907~529659:+ CESC cis rs10419113 0.641 rs61333077 ENSG00000270804.1 CTD-2583A14.11 4.55 8.81e-06 0.00493 0.3 0.29 Pediatric bone mineral density (spine); chr19:57766589 chr19:57867885~57868834:+ CESC cis rs2058059 0.636 rs2960968 ENSG00000205578.5 POM121B -4.55 8.81e-06 0.00494 -0.36 -0.29 Subcutaneous adipose tissue; chr7:72702378 chr7:73293497~73301161:+ CESC cis rs4072705 0.615 rs6478666 ENSG00000224020.1 MIR181A2HG 4.55 8.83e-06 0.00494 0.37 0.29 Menarche (age at onset); chr9:124487064 chr9:124658467~124698631:+ CESC cis rs9918079 0.56 rs4557256 ENSG00000273133.1 RP11-799M12.2 -4.55 8.84e-06 0.00495 -0.38 -0.29 Obesity-related traits; chr4:15625024 chr4:15563698~15564253:- CESC cis rs853679 0.517 rs4713135 ENSG00000219392.1 RP1-265C24.5 -4.55 8.84e-06 0.00495 -0.39 -0.29 Depression; chr6:28071808 chr6:28115628~28116551:+ CESC cis rs1075265 0.589 rs2253760 ENSG00000233266.1 HMGB1P31 4.55 8.85e-06 0.00495 0.37 0.29 Chronotype;Morning vs. evening chronotype; chr2:53806851 chr2:54051334~54051760:+ CESC cis rs10411161 0.58 rs12151288 ENSG00000267905.4 CTD-2616J11.16 4.55 8.85e-06 0.00495 0.38 0.29 Breast cancer; chr19:51878299 chr19:51340695~51344117:+ CESC cis rs7208859 0.573 rs7214313 ENSG00000266490.1 CTD-2349P21.9 4.55 8.86e-06 0.00496 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30792372~30792833:+ CESC cis rs761746 0.582 rs7287054 ENSG00000236132.1 CTA-440B3.1 -4.55 8.87e-06 0.00496 -0.35 -0.29 Intelligence; chr22:31844735 chr22:31816379~31817491:- CESC cis rs2255336 0.81 rs7959328 ENSG00000245648.1 RP11-277P12.20 4.55 8.87e-06 0.00496 0.51 0.29 Blood protein levels; chr12:10361467 chr12:10363769~10398506:+ CESC cis rs34375054 0.525 rs10846829 ENSG00000279233.1 RP11-158L12.4 4.55 8.87e-06 0.00497 0.3 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125110512 chr12:125138245~125141711:+ CESC cis rs61160187 0.582 rs1460961 ENSG00000215032.2 GNL3LP1 4.55 8.87e-06 0.00497 0.34 0.29 Educational attainment (years of education);Educational attainment (college completion); chr5:61116005 chr5:60891935~60893577:- CESC cis rs2255336 0.938 rs2617169 ENSG00000245648.1 RP11-277P12.20 4.55 8.89e-06 0.00497 0.45 0.29 Blood protein levels; chr12:10408225 chr12:10363769~10398506:+ CESC cis rs2255336 0.938 rs2617172 ENSG00000245648.1 RP11-277P12.20 4.55 8.89e-06 0.00497 0.45 0.29 Blood protein levels; chr12:10409887 chr12:10363769~10398506:+ CESC cis rs700651 0.624 rs12105927 ENSG00000222017.1 AC011997.1 4.55 8.89e-06 0.00497 0.37 0.29 Intracranial aneurysm; chr2:198072534 chr2:197693106~197774823:+ CESC cis rs6142102 0.651 rs6059692 ENSG00000276073.1 RP5-1125A11.7 4.55 8.9e-06 0.00498 0.28 0.29 Skin pigmentation; chr20:34158397 chr20:33985617~33988989:- CESC cis rs6686842 1 rs17571940 ENSG00000235358.1 RP11-399E6.1 -4.55 8.9e-06 0.00498 -0.36 -0.29 Height; chr1:41100519 chr1:41242373~41284861:+ CESC cis rs7873102 0.654 rs10814642 ENSG00000230188.1 RP11-405L18.4 4.55 8.91e-06 0.00498 0.38 0.29 Brain structure; chr9:38015040 chr9:37490421~37490893:- CESC cis rs7873102 0.608 rs3802412 ENSG00000230188.1 RP11-405L18.4 4.55 8.91e-06 0.00498 0.38 0.29 Brain structure; chr9:38015732 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10814643 ENSG00000230188.1 RP11-405L18.4 4.55 8.91e-06 0.00498 0.38 0.29 Brain structure; chr9:38018693 chr9:37490421~37490893:- CESC cis rs2243480 1 rs2961102 ENSG00000275400.1 RP4-756H11.5 4.55 8.92e-06 0.00499 0.49 0.29 Diabetic kidney disease; chr7:65959671 chr7:66553805~66554199:- CESC cis rs9309473 0.948 rs10199224 ENSG00000163016.8 ALMS1P 4.55 8.92e-06 0.00499 0.39 0.29 Metabolite levels; chr2:73534319 chr2:73644919~73685576:+ CESC cis rs8030379 0.967 rs7182563 ENSG00000230373.7 GOLGA6L5P -4.55 8.93e-06 0.00499 -0.29 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83879994 chr15:84507885~84516814:- CESC cis rs8030379 0.967 rs11629657 ENSG00000230373.7 GOLGA6L5P -4.55 8.93e-06 0.00499 -0.29 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83880228 chr15:84507885~84516814:- CESC cis rs8030379 0.967 rs7181926 ENSG00000230373.7 GOLGA6L5P -4.55 8.93e-06 0.00499 -0.29 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83880676 chr15:84507885~84516814:- CESC cis rs8030379 0.967 rs6603000 ENSG00000230373.7 GOLGA6L5P -4.55 8.93e-06 0.00499 -0.29 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83883142 chr15:84507885~84516814:- CESC cis rs9322193 0.962 rs7745915 ENSG00000216906.2 RP11-350J20.9 4.55 8.93e-06 0.00499 0.33 0.29 Lung cancer; chr6:149834111 chr6:149904243~149906418:+ CESC cis rs4819052 0.851 rs2838829 ENSG00000223768.1 LINC00205 -4.55 8.94e-06 0.005 -0.35 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45244125 chr21:45293285~45297354:+ CESC cis rs673078 0.607 rs884844 ENSG00000275759.1 RP11-131L12.3 -4.55 8.94e-06 0.005 -0.54 -0.29 Glucose homeostasis traits; chr12:118377033 chr12:118428281~118428870:+ CESC cis rs875971 0.571 rs160641 ENSG00000237310.1 GS1-124K5.4 -4.55 8.95e-06 0.005 -0.32 -0.29 Aortic root size; chr7:66112359 chr7:66493706~66495474:+ CESC cis rs10129255 0.913 rs10140943 ENSG00000211970.3 IGHV4-61 -4.55 8.95e-06 0.005 -0.24 -0.29 Kawasaki disease; chr14:106767441 chr14:106639119~106639657:- CESC cis rs1062177 0.855 rs6884630 ENSG00000253921.1 CTB-113P19.3 -4.55 8.96e-06 0.00501 -0.38 -0.29 Preschool internalizing problems; chr5:151889436 chr5:151753992~151767247:+ CESC cis rs801193 0.66 rs2659914 ENSG00000232559.3 GS1-124K5.12 4.55 8.96e-06 0.00501 0.32 0.29 Aortic root size; chr7:66691927 chr7:66554588~66576923:- CESC cis rs2243480 1 rs316307 ENSG00000228409.4 CCT6P1 4.55 8.98e-06 0.00502 0.44 0.29 Diabetic kidney disease; chr7:66105184 chr7:65751142~65763354:+ CESC cis rs34375054 0.66 rs58624919 ENSG00000279233.1 RP11-158L12.4 4.55 8.98e-06 0.00502 0.32 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125111912 chr12:125138245~125141711:+ CESC cis rs875971 0.545 rs4441996 ENSG00000236529.1 RP13-254B10.1 -4.55 9e-06 0.00502 -0.36 -0.29 Aortic root size; chr7:66123233 chr7:65840212~65840596:+ CESC cis rs751837 0.932 rs7160433 ENSG00000240624.1 RP11-45P15.2 -4.55 9.01e-06 0.00503 -0.45 -0.29 Large B-cell lymphoma; chr14:103020581 chr14:103282933~103283468:+ CESC cis rs17301013 0.507 rs7517516 ENSG00000227373.4 RP11-160H22.5 4.55 9.02e-06 0.00503 0.41 0.29 Systemic lupus erythematosus; chr1:174346187 chr1:174115300~174160004:- CESC cis rs55794721 0.509 rs2375313 ENSG00000261349.1 RP3-465N24.5 -4.55 9.03e-06 0.00504 -0.3 -0.29 Mean corpuscular volume;Plateletcrit; chr1:25421744 chr1:25266102~25267136:- CESC cis rs72772090 0.539 rs11747896 ENSG00000248734.2 CTD-2260A17.1 4.55 9.04e-06 0.00504 0.45 0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777693 chr5:96784777~96785999:+ CESC cis rs916888 0.821 rs70600 ENSG00000261575.2 RP11-259G18.1 4.55 9.04e-06 0.00504 0.45 0.29 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46267037~46268694:+ CESC cis rs2243480 0.901 rs73148097 ENSG00000275400.1 RP4-756H11.5 4.55 9.04e-06 0.00504 0.49 0.29 Diabetic kidney disease; chr7:65966800 chr7:66553805~66554199:- CESC cis rs2243480 1 rs35820085 ENSG00000275400.1 RP4-756H11.5 4.55 9.04e-06 0.00504 0.49 0.29 Diabetic kidney disease; chr7:65977771 chr7:66553805~66554199:- CESC cis rs2243480 1 rs906134 ENSG00000275400.1 RP4-756H11.5 4.55 9.04e-06 0.00504 0.49 0.29 Diabetic kidney disease; chr7:65979301 chr7:66553805~66554199:- CESC cis rs7560272 0.538 rs13006448 ENSG00000273245.1 RP11-434P11.2 -4.55 9.04e-06 0.00505 -0.37 -0.29 Schizophrenia; chr2:73697297 chr2:73750256~73750786:- CESC cis rs5756813 1 rs5756813 ENSG00000233360.4 Z83844.1 4.55 9.06e-06 0.00506 0.32 0.29 Optic cup area;Vertical cup-disc ratio; chr22:37779470 chr22:37641832~37658377:- CESC cis rs7809950 0.954 rs2520242 ENSG00000238832.1 snoU109 4.55 9.09e-06 0.00507 0.35 0.29 Coronary artery disease; chr7:107495875 chr7:107603363~107603507:+ CESC cis rs9847710 0.696 rs2244461 ENSG00000242142.1 SERBP1P3 4.55 9.1e-06 0.00507 0.35 0.29 Ulcerative colitis; chr3:53021826 chr3:53064283~53065091:- CESC cis rs42490 0.868 rs1605997 ENSG00000251136.7 RP11-37B2.1 4.55 9.1e-06 0.00507 0.3 0.29 Leprosy; chr8:89655885 chr8:89609409~89757727:- CESC cis rs1044826 0.642 rs295482 ENSG00000178631.7 ACTG1P1 -4.55 9.1e-06 0.00507 -0.37 -0.29 Obesity-related traits; chr3:139510422 chr3:139493809~139494937:+ CESC cis rs1044826 0.692 rs184155 ENSG00000178631.7 ACTG1P1 -4.55 9.1e-06 0.00507 -0.37 -0.29 Obesity-related traits; chr3:139510930 chr3:139493809~139494937:+ CESC cis rs1044826 0.642 rs432387 ENSG00000178631.7 ACTG1P1 -4.55 9.1e-06 0.00507 -0.37 -0.29 Obesity-related traits; chr3:139513011 chr3:139493809~139494937:+ CESC cis rs897984 0.683 rs9932572 ENSG00000260911.2 RP11-196G11.2 4.54 9.1e-06 0.00507 0.3 0.29 Dementia with Lewy bodies; chr16:30830321 chr16:31043150~31049868:+ CESC cis rs2243480 1 rs73142121 ENSG00000228409.4 CCT6P1 4.54 9.12e-06 0.00508 0.41 0.29 Diabetic kidney disease; chr7:65846219 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34702770 ENSG00000228409.4 CCT6P1 4.54 9.12e-06 0.00508 0.41 0.29 Diabetic kidney disease; chr7:65879836 chr7:65751142~65763354:+ CESC cis rs71403859 0.502 rs12927456 ENSG00000260886.1 TAT-AS1 4.54 9.12e-06 0.00508 0.47 0.29 Post bronchodilator FEV1; chr16:71471803 chr16:71565789~71578187:+ CESC cis rs7189233 0.531 rs8062535 ENSG00000279344.1 RP11-44F14.7 4.54 9.13e-06 0.00508 0.28 0.29 Intelligence (multi-trait analysis); chr16:53478576 chr16:53478957~53481550:- CESC cis rs12429206 0.52 rs1870839 ENSG00000233672.5 RNASEH2B-AS1 -4.54 9.14e-06 0.00509 -0.41 -0.29 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50899732 chr13:50862172~50910764:- CESC cis rs875971 0.545 rs2420612 ENSG00000222364.1 RNU6-96P -4.54 9.15e-06 0.0051 -0.41 -0.29 Aortic root size; chr7:66536825 chr7:66395191~66395286:+ CESC cis rs7131987 0.617 rs3764953 ENSG00000257176.2 RP11-996F15.2 -4.54 9.15e-06 0.0051 -0.36 -0.29 QT interval; chr12:29349303 chr12:29280418~29317848:- CESC cis rs8072100 0.713 rs8075058 ENSG00000228782.6 CTD-2026D20.3 4.54 9.15e-06 0.0051 0.36 0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47405491 chr17:47450568~47492492:- CESC cis rs8072100 0.713 rs11651643 ENSG00000228782.6 CTD-2026D20.3 4.54 9.15e-06 0.0051 0.36 0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47405863 chr17:47450568~47492492:- CESC cis rs8072100 0.713 rs9895776 ENSG00000228782.6 CTD-2026D20.3 4.54 9.15e-06 0.0051 0.36 0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47408637 chr17:47450568~47492492:- CESC cis rs8072100 0.738 rs3736438 ENSG00000228782.6 CTD-2026D20.3 4.54 9.15e-06 0.0051 0.36 0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47409285 chr17:47450568~47492492:- CESC cis rs889512 0.642 rs13337017 ENSG00000280152.1 RP11-331F4.5 -4.54 9.16e-06 0.0051 -0.43 -0.29 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr16:75238469 chr16:75245994~75250077:- CESC cis rs7873102 0.654 rs10283803 ENSG00000230188.1 RP11-405L18.4 4.54 9.16e-06 0.0051 0.38 0.29 Brain structure; chr9:38019148 chr9:37490421~37490893:- CESC cis rs8030379 0.967 rs6603001 ENSG00000230373.7 GOLGA6L5P -4.54 9.16e-06 0.0051 -0.28 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83896516 chr15:84507885~84516814:- CESC cis rs6547705 0.748 rs13010845 ENSG00000231259.4 AC125232.1 -4.54 9.17e-06 0.0051 -0.43 -0.29 Progressive supranuclear palsy; chr2:86662353 chr2:87031815~87053069:- CESC cis rs7560272 0.538 rs12233115 ENSG00000273245.1 RP11-434P11.2 -4.54 9.19e-06 0.00511 -0.37 -0.29 Schizophrenia; chr2:73704764 chr2:73750256~73750786:- CESC cis rs7560272 0.538 rs11126414 ENSG00000273245.1 RP11-434P11.2 -4.54 9.19e-06 0.00511 -0.37 -0.29 Schizophrenia; chr2:73704917 chr2:73750256~73750786:- CESC cis rs7005380 0.62 rs7462302 ENSG00000279347.1 RP11-85I17.2 -4.54 9.19e-06 0.00511 -0.27 -0.29 Interstitial lung disease; chr8:119905531 chr8:119838736~119840385:- CESC cis rs10039254 0.712 rs7736323 ENSG00000249140.1 PRDX2P3 4.54 9.19e-06 0.00511 0.37 0.29 Attention deficit hyperactivity disorder (time to onset); chr5:179146563 chr5:179572156~179572741:+ CESC cis rs2337406 0.925 rs76288499 ENSG00000211974.3 IGHV2-70 -4.54 9.2e-06 0.00512 -0.44 -0.29 Alzheimer's disease (late onset); chr14:106686309 chr14:106723574~106724093:- CESC cis rs8072100 0.656 rs2610367 ENSG00000228782.6 CTD-2026D20.3 4.54 9.21e-06 0.00512 0.35 0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47492449 chr17:47450568~47492492:- CESC cis rs763121 0.889 rs9607557 ENSG00000273076.1 RP3-508I15.22 4.54 9.21e-06 0.00512 0.34 0.29 Menopause (age at onset); chr22:38644274 chr22:38743495~38743910:+ CESC cis rs6964833 0.554 rs112506907 ENSG00000123965.13 PMS2P5 4.54 9.22e-06 0.00513 0.41 0.29 Menarche (age at onset); chr7:74654407 chr7:74894116~74897835:+ CESC cis rs5758659 0.714 rs5758574 ENSG00000273366.1 CTA-989H11.1 4.54 9.22e-06 0.00513 0.36 0.29 Cognitive function; chr22:42085396 chr22:42278188~42278846:+ CESC cis rs7560272 0.502 rs13013228 ENSG00000273245.1 RP11-434P11.2 -4.54 9.22e-06 0.00513 -0.37 -0.29 Schizophrenia; chr2:73698089 chr2:73750256~73750786:- CESC cis rs7188445 0.899 rs17689024 ENSG00000261390.4 RP11-345M22.2 -4.54 9.22e-06 0.00513 -0.38 -0.29 Urate levels; chr16:79706081 chr16:79715232~79770563:- CESC cis rs2439831 0.702 rs7175032 ENSG00000275601.1 AC011330.13 -4.54 9.24e-06 0.00513 -0.46 -0.29 Lung cancer in ever smokers; chr15:43768038 chr15:43642389~43643023:- CESC cis rs7873102 0.63 rs2183128 ENSG00000230188.1 RP11-405L18.4 4.54 9.24e-06 0.00514 0.37 0.29 Brain structure; chr9:38014325 chr9:37490421~37490893:- CESC cis rs34779708 0.733 rs16935945 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35251392 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs12777960 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252098 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs11010146 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252633 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs7083266 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252704 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs7070778 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252760 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs7086715 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252912 chr10:35098006~35127020:- CESC cis rs34779708 0.702 rs7087150 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35253210 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs60553075 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35253534 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs12240638 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35253682 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs12249814 ENSG00000230534.5 RP11-297A16.2 4.54 9.24e-06 0.00514 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35253829 chr10:35098006~35127020:- CESC cis rs11157436 0.958 rs17183356 ENSG00000211813.2 TRAV34 4.54 9.24e-06 0.00514 0.33 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22219101 chr14:22207522~22208129:+ CESC cis rs755249 1 rs76841360 ENSG00000228060.1 RP11-69E11.8 -4.54 9.26e-06 0.00514 -0.34 -0.29 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39594353 chr1:39565160~39573203:+ CESC cis rs17301013 0.507 rs10489255 ENSG00000227373.4 RP11-160H22.5 4.54 9.27e-06 0.00515 0.43 0.29 Systemic lupus erythematosus; chr1:174341985 chr1:174115300~174160004:- CESC cis rs9322193 0.884 rs7744105 ENSG00000216906.2 RP11-350J20.9 4.54 9.27e-06 0.00515 0.33 0.29 Lung cancer; chr6:149849308 chr6:149904243~149906418:+ CESC cis rs9487094 0.67 rs4490694 ENSG00000260273.1 RP11-425D10.10 4.54 9.3e-06 0.00516 0.37 0.29 Height; chr6:109571489 chr6:109382795~109383666:+ CESC cis rs875971 0.545 rs10950025 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66158946 chr7:66493706~66495474:+ CESC cis rs875971 0.52 rs12666485 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66160135 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs67688847 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66161064 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs7787063 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66164012 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs12673308 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66166374 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs67397473 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66168318 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs10950027 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66169164 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs6460276 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66182290 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs67775320 ENSG00000237310.1 GS1-124K5.4 4.54 9.31e-06 0.00517 0.31 0.29 Aortic root size; chr7:66193792 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs316324 ENSG00000237310.1 GS1-124K5.4 -4.54 9.31e-06 0.00517 -0.31 -0.29 Aortic root size; chr7:66145627 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs316323 ENSG00000237310.1 GS1-124K5.4 -4.54 9.31e-06 0.00517 -0.31 -0.29 Aortic root size; chr7:66146002 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs316305 ENSG00000237310.1 GS1-124K5.4 -4.54 9.31e-06 0.00517 -0.31 -0.29 Aortic root size; chr7:66152984 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs316306 ENSG00000237310.1 GS1-124K5.4 -4.54 9.31e-06 0.00517 -0.31 -0.29 Aortic root size; chr7:66153687 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs2460427 ENSG00000237310.1 GS1-124K5.4 -4.54 9.31e-06 0.00517 -0.31 -0.29 Aortic root size; chr7:66154218 chr7:66493706~66495474:+ CESC cis rs7829975 0.582 rs6982832 ENSG00000254340.1 RP11-10A14.3 -4.54 9.31e-06 0.00517 -0.36 -0.29 Mood instability; chr8:8934707 chr8:9141424~9145435:+ CESC cis rs7829975 0.582 rs6983150 ENSG00000254340.1 RP11-10A14.3 -4.54 9.31e-06 0.00517 -0.36 -0.29 Mood instability; chr8:8934916 chr8:9141424~9145435:+ CESC cis rs7131987 0.683 rs3782511 ENSG00000257176.2 RP11-996F15.2 -4.54 9.32e-06 0.00517 -0.36 -0.29 QT interval; chr12:29343291 chr12:29280418~29317848:- CESC cis rs11723261 0.509 rs61792240 ENSG00000211553.1 AC253576.2 -4.54 9.32e-06 0.00518 -0.45 -0.29 Immune response to smallpox vaccine (IL-6); chr4:134876 chr4:136461~136568:+ CESC cis rs34375054 0.66 rs57491100 ENSG00000279233.1 RP11-158L12.4 4.54 9.33e-06 0.00518 0.32 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125108464 chr12:125138245~125141711:+ CESC cis rs34375054 0.66 rs57031290 ENSG00000279233.1 RP11-158L12.4 4.54 9.33e-06 0.00518 0.32 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125108507 chr12:125138245~125141711:+ CESC cis rs763121 0.853 rs4821816 ENSG00000273076.1 RP3-508I15.22 4.54 9.33e-06 0.00518 0.32 0.29 Menopause (age at onset); chr22:38717129 chr22:38743495~38743910:+ CESC cis rs10754283 0.967 rs1934044 ENSG00000231613.1 RP5-943J3.1 -4.54 9.33e-06 0.00518 -0.37 -0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89641942 chr1:89788914~89790492:+ CESC cis rs577676 0.586 rs12031871 ENSG00000271811.1 RP1-79C4.4 4.54 9.36e-06 0.00519 0.39 0.29 Prevalent atrial fibrillation; chr1:170621426 chr1:170667381~170669425:+ CESC cis rs651386 0.505 rs10753817 ENSG00000271811.1 RP1-79C4.4 4.54 9.36e-06 0.00519 0.39 0.29 Atrial fibrillation; chr1:170622667 chr1:170667381~170669425:+ CESC cis rs1538970 0.924 rs12037201 ENSG00000280836.1 AL355480.1 -4.54 9.36e-06 0.00519 -0.37 -0.29 Platelet count; chr1:45475677 chr1:45581219~45581321:- CESC cis rs950776 0.518 rs12903129 ENSG00000279373.1 RP11-650L12.4 4.54 9.36e-06 0.00519 0.35 0.29 Sudden cardiac arrest; chr15:78527264 chr15:78537681~78538946:+ CESC cis rs2243480 1 rs313813 ENSG00000228409.4 CCT6P1 4.54 9.36e-06 0.00519 0.43 0.29 Diabetic kidney disease; chr7:66038513 chr7:65751142~65763354:+ CESC cis rs6686842 0.601 rs12144160 ENSG00000235358.1 RP11-399E6.1 4.54 9.36e-06 0.00519 0.35 0.29 Height; chr1:41009413 chr1:41242373~41284861:+ CESC cis rs9322193 0.923 rs9322197 ENSG00000268592.3 RAET1E-AS1 4.54 9.36e-06 0.00519 0.37 0.29 Lung cancer; chr6:149622577 chr6:149863494~149919507:+ CESC cis rs11096990 0.855 rs2566172 ENSG00000249207.1 RP11-360F5.1 4.54 9.37e-06 0.0052 0.39 0.29 Cognitive function; chr4:39150943 chr4:39112677~39126818:- CESC cis rs9532669 0.926 rs2324737 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40862808 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs35396630 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40863135 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4942001 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40863176 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4942003 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40863270 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs4942004 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40863598 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs9315791 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40863931 chr13:40863599~40863902:- CESC cis rs9532669 0.824 rs9315792 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40863951 chr13:40863599~40863902:- CESC cis rs9532669 0.684 rs7139788 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40864264 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs7338617 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40870787 chr13:40863599~40863902:- CESC cis rs9532669 0.857 rs6560961 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40870878 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs6560962 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40870948 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs6560963 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40871126 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs3610 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40871334 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4942005 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40871636 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4942006 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40871862 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4942008 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40871989 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs2039118 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40872260 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4356347 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40872516 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs7982346 ENSG00000176268.5 CYCSP34 4.54 9.38e-06 0.0052 0.29 0.29 Cervical cancer; chr13:40873273 chr13:40863599~40863902:- CESC cis rs10875746 0.669 rs10467101 ENSG00000240399.1 RP1-228P16.1 -4.54 9.38e-06 0.0052 -0.37 -0.29 Longevity (90 years and older); chr12:48213954 chr12:48054813~48055591:- CESC cis rs1012068 0.96 rs12167583 ENSG00000236132.1 CTA-440B3.1 -4.54 9.39e-06 0.0052 -0.35 -0.29 Chronic hepatitis C infection; chr22:31873725 chr22:31816379~31817491:- CESC cis rs950169 0.614 rs12911536 ENSG00000225151.9 GOLGA2P7 -4.54 9.41e-06 0.00521 -0.44 -0.29 Schizophrenia; chr15:84004278 chr15:84199311~84230136:- CESC cis rs7811142 1 rs28490152 ENSG00000078319.8 PMS2P1 -4.54 9.42e-06 0.00522 -0.47 -0.29 Platelet count; chr7:100423359 chr7:100320992~100341908:- CESC cis rs2439831 0.867 rs486301 ENSG00000275601.1 AC011330.13 -4.54 9.42e-06 0.00522 -0.4 -0.29 Lung cancer in ever smokers; chr15:43544751 chr15:43642389~43643023:- CESC cis rs9309473 0.95 rs10178678 ENSG00000163016.8 ALMS1P 4.54 9.44e-06 0.00523 0.39 0.29 Metabolite levels; chr2:73535109 chr2:73644919~73685576:+ CESC cis rs875971 0.502 rs1796227 ENSG00000226824.5 RP4-756H11.3 4.54 9.44e-06 0.00523 0.43 0.29 Aortic root size; chr7:66622032 chr7:66654538~66669855:+ CESC cis rs2564921 0.615 rs56129941 ENSG00000242142.1 SERBP1P3 -4.54 9.44e-06 0.00523 -0.37 -0.29 Height; chr3:53007328 chr3:53064283~53065091:- CESC cis rs2564921 0.704 rs56155510 ENSG00000242142.1 SERBP1P3 -4.54 9.44e-06 0.00523 -0.37 -0.29 Height; chr3:53009621 chr3:53064283~53065091:- CESC cis rs62229266 0.839 rs11088335 ENSG00000231106.2 LINC01436 4.54 9.44e-06 0.00523 0.42 0.29 Mitral valve prolapse; chr21:36098037 chr21:36005338~36007838:+ CESC cis rs7572733 0.555 rs35563720 ENSG00000222017.1 AC011997.1 4.54 9.45e-06 0.00523 0.37 0.29 Dermatomyositis; chr2:198058351 chr2:197693106~197774823:+ CESC cis rs2243480 1 rs10807702 ENSG00000232559.3 GS1-124K5.12 4.54 9.45e-06 0.00523 0.51 0.29 Diabetic kidney disease; chr7:66302856 chr7:66554588~66576923:- CESC cis rs13108904 0.901 rs12641735 ENSG00000254094.1 AC078852.1 -4.54 9.46e-06 0.00524 -0.35 -0.29 Obesity-related traits; chr4:1310646 chr4:1356581~1358075:+ CESC cis rs6964492 1 rs6964492 ENSG00000226205.1 AC007790.4 -4.54 9.46e-06 0.00524 -0.35 -0.29 Tonsillectomy; chr7:134710822 chr7:133732493~133733595:- CESC cis rs9309711 0.961 rs11675119 ENSG00000225234.1 TRAPPC12-AS1 -4.54 9.48e-06 0.00524 -0.29 -0.29 Neurofibrillary tangles; chr2:3472651 chr2:3481242~3482409:- CESC cis rs11159086 0.793 rs11850070 ENSG00000270000.1 RP3-449M8.9 4.54 9.48e-06 0.00525 0.47 0.29 Advanced glycation end-product levels; chr14:74487575 chr14:74471930~74472360:- CESC cis rs11159086 0.793 rs28378078 ENSG00000270000.1 RP3-449M8.9 4.54 9.48e-06 0.00525 0.47 0.29 Advanced glycation end-product levels; chr14:74487940 chr14:74471930~74472360:- CESC cis rs6693388 0.918 rs902313 ENSG00000229021.2 AL591893.1 4.54 9.49e-06 0.00525 0.34 0.29 Blood metabolite ratios; chr1:151962904 chr1:151994531~152042774:+ CESC cis rs9907295 0.591 rs9908928 ENSG00000271013.1 AC015849.15 -4.54 9.49e-06 0.00525 -0.32 -0.29 Fibroblast growth factor basic levels; chr17:35862013 chr17:35912635~35918010:- CESC cis rs9907295 0.818 rs4796109 ENSG00000270977.1 AC015849.16 -4.54 9.5e-06 0.00525 -0.42 -0.29 Fibroblast growth factor basic levels; chr17:35811904 chr17:35893707~35911023:- CESC cis rs2919917 0.628 rs9298314 ENSG00000254352.1 RP11-578O24.2 4.53 9.52e-06 0.00526 0.39 0.29 Lymphocyte counts; chr8:78660874 chr8:78723796~78724136:- CESC cis rs875971 0.545 rs6460281 ENSG00000236529.1 RP13-254B10.1 4.53 9.53e-06 0.00527 0.36 0.29 Aortic root size; chr7:66216128 chr7:65840212~65840596:+ CESC cis rs875971 0.862 rs1983372 ENSG00000237310.1 GS1-124K5.4 -4.53 9.54e-06 0.00527 -0.28 -0.29 Aortic root size; chr7:66146364 chr7:66493706~66495474:+ CESC cis rs9487094 0.666 rs13219952 ENSG00000260273.1 RP11-425D10.10 4.53 9.54e-06 0.00527 0.36 0.29 Height; chr6:109391084 chr6:109382795~109383666:+ CESC cis rs2929278 0.561 rs2927071 ENSG00000205771.5 CATSPER2P1 -4.53 9.55e-06 0.00528 -0.36 -0.29 Schizophrenia; chr15:43626883 chr15:43726918~43747094:- CESC cis rs801193 0.66 rs2659897 ENSG00000232559.3 GS1-124K5.12 -4.53 9.55e-06 0.00528 -0.32 -0.29 Aortic root size; chr7:66722728 chr7:66554588~66576923:- CESC cis rs1012068 0.92 rs5994443 ENSG00000236132.1 CTA-440B3.1 -4.53 9.56e-06 0.00528 -0.34 -0.29 Chronic hepatitis C infection; chr22:31879367 chr22:31816379~31817491:- CESC cis rs12458462 0.892 rs3786228 ENSG00000274828.1 RP11-567M16.6 -4.53 9.56e-06 0.00528 -0.27 -0.29 Monocyte count; chr18:79704170 chr18:79677287~79679358:- CESC cis rs2739330 0.734 rs2000467 ENSG00000231271.1 AP000350.8 -4.53 9.57e-06 0.00528 -0.36 -0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23949918~23954042:+ CESC cis rs7580658 0.545 rs12477559 ENSG00000236682.1 AC068282.3 -4.53 9.58e-06 0.00529 -0.34 -0.29 Protein C levels; chr2:127194221 chr2:127389130~127400580:+ CESC cis rs9309473 0.95 rs6735946 ENSG00000163016.8 ALMS1P 4.53 9.59e-06 0.00529 0.39 0.29 Metabolite levels; chr2:73562931 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs7583255 ENSG00000163016.8 ALMS1P 4.53 9.59e-06 0.00529 0.39 0.29 Metabolite levels; chr2:73570869 chr2:73644919~73685576:+ CESC cis rs11157436 0.958 rs764160 ENSG00000211813.2 TRAV34 4.53 9.6e-06 0.0053 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22231098 chr14:22207522~22208129:+ CESC cis rs11846409 0.932 rs28378201 ENSG00000211974.3 IGHV2-70 -4.53 9.6e-06 0.0053 -0.38 -0.29 Rheumatic heart disease; chr14:106637262 chr14:106723574~106724093:- CESC cis rs11846409 0.86 rs74091720 ENSG00000211974.3 IGHV2-70 -4.53 9.6e-06 0.0053 -0.38 -0.29 Rheumatic heart disease; chr14:106638192 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs74091728 ENSG00000211974.3 IGHV2-70 -4.53 9.6e-06 0.0053 -0.38 -0.29 Rheumatic heart disease; chr14:106638762 chr14:106723574~106724093:- CESC cis rs7829975 0.714 rs12544992 ENSG00000253893.2 FAM85B -4.53 9.61e-06 0.0053 -0.36 -0.29 Mood instability; chr8:8804171 chr8:8167819~8226614:- CESC cis rs2337406 0.866 rs58154560 ENSG00000274576.2 IGHV2-70 -4.53 9.61e-06 0.0053 -0.35 -0.29 Alzheimer's disease (late onset); chr14:106799601 chr14:106770577~106771020:- CESC cis rs6142102 0.812 rs4911375 ENSG00000276073.1 RP5-1125A11.7 -4.53 9.61e-06 0.0053 -0.29 -0.29 Skin pigmentation; chr20:33928216 chr20:33985617~33988989:- CESC cis rs7191700 0.673 rs12325495 ENSG00000262636.1 CTD-3088G3.4 4.53 9.61e-06 0.0053 0.38 0.29 Multiple sclerosis; chr16:11324471 chr16:11380859~11381118:- CESC cis rs11157436 0.958 rs61972229 ENSG00000211813.2 TRAV34 4.53 9.62e-06 0.0053 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22189754 chr14:22207522~22208129:+ CESC cis rs13108904 0.901 rs12641735 ENSG00000253399.1 AC078852.2 -4.53 9.62e-06 0.0053 -0.35 -0.29 Obesity-related traits; chr4:1310646 chr4:1358479~1359461:+ CESC cis rs12899811 0.512 rs7164916 ENSG00000214432.8 AC068831.10 -4.53 9.63e-06 0.00531 -0.35 -0.29 Type 2 diabetes; chr15:91018216 chr15:91022619~91036611:+ CESC cis rs1862618 0.853 rs2113079 ENSG00000271828.1 CTD-2310F14.1 4.53 9.63e-06 0.00531 0.39 0.29 Initial pursuit acceleration; chr5:56862124 chr5:56927874~56929573:+ CESC cis rs7189233 0.531 rs62048526 ENSG00000279344.1 RP11-44F14.7 4.53 9.63e-06 0.00531 0.28 0.29 Intelligence (multi-trait analysis); chr16:53478014 chr16:53478957~53481550:- CESC cis rs875971 0.545 rs73376401 ENSG00000236529.1 RP13-254B10.1 4.53 9.64e-06 0.00531 0.36 0.29 Aortic root size; chr7:66174841 chr7:65840212~65840596:+ CESC cis rs8031584 0.958 rs7168641 ENSG00000260382.1 RP11-540B6.2 4.53 9.64e-06 0.00531 0.4 0.29 Huntington's disease progression; chr15:30943249 chr15:30882267~30883231:- CESC cis rs1056107 0.763 rs10115594 ENSG00000225513.1 RP11-165N19.2 -4.53 9.65e-06 0.00532 -0.36 -0.29 Colorectal cancer; chr9:112174198 chr9:112173522~112173971:- CESC cis rs2179367 0.959 rs585022 ENSG00000231760.4 RP11-350J20.5 4.53 9.65e-06 0.00532 0.36 0.29 Dupuytren's disease; chr6:149432168 chr6:149796151~149826294:- CESC cis rs7208859 0.623 rs11657662 ENSG00000266490.1 CTD-2349P21.9 -4.53 9.66e-06 0.00532 -0.47 -0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749329 chr17:30792372~30792833:+ CESC cis rs11846409 0.932 rs2583329 ENSG00000211974.3 IGHV2-70 4.53 9.67e-06 0.00533 0.37 0.29 Rheumatic heart disease; chr14:106632971 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs2015469 ENSG00000211974.3 IGHV2-70 -4.53 9.67e-06 0.00533 -0.37 -0.29 Rheumatic heart disease; chr14:106631857 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs56167903 ENSG00000211974.3 IGHV2-70 -4.53 9.67e-06 0.00533 -0.37 -0.29 Rheumatic heart disease; chr14:106632070 chr14:106723574~106724093:- CESC cis rs11846409 0.86 rs10150951 ENSG00000211974.3 IGHV2-70 -4.53 9.67e-06 0.00533 -0.37 -0.29 Rheumatic heart disease; chr14:106632988 chr14:106723574~106724093:- CESC cis rs11846409 0.86 rs17112419 ENSG00000211974.3 IGHV2-70 -4.53 9.67e-06 0.00533 -0.37 -0.29 Rheumatic heart disease; chr14:106633260 chr14:106723574~106724093:- CESC cis rs12439619 0.693 rs9944185 ENSG00000276710.3 CSPG4P8 -4.53 9.68e-06 0.00533 -0.37 -0.29 Intelligence (multi-trait analysis); chr15:82157927 chr15:82459472~82477258:+ CESC cis rs950776 0.518 rs11636131 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78529264 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs11632604 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78529572 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12910289 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78529723 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12910100 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78530325 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12915428 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78531026 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs11630349 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78532266 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12906284 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78532763 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12906846 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78532953 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12907169 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78533156 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12906951 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78533220 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs56007453 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78533897 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12916999 ENSG00000279373.1 RP11-650L12.4 4.53 9.68e-06 0.00533 0.35 0.29 Sudden cardiac arrest; chr15:78534570 chr15:78537681~78538946:+ CESC cis rs4308124 0.679 rs7600458 ENSG00000227992.1 AC108463.2 -4.53 9.68e-06 0.00533 -0.39 -0.29 Vitiligo; chr2:111206013 chr2:111203964~111206215:- CESC cis rs950880 1 rs1420101 ENSG00000234389.1 AC007278.3 -4.53 9.68e-06 0.00533 -0.32 -0.29 Serum protein levels (sST2); chr2:102341256 chr2:102438713~102440475:+ CESC cis rs2439831 1 rs2256764 ENSG00000205771.5 CATSPER2P1 -4.53 9.69e-06 0.00533 -0.46 -0.29 Lung cancer in ever smokers; chr15:43443565 chr15:43726918~43747094:- CESC cis rs1538970 0.816 rs4633317 ENSG00000280836.1 AL355480.1 -4.53 9.69e-06 0.00533 -0.37 -0.29 Platelet count; chr1:45519485 chr1:45581219~45581321:- CESC cis rs6969780 0.524 rs12530948 ENSG00000233429.8 HOTAIRM1 -4.53 9.7e-06 0.00534 -0.4 -0.29 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27161639 chr7:27095647~27100265:+ CESC cis rs516805 0.924 rs476215 ENSG00000279453.1 RP3-425C14.4 -4.53 9.71e-06 0.00534 -0.34 -0.29 Lymphocyte counts; chr6:122440739 chr6:122436789~122439223:- CESC cis rs9532669 0.963 rs9315794 ENSG00000176268.5 CYCSP34 4.53 9.71e-06 0.00534 0.3 0.29 Cervical cancer; chr13:40939489 chr13:40863599~40863902:- CESC cis rs17608059 0.566 rs17676459 ENSG00000141028.6 CDRT15P1 -4.53 9.71e-06 0.00534 -0.31 -0.29 Temperament; chr17:14007198 chr17:14024514~14025488:+ CESC cis rs17608059 0.566 rs5005684 ENSG00000141028.6 CDRT15P1 -4.53 9.71e-06 0.00534 -0.31 -0.29 Temperament; chr17:14007316 chr17:14024514~14025488:+ CESC cis rs9323326 0.559 rs4901836 ENSG00000257621.6 PSMA3-AS1 4.53 9.72e-06 0.00535 0.29 0.29 Gut microbiota (bacterial taxa); chr14:58028629 chr14:58265365~58298134:- CESC cis rs950880 0.71 rs56258475 ENSG00000234389.1 AC007278.3 -4.53 9.72e-06 0.00535 -0.33 -0.29 Serum protein levels (sST2); chr2:102382852 chr2:102438713~102440475:+ CESC cis rs2337406 0.587 rs2583291 ENSG00000211974.3 IGHV2-70 4.53 9.72e-06 0.00535 0.4 0.29 Alzheimer's disease (late onset); chr14:106649293 chr14:106723574~106724093:- CESC cis rs1075265 0.568 rs2542577 ENSG00000233266.1 HMGB1P31 4.53 9.73e-06 0.00535 0.37 0.29 Chronotype;Morning vs. evening chronotype; chr2:53822111 chr2:54051334~54051760:+ CESC cis rs2337406 0.866 rs78462736 ENSG00000211974.3 IGHV2-70 -4.53 9.73e-06 0.00535 -0.46 -0.29 Alzheimer's disease (late onset); chr14:106779942 chr14:106723574~106724093:- CESC cis rs2337406 0.866 rs8016203 ENSG00000211974.3 IGHV2-70 -4.53 9.73e-06 0.00535 -0.46 -0.29 Alzheimer's disease (late onset); chr14:106780575 chr14:106723574~106724093:- CESC cis rs2255336 0.81 rs7139147 ENSG00000245648.1 RP11-277P12.20 4.53 9.73e-06 0.00535 0.5 0.29 Blood protein levels; chr12:10361956 chr12:10363769~10398506:+ CESC cis rs875971 0.545 rs10950025 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66158946 chr7:65840212~65840596:+ CESC cis rs875971 0.52 rs12666485 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66160135 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs67688847 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66161064 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs7787063 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66164012 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs12673308 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66166374 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs67397473 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66168318 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs10950027 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66169164 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs6460276 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66182290 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs67775320 ENSG00000236529.1 RP13-254B10.1 4.53 9.75e-06 0.00536 0.36 0.29 Aortic root size; chr7:66193792 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs316324 ENSG00000236529.1 RP13-254B10.1 -4.53 9.75e-06 0.00536 -0.36 -0.29 Aortic root size; chr7:66145627 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs316323 ENSG00000236529.1 RP13-254B10.1 -4.53 9.75e-06 0.00536 -0.36 -0.29 Aortic root size; chr7:66146002 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs316305 ENSG00000236529.1 RP13-254B10.1 -4.53 9.75e-06 0.00536 -0.36 -0.29 Aortic root size; chr7:66152984 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs316306 ENSG00000236529.1 RP13-254B10.1 -4.53 9.75e-06 0.00536 -0.36 -0.29 Aortic root size; chr7:66153687 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs2460427 ENSG00000236529.1 RP13-254B10.1 -4.53 9.75e-06 0.00536 -0.36 -0.29 Aortic root size; chr7:66154218 chr7:65840212~65840596:+ CESC cis rs7429990 0.932 rs9862913 ENSG00000229759.1 MRPS18AP1 4.53 9.75e-06 0.00536 0.3 0.29 Educational attainment (years of education); chr3:47974682 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs7426976 ENSG00000229759.1 MRPS18AP1 -4.53 9.75e-06 0.00536 -0.3 -0.29 Educational attainment (years of education); chr3:47981083 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs1013431 ENSG00000229759.1 MRPS18AP1 -4.53 9.75e-06 0.00536 -0.3 -0.29 Educational attainment (years of education); chr3:47987628 chr3:48256350~48256938:- CESC cis rs10829156 0.755 rs10732437 ENSG00000240291.1 RP11-499P20.2 4.53 9.75e-06 0.00536 0.33 0.29 Sudden cardiac arrest; chr10:18626973 chr10:18513115~18545651:- CESC cis rs72772090 0.539 rs11750464 ENSG00000248734.2 CTD-2260A17.1 4.53 9.75e-06 0.00536 0.46 0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777327 chr5:96784777~96785999:+ CESC cis rs8030379 1 rs8041056 ENSG00000230373.7 GOLGA6L5P -4.53 9.76e-06 0.00536 -0.28 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83896065 chr15:84507885~84516814:- CESC cis rs1185460 0.546 rs592190 ENSG00000271751.1 RP11-110I1.14 4.53 9.76e-06 0.00536 0.37 0.29 Coronary artery disease; chr11:119084604 chr11:119065263~119065677:- CESC cis rs1185460 0.546 rs589925 ENSG00000271751.1 RP11-110I1.14 4.53 9.76e-06 0.00536 0.37 0.29 Coronary artery disease; chr11:119084969 chr11:119065263~119065677:- CESC cis rs9907295 0.591 rs2291299 ENSG00000271013.1 AC015849.15 -4.53 9.76e-06 0.00536 -0.32 -0.29 Fibroblast growth factor basic levels; chr17:35864402 chr17:35912635~35918010:- CESC cis rs8031584 0.958 rs35256769 ENSG00000260382.1 RP11-540B6.2 4.53 9.76e-06 0.00537 0.4 0.29 Huntington's disease progression; chr15:30945573 chr15:30882267~30883231:- CESC cis rs8031584 0.958 rs11629793 ENSG00000260382.1 RP11-540B6.2 4.53 9.76e-06 0.00537 0.4 0.29 Huntington's disease progression; chr15:30946220 chr15:30882267~30883231:- CESC cis rs11157436 0.958 rs17183308 ENSG00000211813.2 TRAV34 4.53 9.79e-06 0.00538 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22195090 chr14:22207522~22208129:+ CESC cis rs8100891 0.537 rs7258196 ENSG00000267213.4 AC007773.2 -4.53 9.79e-06 0.00538 -0.44 -0.29 Neuroticism; chr19:32453659 chr19:32390050~32405560:- CESC cis rs2337406 0.587 rs2516889 ENSG00000211974.3 IGHV2-70 4.53 9.8e-06 0.00538 0.4 0.29 Alzheimer's disease (late onset); chr14:106648903 chr14:106723574~106724093:- CESC cis rs34375054 0.525 rs7133006 ENSG00000279233.1 RP11-158L12.4 4.53 9.81e-06 0.00538 0.3 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125121577 chr12:125138245~125141711:+ CESC cis rs3096299 0.967 rs28689480 ENSG00000274627.1 RP11-104N10.2 4.53 9.81e-06 0.00538 0.29 0.29 Multiple myeloma (IgH translocation); chr16:89393685 chr16:89516797~89522217:+ CESC cis rs1056107 0.731 rs10114892 ENSG00000225513.1 RP11-165N19.2 -4.53 9.81e-06 0.00539 -0.36 -0.29 Colorectal cancer; chr9:112173696 chr9:112173522~112173971:- CESC cis rs4819052 0.851 rs28442024 ENSG00000223768.1 LINC00205 -4.53 9.81e-06 0.00539 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45254560 chr21:45293285~45297354:+ CESC cis rs875971 0.545 rs13311962 ENSG00000236529.1 RP13-254B10.1 -4.53 9.82e-06 0.00539 -0.35 -0.29 Aortic root size; chr7:66603142 chr7:65840212~65840596:+ CESC cis rs2243480 0.901 rs57126451 ENSG00000228409.4 CCT6P1 4.53 9.84e-06 0.0054 0.42 0.29 Diabetic kidney disease; chr7:65951319 chr7:65751142~65763354:+ CESC cis rs1044826 0.667 rs295471 ENSG00000178631.7 ACTG1P1 4.53 9.85e-06 0.0054 0.37 0.29 Obesity-related traits; chr3:139495080 chr3:139493809~139494937:+ CESC cis rs2177312 0.52 rs10014657 ENSG00000251129.1 RP11-734I18.1 -4.53 9.85e-06 0.0054 -0.37 -0.29 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31908000 chr4:31997397~32155406:+ CESC cis rs950169 0.58 rs11636189 ENSG00000225151.9 GOLGA2P7 -4.53 9.85e-06 0.0054 -0.4 -0.29 Schizophrenia; chr15:84650323 chr15:84199311~84230136:- CESC cis rs11159086 0.793 rs10150696 ENSG00000270000.1 RP3-449M8.9 4.53 9.85e-06 0.00541 0.47 0.29 Advanced glycation end-product levels; chr14:74476723 chr14:74471930~74472360:- CESC cis rs1609391 0.561 rs6439675 ENSG00000239213.4 NCK1-AS1 4.53 9.85e-06 0.00541 0.33 0.29 Neuroticism; chr3:136906594 chr3:136841726~136862054:- CESC cis rs9322193 0.772 rs7738696 ENSG00000268592.3 RAET1E-AS1 4.53 9.86e-06 0.00541 0.4 0.29 Lung cancer; chr6:149848985 chr6:149863494~149919507:+ CESC cis rs1729407 0.814 rs2071521 ENSG00000254851.1 RP11-109L13.1 4.53 9.9e-06 0.00543 0.33 0.29 Apolipoprotein A-IV levels; chr11:116827132 chr11:117135528~117138582:+ CESC cis rs9322193 0.607 rs12204653 ENSG00000231760.4 RP11-350J20.5 4.53 9.92e-06 0.00544 0.44 0.29 Lung cancer; chr6:149891885 chr6:149796151~149826294:- CESC cis rs5742933 0.817 rs4667297 ENSG00000253559.1 OSGEPL1-AS1 4.53 9.92e-06 0.00544 0.36 0.29 Ferritin levels; chr2:189664270 chr2:189762704~189765556:+ CESC cis rs17301013 0.507 rs61218633 ENSG00000227373.4 RP11-160H22.5 4.52 9.93e-06 0.00544 0.4 0.29 Systemic lupus erythematosus; chr1:174375955 chr1:174115300~174160004:- CESC cis rs1075265 0.548 rs2542575 ENSG00000233266.1 HMGB1P31 4.52 9.93e-06 0.00545 0.37 0.29 Chronotype;Morning vs. evening chronotype; chr2:53821221 chr2:54051334~54051760:+ CESC cis rs1853665 1 rs1853665 ENSG00000231760.4 RP11-350J20.5 4.52 9.94e-06 0.00545 0.51 0.29 Radiation response; chr6:149977706 chr6:149796151~149826294:- CESC cis rs11159086 1 rs4899514 ENSG00000259005.1 RP3-449M8.6 -4.52 9.94e-06 0.00545 -0.49 -0.29 Advanced glycation end-product levels; chr14:74473467 chr14:74474007~74474864:- CESC cis rs10129255 0.957 rs7493713 ENSG00000211970.3 IGHV4-61 -4.52 9.95e-06 0.00545 -0.22 -0.29 Kawasaki disease; chr14:106783685 chr14:106639119~106639657:- CESC cis rs17818399 0.675 rs35949012 ENSG00000279254.1 RP11-536C12.1 -4.52 9.95e-06 0.00545 -0.35 -0.29 Height; chr2:46633262 chr2:46668870~46670778:+ CESC cis rs4722166 0.695 rs6946509 ENSG00000179428.2 AC073072.5 -4.52 9.96e-06 0.00546 -0.38 -0.29 Lung cancer; chr7:22769871 chr7:22725395~22727620:- CESC cis rs7580658 0.545 rs885275 ENSG00000236682.1 AC068282.3 -4.52 9.96e-06 0.00546 -0.34 -0.29 Protein C levels; chr2:127193519 chr2:127389130~127400580:+ CESC cis rs10129255 0.5 rs2105989 ENSG00000211970.3 IGHV4-61 -4.52 9.96e-06 0.00546 -0.21 -0.29 Kawasaki disease; chr14:106682199 chr14:106639119~106639657:- CESC cis rs6740322 0.895 rs11684601 ENSG00000234936.1 AC010883.5 4.52 9.98e-06 0.00547 0.3 0.29 Coronary artery disease; chr2:43347103 chr2:43229573~43233394:+ CESC cis rs12468226 0.938 rs3731700 ENSG00000273456.1 RP11-686O6.2 4.52 9.98e-06 0.00547 0.41 0.29 Urate levels; chr2:202291213 chr2:202374932~202375604:- CESC cis rs11638352 1 rs8035212 ENSG00000259479.5 SORD2P -4.52 9.98e-06 0.00547 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44012438 chr15:44826371~44884694:- CESC cis rs2836950 0.561 rs34705151 ENSG00000232608.1 TIMM9P2 4.52 9.99e-06 0.00547 0.32 0.29 Menarche (age at onset); chr21:39181418 chr21:39216624~39217506:+ CESC cis rs7572733 0.555 rs2342558 ENSG00000222017.1 AC011997.1 4.52 9.99e-06 0.00547 0.37 0.29 Dermatomyositis; chr2:198055418 chr2:197693106~197774823:+ CESC cis rs1538970 0.924 rs4660858 ENSG00000280836.1 AL355480.1 -4.52 9.99e-06 0.00547 -0.37 -0.29 Platelet count; chr1:45470679 chr1:45581219~45581321:- CESC cis rs950169 0.58 rs35516100 ENSG00000225151.9 GOLGA2P7 -4.52 1e-05 0.00548 -0.4 -0.29 Schizophrenia; chr15:84652199 chr15:84199311~84230136:- CESC cis rs950169 0.58 rs62021208 ENSG00000225151.9 GOLGA2P7 -4.52 1e-05 0.00548 -0.4 -0.29 Schizophrenia; chr15:84653013 chr15:84199311~84230136:- CESC cis rs6991838 0.806 rs13262793 ENSG00000272010.1 CTD-3025N20.3 4.52 1e-05 0.00549 0.31 0.29 Intelligence (multi-trait analysis); chr8:65549662 chr8:65591850~65592472:- CESC cis rs7829975 0.871 rs572307 ENSG00000253893.2 FAM85B 4.52 1e-05 0.00549 0.36 0.29 Mood instability; chr8:8721301 chr8:8167819~8226614:- CESC cis rs8030379 0.967 rs12916223 ENSG00000230373.7 GOLGA6L5P -4.52 1e-05 0.0055 -0.28 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83883742 chr15:84507885~84516814:- CESC cis rs8030379 0.875 rs28801104 ENSG00000230373.7 GOLGA6L5P -4.52 1e-05 0.0055 -0.28 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83884091 chr15:84507885~84516814:- CESC cis rs8030379 0.967 rs12900412 ENSG00000230373.7 GOLGA6L5P -4.52 1e-05 0.0055 -0.28 -0.29 Waist circumference;Waist circumference adjusted for body mass index; chr15:83884314 chr15:84507885~84516814:- CESC cis rs7873102 0.63 rs4878731 ENSG00000230188.1 RP11-405L18.4 4.52 1.01e-05 0.0055 0.37 0.29 Brain structure; chr9:37999040 chr9:37490421~37490893:- CESC cis rs7714670 0.736 rs1565005 ENSG00000184084.7 CTD-2372A4.1 -4.52 1.01e-05 0.0055 -0.32 -0.29 Venous thromboembolism (SNP x SNP interaction); chr5:73799810 chr5:73803296~73803599:- CESC cis rs9322193 0.887 rs3734295 ENSG00000268592.3 RAET1E-AS1 4.52 1.01e-05 0.00551 0.38 0.29 Lung cancer; chr6:149593917 chr6:149863494~149919507:+ CESC cis rs9322193 0.851 rs9322194 ENSG00000268592.3 RAET1E-AS1 4.52 1.01e-05 0.00551 0.38 0.29 Lung cancer; chr6:149599113 chr6:149863494~149919507:+ CESC cis rs7873102 0.617 rs2244731 ENSG00000230188.1 RP11-405L18.4 4.52 1.01e-05 0.00551 0.37 0.29 Brain structure; chr9:37982919 chr9:37490421~37490893:- CESC cis rs1538970 0.924 rs11211111 ENSG00000280836.1 AL355480.1 -4.52 1.01e-05 0.00551 -0.37 -0.29 Platelet count; chr1:45443110 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs1006216 ENSG00000280836.1 AL355480.1 -4.52 1.01e-05 0.00551 -0.37 -0.29 Platelet count; chr1:45444322 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs1007858 ENSG00000280836.1 AL355480.1 -4.52 1.01e-05 0.00551 -0.37 -0.29 Platelet count; chr1:45446333 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs7528573 ENSG00000280836.1 AL355480.1 -4.52 1.01e-05 0.00551 -0.37 -0.29 Platelet count; chr1:45448188 chr1:45581219~45581321:- CESC cis rs9322193 0.923 rs9689084 ENSG00000268592.3 RAET1E-AS1 4.52 1.01e-05 0.00552 0.37 0.29 Lung cancer; chr6:149639648 chr6:149863494~149919507:+ CESC cis rs7572733 0.555 rs7600269 ENSG00000222017.1 AC011997.1 4.52 1.01e-05 0.00552 0.37 0.29 Dermatomyositis; chr2:198058744 chr2:197693106~197774823:+ CESC cis rs1020064 0.609 rs2576748 ENSG00000235319.1 AC012360.4 4.52 1.01e-05 0.00552 0.34 0.29 AIDS; chr2:105294801 chr2:105324210~105330529:+ CESC cis rs4853012 0.539 rs9789534 ENSG00000257800.1 FNBP1P1 4.52 1.01e-05 0.00552 0.31 0.29 Gestational age at birth (maternal effect); chr2:74135863 chr2:74120680~74123218:+ CESC cis rs9311474 0.713 rs352170 ENSG00000243224.1 RP5-1157M23.2 -4.52 1.01e-05 0.00552 -0.3 -0.29 Electroencephalogram traits; chr3:52202061 chr3:52239258~52241097:+ CESC cis rs6964587 0.933 rs10271174 ENSG00000188693.7 CYP51A1-AS1 -4.52 1.01e-05 0.00553 -0.31 -0.29 Breast cancer; chr7:92156656 chr7:92134604~92180725:+ CESC cis rs875971 0.767 rs12668005 ENSG00000222364.1 RNU6-96P -4.52 1.01e-05 0.00553 -0.35 -0.29 Aortic root size; chr7:66444034 chr7:66395191~66395286:+ CESC cis rs2243480 0.803 rs36127118 ENSG00000275400.1 RP4-756H11.5 4.52 1.01e-05 0.00553 0.5 0.29 Diabetic kidney disease; chr7:66100518 chr7:66553805~66554199:- CESC cis rs8005677 1 rs8006409 ENSG00000279656.1 RP11-298I3.6 4.52 1.01e-05 0.00553 0.36 0.29 Cognitive ability (multi-trait analysis); chr14:22927302 chr14:23023083~23024217:- CESC cis rs2439831 0.85 rs60883262 ENSG00000275601.1 AC011330.13 -4.52 1.01e-05 0.00553 -0.45 -0.29 Lung cancer in ever smokers; chr15:43784305 chr15:43642389~43643023:- CESC cis rs10875746 0.669 rs10431526 ENSG00000240399.1 RP1-228P16.1 -4.52 1.01e-05 0.00554 -0.36 -0.29 Longevity (90 years and older); chr12:48296360 chr12:48054813~48055591:- CESC cis rs6693388 0.749 rs7554859 ENSG00000229021.2 AL591893.1 -4.52 1.01e-05 0.00554 -0.36 -0.29 Blood metabolite ratios; chr1:151965462 chr1:151994531~152042774:+ CESC cis rs7508 0.509 rs414260 ENSG00000253671.1 RP11-806O11.1 -4.52 1.01e-05 0.00554 -0.37 -0.29 Atrial fibrillation; chr8:18046813 chr8:17808941~17820868:+ CESC cis rs2439831 0.85 rs12442129 ENSG00000275601.1 AC011330.13 -4.52 1.02e-05 0.00556 -0.46 -0.29 Lung cancer in ever smokers; chr15:43763658 chr15:43642389~43643023:- CESC cis rs7131987 0.621 rs57803026 ENSG00000257176.2 RP11-996F15.2 -4.52 1.02e-05 0.00556 -0.35 -0.29 QT interval; chr12:29344573 chr12:29280418~29317848:- CESC cis rs875971 0.545 rs12670811 ENSG00000226824.5 RP4-756H11.3 -4.52 1.02e-05 0.00556 -0.41 -0.29 Aortic root size; chr7:66358032 chr7:66654538~66669855:+ CESC cis rs5742933 0.948 rs5743063 ENSG00000253559.1 OSGEPL1-AS1 4.52 1.02e-05 0.00557 0.38 0.29 Ferritin levels; chr2:189829723 chr2:189762704~189765556:+ CESC cis rs6686842 0.897 rs2802565 ENSG00000235358.1 RP11-399E6.1 -4.52 1.02e-05 0.00557 -0.36 -0.29 Height; chr1:41086147 chr1:41242373~41284861:+ CESC cis rs6686842 0.965 rs2802566 ENSG00000235358.1 RP11-399E6.1 -4.52 1.02e-05 0.00557 -0.36 -0.29 Height; chr1:41086309 chr1:41242373~41284861:+ CESC cis rs6686842 0.864 rs6662279 ENSG00000235358.1 RP11-399E6.1 -4.52 1.02e-05 0.00557 -0.36 -0.29 Height; chr1:41087889 chr1:41242373~41284861:+ CESC cis rs1061377 0.965 rs7690465 ENSG00000249685.1 RP11-360F5.3 4.52 1.02e-05 0.00557 0.35 0.29 Uric acid levels; chr4:39147015 chr4:39133913~39135608:+ CESC cis rs72772090 0.539 rs55996659 ENSG00000248734.2 CTD-2260A17.1 -4.52 1.02e-05 0.00557 -0.45 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778446 chr5:96784777~96785999:+ CESC cis rs12439619 0.846 rs62012056 ENSG00000276710.3 CSPG4P8 -4.52 1.02e-05 0.00558 -0.44 -0.29 Intelligence (multi-trait analysis); chr15:82247278 chr15:82459472~82477258:+ CESC cis rs875971 0.545 rs73136346 ENSG00000222364.1 RNU6-96P 4.52 1.02e-05 0.00558 0.4 0.29 Aortic root size; chr7:66101095 chr7:66395191~66395286:+ CESC cis rs3808502 0.527 rs2736389 ENSG00000269918.1 AF131215.9 4.52 1.02e-05 0.00558 0.4 0.29 Neuroticism; chr8:11303801 chr8:11104691~11106704:- CESC cis rs12439619 0.846 rs62012059 ENSG00000276710.3 CSPG4P8 -4.52 1.02e-05 0.00558 -0.43 -0.29 Intelligence (multi-trait analysis); chr15:82251669 chr15:82459472~82477258:+ CESC cis rs75422866 0.867 rs117022227 ENSG00000274902.1 RP1-197B17.4 4.52 1.02e-05 0.00558 0.73 0.29 Pneumonia; chr12:47633282 chr12:47731908~47732351:+ CESC cis rs9309473 0.519 rs35421685 ENSG00000273245.1 RP11-434P11.2 -4.52 1.02e-05 0.00559 -0.37 -0.29 Metabolite levels; chr2:73683011 chr2:73750256~73750786:- CESC cis rs17818399 0.888 rs2346419 ENSG00000279254.1 RP11-536C12.1 -4.52 1.02e-05 0.00559 -0.34 -0.29 Height; chr2:46617930 chr2:46668870~46670778:+ CESC cis rs55794721 0.509 rs6699113 ENSG00000261349.1 RP3-465N24.5 -4.52 1.03e-05 0.0056 -0.29 -0.29 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25266102~25267136:- CESC cis rs55794721 0.509 rs7554255 ENSG00000261349.1 RP3-465N24.5 -4.52 1.03e-05 0.0056 -0.29 -0.29 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25266102~25267136:- CESC cis rs55794721 0.509 rs4649085 ENSG00000261349.1 RP3-465N24.5 -4.52 1.03e-05 0.0056 -0.29 -0.29 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25266102~25267136:- CESC cis rs853679 0.517 rs1904841 ENSG00000219392.1 RP1-265C24.5 -4.52 1.03e-05 0.0056 -0.39 -0.29 Depression; chr6:28140307 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs1904840 ENSG00000219392.1 RP1-265C24.5 -4.52 1.03e-05 0.0056 -0.39 -0.29 Depression; chr6:28140454 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9368555 ENSG00000219392.1 RP1-265C24.5 -4.52 1.03e-05 0.0056 -0.39 -0.29 Depression; chr6:28141189 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393893 ENSG00000219392.1 RP1-265C24.5 -4.52 1.03e-05 0.0056 -0.39 -0.29 Depression; chr6:28141484 chr6:28115628~28116551:+ CESC cis rs9402743 0.781 rs10223338 ENSG00000217482.2 HMGB1P17 4.52 1.03e-05 0.0056 0.34 0.29 Systemic lupus erythematosus; chr6:135680889 chr6:135636086~135636713:- CESC cis rs9402743 0.781 rs2273069 ENSG00000217482.2 HMGB1P17 4.52 1.03e-05 0.0056 0.33 0.29 Systemic lupus erythematosus; chr6:135689660 chr6:135636086~135636713:- CESC cis rs2179367 0.887 rs506268 ENSG00000231760.4 RP11-350J20.5 4.52 1.03e-05 0.0056 0.36 0.29 Dupuytren's disease; chr6:149364481 chr6:149796151~149826294:- CESC cis rs7189233 0.531 rs7203132 ENSG00000279344.1 RP11-44F14.7 -4.52 1.03e-05 0.0056 -0.27 -0.29 Intelligence (multi-trait analysis); chr16:53395863 chr16:53478957~53481550:- CESC cis rs7580658 0.637 rs4560059 ENSG00000236682.1 AC068282.3 -4.52 1.03e-05 0.00561 -0.36 -0.29 Protein C levels; chr2:127214652 chr2:127389130~127400580:+ CESC cis rs7188445 0.871 rs16950997 ENSG00000261390.4 RP11-345M22.2 -4.52 1.03e-05 0.00561 -0.36 -0.29 Urate levels; chr16:79673733 chr16:79715232~79770563:- CESC cis rs12908161 1 rs35316992 ENSG00000225151.9 GOLGA2P7 -4.52 1.03e-05 0.00562 -0.4 -0.29 Schizophrenia; chr15:84704902 chr15:84199311~84230136:- CESC cis rs12908161 1 rs4643294 ENSG00000225151.9 GOLGA2P7 -4.52 1.03e-05 0.00562 -0.4 -0.29 Schizophrenia; chr15:84707022 chr15:84199311~84230136:- CESC cis rs12908161 1 rs62021219 ENSG00000225151.9 GOLGA2P7 -4.52 1.03e-05 0.00562 -0.4 -0.29 Schizophrenia; chr15:84712928 chr15:84199311~84230136:- CESC cis rs12908161 1 rs34900908 ENSG00000225151.9 GOLGA2P7 -4.52 1.03e-05 0.00562 -0.4 -0.29 Schizophrenia; chr15:84714368 chr15:84199311~84230136:- CESC cis rs12908161 1 rs35524990 ENSG00000225151.9 GOLGA2P7 -4.52 1.03e-05 0.00562 -0.4 -0.29 Schizophrenia; chr15:84714972 chr15:84199311~84230136:- CESC cis rs7809950 1 rs2712201 ENSG00000238832.1 snoU109 -4.52 1.03e-05 0.00562 -0.35 -0.29 Coronary artery disease; chr7:107505119 chr7:107603363~107603507:+ CESC cis rs2439831 0.867 rs28729853 ENSG00000275601.1 AC011330.13 -4.52 1.03e-05 0.00563 -0.38 -0.29 Lung cancer in ever smokers; chr15:43381482 chr15:43642389~43643023:- CESC cis rs2439831 0.717 rs9806227 ENSG00000275601.1 AC011330.13 -4.52 1.03e-05 0.00563 -0.38 -0.29 Lung cancer in ever smokers; chr15:43387917 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2584702 ENSG00000275601.1 AC011330.13 -4.52 1.03e-05 0.00563 -0.38 -0.29 Lung cancer in ever smokers; chr15:43392716 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2243434 ENSG00000275601.1 AC011330.13 -4.52 1.03e-05 0.00563 -0.38 -0.29 Lung cancer in ever smokers; chr15:43397669 chr15:43642389~43643023:- CESC cis rs11155671 0.53 rs9371544 ENSG00000223701.3 RAET1E-AS1 4.52 1.03e-05 0.00563 0.32 0.29 Testicular germ cell tumor; chr6:149896224 chr6:149884431~149919508:+ CESC cis rs6565180 0.926 rs8046445 ENSG00000183604.13 SMG1P5 -4.52 1.04e-05 0.00564 -0.29 -0.29 Tonsillectomy; chr16:30374941 chr16:30267553~30335374:- CESC cis rs8059260 0.673 rs7188928 ENSG00000274038.1 RP11-66H6.4 -4.51 1.04e-05 0.00565 -0.42 -0.29 Alcohol consumption over the past year; chr16:10964896 chr16:11056556~11057034:+ CESC cis rs7250849 0.736 rs12459542 ENSG00000273837.1 LLNLR-470E3.1 -4.51 1.04e-05 0.00565 -0.41 -0.29 Blood protein levels; chr19:51660025 chr19:51639478~51639931:- CESC cis rs17301013 0.507 rs6678209 ENSG00000227373.4 RP11-160H22.5 -4.51 1.04e-05 0.00566 -0.41 -0.29 Systemic lupus erythematosus; chr1:174325607 chr1:174115300~174160004:- CESC cis rs2243480 1 rs313803 ENSG00000232559.3 GS1-124K5.12 4.51 1.04e-05 0.00566 0.48 0.29 Diabetic kidney disease; chr7:66049744 chr7:66554588~66576923:- CESC cis rs2243480 1 rs313802 ENSG00000232559.3 GS1-124K5.12 4.51 1.04e-05 0.00566 0.48 0.29 Diabetic kidney disease; chr7:66051386 chr7:66554588~66576923:- CESC cis rs2243480 0.803 rs403089 ENSG00000232559.3 GS1-124K5.12 4.51 1.04e-05 0.00566 0.48 0.29 Diabetic kidney disease; chr7:66052736 chr7:66554588~66576923:- CESC cis rs2243480 1 rs458291 ENSG00000232559.3 GS1-124K5.12 4.51 1.04e-05 0.00566 0.48 0.29 Diabetic kidney disease; chr7:66055492 chr7:66554588~66576923:- CESC cis rs944801 0.608 rs7028570 ENSG00000215221.2 UBA52P6 4.51 1.04e-05 0.00566 0.35 0.29 Type 2 diabetes; chr9:22048684 chr9:22012155~22012536:+ CESC cis rs7809950 0.954 rs2712193 ENSG00000238832.1 snoU109 -4.51 1.04e-05 0.00567 -0.35 -0.29 Coronary artery disease; chr7:107485440 chr7:107603363~107603507:+ CESC cis rs7809950 1 rs2520277 ENSG00000238832.1 snoU109 -4.51 1.04e-05 0.00567 -0.35 -0.29 Coronary artery disease; chr7:107489789 chr7:107603363~107603507:+ CESC cis rs7809950 0.953 rs2237670 ENSG00000238832.1 snoU109 -4.51 1.04e-05 0.00567 -0.35 -0.29 Coronary artery disease; chr7:107491040 chr7:107603363~107603507:+ CESC cis rs7809950 1 rs2237672 ENSG00000238832.1 snoU109 -4.51 1.04e-05 0.00567 -0.35 -0.29 Coronary artery disease; chr7:107491118 chr7:107603363~107603507:+ CESC cis rs9640161 0.673 rs11773351 ENSG00000261305.1 RP4-584D14.7 4.51 1.04e-05 0.00567 0.44 0.29 Blood protein levels;Circulating chemerin levels; chr7:150333874 chr7:150341771~150342607:+ CESC cis rs3091242 0.9 rs669063 ENSG00000261349.1 RP3-465N24.5 -4.51 1.04e-05 0.00567 -0.3 -0.29 Erythrocyte sedimentation rate; chr1:25394663 chr1:25266102~25267136:- CESC cis rs2739330 0.791 rs9612520 ENSG00000228039.3 KB-1125A3.10 4.51 1.04e-05 0.00567 0.35 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23963780~23964374:+ CESC cis rs1799949 1 rs11654731 ENSG00000267681.1 CTD-3199J23.6 -4.51 1.04e-05 0.00567 -0.39 -0.29 Menopause (age at onset); chr17:43174923 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs11651623 ENSG00000267681.1 CTD-3199J23.6 -4.51 1.04e-05 0.00567 -0.39 -0.29 Menopause (age at onset); chr17:43177830 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs11657883 ENSG00000267681.1 CTD-3199J23.6 -4.51 1.04e-05 0.00567 -0.39 -0.29 Menopause (age at onset); chr17:43178007 chr17:43144956~43145255:+ CESC cis rs831571 0.774 rs254858 ENSG00000280620.1 SCAANT1 -4.51 1.04e-05 0.00568 -0.46 -0.29 Type 2 diabetes; chr3:64070579 chr3:63911518~63911772:- CESC cis rs8100891 0.537 rs7253039 ENSG00000267213.4 AC007773.2 -4.51 1.04e-05 0.00568 -0.44 -0.29 Neuroticism; chr19:32482171 chr19:32390050~32405560:- CESC cis rs8100891 0.537 rs737093 ENSG00000267213.4 AC007773.2 -4.51 1.04e-05 0.00568 -0.44 -0.29 Neuroticism; chr19:32486500 chr19:32390050~32405560:- CESC cis rs6142102 0.812 rs2377955 ENSG00000276073.1 RP5-1125A11.7 -4.51 1.04e-05 0.00568 -0.29 -0.29 Skin pigmentation; chr20:33937564 chr20:33985617~33988989:- CESC cis rs6504950 0.813 rs244321 ENSG00000275710.1 RP11-257O5.4 4.51 1.04e-05 0.00568 0.32 0.29 Breast cancer; chr17:55146637 chr17:54964474~54964679:+ CESC cis rs6504950 0.854 rs244322 ENSG00000275710.1 RP11-257O5.4 4.51 1.04e-05 0.00568 0.32 0.29 Breast cancer; chr17:55147398 chr17:54964474~54964679:+ CESC cis rs1044826 0.692 rs176987 ENSG00000178631.7 ACTG1P1 -4.51 1.05e-05 0.00569 -0.37 -0.29 Obesity-related traits; chr3:139514159 chr3:139493809~139494937:+ CESC cis rs1044826 0.692 rs188420 ENSG00000178631.7 ACTG1P1 -4.51 1.05e-05 0.00569 -0.37 -0.29 Obesity-related traits; chr3:139515023 chr3:139493809~139494937:+ CESC cis rs944801 0.608 rs10811645 ENSG00000215221.2 UBA52P6 4.51 1.05e-05 0.00569 0.36 0.29 Type 2 diabetes; chr9:22049657 chr9:22012155~22012536:+ CESC cis rs34779708 0.733 rs3853672 ENSG00000230534.5 RP11-297A16.2 4.51 1.05e-05 0.00569 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35260678 chr10:35098006~35127020:- CESC cis rs875971 0.545 rs11770063 ENSG00000226824.5 RP4-756H11.3 -4.51 1.05e-05 0.00569 -0.43 -0.29 Aortic root size; chr7:66318029 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs3936065 ENSG00000226824.5 RP4-756H11.3 -4.51 1.05e-05 0.00569 -0.43 -0.29 Aortic root size; chr7:66325577 chr7:66654538~66669855:+ CESC cis rs2280018 0.526 rs2966128 ENSG00000188599.16 NPIPP1 -4.51 1.05e-05 0.00569 -0.29 -0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059532 chr16:15104312~15123498:- CESC cis rs6991838 0.778 rs11779601 ENSG00000272010.1 CTD-3025N20.3 4.51 1.05e-05 0.0057 0.33 0.29 Intelligence (multi-trait analysis); chr8:65550241 chr8:65591850~65592472:- CESC cis rs2729354 0.514 rs1967179 ENSG00000265566.2 RN7SL605P -4.51 1.05e-05 0.0057 -0.37 -0.29 Blood protein levels; chr11:57581010 chr11:57528085~57528365:- CESC cis rs8067354 0.83 rs2453913 ENSG00000266701.1 AC005702.4 4.51 1.05e-05 0.0057 0.35 0.29 Hemoglobin concentration; chr17:59782789 chr17:60042546~60042627:- CESC cis rs2739330 0.731 rs4822450 ENSG00000228039.3 KB-1125A3.10 4.51 1.05e-05 0.0057 0.36 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23963780~23964374:+ CESC cis rs12908161 1 rs11638290 ENSG00000225151.9 GOLGA2P7 -4.51 1.05e-05 0.00571 -0.4 -0.29 Schizophrenia; chr15:84684405 chr15:84199311~84230136:- CESC cis rs12908161 0.959 rs34028043 ENSG00000225151.9 GOLGA2P7 -4.51 1.05e-05 0.00571 -0.4 -0.29 Schizophrenia; chr15:84688354 chr15:84199311~84230136:- CESC cis rs12908161 0.959 rs34784022 ENSG00000225151.9 GOLGA2P7 -4.51 1.05e-05 0.00571 -0.4 -0.29 Schizophrenia; chr15:84688675 chr15:84199311~84230136:- CESC cis rs12908161 1 rs12911736 ENSG00000225151.9 GOLGA2P7 -4.51 1.05e-05 0.00571 -0.4 -0.29 Schizophrenia; chr15:84696777 chr15:84199311~84230136:- CESC cis rs12908161 0.959 rs12908699 ENSG00000225151.9 GOLGA2P7 -4.51 1.05e-05 0.00571 -0.4 -0.29 Schizophrenia; chr15:84697172 chr15:84199311~84230136:- CESC cis rs7873102 0.654 rs4878730 ENSG00000230188.1 RP11-405L18.4 4.51 1.05e-05 0.00571 0.37 0.29 Brain structure; chr9:37998757 chr9:37490421~37490893:- CESC cis rs9322193 0.962 rs3763163 ENSG00000223701.3 RAET1E-AS1 4.51 1.05e-05 0.00572 0.33 0.29 Lung cancer; chr6:149819770 chr6:149884431~149919508:+ CESC cis rs4272720 0.51 rs17011757 ENSG00000229870.1 RP11-507K13.6 -4.51 1.05e-05 0.00572 -0.33 -0.29 Platelet count;Plateletcrit; chr10:49079753 chr10:49815096~49815562:+ CESC cis rs875971 0.545 rs313830 ENSG00000222364.1 RNU6-96P 4.51 1.05e-05 0.00573 0.41 0.29 Aortic root size; chr7:66086944 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs313828 ENSG00000222364.1 RNU6-96P 4.51 1.05e-05 0.00573 0.41 0.29 Aortic root size; chr7:66087627 chr7:66395191~66395286:+ CESC cis rs10129255 0.646 rs55995061 ENSG00000211970.3 IGHV4-61 -4.51 1.06e-05 0.00573 -0.22 -0.29 Kawasaki disease; chr14:106799309 chr14:106639119~106639657:- CESC cis rs1023500 0.505 rs134878 ENSG00000273366.1 CTA-989H11.1 -4.51 1.06e-05 0.00574 -0.37 -0.29 Schizophrenia; chr22:42267868 chr22:42278188~42278846:+ CESC cis rs7811142 0.943 rs28578163 ENSG00000078319.8 PMS2P1 -4.51 1.06e-05 0.00574 -0.47 -0.29 Platelet count; chr7:100447131 chr7:100320992~100341908:- CESC cis rs7811142 1 rs67239991 ENSG00000078319.8 PMS2P1 -4.51 1.06e-05 0.00574 -0.47 -0.29 Platelet count; chr7:100448881 chr7:100320992~100341908:- CESC cis rs8059260 0.542 rs11860777 ENSG00000274038.1 RP11-66H6.4 -4.51 1.06e-05 0.00575 -0.45 -0.29 Alcohol consumption over the past year; chr16:11033718 chr16:11056556~11057034:+ CESC cis rs916888 0.821 rs199513 ENSG00000232300.1 FAM215B -4.51 1.06e-05 0.00576 -0.46 -0.29 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46558830~46562795:- CESC cis rs832187 0.776 rs854622 ENSG00000280620.1 SCAANT1 4.51 1.06e-05 0.00576 0.37 0.29 Schizophrenia; chr3:63877166 chr3:63911518~63911772:- CESC cis rs150992 0.568 rs34498 ENSG00000248489.1 CTD-2007H13.3 4.51 1.06e-05 0.00576 0.37 0.29 Body mass index; chr5:98960690 chr5:98929171~98995013:+ CESC cis rs2929278 0.638 rs2016840 ENSG00000249839.1 AC011330.5 4.51 1.06e-05 0.00577 0.29 0.29 Schizophrenia; chr15:43919670 chr15:43663654~43684339:- CESC cis rs1056107 0.7 rs10981293 ENSG00000225513.1 RP11-165N19.2 -4.51 1.06e-05 0.00578 -0.36 -0.29 Colorectal cancer; chr9:112169467 chr9:112173522~112173971:- CESC cis rs7615952 0.599 rs12486459 ENSG00000250012.1 RP11-124N2.1 -4.51 1.06e-05 0.00578 -0.33 -0.29 Blood pressure (smoking interaction); chr3:126022622 chr3:126084220~126095349:+ CESC cis rs7615952 0.599 rs67575510 ENSG00000250012.1 RP11-124N2.1 -4.51 1.06e-05 0.00578 -0.33 -0.29 Blood pressure (smoking interaction); chr3:126023512 chr3:126084220~126095349:+ CESC cis rs7189233 0.531 rs7204496 ENSG00000279344.1 RP11-44F14.7 -4.51 1.07e-05 0.00578 -0.27 -0.29 Intelligence (multi-trait analysis); chr16:53462686 chr16:53478957~53481550:- CESC cis rs1387259 0.931 rs11168474 ENSG00000258273.1 RP11-370I10.4 -4.51 1.07e-05 0.00578 -0.37 -0.29 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48227601 chr12:48333755~48333901:- CESC cis rs8040855 0.86 rs6496775 ENSG00000259295.5 CSPG4P12 -4.51 1.07e-05 0.00578 -0.36 -0.29 Bulimia nervosa; chr15:85164910 chr15:85191438~85213905:+ CESC cis rs7572733 0.555 rs2164071 ENSG00000222017.1 AC011997.1 4.51 1.07e-05 0.00579 0.37 0.29 Dermatomyositis; chr2:198050743 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs13382697 ENSG00000222017.1 AC011997.1 4.51 1.07e-05 0.00579 0.37 0.29 Dermatomyositis; chr2:198055836 chr2:197693106~197774823:+ CESC cis rs748404 0.697 rs491804 ENSG00000205771.5 CATSPER2P1 -4.51 1.07e-05 0.00579 -0.35 -0.29 Lung cancer; chr15:43268627 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs492743 ENSG00000205771.5 CATSPER2P1 -4.51 1.07e-05 0.00579 -0.35 -0.29 Lung cancer; chr15:43268747 chr15:43726918~43747094:- CESC cis rs7811142 0.943 rs28660238 ENSG00000078319.8 PMS2P1 -4.51 1.07e-05 0.00579 -0.46 -0.29 Platelet count; chr7:100425685 chr7:100320992~100341908:- CESC cis rs801193 0.66 rs4610622 ENSG00000237310.1 GS1-124K5.4 4.51 1.07e-05 0.00579 0.28 0.29 Aortic root size; chr7:66759510 chr7:66493706~66495474:+ CESC cis rs950169 0.58 rs11630887 ENSG00000225151.9 GOLGA2P7 -4.51 1.07e-05 0.0058 -0.4 -0.29 Schizophrenia; chr15:84649784 chr15:84199311~84230136:- CESC cis rs9318086 0.648 rs9510927 ENSG00000205861.10 C1QTNF9B-AS1 -4.51 1.07e-05 0.0058 -0.37 -0.29 Myopia (pathological); chr13:23893502 chr13:23888889~23897263:+ CESC cis rs783540 0.867 rs10906984 ENSG00000276710.3 CSPG4P8 -4.51 1.07e-05 0.0058 -0.31 -0.29 Schizophrenia; chr15:82697544 chr15:82459472~82477258:+ CESC cis rs673078 0.607 rs7304342 ENSG00000275759.1 RP11-131L12.3 -4.51 1.07e-05 0.0058 -0.55 -0.29 Glucose homeostasis traits; chr12:118390166 chr12:118428281~118428870:+ CESC cis rs673078 0.615 rs61943397 ENSG00000275759.1 RP11-131L12.3 -4.51 1.07e-05 0.0058 -0.55 -0.29 Glucose homeostasis traits; chr12:118390996 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943398 ENSG00000275759.1 RP11-131L12.3 -4.51 1.07e-05 0.0058 -0.55 -0.29 Glucose homeostasis traits; chr12:118393280 chr12:118428281~118428870:+ CESC cis rs1862618 0.853 rs2113078 ENSG00000271828.1 CTD-2310F14.1 4.51 1.07e-05 0.00581 0.4 0.29 Initial pursuit acceleration; chr5:56791363 chr5:56927874~56929573:+ CESC cis rs11638352 1 rs2706481 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44114119 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2957581 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44117884 chr15:44826371~44884694:- CESC cis rs2733201 1 rs1160066 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44118739 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2615295 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44120400 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2615292 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44122178 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2059628 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44123073 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2733203 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44123404 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2615288 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44123688 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2615287 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44123795 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2733204 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44124814 chr15:44826371~44884694:- CESC cis rs2733201 1 rs2615285 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44125178 chr15:44826371~44884694:- CESC cis rs11638352 1 rs7166715 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44125408 chr15:44826371~44884694:- CESC cis rs11638352 1 rs2706473 ENSG00000259479.5 SORD2P -4.51 1.07e-05 0.00581 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44125537 chr15:44826371~44884694:- CESC cis rs2276314 0.857 rs62101393 ENSG00000278986.1 RP11-723J4.3 -4.51 1.07e-05 0.00582 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36012205 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs62101394 ENSG00000278986.1 RP11-723J4.3 -4.51 1.07e-05 0.00582 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36012336 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs4799409 ENSG00000278986.1 RP11-723J4.3 -4.51 1.07e-05 0.00582 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36012639 chr18:35972151~35973916:+ CESC cis rs2276314 0.762 rs3826600 ENSG00000278986.1 RP11-723J4.3 -4.51 1.07e-05 0.00582 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36029090 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs62101402 ENSG00000278986.1 RP11-723J4.3 -4.51 1.07e-05 0.00582 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36049472 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs28651028 ENSG00000278986.1 RP11-723J4.3 -4.51 1.07e-05 0.00582 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36058947 chr18:35972151~35973916:+ CESC cis rs801193 0.66 rs1016265 ENSG00000237310.1 GS1-124K5.4 4.51 1.08e-05 0.00583 0.28 0.29 Aortic root size; chr7:66749580 chr7:66493706~66495474:+ CESC cis rs516805 0.961 rs1267942 ENSG00000279453.1 RP3-425C14.4 -4.51 1.08e-05 0.00584 -0.34 -0.29 Lymphocyte counts; chr6:122472375 chr6:122436789~122439223:- CESC cis rs516805 0.961 rs471620 ENSG00000279453.1 RP3-425C14.4 -4.51 1.08e-05 0.00584 -0.34 -0.29 Lymphocyte counts; chr6:122473532 chr6:122436789~122439223:- CESC cis rs516805 0.961 rs527978 ENSG00000279453.1 RP3-425C14.4 -4.51 1.08e-05 0.00584 -0.34 -0.29 Lymphocyte counts; chr6:122475225 chr6:122436789~122439223:- CESC cis rs113835537 0.935 rs117480267 ENSG00000255517.5 CTD-3074O7.5 -4.51 1.08e-05 0.00584 -0.46 -0.29 Airway imaging phenotypes; chr11:66631125 chr11:66473490~66480233:- CESC cis rs4308124 0.708 rs10179596 ENSG00000227992.1 AC108463.2 -4.51 1.08e-05 0.00584 -0.39 -0.29 Vitiligo; chr2:111212803 chr2:111203964~111206215:- CESC cis rs4308124 0.708 rs6727313 ENSG00000227992.1 AC108463.2 -4.51 1.08e-05 0.00584 -0.39 -0.29 Vitiligo; chr2:111213963 chr2:111203964~111206215:- CESC cis rs4308124 0.708 rs10178095 ENSG00000227992.1 AC108463.2 -4.51 1.08e-05 0.00584 -0.39 -0.29 Vitiligo; chr2:111214939 chr2:111203964~111206215:- CESC cis rs4974559 0.739 rs10012819 ENSG00000253399.1 AC078852.2 4.51 1.08e-05 0.00584 0.5 0.29 Systolic blood pressure; chr4:1330970 chr4:1358479~1359461:+ CESC cis rs4974559 0.79 rs7654152 ENSG00000253399.1 AC078852.2 4.51 1.08e-05 0.00584 0.5 0.29 Systolic blood pressure; chr4:1331254 chr4:1358479~1359461:+ CESC cis rs4819052 0.807 rs7283915 ENSG00000223768.1 LINC00205 -4.51 1.08e-05 0.00584 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251373 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2838850 ENSG00000223768.1 LINC00205 -4.51 1.08e-05 0.00584 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251530 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs8130285 ENSG00000223768.1 LINC00205 -4.51 1.08e-05 0.00584 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251786 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs2838831 ENSG00000223768.1 LINC00205 -4.51 1.08e-05 0.00584 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45244860 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs4819046 ENSG00000223768.1 LINC00205 -4.51 1.08e-05 0.00584 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45245040 chr21:45293285~45297354:+ CESC cis rs944801 0.608 rs10757266 ENSG00000215221.2 UBA52P6 4.51 1.08e-05 0.00584 0.35 0.29 Type 2 diabetes; chr9:22049556 chr9:22012155~22012536:+ CESC cis rs944801 0.608 rs944799 ENSG00000215221.2 UBA52P6 4.51 1.08e-05 0.00584 0.35 0.29 Type 2 diabetes; chr9:22050614 chr9:22012155~22012536:+ CESC cis rs7560272 0.538 rs3980695 ENSG00000273245.1 RP11-434P11.2 -4.51 1.08e-05 0.00584 -0.36 -0.29 Schizophrenia; chr2:73712425 chr2:73750256~73750786:- CESC cis rs61160187 0.582 rs4700407 ENSG00000215032.2 GNL3LP1 -4.51 1.08e-05 0.00585 -0.33 -0.29 Educational attainment (years of education);Educational attainment (college completion); chr5:61070701 chr5:60891935~60893577:- CESC cis rs10129255 1 rs11621409 ENSG00000211974.3 IGHV2-70 4.51 1.08e-05 0.00585 0.32 0.29 Kawasaki disease; chr14:106695603 chr14:106723574~106724093:- CESC cis rs2243480 0.711 rs1626926 ENSG00000232559.3 GS1-124K5.12 4.5 1.08e-05 0.00586 0.47 0.29 Diabetic kidney disease; chr7:65970805 chr7:66554588~66576923:- CESC cis rs2243480 1 rs781142 ENSG00000232559.3 GS1-124K5.12 4.5 1.08e-05 0.00586 0.47 0.29 Diabetic kidney disease; chr7:65973791 chr7:66554588~66576923:- CESC cis rs77204473 0.744 rs75216569 ENSG00000254851.1 RP11-109L13.1 4.5 1.08e-05 0.00586 0.69 0.29 Sum eosinophil basophil counts;Eosinophil counts; chr11:117036999 chr11:117135528~117138582:+ CESC cis rs12550612 0.83 rs10111172 ENSG00000253616.4 RP11-875O11.3 -4.5 1.08e-05 0.00586 -0.41 -0.29 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23111578 chr8:23071377~23074488:- CESC cis rs34375054 0.525 rs7136220 ENSG00000279233.1 RP11-158L12.4 4.5 1.08e-05 0.00586 0.3 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125118138 chr12:125138245~125141711:+ CESC cis rs5769707 0.667 rs4824069 ENSG00000235111.1 RP1-29C18.8 -4.5 1.08e-05 0.00587 -0.34 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49636677 chr22:49612657~49615716:- CESC cis rs57221529 0.599 rs72707027 ENSG00000225138.6 CTD-2228K2.7 4.5 1.09e-05 0.00587 0.46 0.29 Lung disease severity in cystic fibrosis; chr5:671179 chr5:473236~480884:+ CESC cis rs1862618 0.853 rs33322 ENSG00000271828.1 CTD-2310F14.1 4.5 1.09e-05 0.00587 0.4 0.29 Initial pursuit acceleration; chr5:56879399 chr5:56927874~56929573:+ CESC cis rs7811142 0.943 rs111757992 ENSG00000078319.8 PMS2P1 -4.5 1.09e-05 0.00587 -0.47 -0.29 Platelet count; chr7:100418731 chr7:100320992~100341908:- CESC cis rs10875746 0.625 rs2898065 ENSG00000240399.1 RP1-228P16.1 -4.5 1.09e-05 0.00588 -0.36 -0.29 Longevity (90 years and older); chr12:48250836 chr12:48054813~48055591:- CESC cis rs11685222 0.64 rs57342498 ENSG00000229326.3 AC069154.4 4.5 1.09e-05 0.00588 0.42 0.29 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119682495 chr2:119698623~119700151:+ CESC cis rs17608059 0.566 rs6502327 ENSG00000141028.6 CDRT15P1 -4.5 1.09e-05 0.00588 -0.3 -0.29 Temperament; chr17:14042870 chr17:14024514~14025488:+ CESC cis rs34779708 0.733 rs61449529 ENSG00000230534.5 RP11-297A16.2 4.5 1.09e-05 0.00588 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35254986 chr10:35098006~35127020:- CESC cis rs34779708 0.733 rs59287215 ENSG00000230534.5 RP11-297A16.2 4.5 1.09e-05 0.00588 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35255066 chr10:35098006~35127020:- CESC cis rs34779708 0.702 rs35969476 ENSG00000230534.5 RP11-297A16.2 4.5 1.09e-05 0.00588 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35255390 chr10:35098006~35127020:- CESC cis rs4713118 0.621 rs10484403 ENSG00000219392.1 RP1-265C24.5 -4.5 1.09e-05 0.00588 -0.38 -0.29 Parkinson's disease; chr6:28065745 chr6:28115628~28116551:+ CESC cis rs2243480 1 rs34637256 ENSG00000228409.4 CCT6P1 4.5 1.09e-05 0.00588 0.42 0.29 Diabetic kidney disease; chr7:65895144 chr7:65751142~65763354:+ CESC cis rs11157436 0.871 rs8003190 ENSG00000211813.2 TRAV34 4.5 1.09e-05 0.00589 0.33 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22212096 chr14:22207522~22208129:+ CESC cis rs9487094 0.67 rs12194061 ENSG00000260273.1 RP11-425D10.10 4.5 1.09e-05 0.00589 0.37 0.29 Height; chr6:109546439 chr6:109382795~109383666:+ CESC cis rs6920372 0.731 rs2357124 ENSG00000260273.1 RP11-425D10.10 4.5 1.09e-05 0.00589 0.37 0.29 Height; chr6:109551060 chr6:109382795~109383666:+ CESC cis rs9487094 0.696 rs11153188 ENSG00000260273.1 RP11-425D10.10 4.5 1.09e-05 0.00589 0.37 0.29 Height; chr6:109558247 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs11752791 ENSG00000260273.1 RP11-425D10.10 4.5 1.09e-05 0.00589 0.37 0.29 Height; chr6:109564443 chr6:109382795~109383666:+ CESC cis rs17818399 0.597 rs13385693 ENSG00000279254.1 RP11-536C12.1 -4.5 1.09e-05 0.00589 -0.32 -0.29 Height; chr2:46640019 chr2:46668870~46670778:+ CESC cis rs2564921 0.73 rs73082047 ENSG00000242142.1 SERBP1P3 -4.5 1.09e-05 0.00589 -0.35 -0.29 Height; chr3:53070344 chr3:53064283~53065091:- CESC cis rs1044826 0.642 rs407958 ENSG00000178631.7 ACTG1P1 4.5 1.09e-05 0.00589 0.37 0.29 Obesity-related traits; chr3:139494790 chr3:139493809~139494937:+ CESC cis rs3806843 0.576 rs246074 ENSG00000202111.1 VTRNA1-2 -4.5 1.09e-05 0.0059 -0.3 -0.29 Depressive symptoms (multi-trait analysis); chr5:140928384 chr5:140718925~140719013:+ CESC cis rs2019137 0.56 rs6707386 ENSG00000274877.1 RP11-65I12.1 -4.5 1.09e-05 0.0059 -0.39 -0.29 Lymphocyte counts; chr2:113223445 chr2:113237595~113240825:+ CESC cis rs7508 0.511 rs208025 ENSG00000253671.1 RP11-806O11.1 -4.5 1.09e-05 0.00591 -0.33 -0.29 Atrial fibrillation; chr8:18020661 chr8:17808941~17820868:+ CESC cis rs8059260 1 rs8059260 ENSG00000274038.1 RP11-66H6.4 -4.5 1.09e-05 0.00591 -0.42 -0.29 Alcohol consumption over the past year; chr16:10966294 chr16:11056556~11057034:+ CESC cis rs11779988 0.545 rs439374 ENSG00000253671.1 RP11-806O11.1 -4.5 1.09e-05 0.00591 -0.36 -0.29 Breast cancer; chr8:17929309 chr8:17808941~17820868:+ CESC cis rs73086581 0.898 rs11906452 ENSG00000229539.1 RP11-119B16.2 4.5 1.09e-05 0.00591 0.43 0.29 Response to antidepressants in depression; chr20:4000912 chr20:3888239~3888868:- CESC cis rs2739330 0.76 rs1007888 ENSG00000228039.3 KB-1125A3.10 4.5 1.1e-05 0.00592 0.36 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23963780~23964374:+ CESC cis rs11603023 0.874 rs577396 ENSG00000255422.1 AP002954.4 -4.5 1.1e-05 0.00592 -0.32 -0.29 Cholesterol, total; chr11:118628753 chr11:118704607~118750263:+ CESC cis rs11603023 0.874 rs11216934 ENSG00000255422.1 AP002954.4 -4.5 1.1e-05 0.00592 -0.32 -0.29 Cholesterol, total; chr11:118630742 chr11:118704607~118750263:+ CESC cis rs2243480 0.831 rs7806717 ENSG00000228409.4 CCT6P1 -4.5 1.1e-05 0.00592 -0.42 -0.29 Diabetic kidney disease; chr7:65928187 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34136756 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65916269 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34933526 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65918212 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs6970243 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65923503 chr7:65751142~65763354:+ CESC cis rs2243480 0.708 rs35310401 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65925372 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35058610 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65925938 chr7:65751142~65763354:+ CESC cis rs2243480 0.901 rs35087093 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65940221 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35046236 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65943626 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs36068983 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65944004 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs68189316 ENSG00000228409.4 CCT6P1 4.5 1.1e-05 0.00592 0.42 0.29 Diabetic kidney disease; chr7:65944182 chr7:65751142~65763354:+ CESC cis rs2337406 0.789 rs9324095 ENSG00000274576.2 IGHV2-70 -4.5 1.1e-05 0.00592 -0.35 -0.29 Alzheimer's disease (late onset); chr14:106795885 chr14:106770577~106771020:- CESC cis rs4819052 0.851 rs9979545 ENSG00000223768.1 LINC00205 -4.5 1.1e-05 0.00593 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45259890 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs7276591 ENSG00000223768.1 LINC00205 -4.5 1.1e-05 0.00593 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45260241 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs875621 ENSG00000223768.1 LINC00205 -4.5 1.1e-05 0.00593 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45262380 chr21:45293285~45297354:+ CESC cis rs4141404 0.757 rs5749272 ENSG00000236132.1 CTA-440B3.1 4.5 1.1e-05 0.00593 0.34 0.29 Paclitaxel-induced neuropathy; chr22:31434365 chr22:31816379~31817491:- CESC cis rs4974559 0.739 rs10029534 ENSG00000253399.1 AC078852.2 4.5 1.1e-05 0.00593 0.5 0.29 Systolic blood pressure; chr4:1329120 chr4:1358479~1359461:+ CESC cis rs2255336 1 rs2255336 ENSG00000245648.1 RP11-277P12.20 4.5 1.1e-05 0.00593 0.42 0.29 Blood protein levels; chr12:10379727 chr12:10363769~10398506:+ CESC cis rs9532669 0.926 rs8002809 ENSG00000176268.5 CYCSP34 4.5 1.1e-05 0.00594 0.29 0.29 Cervical cancer; chr13:40872769 chr13:40863599~40863902:- CESC cis rs9532669 0.929 rs7982421 ENSG00000176268.5 CYCSP34 4.5 1.1e-05 0.00594 0.29 0.29 Cervical cancer; chr13:40872776 chr13:40863599~40863902:- CESC cis rs7615952 0.611 rs35321002 ENSG00000248787.1 RP11-666A20.4 -4.5 1.1e-05 0.00594 -0.53 -0.29 Blood pressure (smoking interaction); chr3:125893222 chr3:125908005~125910272:- CESC cis rs2412819 0.597 rs514311 ENSG00000205771.5 CATSPER2P1 -4.5 1.1e-05 0.00594 -0.42 -0.29 Lung cancer; chr15:43869376 chr15:43726918~43747094:- CESC cis rs2412819 0.571 rs495880 ENSG00000205771.5 CATSPER2P1 4.5 1.1e-05 0.00594 0.42 0.29 Lung cancer; chr15:43855067 chr15:43726918~43747094:- CESC cis rs875971 0.545 rs316316 ENSG00000236529.1 RP13-254B10.1 -4.5 1.1e-05 0.00594 -0.35 -0.29 Aortic root size; chr7:66149270 chr7:65840212~65840596:+ CESC cis rs6142102 0.923 rs4911379 ENSG00000276073.1 RP5-1125A11.7 -4.5 1.1e-05 0.00594 -0.28 -0.29 Skin pigmentation; chr20:33947499 chr20:33985617~33988989:- CESC cis rs75422866 0.51 rs73105845 ENSG00000257433.4 RP1-197B17.3 4.5 1.1e-05 0.00594 0.78 0.29 Pneumonia; chr12:47741824 chr12:47706085~47742294:+ CESC cis rs7811142 1 rs112317829 ENSG00000078319.8 PMS2P1 -4.5 1.1e-05 0.00595 -0.47 -0.29 Platelet count; chr7:100445550 chr7:100320992~100341908:- CESC cis rs79349575 0.716 rs595767 ENSG00000270781.1 RP11-501C14.9 -4.5 1.1e-05 0.00595 -0.33 -0.29 Type 2 diabetes; chr17:48880625 chr17:48899131~48899748:+ CESC cis rs2058059 0.636 rs3015917 ENSG00000205578.5 POM121B -4.5 1.1e-05 0.00595 -0.36 -0.29 Subcutaneous adipose tissue; chr7:72679494 chr7:73293497~73301161:+ CESC cis rs7809950 1 rs2712191 ENSG00000238832.1 snoU109 -4.5 1.1e-05 0.00595 -0.35 -0.29 Coronary artery disease; chr7:107542279 chr7:107603363~107603507:+ CESC cis rs6740322 0.895 rs10166994 ENSG00000234936.1 AC010883.5 4.5 1.1e-05 0.00595 0.31 0.29 Coronary artery disease; chr2:43330838 chr2:43229573~43233394:+ CESC cis rs2439831 0.867 rs3213991 ENSG00000275601.1 AC011330.13 -4.5 1.1e-05 0.00595 -0.38 -0.29 Lung cancer in ever smokers; chr15:43378082 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs7163245 ENSG00000275601.1 AC011330.13 -4.5 1.1e-05 0.00595 -0.38 -0.29 Lung cancer in ever smokers; chr15:43379096 chr15:43642389~43643023:- CESC cis rs42490 0.868 rs4961155 ENSG00000251136.7 RP11-37B2.1 4.5 1.1e-05 0.00595 0.3 0.29 Leprosy; chr8:89666035 chr8:89609409~89757727:- CESC cis rs17301013 0.507 rs12084291 ENSG00000227373.4 RP11-160H22.5 4.5 1.1e-05 0.00595 0.39 0.29 Systemic lupus erythematosus; chr1:174395721 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2901815 ENSG00000227373.4 RP11-160H22.5 4.5 1.1e-05 0.00595 0.39 0.29 Systemic lupus erythematosus; chr1:174397404 chr1:174115300~174160004:- CESC cis rs2243480 1 rs6949812 ENSG00000228409.4 CCT6P1 4.5 1.11e-05 0.00596 0.42 0.29 Diabetic kidney disease; chr7:65922114 chr7:65751142~65763354:+ CESC cis rs4713118 0.513 rs149955 ENSG00000219392.1 RP1-265C24.5 -4.5 1.11e-05 0.00596 -0.35 -0.29 Parkinson's disease; chr6:28068447 chr6:28115628~28116551:+ CESC cis rs4819052 0.851 rs58644915 ENSG00000223768.1 LINC00205 -4.5 1.11e-05 0.00596 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45249997 chr21:45293285~45297354:+ CESC cis rs2243480 1 rs1723269 ENSG00000275400.1 RP4-756H11.5 4.5 1.11e-05 0.00597 0.48 0.29 Diabetic kidney disease; chr7:66007799 chr7:66553805~66554199:- CESC cis rs7811142 0.943 rs111493473 ENSG00000078319.8 PMS2P1 -4.5 1.11e-05 0.00597 -0.47 -0.29 Platelet count; chr7:100452119 chr7:100320992~100341908:- CESC cis rs7811142 1 rs11766752 ENSG00000078319.8 PMS2P1 -4.5 1.11e-05 0.00597 -0.47 -0.29 Platelet count; chr7:100475669 chr7:100320992~100341908:- CESC cis rs6844153 0.68 rs6833053 ENSG00000240005.4 RP11-293A21.1 -4.5 1.11e-05 0.00598 -0.39 -0.29 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26870838 chr4:26859806~26860599:- CESC cis rs73086581 1 rs73084594 ENSG00000229539.1 RP11-119B16.2 4.5 1.11e-05 0.00598 0.48 0.29 Response to antidepressants in depression; chr20:3935733 chr20:3888239~3888868:- CESC cis rs4141404 0.818 rs6518737 ENSG00000236132.1 CTA-440B3.1 4.5 1.11e-05 0.00598 0.33 0.29 Paclitaxel-induced neuropathy; chr22:31186676 chr22:31816379~31817491:- CESC cis rs6991838 0.806 rs17302392 ENSG00000272010.1 CTD-3025N20.3 4.5 1.11e-05 0.00598 0.31 0.29 Intelligence (multi-trait analysis); chr8:65551073 chr8:65591850~65592472:- CESC cis rs8100891 0.537 rs73036023 ENSG00000267213.4 AC007773.2 -4.5 1.11e-05 0.00598 -0.46 -0.29 Neuroticism; chr19:32457414 chr19:32390050~32405560:- CESC cis rs6991838 0.778 rs13261559 ENSG00000200714.1 Y_RNA 4.5 1.11e-05 0.00598 0.33 0.29 Intelligence (multi-trait analysis); chr8:65549808 chr8:65592731~65592820:+ CESC cis rs6991838 0.778 rs7843697 ENSG00000200714.1 Y_RNA 4.5 1.11e-05 0.00598 0.33 0.29 Intelligence (multi-trait analysis); chr8:65550533 chr8:65592731~65592820:+ CESC cis rs6991838 0.778 rs7843724 ENSG00000200714.1 Y_RNA 4.5 1.11e-05 0.00598 0.33 0.29 Intelligence (multi-trait analysis); chr8:65550581 chr8:65592731~65592820:+ CESC cis rs6991838 0.806 rs35284121 ENSG00000200714.1 Y_RNA 4.5 1.11e-05 0.00598 0.33 0.29 Intelligence (multi-trait analysis); chr8:65551230 chr8:65592731~65592820:+ CESC cis rs11992186 0.505 rs7845203 ENSG00000253893.2 FAM85B -4.5 1.11e-05 0.00599 -0.38 -0.29 Neuroticism; chr8:8287918 chr8:8167819~8226614:- CESC cis rs997295 0.713 rs3784695 ENSG00000270964.1 RP11-502I4.3 -4.5 1.11e-05 0.00599 -0.27 -0.29 Motion sickness; chr15:67710264 chr15:67541072~67542604:- CESC cis rs9309711 0.772 rs9752251 ENSG00000225234.1 TRAPPC12-AS1 -4.5 1.11e-05 0.00599 -0.3 -0.29 Neurofibrillary tangles; chr2:3486098 chr2:3481242~3482409:- CESC cis rs11157436 1 rs11157440 ENSG00000211813.2 TRAV34 4.5 1.11e-05 0.00599 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22181757 chr14:22207522~22208129:+ CESC cis rs2243480 1 rs781150 ENSG00000275400.1 RP4-756H11.5 4.5 1.11e-05 0.00599 0.48 0.29 Diabetic kidney disease; chr7:66015986 chr7:66553805~66554199:- CESC cis rs2243480 1 rs313798 ENSG00000275400.1 RP4-756H11.5 4.5 1.11e-05 0.00599 0.48 0.29 Diabetic kidney disease; chr7:66028044 chr7:66553805~66554199:- CESC cis rs2243480 1 rs313809 ENSG00000275400.1 RP4-756H11.5 4.5 1.11e-05 0.00599 0.48 0.29 Diabetic kidney disease; chr7:66034996 chr7:66553805~66554199:- CESC cis rs2980439 0.818 rs2948294 ENSG00000253981.4 ALG1L13P 4.5 1.11e-05 0.00599 0.35 0.29 Neuroticism; chr8:8237439 chr8:8236003~8244667:- CESC cis rs8072100 0.713 rs8074451 ENSG00000228782.6 CTD-2026D20.3 4.5 1.11e-05 0.006 0.35 0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47400207 chr17:47450568~47492492:- CESC cis rs34779708 0.733 rs7087099 ENSG00000230534.5 RP11-297A16.2 4.5 1.12e-05 0.006 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35253054 chr10:35098006~35127020:- CESC cis rs7176527 0.796 rs1057946 ENSG00000229212.6 RP11-561C5.4 4.5 1.12e-05 0.006 0.39 0.29 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84639555 chr15:85205440~85234795:- CESC cis rs10129255 0.957 rs10137980 ENSG00000211970.3 IGHV4-61 -4.5 1.12e-05 0.00601 -0.22 -0.29 Kawasaki disease; chr14:106775735 chr14:106639119~106639657:- CESC cis rs5769707 0.642 rs4824070 ENSG00000235111.1 RP1-29C18.8 -4.5 1.12e-05 0.00602 -0.34 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49637873 chr22:49612657~49615716:- CESC cis rs9847710 0.733 rs2581790 ENSG00000242142.1 SERBP1P3 4.5 1.12e-05 0.00603 0.34 0.29 Ulcerative colitis; chr3:53067764 chr3:53064283~53065091:- CESC cis rs3124314 1 rs4845419 ENSG00000229021.2 AL591893.1 -4.5 1.12e-05 0.00603 -0.32 -0.29 Hair morphology; chr1:152168598 chr1:151994531~152042774:+ CESC cis rs9322193 0.962 rs2065664 ENSG00000268592.3 RAET1E-AS1 4.5 1.12e-05 0.00603 0.39 0.29 Lung cancer; chr6:149762485 chr6:149863494~149919507:+ CESC cis rs1799949 1 rs8176273 ENSG00000267681.1 CTD-3199J23.6 -4.5 1.12e-05 0.00604 -0.39 -0.29 Menopause (age at onset); chr17:43059636 chr17:43144956~43145255:+ CESC cis rs116095464 1 rs6555159 ENSG00000250848.1 CTD-2083E4.5 -4.5 1.12e-05 0.00604 -0.49 -0.29 Breast cancer; chr5:311447 chr5:288833~290321:- CESC cis rs9322193 0.923 rs3798761 ENSG00000216906.2 RP11-350J20.9 4.5 1.12e-05 0.00604 0.32 0.29 Lung cancer; chr6:149683643 chr6:149904243~149906418:+ CESC cis rs2980439 0.87 rs2945230 ENSG00000173295.6 FAM86B3P 4.5 1.12e-05 0.00604 0.38 0.29 Neuroticism; chr8:8252414 chr8:8228595~8244865:+ CESC cis rs12439619 0.693 rs7165536 ENSG00000255769.6 GOLGA2P10 -4.5 1.12e-05 0.00604 -0.39 -0.29 Intelligence (multi-trait analysis); chr15:82273743 chr15:82472993~82513950:- CESC cis rs35160687 0.814 rs1863063 ENSG00000273080.1 RP11-301O19.1 4.5 1.13e-05 0.00605 0.32 0.29 Night sleep phenotypes; chr2:86291126 chr2:86195590~86196049:+ CESC cis rs55794721 0.509 rs6699896 ENSG00000261349.1 RP3-465N24.5 -4.5 1.13e-05 0.00605 -0.29 -0.29 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25266102~25267136:- CESC cis rs73086581 1 rs73084575 ENSG00000229539.1 RP11-119B16.2 4.5 1.13e-05 0.00605 0.48 0.29 Response to antidepressants in depression; chr20:3926121 chr20:3888239~3888868:- CESC cis rs4819052 0.851 rs2877019 ENSG00000223768.1 LINC00205 -4.5 1.13e-05 0.00605 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45238732 chr21:45293285~45297354:+ CESC cis rs7560272 0.538 rs13000788 ENSG00000273245.1 RP11-434P11.2 -4.5 1.13e-05 0.00606 -0.36 -0.29 Schizophrenia; chr2:73691185 chr2:73750256~73750786:- CESC cis rs2117029 0.965 rs2293446 ENSG00000258017.1 RP11-386G11.10 -4.5 1.13e-05 0.00606 -0.38 -0.29 Intelligence (multi-trait analysis); chr12:49018926 chr12:49127782~49147869:+ CESC cis rs875971 0.545 rs4718348 ENSG00000226824.5 RP4-756H11.3 -4.5 1.13e-05 0.00606 -0.41 -0.29 Aortic root size; chr7:66441589 chr7:66654538~66669855:+ CESC cis rs6142102 1 rs6059672 ENSG00000276073.1 RP5-1125A11.7 -4.49 1.13e-05 0.00606 -0.3 -0.29 Skin pigmentation; chr20:34117662 chr20:33985617~33988989:- CESC cis rs2276314 0.857 rs59649576 ENSG00000278986.1 RP11-723J4.3 -4.49 1.13e-05 0.00607 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36036112 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs28435069 ENSG00000278986.1 RP11-723J4.3 -4.49 1.13e-05 0.00607 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36048512 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs8087539 ENSG00000278986.1 RP11-723J4.3 -4.49 1.13e-05 0.00607 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36051574 chr18:35972151~35973916:+ CESC cis rs7811142 1 rs60844404 ENSG00000078319.8 PMS2P1 -4.49 1.13e-05 0.00607 -0.47 -0.29 Platelet count; chr7:100482851 chr7:100320992~100341908:- CESC cis rs7811142 1 rs113738841 ENSG00000078319.8 PMS2P1 -4.49 1.13e-05 0.00607 -0.47 -0.29 Platelet count; chr7:100483683 chr7:100320992~100341908:- CESC cis rs11168351 0.864 rs12228750 ENSG00000240399.1 RP1-228P16.1 -4.49 1.13e-05 0.00607 -0.32 -0.29 Bipolar disorder and schizophrenia; chr12:48103214 chr12:48054813~48055591:- CESC cis rs2243480 0.522 rs73150635 ENSG00000228409.4 CCT6P1 4.49 1.13e-05 0.00607 0.51 0.29 Diabetic kidney disease; chr7:66507503 chr7:65751142~65763354:+ CESC cis rs13113518 1 rs13132420 ENSG00000273257.1 RP11-177J6.1 -4.49 1.13e-05 0.00607 -0.37 -0.29 Height; chr4:55526646 chr4:55387949~55388271:+ CESC cis rs9318086 0.712 rs9510916 ENSG00000205861.10 C1QTNF9B-AS1 -4.49 1.13e-05 0.00607 -0.37 -0.29 Myopia (pathological); chr13:23868650 chr13:23888889~23897263:+ CESC cis rs4308124 0.708 rs6716091 ENSG00000227992.1 AC108463.2 -4.49 1.13e-05 0.00608 -0.39 -0.29 Vitiligo; chr2:111233556 chr2:111203964~111206215:- CESC cis rs9309473 0.95 rs11689588 ENSG00000163016.8 ALMS1P 4.49 1.13e-05 0.00608 0.4 0.29 Metabolite levels; chr2:73546564 chr2:73644919~73685576:+ CESC cis rs2841233 0.681 rs2582558 ENSG00000279140.1 RP11-477I4.4 4.49 1.13e-05 0.00608 0.25 0.29 IgG glycosylation; chr14:104881151 chr14:104815449~104815753:- CESC cis rs8059260 0.668 rs79389789 ENSG00000274038.1 RP11-66H6.4 -4.49 1.13e-05 0.00608 -0.47 -0.29 Alcohol consumption over the past year; chr16:11015168 chr16:11056556~11057034:+ CESC cis rs11971779 0.688 rs8137 ENSG00000273391.1 RP11-634H22.1 -4.49 1.13e-05 0.00609 -0.28 -0.29 Diisocyanate-induced asthma; chr7:139419715 chr7:139359032~139359566:- CESC cis rs2412819 0.571 rs2930531 ENSG00000205771.5 CATSPER2P1 4.49 1.14e-05 0.0061 0.42 0.29 Lung cancer; chr15:43829372 chr15:43726918~43747094:- CESC cis rs10129255 0.785 rs10150044 ENSG00000280411.1 IGHV1-69-2 -4.49 1.14e-05 0.0061 -0.21 -0.29 Kawasaki disease; chr14:106775695 chr14:106762092~106762588:- CESC cis rs62229266 0.557 rs4817761 ENSG00000231106.2 LINC01436 4.49 1.14e-05 0.0061 0.42 0.29 Mitral valve prolapse; chr21:36023258 chr21:36005338~36007838:+ CESC cis rs71403859 0.57 rs77809998 ENSG00000260886.1 TAT-AS1 4.49 1.14e-05 0.0061 0.52 0.29 Post bronchodilator FEV1; chr16:71396784 chr16:71565789~71578187:+ CESC cis rs7635879 0.702 rs4687494 ENSG00000230102.6 RP11-407B7.1 -4.49 1.14e-05 0.0061 -0.35 -0.29 Breastfeeding duration; chr3:194010581 chr3:194005259~194070970:- CESC cis rs6026584 1 rs15754 ENSG00000270951.1 RP1-309F20.4 -4.49 1.14e-05 0.0061 -0.36 -0.29 Renal function-related traits (BUN); chr20:58894172 chr20:58876592~58876981:- CESC cis rs9322193 1 rs9399693 ENSG00000268592.3 RAET1E-AS1 4.49 1.14e-05 0.00611 0.37 0.29 Lung cancer; chr6:149612718 chr6:149863494~149919507:+ CESC cis rs875971 0.862 rs6460307 ENSG00000222364.1 RNU6-96P -4.49 1.14e-05 0.00612 -0.34 -0.29 Aortic root size; chr7:66595884 chr7:66395191~66395286:+ CESC cis rs4819052 0.851 rs7276103 ENSG00000223768.1 LINC00205 -4.49 1.14e-05 0.00612 -0.33 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45246163 chr21:45293285~45297354:+ CESC cis rs72772090 0.539 rs17481759 ENSG00000248734.2 CTD-2260A17.1 -4.49 1.14e-05 0.00612 -0.45 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778991 chr5:96784777~96785999:+ CESC cis rs453301 0.571 rs2929456 ENSG00000254340.1 RP11-10A14.3 -4.49 1.14e-05 0.00612 -0.36 -0.29 Joint mobility (Beighton score); chr8:9225906 chr8:9141424~9145435:+ CESC cis rs4319547 0.695 rs55834409 ENSG00000275265.1 RP11-15J22.8 4.49 1.15e-05 0.00614 0.42 0.29 Body mass index; chr12:122378013 chr12:122501187~122501641:+ CESC cis rs4319547 0.695 rs1803290 ENSG00000275265.1 RP11-15J22.8 4.49 1.15e-05 0.00614 0.42 0.29 Body mass index; chr12:122380482 chr12:122501187~122501641:+ CESC cis rs62103177 0.525 rs4799117 ENSG00000261126.6 RP11-795F19.1 -4.49 1.15e-05 0.00614 -0.36 -0.29 Opioid sensitivity; chr18:79996604 chr18:80046900~80095482:+ CESC cis rs62103177 0.525 rs4283293 ENSG00000261126.6 RP11-795F19.1 -4.49 1.15e-05 0.00614 -0.36 -0.29 Opioid sensitivity; chr18:79999582 chr18:80046900~80095482:+ CESC cis rs11846409 0.86 rs59055020 ENSG00000211974.3 IGHV2-70 -4.49 1.15e-05 0.00615 -0.36 -0.29 Rheumatic heart disease; chr14:106631573 chr14:106723574~106724093:- CESC cis rs7188445 0.871 rs8047723 ENSG00000261390.4 RP11-345M22.2 4.49 1.15e-05 0.00615 0.36 0.29 Urate levels; chr16:79671018 chr16:79715232~79770563:- CESC cis rs11685222 0.504 rs939775 ENSG00000229326.3 AC069154.4 -4.49 1.15e-05 0.00618 -0.38 -0.29 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119650824 chr2:119698623~119700151:+ CESC cis rs7809950 0.798 rs10281535 ENSG00000238832.1 snoU109 4.49 1.15e-05 0.00618 0.35 0.29 Coronary artery disease; chr7:107589173 chr7:107603363~107603507:+ CESC cis rs7809950 0.954 rs2189839 ENSG00000238832.1 snoU109 4.49 1.15e-05 0.00618 0.35 0.29 Coronary artery disease; chr7:107589581 chr7:107603363~107603507:+ CESC cis rs9309473 1 rs13421462 ENSG00000163016.8 ALMS1P 4.49 1.15e-05 0.00618 0.39 0.29 Metabolite levels; chr2:73492748 chr2:73644919~73685576:+ CESC cis rs3762637 1 rs7615673 ENSG00000272758.4 RP11-299J3.8 -4.49 1.15e-05 0.00618 -0.4 -0.29 LDL cholesterol levels; chr3:122406697 chr3:122416207~122443180:+ CESC cis rs2408955 0.542 rs7975632 ENSG00000240399.1 RP1-228P16.1 4.49 1.16e-05 0.00618 0.32 0.29 Glycated hemoglobin levels; chr12:48049265 chr12:48054813~48055591:- CESC cis rs71403859 0.502 rs75986475 ENSG00000260886.1 TAT-AS1 4.49 1.16e-05 0.00619 0.46 0.29 Post bronchodilator FEV1; chr16:71430155 chr16:71565789~71578187:+ CESC cis rs7189233 0.531 rs56126229 ENSG00000279344.1 RP11-44F14.7 4.49 1.16e-05 0.00619 0.28 0.29 Intelligence (multi-trait analysis); chr16:53476775 chr16:53478957~53481550:- CESC cis rs2337406 0.925 rs2011167 ENSG00000211974.3 IGHV2-70 -4.49 1.16e-05 0.0062 -0.44 -0.29 Alzheimer's disease (late onset); chr14:106680831 chr14:106723574~106724093:- CESC cis rs442309 0.551 rs1509966 ENSG00000238280.1 RP11-436D10.3 -4.49 1.16e-05 0.0062 -0.34 -0.29 Vogt-Koyanagi-Harada syndrome; chr10:62792847 chr10:62793562~62805887:- CESC cis rs10829156 0.773 rs7909552 ENSG00000240291.1 RP11-499P20.2 4.49 1.16e-05 0.0062 0.3 0.29 Sudden cardiac arrest; chr10:18620407 chr10:18513115~18545651:- CESC cis rs8031584 0.918 rs3817498 ENSG00000260382.1 RP11-540B6.2 4.49 1.16e-05 0.00621 0.39 0.29 Huntington's disease progression; chr15:30976578 chr15:30882267~30883231:- CESC cis rs9322193 0.923 rs9404048 ENSG00000268592.3 RAET1E-AS1 4.49 1.16e-05 0.00621 0.37 0.29 Lung cancer; chr6:149616188 chr6:149863494~149919507:+ CESC cis rs9549367 0.789 rs3764125 ENSG00000269125.1 RP11-98F14.11 4.49 1.16e-05 0.00621 0.43 0.29 Platelet distribution width; chr13:113243334 chr13:113165002~113165183:- CESC cis rs8040855 0.579 rs28521166 ENSG00000259295.5 CSPG4P12 -4.49 1.16e-05 0.00621 -0.33 -0.29 Bulimia nervosa; chr15:85184801 chr15:85191438~85213905:+ CESC cis rs7615952 0.576 rs2276729 ENSG00000250012.1 RP11-124N2.1 -4.49 1.16e-05 0.00622 -0.31 -0.29 Blood pressure (smoking interaction); chr3:126107371 chr3:126084220~126095349:+ CESC cis rs2408955 0.522 rs3997 ENSG00000240399.1 RP1-228P16.1 -4.49 1.16e-05 0.00622 -0.33 -0.29 Glycated hemoglobin levels; chr12:48087804 chr12:48054813~48055591:- CESC cis rs7615952 0.599 rs60847438 ENSG00000250012.1 RP11-124N2.1 -4.49 1.17e-05 0.00623 -0.33 -0.29 Blood pressure (smoking interaction); chr3:126027162 chr3:126084220~126095349:+ CESC cis rs2739330 0.627 rs9608219 ENSG00000228039.3 KB-1125A3.10 4.49 1.17e-05 0.00623 0.35 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23963780~23964374:+ CESC cis rs5758659 0.714 rs5758578 ENSG00000273366.1 CTA-989H11.1 4.49 1.17e-05 0.00623 0.36 0.29 Cognitive function; chr22:42094288 chr22:42278188~42278846:+ CESC cis rs950776 0.518 rs952216 ENSG00000279373.1 RP11-650L12.4 4.49 1.17e-05 0.00623 0.35 0.29 Sudden cardiac arrest; chr15:78526860 chr15:78537681~78538946:+ CESC cis rs34375054 0.525 rs7133864 ENSG00000279233.1 RP11-158L12.4 4.49 1.17e-05 0.00624 0.3 0.29 Post bronchodilator FEV1/FVC ratio; chr12:125121634 chr12:125138245~125141711:+ CESC cis rs7188445 1 rs7188445 ENSG00000261390.4 RP11-345M22.2 -4.49 1.17e-05 0.00624 -0.38 -0.29 Urate levels; chr16:79701090 chr16:79715232~79770563:- CESC cis rs55665837 1 rs10832276 ENSG00000251991.1 RNU7-49P 4.49 1.17e-05 0.00625 0.31 0.29 Vitamin D levels; chr11:14461728 chr11:14478892~14478953:+ CESC cis rs1862618 0.713 rs832549 ENSG00000271828.1 CTD-2310F14.1 4.49 1.17e-05 0.00625 0.39 0.29 Initial pursuit acceleration; chr5:56887715 chr5:56927874~56929573:+ CESC cis rs2919917 0.628 rs10109359 ENSG00000254352.1 RP11-578O24.2 4.49 1.17e-05 0.00625 0.42 0.29 Lymphocyte counts; chr8:78694369 chr8:78723796~78724136:- CESC cis rs17301013 0.507 rs57953555 ENSG00000227373.4 RP11-160H22.5 4.49 1.17e-05 0.00626 0.4 0.29 Systemic lupus erythematosus; chr1:174384958 chr1:174115300~174160004:- CESC cis rs2179367 0.919 rs4897124 ENSG00000231760.4 RP11-350J20.5 4.49 1.17e-05 0.00626 0.37 0.29 Dupuytren's disease; chr6:149442073 chr6:149796151~149826294:- CESC cis rs11638352 1 rs2412852 ENSG00000259479.5 SORD2P -4.49 1.17e-05 0.00626 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44010888 chr15:44826371~44884694:- CESC cis rs6991838 0.725 rs6995134 ENSG00000272010.1 CTD-3025N20.3 4.49 1.17e-05 0.00627 0.31 0.29 Intelligence (multi-trait analysis); chr8:65555472 chr8:65591850~65592472:- CESC cis rs67311347 1 rs9822909 ENSG00000223797.4 ENTPD3-AS1 4.49 1.17e-05 0.00627 0.32 0.29 Renal cell carcinoma; chr3:40415593 chr3:40313802~40453329:- CESC cis rs853679 0.513 rs9468296 ENSG00000219392.1 RP1-265C24.5 -4.49 1.17e-05 0.00627 -0.39 -0.29 Depression; chr6:28145952 chr6:28115628~28116551:+ CESC cis rs4722166 0.63 rs6461667 ENSG00000179428.2 AC073072.5 -4.49 1.17e-05 0.00627 -0.42 -0.29 Lung cancer; chr7:22757124 chr7:22725395~22727620:- CESC cis rs875971 0.545 rs316328 ENSG00000237310.1 GS1-124K5.4 -4.49 1.17e-05 0.00627 -0.3 -0.29 Aortic root size; chr7:66143851 chr7:66493706~66495474:+ CESC cis rs7572733 0.555 rs10202569 ENSG00000222017.1 AC011997.1 4.49 1.17e-05 0.00627 0.37 0.29 Dermatomyositis; chr2:198070002 chr2:197693106~197774823:+ CESC cis rs10129255 0.957 rs10136817 ENSG00000211970.3 IGHV4-61 -4.49 1.18e-05 0.00628 -0.24 -0.29 Kawasaki disease; chr14:106787730 chr14:106639119~106639657:- CESC cis rs1799949 0.965 rs11650132 ENSG00000267681.1 CTD-3199J23.6 -4.49 1.18e-05 0.00628 -0.39 -0.29 Menopause (age at onset); chr17:43174070 chr17:43144956~43145255:+ CESC cis rs34779708 0.931 rs7079205 ENSG00000230534.5 RP11-297A16.2 4.49 1.18e-05 0.00628 0.39 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35035691 chr10:35098006~35127020:- CESC cis rs9322193 0.923 rs9800871 ENSG00000216906.2 RP11-350J20.9 4.49 1.18e-05 0.00628 0.32 0.29 Lung cancer; chr6:149644540 chr6:149904243~149906418:+ CESC cis rs748404 0.697 rs493177 ENSG00000249839.1 AC011330.5 -4.49 1.18e-05 0.00628 -0.3 -0.29 Lung cancer; chr15:43251060 chr15:43663654~43684339:- CESC cis rs116175783 0.793 rs1267044 ENSG00000227403.1 AC009299.3 4.49 1.18e-05 0.00629 0.46 0.29 Intelligence (multi-trait analysis); chr2:161271100 chr2:161244739~161249050:+ CESC cis rs2243480 1 rs3885839 ENSG00000232559.3 GS1-124K5.12 4.49 1.18e-05 0.00629 0.48 0.29 Diabetic kidney disease; chr7:65825416 chr7:66554588~66576923:- CESC cis rs11157436 0.958 rs3811277 ENSG00000211813.2 TRAV34 4.48 1.18e-05 0.0063 0.33 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22190419 chr14:22207522~22208129:+ CESC cis rs1044826 0.642 rs176983 ENSG00000178631.7 ACTG1P1 4.48 1.18e-05 0.0063 0.37 0.29 Obesity-related traits; chr3:139494913 chr3:139493809~139494937:+ CESC cis rs7809950 1 rs10267907 ENSG00000238832.1 snoU109 -4.48 1.18e-05 0.0063 -0.35 -0.29 Coronary artery disease; chr7:107544021 chr7:107603363~107603507:+ CESC cis rs73086581 1 rs73086581 ENSG00000229539.1 RP11-119B16.2 4.48 1.18e-05 0.0063 0.48 0.29 Response to antidepressants in depression; chr20:3996678 chr20:3888239~3888868:- CESC cis rs12439619 0.693 rs4778989 ENSG00000255769.6 GOLGA2P10 -4.48 1.18e-05 0.00631 -0.39 -0.29 Intelligence (multi-trait analysis); chr15:82276963 chr15:82472993~82513950:- CESC cis rs2507838 1 rs11826771 ENSG00000280010.1 AP001350.4 4.48 1.18e-05 0.00631 0.69 0.29 Body mass (lean); chr11:58741499 chr11:58627435~58628528:+ CESC cis rs11603023 0.874 rs613243 ENSG00000255422.1 AP002954.4 -4.48 1.18e-05 0.00631 -0.32 -0.29 Cholesterol, total; chr11:118643304 chr11:118704607~118750263:+ CESC cis rs875971 0.862 rs11773628 ENSG00000232559.3 GS1-124K5.12 -4.48 1.18e-05 0.00632 -0.32 -0.29 Aortic root size; chr7:66517644 chr7:66554588~66576923:- CESC cis rs7809950 0.773 rs62483722 ENSG00000238832.1 snoU109 -4.48 1.19e-05 0.00632 -0.35 -0.29 Coronary artery disease; chr7:107545904 chr7:107603363~107603507:+ CESC cis rs7809950 0.906 rs62483723 ENSG00000238832.1 snoU109 -4.48 1.19e-05 0.00632 -0.35 -0.29 Coronary artery disease; chr7:107545913 chr7:107603363~107603507:+ CESC cis rs7809950 0.953 rs2520267 ENSG00000238832.1 snoU109 -4.48 1.19e-05 0.00632 -0.35 -0.29 Coronary artery disease; chr7:107547052 chr7:107603363~107603507:+ CESC cis rs950169 0.579 rs12912716 ENSG00000225151.9 GOLGA2P7 -4.48 1.19e-05 0.00632 -0.45 -0.29 Schizophrenia; chr15:83995511 chr15:84199311~84230136:- CESC cis rs2243480 0.522 rs778717 ENSG00000228409.4 CCT6P1 4.48 1.19e-05 0.00632 0.51 0.29 Diabetic kidney disease; chr7:66383164 chr7:65751142~65763354:+ CESC cis rs944801 0.608 rs10738605 ENSG00000215221.2 UBA52P6 4.48 1.19e-05 0.00633 0.35 0.29 Type 2 diabetes; chr9:22049131 chr9:22012155~22012536:+ CESC cis rs2733201 1 rs2114421 ENSG00000259479.5 SORD2P -4.48 1.19e-05 0.00633 -0.44 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44020857 chr15:44826371~44884694:- CESC cis rs801193 0.569 rs10950050 ENSG00000222364.1 RNU6-96P -4.48 1.19e-05 0.00633 -0.33 -0.29 Aortic root size; chr7:66774601 chr7:66395191~66395286:+ CESC cis rs2115630 0.875 rs8039472 ENSG00000225151.9 GOLGA2P7 4.48 1.19e-05 0.00633 0.33 0.29 P wave terminal force; chr15:84818413 chr15:84199311~84230136:- CESC cis rs1862618 0.853 rs252887 ENSG00000271828.1 CTD-2310F14.1 4.48 1.19e-05 0.00633 0.4 0.29 Initial pursuit acceleration; chr5:56870361 chr5:56927874~56929573:+ CESC cis rs4713118 0.516 rs6931858 ENSG00000219392.1 RP1-265C24.5 -4.48 1.19e-05 0.00633 -0.4 -0.29 Parkinson's disease; chr6:28110633 chr6:28115628~28116551:+ CESC cis rs67180937 0.844 rs4846384 ENSG00000272750.1 RP11-378J18.8 -4.48 1.19e-05 0.00634 -0.36 -0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222624272 chr1:222658867~222661512:- CESC cis rs860295 0.702 rs12041534 ENSG00000225855.5 RUSC1-AS1 -4.48 1.19e-05 0.00634 -0.24 -0.29 Body mass index; chr1:155437305 chr1:155316863~155324176:- CESC cis rs35160687 0.842 rs1863052 ENSG00000273080.1 RP11-301O19.1 4.48 1.19e-05 0.00634 0.33 0.29 Night sleep phenotypes; chr2:86332235 chr2:86195590~86196049:+ CESC cis rs73086581 1 rs73086588 ENSG00000229539.1 RP11-119B16.2 4.48 1.19e-05 0.00634 0.45 0.29 Response to antidepressants in depression; chr20:4001577 chr20:3888239~3888868:- CESC cis rs7429990 0.93 rs11130152 ENSG00000229759.1 MRPS18AP1 -4.48 1.19e-05 0.00634 -0.3 -0.29 Educational attainment (years of education); chr3:48014919 chr3:48256350~48256938:- CESC cis rs5769707 0.967 rs5769698 ENSG00000235111.1 RP1-29C18.8 -4.48 1.19e-05 0.00635 -0.29 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49604058 chr22:49612657~49615716:- CESC cis rs7005380 0.733 rs2037346 ENSG00000279347.1 RP11-85I17.2 -4.48 1.19e-05 0.00635 -0.26 -0.29 Interstitial lung disease; chr8:119923212 chr8:119838736~119840385:- CESC cis rs71403859 0.73 rs12927768 ENSG00000260886.1 TAT-AS1 4.48 1.19e-05 0.00635 0.46 0.29 Post bronchodilator FEV1; chr16:71611360 chr16:71565789~71578187:+ CESC cis rs9309473 1 rs1114380 ENSG00000163016.8 ALMS1P 4.48 1.19e-05 0.00635 0.39 0.29 Metabolite levels; chr2:73577581 chr2:73644919~73685576:+ CESC cis rs2058059 0.511 rs66624667 ENSG00000205578.5 POM121B -4.48 1.2e-05 0.00637 -0.38 -0.29 Subcutaneous adipose tissue; chr7:72565634 chr7:73293497~73301161:+ CESC cis rs2058059 0.551 rs58608277 ENSG00000205578.5 POM121B -4.48 1.2e-05 0.00637 -0.38 -0.29 Subcutaneous adipose tissue; chr7:72567083 chr7:73293497~73301161:+ CESC cis rs853679 0.517 rs4713145 ENSG00000219392.1 RP1-265C24.5 -4.48 1.2e-05 0.00637 -0.38 -0.29 Depression; chr6:28139049 chr6:28115628~28116551:+ CESC cis rs11638352 0.661 rs2615286 ENSG00000275601.1 AC011330.13 4.48 1.2e-05 0.00638 0.43 0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44124870 chr15:43642389~43643023:- CESC cis rs10419113 0.641 rs12610315 ENSG00000270804.1 CTD-2583A14.11 4.48 1.2e-05 0.00638 0.29 0.29 Pediatric bone mineral density (spine); chr19:57765288 chr19:57867885~57868834:+ CESC cis rs10829156 0.898 rs4748504 ENSG00000240291.1 RP11-499P20.2 4.48 1.2e-05 0.00638 0.31 0.29 Sudden cardiac arrest; chr10:18651868 chr10:18513115~18545651:- CESC cis rs7429990 0.965 rs4858880 ENSG00000229759.1 MRPS18AP1 -4.48 1.2e-05 0.00639 -0.3 -0.29 Educational attainment (years of education); chr3:48062959 chr3:48256350~48256938:- CESC cis rs9307551 0.697 rs9993773 ENSG00000250334.4 LINC00989 -4.48 1.2e-05 0.00639 -0.44 -0.29 Refractive error; chr4:79513450 chr4:79492416~79576460:+ CESC cis rs8100891 0.537 rs4805754 ENSG00000267213.4 AC007773.2 -4.48 1.2e-05 0.00639 -0.47 -0.29 Neuroticism; chr19:32346260 chr19:32390050~32405560:- CESC cis rs5758659 0.714 rs2413668 ENSG00000273366.1 CTA-989H11.1 4.48 1.2e-05 0.0064 0.36 0.29 Cognitive function; chr22:42109837 chr22:42278188~42278846:+ CESC cis rs5758659 0.657 rs5758587 ENSG00000273366.1 CTA-989H11.1 4.48 1.2e-05 0.0064 0.36 0.29 Cognitive function; chr22:42121632 chr22:42278188~42278846:+ CESC cis rs9322193 0.607 rs4870078 ENSG00000231760.4 RP11-350J20.5 -4.48 1.2e-05 0.0064 -0.44 -0.29 Lung cancer; chr6:149880676 chr6:149796151~149826294:- CESC cis rs2243480 0.803 rs36127118 ENSG00000228409.4 CCT6P1 4.48 1.2e-05 0.0064 0.43 0.29 Diabetic kidney disease; chr7:66100518 chr7:65751142~65763354:+ CESC cis rs1969253 0.803 rs863615 ENSG00000205955.4 HSP90AA5P 4.48 1.2e-05 0.00641 0.28 0.29 Major depressive disorder; chr3:184147075 chr3:184115352~184117898:+ CESC cis rs9309473 1 rs11899902 ENSG00000163016.8 ALMS1P 4.48 1.21e-05 0.00641 0.38 0.29 Metabolite levels; chr2:73404436 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs13428235 ENSG00000163016.8 ALMS1P 4.48 1.21e-05 0.00641 0.38 0.29 Metabolite levels; chr2:73406302 chr2:73644919~73685576:+ CESC cis rs10129255 1 rs10141557 ENSG00000280411.1 IGHV1-69-2 -4.48 1.21e-05 0.00641 -0.23 -0.29 Kawasaki disease; chr14:106767990 chr14:106762092~106762588:- CESC cis rs6026584 1 rs6026584 ENSG00000270951.1 RP1-309F20.4 4.48 1.21e-05 0.00642 0.36 0.29 Renal function-related traits (BUN); chr20:58894018 chr20:58876592~58876981:- CESC cis rs673078 0.607 rs61943392 ENSG00000275759.1 RP11-131L12.3 -4.48 1.21e-05 0.00643 -0.57 -0.29 Glucose homeostasis traits; chr12:118382618 chr12:118428281~118428870:+ CESC cis rs9326248 0.861 rs1871757 ENSG00000280143.1 AP000892.6 4.48 1.21e-05 0.00643 0.41 0.29 Blood protein levels; chr11:117159865 chr11:117204967~117210292:+ CESC cis rs6011674 1 rs6011674 ENSG00000275620.1 FLJ16779 4.48 1.21e-05 0.00643 0.53 0.29 Response to cytadine analogues (cytosine arabinoside); chr20:63223100 chr20:63253978~63261615:+ CESC cis rs1707322 1 rs10890350 ENSG00000281133.1 AL355480.3 -4.48 1.21e-05 0.00644 -0.34 -0.29 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45796706 chr1:45580892~45580996:- CESC cis rs16953946 0.649 rs34645828 ENSG00000260896.4 RP11-314O13.1 -4.48 1.21e-05 0.00644 -0.78 -0.29 Inflammatory bowel disease; chr16:80750743 chr16:80828735~80892595:- CESC cis rs1799949 1 rs915945 ENSG00000267681.1 CTD-3199J23.6 -4.48 1.21e-05 0.00645 -0.4 -0.29 Menopause (age at onset); chr17:43027847 chr17:43144956~43145255:+ CESC cis rs9322193 0.923 rs2185352 ENSG00000216906.2 RP11-350J20.9 4.48 1.21e-05 0.00645 0.32 0.29 Lung cancer; chr6:149714640 chr6:149904243~149906418:+ CESC cis rs62355901 0.505 rs72758017 ENSG00000271828.1 CTD-2310F14.1 4.48 1.22e-05 0.00646 0.49 0.29 Breast cancer; chr5:56797732 chr5:56927874~56929573:+ CESC cis rs72627509 0.638 rs12642622 ENSG00000269949.1 RP11-738E22.3 4.48 1.22e-05 0.00646 0.52 0.29 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57036110 chr4:56960927~56961373:- CESC cis rs17818399 0.633 rs2242033 ENSG00000279254.1 RP11-536C12.1 -4.48 1.22e-05 0.00646 -0.32 -0.29 Height; chr2:46615271 chr2:46668870~46670778:+ CESC cis rs17818399 0.708 rs1531133 ENSG00000279254.1 RP11-536C12.1 -4.48 1.22e-05 0.00646 -0.32 -0.29 Height; chr2:46616492 chr2:46668870~46670778:+ CESC cis rs9309473 0.539 rs6745560 ENSG00000273245.1 RP11-434P11.2 4.48 1.22e-05 0.00647 0.36 0.29 Metabolite levels; chr2:73599990 chr2:73750256~73750786:- CESC cis rs7809950 1 rs4730245 ENSG00000238832.1 snoU109 -4.48 1.22e-05 0.00647 -0.35 -0.29 Coronary artery disease; chr7:107446849 chr7:107603363~107603507:+ CESC cis rs7873102 0.654 rs4878736 ENSG00000230188.1 RP11-405L18.4 4.48 1.22e-05 0.00647 0.37 0.29 Brain structure; chr9:38013227 chr9:37490421~37490893:- CESC cis rs5769707 0.542 rs739242 ENSG00000235111.1 RP1-29C18.8 -4.48 1.22e-05 0.00647 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49663468 chr22:49612657~49615716:- CESC cis rs2439831 0.702 rs8033995 ENSG00000275601.1 AC011330.13 -4.48 1.22e-05 0.00648 -0.45 -0.29 Lung cancer in ever smokers; chr15:43721311 chr15:43642389~43643023:- CESC cis rs9650657 0.589 rs6985109 ENSG00000269918.1 AF131215.9 4.48 1.22e-05 0.00648 0.35 0.29 Neuroticism; chr8:10904075 chr8:11104691~11106704:- CESC cis rs6504950 0.888 rs244319 ENSG00000275710.1 RP11-257O5.4 4.48 1.22e-05 0.00649 0.32 0.29 Breast cancer; chr17:55145513 chr17:54964474~54964679:+ CESC cis rs6504950 0.888 rs244320 ENSG00000275710.1 RP11-257O5.4 4.48 1.22e-05 0.00649 0.32 0.29 Breast cancer; chr17:55145559 chr17:54964474~54964679:+ CESC cis rs4974559 0.739 rs28429103 ENSG00000253399.1 AC078852.2 4.48 1.22e-05 0.00649 0.49 0.29 Systolic blood pressure; chr4:1326235 chr4:1358479~1359461:+ CESC cis rs7614311 1 rs7614311 ENSG00000280620.1 SCAANT1 -4.48 1.22e-05 0.00649 -0.46 -0.29 Lung function (FVC);Lung function (FEV1); chr3:63827978 chr3:63911518~63911772:- CESC cis rs2732480 0.5 rs2932093 ENSG00000240399.1 RP1-228P16.1 4.48 1.22e-05 0.00649 0.34 0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48254488 chr12:48054813~48055591:- CESC cis rs755249 1 rs17513135 ENSG00000228060.1 RP11-69E11.8 -4.48 1.22e-05 0.00649 -0.34 -0.29 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39570014 chr1:39565160~39573203:+ CESC cis rs10129255 0.912 rs35468694 ENSG00000211970.3 IGHV4-61 -4.48 1.22e-05 0.00649 -0.22 -0.29 Kawasaki disease; chr14:106784199 chr14:106639119~106639657:- CESC cis rs10129255 0.957 rs8019272 ENSG00000211970.3 IGHV4-61 -4.48 1.22e-05 0.00649 -0.22 -0.29 Kawasaki disease; chr14:106784709 chr14:106639119~106639657:- CESC cis rs6991838 0.806 rs17302392 ENSG00000200714.1 Y_RNA 4.48 1.22e-05 0.00649 0.34 0.29 Intelligence (multi-trait analysis); chr8:65551073 chr8:65592731~65592820:+ CESC cis rs4819052 0.851 rs2838826 ENSG00000223768.1 LINC00205 -4.48 1.22e-05 0.00649 -0.35 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45235870 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs10470246 ENSG00000223768.1 LINC00205 -4.48 1.22e-05 0.00649 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45239102 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs10470247 ENSG00000223768.1 LINC00205 -4.48 1.22e-05 0.00649 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45239103 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs4819043 ENSG00000223768.1 LINC00205 -4.48 1.22e-05 0.00649 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45240163 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs4819044 ENSG00000223768.1 LINC00205 -4.48 1.22e-05 0.00649 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45240203 chr21:45293285~45297354:+ CESC cis rs17783634 0.509 rs11775489 ENSG00000255046.1 RP11-297N6.4 4.48 1.23e-05 0.0065 0.34 0.29 Subjective well-being; chr8:11179334 chr8:11797928~11802568:- CESC cis rs5758659 0.714 rs2284087 ENSG00000273366.1 CTA-989H11.1 4.48 1.23e-05 0.0065 0.36 0.29 Cognitive function; chr22:42089667 chr22:42278188~42278846:+ CESC cis rs6928977 0.863 rs2746419 ENSG00000234084.1 RP3-388E23.2 4.48 1.23e-05 0.00651 0.26 0.29 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135332717 chr6:135301568~135307158:+ CESC cis rs11168351 0.864 rs10875743 ENSG00000240399.1 RP1-228P16.1 -4.48 1.23e-05 0.00651 -0.32 -0.29 Bipolar disorder and schizophrenia; chr12:48104630 chr12:48054813~48055591:- CESC cis rs6686842 0.931 rs4360513 ENSG00000235358.1 RP11-399E6.1 4.48 1.23e-05 0.00651 0.35 0.29 Height; chr1:41015127 chr1:41242373~41284861:+ CESC cis rs2408955 0.522 rs11168408 ENSG00000240399.1 RP1-228P16.1 -4.48 1.23e-05 0.00651 -0.32 -0.29 Glycated hemoglobin levels; chr12:48104544 chr12:48054813~48055591:- CESC cis rs875971 0.862 rs12537823 ENSG00000237310.1 GS1-124K5.4 4.47 1.23e-05 0.00653 0.27 0.29 Aortic root size; chr7:66255897 chr7:66493706~66495474:+ CESC cis rs12458462 0.859 rs34242155 ENSG00000274828.1 RP11-567M16.6 4.47 1.23e-05 0.00653 0.28 0.29 Monocyte count; chr18:79665192 chr18:79677287~79679358:- CESC cis rs11971779 0.68 rs10273527 ENSG00000273391.1 RP11-634H22.1 -4.47 1.23e-05 0.00654 -0.28 -0.29 Diisocyanate-induced asthma; chr7:139351852 chr7:139359032~139359566:- CESC cis rs4819052 0.851 rs2838833 ENSG00000223768.1 LINC00205 -4.47 1.23e-05 0.00654 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45245245 chr21:45293285~45297354:+ CESC cis rs853679 0.517 rs868987 ENSG00000219392.1 RP1-265C24.5 4.47 1.24e-05 0.00657 0.38 0.29 Depression; chr6:28142370 chr6:28115628~28116551:+ CESC cis rs10256972 0.626 rs62433138 ENSG00000225146.1 AC073957.15 4.47 1.24e-05 0.00657 0.33 0.29 Endometriosis;Longevity; chr7:1011241 chr7:1029025~1043891:+ CESC cis rs2492301 0.54 rs10796907 ENSG00000233621.1 LINC01137 -4.47 1.24e-05 0.00658 -0.33 -0.29 Mean corpuscular volume;Mean corpuscular hemoglobin; chr1:37434572 chr1:37454879~37474411:- CESC cis rs919433 0.617 rs700638 ENSG00000222017.1 AC011997.1 4.47 1.24e-05 0.00658 0.37 0.29 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197724226 chr2:197693106~197774823:+ CESC cis rs6452524 0.901 rs4571449 ENSG00000249664.1 CTD-2227C6.2 4.47 1.24e-05 0.00658 0.34 0.29 Hypertension (SNP x SNP interaction); chr5:83175392 chr5:83012285~83013109:- CESC cis rs2439831 0.85 rs7169988 ENSG00000275601.1 AC011330.13 -4.47 1.24e-05 0.00659 -0.46 -0.29 Lung cancer in ever smokers; chr15:43768237 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2412855 ENSG00000259479.5 SORD2P -4.47 1.24e-05 0.00659 -0.43 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44048282 chr15:44826371~44884694:- CESC cis rs1211375 0.628 rs3859141 ENSG00000268836.1 LA16c-OS12.2 4.47 1.25e-05 0.00659 0.29 0.29 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:195080 chr16:185748~186294:- CESC cis rs17818399 0.781 rs12105006 ENSG00000279254.1 RP11-536C12.1 4.47 1.25e-05 0.0066 0.34 0.29 Height; chr2:46635447 chr2:46668870~46670778:+ CESC cis rs6693388 0.671 rs11582739 ENSG00000229021.2 AL591893.1 -4.47 1.25e-05 0.0066 -0.36 -0.29 Blood metabolite ratios; chr1:151962065 chr1:151994531~152042774:+ CESC cis rs526231 0.853 rs2288786 ENSG00000175749.11 EIF3KP1 4.47 1.25e-05 0.0066 0.35 0.29 Primary biliary cholangitis; chr5:103265053 chr5:103032376~103033031:+ CESC cis rs10129255 0.518 rs2006284 ENSG00000224373.3 IGHV4-59 4.47 1.25e-05 0.00661 0.18 0.29 Kawasaki disease; chr14:106676185 chr14:106627249~106627825:- CESC cis rs7873102 0.654 rs2244713 ENSG00000230188.1 RP11-405L18.4 -4.47 1.25e-05 0.00661 -0.37 -0.29 Brain structure; chr9:37983437 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2244712 ENSG00000230188.1 RP11-405L18.4 -4.47 1.25e-05 0.00661 -0.37 -0.29 Brain structure; chr9:37983445 chr9:37490421~37490893:- CESC cis rs11157436 0.958 rs2204963 ENSG00000211813.2 TRAV34 4.47 1.25e-05 0.00661 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22187871 chr14:22207522~22208129:+ CESC cis rs7873102 0.654 rs56405143 ENSG00000230188.1 RP11-405L18.4 4.47 1.25e-05 0.00661 0.37 0.29 Brain structure; chr9:37995102 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10973634 ENSG00000230188.1 RP11-405L18.4 4.47 1.25e-05 0.00661 0.37 0.29 Brain structure; chr9:37995848 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10973636 ENSG00000230188.1 RP11-405L18.4 4.47 1.25e-05 0.00661 0.37 0.29 Brain structure; chr9:37997564 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10814638 ENSG00000230188.1 RP11-405L18.4 4.47 1.25e-05 0.00661 0.37 0.29 Brain structure; chr9:37997790 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs4878729 ENSG00000230188.1 RP11-405L18.4 4.47 1.25e-05 0.00661 0.37 0.29 Brain structure; chr9:37998492 chr9:37490421~37490893:- CESC cis rs10129255 0.957 rs6576233 ENSG00000211970.3 IGHV4-61 -4.47 1.25e-05 0.00661 -0.23 -0.29 Kawasaki disease; chr14:106787239 chr14:106639119~106639657:- CESC cis rs4819052 0.851 rs2330011 ENSG00000223768.1 LINC00205 -4.47 1.25e-05 0.00662 -0.33 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45238583 chr21:45293285~45297354:+ CESC cis rs1862618 0.853 rs832551 ENSG00000271828.1 CTD-2310F14.1 4.47 1.25e-05 0.00662 0.39 0.29 Initial pursuit acceleration; chr5:56884285 chr5:56927874~56929573:+ CESC cis rs1862618 0.713 rs832550 ENSG00000271828.1 CTD-2310F14.1 4.47 1.25e-05 0.00662 0.39 0.29 Initial pursuit acceleration; chr5:56886762 chr5:56927874~56929573:+ CESC cis rs1862618 0.756 rs832548 ENSG00000271828.1 CTD-2310F14.1 4.47 1.25e-05 0.00662 0.39 0.29 Initial pursuit acceleration; chr5:56887810 chr5:56927874~56929573:+ CESC cis rs1862618 0.802 rs832547 ENSG00000271828.1 CTD-2310F14.1 4.47 1.25e-05 0.00662 0.39 0.29 Initial pursuit acceleration; chr5:56888114 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs866222 ENSG00000271828.1 CTD-2310F14.1 4.47 1.25e-05 0.00662 0.39 0.29 Initial pursuit acceleration; chr5:56888617 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs861283 ENSG00000271828.1 CTD-2310F14.1 4.47 1.25e-05 0.00662 0.39 0.29 Initial pursuit acceleration; chr5:56888783 chr5:56927874~56929573:+ CESC cis rs1862618 0.802 rs252900 ENSG00000271828.1 CTD-2310F14.1 4.47 1.25e-05 0.00662 0.39 0.29 Initial pursuit acceleration; chr5:56889454 chr5:56927874~56929573:+ CESC cis rs17301013 0.507 rs6677243 ENSG00000227373.4 RP11-160H22.5 4.47 1.25e-05 0.00663 0.39 0.29 Systemic lupus erythematosus; chr1:174339471 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10912777 ENSG00000227373.4 RP11-160H22.5 4.47 1.25e-05 0.00663 0.39 0.29 Systemic lupus erythematosus; chr1:174393764 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10912778 ENSG00000227373.4 RP11-160H22.5 4.47 1.25e-05 0.00663 0.39 0.29 Systemic lupus erythematosus; chr1:174393827 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2205937 ENSG00000227373.4 RP11-160H22.5 4.47 1.25e-05 0.00663 0.39 0.29 Systemic lupus erythematosus; chr1:174394440 chr1:174115300~174160004:- CESC cis rs4819052 0.679 rs2255761 ENSG00000223768.1 LINC00205 -4.47 1.25e-05 0.00663 -0.32 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45263707 chr21:45293285~45297354:+ CESC cis rs748404 0.626 rs60367691 ENSG00000249839.1 AC011330.5 -4.47 1.26e-05 0.00664 -0.4 -0.29 Lung cancer; chr15:43559201 chr15:43663654~43684339:- CESC cis rs1707322 0.613 rs1473840 ENSG00000280836.1 AL355480.1 4.47 1.26e-05 0.00665 0.37 0.29 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46135525 chr1:45581219~45581321:- CESC cis rs10419113 0.598 rs12610037 ENSG00000270804.1 CTD-2583A14.11 4.47 1.26e-05 0.00665 0.29 0.29 Pediatric bone mineral density (spine); chr19:57752217 chr19:57867885~57868834:+ CESC cis rs62355901 0.83 rs12653202 ENSG00000271828.1 CTD-2310F14.1 4.47 1.26e-05 0.00665 0.38 0.29 Breast cancer; chr5:56721091 chr5:56927874~56929573:+ CESC cis rs7104764 0.507 rs7111364 ENSG00000277290.1 RP11-326C3.16 -4.47 1.26e-05 0.00666 -0.31 -0.29 Menarche (age at onset); chr11:258542 chr11:243099~243483:- CESC cis rs6991838 0.806 rs11777025 ENSG00000272010.1 CTD-3025N20.3 -4.47 1.26e-05 0.00666 -0.31 -0.29 Intelligence (multi-trait analysis); chr8:65551438 chr8:65591850~65592472:- CESC cis rs6951245 0.638 rs74976697 ENSG00000229043.2 AC091729.9 -4.47 1.26e-05 0.00666 -0.4 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1120869 chr7:1160374~1165267:+ CESC cis rs6951245 0.678 rs28600085 ENSG00000229043.2 AC091729.9 -4.47 1.26e-05 0.00666 -0.4 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1130000 chr7:1160374~1165267:+ CESC cis rs6951245 0.706 rs28483034 ENSG00000229043.2 AC091729.9 -4.47 1.26e-05 0.00666 -0.4 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1130535 chr7:1160374~1165267:+ CESC cis rs5758659 0.714 rs5751216 ENSG00000273366.1 CTA-989H11.1 4.47 1.26e-05 0.00666 0.36 0.29 Cognitive function; chr22:42112933 chr22:42278188~42278846:+ CESC cis rs5758659 0.714 rs5758589 ENSG00000273366.1 CTA-989H11.1 4.47 1.26e-05 0.00666 0.36 0.29 Cognitive function; chr22:42122378 chr22:42278188~42278846:+ CESC cis rs10826995 0.808 rs211387 ENSG00000273038.2 RP11-479G22.8 -4.47 1.26e-05 0.00667 -0.34 -0.29 Pulse pressure; chr10:32004406 chr10:32887255~32889311:- CESC cis rs2299587 0.932 rs11776688 ENSG00000253671.1 RP11-806O11.1 -4.47 1.26e-05 0.00667 -0.3 -0.29 Economic and political preferences; chr8:17986417 chr8:17808941~17820868:+ CESC cis rs11155671 0.53 rs6935829 ENSG00000223701.3 RAET1E-AS1 4.47 1.26e-05 0.00667 0.32 0.29 Testicular germ cell tumor; chr6:149896675 chr6:149884431~149919508:+ CESC cis rs875971 0.545 rs1796222 ENSG00000237310.1 GS1-124K5.4 -4.47 1.27e-05 0.00668 -0.32 -0.29 Aortic root size; chr7:66592167 chr7:66493706~66495474:+ CESC cis rs860295 0.557 rs12091730 ENSG00000225855.5 RUSC1-AS1 4.47 1.27e-05 0.00668 0.26 0.29 Body mass index; chr1:155587180 chr1:155316863~155324176:- CESC cis rs6452524 1 rs7349753 ENSG00000249664.1 CTD-2227C6.2 4.47 1.27e-05 0.00668 0.33 0.29 Hypertension (SNP x SNP interaction); chr5:83165632 chr5:83012285~83013109:- CESC cis rs1387259 0.931 rs11168474 ENSG00000240399.1 RP1-228P16.1 4.47 1.27e-05 0.00668 0.35 0.29 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48227601 chr12:48054813~48055591:- CESC cis rs1862618 0.853 rs11739344 ENSG00000271828.1 CTD-2310F14.1 4.47 1.27e-05 0.00668 0.39 0.29 Initial pursuit acceleration; chr5:56815260 chr5:56927874~56929573:+ CESC cis rs6787391 0.933 rs9831844 ENSG00000231249.1 ITPR1-AS1 4.47 1.27e-05 0.00668 0.34 0.29 Breast cancer; chr3:4702363 chr3:4490891~4493163:- CESC cis rs577676 0.586 rs656539 ENSG00000271811.1 RP1-79C4.4 4.47 1.27e-05 0.00669 0.39 0.29 Prevalent atrial fibrillation; chr1:170637213 chr1:170667381~170669425:+ CESC cis rs7927592 0.956 rs7106259 ENSG00000212093.1 AP000807.1 4.47 1.27e-05 0.00669 0.33 0.29 Total body bone mineral density; chr11:68531044 chr11:68506083~68506166:- CESC cis rs11168351 0.833 rs6580652 ENSG00000240399.1 RP1-228P16.1 -4.47 1.27e-05 0.00669 -0.32 -0.29 Bipolar disorder and schizophrenia; chr12:48053322 chr12:48054813~48055591:- CESC cis rs2408955 0.522 rs4760679 ENSG00000240399.1 RP1-228P16.1 -4.47 1.27e-05 0.00669 -0.32 -0.29 Glycated hemoglobin levels; chr12:48067852 chr12:48054813~48055591:- CESC cis rs2564921 0.679 rs12635933 ENSG00000242142.1 SERBP1P3 -4.47 1.27e-05 0.0067 -0.36 -0.29 Height; chr3:53015087 chr3:53064283~53065091:- CESC cis rs897984 0.806 rs12924903 ENSG00000260911.2 RP11-196G11.2 4.47 1.27e-05 0.0067 0.32 0.29 Dementia with Lewy bodies; chr16:30917649 chr16:31043150~31049868:+ CESC cis rs7429990 0.965 rs35199727 ENSG00000229759.1 MRPS18AP1 4.47 1.27e-05 0.0067 0.3 0.29 Educational attainment (years of education); chr3:47905218 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs11707679 ENSG00000229759.1 MRPS18AP1 4.47 1.27e-05 0.0067 0.3 0.29 Educational attainment (years of education); chr3:47915016 chr3:48256350~48256938:- CESC cis rs3096299 0.606 rs4785573 ENSG00000274627.1 RP11-104N10.2 4.47 1.27e-05 0.0067 0.3 0.29 Multiple myeloma (IgH translocation); chr16:89498995 chr16:89516797~89522217:+ CESC cis rs7873102 0.654 rs4878733 ENSG00000230188.1 RP11-405L18.4 -4.47 1.27e-05 0.0067 -0.36 -0.29 Brain structure; chr9:38010028 chr9:37490421~37490893:- CESC cis rs2548724 0.661 rs7716398 ENSG00000250682.4 LINC00491 4.47 1.27e-05 0.00671 0.36 0.29 Type 2 diabetes; chr5:102468541 chr5:102609156~102671559:- CESC cis rs77972916 0.561 rs13411629 ENSG00000234936.1 AC010883.5 4.47 1.27e-05 0.00671 0.36 0.29 Granulocyte percentage of myeloid white cells; chr2:43339851 chr2:43229573~43233394:+ CESC cis rs1816752 0.679 rs8181826 ENSG00000273628.1 RP11-756A22.7 -4.47 1.28e-05 0.00672 -0.33 -0.29 Obesity-related traits; chr13:24396570 chr13:24933006~24936796:+ CESC cis rs2439831 0.85 rs7174208 ENSG00000275601.1 AC011330.13 -4.47 1.28e-05 0.00673 -0.45 -0.29 Lung cancer in ever smokers; chr15:43760484 chr15:43642389~43643023:- CESC cis rs950880 0.71 rs3771171 ENSG00000234389.1 AC007278.3 -4.47 1.28e-05 0.00673 -0.33 -0.29 Serum protein levels (sST2); chr2:102369490 chr2:102438713~102440475:+ CESC cis rs6001482 0.679 rs6001528 ENSG00000236850.4 BMS1P20 -4.47 1.28e-05 0.00674 -0.29 -0.29 Diastolic blood pressure; chr22:22236511 chr22:22303224~22322847:+ CESC cis rs2439831 0.867 rs12443102 ENSG00000275601.1 AC011330.13 -4.47 1.28e-05 0.00674 -0.43 -0.29 Lung cancer in ever smokers; chr15:43639905 chr15:43642389~43643023:- CESC cis rs73086581 0.838 rs73088424 ENSG00000229539.1 RP11-119B16.2 4.47 1.28e-05 0.00674 0.43 0.29 Response to antidepressants in depression; chr20:4020359 chr20:3888239~3888868:- CESC cis rs875971 0.545 rs1796217 ENSG00000236529.1 RP13-254B10.1 -4.47 1.28e-05 0.00674 -0.35 -0.29 Aortic root size; chr7:66620931 chr7:65840212~65840596:+ CESC cis rs783540 0.5 rs1313494 ENSG00000276710.3 CSPG4P8 4.47 1.28e-05 0.00674 0.33 0.29 Schizophrenia; chr15:82605530 chr15:82459472~82477258:+ CESC cis rs875971 1 rs7792762 ENSG00000232559.3 GS1-124K5.12 4.47 1.28e-05 0.00674 0.32 0.29 Aortic root size; chr7:66539151 chr7:66554588~66576923:- CESC cis rs2833693 0.533 rs2833746 ENSG00000261610.1 AP000265.1 4.47 1.28e-05 0.00675 0.35 0.29 Temperament; chr21:32252556 chr21:32259804~32261585:- CESC cis rs8059260 1 rs8057540 ENSG00000274038.1 RP11-66H6.4 -4.47 1.28e-05 0.00675 -0.42 -0.29 Alcohol consumption over the past year; chr16:10951985 chr16:11056556~11057034:+ CESC cis rs17507216 0.718 rs28587782 ENSG00000255769.6 GOLGA2P10 -4.47 1.28e-05 0.00676 -0.43 -0.29 Excessive daytime sleepiness; chr15:82576881 chr15:82472993~82513950:- CESC cis rs9322193 0.923 rs11155671 ENSG00000216906.2 RP11-350J20.9 4.46 1.29e-05 0.00677 0.31 0.29 Lung cancer; chr6:149650996 chr6:149904243~149906418:+ CESC cis rs11079757 0.847 rs16941684 ENSG00000261886.1 RP11-63A1.1 4.46 1.29e-05 0.00677 0.35 0.29 Erythema nodosum in inflammatory bowel disease; chr17:47225320 chr17:46916770~46923034:- CESC cis rs875971 0.545 rs7783889 ENSG00000226824.5 RP4-756H11.3 -4.46 1.29e-05 0.00678 -0.4 -0.29 Aortic root size; chr7:66283366 chr7:66654538~66669855:+ CESC cis rs673078 0.607 rs17440893 ENSG00000275759.1 RP11-131L12.3 -4.46 1.29e-05 0.00678 -0.54 -0.29 Glucose homeostasis traits; chr12:118362532 chr12:118428281~118428870:+ CESC cis rs2439831 0.867 rs4583210 ENSG00000275601.1 AC011330.13 -4.46 1.29e-05 0.00679 -0.38 -0.29 Lung cancer in ever smokers; chr15:43368727 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs28461955 ENSG00000275601.1 AC011330.13 -4.46 1.29e-05 0.00679 -0.38 -0.29 Lung cancer in ever smokers; chr15:43369261 chr15:43642389~43643023:- CESC cis rs2274273 0.624 rs7150234 ENSG00000258413.1 RP11-665C16.6 -4.46 1.29e-05 0.00679 -0.37 -0.29 Protein biomarker; chr14:55335463 chr14:55262767~55272075:- CESC cis rs2404602 0.583 rs12913096 ENSG00000280730.1 AC090181.1 4.46 1.29e-05 0.00679 0.22 0.29 Blood metabolite levels; chr15:76259511 chr15:77056895~77057021:+ CESC cis rs9309473 1 rs6745368 ENSG00000163016.8 ALMS1P 4.46 1.29e-05 0.00679 0.39 0.29 Metabolite levels; chr2:73582847 chr2:73644919~73685576:+ CESC cis rs1823913 0.637 rs11688994 ENSG00000227542.1 AC092614.2 4.46 1.29e-05 0.00679 0.3 0.29 Obesity-related traits; chr2:191266242 chr2:191229165~191246172:- CESC cis rs6687821 0.5 rs6702601 ENSG00000267734.1 RP4-604K5.3 -4.46 1.29e-05 0.00679 -0.34 -0.29 Yeast infection; chr1:87047875 chr1:86932199~86934891:- CESC cis rs7560272 0.538 rs7370393 ENSG00000273245.1 RP11-434P11.2 -4.46 1.29e-05 0.0068 -0.36 -0.29 Schizophrenia; chr2:73698509 chr2:73750256~73750786:- CESC cis rs7811142 1 rs6972167 ENSG00000078319.8 PMS2P1 -4.46 1.29e-05 0.0068 -0.46 -0.29 Platelet count; chr7:100482390 chr7:100320992~100341908:- CESC cis rs2439831 0.85 rs28590651 ENSG00000275601.1 AC011330.13 -4.46 1.29e-05 0.0068 -0.44 -0.29 Lung cancer in ever smokers; chr15:43820818 chr15:43642389~43643023:- CESC cis rs2179367 0.959 rs2262617 ENSG00000231760.4 RP11-350J20.5 4.46 1.29e-05 0.00681 0.37 0.29 Dupuytren's disease; chr6:149438590 chr6:149796151~149826294:- CESC cis rs6693388 0.918 rs6662611 ENSG00000229021.2 AL591893.1 -4.46 1.29e-05 0.00681 -0.34 -0.29 Blood metabolite ratios; chr1:151964009 chr1:151994531~152042774:+ CESC cis rs673078 0.607 rs4766900 ENSG00000275759.1 RP11-131L12.3 -4.46 1.3e-05 0.00682 -0.53 -0.29 Glucose homeostasis traits; chr12:118375139 chr12:118428281~118428870:+ CESC cis rs10043775 1 rs10044061 ENSG00000251330.3 CTD-2283N19.1 -4.46 1.3e-05 0.00682 -0.37 -0.29 Periodontal microbiota; chr5:148396934 chr5:148430159~148430807:- CESC cis rs4819052 0.851 rs13052344 ENSG00000223768.1 LINC00205 -4.46 1.3e-05 0.00683 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45256186 chr21:45293285~45297354:+ CESC cis rs4819052 0.808 rs11909411 ENSG00000223768.1 LINC00205 -4.46 1.3e-05 0.00683 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45256641 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs28676615 ENSG00000223768.1 LINC00205 -4.46 1.3e-05 0.00683 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45256661 chr21:45293285~45297354:+ CESC cis rs4819052 0.851 rs28501512 ENSG00000223768.1 LINC00205 -4.46 1.3e-05 0.00683 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45256787 chr21:45293285~45297354:+ CESC cis rs2858942 0.575 rs2858011 ENSG00000268836.1 LA16c-OS12.2 4.46 1.3e-05 0.00683 0.32 0.29 Mean corpuscular hemoglobin; chr16:197939 chr16:185748~186294:- CESC cis rs4308124 0.708 rs6747657 ENSG00000227992.1 AC108463.2 -4.46 1.3e-05 0.00684 -0.38 -0.29 Vitiligo; chr2:111245586 chr2:111203964~111206215:- CESC cis rs17301013 0.507 rs6701911 ENSG00000227373.4 RP11-160H22.5 4.46 1.3e-05 0.00685 0.39 0.29 Systemic lupus erythematosus; chr1:174364755 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs56148594 ENSG00000227373.4 RP11-160H22.5 4.46 1.3e-05 0.00685 0.39 0.29 Systemic lupus erythematosus; chr1:174383932 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12091056 ENSG00000227373.4 RP11-160H22.5 4.46 1.3e-05 0.00685 0.39 0.29 Systemic lupus erythematosus; chr1:174384470 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs4651019 ENSG00000227373.4 RP11-160H22.5 4.46 1.3e-05 0.00685 0.39 0.29 Systemic lupus erythematosus; chr1:174385079 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10912775 ENSG00000227373.4 RP11-160H22.5 4.46 1.3e-05 0.00685 0.39 0.29 Systemic lupus erythematosus; chr1:174388034 chr1:174115300~174160004:- CESC cis rs11159086 0.793 rs1029701 ENSG00000270000.1 RP3-449M8.9 4.46 1.31e-05 0.00686 0.44 0.29 Advanced glycation end-product levels; chr14:74474112 chr14:74471930~74472360:- CESC cis rs8072100 0.79 rs6505048 ENSG00000228782.6 CTD-2026D20.3 -4.46 1.31e-05 0.00686 -0.35 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47597632 chr17:47450568~47492492:- CESC cis rs673078 0.607 rs17440942 ENSG00000275759.1 RP11-131L12.3 4.46 1.31e-05 0.00686 0.56 0.29 Glucose homeostasis traits; chr12:118394030 chr12:118428281~118428870:+ CESC cis rs4819052 0.851 rs9977178 ENSG00000223768.1 LINC00205 -4.46 1.31e-05 0.00687 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45244616 chr21:45293285~45297354:+ CESC cis rs2019137 0.539 rs6755040 ENSG00000189223.12 PAX8-AS1 -4.46 1.31e-05 0.00687 -0.36 -0.29 Lymphocyte counts; chr2:113223560 chr2:113211522~113276581:+ CESC cis rs6686842 0.932 rs1008505 ENSG00000235358.1 RP11-399E6.1 -4.46 1.31e-05 0.00687 -0.35 -0.29 Height; chr1:41094563 chr1:41242373~41284861:+ CESC cis rs7873102 0.654 rs2244481 ENSG00000230188.1 RP11-405L18.4 -4.46 1.31e-05 0.00688 -0.36 -0.29 Brain structure; chr9:37984734 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2244322 ENSG00000230188.1 RP11-405L18.4 -4.46 1.31e-05 0.00688 -0.36 -0.29 Brain structure; chr9:37986112 chr9:37490421~37490893:- CESC cis rs2015599 0.623 rs7964831 ENSG00000257176.2 RP11-996F15.2 -4.46 1.31e-05 0.00688 -0.34 -0.29 Platelet count;Mean platelet volume; chr12:29286655 chr12:29280418~29317848:- CESC cis rs2439831 0.85 rs12101756 ENSG00000275601.1 AC011330.13 -4.46 1.31e-05 0.00688 -0.45 -0.29 Lung cancer in ever smokers; chr15:43761689 chr15:43642389~43643023:- CESC cis rs7176527 0.579 rs366717 ENSG00000229212.6 RP11-561C5.4 4.46 1.31e-05 0.00688 0.34 0.29 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84544848 chr15:85205440~85234795:- CESC cis rs1799949 0.965 rs11656945 ENSG00000267681.1 CTD-3199J23.6 -4.46 1.31e-05 0.00688 -0.38 -0.29 Menopause (age at onset); chr17:43178248 chr17:43144956~43145255:+ CESC cis rs7829975 0.714 rs11784052 ENSG00000253893.2 FAM85B -4.46 1.31e-05 0.00688 -0.35 -0.29 Mood instability; chr8:8814452 chr8:8167819~8226614:- CESC cis rs7809950 1 rs2712214 ENSG00000238832.1 snoU109 -4.46 1.31e-05 0.00689 -0.35 -0.29 Coronary artery disease; chr7:107547586 chr7:107603363~107603507:+ CESC cis rs992157 0.661 rs10171839 ENSG00000261338.2 RP11-378A13.1 4.46 1.31e-05 0.00689 0.34 0.29 Colorectal cancer; chr2:218186591 chr2:218255319~218257366:+ CESC cis rs11638352 1 rs12900237 ENSG00000259479.5 SORD2P -4.46 1.31e-05 0.00689 -0.43 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44038612 chr15:44826371~44884694:- CESC cis rs2733201 1 rs12591537 ENSG00000259479.5 SORD2P -4.46 1.31e-05 0.00689 -0.43 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44046065 chr15:44826371~44884694:- CESC cis rs62229266 0.839 rs11702763 ENSG00000231106.2 LINC01436 4.46 1.32e-05 0.0069 0.42 0.29 Mitral valve prolapse; chr21:36098406 chr21:36005338~36007838:+ CESC cis rs57549656 0.799 rs2110120 ENSG00000266944.1 AC005262.4 -4.46 1.32e-05 0.00691 -0.36 -0.29 Schizophrenia; chr19:2711415 chr19:3130717~3131398:+ CESC cis rs1729407 0.565 rs2849173 ENSG00000254851.1 RP11-109L13.1 -4.46 1.32e-05 0.00691 -0.33 -0.29 Apolipoprotein A-IV levels; chr11:116826605 chr11:117135528~117138582:+ CESC cis rs7560272 0.501 rs10191988 ENSG00000273245.1 RP11-434P11.2 -4.46 1.32e-05 0.00691 -0.36 -0.29 Schizophrenia; chr2:73720660 chr2:73750256~73750786:- CESC cis rs673078 0.607 rs17512644 ENSG00000275759.1 RP11-131L12.3 -4.46 1.32e-05 0.00691 -0.56 -0.29 Glucose homeostasis traits; chr12:118359963 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs17512652 ENSG00000275759.1 RP11-131L12.3 -4.46 1.32e-05 0.00691 -0.56 -0.29 Glucose homeostasis traits; chr12:118361278 chr12:118428281~118428870:+ CESC cis rs7927592 0.956 rs11228269 ENSG00000212093.1 AP000807.1 4.46 1.32e-05 0.00691 0.33 0.29 Total body bone mineral density; chr11:68522328 chr11:68506083~68506166:- CESC cis rs9929218 0.581 rs7203337 ENSG00000260459.2 FTLP14 4.46 1.32e-05 0.00691 0.36 0.29 Colorectal cancer; chr16:68740897 chr16:68822587~68823070:+ CESC cis rs6991838 0.765 rs6472219 ENSG00000200714.1 Y_RNA 4.46 1.32e-05 0.00691 0.34 0.29 Intelligence (multi-trait analysis); chr8:65644487 chr8:65592731~65592820:+ CESC cis rs74394007 0.92 rs6787952 ENSG00000244515.1 KRT18P34 4.46 1.32e-05 0.00691 0.52 0.29 Total body bone mineral density; chr3:156891586 chr3:157162663~157163932:- CESC cis rs12220238 0.915 rs10824197 ENSG00000213731.2 RAB5CP1 -4.46 1.32e-05 0.00692 -0.48 -0.29 Soluble interleukin-2 receptor subunit alpha; chr10:74523035 chr10:74423435~74424014:- CESC cis rs2276314 0.857 rs72883058 ENSG00000278986.1 RP11-723J4.3 -4.46 1.32e-05 0.00692 -0.32 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36032954 chr18:35972151~35973916:+ CESC cis rs12134133 1 rs61822697 ENSG00000274245.1 RP11-357P18.2 4.46 1.32e-05 0.00692 0.4 0.29 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207311819 chr1:207372559~207373252:+ CESC cis rs11779988 0.545 rs427168 ENSG00000253671.1 RP11-806O11.1 -4.46 1.32e-05 0.00692 -0.36 -0.29 Breast cancer; chr8:17927320 chr8:17808941~17820868:+ CESC cis rs11779988 0.545 rs4124900 ENSG00000253671.1 RP11-806O11.1 -4.46 1.32e-05 0.00692 -0.36 -0.29 Breast cancer; chr8:17927757 chr8:17808941~17820868:+ CESC cis rs11779988 0.545 rs398806 ENSG00000253671.1 RP11-806O11.1 -4.46 1.32e-05 0.00692 -0.36 -0.29 Breast cancer; chr8:17928717 chr8:17808941~17820868:+ CESC cis rs11779988 0.545 rs438873 ENSG00000253671.1 RP11-806O11.1 -4.46 1.32e-05 0.00692 -0.36 -0.29 Breast cancer; chr8:17929007 chr8:17808941~17820868:+ CESC cis rs2337406 0.85 rs1858678 ENSG00000211974.3 IGHV2-70 -4.46 1.32e-05 0.00692 -0.47 -0.29 Alzheimer's disease (late onset); chr14:106706790 chr14:106723574~106724093:- CESC cis rs77972916 0.561 rs17406174 ENSG00000234936.1 AC010883.5 4.46 1.32e-05 0.00694 0.41 0.29 Granulocyte percentage of myeloid white cells; chr2:43330345 chr2:43229573~43233394:+ CESC cis rs77972916 0.518 rs55877805 ENSG00000234936.1 AC010883.5 4.46 1.32e-05 0.00694 0.41 0.29 Granulocyte percentage of myeloid white cells; chr2:43330458 chr2:43229573~43233394:+ CESC cis rs77972916 0.561 rs72788900 ENSG00000234936.1 AC010883.5 4.46 1.32e-05 0.00694 0.41 0.29 Granulocyte percentage of myeloid white cells; chr2:43331948 chr2:43229573~43233394:+ CESC cis rs4974559 0.739 rs10032327 ENSG00000253399.1 AC078852.2 4.46 1.32e-05 0.00694 0.49 0.29 Systolic blood pressure; chr4:1329749 chr4:1358479~1359461:+ CESC cis rs2439831 0.85 rs3097773 ENSG00000275601.1 AC011330.13 4.46 1.32e-05 0.00694 0.39 0.29 Lung cancer in ever smokers; chr15:43600874 chr15:43642389~43643023:- CESC cis rs6991838 0.751 rs35553155 ENSG00000200714.1 Y_RNA 4.46 1.32e-05 0.00694 0.33 0.29 Intelligence (multi-trait analysis); chr8:65551232 chr8:65592731~65592820:+ CESC cis rs6991838 0.806 rs35024820 ENSG00000200714.1 Y_RNA 4.46 1.32e-05 0.00694 0.33 0.29 Intelligence (multi-trait analysis); chr8:65551296 chr8:65592731~65592820:+ CESC cis rs10246939 0.505 rs892354 ENSG00000228775.6 WEE2-AS1 4.46 1.32e-05 0.00694 0.36 0.29 Bitter taste perception; chr7:141844934 chr7:141704338~141738346:- CESC cis rs875971 0.571 rs78668714 ENSG00000226824.5 RP4-756H11.3 -4.46 1.33e-05 0.00695 -0.43 -0.29 Aortic root size; chr7:66474464 chr7:66654538~66669855:+ CESC cis rs5769707 1 rs5769707 ENSG00000235111.1 RP1-29C18.8 -4.46 1.33e-05 0.00695 -0.28 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49619754 chr22:49612657~49615716:- CESC cis rs2919917 0.554 rs2086755 ENSG00000254352.1 RP11-578O24.2 4.46 1.33e-05 0.00695 0.43 0.29 Lymphocyte counts; chr8:78701809 chr8:78723796~78724136:- CESC cis rs2243480 0.803 rs36004293 ENSG00000228409.4 CCT6P1 4.46 1.33e-05 0.00696 0.41 0.29 Diabetic kidney disease; chr7:65951525 chr7:65751142~65763354:+ CESC cis rs2243480 0.803 rs35268390 ENSG00000228409.4 CCT6P1 4.46 1.33e-05 0.00696 0.41 0.29 Diabetic kidney disease; chr7:65951549 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35542501 ENSG00000232559.3 GS1-124K5.12 4.46 1.33e-05 0.00696 0.47 0.29 Diabetic kidney disease; chr7:65966228 chr7:66554588~66576923:- CESC cis rs2243480 0.708 rs781141 ENSG00000232559.3 GS1-124K5.12 4.46 1.33e-05 0.00696 0.47 0.29 Diabetic kidney disease; chr7:65973566 chr7:66554588~66576923:- CESC cis rs189798 0.807 rs9949 ENSG00000253981.4 ALG1L13P 4.46 1.33e-05 0.00697 0.35 0.29 Myopia (pathological); chr8:9137002 chr8:8236003~8244667:- CESC cis rs11770686 0.902 rs7803077 ENSG00000214243.3 AC004980.10 4.46 1.33e-05 0.00697 0.25 0.29 Essential tremor; chr7:75693888 chr7:76650401~76650897:- CESC cis rs7429990 0.965 rs7430913 ENSG00000229759.1 MRPS18AP1 -4.46 1.33e-05 0.00698 -0.3 -0.29 Educational attainment (years of education); chr3:47990867 chr3:48256350~48256938:- CESC cis rs950169 0.649 rs12911612 ENSG00000225151.9 GOLGA2P7 -4.46 1.33e-05 0.00699 -0.43 -0.29 Schizophrenia; chr15:84022262 chr15:84199311~84230136:- CESC cis rs950169 0.649 rs12905952 ENSG00000225151.9 GOLGA2P7 -4.46 1.33e-05 0.00699 -0.43 -0.29 Schizophrenia; chr15:84022509 chr15:84199311~84230136:- CESC cis rs2919917 0.628 rs1036751 ENSG00000254352.1 RP11-578O24.2 -4.46 1.34e-05 0.00699 -0.41 -0.29 Lymphocyte counts; chr8:78729671 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs894222 ENSG00000254352.1 RP11-578O24.2 -4.46 1.34e-05 0.00699 -0.41 -0.29 Lymphocyte counts; chr8:78737034 chr8:78723796~78724136:- CESC cis rs7560272 0.538 rs4241257 ENSG00000273245.1 RP11-434P11.2 -4.46 1.34e-05 0.00699 -0.36 -0.29 Schizophrenia; chr2:73711480 chr2:73750256~73750786:- CESC cis rs9859260 0.744 rs3933 ENSG00000252174.1 RNU7-18P 4.46 1.34e-05 0.007 0.32 0.29 Mean corpuscular volume; chr3:196058126 chr3:196072819~196072880:+ CESC cis rs2836950 0.501 rs13047518 ENSG00000232608.1 TIMM9P2 4.46 1.34e-05 0.007 0.33 0.29 Menarche (age at onset); chr21:39335381 chr21:39216624~39217506:+ CESC cis rs9532669 0.926 rs2039119 ENSG00000176268.5 CYCSP34 -4.46 1.34e-05 0.007 -0.3 -0.29 Cervical cancer; chr13:40872432 chr13:40863599~40863902:- CESC cis rs73086581 0.617 rs2300213 ENSG00000229539.1 RP11-119B16.2 -4.46 1.34e-05 0.00701 -0.37 -0.29 Response to antidepressants in depression; chr20:4006076 chr20:3888239~3888868:- CESC cis rs1799949 1 rs12944597 ENSG00000267681.1 CTD-3199J23.6 -4.45 1.34e-05 0.00702 -0.4 -0.29 Menopause (age at onset); chr17:43035667 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs12942277 ENSG00000267681.1 CTD-3199J23.6 -4.45 1.34e-05 0.00702 -0.4 -0.29 Menopause (age at onset); chr17:43035957 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs34616041 ENSG00000267681.1 CTD-3199J23.6 -4.45 1.34e-05 0.00702 -0.4 -0.29 Menopause (age at onset); chr17:43036769 chr17:43144956~43145255:+ CESC cis rs2408955 0.521 rs1476607 ENSG00000258273.1 RP11-370I10.4 4.45 1.34e-05 0.00702 0.33 0.29 Glycated hemoglobin levels; chr12:48131021 chr12:48333755~48333901:- CESC cis rs9532669 0.926 rs12428966 ENSG00000176268.5 CYCSP34 4.45 1.34e-05 0.00702 0.29 0.29 Cervical cancer; chr13:40876552 chr13:40863599~40863902:- CESC cis rs2243480 1 rs937108 ENSG00000232559.3 GS1-124K5.12 4.45 1.34e-05 0.00703 0.47 0.29 Diabetic kidney disease; chr7:65963465 chr7:66554588~66576923:- CESC cis rs113835537 0.866 rs59566349 ENSG00000255517.5 CTD-3074O7.5 -4.45 1.35e-05 0.00704 -0.46 -0.29 Airway imaging phenotypes; chr11:66598523 chr11:66473490~66480233:- CESC cis rs10129255 0.536 rs17113249 ENSG00000224373.3 IGHV4-59 4.45 1.35e-05 0.00704 0.18 0.29 Kawasaki disease; chr14:106678273 chr14:106627249~106627825:- CESC cis rs875971 0.825 rs28480509 ENSG00000222364.1 RNU6-96P 4.45 1.35e-05 0.00704 0.34 0.29 Aortic root size; chr7:66634237 chr7:66395191~66395286:+ CESC cis rs9907295 0.591 rs11650668 ENSG00000271013.1 AC015849.15 -4.45 1.35e-05 0.00704 -0.33 -0.29 Fibroblast growth factor basic levels; chr17:35822045 chr17:35912635~35918010:- CESC cis rs700651 0.789 rs1976772 ENSG00000222017.1 AC011997.1 4.45 1.35e-05 0.00705 0.37 0.29 Intracranial aneurysm; chr2:198003477 chr2:197693106~197774823:+ CESC cis rs700651 0.757 rs6748683 ENSG00000222017.1 AC011997.1 4.45 1.35e-05 0.00705 0.37 0.29 Intracranial aneurysm; chr2:198013284 chr2:197693106~197774823:+ CESC cis rs62355901 0.505 rs61193961 ENSG00000271828.1 CTD-2310F14.1 4.45 1.35e-05 0.00705 0.49 0.29 Breast cancer; chr5:56792343 chr5:56927874~56929573:+ CESC cis rs2919917 1 rs2919936 ENSG00000254352.1 RP11-578O24.2 4.45 1.35e-05 0.00705 0.37 0.29 Lymphocyte counts; chr8:78721772 chr8:78723796~78724136:- CESC cis rs875971 0.545 rs73148639 ENSG00000226824.5 RP4-756H11.3 -4.45 1.35e-05 0.00705 -0.41 -0.29 Aortic root size; chr7:66390342 chr7:66654538~66669855:+ CESC cis rs1387259 0.759 rs7960122 ENSG00000240399.1 RP1-228P16.1 -4.45 1.35e-05 0.00705 -0.34 -0.29 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48383217 chr12:48054813~48055591:- CESC cis rs9640161 0.636 rs56190213 ENSG00000261305.1 RP4-584D14.7 4.45 1.35e-05 0.00706 0.43 0.29 Blood protein levels;Circulating chemerin levels; chr7:150328631 chr7:150341771~150342607:+ CESC cis rs1729407 0.774 rs2849167 ENSG00000254851.1 RP11-109L13.1 4.45 1.35e-05 0.00707 0.35 0.29 Apolipoprotein A-IV levels; chr11:116814028 chr11:117135528~117138582:+ CESC cis rs9309473 0.748 rs2421552 ENSG00000163016.8 ALMS1P 4.45 1.35e-05 0.00708 0.39 0.29 Metabolite levels; chr2:73531676 chr2:73644919~73685576:+ CESC cis rs1862618 0.853 rs832582 ENSG00000271828.1 CTD-2310F14.1 4.45 1.36e-05 0.00708 0.39 0.29 Initial pursuit acceleration; chr5:56881916 chr5:56927874~56929573:+ CESC cis rs11096990 0.964 rs3733280 ENSG00000249207.1 RP11-360F5.1 4.45 1.36e-05 0.00708 0.35 0.29 Cognitive function; chr4:39269921 chr4:39112677~39126818:- CESC cis rs2739330 0.753 rs4822452 ENSG00000231271.1 AP000350.8 4.45 1.36e-05 0.00709 0.34 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23949918~23954042:+ CESC cis rs7811142 0.72 rs112622797 ENSG00000242294.5 STAG3L5P 4.45 1.36e-05 0.00709 0.35 0.29 Platelet count; chr7:100319793 chr7:100336079~100351900:+ CESC cis rs9309473 0.95 rs17009149 ENSG00000163016.8 ALMS1P 4.45 1.36e-05 0.0071 0.39 0.29 Metabolite levels; chr2:73563241 chr2:73644919~73685576:+ CESC cis rs2243480 0.908 rs55876148 ENSG00000232559.3 GS1-124K5.12 4.45 1.36e-05 0.0071 0.5 0.29 Diabetic kidney disease; chr7:65914813 chr7:66554588~66576923:- CESC cis rs2243480 1 rs56016656 ENSG00000232559.3 GS1-124K5.12 4.45 1.36e-05 0.0071 0.5 0.29 Diabetic kidney disease; chr7:65918494 chr7:66554588~66576923:- CESC cis rs2243480 1 rs56291018 ENSG00000232559.3 GS1-124K5.12 4.45 1.36e-05 0.0071 0.5 0.29 Diabetic kidney disease; chr7:65925352 chr7:66554588~66576923:- CESC cis rs2243480 1 rs36033484 ENSG00000232559.3 GS1-124K5.12 4.45 1.36e-05 0.0071 0.5 0.29 Diabetic kidney disease; chr7:65925571 chr7:66554588~66576923:- CESC cis rs2243480 1 rs34560516 ENSG00000232559.3 GS1-124K5.12 4.45 1.36e-05 0.0071 0.5 0.29 Diabetic kidney disease; chr7:65939105 chr7:66554588~66576923:- CESC cis rs2732480 0.5 rs11168468 ENSG00000240399.1 RP1-228P16.1 4.45 1.36e-05 0.00711 0.35 0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48218682 chr12:48054813~48055591:- CESC cis rs1061377 0.513 rs6840214 ENSG00000249207.1 RP11-360F5.1 4.45 1.36e-05 0.00711 0.39 0.29 Uric acid levels; chr4:39118999 chr4:39112677~39126818:- CESC cis rs13108904 0.901 rs6826029 ENSG00000254094.1 AC078852.1 -4.45 1.36e-05 0.00712 -0.34 -0.29 Obesity-related traits; chr4:1313901 chr4:1356581~1358075:+ CESC cis rs2739330 0.703 rs5760112 ENSG00000228039.3 KB-1125A3.10 4.45 1.36e-05 0.00712 0.35 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23963780~23964374:+ CESC cis rs10129255 0.913 rs28861466 ENSG00000280411.1 IGHV1-69-2 -4.45 1.36e-05 0.00712 -0.23 -0.29 Kawasaki disease; chr14:106718572 chr14:106762092~106762588:- CESC cis rs875971 0.545 rs66594357 ENSG00000226824.5 RP4-756H11.3 -4.45 1.37e-05 0.00713 -0.4 -0.29 Aortic root size; chr7:66327797 chr7:66654538~66669855:+ CESC cis rs73086581 0.568 rs6084541 ENSG00000229539.1 RP11-119B16.2 -4.45 1.37e-05 0.00713 -0.36 -0.29 Response to antidepressants in depression; chr20:3982084 chr20:3888239~3888868:- CESC cis rs7809950 1 rs17154104 ENSG00000238832.1 snoU109 -4.45 1.37e-05 0.00714 -0.33 -0.29 Coronary artery disease; chr7:107450253 chr7:107603363~107603507:+ CESC cis rs17826219 0.585 rs8064302 ENSG00000263531.1 RP13-753N3.1 -4.45 1.37e-05 0.00714 -0.61 -0.29 Body mass index; chr17:30397920 chr17:30863921~30864940:- CESC cis rs2408955 0.522 rs10875721 ENSG00000240399.1 RP1-228P16.1 -4.45 1.37e-05 0.00715 -0.33 -0.29 Glycated hemoglobin levels; chr12:48019810 chr12:48054813~48055591:- CESC cis rs1320333 0.772 rs35181861 ENSG00000233296.1 AC092159.2 4.45 1.37e-05 0.00715 0.55 0.29 Obesity-related traits; chr2:679483 chr2:677186~697371:+ CESC cis rs10129255 0.957 rs12590667 ENSG00000211974.3 IGHV2-70 -4.45 1.37e-05 0.00715 -0.29 -0.29 Kawasaki disease; chr14:106779223 chr14:106723574~106724093:- CESC cis rs2361701 1 rs2361701 ENSG00000279259.1 RP11-334C17.3 4.45 1.37e-05 0.00715 0.38 0.29 IgG glycosylation; chr17:80092818 chr17:80147250~80148596:+ CESC cis rs4722166 0.695 rs35779989 ENSG00000179428.2 AC073072.5 -4.45 1.37e-05 0.00715 -0.37 -0.29 Lung cancer; chr7:22760695 chr7:22725395~22727620:- CESC cis rs9402743 0.781 rs9494331 ENSG00000217482.2 HMGB1P17 -4.45 1.37e-05 0.00716 -0.33 -0.29 Systemic lupus erythematosus; chr6:135685163 chr6:135636086~135636713:- CESC cis rs5758659 0.714 rs133373 ENSG00000273366.1 CTA-989H11.1 -4.45 1.37e-05 0.00716 -0.36 -0.29 Cognitive function; chr22:42069784 chr22:42278188~42278846:+ CESC cis rs72772090 0.539 rs72775810 ENSG00000248734.2 CTD-2260A17.1 -4.45 1.37e-05 0.00716 -0.45 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96849604 chr5:96784777~96785999:+ CESC cis rs11672691 0.67 rs4802119 ENSG00000270164.1 LINC01480 -4.45 1.37e-05 0.00717 -0.33 -0.29 Prostate cancer; chr19:41484417 chr19:41535183~41536904:+ CESC cis rs11685222 0.64 rs59771783 ENSG00000229326.3 AC069154.4 4.45 1.37e-05 0.00717 0.42 0.29 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119683529 chr2:119698623~119700151:+ CESC cis rs2919917 1 rs2046338 ENSG00000254352.1 RP11-578O24.2 4.45 1.38e-05 0.00719 0.36 0.29 Lymphocyte counts; chr8:78723734 chr8:78723796~78724136:- CESC cis rs751837 0.86 rs10150442 ENSG00000240624.1 RP11-45P15.2 -4.45 1.38e-05 0.00719 -0.47 -0.29 Large B-cell lymphoma; chr14:103025291 chr14:103282933~103283468:+ CESC cis rs9322193 0.847 rs12234128 ENSG00000268592.3 RAET1E-AS1 4.45 1.38e-05 0.00719 0.37 0.29 Lung cancer; chr6:149627553 chr6:149863494~149919507:+ CESC cis rs6687821 0.531 rs4518960 ENSG00000267734.1 RP4-604K5.3 -4.45 1.38e-05 0.00719 -0.34 -0.29 Yeast infection; chr1:87048746 chr1:86932199~86934891:- CESC cis rs10788972 0.933 rs4492560 ENSG00000225183.1 RP4-758J24.4 -4.45 1.38e-05 0.00719 -0.33 -0.29 Parkinson disease and lewy body pathology; chr1:54102815 chr1:54089856~54090093:+ CESC cis rs12745968 0.652 rs942753 ENSG00000223787.2 RP4-593M8.1 -4.45 1.38e-05 0.0072 -0.38 -0.29 Bipolar disorder and schizophrenia; chr1:92476909 chr1:92580476~92580821:- CESC cis rs9987353 0.519 rs2929465 ENSG00000173295.6 FAM86B3P -4.45 1.38e-05 0.0072 -0.37 -0.29 Recombination measurement; chr8:9206492 chr8:8228595~8244865:+ CESC cis rs10800713 0.954 rs4504918 ENSG00000260088.1 RP11-92G12.3 4.45 1.38e-05 0.0072 0.44 0.29 Tandem gait; chr1:200588639 chr1:200669507~200694250:+ CESC cis rs4819052 0.851 rs2236444 ENSG00000223768.1 LINC00205 -4.45 1.38e-05 0.00721 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45258311 chr21:45293285~45297354:+ CESC cis rs4272720 0.535 rs12261297 ENSG00000229870.1 RP11-507K13.6 -4.45 1.38e-05 0.00721 -0.33 -0.29 Platelet count;Plateletcrit; chr10:49085213 chr10:49815096~49815562:+ CESC cis rs9907295 0.748 rs11868785 ENSG00000270977.1 AC015849.16 -4.45 1.38e-05 0.00721 -0.37 -0.29 Fibroblast growth factor basic levels; chr17:35812214 chr17:35893707~35911023:- CESC cis rs1930961 1 rs6004669 ENSG00000272942.1 CTA-246H3.12 -4.45 1.38e-05 0.00721 -0.42 -0.29 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25434324~25435070:- CESC cis rs7580658 0.545 rs59318157 ENSG00000236682.1 AC068282.3 -4.45 1.39e-05 0.00721 -0.34 -0.29 Protein C levels; chr2:127192498 chr2:127389130~127400580:+ CESC cis rs2412819 0.545 rs35822148 ENSG00000249839.1 AC011330.5 -4.45 1.39e-05 0.00722 -0.46 -0.29 Lung cancer; chr15:43808084 chr15:43663654~43684339:- CESC cis rs2739330 0.828 rs2877178 ENSG00000231271.1 AP000350.8 4.45 1.39e-05 0.00722 0.35 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23949918~23954042:+ CESC cis rs7826238 0.535 rs2979179 ENSG00000173295.6 FAM86B3P 4.45 1.39e-05 0.00722 0.34 0.29 Systolic blood pressure; chr8:8462519 chr8:8228595~8244865:+ CESC cis rs4819052 0.851 rs13050359 ENSG00000223768.1 LINC00205 -4.45 1.39e-05 0.00722 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45252756 chr21:45293285~45297354:+ CESC cis rs9322193 0.924 rs9498382 ENSG00000216906.2 RP11-350J20.9 4.45 1.39e-05 0.00724 0.31 0.29 Lung cancer; chr6:149610982 chr6:149904243~149906418:+ CESC cis rs7829975 0.774 rs13259216 ENSG00000253893.2 FAM85B -4.45 1.39e-05 0.00724 -0.35 -0.29 Mood instability; chr8:8816091 chr8:8167819~8226614:- CESC cis rs9532669 0.926 rs1055588 ENSG00000176268.5 CYCSP34 4.45 1.39e-05 0.00724 0.29 0.29 Cervical cancer; chr13:40871306 chr13:40863599~40863902:- CESC cis rs8040855 0.794 rs4843024 ENSG00000259295.5 CSPG4P12 -4.45 1.39e-05 0.00724 -0.35 -0.29 Bulimia nervosa; chr15:85162669 chr15:85191438~85213905:+ CESC cis rs11159086 0.938 rs11623040 ENSG00000259005.1 RP3-449M8.6 4.45 1.39e-05 0.00725 0.49 0.29 Advanced glycation end-product levels; chr14:74496743 chr14:74474007~74474864:- CESC cis rs875971 0.545 rs17138156 ENSG00000237310.1 GS1-124K5.4 4.45 1.39e-05 0.00725 0.3 0.29 Aortic root size; chr7:66249708 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs10950029 ENSG00000222364.1 RNU6-96P -4.45 1.4e-05 0.00726 -0.38 -0.29 Aortic root size; chr7:66169334 chr7:66395191~66395286:+ CESC cis rs6452524 0.78 rs10078661 ENSG00000249664.1 CTD-2227C6.2 4.45 1.4e-05 0.00726 0.35 0.29 Hypertension (SNP x SNP interaction); chr5:83182136 chr5:83012285~83013109:- CESC cis rs3020736 0.5 rs6002597 ENSG00000273366.1 CTA-989H11.1 4.45 1.4e-05 0.00726 0.4 0.29 Autism spectrum disorder or schizophrenia; chr22:42092156 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs6002603 ENSG00000273366.1 CTA-989H11.1 4.45 1.4e-05 0.00726 0.4 0.29 Autism spectrum disorder or schizophrenia; chr22:42096358 chr22:42278188~42278846:+ CESC cis rs950776 0.518 rs3813571 ENSG00000279373.1 RP11-650L12.4 4.45 1.4e-05 0.00726 0.34 0.29 Sudden cardiac arrest; chr15:78540450 chr15:78537681~78538946:+ CESC cis rs10129255 0.957 rs10140904 ENSG00000280411.1 IGHV1-69-2 -4.45 1.4e-05 0.00727 -0.21 -0.29 Kawasaki disease; chr14:106776558 chr14:106762092~106762588:- CESC cis rs1538970 0.748 rs11211137 ENSG00000280836.1 AL355480.1 -4.45 1.4e-05 0.00727 -0.37 -0.29 Platelet count; chr1:45548220 chr1:45581219~45581321:- CESC cis rs17507216 0.628 rs28607761 ENSG00000255769.6 GOLGA2P10 -4.44 1.4e-05 0.00728 -0.42 -0.29 Excessive daytime sleepiness; chr15:82715317 chr15:82472993~82513950:- CESC cis rs7104764 0.507 rs7121085 ENSG00000277290.1 RP11-326C3.16 -4.44 1.4e-05 0.00728 -0.32 -0.29 Menarche (age at onset); chr11:258523 chr11:243099~243483:- CESC cis rs875971 0.52 rs160645 ENSG00000222364.1 RNU6-96P 4.44 1.4e-05 0.00729 0.4 0.29 Aortic root size; chr7:66091320 chr7:66395191~66395286:+ CESC cis rs875971 0.789 rs28815324 ENSG00000222364.1 RNU6-96P 4.44 1.4e-05 0.00729 0.4 0.29 Aortic root size; chr7:66100789 chr7:66395191~66395286:+ CESC cis rs7208859 0.573 rs8070182 ENSG00000266490.1 CTD-2349P21.9 4.44 1.4e-05 0.00729 0.43 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30792372~30792833:+ CESC cis rs5758659 0.679 rs134870 ENSG00000273366.1 CTA-989H11.1 -4.44 1.4e-05 0.00729 -0.35 -0.29 Cognitive function; chr22:42256311 chr22:42278188~42278846:+ CESC cis rs755249 0.761 rs61781390 ENSG00000228060.1 RP11-69E11.8 -4.44 1.4e-05 0.0073 -0.34 -0.29 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39610222 chr1:39565160~39573203:+ CESC cis rs1538970 0.924 rs1826691 ENSG00000280836.1 AL355480.1 4.44 1.4e-05 0.0073 0.35 0.29 Platelet count; chr1:45415590 chr1:45581219~45581321:- CESC cis rs801193 0.66 rs10950049 ENSG00000237310.1 GS1-124K5.4 4.44 1.41e-05 0.0073 0.27 0.29 Aortic root size; chr7:66765873 chr7:66493706~66495474:+ CESC cis rs2117029 0.727 rs10875910 ENSG00000258017.1 RP11-386G11.10 -4.44 1.41e-05 0.0073 -0.41 -0.29 Intelligence (multi-trait analysis); chr12:49008610 chr12:49127782~49147869:+ CESC cis rs831571 0.668 rs17069879 ENSG00000280620.1 SCAANT1 -4.44 1.41e-05 0.00731 -0.46 -0.29 Type 2 diabetes; chr3:64097741 chr3:63911518~63911772:- CESC cis rs2548724 0.617 rs62369302 ENSG00000250682.4 LINC00491 4.44 1.41e-05 0.00731 0.37 0.29 Type 2 diabetes; chr5:102372089 chr5:102609156~102671559:- CESC cis rs11685222 0.64 rs113774836 ENSG00000229326.3 AC069154.4 4.44 1.41e-05 0.00731 0.42 0.29 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119666431 chr2:119698623~119700151:+ CESC cis rs11685222 0.64 rs115638349 ENSG00000229326.3 AC069154.4 4.44 1.41e-05 0.00731 0.42 0.29 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119666875 chr2:119698623~119700151:+ CESC cis rs7829975 0.517 rs12542733 ENSG00000253893.2 FAM85B 4.44 1.41e-05 0.00732 0.35 0.29 Mood instability; chr8:8967348 chr8:8167819~8226614:- CESC cis rs950880 0.71 rs3771172 ENSG00000234389.1 AC007278.3 -4.44 1.41e-05 0.00732 -0.33 -0.29 Serum protein levels (sST2); chr2:102369352 chr2:102438713~102440475:+ CESC cis rs9309473 1 rs10187192 ENSG00000163016.8 ALMS1P 4.44 1.41e-05 0.00732 0.4 0.29 Metabolite levels; chr2:73486373 chr2:73644919~73685576:+ CESC cis rs9309473 0.948 rs10183818 ENSG00000163016.8 ALMS1P 4.44 1.41e-05 0.00732 0.4 0.29 Metabolite levels; chr2:73487429 chr2:73644919~73685576:+ CESC cis rs12439619 0.739 rs4778988 ENSG00000278603.1 RP13-608F4.5 4.44 1.41e-05 0.00732 0.41 0.29 Intelligence (multi-trait analysis); chr15:82247996 chr15:82472203~82472426:+ CESC cis rs7015630 0.827 rs13277948 ENSG00000251136.7 RP11-37B2.1 -4.44 1.41e-05 0.00732 -0.32 -0.29 Inflammatory bowel disease;Crohn's disease; chr8:89851500 chr8:89609409~89757727:- CESC cis rs17818399 0.815 rs17768132 ENSG00000279254.1 RP11-536C12.1 4.44 1.41e-05 0.00733 0.36 0.29 Height; chr2:46636110 chr2:46668870~46670778:+ CESC cis rs2564921 0.73 rs2564939 ENSG00000242142.1 SERBP1P3 4.44 1.41e-05 0.00733 0.35 0.29 Height; chr3:53072864 chr3:53064283~53065091:- CESC cis rs1044826 0.692 rs295484 ENSG00000178631.7 ACTG1P1 -4.44 1.41e-05 0.00733 -0.36 -0.29 Obesity-related traits; chr3:139512940 chr3:139493809~139494937:+ CESC cis rs4819052 0.851 rs2838845 ENSG00000223768.1 LINC00205 -4.44 1.41e-05 0.00733 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45250897 chr21:45293285~45297354:+ CESC cis rs9907295 0.591 rs8080959 ENSG00000271013.1 AC015849.15 -4.44 1.41e-05 0.00733 -0.32 -0.29 Fibroblast growth factor basic levels; chr17:35813450 chr17:35912635~35918010:- CESC cis rs950880 0.767 rs6543119 ENSG00000234389.1 AC007278.3 -4.44 1.41e-05 0.00734 -0.31 -0.29 Serum protein levels (sST2); chr2:102346612 chr2:102438713~102440475:+ CESC cis rs950880 0.767 rs13017455 ENSG00000234389.1 AC007278.3 -4.44 1.41e-05 0.00734 -0.31 -0.29 Serum protein levels (sST2); chr2:102348282 chr2:102438713~102440475:+ CESC cis rs5769707 0.609 rs2071890 ENSG00000235111.1 RP1-29C18.8 -4.44 1.41e-05 0.00734 -0.32 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49607643 chr22:49612657~49615716:- CESC cis rs7829975 0.714 rs7823757 ENSG00000253893.2 FAM85B -4.44 1.42e-05 0.00735 -0.34 -0.29 Mood instability; chr8:8812667 chr8:8167819~8226614:- CESC cis rs11779988 0.545 rs422746 ENSG00000253671.1 RP11-806O11.1 -4.44 1.42e-05 0.00735 -0.36 -0.29 Breast cancer; chr8:17926977 chr8:17808941~17820868:+ CESC cis rs77972916 0.519 rs13411327 ENSG00000234936.1 AC010883.5 4.44 1.42e-05 0.00735 0.39 0.29 Granulocyte percentage of myeloid white cells; chr2:43288344 chr2:43229573~43233394:+ CESC cis rs7621025 0.5 rs4678275 ENSG00000239213.4 NCK1-AS1 4.44 1.42e-05 0.00735 0.35 0.29 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136934841 chr3:136841726~136862054:- CESC cis rs6782228 0.883 rs11712115 ENSG00000242551.2 POU5F1P6 4.44 1.42e-05 0.00736 0.34 0.29 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128685426 chr3:128674735~128677005:- CESC cis rs2243480 1 rs1404147 ENSG00000232559.3 GS1-124K5.12 4.44 1.42e-05 0.00736 0.45 0.29 Diabetic kidney disease; chr7:65799537 chr7:66554588~66576923:- CESC cis rs9309473 1 rs11674602 ENSG00000163016.8 ALMS1P 4.44 1.42e-05 0.00736 0.38 0.29 Metabolite levels; chr2:73496058 chr2:73644919~73685576:+ CESC cis rs875971 0.867 rs13227219 ENSG00000237310.1 GS1-124K5.4 4.44 1.42e-05 0.00736 0.28 0.29 Aortic root size; chr7:66379075 chr7:66493706~66495474:+ CESC cis rs10788972 0.683 rs6694397 ENSG00000225183.1 RP4-758J24.4 -4.44 1.42e-05 0.00738 -0.33 -0.29 Parkinson disease and lewy body pathology; chr1:54100637 chr1:54089856~54090093:+ CESC cis rs1061377 0.748 rs35904472 ENSG00000249207.1 RP11-360F5.1 -4.44 1.42e-05 0.00738 -0.35 -0.29 Uric acid levels; chr4:39094901 chr4:39112677~39126818:- CESC cis rs4852324 0.536 rs17009553 ENSG00000237883.1 DGUOK-AS1 4.44 1.42e-05 0.00738 0.76 0.29 Systemic lupus erythematosus; chr2:73992908 chr2:73947642~73981441:- CESC cis rs8059260 1 rs6498139 ENSG00000274038.1 RP11-66H6.4 -4.44 1.42e-05 0.00738 -0.42 -0.29 Alcohol consumption over the past year; chr16:10954066 chr16:11056556~11057034:+ CESC cis rs8059260 1 rs7185978 ENSG00000274038.1 RP11-66H6.4 -4.44 1.42e-05 0.00738 -0.42 -0.29 Alcohol consumption over the past year; chr16:10954417 chr16:11056556~11057034:+ CESC cis rs853679 0.517 rs1947863 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Depression; chr6:28131566 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380056 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Depression; chr6:28136698 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380057 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Depression; chr6:28136856 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs6941992 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Depression; chr6:28138363 chr6:28115628~28116551:+ CESC cis rs4713118 0.516 rs4713142 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Parkinson's disease; chr6:28138569 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs4713143 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Depression; chr6:28138981 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs4713144 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Depression; chr6:28139012 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs3757187 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Depression; chr6:28139876 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs3757185 ENSG00000219392.1 RP1-265C24.5 -4.44 1.42e-05 0.00738 -0.38 -0.29 Depression; chr6:28139998 chr6:28115628~28116551:+ CESC cis rs2243480 1 rs1964692 ENSG00000232559.3 GS1-124K5.12 4.44 1.42e-05 0.00738 0.47 0.29 Diabetic kidney disease; chr7:65989196 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1723267 ENSG00000232559.3 GS1-124K5.12 4.44 1.42e-05 0.00738 0.47 0.29 Diabetic kidney disease; chr7:66008327 chr7:66554588~66576923:- CESC cis rs2243480 1 rs781156 ENSG00000232559.3 GS1-124K5.12 4.44 1.42e-05 0.00738 0.47 0.29 Diabetic kidney disease; chr7:66014154 chr7:66554588~66576923:- CESC cis rs2243480 1 rs451396 ENSG00000232559.3 GS1-124K5.12 4.44 1.42e-05 0.00738 0.47 0.29 Diabetic kidney disease; chr7:66019087 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1715235 ENSG00000232559.3 GS1-124K5.12 4.44 1.42e-05 0.00738 0.47 0.29 Diabetic kidney disease; chr7:66023407 chr7:66554588~66576923:- CESC cis rs7429990 0.965 rs7619882 ENSG00000229759.1 MRPS18AP1 4.44 1.42e-05 0.00739 0.3 0.29 Educational attainment (years of education); chr3:47943334 chr3:48256350~48256938:- CESC cis rs3096299 0.566 rs4129126 ENSG00000274627.1 RP11-104N10.2 4.44 1.42e-05 0.00739 0.29 0.29 Multiple myeloma (IgH translocation); chr16:89495067 chr16:89516797~89522217:+ CESC cis rs7829975 0.623 rs10092965 ENSG00000253893.2 FAM85B -4.44 1.43e-05 0.00739 -0.36 -0.29 Mood instability; chr8:8515975 chr8:8167819~8226614:- CESC cis rs6142102 0.923 rs6059586 ENSG00000275784.1 RP5-1125A11.6 -4.44 1.43e-05 0.00739 -0.3 -0.29 Skin pigmentation; chr20:33952695 chr20:33989480~33991818:- CESC cis rs11157436 1 rs75648426 ENSG00000211813.2 TRAV34 4.44 1.43e-05 0.0074 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22184044 chr14:22207522~22208129:+ CESC cis rs6504622 0.557 rs7213526 ENSG00000263142.4 LRRC37A17P -4.44 1.43e-05 0.0074 -0.22 -0.29 Orofacial clefts; chr17:46933791 chr17:46978481~47054569:+ CESC cis rs4713118 0.615 rs9295747 ENSG00000216901.1 AL022393.7 -4.44 1.43e-05 0.0074 -0.3 -0.29 Parkinson's disease; chr6:27769214 chr6:28176188~28176674:+ CESC cis rs8059260 0.736 rs16957883 ENSG00000274038.1 RP11-66H6.4 -4.44 1.43e-05 0.0074 -0.48 -0.29 Alcohol consumption over the past year; chr16:10994788 chr16:11056556~11057034:+ CESC cis rs875971 0.545 rs7783889 ENSG00000237310.1 GS1-124K5.4 4.44 1.43e-05 0.0074 0.3 0.29 Aortic root size; chr7:66283366 chr7:66493706~66495474:+ CESC cis rs116175783 0.557 rs10490567 ENSG00000227403.1 AC009299.3 4.44 1.43e-05 0.0074 0.45 0.29 Intelligence (multi-trait analysis); chr2:161317267 chr2:161244739~161249050:+ CESC cis rs7873102 0.654 rs2244207 ENSG00000230188.1 RP11-405L18.4 -4.44 1.43e-05 0.0074 -0.36 -0.29 Brain structure; chr9:37986981 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2244006 ENSG00000230188.1 RP11-405L18.4 -4.44 1.43e-05 0.0074 -0.36 -0.29 Brain structure; chr9:37988650 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2265166 ENSG00000230188.1 RP11-405L18.4 -4.44 1.43e-05 0.0074 -0.36 -0.29 Brain structure; chr9:37988832 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs1928232 ENSG00000230188.1 RP11-405L18.4 -4.44 1.43e-05 0.0074 -0.36 -0.29 Brain structure; chr9:37989700 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2243782 ENSG00000230188.1 RP11-405L18.4 -4.44 1.43e-05 0.0074 -0.36 -0.29 Brain structure; chr9:37990696 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10814636 ENSG00000230188.1 RP11-405L18.4 4.44 1.43e-05 0.0074 0.36 0.29 Brain structure; chr9:37991702 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs12338509 ENSG00000230188.1 RP11-405L18.4 4.44 1.43e-05 0.0074 0.36 0.29 Brain structure; chr9:37992585 chr9:37490421~37490893:- CESC cis rs7873102 0.63 rs10814637 ENSG00000230188.1 RP11-405L18.4 4.44 1.43e-05 0.0074 0.36 0.29 Brain structure; chr9:37994337 chr9:37490421~37490893:- CESC cis rs694739 1 rs646153 ENSG00000236935.1 AP003774.1 4.44 1.43e-05 0.0074 0.3 0.29 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64322116 chr11:64325050~64329504:- CESC cis rs875971 0.755 rs76288834 ENSG00000222364.1 RNU6-96P 4.44 1.43e-05 0.00741 0.34 0.29 Aortic root size; chr7:66604815 chr7:66395191~66395286:+ CESC cis rs7829975 0.714 rs60315134 ENSG00000253893.2 FAM85B -4.44 1.43e-05 0.00741 -0.34 -0.29 Mood instability; chr8:8813089 chr8:8167819~8226614:- CESC cis rs2933343 1 rs789213 ENSG00000231305.3 RP11-723O4.2 -4.44 1.43e-05 0.00741 -0.3 -0.29 IgG glycosylation; chr3:128897516 chr3:128861313~128871540:- CESC cis rs4319547 0.695 rs11836188 ENSG00000275265.1 RP11-15J22.8 4.44 1.43e-05 0.00742 0.41 0.29 Body mass index; chr12:122380960 chr12:122501187~122501641:+ CESC cis rs9517320 1 rs9584856 ENSG00000231194.1 FARP1-AS1 4.44 1.43e-05 0.00742 0.34 0.29 Longevity; chr13:98474297 chr13:98435405~98435840:- CESC cis rs7560272 0.502 rs4513320 ENSG00000273245.1 RP11-434P11.2 -4.44 1.44e-05 0.00743 -0.36 -0.29 Schizophrenia; chr2:73693614 chr2:73750256~73750786:- CESC cis rs4819052 0.851 rs4819041 ENSG00000223768.1 LINC00205 -4.44 1.44e-05 0.00744 -0.32 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45240040 chr21:45293285~45297354:+ CESC cis rs4722166 0.695 rs56061963 ENSG00000179428.2 AC073072.5 -4.44 1.44e-05 0.00744 -0.37 -0.29 Lung cancer; chr7:22760778 chr7:22725395~22727620:- CESC cis rs8100891 0.537 rs4805762 ENSG00000267213.4 AC007773.2 -4.44 1.44e-05 0.00744 -0.43 -0.29 Neuroticism; chr19:32473048 chr19:32390050~32405560:- CESC cis rs8100891 0.537 rs1057395 ENSG00000267213.4 AC007773.2 -4.44 1.44e-05 0.00744 -0.43 -0.29 Neuroticism; chr19:32483832 chr19:32390050~32405560:- CESC cis rs8100891 0.537 rs1057397 ENSG00000267213.4 AC007773.2 -4.44 1.44e-05 0.00744 -0.43 -0.29 Neuroticism; chr19:32484007 chr19:32390050~32405560:- CESC cis rs1538970 0.816 rs34673142 ENSG00000280836.1 AL355480.1 -4.44 1.44e-05 0.00745 -0.36 -0.29 Platelet count; chr1:45519889 chr1:45581219~45581321:- CESC cis rs35740288 0.929 rs11073537 ENSG00000202081.1 RNU6-1280P 4.44 1.44e-05 0.00746 0.36 0.29 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85769450 chr15:85651522~85651628:- CESC cis rs3124314 0.964 rs3122305 ENSG00000229021.2 AL591893.1 -4.44 1.44e-05 0.00746 -0.32 -0.29 Hair morphology; chr1:152143762 chr1:151994531~152042774:+ CESC cis rs10754283 0.967 rs4658307 ENSG00000231613.1 RP5-943J3.1 4.44 1.44e-05 0.00746 0.36 0.29 Amyotrophic lateral sclerosis (sporadic); chr1:89652027 chr1:89788914~89790492:+ CESC cis rs3124314 0.964 rs2935208 ENSG00000229021.2 AL591893.1 -4.44 1.44e-05 0.00747 -0.32 -0.29 Hair morphology; chr1:152105383 chr1:151994531~152042774:+ CESC cis rs3124314 0.965 rs2496253 ENSG00000229021.2 AL591893.1 -4.44 1.44e-05 0.00747 -0.32 -0.29 Hair morphology; chr1:152109445 chr1:151994531~152042774:+ CESC cis rs10463554 0.856 rs2432169 ENSG00000175749.11 EIF3KP1 4.44 1.44e-05 0.00747 0.3 0.29 Parkinson's disease; chr5:103179056 chr5:103032376~103033031:+ CESC cis rs116095464 1 rs56075848 ENSG00000250848.1 CTD-2083E4.5 -4.44 1.44e-05 0.00747 -0.49 -0.29 Breast cancer; chr5:308237 chr5:288833~290321:- CESC cis rs3002131 0.688 rs3008650 ENSG00000225265.1 TAF1A-AS1 4.44 1.44e-05 0.00748 0.41 0.29 Interleukin-10 levels; chr1:222589873 chr1:222589825~222593032:+ CESC cis rs916888 0.773 rs538628 ENSG00000261575.2 RP11-259G18.1 4.44 1.44e-05 0.00748 0.42 0.29 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46267037~46268694:+ CESC cis rs7560272 0.501 rs12713798 ENSG00000273245.1 RP11-434P11.2 -4.44 1.45e-05 0.00748 -0.35 -0.29 Schizophrenia; chr2:73759294 chr2:73750256~73750786:- CESC cis rs748404 0.631 rs11070399 ENSG00000205771.5 CATSPER2P1 -4.44 1.45e-05 0.00748 -0.35 -0.29 Lung cancer; chr15:43354149 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs513970 ENSG00000249839.1 AC011330.5 -4.44 1.45e-05 0.00748 -0.3 -0.29 Lung cancer; chr15:43287368 chr15:43663654~43684339:- CESC cis rs889398 1 rs889399 ENSG00000226232.7 RP11-419C5.2 4.44 1.45e-05 0.00748 0.27 0.29 Body mass index; chr16:69522680 chr16:69976388~69996188:- CESC cis rs748404 1 rs17779494 ENSG00000249839.1 AC011330.5 4.44 1.45e-05 0.00749 0.38 0.29 Lung cancer; chr15:43287025 chr15:43663654~43684339:- CESC cis rs4713118 0.662 rs469228 ENSG00000219392.1 RP1-265C24.5 -4.44 1.45e-05 0.00749 -0.36 -0.29 Parkinson's disease; chr6:28002926 chr6:28115628~28116551:+ CESC cis rs4713118 0.54 rs469227 ENSG00000219392.1 RP1-265C24.5 -4.44 1.45e-05 0.00749 -0.36 -0.29 Parkinson's disease; chr6:28002927 chr6:28115628~28116551:+ CESC cis rs17818399 0.815 rs35837037 ENSG00000279254.1 RP11-536C12.1 -4.44 1.45e-05 0.00749 -0.34 -0.29 Height; chr2:46634161 chr2:46668870~46670778:+ CESC cis rs7809950 1 rs7786801 ENSG00000238832.1 snoU109 -4.44 1.45e-05 0.0075 -0.34 -0.29 Coronary artery disease; chr7:107445444 chr7:107603363~107603507:+ CESC cis rs2243480 1 rs34815098 ENSG00000228409.4 CCT6P1 4.44 1.45e-05 0.0075 0.4 0.29 Diabetic kidney disease; chr7:65827267 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35735127 ENSG00000228409.4 CCT6P1 4.44 1.45e-05 0.0075 0.4 0.29 Diabetic kidney disease; chr7:65835436 chr7:65751142~65763354:+ CESC cis rs7811142 1 rs11559117 ENSG00000078319.8 PMS2P1 -4.44 1.45e-05 0.00751 -0.46 -0.29 Platelet count; chr7:100478991 chr7:100320992~100341908:- CESC cis rs7811142 1 rs4463351 ENSG00000078319.8 PMS2P1 -4.44 1.45e-05 0.00751 -0.46 -0.29 Platelet count; chr7:100480603 chr7:100320992~100341908:- CESC cis rs9584850 0.609 rs17574495 ENSG00000231194.1 FARP1-AS1 4.44 1.45e-05 0.00751 0.4 0.29 Neuroticism; chr13:98502859 chr13:98435405~98435840:- CESC cis rs6846071 1 rs6846071 ENSG00000254531.1 FLJ20021 4.44 1.45e-05 0.00751 0.59 0.29 C-reactive protein and white blood cell count; chr4:101481058 chr4:101347780~101348883:+ CESC cis rs9322193 0.886 rs9718079 ENSG00000268592.3 RAET1E-AS1 4.44 1.45e-05 0.00751 0.37 0.29 Lung cancer; chr6:149645947 chr6:149863494~149919507:+ CESC cis rs7674212 0.57 rs2069274 ENSG00000246560.2 RP11-10L12.4 4.44 1.45e-05 0.00752 0.35 0.29 Type 2 diabetes; chr4:103099624 chr4:102828055~102844075:+ CESC cis rs34779708 0.741 rs34397613 ENSG00000230534.5 RP11-297A16.2 4.44 1.45e-05 0.00752 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35261385 chr10:35098006~35127020:- CESC cis rs9907295 0.748 rs2526328 ENSG00000270977.1 AC015849.16 -4.44 1.46e-05 0.00752 -0.38 -0.29 Fibroblast growth factor basic levels; chr17:35932348 chr17:35893707~35911023:- CESC cis rs2439831 0.85 rs11070408 ENSG00000275601.1 AC011330.13 -4.44 1.46e-05 0.00753 -0.45 -0.29 Lung cancer in ever smokers; chr15:43742590 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28595038 ENSG00000275601.1 AC011330.13 -4.44 1.46e-05 0.00753 -0.45 -0.29 Lung cancer in ever smokers; chr15:43752661 chr15:43642389~43643023:- CESC cis rs577676 0.533 rs10800529 ENSG00000271811.1 RP1-79C4.4 4.44 1.46e-05 0.00753 0.38 0.29 Prevalent atrial fibrillation; chr1:170600902 chr1:170667381~170669425:+ CESC cis rs651386 0.529 rs722597 ENSG00000271811.1 RP1-79C4.4 4.44 1.46e-05 0.00753 0.38 0.29 Atrial fibrillation; chr1:170607914 chr1:170667381~170669425:+ CESC cis rs13108904 0.905 rs1680074 ENSG00000254094.1 AC078852.1 4.44 1.46e-05 0.00753 0.35 0.29 Obesity-related traits; chr4:1285833 chr4:1356581~1358075:+ CESC cis rs13108904 0.901 rs1680073 ENSG00000254094.1 AC078852.1 4.44 1.46e-05 0.00753 0.35 0.29 Obesity-related traits; chr4:1286549 chr4:1356581~1358075:+ CESC cis rs950880 0.71 rs67723747 ENSG00000234389.1 AC007278.3 -4.44 1.46e-05 0.00753 -0.32 -0.29 Serum protein levels (sST2); chr2:102353347 chr2:102438713~102440475:+ CESC cis rs950880 0.71 rs56386507 ENSG00000234389.1 AC007278.3 -4.44 1.46e-05 0.00753 -0.32 -0.29 Serum protein levels (sST2); chr2:102354705 chr2:102438713~102440475:+ CESC cis rs10129255 0.957 rs10137980 ENSG00000280411.1 IGHV1-69-2 -4.44 1.46e-05 0.00754 -0.21 -0.29 Kawasaki disease; chr14:106775735 chr14:106762092~106762588:- CESC cis rs11159086 1 rs11626856 ENSG00000259005.1 RP3-449M8.6 4.44 1.46e-05 0.00754 0.49 0.29 Advanced glycation end-product levels; chr14:74469665 chr14:74474007~74474864:- CESC cis rs2019137 0.539 rs4849177 ENSG00000189223.12 PAX8-AS1 -4.43 1.46e-05 0.00756 -0.36 -0.29 Lymphocyte counts; chr2:113225007 chr2:113211522~113276581:+ CESC cis rs13108904 0.875 rs1732099 ENSG00000254094.1 AC078852.1 4.43 1.47e-05 0.00757 0.35 0.29 Obesity-related traits; chr4:1288908 chr4:1356581~1358075:+ CESC cis rs7429990 0.93 rs13075457 ENSG00000229759.1 MRPS18AP1 -4.43 1.47e-05 0.00757 -0.3 -0.29 Educational attainment (years of education); chr3:48013063 chr3:48256350~48256938:- CESC cis rs11638352 0.661 rs2615281 ENSG00000259479.5 SORD2P 4.43 1.47e-05 0.00758 0.43 0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44158391 chr15:44826371~44884694:- CESC cis rs10461617 0.617 rs79742142 ENSG00000271828.1 CTD-2310F14.1 4.43 1.47e-05 0.00758 0.39 0.29 Type 2 diabetes; chr5:56808550 chr5:56927874~56929573:+ CESC cis rs6969780 0.915 rs10085570 ENSG00000233429.8 HOTAIRM1 -4.43 1.47e-05 0.00758 -0.37 -0.29 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27111569 chr7:27095647~27100265:+ CESC cis rs1531343 0.73 rs10878333 ENSG00000276853.1 RP11-305O6.4 -4.43 1.47e-05 0.00758 -0.56 -0.29 Type 2 diabetes; chr12:65773305 chr12:65171262~65171917:+ CESC cis rs1729407 0.625 rs2727789 ENSG00000254851.1 RP11-109L13.1 -4.43 1.47e-05 0.00759 -0.32 -0.29 Apolipoprotein A-IV levels; chr11:116826171 chr11:117135528~117138582:+ CESC cis rs67311347 1 rs10510708 ENSG00000223797.4 ENTPD3-AS1 4.43 1.47e-05 0.00761 0.28 0.29 Renal cell carcinoma; chr3:40363279 chr3:40313802~40453329:- CESC cis rs2243480 1 rs7794661 ENSG00000232559.3 GS1-124K5.12 4.43 1.47e-05 0.00761 0.48 0.29 Diabetic kidney disease; chr7:65924743 chr7:66554588~66576923:- CESC cis rs4272720 0.639 rs4481947 ENSG00000229870.1 RP11-507K13.6 -4.43 1.48e-05 0.00761 -0.33 -0.29 Platelet count;Plateletcrit; chr10:49068252 chr10:49815096~49815562:+ CESC cis rs4239252 0.929 rs4251787 ENSG00000271013.1 AC015849.15 -4.43 1.48e-05 0.00761 -0.32 -0.29 Blood protein levels; chr17:35845577 chr17:35912635~35918010:- CESC cis rs8005677 1 rs1956881 ENSG00000279656.1 RP11-298I3.6 4.43 1.48e-05 0.00762 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22924860 chr14:23023083~23024217:- CESC cis rs8005677 0.962 rs10130756 ENSG00000279656.1 RP11-298I3.6 4.43 1.48e-05 0.00762 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22927391 chr14:23023083~23024217:- CESC cis rs8005677 1 rs2295685 ENSG00000279656.1 RP11-298I3.6 4.43 1.48e-05 0.00762 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22928944 chr14:23023083~23024217:- CESC cis rs8005677 1 rs7145494 ENSG00000279656.1 RP11-298I3.6 4.43 1.48e-05 0.00762 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22930581 chr14:23023083~23024217:- CESC cis rs11157436 0.958 rs17183301 ENSG00000211813.2 TRAV34 4.43 1.48e-05 0.00762 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22190003 chr14:22207522~22208129:+ CESC cis rs5769707 0.935 rs5770594 ENSG00000235111.1 RP1-29C18.8 -4.43 1.48e-05 0.00763 -0.28 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49624849 chr22:49612657~49615716:- CESC cis rs5769707 0.967 rs4524218 ENSG00000235111.1 RP1-29C18.8 -4.43 1.48e-05 0.00763 -0.28 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49624991 chr22:49612657~49615716:- CESC cis rs9918079 0.506 rs7696127 ENSG00000273133.1 RP11-799M12.2 -4.43 1.48e-05 0.00763 -0.37 -0.29 Obesity-related traits; chr4:15641330 chr4:15563698~15564253:- CESC cis rs6686842 0.965 rs12718433 ENSG00000235358.1 RP11-399E6.1 4.43 1.48e-05 0.00763 0.35 0.29 Height; chr1:41001131 chr1:41242373~41284861:+ CESC cis rs67311347 1 rs7641495 ENSG00000223797.4 ENTPD3-AS1 -4.43 1.48e-05 0.00764 -0.28 -0.29 Renal cell carcinoma; chr3:40453199 chr3:40313802~40453329:- CESC cis rs2299587 0.637 rs7832527 ENSG00000253671.1 RP11-806O11.1 -4.43 1.48e-05 0.00764 -0.3 -0.29 Economic and political preferences; chr8:18031834 chr8:17808941~17820868:+ CESC cis rs11976180 0.517 rs6949375 ENSG00000170356.8 OR2A20P -4.43 1.48e-05 0.00764 -0.51 -0.29 Obesity-related traits; chr7:144076758 chr7:144250045~144252957:- CESC cis rs783540 0.5 rs1313494 ENSG00000255769.6 GOLGA2P10 4.43 1.48e-05 0.00765 0.33 0.29 Schizophrenia; chr15:82605530 chr15:82472993~82513950:- CESC cis rs2836950 0.545 rs2836952 ENSG00000232608.1 TIMM9P2 4.43 1.49e-05 0.00766 0.32 0.29 Menarche (age at onset); chr21:39244725 chr21:39216624~39217506:+ CESC cis rs11159086 1 rs4899516 ENSG00000270000.1 RP3-449M8.9 4.43 1.49e-05 0.00766 0.52 0.29 Advanced glycation end-product levels; chr14:74492825 chr14:74471930~74472360:- CESC cis rs11157436 1 rs72638482 ENSG00000211813.2 TRAV34 4.43 1.49e-05 0.00768 0.33 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22153322 chr14:22207522~22208129:+ CESC cis rs13113518 0.557 rs13142096 ENSG00000273257.1 RP11-177J6.1 4.43 1.49e-05 0.00768 0.38 0.29 Height; chr4:55566291 chr4:55387949~55388271:+ CESC cis rs7809950 0.784 rs7803102 ENSG00000238832.1 snoU109 4.43 1.49e-05 0.00769 0.34 0.29 Coronary artery disease; chr7:107608484 chr7:107603363~107603507:+ CESC cis rs7189233 0.531 rs1072910 ENSG00000279344.1 RP11-44F14.7 4.43 1.49e-05 0.00769 0.27 0.29 Intelligence (multi-trait analysis); chr16:53465687 chr16:53478957~53481550:- CESC cis rs2439831 1 rs527921 ENSG00000275601.1 AC011330.13 4.43 1.49e-05 0.00769 0.39 0.29 Lung cancer in ever smokers; chr15:43478218 chr15:43642389~43643023:- CESC cis rs71403859 0.614 rs12447033 ENSG00000260886.1 TAT-AS1 4.43 1.5e-05 0.0077 0.44 0.29 Post bronchodilator FEV1; chr16:71549752 chr16:71565789~71578187:+ CESC cis rs1185460 0.565 rs538478 ENSG00000271751.1 RP11-110I1.14 4.43 1.5e-05 0.0077 0.35 0.29 Coronary artery disease; chr11:119054629 chr11:119065263~119065677:- CESC cis rs1538970 0.924 rs7531253 ENSG00000280836.1 AL355480.1 -4.43 1.5e-05 0.0077 -0.36 -0.29 Platelet count; chr1:45424511 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs11211108 ENSG00000280836.1 AL355480.1 -4.43 1.5e-05 0.0077 -0.36 -0.29 Platelet count; chr1:45425480 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs10890327 ENSG00000280836.1 AL355480.1 -4.43 1.5e-05 0.0077 -0.36 -0.29 Platelet count; chr1:45425786 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs12046816 ENSG00000280836.1 AL355480.1 -4.43 1.5e-05 0.0077 -0.36 -0.29 Platelet count; chr1:45425871 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs4660855 ENSG00000280836.1 AL355480.1 -4.43 1.5e-05 0.0077 -0.36 -0.29 Platelet count; chr1:45434123 chr1:45581219~45581321:- CESC cis rs2015599 0.623 rs3782510 ENSG00000257176.2 RP11-996F15.2 4.43 1.5e-05 0.00772 0.33 0.29 Platelet count;Mean platelet volume; chr12:29301176 chr12:29280418~29317848:- CESC cis rs6964833 1 rs17515241 ENSG00000277053.3 GTF2IP1 4.43 1.5e-05 0.00772 0.34 0.29 Menarche (age at onset); chr7:74717695 chr7:75185385~75237696:- CESC cis rs6001482 0.656 rs1894237 ENSG00000236850.4 BMS1P20 -4.43 1.5e-05 0.00772 -0.29 -0.29 Diastolic blood pressure; chr22:22235546 chr22:22303224~22322847:+ CESC cis rs6001482 0.679 rs1475928 ENSG00000236850.4 BMS1P20 -4.43 1.5e-05 0.00772 -0.29 -0.29 Diastolic blood pressure; chr22:22236137 chr22:22303224~22322847:+ CESC cis rs881375 0.715 rs11794516 ENSG00000226752.6 PSMD5-AS1 -4.43 1.5e-05 0.00773 -0.3 -0.29 Rheumatoid arthritis; chr9:120877952 chr9:120824828~120854385:+ CESC cis rs6964587 0.967 rs10231350 ENSG00000188693.7 CYP51A1-AS1 -4.43 1.5e-05 0.00773 -0.3 -0.29 Breast cancer; chr7:92179185 chr7:92134604~92180725:+ CESC cis rs9309473 0.519 rs6730785 ENSG00000273245.1 RP11-434P11.2 -4.43 1.51e-05 0.00774 -0.36 -0.29 Metabolite levels; chr2:73415275 chr2:73750256~73750786:- CESC cis rs6951245 0.744 rs10265758 ENSG00000229043.2 AC091729.9 -4.43 1.51e-05 0.00775 -0.41 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1132882 chr7:1160374~1165267:+ CESC cis rs8072100 0.738 rs9895509 ENSG00000228782.6 CTD-2026D20.3 -4.43 1.51e-05 0.00775 -0.35 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47472252 chr17:47450568~47492492:- CESC cis rs2522056 0.808 rs1016988 ENSG00000233006.5 AC034220.3 -4.43 1.51e-05 0.00776 -0.38 -0.29 Fibrinogen;Lymphocyte counts; chr5:132408882 chr5:132311285~132369916:- CESC cis rs881375 0.902 rs2900180 ENSG00000226752.6 PSMD5-AS1 -4.43 1.51e-05 0.00776 -0.31 -0.29 Rheumatoid arthritis; chr9:120944104 chr9:120824828~120854385:+ CESC cis rs12439619 0.774 rs2867649 ENSG00000276710.3 CSPG4P8 -4.43 1.51e-05 0.00777 -0.42 -0.29 Intelligence (multi-trait analysis); chr15:82262331 chr15:82459472~82477258:+ CESC cis rs9309473 0.95 rs10169213 ENSG00000163016.8 ALMS1P 4.43 1.51e-05 0.00777 0.38 0.29 Metabolite levels; chr2:73560107 chr2:73644919~73685576:+ CESC cis rs8072100 0.79 rs7222225 ENSG00000228782.6 CTD-2026D20.3 -4.43 1.51e-05 0.00778 -0.35 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47616131 chr17:47450568~47492492:- CESC cis rs8072100 0.79 rs3760371 ENSG00000228782.6 CTD-2026D20.3 -4.43 1.51e-05 0.00778 -0.35 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47618548 chr17:47450568~47492492:- CESC cis rs42490 0.614 rs452694 ENSG00000251136.7 RP11-37B2.1 -4.43 1.51e-05 0.00778 -0.29 -0.29 Leprosy; chr8:89808293 chr8:89609409~89757727:- CESC cis rs42490 0.614 rs445172 ENSG00000251136.7 RP11-37B2.1 -4.43 1.51e-05 0.00778 -0.29 -0.29 Leprosy; chr8:89808322 chr8:89609409~89757727:- CESC cis rs42490 0.59 rs447611 ENSG00000251136.7 RP11-37B2.1 -4.43 1.51e-05 0.00778 -0.29 -0.29 Leprosy; chr8:89808359 chr8:89609409~89757727:- CESC cis rs2564921 0.73 rs2564922 ENSG00000242142.1 SERBP1P3 4.43 1.51e-05 0.00778 0.34 0.29 Height; chr3:53091453 chr3:53064283~53065091:- CESC cis rs4239252 0.929 rs4796116 ENSG00000271013.1 AC015849.15 -4.43 1.51e-05 0.00778 -0.31 -0.29 Blood protein levels; chr17:35841496 chr17:35912635~35918010:- CESC cis rs4239252 0.929 rs4251791 ENSG00000271013.1 AC015849.15 -4.43 1.51e-05 0.00778 -0.31 -0.29 Blood protein levels; chr17:35845711 chr17:35912635~35918010:- CESC cis rs9907295 0.591 rs78655848 ENSG00000271013.1 AC015849.15 -4.43 1.51e-05 0.00778 -0.31 -0.29 Fibroblast growth factor basic levels; chr17:35856952 chr17:35912635~35918010:- CESC cis rs950880 0.71 rs2160202 ENSG00000234389.1 AC007278.3 -4.43 1.52e-05 0.00779 -0.33 -0.29 Serum protein levels (sST2); chr2:102369694 chr2:102438713~102440475:+ CESC cis rs922182 1 rs62021495 ENSG00000239465.1 RP11-330L19.2 -4.43 1.52e-05 0.00779 -0.38 -0.29 Blood protein levels; chr15:63983210 chr15:64631109~64631914:- CESC cis rs860295 0.702 rs5005770 ENSG00000225855.5 RUSC1-AS1 -4.43 1.52e-05 0.00779 -0.24 -0.29 Body mass index; chr1:155375252 chr1:155316863~155324176:- CESC cis rs7208859 0.573 rs56031503 ENSG00000266490.1 CTD-2349P21.9 4.43 1.52e-05 0.00779 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30792372~30792833:+ CESC cis rs950169 0.579 rs11633088 ENSG00000225151.9 GOLGA2P7 4.43 1.52e-05 0.0078 0.44 0.29 Schizophrenia; chr15:84003429 chr15:84199311~84230136:- CESC cis rs700651 0.789 rs1813106 ENSG00000222017.1 AC011997.1 4.43 1.52e-05 0.0078 0.36 0.29 Intracranial aneurysm; chr2:198015865 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs1836234 ENSG00000222017.1 AC011997.1 4.43 1.52e-05 0.0078 0.36 0.29 Dermatomyositis; chr2:198018149 chr2:197693106~197774823:+ CESC cis rs700651 0.789 rs116165148 ENSG00000222017.1 AC011997.1 4.43 1.52e-05 0.0078 0.36 0.29 Intracranial aneurysm; chr2:198023623 chr2:197693106~197774823:+ CESC cis rs700651 0.789 rs1978889 ENSG00000222017.1 AC011997.1 4.43 1.52e-05 0.0078 0.36 0.29 Intracranial aneurysm; chr2:198024642 chr2:197693106~197774823:+ CESC cis rs2522056 0.808 rs7704457 ENSG00000233006.5 AC034220.3 4.43 1.52e-05 0.0078 0.38 0.29 Fibrinogen;Lymphocyte counts; chr5:132409098 chr5:132311285~132369916:- CESC cis rs1707322 1 rs11211232 ENSG00000281133.1 AL355480.3 -4.43 1.52e-05 0.0078 -0.34 -0.29 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45945474 chr1:45580892~45580996:- CESC cis rs2688608 0.592 rs7923045 ENSG00000242288.9 RP11-464F9.1 4.43 1.52e-05 0.0078 0.32 0.29 Inflammatory bowel disease; chr10:73727740 chr10:73674295~73730466:- CESC cis rs2179367 0.887 rs6570965 ENSG00000231760.4 RP11-350J20.5 4.43 1.52e-05 0.0078 0.36 0.29 Dupuytren's disease; chr6:149396340 chr6:149796151~149826294:- CESC cis rs7809950 1 rs2237673 ENSG00000238832.1 snoU109 -4.43 1.52e-05 0.00781 -0.34 -0.29 Coronary artery disease; chr7:107491135 chr7:107603363~107603507:+ CESC cis rs875971 0.545 rs73146609 ENSG00000222364.1 RNU6-96P -4.43 1.52e-05 0.00781 -0.39 -0.29 Aortic root size; chr7:66302477 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs2173571 ENSG00000222364.1 RNU6-96P -4.43 1.52e-05 0.00781 -0.39 -0.29 Aortic root size; chr7:66305392 chr7:66395191~66395286:+ CESC cis rs2739330 0.828 rs2154593 ENSG00000231271.1 AP000350.8 4.43 1.52e-05 0.00782 0.35 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23949918~23954042:+ CESC cis rs1538970 1 rs1538970 ENSG00000280836.1 AL355480.1 -4.43 1.52e-05 0.00782 -0.35 -0.29 Platelet count; chr1:45381890 chr1:45581219~45581321:- CESC cis rs9640161 0.742 rs2108854 ENSG00000261305.1 RP4-584D14.7 -4.43 1.52e-05 0.00782 -0.39 -0.29 Blood protein levels;Circulating chemerin levels; chr7:150320319 chr7:150341771~150342607:+ CESC cis rs1799949 1 rs8176318 ENSG00000267681.1 CTD-3199J23.6 -4.42 1.52e-05 0.00782 -0.38 -0.29 Menopause (age at onset); chr17:43045257 chr17:43144956~43145255:+ CESC cis rs6142102 0.651 rs6119463 ENSG00000276073.1 RP5-1125A11.7 4.42 1.52e-05 0.00782 0.27 0.29 Skin pigmentation; chr20:34149412 chr20:33985617~33988989:- CESC cis rs875971 0.545 rs2420456 ENSG00000226824.5 RP4-756H11.3 -4.42 1.53e-05 0.00784 -0.4 -0.29 Aortic root size; chr7:66280619 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs12671152 ENSG00000222364.1 RNU6-96P -4.42 1.53e-05 0.00785 -0.39 -0.29 Aortic root size; chr7:66311140 chr7:66395191~66395286:+ CESC cis rs6001482 0.647 rs8140302 ENSG00000236850.4 BMS1P20 -4.42 1.53e-05 0.00785 -0.28 -0.29 Diastolic blood pressure; chr22:22234843 chr22:22303224~22322847:+ CESC cis rs2919917 0.628 rs12544041 ENSG00000254352.1 RP11-578O24.2 -4.42 1.53e-05 0.00786 -0.42 -0.29 Lymphocyte counts; chr8:78731404 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs2583759 ENSG00000254352.1 RP11-578O24.2 -4.42 1.53e-05 0.00786 -0.42 -0.29 Lymphocyte counts; chr8:78732729 chr8:78723796~78724136:- CESC cis rs2919917 0.628 rs2583778 ENSG00000254352.1 RP11-578O24.2 -4.42 1.53e-05 0.00786 -0.42 -0.29 Lymphocyte counts; chr8:78738906 chr8:78723796~78724136:- CESC cis rs875971 0.54 rs781152 ENSG00000164669.11 INTS4P1 -4.42 1.53e-05 0.00787 -0.39 -0.29 Aortic root size; chr7:66014585 chr7:65141225~65234216:+ CESC cis rs17711722 0.727 rs781151 ENSG00000164669.11 INTS4P1 -4.42 1.53e-05 0.00787 -0.39 -0.29 Calcium levels; chr7:66014891 chr7:65141225~65234216:+ CESC cis rs1799949 1 rs8070085 ENSG00000267681.1 CTD-3199J23.6 4.42 1.53e-05 0.00787 0.37 0.29 Menopause (age at onset); chr17:43189967 chr17:43144956~43145255:+ CESC cis rs10936632 0.565 rs9865021 ENSG00000242578.1 RP11-469J4.3 -4.42 1.54e-05 0.00788 -0.32 -0.29 Prostate cancer; chr3:170429093 chr3:170410512~170418615:+ CESC cis rs2439831 0.867 rs12323999 ENSG00000275601.1 AC011330.13 -4.42 1.54e-05 0.00788 -0.37 -0.29 Lung cancer in ever smokers; chr15:43390917 chr15:43642389~43643023:- CESC cis rs2732480 0.577 rs2732457 ENSG00000258273.1 RP11-370I10.4 4.42 1.54e-05 0.00788 0.35 0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48364596 chr12:48333755~48333901:- CESC cis rs8040855 0.756 rs2342118 ENSG00000259295.5 CSPG4P12 -4.42 1.54e-05 0.00789 -0.34 -0.29 Bulimia nervosa; chr15:85149785 chr15:85191438~85213905:+ CESC cis rs1538970 0.924 rs11211117 ENSG00000280836.1 AL355480.1 -4.42 1.54e-05 0.00789 -0.36 -0.29 Platelet count; chr1:45464574 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs11211118 ENSG00000280836.1 AL355480.1 -4.42 1.54e-05 0.00789 -0.36 -0.29 Platelet count; chr1:45464598 chr1:45581219~45581321:- CESC cis rs11089937 0.929 rs5750624 ENSG00000211639.2 IGLV4-60 4.42 1.54e-05 0.0079 0.25 0.29 Periodontitis (PAL4Q3); chr22:22165354 chr22:22162199~22162681:+ CESC cis rs755249 0.917 rs61779330 ENSG00000228060.1 RP11-69E11.8 -4.42 1.54e-05 0.00791 -0.35 -0.29 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39501551 chr1:39565160~39573203:+ CESC cis rs755249 0.876 rs72662001 ENSG00000228060.1 RP11-69E11.8 -4.42 1.54e-05 0.00791 -0.35 -0.29 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39501608 chr1:39565160~39573203:+ CESC cis rs755249 0.917 rs72663503 ENSG00000228060.1 RP11-69E11.8 -4.42 1.54e-05 0.00791 -0.35 -0.29 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39503387 chr1:39565160~39573203:+ CESC cis rs755249 0.917 rs61779331 ENSG00000228060.1 RP11-69E11.8 -4.42 1.54e-05 0.00791 -0.35 -0.29 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39505256 chr1:39565160~39573203:+ CESC cis rs783540 0.681 rs1259178 ENSG00000276710.3 CSPG4P8 4.42 1.55e-05 0.00793 0.32 0.29 Schizophrenia; chr15:82603127 chr15:82459472~82477258:+ CESC cis rs11846409 0.932 rs73378158 ENSG00000211974.3 IGHV2-70 -4.42 1.55e-05 0.00793 -0.36 -0.29 Rheumatic heart disease; chr14:106638433 chr14:106723574~106724093:- CESC cis rs2276314 0.857 rs28791905 ENSG00000278986.1 RP11-723J4.3 -4.42 1.55e-05 0.00793 -0.33 -0.29 Endometriosis;Drug-induced torsades de pointes; chr18:36022250 chr18:35972151~35973916:+ CESC cis rs2255336 0.616 rs6488285 ENSG00000245648.1 RP11-277P12.20 4.42 1.55e-05 0.00793 0.48 0.29 Blood protein levels; chr12:10366107 chr12:10363769~10398506:+ CESC cis rs2255336 0.608 rs7957681 ENSG00000245648.1 RP11-277P12.20 4.42 1.55e-05 0.00793 0.48 0.29 Blood protein levels; chr12:10366223 chr12:10363769~10398506:+ CESC cis rs2255336 0.608 rs7958658 ENSG00000245648.1 RP11-277P12.20 4.42 1.55e-05 0.00793 0.48 0.29 Blood protein levels; chr12:10366229 chr12:10363769~10398506:+ CESC cis rs2439831 0.717 rs2470132 ENSG00000275601.1 AC011330.13 -4.42 1.55e-05 0.00794 -0.4 -0.29 Lung cancer in ever smokers; chr15:43543283 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2255051 ENSG00000275601.1 AC011330.13 -4.42 1.55e-05 0.00794 -0.4 -0.29 Lung cancer in ever smokers; chr15:43553963 chr15:43642389~43643023:- CESC cis rs1862618 0.853 rs832583 ENSG00000271828.1 CTD-2310F14.1 4.42 1.55e-05 0.00795 0.39 0.29 Initial pursuit acceleration; chr5:56882390 chr5:56927874~56929573:+ CESC cis rs875971 0.545 rs6460298 ENSG00000226824.5 RP4-756H11.3 -4.42 1.55e-05 0.00795 -0.41 -0.29 Aortic root size; chr7:66442783 chr7:66654538~66669855:+ CESC cis rs2280018 0.526 rs2966129 ENSG00000188599.16 NPIPP1 4.42 1.55e-05 0.00795 0.29 0.29 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059070 chr16:15104312~15123498:- CESC cis rs1031391 0.716 rs10772416 ENSG00000247157.5 LINC01252 -4.42 1.55e-05 0.00795 -0.43 -0.29 Bitter taste perception; chr12:11017488 chr12:11548030~11590369:+ CESC cis rs451417 0.722 rs236189 ENSG00000275632.1 RP5-967N21.11 4.42 1.55e-05 0.00796 0.33 0.29 Menopause (age at onset); chr20:5951544 chr20:6000418~6000941:+ CESC cis rs748404 0.666 rs12899865 ENSG00000249839.1 AC011330.5 -4.42 1.56e-05 0.00796 -0.41 -0.29 Lung cancer; chr15:43448819 chr15:43663654~43684339:- CESC cis rs77204473 1 rs2044426 ENSG00000254851.1 RP11-109L13.1 4.42 1.56e-05 0.00796 0.64 0.29 Sum eosinophil basophil counts;Eosinophil counts; chr11:116885467 chr11:117135528~117138582:+ CESC cis rs2439831 0.764 rs12324584 ENSG00000275601.1 AC011330.13 -4.42 1.56e-05 0.00797 -0.38 -0.29 Lung cancer in ever smokers; chr15:43391248 chr15:43642389~43643023:- CESC cis rs748404 0.516 rs523156 ENSG00000205771.5 CATSPER2P1 4.42 1.56e-05 0.00797 0.35 0.29 Lung cancer; chr15:43519645 chr15:43726918~43747094:- CESC cis rs7246657 0.551 rs10404069 ENSG00000276846.1 CTD-3220F14.3 4.42 1.56e-05 0.00797 0.43 0.29 Coronary artery calcification; chr19:37147502 chr19:37314868~37315620:- CESC cis rs2117029 1 rs10783299 ENSG00000258017.1 RP11-386G11.10 -4.42 1.56e-05 0.00798 -0.38 -0.29 Intelligence (multi-trait analysis); chr12:48996894 chr12:49127782~49147869:+ CESC cis rs9549367 0.789 rs9549718 ENSG00000269125.1 RP11-98F14.11 -4.42 1.56e-05 0.00798 -0.41 -0.29 Platelet distribution width; chr13:113255508 chr13:113165002~113165183:- CESC cis rs8005677 1 rs8006396 ENSG00000279656.1 RP11-298I3.6 4.42 1.56e-05 0.00798 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22911641 chr14:23023083~23024217:- CESC cis rs8005677 1 rs4981446 ENSG00000279656.1 RP11-298I3.6 4.42 1.56e-05 0.00798 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22912204 chr14:23023083~23024217:- CESC cis rs8005677 1 rs4982706 ENSG00000279656.1 RP11-298I3.6 4.42 1.56e-05 0.00798 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22912488 chr14:23023083~23024217:- CESC cis rs8005677 0.926 rs34344888 ENSG00000279656.1 RP11-298I3.6 4.42 1.56e-05 0.00798 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22918376 chr14:23023083~23024217:- CESC cis rs8005677 0.962 rs34917191 ENSG00000279656.1 RP11-298I3.6 4.42 1.56e-05 0.00798 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22918419 chr14:23023083~23024217:- CESC cis rs8005677 1 rs2295683 ENSG00000279656.1 RP11-298I3.6 4.42 1.56e-05 0.00798 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22919173 chr14:23023083~23024217:- CESC cis rs8005677 1 rs4981449 ENSG00000279656.1 RP11-298I3.6 4.42 1.56e-05 0.00798 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22919662 chr14:23023083~23024217:- CESC cis rs2115630 0.645 rs3825877 ENSG00000225151.9 GOLGA2P7 4.42 1.56e-05 0.00799 0.32 0.29 P wave terminal force; chr15:84631400 chr15:84199311~84230136:- CESC cis rs2115630 0.645 rs3825878 ENSG00000225151.9 GOLGA2P7 4.42 1.56e-05 0.00799 0.32 0.29 P wave terminal force; chr15:84631524 chr15:84199311~84230136:- CESC cis rs1823913 1 rs4853563 ENSG00000227542.1 AC092614.2 -4.42 1.56e-05 0.008 -0.29 -0.29 Obesity-related traits; chr2:191254808 chr2:191229165~191246172:- CESC cis rs2771051 0.867 rs35843180 ENSG00000230734.1 RPL10P3 4.42 1.57e-05 0.00802 0.29 0.29 Venous thromboembolism (SNP x SNP interaction); chr9:117529309 chr9:117180628~117181095:- CESC cis rs9309473 0.519 rs1083922 ENSG00000273245.1 RP11-434P11.2 -4.42 1.57e-05 0.00803 -0.36 -0.29 Metabolite levels; chr2:73476876 chr2:73750256~73750786:- CESC cis rs9907295 0.748 rs2526328 ENSG00000271013.1 AC015849.15 -4.42 1.57e-05 0.00803 -0.35 -0.29 Fibroblast growth factor basic levels; chr17:35932348 chr17:35912635~35918010:- CESC cis rs875971 0.545 rs17138149 ENSG00000222364.1 RNU6-96P -4.42 1.57e-05 0.00804 -0.36 -0.29 Aortic root size; chr7:66228193 chr7:66395191~66395286:+ CESC cis rs2255336 0.938 rs12298043 ENSG00000245648.1 RP11-277P12.20 -4.42 1.57e-05 0.00804 -0.45 -0.29 Blood protein levels; chr12:10456883 chr12:10363769~10398506:+ CESC cis rs875971 0.545 rs1796226 ENSG00000237310.1 GS1-124K5.4 4.42 1.57e-05 0.00804 0.3 0.29 Aortic root size; chr7:66622723 chr7:66493706~66495474:+ CESC cis rs2836950 0.501 rs2056844 ENSG00000232608.1 TIMM9P2 4.42 1.57e-05 0.00804 0.32 0.29 Menarche (age at onset); chr21:39298534 chr21:39216624~39217506:+ CESC cis rs9402743 0.816 rs9494332 ENSG00000217482.2 HMGB1P17 4.42 1.58e-05 0.00805 0.32 0.29 Systemic lupus erythematosus; chr6:135687470 chr6:135636086~135636713:- CESC cis rs2836950 0.565 rs3171465 ENSG00000232608.1 TIMM9P2 4.42 1.58e-05 0.00806 0.32 0.29 Menarche (age at onset); chr21:39180381 chr21:39216624~39217506:+ CESC cis rs875971 0.862 rs1167408 ENSG00000232559.3 GS1-124K5.12 -4.42 1.58e-05 0.00806 -0.32 -0.29 Aortic root size; chr7:66091121 chr7:66554588~66576923:- CESC cis rs875971 0.83 rs1167406 ENSG00000232559.3 GS1-124K5.12 -4.42 1.58e-05 0.00806 -0.32 -0.29 Aortic root size; chr7:66091949 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs1167399 ENSG00000232559.3 GS1-124K5.12 -4.42 1.58e-05 0.00806 -0.32 -0.29 Aortic root size; chr7:66096890 chr7:66554588~66576923:- CESC cis rs875971 0.825 rs59466412 ENSG00000232559.3 GS1-124K5.12 -4.42 1.58e-05 0.00806 -0.32 -0.29 Aortic root size; chr7:66100371 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs57866200 ENSG00000232559.3 GS1-124K5.12 -4.42 1.58e-05 0.00806 -0.32 -0.29 Aortic root size; chr7:66100405 chr7:66554588~66576923:- CESC cis rs4819052 0.808 rs2838825 ENSG00000223768.1 LINC00205 -4.42 1.58e-05 0.00806 -0.34 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45235736 chr21:45293285~45297354:+ CESC cis rs783540 0.872 rs2678445 ENSG00000276710.3 CSPG4P8 4.42 1.58e-05 0.00806 0.32 0.29 Schizophrenia; chr15:82577391 chr15:82459472~82477258:+ CESC cis rs9532669 0.89 rs12865032 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40873801 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs34123829 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40873808 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4488324 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40873864 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4288867 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40873880 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4415896 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40874001 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs4415897 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40874035 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4389021 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40874209 chr13:40863599~40863902:- CESC cis rs9532669 0.824 rs4628828 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40874369 chr13:40863599~40863902:- CESC cis rs9532669 0.737 rs34354179 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40874424 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9594445 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40874859 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9594446 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40874863 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4402423 ENSG00000176268.5 CYCSP34 4.42 1.58e-05 0.00807 0.29 0.29 Cervical cancer; chr13:40875010 chr13:40863599~40863902:- CESC cis rs2439831 0.85 rs3862142 ENSG00000275601.1 AC011330.13 -4.42 1.58e-05 0.00807 -0.44 -0.29 Lung cancer in ever smokers; chr15:43772608 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs2277531 ENSG00000275601.1 AC011330.13 -4.42 1.58e-05 0.00807 -0.44 -0.29 Lung cancer in ever smokers; chr15:43776871 chr15:43642389~43643023:- CESC cis rs4319547 0.656 rs3817011 ENSG00000275265.1 RP11-15J22.8 -4.42 1.58e-05 0.00807 -0.39 -0.29 Body mass index; chr12:122335019 chr12:122501187~122501641:+ CESC cis rs34779708 0.733 rs4102764 ENSG00000230534.5 RP11-297A16.2 4.42 1.58e-05 0.00807 0.41 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35256464 chr10:35098006~35127020:- CESC cis rs6496044 0.507 rs62022863 ENSG00000202081.1 RNU6-1280P -4.42 1.58e-05 0.00807 -0.31 -0.29 Interstitial lung disease; chr15:85618822 chr15:85651522~85651628:- CESC cis rs12107539 0.8 rs12497330 ENSG00000240137.4 ERICH6-AS1 -4.42 1.58e-05 0.00808 -0.27 -0.29 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151352163 chr3:150703564~150720146:+ CESC cis rs12107539 0.8 rs13095610 ENSG00000240137.4 ERICH6-AS1 -4.42 1.58e-05 0.00808 -0.27 -0.29 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151352214 chr3:150703564~150720146:+ CESC cis rs17826219 0.706 rs8075357 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Body mass index; chr17:30730179 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs59447372 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30730567 chr17:30792372~30792833:+ CESC cis rs17826219 0.706 rs61643715 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Body mass index; chr17:30730744 chr17:30792372~30792833:+ CESC cis rs17826219 0.636 rs8080829 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Body mass index; chr17:30731712 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs8079891 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30731845 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs73267858 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732719 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs56018041 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732967 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs56095789 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733152 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs11656844 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733579 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs11652533 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733583 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs11652631 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733748 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs79505916 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30735308 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs77498725 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs73267865 ENSG00000266490.1 CTD-2349P21.9 4.42 1.58e-05 0.00808 0.44 0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30792372~30792833:+ CESC cis rs1707322 0.963 rs34907901 ENSG00000281133.1 AL355480.3 -4.42 1.58e-05 0.00808 -0.34 -0.29 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45939542 chr1:45580892~45580996:- CESC cis rs9322193 0.923 rs10747276 ENSG00000216906.2 RP11-350J20.9 4.42 1.58e-05 0.00808 0.32 0.29 Lung cancer; chr6:149758739 chr6:149904243~149906418:+ CESC cis rs7580658 0.637 rs4580338 ENSG00000236682.1 AC068282.3 -4.42 1.59e-05 0.00809 -0.36 -0.29 Protein C levels; chr2:127217361 chr2:127389130~127400580:+ CESC cis rs113835537 0.935 rs79106199 ENSG00000255517.5 CTD-3074O7.5 -4.42 1.59e-05 0.00809 -0.45 -0.29 Airway imaging phenotypes; chr11:66653047 chr11:66473490~66480233:- CESC cis rs113835537 0.935 rs117131621 ENSG00000255517.5 CTD-3074O7.5 -4.42 1.59e-05 0.00809 -0.45 -0.29 Airway imaging phenotypes; chr11:66654863 chr11:66473490~66480233:- CESC cis rs113835537 0.935 rs57043177 ENSG00000255517.5 CTD-3074O7.5 -4.42 1.59e-05 0.00809 -0.45 -0.29 Airway imaging phenotypes; chr11:66655676 chr11:66473490~66480233:- CESC cis rs113835537 0.935 rs75863187 ENSG00000255517.5 CTD-3074O7.5 -4.42 1.59e-05 0.00809 -0.45 -0.29 Airway imaging phenotypes; chr11:66675990 chr11:66473490~66480233:- CESC cis rs2058059 0.636 rs2022928 ENSG00000205578.5 POM121B -4.42 1.59e-05 0.00809 -0.36 -0.29 Subcutaneous adipose tissue; chr7:72707432 chr7:73293497~73301161:+ CESC cis rs1044826 0.647 rs4683463 ENSG00000178631.7 ACTG1P1 4.42 1.59e-05 0.00809 0.36 0.29 Obesity-related traits; chr3:139478104 chr3:139493809~139494937:+ CESC cis rs8177876 0.749 rs2278024 ENSG00000261838.4 RP11-303E16.6 4.42 1.59e-05 0.0081 0.59 0.29 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81045628 chr16:81069854~81076598:+ CESC cis rs8042680 0.522 rs12595616 ENSG00000214432.8 AC068831.10 4.41 1.59e-05 0.00811 0.34 0.29 Type 2 diabetes; chr15:91020283 chr15:91022619~91036611:+ CESC cis rs11846409 0.652 rs10143549 ENSG00000211974.3 IGHV2-70 -4.41 1.59e-05 0.00812 -0.36 -0.29 Rheumatic heart disease; chr14:106644643 chr14:106723574~106724093:- CESC cis rs783540 0.681 rs1259178 ENSG00000255769.6 GOLGA2P10 4.41 1.59e-05 0.00813 0.33 0.29 Schizophrenia; chr15:82603127 chr15:82472993~82513950:- CESC cis rs12134133 1 rs6673333 ENSG00000274245.1 RP11-357P18.2 4.41 1.6e-05 0.00813 0.38 0.29 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207285802 chr1:207372559~207373252:+ CESC cis rs8005677 1 rs1951119 ENSG00000279656.1 RP11-298I3.6 4.41 1.6e-05 0.00814 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22919117 chr14:23023083~23024217:- CESC cis rs2412819 0.571 rs2729494 ENSG00000205771.5 CATSPER2P1 4.41 1.6e-05 0.00814 0.42 0.29 Lung cancer; chr15:43837395 chr15:43726918~43747094:- CESC cis rs9322193 0.962 rs1889473 ENSG00000223701.3 RAET1E-AS1 4.41 1.6e-05 0.00815 0.32 0.29 Lung cancer; chr6:149825485 chr6:149884431~149919508:+ CESC cis rs673078 0.607 rs61943367 ENSG00000275759.1 RP11-131L12.3 -4.41 1.6e-05 0.00815 -0.55 -0.29 Glucose homeostasis traits; chr12:118366316 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943368 ENSG00000275759.1 RP11-131L12.3 -4.41 1.6e-05 0.00815 -0.55 -0.29 Glucose homeostasis traits; chr12:118366568 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943385 ENSG00000275759.1 RP11-131L12.3 -4.41 1.6e-05 0.00815 -0.55 -0.29 Glucose homeostasis traits; chr12:118370339 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943388 ENSG00000275759.1 RP11-131L12.3 -4.41 1.6e-05 0.00815 -0.55 -0.29 Glucose homeostasis traits; chr12:118374590 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943389 ENSG00000275759.1 RP11-131L12.3 -4.41 1.6e-05 0.00815 -0.55 -0.29 Glucose homeostasis traits; chr12:118377467 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs7299040 ENSG00000275759.1 RP11-131L12.3 -4.41 1.6e-05 0.00815 -0.55 -0.29 Glucose homeostasis traits; chr12:118380660 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs7968011 ENSG00000275759.1 RP11-131L12.3 -4.41 1.6e-05 0.00815 -0.55 -0.29 Glucose homeostasis traits; chr12:118382001 chr12:118428281~118428870:+ CESC cis rs17301013 0.507 rs1613634 ENSG00000227373.4 RP11-160H22.5 -4.41 1.6e-05 0.00815 -0.36 -0.29 Systemic lupus erythematosus; chr1:174803184 chr1:174115300~174160004:- CESC cis rs9322193 0.923 rs9505982 ENSG00000268592.3 RAET1E-AS1 4.41 1.6e-05 0.00815 0.36 0.29 Lung cancer; chr6:149618465 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9322196 ENSG00000268592.3 RAET1E-AS1 4.41 1.6e-05 0.00815 0.36 0.29 Lung cancer; chr6:149619645 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs10782310 ENSG00000268592.3 RAET1E-AS1 4.41 1.6e-05 0.00815 0.36 0.29 Lung cancer; chr6:149622458 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs10782311 ENSG00000268592.3 RAET1E-AS1 4.41 1.6e-05 0.00815 0.36 0.29 Lung cancer; chr6:149622592 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs10747275 ENSG00000268592.3 RAET1E-AS1 4.41 1.6e-05 0.00815 0.36 0.29 Lung cancer; chr6:149622782 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9322200 ENSG00000268592.3 RAET1E-AS1 4.41 1.6e-05 0.00815 0.36 0.29 Lung cancer; chr6:149630078 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs9688794 ENSG00000268592.3 RAET1E-AS1 4.41 1.6e-05 0.00815 0.36 0.29 Lung cancer; chr6:149632121 chr6:149863494~149919507:+ CESC cis rs9309473 1 rs10190219 ENSG00000163016.8 ALMS1P 4.41 1.6e-05 0.00815 0.39 0.29 Metabolite levels; chr2:73431203 chr2:73644919~73685576:+ CESC cis rs801193 0.66 rs2659897 ENSG00000237310.1 GS1-124K5.4 -4.41 1.6e-05 0.00815 -0.27 -0.29 Aortic root size; chr7:66722728 chr7:66493706~66495474:+ CESC cis rs7580658 0.724 rs71414745 ENSG00000236682.1 AC068282.3 -4.41 1.6e-05 0.00816 -0.35 -0.29 Protein C levels; chr2:127235012 chr2:127389130~127400580:+ CESC cis rs7615952 0.673 rs16834637 ENSG00000248787.1 RP11-666A20.4 -4.41 1.6e-05 0.00817 -0.51 -0.29 Blood pressure (smoking interaction); chr3:125886628 chr3:125908005~125910272:- CESC cis rs6686842 0.93 rs11209342 ENSG00000235358.1 RP11-399E6.1 4.41 1.61e-05 0.00817 0.34 0.29 Height; chr1:41003994 chr1:41242373~41284861:+ CESC cis rs748404 0.589 rs62020616 ENSG00000249839.1 AC011330.5 -4.41 1.61e-05 0.00817 -0.4 -0.29 Lung cancer; chr15:43558554 chr15:43663654~43684339:- CESC cis rs3096299 0.967 rs28575874 ENSG00000274627.1 RP11-104N10.2 4.41 1.61e-05 0.00818 0.28 0.29 Multiple myeloma (IgH translocation); chr16:89403482 chr16:89516797~89522217:+ CESC cis rs8059260 0.604 rs12102345 ENSG00000274038.1 RP11-66H6.4 -4.41 1.61e-05 0.00818 -0.43 -0.29 Alcohol consumption over the past year; chr16:11053863 chr16:11056556~11057034:+ CESC cis rs2299587 0.698 rs2283113 ENSG00000253671.1 RP11-806O11.1 -4.41 1.61e-05 0.00818 -0.29 -0.29 Economic and political preferences; chr8:18022734 chr8:17808941~17820868:+ CESC cis rs1729407 0.709 rs2098453 ENSG00000254851.1 RP11-109L13.1 -4.41 1.61e-05 0.00818 -0.32 -0.29 Apolipoprotein A-IV levels; chr11:116825964 chr11:117135528~117138582:+ CESC cis rs875971 0.545 rs1796226 ENSG00000226824.5 RP4-756H11.3 -4.41 1.61e-05 0.00819 -0.4 -0.29 Aortic root size; chr7:66622723 chr7:66654538~66669855:+ CESC cis rs72627509 0.68 rs3733309 ENSG00000269949.1 RP11-738E22.3 4.41 1.61e-05 0.00819 0.46 0.29 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56991022 chr4:56960927~56961373:- CESC cis rs897984 0.683 rs12926237 ENSG00000260911.2 RP11-196G11.2 -4.41 1.61e-05 0.0082 -0.3 -0.29 Dementia with Lewy bodies; chr16:30826275 chr16:31043150~31049868:+ CESC cis rs2255336 0.938 rs2417734 ENSG00000245648.1 RP11-277P12.20 4.41 1.61e-05 0.0082 0.4 0.29 Blood protein levels; chr12:10380807 chr12:10363769~10398506:+ CESC cis rs1075265 0.84 rs10084355 ENSG00000233266.1 HMGB1P31 4.41 1.61e-05 0.0082 0.36 0.29 Chronotype;Morning vs. evening chronotype; chr2:54021711 chr2:54051334~54051760:+ CESC cis rs11976180 1 rs1919949 ENSG00000273234.1 OR2A13P -4.41 1.61e-05 0.00821 -0.35 -0.29 Obesity-related traits; chr7:144070630 chr7:144142009~144142938:+ CESC cis rs9309473 0.848 rs9750915 ENSG00000163016.8 ALMS1P 4.41 1.61e-05 0.00821 0.38 0.29 Metabolite levels; chr2:73584753 chr2:73644919~73685576:+ CESC cis rs7809950 1 rs2712215 ENSG00000238832.1 snoU109 -4.41 1.62e-05 0.00822 -0.34 -0.29 Coronary artery disease; chr7:107547762 chr7:107603363~107603507:+ CESC cis rs7188445 0.899 rs7195321 ENSG00000261390.4 RP11-345M22.2 -4.41 1.62e-05 0.00822 -0.37 -0.29 Urate levels; chr16:79701065 chr16:79715232~79770563:- CESC cis rs860295 0.702 rs10908479 ENSG00000225855.5 RUSC1-AS1 4.41 1.62e-05 0.00822 0.24 0.29 Body mass index; chr1:155673612 chr1:155316863~155324176:- CESC cis rs17772222 0.917 rs61983300 ENSG00000258983.2 RP11-507K2.2 4.41 1.62e-05 0.00822 0.35 0.29 Coronary artery calcification; chr14:88754047 chr14:88499334~88515502:+ CESC cis rs6687821 0.531 rs7534656 ENSG00000267734.1 RP4-604K5.3 -4.41 1.62e-05 0.00822 -0.34 -0.29 Yeast infection; chr1:87045715 chr1:86932199~86934891:- CESC cis rs9322193 0.847 rs62439808 ENSG00000268592.3 RAET1E-AS1 4.41 1.62e-05 0.00823 0.36 0.29 Lung cancer; chr6:149629690 chr6:149863494~149919507:+ CESC cis rs2733201 1 rs4419034 ENSG00000259479.5 SORD2P -4.41 1.62e-05 0.00823 -0.42 -0.29 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44056202 chr15:44826371~44884694:- CESC cis rs2271404 1 rs72837860 ENSG00000227992.1 AC108463.2 4.41 1.62e-05 0.00823 0.46 0.29 Atopic dermatitis; chr2:111249995 chr2:111203964~111206215:- CESC cis rs2732480 0.538 rs1387259 ENSG00000240399.1 RP1-228P16.1 -4.41 1.62e-05 0.00823 -0.34 -0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309739 chr12:48054813~48055591:- CESC cis rs5769707 0.749 rs7286706 ENSG00000235111.1 RP1-29C18.8 -4.41 1.62e-05 0.00823 -0.28 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49664698 chr22:49612657~49615716:- CESC cis rs9322193 0.923 rs11155671 ENSG00000268592.3 RAET1E-AS1 4.41 1.62e-05 0.00824 0.36 0.29 Lung cancer; chr6:149650996 chr6:149863494~149919507:+ CESC cis rs2243480 1 rs59794892 ENSG00000228409.4 CCT6P1 4.41 1.62e-05 0.00825 0.42 0.29 Diabetic kidney disease; chr7:65950886 chr7:65751142~65763354:+ CESC cis rs6993244 1 rs6993244 ENSG00000254340.1 RP11-10A14.3 4.41 1.62e-05 0.00825 0.34 0.29 Mean corpuscular hemoglobin; chr8:9005549 chr8:9141424~9145435:+ CESC cis rs7580658 0.545 rs67996371 ENSG00000236682.1 AC068282.3 -4.41 1.63e-05 0.00828 -0.34 -0.29 Protein C levels; chr2:127195841 chr2:127389130~127400580:+ CESC cis rs8059260 0.542 rs7184915 ENSG00000274038.1 RP11-66H6.4 -4.41 1.63e-05 0.00828 -0.44 -0.29 Alcohol consumption over the past year; chr16:11034509 chr16:11056556~11057034:+ CESC cis rs4819052 0.851 rs2838864 ENSG00000223768.1 LINC00205 4.41 1.63e-05 0.00829 0.32 0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45291559 chr21:45293285~45297354:+ CESC cis rs1729407 0.632 rs2071523 ENSG00000254851.1 RP11-109L13.1 -4.41 1.63e-05 0.0083 -0.33 -0.29 Apolipoprotein A-IV levels; chr11:116826628 chr11:117135528~117138582:+ CESC cis rs2299587 0.637 rs6586677 ENSG00000253671.1 RP11-806O11.1 -4.41 1.63e-05 0.0083 -0.3 -0.29 Economic and political preferences; chr8:18033178 chr8:17808941~17820868:+ CESC cis rs9513627 0.748 rs61525545 ENSG00000228889.5 UBAC2-AS1 4.41 1.63e-05 0.0083 0.46 0.29 Obesity-related traits; chr13:99466007 chr13:99196377~99200710:- CESC cis rs9322193 0.886 rs9485408 ENSG00000216906.2 RP11-350J20.9 4.41 1.64e-05 0.00831 0.31 0.29 Lung cancer; chr6:149618888 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs1080670 ENSG00000216906.2 RP11-350J20.9 4.41 1.64e-05 0.00831 0.31 0.29 Lung cancer; chr6:149620161 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs10782312 ENSG00000216906.2 RP11-350J20.9 4.41 1.64e-05 0.00831 0.31 0.29 Lung cancer; chr6:149622669 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9505823 ENSG00000216906.2 RP11-350J20.9 4.41 1.64e-05 0.00831 0.31 0.29 Lung cancer; chr6:149628899 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9689599 ENSG00000216906.2 RP11-350J20.9 4.41 1.64e-05 0.00831 0.31 0.29 Lung cancer; chr6:149631973 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9800580 ENSG00000216906.2 RP11-350J20.9 4.41 1.64e-05 0.00831 0.31 0.29 Lung cancer; chr6:149632845 chr6:149904243~149906418:+ CESC cis rs12908161 1 rs12908161 ENSG00000225151.9 GOLGA2P7 -4.41 1.64e-05 0.00831 -0.41 -0.29 Schizophrenia; chr15:84664594 chr15:84199311~84230136:- CESC cis rs1044826 0.597 rs6803593 ENSG00000178631.7 ACTG1P1 4.41 1.64e-05 0.00831 0.36 0.29 Obesity-related traits; chr3:139475145 chr3:139493809~139494937:+ CESC cis rs1729407 0.659 rs2542050 ENSG00000254851.1 RP11-109L13.1 -4.41 1.64e-05 0.00831 -0.33 -0.29 Apolipoprotein A-IV levels; chr11:116826401 chr11:117135528~117138582:+ CESC cis rs9322193 0.923 rs9322204 ENSG00000268592.3 RAET1E-AS1 4.41 1.64e-05 0.00831 0.36 0.29 Lung cancer; chr6:149636047 chr6:149863494~149919507:+ CESC cis rs2961663 0.881 rs78956869 ENSG00000250420.7 AACSP1 -4.41 1.64e-05 0.00831 -0.69 -0.29 Rheumatoid arthritis; chr5:178184931 chr5:178764861~178818435:- CESC cis rs17818399 0.62 rs6544906 ENSG00000279254.1 RP11-536C12.1 -4.41 1.64e-05 0.00832 -0.31 -0.29 Height; chr2:46636733 chr2:46668870~46670778:+ CESC cis rs2179367 0.92 rs560051 ENSG00000231760.4 RP11-350J20.5 4.41 1.64e-05 0.00832 0.36 0.29 Dupuytren's disease; chr6:149345841 chr6:149796151~149826294:- CESC cis rs6001482 0.662 rs6001526 ENSG00000236850.4 BMS1P20 -4.41 1.64e-05 0.00833 -0.28 -0.29 Diastolic blood pressure; chr22:22234518 chr22:22303224~22322847:+ CESC cis rs4924997 0.772 rs2018675 ENSG00000262769.1 RP11-1113L8.1 -4.41 1.64e-05 0.00833 -0.32 -0.29 Lymphocyte counts; chr17:19538218 chr17:19560111~19597922:- CESC cis rs2015599 0.514 rs10843376 ENSG00000257176.2 RP11-996F15.2 4.41 1.64e-05 0.00833 0.33 0.29 Platelet count;Mean platelet volume; chr12:29283651 chr12:29280418~29317848:- CESC cis rs2439831 1 rs689754 ENSG00000205771.5 CATSPER2P1 -4.41 1.64e-05 0.00834 -0.42 -0.29 Lung cancer in ever smokers; chr15:43483697 chr15:43726918~43747094:- CESC cis rs8005677 1 rs4982710 ENSG00000279656.1 RP11-298I3.6 4.41 1.64e-05 0.00835 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22929693 chr14:23023083~23024217:- CESC cis rs4819052 0.851 rs7279182 ENSG00000223768.1 LINC00205 -4.41 1.65e-05 0.00836 -0.35 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45236197 chr21:45293285~45297354:+ CESC cis rs1707322 1 rs4606257 ENSG00000281133.1 AL355480.3 -4.41 1.65e-05 0.00836 -0.35 -0.29 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45841596 chr1:45580892~45580996:- CESC cis rs957448 1 rs1023767 ENSG00000253704.1 RP11-267M23.4 4.41 1.65e-05 0.00836 0.32 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94518741 chr8:94553722~94569745:+ CESC cis rs2243480 0.901 rs3813708 ENSG00000275400.1 RP4-756H11.5 4.41 1.65e-05 0.00837 0.47 0.29 Diabetic kidney disease; chr7:65840645 chr7:66553805~66554199:- CESC cis rs2243480 1 rs464895 ENSG00000232559.3 GS1-124K5.12 4.41 1.65e-05 0.00837 0.47 0.29 Diabetic kidney disease; chr7:66062119 chr7:66554588~66576923:- CESC cis rs2243480 1 rs160633 ENSG00000232559.3 GS1-124K5.12 4.41 1.65e-05 0.00837 0.47 0.29 Diabetic kidney disease; chr7:66063241 chr7:66554588~66576923:- CESC cis rs916888 0.773 rs199451 ENSG00000261575.2 RP11-259G18.1 4.41 1.65e-05 0.00837 0.42 0.29 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46267037~46268694:+ CESC cis rs9309473 1 rs6546836 ENSG00000163016.8 ALMS1P 4.41 1.65e-05 0.00837 0.37 0.29 Metabolite levels; chr2:73450706 chr2:73644919~73685576:+ CESC cis rs8005677 1 rs10148215 ENSG00000279656.1 RP11-298I3.6 4.41 1.65e-05 0.00838 0.35 0.29 Cognitive ability (multi-trait analysis); chr14:22913136 chr14:23023083~23024217:- CESC cis rs8067354 0.645 rs2102507 ENSG00000266701.1 AC005702.4 4.41 1.65e-05 0.00838 0.38 0.29 Hemoglobin concentration; chr17:59798546 chr17:60042546~60042627:- CESC cis rs8067354 0.645 rs2645491 ENSG00000266701.1 AC005702.4 4.41 1.65e-05 0.00838 0.38 0.29 Hemoglobin concentration; chr17:59799688 chr17:60042546~60042627:- CESC cis rs8067354 0.645 rs2665400 ENSG00000266701.1 AC005702.4 4.41 1.65e-05 0.00838 0.38 0.29 Hemoglobin concentration; chr17:59802840 chr17:60042546~60042627:- CESC cis rs17301013 0.507 rs1883262 ENSG00000227373.4 RP11-160H22.5 4.41 1.66e-05 0.00839 0.38 0.29 Systemic lupus erythematosus; chr1:174401104 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2860959 ENSG00000227373.4 RP11-160H22.5 4.41 1.66e-05 0.00839 0.38 0.29 Systemic lupus erythematosus; chr1:174403704 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10912779 ENSG00000227373.4 RP11-160H22.5 4.41 1.66e-05 0.00839 0.38 0.29 Systemic lupus erythematosus; chr1:174404311 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12090860 ENSG00000227373.4 RP11-160H22.5 4.41 1.66e-05 0.00839 0.38 0.29 Systemic lupus erythematosus; chr1:174405166 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12064126 ENSG00000227373.4 RP11-160H22.5 4.41 1.66e-05 0.00839 0.38 0.29 Systemic lupus erythematosus; chr1:174405312 chr1:174115300~174160004:- CESC cis rs9859260 0.71 rs41298097 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196052284 chr3:196072819~196072880:+ CESC cis rs9859260 0.71 rs34906439 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196052835 chr3:196072819~196072880:+ CESC cis rs9859260 0.744 rs557527 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196053838 chr3:196072819~196072880:+ CESC cis rs9859260 0.71 rs419068 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196055305 chr3:196072819~196072880:+ CESC cis rs9859260 0.71 rs366268 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196055306 chr3:196072819~196072880:+ CESC cis rs9859260 0.744 rs419059 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196055313 chr3:196072819~196072880:+ CESC cis rs9859260 0.744 rs539816 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196057205 chr3:196072819~196072880:+ CESC cis rs9859260 0.744 rs492349 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196057321 chr3:196072819~196072880:+ CESC cis rs9859260 0.744 rs492288 ENSG00000252174.1 RNU7-18P 4.41 1.66e-05 0.0084 0.33 0.29 Mean corpuscular volume; chr3:196057339 chr3:196072819~196072880:+ CESC cis rs8072100 0.79 rs11079783 ENSG00000228782.6 CTD-2026D20.3 -4.41 1.66e-05 0.0084 -0.35 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47608650 chr17:47450568~47492492:- CESC cis rs7208859 0.614 rs7216394 ENSG00000263531.1 RP13-753N3.1 -4.4 1.66e-05 0.0084 -0.6 -0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30498738 chr17:30863921~30864940:- CESC cis rs7829975 0.623 rs7010753 ENSG00000253893.2 FAM85B -4.4 1.66e-05 0.0084 -0.36 -0.29 Mood instability; chr8:8516446 chr8:8167819~8226614:- CESC cis rs2412819 0.571 rs678084 ENSG00000205771.5 CATSPER2P1 4.4 1.66e-05 0.0084 0.42 0.29 Lung cancer; chr15:43828361 chr15:43726918~43747094:- CESC cis rs2337406 0.587 rs10139664 ENSG00000211974.3 IGHV2-70 -4.4 1.66e-05 0.00841 -0.39 -0.29 Alzheimer's disease (late onset); chr14:106647254 chr14:106723574~106724093:- CESC cis rs2337406 0.587 rs10129888 ENSG00000211974.3 IGHV2-70 -4.4 1.66e-05 0.00841 -0.39 -0.29 Alzheimer's disease (late onset); chr14:106647421 chr14:106723574~106724093:- CESC cis rs1799949 1 rs12944430 ENSG00000267681.1 CTD-3199J23.6 -4.4 1.66e-05 0.00841 -0.38 -0.29 Menopause (age at onset); chr17:43178803 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs11653460 ENSG00000267681.1 CTD-3199J23.6 -4.4 1.66e-05 0.00841 -0.38 -0.29 Menopause (age at onset); chr17:43179289 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs11650913 ENSG00000267681.1 CTD-3199J23.6 -4.4 1.66e-05 0.00841 -0.38 -0.29 Menopause (age at onset); chr17:43179580 chr17:43144956~43145255:+ CESC cis rs1799949 1 rs12936831 ENSG00000267681.1 CTD-3199J23.6 -4.4 1.66e-05 0.00841 -0.38 -0.29 Menopause (age at onset); chr17:43179799 chr17:43144956~43145255:+ CESC cis rs1799949 0.93 rs35292991 ENSG00000267681.1 CTD-3199J23.6 -4.4 1.66e-05 0.00841 -0.38 -0.29 Menopause (age at onset); chr17:43181999 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs11658499 ENSG00000267681.1 CTD-3199J23.6 -4.4 1.66e-05 0.00841 -0.38 -0.29 Menopause (age at onset); chr17:43182732 chr17:43144956~43145255:+ CESC cis rs2408955 0.568 rs12099462 ENSG00000240399.1 RP1-228P16.1 -4.4 1.66e-05 0.00842 -0.31 -0.29 Glycated hemoglobin levels; chr12:48109321 chr12:48054813~48055591:- CESC cis rs2732480 0.538 rs1387260 ENSG00000240399.1 RP1-228P16.1 4.4 1.66e-05 0.00842 0.34 0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48309308 chr12:48054813~48055591:- CESC cis rs12468226 0.606 rs10445793 ENSG00000273456.1 RP11-686O6.2 4.4 1.66e-05 0.00842 0.34 0.29 Urate levels; chr2:202190799 chr2:202374932~202375604:- CESC cis rs17818399 0.926 rs13033177 ENSG00000279254.1 RP11-536C12.1 -4.4 1.66e-05 0.00842 -0.36 -0.29 Height; chr2:46603923 chr2:46668870~46670778:+ CESC cis rs6597981 0.675 rs4963120 ENSG00000255284.1 AP006621.5 -4.4 1.66e-05 0.00843 -0.29 -0.29 Breast cancer; chr11:825777 chr11:777578~784297:+ CESC cis rs6604026 0.624 rs11578004 ENSG00000223787.2 RP4-593M8.1 4.4 1.66e-05 0.00843 0.38 0.29 Multiple sclerosis; chr1:92726707 chr1:92580476~92580821:- CESC cis rs6928977 0.896 rs2746429 ENSG00000234084.1 RP3-388E23.2 4.4 1.66e-05 0.00843 0.26 0.29 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135352146 chr6:135301568~135307158:+ CESC cis rs2439831 0.867 rs3213990 ENSG00000275601.1 AC011330.13 -4.4 1.66e-05 0.00843 -0.38 -0.29 Lung cancer in ever smokers; chr15:43378028 chr15:43642389~43643023:- CESC cis rs875971 0.545 rs35459055 ENSG00000226824.5 RP4-756H11.3 -4.4 1.67e-05 0.00843 -0.4 -0.29 Aortic root size; chr7:66479399 chr7:66654538~66669855:+ CESC cis rs8020095 0.571 rs7156655 ENSG00000258561.1 RP11-72M17.1 -4.4 1.67e-05 0.00843 -0.42 -0.29 Depression (quantitative trait); chr14:66889344 chr14:66212810~66509394:- CESC cis rs2117029 0.862 rs10875915 ENSG00000258017.1 RP11-386G11.10 -4.4 1.67e-05 0.00844 -0.38 -0.29 Intelligence (multi-trait analysis); chr12:49036311 chr12:49127782~49147869:+ CESC cis rs875971 0.545 rs73376394 ENSG00000236529.1 RP13-254B10.1 4.4 1.67e-05 0.00844 0.35 0.29 Aortic root size; chr7:66172694 chr7:65840212~65840596:+ CESC cis rs853679 0.517 rs4713146 ENSG00000219392.1 RP1-265C24.5 -4.4 1.67e-05 0.00845 -0.39 -0.29 Depression; chr6:28143758 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393894 ENSG00000219392.1 RP1-265C24.5 -4.4 1.67e-05 0.00845 -0.39 -0.29 Depression; chr6:28144784 chr6:28115628~28116551:+ CESC cis rs7605378 0.528 rs1704191 ENSG00000232732.8 AC073043.1 -4.4 1.67e-05 0.00845 -0.39 -0.29 Osteoporosis; chr2:199951670 chr2:199867396~199911159:- CESC cis rs748404 1 rs12911132 ENSG00000249839.1 AC011330.5 -4.4 1.67e-05 0.00845 -0.38 -0.29 Lung cancer; chr15:43268238 chr15:43663654~43684339:- CESC cis rs11976180 1 rs1533268 ENSG00000273234.1 OR2A13P -4.4 1.67e-05 0.00845 -0.34 -0.29 Obesity-related traits; chr7:144069265 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs1533267 ENSG00000273234.1 OR2A13P -4.4 1.67e-05 0.00845 -0.34 -0.29 Obesity-related traits; chr7:144069347 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs1533266 ENSG00000273234.1 OR2A13P -4.4 1.67e-05 0.00845 -0.34 -0.29 Obesity-related traits; chr7:144069621 chr7:144142009~144142938:+ CESC cis rs9309473 1 rs7598419 ENSG00000163016.8 ALMS1P 4.4 1.67e-05 0.00845 0.39 0.29 Metabolite levels; chr2:73571096 chr2:73644919~73685576:+ CESC cis rs4819052 0.851 rs35560973 ENSG00000223768.1 LINC00205 -4.4 1.67e-05 0.00845 -0.33 -0.29 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45242658 chr21:45293285~45297354:+ CESC cis rs11685222 0.64 rs73948921 ENSG00000229326.3 AC069154.4 4.4 1.67e-05 0.00845 0.41 0.29 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119657257 chr2:119698623~119700151:+ CESC cis rs10129255 0.53 rs11624912 ENSG00000224373.3 IGHV4-59 4.4 1.67e-05 0.00845 0.18 0.29 Kawasaki disease; chr14:106673891 chr14:106627249~106627825:- CESC cis rs2732480 0.5 rs12829841 ENSG00000240399.1 RP1-228P16.1 4.4 1.67e-05 0.00845 0.34 0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48234956 chr12:48054813~48055591:- CESC cis rs2732480 0.523 rs34286639 ENSG00000240399.1 RP1-228P16.1 4.4 1.67e-05 0.00845 0.34 0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48235261 chr12:48054813~48055591:- CESC cis rs1387259 0.929 rs11168484 ENSG00000240399.1 RP1-228P16.1 4.4 1.67e-05 0.00845 0.34 0.29 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48239806 chr12:48054813~48055591:- CESC cis rs2404602 0.716 rs67920045 ENSG00000280730.1 AC090181.1 4.4 1.67e-05 0.00846 0.22 0.29 Blood metabolite levels; chr15:76507743 chr15:77056895~77057021:+ CESC cis rs62355901 0.505 rs56984944 ENSG00000271828.1 CTD-2310F14.1 4.4 1.67e-05 0.00846 0.47 0.29 Breast cancer; chr5:56927671 chr5:56927874~56929573:+ CESC cis rs8062405 0.789 rs1968752 ENSG00000259982.1 CDC37P1 4.4 1.67e-05 0.00846 0.35 0.29 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620264 chr16:28700294~28701540:- CESC cis rs11159086 1 rs11159087 ENSG00000259005.1 RP3-449M8.6 4.4 1.67e-05 0.00846 0.45 0.29 Advanced glycation end-product levels; chr14:74504671 chr14:74474007~74474864:- CESC cis rs763121 0.853 rs4821810 ENSG00000273076.1 RP3-508I15.22 4.4 1.68e-05 0.00847 0.32 0.29 Menopause (age at onset); chr22:38676093 chr22:38743495~38743910:+ CESC cis rs763121 0.853 rs5757234 ENSG00000273076.1 RP3-508I15.22 4.4 1.68e-05 0.00847 0.32 0.29 Menopause (age at onset); chr22:38676681 chr22:38743495~38743910:+ CESC cis rs6991838 0.702 rs34496943 ENSG00000272010.1 CTD-3025N20.3 4.4 1.68e-05 0.00847 0.32 0.29 Intelligence (multi-trait analysis); chr8:65676978 chr8:65591850~65592472:- CESC cis rs6991838 0.733 rs13281090 ENSG00000272010.1 CTD-3025N20.3 4.4 1.68e-05 0.00847 0.32 0.29 Intelligence (multi-trait analysis); chr8:65678244 chr8:65591850~65592472:- CESC cis rs6991838 0.701 rs17395275 ENSG00000272010.1 CTD-3025N20.3 4.4 1.68e-05 0.00847 0.32 0.29 Intelligence (multi-trait analysis); chr8:65679003 chr8:65591850~65592472:- CESC cis rs748404 0.631 rs7166812 ENSG00000205771.5 CATSPER2P1 -4.4 1.68e-05 0.00847 -0.35 -0.29 Lung cancer; chr15:43352562 chr15:43726918~43747094:- CESC cis rs1862618 0.853 rs1423621 ENSG00000271828.1 CTD-2310F14.1 4.4 1.68e-05 0.00847 0.37 0.29 Initial pursuit acceleration; chr5:56805208 chr5:56927874~56929573:+ CESC cis rs116175783 0.557 rs62194490 ENSG00000227403.1 AC009299.3 4.4 1.68e-05 0.00848 0.45 0.29 Intelligence (multi-trait analysis); chr2:161344287 chr2:161244739~161249050:+ CESC cis rs6991838 0.778 rs11782837 ENSG00000200714.1 Y_RNA 4.4 1.68e-05 0.00848 0.34 0.29 Intelligence (multi-trait analysis); chr8:65550328 chr8:65592731~65592820:+ CESC cis rs6565180 1 rs11646130 ENSG00000183604.13 SMG1P5 -4.4 1.68e-05 0.00848 -0.3 -0.29 Tonsillectomy; chr16:30365638 chr16:30267553~30335374:- CESC cis rs113835537 0.877 rs77239910 ENSG00000255517.5 CTD-3074O7.5 -4.4 1.68e-05 0.00849 -0.45 -0.29 Airway imaging phenotypes; chr11:66562168 chr11:66473490~66480233:- CESC cis rs8100891 0.537 rs16967141 ENSG00000267213.4 AC007773.2 -4.4 1.68e-05 0.0085 -0.45 -0.29 Neuroticism; chr19:32480317 chr19:32390050~32405560:- CESC cis rs77204473 1 rs10892056 ENSG00000254851.1 RP11-109L13.1 4.4 1.68e-05 0.00851 0.66 0.29 Sum eosinophil basophil counts;Eosinophil counts; chr11:116999695 chr11:117135528~117138582:+ CESC cis rs8059260 0.668 rs78573173 ENSG00000274038.1 RP11-66H6.4 -4.4 1.68e-05 0.00851 -0.47 -0.29 Alcohol consumption over the past year; chr16:11017642 chr16:11056556~11057034:+ CESC cis rs1538970 0.884 rs61788261 ENSG00000280836.1 AL355480.1 -4.4 1.69e-05 0.00852 -0.36 -0.29 Platelet count; chr1:45433442 chr1:45581219~45581321:- CESC cis rs916888 0.773 rs199448 ENSG00000232300.1 FAM215B 4.4 1.69e-05 0.00853 0.44 0.29 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46558830~46562795:- CESC cis rs6879260 1 rs6879260 ENSG00000248367.1 CTB-129O4.1 -4.4 1.69e-05 0.00853 -0.22 -0.29 Height; chr5:180304014 chr5:180293245~180295253:+ CESC cis rs1538970 0.816 rs9727262 ENSG00000280836.1 AL355480.1 -4.4 1.69e-05 0.00854 -0.36 -0.29 Platelet count; chr1:45532907 chr1:45581219~45581321:- CESC cis rs651386 0.529 rs12072276 ENSG00000271811.1 RP1-79C4.4 4.4 1.69e-05 0.00854 0.38 0.29 Atrial fibrillation; chr1:170624928 chr1:170667381~170669425:+ CESC cis rs651386 0.506 rs11577602 ENSG00000271811.1 RP1-79C4.4 4.4 1.69e-05 0.00854 0.38 0.29 Atrial fibrillation; chr1:170627404 chr1:170667381~170669425:+ CESC cis rs577676 0.586 rs10800530 ENSG00000271811.1 RP1-79C4.4 4.4 1.69e-05 0.00854 0.38 0.29 Prevalent atrial fibrillation; chr1:170627431 chr1:170667381~170669425:+ CESC cis rs651386 0.506 rs10919448 ENSG00000271811.1 RP1-79C4.4 4.4 1.69e-05 0.00854 0.38 0.29 Atrial fibrillation; chr1:170630432 chr1:170667381~170669425:+ CESC cis rs7896729 0.607 rs12765968 ENSG00000215267.7 AKR1C7P -4.4 1.69e-05 0.00854 -0.39 -0.29 Intelligence; chr10:5289482 chr10:5275173~5288470:- CESC cis rs8020095 0.517 rs10047902 ENSG00000258561.1 RP11-72M17.1 -4.4 1.69e-05 0.00854 -0.42 -0.29 Depression (quantitative trait); chr14:66882429 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs6573736 ENSG00000258561.1 RP11-72M17.1 -4.4 1.69e-05 0.00854 -0.43 -0.29 Depression (quantitative trait); chr14:66907967 chr14:66212810~66509394:- CESC cis rs5769707 0.681 rs2319346 ENSG00000235111.1 RP1-29C18.8 -4.4 1.69e-05 0.00854 -0.33 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49635992 chr22:49612657~49615716:- CESC cis rs5769765 0.908 rs9616390 ENSG00000229409.1 RP11-494O16.3 4.4 1.69e-05 0.00854 0.45 0.29 Schizophrenia; chr22:49920641 chr22:49845929~49846090:+ CESC cis rs875971 0.502 rs1796227 ENSG00000237310.1 GS1-124K5.4 -4.4 1.69e-05 0.00855 -0.32 -0.29 Aortic root size; chr7:66622032 chr7:66493706~66495474:+ CESC cis rs10129255 0.5 rs1024350 ENSG00000211972.2 IGHV3-66 4.4 1.69e-05 0.00855 0.2 0.29 Kawasaki disease; chr14:106685105 chr14:106675017~106675544:- CESC cis rs150992 0.505 rs167798 ENSG00000248489.1 CTD-2007H13.3 4.4 1.69e-05 0.00855 0.38 0.29 Body mass index; chr5:98972150 chr5:98929171~98995013:+ CESC cis rs7587476 0.822 rs13018304 ENSG00000229267.2 AC072062.1 -4.4 1.69e-05 0.00855 -0.36 -0.29 Neuroblastoma; chr2:214817494 chr2:214810229~214963274:+ CESC cis rs1538970 0.924 rs12097497 ENSG00000280836.1 AL355480.1 -4.4 1.69e-05 0.00855 -0.35 -0.29 Platelet count; chr1:45414997 chr1:45581219~45581321:- CESC cis rs12712135 0.706 rs6543114 ENSG00000234389.1 AC007278.3 -4.4 1.69e-05 0.00855 -0.33 -0.29 Blood protein levels; chr2:102309534 chr2:102438713~102440475:+ CESC cis rs2404602 0.583 rs35707798 ENSG00000280730.1 AC090181.1 4.4 1.7e-05 0.00855 0.22 0.29 Blood metabolite levels; chr15:76272685 chr15:77056895~77057021:+ CESC cis rs2412819 0.597 rs2412821 ENSG00000249839.1 AC011330.5 -4.4 1.7e-05 0.00856 -0.36 -0.29 Lung cancer; chr15:43864966 chr15:43663654~43684339:- CESC cis rs11779988 0.543 rs410445 ENSG00000253671.1 RP11-806O11.1 -4.4 1.7e-05 0.00856 -0.34 -0.29 Breast cancer; chr8:18024795 chr8:17808941~17820868:+ CESC cis rs950776 0.518 rs55690619 ENSG00000279373.1 RP11-650L12.4 -4.4 1.7e-05 0.00857 -0.34 -0.29 Sudden cardiac arrest; chr15:78541270 chr15:78537681~78538946:+ CESC cis rs7789940 1 rs758944 ENSG00000230305.2 AC004980.9 4.4 1.7e-05 0.00857 0.4 0.29 Multiple sclerosis; chr7:76323980 chr7:76524515~76532692:+ CESC cis rs2833693 0.524 rs8129993 ENSG00000261610.1 AP000265.1 4.4 1.7e-05 0.00858 0.35 0.29 Temperament; chr21:32268841 chr21:32259804~32261585:- CESC cis rs853679 0.542 rs6934769 ENSG00000219392.1 RP1-265C24.5 -4.4 1.7e-05 0.00858 -0.37 -0.29 Depression; chr6:28123153 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs17711801 ENSG00000219392.1 RP1-265C24.5 -4.4 1.7e-05 0.00858 -0.37 -0.29 Depression; chr6:28124529 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs6922063 ENSG00000219392.1 RP1-265C24.5 -4.4 1.7e-05 0.00858 -0.37 -0.29 Depression; chr6:28126588 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs2275508 ENSG00000219392.1 RP1-265C24.5 -4.4 1.7e-05 0.00858 -0.37 -0.29 Depression; chr6:28126953 chr6:28115628~28116551:+ CESC cis rs4713118 0.527 rs9461433 ENSG00000219392.1 RP1-265C24.5 -4.4 1.7e-05 0.00858 -0.37 -0.29 Parkinson's disease; chr6:28127394 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9468292 ENSG00000219392.1 RP1-265C24.5 -4.4 1.7e-05 0.00858 -0.37 -0.29 Depression; chr6:28127577 chr6:28115628~28116551:+ CESC cis rs801193 0.613 rs2659900 ENSG00000237310.1 GS1-124K5.4 4.4 1.7e-05 0.00858 0.27 0.29 Aortic root size; chr7:66719456 chr7:66493706~66495474:+ CESC cis rs801193 0.636 rs2659895 ENSG00000237310.1 GS1-124K5.4 4.4 1.7e-05 0.00858 0.27 0.29 Aortic root size; chr7:66731484 chr7:66493706~66495474:+ CESC cis rs2111504 0.583 rs10853921 ENSG00000267213.4 AC007773.2 -4.4 1.7e-05 0.00859 -0.34 -0.29 Bipolar disorder; chr19:32370899 chr19:32390050~32405560:- CESC cis rs9309473 0.95 rs10206899 ENSG00000163016.8 ALMS1P 4.4 1.71e-05 0.00859 0.4 0.29 Metabolite levels; chr2:73673773 chr2:73644919~73685576:+ CESC cis rs1707322 0.638 rs1416706 ENSG00000280836.1 AL355480.1 4.4 1.71e-05 0.0086 0.36 0.29 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46137172 chr1:45581219~45581321:- CESC cis rs2412819 0.571 rs2930529 ENSG00000249839.1 AC011330.5 4.4 1.71e-05 0.0086 0.36 0.29 Lung cancer; chr15:43819467 chr15:43663654~43684339:- CESC cis rs3135071 1 rs3135071 ENSG00000270195.1 RP11-572O17.1 -4.4 1.71e-05 0.00861 -0.42 -0.29 Influenza A (H1N1) severity; chr4:2404594 chr4:1712821~1713622:+ CESC cis rs11157436 1 rs61972228 ENSG00000211813.2 TRAV34 4.4 1.71e-05 0.00862 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22179460 chr14:22207522~22208129:+ CESC cis rs11157436 1 rs12587157 ENSG00000211813.2 TRAV34 4.4 1.71e-05 0.00862 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22181476 chr14:22207522~22208129:+ CESC cis rs11157436 0.915 rs11622938 ENSG00000211813.2 TRAV34 4.4 1.71e-05 0.00862 0.32 0.29 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22183456 chr14:22207522~22208129:+ CESC cis rs1816213 1 rs16859180 ENSG00000272644.1 RP11-33O4.1 4.4 1.72e-05 0.00864 0.54 0.29 Diastolic blood pressure; chr2:218688745 chr2:219069354~219069809:- CESC cis rs1012068 0.921 rs5994442 ENSG00000236132.1 CTA-440B3.1 -4.4 1.72e-05 0.00864 -0.34 -0.29 Chronic hepatitis C infection; chr22:31875946 chr22:31816379~31817491:- CESC cis rs6782228 0.606 rs6787559 ENSG00000242551.2 POU5F1P6 -4.4 1.72e-05 0.00864 -0.32 -0.29 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128662243 chr3:128674735~128677005:- CESC cis rs6893782 0.83 rs274553 ENSG00000233006.5 AC034220.3 -4.4 1.72e-05 0.00865 -0.37 -0.29 Acylcarnitine levels; chr5:132390140 chr5:132311285~132369916:- CESC cis rs12439619 0.705 rs17354185 ENSG00000276710.3 CSPG4P8 4.4 1.72e-05 0.00865 0.4 0.29 Intelligence (multi-trait analysis); chr15:82133829 chr15:82459472~82477258:+ CESC cis rs17772222 0.74 rs3783885 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88510714 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs11159857 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88510796 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs4390529 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88510853 chr14:88499334~88515502:+ CESC cis rs17772222 0.771 rs4516145 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88510953 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs4594187 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88511071 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs4514599 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88511083 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs61975276 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88511193 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs61975277 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88511202 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs61984675 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88511236 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs73317739 ENSG00000258983.2 RP11-507K2.2 4.4 1.72e-05 0.00866 0.34 0.29 Coronary artery calcification; chr14:88511400 chr14:88499334~88515502:+ CESC cis rs67311347 1 rs962847 ENSG00000223797.4 ENTPD3-AS1 -4.4 1.72e-05 0.00866 -0.28 -0.29 Renal cell carcinoma; chr3:40453665 chr3:40313802~40453329:- CESC cis rs12908161 0.959 rs17598603 ENSG00000225151.9 GOLGA2P7 4.4 1.72e-05 0.00866 0.39 0.29 Schizophrenia; chr15:84656980 chr15:84199311~84230136:- CESC cis rs875971 0.545 rs1638735 ENSG00000224316.1 RP11-479O9.2 4.4 1.72e-05 0.00867 0.36 0.29 Aortic root size; chr7:66630751 chr7:65773620~65802067:+ CESC cis rs6964587 1 rs4644173 ENSG00000188693.7 CYP51A1-AS1 -4.4 1.72e-05 0.00867 -0.3 -0.29 Breast cancer; chr7:92130283 chr7:92134604~92180725:+ CESC cis rs17695224 0.675 rs2109658 ENSG00000268095.1 ZNF649-AS1 -4.4 1.72e-05 0.00868 -0.36 -0.29 HDL cholesterol;HDL cholesterol levels; chr19:51838871 chr19:51888025~51900463:+ CESC cis rs7587476 0.822 rs6726763 ENSG00000229267.2 AC072062.1 -4.4 1.73e-05 0.00868 -0.36 -0.29 Neuroblastoma; chr2:214816856 chr2:214810229~214963274:+ CESC cis rs950880 0.767 rs12712142 ENSG00000234389.1 AC007278.3 4.4 1.73e-05 0.00868 0.31 0.29 Serum protein levels (sST2); chr2:102344124 chr2:102438713~102440475:+ CESC cis rs763121 0.815 rs4821799 ENSG00000273076.1 RP3-508I15.22 4.4 1.73e-05 0.00868 0.32 0.29 Menopause (age at onset); chr22:38625321 chr22:38743495~38743910:+ CESC cis rs42490 0.557 rs426240 ENSG00000251136.7 RP11-37B2.1 -4.4 1.73e-05 0.00868 -0.29 -0.29 Leprosy; chr8:89834573 chr8:89609409~89757727:- CESC cis rs875971 0.756 rs4718328 ENSG00000232559.3 GS1-124K5.12 -4.4 1.73e-05 0.0087 -0.3 -0.29 Aortic root size; chr7:66228350 chr7:66554588~66576923:- CESC cis rs10129255 0.872 rs1858683 ENSG00000211970.3 IGHV4-61 -4.4 1.73e-05 0.0087 -0.22 -0.29 Kawasaki disease; chr14:106670217 chr14:106639119~106639657:- CESC cis rs10129255 0.872 rs8015406 ENSG00000211970.3 IGHV4-61 -4.4 1.73e-05 0.0087 -0.22 -0.29 Kawasaki disease; chr14:106670611 chr14:106639119~106639657:- CESC cis rs2717068 0.598 rs4671319 ENSG00000231043.3 AC007238.1 4.4 1.73e-05 0.0087 0.33 0.29 Epilepsy (generalized); chr2:57723211 chr2:58460292~58462032:- CESC cis rs72772090 0.539 rs17405676 ENSG00000248734.2 CTD-2260A17.1 -4.4 1.73e-05 0.0087 -0.42 -0.29 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96846912 chr5:96784777~96785999:+ CESC cis rs62355901 0.505 rs115495921 ENSG00000271828.1 CTD-2310F14.1 4.39 1.73e-05 0.0087 0.47 0.29 Breast cancer; chr5:56833021 chr5:56927874~56929573:+ CESC cis rs7688540 0.511 rs61794965 ENSG00000211553.1 AC253576.2 -4.39 1.73e-05 0.0087 -0.46 -0.29 Facial morphology (factor 6, height of vermillion lower lip); chr4:177880 chr4:136461~136568:+ CESC cis rs7688540 0.511 rs11731927 ENSG00000211553.1 AC253576.2 -4.39 1.73e-05 0.0087 -0.46 -0.29 Facial morphology (factor 6, height of vermillion lower lip); chr4:180316 chr4:136461~136568:+ CESC cis rs1051424 0.651 rs1292063 ENSG00000266701.1 AC005702.4 -4.39 1.73e-05 0.0087 -0.38 -0.29 Obesity-related traits; chr17:59830407 chr17:60042546~60042627:- CESC cis rs8067354 0.645 rs2645489 ENSG00000266701.1 AC005702.4 4.39 1.73e-05 0.0087 0.38 0.29 Hemoglobin concentration; chr17:59806010 chr17:60042546~60042627:- CESC cis rs8067354 0.645 rs2645486 ENSG00000266701.1 AC005702.4 4.39 1.73e-05 0.0087 0.38 0.29 Hemoglobin concentration; chr17:59808540 chr17:60042546~60042627:- CESC cis rs8067354 0.645 rs2645487 ENSG00000266701.1 AC005702.4 4.39 1.73e-05 0.0087 0.38 0.29 Hemoglobin concentration; chr17:59808764 chr17:60042546~60042627:- CESC cis rs1051424 0.642 rs115869798 ENSG00000266701.1 AC005702.4 4.39 1.73e-05 0.0087 0.38 0.29 Obesity-related traits; chr17:59815468 chr17:60042546~60042627:- CESC cis rs2732480 0.5 rs1387257 ENSG00000240399.1 RP1-228P16.1 4.39 1.73e-05 0.00871 0.34 0.29 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48242883 chr12:48054813~48055591:- CESC cis rs8100891 0.537 rs11880569 ENSG00000267213.4 AC007773.2 -4.39 1.73e-05 0.00871 -0.43 -0.29 Neuroticism; chr19:32478348 chr19:32390050~32405560:- CESC cis rs860295 0.812 rs12131079 ENSG00000225855.5 RUSC1-AS1 -4.39 1.73e-05 0.00871 -0.23 -0.29 Body mass index; chr1:155349877 chr1:155316863~155324176:- CESC cis rs9859260 0.744 rs406271 ENSG00000252174.1 RNU7-18P 4.39 1.74e-05 0.00872 0.33 0.29 Mean corpuscular volume; chr3:196050105 chr3:196072819~196072880:+ CESC cis rs6951245 0.706 rs1133116 ENSG00000229043.2 AC091729.9 -4.39 1.74e-05 0.00873 -0.41 -0.29 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1155579 chr7:1160374~1165267:+ CESC cis rs916888 0.773 rs199439 ENSG00000261575.2 RP11-259G18.1 4.39 1.74e-05 0.00873 0.42 0.29 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46267037~46268694:+ CESC cis rs2548724 0.704 rs62372211 ENSG00000250682.4 LINC00491 4.39 1.74e-05 0.00874 0.37 0.29 Type 2 diabetes; chr5:102301073 chr5:102609156~102671559:- CESC cis rs4272720 0.639 rs59553572 ENSG00000229870.1 RP11-507K13.6 -4.39 1.74e-05 0.00874 -0.33 -0.29 Platelet count;Plateletcrit; chr10:49072882 chr10:49815096~49815562:+ CESC cis rs2274273 0.624 rs11848575 ENSG00000258413.1 RP11-665C16.6 -4.39 1.74e-05 0.00875 -0.37 -0.29 Protein biomarker; chr14:55289070 chr14:55262767~55272075:- CESC cis rs2115630 0.645 rs6496284 ENSG00000225151.9 GOLGA2P7 4.39 1.74e-05 0.00875 0.33 0.29 P wave terminal force; chr15:84635039 chr15:84199311~84230136:- CESC cis rs6556937 0.757 rs4267886 ENSG00000251314.2 CTD-2337A12.1 4.39 1.75e-05 0.00876 0.4 0.29 Blood protein levels; chr5:96661562 chr5:95962001~96631085:+ CESC cis rs10644111 1 rs10644111 ENSG00000188693.7 CYP51A1-AS1 -4.39 1.75e-05 0.00876 -0.3 -0.29 Breast cancer; chr7:92022864 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs2299240 ENSG00000188693.7 CYP51A1-AS1 -4.39 1.75e-05 0.00876 -0.3 -0.29 Breast cancer; chr7:92025304 chr7:92134604~92180725:+ CESC cis rs1823913 1 rs4853562 ENSG00000227542.1 AC092614.2 -4.39 1.75e-05 0.00876 -0.29 -0.29 Obesity-related traits; chr2:191253696 chr2:191229165~191246172:- CESC cis rs1823913 1 rs4853461 ENSG00000227542.1 AC092614.2 -4.39 1.75e-05 0.00876 -0.29 -0.29 Obesity-related traits; chr2:191254572 chr2:191229165~191246172:- CESC cis rs2058059 0.551 rs13225871 ENSG00000205578.5 POM121B -4.39 1.75e-05 0.00878 -0.37 -0.29 Subcutaneous adipose tissue; chr7:72573203 chr7:73293497~73301161:+ CESC cis rs4722166 0.695 rs4722177 ENSG00000179428.2 AC073072.5 -4.39 1.75e-05 0.00878 -0.37 -0.29 Lung cancer; chr7:22758912 chr7:22725395~22727620:- CESC cis rs7809950 1 rs67982599 ENSG00000238832.1 snoU109 -4.39 1.75e-05 0.00878 -0.34 -0.29 Coronary artery disease; chr7:107459659 chr7:107603363~107603507:+ CESC cis rs7809950 1 rs987391 ENSG00000238832.1 snoU109 -4.39 1.75e-05 0.00878 -0.34 -0.29 Coronary artery disease; chr7:107460349 chr7:107603363~107603507:+ CESC cis rs10419113 0.641 rs12611312 ENSG00000270804.1 CTD-2583A14.11 -4.39 1.75e-05 0.00879 -0.29 -0.29 Pediatric bone mineral density (spine); chr19:57764436 chr19:57867885~57868834:+ CESC cis rs9322193 0.923 rs9800871 ENSG00000268592.3 RAET1E-AS1 4.39 1.75e-05 0.00879 0.36 0.29 Lung cancer; chr6:149644540 chr6:149863494~149919507:+ CESC cis rs7560272 0.538 rs17350056 ENSG00000273245.1 RP11-434P11.2 -4.39 1.75e-05 0.0088 -0.36 -0.29 Schizophrenia; chr2:73695750 chr2:73750256~73750786:- CESC cis rs6504622 0.62 rs2191033 ENSG00000263142.4 LRRC37A17P -4.39 1.76e-05 0.00881 -0.22 -0.29 Orofacial clefts; chr17:46927422 chr17:46978481~47054569:+ CESC cis rs2408955 0.522 rs6580650 ENSG00000240399.1 RP1-228P16.1 -4.39 1.76e-05 0.00883 -0.32 -0.29 Glycated hemoglobin levels; chr12:48024773 chr12:48054813~48055591:- CESC cis rs6693388 0.918 rs7554832 ENSG00000229021.2 AL591893.1 -4.39 1.77e-05 0.00885 -0.33 -0.29 Blood metabolite ratios; chr1:151966109 chr1:151994531~152042774:+ CESC cis rs453301 0.624 rs6987558 ENSG00000254340.1 RP11-10A14.3 4.39 1.77e-05 0.00885 0.33 0.29 Joint mobility (Beighton score); chr8:9005011 chr8:9141424~9145435:+ CESC cis rs7873102 0.654 rs10814640 ENSG00000230188.1 RP11-405L18.4 -4.39 1.77e-05 0.00886 -0.37 -0.28 Brain structure; chr9:38014639 chr9:37490421~37490893:- CESC cis rs2548724 0.513 rs1452058 ENSG00000250682.4 LINC00491 4.39 1.77e-05 0.00886 0.37 0.28 Type 2 diabetes; chr5:102307199 chr5:102609156~102671559:- CESC cis rs11976180 1 rs6464573 ENSG00000273234.1 OR2A13P 4.39 1.77e-05 0.00887 0.34 0.28 Obesity-related traits; chr7:144051005 chr7:144142009~144142938:+ CESC cis rs150992 0.504 rs7719649 ENSG00000248489.1 CTD-2007H13.3 4.39 1.77e-05 0.00887 0.39 0.28 Body mass index; chr5:99036711 chr5:98929171~98995013:+ CESC cis rs10788972 0.683 rs4927055 ENSG00000225183.1 RP4-758J24.4 -4.39 1.77e-05 0.00887 -0.34 -0.28 Parkinson disease and lewy body pathology; chr1:54110073 chr1:54089856~54090093:+ CESC cis rs8040855 0.627 rs11632658 ENSG00000259295.5 CSPG4P12 -4.39 1.78e-05 0.00889 -0.35 -0.28 Bulimia nervosa; chr15:85062982 chr15:85191438~85213905:+ CESC cis rs875971 0.545 rs73152714 ENSG00000226824.5 RP4-756H11.3 -4.39 1.78e-05 0.0089 -0.4 -0.28 Aortic root size; chr7:66534641 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs4718364 ENSG00000226824.5 RP4-756H11.3 -4.39 1.78e-05 0.0089 -0.4 -0.28 Aortic root size; chr7:66536353 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs6961853 ENSG00000226824.5 RP4-756H11.3 -4.39 1.78e-05 0.0089 -0.4 -0.28 Aortic root size; chr7:66537035 chr7:66654538~66669855:+ CESC cis rs75422866 0.867 rs78912815 ENSG00000274902.1 RP1-197B17.4 4.39 1.78e-05 0.0089 0.7 0.28 Pneumonia; chr12:47612065 chr12:47731908~47732351:+ CESC cis rs2439831 0.867 rs2255042 ENSG00000205771.5 CATSPER2P1 4.39 1.78e-05 0.0089 0.41 0.28 Lung cancer in ever smokers; chr15:43542120 chr15:43726918~43747094:- CESC cis rs2283792 0.566 rs1005579 ENSG00000224086.5 LL22NC03-86G7.1 -4.39 1.78e-05 0.0089 -0.33 -0.28 Multiple sclerosis; chr22:21946569 chr22:21938293~21977632:+ CESC cis rs9322193 0.923 rs9689723 ENSG00000216906.2 RP11-350J20.9 4.39 1.78e-05 0.0089 0.31 0.28 Lung cancer; chr6:149655935 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9968911 ENSG00000216906.2 RP11-350J20.9 4.39 1.78e-05 0.0089 0.31 0.28 Lung cancer; chr6:149657419 chr6:149904243~149906418:+ CESC cis rs10170846 1 rs10170846 ENSG00000261428.2 RP11-16P6.1 -4.39 1.78e-05 0.00891 -0.32 -0.28 Schizophrenia (inflammation and infection response interaction); chr2:222652986 chr2:222566899~222569719:- CESC cis rs7580658 0.676 rs4662717 ENSG00000236682.1 AC068282.3 -4.39 1.78e-05 0.00891 -0.33 -0.28 Protein C levels; chr2:127255928 chr2:127389130~127400580:+ CESC cis rs55665837 0.922 rs12287212 ENSG00000251991.1 RNU7-49P 4.39 1.78e-05 0.00891 0.32 0.28 Vitamin D levels; chr11:14428315 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs12276938 ENSG00000251991.1 RNU7-49P 4.39 1.78e-05 0.00891 0.32 0.28 Vitamin D levels; chr11:14441942 chr11:14478892~14478953:+ CESC cis rs2274273 0.624 rs10143136 ENSG00000258413.1 RP11-665C16.6 -4.39 1.78e-05 0.00892 -0.37 -0.28 Protein biomarker; chr14:55276810 chr14:55262767~55272075:- CESC cis rs10419113 0.641 rs12983947 ENSG00000270804.1 CTD-2583A14.11 4.39 1.78e-05 0.00893 0.29 0.28 Pediatric bone mineral density (spine); chr19:57763541 chr19:57867885~57868834:+ CESC cis rs875971 0.545 rs4441996 ENSG00000237310.1 GS1-124K5.4 -4.39 1.78e-05 0.00893 -0.3 -0.28 Aortic root size; chr7:66123233 chr7:66493706~66495474:+ CESC cis rs7811142 0.667 rs3873746 ENSG00000078319.8 PMS2P1 -4.39 1.79e-05 0.00894 -0.44 -0.28 Platelet count; chr7:100337474 chr7:100320992~100341908:- CESC cis rs1056107 0.7 rs10817274 ENSG00000225513.1 RP11-165N19.2 -4.39 1.79e-05 0.00894 -0.35 -0.28 Colorectal cancer; chr9:112167691 chr9:112173522~112173971:- CESC cis rs875971 0.545 rs316328 ENSG00000236529.1 RP13-254B10.1 -4.39 1.79e-05 0.00895 -0.33 -0.28 Aortic root size; chr7:66143851 chr7:65840212~65840596:+ CESC cis rs9326248 0.53 rs2000614 ENSG00000280143.1 AP000892.6 4.39 1.79e-05 0.00895 0.5 0.28 Blood protein levels; chr11:117045026 chr11:117204967~117210292:+ CESC cis rs9326248 0.53 rs2000616 ENSG00000280143.1 AP000892.6 4.39 1.79e-05 0.00895 0.5 0.28 Blood protein levels; chr11:117045813 chr11:117204967~117210292:+ CESC cis rs9326248 0.53 rs10750100 ENSG00000280143.1 AP000892.6 4.39 1.79e-05 0.00895 0.5 0.28 Blood protein levels; chr11:117046528 chr11:117204967~117210292:+ CESC cis rs748404 0.666 rs12906481 ENSG00000249839.1 AC011330.5 -4.39 1.79e-05 0.00895 -0.42 -0.28 Lung cancer; chr15:43467356 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs35958032 ENSG00000249839.1 AC011330.5 -4.39 1.79e-05 0.00895 -0.42 -0.28 Lung cancer; chr15:43494397 chr15:43663654~43684339:- CESC cis rs9309473 1 rs9309473 ENSG00000163016.8 ALMS1P 4.39 1.79e-05 0.00896 0.38 0.28 Metabolite levels; chr2:73516855 chr2:73644919~73685576:+ CESC cis rs9907295 0.591 rs4251749 ENSG00000271013.1 AC015849.15 -4.39 1.79e-05 0.00897 -0.32 -0.28 Fibroblast growth factor basic levels; chr17:35823421 chr17:35912635~35918010:- CESC cis rs9907295 0.591 rs4325615 ENSG00000271013.1 AC015849.15 -4.39 1.79e-05 0.00897 -0.32 -0.28 Fibroblast growth factor basic levels; chr17:35826379 chr17:35912635~35918010:- CESC cis rs9907295 0.551 rs28595279 ENSG00000271013.1 AC015849.15 -4.39 1.79e-05 0.00897 -0.32 -0.28 Fibroblast growth factor basic levels; chr17:35826416 chr17:35912635~35918010:- CESC cis rs13108904 0.901 rs4974594 ENSG00000254094.1 AC078852.1 4.39 1.79e-05 0.00898 0.35 0.28 Obesity-related traits; chr4:1306692 chr4:1356581~1358075:+ CESC cis rs12220238 0.822 rs10824193 ENSG00000213731.2 RAB5CP1 -4.39 1.79e-05 0.00898 -0.48 -0.28 Soluble interleukin-2 receptor subunit alpha; chr10:74502001 chr10:74423435~74424014:- CESC cis rs761746 0.579 rs5998121 ENSG00000236132.1 CTA-440B3.1 -4.39 1.79e-05 0.00898 -0.37 -0.28 Intelligence; chr22:31776381 chr22:31816379~31817491:- CESC cis rs761746 0.543 rs5998122 ENSG00000236132.1 CTA-440B3.1 -4.39 1.79e-05 0.00898 -0.37 -0.28 Intelligence; chr22:31777067 chr22:31816379~31817491:- CESC cis rs2243480 0.803 rs423187 ENSG00000275400.1 RP4-756H11.5 4.39 1.8e-05 0.00899 0.49 0.28 Diabetic kidney disease; chr7:66044512 chr7:66553805~66554199:- CESC cis rs12468226 0.606 rs79092351 ENSG00000273456.1 RP11-686O6.2 4.39 1.8e-05 0.00899 0.33 0.28 Urate levels; chr2:202204388 chr2:202374932~202375604:- CESC cis rs11779988 0.545 rs431961 ENSG00000253671.1 RP11-806O11.1 -4.39 1.8e-05 0.009 -0.35 -0.28 Breast cancer; chr8:17928695 chr8:17808941~17820868:+ CESC cis rs761746 0.739 rs131233 ENSG00000236132.1 CTA-440B3.1 -4.39 1.8e-05 0.009 -0.38 -0.28 Intelligence; chr22:31721114 chr22:31816379~31817491:- CESC cis rs853679 0.517 rs4713141 ENSG00000219392.1 RP1-265C24.5 -4.39 1.8e-05 0.00901 -0.37 -0.28 Depression; chr6:28133900 chr6:28115628~28116551:+ CESC cis rs694739 0.726 rs516124 ENSG00000236935.1 AP003774.1 4.39 1.8e-05 0.00901 0.29 0.28 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64360951 chr11:64325050~64329504:- CESC cis rs77204473 1 rs12276805 ENSG00000254851.1 RP11-109L13.1 4.38 1.8e-05 0.00902 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117008043 chr11:117135528~117138582:+ CESC cis rs1815787 1 rs1815787 ENSG00000280143.1 AP000892.6 4.38 1.8e-05 0.00902 0.5 0.28 Subjective well-being; chr11:117050681 chr11:117204967~117210292:+ CESC cis rs7809950 1 rs7793613 ENSG00000238832.1 snoU109 -4.38 1.81e-05 0.00902 -0.34 -0.28 Coronary artery disease; chr7:107610039 chr7:107603363~107603507:+ CESC cis rs875971 0.545 rs10950036 ENSG00000237310.1 GS1-124K5.4 4.38 1.81e-05 0.00902 0.3 0.28 Aortic root size; chr7:66353241 chr7:66493706~66495474:+ CESC cis rs13113518 0.678 rs13149568 ENSG00000249700.7 SRD5A3-AS1 4.38 1.81e-05 0.00902 0.36 0.28 Height; chr4:55370412 chr4:55363971~55395847:- CESC cis rs694739 1 rs499425 ENSG00000236935.1 AP003774.1 -4.38 1.81e-05 0.00903 -0.29 -0.28 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338457 chr11:64325050~64329504:- CESC cis rs6604026 0.624 rs35705463 ENSG00000223787.2 RP4-593M8.1 4.38 1.81e-05 0.00904 0.38 0.28 Multiple sclerosis; chr1:92767766 chr1:92580476~92580821:- CESC cis rs17695224 0.545 rs10853846 ENSG00000268095.1 ZNF649-AS1 4.38 1.81e-05 0.00904 0.36 0.28 HDL cholesterol;HDL cholesterol levels; chr19:51826595 chr19:51888025~51900463:+ CESC cis rs4713118 0.629 rs203888 ENSG00000219392.1 RP1-265C24.5 -4.38 1.81e-05 0.00904 -0.36 -0.28 Parkinson's disease; chr6:28053811 chr6:28115628~28116551:+ CESC cis rs7714584 1 rs4579248 ENSG00000197083.10 ZNF300P1 4.38 1.81e-05 0.00905 0.57 0.28 Crohn's disease; chr5:150888589 chr5:150930645~150946289:- CESC cis rs17826219 0.733 rs7221691 ENSG00000263531.1 RP13-753N3.1 -4.38 1.81e-05 0.00905 -0.59 -0.28 Body mass index; chr17:30396601 chr17:30863921~30864940:- CESC cis rs783540 0.934 rs4779053 ENSG00000276710.3 CSPG4P8 -4.38 1.81e-05 0.00905 -0.31 -0.28 Schizophrenia; chr15:82702846 chr15:82459472~82477258:+ CESC cis rs11159086 1 rs58384818 ENSG00000259005.1 RP3-449M8.6 4.38 1.81e-05 0.00906 0.47 0.28 Advanced glycation end-product levels; chr14:74487045 chr14:74474007~74474864:- CESC cis rs11159086 1 rs17100588 ENSG00000259005.1 RP3-449M8.6 4.38 1.81e-05 0.00906 0.47 0.28 Advanced glycation end-product levels; chr14:74487624 chr14:74474007~74474864:- CESC cis rs9322193 0.923 rs9767554 ENSG00000216906.2 RP11-350J20.9 4.38 1.82e-05 0.00906 0.31 0.28 Lung cancer; chr6:149616860 chr6:149904243~149906418:+ CESC cis rs453301 0.624 rs330049 ENSG00000254340.1 RP11-10A14.3 4.38 1.82e-05 0.00906 0.36 0.28 Joint mobility (Beighton score); chr8:9229789 chr8:9141424~9145435:+ CESC cis rs2243480 1 rs35421653 ENSG00000232559.3 GS1-124K5.12 4.38 1.82e-05 0.00908 0.49 0.28 Diabetic kidney disease; chr7:65898442 chr7:66554588~66576923:- CESC cis rs2283792 0.633 rs240068 ENSG00000224086.5 LL22NC03-86G7.1 -4.38 1.82e-05 0.00908 -0.32 -0.28 Multiple sclerosis; chr22:21936031 chr22:21938293~21977632:+ CESC cis rs2024714 0.546 rs6061677 ENSG00000226332.2 RP11-157P1.4 4.38 1.82e-05 0.00908 0.28 0.28 Longevity; chr20:61623010 chr20:62305432~62306325:- CESC cis rs7250849 0.565 rs73052857 ENSG00000273837.1 LLNLR-470E3.1 -4.38 1.82e-05 0.00909 -0.39 -0.28 Blood protein levels; chr19:51661182 chr19:51639478~51639931:- CESC cis rs7250849 0.565 rs73052859 ENSG00000273837.1 LLNLR-470E3.1 -4.38 1.82e-05 0.00909 -0.39 -0.28 Blood protein levels; chr19:51661210 chr19:51639478~51639931:- CESC cis rs7250849 0.565 rs73052861 ENSG00000273837.1 LLNLR-470E3.1 -4.38 1.82e-05 0.00909 -0.39 -0.28 Blood protein levels; chr19:51661217 chr19:51639478~51639931:- CESC cis rs11690935 0.851 rs6433319 ENSG00000228389.1 AC068039.4 4.38 1.82e-05 0.00909 0.34 0.28 Schizophrenia; chr2:171974442 chr2:171773482~171775844:+ CESC cis rs1853665 0.895 rs9478311 ENSG00000231760.4 RP11-350J20.5 4.38 1.82e-05 0.00909 0.41 0.28 Radiation response; chr6:149965999 chr6:149796151~149826294:- CESC cis rs860295 0.702 rs3738590 ENSG00000225855.5 RUSC1-AS1 4.38 1.82e-05 0.00909 0.24 0.28 Body mass index; chr1:155660961 chr1:155316863~155324176:- CESC cis rs7429990 0.965 rs11130154 ENSG00000229759.1 MRPS18AP1 -4.38 1.82e-05 0.0091 -0.29 -0.28 Educational attainment (years of education); chr3:48027752 chr3:48256350~48256938:- CESC cis rs7429990 0.813 rs7637622 ENSG00000229759.1 MRPS18AP1 -4.38 1.82e-05 0.0091 -0.29 -0.28 Educational attainment (years of education); chr3:48051561 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs7627645 ENSG00000229759.1 MRPS18AP1 -4.38 1.82e-05 0.0091 -0.29 -0.28 Educational attainment (years of education); chr3:48051643 chr3:48256350~48256938:- CESC cis rs1538970 0.961 rs7553318 ENSG00000280836.1 AL355480.1 -4.38 1.83e-05 0.00912 -0.35 -0.28 Platelet count; chr1:45377414 chr1:45581219~45581321:- CESC cis rs7131987 0.622 rs7294598 ENSG00000257176.2 RP11-996F15.2 4.38 1.83e-05 0.00912 0.34 0.28 QT interval; chr12:29379056 chr12:29280418~29317848:- CESC cis rs853679 0.517 rs9295758 ENSG00000219392.1 RP1-265C24.5 -4.38 1.83e-05 0.00912 -0.39 -0.28 Depression; chr6:28152885 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs17774663 ENSG00000219392.1 RP1-265C24.5 -4.38 1.83e-05 0.00912 -0.39 -0.28 Depression; chr6:28153120 chr6:28115628~28116551:+ CESC cis rs9928842 0.54 rs8051363 ENSG00000280152.1 RP11-331F4.5 4.38 1.83e-05 0.00912 0.3 0.28 Alcoholic chronic pancreatitis; chr16:75221319 chr16:75245994~75250077:- CESC cis rs2439831 0.85 rs12441861 ENSG00000275601.1 AC011330.13 -4.38 1.83e-05 0.00913 -0.44 -0.28 Lung cancer in ever smokers; chr15:43768685 chr15:43642389~43643023:- CESC cis rs17507216 0.628 rs4627310 ENSG00000255769.6 GOLGA2P10 -4.38 1.83e-05 0.00913 -0.42 -0.28 Excessive daytime sleepiness; chr15:82708330 chr15:82472993~82513950:- CESC cis rs17507216 0.628 rs4513065 ENSG00000255769.6 GOLGA2P10 -4.38 1.83e-05 0.00913 -0.42 -0.28 Excessive daytime sleepiness; chr15:82712096 chr15:82472993~82513950:- CESC cis rs17507216 0.628 rs28371837 ENSG00000255769.6 GOLGA2P10 -4.38 1.83e-05 0.00913 -0.42 -0.28 Excessive daytime sleepiness; chr15:82714435 chr15:82472993~82513950:- CESC cis rs9584850 0.794 rs17470961 ENSG00000231194.1 FARP1-AS1 4.38 1.83e-05 0.00913 0.34 0.28 Neuroticism; chr13:98483060 chr13:98435405~98435840:- CESC cis rs8177876 0.749 rs10459872 ENSG00000261838.4 RP11-303E16.6 -4.38 1.83e-05 0.00913 -0.59 -0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81061346 chr16:81069854~81076598:+ CESC cis rs42490 0.59 rs441547 ENSG00000251136.7 RP11-37B2.1 -4.38 1.83e-05 0.00913 -0.29 -0.28 Leprosy; chr8:89807954 chr8:89609409~89757727:- CESC cis rs42490 0.614 rs441548 ENSG00000251136.7 RP11-37B2.1 -4.38 1.83e-05 0.00913 -0.29 -0.28 Leprosy; chr8:89807955 chr8:89609409~89757727:- CESC cis rs42490 0.614 rs402434 ENSG00000251136.7 RP11-37B2.1 -4.38 1.83e-05 0.00913 -0.29 -0.28 Leprosy; chr8:89808088 chr8:89609409~89757727:- CESC cis rs763121 0.853 rs1013338 ENSG00000273076.1 RP3-508I15.22 4.38 1.83e-05 0.00914 0.33 0.28 Menopause (age at onset); chr22:38578149 chr22:38743495~38743910:+ CESC cis rs9309473 0.519 rs13022145 ENSG00000273245.1 RP11-434P11.2 -4.38 1.84e-05 0.00915 -0.36 -0.28 Metabolite levels; chr2:73636346 chr2:73750256~73750786:- CESC cis rs2177312 0.52 rs11729202 ENSG00000251129.1 RP11-734I18.1 -4.38 1.84e-05 0.00915 -0.36 -0.28 Very long-chain saturated fatty acid levels (fatty acid 22:0); chr4:31907566 chr4:31997397~32155406:+ CESC cis rs875971 0.862 rs6944374 ENSG00000232559.3 GS1-124K5.12 -4.38 1.84e-05 0.00917 -0.31 -0.28 Aortic root size; chr7:66221942 chr7:66554588~66576923:- CESC cis rs62229266 0.557 rs4817760 ENSG00000231106.2 LINC01436 4.38 1.84e-05 0.00917 0.41 0.28 Mitral valve prolapse; chr21:36023003 chr21:36005338~36007838:+ CESC cis rs7572733 0.534 rs13026569 ENSG00000222017.1 AC011997.1 -4.38 1.84e-05 0.00917 -0.36 -0.28 Dermatomyositis; chr2:197918606 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs4850815 ENSG00000222017.1 AC011997.1 -4.38 1.84e-05 0.00917 -0.36 -0.28 Dermatomyositis; chr2:197921443 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs12619300 ENSG00000222017.1 AC011997.1 -4.38 1.84e-05 0.00917 -0.36 -0.28 Dermatomyositis; chr2:197921766 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1401091 ENSG00000222017.1 AC011997.1 -4.38 1.84e-05 0.00917 -0.36 -0.28 Dermatomyositis; chr2:197925699 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1401092 ENSG00000222017.1 AC011997.1 -4.38 1.84e-05 0.00917 -0.36 -0.28 Dermatomyositis; chr2:197927596 chr2:197693106~197774823:+ CESC cis rs9859260 0.614 rs493661 ENSG00000252174.1 RNU7-18P 4.38 1.84e-05 0.00917 0.33 0.28 Mean corpuscular volume; chr3:196059618 chr3:196072819~196072880:+ CESC cis rs1538970 1 rs4520450 ENSG00000280836.1 AL355480.1 -4.38 1.84e-05 0.00917 -0.35 -0.28 Platelet count; chr1:45369101 chr1:45581219~45581321:- CESC cis rs42490 0.536 rs365871 ENSG00000251136.7 RP11-37B2.1 -4.38 1.84e-05 0.00917 -0.29 -0.28 Leprosy; chr8:89861458 chr8:89609409~89757727:- CESC cis rs42490 0.536 rs386857 ENSG00000251136.7 RP11-37B2.1 -4.38 1.84e-05 0.00917 -0.29 -0.28 Leprosy; chr8:89862824 chr8:89609409~89757727:- CESC cis rs42490 0.536 rs400571 ENSG00000251136.7 RP11-37B2.1 -4.38 1.84e-05 0.00917 -0.29 -0.28 Leprosy; chr8:89863336 chr8:89609409~89757727:- CESC cis rs2564921 0.73 rs56386026 ENSG00000242142.1 SERBP1P3 -4.38 1.84e-05 0.00918 -0.35 -0.28 Height; chr3:53080524 chr3:53064283~53065091:- CESC cis rs673078 0.607 rs2055534 ENSG00000275759.1 RP11-131L12.3 -4.38 1.84e-05 0.00918 -0.56 -0.28 Glucose homeostasis traits; chr12:118386527 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs56157623 ENSG00000275759.1 RP11-131L12.3 -4.38 1.84e-05 0.00918 -0.56 -0.28 Glucose homeostasis traits; chr12:118388162 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs4767669 ENSG00000275759.1 RP11-131L12.3 -4.38 1.84e-05 0.00918 -0.56 -0.28 Glucose homeostasis traits; chr12:118390651 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs4767670 ENSG00000275759.1 RP11-131L12.3 -4.38 1.84e-05 0.00918 -0.56 -0.28 Glucose homeostasis traits; chr12:118390737 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs950288 ENSG00000275759.1 RP11-131L12.3 -4.38 1.84e-05 0.00918 -0.56 -0.28 Glucose homeostasis traits; chr12:118392201 chr12:118428281~118428870:+ CESC cis rs6693388 0.918 rs6703465 ENSG00000229021.2 AL591893.1 -4.38 1.85e-05 0.0092 -0.33 -0.28 Blood metabolite ratios; chr1:151967091 chr1:151994531~152042774:+ CESC cis rs875971 0.862 rs7786892 ENSG00000237310.1 GS1-124K5.4 -4.38 1.85e-05 0.00922 -0.26 -0.28 Aortic root size; chr7:66163889 chr7:66493706~66495474:+ CESC cis rs3020736 0.5 rs4147641 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42086498 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs4147640 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42089288 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs1801311 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42090719 chr22:42278188~42278846:+ CESC cis rs1023500 0.507 rs6002600 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Schizophrenia; chr22:42092902 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs6002601 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42093054 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs6002604 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42097077 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs5996109 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42097094 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs5996110 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42097763 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs9620026 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42102574 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs28791586 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42104479 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs2839708 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42104741 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs6519306 ENSG00000273366.1 CTA-989H11.1 4.38 1.85e-05 0.00922 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42105213 chr22:42278188~42278846:+ CESC cis rs17818399 0.926 rs1824050 ENSG00000279254.1 RP11-536C12.1 -4.38 1.85e-05 0.00922 -0.36 -0.28 Height; chr2:46612338 chr2:46668870~46670778:+ CESC cis rs17818399 0.926 rs1378764 ENSG00000279254.1 RP11-536C12.1 -4.38 1.85e-05 0.00922 -0.36 -0.28 Height; chr2:46612542 chr2:46668870~46670778:+ CESC cis rs7580658 0.676 rs58475809 ENSG00000236682.1 AC068282.3 -4.38 1.85e-05 0.00922 -0.34 -0.28 Protein C levels; chr2:127245074 chr2:127389130~127400580:+ CESC cis rs516805 0.924 rs809770 ENSG00000279453.1 RP3-425C14.4 -4.38 1.85e-05 0.00922 -0.33 -0.28 Lymphocyte counts; chr6:122440061 chr6:122436789~122439223:- CESC cis rs4974559 0.739 rs2335937 ENSG00000253399.1 AC078852.2 4.38 1.85e-05 0.00923 0.49 0.28 Systolic blood pressure; chr4:1327728 chr4:1358479~1359461:+ CESC cis rs4974559 0.739 rs6845586 ENSG00000253399.1 AC078852.2 4.38 1.85e-05 0.00923 0.49 0.28 Systolic blood pressure; chr4:1329282 chr4:1358479~1359461:+ CESC cis rs2243480 1 rs383402 ENSG00000228409.4 CCT6P1 -4.38 1.86e-05 0.00924 -0.39 -0.28 Diabetic kidney disease; chr7:66121666 chr7:65751142~65763354:+ CESC cis rs12681963 0.688 rs61621868 ENSG00000272375.1 RP11-51J9.6 4.38 1.86e-05 0.00924 0.46 0.28 Migraine; chr8:30182621 chr8:30197404~30198048:+ CESC cis rs673078 0.607 rs61943393 ENSG00000275759.1 RP11-131L12.3 -4.38 1.86e-05 0.00924 -0.56 -0.28 Glucose homeostasis traits; chr12:118383650 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs73205576 ENSG00000275759.1 RP11-131L12.3 -4.38 1.86e-05 0.00924 -0.56 -0.28 Glucose homeostasis traits; chr12:118384268 chr12:118428281~118428870:+ CESC cis rs10129255 0.957 rs2007467 ENSG00000280411.1 IGHV1-69-2 4.38 1.86e-05 0.00924 0.22 0.28 Kawasaki disease; chr14:106771605 chr14:106762092~106762588:- CESC cis rs700651 0.789 rs62277902 ENSG00000222017.1 AC011997.1 -4.38 1.86e-05 0.00925 -0.36 -0.28 Intracranial aneurysm; chr2:198014719 chr2:197693106~197774823:+ CESC cis rs7586673 0.578 rs6723840 ENSG00000227403.1 AC009299.3 -4.38 1.86e-05 0.00925 -0.37 -0.28 Intelligence (multi-trait analysis); chr2:161023104 chr2:161244739~161249050:+ CESC cis rs7586673 0.578 rs6723841 ENSG00000227403.1 AC009299.3 -4.38 1.86e-05 0.00925 -0.37 -0.28 Intelligence (multi-trait analysis); chr2:161023105 chr2:161244739~161249050:+ CESC cis rs7429990 0.965 rs5012971 ENSG00000229759.1 MRPS18AP1 -4.38 1.87e-05 0.00928 -0.29 -0.28 Educational attainment (years of education); chr3:48033057 chr3:48256350~48256938:- CESC cis rs17301013 0.507 rs10912759 ENSG00000227373.4 RP11-160H22.5 4.38 1.87e-05 0.00928 0.39 0.28 Systemic lupus erythematosus; chr1:174312178 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6425278 ENSG00000227373.4 RP11-160H22.5 4.38 1.87e-05 0.00928 0.39 0.28 Systemic lupus erythematosus; chr1:174313148 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12083548 ENSG00000227373.4 RP11-160H22.5 4.38 1.87e-05 0.00928 0.39 0.28 Systemic lupus erythematosus; chr1:174319134 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12083814 ENSG00000227373.4 RP11-160H22.5 4.38 1.87e-05 0.00928 0.39 0.28 Systemic lupus erythematosus; chr1:174319917 chr1:174115300~174160004:- CESC cis rs9322193 0.923 rs10782315 ENSG00000216906.2 RP11-350J20.9 4.38 1.87e-05 0.00928 0.31 0.28 Lung cancer; chr6:149743093 chr6:149904243~149906418:+ CESC cis rs6001482 0.523 rs5757595 ENSG00000236850.4 BMS1P20 -4.38 1.87e-05 0.00928 -0.28 -0.28 Diastolic blood pressure; chr22:22235017 chr22:22303224~22322847:+ CESC cis rs673078 0.607 rs61943399 ENSG00000275759.1 RP11-131L12.3 -4.38 1.87e-05 0.00928 -0.55 -0.28 Glucose homeostasis traits; chr12:118393628 chr12:118428281~118428870:+ CESC cis rs17818399 0.781 rs13024534 ENSG00000279254.1 RP11-536C12.1 -4.38 1.87e-05 0.00928 -0.34 -0.28 Height; chr2:46632247 chr2:46668870~46670778:+ CESC cis rs1044826 0.667 rs2083336 ENSG00000178631.7 ACTG1P1 4.38 1.87e-05 0.00928 0.36 0.28 Obesity-related traits; chr3:139482430 chr3:139493809~139494937:+ CESC cis rs1044826 0.642 rs1080371 ENSG00000178631.7 ACTG1P1 4.38 1.87e-05 0.00928 0.36 0.28 Obesity-related traits; chr3:139492052 chr3:139493809~139494937:+ CESC cis rs2276314 0.857 rs56230698 ENSG00000278986.1 RP11-723J4.3 -4.38 1.87e-05 0.00929 -0.32 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36048922 chr18:35972151~35973916:+ CESC cis rs1044826 0.642 rs7652860 ENSG00000178631.7 ACTG1P1 4.38 1.87e-05 0.00929 0.36 0.28 Obesity-related traits; chr3:139486976 chr3:139493809~139494937:+ CESC cis rs1044826 0.642 rs6799312 ENSG00000178631.7 ACTG1P1 4.38 1.87e-05 0.00929 0.36 0.28 Obesity-related traits; chr3:139493090 chr3:139493809~139494937:+ CESC cis rs1044826 0.642 rs186103 ENSG00000178631.7 ACTG1P1 4.38 1.87e-05 0.00929 0.36 0.28 Obesity-related traits; chr3:139493100 chr3:139493809~139494937:+ CESC cis rs6686842 0.932 rs3157 ENSG00000235358.1 RP11-399E6.1 4.38 1.87e-05 0.0093 0.34 0.28 Height; chr1:41027439 chr1:41242373~41284861:+ CESC cis rs9322193 0.923 rs9377230 ENSG00000216906.2 RP11-350J20.9 4.38 1.87e-05 0.0093 0.31 0.28 Lung cancer; chr6:149613607 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs9689702 ENSG00000216906.2 RP11-350J20.9 4.38 1.87e-05 0.0093 0.31 0.28 Lung cancer; chr6:149740720 chr6:149904243~149906418:+ CESC cis rs5742933 1 rs5743061 ENSG00000253559.1 OSGEPL1-AS1 4.38 1.87e-05 0.0093 0.36 0.28 Ferritin levels; chr2:189829540 chr2:189762704~189765556:+ CESC cis rs7429990 0.965 rs7653368 ENSG00000229759.1 MRPS18AP1 4.38 1.88e-05 0.00932 0.29 0.28 Educational attainment (years of education); chr3:47943871 chr3:48256350~48256938:- CESC cis rs10129255 0.833 rs7156689 ENSG00000211974.3 IGHV2-70 4.38 1.88e-05 0.00932 0.3 0.28 Kawasaki disease; chr14:106816039 chr14:106723574~106724093:- CESC cis rs9322193 0.923 rs62441284 ENSG00000216906.2 RP11-350J20.9 4.38 1.88e-05 0.00932 0.32 0.28 Lung cancer; chr6:149751542 chr6:149904243~149906418:+ CESC cis rs7188445 1 rs7190187 ENSG00000261390.4 RP11-345M22.2 -4.38 1.88e-05 0.00934 -0.37 -0.28 Urate levels; chr16:79701281 chr16:79715232~79770563:- CESC cis rs801193 0.548 rs6975044 ENSG00000222364.1 RNU6-96P -4.37 1.88e-05 0.00934 -0.34 -0.28 Aortic root size; chr7:66762495 chr7:66395191~66395286:+ CESC cis rs11685222 0.589 rs72965070 ENSG00000229326.3 AC069154.4 4.37 1.88e-05 0.00934 0.38 0.28 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119659718 chr2:119698623~119700151:+ CESC cis rs6951245 1 rs78185558 ENSG00000229043.2 AC091729.9 -4.37 1.88e-05 0.00934 -0.43 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1050547 chr7:1160374~1165267:+ CESC cis rs1023500 0.573 rs1807494 ENSG00000273366.1 CTA-989H11.1 4.37 1.88e-05 0.00934 0.37 0.28 Schizophrenia; chr22:42078134 chr22:42278188~42278846:+ CESC cis rs1023500 0.573 rs133370 ENSG00000273366.1 CTA-989H11.1 -4.37 1.88e-05 0.00934 -0.37 -0.28 Schizophrenia; chr22:42069256 chr22:42278188~42278846:+ CESC cis rs1023500 0.551 rs133371 ENSG00000273366.1 CTA-989H11.1 -4.37 1.88e-05 0.00934 -0.37 -0.28 Schizophrenia; chr22:42069570 chr22:42278188~42278846:+ CESC cis rs1023500 0.573 rs133374 ENSG00000273366.1 CTA-989H11.1 -4.37 1.88e-05 0.00934 -0.37 -0.28 Schizophrenia; chr22:42069937 chr22:42278188~42278846:+ CESC cis rs1023500 0.529 rs133375 ENSG00000273366.1 CTA-989H11.1 -4.37 1.88e-05 0.00934 -0.37 -0.28 Schizophrenia; chr22:42070505 chr22:42278188~42278846:+ CESC cis rs1023500 0.573 rs133378 ENSG00000273366.1 CTA-989H11.1 -4.37 1.88e-05 0.00934 -0.37 -0.28 Schizophrenia; chr22:42071691 chr22:42278188~42278846:+ CESC cis rs1023500 0.573 rs133382 ENSG00000273366.1 CTA-989H11.1 -4.37 1.88e-05 0.00934 -0.37 -0.28 Schizophrenia; chr22:42075770 chr22:42278188~42278846:+ CESC cis rs7615952 0.673 rs34209763 ENSG00000248787.1 RP11-666A20.4 -4.37 1.89e-05 0.00936 -0.53 -0.28 Blood pressure (smoking interaction); chr3:125880752 chr3:125908005~125910272:- CESC cis rs57221529 0.654 rs12515813 ENSG00000225138.6 CTD-2228K2.7 4.37 1.89e-05 0.00936 0.45 0.28 Lung disease severity in cystic fibrosis; chr5:671711 chr5:473236~480884:+ CESC cis rs6893782 0.887 rs274547 ENSG00000233006.5 AC034220.3 -4.37 1.89e-05 0.00936 -0.37 -0.28 Acylcarnitine levels; chr5:132395612 chr5:132311285~132369916:- CESC cis rs6693388 0.918 rs6662728 ENSG00000229021.2 AL591893.1 -4.37 1.89e-05 0.00936 -0.33 -0.28 Blood metabolite ratios; chr1:151964102 chr1:151994531~152042774:+ CESC cis rs6693388 0.881 rs6587635 ENSG00000229021.2 AL591893.1 -4.37 1.89e-05 0.00936 -0.33 -0.28 Blood metabolite ratios; chr1:151965579 chr1:151994531~152042774:+ CESC cis rs6693388 0.793 rs6587636 ENSG00000229021.2 AL591893.1 -4.37 1.89e-05 0.00936 -0.33 -0.28 Blood metabolite ratios; chr1:151965604 chr1:151994531~152042774:+ CESC cis rs6693388 0.881 rs6587637 ENSG00000229021.2 AL591893.1 -4.37 1.89e-05 0.00936 -0.33 -0.28 Blood metabolite ratios; chr1:151965655 chr1:151994531~152042774:+ CESC cis rs6693388 0.881 rs6587638 ENSG00000229021.2 AL591893.1 -4.37 1.89e-05 0.00936 -0.33 -0.28 Blood metabolite ratios; chr1:151965662 chr1:151994531~152042774:+ CESC cis rs1799955 1 rs9567600 ENSG00000215515.2 IFIT1P1 -4.37 1.89e-05 0.00936 -0.44 -0.28 LDL cholesterol levels; chr13:32359789 chr13:32384660~32386108:+ CESC cis rs1799955 1 rs11571717 ENSG00000215515.2 IFIT1P1 -4.37 1.89e-05 0.00936 -0.44 -0.28 LDL cholesterol levels; chr13:32360774 chr13:32384660~32386108:+ CESC cis rs761746 0.579 rs5998126 ENSG00000236132.1 CTA-440B3.1 -4.37 1.89e-05 0.00937 -0.37 -0.28 Intelligence; chr22:31782416 chr22:31816379~31817491:- CESC cis rs761746 0.614 rs2108108 ENSG00000236132.1 CTA-440B3.1 -4.37 1.89e-05 0.00937 -0.37 -0.28 Intelligence; chr22:31785951 chr22:31816379~31817491:- CESC cis rs761746 0.614 rs8141214 ENSG00000236132.1 CTA-440B3.1 -4.37 1.89e-05 0.00937 -0.37 -0.28 Intelligence; chr22:31800195 chr22:31816379~31817491:- CESC cis rs9584850 0.562 rs17471066 ENSG00000231194.1 FARP1-AS1 4.37 1.89e-05 0.00938 0.4 0.28 Neuroticism; chr13:98512445 chr13:98435405~98435840:- CESC cis rs9918079 0.56 rs6414767 ENSG00000273133.1 RP11-799M12.2 -4.37 1.89e-05 0.00938 -0.37 -0.28 Obesity-related traits; chr4:15654098 chr4:15563698~15564253:- CESC cis rs9322193 0.847 rs4870054 ENSG00000268592.3 RAET1E-AS1 4.37 1.89e-05 0.00938 0.37 0.28 Lung cancer; chr6:149848402 chr6:149863494~149919507:+ CESC cis rs72772090 0.539 rs11750671 ENSG00000248734.2 CTD-2260A17.1 -4.37 1.9e-05 0.00939 -0.44 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96852779 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs72775817 ENSG00000248734.2 CTD-2260A17.1 -4.37 1.9e-05 0.00939 -0.44 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96855006 chr5:96784777~96785999:+ CESC cis rs2243480 1 rs73142122 ENSG00000232559.3 GS1-124K5.12 4.37 1.9e-05 0.00939 0.47 0.28 Diabetic kidney disease; chr7:65846311 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs73142137 ENSG00000232559.3 GS1-124K5.12 4.37 1.9e-05 0.00939 0.47 0.28 Diabetic kidney disease; chr7:65878455 chr7:66554588~66576923:- CESC cis rs2243480 1 rs13247184 ENSG00000232559.3 GS1-124K5.12 4.37 1.9e-05 0.00939 0.47 0.28 Diabetic kidney disease; chr7:65893941 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35283677 ENSG00000232559.3 GS1-124K5.12 4.37 1.9e-05 0.00939 0.47 0.28 Diabetic kidney disease; chr7:65894246 chr7:66554588~66576923:- CESC cis rs4722166 0.63 rs10950916 ENSG00000179428.2 AC073072.5 -4.37 1.9e-05 0.0094 -0.41 -0.28 Lung cancer; chr7:22760048 chr7:22725395~22727620:- CESC cis rs761746 0.921 rs12171042 ENSG00000236132.1 CTA-440B3.1 -4.37 1.9e-05 0.0094 -0.36 -0.28 Intelligence; chr22:31615239 chr22:31816379~31817491:- CESC cis rs61776719 0.747 rs28428561 ENSG00000212541.1 RNU6-510P 4.37 1.9e-05 0.0094 0.32 0.28 Coronary artery disease; chr1:37968634 chr1:37991462~37991569:+ CESC cis rs6604026 0.624 rs35038369 ENSG00000223787.2 RP4-593M8.1 4.37 1.9e-05 0.00941 0.38 0.28 Multiple sclerosis; chr1:92765411 chr1:92580476~92580821:- CESC cis rs6604026 0.624 rs11585590 ENSG00000223787.2 RP4-593M8.1 4.37 1.9e-05 0.00941 0.38 0.28 Multiple sclerosis; chr1:92766823 chr1:92580476~92580821:- CESC cis rs9650657 0.506 rs7823296 ENSG00000255046.1 RP11-297N6.4 4.37 1.9e-05 0.00942 0.31 0.28 Neuroticism; chr8:10921036 chr8:11797928~11802568:- CESC cis rs189798 0.807 rs9949 ENSG00000173295.6 FAM86B3P 4.37 1.9e-05 0.00942 0.38 0.28 Myopia (pathological); chr8:9137002 chr8:8228595~8244865:+ CESC cis rs13113518 1 rs11133388 ENSG00000273257.1 RP11-177J6.1 -4.37 1.9e-05 0.00942 -0.37 -0.28 Height; chr4:55477866 chr4:55387949~55388271:+ CESC cis rs7809950 0.911 rs1015411 ENSG00000238832.1 snoU109 -4.37 1.91e-05 0.00943 -0.35 -0.28 Coronary artery disease; chr7:107495167 chr7:107603363~107603507:+ CESC cis rs7714584 1 rs61530785 ENSG00000197083.10 ZNF300P1 4.37 1.91e-05 0.00943 0.56 0.28 Crohn's disease; chr5:150881802 chr5:150930645~150946289:- CESC cis rs526231 0.853 rs1991797 ENSG00000175749.11 EIF3KP1 4.37 1.91e-05 0.00944 0.34 0.28 Primary biliary cholangitis; chr5:103286752 chr5:103032376~103033031:+ CESC cis rs2732480 0.5 rs2450986 ENSG00000240399.1 RP1-228P16.1 4.37 1.91e-05 0.00944 0.34 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48267905 chr12:48054813~48055591:- CESC cis rs1387259 0.929 rs2634666 ENSG00000240399.1 RP1-228P16.1 4.37 1.91e-05 0.00944 0.34 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48269887 chr12:48054813~48055591:- CESC cis rs62025270 0.632 rs62022943 ENSG00000202081.1 RNU6-1280P -4.37 1.91e-05 0.00944 -0.39 -0.28 Idiopathic pulmonary fibrosis; chr15:85716239 chr15:85651522~85651628:- CESC cis rs11690935 0.851 rs6731562 ENSG00000228389.1 AC068039.4 4.37 1.91e-05 0.00944 0.34 0.28 Schizophrenia; chr2:171941742 chr2:171773482~171775844:+ CESC cis rs11690935 0.851 rs10201430 ENSG00000228389.1 AC068039.4 4.37 1.91e-05 0.00944 0.34 0.28 Schizophrenia; chr2:171956715 chr2:171773482~171775844:+ CESC cis rs17301013 0.507 rs2064150 ENSG00000227373.4 RP11-160H22.5 -4.37 1.91e-05 0.00944 -0.44 -0.28 Systemic lupus erythematosus; chr1:174339289 chr1:174115300~174160004:- CESC cis rs4819052 0.851 rs2838832 ENSG00000223768.1 LINC00205 4.37 1.91e-05 0.00944 0.34 0.28 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45244989 chr21:45293285~45297354:+ CESC cis rs8020095 0.571 rs7147690 ENSG00000258561.1 RP11-72M17.1 4.37 1.91e-05 0.00944 0.43 0.28 Depression (quantitative trait); chr14:66775619 chr14:66212810~66509394:- CESC cis rs1387259 0.79 rs2732445 ENSG00000240399.1 RP1-228P16.1 4.37 1.91e-05 0.00945 0.33 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48251750 chr12:48054813~48055591:- CESC cis rs875971 0.545 rs66594357 ENSG00000237310.1 GS1-124K5.4 4.37 1.91e-05 0.00945 0.3 0.28 Aortic root size; chr7:66327797 chr7:66493706~66495474:+ CESC cis rs8031584 0.918 rs1425292 ENSG00000260382.1 RP11-540B6.2 4.37 1.91e-05 0.00945 0.4 0.28 Huntington's disease progression; chr15:30993219 chr15:30882267~30883231:- CESC cis rs6142102 1 rs4911412 ENSG00000276073.1 RP5-1125A11.7 -4.37 1.91e-05 0.00945 -0.28 -0.28 Skin pigmentation; chr20:34128629 chr20:33985617~33988989:- CESC cis rs9309473 1 rs10179134 ENSG00000163016.8 ALMS1P 4.37 1.91e-05 0.00945 0.38 0.28 Metabolite levels; chr2:73410391 chr2:73644919~73685576:+ CESC cis rs11096990 0.855 rs2711990 ENSG00000249207.1 RP11-360F5.1 4.37 1.92e-05 0.00948 0.35 0.28 Cognitive function; chr4:39150116 chr4:39112677~39126818:- CESC cis rs67311347 1 rs1454497 ENSG00000223797.4 ENTPD3-AS1 -4.37 1.92e-05 0.00948 -0.28 -0.28 Renal cell carcinoma; chr3:40454835 chr3:40313802~40453329:- CESC cis rs1707322 1 rs10890365 ENSG00000281133.1 AL355480.3 -4.37 1.92e-05 0.00949 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893676 chr1:45580892~45580996:- CESC cis rs748404 1 rs748404 ENSG00000249839.1 AC011330.5 -4.37 1.92e-05 0.00949 -0.37 -0.28 Lung cancer; chr15:43267033 chr15:43663654~43684339:- CESC cis rs17507216 0.591 rs7163848 ENSG00000276710.3 CSPG4P8 -4.37 1.92e-05 0.00949 -0.4 -0.28 Excessive daytime sleepiness; chr15:82729563 chr15:82459472~82477258:+ CESC cis rs7005380 0.733 rs9987332 ENSG00000279347.1 RP11-85I17.2 4.37 1.92e-05 0.00949 0.26 0.28 Interstitial lung disease; chr8:119921723 chr8:119838736~119840385:- CESC cis rs9487094 0.67 rs34928881 ENSG00000260273.1 RP11-425D10.10 4.37 1.92e-05 0.00949 0.36 0.28 Height; chr6:109526846 chr6:109382795~109383666:+ CESC cis rs17695224 0.675 rs10405314 ENSG00000268095.1 ZNF649-AS1 4.37 1.93e-05 0.00951 0.36 0.28 HDL cholesterol;HDL cholesterol levels; chr19:51839450 chr19:51888025~51900463:+ CESC cis rs2255336 0.938 rs2255364 ENSG00000245648.1 RP11-277P12.20 4.37 1.93e-05 0.00952 0.41 0.28 Blood protein levels; chr12:10379297 chr12:10363769~10398506:+ CESC cis rs2255336 0.938 rs2255353 ENSG00000245648.1 RP11-277P12.20 4.37 1.93e-05 0.00952 0.41 0.28 Blood protein levels; chr12:10379512 chr12:10363769~10398506:+ CESC cis rs2337406 0.636 rs74090069 ENSG00000274576.2 IGHV2-70 -4.37 1.93e-05 0.00952 -0.32 -0.28 Alzheimer's disease (late onset); chr14:106777532 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs74090071 ENSG00000274576.2 IGHV2-70 -4.37 1.93e-05 0.00952 -0.32 -0.28 Alzheimer's disease (late onset); chr14:106777533 chr14:106770577~106771020:- CESC cis rs11685222 0.504 rs1521911 ENSG00000229326.3 AC069154.4 -4.37 1.93e-05 0.00953 -0.39 -0.28 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119651775 chr2:119698623~119700151:+ CESC cis rs1823913 0.895 rs10931491 ENSG00000227542.1 AC092614.2 -4.37 1.93e-05 0.00953 -0.29 -0.28 Obesity-related traits; chr2:191256087 chr2:191229165~191246172:- CESC cis rs1823913 1 rs11681777 ENSG00000227542.1 AC092614.2 -4.37 1.93e-05 0.00953 -0.29 -0.28 Obesity-related traits; chr2:191256741 chr2:191229165~191246172:- CESC cis rs1823913 1 rs1840377 ENSG00000227542.1 AC092614.2 -4.37 1.93e-05 0.00953 -0.29 -0.28 Obesity-related traits; chr2:191257992 chr2:191229165~191246172:- CESC cis rs1823913 1 rs4853564 ENSG00000227542.1 AC092614.2 -4.37 1.93e-05 0.00953 -0.29 -0.28 Obesity-related traits; chr2:191258939 chr2:191229165~191246172:- CESC cis rs1823913 1 rs4853565 ENSG00000227542.1 AC092614.2 -4.37 1.93e-05 0.00953 -0.29 -0.28 Obesity-related traits; chr2:191259020 chr2:191229165~191246172:- CESC cis rs1823913 1 rs4853462 ENSG00000227542.1 AC092614.2 -4.37 1.93e-05 0.00953 -0.29 -0.28 Obesity-related traits; chr2:191259078 chr2:191229165~191246172:- CESC cis rs5758659 0.504 rs133367 ENSG00000227370.1 RP4-669P10.19 4.37 1.93e-05 0.00953 0.3 0.28 Cognitive function; chr22:42067362 chr22:42132543~42132998:+ CESC cis rs875971 0.545 rs10950029 ENSG00000237310.1 GS1-124K5.4 4.37 1.93e-05 0.00954 0.31 0.28 Aortic root size; chr7:66169334 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs75840613 ENSG00000226824.5 RP4-756H11.3 -4.37 1.93e-05 0.00954 -0.4 -0.28 Aortic root size; chr7:66376399 chr7:66654538~66669855:+ CESC cis rs35160687 0.842 rs10200619 ENSG00000273080.1 RP11-301O19.1 -4.37 1.93e-05 0.00955 -0.32 -0.28 Night sleep phenotypes; chr2:86321725 chr2:86195590~86196049:+ CESC cis rs35160687 0.842 rs7593440 ENSG00000273080.1 RP11-301O19.1 -4.37 1.93e-05 0.00955 -0.32 -0.28 Night sleep phenotypes; chr2:86323534 chr2:86195590~86196049:+ CESC cis rs6001482 0.702 rs5757586 ENSG00000236850.4 BMS1P20 -4.37 1.94e-05 0.00955 -0.28 -0.28 Diastolic blood pressure; chr22:22234458 chr22:22303224~22322847:+ CESC cis rs6001482 0.686 rs9623125 ENSG00000236850.4 BMS1P20 -4.37 1.94e-05 0.00955 -0.28 -0.28 Diastolic blood pressure; chr22:22234600 chr22:22303224~22322847:+ CESC cis rs6001482 0.702 rs9623126 ENSG00000236850.4 BMS1P20 -4.37 1.94e-05 0.00955 -0.28 -0.28 Diastolic blood pressure; chr22:22234624 chr22:22303224~22322847:+ CESC cis rs9907295 0.636 rs4251724 ENSG00000271013.1 AC015849.15 -4.37 1.94e-05 0.00955 -0.32 -0.28 Fibroblast growth factor basic levels; chr17:35816641 chr17:35912635~35918010:- CESC cis rs62355901 0.505 rs3733951 ENSG00000271828.1 CTD-2310F14.1 -4.37 1.94e-05 0.00955 -0.45 -0.28 Breast cancer; chr5:56833976 chr5:56927874~56929573:+ CESC cis rs944801 0.55 rs2151280 ENSG00000215221.2 UBA52P6 4.37 1.94e-05 0.00955 0.33 0.28 Type 2 diabetes; chr9:22034720 chr9:22012155~22012536:+ CESC cis rs1823913 1 rs1823913 ENSG00000227542.1 AC092614.2 4.37 1.94e-05 0.00955 0.29 0.28 Obesity-related traits; chr2:191253321 chr2:191229165~191246172:- CESC cis rs1023500 0.573 rs133377 ENSG00000273366.1 CTA-989H11.1 -4.37 1.94e-05 0.00955 -0.38 -0.28 Schizophrenia; chr22:42070946 chr22:42278188~42278846:+ CESC cis rs2243480 0.706 rs34466769 ENSG00000226824.5 RP4-756H11.3 -4.37 1.94e-05 0.00955 -0.46 -0.28 Diabetic kidney disease; chr7:65988305 chr7:66654538~66669855:+ CESC cis rs35740288 0.862 rs11637444 ENSG00000202081.1 RNU6-1280P 4.37 1.94e-05 0.00955 0.36 0.28 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85767957 chr15:85651522~85651628:- CESC cis rs72772090 0.539 rs11747179 ENSG00000248734.2 CTD-2260A17.1 -4.37 1.94e-05 0.00956 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777265 chr5:96784777~96785999:+ CESC cis rs8177876 0.822 rs10514514 ENSG00000261838.4 RP11-303E16.6 4.37 1.94e-05 0.00957 0.55 0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081668 chr16:81069854~81076598:+ CESC cis rs1707322 1 rs4660335 ENSG00000281133.1 AL355480.3 -4.37 1.94e-05 0.00957 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46009046 chr1:45580892~45580996:- CESC cis rs6687821 0.531 rs6576861 ENSG00000267734.1 RP4-604K5.3 -4.37 1.94e-05 0.00958 -0.33 -0.28 Yeast infection; chr1:87030538 chr1:86932199~86934891:- CESC cis rs950880 1 rs12470864 ENSG00000234389.1 AC007278.3 -4.37 1.94e-05 0.00958 -0.31 -0.28 Serum protein levels (sST2); chr2:102309902 chr2:102438713~102440475:+ CESC cis rs9929218 0.529 rs17715450 ENSG00000260459.2 FTLP14 4.37 1.94e-05 0.00958 0.37 0.28 Colorectal cancer; chr16:68695882 chr16:68822587~68823070:+ CESC cis rs9287719 0.649 rs12617968 ENSG00000243819.4 RN7SL832P -4.37 1.94e-05 0.00959 -0.44 -0.28 Prostate cancer; chr2:10581819 chr2:10690344~10692099:+ CESC cis rs1387259 0.929 rs2956703 ENSG00000240399.1 RP1-228P16.1 4.37 1.95e-05 0.00959 0.34 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48276511 chr12:48054813~48055591:- CESC cis rs1387259 0.931 rs1107654 ENSG00000240399.1 RP1-228P16.1 4.37 1.95e-05 0.00959 0.34 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48287314 chr12:48054813~48055591:- CESC cis rs1387259 0.859 rs2054905 ENSG00000240399.1 RP1-228P16.1 4.37 1.95e-05 0.00959 0.34 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48294168 chr12:48054813~48055591:- CESC cis rs2732480 0.5 rs2732461 ENSG00000240399.1 RP1-228P16.1 4.37 1.95e-05 0.00959 0.34 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48299019 chr12:48054813~48055591:- CESC cis rs1707322 1 rs10789485 ENSG00000281133.1 AL355480.3 -4.37 1.95e-05 0.0096 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45941636 chr1:45580892~45580996:- CESC cis rs1538970 0.816 rs61788356 ENSG00000280836.1 AL355480.1 -4.37 1.95e-05 0.0096 -0.36 -0.28 Platelet count; chr1:45541003 chr1:45581219~45581321:- CESC cis rs875971 0.545 rs1796222 ENSG00000222364.1 RNU6-96P 4.37 1.95e-05 0.0096 0.39 0.28 Aortic root size; chr7:66592167 chr7:66395191~66395286:+ CESC cis rs6981523 0.553 rs11783890 ENSG00000255046.1 RP11-297N6.4 4.37 1.95e-05 0.0096 0.35 0.28 Neuroticism; chr8:11198879 chr8:11797928~11802568:- CESC cis rs6964587 0.9 rs7783674 ENSG00000188693.7 CYP51A1-AS1 -4.37 1.95e-05 0.0096 -0.3 -0.28 Breast cancer; chr7:92154898 chr7:92134604~92180725:+ CESC cis rs3020736 0.5 rs6002614 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42105798 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs2413669 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42111744 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs6002618 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42111855 chr22:42278188~42278846:+ CESC cis rs1023500 0.551 rs61665536 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Schizophrenia; chr22:42116609 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs2413672 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42117257 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs6002623 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42117757 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs11090076 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42118186 chr22:42278188~42278846:+ CESC cis rs3020736 0.519 rs5996116 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42121488 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs764481 ENSG00000273366.1 CTA-989H11.1 4.37 1.95e-05 0.00961 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42122422 chr22:42278188~42278846:+ CESC cis rs748404 0.666 rs12906017 ENSG00000249839.1 AC011330.5 -4.37 1.95e-05 0.00962 -0.42 -0.28 Lung cancer; chr15:43504710 chr15:43663654~43684339:- CESC cis rs4819052 0.851 rs8126930 ENSG00000223768.1 LINC00205 -4.37 1.95e-05 0.00962 -0.32 -0.28 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45251800 chr21:45293285~45297354:+ CESC cis rs2439831 0.867 rs2412778 ENSG00000275601.1 AC011330.13 -4.37 1.96e-05 0.00964 -0.38 -0.28 Lung cancer in ever smokers; chr15:43368784 chr15:43642389~43643023:- CESC cis rs2836950 0.501 rs35994303 ENSG00000232608.1 TIMM9P2 4.37 1.96e-05 0.00964 0.32 0.28 Menarche (age at onset); chr21:39314094 chr21:39216624~39217506:+ CESC cis rs944801 0.609 rs1360590 ENSG00000215221.2 UBA52P6 4.37 1.96e-05 0.00964 0.34 0.28 Type 2 diabetes; chr9:22041444 chr9:22012155~22012536:+ CESC cis rs8067354 0.872 rs1292060 ENSG00000266701.1 AC005702.4 4.37 1.96e-05 0.00965 0.34 0.28 Hemoglobin concentration; chr17:59836488 chr17:60042546~60042627:- CESC cis rs9309473 0.539 rs7574268 ENSG00000273245.1 RP11-434P11.2 -4.37 1.96e-05 0.00966 -0.36 -0.28 Metabolite levels; chr2:73677745 chr2:73750256~73750786:- CESC cis rs5758659 0.633 rs762995 ENSG00000273366.1 CTA-989H11.1 -4.37 1.96e-05 0.00966 -0.35 -0.28 Cognitive function; chr22:42276118 chr22:42278188~42278846:+ CESC cis rs2255336 0.938 rs73070926 ENSG00000245648.1 RP11-277P12.20 -4.36 1.96e-05 0.00967 -0.45 -0.28 Blood protein levels; chr12:10459717 chr12:10363769~10398506:+ CESC cis rs2255336 0.938 rs7298494 ENSG00000245648.1 RP11-277P12.20 -4.36 1.96e-05 0.00967 -0.45 -0.28 Blood protein levels; chr12:10460666 chr12:10363769~10398506:+ CESC cis rs7811142 0.83 rs6979910 ENSG00000078319.8 PMS2P1 -4.36 1.97e-05 0.00967 -0.44 -0.28 Platelet count; chr7:100343007 chr7:100320992~100341908:- CESC cis rs8005677 1 rs1043209 ENSG00000279656.1 RP11-298I3.6 -4.36 1.97e-05 0.00967 -0.35 -0.28 Cognitive ability (multi-trait analysis); chr14:22904777 chr14:23023083~23024217:- CESC cis rs1969253 0.632 rs865808 ENSG00000205955.4 HSP90AA5P 4.36 1.97e-05 0.00968 0.26 0.28 Major depressive disorder; chr3:184141151 chr3:184115352~184117898:+ CESC cis rs77972916 0.609 rs72790903 ENSG00000234936.1 AC010883.5 4.36 1.97e-05 0.00968 0.41 0.28 Granulocyte percentage of myeloid white cells; chr2:43334846 chr2:43229573~43233394:+ CESC cis rs9640161 0.789 rs2159234 ENSG00000261305.1 RP4-584D14.7 4.36 1.97e-05 0.00968 0.39 0.28 Blood protein levels;Circulating chemerin levels; chr7:150323333 chr7:150341771~150342607:+ CESC cis rs9640161 0.702 rs3735175 ENSG00000261305.1 RP4-584D14.7 4.36 1.97e-05 0.00968 0.39 0.28 Blood protein levels;Circulating chemerin levels; chr7:150323368 chr7:150341771~150342607:+ CESC cis rs7615952 0.576 rs4646748 ENSG00000250012.1 RP11-124N2.1 -4.36 1.97e-05 0.00968 -0.31 -0.28 Blood pressure (smoking interaction); chr3:126107486 chr3:126084220~126095349:+ CESC cis rs7951870 0.891 rs7130141 ENSG00000247675.5 LRP4-AS1 -4.36 1.97e-05 0.00969 -0.35 -0.28 Schizophrenia; chr11:46478324 chr11:46846412~46874396:+ CESC cis rs11976180 1 rs2961118 ENSG00000273234.1 OR2A13P -4.36 1.97e-05 0.0097 -0.34 -0.28 Obesity-related traits; chr7:144058350 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2961119 ENSG00000273234.1 OR2A13P -4.36 1.97e-05 0.0097 -0.34 -0.28 Obesity-related traits; chr7:144058759 chr7:144142009~144142938:+ CESC cis rs10129255 0.518 rs7143784 ENSG00000280411.1 IGHV1-69-2 -4.36 1.97e-05 0.0097 -0.19 -0.28 Kawasaki disease; chr14:106687277 chr14:106762092~106762588:- CESC cis rs700651 0.752 rs7592556 ENSG00000222017.1 AC011997.1 4.36 1.97e-05 0.0097 0.36 0.28 Intracranial aneurysm; chr2:198026297 chr2:197693106~197774823:+ CESC cis rs1823913 0.538 rs13432697 ENSG00000280083.1 RP11-317J9.1 -4.36 1.97e-05 0.0097 -0.33 -0.28 Obesity-related traits; chr2:191345944 chr2:191154118~191156070:- CESC cis rs2404602 0.583 rs12907668 ENSG00000280730.1 AC090181.1 4.36 1.97e-05 0.00971 0.22 0.28 Blood metabolite levels; chr15:76297426 chr15:77056895~77057021:+ CESC cis rs4974559 0.739 rs28412861 ENSG00000253399.1 AC078852.2 4.36 1.98e-05 0.00971 0.48 0.28 Systolic blood pressure; chr4:1326304 chr4:1358479~1359461:+ CESC cis rs2439831 1 rs1814538 ENSG00000275601.1 AC011330.13 4.36 1.98e-05 0.00972 0.37 0.28 Lung cancer in ever smokers; chr15:43467576 chr15:43642389~43643023:- CESC cis rs2337406 0.85 rs4774179 ENSG00000274576.2 IGHV2-70 -4.36 1.98e-05 0.00972 -0.36 -0.28 Alzheimer's disease (late onset); chr14:106700837 chr14:106770577~106771020:- CESC cis rs5769707 0.839 rs73176988 ENSG00000235111.1 RP1-29C18.8 -4.36 1.98e-05 0.00972 -0.29 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49596001 chr22:49612657~49615716:- CESC cis rs7572733 0.534 rs11899188 ENSG00000222017.1 AC011997.1 4.36 1.98e-05 0.00974 0.36 0.28 Dermatomyositis; chr2:197875397 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs734037 ENSG00000222017.1 AC011997.1 4.36 1.98e-05 0.00974 0.36 0.28 Dermatomyositis; chr2:197884545 chr2:197693106~197774823:+ CESC cis rs7572733 0.555 rs13395030 ENSG00000222017.1 AC011997.1 4.36 1.98e-05 0.00974 0.36 0.28 Dermatomyositis; chr2:197886082 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs2060488 ENSG00000222017.1 AC011997.1 4.36 1.98e-05 0.00974 0.36 0.28 Dermatomyositis; chr2:197886913 chr2:197693106~197774823:+ CESC cis rs700651 0.821 rs4850812 ENSG00000222017.1 AC011997.1 -4.36 1.98e-05 0.00974 -0.36 -0.28 Intracranial aneurysm; chr2:197878931 chr2:197693106~197774823:+ CESC cis rs73086581 1 rs73088421 ENSG00000229539.1 RP11-119B16.2 4.36 1.98e-05 0.00974 0.45 0.28 Response to antidepressants in depression; chr20:4017224 chr20:3888239~3888868:- CESC cis rs950169 0.545 rs4842841 ENSG00000225151.9 GOLGA2P7 -4.36 1.98e-05 0.00974 -0.43 -0.28 Schizophrenia; chr15:83972373 chr15:84199311~84230136:- CESC cis rs7617773 0.817 rs9819094 ENSG00000228638.1 FCF1P2 -4.36 1.98e-05 0.00974 -0.31 -0.28 Coronary artery disease; chr3:48278068 chr3:48290793~48291375:- CESC cis rs13113518 0.783 rs12504300 ENSG00000273257.1 RP11-177J6.1 4.36 1.98e-05 0.00974 0.38 0.28 Height; chr4:55482360 chr4:55387949~55388271:+ CESC cis rs12291225 0.535 rs16930126 ENSG00000251991.1 RNU7-49P -4.36 1.98e-05 0.00974 -0.33 -0.28 Sense of smell; chr11:14383437 chr11:14478892~14478953:+ CESC cis rs1707322 0.963 rs10890373 ENSG00000281133.1 AL355480.3 -4.36 1.98e-05 0.00974 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45928083 chr1:45580892~45580996:- CESC cis rs11846409 0.932 rs73378155 ENSG00000211974.3 IGHV2-70 -4.36 1.98e-05 0.00975 -0.35 -0.28 Rheumatic heart disease; chr14:106637840 chr14:106723574~106724093:- CESC cis rs700651 0.753 rs10207232 ENSG00000222017.1 AC011997.1 4.36 1.99e-05 0.00976 0.36 0.28 Intracranial aneurysm; chr2:198029089 chr2:197693106~197774823:+ CESC cis rs9640161 0.742 rs2108853 ENSG00000261305.1 RP4-584D14.7 4.36 1.99e-05 0.00976 0.39 0.28 Blood protein levels;Circulating chemerin levels; chr7:150320500 chr7:150341771~150342607:+ CESC cis rs1789 0.839 rs9997068 ENSG00000273133.1 RP11-799M12.2 -4.36 1.99e-05 0.00976 -0.37 -0.28 Blood protein levels; chr4:15649367 chr4:15563698~15564253:- CESC cis rs7429990 0.932 rs7620736 ENSG00000229759.1 MRPS18AP1 -4.36 1.99e-05 0.00977 -0.29 -0.28 Educational attainment (years of education); chr3:48068479 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs6791834 ENSG00000229759.1 MRPS18AP1 -4.36 1.99e-05 0.00977 -0.29 -0.28 Educational attainment (years of education); chr3:48073598 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs35689209 ENSG00000229759.1 MRPS18AP1 -4.36 1.99e-05 0.00977 -0.29 -0.28 Educational attainment (years of education); chr3:48078273 chr3:48256350~48256938:- CESC cis rs17826219 0.789 rs4794873 ENSG00000263531.1 RP13-753N3.1 4.36 1.99e-05 0.00977 0.59 0.28 Body mass index; chr17:30421334 chr17:30863921~30864940:- CESC cis rs1707322 1 rs10890355 ENSG00000281133.1 AL355480.3 -4.36 1.99e-05 0.00977 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45851676 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211204 ENSG00000281133.1 AL355480.3 -4.36 1.99e-05 0.00977 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45852192 chr1:45580892~45580996:- CESC cis rs3020736 0.5 rs8138678 ENSG00000273366.1 CTA-989H11.1 4.36 1.99e-05 0.00978 0.37 0.28 Autism spectrum disorder or schizophrenia; chr22:42120225 chr22:42278188~42278846:+ CESC cis rs9309473 0.519 rs1881246 ENSG00000273245.1 RP11-434P11.2 -4.36 1.99e-05 0.00978 -0.35 -0.28 Metabolite levels; chr2:73422994 chr2:73750256~73750786:- CESC cis rs72772090 0.539 rs11739020 ENSG00000248734.2 CTD-2260A17.1 4.36 1.99e-05 0.00978 0.43 0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778134 chr5:96784777~96785999:+ CESC cis rs944801 0.608 rs10757265 ENSG00000215221.2 UBA52P6 4.36 1.99e-05 0.00979 0.34 0.28 Type 2 diabetes; chr9:22048860 chr9:22012155~22012536:+ CESC cis rs3020736 0.5 rs4147638 ENSG00000273366.1 CTA-989H11.1 4.36 2e-05 0.0098 0.38 0.28 Autism spectrum disorder or schizophrenia; chr22:42091896 chr22:42278188~42278846:+ CESC cis rs2439831 0.85 rs544122 ENSG00000205771.5 CATSPER2P1 -4.36 2e-05 0.0098 -0.43 -0.28 Lung cancer in ever smokers; chr15:43483534 chr15:43726918~43747094:- CESC cis rs11603023 0.967 rs494560 ENSG00000255422.1 AP002954.4 4.36 2e-05 0.0098 0.32 0.28 Cholesterol, total; chr11:118650844 chr11:118704607~118750263:+ CESC cis rs860295 0.557 rs10796944 ENSG00000225855.5 RUSC1-AS1 4.36 2e-05 0.00981 0.26 0.28 Body mass index; chr1:155446537 chr1:155316863~155324176:- CESC cis rs916888 0.773 rs199448 ENSG00000261575.2 RP11-259G18.1 4.36 2e-05 0.00981 0.41 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46267037~46268694:+ CESC cis rs9322193 0.962 rs9397022 ENSG00000223701.3 RAET1E-AS1 4.36 2e-05 0.00981 0.32 0.28 Lung cancer; chr6:149812052 chr6:149884431~149919508:+ CESC cis rs9322193 0.962 rs9397357 ENSG00000223701.3 RAET1E-AS1 4.36 2e-05 0.00981 0.32 0.28 Lung cancer; chr6:149812465 chr6:149884431~149919508:+ CESC cis rs6981523 0.553 rs2409730 ENSG00000255046.1 RP11-297N6.4 4.36 2e-05 0.00981 0.33 0.28 Neuroticism; chr8:11203129 chr8:11797928~11802568:- CESC cis rs2408955 0.522 rs11168408 ENSG00000258273.1 RP11-370I10.4 4.36 2e-05 0.00982 0.33 0.28 Glycated hemoglobin levels; chr12:48104544 chr12:48333755~48333901:- CESC cis rs7819412 0.521 rs9329238 ENSG00000255046.1 RP11-297N6.4 4.36 2.01e-05 0.00984 0.33 0.28 Triglycerides; chr8:11176228 chr8:11797928~11802568:- CESC cis rs7560272 0.538 rs17434634 ENSG00000273245.1 RP11-434P11.2 -4.36 2.01e-05 0.00984 -0.36 -0.28 Schizophrenia; chr2:73695799 chr2:73750256~73750786:- CESC cis rs8020095 0.571 rs6573734 ENSG00000258561.1 RP11-72M17.1 -4.36 2.01e-05 0.00985 -0.42 -0.28 Depression (quantitative trait); chr14:66900212 chr14:66212810~66509394:- CESC cis rs8020095 0.528 rs1950281 ENSG00000258561.1 RP11-72M17.1 -4.36 2.01e-05 0.00985 -0.42 -0.28 Depression (quantitative trait); chr14:66934582 chr14:66212810~66509394:- CESC cis rs3124314 1 rs3001978 ENSG00000229021.2 AL591893.1 -4.36 2.01e-05 0.00986 -0.31 -0.28 Hair morphology; chr1:152153991 chr1:151994531~152042774:+ CESC cis rs9322193 0.961 rs2064520 ENSG00000216906.2 RP11-350J20.9 4.36 2.01e-05 0.00986 0.31 0.28 Lung cancer; chr6:149603650 chr6:149904243~149906418:+ CESC cis rs526231 0.697 rs422115 ENSG00000175749.11 EIF3KP1 4.36 2.01e-05 0.00987 0.37 0.28 Primary biliary cholangitis; chr5:103298639 chr5:103032376~103033031:+ CESC cis rs10043775 1 rs10477376 ENSG00000251330.3 CTD-2283N19.1 4.36 2.01e-05 0.00987 0.37 0.28 Periodontal microbiota; chr5:148405651 chr5:148430159~148430807:- CESC cis rs2243480 1 rs4548056 ENSG00000228409.4 CCT6P1 4.36 2.01e-05 0.00987 0.4 0.28 Diabetic kidney disease; chr7:65833886 chr7:65751142~65763354:+ CESC cis rs72807246 1 rs72807246 ENSG00000228701.1 TNKS2-AS1 4.36 2.01e-05 0.00987 0.49 0.28 Breast cancer; chr10:92172529 chr10:91782839~91798291:- CESC cis rs2337406 1 rs10459466 ENSG00000254174.1 IGHV1-12 4.36 2.01e-05 0.00987 0.3 0.28 Alzheimer's disease (late onset); chr14:106689255 chr14:106122420~106122709:- CESC cis rs950880 0.71 rs17026974 ENSG00000234389.1 AC007278.3 4.36 2.01e-05 0.00987 0.32 0.28 Serum protein levels (sST2); chr2:102335900 chr2:102438713~102440475:+ CESC cis rs1823913 0.538 rs11892998 ENSG00000280083.1 RP11-317J9.1 -4.36 2.02e-05 0.00988 -0.33 -0.28 Obesity-related traits; chr2:191340159 chr2:191154118~191156070:- CESC cis rs11159086 1 rs72730186 ENSG00000259005.1 RP3-449M8.6 4.36 2.02e-05 0.00988 0.49 0.28 Advanced glycation end-product levels; chr14:74475610 chr14:74474007~74474864:- CESC cis rs11779988 0.543 rs415226 ENSG00000253671.1 RP11-806O11.1 -4.36 2.02e-05 0.00989 -0.33 -0.28 Breast cancer; chr8:18038629 chr8:17808941~17820868:+ CESC cis rs7826238 0.564 rs2921053 ENSG00000253893.2 FAM85B -4.36 2.02e-05 0.0099 -0.35 -0.28 Systolic blood pressure; chr8:8462453 chr8:8167819~8226614:- CESC cis rs2739330 0.76 rs1002286 ENSG00000228039.3 KB-1125A3.10 -4.36 2.02e-05 0.00991 -0.34 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23963780~23964374:+ CESC cis rs61542988 1 rs61542988 ENSG00000228649.7 AC005682.5 4.36 2.02e-05 0.00991 0.26 0.28 Fibrinogen levels; chr7:22842672 chr7:22854178~22861579:+ CESC cis rs4648045 0.565 rs11733293 ENSG00000246560.2 RP11-10L12.4 -4.36 2.02e-05 0.00991 -0.37 -0.28 Lymphocyte percentage of white cells; chr4:102624096 chr4:102828055~102844075:+ CESC cis rs79407237 0.635 rs12631431 ENSG00000225733.4 FGD5-AS1 -4.36 2.02e-05 0.00991 -0.41 -0.28 Sjögren's syndrome; chr3:14713756 chr3:14920347~14948424:- CESC cis rs9309473 1 rs10169714 ENSG00000163016.8 ALMS1P 4.36 2.03e-05 0.00993 0.38 0.28 Metabolite levels; chr2:73581646 chr2:73644919~73685576:+ CESC cis rs748404 0.697 rs471122 ENSG00000205771.5 CATSPER2P1 4.36 2.03e-05 0.00993 0.34 0.28 Lung cancer; chr15:43266376 chr15:43726918~43747094:- CESC cis rs77204473 1 rs12274771 ENSG00000254851.1 RP11-109L13.1 4.36 2.03e-05 0.00993 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:116985982 chr11:117135528~117138582:+ CESC cis rs77204473 1 rs12274773 ENSG00000254851.1 RP11-109L13.1 4.36 2.03e-05 0.00993 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:116985993 chr11:117135528~117138582:+ CESC cis rs77204473 1 rs75212922 ENSG00000254851.1 RP11-109L13.1 4.36 2.03e-05 0.00993 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:116986276 chr11:117135528~117138582:+ CESC cis rs77204473 1 rs11216217 ENSG00000254851.1 RP11-109L13.1 4.36 2.03e-05 0.00993 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:116986936 chr11:117135528~117138582:+ CESC cis rs77204473 1 rs11216218 ENSG00000254851.1 RP11-109L13.1 4.36 2.03e-05 0.00993 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:116991945 chr11:117135528~117138582:+ CESC cis rs77204473 1 rs11216219 ENSG00000254851.1 RP11-109L13.1 4.36 2.03e-05 0.00993 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:116992039 chr11:117135528~117138582:+ CESC cis rs6687821 0.531 rs2390217 ENSG00000267734.1 RP4-604K5.3 -4.36 2.03e-05 0.00993 -0.33 -0.28 Yeast infection; chr1:87033896 chr1:86932199~86934891:- CESC cis rs6687821 0.531 rs10873816 ENSG00000267734.1 RP4-604K5.3 -4.36 2.03e-05 0.00993 -0.33 -0.28 Yeast infection; chr1:87035316 chr1:86932199~86934891:- CESC cis rs6687821 0.563 rs1936282 ENSG00000267734.1 RP4-604K5.3 -4.36 2.03e-05 0.00993 -0.33 -0.28 Yeast infection; chr1:87039275 chr1:86932199~86934891:- CESC cis rs6687821 0.531 rs6696540 ENSG00000267734.1 RP4-604K5.3 -4.36 2.03e-05 0.00993 -0.33 -0.28 Yeast infection; chr1:87040444 chr1:86932199~86934891:- CESC cis rs11779988 0.545 rs208058 ENSG00000253671.1 RP11-806O11.1 -4.36 2.03e-05 0.00993 -0.33 -0.28 Breast cancer; chr8:17962924 chr8:17808941~17820868:+ CESC cis rs7951870 1 rs12578042 ENSG00000247675.5 LRP4-AS1 4.36 2.03e-05 0.00993 0.35 0.28 Schizophrenia; chr11:46493454 chr11:46846412~46874396:+ CESC cis rs72772090 0.539 rs10515248 ENSG00000248734.2 CTD-2260A17.1 -4.36 2.03e-05 0.00994 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776301 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs56213813 ENSG00000248734.2 CTD-2260A17.1 -4.36 2.03e-05 0.00994 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776580 chr5:96784777~96785999:+ CESC cis rs72772090 0.52 rs56325109 ENSG00000248734.2 CTD-2260A17.1 -4.36 2.03e-05 0.00994 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776591 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs11747148 ENSG00000248734.2 CTD-2260A17.1 -4.36 2.03e-05 0.00994 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777159 chr5:96784777~96785999:+ CESC cis rs2439831 0.867 rs2251844 ENSG00000275601.1 AC011330.13 -4.36 2.03e-05 0.00995 -0.4 -0.28 Lung cancer in ever smokers; chr15:43544280 chr15:43642389~43643023:- CESC cis rs11846409 0.629 rs76295389 ENSG00000211974.3 IGHV2-70 4.36 2.03e-05 0.00995 0.39 0.28 Rheumatic heart disease; chr14:106650437 chr14:106723574~106724093:- CESC cis rs11846409 0.698 rs71419854 ENSG00000211974.3 IGHV2-70 4.36 2.03e-05 0.00995 0.39 0.28 Rheumatic heart disease; chr14:106650440 chr14:106723574~106724093:- CESC cis rs2337406 0.5 rs71419855 ENSG00000211974.3 IGHV2-70 4.36 2.03e-05 0.00995 0.39 0.28 Alzheimer's disease (late onset); chr14:106650444 chr14:106723574~106724093:- CESC cis rs61776719 0.875 rs10890238 ENSG00000212541.1 RNU6-510P -4.36 2.04e-05 0.00997 -0.32 -0.28 Coronary artery disease; chr1:37979982 chr1:37991462~37991569:+ CESC cis rs35160687 0.814 rs4392258 ENSG00000273080.1 RP11-301O19.1 -4.36 2.04e-05 0.00997 -0.32 -0.28 Night sleep phenotypes; chr2:86325454 chr2:86195590~86196049:+ CESC cis rs35160687 0.842 rs11685863 ENSG00000273080.1 RP11-301O19.1 -4.36 2.04e-05 0.00997 -0.32 -0.28 Night sleep phenotypes; chr2:86327361 chr2:86195590~86196049:+ CESC cis rs7587476 0.784 rs36086595 ENSG00000229267.2 AC072062.1 -4.36 2.04e-05 0.00997 -0.35 -0.28 Neuroblastoma; chr2:214815569 chr2:214810229~214963274:+ CESC cis rs10129255 0.913 rs10140943 ENSG00000280411.1 IGHV1-69-2 -4.36 2.04e-05 0.00997 -0.22 -0.28 Kawasaki disease; chr14:106767441 chr14:106762092~106762588:- CESC cis rs490234 0.702 rs7864945 ENSG00000232630.1 PRPS1P2 -4.36 2.04e-05 0.00998 -0.24 -0.28 Mean arterial pressure; chr9:125611190 chr9:125150653~125151589:+ CESC cis rs2255336 0.873 rs11053806 ENSG00000245648.1 RP11-277P12.20 -4.36 2.04e-05 0.00998 -0.43 -0.28 Blood protein levels; chr12:10455822 chr12:10363769~10398506:+ CESC cis rs9487094 0.67 rs12214639 ENSG00000260273.1 RP11-425D10.10 4.36 2.04e-05 0.00999 0.36 0.28 Height; chr6:109576414 chr6:109382795~109383666:+ CESC cis rs3806843 0.576 rs246009 ENSG00000202111.1 VTRNA1-2 4.36 2.04e-05 0.00999 0.28 0.28 Depressive symptoms (multi-trait analysis); chr5:140958484 chr5:140718925~140719013:+ CESC cis rs801193 0.569 rs35070132 ENSG00000222364.1 RNU6-96P -4.36 2.04e-05 0.01 -0.34 -0.28 Aortic root size; chr7:66773096 chr7:66395191~66395286:+ CESC cis rs7811142 0.775 rs1059129 ENSG00000078319.8 PMS2P1 -4.36 2.05e-05 0.01 -0.44 -0.28 Platelet count; chr7:100328899 chr7:100320992~100341908:- CESC cis rs7811142 0.562 rs7786844 ENSG00000078319.8 PMS2P1 -4.36 2.05e-05 0.01 -0.44 -0.28 Platelet count; chr7:100336385 chr7:100320992~100341908:- CESC cis rs1023500 0.573 rs2269524 ENSG00000273366.1 CTA-989H11.1 4.36 2.05e-05 0.01 0.38 0.28 Schizophrenia; chr22:42079699 chr22:42278188~42278846:+ CESC cis rs1023500 0.573 rs6002592 ENSG00000273366.1 CTA-989H11.1 4.36 2.05e-05 0.01 0.38 0.28 Schizophrenia; chr22:42080750 chr22:42278188~42278846:+ CESC cis rs1023500 0.573 rs4822088 ENSG00000273366.1 CTA-989H11.1 -4.36 2.05e-05 0.01 -0.38 -0.28 Schizophrenia; chr22:42074585 chr22:42278188~42278846:+ CESC cis rs453301 0.571 rs2929454 ENSG00000254340.1 RP11-10A14.3 -4.35 2.05e-05 0.01 -0.35 -0.28 Joint mobility (Beighton score); chr8:9226344 chr8:9141424~9145435:+ CESC cis rs9322193 0.923 rs9371207 ENSG00000216906.2 RP11-350J20.9 4.35 2.05e-05 0.01 0.33 0.28 Lung cancer; chr6:149858087 chr6:149904243~149906418:+ CESC cis rs2274273 0.624 rs7157308 ENSG00000258413.1 RP11-665C16.6 -4.35 2.05e-05 0.01 -0.37 -0.28 Protein biomarker; chr14:55315325 chr14:55262767~55272075:- CESC cis rs7789940 0.904 rs7459185 ENSG00000230305.2 AC004980.9 -4.35 2.05e-05 0.01 -0.39 -0.28 Multiple sclerosis; chr7:76305323 chr7:76524515~76532692:+ CESC cis rs42490 0.664 rs40457 ENSG00000251136.7 RP11-37B2.1 -4.35 2.05e-05 0.01 -0.27 -0.28 Leprosy; chr8:89811459 chr8:89609409~89757727:- CESC cis rs6687821 0.5 rs6693974 ENSG00000267734.1 RP4-604K5.3 -4.35 2.05e-05 0.01 -0.33 -0.28 Yeast infection; chr1:87040438 chr1:86932199~86934891:- CESC cis rs10129255 0.957 rs12589190 ENSG00000211970.3 IGHV4-61 -4.35 2.05e-05 0.01 -0.21 -0.28 Kawasaki disease; chr14:106783079 chr14:106639119~106639657:- CESC cis rs1707322 0.638 rs1707302 ENSG00000280836.1 AL355480.1 4.35 2.06e-05 0.01 0.35 0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46135245 chr1:45581219~45581321:- CESC cis rs7809950 1 rs2057837 ENSG00000238832.1 snoU109 4.35 2.06e-05 0.01 0.34 0.28 Coronary artery disease; chr7:107582280 chr7:107603363~107603507:+ CESC cis rs10829156 0.57 rs7904365 ENSG00000240291.1 RP11-499P20.2 4.35 2.06e-05 0.01 0.3 0.28 Sudden cardiac arrest; chr10:18542375 chr10:18513115~18545651:- CESC cis rs11157436 1 rs11157436 ENSG00000211813.2 TRAV34 -4.35 2.06e-05 0.01 -0.31 -0.28 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22168978 chr14:22207522~22208129:+ CESC cis rs783540 0.867 rs10906984 ENSG00000255769.6 GOLGA2P10 -4.35 2.06e-05 0.01 -0.31 -0.28 Schizophrenia; chr15:82697544 chr15:82472993~82513950:- CESC cis rs6964587 0.967 rs10231496 ENSG00000188693.7 CYP51A1-AS1 -4.35 2.06e-05 0.01 -0.3 -0.28 Breast cancer; chr7:92111818 chr7:92134604~92180725:+ CESC cis rs2058059 0.594 rs3015907 ENSG00000205578.5 POM121B -4.35 2.06e-05 0.01 -0.34 -0.28 Subcutaneous adipose tissue; chr7:72670647 chr7:73293497~73301161:+ CESC cis rs8100891 0.537 rs1030094 ENSG00000267213.4 AC007773.2 -4.35 2.06e-05 0.0101 -0.4 -0.28 Neuroticism; chr19:32419525 chr19:32390050~32405560:- CESC cis rs42490 0.868 rs4961158 ENSG00000251136.7 RP11-37B2.1 4.35 2.06e-05 0.0101 0.29 0.28 Leprosy; chr8:89685607 chr8:89609409~89757727:- CESC cis rs950880 1 rs13001325 ENSG00000234389.1 AC007278.3 -4.35 2.06e-05 0.0101 -0.31 -0.28 Serum protein levels (sST2); chr2:102322576 chr2:102438713~102440475:+ CESC cis rs6740322 0.895 rs10196095 ENSG00000234936.1 AC010883.5 4.35 2.06e-05 0.0101 0.3 0.28 Coronary artery disease; chr2:43344746 chr2:43229573~43233394:+ CESC cis rs8059260 0.736 rs7192695 ENSG00000274038.1 RP11-66H6.4 -4.35 2.06e-05 0.0101 -0.43 -0.28 Alcohol consumption over the past year; chr16:11005395 chr16:11056556~11057034:+ CESC cis rs5758659 0.652 rs133347 ENSG00000273366.1 CTA-989H11.1 -4.35 2.06e-05 0.0101 -0.35 -0.28 Cognitive function; chr22:42027641 chr22:42278188~42278846:+ CESC cis rs9322193 0.923 rs56397000 ENSG00000216906.2 RP11-350J20.9 4.35 2.07e-05 0.0101 0.31 0.28 Lung cancer; chr6:149739347 chr6:149904243~149906418:+ CESC cis rs6991838 0.778 rs11779602 ENSG00000272010.1 CTD-3025N20.3 4.35 2.07e-05 0.0101 0.31 0.28 Intelligence (multi-trait analysis); chr8:65550247 chr8:65591850~65592472:- CESC cis rs172166 0.611 rs203883 ENSG00000219392.1 RP1-265C24.5 -4.35 2.07e-05 0.0101 -0.33 -0.28 Cardiac Troponin-T levels; chr6:28110578 chr6:28115628~28116551:+ CESC cis rs172166 0.611 rs203882 ENSG00000219392.1 RP1-265C24.5 -4.35 2.07e-05 0.0101 -0.33 -0.28 Cardiac Troponin-T levels; chr6:28110724 chr6:28115628~28116551:+ CESC cis rs172166 0.694 rs1770131 ENSG00000219392.1 RP1-265C24.5 -4.35 2.07e-05 0.0101 -0.33 -0.28 Cardiac Troponin-T levels; chr6:28118635 chr6:28115628~28116551:+ CESC cis rs11976180 1 rs2951353 ENSG00000273234.1 OR2A13P -4.35 2.07e-05 0.0101 -0.34 -0.28 Obesity-related traits; chr7:144064023 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2371247 ENSG00000273234.1 OR2A13P -4.35 2.07e-05 0.0101 -0.34 -0.28 Obesity-related traits; chr7:144067086 chr7:144142009~144142938:+ CESC cis rs9322193 0.923 rs9800614 ENSG00000216906.2 RP11-350J20.9 4.35 2.07e-05 0.0101 0.31 0.28 Lung cancer; chr6:149644604 chr6:149904243~149906418:+ CESC cis rs11155671 0.53 rs2342770 ENSG00000223701.3 RAET1E-AS1 4.35 2.07e-05 0.0101 0.31 0.28 Testicular germ cell tumor; chr6:149895549 chr6:149884431~149919508:+ CESC cis rs7615952 0.8 rs35390120 ENSG00000248787.1 RP11-666A20.4 -4.35 2.07e-05 0.0101 -0.53 -0.28 Blood pressure (smoking interaction); chr3:125880966 chr3:125908005~125910272:- CESC cis rs7178909 0.872 rs17241560 ENSG00000259677.1 RP11-493E3.1 4.35 2.08e-05 0.0101 0.32 0.28 Common traits (Other); chr15:89885970 chr15:89876540~89877285:+ CESC cis rs7873102 0.654 rs4878726 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37975558 chr9:37490421~37490893:- CESC cis rs7873102 0.616 rs10738990 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37975924 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs6476669 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37976666 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs3935097 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37977562 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2243401 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37977993 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs870410 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37978586 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2266012 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37979860 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2266013 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37980213 chr9:37490421~37490893:- CESC cis rs7873102 0.617 rs2266014 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37980438 chr9:37490421~37490893:- CESC cis rs7873102 0.597 rs56198718 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37980901 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs2266015 ENSG00000230188.1 RP11-405L18.4 -4.35 2.08e-05 0.0101 -0.36 -0.28 Brain structure; chr9:37981631 chr9:37490421~37490893:- CESC cis rs9309473 1 rs13432605 ENSG00000163016.8 ALMS1P 4.35 2.08e-05 0.0101 0.38 0.28 Metabolite levels; chr2:73583854 chr2:73644919~73685576:+ CESC cis rs35740288 0.685 rs12899481 ENSG00000202081.1 RNU6-1280P 4.35 2.08e-05 0.0101 0.36 0.28 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85765739 chr15:85651522~85651628:- CESC cis rs875971 0.545 rs6969224 ENSG00000222364.1 RNU6-96P -4.35 2.08e-05 0.0101 -0.4 -0.28 Aortic root size; chr7:66370011 chr7:66395191~66395286:+ CESC cis rs42490 0.8 rs56291556 ENSG00000251136.7 RP11-37B2.1 4.35 2.08e-05 0.0101 0.29 0.28 Leprosy; chr8:89662546 chr8:89609409~89757727:- CESC cis rs11159086 1 rs12433848 ENSG00000270000.1 RP3-449M8.9 4.35 2.08e-05 0.0101 0.5 0.28 Advanced glycation end-product levels; chr14:74497570 chr14:74471930~74472360:- CESC cis rs7429990 0.965 rs2166770 ENSG00000229759.1 MRPS18AP1 4.35 2.08e-05 0.0101 0.29 0.28 Educational attainment (years of education); chr3:47964183 chr3:48256350~48256938:- CESC cis rs1538970 0.961 rs884962 ENSG00000280836.1 AL355480.1 -4.35 2.08e-05 0.0101 -0.34 -0.28 Platelet count; chr1:45382309 chr1:45581219~45581321:- CESC cis rs950169 0.614 rs765524 ENSG00000225151.9 GOLGA2P7 -4.35 2.08e-05 0.0101 -0.41 -0.28 Schizophrenia; chr15:84013030 chr15:84199311~84230136:- CESC cis rs4686914 0.892 rs12637415 ENSG00000228804.4 RP11-211G3.3 4.35 2.08e-05 0.0101 0.34 0.28 Metabolite levels; chr3:188002839 chr3:187702313~187733849:+ CESC cis rs17301013 0.507 rs10912766 ENSG00000227373.4 RP11-160H22.5 4.35 2.08e-05 0.0101 0.38 0.28 Systemic lupus erythematosus; chr1:174341129 chr1:174115300~174160004:- CESC cis rs875971 0.545 rs73150604 ENSG00000226824.5 RP4-756H11.3 -4.35 2.09e-05 0.0102 -0.42 -0.28 Aortic root size; chr7:66480545 chr7:66654538~66669855:+ CESC cis rs7829975 0.606 rs6422352 ENSG00000254340.1 RP11-10A14.3 -4.35 2.09e-05 0.0102 -0.34 -0.28 Mood instability; chr8:8936683 chr8:9141424~9145435:+ CESC cis rs7829975 0.606 rs891570 ENSG00000254340.1 RP11-10A14.3 -4.35 2.09e-05 0.0102 -0.34 -0.28 Mood instability; chr8:8936944 chr8:9141424~9145435:+ CESC cis rs75422866 0.867 rs73102140 ENSG00000274902.1 RP1-197B17.4 4.35 2.09e-05 0.0102 0.72 0.28 Pneumonia; chr12:47647497 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102148 ENSG00000274902.1 RP1-197B17.4 4.35 2.09e-05 0.0102 0.72 0.28 Pneumonia; chr12:47648013 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102151 ENSG00000274902.1 RP1-197B17.4 4.35 2.09e-05 0.0102 0.72 0.28 Pneumonia; chr12:47648023 chr12:47731908~47732351:+ CESC cis rs12468226 0.873 rs76552560 ENSG00000273456.1 RP11-686O6.2 4.35 2.09e-05 0.0102 0.41 0.28 Urate levels; chr2:202173123 chr2:202374932~202375604:- CESC cis rs950169 0.512 rs4374136 ENSG00000225151.9 GOLGA2P7 -4.35 2.09e-05 0.0102 -0.44 -0.28 Schizophrenia; chr15:83976255 chr15:84199311~84230136:- CESC cis rs875971 0.545 rs73146609 ENSG00000226824.5 RP4-756H11.3 -4.35 2.09e-05 0.0102 -0.41 -0.28 Aortic root size; chr7:66302477 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs2173571 ENSG00000226824.5 RP4-756H11.3 -4.35 2.09e-05 0.0102 -0.41 -0.28 Aortic root size; chr7:66305392 chr7:66654538~66669855:+ CESC cis rs2255336 0.938 rs10161486 ENSG00000245648.1 RP11-277P12.20 -4.35 2.09e-05 0.0102 -0.43 -0.28 Blood protein levels; chr12:10457167 chr12:10363769~10398506:+ CESC cis rs2255336 0.938 rs73070924 ENSG00000245648.1 RP11-277P12.20 -4.35 2.09e-05 0.0102 -0.43 -0.28 Blood protein levels; chr12:10457386 chr12:10363769~10398506:+ CESC cis rs4272720 0.666 rs35341824 ENSG00000229870.1 RP11-507K13.6 -4.35 2.09e-05 0.0102 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49075199 chr10:49815096~49815562:+ CESC cis rs8031584 0.958 rs34909055 ENSG00000260382.1 RP11-540B6.2 4.35 2.1e-05 0.0102 0.38 0.28 Huntington's disease progression; chr15:30991967 chr15:30882267~30883231:- CESC cis rs6782228 0.565 rs11719239 ENSG00000242551.2 POU5F1P6 -4.35 2.1e-05 0.0102 -0.32 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128700211 chr3:128674735~128677005:- CESC cis rs6782228 0.606 rs2001950 ENSG00000242551.2 POU5F1P6 -4.35 2.1e-05 0.0102 -0.32 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128700913 chr3:128674735~128677005:- CESC cis rs67311347 1 rs1119179 ENSG00000223797.4 ENTPD3-AS1 -4.35 2.1e-05 0.0102 -0.3 -0.28 Renal cell carcinoma; chr3:40383438 chr3:40313802~40453329:- CESC cis rs8005677 1 rs8014936 ENSG00000279656.1 RP11-298I3.6 4.35 2.1e-05 0.0102 0.35 0.28 Cognitive ability (multi-trait analysis); chr14:22905936 chr14:23023083~23024217:- CESC cis rs8005677 1 rs8016061 ENSG00000279656.1 RP11-298I3.6 4.35 2.1e-05 0.0102 0.35 0.28 Cognitive ability (multi-trait analysis); chr14:22906600 chr14:23023083~23024217:- CESC cis rs8005677 1 rs8005677 ENSG00000279656.1 RP11-298I3.6 4.35 2.1e-05 0.0102 0.35 0.28 Cognitive ability (multi-trait analysis); chr14:22907469 chr14:23023083~23024217:- CESC cis rs2833693 0.572 rs2040106 ENSG00000261610.1 AP000265.1 4.35 2.1e-05 0.0102 0.34 0.28 Temperament; chr21:32242397 chr21:32259804~32261585:- CESC cis rs2404602 0.563 rs12914005 ENSG00000259422.1 RP11-593F23.1 4.35 2.1e-05 0.0102 0.32 0.28 Blood metabolite levels; chr15:76473326 chr15:76174891~76181486:- CESC cis rs2404602 0.536 rs7163946 ENSG00000259422.1 RP11-593F23.1 4.35 2.1e-05 0.0102 0.32 0.28 Blood metabolite levels; chr15:76473708 chr15:76174891~76181486:- CESC cis rs5758659 0.652 rs5758553 ENSG00000273366.1 CTA-989H11.1 -4.35 2.1e-05 0.0102 -0.35 -0.28 Cognitive function; chr22:42035425 chr22:42278188~42278846:+ CESC cis rs9322193 0.651 rs9322188 ENSG00000216906.2 RP11-350J20.9 -4.35 2.1e-05 0.0102 -0.31 -0.28 Lung cancer; chr6:149588355 chr6:149904243~149906418:+ CESC cis rs10129255 0.518 rs7143784 ENSG00000211972.2 IGHV3-66 4.35 2.1e-05 0.0102 0.2 0.28 Kawasaki disease; chr14:106687277 chr14:106675017~106675544:- CESC cis rs7811142 1 rs11763511 ENSG00000078319.8 PMS2P1 -4.35 2.11e-05 0.0102 -0.45 -0.28 Platelet count; chr7:100484321 chr7:100320992~100341908:- CESC cis rs2833693 0.572 rs11088213 ENSG00000261610.1 AP000265.1 4.35 2.11e-05 0.0103 0.33 0.28 Temperament; chr21:32241398 chr21:32259804~32261585:- CESC cis rs875971 0.965 rs697968 ENSG00000232559.3 GS1-124K5.12 -4.35 2.11e-05 0.0103 -0.32 -0.28 Aortic root size; chr7:66070046 chr7:66554588~66576923:- CESC cis rs875971 1 rs1183245 ENSG00000232559.3 GS1-124K5.12 -4.35 2.11e-05 0.0103 -0.32 -0.28 Aortic root size; chr7:66076198 chr7:66554588~66576923:- CESC cis rs875971 1 rs1144894 ENSG00000232559.3 GS1-124K5.12 -4.35 2.11e-05 0.0103 -0.32 -0.28 Aortic root size; chr7:66077907 chr7:66554588~66576923:- CESC cis rs75422866 0.867 rs117388682 ENSG00000274902.1 RP1-197B17.4 4.35 2.11e-05 0.0103 0.7 0.28 Pneumonia; chr12:47599713 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs79113930 ENSG00000274902.1 RP1-197B17.4 4.35 2.11e-05 0.0103 0.7 0.28 Pneumonia; chr12:47600628 chr12:47731908~47732351:+ CESC cis rs7429990 0.965 rs4599334 ENSG00000229759.1 MRPS18AP1 -4.35 2.11e-05 0.0103 -0.29 -0.28 Educational attainment (years of education); chr3:48024910 chr3:48256350~48256938:- CESC cis rs2404602 0.536 rs7165025 ENSG00000259422.1 RP11-593F23.1 4.35 2.12e-05 0.0103 0.32 0.28 Blood metabolite levels; chr15:76474093 chr15:76174891~76181486:- CESC cis rs11685222 0.589 rs72965087 ENSG00000229326.3 AC069154.4 4.35 2.12e-05 0.0103 0.41 0.28 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119671942 chr2:119698623~119700151:+ CESC cis rs11685222 0.64 rs72965091 ENSG00000229326.3 AC069154.4 4.35 2.12e-05 0.0103 0.41 0.28 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119673574 chr2:119698623~119700151:+ CESC cis rs74394007 0.92 rs344081 ENSG00000244515.1 KRT18P34 4.35 2.12e-05 0.0103 0.47 0.28 Total body bone mineral density; chr3:156838195 chr3:157162663~157163932:- CESC cis rs74394007 0.92 rs344088 ENSG00000244515.1 KRT18P34 4.35 2.12e-05 0.0103 0.47 0.28 Total body bone mineral density; chr3:156843572 chr3:157162663~157163932:- CESC cis rs74394007 0.92 rs344090 ENSG00000244515.1 KRT18P34 4.35 2.12e-05 0.0103 0.47 0.28 Total body bone mineral density; chr3:156845351 chr3:157162663~157163932:- CESC cis rs1707322 1 rs6672115 ENSG00000281133.1 AL355480.3 -4.35 2.12e-05 0.0103 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45807207 chr1:45580892~45580996:- CESC cis rs1707322 1 rs7539800 ENSG00000281133.1 AL355480.3 4.35 2.12e-05 0.0103 0.34 0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45796457 chr1:45580892~45580996:- CESC cis rs875971 0.545 rs4718335 ENSG00000222364.1 RNU6-96P -4.35 2.12e-05 0.0103 -0.39 -0.28 Aortic root size; chr7:66339619 chr7:66395191~66395286:+ CESC cis rs9640161 0.742 rs2108852 ENSG00000261305.1 RP4-584D14.7 4.35 2.12e-05 0.0103 0.39 0.28 Blood protein levels;Circulating chemerin levels; chr7:150322539 chr7:150341771~150342607:+ CESC cis rs9640161 0.742 rs2108851 ENSG00000261305.1 RP4-584D14.7 4.35 2.12e-05 0.0103 0.39 0.28 Blood protein levels;Circulating chemerin levels; chr7:150322545 chr7:150341771~150342607:+ CESC cis rs133885 0.901 rs133902 ENSG00000100058.11 CRYBB2P1 4.35 2.12e-05 0.0103 0.31 0.28 Mathematical ability in children with dyslexia; chr22:25768112 chr22:25448105~25520854:+ CESC cis rs1075265 0.87 rs6749817 ENSG00000233266.1 HMGB1P31 4.35 2.12e-05 0.0103 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:54032396 chr2:54051334~54051760:+ CESC cis rs12908161 0.959 rs1051168 ENSG00000225151.9 GOLGA2P7 -4.35 2.12e-05 0.0103 -0.39 -0.28 Schizophrenia; chr15:84657289 chr15:84199311~84230136:- CESC cis rs67180937 0.882 rs17163345 ENSG00000272750.1 RP11-378J18.8 -4.35 2.13e-05 0.0103 -0.35 -0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222632876 chr1:222658867~222661512:- CESC cis rs875971 0.545 rs73378304 ENSG00000226824.5 RP4-756H11.3 -4.35 2.13e-05 0.0103 -0.37 -0.28 Aortic root size; chr7:66175760 chr7:66654538~66669855:+ CESC cis rs4819052 0.679 rs2838860 ENSG00000223768.1 LINC00205 -4.35 2.13e-05 0.0103 -0.32 -0.28 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45264989 chr21:45293285~45297354:+ CESC cis rs9309473 1 rs56672945 ENSG00000163016.8 ALMS1P 4.35 2.13e-05 0.0103 0.37 0.28 Metabolite levels; chr2:73395535 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs60844734 ENSG00000163016.8 ALMS1P 4.35 2.13e-05 0.0103 0.37 0.28 Metabolite levels; chr2:73396077 chr2:73644919~73685576:+ CESC cis rs8042680 0.955 rs2034084 ENSG00000214432.8 AC068831.10 -4.35 2.13e-05 0.0103 -0.35 -0.28 Type 2 diabetes; chr15:90963509 chr15:91022619~91036611:+ CESC cis rs1510272 0.515 rs2089735 ENSG00000243926.1 TIPARP-AS1 -4.35 2.13e-05 0.0103 -0.34 -0.28 Testicular germ cell tumor; chr3:156624763 chr3:156671862~156674378:- CESC cis rs3020736 0.5 rs8143153 ENSG00000273366.1 CTA-989H11.1 4.35 2.13e-05 0.0103 0.38 0.28 Autism spectrum disorder or schizophrenia; chr22:42119633 chr22:42278188~42278846:+ CESC cis rs916888 0.779 rs199528 ENSG00000261575.2 RP11-259G18.1 4.35 2.13e-05 0.0103 0.42 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46267037~46268694:+ CESC cis rs916888 0.821 rs199525 ENSG00000261575.2 RP11-259G18.1 4.35 2.13e-05 0.0103 0.42 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46267037~46268694:+ CESC cis rs3096299 0.933 rs2965934 ENSG00000274627.1 RP11-104N10.2 4.35 2.13e-05 0.0103 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89414821 chr16:89516797~89522217:+ CESC cis rs1862618 0.853 rs6885541 ENSG00000271828.1 CTD-2310F14.1 4.35 2.13e-05 0.0103 0.38 0.28 Initial pursuit acceleration; chr5:56815030 chr5:56927874~56929573:+ CESC cis rs8067354 0.872 rs2645488 ENSG00000266701.1 AC005702.4 4.35 2.13e-05 0.0103 0.34 0.28 Hemoglobin concentration; chr17:59812044 chr17:60042546~60042627:- CESC cis rs10129255 0.957 rs12590667 ENSG00000211970.3 IGHV4-61 4.35 2.13e-05 0.0104 0.21 0.28 Kawasaki disease; chr14:106779223 chr14:106639119~106639657:- CESC cis rs11096990 0.821 rs2711991 ENSG00000249207.1 RP11-360F5.1 4.35 2.13e-05 0.0104 0.35 0.28 Cognitive function; chr4:39149733 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2566168 ENSG00000249207.1 RP11-360F5.1 4.35 2.13e-05 0.0104 0.35 0.28 Cognitive function; chr4:39150053 chr4:39112677~39126818:- CESC cis rs74394007 0.92 rs7620458 ENSG00000244515.1 KRT18P34 4.35 2.14e-05 0.0104 0.51 0.28 Total body bone mineral density; chr3:156859061 chr3:157162663~157163932:- CESC cis rs4423214 0.592 rs79634040 ENSG00000254682.1 RP11-660L16.2 -4.34 2.14e-05 0.0104 -0.42 -0.28 Vitamin D levels; chr11:71519123 chr11:71448674~71452157:+ CESC cis rs8080784 0.611 rs6504006 ENSG00000266992.1 DHX40P1 4.34 2.14e-05 0.0104 0.38 0.28 Coronary artery disease; chr17:60921297 chr17:59976009~60002384:- CESC cis rs8080784 0.611 rs7225051 ENSG00000266992.1 DHX40P1 4.34 2.14e-05 0.0104 0.38 0.28 Coronary artery disease; chr17:60921369 chr17:59976009~60002384:- CESC cis rs6687821 0.531 rs4656137 ENSG00000267734.1 RP4-604K5.3 -4.34 2.14e-05 0.0104 -0.33 -0.28 Yeast infection; chr1:87030164 chr1:86932199~86934891:- CESC cis rs7951870 1 rs3802888 ENSG00000247675.5 LRP4-AS1 -4.34 2.14e-05 0.0104 -0.35 -0.28 Schizophrenia; chr11:46494352 chr11:46846412~46874396:+ CESC cis rs2276314 0.857 rs4799408 ENSG00000278986.1 RP11-723J4.3 4.34 2.14e-05 0.0104 0.31 0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36009019 chr18:35972151~35973916:+ CESC cis rs17772222 0.696 rs28666030 ENSG00000258983.2 RP11-507K2.2 4.34 2.14e-05 0.0104 0.33 0.28 Coronary artery calcification; chr14:88511463 chr14:88499334~88515502:+ CESC cis rs17772222 0.74 rs28493481 ENSG00000258983.2 RP11-507K2.2 4.34 2.14e-05 0.0104 0.33 0.28 Coronary artery calcification; chr14:88511491 chr14:88499334~88515502:+ CESC cis rs9987353 0.519 rs2929465 ENSG00000253893.2 FAM85B 4.34 2.14e-05 0.0104 0.36 0.28 Recombination measurement; chr8:9206492 chr8:8167819~8226614:- CESC cis rs1538970 1 rs4660853 ENSG00000280836.1 AL355480.1 -4.34 2.14e-05 0.0104 -0.34 -0.28 Platelet count; chr1:45383418 chr1:45581219~45581321:- CESC cis rs11157436 0.958 rs12432733 ENSG00000211813.2 TRAV34 4.34 2.14e-05 0.0104 0.31 0.28 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22230741 chr14:22207522~22208129:+ CESC cis rs17818399 0.926 rs13032670 ENSG00000279254.1 RP11-536C12.1 -4.34 2.15e-05 0.0104 -0.36 -0.28 Height; chr2:46603655 chr2:46668870~46670778:+ CESC cis rs17818399 0.926 rs35682608 ENSG00000279254.1 RP11-536C12.1 -4.34 2.15e-05 0.0104 -0.36 -0.28 Height; chr2:46609403 chr2:46668870~46670778:+ CESC cis rs2946504 0.501 rs2946509 ENSG00000251468.2 RP11-369K16.1 -4.34 2.15e-05 0.0104 -0.36 -0.28 Type 2 diabetes; chr8:12950782 chr8:12958387~12962200:+ CESC cis rs42490 0.899 rs1397308 ENSG00000251136.7 RP11-37B2.1 4.34 2.15e-05 0.0104 0.29 0.28 Leprosy; chr8:89628493 chr8:89609409~89757727:- CESC cis rs2255336 0.938 rs59906810 ENSG00000245648.1 RP11-277P12.20 -4.34 2.15e-05 0.0104 -0.4 -0.28 Blood protein levels; chr12:10446021 chr12:10363769~10398506:+ CESC cis rs17301013 0.507 rs16846861 ENSG00000227373.4 RP11-160H22.5 4.34 2.15e-05 0.0104 0.43 0.28 Systemic lupus erythematosus; chr1:174338731 chr1:174115300~174160004:- CESC cis rs673078 0.66 rs17512609 ENSG00000275759.1 RP11-131L12.3 -4.34 2.15e-05 0.0104 -0.55 -0.28 Glucose homeostasis traits; chr12:118354072 chr12:118428281~118428870:+ CESC cis rs57502260 0.679 rs72936524 ENSG00000212093.1 AP000807.1 4.34 2.15e-05 0.0104 0.46 0.28 Total body bone mineral density (age 45-60); chr11:68508430 chr11:68506083~68506166:- CESC cis rs9903692 0.954 rs2109984 ENSG00000263412.1 RP5-890E16.2 -4.34 2.15e-05 0.0104 -0.27 -0.28 Pulse pressure; chr17:48093737 chr17:48045141~48048073:- CESC cis rs875971 0.571 rs78668714 ENSG00000222364.1 RNU6-96P -4.34 2.15e-05 0.0104 -0.4 -0.28 Aortic root size; chr7:66474464 chr7:66395191~66395286:+ CESC cis rs8020095 0.571 rs8012063 ENSG00000258561.1 RP11-72M17.1 -4.34 2.15e-05 0.0104 -0.42 -0.28 Depression (quantitative trait); chr14:66967753 chr14:66212810~66509394:- CESC cis rs4272720 0.639 rs4400713 ENSG00000229870.1 RP11-507K13.6 -4.34 2.15e-05 0.0104 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49075862 chr10:49815096~49815562:+ CESC cis rs9309473 0.519 rs7598901 ENSG00000273245.1 RP11-434P11.2 -4.34 2.15e-05 0.0104 -0.35 -0.28 Metabolite levels; chr2:73448717 chr2:73750256~73750786:- CESC cis rs42490 0.837 rs218916 ENSG00000251136.7 RP11-37B2.1 -4.34 2.15e-05 0.0104 -0.29 -0.28 Leprosy; chr8:89688709 chr8:89609409~89757727:- CESC cis rs17507216 0.718 rs17158403 ENSG00000255769.6 GOLGA2P10 -4.34 2.16e-05 0.0104 -0.42 -0.28 Excessive daytime sleepiness; chr15:82572478 chr15:82472993~82513950:- CESC cis rs8072100 0.512 rs9303533 ENSG00000228782.6 CTD-2026D20.3 4.34 2.16e-05 0.0104 0.33 0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309174 chr17:47450568~47492492:- CESC cis rs5758659 0.652 rs133349 ENSG00000273366.1 CTA-989H11.1 -4.34 2.16e-05 0.0104 -0.35 -0.28 Cognitive function; chr22:42032723 chr22:42278188~42278846:+ CESC cis rs10129255 0.719 rs7156660 ENSG00000224373.3 IGHV4-59 4.34 2.16e-05 0.0104 0.19 0.28 Kawasaki disease; chr14:106673171 chr14:106627249~106627825:- CESC cis rs944801 0.566 rs1333036 ENSG00000215221.2 UBA52P6 4.34 2.16e-05 0.0105 0.34 0.28 Type 2 diabetes; chr9:22043820 chr9:22012155~22012536:+ CESC cis rs2439831 0.867 rs2470134 ENSG00000275601.1 AC011330.13 4.34 2.16e-05 0.0105 0.41 0.28 Lung cancer in ever smokers; chr15:43557688 chr15:43642389~43643023:- CESC cis rs2058059 0.681 rs2844177 ENSG00000205578.5 POM121B -4.34 2.16e-05 0.0105 -0.34 -0.28 Subcutaneous adipose tissue; chr7:72657954 chr7:73293497~73301161:+ CESC cis rs875971 0.862 rs2420174 ENSG00000237310.1 GS1-124K5.4 -4.34 2.16e-05 0.0105 -0.26 -0.28 Aortic root size; chr7:66180374 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs2420173 ENSG00000237310.1 GS1-124K5.4 -4.34 2.16e-05 0.0105 -0.26 -0.28 Aortic root size; chr7:66180412 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs4718319 ENSG00000237310.1 GS1-124K5.4 -4.34 2.16e-05 0.0105 -0.26 -0.28 Aortic root size; chr7:66187797 chr7:66493706~66495474:+ CESC cis rs875971 0.723 rs28391294 ENSG00000237310.1 GS1-124K5.4 -4.34 2.16e-05 0.0105 -0.26 -0.28 Aortic root size; chr7:66189328 chr7:66493706~66495474:+ CESC cis rs875971 0.83 rs6967708 ENSG00000237310.1 GS1-124K5.4 -4.34 2.16e-05 0.0105 -0.26 -0.28 Aortic root size; chr7:66192326 chr7:66493706~66495474:+ CESC cis rs875971 0.895 rs7782806 ENSG00000237310.1 GS1-124K5.4 -4.34 2.16e-05 0.0105 -0.26 -0.28 Aortic root size; chr7:66192910 chr7:66493706~66495474:+ CESC cis rs71403859 0.502 rs7195767 ENSG00000260886.1 TAT-AS1 4.34 2.16e-05 0.0105 0.42 0.28 Post bronchodilator FEV1; chr16:71431040 chr16:71565789~71578187:+ CESC cis rs8040855 0.69 rs8041189 ENSG00000259295.5 CSPG4P12 -4.34 2.16e-05 0.0105 -0.36 -0.28 Bulimia nervosa; chr15:85143096 chr15:85191438~85213905:+ CESC cis rs35160687 0.736 rs6746198 ENSG00000273080.1 RP11-301O19.1 -4.34 2.16e-05 0.0105 -0.32 -0.28 Night sleep phenotypes; chr2:86314990 chr2:86195590~86196049:+ CESC cis rs11651753 0.935 rs2525109 ENSG00000264920.1 RP11-6N17.4 4.34 2.17e-05 0.0105 0.32 0.28 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47964961 chr17:47891255~47895812:- CESC cis rs11651753 0.935 rs2525110 ENSG00000264920.1 RP11-6N17.4 4.34 2.17e-05 0.0105 0.32 0.28 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47964999 chr17:47891255~47895812:- CESC cis rs6782228 0.606 rs9828893 ENSG00000242551.2 POU5F1P6 -4.34 2.17e-05 0.0105 -0.31 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128614082 chr3:128674735~128677005:- CESC cis rs992157 0.56 rs7605980 ENSG00000261338.2 RP11-378A13.1 4.34 2.17e-05 0.0105 0.36 0.28 Colorectal cancer; chr2:218236146 chr2:218255319~218257366:+ CESC cis rs7581030 0.55 rs13028024 ENSG00000281195.1 ZNF638-IT1 -4.34 2.17e-05 0.0105 -0.42 -0.28 Testicular germ cell tumor; chr2:71211750 chr2:71373938~71376320:+ CESC cis rs6693388 0.602 rs2338019 ENSG00000229021.2 AL591893.1 4.34 2.17e-05 0.0105 0.31 0.28 Blood metabolite ratios; chr1:151984338 chr1:151994531~152042774:+ CESC cis rs1799949 0.931 rs9912203 ENSG00000267681.1 CTD-3199J23.6 4.34 2.17e-05 0.0105 0.34 0.28 Menopause (age at onset); chr17:43367777 chr17:43144956~43145255:+ CESC cis rs1799949 0.931 rs34474989 ENSG00000267681.1 CTD-3199J23.6 -4.34 2.17e-05 0.0105 -0.34 -0.28 Menopause (age at onset); chr17:43368042 chr17:43144956~43145255:+ CESC cis rs2439831 0.85 rs16950562 ENSG00000275601.1 AC011330.13 -4.34 2.17e-05 0.0105 -0.43 -0.28 Lung cancer in ever smokers; chr15:43744166 chr15:43642389~43643023:- CESC cis rs853679 0.517 rs4711164 ENSG00000219392.1 RP1-265C24.5 -4.34 2.17e-05 0.0105 -0.38 -0.28 Depression; chr6:28147378 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs4711165 ENSG00000219392.1 RP1-265C24.5 -4.34 2.17e-05 0.0105 -0.38 -0.28 Depression; chr6:28147406 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs4713148 ENSG00000219392.1 RP1-265C24.5 -4.34 2.17e-05 0.0105 -0.38 -0.28 Depression; chr6:28148143 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9348794 ENSG00000219392.1 RP1-265C24.5 -4.34 2.17e-05 0.0105 -0.38 -0.28 Depression; chr6:28149979 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9468297 ENSG00000219392.1 RP1-265C24.5 -4.34 2.17e-05 0.0105 -0.38 -0.28 Depression; chr6:28151096 chr6:28115628~28116551:+ CESC cis rs1012068 0.686 rs5998176 ENSG00000236132.1 CTA-440B3.1 -4.34 2.17e-05 0.0105 -0.32 -0.28 Chronic hepatitis C infection; chr22:31922107 chr22:31816379~31817491:- CESC cis rs5769707 0.967 rs739248 ENSG00000235111.1 RP1-29C18.8 -4.34 2.17e-05 0.0105 -0.28 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49631557 chr22:49612657~49615716:- CESC cis rs75422866 0.867 rs35044089 ENSG00000274902.1 RP1-197B17.4 4.34 2.17e-05 0.0105 0.69 0.28 Pneumonia; chr12:47610881 chr12:47731908~47732351:+ CESC cis rs9318086 0.712 rs3794339 ENSG00000205861.10 C1QTNF9B-AS1 -4.34 2.18e-05 0.0105 -0.36 -0.28 Myopia (pathological); chr13:23859926 chr13:23888889~23897263:+ CESC cis rs875971 0.545 rs1796219 ENSG00000222364.1 RNU6-96P 4.34 2.18e-05 0.0105 0.4 0.28 Aortic root size; chr7:66645977 chr7:66395191~66395286:+ CESC cis rs7809950 1 rs2712189 ENSG00000238832.1 snoU109 -4.34 2.18e-05 0.0105 -0.34 -0.28 Coronary artery disease; chr7:107555302 chr7:107603363~107603507:+ CESC cis rs2439831 0.85 rs28504496 ENSG00000275601.1 AC011330.13 -4.34 2.18e-05 0.0105 -0.44 -0.28 Lung cancer in ever smokers; chr15:43724685 chr15:43642389~43643023:- CESC cis rs9318086 0.712 rs1886970 ENSG00000205861.10 C1QTNF9B-AS1 -4.34 2.18e-05 0.0105 -0.36 -0.28 Myopia (pathological); chr13:23866359 chr13:23888889~23897263:+ CESC cis rs72615157 0.561 rs113401658 ENSG00000242294.5 STAG3L5P 4.34 2.18e-05 0.0105 0.29 0.28 Lung function (FEV1/FVC); chr7:100260882 chr7:100336079~100351900:+ CESC cis rs1023500 0.505 rs2143139 ENSG00000273366.1 CTA-989H11.1 -4.34 2.18e-05 0.0105 -0.36 -0.28 Schizophrenia; chr22:42218395 chr22:42278188~42278846:+ CESC cis rs2919917 1 rs2717547 ENSG00000254352.1 RP11-578O24.2 -4.34 2.18e-05 0.0105 -0.36 -0.28 Lymphocyte counts; chr8:78744754 chr8:78723796~78724136:- CESC cis rs2412819 0.571 rs8038068 ENSG00000249839.1 AC011330.5 -4.34 2.18e-05 0.0105 -0.43 -0.28 Lung cancer; chr15:43622175 chr15:43663654~43684339:- CESC cis rs2412819 0.571 rs56246169 ENSG00000249839.1 AC011330.5 -4.34 2.18e-05 0.0105 -0.43 -0.28 Lung cancer; chr15:43628358 chr15:43663654~43684339:- CESC cis rs911555 0.755 rs6575988 ENSG00000244691.1 RPL10AP1 4.34 2.18e-05 0.0105 0.38 0.28 Intelligence (multi-trait analysis); chr14:103434490 chr14:103412119~103412761:- CESC cis rs12580194 0.957 rs12579451 ENSG00000237493.3 RP11-603J24.7 -4.34 2.18e-05 0.0105 -0.39 -0.28 Cancer; chr12:55300332 chr12:55980432~55981035:- CESC cis rs7560272 0.588 rs4852965 ENSG00000273245.1 RP11-434P11.2 -4.34 2.18e-05 0.0105 -0.36 -0.28 Schizophrenia; chr2:73684042 chr2:73750256~73750786:- CESC cis rs4648045 0.565 rs17033014 ENSG00000246560.2 RP11-10L12.4 4.34 2.19e-05 0.0105 0.38 0.28 Lymphocyte percentage of white cells; chr4:102625029 chr4:102828055~102844075:+ CESC cis rs2439831 0.702 rs7171750 ENSG00000275601.1 AC011330.13 -4.34 2.19e-05 0.0105 -0.44 -0.28 Lung cancer in ever smokers; chr15:43733660 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28718261 ENSG00000275601.1 AC011330.13 -4.34 2.19e-05 0.0105 -0.44 -0.28 Lung cancer in ever smokers; chr15:43751595 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs10163054 ENSG00000275601.1 AC011330.13 -4.34 2.19e-05 0.0105 -0.44 -0.28 Lung cancer in ever smokers; chr15:43755440 chr15:43642389~43643023:- CESC cis rs763121 0.819 rs5750629 ENSG00000273076.1 RP3-508I15.22 4.34 2.19e-05 0.0105 0.32 0.28 Menopause (age at onset); chr22:38589060 chr22:38743495~38743910:+ CESC cis rs763121 0.819 rs5757160 ENSG00000273076.1 RP3-508I15.22 4.34 2.19e-05 0.0105 0.32 0.28 Menopause (age at onset); chr22:38593641 chr22:38743495~38743910:+ CESC cis rs763121 0.853 rs5750633 ENSG00000273076.1 RP3-508I15.22 4.34 2.19e-05 0.0105 0.32 0.28 Menopause (age at onset); chr22:38597462 chr22:38743495~38743910:+ CESC cis rs4272720 0.639 rs35462783 ENSG00000229870.1 RP11-507K13.6 -4.34 2.19e-05 0.0105 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49068780 chr10:49815096~49815562:+ CESC cis rs8020095 0.571 rs7157126 ENSG00000258561.1 RP11-72M17.1 -4.34 2.19e-05 0.0105 -0.42 -0.28 Depression (quantitative trait); chr14:67021513 chr14:66212810~66509394:- CESC cis rs2274273 0.624 rs11158034 ENSG00000258413.1 RP11-665C16.6 -4.34 2.19e-05 0.0106 -0.37 -0.28 Protein biomarker; chr14:55286842 chr14:55262767~55272075:- CESC cis rs2274273 0.624 rs11848456 ENSG00000258413.1 RP11-665C16.6 -4.34 2.19e-05 0.0106 -0.37 -0.28 Protein biomarker; chr14:55288674 chr14:55262767~55272075:- CESC cis rs9640161 0.75 rs3735167 ENSG00000261305.1 RP4-584D14.7 4.34 2.19e-05 0.0106 0.42 0.28 Blood protein levels;Circulating chemerin levels; chr7:150342466 chr7:150341771~150342607:+ CESC cis rs2179367 0.959 rs4895789 ENSG00000231760.4 RP11-350J20.5 4.34 2.19e-05 0.0106 0.36 0.28 Dupuytren's disease; chr6:149443518 chr6:149796151~149826294:- CESC cis rs2015599 0.623 rs12581107 ENSG00000257176.2 RP11-996F15.2 -4.34 2.19e-05 0.0106 -0.34 -0.28 Platelet count;Mean platelet volume; chr12:29352358 chr12:29280418~29317848:- CESC cis rs2015599 0.645 rs12578931 ENSG00000257176.2 RP11-996F15.2 -4.34 2.19e-05 0.0106 -0.34 -0.28 Platelet count;Mean platelet volume; chr12:29358608 chr12:29280418~29317848:- CESC cis rs2015599 0.623 rs4931174 ENSG00000257176.2 RP11-996F15.2 -4.34 2.19e-05 0.0106 -0.34 -0.28 Platelet count;Mean platelet volume; chr12:29360545 chr12:29280418~29317848:- CESC cis rs11976180 1 rs7777389 ENSG00000273234.1 OR2A13P -4.34 2.19e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144047709 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs67239267 ENSG00000273234.1 OR2A13P -4.34 2.19e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144048023 chr7:144142009~144142938:+ CESC cis rs4819052 0.851 rs7279011 ENSG00000223768.1 LINC00205 -4.34 2.19e-05 0.0106 -0.34 -0.28 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45236080 chr21:45293285~45297354:+ CESC cis rs1538970 0.851 rs61788285 ENSG00000280836.1 AL355480.1 -4.34 2.2e-05 0.0106 -0.36 -0.28 Platelet count; chr1:45453562 chr1:45581219~45581321:- CESC cis rs1538970 0.781 rs10890330 ENSG00000280836.1 AL355480.1 -4.34 2.2e-05 0.0106 -0.36 -0.28 Platelet count; chr1:45454734 chr1:45581219~45581321:- CESC cis rs72387598 1 rs72387598 ENSG00000280836.1 AL355480.1 -4.34 2.2e-05 0.0106 -0.36 -0.28 Platelet distribution width; chr1:45457307 chr1:45581219~45581321:- CESC cis rs11079757 0.681 rs34811916 ENSG00000262879.4 RP11-156P1.3 4.34 2.2e-05 0.0106 0.32 0.28 Erythema nodosum in inflammatory bowel disease; chr17:47111431 chr17:46984045~47100323:- CESC cis rs860295 0.871 rs6688636 ENSG00000225855.5 RUSC1-AS1 -4.34 2.2e-05 0.0106 -0.22 -0.28 Body mass index; chr1:155509106 chr1:155316863~155324176:- CESC cis rs2243480 1 rs6949812 ENSG00000232559.3 GS1-124K5.12 4.34 2.2e-05 0.0106 0.47 0.28 Diabetic kidney disease; chr7:65922114 chr7:66554588~66576923:- CESC cis rs6964587 1 rs10488510 ENSG00000188693.7 CYP51A1-AS1 -4.34 2.2e-05 0.0106 -0.3 -0.28 Breast cancer; chr7:92030911 chr7:92134604~92180725:+ CESC cis rs7259376 0.503 rs1692603 ENSG00000213971.6 RP11-15H20.6 -4.34 2.2e-05 0.0106 -0.34 -0.28 Menopause (age at onset); chr19:22455504 chr19:23259906~23274251:- CESC cis rs227932 0.764 rs73084758 ENSG00000234286.1 AC006026.13 -4.34 2.2e-05 0.0106 -0.39 -0.28 Schizophrenia; chr7:23804816 chr7:23680195~23680786:- CESC cis rs10156309 0.732 rs12542711 ENSG00000261542.1 RP11-16E18.3 -4.34 2.2e-05 0.0106 -0.56 -0.28 Allergic rhinitis; chr8:62577287 chr8:63215981~63218034:+ CESC cis rs10463554 0.856 rs257292 ENSG00000175749.11 EIF3KP1 4.34 2.2e-05 0.0106 0.3 0.28 Parkinson's disease; chr5:103159047 chr5:103032376~103033031:+ CESC cis rs10463554 0.856 rs257293 ENSG00000175749.11 EIF3KP1 4.34 2.2e-05 0.0106 0.3 0.28 Parkinson's disease; chr5:103159824 chr5:103032376~103033031:+ CESC cis rs7605378 0.567 rs717915 ENSG00000232732.8 AC073043.1 -4.34 2.2e-05 0.0106 -0.38 -0.28 Osteoporosis; chr2:199850043 chr2:199867396~199911159:- CESC cis rs11976180 1 rs2371244 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144060518 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs4726669 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144061098 chr7:144142009~144142938:+ CESC cis rs11976180 0.953 rs2951355 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144063469 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2951354 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144063908 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2961125 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144064677 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2961126 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144065643 chr7:144142009~144142938:+ CESC cis rs11976180 0.953 rs2961127 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144065644 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs1919948 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144065750 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2961128 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144066390 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2371248 ENSG00000273234.1 OR2A13P -4.34 2.2e-05 0.0106 -0.34 -0.28 Obesity-related traits; chr7:144067096 chr7:144142009~144142938:+ CESC cis rs6693388 0.874 rs6703772 ENSG00000229021.2 AL591893.1 -4.34 2.2e-05 0.0106 -0.33 -0.28 Blood metabolite ratios; chr1:151967380 chr1:151994531~152042774:+ CESC cis rs6693388 0.874 rs6691212 ENSG00000229021.2 AL591893.1 -4.34 2.2e-05 0.0106 -0.33 -0.28 Blood metabolite ratios; chr1:151967381 chr1:151994531~152042774:+ CESC cis rs6693388 0.918 rs6657658 ENSG00000229021.2 AL591893.1 -4.34 2.2e-05 0.0106 -0.33 -0.28 Blood metabolite ratios; chr1:151967388 chr1:151994531~152042774:+ CESC cis rs7873102 0.654 rs4878735 ENSG00000230188.1 RP11-405L18.4 4.34 2.21e-05 0.0106 0.36 0.28 Brain structure; chr9:38012495 chr9:37490421~37490893:- CESC cis rs875971 0.862 rs9791712 ENSG00000222364.1 RNU6-96P 4.34 2.21e-05 0.0106 0.34 0.28 Aortic root size; chr7:66640176 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs9791713 ENSG00000222364.1 RNU6-96P 4.34 2.21e-05 0.0106 0.34 0.28 Aortic root size; chr7:66640211 chr7:66395191~66395286:+ CESC cis rs6142102 0.961 rs2377957 ENSG00000275784.1 RP5-1125A11.6 -4.34 2.21e-05 0.0106 -0.29 -0.28 Skin pigmentation; chr20:33966667 chr20:33989480~33991818:- CESC cis rs2243480 1 rs7456042 ENSG00000232559.3 GS1-124K5.12 4.34 2.21e-05 0.0106 0.45 0.28 Diabetic kidney disease; chr7:65834791 chr7:66554588~66576923:- CESC cis rs875971 0.545 rs2420612 ENSG00000237310.1 GS1-124K5.4 4.34 2.21e-05 0.0107 0.32 0.28 Aortic root size; chr7:66536825 chr7:66493706~66495474:+ CESC cis rs7188445 1 rs11150189 ENSG00000261390.4 RP11-345M22.2 -4.34 2.21e-05 0.0107 -0.37 -0.28 Urate levels; chr16:79700330 chr16:79715232~79770563:- CESC cis rs822354 1 rs822354 ENSG00000226652.2 PSMD10P2 4.34 2.21e-05 0.0107 0.31 0.28 Adiponectin levels; chr3:186762417 chr3:186760693~186762050:+ CESC cis rs4974559 0.641 rs28647383 ENSG00000253399.1 AC078852.2 4.34 2.21e-05 0.0107 0.47 0.28 Systolic blood pressure; chr4:1319120 chr4:1358479~1359461:+ CESC cis rs1823913 1 rs4853568 ENSG00000227542.1 AC092614.2 -4.34 2.21e-05 0.0107 -0.29 -0.28 Obesity-related traits; chr2:191261464 chr2:191229165~191246172:- CESC cis rs700651 0.789 rs10497812 ENSG00000222017.1 AC011997.1 -4.34 2.21e-05 0.0107 -0.37 -0.28 Intracranial aneurysm; chr2:198046521 chr2:197693106~197774823:+ CESC cis rs2439831 1 rs565007 ENSG00000275601.1 AC011330.13 -4.34 2.21e-05 0.0107 -0.37 -0.28 Lung cancer in ever smokers; chr15:43424443 chr15:43642389~43643023:- CESC cis rs2439831 1 rs550239 ENSG00000275601.1 AC011330.13 -4.34 2.21e-05 0.0107 -0.37 -0.28 Lung cancer in ever smokers; chr15:43427999 chr15:43642389~43643023:- CESC cis rs7580658 0.724 rs6712213 ENSG00000236682.1 AC068282.3 -4.34 2.21e-05 0.0107 -0.35 -0.28 Protein C levels; chr2:127240654 chr2:127389130~127400580:+ CESC cis rs7429990 0.965 rs7430879 ENSG00000229759.1 MRPS18AP1 -4.34 2.22e-05 0.0107 -0.29 -0.28 Educational attainment (years of education); chr3:47997224 chr3:48256350~48256938:- CESC cis rs7429990 0.932 rs4293721 ENSG00000229759.1 MRPS18AP1 -4.34 2.22e-05 0.0107 -0.29 -0.28 Educational attainment (years of education); chr3:48003647 chr3:48256350~48256938:- CESC cis rs8031584 0.918 rs34693097 ENSG00000260382.1 RP11-540B6.2 4.34 2.22e-05 0.0107 0.39 0.28 Huntington's disease progression; chr15:30961781 chr15:30882267~30883231:- CESC cis rs8031584 0.918 rs35784593 ENSG00000260382.1 RP11-540B6.2 4.34 2.22e-05 0.0107 0.39 0.28 Huntington's disease progression; chr15:30962385 chr15:30882267~30883231:- CESC cis rs12439619 0.693 rs17269819 ENSG00000276710.3 CSPG4P8 -4.34 2.22e-05 0.0107 -0.36 -0.28 Intelligence (multi-trait analysis); chr15:82174660 chr15:82459472~82477258:+ CESC cis rs12439619 0.693 rs8034801 ENSG00000276710.3 CSPG4P8 -4.34 2.22e-05 0.0107 -0.36 -0.28 Intelligence (multi-trait analysis); chr15:82183996 chr15:82459472~82477258:+ CESC cis rs6969780 1 rs6948297 ENSG00000233429.8 HOTAIRM1 4.34 2.22e-05 0.0107 0.4 0.28 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27109785 chr7:27095647~27100265:+ CESC cis rs138171347 1 rs138171347 ENSG00000263164.1 RP11-333E1.2 4.34 2.22e-05 0.0107 0.28 0.28 White blood cell count; chr17:5279912 chr17:5240508~5241543:- CESC cis rs2732480 0.5 rs12828309 ENSG00000240399.1 RP1-228P16.1 4.34 2.22e-05 0.0107 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48247377 chr12:48054813~48055591:- CESC cis rs75920871 1 rs11216221 ENSG00000254851.1 RP11-109L13.1 4.34 2.22e-05 0.0107 0.66 0.28 Subjective well-being; chr11:116997421 chr11:117135528~117138582:+ CESC cis rs7188445 0.966 rs11150188 ENSG00000261390.4 RP11-345M22.2 -4.34 2.22e-05 0.0107 -0.36 -0.28 Urate levels; chr16:79673401 chr16:79715232~79770563:- CESC cis rs6782228 0.565 rs67445542 ENSG00000242551.2 POU5F1P6 -4.34 2.22e-05 0.0107 -0.31 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611683 chr3:128674735~128677005:- CESC cis rs944801 0.608 rs10120806 ENSG00000215221.2 UBA52P6 4.34 2.22e-05 0.0107 0.35 0.28 Type 2 diabetes; chr9:22047946 chr9:22012155~22012536:+ CESC cis rs2732480 1 rs2732480 ENSG00000240399.1 RP1-228P16.1 -4.34 2.23e-05 0.0107 -0.32 -0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342520 chr12:48054813~48055591:- CESC cis rs6686842 1 rs12125555 ENSG00000235358.1 RP11-399E6.1 4.34 2.23e-05 0.0107 0.34 0.28 Height; chr1:41241439 chr1:41242373~41284861:+ CESC cis rs1707322 0.963 rs10789478 ENSG00000281133.1 AL355480.3 -4.33 2.23e-05 0.0107 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45884834 chr1:45580892~45580996:- CESC cis rs748404 0.697 rs546722 ENSG00000249839.1 AC011330.5 -4.33 2.23e-05 0.0107 -0.3 -0.28 Lung cancer; chr15:43288621 chr15:43663654~43684339:- CESC cis rs12134133 1 rs28371597 ENSG00000274245.1 RP11-357P18.2 4.33 2.23e-05 0.0107 0.39 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207323551 chr1:207372559~207373252:+ CESC cis rs4319547 0.695 rs10846746 ENSG00000275265.1 RP11-15J22.8 4.33 2.23e-05 0.0107 0.4 0.28 Body mass index; chr12:122384149 chr12:122501187~122501641:+ CESC cis rs10129255 0.913 rs28861466 ENSG00000211970.3 IGHV4-61 -4.33 2.23e-05 0.0107 -0.23 -0.28 Kawasaki disease; chr14:106718572 chr14:106639119~106639657:- CESC cis rs9322193 0.923 rs10872650 ENSG00000216906.2 RP11-350J20.9 4.33 2.23e-05 0.0107 0.32 0.28 Lung cancer; chr6:149760959 chr6:149904243~149906418:+ CESC cis rs4272720 0.639 rs59869834 ENSG00000229870.1 RP11-507K13.6 -4.33 2.23e-05 0.0107 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49072883 chr10:49815096~49815562:+ CESC cis rs4272720 0.639 rs17011746 ENSG00000229870.1 RP11-507K13.6 -4.33 2.23e-05 0.0107 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49073044 chr10:49815096~49815562:+ CESC cis rs4272720 0.639 rs12256777 ENSG00000229870.1 RP11-507K13.6 -4.33 2.23e-05 0.0107 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49073835 chr10:49815096~49815562:+ CESC cis rs6686842 1 rs213742 ENSG00000235358.1 RP11-399E6.1 -4.33 2.24e-05 0.0107 -0.34 -0.28 Height; chr1:41155455 chr1:41242373~41284861:+ CESC cis rs72772090 0.539 rs72773922 ENSG00000248734.2 CTD-2260A17.1 -4.33 2.24e-05 0.0108 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780956 chr5:96784777~96785999:+ CESC cis rs9309473 1 rs6705489 ENSG00000163016.8 ALMS1P 4.33 2.24e-05 0.0108 0.37 0.28 Metabolite levels; chr2:73421683 chr2:73644919~73685576:+ CESC cis rs2412819 0.571 rs8030536 ENSG00000249839.1 AC011330.5 -4.33 2.24e-05 0.0108 -0.42 -0.28 Lung cancer; chr15:43627365 chr15:43663654~43684339:- CESC cis rs7560272 0.588 rs4852959 ENSG00000273245.1 RP11-434P11.2 -4.33 2.24e-05 0.0108 -0.35 -0.28 Schizophrenia; chr2:73653474 chr2:73750256~73750786:- CESC cis rs2439831 1 rs2584726 ENSG00000275601.1 AC011330.13 -4.33 2.24e-05 0.0108 -0.36 -0.28 Lung cancer in ever smokers; chr15:43423184 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs544122 ENSG00000275601.1 AC011330.13 -4.33 2.24e-05 0.0108 -0.4 -0.28 Lung cancer in ever smokers; chr15:43483534 chr15:43642389~43643023:- CESC cis rs9322193 0.923 rs12529698 ENSG00000216906.2 RP11-350J20.9 4.33 2.24e-05 0.0108 0.3 0.28 Lung cancer; chr6:149650951 chr6:149904243~149906418:+ CESC cis rs6504950 0.888 rs2628315 ENSG00000275710.1 RP11-257O5.4 4.33 2.24e-05 0.0108 0.3 0.28 Breast cancer; chr17:55149261 chr17:54964474~54964679:+ CESC cis rs7572733 0.534 rs700681 ENSG00000222017.1 AC011997.1 4.33 2.25e-05 0.0108 0.35 0.28 Dermatomyositis; chr2:197846778 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700682 ENSG00000222017.1 AC011997.1 4.33 2.25e-05 0.0108 0.35 0.28 Dermatomyositis; chr2:197847586 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700683 ENSG00000222017.1 AC011997.1 4.33 2.25e-05 0.0108 0.35 0.28 Dermatomyositis; chr2:197847608 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700684 ENSG00000222017.1 AC011997.1 4.33 2.25e-05 0.0108 0.35 0.28 Dermatomyositis; chr2:197848375 chr2:197693106~197774823:+ CESC cis rs10129255 0.957 rs11847726 ENSG00000211970.3 IGHV4-61 -4.33 2.25e-05 0.0108 -0.22 -0.28 Kawasaki disease; chr14:106779116 chr14:106639119~106639657:- CESC cis rs860295 0.776 rs11264362 ENSG00000225855.5 RUSC1-AS1 -4.33 2.25e-05 0.0108 -0.22 -0.28 Body mass index; chr1:155345824 chr1:155316863~155324176:- CESC cis rs10875746 0.669 rs61940962 ENSG00000240399.1 RP1-228P16.1 -4.33 2.25e-05 0.0108 -0.37 -0.28 Longevity (90 years and older); chr12:48201694 chr12:48054813~48055591:- CESC cis rs10129255 1 rs11621409 ENSG00000211970.3 IGHV4-61 -4.33 2.25e-05 0.0108 -0.23 -0.28 Kawasaki disease; chr14:106695603 chr14:106639119~106639657:- CESC cis rs1707322 0.964 rs12067716 ENSG00000281133.1 AL355480.3 -4.33 2.25e-05 0.0108 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45968756 chr1:45580892~45580996:- CESC cis rs6782228 0.585 rs9841161 ENSG00000242551.2 POU5F1P6 -4.33 2.25e-05 0.0108 -0.31 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613027 chr3:128674735~128677005:- CESC cis rs6782228 0.606 rs2712405 ENSG00000242551.2 POU5F1P6 -4.33 2.25e-05 0.0108 -0.31 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613239 chr3:128674735~128677005:- CESC cis rs7688540 0.8 rs10003142 ENSG00000211553.1 AC253576.2 -4.33 2.26e-05 0.0108 -0.36 -0.28 Facial morphology (factor 6, height of vermillion lower lip); chr4:297970 chr4:136461~136568:+ CESC cis rs10875746 0.624 rs7297298 ENSG00000240399.1 RP1-228P16.1 -4.33 2.26e-05 0.0108 -0.36 -0.28 Longevity (90 years and older); chr12:48278523 chr12:48054813~48055591:- CESC cis rs3020736 0.5 rs6002605 ENSG00000273366.1 CTA-989H11.1 4.33 2.26e-05 0.0108 0.38 0.28 Autism spectrum disorder or schizophrenia; chr22:42098331 chr22:42278188~42278846:+ CESC cis rs11633886 0.51 rs12594473 ENSG00000273972.1 CTD-2306A12.1 4.33 2.26e-05 0.0109 0.32 0.28 Diisocyanate-induced asthma; chr15:45750399 chr15:45702640~45703183:+ CESC cis rs7429990 0.813 rs7627568 ENSG00000229759.1 MRPS18AP1 -4.33 2.26e-05 0.0109 -0.29 -0.28 Educational attainment (years of education); chr3:48051562 chr3:48256350~48256938:- CESC cis rs7250849 0.565 rs11883221 ENSG00000273837.1 LLNLR-470E3.1 -4.33 2.26e-05 0.0109 -0.35 -0.28 Blood protein levels; chr19:51665579 chr19:51639478~51639931:- CESC cis rs11723261 0.582 rs61792238 ENSG00000211553.1 AC253576.2 -4.33 2.27e-05 0.0109 -0.43 -0.28 Immune response to smallpox vaccine (IL-6); chr4:112398 chr4:136461~136568:+ CESC cis rs72772090 0.634 rs10515246 ENSG00000248734.2 CTD-2260A17.1 -4.33 2.27e-05 0.0109 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96763561 chr5:96784777~96785999:+ CESC cis rs8030379 1 rs7162129 ENSG00000230373.7 GOLGA6L5P -4.33 2.27e-05 0.0109 -0.27 -0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83897692 chr15:84507885~84516814:- CESC cis rs8030379 0.967 rs11857009 ENSG00000230373.7 GOLGA6L5P -4.33 2.27e-05 0.0109 -0.27 -0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83898661 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2046120 ENSG00000230373.7 GOLGA6L5P -4.33 2.27e-05 0.0109 -0.27 -0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83899010 chr15:84507885~84516814:- CESC cis rs8030379 1 rs11259928 ENSG00000230373.7 GOLGA6L5P -4.33 2.27e-05 0.0109 -0.27 -0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83899343 chr15:84507885~84516814:- CESC cis rs4706831 0.647 rs627240 ENSG00000272129.1 RP11-250B2.6 -4.33 2.27e-05 0.0109 -0.32 -0.28 Joint mobility (Beighton score); chr6:80276168 chr6:80355424~80356859:+ CESC cis rs10754283 0.967 rs10737707 ENSG00000231613.1 RP5-943J3.1 4.33 2.27e-05 0.0109 0.35 0.28 Amyotrophic lateral sclerosis (sporadic); chr1:89653745 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs10737708 ENSG00000231613.1 RP5-943J3.1 4.33 2.27e-05 0.0109 0.35 0.28 Amyotrophic lateral sclerosis (sporadic); chr1:89654245 chr1:89788914~89790492:+ CESC cis rs10754283 0.967 rs10801763 ENSG00000231613.1 RP5-943J3.1 4.33 2.27e-05 0.0109 0.35 0.28 Amyotrophic lateral sclerosis (sporadic); chr1:89655263 chr1:89788914~89790492:+ CESC cis rs4072705 0.615 rs7028021 ENSG00000224020.1 MIR181A2HG -4.33 2.27e-05 0.0109 -0.34 -0.28 Menarche (age at onset); chr9:124486743 chr9:124658467~124698631:+ CESC cis rs7572733 0.534 rs58374969 ENSG00000222017.1 AC011997.1 4.33 2.27e-05 0.0109 0.36 0.28 Dermatomyositis; chr2:197899639 chr2:197693106~197774823:+ CESC cis rs10129255 0.957 rs10142918 ENSG00000211970.3 IGHV4-61 -4.33 2.27e-05 0.0109 -0.22 -0.28 Kawasaki disease; chr14:106782206 chr14:106639119~106639657:- CESC cis rs10129255 0.957 rs10142859 ENSG00000211970.3 IGHV4-61 -4.33 2.27e-05 0.0109 -0.22 -0.28 Kawasaki disease; chr14:106782238 chr14:106639119~106639657:- CESC cis rs10129255 0.957 rs10150241 ENSG00000211970.3 IGHV4-61 4.33 2.27e-05 0.0109 0.21 0.28 Kawasaki disease; chr14:106775945 chr14:106639119~106639657:- CESC cis rs1799955 1 rs1799955 ENSG00000215515.2 IFIT1P1 -4.33 2.27e-05 0.0109 -0.44 -0.28 LDL cholesterol levels; chr13:32355095 chr13:32384660~32386108:+ CESC cis rs651386 0.529 rs2206063 ENSG00000271811.1 RP1-79C4.4 -4.33 2.27e-05 0.0109 -0.37 -0.28 Atrial fibrillation; chr1:170615956 chr1:170667381~170669425:+ CESC cis rs2522056 0.935 rs1981524 ENSG00000233006.5 AC034220.3 -4.33 2.28e-05 0.0109 -0.37 -0.28 Fibrinogen;Lymphocyte counts; chr5:132420814 chr5:132311285~132369916:- CESC cis rs17772222 0.876 rs78068036 ENSG00000258983.2 RP11-507K2.2 4.33 2.28e-05 0.0109 0.35 0.28 Coronary artery calcification; chr14:88754817 chr14:88499334~88515502:+ CESC cis rs2439831 0.85 rs8023458 ENSG00000275601.1 AC011330.13 -4.33 2.28e-05 0.0109 -0.43 -0.28 Lung cancer in ever smokers; chr15:43788741 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs16963953 ENSG00000275601.1 AC011330.13 -4.33 2.28e-05 0.0109 -0.43 -0.28 Lung cancer in ever smokers; chr15:43789521 chr15:43642389~43643023:- CESC cis rs9907295 0.901 rs4251729 ENSG00000271013.1 AC015849.15 -4.33 2.28e-05 0.0109 -0.38 -0.28 Fibroblast growth factor basic levels; chr17:35818348 chr17:35912635~35918010:- CESC cis rs9532669 0.926 rs9525418 ENSG00000239827.7 SUGT1P3 4.33 2.28e-05 0.0109 0.32 0.28 Cervical cancer; chr13:40879081 chr13:40908159~40921774:- CESC cis rs6693388 0.526 rs112770825 ENSG00000229021.2 AL591893.1 -4.33 2.28e-05 0.0109 -0.35 -0.28 Blood metabolite ratios; chr1:151993591 chr1:151994531~152042774:+ CESC cis rs6693388 0.789 rs61814883 ENSG00000229021.2 AL591893.1 -4.33 2.28e-05 0.0109 -0.35 -0.28 Blood metabolite ratios; chr1:151998153 chr1:151994531~152042774:+ CESC cis rs7587476 0.862 rs13001462 ENSG00000229267.2 AC072062.1 -4.33 2.28e-05 0.0109 -0.35 -0.28 Neuroblastoma; chr2:214813622 chr2:214810229~214963274:+ CESC cis rs4774565 0.762 rs7164848 ENSG00000244879.4 GABPB1-AS1 4.33 2.28e-05 0.0109 0.28 0.28 Breast cancer; chr15:50370833 chr15:50354959~50372202:+ CESC cis rs5769707 0.904 rs7288869 ENSG00000235111.1 RP1-29C18.8 -4.33 2.28e-05 0.0109 -0.28 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49621679 chr22:49612657~49615716:- CESC cis rs9487094 0.67 rs11754340 ENSG00000260273.1 RP11-425D10.10 4.33 2.29e-05 0.011 0.35 0.28 Height; chr6:109584789 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs13199135 ENSG00000260273.1 RP11-425D10.10 4.33 2.29e-05 0.011 0.35 0.28 Height; chr6:109588639 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs12193719 ENSG00000260273.1 RP11-425D10.10 4.33 2.29e-05 0.011 0.35 0.28 Height; chr6:109589051 chr6:109382795~109383666:+ CESC cis rs4272720 0.666 rs17011744 ENSG00000229870.1 RP11-507K13.6 -4.33 2.29e-05 0.011 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49072989 chr10:49815096~49815562:+ CESC cis rs6565180 1 rs11863150 ENSG00000183604.13 SMG1P5 4.33 2.29e-05 0.011 0.28 0.28 Tonsillectomy; chr16:30374182 chr16:30267553~30335374:- CESC cis rs7580658 0.724 rs6712446 ENSG00000236682.1 AC068282.3 -4.33 2.29e-05 0.011 -0.35 -0.28 Protein C levels; chr2:127240823 chr2:127389130~127400580:+ CESC cis rs1707322 0.638 rs9429095 ENSG00000280836.1 AL355480.1 4.33 2.29e-05 0.011 0.35 0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46137676 chr1:45581219~45581321:- CESC cis rs801193 0.591 rs2707839 ENSG00000237310.1 GS1-124K5.4 4.33 2.29e-05 0.011 0.27 0.28 Aortic root size; chr7:66728097 chr7:66493706~66495474:+ CESC cis rs77204473 1 rs12289032 ENSG00000254851.1 RP11-109L13.1 4.33 2.3e-05 0.011 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117028864 chr11:117135528~117138582:+ CESC cis rs11971779 0.68 rs4077889 ENSG00000273391.1 RP11-634H22.1 4.33 2.3e-05 0.011 0.27 0.28 Diisocyanate-induced asthma; chr7:139349168 chr7:139359032~139359566:- CESC cis rs2919917 0.59 rs2919919 ENSG00000254352.1 RP11-578O24.2 -4.33 2.3e-05 0.011 -0.41 -0.28 Lymphocyte counts; chr8:78745274 chr8:78723796~78724136:- CESC cis rs4319547 0.695 rs10734915 ENSG00000275265.1 RP11-15J22.8 -4.33 2.3e-05 0.011 -0.38 -0.28 Body mass index; chr12:122388861 chr12:122501187~122501641:+ CESC cis rs4319547 0.656 rs10161534 ENSG00000275265.1 RP11-15J22.8 -4.33 2.3e-05 0.011 -0.38 -0.28 Body mass index; chr12:122389317 chr12:122501187~122501641:+ CESC cis rs7580658 0.521 rs35577992 ENSG00000236682.1 AC068282.3 -4.33 2.3e-05 0.011 -0.33 -0.28 Protein C levels; chr2:127183748 chr2:127389130~127400580:+ CESC cis rs875971 0.545 rs2279757 ENSG00000222364.1 RNU6-96P -4.33 2.3e-05 0.011 -0.39 -0.28 Aortic root size; chr7:66363676 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs11766183 ENSG00000222364.1 RNU6-96P -4.33 2.3e-05 0.011 -0.39 -0.28 Aortic root size; chr7:66374173 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs1065265 ENSG00000222364.1 RNU6-96P -4.33 2.3e-05 0.011 -0.39 -0.28 Aortic root size; chr7:66376216 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs7811204 ENSG00000222364.1 RNU6-96P -4.33 2.3e-05 0.011 -0.39 -0.28 Aortic root size; chr7:66387213 chr7:66395191~66395286:+ CESC cis rs3124314 1 rs4845420 ENSG00000229021.2 AL591893.1 4.33 2.3e-05 0.011 0.31 0.28 Hair morphology; chr1:152168728 chr1:151994531~152042774:+ CESC cis rs7819412 0.502 rs10095003 ENSG00000255046.1 RP11-297N6.4 4.33 2.3e-05 0.011 0.34 0.28 Triglycerides; chr8:11184940 chr8:11797928~11802568:- CESC cis rs12908161 1 rs58416181 ENSG00000225151.9 GOLGA2P7 -4.33 2.3e-05 0.011 -0.39 -0.28 Schizophrenia; chr15:84721230 chr15:84199311~84230136:- CESC cis rs6565180 0.926 rs12446288 ENSG00000183604.13 SMG1P5 4.33 2.3e-05 0.011 0.28 0.28 Tonsillectomy; chr16:30377388 chr16:30267553~30335374:- CESC cis rs2337406 0.538 rs2015470 ENSG00000211974.3 IGHV2-70 -4.33 2.31e-05 0.011 -0.34 -0.28 Alzheimer's disease (late onset); chr14:106631885 chr14:106723574~106724093:- CESC cis rs2732480 0.967 rs2732469 ENSG00000258273.1 RP11-370I10.4 -4.33 2.31e-05 0.011 -0.33 -0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48319149 chr12:48333755~48333901:- CESC cis rs9309473 1 rs7564890 ENSG00000163016.8 ALMS1P 4.33 2.31e-05 0.0111 0.37 0.28 Metabolite levels; chr2:73414725 chr2:73644919~73685576:+ CESC cis rs7809950 0.954 rs62482543 ENSG00000238832.1 snoU109 -4.33 2.31e-05 0.0111 -0.33 -0.28 Coronary artery disease; chr7:107440211 chr7:107603363~107603507:+ CESC cis rs950776 0.518 rs12916483 ENSG00000279373.1 RP11-650L12.4 4.33 2.31e-05 0.0111 0.34 0.28 Sudden cardiac arrest; chr15:78540055 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs3813572 ENSG00000279373.1 RP11-650L12.4 4.33 2.31e-05 0.0111 0.34 0.28 Sudden cardiac arrest; chr15:78540246 chr15:78537681~78538946:+ CESC cis rs2933343 0.859 rs789247 ENSG00000231305.3 RP11-723O4.2 4.33 2.32e-05 0.0111 0.29 0.28 IgG glycosylation; chr3:128861742 chr3:128861313~128871540:- CESC cis rs7048146 0.7 rs10759351 ENSG00000213539.4 YBX1P6 4.33 2.32e-05 0.0111 0.33 0.28 Vascular brain injury; chr9:109582738 chr9:109532830~109534332:- CESC cis rs10411161 0.58 rs12151287 ENSG00000267905.4 CTD-2616J11.16 4.33 2.32e-05 0.0111 0.38 0.28 Breast cancer; chr19:51878242 chr19:51340695~51344117:+ CESC cis rs79243044 0.965 rs7103458 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5534595 chr11:5518441~5524955:- CESC cis rs79243044 1 rs7125746 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5534775 chr11:5518441~5524955:- CESC cis rs79243044 1 rs11037984 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5535432 chr11:5518441~5524955:- CESC cis rs79243044 0.965 rs11037985 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5535490 chr11:5518441~5524955:- CESC cis rs79243044 0.965 rs11037994 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5535987 chr11:5518441~5524955:- CESC cis rs79243044 1 rs11038000 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5536474 chr11:5518441~5524955:- CESC cis rs79243044 1 rs11038004 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5536688 chr11:5518441~5524955:- CESC cis rs79243044 1 rs2201868 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5536981 chr11:5518441~5524955:- CESC cis rs3096299 0.591 rs748940 ENSG00000274627.1 RP11-104N10.2 4.33 2.32e-05 0.0111 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89374349 chr16:89516797~89522217:+ CESC cis rs6565180 0.962 rs6565183 ENSG00000183604.13 SMG1P5 -4.33 2.32e-05 0.0111 -0.28 -0.28 Tonsillectomy; chr16:30371434 chr16:30267553~30335374:- CESC cis rs79243044 0.901 rs2879824 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5537412 chr11:5518441~5524955:- CESC cis rs79243044 0.932 rs2879825 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5537413 chr11:5518441~5524955:- CESC cis rs79243044 1 rs12275855 ENSG00000224295.2 AC087380.14 -4.33 2.32e-05 0.0111 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5537972 chr11:5518441~5524955:- CESC cis rs72772090 0.634 rs17402639 ENSG00000248734.2 CTD-2260A17.1 -4.33 2.32e-05 0.0111 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96771301 chr5:96784777~96785999:+ CESC cis rs72772090 0.634 rs72773912 ENSG00000248734.2 CTD-2260A17.1 -4.33 2.32e-05 0.0111 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96772097 chr5:96784777~96785999:+ CESC cis rs1707322 0.963 rs6429581 ENSG00000281133.1 AL355480.3 -4.32 2.32e-05 0.0111 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853424 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs12145287 ENSG00000281133.1 AL355480.3 -4.32 2.32e-05 0.0111 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45859330 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10789479 ENSG00000281133.1 AL355480.3 -4.32 2.32e-05 0.0111 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45886828 chr1:45580892~45580996:- CESC cis rs1707322 0.964 rs7512395 ENSG00000281133.1 AL355480.3 -4.32 2.32e-05 0.0111 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45895505 chr1:45580892~45580996:- CESC cis rs4819052 0.765 rs2838827 ENSG00000223768.1 LINC00205 -4.32 2.32e-05 0.0111 -0.34 -0.28 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45236231 chr21:45293285~45297354:+ CESC cis rs2243480 1 rs2243480 ENSG00000232559.3 GS1-124K5.12 4.32 2.32e-05 0.0111 0.47 0.28 Diabetic kidney disease; chr7:66134209 chr7:66554588~66576923:- CESC cis rs950169 0.92 rs11637666 ENSG00000225151.9 GOLGA2P7 -4.32 2.33e-05 0.0111 -0.43 -0.28 Schizophrenia; chr15:84035122 chr15:84199311~84230136:- CESC cis rs6879260 1 rs729568 ENSG00000248367.1 CTB-129O4.1 4.32 2.33e-05 0.0111 0.21 0.28 Height; chr5:180305350 chr5:180293245~180295253:+ CESC cis rs7259376 0.503 rs1704014 ENSG00000213971.6 RP11-15H20.6 -4.32 2.33e-05 0.0111 -0.34 -0.28 Menopause (age at onset); chr19:22454101 chr19:23259906~23274251:- CESC cis rs7923837 0.687 rs1977833 ENSG00000236493.2 EIF2S2P3 4.32 2.33e-05 0.0111 0.35 0.28 Multiple sclerosis;Body mass index; chr10:92704188 chr10:92668745~92669743:- CESC cis rs11096990 0.819 rs2711992 ENSG00000249207.1 RP11-360F5.1 4.32 2.33e-05 0.0111 0.35 0.28 Cognitive function; chr4:39148651 chr4:39112677~39126818:- CESC cis rs10779751 0.881 rs2744815 ENSG00000230337.1 RP4-635E18.6 4.32 2.33e-05 0.0111 0.38 0.28 Body mass index; chr1:11300900 chr1:11099675~11102100:+ CESC cis rs17428076 0.556 rs12692976 ENSG00000228389.1 AC068039.4 4.32 2.33e-05 0.0111 0.34 0.28 Myopia; chr2:171827893 chr2:171773482~171775844:+ CESC cis rs8031584 0.723 rs711224 ENSG00000260382.1 RP11-540B6.2 -4.32 2.33e-05 0.0111 -0.38 -0.28 Huntington's disease progression; chr15:30835718 chr15:30882267~30883231:- CESC cis rs8081395 0.603 rs1292047 ENSG00000266992.1 DHX40P1 4.32 2.33e-05 0.0111 0.31 0.28 White blood cell count; chr17:59877805 chr17:59976009~60002384:- CESC cis rs9322193 0.516 rs1999632 ENSG00000231760.4 RP11-350J20.5 4.32 2.34e-05 0.0111 0.42 0.28 Lung cancer; chr6:149866737 chr6:149796151~149826294:- CESC cis rs2058059 0.511 rs6970153 ENSG00000205578.5 POM121B -4.32 2.34e-05 0.0111 -0.35 -0.28 Subcutaneous adipose tissue; chr7:72573610 chr7:73293497~73301161:+ CESC cis rs72627509 0.638 rs78272732 ENSG00000269949.1 RP11-738E22.3 4.32 2.34e-05 0.0111 0.47 0.28 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57004371 chr4:56960927~56961373:- CESC cis rs7005380 0.62 rs13282901 ENSG00000279347.1 RP11-85I17.2 -4.32 2.34e-05 0.0112 -0.26 -0.28 Interstitial lung disease; chr8:119881561 chr8:119838736~119840385:- CESC cis rs77204473 1 rs12278943 ENSG00000254851.1 RP11-109L13.1 4.32 2.34e-05 0.0112 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117003642 chr11:117135528~117138582:+ CESC cis rs2337406 0.587 rs916547 ENSG00000254174.1 IGHV1-12 4.32 2.34e-05 0.0112 0.28 0.28 Alzheimer's disease (late onset); chr14:106646735 chr14:106122420~106122709:- CESC cis rs7432375 0.566 rs835636 ENSG00000239213.4 NCK1-AS1 4.32 2.34e-05 0.0112 0.32 0.28 Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia; chr3:136955658 chr3:136841726~136862054:- CESC cis rs150992 0.571 rs34488 ENSG00000248489.1 CTD-2007H13.3 4.32 2.34e-05 0.0112 0.37 0.28 Body mass index; chr5:98977773 chr5:98929171~98995013:+ CESC cis rs150992 0.536 rs179053 ENSG00000248489.1 CTD-2007H13.3 4.32 2.34e-05 0.0112 0.37 0.28 Body mass index; chr5:98979890 chr5:98929171~98995013:+ CESC cis rs860295 0.871 rs12724079 ENSG00000225855.5 RUSC1-AS1 -4.32 2.35e-05 0.0112 -0.22 -0.28 Body mass index; chr1:155464151 chr1:155316863~155324176:- CESC cis rs13113518 0.738 rs6849883 ENSG00000273257.1 RP11-177J6.1 4.32 2.35e-05 0.0112 0.37 0.28 Height; chr4:55387515 chr4:55387949~55388271:+ CESC cis rs1707322 1 rs10890376 ENSG00000281133.1 AL355480.3 -4.32 2.35e-05 0.0112 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940910 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10890381 ENSG00000281133.1 AL355480.3 -4.32 2.35e-05 0.0112 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45986099 chr1:45580892~45580996:- CESC cis rs10875746 0.551 rs3751273 ENSG00000240399.1 RP1-228P16.1 -4.32 2.35e-05 0.0112 -0.37 -0.28 Longevity (90 years and older); chr12:48345655 chr12:48054813~48055591:- CESC cis rs7587476 0.689 rs10498025 ENSG00000229267.2 AC072062.1 -4.32 2.35e-05 0.0112 -0.37 -0.28 Neuroblastoma; chr2:214884532 chr2:214810229~214963274:+ CESC cis rs490234 0.871 rs13288032 ENSG00000232630.1 PRPS1P2 -4.32 2.35e-05 0.0112 -0.24 -0.28 Mean arterial pressure; chr9:125493303 chr9:125150653~125151589:+ CESC cis rs9318086 0.648 rs78881146 ENSG00000205861.10 C1QTNF9B-AS1 -4.32 2.35e-05 0.0112 -0.36 -0.28 Myopia (pathological); chr13:23894565 chr13:23888889~23897263:+ CESC cis rs10129255 0.957 rs10140904 ENSG00000211970.3 IGHV4-61 -4.32 2.35e-05 0.0112 -0.21 -0.28 Kawasaki disease; chr14:106776558 chr14:106639119~106639657:- CESC cis rs7951870 1 rs11038897 ENSG00000247675.5 LRP4-AS1 -4.32 2.35e-05 0.0112 -0.36 -0.28 Schizophrenia; chr11:46449277 chr11:46846412~46874396:+ CESC cis rs73086581 0.838 rs11906481 ENSG00000229539.1 RP11-119B16.2 4.32 2.35e-05 0.0112 0.39 0.28 Response to antidepressants in depression; chr20:4048059 chr20:3888239~3888868:- CESC cis rs2980439 0.525 rs2980508 ENSG00000253893.2 FAM85B -4.32 2.35e-05 0.0112 -0.37 -0.28 Neuroticism; chr8:8314210 chr8:8167819~8226614:- CESC cis rs5742933 0.948 rs7592066 ENSG00000253559.1 OSGEPL1-AS1 4.32 2.35e-05 0.0112 0.33 0.28 Ferritin levels; chr2:189778792 chr2:189762704~189765556:+ CESC cis rs5742933 0.779 rs7595020 ENSG00000253559.1 OSGEPL1-AS1 4.32 2.35e-05 0.0112 0.33 0.28 Ferritin levels; chr2:189778950 chr2:189762704~189765556:+ CESC cis rs11676348 0.774 rs57545959 ENSG00000261338.2 RP11-378A13.1 4.32 2.36e-05 0.0112 0.36 0.28 Ulcerative colitis; chr2:218182995 chr2:218255319~218257366:+ CESC cis rs9309473 1 rs6736866 ENSG00000163016.8 ALMS1P 4.32 2.36e-05 0.0112 0.39 0.28 Metabolite levels; chr2:73434858 chr2:73644919~73685576:+ CESC cis rs2439831 0.702 rs2788 ENSG00000275601.1 AC011330.13 -4.32 2.36e-05 0.0112 -0.43 -0.28 Lung cancer in ever smokers; chr15:43772688 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28891769 ENSG00000275601.1 AC011330.13 -4.32 2.36e-05 0.0112 -0.43 -0.28 Lung cancer in ever smokers; chr15:43780662 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28578398 ENSG00000275601.1 AC011330.13 -4.32 2.36e-05 0.0112 -0.43 -0.28 Lung cancer in ever smokers; chr15:43782848 chr15:43642389~43643023:- CESC cis rs875971 0.545 rs1796222 ENSG00000236529.1 RP13-254B10.1 -4.32 2.36e-05 0.0112 -0.36 -0.28 Aortic root size; chr7:66592167 chr7:65840212~65840596:+ CESC cis rs3806843 0.576 rs246007 ENSG00000202111.1 VTRNA1-2 -4.32 2.36e-05 0.0112 -0.29 -0.28 Depressive symptoms (multi-trait analysis); chr5:140959163 chr5:140718925~140719013:+ CESC cis rs9584850 0.574 rs17471079 ENSG00000231194.1 FARP1-AS1 4.32 2.36e-05 0.0112 0.4 0.28 Neuroticism; chr13:98516467 chr13:98435405~98435840:- CESC cis rs9813712 0.526 rs13065659 ENSG00000228252.7 COL6A4P2 -4.32 2.37e-05 0.0113 -0.33 -0.28 Response to amphetamines; chr3:130231945 chr3:130212823~130273806:+ CESC cis rs4319547 0.695 rs4758648 ENSG00000275265.1 RP11-15J22.8 -4.32 2.37e-05 0.0113 -0.36 -0.28 Body mass index; chr12:122415913 chr12:122501187~122501641:+ CESC cis rs2187895 0.704 rs1476040 ENSG00000271811.1 RP1-79C4.4 4.32 2.37e-05 0.0113 0.34 0.28 Tonsillectomy; chr1:170731617 chr1:170667381~170669425:+ CESC cis rs7873102 0.654 rs7036483 ENSG00000230188.1 RP11-405L18.4 -4.32 2.37e-05 0.0113 -0.36 -0.28 Brain structure; chr9:37972168 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs7037039 ENSG00000230188.1 RP11-405L18.4 -4.32 2.37e-05 0.0113 -0.36 -0.28 Brain structure; chr9:37972378 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10123310 ENSG00000230188.1 RP11-405L18.4 -4.32 2.37e-05 0.0113 -0.36 -0.28 Brain structure; chr9:37972515 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs3802414 ENSG00000230188.1 RP11-405L18.4 -4.32 2.37e-05 0.0113 -0.36 -0.28 Brain structure; chr9:37974484 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs1138374 ENSG00000230188.1 RP11-405L18.4 -4.32 2.37e-05 0.0113 -0.36 -0.28 Brain structure; chr9:37974746 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs6476667 ENSG00000230188.1 RP11-405L18.4 -4.32 2.37e-05 0.0113 -0.36 -0.28 Brain structure; chr9:37975005 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs6476668 ENSG00000230188.1 RP11-405L18.4 -4.32 2.37e-05 0.0113 -0.36 -0.28 Brain structure; chr9:37975107 chr9:37490421~37490893:- CESC cis rs875971 1 rs7792762 ENSG00000237310.1 GS1-124K5.4 4.32 2.37e-05 0.0113 0.27 0.28 Aortic root size; chr7:66539151 chr7:66493706~66495474:+ CESC cis rs6951245 1 rs2363286 ENSG00000229043.2 AC091729.9 -4.32 2.38e-05 0.0113 -0.43 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1051989 chr7:1160374~1165267:+ CESC cis rs77204473 0.744 rs12273545 ENSG00000254851.1 RP11-109L13.1 4.32 2.38e-05 0.0113 0.65 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117040296 chr11:117135528~117138582:+ CESC cis rs77204473 0.744 rs77999164 ENSG00000254851.1 RP11-109L13.1 4.32 2.38e-05 0.0113 0.65 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117041401 chr11:117135528~117138582:+ CESC cis rs77204473 0.744 rs75890305 ENSG00000254851.1 RP11-109L13.1 4.32 2.38e-05 0.0113 0.65 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117049253 chr11:117135528~117138582:+ CESC cis rs77204473 0.744 rs11216252 ENSG00000254851.1 RP11-109L13.1 4.32 2.38e-05 0.0113 0.65 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117057507 chr11:117135528~117138582:+ CESC cis rs77204473 0.744 rs11216253 ENSG00000254851.1 RP11-109L13.1 4.32 2.38e-05 0.0113 0.65 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117057509 chr11:117135528~117138582:+ CESC cis rs9322193 0.923 rs9800614 ENSG00000268592.3 RAET1E-AS1 4.32 2.38e-05 0.0113 0.36 0.28 Lung cancer; chr6:149644604 chr6:149863494~149919507:+ CESC cis rs2404602 0.536 rs1587381 ENSG00000259422.1 RP11-593F23.1 4.32 2.38e-05 0.0113 0.32 0.28 Blood metabolite levels; chr15:76477279 chr15:76174891~76181486:- CESC cis rs2404602 0.536 rs11072599 ENSG00000259422.1 RP11-593F23.1 4.32 2.38e-05 0.0113 0.32 0.28 Blood metabolite levels; chr15:76482167 chr15:76174891~76181486:- CESC cis rs150992 0.504 rs6878136 ENSG00000248489.1 CTD-2007H13.3 -4.32 2.38e-05 0.0113 -0.38 -0.28 Body mass index; chr5:99022487 chr5:98929171~98995013:+ CESC cis rs10129255 0.957 rs8014696 ENSG00000211970.3 IGHV4-61 4.32 2.38e-05 0.0113 0.21 0.28 Kawasaki disease; chr14:106769752 chr14:106639119~106639657:- CESC cis rs1823913 0.927 rs13013390 ENSG00000227542.1 AC092614.2 4.32 2.38e-05 0.0113 0.29 0.28 Obesity-related traits; chr2:191262001 chr2:191229165~191246172:- CESC cis rs2404602 0.716 rs17460201 ENSG00000280730.1 AC090181.1 -4.32 2.38e-05 0.0113 -0.21 -0.28 Blood metabolite levels; chr15:76381286 chr15:77056895~77057021:+ CESC cis rs7923837 0.687 rs1111875 ENSG00000236493.2 EIF2S2P3 4.32 2.38e-05 0.0113 0.35 0.28 Multiple sclerosis;Body mass index; chr10:92703125 chr10:92668745~92669743:- CESC cis rs526231 0.697 rs253759 ENSG00000175749.11 EIF3KP1 4.32 2.38e-05 0.0113 0.37 0.28 Primary biliary cholangitis; chr5:103279974 chr5:103032376~103033031:+ CESC cis rs748404 0.631 rs4296223 ENSG00000205771.5 CATSPER2P1 -4.32 2.38e-05 0.0113 -0.34 -0.28 Lung cancer; chr15:43353048 chr15:43726918~43747094:- CESC cis rs8031584 0.918 rs34331396 ENSG00000260382.1 RP11-540B6.2 4.32 2.39e-05 0.0113 0.39 0.28 Huntington's disease progression; chr15:30956533 chr15:30882267~30883231:- CESC cis rs72772090 0.539 rs111237997 ENSG00000248734.2 CTD-2260A17.1 -4.32 2.39e-05 0.0113 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779249 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs3335 ENSG00000248734.2 CTD-2260A17.1 -4.32 2.39e-05 0.0113 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779366 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs3334 ENSG00000248734.2 CTD-2260A17.1 -4.32 2.39e-05 0.0113 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779381 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs3333 ENSG00000248734.2 CTD-2260A17.1 -4.32 2.39e-05 0.0113 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779407 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs11749811 ENSG00000248734.2 CTD-2260A17.1 -4.32 2.39e-05 0.0113 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780221 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs67140788 ENSG00000248734.2 CTD-2260A17.1 -4.32 2.39e-05 0.0113 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780582 chr5:96784777~96785999:+ CESC cis rs7131987 0.621 rs6487805 ENSG00000257176.2 RP11-996F15.2 4.32 2.39e-05 0.0113 0.33 0.28 QT interval; chr12:29304617 chr12:29280418~29317848:- CESC cis rs763121 0.853 rs5757166 ENSG00000273076.1 RP3-508I15.22 4.32 2.39e-05 0.0114 0.32 0.28 Menopause (age at onset); chr22:38599380 chr22:38743495~38743910:+ CESC cis rs763121 0.819 rs5757169 ENSG00000273076.1 RP3-508I15.22 4.32 2.39e-05 0.0114 0.32 0.28 Menopause (age at onset); chr22:38607490 chr22:38743495~38743910:+ CESC cis rs13113518 0.678 rs13149568 ENSG00000273257.1 RP11-177J6.1 4.32 2.39e-05 0.0114 0.37 0.28 Height; chr4:55370412 chr4:55387949~55388271:+ CESC cis rs17818399 0.815 rs17768138 ENSG00000279254.1 RP11-536C12.1 -4.32 2.39e-05 0.0114 -0.35 -0.28 Height; chr2:46641078 chr2:46668870~46670778:+ CESC cis rs7927592 0.913 rs7118897 ENSG00000212093.1 AP000807.1 4.32 2.39e-05 0.0114 0.32 0.28 Total body bone mineral density; chr11:68593212 chr11:68506083~68506166:- CESC cis rs17507216 0.958 rs72751643 ENSG00000276710.3 CSPG4P8 -4.32 2.39e-05 0.0114 -0.41 -0.28 Excessive daytime sleepiness; chr15:82559444 chr15:82459472~82477258:+ CESC cis rs67311347 1 rs2276868 ENSG00000223797.4 ENTPD3-AS1 -4.32 2.4e-05 0.0114 -0.28 -0.28 Renal cell carcinoma; chr3:40457354 chr3:40313802~40453329:- CESC cis rs67311347 1 rs7625736 ENSG00000223797.4 ENTPD3-AS1 -4.32 2.4e-05 0.0114 -0.27 -0.28 Renal cell carcinoma; chr3:40399854 chr3:40313802~40453329:- CESC cis rs116175783 0.557 rs16845844 ENSG00000227403.1 AC009299.3 -4.32 2.4e-05 0.0114 -0.44 -0.28 Intelligence (multi-trait analysis); chr2:161408759 chr2:161244739~161249050:+ CESC cis rs2933343 0.951 rs1055128 ENSG00000231305.3 RP11-723O4.2 4.32 2.4e-05 0.0114 0.29 0.28 IgG glycosylation; chr3:128872205 chr3:128861313~128871540:- CESC cis rs7572733 0.534 rs6434943 ENSG00000222017.1 AC011997.1 4.32 2.4e-05 0.0114 0.36 0.28 Dermatomyositis; chr2:197897468 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1435568 ENSG00000222017.1 AC011997.1 4.32 2.4e-05 0.0114 0.36 0.28 Dermatomyositis; chr2:197898155 chr2:197693106~197774823:+ CESC cis rs7572733 0.555 rs6729473 ENSG00000222017.1 AC011997.1 4.32 2.4e-05 0.0114 0.36 0.28 Dermatomyositis; chr2:197899204 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs6760891 ENSG00000222017.1 AC011997.1 4.32 2.4e-05 0.0114 0.36 0.28 Dermatomyositis; chr2:197903442 chr2:197693106~197774823:+ CESC cis rs12580194 0.957 rs73118932 ENSG00000237493.3 RP11-603J24.7 -4.32 2.4e-05 0.0114 -0.43 -0.28 Cancer; chr12:55312847 chr12:55980432~55981035:- CESC cis rs875971 1 rs709597 ENSG00000232559.3 GS1-124K5.12 -4.32 2.4e-05 0.0114 -0.3 -0.28 Aortic root size; chr7:66360996 chr7:66554588~66576923:- CESC cis rs77972916 0.505 rs6736400 ENSG00000234936.1 AC010883.5 4.32 2.4e-05 0.0114 0.32 0.28 Granulocyte percentage of myeloid white cells; chr2:43273665 chr2:43229573~43233394:+ CESC cis rs7005380 0.62 rs13259990 ENSG00000279347.1 RP11-85I17.2 -4.32 2.4e-05 0.0114 -0.25 -0.28 Interstitial lung disease; chr8:119894943 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13260933 ENSG00000279347.1 RP11-85I17.2 -4.32 2.4e-05 0.0114 -0.25 -0.28 Interstitial lung disease; chr8:119895010 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs13261304 ENSG00000279347.1 RP11-85I17.2 -4.32 2.4e-05 0.0114 -0.25 -0.28 Interstitial lung disease; chr8:119895180 chr8:119838736~119840385:- CESC cis rs3096299 0.933 rs3096297 ENSG00000274627.1 RP11-104N10.2 4.32 2.4e-05 0.0114 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89386747 chr16:89516797~89522217:+ CESC cis rs10829156 0.898 rs7923072 ENSG00000240291.1 RP11-499P20.2 4.32 2.4e-05 0.0114 0.3 0.28 Sudden cardiac arrest; chr10:18649305 chr10:18513115~18545651:- CESC cis rs7829975 0.501 rs2980769 ENSG00000253893.2 FAM85B -4.32 2.4e-05 0.0114 -0.34 -0.28 Mood instability; chr8:8462781 chr8:8167819~8226614:- CESC cis rs516805 0.748 rs6908508 ENSG00000279453.1 RP3-425C14.4 4.32 2.4e-05 0.0114 0.34 0.28 Lymphocyte counts; chr6:122387857 chr6:122436789~122439223:- CESC cis rs73086581 0.945 rs6037715 ENSG00000229539.1 RP11-119B16.2 4.32 2.4e-05 0.0114 0.44 0.28 Response to antidepressants in depression; chr20:3991519 chr20:3888239~3888868:- CESC cis rs73086581 1 rs17215529 ENSG00000229539.1 RP11-119B16.2 4.32 2.4e-05 0.0114 0.44 0.28 Response to antidepressants in depression; chr20:3994755 chr20:3888239~3888868:- CESC cis rs673078 0.607 rs61943391 ENSG00000275759.1 RP11-131L12.3 -4.32 2.4e-05 0.0114 -0.54 -0.28 Glucose homeostasis traits; chr12:118382603 chr12:118428281~118428870:+ CESC cis rs4819052 0.724 rs1304487 ENSG00000223768.1 LINC00205 4.32 2.41e-05 0.0114 0.32 0.28 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45237368 chr21:45293285~45297354:+ CESC cis rs67311347 1 rs7631893 ENSG00000223797.4 ENTPD3-AS1 4.32 2.41e-05 0.0114 0.27 0.28 Renal cell carcinoma; chr3:40399378 chr3:40313802~40453329:- CESC cis rs875971 0.825 rs1000464 ENSG00000232559.3 GS1-124K5.12 -4.32 2.41e-05 0.0114 -0.29 -0.28 Aortic root size; chr7:66312922 chr7:66554588~66576923:- CESC cis rs7208859 0.573 rs8078182 ENSG00000264538.5 SUZ12P1 -4.32 2.41e-05 0.0114 -0.31 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822646 chr17:30709299~30790908:+ CESC cis rs8030379 1 rs4842838 ENSG00000230373.7 GOLGA6L5P 4.32 2.41e-05 0.0114 0.27 0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83913372 chr15:84507885~84516814:- CESC cis rs8030379 1 rs10906982 ENSG00000230373.7 GOLGA6L5P -4.32 2.41e-05 0.0114 -0.27 -0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83899406 chr15:84507885~84516814:- CESC cis rs3020736 0.5 rs6002616 ENSG00000273366.1 CTA-989H11.1 4.32 2.41e-05 0.0114 0.38 0.28 Autism spectrum disorder or schizophrenia; chr22:42108675 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs7364293 ENSG00000273366.1 CTA-989H11.1 4.32 2.41e-05 0.0114 0.38 0.28 Autism spectrum disorder or schizophrenia; chr22:42110366 chr22:42278188~42278846:+ CESC cis rs922182 1 rs922182 ENSG00000239465.1 RP11-330L19.2 -4.32 2.41e-05 0.0114 -0.37 -0.28 Blood protein levels; chr15:63985443 chr15:64631109~64631914:- CESC cis rs8059260 0.542 rs16957948 ENSG00000274038.1 RP11-66H6.4 -4.32 2.41e-05 0.0114 -0.42 -0.28 Alcohol consumption over the past year; chr16:11034208 chr16:11056556~11057034:+ CESC cis rs2933343 0.951 rs796862 ENSG00000231305.3 RP11-723O4.2 4.32 2.41e-05 0.0114 0.29 0.28 IgG glycosylation; chr3:128874197 chr3:128861313~128871540:- CESC cis rs7809950 1 rs17154077 ENSG00000238832.1 snoU109 4.32 2.42e-05 0.0114 0.33 0.28 Coronary artery disease; chr7:107437496 chr7:107603363~107603507:+ CESC cis rs62355901 0.505 rs12657396 ENSG00000271828.1 CTD-2310F14.1 4.32 2.42e-05 0.0115 0.44 0.28 Breast cancer; chr5:56930778 chr5:56927874~56929573:+ CESC cis rs10885122 0.85 rs4918635 ENSG00000278601.1 RP11-348N5.9 -4.31 2.42e-05 0.0115 -0.41 -0.28 Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;Fasting blood glucose; chr10:111276466 chr10:110907483~110908182:+ CESC cis rs77988765 0.611 rs2509176 ENSG00000279459.1 RP11-826F13.1 4.31 2.42e-05 0.0115 0.36 0.28 Post bronchodilator FEV1/FVC ratio; chr11:70133058 chr11:70603304~70604859:+ CESC cis rs9322193 1 rs9377228 ENSG00000216906.2 RP11-350J20.9 4.31 2.42e-05 0.0115 0.31 0.28 Lung cancer; chr6:149600862 chr6:149904243~149906418:+ CESC cis rs2276314 0.802 rs9963714 ENSG00000278986.1 RP11-723J4.3 -4.31 2.43e-05 0.0115 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36012093 chr18:35972151~35973916:+ CESC cis rs2276314 0.802 rs4799838 ENSG00000278986.1 RP11-723J4.3 -4.31 2.43e-05 0.0115 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36017567 chr18:35972151~35973916:+ CESC cis rs2276314 0.748 rs4799839 ENSG00000278986.1 RP11-723J4.3 -4.31 2.43e-05 0.0115 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36017568 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs28375959 ENSG00000278986.1 RP11-723J4.3 -4.31 2.43e-05 0.0115 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36021571 chr18:35972151~35973916:+ CESC cis rs2276314 0.802 rs58906216 ENSG00000278986.1 RP11-723J4.3 -4.31 2.43e-05 0.0115 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36050334 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs6507157 ENSG00000278986.1 RP11-723J4.3 -4.31 2.43e-05 0.0115 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36051740 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs28396546 ENSG00000278986.1 RP11-723J4.3 -4.31 2.43e-05 0.0115 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36059061 chr18:35972151~35973916:+ CESC cis rs2732480 0.538 rs2732462 ENSG00000240399.1 RP1-228P16.1 4.31 2.43e-05 0.0115 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48302601 chr12:48054813~48055591:- CESC cis rs4713118 0.662 rs149901 ENSG00000219392.1 RP1-265C24.5 -4.31 2.43e-05 0.0115 -0.35 -0.28 Parkinson's disease; chr6:27997725 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs464312 ENSG00000219392.1 RP1-265C24.5 -4.31 2.43e-05 0.0115 -0.35 -0.28 Parkinson's disease; chr6:27999813 chr6:28115628~28116551:+ CESC cis rs9326248 0.574 rs1263173 ENSG00000280143.1 AP000892.6 4.31 2.43e-05 0.0115 0.33 0.28 Blood protein levels; chr11:116810292 chr11:117204967~117210292:+ CESC cis rs2933343 1 rs1680784 ENSG00000231305.3 RP11-723O4.2 4.31 2.43e-05 0.0115 0.3 0.28 IgG glycosylation; chr3:128925615 chr3:128861313~128871540:- CESC cis rs3124314 1 rs10788821 ENSG00000229021.2 AL591893.1 4.31 2.43e-05 0.0115 0.31 0.28 Hair morphology; chr1:152168905 chr1:151994531~152042774:+ CESC cis rs916888 0.773 rs1378358 ENSG00000261575.2 RP11-259G18.1 4.31 2.43e-05 0.0115 0.42 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46267037~46268694:+ CESC cis rs916888 0.773 rs169201 ENSG00000261575.2 RP11-259G18.1 4.31 2.43e-05 0.0115 0.42 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46267037~46268694:+ CESC cis rs8030379 1 rs6603004 ENSG00000230373.7 GOLGA6L5P 4.31 2.43e-05 0.0115 0.27 0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83899752 chr15:84507885~84516814:- CESC cis rs9918079 0.542 rs1789 ENSG00000273133.1 RP11-799M12.2 -4.31 2.43e-05 0.0115 -0.37 -0.28 Obesity-related traits; chr4:15662912 chr4:15563698~15564253:- CESC cis rs2274273 0.624 rs67795323 ENSG00000258413.1 RP11-665C16.6 -4.31 2.43e-05 0.0115 -0.36 -0.28 Protein biomarker; chr14:55331115 chr14:55262767~55272075:- CESC cis rs2274273 0.624 rs8005450 ENSG00000258413.1 RP11-665C16.6 -4.31 2.43e-05 0.0115 -0.36 -0.28 Protein biomarker; chr14:55332447 chr14:55262767~55272075:- CESC cis rs919433 0.617 rs4850807 ENSG00000222017.1 AC011997.1 -4.31 2.43e-05 0.0115 -0.35 -0.28 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197711251 chr2:197693106~197774823:+ CESC cis rs4974559 0.69 rs28515563 ENSG00000253399.1 AC078852.2 4.31 2.44e-05 0.0115 0.47 0.28 Systolic blood pressure; chr4:1321335 chr4:1358479~1359461:+ CESC cis rs57502260 0.704 rs72936570 ENSG00000212093.1 AP000807.1 4.31 2.44e-05 0.0115 0.46 0.28 Total body bone mineral density (age 45-60); chr11:68539671 chr11:68506083~68506166:- CESC cis rs6504622 1 rs2003539 ENSG00000262879.4 RP11-156P1.3 -4.31 2.44e-05 0.0116 -0.32 -0.28 Orofacial clefts; chr17:46947953 chr17:46984045~47100323:- CESC cis rs755249 0.874 rs61779310 ENSG00000228060.1 RP11-69E11.8 -4.31 2.44e-05 0.0116 -0.33 -0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39476625 chr1:39565160~39573203:+ CESC cis rs4819052 0.851 rs1999333 ENSG00000223768.1 LINC00205 -4.31 2.45e-05 0.0116 -0.33 -0.28 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45250486 chr21:45293285~45297354:+ CESC cis rs6740322 0.895 rs10172375 ENSG00000234936.1 AC010883.5 4.31 2.45e-05 0.0116 0.29 0.28 Coronary artery disease; chr2:43344908 chr2:43229573~43233394:+ CESC cis rs7873102 0.654 rs10973633 ENSG00000230188.1 RP11-405L18.4 4.31 2.45e-05 0.0116 0.35 0.28 Brain structure; chr9:37992122 chr9:37490421~37490893:- CESC cis rs17818399 0.89 rs34752561 ENSG00000279254.1 RP11-536C12.1 -4.31 2.45e-05 0.0116 -0.36 -0.28 Height; chr2:46623011 chr2:46668870~46670778:+ CESC cis rs6142102 1 rs6059681 ENSG00000276073.1 RP5-1125A11.7 -4.31 2.45e-05 0.0116 -0.28 -0.28 Skin pigmentation; chr20:34135535 chr20:33985617~33988989:- CESC cis rs875971 0.545 rs1796222 ENSG00000226824.5 RP4-756H11.3 4.31 2.45e-05 0.0116 0.41 0.28 Aortic root size; chr7:66592167 chr7:66654538~66669855:+ CESC cis rs11971779 0.68 rs2355786 ENSG00000273391.1 RP11-634H22.1 -4.31 2.45e-05 0.0116 -0.27 -0.28 Diisocyanate-induced asthma; chr7:139380876 chr7:139359032~139359566:- CESC cis rs35740288 0.857 rs11630274 ENSG00000202081.1 RNU6-1280P 4.31 2.45e-05 0.0116 0.35 0.28 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85745156 chr15:85651522~85651628:- CESC cis rs10829156 0.66 rs7910506 ENSG00000240291.1 RP11-499P20.2 -4.31 2.45e-05 0.0116 -0.31 -0.28 Sudden cardiac arrest; chr10:18518128 chr10:18513115~18545651:- CESC cis rs2412819 0.571 rs12443084 ENSG00000249839.1 AC011330.5 4.31 2.45e-05 0.0116 0.36 0.28 Lung cancer; chr15:43748767 chr15:43663654~43684339:- CESC cis rs2412819 0.571 rs10163069 ENSG00000249839.1 AC011330.5 4.31 2.45e-05 0.0116 0.36 0.28 Lung cancer; chr15:43755372 chr15:43663654~43684339:- CESC cis rs2929278 0.617 rs3986209 ENSG00000249839.1 AC011330.5 4.31 2.45e-05 0.0116 0.36 0.28 Schizophrenia; chr15:43758675 chr15:43663654~43684339:- CESC cis rs9487094 0.644 rs1960325 ENSG00000260273.1 RP11-425D10.10 4.31 2.46e-05 0.0116 0.35 0.28 Height; chr6:109592105 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs12528781 ENSG00000260273.1 RP11-425D10.10 4.31 2.46e-05 0.0116 0.35 0.28 Height; chr6:109608105 chr6:109382795~109383666:+ CESC cis rs950880 1 rs950880 ENSG00000234389.1 AC007278.3 -4.31 2.46e-05 0.0116 -0.3 -0.28 Serum protein levels (sST2); chr2:102316102 chr2:102438713~102440475:+ CESC cis rs42490 0.664 rs421411 ENSG00000251136.7 RP11-37B2.1 -4.31 2.46e-05 0.0116 -0.28 -0.28 Leprosy; chr8:89808665 chr8:89609409~89757727:- CESC cis rs42490 0.664 rs43226 ENSG00000251136.7 RP11-37B2.1 -4.31 2.46e-05 0.0116 -0.28 -0.28 Leprosy; chr8:89809048 chr8:89609409~89757727:- CESC cis rs42490 0.664 rs422559 ENSG00000251136.7 RP11-37B2.1 -4.31 2.46e-05 0.0116 -0.28 -0.28 Leprosy; chr8:89809121 chr8:89609409~89757727:- CESC cis rs6556937 0.71 rs2351245 ENSG00000251314.2 CTD-2337A12.1 4.31 2.46e-05 0.0116 0.39 0.28 Blood protein levels; chr5:96660029 chr5:95962001~96631085:+ CESC cis rs73173548 0.502 rs10452479 ENSG00000247828.6 TMEM161B-AS1 4.31 2.46e-05 0.0116 0.3 0.28 Macular telangiectasia type 2; chr5:88445131 chr5:88268895~88436685:+ CESC cis rs2361701 0.929 rs1467979 ENSG00000279259.1 RP11-334C17.3 -4.31 2.46e-05 0.0116 -0.35 -0.28 IgG glycosylation; chr17:80086944 chr17:80147250~80148596:+ CESC cis rs2739330 0.796 rs1006771 ENSG00000231271.1 AP000350.8 4.31 2.46e-05 0.0116 0.32 0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23949918~23954042:+ CESC cis rs42490 0.689 rs43228 ENSG00000251136.7 RP11-37B2.1 -4.31 2.46e-05 0.0116 -0.29 -0.28 Leprosy; chr8:89816790 chr8:89609409~89757727:- CESC cis rs1707322 1 rs4390216 ENSG00000281133.1 AL355480.3 -4.31 2.46e-05 0.0116 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45800784 chr1:45580892~45580996:- CESC cis rs1707322 0.964 rs10437063 ENSG00000281133.1 AL355480.3 -4.31 2.46e-05 0.0116 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45807994 chr1:45580892~45580996:- CESC cis rs1707322 1 rs6676982 ENSG00000281133.1 AL355480.3 -4.31 2.46e-05 0.0116 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45809729 chr1:45580892~45580996:- CESC cis rs1707322 0.927 rs11211194 ENSG00000281133.1 AL355480.3 -4.31 2.46e-05 0.0116 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45816412 chr1:45580892~45580996:- CESC cis rs2117029 0.965 rs1138908 ENSG00000258017.1 RP11-386G11.10 -4.31 2.46e-05 0.0116 -0.37 -0.28 Intelligence (multi-trait analysis); chr12:49008516 chr12:49127782~49147869:+ CESC cis rs2117029 1 rs2117029 ENSG00000258017.1 RP11-386G11.10 -4.31 2.46e-05 0.0116 -0.37 -0.28 Intelligence (multi-trait analysis); chr12:49014657 chr12:49127782~49147869:+ CESC cis rs4648045 0.565 rs4698860 ENSG00000246560.2 RP11-10L12.4 4.31 2.46e-05 0.0116 0.37 0.28 Lymphocyte percentage of white cells; chr4:102624170 chr4:102828055~102844075:+ CESC cis rs75422866 0.867 rs73113143 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47623060 chr12:47731908~47732351:+ CESC cis rs75422866 0.717 rs73113159 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47631318 chr12:47731908~47732351:+ CESC cis rs75422866 0.717 rs73113161 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47632361 chr12:47731908~47732351:+ CESC cis rs75422866 1 rs73102120 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47637280 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102125 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47637869 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs12426849 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47638975 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs117950951 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47639794 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs7954764 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47641136 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs12422974 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47644559 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs73102127 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47645341 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs75568526 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47649718 chr12:47731908~47732351:+ CESC cis rs75422866 0.867 rs116302411 ENSG00000274902.1 RP1-197B17.4 4.31 2.46e-05 0.0116 0.69 0.28 Pneumonia; chr12:47649788 chr12:47731908~47732351:+ CESC cis rs700651 0.754 rs1518367 ENSG00000222017.1 AC011997.1 4.31 2.46e-05 0.0116 0.35 0.28 Intracranial aneurysm; chr2:197942291 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1518365 ENSG00000222017.1 AC011997.1 4.31 2.46e-05 0.0116 0.35 0.28 Dermatomyositis; chr2:197944686 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1518363 ENSG00000222017.1 AC011997.1 4.31 2.46e-05 0.0116 0.35 0.28 Dermatomyositis; chr2:197945407 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1518361 ENSG00000222017.1 AC011997.1 4.31 2.46e-05 0.0116 0.35 0.28 Dermatomyositis; chr2:197948150 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1464209 ENSG00000222017.1 AC011997.1 4.31 2.46e-05 0.0116 0.35 0.28 Dermatomyositis; chr2:197949672 chr2:197693106~197774823:+ CESC cis rs9309473 0.5 rs1528169 ENSG00000273245.1 RP11-434P11.2 -4.31 2.47e-05 0.0116 -0.35 -0.28 Metabolite levels; chr2:73442058 chr2:73750256~73750786:- CESC cis rs7429990 0.901 rs7433678 ENSG00000229759.1 MRPS18AP1 -4.31 2.47e-05 0.0117 -0.29 -0.28 Educational attainment (years of education); chr3:47995588 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs4392441 ENSG00000229759.1 MRPS18AP1 -4.31 2.47e-05 0.0117 -0.29 -0.28 Educational attainment (years of education); chr3:48036211 chr3:48256350~48256938:- CESC cis rs9640161 0.789 rs3735174 ENSG00000261305.1 RP4-584D14.7 4.31 2.47e-05 0.0117 0.38 0.28 Blood protein levels;Circulating chemerin levels; chr7:150323400 chr7:150341771~150342607:+ CESC cis rs10129255 0.833 rs61997797 ENSG00000211974.3 IGHV2-70 4.31 2.47e-05 0.0117 0.3 0.28 Kawasaki disease; chr14:106815190 chr14:106723574~106724093:- CESC cis rs748404 0.697 rs498227 ENSG00000205771.5 CATSPER2P1 -4.31 2.47e-05 0.0117 -0.34 -0.28 Lung cancer; chr15:43280854 chr15:43726918~43747094:- CESC cis rs17818399 0.89 rs34544165 ENSG00000279254.1 RP11-536C12.1 -4.31 2.47e-05 0.0117 -0.34 -0.28 Height; chr2:46609767 chr2:46668870~46670778:+ CESC cis rs950880 0.961 rs13020553 ENSG00000234389.1 AC007278.3 -4.31 2.47e-05 0.0117 -0.3 -0.28 Serum protein levels (sST2); chr2:102315366 chr2:102438713~102440475:+ CESC cis rs9660180 0.839 rs12040826 ENSG00000268575.1 RP1-283E3.8 -4.31 2.47e-05 0.0117 -0.28 -0.28 Body mass index; chr1:1773848 chr1:1702736~1737688:- CESC cis rs9323326 0.586 rs17734750 ENSG00000257621.6 PSMA3-AS1 -4.31 2.47e-05 0.0117 -0.28 -0.28 Gut microbiota (bacterial taxa); chr14:58014725 chr14:58265365~58298134:- CESC cis rs2274273 0.624 rs67386901 ENSG00000258413.1 RP11-665C16.6 -4.31 2.47e-05 0.0117 -0.37 -0.28 Protein biomarker; chr14:55290646 chr14:55262767~55272075:- CESC cis rs2274273 0.624 rs7140628 ENSG00000258413.1 RP11-665C16.6 -4.31 2.47e-05 0.0117 -0.37 -0.28 Protein biomarker; chr14:55293963 chr14:55262767~55272075:- CESC cis rs8020095 0.571 rs6573752 ENSG00000258561.1 RP11-72M17.1 -4.31 2.48e-05 0.0117 -0.42 -0.28 Depression (quantitative trait); chr14:67123075 chr14:66212810~66509394:- CESC cis rs4272720 0.639 rs12255090 ENSG00000229870.1 RP11-507K13.6 -4.31 2.48e-05 0.0117 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49069653 chr10:49815096~49815562:+ CESC cis rs7829975 0.617 rs4841072 ENSG00000254340.1 RP11-10A14.3 -4.31 2.48e-05 0.0117 -0.34 -0.28 Mood instability; chr8:8933743 chr8:9141424~9145435:+ CESC cis rs801193 0.66 rs2659914 ENSG00000237310.1 GS1-124K5.4 4.31 2.48e-05 0.0117 0.26 0.28 Aortic root size; chr7:66691927 chr7:66493706~66495474:+ CESC cis rs7580658 0.75 rs4497825 ENSG00000236682.1 AC068282.3 -4.31 2.48e-05 0.0117 -0.33 -0.28 Protein C levels; chr2:127303477 chr2:127389130~127400580:+ CESC cis rs7005380 0.62 rs7461290 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119904154 chr8:119838736~119840385:- CESC cis rs7005380 0.58 rs4073560 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119905148 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs7002839 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119906508 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs7006905 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119906683 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs13267896 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119908414 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13275524 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119908701 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs6469867 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119909172 chr8:119838736~119840385:- CESC cis rs7005380 0.58 rs6469868 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119909601 chr8:119838736~119840385:- CESC cis rs7005380 0.606 rs6469869 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119909696 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6469870 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119909773 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6469871 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119909839 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs6469872 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119910007 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs7015470 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119910101 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6995139 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119910157 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10217077 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119910943 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs939242 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119912030 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs939241 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119912297 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10216503 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119912843 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs7824545 ENSG00000279347.1 RP11-85I17.2 -4.31 2.48e-05 0.0117 -0.25 -0.28 Interstitial lung disease; chr8:119913381 chr8:119838736~119840385:- CESC cis rs7188445 0.932 rs11150191 ENSG00000261390.4 RP11-345M22.2 -4.31 2.49e-05 0.0117 -0.37 -0.28 Urate levels; chr16:79700390 chr16:79715232~79770563:- CESC cis rs10740039 0.583 rs9415613 ENSG00000254271.1 RP11-131N11.4 -4.31 2.49e-05 0.0117 -0.36 -0.28 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60747636 chr10:60734342~60741828:+ CESC cis rs13113518 1 rs13113518 ENSG00000273257.1 RP11-177J6.1 4.31 2.49e-05 0.0117 0.37 0.28 Height; chr4:55533481 chr4:55387949~55388271:+ CESC cis rs4308124 0.708 rs6749633 ENSG00000227992.1 AC108463.2 4.31 2.49e-05 0.0117 0.37 0.28 Vitiligo; chr2:111230439 chr2:111203964~111206215:- CESC cis rs2548724 0.755 rs62371010 ENSG00000250682.4 LINC00491 4.31 2.49e-05 0.0117 0.34 0.28 Type 2 diabetes; chr5:102460569 chr5:102609156~102671559:- CESC cis rs17301013 0.507 rs10912762 ENSG00000227373.4 RP11-160H22.5 4.31 2.49e-05 0.0117 0.4 0.28 Systemic lupus erythematosus; chr1:174312477 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12097252 ENSG00000227373.4 RP11-160H22.5 4.31 2.49e-05 0.0117 0.4 0.28 Systemic lupus erythematosus; chr1:174318374 chr1:174115300~174160004:- CESC cis rs3931020 0.657 rs277376 ENSG00000272864.1 RP11-17E13.2 4.31 2.49e-05 0.0117 0.37 0.28 Resistin levels; chr1:74776562 chr1:74698769~74699333:- CESC cis rs11685222 0.589 rs72965074 ENSG00000229326.3 AC069154.4 4.31 2.49e-05 0.0117 0.39 0.28 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119664095 chr2:119698623~119700151:+ CESC cis rs11685222 0.589 rs57403590 ENSG00000229326.3 AC069154.4 4.31 2.49e-05 0.0117 0.39 0.28 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119664371 chr2:119698623~119700151:+ CESC cis rs2243480 1 rs73142166 ENSG00000275400.1 RP4-756H11.5 4.31 2.49e-05 0.0117 0.48 0.28 Diabetic kidney disease; chr7:65910845 chr7:66553805~66554199:- CESC cis rs2243480 1 rs34193460 ENSG00000275400.1 RP4-756H11.5 4.31 2.49e-05 0.0117 0.48 0.28 Diabetic kidney disease; chr7:65928123 chr7:66553805~66554199:- CESC cis rs2243480 1 rs57057549 ENSG00000275400.1 RP4-756H11.5 4.31 2.49e-05 0.0117 0.48 0.28 Diabetic kidney disease; chr7:65940751 chr7:66553805~66554199:- CESC cis rs61160187 0.582 rs12653132 ENSG00000215032.2 GNL3LP1 4.31 2.49e-05 0.0117 0.33 0.28 Educational attainment (years of education);Educational attainment (college completion); chr5:61062881 chr5:60891935~60893577:- CESC cis rs17818399 0.781 rs34449783 ENSG00000279254.1 RP11-536C12.1 -4.31 2.49e-05 0.0118 -0.35 -0.28 Height; chr2:46636416 chr2:46668870~46670778:+ CESC cis rs651386 0.529 rs10919446 ENSG00000271811.1 RP1-79C4.4 -4.31 2.5e-05 0.0118 -0.37 -0.28 Atrial fibrillation; chr1:170624975 chr1:170667381~170669425:+ CESC cis rs860295 0.702 rs2175391 ENSG00000225855.5 RUSC1-AS1 -4.31 2.5e-05 0.0118 -0.23 -0.28 Body mass index; chr1:155655811 chr1:155316863~155324176:- CESC cis rs2439831 0.681 rs956391 ENSG00000275601.1 AC011330.13 4.31 2.5e-05 0.0118 0.4 0.28 Lung cancer in ever smokers; chr15:43325295 chr15:43642389~43643023:- CESC cis rs2243480 1 rs313813 ENSG00000232559.3 GS1-124K5.12 4.31 2.5e-05 0.0118 0.47 0.28 Diabetic kidney disease; chr7:66038513 chr7:66554588~66576923:- CESC cis rs700651 0.789 rs10184395 ENSG00000222017.1 AC011997.1 4.31 2.51e-05 0.0118 0.35 0.28 Intracranial aneurysm; chr2:198029561 chr2:197693106~197774823:+ CESC cis rs150992 0.536 rs161729 ENSG00000248489.1 CTD-2007H13.3 4.31 2.51e-05 0.0118 0.37 0.28 Body mass index; chr5:98982477 chr5:98929171~98995013:+ CESC cis rs150992 0.536 rs161730 ENSG00000248489.1 CTD-2007H13.3 4.31 2.51e-05 0.0118 0.37 0.28 Body mass index; chr5:98982631 chr5:98929171~98995013:+ CESC cis rs8059260 0.604 rs9302458 ENSG00000274038.1 RP11-66H6.4 -4.31 2.51e-05 0.0118 -0.43 -0.28 Alcohol consumption over the past year; chr16:11050352 chr16:11056556~11057034:+ CESC cis rs8042680 0.688 rs11073964 ENSG00000214432.8 AC068831.10 -4.31 2.51e-05 0.0118 -0.35 -0.28 Type 2 diabetes; chr15:91000531 chr15:91022619~91036611:+ CESC cis rs4319547 0.695 rs11057797 ENSG00000275265.1 RP11-15J22.8 4.31 2.51e-05 0.0118 0.4 0.28 Body mass index; chr12:122376185 chr12:122501187~122501641:+ CESC cis rs4319547 0.614 rs10846764 ENSG00000275265.1 RP11-15J22.8 4.31 2.51e-05 0.0118 0.4 0.28 Body mass index; chr12:122389750 chr12:122501187~122501641:+ CESC cis rs2243480 0.522 rs431168 ENSG00000228409.4 CCT6P1 4.31 2.51e-05 0.0118 0.48 0.28 Diabetic kidney disease; chr7:66046617 chr7:65751142~65763354:+ CESC cis rs1707322 1 rs1622208 ENSG00000281133.1 AL355480.3 4.31 2.51e-05 0.0118 0.34 0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46032703 chr1:45580892~45580996:- CESC cis rs440932 0.747 rs330946 ENSG00000253893.2 FAM85B -4.31 2.51e-05 0.0118 -0.34 -0.28 High light scatter reticulocyte percentage of red cells; chr8:9164667 chr8:8167819~8226614:- CESC cis rs9322193 0.926 rs9383546 ENSG00000223701.3 RAET1E-AS1 4.31 2.51e-05 0.0118 0.32 0.28 Lung cancer; chr6:149822743 chr6:149884431~149919508:+ CESC cis rs17301013 0.507 rs10912753 ENSG00000227373.4 RP11-160H22.5 4.31 2.51e-05 0.0118 0.39 0.28 Systemic lupus erythematosus; chr1:174265226 chr1:174115300~174160004:- CESC cis rs1538970 0.781 rs34768551 ENSG00000280836.1 AL355480.1 -4.31 2.52e-05 0.0118 -0.36 -0.28 Platelet count; chr1:45554736 chr1:45581219~45581321:- CESC cis rs6686842 0.965 rs1472570 ENSG00000235358.1 RP11-399E6.1 -4.31 2.52e-05 0.0118 -0.34 -0.28 Height; chr1:41248412 chr1:41242373~41284861:+ CESC cis rs12439619 0.846 rs7496227 ENSG00000276710.3 CSPG4P8 -4.31 2.52e-05 0.0119 -0.41 -0.28 Intelligence (multi-trait analysis); chr15:82275241 chr15:82459472~82477258:+ CESC cis rs8062405 0.573 rs7187575 ENSG00000261067.5 RP11-264B17.3 -4.31 2.52e-05 0.0119 -0.28 -0.28 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28978780 chr16:28974804~28990783:+ CESC cis rs897984 0.806 rs1046276 ENSG00000275263.1 RP11-1072A3.4 4.31 2.52e-05 0.0119 0.37 0.28 Dementia with Lewy bodies; chr16:30903305 chr16:30956872~30957199:- CESC cis rs7809950 1 rs4727681 ENSG00000238832.1 snoU109 -4.3 2.52e-05 0.0119 -0.33 -0.28 Coronary artery disease; chr7:107455699 chr7:107603363~107603507:+ CESC cis rs7809950 1 rs7782057 ENSG00000238832.1 snoU109 -4.3 2.52e-05 0.0119 -0.33 -0.28 Coronary artery disease; chr7:107458432 chr7:107603363~107603507:+ CESC cis rs7005380 0.6 rs10955940 ENSG00000279347.1 RP11-85I17.2 -4.3 2.52e-05 0.0119 -0.25 -0.28 Interstitial lung disease; chr8:119890246 chr8:119838736~119840385:- CESC cis rs950169 0.519 rs7237 ENSG00000225151.9 GOLGA2P7 -4.3 2.52e-05 0.0119 -0.4 -0.28 Schizophrenia; chr15:84643346 chr15:84199311~84230136:- CESC cis rs9309473 1 rs7607014 ENSG00000163016.8 ALMS1P -4.3 2.53e-05 0.0119 -0.35 -0.28 Metabolite levels; chr2:73503047 chr2:73644919~73685576:+ CESC cis rs77204473 0.744 rs80273401 ENSG00000254851.1 RP11-109L13.1 4.3 2.53e-05 0.0119 0.65 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117037990 chr11:117135528~117138582:+ CESC cis rs9907295 0.818 rs9303692 ENSG00000270977.1 AC015849.16 4.3 2.54e-05 0.0119 0.36 0.28 Fibroblast growth factor basic levels; chr17:35861492 chr17:35893707~35911023:- CESC cis rs2439831 0.85 rs694985 ENSG00000275601.1 AC011330.13 -4.3 2.54e-05 0.0119 -0.39 -0.28 Lung cancer in ever smokers; chr15:43521189 chr15:43642389~43643023:- CESC cis rs2058059 0.553 rs2960967 ENSG00000205578.5 POM121B -4.3 2.54e-05 0.0119 -0.34 -0.28 Subcutaneous adipose tissue; chr7:72701793 chr7:73293497~73301161:+ CESC cis rs2404602 0.583 rs3759853 ENSG00000280730.1 AC090181.1 4.3 2.54e-05 0.0119 0.21 0.28 Blood metabolite levels; chr15:76295436 chr15:77056895~77057021:+ CESC cis rs875971 0.545 rs6970498 ENSG00000222364.1 RNU6-96P -4.3 2.54e-05 0.012 -0.38 -0.28 Aortic root size; chr7:66275908 chr7:66395191~66395286:+ CESC cis rs7688540 0.771 rs11723803 ENSG00000211553.1 AC253576.2 -4.3 2.54e-05 0.012 -0.36 -0.28 Facial morphology (factor 6, height of vermillion lower lip); chr4:298580 chr4:136461~136568:+ CESC cis rs2243480 1 rs316327 ENSG00000275400.1 RP4-756H11.5 -4.3 2.54e-05 0.012 -0.47 -0.28 Diabetic kidney disease; chr7:66144214 chr7:66553805~66554199:- CESC cis rs2662776 1 rs10753609 ENSG00000232995.6 RGS5 -4.3 2.55e-05 0.012 -0.3 -0.28 Lead levels in blood; chr1:163190547 chr1:163244505~163321894:- CESC cis rs9487094 0.666 rs4946967 ENSG00000260273.1 RP11-425D10.10 4.3 2.55e-05 0.012 0.34 0.28 Height; chr6:109357369 chr6:109382795~109383666:+ CESC cis rs9322193 1 rs9399693 ENSG00000216906.2 RP11-350J20.9 4.3 2.55e-05 0.012 0.3 0.28 Lung cancer; chr6:149612718 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs11155677 ENSG00000216906.2 RP11-350J20.9 4.3 2.55e-05 0.012 0.31 0.28 Lung cancer; chr6:149756953 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs9480009 ENSG00000216906.2 RP11-350J20.9 4.3 2.55e-05 0.012 0.31 0.28 Lung cancer; chr6:149758502 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9480031 ENSG00000216906.2 RP11-350J20.9 4.3 2.55e-05 0.012 0.31 0.28 Lung cancer; chr6:149758875 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs10872649 ENSG00000216906.2 RP11-350J20.9 4.3 2.55e-05 0.012 0.31 0.28 Lung cancer; chr6:149759454 chr6:149904243~149906418:+ CESC cis rs6565180 0.888 rs12447833 ENSG00000183604.13 SMG1P5 4.3 2.55e-05 0.012 0.29 0.28 Tonsillectomy; chr16:30378993 chr16:30267553~30335374:- CESC cis rs7115242 0.8 rs493134 ENSG00000280143.1 AP000892.6 4.3 2.55e-05 0.012 0.48 0.28 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116962963 chr11:117204967~117210292:+ CESC cis rs944801 0.608 rs7027950 ENSG00000215221.2 UBA52P6 4.3 2.55e-05 0.012 0.34 0.28 Type 2 diabetes; chr9:22048392 chr9:22012155~22012536:+ CESC cis rs6964587 1 rs2075881 ENSG00000188693.7 CYP51A1-AS1 -4.3 2.55e-05 0.012 -0.29 -0.28 Breast cancer; chr7:92105238 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs7785971 ENSG00000188693.7 CYP51A1-AS1 -4.3 2.55e-05 0.012 -0.29 -0.28 Breast cancer; chr7:92107480 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs7802788 ENSG00000188693.7 CYP51A1-AS1 -4.3 2.55e-05 0.012 -0.29 -0.28 Breast cancer; chr7:92107560 chr7:92134604~92180725:+ CESC cis rs7811142 0.666 rs28401739 ENSG00000242294.5 STAG3L5P 4.3 2.55e-05 0.012 0.29 0.28 Platelet count; chr7:100308061 chr7:100336079~100351900:+ CESC cis rs3931020 0.616 rs277381 ENSG00000272864.1 RP11-17E13.2 4.3 2.55e-05 0.012 0.37 0.28 Resistin levels; chr1:74801131 chr1:74698769~74699333:- CESC cis rs11089937 0.626 rs4821784 ENSG00000211638.2 IGLV8-61 -4.3 2.55e-05 0.012 -0.28 -0.28 Periodontitis (PAL4Q3); chr22:22143513 chr22:22098700~22099212:+ CESC cis rs77204473 0.744 rs77955134 ENSG00000254851.1 RP11-109L13.1 4.3 2.55e-05 0.012 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117021652 chr11:117135528~117138582:+ CESC cis rs77204473 0.744 rs77594377 ENSG00000254851.1 RP11-109L13.1 4.3 2.55e-05 0.012 0.66 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117021730 chr11:117135528~117138582:+ CESC cis rs12468226 0.817 rs6722588 ENSG00000273456.1 RP11-686O6.2 -4.3 2.56e-05 0.012 -0.35 -0.28 Urate levels; chr2:202187163 chr2:202374932~202375604:- CESC cis rs5769707 0.935 rs1109320 ENSG00000235111.1 RP1-29C18.8 -4.3 2.56e-05 0.012 -0.28 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49595458 chr22:49612657~49615716:- CESC cis rs2439831 0.85 rs2439832 ENSG00000205771.5 CATSPER2P1 -4.3 2.56e-05 0.012 -0.39 -0.28 Lung cancer in ever smokers; chr15:43487488 chr15:43726918~43747094:- CESC cis rs916888 0.821 rs70600 ENSG00000232300.1 FAM215B 4.3 2.56e-05 0.012 0.46 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46558830~46562795:- CESC cis rs2058059 0.636 rs2960948 ENSG00000205578.5 POM121B -4.3 2.56e-05 0.012 -0.34 -0.28 Subcutaneous adipose tissue; chr7:72685439 chr7:73293497~73301161:+ CESC cis rs2058059 0.512 rs3015937 ENSG00000205578.5 POM121B -4.3 2.56e-05 0.012 -0.34 -0.28 Subcutaneous adipose tissue; chr7:72698883 chr7:73293497~73301161:+ CESC cis rs2058059 0.513 rs2960965 ENSG00000205578.5 POM121B -4.3 2.56e-05 0.012 -0.34 -0.28 Subcutaneous adipose tissue; chr7:72701360 chr7:73293497~73301161:+ CESC cis rs2058059 0.639 rs2960966 ENSG00000205578.5 POM121B -4.3 2.56e-05 0.012 -0.34 -0.28 Subcutaneous adipose tissue; chr7:72701555 chr7:73293497~73301161:+ CESC cis rs2058059 0.595 rs3015844 ENSG00000205578.5 POM121B -4.3 2.56e-05 0.012 -0.34 -0.28 Subcutaneous adipose tissue; chr7:72708751 chr7:73293497~73301161:+ CESC cis rs4273100 1 rs868698 ENSG00000265185.4 SNORD3B-1 4.3 2.56e-05 0.012 0.39 0.28 Schizophrenia; chr17:19281898 chr17:19061912~19062669:+ CESC cis rs875971 0.545 rs12671152 ENSG00000226824.5 RP4-756H11.3 -4.3 2.57e-05 0.012 -0.4 -0.28 Aortic root size; chr7:66311140 chr7:66654538~66669855:+ CESC cis rs7809950 1 rs1544336 ENSG00000238832.1 snoU109 -4.3 2.57e-05 0.012 -0.33 -0.28 Coronary artery disease; chr7:107441970 chr7:107603363~107603507:+ CESC cis rs56309584 0.678 rs8076031 ENSG00000178977.3 LINC00324 -4.3 2.57e-05 0.012 -0.34 -0.28 Initial pursuit acceleration; chr17:8247086 chr17:8220642~8224043:- CESC cis rs8040855 0.599 rs4643289 ENSG00000259295.5 CSPG4P12 -4.3 2.57e-05 0.012 -0.3 -0.28 Bulimia nervosa; chr15:85183483 chr15:85191438~85213905:+ CESC cis rs853679 0.517 rs9357065 ENSG00000219392.1 RP1-265C24.5 -4.3 2.57e-05 0.012 -0.37 -0.28 Depression; chr6:28161802 chr6:28115628~28116551:+ CESC cis rs11157436 0.846 rs12435431 ENSG00000211813.2 TRAV34 4.3 2.57e-05 0.012 0.31 0.28 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22230301 chr14:22207522~22208129:+ CESC cis rs13113518 0.729 rs13120134 ENSG00000273257.1 RP11-177J6.1 4.3 2.57e-05 0.012 0.37 0.28 Height; chr4:55415153 chr4:55387949~55388271:+ CESC cis rs783540 0.872 rs2678445 ENSG00000255769.6 GOLGA2P10 4.3 2.57e-05 0.012 0.33 0.28 Schizophrenia; chr15:82577391 chr15:82472993~82513950:- CESC cis rs10129255 0.912 rs8009135 ENSG00000211970.3 IGHV4-61 -4.3 2.57e-05 0.0121 -0.21 -0.28 Kawasaki disease; chr14:106777528 chr14:106639119~106639657:- CESC cis rs2404602 0.583 rs4381566 ENSG00000280730.1 AC090181.1 4.3 2.57e-05 0.0121 0.21 0.28 Blood metabolite levels; chr15:76296921 chr15:77056895~77057021:+ CESC cis rs6893782 0.83 rs2897160 ENSG00000233006.5 AC034220.3 -4.3 2.57e-05 0.0121 -0.36 -0.28 Acylcarnitine levels; chr5:132405806 chr5:132311285~132369916:- CESC cis rs2732480 0.5 rs1552550 ENSG00000240399.1 RP1-228P16.1 4.3 2.57e-05 0.0121 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48249568 chr12:48054813~48055591:- CESC cis rs2732480 0.5 rs2450991 ENSG00000240399.1 RP1-228P16.1 4.3 2.57e-05 0.0121 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48257838 chr12:48054813~48055591:- CESC cis rs67311347 1 rs9848083 ENSG00000223797.4 ENTPD3-AS1 -4.3 2.57e-05 0.0121 -0.27 -0.28 Renal cell carcinoma; chr3:40425488 chr3:40313802~40453329:- CESC cis rs75422866 0.51 rs73105845 ENSG00000280054.1 RP1-197B17.7 4.3 2.57e-05 0.0121 0.77 0.28 Pneumonia; chr12:47741824 chr12:47728151~47730598:- CESC cis rs7520050 0.667 rs11211176 ENSG00000280836.1 AL355480.1 4.3 2.57e-05 0.0121 0.31 0.28 Reticulocyte count;Red blood cell count; chr1:45757414 chr1:45581219~45581321:- CESC cis rs12468226 0.873 rs79071680 ENSG00000273456.1 RP11-686O6.2 4.3 2.58e-05 0.0121 0.38 0.28 Urate levels; chr2:202191520 chr2:202374932~202375604:- CESC cis rs12468226 0.873 rs79860867 ENSG00000273456.1 RP11-686O6.2 4.3 2.58e-05 0.0121 0.38 0.28 Urate levels; chr2:202192397 chr2:202374932~202375604:- CESC cis rs3738443 1 rs3738443 ENSG00000259865.1 RP11-488L18.10 -4.3 2.58e-05 0.0121 -0.33 -0.28 Alcohol dependence; chr1:247184887 chr1:247187281~247188526:- CESC cis rs2439831 0.85 rs3742982 ENSG00000275601.1 AC011330.13 -4.3 2.58e-05 0.0121 -0.44 -0.28 Lung cancer in ever smokers; chr15:43884483 chr15:43642389~43643023:- CESC cis rs12439619 0.846 rs62010071 ENSG00000276710.3 CSPG4P8 -4.3 2.59e-05 0.0121 -0.42 -0.28 Intelligence (multi-trait analysis); chr15:82289442 chr15:82459472~82477258:+ CESC cis rs6693388 0.602 rs11542015 ENSG00000229021.2 AL591893.1 4.3 2.59e-05 0.0121 0.31 0.28 Blood metabolite ratios; chr1:151993872 chr1:151994531~152042774:+ CESC cis rs6693388 0.602 rs3007708 ENSG00000229021.2 AL591893.1 4.3 2.59e-05 0.0121 0.31 0.28 Blood metabolite ratios; chr1:151995360 chr1:151994531~152042774:+ CESC cis rs9595066 0.627 rs9562536 ENSG00000227258.4 SMIM2-AS1 4.3 2.59e-05 0.0121 0.42 0.28 Schizophrenia; chr13:44157452 chr13:44110451~44240517:+ CESC cis rs10129255 0.957 rs8009464 ENSG00000280411.1 IGHV1-69-2 -4.3 2.59e-05 0.0121 -0.2 -0.28 Kawasaki disease; chr14:106777611 chr14:106762092~106762588:- CESC cis rs116175783 0.557 rs3769968 ENSG00000227403.1 AC009299.3 4.3 2.59e-05 0.0121 0.46 0.28 Intelligence (multi-trait analysis); chr2:161309640 chr2:161244739~161249050:+ CESC cis rs875971 0.545 rs316328 ENSG00000222364.1 RNU6-96P 4.3 2.59e-05 0.0121 0.35 0.28 Aortic root size; chr7:66143851 chr7:66395191~66395286:+ CESC cis rs8020095 0.528 rs13379476 ENSG00000258561.1 RP11-72M17.1 -4.3 2.59e-05 0.0121 -0.42 -0.28 Depression (quantitative trait); chr14:66945016 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs10148117 ENSG00000258561.1 RP11-72M17.1 -4.3 2.59e-05 0.0121 -0.42 -0.28 Depression (quantitative trait); chr14:66959511 chr14:66212810~66509394:- CESC cis rs2243480 1 rs160643 ENSG00000228409.4 CCT6P1 4.3 2.59e-05 0.0121 0.4 0.28 Diabetic kidney disease; chr7:66093235 chr7:65751142~65763354:+ CESC cis rs2015599 0.563 rs11050168 ENSG00000257176.2 RP11-996F15.2 4.3 2.6e-05 0.0121 0.33 0.28 Platelet count;Mean platelet volume; chr12:29273760 chr12:29280418~29317848:- CESC cis rs875971 0.545 rs1638724 ENSG00000226824.5 RP4-756H11.3 4.3 2.6e-05 0.0122 0.4 0.28 Aortic root size; chr7:66575494 chr7:66654538~66669855:+ CESC cis rs7615952 0.576 rs1127717 ENSG00000250012.1 RP11-124N2.1 -4.3 2.6e-05 0.0122 -0.31 -0.28 Blood pressure (smoking interaction); chr3:126107216 chr3:126084220~126095349:+ CESC cis rs1538970 0.924 rs1494812 ENSG00000280836.1 AL355480.1 -4.3 2.6e-05 0.0122 -0.34 -0.28 Platelet count; chr1:45411327 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs2088100 ENSG00000280836.1 AL355480.1 -4.3 2.6e-05 0.0122 -0.34 -0.28 Platelet count; chr1:45411903 chr1:45581219~45581321:- CESC cis rs1538970 0.924 rs6657284 ENSG00000280836.1 AL355480.1 -4.3 2.6e-05 0.0122 -0.34 -0.28 Platelet count; chr1:45413416 chr1:45581219~45581321:- CESC cis rs6782228 0.509 rs4481172 ENSG00000242551.2 POU5F1P6 -4.3 2.6e-05 0.0122 -0.31 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128653814 chr3:128674735~128677005:- CESC cis rs71403859 0.803 rs8063455 ENSG00000260886.1 TAT-AS1 4.3 2.61e-05 0.0122 0.44 0.28 Post bronchodilator FEV1; chr16:71566074 chr16:71565789~71578187:+ CESC cis rs7048146 0.668 rs2150260 ENSG00000213539.4 YBX1P6 4.3 2.61e-05 0.0122 0.32 0.28 Vascular brain injury; chr9:109511914 chr9:109532830~109534332:- CESC cis rs133885 1 rs133889 ENSG00000100058.11 CRYBB2P1 4.3 2.61e-05 0.0122 0.31 0.28 Mathematical ability in children with dyslexia; chr22:25764138 chr22:25448105~25520854:+ CESC cis rs755249 0.876 rs61781391 ENSG00000228060.1 RP11-69E11.8 -4.3 2.61e-05 0.0122 -0.33 -0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39611865 chr1:39565160~39573203:+ CESC cis rs7178909 0.872 rs7174330 ENSG00000259677.1 RP11-493E3.1 -4.3 2.61e-05 0.0122 -0.31 -0.28 Common traits (Other); chr15:89891347 chr15:89876540~89877285:+ CESC cis rs7048146 0.668 rs6477708 ENSG00000213539.4 YBX1P6 4.3 2.61e-05 0.0122 0.32 0.28 Vascular brain injury; chr9:109513462 chr9:109532830~109534332:- CESC cis rs9322193 0.847 rs12234128 ENSG00000216906.2 RP11-350J20.9 4.3 2.61e-05 0.0122 0.3 0.28 Lung cancer; chr6:149627553 chr6:149904243~149906418:+ CESC cis rs1538970 1 rs17395553 ENSG00000280836.1 AL355480.1 -4.3 2.61e-05 0.0122 -0.34 -0.28 Platelet count; chr1:45399089 chr1:45581219~45581321:- CESC cis rs7923837 0.713 rs10882099 ENSG00000236493.2 EIF2S2P3 4.3 2.61e-05 0.0122 0.36 0.28 Multiple sclerosis;Body mass index; chr10:92700893 chr10:92668745~92669743:- CESC cis rs7005380 0.62 rs10217083 ENSG00000279347.1 RP11-85I17.2 -4.3 2.61e-05 0.0122 -0.25 -0.28 Interstitial lung disease; chr8:119911045 chr8:119838736~119840385:- CESC cis rs2733201 1 rs2733208 ENSG00000275601.1 AC011330.13 -4.3 2.61e-05 0.0122 -0.42 -0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44145494 chr15:43642389~43643023:- CESC cis rs3808502 0.527 rs4410870 ENSG00000255310.2 AF131215.2 -4.3 2.61e-05 0.0122 -0.34 -0.28 Neuroticism; chr8:11298611 chr8:11107788~11109726:- CESC cis rs2439831 1 rs2439850 ENSG00000275601.1 AC011330.13 -4.3 2.61e-05 0.0122 -0.37 -0.28 Lung cancer in ever smokers; chr15:43492656 chr15:43642389~43643023:- CESC cis rs2439831 1 rs2467736 ENSG00000275601.1 AC011330.13 -4.3 2.61e-05 0.0122 -0.37 -0.28 Lung cancer in ever smokers; chr15:43492719 chr15:43642389~43643023:- CESC cis rs2439831 1 rs2444250 ENSG00000275601.1 AC011330.13 -4.3 2.61e-05 0.0122 -0.37 -0.28 Lung cancer in ever smokers; chr15:43492853 chr15:43642389~43643023:- CESC cis rs17507216 0.718 rs7165690 ENSG00000255769.6 GOLGA2P10 -4.3 2.61e-05 0.0122 -0.43 -0.28 Excessive daytime sleepiness; chr15:82654804 chr15:82472993~82513950:- CESC cis rs72627509 0.587 rs17087401 ENSG00000269949.1 RP11-738E22.3 4.3 2.61e-05 0.0122 0.5 0.28 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57034989 chr4:56960927~56961373:- CESC cis rs72627509 0.638 rs12648928 ENSG00000269949.1 RP11-738E22.3 4.3 2.61e-05 0.0122 0.5 0.28 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57036340 chr4:56960927~56961373:- CESC cis rs1012068 0.881 rs5998168 ENSG00000236132.1 CTA-440B3.1 -4.3 2.61e-05 0.0122 -0.33 -0.28 Chronic hepatitis C infection; chr22:31901310 chr22:31816379~31817491:- CESC cis rs35740288 0.929 rs11635081 ENSG00000202081.1 RNU6-1280P 4.3 2.62e-05 0.0122 0.36 0.28 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85761029 chr15:85651522~85651628:- CESC cis rs8031584 0.678 rs798127 ENSG00000260382.1 RP11-540B6.2 -4.3 2.62e-05 0.0122 -0.38 -0.28 Huntington's disease progression; chr15:30825200 chr15:30882267~30883231:- CESC cis rs1387259 0.723 rs2732488 ENSG00000240399.1 RP1-228P16.1 4.3 2.62e-05 0.0122 0.32 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48377661 chr12:48054813~48055591:- CESC cis rs1387259 0.758 rs2634670 ENSG00000240399.1 RP1-228P16.1 4.3 2.62e-05 0.0122 0.32 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48378094 chr12:48054813~48055591:- CESC cis rs5769707 0.933 rs2157444 ENSG00000235111.1 RP1-29C18.8 -4.3 2.62e-05 0.0123 -0.29 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49600644 chr22:49612657~49615716:- CESC cis rs2060793 0.519 rs7931291 ENSG00000251991.1 RNU7-49P -4.3 2.62e-05 0.0123 -0.3 -0.28 Vitamin D levels; chr11:14622880 chr11:14478892~14478953:+ CESC cis rs2179367 0.959 rs9285519 ENSG00000231760.4 RP11-350J20.5 4.3 2.62e-05 0.0123 0.35 0.28 Dupuytren's disease; chr6:149371799 chr6:149796151~149826294:- CESC cis rs8042680 0.544 rs2034085 ENSG00000214432.8 AC068831.10 -4.3 2.63e-05 0.0123 -0.33 -0.28 Type 2 diabetes; chr15:90963222 chr15:91022619~91036611:+ CESC cis rs4319547 0.508 rs10846826 ENSG00000275265.1 RP11-15J22.8 -4.3 2.63e-05 0.0123 -0.39 -0.28 Body mass index; chr12:122410440 chr12:122501187~122501641:+ CESC cis rs4319547 0.661 rs10846830 ENSG00000275265.1 RP11-15J22.8 -4.3 2.63e-05 0.0123 -0.39 -0.28 Body mass index; chr12:122412673 chr12:122501187~122501641:+ CESC cis rs9309473 0.948 rs13392691 ENSG00000163016.8 ALMS1P 4.3 2.63e-05 0.0123 0.39 0.28 Metabolite levels; chr2:73521853 chr2:73644919~73685576:+ CESC cis rs7829975 0.774 rs1039915 ENSG00000253893.2 FAM85B -4.3 2.63e-05 0.0123 -0.34 -0.28 Mood instability; chr8:8822104 chr8:8167819~8226614:- CESC cis rs2408955 0.521 rs11168437 ENSG00000258273.1 RP11-370I10.4 -4.3 2.63e-05 0.0123 -0.32 -0.28 Glycated hemoglobin levels; chr12:48172373 chr12:48333755~48333901:- CESC cis rs2439831 1 rs689826 ENSG00000275601.1 AC011330.13 -4.3 2.63e-05 0.0123 -0.37 -0.28 Lung cancer in ever smokers; chr15:43457718 chr15:43642389~43643023:- CESC cis rs4713118 0.621 rs4713132 ENSG00000219392.1 RP1-265C24.5 -4.29 2.63e-05 0.0123 -0.37 -0.28 Parkinson's disease; chr6:28066257 chr6:28115628~28116551:+ CESC cis rs4713118 0.621 rs4713133 ENSG00000219392.1 RP1-265C24.5 -4.29 2.63e-05 0.0123 -0.37 -0.28 Parkinson's disease; chr6:28066263 chr6:28115628~28116551:+ CESC cis rs4713118 0.621 rs4713134 ENSG00000219392.1 RP1-265C24.5 -4.29 2.63e-05 0.0123 -0.37 -0.28 Parkinson's disease; chr6:28066343 chr6:28115628~28116551:+ CESC cis rs9309473 1 rs7580825 ENSG00000163016.8 ALMS1P 4.29 2.63e-05 0.0123 0.37 0.28 Metabolite levels; chr2:73408020 chr2:73644919~73685576:+ CESC cis rs10754283 0.967 rs1953821 ENSG00000231613.1 RP5-943J3.1 4.29 2.63e-05 0.0123 0.36 0.28 Amyotrophic lateral sclerosis (sporadic); chr1:89641539 chr1:89788914~89790492:+ CESC cis rs9640161 0.75 rs11538922 ENSG00000261305.1 RP4-584D14.7 4.29 2.64e-05 0.0123 0.4 0.28 Blood protein levels;Circulating chemerin levels; chr7:150338094 chr7:150341771~150342607:+ CESC cis rs6782228 1 rs11718130 ENSG00000242551.2 POU5F1P6 4.29 2.64e-05 0.0123 0.38 0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611184 chr3:128674735~128677005:- CESC cis rs748404 0.666 rs12908460 ENSG00000249839.1 AC011330.5 -4.29 2.64e-05 0.0123 -0.4 -0.28 Lung cancer; chr15:43413472 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs2230451 ENSG00000249839.1 AC011330.5 -4.29 2.64e-05 0.0123 -0.4 -0.28 Lung cancer; chr15:43415610 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs62021180 ENSG00000249839.1 AC011330.5 -4.29 2.64e-05 0.0123 -0.4 -0.28 Lung cancer; chr15:43420139 chr15:43663654~43684339:- CESC cis rs2790457 0.958 rs2790454 ENSG00000254635.4 WAC-AS1 -4.29 2.64e-05 0.0123 -0.31 -0.28 Multiple myeloma; chr10:28553103 chr10:28522652~28532743:- CESC cis rs3931020 0.616 rs277380 ENSG00000272864.1 RP11-17E13.2 4.29 2.64e-05 0.0123 0.37 0.28 Resistin levels; chr1:74797404 chr1:74698769~74699333:- CESC cis rs3096299 0.933 rs3114848 ENSG00000274627.1 RP11-104N10.2 4.29 2.64e-05 0.0123 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89386363 chr16:89516797~89522217:+ CESC cis rs2243480 1 rs34703416 ENSG00000232559.3 GS1-124K5.12 4.29 2.64e-05 0.0123 0.45 0.28 Diabetic kidney disease; chr7:65835655 chr7:66554588~66576923:- CESC cis rs2412819 0.571 rs66903736 ENSG00000249839.1 AC011330.5 -4.29 2.64e-05 0.0123 -0.43 -0.28 Lung cancer; chr15:43619435 chr15:43663654~43684339:- CESC cis rs2412819 0.571 rs66749753 ENSG00000249839.1 AC011330.5 -4.29 2.64e-05 0.0123 -0.43 -0.28 Lung cancer; chr15:43619601 chr15:43663654~43684339:- CESC cis rs9640161 0.75 rs3735173 ENSG00000261305.1 RP4-584D14.7 4.29 2.65e-05 0.0123 0.38 0.28 Blood protein levels;Circulating chemerin levels; chr7:150323437 chr7:150341771~150342607:+ CESC cis rs7005380 0.62 rs13260088 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119886525 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10103058 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119890830 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10955941 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119891271 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs13257316 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119891494 chr8:119838736~119840385:- CESC cis rs7005380 0.58 rs12681623 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119891616 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13265367 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119891769 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10107251 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119892108 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10094455 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119892436 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10094458 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119892448 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10094587 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119892560 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13249122 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119893679 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13250594 ENSG00000279347.1 RP11-85I17.2 -4.29 2.65e-05 0.0123 -0.25 -0.28 Interstitial lung disease; chr8:119894151 chr8:119838736~119840385:- CESC cis rs12468226 1 rs112306637 ENSG00000273456.1 RP11-686O6.2 4.29 2.65e-05 0.0123 0.39 0.28 Urate levels; chr2:202334195 chr2:202374932~202375604:- CESC cis rs12468226 1 rs111252524 ENSG00000273456.1 RP11-686O6.2 4.29 2.65e-05 0.0123 0.39 0.28 Urate levels; chr2:202334465 chr2:202374932~202375604:- CESC cis rs12468226 1 rs112753638 ENSG00000273456.1 RP11-686O6.2 4.29 2.65e-05 0.0123 0.39 0.28 Urate levels; chr2:202334496 chr2:202374932~202375604:- CESC cis rs12468226 0.935 rs113188021 ENSG00000273456.1 RP11-686O6.2 4.29 2.65e-05 0.0123 0.39 0.28 Urate levels; chr2:202336237 chr2:202374932~202375604:- CESC cis rs12468226 1 rs6731027 ENSG00000273456.1 RP11-686O6.2 4.29 2.65e-05 0.0123 0.39 0.28 Urate levels; chr2:202337443 chr2:202374932~202375604:- CESC cis rs10129255 0.957 rs6576228 ENSG00000211970.3 IGHV4-61 -4.29 2.65e-05 0.0123 -0.21 -0.28 Kawasaki disease; chr14:106778401 chr14:106639119~106639657:- CESC cis rs73086581 1 rs73086595 ENSG00000229539.1 RP11-119B16.2 4.29 2.65e-05 0.0123 0.43 0.28 Response to antidepressants in depression; chr20:4002801 chr20:3888239~3888868:- CESC cis rs73086581 1 rs73086597 ENSG00000229539.1 RP11-119B16.2 4.29 2.65e-05 0.0123 0.43 0.28 Response to antidepressants in depression; chr20:4002924 chr20:3888239~3888868:- CESC cis rs6782228 0.527 rs2811491 ENSG00000242551.2 POU5F1P6 -4.29 2.65e-05 0.0124 -0.31 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128635107 chr3:128674735~128677005:- CESC cis rs763121 0.626 rs5750643 ENSG00000273076.1 RP3-508I15.22 4.29 2.65e-05 0.0124 0.32 0.28 Menopause (age at onset); chr22:38613012 chr22:38743495~38743910:+ CESC cis rs6782228 1 rs6801509 ENSG00000242551.2 POU5F1P6 4.29 2.66e-05 0.0124 0.35 0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128645426 chr3:128674735~128677005:- CESC cis rs2833693 0.574 rs9653707 ENSG00000261610.1 AP000265.1 4.29 2.66e-05 0.0124 0.34 0.28 Temperament; chr21:32179462 chr21:32259804~32261585:- CESC cis rs7250849 0.79 rs7259861 ENSG00000273837.1 LLNLR-470E3.1 -4.29 2.66e-05 0.0124 -0.45 -0.28 Blood protein levels; chr19:51657490 chr19:51639478~51639931:- CESC cis rs10129255 0.957 rs8005468 ENSG00000211970.3 IGHV4-61 -4.29 2.66e-05 0.0124 -0.21 -0.28 Kawasaki disease; chr14:106686431 chr14:106639119~106639657:- CESC cis rs9309473 0.519 rs13027816 ENSG00000273245.1 RP11-434P11.2 -4.29 2.66e-05 0.0124 -0.36 -0.28 Metabolite levels; chr2:73670564 chr2:73750256~73750786:- CESC cis rs9309473 0.519 rs2421584 ENSG00000273245.1 RP11-434P11.2 -4.29 2.66e-05 0.0124 -0.36 -0.28 Metabolite levels; chr2:73671725 chr2:73750256~73750786:- CESC cis rs9309473 0.519 rs2421586 ENSG00000273245.1 RP11-434P11.2 -4.29 2.66e-05 0.0124 -0.36 -0.28 Metabolite levels; chr2:73672592 chr2:73750256~73750786:- CESC cis rs7191700 0.674 rs12597893 ENSG00000262636.1 CTD-3088G3.4 4.29 2.67e-05 0.0124 0.36 0.28 Multiple sclerosis; chr16:11332474 chr16:11380859~11381118:- CESC cis rs2980439 0.846 rs2980437 ENSG00000253981.4 ALG1L13P -4.29 2.67e-05 0.0124 -0.33 -0.28 Neuroticism; chr8:8237241 chr8:8236003~8244667:- CESC cis rs453301 0.682 rs2929308 ENSG00000254340.1 RP11-10A14.3 -4.29 2.67e-05 0.0124 -0.34 -0.28 Joint mobility (Beighton score); chr8:9226611 chr8:9141424~9145435:+ CESC cis rs11685222 0.589 rs17661193 ENSG00000229326.3 AC069154.4 4.29 2.67e-05 0.0124 0.41 0.28 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119684876 chr2:119698623~119700151:+ CESC cis rs17301013 0.507 rs11799704 ENSG00000227373.4 RP11-160H22.5 4.29 2.67e-05 0.0124 0.38 0.28 Systemic lupus erythematosus; chr1:174413640 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2901817 ENSG00000227373.4 RP11-160H22.5 4.29 2.67e-05 0.0124 0.38 0.28 Systemic lupus erythematosus; chr1:174414479 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6701534 ENSG00000227373.4 RP11-160H22.5 4.29 2.67e-05 0.0124 0.38 0.28 Systemic lupus erythematosus; chr1:174418612 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10798312 ENSG00000227373.4 RP11-160H22.5 4.29 2.67e-05 0.0124 0.38 0.28 Systemic lupus erythematosus; chr1:174419089 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs4652422 ENSG00000227373.4 RP11-160H22.5 4.29 2.67e-05 0.0124 0.38 0.28 Systemic lupus erythematosus; chr1:174419501 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs4233181 ENSG00000227373.4 RP11-160H22.5 4.29 2.67e-05 0.0124 0.38 0.28 Systemic lupus erythematosus; chr1:174419697 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10489258 ENSG00000227373.4 RP11-160H22.5 4.29 2.67e-05 0.0124 0.38 0.28 Systemic lupus erythematosus; chr1:174420447 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10798313 ENSG00000227373.4 RP11-160H22.5 4.29 2.67e-05 0.0124 0.38 0.28 Systemic lupus erythematosus; chr1:174420995 chr1:174115300~174160004:- CESC cis rs9487094 0.67 rs12197838 ENSG00000260273.1 RP11-425D10.10 4.29 2.67e-05 0.0124 0.36 0.28 Height; chr6:109672088 chr6:109382795~109383666:+ CESC cis rs12580194 1 rs60206376 ENSG00000237493.3 RP11-603J24.7 -4.29 2.67e-05 0.0124 -0.39 -0.28 Cancer; chr12:55309591 chr12:55980432~55981035:- CESC cis rs7605378 0.528 rs812760 ENSG00000232732.8 AC073043.1 -4.29 2.67e-05 0.0124 -0.38 -0.28 Osteoporosis; chr2:199859649 chr2:199867396~199911159:- CESC cis rs2361701 0.543 rs59252872 ENSG00000279259.1 RP11-334C17.3 4.29 2.67e-05 0.0124 0.35 0.28 IgG glycosylation; chr17:80097448 chr17:80147250~80148596:+ CESC cis rs875971 0.545 rs11770063 ENSG00000222364.1 RNU6-96P -4.29 2.67e-05 0.0124 -0.38 -0.28 Aortic root size; chr7:66318029 chr7:66395191~66395286:+ CESC cis rs875971 0.545 rs3936065 ENSG00000222364.1 RNU6-96P -4.29 2.67e-05 0.0124 -0.38 -0.28 Aortic root size; chr7:66325577 chr7:66395191~66395286:+ CESC cis rs71403859 0.803 rs7203606 ENSG00000260886.1 TAT-AS1 4.29 2.67e-05 0.0124 0.44 0.28 Post bronchodilator FEV1; chr16:71556608 chr16:71565789~71578187:+ CESC cis rs2276314 0.857 rs16967327 ENSG00000278986.1 RP11-723J4.3 -4.29 2.67e-05 0.0124 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36007073 chr18:35972151~35973916:+ CESC cis rs7937890 0.9 rs7118682 ENSG00000254418.1 RP11-21L19.1 -4.29 2.67e-05 0.0124 -0.3 -0.28 Mitochondrial DNA levels; chr11:14253004 chr11:14262846~14273691:- CESC cis rs875971 1 rs3735148 ENSG00000237310.1 GS1-124K5.4 4.29 2.68e-05 0.0124 0.27 0.28 Aortic root size; chr7:66506022 chr7:66493706~66495474:+ CESC cis rs11096990 0.892 rs11930865 ENSG00000249207.1 RP11-360F5.1 4.29 2.68e-05 0.0124 0.33 0.28 Cognitive function; chr4:39218711 chr4:39112677~39126818:- CESC cis rs11096990 0.892 rs7680520 ENSG00000249207.1 RP11-360F5.1 4.29 2.68e-05 0.0124 0.33 0.28 Cognitive function; chr4:39219013 chr4:39112677~39126818:- CESC cis rs73086581 0.787 rs67633417 ENSG00000229539.1 RP11-119B16.2 4.29 2.68e-05 0.0124 0.49 0.28 Response to antidepressants in depression; chr20:3887610 chr20:3888239~3888868:- CESC cis rs73086581 0.787 rs68127408 ENSG00000229539.1 RP11-119B16.2 4.29 2.68e-05 0.0124 0.49 0.28 Response to antidepressants in depression; chr20:3887800 chr20:3888239~3888868:- CESC cis rs17507216 0.628 rs8028130 ENSG00000276710.3 CSPG4P8 -4.29 2.68e-05 0.0124 -0.38 -0.28 Excessive daytime sleepiness; chr15:82734974 chr15:82459472~82477258:+ CESC cis rs2833693 0.574 rs4143359 ENSG00000261610.1 AP000265.1 4.29 2.68e-05 0.0125 0.34 0.28 Temperament; chr21:32179062 chr21:32259804~32261585:- CESC cis rs526231 0.819 rs26233 ENSG00000175749.11 EIF3KP1 4.29 2.68e-05 0.0125 0.34 0.28 Primary biliary cholangitis; chr5:103261115 chr5:103032376~103033031:+ CESC cis rs526231 0.853 rs376286 ENSG00000175749.11 EIF3KP1 4.29 2.68e-05 0.0125 0.34 0.28 Primary biliary cholangitis; chr5:103263689 chr5:103032376~103033031:+ CESC cis rs4742903 0.868 rs4743684 ENSG00000270332.1 SMC2-AS1 4.29 2.68e-05 0.0125 0.27 0.28 Breast cancer;High-grade serous ovarian cancer; chr9:104090104 chr9:104080024~104093073:- CESC cis rs820077 0.605 rs820101 ENSG00000232909.1 RP3-510O8.4 4.29 2.68e-05 0.0125 0.46 0.28 Systemic lupus erythematosus; chr6:35078771 chr6:35733867~35736947:- CESC cis rs7829975 0.902 rs777707 ENSG00000253893.2 FAM85B -4.29 2.69e-05 0.0125 -0.34 -0.28 Mood instability; chr8:8726834 chr8:8167819~8226614:- CESC cis rs73173548 0.502 rs10505856 ENSG00000247828.6 TMEM161B-AS1 4.29 2.69e-05 0.0125 0.3 0.28 Macular telangiectasia type 2; chr5:88440636 chr5:88268895~88436685:+ CESC cis rs7568498 0.564 rs10490563 ENSG00000227403.1 AC009299.3 4.29 2.69e-05 0.0125 0.41 0.28 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161057657 chr2:161244739~161249050:+ CESC cis rs694739 0.628 rs538147 ENSG00000236935.1 AP003774.1 4.29 2.69e-05 0.0125 0.28 0.28 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64362250 chr11:64325050~64329504:- CESC cis rs6951245 0.744 rs1133122 ENSG00000229043.2 AC091729.9 -4.29 2.69e-05 0.0125 -0.4 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1152936 chr7:1160374~1165267:+ CESC cis rs4927850 1 rs7630875 ENSG00000231464.1 AC024937.4 4.29 2.69e-05 0.0125 0.35 0.28 Pancreatic cancer; chr3:196026895 chr3:195996738~195998233:+ CESC cis rs2408955 0.522 rs4760612 ENSG00000240399.1 RP1-228P16.1 -4.29 2.69e-05 0.0125 -0.31 -0.28 Glycated hemoglobin levels; chr12:48028073 chr12:48054813~48055591:- CESC cis rs6604026 0.624 rs11800409 ENSG00000223787.2 RP4-593M8.1 4.29 2.69e-05 0.0125 0.38 0.28 Multiple sclerosis; chr1:92715456 chr1:92580476~92580821:- CESC cis rs2933343 1 rs1683782 ENSG00000231305.3 RP11-723O4.2 4.29 2.69e-05 0.0125 0.3 0.28 IgG glycosylation; chr3:128921434 chr3:128861313~128871540:- CESC cis rs2933343 1 rs6785869 ENSG00000231305.3 RP11-723O4.2 4.29 2.69e-05 0.0125 0.3 0.28 IgG glycosylation; chr3:128924301 chr3:128861313~128871540:- CESC cis rs2933343 1 rs1683778 ENSG00000231305.3 RP11-723O4.2 4.29 2.69e-05 0.0125 0.3 0.28 IgG glycosylation; chr3:128925752 chr3:128861313~128871540:- CESC cis rs10129255 0.957 rs8009464 ENSG00000211970.3 IGHV4-61 -4.29 2.69e-05 0.0125 -0.21 -0.28 Kawasaki disease; chr14:106777611 chr14:106639119~106639657:- CESC cis rs72772090 0.539 rs56319744 ENSG00000248734.2 CTD-2260A17.1 -4.29 2.7e-05 0.0125 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96806235 chr5:96784777~96785999:+ CESC cis rs4789693 0.938 rs12952655 ENSG00000265458.1 RP13-20L14.6 -4.29 2.7e-05 0.0125 -0.34 -0.28 Glucocorticoid-induced osteonecrosis; chr17:82463263 chr17:82454273~82458521:- CESC cis rs12468226 1 rs16839090 ENSG00000273456.1 RP11-686O6.2 4.29 2.7e-05 0.0125 0.34 0.28 Urate levels; chr2:202348338 chr2:202374932~202375604:- CESC cis rs5742933 1 rs4666783 ENSG00000253559.1 OSGEPL1-AS1 -4.29 2.7e-05 0.0125 -0.39 -0.28 Ferritin levels; chr2:189748254 chr2:189762704~189765556:+ CESC cis rs6693388 0.602 rs2999531 ENSG00000229021.2 AL591893.1 -4.29 2.7e-05 0.0125 -0.31 -0.28 Blood metabolite ratios; chr1:151999021 chr1:151994531~152042774:+ CESC cis rs4319547 0.695 rs10773103 ENSG00000275265.1 RP11-15J22.8 4.29 2.7e-05 0.0125 0.4 0.28 Body mass index; chr12:122371985 chr12:122501187~122501641:+ CESC cis rs4319547 0.656 rs28730465 ENSG00000275265.1 RP11-15J22.8 4.29 2.7e-05 0.0125 0.4 0.28 Body mass index; chr12:122379317 chr12:122501187~122501641:+ CESC cis rs875971 0.862 rs778734 ENSG00000232559.3 GS1-124K5.12 4.29 2.7e-05 0.0125 0.3 0.28 Aortic root size; chr7:66349862 chr7:66554588~66576923:- CESC cis rs7811142 1 rs2406253 ENSG00000078319.8 PMS2P1 -4.29 2.7e-05 0.0125 -0.45 -0.28 Platelet count; chr7:100479650 chr7:100320992~100341908:- CESC cis rs6686842 0.562 rs213769 ENSG00000235358.1 RP11-399E6.1 4.29 2.71e-05 0.0126 0.31 0.28 Height; chr1:41149686 chr1:41242373~41284861:+ CESC cis rs1707322 1 rs12124847 ENSG00000281133.1 AL355480.3 -4.29 2.71e-05 0.0126 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45915178 chr1:45580892~45580996:- CESC cis rs74394007 0.85 rs114788586 ENSG00000244515.1 KRT18P34 4.29 2.71e-05 0.0126 0.51 0.28 Total body bone mineral density; chr3:156879053 chr3:157162663~157163932:- CESC cis rs10129255 0.518 rs10150460 ENSG00000211972.2 IGHV3-66 -4.29 2.71e-05 0.0126 -0.19 -0.28 Kawasaki disease; chr14:106677179 chr14:106675017~106675544:- CESC cis rs950169 0.58 rs11633762 ENSG00000225151.9 GOLGA2P7 -4.29 2.72e-05 0.0126 -0.39 -0.28 Schizophrenia; chr15:84643921 chr15:84199311~84230136:- CESC cis rs11089937 0.626 rs5757011 ENSG00000211638.2 IGLV8-61 -4.29 2.72e-05 0.0126 -0.27 -0.28 Periodontitis (PAL4Q3); chr22:22135336 chr22:22098700~22099212:+ CESC cis rs1510272 0.515 rs6807235 ENSG00000243926.1 TIPARP-AS1 -4.29 2.72e-05 0.0126 -0.36 -0.28 Testicular germ cell tumor; chr3:156623812 chr3:156671862~156674378:- CESC cis rs9322193 0.923 rs2297930 ENSG00000216906.2 RP11-350J20.9 4.29 2.72e-05 0.0126 0.31 0.28 Lung cancer; chr6:149718360 chr6:149904243~149906418:+ CESC cis rs9318086 0.648 rs4067969 ENSG00000205861.10 C1QTNF9B-AS1 -4.29 2.72e-05 0.0126 -0.36 -0.28 Myopia (pathological); chr13:23894981 chr13:23888889~23897263:+ CESC cis rs2276314 0.857 rs8097597 ENSG00000278986.1 RP11-723J4.3 -4.29 2.72e-05 0.0126 -0.3 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36039485 chr18:35972151~35973916:+ CESC cis rs1030877 0.515 rs920217 ENSG00000235319.1 AC012360.4 4.29 2.73e-05 0.0126 0.34 0.28 Obesity-related traits; chr2:105288205 chr2:105324210~105330529:+ CESC cis rs4927850 1 rs7625570 ENSG00000231464.1 AC024937.4 4.29 2.73e-05 0.0126 0.36 0.28 Pancreatic cancer; chr3:196020527 chr3:195996738~195998233:+ CESC cis rs2255336 0.938 rs2617152 ENSG00000245648.1 RP11-277P12.20 4.29 2.73e-05 0.0126 0.4 0.28 Blood protein levels; chr12:10380507 chr12:10363769~10398506:+ CESC cis rs2255336 0.882 rs2733847 ENSG00000245648.1 RP11-277P12.20 4.29 2.73e-05 0.0126 0.4 0.28 Blood protein levels; chr12:10380608 chr12:10363769~10398506:+ CESC cis rs950880 1 rs12479210 ENSG00000234389.1 AC007278.3 -4.29 2.73e-05 0.0126 -0.31 -0.28 Serum protein levels (sST2); chr2:102332701 chr2:102438713~102440475:+ CESC cis rs61160187 0.548 rs68104763 ENSG00000215032.2 GNL3LP1 4.29 2.73e-05 0.0127 0.33 0.28 Educational attainment (years of education);Educational attainment (college completion); chr5:61107016 chr5:60891935~60893577:- CESC cis rs11089937 0.597 rs4145535 ENSG00000211638.2 IGLV8-61 -4.29 2.73e-05 0.0127 -0.26 -0.28 Periodontitis (PAL4Q3); chr22:22143981 chr22:22098700~22099212:+ CESC cis rs2439831 0.85 rs67541383 ENSG00000249839.1 AC011330.5 -4.29 2.73e-05 0.0127 -0.45 -0.28 Lung cancer in ever smokers; chr15:43880350 chr15:43663654~43684339:- CESC cis rs453301 0.653 rs2956244 ENSG00000254340.1 RP11-10A14.3 4.29 2.73e-05 0.0127 0.33 0.28 Joint mobility (Beighton score); chr8:9027656 chr8:9141424~9145435:+ CESC cis rs7688540 0.771 rs10027325 ENSG00000211553.1 AC253576.2 -4.29 2.73e-05 0.0127 -0.42 -0.28 Facial morphology (factor 6, height of vermillion lower lip); chr4:288819 chr4:136461~136568:+ CESC cis rs2439831 0.85 rs16977798 ENSG00000275601.1 AC011330.13 -4.29 2.73e-05 0.0127 -0.44 -0.28 Lung cancer in ever smokers; chr15:43859750 chr15:43642389~43643023:- CESC cis rs9309473 1 rs6546837 ENSG00000163016.8 ALMS1P 4.29 2.74e-05 0.0127 0.35 0.28 Metabolite levels; chr2:73450771 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs6546838 ENSG00000163016.8 ALMS1P 4.29 2.74e-05 0.0127 0.35 0.28 Metabolite levels; chr2:73452153 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs6724782 ENSG00000163016.8 ALMS1P 4.29 2.74e-05 0.0127 0.35 0.28 Metabolite levels; chr2:73452863 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs6546839 ENSG00000163016.8 ALMS1P 4.29 2.74e-05 0.0127 0.35 0.28 Metabolite levels; chr2:73453381 chr2:73644919~73685576:+ CESC cis rs853679 0.517 rs9393896 ENSG00000219392.1 RP1-265C24.5 -4.29 2.74e-05 0.0127 -0.37 -0.28 Depression; chr6:28159925 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393897 ENSG00000219392.1 RP1-265C24.5 -4.29 2.74e-05 0.0127 -0.37 -0.28 Depression; chr6:28159932 chr6:28115628~28116551:+ CESC cis rs8030379 1 rs922664 ENSG00000230373.7 GOLGA6L5P -4.29 2.74e-05 0.0127 -0.27 -0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83900803 chr15:84507885~84516814:- CESC cis rs1862618 0.853 rs1833896 ENSG00000271828.1 CTD-2310F14.1 4.29 2.74e-05 0.0127 0.35 0.28 Initial pursuit acceleration; chr5:56801842 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs1862619 ENSG00000271828.1 CTD-2310F14.1 4.29 2.74e-05 0.0127 0.35 0.28 Initial pursuit acceleration; chr5:56802429 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs1559282 ENSG00000271828.1 CTD-2310F14.1 4.29 2.74e-05 0.0127 0.35 0.28 Initial pursuit acceleration; chr5:56803548 chr5:56927874~56929573:+ CESC cis rs1862618 0.853 rs6450409 ENSG00000271828.1 CTD-2310F14.1 4.29 2.74e-05 0.0127 0.35 0.28 Initial pursuit acceleration; chr5:56805572 chr5:56927874~56929573:+ CESC cis rs9309473 1 rs7558944 ENSG00000163016.8 ALMS1P 4.29 2.74e-05 0.0127 0.37 0.28 Metabolite levels; chr2:73583782 chr2:73644919~73685576:+ CESC cis rs10043775 1 rs7727161 ENSG00000251330.3 CTD-2283N19.1 -4.28 2.75e-05 0.0127 -0.36 -0.28 Periodontal microbiota; chr5:148452923 chr5:148430159~148430807:- CESC cis rs2675662 0.525 rs12264025 ENSG00000242288.9 RP11-464F9.1 4.28 2.75e-05 0.0127 0.31 0.28 Psoriasis vulgaris;Psoriasis; chr10:73734692 chr10:73674295~73730466:- CESC cis rs2688608 0.62 rs12253408 ENSG00000242288.9 RP11-464F9.1 4.28 2.75e-05 0.0127 0.31 0.28 Inflammatory bowel disease; chr10:73736198 chr10:73674295~73730466:- CESC cis rs2688608 0.592 rs12253429 ENSG00000242288.9 RP11-464F9.1 4.28 2.75e-05 0.0127 0.31 0.28 Inflammatory bowel disease; chr10:73736403 chr10:73674295~73730466:- CESC cis rs1707322 1 rs12097761 ENSG00000281133.1 AL355480.3 -4.28 2.75e-05 0.0127 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45825490 chr1:45580892~45580996:- CESC cis rs897984 0.537 rs8045637 ENSG00000260911.2 RP11-196G11.2 4.28 2.75e-05 0.0127 0.28 0.28 Dementia with Lewy bodies; chr16:30807341 chr16:31043150~31049868:+ CESC cis rs2439831 1 rs689754 ENSG00000275601.1 AC011330.13 -4.28 2.75e-05 0.0127 -0.38 -0.28 Lung cancer in ever smokers; chr15:43483697 chr15:43642389~43643023:- CESC cis rs1062177 0.855 rs62395861 ENSG00000253921.1 CTB-113P19.3 -4.28 2.75e-05 0.0127 -0.39 -0.28 Preschool internalizing problems; chr5:151889709 chr5:151753992~151767247:+ CESC cis rs1062177 0.95 rs59580263 ENSG00000253921.1 CTB-113P19.3 -4.28 2.75e-05 0.0127 -0.39 -0.28 Preschool internalizing problems; chr5:151890016 chr5:151753992~151767247:+ CESC cis rs10958369 0.541 rs1477955 ENSG00000253369.1 RP11-1081M5.1 4.28 2.75e-05 0.0127 0.32 0.28 Response to antineoplastic agents; chr8:53522666 chr8:53395211~53395946:- CESC cis rs10958369 0.541 rs1477956 ENSG00000253369.1 RP11-1081M5.1 4.28 2.75e-05 0.0127 0.32 0.28 Response to antineoplastic agents; chr8:53522667 chr8:53395211~53395946:- CESC cis rs948562 0.947 rs60767173 ENSG00000269570.2 CMB9-55A18.1 4.28 2.75e-05 0.0127 0.29 0.28 Lymphoma; chr11:58634074 chr11:58611119~58612642:- CESC cis rs9640161 0.742 rs2159235 ENSG00000261305.1 RP4-584D14.7 4.28 2.75e-05 0.0127 0.39 0.28 Blood protein levels;Circulating chemerin levels; chr7:150320139 chr7:150341771~150342607:+ CESC cis rs950776 0.518 rs952215 ENSG00000279373.1 RP11-650L12.4 -4.28 2.75e-05 0.0128 -0.33 -0.28 Sudden cardiac arrest; chr15:78526811 chr15:78537681~78538946:+ CESC cis rs10954213 0.525 rs11770589 ENSG00000275106.1 RP11-309L24.10 -4.28 2.76e-05 0.0128 -0.36 -0.28 Sjögren's syndrome; chr7:128949434 chr7:128952527~128953316:- CESC cis rs6693388 0.647 rs1038747 ENSG00000229021.2 AL591893.1 4.28 2.76e-05 0.0128 0.32 0.28 Blood metabolite ratios; chr1:151969869 chr1:151994531~152042774:+ CESC cis rs875971 0.862 rs880166 ENSG00000237310.1 GS1-124K5.4 -4.28 2.76e-05 0.0128 -0.26 -0.28 Aortic root size; chr7:66205775 chr7:66493706~66495474:+ CESC cis rs2688608 0.592 rs11000757 ENSG00000242288.9 RP11-464F9.1 4.28 2.76e-05 0.0128 0.31 0.28 Inflammatory bowel disease; chr10:73727057 chr10:73674295~73730466:- CESC cis rs2688608 0.592 rs11814282 ENSG00000242288.9 RP11-464F9.1 4.28 2.76e-05 0.0128 0.31 0.28 Inflammatory bowel disease; chr10:73730459 chr10:73674295~73730466:- CESC cis rs2688608 0.53 rs71507081 ENSG00000242288.9 RP11-464F9.1 4.28 2.76e-05 0.0128 0.31 0.28 Inflammatory bowel disease; chr10:73733378 chr10:73674295~73730466:- CESC cis rs7208859 0.614 rs4794874 ENSG00000263531.1 RP13-753N3.1 -4.28 2.76e-05 0.0128 -0.58 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30514300 chr17:30863921~30864940:- CESC cis rs2933343 0.621 rs728838 ENSG00000231305.3 RP11-723O4.2 4.28 2.76e-05 0.0128 0.25 0.28 IgG glycosylation; chr3:128870170 chr3:128861313~128871540:- CESC cis rs7587476 0.784 rs13008641 ENSG00000229267.2 AC072062.1 -4.28 2.76e-05 0.0128 -0.36 -0.28 Neuroblastoma; chr2:214833309 chr2:214810229~214963274:+ CESC cis rs7587476 0.784 rs13032278 ENSG00000229267.2 AC072062.1 -4.28 2.76e-05 0.0128 -0.36 -0.28 Neuroblastoma; chr2:214833310 chr2:214810229~214963274:+ CESC cis rs2243480 1 rs34136756 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65916269 chr7:66554588~66576923:- CESC cis rs2243480 1 rs34933526 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65918212 chr7:66554588~66576923:- CESC cis rs2243480 1 rs6970243 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65923503 chr7:66554588~66576923:- CESC cis rs2243480 0.708 rs35310401 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65925372 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35058610 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65925938 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs35087093 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65940221 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35046236 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65943626 chr7:66554588~66576923:- CESC cis rs2243480 1 rs36068983 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65944004 chr7:66554588~66576923:- CESC cis rs2243480 1 rs68189316 ENSG00000232559.3 GS1-124K5.12 4.28 2.77e-05 0.0128 0.46 0.28 Diabetic kidney disease; chr7:65944182 chr7:66554588~66576923:- CESC cis rs2243480 0.831 rs7806717 ENSG00000232559.3 GS1-124K5.12 -4.28 2.77e-05 0.0128 -0.46 -0.28 Diabetic kidney disease; chr7:65928187 chr7:66554588~66576923:- CESC cis rs519973 0.545 rs524873 ENSG00000279891.1 FLJ42393 -4.28 2.77e-05 0.0128 -0.32 -0.28 Allergic disease (asthma, hay fever or eczema); chr3:187954036 chr3:188178543~188180812:+ CESC cis rs2337406 0.866 rs2027901 ENSG00000274576.2 IGHV2-70 -4.28 2.77e-05 0.0128 -0.37 -0.28 Alzheimer's disease (late onset); chr14:106807164 chr14:106770577~106771020:- CESC cis rs11214589 0.747 rs11214577 ENSG00000270179.1 RP11-159N11.4 4.28 2.77e-05 0.0128 0.31 0.28 Neuroticism; chr11:113333544 chr11:113368478~113369117:+ CESC cis rs11976180 1 rs13243677 ENSG00000273234.1 OR2A13P -4.28 2.77e-05 0.0128 -0.33 -0.28 Obesity-related traits; chr7:144049479 chr7:144142009~144142938:+ CESC cis rs12439619 0.693 rs28689861 ENSG00000276710.3 CSPG4P8 -4.28 2.77e-05 0.0128 -0.35 -0.28 Intelligence (multi-trait analysis); chr15:82206369 chr15:82459472~82477258:+ CESC cis rs6964587 1 rs9785013 ENSG00000188693.7 CYP51A1-AS1 -4.28 2.77e-05 0.0128 -0.3 -0.28 Breast cancer; chr7:92044988 chr7:92134604~92180725:+ CESC cis rs35740288 1 rs11637212 ENSG00000202081.1 RNU6-1280P -4.28 2.77e-05 0.0128 -0.35 -0.28 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85749866 chr15:85651522~85651628:- CESC cis rs2439831 1 rs2467739 ENSG00000275601.1 AC011330.13 -4.28 2.78e-05 0.0128 -0.36 -0.28 Lung cancer in ever smokers; chr15:43447998 chr15:43642389~43643023:- CESC cis rs2439831 1 rs28666488 ENSG00000275601.1 AC011330.13 -4.28 2.78e-05 0.0128 -0.36 -0.28 Lung cancer in ever smokers; chr15:43448892 chr15:43642389~43643023:- CESC cis rs2439831 1 rs2245790 ENSG00000275601.1 AC011330.13 -4.28 2.78e-05 0.0128 -0.36 -0.28 Lung cancer in ever smokers; chr15:43452259 chr15:43642389~43643023:- CESC cis rs440932 0.565 rs19334 ENSG00000254340.1 RP11-10A14.3 4.28 2.78e-05 0.0128 0.34 0.28 High light scatter reticulocyte percentage of red cells; chr8:9152396 chr8:9141424~9145435:+ CESC cis rs875971 0.895 rs4145009 ENSG00000237310.1 GS1-124K5.4 -4.28 2.78e-05 0.0128 -0.26 -0.28 Aortic root size; chr7:66261628 chr7:66493706~66495474:+ CESC cis rs2836950 0.501 rs2836984 ENSG00000232608.1 TIMM9P2 4.28 2.78e-05 0.0129 0.31 0.28 Menarche (age at onset); chr21:39329023 chr21:39216624~39217506:+ CESC cis rs453301 0.686 rs6748 ENSG00000173295.6 FAM86B3P -4.28 2.78e-05 0.0129 -0.36 -0.28 Joint mobility (Beighton score); chr8:9033292 chr8:8228595~8244865:+ CESC cis rs1707322 1 rs7547189 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853842 chr1:45580892~45580996:- CESC cis rs1707322 1 rs7547284 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853893 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211205 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45856202 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4660895 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45864067 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4660318 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45869204 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10890360 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45872772 chr1:45580892~45580996:- CESC cis rs1707322 1 rs6682683 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45876665 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211217 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45882557 chr1:45580892~45580996:- CESC cis rs1707322 1 rs7553924 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45886952 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4641257 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45887917 chr1:45580892~45580996:- CESC cis rs1707322 1 rs6693336 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45888923 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4539075 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45892338 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211219 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893806 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211222 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45902085 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4524994 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45904591 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs9787412 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45905924 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4660896 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45906744 chr1:45580892~45580996:- CESC cis rs1707322 0.928 rs10732844 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45907016 chr1:45580892~45580996:- CESC cis rs1707322 1 rs12133129 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45907676 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs4553121 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45909581 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs6690652 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45911020 chr1:45580892~45580996:- CESC cis rs1707322 1 rs6695421 ENSG00000281133.1 AL355480.3 -4.28 2.78e-05 0.0129 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45914535 chr1:45580892~45580996:- CESC cis rs7581030 0.55 rs34913732 ENSG00000281195.1 ZNF638-IT1 -4.28 2.78e-05 0.0129 -0.42 -0.28 Testicular germ cell tumor; chr2:71214033 chr2:71373938~71376320:+ CESC cis rs875971 0.528 rs801213 ENSG00000226824.5 RP4-756H11.3 4.28 2.78e-05 0.0129 0.39 0.28 Aortic root size; chr7:66549931 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs801212 ENSG00000226824.5 RP4-756H11.3 4.28 2.78e-05 0.0129 0.39 0.28 Aortic root size; chr7:66550643 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs801199 ENSG00000226824.5 RP4-756H11.3 4.28 2.78e-05 0.0129 0.39 0.28 Aortic root size; chr7:66560286 chr7:66654538~66669855:+ CESC cis rs875971 0.545 rs1267814 ENSG00000226824.5 RP4-756H11.3 4.28 2.78e-05 0.0129 0.39 0.28 Aortic root size; chr7:66579422 chr7:66654538~66669855:+ CESC cis rs748404 1 rs66651343 ENSG00000249839.1 AC011330.5 -4.28 2.79e-05 0.0129 -0.37 -0.28 Lung cancer; chr15:43265806 chr15:43663654~43684339:- CESC cis rs17772222 0.958 rs76559451 ENSG00000258983.2 RP11-507K2.2 4.28 2.79e-05 0.0129 0.35 0.28 Coronary artery calcification; chr14:88523193 chr14:88499334~88515502:+ CESC cis rs17772222 0.958 rs1123421 ENSG00000258983.2 RP11-507K2.2 4.28 2.79e-05 0.0129 0.35 0.28 Coronary artery calcification; chr14:88524651 chr14:88499334~88515502:+ CESC cis rs17772222 0.958 rs12436326 ENSG00000258983.2 RP11-507K2.2 4.28 2.79e-05 0.0129 0.35 0.28 Coronary artery calcification; chr14:88533632 chr14:88499334~88515502:+ CESC cis rs17772222 0.958 rs17203789 ENSG00000258983.2 RP11-507K2.2 4.28 2.79e-05 0.0129 0.35 0.28 Coronary artery calcification; chr14:88541362 chr14:88499334~88515502:+ CESC cis rs9322193 0.923 rs4870267 ENSG00000216906.2 RP11-350J20.9 4.28 2.79e-05 0.0129 0.31 0.28 Lung cancer; chr6:149671572 chr6:149904243~149906418:+ CESC cis rs8005677 1 rs11157930 ENSG00000279656.1 RP11-298I3.6 4.28 2.79e-05 0.0129 0.35 0.28 Cognitive ability (multi-trait analysis); chr14:22933962 chr14:23023083~23024217:- CESC cis rs8005677 0.962 rs11157931 ENSG00000279656.1 RP11-298I3.6 4.28 2.79e-05 0.0129 0.35 0.28 Cognitive ability (multi-trait analysis); chr14:22933984 chr14:23023083~23024217:- CESC cis rs3738443 1 rs61839991 ENSG00000259865.1 RP11-488L18.10 4.28 2.8e-05 0.0129 0.33 0.28 Alcohol dependence; chr1:247186284 chr1:247187281~247188526:- CESC cis rs2019137 0.539 rs4849177 ENSG00000274877.1 RP11-65I12.1 -4.28 2.8e-05 0.0129 -0.36 -0.28 Lymphocyte counts; chr2:113225007 chr2:113237595~113240825:+ CESC cis rs761746 0.705 rs10154390 ENSG00000236132.1 CTA-440B3.1 -4.28 2.8e-05 0.0129 -0.35 -0.28 Intelligence; chr22:31655103 chr22:31816379~31817491:- CESC cis rs79349575 0.716 rs46522 ENSG00000270781.1 RP11-501C14.9 -4.28 2.8e-05 0.0129 -0.33 -0.28 Type 2 diabetes; chr17:48911235 chr17:48899131~48899748:+ CESC cis rs2361701 0.929 rs1561810 ENSG00000279259.1 RP11-334C17.3 4.28 2.8e-05 0.0129 0.37 0.28 IgG glycosylation; chr17:80095525 chr17:80147250~80148596:+ CESC cis rs2439831 1 rs2467740 ENSG00000275601.1 AC011330.13 -4.28 2.8e-05 0.0129 -0.36 -0.28 Lung cancer in ever smokers; chr15:43454594 chr15:43642389~43643023:- CESC cis rs3096299 0.935 rs3102387 ENSG00000274627.1 RP11-104N10.2 4.28 2.8e-05 0.0129 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89365868 chr16:89516797~89522217:+ CESC cis rs2277027 1 rs11134789 ENSG00000251405.2 CTB-109A12.1 4.28 2.8e-05 0.0129 0.36 0.28 Pulmonary function;Pulmonary function (smoking interaction); chr5:157517191 chr5:157362615~157460078:- CESC cis rs11779988 0.545 rs415840 ENSG00000253671.1 RP11-806O11.1 -4.28 2.8e-05 0.0129 -0.34 -0.28 Breast cancer; chr8:17924625 chr8:17808941~17820868:+ CESC cis rs6964587 0.872 rs57969083 ENSG00000188693.7 CYP51A1-AS1 -4.28 2.8e-05 0.0129 -0.3 -0.28 Breast cancer; chr7:92036313 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs7789492 ENSG00000188693.7 CYP51A1-AS1 -4.28 2.8e-05 0.0129 -0.3 -0.28 Breast cancer; chr7:92039540 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs926192 ENSG00000188693.7 CYP51A1-AS1 -4.28 2.8e-05 0.0129 -0.3 -0.28 Breast cancer; chr7:92042539 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs6950470 ENSG00000188693.7 CYP51A1-AS1 -4.28 2.8e-05 0.0129 -0.3 -0.28 Breast cancer; chr7:92051327 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs7791138 ENSG00000188693.7 CYP51A1-AS1 -4.28 2.8e-05 0.0129 -0.3 -0.28 Breast cancer; chr7:92057475 chr7:92134604~92180725:+ CESC cis rs875971 0.862 rs4236208 ENSG00000232559.3 GS1-124K5.12 -4.28 2.8e-05 0.0129 -0.3 -0.28 Aortic root size; chr7:66284091 chr7:66554588~66576923:- CESC cis rs17301013 0.507 rs10798310 ENSG00000227373.4 RP11-160H22.5 4.28 2.8e-05 0.0129 0.37 0.28 Systemic lupus erythematosus; chr1:174408581 chr1:174115300~174160004:- CESC cis rs2404602 0.618 rs12442266 ENSG00000280730.1 AC090181.1 4.28 2.81e-05 0.0129 0.21 0.28 Blood metabolite levels; chr15:76274801 chr15:77056895~77057021:+ CESC cis rs3806843 0.576 rs155361 ENSG00000202111.1 VTRNA1-2 -4.28 2.81e-05 0.0129 -0.28 -0.28 Depressive symptoms (multi-trait analysis); chr5:140927699 chr5:140718925~140719013:+ CESC cis rs2276314 0.857 rs9304155 ENSG00000278986.1 RP11-723J4.3 -4.28 2.81e-05 0.0129 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36005747 chr18:35972151~35973916:+ CESC cis rs10129255 0.701 rs2005643 ENSG00000211970.3 IGHV4-61 -4.28 2.81e-05 0.0129 -0.21 -0.28 Kawasaki disease; chr14:106676288 chr14:106639119~106639657:- CESC cis rs1891275 0.509 rs34190234 ENSG00000228701.1 TNKS2-AS1 -4.28 2.81e-05 0.013 -0.33 -0.28 Intelligence (multi-trait analysis); chr10:91683317 chr10:91782839~91798291:- CESC cis rs1891275 0.509 rs76313529 ENSG00000228701.1 TNKS2-AS1 -4.28 2.81e-05 0.013 -0.33 -0.28 Intelligence (multi-trait analysis); chr10:91683319 chr10:91782839~91798291:- CESC cis rs4974559 0.947 rs6847321 ENSG00000253399.1 AC078852.2 4.28 2.81e-05 0.013 0.43 0.28 Systolic blood pressure; chr4:1353586 chr4:1358479~1359461:+ CESC cis rs17711722 0.727 rs35850374 ENSG00000222364.1 RNU6-96P -4.28 2.81e-05 0.013 -0.34 -0.28 Calcium levels; chr7:65892789 chr7:66395191~66395286:+ CESC cis rs7429990 0.93 rs7374516 ENSG00000229759.1 MRPS18AP1 4.28 2.82e-05 0.013 0.29 0.28 Educational attainment (years of education); chr3:47961150 chr3:48256350~48256938:- CESC cis rs2564921 0.704 rs62255931 ENSG00000242142.1 SERBP1P3 -4.28 2.82e-05 0.013 -0.34 -0.28 Height; chr3:53097932 chr3:53064283~53065091:- CESC cis rs1799949 0.965 rs9897425 ENSG00000267681.1 CTD-3199J23.6 -4.28 2.82e-05 0.013 -0.34 -0.28 Menopause (age at onset); chr17:43352811 chr17:43144956~43145255:+ CESC cis rs7789940 1 rs2072435 ENSG00000230305.2 AC004980.9 4.28 2.82e-05 0.013 0.39 0.28 Multiple sclerosis; chr7:76329871 chr7:76524515~76532692:+ CESC cis rs7789940 0.904 rs6948661 ENSG00000230305.2 AC004980.9 4.28 2.82e-05 0.013 0.39 0.28 Multiple sclerosis; chr7:76332330 chr7:76524515~76532692:+ CESC cis rs7789940 0.951 rs7779014 ENSG00000230305.2 AC004980.9 4.28 2.82e-05 0.013 0.39 0.28 Multiple sclerosis; chr7:76346269 chr7:76524515~76532692:+ CESC cis rs7789940 1 rs17149161 ENSG00000230305.2 AC004980.9 4.28 2.82e-05 0.013 0.39 0.28 Multiple sclerosis; chr7:76348912 chr7:76524515~76532692:+ CESC cis rs35160687 0.722 rs6728029 ENSG00000273080.1 RP11-301O19.1 -4.28 2.82e-05 0.013 -0.3 -0.28 Night sleep phenotypes; chr2:86328258 chr2:86195590~86196049:+ CESC cis rs17772222 0.917 rs11159868 ENSG00000258983.2 RP11-507K2.2 4.28 2.82e-05 0.013 0.35 0.28 Coronary artery calcification; chr14:88760528 chr14:88499334~88515502:+ CESC cis rs73086581 1 rs34640283 ENSG00000229539.1 RP11-119B16.2 4.28 2.82e-05 0.013 0.43 0.28 Response to antidepressants in depression; chr20:4008929 chr20:3888239~3888868:- CESC cis rs7809950 1 rs7778270 ENSG00000238832.1 snoU109 4.28 2.82e-05 0.013 0.34 0.28 Coronary artery disease; chr7:107584222 chr7:107603363~107603507:+ CESC cis rs150992 0.504 rs7723242 ENSG00000248489.1 CTD-2007H13.3 -4.28 2.83e-05 0.013 -0.39 -0.28 Body mass index; chr5:99023408 chr5:98929171~98995013:+ CESC cis rs7789940 1 rs76024966 ENSG00000230305.2 AC004980.9 4.28 2.83e-05 0.013 0.4 0.28 Multiple sclerosis; chr7:76365704 chr7:76524515~76532692:+ CESC cis rs7580658 0.724 rs6712551 ENSG00000236682.1 AC068282.3 -4.28 2.83e-05 0.013 -0.34 -0.28 Protein C levels; chr2:127240909 chr2:127389130~127400580:+ CESC cis rs916888 0.773 rs199447 ENSG00000232300.1 FAM215B 4.28 2.83e-05 0.0131 0.45 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46558830~46562795:- CESC cis rs1862618 0.802 rs7733041 ENSG00000271828.1 CTD-2310F14.1 4.28 2.84e-05 0.0131 0.36 0.28 Initial pursuit acceleration; chr5:56811550 chr5:56927874~56929573:+ CESC cis rs7572733 0.84 rs700655 ENSG00000222017.1 AC011997.1 4.28 2.84e-05 0.0131 0.32 0.28 Dermatomyositis; chr2:197778907 chr2:197693106~197774823:+ CESC cis rs6951245 0.744 rs10265736 ENSG00000229043.2 AC091729.9 -4.28 2.84e-05 0.0131 -0.39 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1132829 chr7:1160374~1165267:+ CESC cis rs1020064 0.636 rs2576750 ENSG00000235319.1 AC012360.4 -4.28 2.84e-05 0.0131 -0.33 -0.28 AIDS; chr2:105300178 chr2:105324210~105330529:+ CESC cis rs2019137 0.539 rs11123170 ENSG00000274877.1 RP11-65I12.1 -4.28 2.84e-05 0.0131 -0.37 -0.28 Lymphocyte counts; chr2:113221363 chr2:113237595~113240825:+ CESC cis rs875971 1 rs12532998 ENSG00000237310.1 GS1-124K5.4 4.28 2.84e-05 0.0131 0.27 0.28 Aortic root size; chr7:66502472 chr7:66493706~66495474:+ CESC cis rs9322193 0.923 rs9767105 ENSG00000216906.2 RP11-350J20.9 4.28 2.84e-05 0.0131 0.31 0.28 Lung cancer; chr6:149659591 chr6:149904243~149906418:+ CESC cis rs2243480 0.901 rs2900904 ENSG00000275400.1 RP4-756H11.5 4.28 2.84e-05 0.0131 0.48 0.28 Diabetic kidney disease; chr7:65739282 chr7:66553805~66554199:- CESC cis rs10844706 0.699 rs11052717 ENSG00000256594.6 RP11-705C15.2 4.28 2.84e-05 0.0131 0.33 0.28 Lymphocyte counts;Lymphocyte percentage of white cells; chr12:9726217 chr12:9633419~9658412:+ CESC cis rs860295 0.702 rs34620961 ENSG00000225855.5 RUSC1-AS1 4.28 2.84e-05 0.0131 0.24 0.28 Body mass index; chr1:155680036 chr1:155316863~155324176:- CESC cis rs2439831 1 rs2254321 ENSG00000275601.1 AC011330.13 -4.28 2.85e-05 0.0131 -0.36 -0.28 Lung cancer in ever smokers; chr15:43415344 chr15:43642389~43643023:- CESC cis rs875971 0.545 rs11767262 ENSG00000226824.5 RP4-756H11.3 -4.28 2.85e-05 0.0131 -0.38 -0.28 Aortic root size; chr7:66302237 chr7:66654538~66669855:+ CESC cis rs2337406 1 rs79452530 ENSG00000211974.3 IGHV2-70 -4.28 2.85e-05 0.0131 -0.41 -0.28 Alzheimer's disease (late onset); chr14:106699992 chr14:106723574~106724093:- CESC cis rs13108904 0.935 rs2293633 ENSG00000254094.1 AC078852.1 -4.28 2.85e-05 0.0131 -0.33 -0.28 Obesity-related traits; chr4:1297852 chr4:1356581~1358075:+ CESC cis rs6504622 0.545 rs10853087 ENSG00000263142.4 LRRC37A17P -4.28 2.85e-05 0.0131 -0.21 -0.28 Orofacial clefts; chr17:46928746 chr17:46978481~47054569:+ CESC cis rs7259376 0.525 rs1230300 ENSG00000213971.6 RP11-15H20.6 4.28 2.85e-05 0.0131 0.32 0.28 Menopause (age at onset); chr19:22456547 chr19:23259906~23274251:- CESC cis rs10958369 0.613 rs7812717 ENSG00000253369.1 RP11-1081M5.1 4.28 2.85e-05 0.0131 0.32 0.28 Response to antineoplastic agents; chr8:53521362 chr8:53395211~53395946:- CESC cis rs10958369 0.613 rs1477957 ENSG00000253369.1 RP11-1081M5.1 4.28 2.85e-05 0.0131 0.32 0.28 Response to antineoplastic agents; chr8:53522873 chr8:53395211~53395946:- CESC cis rs72627509 0.629 rs1277313 ENSG00000269949.1 RP11-738E22.3 -4.28 2.85e-05 0.0131 -0.38 -0.28 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57037782 chr4:56960927~56961373:- CESC cis rs7572733 0.534 rs1464211 ENSG00000222017.1 AC011997.1 4.28 2.85e-05 0.0131 0.35 0.28 Dermatomyositis; chr2:197933906 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1607375 ENSG00000222017.1 AC011997.1 4.28 2.85e-05 0.0131 0.35 0.28 Dermatomyositis; chr2:197935663 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs4369854 ENSG00000222017.1 AC011997.1 4.28 2.85e-05 0.0131 0.35 0.28 Dermatomyositis; chr2:197935906 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1983359 ENSG00000222017.1 AC011997.1 4.28 2.85e-05 0.0131 0.35 0.28 Dermatomyositis; chr2:197940374 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs11887138 ENSG00000222017.1 AC011997.1 4.28 2.85e-05 0.0131 0.35 0.28 Dermatomyositis; chr2:197941114 chr2:197693106~197774823:+ CESC cis rs763121 0.853 rs6001175 ENSG00000273076.1 RP3-508I15.22 4.28 2.85e-05 0.0131 0.32 0.28 Menopause (age at onset); chr22:38622329 chr22:38743495~38743910:+ CESC cis rs116175783 0.557 rs2042487 ENSG00000227403.1 AC009299.3 4.28 2.85e-05 0.0131 0.49 0.28 Intelligence (multi-trait analysis); chr2:161293734 chr2:161244739~161249050:+ CESC cis rs2439831 0.681 rs999047 ENSG00000275601.1 AC011330.13 -4.28 2.85e-05 0.0131 -0.36 -0.28 Lung cancer in ever smokers; chr15:43396718 chr15:43642389~43643023:- CESC cis rs2439831 0.681 rs2444036 ENSG00000275601.1 AC011330.13 -4.28 2.85e-05 0.0131 -0.36 -0.28 Lung cancer in ever smokers; chr15:43401910 chr15:43642389~43643023:- CESC cis rs79243044 0.965 rs12417988 ENSG00000224295.2 AC087380.14 -4.28 2.85e-05 0.0131 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5538481 chr11:5518441~5524955:- CESC cis rs3806843 0.576 rs155359 ENSG00000202111.1 VTRNA1-2 -4.28 2.86e-05 0.0131 -0.28 -0.28 Depressive symptoms (multi-trait analysis); chr5:140935840 chr5:140718925~140719013:+ CESC cis rs8031584 0.918 rs61997138 ENSG00000260382.1 RP11-540B6.2 4.27 2.86e-05 0.0132 0.39 0.28 Huntington's disease progression; chr15:30978573 chr15:30882267~30883231:- CESC cis rs8031584 0.918 rs61997140 ENSG00000260382.1 RP11-540B6.2 4.27 2.86e-05 0.0132 0.39 0.28 Huntington's disease progression; chr15:30985109 chr15:30882267~30883231:- CESC cis rs490608 0.628 rs678157 ENSG00000225855.5 RUSC1-AS1 4.27 2.86e-05 0.0132 0.24 0.28 Inflammatory bowel disease; chr1:155688550 chr1:155316863~155324176:- CESC cis rs6782228 1 rs7429360 ENSG00000242551.2 POU5F1P6 4.27 2.86e-05 0.0132 0.34 0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128645954 chr3:128674735~128677005:- CESC cis rs992157 0.56 rs6436047 ENSG00000261338.2 RP11-378A13.1 4.27 2.86e-05 0.0132 0.36 0.28 Colorectal cancer; chr2:218244190 chr2:218255319~218257366:+ CESC cis rs7580658 0.534 rs2089109 ENSG00000236682.1 AC068282.3 -4.27 2.87e-05 0.0132 -0.33 -0.28 Protein C levels; chr2:127193882 chr2:127389130~127400580:+ CESC cis rs8177876 0.822 rs16954582 ENSG00000261838.4 RP11-303E16.6 4.27 2.87e-05 0.0132 0.56 0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080552 chr16:81069854~81076598:+ CESC cis rs8031584 0.958 rs3512 ENSG00000260382.1 RP11-540B6.2 4.27 2.87e-05 0.0132 0.39 0.28 Huntington's disease progression; chr15:30942802 chr15:30882267~30883231:- CESC cis rs7809950 1 rs10243340 ENSG00000238832.1 snoU109 -4.27 2.87e-05 0.0132 -0.34 -0.28 Coronary artery disease; chr7:107450510 chr7:107603363~107603507:+ CESC cis rs1387259 0.929 rs11168460 ENSG00000240399.1 RP1-228P16.1 4.27 2.87e-05 0.0132 0.33 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48203582 chr12:48054813~48055591:- CESC cis rs2732480 0.5 rs7297824 ENSG00000240399.1 RP1-228P16.1 4.27 2.87e-05 0.0132 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48204867 chr12:48054813~48055591:- CESC cis rs2732480 0.5 rs7315820 ENSG00000240399.1 RP1-228P16.1 4.27 2.87e-05 0.0132 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48205155 chr12:48054813~48055591:- CESC cis rs2732480 0.5 rs11168464 ENSG00000240399.1 RP1-228P16.1 4.27 2.87e-05 0.0132 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48208332 chr12:48054813~48055591:- CESC cis rs1387259 0.899 rs7307566 ENSG00000240399.1 RP1-228P16.1 4.27 2.87e-05 0.0132 0.33 0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48210899 chr12:48054813~48055591:- CESC cis rs2243480 1 rs12698509 ENSG00000228409.4 CCT6P1 4.27 2.87e-05 0.0132 0.39 0.28 Diabetic kidney disease; chr7:65953889 chr7:65751142~65763354:+ CESC cis rs9309473 0.519 rs4852950 ENSG00000273245.1 RP11-434P11.2 -4.27 2.87e-05 0.0132 -0.35 -0.28 Metabolite levels; chr2:73637543 chr2:73750256~73750786:- CESC cis rs1538970 1 rs11211101 ENSG00000280836.1 AL355480.1 -4.27 2.87e-05 0.0132 -0.33 -0.28 Platelet count; chr1:45383639 chr1:45581219~45581321:- CESC cis rs8072100 0.967 rs4239162 ENSG00000228782.6 CTD-2026D20.3 4.27 2.87e-05 0.0132 0.32 0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47678444 chr17:47450568~47492492:- CESC cis rs8072100 0.967 rs4239163 ENSG00000228782.6 CTD-2026D20.3 4.27 2.87e-05 0.0132 0.32 0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47678588 chr17:47450568~47492492:- CESC cis rs7829975 0.572 rs28446104 ENSG00000254340.1 RP11-10A14.3 -4.27 2.87e-05 0.0132 -0.35 -0.28 Mood instability; chr8:8938391 chr8:9141424~9145435:+ CESC cis rs2019137 0.56 rs10206269 ENSG00000274877.1 RP11-65I12.1 -4.27 2.87e-05 0.0132 -0.37 -0.28 Lymphocyte counts; chr2:113232816 chr2:113237595~113240825:+ CESC cis rs875971 0.545 rs6970498 ENSG00000226824.5 RP4-756H11.3 -4.27 2.87e-05 0.0132 -0.4 -0.28 Aortic root size; chr7:66275908 chr7:66654538~66669855:+ CESC cis rs11089937 1 rs6001121 ENSG00000211639.2 IGLV4-60 4.27 2.88e-05 0.0132 0.24 0.28 Periodontitis (PAL4Q3); chr22:22149505 chr22:22162199~22162681:+ CESC cis rs9487094 0.67 rs13220915 ENSG00000260273.1 RP11-425D10.10 4.27 2.88e-05 0.0132 0.35 0.28 Height; chr6:109503623 chr6:109382795~109383666:+ CESC cis rs763121 0.853 rs5750627 ENSG00000273076.1 RP3-508I15.22 4.27 2.88e-05 0.0132 0.32 0.28 Menopause (age at onset); chr22:38586316 chr22:38743495~38743910:+ CESC cis rs9322193 0.923 rs9688861 ENSG00000216906.2 RP11-350J20.9 4.27 2.88e-05 0.0132 0.3 0.28 Lung cancer; chr6:149637924 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs7740278 ENSG00000216906.2 RP11-350J20.9 4.27 2.88e-05 0.0132 0.3 0.28 Lung cancer; chr6:149640116 chr6:149904243~149906418:+ CESC cis rs6782228 0.606 rs2811490 ENSG00000242551.2 POU5F1P6 -4.27 2.88e-05 0.0132 -0.31 -0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128632912 chr3:128674735~128677005:- CESC cis rs2733201 1 rs2623019 ENSG00000259479.5 SORD2P -4.27 2.88e-05 0.0132 -0.41 -0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44107430 chr15:44826371~44884694:- CESC cis rs875971 0.928 rs2036263 ENSG00000232559.3 GS1-124K5.12 -4.27 2.88e-05 0.0132 -0.3 -0.28 Aortic root size; chr7:66335210 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10240949 ENSG00000232559.3 GS1-124K5.12 -4.27 2.88e-05 0.0132 -0.3 -0.28 Aortic root size; chr7:66339430 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs7782704 ENSG00000232559.3 GS1-124K5.12 -4.27 2.88e-05 0.0132 -0.3 -0.28 Aortic root size; chr7:66340379 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs6959268 ENSG00000232559.3 GS1-124K5.12 -4.27 2.88e-05 0.0132 -0.3 -0.28 Aortic root size; chr7:66347979 chr7:66554588~66576923:- CESC cis rs57502260 0.704 rs72936599 ENSG00000212093.1 AP000807.1 4.27 2.88e-05 0.0132 0.45 0.28 Total body bone mineral density (age 45-60); chr11:68552937 chr11:68506083~68506166:- CESC cis rs11638352 0.661 rs2555382 ENSG00000275601.1 AC011330.13 -4.27 2.88e-05 0.0132 -0.41 -0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44132118 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2615269 ENSG00000275601.1 AC011330.13 -4.27 2.88e-05 0.0132 -0.41 -0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44135758 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2114422 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44128046 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2555384 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44128702 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2706490 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44130040 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2706491 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44131631 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2706492 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44131648 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2042738 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44134355 chr15:43642389~43643023:- CESC cis rs11638352 1 rs1820485 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44138134 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs2114415 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44140696 chr15:43642389~43643023:- CESC cis rs11638352 0.661 rs1426657 ENSG00000275601.1 AC011330.13 4.27 2.88e-05 0.0132 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44142331 chr15:43642389~43643023:- CESC cis rs10829156 0.898 rs7095666 ENSG00000240291.1 RP11-499P20.2 -4.27 2.88e-05 0.0132 -0.29 -0.28 Sudden cardiac arrest; chr10:18650538 chr10:18513115~18545651:- CESC cis rs916888 0.821 rs415430 ENSG00000232300.1 FAM215B -4.27 2.88e-05 0.0132 -0.44 -0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:46558830~46562795:- CESC cis rs916888 0.779 rs430685 ENSG00000232300.1 FAM215B -4.27 2.88e-05 0.0132 -0.44 -0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:46558830~46562795:- CESC cis rs2439831 0.85 rs524417 ENSG00000205771.5 CATSPER2P1 -4.27 2.88e-05 0.0132 -0.39 -0.28 Lung cancer in ever smokers; chr15:43480176 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs498227 ENSG00000249839.1 AC011330.5 -4.27 2.89e-05 0.0133 -0.29 -0.28 Lung cancer; chr15:43280854 chr15:43663654~43684339:- CESC cis rs9309473 0.5 rs4852952 ENSG00000273245.1 RP11-434P11.2 -4.27 2.89e-05 0.0133 -0.35 -0.28 Metabolite levels; chr2:73642780 chr2:73750256~73750786:- CESC cis rs9309473 0.5 rs4852953 ENSG00000273245.1 RP11-434P11.2 -4.27 2.89e-05 0.0133 -0.35 -0.28 Metabolite levels; chr2:73642781 chr2:73750256~73750786:- CESC cis rs9322193 0.886 rs9322198 ENSG00000216906.2 RP11-350J20.9 4.27 2.89e-05 0.0133 0.3 0.28 Lung cancer; chr6:149623772 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs11155669 ENSG00000216906.2 RP11-350J20.9 4.27 2.89e-05 0.0133 0.3 0.28 Lung cancer; chr6:149633501 chr6:149904243~149906418:+ CESC cis rs9322193 0.887 rs9505824 ENSG00000216906.2 RP11-350J20.9 4.27 2.89e-05 0.0133 0.3 0.28 Lung cancer; chr6:149633663 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9505826 ENSG00000216906.2 RP11-350J20.9 4.27 2.89e-05 0.0133 0.3 0.28 Lung cancer; chr6:149633912 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9766886 ENSG00000216906.2 RP11-350J20.9 4.27 2.89e-05 0.0133 0.3 0.28 Lung cancer; chr6:149637048 chr6:149904243~149906418:+ CESC cis rs3762637 1 rs76599189 ENSG00000272758.4 RP11-299J3.8 -4.27 2.89e-05 0.0133 -0.39 -0.28 LDL cholesterol levels; chr3:122405229 chr3:122416207~122443180:+ CESC cis rs1930961 1 rs6004667 ENSG00000272942.1 CTA-246H3.12 4.27 2.89e-05 0.0133 0.42 0.28 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25434324~25435070:- CESC cis rs62355901 0.505 rs12655082 ENSG00000271828.1 CTD-2310F14.1 4.27 2.89e-05 0.0133 0.44 0.28 Breast cancer; chr5:56930384 chr5:56927874~56929573:+ CESC cis rs9309473 1 rs6710438 ENSG00000163016.8 ALMS1P -4.27 2.89e-05 0.0133 -0.38 -0.28 Metabolite levels; chr2:73592981 chr2:73644919~73685576:+ CESC cis rs1862618 0.853 rs832554 ENSG00000271828.1 CTD-2310F14.1 4.27 2.89e-05 0.0133 0.38 0.28 Initial pursuit acceleration; chr5:56819209 chr5:56927874~56929573:+ CESC cis rs11155671 0.546 rs1999633 ENSG00000231760.4 RP11-350J20.5 4.27 2.9e-05 0.0133 0.39 0.28 Testicular germ cell tumor; chr6:149866576 chr6:149796151~149826294:- CESC cis rs62355901 0.739 rs61055995 ENSG00000271828.1 CTD-2310F14.1 4.27 2.9e-05 0.0133 0.36 0.28 Breast cancer; chr5:56723237 chr5:56927874~56929573:+ CESC cis rs58873874 0.737 rs78738433 ENSG00000251405.2 CTB-109A12.1 4.27 2.9e-05 0.0133 0.77 0.28 Bipolar disorder (body mass index interaction); chr5:157386503 chr5:157362615~157460078:- CESC cis rs9326248 0.817 rs1242127 ENSG00000280143.1 AP000892.6 -4.27 2.9e-05 0.0133 -0.35 -0.28 Blood protein levels; chr11:117205848 chr11:117204967~117210292:+ CESC cis rs875971 0.545 rs2707851 ENSG00000236529.1 RP13-254B10.1 -4.27 2.9e-05 0.0133 -0.34 -0.28 Aortic root size; chr7:66624178 chr7:65840212~65840596:+ CESC cis rs7829975 0.573 rs7842359 ENSG00000254340.1 RP11-10A14.3 -4.27 2.9e-05 0.0133 -0.34 -0.28 Mood instability; chr8:8939568 chr8:9141424~9145435:+ CESC cis rs9322193 0.923 rs9377230 ENSG00000268592.3 RAET1E-AS1 4.27 2.9e-05 0.0133 0.35 0.28 Lung cancer; chr6:149613607 chr6:149863494~149919507:+ CESC cis rs8020095 0.571 rs68178754 ENSG00000258561.1 RP11-72M17.1 -4.27 2.91e-05 0.0133 -0.42 -0.28 Depression (quantitative trait); chr14:66916377 chr14:66212810~66509394:- CESC cis rs8020095 0.528 rs8013943 ENSG00000258561.1 RP11-72M17.1 -4.27 2.91e-05 0.0133 -0.42 -0.28 Depression (quantitative trait); chr14:66916618 chr14:66212810~66509394:- CESC cis rs1075265 0.87 rs17268179 ENSG00000233266.1 HMGB1P31 4.27 2.91e-05 0.0133 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:54036876 chr2:54051334~54051760:+ CESC cis rs1075265 0.818 rs12713253 ENSG00000233266.1 HMGB1P31 4.27 2.91e-05 0.0133 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:54037323 chr2:54051334~54051760:+ CESC cis rs453301 0.658 rs12114954 ENSG00000173295.6 FAM86B3P -4.27 2.91e-05 0.0134 -0.35 -0.28 Joint mobility (Beighton score); chr8:9047352 chr8:8228595~8244865:+ CESC cis rs875971 0.964 rs6978429 ENSG00000237310.1 GS1-124K5.4 4.27 2.91e-05 0.0134 0.27 0.28 Aortic root size; chr7:66494889 chr7:66493706~66495474:+ CESC cis rs875971 1 rs4718357 ENSG00000237310.1 GS1-124K5.4 4.27 2.91e-05 0.0134 0.27 0.28 Aortic root size; chr7:66495891 chr7:66493706~66495474:+ CESC cis rs875971 0.929 rs12535036 ENSG00000237310.1 GS1-124K5.4 4.27 2.91e-05 0.0134 0.27 0.28 Aortic root size; chr7:66499076 chr7:66493706~66495474:+ CESC cis rs875971 1 rs12698523 ENSG00000237310.1 GS1-124K5.4 4.27 2.91e-05 0.0134 0.27 0.28 Aortic root size; chr7:66503126 chr7:66493706~66495474:+ CESC cis rs875971 1 rs6970030 ENSG00000237310.1 GS1-124K5.4 4.27 2.91e-05 0.0134 0.27 0.28 Aortic root size; chr7:66503692 chr7:66493706~66495474:+ CESC cis rs875971 0.928 rs6970357 ENSG00000237310.1 GS1-124K5.4 4.27 2.91e-05 0.0134 0.27 0.28 Aortic root size; chr7:66503891 chr7:66493706~66495474:+ CESC cis rs875971 0.929 rs6970860 ENSG00000237310.1 GS1-124K5.4 4.27 2.91e-05 0.0134 0.27 0.28 Aortic root size; chr7:66511647 chr7:66493706~66495474:+ CESC cis rs875971 1 rs6957199 ENSG00000237310.1 GS1-124K5.4 4.27 2.91e-05 0.0134 0.27 0.28 Aortic root size; chr7:66513532 chr7:66493706~66495474:+ CESC cis rs2276314 0.857 rs28379448 ENSG00000278986.1 RP11-723J4.3 -4.27 2.91e-05 0.0134 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36024401 chr18:35972151~35973916:+ CESC cis rs116175783 0.557 rs1146024 ENSG00000227403.1 AC009299.3 4.27 2.91e-05 0.0134 0.46 0.28 Intelligence (multi-trait analysis); chr2:161282740 chr2:161244739~161249050:+ CESC cis rs12134133 1 rs2661357 ENSG00000274245.1 RP11-357P18.2 4.27 2.91e-05 0.0134 0.35 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310593 chr1:207372559~207373252:+ CESC cis rs8020095 0.571 rs2144909 ENSG00000258561.1 RP11-72M17.1 -4.27 2.91e-05 0.0134 -0.41 -0.28 Depression (quantitative trait); chr14:66858726 chr14:66212810~66509394:- CESC cis rs8020095 0.528 rs1950689 ENSG00000258561.1 RP11-72M17.1 -4.27 2.91e-05 0.0134 -0.41 -0.28 Depression (quantitative trait); chr14:66871960 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs6573728 ENSG00000258561.1 RP11-72M17.1 -4.27 2.91e-05 0.0134 -0.41 -0.28 Depression (quantitative trait); chr14:66877185 chr14:66212810~66509394:- CESC cis rs651386 0.529 rs576736 ENSG00000271811.1 RP1-79C4.4 4.27 2.91e-05 0.0134 0.35 0.28 Atrial fibrillation; chr1:170618074 chr1:170667381~170669425:+ CESC cis rs916888 0.773 rs199457 ENSG00000261575.2 RP11-259G18.1 4.27 2.91e-05 0.0134 0.41 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46267037~46268694:+ CESC cis rs916888 0.687 rs199456 ENSG00000261575.2 RP11-259G18.1 4.27 2.91e-05 0.0134 0.41 0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46267037~46268694:+ CESC cis rs2412819 0.571 rs11070411 ENSG00000205771.5 CATSPER2P1 4.27 2.92e-05 0.0134 0.41 0.28 Lung cancer; chr15:43766436 chr15:43726918~43747094:- CESC cis rs2439831 1 rs2439831 ENSG00000275601.1 AC011330.13 -4.27 2.92e-05 0.0134 -0.37 -0.28 Lung cancer in ever smokers; chr15:43492277 chr15:43642389~43643023:- CESC cis rs875971 0.964 rs6945019 ENSG00000232559.3 GS1-124K5.12 4.27 2.92e-05 0.0134 0.31 0.28 Aortic root size; chr7:66457471 chr7:66554588~66576923:- CESC cis rs3748682 0.731 rs9729719 ENSG00000212541.1 RNU6-510P -4.27 2.92e-05 0.0134 -0.38 -0.28 Hypothyroidism; chr1:37832535 chr1:37991462~37991569:+ CESC cis rs860295 0.702 rs475550 ENSG00000225855.5 RUSC1-AS1 4.27 2.92e-05 0.0134 0.23 0.28 Body mass index; chr1:155682290 chr1:155316863~155324176:- CESC cis rs67311347 1 rs6762251 ENSG00000223797.4 ENTPD3-AS1 -4.27 2.92e-05 0.0134 -0.27 -0.28 Renal cell carcinoma; chr3:40489645 chr3:40313802~40453329:- CESC cis rs7560272 0.723 rs780395 ENSG00000273245.1 RP11-434P11.2 -4.27 2.92e-05 0.0134 -0.34 -0.28 Schizophrenia; chr2:73473726 chr2:73750256~73750786:- CESC cis rs7560272 0.695 rs780394 ENSG00000273245.1 RP11-434P11.2 -4.27 2.92e-05 0.0134 -0.34 -0.28 Schizophrenia; chr2:73473803 chr2:73750256~73750786:- CESC cis rs9323326 0.586 rs4901837 ENSG00000257621.6 PSMA3-AS1 4.27 2.92e-05 0.0134 0.27 0.28 Gut microbiota (bacterial taxa); chr14:58028659 chr14:58265365~58298134:- CESC cis rs7829975 0.742 rs12547493 ENSG00000253981.4 ALG1L13P -4.27 2.92e-05 0.0134 -0.34 -0.28 Mood instability; chr8:8804024 chr8:8236003~8244667:- CESC cis rs4272720 0.639 rs7085823 ENSG00000229870.1 RP11-507K13.6 -4.27 2.92e-05 0.0134 -0.32 -0.28 Platelet count;Plateletcrit; chr10:49076600 chr10:49815096~49815562:+ CESC cis rs7188445 0.871 rs7202770 ENSG00000261390.4 RP11-345M22.2 -4.27 2.92e-05 0.0134 -0.35 -0.28 Urate levels; chr16:79672643 chr16:79715232~79770563:- CESC cis rs7188445 0.835 rs1424231 ENSG00000261390.4 RP11-345M22.2 -4.27 2.92e-05 0.0134 -0.35 -0.28 Urate levels; chr16:79672854 chr16:79715232~79770563:- CESC cis rs451417 1 rs384578 ENSG00000275632.1 RP5-967N21.11 -4.27 2.92e-05 0.0134 -0.36 -0.28 Menopause (age at onset); chr20:6000830 chr20:6000418~6000941:+ CESC cis rs17301013 0.507 rs16828481 ENSG00000227373.4 RP11-160H22.5 4.27 2.92e-05 0.0134 0.38 0.28 Systemic lupus erythematosus; chr1:174415979 chr1:174115300~174160004:- CESC cis rs11638352 0.661 rs2706486 ENSG00000275601.1 AC011330.13 4.27 2.92e-05 0.0134 0.41 0.28 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44136784 chr15:43642389~43643023:- CESC cis rs9929218 1 rs7186084 ENSG00000260459.2 FTLP14 4.27 2.93e-05 0.0134 0.37 0.28 Colorectal cancer; chr16:68782357 chr16:68822587~68823070:+ CESC cis rs4319547 0.695 rs10773167 ENSG00000275265.1 RP11-15J22.8 -4.27 2.93e-05 0.0134 -0.39 -0.28 Body mass index; chr12:122449454 chr12:122501187~122501641:+ CESC cis rs2439831 0.85 rs3816792 ENSG00000275601.1 AC011330.13 4.27 2.93e-05 0.0134 0.44 0.28 Lung cancer in ever smokers; chr15:43824788 chr15:43642389~43643023:- CESC cis rs116095464 1 rs6555160 ENSG00000250848.1 CTD-2083E4.5 4.27 2.93e-05 0.0134 0.44 0.28 Breast cancer; chr5:311554 chr5:288833~290321:- CESC cis rs2019137 0.539 rs6755040 ENSG00000274877.1 RP11-65I12.1 -4.27 2.93e-05 0.0134 -0.36 -0.28 Lymphocyte counts; chr2:113223560 chr2:113237595~113240825:+ CESC cis rs35417517 1 rs35417517 ENSG00000188693.7 CYP51A1-AS1 -4.27 2.93e-05 0.0134 -0.29 -0.28 Breast cancer; chr7:92143417 chr7:92134604~92180725:+ CESC cis rs6964587 0.967 rs6974827 ENSG00000188693.7 CYP51A1-AS1 -4.27 2.93e-05 0.0134 -0.29 -0.28 Breast cancer; chr7:92143631 chr7:92134604~92180725:+ CESC cis rs6964587 0.9 rs6465352 ENSG00000188693.7 CYP51A1-AS1 -4.27 2.93e-05 0.0134 -0.29 -0.28 Breast cancer; chr7:92145803 chr7:92134604~92180725:+ CESC cis rs6964587 0.967 rs6973896 ENSG00000188693.7 CYP51A1-AS1 -4.27 2.93e-05 0.0134 -0.29 -0.28 Breast cancer; chr7:92149151 chr7:92134604~92180725:+ CESC cis rs6964587 0.967 rs1978061 ENSG00000188693.7 CYP51A1-AS1 -4.27 2.93e-05 0.0134 -0.29 -0.28 Breast cancer; chr7:92149928 chr7:92134604~92180725:+ CESC cis rs889398 0.934 rs12923231 ENSG00000226232.7 RP11-419C5.2 4.27 2.93e-05 0.0134 0.26 0.28 Body mass index; chr16:69538989 chr16:69976388~69996188:- CESC cis rs2404602 0.692 rs4886503 ENSG00000280730.1 AC090181.1 -4.27 2.94e-05 0.0134 -0.22 -0.28 Blood metabolite levels; chr15:76816533 chr15:77056895~77057021:+ CESC cis rs11051970 0.918 rs6488050 ENSG00000255760.1 RP11-428G5.5 4.27 2.94e-05 0.0134 0.33 0.28 Response to tocilizumab in rheumatoid arthritis; chr12:32379565 chr12:31877079~31887203:- CESC cis rs10129255 0.785 rs10150044 ENSG00000211970.3 IGHV4-61 -4.27 2.94e-05 0.0134 -0.21 -0.28 Kawasaki disease; chr14:106775695 chr14:106639119~106639657:- CESC cis rs748404 0.631 rs1133395 ENSG00000205771.5 CATSPER2P1 -4.27 2.94e-05 0.0134 -0.34 -0.28 Lung cancer; chr15:43358186 chr15:43726918~43747094:- CESC cis rs7572733 0.534 rs11890137 ENSG00000222017.1 AC011997.1 4.27 2.94e-05 0.0134 0.35 0.28 Dermatomyositis; chr2:197951938 chr2:197693106~197774823:+ CESC cis rs2290159 0.8 rs5746214 ENSG00000274514.1 Metazoa_SRP 4.27 2.94e-05 0.0134 0.36 0.28 Cholesterol, total; chr3:12603254 chr3:12576961~12577237:- CESC cis rs7937890 0.559 rs2034480 ENSG00000251991.1 RNU7-49P 4.27 2.94e-05 0.0134 0.29 0.28 Mitochondrial DNA levels; chr11:14445377 chr11:14478892~14478953:+ CESC cis rs5769707 0.837 rs5770599 ENSG00000235111.1 RP1-29C18.8 -4.27 2.94e-05 0.0134 -0.29 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49626333 chr22:49612657~49615716:- CESC cis rs6740322 0.748 rs13432574 ENSG00000234936.1 AC010883.5 4.27 2.94e-05 0.0135 0.3 0.28 Coronary artery disease; chr2:43317189 chr2:43229573~43233394:+ CESC cis rs7188445 0.871 rs11150187 ENSG00000261390.4 RP11-345M22.2 4.27 2.94e-05 0.0135 0.34 0.28 Urate levels; chr16:79670515 chr16:79715232~79770563:- CESC cis rs2299587 0.866 rs208768 ENSG00000253671.1 RP11-806O11.1 -4.27 2.94e-05 0.0135 -0.29 -0.28 Economic and political preferences; chr8:17946414 chr8:17808941~17820868:+ CESC cis rs7976269 0.583 rs2117997 ENSG00000275476.1 RP11-996F15.4 4.27 2.94e-05 0.0135 0.36 0.28 Male-pattern baldness; chr12:29143428 chr12:29277397~29277882:- CESC cis rs9322193 0.923 rs9404048 ENSG00000216906.2 RP11-350J20.9 4.27 2.94e-05 0.0135 0.3 0.28 Lung cancer; chr6:149616188 chr6:149904243~149906418:+ CESC cis rs875971 0.862 rs9791712 ENSG00000232559.3 GS1-124K5.12 -4.27 2.94e-05 0.0135 -0.31 -0.28 Aortic root size; chr7:66640176 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs9791713 ENSG00000232559.3 GS1-124K5.12 -4.27 2.94e-05 0.0135 -0.31 -0.28 Aortic root size; chr7:66640211 chr7:66554588~66576923:- CESC cis rs950880 0.767 rs13001714 ENSG00000234389.1 AC007278.3 -4.27 2.94e-05 0.0135 -0.3 -0.28 Serum protein levels (sST2); chr2:102344025 chr2:102438713~102440475:+ CESC cis rs17301013 0.507 rs2860955 ENSG00000227373.4 RP11-160H22.5 -4.27 2.95e-05 0.0135 -0.37 -0.28 Systemic lupus erythematosus; chr1:174391380 chr1:174115300~174160004:- CESC cis rs11846409 0.86 rs55745256 ENSG00000211974.3 IGHV2-70 -4.27 2.95e-05 0.0135 -0.36 -0.28 Rheumatic heart disease; chr14:106632365 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs731013 ENSG00000211974.3 IGHV2-70 -4.27 2.95e-05 0.0135 -0.36 -0.28 Rheumatic heart disease; chr14:106632481 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs731012 ENSG00000211974.3 IGHV2-70 -4.27 2.95e-05 0.0135 -0.36 -0.28 Rheumatic heart disease; chr14:106632578 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs731011 ENSG00000211974.3 IGHV2-70 -4.27 2.95e-05 0.0135 -0.36 -0.28 Rheumatic heart disease; chr14:106632619 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs10138537 ENSG00000211974.3 IGHV2-70 -4.27 2.95e-05 0.0135 -0.36 -0.28 Rheumatic heart disease; chr14:106632778 chr14:106723574~106724093:- CESC cis rs11846409 0.932 rs756588 ENSG00000211974.3 IGHV2-70 4.27 2.95e-05 0.0135 0.36 0.28 Rheumatic heart disease; chr14:106632316 chr14:106723574~106724093:- CESC cis rs2933343 1 rs1680790 ENSG00000231305.3 RP11-723O4.2 4.27 2.95e-05 0.0135 0.3 0.28 IgG glycosylation; chr3:128907010 chr3:128861313~128871540:- CESC cis rs6452524 0.87 rs2174976 ENSG00000249664.1 CTD-2227C6.2 4.27 2.95e-05 0.0135 0.32 0.28 Hypertension (SNP x SNP interaction); chr5:83197136 chr5:83012285~83013109:- CESC cis rs71403859 0.502 rs71403847 ENSG00000260886.1 TAT-AS1 4.27 2.95e-05 0.0135 0.44 0.28 Post bronchodilator FEV1; chr16:71434323 chr16:71565789~71578187:+ CESC cis rs9487094 0.67 rs1476388 ENSG00000260273.1 RP11-425D10.10 4.27 2.95e-05 0.0135 0.35 0.28 Height; chr6:109518783 chr6:109382795~109383666:+ CESC cis rs881375 0.967 rs10733648 ENSG00000226752.6 PSMD5-AS1 -4.27 2.95e-05 0.0135 -0.3 -0.28 Rheumatoid arthritis; chr9:120938501 chr9:120824828~120854385:+ CESC cis rs875971 0.545 rs73150604 ENSG00000222364.1 RNU6-96P -4.27 2.95e-05 0.0135 -0.39 -0.28 Aortic root size; chr7:66480545 chr7:66395191~66395286:+ CESC cis rs7829975 0.517 rs12542733 ENSG00000233609.3 RP11-62H7.2 -4.27 2.96e-05 0.0135 -0.27 -0.28 Mood instability; chr8:8967348 chr8:8961200~8979025:+ CESC cis rs875971 0.867 rs1002053 ENSG00000179406.6 LINC00174 4.27 2.96e-05 0.0135 0.3 0.28 Aortic root size; chr7:66333558 chr7:66376044~66401338:- CESC cis rs875971 1 rs6460292 ENSG00000179406.6 LINC00174 4.27 2.96e-05 0.0135 0.3 0.28 Aortic root size; chr7:66345088 chr7:66376044~66401338:- CESC cis rs763121 0.785 rs5750646 ENSG00000273076.1 RP3-508I15.22 4.27 2.96e-05 0.0135 0.32 0.28 Menopause (age at onset); chr22:38617825 chr22:38743495~38743910:+ CESC cis rs8040855 0.658 rs11634877 ENSG00000259295.5 CSPG4P12 4.27 2.96e-05 0.0135 0.34 0.28 Bulimia nervosa; chr15:85068246 chr15:85191438~85213905:+ CESC cis rs8040855 0.627 rs11632175 ENSG00000259295.5 CSPG4P12 4.27 2.96e-05 0.0135 0.34 0.28 Bulimia nervosa; chr15:85068449 chr15:85191438~85213905:+ CESC cis rs440932 0.565 rs19334 ENSG00000173295.6 FAM86B3P 4.27 2.96e-05 0.0135 0.34 0.28 High light scatter reticulocyte percentage of red cells; chr8:9152396 chr8:8228595~8244865:+ CESC cis rs6879260 1 rs7706951 ENSG00000248367.1 CTB-129O4.1 -4.27 2.96e-05 0.0135 -0.21 -0.28 Height; chr5:180306407 chr5:180293245~180295253:+ CESC cis rs6879260 1 rs7730585 ENSG00000248367.1 CTB-129O4.1 -4.27 2.96e-05 0.0135 -0.21 -0.28 Height; chr5:180306440 chr5:180293245~180295253:+ CESC cis rs7188445 1 rs16950982 ENSG00000261390.4 RP11-345M22.2 -4.27 2.96e-05 0.0135 -0.35 -0.28 Urate levels; chr16:79668474 chr16:79715232~79770563:- CESC cis rs2439831 1 rs2444029 ENSG00000275601.1 AC011330.13 -4.27 2.97e-05 0.0135 -0.36 -0.28 Lung cancer in ever smokers; chr15:43445286 chr15:43642389~43643023:- CESC cis rs9309473 1 rs7584575 ENSG00000163016.8 ALMS1P 4.27 2.97e-05 0.0135 0.36 0.28 Metabolite levels; chr2:73439274 chr2:73644919~73685576:+ CESC cis rs7789940 1 rs11765693 ENSG00000230305.2 AC004980.9 4.27 2.97e-05 0.0136 0.39 0.28 Multiple sclerosis; chr7:76356056 chr7:76524515~76532692:+ CESC cis rs7789940 1 rs73140069 ENSG00000230305.2 AC004980.9 4.27 2.97e-05 0.0136 0.39 0.28 Multiple sclerosis; chr7:76357473 chr7:76524515~76532692:+ CESC cis rs1440410 0.835 rs4594668 ENSG00000250326.1 RP11-284M14.1 4.27 2.97e-05 0.0136 0.3 0.28 Ischemic stroke; chr4:143129293 chr4:142933195~143184861:- CESC cis rs7819412 0.654 rs34741518 ENSG00000255046.1 RP11-297N6.4 4.27 2.98e-05 0.0136 0.3 0.28 Triglycerides; chr8:10919350 chr8:11797928~11802568:- CESC cis rs2439831 0.571 rs689883 ENSG00000275601.1 AC011330.13 -4.27 2.98e-05 0.0136 -0.39 -0.28 Lung cancer in ever smokers; chr15:43520398 chr15:43642389~43643023:- CESC cis rs67311347 0.91 rs7617361 ENSG00000223797.4 ENTPD3-AS1 4.27 2.98e-05 0.0136 0.27 0.28 Renal cell carcinoma; chr3:40331768 chr3:40313802~40453329:- CESC cis rs3096299 0.9 rs4785666 ENSG00000274627.1 RP11-104N10.2 4.26 2.98e-05 0.0136 0.27 0.28 Multiple myeloma (IgH translocation); chr16:89396363 chr16:89516797~89522217:+ CESC cis rs6693388 0.75 rs61817697 ENSG00000229021.2 AL591893.1 -4.26 2.98e-05 0.0136 -0.34 -0.28 Blood metabolite ratios; chr1:151918482 chr1:151994531~152042774:+ CESC cis rs2274273 0.624 rs7152390 ENSG00000258413.1 RP11-665C16.6 -4.26 2.99e-05 0.0136 -0.36 -0.28 Protein biomarker; chr14:55344983 chr14:55262767~55272075:- CESC cis rs2274273 0.588 rs9919923 ENSG00000258413.1 RP11-665C16.6 -4.26 2.99e-05 0.0136 -0.36 -0.28 Protein biomarker; chr14:55347181 chr14:55262767~55272075:- CESC cis rs2274273 0.588 rs9919932 ENSG00000258413.1 RP11-665C16.6 -4.26 2.99e-05 0.0136 -0.36 -0.28 Protein biomarker; chr14:55347362 chr14:55262767~55272075:- CESC cis rs7005380 0.62 rs7459671 ENSG00000279347.1 RP11-85I17.2 -4.26 2.99e-05 0.0136 -0.25 -0.28 Interstitial lung disease; chr8:119896646 chr8:119838736~119840385:- CESC cis rs2739330 0.685 rs4822453 ENSG00000272787.1 KB-226F1.2 -4.26 2.99e-05 0.0136 -0.3 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23969211~23969873:+ CESC cis rs17507216 1 rs17507216 ENSG00000276710.3 CSPG4P8 4.26 2.99e-05 0.0136 0.39 0.28 Excessive daytime sleepiness; chr15:82558175 chr15:82459472~82477258:+ CESC cis rs7809950 1 rs2520269 ENSG00000238832.1 snoU109 -4.26 2.99e-05 0.0136 -0.34 -0.28 Coronary artery disease; chr7:107550882 chr7:107603363~107603507:+ CESC cis rs7560272 0.723 rs1083923 ENSG00000273245.1 RP11-434P11.2 -4.26 2.99e-05 0.0136 -0.34 -0.28 Schizophrenia; chr2:73476247 chr2:73750256~73750786:- CESC cis rs9513627 0.92 rs16956607 ENSG00000228889.5 UBAC2-AS1 4.26 2.99e-05 0.0136 0.46 0.28 Obesity-related traits; chr13:99467966 chr13:99196377~99200710:- CESC cis rs9322193 0.884 rs10872646 ENSG00000216906.2 RP11-350J20.9 4.26 3e-05 0.0137 0.31 0.28 Lung cancer; chr6:149746539 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs12528279 ENSG00000216906.2 RP11-350J20.9 4.26 3e-05 0.0137 0.31 0.28 Lung cancer; chr6:149750892 chr6:149904243~149906418:+ CESC cis rs9322193 0.809 rs9479808 ENSG00000216906.2 RP11-350J20.9 4.26 3e-05 0.0137 0.31 0.28 Lung cancer; chr6:149751328 chr6:149904243~149906418:+ CESC cis rs1044826 0.642 rs167187 ENSG00000178631.7 ACTG1P1 -4.26 3e-05 0.0137 -0.35 -0.28 Obesity-related traits; chr3:139518166 chr3:139493809~139494937:+ CESC cis rs9322193 0.923 rs4870529 ENSG00000216906.2 RP11-350J20.9 4.26 3e-05 0.0137 0.31 0.28 Lung cancer; chr6:149716436 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9767309 ENSG00000216906.2 RP11-350J20.9 4.26 3e-05 0.0137 0.31 0.28 Lung cancer; chr6:149716807 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs62441279 ENSG00000216906.2 RP11-350J20.9 4.26 3e-05 0.0137 0.31 0.28 Lung cancer; chr6:149721194 chr6:149904243~149906418:+ CESC cis rs875971 0.545 rs1796219 ENSG00000237310.1 GS1-124K5.4 -4.26 3e-05 0.0137 -0.32 -0.28 Aortic root size; chr7:66645977 chr7:66493706~66495474:+ CESC cis rs7560272 0.538 rs4852975 ENSG00000273245.1 RP11-434P11.2 -4.26 3.01e-05 0.0137 -0.35 -0.28 Schizophrenia; chr2:73705338 chr2:73750256~73750786:- CESC cis rs2732480 0.577 rs1489109 ENSG00000240399.1 RP1-228P16.1 4.26 3.01e-05 0.0137 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344997 chr12:48054813~48055591:- CESC cis rs2732480 0.577 rs1489108 ENSG00000240399.1 RP1-228P16.1 4.26 3.01e-05 0.0137 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344998 chr12:48054813~48055591:- CESC cis rs748404 0.697 rs530683 ENSG00000205771.5 CATSPER2P1 4.26 3.01e-05 0.0137 0.34 0.28 Lung cancer; chr15:43276801 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs1095389 ENSG00000205771.5 CATSPER2P1 -4.26 3.01e-05 0.0137 -0.34 -0.28 Lung cancer; chr15:43274473 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs473554 ENSG00000205771.5 CATSPER2P1 -4.26 3.01e-05 0.0137 -0.34 -0.28 Lung cancer; chr15:43276009 chr15:43726918~43747094:- CESC cis rs763121 0.853 rs4821798 ENSG00000273076.1 RP3-508I15.22 4.26 3.01e-05 0.0137 0.32 0.28 Menopause (age at onset); chr22:38625160 chr22:38743495~38743910:+ CESC cis rs7581030 0.55 rs13012800 ENSG00000281195.1 ZNF638-IT1 -4.26 3.01e-05 0.0137 -0.41 -0.28 Testicular germ cell tumor; chr2:71208961 chr2:71373938~71376320:+ CESC cis rs12025262 0.934 rs10924961 ENSG00000259865.1 RP11-488L18.10 -4.26 3.01e-05 0.0137 -0.25 -0.28 Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50); chr1:247198985 chr1:247187281~247188526:- CESC cis rs11089937 0.637 rs988200 ENSG00000211638.2 IGLV8-61 -4.26 3.01e-05 0.0137 -0.28 -0.28 Periodontitis (PAL4Q3); chr22:22154715 chr22:22098700~22099212:+ CESC cis rs8005677 1 rs7155857 ENSG00000279656.1 RP11-298I3.6 4.26 3.01e-05 0.0137 0.34 0.28 Cognitive ability (multi-trait analysis); chr14:22930850 chr14:23023083~23024217:- CESC cis rs8005677 0.962 rs8003934 ENSG00000279656.1 RP11-298I3.6 4.26 3.01e-05 0.0137 0.34 0.28 Cognitive ability (multi-trait analysis); chr14:22931933 chr14:23023083~23024217:- CESC cis rs6964587 1 rs10225892 ENSG00000188693.7 CYP51A1-AS1 -4.26 3.02e-05 0.0137 -0.3 -0.28 Breast cancer; chr7:92041706 chr7:92134604~92180725:+ CESC cis rs2276314 0.857 rs28530656 ENSG00000278986.1 RP11-723J4.3 4.26 3.02e-05 0.0137 0.29 0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36008737 chr18:35972151~35973916:+ CESC cis rs72627509 0.638 rs1608165 ENSG00000269949.1 RP11-738E22.3 4.26 3.02e-05 0.0137 0.46 0.28 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57028551 chr4:56960927~56961373:- CESC cis rs9595066 0.627 rs4941486 ENSG00000227258.4 SMIM2-AS1 4.26 3.02e-05 0.0137 0.41 0.28 Schizophrenia; chr13:44175021 chr13:44110451~44240517:+ CESC cis rs5769707 0.967 rs9616701 ENSG00000235111.1 RP1-29C18.8 -4.26 3.02e-05 0.0137 -0.28 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49631898 chr22:49612657~49615716:- CESC cis rs11159086 1 rs4899514 ENSG00000270000.1 RP3-449M8.9 -4.26 3.02e-05 0.0138 -0.52 -0.28 Advanced glycation end-product levels; chr14:74473467 chr14:74471930~74472360:- CESC cis rs17711722 0.51 rs11767457 ENSG00000224316.1 RP11-479O9.2 4.26 3.02e-05 0.0138 0.32 0.28 Calcium levels; chr7:65825628 chr7:65773620~65802067:+ CESC cis rs1387259 0.64 rs10783243 ENSG00000240399.1 RP1-228P16.1 -4.26 3.02e-05 0.0138 -0.29 -0.28 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48259220 chr12:48054813~48055591:- CESC cis rs17826219 0.562 rs719600 ENSG00000263531.1 RP13-753N3.1 -4.26 3.02e-05 0.0138 -0.57 -0.28 Body mass index; chr17:30404244 chr17:30863921~30864940:- CESC cis rs673078 0.66 rs17440364 ENSG00000275759.1 RP11-131L12.3 -4.26 3.03e-05 0.0138 -0.58 -0.28 Glucose homeostasis traits; chr12:118186613 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs75752792 ENSG00000275759.1 RP11-131L12.3 -4.26 3.03e-05 0.0138 -0.58 -0.28 Glucose homeostasis traits; chr12:118187005 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs75571641 ENSG00000275759.1 RP11-131L12.3 -4.26 3.03e-05 0.0138 -0.58 -0.28 Glucose homeostasis traits; chr12:118187012 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs17512177 ENSG00000275759.1 RP11-131L12.3 -4.26 3.03e-05 0.0138 -0.58 -0.28 Glucose homeostasis traits; chr12:118192335 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs17512198 ENSG00000275759.1 RP11-131L12.3 -4.26 3.03e-05 0.0138 -0.58 -0.28 Glucose homeostasis traits; chr12:118194217 chr12:118428281~118428870:+ CESC cis rs7684253 1 rs7684253 ENSG00000269949.1 RP11-738E22.3 4.26 3.03e-05 0.0138 0.3 0.28 Migraine; chr4:56861145 chr4:56960927~56961373:- CESC cis rs2276314 0.857 rs3737474 ENSG00000278986.1 RP11-723J4.3 -4.26 3.03e-05 0.0138 -0.31 -0.28 Endometriosis;Drug-induced torsades de pointes; chr18:36033632 chr18:35972151~35973916:+ CESC cis rs1707322 1 rs6677777 ENSG00000281133.1 AL355480.3 -4.26 3.03e-05 0.0138 -0.35 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46010164 chr1:45580892~45580996:- CESC cis rs7572733 0.773 rs13396312 ENSG00000222017.1 AC011997.1 -4.26 3.03e-05 0.0138 -0.32 -0.28 Dermatomyositis; chr2:197628979 chr2:197693106~197774823:+ CESC cis rs8040855 0.894 rs6496770 ENSG00000259295.5 CSPG4P12 -4.26 3.03e-05 0.0138 -0.34 -0.28 Bulimia nervosa; chr15:85161890 chr15:85191438~85213905:+ CESC cis rs875971 0.528 rs801213 ENSG00000236529.1 RP13-254B10.1 -4.26 3.03e-05 0.0138 -0.34 -0.28 Aortic root size; chr7:66549931 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs801212 ENSG00000236529.1 RP13-254B10.1 -4.26 3.03e-05 0.0138 -0.34 -0.28 Aortic root size; chr7:66550643 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs801199 ENSG00000236529.1 RP13-254B10.1 -4.26 3.03e-05 0.0138 -0.34 -0.28 Aortic root size; chr7:66560286 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs1267814 ENSG00000236529.1 RP13-254B10.1 -4.26 3.03e-05 0.0138 -0.34 -0.28 Aortic root size; chr7:66579422 chr7:65840212~65840596:+ CESC cis rs2280018 1 rs2280017 ENSG00000260735.1 RP11-72I8.1 4.26 3.03e-05 0.0138 0.29 0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15057504 chr16:15094411~15109197:+ CESC cis rs1185460 1 rs1799993 ENSG00000271751.1 RP11-110I1.14 4.26 3.04e-05 0.0138 0.35 0.28 Coronary artery disease; chr11:119087417 chr11:119065263~119065677:- CESC cis rs1030877 0.515 rs17030766 ENSG00000235319.1 AC012360.4 4.26 3.04e-05 0.0138 0.34 0.28 Obesity-related traits; chr2:105295448 chr2:105324210~105330529:+ CESC cis rs748404 0.666 rs16957715 ENSG00000249839.1 AC011330.5 -4.26 3.04e-05 0.0138 -0.39 -0.28 Lung cancer; chr15:43416539 chr15:43663654~43684339:- CESC cis rs919433 0.617 rs10931793 ENSG00000222017.1 AC011997.1 -4.26 3.04e-05 0.0138 -0.35 -0.28 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197712861 chr2:197693106~197774823:+ CESC cis rs9322193 0.962 rs9505974 ENSG00000223701.3 RAET1E-AS1 4.26 3.04e-05 0.0138 0.31 0.28 Lung cancer; chr6:149779294 chr6:149884431~149919508:+ CESC cis rs9322193 0.926 rs9689036 ENSG00000223701.3 RAET1E-AS1 4.26 3.04e-05 0.0138 0.31 0.28 Lung cancer; chr6:149780563 chr6:149884431~149919508:+ CESC cis rs9322193 0.962 rs9322218 ENSG00000223701.3 RAET1E-AS1 4.26 3.04e-05 0.0138 0.31 0.28 Lung cancer; chr6:149782183 chr6:149884431~149919508:+ CESC cis rs9322193 0.962 rs9322219 ENSG00000223701.3 RAET1E-AS1 4.26 3.04e-05 0.0138 0.31 0.28 Lung cancer; chr6:149782263 chr6:149884431~149919508:+ CESC cis rs9322193 0.962 rs9322223 ENSG00000223701.3 RAET1E-AS1 4.26 3.04e-05 0.0138 0.31 0.28 Lung cancer; chr6:149801509 chr6:149884431~149919508:+ CESC cis rs10829156 0.732 rs10828834 ENSG00000240291.1 RP11-499P20.2 4.26 3.04e-05 0.0138 0.32 0.28 Sudden cardiac arrest; chr10:18523505 chr10:18513115~18545651:- CESC cis rs10829156 0.732 rs7100884 ENSG00000240291.1 RP11-499P20.2 4.26 3.04e-05 0.0138 0.32 0.28 Sudden cardiac arrest; chr10:18523768 chr10:18513115~18545651:- CESC cis rs4686914 0.963 rs9290867 ENSG00000228804.4 RP11-211G3.3 4.26 3.04e-05 0.0138 0.33 0.28 Metabolite levels; chr3:188003749 chr3:187702313~187733849:+ CESC cis rs4686914 0.963 rs11924549 ENSG00000228804.4 RP11-211G3.3 4.26 3.04e-05 0.0138 0.33 0.28 Metabolite levels; chr3:188004604 chr3:187702313~187733849:+ CESC cis rs4686914 0.963 rs9809023 ENSG00000228804.4 RP11-211G3.3 4.26 3.04e-05 0.0138 0.33 0.28 Metabolite levels; chr3:188005779 chr3:187702313~187733849:+ CESC cis rs4686914 0.963 rs9864543 ENSG00000228804.4 RP11-211G3.3 4.26 3.04e-05 0.0138 0.33 0.28 Metabolite levels; chr3:188006048 chr3:187702313~187733849:+ CESC cis rs11159086 1 rs3759745 ENSG00000259005.1 RP3-449M8.6 4.26 3.04e-05 0.0138 0.43 0.28 Advanced glycation end-product levels; chr14:74495967 chr14:74474007~74474864:- CESC cis rs11159086 1 rs4903232 ENSG00000259005.1 RP3-449M8.6 4.26 3.04e-05 0.0138 0.43 0.28 Advanced glycation end-product levels; chr14:74496585 chr14:74474007~74474864:- CESC cis rs9309473 1 rs10175180 ENSG00000163016.8 ALMS1P 4.26 3.05e-05 0.0138 0.35 0.28 Metabolite levels; chr2:73445995 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs10496191 ENSG00000163016.8 ALMS1P 4.26 3.05e-05 0.0138 0.35 0.28 Metabolite levels; chr2:73446670 chr2:73644919~73685576:+ CESC cis rs4423214 0.592 rs78300366 ENSG00000254682.1 RP11-660L16.2 -4.26 3.05e-05 0.0138 -0.42 -0.28 Vitamin D levels; chr11:71494468 chr11:71448674~71452157:+ CESC cis rs2732480 0.577 rs2634680 ENSG00000240399.1 RP1-228P16.1 4.26 3.05e-05 0.0139 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48340781 chr12:48054813~48055591:- CESC cis rs2732480 0.577 rs2634678 ENSG00000240399.1 RP1-228P16.1 4.26 3.05e-05 0.0139 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48341755 chr12:48054813~48055591:- CESC cis rs13113518 0.683 rs9761521 ENSG00000249700.7 SRD5A3-AS1 4.26 3.05e-05 0.0139 0.34 0.28 Height; chr4:55363436 chr4:55363971~55395847:- CESC cis rs875971 0.545 rs73150604 ENSG00000237310.1 GS1-124K5.4 4.26 3.05e-05 0.0139 0.32 0.28 Aortic root size; chr7:66480545 chr7:66493706~66495474:+ CESC cis rs1510272 0.515 rs6762762 ENSG00000243926.1 TIPARP-AS1 -4.26 3.05e-05 0.0139 -0.35 -0.28 Testicular germ cell tumor; chr3:156625194 chr3:156671862~156674378:- CESC cis rs2274273 0.624 rs4580079 ENSG00000258413.1 RP11-665C16.6 -4.26 3.05e-05 0.0139 -0.36 -0.28 Protein biomarker; chr14:55313648 chr14:55262767~55272075:- CESC cis rs2274273 0.624 rs78205412 ENSG00000258413.1 RP11-665C16.6 -4.26 3.05e-05 0.0139 -0.36 -0.28 Protein biomarker; chr14:55314532 chr14:55262767~55272075:- CESC cis rs7809950 1 rs2520271 ENSG00000238832.1 snoU109 -4.26 3.05e-05 0.0139 -0.33 -0.28 Coronary artery disease; chr7:107554504 chr7:107603363~107603507:+ CESC cis rs7809950 1 rs2237676 ENSG00000238832.1 snoU109 -4.26 3.05e-05 0.0139 -0.33 -0.28 Coronary artery disease; chr7:107557634 chr7:107603363~107603507:+ CESC cis rs7809950 0.953 rs2253271 ENSG00000238832.1 snoU109 -4.26 3.05e-05 0.0139 -0.33 -0.28 Coronary artery disease; chr7:107560807 chr7:107603363~107603507:+ CESC cis rs2243480 0.901 rs35256305 ENSG00000228409.4 CCT6P1 4.26 3.05e-05 0.0139 0.39 0.28 Diabetic kidney disease; chr7:65841418 chr7:65751142~65763354:+ CESC cis rs2243480 0.803 rs34004500 ENSG00000228409.4 CCT6P1 4.26 3.05e-05 0.0139 0.39 0.28 Diabetic kidney disease; chr7:65847191 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35825738 ENSG00000228409.4 CCT6P1 4.26 3.05e-05 0.0139 0.39 0.28 Diabetic kidney disease; chr7:65853040 chr7:65751142~65763354:+ CESC cis rs2243480 0.803 rs35480979 ENSG00000228409.4 CCT6P1 4.26 3.05e-05 0.0139 0.39 0.28 Diabetic kidney disease; chr7:65892097 chr7:65751142~65763354:+ CESC cis rs875971 0.825 rs4587224 ENSG00000232559.3 GS1-124K5.12 -4.26 3.05e-05 0.0139 -0.29 -0.28 Aortic root size; chr7:66271195 chr7:66554588~66576923:- CESC cis rs875971 0.792 rs6971752 ENSG00000232559.3 GS1-124K5.12 -4.26 3.05e-05 0.0139 -0.29 -0.28 Aortic root size; chr7:66272999 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10950033 ENSG00000232559.3 GS1-124K5.12 -4.26 3.05e-05 0.0139 -0.29 -0.28 Aortic root size; chr7:66274686 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs11760844 ENSG00000232559.3 GS1-124K5.12 -4.26 3.05e-05 0.0139 -0.29 -0.28 Aortic root size; chr7:66274896 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs949930 ENSG00000232559.3 GS1-124K5.12 -4.26 3.05e-05 0.0139 -0.29 -0.28 Aortic root size; chr7:66301835 chr7:66554588~66576923:- CESC cis rs1044826 0.642 rs9833307 ENSG00000178631.7 ACTG1P1 4.26 3.05e-05 0.0139 0.34 0.28 Obesity-related traits; chr3:139462528 chr3:139493809~139494937:+ CESC cis rs2280018 0.963 rs12928424 ENSG00000260735.1 RP11-72I8.1 -4.26 3.06e-05 0.0139 -0.3 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15056916 chr16:15094411~15109197:+ CESC cis rs17772222 0.74 rs61975278 ENSG00000258983.2 RP11-507K2.2 4.26 3.06e-05 0.0139 0.32 0.28 Coronary artery calcification; chr14:88511223 chr14:88499334~88515502:+ CESC cis rs7927592 0.956 rs948315 ENSG00000212093.1 AP000807.1 4.26 3.06e-05 0.0139 0.32 0.28 Total body bone mineral density; chr11:68541672 chr11:68506083~68506166:- CESC cis rs761746 0.584 rs62238892 ENSG00000236132.1 CTA-440B3.1 -4.26 3.06e-05 0.0139 -0.37 -0.28 Intelligence; chr22:31765563 chr22:31816379~31817491:- CESC cis rs10754283 0.901 rs10922684 ENSG00000231613.1 RP5-943J3.1 4.26 3.06e-05 0.0139 0.35 0.28 Amyotrophic lateral sclerosis (sporadic); chr1:89652375 chr1:89788914~89790492:+ CESC cis rs72772090 0.634 rs12186366 ENSG00000248734.2 CTD-2260A17.1 -4.26 3.06e-05 0.0139 -0.42 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96753146 chr5:96784777~96785999:+ CESC cis rs2058059 0.551 rs68044527 ENSG00000205578.5 POM121B -4.26 3.06e-05 0.0139 -0.36 -0.28 Subcutaneous adipose tissue; chr7:72599814 chr7:73293497~73301161:+ CESC cis rs2058059 0.551 rs4473912 ENSG00000205578.5 POM121B -4.26 3.06e-05 0.0139 -0.36 -0.28 Subcutaneous adipose tissue; chr7:72600851 chr7:73293497~73301161:+ CESC cis rs2919917 0.628 rs12680932 ENSG00000254352.1 RP11-578O24.2 -4.26 3.06e-05 0.0139 -0.4 -0.28 Lymphocyte counts; chr8:78685516 chr8:78723796~78724136:- CESC cis rs7178909 0.835 rs12437459 ENSG00000259677.1 RP11-493E3.1 4.26 3.07e-05 0.0139 0.31 0.28 Common traits (Other); chr15:89877541 chr15:89876540~89877285:+ CESC cis rs667920 0.5 rs34498968 ENSG00000239213.4 NCK1-AS1 -4.26 3.07e-05 0.0139 -0.45 -0.28 Coronary artery disease; chr3:136476288 chr3:136841726~136862054:- CESC cis rs755249 1 rs4660293 ENSG00000228060.1 RP11-69E11.8 4.26 3.07e-05 0.0139 0.3 0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39562508 chr1:39565160~39573203:+ CESC cis rs42490 0.868 rs12675281 ENSG00000251136.7 RP11-37B2.1 4.26 3.07e-05 0.0139 0.29 0.28 Leprosy; chr8:89681561 chr8:89609409~89757727:- CESC cis rs2771051 0.931 rs12337818 ENSG00000230734.1 RPL10P3 4.26 3.07e-05 0.0139 0.28 0.28 Venous thromboembolism (SNP x SNP interaction); chr9:117534107 chr9:117180628~117181095:- CESC cis rs7727544 0.836 rs10463892 ENSG00000233006.5 AC034220.3 4.26 3.07e-05 0.0139 0.3 0.28 Blood metabolite levels; chr5:132263012 chr5:132311285~132369916:- CESC cis rs7727544 0.901 rs55633655 ENSG00000233006.5 AC034220.3 4.26 3.07e-05 0.0139 0.3 0.28 Blood metabolite levels; chr5:132263063 chr5:132311285~132369916:- CESC cis rs765787 0.53 rs12323957 ENSG00000259520.4 CTD-2651B20.3 -4.26 3.07e-05 0.0139 -0.35 -0.28 Uric acid levels; chr15:45198575 chr15:45251580~45279251:- CESC cis rs9487094 0.689 rs9480936 ENSG00000260273.1 RP11-425D10.10 4.26 3.07e-05 0.0139 0.35 0.28 Height; chr6:109358227 chr6:109382795~109383666:+ CESC cis rs75422866 0.867 rs73111258 ENSG00000274902.1 RP1-197B17.4 4.26 3.07e-05 0.0139 0.69 0.28 Pneumonia; chr12:47597313 chr12:47731908~47732351:+ CESC cis rs4713118 0.662 rs149948 ENSG00000219392.1 RP1-265C24.5 -4.26 3.07e-05 0.0139 -0.34 -0.28 Parkinson's disease; chr6:28007039 chr6:28115628~28116551:+ CESC cis rs2243480 1 rs316315 ENSG00000228409.4 CCT6P1 -4.26 3.07e-05 0.0139 -0.35 -0.28 Diabetic kidney disease; chr7:66126218 chr7:65751142~65763354:+ CESC cis rs1023500 0.573 rs8135801 ENSG00000273366.1 CTA-989H11.1 4.26 3.07e-05 0.0139 0.36 0.28 Schizophrenia; chr22:42079564 chr22:42278188~42278846:+ CESC cis rs7587476 0.784 rs17424051 ENSG00000229267.2 AC072062.1 -4.26 3.07e-05 0.0139 -0.35 -0.28 Neuroblastoma; chr2:214824268 chr2:214810229~214963274:+ CESC cis rs189798 0.807 rs330905 ENSG00000254340.1 RP11-10A14.3 4.26 3.08e-05 0.014 0.35 0.28 Myopia (pathological); chr8:9136041 chr8:9141424~9145435:+ CESC cis rs10129255 0.957 rs10141052 ENSG00000211970.3 IGHV4-61 -4.26 3.08e-05 0.014 -0.21 -0.28 Kawasaki disease; chr14:106776528 chr14:106639119~106639657:- CESC cis rs10129255 0.957 rs10141009 ENSG00000211970.3 IGHV4-61 -4.26 3.08e-05 0.014 -0.21 -0.28 Kawasaki disease; chr14:106776695 chr14:106639119~106639657:- CESC cis rs10129255 0.912 rs6576227 ENSG00000211970.3 IGHV4-61 -4.26 3.08e-05 0.014 -0.21 -0.28 Kawasaki disease; chr14:106778202 chr14:106639119~106639657:- CESC cis rs5769707 0.967 rs763126 ENSG00000235111.1 RP1-29C18.8 4.26 3.08e-05 0.014 0.28 0.28 Monocyte percentage of white cells;Monocyte count; chr22:49594926 chr22:49612657~49615716:- CESC cis rs2243480 1 rs160639 ENSG00000228409.4 CCT6P1 4.26 3.08e-05 0.014 0.41 0.28 Diabetic kidney disease; chr7:66115000 chr7:65751142~65763354:+ CESC cis rs7005380 0.58 rs13265546 ENSG00000279347.1 RP11-85I17.2 -4.26 3.08e-05 0.014 -0.25 -0.28 Interstitial lung disease; chr8:119907735 chr8:119838736~119840385:- CESC cis rs12580194 1 rs73118926 ENSG00000237493.3 RP11-603J24.7 -4.26 3.08e-05 0.014 -0.42 -0.28 Cancer; chr12:55309551 chr12:55980432~55981035:- CESC cis rs4423214 0.592 rs3829251 ENSG00000254682.1 RP11-660L16.2 -4.26 3.08e-05 0.014 -0.43 -0.28 Vitamin D levels; chr11:71483513 chr11:71448674~71452157:+ CESC cis rs4686914 0.927 rs12634556 ENSG00000228804.4 RP11-211G3.3 4.26 3.08e-05 0.014 0.33 0.28 Metabolite levels; chr3:188002899 chr3:187702313~187733849:+ CESC cis rs13108904 0.901 rs6826029 ENSG00000253399.1 AC078852.2 -4.26 3.09e-05 0.014 -0.33 -0.28 Obesity-related traits; chr4:1313901 chr4:1358479~1359461:+ CESC cis rs2187895 1 rs2187895 ENSG00000271811.1 RP1-79C4.4 4.26 3.09e-05 0.014 0.38 0.28 Tonsillectomy; chr1:170715290 chr1:170667381~170669425:+ CESC cis rs2732480 0.577 rs2732479 ENSG00000240399.1 RP1-228P16.1 4.26 3.09e-05 0.014 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342477 chr12:48054813~48055591:- CESC cis rs2732480 0.537 rs1061986 ENSG00000240399.1 RP1-228P16.1 4.26 3.09e-05 0.014 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48342656 chr12:48054813~48055591:- CESC cis rs2732480 0.577 rs2732481 ENSG00000240399.1 RP1-228P16.1 4.26 3.09e-05 0.014 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343202 chr12:48054813~48055591:- CESC cis rs2732480 0.557 rs2732484 ENSG00000240399.1 RP1-228P16.1 4.26 3.09e-05 0.014 0.33 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343462 chr12:48054813~48055591:- CESC cis rs7005380 0.581 rs13265513 ENSG00000279347.1 RP11-85I17.2 4.26 3.09e-05 0.014 0.3 0.28 Interstitial lung disease; chr8:119907686 chr8:119838736~119840385:- CESC cis rs2412819 0.571 rs28410121 ENSG00000249839.1 AC011330.5 4.26 3.09e-05 0.014 0.35 0.28 Lung cancer; chr15:43777831 chr15:43663654~43684339:- CESC cis rs330048 0.525 rs10112237 ENSG00000254340.1 RP11-10A14.3 -4.26 3.09e-05 0.014 -0.34 -0.28 Systemic lupus erythematosus; chr8:9215219 chr8:9141424~9145435:+ CESC cis rs761746 0.739 rs140078 ENSG00000236132.1 CTA-440B3.1 4.26 3.09e-05 0.014 0.34 0.28 Intelligence; chr22:31714177 chr22:31816379~31817491:- CESC cis rs12134133 1 rs2782840 ENSG00000274245.1 RP11-357P18.2 4.26 3.1e-05 0.014 0.34 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310838 chr1:207372559~207373252:+ CESC cis rs10788972 0.683 rs6672905 ENSG00000225183.1 RP4-758J24.4 -4.26 3.1e-05 0.014 -0.33 -0.28 Parkinson disease and lewy body pathology; chr1:54097566 chr1:54089856~54090093:+ CESC cis rs7005380 0.62 rs6987580 ENSG00000279347.1 RP11-85I17.2 4.26 3.1e-05 0.014 0.25 0.28 Interstitial lung disease; chr8:119898140 chr8:119838736~119840385:- CESC cis rs875971 0.862 rs908915 ENSG00000232559.3 GS1-124K5.12 -4.26 3.1e-05 0.014 -0.29 -0.28 Aortic root size; chr7:66149664 chr7:66554588~66576923:- CESC cis rs4686914 0.963 rs9870112 ENSG00000228804.4 RP11-211G3.3 4.25 3.1e-05 0.0141 0.33 0.28 Metabolite levels; chr3:188007050 chr3:187702313~187733849:+ CESC cis rs7829975 0.557 rs7816427 ENSG00000253893.2 FAM85B 4.25 3.11e-05 0.0141 0.38 0.28 Mood instability; chr8:8688374 chr8:8167819~8226614:- CESC cis rs7829975 0.714 rs11777085 ENSG00000253893.2 FAM85B -4.25 3.11e-05 0.0141 -0.34 -0.28 Mood instability; chr8:8814919 chr8:8167819~8226614:- CESC cis rs889398 1 rs889398 ENSG00000226232.7 RP11-419C5.2 4.25 3.11e-05 0.0141 0.26 0.28 Body mass index; chr16:69522812 chr16:69976388~69996188:- CESC cis rs9425766 0.626 rs6691053 ENSG00000224977.1 RP11-160H22.3 -4.25 3.11e-05 0.0141 -0.36 -0.28 Life satisfaction; chr1:173899817 chr1:174022509~174022985:+ CESC cis rs9487094 0.689 rs8465 ENSG00000260273.1 RP11-425D10.10 4.25 3.11e-05 0.0141 0.34 0.28 Height; chr6:109367335 chr6:109382795~109383666:+ CESC cis rs6921919 0.583 rs7764722 ENSG00000216901.1 AL022393.7 4.25 3.11e-05 0.0141 0.3 0.28 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28176188~28176674:+ CESC cis rs12144049 0.705 rs4240879 ENSG00000227045.1 RP11-98D18.1 -4.25 3.11e-05 0.0141 -0.39 -0.28 Inflammatory skin disease;Atopic dermatitis; chr1:152442388 chr1:151701026~151708386:+ CESC cis rs12701220 0.541 rs12535516 ENSG00000224079.1 AC091729.7 4.25 3.11e-05 0.0141 0.41 0.28 Bronchopulmonary dysplasia; chr7:1074804 chr7:1074450~1078036:+ CESC cis rs13113518 1 rs7660980 ENSG00000273257.1 RP11-177J6.1 -4.25 3.11e-05 0.0141 -0.36 -0.28 Height; chr4:55542948 chr4:55387949~55388271:+ CESC cis rs8059260 0.668 rs75811377 ENSG00000274038.1 RP11-66H6.4 -4.25 3.12e-05 0.0141 -0.46 -0.28 Alcohol consumption over the past year; chr16:11023451 chr16:11056556~11057034:+ CESC cis rs9322193 0.923 rs17745062 ENSG00000216906.2 RP11-350J20.9 4.25 3.12e-05 0.0141 0.31 0.28 Lung cancer; chr6:149721079 chr6:149904243~149906418:+ CESC cis rs77204473 0.744 rs12420200 ENSG00000278768.1 BACE1-AS 4.25 3.12e-05 0.0141 0.43 0.28 Sum eosinophil basophil counts;Eosinophil counts; chr11:117127590 chr11:117290874~117293571:+ CESC cis rs116095464 1 rs6873902 ENSG00000250848.1 CTD-2083E4.5 -4.25 3.12e-05 0.0141 -0.45 -0.28 Breast cancer; chr5:313222 chr5:288833~290321:- CESC cis rs116095464 1 rs7736 ENSG00000250848.1 CTD-2083E4.5 -4.25 3.12e-05 0.0141 -0.45 -0.28 Breast cancer; chr5:314820 chr5:288833~290321:- CESC cis rs7896729 0.556 rs35242309 ENSG00000215267.7 AKR1C7P -4.25 3.12e-05 0.0141 -0.37 -0.28 Intelligence; chr10:5293650 chr10:5275173~5288470:- CESC cis rs9322193 0.923 rs57012784 ENSG00000268592.3 RAET1E-AS1 4.25 3.13e-05 0.0142 0.35 0.28 Lung cancer; chr6:149627691 chr6:149863494~149919507:+ CESC cis rs7580658 0.637 rs12463909 ENSG00000236682.1 AC068282.3 4.25 3.13e-05 0.0142 0.34 0.28 Protein C levels; chr2:127214162 chr2:127389130~127400580:+ CESC cis rs8031584 0.505 rs2959036 ENSG00000260382.1 RP11-540B6.2 -4.25 3.13e-05 0.0142 -0.37 -0.28 Huntington's disease progression; chr15:30927539 chr15:30882267~30883231:- CESC cis rs8031584 0.541 rs2955777 ENSG00000260382.1 RP11-540B6.2 -4.25 3.13e-05 0.0142 -0.37 -0.28 Huntington's disease progression; chr15:30927585 chr15:30882267~30883231:- CESC cis rs72772090 0.539 rs11135480 ENSG00000248734.2 CTD-2260A17.1 -4.25 3.13e-05 0.0142 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774878 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs13601 ENSG00000248734.2 CTD-2260A17.1 -4.25 3.13e-05 0.0142 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774892 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs56120748 ENSG00000248734.2 CTD-2260A17.1 -4.25 3.13e-05 0.0142 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774918 chr5:96784777~96785999:+ CESC cis rs72772090 0.539 rs72773917 ENSG00000248734.2 CTD-2260A17.1 -4.25 3.13e-05 0.0142 -0.45 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96775598 chr5:96784777~96785999:+ CESC cis rs71403859 0.73 rs12923781 ENSG00000260886.1 TAT-AS1 4.25 3.13e-05 0.0142 0.43 0.28 Post bronchodilator FEV1; chr16:71619561 chr16:71565789~71578187:+ CESC cis rs7208859 0.614 rs216477 ENSG00000263531.1 RP13-753N3.1 -4.25 3.13e-05 0.0142 -0.58 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30539726 chr17:30863921~30864940:- CESC cis rs7688540 0.771 rs61792114 ENSG00000211553.1 AC253576.2 -4.25 3.13e-05 0.0142 -0.43 -0.28 Facial morphology (factor 6, height of vermillion lower lip); chr4:295350 chr4:136461~136568:+ CESC cis rs769267 1 rs769267 ENSG00000269131.1 AC004447.2 -4.25 3.14e-05 0.0142 -0.23 -0.28 Tonsillectomy; chr19:19336127 chr19:18990893~18993610:+ CESC cis rs75422866 0.867 rs7303895 ENSG00000257433.4 RP1-197B17.3 4.25 3.14e-05 0.0142 0.57 0.28 Pneumonia; chr12:47683290 chr12:47706085~47742294:+ CESC cis rs2980879 0.804 rs2954025 ENSG00000255080.1 RP11-1082L8.3 4.25 3.14e-05 0.0142 0.28 0.28 Adiponectin levels; chr8:125472221 chr8:124834884~124857516:- CESC cis rs9487094 0.67 rs12212476 ENSG00000260273.1 RP11-425D10.10 4.25 3.14e-05 0.0142 0.35 0.28 Height; chr6:109501402 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs12198938 ENSG00000260273.1 RP11-425D10.10 4.25 3.14e-05 0.0142 0.35 0.28 Height; chr6:109501429 chr6:109382795~109383666:+ CESC cis rs12908161 0.96 rs11633450 ENSG00000259728.4 LINC00933 4.25 3.14e-05 0.0142 0.37 0.28 Schizophrenia; chr15:84764056 chr15:84570649~84580175:+ CESC cis rs11779988 0.545 rs397096 ENSG00000253671.1 RP11-806O11.1 4.25 3.14e-05 0.0142 0.33 0.28 Breast cancer; chr8:17941339 chr8:17808941~17820868:+ CESC cis rs2274273 0.624 rs1972221 ENSG00000258413.1 RP11-665C16.6 -4.25 3.14e-05 0.0142 -0.36 -0.28 Protein biomarker; chr14:55318663 chr14:55262767~55272075:- CESC cis rs67311347 0.955 rs4973999 ENSG00000223797.4 ENTPD3-AS1 4.25 3.14e-05 0.0142 0.27 0.28 Renal cell carcinoma; chr3:40418892 chr3:40313802~40453329:- CESC cis rs10043775 1 rs4274968 ENSG00000251330.3 CTD-2283N19.1 -4.25 3.14e-05 0.0142 -0.36 -0.28 Periodontal microbiota; chr5:148446027 chr5:148430159~148430807:- CESC cis rs10043775 1 rs4472255 ENSG00000251330.3 CTD-2283N19.1 -4.25 3.14e-05 0.0142 -0.36 -0.28 Periodontal microbiota; chr5:148446054 chr5:148430159~148430807:- CESC cis rs10043775 1 rs6884076 ENSG00000251330.3 CTD-2283N19.1 -4.25 3.14e-05 0.0142 -0.36 -0.28 Periodontal microbiota; chr5:148447171 chr5:148430159~148430807:- CESC cis rs2019137 0.56 rs7421852 ENSG00000274877.1 RP11-65I12.1 -4.25 3.15e-05 0.0142 -0.37 -0.28 Lymphocyte counts; chr2:113232684 chr2:113237595~113240825:+ CESC cis rs10129255 0.957 rs10142918 ENSG00000280411.1 IGHV1-69-2 -4.25 3.15e-05 0.0142 -0.21 -0.28 Kawasaki disease; chr14:106782206 chr14:106762092~106762588:- CESC cis rs10129255 0.957 rs10142859 ENSG00000280411.1 IGHV1-69-2 -4.25 3.15e-05 0.0142 -0.21 -0.28 Kawasaki disease; chr14:106782238 chr14:106762092~106762588:- CESC cis rs2404602 0.583 rs12592501 ENSG00000280730.1 AC090181.1 4.25 3.15e-05 0.0142 0.21 0.28 Blood metabolite levels; chr15:76262449 chr15:77056895~77057021:+ CESC cis rs2404602 0.583 rs2139190 ENSG00000280730.1 AC090181.1 4.25 3.15e-05 0.0142 0.21 0.28 Blood metabolite levels; chr15:76263198 chr15:77056895~77057021:+ CESC cis rs6921919 0.945 rs16901847 ENSG00000204709.4 LINC01556 4.25 3.15e-05 0.0142 0.33 0.28 Autism spectrum disorder or schizophrenia; chr6:28408074 chr6:28943877~28944537:+ CESC cis rs17711722 0.653 rs2460421 ENSG00000236529.1 RP13-254B10.1 -4.25 3.15e-05 0.0142 -0.3 -0.28 Calcium levels; chr7:66026136 chr7:65840212~65840596:+ CESC cis rs7829975 0.688 rs6995407 ENSG00000253893.2 FAM85B -4.25 3.15e-05 0.0142 -0.37 -0.28 Mood instability; chr8:8527137 chr8:8167819~8226614:- CESC cis rs9532669 0.963 rs9532628 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40875172 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532629 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40875193 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs7491149 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40875216 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532630 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40875472 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs4306385 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40875641 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4406939 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40876108 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4628824 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40876217 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532632 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40876309 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532633 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40876332 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532634 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40876369 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532635 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40876397 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs12428959 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40876638 chr13:40863599~40863902:- CESC cis rs9532669 0.895 rs4942009 ENSG00000176268.5 CYCSP34 4.25 3.15e-05 0.0142 0.28 0.28 Cervical cancer; chr13:40877243 chr13:40863599~40863902:- CESC cis rs9322193 0.923 rs10782316 ENSG00000216906.2 RP11-350J20.9 4.25 3.16e-05 0.0142 0.31 0.28 Lung cancer; chr6:149752755 chr6:149904243~149906418:+ CESC cis rs7581030 0.55 rs34807546 ENSG00000281195.1 ZNF638-IT1 -4.25 3.16e-05 0.0142 -0.42 -0.28 Testicular germ cell tumor; chr2:71212752 chr2:71373938~71376320:+ CESC cis rs7581030 0.55 rs35226067 ENSG00000281195.1 ZNF638-IT1 -4.25 3.16e-05 0.0142 -0.42 -0.28 Testicular germ cell tumor; chr2:71213394 chr2:71373938~71376320:+ CESC cis rs2742417 0.603 rs2742395 ENSG00000244357.3 RN7SL145P 4.25 3.16e-05 0.0143 0.26 0.28 Response to anti-depressant treatment in major depressive disorder; chr3:45717103 chr3:45742675~45742970:+ CESC cis rs987724 0.592 rs1430410 ENSG00000240875.4 LINC00886 -4.25 3.16e-05 0.0143 -0.34 -0.28 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156807773 chr3:156747346~156817062:- CESC cis rs8177876 0.822 rs8177959 ENSG00000261838.4 RP11-303E16.6 4.25 3.16e-05 0.0143 0.57 0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81082082 chr16:81069854~81076598:+ CESC cis rs1707322 1 rs4074225 ENSG00000281133.1 AL355480.3 -4.25 3.16e-05 0.0143 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45926692 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4134387 ENSG00000281133.1 AL355480.3 -4.25 3.16e-05 0.0143 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45929486 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4660332 ENSG00000281133.1 AL355480.3 -4.25 3.16e-05 0.0143 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45995746 chr1:45580892~45580996:- CESC cis rs9987353 0.566 rs13260067 ENSG00000173295.6 FAM86B3P -4.25 3.16e-05 0.0143 -0.36 -0.28 Recombination measurement; chr8:9213523 chr8:8228595~8244865:+ CESC cis rs10875746 0.551 rs12322347 ENSG00000240399.1 RP1-228P16.1 -4.25 3.16e-05 0.0143 -0.36 -0.28 Longevity (90 years and older); chr12:48313915 chr12:48054813~48055591:- CESC cis rs10875746 0.551 rs12322348 ENSG00000240399.1 RP1-228P16.1 -4.25 3.16e-05 0.0143 -0.36 -0.28 Longevity (90 years and older); chr12:48313916 chr12:48054813~48055591:- CESC cis rs79243044 0.965 rs12419693 ENSG00000224295.2 AC087380.14 -4.25 3.16e-05 0.0143 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5535726 chr11:5518441~5524955:- CESC cis rs79243044 1 rs11037993 ENSG00000224295.2 AC087380.14 -4.25 3.16e-05 0.0143 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5535967 chr11:5518441~5524955:- CESC cis rs79243044 0.965 rs11038005 ENSG00000224295.2 AC087380.14 -4.25 3.16e-05 0.0143 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5536729 chr11:5518441~5524955:- CESC cis rs10463554 0.853 rs246902 ENSG00000175749.11 EIF3KP1 4.25 3.16e-05 0.0143 0.29 0.28 Parkinson's disease; chr5:103253553 chr5:103032376~103033031:+ CESC cis rs17695224 0.545 rs10500309 ENSG00000268095.1 ZNF649-AS1 4.25 3.17e-05 0.0143 0.34 0.28 HDL cholesterol;HDL cholesterol levels; chr19:51829123 chr19:51888025~51900463:+ CESC cis rs17695224 0.545 rs8111469 ENSG00000268095.1 ZNF649-AS1 4.25 3.17e-05 0.0143 0.34 0.28 HDL cholesterol;HDL cholesterol levels; chr19:51829272 chr19:51888025~51900463:+ CESC cis rs17695224 0.565 rs61681419 ENSG00000268095.1 ZNF649-AS1 4.25 3.17e-05 0.0143 0.34 0.28 HDL cholesterol;HDL cholesterol levels; chr19:51830726 chr19:51888025~51900463:+ CESC cis rs17695224 0.545 rs13346095 ENSG00000268095.1 ZNF649-AS1 4.25 3.17e-05 0.0143 0.34 0.28 HDL cholesterol;HDL cholesterol levels; chr19:51831092 chr19:51888025~51900463:+ CESC cis rs17695224 0.5 rs13346104 ENSG00000268095.1 ZNF649-AS1 4.25 3.17e-05 0.0143 0.34 0.28 HDL cholesterol;HDL cholesterol levels; chr19:51831173 chr19:51888025~51900463:+ CESC cis rs9322193 0.847 rs868375 ENSG00000216906.2 RP11-350J20.9 4.25 3.17e-05 0.0143 0.33 0.28 Lung cancer; chr6:149844905 chr6:149904243~149906418:+ CESC cis rs7714584 1 rs11167515 ENSG00000197083.10 ZNF300P1 4.25 3.17e-05 0.0143 0.52 0.28 Crohn's disease; chr5:150859909 chr5:150930645~150946289:- CESC cis rs751837 0.932 rs35084986 ENSG00000240624.1 RP11-45P15.2 -4.25 3.17e-05 0.0143 -0.42 -0.28 Large B-cell lymphoma; chr14:103023968 chr14:103282933~103283468:+ CESC cis rs3020736 0.5 rs7292241 ENSG00000273366.1 CTA-989H11.1 4.25 3.17e-05 0.0143 0.38 0.28 Autism spectrum disorder or schizophrenia; chr22:42096059 chr22:42278188~42278846:+ CESC cis rs3020736 0.5 rs5996111 ENSG00000273366.1 CTA-989H11.1 4.25 3.17e-05 0.0143 0.38 0.28 Autism spectrum disorder or schizophrenia; chr22:42097898 chr22:42278188~42278846:+ CESC cis rs8020095 0.528 rs9671368 ENSG00000258561.1 RP11-72M17.1 -4.25 3.17e-05 0.0143 -0.41 -0.28 Depression (quantitative trait); chr14:66796737 chr14:66212810~66509394:- CESC cis rs2274273 0.588 rs2880103 ENSG00000258413.1 RP11-665C16.6 -4.25 3.17e-05 0.0143 -0.36 -0.28 Protein biomarker; chr14:55271114 chr14:55262767~55272075:- CESC cis rs2274273 0.553 rs56166765 ENSG00000258413.1 RP11-665C16.6 -4.25 3.17e-05 0.0143 -0.36 -0.28 Protein biomarker; chr14:55271300 chr14:55262767~55272075:- CESC cis rs516805 0.923 rs491171 ENSG00000279453.1 RP3-425C14.4 -4.25 3.17e-05 0.0143 -0.32 -0.28 Lymphocyte counts; chr6:122408021 chr6:122436789~122439223:- CESC cis rs516805 0.923 rs556675 ENSG00000279453.1 RP3-425C14.4 -4.25 3.17e-05 0.0143 -0.32 -0.28 Lymphocyte counts; chr6:122408083 chr6:122436789~122439223:- CESC cis rs9322193 0.962 rs4380763 ENSG00000216906.2 RP11-350J20.9 4.25 3.17e-05 0.0143 0.31 0.28 Lung cancer; chr6:149678086 chr6:149904243~149906418:+ CESC cis rs7259376 0.525 rs1704016 ENSG00000213971.6 RP11-15H20.6 -4.25 3.18e-05 0.0143 -0.33 -0.28 Menopause (age at onset); chr19:22452581 chr19:23259906~23274251:- CESC cis rs2243480 1 rs6460260 ENSG00000275400.1 RP4-756H11.5 -4.25 3.18e-05 0.0143 -0.47 -0.28 Diabetic kidney disease; chr7:65750468 chr7:66553805~66554199:- CESC cis rs2243480 1 rs6460261 ENSG00000275400.1 RP4-756H11.5 -4.25 3.18e-05 0.0143 -0.47 -0.28 Diabetic kidney disease; chr7:65750593 chr7:66553805~66554199:- CESC cis rs4722166 0.63 rs12537614 ENSG00000179428.2 AC073072.5 -4.25 3.18e-05 0.0143 -0.38 -0.28 Lung cancer; chr7:22749932 chr7:22725395~22727620:- CESC cis rs11089937 0.667 rs11704024 ENSG00000211638.2 IGLV8-61 -4.25 3.18e-05 0.0143 -0.28 -0.28 Periodontitis (PAL4Q3); chr22:22151195 chr22:22098700~22099212:+ CESC cis rs9322193 0.884 rs62439836 ENSG00000216906.2 RP11-350J20.9 4.25 3.18e-05 0.0143 0.31 0.28 Lung cancer; chr6:149669173 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs4869812 ENSG00000216906.2 RP11-350J20.9 4.25 3.18e-05 0.0143 0.31 0.28 Lung cancer; chr6:149669447 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs1572229 ENSG00000216906.2 RP11-350J20.9 4.25 3.19e-05 0.0144 0.31 0.28 Lung cancer; chr6:149743841 chr6:149904243~149906418:+ CESC cis rs9400467 0.506 rs12196873 ENSG00000272356.1 RP5-1112D6.8 4.25 3.19e-05 0.0144 0.34 0.28 Amino acid levels;Blood metabolite levels; chr6:111276855 chr6:111309203~111313517:+ CESC cis rs9309473 1 rs6546835 ENSG00000163016.8 ALMS1P 4.25 3.19e-05 0.0144 0.35 0.28 Metabolite levels; chr2:73437587 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs2901438 ENSG00000163016.8 ALMS1P 4.25 3.19e-05 0.0144 0.35 0.28 Metabolite levels; chr2:73438528 chr2:73644919~73685576:+ CESC cis rs7131987 0.65 rs7973786 ENSG00000257176.2 RP11-996F15.2 -4.25 3.19e-05 0.0144 -0.33 -0.28 QT interval; chr12:29309811 chr12:29280418~29317848:- CESC cis rs7131987 0.718 rs7976961 ENSG00000257176.2 RP11-996F15.2 -4.25 3.19e-05 0.0144 -0.33 -0.28 QT interval; chr12:29310155 chr12:29280418~29317848:- CESC cis rs950880 0.767 rs11123923 ENSG00000234389.1 AC007278.3 -4.25 3.19e-05 0.0144 -0.3 -0.28 Serum protein levels (sST2); chr2:102351384 chr2:102438713~102440475:+ CESC cis rs911555 0.755 rs2273702 ENSG00000244691.1 RPL10AP1 4.25 3.19e-05 0.0144 0.38 0.28 Intelligence (multi-trait analysis); chr14:103451845 chr14:103412119~103412761:- CESC cis rs2933343 0.903 rs2638846 ENSG00000231305.3 RP11-723O4.2 4.25 3.19e-05 0.0144 0.28 0.28 IgG glycosylation; chr3:128868320 chr3:128861313~128871540:- CESC cis rs6782228 1 rs35871360 ENSG00000242551.2 POU5F1P6 4.25 3.19e-05 0.0144 0.34 0.28 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128617286 chr3:128674735~128677005:- CESC cis rs9322193 0.923 rs10872644 ENSG00000216906.2 RP11-350J20.9 4.25 3.19e-05 0.0144 0.31 0.28 Lung cancer; chr6:149741819 chr6:149904243~149906418:+ CESC cis rs875971 0.929 rs4122249 ENSG00000232559.3 GS1-124K5.12 4.25 3.19e-05 0.0144 0.3 0.28 Aortic root size; chr7:66455949 chr7:66554588~66576923:- CESC cis rs6964587 0.967 rs9656003 ENSG00000188693.7 CYP51A1-AS1 -4.25 3.19e-05 0.0144 -0.29 -0.28 Breast cancer; chr7:92137008 chr7:92134604~92180725:+ CESC cis rs9660180 0.875 rs4648727 ENSG00000268575.1 RP1-283E3.8 4.25 3.19e-05 0.0144 0.26 0.28 Body mass index; chr1:1844830 chr1:1702736~1737688:- CESC cis rs72772090 0.634 rs17401901 ENSG00000248734.2 CTD-2260A17.1 -4.25 3.2e-05 0.0144 -0.42 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96756221 chr5:96784777~96785999:+ CESC cis rs72772090 0.634 rs72773906 ENSG00000248734.2 CTD-2260A17.1 -4.25 3.2e-05 0.0144 -0.42 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96756570 chr5:96784777~96785999:+ CESC cis rs9918079 0.56 rs4698409 ENSG00000273133.1 RP11-799M12.2 -4.25 3.2e-05 0.0144 -0.36 -0.28 Obesity-related traits; chr4:15658143 chr4:15563698~15564253:- CESC cis rs651386 0.506 rs12027180 ENSG00000271811.1 RP1-79C4.4 4.25 3.2e-05 0.0144 0.38 0.28 Atrial fibrillation; chr1:170594064 chr1:170667381~170669425:+ CESC cis rs17772222 0.917 rs10143767 ENSG00000258983.2 RP11-507K2.2 4.25 3.2e-05 0.0144 0.34 0.28 Coronary artery calcification; chr14:88514867 chr14:88499334~88515502:+ CESC cis rs451417 1 rs236105 ENSG00000275632.1 RP5-967N21.11 -4.25 3.2e-05 0.0144 -0.34 -0.28 Menopause (age at onset); chr20:5979186 chr20:6000418~6000941:+ CESC cis rs9532669 0.926 rs4334153 ENSG00000176268.5 CYCSP34 4.25 3.2e-05 0.0144 0.28 0.28 Cervical cancer; chr13:40877737 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4309270 ENSG00000176268.5 CYCSP34 4.25 3.2e-05 0.0144 0.28 0.28 Cervical cancer; chr13:40877827 chr13:40863599~40863902:- CESC cis rs7188445 0.871 rs8048928 ENSG00000261390.4 RP11-345M22.2 -4.25 3.2e-05 0.0144 -0.34 -0.28 Urate levels; chr16:79671039 chr16:79715232~79770563:- CESC cis rs1023500 0.573 rs133380 ENSG00000273366.1 CTA-989H11.1 -4.25 3.2e-05 0.0144 -0.35 -0.28 Schizophrenia; chr22:42072906 chr22:42278188~42278846:+ CESC cis rs9287719 0.649 rs12617968 ENSG00000234818.1 AC092687.5 4.25 3.21e-05 0.0144 0.56 0.28 Prostate cancer; chr2:10581819 chr2:10589166~10604830:+ CESC cis rs2337406 0.714 rs2337463 ENSG00000274576.2 IGHV2-70 -4.25 3.21e-05 0.0144 -0.29 -0.28 Alzheimer's disease (late onset); chr14:106816066 chr14:106770577~106771020:- CESC cis rs6964587 0.9 rs11984136 ENSG00000188693.7 CYP51A1-AS1 -4.25 3.21e-05 0.0144 -0.29 -0.28 Breast cancer; chr7:92137639 chr7:92134604~92180725:+ CESC cis rs6964587 0.933 rs28671255 ENSG00000188693.7 CYP51A1-AS1 -4.25 3.21e-05 0.0144 -0.29 -0.28 Breast cancer; chr7:92141391 chr7:92134604~92180725:+ CESC cis rs34375054 0.573 rs12581367 ENSG00000279233.1 RP11-158L12.4 4.25 3.21e-05 0.0144 0.32 0.28 Post bronchodilator FEV1/FVC ratio; chr12:125170095 chr12:125138245~125141711:+ CESC cis rs10129255 1 rs10134517 ENSG00000223648.3 IGHV3-64 4.25 3.21e-05 0.0144 0.25 0.28 Kawasaki disease; chr14:106718498 chr14:106643132~106658258:- CESC cis rs2455601 0.638 rs2742484 ENSG00000254860.4 TMEM9B-AS1 4.25 3.21e-05 0.0144 0.33 0.28 Schizophrenia; chr11:8966536 chr11:8964675~8977527:+ CESC cis rs2455601 0.638 rs2248245 ENSG00000254860.4 TMEM9B-AS1 4.25 3.21e-05 0.0144 0.33 0.28 Schizophrenia; chr11:8966803 chr11:8964675~8977527:+ CESC cis rs875971 0.862 rs10276077 ENSG00000232559.3 GS1-124K5.12 -4.25 3.21e-05 0.0144 -0.29 -0.28 Aortic root size; chr7:66263424 chr7:66554588~66576923:- CESC cis rs7581030 0.55 rs35963842 ENSG00000281195.1 ZNF638-IT1 -4.25 3.21e-05 0.0144 -0.42 -0.28 Testicular germ cell tumor; chr2:71214248 chr2:71373938~71376320:+ CESC cis rs7581030 0.517 rs35073357 ENSG00000281195.1 ZNF638-IT1 -4.25 3.21e-05 0.0144 -0.42 -0.28 Testicular germ cell tumor; chr2:71215623 chr2:71373938~71376320:+ CESC cis rs7581030 0.517 rs17038417 ENSG00000281195.1 ZNF638-IT1 -4.25 3.21e-05 0.0144 -0.42 -0.28 Testicular germ cell tumor; chr2:71216978 chr2:71373938~71376320:+ CESC cis rs7581030 0.55 rs71414897 ENSG00000281195.1 ZNF638-IT1 -4.25 3.21e-05 0.0144 -0.42 -0.28 Testicular germ cell tumor; chr2:71218839 chr2:71373938~71376320:+ CESC cis rs3845817 0.703 rs702887 ENSG00000281920.1 RP11-418H16.1 -4.25 3.22e-05 0.0145 -0.35 -0.28 Bipolar disorder; chr2:65527074 chr2:65623272~65628424:+ CESC cis rs3845817 0.703 rs702888 ENSG00000281920.1 RP11-418H16.1 -4.25 3.22e-05 0.0145 -0.35 -0.28 Bipolar disorder; chr2:65527905 chr2:65623272~65628424:+ CESC cis rs1023500 0.551 rs2859438 ENSG00000273366.1 CTA-989H11.1 -4.25 3.22e-05 0.0145 -0.37 -0.28 Schizophrenia; chr22:42070976 chr22:42278188~42278846:+ CESC cis rs11168351 1 rs11168351 ENSG00000240399.1 RP1-228P16.1 4.25 3.22e-05 0.0145 0.3 0.28 Bipolar disorder and schizophrenia; chr12:48009982 chr12:48054813~48055591:- CESC cis rs2280018 0.963 rs4985147 ENSG00000260735.1 RP11-72I8.1 -4.25 3.22e-05 0.0145 -0.3 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15074903 chr16:15094411~15109197:+ CESC cis rs10129255 0.957 rs10150241 ENSG00000280411.1 IGHV1-69-2 4.25 3.22e-05 0.0145 0.2 0.28 Kawasaki disease; chr14:106775945 chr14:106762092~106762588:- CESC cis rs2991971 0.747 rs2492841 ENSG00000280836.1 AL355480.1 -4.25 3.22e-05 0.0145 -0.31 -0.28 High light scatter reticulocyte count; chr1:45429219 chr1:45581219~45581321:- CESC cis rs748404 0.666 rs35158584 ENSG00000249839.1 AC011330.5 -4.25 3.22e-05 0.0145 -0.4 -0.28 Lung cancer; chr15:43392876 chr15:43663654~43684339:- CESC cis rs7605378 0.528 rs281787 ENSG00000232732.8 AC073043.1 4.25 3.22e-05 0.0145 0.36 0.28 Osteoporosis; chr2:199919515 chr2:199867396~199911159:- CESC cis rs62355901 0.505 rs72759712 ENSG00000271828.1 CTD-2310F14.1 4.25 3.23e-05 0.0145 0.48 0.28 Breast cancer; chr5:56906519 chr5:56927874~56929573:+ CESC cis rs28735056 0.592 rs2277725 ENSG00000267287.1 RP11-567M16.1 4.25 3.23e-05 0.0145 0.31 0.28 Schizophrenia; chr18:79934168 chr18:79576460~79589010:+ CESC cis rs1707322 1 rs10890382 ENSG00000281133.1 AL355480.3 -4.25 3.23e-05 0.0145 -0.34 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46004002 chr1:45580892~45580996:- CESC cis rs7665090 0.87 rs227361 ENSG00000246560.2 RP11-10L12.4 4.25 3.23e-05 0.0145 0.33 0.28 Primary biliary cholangitis; chr4:102665820 chr4:102828055~102844075:+ CESC cis rs1707322 1 rs11211200 ENSG00000281133.1 AL355480.3 -4.25 3.23e-05 0.0145 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45822680 chr1:45580892~45580996:- CESC cis rs1023500 0.573 rs133381 ENSG00000273366.1 CTA-989H11.1 -4.25 3.23e-05 0.0145 -0.38 -0.28 Schizophrenia; chr22:42074604 chr22:42278188~42278846:+ CESC cis rs2243480 1 rs73142162 ENSG00000275400.1 RP4-756H11.5 4.25 3.23e-05 0.0145 0.47 0.28 Diabetic kidney disease; chr7:65909309 chr7:66553805~66554199:- CESC cis rs2243480 0.808 rs12698508 ENSG00000275400.1 RP4-756H11.5 4.25 3.23e-05 0.0145 0.47 0.28 Diabetic kidney disease; chr7:65946971 chr7:66553805~66554199:- CESC cis rs2439831 0.702 rs2467402 ENSG00000275601.1 AC011330.13 4.25 3.23e-05 0.0145 0.39 0.28 Lung cancer in ever smokers; chr15:43732292 chr15:43642389~43643023:- CESC cis rs11976180 1 rs2961120 ENSG00000273234.1 OR2A13P -4.24 3.24e-05 0.0145 -0.33 -0.28 Obesity-related traits; chr7:144059492 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2951360 ENSG00000273234.1 OR2A13P -4.24 3.24e-05 0.0145 -0.33 -0.28 Obesity-related traits; chr7:144060256 chr7:144142009~144142938:+ CESC cis rs1871045 0.722 rs7255063 ENSG00000279103.1 CTC-204F22.1 4.24 3.24e-05 0.0145 0.3 0.28 Waist-to-hip circumference ratio (smoking years interaction); chr19:44849162 chr19:44246478~44248374:- CESC cis rs35955747 0.778 rs9609263 ENSG00000236132.1 CTA-440B3.1 4.24 3.24e-05 0.0146 0.3 0.28 Neutrophil count;Sum basophil neutrophil counts; chr22:31349288 chr22:31816379~31817491:- CESC cis rs897984 0.683 rs8050330 ENSG00000260911.2 RP11-196G11.2 4.24 3.24e-05 0.0146 0.29 0.28 Dementia with Lewy bodies; chr16:30813649 chr16:31043150~31049868:+ CESC cis rs7688540 0.771 rs11730202 ENSG00000211553.1 AC253576.2 -4.24 3.24e-05 0.0146 -0.38 -0.28 Facial morphology (factor 6, height of vermillion lower lip); chr4:216307 chr4:136461~136568:+ CESC cis rs6740322 0.793 rs13414908 ENSG00000234936.1 AC010883.5 4.24 3.25e-05 0.0146 0.29 0.28 Coronary artery disease; chr2:43319519 chr2:43229573~43233394:+ CESC cis rs6740322 0.793 rs9808360 ENSG00000234936.1 AC010883.5 4.24 3.25e-05 0.0146 0.29 0.28 Coronary artery disease; chr2:43319696 chr2:43229573~43233394:+ CESC cis rs12908161 0.92 rs35758837 ENSG00000225151.9 GOLGA2P7 -4.24 3.25e-05 0.0146 -0.38 -0.28 Schizophrenia; chr15:84768151 chr15:84199311~84230136:- CESC cis rs853679 0.517 rs9348796 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28158424 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs11552219 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28159056 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380058 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28159666 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393895 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28159843 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9357066 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28162053 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393898 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28162598 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9368556 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28163375 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9368557 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28163759 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380059 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28164580 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380060 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28164825 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs35227624 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28164948 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380061 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28165025 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9368558 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Depression; chr6:28165528 chr6:28115628~28116551:+ CESC cis rs4713118 0.587 rs9393899 ENSG00000219392.1 RP1-265C24.5 -4.24 3.25e-05 0.0146 -0.37 -0.28 Parkinson's disease; chr6:28165750 chr6:28115628~28116551:+ CESC cis rs7829975 0.742 rs882462 ENSG00000253893.2 FAM85B -4.24 3.25e-05 0.0146 -0.34 -0.28 Mood instability; chr8:8821020 chr8:8167819~8226614:- CESC cis rs34779708 0.733 rs3936503 ENSG00000230534.5 RP11-297A16.2 -4.24 3.25e-05 0.0146 -0.37 -0.28 Inflammatory bowel disease;Crohn's disease; chr10:35260329 chr10:35098006~35127020:- CESC cis rs465969 0.744 rs3851228 ENSG00000255389.1 C6orf3 4.24 3.25e-05 0.0146 0.46 0.28 Psoriasis; chr6:111526988 chr6:111599875~111602295:+ CESC cis rs6001482 0.679 rs5995706 ENSG00000236850.4 BMS1P20 -4.24 3.25e-05 0.0146 -0.27 -0.28 Diastolic blood pressure; chr22:22236371 chr22:22303224~22322847:+ CESC cis rs6001482 0.702 rs7286018 ENSG00000236850.4 BMS1P20 -4.24 3.25e-05 0.0146 -0.27 -0.28 Diastolic blood pressure; chr22:22236464 chr22:22303224~22322847:+ CESC cis rs2412819 0.571 rs12443084 ENSG00000205771.5 CATSPER2P1 4.24 3.25e-05 0.0146 0.4 0.28 Lung cancer; chr15:43748767 chr15:43726918~43747094:- CESC cis rs2412819 0.571 rs10163069 ENSG00000205771.5 CATSPER2P1 4.24 3.25e-05 0.0146 0.4 0.28 Lung cancer; chr15:43755372 chr15:43726918~43747094:- CESC cis rs2929278 0.617 rs3986209 ENSG00000205771.5 CATSPER2P1 4.24 3.25e-05 0.0146 0.4 0.28 Schizophrenia; chr15:43758675 chr15:43726918~43747094:- CESC cis rs875971 0.545 rs73378304 ENSG00000228409.4 CCT6P1 -4.24 3.25e-05 0.0146 -0.28 -0.28 Aortic root size; chr7:66175760 chr7:65751142~65763354:+ CESC cis rs55665837 1 rs10047429 ENSG00000251991.1 RNU7-49P 4.24 3.26e-05 0.0146 0.31 0.28 Vitamin D levels; chr11:14417486 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs10047457 ENSG00000251991.1 RNU7-49P 4.24 3.26e-05 0.0146 0.31 0.28 Vitamin D levels; chr11:14417913 chr11:14478892~14478953:+ CESC cis rs7429990 0.866 rs3732529 ENSG00000229759.1 MRPS18AP1 4.24 3.26e-05 0.0146 0.28 0.28 Educational attainment (years of education); chr3:47928619 chr3:48256350~48256938:- CESC cis rs2833693 0.574 rs11088205 ENSG00000261610.1 AP000265.1 4.24 3.26e-05 0.0146 0.33 0.28 Temperament; chr21:32179989 chr21:32259804~32261585:- CESC cis rs73086581 1 rs6107393 ENSG00000229539.1 RP11-119B16.2 4.24 3.26e-05 0.0146 0.42 0.28 Response to antidepressants in depression; chr20:4007091 chr20:3888239~3888868:- CESC cis rs7259376 0.525 rs1235534 ENSG00000213971.6 RP11-15H20.6 -4.24 3.26e-05 0.0146 -0.33 -0.28 Menopause (age at onset); chr19:22457224 chr19:23259906~23274251:- CESC cis rs7259376 0.503 rs1230302 ENSG00000213971.6 RP11-15H20.6 -4.24 3.26e-05 0.0146 -0.33 -0.28 Menopause (age at onset); chr19:22457935 chr19:23259906~23274251:- CESC cis rs8020095 0.571 rs8019510 ENSG00000258561.1 RP11-72M17.1 -4.24 3.26e-05 0.0146 -0.41 -0.28 Depression (quantitative trait); chr14:67057198 chr14:66212810~66509394:- CESC cis rs2933343 1 rs876756 ENSG00000231305.3 RP11-723O4.2 4.24 3.27e-05 0.0146 0.3 0.28 IgG glycosylation; chr3:128908780 chr3:128861313~128871540:- CESC cis rs2933343 1 rs876755 ENSG00000231305.3 RP11-723O4.2 4.24 3.27e-05 0.0146 0.3 0.28 IgG glycosylation; chr3:128909090 chr3:128861313~128871540:- CESC cis rs9487094 0.67 rs2024852 ENSG00000260273.1 RP11-425D10.10 4.24 3.27e-05 0.0147 0.36 0.28 Height; chr6:109498586 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs13203587 ENSG00000260273.1 RP11-425D10.10 4.24 3.27e-05 0.0147 0.36 0.28 Height; chr6:109499759 chr6:109382795~109383666:+ CESC cis rs7688540 0.8 rs61792060 ENSG00000211553.1 AC253576.2 -4.24 3.27e-05 0.0147 -0.36 -0.28 Facial morphology (factor 6, height of vermillion lower lip); chr4:262661 chr4:136461~136568:+ CESC cis rs755249 0.917 rs61781392 ENSG00000228060.1 RP11-69E11.8 -4.24 3.27e-05 0.0147 -0.32 -0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39617969 chr1:39565160~39573203:+ CESC cis rs755249 0.917 rs61232586 ENSG00000228060.1 RP11-69E11.8 -4.24 3.27e-05 0.0147 -0.32 -0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39620685 chr1:39565160~39573203:+ CESC cis rs755249 0.917 rs61781393 ENSG00000228060.1 RP11-69E11.8 -4.24 3.27e-05 0.0147 -0.32 -0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39622092 chr1:39565160~39573203:+ CESC cis rs2412819 0.571 rs4644832 ENSG00000249839.1 AC011330.5 4.24 3.28e-05 0.0147 0.36 0.28 Lung cancer; chr15:43792507 chr15:43663654~43684339:- CESC cis rs6951245 0.744 rs10275401 ENSG00000229043.2 AC091729.9 -4.24 3.28e-05 0.0147 -0.4 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1174307 chr7:1160374~1165267:+ CESC cis rs2337406 1 rs1858677 ENSG00000274576.2 IGHV2-70 -4.24 3.28e-05 0.0147 -0.35 -0.28 Alzheimer's disease (late onset); chr14:106706828 chr14:106770577~106771020:- CESC cis rs748404 0.65 rs556851 ENSG00000249839.1 AC011330.5 -4.24 3.28e-05 0.0147 -0.29 -0.28 Lung cancer; chr15:43279021 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs567357 ENSG00000249839.1 AC011330.5 -4.24 3.28e-05 0.0147 -0.29 -0.28 Lung cancer; chr15:43279192 chr15:43663654~43684339:- CESC cis rs11770686 0.967 rs2107316 ENSG00000214243.3 AC004980.10 4.24 3.28e-05 0.0147 0.24 0.28 Essential tremor; chr7:75715211 chr7:76650401~76650897:- CESC cis rs6928977 0.802 rs2244745 ENSG00000234084.1 RP3-388E23.2 4.24 3.28e-05 0.0147 0.25 0.28 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135341683 chr6:135301568~135307158:+ CESC cis rs2299587 0.531 rs28839855 ENSG00000253671.1 RP11-806O11.1 -4.24 3.28e-05 0.0147 -0.33 -0.28 Economic and political preferences; chr8:17998474 chr8:17808941~17820868:+ CESC cis rs6928977 0.863 rs2614277 ENSG00000234084.1 RP3-388E23.2 4.24 3.28e-05 0.0147 0.25 0.28 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135333856 chr6:135301568~135307158:+ CESC cis rs9322193 0.923 rs57012784 ENSG00000216906.2 RP11-350J20.9 4.24 3.28e-05 0.0147 0.3 0.28 Lung cancer; chr6:149627691 chr6:149904243~149906418:+ CESC cis rs2019137 0.56 rs7578633 ENSG00000274877.1 RP11-65I12.1 -4.24 3.29e-05 0.0147 -0.37 -0.28 Lymphocyte counts; chr2:113221073 chr2:113237595~113240825:+ CESC cis rs10788972 0.903 rs7537946 ENSG00000225183.1 RP4-758J24.4 -4.24 3.29e-05 0.0147 -0.31 -0.28 Parkinson disease and lewy body pathology; chr1:54073027 chr1:54089856~54090093:+ CESC cis rs61270009 0.738 rs73171756 ENSG00000247828.6 TMEM161B-AS1 4.24 3.29e-05 0.0147 0.3 0.28 Depressive symptoms; chr5:88446454 chr5:88268895~88436685:+ CESC cis rs34286592 0.929 rs1045968 ENSG00000214725.6 CDIPT-AS1 -4.24 3.29e-05 0.0147 -0.5 -0.28 Multiple sclerosis; chr16:29815044 chr16:29863593~29868053:+ CESC cis rs12908161 0.959 rs3748376 ENSG00000259728.4 LINC00933 4.24 3.29e-05 0.0147 0.36 0.28 Schizophrenia; chr15:84785121 chr15:84570649~84580175:+ CESC cis rs3762637 0.941 rs79493664 ENSG00000272758.4 RP11-299J3.8 -4.24 3.29e-05 0.0147 -0.39 -0.28 LDL cholesterol levels; chr3:122390699 chr3:122416207~122443180:+ CESC cis rs12681963 0.688 rs7009988 ENSG00000248159.1 HSPA8P11 4.24 3.29e-05 0.0147 0.55 0.28 Migraine; chr8:30224947 chr8:30237382~30240997:+ CESC cis rs916888 0.821 rs199512 ENSG00000232300.1 FAM215B -4.24 3.29e-05 0.0147 -0.44 -0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46558830~46562795:- CESC cis rs916888 0.821 rs199509 ENSG00000232300.1 FAM215B -4.24 3.29e-05 0.0147 -0.44 -0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46558830~46562795:- CESC cis rs916888 0.821 rs199507 ENSG00000232300.1 FAM215B -4.24 3.29e-05 0.0147 -0.44 -0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46558830~46562795:- CESC cis rs2115630 0.846 rs8024538 ENSG00000225151.9 GOLGA2P7 4.24 3.29e-05 0.0147 0.31 0.28 P wave terminal force; chr15:84825188 chr15:84199311~84230136:- CESC cis rs74394007 0.915 rs116594409 ENSG00000244515.1 KRT18P34 4.24 3.3e-05 0.0148 0.52 0.28 Total body bone mineral density; chr3:156902700 chr3:157162663~157163932:- CESC cis rs74394007 0.831 rs6795327 ENSG00000244515.1 KRT18P34 4.24 3.3e-05 0.0148 0.52 0.28 Total body bone mineral density; chr3:156903759 chr3:157162663~157163932:- CESC cis rs74394007 1 rs6795516 ENSG00000244515.1 KRT18P34 4.24 3.3e-05 0.0148 0.52 0.28 Total body bone mineral density; chr3:156903890 chr3:157162663~157163932:- CESC cis rs9640161 0.789 rs2373751 ENSG00000261305.1 RP4-584D14.7 4.24 3.3e-05 0.0148 0.42 0.28 Blood protein levels;Circulating chemerin levels; chr7:150324510 chr7:150341771~150342607:+ CESC cis rs9532669 1 rs9532669 ENSG00000176268.5 CYCSP34 4.24 3.3e-05 0.0148 0.28 0.28 Cervical cancer; chr13:40927414 chr13:40863599~40863902:- CESC cis rs12107539 0.846 rs3732760 ENSG00000240137.4 ERICH6-AS1 -4.24 3.31e-05 0.0148 -0.26 -0.28 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151357153 chr3:150703564~150720146:+ CESC cis rs526231 0.667 rs187580 ENSG00000175749.11 EIF3KP1 4.24 3.31e-05 0.0148 0.38 0.28 Primary biliary cholangitis; chr5:103291654 chr5:103032376~103033031:+ CESC cis rs7299940 0.967 rs9738957 ENSG00000256250.1 RP11-989F5.1 4.24 3.31e-05 0.0148 0.3 0.28 Panic disorder; chr12:130904256 chr12:130810606~130812438:+ CESC cis rs897984 0.683 rs72799316 ENSG00000260911.2 RP11-196G11.2 4.24 3.31e-05 0.0148 0.28 0.28 Dementia with Lewy bodies; chr16:30815884 chr16:31043150~31049868:+ CESC cis rs1707322 1 rs4660889 ENSG00000281133.1 AL355480.3 -4.24 3.31e-05 0.0148 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45831659 chr1:45580892~45580996:- CESC cis rs5769707 0.967 rs2071904 ENSG00000235111.1 RP1-29C18.8 -4.24 3.31e-05 0.0148 -0.28 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49640829 chr22:49612657~49615716:- CESC cis rs5769707 0.846 rs5770610 ENSG00000235111.1 RP1-29C18.8 -4.24 3.31e-05 0.0148 -0.28 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49643249 chr22:49612657~49615716:- CESC cis rs2274273 0.563 rs79163357 ENSG00000258413.1 RP11-665C16.6 -4.24 3.32e-05 0.0148 -0.36 -0.28 Protein biomarker; chr14:55271731 chr14:55262767~55272075:- CESC cis rs6951245 1 rs74652290 ENSG00000229043.2 AC091729.9 -4.24 3.32e-05 0.0148 -0.43 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1050473 chr7:1160374~1165267:+ CESC cis rs10043775 1 rs4574534 ENSG00000251330.3 CTD-2283N19.1 -4.24 3.32e-05 0.0148 -0.39 -0.28 Periodontal microbiota; chr5:148445932 chr5:148430159~148430807:- CESC cis rs8031584 0.958 rs61997079 ENSG00000260382.1 RP11-540B6.2 4.24 3.32e-05 0.0148 0.38 0.28 Huntington's disease progression; chr15:30946068 chr15:30882267~30883231:- CESC cis rs8031584 0.958 rs11637469 ENSG00000260382.1 RP11-540B6.2 4.24 3.32e-05 0.0148 0.38 0.28 Huntington's disease progression; chr15:30946580 chr15:30882267~30883231:- CESC cis rs8031584 0.958 rs8034856 ENSG00000260382.1 RP11-540B6.2 4.24 3.32e-05 0.0148 0.38 0.28 Huntington's disease progression; chr15:30948754 chr15:30882267~30883231:- CESC cis rs763121 0.814 rs5757212 ENSG00000273076.1 RP3-508I15.22 4.24 3.32e-05 0.0148 0.32 0.28 Menopause (age at onset); chr22:38657752 chr22:38743495~38743910:+ CESC cis rs2836974 0.583 rs9981884 ENSG00000232608.1 TIMM9P2 -4.24 3.32e-05 0.0148 -0.31 -0.28 Cognitive function; chr21:39213707 chr21:39216624~39217506:+ CESC cis rs2732480 0.577 rs2634693 ENSG00000240399.1 RP1-228P16.1 4.24 3.32e-05 0.0148 0.32 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48312715 chr12:48054813~48055591:- CESC cis rs2732480 0.577 rs2634691 ENSG00000240399.1 RP1-228P16.1 4.24 3.32e-05 0.0148 0.32 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48314476 chr12:48054813~48055591:- CESC cis rs2732480 0.557 rs2732441 ENSG00000240399.1 RP1-228P16.1 4.24 3.32e-05 0.0148 0.32 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48329541 chr12:48054813~48055591:- CESC cis rs2732480 0.577 rs2732448 ENSG00000240399.1 RP1-228P16.1 4.24 3.32e-05 0.0148 0.32 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48336817 chr12:48054813~48055591:- CESC cis rs2732480 0.577 rs2732466 ENSG00000240399.1 RP1-228P16.1 4.24 3.32e-05 0.0148 0.32 0.28 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48338676 chr12:48054813~48055591:- CESC cis rs7572733 0.534 rs4850813 ENSG00000222017.1 AC011997.1 -4.24 3.32e-05 0.0148 -0.35 -0.28 Dermatomyositis; chr2:197911258 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs10931794 ENSG00000222017.1 AC011997.1 -4.24 3.32e-05 0.0148 -0.35 -0.28 Dermatomyositis; chr2:197911416 chr2:197693106~197774823:+ CESC cis rs7572733 0.555 rs2341778 ENSG00000222017.1 AC011997.1 -4.24 3.32e-05 0.0148 -0.35 -0.28 Dermatomyositis; chr2:197911822 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs1401095 ENSG00000222017.1 AC011997.1 -4.24 3.32e-05 0.0148 -0.35 -0.28 Dermatomyositis; chr2:197915143 chr2:197693106~197774823:+ CESC cis rs7809950 1 rs3801944 ENSG00000238832.1 snoU109 4.24 3.33e-05 0.0149 0.33 0.28 Coronary artery disease; chr7:107615103 chr7:107603363~107603507:+ CESC cis rs7015630 0.866 rs12675822 ENSG00000251136.7 RP11-37B2.1 4.24 3.33e-05 0.0149 0.31 0.28 Inflammatory bowel disease;Crohn's disease; chr8:89855255 chr8:89609409~89757727:- CESC cis rs13113518 1 rs13122619 ENSG00000273257.1 RP11-177J6.1 4.24 3.33e-05 0.0149 0.36 0.28 Height; chr4:55479339 chr4:55387949~55388271:+ CESC cis rs4819052 0.851 rs4819040 ENSG00000223768.1 LINC00205 -4.24 3.33e-05 0.0149 -0.31 -0.28 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45239847 chr21:45293285~45297354:+ CESC cis rs2790457 0.958 rs2790444 ENSG00000254635.4 WAC-AS1 -4.24 3.33e-05 0.0149 -0.31 -0.28 Multiple myeloma; chr10:28536760 chr10:28522652~28532743:- CESC cis rs519973 0.545 rs2679506 ENSG00000279891.1 FLJ42393 -4.24 3.33e-05 0.0149 -0.32 -0.28 Allergic disease (asthma, hay fever or eczema); chr3:187954235 chr3:188178543~188180812:+ CESC cis rs2243480 1 rs2243480 ENSG00000275400.1 RP4-756H11.5 4.24 3.33e-05 0.0149 0.46 0.28 Diabetic kidney disease; chr7:66134209 chr7:66553805~66554199:- CESC cis rs7615952 0.599 rs16834938 ENSG00000250012.1 RP11-124N2.1 -4.24 3.33e-05 0.0149 -0.28 -0.28 Blood pressure (smoking interaction); chr3:125987203 chr3:126084220~126095349:+ CESC cis rs35123781 1 rs601728 ENSG00000250635.1 CTD-3224K15.2 -4.24 3.34e-05 0.0149 -0.33 -0.28 Schizophrenia; chr5:139677491 chr5:139648999~139649728:- CESC cis rs35123781 1 rs601324 ENSG00000250635.1 CTD-3224K15.2 -4.24 3.34e-05 0.0149 -0.33 -0.28 Schizophrenia; chr5:139677594 chr5:139648999~139649728:- CESC cis rs35123781 1 rs600848 ENSG00000250635.1 CTD-3224K15.2 -4.24 3.34e-05 0.0149 -0.33 -0.28 Schizophrenia; chr5:139677685 chr5:139648999~139649728:- CESC cis rs35123781 1 rs599946 ENSG00000250635.1 CTD-3224K15.2 -4.24 3.34e-05 0.0149 -0.33 -0.28 Schizophrenia; chr5:139677876 chr5:139648999~139649728:- CESC cis rs7829975 0.774 rs11775523 ENSG00000253893.2 FAM85B -4.24 3.34e-05 0.0149 -0.34 -0.28 Mood instability; chr8:8821666 chr8:8167819~8226614:- CESC cis rs9438901 0.655 rs609320 ENSG00000224183.1 SDHDP6 4.24 3.34e-05 0.0149 0.36 0.28 Red cell distribution width; chr1:25390874 chr1:25294164~25294643:- CESC cis rs2439831 1 rs2467743 ENSG00000275601.1 AC011330.13 -4.24 3.34e-05 0.0149 -0.36 -0.28 Lung cancer in ever smokers; chr15:43458148 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2245176 ENSG00000275601.1 AC011330.13 -4.24 3.34e-05 0.0149 -0.36 -0.28 Lung cancer in ever smokers; chr15:43458564 chr15:43642389~43643023:- CESC cis rs2439831 1 rs2245054 ENSG00000275601.1 AC011330.13 -4.24 3.34e-05 0.0149 -0.36 -0.28 Lung cancer in ever smokers; chr15:43459711 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2264876 ENSG00000275601.1 AC011330.13 -4.24 3.34e-05 0.0149 -0.36 -0.28 Lung cancer in ever smokers; chr15:43465221 chr15:43642389~43643023:- CESC cis rs7572733 0.534 rs7572123 ENSG00000222017.1 AC011997.1 4.24 3.34e-05 0.0149 0.35 0.28 Dermatomyositis; chr2:197904913 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs10211202 ENSG00000222017.1 AC011997.1 4.24 3.34e-05 0.0149 0.35 0.28 Dermatomyositis; chr2:197907217 chr2:197693106~197774823:+ CESC cis rs6005807 0.543 rs6005868 ENSG00000226471.5 CTA-292E10.6 -4.24 3.34e-05 0.0149 -0.37 -0.28 Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio; chr22:28769778 chr22:28800683~28848559:+ CESC cis rs12134133 1 rs2782846 ENSG00000274245.1 RP11-357P18.2 4.24 3.34e-05 0.0149 0.34 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207300495 chr1:207372559~207373252:+ CESC cis rs12134133 1 rs2802237 ENSG00000274245.1 RP11-357P18.2 4.24 3.34e-05 0.0149 0.34 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207300825 chr1:207372559~207373252:+ CESC cis rs748404 0.676 rs4401024 ENSG00000205771.5 CATSPER2P1 -4.24 3.34e-05 0.0149 -0.34 -0.28 Lung cancer; chr15:43358137 chr15:43726918~43747094:- CESC cis rs6991838 0.806 rs11777025 ENSG00000200714.1 Y_RNA -4.24 3.34e-05 0.0149 -0.31 -0.28 Intelligence (multi-trait analysis); chr8:65551438 chr8:65592731~65592820:+ CESC cis rs7927592 0.956 rs12277225 ENSG00000212093.1 AP000807.1 4.24 3.35e-05 0.0149 0.31 0.28 Total body bone mineral density; chr11:68573499 chr11:68506083~68506166:- CESC cis rs7829975 0.606 rs7819827 ENSG00000254340.1 RP11-10A14.3 -4.24 3.35e-05 0.0149 -0.34 -0.28 Mood instability; chr8:8939545 chr8:9141424~9145435:+ CESC cis rs12908161 0.96 rs62019463 ENSG00000225151.9 GOLGA2P7 -4.24 3.35e-05 0.0149 -0.38 -0.28 Schizophrenia; chr15:84744856 chr15:84199311~84230136:- CESC cis rs12908161 1 rs62019464 ENSG00000225151.9 GOLGA2P7 -4.24 3.35e-05 0.0149 -0.38 -0.28 Schizophrenia; chr15:84751238 chr15:84199311~84230136:- CESC cis rs12908161 1 rs11637142 ENSG00000225151.9 GOLGA2P7 -4.24 3.35e-05 0.0149 -0.38 -0.28 Schizophrenia; chr15:84752696 chr15:84199311~84230136:- CESC cis rs12908161 1 rs12910012 ENSG00000225151.9 GOLGA2P7 -4.24 3.35e-05 0.0149 -0.38 -0.28 Schizophrenia; chr15:84755431 chr15:84199311~84230136:- CESC cis rs12908161 1 rs12899981 ENSG00000225151.9 GOLGA2P7 -4.24 3.35e-05 0.0149 -0.38 -0.28 Schizophrenia; chr15:84759142 chr15:84199311~84230136:- CESC cis rs1499614 0.522 rs13247442 ENSG00000228409.4 CCT6P1 4.24 3.35e-05 0.0149 0.5 0.28 Gout; chr7:66723871 chr7:65751142~65763354:+ CESC cis rs4272720 0.535 rs12257242 ENSG00000229870.1 RP11-507K13.6 -4.24 3.35e-05 0.0149 -0.33 -0.28 Platelet count;Plateletcrit; chr10:49083355 chr10:49815096~49815562:+ CESC cis rs17818399 0.817 rs17767994 ENSG00000279254.1 RP11-536C12.1 4.24 3.35e-05 0.0149 0.32 0.28 Height; chr2:46632940 chr2:46668870~46670778:+ CESC cis rs919433 0.617 rs12619333 ENSG00000222017.1 AC011997.1 -4.24 3.35e-05 0.0149 -0.35 -0.28 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197702914 chr2:197693106~197774823:+ CESC cis rs7809950 1 rs2520265 ENSG00000238832.1 snoU109 -4.24 3.35e-05 0.0149 -0.33 -0.28 Coronary artery disease; chr7:107540786 chr7:107603363~107603507:+ CESC cis rs526231 0.853 rs187579 ENSG00000175749.11 EIF3KP1 4.24 3.35e-05 0.0149 0.33 0.28 Primary biliary cholangitis; chr5:103269232 chr5:103032376~103033031:+ CESC cis rs2243480 1 rs1039664 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:65984729 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs2456483 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:65996588 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs2949697 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:65999249 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1701750 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:66002158 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1701758 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:66005214 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs1701759 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:66005945 chr7:66554588~66576923:- CESC cis rs2243480 1 rs781149 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:66016297 chr7:66554588~66576923:- CESC cis rs2243480 0.901 rs58207111 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:66021736 chr7:66554588~66576923:- CESC cis rs2243480 1 rs1167613 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:66022452 chr7:66554588~66576923:- CESC cis rs2243480 1 rs313799 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:66029343 chr7:66554588~66576923:- CESC cis rs2243480 1 rs313807 ENSG00000232559.3 GS1-124K5.12 4.24 3.35e-05 0.015 0.45 0.28 Diabetic kidney disease; chr7:66034494 chr7:66554588~66576923:- CESC cis rs2280018 1 rs2280018 ENSG00000260735.1 RP11-72I8.1 -4.24 3.35e-05 0.015 -0.29 -0.28 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15056976 chr16:15094411~15109197:+ CESC cis rs700651 0.789 rs1371663 ENSG00000222017.1 AC011997.1 -4.24 3.36e-05 0.015 -0.36 -0.28 Intracranial aneurysm; chr2:198035581 chr2:197693106~197774823:+ CESC cis rs6964587 0.967 rs7783414 ENSG00000188693.7 CYP51A1-AS1 -4.24 3.36e-05 0.015 -0.29 -0.28 Breast cancer; chr7:92156643 chr7:92134604~92180725:+ CESC cis rs3806843 0.576 rs246024 ENSG00000202111.1 VTRNA1-2 -4.24 3.36e-05 0.015 -0.28 -0.28 Depressive symptoms (multi-trait analysis); chr5:140954367 chr5:140718925~140719013:+ CESC cis rs3806843 0.546 rs246023 ENSG00000202111.1 VTRNA1-2 -4.24 3.36e-05 0.015 -0.28 -0.28 Depressive symptoms (multi-trait analysis); chr5:140954405 chr5:140718925~140719013:+ CESC cis rs801193 0.66 rs1962050 ENSG00000237310.1 GS1-124K5.4 -4.24 3.36e-05 0.015 -0.26 -0.28 Aortic root size; chr7:66775021 chr7:66493706~66495474:+ CESC cis rs763121 0.853 rs138712 ENSG00000273076.1 RP3-508I15.22 4.24 3.36e-05 0.015 0.32 0.28 Menopause (age at onset); chr22:38745595 chr22:38743495~38743910:+ CESC cis rs7829975 0.56 rs56094035 ENSG00000253893.2 FAM85B 4.24 3.36e-05 0.015 0.37 0.28 Mood instability; chr8:8694112 chr8:8167819~8226614:- CESC cis rs7829975 0.539 rs4841012 ENSG00000253893.2 FAM85B 4.24 3.36e-05 0.015 0.37 0.28 Mood instability; chr8:8694200 chr8:8167819~8226614:- CESC cis rs7829975 0.56 rs4841013 ENSG00000253893.2 FAM85B 4.24 3.36e-05 0.015 0.37 0.28 Mood instability; chr8:8694503 chr8:8167819~8226614:- CESC cis rs17695224 0.5 rs4801897 ENSG00000268095.1 ZNF649-AS1 4.24 3.36e-05 0.015 0.34 0.28 HDL cholesterol;HDL cholesterol levels; chr19:51831942 chr19:51888025~51900463:+ CESC cis rs150992 0.537 rs1604450 ENSG00000248489.1 CTD-2007H13.3 -4.24 3.36e-05 0.015 -0.38 -0.28 Body mass index; chr5:99036274 chr5:98929171~98995013:+ CESC cis rs7429990 0.932 rs2166772 ENSG00000229759.1 MRPS18AP1 -4.24 3.36e-05 0.015 -0.28 -0.28 Educational attainment (years of education); chr3:48006384 chr3:48256350~48256938:- CESC cis rs8059260 0.736 rs2302558 ENSG00000274038.1 RP11-66H6.4 -4.24 3.36e-05 0.015 -0.42 -0.28 Alcohol consumption over the past year; chr16:10969154 chr16:11056556~11057034:+ CESC cis rs916888 0.821 rs199506 ENSG00000232300.1 FAM215B -4.24 3.36e-05 0.015 -0.44 -0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46558830~46562795:- CESC cis rs6964587 1 rs6961928 ENSG00000188693.7 CYP51A1-AS1 -4.24 3.36e-05 0.015 -0.29 -0.28 Breast cancer; chr7:92040494 chr7:92134604~92180725:+ CESC cis rs1707322 1 rs6675222 ENSG00000281133.1 AL355480.3 -4.24 3.37e-05 0.015 -0.32 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45860904 chr1:45580892~45580996:- CESC cis rs12439619 0.508 rs11856561 ENSG00000276710.3 CSPG4P8 -4.24 3.37e-05 0.015 -0.3 -0.28 Intelligence (multi-trait analysis); chr15:82161415 chr15:82459472~82477258:+ CESC cis rs73173548 0.502 rs12187348 ENSG00000247828.6 TMEM161B-AS1 4.24 3.37e-05 0.015 0.3 0.28 Macular telangiectasia type 2; chr5:88424724 chr5:88268895~88436685:+ CESC cis rs3126085 0.56 rs11588022 ENSG00000207606.1 MIR554 -4.24 3.37e-05 0.015 -0.44 -0.28 Atopic dermatitis; chr1:152344476 chr1:151545796~151545891:+ CESC cis rs2243480 0.522 rs12698511 ENSG00000228409.4 CCT6P1 4.24 3.37e-05 0.015 0.47 0.28 Diabetic kidney disease; chr7:66009932 chr7:65751142~65763354:+ CESC cis rs74394007 0.92 rs28661978 ENSG00000244515.1 KRT18P34 4.24 3.37e-05 0.015 0.5 0.28 Total body bone mineral density; chr3:156861950 chr3:157162663~157163932:- CESC cis rs74394007 0.92 rs16826864 ENSG00000244515.1 KRT18P34 4.24 3.37e-05 0.015 0.5 0.28 Total body bone mineral density; chr3:156862244 chr3:157162663~157163932:- CESC cis rs74394007 0.92 rs59244547 ENSG00000244515.1 KRT18P34 4.24 3.37e-05 0.015 0.5 0.28 Total body bone mineral density; chr3:156865208 chr3:157162663~157163932:- CESC cis rs9323326 0.586 rs7149087 ENSG00000257621.6 PSMA3-AS1 4.24 3.37e-05 0.015 0.26 0.28 Gut microbiota (bacterial taxa); chr14:58029123 chr14:58265365~58298134:- CESC cis rs35740288 0.857 rs3803506 ENSG00000202081.1 RNU6-1280P 4.23 3.38e-05 0.015 0.34 0.28 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85747709 chr15:85651522~85651628:- CESC cis rs9640161 0.789 rs2098053 ENSG00000261305.1 RP4-584D14.7 4.23 3.38e-05 0.015 0.41 0.28 Blood protein levels;Circulating chemerin levels; chr7:150346116 chr7:150341771~150342607:+ CESC cis rs9640161 0.673 rs34489187 ENSG00000261305.1 RP4-584D14.7 4.23 3.38e-05 0.015 0.41 0.28 Blood protein levels;Circulating chemerin levels; chr7:150347290 chr7:150341771~150342607:+ CESC cis rs7829975 0.624 rs7823056 ENSG00000253893.2 FAM85B -4.23 3.38e-05 0.015 -0.36 -0.28 Mood instability; chr8:8525195 chr8:8167819~8226614:- CESC cis rs2790457 0.958 rs2790455 ENSG00000254635.4 WAC-AS1 -4.23 3.38e-05 0.015 -0.31 -0.28 Multiple myeloma; chr10:28558148 chr10:28522652~28532743:- CESC cis rs2274273 0.624 rs7155954 ENSG00000258413.1 RP11-665C16.6 -4.23 3.38e-05 0.015 -0.36 -0.28 Protein biomarker; chr14:55284225 chr14:55262767~55272075:- CESC cis rs67311347 1 rs13073003 ENSG00000223797.4 ENTPD3-AS1 -4.23 3.38e-05 0.015 -0.27 -0.28 Renal cell carcinoma; chr3:40462835 chr3:40313802~40453329:- CESC cis rs12220238 0.915 rs11000948 ENSG00000213731.2 RAB5CP1 4.23 3.38e-05 0.015 0.45 0.28 Soluble interleukin-2 receptor subunit alpha; chr10:74271963 chr10:74423435~74424014:- CESC cis rs2337406 0.538 rs2015470 ENSG00000223648.3 IGHV3-64 4.23 3.38e-05 0.015 0.29 0.28 Alzheimer's disease (late onset); chr14:106631885 chr14:106643132~106658258:- CESC cis rs9532669 0.926 rs7331435 ENSG00000176268.5 CYCSP34 -4.23 3.38e-05 0.0151 -0.28 -0.28 Cervical cancer; chr13:40862396 chr13:40863599~40863902:- CESC cis rs7005380 0.6 rs4871772 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119895655 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs4871773 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119895671 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs4871012 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119895734 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs4871013 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119895750 chr8:119838736~119840385:- CESC cis rs7005380 0.579 rs7465181 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119896349 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs7462250 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119896367 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13281299 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119897253 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs7832923 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119897540 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6469861 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119897673 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6469862 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119897796 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6469863 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119897910 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6469864 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119897985 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6469865 ENSG00000279347.1 RP11-85I17.2 -4.23 3.39e-05 0.0151 -0.25 -0.28 Interstitial lung disease; chr8:119897995 chr8:119838736~119840385:- CESC cis rs11779988 0.629 rs11780813 ENSG00000253671.1 RP11-806O11.1 -4.23 3.39e-05 0.0151 -0.33 -0.28 Breast cancer; chr8:17998505 chr8:17808941~17820868:+ CESC cis rs10829156 0.699 rs10828879 ENSG00000240291.1 RP11-499P20.2 4.23 3.39e-05 0.0151 0.28 0.28 Sudden cardiac arrest; chr10:18546425 chr10:18513115~18545651:- CESC cis rs748404 0.587 rs9920879 ENSG00000205771.5 CATSPER2P1 -4.23 3.39e-05 0.0151 -0.33 -0.28 Lung cancer; chr15:43347572 chr15:43726918~43747094:- CESC cis rs10043775 1 rs1971431 ENSG00000251330.3 CTD-2283N19.1 -4.23 3.39e-05 0.0151 -0.36 -0.28 Periodontal microbiota; chr5:148452493 chr5:148430159~148430807:- CESC cis rs12220238 0.822 rs7919517 ENSG00000213731.2 RAB5CP1 -4.23 3.4e-05 0.0151 -0.44 -0.28 Soluble interleukin-2 receptor subunit alpha; chr10:74351597 chr10:74423435~74424014:- CESC cis rs7927592 0.956 rs12365160 ENSG00000212093.1 AP000807.1 4.23 3.4e-05 0.0151 0.32 0.28 Total body bone mineral density; chr11:68482951 chr11:68506083~68506166:- CESC cis rs7927592 0.956 rs11228256 ENSG00000212093.1 AP000807.1 4.23 3.4e-05 0.0151 0.32 0.28 Total body bone mineral density; chr11:68483992 chr11:68506083~68506166:- CESC cis rs4319547 0.656 rs7135419 ENSG00000275265.1 RP11-15J22.8 -4.23 3.4e-05 0.0151 -0.39 -0.28 Body mass index; chr12:122427314 chr12:122501187~122501641:+ CESC cis rs9309473 0.948 rs7566385 ENSG00000163016.8 ALMS1P 4.23 3.4e-05 0.0151 0.34 0.28 Metabolite levels; chr2:73529690 chr2:73644919~73685576:+ CESC cis rs10129255 0.957 rs8009948 ENSG00000211970.3 IGHV4-61 -4.23 3.4e-05 0.0151 -0.23 -0.28 Kawasaki disease; chr14:106805607 chr14:106639119~106639657:- CESC cis rs2933343 1 rs789232 ENSG00000231305.3 RP11-723O4.2 4.23 3.4e-05 0.0151 0.29 0.28 IgG glycosylation; chr3:128884237 chr3:128861313~128871540:- CESC cis rs2933343 1 rs1683811 ENSG00000231305.3 RP11-723O4.2 4.23 3.4e-05 0.0151 0.29 0.28 IgG glycosylation; chr3:128893270 chr3:128861313~128871540:- CESC cis rs10788972 0.683 rs12046178 ENSG00000225183.1 RP4-758J24.4 -4.23 3.4e-05 0.0151 -0.32 -0.28 Parkinson disease and lewy body pathology; chr1:54106502 chr1:54089856~54090093:+ CESC cis rs9322193 0.923 rs9688861 ENSG00000268592.3 RAET1E-AS1 4.23 3.41e-05 0.0151 0.35 0.28 Lung cancer; chr6:149637924 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs7740278 ENSG00000268592.3 RAET1E-AS1 4.23 3.41e-05 0.0151 0.35 0.28 Lung cancer; chr6:149640116 chr6:149863494~149919507:+ CESC cis rs9925964 0.933 rs9939417 ENSG00000260911.2 RP11-196G11.2 -4.23 3.41e-05 0.0151 -0.3 -0.28 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31042146 chr16:31043150~31049868:+ CESC cis rs11089937 0.626 rs11089933 ENSG00000211638.2 IGLV8-61 -4.23 3.41e-05 0.0151 -0.28 -0.28 Periodontitis (PAL4Q3); chr22:22145708 chr22:22098700~22099212:+ CESC cis rs2721195 0.967 rs1480000 ENSG00000255182.2 CTD-2517M22.14 -4.23 3.41e-05 0.0151 -0.24 -0.28 Age at first birth; chr8:144476624 chr8:144495458~144505444:- CESC cis rs11976180 1 rs13226728 ENSG00000273234.1 OR2A13P -4.23 3.41e-05 0.0151 -0.32 -0.28 Obesity-related traits; chr7:144049485 chr7:144142009~144142938:+ CESC cis rs875971 0.545 rs6979636 ENSG00000226824.5 RP4-756H11.3 -4.23 3.41e-05 0.0151 -0.39 -0.28 Aortic root size; chr7:66276638 chr7:66654538~66669855:+ CESC cis rs9532669 0.926 rs9532671 ENSG00000176268.5 CYCSP34 4.23 3.41e-05 0.0151 0.28 0.28 Cervical cancer; chr13:40927761 chr13:40863599~40863902:- CESC cis rs9532669 0.833 rs9532672 ENSG00000176268.5 CYCSP34 4.23 3.41e-05 0.0151 0.28 0.28 Cervical cancer; chr13:40928285 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs7324625 ENSG00000176268.5 CYCSP34 4.23 3.41e-05 0.0151 0.28 0.28 Cervical cancer; chr13:40928606 chr13:40863599~40863902:- CESC cis rs6964587 0.9 rs6972027 ENSG00000188693.7 CYP51A1-AS1 -4.23 3.41e-05 0.0152 -0.29 -0.28 Breast cancer; chr7:92152066 chr7:92134604~92180725:+ CESC cis rs6964587 0.935 rs9770444 ENSG00000188693.7 CYP51A1-AS1 -4.23 3.41e-05 0.0152 -0.29 -0.28 Breast cancer; chr7:92153848 chr7:92134604~92180725:+ CESC cis rs11971779 0.715 rs6943973 ENSG00000273391.1 RP11-634H22.1 4.23 3.41e-05 0.0152 0.26 0.28 Diisocyanate-induced asthma; chr7:139345147 chr7:139359032~139359566:- CESC cis rs9650657 0.538 rs6984496 ENSG00000255046.1 RP11-297N6.4 4.23 3.41e-05 0.0152 0.29 0.28 Neuroticism; chr8:10938583 chr8:11797928~11802568:- CESC cis rs1538970 0.962 rs9429160 ENSG00000280836.1 AL355480.1 -4.23 3.41e-05 0.0152 -0.35 -0.28 Platelet count; chr1:45362296 chr1:45581219~45581321:- CESC cis rs79243044 1 rs10769054 ENSG00000224295.2 AC087380.14 -4.23 3.42e-05 0.0152 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5545259 chr11:5518441~5524955:- CESC cis rs79243044 0.932 rs10838300 ENSG00000224295.2 AC087380.14 -4.23 3.42e-05 0.0152 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5545659 chr11:5518441~5524955:- CESC cis rs1538970 0.962 rs2185549 ENSG00000280836.1 AL355480.1 4.23 3.42e-05 0.0152 0.34 0.28 Platelet count; chr1:45348431 chr1:45581219~45581321:- CESC cis rs7005380 0.62 rs6988011 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119898298 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs35272074 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119898543 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs10103660 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119898547 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6993375 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119899390 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs6993797 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119899405 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs6989741 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119899914 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs13257252 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119899993 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs10093230 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119900606 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs9649947 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119901117 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13279398 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119902030 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13277947 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119902192 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs13277992 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119902287 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13253140 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119902668 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs11777705 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119902992 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs12681402 ENSG00000279347.1 RP11-85I17.2 -4.23 3.43e-05 0.0152 -0.25 -0.28 Interstitial lung disease; chr8:119903622 chr8:119838736~119840385:- CESC cis rs67311347 1 rs1466236 ENSG00000223797.4 ENTPD3-AS1 4.23 3.43e-05 0.0152 0.27 0.28 Renal cell carcinoma; chr3:40420671 chr3:40313802~40453329:- CESC cis rs5742933 0.512 rs80277863 ENSG00000253559.1 OSGEPL1-AS1 -4.23 3.43e-05 0.0152 -0.38 -0.28 Ferritin levels; chr2:189766733 chr2:189762704~189765556:+ CESC cis rs2404602 0.583 rs12438741 ENSG00000280730.1 AC090181.1 4.23 3.43e-05 0.0152 0.21 0.28 Blood metabolite levels; chr15:76249773 chr15:77056895~77057021:+ CESC cis rs9309473 0.948 rs10173534 ENSG00000163016.8 ALMS1P 4.23 3.43e-05 0.0152 0.36 0.28 Metabolite levels; chr2:73586305 chr2:73644919~73685576:+ CESC cis rs700651 0.789 rs5007118 ENSG00000222017.1 AC011997.1 4.23 3.44e-05 0.0152 0.36 0.28 Intracranial aneurysm; chr2:198045014 chr2:197693106~197774823:+ CESC cis rs55665837 1 rs3923294 ENSG00000251991.1 RNU7-49P 4.23 3.44e-05 0.0152 0.31 0.28 Vitamin D levels; chr11:14419856 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs12283797 ENSG00000251991.1 RNU7-49P 4.23 3.44e-05 0.0152 0.31 0.28 Vitamin D levels; chr11:14420716 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs10832256 ENSG00000251991.1 RNU7-49P 4.23 3.44e-05 0.0152 0.31 0.28 Vitamin D levels; chr11:14421329 chr11:14478892~14478953:+ CESC cis rs55665837 0.961 rs12795972 ENSG00000251991.1 RNU7-49P 4.23 3.44e-05 0.0152 0.31 0.28 Vitamin D levels; chr11:14422229 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs12287715 ENSG00000251991.1 RNU7-49P 4.23 3.44e-05 0.0152 0.31 0.28 Vitamin D levels; chr11:14423029 chr11:14478892~14478953:+ CESC cis rs1862618 0.853 rs252910 ENSG00000271828.1 CTD-2310F14.1 4.23 3.44e-05 0.0152 0.39 0.28 Initial pursuit acceleration; chr5:56897156 chr5:56927874~56929573:+ CESC cis rs8040855 0.627 rs4842863 ENSG00000259295.5 CSPG4P12 4.23 3.44e-05 0.0153 0.34 0.28 Bulimia nervosa; chr15:85098974 chr15:85191438~85213905:+ CESC cis rs9813712 0.595 rs1453240 ENSG00000228252.7 COL6A4P2 -4.23 3.44e-05 0.0153 -0.35 -0.28 Response to amphetamines; chr3:130282849 chr3:130212823~130273806:+ CESC cis rs9487094 0.67 rs6911700 ENSG00000260273.1 RP11-425D10.10 4.23 3.44e-05 0.0153 0.35 0.28 Height; chr6:109676091 chr6:109382795~109383666:+ CESC cis rs2243480 1 rs73142162 ENSG00000164669.11 INTS4P1 4.23 3.44e-05 0.0153 0.58 0.28 Diabetic kidney disease; chr7:65909309 chr7:65141225~65234216:+ CESC cis rs2243480 0.808 rs12698508 ENSG00000164669.11 INTS4P1 4.23 3.44e-05 0.0153 0.58 0.28 Diabetic kidney disease; chr7:65946971 chr7:65141225~65234216:+ CESC cis rs875971 0.505 rs6955582 ENSG00000222364.1 RNU6-96P -4.23 3.44e-05 0.0153 -0.33 -0.28 Aortic root size; chr7:65966699 chr7:66395191~66395286:+ CESC cis rs1707322 1 rs4298677 ENSG00000281133.1 AL355480.3 -4.23 3.44e-05 0.0153 -0.33 -0.28 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45840947 chr1:45580892~45580996:- CESC cis rs9640161 0.742 rs11983355 ENSG00000261305.1 RP4-584D14.7 4.23 3.45e-05 0.0153 0.39 0.28 Blood protein levels;Circulating chemerin levels; chr7:150319608 chr7:150341771~150342607:+ CESC cis rs4927850 1 rs10881564 ENSG00000231464.1 AC024937.4 4.23 3.45e-05 0.0153 0.35 0.28 Pancreatic cancer; chr3:196023455 chr3:195996738~195998233:+ CESC cis rs6740322 0.895 rs6760797 ENSG00000234936.1 AC010883.5 4.23 3.45e-05 0.0153 0.3 0.28 Coronary artery disease; chr2:43332473 chr2:43229573~43233394:+ CESC cis rs748404 1 rs12909095 ENSG00000249839.1 AC011330.5 -4.23 3.45e-05 0.0153 -0.36 -0.28 Lung cancer; chr15:43265944 chr15:43663654~43684339:- CESC cis rs4319547 0.656 rs7975747 ENSG00000275265.1 RP11-15J22.8 -4.23 3.45e-05 0.0153 -0.39 -0.28 Body mass index; chr12:122332448 chr12:122501187~122501641:+ CESC cis rs8177876 0.642 rs12445303 ENSG00000261838.4 RP11-303E16.6 -4.23 3.45e-05 0.0153 -0.53 -0.28 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081968 chr16:81069854~81076598:+ CESC cis rs17818399 0.708 rs13000706 ENSG00000279254.1 RP11-536C12.1 -4.23 3.45e-05 0.0153 -0.29 -0.28 Height; chr2:46611108 chr2:46668870~46670778:+ CESC cis rs55665837 1 rs12295723 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14428655 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs12295888 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14428985 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs34382046 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14429772 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs7945167 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14430274 chr11:14478892~14478953:+ CESC cis rs55665837 0.961 rs60622588 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14435452 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs11023223 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14435566 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs11023224 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14436193 chr11:14478892~14478953:+ CESC cis rs55665837 0.961 rs11023226 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14437271 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs10832264 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14438436 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs10832268 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14443522 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs10832269 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14443523 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs10832271 ENSG00000251991.1 RNU7-49P 4.23 3.45e-05 0.0153 0.3 0.28 Vitamin D levels; chr11:14445373 chr11:14478892~14478953:+ CESC cis rs17507216 0.588 rs28864981 ENSG00000276710.3 CSPG4P8 -4.23 3.45e-05 0.0153 -0.38 -0.28 Excessive daytime sleepiness; chr15:82695420 chr15:82459472~82477258:+ CESC cis rs17507216 0.628 rs8032321 ENSG00000276710.3 CSPG4P8 -4.23 3.45e-05 0.0153 -0.38 -0.28 Excessive daytime sleepiness; chr15:82698956 chr15:82459472~82477258:+ CESC cis rs17507216 0.628 rs8040488 ENSG00000276710.3 CSPG4P8 -4.23 3.45e-05 0.0153 -0.38 -0.28 Excessive daytime sleepiness; chr15:82699081 chr15:82459472~82477258:+ CESC cis rs7572733 0.534 rs700670 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197822560 chr2:197693106~197774823:+ CESC cis rs7572733 0.555 rs700671 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197825277 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs771009 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197826358 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700672 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197826731 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700673 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197828205 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700674 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197828979 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs700675 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197835492 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs2574832 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197840094 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700678 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197841096 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs7604700 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197853906 chr2:197693106~197774823:+ CESC cis rs7572733 0.555 rs1435569 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197853943 chr2:197693106~197774823:+ CESC cis rs7572733 0.514 rs700686 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197856330 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700687 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197856836 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs696817 ENSG00000222017.1 AC011997.1 4.23 3.46e-05 0.0153 0.35 0.28 Dermatomyositis; chr2:197857501 chr2:197693106~197774823:+ CESC cis rs2933343 0.951 rs789251 ENSG00000231305.3 RP11-723O4.2 4.23 3.46e-05 0.0153 0.29 0.28 IgG glycosylation; chr3:128857927 chr3:128861313~128871540:- CESC cis rs2299587 0.607 rs2237848 ENSG00000253671.1 RP11-806O11.1 -4.23 3.46e-05 0.0153 -0.3 -0.28 Economic and political preferences; chr8:18017095 chr8:17808941~17820868:+ CESC cis rs8030379 1 rs10906983 ENSG00000230373.7 GOLGA6L5P -4.23 3.46e-05 0.0153 -0.27 -0.28 Waist circumference;Waist circumference adjusted for body mass index; chr15:83900431 chr15:84507885~84516814:- CESC cis rs2134046 0.555 rs11854483 ENSG00000278603.1 RP13-608F4.5 4.23 3.46e-05 0.0153 0.34 0.28 Cognitive ability; chr15:82267217 chr15:82472203~82472426:+ CESC cis rs11096990 0.929 rs56037933 ENSG00000249207.1 RP11-360F5.1 4.23 3.46e-05 0.0153 0.33 0.28 Cognitive function; chr4:39225653 chr4:39112677~39126818:- CESC cis rs10958369 0.613 rs10095702 ENSG00000253369.1 RP11-1081M5.1 4.23 3.47e-05 0.0153 0.31 0.28 Response to antineoplastic agents; chr8:53523551 chr8:53395211~53395946:- CESC cis rs8031584 0.678 rs798125 ENSG00000260382.1 RP11-540B6.2 -4.23 3.47e-05 0.0153 -0.37 -0.28 Huntington's disease progression; chr15:30824597 chr15:30882267~30883231:- CESC cis rs8031584 0.697 rs798080 ENSG00000260382.1 RP11-540B6.2 -4.23 3.47e-05 0.0153 -0.37 -0.28 Huntington's disease progression; chr15:30829966 chr15:30882267~30883231:- CESC cis rs12681963 0.541 rs56302321 ENSG00000272375.1 RP11-51J9.6 4.23 3.47e-05 0.0153 0.44 0.28 Migraine; chr8:30183018 chr8:30197404~30198048:+ CESC cis rs12681963 0.688 rs12548744 ENSG00000272375.1 RP11-51J9.6 4.23 3.47e-05 0.0153 0.44 0.28 Migraine; chr8:30184400 chr8:30197404~30198048:+ CESC cis rs10844706 0.699 rs10844615 ENSG00000256594.6 RP11-705C15.2 4.23 3.47e-05 0.0153 0.33 0.28 Lymphocyte counts;Lymphocyte percentage of white cells; chr12:9725646 chr12:9633419~9658412:+ CESC cis rs875971 0.502 rs6460311 ENSG00000222364.1 RNU6-96P 4.23 3.47e-05 0.0153 0.39 0.28 Aortic root size; chr7:66646886 chr7:66395191~66395286:+ CESC cis rs4319547 0.656 rs10734918 ENSG00000275265.1 RP11-15J22.8 -4.23 3.48e-05 0.0154 -0.39 -0.28 Body mass index; chr12:122436965 chr12:122501187~122501641:+ CESC cis rs453301 0.658 rs13271797 ENSG00000173295.6 FAM86B3P -4.23 3.48e-05 0.0154 -0.36 -0.28 Joint mobility (Beighton score); chr8:9028444 chr8:8228595~8244865:+ CESC cis rs9487094 0.626 rs10457192 ENSG00000260273.1 RP11-425D10.10 4.23 3.48e-05 0.0154 0.35 0.28 Height; chr6:109507271 chr6:109382795~109383666:+ CESC cis rs9309473 0.95 rs6745480 ENSG00000163016.8 ALMS1P 4.23 3.48e-05 0.0154 0.35 0.28 Metabolite levels; chr2:73612928 chr2:73644919~73685576:+ CESC cis rs72772090 0.539 rs72775809 ENSG00000248734.2 CTD-2260A17.1 -4.23 3.48e-05 0.0154 -0.43 -0.28 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96847853 chr5:96784777~96785999:+ CESC cis rs453301 0.592 rs4841084 ENSG00000254340.1 RP11-10A14.3 4.23 3.48e-05 0.0154 0.32 0.28 Joint mobility (Beighton score); chr8:9026395 chr8:9141424~9145435:+ CESC cis rs73086581 1 rs56141565 ENSG00000229539.1 RP11-119B16.2 4.23 3.48e-05 0.0154 0.42 0.28 Response to antidepressants in depression; chr20:4017956 chr20:3888239~3888868:- CESC cis rs4713118 0.662 rs9357060 ENSG00000219392.1 RP1-265C24.5 -4.23 3.49e-05 0.0154 -0.36 -0.28 Parkinson's disease; chr6:28056708 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs9468271 ENSG00000219392.1 RP1-265C24.5 -4.23 3.49e-05 0.0154 -0.36 -0.28 Parkinson's disease; chr6:28056792 chr6:28115628~28116551:+ CESC cis rs2243480 0.803 rs55700941 ENSG00000232559.3 GS1-124K5.12 4.23 3.49e-05 0.0154 0.48 0.28 Diabetic kidney disease; chr7:65924813 chr7:66554588~66576923:- CESC cis rs1538970 0.781 rs713358 ENSG00000280836.1 AL355480.1 -4.23 3.49e-05 0.0154 -0.34 -0.28 Platelet count; chr1:45522595 chr1:45581219~45581321:- CESC cis rs7520050 0.667 rs11211176 ENSG00000281133.1 AL355480.3 4.23 3.49e-05 0.0154 0.31 0.28 Reticulocyte count;Red blood cell count; chr1:45757414 chr1:45580892~45580996:- CESC cis rs7572733 0.691 rs11684176 ENSG00000222017.1 AC011997.1 4.23 3.49e-05 0.0154 0.29 0.28 Dermatomyositis; chr2:198090050 chr2:197693106~197774823:+ CESC cis rs761746 0.96 rs5998042 ENSG00000236132.1 CTA-440B3.1 -4.23 3.49e-05 0.0154 -0.34 -0.28 Intelligence; chr22:31557976 chr22:31816379~31817491:- CESC cis rs6893782 0.887 rs274548 ENSG00000233006.5 AC034220.3 -4.23 3.49e-05 0.0154 -0.35 -0.28 Acylcarnitine levels; chr5:132395115 chr5:132311285~132369916:- CESC cis rs875971 0.964 rs60193905 ENSG00000237310.1 GS1-124K5.4 4.23 3.49e-05 0.0154 0.26 0.28 Aortic root size; chr7:66506273 chr7:66493706~66495474:+ CESC cis rs12454023 1 rs3865419 ENSG00000278703.1 RP11-706P11.2 4.23 3.49e-05 0.0154 0.31 0.28 Migraine with aura; chr18:58337962 chr18:57588611~57589091:- CESC cis rs2337406 0.85 rs75196489 ENSG00000274576.2 IGHV2-70 -4.23 3.49e-05 0.0154 -0.35 -0.28 Alzheimer's disease (late onset); chr14:106699438 chr14:106770577~106771020:- CESC cis rs9322193 0.923 rs9689716 ENSG00000216906.2 RP11-350J20.9 4.23 3.49e-05 0.0154 0.3 0.28 Lung cancer; chr6:149655662 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9322207 ENSG00000216906.2 RP11-350J20.9 4.23 3.49e-05 0.0154 0.3 0.28 Lung cancer; chr6:149657185 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9322208 ENSG00000216906.2 RP11-350J20.9 4.23 3.49e-05 0.0154 0.3 0.28 Lung cancer; chr6:149658547 chr6:149904243~149906418:+ CESC cis rs12745968 0.652 rs4970700 ENSG00000223787.2 RP4-593M8.1 4.23 3.5e-05 0.0154 0.37 0.28 Bipolar disorder and schizophrenia; chr1:92509936 chr1:92580476~92580821:- CESC cis rs2688608 0.839 rs2675662 ENSG00000242288.9 RP11-464F9.1 -4.23 3.5e-05 0.0155 -0.31 -0.28 Inflammatory bowel disease; chr10:73839369 chr10:73674295~73730466:- CESC cis rs2688608 0.839 rs2633310 ENSG00000242288.9 RP11-464F9.1 -4.23 3.51e-05 0.0155 -0.31 -0.28 Inflammatory bowel disease; chr10:73834292 chr10:73674295~73730466:- CESC cis rs79243044 1 rs10838299 ENSG00000224295.2 AC087380.14 -4.23 3.51e-05 0.0155 -0.3 -0.28 QRS duration in Tripanosoma cruzi seropositivity; chr11:5545600 chr11:5518441~5524955:- CESC cis rs2115630 0.645 rs3825877 ENSG00000259295.5 CSPG4P12 -4.23 3.51e-05 0.0155 -0.29 -0.28 P wave terminal force; chr15:84631400 chr15:85191438~85213905:+ CESC cis rs2115630 0.645 rs3825878 ENSG00000259295.5 CSPG4P12 -4.23 3.51e-05 0.0155 -0.29 -0.28 P wave terminal force; chr15:84631524 chr15:85191438~85213905:+ CESC cis rs12908161 1 rs17600551 ENSG00000225151.9 GOLGA2P7 -4.23 3.51e-05 0.0155 -0.37 -0.28 Schizophrenia; chr15:84776027 chr15:84199311~84230136:- CESC cis rs12908161 1 rs36033486 ENSG00000225151.9 GOLGA2P7 -4.23 3.51e-05 0.0155 -0.37 -0.28 Schizophrenia; chr15:84776461 chr15:84199311~84230136:- CESC cis rs12908161 1 rs62019469 ENSG00000225151.9 GOLGA2P7 -4.23 3.51e-05 0.0155 -0.37 -0.28 Schizophrenia; chr15:84777989 chr15:84199311~84230136:- CESC cis rs7829975 0.567 rs6601273 ENSG00000254340.1 RP11-10A14.3 -4.23 3.51e-05 0.0155 -0.34 -0.28 Mood instability; chr8:8939009 chr8:9141424~9145435:+ CESC cis rs875971 0.83 rs4718358 ENSG00000237310.1 GS1-124K5.4 4.23 3.51e-05 0.0155 0.26 0.28 Aortic root size; chr7:66508681 chr7:66493706~66495474:+ CESC cis rs4319547 0.619 rs7973869 ENSG00000275265.1 RP11-15J22.8 -4.23 3.51e-05 0.0155 -0.39 -0.28 Body mass index; chr12:122389737 chr12:122501187~122501641:+ CESC cis rs12690897 0.55 rs11760489 ENSG00000229251.3 HNRNPA1P8 -4.23 3.51e-05 0.0155 -0.27 -0.28 Macrophage inflammatory protein 1a levels; chr7:85641028 chr7:84983556~84984506:+ CESC cis rs9929218 0.559 rs12923775 ENSG00000260459.2 FTLP14 4.23 3.51e-05 0.0155 0.35 0.28 Colorectal cancer; chr16:68722547 chr16:68822587~68823070:+ CESC cis rs11976180 1 rs2951372 ENSG00000273234.1 OR2A13P -4.23 3.51e-05 0.0155 -0.32 -0.28 Obesity-related traits; chr7:144052410 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs1320894 ENSG00000273234.1 OR2A13P -4.23 3.51e-05 0.0155 -0.32 -0.28 Obesity-related traits; chr7:144054709 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2951369 ENSG00000273234.1 OR2A13P -4.23 3.51e-05 0.0155 -0.32 -0.28 Obesity-related traits; chr7:144055545 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2951368 ENSG00000273234.1 OR2A13P -4.23 3.51e-05 0.0155 -0.32 -0.28 Obesity-related traits; chr7:144055728 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2961115 ENSG00000273234.1 OR2A13P -4.23 3.51e-05 0.0155 -0.32 -0.28 Obesity-related traits; chr7:144056278 chr7:144142009~144142938:+ CESC cis rs761746 0.96 rs7289075 ENSG00000236132.1 CTA-440B3.1 -4.22 3.51e-05 0.0155 -0.34 -0.28 Intelligence; chr22:31617759 chr22:31816379~31817491:- CESC cis rs2255336 0.938 rs1478310 ENSG00000245648.1 RP11-277P12.20 4.22 3.51e-05 0.0155 0.39 0.28 Blood protein levels; chr12:10382279 chr12:10363769~10398506:+ CESC cis rs7777677 0.925 rs4726544 ENSG00000244273.1 PGBD4P1 -4.22 3.52e-05 0.0155 -0.3 -0.28 Alcoholic chronic pancreatitis; chr7:142659616 chr7:142722358~142722764:+ CESC cis rs55665837 1 rs10832257 ENSG00000251991.1 RNU7-49P 4.22 3.52e-05 0.0155 0.31 0.28 Vitamin D levels; chr11:14421770 chr11:14478892~14478953:+ CESC cis rs9907295 0.579 rs9899866 ENSG00000270977.1 AC015849.16 4.22 3.52e-05 0.0155 0.39 0.28 Fibroblast growth factor basic levels; chr17:35908466 chr17:35893707~35911023:- CESC cis rs490234 0.783 rs28729336 ENSG00000232630.1 PRPS1P2 -4.22 3.52e-05 0.0155 -0.24 -0.28 Mean arterial pressure; chr9:125643209 chr9:125150653~125151589:+ CESC cis rs9487094 0.644 rs910730 ENSG00000260273.1 RP11-425D10.10 4.22 3.52e-05 0.0155 0.34 0.28 Height; chr6:109447092 chr6:109382795~109383666:+ CESC cis rs12468226 0.938 rs12471060 ENSG00000273456.1 RP11-686O6.2 4.22 3.52e-05 0.0155 0.38 0.28 Urate levels; chr2:202309597 chr2:202374932~202375604:- CESC cis rs4319547 0.695 rs10773152 ENSG00000275265.1 RP11-15J22.8 -4.22 3.52e-05 0.0155 -0.39 -0.28 Body mass index; chr12:122425633 chr12:122501187~122501641:+ CESC cis rs889312 0.504 rs62355900 ENSG00000271828.1 CTD-2310F14.1 4.22 3.53e-05 0.0155 0.37 0.28 Breast cancer (early onset);Breast cancer; chr5:56756868 chr5:56927874~56929573:+ CESC cis rs6951245 0.706 rs28522260 ENSG00000229043.2 AC091729.9 -4.22 3.53e-05 0.0156 -0.39 -0.28 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1144328 chr7:1160374~1165267:+ CESC cis rs10788972 0.683 rs6694292 ENSG00000225183.1 RP4-758J24.4 4.22 3.53e-05 0.0156 0.32 0.28 Parkinson disease and lewy body pathology; chr1:54100517 chr1:54089856~54090093:+ CESC cis rs9309473 0.519 rs13017182 ENSG00000273245.1 RP11-434P11.2 -4.22 3.53e-05 0.0156 -0.34 -0.28 Metabolite levels; chr2:73663877 chr2:73750256~73750786:- CESC cis rs8031584 0.541 rs2959037 ENSG00000260382.1 RP11-540B6.2 -4.22 3.53e-05 0.0156 -0.37 -0.28 Huntington's disease progression; chr15:30925961 chr15:30882267~30883231:- CESC cis rs55665837 1 rs12288873 ENSG00000251991.1 RNU7-49P 4.22 3.53e-05 0.0156 0.3 0.28 Vitamin D levels; chr11:14428919 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs11023227 ENSG00000251991.1 RNU7-49P 4.22 3.53e-05 0.0156 0.3 0.28 Vitamin D levels; chr11:14437541 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs11023229 ENSG00000251991.1 RNU7-49P 4.22 3.53e-05 0.0156 0.3 0.28 Vitamin D levels; chr11:14439455 chr11:14478892~14478953:+ CESC cis rs673078 0.607 rs7967900 ENSG00000275759.1 RP11-131L12.3 4.22 3.54e-05 0.0156 0.51 0.28 Glucose homeostasis traits; chr12:118381902 chr12:118428281~118428870:+ CESC cis rs9326248 0.59 rs2542063 ENSG00000280143.1 AP000892.6 4.22 3.54e-05 0.0156 0.33 0.28 Blood protein levels; chr11:116814051 chr11:117204967~117210292:+ CESC cis rs2280018 0.963 rs11075255 ENSG00000260735.1 RP11-72I8.1 -4.22 3.54e-05 0.0156 -0.29 -0.27 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072375 chr16:15094411~15109197:+ CESC cis rs769267 1 rs1009136 ENSG00000269131.1 AC004447.2 4.22 3.54e-05 0.0156 0.23 0.27 Tonsillectomy; chr19:19329619 chr19:18990893~18993610:+ CESC cis rs9322193 0.923 rs10782317 ENSG00000216906.2 RP11-350J20.9 -4.22 3.54e-05 0.0156 -0.31 -0.27 Lung cancer; chr6:149753911 chr6:149904243~149906418:+ CESC cis rs2732480 0.577 rs2732486 ENSG00000240399.1 RP1-228P16.1 4.22 3.54e-05 0.0156 0.33 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344051 chr12:48054813~48055591:- CESC cis rs2732480 0.517 rs2634676 ENSG00000240399.1 RP1-228P16.1 4.22 3.54e-05 0.0156 0.33 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48344453 chr12:48054813~48055591:- CESC cis rs7208859 0.623 rs56325146 ENSG00000266490.1 CTD-2349P21.9 4.22 3.55e-05 0.0156 0.41 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824006 chr17:30792372~30792833:+ CESC cis rs4927850 0.881 rs7624638 ENSG00000231464.1 AC024937.4 4.22 3.55e-05 0.0156 0.35 0.27 Pancreatic cancer; chr3:196021858 chr3:195996738~195998233:+ CESC cis rs528808 1 rs528808 ENSG00000279170.1 RP1-199J3.6 4.22 3.55e-05 0.0156 0.42 0.27 Age-related hearing impairment; chr6:99656413 chr6:99587611~99589898:+ CESC cis rs116095464 0.85 rs6896163 ENSG00000250848.1 CTD-2083E4.5 -4.22 3.55e-05 0.0156 -0.45 -0.27 Breast cancer; chr5:303571 chr5:288833~290321:- CESC cis rs72634258 0.786 rs4405150 ENSG00000238249.2 HMGN2P17 4.22 3.55e-05 0.0156 0.31 0.27 Inflammatory bowel disease; chr1:8113612 chr1:8893409~8894151:+ CESC cis rs3096299 0.606 rs4785674 ENSG00000274627.1 RP11-104N10.2 4.22 3.55e-05 0.0156 0.29 0.27 Multiple myeloma (IgH translocation); chr16:89470205 chr16:89516797~89522217:+ CESC cis rs7587476 0.784 rs62202001 ENSG00000229267.2 AC072062.1 -4.22 3.55e-05 0.0156 -0.35 -0.27 Neuroblastoma; chr2:214825635 chr2:214810229~214963274:+ CESC cis rs7587476 0.736 rs62202002 ENSG00000229267.2 AC072062.1 -4.22 3.55e-05 0.0156 -0.35 -0.27 Neuroblastoma; chr2:214825876 chr2:214810229~214963274:+ CESC cis rs7587476 0.682 rs13009646 ENSG00000229267.2 AC072062.1 -4.22 3.55e-05 0.0156 -0.35 -0.27 Neuroblastoma; chr2:214826535 chr2:214810229~214963274:+ CESC cis rs11096990 0.929 rs55976583 ENSG00000249207.1 RP11-360F5.1 4.22 3.56e-05 0.0157 0.32 0.27 Cognitive function; chr4:39222871 chr4:39112677~39126818:- CESC cis rs2836950 0.52 rs2836966 ENSG00000232608.1 TIMM9P2 4.22 3.56e-05 0.0157 0.31 0.27 Menarche (age at onset); chr21:39265595 chr21:39216624~39217506:+ CESC cis rs12908161 1 rs35726233 ENSG00000225151.9 GOLGA2P7 -4.22 3.56e-05 0.0157 -0.38 -0.27 Schizophrenia; chr15:84794569 chr15:84199311~84230136:- CESC cis rs12908161 1 rs35960805 ENSG00000225151.9 GOLGA2P7 -4.22 3.56e-05 0.0157 -0.38 -0.27 Schizophrenia; chr15:84800749 chr15:84199311~84230136:- CESC cis rs12908161 1 rs12912388 ENSG00000225151.9 GOLGA2P7 -4.22 3.56e-05 0.0157 -0.38 -0.27 Schizophrenia; chr15:84801319 chr15:84199311~84230136:- CESC cis rs2243480 1 rs34637256 ENSG00000232559.3 GS1-124K5.12 4.22 3.56e-05 0.0157 0.46 0.27 Diabetic kidney disease; chr7:65895144 chr7:66554588~66576923:- CESC cis rs5758659 0.569 rs133294 ENSG00000273366.1 CTA-989H11.1 -4.22 3.57e-05 0.0157 -0.35 -0.27 Cognitive function; chr22:41986801 chr22:42278188~42278846:+ CESC cis rs7809950 0.954 rs2520241 ENSG00000238832.1 snoU109 -4.22 3.57e-05 0.0157 -0.32 -0.27 Coronary artery disease; chr7:107494998 chr7:107603363~107603507:+ CESC cis rs12908161 0.92 rs35738019 ENSG00000225151.9 GOLGA2P7 -4.22 3.57e-05 0.0157 -0.37 -0.27 Schizophrenia; chr15:84736979 chr15:84199311~84230136:- CESC cis rs12908161 1 rs34570071 ENSG00000225151.9 GOLGA2P7 -4.22 3.57e-05 0.0157 -0.37 -0.27 Schizophrenia; chr15:84736981 chr15:84199311~84230136:- CESC cis rs12908161 1 rs60957376 ENSG00000225151.9 GOLGA2P7 -4.22 3.57e-05 0.0157 -0.37 -0.27 Schizophrenia; chr15:84737561 chr15:84199311~84230136:- CESC cis rs12908161 1 rs11632465 ENSG00000225151.9 GOLGA2P7 -4.22 3.57e-05 0.0157 -0.37 -0.27 Schizophrenia; chr15:84738814 chr15:84199311~84230136:- CESC cis rs3748682 0.861 rs2291297 ENSG00000212541.1 RNU6-510P -4.22 3.57e-05 0.0157 -0.4 -0.27 Hypothyroidism; chr1:37806988 chr1:37991462~37991569:+ CESC cis rs6740322 1 rs6756736 ENSG00000234936.1 AC010883.5 4.22 3.57e-05 0.0157 0.29 0.27 Coronary artery disease; chr2:43331604 chr2:43229573~43233394:+ CESC cis rs11159086 1 rs17100451 ENSG00000259005.1 RP3-449M8.6 4.22 3.57e-05 0.0157 0.45 0.27 Advanced glycation end-product levels; chr14:74476210 chr14:74474007~74474864:- CESC cis rs783540 0.934 rs4779053 ENSG00000255769.6 GOLGA2P10 -4.22 3.57e-05 0.0157 -0.31 -0.27 Schizophrenia; chr15:82702846 chr15:82472993~82513950:- CESC cis rs12908161 1 rs12908549 ENSG00000225151.9 GOLGA2P7 -4.22 3.57e-05 0.0157 -0.37 -0.27 Schizophrenia; chr15:84779120 chr15:84199311~84230136:- CESC cis rs4072705 0.615 rs4838189 ENSG00000224020.1 MIR181A2HG -4.22 3.58e-05 0.0157 -0.35 -0.27 Menarche (age at onset); chr9:124486647 chr9:124658467~124698631:+ CESC cis rs10875746 0.551 rs2054903 ENSG00000240399.1 RP1-228P16.1 -4.22 3.58e-05 0.0157 -0.34 -0.27 Longevity (90 years and older); chr12:48330710 chr12:48054813~48055591:- CESC cis rs8067354 0.645 rs2645467 ENSG00000266701.1 AC005702.4 4.22 3.58e-05 0.0157 0.36 0.27 Hemoglobin concentration; chr17:59777422 chr17:60042546~60042627:- CESC cis rs7951870 1 rs7951870 ENSG00000247675.5 LRP4-AS1 -4.22 3.58e-05 0.0157 -0.32 -0.27 Schizophrenia; chr11:46351761 chr11:46846412~46874396:+ CESC cis rs2243480 1 rs73142121 ENSG00000232559.3 GS1-124K5.12 4.22 3.58e-05 0.0157 0.44 0.27 Diabetic kidney disease; chr7:65846219 chr7:66554588~66576923:- CESC cis rs2243480 1 rs34702770 ENSG00000232559.3 GS1-124K5.12 4.22 3.58e-05 0.0157 0.44 0.27 Diabetic kidney disease; chr7:65879836 chr7:66554588~66576923:- CESC cis rs1044826 0.619 rs7375091 ENSG00000178631.7 ACTG1P1 -4.22 3.59e-05 0.0158 -0.34 -0.27 Obesity-related traits; chr3:139371547 chr3:139493809~139494937:+ CESC cis rs2522056 1 rs1003533 ENSG00000233006.5 AC034220.3 -4.22 3.59e-05 0.0158 -0.36 -0.27 Fibrinogen;Lymphocyte counts; chr5:132419959 chr5:132311285~132369916:- CESC cis rs77972916 0.505 rs3851318 ENSG00000234936.1 AC010883.5 4.22 3.59e-05 0.0158 0.31 0.27 Granulocyte percentage of myeloid white cells; chr2:43305669 chr2:43229573~43233394:+ CESC cis rs7826238 0.539 rs2945891 ENSG00000253893.2 FAM85B -4.22 3.59e-05 0.0158 -0.37 -0.27 Systolic blood pressure; chr8:8297953 chr8:8167819~8226614:- CESC cis rs10463554 0.889 rs246899 ENSG00000175749.11 EIF3KP1 4.22 3.59e-05 0.0158 0.3 0.27 Parkinson's disease; chr5:103241438 chr5:103032376~103033031:+ CESC cis rs2564921 0.73 rs1811351 ENSG00000242142.1 SERBP1P3 -4.22 3.59e-05 0.0158 -0.34 -0.27 Height; chr3:53064759 chr3:53064283~53065091:- CESC cis rs73086581 1 rs6107391 ENSG00000229539.1 RP11-119B16.2 4.22 3.59e-05 0.0158 0.42 0.27 Response to antidepressants in depression; chr20:4002436 chr20:3888239~3888868:- CESC cis rs1044826 0.619 rs57357132 ENSG00000178631.7 ACTG1P1 -4.22 3.59e-05 0.0158 -0.34 -0.27 Obesity-related traits; chr3:139399516 chr3:139493809~139494937:+ CESC cis rs17772222 0.74 rs10150986 ENSG00000258983.2 RP11-507K2.2 4.22 3.59e-05 0.0158 0.32 0.27 Coronary artery calcification; chr14:88517326 chr14:88499334~88515502:+ CESC cis rs1056107 0.763 rs10759529 ENSG00000225513.1 RP11-165N19.2 -4.22 3.59e-05 0.0158 -0.34 -0.27 Colorectal cancer; chr9:112176651 chr9:112173522~112173971:- CESC cis rs769267 0.965 rs1010207 ENSG00000269131.1 AC004447.2 -4.22 3.59e-05 0.0158 -0.23 -0.27 Tonsillectomy; chr19:19305236 chr19:18990893~18993610:+ CESC cis rs1499614 0.522 rs13247442 ENSG00000232559.3 GS1-124K5.12 4.22 3.59e-05 0.0158 0.57 0.27 Gout; chr7:66723871 chr7:66554588~66576923:- CESC cis rs2276314 1 rs56050783 ENSG00000278986.1 RP11-723J4.3 -4.22 3.6e-05 0.0158 -0.31 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35973828 chr18:35972151~35973916:+ CESC cis rs2276314 1 rs58054756 ENSG00000278986.1 RP11-723J4.3 -4.22 3.6e-05 0.0158 -0.31 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35974090 chr18:35972151~35973916:+ CESC cis rs10129255 0.744 rs28517388 ENSG00000211970.3 IGHV4-61 -4.22 3.6e-05 0.0158 -0.23 -0.27 Kawasaki disease; chr14:106704323 chr14:106639119~106639657:- CESC cis rs860295 0.812 rs11264363 ENSG00000225855.5 RUSC1-AS1 4.22 3.6e-05 0.0158 0.22 0.27 Body mass index; chr1:155348517 chr1:155316863~155324176:- CESC cis rs3096299 0.935 rs3114890 ENSG00000274627.1 RP11-104N10.2 4.22 3.6e-05 0.0158 0.28 0.27 Multiple myeloma (IgH translocation); chr16:89383138 chr16:89516797~89522217:+ CESC cis rs6782228 0.606 rs2712404 ENSG00000242551.2 POU5F1P6 4.22 3.6e-05 0.0158 0.3 0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613836 chr3:128674735~128677005:- CESC cis rs10129255 0.957 rs12590735 ENSG00000211970.3 IGHV4-61 -4.22 3.6e-05 0.0158 -0.21 -0.27 Kawasaki disease; chr14:106779660 chr14:106639119~106639657:- CESC cis rs9318086 0.578 rs2077709 ENSG00000205861.10 C1QTNF9B-AS1 4.22 3.6e-05 0.0158 0.34 0.27 Myopia (pathological); chr13:23901934 chr13:23888889~23897263:+ CESC cis rs5769765 0.908 rs9616370 ENSG00000229409.1 RP11-494O16.3 -4.22 3.61e-05 0.0158 -0.39 -0.27 Schizophrenia; chr22:49912668 chr22:49845929~49846090:+ CESC cis rs6822297 0.522 rs7700108 ENSG00000240005.4 RP11-293A21.1 4.22 3.61e-05 0.0158 0.31 0.27 Obesity-related traits; chr4:26967785 chr4:26859806~26860599:- CESC cis rs6693388 0.647 rs2999534 ENSG00000229021.2 AL591893.1 4.22 3.61e-05 0.0158 0.31 0.27 Blood metabolite ratios; chr1:152003594 chr1:151994531~152042774:+ CESC cis rs10754283 0.967 rs1320563 ENSG00000231613.1 RP5-943J3.1 4.22 3.61e-05 0.0158 0.35 0.27 Amyotrophic lateral sclerosis (sporadic); chr1:89655473 chr1:89788914~89790492:+ CESC cis rs6556937 0.69 rs7704167 ENSG00000251314.2 CTD-2337A12.1 4.22 3.61e-05 0.0158 0.39 0.27 Blood protein levels; chr5:96668659 chr5:95962001~96631085:+ CESC cis rs13113518 0.678 rs7663650 ENSG00000273257.1 RP11-177J6.1 -4.22 3.61e-05 0.0158 -0.36 -0.27 Height; chr4:55364952 chr4:55387949~55388271:+ CESC cis rs2274273 0.624 rs10146637 ENSG00000258413.1 RP11-665C16.6 -4.22 3.61e-05 0.0158 -0.36 -0.27 Protein biomarker; chr14:55278092 chr14:55262767~55272075:- CESC cis rs7048146 0.668 rs1411682 ENSG00000213539.4 YBX1P6 4.22 3.61e-05 0.0158 0.31 0.27 Vascular brain injury; chr9:109514077 chr9:109532830~109534332:- CESC cis rs875971 0.965 rs9969301 ENSG00000237310.1 GS1-124K5.4 -4.22 3.61e-05 0.0158 -0.25 -0.27 Aortic root size; chr7:66316668 chr7:66493706~66495474:+ CESC cis rs1538970 0.504 rs3790585 ENSG00000281133.1 AL355480.3 -4.22 3.61e-05 0.0158 -0.38 -0.27 Platelet count; chr1:45557684 chr1:45580892~45580996:- CESC cis rs67311347 1 rs7633809 ENSG00000223797.4 ENTPD3-AS1 -4.22 3.61e-05 0.0158 -0.27 -0.27 Renal cell carcinoma; chr3:40476246 chr3:40313802~40453329:- CESC cis rs9393777 0.513 rs13190754 ENSG00000241549.7 GUSBP2 4.22 3.62e-05 0.0158 0.35 0.27 Intelligence (multi-trait analysis); chr6:26587178 chr6:26871484~26956554:- CESC cis rs9393777 0.513 rs9379895 ENSG00000241549.7 GUSBP2 4.22 3.62e-05 0.0158 0.35 0.27 Intelligence (multi-trait analysis); chr6:26592479 chr6:26871484~26956554:- CESC cis rs9322193 0.886 rs9718079 ENSG00000216906.2 RP11-350J20.9 4.22 3.62e-05 0.0158 0.3 0.27 Lung cancer; chr6:149645947 chr6:149904243~149906418:+ CESC cis rs12439619 0.846 rs62013464 ENSG00000276710.3 CSPG4P8 -4.22 3.62e-05 0.0158 -0.4 -0.27 Intelligence (multi-trait analysis); chr15:82288250 chr15:82459472~82477258:+ CESC cis rs7429990 0.965 rs184388 ENSG00000229759.1 MRPS18AP1 4.22 3.62e-05 0.0158 0.28 0.27 Educational attainment (years of education); chr3:47898136 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs319696 ENSG00000229759.1 MRPS18AP1 4.22 3.62e-05 0.0158 0.28 0.27 Educational attainment (years of education); chr3:47902371 chr3:48256350~48256938:- CESC cis rs7429990 0.93 rs71323371 ENSG00000229759.1 MRPS18AP1 4.22 3.62e-05 0.0158 0.28 0.27 Educational attainment (years of education); chr3:47904327 chr3:48256350~48256938:- CESC cis rs7429990 0.932 rs34025851 ENSG00000229759.1 MRPS18AP1 4.22 3.62e-05 0.0158 0.28 0.27 Educational attainment (years of education); chr3:47912243 chr3:48256350~48256938:- CESC cis rs6439153 0.933 rs6769662 ENSG00000231305.3 RP11-723O4.2 4.22 3.62e-05 0.0159 0.26 0.27 Pneumococcal bacteremia; chr3:129002467 chr3:128861313~128871540:- CESC cis rs6439153 0.967 rs12695512 ENSG00000231305.3 RP11-723O4.2 4.22 3.62e-05 0.0159 0.26 0.27 Pneumococcal bacteremia; chr3:129003239 chr3:128861313~128871540:- CESC cis rs6439153 0.967 rs12695513 ENSG00000231305.3 RP11-723O4.2 4.22 3.62e-05 0.0159 0.26 0.27 Pneumococcal bacteremia; chr3:129003469 chr3:128861313~128871540:- CESC cis rs75422866 0.867 rs73104163 ENSG00000274902.1 RP1-197B17.4 4.22 3.62e-05 0.0159 0.72 0.27 Pneumonia; chr12:47706187 chr12:47731908~47732351:+ CESC cis rs75422866 1 rs12423045 ENSG00000274902.1 RP1-197B17.4 4.22 3.62e-05 0.0159 0.72 0.27 Pneumonia; chr12:47706275 chr12:47731908~47732351:+ CESC cis rs7568498 0.564 rs9287807 ENSG00000227403.1 AC009299.3 4.22 3.62e-05 0.0159 0.41 0.27 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161058850 chr2:161244739~161249050:+ CESC cis rs801193 0.548 rs2659904 ENSG00000237310.1 GS1-124K5.4 4.22 3.63e-05 0.0159 0.26 0.27 Aortic root size; chr7:66713615 chr7:66493706~66495474:+ CESC cis rs748404 0.697 rs1814323 ENSG00000249839.1 AC011330.5 4.22 3.63e-05 0.0159 0.28 0.27 Lung cancer; chr15:43271039 chr15:43663654~43684339:- CESC cis rs3738443 0.868 rs61840048 ENSG00000259865.1 RP11-488L18.10 4.22 3.63e-05 0.0159 0.3 0.27 Alcohol dependence; chr1:247199829 chr1:247187281~247188526:- CESC cis rs3806843 0.576 rs246072 ENSG00000202111.1 VTRNA1-2 -4.22 3.63e-05 0.0159 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140940841 chr5:140718925~140719013:+ CESC cis rs8030379 1 rs2030840 ENSG00000230373.7 GOLGA6L5P -4.22 3.63e-05 0.0159 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83915382 chr15:84507885~84516814:- CESC cis rs8030379 1 rs1880730 ENSG00000230373.7 GOLGA6L5P -4.22 3.63e-05 0.0159 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83915432 chr15:84507885~84516814:- CESC cis rs61160187 0.582 rs56284222 ENSG00000215032.2 GNL3LP1 4.22 3.63e-05 0.0159 0.33 0.27 Educational attainment (years of education);Educational attainment (college completion); chr5:61065723 chr5:60891935~60893577:- CESC cis rs9847710 0.696 rs2581777 ENSG00000242142.1 SERBP1P3 4.22 3.63e-05 0.0159 0.32 0.27 Ulcerative colitis; chr3:53020711 chr3:53064283~53065091:- CESC cis rs3096299 0.934 rs9927904 ENSG00000274627.1 RP11-104N10.2 4.22 3.63e-05 0.0159 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89396439 chr16:89516797~89522217:+ CESC cis rs6991838 0.8 rs11786598 ENSG00000200714.1 Y_RNA -4.22 3.63e-05 0.0159 -0.33 -0.27 Intelligence (multi-trait analysis); chr8:65559944 chr8:65592731~65592820:+ CESC cis rs2337406 0.706 rs74090742 ENSG00000274576.2 IGHV2-70 -4.22 3.63e-05 0.0159 -0.35 -0.27 Alzheimer's disease (late onset); chr14:106696601 chr14:106770577~106771020:- CESC cis rs2337406 1 rs61268362 ENSG00000274576.2 IGHV2-70 -4.22 3.63e-05 0.0159 -0.35 -0.27 Alzheimer's disease (late onset); chr14:106697010 chr14:106770577~106771020:- CESC cis rs2337406 0.85 rs8014460 ENSG00000274576.2 IGHV2-70 -4.22 3.63e-05 0.0159 -0.35 -0.27 Alzheimer's disease (late onset); chr14:106697140 chr14:106770577~106771020:- CESC cis rs9323326 0.545 rs4901834 ENSG00000257621.6 PSMA3-AS1 4.22 3.64e-05 0.0159 0.27 0.27 Gut microbiota (bacterial taxa); chr14:58028427 chr14:58265365~58298134:- CESC cis rs11971779 0.793 rs11772447 ENSG00000273391.1 RP11-634H22.1 4.22 3.64e-05 0.0159 0.29 0.27 Diisocyanate-induced asthma; chr7:139348843 chr7:139359032~139359566:- CESC cis rs6439153 0.967 rs61480393 ENSG00000231305.3 RP11-723O4.2 4.22 3.64e-05 0.0159 0.26 0.27 Pneumococcal bacteremia; chr3:128980916 chr3:128861313~128871540:- CESC cis rs6439153 1 rs6439153 ENSG00000231305.3 RP11-723O4.2 4.22 3.64e-05 0.0159 0.26 0.27 Pneumococcal bacteremia; chr3:128982287 chr3:128861313~128871540:- CESC cis rs4654899 0.643 rs12123092 ENSG00000227066.1 RP3-340N1.2 -4.22 3.64e-05 0.0159 -0.31 -0.27 Superior frontal gyrus grey matter volume; chr1:20740508 chr1:20154338~20160568:+ CESC cis rs13108904 0.935 rs1620928 ENSG00000254094.1 AC078852.1 4.22 3.64e-05 0.0159 0.33 0.27 Obesity-related traits; chr4:1285336 chr4:1356581~1358075:+ CESC cis rs17695224 0.675 rs1468641 ENSG00000268095.1 ZNF649-AS1 4.22 3.64e-05 0.0159 0.35 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51838366 chr19:51888025~51900463:+ CESC cis rs9309473 1 rs13383871 ENSG00000163016.8 ALMS1P 4.22 3.64e-05 0.0159 0.37 0.27 Metabolite levels; chr2:73404651 chr2:73644919~73685576:+ CESC cis rs34286592 0.929 rs35901559 ENSG00000214725.6 CDIPT-AS1 -4.22 3.64e-05 0.0159 -0.52 -0.27 Multiple sclerosis; chr16:29818294 chr16:29863593~29868053:+ CESC cis rs34286592 0.929 rs11864180 ENSG00000214725.6 CDIPT-AS1 -4.22 3.64e-05 0.0159 -0.52 -0.27 Multiple sclerosis; chr16:29819508 chr16:29863593~29868053:+ CESC cis rs34286592 0.929 rs9923649 ENSG00000214725.6 CDIPT-AS1 -4.22 3.64e-05 0.0159 -0.52 -0.27 Multiple sclerosis; chr16:29820817 chr16:29863593~29868053:+ CESC cis rs11992162 0.967 rs10112888 ENSG00000255020.1 AF131216.5 4.22 3.64e-05 0.0159 0.31 0.27 Monocyte count; chr8:11972699 chr8:11345748~11347502:- CESC cis rs7572733 0.534 rs1435570 ENSG00000222017.1 AC011997.1 4.22 3.64e-05 0.0159 0.35 0.27 Dermatomyositis; chr2:197866647 chr2:197693106~197774823:+ CESC cis rs875971 0.522 rs7784623 ENSG00000222364.1 RNU6-96P -4.22 3.65e-05 0.016 -0.33 -0.27 Aortic root size; chr7:65930047 chr7:66395191~66395286:+ CESC cis rs5760092 0.572 rs738806 ENSG00000099984.9 GSTT2 -4.22 3.65e-05 0.016 -0.37 -0.27 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23980123~23983911:+ CESC cis rs7015630 0.647 rs12679902 ENSG00000251136.7 RP11-37B2.1 -4.22 3.65e-05 0.016 -0.31 -0.27 Inflammatory bowel disease;Crohn's disease; chr8:89845761 chr8:89609409~89757727:- CESC cis rs889398 0.904 rs4783721 ENSG00000226232.7 RP11-419C5.2 4.22 3.66e-05 0.016 0.26 0.27 Body mass index; chr16:69527253 chr16:69976388~69996188:- CESC cis rs12134133 1 rs1429904 ENSG00000274245.1 RP11-357P18.2 4.21 3.66e-05 0.016 0.34 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207288539 chr1:207372559~207373252:+ CESC cis rs12134133 1 rs2782854 ENSG00000274245.1 RP11-357P18.2 4.21 3.66e-05 0.016 0.34 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207289369 chr1:207372559~207373252:+ CESC cis rs5760092 0.755 rs915589 ENSG00000272787.1 KB-226F1.2 4.21 3.66e-05 0.016 0.35 0.27 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23969211~23969873:+ CESC cis rs12908161 0.96 rs17599989 ENSG00000225151.9 GOLGA2P7 -4.21 3.66e-05 0.016 -0.37 -0.27 Schizophrenia; chr15:84742305 chr15:84199311~84230136:- CESC cis rs10129255 0.53 rs11624912 ENSG00000211972.2 IGHV3-66 4.21 3.66e-05 0.016 0.19 0.27 Kawasaki disease; chr14:106673891 chr14:106675017~106675544:- CESC cis rs10043775 1 rs36028618 ENSG00000251330.3 CTD-2283N19.1 -4.21 3.66e-05 0.016 -0.36 -0.27 Periodontal microbiota; chr5:148411578 chr5:148430159~148430807:- CESC cis rs10129255 0.5 rs4774189 ENSG00000280411.1 IGHV1-69-2 -4.21 3.67e-05 0.016 -0.19 -0.27 Kawasaki disease; chr14:106768275 chr14:106762092~106762588:- CESC cis rs7580658 0.75 rs6731176 ENSG00000236682.1 AC068282.3 -4.21 3.67e-05 0.016 -0.32 -0.27 Protein C levels; chr2:127313427 chr2:127389130~127400580:+ CESC cis rs6782228 0.585 rs2712392 ENSG00000242551.2 POU5F1P6 -4.21 3.67e-05 0.016 -0.3 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128705414 chr3:128674735~128677005:- CESC cis rs7131987 0.65 rs11050187 ENSG00000257176.2 RP11-996F15.2 -4.21 3.67e-05 0.016 -0.33 -0.27 QT interval; chr12:29319943 chr12:29280418~29317848:- CESC cis rs2274273 0.624 rs68138420 ENSG00000258413.1 RP11-665C16.6 -4.21 3.67e-05 0.016 -0.36 -0.27 Protein biomarker; chr14:55311249 chr14:55262767~55272075:- CESC cis rs1930961 1 rs997872 ENSG00000272942.1 CTA-246H3.12 -4.21 3.67e-05 0.016 -0.41 -0.27 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25434324~25435070:- CESC cis rs3743266 0.507 rs56261931 ENSG00000245534.5 RORA-AS1 -4.21 3.67e-05 0.016 -0.4 -0.27 Menarche (age at onset); chr15:60439419 chr15:60479178~60630637:+ CESC cis rs62025270 0.632 rs56153788 ENSG00000202081.1 RNU6-1280P -4.21 3.67e-05 0.016 -0.38 -0.27 Idiopathic pulmonary fibrosis; chr15:85627761 chr15:85651522~85651628:- CESC cis rs6686842 0.798 rs12037263 ENSG00000235358.1 RP11-399E6.1 4.21 3.67e-05 0.016 0.33 0.27 Height; chr1:41016828 chr1:41242373~41284861:+ CESC cis rs7829975 0.714 rs59046059 ENSG00000253893.2 FAM85B -4.21 3.68e-05 0.0161 -0.33 -0.27 Mood instability; chr8:8813226 chr8:8167819~8226614:- CESC cis rs2115630 0.967 rs8028490 ENSG00000225151.9 GOLGA2P7 4.21 3.68e-05 0.0161 0.3 0.27 P wave terminal force; chr15:84734657 chr15:84199311~84230136:- CESC cis rs1707322 0.963 rs11211202 ENSG00000281133.1 AL355480.3 -4.21 3.68e-05 0.0161 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45826710 chr1:45580892~45580996:- CESC cis rs875971 0.502 rs11769702 ENSG00000222364.1 RNU6-96P -4.21 3.68e-05 0.0161 -0.38 -0.27 Aortic root size; chr7:66255529 chr7:66395191~66395286:+ CESC cis rs2933343 0.7 rs1683779 ENSG00000231305.3 RP11-723O4.2 4.21 3.68e-05 0.0161 0.26 0.27 IgG glycosylation; chr3:128923205 chr3:128861313~128871540:- CESC cis rs1538970 0.781 rs12049503 ENSG00000280836.1 AL355480.1 -4.21 3.68e-05 0.0161 -0.35 -0.27 Platelet count; chr1:45555884 chr1:45581219~45581321:- CESC cis rs2933343 1 rs2929859 ENSG00000231305.3 RP11-723O4.2 4.21 3.68e-05 0.0161 0.29 0.27 IgG glycosylation; chr3:128889498 chr3:128861313~128871540:- CESC cis rs2522056 0.808 rs17771891 ENSG00000233006.5 AC034220.3 4.21 3.69e-05 0.0161 0.38 0.27 Fibrinogen;Lymphocyte counts; chr5:132408510 chr5:132311285~132369916:- CESC cis rs4713118 0.621 rs9368548 ENSG00000219392.1 RP1-265C24.5 -4.21 3.69e-05 0.0161 -0.37 -0.27 Parkinson's disease; chr6:28066959 chr6:28115628~28116551:+ CESC cis rs10129255 0.701 rs2005643 ENSG00000224373.3 IGHV4-59 4.21 3.69e-05 0.0161 0.19 0.27 Kawasaki disease; chr14:106676288 chr14:106627249~106627825:- CESC cis rs12908161 1 rs3803405 ENSG00000225151.9 GOLGA2P7 -4.21 3.69e-05 0.0161 -0.38 -0.27 Schizophrenia; chr15:84840409 chr15:84199311~84230136:- CESC cis rs17772222 0.917 rs61986664 ENSG00000258983.2 RP11-507K2.2 4.21 3.69e-05 0.0161 0.34 0.27 Coronary artery calcification; chr14:88711251 chr14:88499334~88515502:+ CESC cis rs17772222 0.876 rs61986665 ENSG00000258983.2 RP11-507K2.2 4.21 3.69e-05 0.0161 0.34 0.27 Coronary artery calcification; chr14:88711354 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs8018755 ENSG00000258983.2 RP11-507K2.2 4.21 3.69e-05 0.0161 0.34 0.27 Coronary artery calcification; chr14:88714249 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs8018630 ENSG00000258983.2 RP11-507K2.2 4.21 3.69e-05 0.0161 0.34 0.27 Coronary artery calcification; chr14:88714250 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs8020072 ENSG00000258983.2 RP11-507K2.2 4.21 3.69e-05 0.0161 0.34 0.27 Coronary artery calcification; chr14:88714332 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs12589982 ENSG00000258983.2 RP11-507K2.2 4.21 3.69e-05 0.0161 0.34 0.27 Coronary artery calcification; chr14:88716861 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs61986671 ENSG00000258983.2 RP11-507K2.2 4.21 3.69e-05 0.0161 0.34 0.27 Coronary artery calcification; chr14:88732917 chr14:88499334~88515502:+ CESC cis rs67311347 1 rs6599094 ENSG00000223797.4 ENTPD3-AS1 4.21 3.69e-05 0.0161 0.27 0.27 Renal cell carcinoma; chr3:40358102 chr3:40313802~40453329:- CESC cis rs4713118 0.513 rs149954 ENSG00000219392.1 RP1-265C24.5 -4.21 3.69e-05 0.0161 -0.32 -0.27 Parkinson's disease; chr6:28067468 chr6:28115628~28116551:+ CESC cis rs1969253 0.803 rs843360 ENSG00000205955.4 HSP90AA5P -4.21 3.7e-05 0.0161 -0.26 -0.27 Major depressive disorder; chr3:184148012 chr3:184115352~184117898:+ CESC cis rs9487094 0.6 rs9372213 ENSG00000260273.1 RP11-425D10.10 4.21 3.7e-05 0.0161 0.33 0.27 Height; chr6:109370985 chr6:109382795~109383666:+ CESC cis rs2276314 1 rs4573997 ENSG00000278986.1 RP11-723J4.3 -4.21 3.7e-05 0.0161 -0.31 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35972605 chr18:35972151~35973916:+ CESC cis rs2919917 0.628 rs13267679 ENSG00000254352.1 RP11-578O24.2 -4.21 3.7e-05 0.0162 -0.42 -0.27 Lymphocyte counts; chr8:78711603 chr8:78723796~78724136:- CESC cis rs3764618 1 rs2287754 ENSG00000268006.1 PTOV1-AS1 4.21 3.71e-05 0.0162 0.56 0.27 Follicule stimulating hormone; chr19:48993237 chr19:49838639~49851676:- CESC cis rs6001482 0.679 rs1894238 ENSG00000236850.4 BMS1P20 -4.21 3.71e-05 0.0162 -0.27 -0.27 Diastolic blood pressure; chr22:22235704 chr22:22303224~22322847:+ CESC cis rs7829975 0.572 rs7005000 ENSG00000254340.1 RP11-10A14.3 -4.21 3.71e-05 0.0162 -0.33 -0.27 Mood instability; chr8:8939092 chr8:9141424~9145435:+ CESC cis rs8020095 0.571 rs7156119 ENSG00000258561.1 RP11-72M17.1 -4.21 3.71e-05 0.0162 -0.42 -0.27 Depression (quantitative trait); chr14:67183398 chr14:66212810~66509394:- CESC cis rs4642101 0.824 rs9820977 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12801433 chr3:12070195~12071360:+ CESC cis rs4642101 0.824 rs11717013 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12802363 chr3:12070195~12071360:+ CESC cis rs4642101 0.793 rs3889513 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12802571 chr3:12070195~12071360:+ CESC cis rs4642101 0.824 rs3889514 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12802573 chr3:12070195~12071360:+ CESC cis rs4642101 0.824 rs3889515 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12802613 chr3:12070195~12071360:+ CESC cis rs4642101 0.824 rs9835677 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12803659 chr3:12070195~12071360:+ CESC cis rs4642101 0.855 rs9873475 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12803923 chr3:12070195~12071360:+ CESC cis rs4642101 0.855 rs9836128 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12803927 chr3:12070195~12071360:+ CESC cis rs4642101 0.824 rs9852222 ENSG00000226642.1 ACTG1P12 4.21 3.71e-05 0.0162 0.35 0.27 QRS complex (12-leadsum); chr3:12806992 chr3:12070195~12071360:+ CESC cis rs4319547 0.695 rs10846699 ENSG00000275265.1 RP11-15J22.8 4.21 3.71e-05 0.0162 0.38 0.27 Body mass index; chr12:122368526 chr12:122501187~122501641:+ CESC cis rs116095464 0.681 rs1574220 ENSG00000250848.1 CTD-2083E4.5 -4.21 3.72e-05 0.0162 -0.44 -0.27 Breast cancer; chr5:314403 chr5:288833~290321:- CESC cis rs73086581 0.645 rs2103659 ENSG00000229539.1 RP11-119B16.2 -4.21 3.72e-05 0.0162 -0.33 -0.27 Response to antidepressants in depression; chr20:4001925 chr20:3888239~3888868:- CESC cis rs6991838 0.806 rs13262793 ENSG00000200714.1 Y_RNA 4.21 3.72e-05 0.0162 0.31 0.27 Intelligence (multi-trait analysis); chr8:65549662 chr8:65592731~65592820:+ CESC cis rs8020095 0.571 rs8012660 ENSG00000258561.1 RP11-72M17.1 -4.21 3.72e-05 0.0162 -0.4 -0.27 Depression (quantitative trait); chr14:66833953 chr14:66212810~66509394:- CESC cis rs8059260 0.604 rs741176 ENSG00000274038.1 RP11-66H6.4 4.21 3.72e-05 0.0162 0.4 0.27 Alcohol consumption over the past year; chr16:11051953 chr16:11056556~11057034:+ CESC cis rs73086581 0.687 rs16989002 ENSG00000229539.1 RP11-119B16.2 4.21 3.72e-05 0.0162 0.45 0.27 Response to antidepressants in depression; chr20:3870056 chr20:3888239~3888868:- CESC cis rs673078 0.607 rs882927 ENSG00000275759.1 RP11-131L12.3 -4.21 3.72e-05 0.0162 -0.5 -0.27 Glucose homeostasis traits; chr12:118406737 chr12:118428281~118428870:+ CESC cis rs1707322 1 rs12403666 ENSG00000281133.1 AL355480.3 -4.21 3.72e-05 0.0162 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45965949 chr1:45580892~45580996:- CESC cis rs1707322 1 rs785478 ENSG00000281133.1 AL355480.3 4.21 3.73e-05 0.0162 0.32 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46025963 chr1:45580892~45580996:- CESC cis rs2337406 0.539 rs2583292 ENSG00000254174.1 IGHV1-12 4.21 3.73e-05 0.0162 0.27 0.27 Alzheimer's disease (late onset); chr14:106649040 chr14:106122420~106122709:- CESC cis rs6001482 0.679 rs5750786 ENSG00000236850.4 BMS1P20 -4.21 3.73e-05 0.0162 -0.27 -0.27 Diastolic blood pressure; chr22:22235358 chr22:22303224~22322847:+ CESC cis rs526231 0.784 rs28157 ENSG00000175749.11 EIF3KP1 4.21 3.73e-05 0.0162 0.34 0.27 Primary biliary cholangitis; chr5:103260136 chr5:103032376~103033031:+ CESC cis rs1501911 0.545 rs4703345 ENSG00000248489.1 CTD-2007H13.3 -4.21 3.73e-05 0.0162 -0.38 -0.27 Lung function (FEV1/FVC); chr5:99016679 chr5:98929171~98995013:+ CESC cis rs6928977 0.863 rs2223803 ENSG00000234084.1 RP3-388E23.2 4.21 3.73e-05 0.0162 0.25 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135366924 chr6:135301568~135307158:+ CESC cis rs34286592 1 rs34286592 ENSG00000214725.6 CDIPT-AS1 -4.21 3.73e-05 0.0162 -0.52 -0.27 Multiple sclerosis; chr16:29809159 chr16:29863593~29868053:+ CESC cis rs7604827 0.658 rs73072768 ENSG00000230076.1 AC016708.2 4.21 3.74e-05 0.0163 0.41 0.27 PR interval; chr2:214446865 chr2:214847128~214847445:+ CESC cis rs875971 0.862 rs7809814 ENSG00000232559.3 GS1-124K5.12 -4.21 3.74e-05 0.0163 -0.29 -0.27 Aortic root size; chr7:66150410 chr7:66554588~66576923:- CESC cis rs2136613 0.533 rs10995333 ENSG00000238280.1 RP11-436D10.3 -4.21 3.74e-05 0.0163 -0.32 -0.27 Selective IgA deficiency; chr10:62858034 chr10:62793562~62805887:- CESC cis rs7560272 0.538 rs6732812 ENSG00000273245.1 RP11-434P11.2 -4.21 3.74e-05 0.0163 -0.35 -0.27 Schizophrenia; chr2:73695348 chr2:73750256~73750786:- CESC cis rs10829156 0.625 rs7082235 ENSG00000240291.1 RP11-499P20.2 4.21 3.74e-05 0.0163 0.31 0.27 Sudden cardiac arrest; chr10:18536765 chr10:18513115~18545651:- CESC cis rs9341808 0.727 rs9361599 ENSG00000272129.1 RP11-250B2.6 4.21 3.74e-05 0.0163 0.31 0.27 Sitting height ratio; chr6:80315525 chr6:80355424~80356859:+ CESC cis rs8100891 0.506 rs10408437 ENSG00000267213.4 AC007773.2 -4.21 3.74e-05 0.0163 -0.45 -0.27 Neuroticism; chr19:32497094 chr19:32390050~32405560:- CESC cis rs1023500 0.552 rs133368 ENSG00000273366.1 CTA-989H11.1 -4.21 3.74e-05 0.0163 -0.36 -0.27 Schizophrenia; chr22:42067685 chr22:42278188~42278846:+ CESC cis rs853679 0.517 rs4713150 ENSG00000219392.1 RP1-265C24.5 -4.21 3.74e-05 0.0163 -0.36 -0.27 Depression; chr6:28168434 chr6:28115628~28116551:+ CESC cis rs4713118 0.527 rs4713151 ENSG00000219392.1 RP1-265C24.5 -4.21 3.74e-05 0.0163 -0.36 -0.27 Parkinson's disease; chr6:28168578 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9393901 ENSG00000219392.1 RP1-265C24.5 -4.21 3.74e-05 0.0163 -0.36 -0.27 Depression; chr6:28169019 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs3173443 ENSG00000219392.1 RP1-265C24.5 -4.21 3.74e-05 0.0163 -0.36 -0.27 Depression; chr6:28169249 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs4713152 ENSG00000219392.1 RP1-265C24.5 -4.21 3.74e-05 0.0163 -0.36 -0.27 Depression; chr6:28169676 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9348797 ENSG00000219392.1 RP1-265C24.5 -4.21 3.74e-05 0.0163 -0.36 -0.27 Depression; chr6:28169755 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380062 ENSG00000219392.1 RP1-265C24.5 -4.21 3.74e-05 0.0163 -0.36 -0.27 Depression; chr6:28169791 chr6:28115628~28116551:+ CESC cis rs853679 0.542 rs9380063 ENSG00000219392.1 RP1-265C24.5 -4.21 3.74e-05 0.0163 -0.36 -0.27 Depression; chr6:28170075 chr6:28115628~28116551:+ CESC cis rs950880 0.71 rs2287034 ENSG00000234389.1 AC007278.3 4.21 3.74e-05 0.0163 0.3 0.27 Serum protein levels (sST2); chr2:102394128 chr2:102438713~102440475:+ CESC cis rs9420907 0.579 rs35202847 ENSG00000260461.1 RP11-541N10.3 -4.21 3.74e-05 0.0163 -0.42 -0.27 Telomere length; chr10:103851389 chr10:103877374~103879761:- CESC cis rs11976180 1 rs2951364 ENSG00000273234.1 OR2A13P -4.21 3.75e-05 0.0163 -0.32 -0.27 Obesity-related traits; chr7:144057390 chr7:144142009~144142938:+ CESC cis rs11976180 1 rs2951363 ENSG00000273234.1 OR2A13P -4.21 3.75e-05 0.0163 -0.32 -0.27 Obesity-related traits; chr7:144057631 chr7:144142009~144142938:+ CESC cis rs11159086 1 rs3759745 ENSG00000270000.1 RP3-449M8.9 4.21 3.75e-05 0.0163 0.48 0.27 Advanced glycation end-product levels; chr14:74495967 chr14:74471930~74472360:- CESC cis rs11159086 1 rs4903232 ENSG00000270000.1 RP3-449M8.9 4.21 3.75e-05 0.0163 0.48 0.27 Advanced glycation end-product levels; chr14:74496585 chr14:74471930~74472360:- CESC cis rs79243044 0.965 rs10500648 ENSG00000224295.2 AC087380.14 -4.21 3.75e-05 0.0163 -0.3 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5539775 chr11:5518441~5524955:- CESC cis rs9341808 0.754 rs9352817 ENSG00000272129.1 RP11-250B2.6 4.21 3.75e-05 0.0163 0.31 0.27 Sitting height ratio; chr6:80316162 chr6:80355424~80356859:+ CESC cis rs6844153 0.938 rs12646473 ENSG00000240005.4 RP11-293A21.1 -4.21 3.75e-05 0.0163 -0.4 -0.27 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26873833 chr4:26859806~26860599:- CESC cis rs11672691 0.627 rs6508981 ENSG00000270164.1 LINC01480 -4.21 3.75e-05 0.0163 -0.31 -0.27 Prostate cancer; chr19:41483668 chr19:41535183~41536904:+ CESC cis rs11971779 0.68 rs6978680 ENSG00000273391.1 RP11-634H22.1 -4.21 3.76e-05 0.0163 -0.27 -0.27 Diisocyanate-induced asthma; chr7:139427302 chr7:139359032~139359566:- CESC cis rs919433 0.617 rs2037590 ENSG00000222017.1 AC011997.1 -4.21 3.76e-05 0.0163 -0.35 -0.27 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197720051 chr2:197693106~197774823:+ CESC cis rs11603023 0.967 rs4245184 ENSG00000255422.1 AP002954.4 4.21 3.76e-05 0.0163 0.31 0.27 Cholesterol, total; chr11:118639844 chr11:118704607~118750263:+ CESC cis rs11603023 0.967 rs644273 ENSG00000255422.1 AP002954.4 4.21 3.76e-05 0.0163 0.31 0.27 Cholesterol, total; chr11:118640634 chr11:118704607~118750263:+ CESC cis rs11603023 0.967 rs654423 ENSG00000255422.1 AP002954.4 4.21 3.76e-05 0.0163 0.31 0.27 Cholesterol, total; chr11:118641039 chr11:118704607~118750263:+ CESC cis rs12134133 0.688 rs6540875 ENSG00000274245.1 RP11-357P18.2 4.21 3.76e-05 0.0163 0.4 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207221686 chr1:207372559~207373252:+ CESC cis rs12134133 0.719 rs6696142 ENSG00000274245.1 RP11-357P18.2 4.21 3.76e-05 0.0163 0.4 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207228898 chr1:207372559~207373252:+ CESC cis rs12134133 0.752 rs57003024 ENSG00000274245.1 RP11-357P18.2 4.21 3.76e-05 0.0163 0.4 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207230999 chr1:207372559~207373252:+ CESC cis rs12134133 0.752 rs61821050 ENSG00000274245.1 RP11-357P18.2 4.21 3.76e-05 0.0163 0.4 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207235253 chr1:207372559~207373252:+ CESC cis rs12134133 0.752 rs61821051 ENSG00000274245.1 RP11-357P18.2 4.21 3.76e-05 0.0163 0.4 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207235624 chr1:207372559~207373252:+ CESC cis rs2299587 0.866 rs208767 ENSG00000253671.1 RP11-806O11.1 -4.21 3.76e-05 0.0163 -0.28 -0.27 Economic and political preferences; chr8:17947891 chr8:17808941~17820868:+ CESC cis rs2299587 0.866 rs208766 ENSG00000253671.1 RP11-806O11.1 -4.21 3.76e-05 0.0163 -0.28 -0.27 Economic and political preferences; chr8:17947923 chr8:17808941~17820868:+ CESC cis rs6556937 0.627 rs10067766 ENSG00000251314.2 CTD-2337A12.1 4.21 3.76e-05 0.0164 0.36 0.27 Blood protein levels; chr5:96666316 chr5:95962001~96631085:+ CESC cis rs2283792 0.622 rs5756323 ENSG00000224086.5 LL22NC03-86G7.1 4.21 3.76e-05 0.0164 0.31 0.27 Multiple sclerosis; chr22:21980398 chr22:21938293~21977632:+ CESC cis rs11123694 1 rs11123694 ENSG00000214184.3 AC012487.2 -4.21 3.76e-05 0.0164 -0.31 -0.27 Mean platelet volume; chr2:108448107 chr2:108507515~108534196:- CESC cis rs35740288 0.752 rs11636138 ENSG00000202081.1 RNU6-1280P 4.21 3.77e-05 0.0164 0.34 0.27 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85744316 chr15:85651522~85651628:- CESC cis rs10129255 0.957 rs11846893 ENSG00000211970.3 IGHV4-61 -4.21 3.77e-05 0.0164 -0.2 -0.27 Kawasaki disease; chr14:106779068 chr14:106639119~106639657:- CESC cis rs2439831 1 rs690316 ENSG00000275601.1 AC011330.13 -4.21 3.77e-05 0.0164 -0.36 -0.27 Lung cancer in ever smokers; chr15:43445682 chr15:43642389~43643023:- CESC cis rs748404 0.697 rs493444 ENSG00000249839.1 AC011330.5 -4.21 3.77e-05 0.0164 -0.29 -0.27 Lung cancer; chr15:43274272 chr15:43663654~43684339:- CESC cis rs1823913 1 rs12623832 ENSG00000227542.1 AC092614.2 -4.21 3.77e-05 0.0164 -0.28 -0.27 Obesity-related traits; chr2:191260918 chr2:191229165~191246172:- CESC cis rs7572733 0.534 rs1436131 ENSG00000222017.1 AC011997.1 4.21 3.77e-05 0.0164 0.34 0.27 Dermatomyositis; chr2:197866506 chr2:197693106~197774823:+ CESC cis rs172642 1 rs218696 ENSG00000276384.1 RP11-186B7.7 4.21 3.77e-05 0.0164 0.31 0.27 Metabolite levels (small molecules and protein measures); chr17:6690603 chr17:7557820~7558245:- CESC cis rs8040855 0.621 rs6496796 ENSG00000259774.1 RP11-182J1.13 -4.21 3.78e-05 0.0164 -0.32 -0.27 Bulimia nervosa; chr15:85183617 chr15:84422618~84425882:+ CESC cis rs11603023 0.805 rs687190 ENSG00000255422.1 AP002954.4 -4.21 3.78e-05 0.0164 -0.31 -0.27 Cholesterol, total; chr11:118671674 chr11:118704607~118750263:+ CESC cis rs2274273 0.624 rs7159824 ENSG00000258413.1 RP11-665C16.6 -4.21 3.78e-05 0.0164 -0.36 -0.27 Protein biomarker; chr14:55305818 chr14:55262767~55272075:- CESC cis rs875971 1 rs12533997 ENSG00000237310.1 GS1-124K5.4 4.21 3.78e-05 0.0164 0.26 0.27 Aortic root size; chr7:66500390 chr7:66493706~66495474:+ CESC cis rs875971 0.929 rs10950041 ENSG00000237310.1 GS1-124K5.4 4.21 3.78e-05 0.0164 0.26 0.27 Aortic root size; chr7:66508888 chr7:66493706~66495474:+ CESC cis rs7005380 0.6 rs13267652 ENSG00000279347.1 RP11-85I17.2 -4.21 3.78e-05 0.0164 -0.25 -0.27 Interstitial lung disease; chr8:119878346 chr8:119838736~119840385:- CESC cis rs7005380 0.62 rs13275528 ENSG00000279347.1 RP11-85I17.2 -4.21 3.78e-05 0.0164 -0.25 -0.27 Interstitial lung disease; chr8:119878617 chr8:119838736~119840385:- CESC cis rs6686842 0.965 rs1121866 ENSG00000235358.1 RP11-399E6.1 4.21 3.79e-05 0.0164 0.33 0.27 Height; chr1:41242427 chr1:41242373~41284861:+ CESC cis rs8031584 0.872 rs11634761 ENSG00000260382.1 RP11-540B6.2 4.21 3.79e-05 0.0164 0.38 0.27 Huntington's disease progression; chr15:30950970 chr15:30882267~30883231:- CESC cis rs875971 0.862 rs4368860 ENSG00000232559.3 GS1-124K5.12 -4.21 3.79e-05 0.0165 -0.29 -0.27 Aortic root size; chr7:66143495 chr7:66554588~66576923:- CESC cis rs9322193 0.924 rs9498382 ENSG00000268592.3 RAET1E-AS1 4.21 3.79e-05 0.0165 0.35 0.27 Lung cancer; chr6:149610982 chr6:149863494~149919507:+ CESC cis rs2564921 0.704 rs56058643 ENSG00000242142.1 SERBP1P3 -4.21 3.79e-05 0.0165 -0.34 -0.27 Height; chr3:53093751 chr3:53064283~53065091:- CESC cis rs2564921 0.704 rs55950520 ENSG00000242142.1 SERBP1P3 -4.21 3.79e-05 0.0165 -0.34 -0.27 Height; chr3:53094335 chr3:53064283~53065091:- CESC cis rs8020095 0.571 rs28539317 ENSG00000258561.1 RP11-72M17.1 -4.21 3.79e-05 0.0165 -0.4 -0.27 Depression (quantitative trait); chr14:67014115 chr14:66212810~66509394:- CESC cis rs2733201 1 rs1426658 ENSG00000275601.1 AC011330.13 4.21 3.79e-05 0.0165 0.48 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44046721 chr15:43642389~43643023:- CESC cis rs4642101 0.824 rs9825233 ENSG00000226642.1 ACTG1P12 -4.21 3.79e-05 0.0165 -0.34 -0.27 QRS complex (12-leadsum); chr3:12801869 chr3:12070195~12071360:+ CESC cis rs4819052 0.851 rs2838855 ENSG00000223768.1 LINC00205 4.21 3.79e-05 0.0165 0.32 0.27 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45260651 chr21:45293285~45297354:+ CESC cis rs8005677 1 rs4982709 ENSG00000279656.1 RP11-298I3.6 4.21 3.79e-05 0.0165 0.34 0.27 Cognitive ability (multi-trait analysis); chr14:22925490 chr14:23023083~23024217:- CESC cis rs881375 0.967 rs7039505 ENSG00000226752.6 PSMD5-AS1 -4.21 3.8e-05 0.0165 -0.3 -0.27 Rheumatoid arthritis; chr9:120943667 chr9:120824828~120854385:+ CESC cis rs12134133 1 rs7526831 ENSG00000274245.1 RP11-357P18.2 4.21 3.8e-05 0.0165 0.37 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265261 chr1:207372559~207373252:+ CESC cis rs9322193 1 rs9377228 ENSG00000268592.3 RAET1E-AS1 4.21 3.8e-05 0.0165 0.35 0.27 Lung cancer; chr6:149600862 chr6:149863494~149919507:+ CESC cis rs12550612 1 rs12550612 ENSG00000253616.4 RP11-875O11.3 4.21 3.8e-05 0.0165 0.38 0.27 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23109256 chr8:23071377~23074488:- CESC cis rs10129255 0.912 rs61997792 ENSG00000211970.3 IGHV4-61 -4.21 3.81e-05 0.0165 -0.23 -0.27 Kawasaki disease; chr14:106799304 chr14:106639119~106639657:- CESC cis rs7572733 0.576 rs1865586 ENSG00000222017.1 AC011997.1 -4.21 3.81e-05 0.0165 -0.33 -0.27 Dermatomyositis; chr2:197894144 chr2:197693106~197774823:+ CESC cis rs6991838 0.778 rs11779602 ENSG00000200714.1 Y_RNA 4.21 3.81e-05 0.0165 0.32 0.27 Intelligence (multi-trait analysis); chr8:65550247 chr8:65592731~65592820:+ CESC cis rs67311347 1 rs4973898 ENSG00000223797.4 ENTPD3-AS1 -4.21 3.81e-05 0.0165 -0.27 -0.27 Renal cell carcinoma; chr3:40418041 chr3:40313802~40453329:- CESC cis rs17301013 0.507 rs10912763 ENSG00000227373.4 RP11-160H22.5 4.2 3.81e-05 0.0165 0.38 0.27 Systemic lupus erythematosus; chr1:174316083 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10912764 ENSG00000227373.4 RP11-160H22.5 4.2 3.81e-05 0.0165 0.38 0.27 Systemic lupus erythematosus; chr1:174316085 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10912765 ENSG00000227373.4 RP11-160H22.5 4.2 3.81e-05 0.0165 0.38 0.27 Systemic lupus erythematosus; chr1:174322812 chr1:174115300~174160004:- CESC cis rs6844153 0.887 rs62302535 ENSG00000240005.4 RP11-293A21.1 -4.2 3.81e-05 0.0165 -0.38 -0.27 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26957254 chr4:26859806~26860599:- CESC cis rs8042680 0.614 rs12910825 ENSG00000214432.8 AC068831.10 4.2 3.82e-05 0.0165 0.32 0.27 Type 2 diabetes; chr15:90968030 chr15:91022619~91036611:+ CESC cis rs748404 0.631 rs8042688 ENSG00000205771.5 CATSPER2P1 -4.2 3.82e-05 0.0165 -0.33 -0.27 Lung cancer; chr15:43346327 chr15:43726918~43747094:- CESC cis rs6740322 0.895 rs9309097 ENSG00000234936.1 AC010883.5 4.2 3.82e-05 0.0166 0.29 0.27 Coronary artery disease; chr2:43327258 chr2:43229573~43233394:+ CESC cis rs6740322 0.895 rs13384080 ENSG00000234936.1 AC010883.5 4.2 3.82e-05 0.0166 0.29 0.27 Coronary artery disease; chr2:43330224 chr2:43229573~43233394:+ CESC cis rs17826219 0.706 rs57698184 ENSG00000266490.1 CTD-2349P21.9 4.2 3.82e-05 0.0166 0.43 0.27 Body mass index; chr17:30737900 chr17:30792372~30792833:+ CESC cis rs7208859 0.524 rs59923796 ENSG00000266490.1 CTD-2349P21.9 4.2 3.82e-05 0.0166 0.43 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30792372~30792833:+ CESC cis rs2596230 0.528 rs2596240 ENSG00000278472.1 RP11-74D7.3 4.2 3.83e-05 0.0166 0.42 0.27 Diabetic kidney disease; chr15:33442555 chr15:33972059~33972515:- CESC cis rs10788972 0.634 rs12033409 ENSG00000225183.1 RP4-758J24.4 -4.2 3.83e-05 0.0166 -0.33 -0.27 Parkinson disease and lewy body pathology; chr1:54087238 chr1:54089856~54090093:+ CESC cis rs72772090 0.539 rs72773989 ENSG00000248734.2 CTD-2260A17.1 -4.2 3.83e-05 0.0166 -0.44 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96827910 chr5:96784777~96785999:+ CESC cis rs2412819 0.571 rs2729494 ENSG00000249839.1 AC011330.5 4.2 3.83e-05 0.0166 0.36 0.27 Lung cancer; chr15:43837395 chr15:43663654~43684339:- CESC cis rs2136613 0.505 rs10761674 ENSG00000238280.1 RP11-436D10.3 -4.2 3.83e-05 0.0166 -0.32 -0.27 Selective IgA deficiency; chr10:62858580 chr10:62793562~62805887:- CESC cis rs3806843 0.576 rs246043 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140951339 chr5:140718925~140719013:+ CESC cis rs3806843 0.608 rs246042 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140951382 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246041 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140951543 chr5:140718925~140719013:+ CESC cis rs3806843 0.548 rs246038 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140952114 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246037 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140952261 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246036 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140952301 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246034 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140952479 chr5:140718925~140719013:+ CESC cis rs3806843 0.547 rs246033 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140952530 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246032 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140952962 chr5:140718925~140719013:+ CESC cis rs3806843 0.517 rs246031 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140953522 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246030 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140953569 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246029 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140953641 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246028 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140953928 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246027 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140954016 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246021 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140954919 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246020 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140955186 chr5:140718925~140719013:+ CESC cis rs3806843 0.551 rs246018 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140955458 chr5:140718925~140719013:+ CESC cis rs3806843 0.518 rs173471 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140955641 chr5:140718925~140719013:+ CESC cis rs3806843 0.549 rs246012 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140956692 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246011 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140956820 chr5:140718925~140719013:+ CESC cis rs3806843 0.547 rs246010 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140957050 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246008 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140958900 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246006 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140959643 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246005 ENSG00000202111.1 VTRNA1-2 -4.2 3.84e-05 0.0166 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140960299 chr5:140718925~140719013:+ CESC cis rs2412819 0.571 rs4923964 ENSG00000205771.5 CATSPER2P1 4.2 3.84e-05 0.0166 0.4 0.27 Lung cancer; chr15:43722882 chr15:43726918~43747094:- CESC cis rs875971 0.545 rs1638724 ENSG00000236529.1 RP13-254B10.1 -4.2 3.84e-05 0.0166 -0.33 -0.27 Aortic root size; chr7:66575494 chr7:65840212~65840596:+ CESC cis rs9318086 0.712 rs9510917 ENSG00000205861.10 C1QTNF9B-AS1 -4.2 3.84e-05 0.0166 -0.35 -0.27 Myopia (pathological); chr13:23868707 chr13:23888889~23897263:+ CESC cis rs1930961 1 rs5996946 ENSG00000272942.1 CTA-246H3.12 -4.2 3.84e-05 0.0166 -0.4 -0.27 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25434324~25435070:- CESC cis rs516805 0.923 rs487487 ENSG00000279453.1 RP3-425C14.4 -4.2 3.84e-05 0.0166 -0.32 -0.27 Lymphocyte counts; chr6:122422357 chr6:122436789~122439223:- CESC cis rs516805 0.961 rs556439 ENSG00000279453.1 RP3-425C14.4 -4.2 3.84e-05 0.0166 -0.32 -0.27 Lymphocyte counts; chr6:122423864 chr6:122436789~122439223:- CESC cis rs516805 0.961 rs572632 ENSG00000279453.1 RP3-425C14.4 -4.2 3.84e-05 0.0166 -0.32 -0.27 Lymphocyte counts; chr6:122437753 chr6:122436789~122439223:- CESC cis rs875971 1 rs778726 ENSG00000237310.1 GS1-124K5.4 4.2 3.85e-05 0.0166 0.27 0.27 Aortic root size; chr7:66363744 chr7:66493706~66495474:+ CESC cis rs875971 0.767 rs1695815 ENSG00000237310.1 GS1-124K5.4 4.2 3.85e-05 0.0166 0.27 0.27 Aortic root size; chr7:66366357 chr7:66493706~66495474:+ CESC cis rs875971 1 rs778685 ENSG00000237310.1 GS1-124K5.4 4.2 3.85e-05 0.0166 0.27 0.27 Aortic root size; chr7:66371189 chr7:66493706~66495474:+ CESC cis rs875971 0.929 rs778682 ENSG00000237310.1 GS1-124K5.4 4.2 3.85e-05 0.0166 0.27 0.27 Aortic root size; chr7:66372947 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs11765965 ENSG00000237310.1 GS1-124K5.4 4.2 3.85e-05 0.0166 0.27 0.27 Aortic root size; chr7:66377234 chr7:66493706~66495474:+ CESC cis rs919433 0.617 rs4850809 ENSG00000222017.1 AC011997.1 -4.2 3.85e-05 0.0167 -0.35 -0.27 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197718679 chr2:197693106~197774823:+ CESC cis rs150992 0.504 rs7719562 ENSG00000248489.1 CTD-2007H13.3 -4.2 3.85e-05 0.0167 -0.37 -0.27 Body mass index; chr5:99029419 chr5:98929171~98995013:+ CESC cis rs150992 0.504 rs4583911 ENSG00000248489.1 CTD-2007H13.3 -4.2 3.85e-05 0.0167 -0.37 -0.27 Body mass index; chr5:99031401 chr5:98929171~98995013:+ CESC cis rs10129255 0.833 rs7156689 ENSG00000211970.3 IGHV4-61 -4.2 3.85e-05 0.0167 -0.22 -0.27 Kawasaki disease; chr14:106816039 chr14:106639119~106639657:- CESC cis rs13108904 0.935 rs6853002 ENSG00000254094.1 AC078852.1 -4.2 3.85e-05 0.0167 -0.33 -0.27 Obesity-related traits; chr4:1302203 chr4:1356581~1358075:+ CESC cis rs3806843 0.576 rs246003 ENSG00000202111.1 VTRNA1-2 -4.2 3.85e-05 0.0167 -0.28 -0.27 Depressive symptoms (multi-trait analysis); chr5:140961280 chr5:140718925~140719013:+ CESC cis rs73173548 0.502 rs4451795 ENSG00000247828.6 TMEM161B-AS1 4.2 3.86e-05 0.0167 0.3 0.27 Macular telangiectasia type 2; chr5:88422879 chr5:88268895~88436685:+ CESC cis rs79243044 1 rs7120668 ENSG00000224295.2 AC087380.14 -4.2 3.86e-05 0.0167 -0.3 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5546624 chr11:5518441~5524955:- CESC cis rs1707322 0.929 rs785513 ENSG00000281133.1 AL355480.3 4.2 3.86e-05 0.0167 0.33 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46072648 chr1:45580892~45580996:- CESC cis rs2243480 1 rs35391607 ENSG00000228409.4 CCT6P1 4.2 3.86e-05 0.0167 0.39 0.27 Diabetic kidney disease; chr7:65895842 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs13220979 ENSG00000228409.4 CCT6P1 4.2 3.86e-05 0.0167 0.39 0.27 Diabetic kidney disease; chr7:65898217 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34974928 ENSG00000228409.4 CCT6P1 4.2 3.86e-05 0.0167 0.39 0.27 Diabetic kidney disease; chr7:65899019 chr7:65751142~65763354:+ CESC cis rs2243480 0.803 rs34804747 ENSG00000228409.4 CCT6P1 4.2 3.86e-05 0.0167 0.39 0.27 Diabetic kidney disease; chr7:65947955 chr7:65751142~65763354:+ CESC cis rs2337406 1 rs79452530 ENSG00000274576.2 IGHV2-70 -4.2 3.86e-05 0.0167 -0.34 -0.27 Alzheimer's disease (late onset); chr14:106699992 chr14:106770577~106771020:- CESC cis rs881375 0.967 rs1014529 ENSG00000226752.6 PSMD5-AS1 -4.2 3.86e-05 0.0167 -0.3 -0.27 Rheumatoid arthritis; chr9:120922665 chr9:120824828~120854385:+ CESC cis rs2455601 0.638 rs2742485 ENSG00000254860.4 TMEM9B-AS1 4.2 3.86e-05 0.0167 0.33 0.27 Schizophrenia; chr11:8965240 chr11:8964675~8977527:+ CESC cis rs9322193 0.886 rs9485408 ENSG00000268592.3 RAET1E-AS1 4.2 3.86e-05 0.0167 0.35 0.27 Lung cancer; chr6:149618888 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs1080670 ENSG00000268592.3 RAET1E-AS1 4.2 3.86e-05 0.0167 0.35 0.27 Lung cancer; chr6:149620161 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs10782312 ENSG00000268592.3 RAET1E-AS1 4.2 3.86e-05 0.0167 0.35 0.27 Lung cancer; chr6:149622669 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9505823 ENSG00000268592.3 RAET1E-AS1 4.2 3.86e-05 0.0167 0.35 0.27 Lung cancer; chr6:149628899 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9689599 ENSG00000268592.3 RAET1E-AS1 4.2 3.86e-05 0.0167 0.35 0.27 Lung cancer; chr6:149631973 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9800580 ENSG00000268592.3 RAET1E-AS1 4.2 3.86e-05 0.0167 0.35 0.27 Lung cancer; chr6:149632845 chr6:149863494~149919507:+ CESC cis rs9322193 0.962 rs13215691 ENSG00000223701.3 RAET1E-AS1 4.2 3.86e-05 0.0167 0.31 0.27 Lung cancer; chr6:149792666 chr6:149884431~149919508:+ CESC cis rs9987353 0.566 rs34491841 ENSG00000253893.2 FAM85B 4.2 3.87e-05 0.0167 0.37 0.27 Recombination measurement; chr8:9208000 chr8:8167819~8226614:- CESC cis rs875971 0.545 rs73152714 ENSG00000236529.1 RP13-254B10.1 4.2 3.87e-05 0.0167 0.33 0.27 Aortic root size; chr7:66534641 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs4718364 ENSG00000236529.1 RP13-254B10.1 4.2 3.87e-05 0.0167 0.33 0.27 Aortic root size; chr7:66536353 chr7:65840212~65840596:+ CESC cis rs875971 0.545 rs6961853 ENSG00000236529.1 RP13-254B10.1 4.2 3.87e-05 0.0167 0.33 0.27 Aortic root size; chr7:66537035 chr7:65840212~65840596:+ CESC cis rs1707322 0.964 rs7546237 ENSG00000281133.1 AL355480.3 -4.2 3.87e-05 0.0167 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45819938 chr1:45580892~45580996:- CESC cis rs12220238 0.915 rs11001021 ENSG00000213731.2 RAB5CP1 -4.2 3.87e-05 0.0167 -0.44 -0.27 Soluble interleukin-2 receptor subunit alpha; chr10:74379899 chr10:74423435~74424014:- CESC cis rs1862618 0.853 rs1423620 ENSG00000271828.1 CTD-2310F14.1 4.2 3.87e-05 0.0167 0.35 0.27 Initial pursuit acceleration; chr5:56805169 chr5:56927874~56929573:+ CESC cis rs11685222 0.589 rs11678053 ENSG00000229326.3 AC069154.4 -4.2 3.87e-05 0.0167 -0.37 -0.27 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119659211 chr2:119698623~119700151:+ CESC cis rs6740322 0.901 rs2163228 ENSG00000234936.1 AC010883.5 4.2 3.87e-05 0.0167 0.32 0.27 Coronary artery disease; chr2:43322107 chr2:43229573~43233394:+ CESC cis rs17301013 0.507 rs10489256 ENSG00000227373.4 RP11-160H22.5 4.2 3.87e-05 0.0167 0.41 0.27 Systemic lupus erythematosus; chr1:174359663 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs4651016 ENSG00000227373.4 RP11-160H22.5 4.2 3.87e-05 0.0167 0.41 0.27 Systemic lupus erythematosus; chr1:174375146 chr1:174115300~174160004:- CESC cis rs9494145 0.68 rs35959442 ENSG00000232876.1 CTA-212D2.2 -4.2 3.88e-05 0.0168 -0.33 -0.27 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135103041 chr6:135055033~135060550:+ CESC cis rs2404602 0.716 rs1125932 ENSG00000280730.1 AC090181.1 4.2 3.88e-05 0.0168 0.21 0.27 Blood metabolite levels; chr15:76528199 chr15:77056895~77057021:+ CESC cis rs2404602 0.716 rs66754747 ENSG00000280730.1 AC090181.1 4.2 3.88e-05 0.0168 0.21 0.27 Blood metabolite levels; chr15:76536227 chr15:77056895~77057021:+ CESC cis rs783540 0.9 rs55924160 ENSG00000278603.1 RP13-608F4.5 -4.2 3.88e-05 0.0168 -0.33 -0.27 Schizophrenia; chr15:82613445 chr15:82472203~82472426:+ CESC cis rs2243480 1 rs67728539 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65913137 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs78803505 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65917585 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34577383 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65920739 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs55895244 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65922691 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs7795242 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65925107 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs2177703 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65926730 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs35432774 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65928032 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs56985706 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65929575 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs60683927 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65929781 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs58062456 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65929865 chr7:65751142~65763354:+ CESC cis rs2243480 1 rs34529418 ENSG00000228409.4 CCT6P1 4.2 3.88e-05 0.0168 0.4 0.27 Diabetic kidney disease; chr7:65938222 chr7:65751142~65763354:+ CESC cis rs2771051 0.931 rs1985317 ENSG00000230734.1 RPL10P3 4.2 3.88e-05 0.0168 0.28 0.27 Venous thromboembolism (SNP x SNP interaction); chr9:117530056 chr9:117180628~117181095:- CESC cis rs4448343 0.736 rs2236407 ENSG00000271155.1 RP11-435O5.5 -4.2 3.88e-05 0.0168 -0.3 -0.27 Height; chr9:95475514 chr9:95506235~95507636:+ CESC cis rs67383717 0.527 rs10760718 ENSG00000175611.10 LINC00476 4.2 3.89e-05 0.0168 0.29 0.27 Parkinson's disease (pesticide exposure interaction); chr9:96032397 chr9:95759231~95875977:- CESC cis rs6604026 0.59 rs12749480 ENSG00000223787.2 RP4-593M8.1 4.2 3.89e-05 0.0168 0.37 0.27 Multiple sclerosis; chr1:92714968 chr1:92580476~92580821:- CESC cis rs6604026 0.624 rs35526187 ENSG00000223787.2 RP4-593M8.1 4.2 3.89e-05 0.0168 0.37 0.27 Multiple sclerosis; chr1:92732610 chr1:92580476~92580821:- CESC cis rs6604026 0.624 rs11805698 ENSG00000223787.2 RP4-593M8.1 4.2 3.89e-05 0.0168 0.37 0.27 Multiple sclerosis; chr1:92737695 chr1:92580476~92580821:- CESC cis rs72627509 0.638 rs78933653 ENSG00000269949.1 RP11-738E22.3 4.2 3.89e-05 0.0168 0.45 0.27 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56988674 chr4:56960927~56961373:- CESC cis rs11096990 0.855 rs1597722 ENSG00000249207.1 RP11-360F5.1 -4.2 3.9e-05 0.0168 -0.35 -0.27 Cognitive function; chr4:39173255 chr4:39112677~39126818:- CESC cis rs2439831 1 rs561863 ENSG00000275601.1 AC011330.13 -4.2 3.9e-05 0.0168 -0.36 -0.27 Lung cancer in ever smokers; chr15:43469154 chr15:43642389~43643023:- CESC cis rs2439831 1 rs689596 ENSG00000275601.1 AC011330.13 -4.2 3.9e-05 0.0168 -0.36 -0.27 Lung cancer in ever smokers; chr15:43469519 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs689616 ENSG00000275601.1 AC011330.13 -4.2 3.9e-05 0.0168 -0.36 -0.27 Lung cancer in ever smokers; chr15:43469703 chr15:43642389~43643023:- CESC cis rs2439831 1 rs689647 ENSG00000275601.1 AC011330.13 -4.2 3.9e-05 0.0168 -0.36 -0.27 Lung cancer in ever smokers; chr15:43469998 chr15:43642389~43643023:- CESC cis rs2439831 1 rs101094 ENSG00000275601.1 AC011330.13 -4.2 3.9e-05 0.0168 -0.36 -0.27 Lung cancer in ever smokers; chr15:43495124 chr15:43642389~43643023:- CESC cis rs2439831 1 rs689781 ENSG00000275601.1 AC011330.13 -4.2 3.9e-05 0.0168 -0.36 -0.27 Lung cancer in ever smokers; chr15:43499899 chr15:43642389~43643023:- CESC cis rs2439831 1 rs2584725 ENSG00000275601.1 AC011330.13 -4.2 3.9e-05 0.0168 -0.36 -0.27 Lung cancer in ever smokers; chr15:43500937 chr15:43642389~43643023:- CESC cis rs3750965 0.92 rs10896420 ENSG00000260895.1 RP11-554A11.7 4.2 3.9e-05 0.0168 0.33 0.27 Hair color; chr11:69095579 chr11:69103493~69109094:+ CESC cis rs3750965 0.92 rs10896421 ENSG00000260895.1 RP11-554A11.7 4.2 3.9e-05 0.0168 0.33 0.27 Hair color; chr11:69095580 chr11:69103493~69109094:+ CESC cis rs2732480 0.557 rs2732454 ENSG00000258273.1 RP11-370I10.4 -4.2 3.9e-05 0.0168 -0.33 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48325894 chr12:48333755~48333901:- CESC cis rs2732480 0.557 rs923397 ENSG00000258273.1 RP11-370I10.4 -4.2 3.9e-05 0.0168 -0.33 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48326609 chr12:48333755~48333901:- CESC cis rs2732480 0.557 rs2409004 ENSG00000258273.1 RP11-370I10.4 -4.2 3.9e-05 0.0168 -0.33 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48327668 chr12:48333755~48333901:- CESC cis rs2732480 0.577 rs2450994 ENSG00000258273.1 RP11-370I10.4 -4.2 3.9e-05 0.0168 -0.33 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48328049 chr12:48333755~48333901:- CESC cis rs2243480 1 rs34970380 ENSG00000275400.1 RP4-756H11.5 4.2 3.9e-05 0.0168 0.45 0.27 Diabetic kidney disease; chr7:65966506 chr7:66553805~66554199:- CESC cis rs950776 0.518 rs4886571 ENSG00000279373.1 RP11-650L12.4 -4.2 3.9e-05 0.0168 -0.32 -0.27 Sudden cardiac arrest; chr15:78541416 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs4243083 ENSG00000279373.1 RP11-650L12.4 -4.2 3.9e-05 0.0168 -0.32 -0.27 Sudden cardiac arrest; chr15:78541488 chr15:78537681~78538946:+ CESC cis rs71403859 0.502 rs34380814 ENSG00000260886.1 TAT-AS1 4.2 3.9e-05 0.0168 0.37 0.27 Post bronchodilator FEV1; chr16:71454272 chr16:71565789~71578187:+ CESC cis rs71403859 0.502 rs12708914 ENSG00000260886.1 TAT-AS1 4.2 3.9e-05 0.0168 0.38 0.27 Post bronchodilator FEV1; chr16:71436733 chr16:71565789~71578187:+ CESC cis rs2732480 0.577 rs2634684 ENSG00000240399.1 RP1-228P16.1 -4.2 3.9e-05 0.0168 -0.32 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48337092 chr12:48054813~48055591:- CESC cis rs875971 0.502 rs1796227 ENSG00000222364.1 RNU6-96P 4.2 3.9e-05 0.0168 0.37 0.27 Aortic root size; chr7:66622032 chr7:66395191~66395286:+ CESC cis rs10067881 1 rs10067881 ENSG00000251000.1 AC008592.3 4.2 3.91e-05 0.0169 0.56 0.27 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells; chr5:95826771 chr5:95834424~95835046:- CESC cis rs12220238 0.915 rs11000945 ENSG00000213731.2 RAB5CP1 -4.2 3.91e-05 0.0169 -0.44 -0.27 Soluble interleukin-2 receptor subunit alpha; chr10:74270981 chr10:74423435~74424014:- CESC cis rs2522056 1 rs2706339 ENSG00000233006.5 AC034220.3 -4.2 3.91e-05 0.0169 -0.35 -0.27 Fibrinogen;Lymphocyte counts; chr5:132464413 chr5:132311285~132369916:- CESC cis rs1387259 0.839 rs7486941 ENSG00000240399.1 RP1-228P16.1 -4.2 3.91e-05 0.0169 -0.29 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48184848 chr12:48054813~48055591:- CESC cis rs6951245 1 rs80212261 ENSG00000229043.2 AC091729.9 -4.2 3.91e-05 0.0169 -0.42 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1074376 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs77346188 ENSG00000229043.2 AC091729.9 -4.2 3.91e-05 0.0169 -0.42 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1074387 chr7:1160374~1165267:+ CESC cis rs2276314 1 rs2298716 ENSG00000278986.1 RP11-723J4.3 -4.2 3.91e-05 0.0169 -0.31 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35972635 chr18:35972151~35973916:+ CESC cis rs12468226 0.873 rs1474267 ENSG00000273456.1 RP11-686O6.2 -4.2 3.91e-05 0.0169 -0.35 -0.27 Urate levels; chr2:202178596 chr2:202374932~202375604:- CESC cis rs2933343 0.679 rs789254 ENSG00000231305.3 RP11-723O4.2 4.2 3.91e-05 0.0169 0.26 0.27 IgG glycosylation; chr3:128855750 chr3:128861313~128871540:- CESC cis rs2337406 0.866 rs4774019 ENSG00000211974.3 IGHV2-70 -4.2 3.91e-05 0.0169 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106805386 chr14:106723574~106724093:- CESC cis rs2337406 0.866 rs58850145 ENSG00000211974.3 IGHV2-70 -4.2 3.91e-05 0.0169 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106806185 chr14:106723574~106724093:- CESC cis rs17507216 0.628 rs28737193 ENSG00000255769.6 GOLGA2P10 -4.2 3.91e-05 0.0169 -0.4 -0.27 Excessive daytime sleepiness; chr15:82701318 chr15:82472993~82513950:- CESC cis rs748404 0.534 rs489509 ENSG00000205771.5 CATSPER2P1 -4.2 3.91e-05 0.0169 -0.33 -0.27 Lung cancer; chr15:43294709 chr15:43726918~43747094:- CESC cis rs41298997 1 rs41298997 ENSG00000261000.1 RP11-534L20.5 -4.2 3.92e-05 0.0169 -0.38 -0.27 Psoriasis; chr1:206481989 chr1:206503948~206504456:+ CESC cis rs875971 1 rs778706 ENSG00000237310.1 GS1-124K5.4 4.2 3.92e-05 0.0169 0.27 0.27 Aortic root size; chr7:66395437 chr7:66493706~66495474:+ CESC cis rs875971 0.895 rs778700 ENSG00000237310.1 GS1-124K5.4 4.2 3.92e-05 0.0169 0.27 0.27 Aortic root size; chr7:66401463 chr7:66493706~66495474:+ CESC cis rs875971 1 rs778699 ENSG00000237310.1 GS1-124K5.4 4.2 3.92e-05 0.0169 0.27 0.27 Aortic root size; chr7:66403303 chr7:66493706~66495474:+ CESC cis rs875971 0.929 rs778692 ENSG00000237310.1 GS1-124K5.4 4.2 3.92e-05 0.0169 0.27 0.27 Aortic root size; chr7:66407462 chr7:66493706~66495474:+ CESC cis rs875971 1 rs4718343 ENSG00000237310.1 GS1-124K5.4 4.2 3.92e-05 0.0169 0.27 0.27 Aortic root size; chr7:66409301 chr7:66493706~66495474:+ CESC cis rs875971 1 rs1968225 ENSG00000237310.1 GS1-124K5.4 4.2 3.92e-05 0.0169 0.27 0.27 Aortic root size; chr7:66409786 chr7:66493706~66495474:+ CESC cis rs875971 1 rs6460295 ENSG00000237310.1 GS1-124K5.4 4.2 3.92e-05 0.0169 0.27 0.27 Aortic root size; chr7:66417741 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs6978721 ENSG00000237310.1 GS1-124K5.4 4.2 3.92e-05 0.0169 0.27 0.27 Aortic root size; chr7:66418217 chr7:66493706~66495474:+ CESC cis rs9532669 0.963 rs1056824 ENSG00000176268.5 CYCSP34 4.2 3.92e-05 0.0169 0.28 0.27 Cervical cancer; chr13:40932748 chr13:40863599~40863902:- CESC cis rs853679 0.517 rs9468298 ENSG00000219392.1 RP1-265C24.5 -4.2 3.93e-05 0.0169 -0.37 -0.27 Depression; chr6:28154567 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9295759 ENSG00000219392.1 RP1-265C24.5 -4.2 3.93e-05 0.0169 -0.37 -0.27 Depression; chr6:28156691 chr6:28115628~28116551:+ CESC cis rs2455601 0.786 rs2568068 ENSG00000254860.4 TMEM9B-AS1 4.2 3.93e-05 0.0169 0.32 0.27 Schizophrenia; chr11:8956283 chr11:8964675~8977527:+ CESC cis rs11685222 0.64 rs72967120 ENSG00000229326.3 AC069154.4 4.2 3.93e-05 0.0169 0.4 0.27 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119693702 chr2:119698623~119700151:+ CESC cis rs9323326 0.602 rs8023079 ENSG00000257621.6 PSMA3-AS1 4.2 3.93e-05 0.0169 0.26 0.27 Gut microbiota (bacterial taxa); chr14:58039761 chr14:58265365~58298134:- CESC cis rs34375054 0.624 rs12826658 ENSG00000279233.1 RP11-158L12.4 4.2 3.93e-05 0.0169 0.3 0.27 Post bronchodilator FEV1/FVC ratio; chr12:125195691 chr12:125138245~125141711:+ CESC cis rs2120243 0.533 rs1500921 ENSG00000241544.1 RP11-6F2.5 4.2 3.93e-05 0.0169 0.28 0.27 Hepatocellular carcinoma in hepatitis B infection; chr3:157337638 chr3:157081841~157088547:+ CESC cis rs2120243 0.533 rs62278578 ENSG00000241544.1 RP11-6F2.5 4.2 3.93e-05 0.0169 0.28 0.27 Hepatocellular carcinoma in hepatitis B infection; chr3:157338078 chr3:157081841~157088547:+ CESC cis rs7619708 1 rs7619708 ENSG00000252174.1 RNU7-18P 4.2 3.93e-05 0.0169 0.4 0.27 Red cell distribution width; chr3:196083316 chr3:196072819~196072880:+ CESC cis rs9532669 0.926 rs4270044 ENSG00000176268.5 CYCSP34 4.2 3.93e-05 0.0169 0.28 0.27 Cervical cancer; chr13:40877923 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs11147824 ENSG00000176268.5 CYCSP34 4.2 3.93e-05 0.0169 0.28 0.27 Cervical cancer; chr13:40878183 chr13:40863599~40863902:- CESC cis rs9309473 1 rs11901272 ENSG00000163016.8 ALMS1P 4.2 3.94e-05 0.0169 0.34 0.27 Metabolite levels; chr2:73493317 chr2:73644919~73685576:+ CESC cis rs7250849 0.565 rs7255319 ENSG00000273837.1 LLNLR-470E3.1 4.2 3.94e-05 0.017 0.35 0.27 Blood protein levels; chr19:51664653 chr19:51639478~51639931:- CESC cis rs62355900 0.627 rs59715006 ENSG00000271828.1 CTD-2310F14.1 4.2 3.94e-05 0.017 0.43 0.27 Endometriosis; chr5:56899820 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs61663138 ENSG00000271828.1 CTD-2310F14.1 4.2 3.94e-05 0.017 0.43 0.27 Endometriosis; chr5:56899946 chr5:56927874~56929573:+ CESC cis rs2276314 1 rs62101367 ENSG00000278986.1 RP11-723J4.3 -4.2 3.94e-05 0.017 -0.31 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35970921 chr18:35972151~35973916:+ CESC cis rs3845817 0.675 rs702940 ENSG00000281920.1 RP11-418H16.1 -4.2 3.94e-05 0.017 -0.34 -0.27 Bipolar disorder; chr2:65521007 chr2:65623272~65628424:+ CESC cis rs8031584 0.958 rs11293 ENSG00000260382.1 RP11-540B6.2 4.2 3.94e-05 0.017 0.38 0.27 Huntington's disease progression; chr15:30942778 chr15:30882267~30883231:- CESC cis rs17742757 0.521 rs2736324 ENSG00000255046.1 RP11-297N6.4 -4.2 3.94e-05 0.017 -0.31 -0.27 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:11470673 chr8:11797928~11802568:- CESC cis rs12468226 1 rs11899836 ENSG00000273456.1 RP11-686O6.2 4.2 3.94e-05 0.017 0.34 0.27 Urate levels; chr2:202371316 chr2:202374932~202375604:- CESC cis rs9640161 0.742 rs2159236 ENSG00000261305.1 RP4-584D14.7 4.2 3.94e-05 0.017 0.38 0.27 Blood protein levels;Circulating chemerin levels; chr7:150320125 chr7:150341771~150342607:+ CESC cis rs17695224 0.5 rs4802876 ENSG00000268095.1 ZNF649-AS1 4.2 3.95e-05 0.017 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51831964 chr19:51888025~51900463:+ CESC cis rs875971 0.964 rs1643388 ENSG00000237310.1 GS1-124K5.4 4.2 3.95e-05 0.017 0.27 0.27 Aortic root size; chr7:66379575 chr7:66493706~66495474:+ CESC cis rs875971 1 rs778722 ENSG00000237310.1 GS1-124K5.4 4.2 3.95e-05 0.017 0.27 0.27 Aortic root size; chr7:66379841 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs778721 ENSG00000237310.1 GS1-124K5.4 4.2 3.95e-05 0.017 0.27 0.27 Aortic root size; chr7:66380410 chr7:66493706~66495474:+ CESC cis rs748404 0.723 rs512431 ENSG00000249839.1 AC011330.5 4.2 3.95e-05 0.017 0.28 0.27 Lung cancer; chr15:43249741 chr15:43663654~43684339:- CESC cis rs61160187 0.556 rs10939881 ENSG00000215032.2 GNL3LP1 4.2 3.95e-05 0.017 0.33 0.27 Educational attainment (years of education);Educational attainment (college completion); chr5:61087146 chr5:60891935~60893577:- CESC cis rs2439831 0.702 rs8033995 ENSG00000249839.1 AC011330.5 -4.2 3.96e-05 0.017 -0.39 -0.27 Lung cancer in ever smokers; chr15:43721311 chr15:43663654~43684339:- CESC cis rs2243480 0.901 rs313808 ENSG00000232559.3 GS1-124K5.12 4.2 3.96e-05 0.017 0.45 0.27 Diabetic kidney disease; chr7:66034886 chr7:66554588~66576923:- CESC cis rs875971 0.545 rs75840613 ENSG00000236529.1 RP13-254B10.1 4.2 3.96e-05 0.017 0.34 0.27 Aortic root size; chr7:66376399 chr7:65840212~65840596:+ CESC cis rs4742903 0.935 rs3818626 ENSG00000270332.1 SMC2-AS1 4.2 3.96e-05 0.017 0.27 0.27 Breast cancer;High-grade serous ovarian cancer; chr9:104094352 chr9:104080024~104093073:- CESC cis rs919433 0.617 rs34632716 ENSG00000222017.1 AC011997.1 -4.2 3.96e-05 0.017 -0.34 -0.27 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197677895 chr2:197693106~197774823:+ CESC cis rs75422866 0.702 rs12426387 ENSG00000280054.1 RP1-197B17.7 4.2 3.97e-05 0.0171 0.78 0.27 Pneumonia; chr12:47582915 chr12:47728151~47730598:- CESC cis rs75422866 0.85 rs12423789 ENSG00000280054.1 RP1-197B17.7 4.2 3.97e-05 0.0171 0.78 0.27 Pneumonia; chr12:47583112 chr12:47728151~47730598:- CESC cis rs75422866 0.702 rs73111229 ENSG00000280054.1 RP1-197B17.7 4.2 3.97e-05 0.0171 0.78 0.27 Pneumonia; chr12:47583333 chr12:47728151~47730598:- CESC cis rs13113518 1 rs10462032 ENSG00000273257.1 RP11-177J6.1 4.2 3.97e-05 0.0171 0.36 0.27 Height; chr4:55479069 chr4:55387949~55388271:+ CESC cis rs75422866 0.85 rs73111226 ENSG00000280054.1 RP1-197B17.7 4.2 3.97e-05 0.0171 0.78 0.27 Pneumonia; chr12:47582204 chr12:47728151~47730598:- CESC cis rs1023500 0.596 rs133369 ENSG00000273366.1 CTA-989H11.1 -4.2 3.97e-05 0.0171 -0.37 -0.27 Schizophrenia; chr22:42067810 chr22:42278188~42278846:+ CESC cis rs748404 0.666 rs72709871 ENSG00000249839.1 AC011330.5 -4.19 3.97e-05 0.0171 -0.4 -0.27 Lung cancer; chr15:43499025 chr15:43663654~43684339:- CESC cis rs950776 0.518 rs1979907 ENSG00000279373.1 RP11-650L12.4 -4.19 3.97e-05 0.0171 -0.32 -0.27 Sudden cardiac arrest; chr15:78549897 chr15:78537681~78538946:+ CESC cis rs8030379 1 rs8024418 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83917556 chr15:84507885~84516814:- CESC cis rs8030379 1 rs8042970 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83917616 chr15:84507885~84516814:- CESC cis rs8030379 1 rs11259937 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83919081 chr15:84507885~84516814:- CESC cis rs8030379 1 rs11637866 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83919206 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2135880 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83920861 chr15:84507885~84516814:- CESC cis rs8030379 1 rs1526080 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83921168 chr15:84507885~84516814:- CESC cis rs8030379 1 rs1852264 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83921188 chr15:84507885~84516814:- CESC cis rs8030379 1 rs1526081 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83921314 chr15:84507885~84516814:- CESC cis rs8030379 1 rs8030379 ENSG00000230373.7 GOLGA6L5P -4.19 3.97e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83922158 chr15:84507885~84516814:- CESC cis rs8030379 1 rs4842924 ENSG00000230373.7 GOLGA6L5P 4.19 3.97e-05 0.0171 0.26 0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83918855 chr15:84507885~84516814:- CESC cis rs5758659 0.729 rs134866 ENSG00000273366.1 CTA-989H11.1 -4.19 3.98e-05 0.0171 -0.34 -0.27 Cognitive function; chr22:42254657 chr22:42278188~42278846:+ CESC cis rs151227923 1 rs151227923 ENSG00000273117.1 AC144652.1 4.19 3.98e-05 0.0171 0.27 0.27 Stem cell growth factor beta levels; chr7:155314854 chr7:155295918~155297541:- CESC cis rs140365914 1 rs140365914 ENSG00000273117.1 AC144652.1 4.19 3.98e-05 0.0171 0.27 0.27 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr7:155314860 chr7:155295918~155297541:- CESC cis rs1044826 0.692 rs169824 ENSG00000178631.7 ACTG1P1 -4.19 3.98e-05 0.0171 -0.34 -0.27 Obesity-related traits; chr3:139516164 chr3:139493809~139494937:+ CESC cis rs694739 0.628 rs645078 ENSG00000236935.1 AP003774.1 4.19 3.98e-05 0.0171 0.28 0.27 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64367826 chr11:64325050~64329504:- CESC cis rs12690897 0.531 rs4398827 ENSG00000229251.3 HNRNPA1P8 -4.19 3.98e-05 0.0171 -0.28 -0.27 Macrophage inflammatory protein 1a levels; chr7:85602324 chr7:84983556~84984506:+ CESC cis rs7896729 0.66 rs35162699 ENSG00000215267.7 AKR1C7P -4.19 3.98e-05 0.0171 -0.38 -0.27 Intelligence; chr10:5291718 chr10:5275173~5288470:- CESC cis rs6964587 0.967 rs6465353 ENSG00000188693.7 CYP51A1-AS1 4.19 3.98e-05 0.0171 0.29 0.27 Breast cancer; chr7:92150657 chr7:92134604~92180725:+ CESC cis rs8030379 1 rs7496814 ENSG00000230373.7 GOLGA6L5P -4.19 3.98e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83916207 chr15:84507885~84516814:- CESC cis rs8030379 1 rs1480823 ENSG00000230373.7 GOLGA6L5P -4.19 3.98e-05 0.0171 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83916994 chr15:84507885~84516814:- CESC cis rs67311347 0.955 rs6773383 ENSG00000223797.4 ENTPD3-AS1 4.19 3.98e-05 0.0171 0.27 0.27 Renal cell carcinoma; chr3:40335921 chr3:40313802~40453329:- CESC cis rs9322193 0.923 rs12174716 ENSG00000216906.2 RP11-350J20.9 4.19 3.99e-05 0.0171 0.3 0.27 Lung cancer; chr6:149644487 chr6:149904243~149906418:+ CESC cis rs17695224 0.545 rs7253924 ENSG00000268095.1 ZNF649-AS1 4.19 3.99e-05 0.0171 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51824960 chr19:51888025~51900463:+ CESC cis rs17695224 0.545 rs8109098 ENSG00000268095.1 ZNF649-AS1 4.19 3.99e-05 0.0171 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51825363 chr19:51888025~51900463:+ CESC cis rs1075265 0.84 rs2884254 ENSG00000233266.1 HMGB1P31 4.19 3.99e-05 0.0171 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:53979326 chr2:54051334~54051760:+ CESC cis rs6439153 0.933 rs2630262 ENSG00000231305.3 RP11-723O4.2 -4.19 3.99e-05 0.0171 -0.25 -0.27 Pneumococcal bacteremia; chr3:128958255 chr3:128861313~128871540:- CESC cis rs950169 0.545 rs4354897 ENSG00000225151.9 GOLGA2P7 -4.19 3.99e-05 0.0171 -0.42 -0.27 Schizophrenia; chr15:83976219 chr15:84199311~84230136:- CESC cis rs2412819 0.571 rs4923964 ENSG00000249839.1 AC011330.5 4.19 3.99e-05 0.0171 0.35 0.27 Lung cancer; chr15:43722882 chr15:43663654~43684339:- CESC cis rs34375054 0.624 rs12832525 ENSG00000279233.1 RP11-158L12.4 4.19 3.99e-05 0.0171 0.3 0.27 Post bronchodilator FEV1/FVC ratio; chr12:125195820 chr12:125138245~125141711:+ CESC cis rs9584850 0.52 rs10508036 ENSG00000231194.1 FARP1-AS1 -4.19 3.99e-05 0.0171 -0.36 -0.27 Neuroticism; chr13:98505144 chr13:98435405~98435840:- CESC cis rs6964587 1 rs10245095 ENSG00000188693.7 CYP51A1-AS1 -4.19 3.99e-05 0.0171 -0.29 -0.27 Breast cancer; chr7:92081531 chr7:92134604~92180725:+ CESC cis rs11051970 0.918 rs73084101 ENSG00000255760.1 RP11-428G5.5 4.19 4e-05 0.0171 0.33 0.27 Response to tocilizumab in rheumatoid arthritis; chr12:32391405 chr12:31877079~31887203:- CESC cis rs62025270 0.688 rs62022940 ENSG00000202081.1 RNU6-1280P -4.19 4e-05 0.0171 -0.37 -0.27 Idiopathic pulmonary fibrosis; chr15:85709289 chr15:85651522~85651628:- CESC cis rs10129255 0.957 rs10141052 ENSG00000280411.1 IGHV1-69-2 -4.19 4e-05 0.0171 -0.2 -0.27 Kawasaki disease; chr14:106776528 chr14:106762092~106762588:- CESC cis rs10129255 0.957 rs10141009 ENSG00000280411.1 IGHV1-69-2 -4.19 4e-05 0.0171 -0.2 -0.27 Kawasaki disease; chr14:106776695 chr14:106762092~106762588:- CESC cis rs10129255 0.912 rs6576227 ENSG00000280411.1 IGHV1-69-2 -4.19 4e-05 0.0171 -0.2 -0.27 Kawasaki disease; chr14:106778202 chr14:106762092~106762588:- CESC cis rs916888 0.773 rs199443 ENSG00000261575.2 RP11-259G18.1 4.19 4e-05 0.0172 0.4 0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46267037~46268694:+ CESC cis rs2412819 0.571 rs528764 ENSG00000205771.5 CATSPER2P1 4.19 4e-05 0.0172 0.4 0.27 Lung cancer; chr15:43838650 chr15:43726918~43747094:- CESC cis rs889312 0.532 rs16886165 ENSG00000271828.1 CTD-2310F14.1 4.19 4e-05 0.0172 0.36 0.27 Breast cancer (early onset);Breast cancer; chr5:56727256 chr5:56927874~56929573:+ CESC cis rs7927592 0.913 rs10896330 ENSG00000212093.1 AP000807.1 4.19 4e-05 0.0172 0.31 0.27 Total body bone mineral density; chr11:68487530 chr11:68506083~68506166:- CESC cis rs853679 0.567 rs3799499 ENSG00000204709.4 LINC01556 4.19 4e-05 0.0172 0.32 0.27 Depression; chr6:28386473 chr6:28943877~28944537:+ CESC cis rs7299940 0.694 rs12296337 ENSG00000256250.1 RP11-989F5.1 4.19 4.01e-05 0.0172 0.3 0.27 Panic disorder; chr12:130891406 chr12:130810606~130812438:+ CESC cis rs2836950 0.545 rs1888489 ENSG00000232608.1 TIMM9P2 4.19 4.01e-05 0.0172 0.3 0.27 Menarche (age at onset); chr21:39161238 chr21:39216624~39217506:+ CESC cis rs4356203 0.519 rs214097 ENSG00000272034.1 SNORD14A -4.19 4.01e-05 0.0172 -0.28 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17269952 chr11:17074654~17074744:- CESC cis rs3806843 0.576 rs155363 ENSG00000202111.1 VTRNA1-2 -4.19 4.02e-05 0.0172 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140921958 chr5:140718925~140719013:+ CESC cis rs875971 0.522 rs6960048 ENSG00000222364.1 RNU6-96P -4.19 4.02e-05 0.0172 -0.33 -0.27 Aortic root size; chr7:65943052 chr7:66395191~66395286:+ CESC cis rs2771051 0.867 rs7850478 ENSG00000230734.1 RPL10P3 4.19 4.03e-05 0.0173 0.28 0.27 Venous thromboembolism (SNP x SNP interaction); chr9:117524560 chr9:117180628~117181095:- CESC cis rs6879260 1 rs6874653 ENSG00000248367.1 CTB-129O4.1 -4.19 4.03e-05 0.0173 -0.21 -0.27 Height; chr5:180303843 chr5:180293245~180295253:+ CESC cis rs9532669 0.963 rs9562238 ENSG00000239827.7 SUGT1P3 -4.19 4.03e-05 0.0173 -0.3 -0.27 Cervical cancer; chr13:40924785 chr13:40908159~40921774:- CESC cis rs2836950 0.52 rs11911087 ENSG00000232608.1 TIMM9P2 4.19 4.03e-05 0.0173 0.31 0.27 Menarche (age at onset); chr21:39293266 chr21:39216624~39217506:+ CESC cis rs71403859 0.502 rs12919417 ENSG00000260886.1 TAT-AS1 -4.19 4.03e-05 0.0173 -0.41 -0.27 Post bronchodilator FEV1; chr16:71545808 chr16:71565789~71578187:+ CESC cis rs1972460 0.506 rs62012050 ENSG00000278603.1 RP13-608F4.5 4.19 4.04e-05 0.0173 0.38 0.27 Intelligence (multi-trait analysis); chr15:82239933 chr15:82472203~82472426:+ CESC cis rs12908161 0.959 rs62019472 ENSG00000225151.9 GOLGA2P7 -4.19 4.04e-05 0.0173 -0.37 -0.27 Schizophrenia; chr15:84788262 chr15:84199311~84230136:- CESC cis rs9309473 0.519 rs2421574 ENSG00000273245.1 RP11-434P11.2 -4.19 4.04e-05 0.0173 -0.34 -0.27 Metabolite levels; chr2:73681640 chr2:73750256~73750786:- CESC cis rs2439831 1 rs2444032 ENSG00000275601.1 AC011330.13 -4.19 4.04e-05 0.0173 -0.36 -0.27 Lung cancer in ever smokers; chr15:43463148 chr15:43642389~43643023:- CESC cis rs11089937 0.667 rs10483108 ENSG00000211638.2 IGLV8-61 -4.19 4.04e-05 0.0173 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22152664 chr22:22098700~22099212:+ CESC cis rs10129255 0.957 rs6576228 ENSG00000280411.1 IGHV1-69-2 -4.19 4.04e-05 0.0173 -0.2 -0.27 Kawasaki disease; chr14:106778401 chr14:106762092~106762588:- CESC cis rs2439831 0.85 rs2228368 ENSG00000275601.1 AC011330.13 -4.19 4.04e-05 0.0173 -0.43 -0.27 Lung cancer in ever smokers; chr15:43809812 chr15:43642389~43643023:- CESC cis rs158856 0.674 rs158867 ENSG00000275418.1 RP11-126O1.6 4.19 4.05e-05 0.0173 0.3 0.27 Insomnia (caffeine-induced); chr18:58235094 chr18:58659858~58660524:+ CESC cis rs7580658 0.545 rs13006847 ENSG00000236682.1 AC068282.3 4.19 4.05e-05 0.0173 0.32 0.27 Protein C levels; chr2:127194687 chr2:127389130~127400580:+ CESC cis rs67311347 1 rs4974017 ENSG00000223797.4 ENTPD3-AS1 4.19 4.05e-05 0.0173 0.26 0.27 Renal cell carcinoma; chr3:40432028 chr3:40313802~40453329:- CESC cis rs12908161 0.96 rs17599989 ENSG00000259728.4 LINC00933 4.19 4.05e-05 0.0173 0.35 0.27 Schizophrenia; chr15:84742305 chr15:84570649~84580175:+ CESC cis rs8020095 0.571 rs1918483 ENSG00000258561.1 RP11-72M17.1 -4.19 4.05e-05 0.0173 -0.41 -0.27 Depression (quantitative trait); chr14:67140906 chr14:66212810~66509394:- CESC cis rs7048146 0.668 rs7341726 ENSG00000213539.4 YBX1P6 4.19 4.05e-05 0.0173 0.31 0.27 Vascular brain injury; chr9:109513495 chr9:109532830~109534332:- CESC cis rs11159086 0.793 rs1029701 ENSG00000259005.1 RP3-449M8.6 4.19 4.05e-05 0.0173 0.37 0.27 Advanced glycation end-product levels; chr14:74474112 chr14:74474007~74474864:- CESC cis rs989507 0.784 rs7079404 ENSG00000214807.2 NPM1P31 -4.19 4.06e-05 0.0174 -0.53 -0.27 Obesity-related traits; chr10:125456235 chr10:124867510~124868326:+ CESC cis rs7572733 0.515 rs1518368 ENSG00000222017.1 AC011997.1 4.19 4.06e-05 0.0174 0.35 0.27 Dermatomyositis; chr2:197974421 chr2:197693106~197774823:+ CESC cis rs755249 0.833 rs61779313 ENSG00000228060.1 RP11-69E11.8 -4.19 4.07e-05 0.0174 -0.32 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39478577 chr1:39565160~39573203:+ CESC cis rs889398 0.967 rs2032912 ENSG00000226232.7 RP11-419C5.2 4.19 4.07e-05 0.0174 0.25 0.27 Body mass index; chr16:69534400 chr16:69976388~69996188:- CESC cis rs7614311 0.681 rs12631045 ENSG00000271843.1 RP11-245J9.5 -4.19 4.07e-05 0.0174 -0.38 -0.27 Lung function (FVC);Lung function (FEV1); chr3:63870409 chr3:64008082~64008692:- CESC cis rs8031584 0.958 rs34294266 ENSG00000260382.1 RP11-540B6.2 4.19 4.08e-05 0.0174 0.38 0.27 Huntington's disease progression; chr15:30954637 chr15:30882267~30883231:- CESC cis rs6782228 1 rs6782407 ENSG00000242551.2 POU5F1P6 4.19 4.08e-05 0.0174 0.33 0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619905 chr3:128674735~128677005:- CESC cis rs9813712 0.595 rs1453238 ENSG00000228252.7 COL6A4P2 4.19 4.08e-05 0.0174 0.34 0.27 Response to amphetamines; chr3:130290494 chr3:130212823~130273806:+ CESC cis rs8030379 1 rs2401173 ENSG00000230373.7 GOLGA6L5P -4.19 4.08e-05 0.0175 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83908218 chr15:84507885~84516814:- CESC cis rs11971779 0.68 rs7805767 ENSG00000273391.1 RP11-634H22.1 4.19 4.09e-05 0.0175 0.26 0.27 Diisocyanate-induced asthma; chr7:139426669 chr7:139359032~139359566:- CESC cis rs11971779 0.648 rs6467852 ENSG00000273391.1 RP11-634H22.1 4.19 4.09e-05 0.0175 0.26 0.27 Diisocyanate-induced asthma; chr7:139427845 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs7779314 ENSG00000273391.1 RP11-634H22.1 4.19 4.09e-05 0.0175 0.26 0.27 Diisocyanate-induced asthma; chr7:139427950 chr7:139359032~139359566:- CESC cis rs11971779 0.715 rs7779390 ENSG00000273391.1 RP11-634H22.1 4.19 4.09e-05 0.0175 0.26 0.27 Diisocyanate-induced asthma; chr7:139428207 chr7:139359032~139359566:- CESC cis rs11971779 0.553 rs36002669 ENSG00000273391.1 RP11-634H22.1 4.19 4.09e-05 0.0175 0.26 0.27 Diisocyanate-induced asthma; chr7:139428415 chr7:139359032~139359566:- CESC cis rs11971779 0.584 rs34762928 ENSG00000273391.1 RP11-634H22.1 4.19 4.09e-05 0.0175 0.26 0.27 Diisocyanate-induced asthma; chr7:139428422 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs11760420 ENSG00000273391.1 RP11-634H22.1 4.19 4.09e-05 0.0175 0.26 0.27 Diisocyanate-induced asthma; chr7:139430022 chr7:139359032~139359566:- CESC cis rs11971779 0.553 rs10228643 ENSG00000273391.1 RP11-634H22.1 4.19 4.09e-05 0.0175 0.26 0.27 Diisocyanate-induced asthma; chr7:139430674 chr7:139359032~139359566:- CESC cis rs4742903 0.967 rs4742904 ENSG00000270332.1 SMC2-AS1 4.19 4.09e-05 0.0175 0.27 0.27 Breast cancer;High-grade serous ovarian cancer; chr9:104094671 chr9:104080024~104093073:- CESC cis rs6439153 0.901 rs2630263 ENSG00000231305.3 RP11-723O4.2 4.19 4.09e-05 0.0175 0.26 0.27 Pneumococcal bacteremia; chr3:128969475 chr3:128861313~128871540:- CESC cis rs11779988 0.545 rs404186 ENSG00000253671.1 RP11-806O11.1 -4.19 4.09e-05 0.0175 -0.33 -0.27 Breast cancer; chr8:17937987 chr8:17808941~17820868:+ CESC cis rs9903692 0.909 rs1468270 ENSG00000263412.1 RP5-890E16.2 -4.19 4.09e-05 0.0175 -0.27 -0.27 Pulse pressure; chr17:48047829 chr17:48045141~48048073:- CESC cis rs9903692 0.779 rs2285863 ENSG00000263412.1 RP5-890E16.2 -4.19 4.09e-05 0.0175 -0.27 -0.27 Pulse pressure; chr17:48048616 chr17:48045141~48048073:- CESC cis rs7189233 0.592 rs2024449 ENSG00000279344.1 RP11-44F14.7 4.19 4.09e-05 0.0175 0.26 0.27 Intelligence (multi-trait analysis); chr16:53460705 chr16:53478957~53481550:- CESC cis rs4319547 0.698 rs4039670 ENSG00000275265.1 RP11-15J22.8 -4.19 4.09e-05 0.0175 -0.38 -0.27 Body mass index; chr12:122338108 chr12:122501187~122501641:+ CESC cis rs10788972 0.634 rs66746724 ENSG00000225183.1 RP4-758J24.4 -4.19 4.1e-05 0.0175 -0.32 -0.27 Parkinson disease and lewy body pathology; chr1:54094999 chr1:54089856~54090093:+ CESC cis rs1012068 0.662 rs11703779 ENSG00000236132.1 CTA-440B3.1 -4.19 4.1e-05 0.0175 -0.31 -0.27 Chronic hepatitis C infection; chr22:31926398 chr22:31816379~31817491:- CESC cis rs6893782 0.887 rs274551 ENSG00000233006.5 AC034220.3 -4.19 4.1e-05 0.0175 -0.36 -0.27 Acylcarnitine levels; chr5:132391988 chr5:132311285~132369916:- CESC cis rs950776 0.518 rs12914694 ENSG00000279373.1 RP11-650L12.4 4.19 4.1e-05 0.0175 0.33 0.27 Sudden cardiac arrest; chr15:78522102 chr15:78537681~78538946:+ CESC cis rs1012068 0.686 rs5994451 ENSG00000236132.1 CTA-440B3.1 -4.19 4.1e-05 0.0175 -0.31 -0.27 Chronic hepatitis C infection; chr22:31927525 chr22:31816379~31817491:- CESC cis rs875971 0.898 rs6977501 ENSG00000232559.3 GS1-124K5.12 -4.19 4.1e-05 0.0175 -0.29 -0.27 Aortic root size; chr7:66228355 chr7:66554588~66576923:- CESC cis rs1020064 0.945 rs1030878 ENSG00000235319.1 AC012360.4 -4.19 4.11e-05 0.0175 -0.34 -0.27 AIDS; chr2:105294141 chr2:105324210~105330529:+ CESC cis rs2337406 0.866 rs4774019 ENSG00000274576.2 IGHV2-70 -4.19 4.11e-05 0.0175 -0.36 -0.27 Alzheimer's disease (late onset); chr14:106805386 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs58850145 ENSG00000274576.2 IGHV2-70 -4.19 4.11e-05 0.0175 -0.36 -0.27 Alzheimer's disease (late onset); chr14:106806185 chr14:106770577~106771020:- CESC cis rs10043775 1 rs9325095 ENSG00000251330.3 CTD-2283N19.1 -4.19 4.12e-05 0.0176 -0.35 -0.27 Periodontal microbiota; chr5:148405595 chr5:148430159~148430807:- CESC cis rs7397814 0.558 rs4764447 ENSG00000214776.8 RP11-726G1.1 -4.19 4.12e-05 0.0176 -0.31 -0.27 IgG glycosylation; chr12:9426513 chr12:9467552~9576275:+ CESC cis rs748404 0.666 rs7177146 ENSG00000249839.1 AC011330.5 -4.19 4.12e-05 0.0176 -0.4 -0.27 Lung cancer; chr15:43506110 chr15:43663654~43684339:- CESC cis rs7811142 0.83 rs118119933 ENSG00000242294.5 STAG3L5P 4.19 4.12e-05 0.0176 0.31 0.27 Platelet count; chr7:100341427 chr7:100336079~100351900:+ CESC cis rs13113518 0.738 rs6849883 ENSG00000249700.7 SRD5A3-AS1 4.19 4.12e-05 0.0176 0.35 0.27 Height; chr4:55387515 chr4:55363971~55395847:- CESC cis rs875971 0.545 rs73148639 ENSG00000236529.1 RP13-254B10.1 4.19 4.13e-05 0.0176 0.33 0.27 Aortic root size; chr7:66390342 chr7:65840212~65840596:+ CESC cis rs875971 1 rs1144895 ENSG00000232559.3 GS1-124K5.12 -4.19 4.13e-05 0.0176 -0.31 -0.27 Aortic root size; chr7:66076320 chr7:66554588~66576923:- CESC cis rs733592 0.507 rs10875739 ENSG00000257735.1 RP11-370I10.6 4.19 4.13e-05 0.0176 0.31 0.27 Plateletcrit; chr12:48087136 chr12:48350945~48442411:+ CESC cis rs4819052 0.565 rs35776291 ENSG00000223768.1 LINC00205 -4.19 4.13e-05 0.0176 -0.3 -0.27 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45286227 chr21:45293285~45297354:+ CESC cis rs916888 0.773 rs199445 ENSG00000261575.2 RP11-259G18.1 4.19 4.13e-05 0.0176 0.4 0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46267037~46268694:+ CESC cis rs2439831 0.85 rs3736180 ENSG00000275601.1 AC011330.13 -4.19 4.13e-05 0.0176 -0.43 -0.27 Lung cancer in ever smokers; chr15:43814426 chr15:43642389~43643023:- CESC cis rs916888 0.821 rs199505 ENSG00000232300.1 FAM215B -4.19 4.13e-05 0.0176 -0.43 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46558830~46562795:- CESC cis rs916888 0.821 rs70602 ENSG00000232300.1 FAM215B -4.19 4.13e-05 0.0176 -0.43 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46558830~46562795:- CESC cis rs9322193 0.847 rs12210605 ENSG00000216906.2 RP11-350J20.9 4.18 4.14e-05 0.0176 0.31 0.27 Lung cancer; chr6:149817267 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9371199 ENSG00000216906.2 RP11-350J20.9 4.18 4.14e-05 0.0176 0.31 0.27 Lung cancer; chr6:149817526 chr6:149904243~149906418:+ CESC cis rs875971 0.545 rs35459055 ENSG00000236529.1 RP13-254B10.1 4.18 4.14e-05 0.0176 0.33 0.27 Aortic root size; chr7:66479399 chr7:65840212~65840596:+ CESC cis rs748404 0.631 rs6493084 ENSG00000205771.5 CATSPER2P1 -4.18 4.14e-05 0.0176 -0.33 -0.27 Lung cancer; chr15:43355429 chr15:43726918~43747094:- CESC cis rs748404 0.631 rs12905772 ENSG00000205771.5 CATSPER2P1 -4.18 4.14e-05 0.0176 -0.33 -0.27 Lung cancer; chr15:43356246 chr15:43726918~43747094:- CESC cis rs6951245 0.882 rs56048221 ENSG00000229043.2 AC091729.9 -4.18 4.15e-05 0.0177 -0.39 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1052897 chr7:1160374~1165267:+ CESC cis rs875971 0.505 rs2462573 ENSG00000222364.1 RNU6-96P 4.18 4.15e-05 0.0177 0.32 0.27 Aortic root size; chr7:66042405 chr7:66395191~66395286:+ CESC cis rs875971 0.505 rs1167385 ENSG00000222364.1 RNU6-96P 4.18 4.15e-05 0.0177 0.32 0.27 Aortic root size; chr7:66048321 chr7:66395191~66395286:+ CESC cis rs6822297 0.504 rs9291487 ENSG00000240005.4 RP11-293A21.1 4.18 4.15e-05 0.0177 0.31 0.27 Obesity-related traits; chr4:26965862 chr4:26859806~26860599:- CESC cis rs2236295 0.503 rs10822064 ENSG00000238280.1 RP11-436D10.3 4.18 4.15e-05 0.0177 0.34 0.27 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks); chr10:62849964 chr10:62793562~62805887:- CESC cis rs7588654 0.793 rs16859517 ENSG00000231802.1 AC009502.1 4.18 4.15e-05 0.0177 0.6 0.27 Height; chr2:219084462 chr2:219684030~219684795:- CESC cis rs7005380 0.581 rs7005888 ENSG00000279347.1 RP11-85I17.2 -4.18 4.15e-05 0.0177 -0.3 -0.27 Interstitial lung disease; chr8:119919371 chr8:119838736~119840385:- CESC cis rs13113518 0.812 rs12648271 ENSG00000273257.1 RP11-177J6.1 4.18 4.15e-05 0.0177 0.37 0.27 Height; chr4:55501955 chr4:55387949~55388271:+ CESC cis rs7131987 0.65 rs16934135 ENSG00000257176.2 RP11-996F15.2 -4.18 4.15e-05 0.0177 -0.32 -0.27 QT interval; chr12:29331030 chr12:29280418~29317848:- CESC cis rs9322193 0.847 rs56103941 ENSG00000216906.2 RP11-350J20.9 4.18 4.16e-05 0.0177 0.31 0.27 Lung cancer; chr6:149816095 chr6:149904243~149906418:+ CESC cis rs875971 1 rs6979382 ENSG00000237310.1 GS1-124K5.4 4.18 4.16e-05 0.0177 0.26 0.27 Aortic root size; chr7:66421388 chr7:66493706~66495474:+ CESC cis rs875971 1 rs6961990 ENSG00000237310.1 GS1-124K5.4 4.18 4.16e-05 0.0177 0.26 0.27 Aortic root size; chr7:66423583 chr7:66493706~66495474:+ CESC cis rs11971779 0.616 rs6967932 ENSG00000273391.1 RP11-634H22.1 4.18 4.16e-05 0.0177 0.26 0.27 Diisocyanate-induced asthma; chr7:139337635 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs6467836 ENSG00000273391.1 RP11-634H22.1 4.18 4.16e-05 0.0177 0.26 0.27 Diisocyanate-induced asthma; chr7:139338771 chr7:139359032~139359566:- CESC cis rs8072100 0.846 rs6503796 ENSG00000228782.6 CTD-2026D20.3 4.18 4.16e-05 0.0177 0.33 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47687883 chr17:47450568~47492492:- CESC cis rs6928977 0.832 rs2614286 ENSG00000234084.1 RP3-388E23.2 -4.18 4.16e-05 0.0177 -0.25 -0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135371533 chr6:135301568~135307158:+ CESC cis rs2933343 0.951 rs7648327 ENSG00000231305.3 RP11-723O4.2 4.18 4.16e-05 0.0177 0.28 0.27 IgG glycosylation; chr3:128851865 chr3:128861313~128871540:- CESC cis rs17772222 0.917 rs12588535 ENSG00000258983.2 RP11-507K2.2 4.18 4.16e-05 0.0177 0.34 0.27 Coronary artery calcification; chr14:88781900 chr14:88499334~88515502:+ CESC cis rs9532669 0.926 rs9532654 ENSG00000176268.5 CYCSP34 4.18 4.17e-05 0.0177 0.27 0.27 Cervical cancer; chr13:40909812 chr13:40863599~40863902:- CESC cis rs6740322 0.748 rs6544636 ENSG00000234936.1 AC010883.5 4.18 4.17e-05 0.0177 0.29 0.27 Coronary artery disease; chr2:43260347 chr2:43229573~43233394:+ CESC cis rs875971 0.895 rs3857684 ENSG00000237310.1 GS1-124K5.4 4.18 4.17e-05 0.0177 0.26 0.27 Aortic root size; chr7:66473171 chr7:66493706~66495474:+ CESC cis rs875971 0.893 rs62465470 ENSG00000232559.3 GS1-124K5.12 -4.18 4.17e-05 0.0178 -0.29 -0.27 Aortic root size; chr7:66136231 chr7:66554588~66576923:- CESC cis rs4713118 0.621 rs9295756 ENSG00000219392.1 RP1-265C24.5 -4.18 4.17e-05 0.0178 -0.37 -0.27 Parkinson's disease; chr6:28065618 chr6:28115628~28116551:+ CESC cis rs748404 0.697 rs546170 ENSG00000249839.1 AC011330.5 -4.18 4.18e-05 0.0178 -0.28 -0.27 Lung cancer; chr15:43272651 chr15:43663654~43684339:- CESC cis rs919433 0.617 rs4850436 ENSG00000222017.1 AC011997.1 -4.18 4.18e-05 0.0178 -0.34 -0.27 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197676674 chr2:197693106~197774823:+ CESC cis rs7829975 0.742 rs1533058 ENSG00000173295.6 FAM86B3P 4.18 4.18e-05 0.0178 0.35 0.27 Mood instability; chr8:8827680 chr8:8228595~8244865:+ CESC cis rs4927850 0.957 rs4927851 ENSG00000231464.1 AC024937.4 4.18 4.18e-05 0.0178 0.34 0.27 Pancreatic cancer; chr3:196024982 chr3:195996738~195998233:+ CESC cis rs4927850 0.918 rs4361313 ENSG00000231464.1 AC024937.4 4.18 4.18e-05 0.0178 0.34 0.27 Pancreatic cancer; chr3:196025389 chr3:195996738~195998233:+ CESC cis rs3124314 1 rs6700989 ENSG00000229021.2 AL591893.1 -4.18 4.18e-05 0.0178 -0.3 -0.27 Hair morphology; chr1:152166833 chr1:151994531~152042774:+ CESC cis rs77204473 0.744 rs6589606 ENSG00000254851.1 RP11-109L13.1 4.18 4.19e-05 0.0178 0.58 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117222170 chr11:117135528~117138582:+ CESC cis rs7131987 0.65 rs11050208 ENSG00000257176.2 RP11-996F15.2 -4.18 4.2e-05 0.0178 -0.35 -0.27 QT interval; chr12:29357436 chr12:29280418~29317848:- CESC cis rs875971 0.545 rs4718348 ENSG00000236529.1 RP13-254B10.1 4.18 4.2e-05 0.0179 0.33 0.27 Aortic root size; chr7:66441589 chr7:65840212~65840596:+ CESC cis rs11089937 0.609 rs9622980 ENSG00000211638.2 IGLV8-61 -4.18 4.2e-05 0.0179 -0.27 -0.27 Periodontitis (PAL4Q3); chr22:22149888 chr22:22098700~22099212:+ CESC cis rs875971 0.545 rs17138149 ENSG00000236529.1 RP13-254B10.1 4.18 4.2e-05 0.0179 0.32 0.27 Aortic root size; chr7:66228193 chr7:65840212~65840596:+ CESC cis rs2337406 0.866 rs7144369 ENSG00000211974.3 IGHV2-70 -4.18 4.2e-05 0.0179 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106793065 chr14:106723574~106724093:- CESC cis rs2337406 0.866 rs78525520 ENSG00000211974.3 IGHV2-70 -4.18 4.2e-05 0.0179 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106795643 chr14:106723574~106724093:- CESC cis rs10129255 0.646 rs55995061 ENSG00000211974.3 IGHV2-70 -4.18 4.2e-05 0.0179 -0.43 -0.27 Kawasaki disease; chr14:106799309 chr14:106723574~106724093:- CESC cis rs2337406 0.866 rs76871148 ENSG00000211974.3 IGHV2-70 -4.18 4.2e-05 0.0179 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106799722 chr14:106723574~106724093:- CESC cis rs2337406 0.866 rs61521632 ENSG00000211974.3 IGHV2-70 -4.18 4.2e-05 0.0179 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106801091 chr14:106723574~106724093:- CESC cis rs875971 0.862 rs1860469 ENSG00000222364.1 RNU6-96P 4.18 4.21e-05 0.0179 0.32 0.27 Aortic root size; chr7:66641888 chr7:66395191~66395286:+ CESC cis rs875971 0.862 rs4718383 ENSG00000222364.1 RNU6-96P 4.18 4.21e-05 0.0179 0.32 0.27 Aortic root size; chr7:66643422 chr7:66395191~66395286:+ CESC cis rs9322193 0.962 rs9478848 ENSG00000223701.3 RAET1E-AS1 4.18 4.21e-05 0.0179 0.31 0.27 Lung cancer; chr6:149825080 chr6:149884431~149919508:+ CESC cis rs10043775 0.958 rs12717974 ENSG00000251330.3 CTD-2283N19.1 -4.18 4.21e-05 0.0179 -0.36 -0.27 Periodontal microbiota; chr5:148449614 chr5:148430159~148430807:- CESC cis rs12580194 1 rs12582022 ENSG00000237493.3 RP11-603J24.7 -4.18 4.21e-05 0.0179 -0.38 -0.27 Cancer; chr12:55300576 chr12:55980432~55981035:- CESC cis rs950169 0.579 rs62027818 ENSG00000225151.9 GOLGA2P7 -4.18 4.21e-05 0.0179 -0.42 -0.27 Schizophrenia; chr15:83992393 chr15:84199311~84230136:- CESC cis rs8059260 0.604 rs8052325 ENSG00000274038.1 RP11-66H6.4 -4.18 4.21e-05 0.0179 -0.4 -0.27 Alcohol consumption over the past year; chr16:11044121 chr16:11056556~11057034:+ CESC cis rs12468226 1 rs7597469 ENSG00000273456.1 RP11-686O6.2 4.18 4.21e-05 0.0179 0.37 0.27 Urate levels; chr2:202329547 chr2:202374932~202375604:- CESC cis rs12468226 1 rs113877751 ENSG00000273456.1 RP11-686O6.2 4.18 4.21e-05 0.0179 0.37 0.27 Urate levels; chr2:202329998 chr2:202374932~202375604:- CESC cis rs12468226 0.935 rs113021930 ENSG00000273456.1 RP11-686O6.2 4.18 4.21e-05 0.0179 0.37 0.27 Urate levels; chr2:202330448 chr2:202374932~202375604:- CESC cis rs12468226 1 rs113491584 ENSG00000273456.1 RP11-686O6.2 4.18 4.21e-05 0.0179 0.37 0.27 Urate levels; chr2:202331724 chr2:202374932~202375604:- CESC cis rs9309473 0.95 rs7567585 ENSG00000163016.8 ALMS1P 4.18 4.21e-05 0.0179 0.34 0.27 Metabolite levels; chr2:73524839 chr2:73644919~73685576:+ CESC cis rs694739 0.628 rs508168 ENSG00000236935.1 AP003774.1 4.18 4.21e-05 0.0179 0.28 0.27 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64367963 chr11:64325050~64329504:- CESC cis rs694739 0.595 rs11606015 ENSG00000236935.1 AP003774.1 4.18 4.21e-05 0.0179 0.28 0.27 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64369405 chr11:64325050~64329504:- CESC cis rs694739 0.628 rs11606081 ENSG00000236935.1 AP003774.1 4.18 4.21e-05 0.0179 0.28 0.27 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64370403 chr11:64325050~64329504:- CESC cis rs67311347 1 rs7612015 ENSG00000223797.4 ENTPD3-AS1 4.18 4.21e-05 0.0179 0.27 0.27 Renal cell carcinoma; chr3:40358483 chr3:40313802~40453329:- CESC cis rs6964587 0.843 rs56075286 ENSG00000188693.7 CYP51A1-AS1 -4.18 4.21e-05 0.0179 -0.29 -0.27 Breast cancer; chr7:92102204 chr7:92134604~92180725:+ CESC cis rs9322193 0.923 rs12660304 ENSG00000216906.2 RP11-350J20.9 4.18 4.22e-05 0.0179 0.3 0.27 Lung cancer; chr6:149739647 chr6:149904243~149906418:+ CESC cis rs516805 1 rs516805 ENSG00000279453.1 RP3-425C14.4 -4.18 4.22e-05 0.0179 -0.31 -0.27 Lymphocyte counts; chr6:122398486 chr6:122436789~122439223:- CESC cis rs35955747 0.722 rs5997898 ENSG00000236132.1 CTA-440B3.1 4.18 4.22e-05 0.0179 0.3 0.27 Neutrophil count;Sum basophil neutrophil counts; chr22:31176977 chr22:31816379~31817491:- CESC cis rs12134133 0.752 rs4844579 ENSG00000274245.1 RP11-357P18.2 4.18 4.22e-05 0.0179 0.39 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207204546 chr1:207372559~207373252:+ CESC cis rs71403859 0.502 rs8053720 ENSG00000260886.1 TAT-AS1 4.18 4.22e-05 0.0179 0.4 0.27 Post bronchodilator FEV1; chr16:71422239 chr16:71565789~71578187:+ CESC cis rs7873102 0.593 rs2244203 ENSG00000230188.1 RP11-405L18.4 -4.18 4.22e-05 0.0179 -0.34 -0.27 Brain structure; chr9:37987147 chr9:37490421~37490893:- CESC cis rs6687821 0.531 rs4357505 ENSG00000267734.1 RP4-604K5.3 4.18 4.22e-05 0.0179 0.31 0.27 Yeast infection; chr1:87018785 chr1:86932199~86934891:- CESC cis rs12134133 1 rs4844590 ENSG00000274245.1 RP11-357P18.2 4.18 4.22e-05 0.0179 0.35 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207322784 chr1:207372559~207373252:+ CESC cis rs950169 0.579 rs881983 ENSG00000225151.9 GOLGA2P7 -4.18 4.23e-05 0.0179 -0.42 -0.27 Schizophrenia; chr15:83978556 chr15:84199311~84230136:- CESC cis rs2836950 0.527 rs2836958 ENSG00000232608.1 TIMM9P2 4.18 4.23e-05 0.0179 0.3 0.27 Menarche (age at onset); chr21:39251600 chr21:39216624~39217506:+ CESC cis rs9487094 0.67 rs749517 ENSG00000260273.1 RP11-425D10.10 -4.18 4.23e-05 0.018 -0.35 -0.27 Height; chr6:109531713 chr6:109382795~109383666:+ CESC cis rs9532669 0.963 rs3887418 ENSG00000176268.5 CYCSP34 4.18 4.23e-05 0.018 0.28 0.27 Cervical cancer; chr13:40940560 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs1056820 ENSG00000176268.5 CYCSP34 4.18 4.23e-05 0.018 0.28 0.27 Cervical cancer; chr13:40941150 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532678 ENSG00000176268.5 CYCSP34 4.18 4.23e-05 0.018 0.28 0.27 Cervical cancer; chr13:40941862 chr13:40863599~40863902:- CESC cis rs62025270 0.688 rs7179917 ENSG00000202081.1 RNU6-1280P -4.18 4.23e-05 0.018 -0.38 -0.27 Idiopathic pulmonary fibrosis; chr15:85722413 chr15:85651522~85651628:- CESC cis rs8040855 0.627 rs12904238 ENSG00000259295.5 CSPG4P12 4.18 4.23e-05 0.018 0.34 0.27 Bulimia nervosa; chr15:85096610 chr15:85191438~85213905:+ CESC cis rs2243480 0.666 rs1880311 ENSG00000275400.1 RP4-756H11.5 -4.18 4.23e-05 0.018 -0.46 -0.27 Diabetic kidney disease; chr7:65811765 chr7:66553805~66554199:- CESC cis rs11159086 0.941 rs11846588 ENSG00000259005.1 RP3-449M8.6 4.18 4.24e-05 0.018 0.43 0.27 Advanced glycation end-product levels; chr14:74505398 chr14:74474007~74474864:- CESC cis rs11159086 0.941 rs12434836 ENSG00000270000.1 RP3-449M8.9 4.18 4.24e-05 0.018 0.53 0.27 Advanced glycation end-product levels; chr14:74468887 chr14:74471930~74472360:- CESC cis rs9640161 0.702 rs1962004 ENSG00000261305.1 RP4-584D14.7 4.18 4.24e-05 0.018 0.41 0.27 Blood protein levels;Circulating chemerin levels; chr7:150323292 chr7:150341771~150342607:+ CESC cis rs12908161 1 rs12903134 ENSG00000225151.9 GOLGA2P7 -4.18 4.24e-05 0.018 -0.37 -0.27 Schizophrenia; chr15:84794468 chr15:84199311~84230136:- CESC cis rs673078 0.607 rs16948230 ENSG00000275759.1 RP11-131L12.3 -4.18 4.24e-05 0.018 -0.55 -0.27 Glucose homeostasis traits; chr12:118277086 chr12:118428281~118428870:+ CESC cis rs7809950 1 rs2520268 ENSG00000238832.1 snoU109 -4.18 4.24e-05 0.018 -0.34 -0.27 Coronary artery disease; chr7:107550716 chr7:107603363~107603507:+ CESC cis rs11685222 0.504 rs10188890 ENSG00000229326.3 AC069154.4 -4.18 4.25e-05 0.018 -0.38 -0.27 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119683757 chr2:119698623~119700151:+ CESC cis rs1799949 0.965 rs2236762 ENSG00000267681.1 CTD-3199J23.6 -4.18 4.25e-05 0.018 -0.33 -0.27 Menopause (age at onset); chr17:43074658 chr17:43144956~43145255:+ CESC cis rs7005380 0.62 rs7387694 ENSG00000279347.1 RP11-85I17.2 -4.18 4.25e-05 0.018 -0.24 -0.27 Interstitial lung disease; chr8:119885261 chr8:119838736~119840385:- CESC cis rs9826463 0.514 rs9851381 ENSG00000240950.1 RP11-372E1.1 -4.18 4.25e-05 0.018 -0.24 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr3:142803548 chr3:142827096~142827728:- CESC cis rs453301 0.653 rs1045529 ENSG00000254340.1 RP11-10A14.3 -4.18 4.25e-05 0.018 -0.33 -0.27 Joint mobility (Beighton score); chr8:9032588 chr8:9141424~9145435:+ CESC cis rs9322193 0.923 rs9767123 ENSG00000216906.2 RP11-350J20.9 4.18 4.25e-05 0.018 0.3 0.27 Lung cancer; chr6:149660323 chr6:149904243~149906418:+ CESC cis rs12134133 1 rs61822669 ENSG00000274245.1 RP11-357P18.2 4.18 4.25e-05 0.018 0.36 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207247869 chr1:207372559~207373252:+ CESC cis rs12144049 0.705 rs1923497 ENSG00000227045.1 RP11-98D18.1 -4.18 4.25e-05 0.018 -0.41 -0.27 Inflammatory skin disease;Atopic dermatitis; chr1:152450947 chr1:151701026~151708386:+ CESC cis rs11096990 0.964 rs7678689 ENSG00000249207.1 RP11-360F5.1 4.18 4.25e-05 0.018 0.33 0.27 Cognitive function; chr4:39261140 chr4:39112677~39126818:- CESC cis rs2337406 1 rs11161002 ENSG00000211974.3 IGHV2-70 -4.18 4.26e-05 0.018 -0.42 -0.27 Alzheimer's disease (late onset); chr14:106702202 chr14:106723574~106724093:- CESC cis rs8067354 0.789 rs4622571 ENSG00000266701.1 AC005702.4 4.18 4.26e-05 0.018 0.33 0.27 Hemoglobin concentration; chr17:59807036 chr17:60042546~60042627:- CESC cis rs256277 0.544 rs34942 ENSG00000270067.1 CTC-487M23.5 4.18 4.26e-05 0.0181 0.31 0.27 Coronary artery disease; chr5:111999104 chr5:112893333~112894001:+ CESC cis rs9322193 0.962 rs1413655 ENSG00000223701.3 RAET1E-AS1 4.18 4.26e-05 0.0181 0.31 0.27 Lung cancer; chr6:149821815 chr6:149884431~149919508:+ CESC cis rs875971 0.505 rs1167386 ENSG00000222364.1 RNU6-96P 4.18 4.26e-05 0.0181 0.32 0.27 Aortic root size; chr7:66048109 chr7:66395191~66395286:+ CESC cis rs10129255 0.826 rs7150693 ENSG00000211970.3 IGHV4-61 -4.18 4.26e-05 0.0181 -0.22 -0.27 Kawasaki disease; chr14:106705382 chr14:106639119~106639657:- CESC cis rs7789940 0.904 rs12531348 ENSG00000230305.2 AC004980.9 4.18 4.26e-05 0.0181 0.4 0.27 Multiple sclerosis; chr7:76307874 chr7:76524515~76532692:+ CESC cis rs7789940 0.904 rs61294900 ENSG00000230305.2 AC004980.9 4.18 4.26e-05 0.0181 0.4 0.27 Multiple sclerosis; chr7:76307895 chr7:76524515~76532692:+ CESC cis rs12550612 0.83 rs9918919 ENSG00000253616.4 RP11-875O11.3 4.18 4.26e-05 0.0181 0.38 0.27 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23109777 chr8:23071377~23074488:- CESC cis rs916888 0.773 rs199533 ENSG00000232300.1 FAM215B 4.18 4.26e-05 0.0181 0.43 0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46558830~46562795:- CESC cis rs6928977 0.863 rs6918097 ENSG00000213117.4 RP3-352A20.1 4.18 4.26e-05 0.0181 0.32 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135314411 chr6:134897874~134898759:+ CESC cis rs12690897 0.501 rs12704158 ENSG00000229251.3 HNRNPA1P8 -4.18 4.27e-05 0.0181 -0.27 -0.27 Macrophage inflammatory protein 1a levels; chr7:85640537 chr7:84983556~84984506:+ CESC cis rs1707322 0.963 rs10789484 ENSG00000281133.1 AL355480.3 -4.18 4.27e-05 0.0181 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45941306 chr1:45580892~45580996:- CESC cis rs1707322 1 rs7527079 ENSG00000281133.1 AL355480.3 -4.18 4.27e-05 0.0181 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45947778 chr1:45580892~45580996:- CESC cis rs1707322 1 rs34446427 ENSG00000281133.1 AL355480.3 -4.18 4.27e-05 0.0181 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45951983 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs4660900 ENSG00000281133.1 AL355480.3 -4.18 4.27e-05 0.0181 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45953933 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4454479 ENSG00000281133.1 AL355480.3 -4.18 4.27e-05 0.0181 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45957883 chr1:45580892~45580996:- CESC cis rs1707322 1 rs7517560 ENSG00000281133.1 AL355480.3 -4.18 4.27e-05 0.0181 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45960271 chr1:45580892~45580996:- CESC cis rs1707322 1 rs12077546 ENSG00000281133.1 AL355480.3 -4.18 4.27e-05 0.0181 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45966134 chr1:45580892~45580996:- CESC cis rs1707322 1 rs12124291 ENSG00000281133.1 AL355480.3 -4.18 4.27e-05 0.0181 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45966460 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10890378 ENSG00000281133.1 AL355480.3 4.18 4.27e-05 0.0181 0.32 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45944985 chr1:45580892~45580996:- CESC cis rs490234 0.702 rs13285587 ENSG00000232630.1 PRPS1P2 -4.18 4.27e-05 0.0181 -0.23 -0.27 Mean arterial pressure; chr9:125470779 chr9:125150653~125151589:+ CESC cis rs35160687 0.842 rs1863051 ENSG00000273080.1 RP11-301O19.1 4.18 4.27e-05 0.0181 0.3 0.27 Night sleep phenotypes; chr2:86332025 chr2:86195590~86196049:+ CESC cis rs7714584 1 rs1428551 ENSG00000197083.10 ZNF300P1 4.18 4.27e-05 0.0181 0.45 0.27 Crohn's disease; chr5:150880270 chr5:150930645~150946289:- CESC cis rs6142102 0.961 rs2284389 ENSG00000275784.1 RP5-1125A11.6 -4.18 4.27e-05 0.0181 -0.28 -0.27 Skin pigmentation; chr20:34069035 chr20:33989480~33991818:- CESC cis rs4713118 0.629 rs203890 ENSG00000219392.1 RP1-265C24.5 -4.18 4.27e-05 0.0181 -0.36 -0.27 Parkinson's disease; chr6:28054470 chr6:28115628~28116551:+ CESC cis rs748404 0.626 rs17780920 ENSG00000249839.1 AC011330.5 -4.18 4.28e-05 0.0181 -0.38 -0.27 Lung cancer; chr15:43370164 chr15:43663654~43684339:- CESC cis rs8127691 0.967 rs762423 ENSG00000225331.1 AP001055.6 4.18 4.28e-05 0.0181 0.33 0.27 Inflammatory bowel disease; chr21:44195803 chr21:44158740~44160076:- CESC cis rs12908161 1 rs3803405 ENSG00000259728.4 LINC00933 4.18 4.28e-05 0.0181 0.36 0.27 Schizophrenia; chr15:84840409 chr15:84570649~84580175:+ CESC cis rs700651 0.821 rs770661 ENSG00000222017.1 AC011997.1 4.18 4.28e-05 0.0181 0.34 0.27 Intracranial aneurysm; chr2:197860720 chr2:197693106~197774823:+ CESC cis rs700651 0.821 rs700690 ENSG00000222017.1 AC011997.1 4.18 4.28e-05 0.0181 0.34 0.27 Intracranial aneurysm; chr2:197862902 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs700692 ENSG00000222017.1 AC011997.1 4.18 4.28e-05 0.0181 0.34 0.27 Dermatomyositis; chr2:197863776 chr2:197693106~197774823:+ CESC cis rs7572733 0.534 rs770662 ENSG00000222017.1 AC011997.1 4.18 4.28e-05 0.0181 0.34 0.27 Dermatomyositis; chr2:197864559 chr2:197693106~197774823:+ CESC cis rs9341808 0.739 rs4706831 ENSG00000272129.1 RP11-250B2.6 4.18 4.28e-05 0.0181 0.31 0.27 Sitting height ratio; chr6:80297982 chr6:80355424~80356859:+ CESC cis rs8059260 0.542 rs80000109 ENSG00000274038.1 RP11-66H6.4 -4.18 4.29e-05 0.0181 -0.42 -0.27 Alcohol consumption over the past year; chr16:11031457 chr16:11056556~11057034:+ CESC cis rs6693388 0.647 rs2999508 ENSG00000229021.2 AL591893.1 4.18 4.29e-05 0.0182 0.32 0.27 Blood metabolite ratios; chr1:151961971 chr1:151994531~152042774:+ CESC cis rs113835537 0.866 rs59320108 ENSG00000255517.5 CTD-3074O7.5 -4.18 4.29e-05 0.0182 -0.43 -0.27 Airway imaging phenotypes; chr11:66598525 chr11:66473490~66480233:- CESC cis rs673078 0.66 rs17512142 ENSG00000275759.1 RP11-131L12.3 -4.18 4.29e-05 0.0182 -0.58 -0.27 Glucose homeostasis traits; chr12:118186186 chr12:118428281~118428870:+ CESC cis rs2732480 0.557 rs2634682 ENSG00000240399.1 RP1-228P16.1 4.18 4.29e-05 0.0182 0.32 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48339160 chr12:48054813~48055591:- CESC cis rs8030379 0.811 rs7162542 ENSG00000230373.7 GOLGA6L5P -4.18 4.29e-05 0.0182 -0.29 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83845538 chr15:84507885~84516814:- CESC cis rs700651 0.786 rs58224025 ENSG00000222017.1 AC011997.1 4.18 4.3e-05 0.0182 0.34 0.27 Intracranial aneurysm; chr2:197957264 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs1401096 ENSG00000222017.1 AC011997.1 4.18 4.3e-05 0.0182 0.34 0.27 Dermatomyositis; chr2:197959104 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs13408411 ENSG00000222017.1 AC011997.1 4.18 4.3e-05 0.0182 0.34 0.27 Dermatomyositis; chr2:197960738 chr2:197693106~197774823:+ CESC cis rs700651 0.752 rs1850631 ENSG00000222017.1 AC011997.1 4.18 4.3e-05 0.0182 0.34 0.27 Intracranial aneurysm; chr2:197964744 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs6752458 ENSG00000222017.1 AC011997.1 4.18 4.3e-05 0.0182 0.34 0.27 Dermatomyositis; chr2:197970382 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs1356542 ENSG00000222017.1 AC011997.1 4.18 4.3e-05 0.0182 0.34 0.27 Dermatomyositis; chr2:197970978 chr2:197693106~197774823:+ CESC cis rs10129255 0.957 rs10136560 ENSG00000211970.3 IGHV4-61 -4.18 4.3e-05 0.0182 -0.22 -0.27 Kawasaki disease; chr14:106787630 chr14:106639119~106639657:- CESC cis rs1387259 0.69 rs1601985 ENSG00000258273.1 RP11-370I10.4 -4.18 4.3e-05 0.0182 -0.33 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48368131 chr12:48333755~48333901:- CESC cis rs4789693 0.938 rs8078595 ENSG00000265458.1 RP13-20L14.6 4.18 4.3e-05 0.0182 0.33 0.27 Glucocorticoid-induced osteonecrosis; chr17:82469112 chr17:82454273~82458521:- CESC cis rs67311347 1 rs6762997 ENSG00000223797.4 ENTPD3-AS1 4.18 4.3e-05 0.0182 0.26 0.27 Renal cell carcinoma; chr3:40436660 chr3:40313802~40453329:- CESC cis rs5769707 0.521 rs739244 ENSG00000235111.1 RP1-29C18.8 -4.18 4.3e-05 0.0182 -0.29 -0.27 Monocyte percentage of white cells;Monocyte count; chr22:49666510 chr22:49612657~49615716:- CESC cis rs2243480 1 rs4718317 ENSG00000226824.5 RP4-756H11.3 4.18 4.3e-05 0.0182 0.52 0.27 Diabetic kidney disease; chr7:66183914 chr7:66654538~66669855:+ CESC cis rs11051970 0.918 rs1055876 ENSG00000255760.1 RP11-428G5.5 4.18 4.3e-05 0.0182 0.33 0.27 Response to tocilizumab in rheumatoid arthritis; chr12:32383266 chr12:31877079~31887203:- CESC cis rs71403859 0.502 rs71403849 ENSG00000260886.1 TAT-AS1 4.18 4.3e-05 0.0182 0.4 0.27 Post bronchodilator FEV1; chr16:71450462 chr16:71565789~71578187:+ CESC cis rs9532669 0.89 rs2324738 ENSG00000176268.5 CYCSP34 4.18 4.31e-05 0.0182 0.27 0.27 Cervical cancer; chr13:40925242 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs2324739 ENSG00000176268.5 CYCSP34 4.18 4.31e-05 0.0182 0.27 0.27 Cervical cancer; chr13:40925479 chr13:40863599~40863902:- CESC cis rs853679 0.567 rs7774981 ENSG00000204709.4 LINC01556 4.18 4.31e-05 0.0182 0.32 0.27 Depression; chr6:28379133 chr6:28943877~28944537:+ CESC cis rs853679 0.567 rs7754960 ENSG00000204709.4 LINC01556 4.18 4.31e-05 0.0182 0.32 0.27 Depression; chr6:28379168 chr6:28943877~28944537:+ CESC cis rs6001482 0.702 rs5757581 ENSG00000236850.4 BMS1P20 4.18 4.31e-05 0.0182 0.26 0.27 Diastolic blood pressure; chr22:22234220 chr22:22303224~22322847:+ CESC cis rs1799949 0.859 rs11657004 ENSG00000267681.1 CTD-3199J23.6 -4.17 4.31e-05 0.0182 -0.33 -0.27 Menopause (age at onset); chr17:43365383 chr17:43144956~43145255:+ CESC cis rs523522 0.962 rs4766969 ENSG00000278344.1 RP11-18C24.8 4.17 4.31e-05 0.0182 0.33 0.27 High light scatter reticulocyte count; chr12:120550435 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs12309824 ENSG00000278344.1 RP11-18C24.8 4.17 4.31e-05 0.0182 0.33 0.27 High light scatter reticulocyte count; chr12:120552779 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs3213565 ENSG00000278344.1 RP11-18C24.8 4.17 4.31e-05 0.0182 0.33 0.27 High light scatter reticulocyte count; chr12:120554598 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs4767914 ENSG00000278344.1 RP11-18C24.8 4.17 4.31e-05 0.0182 0.33 0.27 High light scatter reticulocyte count; chr12:120556014 chr12:120500735~120501090:- CESC cis rs11971779 0.715 rs11772771 ENSG00000273391.1 RP11-634H22.1 4.17 4.31e-05 0.0182 0.27 0.27 Diisocyanate-induced asthma; chr7:139374057 chr7:139359032~139359566:- CESC cis rs4718428 1 rs12534637 ENSG00000273142.1 RP11-458F8.4 -4.17 4.31e-05 0.0182 -0.27 -0.27 Corneal structure; chr7:66862667 chr7:66902857~66906297:+ CESC cis rs58873874 0.737 rs78565801 ENSG00000251405.2 CTB-109A12.1 4.17 4.32e-05 0.0182 0.7 0.27 Bipolar disorder (body mass index interaction); chr5:157459326 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs79951742 ENSG00000251405.2 CTB-109A12.1 4.17 4.32e-05 0.0182 0.7 0.27 Bipolar disorder (body mass index interaction); chr5:157459705 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs76634949 ENSG00000251405.2 CTB-109A12.1 4.17 4.32e-05 0.0182 0.7 0.27 Bipolar disorder (body mass index interaction); chr5:157463391 chr5:157362615~157460078:- CESC cis rs1969253 0.712 rs843343 ENSG00000205955.4 HSP90AA5P -4.17 4.32e-05 0.0182 -0.27 -0.27 Major depressive disorder; chr3:184190114 chr3:184115352~184117898:+ CESC cis rs7923609 0.578 rs10761789 ENSG00000232075.1 MRPL35P2 -4.17 4.32e-05 0.0182 -0.3 -0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63636804 chr10:63634317~63634827:- CESC cis rs9400467 0.506 rs79788276 ENSG00000272356.1 RP5-1112D6.8 -4.17 4.32e-05 0.0183 -0.34 -0.27 Amino acid levels;Blood metabolite levels; chr6:111278011 chr6:111309203~111313517:+ CESC cis rs2688608 0.592 rs10824031 ENSG00000242288.9 RP11-464F9.1 4.17 4.32e-05 0.0183 0.3 0.27 Inflammatory bowel disease; chr10:73749515 chr10:73674295~73730466:- CESC cis rs2564921 0.73 rs62255895 ENSG00000242142.1 SERBP1P3 -4.17 4.32e-05 0.0183 -0.34 -0.27 Height; chr3:53027969 chr3:53064283~53065091:- CESC cis rs2412819 0.597 rs7181912 ENSG00000249839.1 AC011330.5 4.17 4.32e-05 0.0183 0.35 0.27 Lung cancer; chr15:43770676 chr15:43663654~43684339:- CESC cis rs2412819 0.545 rs3862143 ENSG00000249839.1 AC011330.5 4.17 4.32e-05 0.0183 0.35 0.27 Lung cancer; chr15:43779282 chr15:43663654~43684339:- CESC cis rs875971 1 rs6979382 ENSG00000232559.3 GS1-124K5.12 4.17 4.33e-05 0.0183 0.3 0.27 Aortic root size; chr7:66421388 chr7:66554588~66576923:- CESC cis rs875971 1 rs6961990 ENSG00000232559.3 GS1-124K5.12 4.17 4.33e-05 0.0183 0.3 0.27 Aortic root size; chr7:66423583 chr7:66554588~66576923:- CESC cis rs10129255 0.957 rs10136781 ENSG00000211970.3 IGHV4-61 -4.17 4.33e-05 0.0183 -0.2 -0.27 Kawasaki disease; chr14:106780451 chr14:106639119~106639657:- CESC cis rs10129255 0.957 rs8022165 ENSG00000211970.3 IGHV4-61 -4.17 4.33e-05 0.0183 -0.2 -0.27 Kawasaki disease; chr14:106781682 chr14:106639119~106639657:- CESC cis rs10129255 0.917 rs8022493 ENSG00000211970.3 IGHV4-61 -4.17 4.33e-05 0.0183 -0.2 -0.27 Kawasaki disease; chr14:106781820 chr14:106639119~106639657:- CESC cis rs5758659 0.504 rs133367 ENSG00000273366.1 CTA-989H11.1 4.17 4.33e-05 0.0183 0.34 0.27 Cognitive function; chr22:42067362 chr22:42278188~42278846:+ CESC cis rs17301013 0.507 rs2142864 ENSG00000227373.4 RP11-160H22.5 4.17 4.33e-05 0.0183 0.38 0.27 Systemic lupus erythematosus; chr1:174304924 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2860909 ENSG00000227373.4 RP11-160H22.5 4.17 4.33e-05 0.0183 0.38 0.27 Systemic lupus erythematosus; chr1:174305211 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs7553317 ENSG00000227373.4 RP11-160H22.5 4.17 4.33e-05 0.0183 0.38 0.27 Systemic lupus erythematosus; chr1:174307182 chr1:174115300~174160004:- CESC cis rs1044826 0.642 rs2071388 ENSG00000178631.7 ACTG1P1 -4.17 4.34e-05 0.0183 -0.34 -0.27 Obesity-related traits; chr3:139517841 chr3:139493809~139494937:+ CESC cis rs1056107 0.831 rs10125827 ENSG00000225513.1 RP11-165N19.2 4.17 4.34e-05 0.0183 0.33 0.27 Colorectal cancer; chr9:112182226 chr9:112173522~112173971:- CESC cis rs17711722 0.503 rs453835 ENSG00000236529.1 RP13-254B10.1 -4.17 4.34e-05 0.0183 -0.29 -0.27 Calcium levels; chr7:66046172 chr7:65840212~65840596:+ CESC cis rs11685222 0.589 rs72965075 ENSG00000229326.3 AC069154.4 4.17 4.34e-05 0.0183 0.38 0.27 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119664123 chr2:119698623~119700151:+ CESC cis rs673078 0.607 rs17441172 ENSG00000275759.1 RP11-131L12.3 4.17 4.34e-05 0.0183 0.53 0.27 Glucose homeostasis traits; chr12:118430456 chr12:118428281~118428870:+ CESC cis rs7567389 0.74 rs4536600 ENSG00000236682.1 AC068282.3 -4.17 4.34e-05 0.0183 -0.35 -0.27 Self-rated health; chr2:127244996 chr2:127389130~127400580:+ CESC cis rs6693388 0.668 rs2338206 ENSG00000229021.2 AL591893.1 -4.17 4.35e-05 0.0184 -0.34 -0.27 Blood metabolite ratios; chr1:151919750 chr1:151994531~152042774:+ CESC cis rs1707322 1 rs34444543 ENSG00000281133.1 AL355480.3 -4.17 4.35e-05 0.0184 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893190 chr1:45580892~45580996:- CESC cis rs2439831 0.85 rs7168158 ENSG00000249839.1 AC011330.5 -4.17 4.35e-05 0.0184 -0.39 -0.27 Lung cancer in ever smokers; chr15:43758178 chr15:43663654~43684339:- CESC cis rs4927850 1 rs10881563 ENSG00000231464.1 AC024937.4 4.17 4.35e-05 0.0184 0.35 0.27 Pancreatic cancer; chr3:196023354 chr3:195996738~195998233:+ CESC cis rs11633886 0.528 rs2248216 ENSG00000273972.1 CTD-2306A12.1 4.17 4.35e-05 0.0184 0.31 0.27 Diisocyanate-induced asthma; chr15:45809383 chr15:45702640~45703183:+ CESC cis rs7259376 0.525 rs1692599 ENSG00000213971.6 RP11-15H20.6 -4.17 4.35e-05 0.0184 -0.33 -0.27 Menopause (age at onset); chr19:22452746 chr19:23259906~23274251:- CESC cis rs2688608 0.62 rs7080350 ENSG00000242288.9 RP11-464F9.1 -4.17 4.36e-05 0.0184 -0.3 -0.27 Inflammatory bowel disease; chr10:73818085 chr10:73674295~73730466:- CESC cis rs61160187 0.582 rs17444495 ENSG00000215032.2 GNL3LP1 4.17 4.36e-05 0.0184 0.32 0.27 Educational attainment (years of education);Educational attainment (college completion); chr5:61059457 chr5:60891935~60893577:- CESC cis rs7015630 0.866 rs12680009 ENSG00000251136.7 RP11-37B2.1 -4.17 4.36e-05 0.0184 -0.31 -0.27 Inflammatory bowel disease;Crohn's disease; chr8:89855155 chr8:89609409~89757727:- CESC cis rs950776 0.518 rs8053 ENSG00000279373.1 RP11-650L12.4 -4.17 4.36e-05 0.0184 -0.32 -0.27 Sudden cardiac arrest; chr15:78548878 chr15:78537681~78538946:+ CESC cis rs1707322 1 rs10890380 ENSG00000281133.1 AL355480.3 -4.17 4.36e-05 0.0184 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45983797 chr1:45580892~45580996:- CESC cis rs62025270 0.632 rs1807309 ENSG00000202081.1 RNU6-1280P -4.17 4.36e-05 0.0184 -0.37 -0.27 Idiopathic pulmonary fibrosis; chr15:85668526 chr15:85651522~85651628:- CESC cis rs875971 0.862 rs4718330 ENSG00000232559.3 GS1-124K5.12 -4.17 4.36e-05 0.0184 -0.28 -0.27 Aortic root size; chr7:66250256 chr7:66554588~66576923:- CESC cis rs10129255 0.833 rs61997797 ENSG00000211970.3 IGHV4-61 -4.17 4.37e-05 0.0184 -0.22 -0.27 Kawasaki disease; chr14:106815190 chr14:106639119~106639657:- CESC cis rs12134133 1 rs7553157 ENSG00000274245.1 RP11-357P18.2 4.17 4.37e-05 0.0184 0.34 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207283922 chr1:207372559~207373252:+ CESC cis rs8020095 0.571 rs3784078 ENSG00000258561.1 RP11-72M17.1 -4.17 4.37e-05 0.0184 -0.41 -0.27 Depression (quantitative trait); chr14:67092993 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs7493580 ENSG00000258561.1 RP11-72M17.1 -4.17 4.37e-05 0.0184 -0.41 -0.27 Depression (quantitative trait); chr14:67113733 chr14:66212810~66509394:- CESC cis rs2288884 0.515 rs8112458 ENSG00000275055.1 CTC-471J1.11 -4.17 4.37e-05 0.0184 -0.31 -0.27 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52030052 chr19:52049007~52049754:+ CESC cis rs9925964 0.933 rs12448321 ENSG00000260911.2 RP11-196G11.2 -4.17 4.37e-05 0.0184 -0.3 -0.27 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31036959 chr16:31043150~31049868:+ CESC cis rs2274273 0.624 rs7151754 ENSG00000258413.1 RP11-665C16.6 -4.17 4.37e-05 0.0184 -0.35 -0.27 Protein biomarker; chr14:55321783 chr14:55262767~55272075:- CESC cis rs61160187 0.582 rs28436304 ENSG00000215032.2 GNL3LP1 4.17 4.37e-05 0.0184 0.32 0.27 Educational attainment (years of education);Educational attainment (college completion); chr5:61038584 chr5:60891935~60893577:- CESC cis rs2274273 0.648 rs58553156 ENSG00000258413.1 RP11-665C16.6 -4.17 4.37e-05 0.0184 -0.34 -0.27 Protein biomarker; chr14:55115976 chr14:55262767~55272075:- CESC cis rs769267 0.896 rs2074298 ENSG00000269131.1 AC004447.2 -4.17 4.37e-05 0.0184 -0.22 -0.27 Tonsillectomy; chr19:19266907 chr19:18990893~18993610:+ CESC cis rs7829975 0.54 rs2976909 ENSG00000173295.6 FAM86B3P -4.17 4.37e-05 0.0184 -0.33 -0.27 Mood instability; chr8:8489180 chr8:8228595~8244865:+ CESC cis rs453301 0.686 rs4840389 ENSG00000173295.6 FAM86B3P -4.17 4.37e-05 0.0184 -0.35 -0.27 Joint mobility (Beighton score); chr8:9026993 chr8:8228595~8244865:+ CESC cis rs4718428 1 rs4718428 ENSG00000273142.1 RP11-458F8.4 -4.17 4.37e-05 0.0184 -0.27 -0.27 Corneal structure; chr7:66956459 chr7:66902857~66906297:+ CESC cis rs12468226 0.873 rs12472035 ENSG00000273456.1 RP11-686O6.2 4.17 4.38e-05 0.0185 0.37 0.27 Urate levels; chr2:202221970 chr2:202374932~202375604:- CESC cis rs17772222 0.874 rs78077739 ENSG00000258983.2 RP11-507K2.2 4.17 4.38e-05 0.0185 0.34 0.27 Coronary artery calcification; chr14:88741176 chr14:88499334~88515502:+ CESC cis rs9813712 0.595 rs12490957 ENSG00000228252.7 COL6A4P2 4.17 4.38e-05 0.0185 0.31 0.27 Response to amphetamines; chr3:130287851 chr3:130212823~130273806:+ CESC cis rs9640161 0.789 rs6964110 ENSG00000261305.1 RP4-584D14.7 4.17 4.38e-05 0.0185 0.37 0.27 Blood protein levels;Circulating chemerin levels; chr7:150344747 chr7:150341771~150342607:+ CESC cis rs6951245 1 rs113146460 ENSG00000229043.2 AC091729.9 -4.17 4.38e-05 0.0185 -0.41 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1065528 chr7:1160374~1165267:+ CESC cis rs6951245 0.935 rs61753396 ENSG00000229043.2 AC091729.9 -4.17 4.38e-05 0.0185 -0.41 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1065736 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs79327308 ENSG00000229043.2 AC091729.9 -4.17 4.38e-05 0.0185 -0.41 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1068505 chr7:1160374~1165267:+ CESC cis rs6951245 0.938 rs117729148 ENSG00000229043.2 AC091729.9 -4.17 4.38e-05 0.0185 -0.41 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1068895 chr7:1160374~1165267:+ CESC cis rs2836950 0.545 rs8132424 ENSG00000255568.3 BRWD1-AS2 4.17 4.39e-05 0.0185 0.22 0.27 Menarche (age at onset); chr21:39212486 chr21:39313935~39314962:+ CESC cis rs875971 1 rs10215948 ENSG00000237310.1 GS1-124K5.4 -4.17 4.39e-05 0.0185 -0.25 -0.27 Aortic root size; chr7:66282799 chr7:66493706~66495474:+ CESC cis rs11992162 0.967 rs7836456 ENSG00000255020.1 AF131216.5 4.17 4.39e-05 0.0185 0.31 0.27 Monocyte count; chr8:11971666 chr8:11345748~11347502:- CESC cis rs6964587 0.967 rs2040499 ENSG00000188693.7 CYP51A1-AS1 4.17 4.39e-05 0.0185 0.29 0.27 Breast cancer; chr7:92180343 chr7:92134604~92180725:+ CESC cis rs2337406 0.866 rs7153964 ENSG00000211974.3 IGHV2-70 -4.17 4.39e-05 0.0185 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106790480 chr14:106723574~106724093:- CESC cis rs2337406 0.866 rs2301536 ENSG00000211974.3 IGHV2-70 -4.17 4.39e-05 0.0185 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106790636 chr14:106723574~106724093:- CESC cis rs9309473 0.519 rs7606947 ENSG00000273245.1 RP11-434P11.2 4.17 4.39e-05 0.0185 0.34 0.27 Metabolite levels; chr2:73682691 chr2:73750256~73750786:- CESC cis rs7429990 0.965 rs1550914 ENSG00000229759.1 MRPS18AP1 4.17 4.4e-05 0.0185 0.27 0.27 Educational attainment (years of education); chr3:47953678 chr3:48256350~48256938:- CESC cis rs733592 0.599 rs12819124 ENSG00000258273.1 RP11-370I10.4 -4.17 4.4e-05 0.0185 -0.3 -0.27 Plateletcrit; chr12:48015271 chr12:48333755~48333901:- CESC cis rs10129255 1 rs11627342 ENSG00000211970.3 IGHV4-61 -4.17 4.4e-05 0.0185 -0.21 -0.27 Kawasaki disease; chr14:106675823 chr14:106639119~106639657:- CESC cis rs2933343 1 rs789227 ENSG00000231305.3 RP11-723O4.2 4.17 4.4e-05 0.0185 0.29 0.27 IgG glycosylation; chr3:128881742 chr3:128861313~128871540:- CESC cis rs748404 0.578 rs576557 ENSG00000205771.5 CATSPER2P1 -4.17 4.4e-05 0.0185 -0.32 -0.27 Lung cancer; chr15:43305539 chr15:43726918~43747094:- CESC cis rs3806843 0.547 rs246065 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140944053 chr5:140718925~140719013:+ CESC cis rs3806843 0.551 rs184996 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140944188 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246064 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140944724 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246063 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140944907 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246062 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140944995 chr5:140718925~140719013:+ CESC cis rs3806843 0.521 rs246061 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140945071 chr5:140718925~140719013:+ CESC cis rs3806843 0.607 rs246060 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140945164 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246059 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140945425 chr5:140718925~140719013:+ CESC cis rs3806843 0.548 rs246058 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140945549 chr5:140718925~140719013:+ CESC cis rs3806843 0.548 rs246057 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140945998 chr5:140718925~140719013:+ CESC cis rs3806843 0.548 rs246056 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140946015 chr5:140718925~140719013:+ CESC cis rs3806843 0.548 rs246055 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140946077 chr5:140718925~140719013:+ CESC cis rs3806843 0.547 rs246054 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140946574 chr5:140718925~140719013:+ CESC cis rs3806843 0.548 rs246052 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140946828 chr5:140718925~140719013:+ CESC cis rs3806843 0.52 rs246051 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140946879 chr5:140718925~140719013:+ CESC cis rs31872 0.521 rs246050 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Visceral adipose tissue adjusted for BMI; chr5:140947275 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246049 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140948005 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246047 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140948752 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246046 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140949679 chr5:140718925~140719013:+ CESC cis rs3806843 0.576 rs246045 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140950299 chr5:140718925~140719013:+ CESC cis rs3806843 0.607 rs246044 ENSG00000202111.1 VTRNA1-2 -4.17 4.4e-05 0.0185 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140951071 chr5:140718925~140719013:+ CESC cis rs2337406 0.866 rs7140974 ENSG00000211974.3 IGHV2-70 -4.17 4.4e-05 0.0185 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106795976 chr14:106723574~106724093:- CESC cis rs875971 0.545 rs73376394 ENSG00000237310.1 GS1-124K5.4 4.17 4.4e-05 0.0185 0.29 0.27 Aortic root size; chr7:66172694 chr7:66493706~66495474:+ CESC cis rs6439153 0.933 rs11711812 ENSG00000231305.3 RP11-723O4.2 4.17 4.4e-05 0.0185 0.26 0.27 Pneumococcal bacteremia; chr3:128989711 chr3:128861313~128871540:- CESC cis rs6439153 0.933 rs7648877 ENSG00000231305.3 RP11-723O4.2 4.17 4.4e-05 0.0185 0.26 0.27 Pneumococcal bacteremia; chr3:128991137 chr3:128861313~128871540:- CESC cis rs17818399 0.962 rs7565274 ENSG00000279254.1 RP11-536C12.1 -4.17 4.41e-05 0.0185 -0.34 -0.27 Height; chr2:46614722 chr2:46668870~46670778:+ CESC cis rs7429990 0.965 rs319689 ENSG00000229759.1 MRPS18AP1 4.17 4.41e-05 0.0185 0.28 0.27 Educational attainment (years of education); chr3:47886677 chr3:48256350~48256938:- CESC cis rs11779988 0.63 rs17635854 ENSG00000253671.1 RP11-806O11.1 -4.17 4.41e-05 0.0186 -0.31 -0.27 Breast cancer; chr8:18038225 chr8:17808941~17820868:+ CESC cis rs7131987 0.65 rs7957339 ENSG00000257176.2 RP11-996F15.2 -4.17 4.41e-05 0.0186 -0.32 -0.27 QT interval; chr12:29303562 chr12:29280418~29317848:- CESC cis rs7131987 0.65 rs7954871 ENSG00000257176.2 RP11-996F15.2 -4.17 4.41e-05 0.0186 -0.32 -0.27 QT interval; chr12:29306799 chr12:29280418~29317848:- CESC cis rs7131987 0.621 rs11050181 ENSG00000257176.2 RP11-996F15.2 -4.17 4.41e-05 0.0186 -0.32 -0.27 QT interval; chr12:29314736 chr12:29280418~29317848:- CESC cis rs875971 0.545 rs17138156 ENSG00000236529.1 RP13-254B10.1 4.17 4.41e-05 0.0186 0.32 0.27 Aortic root size; chr7:66249708 chr7:65840212~65840596:+ CESC cis rs875971 0.862 rs1612452 ENSG00000232559.3 GS1-124K5.12 -4.17 4.41e-05 0.0186 -0.3 -0.27 Aortic root size; chr7:66108909 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs1167390 ENSG00000232559.3 GS1-124K5.12 -4.17 4.41e-05 0.0186 -0.3 -0.27 Aortic root size; chr7:66110906 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs35034167 ENSG00000232559.3 GS1-124K5.12 -4.17 4.41e-05 0.0186 -0.3 -0.27 Aortic root size; chr7:66115179 chr7:66554588~66576923:- CESC cis rs875971 1 rs4718307 ENSG00000179406.6 LINC00174 4.17 4.41e-05 0.0186 0.29 0.27 Aortic root size; chr7:66146001 chr7:66376044~66401338:- CESC cis rs875971 1 rs7801282 ENSG00000179406.6 LINC00174 4.17 4.41e-05 0.0186 0.29 0.27 Aortic root size; chr7:66148700 chr7:66376044~66401338:- CESC cis rs2115630 0.645 rs1107179 ENSG00000225151.9 GOLGA2P7 -4.17 4.41e-05 0.0186 -0.31 -0.27 P wave terminal force; chr15:84655131 chr15:84199311~84230136:- CESC cis rs673078 0.607 rs55929628 ENSG00000275759.1 RP11-131L12.3 -4.17 4.41e-05 0.0186 -0.54 -0.27 Glucose homeostasis traits; chr12:118371332 chr12:118428281~118428870:+ CESC cis rs9309473 1 rs6740223 ENSG00000163016.8 ALMS1P 4.17 4.41e-05 0.0186 0.34 0.27 Metabolite levels; chr2:73426204 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs6707722 ENSG00000163016.8 ALMS1P 4.17 4.41e-05 0.0186 0.34 0.27 Metabolite levels; chr2:73427235 chr2:73644919~73685576:+ CESC cis rs36093924 0.646 rs7285557 ENSG00000273366.1 CTA-989H11.1 4.17 4.41e-05 0.0186 0.34 0.27 Intelligence; chr22:41952786 chr22:42278188~42278846:+ CESC cis rs11633886 0.528 rs2248207 ENSG00000273972.1 CTD-2306A12.1 4.17 4.42e-05 0.0186 0.31 0.27 Diisocyanate-induced asthma; chr15:45809215 chr15:45702640~45703183:+ CESC cis rs11685222 0.64 rs78435291 ENSG00000229326.3 AC069154.4 4.17 4.42e-05 0.0186 0.39 0.27 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119676827 chr2:119698623~119700151:+ CESC cis rs7587476 1 rs7587476 ENSG00000229267.2 AC072062.1 4.17 4.42e-05 0.0186 0.34 0.27 Neuroblastoma; chr2:214789163 chr2:214810229~214963274:+ CESC cis rs875971 1 rs6958271 ENSG00000237310.1 GS1-124K5.4 4.17 4.42e-05 0.0186 0.26 0.27 Aortic root size; chr7:66514344 chr7:66493706~66495474:+ CESC cis rs875971 1 rs6958277 ENSG00000237310.1 GS1-124K5.4 4.17 4.42e-05 0.0186 0.26 0.27 Aortic root size; chr7:66514362 chr7:66493706~66495474:+ CESC cis rs9640161 0.871 rs56156367 ENSG00000261305.1 RP4-584D14.7 4.17 4.42e-05 0.0186 0.4 0.27 Blood protein levels;Circulating chemerin levels; chr7:150350112 chr7:150341771~150342607:+ CESC cis rs17695224 0.585 rs721890 ENSG00000268095.1 ZNF649-AS1 4.17 4.42e-05 0.0186 0.35 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51837808 chr19:51888025~51900463:+ CESC cis rs17695224 0.701 rs721889 ENSG00000268095.1 ZNF649-AS1 4.17 4.42e-05 0.0186 0.35 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51837996 chr19:51888025~51900463:+ CESC cis rs17695224 0.701 rs1468642 ENSG00000268095.1 ZNF649-AS1 4.17 4.42e-05 0.0186 0.35 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51838504 chr19:51888025~51900463:+ CESC cis rs10129255 0.912 rs8009135 ENSG00000280411.1 IGHV1-69-2 -4.17 4.43e-05 0.0186 -0.2 -0.27 Kawasaki disease; chr14:106777528 chr14:106762092~106762588:- CESC cis rs12908161 0.959 rs34342559 ENSG00000259728.4 LINC00933 4.17 4.43e-05 0.0186 0.35 0.27 Schizophrenia; chr15:84788040 chr15:84570649~84580175:+ CESC cis rs12908161 0.959 rs35557864 ENSG00000259728.4 LINC00933 4.17 4.43e-05 0.0186 0.35 0.27 Schizophrenia; chr15:84788398 chr15:84570649~84580175:+ CESC cis rs9595066 0.548 rs9562537 ENSG00000227258.4 SMIM2-AS1 4.17 4.43e-05 0.0186 0.42 0.27 Schizophrenia; chr13:44181651 chr13:44110451~44240517:+ CESC cis rs58873874 0.737 rs79339674 ENSG00000251405.2 CTB-109A12.1 4.17 4.43e-05 0.0186 0.69 0.27 Bipolar disorder (body mass index interaction); chr5:157464318 chr5:157362615~157460078:- CESC cis rs9487094 0.626 rs1980591 ENSG00000260273.1 RP11-425D10.10 4.17 4.43e-05 0.0186 0.34 0.27 Height; chr6:109618620 chr6:109382795~109383666:+ CESC cis rs9487094 0.696 rs12191353 ENSG00000260273.1 RP11-425D10.10 4.17 4.43e-05 0.0186 0.34 0.27 Height; chr6:109620772 chr6:109382795~109383666:+ CESC cis rs42490 0.664 rs39516 ENSG00000251136.7 RP11-37B2.1 -4.17 4.43e-05 0.0186 -0.28 -0.27 Leprosy; chr8:89822157 chr8:89609409~89757727:- CESC cis rs6928977 0.896 rs2614284 ENSG00000234084.1 RP3-388E23.2 4.17 4.44e-05 0.0186 0.25 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135368697 chr6:135301568~135307158:+ CESC cis rs7581030 0.583 rs2058896 ENSG00000281195.1 ZNF638-IT1 -4.17 4.44e-05 0.0186 -0.33 -0.27 Testicular germ cell tumor; chr2:71291041 chr2:71373938~71376320:+ CESC cis rs62097350 0.877 rs11659839 ENSG00000270469.1 RP11-411B10.8 4.17 4.44e-05 0.0187 0.53 0.27 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr18:13301558 chr18:14053951~14054761:+ CESC cis rs6693388 0.75 rs56313205 ENSG00000229021.2 AL591893.1 -4.17 4.44e-05 0.0187 -0.34 -0.27 Blood metabolite ratios; chr1:151931633 chr1:151994531~152042774:+ CESC cis rs55665837 1 rs34980103 ENSG00000251991.1 RNU7-49P 4.17 4.44e-05 0.0187 0.3 0.27 Vitamin D levels; chr11:14491339 chr11:14478892~14478953:+ CESC cis rs7208859 0.673 rs999798 ENSG00000264538.5 SUZ12P1 -4.17 4.44e-05 0.0187 -0.29 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831822 chr17:30709299~30790908:+ CESC cis rs2412819 0.571 rs678084 ENSG00000249839.1 AC011330.5 4.17 4.44e-05 0.0187 0.35 0.27 Lung cancer; chr15:43828361 chr15:43663654~43684339:- CESC cis rs10129255 0.5 rs2105991 ENSG00000224373.3 IGHV4-59 4.17 4.44e-05 0.0187 0.17 0.27 Kawasaki disease; chr14:106682022 chr14:106627249~106627825:- CESC cis rs919433 0.647 rs1979239 ENSG00000222017.1 AC011997.1 4.17 4.44e-05 0.0187 0.35 0.27 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197633592 chr2:197693106~197774823:+ CESC cis rs8059260 0.673 rs77240340 ENSG00000274038.1 RP11-66H6.4 -4.17 4.45e-05 0.0187 -0.49 -0.27 Alcohol consumption over the past year; chr16:10945778 chr16:11056556~11057034:+ CESC cis rs8020095 0.571 rs10138865 ENSG00000258561.1 RP11-72M17.1 -4.17 4.45e-05 0.0187 -0.41 -0.27 Depression (quantitative trait); chr14:67140085 chr14:66212810~66509394:- CESC cis rs7208859 0.673 rs999796 ENSG00000264538.5 SUZ12P1 -4.17 4.45e-05 0.0187 -0.3 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832386 chr17:30709299~30790908:+ CESC cis rs74394007 0.92 rs7617912 ENSG00000244515.1 KRT18P34 4.17 4.45e-05 0.0187 0.49 0.27 Total body bone mineral density; chr3:156858623 chr3:157162663~157163932:- CESC cis rs6928977 0.896 rs9321501 ENSG00000234084.1 RP3-388E23.2 4.17 4.45e-05 0.0187 0.24 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135320279 chr6:135301568~135307158:+ CESC cis rs10129255 0.5 rs10143242 ENSG00000224373.3 IGHV4-59 4.17 4.46e-05 0.0187 0.17 0.27 Kawasaki disease; chr14:106681814 chr14:106627249~106627825:- CESC cis rs6928977 0.896 rs2614285 ENSG00000234084.1 RP3-388E23.2 4.17 4.46e-05 0.0187 0.24 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135371480 chr6:135301568~135307158:+ CESC cis rs10129255 0.912 rs61997792 ENSG00000211974.3 IGHV2-70 4.17 4.46e-05 0.0187 0.3 0.27 Kawasaki disease; chr14:106799304 chr14:106723574~106724093:- CESC cis rs9487094 0.666 rs1074765 ENSG00000260273.1 RP11-425D10.10 -4.17 4.46e-05 0.0187 -0.33 -0.27 Height; chr6:109360458 chr6:109382795~109383666:+ CESC cis rs1501911 0.611 rs10041261 ENSG00000248489.1 CTD-2007H13.3 -4.17 4.46e-05 0.0187 -0.36 -0.27 Lung function (FEV1/FVC); chr5:99023435 chr5:98929171~98995013:+ CESC cis rs6439153 0.743 rs71331685 ENSG00000231305.3 RP11-723O4.2 4.17 4.46e-05 0.0187 0.26 0.27 Pneumococcal bacteremia; chr3:128992582 chr3:128861313~128871540:- CESC cis rs58873874 0.737 rs11739062 ENSG00000251405.2 CTB-109A12.1 4.17 4.46e-05 0.0187 0.7 0.27 Bipolar disorder (body mass index interaction); chr5:157474693 chr5:157362615~157460078:- CESC cis rs763121 0.853 rs5750649 ENSG00000273076.1 RP3-508I15.22 4.17 4.47e-05 0.0187 0.31 0.27 Menopause (age at onset); chr22:38640764 chr22:38743495~38743910:+ CESC cis rs763121 0.853 rs6519124 ENSG00000273076.1 RP3-508I15.22 4.17 4.47e-05 0.0187 0.31 0.27 Menopause (age at onset); chr22:38649094 chr22:38743495~38743910:+ CESC cis rs763121 0.853 rs5750652 ENSG00000273076.1 RP3-508I15.22 4.17 4.47e-05 0.0187 0.31 0.27 Menopause (age at onset); chr22:38652311 chr22:38743495~38743910:+ CESC cis rs2554380 0.6 rs6602986 ENSG00000230373.7 GOLGA6L5P -4.17 4.47e-05 0.0187 -0.34 -0.27 Height; chr15:83778347 chr15:84507885~84516814:- CESC cis rs3806843 0.576 rs405192 ENSG00000202111.1 VTRNA1-2 -4.17 4.47e-05 0.0187 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140945125 chr5:140718925~140719013:+ CESC cis rs7714670 0.871 rs12515096 ENSG00000184084.7 CTD-2372A4.1 -4.17 4.47e-05 0.0187 -0.31 -0.27 Venous thromboembolism (SNP x SNP interaction); chr5:73788505 chr5:73803296~73803599:- CESC cis rs2522056 1 rs2522054 ENSG00000233006.5 AC034220.3 -4.17 4.47e-05 0.0188 -0.35 -0.27 Fibrinogen;Lymphocyte counts; chr5:132463834 chr5:132311285~132369916:- CESC cis rs72634258 0.842 rs6668846 ENSG00000238249.2 HMGN2P17 4.17 4.47e-05 0.0188 0.3 0.27 Inflammatory bowel disease; chr1:8092042 chr1:8893409~8894151:+ CESC cis rs12468226 0.873 rs12470401 ENSG00000273456.1 RP11-686O6.2 4.17 4.47e-05 0.0188 0.35 0.27 Urate levels; chr2:202236436 chr2:202374932~202375604:- CESC cis rs12107539 1 rs11926145 ENSG00000240137.4 ERICH6-AS1 -4.17 4.48e-05 0.0188 -0.27 -0.27 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151302140 chr3:150703564~150720146:+ CESC cis rs11159086 1 rs4903233 ENSG00000259005.1 RP3-449M8.6 4.17 4.48e-05 0.0188 0.41 0.27 Advanced glycation end-product levels; chr14:74497291 chr14:74474007~74474864:- CESC cis rs12107539 1 rs6784934 ENSG00000240137.4 ERICH6-AS1 -4.17 4.48e-05 0.0188 -0.27 -0.27 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151321230 chr3:150703564~150720146:+ CESC cis rs12220238 0.822 rs10824160 ENSG00000213731.2 RAB5CP1 -4.17 4.48e-05 0.0188 -0.44 -0.27 Soluble interleukin-2 receptor subunit alpha; chr10:74372509 chr10:74423435~74424014:- CESC cis rs12220238 0.915 rs10824164 ENSG00000213731.2 RAB5CP1 -4.17 4.48e-05 0.0188 -0.44 -0.27 Soluble interleukin-2 receptor subunit alpha; chr10:74377274 chr10:74423435~74424014:- CESC cis rs71403859 0.502 rs34766979 ENSG00000260886.1 TAT-AS1 4.17 4.48e-05 0.0188 0.43 0.27 Post bronchodilator FEV1; chr16:71441608 chr16:71565789~71578187:+ CESC cis rs9322193 0.884 rs9322210 ENSG00000216906.2 RP11-350J20.9 4.17 4.49e-05 0.0188 0.3 0.27 Lung cancer; chr6:149695440 chr6:149904243~149906418:+ CESC cis rs1598856 1 rs93059 ENSG00000246560.2 RP11-10L12.4 4.16 4.49e-05 0.0188 0.33 0.27 Primary biliary cholangitis; chr4:102547361 chr4:102828055~102844075:+ CESC cis rs12935418 0.887 rs3743503 ENSG00000261838.4 RP11-303E16.6 4.16 4.49e-05 0.0188 0.5 0.27 Mean corpuscular volume; chr16:81022836 chr16:81069854~81076598:+ CESC cis rs2243480 1 rs781157 ENSG00000232559.3 GS1-124K5.12 4.16 4.49e-05 0.0188 0.45 0.27 Diabetic kidney disease; chr7:66013324 chr7:66554588~66576923:- CESC cis rs875971 0.502 rs6460311 ENSG00000236529.1 RP13-254B10.1 -4.16 4.49e-05 0.0188 -0.35 -0.27 Aortic root size; chr7:66646886 chr7:65840212~65840596:+ CESC cis rs3750965 0.959 rs4930265 ENSG00000260895.1 RP11-554A11.7 4.16 4.49e-05 0.0188 0.34 0.27 Hair color; chr11:69088486 chr11:69103493~69109094:+ CESC cis rs10844706 0.666 rs10844609 ENSG00000256594.6 RP11-705C15.2 4.16 4.49e-05 0.0188 0.32 0.27 Lymphocyte counts;Lymphocyte percentage of white cells; chr12:9723909 chr12:9633419~9658412:+ CESC cis rs4713118 0.662 rs9380046 ENSG00000219392.1 RP1-265C24.5 -4.16 4.49e-05 0.0188 -0.36 -0.27 Parkinson's disease; chr6:28062721 chr6:28115628~28116551:+ CESC cis rs9322193 0.887 rs3777949 ENSG00000216906.2 RP11-350J20.9 4.16 4.5e-05 0.0188 0.3 0.27 Lung cancer; chr6:149596021 chr6:149904243~149906418:+ CESC cis rs11779988 0.545 rs208759 ENSG00000253671.1 RP11-806O11.1 -4.16 4.5e-05 0.0188 -0.32 -0.27 Breast cancer; chr8:17950420 chr8:17808941~17820868:+ CESC cis rs875971 0.862 rs709596 ENSG00000232559.3 GS1-124K5.12 4.16 4.5e-05 0.0189 0.29 0.27 Aortic root size; chr7:66360926 chr7:66554588~66576923:- CESC cis rs2015599 0.549 rs7956305 ENSG00000257176.2 RP11-996F15.2 4.16 4.5e-05 0.0189 0.32 0.27 Platelet count;Mean platelet volume; chr12:29308639 chr12:29280418~29317848:- CESC cis rs2015599 0.543 rs6487807 ENSG00000257176.2 RP11-996F15.2 4.16 4.5e-05 0.0189 0.32 0.27 Platelet count;Mean platelet volume; chr12:29309291 chr12:29280418~29317848:- CESC cis rs3738443 0.817 rs6698690 ENSG00000259865.1 RP11-488L18.10 4.16 4.5e-05 0.0189 0.29 0.27 Alcohol dependence; chr1:247199176 chr1:247187281~247188526:- CESC cis rs7951870 1 rs60722866 ENSG00000247675.5 LRP4-AS1 -4.16 4.5e-05 0.0189 -0.35 -0.27 Schizophrenia; chr11:46628888 chr11:46846412~46874396:+ CESC cis rs6142102 0.961 rs8119937 ENSG00000276073.1 RP5-1125A11.7 -4.16 4.5e-05 0.0189 -0.25 -0.27 Skin pigmentation; chr20:34057745 chr20:33985617~33988989:- CESC cis rs9813712 0.595 rs1901787 ENSG00000228252.7 COL6A4P2 4.16 4.5e-05 0.0189 0.34 0.27 Response to amphetamines; chr3:130288678 chr3:130212823~130273806:+ CESC cis rs9813712 0.547 rs6807290 ENSG00000228252.7 COL6A4P2 4.16 4.5e-05 0.0189 0.34 0.27 Response to amphetamines; chr3:130297952 chr3:130212823~130273806:+ CESC cis rs9517320 1 rs12864890 ENSG00000231194.1 FARP1-AS1 4.16 4.51e-05 0.0189 0.31 0.27 Longevity; chr13:98474203 chr13:98435405~98435840:- CESC cis rs748404 0.666 rs34178146 ENSG00000249839.1 AC011330.5 -4.16 4.51e-05 0.0189 -0.39 -0.27 Lung cancer; chr15:43384406 chr15:43663654~43684339:- CESC cis rs8072100 0.79 rs34200664 ENSG00000228782.6 CTD-2026D20.3 -4.16 4.51e-05 0.0189 -0.33 -0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47667286 chr17:47450568~47492492:- CESC cis rs6991838 0.806 rs4285523 ENSG00000272010.1 CTD-3025N20.3 4.16 4.51e-05 0.0189 0.3 0.27 Intelligence (multi-trait analysis); chr8:65552095 chr8:65591850~65592472:- CESC cis rs1538970 0.961 rs7543428 ENSG00000280836.1 AL355480.1 -4.16 4.52e-05 0.0189 -0.33 -0.27 Platelet count; chr1:45373971 chr1:45581219~45581321:- CESC cis rs1707322 1 rs7532204 ENSG00000281133.1 AL355480.3 4.16 4.52e-05 0.0189 0.32 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46019403 chr1:45580892~45580996:- CESC cis rs1707322 0.835 rs946525 ENSG00000281133.1 AL355480.3 4.16 4.52e-05 0.0189 0.32 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46021605 chr1:45580892~45580996:- CESC cis rs1707322 1 rs946524 ENSG00000281133.1 AL355480.3 4.16 4.52e-05 0.0189 0.32 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46021888 chr1:45580892~45580996:- CESC cis rs7811142 0.83 rs11768967 ENSG00000242294.5 STAG3L5P 4.16 4.52e-05 0.0189 0.26 0.27 Platelet count; chr7:100370021 chr7:100336079~100351900:+ CESC cis rs987710 1 rs987710 ENSG00000211639.2 IGLV4-60 -4.16 4.52e-05 0.0189 -0.26 -0.27 Iron status biomarkers;Iron deficiency; chr22:22158022 chr22:22162199~22162681:+ CESC cis rs3806843 0.576 rs246066 ENSG00000202111.1 VTRNA1-2 -4.16 4.52e-05 0.0189 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140943562 chr5:140718925~140719013:+ CESC cis rs897984 0.644 rs73524556 ENSG00000260911.2 RP11-196G11.2 4.16 4.53e-05 0.019 0.27 0.27 Dementia with Lewy bodies; chr16:30811841 chr16:31043150~31049868:+ CESC cis rs9640161 0.789 rs28432021 ENSG00000261305.1 RP4-584D14.7 4.16 4.53e-05 0.019 0.39 0.27 Blood protein levels;Circulating chemerin levels; chr7:150349146 chr7:150341771~150342607:+ CESC cis rs2117029 1 rs3782357 ENSG00000258017.1 RP11-386G11.10 -4.16 4.53e-05 0.019 -0.36 -0.27 Intelligence (multi-trait analysis); chr12:49033869 chr12:49127782~49147869:+ CESC cis rs875971 0.545 rs6969224 ENSG00000237310.1 GS1-124K5.4 4.16 4.53e-05 0.019 0.31 0.27 Aortic root size; chr7:66370011 chr7:66493706~66495474:+ CESC cis rs673078 0.607 rs73207564 ENSG00000275759.1 RP11-131L12.3 -4.16 4.54e-05 0.019 -0.52 -0.27 Glucose homeostasis traits; chr12:118429566 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943447 ENSG00000275759.1 RP11-131L12.3 -4.16 4.54e-05 0.019 -0.52 -0.27 Glucose homeostasis traits; chr12:118430598 chr12:118428281~118428870:+ CESC cis rs7927592 0.871 rs871212 ENSG00000212093.1 AP000807.1 4.16 4.54e-05 0.019 0.31 0.27 Total body bone mineral density; chr11:68581227 chr11:68506083~68506166:- CESC cis rs7927592 1 rs7927592 ENSG00000212093.1 AP000807.1 4.16 4.54e-05 0.019 0.31 0.27 Total body bone mineral density; chr11:68602492 chr11:68506083~68506166:- CESC cis rs8177876 0.57 rs11863158 ENSG00000261838.4 RP11-303E16.6 4.16 4.54e-05 0.019 0.52 0.27 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81034525 chr16:81069854~81076598:+ CESC cis rs8177876 0.658 rs11150337 ENSG00000261838.4 RP11-303E16.6 4.16 4.54e-05 0.019 0.52 0.27 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81035712 chr16:81069854~81076598:+ CESC cis rs919433 0.679 rs10497806 ENSG00000222017.1 AC011997.1 4.16 4.54e-05 0.019 0.35 0.27 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197644227 chr2:197693106~197774823:+ CESC cis rs6001482 0.679 rs8142710 ENSG00000236850.4 BMS1P20 -4.16 4.54e-05 0.019 -0.27 -0.27 Diastolic blood pressure; chr22:22233044 chr22:22303224~22322847:+ CESC cis rs2115630 0.645 rs4842978 ENSG00000225151.9 GOLGA2P7 4.16 4.54e-05 0.019 0.31 0.27 P wave terminal force; chr15:84654022 chr15:84199311~84230136:- CESC cis rs9322193 0.923 rs9767554 ENSG00000268592.3 RAET1E-AS1 4.16 4.54e-05 0.019 0.34 0.27 Lung cancer; chr6:149616860 chr6:149863494~149919507:+ CESC cis rs2243480 1 rs35421653 ENSG00000164669.11 INTS4P1 4.16 4.54e-05 0.019 0.57 0.27 Diabetic kidney disease; chr7:65898442 chr7:65141225~65234216:+ CESC cis rs2836950 0.545 rs2836956 ENSG00000232608.1 TIMM9P2 -4.16 4.55e-05 0.019 -0.3 -0.27 Menarche (age at onset); chr21:39251092 chr21:39216624~39217506:+ CESC cis rs860295 0.729 rs4971072 ENSG00000225855.5 RUSC1-AS1 -4.16 4.55e-05 0.019 -0.21 -0.27 Body mass index; chr1:155304078 chr1:155316863~155324176:- CESC cis rs12468226 0.873 rs59293950 ENSG00000273456.1 RP11-686O6.2 4.16 4.56e-05 0.019 0.36 0.27 Urate levels; chr2:202214069 chr2:202374932~202375604:- CESC cis rs9640161 0.711 rs3735170 ENSG00000261305.1 RP4-584D14.7 4.16 4.56e-05 0.0191 0.38 0.27 Blood protein levels;Circulating chemerin levels; chr7:150337095 chr7:150341771~150342607:+ CESC cis rs9640161 0.75 rs3735169 ENSG00000261305.1 RP4-584D14.7 4.16 4.56e-05 0.0191 0.38 0.27 Blood protein levels;Circulating chemerin levels; chr7:150337289 chr7:150341771~150342607:+ CESC cis rs2439831 0.85 rs2439832 ENSG00000275601.1 AC011330.13 -4.16 4.56e-05 0.0191 -0.36 -0.27 Lung cancer in ever smokers; chr15:43487488 chr15:43642389~43643023:- CESC cis rs12745968 0.62 rs11164607 ENSG00000223787.2 RP4-593M8.1 -4.16 4.56e-05 0.0191 -0.37 -0.27 Bipolar disorder and schizophrenia; chr1:92481581 chr1:92580476~92580821:- CESC cis rs2235544 0.639 rs6672989 ENSG00000225183.1 RP4-758J24.4 -4.16 4.56e-05 0.0191 -0.31 -0.27 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54008799 chr1:54089856~54090093:+ CESC cis rs6687821 0.5 rs6703683 ENSG00000267734.1 RP4-604K5.3 -4.16 4.57e-05 0.0191 -0.33 -0.27 Yeast infection; chr1:87042656 chr1:86932199~86934891:- CESC cis rs875971 1 rs6945843 ENSG00000179406.6 LINC00174 4.16 4.57e-05 0.0191 0.29 0.27 Aortic root size; chr7:66269796 chr7:66376044~66401338:- CESC cis rs875971 0.545 rs6950988 ENSG00000236529.1 RP13-254B10.1 4.16 4.57e-05 0.0191 0.33 0.27 Aortic root size; chr7:66511428 chr7:65840212~65840596:+ CESC cis rs13434995 0.635 rs1818461 ENSG00000273257.1 RP11-177J6.1 -4.16 4.57e-05 0.0191 -0.4 -0.27 Adiponectin levels; chr4:55379156 chr4:55387949~55388271:+ CESC cis rs6110809 0.542 rs6135565 ENSG00000273998.1 RP4-777L9.2 -4.16 4.58e-05 0.0191 -0.51 -0.27 Thyroid-associated orbitopathy in graves' disease; chr20:15831630 chr20:16576068~16579615:+ CESC cis rs9309473 0.847 rs4547554 ENSG00000163016.8 ALMS1P 4.16 4.58e-05 0.0191 0.37 0.27 Metabolite levels; chr2:73640735 chr2:73644919~73685576:+ CESC cis rs9309473 0.847 rs13538 ENSG00000163016.8 ALMS1P 4.16 4.58e-05 0.0191 0.37 0.27 Metabolite levels; chr2:73641201 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs13431529 ENSG00000163016.8 ALMS1P 4.16 4.58e-05 0.0191 0.37 0.27 Metabolite levels; chr2:73648914 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs13408433 ENSG00000163016.8 ALMS1P 4.16 4.58e-05 0.0191 0.37 0.27 Metabolite levels; chr2:73655945 chr2:73644919~73685576:+ CESC cis rs12107539 0.846 rs7428575 ENSG00000240137.4 ERICH6-AS1 -4.16 4.58e-05 0.0191 -0.26 -0.27 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151356835 chr3:150703564~150720146:+ CESC cis rs897984 0.683 rs13337900 ENSG00000260911.2 RP11-196G11.2 4.16 4.58e-05 0.0191 0.27 0.27 Dementia with Lewy bodies; chr16:30811088 chr16:31043150~31049868:+ CESC cis rs875971 0.545 rs7810213 ENSG00000237310.1 GS1-124K5.4 4.16 4.58e-05 0.0191 0.31 0.27 Aortic root size; chr7:66481592 chr7:66493706~66495474:+ CESC cis rs9322193 0.923 rs7767622 ENSG00000216906.2 RP11-350J20.9 4.16 4.59e-05 0.0192 0.3 0.27 Lung cancer; chr6:149681766 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs4421206 ENSG00000216906.2 RP11-350J20.9 4.16 4.59e-05 0.0192 0.3 0.27 Lung cancer; chr6:149682891 chr6:149904243~149906418:+ CESC cis rs4470914 0.825 rs57176772 ENSG00000237921.2 AC004543.2 4.16 4.59e-05 0.0192 0.41 0.27 Height; chr7:19592972 chr7:19813685~19818090:- CESC cis rs4072705 0.615 rs7851737 ENSG00000224020.1 MIR181A2HG 4.16 4.59e-05 0.0192 0.34 0.27 Menarche (age at onset); chr9:124485652 chr9:124658467~124698631:+ CESC cis rs881375 0.669 rs73541868 ENSG00000226752.6 PSMD5-AS1 -4.16 4.59e-05 0.0192 -0.28 -0.27 Rheumatoid arthritis; chr9:120876986 chr9:120824828~120854385:+ CESC cis rs453301 0.571 rs2929456 ENSG00000173295.6 FAM86B3P -4.16 4.59e-05 0.0192 -0.34 -0.27 Joint mobility (Beighton score); chr8:9225906 chr8:8228595~8244865:+ CESC cis rs1012068 0.924 rs5994449 ENSG00000236132.1 CTA-440B3.1 -4.16 4.59e-05 0.0192 -0.32 -0.27 Chronic hepatitis C infection; chr22:31908193 chr22:31816379~31817491:- CESC cis rs1012068 0.924 rs5998173 ENSG00000236132.1 CTA-440B3.1 -4.16 4.59e-05 0.0192 -0.32 -0.27 Chronic hepatitis C infection; chr22:31909985 chr22:31816379~31817491:- CESC cis rs17507216 0.718 rs7161977 ENSG00000255769.6 GOLGA2P10 -4.16 4.59e-05 0.0192 -0.42 -0.27 Excessive daytime sleepiness; chr15:82646782 chr15:82472993~82513950:- CESC cis rs9532669 0.963 rs4941391 ENSG00000176268.5 CYCSP34 4.16 4.59e-05 0.0192 0.28 0.27 Cervical cancer; chr13:40939787 chr13:40863599~40863902:- CESC cis rs3124314 1 rs3124315 ENSG00000229021.2 AL591893.1 -4.16 4.59e-05 0.0192 -0.3 -0.27 Hair morphology; chr1:152067235 chr1:151994531~152042774:+ CESC cis rs17695224 0.5 rs4802877 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51831991 chr19:51888025~51900463:+ CESC cis rs17695224 0.52 rs4801898 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51832064 chr19:51888025~51900463:+ CESC cis rs17695224 0.545 rs17761960 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51832275 chr19:51888025~51900463:+ CESC cis rs17695224 0.565 rs7248523 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51833888 chr19:51888025~51900463:+ CESC cis rs17695224 0.585 rs10406893 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51833901 chr19:51888025~51900463:+ CESC cis rs17695224 0.545 rs10406732 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51833974 chr19:51888025~51900463:+ CESC cis rs17695224 0.519 rs2159654 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51834004 chr19:51888025~51900463:+ CESC cis rs17695224 0.5 rs2159655 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51834006 chr19:51888025~51900463:+ CESC cis rs17695224 0.527 rs2903546 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51834082 chr19:51888025~51900463:+ CESC cis rs17695224 0.527 rs7250063 ENSG00000268095.1 ZNF649-AS1 4.16 4.6e-05 0.0192 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51834447 chr19:51888025~51900463:+ CESC cis rs34286592 0.929 rs8058824 ENSG00000214725.6 CDIPT-AS1 -4.16 4.6e-05 0.0192 -0.49 -0.27 Multiple sclerosis; chr16:29817389 chr16:29863593~29868053:+ CESC cis rs4819052 0.679 rs4819053 ENSG00000223768.1 LINC00205 4.16 4.61e-05 0.0192 0.3 0.27 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45291442 chr21:45293285~45297354:+ CESC cis rs11976180 1 rs1320893 ENSG00000273234.1 OR2A13P -4.16 4.61e-05 0.0192 -0.31 -0.27 Obesity-related traits; chr7:144055019 chr7:144142009~144142938:+ CESC cis rs875971 0.862 rs28470208 ENSG00000232559.3 GS1-124K5.12 -4.16 4.61e-05 0.0192 -0.3 -0.27 Aortic root size; chr7:66119713 chr7:66554588~66576923:- CESC cis rs12107539 0.958 rs10513391 ENSG00000240137.4 ERICH6-AS1 4.16 4.61e-05 0.0192 0.27 0.27 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151266639 chr3:150703564~150720146:+ CESC cis rs1707322 0.964 rs6675259 ENSG00000281133.1 AL355480.3 4.16 4.62e-05 0.0193 0.33 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46036623 chr1:45580892~45580996:- CESC cis rs7617773 0.817 rs9830016 ENSG00000228638.1 FCF1P2 -4.16 4.62e-05 0.0193 -0.27 -0.27 Coronary artery disease; chr3:48241004 chr3:48290793~48291375:- CESC cis rs12908161 1 rs17601029 ENSG00000225151.9 GOLGA2P7 -4.16 4.62e-05 0.0193 -0.37 -0.27 Schizophrenia; chr15:84804478 chr15:84199311~84230136:- CESC cis rs2274273 0.6 rs35112084 ENSG00000258413.1 RP11-665C16.6 -4.16 4.62e-05 0.0193 -0.35 -0.27 Protein biomarker; chr14:55314382 chr14:55262767~55272075:- CESC cis rs10875746 0.551 rs3185921 ENSG00000240399.1 RP1-228P16.1 -4.16 4.63e-05 0.0193 -0.35 -0.27 Longevity (90 years and older); chr12:48340948 chr12:48054813~48055591:- CESC cis rs748404 0.65 rs518234 ENSG00000249839.1 AC011330.5 -4.16 4.63e-05 0.0193 -0.28 -0.27 Lung cancer; chr15:43281223 chr15:43663654~43684339:- CESC cis rs748404 0.65 rs518261 ENSG00000249839.1 AC011330.5 -4.16 4.63e-05 0.0193 -0.28 -0.27 Lung cancer; chr15:43281231 chr15:43663654~43684339:- CESC cis rs748404 0.723 rs11853991 ENSG00000249839.1 AC011330.5 -4.16 4.63e-05 0.0193 -0.32 -0.27 Lung cancer; chr15:43265351 chr15:43663654~43684339:- CESC cis rs7614311 0.594 rs3774709 ENSG00000271843.1 RP11-245J9.5 -4.16 4.64e-05 0.0193 -0.37 -0.27 Lung function (FVC);Lung function (FEV1); chr3:63896800 chr3:64008082~64008692:- CESC cis rs11168618 1 rs12815544 ENSG00000257735.1 RP11-370I10.6 4.16 4.64e-05 0.0193 0.3 0.27 Adiponectin levels; chr12:48555825 chr12:48350945~48442411:+ CESC cis rs4319547 0.656 rs9788145 ENSG00000275265.1 RP11-15J22.8 -4.16 4.64e-05 0.0193 -0.38 -0.27 Body mass index; chr12:122414975 chr12:122501187~122501641:+ CESC cis rs1799949 0.965 rs9646413 ENSG00000267681.1 CTD-3199J23.6 -4.16 4.64e-05 0.0193 -0.34 -0.27 Menopause (age at onset); chr17:43348789 chr17:43144956~43145255:+ CESC cis rs10829156 0.66 rs7918933 ENSG00000240291.1 RP11-499P20.2 4.16 4.64e-05 0.0193 0.3 0.27 Sudden cardiac arrest; chr10:18517434 chr10:18513115~18545651:- CESC cis rs62355901 0.609 rs66893416 ENSG00000271828.1 CTD-2310F14.1 4.16 4.64e-05 0.0193 0.37 0.27 Breast cancer; chr5:56755769 chr5:56927874~56929573:+ CESC cis rs944801 0.566 rs10965215 ENSG00000277653.1 CDKN2B-AS -4.16 4.65e-05 0.0194 -0.25 -0.27 Type 2 diabetes; chr9:22029446 chr9:22117665~22117814:+ CESC cis rs2243480 1 rs3885839 ENSG00000275400.1 RP4-756H11.5 4.16 4.65e-05 0.0194 0.45 0.27 Diabetic kidney disease; chr7:65825416 chr7:66553805~66554199:- CESC cis rs2439831 0.867 rs2255440 ENSG00000275601.1 AC011330.13 -4.16 4.65e-05 0.0194 -0.37 -0.27 Lung cancer in ever smokers; chr15:43538269 chr15:43642389~43643023:- CESC cis rs2412819 0.597 rs514311 ENSG00000249839.1 AC011330.5 -4.16 4.65e-05 0.0194 -0.35 -0.27 Lung cancer; chr15:43869376 chr15:43663654~43684339:- CESC cis rs2412819 0.571 rs495880 ENSG00000249839.1 AC011330.5 4.16 4.65e-05 0.0194 0.35 0.27 Lung cancer; chr15:43855067 chr15:43663654~43684339:- CESC cis rs7809950 1 rs2808 ENSG00000238832.1 snoU109 4.16 4.65e-05 0.0194 0.33 0.27 Coronary artery disease; chr7:107620411 chr7:107603363~107603507:+ CESC cis rs7809950 1 rs10274041 ENSG00000238832.1 snoU109 4.16 4.65e-05 0.0194 0.33 0.27 Coronary artery disease; chr7:107621111 chr7:107603363~107603507:+ CESC cis rs9513627 1 rs7338537 ENSG00000228889.5 UBAC2-AS1 4.16 4.66e-05 0.0194 0.47 0.27 Obesity-related traits; chr13:99467327 chr13:99196377~99200710:- CESC cis rs9513627 1 rs7338761 ENSG00000228889.5 UBAC2-AS1 4.16 4.66e-05 0.0194 0.47 0.27 Obesity-related traits; chr13:99467477 chr13:99196377~99200710:- CESC cis rs9513627 1 rs7317330 ENSG00000228889.5 UBAC2-AS1 4.16 4.66e-05 0.0194 0.47 0.27 Obesity-related traits; chr13:99467622 chr13:99196377~99200710:- CESC cis rs8020095 0.571 rs10141947 ENSG00000258561.1 RP11-72M17.1 -4.16 4.66e-05 0.0194 -0.41 -0.27 Depression (quantitative trait); chr14:67075961 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs9323493 ENSG00000258561.1 RP11-72M17.1 -4.16 4.66e-05 0.0194 -0.41 -0.27 Depression (quantitative trait); chr14:67079463 chr14:66212810~66509394:- CESC cis rs9309473 1 rs2056486 ENSG00000163016.8 ALMS1P 4.16 4.66e-05 0.0194 0.34 0.27 Metabolite levels; chr2:73490440 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs10193972 ENSG00000163016.8 ALMS1P 4.16 4.66e-05 0.0194 0.34 0.27 Metabolite levels; chr2:73490529 chr2:73644919~73685576:+ CESC cis rs875971 1 rs9986696 ENSG00000237310.1 GS1-124K5.4 -4.16 4.67e-05 0.0194 -0.25 -0.27 Aortic root size; chr7:66239589 chr7:66493706~66495474:+ CESC cis rs8059260 0.545 rs2286972 ENSG00000274038.1 RP11-66H6.4 -4.16 4.67e-05 0.0194 -0.42 -0.27 Alcohol consumption over the past year; chr16:11061141 chr16:11056556~11057034:+ CESC cis rs11638352 1 rs12900880 ENSG00000275601.1 AC011330.13 4.16 4.67e-05 0.0194 0.47 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44047400 chr15:43642389~43643023:- CESC cis rs875971 0.964 rs6945019 ENSG00000237310.1 GS1-124K5.4 4.16 4.67e-05 0.0194 0.26 0.27 Aortic root size; chr7:66457471 chr7:66493706~66495474:+ CESC cis rs7714584 1 rs4958852 ENSG00000197083.10 ZNF300P1 4.16 4.67e-05 0.0194 0.61 0.27 Crohn's disease; chr5:150951069 chr5:150930645~150946289:- CESC cis rs526231 0.697 rs253754 ENSG00000175749.11 EIF3KP1 4.16 4.67e-05 0.0194 0.35 0.27 Primary biliary cholangitis; chr5:103296261 chr5:103032376~103033031:+ CESC cis rs897984 0.683 rs8046001 ENSG00000260911.2 RP11-196G11.2 4.15 4.68e-05 0.0195 0.28 0.27 Dementia with Lewy bodies; chr16:30822000 chr16:31043150~31049868:+ CESC cis rs7829975 0.582 rs448231 ENSG00000254340.1 RP11-10A14.3 -4.15 4.68e-05 0.0195 -0.33 -0.27 Mood instability; chr8:8932549 chr8:9141424~9145435:+ CESC cis rs4713118 0.662 rs149970 ENSG00000219392.1 RP1-265C24.5 -4.15 4.68e-05 0.0195 -0.33 -0.27 Parkinson's disease; chr6:28012442 chr6:28115628~28116551:+ CESC cis rs7580658 0.724 rs4662711 ENSG00000236682.1 AC068282.3 -4.15 4.68e-05 0.0195 -0.33 -0.27 Protein C levels; chr2:127233264 chr2:127389130~127400580:+ CESC cis rs4072705 0.586 rs7869042 ENSG00000224020.1 MIR181A2HG 4.15 4.68e-05 0.0195 0.34 0.27 Menarche (age at onset); chr9:124484472 chr9:124658467~124698631:+ CESC cis rs10413103 0.657 rs4805867 ENSG00000242325.1 RPS12P31 4.15 4.68e-05 0.0195 0.36 0.27 Granulocyte percentage of myeloid white cells; chr19:33271351 chr19:32636078~32636475:+ CESC cis rs7637701 0.818 rs11717133 ENSG00000240875.4 LINC00886 -4.15 4.68e-05 0.0195 -0.34 -0.27 Breast cancer; chr3:156816792 chr3:156747346~156817062:- CESC cis rs77972916 0.505 rs11899984 ENSG00000234936.1 AC010883.5 4.15 4.68e-05 0.0195 0.3 0.27 Granulocyte percentage of myeloid white cells; chr2:43351107 chr2:43229573~43233394:+ CESC cis rs523522 0.962 rs10849759 ENSG00000278344.1 RP11-18C24.8 4.15 4.69e-05 0.0195 0.33 0.27 High light scatter reticulocyte count; chr12:120556685 chr12:120500735~120501090:- CESC cis rs11159086 1 rs11159086 ENSG00000270000.1 RP3-449M8.9 4.15 4.69e-05 0.0195 0.47 0.27 Advanced glycation end-product levels; chr14:74495572 chr14:74471930~74472360:- CESC cis rs6693388 0.918 rs11204920 ENSG00000229021.2 AL591893.1 -4.15 4.69e-05 0.0195 -0.32 -0.27 Blood metabolite ratios; chr1:151961486 chr1:151994531~152042774:+ CESC cis rs5758659 0.594 rs739292 ENSG00000273366.1 CTA-989H11.1 -4.15 4.69e-05 0.0195 -0.34 -0.27 Cognitive function; chr22:41972853 chr22:42278188~42278846:+ CESC cis rs62025270 0.576 rs62022947 ENSG00000202081.1 RNU6-1280P -4.15 4.7e-05 0.0195 -0.36 -0.27 Idiopathic pulmonary fibrosis; chr15:85728091 chr15:85651522~85651628:- CESC cis rs6163 0.508 rs11191381 ENSG00000236937.2 PTGES3P4 4.15 4.7e-05 0.0195 0.39 0.27 Waist circumference;Hip circumference; chr10:102733687 chr10:102845595~102845950:+ CESC cis rs6163 0.54 rs11191385 ENSG00000236937.2 PTGES3P4 4.15 4.7e-05 0.0195 0.39 0.27 Waist circumference;Hip circumference; chr10:102753292 chr10:102845595~102845950:+ CESC cis rs131777 0.532 rs131747 ENSG00000205559.3 CHKB-AS1 -4.15 4.7e-05 0.0195 -0.31 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586645 chr22:50583026~50583877:+ CESC cis rs853679 0.517 rs1947862 ENSG00000219392.1 RP1-265C24.5 -4.15 4.7e-05 0.0195 -0.36 -0.27 Depression; chr6:28137418 chr6:28115628~28116551:+ CESC cis rs6504622 0.935 rs17608961 ENSG00000263142.4 LRRC37A17P -4.15 4.7e-05 0.0195 -0.22 -0.27 Orofacial clefts; chr17:46952302 chr17:46978481~47054569:+ CESC cis rs10129255 0.957 rs8009948 ENSG00000211974.3 IGHV2-70 4.15 4.7e-05 0.0195 0.31 0.27 Kawasaki disease; chr14:106805607 chr14:106723574~106724093:- CESC cis rs6604026 0.589 rs11800848 ENSG00000223787.2 RP4-593M8.1 4.15 4.7e-05 0.0195 0.37 0.27 Multiple sclerosis; chr1:92662370 chr1:92580476~92580821:- CESC cis rs769267 0.965 rs12977937 ENSG00000269131.1 AC004447.2 -4.15 4.7e-05 0.0195 -0.22 -0.27 Tonsillectomy; chr19:19319166 chr19:18990893~18993610:+ CESC cis rs2404602 0.583 rs12908334 ENSG00000280730.1 AC090181.1 4.15 4.7e-05 0.0195 0.21 0.27 Blood metabolite levels; chr15:76289251 chr15:77056895~77057021:+ CESC cis rs11159086 1 rs58384818 ENSG00000270000.1 RP3-449M8.9 4.15 4.7e-05 0.0195 0.5 0.27 Advanced glycation end-product levels; chr14:74487045 chr14:74471930~74472360:- CESC cis rs11159086 1 rs17100588 ENSG00000270000.1 RP3-449M8.9 4.15 4.7e-05 0.0195 0.5 0.27 Advanced glycation end-product levels; chr14:74487624 chr14:74471930~74472360:- CESC cis rs11155671 0.53 rs7763849 ENSG00000223701.3 RAET1E-AS1 4.15 4.71e-05 0.0195 0.3 0.27 Testicular germ cell tumor; chr6:149885244 chr6:149884431~149919508:+ CESC cis rs11159086 1 rs11159086 ENSG00000259005.1 RP3-449M8.6 4.15 4.71e-05 0.0196 0.42 0.27 Advanced glycation end-product levels; chr14:74495572 chr14:74474007~74474864:- CESC cis rs1707322 0.964 rs10890358 ENSG00000281133.1 AL355480.3 -4.15 4.71e-05 0.0196 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853353 chr1:45580892~45580996:- CESC cis rs2283792 0.812 rs240064 ENSG00000224086.5 LL22NC03-86G7.1 4.15 4.71e-05 0.0196 0.3 0.27 Multiple sclerosis; chr22:21927265 chr22:21938293~21977632:+ CESC cis rs748404 0.697 rs530188 ENSG00000249839.1 AC011330.5 -4.15 4.71e-05 0.0196 -0.28 -0.27 Lung cancer; chr15:43253116 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs475227 ENSG00000249839.1 AC011330.5 -4.15 4.71e-05 0.0196 -0.28 -0.27 Lung cancer; chr15:43254248 chr15:43663654~43684339:- CESC cis rs13108904 0.775 rs2279282 ENSG00000254094.1 AC078852.1 -4.15 4.71e-05 0.0196 -0.32 -0.27 Obesity-related traits; chr4:1222245 chr4:1356581~1358075:+ CESC cis rs2243480 0.901 rs57126451 ENSG00000232559.3 GS1-124K5.12 4.15 4.71e-05 0.0196 0.44 0.27 Diabetic kidney disease; chr7:65951319 chr7:66554588~66576923:- CESC cis rs944801 0.565 rs8181047 ENSG00000240498.5 CDKN2B-AS1 4.15 4.71e-05 0.0196 0.28 0.27 Type 2 diabetes; chr9:22064466 chr9:21994778~22121097:+ CESC cis rs9309473 0.948 rs2421550 ENSG00000163016.8 ALMS1P 4.15 4.72e-05 0.0196 0.34 0.27 Metabolite levels; chr2:73431558 chr2:73644919~73685576:+ CESC cis rs2243480 1 rs73150014 ENSG00000275400.1 RP4-756H11.5 4.15 4.72e-05 0.0196 0.45 0.27 Diabetic kidney disease; chr7:65985932 chr7:66553805~66554199:- CESC cis rs2243480 1 rs1723270 ENSG00000275400.1 RP4-756H11.5 4.15 4.72e-05 0.0196 0.45 0.27 Diabetic kidney disease; chr7:66004843 chr7:66553805~66554199:- CESC cis rs2243480 1 rs35396113 ENSG00000275400.1 RP4-756H11.5 4.15 4.72e-05 0.0196 0.45 0.27 Diabetic kidney disease; chr7:66030474 chr7:66553805~66554199:- CESC cis rs58873874 0.737 rs75326191 ENSG00000251405.2 CTB-109A12.1 4.15 4.72e-05 0.0196 0.7 0.27 Bipolar disorder (body mass index interaction); chr5:157445797 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs75022277 ENSG00000251405.2 CTB-109A12.1 4.15 4.72e-05 0.0196 0.7 0.27 Bipolar disorder (body mass index interaction); chr5:157454954 chr5:157362615~157460078:- CESC cis rs7176527 0.8 rs56747535 ENSG00000229212.6 RP11-561C5.4 4.15 4.72e-05 0.0196 0.35 0.27 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84632709 chr15:85205440~85234795:- CESC cis rs8020095 0.528 rs2064489 ENSG00000258561.1 RP11-72M17.1 -4.15 4.72e-05 0.0196 -0.4 -0.27 Depression (quantitative trait); chr14:67009780 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs10133107 ENSG00000258561.1 RP11-72M17.1 -4.15 4.72e-05 0.0196 -0.4 -0.27 Depression (quantitative trait); chr14:67010147 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs1955606 ENSG00000258561.1 RP11-72M17.1 -4.15 4.72e-05 0.0196 -0.4 -0.27 Depression (quantitative trait); chr14:67010930 chr14:66212810~66509394:- CESC cis rs9918079 0.524 rs4235379 ENSG00000273133.1 RP11-799M12.2 -4.15 4.72e-05 0.0196 -0.37 -0.27 Obesity-related traits; chr4:15657655 chr4:15563698~15564253:- CESC cis rs13631 0.894 rs7856589 ENSG00000268996.3 MAN1B1-AS1 -4.15 4.72e-05 0.0196 -0.25 -0.27 Cerebrospinal fluid biomarker levels; chr9:137109469 chr9:137084946~137086817:- CESC cis rs11250098 0.541 rs6997997 ENSG00000269918.1 AF131215.9 -4.15 4.73e-05 0.0196 -0.35 -0.27 Morning vs. evening chronotype; chr8:10908572 chr8:11104691~11106704:- CESC cis rs3091242 1 rs646867 ENSG00000224183.1 SDHDP6 -4.15 4.73e-05 0.0196 -0.29 -0.27 Erythrocyte sedimentation rate; chr1:25382767 chr1:25294164~25294643:- CESC cis rs5758659 0.716 rs5758661 ENSG00000273366.1 CTA-989H11.1 -4.15 4.73e-05 0.0196 -0.34 -0.27 Cognitive function; chr22:42228439 chr22:42278188~42278846:+ CESC cis rs2439831 0.85 rs10438303 ENSG00000249839.1 AC011330.5 -4.15 4.73e-05 0.0196 -0.39 -0.27 Lung cancer in ever smokers; chr15:43724219 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs12441127 ENSG00000249839.1 AC011330.5 -4.15 4.73e-05 0.0196 -0.39 -0.27 Lung cancer in ever smokers; chr15:43728977 chr15:43663654~43684339:- CESC cis rs67311347 1 rs56992941 ENSG00000223797.4 ENTPD3-AS1 4.15 4.73e-05 0.0196 0.26 0.27 Renal cell carcinoma; chr3:40430943 chr3:40313802~40453329:- CESC cis rs9309473 1 rs6756987 ENSG00000163016.8 ALMS1P 4.15 4.73e-05 0.0196 0.34 0.27 Metabolite levels; chr2:73459950 chr2:73644919~73685576:+ CESC cis rs8020095 0.571 rs2281676 ENSG00000258561.1 RP11-72M17.1 4.15 4.73e-05 0.0196 0.4 0.27 Depression (quantitative trait); chr14:67171738 chr14:66212810~66509394:- CESC cis rs9487094 0.626 rs7773950 ENSG00000260273.1 RP11-425D10.10 4.15 4.74e-05 0.0196 0.35 0.27 Height; chr6:109494237 chr6:109382795~109383666:+ CESC cis rs11089937 0.568 rs5756988 ENSG00000211638.2 IGLV8-61 4.15 4.74e-05 0.0197 0.26 0.27 Periodontitis (PAL4Q3); chr22:22132397 chr22:22098700~22099212:+ CESC cis rs453301 0.571 rs330048 ENSG00000254340.1 RP11-10A14.3 -4.15 4.74e-05 0.0197 -0.34 -0.27 Joint mobility (Beighton score); chr8:9229768 chr8:9141424~9145435:+ CESC cis rs67180937 0.553 rs1498382 ENSG00000272750.1 RP11-378J18.8 4.15 4.74e-05 0.0197 0.37 0.27 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222641495 chr1:222658867~222661512:- CESC cis rs2243480 1 rs1404147 ENSG00000275400.1 RP4-756H11.5 4.15 4.74e-05 0.0197 0.42 0.27 Diabetic kidney disease; chr7:65799537 chr7:66553805~66554199:- CESC cis rs9847710 0.733 rs2581809 ENSG00000242142.1 SERBP1P3 4.15 4.75e-05 0.0197 0.32 0.27 Ulcerative colitis; chr3:53055667 chr3:53064283~53065091:- CESC cis rs950880 1 rs13019081 ENSG00000234389.1 AC007278.3 4.15 4.75e-05 0.0197 0.3 0.27 Serum protein levels (sST2); chr2:102334362 chr2:102438713~102440475:+ CESC cis rs7829975 0.509 rs7838674 ENSG00000254340.1 RP11-10A14.3 -4.15 4.75e-05 0.0197 -0.33 -0.27 Mood instability; chr8:8939563 chr8:9141424~9145435:+ CESC cis rs7429990 0.965 rs2882668 ENSG00000229759.1 MRPS18AP1 4.15 4.75e-05 0.0197 0.27 0.27 Educational attainment (years of education); chr3:47938816 chr3:48256350~48256938:- CESC cis rs7560272 0.512 rs4530394 ENSG00000273245.1 RP11-434P11.2 -4.15 4.75e-05 0.0197 -0.34 -0.27 Schizophrenia; chr2:73702523 chr2:73750256~73750786:- CESC cis rs6687821 0.531 rs6661530 ENSG00000267734.1 RP4-604K5.3 4.15 4.75e-05 0.0197 0.3 0.27 Yeast infection; chr1:87020367 chr1:86932199~86934891:- CESC cis rs6088590 0.61 rs6120663 ENSG00000275784.1 RP5-1125A11.6 4.15 4.76e-05 0.0197 0.27 0.27 Coronary artery disease; chr20:34494101 chr20:33989480~33991818:- CESC cis rs10129255 0.957 rs8009638 ENSG00000280411.1 IGHV1-69-2 -4.15 4.76e-05 0.0197 -0.2 -0.27 Kawasaki disease; chr14:106777570 chr14:106762092~106762588:- CESC cis rs10875746 0.517 rs12721420 ENSG00000240399.1 RP1-228P16.1 -4.15 4.76e-05 0.0197 -0.36 -0.27 Longevity (90 years and older); chr12:47965011 chr12:48054813~48055591:- CESC cis rs55665837 1 rs55665837 ENSG00000251991.1 RNU7-49P 4.15 4.77e-05 0.0197 0.31 0.27 Vitamin D levels; chr11:14473503 chr11:14478892~14478953:+ CESC cis rs11089937 0.667 rs10483107 ENSG00000211638.2 IGLV8-61 -4.15 4.77e-05 0.0198 -0.27 -0.27 Periodontitis (PAL4Q3); chr22:22151036 chr22:22098700~22099212:+ CESC cis rs2243480 1 rs12698509 ENSG00000232559.3 GS1-124K5.12 4.15 4.78e-05 0.0198 0.43 0.27 Diabetic kidney disease; chr7:65953889 chr7:66554588~66576923:- CESC cis rs10129255 0.957 rs17113284 ENSG00000211970.3 IGHV4-61 4.15 4.78e-05 0.0198 0.21 0.27 Kawasaki disease; chr14:106684476 chr14:106639119~106639657:- CESC cis rs916888 0.821 rs199514 ENSG00000232300.1 FAM215B -4.15 4.78e-05 0.0198 -0.44 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46558830~46562795:- CESC cis rs9907295 1 rs9907295 ENSG00000271013.1 AC015849.15 -4.15 4.78e-05 0.0198 -0.39 -0.27 Fibroblast growth factor basic levels; chr17:35930309 chr17:35912635~35918010:- CESC cis rs2412819 0.597 rs541871 ENSG00000249839.1 AC011330.5 -4.15 4.78e-05 0.0198 -0.35 -0.27 Lung cancer; chr15:43868656 chr15:43663654~43684339:- CESC cis rs7829975 0.56 rs6994131 ENSG00000253893.2 FAM85B 4.15 4.78e-05 0.0198 0.36 0.27 Mood instability; chr8:8693448 chr8:8167819~8226614:- CESC cis rs6439153 0.933 rs34193129 ENSG00000231305.3 RP11-723O4.2 4.15 4.78e-05 0.0198 0.26 0.27 Pneumococcal bacteremia; chr3:128972564 chr3:128861313~128871540:- CESC cis rs10411161 0.58 rs10409620 ENSG00000267905.4 CTD-2616J11.16 4.15 4.79e-05 0.0198 0.35 0.27 Breast cancer; chr19:51867923 chr19:51340695~51344117:+ CESC cis rs9309473 0.95 rs6756885 ENSG00000163016.8 ALMS1P 4.15 4.79e-05 0.0198 0.36 0.27 Metabolite levels; chr2:73578045 chr2:73644919~73685576:+ CESC cis rs71403859 0.73 rs17347255 ENSG00000260886.1 TAT-AS1 4.15 4.79e-05 0.0198 0.42 0.27 Post bronchodilator FEV1; chr16:71553322 chr16:71565789~71578187:+ CESC cis rs11089937 0.597 rs5757007 ENSG00000211638.2 IGLV8-61 -4.15 4.79e-05 0.0198 -0.26 -0.27 Periodontitis (PAL4Q3); chr22:22135167 chr22:22098700~22099212:+ CESC cis rs17772222 0.917 rs1956406 ENSG00000258983.2 RP11-507K2.2 4.15 4.8e-05 0.0198 0.33 0.27 Coronary artery calcification; chr14:88749711 chr14:88499334~88515502:+ CESC cis rs7829975 0.501 rs2980769 ENSG00000173295.6 FAM86B3P 4.15 4.8e-05 0.0198 0.33 0.27 Mood instability; chr8:8462781 chr8:8228595~8244865:+ CESC cis rs2836950 0.565 rs2150413 ENSG00000232608.1 TIMM9P2 4.15 4.8e-05 0.0199 0.3 0.27 Menarche (age at onset); chr21:39242952 chr21:39216624~39217506:+ CESC cis rs853679 0.517 rs9283884 ENSG00000219392.1 RP1-265C24.5 4.15 4.8e-05 0.0199 0.36 0.27 Depression; chr6:28167882 chr6:28115628~28116551:+ CESC cis rs875971 0.965 rs28682868 ENSG00000179406.6 LINC00174 4.15 4.8e-05 0.0199 0.29 0.27 Aortic root size; chr7:66224822 chr7:66376044~66401338:- CESC cis rs2337406 0.85 rs4774179 ENSG00000211974.3 IGHV2-70 -4.15 4.8e-05 0.0199 -0.4 -0.27 Alzheimer's disease (late onset); chr14:106700837 chr14:106723574~106724093:- CESC cis rs2993535 0.558 rs6690787 ENSG00000224763.1 FDPSP8 4.15 4.8e-05 0.0199 0.57 0.27 Hip circumference adjusted for BMI; chr1:212081916 chr1:211660189~211661277:- CESC cis rs62025270 0.632 rs62022915 ENSG00000202081.1 RNU6-1280P -4.15 4.8e-05 0.0199 -0.37 -0.27 Idiopathic pulmonary fibrosis; chr15:85670365 chr15:85651522~85651628:- CESC cis rs6439153 0.743 rs71331685 ENSG00000261159.1 RP11-723O4.9 4.15 4.8e-05 0.0199 0.28 0.27 Pneumococcal bacteremia; chr3:128992582 chr3:128859716~128860526:- CESC cis rs7131987 0.683 rs7954278 ENSG00000257176.2 RP11-996F15.2 -4.15 4.8e-05 0.0199 -0.32 -0.27 QT interval; chr12:29306357 chr12:29280418~29317848:- CESC cis rs7893279 0.505 rs7072624 ENSG00000240291.1 RP11-499P20.2 -4.15 4.8e-05 0.0199 -0.31 -0.27 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18670865 chr10:18513115~18545651:- CESC cis rs7208859 0.623 rs609063 ENSG00000266490.1 CTD-2349P21.9 4.15 4.81e-05 0.0199 0.45 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624495 chr17:30792372~30792833:+ CESC cis rs7621025 0.542 rs71336078 ENSG00000239213.4 NCK1-AS1 -4.15 4.81e-05 0.0199 -0.42 -0.27 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136770760 chr3:136841726~136862054:- CESC cis rs227932 0.764 rs78660981 ENSG00000234286.1 AC006026.13 -4.15 4.81e-05 0.0199 -0.37 -0.27 Schizophrenia; chr7:23719296 chr7:23680195~23680786:- CESC cis rs2732480 0.538 rs2468943 ENSG00000240399.1 RP1-228P16.1 -4.15 4.81e-05 0.0199 -0.31 -0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48353466 chr12:48054813~48055591:- CESC cis rs10129255 0.956 rs10137268 ENSG00000211974.3 IGHV2-70 4.15 4.81e-05 0.0199 0.29 0.27 Kawasaki disease; chr14:106697402 chr14:106723574~106724093:- CESC cis rs6991838 0.778 rs11779601 ENSG00000200714.1 Y_RNA 4.15 4.81e-05 0.0199 0.33 0.27 Intelligence (multi-trait analysis); chr8:65550241 chr8:65592731~65592820:+ CESC cis rs2019137 0.56 rs4849179 ENSG00000189223.12 PAX8-AS1 -4.15 4.81e-05 0.0199 -0.34 -0.27 Lymphocyte counts; chr2:113227593 chr2:113211522~113276581:+ CESC cis rs453301 0.658 rs6986044 ENSG00000173295.6 FAM86B3P -4.15 4.81e-05 0.0199 -0.35 -0.27 Joint mobility (Beighton score); chr8:9017276 chr8:8228595~8244865:+ CESC cis rs2688608 0.839 rs2633311 ENSG00000242288.9 RP11-464F9.1 -4.15 4.81e-05 0.0199 -0.3 -0.27 Inflammatory bowel disease; chr10:73838341 chr10:73674295~73730466:- CESC cis rs6142102 0.924 rs6059662 ENSG00000276073.1 RP5-1125A11.7 4.15 4.82e-05 0.0199 0.27 0.27 Skin pigmentation; chr20:34087921 chr20:33985617~33988989:- CESC cis rs7873102 0.654 rs10114348 ENSG00000230188.1 RP11-405L18.4 -4.15 4.82e-05 0.0199 -0.36 -0.27 Brain structure; chr9:37960696 chr9:37490421~37490893:- CESC cis rs9487094 0.67 rs11153183 ENSG00000260273.1 RP11-425D10.10 4.15 4.82e-05 0.0199 0.35 0.27 Height; chr6:109496073 chr6:109382795~109383666:+ CESC cis rs761746 0.577 rs2012150 ENSG00000236132.1 CTA-440B3.1 -4.15 4.82e-05 0.0199 -0.35 -0.27 Intelligence; chr22:31820153 chr22:31816379~31817491:- CESC cis rs4072705 0.646 rs2416933 ENSG00000224020.1 MIR181A2HG 4.15 4.83e-05 0.0199 0.33 0.27 Menarche (age at onset); chr9:124483250 chr9:124658467~124698631:+ CESC cis rs1211375 0.606 rs1203977 ENSG00000268836.1 LA16c-OS12.2 -4.15 4.83e-05 0.0199 -0.26 -0.27 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:206279 chr16:185748~186294:- CESC cis rs6969780 0.915 rs12666919 ENSG00000233429.8 HOTAIRM1 -4.15 4.83e-05 0.0199 -0.39 -0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149879 chr7:27095647~27100265:+ CESC cis rs6969780 0.915 rs886339 ENSG00000233429.8 HOTAIRM1 -4.15 4.83e-05 0.0199 -0.39 -0.27 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27151051 chr7:27095647~27100265:+ CESC cis rs8074751 0.689 rs35452323 ENSG00000266644.1 RP11-927P21.2 4.15 4.83e-05 0.02 0.3 0.27 Attention deficit hyperactivity disorder; chr17:65642718 chr17:64899766~64900716:+ CESC cis rs2408955 0.515 rs10875742 ENSG00000240399.1 RP1-228P16.1 -4.15 4.83e-05 0.02 -0.29 -0.27 Glycated hemoglobin levels; chr12:48099591 chr12:48054813~48055591:- CESC cis rs875971 0.545 rs7810213 ENSG00000222364.1 RNU6-96P -4.15 4.83e-05 0.02 -0.39 -0.27 Aortic root size; chr7:66481592 chr7:66395191~66395286:+ CESC cis rs6693388 0.71 rs2012674 ENSG00000229021.2 AL591893.1 -4.15 4.83e-05 0.02 -0.34 -0.27 Blood metabolite ratios; chr1:152007294 chr1:151994531~152042774:+ CESC cis rs2714337 0.507 rs2842362 ENSG00000233503.1 HNRNPLP1 -4.15 4.83e-05 0.02 -0.35 -0.27 Fasting blood glucose (BMI interaction);Fasting blood glucose; chr6:7265822 chr6:7481094~7482594:- CESC cis rs4489787 0.527 rs2731085 ENSG00000206612.1 SNORA2A 4.15 4.84e-05 0.02 0.31 0.27 Prostate cancer (SNP x SNP interaction); chr12:48507516 chr12:48656648~48656782:- CESC cis rs916888 0.738 rs199515 ENSG00000232300.1 FAM215B -4.15 4.84e-05 0.02 -0.42 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46558830~46562795:- CESC cis rs6604026 0.59 rs12743005 ENSG00000223787.2 RP4-593M8.1 4.15 4.84e-05 0.02 0.36 0.27 Multiple sclerosis; chr1:92727181 chr1:92580476~92580821:- CESC cis rs6604026 0.624 rs34761380 ENSG00000223787.2 RP4-593M8.1 4.15 4.84e-05 0.02 0.36 0.27 Multiple sclerosis; chr1:92731928 chr1:92580476~92580821:- CESC cis rs6604026 0.59 rs35241270 ENSG00000223787.2 RP4-593M8.1 4.15 4.84e-05 0.02 0.36 0.27 Multiple sclerosis; chr1:92739957 chr1:92580476~92580821:- CESC cis rs6604026 0.624 rs12746893 ENSG00000223787.2 RP4-593M8.1 4.15 4.84e-05 0.02 0.36 0.27 Multiple sclerosis; chr1:92745319 chr1:92580476~92580821:- CESC cis rs6604026 0.624 rs11164803 ENSG00000223787.2 RP4-593M8.1 4.15 4.84e-05 0.02 0.36 0.27 Multiple sclerosis; chr1:92746363 chr1:92580476~92580821:- CESC cis rs7508 0.576 rs208060 ENSG00000253671.1 RP11-806O11.1 -4.15 4.84e-05 0.02 -0.28 -0.27 Atrial fibrillation; chr8:17962252 chr8:17808941~17820868:+ CESC cis rs2439831 1 rs527921 ENSG00000205771.5 CATSPER2P1 4.15 4.84e-05 0.02 0.38 0.27 Lung cancer in ever smokers; chr15:43478218 chr15:43726918~43747094:- CESC cis rs7243790 0.805 rs12458280 ENSG00000277324.1 RP11-850A17.1 -4.15 4.84e-05 0.02 -0.3 -0.27 Diastolic blood pressure; chr18:54386772 chr18:54268346~54270028:- CESC cis rs1124769 0.672 rs12591438 ENSG00000259378.1 DCAF13P3 4.15 4.84e-05 0.02 0.36 0.27 Cognitive performance; chr15:50850995 chr15:50944663~50945996:+ CESC cis rs7429990 0.965 rs319692 ENSG00000229759.1 MRPS18AP1 4.15 4.84e-05 0.02 0.28 0.27 Educational attainment (years of education); chr3:47882827 chr3:48256350~48256938:- CESC cis rs700651 0.789 rs6434949 ENSG00000222017.1 AC011997.1 4.15 4.84e-05 0.02 0.34 0.27 Intracranial aneurysm; chr2:197990786 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs6724526 ENSG00000222017.1 AC011997.1 4.15 4.84e-05 0.02 0.34 0.27 Dermatomyositis; chr2:197993677 chr2:197693106~197774823:+ CESC cis rs7572733 0.515 rs893808 ENSG00000222017.1 AC011997.1 4.15 4.84e-05 0.02 0.34 0.27 Dermatomyositis; chr2:197996113 chr2:197693106~197774823:+ CESC cis rs804280 0.509 rs12719915 ENSG00000255495.1 AC145124.2 -4.15 4.85e-05 0.02 -0.33 -0.27 Myopia (pathological); chr8:11928746 chr8:12194467~12196280:+ CESC cis rs919433 0.68 rs2124317 ENSG00000222017.1 AC011997.1 4.15 4.85e-05 0.02 0.33 0.27 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197612882 chr2:197693106~197774823:+ CESC cis rs7208859 0.623 rs383436 ENSG00000266490.1 CTD-2349P21.9 4.15 4.85e-05 0.02 0.45 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30632161 chr17:30792372~30792833:+ CESC cis rs17826219 0.714 rs11650821 ENSG00000266490.1 CTD-2349P21.9 4.15 4.85e-05 0.02 0.45 0.27 Body mass index; chr17:30641132 chr17:30792372~30792833:+ CESC cis rs9309473 1 rs10496193 ENSG00000163016.8 ALMS1P 4.15 4.85e-05 0.02 0.34 0.27 Metabolite levels; chr2:73546376 chr2:73644919~73685576:+ CESC cis rs9309473 0.898 rs11126403 ENSG00000163016.8 ALMS1P 4.15 4.85e-05 0.02 0.34 0.27 Metabolite levels; chr2:73569796 chr2:73644919~73685576:+ CESC cis rs9309473 0.898 rs11126404 ENSG00000163016.8 ALMS1P 4.15 4.85e-05 0.02 0.34 0.27 Metabolite levels; chr2:73569797 chr2:73644919~73685576:+ CESC cis rs11168618 1 rs10875833 ENSG00000257735.1 RP11-370I10.6 4.15 4.85e-05 0.02 0.3 0.27 Adiponectin levels; chr12:48559585 chr12:48350945~48442411:+ CESC cis rs11168618 1 rs11168637 ENSG00000257735.1 RP11-370I10.6 4.15 4.85e-05 0.02 0.3 0.27 Adiponectin levels; chr12:48559721 chr12:48350945~48442411:+ CESC cis rs6001482 0.573 rs4990163 ENSG00000236850.4 BMS1P20 -4.15 4.85e-05 0.02 -0.27 -0.27 Diastolic blood pressure; chr22:22233778 chr22:22303224~22322847:+ CESC cis rs9813712 0.595 rs6439226 ENSG00000228252.7 COL6A4P2 4.15 4.86e-05 0.02 0.34 0.27 Response to amphetamines; chr3:130283686 chr3:130212823~130273806:+ CESC cis rs4934494 0.834 rs1359624 ENSG00000232229.4 LINC00865 -4.15 4.86e-05 0.02 -0.34 -0.27 Red blood cell count; chr10:89635671 chr10:89829510~89840861:+ CESC cis rs7829975 0.714 rs4840362 ENSG00000253893.2 FAM85B 4.15 4.86e-05 0.0201 0.32 0.27 Mood instability; chr8:8812572 chr8:8167819~8226614:- CESC cis rs2455601 0.638 rs2742478 ENSG00000254860.4 TMEM9B-AS1 4.15 4.86e-05 0.0201 0.33 0.27 Schizophrenia; chr11:8974552 chr11:8964675~8977527:+ CESC cis rs10129255 0.869 rs7150549 ENSG00000211974.3 IGHV2-70 4.15 4.86e-05 0.0201 0.3 0.27 Kawasaki disease; chr14:106705441 chr14:106723574~106724093:- CESC cis rs860295 0.836 rs1360554 ENSG00000225855.5 RUSC1-AS1 -4.15 4.86e-05 0.0201 -0.21 -0.27 Body mass index; chr1:155503565 chr1:155316863~155324176:- CESC cis rs1862618 0.671 rs2591955 ENSG00000271828.1 CTD-2310F14.1 -4.15 4.86e-05 0.0201 -0.33 -0.27 Initial pursuit acceleration; chr5:56949121 chr5:56927874~56929573:+ CESC cis rs1862618 0.641 rs2591954 ENSG00000271828.1 CTD-2310F14.1 -4.15 4.86e-05 0.0201 -0.33 -0.27 Initial pursuit acceleration; chr5:56949217 chr5:56927874~56929573:+ CESC cis rs1862618 0.671 rs906631 ENSG00000271828.1 CTD-2310F14.1 -4.15 4.86e-05 0.0201 -0.33 -0.27 Initial pursuit acceleration; chr5:56949976 chr5:56927874~56929573:+ CESC cis rs748404 0.697 rs530683 ENSG00000249839.1 AC011330.5 4.14 4.87e-05 0.0201 0.29 0.27 Lung cancer; chr15:43276801 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs1095389 ENSG00000249839.1 AC011330.5 -4.14 4.87e-05 0.0201 -0.29 -0.27 Lung cancer; chr15:43274473 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs473554 ENSG00000249839.1 AC011330.5 -4.14 4.87e-05 0.0201 -0.29 -0.27 Lung cancer; chr15:43276009 chr15:43663654~43684339:- CESC cis rs6142102 1 rs2378078 ENSG00000276073.1 RP5-1125A11.7 -4.14 4.87e-05 0.0201 -0.29 -0.27 Skin pigmentation; chr20:34126922 chr20:33985617~33988989:- CESC cis rs67311347 0.866 rs2371183 ENSG00000223797.4 ENTPD3-AS1 -4.14 4.87e-05 0.0201 -0.26 -0.27 Renal cell carcinoma; chr3:40292756 chr3:40313802~40453329:- CESC cis rs9322193 0.923 rs11155674 ENSG00000216906.2 RP11-350J20.9 4.14 4.87e-05 0.0201 0.3 0.27 Lung cancer; chr6:149711111 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs12174349 ENSG00000216906.2 RP11-350J20.9 4.14 4.87e-05 0.0201 0.3 0.27 Lung cancer; chr6:149718012 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs2297932 ENSG00000216906.2 RP11-350J20.9 4.14 4.87e-05 0.0201 0.3 0.27 Lung cancer; chr6:149718225 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs2297928 ENSG00000216906.2 RP11-350J20.9 4.14 4.87e-05 0.0201 0.3 0.27 Lung cancer; chr6:149718584 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9479094 ENSG00000216906.2 RP11-350J20.9 4.14 4.87e-05 0.0201 0.3 0.27 Lung cancer; chr6:149725083 chr6:149904243~149906418:+ CESC cis rs4266144 0.544 rs6805781 ENSG00000244515.1 KRT18P34 4.14 4.87e-05 0.0201 0.32 0.27 Coronary artery disease; chr3:157112780 chr3:157162663~157163932:- CESC cis rs11992162 0.967 rs10088415 ENSG00000255020.1 AF131216.5 -4.14 4.87e-05 0.0201 -0.3 -0.27 Monocyte count; chr8:11973316 chr8:11345748~11347502:- CESC cis rs6740322 0.748 rs6544635 ENSG00000234936.1 AC010883.5 4.14 4.88e-05 0.0201 0.29 0.27 Coronary artery disease; chr2:43259565 chr2:43229573~43233394:+ CESC cis rs7714584 1 rs4958842 ENSG00000197083.10 ZNF300P1 4.14 4.88e-05 0.0201 0.5 0.27 Crohn's disease; chr5:150845315 chr5:150930645~150946289:- CESC cis rs4448343 0.736 rs2297086 ENSG00000271155.1 RP11-435O5.5 -4.14 4.88e-05 0.0201 -0.31 -0.27 Height; chr9:95477838 chr9:95506235~95507636:+ CESC cis rs7614311 0.594 rs58473894 ENSG00000271843.1 RP11-245J9.5 -4.14 4.88e-05 0.0201 -0.38 -0.27 Lung function (FVC);Lung function (FEV1); chr3:63871532 chr3:64008082~64008692:- CESC cis rs526231 0.782 rs434816 ENSG00000175749.11 EIF3KP1 4.14 4.88e-05 0.0201 0.33 0.27 Primary biliary cholangitis; chr5:103263627 chr5:103032376~103033031:+ CESC cis rs62246343 0.605 rs34665459 ENSG00000206573.7 THUMPD3-AS1 -4.14 4.88e-05 0.0201 -0.29 -0.27 Fibrinogen levels; chr3:9423041 chr3:9349689~9398579:- CESC cis rs950169 0.579 rs12913054 ENSG00000225151.9 GOLGA2P7 -4.14 4.89e-05 0.0201 -0.42 -0.27 Schizophrenia; chr15:83995704 chr15:84199311~84230136:- CESC cis rs7243790 0.774 rs7240534 ENSG00000277324.1 RP11-850A17.1 -4.14 4.89e-05 0.0201 -0.31 -0.27 Diastolic blood pressure; chr18:54359527 chr18:54268346~54270028:- CESC cis rs10754283 0.967 rs10922685 ENSG00000231613.1 RP5-943J3.1 4.14 4.89e-05 0.0201 0.35 0.27 Amyotrophic lateral sclerosis (sporadic); chr1:89652761 chr1:89788914~89790492:+ CESC cis rs2439831 0.85 rs524417 ENSG00000275601.1 AC011330.13 -4.14 4.89e-05 0.0202 -0.36 -0.27 Lung cancer in ever smokers; chr15:43480176 chr15:43642389~43643023:- CESC cis rs9532669 0.963 rs9315794 ENSG00000239827.7 SUGT1P3 -4.14 4.89e-05 0.0202 -0.29 -0.27 Cervical cancer; chr13:40939489 chr13:40908159~40921774:- CESC cis rs7250849 0.529 rs16982912 ENSG00000273837.1 LLNLR-470E3.1 -4.14 4.9e-05 0.0202 -0.33 -0.27 Blood protein levels; chr19:51661874 chr19:51639478~51639931:- CESC cis rs7829975 0.593 rs2921051 ENSG00000173295.6 FAM86B3P 4.14 4.9e-05 0.0202 0.34 0.27 Mood instability; chr8:8462594 chr8:8228595~8244865:+ CESC cis rs916888 0.821 rs199505 ENSG00000261575.2 RP11-259G18.1 -4.14 4.91e-05 0.0202 -0.4 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46267037~46268694:+ CESC cis rs916888 0.821 rs70602 ENSG00000261575.2 RP11-259G18.1 -4.14 4.91e-05 0.0202 -0.4 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46267037~46268694:+ CESC cis rs875971 0.965 rs10267430 ENSG00000179406.6 LINC00174 4.14 4.91e-05 0.0202 0.28 0.27 Aortic root size; chr7:66278036 chr7:66376044~66401338:- CESC cis rs2299587 0.841 rs2237849 ENSG00000253671.1 RP11-806O11.1 -4.14 4.91e-05 0.0202 -0.28 -0.27 Economic and political preferences; chr8:18017373 chr8:17808941~17820868:+ CESC cis rs9532669 0.857 rs9525427 ENSG00000176268.5 CYCSP34 4.14 4.92e-05 0.0202 0.27 0.27 Cervical cancer; chr13:40918029 chr13:40863599~40863902:- CESC cis rs12701220 0.739 rs2293523 ENSG00000224079.1 AC091729.7 4.14 4.92e-05 0.0202 0.41 0.27 Bronchopulmonary dysplasia; chr7:1058882 chr7:1074450~1078036:+ CESC cis rs916888 0.773 rs199534 ENSG00000261575.2 RP11-259G18.1 4.14 4.92e-05 0.0203 0.4 0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46267037~46268694:+ CESC cis rs17301013 0.507 rs12091076 ENSG00000227373.4 RP11-160H22.5 4.14 4.92e-05 0.0203 0.42 0.27 Systemic lupus erythematosus; chr1:174321545 chr1:174115300~174160004:- CESC cis rs10875746 0.669 rs17122812 ENSG00000240399.1 RP1-228P16.1 -4.14 4.93e-05 0.0203 -0.35 -0.27 Longevity (90 years and older); chr12:48203270 chr12:48054813~48055591:- CESC cis rs1707322 1 rs10158032 ENSG00000281133.1 AL355480.3 -4.14 4.93e-05 0.0203 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45867029 chr1:45580892~45580996:- CESC cis rs6693388 0.647 rs2932581 ENSG00000229021.2 AL591893.1 4.14 4.93e-05 0.0203 0.31 0.27 Blood metabolite ratios; chr1:151961487 chr1:151994531~152042774:+ CESC cis rs1387259 0.619 rs7134565 ENSG00000240399.1 RP1-228P16.1 -4.14 4.93e-05 0.0203 -0.28 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48236241 chr12:48054813~48055591:- CESC cis rs2015599 0.525 rs7959145 ENSG00000257176.2 RP11-996F15.2 4.14 4.93e-05 0.0203 0.32 0.27 Platelet count;Mean platelet volume; chr12:29330850 chr12:29280418~29317848:- CESC cis rs2015599 0.525 rs7961943 ENSG00000257176.2 RP11-996F15.2 4.14 4.93e-05 0.0203 0.32 0.27 Platelet count;Mean platelet volume; chr12:29331146 chr12:29280418~29317848:- CESC cis rs2015599 0.525 rs10743656 ENSG00000257176.2 RP11-996F15.2 4.14 4.93e-05 0.0203 0.32 0.27 Platelet count;Mean platelet volume; chr12:29332516 chr12:29280418~29317848:- CESC cis rs3738443 0.953 rs56065612 ENSG00000259865.1 RP11-488L18.10 4.14 4.93e-05 0.0203 0.32 0.27 Alcohol dependence; chr1:247194812 chr1:247187281~247188526:- CESC cis rs3738443 0.953 rs61839997 ENSG00000259865.1 RP11-488L18.10 4.14 4.93e-05 0.0203 0.32 0.27 Alcohol dependence; chr1:247197867 chr1:247187281~247188526:- CESC cis rs6928977 0.896 rs2614259 ENSG00000234084.1 RP3-388E23.2 4.14 4.94e-05 0.0203 0.24 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135356114 chr6:135301568~135307158:+ CESC cis rs8067354 0.789 rs4622571 ENSG00000266992.1 DHX40P1 4.14 4.94e-05 0.0203 0.3 0.27 Hemoglobin concentration; chr17:59807036 chr17:59976009~60002384:- CESC cis rs783540 0.846 rs783539 ENSG00000278603.1 RP13-608F4.5 -4.14 4.94e-05 0.0203 -0.32 -0.27 Schizophrenia; chr15:82585320 chr15:82472203~82472426:+ CESC cis rs9532669 0.926 rs7322399 ENSG00000239827.7 SUGT1P3 -4.14 4.94e-05 0.0203 -0.3 -0.27 Cervical cancer; chr13:40952511 chr13:40908159~40921774:- CESC cis rs9532669 0.926 rs7322097 ENSG00000239827.7 SUGT1P3 -4.14 4.94e-05 0.0203 -0.3 -0.27 Cervical cancer; chr13:40952513 chr13:40908159~40921774:- CESC cis rs10129255 0.719 rs7156660 ENSG00000223648.3 IGHV3-64 4.14 4.94e-05 0.0203 0.23 0.27 Kawasaki disease; chr14:106673171 chr14:106643132~106658258:- CESC cis rs8062405 0.573 rs7140 ENSG00000261067.5 RP11-264B17.3 -4.14 4.94e-05 0.0203 -0.27 -0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28984436 chr16:28974804~28990783:+ CESC cis rs7829975 0.84 rs572366 ENSG00000253893.2 FAM85B -4.14 4.94e-05 0.0203 -0.33 -0.27 Mood instability; chr8:8721284 chr8:8167819~8226614:- CESC cis rs8020095 0.571 rs8010261 ENSG00000258561.1 RP11-72M17.1 -4.14 4.94e-05 0.0203 -0.4 -0.27 Depression (quantitative trait); chr14:67141400 chr14:66212810~66509394:- CESC cis rs17373728 0.585 rs1912709 ENSG00000249395.2 CASC9 -4.14 4.94e-05 0.0203 -0.43 -0.27 Diabetic kidney disease; chr8:75266328 chr8:75223404~75324741:- CESC cis rs875971 0.545 rs6970498 ENSG00000237310.1 GS1-124K5.4 4.14 4.94e-05 0.0203 0.3 0.27 Aortic root size; chr7:66275908 chr7:66493706~66495474:+ CESC cis rs748404 0.697 rs471122 ENSG00000249839.1 AC011330.5 4.14 4.95e-05 0.0203 0.29 0.27 Lung cancer; chr15:43266376 chr15:43663654~43684339:- CESC cis rs2286503 1 rs2286499 ENSG00000228649.7 AC005682.5 4.14 4.95e-05 0.0203 0.24 0.27 Fibrinogen; chr7:22817858 chr7:22854178~22861579:+ CESC cis rs9532669 0.926 rs4454835 ENSG00000176268.5 CYCSP34 4.14 4.95e-05 0.0204 0.28 0.27 Cervical cancer; chr13:40928978 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs1571116 ENSG00000176268.5 CYCSP34 4.14 4.95e-05 0.0204 0.28 0.27 Cervical cancer; chr13:40929765 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs9532673 ENSG00000176268.5 CYCSP34 4.14 4.95e-05 0.0204 0.28 0.27 Cervical cancer; chr13:40930412 chr13:40863599~40863902:- CESC cis rs2771051 0.931 rs12551938 ENSG00000230734.1 RPL10P3 4.14 4.95e-05 0.0204 0.27 0.27 Venous thromboembolism (SNP x SNP interaction); chr9:117535869 chr9:117180628~117181095:- CESC cis rs9487094 0.689 rs1476387 ENSG00000260273.1 RP11-425D10.10 4.14 4.96e-05 0.0204 0.33 0.27 Height; chr6:109443332 chr6:109382795~109383666:+ CESC cis rs11051970 0.918 rs7309706 ENSG00000255760.1 RP11-428G5.5 4.14 4.96e-05 0.0204 0.33 0.27 Response to tocilizumab in rheumatoid arthritis; chr12:32385274 chr12:31877079~31887203:- CESC cis rs12908161 0.959 rs34342559 ENSG00000225151.9 GOLGA2P7 -4.14 4.96e-05 0.0204 -0.37 -0.27 Schizophrenia; chr15:84788040 chr15:84199311~84230136:- CESC cis rs12908161 0.959 rs35557864 ENSG00000225151.9 GOLGA2P7 -4.14 4.96e-05 0.0204 -0.37 -0.27 Schizophrenia; chr15:84788398 chr15:84199311~84230136:- CESC cis rs75422866 0.867 rs73113139 ENSG00000274902.1 RP1-197B17.4 4.14 4.96e-05 0.0204 0.68 0.27 Pneumonia; chr12:47622826 chr12:47731908~47732351:+ CESC cis rs1707322 0.928 rs6681068 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45932710 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211228 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45934168 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs11211229 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45934845 chr1:45580892~45580996:- CESC cis rs1707322 1 rs9803784 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45936235 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs12022335 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45937060 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10890375 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940909 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10890377 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940922 chr1:45580892~45580996:- CESC cis rs1707322 1 rs6671754 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45968318 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs6666763 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45970779 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4489497 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45973026 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211235 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45974703 chr1:45580892~45580996:- CESC cis rs1707322 0.893 rs9919275 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45975688 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211236 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45978095 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4660328 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45979159 chr1:45580892~45580996:- CESC cis rs1707322 0.928 rs61785614 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45980375 chr1:45580892~45580996:- CESC cis rs1707322 1 rs9793167 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45981128 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211237 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45981657 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs11211238 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45983743 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4460583 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45984246 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs4459051 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45985531 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211239 ENSG00000281133.1 AL355480.3 -4.14 4.96e-05 0.0204 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45986275 chr1:45580892~45580996:- CESC cis rs3096299 0.866 rs4238829 ENSG00000274627.1 RP11-104N10.2 4.14 4.96e-05 0.0204 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89395854 chr16:89516797~89522217:+ CESC cis rs523079 0.515 rs493784 ENSG00000239093.1 snoU13 4.14 4.96e-05 0.0204 0.38 0.27 Glucose homeostasis traits; chr3:187902066 chr3:187423315~187423419:+ CESC cis rs451417 1 rs236120 ENSG00000275632.1 RP5-967N21.11 4.14 4.96e-05 0.0204 0.36 0.27 Menopause (age at onset); chr20:5959003 chr20:6000418~6000941:+ CESC cis rs4272720 0.639 rs12244666 ENSG00000229870.1 RP11-507K13.6 -4.14 4.97e-05 0.0204 -0.31 -0.27 Platelet count;Plateletcrit; chr10:49062332 chr10:49815096~49815562:+ CESC cis rs4272720 0.639 rs12244748 ENSG00000229870.1 RP11-507K13.6 -4.14 4.97e-05 0.0204 -0.31 -0.27 Platelet count;Plateletcrit; chr10:49062418 chr10:49815096~49815562:+ CESC cis rs4272720 0.639 rs4402204 ENSG00000229870.1 RP11-507K13.6 -4.14 4.97e-05 0.0204 -0.31 -0.27 Platelet count;Plateletcrit; chr10:49063812 chr10:49815096~49815562:+ CESC cis rs4272720 0.587 rs12253426 ENSG00000229870.1 RP11-507K13.6 -4.14 4.97e-05 0.0204 -0.31 -0.27 Platelet count;Plateletcrit; chr10:49067014 chr10:49815096~49815562:+ CESC cis rs10129255 0.536 rs17113249 ENSG00000211972.2 IGHV3-66 4.14 4.97e-05 0.0204 0.19 0.27 Kawasaki disease; chr14:106678273 chr14:106675017~106675544:- CESC cis rs73086581 0.787 rs67724338 ENSG00000229539.1 RP11-119B16.2 4.14 4.97e-05 0.0204 0.47 0.27 Response to antidepressants in depression; chr20:3888410 chr20:3888239~3888868:- CESC cis rs73086581 0.787 rs67202952 ENSG00000229539.1 RP11-119B16.2 4.14 4.97e-05 0.0204 0.47 0.27 Response to antidepressants in depression; chr20:3888452 chr20:3888239~3888868:- CESC cis rs17818399 0.712 rs13008088 ENSG00000279254.1 RP11-536C12.1 -4.14 4.97e-05 0.0204 -0.32 -0.27 Height; chr2:46554441 chr2:46668870~46670778:+ CESC cis rs7714670 0.871 rs4599517 ENSG00000184084.7 CTD-2372A4.1 -4.14 4.98e-05 0.0204 -0.31 -0.27 Venous thromboembolism (SNP x SNP interaction); chr5:73787117 chr5:73803296~73803599:- CESC cis rs700651 0.789 rs10190226 ENSG00000222017.1 AC011997.1 -4.14 4.98e-05 0.0204 -0.35 -0.27 Intracranial aneurysm; chr2:198036840 chr2:197693106~197774823:+ CESC cis rs5760092 0.618 rs5996631 ENSG00000272787.1 KB-226F1.2 4.14 4.98e-05 0.0204 0.32 0.27 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23969211~23969873:+ CESC cis rs8080784 1 rs60049100 ENSG00000266992.1 DHX40P1 4.14 4.98e-05 0.0204 0.34 0.27 Coronary artery disease; chr17:60832197 chr17:59976009~60002384:- CESC cis rs8080784 1 rs6504000 ENSG00000266992.1 DHX40P1 4.14 4.98e-05 0.0204 0.34 0.27 Coronary artery disease; chr17:60833694 chr17:59976009~60002384:- CESC cis rs875971 0.964 rs778735 ENSG00000237310.1 GS1-124K5.4 4.14 4.98e-05 0.0205 0.26 0.27 Aortic root size; chr7:66349822 chr7:66493706~66495474:+ CESC cis rs17826219 0.636 rs12946563 ENSG00000266490.1 CTD-2349P21.9 4.14 4.98e-05 0.0205 0.41 0.27 Body mass index; chr17:30776148 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs8068645 ENSG00000266490.1 CTD-2349P21.9 4.14 4.98e-05 0.0205 0.41 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs55811708 ENSG00000266490.1 CTD-2349P21.9 4.14 4.98e-05 0.0205 0.41 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30792372~30792833:+ CESC cis rs12130219 1 rs12130219 ENSG00000237975.5 FLG-AS1 4.14 4.98e-05 0.0205 0.37 0.27 Inflammatory skin disease; chr1:152189630 chr1:152168125~152445456:+ CESC cis rs8100891 0.537 rs11883143 ENSG00000267213.4 AC007773.2 -4.14 4.98e-05 0.0205 -0.39 -0.27 Neuroticism; chr19:32478350 chr19:32390050~32405560:- CESC cis rs7674212 0.541 rs2720471 ENSG00000246560.2 RP11-10L12.4 4.14 4.98e-05 0.0205 0.33 0.27 Type 2 diabetes; chr4:103102683 chr4:102828055~102844075:+ CESC cis rs2274273 0.588 rs2297816 ENSG00000258413.1 RP11-665C16.6 -4.14 4.99e-05 0.0205 -0.35 -0.27 Protein biomarker; chr14:55366320 chr14:55262767~55272075:- CESC cis rs75422866 0.867 rs7303895 ENSG00000274902.1 RP1-197B17.4 4.14 4.99e-05 0.0205 0.56 0.27 Pneumonia; chr12:47683290 chr12:47731908~47732351:+ CESC cis rs9450351 0.744 rs7772723 ENSG00000203875.9 SNHG5 -4.14 4.99e-05 0.0205 -0.54 -0.27 Interferon gamma-induced protein 10 levels; chr6:85913980 chr6:85660950~85678736:- CESC cis rs12908161 0.959 rs12906348 ENSG00000259728.4 LINC00933 4.14 4.99e-05 0.0205 0.35 0.27 Schizophrenia; chr15:84786190 chr15:84570649~84580175:+ CESC cis rs875971 0.964 rs778723 ENSG00000237310.1 GS1-124K5.4 4.14 4.99e-05 0.0205 0.26 0.27 Aortic root size; chr7:66364510 chr7:66493706~66495474:+ CESC cis rs7005380 0.62 rs28669275 ENSG00000279347.1 RP11-85I17.2 -4.14 5e-05 0.0205 -0.25 -0.27 Interstitial lung disease; chr8:119889713 chr8:119838736~119840385:- CESC cis rs67311347 0.911 rs9849224 ENSG00000223797.4 ENTPD3-AS1 4.14 5e-05 0.0205 0.26 0.27 Renal cell carcinoma; chr3:40351071 chr3:40313802~40453329:- CESC cis rs3764618 1 rs3764617 ENSG00000268006.1 PTOV1-AS1 4.14 5e-05 0.0205 0.58 0.27 Follicule stimulating hormone; chr19:48993866 chr19:49838639~49851676:- CESC cis rs11638352 1 rs2957581 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44117884 chr15:43642389~43643023:- CESC cis rs2733201 1 rs1160066 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44118739 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2615295 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44120400 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2615292 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44122178 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2059628 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44123073 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2733203 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44123404 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2615288 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44123688 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2615287 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44123795 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2733204 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44124814 chr15:43642389~43643023:- CESC cis rs2733201 1 rs2615285 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44125178 chr15:43642389~43643023:- CESC cis rs11638352 1 rs7166715 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44125408 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2706473 ENSG00000275601.1 AC011330.13 4.14 5e-05 0.0205 0.42 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44125537 chr15:43642389~43643023:- CESC cis rs7873102 0.654 rs2243893 ENSG00000230188.1 RP11-405L18.4 4.14 5e-05 0.0205 0.33 0.27 Brain structure; chr9:37989896 chr9:37490421~37490893:- CESC cis rs17818399 0.815 rs62136873 ENSG00000279254.1 RP11-536C12.1 -4.14 5e-05 0.0205 -0.34 -0.27 Height; chr2:46634098 chr2:46668870~46670778:+ CESC cis rs9309473 1 rs58603761 ENSG00000163016.8 ALMS1P 4.14 5e-05 0.0205 0.34 0.27 Metabolite levels; chr2:73499478 chr2:73644919~73685576:+ CESC cis rs9487094 0.601 rs4945831 ENSG00000260273.1 RP11-425D10.10 4.14 5e-05 0.0205 0.33 0.27 Height; chr6:109440234 chr6:109382795~109383666:+ CESC cis rs9640161 0.789 rs28439010 ENSG00000261305.1 RP4-584D14.7 4.14 5.01e-05 0.0205 0.39 0.27 Blood protein levels;Circulating chemerin levels; chr7:150349187 chr7:150341771~150342607:+ CESC cis rs11089937 0.597 rs4821772 ENSG00000211638.2 IGLV8-61 4.14 5.01e-05 0.0205 0.25 0.27 Periodontitis (PAL4Q3); chr22:22131383 chr22:22098700~22099212:+ CESC cis rs1075265 0.87 rs7569214 ENSG00000233266.1 HMGB1P31 4.14 5.01e-05 0.0205 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:53989049 chr2:54051334~54051760:+ CESC cis rs7572733 0.534 rs7557203 ENSG00000222017.1 AC011997.1 4.14 5.01e-05 0.0205 0.34 0.27 Dermatomyositis; chr2:197930926 chr2:197693106~197774823:+ CESC cis rs7829975 0.577 rs17684466 ENSG00000253893.2 FAM85B 4.14 5.01e-05 0.0205 0.37 0.27 Mood instability; chr8:8687723 chr8:8167819~8226614:- CESC cis rs673078 0.517 rs73205578 ENSG00000275759.1 RP11-131L12.3 -4.14 5.02e-05 0.0206 -0.55 -0.27 Glucose homeostasis traits; chr12:118385113 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs73205579 ENSG00000275759.1 RP11-131L12.3 -4.14 5.02e-05 0.0206 -0.55 -0.27 Glucose homeostasis traits; chr12:118385125 chr12:118428281~118428870:+ CESC cis rs7429990 0.965 rs4858887 ENSG00000229759.1 MRPS18AP1 -4.14 5.02e-05 0.0206 -0.29 -0.27 Educational attainment (years of education); chr3:48050527 chr3:48256350~48256938:- CESC cis rs832187 0.704 rs832195 ENSG00000280620.1 SCAANT1 -4.14 5.02e-05 0.0206 -0.38 -0.27 Schizophrenia; chr3:63878936 chr3:63911518~63911772:- CESC cis rs1185460 1 rs15818 ENSG00000271751.1 RP11-110I1.14 -4.14 5.03e-05 0.0206 -0.36 -0.27 Coronary artery disease; chr11:119081463 chr11:119065263~119065677:- CESC cis rs4319547 0.695 rs4758662 ENSG00000275265.1 RP11-15J22.8 -4.14 5.03e-05 0.0206 -0.38 -0.27 Body mass index; chr12:122440231 chr12:122501187~122501641:+ CESC cis rs4319547 0.695 rs4758643 ENSG00000275265.1 RP11-15J22.8 -4.14 5.03e-05 0.0206 -0.38 -0.27 Body mass index; chr12:122440272 chr12:122501187~122501641:+ CESC cis rs11051970 0.918 rs76930558 ENSG00000255760.1 RP11-428G5.5 4.14 5.03e-05 0.0206 0.32 0.27 Response to tocilizumab in rheumatoid arthritis; chr12:32385905 chr12:31877079~31887203:- CESC cis rs11051970 0.918 rs73084099 ENSG00000255760.1 RP11-428G5.5 4.14 5.03e-05 0.0206 0.32 0.27 Response to tocilizumab in rheumatoid arthritis; chr12:32386817 chr12:31877079~31887203:- CESC cis rs10129255 0.957 rs8009638 ENSG00000211970.3 IGHV4-61 -4.14 5.03e-05 0.0206 -0.21 -0.27 Kawasaki disease; chr14:106777570 chr14:106639119~106639657:- CESC cis rs9322193 0.923 rs9766037 ENSG00000268592.3 RAET1E-AS1 4.14 5.03e-05 0.0206 0.35 0.27 Lung cancer; chr6:149616921 chr6:149863494~149919507:+ CESC cis rs9309473 0.519 rs2421583 ENSG00000273245.1 RP11-434P11.2 -4.14 5.03e-05 0.0206 -0.35 -0.27 Metabolite levels; chr2:73671658 chr2:73750256~73750786:- CESC cis rs172166 0.694 rs1225716 ENSG00000219392.1 RP1-265C24.5 -4.14 5.03e-05 0.0206 -0.32 -0.27 Cardiac Troponin-T levels; chr6:28145968 chr6:28115628~28116551:+ CESC cis rs2439831 0.85 rs558656 ENSG00000275601.1 AC011330.13 -4.14 5.03e-05 0.0206 -0.35 -0.27 Lung cancer in ever smokers; chr15:43431316 chr15:43642389~43643023:- CESC cis rs4272720 0.639 rs2264847 ENSG00000229870.1 RP11-507K13.6 4.14 5.03e-05 0.0206 0.31 0.27 Platelet count;Plateletcrit; chr10:49046221 chr10:49815096~49815562:+ CESC cis rs4272720 0.639 rs2137911 ENSG00000229870.1 RP11-507K13.6 4.14 5.03e-05 0.0206 0.31 0.27 Platelet count;Plateletcrit; chr10:49049685 chr10:49815096~49815562:+ CESC cis rs6782228 0.509 rs2811495 ENSG00000242551.2 POU5F1P6 -4.14 5.04e-05 0.0206 -0.3 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128641114 chr3:128674735~128677005:- CESC cis rs6782228 0.565 rs2811496 ENSG00000242551.2 POU5F1P6 -4.14 5.04e-05 0.0206 -0.3 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128641115 chr3:128674735~128677005:- CESC cis rs853679 1 rs1778508 ENSG00000219392.1 RP1-265C24.5 4.14 5.04e-05 0.0206 0.39 0.27 Depression; chr6:28262103 chr6:28115628~28116551:+ CESC cis rs860295 0.871 rs6696888 ENSG00000225855.5 RUSC1-AS1 -4.14 5.04e-05 0.0206 -0.21 -0.27 Body mass index; chr1:155539091 chr1:155316863~155324176:- CESC cis rs11633886 0.528 rs3914852 ENSG00000273972.1 CTD-2306A12.1 4.14 5.04e-05 0.0206 0.31 0.27 Diisocyanate-induced asthma; chr15:45808853 chr15:45702640~45703183:+ CESC cis rs55665837 1 rs10766182 ENSG00000251991.1 RNU7-49P 4.14 5.04e-05 0.0207 0.3 0.27 Vitamin D levels; chr11:14477990 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs12364959 ENSG00000251991.1 RNU7-49P 4.14 5.04e-05 0.0207 0.3 0.27 Vitamin D levels; chr11:14485889 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs12792120 ENSG00000251991.1 RNU7-49P 4.14 5.04e-05 0.0207 0.3 0.27 Vitamin D levels; chr11:14447897 chr11:14478892~14478953:+ CESC cis rs55665837 0.961 rs12576926 ENSG00000251991.1 RNU7-49P 4.14 5.04e-05 0.0207 0.3 0.27 Vitamin D levels; chr11:14458746 chr11:14478892~14478953:+ CESC cis rs10461617 0.617 rs6874733 ENSG00000271828.1 CTD-2310F14.1 4.14 5.05e-05 0.0207 0.34 0.27 Type 2 diabetes; chr5:56773773 chr5:56927874~56929573:+ CESC cis rs860295 0.702 rs12047756 ENSG00000225855.5 RUSC1-AS1 4.14 5.05e-05 0.0207 0.23 0.27 Body mass index; chr1:155655153 chr1:155316863~155324176:- CESC cis rs7615952 0.599 rs67566088 ENSG00000250012.1 RP11-124N2.1 -4.14 5.05e-05 0.0207 -0.31 -0.27 Blood pressure (smoking interaction); chr3:126050130 chr3:126084220~126095349:+ CESC cis rs7615952 0.641 rs12495947 ENSG00000250012.1 RP11-124N2.1 -4.14 5.05e-05 0.0207 -0.31 -0.27 Blood pressure (smoking interaction); chr3:126052855 chr3:126084220~126095349:+ CESC cis rs7615952 0.641 rs6805074 ENSG00000250012.1 RP11-124N2.1 -4.14 5.05e-05 0.0207 -0.31 -0.27 Blood pressure (smoking interaction); chr3:126053431 chr3:126084220~126095349:+ CESC cis rs7615952 0.641 rs66520539 ENSG00000250012.1 RP11-124N2.1 -4.14 5.05e-05 0.0207 -0.31 -0.27 Blood pressure (smoking interaction); chr3:126061531 chr3:126084220~126095349:+ CESC cis rs7927592 0.956 rs7124078 ENSG00000212093.1 AP000807.1 4.14 5.05e-05 0.0207 0.31 0.27 Total body bone mineral density; chr11:68531165 chr11:68506083~68506166:- CESC cis rs8040855 0.627 rs4843019 ENSG00000259295.5 CSPG4P12 -4.14 5.05e-05 0.0207 -0.33 -0.27 Bulimia nervosa; chr15:85101228 chr15:85191438~85213905:+ CESC cis rs7048146 0.668 rs10124300 ENSG00000213539.4 YBX1P6 -4.14 5.05e-05 0.0207 -0.31 -0.27 Vascular brain injury; chr9:109515460 chr9:109532830~109534332:- CESC cis rs8020095 0.571 rs723432 ENSG00000258561.1 RP11-72M17.1 -4.14 5.05e-05 0.0207 -0.39 -0.27 Depression (quantitative trait); chr14:66912298 chr14:66212810~66509394:- CESC cis rs7178909 0.872 rs3867167 ENSG00000259677.1 RP11-493E3.1 4.14 5.05e-05 0.0207 0.3 0.27 Common traits (Other); chr15:89890558 chr15:89876540~89877285:+ CESC cis rs11633886 0.565 rs17554726 ENSG00000273972.1 CTD-2306A12.1 4.14 5.05e-05 0.0207 0.31 0.27 Diisocyanate-induced asthma; chr15:45759272 chr15:45702640~45703183:+ CESC cis rs8005677 1 rs4982712 ENSG00000279656.1 RP11-298I3.6 4.14 5.06e-05 0.0207 0.35 0.27 Cognitive ability (multi-trait analysis); chr14:22934519 chr14:23023083~23024217:- CESC cis rs72615157 0.561 rs113844570 ENSG00000242294.5 STAG3L5P 4.14 5.06e-05 0.0207 0.28 0.27 Lung function (FEV1/FVC); chr7:100276155 chr7:100336079~100351900:+ CESC cis rs3738443 0.868 rs7546908 ENSG00000259865.1 RP11-488L18.10 -4.14 5.06e-05 0.0207 -0.29 -0.27 Alcohol dependence; chr1:247200531 chr1:247187281~247188526:- CESC cis rs12690897 0.501 rs12704157 ENSG00000229251.3 HNRNPA1P8 -4.14 5.06e-05 0.0207 -0.27 -0.27 Macrophage inflammatory protein 1a levels; chr7:85640517 chr7:84983556~84984506:+ CESC cis rs7208859 0.725 rs7210904 ENSG00000264538.5 SUZ12P1 -4.14 5.06e-05 0.0207 -0.29 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843187 chr17:30709299~30790908:+ CESC cis rs733592 0.599 rs12819124 ENSG00000240399.1 RP1-228P16.1 4.14 5.06e-05 0.0207 0.29 0.27 Plateletcrit; chr12:48015271 chr12:48054813~48055591:- CESC cis rs12134133 1 rs2564973 ENSG00000274245.1 RP11-357P18.2 4.14 5.06e-05 0.0207 0.34 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207306759 chr1:207372559~207373252:+ CESC cis rs673078 0.66 rs11068917 ENSG00000275409.1 RP11-131L12.4 -4.14 5.06e-05 0.0207 -0.4 -0.27 Glucose homeostasis traits; chr12:118353315 chr12:118430147~118430699:+ CESC cis rs9322193 0.923 rs4354168 ENSG00000216906.2 RP11-350J20.9 4.14 5.06e-05 0.0207 0.3 0.27 Lung cancer; chr6:149696642 chr6:149904243~149906418:+ CESC cis rs2243480 1 rs34815098 ENSG00000232559.3 GS1-124K5.12 4.14 5.06e-05 0.0207 0.43 0.27 Diabetic kidney disease; chr7:65827267 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35735127 ENSG00000232559.3 GS1-124K5.12 4.14 5.06e-05 0.0207 0.43 0.27 Diabetic kidney disease; chr7:65835436 chr7:66554588~66576923:- CESC cis rs8040855 0.542 rs2342122 ENSG00000259774.1 RP11-182J1.13 -4.13 5.07e-05 0.0207 -0.32 -0.27 Bulimia nervosa; chr15:85185304 chr15:84422618~84425882:+ CESC cis rs8040855 0.644 rs2342120 ENSG00000259774.1 RP11-182J1.13 -4.13 5.07e-05 0.0207 -0.32 -0.27 Bulimia nervosa; chr15:85185589 chr15:84422618~84425882:+ CESC cis rs116095464 0.867 rs10061296 ENSG00000250848.1 CTD-2083E4.5 -4.13 5.07e-05 0.0207 -0.45 -0.27 Breast cancer; chr5:312138 chr5:288833~290321:- CESC cis rs948562 0.947 rs2298607 ENSG00000269570.2 CMB9-55A18.1 4.13 5.07e-05 0.0207 0.29 0.27 Lymphoma; chr11:58637026 chr11:58611119~58612642:- CESC cis rs988913 0.706 rs4715489 ENSG00000224984.1 RP11-524H19.2 4.13 5.07e-05 0.0207 0.27 0.27 Menarche (age at onset); chr6:54868167 chr6:54840118~54840855:- CESC cis rs3892630 0.588 rs7248798 ENSG00000267475.1 CTD-2538C1.2 -4.13 5.07e-05 0.0208 -0.38 -0.27 Red blood cell traits; chr19:32812778 chr19:32687089~32691750:- CESC cis rs3892630 0.619 rs61062732 ENSG00000267475.1 CTD-2538C1.2 -4.13 5.07e-05 0.0208 -0.38 -0.27 Red blood cell traits; chr19:32813811 chr19:32687089~32691750:- CESC cis rs2688608 0.62 rs7076525 ENSG00000242288.9 RP11-464F9.1 4.13 5.07e-05 0.0208 0.3 0.27 Inflammatory bowel disease; chr10:73753039 chr10:73674295~73730466:- CESC cis rs2276314 1 rs4799832 ENSG00000278986.1 RP11-723J4.3 -4.13 5.08e-05 0.0208 -0.31 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35979683 chr18:35972151~35973916:+ CESC cis rs2274273 0.624 rs7154796 ENSG00000258413.1 RP11-665C16.6 -4.13 5.08e-05 0.0208 -0.35 -0.27 Protein biomarker; chr14:55304740 chr14:55262767~55272075:- CESC cis rs10129255 0.957 rs12590799 ENSG00000211970.3 IGHV4-61 -4.13 5.08e-05 0.0208 -0.2 -0.27 Kawasaki disease; chr14:106779713 chr14:106639119~106639657:- CESC cis rs1569175 0.826 rs4673704 ENSG00000213938.3 SEPHS1P6 -4.13 5.08e-05 0.0208 -0.52 -0.27 Response to treatment for acute lymphoblastic leukemia; chr2:200108356 chr2:199659551~199660729:+ CESC cis rs7208859 0.725 rs9910051 ENSG00000264538.5 SUZ12P1 -4.13 5.08e-05 0.0208 -0.3 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834184 chr17:30709299~30790908:+ CESC cis rs7131987 0.65 rs10843384 ENSG00000257176.2 RP11-996F15.2 -4.13 5.08e-05 0.0208 -0.32 -0.27 QT interval; chr12:29319476 chr12:29280418~29317848:- CESC cis rs7131987 0.65 rs11050188 ENSG00000257176.2 RP11-996F15.2 -4.13 5.08e-05 0.0208 -0.32 -0.27 QT interval; chr12:29320175 chr12:29280418~29317848:- CESC cis rs7131987 0.683 rs12366505 ENSG00000257176.2 RP11-996F15.2 -4.13 5.08e-05 0.0208 -0.32 -0.27 QT interval; chr12:29321177 chr12:29280418~29317848:- CESC cis rs7131987 0.65 rs12366527 ENSG00000257176.2 RP11-996F15.2 -4.13 5.08e-05 0.0208 -0.32 -0.27 QT interval; chr12:29321323 chr12:29280418~29317848:- CESC cis rs7131987 0.65 rs7311912 ENSG00000257176.2 RP11-996F15.2 -4.13 5.08e-05 0.0208 -0.32 -0.27 QT interval; chr12:29322770 chr12:29280418~29317848:- CESC cis rs875971 1 rs778710 ENSG00000237310.1 GS1-124K5.4 4.13 5.08e-05 0.0208 0.26 0.27 Aortic root size; chr7:66389847 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs778708 ENSG00000237310.1 GS1-124K5.4 4.13 5.08e-05 0.0208 0.26 0.27 Aortic root size; chr7:66391332 chr7:66493706~66495474:+ CESC cis rs875971 1 rs778696 ENSG00000237310.1 GS1-124K5.4 4.13 5.08e-05 0.0208 0.26 0.27 Aortic root size; chr7:66405826 chr7:66493706~66495474:+ CESC cis rs875971 1 rs778694 ENSG00000237310.1 GS1-124K5.4 4.13 5.08e-05 0.0208 0.26 0.27 Aortic root size; chr7:66406571 chr7:66493706~66495474:+ CESC cis rs875971 1 rs4718344 ENSG00000237310.1 GS1-124K5.4 4.13 5.08e-05 0.0208 0.26 0.27 Aortic root size; chr7:66409394 chr7:66493706~66495474:+ CESC cis rs875971 0.737 rs7803424 ENSG00000237310.1 GS1-124K5.4 4.13 5.08e-05 0.0208 0.26 0.27 Aortic root size; chr7:66415618 chr7:66493706~66495474:+ CESC cis rs875971 0.83 rs7799834 ENSG00000237310.1 GS1-124K5.4 4.13 5.08e-05 0.0208 0.26 0.27 Aortic root size; chr7:66415707 chr7:66493706~66495474:+ CESC cis rs2243480 1 rs4718269 ENSG00000232559.3 GS1-124K5.12 -4.13 5.09e-05 0.0208 -0.45 -0.27 Diabetic kidney disease; chr7:65735810 chr7:66554588~66576923:- CESC cis rs5758659 0.716 rs2143138 ENSG00000273366.1 CTA-989H11.1 -4.13 5.09e-05 0.0208 -0.34 -0.27 Cognitive function; chr22:42222334 chr22:42278188~42278846:+ CESC cis rs3925075 0.5 rs11641624 ENSG00000260911.2 RP11-196G11.2 -4.13 5.09e-05 0.0208 -0.29 -0.27 IgA nephropathy; chr16:31257664 chr16:31043150~31049868:+ CESC cis rs10129255 0.5 rs2105991 ENSG00000211972.2 IGHV3-66 4.13 5.09e-05 0.0208 0.19 0.27 Kawasaki disease; chr14:106682022 chr14:106675017~106675544:- CESC cis rs9400467 0.506 rs78051065 ENSG00000272356.1 RP5-1112D6.8 -4.13 5.09e-05 0.0208 -0.34 -0.27 Amino acid levels;Blood metabolite levels; chr6:111279203 chr6:111309203~111313517:+ CESC cis rs6981523 0.553 rs11783045 ENSG00000255046.1 RP11-297N6.4 4.13 5.09e-05 0.0208 0.31 0.27 Neuroticism; chr8:11198666 chr8:11797928~11802568:- CESC cis rs9322193 0.923 rs4455682 ENSG00000216906.2 RP11-350J20.9 4.13 5.1e-05 0.0208 0.3 0.27 Lung cancer; chr6:149700161 chr6:149904243~149906418:+ CESC cis rs17301013 0.507 rs4652460 ENSG00000227373.4 RP11-160H22.5 4.13 5.1e-05 0.0208 0.35 0.27 Systemic lupus erythematosus; chr1:174459499 chr1:174115300~174160004:- CESC cis rs2404602 0.716 rs4886813 ENSG00000280730.1 AC090181.1 -4.13 5.1e-05 0.0208 -0.2 -0.27 Blood metabolite levels; chr15:76545880 chr15:77056895~77057021:+ CESC cis rs75422866 0.51 rs73105818 ENSG00000257433.4 RP1-197B17.3 4.13 5.1e-05 0.0208 0.65 0.27 Pneumonia; chr12:47726538 chr12:47706085~47742294:+ CESC cis rs7243790 0.846 rs56053948 ENSG00000277324.1 RP11-850A17.1 -4.13 5.1e-05 0.0208 -0.31 -0.27 Diastolic blood pressure; chr18:54434295 chr18:54268346~54270028:- CESC cis rs9322193 0.847 rs62439808 ENSG00000216906.2 RP11-350J20.9 4.13 5.1e-05 0.0208 0.29 0.27 Lung cancer; chr6:149629690 chr6:149904243~149906418:+ CESC cis rs9532669 0.89 rs9532676 ENSG00000176268.5 CYCSP34 4.13 5.1e-05 0.0208 0.28 0.27 Cervical cancer; chr13:40935626 chr13:40863599~40863902:- CESC cis rs763121 0.853 rs1569716 ENSG00000273076.1 RP3-508I15.22 4.13 5.11e-05 0.0209 0.31 0.27 Menopause (age at onset); chr22:38602514 chr22:38743495~38743910:+ CESC cis rs17711722 0.727 rs1880555 ENSG00000222364.1 RNU6-96P -4.13 5.11e-05 0.0209 -0.33 -0.27 Calcium levels; chr7:65967580 chr7:66395191~66395286:+ CESC cis rs9532669 0.926 rs9532657 ENSG00000239827.7 SUGT1P3 4.13 5.11e-05 0.0209 0.29 0.27 Cervical cancer; chr13:40918208 chr13:40908159~40921774:- CESC cis rs4877691 0.522 rs17085530 ENSG00000267559.4 RP11-383M4.6 4.13 5.11e-05 0.0209 0.38 0.27 Airway imaging phenotypes; chr9:82476303 chr9:81930226~81977089:- CESC cis rs1113500 0.966 rs11185249 ENSG00000226822.1 RP11-356N1.2 4.13 5.11e-05 0.0209 0.35 0.27 Growth-regulated protein alpha levels; chr1:108069024 chr1:108071482~108074519:+ CESC cis rs6546537 0.911 rs62133968 ENSG00000231024.1 AC092431.3 4.13 5.11e-05 0.0209 0.33 0.27 Serum thyroid-stimulating hormone levels; chr2:69664778 chr2:69700192~69713847:- CESC cis rs133885 1 rs133890 ENSG00000100058.11 CRYBB2P1 4.13 5.12e-05 0.0209 0.3 0.27 Mathematical ability in children with dyslexia; chr22:25764194 chr22:25448105~25520854:+ CESC cis rs2337406 0.587 rs11624678 ENSG00000254174.1 IGHV1-12 -4.13 5.12e-05 0.0209 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106650408 chr14:106122420~106122709:- CESC cis rs11846409 0.587 rs1806881 ENSG00000254174.1 IGHV1-12 -4.13 5.12e-05 0.0209 -0.27 -0.27 Rheumatic heart disease; chr14:106650770 chr14:106122420~106122709:- CESC cis rs6879260 1 rs888922 ENSG00000248367.1 CTB-129O4.1 -4.13 5.12e-05 0.0209 -0.21 -0.27 Height; chr5:180304635 chr5:180293245~180295253:+ CESC cis rs875971 0.929 rs778712 ENSG00000237310.1 GS1-124K5.4 4.13 5.12e-05 0.0209 0.26 0.27 Aortic root size; chr7:66384991 chr7:66493706~66495474:+ CESC cis rs9532669 0.853 rs9315795 ENSG00000239827.7 SUGT1P3 -4.13 5.12e-05 0.0209 -0.3 -0.27 Cervical cancer; chr13:40943382 chr13:40908159~40921774:- CESC cis rs9532669 0.963 rs3764056 ENSG00000239827.7 SUGT1P3 -4.13 5.12e-05 0.0209 -0.3 -0.27 Cervical cancer; chr13:40943849 chr13:40908159~40921774:- CESC cis rs9532669 0.963 rs7989303 ENSG00000239827.7 SUGT1P3 -4.13 5.12e-05 0.0209 -0.3 -0.27 Cervical cancer; chr13:40950087 chr13:40908159~40921774:- CESC cis rs9532669 0.963 rs3736953 ENSG00000239827.7 SUGT1P3 -4.13 5.12e-05 0.0209 -0.3 -0.27 Cervical cancer; chr13:40951450 chr13:40908159~40921774:- CESC cis rs61160187 0.582 rs7713481 ENSG00000215032.2 GNL3LP1 4.13 5.12e-05 0.0209 0.32 0.27 Educational attainment (years of education);Educational attainment (college completion); chr5:61093038 chr5:60891935~60893577:- CESC cis rs61160187 0.582 rs7737276 ENSG00000215032.2 GNL3LP1 4.13 5.12e-05 0.0209 0.32 0.27 Educational attainment (years of education);Educational attainment (college completion); chr5:61102467 chr5:60891935~60893577:- CESC cis rs2803122 0.501 rs10811140 ENSG00000273226.1 RP11-513M16.8 -4.13 5.12e-05 0.0209 -0.32 -0.27 Pulse pressure; chr9:19230401 chr9:19375451~19375996:+ CESC cis rs10129255 0.5 rs10143242 ENSG00000211972.2 IGHV3-66 4.13 5.12e-05 0.0209 0.19 0.27 Kawasaki disease; chr14:106681814 chr14:106675017~106675544:- CESC cis rs1387259 0.759 rs7960122 ENSG00000258273.1 RP11-370I10.4 4.13 5.12e-05 0.0209 0.33 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48383217 chr12:48333755~48333901:- CESC cis rs7829975 0.871 rs777709 ENSG00000253893.2 FAM85B 4.13 5.14e-05 0.0209 0.33 0.27 Mood instability; chr8:8726362 chr8:8167819~8226614:- CESC cis rs12908161 0.959 rs62019472 ENSG00000259728.4 LINC00933 4.13 5.14e-05 0.021 0.35 0.27 Schizophrenia; chr15:84788262 chr15:84570649~84580175:+ CESC cis rs7951870 1 rs35623865 ENSG00000247675.5 LRP4-AS1 -4.13 5.14e-05 0.021 -0.34 -0.27 Schizophrenia; chr11:46609631 chr11:46846412~46874396:+ CESC cis rs7951870 1 rs61884264 ENSG00000247675.5 LRP4-AS1 -4.13 5.14e-05 0.021 -0.34 -0.27 Schizophrenia; chr11:46618032 chr11:46846412~46874396:+ CESC cis rs7951870 0.891 rs7122039 ENSG00000247675.5 LRP4-AS1 -4.13 5.14e-05 0.021 -0.34 -0.27 Schizophrenia; chr11:46624480 chr11:46846412~46874396:+ CESC cis rs55665837 1 rs10832275 ENSG00000251991.1 RNU7-49P 4.13 5.14e-05 0.021 0.3 0.27 Vitamin D levels; chr11:14456678 chr11:14478892~14478953:+ CESC cis rs9513627 0.749 rs73556149 ENSG00000228889.5 UBAC2-AS1 4.13 5.14e-05 0.021 0.5 0.27 Obesity-related traits; chr13:99464758 chr13:99196377~99200710:- CESC cis rs875971 0.867 rs1002053 ENSG00000237310.1 GS1-124K5.4 -4.13 5.14e-05 0.021 -0.25 -0.27 Aortic root size; chr7:66333558 chr7:66493706~66495474:+ CESC cis rs875971 1 rs6460292 ENSG00000237310.1 GS1-124K5.4 -4.13 5.14e-05 0.021 -0.25 -0.27 Aortic root size; chr7:66345088 chr7:66493706~66495474:+ CESC cis rs11221522 0.762 rs10893972 ENSG00000281097.1 LINC01395 4.13 5.14e-05 0.021 0.3 0.27 Metabolite levels (5-HIAA); chr11:129086517 chr11:129612116~129617269:- CESC cis rs7580658 0.676 rs12465955 ENSG00000236682.1 AC068282.3 -4.13 5.15e-05 0.021 -0.32 -0.27 Protein C levels; chr2:127249498 chr2:127389130~127400580:+ CESC cis rs2412819 0.571 rs2930530 ENSG00000249839.1 AC011330.5 4.13 5.15e-05 0.021 0.35 0.27 Lung cancer; chr15:43823268 chr15:43663654~43684339:- CESC cis rs11089937 0.667 rs5757081 ENSG00000211638.2 IGLV8-61 -4.13 5.15e-05 0.021 -0.25 -0.27 Periodontitis (PAL4Q3); chr22:22146272 chr22:22098700~22099212:+ CESC cis rs13108904 0.518 rs4974603 ENSG00000254094.1 AC078852.1 -4.13 5.15e-05 0.021 -0.33 -0.27 Obesity-related traits; chr4:1349380 chr4:1356581~1358075:+ CESC cis rs748404 0.697 rs493177 ENSG00000205771.5 CATSPER2P1 -4.13 5.15e-05 0.021 -0.32 -0.27 Lung cancer; chr15:43251060 chr15:43726918~43747094:- CESC cis rs2980439 0.525 rs2945238 ENSG00000253893.2 FAM85B -4.13 5.15e-05 0.021 -0.35 -0.27 Neuroticism; chr8:8312614 chr8:8167819~8226614:- CESC cis rs1729407 0.649 rs2849176 ENSG00000254851.1 RP11-109L13.1 4.13 5.15e-05 0.021 0.29 0.27 Apolipoprotein A-IV levels; chr11:116826205 chr11:117135528~117138582:+ CESC cis rs11096990 0.964 rs4974999 ENSG00000249207.1 RP11-360F5.1 -4.13 5.15e-05 0.021 -0.33 -0.27 Cognitive function; chr4:39262294 chr4:39112677~39126818:- CESC cis rs7688540 0.771 rs1986557 ENSG00000211553.1 AC253576.2 -4.13 5.15e-05 0.021 -0.41 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:289329 chr4:136461~136568:+ CESC cis rs748404 0.666 rs12905220 ENSG00000249839.1 AC011330.5 -4.13 5.15e-05 0.021 -0.39 -0.27 Lung cancer; chr15:43465641 chr15:43663654~43684339:- CESC cis rs6693388 0.918 rs971887 ENSG00000229021.2 AL591893.1 -4.13 5.15e-05 0.021 -0.32 -0.27 Blood metabolite ratios; chr1:151971021 chr1:151994531~152042774:+ CESC cis rs2933343 0.621 rs789249 ENSG00000231305.3 RP11-723O4.2 4.13 5.16e-05 0.021 0.25 0.27 IgG glycosylation; chr3:128859610 chr3:128861313~128871540:- CESC cis rs7551222 0.716 rs11240751 ENSG00000240219.1 RP11-430C7.5 4.13 5.16e-05 0.021 0.3 0.27 Schizophrenia; chr1:204492922 chr1:204626775~204629712:+ CESC cis rs2439831 0.85 rs8032649 ENSG00000249839.1 AC011330.5 4.13 5.16e-05 0.021 0.39 0.27 Lung cancer in ever smokers; chr15:43842724 chr15:43663654~43684339:- CESC cis rs1775715 0.707 rs2799019 ENSG00000231245.2 C1DP1 -4.13 5.16e-05 0.021 -0.33 -0.27 Bipolar disorder with mood-incongruent psychosis; chr10:31853922 chr10:32511336~32511737:- CESC cis rs6540731 0.935 rs903120 ENSG00000226251.4 RP11-15I11.3 -4.13 5.16e-05 0.021 -0.3 -0.27 Intelligence (childhood); chr1:212231830 chr1:212225278~212238977:- CESC cis rs6540731 1 rs2087946 ENSG00000226251.4 RP11-15I11.3 -4.13 5.16e-05 0.021 -0.3 -0.27 Intelligence (childhood); chr1:212232054 chr1:212225278~212238977:- CESC cis rs6540731 1 rs903121 ENSG00000226251.4 RP11-15I11.3 -4.13 5.16e-05 0.021 -0.3 -0.27 Intelligence (childhood); chr1:212232113 chr1:212225278~212238977:- CESC cis rs6540731 1 rs2012917 ENSG00000226251.4 RP11-15I11.3 -4.13 5.16e-05 0.021 -0.3 -0.27 Intelligence (childhood); chr1:212232429 chr1:212225278~212238977:- CESC cis rs2836950 0.501 rs2070865 ENSG00000232608.1 TIMM9P2 4.13 5.16e-05 0.021 0.31 0.27 Menarche (age at onset); chr21:39343593 chr21:39216624~39217506:+ CESC cis rs6740322 0.895 rs6738717 ENSG00000234936.1 AC010883.5 4.13 5.16e-05 0.021 0.28 0.27 Coronary artery disease; chr2:43346531 chr2:43229573~43233394:+ CESC cis rs9925964 0.933 rs10871454 ENSG00000260911.2 RP11-196G11.2 -4.13 5.16e-05 0.021 -0.29 -0.27 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31036758 chr16:31043150~31049868:+ CESC cis rs10129255 0.518 rs2006284 ENSG00000211972.2 IGHV3-66 4.13 5.17e-05 0.021 0.19 0.27 Kawasaki disease; chr14:106676185 chr14:106675017~106675544:- CESC cis rs9322193 0.923 rs9505982 ENSG00000216906.2 RP11-350J20.9 4.13 5.17e-05 0.021 0.29 0.27 Lung cancer; chr6:149618465 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9322196 ENSG00000216906.2 RP11-350J20.9 4.13 5.17e-05 0.021 0.29 0.27 Lung cancer; chr6:149619645 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs10782310 ENSG00000216906.2 RP11-350J20.9 4.13 5.17e-05 0.021 0.29 0.27 Lung cancer; chr6:149622458 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs10782311 ENSG00000216906.2 RP11-350J20.9 4.13 5.17e-05 0.021 0.29 0.27 Lung cancer; chr6:149622592 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs10747275 ENSG00000216906.2 RP11-350J20.9 4.13 5.17e-05 0.021 0.29 0.27 Lung cancer; chr6:149622782 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9322200 ENSG00000216906.2 RP11-350J20.9 4.13 5.17e-05 0.021 0.29 0.27 Lung cancer; chr6:149630078 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs9688794 ENSG00000216906.2 RP11-350J20.9 4.13 5.17e-05 0.021 0.29 0.27 Lung cancer; chr6:149632121 chr6:149904243~149906418:+ CESC cis rs6693388 0.789 rs3791153 ENSG00000229021.2 AL591893.1 -4.13 5.17e-05 0.021 -0.32 -0.27 Blood metabolite ratios; chr1:151985668 chr1:151994531~152042774:+ CESC cis rs2625529 0.938 rs2625530 ENSG00000260037.4 CTD-2524L6.3 -4.13 5.17e-05 0.021 -0.41 -0.27 Red blood cell count; chr15:71833693 chr15:71818396~71823384:+ CESC cis rs6540731 0.967 rs4951581 ENSG00000226251.4 RP11-15I11.3 -4.13 5.17e-05 0.021 -0.3 -0.27 Intelligence (childhood); chr1:212228770 chr1:212225278~212238977:- CESC cis rs6662572 1 rs6662999 ENSG00000280836.1 AL355480.1 4.13 5.17e-05 0.0211 0.39 0.27 Blood protein levels; chr1:45653679 chr1:45581219~45581321:- CESC cis rs12134133 1 rs1583090 ENSG00000274245.1 RP11-357P18.2 4.13 5.17e-05 0.0211 0.36 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207262438 chr1:207372559~207373252:+ CESC cis rs7937890 0.504 rs2575847 ENSG00000251991.1 RNU7-49P 4.13 5.18e-05 0.0211 0.29 0.27 Mitochondrial DNA levels; chr11:14449626 chr11:14478892~14478953:+ CESC cis rs7937890 0.559 rs2575825 ENSG00000251991.1 RNU7-49P 4.13 5.18e-05 0.0211 0.29 0.27 Mitochondrial DNA levels; chr11:14450550 chr11:14478892~14478953:+ CESC cis rs7937890 0.532 rs2575827 ENSG00000251991.1 RNU7-49P 4.13 5.18e-05 0.0211 0.29 0.27 Mitochondrial DNA levels; chr11:14453969 chr11:14478892~14478953:+ CESC cis rs7937890 0.532 rs2256884 ENSG00000251991.1 RNU7-49P 4.13 5.18e-05 0.0211 0.29 0.27 Mitochondrial DNA levels; chr11:14454856 chr11:14478892~14478953:+ CESC cis rs7937890 0.559 rs2597206 ENSG00000251991.1 RNU7-49P 4.13 5.18e-05 0.0211 0.29 0.27 Mitochondrial DNA levels; chr11:14455992 chr11:14478892~14478953:+ CESC cis rs7429990 0.965 rs2631721 ENSG00000229759.1 MRPS18AP1 4.13 5.18e-05 0.0211 0.27 0.27 Educational attainment (years of education); chr3:47881807 chr3:48256350~48256938:- CESC cis rs5758659 0.652 rs4822084 ENSG00000273366.1 CTA-989H11.1 4.13 5.18e-05 0.0211 0.34 0.27 Cognitive function; chr22:42039864 chr22:42278188~42278846:+ CESC cis rs6782228 1 rs35604103 ENSG00000242551.2 POU5F1P6 4.13 5.18e-05 0.0211 0.33 0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128616009 chr3:128674735~128677005:- CESC cis rs11638352 0.661 rs2706488 ENSG00000259479.5 SORD2P -4.13 5.18e-05 0.0211 -0.39 -0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44097699 chr15:44826371~44884694:- CESC cis rs2337406 0.866 rs2027901 ENSG00000211974.3 IGHV2-70 -4.13 5.18e-05 0.0211 -0.42 -0.27 Alzheimer's disease (late onset); chr14:106807164 chr14:106723574~106724093:- CESC cis rs2771051 0.931 rs10983690 ENSG00000230734.1 RPL10P3 -4.13 5.18e-05 0.0211 -0.27 -0.27 Venous thromboembolism (SNP x SNP interaction); chr9:117535460 chr9:117180628~117181095:- CESC cis rs875971 1 rs709595 ENSG00000179406.6 LINC00174 -4.13 5.18e-05 0.0211 -0.29 -0.27 Aortic root size; chr7:66352346 chr7:66376044~66401338:- CESC cis rs875971 1 rs811880 ENSG00000179406.6 LINC00174 -4.13 5.18e-05 0.0211 -0.29 -0.27 Aortic root size; chr7:66353659 chr7:66376044~66401338:- CESC cis rs9322193 0.923 rs9689084 ENSG00000216906.2 RP11-350J20.9 4.13 5.18e-05 0.0211 0.29 0.27 Lung cancer; chr6:149639648 chr6:149904243~149906418:+ CESC cis rs853679 0.55 rs1233701 ENSG00000219392.1 RP1-265C24.5 4.13 5.18e-05 0.0211 0.33 0.27 Depression; chr6:28200948 chr6:28115628~28116551:+ CESC cis rs2733201 1 rs2623019 ENSG00000275601.1 AC011330.13 4.13 5.18e-05 0.0211 0.41 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44107430 chr15:43642389~43643023:- CESC cis rs67311347 1 rs977652 ENSG00000223797.4 ENTPD3-AS1 4.13 5.19e-05 0.0211 0.26 0.27 Renal cell carcinoma; chr3:40437678 chr3:40313802~40453329:- CESC cis rs1044826 0.642 rs4607068 ENSG00000178631.7 ACTG1P1 4.13 5.19e-05 0.0211 0.33 0.27 Obesity-related traits; chr3:139444152 chr3:139493809~139494937:+ CESC cis rs5760092 0.618 rs4461358 ENSG00000272787.1 KB-226F1.2 4.13 5.19e-05 0.0211 0.32 0.27 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23969211~23969873:+ CESC cis rs11971779 0.68 rs17691238 ENSG00000273391.1 RP11-634H22.1 -4.13 5.19e-05 0.0211 -0.26 -0.27 Diisocyanate-induced asthma; chr7:139367538 chr7:139359032~139359566:- CESC cis rs9487094 0.62 rs6939953 ENSG00000260273.1 RP11-425D10.10 4.13 5.19e-05 0.0211 0.33 0.27 Height; chr6:109390116 chr6:109382795~109383666:+ CESC cis rs6844153 0.68 rs61047003 ENSG00000240005.4 RP11-293A21.1 -4.13 5.2e-05 0.0211 -0.35 -0.27 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26937139 chr4:26859806~26860599:- CESC cis rs4319547 0.695 rs6489002 ENSG00000275265.1 RP11-15J22.8 -4.13 5.2e-05 0.0211 -0.37 -0.27 Body mass index; chr12:122445275 chr12:122501187~122501641:+ CESC cis rs4319547 0.619 rs10744208 ENSG00000275265.1 RP11-15J22.8 -4.13 5.2e-05 0.0211 -0.37 -0.27 Body mass index; chr12:122447012 chr12:122501187~122501641:+ CESC cis rs4319547 0.656 rs10744209 ENSG00000275265.1 RP11-15J22.8 -4.13 5.2e-05 0.0211 -0.37 -0.27 Body mass index; chr12:122447021 chr12:122501187~122501641:+ CESC cis rs4319547 0.626 rs10744210 ENSG00000275265.1 RP11-15J22.8 -4.13 5.2e-05 0.0211 -0.37 -0.27 Body mass index; chr12:122447246 chr12:122501187~122501641:+ CESC cis rs4319547 0.695 rs10744211 ENSG00000275265.1 RP11-15J22.8 -4.13 5.2e-05 0.0211 -0.37 -0.27 Body mass index; chr12:122447273 chr12:122501187~122501641:+ CESC cis rs73086581 0.524 rs2253977 ENSG00000229539.1 RP11-119B16.2 -4.13 5.2e-05 0.0212 -0.33 -0.27 Response to antidepressants in depression; chr20:3958493 chr20:3888239~3888868:- CESC cis rs9987353 0.589 rs1053036 ENSG00000253893.2 FAM85B 4.13 5.21e-05 0.0212 0.35 0.27 Recombination measurement; chr8:9202567 chr8:8167819~8226614:- CESC cis rs8040855 0.559 rs6496801 ENSG00000259774.1 RP11-182J1.13 -4.13 5.21e-05 0.0212 -0.33 -0.27 Bulimia nervosa; chr15:85185168 chr15:84422618~84425882:+ CESC cis rs116095464 1 rs7721278 ENSG00000250848.1 CTD-2083E4.5 -4.13 5.21e-05 0.0212 -0.43 -0.27 Breast cancer; chr5:310415 chr5:288833~290321:- CESC cis rs12908161 1 rs35808647 ENSG00000225151.9 GOLGA2P7 -4.13 5.21e-05 0.0212 -0.37 -0.27 Schizophrenia; chr15:84834210 chr15:84199311~84230136:- CESC cis rs7829975 0.572 rs28730413 ENSG00000254340.1 RP11-10A14.3 -4.13 5.21e-05 0.0212 -0.33 -0.27 Mood instability; chr8:8937937 chr8:9141424~9145435:+ CESC cis rs2058059 0.551 rs72608543 ENSG00000205578.5 POM121B -4.13 5.21e-05 0.0212 -0.35 -0.27 Subcutaneous adipose tissue; chr7:72597693 chr7:73293497~73301161:+ CESC cis rs2439831 0.85 rs12440573 ENSG00000275601.1 AC011330.13 -4.13 5.21e-05 0.0212 -0.42 -0.27 Lung cancer in ever smokers; chr15:43816799 chr15:43642389~43643023:- CESC cis rs2933343 0.649 rs728839 ENSG00000231305.3 RP11-723O4.2 4.13 5.21e-05 0.0212 0.25 0.27 IgG glycosylation; chr3:128870516 chr3:128861313~128871540:- CESC cis rs7688540 0.771 rs77234191 ENSG00000211553.1 AC253576.2 -4.13 5.21e-05 0.0212 -0.42 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:264505 chr4:136461~136568:+ CESC cis rs6439153 0.933 rs900381 ENSG00000231305.3 RP11-723O4.2 4.13 5.22e-05 0.0212 0.26 0.27 Pneumococcal bacteremia; chr3:128994612 chr3:128861313~128871540:- CESC cis rs2790457 0.792 rs1265830 ENSG00000254635.4 WAC-AS1 4.13 5.22e-05 0.0212 0.32 0.27 Multiple myeloma; chr10:28623294 chr10:28522652~28532743:- CESC cis rs7259376 0.525 rs1692601 ENSG00000213971.6 RP11-15H20.6 -4.13 5.22e-05 0.0212 -0.33 -0.27 Menopause (age at onset); chr19:22453333 chr19:23259906~23274251:- CESC cis rs9322193 0.923 rs9322204 ENSG00000216906.2 RP11-350J20.9 4.13 5.22e-05 0.0212 0.29 0.27 Lung cancer; chr6:149636047 chr6:149904243~149906418:+ CESC cis rs1387259 0.723 rs2732488 ENSG00000258273.1 RP11-370I10.4 -4.13 5.22e-05 0.0212 -0.32 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48377661 chr12:48333755~48333901:- CESC cis rs1387259 0.758 rs2634670 ENSG00000258273.1 RP11-370I10.4 -4.13 5.22e-05 0.0212 -0.32 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48378094 chr12:48333755~48333901:- CESC cis rs2412819 0.571 rs4644832 ENSG00000205771.5 CATSPER2P1 4.13 5.22e-05 0.0212 0.4 0.27 Lung cancer; chr15:43792507 chr15:43726918~43747094:- CESC cis rs1124769 0.719 rs7170302 ENSG00000259378.1 DCAF13P3 -4.13 5.22e-05 0.0212 -0.36 -0.27 Cognitive performance; chr15:50918913 chr15:50944663~50945996:+ CESC cis rs7243790 1 rs7243790 ENSG00000277324.1 RP11-850A17.1 -4.13 5.23e-05 0.0212 -0.31 -0.27 Diastolic blood pressure; chr18:54435393 chr18:54268346~54270028:- CESC cis rs7243790 1 rs17473264 ENSG00000277324.1 RP11-850A17.1 -4.13 5.23e-05 0.0212 -0.31 -0.27 Diastolic blood pressure; chr18:54436534 chr18:54268346~54270028:- CESC cis rs7243790 1 rs55756660 ENSG00000277324.1 RP11-850A17.1 -4.13 5.23e-05 0.0212 -0.31 -0.27 Diastolic blood pressure; chr18:54436614 chr18:54268346~54270028:- CESC cis rs9487094 0.689 rs9487103 ENSG00000260273.1 RP11-425D10.10 4.13 5.23e-05 0.0212 0.33 0.27 Height; chr6:109430292 chr6:109382795~109383666:+ CESC cis rs2286503 1 rs1029740 ENSG00000228649.7 AC005682.5 4.13 5.23e-05 0.0212 0.24 0.27 Fibrinogen; chr7:22833967 chr7:22854178~22861579:+ CESC cis rs9487094 0.67 rs1998811 ENSG00000260273.1 RP11-425D10.10 4.13 5.23e-05 0.0212 0.35 0.27 Height; chr6:109490935 chr6:109382795~109383666:+ CESC cis rs319690 1 rs319690 ENSG00000229759.1 MRPS18AP1 4.13 5.23e-05 0.0212 0.28 0.27 Diastolic blood pressure;Systolic blood pressure;Blood pressure; chr3:47885994 chr3:48256350~48256938:- CESC cis rs2455601 0.744 rs2163626 ENSG00000254860.4 TMEM9B-AS1 4.13 5.23e-05 0.0212 0.33 0.27 Schizophrenia; chr11:8962000 chr11:8964675~8977527:+ CESC cis rs875971 0.522 rs34973832 ENSG00000222364.1 RNU6-96P -4.13 5.23e-05 0.0212 -0.33 -0.27 Aortic root size; chr7:65931217 chr7:66395191~66395286:+ CESC cis rs17711722 0.74 rs7809991 ENSG00000222364.1 RNU6-96P -4.13 5.23e-05 0.0212 -0.33 -0.27 Calcium levels; chr7:65941231 chr7:66395191~66395286:+ CESC cis rs9487094 0.6 rs10457193 ENSG00000260273.1 RP11-425D10.10 4.13 5.23e-05 0.0212 0.34 0.27 Height; chr6:109507364 chr6:109382795~109383666:+ CESC cis rs9487094 0.558 rs10457194 ENSG00000260273.1 RP11-425D10.10 4.13 5.23e-05 0.0212 0.34 0.27 Height; chr6:109507366 chr6:109382795~109383666:+ CESC cis rs9918079 0.56 rs4698406 ENSG00000273133.1 RP11-799M12.2 -4.13 5.24e-05 0.0213 -0.38 -0.27 Obesity-related traits; chr4:15638994 chr4:15563698~15564253:- CESC cis rs875971 0.545 rs6460298 ENSG00000236529.1 RP13-254B10.1 4.13 5.24e-05 0.0213 0.33 0.27 Aortic root size; chr7:66442783 chr7:65840212~65840596:+ CESC cis rs2439831 1 rs565007 ENSG00000205771.5 CATSPER2P1 -4.13 5.24e-05 0.0213 -0.37 -0.27 Lung cancer in ever smokers; chr15:43424443 chr15:43726918~43747094:- CESC cis rs2439831 1 rs550239 ENSG00000205771.5 CATSPER2P1 -4.13 5.24e-05 0.0213 -0.37 -0.27 Lung cancer in ever smokers; chr15:43427999 chr15:43726918~43747094:- CESC cis rs9322193 0.886 rs9322198 ENSG00000268592.3 RAET1E-AS1 4.13 5.24e-05 0.0213 0.34 0.27 Lung cancer; chr6:149623772 chr6:149863494~149919507:+ CESC cis rs9322193 0.884 rs11155669 ENSG00000268592.3 RAET1E-AS1 4.13 5.24e-05 0.0213 0.34 0.27 Lung cancer; chr6:149633501 chr6:149863494~149919507:+ CESC cis rs9322193 0.887 rs9505824 ENSG00000268592.3 RAET1E-AS1 4.13 5.24e-05 0.0213 0.34 0.27 Lung cancer; chr6:149633663 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9505826 ENSG00000268592.3 RAET1E-AS1 4.13 5.24e-05 0.0213 0.34 0.27 Lung cancer; chr6:149633912 chr6:149863494~149919507:+ CESC cis rs9322193 0.923 rs9766886 ENSG00000268592.3 RAET1E-AS1 4.13 5.24e-05 0.0213 0.34 0.27 Lung cancer; chr6:149637048 chr6:149863494~149919507:+ CESC cis rs67311347 1 rs2276870 ENSG00000223797.4 ENTPD3-AS1 -4.13 5.25e-05 0.0213 -0.27 -0.27 Renal cell carcinoma; chr3:40457691 chr3:40313802~40453329:- CESC cis rs61776719 0.738 rs7555461 ENSG00000212541.1 RNU6-510P 4.13 5.25e-05 0.0213 0.31 0.27 Coronary artery disease; chr1:37979077 chr1:37991462~37991569:+ CESC cis rs72634258 0.842 rs6577463 ENSG00000238249.2 HMGN2P17 4.13 5.25e-05 0.0213 0.3 0.27 Inflammatory bowel disease; chr1:8109425 chr1:8893409~8894151:+ CESC cis rs72634258 0.699 rs12128234 ENSG00000238249.2 HMGN2P17 4.13 5.25e-05 0.0213 0.3 0.27 Inflammatory bowel disease; chr1:8110159 chr1:8893409~8894151:+ CESC cis rs17772222 0.917 rs61986669 ENSG00000258983.2 RP11-507K2.2 4.13 5.25e-05 0.0213 0.34 0.27 Coronary artery calcification; chr14:88727121 chr14:88499334~88515502:+ CESC cis rs7048146 0.577 rs10979952 ENSG00000213539.4 YBX1P6 4.13 5.25e-05 0.0213 0.3 0.27 Vascular brain injury; chr9:109587348 chr9:109532830~109534332:- CESC cis rs79243044 0.965 rs10838302 ENSG00000224295.2 AC087380.14 -4.13 5.25e-05 0.0213 -0.29 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5546479 chr11:5518441~5524955:- CESC cis rs79243044 1 rs7131305 ENSG00000224295.2 AC087380.14 -4.13 5.25e-05 0.0213 -0.29 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5546505 chr11:5518441~5524955:- CESC cis rs9322193 0.923 rs9688517 ENSG00000216906.2 RP11-350J20.9 4.13 5.25e-05 0.0213 0.3 0.27 Lung cancer; chr6:149740655 chr6:149904243~149906418:+ CESC cis rs11159086 1 rs72730186 ENSG00000270000.1 RP3-449M8.9 4.13 5.26e-05 0.0213 0.53 0.27 Advanced glycation end-product levels; chr14:74475610 chr14:74471930~74472360:- CESC cis rs875971 0.545 rs7810213 ENSG00000226824.5 RP4-756H11.3 -4.13 5.27e-05 0.0214 -0.41 -0.27 Aortic root size; chr7:66481592 chr7:66654538~66669855:+ CESC cis rs9487094 0.67 rs2024853 ENSG00000260273.1 RP11-425D10.10 4.13 5.27e-05 0.0214 0.34 0.27 Height; chr6:109498751 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs12197180 ENSG00000260273.1 RP11-425D10.10 4.13 5.27e-05 0.0214 0.34 0.27 Height; chr6:109500687 chr6:109382795~109383666:+ CESC cis rs10129255 0.957 rs12590667 ENSG00000223648.3 IGHV3-64 -4.12 5.28e-05 0.0214 -0.24 -0.27 Kawasaki disease; chr14:106779223 chr14:106643132~106658258:- CESC cis rs2548724 0.755 rs56218837 ENSG00000250682.4 LINC00491 4.12 5.28e-05 0.0214 0.33 0.27 Type 2 diabetes; chr5:102464083 chr5:102609156~102671559:- CESC cis rs75422866 0.764 rs73104177 ENSG00000274902.1 RP1-197B17.4 4.12 5.28e-05 0.0214 0.71 0.27 Pneumonia; chr12:47713550 chr12:47731908~47732351:+ CESC cis rs75422866 0.764 rs73104184 ENSG00000274902.1 RP1-197B17.4 4.12 5.28e-05 0.0214 0.71 0.27 Pneumonia; chr12:47715623 chr12:47731908~47732351:+ CESC cis rs75422866 0.85 rs73111212 ENSG00000280054.1 RP1-197B17.7 4.12 5.28e-05 0.0214 0.75 0.27 Pneumonia; chr12:47577638 chr12:47728151~47730598:- CESC cis rs75422866 0.85 rs73111216 ENSG00000280054.1 RP1-197B17.7 4.12 5.28e-05 0.0214 0.75 0.27 Pneumonia; chr12:47577671 chr12:47728151~47730598:- CESC cis rs75422866 0.85 rs73111217 ENSG00000280054.1 RP1-197B17.7 4.12 5.28e-05 0.0214 0.75 0.27 Pneumonia; chr12:47577693 chr12:47728151~47730598:- CESC cis rs769267 0.93 rs7254748 ENSG00000269131.1 AC004447.2 -4.12 5.28e-05 0.0214 -0.22 -0.27 Tonsillectomy; chr19:19286670 chr19:18990893~18993610:+ CESC cis rs7587476 0.784 rs34112702 ENSG00000229267.2 AC072062.1 -4.12 5.28e-05 0.0214 -0.35 -0.27 Neuroblastoma; chr2:214831278 chr2:214810229~214963274:+ CESC cis rs7937890 0.559 rs4369365 ENSG00000251991.1 RNU7-49P 4.12 5.28e-05 0.0214 0.28 0.27 Mitochondrial DNA levels; chr11:14422969 chr11:14478892~14478953:+ CESC cis rs7688540 0.771 rs11722197 ENSG00000211553.1 AC253576.2 -4.12 5.28e-05 0.0214 -0.42 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:287918 chr4:136461~136568:+ CESC cis rs7688540 0.771 rs11723261 ENSG00000211553.1 AC253576.2 -4.12 5.28e-05 0.0214 -0.42 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:288710 chr4:136461~136568:+ CESC cis rs113835537 0.935 rs76228630 ENSG00000255517.5 CTD-3074O7.5 -4.12 5.29e-05 0.0214 -0.43 -0.27 Airway imaging phenotypes; chr11:66691205 chr11:66473490~66480233:- CESC cis rs113835537 0.935 rs79496339 ENSG00000255517.5 CTD-3074O7.5 -4.12 5.29e-05 0.0214 -0.43 -0.27 Airway imaging phenotypes; chr11:66700298 chr11:66473490~66480233:- CESC cis rs9532669 0.926 rs9532657 ENSG00000176268.5 CYCSP34 -4.12 5.29e-05 0.0214 -0.27 -0.27 Cervical cancer; chr13:40918208 chr13:40863599~40863902:- CESC cis rs6439153 0.933 rs810952 ENSG00000231305.3 RP11-723O4.2 4.12 5.3e-05 0.0214 0.26 0.27 Pneumococcal bacteremia; chr3:128967062 chr3:128861313~128871540:- CESC cis rs453301 0.682 rs2929308 ENSG00000173295.6 FAM86B3P -4.12 5.3e-05 0.0215 -0.33 -0.27 Joint mobility (Beighton score); chr8:9226611 chr8:8228595~8244865:+ CESC cis rs8023445 0.85 rs16961733 ENSG00000275580.1 RP11-295H24.4 -4.12 5.3e-05 0.0215 -0.36 -0.27 Major depressive disorder; chr15:48856159 chr15:49343608~49344254:+ CESC cis rs3892630 0.588 rs2287881 ENSG00000267475.1 CTD-2538C1.2 4.12 5.3e-05 0.0215 0.37 0.27 Red blood cell traits; chr19:32842249 chr19:32687089~32691750:- CESC cis rs2337406 0.778 rs58113768 ENSG00000254174.1 IGHV1-12 4.12 5.3e-05 0.0215 0.3 0.27 Alzheimer's disease (late onset); chr14:106700213 chr14:106122420~106122709:- CESC cis rs9309473 1 rs7576245 ENSG00000163016.8 ALMS1P 4.12 5.3e-05 0.0215 0.34 0.27 Metabolite levels; chr2:73602551 chr2:73644919~73685576:+ CESC cis rs9907295 0.71 rs9894083 ENSG00000271013.1 AC015849.15 -4.12 5.31e-05 0.0215 -0.37 -0.27 Fibroblast growth factor basic levels; chr17:35842151 chr17:35912635~35918010:- CESC cis rs55794721 0.509 rs6699113 ENSG00000224183.1 SDHDP6 -4.12 5.31e-05 0.0215 -0.28 -0.27 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25294164~25294643:- CESC cis rs55794721 0.509 rs7554255 ENSG00000224183.1 SDHDP6 -4.12 5.31e-05 0.0215 -0.28 -0.27 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25294164~25294643:- CESC cis rs55794721 0.509 rs4649085 ENSG00000224183.1 SDHDP6 -4.12 5.31e-05 0.0215 -0.28 -0.27 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25294164~25294643:- CESC cis rs673078 0.607 rs2036314 ENSG00000275759.1 RP11-131L12.3 -4.12 5.31e-05 0.0215 -0.43 -0.27 Glucose homeostasis traits; chr12:118367132 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943369 ENSG00000275759.1 RP11-131L12.3 -4.12 5.31e-05 0.0215 -0.43 -0.27 Glucose homeostasis traits; chr12:118368145 chr12:118428281~118428870:+ CESC cis rs8040855 0.93 rs6496767 ENSG00000259295.5 CSPG4P12 -4.12 5.31e-05 0.0215 -0.34 -0.27 Bulimia nervosa; chr15:85159522 chr15:85191438~85213905:+ CESC cis rs8020095 0.528 rs1955604 ENSG00000258561.1 RP11-72M17.1 -4.12 5.31e-05 0.0215 -0.4 -0.27 Depression (quantitative trait); chr14:66969723 chr14:66212810~66509394:- CESC cis rs77204473 0.744 rs11606480 ENSG00000254851.1 RP11-109L13.1 4.12 5.32e-05 0.0215 0.54 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117194817 chr11:117135528~117138582:+ CESC cis rs224278 0.509 rs1509952 ENSG00000238280.1 RP11-436D10.3 -4.12 5.32e-05 0.0215 -0.41 -0.27 Ewing sarcoma; chr10:62979908 chr10:62793562~62805887:- CESC cis rs2019137 0.56 rs10175462 ENSG00000189223.12 PAX8-AS1 -4.12 5.32e-05 0.0215 -0.33 -0.27 Lymphocyte counts; chr2:113230915 chr2:113211522~113276581:+ CESC cis rs57502260 0.704 rs17149179 ENSG00000212093.1 AP000807.1 4.12 5.32e-05 0.0215 0.44 0.27 Total body bone mineral density (age 45-60); chr11:68584254 chr11:68506083~68506166:- CESC cis rs74394007 0.92 rs115503737 ENSG00000244515.1 KRT18P34 4.12 5.32e-05 0.0215 0.49 0.27 Total body bone mineral density; chr3:156879464 chr3:157162663~157163932:- CESC cis rs9532669 0.926 rs2324742 ENSG00000239827.7 SUGT1P3 -4.12 5.32e-05 0.0215 -0.29 -0.27 Cervical cancer; chr13:40919059 chr13:40908159~40921774:- CESC cis rs9532669 0.857 rs9594455 ENSG00000239827.7 SUGT1P3 -4.12 5.32e-05 0.0215 -0.29 -0.27 Cervical cancer; chr13:40919452 chr13:40908159~40921774:- CESC cis rs9532669 0.926 rs9532659 ENSG00000239827.7 SUGT1P3 -4.12 5.32e-05 0.0215 -0.29 -0.27 Cervical cancer; chr13:40920380 chr13:40908159~40921774:- CESC cis rs9532669 0.89 rs9594457 ENSG00000239827.7 SUGT1P3 -4.12 5.32e-05 0.0215 -0.29 -0.27 Cervical cancer; chr13:40920439 chr13:40908159~40921774:- CESC cis rs9532669 0.926 rs9594458 ENSG00000239827.7 SUGT1P3 -4.12 5.32e-05 0.0215 -0.29 -0.27 Cervical cancer; chr13:40920448 chr13:40908159~40921774:- CESC cis rs9532669 0.926 rs9590562 ENSG00000239827.7 SUGT1P3 -4.12 5.32e-05 0.0215 -0.29 -0.27 Cervical cancer; chr13:40920503 chr13:40908159~40921774:- CESC cis rs9532669 0.963 rs12857052 ENSG00000239827.7 SUGT1P3 -4.12 5.32e-05 0.0215 -0.29 -0.27 Cervical cancer; chr13:40920831 chr13:40908159~40921774:- CESC cis rs7005380 0.58 rs13263296 ENSG00000279347.1 RP11-85I17.2 -4.12 5.33e-05 0.0215 -0.25 -0.27 Interstitial lung disease; chr8:119874305 chr8:119838736~119840385:- CESC cis rs1401999 0.546 rs4148593 ENSG00000272922.1 RP11-329B9.5 -4.12 5.33e-05 0.0215 -0.29 -0.27 Anterior chamber depth; chr3:183932082 chr3:184742818~184743284:+ CESC cis rs60311166 1 rs934839 ENSG00000242142.1 SERBP1P3 -4.12 5.33e-05 0.0215 -0.49 -0.27 CTACK levels; chr3:52649882 chr3:53064283~53065091:- CESC cis rs2404602 0.716 rs8025134 ENSG00000280730.1 AC090181.1 4.12 5.33e-05 0.0215 0.21 0.27 Blood metabolite levels; chr15:76489388 chr15:77056895~77057021:+ CESC cis rs2337406 0.789 rs112027230 ENSG00000274576.2 IGHV2-70 -4.12 5.33e-05 0.0215 -0.36 -0.27 Alzheimer's disease (late onset); chr14:106810329 chr14:106770577~106771020:- CESC cis rs11971779 0.715 rs7787398 ENSG00000273391.1 RP11-634H22.1 4.12 5.33e-05 0.0216 0.27 0.27 Diisocyanate-induced asthma; chr7:139377100 chr7:139359032~139359566:- CESC cis rs7191700 0.644 rs918738 ENSG00000262636.1 CTD-3088G3.4 -4.12 5.33e-05 0.0216 -0.35 -0.27 Multiple sclerosis; chr16:11345822 chr16:11380859~11381118:- CESC cis rs516805 0.847 rs520867 ENSG00000279453.1 RP3-425C14.4 -4.12 5.34e-05 0.0216 -0.31 -0.27 Lymphocyte counts; chr6:122465501 chr6:122436789~122439223:- CESC cis rs516805 0.961 rs693669 ENSG00000279453.1 RP3-425C14.4 -4.12 5.34e-05 0.0216 -0.31 -0.27 Lymphocyte counts; chr6:122465690 chr6:122436789~122439223:- CESC cis rs17772222 0.958 rs60878614 ENSG00000258983.2 RP11-507K2.2 4.12 5.34e-05 0.0216 0.34 0.27 Coronary artery calcification; chr14:88513871 chr14:88499334~88515502:+ CESC cis rs17301013 0.581 rs12082139 ENSG00000227373.4 RP11-160H22.5 4.12 5.34e-05 0.0216 0.33 0.27 Systemic lupus erythematosus; chr1:174589043 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs12067463 ENSG00000227373.4 RP11-160H22.5 4.12 5.34e-05 0.0216 0.33 0.27 Systemic lupus erythematosus; chr1:174625437 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs10912823 ENSG00000227373.4 RP11-160H22.5 4.12 5.34e-05 0.0216 0.33 0.27 Systemic lupus erythematosus; chr1:174625602 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs6677874 ENSG00000227373.4 RP11-160H22.5 4.12 5.34e-05 0.0216 0.33 0.27 Systemic lupus erythematosus; chr1:174628410 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs333423 ENSG00000227373.4 RP11-160H22.5 4.12 5.34e-05 0.0216 0.33 0.27 Systemic lupus erythematosus; chr1:174666557 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs333437 ENSG00000227373.4 RP11-160H22.5 4.12 5.34e-05 0.0216 0.33 0.27 Systemic lupus erythematosus; chr1:174672224 chr1:174115300~174160004:- CESC cis rs67311347 1 rs73080137 ENSG00000223797.4 ENTPD3-AS1 4.12 5.35e-05 0.0216 0.27 0.27 Renal cell carcinoma; chr3:40474921 chr3:40313802~40453329:- CESC cis rs7688540 0.771 rs4129956 ENSG00000211553.1 AC253576.2 -4.12 5.35e-05 0.0216 -0.42 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:308219 chr4:136461~136568:+ CESC cis rs694739 0.541 rs61886926 ENSG00000236935.1 AP003774.1 4.12 5.35e-05 0.0216 0.28 0.27 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64366080 chr11:64325050~64329504:- CESC cis rs694739 0.628 rs617051 ENSG00000236935.1 AP003774.1 4.12 5.35e-05 0.0216 0.28 0.27 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64366166 chr11:64325050~64329504:- CESC cis rs7937890 0.532 rs2575833 ENSG00000251991.1 RNU7-49P 4.12 5.35e-05 0.0216 0.29 0.27 Mitochondrial DNA levels; chr11:14470959 chr11:14478892~14478953:+ CESC cis rs2439831 0.681 rs2242067 ENSG00000205771.5 CATSPER2P1 -4.12 5.35e-05 0.0216 -0.42 -0.27 Lung cancer in ever smokers; chr15:43407105 chr15:43726918~43747094:- CESC cis rs2276314 1 rs1540042 ENSG00000278986.1 RP11-723J4.3 -4.12 5.35e-05 0.0216 -0.3 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35975273 chr18:35972151~35973916:+ CESC cis rs11159086 1 rs11159087 ENSG00000270000.1 RP3-449M8.9 4.12 5.36e-05 0.0216 0.48 0.27 Advanced glycation end-product levels; chr14:74504671 chr14:74471930~74472360:- CESC cis rs11089937 0.597 rs6001072 ENSG00000211638.2 IGLV8-61 -4.12 5.36e-05 0.0216 -0.26 -0.27 Periodontitis (PAL4Q3); chr22:22133629 chr22:22098700~22099212:+ CESC cis rs12908161 1 rs35808647 ENSG00000259728.4 LINC00933 4.12 5.36e-05 0.0217 0.35 0.27 Schizophrenia; chr15:84834210 chr15:84570649~84580175:+ CESC cis rs7829975 0.623 rs10087493 ENSG00000253893.2 FAM85B 4.12 5.36e-05 0.0217 0.33 0.27 Mood instability; chr8:8516047 chr8:8167819~8226614:- CESC cis rs77636220 1 rs73686537 ENSG00000270673.1 YTHDF3-AS1 -4.12 5.37e-05 0.0217 -0.48 -0.27 Body mass index; chr8:63728569 chr8:63167725~63168442:- CESC cis rs17301013 0.507 rs10912789 ENSG00000227373.4 RP11-160H22.5 4.12 5.37e-05 0.0217 0.36 0.27 Systemic lupus erythematosus; chr1:174465616 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6684141 ENSG00000227373.4 RP11-160H22.5 4.12 5.37e-05 0.0217 0.36 0.27 Systemic lupus erythematosus; chr1:174467305 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12058377 ENSG00000227373.4 RP11-160H22.5 4.12 5.37e-05 0.0217 0.36 0.27 Systemic lupus erythematosus; chr1:174470971 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6656925 ENSG00000227373.4 RP11-160H22.5 4.12 5.37e-05 0.0217 0.36 0.27 Systemic lupus erythematosus; chr1:174474161 chr1:174115300~174160004:- CESC cis rs55794721 0.509 rs6699896 ENSG00000224183.1 SDHDP6 -4.12 5.37e-05 0.0217 -0.29 -0.27 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25294164~25294643:- CESC cis rs57221529 0.608 rs11749927 ENSG00000225138.6 CTD-2228K2.7 4.12 5.38e-05 0.0217 0.39 0.27 Lung disease severity in cystic fibrosis; chr5:668727 chr5:473236~480884:+ CESC cis rs35740288 0.929 rs11556865 ENSG00000202081.1 RNU6-1280P 4.12 5.38e-05 0.0217 0.34 0.27 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85759949 chr15:85651522~85651628:- CESC cis rs1930961 1 rs7285549 ENSG00000272942.1 CTA-246H3.12 -4.12 5.38e-05 0.0217 -0.39 -0.27 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25434324~25435070:- CESC cis rs13113518 1 rs9312661 ENSG00000273257.1 RP11-177J6.1 4.12 5.38e-05 0.0217 0.35 0.27 Height; chr4:55476159 chr4:55387949~55388271:+ CESC cis rs4272720 0.535 rs35922675 ENSG00000229870.1 RP11-507K13.6 -4.12 5.38e-05 0.0217 -0.32 -0.27 Platelet count;Plateletcrit; chr10:49081583 chr10:49815096~49815562:+ CESC cis rs4272720 0.535 rs56291725 ENSG00000229870.1 RP11-507K13.6 -4.12 5.38e-05 0.0217 -0.32 -0.27 Platelet count;Plateletcrit; chr10:49081940 chr10:49815096~49815562:+ CESC cis rs4272720 0.535 rs58154726 ENSG00000229870.1 RP11-507K13.6 -4.12 5.38e-05 0.0217 -0.32 -0.27 Platelet count;Plateletcrit; chr10:49082451 chr10:49815096~49815562:+ CESC cis rs4272720 0.535 rs68065270 ENSG00000229870.1 RP11-507K13.6 -4.12 5.38e-05 0.0217 -0.32 -0.27 Platelet count;Plateletcrit; chr10:49082473 chr10:49815096~49815562:+ CESC cis rs67180937 0.645 rs1909197 ENSG00000272750.1 RP11-378J18.8 -4.12 5.38e-05 0.0217 -0.35 -0.27 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222645879 chr1:222658867~222661512:- CESC cis rs2115630 0.645 rs6496284 ENSG00000259295.5 CSPG4P12 -4.12 5.38e-05 0.0217 -0.28 -0.27 P wave terminal force; chr15:84635039 chr15:85191438~85213905:+ CESC cis rs9987353 0.519 rs13276350 ENSG00000253893.2 FAM85B 4.12 5.39e-05 0.0217 0.37 0.27 Recombination measurement; chr8:9205647 chr8:8167819~8226614:- CESC cis rs9309473 1 rs3738848 ENSG00000163016.8 ALMS1P 4.12 5.39e-05 0.0218 0.33 0.27 Metabolite levels; chr2:73534754 chr2:73644919~73685576:+ CESC cis rs2564921 0.693 rs2581798 ENSG00000242142.1 SERBP1P3 4.12 5.39e-05 0.0218 0.32 0.27 Height; chr3:53073584 chr3:53064283~53065091:- CESC cis rs8081395 0.627 rs12952730 ENSG00000266992.1 DHX40P1 4.12 5.39e-05 0.0218 0.3 0.27 White blood cell count; chr17:59901475 chr17:59976009~60002384:- CESC cis rs9322193 0.924 rs9322189 ENSG00000216906.2 RP11-350J20.9 4.12 5.39e-05 0.0218 0.3 0.27 Lung cancer; chr6:149588797 chr6:149904243~149906418:+ CESC cis rs9322193 0.884 rs880245 ENSG00000223701.3 RAET1E-AS1 -4.12 5.39e-05 0.0218 -0.32 -0.27 Lung cancer; chr6:149846262 chr6:149884431~149919508:+ CESC cis rs853679 1 rs7740487 ENSG00000219392.1 RP1-265C24.5 -4.12 5.4e-05 0.0218 -0.42 -0.27 Depression; chr6:28248708 chr6:28115628~28116551:+ CESC cis rs853679 0.882 rs9468287 ENSG00000219392.1 RP1-265C24.5 -4.12 5.4e-05 0.0218 -0.45 -0.27 Depression; chr6:28111963 chr6:28115628~28116551:+ CESC cis rs10129255 0.701 rs2005643 ENSG00000223648.3 IGHV3-64 4.12 5.4e-05 0.0218 0.23 0.27 Kawasaki disease; chr14:106676288 chr14:106643132~106658258:- CESC cis rs9309473 0.898 rs28879089 ENSG00000163016.8 ALMS1P 4.12 5.4e-05 0.0218 0.36 0.27 Metabolite levels; chr2:73585759 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs7582606 ENSG00000163016.8 ALMS1P 4.12 5.4e-05 0.0218 0.36 0.27 Metabolite levels; chr2:73586818 chr2:73644919~73685576:+ CESC cis rs875971 0.862 rs4149461 ENSG00000232559.3 GS1-124K5.12 -4.12 5.41e-05 0.0218 -0.28 -0.27 Aortic root size; chr7:66279745 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10261398 ENSG00000232559.3 GS1-124K5.12 -4.12 5.41e-05 0.0218 -0.28 -0.27 Aortic root size; chr7:66285177 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10224872 ENSG00000232559.3 GS1-124K5.12 -4.12 5.41e-05 0.0218 -0.28 -0.27 Aortic root size; chr7:66294786 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs10282433 ENSG00000232559.3 GS1-124K5.12 -4.12 5.41e-05 0.0218 -0.28 -0.27 Aortic root size; chr7:66256452 chr7:66554588~66576923:- CESC cis rs7580658 0.509 rs12477653 ENSG00000236682.1 AC068282.3 -4.12 5.42e-05 0.0218 -0.32 -0.27 Protein C levels; chr2:127194505 chr2:127389130~127400580:+ CESC cis rs7580658 0.545 rs13001179 ENSG00000236682.1 AC068282.3 -4.12 5.42e-05 0.0218 -0.32 -0.27 Protein C levels; chr2:127194617 chr2:127389130~127400580:+ CESC cis rs7580658 0.545 rs13001184 ENSG00000236682.1 AC068282.3 -4.12 5.42e-05 0.0218 -0.32 -0.27 Protein C levels; chr2:127194630 chr2:127389130~127400580:+ CESC cis rs4272720 0.535 rs34364659 ENSG00000229870.1 RP11-507K13.6 -4.12 5.42e-05 0.0218 -0.32 -0.27 Platelet count;Plateletcrit; chr10:49082631 chr10:49815096~49815562:+ CESC cis rs3796352 1 rs11718752 ENSG00000280417.1 RP11-5O17.1 -4.12 5.42e-05 0.0218 -0.41 -0.27 Immune reponse to smallpox (secreted IL-2); chr3:53096729 chr3:53046166~53048122:+ CESC cis rs4660456 0.597 rs7518568 ENSG00000237899.1 RP4-739H11.3 4.12 5.42e-05 0.0218 0.32 0.27 Platelet count; chr1:40708508 chr1:40669089~40687588:- CESC cis rs35740288 0.929 rs3858927 ENSG00000202081.1 RNU6-1280P 4.12 5.42e-05 0.0218 0.33 0.27 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85758385 chr15:85651522~85651628:- CESC cis rs35740288 0.895 rs3743332 ENSG00000202081.1 RNU6-1280P 4.12 5.42e-05 0.0218 0.33 0.27 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85760520 chr15:85651522~85651628:- CESC cis rs17772222 0.917 rs61986670 ENSG00000258983.2 RP11-507K2.2 4.12 5.42e-05 0.0218 0.33 0.27 Coronary artery calcification; chr14:88730875 chr14:88499334~88515502:+ CESC cis rs4356203 0.933 rs12801545 ENSG00000272034.1 SNORD14A 4.12 5.43e-05 0.0219 0.3 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17244629 chr11:17074654~17074744:- CESC cis rs523522 0.962 rs7471 ENSG00000278344.1 RP11-18C24.8 4.12 5.43e-05 0.0219 0.33 0.27 High light scatter reticulocyte count; chr12:120503412 chr12:120500735~120501090:- CESC cis rs2136613 0.533 rs10995332 ENSG00000238280.1 RP11-436D10.3 -4.12 5.44e-05 0.0219 -0.31 -0.27 Selective IgA deficiency; chr10:62857905 chr10:62793562~62805887:- CESC cis rs8020095 0.571 rs2039055 ENSG00000258561.1 RP11-72M17.1 -4.12 5.44e-05 0.0219 -0.4 -0.27 Depression (quantitative trait); chr14:67114076 chr14:66212810~66509394:- CESC cis rs2662776 0.521 rs2999966 ENSG00000232995.6 RGS5 -4.12 5.44e-05 0.0219 -0.29 -0.27 Lead levels in blood; chr1:163197240 chr1:163244505~163321894:- CESC cis rs2276314 0.857 rs62101376 ENSG00000278986.1 RP11-723J4.3 -4.12 5.44e-05 0.0219 -0.31 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36002992 chr18:35972151~35973916:+ CESC cis rs17507216 0.591 rs7163848 ENSG00000278603.1 RP13-608F4.5 4.12 5.44e-05 0.0219 0.43 0.27 Excessive daytime sleepiness; chr15:82729563 chr15:82472203~82472426:+ CESC cis rs7216064 0.765 rs6504550 ENSG00000278730.1 RP11-147L13.11 -4.12 5.44e-05 0.0219 -0.28 -0.27 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67898426 chr17:68126666~68129586:+ CESC cis rs5769707 0.967 rs17182154 ENSG00000235111.1 RP1-29C18.8 -4.12 5.44e-05 0.0219 -0.27 -0.27 Monocyte percentage of white cells;Monocyte count; chr22:49596822 chr22:49612657~49615716:- CESC cis rs4819052 0.851 rs914214 ENSG00000215447.6 BX322557.10 -4.12 5.45e-05 0.0219 -0.23 -0.27 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45277905 chr21:45288052~45291738:+ CESC cis rs9309473 1 rs6711033 ENSG00000163016.8 ALMS1P 4.12 5.45e-05 0.0219 0.34 0.27 Metabolite levels; chr2:73519516 chr2:73644919~73685576:+ CESC cis rs12468226 0.938 rs16839065 ENSG00000273456.1 RP11-686O6.2 4.12 5.46e-05 0.022 0.36 0.27 Urate levels; chr2:202308774 chr2:202374932~202375604:- CESC cis rs12468226 0.938 rs115418918 ENSG00000273456.1 RP11-686O6.2 4.12 5.46e-05 0.022 0.36 0.27 Urate levels; chr2:202315145 chr2:202374932~202375604:- CESC cis rs12468226 0.938 rs114922024 ENSG00000273456.1 RP11-686O6.2 4.12 5.46e-05 0.022 0.36 0.27 Urate levels; chr2:202315958 chr2:202374932~202375604:- CESC cis rs12468226 0.938 rs77261109 ENSG00000273456.1 RP11-686O6.2 4.12 5.46e-05 0.022 0.36 0.27 Urate levels; chr2:202316233 chr2:202374932~202375604:- CESC cis rs12468226 0.938 rs12466003 ENSG00000273456.1 RP11-686O6.2 4.12 5.46e-05 0.022 0.36 0.27 Urate levels; chr2:202317317 chr2:202374932~202375604:- CESC cis rs12468226 0.938 rs76501067 ENSG00000273456.1 RP11-686O6.2 4.12 5.46e-05 0.022 0.36 0.27 Urate levels; chr2:202318042 chr2:202374932~202375604:- CESC cis rs67311347 0.956 rs9822870 ENSG00000223797.4 ENTPD3-AS1 -4.12 5.46e-05 0.022 -0.26 -0.27 Renal cell carcinoma; chr3:40473399 chr3:40313802~40453329:- CESC cis rs10829156 0.898 rs6482565 ENSG00000240291.1 RP11-499P20.2 4.12 5.46e-05 0.022 0.29 0.27 Sudden cardiac arrest; chr10:18611664 chr10:18513115~18545651:- CESC cis rs7829975 0.623 rs10092965 ENSG00000173295.6 FAM86B3P 4.12 5.46e-05 0.022 0.34 0.27 Mood instability; chr8:8515975 chr8:8228595~8244865:+ CESC cis rs761746 0.96 rs4820983 ENSG00000236132.1 CTA-440B3.1 4.12 5.46e-05 0.022 0.32 0.27 Intelligence; chr22:31533668 chr22:31816379~31817491:- CESC cis rs1044826 0.642 rs9826544 ENSG00000178631.7 ACTG1P1 4.12 5.47e-05 0.022 0.33 0.27 Obesity-related traits; chr3:139443989 chr3:139493809~139494937:+ CESC cis rs12107539 0.846 rs3732759 ENSG00000240137.4 ERICH6-AS1 4.12 5.47e-05 0.022 0.25 0.27 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151357137 chr3:150703564~150720146:+ CESC cis rs5742933 0.744 rs13002216 ENSG00000253559.1 OSGEPL1-AS1 4.12 5.47e-05 0.022 0.31 0.27 Ferritin levels; chr2:189746358 chr2:189762704~189765556:+ CESC cis rs6142102 0.886 rs6142098 ENSG00000275784.1 RP5-1125A11.6 -4.12 5.47e-05 0.022 -0.28 -0.27 Skin pigmentation; chr20:34100488 chr20:33989480~33991818:- CESC cis rs6142102 0.961 rs6087557 ENSG00000275784.1 RP5-1125A11.6 -4.12 5.47e-05 0.022 -0.28 -0.27 Skin pigmentation; chr20:34110469 chr20:33989480~33991818:- CESC cis rs875971 0.505 rs1723275 ENSG00000222364.1 RNU6-96P 4.12 5.48e-05 0.022 0.32 0.27 Aortic root size; chr7:66039646 chr7:66395191~66395286:+ CESC cis rs72772090 0.539 rs10515247 ENSG00000248734.2 CTD-2260A17.1 -4.12 5.48e-05 0.022 -0.43 -0.27 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776022 chr5:96784777~96785999:+ CESC cis rs6782228 0.606 rs2811500 ENSG00000242551.2 POU5F1P6 -4.12 5.48e-05 0.022 -0.3 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128647413 chr3:128674735~128677005:- CESC cis rs453301 0.658 rs6983877 ENSG00000173295.6 FAM86B3P -4.12 5.49e-05 0.0221 -0.34 -0.27 Joint mobility (Beighton score); chr8:9047129 chr8:8228595~8244865:+ CESC cis rs5758659 0.622 rs6519298 ENSG00000273366.1 CTA-989H11.1 -4.11 5.49e-05 0.0221 -0.33 -0.27 Cognitive function; chr22:41968993 chr22:42278188~42278846:+ CESC cis rs11250098 0.541 rs6997839 ENSG00000269918.1 AF131215.9 -4.11 5.5e-05 0.0221 -0.34 -0.27 Morning vs. evening chronotype; chr8:10908518 chr8:11104691~11106704:- CESC cis rs748404 0.626 rs62021176 ENSG00000249839.1 AC011330.5 -4.11 5.5e-05 0.0221 -0.38 -0.27 Lung cancer; chr15:43388014 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs16957680 ENSG00000249839.1 AC011330.5 -4.11 5.5e-05 0.0221 -0.38 -0.27 Lung cancer; chr15:43396207 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs7180812 ENSG00000249839.1 AC011330.5 -4.11 5.5e-05 0.0221 -0.38 -0.27 Lung cancer; chr15:43403033 chr15:43663654~43684339:- CESC cis rs9517320 0.935 rs9645891 ENSG00000231194.1 FARP1-AS1 4.11 5.51e-05 0.0221 0.31 0.27 Longevity; chr13:98474546 chr13:98435405~98435840:- CESC cis rs12134133 1 rs2782848 ENSG00000274245.1 RP11-357P18.2 4.11 5.51e-05 0.0221 0.33 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207293407 chr1:207372559~207373252:+ CESC cis rs13392177 0.684 rs11695527 ENSG00000261338.2 RP11-378A13.1 4.11 5.51e-05 0.0221 0.34 0.27 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218203380 chr2:218255319~218257366:+ CESC cis rs2439831 1 rs690263 ENSG00000275601.1 AC011330.13 -4.11 5.51e-05 0.0221 -0.35 -0.27 Lung cancer in ever smokers; chr15:43412267 chr15:43642389~43643023:- CESC cis rs4927850 0.958 rs1975582 ENSG00000231464.1 AC024937.4 4.11 5.51e-05 0.0221 0.34 0.27 Pancreatic cancer; chr3:196024568 chr3:195996738~195998233:+ CESC cis rs62025270 0.688 rs10163064 ENSG00000202081.1 RNU6-1280P -4.11 5.51e-05 0.0222 -0.36 -0.27 Idiopathic pulmonary fibrosis; chr15:85734289 chr15:85651522~85651628:- CESC cis rs9322193 0.923 rs3924871 ENSG00000216906.2 RP11-350J20.9 4.11 5.52e-05 0.0222 0.3 0.27 Lung cancer; chr6:149662080 chr6:149904243~149906418:+ CESC cis rs9517320 1 rs9517322 ENSG00000231194.1 FARP1-AS1 4.11 5.52e-05 0.0222 0.31 0.27 Longevity; chr13:98474084 chr13:98435405~98435840:- CESC cis rs9517320 1 rs9645890 ENSG00000231194.1 FARP1-AS1 4.11 5.52e-05 0.0222 0.31 0.27 Longevity; chr13:98474383 chr13:98435405~98435840:- CESC cis rs8081395 0.627 rs180536 ENSG00000266992.1 DHX40P1 4.11 5.52e-05 0.0222 0.3 0.27 White blood cell count; chr17:59919445 chr17:59976009~60002384:- CESC cis rs7937890 0.531 rs2575828 ENSG00000251991.1 RNU7-49P 4.11 5.52e-05 0.0222 0.29 0.27 Mitochondrial DNA levels; chr11:14462646 chr11:14478892~14478953:+ CESC cis rs7937890 0.559 rs2575829 ENSG00000251991.1 RNU7-49P 4.11 5.52e-05 0.0222 0.29 0.27 Mitochondrial DNA levels; chr11:14463475 chr11:14478892~14478953:+ CESC cis rs7937890 0.559 rs2597201 ENSG00000251991.1 RNU7-49P 4.11 5.52e-05 0.0222 0.29 0.27 Mitochondrial DNA levels; chr11:14463858 chr11:14478892~14478953:+ CESC cis rs7937890 0.559 rs2597200 ENSG00000251991.1 RNU7-49P 4.11 5.52e-05 0.0222 0.29 0.27 Mitochondrial DNA levels; chr11:14464054 chr11:14478892~14478953:+ CESC cis rs7937890 0.559 rs2575830 ENSG00000251991.1 RNU7-49P 4.11 5.52e-05 0.0222 0.29 0.27 Mitochondrial DNA levels; chr11:14464056 chr11:14478892~14478953:+ CESC cis rs7937890 0.559 rs2575831 ENSG00000251991.1 RNU7-49P 4.11 5.52e-05 0.0222 0.29 0.27 Mitochondrial DNA levels; chr11:14464648 chr11:14478892~14478953:+ CESC cis rs7937890 0.532 rs2575832 ENSG00000251991.1 RNU7-49P 4.11 5.52e-05 0.0222 0.29 0.27 Mitochondrial DNA levels; chr11:14467264 chr11:14478892~14478953:+ CESC cis rs7937890 0.559 rs2597197 ENSG00000251991.1 RNU7-49P 4.11 5.52e-05 0.0222 0.29 0.27 Mitochondrial DNA levels; chr11:14468286 chr11:14478892~14478953:+ CESC cis rs7829975 0.623 rs10087493 ENSG00000253981.4 ALG1L13P -4.11 5.52e-05 0.0222 -0.3 -0.27 Mood instability; chr8:8516047 chr8:8236003~8244667:- CESC cis rs761746 0.96 rs9956 ENSG00000236132.1 CTA-440B3.1 -4.11 5.52e-05 0.0222 -0.34 -0.27 Intelligence; chr22:31619464 chr22:31816379~31817491:- CESC cis rs67311347 1 rs2168111 ENSG00000223797.4 ENTPD3-AS1 4.11 5.52e-05 0.0222 0.26 0.27 Renal cell carcinoma; chr3:40353834 chr3:40313802~40453329:- CESC cis rs7789940 0.904 rs56919252 ENSG00000230305.2 AC004980.9 4.11 5.52e-05 0.0222 0.4 0.27 Multiple sclerosis; chr7:76308203 chr7:76524515~76532692:+ CESC cis rs4272720 0.639 rs7088718 ENSG00000229870.1 RP11-507K13.6 -4.11 5.53e-05 0.0222 -0.31 -0.27 Platelet count;Plateletcrit; chr10:49061639 chr10:49815096~49815562:+ CESC cis rs4272720 0.639 rs7073208 ENSG00000229870.1 RP11-507K13.6 -4.11 5.53e-05 0.0222 -0.31 -0.27 Platelet count;Plateletcrit; chr10:49061668 chr10:49815096~49815562:+ CESC cis rs10129255 0.957 rs7493713 ENSG00000280411.1 IGHV1-69-2 -4.11 5.53e-05 0.0222 -0.2 -0.27 Kawasaki disease; chr14:106783685 chr14:106762092~106762588:- CESC cis rs6928977 0.896 rs2064431 ENSG00000234084.1 RP3-388E23.2 4.11 5.53e-05 0.0222 0.24 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135324065 chr6:135301568~135307158:+ CESC cis rs6928977 0.896 rs1012645 ENSG00000234084.1 RP3-388E23.2 4.11 5.53e-05 0.0222 0.24 0.27 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135324309 chr6:135301568~135307158:+ CESC cis rs6740322 0.895 rs6710656 ENSG00000234936.1 AC010883.5 4.11 5.53e-05 0.0222 0.28 0.27 Coronary artery disease; chr2:43339802 chr2:43229573~43233394:+ CESC cis rs10129255 0.784 rs7147210 ENSG00000211974.3 IGHV2-70 4.11 5.54e-05 0.0222 0.29 0.27 Kawasaki disease; chr14:106705271 chr14:106723574~106724093:- CESC cis rs7208859 0.725 rs9915802 ENSG00000264538.5 SUZ12P1 -4.11 5.54e-05 0.0222 -0.29 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846040 chr17:30709299~30790908:+ CESC cis rs7208859 0.725 rs7342938 ENSG00000264538.5 SUZ12P1 -4.11 5.54e-05 0.0222 -0.29 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862812 chr17:30709299~30790908:+ CESC cis rs7208859 0.725 rs6505215 ENSG00000264538.5 SUZ12P1 -4.11 5.54e-05 0.0222 -0.29 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862885 chr17:30709299~30790908:+ CESC cis rs2274273 0.624 rs10129505 ENSG00000258413.1 RP11-665C16.6 -4.11 5.54e-05 0.0222 -0.35 -0.27 Protein biomarker; chr14:55309657 chr14:55262767~55272075:- CESC cis rs2439831 1 rs2439841 ENSG00000205771.5 CATSPER2P1 -4.11 5.54e-05 0.0222 -0.38 -0.27 Lung cancer in ever smokers; chr15:43442551 chr15:43726918~43747094:- CESC cis rs1387259 0.839 rs7487682 ENSG00000258273.1 RP11-370I10.4 4.11 5.55e-05 0.0222 0.3 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48185882 chr12:48333755~48333901:- CESC cis rs916888 0.697 rs199516 ENSG00000232300.1 FAM215B -4.11 5.55e-05 0.0223 -0.42 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46558830~46562795:- CESC cis rs1124769 0.672 rs12909760 ENSG00000259378.1 DCAF13P3 4.11 5.55e-05 0.0223 0.36 0.27 Cognitive performance; chr15:50870064 chr15:50944663~50945996:+ CESC cis rs1124769 0.672 rs8043017 ENSG00000259378.1 DCAF13P3 4.11 5.55e-05 0.0223 0.36 0.27 Cognitive performance; chr15:50871799 chr15:50944663~50945996:+ CESC cis rs1124769 0.672 rs2619696 ENSG00000259378.1 DCAF13P3 -4.11 5.55e-05 0.0223 -0.36 -0.27 Cognitive performance; chr15:50868814 chr15:50944663~50945996:+ CESC cis rs12908161 0.959 rs3748376 ENSG00000225151.9 GOLGA2P7 -4.11 5.56e-05 0.0223 -0.37 -0.27 Schizophrenia; chr15:84785121 chr15:84199311~84230136:- CESC cis rs875971 0.571 rs78668714 ENSG00000237310.1 GS1-124K5.4 4.11 5.56e-05 0.0223 0.31 0.27 Aortic root size; chr7:66474464 chr7:66493706~66495474:+ CESC cis rs75422866 0.85 rs73111210 ENSG00000280054.1 RP1-197B17.7 4.11 5.56e-05 0.0223 0.75 0.27 Pneumonia; chr12:47576949 chr12:47728151~47730598:- CESC cis rs11168351 0.927 rs10875716 ENSG00000240399.1 RP1-228P16.1 4.11 5.56e-05 0.0223 0.3 0.27 Bipolar disorder and schizophrenia; chr12:47995240 chr12:48054813~48055591:- CESC cis rs6504622 0.935 rs17608961 ENSG00000262879.4 RP11-156P1.3 -4.11 5.56e-05 0.0223 -0.3 -0.27 Orofacial clefts; chr17:46952302 chr17:46984045~47100323:- CESC cis rs6740322 0.895 rs9309098 ENSG00000234936.1 AC010883.5 -4.11 5.57e-05 0.0223 -0.28 -0.27 Coronary artery disease; chr2:43327833 chr2:43229573~43233394:+ CESC cis rs13434995 0.589 rs499110 ENSG00000273257.1 RP11-177J6.1 -4.11 5.57e-05 0.0223 -0.38 -0.27 Adiponectin levels; chr4:55381628 chr4:55387949~55388271:+ CESC cis rs6951245 0.608 rs10252234 ENSG00000229043.2 AC091729.9 -4.11 5.57e-05 0.0223 -0.34 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1074745 chr7:1160374~1165267:+ CESC cis rs8100891 0.537 rs2111504 ENSG00000267213.4 AC007773.2 -4.11 5.57e-05 0.0223 -0.38 -0.27 Neuroticism; chr19:32426549 chr19:32390050~32405560:- CESC cis rs6005807 0.543 rs6005866 ENSG00000226471.5 CTA-292E10.6 -4.11 5.57e-05 0.0223 -0.36 -0.27 Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio; chr22:28766952 chr22:28800683~28848559:+ CESC cis rs172166 0.694 rs1631552 ENSG00000219392.1 RP1-265C24.5 -4.11 5.58e-05 0.0223 -0.31 -0.27 Cardiac Troponin-T levels; chr6:28121921 chr6:28115628~28116551:+ CESC cis rs67311347 1 rs6801185 ENSG00000223797.4 ENTPD3-AS1 -4.11 5.58e-05 0.0223 -0.26 -0.27 Renal cell carcinoma; chr3:40463569 chr3:40313802~40453329:- CESC cis rs67311347 1 rs13095055 ENSG00000223797.4 ENTPD3-AS1 -4.11 5.58e-05 0.0223 -0.26 -0.27 Renal cell carcinoma; chr3:40464175 chr3:40313802~40453329:- CESC cis rs9309473 0.519 rs6746971 ENSG00000163016.8 ALMS1P 4.11 5.58e-05 0.0223 0.32 0.27 Metabolite levels; chr2:73442334 chr2:73644919~73685576:+ CESC cis rs3096299 0.967 rs2965827 ENSG00000274627.1 RP11-104N10.2 -4.11 5.58e-05 0.0223 -0.26 -0.27 Multiple myeloma (IgH translocation); chr16:89390942 chr16:89516797~89522217:+ CESC cis rs875971 0.545 rs75577046 ENSG00000226824.5 RP4-756H11.3 -4.11 5.59e-05 0.0224 -0.39 -0.27 Aortic root size; chr7:66493729 chr7:66654538~66669855:+ CESC cis rs7615316 0.934 rs6782400 ENSG00000244327.1 RP11-383G6.3 4.11 5.59e-05 0.0224 0.29 0.27 Mean corpuscular volume;Mean corpuscular hemoglobin; chr3:142576526 chr3:142465315~142472337:- CESC cis rs4500972 1 rs4500972 ENSG00000163016.8 ALMS1P 4.11 5.6e-05 0.0224 0.33 0.27 Glomerular filtration rate (creatinine); chr2:73540770 chr2:73644919~73685576:+ CESC cis rs2836950 0.502 rs12627205 ENSG00000232608.1 TIMM9P2 4.11 5.6e-05 0.0224 0.3 0.27 Menarche (age at onset); chr21:39258101 chr21:39216624~39217506:+ CESC cis rs875971 0.545 rs4718325 ENSG00000226824.5 RP4-756H11.3 -4.11 5.6e-05 0.0224 -0.4 -0.27 Aortic root size; chr7:66215323 chr7:66654538~66669855:+ CESC cis rs36423 0.702 rs1205076 ENSG00000266869.1 RP6-114E22.1 4.11 5.6e-05 0.0224 0.45 0.27 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71871335 chr14:71848606~71908430:+ CESC cis rs7927592 0.956 rs10896334 ENSG00000212093.1 AP000807.1 4.11 5.6e-05 0.0224 0.3 0.27 Total body bone mineral density; chr11:68514026 chr11:68506083~68506166:- CESC cis rs10129255 1 rs4612959 ENSG00000223648.3 IGHV3-64 4.11 5.6e-05 0.0224 0.24 0.27 Kawasaki disease; chr14:106767055 chr14:106643132~106658258:- CESC cis rs62025270 0.632 rs62022919 ENSG00000202081.1 RNU6-1280P -4.11 5.6e-05 0.0224 -0.37 -0.27 Idiopathic pulmonary fibrosis; chr15:85675079 chr15:85651522~85651628:- CESC cis rs62025270 0.632 rs17636096 ENSG00000202081.1 RNU6-1280P -4.11 5.6e-05 0.0224 -0.37 -0.27 Idiopathic pulmonary fibrosis; chr15:85675503 chr15:85651522~85651628:- CESC cis rs10129255 0.957 rs6576228 ENSG00000211974.3 IGHV2-70 4.11 5.6e-05 0.0224 0.27 0.27 Kawasaki disease; chr14:106778401 chr14:106723574~106724093:- CESC cis rs9309473 0.948 rs7603647 ENSG00000163016.8 ALMS1P 4.11 5.6e-05 0.0224 0.35 0.27 Metabolite levels; chr2:73590111 chr2:73644919~73685576:+ CESC cis rs17507216 0.718 rs72751675 ENSG00000255769.6 GOLGA2P10 -4.11 5.61e-05 0.0224 -0.42 -0.27 Excessive daytime sleepiness; chr15:82630452 chr15:82472993~82513950:- CESC cis rs9322193 0.923 rs9800806 ENSG00000216906.2 RP11-350J20.9 4.11 5.61e-05 0.0224 0.3 0.27 Lung cancer; chr6:149740350 chr6:149904243~149906418:+ CESC cis rs8020095 0.528 rs6573724 ENSG00000258561.1 RP11-72M17.1 -4.11 5.61e-05 0.0224 -0.4 -0.27 Depression (quantitative trait); chr14:66773847 chr14:66212810~66509394:- CESC cis rs769267 0.899 rs3934667 ENSG00000269131.1 AC004447.2 4.11 5.62e-05 0.0224 0.22 0.27 Tonsillectomy; chr19:19320614 chr19:18990893~18993610:+ CESC cis rs992157 0.56 rs12987130 ENSG00000261338.2 RP11-378A13.1 -4.11 5.62e-05 0.0224 -0.34 -0.27 Colorectal cancer; chr2:218240267 chr2:218255319~218257366:+ CESC cis rs2277027 1 rs3734030 ENSG00000251405.2 CTB-109A12.1 4.11 5.62e-05 0.0224 0.34 0.27 Pulmonary function;Pulmonary function (smoking interaction); chr5:157512872 chr5:157362615~157460078:- CESC cis rs6782228 0.606 rs7627549 ENSG00000242551.2 POU5F1P6 -4.11 5.62e-05 0.0225 -0.3 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128634236 chr3:128674735~128677005:- CESC cis rs7250849 0.529 rs73052877 ENSG00000273837.1 LLNLR-470E3.1 -4.11 5.62e-05 0.0225 -0.34 -0.27 Blood protein levels; chr19:51662744 chr19:51639478~51639931:- CESC cis rs748404 0.556 rs574856 ENSG00000205771.5 CATSPER2P1 4.11 5.63e-05 0.0225 0.33 0.27 Lung cancer; chr15:43168636 chr15:43726918~43747094:- CESC cis rs6693388 0.602 rs2999526 ENSG00000229021.2 AL591893.1 -4.11 5.63e-05 0.0225 -0.29 -0.27 Blood metabolite ratios; chr1:151979219 chr1:151994531~152042774:+ CESC cis rs6546537 0.911 rs4852898 ENSG00000231024.1 AC092431.3 4.11 5.63e-05 0.0225 0.34 0.27 Serum thyroid-stimulating hormone levels; chr2:69645665 chr2:69700192~69713847:- CESC cis rs2439831 1 rs2467743 ENSG00000205771.5 CATSPER2P1 -4.11 5.63e-05 0.0225 -0.37 -0.27 Lung cancer in ever smokers; chr15:43458148 chr15:43726918~43747094:- CESC cis rs2439831 0.867 rs2245176 ENSG00000205771.5 CATSPER2P1 -4.11 5.63e-05 0.0225 -0.37 -0.27 Lung cancer in ever smokers; chr15:43458564 chr15:43726918~43747094:- CESC cis rs2439831 1 rs2245054 ENSG00000205771.5 CATSPER2P1 -4.11 5.63e-05 0.0225 -0.37 -0.27 Lung cancer in ever smokers; chr15:43459711 chr15:43726918~43747094:- CESC cis rs2439831 0.867 rs2264876 ENSG00000205771.5 CATSPER2P1 -4.11 5.63e-05 0.0225 -0.37 -0.27 Lung cancer in ever smokers; chr15:43465221 chr15:43726918~43747094:- CESC cis rs7927592 0.956 rs12271290 ENSG00000212093.1 AP000807.1 -4.11 5.63e-05 0.0225 -0.3 -0.27 Total body bone mineral density; chr11:68558768 chr11:68506083~68506166:- CESC cis rs2439831 0.85 rs11070408 ENSG00000249839.1 AC011330.5 -4.11 5.63e-05 0.0225 -0.39 -0.27 Lung cancer in ever smokers; chr15:43742590 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs28595038 ENSG00000249839.1 AC011330.5 -4.11 5.63e-05 0.0225 -0.39 -0.27 Lung cancer in ever smokers; chr15:43752661 chr15:43663654~43684339:- CESC cis rs3096299 0.967 rs7205785 ENSG00000274627.1 RP11-104N10.2 4.11 5.64e-05 0.0225 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89392576 chr16:89516797~89522217:+ CESC cis rs62355901 1 rs62355901 ENSG00000271828.1 CTD-2310F14.1 4.11 5.64e-05 0.0225 0.36 0.27 Breast cancer; chr5:56757708 chr5:56927874~56929573:+ CESC cis rs9907295 0.591 rs3760327 ENSG00000271013.1 AC015849.15 -4.11 5.64e-05 0.0225 -0.29 -0.27 Fibroblast growth factor basic levels; chr17:35836383 chr17:35912635~35918010:- CESC cis rs79243044 0.965 rs11038048 ENSG00000224295.2 AC087380.14 -4.11 5.64e-05 0.0225 -0.29 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5545656 chr11:5518441~5524955:- CESC cis rs6693388 0.666 rs6672064 ENSG00000229021.2 AL591893.1 -4.11 5.65e-05 0.0225 -0.33 -0.27 Blood metabolite ratios; chr1:151912023 chr1:151994531~152042774:+ CESC cis rs769267 0.965 rs12460764 ENSG00000269131.1 AC004447.2 4.11 5.65e-05 0.0225 0.22 0.27 Tonsillectomy; chr19:19321154 chr19:18990893~18993610:+ CESC cis rs769267 1 rs7246748 ENSG00000269131.1 AC004447.2 4.11 5.65e-05 0.0225 0.22 0.27 Tonsillectomy; chr19:19322296 chr19:18990893~18993610:+ CESC cis rs769267 0.965 rs7254230 ENSG00000269131.1 AC004447.2 4.11 5.65e-05 0.0225 0.22 0.27 Tonsillectomy; chr19:19323541 chr19:18990893~18993610:+ CESC cis rs769267 1 rs7247309 ENSG00000269131.1 AC004447.2 4.11 5.65e-05 0.0225 0.22 0.27 Tonsillectomy; chr19:19328822 chr19:18990893~18993610:+ CESC cis rs12690897 0.501 rs7803726 ENSG00000229251.3 HNRNPA1P8 -4.11 5.65e-05 0.0226 -0.27 -0.27 Macrophage inflammatory protein 1a levels; chr7:85641957 chr7:84983556~84984506:+ CESC cis rs12690897 0.501 rs7786870 ENSG00000229251.3 HNRNPA1P8 -4.11 5.65e-05 0.0226 -0.27 -0.27 Macrophage inflammatory protein 1a levels; chr7:85641982 chr7:84983556~84984506:+ CESC cis rs17301013 0.507 rs116545832 ENSG00000227373.4 RP11-160H22.5 4.11 5.65e-05 0.0226 0.36 0.27 Systemic lupus erythematosus; chr1:174438725 chr1:174115300~174160004:- CESC cis rs7247513 0.856 rs2162863 ENSG00000230310.1 CTD-2192J16.11 -4.11 5.65e-05 0.0226 -0.33 -0.27 Bipolar disorder; chr19:12588963 chr19:12552597~12553644:+ CESC cis rs7247513 1 rs8104385 ENSG00000230310.1 CTD-2192J16.11 -4.11 5.65e-05 0.0226 -0.33 -0.27 Bipolar disorder; chr19:12589470 chr19:12552597~12553644:+ CESC cis rs9309473 1 rs11689392 ENSG00000163016.8 ALMS1P 4.11 5.66e-05 0.0226 0.34 0.27 Metabolite levels; chr2:73394898 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs10184268 ENSG00000163016.8 ALMS1P 4.11 5.66e-05 0.0226 0.34 0.27 Metabolite levels; chr2:73399916 chr2:73644919~73685576:+ CESC cis rs34375054 0.624 rs7132026 ENSG00000279233.1 RP11-158L12.4 -4.11 5.66e-05 0.0226 -0.3 -0.27 Post bronchodilator FEV1/FVC ratio; chr12:125193550 chr12:125138245~125141711:+ CESC cis rs73173548 0.502 rs12516483 ENSG00000247828.6 TMEM161B-AS1 4.11 5.66e-05 0.0226 0.29 0.27 Macular telangiectasia type 2; chr5:88454718 chr5:88268895~88436685:+ CESC cis rs58873874 0.737 rs11134766 ENSG00000251405.2 CTB-109A12.1 4.11 5.67e-05 0.0226 0.71 0.27 Bipolar disorder (body mass index interaction); chr5:157481309 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs11134767 ENSG00000251405.2 CTB-109A12.1 4.11 5.67e-05 0.0226 0.71 0.27 Bipolar disorder (body mass index interaction); chr5:157481645 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs11466807 ENSG00000251405.2 CTB-109A12.1 4.11 5.67e-05 0.0226 0.71 0.27 Bipolar disorder (body mass index interaction); chr5:157487920 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs77273565 ENSG00000251405.2 CTB-109A12.1 4.11 5.67e-05 0.0226 0.71 0.27 Bipolar disorder (body mass index interaction); chr5:157489547 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs111759027 ENSG00000251405.2 CTB-109A12.1 4.11 5.67e-05 0.0226 0.71 0.27 Bipolar disorder (body mass index interaction); chr5:157489628 chr5:157362615~157460078:- CESC cis rs12188300 0.515 rs13357093 ENSG00000249738.5 AC008697.1 4.11 5.67e-05 0.0226 0.41 0.27 Psoriatic arthritis; chr5:159433588 chr5:159310933~159362834:+ CESC cis rs875971 0.522 rs10807697 ENSG00000222364.1 RNU6-96P -4.11 5.67e-05 0.0226 -0.32 -0.27 Aortic root size; chr7:65951183 chr7:66395191~66395286:+ CESC cis rs8177876 0.597 rs2317085 ENSG00000261838.4 RP11-303E16.6 -4.11 5.67e-05 0.0226 -0.53 -0.27 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81104460 chr16:81069854~81076598:+ CESC cis rs10129255 0.957 rs4387509 ENSG00000211974.3 IGHV2-70 4.11 5.67e-05 0.0226 0.29 0.27 Kawasaki disease; chr14:106704386 chr14:106723574~106724093:- CESC cis rs2733201 1 rs2042741 ENSG00000259479.5 SORD2P -4.11 5.67e-05 0.0226 -0.41 -0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44098088 chr15:44826371~44884694:- CESC cis rs6141600 0.627 rs8117803 ENSG00000260032.1 LINC00657 -4.11 5.68e-05 0.0226 -0.39 -0.27 Height;Hip circumference; chr20:36093606 chr20:36045622~36050960:- CESC cis rs2439831 1 rs2467740 ENSG00000205771.5 CATSPER2P1 -4.11 5.68e-05 0.0226 -0.37 -0.27 Lung cancer in ever smokers; chr15:43454594 chr15:43726918~43747094:- CESC cis rs35828350 1 rs35828350 ENSG00000225151.9 GOLGA2P7 -4.11 5.68e-05 0.0226 -0.38 -0.27 Autism spectrum disorder or schizophrenia; chr15:84812610 chr15:84199311~84230136:- CESC cis rs12908161 1 rs56864281 ENSG00000225151.9 GOLGA2P7 -4.11 5.68e-05 0.0226 -0.38 -0.27 Schizophrenia; chr15:84814418 chr15:84199311~84230136:- CESC cis rs6687821 0.637 rs493341 ENSG00000267734.1 RP4-604K5.3 4.11 5.68e-05 0.0227 0.3 0.27 Yeast infection; chr1:86845499 chr1:86932199~86934891:- CESC cis rs875971 0.862 rs6460290 ENSG00000232559.3 GS1-124K5.12 -4.11 5.69e-05 0.0227 -0.29 -0.27 Aortic root size; chr7:66344119 chr7:66554588~66576923:- CESC cis rs673078 0.607 rs61943403 ENSG00000275759.1 RP11-131L12.3 -4.11 5.69e-05 0.0227 -0.49 -0.27 Glucose homeostasis traits; chr12:118399887 chr12:118428281~118428870:+ CESC cis rs2243480 0.803 rs55700941 ENSG00000164669.11 INTS4P1 4.11 5.69e-05 0.0227 0.57 0.27 Diabetic kidney disease; chr7:65924813 chr7:65141225~65234216:+ CESC cis rs2243480 0.803 rs36004293 ENSG00000232559.3 GS1-124K5.12 4.11 5.69e-05 0.0227 0.44 0.27 Diabetic kidney disease; chr7:65951525 chr7:66554588~66576923:- CESC cis rs2243480 0.803 rs35268390 ENSG00000232559.3 GS1-124K5.12 4.11 5.69e-05 0.0227 0.44 0.27 Diabetic kidney disease; chr7:65951549 chr7:66554588~66576923:- CESC cis rs673078 0.607 rs17512483 ENSG00000275759.1 RP11-131L12.3 4.11 5.69e-05 0.0227 0.59 0.27 Glucose homeostasis traits; chr12:118312380 chr12:118428281~118428870:+ CESC cis rs6439153 0.933 rs2630262 ENSG00000261159.1 RP11-723O4.9 -4.11 5.7e-05 0.0227 -0.27 -0.27 Pneumococcal bacteremia; chr3:128958255 chr3:128859716~128860526:- CESC cis rs10129255 0.957 rs8009073 ENSG00000211974.3 IGHV2-70 4.11 5.7e-05 0.0227 0.28 0.27 Kawasaki disease; chr14:106777278 chr14:106723574~106724093:- CESC cis rs8177876 0.543 rs2317086 ENSG00000261838.4 RP11-303E16.6 -4.11 5.7e-05 0.0227 -0.53 -0.27 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81104468 chr16:81069854~81076598:+ CESC cis rs2908197 0.806 rs2961047 ENSG00000186704.9 DTX2P1 4.11 5.7e-05 0.0227 0.3 0.27 3-hydroxypropylmercapturic acid levels in smokers; chr7:76305739 chr7:76978617~77004308:+ CESC cis rs453301 0.686 rs2409120 ENSG00000173295.6 FAM86B3P -4.11 5.7e-05 0.0227 -0.35 -0.27 Joint mobility (Beighton score); chr8:9025061 chr8:8228595~8244865:+ CESC cis rs6546537 0.911 rs13027712 ENSG00000231024.1 AC092431.3 4.11 5.7e-05 0.0227 0.33 0.27 Serum thyroid-stimulating hormone levels; chr2:69664235 chr2:69700192~69713847:- CESC cis rs6546537 0.868 rs62133967 ENSG00000231024.1 AC092431.3 4.11 5.7e-05 0.0227 0.33 0.27 Serum thyroid-stimulating hormone levels; chr2:69664576 chr2:69700192~69713847:- CESC cis rs7246657 0.722 rs12974225 ENSG00000276846.1 CTD-3220F14.3 -4.11 5.71e-05 0.0227 -0.33 -0.27 Coronary artery calcification; chr19:37749458 chr19:37314868~37315620:- CESC cis rs13108904 0.935 rs1732102 ENSG00000254094.1 AC078852.1 4.11 5.71e-05 0.0227 0.32 0.27 Obesity-related traits; chr4:1284136 chr4:1356581~1358075:+ CESC cis rs875971 0.545 rs1796217 ENSG00000226824.5 RP4-756H11.3 4.1 5.72e-05 0.0228 0.38 0.27 Aortic root size; chr7:66620931 chr7:66654538~66669855:+ CESC cis rs10829156 0.796 rs6482567 ENSG00000240291.1 RP11-499P20.2 4.1 5.72e-05 0.0228 0.3 0.27 Sudden cardiac arrest; chr10:18625860 chr10:18513115~18545651:- CESC cis rs875971 0.964 rs6978429 ENSG00000232559.3 GS1-124K5.12 4.1 5.72e-05 0.0228 0.3 0.27 Aortic root size; chr7:66494889 chr7:66554588~66576923:- CESC cis rs875971 1 rs4718357 ENSG00000232559.3 GS1-124K5.12 4.1 5.72e-05 0.0228 0.3 0.27 Aortic root size; chr7:66495891 chr7:66554588~66576923:- CESC cis rs875971 0.929 rs12535036 ENSG00000232559.3 GS1-124K5.12 4.1 5.72e-05 0.0228 0.3 0.27 Aortic root size; chr7:66499076 chr7:66554588~66576923:- CESC cis rs875971 1 rs12698523 ENSG00000232559.3 GS1-124K5.12 4.1 5.72e-05 0.0228 0.3 0.27 Aortic root size; chr7:66503126 chr7:66554588~66576923:- CESC cis rs875971 1 rs6970030 ENSG00000232559.3 GS1-124K5.12 4.1 5.72e-05 0.0228 0.3 0.27 Aortic root size; chr7:66503692 chr7:66554588~66576923:- CESC cis rs875971 0.928 rs6970357 ENSG00000232559.3 GS1-124K5.12 4.1 5.72e-05 0.0228 0.3 0.27 Aortic root size; chr7:66503891 chr7:66554588~66576923:- CESC cis rs875971 0.929 rs6970860 ENSG00000232559.3 GS1-124K5.12 4.1 5.72e-05 0.0228 0.3 0.27 Aortic root size; chr7:66511647 chr7:66554588~66576923:- CESC cis rs875971 1 rs6957199 ENSG00000232559.3 GS1-124K5.12 4.1 5.72e-05 0.0228 0.3 0.27 Aortic root size; chr7:66513532 chr7:66554588~66576923:- CESC cis rs17301013 0.507 rs10912757 ENSG00000227373.4 RP11-160H22.5 4.1 5.72e-05 0.0228 0.38 0.27 Systemic lupus erythematosus; chr1:174299064 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6693198 ENSG00000227373.4 RP11-160H22.5 4.1 5.72e-05 0.0228 0.38 0.27 Systemic lupus erythematosus; chr1:174304301 chr1:174115300~174160004:- CESC cis rs875971 1 rs11974219 ENSG00000179406.6 LINC00174 4.1 5.72e-05 0.0228 0.28 0.27 Aortic root size; chr7:66182423 chr7:66376044~66401338:- CESC cis rs7809950 1 rs2253146 ENSG00000238832.1 snoU109 -4.1 5.72e-05 0.0228 -0.32 -0.27 Coronary artery disease; chr7:107559874 chr7:107603363~107603507:+ CESC cis rs7809950 0.906 rs2253269 ENSG00000238832.1 snoU109 -4.1 5.72e-05 0.0228 -0.32 -0.27 Coronary artery disease; chr7:107560669 chr7:107603363~107603507:+ CESC cis rs8042680 0.592 rs2001217 ENSG00000258725.1 PRC1-AS1 4.1 5.72e-05 0.0228 0.29 0.27 Type 2 diabetes; chr15:90955016 chr15:90966345~90988624:+ CESC cis rs3213758 0.588 rs12931642 ENSG00000275191.1 RP11-36I17.2 -4.1 5.73e-05 0.0228 -0.54 -0.27 Vitiligo (non-segmental); chr16:53565725 chr16:53628256~53628816:- CESC cis rs2277027 1 rs4579242 ENSG00000251405.2 CTB-109A12.1 4.1 5.73e-05 0.0228 0.34 0.27 Pulmonary function;Pulmonary function (smoking interaction); chr5:157512490 chr5:157362615~157460078:- CESC cis rs9322193 0.884 rs1108889 ENSG00000223701.3 RAET1E-AS1 4.1 5.73e-05 0.0228 0.32 0.27 Lung cancer; chr6:149845433 chr6:149884431~149919508:+ CESC cis rs2564921 0.73 rs12633064 ENSG00000242142.1 SERBP1P3 -4.1 5.73e-05 0.0228 -0.34 -0.27 Height; chr3:53027361 chr3:53064283~53065091:- CESC cis rs11098499 0.691 rs12510133 ENSG00000248280.1 RP11-33B1.2 4.1 5.73e-05 0.0228 0.3 0.27 Corneal astigmatism; chr4:119350189 chr4:119440561~119450157:- CESC cis rs11098499 0.754 rs12506487 ENSG00000248280.1 RP11-33B1.2 4.1 5.73e-05 0.0228 0.3 0.27 Corneal astigmatism; chr4:119350206 chr4:119440561~119450157:- CESC cis rs11098499 0.691 rs12502524 ENSG00000248280.1 RP11-33B1.2 4.1 5.73e-05 0.0228 0.3 0.27 Corneal astigmatism; chr4:119350259 chr4:119440561~119450157:- CESC cis rs11098499 0.691 rs28396837 ENSG00000248280.1 RP11-33B1.2 4.1 5.73e-05 0.0228 0.3 0.27 Corneal astigmatism; chr4:119350386 chr4:119440561~119450157:- CESC cis rs11098499 0.629 rs28369518 ENSG00000248280.1 RP11-33B1.2 4.1 5.73e-05 0.0228 0.3 0.27 Corneal astigmatism; chr4:119350475 chr4:119440561~119450157:- CESC cis rs11098499 0.722 rs10025925 ENSG00000248280.1 RP11-33B1.2 4.1 5.73e-05 0.0228 0.3 0.27 Corneal astigmatism; chr4:119350589 chr4:119440561~119450157:- CESC cis rs10129255 0.957 rs11846893 ENSG00000280411.1 IGHV1-69-2 -4.1 5.73e-05 0.0228 -0.19 -0.27 Kawasaki disease; chr14:106779068 chr14:106762092~106762588:- CESC cis rs11976180 1 rs6464574 ENSG00000273234.1 OR2A13P -4.1 5.73e-05 0.0228 -0.34 -0.27 Obesity-related traits; chr7:144051164 chr7:144142009~144142938:+ CESC cis rs116095464 1 rs56235400 ENSG00000250848.1 CTD-2083E4.5 -4.1 5.73e-05 0.0228 -0.44 -0.27 Breast cancer; chr5:312510 chr5:288833~290321:- CESC cis rs875971 0.83 rs4718358 ENSG00000232559.3 GS1-124K5.12 4.1 5.73e-05 0.0228 0.29 0.27 Aortic root size; chr7:66508681 chr7:66554588~66576923:- CESC cis rs2425143 0.547 rs6141583 ENSG00000201151.1 SNORD56 -4.1 5.73e-05 0.0228 -0.4 -0.27 Blood protein levels; chr20:35984912 chr20:35117136~35117207:- CESC cis rs7208859 0.623 rs7220289 ENSG00000266490.1 CTD-2349P21.9 4.1 5.74e-05 0.0228 0.41 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30776744 chr17:30792372~30792833:+ CESC cis rs2179367 0.959 rs652807 ENSG00000231760.4 RP11-350J20.5 -4.1 5.74e-05 0.0228 -0.32 -0.27 Dupuytren's disease; chr6:149416359 chr6:149796151~149826294:- CESC cis rs1023500 0.551 rs133355 ENSG00000273366.1 CTA-989H11.1 -4.1 5.74e-05 0.0228 -0.36 -0.27 Schizophrenia; chr22:42044281 chr22:42278188~42278846:+ CESC cis rs7572733 0.534 rs1589162 ENSG00000222017.1 AC011997.1 4.1 5.74e-05 0.0228 0.35 0.27 Dermatomyositis; chr2:197917968 chr2:197693106~197774823:+ CESC cis rs769267 0.965 rs735273 ENSG00000269131.1 AC004447.2 -4.1 5.75e-05 0.0228 -0.22 -0.27 Tonsillectomy; chr19:19274602 chr19:18990893~18993610:+ CESC cis rs769267 0.965 rs8103496 ENSG00000269131.1 AC004447.2 -4.1 5.75e-05 0.0228 -0.22 -0.27 Tonsillectomy; chr19:19275206 chr19:18990893~18993610:+ CESC cis rs769267 0.896 rs11882123 ENSG00000269131.1 AC004447.2 -4.1 5.75e-05 0.0228 -0.22 -0.27 Tonsillectomy; chr19:19275530 chr19:18990893~18993610:+ CESC cis rs769267 0.965 rs2017964 ENSG00000269131.1 AC004447.2 -4.1 5.75e-05 0.0228 -0.22 -0.27 Tonsillectomy; chr19:19276340 chr19:18990893~18993610:+ CESC cis rs769267 0.965 rs8101938 ENSG00000269131.1 AC004447.2 -4.1 5.75e-05 0.0228 -0.22 -0.27 Tonsillectomy; chr19:19279688 chr19:18990893~18993610:+ CESC cis rs769267 0.93 rs2301784 ENSG00000269131.1 AC004447.2 -4.1 5.75e-05 0.0228 -0.22 -0.27 Tonsillectomy; chr19:19279940 chr19:18990893~18993610:+ CESC cis rs769267 0.965 rs6511026 ENSG00000269131.1 AC004447.2 -4.1 5.75e-05 0.0228 -0.22 -0.27 Tonsillectomy; chr19:19280593 chr19:18990893~18993610:+ CESC cis rs769267 0.965 rs2269873 ENSG00000269131.1 AC004447.2 -4.1 5.75e-05 0.0228 -0.22 -0.27 Tonsillectomy; chr19:19281592 chr19:18990893~18993610:+ CESC cis rs875971 0.964 rs697969 ENSG00000232559.3 GS1-124K5.12 -4.1 5.75e-05 0.0228 -0.3 -0.27 Aortic root size; chr7:66093491 chr7:66554588~66576923:- CESC cis rs875971 1 rs1182882 ENSG00000232559.3 GS1-124K5.12 -4.1 5.75e-05 0.0228 -0.3 -0.27 Aortic root size; chr7:66097076 chr7:66554588~66576923:- CESC cis rs453301 0.686 rs13252797 ENSG00000253893.2 FAM85B -4.1 5.75e-05 0.0228 -0.36 -0.27 Joint mobility (Beighton score); chr8:9003920 chr8:8167819~8226614:- CESC cis rs9487094 0.67 rs7767525 ENSG00000260273.1 RP11-425D10.10 4.1 5.75e-05 0.0229 0.34 0.27 Height; chr6:109646187 chr6:109382795~109383666:+ CESC cis rs9487094 0.504 rs71541003 ENSG00000260273.1 RP11-425D10.10 4.1 5.75e-05 0.0229 0.34 0.27 Height; chr6:109652694 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs3899233 ENSG00000260273.1 RP11-425D10.10 4.1 5.75e-05 0.0229 0.34 0.27 Height; chr6:109655791 chr6:109382795~109383666:+ CESC cis rs2337406 0.925 rs873534 ENSG00000254174.1 IGHV1-12 4.1 5.75e-05 0.0229 0.29 0.27 Alzheimer's disease (late onset); chr14:106667423 chr14:106122420~106122709:- CESC cis rs3750965 0.959 rs11228490 ENSG00000260895.1 RP11-554A11.7 -4.1 5.75e-05 0.0229 -0.32 -0.27 Hair color; chr11:69093404 chr11:69103493~69109094:+ CESC cis rs7605378 0.528 rs281767 ENSG00000232732.8 AC073043.1 -4.1 5.75e-05 0.0229 -0.36 -0.27 Osteoporosis; chr2:199958558 chr2:199867396~199911159:- CESC cis rs9322193 0.923 rs9383812 ENSG00000216906.2 RP11-350J20.9 4.1 5.76e-05 0.0229 0.29 0.27 Lung cancer; chr6:149712355 chr6:149904243~149906418:+ CESC cis rs9322193 0.847 rs9383844 ENSG00000216906.2 RP11-350J20.9 4.1 5.76e-05 0.0229 0.29 0.27 Lung cancer; chr6:149716268 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs9479494 ENSG00000216906.2 RP11-350J20.9 4.1 5.76e-05 0.0229 0.3 0.27 Lung cancer; chr6:149739108 chr6:149904243~149906418:+ CESC cis rs17711722 0.528 rs73138179 ENSG00000224316.1 RP11-479O9.2 4.1 5.76e-05 0.0229 0.31 0.27 Calcium levels; chr7:65829495 chr7:65773620~65802067:+ CESC cis rs17695224 0.545 rs4802875 ENSG00000268095.1 ZNF649-AS1 4.1 5.77e-05 0.0229 0.33 0.27 HDL cholesterol;HDL cholesterol levels; chr19:51827056 chr19:51888025~51900463:+ CESC cis rs2243480 1 rs11538349 ENSG00000228409.4 CCT6P1 4.1 5.77e-05 0.0229 0.37 0.27 Diabetic kidney disease; chr7:65956884 chr7:65751142~65763354:+ CESC cis rs10129255 0.957 rs12590799 ENSG00000280411.1 IGHV1-69-2 -4.1 5.77e-05 0.0229 -0.19 -0.27 Kawasaki disease; chr14:106779713 chr14:106762092~106762588:- CESC cis rs12468226 0.873 rs3181153 ENSG00000273456.1 RP11-686O6.2 -4.1 5.77e-05 0.0229 -0.32 -0.27 Urate levels; chr2:202205155 chr2:202374932~202375604:- CESC cis rs67311347 1 rs9332450 ENSG00000223797.4 ENTPD3-AS1 -4.1 5.77e-05 0.0229 -0.26 -0.27 Renal cell carcinoma; chr3:40416550 chr3:40313802~40453329:- CESC cis rs1816537 0.537 rs4936263 ENSG00000256452.1 RP11-667M19.10 -4.1 5.77e-05 0.0229 -0.25 -0.27 Body mass index; chr11:113156436 chr11:113818077~113822458:+ CESC cis rs11157436 0.874 rs35951144 ENSG00000211813.2 TRAV34 4.1 5.77e-05 0.0229 0.27 0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22149973 chr14:22207522~22208129:+ CESC cis rs8062405 0.573 rs6565300 ENSG00000261067.5 RP11-264B17.3 4.1 5.77e-05 0.0229 0.26 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28981728 chr16:28974804~28990783:+ CESC cis rs9309473 1 rs6753344 ENSG00000163016.8 ALMS1P -4.1 5.78e-05 0.0229 -0.35 -0.27 Metabolite levels; chr2:73426010 chr2:73644919~73685576:+ CESC cis rs875971 0.545 rs3735147 ENSG00000236529.1 RP13-254B10.1 4.1 5.78e-05 0.0229 0.33 0.27 Aortic root size; chr7:66505541 chr7:65840212~65840596:+ CESC cis rs8030379 1 rs11259933 ENSG00000230373.7 GOLGA6L5P -4.1 5.78e-05 0.0229 -0.26 -0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83911404 chr15:84507885~84516814:- CESC cis rs12908161 0.959 rs17534709 ENSG00000225151.9 GOLGA2P7 -4.1 5.78e-05 0.0229 -0.37 -0.27 Schizophrenia; chr15:84771166 chr15:84199311~84230136:- CESC cis rs832187 0.629 rs7624403 ENSG00000280620.1 SCAANT1 4.1 5.78e-05 0.0229 0.36 0.27 Schizophrenia; chr3:63984401 chr3:63911518~63911772:- CESC cis rs67311347 0.956 rs7640228 ENSG00000223797.4 ENTPD3-AS1 -4.1 5.78e-05 0.023 -0.27 -0.27 Renal cell carcinoma; chr3:40474699 chr3:40313802~40453329:- CESC cis rs8062405 0.558 rs151228 ENSG00000259982.1 CDC37P1 4.1 5.78e-05 0.023 0.33 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28551705 chr16:28700294~28701540:- CESC cis rs2274273 0.624 rs66551709 ENSG00000258413.1 RP11-665C16.6 -4.1 5.79e-05 0.023 -0.34 -0.27 Protein biomarker; chr14:55324304 chr14:55262767~55272075:- CESC cis rs875971 1 rs2087647 ENSG00000179406.6 LINC00174 4.1 5.79e-05 0.023 0.29 0.27 Aortic root size; chr7:66128201 chr7:66376044~66401338:- CESC cis rs875971 1 rs6958484 ENSG00000179406.6 LINC00174 4.1 5.79e-05 0.023 0.29 0.27 Aortic root size; chr7:66134459 chr7:66376044~66401338:- CESC cis rs75422866 0.764 rs73104188 ENSG00000274902.1 RP1-197B17.4 4.1 5.79e-05 0.023 0.71 0.27 Pneumonia; chr12:47715885 chr12:47731908~47732351:+ CESC cis rs1056107 0.831 rs11787835 ENSG00000225513.1 RP11-165N19.2 -4.1 5.8e-05 0.023 -0.33 -0.27 Colorectal cancer; chr9:112188318 chr9:112173522~112173971:- CESC cis rs2255336 0.938 rs12578507 ENSG00000245648.1 RP11-277P12.20 -4.1 5.8e-05 0.023 -0.41 -0.27 Blood protein levels; chr12:10470396 chr12:10363769~10398506:+ CESC cis rs227932 0.571 rs12536173 ENSG00000234286.1 AC006026.13 -4.1 5.8e-05 0.023 -0.37 -0.27 Schizophrenia; chr7:23834413 chr7:23680195~23680786:- CESC cis rs1124769 0.719 rs1147140 ENSG00000259378.1 DCAF13P3 -4.1 5.8e-05 0.023 -0.36 -0.27 Cognitive performance; chr15:50878226 chr15:50944663~50945996:+ CESC cis rs12144049 0.672 rs10736384 ENSG00000227045.1 RP11-98D18.1 -4.1 5.8e-05 0.023 -0.41 -0.27 Inflammatory skin disease;Atopic dermatitis; chr1:152467019 chr1:151701026~151708386:+ CESC cis rs12468226 0.873 rs78798541 ENSG00000273456.1 RP11-686O6.2 4.1 5.81e-05 0.023 0.36 0.27 Urate levels; chr2:202194708 chr2:202374932~202375604:- CESC cis rs62025270 0.632 rs62022942 ENSG00000202081.1 RNU6-1280P -4.1 5.81e-05 0.023 -0.38 -0.27 Idiopathic pulmonary fibrosis; chr15:85715337 chr15:85651522~85651628:- CESC cis rs2439831 1 rs2251538 ENSG00000275601.1 AC011330.13 -4.1 5.81e-05 0.0231 -0.35 -0.27 Lung cancer in ever smokers; chr15:43475011 chr15:43642389~43643023:- CESC cis rs4842666 0.915 rs117742247 ENSG00000258302.2 RP11-981P6.1 4.1 5.82e-05 0.0231 0.41 0.27 Blood pressure; chr12:89597536 chr12:89561129~89594878:+ CESC cis rs8072100 0.713 rs2136750 ENSG00000228782.6 CTD-2026D20.3 4.1 5.82e-05 0.0231 0.32 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47378734 chr17:47450568~47492492:- CESC cis rs7404843 0.704 rs112251447 ENSG00000260735.1 RP11-72I8.1 4.1 5.82e-05 0.0231 0.49 0.27 Testicular germ cell tumor; chr16:15428015 chr16:15094411~15109197:+ CESC cis rs526231 0.853 rs2561477 ENSG00000175749.11 EIF3KP1 4.1 5.82e-05 0.0231 0.34 0.27 Primary biliary cholangitis; chr5:103273223 chr5:103032376~103033031:+ CESC cis rs10129255 0.957 rs10136781 ENSG00000280411.1 IGHV1-69-2 -4.1 5.82e-05 0.0231 -0.19 -0.27 Kawasaki disease; chr14:106780451 chr14:106762092~106762588:- CESC cis rs10129255 0.957 rs8022165 ENSG00000280411.1 IGHV1-69-2 -4.1 5.82e-05 0.0231 -0.19 -0.27 Kawasaki disease; chr14:106781682 chr14:106762092~106762588:- CESC cis rs10129255 0.917 rs8022493 ENSG00000280411.1 IGHV1-69-2 -4.1 5.82e-05 0.0231 -0.19 -0.27 Kawasaki disease; chr14:106781820 chr14:106762092~106762588:- CESC cis rs58873874 0.737 rs10515750 ENSG00000251405.2 CTB-109A12.1 4.1 5.83e-05 0.0231 0.66 0.27 Bipolar disorder (body mass index interaction); chr5:157383064 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs10061544 ENSG00000251405.2 CTB-109A12.1 4.1 5.83e-05 0.0231 0.66 0.27 Bipolar disorder (body mass index interaction); chr5:157383871 chr5:157362615~157460078:- CESC cis rs58873874 0.737 rs10078836 ENSG00000251405.2 CTB-109A12.1 4.1 5.83e-05 0.0231 0.66 0.27 Bipolar disorder (body mass index interaction); chr5:157384604 chr5:157362615~157460078:- CESC cis rs13108904 0.935 rs1732100 ENSG00000254094.1 AC078852.1 4.1 5.83e-05 0.0231 0.32 0.27 Obesity-related traits; chr4:1287973 chr4:1356581~1358075:+ CESC cis rs2412819 0.571 rs2930530 ENSG00000205771.5 CATSPER2P1 4.1 5.83e-05 0.0231 0.39 0.27 Lung cancer; chr15:43823268 chr15:43726918~43747094:- CESC cis rs2243480 1 rs59794892 ENSG00000232559.3 GS1-124K5.12 4.1 5.83e-05 0.0231 0.45 0.27 Diabetic kidney disease; chr7:65950886 chr7:66554588~66576923:- CESC cis rs1134634 1 rs1134634 ENSG00000273133.1 RP11-799M12.2 4.1 5.84e-05 0.0231 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15601446 chr4:15563698~15564253:- CESC cis rs1930961 1 rs1930961 ENSG00000272942.1 CTA-246H3.12 -4.1 5.84e-05 0.0231 -0.37 -0.27 Bipolar disorder with mood-incongruent psychosis; chr22:25479298 chr22:25434324~25435070:- CESC cis rs2688608 0.725 rs2688623 ENSG00000242288.9 RP11-464F9.1 4.1 5.84e-05 0.0231 0.3 0.27 Inflammatory bowel disease; chr10:73929857 chr10:73674295~73730466:- CESC cis rs769267 1 rs12985655 ENSG00000269131.1 AC004447.2 4.1 5.84e-05 0.0231 0.22 0.27 Tonsillectomy; chr19:19331625 chr19:18990893~18993610:+ CESC cis rs769267 1 rs8103197 ENSG00000269131.1 AC004447.2 4.1 5.84e-05 0.0231 0.22 0.27 Tonsillectomy; chr19:19332657 chr19:18990893~18993610:+ CESC cis rs7248779 0.512 rs12610522 ENSG00000261342.1 AC006538.1 -4.1 5.84e-05 0.0231 -0.33 -0.27 Cortisol levels (saliva); chr19:2413230 chr19:2727743~2729327:- CESC cis rs2115630 1 rs10220733 ENSG00000225151.9 GOLGA2P7 4.1 5.85e-05 0.0231 0.3 0.27 P wave terminal force; chr15:84737633 chr15:84199311~84230136:- CESC cis rs669446 0.562 rs304303 ENSG00000236200.4 KDM4A-AS1 -4.1 5.85e-05 0.0232 -0.34 -0.27 Amyotrophic lateral sclerosis (age of onset); chr1:43712399 chr1:43699765~43708138:- CESC cis rs2455601 0.638 rs11042148 ENSG00000254860.4 TMEM9B-AS1 4.1 5.85e-05 0.0232 0.33 0.27 Schizophrenia; chr11:8987127 chr11:8964675~8977527:+ CESC cis rs2337406 0.714 rs7145254 ENSG00000274576.2 IGHV2-70 -4.1 5.86e-05 0.0232 -0.29 -0.27 Alzheimer's disease (late onset); chr14:106817783 chr14:106770577~106771020:- CESC cis rs2337406 0.538 rs10141701 ENSG00000211974.3 IGHV2-70 -4.1 5.86e-05 0.0232 -0.31 -0.27 Alzheimer's disease (late onset); chr14:106633467 chr14:106723574~106724093:- CESC cis rs2812378 0.527 rs10972214 ENSG00000227852.1 RP11-156G14.6 4.1 5.86e-05 0.0232 0.33 0.27 Rheumatoid arthritis; chr9:34734197 chr9:35592786~35592951:+ CESC cis rs2812378 0.527 rs10814139 ENSG00000227852.1 RP11-156G14.6 4.1 5.86e-05 0.0232 0.33 0.27 Rheumatoid arthritis; chr9:34734460 chr9:35592786~35592951:+ CESC cis rs9309473 1 rs3813227 ENSG00000163016.8 ALMS1P -4.1 5.86e-05 0.0232 -0.33 -0.27 Metabolite levels; chr2:73424839 chr2:73644919~73685576:+ CESC cis rs75920871 0.588 rs7118591 ENSG00000254851.1 RP11-109L13.1 -4.1 5.87e-05 0.0232 -0.35 -0.27 Subjective well-being; chr11:117037741 chr11:117135528~117138582:+ CESC cis rs3806843 0.583 rs408652 ENSG00000202111.1 VTRNA1-2 -4.1 5.87e-05 0.0232 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140950428 chr5:140718925~140719013:+ CESC cis rs11971779 0.68 rs1862879 ENSG00000273391.1 RP11-634H22.1 4.1 5.87e-05 0.0232 0.25 0.27 Diisocyanate-induced asthma; chr7:139335205 chr7:139359032~139359566:- CESC cis rs4974559 0.947 rs10006381 ENSG00000253399.1 AC078852.2 4.1 5.88e-05 0.0233 0.45 0.27 Systolic blood pressure; chr4:1365521 chr4:1358479~1359461:+ CESC cis rs6439153 0.933 rs6799008 ENSG00000261159.1 RP11-723O4.9 4.1 5.88e-05 0.0233 0.28 0.27 Pneumococcal bacteremia; chr3:128998544 chr3:128859716~128860526:- CESC cis rs6439153 0.933 rs1871951 ENSG00000261159.1 RP11-723O4.9 4.1 5.88e-05 0.0233 0.28 0.27 Pneumococcal bacteremia; chr3:129001644 chr3:128859716~128860526:- CESC cis rs67311347 0.956 rs4974029 ENSG00000223797.4 ENTPD3-AS1 4.1 5.89e-05 0.0233 0.26 0.27 Renal cell carcinoma; chr3:40479827 chr3:40313802~40453329:- CESC cis rs13113518 1 rs4864542 ENSG00000273257.1 RP11-177J6.1 -4.1 5.89e-05 0.0233 -0.35 -0.27 Height; chr4:55487920 chr4:55387949~55388271:+ CESC cis rs7621025 0.505 rs13063893 ENSG00000239213.4 NCK1-AS1 -4.1 5.89e-05 0.0233 -0.42 -0.27 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136668796 chr3:136841726~136862054:- CESC cis rs2276314 0.857 rs62101379 ENSG00000278986.1 RP11-723J4.3 -4.1 5.89e-05 0.0233 -0.3 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:36004939 chr18:35972151~35973916:+ CESC cis rs8080784 0.866 rs56218356 ENSG00000266701.1 AC005702.4 4.1 5.89e-05 0.0233 0.38 0.27 Coronary artery disease; chr17:60946069 chr17:60042546~60042627:- CESC cis rs989507 0.784 rs11592550 ENSG00000214807.2 NPM1P31 4.1 5.9e-05 0.0233 0.48 0.27 Obesity-related traits; chr10:125443045 chr10:124867510~124868326:+ CESC cis rs783540 0.869 rs783533 ENSG00000276710.3 CSPG4P8 4.1 5.9e-05 0.0233 0.29 0.27 Schizophrenia; chr15:82581437 chr15:82459472~82477258:+ CESC cis rs1012068 0.686 rs4820996 ENSG00000236132.1 CTA-440B3.1 -4.1 5.9e-05 0.0233 -0.3 -0.27 Chronic hepatitis C infection; chr22:31928044 chr22:31816379~31817491:- CESC cis rs6693388 0.846 rs6587640 ENSG00000229021.2 AL591893.1 4.1 5.91e-05 0.0233 0.3 0.27 Blood metabolite ratios; chr1:151982754 chr1:151994531~152042774:+ CESC cis rs4141404 0.512 rs1018490 ENSG00000236132.1 CTA-440B3.1 -4.1 5.91e-05 0.0234 -0.32 -0.27 Paclitaxel-induced neuropathy; chr22:31600639 chr22:31816379~31817491:- CESC cis rs875971 1 rs12532998 ENSG00000232559.3 GS1-124K5.12 4.1 5.91e-05 0.0234 0.29 0.27 Aortic root size; chr7:66502472 chr7:66554588~66576923:- CESC cis rs2933343 0.953 rs2933344 ENSG00000231305.3 RP11-723O4.2 4.1 5.91e-05 0.0234 0.28 0.27 IgG glycosylation; chr3:128939872 chr3:128861313~128871540:- CESC cis rs11638352 1 rs2706481 ENSG00000275601.1 AC011330.13 4.1 5.91e-05 0.0234 0.41 0.27 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44114119 chr15:43642389~43643023:- CESC cis rs11096990 0.892 rs11932351 ENSG00000249207.1 RP11-360F5.1 4.1 5.91e-05 0.0234 0.31 0.27 Cognitive function; chr4:39229837 chr4:39112677~39126818:- CESC cis rs116095464 1 rs2015774 ENSG00000250848.1 CTD-2083E4.5 -4.1 5.91e-05 0.0234 -0.44 -0.27 Breast cancer; chr5:312843 chr5:288833~290321:- CESC cis rs3091242 0.967 rs1053438 ENSG00000224183.1 SDHDP6 4.1 5.92e-05 0.0234 0.29 0.27 Erythrocyte sedimentation rate; chr1:25361410 chr1:25294164~25294643:- CESC cis rs17301013 0.507 rs10912786 ENSG00000227373.4 RP11-160H22.5 4.1 5.92e-05 0.0234 0.37 0.27 Systemic lupus erythematosus; chr1:174427609 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12074416 ENSG00000227373.4 RP11-160H22.5 4.1 5.92e-05 0.0234 0.37 0.27 Systemic lupus erythematosus; chr1:174430109 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12069134 ENSG00000227373.4 RP11-160H22.5 4.1 5.92e-05 0.0234 0.37 0.27 Systemic lupus erythematosus; chr1:174434287 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6677262 ENSG00000227373.4 RP11-160H22.5 4.1 5.92e-05 0.0234 0.37 0.27 Systemic lupus erythematosus; chr1:174434539 chr1:174115300~174160004:- CESC cis rs2255336 0.938 rs1382265 ENSG00000245648.1 RP11-277P12.20 4.1 5.92e-05 0.0234 0.39 0.27 Blood protein levels; chr12:10381206 chr12:10363769~10398506:+ CESC cis rs2255336 0.882 rs2733853 ENSG00000245648.1 RP11-277P12.20 4.1 5.92e-05 0.0234 0.39 0.27 Blood protein levels; chr12:10381483 chr12:10363769~10398506:+ CESC cis rs2255336 0.938 rs1600127 ENSG00000245648.1 RP11-277P12.20 4.1 5.92e-05 0.0234 0.39 0.27 Blood protein levels; chr12:10383648 chr12:10363769~10398506:+ CESC cis rs2255336 0.882 rs2617156 ENSG00000245648.1 RP11-277P12.20 4.1 5.92e-05 0.0234 0.39 0.27 Blood protein levels; chr12:10384280 chr12:10363769~10398506:+ CESC cis rs2255336 0.938 rs2617157 ENSG00000245648.1 RP11-277P12.20 4.1 5.92e-05 0.0234 0.39 0.27 Blood protein levels; chr12:10384299 chr12:10363769~10398506:+ CESC cis rs2255336 0.938 rs2927561 ENSG00000245648.1 RP11-277P12.20 4.1 5.92e-05 0.0234 0.39 0.27 Blood protein levels; chr12:10384974 chr12:10363769~10398506:+ CESC cis rs2255336 0.882 rs2126889 ENSG00000245648.1 RP11-277P12.20 4.1 5.92e-05 0.0234 0.39 0.27 Blood protein levels; chr12:10385280 chr12:10363769~10398506:+ CESC cis rs7560272 0.723 rs1083919 ENSG00000273245.1 RP11-434P11.2 -4.1 5.92e-05 0.0234 -0.33 -0.27 Schizophrenia; chr2:73486736 chr2:73750256~73750786:- CESC cis rs2115630 1 rs1030863 ENSG00000225151.9 GOLGA2P7 4.1 5.92e-05 0.0234 0.3 0.27 P wave terminal force; chr15:84739404 chr15:84199311~84230136:- CESC cis rs8062405 0.54 rs480400 ENSG00000259982.1 CDC37P1 4.1 5.93e-05 0.0234 0.33 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28563294 chr16:28700294~28701540:- CESC cis rs875971 1 rs6961717 ENSG00000179406.6 LINC00174 4.1 5.93e-05 0.0234 0.29 0.27 Aortic root size; chr7:66122550 chr7:66376044~66401338:- CESC cis rs9309473 1 rs6755241 ENSG00000163016.8 ALMS1P 4.1 5.93e-05 0.0234 0.36 0.27 Metabolite levels; chr2:73414236 chr2:73644919~73685576:+ CESC cis rs6844153 0.752 rs12641261 ENSG00000240005.4 RP11-293A21.1 -4.1 5.93e-05 0.0234 -0.35 -0.27 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26872814 chr4:26859806~26860599:- CESC cis rs7937890 0.904 rs11023169 ENSG00000254418.1 RP11-21L19.1 -4.1 5.93e-05 0.0234 -0.3 -0.27 Mitochondrial DNA levels; chr11:14269439 chr11:14262846~14273691:- CESC cis rs6693388 0.918 rs4845719 ENSG00000229021.2 AL591893.1 -4.1 5.93e-05 0.0234 -0.32 -0.27 Blood metabolite ratios; chr1:151960884 chr1:151994531~152042774:+ CESC cis rs6693388 0.918 rs11204919 ENSG00000229021.2 AL591893.1 -4.1 5.93e-05 0.0234 -0.32 -0.27 Blood metabolite ratios; chr1:151961323 chr1:151994531~152042774:+ CESC cis rs9650657 0.537 rs11250092 ENSG00000255046.1 RP11-297N6.4 -4.1 5.93e-05 0.0234 -0.29 -0.27 Neuroticism; chr8:10929033 chr8:11797928~11802568:- CESC cis rs2439831 0.85 rs28524541 ENSG00000249839.1 AC011330.5 -4.1 5.93e-05 0.0234 -0.39 -0.27 Lung cancer in ever smokers; chr15:43832633 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs28858500 ENSG00000249839.1 AC011330.5 -4.1 5.93e-05 0.0234 -0.39 -0.27 Lung cancer in ever smokers; chr15:43864744 chr15:43663654~43684339:- CESC cis rs2564921 0.57 rs3821831 ENSG00000242142.1 SERBP1P3 -4.1 5.94e-05 0.0234 -0.33 -0.27 Height; chr3:52819385 chr3:53064283~53065091:- CESC cis rs6775745 1 rs6439340 ENSG00000240854.1 RP11-64K7.1 -4.1 5.94e-05 0.0234 -0.39 -0.27 Neutrophil count; chr3:132078656 chr3:132175402~132176711:+ CESC cis rs6775745 0.901 rs2369369 ENSG00000240854.1 RP11-64K7.1 -4.1 5.94e-05 0.0234 -0.39 -0.27 Neutrophil count; chr3:132079154 chr3:132175402~132176711:+ CESC cis rs5742933 0.817 rs2033870 ENSG00000253559.1 OSGEPL1-AS1 -4.1 5.94e-05 0.0234 -0.31 -0.27 Ferritin levels; chr2:189739104 chr2:189762704~189765556:+ CESC cis rs875971 0.545 rs3735147 ENSG00000226824.5 RP4-756H11.3 -4.1 5.94e-05 0.0235 -0.38 -0.27 Aortic root size; chr7:66505541 chr7:66654538~66669855:+ CESC cis rs10129255 0.957 rs10142918 ENSG00000223648.3 IGHV3-64 4.1 5.94e-05 0.0235 0.24 0.27 Kawasaki disease; chr14:106782206 chr14:106643132~106658258:- CESC cis rs10129255 0.957 rs10142859 ENSG00000223648.3 IGHV3-64 4.1 5.94e-05 0.0235 0.24 0.27 Kawasaki disease; chr14:106782238 chr14:106643132~106658258:- CESC cis rs1865760 0.588 rs9467658 ENSG00000272462.2 U91328.19 -4.1 5.94e-05 0.0235 -0.25 -0.27 Height; chr6:26010653 chr6:25992662~26001775:+ CESC cis rs748404 0.626 rs34212866 ENSG00000249839.1 AC011330.5 -4.1 5.94e-05 0.0235 -0.38 -0.27 Lung cancer; chr15:43410766 chr15:43663654~43684339:- CESC cis rs10043775 1 rs4639212 ENSG00000251330.3 CTD-2283N19.1 -4.1 5.94e-05 0.0235 -0.35 -0.27 Periodontal microbiota; chr5:148413387 chr5:148430159~148430807:- CESC cis rs10043775 1 rs13354454 ENSG00000251330.3 CTD-2283N19.1 -4.1 5.94e-05 0.0235 -0.35 -0.27 Periodontal microbiota; chr5:148414845 chr5:148430159~148430807:- CESC cis rs2337406 1 rs75651733 ENSG00000254174.1 IGHV1-12 4.1 5.94e-05 0.0235 0.3 0.27 Alzheimer's disease (late onset); chr14:106701309 chr14:106122420~106122709:- CESC cis rs7809950 0.862 rs12112877 ENSG00000238832.1 snoU109 -4.1 5.95e-05 0.0235 -0.32 -0.27 Coronary artery disease; chr7:107300879 chr7:107603363~107603507:+ CESC cis rs6951245 0.832 rs79808627 ENSG00000229043.2 AC091729.9 -4.1 5.95e-05 0.0235 -0.39 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1052883 chr7:1160374~1165267:+ CESC cis rs3091242 0.904 rs6661533 ENSG00000224183.1 SDHDP6 -4.1 5.95e-05 0.0235 -0.28 -0.27 Erythrocyte sedimentation rate; chr1:25445224 chr1:25294164~25294643:- CESC cis rs9907295 0.591 rs3817655 ENSG00000271013.1 AC015849.15 4.1 5.95e-05 0.0235 0.3 0.27 Fibroblast growth factor basic levels; chr17:35872637 chr17:35912635~35918010:- CESC cis rs875971 0.597 rs11763224 ENSG00000236529.1 RP13-254B10.1 4.1 5.95e-05 0.0235 0.34 0.27 Aortic root size; chr7:66518628 chr7:65840212~65840596:+ CESC cis rs3091242 0.967 rs3093614 ENSG00000224183.1 SDHDP6 4.1 5.95e-05 0.0235 0.29 0.27 Erythrocyte sedimentation rate; chr1:25351353 chr1:25294164~25294643:- CESC cis rs4272720 0.639 rs2246673 ENSG00000229870.1 RP11-507K13.6 4.09 5.95e-05 0.0235 0.31 0.27 Platelet count;Plateletcrit; chr10:49048870 chr10:49815096~49815562:+ CESC cis rs2439831 1 rs2584726 ENSG00000205771.5 CATSPER2P1 -4.09 5.95e-05 0.0235 -0.36 -0.27 Lung cancer in ever smokers; chr15:43423184 chr15:43726918~43747094:- CESC cis rs1667255 1 rs1611949 ENSG00000266521.1 RP11-650P15.1 4.09 5.95e-05 0.0235 0.32 0.27 Retinol levels; chr18:31607203 chr18:31496645~31497195:- CESC cis rs875971 1 rs3735148 ENSG00000232559.3 GS1-124K5.12 4.09 5.95e-05 0.0235 0.29 0.27 Aortic root size; chr7:66506022 chr7:66554588~66576923:- CESC cis rs1707322 1 rs6429588 ENSG00000281133.1 AL355480.3 -4.09 5.96e-05 0.0235 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45988386 chr1:45580892~45580996:- CESC cis rs1707322 1 rs12097799 ENSG00000281133.1 AL355480.3 -4.09 5.96e-05 0.0235 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45994214 chr1:45580892~45580996:- CESC cis rs6547705 0.581 rs1400032 ENSG00000231259.4 AC125232.1 -4.09 5.96e-05 0.0235 -0.4 -0.27 Progressive supranuclear palsy; chr2:86696060 chr2:87031815~87053069:- CESC cis rs875971 1 rs4717300 ENSG00000237310.1 GS1-124K5.4 4.09 5.96e-05 0.0235 0.26 0.27 Aortic root size; chr7:66482393 chr7:66493706~66495474:+ CESC cis rs6504622 0.967 rs11869840 ENSG00000262879.4 RP11-156P1.3 -4.09 5.96e-05 0.0235 -0.3 -0.27 Orofacial clefts; chr17:46918734 chr17:46984045~47100323:- CESC cis rs950776 0.616 rs3743077 ENSG00000279373.1 RP11-650L12.4 4.09 5.97e-05 0.0235 0.34 0.27 Sudden cardiac arrest; chr15:78602554 chr15:78537681~78538946:+ CESC cis rs2439831 0.867 rs2412780 ENSG00000275601.1 AC011330.13 -4.09 5.97e-05 0.0235 -0.35 -0.27 Lung cancer in ever smokers; chr15:43363596 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2412779 ENSG00000275601.1 AC011330.13 -4.09 5.97e-05 0.0235 -0.35 -0.27 Lung cancer in ever smokers; chr15:43363729 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs2899082 ENSG00000275601.1 AC011330.13 -4.09 5.97e-05 0.0235 -0.35 -0.27 Lung cancer in ever smokers; chr15:43363845 chr15:43642389~43643023:- CESC cis rs1707322 1 rs10890370 ENSG00000281133.1 AL355480.3 -4.09 5.97e-05 0.0235 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45923545 chr1:45580892~45580996:- CESC cis rs1501911 0.588 rs709389 ENSG00000248489.1 CTD-2007H13.3 4.09 5.97e-05 0.0235 0.34 0.27 Lung function (FEV1/FVC); chr5:98994011 chr5:98929171~98995013:+ CESC cis rs748404 0.578 rs2278856 ENSG00000205771.5 CATSPER2P1 -4.09 5.97e-05 0.0235 -0.32 -0.27 Lung cancer; chr15:43339158 chr15:43726918~43747094:- CESC cis rs2337406 0.587 rs10150642 ENSG00000211974.3 IGHV2-70 4.09 5.97e-05 0.0235 0.33 0.27 Alzheimer's disease (late onset); chr14:106647269 chr14:106723574~106724093:- CESC cis rs10039254 0.712 rs10066034 ENSG00000249140.1 PRDX2P3 -4.09 5.97e-05 0.0235 -0.32 -0.27 Attention deficit hyperactivity disorder (time to onset); chr5:179148428 chr5:179572156~179572741:+ CESC cis rs172166 0.637 rs1071893 ENSG00000216901.1 AL022393.7 4.09 5.97e-05 0.0236 0.29 0.27 Cardiac Troponin-T levels; chr6:28199857 chr6:28176188~28176674:+ CESC cis rs801193 0.839 rs6968619 ENSG00000237310.1 GS1-124K5.4 -4.09 5.97e-05 0.0236 -0.25 -0.27 Aortic root size; chr7:66603880 chr7:66493706~66495474:+ CESC cis rs11971779 0.68 rs10229358 ENSG00000273391.1 RP11-634H22.1 -4.09 5.97e-05 0.0236 -0.26 -0.27 Diisocyanate-induced asthma; chr7:139367799 chr7:139359032~139359566:- CESC cis rs875971 1 rs709595 ENSG00000237310.1 GS1-124K5.4 4.09 5.97e-05 0.0236 0.25 0.27 Aortic root size; chr7:66352346 chr7:66493706~66495474:+ CESC cis rs875971 1 rs811880 ENSG00000237310.1 GS1-124K5.4 4.09 5.97e-05 0.0236 0.25 0.27 Aortic root size; chr7:66353659 chr7:66493706~66495474:+ CESC cis rs1075265 0.875 rs12616212 ENSG00000233266.1 HMGB1P31 4.09 5.98e-05 0.0236 0.35 0.27 Chronotype;Morning vs. evening chronotype; chr2:54039109 chr2:54051334~54051760:+ CESC cis rs7560272 0.538 rs12052539 ENSG00000273245.1 RP11-434P11.2 4.09 5.98e-05 0.0236 0.32 0.27 Schizophrenia; chr2:73710026 chr2:73750256~73750786:- CESC cis rs9876781 0.559 rs7610524 ENSG00000229759.1 MRPS18AP1 4.09 5.98e-05 0.0236 0.27 0.27 Longevity; chr3:48353882 chr3:48256350~48256938:- CESC cis rs3096299 0.933 rs747485 ENSG00000274627.1 RP11-104N10.2 4.09 5.98e-05 0.0236 0.26 0.27 Multiple myeloma (IgH translocation); chr16:89407686 chr16:89516797~89522217:+ CESC cis rs451417 1 rs379418 ENSG00000275632.1 RP5-967N21.11 4.09 5.98e-05 0.0236 0.35 0.27 Menopause (age at onset); chr20:5961561 chr20:6000418~6000941:+ CESC cis rs77204473 0.744 rs2269399 ENSG00000254851.1 RP11-109L13.1 4.09 5.99e-05 0.0236 0.54 0.27 Sum eosinophil basophil counts;Eosinophil counts; chr11:117195637 chr11:117135528~117138582:+ CESC cis rs3748682 0.861 rs28625842 ENSG00000212541.1 RNU6-510P -4.09 5.99e-05 0.0236 -0.36 -0.27 Hypothyroidism; chr1:37845114 chr1:37991462~37991569:+ CESC cis rs8091660 0.929 rs11082685 ENSG00000278983.1 RP11-426J5.3 4.09 5.99e-05 0.0236 0.33 0.27 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48566806 chr18:48564795~48568342:+ CESC cis rs673078 0.571 rs17440823 ENSG00000275759.1 RP11-131L12.3 -4.09 5.99e-05 0.0236 -0.53 -0.27 Glucose homeostasis traits; chr12:118353023 chr12:118428281~118428870:+ CESC cis rs7688540 0.771 rs17164747 ENSG00000211553.1 AC253576.2 -4.09 5.99e-05 0.0236 -0.42 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:266798 chr4:136461~136568:+ CESC cis rs7688540 0.771 rs7665727 ENSG00000211553.1 AC253576.2 -4.09 5.99e-05 0.0236 -0.42 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:283268 chr4:136461~136568:+ CESC cis rs2412819 0.597 rs7181912 ENSG00000205771.5 CATSPER2P1 4.09 6e-05 0.0236 0.39 0.27 Lung cancer; chr15:43770676 chr15:43726918~43747094:- CESC cis rs2412819 0.545 rs3862143 ENSG00000205771.5 CATSPER2P1 4.09 6e-05 0.0236 0.39 0.27 Lung cancer; chr15:43779282 chr15:43726918~43747094:- CESC cis rs13108904 0.875 rs10024013 ENSG00000254094.1 AC078852.1 4.09 6e-05 0.0236 0.32 0.27 Obesity-related traits; chr4:1287004 chr4:1356581~1358075:+ CESC cis rs13108904 0.935 rs1680072 ENSG00000254094.1 AC078852.1 4.09 6e-05 0.0236 0.32 0.27 Obesity-related traits; chr4:1287907 chr4:1356581~1358075:+ CESC cis rs42490 0.638 rs28144 ENSG00000251136.7 RP11-37B2.1 -4.09 6e-05 0.0236 -0.26 -0.27 Leprosy; chr8:89810531 chr8:89609409~89757727:- CESC cis rs61160187 0.555 rs34608 ENSG00000215032.2 GNL3LP1 4.09 6e-05 0.0236 0.33 0.27 Educational attainment (years of education);Educational attainment (college completion); chr5:61161807 chr5:60891935~60893577:- CESC cis rs4072705 0.615 rs7869829 ENSG00000224020.1 MIR181A2HG 4.09 6e-05 0.0237 0.34 0.27 Menarche (age at onset); chr9:124484898 chr9:124658467~124698631:+ CESC cis rs11096990 0.855 rs2711935 ENSG00000249207.1 RP11-360F5.1 4.09 6e-05 0.0237 0.36 0.27 Cognitive function; chr4:39160837 chr4:39112677~39126818:- CESC cis rs801193 0.805 rs12532355 ENSG00000237310.1 GS1-124K5.4 -4.09 6e-05 0.0237 -0.25 -0.27 Aortic root size; chr7:66605597 chr7:66493706~66495474:+ CESC cis rs9309473 0.948 rs10170849 ENSG00000163016.8 ALMS1P 4.09 6.01e-05 0.0237 0.33 0.27 Metabolite levels; chr2:73520805 chr2:73644919~73685576:+ CESC cis rs9309473 0.948 rs6719753 ENSG00000163016.8 ALMS1P 4.09 6.01e-05 0.0237 0.33 0.27 Metabolite levels; chr2:73521927 chr2:73644919~73685576:+ CESC cis rs9921338 0.781 rs7205925 ENSG00000262636.1 CTD-3088G3.4 -4.09 6.01e-05 0.0237 -0.37 -0.27 Vein graft stenosis in coronary artery bypass grafting; chr16:11368621 chr16:11380859~11381118:- CESC cis rs10043775 1 rs4349707 ENSG00000251330.3 CTD-2283N19.1 -4.09 6.01e-05 0.0237 -0.35 -0.27 Periodontal microbiota; chr5:148408875 chr5:148430159~148430807:- CESC cis rs11971779 0.648 rs9656512 ENSG00000273391.1 RP11-634H22.1 4.09 6.01e-05 0.0237 0.25 0.27 Diisocyanate-induced asthma; chr7:139369300 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6949599 ENSG00000273391.1 RP11-634H22.1 4.09 6.01e-05 0.0237 0.25 0.27 Diisocyanate-induced asthma; chr7:139369442 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs6949963 ENSG00000273391.1 RP11-634H22.1 4.09 6.01e-05 0.0237 0.25 0.27 Diisocyanate-induced asthma; chr7:139369579 chr7:139359032~139359566:- CESC cis rs11971779 0.555 rs6950143 ENSG00000273391.1 RP11-634H22.1 4.09 6.01e-05 0.0237 0.25 0.27 Diisocyanate-induced asthma; chr7:139369672 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6954531 ENSG00000273391.1 RP11-634H22.1 4.09 6.01e-05 0.0237 0.25 0.27 Diisocyanate-induced asthma; chr7:139369960 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6954547 ENSG00000273391.1 RP11-634H22.1 4.09 6.01e-05 0.0237 0.25 0.27 Diisocyanate-induced asthma; chr7:139369988 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs7788777 ENSG00000273391.1 RP11-634H22.1 4.09 6.01e-05 0.0237 0.25 0.27 Diisocyanate-induced asthma; chr7:139370447 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6963867 ENSG00000273391.1 RP11-634H22.1 4.09 6.01e-05 0.0237 0.25 0.27 Diisocyanate-induced asthma; chr7:139375218 chr7:139359032~139359566:- CESC cis rs801193 0.839 rs12534943 ENSG00000237310.1 GS1-124K5.4 -4.09 6.02e-05 0.0237 -0.25 -0.27 Aortic root size; chr7:66605533 chr7:66493706~66495474:+ CESC cis rs9908102 0.74 rs2286336 ENSG00000263648.1 RP11-471L13.3 4.09 6.02e-05 0.0237 0.39 0.27 Schizophrenia; chr17:13012624 chr17:12115547~12115885:+ CESC cis rs13434995 0.589 rs861029 ENSG00000273257.1 RP11-177J6.1 -4.09 6.02e-05 0.0237 -0.39 -0.27 Adiponectin levels; chr4:55379470 chr4:55387949~55388271:+ CESC cis rs5742933 1 rs1550388 ENSG00000253559.1 OSGEPL1-AS1 4.09 6.02e-05 0.0237 0.38 0.27 Ferritin levels; chr2:189739054 chr2:189762704~189765556:+ CESC cis rs7873102 0.544 rs735741 ENSG00000230188.1 RP11-405L18.4 -4.09 6.02e-05 0.0237 -0.34 -0.27 Brain structure; chr9:37944492 chr9:37490421~37490893:- CESC cis rs783540 0.835 rs8030185 ENSG00000276710.3 CSPG4P8 -4.09 6.02e-05 0.0237 -0.29 -0.27 Schizophrenia; chr15:82722785 chr15:82459472~82477258:+ CESC cis rs2554380 0.628 rs963690 ENSG00000230373.7 GOLGA6L5P -4.09 6.03e-05 0.0237 -0.33 -0.27 Height; chr15:83771068 chr15:84507885~84516814:- CESC cis rs2554380 0.628 rs2081541 ENSG00000230373.7 GOLGA6L5P -4.09 6.03e-05 0.0237 -0.33 -0.27 Height; chr15:83774934 chr15:84507885~84516814:- CESC cis rs8040855 0.627 rs62019482 ENSG00000259295.5 CSPG4P12 4.09 6.03e-05 0.0237 0.33 0.27 Bulimia nervosa; chr15:85071796 chr15:85191438~85213905:+ CESC cis rs7829975 0.606 rs10112585 ENSG00000254340.1 RP11-10A14.3 -4.09 6.03e-05 0.0237 -0.32 -0.27 Mood instability; chr8:8937520 chr8:9141424~9145435:+ CESC cis rs4713118 0.629 rs203889 ENSG00000219392.1 RP1-265C24.5 -4.09 6.03e-05 0.0237 -0.35 -0.27 Parkinson's disease; chr6:28053997 chr6:28115628~28116551:+ CESC cis rs7572733 0.555 rs6434954 ENSG00000222017.1 AC011997.1 4.09 6.03e-05 0.0237 0.34 0.27 Dermatomyositis; chr2:198064992 chr2:197693106~197774823:+ CESC cis rs6540731 1 rs35209719 ENSG00000226251.4 RP11-15I11.3 -4.09 6.03e-05 0.0237 -0.3 -0.27 Intelligence (childhood); chr1:212228335 chr1:212225278~212238977:- CESC cis rs860295 0.871 rs11582072 ENSG00000225855.5 RUSC1-AS1 -4.09 6.04e-05 0.0238 -0.21 -0.27 Body mass index; chr1:155507779 chr1:155316863~155324176:- CESC cis rs2299587 0.762 rs417088 ENSG00000253671.1 RP11-806O11.1 -4.09 6.05e-05 0.0238 -0.27 -0.27 Economic and political preferences; chr8:17933709 chr8:17808941~17820868:+ CESC cis rs79243044 1 rs10838290 ENSG00000224295.2 AC087380.14 -4.09 6.05e-05 0.0238 -0.29 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5538920 chr11:5518441~5524955:- CESC cis rs79243044 0.965 rs10500649 ENSG00000224295.2 AC087380.14 -4.09 6.05e-05 0.0238 -0.29 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5539873 chr11:5518441~5524955:- CESC cis rs950776 0.518 rs4886572 ENSG00000279373.1 RP11-650L12.4 -4.09 6.05e-05 0.0238 -0.31 -0.27 Sudden cardiac arrest; chr15:78545110 chr15:78537681~78538946:+ CESC cis rs6504622 1 rs1047779 ENSG00000262879.4 RP11-156P1.3 -4.09 6.05e-05 0.0238 -0.3 -0.27 Orofacial clefts; chr17:46941877 chr17:46984045~47100323:- CESC cis rs6504622 1 rs6504622 ENSG00000262879.4 RP11-156P1.3 4.09 6.05e-05 0.0238 0.3 0.27 Orofacial clefts; chr17:46942365 chr17:46984045~47100323:- CESC cis rs1124769 0.685 rs2574754 ENSG00000259378.1 DCAF13P3 4.09 6.05e-05 0.0238 0.35 0.27 Cognitive performance; chr15:50832242 chr15:50944663~50945996:+ CESC cis rs1124769 0.672 rs2663530 ENSG00000259378.1 DCAF13P3 4.09 6.05e-05 0.0238 0.35 0.27 Cognitive performance; chr15:50835453 chr15:50944663~50945996:+ CESC cis rs453301 0.653 rs7005133 ENSG00000254340.1 RP11-10A14.3 4.09 6.05e-05 0.0238 0.33 0.27 Joint mobility (Beighton score); chr8:9043712 chr8:9141424~9145435:+ CESC cis rs6964587 0.934 rs6465344 ENSG00000188693.7 CYP51A1-AS1 -4.09 6.05e-05 0.0238 -0.28 -0.27 Breast cancer; chr7:92010959 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs6967256 ENSG00000188693.7 CYP51A1-AS1 -4.09 6.05e-05 0.0238 -0.28 -0.27 Breast cancer; chr7:92013905 chr7:92134604~92180725:+ CESC cis rs6964587 0.967 rs28594877 ENSG00000188693.7 CYP51A1-AS1 -4.09 6.05e-05 0.0238 -0.28 -0.27 Breast cancer; chr7:92014756 chr7:92134604~92180725:+ CESC cis rs6964587 0.967 rs7788092 ENSG00000188693.7 CYP51A1-AS1 -4.09 6.05e-05 0.0238 -0.28 -0.27 Breast cancer; chr7:92016884 chr7:92134604~92180725:+ CESC cis rs67311347 0.955 rs6599100 ENSG00000223797.4 ENTPD3-AS1 4.09 6.05e-05 0.0238 0.26 0.27 Renal cell carcinoma; chr3:40405871 chr3:40313802~40453329:- CESC cis rs2134046 0.587 rs11854289 ENSG00000278603.1 RP13-608F4.5 -4.09 6.06e-05 0.0238 -0.33 -0.27 Cognitive ability; chr15:82266461 chr15:82472203~82472426:+ CESC cis rs916888 0.779 rs199528 ENSG00000232300.1 FAM215B 4.09 6.06e-05 0.0238 0.43 0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46558830~46562795:- CESC cis rs916888 0.821 rs199525 ENSG00000232300.1 FAM215B 4.09 6.06e-05 0.0238 0.43 0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46558830~46562795:- CESC cis rs11685222 0.513 rs55796546 ENSG00000229326.3 AC069154.4 4.09 6.06e-05 0.0238 0.37 0.27 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119658623 chr2:119698623~119700151:+ CESC cis rs10043775 1 rs13174567 ENSG00000251330.3 CTD-2283N19.1 -4.09 6.06e-05 0.0238 -0.35 -0.27 Periodontal microbiota; chr5:148432003 chr5:148430159~148430807:- CESC cis rs9309473 0.5 rs2421664 ENSG00000273245.1 RP11-434P11.2 -4.09 6.06e-05 0.0238 -0.33 -0.27 Metabolite levels; chr2:73631754 chr2:73750256~73750786:- CESC cis rs13108904 0.935 rs922698 ENSG00000254094.1 AC078852.1 4.09 6.06e-05 0.0238 0.32 0.27 Obesity-related traits; chr4:1288934 chr4:1356581~1358075:+ CESC cis rs2439831 0.85 rs7174208 ENSG00000249839.1 AC011330.5 -4.09 6.06e-05 0.0238 -0.38 -0.27 Lung cancer in ever smokers; chr15:43760484 chr15:43663654~43684339:- CESC cis rs10129255 0.957 rs1024349 ENSG00000211970.3 IGHV4-61 -4.09 6.07e-05 0.0238 -0.21 -0.27 Kawasaki disease; chr14:106689997 chr14:106639119~106639657:- CESC cis rs2836950 0.52 rs59916147 ENSG00000255568.3 BRWD1-AS2 -4.09 6.07e-05 0.0238 -0.22 -0.27 Menarche (age at onset); chr21:39262776 chr21:39313935~39314962:+ CESC cis rs1044826 0.597 rs6772199 ENSG00000178631.7 ACTG1P1 4.09 6.07e-05 0.0238 0.33 0.27 Obesity-related traits; chr3:139459291 chr3:139493809~139494937:+ CESC cis rs6951245 0.832 rs10266519 ENSG00000229043.2 AC091729.9 -4.09 6.07e-05 0.0239 -0.39 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1103341 chr7:1160374~1165267:+ CESC cis rs4877691 0.522 rs12684960 ENSG00000267559.4 RP11-383M4.6 -4.09 6.07e-05 0.0239 -0.37 -0.27 Airway imaging phenotypes; chr9:82469829 chr9:81930226~81977089:- CESC cis rs17301013 0.507 rs6700482 ENSG00000227373.4 RP11-160H22.5 4.09 6.07e-05 0.0239 0.38 0.27 Systemic lupus erythematosus; chr1:174306699 chr1:174115300~174160004:- CESC cis rs992157 0.56 rs6436048 ENSG00000261338.2 RP11-378A13.1 4.09 6.07e-05 0.0239 0.35 0.27 Colorectal cancer; chr2:218244310 chr2:218255319~218257366:+ CESC cis rs67311347 1 rs9834052 ENSG00000223797.4 ENTPD3-AS1 4.09 6.07e-05 0.0239 0.26 0.27 Renal cell carcinoma; chr3:40357569 chr3:40313802~40453329:- CESC cis rs9322193 0.923 rs66516768 ENSG00000216906.2 RP11-350J20.9 4.09 6.08e-05 0.0239 0.3 0.27 Lung cancer; chr6:149671999 chr6:149904243~149906418:+ CESC cis rs2836950 0.52 rs59916147 ENSG00000232608.1 TIMM9P2 4.09 6.08e-05 0.0239 0.3 0.27 Menarche (age at onset); chr21:39262776 chr21:39216624~39217506:+ CESC cis rs2688608 0.56 rs10128354 ENSG00000242288.9 RP11-464F9.1 4.09 6.08e-05 0.0239 0.3 0.27 Inflammatory bowel disease; chr10:73710287 chr10:73674295~73730466:- CESC cis rs853679 0.517 rs9295761 ENSG00000219392.1 RP1-265C24.5 -4.09 6.08e-05 0.0239 -0.35 -0.27 Depression; chr6:28180209 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs9393881 ENSG00000219392.1 RP1-265C24.5 -4.09 6.08e-05 0.0239 -0.36 -0.27 Parkinson's disease; chr6:28055973 chr6:28115628~28116551:+ CESC cis rs2688608 0.617 rs6480709 ENSG00000242288.9 RP11-464F9.1 4.09 6.08e-05 0.0239 0.3 0.27 Inflammatory bowel disease; chr10:73719367 chr10:73674295~73730466:- CESC cis rs2688608 0.592 rs12253482 ENSG00000242288.9 RP11-464F9.1 4.09 6.08e-05 0.0239 0.3 0.27 Inflammatory bowel disease; chr10:73736372 chr10:73674295~73730466:- CESC cis rs2688608 0.618 rs28553894 ENSG00000242288.9 RP11-464F9.1 4.09 6.08e-05 0.0239 0.3 0.27 Inflammatory bowel disease; chr10:73730085 chr10:73674295~73730466:- CESC cis rs2688608 0.618 rs28718766 ENSG00000242288.9 RP11-464F9.1 4.09 6.08e-05 0.0239 0.3 0.27 Inflammatory bowel disease; chr10:73730086 chr10:73674295~73730466:- CESC cis rs6844153 0.752 rs58968032 ENSG00000240005.4 RP11-293A21.1 -4.09 6.08e-05 0.0239 -0.37 -0.27 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26884674 chr4:26859806~26860599:- CESC cis rs516805 0.706 rs1267943 ENSG00000279453.1 RP3-425C14.4 -4.09 6.09e-05 0.0239 -0.35 -0.27 Lymphocyte counts; chr6:122462498 chr6:122436789~122439223:- CESC cis rs71403859 0.614 rs12149533 ENSG00000260886.1 TAT-AS1 4.09 6.09e-05 0.0239 0.44 0.27 Post bronchodilator FEV1; chr16:71768043 chr16:71565789~71578187:+ CESC cis rs9532669 0.963 rs3887418 ENSG00000239827.7 SUGT1P3 -4.09 6.09e-05 0.0239 -0.3 -0.27 Cervical cancer; chr13:40940560 chr13:40908159~40921774:- CESC cis rs9532669 0.926 rs1056820 ENSG00000239827.7 SUGT1P3 -4.09 6.09e-05 0.0239 -0.3 -0.27 Cervical cancer; chr13:40941150 chr13:40908159~40921774:- CESC cis rs9532669 0.926 rs9532678 ENSG00000239827.7 SUGT1P3 -4.09 6.09e-05 0.0239 -0.3 -0.27 Cervical cancer; chr13:40941862 chr13:40908159~40921774:- CESC cis rs2276314 1 rs2276314 ENSG00000278986.1 RP11-723J4.3 4.09 6.09e-05 0.0239 0.3 0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35977503 chr18:35972151~35973916:+ CESC cis rs944801 0.587 rs7049105 ENSG00000215221.2 UBA52P6 -4.09 6.09e-05 0.0239 -0.31 -0.27 Type 2 diabetes; chr9:22028802 chr9:22012155~22012536:+ CESC cis rs875971 0.862 rs7786892 ENSG00000232559.3 GS1-124K5.12 -4.09 6.09e-05 0.0239 -0.28 -0.27 Aortic root size; chr7:66163889 chr7:66554588~66576923:- CESC cis rs3738443 0.868 rs7551871 ENSG00000259865.1 RP11-488L18.10 4.09 6.1e-05 0.0239 0.28 0.27 Alcohol dependence; chr1:247199888 chr1:247187281~247188526:- CESC cis rs9532669 0.963 rs4941391 ENSG00000239827.7 SUGT1P3 -4.09 6.11e-05 0.024 -0.3 -0.27 Cervical cancer; chr13:40939787 chr13:40908159~40921774:- CESC cis rs7811142 0.667 rs3873746 ENSG00000242294.5 STAG3L5P 4.09 6.11e-05 0.024 0.26 0.27 Platelet count; chr7:100337474 chr7:100336079~100351900:+ CESC cis rs860295 0.836 rs35615695 ENSG00000225855.5 RUSC1-AS1 -4.09 6.11e-05 0.024 -0.21 -0.27 Body mass index; chr1:155531223 chr1:155316863~155324176:- CESC cis rs2060793 0.519 rs10832285 ENSG00000251991.1 RNU7-49P 4.09 6.11e-05 0.024 0.28 0.27 Vitamin D levels; chr11:14628031 chr11:14478892~14478953:+ CESC cis rs4819052 0.766 rs4819035 ENSG00000223768.1 LINC00205 -4.09 6.11e-05 0.024 -0.33 -0.27 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45225800 chr21:45293285~45297354:+ CESC cis rs2337406 0.866 rs2301535 ENSG00000211974.3 IGHV2-70 -4.09 6.11e-05 0.024 -0.43 -0.27 Alzheimer's disease (late onset); chr14:106790663 chr14:106723574~106724093:- CESC cis rs8100891 0.537 rs73038232 ENSG00000267213.4 AC007773.2 -4.09 6.11e-05 0.024 -0.46 -0.27 Neuroticism; chr19:32496747 chr19:32390050~32405560:- CESC cis rs748404 0.534 rs489509 ENSG00000249839.1 AC011330.5 -4.09 6.11e-05 0.024 -0.29 -0.27 Lung cancer; chr15:43294709 chr15:43663654~43684339:- CESC cis rs11971779 0.648 rs6947309 ENSG00000273391.1 RP11-634H22.1 4.09 6.12e-05 0.024 0.26 0.27 Diisocyanate-induced asthma; chr7:139351084 chr7:139359032~139359566:- CESC cis rs7829975 0.846 rs11779061 ENSG00000253893.2 FAM85B 4.09 6.12e-05 0.024 0.33 0.27 Mood instability; chr8:8691922 chr8:8167819~8226614:- CESC cis rs8072100 0.713 rs2292346 ENSG00000228782.6 CTD-2026D20.3 4.09 6.12e-05 0.024 0.32 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47378107 chr17:47450568~47492492:- CESC cis rs8072100 0.713 rs9807106 ENSG00000228782.6 CTD-2026D20.3 4.09 6.12e-05 0.024 0.32 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47379736 chr17:47450568~47492492:- CESC cis rs8072100 0.666 rs9913014 ENSG00000228782.6 CTD-2026D20.3 4.09 6.12e-05 0.024 0.32 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47382823 chr17:47450568~47492492:- CESC cis rs8072100 0.607 rs9894594 ENSG00000228782.6 CTD-2026D20.3 4.09 6.12e-05 0.024 0.32 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47384017 chr17:47450568~47492492:- CESC cis rs2436845 0.627 rs2679750 ENSG00000253320.4 KB-1507C5.2 -4.09 6.12e-05 0.024 -0.35 -0.27 Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts; chr8:102848164 chr8:102864300~102977876:+ CESC cis rs2436845 0.603 rs2679753 ENSG00000253320.4 KB-1507C5.2 -4.09 6.12e-05 0.024 -0.35 -0.27 Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts; chr8:102855232 chr8:102864300~102977876:+ CESC cis rs769267 0.965 rs4808937 ENSG00000269131.1 AC004447.2 -4.09 6.13e-05 0.024 -0.22 -0.27 Tonsillectomy; chr19:19287196 chr19:18990893~18993610:+ CESC cis rs769267 0.965 rs4808938 ENSG00000269131.1 AC004447.2 -4.09 6.13e-05 0.024 -0.22 -0.27 Tonsillectomy; chr19:19290409 chr19:18990893~18993610:+ CESC cis rs769267 0.93 rs7254927 ENSG00000269131.1 AC004447.2 -4.09 6.13e-05 0.024 -0.22 -0.27 Tonsillectomy; chr19:19293977 chr19:18990893~18993610:+ CESC cis rs769267 0.965 rs2023882 ENSG00000269131.1 AC004447.2 -4.09 6.13e-05 0.024 -0.22 -0.27 Tonsillectomy; chr19:19294596 chr19:18990893~18993610:+ CESC cis rs875971 0.502 rs2465121 ENSG00000226824.5 RP4-756H11.3 4.09 6.13e-05 0.024 0.4 0.27 Aortic root size; chr7:66156017 chr7:66654538~66669855:+ CESC cis rs7208859 0.573 rs55661352 ENSG00000266490.1 CTD-2349P21.9 4.09 6.14e-05 0.0241 0.42 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30792372~30792833:+ CESC cis rs3096299 0.9 rs3114867 ENSG00000274627.1 RP11-104N10.2 4.09 6.14e-05 0.0241 0.26 0.27 Multiple myeloma (IgH translocation); chr16:89362559 chr16:89516797~89522217:+ CESC cis rs6439153 0.933 rs9822511 ENSG00000231305.3 RP11-723O4.2 4.09 6.14e-05 0.0241 0.26 0.27 Pneumococcal bacteremia; chr3:128986724 chr3:128861313~128871540:- CESC cis rs7598759 0.712 rs12991636 ENSG00000181798.2 LINC00471 -4.09 6.14e-05 0.0241 -0.29 -0.27 Noise-induced hearing loss; chr2:231468955 chr2:231508426~231514339:- CESC cis rs11971779 0.688 rs1862880 ENSG00000273391.1 RP11-634H22.1 4.09 6.14e-05 0.0241 0.28 0.27 Diisocyanate-induced asthma; chr7:139335354 chr7:139359032~139359566:- CESC cis rs8031584 0.678 rs8035703 ENSG00000260382.1 RP11-540B6.2 4.09 6.15e-05 0.0241 0.36 0.27 Huntington's disease progression; chr15:30876269 chr15:30882267~30883231:- CESC cis rs343092 0.572 rs2583951 ENSG00000276853.1 RP11-305O6.4 4.09 6.15e-05 0.0241 0.55 0.27 Type 2 diabetes; chr12:65788474 chr12:65171262~65171917:+ CESC cis rs4272720 0.51 rs34878380 ENSG00000229870.1 RP11-507K13.6 -4.09 6.16e-05 0.0241 -0.31 -0.27 Platelet count;Plateletcrit; chr10:49085014 chr10:49815096~49815562:+ CESC cis rs9929218 0.52 rs1078621 ENSG00000260459.2 FTLP14 4.09 6.16e-05 0.0241 0.34 0.27 Colorectal cancer; chr16:68745093 chr16:68822587~68823070:+ CESC cis rs7714584 1 rs3900064 ENSG00000197083.10 ZNF300P1 -4.09 6.16e-05 0.0241 -0.44 -0.27 Crohn's disease; chr5:150884852 chr5:150930645~150946289:- CESC cis rs453301 0.686 rs11785819 ENSG00000173295.6 FAM86B3P -4.09 6.16e-05 0.0241 -0.35 -0.27 Joint mobility (Beighton score); chr8:9012868 chr8:8228595~8244865:+ CESC cis rs9847710 0.683 rs2581818 ENSG00000242142.1 SERBP1P3 4.09 6.16e-05 0.0241 0.31 0.27 Ulcerative colitis; chr3:53037636 chr3:53064283~53065091:- CESC cis rs1538970 0.962 rs7544178 ENSG00000280836.1 AL355480.1 -4.09 6.16e-05 0.0241 -0.33 -0.27 Platelet count; chr1:45353397 chr1:45581219~45581321:- CESC cis rs875971 0.545 rs75577046 ENSG00000236529.1 RP13-254B10.1 4.09 6.16e-05 0.0242 0.33 0.27 Aortic root size; chr7:66493729 chr7:65840212~65840596:+ CESC cis rs853679 0.567 rs2232427 ENSG00000204709.4 LINC01556 4.09 6.16e-05 0.0242 0.31 0.27 Depression; chr6:28391932 chr6:28943877~28944537:+ CESC cis rs10129255 0.957 rs2007467 ENSG00000211970.3 IGHV4-61 4.09 6.16e-05 0.0242 0.21 0.27 Kawasaki disease; chr14:106771605 chr14:106639119~106639657:- CESC cis rs12681963 0.688 rs73242322 ENSG00000272375.1 RP11-51J9.6 4.09 6.17e-05 0.0242 0.46 0.27 Migraine; chr8:30177573 chr8:30197404~30198048:+ CESC cis rs2732480 0.967 rs2732469 ENSG00000240399.1 RP1-228P16.1 4.09 6.17e-05 0.0242 0.3 0.27 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48319149 chr12:48054813~48055591:- CESC cis rs922182 1 rs1460546 ENSG00000239465.1 RP11-330L19.2 -4.09 6.18e-05 0.0242 -0.36 -0.27 Blood protein levels; chr15:63990909 chr15:64631109~64631914:- CESC cis rs897984 0.646 rs9938088 ENSG00000260911.2 RP11-196G11.2 4.09 6.18e-05 0.0242 0.27 0.27 Dementia with Lewy bodies; chr16:30818683 chr16:31043150~31049868:+ CESC cis rs2299587 0.813 rs10103879 ENSG00000253671.1 RP11-806O11.1 -4.09 6.18e-05 0.0242 -0.28 -0.27 Economic and political preferences; chr8:18013747 chr8:17808941~17820868:+ CESC cis rs12144049 0.705 rs7512558 ENSG00000227045.1 RP11-98D18.1 -4.09 6.18e-05 0.0242 -0.41 -0.27 Inflammatory skin disease;Atopic dermatitis; chr1:152466120 chr1:151701026~151708386:+ CESC cis rs9309473 0.95 rs6546847 ENSG00000163016.8 ALMS1P 4.09 6.18e-05 0.0242 0.33 0.27 Metabolite levels; chr2:73558231 chr2:73644919~73685576:+ CESC cis rs2404602 0.716 rs17362383 ENSG00000280730.1 AC090181.1 4.09 6.19e-05 0.0242 0.21 0.27 Blood metabolite levels; chr15:76358361 chr15:77056895~77057021:+ CESC cis rs11633886 0.528 rs2247958 ENSG00000273972.1 CTD-2306A12.1 4.09 6.19e-05 0.0242 0.31 0.27 Diisocyanate-induced asthma; chr15:45807336 chr15:45702640~45703183:+ CESC cis rs700651 0.685 rs976180 ENSG00000222017.1 AC011997.1 -4.09 6.19e-05 0.0242 -0.33 -0.27 Intracranial aneurysm; chr2:198015719 chr2:197693106~197774823:+ CESC cis rs79243044 1 rs10838291 ENSG00000224295.2 AC087380.14 -4.09 6.19e-05 0.0242 -0.29 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5538996 chr11:5518441~5524955:- CESC cis rs7688540 0.8 rs73793597 ENSG00000211553.1 AC253576.2 -4.09 6.19e-05 0.0242 -0.35 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:262116 chr4:136461~136568:+ CESC cis rs875971 0.545 rs73142245 ENSG00000222364.1 RNU6-96P -4.09 6.19e-05 0.0242 -0.37 -0.27 Aortic root size; chr7:66226662 chr7:66395191~66395286:+ CESC cis rs62355901 0.505 rs62356565 ENSG00000271828.1 CTD-2310F14.1 4.09 6.19e-05 0.0242 0.42 0.27 Breast cancer; chr5:56948139 chr5:56927874~56929573:+ CESC cis rs8098316 0.543 rs9304284 ENSG00000266283.1 RP11-627G18.1 -4.08 6.19e-05 0.0242 -0.42 -0.27 Height; chr18:23117390 chr18:22200619~22205229:- CESC cis rs673078 0.66 rs61945180 ENSG00000275759.1 RP11-131L12.3 -4.08 6.2e-05 0.0242 -0.55 -0.27 Glucose homeostasis traits; chr12:118216335 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs61945181 ENSG00000275759.1 RP11-131L12.3 -4.08 6.2e-05 0.0242 -0.55 -0.27 Glucose homeostasis traits; chr12:118216651 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs61945183 ENSG00000275759.1 RP11-131L12.3 -4.08 6.2e-05 0.0242 -0.55 -0.27 Glucose homeostasis traits; chr12:118221966 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs16948193 ENSG00000275759.1 RP11-131L12.3 -4.08 6.2e-05 0.0242 -0.55 -0.27 Glucose homeostasis traits; chr12:118227115 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs61945187 ENSG00000275759.1 RP11-131L12.3 -4.08 6.2e-05 0.0242 -0.55 -0.27 Glucose homeostasis traits; chr12:118228989 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs73205512 ENSG00000275759.1 RP11-131L12.3 -4.08 6.2e-05 0.0242 -0.55 -0.27 Glucose homeostasis traits; chr12:118235770 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs61945206 ENSG00000275759.1 RP11-131L12.3 -4.08 6.2e-05 0.0242 -0.55 -0.27 Glucose homeostasis traits; chr12:118238295 chr12:118428281~118428870:+ CESC cis rs875971 0.522 rs2008188 ENSG00000222364.1 RNU6-96P -4.08 6.2e-05 0.0242 -0.32 -0.27 Aortic root size; chr7:65964026 chr7:66395191~66395286:+ CESC cis rs1707322 1 rs3922887 ENSG00000281133.1 AL355480.3 -4.08 6.2e-05 0.0243 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46008130 chr1:45580892~45580996:- CESC cis rs1707322 1 rs3922886 ENSG00000281133.1 AL355480.3 -4.08 6.2e-05 0.0243 -0.32 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46008230 chr1:45580892~45580996:- CESC cis rs62355901 0.505 rs16886257 ENSG00000271828.1 CTD-2310F14.1 4.08 6.2e-05 0.0243 0.44 0.27 Breast cancer; chr5:56766994 chr5:56927874~56929573:+ CESC cis rs1799949 0.536 rs4793227 ENSG00000267681.1 CTD-3199J23.6 -4.08 6.2e-05 0.0243 -0.33 -0.27 Menopause (age at onset); chr17:43334882 chr17:43144956~43145255:+ CESC cis rs490234 0.676 rs4838263 ENSG00000232630.1 PRPS1P2 -4.08 6.2e-05 0.0243 -0.23 -0.27 Mean arterial pressure; chr9:125462920 chr9:125150653~125151589:+ CESC cis rs7572733 0.534 rs700685 ENSG00000222017.1 AC011997.1 4.08 6.21e-05 0.0243 0.33 0.27 Dermatomyositis; chr2:197851248 chr2:197693106~197774823:+ CESC cis rs2404602 0.583 rs12898415 ENSG00000280730.1 AC090181.1 4.08 6.21e-05 0.0243 0.2 0.27 Blood metabolite levels; chr15:76281891 chr15:77056895~77057021:+ CESC cis rs916888 0.821 rs199504 ENSG00000261575.2 RP11-259G18.1 -4.08 6.21e-05 0.0243 -0.39 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46267037~46268694:+ CESC cis rs8031584 0.541 rs2955797 ENSG00000260382.1 RP11-540B6.2 -4.08 6.21e-05 0.0243 -0.35 -0.27 Huntington's disease progression; chr15:30918778 chr15:30882267~30883231:- CESC cis rs56156301 1 rs1845431 ENSG00000253633.1 KB-1980E6.3 4.08 6.22e-05 0.0243 0.56 0.27 Pelvic organ prolapse; chr8:103156620 chr8:102528740~102538668:+ CESC cis rs703842 1 rs2069502 ENSG00000270039.1 RP11-571M6.17 4.08 6.22e-05 0.0243 0.33 0.27 Multiple sclerosis; chr12:57750882 chr12:57803838~57804415:+ CESC cis rs16953946 0.881 rs8052236 ENSG00000260896.4 RP11-314O13.1 -4.08 6.22e-05 0.0243 -0.6 -0.27 Inflammatory bowel disease; chr16:80755665 chr16:80828735~80892595:- CESC cis rs748404 0.706 rs57728767 ENSG00000249839.1 AC011330.5 -4.08 6.23e-05 0.0243 -0.4 -0.27 Lung cancer; chr15:43473639 chr15:43663654~43684339:- CESC cis rs11976180 0.569 rs12703565 ENSG00000170356.8 OR2A20P -4.08 6.23e-05 0.0243 -0.48 -0.27 Obesity-related traits; chr7:144057308 chr7:144250045~144252957:- CESC cis rs1124769 0.692 rs3825797 ENSG00000259378.1 DCAF13P3 4.08 6.23e-05 0.0244 0.36 0.27 Cognitive performance; chr15:50933486 chr15:50944663~50945996:+ CESC cis rs2115630 0.967 rs12595786 ENSG00000225151.9 GOLGA2P7 4.08 6.24e-05 0.0244 0.3 0.27 P wave terminal force; chr15:84793439 chr15:84199311~84230136:- CESC cis rs2276314 0.947 rs4799831 ENSG00000278986.1 RP11-723J4.3 -4.08 6.24e-05 0.0244 -0.31 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35974812 chr18:35972151~35973916:+ CESC cis rs2412819 0.571 rs2930531 ENSG00000249839.1 AC011330.5 4.08 6.24e-05 0.0244 0.34 0.27 Lung cancer; chr15:43829372 chr15:43663654~43684339:- CESC cis rs9532669 0.89 rs11619117 ENSG00000176268.5 CYCSP34 4.08 6.24e-05 0.0244 0.27 0.27 Cervical cancer; chr13:40880020 chr13:40863599~40863902:- CESC cis rs11971779 0.68 rs7783619 ENSG00000273391.1 RP11-634H22.1 4.08 6.24e-05 0.0244 0.25 0.27 Diisocyanate-induced asthma; chr7:139376691 chr7:139359032~139359566:- CESC cis rs2439831 1 rs2251538 ENSG00000205771.5 CATSPER2P1 -4.08 6.25e-05 0.0244 -0.37 -0.27 Lung cancer in ever smokers; chr15:43475011 chr15:43726918~43747094:- CESC cis rs9322193 0.923 rs9322209 ENSG00000216906.2 RP11-350J20.9 4.08 6.25e-05 0.0244 0.3 0.27 Lung cancer; chr6:149691226 chr6:149904243~149906418:+ CESC cis rs7572733 0.555 rs7590828 ENSG00000222017.1 AC011997.1 -4.08 6.25e-05 0.0244 -0.31 -0.27 Dermatomyositis; chr2:198075527 chr2:197693106~197774823:+ CESC cis rs11089937 0.597 rs11704434 ENSG00000211638.2 IGLV8-61 -4.08 6.26e-05 0.0244 -0.27 -0.27 Periodontitis (PAL4Q3); chr22:22131715 chr22:22098700~22099212:+ CESC cis rs17826219 0.5 rs117560728 ENSG00000266490.1 CTD-2349P21.9 4.08 6.26e-05 0.0245 0.47 0.27 Body mass index; chr17:30743920 chr17:30792372~30792833:+ CESC cis rs12908161 1 rs12903134 ENSG00000259728.4 LINC00933 4.08 6.26e-05 0.0245 0.34 0.27 Schizophrenia; chr15:84794468 chr15:84570649~84580175:+ CESC cis rs11089937 0.512 rs6001073 ENSG00000211638.2 IGLV8-61 -4.08 6.27e-05 0.0245 -0.26 -0.27 Periodontitis (PAL4Q3); chr22:22133650 chr22:22098700~22099212:+ CESC cis rs11089937 0.539 rs6001075 ENSG00000211638.2 IGLV8-61 -4.08 6.27e-05 0.0245 -0.26 -0.27 Periodontitis (PAL4Q3); chr22:22133765 chr22:22098700~22099212:+ CESC cis rs11089937 0.597 rs6001076 ENSG00000211638.2 IGLV8-61 -4.08 6.27e-05 0.0245 -0.26 -0.27 Periodontitis (PAL4Q3); chr22:22133873 chr22:22098700~22099212:+ CESC cis rs11089937 0.597 rs5995560 ENSG00000211638.2 IGLV8-61 -4.08 6.27e-05 0.0245 -0.26 -0.27 Periodontitis (PAL4Q3); chr22:22133989 chr22:22098700~22099212:+ CESC cis rs11089937 0.568 rs6001078 ENSG00000211638.2 IGLV8-61 -4.08 6.27e-05 0.0245 -0.26 -0.27 Periodontitis (PAL4Q3); chr22:22134365 chr22:22098700~22099212:+ CESC cis rs11089937 0.597 rs5757005 ENSG00000211638.2 IGLV8-61 -4.08 6.27e-05 0.0245 -0.26 -0.27 Periodontitis (PAL4Q3); chr22:22134775 chr22:22098700~22099212:+ CESC cis rs17301013 0.606 rs7536987 ENSG00000227373.4 RP11-160H22.5 4.08 6.27e-05 0.0245 0.32 0.27 Systemic lupus erythematosus; chr1:174367978 chr1:174115300~174160004:- CESC cis rs17301013 0.556 rs10912774 ENSG00000227373.4 RP11-160H22.5 4.08 6.27e-05 0.0245 0.32 0.27 Systemic lupus erythematosus; chr1:174387706 chr1:174115300~174160004:- CESC cis rs7428 0.847 rs1969260 ENSG00000273196.1 RP11-717A5.2 4.08 6.27e-05 0.0245 0.3 0.27 Ear protrusion; chr2:85341687 chr2:85387074~85387146:- CESC cis rs11096990 0.855 rs2566170 ENSG00000249207.1 RP11-360F5.1 4.08 6.27e-05 0.0245 0.35 0.27 Cognitive function; chr4:39150757 chr4:39112677~39126818:- CESC cis rs10413103 0.568 rs889108 ENSG00000242325.1 RPS12P31 -4.08 6.27e-05 0.0245 -0.36 -0.27 Granulocyte percentage of myeloid white cells; chr19:33272215 chr19:32636078~32636475:+ CESC cis rs673078 0.66 rs10507286 ENSG00000275759.1 RP11-131L12.3 -4.08 6.27e-05 0.0245 -0.55 -0.27 Glucose homeostasis traits; chr12:118197101 chr12:118428281~118428870:+ CESC cis rs673078 0.571 rs7954330 ENSG00000275759.1 RP11-131L12.3 -4.08 6.27e-05 0.0245 -0.55 -0.27 Glucose homeostasis traits; chr12:118275284 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs16948234 ENSG00000275759.1 RP11-131L12.3 4.08 6.27e-05 0.0245 0.55 0.27 Glucose homeostasis traits; chr12:118282464 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs56708462 ENSG00000275759.1 RP11-131L12.3 -4.08 6.27e-05 0.0245 -0.55 -0.27 Glucose homeostasis traits; chr12:118284135 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs7962185 ENSG00000275759.1 RP11-131L12.3 -4.08 6.27e-05 0.0245 -0.55 -0.27 Glucose homeostasis traits; chr12:118287842 chr12:118428281~118428870:+ CESC cis rs3096299 0.679 rs3096322 ENSG00000274627.1 RP11-104N10.2 -4.08 6.27e-05 0.0245 -0.27 -0.27 Multiple myeloma (IgH translocation); chr16:89374715 chr16:89516797~89522217:+ CESC cis rs875971 0.545 rs6950988 ENSG00000226824.5 RP4-756H11.3 -4.08 6.27e-05 0.0245 -0.38 -0.27 Aortic root size; chr7:66511428 chr7:66654538~66669855:+ CESC cis rs10129255 0.5 rs2105991 ENSG00000280411.1 IGHV1-69-2 -4.08 6.27e-05 0.0245 -0.18 -0.27 Kawasaki disease; chr14:106682022 chr14:106762092~106762588:- CESC cis rs7714670 0.871 rs11738813 ENSG00000184084.7 CTD-2372A4.1 -4.08 6.27e-05 0.0245 -0.31 -0.27 Venous thromboembolism (SNP x SNP interaction); chr5:73792077 chr5:73803296~73803599:- CESC cis rs801193 1 rs3778909 ENSG00000230358.3 RP11-166O4.1 -4.08 6.27e-05 0.0245 -0.36 -0.27 Aortic root size; chr7:66790659 chr7:67279778~67286230:+ CESC cis rs8177876 0.749 rs11537 ENSG00000261838.4 RP11-303E16.6 4.08 6.28e-05 0.0245 0.54 0.27 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046894 chr16:81069854~81076598:+ CESC cis rs2790457 0.958 rs2532744 ENSG00000254635.4 WAC-AS1 -4.08 6.28e-05 0.0245 -0.3 -0.27 Multiple myeloma; chr10:28613689 chr10:28522652~28532743:- CESC cis rs17711722 0.701 rs4467826 ENSG00000222364.1 RNU6-96P -4.08 6.28e-05 0.0245 -0.32 -0.27 Calcium levels; chr7:65903721 chr7:66395191~66395286:+ CESC cis rs1707322 1 rs4073847 ENSG00000281133.1 AL355480.3 4.08 6.28e-05 0.0245 0.32 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45997340 chr1:45580892~45580996:- CESC cis rs9322193 0.923 rs35961297 ENSG00000216906.2 RP11-350J20.9 4.08 6.29e-05 0.0245 0.3 0.27 Lung cancer; chr6:149667929 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs35967444 ENSG00000216906.2 RP11-350J20.9 4.08 6.29e-05 0.0245 0.3 0.27 Lung cancer; chr6:149675588 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs62439842 ENSG00000216906.2 RP11-350J20.9 4.08 6.29e-05 0.0245 0.3 0.27 Lung cancer; chr6:149675847 chr6:149904243~149906418:+ CESC cis rs10844706 0.699 rs741199 ENSG00000256594.6 RP11-705C15.2 4.08 6.29e-05 0.0245 0.32 0.27 Lymphocyte counts;Lymphocyte percentage of white cells; chr12:9720769 chr12:9633419~9658412:+ CESC cis rs10129255 0.5 rs1974468 ENSG00000224373.3 IGHV4-59 4.08 6.29e-05 0.0245 0.17 0.27 Kawasaki disease; chr14:106686149 chr14:106627249~106627825:- CESC cis rs853679 0.769 rs7752608 ENSG00000219392.1 RP1-265C24.5 -4.08 6.29e-05 0.0245 -0.47 -0.27 Depression; chr6:28333418 chr6:28115628~28116551:+ CESC cis rs2439831 1 rs690436 ENSG00000275601.1 AC011330.13 -4.08 6.29e-05 0.0245 -0.35 -0.27 Lung cancer in ever smokers; chr15:43469007 chr15:43642389~43643023:- CESC cis rs2439831 1 rs2264239 ENSG00000275601.1 AC011330.13 -4.08 6.29e-05 0.0245 -0.35 -0.27 Lung cancer in ever smokers; chr15:43473335 chr15:43642389~43643023:- CESC cis rs6976664 0.705 rs7799222 ENSG00000235314.1 LINC00957 4.08 6.3e-05 0.0246 0.34 0.27 Pursuit maintenance gain; chr7:44973162 chr7:44039171~44042306:+ CESC cis rs11250098 0.574 rs7015168 ENSG00000269918.1 AF131215.9 -4.08 6.3e-05 0.0246 -0.34 -0.27 Morning vs. evening chronotype; chr8:10914700 chr8:11104691~11106704:- CESC cis rs9826463 0.752 rs1132030 ENSG00000240950.1 RP11-372E1.1 -4.08 6.3e-05 0.0246 -0.23 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr3:142806016 chr3:142827096~142827728:- CESC cis rs2688608 0.592 rs7909544 ENSG00000242288.9 RP11-464F9.1 4.08 6.3e-05 0.0246 0.3 0.27 Inflammatory bowel disease; chr10:73724246 chr10:73674295~73730466:- CESC cis rs2276314 0.857 rs9960670 ENSG00000278986.1 RP11-723J4.3 -4.08 6.3e-05 0.0246 -0.3 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35997749 chr18:35972151~35973916:+ CESC cis rs2276314 0.857 rs28431958 ENSG00000278986.1 RP11-723J4.3 -4.08 6.3e-05 0.0246 -0.3 -0.27 Endometriosis;Drug-induced torsades de pointes; chr18:35998438 chr18:35972151~35973916:+ CESC cis rs2688608 0.592 rs7076585 ENSG00000242288.9 RP11-464F9.1 4.08 6.3e-05 0.0246 0.3 0.27 Inflammatory bowel disease; chr10:73743934 chr10:73674295~73730466:- CESC cis rs3091242 0.933 rs35148262 ENSG00000224183.1 SDHDP6 -4.08 6.3e-05 0.0246 -0.28 -0.27 Erythrocyte sedimentation rate; chr1:25440132 chr1:25294164~25294643:- CESC cis rs6499755 0.901 rs2042447 ENSG00000260135.5 RP11-212I21.2 4.08 6.3e-05 0.0246 0.33 0.27 Hypospadias; chr16:55318110 chr16:55426797~55462297:- CESC cis rs116175783 0.557 rs62197081 ENSG00000227403.1 AC009299.3 4.08 6.31e-05 0.0246 0.43 0.27 Intelligence (multi-trait analysis); chr2:161336814 chr2:161244739~161249050:+ CESC cis rs2688608 0.592 rs3933085 ENSG00000242288.9 RP11-464F9.1 4.08 6.31e-05 0.0246 0.3 0.27 Inflammatory bowel disease; chr10:73723573 chr10:73674295~73730466:- CESC cis rs2688608 0.592 rs10762559 ENSG00000242288.9 RP11-464F9.1 4.08 6.31e-05 0.0246 0.3 0.27 Inflammatory bowel disease; chr10:73726695 chr10:73674295~73730466:- CESC cis rs1538970 0.924 rs3790582 ENSG00000280836.1 AL355480.1 -4.08 6.31e-05 0.0246 -0.33 -0.27 Platelet count; chr1:45421616 chr1:45581219~45581321:- CESC cis rs9309473 1 rs10186501 ENSG00000163016.8 ALMS1P 4.08 6.31e-05 0.0246 0.33 0.27 Metabolite levels; chr2:73470717 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs10189574 ENSG00000163016.8 ALMS1P 4.08 6.31e-05 0.0246 0.33 0.27 Metabolite levels; chr2:73471391 chr2:73644919~73685576:+ CESC cis rs3806843 0.576 rs246002 ENSG00000202111.1 VTRNA1-2 -4.08 6.31e-05 0.0246 -0.27 -0.27 Depressive symptoms (multi-trait analysis); chr5:140961519 chr5:140718925~140719013:+ CESC cis rs9322193 0.923 rs35830138 ENSG00000216906.2 RP11-350J20.9 4.08 6.31e-05 0.0246 0.3 0.27 Lung cancer; chr6:149668635 chr6:149904243~149906418:+ CESC cis rs516805 0.847 rs520046 ENSG00000279453.1 RP3-425C14.4 -4.08 6.31e-05 0.0246 -0.31 -0.27 Lymphocyte counts; chr6:122446048 chr6:122436789~122439223:- CESC cis rs7246657 0.508 rs10419845 ENSG00000276846.1 CTD-3220F14.3 4.08 6.32e-05 0.0246 0.41 0.27 Coronary artery calcification; chr19:37000290 chr19:37314868~37315620:- CESC cis rs7527939 0.556 rs79471150 ENSG00000276335.1 MIR205 4.08 6.32e-05 0.0246 0.43 0.27 Schizophrenia; chr1:210363436 chr1:209432133~209432242:+ CESC cis rs11159086 1 rs4903233 ENSG00000270000.1 RP3-449M8.9 4.08 6.32e-05 0.0246 0.46 0.27 Advanced glycation end-product levels; chr14:74497291 chr14:74471930~74472360:- CESC cis rs4319547 0.656 rs10773088 ENSG00000275265.1 RP11-15J22.8 -4.08 6.32e-05 0.0246 -0.37 -0.27 Body mass index; chr12:122343522 chr12:122501187~122501641:+ CESC cis rs4319547 0.656 rs1553179 ENSG00000275265.1 RP11-15J22.8 -4.08 6.32e-05 0.0246 -0.37 -0.27 Body mass index; chr12:122346526 chr12:122501187~122501641:+ CESC cis rs2688608 0.588 rs10128205 ENSG00000242288.9 RP11-464F9.1 4.08 6.32e-05 0.0246 0.3 0.27 Inflammatory bowel disease; chr10:73709890 chr10:73674295~73730466:- CESC cis rs453301 0.592 rs4841084 ENSG00000253893.2 FAM85B -4.08 6.32e-05 0.0247 -0.32 -0.27 Joint mobility (Beighton score); chr8:9026395 chr8:8167819~8226614:- CESC cis rs67311347 1 rs11539046 ENSG00000223797.4 ENTPD3-AS1 -4.08 6.32e-05 0.0247 -0.27 -0.27 Renal cell carcinoma; chr3:40462318 chr3:40313802~40453329:- CESC cis rs11089937 0.626 rs10483106 ENSG00000211638.2 IGLV8-61 -4.08 6.32e-05 0.0247 -0.28 -0.27 Periodontitis (PAL4Q3); chr22:22149240 chr22:22098700~22099212:+ CESC cis rs7688540 0.771 rs61792116 ENSG00000211553.1 AC253576.2 -4.08 6.33e-05 0.0247 -0.41 -0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:307288 chr4:136461~136568:+ CESC cis rs17152411 0.625 rs7099073 ENSG00000232334.1 RP11-47G11.2 -4.08 6.33e-05 0.0247 -0.29 -0.27 Height; chr10:124921078 chr10:124004304~124004828:- CESC cis rs12468226 1 rs79919139 ENSG00000273456.1 RP11-686O6.2 4.08 6.33e-05 0.0247 0.35 0.27 Urate levels; chr2:202382786 chr2:202374932~202375604:- CESC cis rs9601248 0.841 rs9545146 ENSG00000227676.3 LINC01068 -4.08 6.33e-05 0.0247 -0.3 -0.27 Major depressive disorder; chr13:79601471 chr13:79566727~79571436:+ CESC cis rs17772222 0.917 rs61984737 ENSG00000258983.2 RP11-507K2.2 4.08 6.34e-05 0.0247 0.33 0.27 Coronary artery calcification; chr14:88637028 chr14:88499334~88515502:+ CESC cis rs7572733 0.576 rs1368989 ENSG00000222017.1 AC011997.1 4.08 6.34e-05 0.0247 0.34 0.27 Dermatomyositis; chr2:198072358 chr2:197693106~197774823:+ CESC cis rs10129255 0.5 rs4774008 ENSG00000211970.3 IGHV4-61 -4.08 6.34e-05 0.0247 -0.19 -0.27 Kawasaki disease; chr14:106681273 chr14:106639119~106639657:- CESC cis rs7428 1 rs7428 ENSG00000273196.1 RP11-717A5.2 -4.08 6.34e-05 0.0247 -0.3 -0.27 Ear protrusion; chr2:85318367 chr2:85387074~85387146:- CESC cis rs11633886 0.528 rs2899383 ENSG00000273972.1 CTD-2306A12.1 4.08 6.35e-05 0.0247 0.3 0.27 Diisocyanate-induced asthma; chr15:45804853 chr15:45702640~45703183:+ CESC cis rs2554380 0.628 rs4843156 ENSG00000230373.7 GOLGA6L5P -4.08 6.35e-05 0.0247 -0.33 -0.27 Height; chr15:83788593 chr15:84507885~84516814:- CESC cis rs4803480 0.578 rs7252454 ENSG00000270164.1 LINC01480 -4.08 6.35e-05 0.0247 -0.31 -0.27 Schizophrenia; chr19:41527343 chr19:41535183~41536904:+ CESC cis rs6921919 1 rs6921919 ENSG00000204709.4 LINC01556 4.08 6.35e-05 0.0247 0.32 0.27 Autism spectrum disorder or schizophrenia; chr6:28357424 chr6:28943877~28944537:+ CESC cis rs17807624 1 rs17807624 ENSG00000255046.1 RP11-297N6.4 4.08 6.35e-05 0.0247 0.27 0.27 Systemic lupus erythematosus; chr8:11605506 chr8:11797928~11802568:- CESC cis rs7829975 0.593 rs2921051 ENSG00000253893.2 FAM85B -4.08 6.36e-05 0.0248 -0.33 -0.27 Mood instability; chr8:8462594 chr8:8167819~8226614:- CESC cis rs116175783 0.557 rs1267058 ENSG00000227403.1 AC009299.3 -4.08 6.36e-05 0.0248 -0.43 -0.27 Intelligence (multi-trait analysis); chr2:161264934 chr2:161244739~161249050:+ CESC cis rs6439153 0.933 rs6769662 ENSG00000261159.1 RP11-723O4.9 4.08 6.37e-05 0.0248 0.27 0.27 Pneumococcal bacteremia; chr3:129002467 chr3:128859716~128860526:- CESC cis rs6439153 0.967 rs12695512 ENSG00000261159.1 RP11-723O4.9 4.08 6.37e-05 0.0248 0.27 0.27 Pneumococcal bacteremia; chr3:129003239 chr3:128859716~128860526:- CESC cis rs6439153 0.967 rs12695513 ENSG00000261159.1 RP11-723O4.9 4.08 6.37e-05 0.0248 0.27 0.27 Pneumococcal bacteremia; chr3:129003469 chr3:128859716~128860526:- CESC cis rs2235544 0.639 rs72664117 ENSG00000225183.1 RP4-758J24.4 -4.08 6.37e-05 0.0248 -0.3 -0.27 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54011258 chr1:54089856~54090093:+ CESC cis rs748404 0.631 rs6493083 ENSG00000205771.5 CATSPER2P1 -4.08 6.37e-05 0.0248 -0.32 -0.27 Lung cancer; chr15:43345787 chr15:43726918~43747094:- CESC cis rs17507216 0.609 rs1431716 ENSG00000255769.6 GOLGA2P10 -4.08 6.37e-05 0.0248 -0.42 -0.27 Excessive daytime sleepiness; chr15:82676180 chr15:82472993~82513950:- CESC cis rs887829 0.57 rs6759892 ENSG00000263941.2 RN7SL32P 4.08 6.37e-05 0.0248 0.32 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233693023 chr2:233205199~233205479:+ CESC cis rs77988765 0.611 rs2509175 ENSG00000279459.1 RP11-826F13.1 4.08 6.37e-05 0.0248 0.34 0.27 Post bronchodilator FEV1/FVC ratio; chr11:70132532 chr11:70603304~70604859:+ CESC cis rs12908161 1 rs35726233 ENSG00000259728.4 LINC00933 4.08 6.38e-05 0.0248 0.34 0.27 Schizophrenia; chr15:84794569 chr15:84570649~84580175:+ CESC cis rs12908161 1 rs35960805 ENSG00000259728.4 LINC00933 4.08 6.38e-05 0.0248 0.34 0.27 Schizophrenia; chr15:84800749 chr15:84570649~84580175:+ CESC cis rs12908161 1 rs12912388 ENSG00000259728.4 LINC00933 4.08 6.38e-05 0.0248 0.34 0.27 Schizophrenia; chr15:84801319 chr15:84570649~84580175:+ CESC cis rs7246657 0.722 rs958305 ENSG00000276846.1 CTD-3220F14.3 -4.08 6.38e-05 0.0248 -0.32 -0.27 Coronary artery calcification; chr19:37698539 chr19:37314868~37315620:- CESC cis rs4794202 0.7 rs11649750 ENSG00000264920.1 RP11-6N17.4 -4.08 6.38e-05 0.0248 -0.48 -0.27 Alzheimer's disease (cognitive decline); chr17:47872656 chr17:47891255~47895812:- CESC cis rs9322193 0.607 rs9322229 ENSG00000216906.2 RP11-350J20.9 4.08 6.38e-05 0.0248 0.33 0.27 Lung cancer; chr6:149908949 chr6:149904243~149906418:+ CESC cis rs875971 1 rs2220626 ENSG00000232559.3 GS1-124K5.12 -4.08 6.38e-05 0.0248 -0.3 -0.27 Aortic root size; chr7:66081075 chr7:66554588~66576923:- CESC cis rs9393777 0.513 rs11967852 ENSG00000241549.7 GUSBP2 4.08 6.38e-05 0.0248 0.34 0.27 Intelligence (multi-trait analysis); chr6:26612642 chr6:26871484~26956554:- CESC cis rs7605378 0.528 rs281780 ENSG00000232732.8 AC073043.1 -4.08 6.38e-05 0.0248 -0.36 -0.27 Osteoporosis; chr2:199891608 chr2:199867396~199911159:- CESC cis rs7605378 0.528 rs1704190 ENSG00000232732.8 AC073043.1 -4.08 6.38e-05 0.0248 -0.36 -0.27 Osteoporosis; chr2:199895906 chr2:199867396~199911159:- CESC cis rs12468226 1 rs13389798 ENSG00000273456.1 RP11-686O6.2 4.08 6.39e-05 0.0248 0.34 0.27 Urate levels; chr2:202348370 chr2:202374932~202375604:- CESC cis rs875971 0.522 rs709604 ENSG00000222364.1 RNU6-96P 4.08 6.39e-05 0.0248 0.32 0.27 Aortic root size; chr7:66032447 chr7:66395191~66395286:+ CESC cis rs8062405 0.573 rs8045689 ENSG00000261067.5 RP11-264B17.3 -4.08 6.39e-05 0.0248 -0.27 -0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28976948 chr16:28974804~28990783:+ CESC cis rs755249 0.761 rs3768321 ENSG00000228060.1 RP11-69E11.8 -4.08 6.39e-05 0.0249 -0.36 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39570256 chr1:39565160~39573203:+ CESC cis rs2688608 0.592 rs11000759 ENSG00000242288.9 RP11-464F9.1 4.08 6.4e-05 0.0249 0.3 0.27 Inflammatory bowel disease; chr10:73733968 chr10:73674295~73730466:- CESC cis rs2908197 0.806 rs6465098 ENSG00000127957.15 PMS2P3 4.08 6.4e-05 0.0249 0.31 0.27 3-hydroxypropylmercapturic acid levels in smokers; chr7:76343630 chr7:75502930~75528148:- CESC cis rs12220238 0.915 rs11001027 ENSG00000213731.2 RAB5CP1 -4.08 6.4e-05 0.0249 -0.44 -0.27 Soluble interleukin-2 receptor subunit alpha; chr10:74392897 chr10:74423435~74424014:- CESC cis rs12220238 0.915 rs61045754 ENSG00000213731.2 RAB5CP1 -4.08 6.4e-05 0.0249 -0.44 -0.27 Soluble interleukin-2 receptor subunit alpha; chr10:74393367 chr10:74423435~74424014:- CESC cis rs440932 0.717 rs330944 ENSG00000253893.2 FAM85B -4.08 6.4e-05 0.0249 -0.32 -0.27 High light scatter reticulocyte percentage of red cells; chr8:9163783 chr8:8167819~8226614:- CESC cis rs6547705 0.777 rs4832307 ENSG00000231259.4 AC125232.1 -4.08 6.4e-05 0.0249 -0.4 -0.27 Progressive supranuclear palsy; chr2:86682915 chr2:87031815~87053069:- CESC cis rs12690897 0.501 rs10229435 ENSG00000229251.3 HNRNPA1P8 -4.08 6.4e-05 0.0249 -0.28 -0.27 Macrophage inflammatory protein 1a levels; chr7:85577336 chr7:84983556~84984506:+ CESC cis rs2404602 0.669 rs12916324 ENSG00000280730.1 AC090181.1 4.08 6.41e-05 0.0249 0.21 0.27 Blood metabolite levels; chr15:76887262 chr15:77056895~77057021:+ CESC cis rs875971 0.838 rs2173570 ENSG00000237310.1 GS1-124K5.4 -4.08 6.41e-05 0.0249 -0.24 -0.27 Aortic root size; chr7:66297976 chr7:66493706~66495474:+ CESC cis rs875971 1 rs697970 ENSG00000232559.3 GS1-124K5.12 -4.08 6.41e-05 0.0249 -0.3 -0.27 Aortic root size; chr7:66095065 chr7:66554588~66576923:- CESC cis rs2439831 0.85 rs28684672 ENSG00000275601.1 AC011330.13 -4.08 6.42e-05 0.0249 -0.42 -0.27 Lung cancer in ever smokers; chr15:43815464 chr15:43642389~43643023:- CESC cis rs3738443 0.904 rs61840474 ENSG00000259865.1 RP11-488L18.10 4.08 6.42e-05 0.0249 0.32 0.27 Alcohol dependence; chr1:247225109 chr1:247187281~247188526:- CESC cis rs3738443 0.904 rs61840475 ENSG00000259865.1 RP11-488L18.10 4.08 6.42e-05 0.0249 0.32 0.27 Alcohol dependence; chr1:247225818 chr1:247187281~247188526:- CESC cis rs10129255 0.957 rs10136817 ENSG00000211974.3 IGHV2-70 4.08 6.42e-05 0.025 0.3 0.27 Kawasaki disease; chr14:106787730 chr14:106723574~106724093:- CESC cis rs8020095 0.571 rs17247792 ENSG00000258561.1 RP11-72M17.1 -4.08 6.42e-05 0.025 -0.4 -0.27 Depression (quantitative trait); chr14:66767739 chr14:66212810~66509394:- CESC cis rs75422866 0.764 rs73104177 ENSG00000280054.1 RP1-197B17.7 4.08 6.42e-05 0.025 0.72 0.27 Pneumonia; chr12:47713550 chr12:47728151~47730598:- CESC cis rs75422866 0.764 rs73104184 ENSG00000280054.1 RP1-197B17.7 4.08 6.42e-05 0.025 0.72 0.27 Pneumonia; chr12:47715623 chr12:47728151~47730598:- CESC cis rs1387259 0.69 rs1601985 ENSG00000240399.1 RP1-228P16.1 4.08 6.42e-05 0.025 0.31 0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48368131 chr12:48054813~48055591:- CESC cis rs783540 0.846 rs2099259 ENSG00000278603.1 RP13-608F4.5 4.08 6.43e-05 0.025 0.32 0.27 Schizophrenia; chr15:82654937 chr15:82472203~82472426:+ CESC cis rs2836950 0.501 rs4818018 ENSG00000255568.3 BRWD1-AS2 -4.08 6.43e-05 0.025 -0.22 -0.27 Menarche (age at onset); chr21:39322146 chr21:39313935~39314962:+ CESC cis rs2836950 0.501 rs4818019 ENSG00000255568.3 BRWD1-AS2 -4.08 6.43e-05 0.025 -0.22 -0.27 Menarche (age at onset); chr21:39322530 chr21:39313935~39314962:+ CESC cis rs7208859 0.623 rs7214570 ENSG00000266490.1 CTD-2349P21.9 4.08 6.44e-05 0.025 0.39 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30792372~30792833:+ CESC cis rs3748682 0.808 rs12728438 ENSG00000212541.1 RNU6-510P -4.08 6.44e-05 0.025 -0.37 -0.27 Hypothyroidism; chr1:37883728 chr1:37991462~37991569:+ CESC cis rs1387259 0.619 rs2130095 ENSG00000240399.1 RP1-228P16.1 -4.08 6.44e-05 0.025 -0.28 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48244972 chr12:48054813~48055591:- CESC cis rs3096299 0.933 rs2965823 ENSG00000274627.1 RP11-104N10.2 4.08 6.44e-05 0.025 0.26 0.27 Multiple myeloma (IgH translocation); chr16:89388516 chr16:89516797~89522217:+ CESC cis rs7259376 0.525 rs1692594 ENSG00000213971.6 RP11-15H20.6 -4.08 6.44e-05 0.025 -0.33 -0.27 Menopause (age at onset); chr19:22451796 chr19:23259906~23274251:- CESC cis rs8080784 1 rs2889993 ENSG00000266701.1 AC005702.4 4.08 6.44e-05 0.025 0.37 0.27 Coronary artery disease; chr17:60949179 chr17:60042546~60042627:- CESC cis rs1153858 0.562 rs8025019 ENSG00000259520.4 CTD-2651B20.3 -4.08 6.44e-05 0.025 -0.51 -0.27 Homoarginine levels; chr15:45443667 chr15:45251580~45279251:- CESC cis rs523522 0.847 rs11065132 ENSG00000278344.1 RP11-18C24.8 4.08 6.44e-05 0.025 0.33 0.27 High light scatter reticulocyte count; chr12:120470656 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs4767902 ENSG00000278344.1 RP11-18C24.8 4.08 6.44e-05 0.025 0.33 0.27 High light scatter reticulocyte count; chr12:120472201 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs10849753 ENSG00000278344.1 RP11-18C24.8 4.08 6.44e-05 0.025 0.33 0.27 High light scatter reticulocyte count; chr12:120473010 chr12:120500735~120501090:- CESC cis rs2933343 1 rs2933343 ENSG00000231305.3 RP11-723O4.2 4.08 6.44e-05 0.025 0.29 0.27 IgG glycosylation; chr3:128939649 chr3:128861313~128871540:- CESC cis rs5022942 0.591 rs2685469 ENSG00000251331.5 RP11-689K5.3 4.08 6.45e-05 0.025 0.34 0.27 Myopia; chr4:81067187 chr4:81602797~82044244:- CESC cis rs7621025 0.505 rs34281413 ENSG00000239213.4 NCK1-AS1 -4.07 6.45e-05 0.025 -0.42 -0.27 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136743018 chr3:136841726~136862054:- CESC cis rs11971779 0.68 rs17613690 ENSG00000273391.1 RP11-634H22.1 -4.07 6.45e-05 0.025 -0.26 -0.27 Diisocyanate-induced asthma; chr7:139403655 chr7:139359032~139359566:- CESC cis rs1440410 0.798 rs34664017 ENSG00000250326.1 RP11-284M14.1 -4.07 6.45e-05 0.025 -0.29 -0.27 Ischemic stroke; chr4:143173191 chr4:142933195~143184861:- CESC cis rs1546924 0.647 rs197422 ENSG00000227811.2 FAM212B-AS1 -4.07 6.45e-05 0.025 -0.29 -0.27 Body mass index; chr1:111774890 chr1:111739841~111747798:+ CESC cis rs875971 0.964 rs55748098 ENSG00000179406.6 LINC00174 4.07 6.45e-05 0.025 0.28 0.27 Aortic root size; chr7:66298631 chr7:66376044~66401338:- CESC cis rs2439831 1 rs689826 ENSG00000205771.5 CATSPER2P1 -4.07 6.46e-05 0.0251 -0.37 -0.27 Lung cancer in ever smokers; chr15:43457718 chr15:43726918~43747094:- CESC cis rs1799949 0.683 rs55737636 ENSG00000267681.1 CTD-3199J23.6 -4.07 6.46e-05 0.0251 -0.32 -0.27 Menopause (age at onset); chr17:43112722 chr17:43144956~43145255:+ CESC cis rs9527 0.59 rs1475642 ENSG00000236937.2 PTGES3P4 -4.07 6.46e-05 0.0251 -0.4 -0.27 Arsenic metabolism; chr10:102786426 chr10:102845595~102845950:+ CESC cis rs751837 1 rs751837 ENSG00000240624.1 RP11-45P15.2 4.07 6.46e-05 0.0251 0.38 0.27 Large B-cell lymphoma; chr14:103018488 chr14:103282933~103283468:+ CESC cis rs5742933 0.857 rs7571089 ENSG00000253559.1 OSGEPL1-AS1 4.07 6.47e-05 0.0251 0.32 0.27 Ferritin levels; chr2:189697067 chr2:189762704~189765556:+ CESC cis rs72634258 0.732 rs6577464 ENSG00000238249.2 HMGN2P17 4.07 6.47e-05 0.0251 0.29 0.27 Inflammatory bowel disease; chr1:8111242 chr1:8893409~8894151:+ CESC cis rs2688608 0.592 rs10762563 ENSG00000242288.9 RP11-464F9.1 4.07 6.47e-05 0.0251 0.3 0.27 Inflammatory bowel disease; chr10:73765044 chr10:73674295~73730466:- CESC cis rs8059260 0.673 rs8056854 ENSG00000274038.1 RP11-66H6.4 -4.07 6.47e-05 0.0251 -0.49 -0.27 Alcohol consumption over the past year; chr16:10947858 chr16:11056556~11057034:+ CESC cis rs17818399 0.735 rs11894342 ENSG00000279254.1 RP11-536C12.1 -4.07 6.48e-05 0.0251 -0.29 -0.27 Height; chr2:46609300 chr2:46668870~46670778:+ CESC cis rs11971779 0.715 rs10265 ENSG00000273391.1 RP11-634H22.1 4.07 6.48e-05 0.0251 0.25 0.27 Diisocyanate-induced asthma; chr7:139341406 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs6965143 ENSG00000273391.1 RP11-634H22.1 4.07 6.48e-05 0.0251 0.25 0.27 Diisocyanate-induced asthma; chr7:139341862 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs11771715 ENSG00000273391.1 RP11-634H22.1 4.07 6.48e-05 0.0251 0.25 0.27 Diisocyanate-induced asthma; chr7:139342750 chr7:139359032~139359566:- CESC cis rs11971779 0.648 rs4732367 ENSG00000273391.1 RP11-634H22.1 4.07 6.48e-05 0.0251 0.25 0.27 Diisocyanate-induced asthma; chr7:139343356 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs7808740 ENSG00000273391.1 RP11-634H22.1 4.07 6.48e-05 0.0251 0.25 0.27 Diisocyanate-induced asthma; chr7:139344209 chr7:139359032~139359566:- CESC cis rs67311347 1 rs4973878 ENSG00000223797.4 ENTPD3-AS1 4.07 6.49e-05 0.0252 0.26 0.27 Renal cell carcinoma; chr3:40366074 chr3:40313802~40453329:- CESC cis rs17301013 0.606 rs16846938 ENSG00000227373.4 RP11-160H22.5 4.07 6.49e-05 0.0252 0.32 0.27 Systemic lupus erythematosus; chr1:174400537 chr1:174115300~174160004:- CESC cis rs2933343 0.621 rs789241 ENSG00000231305.3 RP11-723O4.2 4.07 6.49e-05 0.0252 0.25 0.27 IgG glycosylation; chr3:128866909 chr3:128861313~128871540:- CESC cis rs2933343 0.649 rs2638845 ENSG00000231305.3 RP11-723O4.2 4.07 6.49e-05 0.0252 0.25 0.27 IgG glycosylation; chr3:128868526 chr3:128861313~128871540:- CESC cis rs11779988 0.629 rs7465361 ENSG00000253671.1 RP11-806O11.1 -4.07 6.49e-05 0.0252 -0.32 -0.27 Breast cancer; chr8:17996646 chr8:17808941~17820868:+ CESC cis rs11633886 0.565 rs28567025 ENSG00000273972.1 CTD-2306A12.1 4.07 6.49e-05 0.0252 0.31 0.27 Diisocyanate-induced asthma; chr15:45767239 chr15:45702640~45703183:+ CESC cis rs4819052 0.851 rs7275468 ENSG00000223768.1 LINC00205 -4.07 6.49e-05 0.0252 -0.31 -0.27 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45236584 chr21:45293285~45297354:+ CESC cis rs2243480 0.901 rs3813708 ENSG00000164669.11 INTS4P1 4.07 6.49e-05 0.0252 0.54 0.27 Diabetic kidney disease; chr7:65840645 chr7:65141225~65234216:+ CESC cis rs11083475 0.792 rs11083473 ENSG00000267892.1 CTD-2540F13.2 -4.07 6.49e-05 0.0252 -0.3 -0.27 Heart rate; chr19:38689294 chr19:38738284~38739863:+ CESC cis rs7243790 1 rs17558111 ENSG00000277324.1 RP11-850A17.1 -4.07 6.5e-05 0.0252 -0.3 -0.27 Diastolic blood pressure; chr18:54437583 chr18:54268346~54270028:- CESC cis rs7811142 0.775 rs1059129 ENSG00000242294.5 STAG3L5P 4.07 6.5e-05 0.0252 0.26 0.27 Platelet count; chr7:100328899 chr7:100336079~100351900:+ CESC cis rs7811142 0.562 rs7786844 ENSG00000242294.5 STAG3L5P 4.07 6.5e-05 0.0252 0.26 0.27 Platelet count; chr7:100336385 chr7:100336079~100351900:+ CESC cis rs7044106 1 rs7044106 ENSG00000238181.2 AHCYP2 -4.07 6.51e-05 0.0252 -0.37 -0.27 Hip circumference adjusted for BMI; chr9:120731784 chr9:120720673~120721972:+ CESC cis rs1969253 0.803 rs843362 ENSG00000205955.4 HSP90AA5P -4.07 6.51e-05 0.0252 -0.25 -0.27 Major depressive disorder; chr3:184146241 chr3:184115352~184117898:+ CESC cis rs2439831 0.85 rs12442297 ENSG00000249839.1 AC011330.5 -4.07 6.51e-05 0.0252 -0.41 -0.27 Lung cancer in ever smokers; chr15:43876272 chr15:43663654~43684339:- CESC cis rs7924176 0.601 rs7089391 ENSG00000213731.2 RAB5CP1 -4.07 6.52e-05 0.0252 -0.29 -0.27 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74177762 chr10:74423435~74424014:- CESC cis rs7924176 0.601 rs7093532 ENSG00000213731.2 RAB5CP1 -4.07 6.52e-05 0.0252 -0.29 -0.27 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74178282 chr10:74423435~74424014:- CESC cis rs7789940 0.904 rs6953281 ENSG00000230305.2 AC004980.9 4.07 6.52e-05 0.0253 0.39 0.27 Multiple sclerosis; chr7:76317626 chr7:76524515~76532692:+ CESC cis rs7789940 0.951 rs7787526 ENSG00000230305.2 AC004980.9 4.07 6.52e-05 0.0253 0.39 0.27 Multiple sclerosis; chr7:76318236 chr7:76524515~76532692:+ CESC cis rs6782228 0.585 rs2811492 ENSG00000242551.2 POU5F1P6 -4.07 6.52e-05 0.0253 -0.29 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128637436 chr3:128674735~128677005:- CESC cis rs6782228 0.606 rs1697 ENSG00000242551.2 POU5F1P6 -4.07 6.52e-05 0.0253 -0.29 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128638009 chr3:128674735~128677005:- CESC cis rs6782228 0.585 rs3122175 ENSG00000242551.2 POU5F1P6 -4.07 6.52e-05 0.0253 -0.29 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128642433 chr3:128674735~128677005:- CESC cis rs6782228 0.606 rs2811497 ENSG00000242551.2 POU5F1P6 -4.07 6.52e-05 0.0253 -0.29 -0.27 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128644489 chr3:128674735~128677005:- CESC cis rs10043775 1 rs34685718 ENSG00000251330.3 CTD-2283N19.1 -4.07 6.52e-05 0.0253 -0.33 -0.27 Periodontal microbiota; chr5:148402169 chr5:148430159~148430807:- CESC cis rs9903692 0.657 rs1452665 ENSG00000263412.1 RP5-890E16.2 -4.07 6.52e-05 0.0253 -0.27 -0.27 Pulse pressure; chr17:48219789 chr17:48045141~48048073:- CESC cis rs1707322 1 rs6687301 ENSG00000281133.1 AL355480.3 -4.07 6.53e-05 0.0253 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45917180 chr1:45580892~45580996:- CESC cis rs875971 1 rs6958271 ENSG00000232559.3 GS1-124K5.12 4.07 6.53e-05 0.0253 0.3 0.27 Aortic root size; chr7:66514344 chr7:66554588~66576923:- CESC cis rs875971 1 rs6958277 ENSG00000232559.3 GS1-124K5.12 4.07 6.53e-05 0.0253 0.3 0.27 Aortic root size; chr7:66514362 chr7:66554588~66576923:- CESC cis rs2625529 0.878 rs16956302 ENSG00000260037.4 CTD-2524L6.3 -4.07 6.53e-05 0.0253 -0.4 -0.27 Red blood cell count; chr15:71843902 chr15:71818396~71823384:+ CESC cis rs875971 1 rs10257427 ENSG00000179406.6 LINC00174 4.07 6.53e-05 0.0253 0.28 0.27 Aortic root size; chr7:66278221 chr7:66376044~66401338:- CESC cis rs8080784 1 rs7225581 ENSG00000266992.1 DHX40P1 4.07 6.53e-05 0.0253 0.34 0.27 Coronary artery disease; chr17:60940452 chr17:59976009~60002384:- CESC cis rs1707322 1 rs11211190 ENSG00000281133.1 AL355480.3 -4.07 6.54e-05 0.0253 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45800583 chr1:45580892~45580996:- CESC cis rs1707322 1 rs6429580 ENSG00000281133.1 AL355480.3 -4.07 6.54e-05 0.0253 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45809976 chr1:45580892~45580996:- CESC cis rs2337406 1 rs7145172 ENSG00000274576.2 IGHV2-70 -4.07 6.54e-05 0.0253 -0.34 -0.27 Alzheimer's disease (late onset); chr14:106704924 chr14:106770577~106771020:- CESC cis rs2235544 0.588 rs638749 ENSG00000225183.1 RP4-758J24.4 4.07 6.54e-05 0.0253 0.3 0.27 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:53984817 chr1:54089856~54090093:+ CESC cis rs2243480 1 rs73142122 ENSG00000275400.1 RP4-756H11.5 4.07 6.54e-05 0.0253 0.44 0.27 Diabetic kidney disease; chr7:65846311 chr7:66553805~66554199:- CESC cis rs2243480 0.901 rs73142137 ENSG00000275400.1 RP4-756H11.5 4.07 6.54e-05 0.0253 0.44 0.27 Diabetic kidney disease; chr7:65878455 chr7:66553805~66554199:- CESC cis rs2243480 1 rs13247184 ENSG00000275400.1 RP4-756H11.5 4.07 6.54e-05 0.0253 0.44 0.27 Diabetic kidney disease; chr7:65893941 chr7:66553805~66554199:- CESC cis rs2243480 1 rs35283677 ENSG00000275400.1 RP4-756H11.5 4.07 6.54e-05 0.0253 0.44 0.27 Diabetic kidney disease; chr7:65894246 chr7:66553805~66554199:- CESC cis rs7572733 0.534 rs700680 ENSG00000222017.1 AC011997.1 -4.07 6.54e-05 0.0253 -0.33 -0.27 Dermatomyositis; chr2:197843226 chr2:197693106~197774823:+ CESC cis rs11779988 0.545 rs454692 ENSG00000253671.1 RP11-806O11.1 -4.07 6.54e-05 0.0253 -0.32 -0.27 Breast cancer; chr8:17931789 chr8:17808941~17820868:+ CESC cis rs2243480 1 rs2243480 ENSG00000228409.4 CCT6P1 4.07 6.54e-05 0.0253 0.39 0.27 Diabetic kidney disease; chr7:66134209 chr7:65751142~65763354:+ CESC cis rs972578 0.668 rs9607961 ENSG00000274717.1 RP1-47A17.1 -4.07 6.55e-05 0.0254 -0.31 -0.27 Mean platelet volume; chr22:42836812 chr22:42791814~42794313:- CESC cis rs11971779 0.68 rs6965212 ENSG00000273391.1 RP11-634H22.1 4.07 6.56e-05 0.0254 0.25 0.27 Diisocyanate-induced asthma; chr7:139341719 chr7:139359032~139359566:- CESC cis rs11096990 0.855 rs2566184 ENSG00000249207.1 RP11-360F5.1 4.07 6.56e-05 0.0254 0.35 0.27 Cognitive function; chr4:39162700 chr4:39112677~39126818:- CESC cis rs875971 0.825 rs1129531 ENSG00000237310.1 GS1-124K5.4 -4.07 6.56e-05 0.0254 -0.25 -0.27 Aortic root size; chr7:66154117 chr7:66493706~66495474:+ CESC cis rs6740322 0.948 rs6722694 ENSG00000234936.1 AC010883.5 4.07 6.57e-05 0.0254 0.28 0.27 Coronary artery disease; chr2:43342659 chr2:43229573~43233394:+ CESC cis rs7811142 0.83 rs7792959 ENSG00000242294.5 STAG3L5P 4.07 6.58e-05 0.0254 0.27 0.27 Platelet count; chr7:100374780 chr7:100336079~100351900:+ CESC cis rs7811142 0.83 rs6975660 ENSG00000242294.5 STAG3L5P 4.07 6.58e-05 0.0254 0.27 0.27 Platelet count; chr7:100377643 chr7:100336079~100351900:+ CESC cis rs7811142 0.83 rs73401443 ENSG00000242294.5 STAG3L5P 4.07 6.58e-05 0.0254 0.27 0.27 Platelet count; chr7:100379959 chr7:100336079~100351900:+ CESC cis rs1799955 1 rs11571725 ENSG00000215515.2 IFIT1P1 4.07 6.58e-05 0.0254 0.4 0.27 LDL cholesterol levels; chr13:32364744 chr13:32384660~32386108:+ CESC cis rs2962250 0.607 rs62368779 ENSG00000213956.4 RP11-269M20.1 -4.07 6.58e-05 0.0255 -0.62 -0.27 Schizophrenia; chr5:51050599 chr5:50633124~50633602:+ CESC cis rs9532669 0.926 rs2875421 ENSG00000176268.5 CYCSP34 4.07 6.58e-05 0.0255 0.28 0.27 Cervical cancer; chr13:40936536 chr13:40863599~40863902:- CESC cis rs11971779 0.68 rs7801613 ENSG00000273391.1 RP11-634H22.1 -4.07 6.58e-05 0.0255 -0.26 -0.27 Diisocyanate-induced asthma; chr7:139355181 chr7:139359032~139359566:- CESC cis rs9532669 0.963 rs9532681 ENSG00000176268.5 CYCSP34 4.07 6.58e-05 0.0255 0.28 0.27 Cervical cancer; chr13:40951633 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4516083 ENSG00000176268.5 CYCSP34 4.07 6.58e-05 0.0255 0.28 0.27 Cervical cancer; chr13:40951783 chr13:40863599~40863902:- CESC cis rs8020095 0.571 rs8022657 ENSG00000258561.1 RP11-72M17.1 -4.07 6.59e-05 0.0255 -0.38 -0.27 Depression (quantitative trait); chr14:66923782 chr14:66212810~66509394:- CESC cis rs2404602 0.692 rs55729975 ENSG00000280730.1 AC090181.1 4.07 6.59e-05 0.0255 0.21 0.27 Blood metabolite levels; chr15:76510885 chr15:77056895~77057021:+ CESC cis rs10875746 0.551 rs1471998 ENSG00000240399.1 RP1-228P16.1 -4.07 6.59e-05 0.0255 -0.34 -0.27 Longevity (90 years and older); chr12:48318219 chr12:48054813~48055591:- CESC cis rs10875746 0.551 rs2054904 ENSG00000240399.1 RP1-228P16.1 -4.07 6.59e-05 0.0255 -0.34 -0.27 Longevity (90 years and older); chr12:48330571 chr12:48054813~48055591:- CESC cis rs2255336 0.938 rs12315123 ENSG00000245648.1 RP11-277P12.20 -4.07 6.59e-05 0.0255 -0.41 -0.27 Blood protein levels; chr12:10481540 chr12:10363769~10398506:+ CESC cis rs7789940 0.904 rs7459185 ENSG00000127957.15 PMS2P3 -4.07 6.59e-05 0.0255 -0.32 -0.27 Multiple sclerosis; chr7:76305323 chr7:75502930~75528148:- CESC cis rs6687821 0.531 rs11161930 ENSG00000267734.1 RP4-604K5.3 -4.07 6.59e-05 0.0255 -0.31 -0.27 Yeast infection; chr1:87056097 chr1:86932199~86934891:- CESC cis rs673078 0.607 rs17512763 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118400974 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943404 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118402062 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs7136676 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118403605 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs17441033 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118404101 chr12:118428281~118428870:+ CESC cis rs673078 0.562 rs61943405 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118405030 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943406 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118405767 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs17441075 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118410542 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs965524 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118412361 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs74685643 ENSG00000275759.1 RP11-131L12.3 -4.07 6.59e-05 0.0255 -0.5 -0.27 Glucose homeostasis traits; chr12:118412761 chr12:118428281~118428870:+ CESC cis rs7572733 0.534 rs4550664 ENSG00000222017.1 AC011997.1 4.07 6.59e-05 0.0255 0.33 0.27 Dermatomyositis; chr2:197826681 chr2:197693106~197774823:+ CESC cis rs875971 0.545 rs6979636 ENSG00000237310.1 GS1-124K5.4 4.07 6.6e-05 0.0255 0.29 0.27 Aortic root size; chr7:66276638 chr7:66493706~66495474:+ CESC cis rs12908161 0.959 rs12906348 ENSG00000225151.9 GOLGA2P7 -4.07 6.6e-05 0.0255 -0.36 -0.27 Schizophrenia; chr15:84786190 chr15:84199311~84230136:- CESC cis rs1412337 1 rs909947 ENSG00000225826.1 LINC00626 4.07 6.6e-05 0.0255 0.36 0.27 Morbidity-free survival; chr1:168646518 chr1:168786939~168792886:+ CESC cis rs6556937 0.71 rs10075736 ENSG00000251314.2 CTD-2337A12.1 4.07 6.61e-05 0.0255 0.38 0.27 Blood protein levels; chr5:96654353 chr5:95962001~96631085:+ CESC cis rs8031584 0.958 rs7176569 ENSG00000260382.1 RP11-540B6.2 -4.07 6.61e-05 0.0255 -0.37 -0.27 Huntington's disease progression; chr15:30952292 chr15:30882267~30883231:- CESC cis rs7580658 0.724 rs12623948 ENSG00000236682.1 AC068282.3 -4.07 6.61e-05 0.0255 -0.33 -0.27 Protein C levels; chr2:127243766 chr2:127389130~127400580:+ CESC cis rs9987353 0.519 rs11779181 ENSG00000173295.6 FAM86B3P 4.07 6.61e-05 0.0256 0.35 0.27 Recombination measurement; chr8:9205517 chr8:8228595~8244865:+ CESC cis rs761746 0.739 rs5998072 ENSG00000236132.1 CTA-440B3.1 -4.07 6.62e-05 0.0256 -0.35 -0.27 Intelligence; chr22:31652388 chr22:31816379~31817491:- CESC cis rs7208859 0.623 rs3794796 ENSG00000266490.1 CTD-2349P21.9 4.07 6.62e-05 0.0256 0.42 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30792372~30792833:+ CESC cis rs11157436 0.958 rs17255510 ENSG00000211813.2 TRAV34 -4.07 6.62e-05 0.0256 -0.29 -0.27 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22194962 chr14:22207522~22208129:+ CESC cis rs453301 0.653 rs7853 ENSG00000254340.1 RP11-10A14.3 4.07 6.63e-05 0.0256 0.33 0.27 Joint mobility (Beighton score); chr8:9033304 chr8:9141424~9145435:+ CESC cis rs875971 1 rs2036264 ENSG00000237310.1 GS1-124K5.4 -4.07 6.63e-05 0.0256 -0.25 -0.27 Aortic root size; chr7:66334917 chr7:66493706~66495474:+ CESC cis rs875971 1 rs7783613 ENSG00000237310.1 GS1-124K5.4 -4.07 6.63e-05 0.0256 -0.25 -0.27 Aortic root size; chr7:66340274 chr7:66493706~66495474:+ CESC cis rs4072705 0.586 rs7855247 ENSG00000224020.1 MIR181A2HG 4.07 6.63e-05 0.0256 0.33 0.27 Menarche (age at onset); chr9:124484365 chr9:124658467~124698631:+ CESC cis rs2839627 1 rs2401195 ENSG00000215458.7 AATBC -4.07 6.63e-05 0.0256 -0.35 -0.27 Information processing speed; chr21:43046777 chr21:43805758~43812567:- CESC cis rs748404 0.697 rs513970 ENSG00000205771.5 CATSPER2P1 -4.07 6.64e-05 0.0256 -0.31 -0.27 Lung cancer; chr15:43287368 chr15:43726918~43747094:- CESC cis rs17818399 1 rs17818399 ENSG00000279254.1 RP11-536C12.1 -4.07 6.64e-05 0.0256 -0.33 -0.27 Height; chr2:46598887 chr2:46668870~46670778:+ CESC cis rs6693388 0.918 rs7541099 ENSG00000229021.2 AL591893.1 -4.07 6.64e-05 0.0256 -0.31 -0.27 Blood metabolite ratios; chr1:151966287 chr1:151994531~152042774:+ CESC cis rs6005807 0.543 rs2235432 ENSG00000226471.5 CTA-292E10.6 -4.07 6.65e-05 0.0257 -0.35 -0.27 Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio; chr22:28773432 chr22:28800683~28848559:+ CESC cis rs6005807 0.543 rs2294431 ENSG00000226471.5 CTA-292E10.6 -4.07 6.65e-05 0.0257 -0.35 -0.27 Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio; chr22:28781212 chr22:28800683~28848559:+ CESC cis rs1075265 0.692 rs805361 ENSG00000233266.1 HMGB1P31 4.07 6.65e-05 0.0257 0.35 0.27 Chronotype;Morning vs. evening chronotype; chr2:53938709 chr2:54051334~54051760:+ CESC cis rs7896729 1 rs1344355 ENSG00000215267.7 AKR1C7P -4.07 6.65e-05 0.0257 -0.31 -0.27 Intelligence; chr10:5296599 chr10:5275173~5288470:- CESC cis rs9903692 0.954 rs9889470 ENSG00000263412.1 RP5-890E16.2 -4.07 6.65e-05 0.0257 -0.27 -0.27 Pulse pressure; chr17:48233713 chr17:48045141~48048073:- CESC cis rs2439831 0.85 rs7181039 ENSG00000249839.1 AC011330.5 -4.07 6.65e-05 0.0257 -0.41 -0.27 Lung cancer in ever smokers; chr15:43886914 chr15:43663654~43684339:- CESC cis rs442309 0.551 rs10822056 ENSG00000238280.1 RP11-436D10.3 -4.07 6.66e-05 0.0257 -0.32 -0.27 Vogt-Koyanagi-Harada syndrome; chr10:62754351 chr10:62793562~62805887:- CESC cis rs1964356 0.967 rs2953802 ENSG00000173295.6 FAM86B3P 4.07 6.66e-05 0.0257 0.31 0.27 Mean corpuscular volume; chr8:8994371 chr8:8228595~8244865:+ CESC cis rs5742933 0.725 rs1132360 ENSG00000253559.1 OSGEPL1-AS1 4.07 6.67e-05 0.0257 0.32 0.27 Ferritin levels; chr2:189661498 chr2:189762704~189765556:+ CESC cis rs2243480 1 rs466983 ENSG00000275400.1 RP4-756H11.5 4.07 6.67e-05 0.0257 0.44 0.27 Diabetic kidney disease; chr7:66055509 chr7:66553805~66554199:- CESC cis rs459482 0.587 rs469083 ENSG00000228318.3 AP001610.5 4.07 6.67e-05 0.0257 0.28 0.27 IgG glycosylation; chr21:41436789 chr21:41441056~41445708:- CESC cis rs11045000 0.614 rs75169772 ENSG00000255909.1 PDCD5P1 -4.07 6.67e-05 0.0257 -0.61 -0.27 Ossification of the posterior longitudinal ligament of the spine; chr12:20043220 chr12:19413153~19413461:+ CESC cis rs2277027 1 rs10866659 ENSG00000251405.2 CTB-109A12.1 -4.07 6.67e-05 0.0257 -0.34 -0.27 Pulmonary function;Pulmonary function (smoking interaction); chr5:157510035 chr5:157362615~157460078:- CESC cis rs12908161 1 rs12908549 ENSG00000259728.4 LINC00933 4.07 6.67e-05 0.0257 0.34 0.27 Schizophrenia; chr15:84779120 chr15:84570649~84580175:+ CESC cis rs62246343 0.605 rs4328788 ENSG00000206573.7 THUMPD3-AS1 -4.07 6.67e-05 0.0257 -0.29 -0.27 Fibrinogen levels; chr3:9415577 chr3:9349689~9398579:- CESC cis rs62246343 0.605 rs4308263 ENSG00000206573.7 THUMPD3-AS1 -4.07 6.67e-05 0.0257 -0.29 -0.27 Fibrinogen levels; chr3:9415674 chr3:9349689~9398579:- CESC cis rs9323326 0.586 rs55701552 ENSG00000257621.6 PSMA3-AS1 4.07 6.68e-05 0.0257 0.27 0.27 Gut microbiota (bacterial taxa); chr14:58016607 chr14:58265365~58298134:- CESC cis rs8067354 0.609 rs1292066 ENSG00000266701.1 AC005702.4 4.07 6.68e-05 0.0258 0.35 0.27 Hemoglobin concentration; chr17:59854953 chr17:60042546~60042627:- CESC cis rs17301013 0.507 rs12065326 ENSG00000227373.4 RP11-160H22.5 4.07 6.68e-05 0.0258 0.37 0.27 Systemic lupus erythematosus; chr1:174426892 chr1:174115300~174160004:- CESC cis rs875971 1 rs55962648 ENSG00000179406.6 LINC00174 4.07 6.69e-05 0.0258 0.28 0.27 Aortic root size; chr7:66160764 chr7:66376044~66401338:- CESC cis rs875971 1 rs2420168 ENSG00000179406.6 LINC00174 4.07 6.69e-05 0.0258 0.28 0.27 Aortic root size; chr7:66165644 chr7:66376044~66401338:- CESC cis rs875971 1 rs1565531 ENSG00000179406.6 LINC00174 4.07 6.69e-05 0.0258 0.28 0.27 Aortic root size; chr7:66198126 chr7:66376044~66401338:- CESC cis rs11971779 0.68 rs11980313 ENSG00000273391.1 RP11-634H22.1 4.07 6.69e-05 0.0258 0.25 0.27 Diisocyanate-induced asthma; chr7:139349897 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6962186 ENSG00000273391.1 RP11-634H22.1 4.07 6.69e-05 0.0258 0.25 0.27 Diisocyanate-induced asthma; chr7:139350060 chr7:139359032~139359566:- CESC cis rs8067354 0.872 rs2645488 ENSG00000266992.1 DHX40P1 4.07 6.69e-05 0.0258 0.3 0.27 Hemoglobin concentration; chr17:59812044 chr17:59976009~60002384:- CESC cis rs17301013 0.507 rs16847335 ENSG00000227373.4 RP11-160H22.5 4.07 6.69e-05 0.0258 0.4 0.27 Systemic lupus erythematosus; chr1:174682746 chr1:174115300~174160004:- CESC cis rs17818399 0.962 rs2122715 ENSG00000279254.1 RP11-536C12.1 -4.07 6.69e-05 0.0258 -0.33 -0.27 Height; chr2:46618710 chr2:46668870~46670778:+ CESC cis rs516805 0.781 rs477425 ENSG00000279453.1 RP3-425C14.4 -4.07 6.69e-05 0.0258 -0.33 -0.27 Lymphocyte counts; chr6:122393627 chr6:122436789~122439223:- CESC cis rs12908161 1 rs17601029 ENSG00000259728.4 LINC00933 4.07 6.69e-05 0.0258 0.34 0.27 Schizophrenia; chr15:84804478 chr15:84570649~84580175:+ CESC cis rs2243480 1 rs67728539 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65913137 chr7:66554588~66576923:- CESC cis rs2243480 1 rs78803505 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65917585 chr7:66554588~66576923:- CESC cis rs2243480 1 rs34577383 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65920739 chr7:66554588~66576923:- CESC cis rs2243480 1 rs55895244 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65922691 chr7:66554588~66576923:- CESC cis rs2243480 1 rs7795242 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65925107 chr7:66554588~66576923:- CESC cis rs2243480 1 rs2177703 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65926730 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35432774 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65928032 chr7:66554588~66576923:- CESC cis rs2243480 1 rs56985706 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65929575 chr7:66554588~66576923:- CESC cis rs2243480 1 rs60683927 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65929781 chr7:66554588~66576923:- CESC cis rs2243480 1 rs58062456 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65929865 chr7:66554588~66576923:- CESC cis rs2243480 1 rs34529418 ENSG00000232559.3 GS1-124K5.12 4.07 6.69e-05 0.0258 0.44 0.27 Diabetic kidney disease; chr7:65938222 chr7:66554588~66576923:- CESC cis rs700651 0.856 rs9288280 ENSG00000222017.1 AC011997.1 4.07 6.69e-05 0.0258 0.33 0.27 Intracranial aneurysm; chr2:197879600 chr2:197693106~197774823:+ CESC cis rs2564921 0.73 rs58492539 ENSG00000242142.1 SERBP1P3 -4.07 6.69e-05 0.0258 -0.33 -0.27 Height; chr3:53052712 chr3:53064283~53065091:- CESC cis rs4718428 1 rs1830070 ENSG00000273142.1 RP11-458F8.4 -4.07 6.7e-05 0.0258 -0.26 -0.27 Corneal structure; chr7:66884684 chr7:66902857~66906297:+ CESC cis rs7524102 0.561 rs7550872 ENSG00000218510.5 LINC00339 -4.07 6.7e-05 0.0258 -0.36 -0.27 Bone mineral density;Ulcerative colitis;Bone mineral density (spine);Dupuytren's disease;Bone mineral density (hip); chr1:22384885 chr1:22025188~22031223:+ CESC cis rs875971 1 rs2077593 ENSG00000237310.1 GS1-124K5.4 4.07 6.7e-05 0.0258 0.26 0.27 Aortic root size; chr7:66427543 chr7:66493706~66495474:+ CESC cis rs2439831 0.867 rs2245715 ENSG00000275601.1 AC011330.13 -4.07 6.7e-05 0.0258 -0.36 -0.27 Lung cancer in ever smokers; chr15:43525854 chr15:43642389~43643023:- CESC cis rs10129255 1 rs10134517 ENSG00000211974.3 IGHV2-70 4.07 6.7e-05 0.0258 0.28 0.27 Kawasaki disease; chr14:106718498 chr14:106723574~106724093:- CESC cis rs17428076 0.514 rs3821095 ENSG00000228389.1 AC068039.4 4.07 6.7e-05 0.0258 0.31 0.27 Myopia; chr2:171827496 chr2:171773482~171775844:+ CESC cis rs2060793 0.519 rs1357332 ENSG00000251991.1 RNU7-49P 4.07 6.71e-05 0.0258 0.28 0.27 Vitamin D levels; chr11:14618570 chr11:14478892~14478953:+ CESC cis rs7508 0.511 rs208026 ENSG00000253671.1 RP11-806O11.1 -4.06 6.71e-05 0.0258 -0.31 -0.27 Atrial fibrillation; chr8:18020646 chr8:17808941~17820868:+ CESC cis rs9584850 0.54 rs61969407 ENSG00000231194.1 FARP1-AS1 4.06 6.71e-05 0.0258 0.36 0.27 Neuroticism; chr13:98466906 chr13:98435405~98435840:- CESC cis rs224278 0.509 rs1888968 ENSG00000238280.1 RP11-436D10.3 -4.06 6.71e-05 0.0258 -0.41 -0.27 Ewing sarcoma; chr10:62943608 chr10:62793562~62805887:- CESC cis rs224278 0.509 rs4237316 ENSG00000238280.1 RP11-436D10.3 -4.06 6.71e-05 0.0258 -0.41 -0.27 Ewing sarcoma; chr10:62943764 chr10:62793562~62805887:- CESC cis rs6879260 1 rs7725605 ENSG00000248367.1 CTB-129O4.1 -4.06 6.71e-05 0.0258 -0.2 -0.27 Height; chr5:180305678 chr5:180293245~180295253:+ CESC cis rs1667255 1 rs7243588 ENSG00000266521.1 RP11-650P15.1 4.06 6.71e-05 0.0259 0.3 0.27 Retinol levels; chr18:31580649 chr18:31496645~31497195:- CESC cis rs6687821 0.637 rs548440 ENSG00000267734.1 RP4-604K5.3 4.06 6.72e-05 0.0259 0.3 0.27 Yeast infection; chr1:86846948 chr1:86932199~86934891:- CESC cis rs10129255 0.957 rs11846893 ENSG00000211974.3 IGHV2-70 4.06 6.72e-05 0.0259 0.26 0.27 Kawasaki disease; chr14:106779068 chr14:106723574~106724093:- CESC cis rs7551222 0.716 rs10494852 ENSG00000240219.1 RP11-430C7.5 -4.06 6.72e-05 0.0259 -0.29 -0.27 Schizophrenia; chr1:204488658 chr1:204626775~204629712:+ CESC cis rs875971 0.898 rs6977501 ENSG00000237310.1 GS1-124K5.4 -4.06 6.72e-05 0.0259 -0.24 -0.27 Aortic root size; chr7:66228355 chr7:66493706~66495474:+ CESC cis rs12107539 1 rs12497019 ENSG00000240137.4 ERICH6-AS1 -4.06 6.72e-05 0.0259 -0.27 -0.27 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151327115 chr3:150703564~150720146:+ CESC cis rs875971 1 rs4717292 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66430611 chr7:66493706~66495474:+ CESC cis rs875971 0.895 rs10755833 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66448930 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs12668936 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66449417 chr7:66493706~66495474:+ CESC cis rs875971 0.895 rs1833495 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66456608 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs6945032 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66457499 chr7:66493706~66495474:+ CESC cis rs875971 0.929 rs12673810 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66458866 chr7:66493706~66495474:+ CESC cis rs875971 1 rs35149210 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66464938 chr7:66493706~66495474:+ CESC cis rs875971 1 rs6961155 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66468308 chr7:66493706~66495474:+ CESC cis rs875971 1 rs7789768 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66473993 chr7:66493706~66495474:+ CESC cis rs875971 1 rs1363055 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66478288 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs9691480 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66479319 chr7:66493706~66495474:+ CESC cis rs875971 1 rs7789554 ENSG00000237310.1 GS1-124K5.4 4.06 6.72e-05 0.0259 0.26 0.27 Aortic root size; chr7:66481051 chr7:66493706~66495474:+ CESC cis rs9309473 0.861 rs6546857 ENSG00000163016.8 ALMS1P 4.06 6.73e-05 0.0259 0.36 0.27 Metabolite levels; chr2:73610828 chr2:73644919~73685576:+ CESC cis rs8127691 0.904 rs7282490 ENSG00000225331.1 AP001055.6 4.06 6.73e-05 0.0259 0.32 0.27 Inflammatory bowel disease; chr21:44195858 chr21:44158740~44160076:- CESC cis rs9487094 0.689 rs9480949 ENSG00000260273.1 RP11-425D10.10 4.06 6.73e-05 0.0259 0.33 0.27 Height; chr6:109407238 chr6:109382795~109383666:+ CESC cis rs950776 0.518 rs1504545 ENSG00000279373.1 RP11-650L12.4 -4.06 6.73e-05 0.0259 -0.32 -0.27 Sudden cardiac arrest; chr15:78526129 chr15:78537681~78538946:+ CESC cis rs875971 0.929 rs34406470 ENSG00000237310.1 GS1-124K5.4 4.06 6.73e-05 0.0259 0.26 0.27 Aortic root size; chr7:66464969 chr7:66493706~66495474:+ CESC cis rs875971 0.895 rs3857684 ENSG00000232559.3 GS1-124K5.12 4.06 6.73e-05 0.0259 0.29 0.27 Aortic root size; chr7:66473171 chr7:66554588~66576923:- CESC cis rs12430683 0.818 rs874732 ENSG00000280710.1 RP11-214F16.8 4.06 6.74e-05 0.0259 0.33 0.27 QRS interval (sulfonylurea treatment interaction); chr13:98770161 chr13:99498524~99501315:+ CESC cis rs79243044 0.965 rs12274861 ENSG00000224295.2 AC087380.14 4.06 6.74e-05 0.0259 0.3 0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5545789 chr11:5518441~5524955:- CESC cis rs4686914 0.963 rs9880162 ENSG00000228804.4 RP11-211G3.3 4.06 6.74e-05 0.0259 0.31 0.27 Metabolite levels; chr3:188001560 chr3:187702313~187733849:+ CESC cis rs2625529 0.938 rs4238447 ENSG00000260037.4 CTD-2524L6.3 -4.06 6.74e-05 0.0259 -0.4 -0.27 Red blood cell count; chr15:71839539 chr15:71818396~71823384:+ CESC cis rs7176527 1 rs3762169 ENSG00000229212.6 RP11-561C5.4 4.06 6.74e-05 0.0259 0.33 0.27 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84598728 chr15:85205440~85234795:- CESC cis rs11846409 0.932 rs73378158 ENSG00000223648.3 IGHV3-64 4.06 6.74e-05 0.0259 0.29 0.27 Rheumatic heart disease; chr14:106638433 chr14:106643132~106658258:- CESC cis rs7551222 0.646 rs1398148 ENSG00000240219.1 RP11-430C7.5 4.06 6.74e-05 0.0259 0.3 0.27 Schizophrenia; chr1:204489200 chr1:204626775~204629712:+ CESC cis rs5742933 0.857 rs1233282 ENSG00000253559.1 OSGEPL1-AS1 -4.06 6.74e-05 0.0259 -0.31 -0.27 Ferritin levels; chr2:189823518 chr2:189762704~189765556:+ CESC cis rs7572733 0.515 rs11891555 ENSG00000222017.1 AC011997.1 4.06 6.75e-05 0.026 0.34 0.27 Dermatomyositis; chr2:197988816 chr2:197693106~197774823:+ CESC cis rs10779751 0.734 rs910660 ENSG00000230337.1 RP4-635E18.6 -4.06 6.76e-05 0.026 -0.37 -0.27 Body mass index; chr1:11070586 chr1:11099675~11102100:+ CESC cis rs10129255 0.869 rs7150549 ENSG00000211970.3 IGHV4-61 -4.06 6.76e-05 0.026 -0.22 -0.27 Kawasaki disease; chr14:106705441 chr14:106639119~106639657:- CESC cis rs79243044 0.965 rs1995157 ENSG00000224295.2 AC087380.14 -4.06 6.76e-05 0.026 -0.29 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5544821 chr11:5518441~5524955:- CESC cis rs853679 1 rs1679732 ENSG00000219392.1 RP1-265C24.5 4.06 6.77e-05 0.026 0.4 0.27 Depression; chr6:28253486 chr6:28115628~28116551:+ CESC cis rs1799949 0.93 rs1554063 ENSG00000267681.1 CTD-3199J23.6 -4.06 6.77e-05 0.026 -0.32 -0.27 Menopause (age at onset); chr17:43135128 chr17:43144956~43145255:+ CESC cis rs1538970 0.962 rs4660849 ENSG00000280836.1 AL355480.1 4.06 6.77e-05 0.026 0.33 0.27 Platelet count; chr1:45354200 chr1:45581219~45581321:- CESC cis rs1538970 0.962 rs9429075 ENSG00000280836.1 AL355480.1 -4.06 6.77e-05 0.026 -0.33 -0.27 Platelet count; chr1:45352749 chr1:45581219~45581321:- CESC cis rs1538970 0.962 rs4660301 ENSG00000280836.1 AL355480.1 -4.06 6.77e-05 0.026 -0.33 -0.27 Platelet count; chr1:45354477 chr1:45581219~45581321:- CESC cis rs1538970 0.962 rs9429077 ENSG00000280836.1 AL355480.1 -4.06 6.77e-05 0.026 -0.33 -0.27 Platelet count; chr1:45354995 chr1:45581219~45581321:- CESC cis rs944797 0.606 rs10811650 ENSG00000215221.2 UBA52P6 4.06 6.78e-05 0.026 0.34 0.27 Coronary heart disease; chr9:22067594 chr9:22012155~22012536:+ CESC cis rs2243480 0.522 rs778717 ENSG00000232559.3 GS1-124K5.12 4.06 6.79e-05 0.0261 0.53 0.27 Diabetic kidney disease; chr7:66383164 chr7:66554588~66576923:- CESC cis rs79243044 0.901 rs4910817 ENSG00000224295.2 AC087380.14 -4.06 6.79e-05 0.0261 -0.29 -0.27 QRS duration in Tripanosoma cruzi seropositivity; chr11:5544425 chr11:5518441~5524955:- CESC cis rs8080784 1 rs6504010 ENSG00000266992.1 DHX40P1 4.06 6.79e-05 0.0261 0.34 0.27 Coronary artery disease; chr17:60940945 chr17:59976009~60002384:- CESC cis rs453301 0.571 rs2929456 ENSG00000253893.2 FAM85B 4.06 6.8e-05 0.0261 0.33 0.27 Joint mobility (Beighton score); chr8:9225906 chr8:8167819~8226614:- CESC cis rs2548724 0.588 rs17333350 ENSG00000247402.2 CTD-2340E1.2 -4.06 6.8e-05 0.0261 -0.3 -0.27 Type 2 diabetes; chr5:102478905 chr5:102605635~102606197:+ CESC cis rs490234 0.812 rs17259739 ENSG00000232630.1 PRPS1P2 4.06 6.8e-05 0.0261 0.23 0.27 Mean arterial pressure; chr9:125694360 chr9:125150653~125151589:+ CESC cis rs9532669 0.963 rs1056835 ENSG00000176268.5 CYCSP34 4.06 6.8e-05 0.0261 0.27 0.27 Cervical cancer; chr13:40932585 chr13:40863599~40863902:- CESC cis rs2439831 0.85 rs2228368 ENSG00000249839.1 AC011330.5 -4.06 6.8e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43809812 chr15:43663654~43684339:- CESC cis rs8030379 1 rs11259936 ENSG00000230373.7 GOLGA6L5P 4.06 6.8e-05 0.0261 0.26 0.27 Waist circumference;Waist circumference adjusted for body mass index; chr15:83911830 chr15:84507885~84516814:- CESC cis rs7896729 0.943 rs17134635 ENSG00000215267.7 AKR1C7P -4.06 6.8e-05 0.0261 -0.29 -0.27 Intelligence; chr10:5295780 chr10:5275173~5288470:- CESC cis rs8031584 0.706 rs2177670 ENSG00000260382.1 RP11-540B6.2 4.06 6.8e-05 0.0261 0.36 0.27 Huntington's disease progression; chr15:30865548 chr15:30882267~30883231:- CESC cis rs8031584 0.678 rs36047941 ENSG00000260382.1 RP11-540B6.2 4.06 6.8e-05 0.0261 0.36 0.27 Huntington's disease progression; chr15:30867032 chr15:30882267~30883231:- CESC cis rs8031584 0.678 rs4779790 ENSG00000260382.1 RP11-540B6.2 4.06 6.8e-05 0.0261 0.36 0.27 Huntington's disease progression; chr15:30872392 chr15:30882267~30883231:- CESC cis rs2439831 1 rs690316 ENSG00000205771.5 CATSPER2P1 -4.06 6.81e-05 0.0261 -0.37 -0.27 Lung cancer in ever smokers; chr15:43445682 chr15:43726918~43747094:- CESC cis rs6879260 1 rs10903252 ENSG00000248367.1 CTB-129O4.1 -4.06 6.81e-05 0.0261 -0.19 -0.27 Height; chr5:180306934 chr5:180293245~180295253:+ CESC cis rs1707322 1 rs6657720 ENSG00000281133.1 AL355480.3 -4.06 6.81e-05 0.0261 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45920597 chr1:45580892~45580996:- CESC cis rs1707322 1 rs7519181 ENSG00000281133.1 AL355480.3 -4.06 6.81e-05 0.0261 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45922157 chr1:45580892~45580996:- CESC cis rs1707322 1 rs7526369 ENSG00000281133.1 AL355480.3 -4.06 6.81e-05 0.0261 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45924888 chr1:45580892~45580996:- CESC cis rs1707322 0.963 rs10890371 ENSG00000281133.1 AL355480.3 -4.06 6.81e-05 0.0261 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45925225 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10890372 ENSG00000281133.1 AL355480.3 -4.06 6.81e-05 0.0261 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45925348 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211243 ENSG00000281133.1 AL355480.3 -4.06 6.81e-05 0.0261 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45989761 chr1:45580892~45580996:- CESC cis rs1707322 1 rs11211244 ENSG00000281133.1 AL355480.3 -4.06 6.81e-05 0.0261 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45991001 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4660903 ENSG00000281133.1 AL355480.3 -4.06 6.81e-05 0.0261 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45991929 chr1:45580892~45580996:- CESC cis rs1707322 1 rs4660905 ENSG00000281133.1 AL355480.3 4.06 6.81e-05 0.0261 0.31 0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45995915 chr1:45580892~45580996:- CESC cis rs950776 0.518 rs62008194 ENSG00000279373.1 RP11-650L12.4 4.06 6.81e-05 0.0261 0.32 0.27 Sudden cardiac arrest; chr15:78521463 chr15:78537681~78538946:+ CESC cis rs11685222 0.64 rs114685812 ENSG00000229326.3 AC069154.4 4.06 6.81e-05 0.0261 0.4 0.27 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119668313 chr2:119698623~119700151:+ CESC cis rs2548724 0.617 rs7710414 ENSG00000250682.4 LINC00491 4.06 6.81e-05 0.0261 0.31 0.27 Type 2 diabetes; chr5:102296671 chr5:102609156~102671559:- CESC cis rs761746 0.96 rs4820982 ENSG00000236132.1 CTA-440B3.1 4.06 6.81e-05 0.0261 0.32 0.27 Intelligence; chr22:31533494 chr22:31816379~31817491:- CESC cis rs7937890 0.904 rs67623158 ENSG00000254418.1 RP11-21L19.1 -4.06 6.81e-05 0.0261 -0.29 -0.27 Mitochondrial DNA levels; chr11:14273650 chr11:14262846~14273691:- CESC cis rs1387259 0.759 rs7960122 ENSG00000257735.1 RP11-370I10.6 -4.06 6.81e-05 0.0261 -0.33 -0.27 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48383217 chr12:48350945~48442411:+ CESC cis rs17301013 0.507 rs10912817 ENSG00000227373.4 RP11-160H22.5 4.06 6.81e-05 0.0261 0.35 0.27 Systemic lupus erythematosus; chr1:174615581 chr1:174115300~174160004:- CESC cis rs2439831 0.85 rs28564774 ENSG00000249839.1 AC011330.5 -4.06 6.81e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43833277 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs28513374 ENSG00000249839.1 AC011330.5 -4.06 6.81e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43833297 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs7169322 ENSG00000249839.1 AC011330.5 -4.06 6.81e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43838816 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs28707214 ENSG00000249839.1 AC011330.5 -4.06 6.81e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43839425 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs28413704 ENSG00000249839.1 AC011330.5 -4.06 6.81e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43856229 chr15:43663654~43684339:- CESC cis rs2439831 0.702 rs9989313 ENSG00000249839.1 AC011330.5 -4.06 6.81e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43860619 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs61390361 ENSG00000249839.1 AC011330.5 -4.06 6.81e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43867644 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs11856795 ENSG00000249839.1 AC011330.5 -4.06 6.81e-05 0.0261 -0.39 -0.27 Lung cancer in ever smokers; chr15:43868384 chr15:43663654~43684339:- CESC cis rs17818399 0.815 rs17819022 ENSG00000279254.1 RP11-536C12.1 -4.06 6.82e-05 0.0261 -0.33 -0.27 Height; chr2:46623432 chr2:46668870~46670778:+ CESC cis rs4423214 0.559 rs7949129 ENSG00000254682.1 RP11-660L16.2 -4.06 6.82e-05 0.0261 -0.4 -0.27 Vitamin D levels; chr11:71482089 chr11:71448674~71452157:+ CESC cis rs7598759 0.712 rs6740474 ENSG00000181798.2 LINC00471 -4.06 6.82e-05 0.0262 -0.29 -0.27 Noise-induced hearing loss; chr2:231467120 chr2:231508426~231514339:- CESC cis rs7598759 0.712 rs6727372 ENSG00000181798.2 LINC00471 -4.06 6.82e-05 0.0262 -0.29 -0.27 Noise-induced hearing loss; chr2:231467195 chr2:231508426~231514339:- CESC cis rs7598759 0.712 rs6727510 ENSG00000181798.2 LINC00471 -4.06 6.82e-05 0.0262 -0.29 -0.27 Noise-induced hearing loss; chr2:231467305 chr2:231508426~231514339:- CESC cis rs7598759 0.675 rs6727530 ENSG00000181798.2 LINC00471 -4.06 6.82e-05 0.0262 -0.29 -0.27 Noise-induced hearing loss; chr2:231467347 chr2:231508426~231514339:- CESC cis rs7598759 0.712 rs10933372 ENSG00000181798.2 LINC00471 -4.06 6.82e-05 0.0262 -0.29 -0.27 Noise-induced hearing loss; chr2:231467614 chr2:231508426~231514339:- CESC cis rs7598759 0.712 rs997400 ENSG00000181798.2 LINC00471 -4.06 6.82e-05 0.0262 -0.29 -0.27 Noise-induced hearing loss; chr2:231468136 chr2:231508426~231514339:- CESC cis rs875971 0.895 rs7788984 ENSG00000237310.1 GS1-124K5.4 4.06 6.82e-05 0.0262 0.25 0.27 Aortic root size; chr7:66450629 chr7:66493706~66495474:+ CESC cis rs1044826 0.642 rs6784684 ENSG00000178631.7 ACTG1P1 4.06 6.82e-05 0.0262 0.33 0.27 Obesity-related traits; chr3:139458792 chr3:139493809~139494937:+ CESC cis rs2255336 0.938 rs2126888 ENSG00000245648.1 RP11-277P12.20 4.06 6.82e-05 0.0262 0.43 0.27 Blood protein levels; chr12:10393789 chr12:10363769~10398506:+ CESC cis rs1707322 1 rs11211223 ENSG00000281133.1 AL355480.3 -4.06 6.82e-05 0.0262 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45914933 chr1:45580892~45580996:- CESC cis rs17772222 0.958 rs10134008 ENSG00000258983.2 RP11-507K2.2 4.06 6.83e-05 0.0262 0.34 0.27 Coronary artery calcification; chr14:88549183 chr14:88499334~88515502:+ CESC cis rs17772222 0.958 rs891750 ENSG00000258983.2 RP11-507K2.2 4.06 6.83e-05 0.0262 0.34 0.27 Coronary artery calcification; chr14:88550856 chr14:88499334~88515502:+ CESC cis rs17772222 0.958 rs891749 ENSG00000258983.2 RP11-507K2.2 4.06 6.83e-05 0.0262 0.34 0.27 Coronary artery calcification; chr14:88550893 chr14:88499334~88515502:+ CESC cis rs1707322 1 rs11211248 ENSG00000281133.1 AL355480.3 -4.06 6.83e-05 0.0262 -0.31 -0.27 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46011172 chr1:45580892~45580996:- CESC cis rs7927592 0.956 rs10896337 ENSG00000212093.1 AP000807.1 4.06 6.83e-05 0.0262 0.3 0.27 Total body bone mineral density; chr11:68516768 chr11:68506083~68506166:- CESC cis rs6693388 0.789 rs16833743 ENSG00000229021.2 AL591893.1 -4.06 6.84e-05 0.0262 -0.32 -0.27 Blood metabolite ratios; chr1:151992403 chr1:151994531~152042774:+ CESC cis rs1124769 0.692 rs1147137 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50889686 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs2619689 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50892386 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs2619690 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50894018 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs1147134 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50896339 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs2663542 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50899224 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs1147132 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50900036 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs2663540 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50901062 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs1135397 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50907567 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs2614788 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50908084 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs2663531 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50912552 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs936482 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50918444 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs7170310 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50918934 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs2663557 ENSG00000259378.1 DCAF13P3 -4.06 6.84e-05 0.0262 -0.35 -0.27 Cognitive performance; chr15:50921427 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs58137325 ENSG00000259378.1 DCAF13P3 4.06 6.84e-05 0.0262 0.35 0.27 Cognitive performance; chr15:50922186 chr15:50944663~50945996:+ CESC cis rs1124769 0.7 rs35573737 ENSG00000259378.1 DCAF13P3 4.06 6.84e-05 0.0262 0.35 0.27 Cognitive performance; chr15:50924623 chr15:50944663~50945996:+ CESC cis rs2439831 0.618 rs8023508 ENSG00000275601.1 AC011330.13 4.06 6.84e-05 0.0262 0.38 0.27 Lung cancer in ever smokers; chr15:43883905 chr15:43642389~43643023:- CESC cis rs62103177 0.565 rs473119 ENSG00000261126.6 RP11-795F19.1 -4.06 6.85e-05 0.0262 -0.35 -0.27 Opioid sensitivity; chr18:80091557 chr18:80046900~80095482:+ CESC cis rs7924176 0.564 rs10762588 ENSG00000213731.2 RAB5CP1 -4.06 6.85e-05 0.0262 -0.3 -0.27 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74226087 chr10:74423435~74424014:- CESC cis rs7924176 0.564 rs4564273 ENSG00000213731.2 RAB5CP1 -4.06 6.85e-05 0.0262 -0.3 -0.27 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74230154 chr10:74423435~74424014:- CESC cis rs916888 0.773 rs199533 ENSG00000261575.2 RP11-259G18.1 4.06 6.85e-05 0.0262 0.39 0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46267037~46268694:+ CESC cis rs7665090 0.528 rs3774968 ENSG00000246560.2 RP11-10L12.4 4.06 6.85e-05 0.0263 0.32 0.27 Primary biliary cholangitis; chr4:102609955 chr4:102828055~102844075:+ CESC cis rs523522 0.962 rs1050187 ENSG00000278344.1 RP11-18C24.8 -4.06 6.86e-05 0.0263 -0.33 -0.27 High light scatter reticulocyte count; chr12:120464308 chr12:120500735~120501090:- CESC cis rs516805 0.961 rs544099 ENSG00000279453.1 RP3-425C14.4 4.06 6.86e-05 0.0263 0.3 0.27 Lymphocyte counts; chr6:122479837 chr6:122436789~122439223:- CESC cis rs11676348 0.774 rs13397673 ENSG00000261338.2 RP11-378A13.1 -4.06 6.86e-05 0.0263 -0.34 -0.27 Ulcerative colitis; chr2:218183059 chr2:218255319~218257366:+ CESC cis rs9532669 0.853 rs9315795 ENSG00000176268.5 CYCSP34 4.06 6.86e-05 0.0263 0.28 0.27 Cervical cancer; chr13:40943382 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs3764056 ENSG00000176268.5 CYCSP34 4.06 6.86e-05 0.0263 0.28 0.27 Cervical cancer; chr13:40943849 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs7989303 ENSG00000176268.5 CYCSP34 4.06 6.86e-05 0.0263 0.28 0.27 Cervical cancer; chr13:40950087 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs3736953 ENSG00000176268.5 CYCSP34 4.06 6.86e-05 0.0263 0.28 0.27 Cervical cancer; chr13:40951450 chr13:40863599~40863902:- CESC cis rs4819052 0.807 rs1075788 ENSG00000223768.1 LINC00205 -4.06 6.87e-05 0.0263 -0.31 -0.27 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45246649 chr21:45293285~45297354:+ CESC cis rs2929278 0.638 rs2016840 ENSG00000205771.5 CATSPER2P1 4.06 6.87e-05 0.0263 0.3 0.27 Schizophrenia; chr15:43919670 chr15:43726918~43747094:- CESC cis rs9300255 0.544 rs1716175 ENSG00000235423.7 RP11-282O18.3 4.06 6.87e-05 0.0263 0.35 0.27 Neutrophil percentage of white cells; chr12:123173841 chr12:123252030~123261483:- CESC cis rs3764618 0.892 rs3764616 ENSG00000268006.1 PTOV1-AS1 4.06 6.87e-05 0.0263 0.57 0.27 Follicule stimulating hormone; chr19:48993765 chr19:49838639~49851676:- CESC cis rs3764618 1 rs3764619 ENSG00000268006.1 PTOV1-AS1 4.06 6.87e-05 0.0263 0.57 0.27 Follicule stimulating hormone; chr19:48994020 chr19:49838639~49851676:- CESC cis rs3764618 1 rs16981031 ENSG00000268006.1 PTOV1-AS1 4.06 6.87e-05 0.0263 0.57 0.27 Follicule stimulating hormone; chr19:48994196 chr19:49838639~49851676:- CESC cis rs6740322 0.895 rs28456986 ENSG00000234936.1 AC010883.5 4.06 6.87e-05 0.0263 0.28 0.27 Coronary artery disease; chr2:43326182 chr2:43229573~43233394:+ CESC cis rs6740322 0.895 rs10210125 ENSG00000234936.1 AC010883.5 4.06 6.87e-05 0.0263 0.28 0.27 Coronary artery disease; chr2:43329294 chr2:43229573~43233394:+ CESC cis rs853679 1 rs1679709 ENSG00000219392.1 RP1-265C24.5 4.06 6.87e-05 0.0263 0.41 0.27 Depression; chr6:28260564 chr6:28115628~28116551:+ CESC cis rs2404602 0.536 rs17364330 ENSG00000259422.1 RP11-593F23.1 4.06 6.88e-05 0.0263 0.3 0.27 Blood metabolite levels; chr15:76473044 chr15:76174891~76181486:- CESC cis rs2548724 0.587 rs59399361 ENSG00000247402.2 CTD-2340E1.2 4.06 6.88e-05 0.0263 0.3 0.27 Type 2 diabetes; chr5:102413414 chr5:102605635~102606197:+ CESC cis rs4713118 0.662 rs9380045 ENSG00000219392.1 RP1-265C24.5 -4.06 6.88e-05 0.0263 -0.35 -0.27 Parkinson's disease; chr6:28057501 chr6:28115628~28116551:+ CESC cis rs4713118 0.616 rs9348789 ENSG00000219392.1 RP1-265C24.5 -4.06 6.88e-05 0.0263 -0.35 -0.27 Parkinson's disease; chr6:28057708 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs9468274 ENSG00000219392.1 RP1-265C24.5 -4.06 6.88e-05 0.0263 -0.35 -0.27 Parkinson's disease; chr6:28058299 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs9468275 ENSG00000219392.1 RP1-265C24.5 -4.06 6.88e-05 0.0263 -0.35 -0.27 Parkinson's disease; chr6:28058358 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs9468276 ENSG00000219392.1 RP1-265C24.5 -4.06 6.88e-05 0.0263 -0.35 -0.27 Parkinson's disease; chr6:28059910 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs9468277 ENSG00000219392.1 RP1-265C24.5 -4.06 6.88e-05 0.0263 -0.35 -0.27 Parkinson's disease; chr6:28060612 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs9468278 ENSG00000219392.1 RP1-265C24.5 -4.06 6.88e-05 0.0263 -0.35 -0.27 Parkinson's disease; chr6:28060704 chr6:28115628~28116551:+ CESC cis rs4713118 0.662 rs13218430 ENSG00000219392.1 RP1-265C24.5 -4.06 6.88e-05 0.0263 -0.35 -0.27 Parkinson's disease; chr6:28062059 chr6:28115628~28116551:+ CESC cis rs8062405 0.54 rs151226 ENSG00000259982.1 CDC37P1 4.06 6.89e-05 0.0264 0.33 0.27 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28538502 chr16:28700294~28701540:- CESC cis rs7811142 0.83 rs6979910 ENSG00000242294.5 STAG3L5P 4.06 6.89e-05 0.0264 0.26 0.27 Platelet count; chr7:100343007 chr7:100336079~100351900:+ CESC cis rs8020095 0.571 rs10131614 ENSG00000258561.1 RP11-72M17.1 -4.06 6.89e-05 0.0264 -0.39 -0.27 Depression (quantitative trait); chr14:66896825 chr14:66212810~66509394:- CESC cis rs2961663 0.614 rs7379857 ENSG00000250420.7 AACSP1 4.06 6.89e-05 0.0264 0.48 0.27 Rheumatoid arthritis; chr5:178184816 chr5:178764861~178818435:- CESC cis rs2961663 0.667 rs7380658 ENSG00000250420.7 AACSP1 4.06 6.89e-05 0.0264 0.48 0.27 Rheumatoid arthritis; chr5:178185033 chr5:178764861~178818435:- CESC cis rs2961663 0.667 rs7719717 ENSG00000250420.7 AACSP1 4.06 6.89e-05 0.0264 0.48 0.27 Rheumatoid arthritis; chr5:178185292 chr5:178764861~178818435:- CESC cis rs7568498 0.517 rs11678856 ENSG00000227403.1 AC009299.3 4.06 6.89e-05 0.0264 0.39 0.27 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161068932 chr2:161244739~161249050:+ CESC cis rs6951245 0.507 rs11763865 ENSG00000229043.2 AC091729.9 -4.06 6.9e-05 0.0264 -0.33 -0.27 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1154638 chr7:1160374~1165267:+ CESC cis rs7621025 0.505 rs34613715 ENSG00000239213.4 NCK1-AS1 -4.06 6.9e-05 0.0264 -0.42 -0.27 C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index; chr3:136736165 chr3:136841726~136862054:- CESC cis rs919433 0.713 rs1455653 ENSG00000222017.1 AC011997.1 4.06 6.9e-05 0.0264 0.33 0.27 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197613596 chr2:197693106~197774823:+ CESC cis rs62355901 0.505 rs62356561 ENSG00000271828.1 CTD-2310F14.1 4.06 6.9e-05 0.0264 0.41 0.27 Breast cancer; chr5:56933826 chr5:56927874~56929573:+ CESC cis rs11159086 1 rs11626856 ENSG00000270000.1 RP3-449M8.9 4.06 6.9e-05 0.0264 0.51 0.27 Advanced glycation end-product levels; chr14:74469665 chr14:74471930~74472360:- CESC cis rs8020095 0.571 rs9323483 ENSG00000258561.1 RP11-72M17.1 -4.06 6.9e-05 0.0264 -0.38 -0.27 Depression (quantitative trait); chr14:66772889 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs9323484 ENSG00000258561.1 RP11-72M17.1 -4.06 6.9e-05 0.0264 -0.38 -0.27 Depression (quantitative trait); chr14:66772914 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs7142669 ENSG00000258561.1 RP11-72M17.1 -4.06 6.9e-05 0.0264 -0.38 -0.27 Depression (quantitative trait); chr14:66783674 chr14:66212810~66509394:- CESC cis rs11096990 0.855 rs2566181 ENSG00000249207.1 RP11-360F5.1 4.06 6.91e-05 0.0264 0.35 0.26 Cognitive function; chr4:39157987 chr4:39112677~39126818:- CESC cis rs11096990 0.819 rs2381225 ENSG00000249207.1 RP11-360F5.1 4.06 6.91e-05 0.0264 0.35 0.26 Cognitive function; chr4:39158915 chr4:39112677~39126818:- CESC cis rs11096990 0.819 rs1367297 ENSG00000249207.1 RP11-360F5.1 4.06 6.91e-05 0.0264 0.35 0.26 Cognitive function; chr4:39159614 chr4:39112677~39126818:- CESC cis rs12468226 1 rs58288071 ENSG00000273456.1 RP11-686O6.2 4.06 6.91e-05 0.0264 0.35 0.26 Urate levels; chr2:202350016 chr2:202374932~202375604:- CESC cis rs875971 0.895 rs7788984 ENSG00000232559.3 GS1-124K5.12 4.06 6.91e-05 0.0264 0.29 0.26 Aortic root size; chr7:66450629 chr7:66554588~66576923:- CESC cis rs783540 0.5 rs7163840 ENSG00000278202.1 RP11-152F13.8 4.06 6.91e-05 0.0264 0.25 0.26 Schizophrenia; chr15:82729551 chr15:82418651~82434235:+ CESC cis rs57502260 0.704 rs12286536 ENSG00000212093.1 AP000807.1 4.06 6.91e-05 0.0264 0.42 0.26 Total body bone mineral density (age 45-60); chr11:68522766 chr11:68506083~68506166:- CESC cis rs4852708 0.687 rs7572014 ENSG00000237751.2 LINC01143 -4.06 6.91e-05 0.0264 -0.54 -0.26 IgG glycosylation; chr2:70892771 chr2:70887871~70889959:+ CESC cis rs11779988 0.545 rs448882 ENSG00000253671.1 RP11-806O11.1 -4.06 6.92e-05 0.0264 -0.32 -0.26 Breast cancer; chr8:17936530 chr8:17808941~17820868:+ CESC cis rs3091242 0.933 rs61775174 ENSG00000224183.1 SDHDP6 4.06 6.92e-05 0.0264 0.29 0.26 Erythrocyte sedimentation rate; chr1:25460822 chr1:25294164~25294643:- CESC cis rs7598759 0.679 rs6740843 ENSG00000181798.2 LINC00471 -4.06 6.92e-05 0.0265 -0.29 -0.26 Noise-induced hearing loss; chr2:231467428 chr2:231508426~231514339:- CESC cis rs2861422 0.53 rs347689 ENSG00000233597.3 RP11-343B5.1 4.06 6.92e-05 0.0265 0.38 0.26 Glomerular filtration rate (creatinine); chr3:142063048 chr3:142043623~142044198:- CESC cis rs801193 0.904 rs4718403 ENSG00000230358.3 RP11-166O4.1 -4.06 6.93e-05 0.0265 -0.36 -0.26 Aortic root size; chr7:66777742 chr7:67279778~67286230:+ CESC cis rs4308124 1 rs62160391 ENSG00000227992.1 AC108463.2 -4.06 6.93e-05 0.0265 -0.3 -0.26 Vitiligo; chr2:111251258 chr2:111203964~111206215:- CESC cis rs4272720 0.535 rs72785015 ENSG00000229870.1 RP11-507K13.6 -4.06 6.93e-05 0.0265 -0.31 -0.26 Platelet count;Plateletcrit; chr10:49077861 chr10:49815096~49815562:+ CESC cis rs1707322 1 rs785467 ENSG00000281133.1 AL355480.3 4.06 6.93e-05 0.0265 0.32 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055887 chr1:45580892~45580996:- CESC cis rs2836950 0.501 rs11702505 ENSG00000255568.3 BRWD1-AS2 -4.06 6.93e-05 0.0265 -0.22 -0.26 Menarche (age at onset); chr21:39328688 chr21:39313935~39314962:+ CESC cis rs2836950 0.501 rs2836985 ENSG00000255568.3 BRWD1-AS2 -4.06 6.93e-05 0.0265 -0.22 -0.26 Menarche (age at onset); chr21:39329243 chr21:39313935~39314962:+ CESC cis rs1667255 1 rs1080094 ENSG00000266521.1 RP11-650P15.1 4.06 6.93e-05 0.0265 0.32 0.26 Retinol levels; chr18:31593832 chr18:31496645~31497195:- CESC cis rs7208859 0.623 rs8081299 ENSG00000266490.1 CTD-2349P21.9 4.06 6.93e-05 0.0265 0.41 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777278 chr17:30792372~30792833:+ CESC cis rs9640161 0.636 rs3735171 ENSG00000261305.1 RP4-584D14.7 4.06 6.94e-05 0.0265 0.37 0.26 Blood protein levels;Circulating chemerin levels; chr7:150336793 chr7:150341771~150342607:+ CESC cis rs6969780 1 rs73071550 ENSG00000233429.8 HOTAIRM1 4.06 6.94e-05 0.0265 0.37 0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27109480 chr7:27095647~27100265:+ CESC cis rs7614311 0.954 rs2291533 ENSG00000271843.1 RP11-245J9.5 4.06 6.94e-05 0.0265 0.36 0.26 Lung function (FVC);Lung function (FEV1); chr3:63831754 chr3:64008082~64008692:- CESC cis rs7429990 0.965 rs319685 ENSG00000229759.1 MRPS18AP1 4.06 6.94e-05 0.0265 0.27 0.26 Educational attainment (years of education); chr3:47890494 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs34380889 ENSG00000229759.1 MRPS18AP1 4.06 6.94e-05 0.0265 0.27 0.26 Educational attainment (years of education); chr3:47905692 chr3:48256350~48256938:- CESC cis rs7429990 0.965 rs4858871 ENSG00000229759.1 MRPS18AP1 4.06 6.94e-05 0.0265 0.27 0.26 Educational attainment (years of education); chr3:47911915 chr3:48256350~48256938:- CESC cis rs2439831 0.85 rs9944216 ENSG00000249839.1 AC011330.5 4.06 6.94e-05 0.0265 0.4 0.26 Lung cancer in ever smokers; chr15:43868575 chr15:43663654~43684339:- CESC cis rs1501911 0.527 rs161934 ENSG00000248489.1 CTD-2007H13.3 -4.06 6.94e-05 0.0265 -0.3 -0.26 Lung function (FEV1/FVC); chr5:98981283 chr5:98929171~98995013:+ CESC cis rs9309473 0.5 rs13022837 ENSG00000273245.1 RP11-434P11.2 -4.06 6.95e-05 0.0265 -0.34 -0.26 Metabolite levels; chr2:73685440 chr2:73750256~73750786:- CESC cis rs4319547 0.656 rs10773075 ENSG00000275265.1 RP11-15J22.8 -4.06 6.95e-05 0.0265 -0.37 -0.26 Body mass index; chr12:122329689 chr12:122501187~122501641:+ CESC cis rs4319547 0.62 rs12372756 ENSG00000275265.1 RP11-15J22.8 -4.06 6.95e-05 0.0265 -0.37 -0.26 Body mass index; chr12:122330583 chr12:122501187~122501641:+ CESC cis rs4319547 0.585 rs7953007 ENSG00000275265.1 RP11-15J22.8 -4.06 6.95e-05 0.0265 -0.37 -0.26 Body mass index; chr12:122332430 chr12:122501187~122501641:+ CESC cis rs17772222 0.917 rs17260408 ENSG00000258983.2 RP11-507K2.2 4.06 6.95e-05 0.0265 0.33 0.26 Coronary artery calcification; chr14:88715464 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs8021690 ENSG00000258983.2 RP11-507K2.2 4.06 6.95e-05 0.0265 0.33 0.26 Coronary artery calcification; chr14:88717806 chr14:88499334~88515502:+ CESC cis rs10853057 1 rs10853057 ENSG00000214174.7 AMZ2P1 4.06 6.95e-05 0.0266 0.39 0.26 White matter microstructure (global fractional anisotropy); chr17:65001905 chr17:64966550~64975576:- CESC cis rs8040855 0.597 rs994989 ENSG00000259295.5 CSPG4P12 4.06 6.95e-05 0.0266 0.34 0.26 Bulimia nervosa; chr15:85117485 chr15:85191438~85213905:+ CESC cis rs5742933 0.857 rs11685425 ENSG00000273240.1 RP11-455J20.3 4.06 6.96e-05 0.0266 0.29 0.26 Ferritin levels; chr2:189747977 chr2:189763859~189764456:- CESC cis rs10461617 0.617 rs1423623 ENSG00000271828.1 CTD-2310F14.1 -4.06 6.96e-05 0.0266 -0.32 -0.26 Type 2 diabetes; chr5:56769748 chr5:56927874~56929573:+ CESC cis rs1075265 0.729 rs10201364 ENSG00000233266.1 HMGB1P31 4.06 6.96e-05 0.0266 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53990220 chr2:54051334~54051760:+ CESC cis rs950776 0.506 rs12915366 ENSG00000279373.1 RP11-650L12.4 4.06 6.97e-05 0.0266 0.32 0.26 Sudden cardiac arrest; chr15:78539411 chr15:78537681~78538946:+ CESC cis rs950776 0.531 rs12915652 ENSG00000279373.1 RP11-650L12.4 4.06 6.97e-05 0.0266 0.32 0.26 Sudden cardiac arrest; chr15:78539586 chr15:78537681~78538946:+ CESC cis rs875971 0.895 rs1974769 ENSG00000237310.1 GS1-124K5.4 4.06 6.97e-05 0.0266 0.26 0.26 Aortic root size; chr7:66485627 chr7:66493706~66495474:+ CESC cis rs875971 0.895 rs6460300 ENSG00000237310.1 GS1-124K5.4 4.06 6.97e-05 0.0266 0.26 0.26 Aortic root size; chr7:66487937 chr7:66493706~66495474:+ CESC cis rs10129255 0.5 rs1974468 ENSG00000211970.3 IGHV4-61 -4.06 6.97e-05 0.0266 -0.18 -0.26 Kawasaki disease; chr14:106686149 chr14:106639119~106639657:- CESC cis rs875971 1 rs4717292 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66430611 chr7:66554588~66576923:- CESC cis rs875971 0.895 rs10755833 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66448930 chr7:66554588~66576923:- CESC cis rs875971 0.964 rs12668936 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66449417 chr7:66554588~66576923:- CESC cis rs875971 0.895 rs1833495 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66456608 chr7:66554588~66576923:- CESC cis rs875971 0.964 rs6945032 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66457499 chr7:66554588~66576923:- CESC cis rs875971 0.929 rs12673810 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66458866 chr7:66554588~66576923:- CESC cis rs875971 1 rs35149210 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66464938 chr7:66554588~66576923:- CESC cis rs875971 1 rs6961155 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66468308 chr7:66554588~66576923:- CESC cis rs875971 1 rs7789768 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66473993 chr7:66554588~66576923:- CESC cis rs875971 1 rs1363055 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66478288 chr7:66554588~66576923:- CESC cis rs875971 0.964 rs9691480 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66479319 chr7:66554588~66576923:- CESC cis rs875971 1 rs7789554 ENSG00000232559.3 GS1-124K5.12 4.06 6.97e-05 0.0266 0.29 0.26 Aortic root size; chr7:66481051 chr7:66554588~66576923:- CESC cis rs7598759 0.588 rs6737291 ENSG00000181798.2 LINC00471 -4.06 6.97e-05 0.0266 -0.29 -0.26 Noise-induced hearing loss; chr2:231464848 chr2:231508426~231514339:- CESC cis rs9323326 0.586 rs8019695 ENSG00000257621.6 PSMA3-AS1 4.06 6.97e-05 0.0266 0.27 0.26 Gut microbiota (bacterial taxa); chr14:58017747 chr14:58265365~58298134:- CESC cis rs6687821 0.681 rs526985 ENSG00000267734.1 RP4-604K5.3 4.06 6.97e-05 0.0266 0.29 0.26 Yeast infection; chr1:86850735 chr1:86932199~86934891:- CESC cis rs2337406 0.85 rs11849578 ENSG00000254174.1 IGHV1-12 4.06 6.98e-05 0.0266 0.29 0.26 Alzheimer's disease (late onset); chr14:106670302 chr14:106122420~106122709:- CESC cis rs6142102 0.961 rs2284386 ENSG00000275784.1 RP5-1125A11.6 -4.06 6.98e-05 0.0266 -0.27 -0.26 Skin pigmentation; chr20:34056590 chr20:33989480~33991818:- CESC cis rs5769707 0.837 rs5769709 ENSG00000235111.1 RP1-29C18.8 -4.05 6.98e-05 0.0266 -0.28 -0.26 Monocyte percentage of white cells;Monocyte count; chr22:49628109 chr22:49612657~49615716:- CESC cis rs1871045 0.722 rs4802240 ENSG00000279103.1 CTC-204F22.1 4.05 6.99e-05 0.0266 0.29 0.26 Waist-to-hip circumference ratio (smoking years interaction); chr19:44849547 chr19:44246478~44248374:- CESC cis rs7688540 0.771 rs61795007 ENSG00000211553.1 AC253576.2 -4.05 6.99e-05 0.0267 -0.4 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:261475 chr4:136461~136568:+ CESC cis rs11250098 0.567 rs4326350 ENSG00000269918.1 AF131215.9 4.05 6.99e-05 0.0267 0.32 0.26 Morning vs. evening chronotype; chr8:10906145 chr8:11104691~11106704:- CESC cis rs875971 1 rs875971 ENSG00000232559.3 GS1-124K5.12 -4.05 6.99e-05 0.0267 -0.28 -0.26 Aortic root size; chr7:66152608 chr7:66554588~66576923:- CESC cis rs2439831 1 rs2253708 ENSG00000275601.1 AC011330.13 -4.05 6.99e-05 0.0267 -0.35 -0.26 Lung cancer in ever smokers; chr15:43505075 chr15:43642389~43643023:- CESC cis rs11096990 0.964 rs9998591 ENSG00000249207.1 RP11-360F5.1 -4.05 7e-05 0.0267 -0.32 -0.26 Cognitive function; chr4:39240491 chr4:39112677~39126818:- CESC cis rs669446 0.591 rs607062 ENSG00000236200.4 KDM4A-AS1 -4.05 7e-05 0.0267 -0.32 -0.26 Amyotrophic lateral sclerosis (age of onset); chr1:43667345 chr1:43699765~43708138:- CESC cis rs116175783 0.557 rs1733180 ENSG00000227403.1 AC009299.3 -4.05 7e-05 0.0267 -0.44 -0.26 Intelligence (multi-trait analysis); chr2:161277119 chr2:161244739~161249050:+ CESC cis rs6687821 0.773 rs12097495 ENSG00000267734.1 RP4-604K5.3 4.05 7e-05 0.0267 0.33 0.26 Yeast infection; chr1:86749925 chr1:86932199~86934891:- CESC cis rs8080784 0.673 rs8074536 ENSG00000266701.1 AC005702.4 4.05 7e-05 0.0267 0.4 0.26 Coronary artery disease; chr17:60775542 chr17:60042546~60042627:- CESC cis rs17772222 0.876 rs58655091 ENSG00000258983.2 RP11-507K2.2 4.05 7.01e-05 0.0267 0.33 0.26 Coronary artery calcification; chr14:88748567 chr14:88499334~88515502:+ CESC cis rs1713985 1 rs1713985 ENSG00000269949.1 RP11-738E22.3 -4.05 7.01e-05 0.0267 -0.46 -0.26 Age-related macular degeneration; chr4:56920284 chr4:56960927~56961373:- CESC cis rs7429990 0.965 rs4858881 ENSG00000229759.1 MRPS18AP1 -4.05 7.01e-05 0.0267 -0.27 -0.26 Educational attainment (years of education); chr3:48082306 chr3:48256350~48256938:- CESC cis rs7819412 0.74 rs7844536 ENSG00000255046.1 RP11-297N6.4 4.05 7.02e-05 0.0267 0.3 0.26 Triglycerides; chr8:11176519 chr8:11797928~11802568:- CESC cis rs9532669 0.926 rs7322399 ENSG00000176268.5 CYCSP34 4.05 7.02e-05 0.0268 0.28 0.26 Cervical cancer; chr13:40952511 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs7322097 ENSG00000176268.5 CYCSP34 4.05 7.02e-05 0.0268 0.28 0.26 Cervical cancer; chr13:40952513 chr13:40863599~40863902:- CESC cis rs74394007 0.92 rs2874490 ENSG00000244515.1 KRT18P34 4.05 7.02e-05 0.0268 0.45 0.26 Total body bone mineral density; chr3:156917724 chr3:157162663~157163932:- CESC cis rs2274273 0.624 rs66464079 ENSG00000258413.1 RP11-665C16.6 -4.05 7.03e-05 0.0268 -0.34 -0.26 Protein biomarker; chr14:55299446 chr14:55262767~55272075:- CESC cis rs17695224 0.63 rs4802879 ENSG00000268095.1 ZNF649-AS1 4.05 7.03e-05 0.0268 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51837122 chr19:51888025~51900463:+ CESC cis rs17695224 0.611 rs4802880 ENSG00000268095.1 ZNF649-AS1 4.05 7.03e-05 0.0268 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51837123 chr19:51888025~51900463:+ CESC cis rs17695224 0.675 rs3948650 ENSG00000268095.1 ZNF649-AS1 4.05 7.03e-05 0.0268 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51837446 chr19:51888025~51900463:+ CESC cis rs2243480 1 rs437889 ENSG00000275400.1 RP4-756H11.5 4.05 7.03e-05 0.0268 0.45 0.26 Diabetic kidney disease; chr7:66044247 chr7:66553805~66554199:- CESC cis rs2404602 0.692 rs12904198 ENSG00000280730.1 AC090181.1 4.05 7.04e-05 0.0268 0.2 0.26 Blood metabolite levels; chr15:76854637 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs2137307 ENSG00000280730.1 AC090181.1 4.05 7.04e-05 0.0268 0.2 0.26 Blood metabolite levels; chr15:76856679 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs12594556 ENSG00000280730.1 AC090181.1 4.05 7.04e-05 0.0268 0.2 0.26 Blood metabolite levels; chr15:76873022 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs12595586 ENSG00000280730.1 AC090181.1 4.05 7.04e-05 0.0268 0.2 0.26 Blood metabolite levels; chr15:76879869 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs4360890 ENSG00000280730.1 AC090181.1 4.05 7.04e-05 0.0268 0.2 0.26 Blood metabolite levels; chr15:76880954 chr15:77056895~77057021:+ CESC cis rs7819412 0.521 rs2409720 ENSG00000255046.1 RP11-297N6.4 4.05 7.04e-05 0.0268 0.3 0.26 Triglycerides; chr8:11180394 chr8:11797928~11802568:- CESC cis rs7429990 0.965 rs6772396 ENSG00000229759.1 MRPS18AP1 4.05 7.05e-05 0.0268 0.27 0.26 Educational attainment (years of education); chr3:47918280 chr3:48256350~48256938:- CESC cis rs7005380 0.581 rs7007672 ENSG00000279347.1 RP11-85I17.2 -4.05 7.05e-05 0.0268 -0.29 -0.26 Interstitial lung disease; chr8:119906981 chr8:119838736~119840385:- CESC cis rs7005380 0.525 rs7000068 ENSG00000279347.1 RP11-85I17.2 -4.05 7.05e-05 0.0268 -0.29 -0.26 Interstitial lung disease; chr8:119910723 chr8:119838736~119840385:- CESC cis rs7005380 0.538 rs7000488 ENSG00000279347.1 RP11-85I17.2 -4.05 7.05e-05 0.0268 -0.29 -0.26 Interstitial lung disease; chr8:119911059 chr8:119838736~119840385:- CESC cis rs6997458 0.742 rs7841178 ENSG00000253549.4 RP11-317J10.2 -4.05 7.05e-05 0.0269 -0.31 -0.26 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85425690 chr8:85441851~85464915:- CESC cis rs6951245 0.786 rs77943789 ENSG00000229043.2 AC091729.9 -4.05 7.05e-05 0.0269 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1100522 chr7:1160374~1165267:+ CESC cis rs17772222 0.917 rs8006652 ENSG00000258983.2 RP11-507K2.2 4.05 7.05e-05 0.0269 0.32 0.26 Coronary artery calcification; chr14:88631290 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs12431548 ENSG00000258983.2 RP11-507K2.2 4.05 7.05e-05 0.0269 0.32 0.26 Coronary artery calcification; chr14:88635826 chr14:88499334~88515502:+ CESC cis rs9487094 0.689 rs2884037 ENSG00000260273.1 RP11-425D10.10 4.05 7.05e-05 0.0269 0.32 0.26 Height; chr6:109354092 chr6:109382795~109383666:+ CESC cis rs748404 0.631 rs28702649 ENSG00000205771.5 CATSPER2P1 -4.05 7.06e-05 0.0269 -0.32 -0.26 Lung cancer; chr15:43356431 chr15:43726918~43747094:- CESC cis rs17826219 0.706 rs2322197 ENSG00000266490.1 CTD-2349P21.9 4.05 7.06e-05 0.0269 0.39 0.26 Body mass index; chr17:30778787 chr17:30792372~30792833:+ CESC cis rs9532669 0.963 rs4343141 ENSG00000176268.5 CYCSP34 4.05 7.06e-05 0.0269 0.28 0.26 Cervical cancer; chr13:40940497 chr13:40863599~40863902:- CESC cis rs881375 0.933 rs7031096 ENSG00000226752.6 PSMD5-AS1 -4.05 7.07e-05 0.0269 -0.29 -0.26 Rheumatoid arthritis; chr9:120932664 chr9:120824828~120854385:+ CESC cis rs881375 0.967 rs10739580 ENSG00000226752.6 PSMD5-AS1 -4.05 7.07e-05 0.0269 -0.29 -0.26 Rheumatoid arthritis; chr9:120933004 chr9:120824828~120854385:+ CESC cis rs875971 0.545 rs2420612 ENSG00000236529.1 RP13-254B10.1 4.05 7.07e-05 0.0269 0.34 0.26 Aortic root size; chr7:66536825 chr7:65840212~65840596:+ CESC cis rs6439153 0.933 rs6799008 ENSG00000231305.3 RP11-723O4.2 4.05 7.07e-05 0.0269 0.26 0.26 Pneumococcal bacteremia; chr3:128998544 chr3:128861313~128871540:- CESC cis rs6439153 0.933 rs1871951 ENSG00000231305.3 RP11-723O4.2 4.05 7.07e-05 0.0269 0.26 0.26 Pneumococcal bacteremia; chr3:129001644 chr3:128861313~128871540:- CESC cis rs875971 0.862 rs7803416 ENSG00000237310.1 GS1-124K5.4 4.05 7.07e-05 0.0269 0.26 0.26 Aortic root size; chr7:66489212 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs1981799 ENSG00000237310.1 GS1-124K5.4 4.05 7.07e-05 0.0269 0.26 0.26 Aortic root size; chr7:66490572 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs2277911 ENSG00000237310.1 GS1-124K5.4 4.05 7.07e-05 0.0269 0.26 0.26 Aortic root size; chr7:66493638 chr7:66493706~66495474:+ CESC cis rs7429990 0.965 rs319684 ENSG00000229759.1 MRPS18AP1 4.05 7.07e-05 0.0269 0.27 0.26 Educational attainment (years of education); chr3:47890784 chr3:48256350~48256938:- CESC cis rs7429990 0.932 rs810334 ENSG00000229759.1 MRPS18AP1 4.05 7.07e-05 0.0269 0.27 0.26 Educational attainment (years of education); chr3:47893813 chr3:48256350~48256938:- CESC cis rs2733201 1 rs2706472 ENSG00000275601.1 AC011330.13 4.05 7.07e-05 0.0269 0.39 0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44141094 chr15:43642389~43643023:- CESC cis rs11779988 0.545 rs208764 ENSG00000253671.1 RP11-806O11.1 -4.05 7.08e-05 0.0269 -0.32 -0.26 Breast cancer; chr8:17948761 chr8:17808941~17820868:+ CESC cis rs11779988 0.545 rs208763 ENSG00000253671.1 RP11-806O11.1 -4.05 7.08e-05 0.0269 -0.32 -0.26 Breast cancer; chr8:17948973 chr8:17808941~17820868:+ CESC cis rs11779988 0.545 rs208762 ENSG00000253671.1 RP11-806O11.1 -4.05 7.08e-05 0.0269 -0.32 -0.26 Breast cancer; chr8:17949225 chr8:17808941~17820868:+ CESC cis rs7688540 0.771 rs79366248 ENSG00000211553.1 AC253576.2 -4.05 7.08e-05 0.0269 -0.41 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:272870 chr4:136461~136568:+ CESC cis rs7688540 0.771 rs11722521 ENSG00000211553.1 AC253576.2 -4.05 7.08e-05 0.0269 -0.41 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:282976 chr4:136461~136568:+ CESC cis rs453301 0.686 rs7814328 ENSG00000173295.6 FAM86B3P -4.05 7.09e-05 0.027 -0.34 -0.26 Joint mobility (Beighton score); chr8:9018719 chr8:8228595~8244865:+ CESC cis rs11098499 0.604 rs2389886 ENSG00000248280.1 RP11-33B1.2 4.05 7.09e-05 0.027 0.3 0.26 Corneal astigmatism; chr4:119649267 chr4:119440561~119450157:- CESC cis rs71403859 0.73 rs12922775 ENSG00000260886.1 TAT-AS1 4.05 7.09e-05 0.027 0.41 0.26 Post bronchodilator FEV1; chr16:71550451 chr16:71565789~71578187:+ CESC cis rs9309473 0.5 rs10865398 ENSG00000273245.1 RP11-434P11.2 -4.05 7.09e-05 0.027 -0.33 -0.26 Metabolite levels; chr2:73514370 chr2:73750256~73750786:- CESC cis rs8020095 0.571 rs7141519 ENSG00000258561.1 RP11-72M17.1 -4.05 7.1e-05 0.027 -0.4 -0.26 Depression (quantitative trait); chr14:67057808 chr14:66212810~66509394:- CESC cis rs875971 0.929 rs34406470 ENSG00000232559.3 GS1-124K5.12 4.05 7.1e-05 0.027 0.29 0.26 Aortic root size; chr7:66464969 chr7:66554588~66576923:- CESC cis rs10461617 0.541 rs860581 ENSG00000271828.1 CTD-2310F14.1 4.05 7.1e-05 0.027 0.42 0.26 Type 2 diabetes; chr5:56854710 chr5:56927874~56929573:+ CESC cis rs490234 0.702 rs4838279 ENSG00000232630.1 PRPS1P2 -4.05 7.1e-05 0.027 -0.23 -0.26 Mean arterial pressure; chr9:125649447 chr9:125150653~125151589:+ CESC cis rs490234 0.702 rs13284551 ENSG00000232630.1 PRPS1P2 -4.05 7.1e-05 0.027 -0.23 -0.26 Mean arterial pressure; chr9:125649690 chr9:125150653~125151589:+ CESC cis rs1387259 0.839 rs7486941 ENSG00000258273.1 RP11-370I10.4 4.05 7.1e-05 0.027 0.29 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48184848 chr12:48333755~48333901:- CESC cis rs763121 0.853 rs3788544 ENSG00000228274.3 RP3-508I15.9 -4.05 7.1e-05 0.027 -0.27 -0.26 Menopause (age at onset); chr22:38668961 chr22:38667585~38681820:- CESC cis rs7572733 0.515 rs6726506 ENSG00000222017.1 AC011997.1 4.05 7.11e-05 0.027 0.34 0.26 Dermatomyositis; chr2:197981762 chr2:197693106~197774823:+ CESC cis rs4927850 1 rs7627706 ENSG00000231464.1 AC024937.4 4.05 7.11e-05 0.027 0.33 0.26 Pancreatic cancer; chr3:196026482 chr3:195996738~195998233:+ CESC cis rs4927850 0.881 rs7630489 ENSG00000231464.1 AC024937.4 4.05 7.11e-05 0.027 0.33 0.26 Pancreatic cancer; chr3:196026530 chr3:195996738~195998233:+ CESC cis rs4927850 1 rs7627868 ENSG00000231464.1 AC024937.4 4.05 7.11e-05 0.027 0.33 0.26 Pancreatic cancer; chr3:196026602 chr3:195996738~195998233:+ CESC cis rs34421088 0.564 rs6983129 ENSG00000255046.1 RP11-297N6.4 -4.05 7.12e-05 0.027 -0.29 -0.26 Neuroticism; chr8:11733627 chr8:11797928~11802568:- CESC cis rs2015599 0.525 rs10771514 ENSG00000257176.2 RP11-996F15.2 4.05 7.12e-05 0.0271 0.31 0.26 Platelet count;Mean platelet volume; chr12:29315751 chr12:29280418~29317848:- CESC cis rs2015599 0.525 rs7298031 ENSG00000257176.2 RP11-996F15.2 4.05 7.12e-05 0.0271 0.31 0.26 Platelet count;Mean platelet volume; chr12:29317333 chr12:29280418~29317848:- CESC cis rs2015599 0.525 rs2016832 ENSG00000257176.2 RP11-996F15.2 4.05 7.12e-05 0.0271 0.31 0.26 Platelet count;Mean platelet volume; chr12:29318199 chr12:29280418~29317848:- CESC cis rs9322193 0.923 rs1934534 ENSG00000216906.2 RP11-350J20.9 4.05 7.13e-05 0.0271 0.29 0.26 Lung cancer; chr6:149711896 chr6:149904243~149906418:+ CESC cis rs2404602 0.692 rs4641709 ENSG00000280730.1 AC090181.1 -4.05 7.13e-05 0.0271 -0.2 -0.26 Blood metabolite levels; chr15:76755395 chr15:77056895~77057021:+ CESC cis rs748404 0.666 rs34633582 ENSG00000249839.1 AC011330.5 -4.05 7.13e-05 0.0271 -0.38 -0.26 Lung cancer; chr15:43462683 chr15:43663654~43684339:- CESC cis rs7005380 0.58 rs10110216 ENSG00000279347.1 RP11-85I17.2 -4.05 7.14e-05 0.0271 -0.24 -0.26 Interstitial lung disease; chr8:119875307 chr8:119838736~119840385:- CESC cis rs7005380 0.58 rs10110223 ENSG00000279347.1 RP11-85I17.2 -4.05 7.14e-05 0.0271 -0.24 -0.26 Interstitial lung disease; chr8:119875326 chr8:119838736~119840385:- CESC cis rs6951245 0.882 rs10256720 ENSG00000229043.2 AC091729.9 -4.05 7.14e-05 0.0271 -0.4 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1171189 chr7:1160374~1165267:+ CESC cis rs801193 1 rs4717319 ENSG00000230358.3 RP11-166O4.1 -4.05 7.14e-05 0.0271 -0.36 -0.26 Aortic root size; chr7:66777606 chr7:67279778~67286230:+ CESC cis rs919433 0.679 rs10166328 ENSG00000222017.1 AC011997.1 4.05 7.14e-05 0.0271 0.34 0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197647193 chr2:197693106~197774823:+ CESC cis rs7937890 0.559 rs1116739 ENSG00000251991.1 RNU7-49P 4.05 7.15e-05 0.0271 0.28 0.26 Mitochondrial DNA levels; chr11:14467636 chr11:14478892~14478953:+ CESC cis rs17772222 0.917 rs17188228 ENSG00000258983.2 RP11-507K2.2 4.05 7.15e-05 0.0271 0.33 0.26 Coronary artery calcification; chr14:88738921 chr14:88499334~88515502:+ CESC cis rs9322193 0.962 rs7740784 ENSG00000216906.2 RP11-350J20.9 4.05 7.15e-05 0.0271 0.3 0.26 Lung cancer; chr6:149833364 chr6:149904243~149906418:+ CESC cis rs2243480 1 rs2462569 ENSG00000232559.3 GS1-124K5.12 -4.05 7.15e-05 0.0271 -0.42 -0.26 Diabetic kidney disease; chr7:66009859 chr7:66554588~66576923:- CESC cis rs9925964 0.9 rs56813533 ENSG00000260911.2 RP11-196G11.2 -4.05 7.15e-05 0.0271 -0.29 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31059160 chr16:31043150~31049868:+ CESC cis rs875971 1 rs2420591 ENSG00000237310.1 GS1-124K5.4 4.05 7.16e-05 0.0272 0.25 0.26 Aortic root size; chr7:66447394 chr7:66493706~66495474:+ CESC cis rs950776 0.518 rs4887062 ENSG00000279373.1 RP11-650L12.4 -4.05 7.17e-05 0.0272 -0.32 -0.26 Sudden cardiac arrest; chr15:78545459 chr15:78537681~78538946:+ CESC cis rs72772090 0.539 rs72775818 ENSG00000248734.2 CTD-2260A17.1 -4.05 7.17e-05 0.0272 -0.43 -0.26 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96857512 chr5:96784777~96785999:+ CESC cis rs1135642 0.57 rs11722689 ENSG00000270244.1 RP11-123J14.4 4.05 7.18e-05 0.0272 0.65 0.26 Food addiction; chr4:76942058 chr4:76886029~76886370:- CESC cis rs875971 1 rs9986696 ENSG00000232559.3 GS1-124K5.12 -4.05 7.18e-05 0.0272 -0.28 -0.26 Aortic root size; chr7:66239589 chr7:66554588~66576923:- CESC cis rs35740288 0.929 rs1978391 ENSG00000202081.1 RNU6-1280P -4.05 7.18e-05 0.0272 -0.33 -0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85768464 chr15:85651522~85651628:- CESC cis rs2439831 1 rs2439841 ENSG00000275601.1 AC011330.13 -4.05 7.18e-05 0.0272 -0.36 -0.26 Lung cancer in ever smokers; chr15:43442551 chr15:43642389~43643023:- CESC cis rs111315781 1 rs111315781 ENSG00000183308.6 AC005037.3 4.05 7.19e-05 0.0273 0.43 0.26 Triptolide cytotoxicity; chr2:200874001 chr2:200963263~201009102:+ CESC cis rs2933343 0.679 rs789221 ENSG00000231305.3 RP11-723O4.2 4.05 7.19e-05 0.0273 0.24 0.26 IgG glycosylation; chr3:128872782 chr3:128861313~128871540:- CESC cis rs769267 0.965 rs2074303 ENSG00000269131.1 AC004447.2 -4.05 7.19e-05 0.0273 -0.22 -0.26 Tonsillectomy; chr19:19270946 chr19:18990893~18993610:+ CESC cis rs1707322 1 rs7531911 ENSG00000281133.1 AL355480.3 -4.05 7.19e-05 0.0273 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45864751 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10890359 ENSG00000281133.1 AL355480.3 -4.05 7.19e-05 0.0273 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45870963 chr1:45580892~45580996:- CESC cis rs1707322 0.928 rs7527244 ENSG00000281133.1 AL355480.3 -4.05 7.19e-05 0.0273 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45903100 chr1:45580892~45580996:- CESC cis rs7688540 0.771 rs74984113 ENSG00000211553.1 AC253576.2 -4.05 7.19e-05 0.0273 -0.41 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:256733 chr4:136461~136568:+ CESC cis rs453301 0.686 rs17702602 ENSG00000173295.6 FAM86B3P -4.05 7.19e-05 0.0273 -0.35 -0.26 Joint mobility (Beighton score); chr8:9051086 chr8:8228595~8244865:+ CESC cis rs67311347 1 rs9882171 ENSG00000223797.4 ENTPD3-AS1 4.05 7.2e-05 0.0273 0.26 0.26 Renal cell carcinoma; chr3:40477330 chr3:40313802~40453329:- CESC cis rs1075265 0.568 rs805416 ENSG00000233266.1 HMGB1P31 -4.05 7.2e-05 0.0273 -0.35 -0.26 Chronotype;Morning vs. evening chronotype; chr2:53898121 chr2:54051334~54051760:+ CESC cis rs875971 0.862 rs6460290 ENSG00000179406.6 LINC00174 4.05 7.2e-05 0.0273 0.28 0.26 Aortic root size; chr7:66344119 chr7:66376044~66401338:- CESC cis rs6969780 0.915 rs7341470 ENSG00000233429.8 HOTAIRM1 -4.05 7.21e-05 0.0273 -0.37 -0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27145223 chr7:27095647~27100265:+ CESC cis rs35740288 0.822 rs11629690 ENSG00000202081.1 RNU6-1280P 4.05 7.21e-05 0.0273 0.33 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85744493 chr15:85651522~85651628:- CESC cis rs875971 0.895 rs12698520 ENSG00000237310.1 GS1-124K5.4 4.05 7.21e-05 0.0273 0.25 0.26 Aortic root size; chr7:66453720 chr7:66493706~66495474:+ CESC cis rs1012068 0.662 rs5753816 ENSG00000236132.1 CTA-440B3.1 -4.05 7.21e-05 0.0273 -0.3 -0.26 Chronic hepatitis C infection; chr22:31916856 chr22:31816379~31817491:- CESC cis rs343092 0.572 rs2583933 ENSG00000276853.1 RP11-305O6.4 4.05 7.21e-05 0.0273 0.54 0.26 Type 2 diabetes; chr12:65784685 chr12:65171262~65171917:+ CESC cis rs343092 0.572 rs2612044 ENSG00000276853.1 RP11-305O6.4 4.05 7.21e-05 0.0273 0.54 0.26 Type 2 diabetes; chr12:65789612 chr12:65171262~65171917:+ CESC cis rs343092 0.572 rs2612043 ENSG00000276853.1 RP11-305O6.4 4.05 7.21e-05 0.0273 0.54 0.26 Type 2 diabetes; chr12:65789720 chr12:65171262~65171917:+ CESC cis rs343092 0.572 rs2583952 ENSG00000276853.1 RP11-305O6.4 4.05 7.21e-05 0.0273 0.54 0.26 Type 2 diabetes; chr12:65791077 chr12:65171262~65171917:+ CESC cis rs343092 0.572 rs2583953 ENSG00000276853.1 RP11-305O6.4 4.05 7.21e-05 0.0273 0.54 0.26 Type 2 diabetes; chr12:65791202 chr12:65171262~65171917:+ CESC cis rs67311347 1 rs4246666 ENSG00000223797.4 ENTPD3-AS1 4.05 7.21e-05 0.0273 0.26 0.26 Renal cell carcinoma; chr3:40366179 chr3:40313802~40453329:- CESC cis rs2404602 0.692 rs35999717 ENSG00000280730.1 AC090181.1 4.05 7.21e-05 0.0273 0.2 0.26 Blood metabolite levels; chr15:76901026 chr15:77056895~77057021:+ CESC cis rs11089937 0.597 rs9619794 ENSG00000211638.2 IGLV8-61 -4.05 7.22e-05 0.0273 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22132999 chr22:22098700~22099212:+ CESC cis rs12908161 1 rs35630683 ENSG00000225151.9 GOLGA2P7 -4.05 7.22e-05 0.0273 -0.37 -0.26 Schizophrenia; chr15:84806000 chr15:84199311~84230136:- CESC cis rs6504622 0.935 rs62075889 ENSG00000262879.4 RP11-156P1.3 -4.05 7.22e-05 0.0273 -0.3 -0.26 Orofacial clefts; chr17:46950671 chr17:46984045~47100323:- CESC cis rs6504622 1 rs12940071 ENSG00000262879.4 RP11-156P1.3 -4.05 7.22e-05 0.0273 -0.3 -0.26 Orofacial clefts; chr17:46950686 chr17:46984045~47100323:- CESC cis rs12186641 0.786 rs12153339 ENSG00000259663.2 CTD-2314G24.2 4.05 7.22e-05 0.0273 0.64 0.26 Congenital heart disease; chr5:51881771 chr5:51372736~51383332:- CESC cis rs17301013 0.507 rs72715262 ENSG00000227373.4 RP11-160H22.5 4.05 7.22e-05 0.0273 0.41 0.26 Systemic lupus erythematosus; chr1:174607088 chr1:174115300~174160004:- CESC cis rs2439831 1 rs2444029 ENSG00000205771.5 CATSPER2P1 -4.05 7.22e-05 0.0273 -0.36 -0.26 Lung cancer in ever smokers; chr15:43445286 chr15:43726918~43747094:- CESC cis rs875971 1 rs6963646 ENSG00000179406.6 LINC00174 4.05 7.23e-05 0.0274 0.28 0.26 Aortic root size; chr7:66220780 chr7:66376044~66401338:- CESC cis rs6005807 0.543 rs12168849 ENSG00000226471.5 CTA-292E10.6 -4.05 7.23e-05 0.0274 -0.35 -0.26 Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio; chr22:28806075 chr22:28800683~28848559:+ CESC cis rs831571 0.774 rs40610 ENSG00000280620.1 SCAANT1 4.05 7.24e-05 0.0274 0.41 0.26 Type 2 diabetes; chr3:64023832 chr3:63911518~63911772:- CESC cis rs9308062 1 rs9308062 ENSG00000273449.1 RP11-218F10.3 -4.05 7.24e-05 0.0274 -0.26 -0.26 Small cell lung carcinoma; chr4:163517048 chr4:163529771~163530697:+ CESC cis rs875971 0.964 rs778735 ENSG00000232559.3 GS1-124K5.12 4.05 7.24e-05 0.0274 0.29 0.26 Aortic root size; chr7:66349822 chr7:66554588~66576923:- CESC cis rs6686842 0.965 rs10889792 ENSG00000235358.1 RP11-399E6.1 -4.05 7.24e-05 0.0274 -0.31 -0.26 Height; chr1:41025213 chr1:41242373~41284861:+ CESC cis rs3738443 0.868 rs56029850 ENSG00000259865.1 RP11-488L18.10 4.05 7.24e-05 0.0274 0.28 0.26 Alcohol dependence; chr1:247201027 chr1:247187281~247188526:- CESC cis rs3738443 0.868 rs55643126 ENSG00000259865.1 RP11-488L18.10 4.05 7.24e-05 0.0274 0.28 0.26 Alcohol dependence; chr1:247201042 chr1:247187281~247188526:- CESC cis rs7727544 0.904 rs58835386 ENSG00000233006.5 AC034220.3 4.05 7.24e-05 0.0274 0.29 0.26 Blood metabolite levels; chr5:132264866 chr5:132311285~132369916:- CESC cis rs77972916 0.505 rs1322 ENSG00000276967.1 AC019129.2 -4.05 7.25e-05 0.0274 -0.39 -0.26 Granulocyte percentage of myeloid white cells; chr2:43294028 chr2:44065488~44065544:- CESC cis rs9309473 0.948 rs2421577 ENSG00000163016.8 ALMS1P 4.05 7.25e-05 0.0274 0.33 0.26 Metabolite levels; chr2:73613871 chr2:73644919~73685576:+ CESC cis rs72627123 0.867 rs75773875 ENSG00000270140.1 RP5-1021I20.6 -4.05 7.25e-05 0.0274 -0.61 -0.26 Morning vs. evening chronotype; chr14:74031350 chr14:73905267~73905636:+ CESC cis rs763121 0.819 rs138700 ENSG00000273076.1 RP3-508I15.22 4.05 7.25e-05 0.0274 0.31 0.26 Menopause (age at onset); chr22:38733994 chr22:38743495~38743910:+ CESC cis rs17818399 0.574 rs6544907 ENSG00000279254.1 RP11-536C12.1 -4.05 7.26e-05 0.0275 -0.29 -0.26 Height; chr2:46641180 chr2:46668870~46670778:+ CESC cis rs2713936 0.538 rs8040189 ENSG00000277245.1 RP11-48G14.3 -4.05 7.26e-05 0.0275 -0.29 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr15:56062847 chr15:56447120~56447697:+ CESC cis rs11096990 0.964 rs6831700 ENSG00000249207.1 RP11-360F5.1 -4.05 7.26e-05 0.0275 -0.31 -0.26 Cognitive function; chr4:39255344 chr4:39112677~39126818:- CESC cis rs11638352 0.661 rs2615278 ENSG00000275601.1 AC011330.13 4.04 7.26e-05 0.0275 0.39 0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44166436 chr15:43642389~43643023:- CESC cis rs8030379 1 rs1471553 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83902286 chr15:84507885~84516814:- CESC cis rs8030379 1 rs1564475 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83903477 chr15:84507885~84516814:- CESC cis rs8030379 1 rs7183263 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83904289 chr15:84507885~84516814:- CESC cis rs8030379 1 rs7178962 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83904496 chr15:84507885~84516814:- CESC cis rs8030379 0.967 rs899926 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83904739 chr15:84507885~84516814:- CESC cis rs8030379 0.967 rs8029387 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83906523 chr15:84507885~84516814:- CESC cis rs8030379 0.935 rs1815172 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83907080 chr15:84507885~84516814:- CESC cis rs8030379 1 rs1810049 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83907300 chr15:84507885~84516814:- CESC cis rs8030379 1 rs11853052 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83907407 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2401172 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83908205 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2401174 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83908240 chr15:84507885~84516814:- CESC cis rs8030379 1 rs11259929 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83908450 chr15:84507885~84516814:- CESC cis rs8030379 1 rs11259930 ENSG00000230373.7 GOLGA6L5P -4.04 7.26e-05 0.0275 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83908598 chr15:84507885~84516814:- CESC cis rs8080784 0.932 rs7223521 ENSG00000266992.1 DHX40P1 4.04 7.27e-05 0.0275 0.34 0.26 Coronary artery disease; chr17:60952326 chr17:59976009~60002384:- CESC cis rs8080784 1 rs1119805 ENSG00000266992.1 DHX40P1 4.04 7.27e-05 0.0275 0.34 0.26 Coronary artery disease; chr17:60952677 chr17:59976009~60002384:- CESC cis rs8080784 1 rs1988961 ENSG00000266992.1 DHX40P1 4.04 7.27e-05 0.0275 0.34 0.26 Coronary artery disease; chr17:60952768 chr17:59976009~60002384:- CESC cis rs8080784 1 rs9890322 ENSG00000266992.1 DHX40P1 4.04 7.27e-05 0.0275 0.34 0.26 Coronary artery disease; chr17:60954181 chr17:59976009~60002384:- CESC cis rs8080784 1 rs9916145 ENSG00000266992.1 DHX40P1 4.04 7.27e-05 0.0275 0.34 0.26 Coronary artery disease; chr17:60954247 chr17:59976009~60002384:- CESC cis rs9309473 0.95 rs13391258 ENSG00000163016.8 ALMS1P 4.04 7.27e-05 0.0275 0.33 0.26 Metabolite levels; chr2:73621806 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs6705977 ENSG00000163016.8 ALMS1P 4.04 7.27e-05 0.0275 0.33 0.26 Metabolite levels; chr2:73622043 chr2:73644919~73685576:+ CESC cis rs9309473 0.898 rs6546861 ENSG00000163016.8 ALMS1P 4.04 7.27e-05 0.0275 0.33 0.26 Metabolite levels; chr2:73622734 chr2:73644919~73685576:+ CESC cis rs7688540 0.771 rs4582105 ENSG00000211553.1 AC253576.2 -4.04 7.27e-05 0.0275 -0.42 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:252553 chr4:136461~136568:+ CESC cis rs9309473 1 rs7604682 ENSG00000163016.8 ALMS1P 4.04 7.27e-05 0.0275 0.33 0.26 Metabolite levels; chr2:73560899 chr2:73644919~73685576:+ CESC cis rs9309473 0.898 rs7580750 ENSG00000163016.8 ALMS1P 4.04 7.27e-05 0.0275 0.33 0.26 Metabolite levels; chr2:73560999 chr2:73644919~73685576:+ CESC cis rs10829156 0.66 rs10828901 ENSG00000240291.1 RP11-499P20.2 4.04 7.28e-05 0.0275 0.28 0.26 Sudden cardiac arrest; chr10:18552161 chr10:18513115~18545651:- CESC cis rs748404 0.723 rs512431 ENSG00000205771.5 CATSPER2P1 4.04 7.28e-05 0.0275 0.31 0.26 Lung cancer; chr15:43249741 chr15:43726918~43747094:- CESC cis rs2739330 0.76 rs5751760 ENSG00000228039.3 KB-1125A3.10 4.04 7.28e-05 0.0275 0.32 0.26 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23963780~23964374:+ CESC cis rs17772222 0.917 rs2004329 ENSG00000258983.2 RP11-507K2.2 4.04 7.28e-05 0.0275 0.33 0.26 Coronary artery calcification; chr14:88532965 chr14:88499334~88515502:+ CESC cis rs6693388 0.602 rs2999528 ENSG00000229021.2 AL591893.1 4.04 7.28e-05 0.0275 0.29 0.26 Blood metabolite ratios; chr1:151980409 chr1:151994531~152042774:+ CESC cis rs12489946 0.818 rs62408925 ENSG00000249407.1 IL20RB-AS1 -4.04 7.28e-05 0.0275 -0.3 -0.26 Initial pursuit acceleration; chr3:137071697 chr3:136959125~136982196:- CESC cis rs6142102 0.961 rs6120519 ENSG00000275784.1 RP5-1125A11.6 -4.04 7.28e-05 0.0275 -0.28 -0.26 Skin pigmentation; chr20:34100307 chr20:33989480~33991818:- CESC cis rs8020095 0.571 rs10136043 ENSG00000258561.1 RP11-72M17.1 -4.04 7.3e-05 0.0276 -0.39 -0.26 Depression (quantitative trait); chr14:66973521 chr14:66212810~66509394:- CESC cis rs10043775 1 rs3734120 ENSG00000251330.3 CTD-2283N19.1 -4.04 7.3e-05 0.0276 -0.34 -0.26 Periodontal microbiota; chr5:148441906 chr5:148430159~148430807:- CESC cis rs950880 0.553 rs3755272 ENSG00000234389.1 AC007278.3 -4.04 7.3e-05 0.0276 -0.31 -0.26 Serum protein levels (sST2); chr2:102417365 chr2:102438713~102440475:+ CESC cis rs8059260 0.611 rs34143079 ENSG00000274038.1 RP11-66H6.4 -4.04 7.3e-05 0.0276 -0.49 -0.26 Alcohol consumption over the past year; chr16:11069069 chr16:11056556~11057034:+ CESC cis rs8059260 0.541 rs7195452 ENSG00000274038.1 RP11-66H6.4 -4.04 7.3e-05 0.0276 -0.49 -0.26 Alcohol consumption over the past year; chr16:11069469 chr16:11056556~11057034:+ CESC cis rs7789940 0.857 rs12532935 ENSG00000230305.2 AC004980.9 4.04 7.3e-05 0.0276 0.39 0.26 Multiple sclerosis; chr7:76310381 chr7:76524515~76532692:+ CESC cis rs673078 0.66 rs61943524 ENSG00000275759.1 RP11-131L12.3 -4.04 7.3e-05 0.0276 -0.56 -0.26 Glucose homeostasis traits; chr12:118151530 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs17440315 ENSG00000275759.1 RP11-131L12.3 -4.04 7.3e-05 0.0276 -0.56 -0.26 Glucose homeostasis traits; chr12:118158819 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs73220119 ENSG00000275759.1 RP11-131L12.3 -4.04 7.3e-05 0.0276 -0.56 -0.26 Glucose homeostasis traits; chr12:118159864 chr12:118428281~118428870:+ CESC cis rs6142102 0.961 rs2268089 ENSG00000275784.1 RP5-1125A11.6 -4.04 7.3e-05 0.0276 -0.28 -0.26 Skin pigmentation; chr20:34079492 chr20:33989480~33991818:- CESC cis rs6142102 0.961 rs6119447 ENSG00000275784.1 RP5-1125A11.6 -4.04 7.3e-05 0.0276 -0.28 -0.26 Skin pigmentation; chr20:34080770 chr20:33989480~33991818:- CESC cis rs55794721 0.509 rs12027110 ENSG00000224183.1 SDHDP6 -4.04 7.3e-05 0.0276 -0.28 -0.26 Mean corpuscular volume;Plateletcrit; chr1:25449191 chr1:25294164~25294643:- CESC cis rs1871045 0.722 rs1871047 ENSG00000279103.1 CTC-204F22.1 4.04 7.31e-05 0.0276 0.29 0.26 Waist-to-hip circumference ratio (smoking years interaction); chr19:44848489 chr19:44246478~44248374:- CESC cis rs4272720 0.666 rs7070387 ENSG00000229870.1 RP11-507K13.6 -4.04 7.31e-05 0.0276 -0.31 -0.26 Platelet count;Plateletcrit; chr10:49058244 chr10:49815096~49815562:+ CESC cis rs9532669 0.963 rs9532681 ENSG00000239827.7 SUGT1P3 -4.04 7.32e-05 0.0276 -0.3 -0.26 Cervical cancer; chr13:40951633 chr13:40908159~40921774:- CESC cis rs9532669 0.926 rs4516083 ENSG00000239827.7 SUGT1P3 -4.04 7.32e-05 0.0276 -0.3 -0.26 Cervical cancer; chr13:40951783 chr13:40908159~40921774:- CESC cis rs911555 0.673 rs7144271 ENSG00000244691.1 RPL10AP1 -4.04 7.32e-05 0.0276 -0.36 -0.26 Intelligence (multi-trait analysis); chr14:103424337 chr14:103412119~103412761:- CESC cis rs948562 0.642 rs60483579 ENSG00000269570.2 CMB9-55A18.1 4.04 7.32e-05 0.0276 0.32 0.26 Lymphoma; chr11:58660991 chr11:58611119~58612642:- CESC cis rs9400467 0.537 rs12211045 ENSG00000271607.1 RP3-418A9.3 4.04 7.32e-05 0.0276 0.42 0.26 Amino acid levels;Blood metabolite levels; chr6:111176913 chr6:110863860~110864451:+ CESC cis rs673078 0.66 rs76621503 ENSG00000275759.1 RP11-131L12.3 -4.04 7.32e-05 0.0276 -0.56 -0.26 Glucose homeostasis traits; chr12:118179370 chr12:118428281~118428870:+ CESC cis rs875971 0.895 rs12698520 ENSG00000232559.3 GS1-124K5.12 4.04 7.32e-05 0.0276 0.29 0.26 Aortic root size; chr7:66453720 chr7:66554588~66576923:- CESC cis rs4272720 0.666 rs7896344 ENSG00000229870.1 RP11-507K13.6 -4.04 7.32e-05 0.0276 -0.3 -0.26 Platelet count;Plateletcrit; chr10:49052831 chr10:49815096~49815562:+ CESC cis rs2688608 0.592 rs10762560 ENSG00000242288.9 RP11-464F9.1 4.04 7.32e-05 0.0276 0.29 0.26 Inflammatory bowel disease; chr10:73735647 chr10:73674295~73730466:- CESC cis rs12468226 1 rs12472408 ENSG00000273456.1 RP11-686O6.2 4.04 7.33e-05 0.0277 0.35 0.26 Urate levels; chr2:202413973 chr2:202374932~202375604:- CESC cis rs75422866 0.764 rs73104188 ENSG00000280054.1 RP1-197B17.7 4.04 7.33e-05 0.0277 0.71 0.26 Pneumonia; chr12:47715885 chr12:47728151~47730598:- CESC cis rs55665837 1 rs12804549 ENSG00000251991.1 RNU7-49P 4.04 7.33e-05 0.0277 0.29 0.26 Vitamin D levels; chr11:14416212 chr11:14478892~14478953:+ CESC cis rs8067354 0.83 rs2453913 ENSG00000266992.1 DHX40P1 4.04 7.33e-05 0.0277 0.29 0.26 Hemoglobin concentration; chr17:59782789 chr17:59976009~60002384:- CESC cis rs10788972 0.873 rs4926619 ENSG00000225183.1 RP4-758J24.4 -4.04 7.34e-05 0.0277 -0.29 -0.26 Parkinson disease and lewy body pathology; chr1:54092428 chr1:54089856~54090093:+ CESC cis rs11971779 0.59 rs6467839 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139378044 chr7:139359032~139359566:- CESC cis rs11971779 0.618 rs10085814 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139379343 chr7:139359032~139359566:- CESC cis rs11971779 0.715 rs10085527 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139379614 chr7:139359032~139359566:- CESC cis rs11971779 0.65 rs10085842 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139379836 chr7:139359032~139359566:- CESC cis rs11971779 0.648 rs28754644 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139380311 chr7:139359032~139359566:- CESC cis rs11971779 0.715 rs6954219 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139380364 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6467840 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139380655 chr7:139359032~139359566:- CESC cis rs11971779 0.564 rs6467841 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139381346 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs7792752 ENSG00000273391.1 RP11-634H22.1 4.04 7.34e-05 0.0277 0.25 0.26 Diisocyanate-induced asthma; chr7:139381450 chr7:139359032~139359566:- CESC cis rs2115630 0.967 rs11073702 ENSG00000225151.9 GOLGA2P7 4.04 7.34e-05 0.0277 0.3 0.26 P wave terminal force; chr15:84766840 chr15:84199311~84230136:- CESC cis rs4319547 0.656 rs6488951 ENSG00000275265.1 RP11-15J22.8 -4.04 7.34e-05 0.0277 -0.37 -0.26 Body mass index; chr12:122389381 chr12:122501187~122501641:+ CESC cis rs2548724 0.716 rs62370977 ENSG00000250682.4 LINC00491 4.04 7.35e-05 0.0277 0.32 0.26 Type 2 diabetes; chr5:102433366 chr5:102609156~102671559:- CESC cis rs2688608 0.587 rs2894040 ENSG00000242288.9 RP11-464F9.1 4.04 7.35e-05 0.0277 0.29 0.26 Inflammatory bowel disease; chr10:73718401 chr10:73674295~73730466:- CESC cis rs2688608 0.592 rs3849967 ENSG00000242288.9 RP11-464F9.1 4.04 7.35e-05 0.0277 0.29 0.26 Inflammatory bowel disease; chr10:73723608 chr10:73674295~73730466:- CESC cis rs2688608 0.592 rs7909802 ENSG00000242288.9 RP11-464F9.1 4.04 7.35e-05 0.0277 0.29 0.26 Inflammatory bowel disease; chr10:73724428 chr10:73674295~73730466:- CESC cis rs2688608 0.592 rs11000758 ENSG00000242288.9 RP11-464F9.1 4.04 7.35e-05 0.0277 0.29 0.26 Inflammatory bowel disease; chr10:73733852 chr10:73674295~73730466:- CESC cis rs11096990 0.855 rs56275407 ENSG00000249207.1 RP11-360F5.1 4.04 7.35e-05 0.0277 0.34 0.26 Cognitive function; chr4:39177224 chr4:39112677~39126818:- CESC cis rs7243790 0.805 rs12604412 ENSG00000277324.1 RP11-850A17.1 -4.04 7.35e-05 0.0277 -0.3 -0.26 Diastolic blood pressure; chr18:54372922 chr18:54268346~54270028:- CESC cis rs34375054 0.624 rs7295689 ENSG00000279233.1 RP11-158L12.4 4.04 7.35e-05 0.0277 0.29 0.26 Post bronchodilator FEV1/FVC ratio; chr12:125196376 chr12:125138245~125141711:+ CESC cis rs348196 0.672 rs670876 ENSG00000225855.5 RUSC1-AS1 4.04 7.36e-05 0.0277 0.23 0.26 Breast cancer; chr1:155701887 chr1:155316863~155324176:- CESC cis rs1044826 0.642 rs6787649 ENSG00000178631.7 ACTG1P1 4.04 7.36e-05 0.0277 0.33 0.26 Obesity-related traits; chr3:139474479 chr3:139493809~139494937:+ CESC cis rs6452524 0.935 rs7736296 ENSG00000271862.1 RP11-343L5.2 -4.04 7.36e-05 0.0277 -0.24 -0.26 Hypertension (SNP x SNP interaction); chr5:83082421 chr5:83049376~83050964:- CESC cis rs8030379 1 rs1480827 ENSG00000230373.7 GOLGA6L5P -4.04 7.36e-05 0.0277 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83909040 chr15:84507885~84516814:- CESC cis rs11089937 0.626 rs5757013 ENSG00000211638.2 IGLV8-61 -4.04 7.36e-05 0.0277 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22135544 chr22:22098700~22099212:+ CESC cis rs11089937 0.626 rs5757014 ENSG00000211638.2 IGLV8-61 -4.04 7.36e-05 0.0277 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22135612 chr22:22098700~22099212:+ CESC cis rs62355900 0.627 rs61243567 ENSG00000271828.1 CTD-2310F14.1 4.04 7.36e-05 0.0277 0.41 0.26 Endometriosis; chr5:56867986 chr5:56927874~56929573:+ CESC cis rs17270561 0.779 rs1165200 ENSG00000272462.2 U91328.19 4.04 7.37e-05 0.0278 0.29 0.26 Iron status biomarkers; chr6:25874984 chr6:25992662~26001775:+ CESC cis rs2833693 0.574 rs9653707 ENSG00000256073.3 URB1-AS1 -4.04 7.37e-05 0.0278 -0.24 -0.26 Temperament; chr21:32179462 chr21:32393130~32393960:+ CESC cis rs1044826 0.642 rs2118981 ENSG00000178631.7 ACTG1P1 4.04 7.38e-05 0.0278 0.32 0.26 Obesity-related traits; chr3:139460011 chr3:139493809~139494937:+ CESC cis rs36093924 0.646 rs5996092 ENSG00000273366.1 CTA-989H11.1 4.04 7.38e-05 0.0278 0.33 0.26 Intelligence; chr22:41948404 chr22:42278188~42278846:+ CESC cis rs9309473 0.95 rs11126412 ENSG00000163016.8 ALMS1P 4.04 7.38e-05 0.0278 0.37 0.26 Metabolite levels; chr2:73660507 chr2:73644919~73685576:+ CESC cis rs1056107 0.7 rs10981292 ENSG00000225513.1 RP11-165N19.2 -4.04 7.38e-05 0.0278 -0.33 -0.26 Colorectal cancer; chr9:112168294 chr9:112173522~112173971:- CESC cis rs9487094 0.67 rs7755941 ENSG00000260273.1 RP11-425D10.10 4.04 7.38e-05 0.0278 0.34 0.26 Height; chr6:109494148 chr6:109382795~109383666:+ CESC cis rs10129255 0.957 rs4387509 ENSG00000211970.3 IGHV4-61 -4.04 7.39e-05 0.0278 -0.21 -0.26 Kawasaki disease; chr14:106704386 chr14:106639119~106639657:- CESC cis rs2439831 0.867 rs8039638 ENSG00000275601.1 AC011330.13 -4.04 7.39e-05 0.0279 -0.35 -0.26 Lung cancer in ever smokers; chr15:43342207 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs28415933 ENSG00000275601.1 AC011330.13 -4.04 7.39e-05 0.0279 -0.35 -0.26 Lung cancer in ever smokers; chr15:43343602 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs12324572 ENSG00000275601.1 AC011330.13 -4.04 7.39e-05 0.0279 -0.35 -0.26 Lung cancer in ever smokers; chr15:43344002 chr15:43642389~43643023:- CESC cis rs2617170 0.885 rs7975996 ENSG00000245648.1 RP11-277P12.20 4.04 7.4e-05 0.0279 0.36 0.26 Behcet's disease; chr12:10372324 chr12:10363769~10398506:+ CESC cis rs673078 0.66 rs61943535 ENSG00000275759.1 RP11-131L12.3 -4.04 7.4e-05 0.0279 -0.56 -0.26 Glucose homeostasis traits; chr12:118168307 chr12:118428281~118428870:+ CESC cis rs12701220 0.542 rs6957866 ENSG00000224079.1 AC091729.7 4.04 7.4e-05 0.0279 0.41 0.26 Bronchopulmonary dysplasia; chr7:1072038 chr7:1074450~1078036:+ CESC cis rs12701220 0.689 rs6973645 ENSG00000224079.1 AC091729.7 4.04 7.4e-05 0.0279 0.41 0.26 Bronchopulmonary dysplasia; chr7:1072610 chr7:1074450~1078036:+ CESC cis rs612683 0.735 rs10493923 ENSG00000261254.2 RP4-714D9.5 4.04 7.4e-05 0.0279 0.24 0.26 Breast cancer; chr1:100464698 chr1:100030566~100035637:+ CESC cis rs2235544 0.613 rs651381 ENSG00000225183.1 RP4-758J24.4 4.04 7.4e-05 0.0279 0.29 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:53985325 chr1:54089856~54090093:+ CESC cis rs11051970 0.879 rs73081911 ENSG00000255760.1 RP11-428G5.5 4.04 7.41e-05 0.0279 0.32 0.26 Response to tocilizumab in rheumatoid arthritis; chr12:32386190 chr12:31877079~31887203:- CESC cis rs1044826 0.692 rs188421 ENSG00000178631.7 ACTG1P1 -4.04 7.41e-05 0.0279 -0.32 -0.26 Obesity-related traits; chr3:139515224 chr3:139493809~139494937:+ CESC cis rs150992 0.536 rs10479348 ENSG00000248489.1 CTD-2007H13.3 -4.04 7.41e-05 0.0279 -0.37 -0.26 Body mass index; chr5:99013022 chr5:98929171~98995013:+ CESC cis rs2408955 0.522 rs3997 ENSG00000258273.1 RP11-370I10.4 4.04 7.41e-05 0.0279 0.31 0.26 Glycated hemoglobin levels; chr12:48087804 chr12:48333755~48333901:- CESC cis rs10129255 0.957 rs10141052 ENSG00000211974.3 IGHV2-70 4.04 7.42e-05 0.0279 0.26 0.26 Kawasaki disease; chr14:106776528 chr14:106723574~106724093:- CESC cis rs10129255 0.957 rs10141009 ENSG00000211974.3 IGHV2-70 4.04 7.42e-05 0.0279 0.26 0.26 Kawasaki disease; chr14:106776695 chr14:106723574~106724093:- CESC cis rs10129255 0.912 rs6576227 ENSG00000211974.3 IGHV2-70 4.04 7.42e-05 0.0279 0.26 0.26 Kawasaki disease; chr14:106778202 chr14:106723574~106724093:- CESC cis rs8020095 0.571 rs6573726 ENSG00000258561.1 RP11-72M17.1 -4.04 7.42e-05 0.0279 -0.39 -0.26 Depression (quantitative trait); chr14:66857810 chr14:66212810~66509394:- CESC cis rs2243480 1 rs2961102 ENSG00000164669.11 INTS4P1 4.04 7.42e-05 0.0279 0.54 0.26 Diabetic kidney disease; chr7:65959671 chr7:65141225~65234216:+ CESC cis rs2836950 0.565 rs7278297 ENSG00000255568.3 BRWD1-AS2 -4.04 7.42e-05 0.0279 -0.22 -0.26 Menarche (age at onset); chr21:39253826 chr21:39313935~39314962:+ CESC cis rs6683071 0.501 rs3002146 ENSG00000272750.1 RP11-378J18.8 4.04 7.42e-05 0.0279 0.37 0.26 Cognitive performance; chr1:222636066 chr1:222658867~222661512:- CESC cis rs67180937 0.553 rs1391557 ENSG00000272750.1 RP11-378J18.8 4.04 7.42e-05 0.0279 0.37 0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222636274 chr1:222658867~222661512:- CESC cis rs11098499 0.722 rs7673476 ENSG00000248280.1 RP11-33B1.2 4.04 7.43e-05 0.0279 0.29 0.26 Corneal astigmatism; chr4:119327528 chr4:119440561~119450157:- CESC cis rs875971 0.502 rs11769702 ENSG00000226824.5 RP4-756H11.3 -4.04 7.43e-05 0.0279 -0.38 -0.26 Aortic root size; chr7:66255529 chr7:66654538~66669855:+ CESC cis rs2486288 0.656 rs9921035 ENSG00000259932.1 CTD-2651B20.7 4.04 7.43e-05 0.0279 0.35 0.26 Glomerular filtration rate; chr15:45254462 chr15:45198517~45199139:- CESC cis rs7924176 0.58 rs7912162 ENSG00000213731.2 RAB5CP1 -4.04 7.44e-05 0.028 -0.29 -0.26 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74162005 chr10:74423435~74424014:- CESC cis rs7665090 0.846 rs4496586 ENSG00000246560.2 RP11-10L12.4 4.04 7.44e-05 0.028 0.35 0.26 Primary biliary cholangitis; chr4:102636154 chr4:102828055~102844075:+ CESC cis rs1124769 0.672 rs12050528 ENSG00000259378.1 DCAF13P3 4.04 7.44e-05 0.028 0.35 0.26 Cognitive performance; chr15:50810917 chr15:50944663~50945996:+ CESC cis rs8020095 0.571 rs8006371 ENSG00000258561.1 RP11-72M17.1 -4.04 7.44e-05 0.028 -0.39 -0.26 Depression (quantitative trait); chr14:66908624 chr14:66212810~66509394:- CESC cis rs8020095 0.528 rs7147570 ENSG00000258561.1 RP11-72M17.1 -4.04 7.44e-05 0.028 -0.39 -0.26 Depression (quantitative trait); chr14:66925186 chr14:66212810~66509394:- CESC cis rs8020095 0.528 rs7152422 ENSG00000258561.1 RP11-72M17.1 -4.04 7.44e-05 0.028 -0.39 -0.26 Depression (quantitative trait); chr14:66925540 chr14:66212810~66509394:- CESC cis rs1871045 0.786 rs1871046 ENSG00000279103.1 CTC-204F22.1 4.04 7.44e-05 0.028 0.29 0.26 Waist-to-hip circumference ratio (smoking years interaction); chr19:44848680 chr19:44246478~44248374:- CESC cis rs11159086 1 rs17100451 ENSG00000270000.1 RP3-449M8.9 4.04 7.44e-05 0.028 0.49 0.26 Advanced glycation end-product levels; chr14:74476210 chr14:74471930~74472360:- CESC cis rs11096990 0.855 rs2566173 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39151111 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2711988 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39151128 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2043102 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39151292 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2711986 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39152258 chr4:39112677~39126818:- CESC cis rs11096990 0.75 rs2465242 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39153796 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2465243 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39154036 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2566176 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39154373 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2566177 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39154558 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2566178 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39155194 chr4:39112677~39126818:- CESC cis rs11096990 0.819 rs2435528 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39155916 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2711933 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39156090 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2711934 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39156254 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2566179 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39156413 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2566180 ENSG00000249207.1 RP11-360F5.1 4.04 7.45e-05 0.028 0.34 0.26 Cognitive function; chr4:39157381 chr4:39112677~39126818:- CESC cis rs7727544 0.618 rs2631367 ENSG00000233006.5 AC034220.3 -4.04 7.45e-05 0.028 -0.31 -0.26 Blood metabolite levels; chr5:132369766 chr5:132311285~132369916:- CESC cis rs915071 0.686 rs8009524 ENSG00000258655.2 ARHGAP5-AS1 4.04 7.45e-05 0.028 0.31 0.26 Bipolar disorder and schizophrenia; chr14:31991193 chr14:32074946~32076793:- CESC cis rs17507216 0.718 rs17158403 ENSG00000276710.3 CSPG4P8 -4.04 7.46e-05 0.028 -0.38 -0.26 Excessive daytime sleepiness; chr15:82572478 chr15:82459472~82477258:+ CESC cis rs3213758 0.541 rs5005161 ENSG00000275191.1 RP11-36I17.2 -4.04 7.46e-05 0.028 -0.42 -0.26 Vitiligo (non-segmental); chr16:53664764 chr16:53628256~53628816:- CESC cis rs490234 0.812 rs13300639 ENSG00000232630.1 PRPS1P2 -4.04 7.46e-05 0.028 -0.23 -0.26 Mean arterial pressure; chr9:125645019 chr9:125150653~125151589:+ CESC cis rs875971 0.862 rs1983372 ENSG00000232559.3 GS1-124K5.12 -4.04 7.46e-05 0.028 -0.28 -0.26 Aortic root size; chr7:66146364 chr7:66554588~66576923:- CESC cis rs1865760 0.566 rs9348706 ENSG00000272462.2 U91328.19 -4.04 7.46e-05 0.028 -0.25 -0.26 Height; chr6:26065253 chr6:25992662~26001775:+ CESC cis rs673078 0.615 rs61943528 ENSG00000275759.1 RP11-131L12.3 -4.04 7.46e-05 0.028 -0.56 -0.26 Glucose homeostasis traits; chr12:118163134 chr12:118428281~118428870:+ CESC cis rs6693388 0.671 rs56170235 ENSG00000229021.2 AL591893.1 -4.04 7.47e-05 0.0281 -0.33 -0.26 Blood metabolite ratios; chr1:151900278 chr1:151994531~152042774:+ CESC cis rs6693388 0.713 rs57674198 ENSG00000229021.2 AL591893.1 -4.04 7.47e-05 0.0281 -0.33 -0.26 Blood metabolite ratios; chr1:151903597 chr1:151994531~152042774:+ CESC cis rs6693388 0.631 rs61817695 ENSG00000229021.2 AL591893.1 -4.04 7.47e-05 0.0281 -0.33 -0.26 Blood metabolite ratios; chr1:151907200 chr1:151994531~152042774:+ CESC cis rs2404602 0.692 rs2120108 ENSG00000280730.1 AC090181.1 -4.04 7.47e-05 0.0281 -0.21 -0.26 Blood metabolite levels; chr15:76577588 chr15:77056895~77057021:+ CESC cis rs10129255 0.784 rs7147210 ENSG00000211970.3 IGHV4-61 -4.04 7.47e-05 0.0281 -0.21 -0.26 Kawasaki disease; chr14:106705271 chr14:106639119~106639657:- CESC cis rs3748682 0.861 rs28411034 ENSG00000212541.1 RNU6-510P -4.04 7.47e-05 0.0281 -0.36 -0.26 Hypothyroidism; chr1:37811325 chr1:37991462~37991569:+ CESC cis rs3748682 0.821 rs12751325 ENSG00000212541.1 RNU6-510P -4.04 7.47e-05 0.0281 -0.36 -0.26 Hypothyroidism; chr1:37823711 chr1:37991462~37991569:+ CESC cis rs3748682 0.731 rs3891572 ENSG00000212541.1 RNU6-510P -4.04 7.47e-05 0.0281 -0.36 -0.26 Hypothyroidism; chr1:37833204 chr1:37991462~37991569:+ CESC cis rs10129255 0.912 rs35468694 ENSG00000280411.1 IGHV1-69-2 -4.04 7.47e-05 0.0281 -0.19 -0.26 Kawasaki disease; chr14:106784199 chr14:106762092~106762588:- CESC cis rs10129255 0.957 rs8019272 ENSG00000280411.1 IGHV1-69-2 -4.04 7.47e-05 0.0281 -0.19 -0.26 Kawasaki disease; chr14:106784709 chr14:106762092~106762588:- CESC cis rs67311347 1 rs2305522 ENSG00000223797.4 ENTPD3-AS1 4.04 7.47e-05 0.0281 0.26 0.26 Renal cell carcinoma; chr3:40387867 chr3:40313802~40453329:- CESC cis rs67311347 1 rs7636719 ENSG00000223797.4 ENTPD3-AS1 4.04 7.47e-05 0.0281 0.26 0.26 Renal cell carcinoma; chr3:40390593 chr3:40313802~40453329:- CESC cis rs2337406 0.706 rs74090742 ENSG00000211974.3 IGHV2-70 -4.04 7.47e-05 0.0281 -0.39 -0.26 Alzheimer's disease (late onset); chr14:106696601 chr14:106723574~106724093:- CESC cis rs2337406 1 rs61268362 ENSG00000211974.3 IGHV2-70 -4.04 7.47e-05 0.0281 -0.39 -0.26 Alzheimer's disease (late onset); chr14:106697010 chr14:106723574~106724093:- CESC cis rs2337406 0.85 rs8014460 ENSG00000211974.3 IGHV2-70 -4.04 7.47e-05 0.0281 -0.39 -0.26 Alzheimer's disease (late onset); chr14:106697140 chr14:106723574~106724093:- CESC cis rs2833693 0.574 rs4143359 ENSG00000256073.3 URB1-AS1 -4.04 7.48e-05 0.0281 -0.24 -0.26 Temperament; chr21:32179062 chr21:32393130~32393960:+ CESC cis rs763121 0.853 rs6001214 ENSG00000273076.1 RP3-508I15.22 4.04 7.48e-05 0.0281 0.3 0.26 Menopause (age at onset); chr22:38753150 chr22:38743495~38743910:+ CESC cis rs2404602 0.692 rs12910734 ENSG00000280730.1 AC090181.1 4.04 7.48e-05 0.0281 0.2 0.26 Blood metabolite levels; chr15:76857590 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs12911174 ENSG00000280730.1 AC090181.1 4.04 7.48e-05 0.0281 0.2 0.26 Blood metabolite levels; chr15:76857602 chr15:77056895~77057021:+ CESC cis rs2404602 0.669 rs17464903 ENSG00000280730.1 AC090181.1 4.04 7.48e-05 0.0281 0.2 0.26 Blood metabolite levels; chr15:76903145 chr15:77056895~77057021:+ CESC cis rs343092 0.507 rs2583923 ENSG00000276853.1 RP11-305O6.4 4.04 7.48e-05 0.0281 0.49 0.26 Type 2 diabetes; chr12:65779527 chr12:65171262~65171917:+ CESC cis rs343092 0.507 rs2260622 ENSG00000276853.1 RP11-305O6.4 4.04 7.48e-05 0.0281 0.49 0.26 Type 2 diabetes; chr12:65779766 chr12:65171262~65171917:+ CESC cis rs343092 0.507 rs2358950 ENSG00000276853.1 RP11-305O6.4 4.04 7.48e-05 0.0281 0.49 0.26 Type 2 diabetes; chr12:65779888 chr12:65171262~65171917:+ CESC cis rs853679 0.517 rs12332979 ENSG00000219392.1 RP1-265C24.5 -4.04 7.49e-05 0.0281 -0.35 -0.26 Depression; chr6:28173770 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs67878650 ENSG00000219392.1 RP1-265C24.5 -4.04 7.49e-05 0.0281 -0.35 -0.26 Depression; chr6:28174809 chr6:28115628~28116551:+ CESC cis rs853679 0.569 rs9348798 ENSG00000219392.1 RP1-265C24.5 -4.04 7.49e-05 0.0281 -0.35 -0.26 Depression; chr6:28175233 chr6:28115628~28116551:+ CESC cis rs853679 0.517 rs9380065 ENSG00000219392.1 RP1-265C24.5 -4.04 7.49e-05 0.0281 -0.35 -0.26 Depression; chr6:28176973 chr6:28115628~28116551:+ CESC cis rs7560272 0.723 rs7585119 ENSG00000273245.1 RP11-434P11.2 4.04 7.49e-05 0.0281 0.33 0.26 Schizophrenia; chr2:73497552 chr2:73750256~73750786:- CESC cis rs7560272 0.723 rs7562047 ENSG00000273245.1 RP11-434P11.2 4.04 7.49e-05 0.0281 0.33 0.26 Schizophrenia; chr2:73498041 chr2:73750256~73750786:- CESC cis rs2439831 1 rs561863 ENSG00000205771.5 CATSPER2P1 -4.04 7.49e-05 0.0281 -0.36 -0.26 Lung cancer in ever smokers; chr15:43469154 chr15:43726918~43747094:- CESC cis rs2439831 1 rs689596 ENSG00000205771.5 CATSPER2P1 -4.04 7.49e-05 0.0281 -0.36 -0.26 Lung cancer in ever smokers; chr15:43469519 chr15:43726918~43747094:- CESC cis rs2439831 0.867 rs689616 ENSG00000205771.5 CATSPER2P1 -4.04 7.49e-05 0.0281 -0.36 -0.26 Lung cancer in ever smokers; chr15:43469703 chr15:43726918~43747094:- CESC cis rs2439831 1 rs689647 ENSG00000205771.5 CATSPER2P1 -4.04 7.49e-05 0.0281 -0.36 -0.26 Lung cancer in ever smokers; chr15:43469998 chr15:43726918~43747094:- CESC cis rs2439831 1 rs101094 ENSG00000205771.5 CATSPER2P1 -4.04 7.49e-05 0.0281 -0.36 -0.26 Lung cancer in ever smokers; chr15:43495124 chr15:43726918~43747094:- CESC cis rs2439831 1 rs689781 ENSG00000205771.5 CATSPER2P1 -4.04 7.49e-05 0.0281 -0.36 -0.26 Lung cancer in ever smokers; chr15:43499899 chr15:43726918~43747094:- CESC cis rs2439831 1 rs2584725 ENSG00000205771.5 CATSPER2P1 -4.04 7.49e-05 0.0281 -0.36 -0.26 Lung cancer in ever smokers; chr15:43500937 chr15:43726918~43747094:- CESC cis rs9907295 1 rs9904675 ENSG00000271013.1 AC015849.15 -4.04 7.49e-05 0.0281 -0.37 -0.26 Fibroblast growth factor basic levels; chr17:35921435 chr17:35912635~35918010:- CESC cis rs2688608 0.592 rs7080579 ENSG00000242288.9 RP11-464F9.1 4.04 7.49e-05 0.0281 0.29 0.26 Inflammatory bowel disease; chr10:73744271 chr10:73674295~73730466:- CESC cis rs2439831 0.85 rs28413881 ENSG00000249839.1 AC011330.5 -4.04 7.49e-05 0.0281 -0.41 -0.26 Lung cancer in ever smokers; chr15:43881901 chr15:43663654~43684339:- CESC cis rs12144049 0.662 rs1923500 ENSG00000227045.1 RP11-98D18.1 -4.04 7.49e-05 0.0281 -0.37 -0.26 Inflammatory skin disease;Atopic dermatitis; chr1:152440549 chr1:151701026~151708386:+ CESC cis rs17301013 0.507 rs11802092 ENSG00000227373.4 RP11-160H22.5 4.04 7.5e-05 0.0281 0.35 0.26 Systemic lupus erythematosus; chr1:174601773 chr1:174115300~174160004:- CESC cis rs9341808 0.53 rs3805877 ENSG00000272129.1 RP11-250B2.6 4.04 7.5e-05 0.0281 0.3 0.26 Sitting height ratio; chr6:80321812 chr6:80355424~80356859:+ CESC cis rs9341808 0.53 rs3805876 ENSG00000272129.1 RP11-250B2.6 4.04 7.5e-05 0.0281 0.3 0.26 Sitting height ratio; chr6:80321822 chr6:80355424~80356859:+ CESC cis rs673078 0.66 rs17512219 ENSG00000275759.1 RP11-131L12.3 -4.04 7.5e-05 0.0282 -0.56 -0.26 Glucose homeostasis traits; chr12:118211468 chr12:118428281~118428870:+ CESC cis rs755249 0.567 rs61779306 ENSG00000228060.1 RP11-69E11.8 -4.04 7.51e-05 0.0282 -0.31 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39456754 chr1:39565160~39573203:+ CESC cis rs950776 0.518 rs12900783 ENSG00000279373.1 RP11-650L12.4 4.04 7.51e-05 0.0282 0.31 0.26 Sudden cardiac arrest; chr15:78523181 chr15:78537681~78538946:+ CESC cis rs950776 0.518 rs12594391 ENSG00000279373.1 RP11-650L12.4 4.04 7.51e-05 0.0282 0.31 0.26 Sudden cardiac arrest; chr15:78523898 chr15:78537681~78538946:+ CESC cis rs612683 0.735 rs3754131 ENSG00000261254.2 RP4-714D9.5 -4.04 7.51e-05 0.0282 -0.24 -0.26 Breast cancer; chr1:100465517 chr1:100030566~100035637:+ CESC cis rs2993535 1 rs4951436 ENSG00000233626.2 RP11-565J7.1 -4.04 7.51e-05 0.0282 -0.57 -0.26 Hip circumference adjusted for BMI; chr1:212062815 chr1:211936249~211936634:+ CESC cis rs9532669 0.963 rs4600338 ENSG00000176268.5 CYCSP34 4.04 7.51e-05 0.0282 0.27 0.26 Cervical cancer; chr13:40925175 chr13:40863599~40863902:- CESC cis rs6951245 0.542 rs28460147 ENSG00000229043.2 AC091729.9 -4.04 7.51e-05 0.0282 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1177556 chr7:1160374~1165267:+ CESC cis rs8030379 0.967 rs8028359 ENSG00000230373.7 GOLGA6L5P -4.04 7.52e-05 0.0282 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83906593 chr15:84507885~84516814:- CESC cis rs62025270 0.632 rs3169119 ENSG00000202081.1 RNU6-1280P -4.04 7.52e-05 0.0282 -0.37 -0.26 Idiopathic pulmonary fibrosis; chr15:85748038 chr15:85651522~85651628:- CESC cis rs9487094 0.67 rs1406899 ENSG00000260273.1 RP11-425D10.10 4.04 7.52e-05 0.0282 0.34 0.26 Height; chr6:109495102 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs11754455 ENSG00000260273.1 RP11-425D10.10 4.04 7.52e-05 0.0282 0.34 0.26 Height; chr6:109496680 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs2024849 ENSG00000260273.1 RP11-425D10.10 4.04 7.52e-05 0.0282 0.34 0.26 Height; chr6:109497088 chr6:109382795~109383666:+ CESC cis rs8020095 0.571 rs1138802 ENSG00000258561.1 RP11-72M17.1 -4.04 7.53e-05 0.0282 -0.39 -0.26 Depression (quantitative trait); chr14:66972952 chr14:66212810~66509394:- CESC cis rs7924176 0.601 rs12414280 ENSG00000213731.2 RAB5CP1 -4.04 7.53e-05 0.0282 -0.29 -0.26 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74174642 chr10:74423435~74424014:- CESC cis rs7746199 0.736 rs34573979 ENSG00000219392.1 RP1-265C24.5 -4.04 7.54e-05 0.0283 -0.53 -0.26 Gait speed in old age;Autism spectrum disorder or schizophrenia; chr6:27512747 chr6:28115628~28116551:+ CESC cis rs6928977 0.5 rs6925161 ENSG00000234084.1 RP3-388E23.2 -4.04 7.54e-05 0.0283 -0.23 -0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135615496 chr6:135301568~135307158:+ CESC cis rs11976180 1 rs2951308 ENSG00000273234.1 OR2A13P 4.04 7.54e-05 0.0283 0.32 0.26 Obesity-related traits; chr7:144070056 chr7:144142009~144142938:+ CESC cis rs8062405 0.558 rs231976 ENSG00000259982.1 CDC37P1 4.04 7.54e-05 0.0283 0.32 0.26 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534266 chr16:28700294~28701540:- CESC cis rs7246657 0.551 rs11084873 ENSG00000276846.1 CTD-3220F14.3 4.04 7.54e-05 0.0283 0.4 0.26 Coronary artery calcification; chr19:37093008 chr19:37314868~37315620:- CESC cis rs1799949 0.929 rs799906 ENSG00000267681.1 CTD-3199J23.6 -4.04 7.54e-05 0.0283 -0.32 -0.26 Menopause (age at onset); chr17:43126099 chr17:43144956~43145255:+ CESC cis rs1799949 0.965 rs799908 ENSG00000267681.1 CTD-3199J23.6 -4.04 7.54e-05 0.0283 -0.32 -0.26 Menopause (age at onset); chr17:43126899 chr17:43144956~43145255:+ CESC cis rs42490 0.57 rs454561 ENSG00000251136.7 RP11-37B2.1 -4.04 7.54e-05 0.0283 -0.27 -0.26 Leprosy; chr8:89824387 chr8:89609409~89757727:- CESC cis rs1552244 1 rs17032299 ENSG00000180385.7 EMC3-AS1 4.04 7.54e-05 0.0283 0.32 0.26 Alzheimer's disease; chr3:10045954 chr3:9986893~10006990:+ CESC cis rs1440410 0.835 rs7685075 ENSG00000250326.1 RP11-284M14.1 -4.04 7.54e-05 0.0283 -0.28 -0.26 Ischemic stroke; chr4:143133546 chr4:142933195~143184861:- CESC cis rs1440410 0.835 rs10155324 ENSG00000250326.1 RP11-284M14.1 -4.04 7.54e-05 0.0283 -0.28 -0.26 Ischemic stroke; chr4:143135820 chr4:142933195~143184861:- CESC cis rs1440410 0.835 rs6537150 ENSG00000250326.1 RP11-284M14.1 -4.04 7.54e-05 0.0283 -0.28 -0.26 Ischemic stroke; chr4:143146716 chr4:142933195~143184861:- CESC cis rs1440410 0.835 rs4337690 ENSG00000250326.1 RP11-284M14.1 -4.04 7.54e-05 0.0283 -0.28 -0.26 Ischemic stroke; chr4:143148408 chr4:142933195~143184861:- CESC cis rs1440410 0.835 rs13139558 ENSG00000250326.1 RP11-284M14.1 -4.04 7.54e-05 0.0283 -0.28 -0.26 Ischemic stroke; chr4:143149410 chr4:142933195~143184861:- CESC cis rs1440410 0.835 rs7670439 ENSG00000250326.1 RP11-284M14.1 -4.04 7.54e-05 0.0283 -0.28 -0.26 Ischemic stroke; chr4:143159114 chr4:142933195~143184861:- CESC cis rs1440410 0.835 rs10011709 ENSG00000250326.1 RP11-284M14.1 -4.04 7.54e-05 0.0283 -0.28 -0.26 Ischemic stroke; chr4:143159347 chr4:142933195~143184861:- CESC cis rs1440410 0.835 rs10015190 ENSG00000250326.1 RP11-284M14.1 -4.04 7.54e-05 0.0283 -0.28 -0.26 Ischemic stroke; chr4:143160595 chr4:142933195~143184861:- CESC cis rs8040855 0.627 rs11631548 ENSG00000259295.5 CSPG4P12 4.04 7.55e-05 0.0283 0.33 0.26 Bulimia nervosa; chr15:85076017 chr15:85191438~85213905:+ CESC cis rs875971 1 rs709597 ENSG00000237310.1 GS1-124K5.4 -4.04 7.55e-05 0.0283 -0.25 -0.26 Aortic root size; chr7:66360996 chr7:66493706~66495474:+ CESC cis rs7688540 0.656 rs79657896 ENSG00000211553.1 AC253576.2 -4.04 7.55e-05 0.0283 -0.4 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:305472 chr4:136461~136568:+ CESC cis rs7819412 0.521 rs10110684 ENSG00000255046.1 RP11-297N6.4 4.04 7.55e-05 0.0283 0.31 0.26 Triglycerides; chr8:11181650 chr8:11797928~11802568:- CESC cis rs7819412 0.54 rs2409726 ENSG00000255046.1 RP11-297N6.4 4.04 7.55e-05 0.0283 0.31 0.26 Triglycerides; chr8:11185629 chr8:11797928~11802568:- CESC cis rs72627123 0.867 rs73303116 ENSG00000270140.1 RP5-1021I20.6 -4.03 7.56e-05 0.0283 -0.61 -0.26 Morning vs. evening chronotype; chr14:74016912 chr14:73905267~73905636:+ CESC cis rs72627123 0.867 rs112464051 ENSG00000270140.1 RP5-1021I20.6 -4.03 7.56e-05 0.0283 -0.61 -0.26 Morning vs. evening chronotype; chr14:74017272 chr14:73905267~73905636:+ CESC cis rs72627123 0.867 rs58894370 ENSG00000270140.1 RP5-1021I20.6 -4.03 7.56e-05 0.0283 -0.61 -0.26 Morning vs. evening chronotype; chr14:74018679 chr14:73905267~73905636:+ CESC cis rs72627123 0.867 rs57731447 ENSG00000270140.1 RP5-1021I20.6 -4.03 7.56e-05 0.0283 -0.61 -0.26 Morning vs. evening chronotype; chr14:74020818 chr14:73905267~73905636:+ CESC cis rs72627123 0.867 rs57685514 ENSG00000270140.1 RP5-1021I20.6 -4.03 7.56e-05 0.0283 -0.61 -0.26 Morning vs. evening chronotype; chr14:74020889 chr14:73905267~73905636:+ CESC cis rs2725544 0.955 rs784410 ENSG00000273925.1 RP11-227D13.5 -4.03 7.56e-05 0.0283 -0.45 -0.26 Insomnia; chr15:48705579 chr15:48662531~48663056:- CESC cis rs1124769 0.719 rs2619692 ENSG00000259378.1 DCAF13P3 -4.03 7.57e-05 0.0283 -0.35 -0.26 Cognitive performance; chr15:50902968 chr15:50944663~50945996:+ CESC cis rs3213758 0.541 rs10852520 ENSG00000275191.1 RP11-36I17.2 -4.03 7.57e-05 0.0283 -0.42 -0.26 Vitiligo (non-segmental); chr16:53676961 chr16:53628256~53628816:- CESC cis rs67981189 0.542 rs17109053 ENSG00000269927.1 RP6-91H8.3 4.03 7.57e-05 0.0284 0.28 0.26 Schizophrenia; chr14:71142981 chr14:71141125~71143253:- CESC cis rs853679 0.513 rs13437444 ENSG00000219392.1 RP1-265C24.5 -4.03 7.57e-05 0.0284 -0.41 -0.26 Depression; chr6:28103220 chr6:28115628~28116551:+ CESC cis rs5758659 0.737 rs10854749 ENSG00000273366.1 CTA-989H11.1 -4.03 7.58e-05 0.0284 -0.34 -0.26 Cognitive function; chr22:42051337 chr22:42278188~42278846:+ CESC cis rs17772222 0.876 rs12587598 ENSG00000258983.2 RP11-507K2.2 4.03 7.58e-05 0.0284 0.31 0.26 Coronary artery calcification; chr14:88729474 chr14:88499334~88515502:+ CESC cis rs7688540 0.511 rs61794969 ENSG00000211553.1 AC253576.2 -4.03 7.58e-05 0.0284 -0.42 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:194242 chr4:136461~136568:+ CESC cis rs2688608 0.592 rs11000760 ENSG00000242288.9 RP11-464F9.1 4.03 7.58e-05 0.0284 0.29 0.26 Inflammatory bowel disease; chr10:73733976 chr10:73674295~73730466:- CESC cis rs7429990 0.965 rs796566 ENSG00000229759.1 MRPS18AP1 4.03 7.58e-05 0.0284 0.27 0.26 Educational attainment (years of education); chr3:47896864 chr3:48256350~48256938:- CESC cis rs875971 0.545 rs73142245 ENSG00000237310.1 GS1-124K5.4 4.03 7.58e-05 0.0284 0.3 0.26 Aortic root size; chr7:66226662 chr7:66493706~66495474:+ CESC cis rs9300255 0.544 rs1790123 ENSG00000235423.7 RP11-282O18.3 4.03 7.58e-05 0.0284 0.38 0.26 Neutrophil percentage of white cells; chr12:123174995 chr12:123252030~123261483:- CESC cis rs4722166 0.541 rs1800795 ENSG00000225541.1 AC002480.5 -4.03 7.59e-05 0.0284 -0.37 -0.26 Lung cancer; chr7:22727026 chr7:22571607~22661792:- CESC cis rs9326248 0.53 rs7121347 ENSG00000280143.1 AP000892.6 4.03 7.59e-05 0.0284 0.46 0.26 Blood protein levels; chr11:116996493 chr11:117204967~117210292:+ CESC cis rs10043775 0.915 rs10077690 ENSG00000251330.3 CTD-2283N19.1 -4.03 7.59e-05 0.0284 -0.36 -0.26 Periodontal microbiota; chr5:148409235 chr5:148430159~148430807:- CESC cis rs2836950 0.565 rs2150414 ENSG00000232608.1 TIMM9P2 4.03 7.59e-05 0.0284 0.29 0.26 Menarche (age at onset); chr21:39243062 chr21:39216624~39217506:+ CESC cis rs7688540 0.771 rs11723615 ENSG00000211553.1 AC253576.2 -4.03 7.59e-05 0.0284 -0.38 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:283194 chr4:136461~136568:+ CESC cis rs2898681 0.58 rs41279517 ENSG00000248375.1 RP11-177B4.1 -4.03 7.6e-05 0.0284 -0.5 -0.26 Optic nerve measurement (cup area); chr4:52863604 chr4:52720081~52720831:- CESC cis rs2898681 0.567 rs77657787 ENSG00000248375.1 RP11-177B4.1 -4.03 7.6e-05 0.0284 -0.5 -0.26 Optic nerve measurement (cup area); chr4:52863814 chr4:52720081~52720831:- CESC cis rs2404602 0.692 rs7169663 ENSG00000280730.1 AC090181.1 4.03 7.6e-05 0.0284 0.2 0.26 Blood metabolite levels; chr15:76900502 chr15:77056895~77057021:+ CESC cis rs1707322 1 rs946527 ENSG00000281133.1 AL355480.3 -4.03 7.6e-05 0.0284 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46020298 chr1:45580892~45580996:- CESC cis rs673078 0.66 rs17440433 ENSG00000275759.1 RP11-131L12.3 -4.03 7.6e-05 0.0284 -0.56 -0.26 Glucose homeostasis traits; chr12:118201507 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs73205531 ENSG00000275759.1 RP11-131L12.3 -4.03 7.6e-05 0.0284 -0.56 -0.26 Glucose homeostasis traits; chr12:118282063 chr12:118428281~118428870:+ CESC cis rs523522 0.962 rs603574 ENSG00000278344.1 RP11-18C24.8 4.03 7.6e-05 0.0284 0.32 0.26 High light scatter reticulocyte count; chr12:120560640 chr12:120500735~120501090:- CESC cis rs11685222 0.545 rs11684353 ENSG00000229326.3 AC069154.4 4.03 7.6e-05 0.0285 0.37 0.26 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119680939 chr2:119698623~119700151:+ CESC cis rs13385 0.769 rs7726349 ENSG00000202111.1 VTRNA1-2 4.03 7.61e-05 0.0285 0.37 0.26 Atrial fibrillation; chr5:140158186 chr5:140718925~140719013:+ CESC cis rs881375 0.933 rs4837804 ENSG00000226752.6 PSMD5-AS1 -4.03 7.61e-05 0.0285 -0.29 -0.26 Rheumatoid arthritis; chr9:120943026 chr9:120824828~120854385:+ CESC cis rs875971 0.502 rs1796227 ENSG00000236529.1 RP13-254B10.1 -4.03 7.61e-05 0.0285 -0.33 -0.26 Aortic root size; chr7:66622032 chr7:65840212~65840596:+ CESC cis rs35123781 0.654 rs356484 ENSG00000250635.1 CTD-3224K15.2 -4.03 7.61e-05 0.0285 -0.35 -0.26 Schizophrenia; chr5:139704853 chr5:139648999~139649728:- CESC cis rs2281636 0.723 rs2150916 ENSG00000233690.1 EBAG9P1 4.03 7.62e-05 0.0285 0.27 0.26 Obesity-related traits; chr10:99692737 chr10:99697407~99697949:- CESC cis rs11971779 0.68 rs7795520 ENSG00000273391.1 RP11-634H22.1 4.03 7.62e-05 0.0285 0.25 0.26 Diisocyanate-induced asthma; chr7:139394461 chr7:139359032~139359566:- CESC cis rs1775715 0.737 rs1419171 ENSG00000231245.2 C1DP1 -4.03 7.63e-05 0.0285 -0.34 -0.26 Bipolar disorder with mood-incongruent psychosis; chr10:31925903 chr10:32511336~32511737:- CESC cis rs72627509 0.629 rs1718824 ENSG00000269949.1 RP11-738E22.3 -4.03 7.64e-05 0.0286 -0.37 -0.26 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57037581 chr4:56960927~56961373:- CESC cis rs6141600 0.627 rs6579275 ENSG00000260032.1 LINC00657 -4.03 7.64e-05 0.0286 -0.39 -0.26 Height;Hip circumference; chr20:36065062 chr20:36045622~36050960:- CESC cis rs6556937 0.562 rs6897588 ENSG00000251314.2 CTD-2337A12.1 4.03 7.64e-05 0.0286 0.35 0.26 Blood protein levels; chr5:96667445 chr5:95962001~96631085:+ CESC cis rs7829975 0.659 rs4382480 ENSG00000253893.2 FAM85B -4.03 7.65e-05 0.0286 -0.33 -0.26 Mood instability; chr8:8863963 chr8:8167819~8226614:- CESC cis rs11971779 0.68 rs11765421 ENSG00000273391.1 RP11-634H22.1 4.03 7.65e-05 0.0286 0.25 0.26 Diisocyanate-induced asthma; chr7:139340348 chr7:139359032~139359566:- CESC cis rs7688540 0.8 rs12501727 ENSG00000211553.1 AC253576.2 -4.03 7.65e-05 0.0286 -0.35 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:294285 chr4:136461~136568:+ CESC cis rs2404602 0.692 rs12437733 ENSG00000280730.1 AC090181.1 4.03 7.65e-05 0.0286 0.2 0.26 Blood metabolite levels; chr15:76863221 chr15:77056895~77057021:+ CESC cis rs2404602 0.669 rs17367297 ENSG00000280730.1 AC090181.1 4.03 7.65e-05 0.0286 0.2 0.26 Blood metabolite levels; chr15:76865685 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs12913810 ENSG00000280730.1 AC090181.1 4.03 7.65e-05 0.0286 0.2 0.26 Blood metabolite levels; chr15:76874334 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs58889902 ENSG00000280730.1 AC090181.1 4.03 7.65e-05 0.0286 0.2 0.26 Blood metabolite levels; chr15:76880729 chr15:77056895~77057021:+ CESC cis rs76878669 0.561 rs7117630 ENSG00000255468.5 RP11-867G23.8 4.03 7.66e-05 0.0286 0.29 0.26 Educational attainment (years of education); chr11:66387306 chr11:66347950~66364804:+ CESC cis rs2276314 1 rs4799834 ENSG00000278986.1 RP11-723J4.3 -4.03 7.66e-05 0.0286 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35986280 chr18:35972151~35973916:+ CESC cis rs453301 0.571 rs2929454 ENSG00000253893.2 FAM85B 4.03 7.66e-05 0.0286 0.33 0.26 Joint mobility (Beighton score); chr8:9226344 chr8:8167819~8226614:- CESC cis rs13113518 0.729 rs13120134 ENSG00000249700.7 SRD5A3-AS1 4.03 7.66e-05 0.0286 0.34 0.26 Height; chr4:55415153 chr4:55363971~55395847:- CESC cis rs860295 0.557 rs10796944 ENSG00000232093.1 RP11-307C12.11 4.03 7.66e-05 0.0286 0.29 0.26 Body mass index; chr1:155446537 chr1:155045191~155046118:- CESC cis rs7508 0.512 rs3850750 ENSG00000253671.1 RP11-806O11.1 -4.03 7.66e-05 0.0286 -0.27 -0.26 Atrial fibrillation; chr8:18029238 chr8:17808941~17820868:+ CESC cis rs853679 0.769 rs17720293 ENSG00000219392.1 RP1-265C24.5 -4.03 7.66e-05 0.0286 -0.47 -0.26 Depression; chr6:28246920 chr6:28115628~28116551:+ CESC cis rs10129255 0.5 rs1024350 ENSG00000280411.1 IGHV1-69-2 -4.03 7.66e-05 0.0286 -0.18 -0.26 Kawasaki disease; chr14:106685105 chr14:106762092~106762588:- CESC cis rs4272720 0.535 rs17700872 ENSG00000229870.1 RP11-507K13.6 -4.03 7.66e-05 0.0286 -0.31 -0.26 Platelet count;Plateletcrit; chr10:49079822 chr10:49815096~49815562:+ CESC cis rs11157436 1 rs11157440 ENSG00000211812.1 TRAV26-2 -4.03 7.66e-05 0.0286 -0.3 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22181757 chr14:22202583~22203368:+ CESC cis rs7829975 0.617 rs4841071 ENSG00000254340.1 RP11-10A14.3 4.03 7.66e-05 0.0286 0.32 0.26 Mood instability; chr8:8933634 chr8:9141424~9145435:+ CESC cis rs2404602 0.71 rs2469541 ENSG00000280730.1 AC090181.1 -4.03 7.67e-05 0.0286 -0.21 -0.26 Blood metabolite levels; chr15:76269777 chr15:77056895~77057021:+ CESC cis rs7617773 0.817 rs9818937 ENSG00000228638.1 FCF1P2 -4.03 7.67e-05 0.0287 -0.28 -0.26 Coronary artery disease; chr3:48283791 chr3:48290793~48291375:- CESC cis rs2725544 1 rs2013682 ENSG00000273925.1 RP11-227D13.5 -4.03 7.67e-05 0.0287 -0.44 -0.26 Insomnia; chr15:48705447 chr15:48662531~48663056:- CESC cis rs1023500 0.552 rs5758566 ENSG00000273366.1 CTA-989H11.1 -4.03 7.67e-05 0.0287 -0.35 -0.26 Schizophrenia; chr22:42058350 chr22:42278188~42278846:+ CESC cis rs769267 0.965 rs10419245 ENSG00000269131.1 AC004447.2 -4.03 7.68e-05 0.0287 -0.22 -0.26 Tonsillectomy; chr19:19272946 chr19:18990893~18993610:+ CESC cis rs6439153 0.933 rs11711812 ENSG00000261159.1 RP11-723O4.9 4.03 7.68e-05 0.0287 0.27 0.26 Pneumococcal bacteremia; chr3:128989711 chr3:128859716~128860526:- CESC cis rs6439153 0.933 rs7648877 ENSG00000261159.1 RP11-723O4.9 4.03 7.68e-05 0.0287 0.27 0.26 Pneumococcal bacteremia; chr3:128991137 chr3:128859716~128860526:- CESC cis rs7829975 0.711 rs4841051 ENSG00000253893.2 FAM85B 4.03 7.68e-05 0.0287 0.33 0.26 Mood instability; chr8:8828136 chr8:8167819~8226614:- CESC cis rs10129255 0.872 rs1858683 ENSG00000224373.3 IGHV4-59 4.03 7.68e-05 0.0287 0.19 0.26 Kawasaki disease; chr14:106670217 chr14:106627249~106627825:- CESC cis rs10129255 0.872 rs8015406 ENSG00000224373.3 IGHV4-59 4.03 7.68e-05 0.0287 0.19 0.26 Kawasaki disease; chr14:106670611 chr14:106627249~106627825:- CESC cis rs5758659 0.716 rs86669 ENSG00000273366.1 CTA-989H11.1 -4.03 7.68e-05 0.0287 -0.32 -0.26 Cognitive function; chr22:42284794 chr22:42278188~42278846:+ CESC cis rs9322193 0.923 rs2342765 ENSG00000223701.3 RAET1E-AS1 4.03 7.69e-05 0.0287 0.31 0.26 Lung cancer; chr6:149858873 chr6:149884431~149919508:+ CESC cis rs17301013 0.507 rs16847337 ENSG00000227373.4 RP11-160H22.5 -4.03 7.69e-05 0.0287 -0.39 -0.26 Systemic lupus erythematosus; chr1:174683121 chr1:174115300~174160004:- CESC cis rs9847710 0.733 rs9818819 ENSG00000242142.1 SERBP1P3 4.03 7.69e-05 0.0287 0.31 0.26 Ulcerative colitis; chr3:53042739 chr3:53064283~53065091:- CESC cis rs71403859 0.57 rs76231867 ENSG00000260886.1 TAT-AS1 4.03 7.7e-05 0.0287 0.4 0.26 Post bronchodilator FEV1; chr16:71416023 chr16:71565789~71578187:+ CESC cis rs71403859 0.57 rs78972826 ENSG00000260886.1 TAT-AS1 4.03 7.7e-05 0.0287 0.4 0.26 Post bronchodilator FEV1; chr16:71420361 chr16:71565789~71578187:+ CESC cis rs7617773 0.779 rs11718329 ENSG00000228638.1 FCF1P2 -4.03 7.7e-05 0.0287 -0.28 -0.26 Coronary artery disease; chr3:48268338 chr3:48290793~48291375:- CESC cis rs748404 0.697 rs501884 ENSG00000249839.1 AC011330.5 -4.03 7.71e-05 0.0288 -0.27 -0.26 Lung cancer; chr15:43261784 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs504417 ENSG00000249839.1 AC011330.5 -4.03 7.71e-05 0.0288 -0.27 -0.26 Lung cancer; chr15:43262028 chr15:43663654~43684339:- CESC cis rs748404 0.723 rs560134 ENSG00000249839.1 AC011330.5 -4.03 7.71e-05 0.0288 -0.27 -0.26 Lung cancer; chr15:43263501 chr15:43663654~43684339:- CESC cis rs7247513 1 rs2042947 ENSG00000230310.1 CTD-2192J16.11 -4.03 7.71e-05 0.0288 -0.32 -0.26 Bipolar disorder; chr19:12582289 chr19:12552597~12553644:+ CESC cis rs9393777 0.513 rs7754159 ENSG00000241549.7 GUSBP2 4.03 7.72e-05 0.0288 0.34 0.26 Intelligence (multi-trait analysis); chr6:26620084 chr6:26871484~26956554:- CESC cis rs9379850 0.73 rs9393738 ENSG00000241549.7 GUSBP2 4.03 7.72e-05 0.0288 0.34 0.26 Intelligence (multi-trait analysis); chr6:26620430 chr6:26871484~26956554:- CESC cis rs2836950 0.501 rs62223052 ENSG00000255568.3 BRWD1-AS2 -4.03 7.73e-05 0.0288 -0.22 -0.26 Menarche (age at onset); chr21:39336776 chr21:39313935~39314962:+ CESC cis rs3096299 0.967 rs28644774 ENSG00000274627.1 RP11-104N10.2 4.03 7.73e-05 0.0288 0.26 0.26 Multiple myeloma (IgH translocation); chr16:89405773 chr16:89516797~89522217:+ CESC cis rs13108904 0.935 rs3755920 ENSG00000253399.1 AC078852.2 -4.03 7.73e-05 0.0288 -0.3 -0.26 Obesity-related traits; chr4:1249829 chr4:1358479~1359461:+ CESC cis rs11779988 0.545 rs436506 ENSG00000253671.1 RP11-806O11.1 4.03 7.73e-05 0.0288 0.33 0.26 Breast cancer; chr8:17940734 chr8:17808941~17820868:+ CESC cis rs11638352 1 rs890465 ENSG00000275601.1 AC011330.13 -4.03 7.74e-05 0.0289 -0.39 -0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44064265 chr15:43642389~43643023:- CESC cis rs11971779 0.616 rs1862878 ENSG00000273391.1 RP11-634H22.1 4.03 7.74e-05 0.0289 0.25 0.26 Diisocyanate-induced asthma; chr7:139335168 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6467837 ENSG00000273391.1 RP11-634H22.1 4.03 7.74e-05 0.0289 0.25 0.26 Diisocyanate-induced asthma; chr7:139338829 chr7:139359032~139359566:- CESC cis rs875971 1 rs2420591 ENSG00000232559.3 GS1-124K5.12 4.03 7.74e-05 0.0289 0.29 0.26 Aortic root size; chr7:66447394 chr7:66554588~66576923:- CESC cis rs3748682 0.861 rs28420383 ENSG00000212541.1 RNU6-510P -4.03 7.74e-05 0.0289 -0.36 -0.26 Hypothyroidism; chr1:37880733 chr1:37991462~37991569:+ CESC cis rs79243044 1 rs1995156 ENSG00000224295.2 AC087380.14 -4.03 7.75e-05 0.0289 -0.29 -0.26 QRS duration in Tripanosoma cruzi seropositivity; chr11:5544882 chr11:5518441~5524955:- CESC cis rs867371 1 rs7181655 ENSG00000255769.6 GOLGA2P10 -4.03 7.75e-05 0.0289 -0.3 -0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163275 chr15:82472993~82513950:- CESC cis rs867371 1 rs7180584 ENSG00000255769.6 GOLGA2P10 -4.03 7.75e-05 0.0289 -0.3 -0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163493 chr15:82472993~82513950:- CESC cis rs9322193 0.961 rs2064520 ENSG00000268592.3 RAET1E-AS1 4.03 7.75e-05 0.0289 0.33 0.26 Lung cancer; chr6:149603650 chr6:149863494~149919507:+ CESC cis rs12745968 0.619 rs10874738 ENSG00000223787.2 RP4-593M8.1 -4.03 7.76e-05 0.0289 -0.32 -0.26 Bipolar disorder and schizophrenia; chr1:92758662 chr1:92580476~92580821:- CESC cis rs12745968 0.685 rs11164807 ENSG00000223787.2 RP4-593M8.1 -4.03 7.76e-05 0.0289 -0.32 -0.26 Bipolar disorder and schizophrenia; chr1:92768538 chr1:92580476~92580821:- CESC cis rs673078 0.607 rs61946067 ENSG00000275759.1 RP11-131L12.3 -4.03 7.76e-05 0.0289 -0.56 -0.26 Glucose homeostasis traits; chr12:118303152 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs61946068 ENSG00000275759.1 RP11-131L12.3 -4.03 7.76e-05 0.0289 -0.56 -0.26 Glucose homeostasis traits; chr12:118305861 chr12:118428281~118428870:+ CESC cis rs1538970 0.816 rs868351 ENSG00000280836.1 AL355480.1 -4.03 7.76e-05 0.0289 -0.31 -0.26 Platelet count; chr1:45544146 chr1:45581219~45581321:- CESC cis rs1790761 0.505 rs7938563 ENSG00000201684.1 RN7SKP239 -4.03 7.76e-05 0.0289 -0.27 -0.26 Mean corpuscular volume; chr11:67536660 chr11:67362414~67362708:+ CESC cis rs1345301 1 rs12475055 ENSG00000234389.1 AC007278.3 4.03 7.76e-05 0.0289 0.26 0.26 Waist circumference; chr2:102262431 chr2:102438713~102440475:+ CESC cis rs1185460 0.546 rs2508948 ENSG00000271751.1 RP11-110I1.14 4.03 7.76e-05 0.0289 0.34 0.26 Coronary artery disease; chr11:119080932 chr11:119065263~119065677:- CESC cis rs2337406 1 rs1858677 ENSG00000211974.3 IGHV2-70 -4.03 7.76e-05 0.0289 -0.39 -0.26 Alzheimer's disease (late onset); chr14:106706828 chr14:106723574~106724093:- CESC cis rs6951245 0.81 rs117800627 ENSG00000229043.2 AC091729.9 -4.03 7.77e-05 0.029 -0.4 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1041439 chr7:1160374~1165267:+ CESC cis rs8062405 1 rs12446589 ENSG00000261067.5 RP11-264B17.3 4.03 7.77e-05 0.029 0.25 0.26 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859641 chr16:28974804~28990783:+ CESC cis rs11976180 1 rs2961144 ENSG00000273234.1 OR2A13P 4.03 7.77e-05 0.029 0.31 0.26 Obesity-related traits; chr7:144050777 chr7:144142009~144142938:+ CESC cis rs2548724 0.716 rs62371032 ENSG00000250682.4 LINC00491 4.03 7.77e-05 0.029 0.33 0.26 Type 2 diabetes; chr5:102477185 chr5:102609156~102671559:- CESC cis rs17818399 0.548 rs1989720 ENSG00000279254.1 RP11-536C12.1 -4.03 7.77e-05 0.029 -0.29 -0.26 Height; chr2:46627225 chr2:46668870~46670778:+ CESC cis rs17818399 0.62 rs7598578 ENSG00000279254.1 RP11-536C12.1 -4.03 7.77e-05 0.029 -0.29 -0.26 Height; chr2:46629946 chr2:46668870~46670778:+ CESC cis rs17818399 0.62 rs1598517 ENSG00000279254.1 RP11-536C12.1 -4.03 7.77e-05 0.029 -0.29 -0.26 Height; chr2:46630262 chr2:46668870~46670778:+ CESC cis rs17818399 0.62 rs6739397 ENSG00000279254.1 RP11-536C12.1 -4.03 7.77e-05 0.029 -0.29 -0.26 Height; chr2:46631182 chr2:46668870~46670778:+ CESC cis rs7976269 0.583 rs2117997 ENSG00000257176.2 RP11-996F15.2 4.03 7.77e-05 0.029 0.35 0.26 Male-pattern baldness; chr12:29143428 chr12:29280418~29317848:- CESC cis rs9601248 0.51 rs9601250 ENSG00000227676.3 LINC01068 4.03 7.77e-05 0.029 0.31 0.26 Major depressive disorder; chr13:79614567 chr13:79566727~79571436:+ CESC cis rs748404 0.697 rs530188 ENSG00000205771.5 CATSPER2P1 -4.03 7.77e-05 0.029 -0.31 -0.26 Lung cancer; chr15:43253116 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs475227 ENSG00000205771.5 CATSPER2P1 -4.03 7.77e-05 0.029 -0.31 -0.26 Lung cancer; chr15:43254248 chr15:43726918~43747094:- CESC cis rs62355901 0.505 rs62355944 ENSG00000271828.1 CTD-2310F14.1 4.03 7.78e-05 0.029 0.45 0.26 Breast cancer; chr5:56816871 chr5:56927874~56929573:+ CESC cis rs6969780 1 rs73071548 ENSG00000233429.8 HOTAIRM1 4.03 7.78e-05 0.029 0.37 0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27107811 chr7:27095647~27100265:+ CESC cis rs224278 0.531 rs953026 ENSG00000238280.1 RP11-436D10.3 -4.03 7.79e-05 0.029 -0.4 -0.26 Ewing sarcoma; chr10:62894442 chr10:62793562~62805887:- CESC cis rs673078 0.607 rs7309484 ENSG00000275759.1 RP11-131L12.3 -4.03 7.79e-05 0.029 -0.49 -0.26 Glucose homeostasis traits; chr12:118400833 chr12:118428281~118428870:+ CESC cis rs4974559 0.739 rs6599298 ENSG00000253399.1 AC078852.2 4.03 7.79e-05 0.029 0.44 0.26 Systolic blood pressure; chr4:1304334 chr4:1358479~1359461:+ CESC cis rs2299587 0.866 rs208765 ENSG00000253671.1 RP11-806O11.1 4.03 7.8e-05 0.029 0.27 0.26 Economic and political preferences; chr8:17947939 chr8:17808941~17820868:+ CESC cis rs6061231 0.624 rs8668 ENSG00000273619.1 RP5-908M14.9 4.03 7.8e-05 0.029 0.26 0.26 Colorectal cancer; chr20:62389008 chr20:62386303~62386970:- CESC cis rs9847710 0.838 rs2581795 ENSG00000242142.1 SERBP1P3 -4.03 7.8e-05 0.029 -0.28 -0.26 Ulcerative colitis; chr3:53004770 chr3:53064283~53065091:- CESC cis rs8081395 0.58 rs180515 ENSG00000266992.1 DHX40P1 4.03 7.8e-05 0.029 0.29 0.26 White blood cell count; chr17:59946914 chr17:59976009~60002384:- CESC cis rs11096990 0.855 rs3796524 ENSG00000249207.1 RP11-360F5.1 4.03 7.8e-05 0.029 0.33 0.26 Cognitive function; chr4:39194367 chr4:39112677~39126818:- CESC cis rs11096990 0.892 rs4974924 ENSG00000249207.1 RP11-360F5.1 4.03 7.8e-05 0.029 0.33 0.26 Cognitive function; chr4:39196091 chr4:39112677~39126818:- CESC cis rs2439831 0.702 rs495175 ENSG00000275601.1 AC011330.13 -4.03 7.8e-05 0.029 -0.36 -0.26 Lung cancer in ever smokers; chr15:43506486 chr15:43642389~43643023:- CESC cis rs875971 0.545 rs13311962 ENSG00000226824.5 RP4-756H11.3 4.03 7.81e-05 0.029 0.37 0.26 Aortic root size; chr7:66603142 chr7:66654538~66669855:+ CESC cis rs9907295 0.818 rs4796115 ENSG00000271013.1 AC015849.15 -4.03 7.81e-05 0.029 -0.36 -0.26 Fibroblast growth factor basic levels; chr17:35841315 chr17:35912635~35918010:- CESC cis rs801193 1 rs2659915 ENSG00000222364.1 RNU6-96P -4.03 7.81e-05 0.029 -0.31 -0.26 Aortic root size; chr7:66688114 chr7:66395191~66395286:+ CESC cis rs988913 1 rs960834 ENSG00000224984.1 RP11-524H19.2 4.03 7.81e-05 0.029 0.28 0.26 Menarche (age at onset); chr6:54958633 chr6:54840118~54840855:- CESC cis rs748404 0.697 rs546722 ENSG00000205771.5 CATSPER2P1 -4.03 7.81e-05 0.0291 -0.31 -0.26 Lung cancer; chr15:43288621 chr15:43726918~43747094:- CESC cis rs853679 1 rs9986596 ENSG00000219392.1 RP1-265C24.5 -4.03 7.81e-05 0.0291 -0.41 -0.26 Depression; chr6:28251883 chr6:28115628~28116551:+ CESC cis rs7560272 0.538 rs17434655 ENSG00000273245.1 RP11-434P11.2 4.03 7.81e-05 0.0291 0.32 0.26 Schizophrenia; chr2:73695962 chr2:73750256~73750786:- CESC cis rs523522 0.962 rs4767905 ENSG00000278344.1 RP11-18C24.8 4.03 7.82e-05 0.0291 0.32 0.26 High light scatter reticulocyte count; chr12:120493032 chr12:120500735~120501090:- CESC cis rs7572733 0.773 rs13427590 ENSG00000222017.1 AC011997.1 4.03 7.82e-05 0.0291 0.3 0.26 Dermatomyositis; chr2:197652097 chr2:197693106~197774823:+ CESC cis rs13434995 0.589 rs496055 ENSG00000273257.1 RP11-177J6.1 -4.03 7.82e-05 0.0291 -0.38 -0.26 Adiponectin levels; chr4:55383670 chr4:55387949~55388271:+ CESC cis rs2243480 1 rs402418 ENSG00000275400.1 RP4-756H11.5 4.03 7.83e-05 0.0291 0.44 0.26 Diabetic kidney disease; chr7:66044482 chr7:66553805~66554199:- CESC cis rs2243480 1 rs431318 ENSG00000275400.1 RP4-756H11.5 4.03 7.83e-05 0.0291 0.44 0.26 Diabetic kidney disease; chr7:66046610 chr7:66553805~66554199:- CESC cis rs10129255 1 rs9324091 ENSG00000211970.3 IGHV4-61 -4.03 7.84e-05 0.0292 -0.2 -0.26 Kawasaki disease; chr14:106676625 chr14:106639119~106639657:- CESC cis rs133885 1 rs133885 ENSG00000100058.11 CRYBB2P1 4.03 7.84e-05 0.0292 0.29 0.26 Mathematical ability in children with dyslexia; chr22:25763322 chr22:25448105~25520854:+ CESC cis rs7174755 0.637 rs10152713 ENSG00000260657.2 RP11-315D16.4 -4.03 7.85e-05 0.0292 -0.31 -0.26 Major depressive disorder; chr15:68179553 chr15:68267792~68277994:- CESC cis rs2839627 0.85 rs73220903 ENSG00000215458.7 AATBC -4.03 7.85e-05 0.0292 -0.35 -0.26 Information processing speed; chr21:43047405 chr21:43805758~43812567:- CESC cis rs8072100 0.807 rs4561509 ENSG00000228782.6 CTD-2026D20.3 4.03 7.85e-05 0.0292 0.31 0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47704433 chr17:47450568~47492492:- CESC cis rs13028485 0.5 rs631051 ENSG00000271151.1 RP11-394I13.2 4.03 7.85e-05 0.0292 0.36 0.26 Multiple myeloma (IgH translocation); chr2:173669117 chr2:173968351~173969418:+ CESC cis rs8040855 0.627 rs4980357 ENSG00000259295.5 CSPG4P12 4.03 7.86e-05 0.0292 0.32 0.26 Bulimia nervosa; chr15:85064878 chr15:85191438~85213905:+ CESC cis rs8040855 0.627 rs4980356 ENSG00000259295.5 CSPG4P12 4.03 7.86e-05 0.0292 0.32 0.26 Bulimia nervosa; chr15:85064901 chr15:85191438~85213905:+ CESC cis rs3768617 0.706 rs6678517 ENSG00000224468.3 RP11-181K3.4 -4.03 7.86e-05 0.0292 -0.26 -0.26 Fuchs's corneal dystrophy; chr1:183033504 chr1:183138402~183141282:- CESC cis rs7572733 0.711 rs6728904 ENSG00000222017.1 AC011997.1 4.03 7.86e-05 0.0292 0.3 0.26 Dermatomyositis; chr2:197628113 chr2:197693106~197774823:+ CESC cis rs10936632 0.565 rs6794467 ENSG00000242578.1 RP11-469J4.3 -4.03 7.86e-05 0.0292 -0.29 -0.26 Prostate cancer; chr3:170430203 chr3:170410512~170418615:+ CESC cis rs79243044 1 rs10838277 ENSG00000224295.2 AC087380.14 -4.03 7.86e-05 0.0292 -0.28 -0.26 QRS duration in Tripanosoma cruzi seropositivity; chr11:5534321 chr11:5518441~5524955:- CESC cis rs9309473 1 rs11899740 ENSG00000163016.8 ALMS1P 4.03 7.86e-05 0.0292 0.36 0.26 Metabolite levels; chr2:73404084 chr2:73644919~73685576:+ CESC cis rs2255336 0.817 rs4764430 ENSG00000245648.1 RP11-277P12.20 4.03 7.86e-05 0.0292 0.44 0.26 Blood protein levels; chr12:10365209 chr12:10363769~10398506:+ CESC cis rs62445005 1 rs62445005 ENSG00000211699.2 TRGV3 4.02 7.86e-05 0.0292 0.25 0.26 Shingles; chr7:38346957 chr7:38358512~38359162:- CESC cis rs8030379 1 rs2401176 ENSG00000230373.7 GOLGA6L5P -4.02 7.86e-05 0.0292 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83909612 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2401179 ENSG00000230373.7 GOLGA6L5P -4.02 7.86e-05 0.0292 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83910196 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2401180 ENSG00000230373.7 GOLGA6L5P -4.02 7.86e-05 0.0292 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83910434 chr15:84507885~84516814:- CESC cis rs2243480 0.522 rs1638736 ENSG00000232559.3 GS1-124K5.12 4.02 7.87e-05 0.0292 0.48 0.26 Diabetic kidney disease; chr7:66627321 chr7:66554588~66576923:- CESC cis rs2439831 0.702 rs7171750 ENSG00000249839.1 AC011330.5 -4.02 7.87e-05 0.0292 -0.38 -0.26 Lung cancer in ever smokers; chr15:43733660 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs28718261 ENSG00000249839.1 AC011330.5 -4.02 7.87e-05 0.0292 -0.38 -0.26 Lung cancer in ever smokers; chr15:43751595 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs10163054 ENSG00000249839.1 AC011330.5 -4.02 7.87e-05 0.0292 -0.38 -0.26 Lung cancer in ever smokers; chr15:43755440 chr15:43663654~43684339:- CESC cis rs6782228 0.606 rs6439135 ENSG00000242551.2 POU5F1P6 -4.02 7.89e-05 0.0293 -0.29 -0.26 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128639790 chr3:128674735~128677005:- CESC cis rs4072705 0.586 rs7023736 ENSG00000224020.1 MIR181A2HG -4.02 7.89e-05 0.0293 -0.33 -0.26 Menarche (age at onset); chr9:124485667 chr9:124658467~124698631:+ CESC cis rs6844153 0.715 rs73813220 ENSG00000240005.4 RP11-293A21.1 -4.02 7.89e-05 0.0293 -0.35 -0.26 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26920224 chr4:26859806~26860599:- CESC cis rs8062405 0.573 rs11645306 ENSG00000261067.5 RP11-264B17.3 -4.02 7.89e-05 0.0293 -0.26 -0.26 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28972615 chr16:28974804~28990783:+ CESC cis rs9517320 0.935 rs1886089 ENSG00000231194.1 FARP1-AS1 4.02 7.9e-05 0.0293 0.3 0.26 Longevity; chr13:98472102 chr13:98435405~98435840:- CESC cis rs6951245 0.935 rs79143504 ENSG00000229043.2 AC091729.9 -4.02 7.91e-05 0.0293 -0.4 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1070576 chr7:1160374~1165267:+ CESC cis rs673078 0.66 rs61945190 ENSG00000275759.1 RP11-131L12.3 -4.02 7.91e-05 0.0293 -0.55 -0.26 Glucose homeostasis traits; chr12:118231345 chr12:118428281~118428870:+ CESC cis rs673078 0.66 rs7977403 ENSG00000275759.1 RP11-131L12.3 -4.02 7.91e-05 0.0293 -0.55 -0.26 Glucose homeostasis traits; chr12:118233446 chr12:118428281~118428870:+ CESC cis rs9341808 0.556 rs1474791 ENSG00000272129.1 RP11-250B2.6 4.02 7.91e-05 0.0293 0.3 0.26 Sitting height ratio; chr6:80323380 chr6:80355424~80356859:+ CESC cis rs2235544 0.664 rs55766128 ENSG00000225183.1 RP4-758J24.4 -4.02 7.91e-05 0.0293 -0.29 -0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54012053 chr1:54089856~54090093:+ CESC cis rs7665090 0.87 rs228614 ENSG00000246560.2 RP11-10L12.4 -4.02 7.92e-05 0.0294 -0.32 -0.26 Primary biliary cholangitis; chr4:102657480 chr4:102828055~102844075:+ CESC cis rs7829975 0.617 rs4841072 ENSG00000253893.2 FAM85B 4.02 7.92e-05 0.0294 0.33 0.26 Mood instability; chr8:8933743 chr8:8167819~8226614:- CESC cis rs113835537 0.808 rs10896128 ENSG00000255517.5 CTD-3074O7.5 -4.02 7.92e-05 0.0294 -0.38 -0.26 Airway imaging phenotypes; chr11:66557058 chr11:66473490~66480233:- CESC cis rs7829975 0.658 rs907181 ENSG00000253893.2 FAM85B -4.02 7.92e-05 0.0294 -0.32 -0.26 Mood instability; chr8:8845365 chr8:8167819~8226614:- CESC cis rs703842 1 rs10747783 ENSG00000270039.1 RP11-571M6.17 -4.02 7.94e-05 0.0294 -0.32 -0.26 Multiple sclerosis; chr12:57782831 chr12:57803838~57804415:+ CESC cis rs703842 0.964 rs10431552 ENSG00000270039.1 RP11-571M6.17 -4.02 7.94e-05 0.0294 -0.32 -0.26 Multiple sclerosis; chr12:57784365 chr12:57803838~57804415:+ CESC cis rs2790457 0.958 rs1265829 ENSG00000254635.4 WAC-AS1 -4.02 7.95e-05 0.0294 -0.3 -0.26 Multiple myeloma; chr10:28622374 chr10:28522652~28532743:- CESC cis rs9322193 0.607 rs9322229 ENSG00000268592.3 RAET1E-AS1 4.02 7.95e-05 0.0295 0.38 0.26 Lung cancer; chr6:149908949 chr6:149863494~149919507:+ CESC cis rs453301 0.686 rs6987107 ENSG00000173295.6 FAM86B3P -4.02 7.95e-05 0.0295 -0.34 -0.26 Joint mobility (Beighton score); chr8:9036071 chr8:8228595~8244865:+ CESC cis rs2439831 1 rs690436 ENSG00000205771.5 CATSPER2P1 -4.02 7.95e-05 0.0295 -0.37 -0.26 Lung cancer in ever smokers; chr15:43469007 chr15:43726918~43747094:- CESC cis rs2439831 1 rs2264239 ENSG00000205771.5 CATSPER2P1 -4.02 7.95e-05 0.0295 -0.37 -0.26 Lung cancer in ever smokers; chr15:43473335 chr15:43726918~43747094:- CESC cis rs71403859 0.73 rs12447672 ENSG00000260886.1 TAT-AS1 4.02 7.95e-05 0.0295 0.42 0.26 Post bronchodilator FEV1; chr16:71681228 chr16:71565789~71578187:+ CESC cis rs2019137 0.56 rs4849179 ENSG00000274877.1 RP11-65I12.1 -4.02 7.96e-05 0.0295 -0.34 -0.26 Lymphocyte counts; chr2:113227593 chr2:113237595~113240825:+ CESC cis rs769267 0.93 rs2315022 ENSG00000269131.1 AC004447.2 -4.02 7.96e-05 0.0295 -0.21 -0.26 Tonsillectomy; chr19:19302572 chr19:18990893~18993610:+ CESC cis rs9322193 0.566 rs4870118 ENSG00000268592.3 RAET1E-AS1 -4.02 7.96e-05 0.0295 -0.4 -0.26 Lung cancer; chr6:149923877 chr6:149863494~149919507:+ CESC cis rs9322193 0.566 rs4869767 ENSG00000268592.3 RAET1E-AS1 -4.02 7.96e-05 0.0295 -0.4 -0.26 Lung cancer; chr6:149923974 chr6:149863494~149919507:+ CESC cis rs9322193 0.566 rs4869768 ENSG00000268592.3 RAET1E-AS1 -4.02 7.96e-05 0.0295 -0.4 -0.26 Lung cancer; chr6:149924067 chr6:149863494~149919507:+ CESC cis rs1538970 1 rs9326141 ENSG00000280836.1 AL355480.1 4.02 7.98e-05 0.0295 0.32 0.26 Platelet count; chr1:45363271 chr1:45581219~45581321:- CESC cis rs10170310 0.872 rs62161711 ENSG00000228043.4 AC097721.2 4.02 7.98e-05 0.0296 0.37 0.26 Response to antipsychotic treatment; chr2:138501652 chr2:138418284~138501698:- CESC cis rs8072100 0.869 rs4439799 ENSG00000228782.6 CTD-2026D20.3 4.02 7.98e-05 0.0296 0.31 0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47704233 chr17:47450568~47492492:- CESC cis rs12144049 0.705 rs4240881 ENSG00000227045.1 RP11-98D18.1 -4.02 7.99e-05 0.0296 -0.4 -0.26 Inflammatory skin disease;Atopic dermatitis; chr1:152442504 chr1:151701026~151708386:+ CESC cis rs17301013 0.507 rs3118990 ENSG00000227373.4 RP11-160H22.5 -4.02 7.99e-05 0.0296 -0.35 -0.26 Systemic lupus erythematosus; chr1:174818586 chr1:174115300~174160004:- CESC cis rs7246657 0.55 rs10411176 ENSG00000276846.1 CTD-3220F14.3 4.02 7.99e-05 0.0296 0.43 0.26 Coronary artery calcification; chr19:37196051 chr19:37314868~37315620:- CESC cis rs11685222 0.513 rs116092847 ENSG00000229326.3 AC069154.4 4.02 7.99e-05 0.0296 0.38 0.26 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119661848 chr2:119698623~119700151:+ CESC cis rs72820985 1 rs74030461 ENSG00000260896.4 RP11-314O13.1 -4.02 7.99e-05 0.0296 -0.48 -0.26 Breast cancer; chr16:80807224 chr16:80828735~80892595:- CESC cis rs224278 0.531 rs4746745 ENSG00000238280.1 RP11-436D10.3 -4.02 8e-05 0.0296 -0.4 -0.26 Ewing sarcoma; chr10:62939583 chr10:62793562~62805887:- CESC cis rs9826463 0.68 rs9849461 ENSG00000240950.1 RP11-372E1.1 -4.02 8e-05 0.0296 -0.23 -0.26 QRS duration in Tripanosoma cruzi seropositivity; chr3:142808328 chr3:142827096~142827728:- CESC cis rs1075265 0.783 rs805450 ENSG00000233266.1 HMGB1P31 4.02 8.01e-05 0.0296 0.34 0.26 Chronotype;Morning vs. evening chronotype; chr2:53951772 chr2:54051334~54051760:+ CESC cis rs783540 0.9 rs12916980 ENSG00000278603.1 RP13-608F4.5 -4.02 8.01e-05 0.0296 -0.32 -0.26 Schizophrenia; chr15:82637696 chr15:82472203~82472426:+ CESC cis rs73173548 0.502 rs6452789 ENSG00000247828.6 TMEM161B-AS1 4.02 8.02e-05 0.0297 0.28 0.26 Macular telangiectasia type 2; chr5:88429498 chr5:88268895~88436685:+ CESC cis rs2276314 1 rs9304153 ENSG00000278986.1 RP11-723J4.3 -4.02 8.02e-05 0.0297 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35982187 chr18:35972151~35973916:+ CESC cis rs2276314 1 rs9304154 ENSG00000278986.1 RP11-723J4.3 -4.02 8.02e-05 0.0297 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35982264 chr18:35972151~35973916:+ CESC cis rs8030379 1 rs11259932 ENSG00000230373.7 GOLGA6L5P -4.02 8.02e-05 0.0297 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83911305 chr15:84507885~84516814:- CESC cis rs8030379 1 rs11259934 ENSG00000230373.7 GOLGA6L5P -4.02 8.02e-05 0.0297 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83911419 chr15:84507885~84516814:- CESC cis rs8030379 1 rs11259935 ENSG00000230373.7 GOLGA6L5P -4.02 8.02e-05 0.0297 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83911675 chr15:84507885~84516814:- CESC cis rs8030379 1 rs12914857 ENSG00000230373.7 GOLGA6L5P -4.02 8.02e-05 0.0297 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83912414 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2055712 ENSG00000230373.7 GOLGA6L5P -4.02 8.02e-05 0.0297 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83912853 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2061999 ENSG00000230373.7 GOLGA6L5P -4.02 8.02e-05 0.0297 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83913988 chr15:84507885~84516814:- CESC cis rs8030379 1 rs3934135 ENSG00000230373.7 GOLGA6L5P -4.02 8.02e-05 0.0297 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83915047 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2030838 ENSG00000230373.7 GOLGA6L5P -4.02 8.02e-05 0.0297 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83915058 chr15:84507885~84516814:- CESC cis rs7924176 0.549 rs2395076 ENSG00000213731.2 RAB5CP1 -4.02 8.03e-05 0.0297 -0.29 -0.26 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74172081 chr10:74423435~74424014:- CESC cis rs2243480 1 rs3885839 ENSG00000164669.11 INTS4P1 4.02 8.03e-05 0.0297 0.53 0.26 Diabetic kidney disease; chr7:65825416 chr7:65141225~65234216:+ CESC cis rs116095464 1 rs1567956 ENSG00000250848.1 CTD-2083E4.5 -4.02 8.03e-05 0.0297 -0.44 -0.26 Breast cancer; chr5:315501 chr5:288833~290321:- CESC cis rs875971 0.862 rs2420174 ENSG00000232559.3 GS1-124K5.12 -4.02 8.03e-05 0.0297 -0.28 -0.26 Aortic root size; chr7:66180374 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs2420173 ENSG00000232559.3 GS1-124K5.12 -4.02 8.03e-05 0.0297 -0.28 -0.26 Aortic root size; chr7:66180412 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs4718319 ENSG00000232559.3 GS1-124K5.12 -4.02 8.03e-05 0.0297 -0.28 -0.26 Aortic root size; chr7:66187797 chr7:66554588~66576923:- CESC cis rs875971 0.723 rs28391294 ENSG00000232559.3 GS1-124K5.12 -4.02 8.03e-05 0.0297 -0.28 -0.26 Aortic root size; chr7:66189328 chr7:66554588~66576923:- CESC cis rs875971 0.83 rs6967708 ENSG00000232559.3 GS1-124K5.12 -4.02 8.03e-05 0.0297 -0.28 -0.26 Aortic root size; chr7:66192326 chr7:66554588~66576923:- CESC cis rs875971 0.895 rs7782806 ENSG00000232559.3 GS1-124K5.12 -4.02 8.03e-05 0.0297 -0.28 -0.26 Aortic root size; chr7:66192910 chr7:66554588~66576923:- CESC cis rs853679 0.517 rs17711344 ENSG00000219392.1 RP1-265C24.5 4.02 8.03e-05 0.0297 0.34 0.26 Depression; chr6:28109824 chr6:28115628~28116551:+ CESC cis rs7714584 1 rs11167526 ENSG00000197083.10 ZNF300P1 4.02 8.04e-05 0.0297 0.59 0.26 Crohn's disease; chr5:150952919 chr5:150930645~150946289:- CESC cis rs916888 0.773 rs199534 ENSG00000232300.1 FAM215B 4.02 8.04e-05 0.0297 0.42 0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46558830~46562795:- CESC cis rs71403859 0.667 rs12924650 ENSG00000260886.1 TAT-AS1 4.02 8.04e-05 0.0297 0.43 0.26 Post bronchodilator FEV1; chr16:71672005 chr16:71565789~71578187:+ CESC cis rs2136613 0.533 rs1571922 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62851189 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10822066 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62851432 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10740091 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62851628 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10822067 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62851949 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10761669 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62852050 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10509173 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62852129 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10822068 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62852505 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10822069 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62853482 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10995331 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62853948 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10822070 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62854149 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs4141617 ENSG00000238280.1 RP11-436D10.3 -4.02 8.04e-05 0.0297 -0.3 -0.26 Selective IgA deficiency; chr10:62854308 chr10:62793562~62805887:- CESC cis rs916888 0.773 rs199447 ENSG00000261575.2 RP11-259G18.1 4.02 8.04e-05 0.0297 0.39 0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46267037~46268694:+ CESC cis rs9487094 0.666 rs9480958 ENSG00000260273.1 RP11-425D10.10 -4.02 8.05e-05 0.0297 -0.32 -0.26 Height; chr6:109432968 chr6:109382795~109383666:+ CESC cis rs9309473 0.948 rs13391552 ENSG00000163016.8 ALMS1P 4.02 8.05e-05 0.0297 0.35 0.26 Metabolite levels; chr2:73591809 chr2:73644919~73685576:+ CESC cis rs1667255 1 rs1080093 ENSG00000266521.1 RP11-650P15.1 4.02 8.05e-05 0.0298 0.31 0.26 Retinol levels; chr18:31593717 chr18:31496645~31497195:- CESC cis rs748404 0.697 rs491804 ENSG00000249839.1 AC011330.5 -4.02 8.05e-05 0.0298 -0.28 -0.26 Lung cancer; chr15:43268627 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs492743 ENSG00000249839.1 AC011330.5 -4.02 8.05e-05 0.0298 -0.28 -0.26 Lung cancer; chr15:43268747 chr15:43663654~43684339:- CESC cis rs2235544 0.565 rs928441 ENSG00000225183.1 RP4-758J24.4 -4.02 8.05e-05 0.0298 -0.3 -0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54007695 chr1:54089856~54090093:+ CESC cis rs2235544 0.541 rs928442 ENSG00000225183.1 RP4-758J24.4 -4.02 8.05e-05 0.0298 -0.3 -0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54007815 chr1:54089856~54090093:+ CESC cis rs2235544 0.565 rs928444 ENSG00000225183.1 RP4-758J24.4 4.02 8.05e-05 0.0298 0.3 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54007875 chr1:54089856~54090093:+ CESC cis rs526231 0.819 rs403214 ENSG00000175749.11 EIF3KP1 4.02 8.05e-05 0.0298 0.32 0.26 Primary biliary cholangitis; chr5:103268000 chr5:103032376~103033031:+ CESC cis rs875971 0.545 rs12671152 ENSG00000236529.1 RP13-254B10.1 4.02 8.05e-05 0.0298 0.33 0.26 Aortic root size; chr7:66311140 chr7:65840212~65840596:+ CESC cis rs2406342 1 rs11663505 ENSG00000279433.1 RP11-4B16.1 4.02 8.06e-05 0.0298 0.28 0.26 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin); chr18:76779369 chr18:77108284~77110537:- CESC cis rs2243480 1 rs73142166 ENSG00000164669.11 INTS4P1 4.02 8.07e-05 0.0298 0.56 0.26 Diabetic kidney disease; chr7:65910845 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs34193460 ENSG00000164669.11 INTS4P1 4.02 8.07e-05 0.0298 0.56 0.26 Diabetic kidney disease; chr7:65928123 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs57057549 ENSG00000164669.11 INTS4P1 4.02 8.07e-05 0.0298 0.56 0.26 Diabetic kidney disease; chr7:65940751 chr7:65141225~65234216:+ CESC cis rs2916733 0.607 rs2442507 ENSG00000246089.3 RP11-115C21.2 -4.02 8.07e-05 0.0298 -0.32 -0.26 Epirubicin-induced leukopenia; chr8:6447583 chr8:6403551~6407142:- CESC cis rs11096990 1 rs11096990 ENSG00000249207.1 RP11-360F5.1 -4.02 8.07e-05 0.0298 -0.31 -0.26 Cognitive function; chr4:39285329 chr4:39112677~39126818:- CESC cis rs7688540 0.8 rs2353599 ENSG00000211553.1 AC253576.2 -4.02 8.08e-05 0.0298 -0.34 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:286637 chr4:136461~136568:+ CESC cis rs7212798 1 rs7212798 ENSG00000266992.1 DHX40P1 4.02 8.08e-05 0.0298 0.33 0.26 Myocardial infarction;Coronary artery disease; chr17:60936127 chr17:59976009~60002384:- CESC cis rs12220238 0.915 rs11001020 ENSG00000213731.2 RAB5CP1 -4.02 8.08e-05 0.0298 -0.42 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74379459 chr10:74423435~74424014:- CESC cis rs4660456 0.596 rs1534956 ENSG00000237899.1 RP4-739H11.3 4.02 8.08e-05 0.0298 0.32 0.26 Platelet count; chr1:40720771 chr1:40669089~40687588:- CESC cis rs2243480 0.901 rs35256305 ENSG00000232559.3 GS1-124K5.12 4.02 8.08e-05 0.0298 0.42 0.26 Diabetic kidney disease; chr7:65841418 chr7:66554588~66576923:- CESC cis rs2243480 0.803 rs34004500 ENSG00000232559.3 GS1-124K5.12 4.02 8.08e-05 0.0298 0.42 0.26 Diabetic kidney disease; chr7:65847191 chr7:66554588~66576923:- CESC cis rs2243480 1 rs35825738 ENSG00000232559.3 GS1-124K5.12 4.02 8.08e-05 0.0298 0.42 0.26 Diabetic kidney disease; chr7:65853040 chr7:66554588~66576923:- CESC cis rs2243480 0.803 rs35480979 ENSG00000232559.3 GS1-124K5.12 4.02 8.08e-05 0.0298 0.42 0.26 Diabetic kidney disease; chr7:65892097 chr7:66554588~66576923:- CESC cis rs17695224 0.675 rs10422421 ENSG00000268095.1 ZNF649-AS1 4.02 8.09e-05 0.0299 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51836479 chr19:51888025~51900463:+ CESC cis rs17695224 0.675 rs10422984 ENSG00000268095.1 ZNF649-AS1 4.02 8.09e-05 0.0299 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51836492 chr19:51888025~51900463:+ CESC cis rs17695224 0.675 rs10422606 ENSG00000268095.1 ZNF649-AS1 4.02 8.09e-05 0.0299 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51836494 chr19:51888025~51900463:+ CESC cis rs875971 0.545 rs2279757 ENSG00000237310.1 GS1-124K5.4 4.02 8.09e-05 0.0299 0.3 0.26 Aortic root size; chr7:66363676 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs11766183 ENSG00000237310.1 GS1-124K5.4 4.02 8.09e-05 0.0299 0.3 0.26 Aortic root size; chr7:66374173 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs1065265 ENSG00000237310.1 GS1-124K5.4 4.02 8.09e-05 0.0299 0.3 0.26 Aortic root size; chr7:66376216 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs7811204 ENSG00000237310.1 GS1-124K5.4 4.02 8.09e-05 0.0299 0.3 0.26 Aortic root size; chr7:66387213 chr7:66493706~66495474:+ CESC cis rs1865760 0.566 rs9366634 ENSG00000272462.2 U91328.19 -4.02 8.09e-05 0.0299 -0.26 -0.26 Height; chr6:26072168 chr6:25992662~26001775:+ CESC cis rs73086581 0.741 rs17212649 ENSG00000229539.1 RP11-119B16.2 4.02 8.09e-05 0.0299 0.45 0.26 Response to antidepressants in depression; chr20:3872446 chr20:3888239~3888868:- CESC cis rs11051970 0.918 rs7309115 ENSG00000255760.1 RP11-428G5.5 4.02 8.09e-05 0.0299 0.32 0.26 Response to tocilizumab in rheumatoid arthritis; chr12:32388307 chr12:31877079~31887203:- CESC cis rs875971 0.862 rs6460282 ENSG00000236529.1 RP13-254B10.1 -4.02 8.1e-05 0.0299 -0.29 -0.26 Aortic root size; chr7:66226259 chr7:65840212~65840596:+ CESC cis rs919433 0.713 rs2045245 ENSG00000222017.1 AC011997.1 4.02 8.1e-05 0.0299 0.34 0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197620617 chr2:197693106~197774823:+ CESC cis rs6844153 0.752 rs11737218 ENSG00000240005.4 RP11-293A21.1 4.02 8.1e-05 0.0299 0.33 0.26 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26884151 chr4:26859806~26860599:- CESC cis rs2033711 0.87 rs1465789 ENSG00000269473.1 CTD-2619J13.19 4.02 8.1e-05 0.0299 0.3 0.26 Uric acid clearance; chr19:58434689 chr19:58440448~58445849:+ CESC cis rs4974559 0.739 rs28411197 ENSG00000253399.1 AC078852.2 4.02 8.1e-05 0.0299 0.45 0.26 Systolic blood pressure; chr4:1285993 chr4:1358479~1359461:+ CESC cis rs4974559 0.739 rs28573879 ENSG00000253399.1 AC078852.2 4.02 8.1e-05 0.0299 0.45 0.26 Systolic blood pressure; chr4:1292122 chr4:1358479~1359461:+ CESC cis rs4974559 0.69 rs28641665 ENSG00000253399.1 AC078852.2 4.02 8.1e-05 0.0299 0.45 0.26 Systolic blood pressure; chr4:1294993 chr4:1358479~1359461:+ CESC cis rs4974559 0.739 rs28444605 ENSG00000253399.1 AC078852.2 4.02 8.1e-05 0.0299 0.45 0.26 Systolic blood pressure; chr4:1296493 chr4:1358479~1359461:+ CESC cis rs9876781 0.53 rs11708617 ENSG00000229759.1 MRPS18AP1 4.02 8.11e-05 0.0299 0.26 0.26 Longevity; chr3:48354819 chr3:48256350~48256938:- CESC cis rs453301 0.653 rs1045529 ENSG00000173295.6 FAM86B3P -4.02 8.11e-05 0.0299 -0.32 -0.26 Joint mobility (Beighton score); chr8:9032588 chr8:8228595~8244865:+ CESC cis rs8177876 0.822 rs4324141 ENSG00000261838.4 RP11-303E16.6 -4.02 8.11e-05 0.0299 -0.51 -0.26 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81081220 chr16:81069854~81076598:+ CESC cis rs3091242 1 rs9689 ENSG00000224183.1 SDHDP6 -4.02 8.12e-05 0.0299 -0.28 -0.26 Erythrocyte sedimentation rate; chr1:25361785 chr1:25294164~25294643:- CESC cis rs4272720 0.639 rs2264846 ENSG00000229870.1 RP11-507K13.6 4.02 8.12e-05 0.0299 0.3 0.26 Platelet count;Plateletcrit; chr10:49045142 chr10:49815096~49815562:+ CESC cis rs6693388 0.671 rs6684312 ENSG00000229021.2 AL591893.1 -4.02 8.12e-05 0.0299 -0.31 -0.26 Blood metabolite ratios; chr1:151872174 chr1:151994531~152042774:+ CESC cis rs7208859 0.673 rs216410 ENSG00000264538.5 SUZ12P1 4.02 8.12e-05 0.0299 0.29 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576813 chr17:30709299~30790908:+ CESC cis rs61160187 0.582 rs34619 ENSG00000215032.2 GNL3LP1 4.02 8.12e-05 0.0299 0.32 0.26 Educational attainment (years of education);Educational attainment (college completion); chr5:61169538 chr5:60891935~60893577:- CESC cis rs10129255 0.83 rs61997609 ENSG00000211974.3 IGHV2-70 4.02 8.12e-05 0.03 0.28 0.26 Kawasaki disease; chr14:106692376 chr14:106723574~106724093:- CESC cis rs2136613 0.533 rs10761673 ENSG00000238280.1 RP11-436D10.3 -4.02 8.12e-05 0.03 -0.3 -0.26 Selective IgA deficiency; chr10:62855691 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10822071 ENSG00000238280.1 RP11-436D10.3 -4.02 8.12e-05 0.03 -0.3 -0.26 Selective IgA deficiency; chr10:62855716 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs10822072 ENSG00000238280.1 RP11-436D10.3 -4.02 8.12e-05 0.03 -0.3 -0.26 Selective IgA deficiency; chr10:62856010 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs1509958 ENSG00000238280.1 RP11-436D10.3 -4.02 8.12e-05 0.03 -0.3 -0.26 Selective IgA deficiency; chr10:62856390 chr10:62793562~62805887:- CESC cis rs2136613 0.533 rs12258444 ENSG00000238280.1 RP11-436D10.3 -4.02 8.12e-05 0.03 -0.3 -0.26 Selective IgA deficiency; chr10:62856825 chr10:62793562~62805887:- CESC cis rs2276314 1 rs2298715 ENSG00000278986.1 RP11-723J4.3 -4.02 8.13e-05 0.03 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35972462 chr18:35972151~35973916:+ CESC cis rs76878669 0.606 rs2282531 ENSG00000255468.5 RP11-867G23.8 4.02 8.13e-05 0.03 0.3 0.26 Educational attainment (years of education); chr11:66332023 chr11:66347950~66364804:+ CESC cis rs9494145 0.68 rs4895440 ENSG00000232876.1 CTA-212D2.2 -4.02 8.13e-05 0.03 -0.31 -0.26 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135105420 chr6:135055033~135060550:+ CESC cis rs10829156 0.66 rs11014830 ENSG00000240291.1 RP11-499P20.2 4.02 8.13e-05 0.03 0.28 0.26 Sudden cardiac arrest; chr10:18551504 chr10:18513115~18545651:- CESC cis rs2337406 1 rs7145100 ENSG00000274576.2 IGHV2-70 -4.02 8.13e-05 0.03 -0.34 -0.26 Alzheimer's disease (late onset); chr14:106704673 chr14:106770577~106771020:- CESC cis rs10483853 0.525 rs7158272 ENSG00000258695.2 RP3-414A15.2 4.02 8.14e-05 0.03 0.37 0.26 Coronary artery calcification; chr14:73476486 chr14:73522878~73530610:+ CESC cis rs17301013 0.507 rs72713528 ENSG00000227373.4 RP11-160H22.5 4.02 8.14e-05 0.03 0.41 0.26 Systemic lupus erythematosus; chr1:174319862 chr1:174115300~174160004:- CESC cis rs10129255 0.518 rs28378320 ENSG00000211970.3 IGHV4-61 -4.02 8.15e-05 0.03 -0.18 -0.26 Kawasaki disease; chr14:106808609 chr14:106639119~106639657:- CESC cis rs2771051 0.931 rs6478307 ENSG00000230734.1 RPL10P3 4.02 8.15e-05 0.03 0.27 0.26 Venous thromboembolism (SNP x SNP interaction); chr9:117526732 chr9:117180628~117181095:- CESC cis rs13434995 0.589 rs62306207 ENSG00000273257.1 RP11-177J6.1 -4.02 8.15e-05 0.03 -0.38 -0.26 Adiponectin levels; chr4:55384548 chr4:55387949~55388271:+ CESC cis rs13434995 0.589 rs62305201 ENSG00000273257.1 RP11-177J6.1 -4.02 8.15e-05 0.03 -0.38 -0.26 Adiponectin levels; chr4:55386778 chr4:55387949~55388271:+ CESC cis rs13434995 0.589 rs62305202 ENSG00000273257.1 RP11-177J6.1 -4.02 8.15e-05 0.03 -0.38 -0.26 Adiponectin levels; chr4:55386861 chr4:55387949~55388271:+ CESC cis rs9311474 0.713 rs352166 ENSG00000243224.1 RP5-1157M23.2 -4.02 8.15e-05 0.03 -0.27 -0.26 Electroencephalogram traits; chr3:52204661 chr3:52239258~52241097:+ CESC cis rs9309473 0.5 rs10189578 ENSG00000273245.1 RP11-434P11.2 4.02 8.16e-05 0.0301 0.32 0.26 Metabolite levels; chr2:73501482 chr2:73750256~73750786:- CESC cis rs1707322 1 rs4660336 ENSG00000281133.1 AL355480.3 4.02 8.16e-05 0.0301 0.31 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46022304 chr1:45580892~45580996:- CESC cis rs9309473 0.519 rs2178154 ENSG00000163016.8 ALMS1P -4.02 8.16e-05 0.0301 -0.32 -0.26 Metabolite levels; chr2:73434610 chr2:73644919~73685576:+ CESC cis rs875971 0.929 rs778712 ENSG00000179406.6 LINC00174 -4.02 8.16e-05 0.0301 -0.29 -0.26 Aortic root size; chr7:66384991 chr7:66376044~66401338:- CESC cis rs10129255 0.957 rs12589190 ENSG00000280411.1 IGHV1-69-2 -4.02 8.16e-05 0.0301 -0.19 -0.26 Kawasaki disease; chr14:106783079 chr14:106762092~106762588:- CESC cis rs853679 0.882 rs9461432 ENSG00000219392.1 RP1-265C24.5 -4.02 8.17e-05 0.0301 -0.43 -0.26 Depression; chr6:28119105 chr6:28115628~28116551:+ CESC cis rs12134133 1 rs6668683 ENSG00000274245.1 RP11-357P18.2 4.02 8.17e-05 0.0301 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207285846 chr1:207372559~207373252:+ CESC cis rs12134133 1 rs10494889 ENSG00000274245.1 RP11-357P18.2 4.02 8.17e-05 0.0301 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207286963 chr1:207372559~207373252:+ CESC cis rs12134133 0.962 rs2564970 ENSG00000274245.1 RP11-357P18.2 4.02 8.17e-05 0.0301 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207290696 chr1:207372559~207373252:+ CESC cis rs12134133 1 rs2782851 ENSG00000274245.1 RP11-357P18.2 4.02 8.17e-05 0.0301 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207291717 chr1:207372559~207373252:+ CESC cis rs12134133 1 rs2782850 ENSG00000274245.1 RP11-357P18.2 4.02 8.17e-05 0.0301 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207292092 chr1:207372559~207373252:+ CESC cis rs4423214 0.559 rs10898201 ENSG00000254682.1 RP11-660L16.2 -4.02 8.17e-05 0.0301 -0.4 -0.26 Vitamin D levels; chr11:71490481 chr11:71448674~71452157:+ CESC cis rs2836950 0.501 rs11088470 ENSG00000255568.3 BRWD1-AS2 -4.02 8.17e-05 0.0301 -0.21 -0.26 Menarche (age at onset); chr21:39317236 chr21:39313935~39314962:+ CESC cis rs2836950 0.501 rs2836983 ENSG00000255568.3 BRWD1-AS2 -4.02 8.17e-05 0.0301 -0.21 -0.26 Menarche (age at onset); chr21:39317410 chr21:39313935~39314962:+ CESC cis rs7615952 0.641 rs4422257 ENSG00000250012.1 RP11-124N2.1 -4.02 8.17e-05 0.0301 -0.3 -0.26 Blood pressure (smoking interaction); chr3:126055520 chr3:126084220~126095349:+ CESC cis rs8074751 0.689 rs8068462 ENSG00000266644.1 RP11-927P21.2 -4.02 8.17e-05 0.0301 -0.29 -0.26 Attention deficit hyperactivity disorder; chr17:65643774 chr17:64899766~64900716:+ CESC cis rs763121 0.853 rs4821816 ENSG00000228274.3 RP3-508I15.9 -4.01 8.18e-05 0.0301 -0.24 -0.26 Menopause (age at onset); chr22:38717129 chr22:38667585~38681820:- CESC cis rs13256369 1 rs9329166 ENSG00000173295.6 FAM86B3P 4.01 8.18e-05 0.0301 0.38 0.26 Obesity-related traits; chr8:8719145 chr8:8228595~8244865:+ CESC cis rs523522 0.962 rs3759394 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120495370 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs2233676 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120495804 chr12:120500735~120501090:- CESC cis rs523522 0.923 rs3916065 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120496821 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs9788155 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120500605 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs10849754 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120502615 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs11065145 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120509616 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs4766968 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120509985 chr12:120500735~120501090:- CESC cis rs523522 0.923 rs10774553 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120517181 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs11065149 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120519160 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs10849757 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120526211 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs55848094 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120528856 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs3742052 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120529118 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs10849758 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120533346 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs11065154 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120533614 chr12:120500735~120501090:- CESC cis rs523522 0.926 rs10774555 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120534175 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs4767912 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120543399 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs7488320 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120543827 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs12814055 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120549588 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs12371550 ENSG00000278344.1 RP11-18C24.8 4.01 8.18e-05 0.0301 0.32 0.26 High light scatter reticulocyte count; chr12:120549840 chr12:120500735~120501090:- CESC cis rs17152411 0.652 rs4962712 ENSG00000232334.1 RP11-47G11.2 4.01 8.18e-05 0.0301 0.29 0.26 Height; chr10:124958483 chr10:124004304~124004828:- CESC cis rs6556937 0.71 rs10039522 ENSG00000251314.2 CTD-2337A12.1 4.01 8.18e-05 0.0301 0.37 0.26 Blood protein levels; chr5:96655165 chr5:95962001~96631085:+ CESC cis rs6556937 0.71 rs10045215 ENSG00000251314.2 CTD-2337A12.1 4.01 8.18e-05 0.0301 0.37 0.26 Blood protein levels; chr5:96655167 chr5:95962001~96631085:+ CESC cis rs9322193 0.847 rs880246 ENSG00000223701.3 RAET1E-AS1 4.01 8.19e-05 0.0301 0.32 0.26 Lung cancer; chr6:149845972 chr6:149884431~149919508:+ CESC cis rs2277027 1 rs4331881 ENSG00000251405.2 CTB-109A12.1 4.01 8.19e-05 0.0301 0.34 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157517467 chr5:157362615~157460078:- CESC cis rs875971 1 rs778710 ENSG00000179406.6 LINC00174 -4.01 8.19e-05 0.0301 -0.29 -0.26 Aortic root size; chr7:66389847 chr7:66376044~66401338:- CESC cis rs875971 0.964 rs778708 ENSG00000179406.6 LINC00174 -4.01 8.19e-05 0.0301 -0.29 -0.26 Aortic root size; chr7:66391332 chr7:66376044~66401338:- CESC cis rs875971 1 rs778696 ENSG00000179406.6 LINC00174 -4.01 8.19e-05 0.0301 -0.29 -0.26 Aortic root size; chr7:66405826 chr7:66376044~66401338:- CESC cis rs875971 1 rs778694 ENSG00000179406.6 LINC00174 -4.01 8.19e-05 0.0301 -0.29 -0.26 Aortic root size; chr7:66406571 chr7:66376044~66401338:- CESC cis rs875971 1 rs4718344 ENSG00000179406.6 LINC00174 -4.01 8.19e-05 0.0301 -0.29 -0.26 Aortic root size; chr7:66409394 chr7:66376044~66401338:- CESC cis rs875971 0.737 rs7803424 ENSG00000179406.6 LINC00174 -4.01 8.19e-05 0.0301 -0.29 -0.26 Aortic root size; chr7:66415618 chr7:66376044~66401338:- CESC cis rs875971 0.83 rs7799834 ENSG00000179406.6 LINC00174 -4.01 8.19e-05 0.0301 -0.29 -0.26 Aortic root size; chr7:66415707 chr7:66376044~66401338:- CESC cis rs6547705 0.858 rs12714202 ENSG00000231259.4 AC125232.1 4.01 8.2e-05 0.0302 0.38 0.26 Progressive supranuclear palsy; chr2:86672815 chr2:87031815~87053069:- CESC cis rs2836950 0.501 rs2836980 ENSG00000255568.3 BRWD1-AS2 -4.01 8.2e-05 0.0302 -0.21 -0.26 Menarche (age at onset); chr21:39315692 chr21:39313935~39314962:+ CESC cis rs7896729 0.882 rs11253084 ENSG00000215267.7 AKR1C7P -4.01 8.2e-05 0.0302 -0.3 -0.26 Intelligence; chr10:5303693 chr10:5275173~5288470:- CESC cis rs7896729 1 rs11253088 ENSG00000215267.7 AKR1C7P -4.01 8.2e-05 0.0302 -0.3 -0.26 Intelligence; chr10:5304721 chr10:5275173~5288470:- CESC cis rs7896729 0.943 rs11253089 ENSG00000215267.7 AKR1C7P -4.01 8.2e-05 0.0302 -0.3 -0.26 Intelligence; chr10:5304809 chr10:5275173~5288470:- CESC cis rs523522 0.924 rs11065150 ENSG00000278344.1 RP11-18C24.8 4.01 8.2e-05 0.0302 0.32 0.26 High light scatter reticulocyte count; chr12:120521072 chr12:120500735~120501090:- CESC cis rs76878669 0.561 rs10791872 ENSG00000255468.5 RP11-867G23.8 4.01 8.2e-05 0.0302 0.3 0.26 Educational attainment (years of education); chr11:66370963 chr11:66347950~66364804:+ CESC cis rs74405815 0.702 rs75678080 ENSG00000248557.1 RP11-390G14.1 4.01 8.2e-05 0.0302 0.57 0.26 Response to paliperidone in schizophrenia (positive Marder score); chr3:126844650 chr3:126624792~126626061:+ CESC cis rs2235544 0.664 rs12036530 ENSG00000225183.1 RP4-758J24.4 -4.01 8.21e-05 0.0302 -0.29 -0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54010650 chr1:54089856~54090093:+ CESC cis rs2235544 0.664 rs41366847 ENSG00000225183.1 RP4-758J24.4 -4.01 8.21e-05 0.0302 -0.29 -0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54011294 chr1:54089856~54090093:+ CESC cis rs12107539 0.8 rs10935839 ENSG00000240137.4 ERICH6-AS1 -4.01 8.21e-05 0.0302 -0.25 -0.26 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151352904 chr3:150703564~150720146:+ CESC cis rs950173 1 rs13000153 ENSG00000228389.1 AC068039.4 4.01 8.21e-05 0.0302 0.55 0.26 Hippocampal volume; chr2:171729557 chr2:171773482~171775844:+ CESC cis rs2708377 0.858 rs115781584 ENSG00000212125.2 TAS2R15P 4.01 8.22e-05 0.0302 0.44 0.26 Bitter taste perception; chr12:11151961 chr12:10964425~10965352:- CESC cis rs11168351 0.926 rs10875719 ENSG00000240399.1 RP1-228P16.1 4.01 8.22e-05 0.0302 0.3 0.26 Bipolar disorder and schizophrenia; chr12:48017375 chr12:48054813~48055591:- CESC cis rs523522 0.571 rs11065120 ENSG00000278344.1 RP11-18C24.8 4.01 8.22e-05 0.0302 0.35 0.26 High light scatter reticulocyte count; chr12:120437653 chr12:120500735~120501090:- CESC cis rs748404 0.666 rs72709879 ENSG00000249839.1 AC011330.5 -4.01 8.22e-05 0.0303 -0.38 -0.26 Lung cancer; chr15:43507777 chr15:43663654~43684339:- CESC cis rs2408955 0.521 rs7301003 ENSG00000226413.2 OR8T1P 4.01 8.22e-05 0.0303 0.34 0.26 Glycated hemoglobin levels; chr12:48156444 chr12:48442030~48442947:- CESC cis rs8030379 1 rs11633301 ENSG00000230373.7 GOLGA6L5P 4.01 8.23e-05 0.0303 0.25 0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83916286 chr15:84507885~84516814:- CESC cis rs8030379 1 rs2401175 ENSG00000230373.7 GOLGA6L5P 4.01 8.23e-05 0.0303 0.25 0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83909465 chr15:84507885~84516814:- CESC cis rs875971 1 rs1167612 ENSG00000232559.3 GS1-124K5.12 -4.01 8.23e-05 0.0303 -0.29 -0.26 Aortic root size; chr7:66102989 chr7:66554588~66576923:- CESC cis rs875971 0.577 rs34888281 ENSG00000164669.11 INTS4P1 4.01 8.24e-05 0.0303 0.36 0.26 Aortic root size; chr7:66120784 chr7:65141225~65234216:+ CESC cis rs7924176 0.601 rs7099026 ENSG00000213731.2 RAB5CP1 -4.01 8.24e-05 0.0303 -0.28 -0.26 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74128770 chr10:74423435~74424014:- CESC cis rs62355900 0.627 rs58292679 ENSG00000271828.1 CTD-2310F14.1 4.01 8.24e-05 0.0303 0.41 0.26 Endometriosis; chr5:56839989 chr5:56927874~56929573:+ CESC cis rs11976180 1 rs2961117 ENSG00000273234.1 OR2A13P -4.01 8.24e-05 0.0303 -0.31 -0.26 Obesity-related traits; chr7:144058160 chr7:144142009~144142938:+ CESC cis rs875971 0.825 rs1129531 ENSG00000179406.6 LINC00174 4.01 8.24e-05 0.0303 0.28 0.26 Aortic root size; chr7:66154117 chr7:66376044~66401338:- CESC cis rs7873102 0.654 rs3861003 ENSG00000230188.1 RP11-405L18.4 -4.01 8.25e-05 0.0303 -0.34 -0.26 Brain structure; chr9:37952634 chr9:37490421~37490893:- CESC cis rs755249 0.567 rs61779309 ENSG00000228060.1 RP11-69E11.8 -4.01 8.25e-05 0.0303 -0.31 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39474827 chr1:39565160~39573203:+ CESC cis rs763121 0.853 rs138702 ENSG00000273076.1 RP3-508I15.22 -4.01 8.25e-05 0.0303 -0.31 -0.26 Menopause (age at onset); chr22:38736596 chr22:38743495~38743910:+ CESC cis rs9640161 0.659 rs7806429 ENSG00000261305.1 RP4-584D14.7 4.01 8.26e-05 0.0303 0.37 0.26 Blood protein levels;Circulating chemerin levels; chr7:150316304 chr7:150341771~150342607:+ CESC cis rs694739 0.726 rs17857342 ENSG00000236935.1 AP003774.1 4.01 8.26e-05 0.0303 0.27 0.26 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64371433 chr11:64325050~64329504:- CESC cis rs7560272 0.538 rs4852976 ENSG00000163016.8 ALMS1P -4.01 8.26e-05 0.0304 -0.32 -0.26 Schizophrenia; chr2:73709195 chr2:73644919~73685576:+ CESC cis rs7508 0.576 rs208062 ENSG00000253671.1 RP11-806O11.1 -4.01 8.26e-05 0.0304 -0.27 -0.26 Atrial fibrillation; chr8:17960929 chr8:17808941~17820868:+ CESC cis rs769267 0.965 rs2074299 ENSG00000269131.1 AC004447.2 -4.01 8.26e-05 0.0304 -0.22 -0.26 Tonsillectomy; chr19:19269837 chr19:18990893~18993610:+ CESC cis rs748404 0.706 rs35975365 ENSG00000249839.1 AC011330.5 -4.01 8.27e-05 0.0304 -0.41 -0.26 Lung cancer; chr15:43379347 chr15:43663654~43684339:- CESC cis rs3738443 0.904 rs61840000 ENSG00000259865.1 RP11-488L18.10 4.01 8.27e-05 0.0304 0.31 0.26 Alcohol dependence; chr1:247199027 chr1:247187281~247188526:- CESC cis rs13113518 0.812 rs1522114 ENSG00000273257.1 RP11-177J6.1 4.01 8.27e-05 0.0304 0.35 0.26 Height; chr4:55489895 chr4:55387949~55388271:+ CESC cis rs72627123 0.867 rs8015927 ENSG00000270140.1 RP5-1021I20.6 4.01 8.27e-05 0.0304 0.59 0.26 Morning vs. evening chronotype; chr14:73999053 chr14:73905267~73905636:+ CESC cis rs8080784 0.673 rs8078754 ENSG00000266701.1 AC005702.4 4.01 8.27e-05 0.0304 0.39 0.26 Coronary artery disease; chr17:60775903 chr17:60042546~60042627:- CESC cis rs8080784 0.551 rs9897546 ENSG00000266701.1 AC005702.4 4.01 8.27e-05 0.0304 0.39 0.26 Coronary artery disease; chr17:60777351 chr17:60042546~60042627:- CESC cis rs8080784 0.673 rs9903592 ENSG00000266701.1 AC005702.4 4.01 8.27e-05 0.0304 0.39 0.26 Coronary artery disease; chr17:60777632 chr17:60042546~60042627:- CESC cis rs8080784 0.673 rs7214945 ENSG00000266701.1 AC005702.4 4.01 8.27e-05 0.0304 0.39 0.26 Coronary artery disease; chr17:60779801 chr17:60042546~60042627:- CESC cis rs8080784 0.611 rs7214801 ENSG00000266701.1 AC005702.4 4.01 8.27e-05 0.0304 0.39 0.26 Coronary artery disease; chr17:60780483 chr17:60042546~60042627:- CESC cis rs8080784 0.673 rs7211676 ENSG00000266701.1 AC005702.4 4.01 8.27e-05 0.0304 0.39 0.26 Coronary artery disease; chr17:60783351 chr17:60042546~60042627:- CESC cis rs8080784 0.673 rs73316760 ENSG00000266701.1 AC005702.4 4.01 8.27e-05 0.0304 0.39 0.26 Coronary artery disease; chr17:60784817 chr17:60042546~60042627:- CESC cis rs3096299 0.606 rs2965946 ENSG00000274627.1 RP11-104N10.2 4.01 8.28e-05 0.0304 0.28 0.26 Multiple myeloma (IgH translocation); chr16:89450204 chr16:89516797~89522217:+ CESC cis rs62355901 0.505 rs12657615 ENSG00000271828.1 CTD-2310F14.1 4.01 8.28e-05 0.0304 0.43 0.26 Breast cancer; chr5:56768306 chr5:56927874~56929573:+ CESC cis rs2276314 1 rs4799835 ENSG00000278986.1 RP11-723J4.3 -4.01 8.28e-05 0.0304 -0.31 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35991305 chr18:35972151~35973916:+ CESC cis rs9318086 0.753 rs9553094 ENSG00000205861.10 C1QTNF9B-AS1 4.01 8.28e-05 0.0304 0.32 0.26 Myopia (pathological); chr13:23900474 chr13:23888889~23897263:+ CESC cis rs17507216 0.628 rs28607761 ENSG00000276710.3 CSPG4P8 -4.01 8.28e-05 0.0304 -0.37 -0.26 Excessive daytime sleepiness; chr15:82715317 chr15:82459472~82477258:+ CESC cis rs72634501 0.622 rs4660416 ENSG00000228060.1 RP11-69E11.8 -4.01 8.29e-05 0.0304 -0.3 -0.26 HDL cholesterol; chr1:39113314 chr1:39565160~39573203:+ CESC cis rs8080784 0.866 rs56218356 ENSG00000266992.1 DHX40P1 4.01 8.29e-05 0.0304 0.34 0.26 Coronary artery disease; chr17:60946069 chr17:59976009~60002384:- CESC cis rs8040855 0.644 rs7495437 ENSG00000259774.1 RP11-182J1.13 -4.01 8.29e-05 0.0304 -0.31 -0.26 Bulimia nervosa; chr15:85183059 chr15:84422618~84425882:+ CESC cis rs67311347 1 rs11714912 ENSG00000223797.4 ENTPD3-AS1 -4.01 8.29e-05 0.0305 -0.25 -0.26 Renal cell carcinoma; chr3:40452574 chr3:40313802~40453329:- CESC cis rs516805 0.706 rs541551 ENSG00000279453.1 RP3-425C14.4 -4.01 8.29e-05 0.0305 -0.34 -0.26 Lymphocyte counts; chr6:122462736 chr6:122436789~122439223:- CESC cis rs516805 0.748 rs562616 ENSG00000279453.1 RP3-425C14.4 -4.01 8.29e-05 0.0305 -0.34 -0.26 Lymphocyte counts; chr6:122467041 chr6:122436789~122439223:- CESC cis rs17695224 0.675 rs7252671 ENSG00000268095.1 ZNF649-AS1 4.01 8.3e-05 0.0305 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51834830 chr19:51888025~51900463:+ CESC cis rs17695224 0.675 rs56177367 ENSG00000268095.1 ZNF649-AS1 4.01 8.3e-05 0.0305 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51835343 chr19:51888025~51900463:+ CESC cis rs17695224 0.611 rs10420568 ENSG00000268095.1 ZNF649-AS1 4.01 8.3e-05 0.0305 0.34 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51835662 chr19:51888025~51900463:+ CESC cis rs9309473 0.95 rs6546858 ENSG00000163016.8 ALMS1P 4.01 8.31e-05 0.0305 0.33 0.26 Metabolite levels; chr2:73611486 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs6546859 ENSG00000163016.8 ALMS1P 4.01 8.31e-05 0.0305 0.33 0.26 Metabolite levels; chr2:73614928 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs7566364 ENSG00000163016.8 ALMS1P 4.01 8.31e-05 0.0305 0.33 0.26 Metabolite levels; chr2:73615762 chr2:73644919~73685576:+ CESC cis rs7572733 0.515 rs35730302 ENSG00000222017.1 AC011997.1 -4.01 8.31e-05 0.0305 -0.33 -0.26 Dermatomyositis; chr2:197953902 chr2:197693106~197774823:+ CESC cis rs17507216 0.718 rs72751662 ENSG00000255769.6 GOLGA2P10 -4.01 8.31e-05 0.0305 -0.42 -0.26 Excessive daytime sleepiness; chr15:82594705 chr15:82472993~82513950:- CESC cis rs67311347 1 rs7628796 ENSG00000223797.4 ENTPD3-AS1 -4.01 8.31e-05 0.0305 -0.26 -0.26 Renal cell carcinoma; chr3:40465841 chr3:40313802~40453329:- CESC cis rs3925075 0.524 rs889549 ENSG00000260911.2 RP11-196G11.2 -4.01 8.32e-05 0.0305 -0.28 -0.26 IgA nephropathy; chr16:31255630 chr16:31043150~31049868:+ CESC cis rs9309473 0.95 rs10189885 ENSG00000163016.8 ALMS1P 4.01 8.32e-05 0.0305 0.36 0.26 Metabolite levels; chr2:73649928 chr2:73644919~73685576:+ CESC cis rs10129255 0.536 rs10139058 ENSG00000280411.1 IGHV1-69-2 -4.01 8.32e-05 0.0305 -0.18 -0.26 Kawasaki disease; chr14:106685899 chr14:106762092~106762588:- CESC cis rs10129255 0.536 rs8004835 ENSG00000280411.1 IGHV1-69-2 -4.01 8.32e-05 0.0305 -0.18 -0.26 Kawasaki disease; chr14:106686361 chr14:106762092~106762588:- CESC cis rs62025270 0.632 rs74025655 ENSG00000202081.1 RNU6-1280P -4.01 8.32e-05 0.0305 -0.35 -0.26 Idiopathic pulmonary fibrosis; chr15:85674319 chr15:85651522~85651628:- CESC cis rs1030877 0.515 rs2679893 ENSG00000235319.1 AC012360.4 -4.01 8.32e-05 0.0305 -0.32 -0.26 Obesity-related traits; chr2:105293097 chr2:105324210~105330529:+ CESC cis rs6142102 0.923 rs3787230 ENSG00000275784.1 RP5-1125A11.6 -4.01 8.32e-05 0.0305 -0.27 -0.26 Skin pigmentation; chr20:34052466 chr20:33989480~33991818:- CESC cis rs761746 0.739 rs5994420 ENSG00000236132.1 CTA-440B3.1 -4.01 8.33e-05 0.0305 -0.34 -0.26 Intelligence; chr22:31674765 chr22:31816379~31817491:- CESC cis rs7688540 0.771 rs77078697 ENSG00000211553.1 AC253576.2 -4.01 8.33e-05 0.0305 -0.39 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:258259 chr4:136461~136568:+ CESC cis rs7688540 0.771 rs61795006 ENSG00000211553.1 AC253576.2 -4.01 8.33e-05 0.0305 -0.39 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:259812 chr4:136461~136568:+ CESC cis rs2019137 0.56 rs10175462 ENSG00000274877.1 RP11-65I12.1 -4.01 8.33e-05 0.0305 -0.33 -0.26 Lymphocyte counts; chr2:113230915 chr2:113237595~113240825:+ CESC cis rs61160187 0.549 rs12518404 ENSG00000215032.2 GNL3LP1 4.01 8.33e-05 0.0305 0.31 0.26 Educational attainment (years of education);Educational attainment (college completion); chr5:61046169 chr5:60891935~60893577:- CESC cis rs7131987 0.65 rs7301398 ENSG00000257176.2 RP11-996F15.2 -4.01 8.33e-05 0.0305 -0.32 -0.26 QT interval; chr12:29302457 chr12:29280418~29317848:- CESC cis rs7131987 0.65 rs7301188 ENSG00000257176.2 RP11-996F15.2 -4.01 8.33e-05 0.0305 -0.32 -0.26 QT interval; chr12:29302458 chr12:29280418~29317848:- CESC cis rs4319547 0.656 rs2173582 ENSG00000275265.1 RP11-15J22.8 -4.01 8.33e-05 0.0306 -0.37 -0.26 Body mass index; chr12:122340147 chr12:122501187~122501641:+ CESC cis rs783540 0.835 rs8030185 ENSG00000255769.6 GOLGA2P10 -4.01 8.34e-05 0.0306 -0.29 -0.26 Schizophrenia; chr15:82722785 chr15:82472993~82513950:- CESC cis rs2235544 0.565 rs635509 ENSG00000225183.1 RP4-758J24.4 4.01 8.34e-05 0.0306 0.3 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54003554 chr1:54089856~54090093:+ CESC cis rs2235544 0.55 rs12075159 ENSG00000225183.1 RP4-758J24.4 4.01 8.34e-05 0.0306 0.3 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54004561 chr1:54089856~54090093:+ CESC cis rs62025270 0.632 rs7163838 ENSG00000202081.1 RNU6-1280P -4.01 8.34e-05 0.0306 -0.35 -0.26 Idiopathic pulmonary fibrosis; chr15:85664390 chr15:85651522~85651628:- CESC cis rs7951870 0.945 rs11038906 ENSG00000247675.5 LRP4-AS1 -4.01 8.34e-05 0.0306 -0.34 -0.26 Schizophrenia; chr11:46514892 chr11:46846412~46874396:+ CESC cis rs9532669 0.89 rs9525417 ENSG00000176268.5 CYCSP34 4.01 8.34e-05 0.0306 0.27 0.26 Cervical cancer; chr13:40878431 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs9532638 ENSG00000176268.5 CYCSP34 4.01 8.34e-05 0.0306 0.27 0.26 Cervical cancer; chr13:40878471 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs7997536 ENSG00000176268.5 CYCSP34 4.01 8.34e-05 0.0306 0.27 0.26 Cervical cancer; chr13:40878685 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs7997560 ENSG00000176268.5 CYCSP34 4.01 8.34e-05 0.0306 0.27 0.26 Cervical cancer; chr13:40878723 chr13:40863599~40863902:- CESC cis rs61869271 0.805 rs769119 ENSG00000236799.1 RP11-383C6.2 -4.01 8.35e-05 0.0306 -0.33 -0.26 Tonsillectomy; chr10:115018916 chr10:114994657~114996593:+ CESC cis rs1969253 0.712 rs843342 ENSG00000205955.4 HSP90AA5P -4.01 8.35e-05 0.0306 -0.26 -0.26 Major depressive disorder; chr3:184190214 chr3:184115352~184117898:+ CESC cis rs7617773 0.78 rs6442111 ENSG00000228638.1 FCF1P2 -4.01 8.36e-05 0.0306 -0.28 -0.26 Coronary artery disease; chr3:48270570 chr3:48290793~48291375:- CESC cis rs7617773 0.851 rs6775179 ENSG00000228638.1 FCF1P2 -4.01 8.36e-05 0.0306 -0.28 -0.26 Coronary artery disease; chr3:48271928 chr3:48290793~48291375:- CESC cis rs2337406 1 rs17113331 ENSG00000254174.1 IGHV1-12 4.01 8.36e-05 0.0306 0.29 0.26 Alzheimer's disease (late onset); chr14:106703843 chr14:106122420~106122709:- CESC cis rs853679 1 rs68141011 ENSG00000219392.1 RP1-265C24.5 -4.01 8.36e-05 0.0306 -0.4 -0.26 Depression; chr6:28250019 chr6:28115628~28116551:+ CESC cis rs853679 1 rs13200462 ENSG00000219392.1 RP1-265C24.5 -4.01 8.36e-05 0.0306 -0.4 -0.26 Depression; chr6:28250421 chr6:28115628~28116551:+ CESC cis rs2439831 0.85 rs12101756 ENSG00000249839.1 AC011330.5 -4.01 8.36e-05 0.0306 -0.38 -0.26 Lung cancer in ever smokers; chr15:43761689 chr15:43663654~43684339:- CESC cis rs5742933 1 rs2289404 ENSG00000253559.1 OSGEPL1-AS1 -4.01 8.36e-05 0.0307 -0.37 -0.26 Ferritin levels; chr2:189771288 chr2:189762704~189765556:+ CESC cis rs6775745 0.901 rs10470324 ENSG00000240854.1 RP11-64K7.1 -4.01 8.37e-05 0.0307 -0.37 -0.26 Neutrophil count; chr3:132083190 chr3:132175402~132176711:+ CESC cis rs77106637 0.929 rs74333814 ENSG00000202522.1 Y_RNA 4.01 8.37e-05 0.0307 0.41 0.26 Type 2 diabetes; chr11:72746442 chr11:72766004~72766116:+ CESC cis rs761746 0.739 rs9621317 ENSG00000236132.1 CTA-440B3.1 -4.01 8.37e-05 0.0307 -0.34 -0.26 Intelligence; chr22:31698060 chr22:31816379~31817491:- CESC cis rs703842 0.963 rs2291617 ENSG00000270039.1 RP11-571M6.17 -4.01 8.37e-05 0.0307 -0.32 -0.26 Multiple sclerosis; chr12:57772620 chr12:57803838~57804415:+ CESC cis rs2625529 0.816 rs4777467 ENSG00000260037.4 CTD-2524L6.3 -4.01 8.37e-05 0.0307 -0.39 -0.26 Red blood cell count; chr15:71846137 chr15:71818396~71823384:+ CESC cis rs2277027 1 rs1422795 ENSG00000251405.2 CTB-109A12.1 -4.01 8.37e-05 0.0307 -0.33 -0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157509356 chr5:157362615~157460078:- CESC cis rs748404 0.666 rs34591748 ENSG00000249839.1 AC011330.5 -4.01 8.38e-05 0.0307 -0.39 -0.26 Lung cancer; chr15:43334917 chr15:43663654~43684339:- CESC cis rs7131987 0.65 rs4331146 ENSG00000257176.2 RP11-996F15.2 -4.01 8.38e-05 0.0307 -0.32 -0.26 QT interval; chr12:29287150 chr12:29280418~29317848:- CESC cis rs12107539 1 rs12107539 ENSG00000240137.4 ERICH6-AS1 -4.01 8.38e-05 0.0307 -0.26 -0.26 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151324676 chr3:150703564~150720146:+ CESC cis rs924712 0.513 rs12210299 ENSG00000224984.1 RP11-524H19.2 -4.01 8.39e-05 0.0307 -0.27 -0.26 Breast cancer; chr6:54851386 chr6:54840118~54840855:- CESC cis rs2732480 0.5 rs7966829 ENSG00000258273.1 RP11-370I10.4 -4.01 8.39e-05 0.0307 -0.32 -0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48221820 chr12:48333755~48333901:- CESC cis rs8072100 0.79 rs11656856 ENSG00000228782.6 CTD-2026D20.3 -4.01 8.39e-05 0.0307 -0.31 -0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47637305 chr17:47450568~47492492:- CESC cis rs2243480 1 rs73142122 ENSG00000164669.11 INTS4P1 4.01 8.39e-05 0.0307 0.53 0.26 Diabetic kidney disease; chr7:65846311 chr7:65141225~65234216:+ CESC cis rs2243480 0.901 rs73142137 ENSG00000164669.11 INTS4P1 4.01 8.39e-05 0.0307 0.53 0.26 Diabetic kidney disease; chr7:65878455 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs13247184 ENSG00000164669.11 INTS4P1 4.01 8.39e-05 0.0307 0.53 0.26 Diabetic kidney disease; chr7:65893941 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs35283677 ENSG00000164669.11 INTS4P1 4.01 8.39e-05 0.0307 0.53 0.26 Diabetic kidney disease; chr7:65894246 chr7:65141225~65234216:+ CESC cis rs748404 0.578 rs510108 ENSG00000205771.5 CATSPER2P1 -4.01 8.4e-05 0.0307 -0.31 -0.26 Lung cancer; chr15:43313241 chr15:43726918~43747094:- CESC cis rs673078 0.66 rs16948197 ENSG00000275759.1 RP11-131L12.3 4.01 8.4e-05 0.0307 0.53 0.26 Glucose homeostasis traits; chr12:118239135 chr12:118428281~118428870:+ CESC cis rs9487094 0.67 rs12199154 ENSG00000260273.1 RP11-425D10.10 -4.01 8.41e-05 0.0308 -0.33 -0.26 Height; chr6:109501793 chr6:109382795~109383666:+ CESC cis rs9532669 0.963 rs1056835 ENSG00000239827.7 SUGT1P3 -4.01 8.41e-05 0.0308 -0.29 -0.26 Cervical cancer; chr13:40932585 chr13:40908159~40921774:- CESC cis rs2404602 0.692 rs1116535 ENSG00000280730.1 AC090181.1 -4.01 8.41e-05 0.0308 -0.2 -0.26 Blood metabolite levels; chr15:76717173 chr15:77056895~77057021:+ CESC cis rs7703051 0.585 rs918623 ENSG00000271815.1 CTD-2235C13.3 -4.01 8.41e-05 0.0308 -0.36 -0.26 Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes; chr5:75300857 chr5:75363760~75364242:+ CESC cis rs10129255 0.719 rs7156660 ENSG00000211974.3 IGHV2-70 4.01 8.41e-05 0.0308 0.26 0.26 Kawasaki disease; chr14:106673171 chr14:106723574~106724093:- CESC cis rs6997458 0.869 rs11261474 ENSG00000253549.4 RP11-317J10.2 4.01 8.41e-05 0.0308 0.31 0.26 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85382421 chr8:85441851~85464915:- CESC cis rs10958369 0.613 rs7829521 ENSG00000253369.1 RP11-1081M5.1 4.01 8.41e-05 0.0308 0.3 0.26 Response to antineoplastic agents; chr8:53521328 chr8:53395211~53395946:- CESC cis rs831571 0.55 rs153734 ENSG00000280620.1 SCAANT1 4.01 8.41e-05 0.0308 0.41 0.26 Type 2 diabetes; chr3:64092333 chr3:63911518~63911772:- CESC cis rs755249 0.583 rs61779328 ENSG00000228060.1 RP11-69E11.8 -4.01 8.41e-05 0.0308 -0.35 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39487795 chr1:39565160~39573203:+ CESC cis rs2554380 0.628 rs919069 ENSG00000230373.7 GOLGA6L5P -4.01 8.42e-05 0.0308 -0.32 -0.26 Height; chr15:83775776 chr15:84507885~84516814:- CESC cis rs2554380 0.628 rs6602990 ENSG00000230373.7 GOLGA6L5P -4.01 8.42e-05 0.0308 -0.32 -0.26 Height; chr15:83783470 chr15:84507885~84516814:- CESC cis rs16865252 0.85 rs67695221 ENSG00000213169.3 RP11-393N4.2 4.01 8.42e-05 0.0308 0.33 0.26 Blood osmolality (transformed sodium); chr3:174833018 chr3:174377244~174378005:+ CESC cis rs875971 0.502 rs2465121 ENSG00000222364.1 RNU6-96P 4.01 8.42e-05 0.0308 0.37 0.26 Aortic root size; chr7:66156017 chr7:66395191~66395286:+ CESC cis rs9322193 0.923 rs9800736 ENSG00000216906.2 RP11-350J20.9 4.01 8.42e-05 0.0308 0.29 0.26 Lung cancer; chr6:149661281 chr6:149904243~149906418:+ CESC cis rs2302729 0.545 rs10161275 ENSG00000243663.1 RPS4XP14 -4.01 8.43e-05 0.0308 -0.29 -0.26 Sleep quality; chr12:2661852 chr12:1757231~1758011:- CESC cis rs7005380 0.62 rs7387264 ENSG00000279347.1 RP11-85I17.2 -4.01 8.43e-05 0.0308 -0.24 -0.26 Interstitial lung disease; chr8:119913758 chr8:119838736~119840385:- CESC cis rs7581030 0.517 rs13033146 ENSG00000281195.1 ZNF638-IT1 -4.01 8.44e-05 0.0308 -0.39 -0.26 Testicular germ cell tumor; chr2:71217798 chr2:71373938~71376320:+ CESC cis rs7005380 0.581 rs9649949 ENSG00000279347.1 RP11-85I17.2 -4.01 8.44e-05 0.0308 -0.28 -0.26 Interstitial lung disease; chr8:119901335 chr8:119838736~119840385:- CESC cis rs7005380 0.581 rs12677306 ENSG00000279347.1 RP11-85I17.2 -4.01 8.44e-05 0.0308 -0.28 -0.26 Interstitial lung disease; chr8:119903842 chr8:119838736~119840385:- CESC cis rs7005380 0.538 rs7461170 ENSG00000279347.1 RP11-85I17.2 -4.01 8.44e-05 0.0308 -0.28 -0.26 Interstitial lung disease; chr8:119904014 chr8:119838736~119840385:- CESC cis rs17818399 1 rs62136864 ENSG00000279254.1 RP11-536C12.1 -4.01 8.44e-05 0.0309 -0.32 -0.26 Height; chr2:46601985 chr2:46668870~46670778:+ CESC cis rs5758659 0.652 rs133300 ENSG00000273366.1 CTA-989H11.1 -4.01 8.44e-05 0.0309 -0.33 -0.26 Cognitive function; chr22:41993835 chr22:42278188~42278846:+ CESC cis rs875971 1 rs875971 ENSG00000237310.1 GS1-124K5.4 -4.01 8.45e-05 0.0309 -0.24 -0.26 Aortic root size; chr7:66152608 chr7:66493706~66495474:+ CESC cis rs950880 0.553 rs2241116 ENSG00000234389.1 AC007278.3 -4.01 8.45e-05 0.0309 -0.3 -0.26 Serum protein levels (sST2); chr2:102386805 chr2:102438713~102440475:+ CESC cis rs2144940 0.545 rs844847 ENSG00000232645.4 LINC01431 -4.01 8.45e-05 0.0309 -0.41 -0.26 Venous thromboembolism; chr20:23112063 chr20:23356594~23358116:- CESC cis rs17301013 0.507 rs16846949 ENSG00000227373.4 RP11-160H22.5 4.01 8.45e-05 0.0309 0.4 0.26 Systemic lupus erythematosus; chr1:174402071 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs7413513 ENSG00000227373.4 RP11-160H22.5 4.01 8.45e-05 0.0309 0.4 0.26 Systemic lupus erythematosus; chr1:174403163 chr1:174115300~174160004:- CESC cis rs35740288 0.77 rs1382538 ENSG00000202081.1 RNU6-1280P 4.01 8.45e-05 0.0309 0.34 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85622665 chr15:85651522~85651628:- CESC cis rs16885979 1 rs12664791 ENSG00000224984.1 RP11-524H19.2 4.01 8.45e-05 0.0309 0.54 0.26 Daytime sleep phenotypes; chr6:54829547 chr6:54840118~54840855:- CESC cis rs172166 0.637 rs1233708 ENSG00000216901.1 AL022393.7 4.01 8.45e-05 0.0309 0.3 0.26 Cardiac Troponin-T levels; chr6:28205441 chr6:28176188~28176674:+ CESC cis rs1799949 1 rs35070007 ENSG00000267681.1 CTD-3199J23.6 4.01 8.45e-05 0.0309 0.32 0.26 Menopause (age at onset); chr17:43164730 chr17:43144956~43145255:+ CESC cis rs875971 1 rs9986696 ENSG00000179406.6 LINC00174 4.01 8.46e-05 0.0309 0.27 0.26 Aortic root size; chr7:66239589 chr7:66376044~66401338:- CESC cis rs10129255 0.701 rs2005643 ENSG00000211974.3 IGHV2-70 4.01 8.46e-05 0.0309 0.26 0.26 Kawasaki disease; chr14:106676288 chr14:106723574~106724093:- CESC cis rs2717068 0.526 rs2125924 ENSG00000231043.3 AC007238.1 4.01 8.46e-05 0.0309 0.31 0.26 Epilepsy (generalized); chr2:57716432 chr2:58460292~58462032:- CESC cis rs875971 1 rs2077593 ENSG00000232559.3 GS1-124K5.12 4.01 8.46e-05 0.0309 0.29 0.26 Aortic root size; chr7:66427543 chr7:66554588~66576923:- CESC cis rs2721195 0.719 rs4925811 ENSG00000255182.2 CTD-2517M22.14 -4.01 8.46e-05 0.0309 -0.22 -0.26 Age at first birth; chr8:144577063 chr8:144495458~144505444:- CESC cis rs516805 0.748 rs577744 ENSG00000279453.1 RP3-425C14.4 -4.01 8.46e-05 0.0309 -0.34 -0.26 Lymphocyte counts; chr6:122447712 chr6:122436789~122439223:- CESC cis rs17206232 1 rs17206232 ENSG00000269961.1 CTD-2033C11.1 -4.01 8.47e-05 0.0309 -0.36 -0.26 Schizophrenia; chr5:65137573 chr5:65924629~65925135:- CESC cis rs875971 0.545 rs6979636 ENSG00000222364.1 RNU6-96P -4.01 8.47e-05 0.0309 -0.35 -0.26 Aortic root size; chr7:66276638 chr7:66395191~66395286:+ CESC cis rs875971 1 rs1981798 ENSG00000237310.1 GS1-124K5.4 4.01 8.47e-05 0.0309 0.25 0.26 Aortic root size; chr7:66489916 chr7:66493706~66495474:+ CESC cis rs2274273 0.624 rs8014477 ENSG00000258413.1 RP11-665C16.6 4.01 8.48e-05 0.031 0.34 0.26 Protein biomarker; chr14:55374759 chr14:55262767~55272075:- CESC cis rs8080784 1 rs2889993 ENSG00000266992.1 DHX40P1 4.01 8.48e-05 0.031 0.34 0.26 Coronary artery disease; chr17:60949179 chr17:59976009~60002384:- CESC cis rs516805 0.961 rs483933 ENSG00000279453.1 RP3-425C14.4 -4.01 8.48e-05 0.031 -0.3 -0.26 Lymphocyte counts; chr6:122460377 chr6:122436789~122439223:- CESC cis rs7727544 0.606 rs2631360 ENSG00000233006.5 AC034220.3 4.01 8.48e-05 0.031 0.29 0.26 Blood metabolite levels; chr5:132371737 chr5:132311285~132369916:- CESC cis rs2277027 1 rs2277027 ENSG00000251405.2 CTB-109A12.1 4.01 8.48e-05 0.031 0.32 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157505368 chr5:157362615~157460078:- CESC cis rs2277027 0.956 rs10078178 ENSG00000251405.2 CTB-109A12.1 4.01 8.48e-05 0.031 0.32 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157505976 chr5:157362615~157460078:- CESC cis rs2277027 1 rs9313617 ENSG00000251405.2 CTB-109A12.1 4.01 8.48e-05 0.031 0.32 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157506450 chr5:157362615~157460078:- CESC cis rs2439831 0.85 rs12441984 ENSG00000249839.1 AC011330.5 -4.01 8.48e-05 0.031 -0.38 -0.26 Lung cancer in ever smokers; chr15:43834087 chr15:43663654~43684339:- CESC cis rs8127691 0.967 rs762422 ENSG00000225331.1 AP001055.6 -4.01 8.49e-05 0.031 -0.32 -0.26 Inflammatory bowel disease; chr21:44195755 chr21:44158740~44160076:- CESC cis rs1124769 0.692 rs12595526 ENSG00000259378.1 DCAF13P3 4.01 8.49e-05 0.031 0.35 0.26 Cognitive performance; chr15:50932824 chr15:50944663~50945996:+ CESC cis rs2019137 0.56 rs11123172 ENSG00000189223.12 PAX8-AS1 4.01 8.49e-05 0.031 0.33 0.26 Lymphocyte counts; chr2:113226726 chr2:113211522~113276581:+ CESC cis rs10483853 0.806 rs12586996 ENSG00000258695.2 RP3-414A15.2 4.01 8.5e-05 0.031 0.36 0.26 Coronary artery calcification; chr14:73342516 chr14:73522878~73530610:+ CESC cis rs2243480 1 rs35391607 ENSG00000232559.3 GS1-124K5.12 4.01 8.5e-05 0.031 0.43 0.26 Diabetic kidney disease; chr7:65895842 chr7:66554588~66576923:- CESC cis rs2243480 1 rs13220979 ENSG00000232559.3 GS1-124K5.12 4.01 8.5e-05 0.031 0.43 0.26 Diabetic kidney disease; chr7:65898217 chr7:66554588~66576923:- CESC cis rs2243480 1 rs34974928 ENSG00000232559.3 GS1-124K5.12 4.01 8.5e-05 0.031 0.43 0.26 Diabetic kidney disease; chr7:65899019 chr7:66554588~66576923:- CESC cis rs2243480 0.803 rs34804747 ENSG00000232559.3 GS1-124K5.12 4.01 8.5e-05 0.031 0.43 0.26 Diabetic kidney disease; chr7:65947955 chr7:66554588~66576923:- CESC cis rs2276314 1 rs8086395 ENSG00000278986.1 RP11-723J4.3 -4.01 8.51e-05 0.031 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35984629 chr18:35972151~35973916:+ CESC cis rs2276314 0.947 rs3898595 ENSG00000278986.1 RP11-723J4.3 -4.01 8.51e-05 0.031 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35985922 chr18:35972151~35973916:+ CESC cis rs11971779 0.793 rs11543827 ENSG00000273391.1 RP11-634H22.1 4 8.51e-05 0.031 0.28 0.26 Diisocyanate-induced asthma; chr7:139347947 chr7:139359032~139359566:- CESC cis rs7617773 0.78 rs34523942 ENSG00000228638.1 FCF1P2 -4 8.51e-05 0.0311 -0.28 -0.26 Coronary artery disease; chr3:48301179 chr3:48290793~48291375:- CESC cis rs79243044 1 rs10838276 ENSG00000224295.2 AC087380.14 4 8.51e-05 0.0311 0.29 0.26 QRS duration in Tripanosoma cruzi seropositivity; chr11:5534273 chr11:5518441~5524955:- CESC cis rs9918079 0.542 rs7688984 ENSG00000273133.1 RP11-799M12.2 -4 8.52e-05 0.0311 -0.35 -0.26 Obesity-related traits; chr4:15655630 chr4:15563698~15564253:- CESC cis rs11089937 0.568 rs5756989 ENSG00000211638.2 IGLV8-61 -4 8.52e-05 0.0311 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22132415 chr22:22098700~22099212:+ CESC cis rs673078 0.607 rs73207504 ENSG00000275759.1 RP11-131L12.3 -4 8.52e-05 0.0311 -0.5 -0.26 Glucose homeostasis traits; chr12:118427914 chr12:118428281~118428870:+ CESC cis rs11971779 0.793 rs4732366 ENSG00000273391.1 RP11-634H22.1 4 8.53e-05 0.0311 0.28 0.26 Diisocyanate-induced asthma; chr7:139343099 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs4732369 ENSG00000273391.1 RP11-634H22.1 4 8.54e-05 0.0311 0.25 0.26 Diisocyanate-induced asthma; chr7:139384427 chr7:139359032~139359566:- CESC cis rs875971 1 rs6460296 ENSG00000237310.1 GS1-124K5.4 4 8.54e-05 0.0311 0.25 0.26 Aortic root size; chr7:66430152 chr7:66493706~66495474:+ CESC cis rs875971 1 rs2042133 ENSG00000237310.1 GS1-124K5.4 4 8.54e-05 0.0311 0.25 0.26 Aortic root size; chr7:66466935 chr7:66493706~66495474:+ CESC cis rs875971 0.964 rs2161065 ENSG00000237310.1 GS1-124K5.4 4 8.54e-05 0.0311 0.25 0.26 Aortic root size; chr7:66467918 chr7:66493706~66495474:+ CESC cis rs875971 0.862 rs12698521 ENSG00000237310.1 GS1-124K5.4 4 8.54e-05 0.0311 0.25 0.26 Aortic root size; chr7:66474502 chr7:66493706~66495474:+ CESC cis rs2239557 0.529 rs2041185 ENSG00000259065.1 RP5-1021I20.1 4 8.54e-05 0.0311 0.36 0.26 Common traits (Other); chr14:73815387 chr14:73787360~73803270:+ CESC cis rs7617773 0.817 rs6801801 ENSG00000228638.1 FCF1P2 -4 8.54e-05 0.0311 -0.28 -0.26 Coronary artery disease; chr3:48284943 chr3:48290793~48291375:- CESC cis rs17301013 0.507 rs10912758 ENSG00000227373.4 RP11-160H22.5 4 8.55e-05 0.0312 0.37 0.26 Systemic lupus erythematosus; chr1:174300822 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs1121537 ENSG00000227373.4 RP11-160H22.5 4 8.55e-05 0.0312 0.37 0.26 Systemic lupus erythematosus; chr1:174307568 chr1:174115300~174160004:- CESC cis rs62025270 0.688 rs7164373 ENSG00000202081.1 RNU6-1280P -4 8.55e-05 0.0312 -0.36 -0.26 Idiopathic pulmonary fibrosis; chr15:85722432 chr15:85651522~85651628:- CESC cis rs7688540 0.771 rs7674560 ENSG00000211553.1 AC253576.2 -4 8.55e-05 0.0312 -0.39 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:269530 chr4:136461~136568:+ CESC cis rs7617773 0.817 rs9837228 ENSG00000228638.1 FCF1P2 4 8.55e-05 0.0312 0.28 0.26 Coronary artery disease; chr3:48282976 chr3:48290793~48291375:- CESC cis rs453301 0.686 rs7017868 ENSG00000173295.6 FAM86B3P -4 8.55e-05 0.0312 -0.34 -0.26 Joint mobility (Beighton score); chr8:9015783 chr8:8228595~8244865:+ CESC cis rs453301 0.686 rs3895823 ENSG00000173295.6 FAM86B3P -4 8.55e-05 0.0312 -0.34 -0.26 Joint mobility (Beighton score); chr8:9016136 chr8:8228595~8244865:+ CESC cis rs881375 0.9 rs1930786 ENSG00000226752.6 PSMD5-AS1 -4 8.56e-05 0.0312 -0.28 -0.26 Rheumatoid arthritis; chr9:120929191 chr9:120824828~120854385:+ CESC cis rs881375 0.967 rs7864019 ENSG00000226752.6 PSMD5-AS1 -4 8.56e-05 0.0312 -0.28 -0.26 Rheumatoid arthritis; chr9:120930590 chr9:120824828~120854385:+ CESC cis rs881375 0.967 rs10739579 ENSG00000226752.6 PSMD5-AS1 -4 8.56e-05 0.0312 -0.28 -0.26 Rheumatoid arthritis; chr9:120932510 chr9:120824828~120854385:+ CESC cis rs1862618 0.641 rs170733 ENSG00000271828.1 CTD-2310F14.1 -4 8.57e-05 0.0312 -0.32 -0.26 Initial pursuit acceleration; chr5:56953424 chr5:56927874~56929573:+ CESC cis rs6687821 0.531 rs4656135 ENSG00000267734.1 RP4-604K5.3 -4 8.57e-05 0.0312 -0.31 -0.26 Yeast infection; chr1:87023404 chr1:86932199~86934891:- CESC cis rs393155 0.517 rs330050 ENSG00000254340.1 RP11-10A14.3 -4 8.57e-05 0.0312 -0.32 -0.26 Neuroticism; chr8:9230169 chr8:9141424~9145435:+ CESC cis rs453301 0.571 rs330054 ENSG00000254340.1 RP11-10A14.3 -4 8.57e-05 0.0312 -0.32 -0.26 Joint mobility (Beighton score); chr8:9230781 chr8:9141424~9145435:+ CESC cis rs7044106 0.69 rs10739569 ENSG00000238181.2 AHCYP2 -4 8.57e-05 0.0312 -0.32 -0.26 Hip circumference adjusted for BMI; chr9:120598749 chr9:120720673~120721972:+ CESC cis rs7208859 0.615 rs216462 ENSG00000266490.1 CTD-2349P21.9 -4 8.58e-05 0.0313 -0.45 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30568879 chr17:30792372~30792833:+ CESC cis rs61743561 0.512 rs2651195 ENSG00000179157.4 RPS2P28 4 8.58e-05 0.0313 0.45 0.26 Obesity-related traits; chr6:43220028 chr6:43363479~43364219:+ CESC cis rs875971 0.502 rs2465121 ENSG00000236529.1 RP13-254B10.1 -4 8.58e-05 0.0313 -0.34 -0.26 Aortic root size; chr7:66156017 chr7:65840212~65840596:+ CESC cis rs451417 1 rs236110 ENSG00000275632.1 RP5-967N21.11 4 8.58e-05 0.0313 0.34 0.26 Menopause (age at onset); chr20:5952462 chr20:6000418~6000941:+ CESC cis rs4272720 0.666 rs9804403 ENSG00000229870.1 RP11-507K13.6 -4 8.58e-05 0.0313 -0.3 -0.26 Platelet count;Plateletcrit; chr10:49054099 chr10:49815096~49815562:+ CESC cis rs3124314 1 rs12033735 ENSG00000229021.2 AL591893.1 -4 8.59e-05 0.0313 -0.28 -0.26 Hair morphology; chr1:152167815 chr1:151994531~152042774:+ CESC cis rs1729407 0.695 rs1263176 ENSG00000254851.1 RP11-109L13.1 -4 8.59e-05 0.0313 -0.29 -0.26 Apolipoprotein A-IV levels; chr11:116819407 chr11:117135528~117138582:+ CESC cis rs5769765 0.819 rs9616377 ENSG00000229409.1 RP11-494O16.3 4 8.59e-05 0.0313 0.38 0.26 Schizophrenia; chr22:49917232 chr22:49845929~49846090:+ CESC cis rs12908161 0.92 rs35758837 ENSG00000259728.4 LINC00933 4 8.59e-05 0.0313 0.34 0.26 Schizophrenia; chr15:84768151 chr15:84570649~84580175:+ CESC cis rs11096990 0.855 rs2566183 ENSG00000249207.1 RP11-360F5.1 4 8.6e-05 0.0313 0.34 0.26 Cognitive function; chr4:39162288 chr4:39112677~39126818:- CESC cis rs7005380 0.581 rs13265734 ENSG00000279347.1 RP11-85I17.2 -4 8.6e-05 0.0313 -0.29 -0.26 Interstitial lung disease; chr8:119907708 chr8:119838736~119840385:- CESC cis rs950880 0.677 rs17027087 ENSG00000234389.1 AC007278.3 -4 8.6e-05 0.0313 -0.28 -0.26 Serum protein levels (sST2); chr2:102399458 chr2:102438713~102440475:+ CESC cis rs8030379 1 rs2030839 ENSG00000230373.7 GOLGA6L5P -4 8.6e-05 0.0313 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83915207 chr15:84507885~84516814:- CESC cis rs7282265 0.646 rs9981615 ENSG00000260583.1 AP000223.42 4 8.6e-05 0.0313 0.35 0.26 Chronic sinus infection; chr21:25395156 chr21:25582770~25583326:- CESC cis rs7937890 0.505 rs4403769 ENSG00000251991.1 RNU7-49P 4 8.61e-05 0.0313 0.28 0.26 Mitochondrial DNA levels; chr11:14428630 chr11:14478892~14478953:+ CESC cis rs11157436 1 rs61972228 ENSG00000211812.1 TRAV26-2 -4 8.61e-05 0.0313 -0.29 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22179460 chr14:22202583~22203368:+ CESC cis rs11157436 1 rs12587157 ENSG00000211812.1 TRAV26-2 -4 8.61e-05 0.0313 -0.29 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22181476 chr14:22202583~22203368:+ CESC cis rs11157436 0.915 rs11622938 ENSG00000211812.1 TRAV26-2 -4 8.61e-05 0.0313 -0.29 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22183456 chr14:22202583~22203368:+ CESC cis rs7524102 0.636 rs7513562 ENSG00000218510.5 LINC00339 -4 8.61e-05 0.0314 -0.36 -0.26 Bone mineral density;Ulcerative colitis;Bone mineral density (spine);Dupuytren's disease;Bone mineral density (hip); chr1:22384676 chr1:22025188~22031223:+ CESC cis rs1045529 0.524 rs34251783 ENSG00000173295.6 FAM86B3P -4 8.62e-05 0.0314 -0.34 -0.26 Myopia (pathological);Myopia; chr8:9033866 chr8:8228595~8244865:+ CESC cis rs77972916 0.561 rs10167415 ENSG00000234936.1 AC010883.5 4 8.62e-05 0.0314 0.33 0.26 Granulocyte percentage of myeloid white cells; chr2:43325321 chr2:43229573~43233394:+ CESC cis rs9487094 0.67 rs2277114 ENSG00000260273.1 RP11-425D10.10 4 8.62e-05 0.0314 0.33 0.26 Height; chr6:109506513 chr6:109382795~109383666:+ CESC cis rs10829156 0.699 rs6482516 ENSG00000240291.1 RP11-499P20.2 4 8.62e-05 0.0314 0.28 0.26 Sudden cardiac arrest; chr10:18550421 chr10:18513115~18545651:- CESC cis rs10043775 0.915 rs12717973 ENSG00000251330.3 CTD-2283N19.1 -4 8.63e-05 0.0314 -0.36 -0.26 Periodontal microbiota; chr5:148414408 chr5:148430159~148430807:- CESC cis rs1816537 0.625 rs10891518 ENSG00000256452.1 RP11-667M19.10 4 8.63e-05 0.0314 0.25 0.26 Body mass index; chr11:113148242 chr11:113818077~113822458:+ CESC cis rs916888 0.773 rs199451 ENSG00000232300.1 FAM215B 4 8.63e-05 0.0314 0.42 0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46558830~46562795:- CESC cis rs889398 0.967 rs62052816 ENSG00000226232.7 RP11-419C5.2 4 8.64e-05 0.0314 0.24 0.26 Body mass index; chr16:69529503 chr16:69976388~69996188:- CESC cis rs889398 0.967 rs12929503 ENSG00000226232.7 RP11-419C5.2 4 8.64e-05 0.0314 0.24 0.26 Body mass index; chr16:69531558 chr16:69976388~69996188:- CESC cis rs889398 0.935 rs12933292 ENSG00000226232.7 RP11-419C5.2 4 8.64e-05 0.0314 0.24 0.26 Body mass index; chr16:69532406 chr16:69976388~69996188:- CESC cis rs853679 0.55 rs1233699 ENSG00000219392.1 RP1-265C24.5 -4 8.64e-05 0.0314 -0.32 -0.26 Depression; chr6:28201380 chr6:28115628~28116551:+ CESC cis rs11971779 0.616 rs6974907 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139383983 chr7:139359032~139359566:- CESC cis rs11971779 0.584 rs10236055 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139385245 chr7:139359032~139359566:- CESC cis rs11971779 0.584 rs6942519 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139385344 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6467843 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139385777 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs2355785 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139386237 chr7:139359032~139359566:- CESC cis rs11971779 0.588 rs6972408 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139386728 chr7:139359032~139359566:- CESC cis rs11971779 0.625 rs2355784 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139387747 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs2883772 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139388010 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs28579232 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139388370 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs2355783 ENSG00000273391.1 RP11-634H22.1 4 8.64e-05 0.0314 0.25 0.26 Diisocyanate-induced asthma; chr7:139391133 chr7:139359032~139359566:- CESC cis rs172166 0.694 rs1150666 ENSG00000219392.1 RP1-265C24.5 -4 8.65e-05 0.0315 -0.31 -0.26 Cardiac Troponin-T levels; chr6:28156150 chr6:28115628~28116551:+ CESC cis rs35740288 0.857 rs11632034 ENSG00000202081.1 RNU6-1280P 4 8.65e-05 0.0315 0.32 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85740841 chr15:85651522~85651628:- CESC cis rs638893 0.842 rs480791 ENSG00000278376.1 RP11-158I9.8 -4 8.65e-05 0.0315 -0.4 -0.26 Vitiligo; chr11:118833546 chr11:118791254~118793137:+ CESC cis rs36093924 0.646 rs4822069 ENSG00000273366.1 CTA-989H11.1 4 8.66e-05 0.0315 0.33 0.26 Intelligence; chr22:41955477 chr22:42278188~42278846:+ CESC cis rs2288884 0.537 rs7254254 ENSG00000275055.1 CTC-471J1.11 -4 8.66e-05 0.0315 -0.3 -0.26 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52035824 chr19:52049007~52049754:+ CESC cis rs748404 0.666 rs12907870 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43453971 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs72709850 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43462486 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs36078097 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43466209 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs7181783 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43469723 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs35903301 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43472332 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs34002293 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43472401 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs34181131 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43478527 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs7173383 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43480838 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs55801120 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43495042 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs12911740 ENSG00000249839.1 AC011330.5 -4 8.66e-05 0.0315 -0.37 -0.26 Lung cancer; chr15:43498254 chr15:43663654~43684339:- CESC cis rs11089937 0.597 rs5756991 ENSG00000211638.2 IGLV8-61 -4 8.66e-05 0.0315 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22132541 chr22:22098700~22099212:+ CESC cis rs2552220 0.647 rs2700714 ENSG00000246089.3 RP11-115C21.2 4 8.66e-05 0.0315 0.26 0.26 Interleukin-8 levels; chr8:6141899 chr8:6403551~6407142:- CESC cis rs7560272 0.501 rs2421676 ENSG00000273245.1 RP11-434P11.2 -4 8.66e-05 0.0315 -0.32 -0.26 Schizophrenia; chr2:73738960 chr2:73750256~73750786:- CESC cis rs42490 0.664 rs43227 ENSG00000251136.7 RP11-37B2.1 -4 8.66e-05 0.0315 -0.26 -0.26 Leprosy; chr8:89809351 chr8:89609409~89757727:- CESC cis rs62355901 0.545 rs58774999 ENSG00000271828.1 CTD-2310F14.1 4 8.67e-05 0.0315 0.41 0.26 Breast cancer; chr5:56798018 chr5:56927874~56929573:+ CESC cis rs950880 0.553 rs2293225 ENSG00000234389.1 AC007278.3 -4 8.67e-05 0.0315 -0.3 -0.26 Serum protein levels (sST2); chr2:102419429 chr2:102438713~102440475:+ CESC cis rs67311347 1 rs66841330 ENSG00000223797.4 ENTPD3-AS1 4 8.67e-05 0.0315 0.27 0.26 Renal cell carcinoma; chr3:40489632 chr3:40313802~40453329:- CESC cis rs6504622 0.967 rs11869840 ENSG00000263142.4 LRRC37A17P -4 8.67e-05 0.0315 -0.21 -0.26 Orofacial clefts; chr17:46918734 chr17:46978481~47054569:+ CESC cis rs7951870 0.945 rs58147945 ENSG00000247675.5 LRP4-AS1 -4 8.68e-05 0.0315 -0.33 -0.26 Schizophrenia; chr11:46479104 chr11:46846412~46874396:+ CESC cis rs7951870 1 rs1489192 ENSG00000247675.5 LRP4-AS1 -4 8.68e-05 0.0315 -0.33 -0.26 Schizophrenia; chr11:46487794 chr11:46846412~46874396:+ CESC cis rs4319547 0.626 rs11057882 ENSG00000275265.1 RP11-15J22.8 -4 8.68e-05 0.0315 -0.37 -0.26 Body mass index; chr12:122390499 chr12:122501187~122501641:+ CESC cis rs4319547 0.695 rs7969429 ENSG00000275265.1 RP11-15J22.8 -4 8.68e-05 0.0315 -0.37 -0.26 Body mass index; chr12:122391059 chr12:122501187~122501641:+ CESC cis rs13268726 0.512 rs12682006 ENSG00000253167.1 KIAA0196-AS1 4 8.68e-05 0.0315 0.3 0.26 Amyotrophic lateral sclerosis; chr8:125083626 chr8:125040684~125044989:+ CESC cis rs8020095 0.571 rs8012776 ENSG00000258561.1 RP11-72M17.1 -4 8.68e-05 0.0315 -0.38 -0.26 Depression (quantitative trait); chr14:67121161 chr14:66212810~66509394:- CESC cis rs8042680 0.688 rs28404354 ENSG00000214432.8 AC068831.10 -4 8.68e-05 0.0315 -0.5 -0.26 Type 2 diabetes; chr15:90995820 chr15:91022619~91036611:+ CESC cis rs4713118 0.868 rs10484401 ENSG00000219392.1 RP1-265C24.5 4 8.68e-05 0.0315 0.33 0.26 Parkinson's disease; chr6:27778811 chr6:28115628~28116551:+ CESC cis rs4974559 0.739 rs3817604 ENSG00000253399.1 AC078852.2 4 8.69e-05 0.0316 0.45 0.26 Systolic blood pressure; chr4:1297549 chr4:1358479~1359461:+ CESC cis rs2425143 0.514 rs8114246 ENSG00000201151.1 SNORD56 -4 8.69e-05 0.0316 -0.37 -0.26 Blood protein levels; chr20:35994057 chr20:35117136~35117207:- CESC cis rs7429990 0.932 rs60446735 ENSG00000229759.1 MRPS18AP1 4 8.7e-05 0.0316 0.27 0.26 Educational attainment (years of education); chr3:47929958 chr3:48256350~48256938:- CESC cis rs8020095 0.571 rs10138850 ENSG00000258561.1 RP11-72M17.1 4 8.7e-05 0.0316 0.39 0.26 Depression (quantitative trait); chr14:67140051 chr14:66212810~66509394:- CESC cis rs748404 0.697 rs554001 ENSG00000249839.1 AC011330.5 -4 8.7e-05 0.0316 -0.27 -0.26 Lung cancer; chr15:43259721 chr15:43663654~43684339:- CESC cis rs8127691 0.967 rs4380337 ENSG00000225331.1 AP001055.6 4 8.7e-05 0.0316 0.32 0.26 Inflammatory bowel disease; chr21:44196166 chr21:44158740~44160076:- CESC cis rs440932 1 rs378974 ENSG00000253893.2 FAM85B -4 8.71e-05 0.0316 -0.32 -0.26 High light scatter reticulocyte percentage of red cells; chr8:9169129 chr8:8167819~8226614:- CESC cis rs8020095 0.571 rs10136344 ENSG00000258561.1 RP11-72M17.1 -4 8.72e-05 0.0317 -0.39 -0.26 Depression (quantitative trait); chr14:66943760 chr14:66212810~66509394:- CESC cis rs227932 0.541 rs78177212 ENSG00000234286.1 AC006026.13 -4 8.72e-05 0.0317 -0.35 -0.26 Schizophrenia; chr7:23770500 chr7:23680195~23680786:- CESC cis rs673078 0.66 rs17440336 ENSG00000275759.1 RP11-131L12.3 4 8.72e-05 0.0317 0.52 0.26 Glucose homeostasis traits; chr12:118163305 chr12:118428281~118428870:+ CESC cis rs11098499 0.909 rs73842633 ENSG00000248280.1 RP11-33B1.2 4 8.72e-05 0.0317 0.31 0.26 Corneal astigmatism; chr4:119454309 chr4:119440561~119450157:- CESC cis rs2721195 0.614 rs12719778 ENSG00000255182.2 CTD-2517M22.14 4 8.73e-05 0.0317 0.23 0.26 Age at first birth; chr8:144654498 chr8:144495458~144505444:- CESC cis rs4927850 1 rs4927850 ENSG00000231464.1 AC024937.4 -4 8.74e-05 0.0317 -0.32 -0.26 Pancreatic cancer; chr3:196024759 chr3:195996738~195998233:+ CESC cis rs11098499 0.644 rs7693919 ENSG00000248280.1 RP11-33B1.2 4 8.74e-05 0.0317 0.29 0.26 Corneal astigmatism; chr4:119619416 chr4:119440561~119450157:- CESC cis rs1124769 0.671 rs36004063 ENSG00000259378.1 DCAF13P3 4 8.74e-05 0.0317 0.35 0.26 Cognitive performance; chr15:50938637 chr15:50944663~50945996:+ CESC cis rs7178909 0.902 rs8033554 ENSG00000259677.1 RP11-493E3.1 4 8.74e-05 0.0317 0.3 0.26 Common traits (Other); chr15:89898337 chr15:89876540~89877285:+ CESC cis rs9309473 1 rs7585004 ENSG00000163016.8 ALMS1P 4 8.74e-05 0.0317 0.33 0.26 Metabolite levels; chr2:73439517 chr2:73644919~73685576:+ CESC cis rs860295 0.557 rs12035524 ENSG00000225855.5 RUSC1-AS1 4 8.74e-05 0.0317 0.24 0.26 Body mass index; chr1:155697311 chr1:155316863~155324176:- CESC cis rs17301013 0.507 rs11807229 ENSG00000227373.4 RP11-160H22.5 4 8.74e-05 0.0317 0.41 0.26 Systemic lupus erythematosus; chr1:174519456 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs72715237 ENSG00000227373.4 RP11-160H22.5 4 8.74e-05 0.0317 0.41 0.26 Systemic lupus erythematosus; chr1:174550527 chr1:174115300~174160004:- CESC cis rs7246657 0.551 rs12978093 ENSG00000276846.1 CTD-3220F14.3 4 8.75e-05 0.0317 0.39 0.26 Coronary artery calcification; chr19:37093514 chr19:37314868~37315620:- CESC cis rs2708377 0.789 rs3911150 ENSG00000212125.2 TAS2R15P -4 8.75e-05 0.0317 -0.39 -0.26 Bitter taste perception; chr12:11049649 chr12:10964425~10965352:- CESC cis rs7208859 0.623 rs79607958 ENSG00000266490.1 CTD-2349P21.9 4 8.75e-05 0.0317 0.44 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607530 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs75136574 ENSG00000266490.1 CTD-2349P21.9 4 8.75e-05 0.0317 0.44 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607531 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs77544470 ENSG00000266490.1 CTD-2349P21.9 4 8.75e-05 0.0317 0.44 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607532 chr17:30792372~30792833:+ CESC cis rs34375054 1 rs34375054 ENSG00000279233.1 RP11-158L12.4 4 8.75e-05 0.0318 0.26 0.26 Post bronchodilator FEV1/FVC ratio; chr12:125181350 chr12:125138245~125141711:+ CESC cis rs769267 0.93 rs2301786 ENSG00000269131.1 AC004447.2 -4 8.75e-05 0.0318 -0.21 -0.26 Tonsillectomy; chr19:19303138 chr19:18990893~18993610:+ CESC cis rs12468226 0.752 rs79058237 ENSG00000273456.1 RP11-686O6.2 4 8.77e-05 0.0318 0.39 0.26 Urate levels; chr2:202140247 chr2:202374932~202375604:- CESC cis rs3091242 0.804 rs631133 ENSG00000224183.1 SDHDP6 -4 8.77e-05 0.0318 -0.28 -0.26 Erythrocyte sedimentation rate; chr1:25397655 chr1:25294164~25294643:- CESC cis rs12134133 1 rs1782468 ENSG00000274245.1 RP11-357P18.2 4 8.77e-05 0.0318 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207297070 chr1:207372559~207373252:+ CESC cis rs937213 0.712 rs2279580 ENSG00000259345.4 RP11-624L4.1 4 8.78e-05 0.0318 0.29 0.26 Endometrial cancer;Endometrial endometrioid carcinoma; chr15:40008013 chr15:38865322~39427195:- CESC cis rs7560272 0.682 rs2421546 ENSG00000273245.1 RP11-434P11.2 -4 8.78e-05 0.0319 -0.33 -0.26 Schizophrenia; chr2:73413949 chr2:73750256~73750786:- CESC cis rs6439153 0.901 rs2630263 ENSG00000261159.1 RP11-723O4.9 4 8.78e-05 0.0319 0.27 0.26 Pneumococcal bacteremia; chr3:128969475 chr3:128859716~128860526:- CESC cis rs62025270 0.632 rs62022924 ENSG00000202081.1 RNU6-1280P -4 8.79e-05 0.0319 -0.36 -0.26 Idiopathic pulmonary fibrosis; chr15:85692276 chr15:85651522~85651628:- CESC cis rs62025270 0.576 rs62022925 ENSG00000202081.1 RNU6-1280P -4 8.79e-05 0.0319 -0.36 -0.26 Idiopathic pulmonary fibrosis; chr15:85692835 chr15:85651522~85651628:- CESC cis rs7714584 0.793 rs12653039 ENSG00000197083.10 ZNF300P1 4 8.79e-05 0.0319 0.46 0.26 Crohn's disease; chr5:150873069 chr5:150930645~150946289:- CESC cis rs11096990 0.892 rs2381349 ENSG00000249207.1 RP11-360F5.1 4 8.79e-05 0.0319 0.32 0.26 Cognitive function; chr4:39210390 chr4:39112677~39126818:- CESC cis rs7829975 0.56 rs17154599 ENSG00000173295.6 FAM86B3P -4 8.79e-05 0.0319 -0.34 -0.26 Mood instability; chr8:8693908 chr8:8228595~8244865:+ CESC cis rs875971 0.545 rs73142233 ENSG00000222364.1 RNU6-96P -4 8.79e-05 0.0319 -0.37 -0.26 Aortic root size; chr7:66221293 chr7:66395191~66395286:+ CESC cis rs9925964 0.933 rs2303223 ENSG00000260911.2 RP11-196G11.2 -4 8.79e-05 0.0319 -0.29 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31063854 chr16:31043150~31049868:+ CESC cis rs992157 0.56 rs6738394 ENSG00000261338.2 RP11-378A13.1 -4 8.8e-05 0.0319 -0.33 -0.26 Colorectal cancer; chr2:218245902 chr2:218255319~218257366:+ CESC cis rs7688540 0.771 rs78343340 ENSG00000211553.1 AC253576.2 -4 8.8e-05 0.0319 -0.41 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:273648 chr4:136461~136568:+ CESC cis rs7560272 0.512 rs2421677 ENSG00000273245.1 RP11-434P11.2 -4 8.8e-05 0.0319 -0.33 -0.26 Schizophrenia; chr2:73738790 chr2:73750256~73750786:- CESC cis rs11976180 0.569 rs12703565 ENSG00000228960.5 OR2A9P -4 8.8e-05 0.0319 -0.49 -0.26 Obesity-related traits; chr7:144057308 chr7:144294480~144300934:+ CESC cis rs2439831 1 rs2444032 ENSG00000205771.5 CATSPER2P1 -4 8.8e-05 0.0319 -0.36 -0.26 Lung cancer in ever smokers; chr15:43463148 chr15:43726918~43747094:- CESC cis rs6504622 0.537 rs197919 ENSG00000263142.4 LRRC37A17P 4 8.8e-05 0.0319 0.2 0.26 Orofacial clefts; chr17:46926309 chr17:46978481~47054569:+ CESC cis rs2733201 1 rs2042741 ENSG00000275601.1 AC011330.13 4 8.8e-05 0.0319 0.41 0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44098088 chr15:43642389~43643023:- CESC cis rs71403859 0.614 rs12935422 ENSG00000260886.1 TAT-AS1 4 8.8e-05 0.0319 0.42 0.26 Post bronchodilator FEV1; chr16:71630322 chr16:71565789~71578187:+ CESC cis rs73173548 0.502 rs6865693 ENSG00000247828.6 TMEM161B-AS1 4 8.81e-05 0.0319 0.28 0.26 Macular telangiectasia type 2; chr5:88419422 chr5:88268895~88436685:+ CESC cis rs6546537 0.826 rs2704443 ENSG00000231024.1 AC092431.3 4 8.81e-05 0.0319 0.32 0.26 Serum thyroid-stimulating hormone levels; chr2:69662206 chr2:69700192~69713847:- CESC cis rs875971 0.964 rs778723 ENSG00000179406.6 LINC00174 -4 8.81e-05 0.0319 -0.28 -0.26 Aortic root size; chr7:66364510 chr7:66376044~66401338:- CESC cis rs9322193 0.923 rs9478291 ENSG00000216906.2 RP11-350J20.9 4 8.81e-05 0.0319 0.29 0.26 Lung cancer; chr6:149729434 chr6:149904243~149906418:+ CESC cis rs17772222 0.876 rs61983303 ENSG00000258983.2 RP11-507K2.2 4 8.81e-05 0.0319 0.32 0.26 Coronary artery calcification; chr14:88764459 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs2224333 ENSG00000258983.2 RP11-507K2.2 4 8.81e-05 0.0319 0.32 0.26 Coronary artery calcification; chr14:88768748 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs12590826 ENSG00000258983.2 RP11-507K2.2 4 8.81e-05 0.0319 0.32 0.26 Coronary artery calcification; chr14:88769357 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs57889459 ENSG00000258983.2 RP11-507K2.2 4 8.81e-05 0.0319 0.32 0.26 Coronary artery calcification; chr14:88770820 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs58550317 ENSG00000258983.2 RP11-507K2.2 4 8.81e-05 0.0319 0.32 0.26 Coronary artery calcification; chr14:88775243 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs61982733 ENSG00000258983.2 RP11-507K2.2 4 8.81e-05 0.0319 0.32 0.26 Coronary artery calcification; chr14:88776244 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs2145120 ENSG00000258983.2 RP11-507K2.2 4 8.81e-05 0.0319 0.32 0.26 Coronary artery calcification; chr14:88777699 chr14:88499334~88515502:+ CESC cis rs17818399 0.547 rs4953400 ENSG00000279254.1 RP11-536C12.1 -4 8.82e-05 0.0319 -0.32 -0.26 Height; chr2:46550069 chr2:46668870~46670778:+ CESC cis rs9309473 0.95 rs1052162 ENSG00000163016.8 ALMS1P -4 8.82e-05 0.0319 -0.32 -0.26 Metabolite levels; chr2:73602245 chr2:73644919~73685576:+ CESC cis rs763121 0.853 rs4821810 ENSG00000228274.3 RP3-508I15.9 -4 8.83e-05 0.032 -0.24 -0.26 Menopause (age at onset); chr22:38676093 chr22:38667585~38681820:- CESC cis rs763121 0.853 rs5757234 ENSG00000228274.3 RP3-508I15.9 -4 8.83e-05 0.032 -0.24 -0.26 Menopause (age at onset); chr22:38676681 chr22:38667585~38681820:- CESC cis rs7937890 0.559 rs2597196 ENSG00000251991.1 RNU7-49P -4 8.83e-05 0.032 -0.28 -0.26 Mitochondrial DNA levels; chr11:14470055 chr11:14478892~14478953:+ CESC cis rs2243480 0.522 rs73150635 ENSG00000232559.3 GS1-124K5.12 4 8.83e-05 0.032 0.53 0.26 Diabetic kidney disease; chr7:66507503 chr7:66554588~66576923:- CESC cis rs7809950 1 rs2237677 ENSG00000238832.1 snoU109 -4 8.83e-05 0.032 -0.31 -0.26 Coronary artery disease; chr7:107562057 chr7:107603363~107603507:+ CESC cis rs911555 0.755 rs34411783 ENSG00000244691.1 RPL10AP1 4 8.83e-05 0.032 0.36 0.26 Intelligence (multi-trait analysis); chr14:103434302 chr14:103412119~103412761:- CESC cis rs12908161 1 rs17600551 ENSG00000259728.4 LINC00933 4 8.83e-05 0.032 0.34 0.26 Schizophrenia; chr15:84776027 chr15:84570649~84580175:+ CESC cis rs12908161 1 rs36033486 ENSG00000259728.4 LINC00933 4 8.83e-05 0.032 0.34 0.26 Schizophrenia; chr15:84776461 chr15:84570649~84580175:+ CESC cis rs12908161 1 rs62019469 ENSG00000259728.4 LINC00933 4 8.83e-05 0.032 0.34 0.26 Schizophrenia; chr15:84777989 chr15:84570649~84580175:+ CESC cis rs875971 0.502 rs11769702 ENSG00000237310.1 GS1-124K5.4 4 8.84e-05 0.032 0.29 0.26 Aortic root size; chr7:66255529 chr7:66493706~66495474:+ CESC cis rs9320282 0.587 rs1546721 ENSG00000243587.6 C6orf183 -4 8.84e-05 0.032 -0.31 -0.26 Basophil percentage of white cells;White blood cell count (basophil); chr6:109304593 chr6:109165833~109271014:+ CESC cis rs6687821 0.593 rs797947 ENSG00000267734.1 RP4-604K5.3 4 8.84e-05 0.032 0.3 0.26 Yeast infection; chr1:86844606 chr1:86932199~86934891:- CESC cis rs8030379 0.967 rs62027761 ENSG00000230373.7 GOLGA6L5P -4 8.84e-05 0.032 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83903845 chr15:84507885~84516814:- CESC cis rs8030379 1 rs117031571 ENSG00000230373.7 GOLGA6L5P -4 8.84e-05 0.032 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83903902 chr15:84507885~84516814:- CESC cis rs10129255 0.5 rs1024350 ENSG00000224373.3 IGHV4-59 4 8.84e-05 0.032 0.16 0.26 Kawasaki disease; chr14:106685105 chr14:106627249~106627825:- CESC cis rs7567389 0.74 rs1604817 ENSG00000236682.1 AC068282.3 4 8.84e-05 0.032 0.34 0.26 Self-rated health; chr2:127242345 chr2:127389130~127400580:+ CESC cis rs12200782 0.505 rs7765920 ENSG00000241549.7 GUSBP2 4 8.85e-05 0.032 0.33 0.26 Small cell lung carcinoma; chr6:26514543 chr6:26871484~26956554:- CESC cis rs748404 0.601 rs489964 ENSG00000205771.5 CATSPER2P1 3.99 8.85e-05 0.032 0.32 0.26 Lung cancer; chr15:43225356 chr15:43726918~43747094:- CESC cis rs875971 0.545 rs73146609 ENSG00000237310.1 GS1-124K5.4 3.99 8.85e-05 0.0321 0.29 0.26 Aortic root size; chr7:66302477 chr7:66493706~66495474:+ CESC cis rs875971 0.545 rs2173571 ENSG00000237310.1 GS1-124K5.4 3.99 8.85e-05 0.0321 0.29 0.26 Aortic root size; chr7:66305392 chr7:66493706~66495474:+ CESC cis rs7829975 0.846 rs1879957 ENSG00000253893.2 FAM85B 3.99 8.86e-05 0.0321 0.33 0.26 Mood instability; chr8:8687298 chr8:8167819~8226614:- CESC cis rs804280 0.509 rs12719915 ENSG00000269918.1 AF131215.9 -3.99 8.86e-05 0.0321 -0.31 -0.26 Myopia (pathological); chr8:11928746 chr8:11104691~11106704:- CESC cis rs7250849 1 rs7250849 ENSG00000273837.1 LLNLR-470E3.1 3.99 8.86e-05 0.0321 0.42 0.26 Blood protein levels; chr19:51655063 chr19:51639478~51639931:- CESC cis rs2980439 0.525 rs2945238 ENSG00000173295.6 FAM86B3P 3.99 8.86e-05 0.0321 0.34 0.26 Neuroticism; chr8:8312614 chr8:8228595~8244865:+ CESC cis rs42490 0.638 rs40637 ENSG00000251136.7 RP11-37B2.1 -3.99 8.86e-05 0.0321 -0.26 -0.26 Leprosy; chr8:89811082 chr8:89609409~89757727:- CESC cis rs5742933 0.842 rs1225101 ENSG00000253559.1 OSGEPL1-AS1 -3.99 8.87e-05 0.0321 -0.36 -0.26 Ferritin levels; chr2:189740695 chr2:189762704~189765556:+ CESC cis rs7924176 0.564 rs6480727 ENSG00000213731.2 RAB5CP1 -3.99 8.87e-05 0.0321 -0.29 -0.26 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74243315 chr10:74423435~74424014:- CESC cis rs7924176 0.58 rs12360119 ENSG00000213731.2 RAB5CP1 -3.99 8.87e-05 0.0321 -0.29 -0.26 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74255558 chr10:74423435~74424014:- CESC cis rs4272720 0.535 rs12776460 ENSG00000229870.1 RP11-507K13.6 -3.99 8.87e-05 0.0321 -0.31 -0.26 Platelet count;Plateletcrit; chr10:49080886 chr10:49815096~49815562:+ CESC cis rs875971 0.545 rs4718325 ENSG00000222364.1 RNU6-96P -3.99 8.87e-05 0.0321 -0.37 -0.26 Aortic root size; chr7:66215323 chr7:66395191~66395286:+ CESC cis rs957448 0.687 rs10104041 ENSG00000253704.1 RP11-267M23.4 3.99 8.87e-05 0.0321 0.28 0.26 Nonsyndromic cleft lip with cleft palate; chr8:94559374 chr8:94553722~94569745:+ CESC cis rs875971 1 rs778726 ENSG00000232559.3 GS1-124K5.12 3.99 8.87e-05 0.0321 0.29 0.26 Aortic root size; chr7:66363744 chr7:66554588~66576923:- CESC cis rs875971 0.767 rs1695815 ENSG00000232559.3 GS1-124K5.12 3.99 8.87e-05 0.0321 0.29 0.26 Aortic root size; chr7:66366357 chr7:66554588~66576923:- CESC cis rs875971 1 rs778685 ENSG00000232559.3 GS1-124K5.12 3.99 8.87e-05 0.0321 0.29 0.26 Aortic root size; chr7:66371189 chr7:66554588~66576923:- CESC cis rs875971 0.929 rs778682 ENSG00000232559.3 GS1-124K5.12 3.99 8.87e-05 0.0321 0.29 0.26 Aortic root size; chr7:66372947 chr7:66554588~66576923:- CESC cis rs875971 0.964 rs11765965 ENSG00000232559.3 GS1-124K5.12 3.99 8.87e-05 0.0321 0.29 0.26 Aortic root size; chr7:66377234 chr7:66554588~66576923:- CESC cis rs2564921 0.73 rs6781896 ENSG00000242142.1 SERBP1P3 -3.99 8.88e-05 0.0321 -0.32 -0.26 Height; chr3:53047596 chr3:53064283~53065091:- CESC cis rs2243480 0.901 rs35823062 ENSG00000067601.7 PMS2P4 3.99 8.88e-05 0.0321 0.5 0.26 Diabetic kidney disease; chr7:66500834 chr7:67295608~67302907:- CESC cis rs6452524 0.904 rs10474095 ENSG00000249664.1 CTD-2227C6.2 3.99 8.88e-05 0.0321 0.31 0.26 Hypertension (SNP x SNP interaction); chr5:83154887 chr5:83012285~83013109:- CESC cis rs1964356 0.967 rs17701675 ENSG00000173295.6 FAM86B3P -3.99 8.89e-05 0.0321 -0.3 -0.26 Mean corpuscular volume; chr8:8993123 chr8:8228595~8244865:+ CESC cis rs1440410 0.798 rs1605581 ENSG00000250326.1 RP11-284M14.1 -3.99 8.89e-05 0.0321 -0.28 -0.26 Ischemic stroke; chr4:143245634 chr4:142933195~143184861:- CESC cis rs1440410 0.798 rs1039763 ENSG00000250326.1 RP11-284M14.1 -3.99 8.89e-05 0.0321 -0.28 -0.26 Ischemic stroke; chr4:143246860 chr4:142933195~143184861:- CESC cis rs1440410 0.763 rs1039762 ENSG00000250326.1 RP11-284M14.1 -3.99 8.89e-05 0.0321 -0.28 -0.26 Ischemic stroke; chr4:143246893 chr4:142933195~143184861:- CESC cis rs1440410 0.798 rs10002867 ENSG00000250326.1 RP11-284M14.1 -3.99 8.89e-05 0.0321 -0.28 -0.26 Ischemic stroke; chr4:143248497 chr4:142933195~143184861:- CESC cis rs875971 0.895 rs4718349 ENSG00000232559.3 GS1-124K5.12 3.99 8.9e-05 0.0322 0.29 0.26 Aortic root size; chr7:66444024 chr7:66554588~66576923:- CESC cis rs7688540 0.8 rs12506277 ENSG00000211553.1 AC253576.2 -3.99 8.9e-05 0.0322 -0.35 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:293860 chr4:136461~136568:+ CESC cis rs9925964 0.933 rs11150604 ENSG00000260911.2 RP11-196G11.2 -3.99 8.9e-05 0.0322 -0.28 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31025699 chr16:31043150~31049868:+ CESC cis rs11096990 0.928 rs2008681 ENSG00000249207.1 RP11-360F5.1 3.99 8.91e-05 0.0322 0.31 0.26 Cognitive function; chr4:39266396 chr4:39112677~39126818:- CESC cis rs9813712 0.595 rs1993217 ENSG00000228252.7 COL6A4P2 -3.99 8.91e-05 0.0322 -0.33 -0.26 Response to amphetamines; chr3:130284832 chr3:130212823~130273806:+ CESC cis rs17301013 0.531 rs332806 ENSG00000227373.4 RP11-160H22.5 3.99 8.91e-05 0.0322 0.34 0.26 Systemic lupus erythematosus; chr1:174653645 chr1:174115300~174160004:- CESC cis rs11157436 0.918 rs1076546 ENSG00000211813.2 TRAV34 3.99 8.92e-05 0.0322 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22159015 chr14:22207522~22208129:+ CESC cis rs7138803 0.51 rs2336448 ENSG00000257464.1 RP11-161H23.8 -3.99 8.92e-05 0.0322 -0.27 -0.26 Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index; chr12:49818845 chr12:49442424~49442652:- CESC cis rs7216064 0.911 rs6504551 ENSG00000278730.1 RP11-147L13.11 -3.99 8.92e-05 0.0322 -0.27 -0.26 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67907210 chr17:68126666~68129586:+ CESC cis rs7688540 0.511 rs10003260 ENSG00000211553.1 AC253576.2 -3.99 8.92e-05 0.0322 -0.42 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:191053 chr4:136461~136568:+ CESC cis rs1030877 0.515 rs2679895 ENSG00000235319.1 AC012360.4 -3.99 8.93e-05 0.0322 -0.32 -0.26 Obesity-related traits; chr2:105290023 chr2:105324210~105330529:+ CESC cis rs523522 0.892 rs4767916 ENSG00000278344.1 RP11-18C24.8 3.99 8.93e-05 0.0322 0.32 0.26 High light scatter reticulocyte count; chr12:120586229 chr12:120500735~120501090:- CESC cis rs748404 0.666 rs12900259 ENSG00000249839.1 AC011330.5 -3.99 8.93e-05 0.0322 -0.37 -0.26 Lung cancer; chr15:43427369 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs34921640 ENSG00000249839.1 AC011330.5 -3.99 8.93e-05 0.0322 -0.37 -0.26 Lung cancer; chr15:43429187 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs62020574 ENSG00000249839.1 AC011330.5 -3.99 8.93e-05 0.0322 -0.37 -0.26 Lung cancer; chr15:43429380 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs16957730 ENSG00000249839.1 AC011330.5 -3.99 8.93e-05 0.0322 -0.37 -0.26 Lung cancer; chr15:43438288 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs12913977 ENSG00000249839.1 AC011330.5 -3.99 8.93e-05 0.0322 -0.37 -0.26 Lung cancer; chr15:43438913 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs12914122 ENSG00000249839.1 AC011330.5 -3.99 8.93e-05 0.0322 -0.37 -0.26 Lung cancer; chr15:43438956 chr15:43663654~43684339:- CESC cis rs748404 0.666 rs34697113 ENSG00000249839.1 AC011330.5 -3.99 8.93e-05 0.0322 -0.37 -0.26 Lung cancer; chr15:43442041 chr15:43663654~43684339:- CESC cis rs6001482 0.638 rs5757574 ENSG00000236850.4 BMS1P20 -3.99 8.93e-05 0.0322 -0.26 -0.26 Diastolic blood pressure; chr22:22231597 chr22:22303224~22322847:+ CESC cis rs10129255 0.5 rs4774008 ENSG00000224373.3 IGHV4-59 3.99 8.93e-05 0.0322 0.17 0.26 Kawasaki disease; chr14:106681273 chr14:106627249~106627825:- CESC cis rs9532669 0.926 rs9532689 ENSG00000239827.7 SUGT1P3 -3.99 8.94e-05 0.0323 -0.3 -0.26 Cervical cancer; chr13:40957990 chr13:40908159~40921774:- CESC cis rs4648045 0.565 rs4698862 ENSG00000246560.2 RP11-10L12.4 3.99 8.95e-05 0.0323 0.35 0.26 Lymphocyte percentage of white cells; chr4:102624640 chr4:102828055~102844075:+ CESC cis rs4648045 0.565 rs4698863 ENSG00000246560.2 RP11-10L12.4 3.99 8.95e-05 0.0323 0.35 0.26 Lymphocyte percentage of white cells; chr4:102624691 chr4:102828055~102844075:+ CESC cis rs2439831 1 rs2439831 ENSG00000205771.5 CATSPER2P1 -3.99 8.95e-05 0.0323 -0.37 -0.26 Lung cancer in ever smokers; chr15:43492277 chr15:43726918~43747094:- CESC cis rs12130219 1 rs1552994 ENSG00000237975.5 FLG-AS1 3.99 8.95e-05 0.0323 0.36 0.26 Inflammatory skin disease; chr1:152198985 chr1:152168125~152445456:+ CESC cis rs12130219 1 rs12733173 ENSG00000237975.5 FLG-AS1 3.99 8.95e-05 0.0323 0.36 0.26 Inflammatory skin disease; chr1:152201496 chr1:152168125~152445456:+ CESC cis rs1531343 0.73 rs2583921 ENSG00000276853.1 RP11-305O6.4 3.99 8.95e-05 0.0323 0.51 0.26 Type 2 diabetes; chr12:65776701 chr12:65171262~65171917:+ CESC cis rs7688540 0.511 rs75433628 ENSG00000211553.1 AC253576.2 -3.99 8.95e-05 0.0323 -0.42 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:184563 chr4:136461~136568:+ CESC cis rs7688540 0.511 rs4522818 ENSG00000211553.1 AC253576.2 -3.99 8.95e-05 0.0323 -0.42 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:187973 chr4:136461~136568:+ CESC cis rs11096990 0.964 rs11096986 ENSG00000249207.1 RP11-360F5.1 3.99 8.96e-05 0.0323 0.31 0.26 Cognitive function; chr4:39257122 chr4:39112677~39126818:- CESC cis rs11096990 0.964 rs6828598 ENSG00000249207.1 RP11-360F5.1 3.99 8.96e-05 0.0323 0.31 0.26 Cognitive function; chr4:39259850 chr4:39112677~39126818:- CESC cis rs853679 1 rs2799079 ENSG00000219392.1 RP1-265C24.5 -3.99 8.96e-05 0.0323 -0.37 -0.26 Depression; chr6:28267398 chr6:28115628~28116551:+ CESC cis rs1823913 0.637 rs4853569 ENSG00000227542.1 AC092614.2 -3.99 8.96e-05 0.0323 -0.27 -0.26 Obesity-related traits; chr2:191266970 chr2:191229165~191246172:- CESC cis rs2337406 1 rs11850600 ENSG00000254174.1 IGHV1-12 3.99 8.97e-05 0.0323 0.28 0.26 Alzheimer's disease (late onset); chr14:106670765 chr14:106122420~106122709:- CESC cis rs10043775 1 rs34269182 ENSG00000251330.3 CTD-2283N19.1 -3.99 8.97e-05 0.0324 -0.34 -0.26 Periodontal microbiota; chr5:148444850 chr5:148430159~148430807:- CESC cis rs10043775 0.874 rs4574533 ENSG00000251330.3 CTD-2283N19.1 -3.99 8.97e-05 0.0324 -0.34 -0.26 Periodontal microbiota; chr5:148445782 chr5:148430159~148430807:- CESC cis rs10043775 1 rs4274967 ENSG00000251330.3 CTD-2283N19.1 -3.99 8.97e-05 0.0324 -0.34 -0.26 Periodontal microbiota; chr5:148445876 chr5:148430159~148430807:- CESC cis rs10043775 1 rs9325098 ENSG00000251330.3 CTD-2283N19.1 -3.99 8.97e-05 0.0324 -0.34 -0.26 Periodontal microbiota; chr5:148447875 chr5:148430159~148430807:- CESC cis rs8031584 0.678 rs3122 ENSG00000260382.1 RP11-540B6.2 -3.99 8.97e-05 0.0324 -0.36 -0.26 Huntington's disease progression; chr15:30878087 chr15:30882267~30883231:- CESC cis rs11221522 0.92 rs11221561 ENSG00000281097.1 LINC01395 3.99 8.97e-05 0.0324 0.29 0.26 Metabolite levels (5-HIAA); chr11:129088713 chr11:129612116~129617269:- CESC cis rs4272720 0.666 rs12774293 ENSG00000229870.1 RP11-507K13.6 -3.99 8.97e-05 0.0324 -0.3 -0.26 Platelet count;Plateletcrit; chr10:49059448 chr10:49815096~49815562:+ CESC cis rs11997175 0.545 rs7388496 ENSG00000272338.2 RP11-722E23.2 3.99 8.97e-05 0.0324 0.29 0.26 Body mass index; chr8:33810380 chr8:33360839~33361415:- CESC cis rs451417 0.841 rs12106220 ENSG00000275632.1 RP5-967N21.11 3.99 8.98e-05 0.0324 0.35 0.26 Menopause (age at onset); chr20:5963609 chr20:6000418~6000941:+ CESC cis rs11089937 0.963 rs2073454 ENSG00000211639.2 IGLV4-60 3.99 8.98e-05 0.0324 0.23 0.26 Periodontitis (PAL4Q3); chr22:22163086 chr22:22162199~22162681:+ CESC cis rs10129255 0.956 rs10137268 ENSG00000211970.3 IGHV4-61 -3.99 8.98e-05 0.0324 -0.21 -0.26 Kawasaki disease; chr14:106697402 chr14:106639119~106639657:- CESC cis rs7873102 0.654 rs7023815 ENSG00000230188.1 RP11-405L18.4 -3.99 8.98e-05 0.0324 -0.35 -0.26 Brain structure; chr9:37967581 chr9:37490421~37490893:- CESC cis rs2548724 0.716 rs10515326 ENSG00000250682.4 LINC00491 3.99 8.98e-05 0.0324 0.31 0.26 Type 2 diabetes; chr5:102478044 chr5:102609156~102671559:- CESC cis rs673078 0.607 rs11068926 ENSG00000275759.1 RP11-131L12.3 -3.99 8.99e-05 0.0324 -0.43 -0.26 Glucose homeostasis traits; chr12:118367320 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs4442583 ENSG00000275759.1 RP11-131L12.3 -3.99 8.99e-05 0.0324 -0.43 -0.26 Glucose homeostasis traits; chr12:118367914 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943370 ENSG00000275759.1 RP11-131L12.3 -3.99 8.99e-05 0.0324 -0.43 -0.26 Glucose homeostasis traits; chr12:118369469 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943371 ENSG00000275759.1 RP11-131L12.3 -3.99 8.99e-05 0.0324 -0.43 -0.26 Glucose homeostasis traits; chr12:118369600 chr12:118428281~118428870:+ CESC cis rs8072100 0.817 rs7213086 ENSG00000228782.6 CTD-2026D20.3 3.99 8.99e-05 0.0324 0.31 0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47674944 chr17:47450568~47492492:- CESC cis rs6662572 0.906 rs11582058 ENSG00000281133.1 AL355480.3 -3.99 8.99e-05 0.0324 -0.34 -0.26 Blood protein levels; chr1:45779751 chr1:45580892~45580996:- CESC cis rs62025270 0.631 rs55968154 ENSG00000202081.1 RNU6-1280P -3.99 8.99e-05 0.0324 -0.37 -0.26 Idiopathic pulmonary fibrosis; chr15:85725399 chr15:85651522~85651628:- CESC cis rs62025270 0.688 rs55851385 ENSG00000202081.1 RNU6-1280P -3.99 8.99e-05 0.0324 -0.37 -0.26 Idiopathic pulmonary fibrosis; chr15:85725400 chr15:85651522~85651628:- CESC cis rs3764618 1 rs3810176 ENSG00000268006.1 PTOV1-AS1 -3.99 8.99e-05 0.0324 -0.51 -0.26 Follicule stimulating hormone; chr19:48993529 chr19:49838639~49851676:- CESC cis rs875971 0.965 rs10267430 ENSG00000237310.1 GS1-124K5.4 -3.99 8.99e-05 0.0324 -0.24 -0.26 Aortic root size; chr7:66278036 chr7:66493706~66495474:+ CESC cis rs67311347 0.956 rs11714871 ENSG00000223797.4 ENTPD3-AS1 3.99 8.99e-05 0.0324 0.26 0.26 Renal cell carcinoma; chr3:40387447 chr3:40313802~40453329:- CESC cis rs67311347 1 rs2305521 ENSG00000223797.4 ENTPD3-AS1 3.99 8.99e-05 0.0324 0.26 0.26 Renal cell carcinoma; chr3:40387692 chr3:40313802~40453329:- CESC cis rs453301 0.522 rs1964356 ENSG00000254340.1 RP11-10A14.3 3.99 9e-05 0.0324 0.3 0.26 Joint mobility (Beighton score); chr8:8995760 chr8:9141424~9145435:+ CESC cis rs8067354 0.872 rs1292060 ENSG00000266992.1 DHX40P1 3.99 9e-05 0.0324 0.29 0.26 Hemoglobin concentration; chr17:59836488 chr17:59976009~60002384:- CESC cis rs763121 0.853 rs1043441 ENSG00000273076.1 RP3-508I15.22 3.99 9e-05 0.0324 0.31 0.26 Menopause (age at onset); chr22:38734959 chr22:38743495~38743910:+ CESC cis rs36093924 0.646 rs5996094 ENSG00000273366.1 CTA-989H11.1 3.99 9e-05 0.0324 0.33 0.26 Intelligence; chr22:41951056 chr22:42278188~42278846:+ CESC cis rs75422866 0.867 rs73104163 ENSG00000280054.1 RP1-197B17.7 3.99 9e-05 0.0325 0.7 0.26 Pneumonia; chr12:47706187 chr12:47728151~47730598:- CESC cis rs75422866 1 rs12423045 ENSG00000280054.1 RP1-197B17.7 3.99 9e-05 0.0325 0.7 0.26 Pneumonia; chr12:47706275 chr12:47728151~47730598:- CESC cis rs801193 0.904 rs4718405 ENSG00000230358.3 RP11-166O4.1 -3.99 9.01e-05 0.0325 -0.36 -0.26 Aortic root size; chr7:66789659 chr7:67279778~67286230:+ CESC cis rs673078 0.607 rs2036314 ENSG00000275409.1 RP11-131L12.4 -3.99 9.02e-05 0.0325 -0.4 -0.26 Glucose homeostasis traits; chr12:118367132 chr12:118430147~118430699:+ CESC cis rs673078 0.607 rs61943369 ENSG00000275409.1 RP11-131L12.4 -3.99 9.02e-05 0.0325 -0.4 -0.26 Glucose homeostasis traits; chr12:118368145 chr12:118430147~118430699:+ CESC cis rs2179367 0.887 rs2143076 ENSG00000231760.4 RP11-350J20.5 3.99 9.02e-05 0.0325 0.32 0.26 Dupuytren's disease; chr6:149425315 chr6:149796151~149826294:- CESC cis rs3018712 0.532 rs28551086 ENSG00000212093.1 AP000807.1 3.99 9.03e-05 0.0325 0.41 0.26 Total body bone mineral density; chr11:68633271 chr11:68506083~68506166:- CESC cis rs6964587 1 rs3753108 ENSG00000188693.7 CYP51A1-AS1 -3.99 9.04e-05 0.0326 -0.28 -0.26 Breast cancer; chr7:92000670 chr7:92134604~92180725:+ CESC cis rs2739330 0.76 rs5760095 ENSG00000228039.3 KB-1125A3.10 3.99 9.04e-05 0.0326 0.33 0.26 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23963780~23964374:+ CESC cis rs8070463 0.515 rs11655943 ENSG00000228782.6 CTD-2026D20.3 3.99 9.05e-05 0.0326 0.31 0.26 Multiple sclerosis;Ankylosing spondylitis; chr17:47308274 chr17:47450568~47492492:- CESC cis rs875971 0.545 rs73142233 ENSG00000236529.1 RP13-254B10.1 3.99 9.05e-05 0.0326 0.34 0.26 Aortic root size; chr7:66221293 chr7:65840212~65840596:+ CESC cis rs6782228 0.606 rs7650156 ENSG00000242551.2 POU5F1P6 -3.99 9.05e-05 0.0326 -0.29 -0.26 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128642712 chr3:128674735~128677005:- CESC cis rs2404602 0.692 rs34272342 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76719935 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs67570291 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76728161 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs1471780 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76734185 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs4442773 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76739292 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs60658665 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76750167 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs12910382 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76761101 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs12911902 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76761234 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs4383105 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76763169 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs7174673 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76779657 chr15:77056895~77057021:+ CESC cis rs2404602 0.655 rs8028294 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76792536 chr15:77056895~77057021:+ CESC cis rs2404602 0.669 rs12441484 ENSG00000280730.1 AC090181.1 3.99 9.05e-05 0.0326 0.2 0.26 Blood metabolite levels; chr15:76817534 chr15:77056895~77057021:+ CESC cis rs7951870 0.945 rs11038973 ENSG00000247675.5 LRP4-AS1 -3.99 9.05e-05 0.0326 -0.38 -0.26 Schizophrenia; chr11:46707402 chr11:46846412~46874396:+ CESC cis rs7951870 0.945 rs11038974 ENSG00000247675.5 LRP4-AS1 -3.99 9.05e-05 0.0326 -0.38 -0.26 Schizophrenia; chr11:46707404 chr11:46846412~46874396:+ CESC cis rs17301013 0.507 rs10912828 ENSG00000227373.4 RP11-160H22.5 3.99 9.05e-05 0.0326 0.34 0.26 Systemic lupus erythematosus; chr1:174635701 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs10912829 ENSG00000227373.4 RP11-160H22.5 3.99 9.05e-05 0.0326 0.34 0.26 Systemic lupus erythematosus; chr1:174635894 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs395109 ENSG00000227373.4 RP11-160H22.5 3.99 9.05e-05 0.0326 0.34 0.26 Systemic lupus erythematosus; chr1:174641233 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2760058 ENSG00000227373.4 RP11-160H22.5 3.99 9.05e-05 0.0326 0.34 0.26 Systemic lupus erythematosus; chr1:174641320 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs411665 ENSG00000227373.4 RP11-160H22.5 3.99 9.05e-05 0.0326 0.34 0.26 Systemic lupus erythematosus; chr1:174656563 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2771401 ENSG00000227373.4 RP11-160H22.5 3.99 9.05e-05 0.0326 0.34 0.26 Systemic lupus erythematosus; chr1:174678302 chr1:174115300~174160004:- CESC cis rs875971 1 rs875971 ENSG00000179406.6 LINC00174 3.99 9.06e-05 0.0326 0.28 0.26 Aortic root size; chr7:66152608 chr7:66376044~66401338:- CESC cis rs1707322 1 rs6661500 ENSG00000281133.1 AL355480.3 -3.99 9.06e-05 0.0326 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45999990 chr1:45580892~45580996:- CESC cis rs34526934 0.608 rs2857539 ENSG00000226363.3 HAGLROS 3.99 9.06e-05 0.0326 0.42 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176160135 chr2:176177717~176179008:+ CESC cis rs4957048 0.541 rs12519390 ENSG00000225138.6 CTD-2228K2.7 3.99 9.06e-05 0.0326 0.44 0.26 Ulcerative colitis; chr5:676431 chr5:473236~480884:+ CESC cis rs1829883 0.748 rs1916598 ENSG00000248489.1 CTD-2007H13.3 3.99 9.06e-05 0.0326 0.28 0.26 Hemostatic factors and hematological phenotypes; chr5:99407584 chr5:98929171~98995013:+ CESC cis rs5742933 0.948 rs2264018 ENSG00000253559.1 OSGEPL1-AS1 -3.99 9.06e-05 0.0326 -0.35 -0.26 Ferritin levels; chr2:189712052 chr2:189762704~189765556:+ CESC cis rs6693388 0.602 rs2932590 ENSG00000229021.2 AL591893.1 -3.99 9.07e-05 0.0326 -0.29 -0.26 Blood metabolite ratios; chr1:151981287 chr1:151994531~152042774:+ CESC cis rs13113518 1 rs13115828 ENSG00000273257.1 RP11-177J6.1 3.99 9.07e-05 0.0326 0.34 0.26 Height; chr4:55551447 chr4:55387949~55388271:+ CESC cis rs7923837 0.683 rs10509645 ENSG00000236493.2 EIF2S2P3 3.99 9.07e-05 0.0326 0.33 0.26 Multiple sclerosis;Body mass index; chr10:92518109 chr10:92668745~92669743:- CESC cis rs74394007 0.915 rs344086 ENSG00000244515.1 KRT18P34 3.99 9.07e-05 0.0326 0.47 0.26 Total body bone mineral density; chr3:156841656 chr3:157162663~157163932:- CESC cis rs2933343 0.7 rs2249514 ENSG00000231305.3 RP11-723O4.2 3.99 9.07e-05 0.0326 0.25 0.26 IgG glycosylation; chr3:128924969 chr3:128861313~128871540:- CESC cis rs2933343 0.7 rs2630257 ENSG00000231305.3 RP11-723O4.2 3.99 9.07e-05 0.0326 0.25 0.26 IgG glycosylation; chr3:128925172 chr3:128861313~128871540:- CESC cis rs2933343 0.729 rs1680785 ENSG00000231305.3 RP11-723O4.2 3.99 9.07e-05 0.0326 0.25 0.26 IgG glycosylation; chr3:128925973 chr3:128861313~128871540:- CESC cis rs2933343 0.729 rs1680786 ENSG00000231305.3 RP11-723O4.2 3.99 9.07e-05 0.0326 0.25 0.26 IgG glycosylation; chr3:128925997 chr3:128861313~128871540:- CESC cis rs7429990 0.965 rs319682 ENSG00000229759.1 MRPS18AP1 3.99 9.08e-05 0.0327 0.27 0.26 Educational attainment (years of education); chr3:47873628 chr3:48256350~48256938:- CESC cis rs13113518 0.729 rs12641881 ENSG00000273257.1 RP11-177J6.1 3.99 9.08e-05 0.0327 0.35 0.26 Height; chr4:55401306 chr4:55387949~55388271:+ CESC cis rs7216064 0.532 rs3890640 ENSG00000267023.4 LRRC37A16P 3.99 9.09e-05 0.0327 0.26 0.26 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68056912 chr17:68125777~68152468:- CESC cis rs7216064 0.589 rs8072723 ENSG00000267023.4 LRRC37A16P 3.99 9.09e-05 0.0327 0.26 0.26 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68060854 chr17:68125777~68152468:- CESC cis rs7826238 0.564 rs2921053 ENSG00000173295.6 FAM86B3P 3.99 9.09e-05 0.0327 0.32 0.26 Systolic blood pressure; chr8:8462453 chr8:8228595~8244865:+ CESC cis rs6951245 1 rs80031817 ENSG00000229043.2 AC091729.9 -3.99 9.09e-05 0.0327 -0.4 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057157 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs78143408 ENSG00000229043.2 AC091729.9 -3.99 9.09e-05 0.0327 -0.4 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057210 chr7:1160374~1165267:+ CESC cis rs6951245 0.938 rs78351779 ENSG00000229043.2 AC091729.9 -3.99 9.09e-05 0.0327 -0.4 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057387 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs11761941 ENSG00000229043.2 AC091729.9 -3.99 9.09e-05 0.0327 -0.4 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057547 chr7:1160374~1165267:+ CESC cis rs2243480 1 rs11538349 ENSG00000232559.3 GS1-124K5.12 3.99 9.09e-05 0.0327 0.41 0.26 Diabetic kidney disease; chr7:65956884 chr7:66554588~66576923:- CESC cis rs6540731 0.967 rs2884512 ENSG00000226251.4 RP11-15I11.3 -3.99 9.09e-05 0.0327 -0.29 -0.26 Intelligence (childhood); chr1:212229848 chr1:212225278~212238977:- CESC cis rs2282802 0.758 rs739954 ENSG00000249526.1 CTB-35F21.1 3.99 9.09e-05 0.0327 0.31 0.26 Intelligence (multi-trait analysis); chr5:140322335 chr5:139684645~139745010:+ CESC cis rs8030379 1 rs10152139 ENSG00000230373.7 GOLGA6L5P -3.99 9.09e-05 0.0327 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83901510 chr15:84507885~84516814:- CESC cis rs56309584 0.71 rs7211247 ENSG00000178977.3 LINC00324 -3.99 9.09e-05 0.0327 -0.3 -0.26 Initial pursuit acceleration; chr17:8240835 chr17:8220642~8224043:- CESC cis rs673078 0.66 rs17512574 ENSG00000275759.1 RP11-131L12.3 -3.99 9.1e-05 0.0327 -0.46 -0.26 Glucose homeostasis traits; chr12:118350198 chr12:118428281~118428870:+ CESC cis rs2277027 0.956 rs13361953 ENSG00000251405.2 CTB-109A12.1 3.99 9.1e-05 0.0327 0.32 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157499434 chr5:157362615~157460078:- CESC cis rs2277027 0.956 rs12522418 ENSG00000251405.2 CTB-109A12.1 3.99 9.1e-05 0.0327 0.32 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157499769 chr5:157362615~157460078:- CESC cis rs62355900 0.627 rs16886400 ENSG00000271828.1 CTD-2310F14.1 3.99 9.1e-05 0.0327 0.41 0.26 Endometriosis; chr5:56841605 chr5:56927874~56929573:+ CESC cis rs4713118 0.513 rs149950 ENSG00000219392.1 RP1-265C24.5 -3.99 9.1e-05 0.0327 -0.3 -0.26 Parkinson's disease; chr6:28065261 chr6:28115628~28116551:+ CESC cis rs4713118 0.513 rs149951 ENSG00000219392.1 RP1-265C24.5 -3.99 9.1e-05 0.0327 -0.3 -0.26 Parkinson's disease; chr6:28065309 chr6:28115628~28116551:+ CESC cis rs9382484 0.594 rs2653349 ENSG00000224984.1 RP11-524H19.2 3.99 9.11e-05 0.0328 0.31 0.26 Ease of getting up in the morning; chr6:55277539 chr6:54840118~54840855:- CESC cis rs77106637 0.929 rs77464186 ENSG00000202522.1 Y_RNA 3.99 9.11e-05 0.0328 0.41 0.26 Type 2 diabetes; chr11:72749353 chr11:72766004~72766116:+ CESC cis rs77106637 0.858 rs7109575 ENSG00000202522.1 Y_RNA 3.99 9.11e-05 0.0328 0.41 0.26 Type 2 diabetes; chr11:72752390 chr11:72766004~72766116:+ CESC cis rs2274273 0.588 rs7155054 ENSG00000258413.1 RP11-665C16.6 -3.99 9.12e-05 0.0328 -0.34 -0.26 Protein biomarker; chr14:55283944 chr14:55262767~55272075:- CESC cis rs2286503 0.966 rs6949233 ENSG00000228649.7 AC005682.5 3.99 9.12e-05 0.0328 0.23 0.26 Fibrinogen; chr7:22818572 chr7:22854178~22861579:+ CESC cis rs8030379 1 rs8024628 ENSG00000230373.7 GOLGA6L5P -3.99 9.12e-05 0.0328 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83917711 chr15:84507885~84516814:- CESC cis rs8030379 1 rs8029016 ENSG00000230373.7 GOLGA6L5P -3.99 9.12e-05 0.0328 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83917712 chr15:84507885~84516814:- CESC cis rs7508 0.512 rs28562392 ENSG00000253671.1 RP11-806O11.1 -3.99 9.12e-05 0.0328 -0.27 -0.26 Atrial fibrillation; chr8:18032922 chr8:17808941~17820868:+ CESC cis rs7829975 0.577 rs940032 ENSG00000253893.2 FAM85B 3.99 9.12e-05 0.0328 0.36 0.26 Mood instability; chr8:8688833 chr8:8167819~8226614:- CESC cis rs875971 0.545 rs1638735 ENSG00000222364.1 RNU6-96P -3.99 9.13e-05 0.0328 -0.34 -0.26 Aortic root size; chr7:66630751 chr7:66395191~66395286:+ CESC cis rs6844153 0.68 rs11729927 ENSG00000240005.4 RP11-293A21.1 -3.99 9.14e-05 0.0328 -0.35 -0.26 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26922178 chr4:26859806~26860599:- CESC cis rs8030379 1 rs1564474 ENSG00000230373.7 GOLGA6L5P -3.99 9.16e-05 0.0329 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83901281 chr15:84507885~84516814:- CESC cis rs8030379 1 rs10152119 ENSG00000230373.7 GOLGA6L5P -3.99 9.16e-05 0.0329 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83901629 chr15:84507885~84516814:- CESC cis rs8030379 1 rs1471552 ENSG00000230373.7 GOLGA6L5P -3.99 9.16e-05 0.0329 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83901982 chr15:84507885~84516814:- CESC cis rs3026101 0.671 rs11868032 ENSG00000262678.1 RP5-1050D4.4 3.99 9.16e-05 0.0329 0.22 0.26 Body mass index; chr17:5380322 chr17:4986466~4987324:+ CESC cis rs5769707 0.732 rs135865 ENSG00000235111.1 RP1-29C18.8 -3.99 9.16e-05 0.0329 -0.27 -0.26 Monocyte percentage of white cells;Monocyte count; chr22:49611181 chr22:49612657~49615716:- CESC cis rs10779751 0.734 rs1130683 ENSG00000230337.1 RP4-635E18.6 3.99 9.16e-05 0.0329 0.36 0.26 Body mass index; chr1:11072160 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2791650 ENSG00000230337.1 RP4-635E18.6 3.99 9.16e-05 0.0329 0.36 0.26 Body mass index; chr1:11072484 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2791649 ENSG00000230337.1 RP4-635E18.6 3.99 9.16e-05 0.0329 0.36 0.26 Body mass index; chr1:11072504 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2791648 ENSG00000230337.1 RP4-635E18.6 3.99 9.16e-05 0.0329 0.36 0.26 Body mass index; chr1:11072581 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2791647 ENSG00000230337.1 RP4-635E18.6 3.99 9.16e-05 0.0329 0.36 0.26 Body mass index; chr1:11072744 chr1:11099675~11102100:+ CESC cis rs10779751 0.69 rs2791646 ENSG00000230337.1 RP4-635E18.6 3.99 9.16e-05 0.0329 0.36 0.26 Body mass index; chr1:11073185 chr1:11099675~11102100:+ CESC cis rs11971779 0.616 rs10278377 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139418325 chr7:139359032~139359566:- CESC cis rs11971779 0.618 rs13068 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139419395 chr7:139359032~139359566:- CESC cis rs11971779 0.648 rs6946113 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139421380 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6946393 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139421423 chr7:139359032~139359566:- CESC cis rs11971779 0.553 rs10269108 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139421586 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs9683 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139422993 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs10085901 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139424243 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs10085902 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139424359 chr7:139359032~139359566:- CESC cis rs11971779 0.617 rs66652773 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139424827 chr7:139359032~139359566:- CESC cis rs11971779 0.648 rs10085708 ENSG00000273391.1 RP11-634H22.1 3.99 9.16e-05 0.0329 0.25 0.26 Diisocyanate-induced asthma; chr7:139426208 chr7:139359032~139359566:- CESC cis rs113835537 1 rs113835537 ENSG00000255517.5 CTD-3074O7.5 -3.99 9.17e-05 0.0329 -0.39 -0.26 Airway imaging phenotypes; chr11:66572168 chr11:66473490~66480233:- CESC cis rs11673344 0.526 rs35153242 ENSG00000226686.6 LINC01535 -3.99 9.17e-05 0.0329 -0.38 -0.26 Obesity-related traits; chr19:37660841 chr19:37251912~37265535:+ CESC cis rs2836950 0.501 rs4818018 ENSG00000232608.1 TIMM9P2 3.99 9.17e-05 0.0329 0.29 0.26 Menarche (age at onset); chr21:39322146 chr21:39216624~39217506:+ CESC cis rs2836950 0.501 rs4818019 ENSG00000232608.1 TIMM9P2 3.99 9.17e-05 0.0329 0.29 0.26 Menarche (age at onset); chr21:39322530 chr21:39216624~39217506:+ CESC cis rs17301013 0.507 rs12065527 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174627066 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12064403 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174627067 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12065825 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174627902 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6667107 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174628667 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs333454 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174653939 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs333452 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174654718 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs333438 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174672782 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs464540 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174679250 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs467437 ENSG00000227373.4 RP11-160H22.5 3.99 9.17e-05 0.0329 0.34 0.26 Systemic lupus erythematosus; chr1:174679861 chr1:174115300~174160004:- CESC cis rs113835537 0.935 rs3867133 ENSG00000255517.5 CTD-3074O7.5 3.99 9.17e-05 0.0329 0.4 0.26 Airway imaging phenotypes; chr11:66684491 chr11:66473490~66480233:- CESC cis rs10788972 0.658 rs12046885 ENSG00000225183.1 RP4-758J24.4 -3.99 9.18e-05 0.0329 -0.31 -0.26 Parkinson disease and lewy body pathology; chr1:54091617 chr1:54089856~54090093:+ CESC cis rs9393777 0.513 rs9379905 ENSG00000241549.7 GUSBP2 3.99 9.18e-05 0.0329 0.33 0.26 Intelligence (multi-trait analysis); chr6:26630762 chr6:26871484~26956554:- CESC cis rs9393777 0.513 rs9295702 ENSG00000241549.7 GUSBP2 3.99 9.18e-05 0.0329 0.33 0.26 Intelligence (multi-trait analysis); chr6:26633812 chr6:26871484~26956554:- CESC cis rs9393777 0.513 rs9348728 ENSG00000241549.7 GUSBP2 3.99 9.18e-05 0.0329 0.33 0.26 Intelligence (multi-trait analysis); chr6:26634208 chr6:26871484~26956554:- CESC cis rs453301 0.719 rs34004903 ENSG00000173295.6 FAM86B3P -3.99 9.18e-05 0.0329 -0.33 -0.26 Joint mobility (Beighton score); chr8:9035094 chr8:8228595~8244865:+ CESC cis rs453301 0.686 rs10217044 ENSG00000173295.6 FAM86B3P -3.99 9.18e-05 0.0329 -0.33 -0.26 Joint mobility (Beighton score); chr8:9037242 chr8:8228595~8244865:+ CESC cis rs17772222 0.917 rs4635267 ENSG00000258983.2 RP11-507K2.2 3.99 9.18e-05 0.033 0.32 0.26 Coronary artery calcification; chr14:88621922 chr14:88499334~88515502:+ CESC cis rs17772222 0.876 rs56144430 ENSG00000258983.2 RP11-507K2.2 3.99 9.18e-05 0.033 0.32 0.26 Coronary artery calcification; chr14:88622013 chr14:88499334~88515502:+ CESC cis rs2281636 0.723 rs11190246 ENSG00000233690.1 EBAG9P1 3.99 9.19e-05 0.033 0.27 0.26 Obesity-related traits; chr10:99691854 chr10:99697407~99697949:- CESC cis rs875971 0.862 rs10274883 ENSG00000275400.1 RP4-756H11.5 -3.99 9.19e-05 0.033 -0.28 -0.26 Aortic root size; chr7:66651104 chr7:66553805~66554199:- CESC cis rs801193 0.548 rs2109297 ENSG00000275400.1 RP4-756H11.5 -3.99 9.19e-05 0.033 -0.28 -0.26 Aortic root size; chr7:66657397 chr7:66553805~66554199:- CESC cis rs801193 0.569 rs6978178 ENSG00000275400.1 RP4-756H11.5 -3.99 9.19e-05 0.033 -0.28 -0.26 Aortic root size; chr7:66658097 chr7:66553805~66554199:- CESC cis rs801193 0.591 rs721717 ENSG00000275400.1 RP4-756H11.5 -3.99 9.19e-05 0.033 -0.28 -0.26 Aortic root size; chr7:66665305 chr7:66553805~66554199:- CESC cis rs867371 1 rs6495642 ENSG00000255769.6 GOLGA2P10 -3.99 9.19e-05 0.033 -0.3 -0.26 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82165156 chr15:82472993~82513950:- CESC cis rs77972916 0.505 rs1322 ENSG00000234936.1 AC010883.5 3.99 9.19e-05 0.033 0.3 0.26 Granulocyte percentage of myeloid white cells; chr2:43294028 chr2:43229573~43233394:+ CESC cis rs7551222 0.752 rs1380576 ENSG00000240219.1 RP11-430C7.5 3.99 9.19e-05 0.033 0.29 0.26 Schizophrenia; chr1:204519150 chr1:204626775~204629712:+ CESC cis rs2272306 0.614 rs822685 ENSG00000251151.2 HOXC-AS3 -3.99 9.19e-05 0.033 -0.39 -0.26 Obesity-related traits; chr12:53120133 chr12:53981509~53985519:- CESC cis rs12745968 0.594 rs10735781 ENSG00000223787.2 RP4-593M8.1 -3.99 9.19e-05 0.033 -0.32 -0.26 Bipolar disorder and schizophrenia; chr1:92655550 chr1:92580476~92580821:- CESC cis rs10129255 0.957 rs10140904 ENSG00000223648.3 IGHV3-64 3.99 9.19e-05 0.033 0.23 0.26 Kawasaki disease; chr14:106776558 chr14:106643132~106658258:- CESC cis rs11098499 0.82 rs28535956 ENSG00000249244.1 RP11-548H18.2 -3.99 9.19e-05 0.033 -0.27 -0.26 Corneal astigmatism; chr4:119615703 chr4:119391831~119395335:- CESC cis rs7560272 0.538 rs4852977 ENSG00000273245.1 RP11-434P11.2 -3.99 9.2e-05 0.033 -0.32 -0.26 Schizophrenia; chr2:73711168 chr2:73750256~73750786:- CESC cis rs4713118 0.597 rs172166 ENSG00000219392.1 RP1-265C24.5 -3.99 9.2e-05 0.033 -0.35 -0.26 Parkinson's disease; chr6:28053042 chr6:28115628~28116551:+ CESC cis rs270601 0.77 rs10463891 ENSG00000233006.5 AC034220.3 -3.99 9.2e-05 0.033 -0.27 -0.26 Acylcarnitine levels; chr5:132261699 chr5:132311285~132369916:- CESC cis rs2274273 0.624 rs8015211 ENSG00000258413.1 RP11-665C16.6 -3.99 9.2e-05 0.033 -0.34 -0.26 Protein biomarker; chr14:55374729 chr14:55262767~55272075:- CESC cis rs17818399 0.62 rs1080871 ENSG00000279254.1 RP11-536C12.1 -3.98 9.2e-05 0.033 -0.29 -0.26 Height; chr2:46627569 chr2:46668870~46670778:+ CESC cis rs2948294 0.588 rs4840913 ENSG00000253893.2 FAM85B -3.98 9.21e-05 0.033 -0.33 -0.26 Red cell distribution width; chr8:8259384 chr8:8167819~8226614:- CESC cis rs9393777 0.513 rs9393737 ENSG00000241549.7 GUSBP2 -3.98 9.21e-05 0.033 -0.32 -0.26 Intelligence (multi-trait analysis); chr6:26617078 chr6:26871484~26956554:- CESC cis rs17818399 0.62 rs3087822 ENSG00000279254.1 RP11-536C12.1 3.98 9.22e-05 0.033 0.28 0.26 Height; chr2:46624894 chr2:46668870~46670778:+ CESC cis rs10129255 0.957 rs10136560 ENSG00000211974.3 IGHV2-70 3.98 9.22e-05 0.033 0.29 0.26 Kawasaki disease; chr14:106787630 chr14:106723574~106724093:- CESC cis rs2548724 0.755 rs11950639 ENSG00000250682.4 LINC00491 3.98 9.22e-05 0.033 0.31 0.26 Type 2 diabetes; chr5:102442092 chr5:102609156~102671559:- CESC cis rs2548724 0.716 rs10434748 ENSG00000250682.4 LINC00491 3.98 9.22e-05 0.033 0.31 0.26 Type 2 diabetes; chr5:102455814 chr5:102609156~102671559:- CESC cis rs2548724 0.66 rs10434749 ENSG00000250682.4 LINC00491 3.98 9.22e-05 0.033 0.31 0.26 Type 2 diabetes; chr5:102456271 chr5:102609156~102671559:- CESC cis rs62355900 0.627 rs9292123 ENSG00000271828.1 CTD-2310F14.1 3.98 9.22e-05 0.0331 0.38 0.26 Endometriosis; chr5:56807982 chr5:56927874~56929573:+ CESC cis rs3796352 1 rs11707780 ENSG00000280417.1 RP11-5O17.1 3.98 9.22e-05 0.0331 0.38 0.26 Immune reponse to smallpox (secreted IL-2); chr3:53050310 chr3:53046166~53048122:+ CESC cis rs9487094 0.666 rs736830 ENSG00000260273.1 RP11-425D10.10 3.98 9.22e-05 0.0331 0.32 0.26 Height; chr6:109392096 chr6:109382795~109383666:+ CESC cis rs2486288 0.656 rs12908581 ENSG00000259479.5 SORD2P -3.98 9.22e-05 0.0331 -0.31 -0.26 Glomerular filtration rate; chr15:45256437 chr15:44826371~44884694:- CESC cis rs72772090 0.539 rs10515250 ENSG00000248734.2 CTD-2260A17.1 -3.98 9.23e-05 0.0331 -0.42 -0.26 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96814490 chr5:96784777~96785999:+ CESC cis rs10129255 0.53 rs11624912 ENSG00000211970.3 IGHV4-61 -3.98 9.23e-05 0.0331 -0.18 -0.26 Kawasaki disease; chr14:106673891 chr14:106639119~106639657:- CESC cis rs2908197 0.806 rs12534035 ENSG00000127957.15 PMS2P3 3.98 9.23e-05 0.0331 0.3 0.26 3-hydroxypropylmercapturic acid levels in smokers; chr7:76351629 chr7:75502930~75528148:- CESC cis rs853679 0.517 rs9283884 ENSG00000280107.1 AL022393.9 3.98 9.23e-05 0.0331 0.35 0.26 Depression; chr6:28167882 chr6:28170845~28172521:+ CESC cis rs11157436 0.918 rs11157426 ENSG00000211812.1 TRAV26-2 -3.98 9.23e-05 0.0331 -0.27 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22153691 chr14:22202583~22203368:+ CESC cis rs11157436 0.918 rs11157427 ENSG00000211812.1 TRAV26-2 -3.98 9.23e-05 0.0331 -0.27 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22154291 chr14:22202583~22203368:+ CESC cis rs11157436 0.792 rs12433875 ENSG00000211812.1 TRAV26-2 -3.98 9.23e-05 0.0331 -0.27 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22154490 chr14:22202583~22203368:+ CESC cis rs2288884 0.537 rs12151270 ENSG00000275055.1 CTC-471J1.11 -3.98 9.23e-05 0.0331 -0.29 -0.26 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52058984 chr19:52049007~52049754:+ CESC cis rs875971 0.545 rs73142265 ENSG00000236529.1 RP13-254B10.1 3.98 9.24e-05 0.0331 0.33 0.26 Aortic root size; chr7:66234510 chr7:65840212~65840596:+ CESC cis rs7243790 0.805 rs12458588 ENSG00000277324.1 RP11-850A17.1 -3.98 9.24e-05 0.0331 -0.29 -0.26 Diastolic blood pressure; chr18:54377323 chr18:54268346~54270028:- CESC cis rs875971 0.965 rs6971509 ENSG00000232559.3 GS1-124K5.12 -3.98 9.25e-05 0.0331 -0.27 -0.26 Aortic root size; chr7:66249983 chr7:66554588~66576923:- CESC cis rs453301 0.686 rs11785634 ENSG00000173295.6 FAM86B3P -3.98 9.25e-05 0.0331 -0.34 -0.26 Joint mobility (Beighton score); chr8:9035087 chr8:8228595~8244865:+ CESC cis rs9309473 0.519 rs12991161 ENSG00000273245.1 RP11-434P11.2 -3.98 9.25e-05 0.0332 -0.33 -0.26 Metabolite levels; chr2:73644244 chr2:73750256~73750786:- CESC cis rs7586673 0.725 rs6757645 ENSG00000227403.1 AC009299.3 -3.98 9.26e-05 0.0332 -0.34 -0.26 Intelligence (multi-trait analysis); chr2:161034871 chr2:161244739~161249050:+ CESC cis rs889312 0.532 rs16886181 ENSG00000271828.1 CTD-2310F14.1 3.98 9.26e-05 0.0332 0.35 0.26 Breast cancer (early onset);Breast cancer; chr5:56733416 chr5:56927874~56929573:+ CESC cis rs17657012 1 rs1951439 ENSG00000259318.1 RP11-454L9.2 -3.98 9.26e-05 0.0332 -0.44 -0.26 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr14:54708105 chr14:55394940~55395233:- CESC cis rs875971 1 rs778706 ENSG00000232559.3 GS1-124K5.12 3.98 9.27e-05 0.0332 0.29 0.26 Aortic root size; chr7:66395437 chr7:66554588~66576923:- CESC cis rs875971 0.895 rs778700 ENSG00000232559.3 GS1-124K5.12 3.98 9.27e-05 0.0332 0.29 0.26 Aortic root size; chr7:66401463 chr7:66554588~66576923:- CESC cis rs875971 1 rs778699 ENSG00000232559.3 GS1-124K5.12 3.98 9.27e-05 0.0332 0.29 0.26 Aortic root size; chr7:66403303 chr7:66554588~66576923:- CESC cis rs875971 0.929 rs778692 ENSG00000232559.3 GS1-124K5.12 3.98 9.27e-05 0.0332 0.29 0.26 Aortic root size; chr7:66407462 chr7:66554588~66576923:- CESC cis rs875971 1 rs4718343 ENSG00000232559.3 GS1-124K5.12 3.98 9.27e-05 0.0332 0.29 0.26 Aortic root size; chr7:66409301 chr7:66554588~66576923:- CESC cis rs875971 1 rs1968225 ENSG00000232559.3 GS1-124K5.12 3.98 9.27e-05 0.0332 0.29 0.26 Aortic root size; chr7:66409786 chr7:66554588~66576923:- CESC cis rs875971 1 rs6460295 ENSG00000232559.3 GS1-124K5.12 3.98 9.27e-05 0.0332 0.29 0.26 Aortic root size; chr7:66417741 chr7:66554588~66576923:- CESC cis rs875971 0.964 rs6978721 ENSG00000232559.3 GS1-124K5.12 3.98 9.27e-05 0.0332 0.29 0.26 Aortic root size; chr7:66418217 chr7:66554588~66576923:- CESC cis rs1707322 1 rs4660331 ENSG00000281133.1 AL355480.3 -3.98 9.27e-05 0.0332 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45993111 chr1:45580892~45580996:- CESC cis rs116139393 0.611 rs62439722 ENSG00000187953.9 PMS2CL -3.98 9.27e-05 0.0332 -0.35 -0.26 Alzheimer's disease (APOE e4 interaction); chr7:6725309 chr7:6710128~6753862:+ CESC cis rs7615316 0.934 rs6440088 ENSG00000244327.1 RP11-383G6.3 3.98 9.27e-05 0.0332 0.29 0.26 Mean corpuscular volume;Mean corpuscular hemoglobin; chr3:142551517 chr3:142465315~142472337:- CESC cis rs1124769 0.719 rs1147138 ENSG00000259378.1 DCAF13P3 -3.98 9.28e-05 0.0332 -0.36 -0.26 Cognitive performance; chr15:50885439 chr15:50944663~50945996:+ CESC cis rs875971 0.965 rs6971509 ENSG00000237310.1 GS1-124K5.4 -3.98 9.29e-05 0.0332 -0.24 -0.26 Aortic root size; chr7:66249983 chr7:66493706~66495474:+ CESC cis rs2836950 0.565 rs2836943 ENSG00000255568.3 BRWD1-AS2 -3.98 9.29e-05 0.0333 -0.22 -0.26 Menarche (age at onset); chr21:39220685 chr21:39313935~39314962:+ CESC cis rs2552220 0.818 rs11778742 ENSG00000246089.3 RP11-115C21.2 -3.98 9.3e-05 0.0333 -0.28 -0.26 Interleukin-8 levels; chr8:6155553 chr8:6403551~6407142:- CESC cis rs748404 0.666 rs60018990 ENSG00000249839.1 AC011330.5 -3.98 9.3e-05 0.0333 -0.37 -0.26 Lung cancer; chr15:43504606 chr15:43663654~43684339:- CESC cis rs2882667 0.69 rs9327827 ENSG00000250159.5 RP11-381K20.2 3.98 9.3e-05 0.0333 0.38 0.26 Age-related hearing impairment (SNP x SNP interaction); chr5:138846639 chr5:137814333~137889336:- CESC cis rs11096990 0.964 rs16988409 ENSG00000249207.1 RP11-360F5.1 -3.98 9.3e-05 0.0333 -0.29 -0.26 Cognitive function; chr4:39267730 chr4:39112677~39126818:- CESC cis rs11159086 1 rs8006909 ENSG00000270000.1 RP3-449M8.9 3.98 9.31e-05 0.0333 0.48 0.26 Advanced glycation end-product levels; chr14:74478085 chr14:74471930~74472360:- CESC cis rs11159086 1 rs8006958 ENSG00000270000.1 RP3-449M8.9 3.98 9.31e-05 0.0333 0.48 0.26 Advanced glycation end-product levels; chr14:74478148 chr14:74471930~74472360:- CESC cis rs13113518 1 rs4865007 ENSG00000273257.1 RP11-177J6.1 -3.98 9.31e-05 0.0333 -0.34 -0.26 Height; chr4:55537550 chr4:55387949~55388271:+ CESC cis rs9532669 0.963 rs9562238 ENSG00000176268.5 CYCSP34 3.98 9.31e-05 0.0333 0.26 0.26 Cervical cancer; chr13:40924785 chr13:40863599~40863902:- CESC cis rs224278 0.789 rs224302 ENSG00000238280.1 RP11-436D10.3 3.98 9.32e-05 0.0334 0.31 0.26 Ewing sarcoma; chr10:62833045 chr10:62793562~62805887:- CESC cis rs2625529 0.938 rs2742323 ENSG00000260037.4 CTD-2524L6.3 3.98 9.32e-05 0.0334 0.39 0.26 Red blood cell count; chr15:71824437 chr15:71818396~71823384:+ CESC cis rs875971 0.545 rs1909508 ENSG00000226824.5 RP4-756H11.3 -3.98 9.32e-05 0.0334 -0.35 -0.26 Aortic root size; chr7:66301366 chr7:66654538~66669855:+ CESC cis rs72820985 1 rs16954075 ENSG00000260896.4 RP11-314O13.1 -3.98 9.32e-05 0.0334 -0.43 -0.26 Breast cancer; chr16:80813665 chr16:80828735~80892595:- CESC cis rs7789940 0.81 rs12533978 ENSG00000230305.2 AC004980.9 3.98 9.33e-05 0.0334 0.39 0.26 Multiple sclerosis; chr7:76314035 chr7:76524515~76532692:+ CESC cis rs172166 0.637 rs1225597 ENSG00000216901.1 AL022393.7 3.98 9.33e-05 0.0334 0.29 0.26 Cardiac Troponin-T levels; chr6:28194309 chr6:28176188~28176674:+ CESC cis rs6740462 0.521 rs11885144 ENSG00000273763.1 RP11-420C9.1 -3.98 9.34e-05 0.0334 -0.41 -0.26 Inflammatory bowel disease;Crohn's disease; chr2:65459227 chr2:65203571~65203813:- CESC cis rs7243790 0.805 rs3809947 ENSG00000277324.1 RP11-850A17.1 -3.98 9.34e-05 0.0334 -0.29 -0.26 Diastolic blood pressure; chr18:54380396 chr18:54268346~54270028:- CESC cis rs9601248 1 rs9601248 ENSG00000227676.3 LINC01068 -3.98 9.34e-05 0.0334 -0.31 -0.26 Major depressive disorder; chr13:79594869 chr13:79566727~79571436:+ CESC cis rs9847710 0.733 rs7613013 ENSG00000242142.1 SERBP1P3 3.98 9.34e-05 0.0334 0.3 0.26 Ulcerative colitis; chr3:53043790 chr3:53064283~53065091:- CESC cis rs6782228 0.606 rs2253144 ENSG00000242551.2 POU5F1P6 3.98 9.34e-05 0.0334 0.27 0.26 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611077 chr3:128674735~128677005:- CESC cis rs748404 0.697 rs579651 ENSG00000249839.1 AC011330.5 -3.98 9.35e-05 0.0334 -0.28 -0.26 Lung cancer; chr15:43266178 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs473016 ENSG00000249839.1 AC011330.5 -3.98 9.35e-05 0.0334 -0.28 -0.26 Lung cancer; chr15:43266625 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs531910 ENSG00000249839.1 AC011330.5 -3.98 9.35e-05 0.0334 -0.28 -0.26 Lung cancer; chr15:43268409 chr15:43663654~43684339:- CESC cis rs9487094 0.666 rs974034 ENSG00000260273.1 RP11-425D10.10 3.98 9.35e-05 0.0334 0.32 0.26 Height; chr6:109368228 chr6:109382795~109383666:+ CESC cis rs9487094 0.689 rs3818933 ENSG00000260273.1 RP11-425D10.10 3.98 9.35e-05 0.0334 0.32 0.26 Height; chr6:109370741 chr6:109382795~109383666:+ CESC cis rs9487094 0.689 rs9487076 ENSG00000260273.1 RP11-425D10.10 3.98 9.35e-05 0.0334 0.32 0.26 Height; chr6:109371524 chr6:109382795~109383666:+ CESC cis rs1707322 1 rs7538978 ENSG00000281133.1 AL355480.3 3.98 9.35e-05 0.0334 0.31 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46039382 chr1:45580892~45580996:- CESC cis rs13113518 0.729 rs12641881 ENSG00000249700.7 SRD5A3-AS1 3.98 9.35e-05 0.0334 0.34 0.26 Height; chr4:55401306 chr4:55363971~55395847:- CESC cis rs11096990 0.855 rs4974986 ENSG00000249207.1 RP11-360F5.1 3.98 9.35e-05 0.0334 0.33 0.26 Cognitive function; chr4:39165308 chr4:39112677~39126818:- CESC cis rs9903692 0.954 rs12936731 ENSG00000263412.1 RP5-890E16.2 -3.98 9.35e-05 0.0335 -0.26 -0.26 Pulse pressure; chr17:48050997 chr17:48045141~48048073:- CESC cis rs9903692 0.909 rs9899275 ENSG00000263412.1 RP5-890E16.2 -3.98 9.35e-05 0.0335 -0.26 -0.26 Pulse pressure; chr17:48051953 chr17:48045141~48048073:- CESC cis rs9903692 0.954 rs12450620 ENSG00000263412.1 RP5-890E16.2 -3.98 9.35e-05 0.0335 -0.26 -0.26 Pulse pressure; chr17:48052892 chr17:48045141~48048073:- CESC cis rs9903692 0.954 rs7212202 ENSG00000263412.1 RP5-890E16.2 -3.98 9.35e-05 0.0335 -0.26 -0.26 Pulse pressure; chr17:48055361 chr17:48045141~48048073:- CESC cis rs9903692 0.954 rs34750858 ENSG00000263412.1 RP5-890E16.2 -3.98 9.35e-05 0.0335 -0.26 -0.26 Pulse pressure; chr17:48055575 chr17:48045141~48048073:- CESC cis rs8080784 0.932 rs7223521 ENSG00000266701.1 AC005702.4 3.98 9.35e-05 0.0335 0.37 0.26 Coronary artery disease; chr17:60952326 chr17:60042546~60042627:- CESC cis rs8080784 1 rs1119805 ENSG00000266701.1 AC005702.4 3.98 9.35e-05 0.0335 0.37 0.26 Coronary artery disease; chr17:60952677 chr17:60042546~60042627:- CESC cis rs8080784 1 rs1988961 ENSG00000266701.1 AC005702.4 3.98 9.35e-05 0.0335 0.37 0.26 Coronary artery disease; chr17:60952768 chr17:60042546~60042627:- CESC cis rs8080784 1 rs9890322 ENSG00000266701.1 AC005702.4 3.98 9.35e-05 0.0335 0.37 0.26 Coronary artery disease; chr17:60954181 chr17:60042546~60042627:- CESC cis rs8080784 1 rs9916145 ENSG00000266701.1 AC005702.4 3.98 9.35e-05 0.0335 0.37 0.26 Coronary artery disease; chr17:60954247 chr17:60042546~60042627:- CESC cis rs12690897 0.501 rs10256465 ENSG00000229251.3 HNRNPA1P8 -3.98 9.37e-05 0.0335 -0.26 -0.26 Macrophage inflammatory protein 1a levels; chr7:85644538 chr7:84983556~84984506:+ CESC cis rs9322193 0.923 rs11155670 ENSG00000216906.2 RP11-350J20.9 3.98 9.37e-05 0.0335 0.28 0.26 Lung cancer; chr6:149644992 chr6:149904243~149906418:+ CESC cis rs2921036 0.529 rs2979192 ENSG00000173295.6 FAM86B3P 3.98 9.37e-05 0.0335 0.32 0.26 Neuroticism; chr8:8480637 chr8:8228595~8244865:+ CESC cis rs875971 0.862 rs6944374 ENSG00000222364.1 RNU6-96P 3.98 9.38e-05 0.0335 0.31 0.26 Aortic root size; chr7:66221942 chr7:66395191~66395286:+ CESC cis rs2120243 0.504 rs114107407 ENSG00000241544.1 RP11-6F2.5 3.98 9.38e-05 0.0335 0.27 0.26 Hepatocellular carcinoma in hepatitis B infection; chr3:157344846 chr3:157081841~157088547:+ CESC cis rs4819052 0.851 rs2838867 ENSG00000223768.1 LINC00205 -3.98 9.38e-05 0.0335 -0.31 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45293177 chr21:45293285~45297354:+ CESC cis rs2836950 0.509 rs4816618 ENSG00000255568.3 BRWD1-AS2 -3.98 9.39e-05 0.0336 -0.21 -0.26 Menarche (age at onset); chr21:39227603 chr21:39313935~39314962:+ CESC cis rs2836950 0.527 rs2836948 ENSG00000255568.3 BRWD1-AS2 -3.98 9.39e-05 0.0336 -0.21 -0.26 Menarche (age at onset); chr21:39227751 chr21:39313935~39314962:+ CESC cis rs12690897 0.501 rs12704160 ENSG00000229251.3 HNRNPA1P8 -3.98 9.4e-05 0.0336 -0.26 -0.26 Macrophage inflammatory protein 1a levels; chr7:85647555 chr7:84983556~84984506:+ CESC cis rs4146922 1 rs58680090 ENSG00000212175.1 SNORA12 -3.98 9.41e-05 0.0336 -0.29 -0.26 Height; chr2:55853244 chr2:55565703~55565850:+ CESC cis rs10829156 0.786 rs7077786 ENSG00000240291.1 RP11-499P20.2 3.98 9.41e-05 0.0336 0.29 0.26 Sudden cardiac arrest; chr10:18603453 chr10:18513115~18545651:- CESC cis rs7208859 0.725 rs9891656 ENSG00000264538.5 SUZ12P1 -3.98 9.41e-05 0.0336 -0.28 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30709299~30790908:+ CESC cis rs6951245 1 rs11767527 ENSG00000229043.2 AC091729.9 -3.98 9.41e-05 0.0336 -0.4 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1057758 chr7:1160374~1165267:+ CESC cis rs6775745 1 rs7651714 ENSG00000240854.1 RP11-64K7.1 -3.98 9.42e-05 0.0336 -0.37 -0.26 Neutrophil count; chr3:132085040 chr3:132175402~132176711:+ CESC cis rs16885979 1 rs17682328 ENSG00000224984.1 RP11-524H19.2 -3.98 9.42e-05 0.0336 -0.56 -0.26 Daytime sleep phenotypes; chr6:54845278 chr6:54840118~54840855:- CESC cis rs17818399 0.597 rs12104572 ENSG00000279254.1 RP11-536C12.1 -3.98 9.43e-05 0.0337 -0.29 -0.26 Height; chr2:46635327 chr2:46668870~46670778:+ CESC cis rs62445005 1 rs62445005 ENSG00000211698.2 TRGV4 3.98 9.43e-05 0.0337 0.25 0.26 Shingles; chr7:38346957 chr7:38353715~38354517:- CESC cis rs875971 1 rs10257427 ENSG00000237310.1 GS1-124K5.4 -3.98 9.44e-05 0.0337 -0.24 -0.26 Aortic root size; chr7:66278221 chr7:66493706~66495474:+ CESC cis rs2404602 0.692 rs35557205 ENSG00000280730.1 AC090181.1 3.98 9.44e-05 0.0337 0.21 0.26 Blood metabolite levels; chr15:76838370 chr15:77056895~77057021:+ CESC cis rs3925075 0.531 rs9673519 ENSG00000260911.2 RP11-196G11.2 -3.98 9.44e-05 0.0337 -0.27 -0.26 IgA nephropathy; chr16:31336236 chr16:31043150~31049868:+ CESC cis rs10129255 0.826 rs7150693 ENSG00000280411.1 IGHV1-69-2 -3.98 9.44e-05 0.0337 -0.21 -0.26 Kawasaki disease; chr14:106705382 chr14:106762092~106762588:- CESC cis rs2455601 0.574 rs2568094 ENSG00000254860.4 TMEM9B-AS1 3.98 9.44e-05 0.0337 0.31 0.26 Schizophrenia; chr11:8970671 chr11:8964675~8977527:+ CESC cis rs875971 0.862 rs1983372 ENSG00000179406.6 LINC00174 3.98 9.45e-05 0.0337 0.28 0.26 Aortic root size; chr7:66146364 chr7:66376044~66401338:- CESC cis rs5742933 1 rs12622902 ENSG00000253559.1 OSGEPL1-AS1 -3.98 9.45e-05 0.0337 -0.36 -0.26 Ferritin levels; chr2:189776263 chr2:189762704~189765556:+ CESC cis rs875971 0.964 rs55748098 ENSG00000237310.1 GS1-124K5.4 -3.98 9.45e-05 0.0337 -0.24 -0.26 Aortic root size; chr7:66298631 chr7:66493706~66495474:+ CESC cis rs1030877 0.521 rs2576747 ENSG00000235319.1 AC012360.4 -3.98 9.45e-05 0.0338 -0.29 -0.26 Obesity-related traits; chr2:105362219 chr2:105324210~105330529:+ CESC cis rs34526934 0.608 rs34720456 ENSG00000226363.3 HAGLROS 3.98 9.45e-05 0.0338 0.42 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176162564 chr2:176177717~176179008:+ CESC cis rs34526934 0.608 rs7591820 ENSG00000226363.3 HAGLROS 3.98 9.45e-05 0.0338 0.42 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176163416 chr2:176177717~176179008:+ CESC cis rs34526934 0.608 rs7606110 ENSG00000226363.3 HAGLROS 3.98 9.45e-05 0.0338 0.42 0.26 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176163823 chr2:176177717~176179008:+ CESC cis rs7951870 1 rs12292425 ENSG00000247675.5 LRP4-AS1 -3.98 9.46e-05 0.0338 -0.36 -0.26 Schizophrenia; chr11:46622593 chr11:46846412~46874396:+ CESC cis rs34286592 0.929 rs11863748 ENSG00000214725.6 CDIPT-AS1 -3.98 9.46e-05 0.0338 -0.49 -0.26 Multiple sclerosis; chr16:29824267 chr16:29863593~29868053:+ CESC cis rs853679 0.567 rs1005126 ENSG00000204709.4 LINC01556 3.98 9.47e-05 0.0338 0.3 0.26 Depression; chr6:28399846 chr6:28943877~28944537:+ CESC cis rs12468226 1 rs7587234 ENSG00000273456.1 RP11-686O6.2 3.98 9.48e-05 0.0338 0.33 0.26 Urate levels; chr2:202351699 chr2:202374932~202375604:- CESC cis rs17301013 0.659 rs59649440 ENSG00000227373.4 RP11-160H22.5 3.98 9.48e-05 0.0338 0.32 0.26 Systemic lupus erythematosus; chr1:174332024 chr1:174115300~174160004:- CESC cis rs7005380 0.58 rs11781657 ENSG00000279347.1 RP11-85I17.2 -3.98 9.48e-05 0.0338 -0.24 -0.26 Interstitial lung disease; chr8:119877002 chr8:119838736~119840385:- CESC cis rs585510 1 rs585510 ENSG00000278344.1 RP11-18C24.8 3.98 9.49e-05 0.0338 0.32 0.26 Reticulocyte fraction of red cells; chr12:120562330 chr12:120500735~120501090:- CESC cis rs1020064 0.636 rs1529975 ENSG00000235319.1 AC012360.4 -3.98 9.49e-05 0.0338 -0.31 -0.26 AIDS; chr2:105313444 chr2:105324210~105330529:+ CESC cis rs17301013 0.507 rs1793320 ENSG00000227373.4 RP11-160H22.5 3.98 9.49e-05 0.0338 0.34 0.26 Systemic lupus erythematosus; chr1:174796308 chr1:174115300~174160004:- CESC cis rs11030122 1 rs11030122 ENSG00000230593.3 AC090804.1 3.98 9.49e-05 0.0339 0.31 0.26 Mean platelet volume;Platelet distribution width; chr11:3865946 chr11:3892398~3892887:- CESC cis rs7104764 0.507 rs6598056 ENSG00000251661.3 RP11-326C3.11 -3.98 9.49e-05 0.0339 -0.32 -0.26 Menarche (age at onset); chr11:252283 chr11:318640~325631:+ CESC cis rs2337406 1 rs7145172 ENSG00000211974.3 IGHV2-70 -3.98 9.49e-05 0.0339 -0.39 -0.26 Alzheimer's disease (late onset); chr14:106704924 chr14:106723574~106724093:- CESC cis rs2117029 1 rs10875913 ENSG00000258017.1 RP11-386G11.10 -3.98 9.5e-05 0.0339 -0.34 -0.26 Intelligence (multi-trait analysis); chr12:49025525 chr12:49127782~49147869:+ CESC cis rs10129255 0.784 rs7147210 ENSG00000280411.1 IGHV1-69-2 -3.98 9.5e-05 0.0339 -0.21 -0.26 Kawasaki disease; chr14:106705271 chr14:106762092~106762588:- CESC cis rs2297363 1 rs2297363 ENSG00000213073.4 RP11-288H12.3 -3.98 9.5e-05 0.0339 -0.31 -0.26 Total cholesterol levels;Blood protein levels; chr6:160085430 chr6:160093082~160096212:+ CESC cis rs2732480 0.538 rs2468943 ENSG00000258273.1 RP11-370I10.4 3.98 9.5e-05 0.0339 0.31 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48353466 chr12:48333755~48333901:- CESC cis rs10129255 0.744 rs28517388 ENSG00000280411.1 IGHV1-69-2 -3.98 9.51e-05 0.0339 -0.21 -0.26 Kawasaki disease; chr14:106704323 chr14:106762092~106762588:- CESC cis rs9532669 0.963 rs4942012 ENSG00000239827.7 SUGT1P3 -3.98 9.51e-05 0.0339 -0.28 -0.26 Cervical cancer; chr13:40939112 chr13:40908159~40921774:- CESC cis rs4877691 0.522 rs17085531 ENSG00000267559.4 RP11-383M4.6 3.98 9.51e-05 0.0339 0.36 0.26 Airway imaging phenotypes; chr9:82476446 chr9:81930226~81977089:- CESC cis rs9532669 0.926 rs9532643 ENSG00000176268.5 CYCSP34 3.98 9.52e-05 0.0339 0.26 0.26 Cervical cancer; chr13:40880800 chr13:40863599~40863902:- CESC cis rs2562784 1 rs2562784 ENSG00000279758.1 RP11-752G15.10 3.98 9.52e-05 0.0339 0.27 0.26 Height; chr15:83617740 chr15:82738386~82739122:+ CESC cis rs224278 0.509 rs6479860 ENSG00000238280.1 RP11-436D10.3 -3.98 9.52e-05 0.0339 -0.41 -0.26 Ewing sarcoma; chr10:62986105 chr10:62793562~62805887:- CESC cis rs9322193 0.887 rs3777949 ENSG00000268592.3 RAET1E-AS1 3.98 9.52e-05 0.0339 0.33 0.26 Lung cancer; chr6:149596021 chr6:149863494~149919507:+ CESC cis rs2276314 0.793 rs77590522 ENSG00000278986.1 RP11-723J4.3 -3.98 9.52e-05 0.0339 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:36049447 chr18:35972151~35973916:+ CESC cis rs988913 0.723 rs4715520 ENSG00000224984.1 RP11-524H19.2 -3.98 9.53e-05 0.034 -0.26 -0.26 Menarche (age at onset); chr6:55131197 chr6:54840118~54840855:- CESC cis rs875971 1 rs7781698 ENSG00000232559.3 GS1-124K5.12 3.98 9.53e-05 0.034 0.28 0.26 Aortic root size; chr7:66431325 chr7:66554588~66576923:- CESC cis rs2337406 1 rs17112416 ENSG00000254174.1 IGHV1-12 -3.98 9.53e-05 0.034 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106686773 chr14:106122420~106122709:- CESC cis rs7873102 0.63 rs10973624 ENSG00000230188.1 RP11-405L18.4 -3.98 9.53e-05 0.034 -0.34 -0.26 Brain structure; chr9:37964733 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs7857446 ENSG00000230188.1 RP11-405L18.4 -3.98 9.53e-05 0.034 -0.34 -0.26 Brain structure; chr9:37965644 chr9:37490421~37490893:- CESC cis rs7873102 0.58 rs4637937 ENSG00000230188.1 RP11-405L18.4 -3.98 9.53e-05 0.034 -0.34 -0.26 Brain structure; chr9:37965819 chr9:37490421~37490893:- CESC cis rs7873102 0.63 rs4637938 ENSG00000230188.1 RP11-405L18.4 -3.98 9.53e-05 0.034 -0.34 -0.26 Brain structure; chr9:37966134 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs7862130 ENSG00000230188.1 RP11-405L18.4 -3.98 9.53e-05 0.034 -0.34 -0.26 Brain structure; chr9:37966973 chr9:37490421~37490893:- CESC cis rs10129255 0.957 rs12590667 ENSG00000280411.1 IGHV1-69-2 3.98 9.53e-05 0.034 0.19 0.26 Kawasaki disease; chr14:106779223 chr14:106762092~106762588:- CESC cis rs55665837 0.961 rs11023237 ENSG00000251991.1 RNU7-49P 3.98 9.53e-05 0.034 0.29 0.26 Vitamin D levels; chr11:14478788 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs10466412 ENSG00000251991.1 RNU7-49P 3.98 9.53e-05 0.034 0.29 0.26 Vitamin D levels; chr11:14483643 chr11:14478892~14478953:+ CESC cis rs7951870 1 rs61882709 ENSG00000247675.5 LRP4-AS1 -3.98 9.54e-05 0.034 -0.33 -0.26 Schizophrenia; chr11:46450864 chr11:46846412~46874396:+ CESC cis rs7727544 0.904 rs7736102 ENSG00000233006.5 AC034220.3 3.98 9.55e-05 0.034 0.29 0.26 Blood metabolite levels; chr5:132268564 chr5:132311285~132369916:- CESC cis rs7727544 0.904 rs6897575 ENSG00000233006.5 AC034220.3 3.98 9.55e-05 0.034 0.29 0.26 Blood metabolite levels; chr5:132268842 chr5:132311285~132369916:- CESC cis rs12220238 0.822 rs11000979 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74308107 chr10:74423435~74424014:- CESC cis rs12220238 0.915 rs7073139 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74311431 chr10:74423435~74424014:- CESC cis rs12220238 0.915 rs11000987 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74313507 chr10:74423435~74424014:- CESC cis rs12220238 0.915 rs11000988 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74313965 chr10:74423435~74424014:- CESC cis rs12220238 0.915 rs10824148 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74318256 chr10:74423435~74424014:- CESC cis rs12220238 0.822 rs2395087 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74322879 chr10:74423435~74424014:- CESC cis rs12220238 0.915 rs2894235 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74323187 chr10:74423435~74424014:- CESC cis rs12220238 0.822 rs73286281 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74323579 chr10:74423435~74424014:- CESC cis rs12220238 0.915 rs11001003 ENSG00000213731.2 RAB5CP1 -3.98 9.55e-05 0.034 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74340186 chr10:74423435~74424014:- CESC cis rs7665090 1 rs909349 ENSG00000246560.2 RP11-10L12.4 -3.98 9.55e-05 0.034 -0.32 -0.26 Primary biliary cholangitis; chr4:102635159 chr4:102828055~102844075:+ CESC cis rs875971 1 rs10215948 ENSG00000179406.6 LINC00174 3.98 9.55e-05 0.034 0.27 0.26 Aortic root size; chr7:66282799 chr7:66376044~66401338:- CESC cis rs17301013 0.507 rs10912822 ENSG00000227373.4 RP11-160H22.5 3.98 9.56e-05 0.034 0.34 0.26 Systemic lupus erythematosus; chr1:174624490 chr1:174115300~174160004:- CESC cis rs875971 0.964 rs1643388 ENSG00000232559.3 GS1-124K5.12 3.98 9.57e-05 0.0341 0.29 0.26 Aortic root size; chr7:66379575 chr7:66554588~66576923:- CESC cis rs875971 1 rs778722 ENSG00000232559.3 GS1-124K5.12 3.98 9.57e-05 0.0341 0.29 0.26 Aortic root size; chr7:66379841 chr7:66554588~66576923:- CESC cis rs875971 0.964 rs778721 ENSG00000232559.3 GS1-124K5.12 3.98 9.57e-05 0.0341 0.29 0.26 Aortic root size; chr7:66380410 chr7:66554588~66576923:- CESC cis rs10995356 0.932 rs10822082 ENSG00000238280.1 RP11-436D10.3 3.98 9.57e-05 0.0341 0.31 0.26 Temperament; chr10:62917547 chr10:62793562~62805887:- CESC cis rs1670685 0.609 rs1014066 ENSG00000247137.7 RP11-727A23.5 -3.97 9.57e-05 0.0341 -0.41 -0.26 Urate levels in overweight individuals; chr11:84138472 chr11:83184491~83193794:- CESC cis rs3796352 1 rs11714876 ENSG00000280417.1 RP11-5O17.1 3.97 9.57e-05 0.0341 0.43 0.26 Immune reponse to smallpox (secreted IL-2); chr3:53067624 chr3:53046166~53048122:+ CESC cis rs10844706 0.699 rs2401390 ENSG00000256594.6 RP11-705C15.2 3.97 9.57e-05 0.0341 0.31 0.26 Lymphocyte counts;Lymphocyte percentage of white cells; chr12:9719218 chr12:9633419~9658412:+ CESC cis rs875971 1 rs6961717 ENSG00000237310.1 GS1-124K5.4 -3.97 9.58e-05 0.0341 -0.24 -0.26 Aortic root size; chr7:66122550 chr7:66493706~66495474:+ CESC cis rs11221522 0.92 rs10488729 ENSG00000281097.1 LINC01395 -3.97 9.58e-05 0.0341 -0.27 -0.26 Metabolite levels (5-HIAA); chr11:129092775 chr11:129612116~129617269:- CESC cis rs2111504 0.887 rs68013007 ENSG00000267213.4 AC007773.2 -3.97 9.58e-05 0.0341 -0.38 -0.26 Bipolar disorder; chr19:32447775 chr19:32390050~32405560:- CESC cis rs7896729 1 rs1344354 ENSG00000215267.7 AKR1C7P 3.97 9.59e-05 0.0341 0.3 0.26 Intelligence; chr10:5297111 chr10:5275173~5288470:- CESC cis rs11089937 0.54 rs5756992 ENSG00000211638.2 IGLV8-61 -3.97 9.59e-05 0.0341 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22132636 chr22:22098700~22099212:+ CESC cis rs11089937 0.597 rs9619793 ENSG00000211638.2 IGLV8-61 -3.97 9.59e-05 0.0341 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22132952 chr22:22098700~22099212:+ CESC cis rs4319547 0.656 rs10846664 ENSG00000275265.1 RP11-15J22.8 3.97 9.59e-05 0.0341 0.36 0.26 Body mass index; chr12:122339230 chr12:122501187~122501641:+ CESC cis rs17301013 0.606 rs11487399 ENSG00000227373.4 RP11-160H22.5 3.97 9.59e-05 0.0341 0.33 0.26 Systemic lupus erythematosus; chr1:174527129 chr1:174115300~174160004:- CESC cis rs1838105 0.64 rs9889451 ENSG00000263142.4 LRRC37A17P 3.97 9.59e-05 0.0341 0.2 0.26 Nonsyndromic cleft lip with cleft palate; chr17:47076509 chr17:46978481~47054569:+ CESC cis rs2408955 0.501 rs8716 ENSG00000226413.2 OR8T1P 3.97 9.6e-05 0.0341 0.33 0.26 Glycated hemoglobin levels; chr12:48145699 chr12:48442030~48442947:- CESC cis rs7428 0.962 rs3637 ENSG00000273196.1 RP11-717A5.2 3.97 9.6e-05 0.0341 0.3 0.26 Ear protrusion; chr2:85322751 chr2:85387074~85387146:- CESC cis rs6997458 0.774 rs6984619 ENSG00000253549.4 RP11-317J10.2 3.97 9.6e-05 0.0341 0.31 0.26 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85419149 chr8:85441851~85464915:- CESC cis rs7923452 0.938 rs67812762 ENSG00000237135.1 DDX10P1 -3.97 9.6e-05 0.0341 -0.39 -0.26 Itch intensity from mosquito bite; chr10:30470550 chr10:30919012~30921235:- CESC cis rs922182 0.967 rs17788704 ENSG00000239465.1 RP11-330L19.2 3.97 9.6e-05 0.0341 0.34 0.26 Blood protein levels; chr15:63984898 chr15:64631109~64631914:- CESC cis rs7138803 0.51 rs7977112 ENSG00000257464.1 RP11-161H23.8 -3.97 9.61e-05 0.0341 -0.26 -0.26 Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index; chr12:49815835 chr12:49442424~49442652:- CESC cis rs9925964 0.933 rs881929 ENSG00000260911.2 RP11-196G11.2 -3.97 9.61e-05 0.0341 -0.28 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31068050 chr16:31043150~31049868:+ CESC cis rs748404 0.578 rs512628 ENSG00000205771.5 CATSPER2P1 -3.97 9.61e-05 0.0341 -0.31 -0.26 Lung cancer; chr15:43326536 chr15:43726918~43747094:- CESC cis rs1707322 0.964 rs6697830 ENSG00000281133.1 AL355480.3 -3.97 9.61e-05 0.0341 -0.3 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45824805 chr1:45580892~45580996:- CESC cis rs1707322 1 rs12060274 ENSG00000281133.1 AL355480.3 -3.97 9.61e-05 0.0341 -0.3 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45825390 chr1:45580892~45580996:- CESC cis rs1707322 1 rs10890353 ENSG00000281133.1 AL355480.3 -3.97 9.61e-05 0.0341 -0.3 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45832711 chr1:45580892~45580996:- CESC cis rs4713118 0.512 rs2622319 ENSG00000219392.1 RP1-265C24.5 -3.97 9.61e-05 0.0341 -0.31 -0.26 Parkinson's disease; chr6:28152623 chr6:28115628~28116551:+ CESC cis rs9925964 0.935 rs4527034 ENSG00000260911.2 RP11-196G11.2 3.97 9.62e-05 0.0342 0.28 0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31120293 chr16:31043150~31049868:+ CESC cis rs7951870 1 rs11038914 ENSG00000247675.5 LRP4-AS1 3.97 9.62e-05 0.0342 0.31 0.26 Schizophrenia; chr11:46539751 chr11:46846412~46874396:+ CESC cis rs12908161 0.959 rs17534709 ENSG00000259728.4 LINC00933 3.97 9.63e-05 0.0342 0.34 0.26 Schizophrenia; chr15:84771166 chr15:84570649~84580175:+ CESC cis rs1862618 0.671 rs252897 ENSG00000271828.1 CTD-2310F14.1 3.97 9.63e-05 0.0342 0.31 0.26 Initial pursuit acceleration; chr5:56927173 chr5:56927874~56929573:+ CESC cis rs7688540 0.511 rs77815676 ENSG00000211553.1 AC253576.2 -3.97 9.63e-05 0.0342 -0.41 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:196080 chr4:136461~136568:+ CESC cis rs7688540 0.511 rs76125013 ENSG00000211553.1 AC253576.2 -3.97 9.63e-05 0.0342 -0.41 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:201493 chr4:136461~136568:+ CESC cis rs2836950 0.565 rs7278297 ENSG00000232608.1 TIMM9P2 3.97 9.63e-05 0.0342 0.29 0.26 Menarche (age at onset); chr21:39253826 chr21:39216624~39217506:+ CESC cis rs7615316 0.934 rs2227930 ENSG00000244327.1 RP11-383G6.3 3.97 9.63e-05 0.0342 0.28 0.26 Mean corpuscular volume;Mean corpuscular hemoglobin; chr3:142558733 chr3:142465315~142472337:- CESC cis rs7615316 0.934 rs6440089 ENSG00000244327.1 RP11-383G6.3 3.97 9.63e-05 0.0342 0.28 0.26 Mean corpuscular volume;Mean corpuscular hemoglobin; chr3:142560954 chr3:142465315~142472337:- CESC cis rs7615316 0.934 rs2227928 ENSG00000244327.1 RP11-383G6.3 3.97 9.63e-05 0.0342 0.28 0.26 Mean corpuscular volume;Mean corpuscular hemoglobin; chr3:142562770 chr3:142465315~142472337:- CESC cis rs10129255 0.5 rs2027902 ENSG00000211972.2 IGHV3-66 3.97 9.64e-05 0.0342 0.2 0.26 Kawasaki disease; chr14:106807157 chr14:106675017~106675544:- CESC cis rs10483853 0.525 rs2302041 ENSG00000258695.2 RP3-414A15.2 -3.97 9.64e-05 0.0342 -0.39 -0.26 Coronary artery calcification; chr14:73494166 chr14:73522878~73530610:+ CESC cis rs79243044 1 rs34822023 ENSG00000224295.2 AC087380.14 -3.97 9.64e-05 0.0342 -0.28 -0.26 QRS duration in Tripanosoma cruzi seropositivity; chr11:5534014 chr11:5518441~5524955:- CESC cis rs79243044 1 rs35601051 ENSG00000224295.2 AC087380.14 -3.97 9.64e-05 0.0342 -0.28 -0.26 QRS duration in Tripanosoma cruzi seropositivity; chr11:5534017 chr11:5518441~5524955:- CESC cis rs9309473 0.948 rs7607892 ENSG00000163016.8 ALMS1P 3.97 9.65e-05 0.0342 0.35 0.26 Metabolite levels; chr2:73591580 chr2:73644919~73685576:+ CESC cis rs67981189 0.501 rs2810104 ENSG00000269927.1 RP6-91H8.3 3.97 9.65e-05 0.0343 0.29 0.26 Schizophrenia; chr14:70958096 chr14:71141125~71143253:- CESC cis rs875971 0.545 rs4718325 ENSG00000236529.1 RP13-254B10.1 3.97 9.66e-05 0.0343 0.33 0.26 Aortic root size; chr7:66215323 chr7:65840212~65840596:+ CESC cis rs919433 0.519 rs700656 ENSG00000222017.1 AC011997.1 3.97 9.66e-05 0.0343 0.33 0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197788943 chr2:197693106~197774823:+ CESC cis rs6439153 0.933 rs34193129 ENSG00000261159.1 RP11-723O4.9 3.97 9.66e-05 0.0343 0.27 0.26 Pneumococcal bacteremia; chr3:128972564 chr3:128859716~128860526:- CESC cis rs7580658 0.545 rs885276 ENSG00000236682.1 AC068282.3 -3.97 9.67e-05 0.0343 -0.31 -0.26 Protein C levels; chr2:127193328 chr2:127389130~127400580:+ CESC cis rs7178909 0.872 rs7179633 ENSG00000259677.1 RP11-493E3.1 3.97 9.67e-05 0.0343 0.3 0.26 Common traits (Other); chr15:89891645 chr15:89876540~89877285:+ CESC cis rs7178909 0.872 rs28865973 ENSG00000259677.1 RP11-493E3.1 3.97 9.67e-05 0.0343 0.3 0.26 Common traits (Other); chr15:89891946 chr15:89876540~89877285:+ CESC cis rs10129255 0.957 rs8014696 ENSG00000223648.3 IGHV3-64 -3.97 9.67e-05 0.0343 -0.22 -0.26 Kawasaki disease; chr14:106769752 chr14:106643132~106658258:- CESC cis rs3806843 0.576 rs155360 ENSG00000202111.1 VTRNA1-2 -3.97 9.67e-05 0.0343 -0.26 -0.26 Depressive symptoms (multi-trait analysis); chr5:140929431 chr5:140718925~140719013:+ CESC cis rs7243790 1 rs10502990 ENSG00000277324.1 RP11-850A17.1 3.97 9.68e-05 0.0343 0.29 0.26 Diastolic blood pressure; chr18:54438168 chr18:54268346~54270028:- CESC cis rs9847710 0.708 rs2581811 ENSG00000242142.1 SERBP1P3 3.97 9.68e-05 0.0344 0.3 0.26 Ulcerative colitis; chr3:53051785 chr3:53064283~53065091:- CESC cis rs2261181 0.803 rs2612065 ENSG00000276853.1 RP11-305O6.4 3.97 9.68e-05 0.0344 0.62 0.26 Type 2 diabetes; chr12:65778991 chr12:65171262~65171917:+ CESC cis rs2060793 0.519 rs2597212 ENSG00000251991.1 RNU7-49P -3.97 9.69e-05 0.0344 -0.28 -0.26 Vitamin D levels; chr11:14560216 chr11:14478892~14478953:+ CESC cis rs10129255 0.5 rs8011115 ENSG00000211972.2 IGHV3-66 3.97 9.69e-05 0.0344 0.19 0.26 Kawasaki disease; chr14:106786292 chr14:106675017~106675544:- CESC cis rs12134133 1 rs7521457 ENSG00000274245.1 RP11-357P18.2 3.97 9.69e-05 0.0344 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207283802 chr1:207372559~207373252:+ CESC cis rs12134133 1 rs7553339 ENSG00000274245.1 RP11-357P18.2 3.97 9.69e-05 0.0344 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207284075 chr1:207372559~207373252:+ CESC cis rs12134133 1 rs12134133 ENSG00000274245.1 RP11-357P18.2 3.97 9.69e-05 0.0344 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207284500 chr1:207372559~207373252:+ CESC cis rs2564921 0.73 rs2253675 ENSG00000242142.1 SERBP1P3 -3.97 9.7e-05 0.0344 -0.31 -0.26 Height; chr3:53085518 chr3:53064283~53065091:- CESC cis rs10129255 0.83 rs61997609 ENSG00000211970.3 IGHV4-61 -3.97 9.7e-05 0.0344 -0.2 -0.26 Kawasaki disease; chr14:106692376 chr14:106639119~106639657:- CESC cis rs75422866 0.51 rs73105819 ENSG00000257433.4 RP1-197B17.3 3.97 9.71e-05 0.0344 0.66 0.26 Pneumonia; chr12:47727190 chr12:47706085~47742294:+ CESC cis rs7819412 0.525 rs10086521 ENSG00000255046.1 RP11-297N6.4 3.97 9.71e-05 0.0344 0.28 0.26 Triglycerides; chr8:10926259 chr8:11797928~11802568:- CESC cis rs1707322 1 rs785465 ENSG00000281133.1 AL355480.3 -3.97 9.71e-05 0.0344 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46056905 chr1:45580892~45580996:- CESC cis rs12439619 1 rs35152457 ENSG00000278603.1 RP13-608F4.5 3.97 9.71e-05 0.0344 0.37 0.26 Intelligence (multi-trait analysis); chr15:82254207 chr15:82472203~82472426:+ CESC cis rs763121 0.853 rs5750677 ENSG00000273076.1 RP3-508I15.22 3.97 9.71e-05 0.0344 0.3 0.26 Menopause (age at onset); chr22:38751710 chr22:38743495~38743910:+ CESC cis rs763121 0.853 rs2072798 ENSG00000273076.1 RP3-508I15.22 3.97 9.71e-05 0.0344 0.3 0.26 Menopause (age at onset); chr22:38752478 chr22:38743495~38743910:+ CESC cis rs7178909 0.872 rs3931863 ENSG00000259677.1 RP11-493E3.1 3.97 9.72e-05 0.0345 0.3 0.26 Common traits (Other); chr15:89890681 chr15:89876540~89877285:+ CESC cis rs490234 0.812 rs13286111 ENSG00000232630.1 PRPS1P2 -3.97 9.72e-05 0.0345 -0.22 -0.26 Mean arterial pressure; chr9:125667672 chr9:125150653~125151589:+ CESC cis rs10170310 0.515 rs35141237 ENSG00000241772.2 AC092620.2 3.97 9.72e-05 0.0345 0.43 0.26 Response to antipsychotic treatment; chr2:138595405 chr2:138569090~138574458:+ CESC cis rs10170310 0.515 rs71419597 ENSG00000241772.2 AC092620.2 3.97 9.72e-05 0.0345 0.43 0.26 Response to antipsychotic treatment; chr2:138598524 chr2:138569090~138574458:+ CESC cis rs2277027 0.518 rs2863747 ENSG00000251405.2 CTB-109A12.1 3.97 9.72e-05 0.0345 0.34 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157503776 chr5:157362615~157460078:- CESC cis rs55665837 1 rs2305305 ENSG00000251991.1 RNU7-49P 3.97 9.73e-05 0.0345 0.29 0.26 Vitamin D levels; chr11:14519396 chr11:14478892~14478953:+ CESC cis rs763121 0.853 rs6001173 ENSG00000273076.1 RP3-508I15.22 3.97 9.73e-05 0.0345 0.3 0.26 Menopause (age at onset); chr22:38619297 chr22:38743495~38743910:+ CESC cis rs875971 0.545 rs66594357 ENSG00000236529.1 RP13-254B10.1 3.97 9.73e-05 0.0345 0.31 0.26 Aortic root size; chr7:66327797 chr7:65840212~65840596:+ CESC cis rs875971 1 rs2087647 ENSG00000237310.1 GS1-124K5.4 -3.97 9.73e-05 0.0345 -0.24 -0.26 Aortic root size; chr7:66128201 chr7:66493706~66495474:+ CESC cis rs875971 1 rs6958484 ENSG00000237310.1 GS1-124K5.4 -3.97 9.73e-05 0.0345 -0.24 -0.26 Aortic root size; chr7:66134459 chr7:66493706~66495474:+ CESC cis rs6997458 0.785 rs6996345 ENSG00000253549.4 RP11-317J10.2 3.97 9.74e-05 0.0345 0.31 0.26 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85418846 chr8:85441851~85464915:- CESC cis rs8031584 0.678 rs4779496 ENSG00000260382.1 RP11-540B6.2 3.97 9.74e-05 0.0345 0.35 0.26 Huntington's disease progression; chr15:30858851 chr15:30882267~30883231:- CESC cis rs8031584 0.678 rs4779497 ENSG00000260382.1 RP11-540B6.2 3.97 9.74e-05 0.0345 0.35 0.26 Huntington's disease progression; chr15:30859162 chr15:30882267~30883231:- CESC cis rs8031584 0.678 rs8028173 ENSG00000260382.1 RP11-540B6.2 3.97 9.74e-05 0.0345 0.35 0.26 Huntington's disease progression; chr15:30863546 chr15:30882267~30883231:- CESC cis rs9925964 0.967 rs14235 ENSG00000260911.2 RP11-196G11.2 -3.97 9.74e-05 0.0345 -0.29 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31110472 chr16:31043150~31049868:+ CESC cis rs12439619 0.693 rs4778989 ENSG00000276710.3 CSPG4P8 -3.97 9.75e-05 0.0345 -0.34 -0.26 Intelligence (multi-trait analysis); chr15:82276963 chr15:82459472~82477258:+ CESC cis rs875971 0.862 rs880166 ENSG00000232559.3 GS1-124K5.12 -3.97 9.75e-05 0.0345 -0.28 -0.26 Aortic root size; chr7:66205775 chr7:66554588~66576923:- CESC cis rs875971 0.965 rs9969301 ENSG00000179406.6 LINC00174 3.97 9.75e-05 0.0345 0.27 0.26 Aortic root size; chr7:66316668 chr7:66376044~66401338:- CESC cis rs10129255 0.869 rs7150549 ENSG00000280411.1 IGHV1-69-2 -3.97 9.75e-05 0.0345 -0.21 -0.26 Kawasaki disease; chr14:106705441 chr14:106762092~106762588:- CESC cis rs9918079 0.56 rs6449153 ENSG00000273133.1 RP11-799M12.2 -3.97 9.75e-05 0.0346 -0.36 -0.26 Obesity-related traits; chr4:15629593 chr4:15563698~15564253:- CESC cis rs7829975 0.617 rs4841071 ENSG00000253893.2 FAM85B -3.97 9.75e-05 0.0346 -0.32 -0.26 Mood instability; chr8:8933634 chr8:8167819~8226614:- CESC cis rs4713118 0.662 rs149961 ENSG00000219392.1 RP1-265C24.5 -3.97 9.76e-05 0.0346 -0.34 -0.26 Parkinson's disease; chr6:28047791 chr6:28115628~28116551:+ CESC cis rs7811142 0.775 rs1636980 ENSG00000078319.8 PMS2P1 3.97 9.76e-05 0.0346 0.41 0.26 Platelet count; chr7:100341241 chr7:100320992~100341908:- CESC cis rs2430307 0.556 rs3930019 ENSG00000214243.3 AC004980.10 3.97 9.76e-05 0.0346 0.32 0.26 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr7:76912293 chr7:76650401~76650897:- CESC cis rs9322193 0.962 rs7818 ENSG00000223701.3 RAET1E-AS1 3.97 9.76e-05 0.0346 0.29 0.26 Lung cancer; chr6:149810956 chr6:149884431~149919508:+ CESC cis rs516805 0.52 rs554482 ENSG00000218180.2 SLC25A5P7 3.97 9.77e-05 0.0346 0.31 0.26 Lymphocyte counts; chr6:122419645 chr6:121653795~121654690:+ CESC cis rs516805 0.502 rs578868 ENSG00000218180.2 SLC25A5P7 3.97 9.77e-05 0.0346 0.31 0.26 Lymphocyte counts; chr6:122421230 chr6:121653795~121654690:+ CESC cis rs516805 0.52 rs576247 ENSG00000218180.2 SLC25A5P7 3.97 9.77e-05 0.0346 0.31 0.26 Lymphocyte counts; chr6:122425793 chr6:121653795~121654690:+ CESC cis rs1362153 0.73 rs2486008 ENSG00000234093.3 RPS15AP11 3.97 9.77e-05 0.0346 0.4 0.26 Alcohol dependence (age at onset); chr1:43974113 chr1:44780331~44780715:- CESC cis rs12439619 1 rs12439619 ENSG00000278603.1 RP13-608F4.5 3.97 9.78e-05 0.0346 0.36 0.26 Intelligence (multi-trait analysis); chr15:82254605 chr15:82472203~82472426:+ CESC cis rs9341808 0.556 rs1535075 ENSG00000272129.1 RP11-250B2.6 3.97 9.78e-05 0.0346 0.3 0.26 Sitting height ratio; chr6:80325089 chr6:80355424~80356859:+ CESC cis rs9987353 0.566 rs6998368 ENSG00000253893.2 FAM85B 3.97 9.78e-05 0.0346 0.35 0.26 Recombination measurement; chr8:9212778 chr8:8167819~8226614:- CESC cis rs875971 1 rs7781698 ENSG00000179406.6 LINC00174 -3.97 9.79e-05 0.0347 -0.28 -0.26 Aortic root size; chr7:66431325 chr7:66376044~66401338:- CESC cis rs6991838 0.725 rs6995134 ENSG00000200714.1 Y_RNA 3.97 9.79e-05 0.0347 0.3 0.26 Intelligence (multi-trait analysis); chr8:65555472 chr8:65592731~65592820:+ CESC cis rs11089937 0.568 rs12159174 ENSG00000211638.2 IGLV8-61 -3.97 9.79e-05 0.0347 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22131639 chr22:22098700~22099212:+ CESC cis rs2404602 0.692 rs34181263 ENSG00000280730.1 AC090181.1 3.97 9.79e-05 0.0347 0.2 0.26 Blood metabolite levels; chr15:76773047 chr15:77056895~77057021:+ CESC cis rs10129255 0.957 rs11847726 ENSG00000211974.3 IGHV2-70 3.97 9.8e-05 0.0347 0.27 0.26 Kawasaki disease; chr14:106779116 chr14:106723574~106724093:- CESC cis rs67180937 0.504 rs3008625 ENSG00000272750.1 RP11-378J18.8 3.97 9.8e-05 0.0347 0.36 0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222646680 chr1:222658867~222661512:- CESC cis rs2404602 0.716 rs12441247 ENSG00000280730.1 AC090181.1 3.97 9.8e-05 0.0347 0.2 0.26 Blood metabolite levels; chr15:76519975 chr15:77056895~77057021:+ CESC cis rs11637445 0.603 rs1478941 ENSG00000270964.1 RP11-502I4.3 3.97 9.81e-05 0.0347 0.27 0.26 Posterior cortical atrophy and Alzheimer's disease; chr15:67834803 chr15:67541072~67542604:- CESC cis rs2408955 0.504 rs11168441 ENSG00000258273.1 RP11-370I10.4 -3.97 9.81e-05 0.0347 -0.31 -0.26 Glycated hemoglobin levels; chr12:48182271 chr12:48333755~48333901:- CESC cis rs12777 0.702 rs739719 ENSG00000233006.5 AC034220.3 3.97 9.82e-05 0.0347 0.4 0.26 Fibrinogen levels; chr5:132537173 chr5:132311285~132369916:- CESC cis rs1124769 0.719 rs2291107 ENSG00000259378.1 DCAF13P3 3.97 9.82e-05 0.0347 0.35 0.26 Cognitive performance; chr15:50941615 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs1871460 ENSG00000259378.1 DCAF13P3 3.97 9.82e-05 0.0347 0.35 0.26 Cognitive performance; chr15:50943272 chr15:50944663~50945996:+ CESC cis rs5742933 0.948 rs7592066 ENSG00000273240.1 RP11-455J20.3 3.97 9.82e-05 0.0347 0.28 0.26 Ferritin levels; chr2:189778792 chr2:189763859~189764456:- CESC cis rs5742933 0.779 rs7595020 ENSG00000273240.1 RP11-455J20.3 3.97 9.82e-05 0.0347 0.28 0.26 Ferritin levels; chr2:189778950 chr2:189763859~189764456:- CESC cis rs4272720 0.535 rs12769361 ENSG00000229870.1 RP11-507K13.6 -3.97 9.82e-05 0.0348 -0.3 -0.26 Platelet count;Plateletcrit; chr10:49078575 chr10:49815096~49815562:+ CESC cis rs7131987 0.65 rs10843377 ENSG00000257176.2 RP11-996F15.2 3.97 9.83e-05 0.0348 0.31 0.26 QT interval; chr12:29284120 chr12:29280418~29317848:- CESC cis rs916888 0.773 rs1378358 ENSG00000232300.1 FAM215B 3.97 9.83e-05 0.0348 0.42 0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46558830~46562795:- CESC cis rs916888 0.773 rs169201 ENSG00000232300.1 FAM215B 3.97 9.83e-05 0.0348 0.42 0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46558830~46562795:- CESC cis rs9660180 0.62 rs34298494 ENSG00000231050.1 RP1-140A9.1 -3.97 9.83e-05 0.0348 -0.31 -0.26 Body mass index; chr1:1731963 chr1:1891471~1892658:+ CESC cis rs7674212 0.57 rs6841136 ENSG00000246560.2 RP11-10L12.4 3.97 9.83e-05 0.0348 0.31 0.26 Type 2 diabetes; chr4:103182352 chr4:102828055~102844075:+ CESC cis rs6951245 0.935 rs61910751 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1058259 chr7:1160374~1165267:+ CESC cis rs6951245 0.872 rs77434655 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1058769 chr7:1160374~1165267:+ CESC cis rs6951245 0.872 rs75398423 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1058778 chr7:1160374~1165267:+ CESC cis rs6951245 0.872 rs112309216 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1060660 chr7:1160374~1165267:+ CESC cis rs6951245 0.872 rs76161580 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1060671 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs76388414 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061058 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs77305932 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061225 chr7:1160374~1165267:+ CESC cis rs6951245 0.872 rs11768486 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061654 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs11766526 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061797 chr7:1160374~1165267:+ CESC cis rs6951245 0.938 rs113642700 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1066018 chr7:1160374~1165267:+ CESC cis rs6951245 0.935 rs113365567 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1069149 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs74887741 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1071022 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs79617366 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1072322 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs111899361 ENSG00000229043.2 AC091729.9 -3.97 9.83e-05 0.0348 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1072712 chr7:1160374~1165267:+ CESC cis rs10129255 0.556 rs9324093 ENSG00000280411.1 IGHV1-69-2 -3.97 9.84e-05 0.0348 -0.18 -0.26 Kawasaki disease; chr14:106683893 chr14:106762092~106762588:- CESC cis rs7089973 0.523 rs61869297 ENSG00000236799.1 RP11-383C6.2 -3.97 9.84e-05 0.0348 -0.32 -0.26 Bipolar disorder or attention deficit hyperactivity disorder; chr10:115019246 chr10:114994657~114996593:+ CESC cis rs2276314 1 rs16967317 ENSG00000278986.1 RP11-723J4.3 -3.97 9.84e-05 0.0348 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35993437 chr18:35972151~35973916:+ CESC cis rs9487094 0.666 rs2236084 ENSG00000260273.1 RP11-425D10.10 3.97 9.84e-05 0.0348 0.33 0.26 Height; chr6:109476101 chr6:109382795~109383666:+ CESC cis rs9487094 0.696 rs1853330 ENSG00000260273.1 RP11-425D10.10 3.97 9.85e-05 0.0348 0.32 0.26 Height; chr6:109375548 chr6:109382795~109383666:+ CESC cis rs440932 1 rs440932 ENSG00000254340.1 RP11-10A14.3 3.97 9.85e-05 0.0348 0.31 0.26 High light scatter reticulocyte percentage of red cells; chr8:9169419 chr8:9141424~9145435:+ CESC cis rs11096990 0.855 rs11737290 ENSG00000249207.1 RP11-360F5.1 3.97 9.85e-05 0.0348 0.33 0.26 Cognitive function; chr4:39192318 chr4:39112677~39126818:- CESC cis rs11633886 0.585 rs12915174 ENSG00000273972.1 CTD-2306A12.1 3.97 9.85e-05 0.0348 0.29 0.26 Diisocyanate-induced asthma; chr15:45787505 chr15:45702640~45703183:+ CESC cis rs13113518 1 rs11133378 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55439472 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs11942279 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55439652 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs3805148 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55440643 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs11133380 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55441110 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs12510110 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55441567 chr4:55387949~55388271:+ CESC cis rs13113518 0.966 rs12510990 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55441907 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs3805149 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55442184 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs11945370 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55442875 chr4:55387949~55388271:+ CESC cis rs13113518 0.966 rs12647677 ENSG00000273257.1 RP11-177J6.1 3.97 9.86e-05 0.0349 0.34 0.26 Height; chr4:55444253 chr4:55387949~55388271:+ CESC cis rs3768617 0.745 rs4546885 ENSG00000224468.3 RP11-181K3.4 -3.97 9.87e-05 0.0349 -0.26 -0.26 Fuchs's corneal dystrophy; chr1:183056420 chr1:183138402~183141282:- CESC cis rs453301 0.686 rs11787026 ENSG00000173295.6 FAM86B3P 3.97 9.87e-05 0.0349 0.33 0.26 Joint mobility (Beighton score); chr8:9044861 chr8:8228595~8244865:+ CESC cis rs9309473 0.898 rs6546851 ENSG00000163016.8 ALMS1P 3.97 9.87e-05 0.0349 0.32 0.26 Metabolite levels; chr2:73606156 chr2:73644919~73685576:+ CESC cis rs10129255 1 rs61997605 ENSG00000211970.3 IGHV4-61 -3.97 9.87e-05 0.0349 -0.2 -0.26 Kawasaki disease; chr14:106678368 chr14:106639119~106639657:- CESC cis rs7048146 0.652 rs10125565 ENSG00000213539.4 YBX1P6 3.97 9.87e-05 0.0349 0.29 0.26 Vascular brain injury; chr9:109593113 chr9:109532830~109534332:- CESC cis rs2286503 1 rs2286503 ENSG00000228649.7 AC005682.5 3.97 9.88e-05 0.0349 0.23 0.26 Fibrinogen; chr7:22816987 chr7:22854178~22861579:+ CESC cis rs72634258 0.842 rs4325151 ENSG00000238249.2 HMGN2P17 3.97 9.88e-05 0.0349 0.28 0.26 Inflammatory bowel disease; chr1:8108857 chr1:8893409~8894151:+ CESC cis rs7617773 0.779 rs9833309 ENSG00000228638.1 FCF1P2 -3.97 9.89e-05 0.0349 -0.28 -0.26 Coronary artery disease; chr3:48285960 chr3:48290793~48291375:- CESC cis rs7617773 0.817 rs9853804 ENSG00000228638.1 FCF1P2 -3.97 9.89e-05 0.0349 -0.28 -0.26 Coronary artery disease; chr3:48286239 chr3:48290793~48291375:- CESC cis rs7617773 0.817 rs9834095 ENSG00000228638.1 FCF1P2 -3.97 9.89e-05 0.0349 -0.28 -0.26 Coronary artery disease; chr3:48286261 chr3:48290793~48291375:- CESC cis rs7617773 0.817 rs4131361 ENSG00000228638.1 FCF1P2 -3.97 9.89e-05 0.0349 -0.28 -0.26 Coronary artery disease; chr3:48287322 chr3:48290793~48291375:- CESC cis rs7617773 0.817 rs4131362 ENSG00000228638.1 FCF1P2 -3.97 9.89e-05 0.0349 -0.28 -0.26 Coronary artery disease; chr3:48287546 chr3:48290793~48291375:- CESC cis rs12468226 0.935 rs75597391 ENSG00000273456.1 RP11-686O6.2 3.97 9.89e-05 0.0349 0.34 0.26 Urate levels; chr2:202398850 chr2:202374932~202375604:- CESC cis rs2933343 0.621 rs789242 ENSG00000231305.3 RP11-723O4.2 3.97 9.89e-05 0.0349 0.24 0.26 IgG glycosylation; chr3:128866864 chr3:128861313~128871540:- CESC cis rs2408955 0.541 rs11168428 ENSG00000226413.2 OR8T1P -3.97 9.9e-05 0.035 -0.33 -0.26 Glycated hemoglobin levels; chr12:48153345 chr12:48442030~48442947:- CESC cis rs17301013 0.507 rs2146564 ENSG00000227373.4 RP11-160H22.5 3.97 9.9e-05 0.035 0.39 0.26 Systemic lupus erythematosus; chr1:174716214 chr1:174115300~174160004:- CESC cis rs2243480 1 rs778729 ENSG00000067601.7 PMS2P4 3.97 9.9e-05 0.035 0.49 0.26 Diabetic kidney disease; chr7:66359432 chr7:67295608~67302907:- CESC cis rs2243480 0.901 rs778687 ENSG00000067601.7 PMS2P4 3.97 9.9e-05 0.035 0.49 0.26 Diabetic kidney disease; chr7:66370832 chr7:67295608~67302907:- CESC cis rs2243480 1 rs778679 ENSG00000067601.7 PMS2P4 3.97 9.9e-05 0.035 0.49 0.26 Diabetic kidney disease; chr7:66375924 chr7:67295608~67302907:- CESC cis rs2243480 1 rs778704 ENSG00000067601.7 PMS2P4 3.97 9.9e-05 0.035 0.49 0.26 Diabetic kidney disease; chr7:66398480 chr7:67295608~67302907:- CESC cis rs2243480 0.901 rs778693 ENSG00000067601.7 PMS2P4 3.97 9.9e-05 0.035 0.49 0.26 Diabetic kidney disease; chr7:66407358 chr7:67295608~67302907:- CESC cis rs2243480 1 rs778691 ENSG00000067601.7 PMS2P4 3.97 9.9e-05 0.035 0.49 0.26 Diabetic kidney disease; chr7:66408105 chr7:67295608~67302907:- CESC cis rs2243480 1 rs13235972 ENSG00000067601.7 PMS2P4 3.97 9.9e-05 0.035 0.49 0.26 Diabetic kidney disease; chr7:66418618 chr7:67295608~67302907:- CESC cis rs2243480 1 rs34192067 ENSG00000067601.7 PMS2P4 3.97 9.9e-05 0.035 0.49 0.26 Diabetic kidney disease; chr7:66422670 chr7:67295608~67302907:- CESC cis rs801193 0.569 rs13242290 ENSG00000275400.1 RP4-756H11.5 -3.97 9.9e-05 0.035 -0.28 -0.26 Aortic root size; chr7:66656898 chr7:66553805~66554199:- CESC cis rs11603023 0.967 rs7936556 ENSG00000255422.1 AP002954.4 3.97 9.91e-05 0.035 0.29 0.26 Cholesterol, total; chr11:118630582 chr11:118704607~118750263:+ CESC cis rs2361701 0.636 rs1982244 ENSG00000275479.1 RP11-334C17.6 3.97 9.91e-05 0.035 0.29 0.26 IgG glycosylation; chr17:80095149 chr17:80149627~80149798:+ CESC cis rs9399135 0.773 rs949895 ENSG00000232876.1 CTA-212D2.2 -3.97 9.91e-05 0.035 -0.3 -0.26 Red blood cell count; chr6:135084221 chr6:135055033~135060550:+ CESC cis rs465969 0.744 rs71562296 ENSG00000255389.1 C6orf3 -3.97 9.92e-05 0.035 -0.51 -0.26 Psoriasis; chr6:111521444 chr6:111599875~111602295:+ CESC cis rs465969 0.744 rs6939657 ENSG00000255389.1 C6orf3 -3.97 9.92e-05 0.035 -0.51 -0.26 Psoriasis; chr6:111521822 chr6:111599875~111602295:+ CESC cis rs5758659 0.569 rs133293 ENSG00000273366.1 CTA-989H11.1 -3.97 9.92e-05 0.035 -0.33 -0.26 Cognitive function; chr22:41986793 chr22:42278188~42278846:+ CESC cis rs9309473 0.95 rs6711001 ENSG00000163016.8 ALMS1P 3.97 9.92e-05 0.035 0.33 0.26 Metabolite levels; chr2:73623693 chr2:73644919~73685576:+ CESC cis rs224278 0.509 rs1912369 ENSG00000238280.1 RP11-436D10.3 -3.97 9.92e-05 0.035 -0.4 -0.26 Ewing sarcoma; chr10:62960133 chr10:62793562~62805887:- CESC cis rs72627123 0.867 rs73301500 ENSG00000270140.1 RP5-1021I20.6 -3.97 9.93e-05 0.035 -0.62 -0.26 Morning vs. evening chronotype; chr14:74006710 chr14:73905267~73905636:+ CESC cis rs4819052 0.851 rs1056099 ENSG00000235374.2 SSR4P1 -3.97 9.93e-05 0.035 -0.32 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45258977 chr21:45070952~45074165:- CESC cis rs4819052 0.851 rs2236446 ENSG00000235374.2 SSR4P1 -3.97 9.93e-05 0.035 -0.32 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45259070 chr21:45070952~45074165:- CESC cis rs2439831 1 rs690002 ENSG00000275601.1 AC011330.13 -3.97 9.93e-05 0.035 -0.34 -0.26 Lung cancer in ever smokers; chr15:43437151 chr15:43642389~43643023:- CESC cis rs2439831 1 rs537115 ENSG00000275601.1 AC011330.13 -3.97 9.93e-05 0.035 -0.34 -0.26 Lung cancer in ever smokers; chr15:43437750 chr15:43642389~43643023:- CESC cis rs2788869 0.887 rs1225763 ENSG00000237685.1 RP11-360O19.4 3.97 9.93e-05 0.035 0.32 0.26 Obstetric antiphospholipid syndrome; chr6:10924010 chr6:10511036~10514546:- CESC cis rs72772090 0.539 rs11748328 ENSG00000248734.2 CTD-2260A17.1 -3.97 9.94e-05 0.0351 -0.42 -0.26 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96834213 chr5:96784777~96785999:+ CESC cis rs453301 0.686 rs1045527 ENSG00000173295.6 FAM86B3P -3.97 9.94e-05 0.0351 -0.33 -0.26 Joint mobility (Beighton score); chr8:9032531 chr8:8228595~8244865:+ CESC cis rs769267 0.965 rs2315025 ENSG00000269131.1 AC004447.2 -3.97 9.94e-05 0.0351 -0.22 -0.26 Tonsillectomy; chr19:19315800 chr19:18990893~18993610:+ CESC cis rs2274273 0.624 rs7151581 ENSG00000258413.1 RP11-665C16.6 3.96 9.95e-05 0.0351 0.33 0.26 Protein biomarker; chr14:55321727 chr14:55262767~55272075:- CESC cis rs875971 0.545 rs73142265 ENSG00000237310.1 GS1-124K5.4 3.96 9.95e-05 0.0351 0.29 0.26 Aortic root size; chr7:66234510 chr7:66493706~66495474:+ CESC cis rs28673728 0.897 rs28391281 ENSG00000212541.1 RNU6-510P -3.96 9.96e-05 0.0351 -0.29 -0.26 Red cell distribution width; chr1:37943302 chr1:37991462~37991569:+ CESC cis rs28673728 0.868 rs28380108 ENSG00000212541.1 RNU6-510P -3.96 9.96e-05 0.0351 -0.29 -0.26 Red cell distribution width; chr1:37943431 chr1:37991462~37991569:+ CESC cis rs12439619 0.693 rs7165536 ENSG00000276710.3 CSPG4P8 -3.96 9.96e-05 0.0351 -0.34 -0.26 Intelligence (multi-trait analysis); chr15:82273743 chr15:82459472~82477258:+ CESC cis rs7500321 1 rs7500321 ENSG00000261067.5 RP11-264B17.3 -3.96 9.96e-05 0.0351 -0.26 -0.26 Intelligence (multi-trait analysis); chr16:28965699 chr16:28974804~28990783:+ CESC cis rs11157436 0.83 rs61972214 ENSG00000211813.2 TRAV34 3.96 9.97e-05 0.0351 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22152416 chr14:22207522~22208129:+ CESC cis rs950169 0.58 rs17532346 ENSG00000259728.4 LINC00933 3.96 9.97e-05 0.0352 0.33 0.26 Schizophrenia; chr15:84628264 chr15:84570649~84580175:+ CESC cis rs5742933 0.817 rs11679767 ENSG00000253559.1 OSGEPL1-AS1 3.96 9.98e-05 0.0352 0.31 0.26 Ferritin levels; chr2:189681574 chr2:189762704~189765556:+ CESC cis rs2243480 0.908 rs55876148 ENSG00000275400.1 RP4-756H11.5 3.96 9.98e-05 0.0352 0.44 0.26 Diabetic kidney disease; chr7:65914813 chr7:66553805~66554199:- CESC cis rs2243480 1 rs56016656 ENSG00000275400.1 RP4-756H11.5 3.96 9.98e-05 0.0352 0.44 0.26 Diabetic kidney disease; chr7:65918494 chr7:66553805~66554199:- CESC cis rs2243480 1 rs56291018 ENSG00000275400.1 RP4-756H11.5 3.96 9.98e-05 0.0352 0.44 0.26 Diabetic kidney disease; chr7:65925352 chr7:66553805~66554199:- CESC cis rs2243480 1 rs36033484 ENSG00000275400.1 RP4-756H11.5 3.96 9.98e-05 0.0352 0.44 0.26 Diabetic kidney disease; chr7:65925571 chr7:66553805~66554199:- CESC cis rs2243480 1 rs34560516 ENSG00000275400.1 RP4-756H11.5 3.96 9.98e-05 0.0352 0.44 0.26 Diabetic kidney disease; chr7:65939105 chr7:66553805~66554199:- CESC cis rs9487094 0.626 rs12192776 ENSG00000260273.1 RP11-425D10.10 3.96 9.98e-05 0.0352 0.33 0.26 Height; chr6:109634150 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs12194157 ENSG00000260273.1 RP11-425D10.10 3.96 9.98e-05 0.0352 0.33 0.26 Height; chr6:109640141 chr6:109382795~109383666:+ CESC cis rs9487094 0.67 rs12197950 ENSG00000260273.1 RP11-425D10.10 3.96 9.98e-05 0.0352 0.33 0.26 Height; chr6:109642186 chr6:109382795~109383666:+ CESC cis rs3768617 0.706 rs9943067 ENSG00000224468.3 RP11-181K3.4 -3.96 9.99e-05 0.0352 -0.26 -0.26 Fuchs's corneal dystrophy; chr1:183005967 chr1:183138402~183141282:- CESC cis rs4819052 0.851 rs914218 ENSG00000215447.6 BX322557.10 -3.96 9.99e-05 0.0352 -0.22 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45278530 chr21:45288052~45291738:+ CESC cis rs2408955 0.521 rs10875749 ENSG00000226413.2 OR8T1P -3.96 9.99e-05 0.0352 -0.33 -0.26 Glycated hemoglobin levels; chr12:48138134 chr12:48442030~48442947:- CESC cis rs2060793 0.539 rs962025 ENSG00000251991.1 RNU7-49P 3.96 9.99e-05 0.0352 0.27 0.26 Vitamin D levels; chr11:14618744 chr11:14478892~14478953:+ CESC cis rs7560272 0.538 rs1806683 ENSG00000273245.1 RP11-434P11.2 3.96 1e-04 0.0352 0.32 0.26 Schizophrenia; chr2:73712685 chr2:73750256~73750786:- CESC cis rs2439831 1 rs2439850 ENSG00000205771.5 CATSPER2P1 -3.96 1e-04 0.0352 -0.36 -0.26 Lung cancer in ever smokers; chr15:43492656 chr15:43726918~43747094:- CESC cis rs2439831 1 rs2467736 ENSG00000205771.5 CATSPER2P1 -3.96 1e-04 0.0352 -0.36 -0.26 Lung cancer in ever smokers; chr15:43492719 chr15:43726918~43747094:- CESC cis rs2439831 1 rs2444250 ENSG00000205771.5 CATSPER2P1 -3.96 1e-04 0.0352 -0.36 -0.26 Lung cancer in ever smokers; chr15:43492853 chr15:43726918~43747094:- CESC cis rs11089937 0.626 rs9622968 ENSG00000211638.2 IGLV8-61 -3.96 1e-04 0.0352 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22144916 chr22:22098700~22099212:+ CESC cis rs11089937 0.54 rs9622920 ENSG00000211638.2 IGLV8-61 3.96 1e-04 0.0352 0.24 0.26 Periodontitis (PAL4Q3); chr22:22133024 chr22:22098700~22099212:+ CESC cis rs2688608 0.592 rs2306328 ENSG00000242288.9 RP11-464F9.1 3.96 1e-04 0.0352 0.29 0.26 Inflammatory bowel disease; chr10:73819752 chr10:73674295~73730466:- CESC cis rs2337406 0.778 rs56965016 ENSG00000254174.1 IGHV1-12 3.96 1e-04 0.0352 0.27 0.26 Alzheimer's disease (late onset); chr14:106656649 chr14:106122420~106122709:- CESC cis rs2337406 0.778 rs56658355 ENSG00000254174.1 IGHV1-12 3.96 1e-04 0.0352 0.27 0.26 Alzheimer's disease (late onset); chr14:106662151 chr14:106122420~106122709:- CESC cis rs2337406 0.925 rs10131226 ENSG00000254174.1 IGHV1-12 3.96 1e-04 0.0352 0.27 0.26 Alzheimer's disease (late onset); chr14:106665764 chr14:106122420~106122709:- CESC cis rs755249 0.567 rs61779308 ENSG00000228060.1 RP11-69E11.8 -3.96 1e-04 0.0352 -0.31 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39472585 chr1:39565160~39573203:+ CESC cis rs2688608 0.62 rs7098444 ENSG00000242288.9 RP11-464F9.1 3.96 1e-04 0.0352 0.29 0.26 Inflammatory bowel disease; chr10:73820284 chr10:73674295~73730466:- CESC cis rs881375 0.9 rs1008383 ENSG00000226752.6 PSMD5-AS1 -3.96 1e-04 0.0353 -0.28 -0.26 Rheumatoid arthritis; chr9:120921301 chr9:120824828~120854385:+ CESC cis rs881375 0.933 rs1548784 ENSG00000226752.6 PSMD5-AS1 -3.96 1e-04 0.0353 -0.28 -0.26 Rheumatoid arthritis; chr9:120923002 chr9:120824828~120854385:+ CESC cis rs881375 0.967 rs7034492 ENSG00000226752.6 PSMD5-AS1 -3.96 1e-04 0.0353 -0.28 -0.26 Rheumatoid arthritis; chr9:120924933 chr9:120824828~120854385:+ CESC cis rs881375 0.967 rs7034653 ENSG00000226752.6 PSMD5-AS1 -3.96 1e-04 0.0353 -0.28 -0.26 Rheumatoid arthritis; chr9:120925094 chr9:120824828~120854385:+ CESC cis rs11971779 0.68 rs111461944 ENSG00000273391.1 RP11-634H22.1 3.96 1e-04 0.0353 0.25 0.26 Diisocyanate-induced asthma; chr7:139393157 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs12154842 ENSG00000273391.1 RP11-634H22.1 3.96 1e-04 0.0353 0.25 0.26 Diisocyanate-induced asthma; chr7:139393738 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6467846 ENSG00000273391.1 RP11-634H22.1 3.96 1e-04 0.0353 0.25 0.26 Diisocyanate-induced asthma; chr7:139394639 chr7:139359032~139359566:- CESC cis rs6687821 0.681 rs481583 ENSG00000267734.1 RP4-604K5.3 3.96 1e-04 0.0353 0.29 0.26 Yeast infection; chr1:86849596 chr1:86932199~86934891:- CESC cis rs2404602 0.716 rs56351018 ENSG00000280730.1 AC090181.1 3.96 1e-04 0.0353 0.2 0.26 Blood metabolite levels; chr15:76532250 chr15:77056895~77057021:+ CESC cis rs5742933 0.817 rs6942 ENSG00000253559.1 OSGEPL1-AS1 3.96 1e-04 0.0353 0.31 0.26 Ferritin levels; chr2:189771685 chr2:189762704~189765556:+ CESC cis rs13113518 0.812 rs7667741 ENSG00000273257.1 RP11-177J6.1 3.96 1e-04 0.0353 0.34 0.26 Height; chr4:55544621 chr4:55387949~55388271:+ CESC cis rs911555 0.755 rs975892 ENSG00000244691.1 RPL10AP1 -3.96 1e-04 0.0353 -0.36 -0.26 Intelligence (multi-trait analysis); chr14:103417012 chr14:103412119~103412761:- CESC cis rs453301 0.571 rs330057 ENSG00000254340.1 RP11-10A14.3 -3.96 1e-04 0.0353 -0.32 -0.26 Joint mobility (Beighton score); chr8:9232283 chr8:9141424~9145435:+ CESC cis rs922182 0.904 rs9972469 ENSG00000239465.1 RP11-330L19.2 -3.96 1e-04 0.0353 -0.35 -0.26 Blood protein levels; chr15:63991594 chr15:64631109~64631914:- CESC cis rs2548724 0.738 rs1982418 ENSG00000250682.4 LINC00491 3.96 1e-04 0.0354 0.33 0.26 Type 2 diabetes; chr5:102302677 chr5:102609156~102671559:- CESC cis rs9650657 0.513 rs4841459 ENSG00000255046.1 RP11-297N6.4 3.96 1e-04 0.0354 0.28 0.26 Neuroticism; chr8:10924932 chr8:11797928~11802568:- CESC cis rs1075265 0.692 rs805358 ENSG00000233266.1 HMGB1P31 3.96 1e-04 0.0354 0.34 0.26 Chronotype;Morning vs. evening chronotype; chr2:53934885 chr2:54051334~54051760:+ CESC cis rs2337406 0.929 rs11847182 ENSG00000254174.1 IGHV1-12 3.96 0.000101 0.0354 0.29 0.26 Alzheimer's disease (late onset); chr14:106697724 chr14:106122420~106122709:- CESC cis rs4713118 0.629 rs149899 ENSG00000219392.1 RP1-265C24.5 -3.96 0.000101 0.0354 -0.34 -0.26 Parkinson's disease; chr6:28052201 chr6:28115628~28116551:+ CESC cis rs4713118 0.629 rs172165 ENSG00000219392.1 RP1-265C24.5 -3.96 0.000101 0.0354 -0.34 -0.26 Parkinson's disease; chr6:28053036 chr6:28115628~28116551:+ CESC cis rs9434723 0.536 rs12072683 ENSG00000231181.1 RP13-15M17.1 -3.96 0.000101 0.0354 -0.32 -0.26 Height; chr1:9225959 chr1:9576427~9576985:+ CESC cis rs6452524 0.618 rs6452501 ENSG00000271862.1 RP11-343L5.2 3.96 0.000101 0.0354 0.23 0.26 Hypertension (SNP x SNP interaction); chr5:83068681 chr5:83049376~83050964:- CESC cis rs11157436 0.918 rs1983520 ENSG00000211813.2 TRAV34 3.96 0.000101 0.0354 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150390 chr14:22207522~22208129:+ CESC cis rs11157436 0.918 rs1983522 ENSG00000211813.2 TRAV34 3.96 0.000101 0.0354 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150588 chr14:22207522~22208129:+ CESC cis rs11157436 0.918 rs12586393 ENSG00000211813.2 TRAV34 3.96 0.000101 0.0354 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150815 chr14:22207522~22208129:+ CESC cis rs75422866 0.51 rs75424057 ENSG00000257433.4 RP1-197B17.3 3.96 0.000101 0.0354 0.67 0.26 Pneumonia; chr12:47737294 chr12:47706085~47742294:+ CESC cis rs12908161 0.96 rs11633450 ENSG00000225151.9 GOLGA2P7 -3.96 0.000101 0.0354 -0.36 -0.26 Schizophrenia; chr15:84764056 chr15:84199311~84230136:- CESC cis rs9450351 0.744 rs9450317 ENSG00000203875.9 SNHG5 -3.96 0.000101 0.0354 -0.54 -0.26 Interferon gamma-induced protein 10 levels; chr6:85715052 chr6:85660950~85678736:- CESC cis rs6439153 0.933 rs9822511 ENSG00000261159.1 RP11-723O4.9 3.96 0.000101 0.0354 0.27 0.26 Pneumococcal bacteremia; chr3:128986724 chr3:128859716~128860526:- CESC cis rs13113518 1 rs11133388 ENSG00000249700.7 SRD5A3-AS1 -3.96 0.000101 0.0354 -0.33 -0.26 Height; chr4:55477866 chr4:55363971~55395847:- CESC cis rs2288884 0.515 rs11084133 ENSG00000275055.1 CTC-471J1.11 -3.96 0.000101 0.0354 -0.29 -0.26 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52041125 chr19:52049007~52049754:+ CESC cis rs2288884 0.515 rs3752118 ENSG00000275055.1 CTC-471J1.11 -3.96 0.000101 0.0354 -0.29 -0.26 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52048233 chr19:52049007~52049754:+ CESC cis rs2288884 0.537 rs12151130 ENSG00000275055.1 CTC-471J1.11 -3.96 0.000101 0.0354 -0.29 -0.26 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52060531 chr19:52049007~52049754:+ CESC cis rs755249 0.567 rs41270821 ENSG00000228060.1 RP11-69E11.8 -3.96 0.000101 0.0355 -0.3 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39458060 chr1:39565160~39573203:+ CESC cis rs755249 0.567 rs2296175 ENSG00000228060.1 RP11-69E11.8 -3.96 0.000101 0.0355 -0.3 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39458726 chr1:39565160~39573203:+ CESC cis rs3096299 0.933 rs2965824 ENSG00000274627.1 RP11-104N10.2 3.96 0.000101 0.0355 0.26 0.26 Multiple myeloma (IgH translocation); chr16:89388898 chr16:89516797~89522217:+ CESC cis rs490234 0.812 rs12351825 ENSG00000232630.1 PRPS1P2 -3.96 0.000101 0.0355 -0.22 -0.26 Mean arterial pressure; chr9:125503457 chr9:125150653~125151589:+ CESC cis rs8020095 0.571 rs7158228 ENSG00000258561.1 RP11-72M17.1 -3.96 0.000101 0.0355 -0.39 -0.26 Depression (quantitative trait); chr14:67096006 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs7157418 ENSG00000258561.1 RP11-72M17.1 -3.96 0.000101 0.0355 -0.39 -0.26 Depression (quantitative trait); chr14:67096098 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs17248252 ENSG00000258561.1 RP11-72M17.1 -3.96 0.000101 0.0355 -0.39 -0.26 Depression (quantitative trait); chr14:67096212 chr14:66212810~66509394:- CESC cis rs10129255 0.826 rs7150693 ENSG00000211974.3 IGHV2-70 3.96 0.000101 0.0355 0.28 0.26 Kawasaki disease; chr14:106705382 chr14:106723574~106724093:- CESC cis rs4713118 0.629 rs203888 ENSG00000280107.1 AL022393.9 -3.96 0.000101 0.0355 -0.34 -0.26 Parkinson's disease; chr6:28053811 chr6:28170845~28172521:+ CESC cis rs5742933 1 rs55792400 ENSG00000253559.1 OSGEPL1-AS1 -3.96 0.000101 0.0355 -0.37 -0.26 Ferritin levels; chr2:189686708 chr2:189762704~189765556:+ CESC cis rs5742933 0.947 rs62185871 ENSG00000253559.1 OSGEPL1-AS1 -3.96 0.000101 0.0355 -0.37 -0.26 Ferritin levels; chr2:189686980 chr2:189762704~189765556:+ CESC cis rs7178909 0.872 rs28468074 ENSG00000259677.1 RP11-493E3.1 3.96 0.000101 0.0355 0.29 0.26 Common traits (Other); chr15:89892368 chr15:89876540~89877285:+ CESC cis rs7178909 0.872 rs61345389 ENSG00000259677.1 RP11-493E3.1 3.96 0.000101 0.0355 0.29 0.26 Common traits (Other); chr15:89892653 chr15:89876540~89877285:+ CESC cis rs7216064 0.651 rs12947658 ENSG00000267023.4 LRRC37A16P 3.96 0.000101 0.0355 0.24 0.26 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67906890 chr17:68125777~68152468:- CESC cis rs12701220 0.689 rs12533004 ENSG00000224079.1 AC091729.7 3.96 0.000101 0.0355 0.4 0.26 Bronchopulmonary dysplasia; chr7:1055774 chr7:1074450~1078036:+ CESC cis rs12701220 0.689 rs12530960 ENSG00000224079.1 AC091729.7 3.96 0.000101 0.0355 0.4 0.26 Bronchopulmonary dysplasia; chr7:1055835 chr7:1074450~1078036:+ CESC cis rs12701220 0.59 rs1881124 ENSG00000224079.1 AC091729.7 3.96 0.000101 0.0355 0.4 0.26 Bronchopulmonary dysplasia; chr7:1057130 chr7:1074450~1078036:+ CESC cis rs1816752 0.716 rs9553289 ENSG00000273628.1 RP11-756A22.7 -3.96 0.000101 0.0355 -0.29 -0.26 Obesity-related traits; chr13:24400640 chr13:24933006~24936796:+ CESC cis rs9309473 0.95 rs7596773 ENSG00000163016.8 ALMS1P 3.96 0.000101 0.0355 0.35 0.26 Metabolite levels; chr2:73618873 chr2:73644919~73685576:+ CESC cis rs4927850 1 rs4927850 ENSG00000273009.1 RP11-352G9.1 3.96 0.000101 0.0356 0.34 0.26 Pancreatic cancer; chr3:196024759 chr3:195913078~195913683:- CESC cis rs17767392 0.67 rs11849508 ENSG00000266869.1 RP6-114E22.1 -3.96 0.000101 0.0356 -0.37 -0.26 Mitral valve prolapse; chr14:71256347 chr14:71848606~71908430:+ CESC cis rs6580649 0.574 rs7964359 ENSG00000258273.1 RP11-370I10.4 -3.96 0.000101 0.0356 -0.29 -0.26 Lung cancer; chr12:48016783 chr12:48333755~48333901:- CESC cis rs3845817 0.868 rs702938 ENSG00000281920.1 RP11-418H16.1 3.96 0.000101 0.0356 0.33 0.26 Bipolar disorder; chr2:65520308 chr2:65623272~65628424:+ CESC cis rs2243480 0.901 rs73148097 ENSG00000164669.11 INTS4P1 3.96 0.000101 0.0356 0.53 0.26 Diabetic kidney disease; chr7:65966800 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs35820085 ENSG00000164669.11 INTS4P1 3.96 0.000101 0.0356 0.53 0.26 Diabetic kidney disease; chr7:65977771 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs906134 ENSG00000164669.11 INTS4P1 3.96 0.000101 0.0356 0.53 0.26 Diabetic kidney disease; chr7:65979301 chr7:65141225~65234216:+ CESC cis rs7005380 0.62 rs7388508 ENSG00000279347.1 RP11-85I17.2 -3.96 0.000101 0.0356 -0.23 -0.26 Interstitial lung disease; chr8:119913913 chr8:119838736~119840385:- CESC cis rs7005380 0.6 rs1607624 ENSG00000279347.1 RP11-85I17.2 -3.96 0.000101 0.0356 -0.23 -0.26 Interstitial lung disease; chr8:119917049 chr8:119838736~119840385:- CESC cis rs55665837 1 rs10832278 ENSG00000251991.1 RNU7-49P 3.96 0.000101 0.0356 0.29 0.26 Vitamin D levels; chr11:14475073 chr11:14478892~14478953:+ CESC cis rs181553 0.504 rs7237062 ENSG00000266696.1 RP11-30L3.2 3.96 0.000101 0.0356 0.33 0.26 Hip circumference adjusted for BMI; chr18:49200883 chr18:49205912~49208781:+ CESC cis rs2286503 1 rs2286501 ENSG00000228649.7 AC005682.5 3.96 0.000101 0.0356 0.23 0.26 Fibrinogen; chr7:22817166 chr7:22854178~22861579:+ CESC cis rs6565180 1 rs12930787 ENSG00000183604.13 SMG1P5 -3.96 0.000101 0.0356 -0.27 -0.26 Tonsillectomy; chr16:30369982 chr16:30267553~30335374:- CESC cis rs853679 1 rs10456362 ENSG00000219392.1 RP1-265C24.5 3.96 0.000101 0.0356 0.36 0.26 Depression; chr6:28254038 chr6:28115628~28116551:+ CESC cis rs343092 0.507 rs2612067 ENSG00000276853.1 RP11-305O6.4 3.96 0.000101 0.0356 0.49 0.26 Type 2 diabetes; chr12:65776383 chr12:65171262~65171917:+ CESC cis rs343092 0.507 rs2884591 ENSG00000276853.1 RP11-305O6.4 3.96 0.000101 0.0356 0.49 0.26 Type 2 diabetes; chr12:65777273 chr12:65171262~65171917:+ CESC cis rs343092 0.507 rs2260548 ENSG00000276853.1 RP11-305O6.4 3.96 0.000101 0.0356 0.49 0.26 Type 2 diabetes; chr12:65777581 chr12:65171262~65171917:+ CESC cis rs9601248 0.711 rs9530937 ENSG00000227676.3 LINC01068 -3.96 0.000101 0.0356 -0.3 -0.26 Major depressive disorder; chr13:79603701 chr13:79566727~79571436:+ CESC cis rs75422866 0.51 rs35784744 ENSG00000257433.4 RP1-197B17.3 3.96 0.000102 0.0357 0.66 0.26 Pneumonia; chr12:47729646 chr12:47706085~47742294:+ CESC cis rs10043775 1 rs10060623 ENSG00000251330.3 CTD-2283N19.1 -3.96 0.000102 0.0357 -0.34 -0.26 Periodontal microbiota; chr5:148411636 chr5:148430159~148430807:- CESC cis rs11971779 0.68 rs10242419 ENSG00000273391.1 RP11-634H22.1 -3.96 0.000102 0.0357 -0.25 -0.26 Diisocyanate-induced asthma; chr7:139404634 chr7:139359032~139359566:- CESC cis rs2337406 0.866 rs7144369 ENSG00000274576.2 IGHV2-70 -3.96 0.000102 0.0357 -0.35 -0.26 Alzheimer's disease (late onset); chr14:106793065 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs78525520 ENSG00000274576.2 IGHV2-70 -3.96 0.000102 0.0357 -0.35 -0.26 Alzheimer's disease (late onset); chr14:106795643 chr14:106770577~106771020:- CESC cis rs10129255 0.646 rs55995061 ENSG00000274576.2 IGHV2-70 -3.96 0.000102 0.0357 -0.35 -0.26 Kawasaki disease; chr14:106799309 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs76871148 ENSG00000274576.2 IGHV2-70 -3.96 0.000102 0.0357 -0.35 -0.26 Alzheimer's disease (late onset); chr14:106799722 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs61521632 ENSG00000274576.2 IGHV2-70 -3.96 0.000102 0.0357 -0.35 -0.26 Alzheimer's disease (late onset); chr14:106801091 chr14:106770577~106771020:- CESC cis rs6141600 0.627 rs67619039 ENSG00000260032.1 LINC00657 -3.96 0.000102 0.0357 -0.38 -0.26 Height;Hip circumference; chr20:36080436 chr20:36045622~36050960:- CESC cis rs2455601 0.671 rs2568091 ENSG00000254860.4 TMEM9B-AS1 3.96 0.000102 0.0357 0.31 0.26 Schizophrenia; chr11:8964501 chr11:8964675~8977527:+ CESC cis rs17213965 0.925 rs62030569 ENSG00000188599.16 NPIPP1 -3.96 0.000102 0.0357 -0.4 -0.26 Waist-hip ratio; chr16:15786892 chr16:15104312~15123498:- CESC cis rs1113500 0.748 rs1781048 ENSG00000226822.1 RP11-356N1.2 3.96 0.000102 0.0357 0.32 0.26 Growth-regulated protein alpha levels; chr1:108012428 chr1:108071482~108074519:+ CESC cis rs6951245 1 rs80094748 ENSG00000229043.2 AC091729.9 -3.96 0.000102 0.0357 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1064322 chr7:1160374~1165267:+ CESC cis rs13113518 0.812 rs12500456 ENSG00000273257.1 RP11-177J6.1 3.96 0.000102 0.0357 0.34 0.26 Height; chr4:55561053 chr4:55387949~55388271:+ CESC cis rs13113518 0.812 rs13116035 ENSG00000273257.1 RP11-177J6.1 3.96 0.000102 0.0357 0.34 0.26 Height; chr4:55561218 chr4:55387949~55388271:+ CESC cis rs56309584 0.755 rs66582670 ENSG00000178977.3 LINC00324 -3.96 0.000102 0.0357 -0.3 -0.26 Initial pursuit acceleration; chr17:8236021 chr17:8220642~8224043:- CESC cis rs8067354 0.609 rs1292066 ENSG00000266992.1 DHX40P1 3.96 0.000102 0.0357 0.32 0.26 Hemoglobin concentration; chr17:59854953 chr17:59976009~60002384:- CESC cis rs8072100 0.57 rs9905073 ENSG00000228782.6 CTD-2026D20.3 3.96 0.000102 0.0357 0.31 0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47390930 chr17:47450568~47492492:- CESC cis rs673078 0.607 rs7307393 ENSG00000275759.1 RP11-131L12.3 -3.96 0.000102 0.0357 -0.55 -0.26 Glucose homeostasis traits; chr12:118308537 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs17440669 ENSG00000275759.1 RP11-131L12.3 -3.96 0.000102 0.0357 -0.55 -0.26 Glucose homeostasis traits; chr12:118310397 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs7309671 ENSG00000275759.1 RP11-131L12.3 -3.96 0.000102 0.0357 -0.55 -0.26 Glucose homeostasis traits; chr12:118313188 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs17512525 ENSG00000275759.1 RP11-131L12.3 -3.96 0.000102 0.0357 -0.55 -0.26 Glucose homeostasis traits; chr12:118315467 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs17440774 ENSG00000275759.1 RP11-131L12.3 -3.96 0.000102 0.0357 -0.55 -0.26 Glucose homeostasis traits; chr12:118316155 chr12:118428281~118428870:+ CESC cis rs911555 0.755 rs7148567 ENSG00000244691.1 RPL10AP1 -3.96 0.000102 0.0357 -0.36 -0.26 Intelligence (multi-trait analysis); chr14:103415897 chr14:103412119~103412761:- CESC cis rs911555 0.755 rs10144051 ENSG00000244691.1 RPL10AP1 -3.96 0.000102 0.0357 -0.36 -0.26 Intelligence (multi-trait analysis); chr14:103419594 chr14:103412119~103412761:- CESC cis rs911555 0.723 rs6575986 ENSG00000244691.1 RPL10AP1 -3.96 0.000102 0.0357 -0.36 -0.26 Intelligence (multi-trait analysis); chr14:103420334 chr14:103412119~103412761:- CESC cis rs875971 0.545 rs73142245 ENSG00000236529.1 RP13-254B10.1 3.96 0.000102 0.0357 0.33 0.26 Aortic root size; chr7:66226662 chr7:65840212~65840596:+ CESC cis rs4951018 0.526 rs4601639 ENSG00000213041.4 RP11-383G10.3 -3.96 0.000102 0.0358 -0.33 -0.26 Prostate-specific antigen levels; chr1:205687455 chr1:205202191~205202742:+ CESC cis rs2032314 0.803 rs12483337 ENSG00000223799.1 IL10RB-AS1 3.96 0.000102 0.0358 0.47 0.26 Red blood cell traits; chr21:33870507 chr21:33263873~33266260:- CESC cis rs13113518 0.812 rs12648271 ENSG00000249700.7 SRD5A3-AS1 3.96 0.000102 0.0358 0.33 0.26 Height; chr4:55501955 chr4:55363971~55395847:- CESC cis rs17301013 0.507 rs2281011 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174509890 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2072759 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174510189 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs4652511 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174515500 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs4652513 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174515794 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6665535 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174522480 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12084948 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174525776 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs11809482 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174530269 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs909533 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174531428 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12093966 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174535120 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs7550472 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174536442 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs11484645 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174542993 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12063545 ENSG00000227373.4 RP11-160H22.5 3.96 0.000102 0.0358 0.35 0.26 Systemic lupus erythematosus; chr1:174552863 chr1:174115300~174160004:- CESC cis rs7674212 0.54 rs2711897 ENSG00000246560.2 RP11-10L12.4 3.96 0.000102 0.0358 0.31 0.26 Type 2 diabetes; chr4:103102410 chr4:102828055~102844075:+ CESC cis rs1056107 0.831 rs7856196 ENSG00000225513.1 RP11-165N19.2 -3.96 0.000102 0.0358 -0.33 -0.26 Colorectal cancer; chr9:112181635 chr9:112173522~112173971:- CESC cis rs2243480 1 rs160634 ENSG00000232559.3 GS1-124K5.12 -3.96 0.000102 0.0358 -0.38 -0.26 Diabetic kidney disease; chr7:66063677 chr7:66554588~66576923:- CESC cis rs2790457 1 rs2790457 ENSG00000254635.4 WAC-AS1 -3.96 0.000102 0.0358 -0.3 -0.26 Multiple myeloma; chr10:28567890 chr10:28522652~28532743:- CESC cis rs2277027 0.955 rs7728609 ENSG00000251405.2 CTB-109A12.1 3.96 0.000102 0.0358 0.32 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157508516 chr5:157362615~157460078:- CESC cis rs2277027 1 rs7729274 ENSG00000251405.2 CTB-109A12.1 3.96 0.000102 0.0358 0.32 0.26 Pulmonary function;Pulmonary function (smoking interaction); chr5:157508900 chr5:157362615~157460078:- CESC cis rs1478897 0.804 rs9329246 ENSG00000255046.1 RP11-297N6.4 -3.96 0.000102 0.0358 -0.28 -0.26 Systemic lupus erythematosus; chr8:11535371 chr8:11797928~11802568:- CESC cis rs10129255 0.957 rs10138532 ENSG00000211970.3 IGHV4-61 -3.96 0.000102 0.0358 -0.22 -0.26 Kawasaki disease; chr14:106803901 chr14:106639119~106639657:- CESC cis rs2115630 0.691 rs8040066 ENSG00000259295.5 CSPG4P12 -3.96 0.000102 0.0358 -0.27 -0.26 P wave terminal force; chr15:84633234 chr15:85191438~85213905:+ CESC cis rs8040855 0.627 rs3816105 ENSG00000259295.5 CSPG4P12 3.96 0.000102 0.0359 0.32 0.26 Bulimia nervosa; chr15:85097680 chr15:85191438~85213905:+ CESC cis rs8040855 0.627 rs2304418 ENSG00000259295.5 CSPG4P12 3.96 0.000102 0.0359 0.32 0.26 Bulimia nervosa; chr15:85097752 chr15:85191438~85213905:+ CESC cis rs875971 1 rs4718307 ENSG00000237310.1 GS1-124K5.4 -3.96 0.000102 0.0359 -0.24 -0.26 Aortic root size; chr7:66146001 chr7:66493706~66495474:+ CESC cis rs875971 1 rs7801282 ENSG00000237310.1 GS1-124K5.4 -3.96 0.000102 0.0359 -0.24 -0.26 Aortic root size; chr7:66148700 chr7:66493706~66495474:+ CESC cis rs8062405 0.655 rs7184597 ENSG00000261067.5 RP11-264B17.3 -3.96 0.000102 0.0359 -0.26 -0.26 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910488 chr16:28974804~28990783:+ CESC cis rs7714584 1 rs12652003 ENSG00000197083.10 ZNF300P1 3.96 0.000102 0.0359 0.47 0.26 Crohn's disease; chr5:150852383 chr5:150930645~150946289:- CESC cis rs34779708 0.733 rs60616028 ENSG00000230534.5 RP11-297A16.2 3.96 0.000102 0.0359 0.38 0.26 Inflammatory bowel disease;Crohn's disease; chr10:35254874 chr10:35098006~35127020:- CESC cis rs490234 0.702 rs4838275 ENSG00000232630.1 PRPS1P2 -3.96 0.000102 0.0359 -0.22 -0.26 Mean arterial pressure; chr9:125590506 chr9:125150653~125151589:+ CESC cis rs2439831 0.85 rs3816792 ENSG00000249839.1 AC011330.5 3.96 0.000102 0.0359 0.38 0.26 Lung cancer in ever smokers; chr15:43824788 chr15:43663654~43684339:- CESC cis rs2243480 1 rs427044 ENSG00000275400.1 RP4-756H11.5 3.96 0.000102 0.0359 0.44 0.26 Diabetic kidney disease; chr7:66043558 chr7:66553805~66554199:- CESC cis rs2288884 0.515 rs9676397 ENSG00000275055.1 CTC-471J1.11 -3.96 0.000103 0.0359 -0.29 -0.26 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52076750 chr19:52049007~52049754:+ CESC cis rs2243480 1 rs937108 ENSG00000275400.1 RP4-756H11.5 3.96 0.000103 0.0359 0.42 0.26 Diabetic kidney disease; chr7:65963465 chr7:66553805~66554199:- CESC cis rs11089937 0.626 rs2213161 ENSG00000211638.2 IGLV8-61 -3.96 0.000103 0.0359 -0.26 -0.26 Periodontitis (PAL4Q3); chr22:22143005 chr22:22098700~22099212:+ CESC cis rs55726902 1 rs55726902 ENSG00000276691.1 RP5-1057I20.5 3.96 0.000103 0.0359 0.37 0.26 Allergic disease (asthma, hay fever or eczema); chr12:47803199 chr12:47788426~47788971:+ CESC cis rs6997458 0.652 rs7827051 ENSG00000253549.4 RP11-317J10.2 3.96 0.000103 0.0359 0.31 0.26 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85425619 chr8:85441851~85464915:- CESC cis rs6504622 0.902 rs1052586 ENSG00000262879.4 RP11-156P1.3 -3.96 0.000103 0.0359 -0.28 -0.26 Orofacial clefts; chr17:46941097 chr17:46984045~47100323:- CESC cis rs10129255 1 rs11621409 ENSG00000280411.1 IGHV1-69-2 -3.96 0.000103 0.036 -0.2 -0.26 Kawasaki disease; chr14:106695603 chr14:106762092~106762588:- CESC cis rs612683 0.759 rs12722868 ENSG00000261254.2 RP4-714D9.5 -3.96 0.000103 0.036 -0.24 -0.26 Breast cancer; chr1:100490922 chr1:100030566~100035637:+ CESC cis rs7580658 0.68 rs2069931 ENSG00000236682.1 AC068282.3 -3.96 0.000103 0.036 -0.34 -0.26 Protein C levels; chr2:127427993 chr2:127389130~127400580:+ CESC cis rs62355900 0.627 rs62358073 ENSG00000271828.1 CTD-2310F14.1 3.96 0.000103 0.036 0.41 0.26 Endometriosis; chr5:56831013 chr5:56927874~56929573:+ CESC cis rs9847710 0.869 rs2564917 ENSG00000242142.1 SERBP1P3 3.96 0.000103 0.036 0.28 0.26 Ulcerative colitis; chr3:53003679 chr3:53064283~53065091:- CESC cis rs442309 0.574 rs7895364 ENSG00000238280.1 RP11-436D10.3 -3.96 0.000103 0.036 -0.32 -0.26 Vogt-Koyanagi-Harada syndrome; chr10:62725053 chr10:62793562~62805887:- CESC cis rs1707322 1 rs4660334 ENSG00000281133.1 AL355480.3 -3.96 0.000103 0.036 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45996454 chr1:45580892~45580996:- CESC cis rs13113518 0.812 rs6849474 ENSG00000273257.1 RP11-177J6.1 3.96 0.000103 0.036 0.34 0.26 Height; chr4:55452295 chr4:55387949~55388271:+ CESC cis rs13113518 0.812 rs4864996 ENSG00000273257.1 RP11-177J6.1 3.96 0.000103 0.036 0.34 0.26 Height; chr4:55452921 chr4:55387949~55388271:+ CESC cis rs13113518 0.812 rs2412648 ENSG00000273257.1 RP11-177J6.1 3.96 0.000103 0.036 0.34 0.26 Height; chr4:55454900 chr4:55387949~55388271:+ CESC cis rs13113518 0.812 rs12512737 ENSG00000273257.1 RP11-177J6.1 3.96 0.000103 0.036 0.34 0.26 Height; chr4:55454938 chr4:55387949~55388271:+ CESC cis rs13113518 0.812 rs13125984 ENSG00000273257.1 RP11-177J6.1 3.96 0.000103 0.036 0.34 0.26 Height; chr4:55455102 chr4:55387949~55388271:+ CESC cis rs2337406 0.714 rs7152055 ENSG00000274576.2 IGHV2-70 -3.96 0.000103 0.036 -0.3 -0.26 Alzheimer's disease (late onset); chr14:106818996 chr14:106770577~106771020:- CESC cis rs9987353 0.544 rs2929469 ENSG00000173295.6 FAM86B3P 3.96 0.000103 0.036 0.35 0.26 Recombination measurement; chr8:9205146 chr8:8228595~8244865:+ CESC cis rs6504622 1 rs2003539 ENSG00000263142.4 LRRC37A17P -3.96 0.000103 0.036 -0.21 -0.26 Orofacial clefts; chr17:46947953 chr17:46978481~47054569:+ CESC cis rs9513627 0.915 rs9582298 ENSG00000228889.5 UBAC2-AS1 3.96 0.000103 0.036 0.44 0.26 Obesity-related traits; chr13:99466453 chr13:99196377~99200710:- CESC cis rs9513627 0.915 rs9585070 ENSG00000228889.5 UBAC2-AS1 3.96 0.000103 0.036 0.44 0.26 Obesity-related traits; chr13:99466589 chr13:99196377~99200710:- CESC cis rs72634258 0.716 rs12067391 ENSG00000238249.2 HMGN2P17 3.96 0.000103 0.036 0.29 0.26 Inflammatory bowel disease; chr1:8103798 chr1:8893409~8894151:+ CESC cis rs13113518 0.783 rs12504300 ENSG00000249700.7 SRD5A3-AS1 3.96 0.000103 0.036 0.33 0.26 Height; chr4:55482360 chr4:55363971~55395847:- CESC cis rs8040855 0.627 rs11630697 ENSG00000259295.5 CSPG4P12 3.96 0.000103 0.036 0.32 0.26 Bulimia nervosa; chr15:85063214 chr15:85191438~85213905:+ CESC cis rs733592 0.507 rs7304428 ENSG00000257735.1 RP11-370I10.6 -3.96 0.000103 0.0361 -0.28 -0.26 Plateletcrit; chr12:48100492 chr12:48350945~48442411:+ CESC cis rs2833693 0.574 rs11088205 ENSG00000256073.3 URB1-AS1 -3.96 0.000103 0.0361 -0.23 -0.26 Temperament; chr21:32179989 chr21:32393130~32393960:+ CESC cis rs12460587 0.622 rs7247612 ENSG00000275055.1 CTC-471J1.11 -3.96 0.000103 0.0361 -0.3 -0.26 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52082336 chr19:52049007~52049754:+ CESC cis rs7524102 0.636 rs6695165 ENSG00000218510.5 LINC00339 -3.96 0.000103 0.0361 -0.36 -0.26 Bone mineral density;Ulcerative colitis;Bone mineral density (spine);Dupuytren's disease;Bone mineral density (hip); chr1:22384109 chr1:22025188~22031223:+ CESC cis rs1075265 0.783 rs805453 ENSG00000233266.1 HMGB1P31 3.96 0.000103 0.0361 0.34 0.26 Chronotype;Morning vs. evening chronotype; chr2:53955761 chr2:54051334~54051760:+ CESC cis rs523522 0.962 rs687873 ENSG00000278344.1 RP11-18C24.8 3.96 0.000103 0.0361 0.32 0.26 High light scatter reticulocyte count; chr12:120581831 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs670568 ENSG00000278344.1 RP11-18C24.8 3.96 0.000103 0.0361 0.32 0.26 High light scatter reticulocyte count; chr12:120583403 chr12:120500735~120501090:- CESC cis rs523522 0.962 rs655530 ENSG00000278344.1 RP11-18C24.8 3.96 0.000103 0.0361 0.32 0.26 High light scatter reticulocyte count; chr12:120584472 chr12:120500735~120501090:- CESC cis rs523522 0.673 rs643372 ENSG00000278344.1 RP11-18C24.8 3.96 0.000103 0.0361 0.32 0.26 High light scatter reticulocyte count; chr12:120584837 chr12:120500735~120501090:- CESC cis rs9309473 0.519 rs4852951 ENSG00000273245.1 RP11-434P11.2 -3.96 0.000103 0.0361 -0.33 -0.26 Metabolite levels; chr2:73642669 chr2:73750256~73750786:- CESC cis rs6504622 0.934 rs3760377 ENSG00000263142.4 LRRC37A17P -3.96 0.000103 0.0361 -0.21 -0.26 Orofacial clefts; chr17:46964713 chr17:46978481~47054569:+ CESC cis rs6504622 1 rs11079745 ENSG00000263142.4 LRRC37A17P -3.96 0.000103 0.0361 -0.21 -0.26 Orofacial clefts; chr17:46966781 chr17:46978481~47054569:+ CESC cis rs1075265 0.84 rs805309 ENSG00000233266.1 HMGB1P31 3.96 0.000103 0.0361 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:53968877 chr2:54051334~54051760:+ CESC cis rs4742903 0.967 rs10125661 ENSG00000270332.1 SMC2-AS1 3.96 0.000103 0.0361 0.25 0.26 Breast cancer;High-grade serous ovarian cancer; chr9:104106162 chr9:104080024~104093073:- CESC cis rs3136516 0.504 rs11038910 ENSG00000247675.5 LRP4-AS1 -3.96 0.000103 0.0361 -0.26 -0.26 Venous thromboembolism; chr11:46521974 chr11:46846412~46874396:+ CESC cis rs11637445 1 rs11637445 ENSG00000270964.1 RP11-502I4.3 -3.96 0.000103 0.0361 -0.28 -0.26 Posterior cortical atrophy and Alzheimer's disease; chr15:67699268 chr15:67541072~67542604:- CESC cis rs2115630 1 rs58581703 ENSG00000225151.9 GOLGA2P7 3.96 0.000103 0.0361 0.29 0.26 P wave terminal force; chr15:84733704 chr15:84199311~84230136:- CESC cis rs7703051 0.52 rs13354746 ENSG00000271815.1 CTD-2235C13.3 -3.96 0.000103 0.0361 -0.35 -0.26 Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes; chr5:75323307 chr5:75363760~75364242:+ CESC cis rs4819052 0.918 rs34886433 ENSG00000223768.1 LINC00205 -3.96 0.000103 0.0361 -0.34 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45260623 chr21:45293285~45297354:+ CESC cis rs490234 0.676 rs4838264 ENSG00000232630.1 PRPS1P2 -3.96 0.000103 0.0362 -0.22 -0.26 Mean arterial pressure; chr9:125463282 chr9:125150653~125151589:+ CESC cis rs916888 0.773 rs199457 ENSG00000232300.1 FAM215B 3.96 0.000103 0.0362 0.42 0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46558830~46562795:- CESC cis rs916888 0.687 rs199456 ENSG00000232300.1 FAM215B 3.96 0.000103 0.0362 0.42 0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46558830~46562795:- CESC cis rs4706831 0.625 rs638056 ENSG00000272129.1 RP11-250B2.6 -3.96 0.000103 0.0362 -0.29 -0.26 Joint mobility (Beighton score); chr6:80271091 chr6:80355424~80356859:+ CESC cis rs17301013 0.507 rs12082012 ENSG00000227373.4 RP11-160H22.5 3.96 0.000103 0.0362 0.34 0.26 Systemic lupus erythematosus; chr1:174588729 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12085652 ENSG00000227373.4 RP11-160H22.5 3.96 0.000103 0.0362 0.34 0.26 Systemic lupus erythematosus; chr1:174588864 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs4451598 ENSG00000227373.4 RP11-160H22.5 3.96 0.000103 0.0362 0.34 0.26 Systemic lupus erythematosus; chr1:174606576 chr1:174115300~174160004:- CESC cis rs9517320 0.934 rs9517319 ENSG00000231194.1 FARP1-AS1 3.96 0.000103 0.0362 0.29 0.26 Longevity; chr13:98473702 chr13:98435405~98435840:- CESC cis rs5742933 0.817 rs3816196 ENSG00000253559.1 OSGEPL1-AS1 3.96 0.000103 0.0362 0.31 0.26 Ferritin levels; chr2:189775749 chr2:189762704~189765556:+ CESC cis rs67311347 1 rs73080138 ENSG00000223797.4 ENTPD3-AS1 3.96 0.000103 0.0362 0.25 0.26 Renal cell carcinoma; chr3:40474926 chr3:40313802~40453329:- CESC cis rs944801 0.566 rs10965215 ENSG00000215221.2 UBA52P6 -3.96 0.000103 0.0362 -0.3 -0.26 Type 2 diabetes; chr9:22029446 chr9:22012155~22012536:+ CESC cis rs526231 0.819 rs35803 ENSG00000175749.11 EIF3KP1 3.95 0.000104 0.0362 0.32 0.26 Primary biliary cholangitis; chr5:103271241 chr5:103032376~103033031:+ CESC cis rs8031584 0.918 rs11639169 ENSG00000260382.1 RP11-540B6.2 3.95 0.000104 0.0362 0.36 0.26 Huntington's disease progression; chr15:30963235 chr15:30882267~30883231:- CESC cis rs3091242 0.933 rs3093584 ENSG00000224183.1 SDHDP6 3.95 0.000104 0.0362 0.28 0.26 Erythrocyte sedimentation rate; chr1:25342223 chr1:25294164~25294643:- CESC cis rs516805 0.63 rs4245520 ENSG00000279453.1 RP3-425C14.4 -3.95 0.000104 0.0362 -0.34 -0.26 Lymphocyte counts; chr6:122106477 chr6:122436789~122439223:- CESC cis rs9532669 0.963 rs4343141 ENSG00000239827.7 SUGT1P3 -3.95 0.000104 0.0362 -0.29 -0.26 Cervical cancer; chr13:40940497 chr13:40908159~40921774:- CESC cis rs11690935 0.595 rs788166 ENSG00000228389.1 AC068039.4 -3.95 0.000104 0.0362 -0.31 -0.26 Schizophrenia; chr2:172050761 chr2:171773482~171775844:+ CESC cis rs783540 0.632 rs17356528 ENSG00000278202.1 RP11-152F13.8 3.95 0.000104 0.0362 0.23 0.26 Schizophrenia; chr15:82636799 chr15:82418651~82434235:+ CESC cis rs7243790 0.805 rs7243441 ENSG00000277324.1 RP11-850A17.1 -3.95 0.000104 0.0362 -0.29 -0.26 Diastolic blood pressure; chr18:54391363 chr18:54268346~54270028:- CESC cis rs2337406 0.866 rs7140974 ENSG00000274576.2 IGHV2-70 -3.95 0.000104 0.0362 -0.35 -0.26 Alzheimer's disease (late onset); chr14:106795976 chr14:106770577~106771020:- CESC cis rs1124769 0.719 rs12916845 ENSG00000259378.1 DCAF13P3 3.95 0.000104 0.0362 0.34 0.26 Cognitive performance; chr15:50936255 chr15:50944663~50945996:+ CESC cis rs1075265 0.744 rs2909460 ENSG00000233266.1 HMGB1P31 3.95 0.000104 0.0362 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:53967611 chr2:54051334~54051760:+ CESC cis rs1075265 0.811 rs805308 ENSG00000233266.1 HMGB1P31 3.95 0.000104 0.0362 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:53967797 chr2:54051334~54051760:+ CESC cis rs6740322 0.895 rs6711966 ENSG00000234936.1 AC010883.5 3.95 0.000104 0.0363 0.27 0.26 Coronary artery disease; chr2:43334850 chr2:43229573~43233394:+ CESC cis rs6740322 0.843 rs6727237 ENSG00000234936.1 AC010883.5 3.95 0.000104 0.0363 0.27 0.26 Coronary artery disease; chr2:43334861 chr2:43229573~43233394:+ CESC cis rs875971 0.545 rs1547529 ENSG00000226824.5 RP4-756H11.3 -3.95 0.000104 0.0363 -0.35 -0.26 Aortic root size; chr7:66258859 chr7:66654538~66669855:+ CESC cis rs11846409 0.652 rs10143549 ENSG00000223648.3 IGHV3-64 3.95 0.000104 0.0363 0.28 0.26 Rheumatic heart disease; chr14:106644643 chr14:106643132~106658258:- CESC cis rs224278 0.509 rs4147153 ENSG00000238280.1 RP11-436D10.3 3.95 0.000104 0.0363 0.41 0.26 Ewing sarcoma; chr10:62959167 chr10:62793562~62805887:- CESC cis rs67311347 1 rs6795475 ENSG00000223797.4 ENTPD3-AS1 3.95 0.000104 0.0363 0.26 0.26 Renal cell carcinoma; chr3:40447790 chr3:40313802~40453329:- CESC cis rs8127691 0.967 rs4317019 ENSG00000225331.1 AP001055.6 3.95 0.000104 0.0363 0.32 0.26 Inflammatory bowel disease; chr21:44196392 chr21:44158740~44160076:- CESC cis rs8067354 0.831 rs2333617 ENSG00000266701.1 AC005702.4 -3.95 0.000104 0.0363 -0.32 -0.26 Hemoglobin concentration; chr17:59818859 chr17:60042546~60042627:- CESC cis rs8067354 0.872 rs7224006 ENSG00000266701.1 AC005702.4 -3.95 0.000104 0.0363 -0.32 -0.26 Hemoglobin concentration; chr17:59818977 chr17:60042546~60042627:- CESC cis rs8067354 0.872 rs1295925 ENSG00000266701.1 AC005702.4 -3.95 0.000104 0.0363 -0.32 -0.26 Hemoglobin concentration; chr17:59832902 chr17:60042546~60042627:- CESC cis rs7617773 0.817 rs6791930 ENSG00000228638.1 FCF1P2 -3.95 0.000104 0.0363 -0.28 -0.26 Coronary artery disease; chr3:48288410 chr3:48290793~48291375:- CESC cis rs7617773 0.817 rs6794644 ENSG00000228638.1 FCF1P2 -3.95 0.000104 0.0363 -0.28 -0.26 Coronary artery disease; chr3:48288547 chr3:48290793~48291375:- CESC cis rs453301 0.653 rs1045529 ENSG00000253981.4 ALG1L13P -3.95 0.000104 0.0363 -0.29 -0.26 Joint mobility (Beighton score); chr8:9032588 chr8:8236003~8244667:- CESC cis rs10129255 0.913 rs28861466 ENSG00000211974.3 IGHV2-70 3.95 0.000104 0.0363 0.28 0.26 Kawasaki disease; chr14:106718572 chr14:106723574~106724093:- CESC cis rs2243480 0.908 rs55876148 ENSG00000164669.11 INTS4P1 3.95 0.000104 0.0363 0.55 0.26 Diabetic kidney disease; chr7:65914813 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs56016656 ENSG00000164669.11 INTS4P1 3.95 0.000104 0.0363 0.55 0.26 Diabetic kidney disease; chr7:65918494 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs56291018 ENSG00000164669.11 INTS4P1 3.95 0.000104 0.0363 0.55 0.26 Diabetic kidney disease; chr7:65925352 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs36033484 ENSG00000164669.11 INTS4P1 3.95 0.000104 0.0363 0.55 0.26 Diabetic kidney disease; chr7:65925571 chr7:65141225~65234216:+ CESC cis rs2243480 1 rs34560516 ENSG00000164669.11 INTS4P1 3.95 0.000104 0.0363 0.55 0.26 Diabetic kidney disease; chr7:65939105 chr7:65141225~65234216:+ CESC cis rs6504622 1 rs1047779 ENSG00000263142.4 LRRC37A17P -3.95 0.000104 0.0363 -0.21 -0.26 Orofacial clefts; chr17:46941877 chr17:46978481~47054569:+ CESC cis rs6504622 1 rs6504622 ENSG00000263142.4 LRRC37A17P 3.95 0.000104 0.0363 0.21 0.26 Orofacial clefts; chr17:46942365 chr17:46978481~47054569:+ CESC cis rs919433 0.68 rs1563340 ENSG00000222017.1 AC011997.1 3.95 0.000104 0.0363 0.34 0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197549989 chr2:197693106~197774823:+ CESC cis rs7951870 1 rs12283172 ENSG00000247675.5 LRP4-AS1 3.95 0.000104 0.0363 0.35 0.26 Schizophrenia; chr11:46420976 chr11:46846412~46874396:+ CESC cis rs673078 0.607 rs7137055 ENSG00000275759.1 RP11-131L12.3 -3.95 0.000104 0.0363 -0.49 -0.26 Glucose homeostasis traits; chr12:118395030 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs7137184 ENSG00000275759.1 RP11-131L12.3 -3.95 0.000104 0.0363 -0.49 -0.26 Glucose homeostasis traits; chr12:118395163 chr12:118428281~118428870:+ CESC cis rs673078 0.562 rs4767672 ENSG00000275759.1 RP11-131L12.3 -3.95 0.000104 0.0363 -0.49 -0.26 Glucose homeostasis traits; chr12:118397048 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs73205594 ENSG00000275759.1 RP11-131L12.3 -3.95 0.000104 0.0363 -0.49 -0.26 Glucose homeostasis traits; chr12:118397168 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943400 ENSG00000275759.1 RP11-131L12.3 -3.95 0.000104 0.0363 -0.49 -0.26 Glucose homeostasis traits; chr12:118398236 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943401 ENSG00000275759.1 RP11-131L12.3 -3.95 0.000104 0.0363 -0.49 -0.26 Glucose homeostasis traits; chr12:118398527 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943402 ENSG00000275759.1 RP11-131L12.3 -3.95 0.000104 0.0363 -0.49 -0.26 Glucose homeostasis traits; chr12:118398808 chr12:118428281~118428870:+ CESC cis rs919433 0.68 rs7605813 ENSG00000222017.1 AC011997.1 3.95 0.000104 0.0363 0.33 0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197510605 chr2:197693106~197774823:+ CESC cis rs453301 0.653 rs1562211 ENSG00000253893.2 FAM85B 3.95 0.000104 0.0363 0.31 0.26 Joint mobility (Beighton score); chr8:9044914 chr8:8167819~8226614:- CESC cis rs11096990 0.964 rs16995206 ENSG00000249207.1 RP11-360F5.1 3.95 0.000104 0.0364 0.31 0.26 Cognitive function; chr4:39262887 chr4:39112677~39126818:- CESC cis rs76747430 0.528 rs5750913 ENSG00000213857.3 RP11-12M9.4 3.95 0.000104 0.0364 0.32 0.26 Facial morphology (factor 20); chr22:40244281 chr22:41074180~41075239:- CESC cis rs2439831 0.85 rs12442129 ENSG00000249839.1 AC011330.5 -3.95 0.000104 0.0364 -0.37 -0.26 Lung cancer in ever smokers; chr15:43763658 chr15:43663654~43684339:- CESC cis rs9908102 0.74 rs733889 ENSG00000263648.1 RP11-471L13.3 -3.95 0.000104 0.0364 -0.38 -0.26 Schizophrenia; chr17:13014801 chr17:12115547~12115885:+ CESC cis rs9908102 0.71 rs4792313 ENSG00000263648.1 RP11-471L13.3 -3.95 0.000104 0.0364 -0.38 -0.26 Schizophrenia; chr17:13014979 chr17:12115547~12115885:+ CESC cis rs9908102 0.71 rs4792314 ENSG00000263648.1 RP11-471L13.3 -3.95 0.000104 0.0364 -0.38 -0.26 Schizophrenia; chr17:13015134 chr17:12115547~12115885:+ CESC cis rs6504622 0.905 rs736603 ENSG00000262879.4 RP11-156P1.3 3.95 0.000104 0.0364 0.29 0.26 Orofacial clefts; chr17:46947379 chr17:46984045~47100323:- CESC cis rs6504622 0.905 rs736604 ENSG00000262879.4 RP11-156P1.3 3.95 0.000104 0.0364 0.29 0.26 Orofacial clefts; chr17:46947443 chr17:46984045~47100323:- CESC cis rs2439831 0.85 rs28524541 ENSG00000275601.1 AC011330.13 -3.95 0.000104 0.0364 -0.41 -0.26 Lung cancer in ever smokers; chr15:43832633 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28858500 ENSG00000275601.1 AC011330.13 -3.95 0.000104 0.0364 -0.41 -0.26 Lung cancer in ever smokers; chr15:43864744 chr15:43642389~43643023:- CESC cis rs516805 0.59 rs13371 ENSG00000279453.1 RP3-425C14.4 -3.95 0.000104 0.0364 -0.33 -0.26 Lymphocyte counts; chr6:122443881 chr6:122436789~122439223:- CESC cis rs9309473 0.5 rs2421582 ENSG00000273245.1 RP11-434P11.2 -3.95 0.000104 0.0364 -0.33 -0.26 Metabolite levels; chr2:73671293 chr2:73750256~73750786:- CESC cis rs10170310 0.515 rs12990836 ENSG00000241772.2 AC092620.2 3.95 0.000104 0.0364 0.43 0.26 Response to antipsychotic treatment; chr2:138590282 chr2:138569090~138574458:+ CESC cis rs13113518 0.966 rs12506788 ENSG00000273257.1 RP11-177J6.1 3.95 0.000104 0.0364 0.34 0.26 Height; chr4:55477426 chr4:55387949~55388271:+ CESC cis rs7873102 0.654 rs10758466 ENSG00000230188.1 RP11-405L18.4 -3.95 0.000104 0.0364 -0.34 -0.26 Brain structure; chr9:37969038 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs7874305 ENSG00000230188.1 RP11-405L18.4 -3.95 0.000104 0.0364 -0.34 -0.26 Brain structure; chr9:37969885 chr9:37490421~37490893:- CESC cis rs3748682 0.821 rs12030690 ENSG00000212541.1 RNU6-510P -3.95 0.000104 0.0364 -0.37 -0.26 Hypothyroidism; chr1:37792335 chr1:37991462~37991569:+ CESC cis rs17772222 0.917 rs17260380 ENSG00000258983.2 RP11-507K2.2 3.95 0.000104 0.0364 0.32 0.26 Coronary artery calcification; chr14:88682142 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs58984912 ENSG00000258983.2 RP11-507K2.2 3.95 0.000104 0.0364 0.32 0.26 Coronary artery calcification; chr14:88698172 chr14:88499334~88515502:+ CESC cis rs17772222 0.917 rs17188207 ENSG00000258983.2 RP11-507K2.2 3.95 0.000104 0.0364 0.32 0.26 Coronary artery calcification; chr14:88699579 chr14:88499334~88515502:+ CESC cis rs12429206 0.512 rs9535530 ENSG00000233672.5 RNASEH2B-AS1 -3.95 0.000104 0.0364 -0.32 -0.26 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50925136 chr13:50862172~50910764:- CESC cis rs7615316 0.816 rs13065075 ENSG00000244327.1 RP11-383G6.3 3.95 0.000105 0.0364 0.28 0.26 Mean corpuscular volume;Mean corpuscular hemoglobin; chr3:142546324 chr3:142465315~142472337:- CESC cis rs17301013 0.507 rs6697959 ENSG00000227373.4 RP11-160H22.5 3.95 0.000105 0.0365 0.37 0.26 Systemic lupus erythematosus; chr1:174285450 chr1:174115300~174160004:- CESC cis rs6142102 0.961 rs1883524 ENSG00000275784.1 RP5-1125A11.6 -3.95 0.000105 0.0365 -0.27 -0.26 Skin pigmentation; chr20:34038301 chr20:33989480~33991818:- CESC cis rs4356203 0.905 rs7930058 ENSG00000272034.1 SNORD14A -3.95 0.000105 0.0365 -0.25 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17045071 chr11:17074654~17074744:- CESC cis rs2243480 0.901 rs778730 ENSG00000067601.7 PMS2P4 3.95 0.000105 0.0365 0.49 0.26 Diabetic kidney disease; chr7:66358338 chr7:67295608~67302907:- CESC cis rs56309584 0.883 rs9896745 ENSG00000178977.3 LINC00324 -3.95 0.000105 0.0365 -0.32 -0.26 Initial pursuit acceleration; chr17:8238811 chr17:8220642~8224043:- CESC cis rs5769765 0.825 rs7511620 ENSG00000229409.1 RP11-494O16.3 3.95 0.000105 0.0365 0.37 0.26 Schizophrenia; chr22:49914284 chr22:49845929~49846090:+ CESC cis rs6969780 0.915 rs3807597 ENSG00000233429.8 HOTAIRM1 -3.95 0.000105 0.0365 -0.38 -0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149576 chr7:27095647~27100265:+ CESC cis rs6969780 0.915 rs12666926 ENSG00000233429.8 HOTAIRM1 -3.95 0.000105 0.0365 -0.38 -0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149942 chr7:27095647~27100265:+ CESC cis rs8074751 0.689 rs9896420 ENSG00000266644.1 RP11-927P21.2 3.95 0.000105 0.0365 0.28 0.26 Attention deficit hyperactivity disorder; chr17:65642997 chr17:64899766~64900716:+ CESC cis rs6687821 0.5 rs7519975 ENSG00000267734.1 RP4-604K5.3 -3.95 0.000105 0.0365 -0.29 -0.26 Yeast infection; chr1:87021355 chr1:86932199~86934891:- CESC cis rs4819052 0.851 rs2236443 ENSG00000235374.2 SSR4P1 -3.95 0.000105 0.0365 -0.32 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45258259 chr21:45070952~45074165:- CESC cis rs733592 0.56 rs2158515 ENSG00000257735.1 RP11-370I10.6 -3.95 0.000105 0.0365 -0.28 -0.26 Plateletcrit; chr12:48113885 chr12:48350945~48442411:+ CESC cis rs17301013 0.507 rs1793316 ENSG00000227373.4 RP11-160H22.5 3.95 0.000105 0.0365 0.34 0.26 Systemic lupus erythematosus; chr1:174825006 chr1:174115300~174160004:- CESC cis rs224278 0.553 rs6479846 ENSG00000238280.1 RP11-436D10.3 -3.95 0.000105 0.0365 -0.39 -0.26 Ewing sarcoma; chr10:62895711 chr10:62793562~62805887:- CESC cis rs6740322 0.841 rs10211126 ENSG00000234936.1 AC010883.5 3.95 0.000105 0.0365 0.28 0.26 Coronary artery disease; chr2:43324277 chr2:43229573~43233394:+ CESC cis rs10129255 0.957 rs2013423 ENSG00000211970.3 IGHV4-61 -3.95 0.000105 0.0365 -0.2 -0.26 Kawasaki disease; chr14:106690675 chr14:106639119~106639657:- CESC cis rs10129255 0.957 rs56134540 ENSG00000211970.3 IGHV4-61 -3.95 0.000105 0.0365 -0.2 -0.26 Kawasaki disease; chr14:106691290 chr14:106639119~106639657:- CESC cis rs11168351 0.591 rs4258439 ENSG00000257735.1 RP11-370I10.6 -3.95 0.000105 0.0365 -0.28 -0.26 Bipolar disorder and schizophrenia; chr12:48074869 chr12:48350945~48442411:+ CESC cis rs733592 0.507 rs10747529 ENSG00000257735.1 RP11-370I10.6 -3.95 0.000105 0.0365 -0.28 -0.26 Plateletcrit; chr12:48079586 chr12:48350945~48442411:+ CESC cis rs67311347 0.869 rs6790495 ENSG00000223797.4 ENTPD3-AS1 3.95 0.000105 0.0365 0.26 0.26 Renal cell carcinoma; chr3:40325279 chr3:40313802~40453329:- CESC cis rs67311347 0.869 rs7646899 ENSG00000223797.4 ENTPD3-AS1 3.95 0.000105 0.0365 0.26 0.26 Renal cell carcinoma; chr3:40325491 chr3:40313802~40453329:- CESC cis rs916888 0.821 rs199513 ENSG00000261575.2 RP11-259G18.1 -3.95 0.000105 0.0365 -0.38 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46267037~46268694:+ CESC cis rs76878669 0.561 rs7948058 ENSG00000255468.5 RP11-867G23.8 3.95 0.000105 0.0365 0.29 0.26 Educational attainment (years of education); chr11:66380640 chr11:66347950~66364804:+ CESC cis rs9322193 0.962 rs2342764 ENSG00000216906.2 RP11-350J20.9 3.95 0.000105 0.0365 0.3 0.26 Lung cancer; chr6:149835068 chr6:149904243~149906418:+ CESC cis rs748404 0.578 rs507178 ENSG00000205771.5 CATSPER2P1 -3.95 0.000105 0.0365 -0.31 -0.26 Lung cancer; chr15:43317937 chr15:43726918~43747094:- CESC cis rs748404 0.578 rs478028 ENSG00000205771.5 CATSPER2P1 -3.95 0.000105 0.0365 -0.31 -0.26 Lung cancer; chr15:43318574 chr15:43726918~43747094:- CESC cis rs748404 0.578 rs552701 ENSG00000205771.5 CATSPER2P1 -3.95 0.000105 0.0365 -0.31 -0.26 Lung cancer; chr15:43321612 chr15:43726918~43747094:- CESC cis rs748404 0.578 rs573615 ENSG00000205771.5 CATSPER2P1 -3.95 0.000105 0.0365 -0.31 -0.26 Lung cancer; chr15:43322083 chr15:43726918~43747094:- CESC cis rs2439831 1 rs2467739 ENSG00000205771.5 CATSPER2P1 -3.95 0.000105 0.0365 -0.35 -0.26 Lung cancer in ever smokers; chr15:43447998 chr15:43726918~43747094:- CESC cis rs2439831 1 rs28666488 ENSG00000205771.5 CATSPER2P1 -3.95 0.000105 0.0365 -0.35 -0.26 Lung cancer in ever smokers; chr15:43448892 chr15:43726918~43747094:- CESC cis rs2439831 1 rs2245790 ENSG00000205771.5 CATSPER2P1 -3.95 0.000105 0.0365 -0.35 -0.26 Lung cancer in ever smokers; chr15:43452259 chr15:43726918~43747094:- CESC cis rs3217992 0.77 rs3218020 ENSG00000277653.1 CDKN2B-AS 3.95 0.000105 0.0365 0.27 0.26 Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale); chr9:21997873 chr9:22117665~22117814:+ CESC cis rs11770686 0.967 rs2240138 ENSG00000214243.3 AC004980.10 3.95 0.000105 0.0365 0.22 0.26 Essential tremor; chr7:75712553 chr7:76650401~76650897:- CESC cis rs13113518 0.783 rs2171618 ENSG00000273257.1 RP11-177J6.1 3.95 0.000105 0.0366 0.34 0.26 Height; chr4:55564241 chr4:55387949~55388271:+ CESC cis rs6142102 0.651 rs1015361 ENSG00000276073.1 RP5-1125A11.7 3.95 0.000105 0.0366 0.25 0.26 Skin pigmentation; chr20:34150880 chr20:33985617~33988989:- CESC cis rs911555 0.755 rs10148970 ENSG00000244691.1 RPL10AP1 -3.95 0.000105 0.0366 -0.36 -0.26 Intelligence (multi-trait analysis); chr14:103425663 chr14:103412119~103412761:- CESC cis rs875971 0.545 rs1796226 ENSG00000236529.1 RP13-254B10.1 3.95 0.000105 0.0366 0.31 0.26 Aortic root size; chr7:66622723 chr7:65840212~65840596:+ CESC cis rs74394007 1 rs344077 ENSG00000244515.1 KRT18P34 3.95 0.000105 0.0366 0.47 0.26 Total body bone mineral density; chr3:156835457 chr3:157162663~157163932:- CESC cis rs74394007 1 rs171080 ENSG00000244515.1 KRT18P34 3.95 0.000105 0.0366 0.47 0.26 Total body bone mineral density; chr3:156837711 chr3:157162663~157163932:- CESC cis rs74394007 1 rs344091 ENSG00000244515.1 KRT18P34 3.95 0.000105 0.0366 0.47 0.26 Total body bone mineral density; chr3:156846318 chr3:157162663~157163932:- CESC cis rs875971 0.508 rs10258739 ENSG00000237310.1 GS1-124K5.4 -3.95 0.000105 0.0366 -0.23 -0.26 Aortic root size; chr7:66597948 chr7:66493706~66495474:+ CESC cis rs2406342 0.96 rs4890871 ENSG00000279433.1 RP11-4B16.1 -3.95 0.000105 0.0366 -0.29 -0.26 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin); chr18:76772778 chr18:77108284~77110537:- CESC cis rs1020064 0.636 rs2679883 ENSG00000235319.1 AC012360.4 -3.95 0.000105 0.0366 -0.3 -0.26 AIDS; chr2:105333211 chr2:105324210~105330529:+ CESC cis rs763121 0.853 rs2076028 ENSG00000273076.1 RP3-508I15.22 3.95 0.000105 0.0367 0.3 0.26 Menopause (age at onset); chr22:38754445 chr22:38743495~38743910:+ CESC cis rs7428 1 rs72840063 ENSG00000273196.1 RP11-717A5.2 3.95 0.000105 0.0367 0.3 0.26 Ear protrusion; chr2:85323273 chr2:85387074~85387146:- CESC cis rs2299587 0.762 rs208771 ENSG00000253671.1 RP11-806O11.1 -3.95 0.000105 0.0367 -0.26 -0.26 Economic and political preferences; chr8:17942963 chr8:17808941~17820868:+ CESC cis rs801193 0.569 rs881285 ENSG00000275400.1 RP4-756H11.5 -3.95 0.000105 0.0367 -0.28 -0.26 Aortic root size; chr7:66654433 chr7:66553805~66554199:- CESC cis rs801193 0.569 rs3846973 ENSG00000275400.1 RP4-756H11.5 -3.95 0.000105 0.0367 -0.28 -0.26 Aortic root size; chr7:66655048 chr7:66553805~66554199:- CESC cis rs801193 0.569 rs2013908 ENSG00000275400.1 RP4-756H11.5 -3.95 0.000105 0.0367 -0.28 -0.26 Aortic root size; chr7:66656082 chr7:66553805~66554199:- CESC cis rs801193 0.569 rs6951302 ENSG00000275400.1 RP4-756H11.5 -3.95 0.000105 0.0367 -0.28 -0.26 Aortic root size; chr7:66667525 chr7:66553805~66554199:- CESC cis rs2221593 0.502 rs2501851 ENSG00000198468.6 FLVCR1-AS1 -3.95 0.000105 0.0367 -0.37 -0.26 Leprosy; chr1:212674065 chr1:212852108~212858088:- CESC cis rs11846409 0.872 rs74091715 ENSG00000274576.2 IGHV2-70 -3.95 0.000105 0.0367 -0.31 -0.26 Rheumatic heart disease; chr14:106637731 chr14:106770577~106771020:- CESC cis rs11846409 0.932 rs74091721 ENSG00000274576.2 IGHV2-70 -3.95 0.000105 0.0367 -0.31 -0.26 Rheumatic heart disease; chr14:106638262 chr14:106770577~106771020:- CESC cis rs9309473 0.5 rs12996463 ENSG00000163016.8 ALMS1P -3.95 0.000105 0.0367 -0.32 -0.26 Metabolite levels; chr2:73428368 chr2:73644919~73685576:+ CESC cis rs875971 0.862 rs908915 ENSG00000179406.6 LINC00174 3.95 0.000105 0.0367 0.27 0.26 Aortic root size; chr7:66149664 chr7:66376044~66401338:- CESC cis rs6964587 1 rs2282970 ENSG00000188693.7 CYP51A1-AS1 -3.95 0.000105 0.0367 -0.28 -0.26 Breast cancer; chr7:91954967 chr7:92134604~92180725:+ CESC cis rs875971 0.508 rs10242423 ENSG00000237310.1 GS1-124K5.4 -3.95 0.000106 0.0367 -0.24 -0.26 Aortic root size; chr7:66594188 chr7:66493706~66495474:+ CESC cis rs875971 0.508 rs10253883 ENSG00000237310.1 GS1-124K5.4 -3.95 0.000106 0.0367 -0.24 -0.26 Aortic root size; chr7:66596151 chr7:66493706~66495474:+ CESC cis rs11089937 0.568 rs12160317 ENSG00000211638.2 IGLV8-61 -3.95 0.000106 0.0367 -0.25 -0.26 Periodontitis (PAL4Q3); chr22:22131619 chr22:22098700~22099212:+ CESC cis rs2243480 0.522 rs778717 ENSG00000067601.7 PMS2P4 3.95 0.000106 0.0367 0.57 0.26 Diabetic kidney disease; chr7:66383164 chr7:67295608~67302907:- CESC cis rs13108904 0.517 rs13128825 ENSG00000254094.1 AC078852.1 -3.95 0.000106 0.0367 -0.31 -0.26 Obesity-related traits; chr4:1340219 chr4:1356581~1358075:+ CESC cis rs13108904 0.517 rs13134568 ENSG00000254094.1 AC078852.1 -3.95 0.000106 0.0367 -0.31 -0.26 Obesity-related traits; chr4:1340501 chr4:1356581~1358075:+ CESC cis rs13108904 0.539 rs13145722 ENSG00000254094.1 AC078852.1 -3.95 0.000106 0.0367 -0.31 -0.26 Obesity-related traits; chr4:1344634 chr4:1356581~1358075:+ CESC cis rs703842 0.963 rs2069506 ENSG00000270039.1 RP11-571M6.17 -3.95 0.000106 0.0367 -0.32 -0.26 Multiple sclerosis; chr12:57749071 chr12:57803838~57804415:+ CESC cis rs748404 0.666 rs34515241 ENSG00000249839.1 AC011330.5 -3.95 0.000106 0.0367 -0.39 -0.26 Lung cancer; chr15:43342011 chr15:43663654~43684339:- CESC cis rs875971 0.508 rs10950045 ENSG00000237310.1 GS1-124K5.4 -3.95 0.000106 0.0368 -0.24 -0.26 Aortic root size; chr7:66601386 chr7:66493706~66495474:+ CESC cis rs8042680 0.503 rs7601 ENSG00000214432.8 AC068831.10 3.95 0.000106 0.0368 0.31 0.26 Type 2 diabetes; chr15:90966362 chr15:91022619~91036611:+ CESC cis rs8080784 0.8 rs9902531 ENSG00000266701.1 AC005702.4 3.95 0.000106 0.0368 0.46 0.26 Coronary artery disease; chr17:60878257 chr17:60042546~60042627:- CESC cis rs2933343 0.649 rs789219 ENSG00000231305.3 RP11-723O4.2 3.95 0.000106 0.0368 0.24 0.26 IgG glycosylation; chr3:128873677 chr3:128861313~128871540:- CESC cis rs7560272 0.695 rs780393 ENSG00000163016.8 ALMS1P -3.95 0.000106 0.0368 -0.31 -0.26 Schizophrenia; chr2:73474542 chr2:73644919~73685576:+ CESC cis rs7560272 0.723 rs780391 ENSG00000163016.8 ALMS1P -3.95 0.000106 0.0368 -0.31 -0.26 Schizophrenia; chr2:73476777 chr2:73644919~73685576:+ CESC cis rs673078 0.607 rs17440956 ENSG00000275759.1 RP11-131L12.3 3.95 0.000106 0.0368 0.52 0.26 Glucose homeostasis traits; chr12:118394639 chr12:118428281~118428870:+ CESC cis rs61776719 0.52 rs72661887 ENSG00000212541.1 RNU6-510P -3.95 0.000106 0.0368 -0.29 -0.26 Coronary artery disease; chr1:37950638 chr1:37991462~37991569:+ CESC cis rs1864585 0.806 rs55831243 ENSG00000255046.1 RP11-297N6.4 3.95 0.000106 0.0368 0.42 0.26 Neutrophil percentage of white cells;Lymphocyte percentage of white cells; chr8:10872563 chr8:11797928~11802568:- CESC cis rs1009077 0.68 rs3775850 ENSG00000245958.5 RP11-33B1.1 3.95 0.000106 0.0368 0.34 0.26 Endometriosis; chr4:119529863 chr4:119454791~119552025:+ CESC cis rs1044826 0.642 rs9859864 ENSG00000178631.7 ACTG1P1 -3.95 0.000106 0.0368 -0.31 -0.26 Obesity-related traits; chr3:139372377 chr3:139493809~139494937:+ CESC cis rs5758659 0.652 rs133303 ENSG00000273366.1 CTA-989H11.1 -3.95 0.000106 0.0368 -0.33 -0.26 Cognitive function; chr22:41999238 chr22:42278188~42278846:+ CESC cis rs5742933 1 rs12619808 ENSG00000253559.1 OSGEPL1-AS1 -3.95 0.000106 0.0368 -0.36 -0.26 Ferritin levels; chr2:189776458 chr2:189762704~189765556:+ CESC cis rs7829975 0.742 rs12547493 ENSG00000254340.1 RP11-10A14.3 -3.95 0.000106 0.0369 -0.34 -0.26 Mood instability; chr8:8804024 chr8:9141424~9145435:+ CESC cis rs12935418 0.83 rs12448368 ENSG00000261838.4 RP11-303E16.6 -3.95 0.000106 0.0369 -0.45 -0.26 Mean corpuscular volume; chr16:81011342 chr16:81069854~81076598:+ CESC cis rs6504622 1 rs4968285 ENSG00000262879.4 RP11-156P1.3 -3.95 0.000106 0.0369 -0.28 -0.26 Orofacial clefts; chr17:46938266 chr17:46984045~47100323:- CESC cis rs8067354 0.789 rs1292068 ENSG00000266701.1 AC005702.4 3.95 0.000106 0.0369 0.31 0.26 Hemoglobin concentration; chr17:59851958 chr17:60042546~60042627:- CESC cis rs7572733 0.534 rs700662 ENSG00000222017.1 AC011997.1 3.95 0.000106 0.0369 0.33 0.26 Dermatomyositis; chr2:197804027 chr2:197693106~197774823:+ CESC cis rs67311347 0.955 rs6782746 ENSG00000223797.4 ENTPD3-AS1 -3.95 0.000106 0.037 -0.26 -0.26 Renal cell carcinoma; chr3:40469101 chr3:40313802~40453329:- CESC cis rs67311347 1 rs7628247 ENSG00000223797.4 ENTPD3-AS1 -3.95 0.000106 0.037 -0.26 -0.26 Renal cell carcinoma; chr3:40471191 chr3:40313802~40453329:- CESC cis rs67311347 0.91 rs7651204 ENSG00000223797.4 ENTPD3-AS1 -3.95 0.000106 0.037 -0.26 -0.26 Renal cell carcinoma; chr3:40471344 chr3:40313802~40453329:- CESC cis rs34375054 0.573 rs12831151 ENSG00000279233.1 RP11-158L12.4 3.95 0.000106 0.037 0.3 0.26 Post bronchodilator FEV1/FVC ratio; chr12:125171717 chr12:125138245~125141711:+ CESC cis rs7208859 0.623 rs56378576 ENSG00000266490.1 CTD-2349P21.9 3.95 0.000107 0.037 0.41 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30683102 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs35916850 ENSG00000266490.1 CTD-2349P21.9 3.95 0.000107 0.037 0.41 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30684155 chr17:30792372~30792833:+ CESC cis rs11846409 0.789 rs34917868 ENSG00000254174.1 IGHV1-12 3.95 0.000107 0.037 0.26 0.26 Rheumatic heart disease; chr14:106618321 chr14:106122420~106122709:- CESC cis rs4819052 0.808 rs2246697 ENSG00000215447.6 BX322557.10 -3.95 0.000107 0.037 -0.22 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45270084 chr21:45288052~45291738:+ CESC cis rs4819052 0.819 rs7279136 ENSG00000215447.6 BX322557.10 -3.95 0.000107 0.037 -0.22 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45272372 chr21:45288052~45291738:+ CESC cis rs4819052 0.788 rs4819051 ENSG00000215447.6 BX322557.10 -3.95 0.000107 0.037 -0.22 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45273213 chr21:45288052~45291738:+ CESC cis rs4819052 0.819 rs8134084 ENSG00000215447.6 BX322557.10 -3.95 0.000107 0.037 -0.22 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45273380 chr21:45288052~45291738:+ CESC cis rs4819052 0.851 rs7276828 ENSG00000215447.6 BX322557.10 -3.95 0.000107 0.037 -0.22 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45275124 chr21:45288052~45291738:+ CESC cis rs4819052 0.851 rs7281263 ENSG00000215447.6 BX322557.10 -3.95 0.000107 0.037 -0.22 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45275691 chr21:45288052~45291738:+ CESC cis rs28374715 0.681 rs7168307 ENSG00000247556.5 OIP5-AS1 3.95 0.000107 0.037 0.3 0.26 Ulcerative colitis; chr15:41328336 chr15:41283990~41309737:+ CESC cis rs950776 0.72 rs11637890 ENSG00000261762.1 RP11-650L12.2 -3.95 0.000107 0.037 -0.38 -0.26 Sudden cardiac arrest; chr15:78643077 chr15:78589123~78591276:- CESC cis rs2408955 0.501 rs8716 ENSG00000258273.1 RP11-370I10.4 -3.95 0.000107 0.037 -0.3 -0.26 Glycated hemoglobin levels; chr12:48145699 chr12:48333755~48333901:- CESC cis rs2439831 0.867 rs3213990 ENSG00000205771.5 CATSPER2P1 -3.95 0.000107 0.037 -0.36 -0.26 Lung cancer in ever smokers; chr15:43378028 chr15:43726918~43747094:- CESC cis rs9925964 0.804 rs9926533 ENSG00000260911.2 RP11-196G11.2 -3.95 0.000107 0.037 -0.27 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31002858 chr16:31043150~31049868:+ CESC cis rs7824557 0.688 rs2572397 ENSG00000269918.1 AF131215.9 3.95 0.000107 0.037 0.32 0.26 Retinal vascular caliber; chr8:11318894 chr8:11104691~11106704:- CESC cis rs2907092 0.662 rs2905995 ENSG00000271980.1 CTD-2256P15.4 -3.95 0.000107 0.037 -0.28 -0.26 Common carotid intima-media thickness in HIV infection; chr5:11099954 chr5:10264597~10267146:- CESC cis rs2836950 0.501 rs11702505 ENSG00000232608.1 TIMM9P2 3.95 0.000107 0.037 0.29 0.26 Menarche (age at onset); chr21:39328688 chr21:39216624~39217506:+ CESC cis rs2836950 0.501 rs2836985 ENSG00000232608.1 TIMM9P2 3.95 0.000107 0.037 0.29 0.26 Menarche (age at onset); chr21:39329243 chr21:39216624~39217506:+ CESC cis rs1044826 0.619 rs6439856 ENSG00000178631.7 ACTG1P1 -3.95 0.000107 0.037 -0.32 -0.26 Obesity-related traits; chr3:139416026 chr3:139493809~139494937:+ CESC cis rs7299940 1 rs7299940 ENSG00000256250.1 RP11-989F5.1 -3.95 0.000107 0.037 -0.27 -0.26 Panic disorder; chr12:130906209 chr12:130810606~130812438:+ CESC cis rs3091242 0.933 rs35497030 ENSG00000224183.1 SDHDP6 3.95 0.000107 0.0371 0.28 0.26 Erythrocyte sedimentation rate; chr1:25456575 chr1:25294164~25294643:- CESC cis rs875971 1 rs6946143 ENSG00000237310.1 GS1-124K5.4 3.95 0.000107 0.0371 0.25 0.26 Aortic root size; chr7:66114735 chr7:66493706~66495474:+ CESC cis rs9532669 0.89 rs4941999 ENSG00000239827.7 SUGT1P3 -3.95 0.000107 0.0371 -0.29 -0.26 Cervical cancer; chr13:40859926 chr13:40908159~40921774:- CESC cis rs2404602 0.692 rs58361452 ENSG00000280730.1 AC090181.1 3.95 0.000107 0.0371 0.2 0.26 Blood metabolite levels; chr15:76681031 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs8043474 ENSG00000280730.1 AC090181.1 3.95 0.000107 0.0371 0.2 0.26 Blood metabolite levels; chr15:76682382 chr15:77056895~77057021:+ CESC cis rs2404602 0.692 rs35138393 ENSG00000280730.1 AC090181.1 3.95 0.000107 0.0371 0.2 0.26 Blood metabolite levels; chr15:76685276 chr15:77056895~77057021:+ CESC cis rs2404602 0.669 rs12595313 ENSG00000280730.1 AC090181.1 3.95 0.000107 0.0371 0.2 0.26 Blood metabolite levels; chr15:76686029 chr15:77056895~77057021:+ CESC cis rs6687821 0.515 rs1970607 ENSG00000267734.1 RP4-604K5.3 3.95 0.000107 0.0371 0.29 0.26 Yeast infection; chr1:86962619 chr1:86932199~86934891:- CESC cis rs8040855 0.627 rs12913859 ENSG00000259295.5 CSPG4P12 3.95 0.000107 0.0371 0.32 0.26 Bulimia nervosa; chr15:85095187 chr15:85191438~85213905:+ CESC cis rs10794657 0.527 rs946672 ENSG00000261349.1 RP3-465N24.5 3.95 0.000107 0.0371 0.46 0.26 Adiponectin levels; chr1:24285308 chr1:25266102~25267136:- CESC cis rs516805 0.781 rs560717 ENSG00000279453.1 RP3-425C14.4 -3.95 0.000107 0.0371 -0.33 -0.26 Lymphocyte counts; chr6:122482909 chr6:122436789~122439223:- CESC cis rs2404602 0.716 rs56216512 ENSG00000280730.1 AC090181.1 3.95 0.000107 0.0372 0.2 0.26 Blood metabolite levels; chr15:76394595 chr15:77056895~77057021:+ CESC cis rs1799949 0.894 rs71367985 ENSG00000267681.1 CTD-3199J23.6 -3.95 0.000107 0.0372 -0.32 -0.26 Menopause (age at onset); chr17:43222443 chr17:43144956~43145255:+ CESC cis rs875971 1 rs6946143 ENSG00000179406.6 LINC00174 -3.95 0.000107 0.0372 -0.28 -0.26 Aortic root size; chr7:66114735 chr7:66376044~66401338:- CESC cis rs453301 0.598 rs2921383 ENSG00000254340.1 RP11-10A14.3 3.95 0.000107 0.0372 0.31 0.26 Joint mobility (Beighton score); chr8:9034711 chr8:9141424~9145435:+ CESC cis rs3096299 0.967 rs2965932 ENSG00000274627.1 RP11-104N10.2 -3.95 0.000107 0.0372 -0.25 -0.26 Multiple myeloma (IgH translocation); chr16:89410643 chr16:89516797~89522217:+ CESC cis rs6452524 0.648 rs27364 ENSG00000271862.1 RP11-343L5.2 3.95 0.000107 0.0372 0.23 0.26 Hypertension (SNP x SNP interaction); chr5:83052137 chr5:83049376~83050964:- CESC cis rs73173548 0.502 rs4144466 ENSG00000247828.6 TMEM161B-AS1 3.95 0.000107 0.0372 0.28 0.26 Macular telangiectasia type 2; chr5:88412379 chr5:88268895~88436685:+ CESC cis rs67311347 1 rs12633431 ENSG00000223797.4 ENTPD3-AS1 -3.95 0.000107 0.0372 -0.26 -0.26 Renal cell carcinoma; chr3:40464249 chr3:40313802~40453329:- CESC cis rs67311347 0.956 rs6771527 ENSG00000223797.4 ENTPD3-AS1 -3.95 0.000107 0.0372 -0.26 -0.26 Renal cell carcinoma; chr3:40465057 chr3:40313802~40453329:- CESC cis rs4319547 0.586 rs7956480 ENSG00000275265.1 RP11-15J22.8 -3.95 0.000107 0.0372 -0.36 -0.26 Body mass index; chr12:122332960 chr12:122501187~122501641:+ CESC cis rs7508 0.553 rs7828234 ENSG00000253671.1 RP11-806O11.1 -3.95 0.000107 0.0372 -0.26 -0.26 Atrial fibrillation; chr8:18025891 chr8:17808941~17820868:+ CESC cis rs2299587 0.841 rs3213605 ENSG00000253671.1 RP11-806O11.1 -3.95 0.000107 0.0372 -0.26 -0.26 Economic and political preferences; chr8:18027582 chr8:17808941~17820868:+ CESC cis rs11649653 0.502 rs62057232 ENSG00000260911.2 RP11-196G11.2 -3.95 0.000107 0.0372 -0.28 -0.26 Triglycerides; chr16:30809545 chr16:31043150~31049868:+ CESC cis rs10170310 1 rs12691947 ENSG00000228043.4 AC097721.2 3.95 0.000107 0.0373 0.36 0.26 Response to antipsychotic treatment; chr2:138506901 chr2:138418284~138501698:- CESC cis rs10170310 1 rs6720716 ENSG00000228043.4 AC097721.2 3.95 0.000107 0.0373 0.36 0.26 Response to antipsychotic treatment; chr2:138511232 chr2:138418284~138501698:- CESC cis rs10178409 1 rs10178409 ENSG00000163016.8 ALMS1P 3.95 0.000107 0.0373 0.35 0.26 Urinary metabolites; chr2:73628380 chr2:73644919~73685576:+ CESC cis rs875971 0.545 rs73142233 ENSG00000226824.5 RP4-756H11.3 -3.95 0.000108 0.0373 -0.38 -0.26 Aortic root size; chr7:66221293 chr7:66654538~66669855:+ CESC cis rs11971779 0.59 rs4732374 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139406707 chr7:139359032~139359566:- CESC cis rs11971779 0.648 rs9642121 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139407875 chr7:139359032~139359566:- CESC cis rs11971779 0.715 rs7781459 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139409136 chr7:139359032~139359566:- CESC cis rs11971779 0.584 rs7786469 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139409875 chr7:139359032~139359566:- CESC cis rs11971779 0.584 rs17613864 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139410841 chr7:139359032~139359566:- CESC cis rs11971779 0.555 rs4728466 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139411619 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs4732376 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139413278 chr7:139359032~139359566:- CESC cis rs11971779 0.648 rs6974099 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139413820 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs10261557 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139414291 chr7:139359032~139359566:- CESC cis rs11971779 0.553 rs11973507 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139414715 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs10265718 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139415322 chr7:139359032~139359566:- CESC cis rs11971779 0.553 rs10085770 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139415603 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs2355788 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139417151 chr7:139359032~139359566:- CESC cis rs11971779 0.618 rs3778931 ENSG00000273391.1 RP11-634H22.1 3.95 0.000108 0.0373 0.25 0.26 Diisocyanate-induced asthma; chr7:139417744 chr7:139359032~139359566:- CESC cis rs2408955 0.521 rs10875749 ENSG00000258273.1 RP11-370I10.4 3.94 0.000108 0.0373 0.3 0.26 Glycated hemoglobin levels; chr12:48138134 chr12:48333755~48333901:- CESC cis rs11770686 0.905 rs1052 ENSG00000214243.3 AC004980.10 3.94 0.000108 0.0373 0.22 0.26 Essential tremor; chr7:75710916 chr7:76650401~76650897:- CESC cis rs8030379 1 rs940934 ENSG00000230373.7 GOLGA6L5P -3.94 0.000108 0.0373 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83906776 chr15:84507885~84516814:- CESC cis rs988913 0.793 rs9370333 ENSG00000224984.1 RP11-524H19.2 3.94 0.000108 0.0373 0.28 0.26 Menarche (age at onset); chr6:54873448 chr6:54840118~54840855:- CESC cis rs11157436 0.918 rs2178788 ENSG00000211813.2 TRAV34 3.94 0.000108 0.0373 0.26 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22150916 chr14:22207522~22208129:+ CESC cis rs7923837 0.687 rs10882101 ENSG00000236493.2 EIF2S2P3 3.94 0.000108 0.0374 0.32 0.26 Multiple sclerosis;Body mass index; chr10:92702670 chr10:92668745~92669743:- CESC cis rs13113518 0.812 rs13107810 ENSG00000273257.1 RP11-177J6.1 3.94 0.000108 0.0374 0.34 0.26 Height; chr4:55542243 chr4:55387949~55388271:+ CESC cis rs875971 1 rs12533997 ENSG00000232559.3 GS1-124K5.12 3.94 0.000108 0.0374 0.28 0.26 Aortic root size; chr7:66500390 chr7:66554588~66576923:- CESC cis rs875971 0.929 rs10950041 ENSG00000232559.3 GS1-124K5.12 3.94 0.000108 0.0374 0.28 0.26 Aortic root size; chr7:66508888 chr7:66554588~66576923:- CESC cis rs875971 0.545 rs2707851 ENSG00000224316.1 RP11-479O9.2 -3.94 0.000108 0.0374 -0.33 -0.26 Aortic root size; chr7:66624178 chr7:65773620~65802067:+ CESC cis rs523079 0.515 rs2590442 ENSG00000228952.1 RP11-567G11.1 -3.94 0.000108 0.0374 -0.38 -0.26 Glucose homeostasis traits; chr3:187904019 chr3:187448845~187449450:+ CESC cis rs11096990 0.892 rs11937540 ENSG00000249207.1 RP11-360F5.1 3.94 0.000108 0.0374 0.33 0.26 Cognitive function; chr4:39179897 chr4:39112677~39126818:- CESC cis rs11096990 0.892 rs28639548 ENSG00000249207.1 RP11-360F5.1 3.94 0.000108 0.0374 0.33 0.26 Cognitive function; chr4:39185530 chr4:39112677~39126818:- CESC cis rs7829975 0.66 rs10093926 ENSG00000253893.2 FAM85B 3.94 0.000108 0.0374 0.32 0.26 Mood instability; chr8:8691510 chr8:8167819~8226614:- CESC cis rs875971 1 rs4717300 ENSG00000232559.3 GS1-124K5.12 3.94 0.000108 0.0374 0.29 0.26 Aortic root size; chr7:66482393 chr7:66554588~66576923:- CESC cis rs9322193 0.566 rs9397070 ENSG00000268592.3 RAET1E-AS1 -3.94 0.000108 0.0374 -0.38 -0.26 Lung cancer; chr6:149922073 chr6:149863494~149919507:+ CESC cis rs7617773 0.817 rs6800492 ENSG00000228638.1 FCF1P2 -3.94 0.000108 0.0374 -0.28 -0.26 Coronary artery disease; chr3:48282400 chr3:48290793~48291375:- CESC cis rs9925964 1 rs9925964 ENSG00000260911.2 RP11-196G11.2 -3.94 0.000108 0.0375 -0.29 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31118574 chr16:31043150~31049868:+ CESC cis rs9925964 0.967 rs4889620 ENSG00000260911.2 RP11-196G11.2 -3.94 0.000108 0.0375 -0.29 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31119853 chr16:31043150~31049868:+ CESC cis rs761746 0.921 rs761747 ENSG00000236132.1 CTA-440B3.1 -3.94 0.000108 0.0375 -0.32 -0.26 Intelligence; chr22:31605849 chr22:31816379~31817491:- CESC cis rs2286503 0.966 rs2286507 ENSG00000228649.7 AC005682.5 3.94 0.000108 0.0375 0.23 0.26 Fibrinogen; chr7:22815141 chr7:22854178~22861579:+ CESC cis rs11971779 0.648 rs10230407 ENSG00000273391.1 RP11-634H22.1 3.94 0.000108 0.0375 0.25 0.26 Diisocyanate-induced asthma; chr7:139419147 chr7:139359032~139359566:- CESC cis rs10170310 0.515 rs4954937 ENSG00000241772.2 AC092620.2 3.94 0.000108 0.0375 0.43 0.26 Response to antipsychotic treatment; chr2:138573096 chr2:138569090~138574458:+ CESC cis rs1707322 1 rs1707317 ENSG00000281133.1 AL355480.3 3.94 0.000108 0.0375 0.31 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46044970 chr1:45580892~45580996:- CESC cis rs919433 0.713 rs6719483 ENSG00000222017.1 AC011997.1 3.94 0.000108 0.0375 0.32 0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197608162 chr2:197693106~197774823:+ CESC cis rs2439831 0.85 rs7183809 ENSG00000275601.1 AC011330.13 -3.94 0.000108 0.0375 -0.4 -0.26 Lung cancer in ever smokers; chr15:43828670 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs3759790 ENSG00000275601.1 AC011330.13 -3.94 0.000108 0.0375 -0.4 -0.26 Lung cancer in ever smokers; chr15:43828832 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs68079546 ENSG00000275601.1 AC011330.13 -3.94 0.000108 0.0375 -0.4 -0.26 Lung cancer in ever smokers; chr15:43844759 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs56909447 ENSG00000275601.1 AC011330.13 -3.94 0.000108 0.0375 -0.4 -0.26 Lung cancer in ever smokers; chr15:43845420 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28476182 ENSG00000275601.1 AC011330.13 -3.94 0.000108 0.0375 -0.4 -0.26 Lung cancer in ever smokers; chr15:43847445 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28696802 ENSG00000275601.1 AC011330.13 -3.94 0.000108 0.0375 -0.4 -0.26 Lung cancer in ever smokers; chr15:43848197 chr15:43642389~43643023:- CESC cis rs17301013 0.606 rs1618408 ENSG00000227373.4 RP11-160H22.5 -3.94 0.000108 0.0375 -0.32 -0.26 Systemic lupus erythematosus; chr1:174777402 chr1:174115300~174160004:- CESC cis rs9513627 0.833 rs73556129 ENSG00000228889.5 UBAC2-AS1 3.94 0.000108 0.0375 0.46 0.26 Obesity-related traits; chr13:99460913 chr13:99196377~99200710:- CESC cis rs10129255 0.957 rs12590799 ENSG00000211974.3 IGHV2-70 3.94 0.000108 0.0375 0.26 0.26 Kawasaki disease; chr14:106779713 chr14:106723574~106724093:- CESC cis rs516805 0.886 rs557528 ENSG00000279453.1 RP3-425C14.4 -3.94 0.000108 0.0375 -0.3 -0.26 Lymphocyte counts; chr6:122482793 chr6:122436789~122439223:- CESC cis rs516805 0.961 rs559721 ENSG00000279453.1 RP3-425C14.4 -3.94 0.000108 0.0375 -0.3 -0.26 Lymphocyte counts; chr6:122482796 chr6:122436789~122439223:- CESC cis rs516805 0.923 rs538457 ENSG00000279453.1 RP3-425C14.4 -3.94 0.000108 0.0375 -0.3 -0.26 Lymphocyte counts; chr6:122485610 chr6:122436789~122439223:- CESC cis rs516805 0.961 rs9385248 ENSG00000279453.1 RP3-425C14.4 -3.94 0.000108 0.0375 -0.3 -0.26 Lymphocyte counts; chr6:122490982 chr6:122436789~122439223:- CESC cis rs12107539 0.918 rs2307020 ENSG00000240137.4 ERICH6-AS1 -3.94 0.000108 0.0375 -0.24 -0.26 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151336837 chr3:150703564~150720146:+ CESC cis rs9322193 0.884 rs7743823 ENSG00000223701.3 RAET1E-AS1 3.94 0.000108 0.0375 0.31 0.26 Lung cancer; chr6:149849744 chr6:149884431~149919508:+ CESC cis rs453301 0.624 rs330056 ENSG00000254340.1 RP11-10A14.3 -3.94 0.000108 0.0375 -0.32 -0.26 Joint mobility (Beighton score); chr8:9232185 chr8:9141424~9145435:+ CESC cis rs453301 0.624 rs330058 ENSG00000254340.1 RP11-10A14.3 -3.94 0.000108 0.0375 -0.32 -0.26 Joint mobility (Beighton score); chr8:9232299 chr8:9141424~9145435:+ CESC cis rs6504622 1 rs4968286 ENSG00000262879.4 RP11-156P1.3 -3.94 0.000108 0.0375 -0.29 -0.26 Orofacial clefts; chr17:46940279 chr17:46984045~47100323:- CESC cis rs6740322 1 rs4128209 ENSG00000234936.1 AC010883.5 3.94 0.000109 0.0376 0.27 0.26 Coronary artery disease; chr2:43327590 chr2:43229573~43233394:+ CESC cis rs4319547 0.695 rs4758666 ENSG00000275265.1 RP11-15J22.8 -3.94 0.000109 0.0376 -0.33 -0.26 Body mass index; chr12:122418293 chr12:122501187~122501641:+ CESC cis rs4978813 0.5 rs10759345 ENSG00000213539.4 YBX1P6 -3.94 0.000109 0.0376 -0.32 -0.26 Plantar warts; chr9:109516765 chr9:109532830~109534332:- CESC cis rs62103177 0.608 rs613847 ENSG00000261126.6 RP11-795F19.1 -3.94 0.000109 0.0376 -0.33 -0.26 Opioid sensitivity; chr18:80087736 chr18:80046900~80095482:+ CESC cis rs62103177 0.525 rs612913 ENSG00000261126.6 RP11-795F19.1 -3.94 0.000109 0.0376 -0.33 -0.26 Opioid sensitivity; chr18:80087974 chr18:80046900~80095482:+ CESC cis rs1075265 0.783 rs698858 ENSG00000233266.1 HMGB1P31 3.94 0.000109 0.0376 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53943333 chr2:54051334~54051760:+ CESC cis rs2261181 0.542 rs11833342 ENSG00000276853.1 RP11-305O6.4 3.94 0.000109 0.0376 0.5 0.26 Type 2 diabetes; chr12:65776889 chr12:65171262~65171917:+ CESC cis rs12580194 1 rs12579030 ENSG00000237493.3 RP11-603J24.7 -3.94 0.000109 0.0376 -0.35 -0.26 Cancer; chr12:55295410 chr12:55980432~55981035:- CESC cis rs12580194 1 rs12582734 ENSG00000237493.3 RP11-603J24.7 -3.94 0.000109 0.0376 -0.35 -0.26 Cancer; chr12:55295788 chr12:55980432~55981035:- CESC cis rs2552220 0.933 rs13268523 ENSG00000246089.3 RP11-115C21.2 -3.94 0.000109 0.0376 -0.27 -0.26 Interleukin-8 levels; chr8:6137956 chr8:6403551~6407142:- CESC cis rs3213758 0.588 rs12928335 ENSG00000275191.1 RP11-36I17.2 -3.94 0.000109 0.0376 -0.54 -0.26 Vitiligo (non-segmental); chr16:53580834 chr16:53628256~53628816:- CESC cis rs62355900 0.627 rs16886463 ENSG00000271828.1 CTD-2310F14.1 3.94 0.000109 0.0376 0.4 0.26 Endometriosis; chr5:56883514 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs62358106 ENSG00000271828.1 CTD-2310F14.1 3.94 0.000109 0.0376 0.4 0.26 Endometriosis; chr5:56885542 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs3817119 ENSG00000271828.1 CTD-2310F14.1 3.94 0.000109 0.0376 0.4 0.26 Endometriosis; chr5:56887916 chr5:56927874~56929573:+ CESC cis rs7829975 0.572 rs28730413 ENSG00000253893.2 FAM85B 3.94 0.000109 0.0376 0.32 0.26 Mood instability; chr8:8937937 chr8:8167819~8226614:- CESC cis rs17711722 0.727 rs2658585 ENSG00000222364.1 RNU6-96P -3.94 0.000109 0.0377 -0.32 -0.26 Calcium levels; chr7:65996954 chr7:66395191~66395286:+ CESC cis rs2274273 0.6 rs10134317 ENSG00000258413.1 RP11-665C16.6 -3.94 0.000109 0.0377 -0.33 -0.26 Protein biomarker; chr14:55326730 chr14:55262767~55272075:- CESC cis rs10129255 0.5 rs2105989 ENSG00000224373.3 IGHV4-59 3.94 0.000109 0.0377 0.17 0.26 Kawasaki disease; chr14:106682199 chr14:106627249~106627825:- CESC cis rs761746 0.804 rs5749304 ENSG00000236132.1 CTA-440B3.1 3.94 0.000109 0.0377 0.32 0.26 Intelligence; chr22:31571789 chr22:31816379~31817491:- CESC cis rs3796352 1 rs35163227 ENSG00000280417.1 RP11-5O17.1 -3.94 0.000109 0.0377 -0.47 -0.26 Immune reponse to smallpox (secreted IL-2); chr3:53093860 chr3:53046166~53048122:+ CESC cis rs11971779 0.878 rs4732378 ENSG00000273391.1 RP11-634H22.1 3.94 0.000109 0.0377 0.31 0.26 Diisocyanate-induced asthma; chr7:139435649 chr7:139359032~139359566:- CESC cis rs4877691 0.522 rs3904318 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82469139 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs3904320 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82469244 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs7857318 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82470347 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs7860745 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82470828 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs7847565 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82471221 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs11139576 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82472142 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs13290288 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82472333 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs12555428 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82472569 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs7046838 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82474236 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs7046852 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82474325 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs56291243 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82474763 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs12683121 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82475642 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs12685162 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82475758 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs67968529 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82476563 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs7021813 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82476792 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs7036901 ENSG00000267559.4 RP11-383M4.6 3.94 0.000109 0.0377 0.36 0.26 Airway imaging phenotypes; chr9:82476997 chr9:81930226~81977089:- CESC cis rs17301013 0.507 rs1622802 ENSG00000227373.4 RP11-160H22.5 -3.94 0.000109 0.0377 -0.34 -0.26 Systemic lupus erythematosus; chr1:174766066 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs1329281 ENSG00000227373.4 RP11-160H22.5 -3.94 0.000109 0.0377 -0.34 -0.26 Systemic lupus erythematosus; chr1:174766432 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs6696465 ENSG00000227373.4 RP11-160H22.5 -3.94 0.000109 0.0377 -0.34 -0.26 Systemic lupus erythematosus; chr1:174769700 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs1793292 ENSG00000227373.4 RP11-160H22.5 -3.94 0.000109 0.0377 -0.34 -0.26 Systemic lupus erythematosus; chr1:174778185 chr1:174115300~174160004:- CESC cis rs17301013 0.531 rs1653634 ENSG00000227373.4 RP11-160H22.5 -3.94 0.000109 0.0377 -0.34 -0.26 Systemic lupus erythematosus; chr1:174783348 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs1793298 ENSG00000227373.4 RP11-160H22.5 -3.94 0.000109 0.0377 -0.34 -0.26 Systemic lupus erythematosus; chr1:174784601 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs398350 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174706168 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs3117843 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174711581 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs332786 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174713584 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs332779 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174716623 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs332781 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174718483 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs193082 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174725439 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs460878 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174732645 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs2568096 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174735463 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs333436 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174739069 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs392307 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174744243 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs3117838 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174749205 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs1923818 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174749737 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs332801 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174753192 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs332800 ENSG00000227373.4 RP11-160H22.5 3.94 0.000109 0.0377 0.34 0.26 Systemic lupus erythematosus; chr1:174753467 chr1:174115300~174160004:- CESC cis rs3091242 1 rs3091242 ENSG00000224183.1 SDHDP6 -3.94 0.000109 0.0377 -0.28 -0.26 Erythrocyte sedimentation rate; chr1:25348294 chr1:25294164~25294643:- CESC cis rs3091242 0.967 rs3091240 ENSG00000224183.1 SDHDP6 -3.94 0.000109 0.0377 -0.28 -0.26 Erythrocyte sedimentation rate; chr1:25350444 chr1:25294164~25294643:- CESC cis rs3091242 0.935 rs3093632 ENSG00000224183.1 SDHDP6 -3.94 0.000109 0.0377 -0.28 -0.26 Erythrocyte sedimentation rate; chr1:25357521 chr1:25294164~25294643:- CESC cis rs10056811 0.538 rs2035191 ENSG00000271815.1 CTD-2235C13.3 -3.94 0.000109 0.0377 -0.38 -0.26 Coronary artery disease; chr5:75117888 chr5:75363760~75364242:+ CESC cis rs7896729 1 rs11253080 ENSG00000215267.7 AKR1C7P -3.94 0.000109 0.0377 -0.3 -0.26 Intelligence; chr10:5296145 chr10:5275173~5288470:- CESC cis rs783540 0.934 rs4779050 ENSG00000276710.3 CSPG4P8 -3.94 0.000109 0.0377 -0.28 -0.26 Schizophrenia; chr15:82699986 chr15:82459472~82477258:+ CESC cis rs6142102 0.961 rs6120487 ENSG00000275784.1 RP5-1125A11.6 -3.94 0.000109 0.0378 -0.27 -0.26 Skin pigmentation; chr20:34034802 chr20:33989480~33991818:- CESC cis rs9925964 0.967 rs2032915 ENSG00000260911.2 RP11-196G11.2 -3.94 0.000109 0.0378 -0.29 -0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31106092 chr16:31043150~31049868:+ CESC cis rs2235544 0.588 rs664758 ENSG00000225183.1 RP4-758J24.4 3.94 0.000109 0.0378 0.28 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:53995590 chr1:54089856~54090093:+ CESC cis rs11971779 0.793 rs11764426 ENSG00000273391.1 RP11-634H22.1 3.94 0.000109 0.0378 0.27 0.26 Diisocyanate-induced asthma; chr7:139339304 chr7:139359032~139359566:- CESC cis rs2961663 0.667 rs9329136 ENSG00000250420.7 AACSP1 -3.94 0.000109 0.0378 -0.48 -0.26 Rheumatoid arthritis; chr5:178184647 chr5:178764861~178818435:- CESC cis rs17695224 0.675 rs2109656 ENSG00000268095.1 ZNF649-AS1 3.94 0.000109 0.0378 0.33 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51837424 chr19:51888025~51900463:+ CESC cis rs11638352 0.661 rs11857696 ENSG00000275601.1 AC011330.13 3.94 0.000109 0.0378 0.39 0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44074060 chr15:43642389~43643023:- CESC cis rs9517320 1 rs9513430 ENSG00000231194.1 FARP1-AS1 3.94 0.00011 0.0378 0.3 0.26 Longevity; chr13:98474998 chr13:98435405~98435840:- CESC cis rs67180937 0.553 rs2936020 ENSG00000272750.1 RP11-378J18.8 3.94 0.00011 0.0378 0.36 0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222655754 chr1:222658867~222661512:- CESC cis rs9300255 0.537 rs1619561 ENSG00000235423.7 RP11-282O18.3 3.94 0.00011 0.0378 0.34 0.26 Neutrophil percentage of white cells; chr12:123135721 chr12:123252030~123261483:- CESC cis rs11096990 0.964 rs56284364 ENSG00000249207.1 RP11-360F5.1 3.94 0.00011 0.0378 0.31 0.26 Cognitive function; chr4:39255028 chr4:39112677~39126818:- CESC cis rs77972916 0.505 rs6736400 ENSG00000276967.1 AC019129.2 -3.94 0.00011 0.0378 -0.38 -0.26 Granulocyte percentage of myeloid white cells; chr2:43273665 chr2:44065488~44065544:- CESC cis rs11649653 0.502 rs4889490 ENSG00000260911.2 RP11-196G11.2 3.94 0.00011 0.0378 0.28 0.26 Triglycerides; chr16:30811726 chr16:31043150~31049868:+ CESC cis rs853679 0.517 rs1904841 ENSG00000280107.1 AL022393.9 -3.94 0.00011 0.0378 -0.35 -0.26 Depression; chr6:28140307 chr6:28170845~28172521:+ CESC cis rs853679 0.517 rs1904840 ENSG00000280107.1 AL022393.9 -3.94 0.00011 0.0378 -0.35 -0.26 Depression; chr6:28140454 chr6:28170845~28172521:+ CESC cis rs853679 0.517 rs9368555 ENSG00000280107.1 AL022393.9 -3.94 0.00011 0.0378 -0.35 -0.26 Depression; chr6:28141189 chr6:28170845~28172521:+ CESC cis rs853679 0.517 rs9393893 ENSG00000280107.1 AL022393.9 -3.94 0.00011 0.0378 -0.35 -0.26 Depression; chr6:28141484 chr6:28170845~28172521:+ CESC cis rs9487094 0.689 rs9487069 ENSG00000260273.1 RP11-425D10.10 3.94 0.00011 0.0378 0.32 0.26 Height; chr6:109358652 chr6:109382795~109383666:+ CESC cis rs9487094 0.666 rs9480956 ENSG00000260273.1 RP11-425D10.10 3.94 0.00011 0.0379 0.32 0.26 Height; chr6:109424305 chr6:109382795~109383666:+ CESC cis rs9487094 0.689 rs12214147 ENSG00000260273.1 RP11-425D10.10 3.94 0.00011 0.0379 0.32 0.26 Height; chr6:109425054 chr6:109382795~109383666:+ CESC cis rs9487094 0.689 rs17070591 ENSG00000260273.1 RP11-425D10.10 3.94 0.00011 0.0379 0.32 0.26 Height; chr6:109426518 chr6:109382795~109383666:+ CESC cis rs9487094 0.666 rs7751582 ENSG00000260273.1 RP11-425D10.10 3.94 0.00011 0.0379 0.32 0.26 Height; chr6:109427644 chr6:109382795~109383666:+ CESC cis rs17122021 0.625 rs3759001 ENSG00000278376.1 RP11-158I9.8 3.94 0.00011 0.0379 0.23 0.26 Pain; chr11:118265030 chr11:118791254~118793137:+ CESC cis rs227932 0.571 rs3801898 ENSG00000234286.1 AC006026.13 -3.94 0.00011 0.0379 -0.36 -0.26 Schizophrenia; chr7:23762526 chr7:23680195~23680786:- CESC cis rs11770686 0.967 rs13231091 ENSG00000214243.3 AC004980.10 3.94 0.00011 0.0379 0.23 0.26 Essential tremor; chr7:75714420 chr7:76650401~76650897:- CESC cis rs875971 0.545 rs73378304 ENSG00000179406.6 LINC00174 -3.94 0.00011 0.0379 -0.29 -0.26 Aortic root size; chr7:66175760 chr7:66376044~66401338:- CESC cis rs8123073 1 rs6058880 ENSG00000125997.5 BPIFB9P -3.94 0.00011 0.038 -0.61 -0.26 Attention deficit hyperactivity disorder (combined symptoms); chr20:32774614 chr20:33347720~33354444:+ CESC cis rs748404 0.697 rs555001 ENSG00000249839.1 AC011330.5 -3.94 0.00011 0.038 -0.28 -0.26 Lung cancer; chr15:43253530 chr15:43663654~43684339:- CESC cis rs748404 0.697 rs475261 ENSG00000249839.1 AC011330.5 -3.94 0.00011 0.038 -0.28 -0.26 Lung cancer; chr15:43254258 chr15:43663654~43684339:- CESC cis rs12134133 1 rs2782842 ENSG00000274245.1 RP11-357P18.2 3.94 0.00011 0.038 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310231 chr1:207372559~207373252:+ CESC cis rs12144049 0.705 rs2146115 ENSG00000227045.1 RP11-98D18.1 -3.94 0.00011 0.038 -0.38 -0.26 Inflammatory skin disease;Atopic dermatitis; chr1:152471019 chr1:151701026~151708386:+ CESC cis rs12681963 0.688 rs7004466 ENSG00000272375.1 RP11-51J9.6 3.94 0.00011 0.038 0.49 0.26 Migraine; chr8:30196778 chr8:30197404~30198048:+ CESC cis rs12681963 0.688 rs7004806 ENSG00000272375.1 RP11-51J9.6 3.94 0.00011 0.038 0.49 0.26 Migraine; chr8:30197002 chr8:30197404~30198048:+ CESC cis rs9532669 0.926 rs2324742 ENSG00000176268.5 CYCSP34 3.94 0.00011 0.038 0.26 0.26 Cervical cancer; chr13:40919059 chr13:40863599~40863902:- CESC cis rs9532669 0.857 rs9594455 ENSG00000176268.5 CYCSP34 3.94 0.00011 0.038 0.26 0.26 Cervical cancer; chr13:40919452 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532659 ENSG00000176268.5 CYCSP34 3.94 0.00011 0.038 0.26 0.26 Cervical cancer; chr13:40920380 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs9594457 ENSG00000176268.5 CYCSP34 3.94 0.00011 0.038 0.26 0.26 Cervical cancer; chr13:40920439 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9594458 ENSG00000176268.5 CYCSP34 3.94 0.00011 0.038 0.26 0.26 Cervical cancer; chr13:40920448 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9590562 ENSG00000176268.5 CYCSP34 3.94 0.00011 0.038 0.26 0.26 Cervical cancer; chr13:40920503 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs12857052 ENSG00000176268.5 CYCSP34 3.94 0.00011 0.038 0.26 0.26 Cervical cancer; chr13:40920831 chr13:40863599~40863902:- CESC cis rs10056811 0.538 rs3923323 ENSG00000271815.1 CTD-2235C13.3 3.94 0.00011 0.038 0.4 0.26 Coronary artery disease; chr5:75076316 chr5:75363760~75364242:+ CESC cis rs62355901 0.545 rs62355938 ENSG00000271828.1 CTD-2310F14.1 3.94 0.00011 0.038 0.4 0.26 Breast cancer; chr5:56798887 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs1862620 ENSG00000271828.1 CTD-2310F14.1 3.94 0.00011 0.038 0.4 0.26 Endometriosis; chr5:56802543 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs62355941 ENSG00000271828.1 CTD-2310F14.1 3.94 0.00011 0.038 0.4 0.26 Endometriosis; chr5:56807871 chr5:56927874~56929573:+ CESC cis rs62025270 0.632 rs62022918 ENSG00000202081.1 RNU6-1280P -3.94 0.00011 0.038 -0.35 -0.26 Idiopathic pulmonary fibrosis; chr15:85675053 chr15:85651522~85651628:- CESC cis rs1707322 1 rs1707322 ENSG00000281133.1 AL355480.3 -3.94 0.00011 0.038 -0.3 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46039475 chr1:45580892~45580996:- CESC cis rs3015497 0.505 rs17791470 ENSG00000269906.1 RP11-248J18.2 3.94 0.00011 0.0381 0.32 0.26 Mean platelet volume; chr14:50473181 chr14:50662511~50663178:- CESC cis rs1775715 0.707 rs2808094 ENSG00000231245.2 C1DP1 -3.94 0.00011 0.0381 -0.32 -0.26 Bipolar disorder with mood-incongruent psychosis; chr10:31844828 chr10:32511336~32511737:- CESC cis rs1775715 0.644 rs2799022 ENSG00000231245.2 C1DP1 -3.94 0.00011 0.0381 -0.32 -0.26 Bipolar disorder with mood-incongruent psychosis; chr10:31848270 chr10:32511336~32511737:- CESC cis rs763121 0.853 rs5757253 ENSG00000228274.3 RP3-508I15.9 -3.94 0.00011 0.0381 -0.24 -0.26 Menopause (age at onset); chr22:38708315 chr22:38667585~38681820:- CESC cis rs13113518 0.902 rs12505266 ENSG00000273257.1 RP11-177J6.1 3.94 0.00011 0.0381 0.34 0.26 Height; chr4:55546002 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs56154935 ENSG00000273257.1 RP11-177J6.1 3.94 0.00011 0.0381 0.34 0.26 Height; chr4:55546378 chr4:55387949~55388271:+ CESC cis rs748404 0.697 rs572959 ENSG00000249839.1 AC011330.5 -3.94 0.00011 0.0381 -0.27 -0.26 Lung cancer; chr15:43258304 chr15:43663654~43684339:- CESC cis rs9487094 0.689 rs9487070 ENSG00000260273.1 RP11-425D10.10 3.94 0.00011 0.0381 0.31 0.26 Height; chr6:109361200 chr6:109382795~109383666:+ CESC cis rs7789940 0.951 rs73140055 ENSG00000230305.2 AC004980.9 3.94 0.000111 0.0381 0.36 0.26 Multiple sclerosis; chr7:76346460 chr7:76524515~76532692:+ CESC cis rs9322193 0.923 rs7769101 ENSG00000223701.3 RAET1E-AS1 3.94 0.000111 0.0381 0.32 0.26 Lung cancer; chr6:149848768 chr6:149884431~149919508:+ CESC cis rs8031584 0.56 rs1056118 ENSG00000260382.1 RP11-540B6.2 -3.94 0.000111 0.0381 -0.34 -0.26 Huntington's disease progression; chr15:30911583 chr15:30882267~30883231:- CESC cis rs2404602 0.716 rs117129193 ENSG00000280730.1 AC090181.1 3.94 0.000111 0.0381 0.2 0.26 Blood metabolite levels; chr15:76364462 chr15:77056895~77057021:+ CESC cis rs6969780 0.63 rs10238095 ENSG00000233429.8 HOTAIRM1 -3.94 0.000111 0.0381 -0.32 -0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27157024 chr7:27095647~27100265:+ CESC cis rs8050871 0.585 rs9935426 ENSG00000260593.1 RP11-432I5.2 3.94 0.000111 0.0382 0.27 0.26 Breast cancer; chr16:71498025 chr16:71623708~71626816:- CESC cis rs3960554 0.709 rs73138006 ENSG00000230305.2 AC004980.9 3.94 0.000111 0.0382 0.43 0.26 Eotaxin levels; chr7:76140672 chr7:76524515~76532692:+ CESC cis rs2337406 1 rs7145100 ENSG00000211974.3 IGHV2-70 -3.94 0.000111 0.0382 -0.39 -0.26 Alzheimer's disease (late onset); chr14:106704673 chr14:106723574~106724093:- CESC cis rs2688608 0.592 rs7908825 ENSG00000242288.9 RP11-464F9.1 -3.94 0.000111 0.0382 -0.29 -0.26 Inflammatory bowel disease; chr10:73794783 chr10:73674295~73730466:- CESC cis rs1799955 0.935 rs9634672 ENSG00000215515.2 IFIT1P1 -3.94 0.000111 0.0382 -0.4 -0.26 LDL cholesterol levels; chr13:32369919 chr13:32384660~32386108:+ CESC cis rs1799955 0.935 rs9567609 ENSG00000215515.2 IFIT1P1 -3.94 0.000111 0.0382 -0.4 -0.26 LDL cholesterol levels; chr13:32371580 chr13:32384660~32386108:+ CESC cis rs4272720 0.526 rs7906722 ENSG00000229870.1 RP11-507K13.6 -3.94 0.000111 0.0382 -0.29 -0.26 Platelet count;Plateletcrit; chr10:49063190 chr10:49815096~49815562:+ CESC cis rs948562 0.895 rs7484263 ENSG00000269570.2 CMB9-55A18.1 3.94 0.000111 0.0382 0.27 0.26 Lymphoma; chr11:58608080 chr11:58611119~58612642:- CESC cis rs1707322 1 rs785469 ENSG00000281133.1 AL355480.3 3.94 0.000111 0.0382 0.3 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055419 chr1:45580892~45580996:- CESC cis rs1707322 1 rs785468 ENSG00000281133.1 AL355480.3 3.94 0.000111 0.0382 0.3 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055845 chr1:45580892~45580996:- CESC cis rs7005380 0.581 rs10099088 ENSG00000279347.1 RP11-85I17.2 -3.94 0.000111 0.0382 -0.28 -0.26 Interstitial lung disease; chr8:119927418 chr8:119838736~119840385:- CESC cis rs8040855 0.644 rs4635318 ENSG00000259774.1 RP11-182J1.13 -3.94 0.000111 0.0382 -0.3 -0.26 Bulimia nervosa; chr15:85183506 chr15:84422618~84425882:+ CESC cis rs9650657 0.571 rs4240673 ENSG00000269918.1 AF131215.9 -3.94 0.000111 0.0382 -0.31 -0.26 Neuroticism; chr8:10930102 chr8:11104691~11106704:- CESC cis rs2408955 0.5 rs12816820 ENSG00000226413.2 OR8T1P 3.94 0.000111 0.0382 0.33 0.26 Glycated hemoglobin levels; chr12:48164542 chr12:48442030~48442947:- CESC cis rs8127691 0.967 rs2838521 ENSG00000225331.1 AP001055.6 -3.94 0.000111 0.0382 -0.32 -0.26 Inflammatory bowel disease; chr21:44196034 chr21:44158740~44160076:- CESC cis rs751837 0.932 rs1106679 ENSG00000240624.1 RP11-45P15.2 3.94 0.000111 0.0382 0.37 0.26 Large B-cell lymphoma; chr14:103019315 chr14:103282933~103283468:+ CESC cis rs7688540 0.771 rs11248013 ENSG00000211553.1 AC253576.2 -3.94 0.000111 0.0383 -0.4 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:317636 chr4:136461~136568:+ CESC cis rs4319547 0.585 rs10846792 ENSG00000275265.1 RP11-15J22.8 -3.94 0.000111 0.0383 -0.36 -0.26 Body mass index; chr12:122397827 chr12:122501187~122501641:+ CESC cis rs523522 0.962 rs2393590 ENSG00000278344.1 RP11-18C24.8 3.94 0.000111 0.0383 0.31 0.26 High light scatter reticulocyte count; chr12:120476097 chr12:120500735~120501090:- CESC cis rs9322193 0.962 rs17673294 ENSG00000223701.3 RAET1E-AS1 3.94 0.000111 0.0383 0.3 0.26 Lung cancer; chr6:149813857 chr6:149884431~149919508:+ CESC cis rs9907295 0.591 rs8069014 ENSG00000271013.1 AC015849.15 -3.94 0.000111 0.0383 -0.29 -0.26 Fibroblast growth factor basic levels; chr17:35872994 chr17:35912635~35918010:- CESC cis rs9513627 0.749 rs73556143 ENSG00000228889.5 UBAC2-AS1 3.94 0.000111 0.0383 0.48 0.26 Obesity-related traits; chr13:99464653 chr13:99196377~99200710:- CESC cis rs9513627 0.833 rs73556146 ENSG00000228889.5 UBAC2-AS1 3.94 0.000111 0.0383 0.48 0.26 Obesity-related traits; chr13:99464666 chr13:99196377~99200710:- CESC cis rs10129255 0.5 rs9324092 ENSG00000224373.3 IGHV4-59 -3.94 0.000111 0.0383 -0.16 -0.26 Kawasaki disease; chr14:106683806 chr14:106627249~106627825:- CESC cis rs4319547 0.915 rs10773208 ENSG00000275265.1 RP11-15J22.8 -3.94 0.000111 0.0383 -0.37 -0.26 Body mass index; chr12:122485609 chr12:122501187~122501641:+ CESC cis rs4319547 0.915 rs11058402 ENSG00000275265.1 RP11-15J22.8 -3.94 0.000111 0.0383 -0.37 -0.26 Body mass index; chr12:122496506 chr12:122501187~122501641:+ CESC cis rs4319547 0.915 rs1473553 ENSG00000275265.1 RP11-15J22.8 -3.94 0.000111 0.0383 -0.37 -0.26 Body mass index; chr12:122500510 chr12:122501187~122501641:+ CESC cis rs6991838 0.806 rs4285523 ENSG00000200714.1 Y_RNA 3.94 0.000111 0.0383 0.31 0.26 Intelligence (multi-trait analysis); chr8:65552095 chr8:65592731~65592820:+ CESC cis rs11157436 1 rs75648426 ENSG00000211812.1 TRAV26-2 -3.94 0.000111 0.0383 -0.29 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22184044 chr14:22202583~22203368:+ CESC cis rs2439831 0.85 rs3862142 ENSG00000249839.1 AC011330.5 -3.94 0.000111 0.0383 -0.37 -0.26 Lung cancer in ever smokers; chr15:43772608 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs2277531 ENSG00000249839.1 AC011330.5 -3.94 0.000111 0.0383 -0.37 -0.26 Lung cancer in ever smokers; chr15:43776871 chr15:43663654~43684339:- CESC cis rs13113518 0.812 rs56055342 ENSG00000273257.1 RP11-177J6.1 3.94 0.000111 0.0383 0.34 0.26 Height; chr4:55540928 chr4:55387949~55388271:+ CESC cis rs13108904 0.517 rs4974551 ENSG00000254094.1 AC078852.1 -3.94 0.000111 0.0383 -0.31 -0.26 Obesity-related traits; chr4:1342622 chr4:1356581~1358075:+ CESC cis rs35883536 0.933 rs1409419 ENSG00000235795.1 RP11-421L21.2 3.94 0.000111 0.0383 0.31 0.26 Monocyte count; chr1:100717840 chr1:100995473~100996260:+ CESC cis rs12019361 0.541 rs56364292 ENSG00000224046.1 AC005076.5 3.94 0.000111 0.0383 0.47 0.26 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN); chr7:87558776 chr7:87151423~87152420:- CESC cis rs12019361 0.541 rs28381868 ENSG00000224046.1 AC005076.5 3.94 0.000111 0.0383 0.47 0.26 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN); chr7:87559868 chr7:87151423~87152420:- CESC cis rs1075265 0.572 rs62139835 ENSG00000233266.1 HMGB1P31 3.94 0.000111 0.0383 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53682307 chr2:54051334~54051760:+ CESC cis rs12220777 0.786 rs2342607 ENSG00000230091.5 TMEM254-AS1 3.94 0.000111 0.0383 0.48 0.26 Chronic obstructive pulmonary disease-related biomarkers; chr10:80061733 chr10:80046860~80078912:- CESC cis rs597205 0.541 rs639154 ENSG00000231437.3 RP11-88H9.2 -3.94 0.000112 0.0384 -0.34 -0.26 Gut microbiota (bacterial taxa); chr1:111867900 chr1:111989770~111998842:+ CESC cis rs8074751 0.57 rs7218878 ENSG00000266644.1 RP11-927P21.2 3.94 0.000112 0.0384 0.29 0.26 Attention deficit hyperactivity disorder; chr17:65634456 chr17:64899766~64900716:+ CESC cis rs9309473 0.95 rs2947860 ENSG00000163016.8 ALMS1P 3.94 0.000112 0.0384 0.34 0.26 Metabolite levels; chr2:73628259 chr2:73644919~73685576:+ CESC cis rs763121 0.853 rs2072794 ENSG00000273076.1 RP3-508I15.22 3.94 0.000112 0.0384 0.3 0.26 Menopause (age at onset); chr22:38754538 chr22:38743495~38743910:+ CESC cis rs453301 0.653 rs11784393 ENSG00000254340.1 RP11-10A14.3 3.94 0.000112 0.0384 0.31 0.26 Joint mobility (Beighton score); chr8:9045624 chr8:9141424~9145435:+ CESC cis rs8080784 0.611 rs6504006 ENSG00000266701.1 AC005702.4 3.94 0.000112 0.0384 0.38 0.26 Coronary artery disease; chr17:60921297 chr17:60042546~60042627:- CESC cis rs8080784 0.611 rs7225051 ENSG00000266701.1 AC005702.4 3.94 0.000112 0.0384 0.38 0.26 Coronary artery disease; chr17:60921369 chr17:60042546~60042627:- CESC cis rs17507216 0.718 rs28587782 ENSG00000276710.3 CSPG4P8 -3.94 0.000112 0.0384 -0.37 -0.26 Excessive daytime sleepiness; chr15:82576881 chr15:82459472~82477258:+ CESC cis rs10463554 0.853 rs246903 ENSG00000175749.11 EIF3KP1 3.94 0.000112 0.0384 0.27 0.26 Parkinson's disease; chr5:103253753 chr5:103032376~103033031:+ CESC cis rs8031584 0.651 rs28664821 ENSG00000260382.1 RP11-540B6.2 -3.93 0.000112 0.0385 -0.34 -0.26 Huntington's disease progression; chr15:30880120 chr15:30882267~30883231:- CESC cis rs6750795 0.87 rs6754952 ENSG00000181798.2 LINC00471 3.93 0.000112 0.0385 0.27 0.26 Height; chr2:231516534 chr2:231508426~231514339:- CESC cis rs7811142 0.779 rs111312383 ENSG00000242294.5 STAG3L5P 3.93 0.000112 0.0385 0.29 0.26 Platelet count; chr7:100307702 chr7:100336079~100351900:+ CESC cis rs7811142 0.779 rs28680963 ENSG00000242294.5 STAG3L5P 3.93 0.000112 0.0385 0.29 0.26 Platelet count; chr7:100307852 chr7:100336079~100351900:+ CESC cis rs875971 0.545 rs316316 ENSG00000226824.5 RP4-756H11.3 3.93 0.000112 0.0385 0.36 0.26 Aortic root size; chr7:66149270 chr7:66654538~66669855:+ CESC cis rs6540731 1 rs4362041 ENSG00000226251.4 RP11-15I11.3 -3.93 0.000112 0.0385 -0.29 -0.26 Intelligence (childhood); chr1:212227127 chr1:212225278~212238977:- CESC cis rs875971 0.964 rs60193905 ENSG00000232559.3 GS1-124K5.12 3.93 0.000112 0.0385 0.28 0.26 Aortic root size; chr7:66506273 chr7:66554588~66576923:- CESC cis rs9532669 0.963 rs4942012 ENSG00000176268.5 CYCSP34 3.93 0.000112 0.0385 0.26 0.26 Cervical cancer; chr13:40939112 chr13:40863599~40863902:- CESC cis rs17772222 0.958 rs74074098 ENSG00000258983.2 RP11-507K2.2 3.93 0.000112 0.0385 0.32 0.26 Coronary artery calcification; chr14:88484213 chr14:88499334~88515502:+ CESC cis rs17772222 0.876 rs12587528 ENSG00000258983.2 RP11-507K2.2 3.93 0.000112 0.0385 0.32 0.26 Coronary artery calcification; chr14:88487652 chr14:88499334~88515502:+ CESC cis rs17772222 0.837 rs1864748 ENSG00000258983.2 RP11-507K2.2 3.93 0.000112 0.0385 0.32 0.26 Coronary artery calcification; chr14:88488847 chr14:88499334~88515502:+ CESC cis rs10129255 0.536 rs6576201 ENSG00000280411.1 IGHV1-69-2 3.93 0.000112 0.0385 0.17 0.26 Kawasaki disease; chr14:106683696 chr14:106762092~106762588:- CESC cis rs1075265 0.62 rs10192626 ENSG00000272156.1 RP11-477N3.1 -3.93 0.000112 0.0385 -0.31 -0.26 Chronotype;Morning vs. evening chronotype; chr2:53760885 chr2:54082554~54085066:+ CESC cis rs10392 0.543 rs56660421 ENSG00000274825.1 RP4-616B8.5 -3.93 0.000112 0.0385 -0.27 -0.26 Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis; chr20:38930686 chr20:38955910~38956547:+ CESC cis rs2115630 0.905 rs6496401 ENSG00000225151.9 GOLGA2P7 3.93 0.000112 0.0385 0.29 0.26 P wave terminal force; chr15:84754562 chr15:84199311~84230136:- CESC cis rs2439831 0.867 rs6493082 ENSG00000275601.1 AC011330.13 -3.93 0.000112 0.0385 -0.34 -0.26 Lung cancer in ever smokers; chr15:43342610 chr15:43642389~43643023:- CESC cis rs2439831 0.867 rs8041132 ENSG00000275601.1 AC011330.13 -3.93 0.000112 0.0385 -0.34 -0.26 Lung cancer in ever smokers; chr15:43342938 chr15:43642389~43643023:- CESC cis rs10129255 0.518 rs7143784 ENSG00000211970.3 IGHV4-61 -3.93 0.000112 0.0386 -0.18 -0.26 Kawasaki disease; chr14:106687277 chr14:106639119~106639657:- CESC cis rs2281636 0.723 rs3740078 ENSG00000233690.1 EBAG9P1 3.93 0.000112 0.0386 0.27 0.26 Obesity-related traits; chr10:99685834 chr10:99697407~99697949:- CESC cis rs1799949 0.965 rs9646418 ENSG00000267681.1 CTD-3199J23.6 -3.93 0.000112 0.0386 -0.31 -0.26 Menopause (age at onset); chr17:43348533 chr17:43144956~43145255:+ CESC cis rs224278 0.509 rs4746746 ENSG00000238280.1 RP11-436D10.3 3.93 0.000112 0.0386 0.39 0.26 Ewing sarcoma; chr10:62940221 chr10:62793562~62805887:- CESC cis rs453301 0.624 rs6987558 ENSG00000173295.6 FAM86B3P 3.93 0.000112 0.0386 0.31 0.26 Joint mobility (Beighton score); chr8:9005011 chr8:8228595~8244865:+ CESC cis rs6740322 0.841 rs10210507 ENSG00000234936.1 AC010883.5 3.93 0.000112 0.0386 0.28 0.26 Coronary artery disease; chr2:43329497 chr2:43229573~43233394:+ CESC cis rs62025270 0.688 rs11073516 ENSG00000202081.1 RNU6-1280P -3.93 0.000112 0.0386 -0.36 -0.26 Idiopathic pulmonary fibrosis; chr15:85741996 chr15:85651522~85651628:- CESC cis rs3925075 0.531 rs4608351 ENSG00000260911.2 RP11-196G11.2 -3.93 0.000112 0.0386 -0.27 -0.26 IgA nephropathy; chr16:31337527 chr16:31043150~31049868:+ CESC cis rs3925075 0.531 rs4261553 ENSG00000260911.2 RP11-196G11.2 -3.93 0.000112 0.0386 -0.27 -0.26 IgA nephropathy; chr16:31337843 chr16:31043150~31049868:+ CESC cis rs72480748 0.509 rs3865457 ENSG00000269069.1 CTC-471F3.5 -3.93 0.000113 0.0386 -0.32 -0.26 Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);Post bronchodilator FEV1; chr19:40893064 chr19:40023384~40025502:- CESC cis rs2554380 0.628 rs4843158 ENSG00000230373.7 GOLGA6L5P -3.93 0.000113 0.0386 -0.32 -0.26 Height; chr15:83802884 chr15:84507885~84516814:- CESC cis rs6693388 0.601 rs2999512 ENSG00000229021.2 AL591893.1 3.93 0.000113 0.0386 0.29 0.26 Blood metabolite ratios; chr1:151973616 chr1:151994531~152042774:+ CESC cis rs875971 0.895 rs4145009 ENSG00000232559.3 GS1-124K5.12 -3.93 0.000113 0.0387 -0.28 -0.26 Aortic root size; chr7:66261628 chr7:66554588~66576923:- CESC cis rs1124769 0.619 rs12904435 ENSG00000259378.1 DCAF13P3 3.93 0.000113 0.0387 0.34 0.26 Cognitive performance; chr15:50818006 chr15:50944663~50945996:+ CESC cis rs61160187 0.582 rs1526896 ENSG00000215032.2 GNL3LP1 3.93 0.000113 0.0387 0.31 0.26 Educational attainment (years of education);Educational attainment (college completion); chr5:61063883 chr5:60891935~60893577:- CESC cis rs2243480 0.901 rs34807232 ENSG00000067601.7 PMS2P4 3.93 0.000113 0.0387 0.49 0.26 Diabetic kidney disease; chr7:66500146 chr7:67295608~67302907:- CESC cis rs9309473 0.95 rs6546849 ENSG00000163016.8 ALMS1P 3.93 0.000113 0.0387 0.32 0.26 Metabolite levels; chr2:73603910 chr2:73644919~73685576:+ CESC cis rs9309473 0.851 rs6546850 ENSG00000163016.8 ALMS1P 3.93 0.000113 0.0387 0.32 0.26 Metabolite levels; chr2:73604020 chr2:73644919~73685576:+ CESC cis rs9309473 0.898 rs6546852 ENSG00000163016.8 ALMS1P 3.93 0.000113 0.0387 0.32 0.26 Metabolite levels; chr2:73606304 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs6546853 ENSG00000163016.8 ALMS1P 3.93 0.000113 0.0387 0.32 0.26 Metabolite levels; chr2:73606612 chr2:73644919~73685576:+ CESC cis rs10392 0.516 rs3752293 ENSG00000274825.1 RP4-616B8.5 3.93 0.000113 0.0387 0.27 0.26 Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis; chr20:38942082 chr20:38955910~38956547:+ CESC cis rs17711722 0.528 rs73138179 ENSG00000226824.5 RP4-756H11.3 -3.93 0.000113 0.0387 -0.33 -0.26 Calcium levels; chr7:65829495 chr7:66654538~66669855:+ CESC cis rs769267 0.965 rs2074296 ENSG00000269131.1 AC004447.2 -3.93 0.000113 0.0387 -0.21 -0.26 Tonsillectomy; chr19:19262880 chr19:18990893~18993610:+ CESC cis rs7178909 0.872 rs57715404 ENSG00000259677.1 RP11-493E3.1 3.93 0.000113 0.0387 0.29 0.26 Common traits (Other); chr15:89890726 chr15:89876540~89877285:+ CESC cis rs7429990 0.965 rs800762 ENSG00000229759.1 MRPS18AP1 3.93 0.000113 0.0387 0.26 0.26 Educational attainment (years of education); chr3:47864080 chr3:48256350~48256938:- CESC cis rs644587 0.559 rs475825 ENSG00000260572.1 RP11-16N11.2 -3.93 0.000113 0.0387 -0.35 -0.26 Primary biliary cholangitis; chr3:159992541 chr3:160753428~160755142:- CESC cis rs644587 0.559 rs2243131 ENSG00000260572.1 RP11-16N11.2 -3.93 0.000113 0.0387 -0.35 -0.26 Primary biliary cholangitis; chr3:159994271 chr3:160753428~160755142:- CESC cis rs10129255 0.957 rs8009464 ENSG00000211974.3 IGHV2-70 3.93 0.000113 0.0387 0.26 0.26 Kawasaki disease; chr14:106777611 chr14:106723574~106724093:- CESC cis rs12220238 0.841 rs11000952 ENSG00000213731.2 RAB5CP1 -3.93 0.000113 0.0387 -0.43 -0.26 Soluble interleukin-2 receptor subunit alpha; chr10:74277578 chr10:74423435~74424014:- CESC cis rs2235544 0.565 rs72664114 ENSG00000225183.1 RP4-758J24.4 -3.93 0.000113 0.0387 -0.3 -0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54006074 chr1:54089856~54090093:+ CESC cis rs2235544 0.565 rs635059 ENSG00000225183.1 RP4-758J24.4 3.93 0.000113 0.0387 0.3 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54003447 chr1:54089856~54090093:+ CESC cis rs10788972 0.51 rs665817 ENSG00000225183.1 RP4-758J24.4 3.93 0.000113 0.0387 0.3 0.26 Parkinson disease and lewy body pathology; chr1:54004275 chr1:54089856~54090093:+ CESC cis rs2235544 0.542 rs585269 ENSG00000225183.1 RP4-758J24.4 3.93 0.000113 0.0387 0.3 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54004303 chr1:54089856~54090093:+ CESC cis rs2235544 0.542 rs11206272 ENSG00000225183.1 RP4-758J24.4 3.93 0.000113 0.0387 0.3 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54004362 chr1:54089856~54090093:+ CESC cis rs2235544 0.542 rs679801 ENSG00000225183.1 RP4-758J24.4 3.93 0.000113 0.0387 0.3 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54005084 chr1:54089856~54090093:+ CESC cis rs9322193 0.923 rs9766004 ENSG00000216906.2 RP11-350J20.9 3.93 0.000113 0.0388 0.29 0.26 Lung cancer; chr6:149754363 chr6:149904243~149906418:+ CESC cis rs7216064 0.734 rs12942774 ENSG00000267023.4 LRRC37A16P 3.93 0.000113 0.0388 0.23 0.26 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67971446 chr17:68125777~68152468:- CESC cis rs1345301 1 rs1420093 ENSG00000234389.1 AC007278.3 -3.93 0.000113 0.0388 -0.26 -0.26 Waist circumference; chr2:102253998 chr2:102438713~102440475:+ CESC cis rs1345301 1 rs10200410 ENSG00000234389.1 AC007278.3 -3.93 0.000113 0.0388 -0.26 -0.26 Waist circumference; chr2:102254411 chr2:102438713~102440475:+ CESC cis rs4713118 0.513 rs9368547 ENSG00000219392.1 RP1-265C24.5 -3.93 0.000113 0.0388 -0.3 -0.26 Parkinson's disease; chr6:28060289 chr6:28115628~28116551:+ CESC cis rs7811142 0.83 rs11765869 ENSG00000242294.5 STAG3L5P 3.93 0.000113 0.0388 0.28 0.26 Platelet count; chr7:100367166 chr7:100336079~100351900:+ CESC cis rs7811142 0.83 rs705866 ENSG00000242294.5 STAG3L5P 3.93 0.000113 0.0388 0.28 0.26 Platelet count; chr7:100367662 chr7:100336079~100351900:+ CESC cis rs7811142 0.83 rs6965458 ENSG00000242294.5 STAG3L5P 3.93 0.000113 0.0388 0.28 0.26 Platelet count; chr7:100375779 chr7:100336079~100351900:+ CESC cis rs7829975 0.509 rs7838674 ENSG00000253893.2 FAM85B 3.93 0.000113 0.0388 0.32 0.26 Mood instability; chr8:8939563 chr8:8167819~8226614:- CESC cis rs7826238 0.566 rs2945886 ENSG00000173295.6 FAM86B3P 3.93 0.000113 0.0388 0.33 0.26 Systolic blood pressure; chr8:8290748 chr8:8228595~8244865:+ CESC cis rs2412819 0.571 rs11070411 ENSG00000249839.1 AC011330.5 3.93 0.000113 0.0388 0.34 0.26 Lung cancer; chr15:43766436 chr15:43663654~43684339:- CESC cis rs915071 0.967 rs4981942 ENSG00000258655.2 ARHGAP5-AS1 3.93 0.000113 0.0388 0.32 0.26 Bipolar disorder and schizophrenia; chr14:31974140 chr14:32074946~32076793:- CESC cis rs703842 1 rs11172344 ENSG00000270039.1 RP11-571M6.17 -3.93 0.000113 0.0388 -0.31 -0.26 Multiple sclerosis; chr12:57799665 chr12:57803838~57804415:+ CESC cis rs703842 1 rs10783848 ENSG00000270039.1 RP11-571M6.17 -3.93 0.000113 0.0388 -0.31 -0.26 Multiple sclerosis; chr12:57802745 chr12:57803838~57804415:+ CESC cis rs9584850 0.574 rs60492361 ENSG00000231194.1 FARP1-AS1 3.93 0.000113 0.0388 0.35 0.26 Neuroticism; chr13:98520399 chr13:98435405~98435840:- CESC cis rs7937890 0.559 rs2597208 ENSG00000251991.1 RNU7-49P 3.93 0.000113 0.0388 0.27 0.26 Mitochondrial DNA levels; chr11:14450783 chr11:14478892~14478953:+ CESC cis rs4713118 0.513 rs183244 ENSG00000219392.1 RP1-265C24.5 -3.93 0.000113 0.0388 -0.3 -0.26 Parkinson's disease; chr6:28064060 chr6:28115628~28116551:+ CESC cis rs3892630 0.588 rs8106748 ENSG00000267475.1 CTD-2538C1.2 -3.93 0.000113 0.0388 -0.36 -0.26 Red blood cell traits; chr19:32791891 chr19:32687089~32691750:- CESC cis rs7210990 0.765 rs21180 ENSG00000278864.1 RP11-45M22.2 -3.93 0.000113 0.0388 -0.18 -0.26 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr17:16184694 chr17:17181504~17183257:+ CESC cis rs612683 0.658 rs12407689 ENSG00000261254.2 RP4-714D9.5 -3.93 0.000113 0.0388 -0.23 -0.26 Breast cancer; chr1:100534029 chr1:100030566~100035637:+ CESC cis rs10829156 0.538 rs61840846 ENSG00000240291.1 RP11-499P20.2 3.93 0.000113 0.0388 0.29 0.26 Sudden cardiac arrest; chr10:18606393 chr10:18513115~18545651:- CESC cis rs2290159 0.747 rs6777175 ENSG00000274514.1 Metazoa_SRP 3.93 0.000113 0.0389 0.34 0.26 Cholesterol, total; chr3:12604756 chr3:12576961~12577237:- CESC cis rs2290159 0.8 rs2290162 ENSG00000274514.1 Metazoa_SRP 3.93 0.000113 0.0389 0.34 0.26 Cholesterol, total; chr3:12605958 chr3:12576961~12577237:- CESC cis rs1707322 1 rs4660906 ENSG00000281133.1 AL355480.3 -3.93 0.000114 0.0389 -0.31 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46005188 chr1:45580892~45580996:- CESC cis rs6951245 0.745 rs79788515 ENSG00000229043.2 AC091729.9 -3.93 0.000114 0.0389 -0.39 -0.26 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1061443 chr7:1160374~1165267:+ CESC cis rs6142102 0.961 rs4911392 ENSG00000275784.1 RP5-1125A11.6 -3.93 0.000114 0.0389 -0.27 -0.26 Skin pigmentation; chr20:33982712 chr20:33989480~33991818:- CESC cis rs6142102 0.961 rs4911393 ENSG00000275784.1 RP5-1125A11.6 -3.93 0.000114 0.0389 -0.27 -0.26 Skin pigmentation; chr20:33983120 chr20:33989480~33991818:- CESC cis rs6142102 0.961 rs2300204 ENSG00000275784.1 RP5-1125A11.6 -3.93 0.000114 0.0389 -0.27 -0.26 Skin pigmentation; chr20:34000967 chr20:33989480~33991818:- CESC cis rs6142102 0.961 rs1055857 ENSG00000275784.1 RP5-1125A11.6 -3.93 0.000114 0.0389 -0.27 -0.26 Skin pigmentation; chr20:34026067 chr20:33989480~33991818:- CESC cis rs10779751 0.77 rs2486922 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11064828 chr1:11099675~11102100:+ CESC cis rs10779751 0.61 rs2486921 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11064886 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2261317 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11064922 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2486920 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11064993 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2039840 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11065809 chr1:11099675~11102100:+ CESC cis rs10779751 0.69 rs2791659 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11066512 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs6701726 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11066884 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2261217 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11067707 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2791658 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11067814 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2791657 ENSG00000230337.1 RP4-635E18.6 3.93 0.000114 0.0389 0.36 0.26 Body mass index; chr1:11067944 chr1:11099675~11102100:+ CESC cis rs10129255 0.53 rs11624912 ENSG00000280411.1 IGHV1-69-2 -3.93 0.000114 0.0389 -0.17 -0.26 Kawasaki disease; chr14:106673891 chr14:106762092~106762588:- CESC cis rs2243480 1 rs4548056 ENSG00000232559.3 GS1-124K5.12 3.93 0.000114 0.0389 0.41 0.26 Diabetic kidney disease; chr7:65833886 chr7:66554588~66576923:- CESC cis rs5742933 0.857 rs12471217 ENSG00000253559.1 OSGEPL1-AS1 3.93 0.000114 0.0389 0.31 0.26 Ferritin levels; chr2:189707337 chr2:189762704~189765556:+ CESC cis rs9907295 0.584 rs9913559 ENSG00000270977.1 AC015849.16 -3.93 0.000114 0.0389 -0.37 -0.26 Fibroblast growth factor basic levels; chr17:35930065 chr17:35893707~35911023:- CESC cis rs8072100 0.688 rs7221224 ENSG00000228782.6 CTD-2026D20.3 -3.93 0.000114 0.039 -0.31 -0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47341695 chr17:47450568~47492492:- CESC cis rs453301 0.682 rs2929451 ENSG00000254340.1 RP11-10A14.3 3.93 0.000114 0.039 0.3 0.26 Joint mobility (Beighton score); chr8:9227785 chr8:9141424~9145435:+ CESC cis rs8020095 0.571 rs8018750 ENSG00000258561.1 RP11-72M17.1 -3.93 0.000114 0.039 -0.38 -0.26 Depression (quantitative trait); chr14:66968850 chr14:66212810~66509394:- CESC cis rs6687821 0.531 rs7553360 ENSG00000267734.1 RP4-604K5.3 -3.93 0.000114 0.039 -0.29 -0.26 Yeast infection; chr1:87069032 chr1:86932199~86934891:- CESC cis rs916888 0.821 rs199504 ENSG00000232300.1 FAM215B -3.93 0.000114 0.039 -0.41 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46558830~46562795:- CESC cis rs6782228 0.848 rs6439140 ENSG00000242551.2 POU5F1P6 3.93 0.000114 0.039 0.31 0.26 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128699917 chr3:128674735~128677005:- CESC cis rs972578 0.715 rs738537 ENSG00000274717.1 RP1-47A17.1 -3.93 0.000114 0.039 -0.3 -0.26 Mean platelet volume; chr22:42881916 chr22:42791814~42794313:- CESC cis rs2412819 0.571 rs514255 ENSG00000249839.1 AC011330.5 -3.93 0.000114 0.039 -0.33 -0.26 Lung cancer; chr15:43893134 chr15:43663654~43684339:- CESC cis rs2991971 0.81 rs781058 ENSG00000280836.1 AL355480.1 -3.93 0.000114 0.039 -0.28 -0.26 High light scatter reticulocyte count; chr1:45469384 chr1:45581219~45581321:- CESC cis rs17818399 0.788 rs17818315 ENSG00000279254.1 RP11-536C12.1 -3.93 0.000114 0.039 -0.32 -0.26 Height; chr2:46591853 chr2:46668870~46670778:+ CESC cis rs75422866 0.702 rs12426387 ENSG00000257433.4 RP1-197B17.3 3.93 0.000114 0.039 0.71 0.26 Pneumonia; chr12:47582915 chr12:47706085~47742294:+ CESC cis rs75422866 0.85 rs12423789 ENSG00000257433.4 RP1-197B17.3 3.93 0.000114 0.039 0.71 0.26 Pneumonia; chr12:47583112 chr12:47706085~47742294:+ CESC cis rs75422866 0.702 rs73111229 ENSG00000257433.4 RP1-197B17.3 3.93 0.000114 0.039 0.71 0.26 Pneumonia; chr12:47583333 chr12:47706085~47742294:+ CESC cis rs12435908 1 rs10083488 ENSG00000259078.2 PTBP1P 3.93 0.000114 0.039 0.4 0.26 Ischemic stroke; chr14:65386628 chr14:65279267~65281166:+ CESC cis rs11159086 0.941 rs11846588 ENSG00000270000.1 RP3-449M8.9 3.93 0.000114 0.039 0.46 0.26 Advanced glycation end-product levels; chr14:74505398 chr14:74471930~74472360:- CESC cis rs62344088 0.59 rs6889904 ENSG00000250848.1 CTD-2083E4.5 -3.93 0.000114 0.039 -0.43 -0.26 Asthma (childhood onset); chr5:177149 chr5:288833~290321:- CESC cis rs8080784 1 rs9914032 ENSG00000266992.1 DHX40P1 3.93 0.000114 0.0391 0.33 0.26 Coronary artery disease; chr17:60890424 chr17:59976009~60002384:- CESC cis rs8080784 1 rs9303430 ENSG00000266992.1 DHX40P1 3.93 0.000114 0.0391 0.33 0.26 Coronary artery disease; chr17:60891695 chr17:59976009~60002384:- CESC cis rs783540 0.934 rs10400906 ENSG00000276710.3 CSPG4P8 -3.93 0.000114 0.0391 -0.27 -0.26 Schizophrenia; chr15:82628387 chr15:82459472~82477258:+ CESC cis rs9322193 0.884 rs7769115 ENSG00000223701.3 RAET1E-AS1 3.93 0.000114 0.0391 0.3 0.26 Lung cancer; chr6:149848796 chr6:149884431~149919508:+ CESC cis rs5742933 0.817 rs7591929 ENSG00000273240.1 RP11-455J20.3 3.93 0.000114 0.0391 0.28 0.26 Ferritin levels; chr2:189778531 chr2:189763859~189764456:- CESC cis rs2243480 0.615 rs34363376 ENSG00000067601.7 PMS2P4 3.93 0.000114 0.0391 0.5 0.26 Diabetic kidney disease; chr7:66474549 chr7:67295608~67302907:- CESC cis rs9987353 0.566 rs34389718 ENSG00000173295.6 FAM86B3P -3.93 0.000114 0.0391 -0.34 -0.26 Recombination measurement; chr8:9208015 chr8:8228595~8244865:+ CESC cis rs8059260 1 rs6498138 ENSG00000274038.1 RP11-66H6.4 3.93 0.000114 0.0391 0.35 0.26 Alcohol consumption over the past year; chr16:10951421 chr16:11056556~11057034:+ CESC cis rs67180937 0.553 rs2936023 ENSG00000272750.1 RP11-378J18.8 3.93 0.000114 0.0391 0.36 0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222656989 chr1:222658867~222661512:- CESC cis rs74394007 0.92 rs7609851 ENSG00000244515.1 KRT18P34 3.93 0.000114 0.0391 0.42 0.26 Total body bone mineral density; chr3:156920714 chr3:157162663~157163932:- CESC cis rs9309473 1 rs1534471 ENSG00000163016.8 ALMS1P 3.93 0.000115 0.0392 0.32 0.26 Metabolite levels; chr2:73420380 chr2:73644919~73685576:+ CESC cis rs2842992 0.724 rs9365097 ENSG00000237927.1 RP3-393E18.2 -3.93 0.000115 0.0392 -0.32 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159790227 chr6:159586955~159589169:- CESC cis rs7560272 0.501 rs2006997 ENSG00000163016.8 ALMS1P -3.93 0.000115 0.0392 -0.32 -0.26 Schizophrenia; chr2:73720719 chr2:73644919~73685576:+ CESC cis rs7524102 0.636 rs59016073 ENSG00000218510.5 LINC00339 -3.93 0.000115 0.0392 -0.35 -0.26 Bone mineral density;Ulcerative colitis;Bone mineral density (spine);Dupuytren's disease;Bone mineral density (hip); chr1:22382802 chr1:22025188~22031223:+ CESC cis rs733592 0.507 rs56129148 ENSG00000257735.1 RP11-370I10.6 -3.93 0.000115 0.0392 -0.28 -0.26 Plateletcrit; chr12:48091747 chr12:48350945~48442411:+ CESC cis rs6080212 0.859 rs4563306 ENSG00000228809.2 RP4-705D16.3 3.93 0.000115 0.0392 0.38 0.26 Emphysema imaging phenotypes; chr20:16305985 chr20:16714844~16730948:- CESC cis rs12144049 0.696 rs4845434 ENSG00000227045.1 RP11-98D18.1 -3.93 0.000115 0.0392 -0.39 -0.26 Inflammatory skin disease;Atopic dermatitis; chr1:152442086 chr1:151701026~151708386:+ CESC cis rs12144049 0.705 rs4240880 ENSG00000227045.1 RP11-98D18.1 -3.93 0.000115 0.0392 -0.39 -0.26 Inflammatory skin disease;Atopic dermatitis; chr1:152442394 chr1:151701026~151708386:+ CESC cis rs11159086 1 rs8006909 ENSG00000259005.1 RP3-449M8.6 3.93 0.000115 0.0392 0.42 0.26 Advanced glycation end-product levels; chr14:74478085 chr14:74474007~74474864:- CESC cis rs11159086 1 rs8006958 ENSG00000259005.1 RP3-449M8.6 3.93 0.000115 0.0392 0.42 0.26 Advanced glycation end-product levels; chr14:74478148 chr14:74474007~74474864:- CESC cis rs13179411 0.517 rs34981024 ENSG00000273345.4 CTD-2410N18.4 -3.93 0.000115 0.0392 -0.26 -0.26 Menarche (age at onset); chr5:134563661 chr5:134205614~134371044:- CESC cis rs2115630 1 rs11854313 ENSG00000225151.9 GOLGA2P7 3.93 0.000115 0.0392 0.29 0.26 P wave terminal force; chr15:84760817 chr15:84199311~84230136:- CESC cis rs12935418 0.83 rs12928638 ENSG00000261838.4 RP11-303E16.6 3.93 0.000115 0.0392 0.43 0.26 Mean corpuscular volume; chr16:81016195 chr16:81069854~81076598:+ CESC cis rs13113518 0.966 rs13144598 ENSG00000273257.1 RP11-177J6.1 3.93 0.000115 0.0392 0.34 0.26 Height; chr4:55570311 chr4:55387949~55388271:+ CESC cis rs9487094 0.67 rs11755641 ENSG00000260273.1 RP11-425D10.10 3.93 0.000115 0.0392 0.33 0.26 Height; chr6:109586733 chr6:109382795~109383666:+ CESC cis rs1838105 0.64 rs12603447 ENSG00000263142.4 LRRC37A17P 3.93 0.000115 0.0393 0.2 0.26 Nonsyndromic cleft lip with cleft palate; chr17:47068871 chr17:46978481~47054569:+ CESC cis rs2281636 0.723 rs1128642 ENSG00000233690.1 EBAG9P1 3.93 0.000115 0.0393 0.27 0.26 Obesity-related traits; chr10:99711938 chr10:99697407~99697949:- CESC cis rs10829156 0.741 rs9731044 ENSG00000240291.1 RP11-499P20.2 3.93 0.000115 0.0393 0.29 0.26 Sudden cardiac arrest; chr10:18605356 chr10:18513115~18545651:- CESC cis rs2286503 0.65 rs1990279 ENSG00000221740.1 SNORD93 3.93 0.000115 0.0393 0.26 0.26 Fibrinogen; chr7:22851123 chr7:22856613~22856686:+ CESC cis rs853679 1 rs1778511 ENSG00000219392.1 RP1-265C24.5 3.93 0.000115 0.0393 0.38 0.26 Depression; chr6:28261633 chr6:28115628~28116551:+ CESC cis rs11089937 0.524 rs2877021 ENSG00000183506.15 PI4KAP2 3.93 0.000115 0.0393 0.29 0.26 Periodontitis (PAL4Q3); chr22:22165909 chr22:21473000~21517533:- CESC cis rs2243480 1 rs313814 ENSG00000275400.1 RP4-756H11.5 3.93 0.000115 0.0393 0.43 0.26 Diabetic kidney disease; chr7:66038306 chr7:66553805~66554199:- CESC cis rs9595066 0.712 rs4391951 ENSG00000227258.4 SMIM2-AS1 -3.93 0.000115 0.0393 -0.38 -0.26 Schizophrenia; chr13:44180935 chr13:44110451~44240517:+ CESC cis rs2333194 0.772 rs12589739 ENSG00000258559.2 AC005519.4 3.93 0.000115 0.0393 0.2 0.26 Bipolar disorder with mood-incongruent psychosis; chr14:73436348 chr14:74289127~74294425:- CESC cis rs6740322 0.643 rs13390381 ENSG00000234936.1 AC010883.5 3.93 0.000115 0.0393 0.28 0.26 Coronary artery disease; chr2:43307275 chr2:43229573~43233394:+ CESC cis rs9323326 0.602 rs8018047 ENSG00000257621.6 PSMA3-AS1 3.93 0.000115 0.0393 0.24 0.26 Gut microbiota (bacterial taxa); chr14:58038944 chr14:58265365~58298134:- CESC cis rs988913 0.706 rs7761336 ENSG00000224984.1 RP11-524H19.2 3.93 0.000115 0.0394 0.26 0.26 Menarche (age at onset); chr6:54869804 chr6:54840118~54840855:- CESC cis rs35740288 0.929 rs11630585 ENSG00000202081.1 RNU6-1280P 3.93 0.000115 0.0394 0.32 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85762773 chr15:85651522~85651628:- CESC cis rs35740288 0.929 rs11636821 ENSG00000202081.1 RNU6-1280P 3.93 0.000115 0.0394 0.32 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85762774 chr15:85651522~85651628:- CESC cis rs35740288 0.929 rs11630684 ENSG00000202081.1 RNU6-1280P 3.93 0.000115 0.0394 0.32 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85763025 chr15:85651522~85651628:- CESC cis rs2439831 0.85 rs9944216 ENSG00000275601.1 AC011330.13 3.93 0.000115 0.0394 0.41 0.26 Lung cancer in ever smokers; chr15:43868575 chr15:43642389~43643023:- CESC cis rs3824347 0.739 rs11144194 ENSG00000203321.2 C9orf41-AS1 3.93 0.000115 0.0394 0.26 0.26 Urinary magnesium-to-creatinine ratio; chr9:75021996 chr9:74952968~74996293:+ CESC cis rs35123781 0.654 rs356486 ENSG00000250635.1 CTD-3224K15.2 3.93 0.000115 0.0394 0.33 0.26 Schizophrenia; chr5:139705518 chr5:139648999~139649728:- CESC cis rs17301013 0.507 rs12066504 ENSG00000227373.4 RP11-160H22.5 3.93 0.000115 0.0394 0.36 0.26 Systemic lupus erythematosus; chr1:174288695 chr1:174115300~174160004:- CESC cis rs988913 0.706 rs1155749 ENSG00000224984.1 RP11-524H19.2 3.93 0.000115 0.0394 0.26 0.26 Menarche (age at onset); chr6:54865585 chr6:54840118~54840855:- CESC cis rs13113518 0.557 rs13142096 ENSG00000249700.7 SRD5A3-AS1 3.93 0.000115 0.0394 0.33 0.26 Height; chr4:55566291 chr4:55363971~55395847:- CESC cis rs2836950 0.52 rs8133927 ENSG00000255568.3 BRWD1-AS2 -3.93 0.000115 0.0394 -0.21 -0.26 Menarche (age at onset); chr21:39318035 chr21:39313935~39314962:+ CESC cis rs2836950 0.52 rs8133928 ENSG00000255568.3 BRWD1-AS2 -3.93 0.000115 0.0394 -0.21 -0.26 Menarche (age at onset); chr21:39318037 chr21:39313935~39314962:+ CESC cis rs11971779 0.68 rs4728465 ENSG00000273391.1 RP11-634H22.1 3.93 0.000115 0.0394 0.26 0.26 Diisocyanate-induced asthma; chr7:139384315 chr7:139359032~139359566:- CESC cis rs11971779 0.715 rs55714903 ENSG00000273391.1 RP11-634H22.1 3.93 0.000115 0.0394 0.26 0.26 Diisocyanate-induced asthma; chr7:139389844 chr7:139359032~139359566:- CESC cis rs10129255 0.5 rs8021941 ENSG00000224373.3 IGHV4-59 3.93 0.000115 0.0394 0.16 0.26 Kawasaki disease; chr14:106781490 chr14:106627249~106627825:- CESC cis rs76878669 0.561 rs2236679 ENSG00000255468.5 RP11-867G23.8 3.93 0.000115 0.0394 0.29 0.26 Educational attainment (years of education); chr11:66341423 chr11:66347950~66364804:+ CESC cis rs4686914 0.963 rs11924318 ENSG00000228804.4 RP11-211G3.3 3.93 0.000115 0.0394 0.3 0.26 Metabolite levels; chr3:188009727 chr3:187702313~187733849:+ CESC cis rs769267 0.965 rs2074550 ENSG00000269131.1 AC004447.2 -3.93 0.000115 0.0394 -0.21 -0.26 Tonsillectomy; chr19:19276934 chr19:18990893~18993610:+ CESC cis rs6556937 0.627 rs4590196 ENSG00000251314.2 CTD-2337A12.1 3.93 0.000116 0.0394 0.33 0.26 Blood protein levels; chr5:96661581 chr5:95962001~96631085:+ CESC cis rs6504950 0.566 rs7208403 ENSG00000275710.1 RP11-257O5.4 3.93 0.000116 0.0394 0.27 0.26 Breast cancer; chr17:54969306 chr17:54964474~54964679:+ CESC cis rs11096990 0.892 rs11931354 ENSG00000249207.1 RP11-360F5.1 3.93 0.000116 0.0394 0.3 0.26 Cognitive function; chr4:39229856 chr4:39112677~39126818:- CESC cis rs6921919 0.583 rs2041230 ENSG00000216901.1 AL022393.7 3.93 0.000116 0.0394 0.28 0.26 Autism spectrum disorder or schizophrenia; chr6:28397738 chr6:28176188~28176674:+ CESC cis rs8031584 0.541 rs1983459 ENSG00000270015.1 RP11-540B6.6 -3.93 0.000116 0.0394 -0.25 -0.26 Huntington's disease progression; chr15:30916546 chr15:30926514~30928407:+ CESC cis rs6504663 0.558 rs7627 ENSG00000262006.1 RP11-700H6.4 3.93 0.000116 0.0394 0.32 0.26 Visceral fat; chr17:50474793 chr17:50909637~50910232:- CESC cis rs77972916 0.505 rs6727824 ENSG00000276967.1 AC019129.2 -3.93 0.000116 0.0395 -0.38 -0.26 Granulocyte percentage of myeloid white cells; chr2:43301238 chr2:44065488~44065544:- CESC cis rs875971 1 rs2036264 ENSG00000232559.3 GS1-124K5.12 -3.93 0.000116 0.0395 -0.28 -0.26 Aortic root size; chr7:66334917 chr7:66554588~66576923:- CESC cis rs875971 1 rs7783613 ENSG00000232559.3 GS1-124K5.12 -3.93 0.000116 0.0395 -0.28 -0.26 Aortic root size; chr7:66340274 chr7:66554588~66576923:- CESC cis rs2836950 0.545 rs8132143 ENSG00000255568.3 BRWD1-AS2 -3.93 0.000116 0.0395 -0.21 -0.26 Menarche (age at onset); chr21:39212332 chr21:39313935~39314962:+ CESC cis rs7829975 0.501 rs4840353 ENSG00000253893.2 FAM85B 3.93 0.000116 0.0395 0.34 0.26 Mood instability; chr8:8723060 chr8:8167819~8226614:- CESC cis rs67311347 1 rs951560 ENSG00000223797.4 ENTPD3-AS1 3.93 0.000116 0.0395 0.25 0.26 Renal cell carcinoma; chr3:40421980 chr3:40313802~40453329:- CESC cis rs490234 0.812 rs12341150 ENSG00000232630.1 PRPS1P2 -3.93 0.000116 0.0395 -0.22 -0.26 Mean arterial pressure; chr9:125578491 chr9:125150653~125151589:+ CESC cis rs11633886 0.528 rs2460632 ENSG00000273972.1 CTD-2306A12.1 3.93 0.000116 0.0395 0.3 0.26 Diisocyanate-induced asthma; chr15:45803763 chr15:45702640~45703183:+ CESC cis rs7572733 0.576 rs6734781 ENSG00000222017.1 AC011997.1 3.93 0.000116 0.0395 0.33 0.26 Dermatomyositis; chr2:197895249 chr2:197693106~197774823:+ CESC cis rs2243480 0.708 rs35825036 ENSG00000067601.7 PMS2P4 3.93 0.000116 0.0395 0.49 0.26 Diabetic kidney disease; chr7:66521515 chr7:67295608~67302907:- CESC cis rs2243480 0.803 rs13224048 ENSG00000067601.7 PMS2P4 3.93 0.000116 0.0395 0.49 0.26 Diabetic kidney disease; chr7:66528779 chr7:67295608~67302907:- CESC cis rs2243480 1 rs13237037 ENSG00000067601.7 PMS2P4 3.93 0.000116 0.0395 0.49 0.26 Diabetic kidney disease; chr7:66532895 chr7:67295608~67302907:- CESC cis rs116175783 0.557 rs2303318 ENSG00000227403.1 AC009299.3 3.93 0.000116 0.0395 0.42 0.26 Intelligence (multi-trait analysis); chr2:161367984 chr2:161244739~161249050:+ CESC cis rs76878669 0.561 rs10750784 ENSG00000255468.5 RP11-867G23.8 3.93 0.000116 0.0395 0.29 0.26 Educational attainment (years of education); chr11:66343195 chr11:66347950~66364804:+ CESC cis rs116966368 0.602 rs1496478 ENSG00000266296.1 ARIH2P1 3.93 0.000116 0.0395 0.33 0.26 Neuroticism; chr18:28688999 chr18:28651732~28653208:+ CESC cis rs8031584 0.56 rs7171208 ENSG00000260382.1 RP11-540B6.2 -3.93 0.000116 0.0395 -0.34 -0.26 Huntington's disease progression; chr15:30906726 chr15:30882267~30883231:- CESC cis rs1538970 0.962 rs3219472 ENSG00000280836.1 AL355480.1 3.93 0.000116 0.0395 0.34 0.26 Platelet count; chr1:45338378 chr1:45581219~45581321:- CESC cis rs950776 0.518 rs8025429 ENSG00000279373.1 RP11-650L12.4 -3.93 0.000116 0.0395 -0.3 -0.26 Sudden cardiac arrest; chr15:78544020 chr15:78537681~78538946:+ CESC cis rs4919687 0.679 rs12762176 ENSG00000236937.2 PTGES3P4 3.93 0.000116 0.0395 0.35 0.26 Colorectal cancer; chr10:102739475 chr10:102845595~102845950:+ CESC cis rs7688540 0.771 rs12505835 ENSG00000211553.1 AC253576.2 -3.93 0.000116 0.0395 -0.41 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:303736 chr4:136461~136568:+ CESC cis rs6504622 0.537 rs1662577 ENSG00000263142.4 LRRC37A17P 3.93 0.000116 0.0395 0.2 0.26 Orofacial clefts; chr17:46919393 chr17:46978481~47054569:+ CESC cis rs6504622 0.537 rs2920397 ENSG00000263142.4 LRRC37A17P 3.93 0.000116 0.0395 0.2 0.26 Orofacial clefts; chr17:46919963 chr17:46978481~47054569:+ CESC cis rs17767392 0.67 rs2159145 ENSG00000266869.1 RP6-114E22.1 -3.93 0.000116 0.0396 -0.36 -0.26 Mitral valve prolapse; chr14:71259634 chr14:71848606~71908430:+ CESC cis rs9311474 0.713 rs352165 ENSG00000243224.1 RP5-1157M23.2 -3.93 0.000116 0.0396 -0.26 -0.26 Electroencephalogram traits; chr3:52208886 chr3:52239258~52241097:+ CESC cis rs4489787 0.568 rs2731065 ENSG00000206612.1 SNORA2A 3.93 0.000116 0.0396 0.29 0.26 Prostate cancer (SNP x SNP interaction); chr12:48499140 chr12:48656648~48656782:- CESC cis rs224278 0.531 rs7071512 ENSG00000238280.1 RP11-436D10.3 -3.93 0.000116 0.0396 -0.39 -0.26 Ewing sarcoma; chr10:62916880 chr10:62793562~62805887:- CESC cis rs875971 0.545 rs10950029 ENSG00000224316.1 RP11-479O9.2 3.93 0.000116 0.0396 0.33 0.26 Aortic root size; chr7:66169334 chr7:65773620~65802067:+ CESC cis rs13108904 0.521 rs4974609 ENSG00000254094.1 AC078852.1 3.93 0.000116 0.0396 0.3 0.26 Obesity-related traits; chr4:1363136 chr4:1356581~1358075:+ CESC cis rs2688608 0.592 rs10824032 ENSG00000242288.9 RP11-464F9.1 3.93 0.000116 0.0396 0.28 0.26 Inflammatory bowel disease; chr10:73768372 chr10:73674295~73730466:- CESC cis rs11089937 0.626 rs11704092 ENSG00000211638.2 IGLV8-61 -3.93 0.000116 0.0396 -0.26 -0.26 Periodontitis (PAL4Q3); chr22:22135815 chr22:22098700~22099212:+ CESC cis rs12745968 0.652 rs4565725 ENSG00000223787.2 RP4-593M8.1 -3.93 0.000116 0.0396 -0.35 -0.26 Bipolar disorder and schizophrenia; chr1:92485380 chr1:92580476~92580821:- CESC cis rs17507216 0.681 rs28877110 ENSG00000255769.6 GOLGA2P10 -3.93 0.000116 0.0396 -0.4 -0.26 Excessive daytime sleepiness; chr15:82672111 chr15:82472993~82513950:- CESC cis rs11638352 1 rs1808509 ENSG00000275601.1 AC011330.13 3.92 0.000116 0.0396 0.39 0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44117341 chr15:43642389~43643023:- CESC cis rs11638352 1 rs2555385 ENSG00000275601.1 AC011330.13 3.92 0.000116 0.0396 0.39 0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44127261 chr15:43642389~43643023:- CESC cis rs783540 0.542 rs62009945 ENSG00000278202.1 RP11-152F13.8 3.92 0.000116 0.0396 0.24 0.26 Schizophrenia; chr15:82631205 chr15:82418651~82434235:+ CESC cis rs7727544 1 rs7727038 ENSG00000233006.5 AC034220.3 3.92 0.000116 0.0396 0.28 0.26 Blood metabolite levels; chr5:132254564 chr5:132311285~132369916:- CESC cis rs7727544 1 rs7727544 ENSG00000233006.5 AC034220.3 3.92 0.000116 0.0396 0.28 0.26 Blood metabolite levels; chr5:132254841 chr5:132311285~132369916:- CESC cis rs2276314 1 rs9956938 ENSG00000278986.1 RP11-723J4.3 -3.92 0.000116 0.0396 -0.3 -0.26 Endometriosis;Drug-induced torsades de pointes; chr18:35987098 chr18:35972151~35973916:+ CESC cis rs2243480 1 rs4718270 ENSG00000275400.1 RP4-756H11.5 3.92 0.000116 0.0397 0.44 0.26 Diabetic kidney disease; chr7:65737415 chr7:66553805~66554199:- CESC cis rs10129255 0.5 rs1024350 ENSG00000211970.3 IGHV4-61 -3.92 0.000116 0.0397 -0.18 -0.26 Kawasaki disease; chr14:106685105 chr14:106639119~106639657:- CESC cis rs1113500 0.799 rs1777459 ENSG00000226822.1 RP11-356N1.2 -3.92 0.000116 0.0397 -0.34 -0.26 Growth-regulated protein alpha levels; chr1:108042377 chr1:108071482~108074519:+ CESC cis rs117533700 1 rs10410950 ENSG00000267633.1 CTB-5E10.3 3.92 0.000116 0.0397 0.58 0.26 Monocyte count; chr19:13018047 chr19:13772118~13774118:- CESC cis rs11971779 0.68 rs7805824 ENSG00000273391.1 RP11-634H22.1 -3.92 0.000117 0.0397 -0.25 -0.26 Diisocyanate-induced asthma; chr7:139426423 chr7:139359032~139359566:- CESC cis rs13108904 0.56 rs11247994 ENSG00000254094.1 AC078852.1 -3.92 0.000117 0.0397 -0.32 -0.26 Obesity-related traits; chr4:1349932 chr4:1356581~1358075:+ CESC cis rs881375 0.934 rs2159778 ENSG00000226752.6 PSMD5-AS1 -3.92 0.000117 0.0397 -0.28 -0.26 Rheumatoid arthritis; chr9:120915851 chr9:120824828~120854385:+ CESC cis rs57549656 0.615 rs8105469 ENSG00000279590.1 AC005786.6 3.92 0.000117 0.0397 0.31 0.26 Schizophrenia; chr19:2678888 chr19:3567278~3567959:- CESC cis rs1113500 0.933 rs61797344 ENSG00000226822.1 RP11-356N1.2 3.92 0.000117 0.0397 0.33 0.26 Growth-regulated protein alpha levels; chr1:108079958 chr1:108071482~108074519:+ CESC cis rs75422866 0.541 rs12425816 ENSG00000257433.4 RP1-197B17.3 3.92 0.000117 0.0397 0.66 0.26 Pneumonia; chr12:47731419 chr12:47706085~47742294:+ CESC cis rs75422866 0.51 rs73105829 ENSG00000257433.4 RP1-197B17.3 3.92 0.000117 0.0397 0.66 0.26 Pneumonia; chr12:47734162 chr12:47706085~47742294:+ CESC cis rs7560272 0.501 rs11894953 ENSG00000273245.1 RP11-434P11.2 3.92 0.000117 0.0397 0.32 0.26 Schizophrenia; chr2:73737504 chr2:73750256~73750786:- CESC cis rs4423214 0.592 rs10898223 ENSG00000254682.1 RP11-660L16.2 -3.92 0.000117 0.0397 -0.38 -0.26 Vitamin D levels; chr11:71508218 chr11:71448674~71452157:+ CESC cis rs987724 0.512 rs9842198 ENSG00000240875.4 LINC00886 -3.92 0.000117 0.0397 -0.32 -0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156821415 chr3:156747346~156817062:- CESC cis rs9925964 0.967 rs2855475 ENSG00000260911.2 RP11-196G11.2 3.92 0.000117 0.0397 0.28 0.26 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31136227 chr16:31043150~31049868:+ CESC cis rs2898290 0.54 rs12677146 ENSG00000255046.1 RP11-297N6.4 3.92 0.000117 0.0398 0.28 0.26 Systolic blood pressure; chr8:11593228 chr8:11797928~11802568:- CESC cis rs6844153 0.627 rs11730235 ENSG00000240005.4 RP11-293A21.1 -3.92 0.000117 0.0398 -0.35 -0.26 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26922822 chr4:26859806~26860599:- CESC cis rs2552220 0.548 rs2700710 ENSG00000246089.3 RP11-115C21.2 -3.92 0.000117 0.0398 -0.27 -0.26 Interleukin-8 levels; chr8:6138063 chr8:6403551~6407142:- CESC cis rs2552220 0.868 rs13268844 ENSG00000246089.3 RP11-115C21.2 -3.92 0.000117 0.0398 -0.27 -0.26 Interleukin-8 levels; chr8:6138065 chr8:6403551~6407142:- CESC cis rs763121 0.853 rs2284073 ENSG00000228274.3 RP3-508I15.9 -3.92 0.000117 0.0398 -0.24 -0.26 Menopause (age at onset); chr22:38709943 chr22:38667585~38681820:- CESC cis rs10039254 0.712 rs2303644 ENSG00000249140.1 PRDX2P3 3.92 0.000117 0.0398 0.32 0.26 Attention deficit hyperactivity disorder (time to onset); chr5:179128044 chr5:179572156~179572741:+ CESC cis rs8020095 0.571 rs7145917 ENSG00000258561.1 RP11-72M17.1 -3.92 0.000117 0.0398 -0.38 -0.26 Depression (quantitative trait); chr14:66905809 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs728647 ENSG00000258561.1 RP11-72M17.1 -3.92 0.000117 0.0398 -0.38 -0.26 Depression (quantitative trait); chr14:66911338 chr14:66212810~66509394:- CESC cis rs61776719 0.52 rs11485595 ENSG00000212541.1 RNU6-510P -3.92 0.000117 0.0398 -0.29 -0.26 Coronary artery disease; chr1:37945678 chr1:37991462~37991569:+ CESC cis rs4319547 0.737 rs10773176 ENSG00000275265.1 RP11-15J22.8 -3.92 0.000117 0.0398 -0.33 -0.26 Body mass index; chr12:122460166 chr12:122501187~122501641:+ CESC cis rs4319547 0.698 rs10773178 ENSG00000275265.1 RP11-15J22.8 -3.92 0.000117 0.0398 -0.33 -0.26 Body mass index; chr12:122460205 chr12:122501187~122501641:+ CESC cis rs3750965 0.959 rs3168115 ENSG00000260895.1 RP11-554A11.7 -3.92 0.000117 0.0398 -0.31 -0.26 Hair color; chr11:69090622 chr11:69103493~69109094:+ CESC cis rs11685222 0.589 rs72965093 ENSG00000229326.3 AC069154.4 3.92 0.000117 0.0398 0.36 0.26 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119674583 chr2:119698623~119700151:+ CESC cis rs11685222 0.64 rs73948943 ENSG00000229326.3 AC069154.4 3.92 0.000117 0.0398 0.36 0.26 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119675043 chr2:119698623~119700151:+ CESC cis rs748404 0.697 rs505249 ENSG00000249839.1 AC011330.5 -3.92 0.000117 0.0398 -0.27 -0.26 Lung cancer; chr15:43267762 chr15:43663654~43684339:- CESC cis rs7824557 0.724 rs2251473 ENSG00000269918.1 AF131215.9 3.92 0.000117 0.0398 0.32 0.26 Retinal vascular caliber; chr8:11319617 chr8:11104691~11106704:- CESC cis rs72946119 0.5 rs1549116 ENSG00000229267.2 AC072062.1 -3.92 0.000117 0.0398 -0.27 -0.26 Post bronchodilator FEV1/FVC ratio in COPD; chr2:214244866 chr2:214810229~214963274:+ CESC cis rs736408 0.609 rs2336545 ENSG00000243224.1 RP5-1157M23.2 3.92 0.000117 0.0398 0.27 0.26 Bipolar disorder; chr3:52753587 chr3:52239258~52241097:+ CESC cis rs8080784 1 rs9915526 ENSG00000266992.1 DHX40P1 3.92 0.000117 0.0398 0.33 0.26 Coronary artery disease; chr17:60906188 chr17:59976009~60002384:- CESC cis rs8080784 1 rs6504005 ENSG00000266992.1 DHX40P1 3.92 0.000117 0.0398 0.33 0.26 Coronary artery disease; chr17:60908676 chr17:59976009~60002384:- CESC cis rs8080784 1 rs9900518 ENSG00000266992.1 DHX40P1 3.92 0.000117 0.0398 0.33 0.26 Coronary artery disease; chr17:60913418 chr17:59976009~60002384:- CESC cis rs8080784 0.932 rs2120222 ENSG00000266992.1 DHX40P1 3.92 0.000117 0.0398 0.33 0.26 Coronary artery disease; chr17:60918847 chr17:59976009~60002384:- CESC cis rs12745968 0.652 rs11164601 ENSG00000223787.2 RP4-593M8.1 -3.92 0.000117 0.0398 -0.35 -0.26 Bipolar disorder and schizophrenia; chr1:92479950 chr1:92580476~92580821:- CESC cis rs761746 0.96 rs5998035 ENSG00000236132.1 CTA-440B3.1 -3.92 0.000117 0.0398 -0.32 -0.26 Intelligence; chr22:31543626 chr22:31816379~31817491:- CESC cis rs17772222 0.876 rs12586348 ENSG00000258983.2 RP11-507K2.2 3.92 0.000117 0.0398 0.32 0.26 Coronary artery calcification; chr14:88643523 chr14:88499334~88515502:+ CESC cis rs17666538 0.585 rs336444 ENSG00000254207.1 RP11-43A14.1 -3.92 0.000117 0.0398 -0.47 -0.26 IgG glycosylation; chr8:683123 chr8:725188~725877:- CESC cis rs2243480 1 rs383402 ENSG00000226824.5 RP4-756H11.3 3.92 0.000117 0.0399 0.47 0.26 Diabetic kidney disease; chr7:66121666 chr7:66654538~66669855:+ CESC cis rs12134133 1 rs11584921 ENSG00000274245.1 RP11-357P18.2 3.92 0.000117 0.0399 0.33 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207268630 chr1:207372559~207373252:+ CESC cis rs1908814 0.503 rs34657250 ENSG00000269918.1 AF131215.9 -3.92 0.000117 0.0399 -0.31 -0.26 Neuroticism; chr8:11937864 chr8:11104691~11106704:- CESC cis rs10043775 1 rs10043775 ENSG00000251330.3 CTD-2283N19.1 -3.92 0.000117 0.0399 -0.33 -0.26 Periodontal microbiota; chr5:148425557 chr5:148430159~148430807:- CESC cis rs2933343 0.729 rs813945 ENSG00000231305.3 RP11-723O4.2 3.92 0.000117 0.0399 0.24 0.26 IgG glycosylation; chr3:128942094 chr3:128861313~128871540:- CESC cis rs5742933 0.948 rs6434365 ENSG00000253559.1 OSGEPL1-AS1 -3.92 0.000117 0.0399 -0.36 -0.26 Ferritin levels; chr2:189707695 chr2:189762704~189765556:+ CESC cis rs7191700 0.644 rs12149160 ENSG00000262636.1 CTD-3088G3.4 -3.92 0.000117 0.0399 -0.33 -0.26 Multiple sclerosis; chr16:11345446 chr16:11380859~11381118:- CESC cis rs4742903 0.933 rs10820608 ENSG00000270332.1 SMC2-AS1 3.92 0.000117 0.0399 0.25 0.26 Breast cancer;High-grade serous ovarian cancer; chr9:104128559 chr9:104080024~104093073:- CESC cis rs8127691 0.967 rs8134436 ENSG00000225331.1 AP001055.6 3.92 0.000117 0.0399 0.31 0.26 Inflammatory bowel disease; chr21:44196614 chr21:44158740~44160076:- CESC cis rs7131987 0.903 rs2194519 ENSG00000257176.2 RP11-996F15.2 3.92 0.000117 0.0399 0.3 0.26 QT interval; chr12:29270650 chr12:29280418~29317848:- CESC cis rs76878669 0.561 rs55998145 ENSG00000255468.5 RP11-867G23.8 -3.92 0.000117 0.0399 -0.29 -0.26 Educational attainment (years of education); chr11:66385115 chr11:66347950~66364804:+ CESC cis rs801193 0.569 rs4717315 ENSG00000275400.1 RP4-756H11.5 3.92 0.000118 0.0399 0.28 0.26 Aortic root size; chr7:66713338 chr7:66553805~66554199:- CESC cis rs801193 0.548 rs2659891 ENSG00000275400.1 RP4-756H11.5 3.92 0.000118 0.0399 0.28 0.26 Aortic root size; chr7:66736127 chr7:66553805~66554199:- CESC cis rs801193 0.548 rs7805152 ENSG00000275400.1 RP4-756H11.5 3.92 0.000118 0.0399 0.28 0.26 Aortic root size; chr7:66744266 chr7:66553805~66554199:- CESC cis rs7429990 1 rs1684942 ENSG00000229759.1 MRPS18AP1 3.92 0.000118 0.0399 0.26 0.26 Educational attainment (years of education); chr3:47859213 chr3:48256350~48256938:- CESC cis rs7131987 0.65 rs67146951 ENSG00000257176.2 RP11-996F15.2 -3.92 0.000118 0.0399 -0.31 -0.26 QT interval; chr12:29297620 chr12:29280418~29317848:- CESC cis rs7131987 0.65 rs10843382 ENSG00000257176.2 RP11-996F15.2 -3.92 0.000118 0.0399 -0.31 -0.26 QT interval; chr12:29298788 chr12:29280418~29317848:- CESC cis rs7131987 0.65 rs3782509 ENSG00000257176.2 RP11-996F15.2 -3.92 0.000118 0.0399 -0.31 -0.26 QT interval; chr12:29300845 chr12:29280418~29317848:- CESC cis rs4146922 0.592 rs11125606 ENSG00000212175.1 SNORA12 -3.92 0.000118 0.0399 -0.28 -0.26 Height; chr2:55849699 chr2:55565703~55565850:+ CESC cis rs4146922 0.774 rs17369648 ENSG00000212175.1 SNORA12 -3.92 0.000118 0.0399 -0.28 -0.26 Height; chr2:55855440 chr2:55565703~55565850:+ CESC cis rs4489787 0.568 rs2731066 ENSG00000206612.1 SNORA2A 3.92 0.000118 0.0399 0.3 0.26 Prostate cancer (SNP x SNP interaction); chr12:48504780 chr12:48656648~48656782:- CESC cis rs4489787 0.568 rs2705160 ENSG00000206612.1 SNORA2A 3.92 0.000118 0.0399 0.3 0.26 Prostate cancer (SNP x SNP interaction); chr12:48507373 chr12:48656648~48656782:- CESC cis rs9494145 0.68 rs4895441 ENSG00000232876.1 CTA-212D2.2 3.92 0.000118 0.04 0.32 0.26 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135105435 chr6:135055033~135060550:+ CESC cis rs13113518 0.902 rs3805150 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55446869 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs4864990 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55447523 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs4864993 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55450662 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs11133381 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55450812 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs4864995 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55452853 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs12651640 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55454154 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs1554483 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55455650 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs1464490 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55456620 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs10517346 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55457027 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs11133384 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.04 0.33 0.26 Height; chr4:55457086 chr4:55387949~55388271:+ CESC cis rs9860250 0.945 rs76115083 ENSG00000175841.8 FAM172BP 3.92 0.000118 0.04 0.41 0.26 Optic disc area; chr3:100940559 chr3:101521891~101522979:+ CESC cis rs10129255 0.957 rs4387509 ENSG00000280411.1 IGHV1-69-2 -3.92 0.000118 0.04 -0.2 -0.26 Kawasaki disease; chr14:106704386 chr14:106762092~106762588:- CESC cis rs17695224 0.585 rs7252487 ENSG00000268095.1 ZNF649-AS1 3.92 0.000118 0.04 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr19:51821490 chr19:51888025~51900463:+ CESC cis rs801193 0.935 rs11772264 ENSG00000230358.3 RP11-166O4.1 -3.92 0.000118 0.04 -0.35 -0.26 Aortic root size; chr7:66711400 chr7:67279778~67286230:+ CESC cis rs490234 0.702 rs4838274 ENSG00000232630.1 PRPS1P2 -3.92 0.000118 0.04 -0.22 -0.26 Mean arterial pressure; chr9:125583715 chr9:125150653~125151589:+ CESC cis rs7789940 0.904 rs12531348 ENSG00000127957.15 PMS2P3 3.92 0.000118 0.04 0.33 0.26 Multiple sclerosis; chr7:76307874 chr7:75502930~75528148:- CESC cis rs7789940 0.904 rs61294900 ENSG00000127957.15 PMS2P3 3.92 0.000118 0.04 0.33 0.26 Multiple sclerosis; chr7:76307895 chr7:75502930~75528148:- CESC cis rs3126085 0.56 rs72698932 ENSG00000207606.1 MIR554 -3.92 0.000118 0.04 -0.39 -0.26 Atopic dermatitis; chr1:152383044 chr1:151545796~151545891:+ CESC cis rs4877691 0.522 rs35294902 ENSG00000267559.4 RP11-383M4.6 3.92 0.000118 0.0401 0.36 0.26 Airway imaging phenotypes; chr9:82478327 chr9:81930226~81977089:- CESC cis rs6452524 0.56 rs6895174 ENSG00000271862.1 RP11-343L5.2 3.92 0.000118 0.0401 0.23 0.26 Hypertension (SNP x SNP interaction); chr5:83071606 chr5:83049376~83050964:- CESC cis rs860295 0.557 rs348196 ENSG00000225855.5 RUSC1-AS1 3.92 0.000118 0.0401 0.22 0.26 Body mass index; chr1:155697170 chr1:155316863~155324176:- CESC cis rs9322193 0.847 rs12210605 ENSG00000223701.3 RAET1E-AS1 3.92 0.000118 0.0401 0.3 0.26 Lung cancer; chr6:149817267 chr6:149884431~149919508:+ CESC cis rs9322193 0.923 rs9371199 ENSG00000223701.3 RAET1E-AS1 3.92 0.000118 0.0401 0.3 0.26 Lung cancer; chr6:149817526 chr6:149884431~149919508:+ CESC cis rs7727544 1 rs10076701 ENSG00000233006.5 AC034220.3 3.92 0.000118 0.0401 0.28 0.26 Blood metabolite levels; chr5:132260726 chr5:132311285~132369916:- CESC cis rs1030877 0.515 rs1020064 ENSG00000235319.1 AC012360.4 -3.92 0.000118 0.0401 -0.31 -0.26 Obesity-related traits; chr2:105281283 chr2:105324210~105330529:+ CESC cis rs1030877 0.515 rs2576741 ENSG00000235319.1 AC012360.4 -3.92 0.000118 0.0401 -0.31 -0.26 Obesity-related traits; chr2:105281507 chr2:105324210~105330529:+ CESC cis rs2836950 0.527 rs2836958 ENSG00000255568.3 BRWD1-AS2 -3.92 0.000118 0.0401 -0.21 -0.26 Menarche (age at onset); chr21:39251600 chr21:39313935~39314962:+ CESC cis rs13113518 0.812 rs12500686 ENSG00000273257.1 RP11-177J6.1 3.92 0.000118 0.0401 0.35 0.26 Height; chr4:55457922 chr4:55387949~55388271:+ CESC cis rs10829156 0.699 rs10764584 ENSG00000240291.1 RP11-499P20.2 -3.92 0.000118 0.0401 -0.27 -0.26 Sudden cardiac arrest; chr10:18546396 chr10:18513115~18545651:- CESC cis rs7005380 0.581 rs12679478 ENSG00000279347.1 RP11-85I17.2 -3.92 0.000118 0.0402 -0.28 -0.26 Interstitial lung disease; chr8:119903994 chr8:119838736~119840385:- CESC cis rs17711722 0.701 rs55773927 ENSG00000222364.1 RNU6-96P -3.92 0.000118 0.0402 -0.31 -0.26 Calcium levels; chr7:65872915 chr7:66395191~66395286:+ CESC cis rs1501911 0.566 rs709387 ENSG00000248489.1 CTD-2007H13.3 3.92 0.000119 0.0402 0.34 0.26 Lung function (FEV1/FVC); chr5:98994337 chr5:98929171~98995013:+ CESC cis rs73219805 1 rs1042992 ENSG00000228451.3 SDAD1P1 3.92 0.000119 0.0402 0.36 0.26 Schizophrenia; chr8:26411675 chr8:26379259~26382953:- CESC cis rs10754283 0.934 rs10493829 ENSG00000231613.1 RP5-943J3.1 3.92 0.000119 0.0402 0.33 0.26 Amyotrophic lateral sclerosis (sporadic); chr1:89652274 chr1:89788914~89790492:+ CESC cis rs1320333 0.685 rs6710875 ENSG00000233296.1 AC092159.2 -3.92 0.000119 0.0402 -0.42 -0.26 Obesity-related traits; chr2:699976 chr2:677186~697371:+ CESC cis rs17301013 0.507 rs11799535 ENSG00000227373.4 RP11-160H22.5 3.92 0.000119 0.0402 0.39 0.26 Systemic lupus erythematosus; chr1:174415790 chr1:174115300~174160004:- CESC cis rs42490 0.625 rs425312 ENSG00000251136.7 RP11-37B2.1 -3.92 0.000119 0.0402 -0.26 -0.26 Leprosy; chr8:89834127 chr8:89609409~89757727:- CESC cis rs11157436 0.958 rs61972229 ENSG00000211812.1 TRAV26-2 -3.92 0.000119 0.0402 -0.29 -0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22189754 chr14:22202583~22203368:+ CESC cis rs2980879 0.804 rs7828113 ENSG00000255080.1 RP11-1082L8.3 3.92 0.000119 0.0402 0.26 0.26 Adiponectin levels; chr8:125473225 chr8:124834884~124857516:- CESC cis rs2742417 0.603 rs2742457 ENSG00000244357.3 RN7SL145P 3.92 0.000119 0.0402 0.24 0.26 Response to anti-depressant treatment in major depressive disorder; chr3:45725995 chr3:45742675~45742970:+ CESC cis rs2732480 0.557 rs2732454 ENSG00000240399.1 RP1-228P16.1 3.92 0.000119 0.0402 0.29 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48325894 chr12:48054813~48055591:- CESC cis rs2732480 0.557 rs923397 ENSG00000240399.1 RP1-228P16.1 3.92 0.000119 0.0402 0.29 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48326609 chr12:48054813~48055591:- CESC cis rs2732480 0.557 rs2409004 ENSG00000240399.1 RP1-228P16.1 3.92 0.000119 0.0402 0.29 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48327668 chr12:48054813~48055591:- CESC cis rs2732480 0.577 rs2450994 ENSG00000240399.1 RP1-228P16.1 3.92 0.000119 0.0402 0.29 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48328049 chr12:48054813~48055591:- CESC cis rs7811142 1 rs68116612 ENSG00000078319.8 PMS2P1 -3.92 0.000119 0.0402 -0.41 -0.26 Platelet count; chr7:100408870 chr7:100320992~100341908:- CESC cis rs889398 0.9 rs62052815 ENSG00000226232.7 RP11-419C5.2 3.92 0.000119 0.0402 0.24 0.26 Body mass index; chr16:69527923 chr16:69976388~69996188:- CESC cis rs2117029 0.767 rs11614738 ENSG00000258017.1 RP11-386G11.10 -3.92 0.000119 0.0402 -0.37 -0.26 Intelligence (multi-trait analysis); chr12:49030833 chr12:49127782~49147869:+ CESC cis rs2117029 0.767 rs3741622 ENSG00000258017.1 RP11-386G11.10 -3.92 0.000119 0.0402 -0.37 -0.26 Intelligence (multi-trait analysis); chr12:49032195 chr12:49127782~49147869:+ CESC cis rs17739794 0.502 rs3860879 ENSG00000254207.1 RP11-43A14.1 -3.92 0.000119 0.0403 -0.35 -0.26 Clozapine-induced cytotoxicity; chr8:859489 chr8:725188~725877:- CESC cis rs9420907 0.579 rs11191827 ENSG00000260461.1 RP11-541N10.3 -3.92 0.000119 0.0403 -0.41 -0.26 Telomere length; chr10:103850064 chr10:103877374~103879761:- CESC cis rs919433 0.617 rs10460394 ENSG00000222017.1 AC011997.1 -3.92 0.000119 0.0403 -0.33 -0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197684017 chr2:197693106~197774823:+ CESC cis rs441051 0.586 rs400218 ENSG00000236861.5 AC006378.2 -3.92 0.000119 0.0403 -0.28 -0.26 Mean forced vital capacity from 2 exams; chr7:94426694 chr7:93969442~94011113:+ CESC cis rs6969780 1 rs6461985 ENSG00000233429.8 HOTAIRM1 3.92 0.000119 0.0404 0.36 0.26 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27111015 chr7:27095647~27100265:+ CESC cis rs875971 0.545 rs73376401 ENSG00000226824.5 RP4-756H11.3 -3.92 0.000119 0.0404 -0.36 -0.26 Aortic root size; chr7:66174841 chr7:66654538~66669855:+ CESC cis rs6540731 1 rs11119885 ENSG00000226251.4 RP11-15I11.3 -3.92 0.000119 0.0404 -0.29 -0.26 Intelligence (childhood); chr1:212227656 chr1:212225278~212238977:- CESC cis rs11098499 0.722 rs17595727 ENSG00000248280.1 RP11-33B1.2 -3.92 0.000119 0.0404 -0.29 -0.26 Corneal astigmatism; chr4:119340919 chr4:119440561~119450157:- CESC cis rs9621305 0.925 rs17761473 ENSG00000228839.4 PIK3IP1-AS1 3.92 0.000119 0.0404 0.56 0.26 Intelligence; chr22:31821176 chr22:31292499~31338021:+ CESC cis rs7617773 0.784 rs9850672 ENSG00000228638.1 FCF1P2 -3.92 0.000119 0.0404 -0.27 -0.26 Coronary artery disease; chr3:48259682 chr3:48290793~48291375:- CESC cis rs4146922 1 rs1346789 ENSG00000212175.1 SNORA12 -3.92 0.000119 0.0404 -0.29 -0.26 Height; chr2:55864917 chr2:55565703~55565850:+ CESC cis rs9326248 0.53 rs7114963 ENSG00000280143.1 AP000892.6 3.92 0.000119 0.0404 0.45 0.26 Blood protein levels; chr11:117005267 chr11:117204967~117210292:+ CESC cis rs7115242 0.72 rs10790169 ENSG00000280143.1 AP000892.6 3.92 0.000119 0.0404 0.45 0.26 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117006443 chr11:117204967~117210292:+ CESC cis rs4272720 0.59 rs7897289 ENSG00000229870.1 RP11-507K13.6 -3.92 0.000119 0.0404 -0.29 -0.26 Platelet count;Plateletcrit; chr10:49060718 chr10:49815096~49815562:+ CESC cis rs2337406 1 rs17112416 ENSG00000225698.3 IGHV3-72 -3.92 0.00012 0.0405 -0.3 -0.26 Alzheimer's disease (late onset); chr14:106686773 chr14:106790691~106791233:- CESC cis rs7688540 0.713 rs12511388 ENSG00000211553.1 AC253576.2 -3.92 0.00012 0.0405 -0.39 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:303758 chr4:136461~136568:+ CESC cis rs673078 0.607 rs17441061 ENSG00000275759.1 RP11-131L12.3 -3.92 0.00012 0.0405 -0.49 -0.26 Glucose homeostasis traits; chr12:118409847 chr12:118428281~118428870:+ CESC cis rs73086581 0.592 rs2300217 ENSG00000229539.1 RP11-119B16.2 3.92 0.00012 0.0405 0.3 0.26 Response to antidepressants in depression; chr20:3957928 chr20:3888239~3888868:- CESC cis rs1113500 0.933 rs11185250 ENSG00000226822.1 RP11-356N1.2 3.92 0.00012 0.0405 0.33 0.26 Growth-regulated protein alpha levels; chr1:108073795 chr1:108071482~108074519:+ CESC cis rs1113500 0.933 rs1419003 ENSG00000226822.1 RP11-356N1.2 3.92 0.00012 0.0405 0.33 0.26 Growth-regulated protein alpha levels; chr1:108074333 chr1:108071482~108074519:+ CESC cis rs8020095 0.571 rs8009087 ENSG00000258561.1 RP11-72M17.1 3.92 0.00012 0.0405 0.37 0.26 Depression (quantitative trait); chr14:67097493 chr14:66212810~66509394:- CESC cis rs6504950 0.566 rs12937360 ENSG00000275710.1 RP11-257O5.4 3.92 0.00012 0.0405 0.27 0.26 Breast cancer; chr17:54968937 chr17:54964474~54964679:+ CESC cis rs6504950 0.566 rs7226272 ENSG00000275710.1 RP11-257O5.4 3.92 0.00012 0.0405 0.27 0.26 Breast cancer; chr17:54969086 chr17:54964474~54964679:+ CESC cis rs10043775 1 rs12513547 ENSG00000251330.3 CTD-2283N19.1 -3.92 0.00012 0.0405 -0.33 -0.26 Periodontal microbiota; chr5:148431902 chr5:148430159~148430807:- CESC cis rs8059260 0.542 rs7196077 ENSG00000274038.1 RP11-66H6.4 -3.92 0.00012 0.0405 -0.38 -0.26 Alcohol consumption over the past year; chr16:11033198 chr16:11056556~11057034:+ CESC cis rs13385 0.769 rs722437 ENSG00000202111.1 VTRNA1-2 3.92 0.00012 0.0405 0.35 0.26 Atrial fibrillation; chr5:140166144 chr5:140718925~140719013:+ CESC cis rs13385 0.769 rs34266577 ENSG00000202111.1 VTRNA1-2 3.92 0.00012 0.0405 0.35 0.26 Atrial fibrillation; chr5:140168212 chr5:140718925~140719013:+ CESC cis rs13385 0.769 rs56997077 ENSG00000202111.1 VTRNA1-2 3.92 0.00012 0.0405 0.35 0.26 Atrial fibrillation; chr5:140178827 chr5:140718925~140719013:+ CESC cis rs13385 0.769 rs34994530 ENSG00000202111.1 VTRNA1-2 3.92 0.00012 0.0405 0.35 0.26 Atrial fibrillation; chr5:140179084 chr5:140718925~140719013:+ CESC cis rs9329221 0.62 rs6601427 ENSG00000269918.1 AF131215.9 -3.92 0.00012 0.0405 -0.3 -0.26 Neuroticism; chr8:10298515 chr8:11104691~11106704:- CESC cis rs2243480 1 rs7794661 ENSG00000275400.1 RP4-756H11.5 3.92 0.00012 0.0406 0.43 0.26 Diabetic kidney disease; chr7:65924743 chr7:66553805~66554199:- CESC cis rs9487094 0.666 rs746794 ENSG00000260273.1 RP11-425D10.10 3.92 0.00012 0.0406 0.31 0.26 Height; chr6:109391534 chr6:109382795~109383666:+ CESC cis rs9487094 0.643 rs730089 ENSG00000260273.1 RP11-425D10.10 3.92 0.00012 0.0406 0.31 0.26 Height; chr6:109393881 chr6:109382795~109383666:+ CESC cis rs987724 0.592 rs1430411 ENSG00000240875.4 LINC00886 -3.92 0.00012 0.0406 -0.32 -0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156807607 chr3:156747346~156817062:- CESC cis rs1113500 0.836 rs1122158 ENSG00000226822.1 RP11-356N1.2 3.92 0.00012 0.0406 0.33 0.26 Growth-regulated protein alpha levels; chr1:108046046 chr1:108071482~108074519:+ CESC cis rs75422866 0.85 rs73111226 ENSG00000257433.4 RP1-197B17.3 3.92 0.00012 0.0406 0.71 0.26 Pneumonia; chr12:47582204 chr12:47706085~47742294:+ CESC cis rs11971779 0.68 rs6467848 ENSG00000273391.1 RP11-634H22.1 3.92 0.00012 0.0406 0.24 0.26 Diisocyanate-induced asthma; chr7:139395459 chr7:139359032~139359566:- CESC cis rs733592 0.524 rs10875741 ENSG00000257735.1 RP11-370I10.6 -3.92 0.00012 0.0407 -0.28 -0.26 Plateletcrit; chr12:48099139 chr12:48350945~48442411:+ CESC cis rs3768617 0.706 rs11588675 ENSG00000224468.3 RP11-181K3.4 -3.92 0.00012 0.0407 -0.26 -0.26 Fuchs's corneal dystrophy; chr1:183018917 chr1:183138402~183141282:- CESC cis rs875971 0.545 rs73142245 ENSG00000226824.5 RP4-756H11.3 -3.92 0.00012 0.0407 -0.38 -0.26 Aortic root size; chr7:66226662 chr7:66654538~66669855:+ CESC cis rs988913 1 rs6902422 ENSG00000224984.1 RP11-524H19.2 -3.92 0.00012 0.0407 -0.27 -0.26 Menarche (age at onset); chr6:54946412 chr6:54840118~54840855:- CESC cis rs490234 0.651 rs13291556 ENSG00000232630.1 PRPS1P2 -3.92 0.00012 0.0407 -0.22 -0.26 Mean arterial pressure; chr9:125478643 chr9:125150653~125151589:+ CESC cis rs62344088 0.59 rs62345236 ENSG00000260774.1 CTD-2083E4.4 -3.92 0.00012 0.0407 -0.49 -0.26 Asthma (childhood onset); chr5:283404 chr5:213898~217279:- CESC cis rs13113518 1 rs7662966 ENSG00000273257.1 RP11-177J6.1 3.92 0.00012 0.0407 0.33 0.26 Height; chr4:55548261 chr4:55387949~55388271:+ CESC cis rs2439831 1 rs2253708 ENSG00000205771.5 CATSPER2P1 -3.92 0.00012 0.0407 -0.36 -0.26 Lung cancer in ever smokers; chr15:43505075 chr15:43726918~43747094:- CESC cis rs453301 0.682 rs2929308 ENSG00000253981.4 ALG1L13P -3.92 0.00012 0.0407 -0.29 -0.26 Joint mobility (Beighton score); chr8:9226611 chr8:8236003~8244667:- CESC cis rs6740322 0.748 rs6727631 ENSG00000234936.1 AC010883.5 3.92 0.00012 0.0407 0.27 0.26 Coronary artery disease; chr2:43243269 chr2:43229573~43233394:+ CESC cis rs801193 0.844 rs732465 ENSG00000237310.1 GS1-124K5.4 3.92 0.000121 0.0407 0.24 0.26 Aortic root size; chr7:66533463 chr7:66493706~66495474:+ CESC cis rs801193 0.773 rs801207 ENSG00000237310.1 GS1-124K5.4 -3.92 0.000121 0.0407 -0.24 -0.26 Aortic root size; chr7:66555603 chr7:66493706~66495474:+ CESC cis rs875971 0.543 rs801191 ENSG00000237310.1 GS1-124K5.4 -3.92 0.000121 0.0407 -0.24 -0.26 Aortic root size; chr7:66567968 chr7:66493706~66495474:+ CESC cis rs875971 0.508 rs6947808 ENSG00000237310.1 GS1-124K5.4 -3.92 0.000121 0.0407 -0.24 -0.26 Aortic root size; chr7:66580095 chr7:66493706~66495474:+ CESC cis rs2243480 0.711 rs1626926 ENSG00000275400.1 RP4-756H11.5 3.92 0.000121 0.0407 0.41 0.26 Diabetic kidney disease; chr7:65970805 chr7:66553805~66554199:- CESC cis rs2243480 1 rs781142 ENSG00000275400.1 RP4-756H11.5 3.92 0.000121 0.0407 0.41 0.26 Diabetic kidney disease; chr7:65973791 chr7:66553805~66554199:- CESC cis rs9393777 0.513 rs6936555 ENSG00000241549.7 GUSBP2 3.92 0.000121 0.0407 0.33 0.26 Intelligence (multi-trait analysis); chr6:26640658 chr6:26871484~26956554:- CESC cis rs9393777 0.582 rs6936561 ENSG00000241549.7 GUSBP2 3.92 0.000121 0.0407 0.33 0.26 Intelligence (multi-trait analysis); chr6:26640667 chr6:26871484~26956554:- CESC cis rs13113518 0.678 rs7663650 ENSG00000249700.7 SRD5A3-AS1 -3.92 0.000121 0.0407 -0.32 -0.26 Height; chr4:55364952 chr4:55363971~55395847:- CESC cis rs8080784 0.673 rs7225403 ENSG00000266934.1 RP11-332H18.3 3.92 0.000121 0.0407 0.31 0.26 Coronary artery disease; chr17:60797869 chr17:61382785~61384680:+ CESC cis rs972578 0.765 rs4374465 ENSG00000274717.1 RP1-47A17.1 -3.92 0.000121 0.0408 -0.3 -0.26 Mean platelet volume; chr22:42887256 chr22:42791814~42794313:- CESC cis rs2439831 0.85 rs3736180 ENSG00000249839.1 AC011330.5 -3.92 0.000121 0.0408 -0.38 -0.26 Lung cancer in ever smokers; chr15:43814426 chr15:43663654~43684339:- CESC cis rs2408955 0.521 rs1476607 ENSG00000226413.2 OR8T1P -3.92 0.000121 0.0408 -0.33 -0.26 Glycated hemoglobin levels; chr12:48131021 chr12:48442030~48442947:- CESC cis rs6964587 0.904 rs6465339 ENSG00000188693.7 CYP51A1-AS1 3.92 0.000121 0.0408 0.28 0.26 Breast cancer; chr7:91941476 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs12666179 ENSG00000188693.7 CYP51A1-AS1 3.92 0.000121 0.0408 0.28 0.26 Breast cancer; chr7:91944796 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs417 ENSG00000188693.7 CYP51A1-AS1 3.92 0.000121 0.0408 0.28 0.26 Breast cancer; chr7:91951807 chr7:92134604~92180725:+ CESC cis rs11971779 0.68 rs6947215 ENSG00000273391.1 RP11-634H22.1 3.92 0.000121 0.0408 0.24 0.26 Diisocyanate-induced asthma; chr7:139341892 chr7:139359032~139359566:- CESC cis rs5769765 0.862 rs56377703 ENSG00000229409.1 RP11-494O16.3 3.92 0.000121 0.0408 0.37 0.26 Schizophrenia; chr22:49913292 chr22:49845929~49846090:+ CESC cis rs5742933 0.857 rs2289226 ENSG00000253559.1 OSGEPL1-AS1 -3.92 0.000121 0.0408 -0.31 -0.26 Ferritin levels; chr2:189661479 chr2:189762704~189765556:+ CESC cis rs10779751 0.881 rs2744820 ENSG00000230337.1 RP4-635E18.6 -3.92 0.000121 0.0408 -0.36 -0.26 Body mass index; chr1:11304958 chr1:11099675~11102100:+ CESC cis rs1075265 0.584 rs10164409 ENSG00000233266.1 HMGB1P31 3.92 0.000121 0.0408 0.33 0.26 Chronotype;Morning vs. evening chronotype; chr2:53940867 chr2:54051334~54051760:+ CESC cis rs12291225 0.535 rs10832248 ENSG00000251991.1 RNU7-49P 3.92 0.000121 0.0408 0.3 0.26 Sense of smell; chr11:14391541 chr11:14478892~14478953:+ CESC cis rs612683 0.694 rs6688166 ENSG00000261254.2 RP4-714D9.5 -3.92 0.000121 0.0408 -0.23 -0.26 Breast cancer; chr1:100535161 chr1:100030566~100035637:+ CESC cis rs612683 0.694 rs6688364 ENSG00000261254.2 RP4-714D9.5 -3.92 0.000121 0.0408 -0.23 -0.26 Breast cancer; chr1:100535318 chr1:100030566~100035637:+ CESC cis rs2842992 0.724 rs9347340 ENSG00000237927.1 RP3-393E18.2 3.92 0.000121 0.0408 0.31 0.26 Age-related macular degeneration (geographic atrophy); chr6:159767859 chr6:159586955~159589169:- CESC cis rs919433 0.713 rs13411968 ENSG00000222017.1 AC011997.1 3.91 0.000121 0.0408 0.32 0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197602417 chr2:197693106~197774823:+ CESC cis rs2581828 0.646 rs2564944 ENSG00000242142.1 SERBP1P3 3.91 0.000121 0.0408 0.3 0.26 Crohn's disease; chr3:53114439 chr3:53064283~53065091:- CESC cis rs12134133 0.962 rs2039543 ENSG00000274245.1 RP11-357P18.2 3.91 0.000121 0.0408 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207294228 chr1:207372559~207373252:+ CESC cis rs12134133 1 rs2802232 ENSG00000274245.1 RP11-357P18.2 3.91 0.000121 0.0408 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207294806 chr1:207372559~207373252:+ CESC cis rs12134133 0.962 rs2782847 ENSG00000274245.1 RP11-357P18.2 3.91 0.000121 0.0408 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207295766 chr1:207372559~207373252:+ CESC cis rs11157436 0.918 rs7159024 ENSG00000211813.2 TRAV34 3.91 0.000121 0.0408 0.27 0.26 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22228760 chr14:22207522~22208129:+ CESC cis rs16865252 0.85 rs73047977 ENSG00000213169.3 RP11-393N4.2 3.91 0.000121 0.0408 0.33 0.26 Blood osmolality (transformed sodium); chr3:174839863 chr3:174377244~174378005:+ CESC cis rs7138803 0.508 rs2290442 ENSG00000257464.1 RP11-161H23.8 -3.91 0.000121 0.0409 -0.26 -0.26 Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index; chr12:49791551 chr12:49442424~49442652:- CESC cis rs72759215 1 rs72759215 ENSG00000215032.2 GNL3LP1 3.91 0.000121 0.0409 0.31 0.26 Intelligence (multi-trait analysis); chr5:61056756 chr5:60891935~60893577:- CESC cis rs10829156 0.898 rs10741120 ENSG00000240291.1 RP11-499P20.2 3.91 0.000121 0.0409 0.29 0.26 Sudden cardiac arrest; chr10:18641063 chr10:18513115~18545651:- CESC cis rs2596230 0.66 rs2676024 ENSG00000278472.1 RP11-74D7.3 -3.91 0.000121 0.0409 -0.43 -0.26 Diabetic kidney disease; chr15:33439259 chr15:33972059~33972515:- CESC cis rs987724 0.571 rs7641929 ENSG00000240875.4 LINC00886 -3.91 0.000121 0.0409 -0.32 -0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156811605 chr3:156747346~156817062:- CESC cis rs987724 0.531 rs12492804 ENSG00000240875.4 LINC00886 -3.91 0.000121 0.0409 -0.32 -0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156814356 chr3:156747346~156817062:- CESC cis rs987724 0.592 rs12497539 ENSG00000240875.4 LINC00886 -3.91 0.000121 0.0409 -0.32 -0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156816148 chr3:156747346~156817062:- CESC cis rs987724 0.571 rs59717073 ENSG00000240875.4 LINC00886 -3.91 0.000121 0.0409 -0.32 -0.26 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156816456 chr3:156747346~156817062:- CESC cis rs116175783 0.557 rs62188138 ENSG00000227403.1 AC009299.3 3.91 0.000121 0.0409 0.42 0.26 Intelligence (multi-trait analysis); chr2:161410935 chr2:161244739~161249050:+ CESC cis rs116175783 0.557 rs6710414 ENSG00000227403.1 AC009299.3 3.91 0.000121 0.0409 0.42 0.26 Intelligence (multi-trait analysis); chr2:161412004 chr2:161244739~161249050:+ CESC cis rs7216064 0.589 rs7213585 ENSG00000278730.1 RP11-147L13.11 -3.91 0.000121 0.0409 -0.27 -0.26 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68066200 chr17:68126666~68129586:+ CESC cis rs9322193 0.847 rs56103941 ENSG00000223701.3 RAET1E-AS1 3.91 0.000121 0.0409 0.3 0.26 Lung cancer; chr6:149816095 chr6:149884431~149919508:+ CESC cis rs35740288 0.822 rs11630179 ENSG00000202081.1 RNU6-1280P 3.91 0.000121 0.0409 0.32 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85739703 chr15:85651522~85651628:- CESC cis rs7178375 0.678 rs34678577 ENSG00000269974.1 RP11-932O9.10 3.91 0.000121 0.0409 0.32 0.26 Hypertriglyceridemia; chr15:30885262 chr15:30648797~30649529:+ CESC cis rs6540731 1 rs1389369 ENSG00000226251.4 RP11-15I11.3 -3.91 0.000121 0.0409 -0.29 -0.26 Intelligence (childhood); chr1:212227194 chr1:212225278~212238977:- CESC cis rs6540731 1 rs1389370 ENSG00000226251.4 RP11-15I11.3 -3.91 0.000121 0.0409 -0.29 -0.26 Intelligence (childhood); chr1:212227275 chr1:212225278~212238977:- CESC cis rs6540731 1 rs6540735 ENSG00000226251.4 RP11-15I11.3 -3.91 0.000121 0.0409 -0.29 -0.26 Intelligence (childhood); chr1:212227418 chr1:212225278~212238977:- CESC cis rs6540731 1 rs6657900 ENSG00000226251.4 RP11-15I11.3 -3.91 0.000121 0.0409 -0.29 -0.26 Intelligence (childhood); chr1:212227524 chr1:212225278~212238977:- CESC cis rs9595066 0.627 rs4432167 ENSG00000227258.4 SMIM2-AS1 -3.91 0.000121 0.0409 -0.38 -0.26 Schizophrenia; chr13:44178225 chr13:44110451~44240517:+ CESC cis rs9595066 0.627 rs4394973 ENSG00000227258.4 SMIM2-AS1 -3.91 0.000121 0.0409 -0.38 -0.26 Schizophrenia; chr13:44179173 chr13:44110451~44240517:+ CESC cis rs9341808 0.727 rs4706834 ENSG00000272129.1 RP11-250B2.6 3.91 0.000121 0.041 0.29 0.26 Sitting height ratio; chr6:80302888 chr6:80355424~80356859:+ CESC cis rs4650376 0.789 rs1780719 ENSG00000235613.2 NSRP1P1 -3.91 0.000121 0.041 -0.47 -0.26 IgG glycosylation; chr1:78720954 chr1:77847110~77848802:+ CESC cis rs4650376 0.789 rs1751523 ENSG00000235613.2 NSRP1P1 -3.91 0.000121 0.041 -0.47 -0.26 IgG glycosylation; chr1:78721181 chr1:77847110~77848802:+ CESC cis rs4650376 0.789 rs2801038 ENSG00000235613.2 NSRP1P1 -3.91 0.000121 0.041 -0.47 -0.26 IgG glycosylation; chr1:78723291 chr1:77847110~77848802:+ CESC cis rs4650376 0.789 rs1780723 ENSG00000235613.2 NSRP1P1 -3.91 0.000121 0.041 -0.47 -0.26 IgG glycosylation; chr1:78723391 chr1:77847110~77848802:+ CESC cis rs4650376 0.789 rs1751518 ENSG00000235613.2 NSRP1P1 -3.91 0.000121 0.041 -0.47 -0.26 IgG glycosylation; chr1:78724694 chr1:77847110~77848802:+ CESC cis rs4650376 0.789 rs1780724 ENSG00000235613.2 NSRP1P1 -3.91 0.000121 0.041 -0.47 -0.26 IgG glycosylation; chr1:78724834 chr1:77847110~77848802:+ CESC cis rs4650376 0.789 rs1751517 ENSG00000235613.2 NSRP1P1 -3.91 0.000121 0.041 -0.47 -0.26 IgG glycosylation; chr1:78725640 chr1:77847110~77848802:+ CESC cis rs77106637 0.86 rs7129793 ENSG00000202522.1 Y_RNA 3.91 0.000121 0.041 0.4 0.26 Type 2 diabetes; chr11:72744840 chr11:72766004~72766116:+ CESC cis rs13108904 0.935 rs4974575 ENSG00000253399.1 AC078852.2 -3.91 0.000121 0.041 -0.3 -0.26 Obesity-related traits; chr4:1258240 chr4:1358479~1359461:+ CESC cis rs853679 0.556 rs45509595 ENSG00000219392.1 RP1-265C24.5 -3.91 0.000121 0.041 -0.55 -0.26 Depression; chr6:27873148 chr6:28115628~28116551:+ CESC cis rs11168618 0.74 rs7312017 ENSG00000257735.1 RP11-370I10.6 3.91 0.000122 0.041 0.27 0.26 Adiponectin levels; chr12:48560442 chr12:48350945~48442411:+ CESC cis rs224278 0.509 rs1115705 ENSG00000238280.1 RP11-436D10.3 -3.91 0.000122 0.041 -0.4 -0.26 Ewing sarcoma; chr10:62945426 chr10:62793562~62805887:- CESC cis rs12745968 0.653 rs6604008 ENSG00000223787.2 RP4-593M8.1 -3.91 0.000122 0.041 -0.34 -0.26 Bipolar disorder and schizophrenia; chr1:92711884 chr1:92580476~92580821:- CESC cis rs6844153 1 rs57686546 ENSG00000240005.4 RP11-293A21.1 -3.91 0.000122 0.041 -0.37 -0.26 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26915162 chr4:26859806~26860599:- CESC cis rs9907295 0.901 rs56294660 ENSG00000271013.1 AC015849.15 -3.91 0.000122 0.041 -0.35 -0.26 Fibroblast growth factor basic levels; chr17:35901470 chr17:35912635~35918010:- CESC cis rs9487094 0.922 rs2236582 ENSG00000260273.1 RP11-425D10.10 -3.91 0.000122 0.041 -0.32 -0.26 Height; chr6:109444615 chr6:109382795~109383666:+ CESC cis rs2179367 0.959 rs562428 ENSG00000231760.4 RP11-350J20.5 3.91 0.000122 0.041 0.32 0.26 Dupuytren's disease; chr6:149326389 chr6:149796151~149826294:- CESC cis rs2274273 0.588 rs7154831 ENSG00000258413.1 RP11-665C16.6 -3.91 0.000122 0.041 -0.34 -0.26 Protein biomarker; chr14:55357247 chr14:55262767~55272075:- CESC cis rs2274273 0.588 rs58296156 ENSG00000258413.1 RP11-665C16.6 -3.91 0.000122 0.041 -0.34 -0.26 Protein biomarker; chr14:55361609 chr14:55262767~55272075:- CESC cis rs2274273 0.588 rs7158791 ENSG00000258413.1 RP11-665C16.6 -3.91 0.000122 0.041 -0.34 -0.26 Protein biomarker; chr14:55361889 chr14:55262767~55272075:- CESC cis rs8040855 0.627 rs12905036 ENSG00000259295.5 CSPG4P12 3.91 0.000122 0.041 0.32 0.26 Bulimia nervosa; chr15:85094557 chr15:85191438~85213905:+ CESC cis rs10043775 0.831 rs10072958 ENSG00000251330.3 CTD-2283N19.1 -3.91 0.000122 0.041 -0.31 -0.26 Periodontal microbiota; chr5:148310336 chr5:148430159~148430807:- CESC cis rs12216125 0.554 rs6942196 ENSG00000272462.2 U91328.19 -3.91 0.000122 0.0411 -0.25 -0.26 Iron status biomarkers; chr6:26072576 chr6:25992662~26001775:+ CESC cis rs1865760 0.566 rs1539183 ENSG00000272462.2 U91328.19 -3.91 0.000122 0.0411 -0.25 -0.26 Height; chr6:26074823 chr6:25992662~26001775:+ CESC cis rs2404602 0.536 rs12915248 ENSG00000259422.1 RP11-593F23.1 3.91 0.000122 0.0411 0.29 0.26 Blood metabolite levels; chr15:76473274 chr15:76174891~76181486:- CESC cis rs2115630 1 rs56074163 ENSG00000225151.9 GOLGA2P7 3.91 0.000122 0.0411 0.29 0.26 P wave terminal force; chr15:84808101 chr15:84199311~84230136:- CESC cis rs6844153 0.752 rs12650172 ENSG00000240005.4 RP11-293A21.1 -3.91 0.000122 0.0411 -0.33 -0.26 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26872784 chr4:26859806~26860599:- CESC cis rs950776 0.667 rs57728226 ENSG00000261762.1 RP11-650L12.2 3.91 0.000122 0.0411 0.38 0.26 Sudden cardiac arrest; chr15:78637008 chr15:78589123~78591276:- CESC cis rs357894 1 rs357894 ENSG00000266696.1 RP11-30L3.2 3.91 0.000122 0.0411 0.29 0.26 Dental caries; chr18:49053600 chr18:49205912~49208781:+ CESC cis rs2274273 0.934 rs10139337 ENSG00000258413.1 RP11-665C16.6 -3.91 0.000122 0.0412 -0.31 -0.26 Protein biomarker; chr14:55275395 chr14:55262767~55272075:- CESC cis rs2439831 0.85 rs558656 ENSG00000205771.5 CATSPER2P1 -3.91 0.000122 0.0412 -0.35 -0.26 Lung cancer in ever smokers; chr15:43431316 chr15:43726918~43747094:- CESC cis rs10129255 0.957 rs11847726 ENSG00000223648.3 IGHV3-64 3.91 0.000122 0.0412 0.23 0.26 Kawasaki disease; chr14:106779116 chr14:106643132~106658258:- CESC cis rs7200543 1 rs3803575 ENSG00000260735.1 RP11-72I8.1 -3.91 0.000122 0.0412 -0.3 -0.26 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15044590 chr16:15094411~15109197:+ CESC cis rs6499755 0.932 rs714507 ENSG00000260135.5 RP11-212I21.2 -3.91 0.000122 0.0412 -0.32 -0.26 Hypospadias; chr16:55305865 chr16:55426797~55462297:- CESC cis rs10129255 0.957 rs12590735 ENSG00000223648.3 IGHV3-64 3.91 0.000122 0.0412 0.23 0.26 Kawasaki disease; chr14:106779660 chr14:106643132~106658258:- CESC cis rs801193 0.569 rs35070132 ENSG00000275400.1 RP4-756H11.5 3.91 0.000122 0.0412 0.28 0.26 Aortic root size; chr7:66773096 chr7:66553805~66554199:- CESC cis rs2408955 0.521 rs11168437 ENSG00000226413.2 OR8T1P 3.91 0.000122 0.0412 0.33 0.26 Glycated hemoglobin levels; chr12:48172373 chr12:48442030~48442947:- CESC cis rs9987353 0.518 rs4841110 ENSG00000173295.6 FAM86B3P 3.91 0.000122 0.0412 0.34 0.26 Recombination measurement; chr8:9228513 chr8:8228595~8244865:+ CESC cis rs13108904 0.935 rs13148614 ENSG00000253399.1 AC078852.2 -3.91 0.000122 0.0412 -0.3 -0.26 Obesity-related traits; chr4:1254569 chr4:1358479~1359461:+ CESC cis rs4141488 1 rs4141488 ENSG00000261481.1 RP11-77H9.6 3.91 0.000122 0.0412 0.27 0.26 Waist circumference adjusted for BMI (smoking interaction); chr16:9535210 chr16:8869251~8870032:+ CESC cis rs11089937 0.597 rs4821774 ENSG00000211638.2 IGLV8-61 -3.91 0.000122 0.0412 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22131536 chr22:22098700~22099212:+ CESC cis rs8030379 1 rs1564473 ENSG00000230373.7 GOLGA6L5P -3.91 0.000122 0.0412 -0.25 -0.26 Waist circumference;Waist circumference adjusted for body mass index; chr15:83901190 chr15:84507885~84516814:- CESC cis rs6540731 1 rs12402397 ENSG00000226251.4 RP11-15I11.3 -3.91 0.000122 0.0412 -0.29 -0.26 Intelligence (childhood); chr1:212222602 chr1:212225278~212238977:- CESC cis rs6540731 1 rs7518329 ENSG00000226251.4 RP11-15I11.3 -3.91 0.000122 0.0412 -0.29 -0.26 Intelligence (childhood); chr1:212225191 chr1:212225278~212238977:- CESC cis rs9532669 0.926 rs12872288 ENSG00000176268.5 CYCSP34 3.91 0.000122 0.0412 0.26 0.26 Cervical cancer; chr13:40880268 chr13:40863599~40863902:- CESC cis rs7216064 0.651 rs12947658 ENSG00000278730.1 RP11-147L13.11 3.91 0.000122 0.0412 0.26 0.26 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67906890 chr17:68126666~68129586:+ CESC cis rs7178572 0.568 rs3743479 ENSG00000196274.5 Metazoa_SRP 3.91 0.000122 0.0412 0.31 0.26 Type 2 diabetes; chr15:77114054 chr15:76230048~76230390:- CESC cis rs5742933 0.817 rs1055091 ENSG00000253559.1 OSGEPL1-AS1 3.91 0.000123 0.0413 0.3 0.26 Ferritin levels; chr2:189770417 chr2:189762704~189765556:+ CESC cis rs875971 0.862 rs709596 ENSG00000179406.6 LINC00174 -3.91 0.000123 0.0413 -0.27 -0.26 Aortic root size; chr7:66360926 chr7:66376044~66401338:- CESC cis rs748404 0.666 rs8027748 ENSG00000249839.1 AC011330.5 -3.91 0.000123 0.0413 -0.38 -0.26 Lung cancer; chr15:43447622 chr15:43663654~43684339:- CESC cis rs11098499 0.57 rs6832740 ENSG00000248280.1 RP11-33B1.2 3.91 0.000123 0.0413 0.28 0.26 Corneal astigmatism; chr4:119624981 chr4:119440561~119450157:- CESC cis rs11098499 0.644 rs6855918 ENSG00000248280.1 RP11-33B1.2 3.91 0.000123 0.0413 0.28 0.26 Corneal astigmatism; chr4:119625144 chr4:119440561~119450157:- CESC cis rs9900062 0.844 rs9908143 ENSG00000270714.1 MINOS1P2 -3.91 0.000123 0.0413 -0.37 -0.26 QT interval; chr17:64758468 chr17:64747264~64747492:- CESC cis rs944801 0.608 rs10811645 ENSG00000240498.5 CDKN2B-AS1 3.91 0.000123 0.0414 0.23 0.26 Type 2 diabetes; chr9:22049657 chr9:21994778~22121097:+ CESC cis rs4819052 0.851 rs2838826 ENSG00000215447.6 BX322557.10 -3.91 0.000123 0.0414 -0.23 -0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45235870 chr21:45288052~45291738:+ CESC cis rs2439831 0.85 rs3825783 ENSG00000249839.1 AC011330.5 -3.91 0.000123 0.0414 -0.37 -0.26 Lung cancer in ever smokers; chr15:43810111 chr15:43663654~43684339:- CESC cis rs9859260 0.555 rs9877493 ENSG00000252174.1 RNU7-18P -3.91 0.000123 0.0414 -0.31 -0.26 Mean corpuscular volume; chr3:196105276 chr3:196072819~196072880:+ CESC cis rs1400816 0.85 rs2028671 ENSG00000225205.4 AC093818.1 3.91 0.000123 0.0414 0.38 0.26 Amyotrophic lateral sclerosis (sporadic); chr2:171987925 chr2:172480840~172556596:- CESC cis rs17027258 0.697 rs1468789 ENSG00000234389.1 AC007278.3 -3.91 0.000123 0.0414 -0.31 -0.26 White blood cell types; chr2:102476044 chr2:102438713~102440475:+ CESC cis rs9322193 0.772 rs7738696 ENSG00000223701.3 RAET1E-AS1 3.91 0.000123 0.0414 0.31 0.26 Lung cancer; chr6:149848985 chr6:149884431~149919508:+ CESC cis rs4927850 1 rs7614767 ENSG00000273009.1 RP11-352G9.1 -3.91 0.000123 0.0414 -0.33 -0.26 Pancreatic cancer; chr3:196026580 chr3:195913078~195913683:- CESC cis rs116966368 0.602 rs356865 ENSG00000266296.1 ARIH2P1 3.91 0.000123 0.0414 0.33 0.26 Neuroticism; chr18:28711508 chr18:28651732~28653208:+ CESC cis rs2933343 0.672 rs1872545 ENSG00000231305.3 RP11-723O4.2 3.91 0.000123 0.0414 0.24 0.26 IgG glycosylation; chr3:128926196 chr3:128861313~128871540:- CESC cis rs875971 0.545 rs73376401 ENSG00000224316.1 RP11-479O9.2 3.91 0.000123 0.0414 0.32 0.26 Aortic root size; chr7:66174841 chr7:65773620~65802067:+ CESC cis rs2243480 1 rs34703416 ENSG00000275400.1 RP4-756H11.5 3.91 0.000123 0.0414 0.41 0.26 Diabetic kidney disease; chr7:65835655 chr7:66553805~66554199:- CESC cis rs79464052 0.571 rs122752 ENSG00000228737.2 AC008781.7 -3.91 0.000123 0.0415 -0.55 -0.26 Diffuse large B cell lymphoma; chr5:141527139 chr5:141618414~141626481:+ CESC cis rs77204473 0.744 rs12277910 ENSG00000254851.1 RP11-109L13.1 -3.91 0.000123 0.0415 -0.53 -0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:117087817 chr11:117135528~117138582:+ CESC cis rs75422866 0.85 rs73111210 ENSG00000257433.4 RP1-197B17.3 3.91 0.000123 0.0415 0.7 0.26 Pneumonia; chr12:47576949 chr12:47706085~47742294:+ CESC cis rs61160187 0.582 rs2049579 ENSG00000215032.2 GNL3LP1 3.91 0.000123 0.0415 0.3 0.26 Educational attainment (years of education);Educational attainment (college completion); chr5:61054838 chr5:60891935~60893577:- CESC cis rs8067354 0.872 rs2645466 ENSG00000266701.1 AC005702.4 3.91 0.000123 0.0415 0.31 0.26 Hemoglobin concentration; chr17:59775853 chr17:60042546~60042627:- CESC cis rs2299587 1 rs2299587 ENSG00000253671.1 RP11-806O11.1 -3.91 0.000123 0.0415 -0.26 -0.26 Economic and political preferences; chr8:17943260 chr8:17808941~17820868:+ CESC cis rs7247513 1 rs7247513 ENSG00000230310.1 CTD-2192J16.11 -3.91 0.000123 0.0415 -0.31 -0.26 Bipolar disorder; chr19:12580371 chr19:12552597~12553644:+ CESC cis rs2281636 0.723 rs11190255 ENSG00000233690.1 EBAG9P1 3.91 0.000124 0.0415 0.27 0.26 Obesity-related traits; chr10:99714742 chr10:99697407~99697949:- CESC cis rs2439831 0.85 rs694985 ENSG00000205771.5 CATSPER2P1 -3.91 0.000124 0.0415 -0.37 -0.26 Lung cancer in ever smokers; chr15:43521189 chr15:43726918~43747094:- CESC cis rs57502260 0.704 rs55975204 ENSG00000212093.1 AP000807.1 3.91 0.000124 0.0416 0.41 0.26 Total body bone mineral density (age 45-60); chr11:68481656 chr11:68506083~68506166:- CESC cis rs2732480 0.5 rs7966829 ENSG00000240399.1 RP1-228P16.1 3.91 0.000124 0.0416 0.3 0.26 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48221820 chr12:48054813~48055591:- CESC cis rs11638352 1 rs12900237 ENSG00000275601.1 AC011330.13 3.91 0.000124 0.0416 0.39 0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44038612 chr15:43642389~43643023:- CESC cis rs2733201 1 rs12591537 ENSG00000275601.1 AC011330.13 3.91 0.000124 0.0416 0.39 0.26 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44046065 chr15:43642389~43643023:- CESC cis rs13113518 0.812 rs11133385 ENSG00000273257.1 RP11-177J6.1 3.91 0.000124 0.0416 0.34 0.26 Height; chr4:55460485 chr4:55387949~55388271:+ CESC cis rs13113518 0.841 rs7699867 ENSG00000273257.1 RP11-177J6.1 3.91 0.000124 0.0416 0.34 0.26 Height; chr4:55483718 chr4:55387949~55388271:+ CESC cis rs13113518 0.783 rs11133389 ENSG00000273257.1 RP11-177J6.1 3.91 0.000124 0.0416 0.34 0.26 Height; chr4:55486718 chr4:55387949~55388271:+ CESC cis rs1707322 1 rs34694458 ENSG00000281133.1 AL355480.3 -3.91 0.000124 0.0416 -0.3 -0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45867024 chr1:45580892~45580996:- CESC cis rs875971 0.929 rs34406470 ENSG00000179406.6 LINC00174 -3.91 0.000124 0.0416 -0.28 -0.26 Aortic root size; chr7:66464969 chr7:66376044~66401338:- CESC cis rs6693388 0.749 rs12095483 ENSG00000229021.2 AL591893.1 -3.91 0.000124 0.0416 -0.32 -0.26 Blood metabolite ratios; chr1:151949498 chr1:151994531~152042774:+ CESC cis rs6693388 0.789 rs61817725 ENSG00000229021.2 AL591893.1 -3.91 0.000124 0.0416 -0.32 -0.26 Blood metabolite ratios; chr1:151950701 chr1:151994531~152042774:+ CESC cis rs12134133 1 rs6660254 ENSG00000274245.1 RP11-357P18.2 3.91 0.000124 0.0416 0.33 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207272746 chr1:207372559~207373252:+ CESC cis rs2235544 0.565 rs635045 ENSG00000225183.1 RP4-758J24.4 3.91 0.000124 0.0416 0.29 0.26 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54003436 chr1:54089856~54090093:+ CESC cis rs62355900 0.636 rs62355907 ENSG00000271828.1 CTD-2310F14.1 3.91 0.000124 0.0416 0.4 0.26 Endometriosis; chr5:56775503 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs16886407 ENSG00000271828.1 CTD-2310F14.1 3.91 0.000124 0.0416 0.4 0.26 Endometriosis; chr5:56845540 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs16886419 ENSG00000271828.1 CTD-2310F14.1 3.91 0.000124 0.0416 0.4 0.26 Endometriosis; chr5:56847034 chr5:56927874~56929573:+ CESC cis rs62355901 0.545 rs1862621 ENSG00000271828.1 CTD-2310F14.1 3.91 0.000124 0.0416 0.4 0.26 Breast cancer; chr5:56847332 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs62358076 ENSG00000271828.1 CTD-2310F14.1 3.91 0.000124 0.0416 0.4 0.26 Endometriosis; chr5:56848189 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs16886424 ENSG00000271828.1 CTD-2310F14.1 3.91 0.000124 0.0416 0.4 0.26 Endometriosis; chr5:56850866 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs16886429 ENSG00000271828.1 CTD-2310F14.1 3.91 0.000124 0.0416 0.4 0.26 Endometriosis; chr5:56857265 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs62358104 ENSG00000271828.1 CTD-2310F14.1 3.91 0.000124 0.0416 0.4 0.26 Endometriosis; chr5:56863344 chr5:56927874~56929573:+ CESC cis rs7560272 0.538 rs12052539 ENSG00000163016.8 ALMS1P 3.91 0.000124 0.0416 0.3 0.26 Schizophrenia; chr2:73710026 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs6546860 ENSG00000163016.8 ALMS1P 3.91 0.000124 0.0416 0.32 0.26 Metabolite levels; chr2:73617122 chr2:73644919~73685576:+ CESC cis rs9309473 0.797 rs6723247 ENSG00000163016.8 ALMS1P 3.91 0.000124 0.0416 0.32 0.26 Metabolite levels; chr2:73619622 chr2:73644919~73685576:+ CESC cis rs9517320 1 rs7338549 ENSG00000231194.1 FARP1-AS1 3.91 0.000124 0.0417 0.29 0.26 Longevity; chr13:98490491 chr13:98435405~98435840:- CESC cis rs2221593 0.502 rs2456812 ENSG00000198468.6 FLVCR1-AS1 -3.91 0.000124 0.0417 -0.37 -0.26 Leprosy; chr1:212678671 chr1:212852108~212858088:- CESC cis rs916888 0.773 rs199535 ENSG00000232300.1 FAM215B 3.91 0.000124 0.0417 0.4 0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46558830~46562795:- CESC cis rs2179367 0.887 rs2789492 ENSG00000231760.4 RP11-350J20.5 -3.91 0.000124 0.0417 -0.31 -0.26 Dupuytren's disease; chr6:149426243 chr6:149796151~149826294:- CESC cis rs10043775 0.957 rs10042369 ENSG00000251330.3 CTD-2283N19.1 -3.91 0.000124 0.0417 -0.33 -0.26 Periodontal microbiota; chr5:148424507 chr5:148430159~148430807:- CESC cis rs256277 0.544 rs26539 ENSG00000270067.1 CTC-487M23.5 3.91 0.000124 0.0417 0.29 0.26 Coronary artery disease; chr5:112015662 chr5:112893333~112894001:+ CESC cis rs12134133 1 rs6660557 ENSG00000274245.1 RP11-357P18.2 3.91 0.000124 0.0417 0.32 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207281251 chr1:207372559~207373252:+ CESC cis rs763121 0.853 rs6001204 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000124 0.0417 -0.24 -0.26 Menopause (age at onset); chr22:38704234 chr22:38667585~38681820:- CESC cis rs7829975 0.623 rs7010753 ENSG00000173295.6 FAM86B3P 3.91 0.000124 0.0417 0.32 0.26 Mood instability; chr8:8516446 chr8:8228595~8244865:+ CESC cis rs9402743 0.671 rs4896157 ENSG00000234084.1 RP3-388E23.2 -3.91 0.000124 0.0417 -0.22 -0.26 Systemic lupus erythematosus; chr6:135620981 chr6:135301568~135307158:+ CESC cis rs9402743 0.599 rs6919741 ENSG00000234084.1 RP3-388E23.2 -3.91 0.000124 0.0417 -0.22 -0.26 Systemic lupus erythematosus; chr6:135622057 chr6:135301568~135307158:+ CESC cis rs9402743 0.671 rs9321516 ENSG00000234084.1 RP3-388E23.2 -3.91 0.000124 0.0417 -0.22 -0.26 Systemic lupus erythematosus; chr6:135622150 chr6:135301568~135307158:+ CESC cis rs9402743 0.598 rs7761716 ENSG00000234084.1 RP3-388E23.2 -3.91 0.000124 0.0417 -0.22 -0.26 Systemic lupus erythematosus; chr6:135623243 chr6:135301568~135307158:+ CESC cis rs9402743 0.671 rs7762139 ENSG00000234084.1 RP3-388E23.2 -3.91 0.000124 0.0417 -0.22 -0.26 Systemic lupus erythematosus; chr6:135623289 chr6:135301568~135307158:+ CESC cis rs2034650 0.544 rs8034416 ENSG00000223313.1 RNU6-516P 3.91 0.000124 0.0417 0.31 0.26 Interstitial lung disease; chr15:40411140 chr15:40529570~40529673:+ CESC cis rs2548724 0.645 rs62372171 ENSG00000250682.4 LINC00491 3.91 0.000124 0.0417 0.33 0.26 Type 2 diabetes; chr5:102298873 chr5:102609156~102671559:- CESC cis rs1023500 0.573 rs2413666 ENSG00000273366.1 CTA-989H11.1 -3.91 0.000124 0.0417 -0.34 -0.26 Schizophrenia; chr22:42063618 chr22:42278188~42278846:+ CESC cis rs36423 0.528 rs1205066 ENSG00000266869.1 RP6-114E22.1 3.91 0.000124 0.0417 0.41 0.26 Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN); chr14:71880340 chr14:71848606~71908430:+ CESC cis rs375092 0.543 rs449271 ENSG00000230658.1 KLHL7-AS1 3.91 0.000124 0.0417 0.38 0.26 Personality dimensions; chr7:23376798 chr7:23101228~23105703:- CESC cis rs17772222 0.958 rs2274737 ENSG00000258983.2 RP11-507K2.2 3.91 0.000124 0.0417 0.32 0.26 Coronary artery calcification; chr14:88469307 chr14:88499334~88515502:+ CESC cis rs17301013 0.507 rs72717608 ENSG00000227373.4 RP11-160H22.5 3.91 0.000124 0.0417 0.39 0.26 Systemic lupus erythematosus; chr1:174788316 chr1:174115300~174160004:- CESC cis rs3925075 0.5 rs11645526 ENSG00000260911.2 RP11-196G11.2 -3.91 0.000124 0.0417 -0.27 -0.26 IgA nephropathy; chr16:31256918 chr16:31043150~31049868:+ CESC cis rs2337406 0.539 rs2583290 ENSG00000211974.3 IGHV2-70 3.91 0.000124 0.0417 0.33 0.26 Alzheimer's disease (late onset); chr14:106650277 chr14:106723574~106724093:- CESC cis rs6540731 0.967 rs1472226 ENSG00000226251.4 RP11-15I11.3 -3.91 0.000124 0.0417 -0.29 -0.26 Intelligence (childhood); chr1:212229238 chr1:212225278~212238977:- CESC cis rs11971779 0.648 rs6467849 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139395766 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs1986447 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139397334 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs7779900 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139398241 chr7:139359032~139359566:- CESC cis rs11971779 0.59 rs9642120 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139399225 chr7:139359032~139359566:- CESC cis rs11971779 0.648 rs7799165 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139400211 chr7:139359032~139359566:- CESC cis rs11971779 0.618 rs9640925 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139400542 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs7804388 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139401667 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs4732373 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139401789 chr7:139359032~139359566:- CESC cis rs11971779 0.618 rs6943788 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139402951 chr7:139359032~139359566:- CESC cis rs11971779 0.523 rs10279160 ENSG00000273391.1 RP11-634H22.1 3.91 0.000124 0.0417 0.24 0.26 Diisocyanate-induced asthma; chr7:139406015 chr7:139359032~139359566:- CESC cis rs8020095 0.571 rs7157394 ENSG00000258561.1 RP11-72M17.1 -3.91 0.000124 0.0417 -0.38 -0.26 Depression (quantitative trait); chr14:67096052 chr14:66212810~66509394:- CESC cis rs853679 1 rs853676 ENSG00000219392.1 RP1-265C24.5 -3.91 0.000124 0.0418 -0.38 -0.26 Depression; chr6:28331910 chr6:28115628~28116551:+ CESC cis rs10779751 0.734 rs12569242 ENSG00000230337.1 RP4-635E18.6 3.91 0.000124 0.0418 0.36 0.26 Body mass index; chr1:11067454 chr1:11099675~11102100:+ CESC cis rs35740288 0.822 rs17637142 ENSG00000202081.1 RNU6-1280P 3.91 0.000125 0.0418 0.31 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85697272 chr15:85651522~85651628:- CESC cis rs35740288 0.787 rs35250181 ENSG00000202081.1 RNU6-1280P 3.91 0.000125 0.0418 0.31 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85699431 chr15:85651522~85651628:- CESC cis rs35740288 0.787 rs11635418 ENSG00000202081.1 RNU6-1280P 3.91 0.000125 0.0418 0.31 0.26 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85700947 chr15:85651522~85651628:- CESC cis rs42490 0.638 rs369771 ENSG00000251136.7 RP11-37B2.1 -3.91 0.000125 0.0418 -0.26 -0.26 Leprosy; chr8:89823884 chr8:89609409~89757727:- CESC cis rs9309473 1 rs10187416 ENSG00000163016.8 ALMS1P 3.91 0.000125 0.0418 0.33 0.26 Metabolite levels; chr2:73486614 chr2:73644919~73685576:+ CESC cis rs9309473 0.95 rs10207264 ENSG00000163016.8 ALMS1P 3.91 0.000125 0.0418 0.33 0.26 Metabolite levels; chr2:73486970 chr2:73644919~73685576:+ CESC cis rs2407103 1 rs16885876 ENSG00000253123.3 RP11-527N22.1 -3.91 0.000125 0.0418 -0.48 -0.26 Insulin resistance/response; chr8:37082437 chr8:37326575~37331984:- CESC cis rs67311347 0.955 rs11719205 ENSG00000223797.4 ENTPD3-AS1 3.91 0.000125 0.0418 0.25 0.26 Renal cell carcinoma; chr3:40375767 chr3:40313802~40453329:- CESC cis rs9487094 0.689 rs1074766 ENSG00000260273.1 RP11-425D10.10 3.91 0.000125 0.0418 0.31 0.26 Height; chr6:109360263 chr6:109382795~109383666:+ CESC cis rs6540731 1 rs6540733 ENSG00000226251.4 RP11-15I11.3 -3.91 0.000125 0.0418 -0.29 -0.26 Intelligence (childhood); chr1:212219611 chr1:212225278~212238977:- CESC cis rs853679 0.607 rs17763089 ENSG00000219392.1 RP1-265C24.5 -3.91 0.000125 0.0418 -0.52 -0.26 Depression; chr6:27867440 chr6:28115628~28116551:+ CESC cis rs853679 0.546 rs17695758 ENSG00000219392.1 RP1-265C24.5 -3.91 0.000125 0.0418 -0.52 -0.26 Depression; chr6:27869405 chr6:28115628~28116551:+ CESC cis rs6928977 0.5 rs719885 ENSG00000234084.1 RP3-388E23.2 -3.91 0.000125 0.0418 -0.22 -0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135618217 chr6:135301568~135307158:+ CESC cis rs2002030 0.658 rs11774655 ENSG00000254866.2 DEFB109P3 -3.91 0.000125 0.0418 -0.56 -0.26 Cognitive performance; chr8:11413917 chr8:12150895~12151134:- CESC cis rs4356203 0.875 rs11024136 ENSG00000272034.1 SNORD14A -3.91 0.000125 0.0418 -0.25 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17042850 chr11:17074654~17074744:- CESC cis rs2243480 1 rs4149468 ENSG00000067601.7 PMS2P4 3.91 0.000125 0.0419 0.49 0.26 Diabetic kidney disease; chr7:66360703 chr7:67295608~67302907:- CESC cis rs988913 0.793 rs995851 ENSG00000224984.1 RP11-524H19.2 3.91 0.000125 0.0419 0.27 0.26 Menarche (age at onset); chr6:54870796 chr6:54840118~54840855:- CESC cis rs783540 0.521 rs28719490 ENSG00000278202.1 RP11-152F13.8 -3.91 0.000125 0.0419 -0.24 -0.26 Schizophrenia; chr15:82720688 chr15:82418651~82434235:+ CESC cis rs853679 0.517 rs6932109 ENSG00000280107.1 AL022393.9 3.91 0.000125 0.0419 0.34 0.26 Depression; chr6:28110525 chr6:28170845~28172521:+ CESC cis rs6687821 0.531 rs4623671 ENSG00000267734.1 RP4-604K5.3 -3.91 0.000125 0.0419 -0.29 -0.26 Yeast infection; chr1:87018537 chr1:86932199~86934891:- CESC cis rs7923837 0.65 rs11187007 ENSG00000236493.2 EIF2S2P3 3.91 0.000125 0.0419 0.33 0.26 Multiple sclerosis;Body mass index; chr10:92454823 chr10:92668745~92669743:- CESC cis rs11779988 0.545 rs411531 ENSG00000253671.1 RP11-806O11.1 -3.91 0.000125 0.042 -0.31 -0.26 Breast cancer; chr8:17938425 chr8:17808941~17820868:+ CESC cis rs2638953 0.604 rs10843100 ENSG00000278733.1 RP11-425D17.1 -3.91 0.000125 0.042 -0.39 -0.26 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28117101 chr12:28185625~28186190:- CESC cis rs2641697 0.927 rs2641698 ENSG00000270124.1 RP11-118F19.1 3.91 0.000125 0.042 0.3 0.26 Mortality in sepsis; chr16:84852424 chr16:85580009~85583571:- CESC cis rs17301013 0.507 rs1653630 ENSG00000227373.4 RP11-160H22.5 -3.91 0.000125 0.042 -0.34 -0.26 Systemic lupus erythematosus; chr1:174791810 chr1:174115300~174160004:- CESC cis rs10895275 0.886 rs2187525 ENSG00000277459.1 RP11-732A21.3 3.91 0.000125 0.042 0.26 0.26 Migraine; chr11:102178985 chr11:102109827~102110457:- CESC cis rs801193 0.591 rs4506088 ENSG00000275400.1 RP4-756H11.5 -3.91 0.000125 0.042 -0.28 -0.26 Aortic root size; chr7:66670470 chr7:66553805~66554199:- CESC cis rs9326248 0.53 rs10732856 ENSG00000280143.1 AP000892.6 3.91 0.000125 0.042 0.43 0.26 Blood protein levels; chr11:117036397 chr11:117204967~117210292:+ CESC cis rs11992162 1 rs7460395 ENSG00000269918.1 AF131215.9 3.91 0.000125 0.042 0.31 0.26 Monocyte count; chr8:11977866 chr8:11104691~11106704:- CESC cis rs9487094 0.67 rs1885691 ENSG00000260273.1 RP11-425D10.10 3.91 0.000125 0.042 0.31 0.26 Height; chr6:109382188 chr6:109382795~109383666:+ CESC cis rs516805 0.63 rs499825 ENSG00000279453.1 RP3-425C14.4 -3.91 0.000125 0.042 -0.32 -0.26 Lymphocyte counts; chr6:122454050 chr6:122436789~122439223:- CESC cis rs2337406 0.85 rs75196489 ENSG00000211974.3 IGHV2-70 -3.91 0.000126 0.042 -0.38 -0.26 Alzheimer's disease (late onset); chr14:106699438 chr14:106723574~106724093:- CESC cis rs703842 1 rs2072052 ENSG00000270039.1 RP11-571M6.17 -3.91 0.000126 0.042 -0.31 -0.26 Multiple sclerosis; chr12:57752936 chr12:57803838~57804415:+ CESC cis rs2243480 0.901 rs13237344 ENSG00000067601.7 PMS2P4 3.91 0.000126 0.0421 0.49 0.26 Diabetic kidney disease; chr7:66557269 chr7:67295608~67302907:- CESC cis rs77926410 0.685 rs7309785 ENSG00000245648.1 RP11-277P12.20 3.91 0.000126 0.0421 0.39 0.26 Mean corpuscular volume; chr12:10457947 chr12:10363769~10398506:+ CESC cis rs7937890 0.904 rs7484197 ENSG00000254418.1 RP11-21L19.1 3.9 0.000126 0.0421 0.28 0.26 Mitochondrial DNA levels; chr11:14262108 chr11:14262846~14273691:- CESC cis rs875971 0.545 rs10950036 ENSG00000236529.1 RP13-254B10.1 3.9 0.000126 0.0421 0.3 0.26 Aortic root size; chr7:66353241 chr7:65840212~65840596:+ CESC cis rs875971 0.597 rs11763224 ENSG00000226824.5 RP4-756H11.3 -3.9 0.000126 0.0421 -0.37 -0.26 Aortic root size; chr7:66518628 chr7:66654538~66669855:+ CESC cis rs77636220 1 rs16930623 ENSG00000270673.1 YTHDF3-AS1 3.9 0.000126 0.0421 0.4 0.26 Body mass index; chr8:63728138 chr8:63167725~63168442:- CESC cis rs6504622 0.935 rs62075889 ENSG00000263142.4 LRRC37A17P -3.9 0.000126 0.0421 -0.21 -0.26 Orofacial clefts; chr17:46950671 chr17:46978481~47054569:+ CESC cis rs6504622 1 rs12940071 ENSG00000263142.4 LRRC37A17P -3.9 0.000126 0.0421 -0.21 -0.26 Orofacial clefts; chr17:46950686 chr17:46978481~47054569:+ CESC cis rs490234 0.702 rs10120000 ENSG00000232630.1 PRPS1P2 -3.9 0.000126 0.0421 -0.22 -0.26 Mean arterial pressure; chr9:125526149 chr9:125150653~125151589:+ CESC cis rs4666002 0.51 rs74446114 ENSG00000223522.1 AC093690.1 3.9 0.000126 0.0421 0.35 0.26 Phospholipid levels (plasma); chr2:27843255 chr2:28307691~28310459:- CESC cis rs17301013 0.507 rs6689153 ENSG00000227373.4 RP11-160H22.5 3.9 0.000126 0.0421 0.33 0.26 Systemic lupus erythematosus; chr1:174639550 chr1:174115300~174160004:- CESC cis rs2408955 0.568 rs12099462 ENSG00000258273.1 RP11-370I10.4 3.9 0.000126 0.0421 0.29 0.26 Glycated hemoglobin levels; chr12:48109321 chr12:48333755~48333901:- CESC cis rs9393777 0.588 rs11967935 ENSG00000241549.7 GUSBP2 3.9 0.000126 0.0421 0.32 0.26 Intelligence (multi-trait analysis); chr6:26560444 chr6:26871484~26956554:- CESC cis rs55794721 0.509 rs12027135 ENSG00000261349.1 RP3-465N24.5 -3.9 0.000126 0.0421 -0.26 -0.26 Mean corpuscular volume;Plateletcrit; chr1:25449242 chr1:25266102~25267136:- CESC cis rs8031584 0.652 rs2691683 ENSG00000260382.1 RP11-540B6.2 -3.9 0.000126 0.0421 -0.35 -0.26 Huntington's disease progression; chr15:30842857 chr15:30882267~30883231:- CESC cis rs2243480 1 rs35421653 ENSG00000275400.1 RP4-756H11.5 3.9 0.000126 0.0422 0.44 0.26 Diabetic kidney disease; chr7:65898442 chr7:66553805~66554199:- CESC cis rs17301013 0.507 rs10798324 ENSG00000227373.4 RP11-160H22.5 -3.9 0.000126 0.0422 -0.33 -0.26 Systemic lupus erythematosus; chr1:174787485 chr1:174115300~174160004:- CESC cis rs703842 1 rs10783847 ENSG00000270039.1 RP11-571M6.17 -3.9 0.000126 0.0422 -0.31 -0.26 Multiple sclerosis; chr12:57802664 chr12:57803838~57804415:+ CESC cis rs7665090 0.87 rs228616 ENSG00000246560.2 RP11-10L12.4 -3.9 0.000126 0.0422 -0.32 -0.26 Primary biliary cholangitis; chr4:102658534 chr4:102828055~102844075:+ CESC cis rs9322193 0.884 rs9688699 ENSG00000216906.2 RP11-350J20.9 3.9 0.000126 0.0422 0.29 0.26 Lung cancer; chr6:149733680 chr6:149904243~149906418:+ CESC cis rs62025270 0.649 rs12148610 ENSG00000202081.1 RNU6-1280P -3.9 0.000126 0.0422 -0.35 -0.26 Idiopathic pulmonary fibrosis; chr15:85702697 chr15:85651522~85651628:- CESC cis rs62355900 0.627 rs61141156 ENSG00000271828.1 CTD-2310F14.1 3.9 0.000126 0.0423 0.4 0.26 Endometriosis; chr5:56842951 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs58151318 ENSG00000271828.1 CTD-2310F14.1 3.9 0.000126 0.0423 0.4 0.26 Endometriosis; chr5:56843355 chr5:56927874~56929573:+ CESC cis rs4877691 0.522 rs12683715 ENSG00000267559.4 RP11-383M4.6 -3.9 0.000126 0.0423 -0.35 -0.26 Airway imaging phenotypes; chr9:82477804 chr9:81930226~81977089:- CESC cis rs673078 0.607 rs73207578 ENSG00000275759.1 RP11-131L12.3 -3.9 0.000126 0.0423 -0.49 -0.26 Glucose homeostasis traits; chr12:118447080 chr12:118428281~118428870:+ CESC cis rs6740462 0.537 rs9677304 ENSG00000273763.1 RP11-420C9.1 -3.9 0.000126 0.0423 -0.4 -0.26 Inflammatory bowel disease;Crohn's disease; chr2:65456696 chr2:65203571~65203813:- CESC cis rs7896729 0.598 rs6601942 ENSG00000215267.7 AKR1C7P -3.9 0.000126 0.0423 -0.33 -0.26 Intelligence; chr10:5304122 chr10:5275173~5288470:- CESC cis rs9323326 0.602 rs8018443 ENSG00000257621.6 PSMA3-AS1 3.9 0.000126 0.0423 0.24 0.26 Gut microbiota (bacterial taxa); chr14:58039176 chr14:58265365~58298134:- CESC cis rs2790457 0.917 rs1265831 ENSG00000254635.4 WAC-AS1 -3.9 0.000127 0.0423 -0.3 -0.26 Multiple myeloma; chr10:28623921 chr10:28522652~28532743:- CESC cis rs11608355 0.538 rs10850074 ENSG00000257221.1 RP11-689B22.2 -3.9 0.000127 0.0423 -0.23 -0.26 Neuroticism; chr12:109362726 chr12:108628687~108641318:+ CESC cis rs10129255 0.785 rs10150044 ENSG00000211974.3 IGHV2-70 3.9 0.000127 0.0423 0.26 0.26 Kawasaki disease; chr14:106775695 chr14:106723574~106724093:- CESC cis rs9903692 0.954 rs9899461 ENSG00000263412.1 RP5-890E16.2 3.9 0.000127 0.0423 0.27 0.26 Pulse pressure; chr17:48051991 chr17:48045141~48048073:- CESC cis rs801193 0.569 rs2659907 ENSG00000275400.1 RP4-756H11.5 3.9 0.000127 0.0423 0.28 0.26 Aortic root size; chr7:66699045 chr7:66553805~66554199:- CESC cis rs6546537 0.955 rs1396798 ENSG00000231024.1 AC092431.3 3.9 0.000127 0.0424 0.3 0.26 Serum thyroid-stimulating hormone levels; chr2:69660705 chr2:69700192~69713847:- CESC cis rs7873102 0.702 rs4878734 ENSG00000230188.1 RP11-405L18.4 -3.9 0.000127 0.0424 -0.32 -0.26 Brain structure; chr9:38010088 chr9:37490421~37490893:- CESC cis rs2439831 0.85 rs8023458 ENSG00000249839.1 AC011330.5 -3.9 0.000127 0.0424 -0.37 -0.26 Lung cancer in ever smokers; chr15:43788741 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs16963953 ENSG00000249839.1 AC011330.5 -3.9 0.000127 0.0424 -0.37 -0.26 Lung cancer in ever smokers; chr15:43789521 chr15:43663654~43684339:- CESC cis rs453301 0.571 rs2929452 ENSG00000254340.1 RP11-10A14.3 -3.9 0.000127 0.0424 -0.31 -0.26 Joint mobility (Beighton score); chr8:9226955 chr8:9141424~9145435:+ CESC cis rs2412819 0.571 rs4923965 ENSG00000249839.1 AC011330.5 3.9 0.000127 0.0424 0.34 0.26 Lung cancer; chr15:43790232 chr15:43663654~43684339:- CESC cis rs2412819 0.571 rs6493090 ENSG00000249839.1 AC011330.5 3.9 0.000127 0.0424 0.34 0.26 Lung cancer; chr15:43792084 chr15:43663654~43684339:- CESC cis rs875971 0.545 rs1796219 ENSG00000224316.1 RP11-479O9.2 -3.9 0.000127 0.0424 -0.35 -0.26 Aortic root size; chr7:66645977 chr7:65773620~65802067:+ CESC cis rs67311347 1 rs13324109 ENSG00000223797.4 ENTPD3-AS1 3.9 0.000127 0.0424 0.25 0.26 Renal cell carcinoma; chr3:40419276 chr3:40313802~40453329:- CESC cis rs453301 0.506 rs476845 ENSG00000253893.2 FAM85B 3.9 0.000127 0.0424 0.3 0.26 Joint mobility (Beighton score); chr8:8765367 chr8:8167819~8226614:- CESC cis rs5742933 0.857 rs11685425 ENSG00000253559.1 OSGEPL1-AS1 3.9 0.000127 0.0424 0.3 0.26 Ferritin levels; chr2:189747977 chr2:189762704~189765556:+ CESC cis rs9322193 0.884 rs2064521 ENSG00000268592.3 RAET1E-AS1 -3.9 0.000127 0.0424 -0.34 -0.26 Lung cancer; chr6:149625336 chr6:149863494~149919507:+ CESC cis rs2548724 0.716 rs6881112 ENSG00000250682.4 LINC00491 3.9 0.000127 0.0425 0.31 0.26 Type 2 diabetes; chr5:102440038 chr5:102609156~102671559:- CESC cis rs1113500 0.933 rs61797345 ENSG00000226822.1 RP11-356N1.2 3.9 0.000127 0.0425 0.33 0.26 Growth-regulated protein alpha levels; chr1:108081106 chr1:108071482~108074519:+ CESC cis rs1113500 0.933 rs10494089 ENSG00000226822.1 RP11-356N1.2 3.9 0.000127 0.0425 0.33 0.26 Growth-regulated protein alpha levels; chr1:108084073 chr1:108071482~108074519:+ CESC cis rs1113500 0.933 rs745795 ENSG00000226822.1 RP11-356N1.2 3.9 0.000127 0.0425 0.33 0.26 Growth-regulated protein alpha levels; chr1:108086723 chr1:108071482~108074519:+ CESC cis rs1113500 0.933 rs2077259 ENSG00000226822.1 RP11-356N1.2 3.9 0.000127 0.0425 0.33 0.26 Growth-regulated protein alpha levels; chr1:108086929 chr1:108071482~108074519:+ CESC cis rs10129255 0.536 rs17113249 ENSG00000280411.1 IGHV1-69-2 -3.9 0.000127 0.0425 -0.17 -0.26 Kawasaki disease; chr14:106678273 chr14:106762092~106762588:- CESC cis rs1075265 0.54 rs2542587 ENSG00000272156.1 RP11-477N3.1 -3.9 0.000127 0.0425 -0.31 -0.26 Chronotype;Morning vs. evening chronotype; chr2:53788839 chr2:54082554~54085066:+ CESC cis rs1075265 0.563 rs2692537 ENSG00000272156.1 RP11-477N3.1 -3.9 0.000127 0.0425 -0.31 -0.26 Chronotype;Morning vs. evening chronotype; chr2:53788840 chr2:54082554~54085066:+ CESC cis rs17301013 0.507 rs74128393 ENSG00000227373.4 RP11-160H22.5 3.9 0.000127 0.0425 0.38 0.26 Systemic lupus erythematosus; chr1:174407961 chr1:174115300~174160004:- CESC cis rs3105491 0.616 rs7557572 ENSG00000274877.1 RP11-65I12.1 -3.9 0.000127 0.0425 -0.46 -0.26 Systolic blood pressure in sickle cell anemia; chr2:114201482 chr2:113237595~113240825:+ CESC cis rs17301013 0.507 rs72715224 ENSG00000227373.4 RP11-160H22.5 3.9 0.000127 0.0425 0.36 0.26 Systemic lupus erythematosus; chr1:174534256 chr1:174115300~174160004:- CESC cis rs7809950 1 rs986994 ENSG00000238832.1 snoU109 -3.9 0.000128 0.0425 -0.31 -0.26 Coronary artery disease; chr7:107463670 chr7:107603363~107603507:+ CESC cis rs8127691 0.967 rs4456788 ENSG00000225331.1 AP001055.6 3.9 0.000128 0.0426 0.31 0.26 Inflammatory bowel disease; chr21:44196441 chr21:44158740~44160076:- CESC cis rs9907295 0.748 rs4795091 ENSG00000271013.1 AC015849.15 -3.9 0.000128 0.0426 -0.35 -0.26 Fibroblast growth factor basic levels; chr17:35814874 chr17:35912635~35918010:- CESC cis rs9907295 0.71 rs4795092 ENSG00000271013.1 AC015849.15 -3.9 0.000128 0.0426 -0.35 -0.26 Fibroblast growth factor basic levels; chr17:35814967 chr17:35912635~35918010:- CESC cis rs875971 1 rs2036264 ENSG00000179406.6 LINC00174 3.9 0.000128 0.0426 0.27 0.26 Aortic root size; chr7:66334917 chr7:66376044~66401338:- CESC cis rs875971 1 rs7783613 ENSG00000179406.6 LINC00174 3.9 0.000128 0.0426 0.27 0.26 Aortic root size; chr7:66340274 chr7:66376044~66401338:- CESC cis rs2742417 0.603 rs1962800 ENSG00000244357.3 RN7SL145P 3.9 0.000128 0.0426 0.25 0.26 Response to anti-depressant treatment in major depressive disorder; chr3:45738451 chr3:45742675~45742970:+ CESC cis rs2302729 0.578 rs11062298 ENSG00000243663.1 RPS4XP14 -3.9 0.000128 0.0426 -0.28 -0.26 Sleep quality; chr12:2662543 chr12:1757231~1758011:- CESC cis rs9866261 0.695 rs11706709 ENSG00000241359.1 SYNPR-AS1 -3.9 0.000128 0.0426 -0.34 -0.26 Asthma; chr3:64525341 chr3:63423596~63550051:- CESC cis rs490234 0.841 rs10114882 ENSG00000232630.1 PRPS1P2 -3.9 0.000128 0.0426 -0.22 -0.26 Mean arterial pressure; chr9:125541146 chr9:125150653~125151589:+ CESC cis rs516805 0.502 rs508468 ENSG00000218180.2 SLC25A5P7 3.9 0.000128 0.0426 0.3 0.26 Lymphocyte counts; chr6:122441902 chr6:121653795~121654690:+ CESC cis rs944801 0.566 rs10115049 ENSG00000277653.1 CDKN2B-AS 3.9 0.000128 0.0426 0.24 0.26 Type 2 diabetes; chr9:22032120 chr9:22117665~22117814:+ CESC cis rs6844153 0.752 rs10029307 ENSG00000240005.4 RP11-293A21.1 -3.9 0.000128 0.0426 -0.33 -0.26 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26902591 chr4:26859806~26860599:- CESC cis rs73222236 0.825 rs9843801 ENSG00000242968.1 RP11-731C17.1 -3.9 0.000128 0.0426 -0.28 -0.26 Coronary artery disease; chr3:136281904 chr3:136808551~136809623:- CESC cis rs748404 0.626 rs57938858 ENSG00000249839.1 AC011330.5 -3.9 0.000128 0.0426 -0.38 -0.26 Lung cancer; chr15:43520259 chr15:43663654~43684339:- CESC cis rs17772222 0.958 rs17798341 ENSG00000258983.2 RP11-507K2.2 3.9 0.000128 0.0426 0.33 0.26 Coronary artery calcification; chr14:88548201 chr14:88499334~88515502:+ CESC cis rs12435908 1 rs10083346 ENSG00000259078.2 PTBP1P 3.9 0.000128 0.0426 0.4 0.26 Ischemic stroke; chr14:65386555 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs10083348 ENSG00000259078.2 PTBP1P 3.9 0.000128 0.0426 0.4 0.26 Ischemic stroke; chr14:65386683 chr14:65279267~65281166:+ CESC cis rs748404 0.697 rs572959 ENSG00000205771.5 CATSPER2P1 -3.9 0.000128 0.0427 -0.3 -0.26 Lung cancer; chr15:43258304 chr15:43726918~43747094:- CESC cis rs1930961 1 rs6004673 ENSG00000272942.1 CTA-246H3.12 -3.9 0.000128 0.0427 -0.39 -0.26 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25434324~25435070:- CESC cis rs2179367 0.959 rs521845 ENSG00000231760.4 RP11-350J20.5 -3.9 0.000128 0.0427 -0.31 -0.26 Dupuytren's disease; chr6:149350562 chr6:149796151~149826294:- CESC cis rs1501911 0.527 rs109843 ENSG00000248489.1 CTD-2007H13.3 3.9 0.000128 0.0427 0.29 0.26 Lung function (FEV1/FVC); chr5:98985233 chr5:98929171~98995013:+ CESC cis rs61869271 0.805 rs7086663 ENSG00000236799.1 RP11-383C6.2 -3.9 0.000128 0.0427 -0.32 -0.26 Tonsillectomy; chr10:115006577 chr10:114994657~114996593:+ CESC cis rs881375 0.967 rs1930781 ENSG00000226752.6 PSMD5-AS1 -3.9 0.000128 0.0427 -0.28 -0.26 Rheumatoid arthritis; chr9:120925556 chr9:120824828~120854385:+ CESC cis rs881375 0.967 rs2416806 ENSG00000226752.6 PSMD5-AS1 -3.9 0.000128 0.0427 -0.28 -0.26 Rheumatoid arthritis; chr9:120928014 chr9:120824828~120854385:+ CESC cis rs881375 0.933 rs7028641 ENSG00000226752.6 PSMD5-AS1 -3.9 0.000128 0.0427 -0.28 -0.26 Rheumatoid arthritis; chr9:120928863 chr9:120824828~120854385:+ CESC cis rs2303759 0.551 rs7249040 ENSG00000268686.1 AC010524.2 -3.9 0.000128 0.0427 -0.39 -0.26 Multiple sclerosis; chr19:49287345 chr19:49368705~49388081:- CESC cis rs7508 0.512 rs2283109 ENSG00000253671.1 RP11-806O11.1 -3.9 0.000128 0.0428 -0.26 -0.26 Atrial fibrillation; chr8:18021063 chr8:17808941~17820868:+ CESC cis rs5742933 0.857 rs893784 ENSG00000253559.1 OSGEPL1-AS1 -3.9 0.000128 0.0428 -0.31 -0.26 Ferritin levels; chr2:189671557 chr2:189762704~189765556:+ CESC cis rs7508 0.512 rs2283114 ENSG00000253671.1 RP11-806O11.1 -3.9 0.000128 0.0428 -0.26 -0.26 Atrial fibrillation; chr8:18022751 chr8:17808941~17820868:+ CESC cis rs7508 0.512 rs3886398 ENSG00000253671.1 RP11-806O11.1 -3.9 0.000128 0.0428 -0.26 -0.26 Atrial fibrillation; chr8:18023107 chr8:17808941~17820868:+ CESC cis rs2299587 0.786 rs3886397 ENSG00000253671.1 RP11-806O11.1 -3.9 0.000128 0.0428 -0.26 -0.26 Economic and political preferences; chr8:18023116 chr8:17808941~17820868:+ CESC cis rs4775302 0.967 rs1564780 ENSG00000275709.1 RP11-96O20.5 -3.9 0.000128 0.0428 -0.27 -0.26 Prostate cancer; chr15:46349668 chr15:45585757~45586304:- CESC cis rs2404602 0.716 rs12917430 ENSG00000280730.1 AC090181.1 3.9 0.000128 0.0428 0.2 0.26 Blood metabolite levels; chr15:76382019 chr15:77056895~77057021:+ CESC cis rs10129255 0.957 rs10137980 ENSG00000211974.3 IGHV2-70 3.9 0.000128 0.0428 0.26 0.26 Kawasaki disease; chr14:106775735 chr14:106723574~106724093:- CESC cis rs2243480 0.908 rs4718273 ENSG00000275400.1 RP4-756H11.5 -3.9 0.000129 0.0428 -0.44 -0.26 Diabetic kidney disease; chr7:65751112 chr7:66553805~66554199:- CESC cis rs1823913 0.599 rs1823912 ENSG00000227542.1 AC092614.2 3.9 0.000129 0.0428 0.26 0.26 Obesity-related traits; chr2:191266388 chr2:191229165~191246172:- CESC cis rs3091242 0.836 rs34997029 ENSG00000261349.1 RP3-465N24.5 3.9 0.000129 0.0428 0.26 0.26 Erythrocyte sedimentation rate; chr1:25457332 chr1:25266102~25267136:- CESC cis rs13113518 1 rs13136282 ENSG00000273257.1 RP11-177J6.1 3.9 0.000129 0.0428 0.33 0.26 Height; chr4:55551845 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs11934897 ENSG00000273257.1 RP11-177J6.1 3.9 0.000129 0.0428 0.33 0.26 Height; chr4:55553396 chr4:55387949~55388271:+ CESC cis rs13113518 0.934 rs11932293 ENSG00000273257.1 RP11-177J6.1 3.9 0.000129 0.0428 0.33 0.26 Height; chr4:55554025 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs4865011 ENSG00000273257.1 RP11-177J6.1 3.9 0.000129 0.0428 0.33 0.26 Height; chr4:55554456 chr4:55387949~55388271:+ CESC cis rs2117029 0.737 rs34436857 ENSG00000258017.1 RP11-386G11.10 -3.9 0.000129 0.0428 -0.37 -0.26 Intelligence (multi-trait analysis); chr12:49045738 chr12:49127782~49147869:+ CESC cis rs1707322 0.89 rs2297883 ENSG00000281133.1 AL355480.3 3.9 0.000129 0.0428 0.3 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46045815 chr1:45580892~45580996:- CESC cis rs1707322 1 rs1707338 ENSG00000281133.1 AL355480.3 3.9 0.000129 0.0428 0.3 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46046309 chr1:45580892~45580996:- CESC cis rs1707322 0.964 rs1707339 ENSG00000281133.1 AL355480.3 3.9 0.000129 0.0428 0.3 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46047507 chr1:45580892~45580996:- CESC cis rs1707322 1 rs1768818 ENSG00000281133.1 AL355480.3 3.9 0.000129 0.0428 0.3 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46048614 chr1:45580892~45580996:- CESC cis rs1707322 1 rs1768817 ENSG00000281133.1 AL355480.3 3.9 0.000129 0.0428 0.3 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46048862 chr1:45580892~45580996:- CESC cis rs1707322 1 rs785470 ENSG00000281133.1 AL355480.3 3.9 0.000129 0.0428 0.3 0.26 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46053950 chr1:45580892~45580996:- CESC cis rs9322193 0.847 rs868375 ENSG00000223701.3 RAET1E-AS1 3.9 0.000129 0.0428 0.31 0.26 Lung cancer; chr6:149844905 chr6:149884431~149919508:+ CESC cis rs751837 0.518 rs74085588 ENSG00000240624.1 RP11-45P15.2 -3.9 0.000129 0.0428 -0.47 -0.26 Large B-cell lymphoma; chr14:102990365 chr14:103282933~103283468:+ CESC cis rs10129255 0.518 rs2006284 ENSG00000280411.1 IGHV1-69-2 -3.9 0.000129 0.0428 -0.17 -0.26 Kawasaki disease; chr14:106676185 chr14:106762092~106762588:- CESC cis rs5742933 0.762 rs12992061 ENSG00000253559.1 OSGEPL1-AS1 3.9 0.000129 0.0429 0.3 0.26 Ferritin levels; chr2:189736026 chr2:189762704~189765556:+ CESC cis rs67311347 1 rs9835219 ENSG00000223797.4 ENTPD3-AS1 3.9 0.000129 0.0429 0.26 0.26 Renal cell carcinoma; chr3:40382602 chr3:40313802~40453329:- CESC cis rs67311347 1 rs7642552 ENSG00000223797.4 ENTPD3-AS1 3.9 0.000129 0.0429 0.26 0.26 Renal cell carcinoma; chr3:40383325 chr3:40313802~40453329:- CESC cis rs116139393 0.611 rs7792579 ENSG00000187953.9 PMS2CL -3.9 0.000129 0.0429 -0.35 -0.26 Alzheimer's disease (APOE e4 interaction); chr7:6725962 chr7:6710128~6753862:+ CESC cis rs7688540 0.8 rs9328737 ENSG00000211553.1 AC253576.2 -3.9 0.000129 0.0429 -0.34 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:252176 chr4:136461~136568:+ CESC cis rs875971 0.545 rs1547529 ENSG00000236529.1 RP13-254B10.1 3.9 0.000129 0.0429 0.3 0.26 Aortic root size; chr7:66258859 chr7:65840212~65840596:+ CESC cis rs5753618 0.583 rs7287267 ENSG00000236132.1 CTA-440B3.1 -3.9 0.000129 0.0429 -0.31 -0.26 Colorectal cancer; chr22:31352429 chr22:31816379~31817491:- CESC cis rs490234 0.676 rs13293034 ENSG00000232630.1 PRPS1P2 -3.9 0.000129 0.0429 -0.22 -0.26 Mean arterial pressure; chr9:125494672 chr9:125150653~125151589:+ CESC cis rs490234 0.702 rs13284572 ENSG00000232630.1 PRPS1P2 -3.9 0.000129 0.0429 -0.22 -0.26 Mean arterial pressure; chr9:125495991 chr9:125150653~125151589:+ CESC cis rs490234 0.702 rs1891035 ENSG00000232630.1 PRPS1P2 -3.9 0.000129 0.0429 -0.22 -0.26 Mean arterial pressure; chr9:125496405 chr9:125150653~125151589:+ CESC cis rs76878669 0.561 rs10896112 ENSG00000255468.5 RP11-867G23.8 3.9 0.000129 0.0429 0.29 0.26 Educational attainment (years of education); chr11:66349365 chr11:66347950~66364804:+ CESC cis rs76878669 0.538 rs73489638 ENSG00000255468.5 RP11-867G23.8 3.9 0.000129 0.0429 0.29 0.26 Educational attainment (years of education); chr11:66360168 chr11:66347950~66364804:+ CESC cis rs748404 0.697 rs501884 ENSG00000205771.5 CATSPER2P1 -3.9 0.000129 0.0429 -0.3 -0.26 Lung cancer; chr15:43261784 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs504417 ENSG00000205771.5 CATSPER2P1 -3.9 0.000129 0.0429 -0.3 -0.26 Lung cancer; chr15:43262028 chr15:43726918~43747094:- CESC cis rs748404 0.723 rs560134 ENSG00000205771.5 CATSPER2P1 -3.9 0.000129 0.0429 -0.3 -0.26 Lung cancer; chr15:43263501 chr15:43726918~43747094:- CESC cis rs8081395 0.775 rs2526355 ENSG00000266992.1 DHX40P1 3.9 0.000129 0.0429 0.27 0.26 White blood cell count; chr17:59875872 chr17:59976009~60002384:- CESC cis rs1292048 1 rs1292048 ENSG00000266992.1 DHX40P1 3.9 0.000129 0.0429 0.27 0.26 Red cell distribution width; chr17:59877710 chr17:59976009~60002384:- CESC cis rs748404 0.697 rs554001 ENSG00000205771.5 CATSPER2P1 -3.9 0.000129 0.0429 -0.3 -0.26 Lung cancer; chr15:43259721 chr15:43726918~43747094:- CESC cis rs1345301 1 rs13405355 ENSG00000234389.1 AC007278.3 -3.9 0.000129 0.0429 -0.25 -0.26 Waist circumference; chr2:102261746 chr2:102438713~102440475:+ CESC cis rs62025270 0.632 rs10520594 ENSG00000202081.1 RNU6-1280P 3.9 0.000129 0.0429 0.34 0.26 Idiopathic pulmonary fibrosis; chr15:85585410 chr15:85651522~85651628:- CESC cis rs9322193 0.962 rs2151912 ENSG00000223701.3 RAET1E-AS1 3.9 0.000129 0.0429 0.3 0.26 Lung cancer; chr6:149831772 chr6:149884431~149919508:+ CESC cis rs1976403 0.659 rs10799700 ENSG00000227001.3 NBPF2P 3.9 0.000129 0.0429 0.27 0.26 Liver enzyme levels (alkaline phosphatase); chr1:21494475 chr1:21424625~21427967:- CESC cis rs62355900 0.627 rs16886403 ENSG00000271828.1 CTD-2310F14.1 3.9 0.000129 0.043 0.4 0.26 Endometriosis; chr5:56843419 chr5:56927874~56929573:+ CESC cis rs2439831 0.85 rs7179388 ENSG00000249839.1 AC011330.5 -3.9 0.000129 0.043 -0.39 -0.26 Lung cancer in ever smokers; chr15:43831747 chr15:43663654~43684339:- CESC cis rs2439831 0.702 rs16977724 ENSG00000249839.1 AC011330.5 -3.9 0.000129 0.043 -0.39 -0.26 Lung cancer in ever smokers; chr15:43859101 chr15:43663654~43684339:- CESC cis rs875971 1 rs6945843 ENSG00000237310.1 GS1-124K5.4 -3.9 0.000129 0.043 -0.24 -0.26 Aortic root size; chr7:66269796 chr7:66493706~66495474:+ CESC cis rs4819052 1 rs2297285 ENSG00000223768.1 LINC00205 3.9 0.000129 0.043 0.33 0.26 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45285706 chr21:45293285~45297354:+ CESC cis rs13113518 0.934 rs11133397 ENSG00000273257.1 RP11-177J6.1 3.9 0.000129 0.043 0.33 0.26 Height; chr4:55534166 chr4:55387949~55388271:+ CESC cis rs13113518 0.934 rs11133398 ENSG00000273257.1 RP11-177J6.1 3.9 0.000129 0.043 0.33 0.26 Height; chr4:55534180 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs13152173 ENSG00000273257.1 RP11-177J6.1 3.9 0.000129 0.043 0.33 0.26 Height; chr4:55534788 chr4:55387949~55388271:+ CESC cis rs2261181 0.803 rs2612057 ENSG00000276853.1 RP11-305O6.4 3.9 0.000129 0.043 0.61 0.26 Type 2 diabetes; chr12:65843630 chr12:65171262~65171917:+ CESC cis rs2261181 0.522 rs2583936 ENSG00000276853.1 RP11-305O6.4 3.9 0.000129 0.043 0.61 0.26 Type 2 diabetes; chr12:65845272 chr12:65171262~65171917:+ CESC cis rs3213758 0.541 rs7187504 ENSG00000275191.1 RP11-36I17.2 -3.9 0.00013 0.043 -0.43 -0.26 Vitiligo (non-segmental); chr16:53696788 chr16:53628256~53628816:- CESC cis rs3213758 0.541 rs7204936 ENSG00000275191.1 RP11-36I17.2 -3.9 0.00013 0.043 -0.43 -0.26 Vitiligo (non-segmental); chr16:53696879 chr16:53628256~53628816:- CESC cis rs875971 0.545 rs12670811 ENSG00000236529.1 RP13-254B10.1 3.9 0.00013 0.043 0.31 0.26 Aortic root size; chr7:66358032 chr7:65840212~65840596:+ CESC cis rs7811142 0.83 rs10085549 ENSG00000242294.5 STAG3L5P 3.9 0.00013 0.043 0.26 0.26 Platelet count; chr7:100385512 chr7:100336079~100351900:+ CESC cis rs1799949 0.628 rs4474733 ENSG00000267681.1 CTD-3199J23.6 -3.9 0.00013 0.043 -0.37 -0.26 Menopause (age at onset); chr17:43356292 chr17:43144956~43145255:+ CESC cis rs972578 0.715 rs4822205 ENSG00000274717.1 RP1-47A17.1 -3.9 0.00013 0.043 -0.3 -0.26 Mean platelet volume; chr22:42850812 chr22:42791814~42794313:- CESC cis rs17772222 0.917 rs61984684 ENSG00000258983.2 RP11-507K2.2 3.9 0.00013 0.0431 0.33 0.26 Coronary artery calcification; chr14:88559104 chr14:88499334~88515502:+ CESC cis rs3217992 0.77 rs3218020 ENSG00000215221.2 UBA52P6 3.9 0.00013 0.0431 0.33 0.26 Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale); chr9:21997873 chr9:22012155~22012536:+ CESC cis rs67180937 0.645 rs2270707 ENSG00000272750.1 RP11-378J18.8 3.9 0.00013 0.0431 0.33 0.26 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222664252 chr1:222658867~222661512:- CESC cis rs67981189 0.529 rs8181986 ENSG00000269927.1 RP6-91H8.3 3.9 0.00013 0.0431 0.28 0.26 Schizophrenia; chr14:71115527 chr14:71141125~71143253:- CESC cis rs748404 0.666 rs66629206 ENSG00000249839.1 AC011330.5 -3.9 0.00013 0.0431 -0.37 -0.26 Lung cancer; chr15:43458804 chr15:43663654~43684339:- CESC cis rs11089937 0.864 rs5757041 ENSG00000211639.2 IGLV4-60 3.9 0.00013 0.0431 0.23 0.26 Periodontitis (PAL4Q3); chr22:22140538 chr22:22162199~22162681:+ CESC cis rs7246657 0.638 rs7246461 ENSG00000276846.1 CTD-3220F14.3 -3.9 0.00013 0.0431 -0.31 -0.26 Coronary artery calcification; chr19:37705680 chr19:37314868~37315620:- CESC cis rs17772222 0.917 rs12587200 ENSG00000258983.2 RP11-507K2.2 3.9 0.00013 0.0431 0.31 0.26 Coronary artery calcification; chr14:88632060 chr14:88499334~88515502:+ CESC cis rs4742903 0.967 rs7871759 ENSG00000270332.1 SMC2-AS1 3.9 0.00013 0.0431 0.25 0.26 Breast cancer;High-grade serous ovarian cancer; chr9:104103157 chr9:104080024~104093073:- CESC cis rs2243480 1 rs958550 ENSG00000275400.1 RP4-756H11.5 -3.9 0.00013 0.0431 -0.44 -0.26 Diabetic kidney disease; chr7:66170692 chr7:66553805~66554199:- CESC cis rs9908102 0.77 rs8071726 ENSG00000263648.1 RP11-471L13.3 -3.9 0.00013 0.0431 -0.35 -0.26 Schizophrenia; chr17:13011267 chr17:12115547~12115885:+ CESC cis rs11971779 0.616 rs10269683 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0431 0.24 0.26 Diisocyanate-induced asthma; chr7:139416122 chr7:139359032~139359566:- CESC cis rs13179411 0.517 rs35096828 ENSG00000273345.4 CTD-2410N18.4 -3.9 0.00013 0.0431 -0.26 -0.26 Menarche (age at onset); chr5:134561749 chr5:134205614~134371044:- CESC cis rs13179411 0.517 rs10056247 ENSG00000273345.4 CTD-2410N18.4 -3.9 0.00013 0.0431 -0.26 -0.26 Menarche (age at onset); chr5:134562446 chr5:134205614~134371044:- CESC cis rs2404602 0.692 rs58973160 ENSG00000280730.1 AC090181.1 3.9 0.00013 0.0431 0.2 0.26 Blood metabolite levels; chr15:76708001 chr15:77056895~77057021:+ CESC cis rs875971 1 rs6460296 ENSG00000232559.3 GS1-124K5.12 3.9 0.00013 0.0431 0.28 0.26 Aortic root size; chr7:66430152 chr7:66554588~66576923:- CESC cis rs875971 1 rs2042133 ENSG00000232559.3 GS1-124K5.12 3.9 0.00013 0.0431 0.28 0.26 Aortic root size; chr7:66466935 chr7:66554588~66576923:- CESC cis rs875971 0.964 rs2161065 ENSG00000232559.3 GS1-124K5.12 3.9 0.00013 0.0431 0.28 0.26 Aortic root size; chr7:66467918 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs12698521 ENSG00000232559.3 GS1-124K5.12 3.9 0.00013 0.0431 0.28 0.26 Aortic root size; chr7:66474502 chr7:66554588~66576923:- CESC cis rs9348440 0.615 rs9465837 ENSG00000226786.2 RP1-167F1.2 3.9 0.00013 0.0432 0.31 0.26 Glycemic traits; chr6:20623948 chr6:19534944~19839080:- CESC cis rs3738443 0.868 rs12569042 ENSG00000259865.1 RP11-488L18.10 3.9 0.00013 0.0432 0.28 0.26 Alcohol dependence; chr1:247203078 chr1:247187281~247188526:- CESC cis rs11051970 0.918 rs12229856 ENSG00000255760.1 RP11-428G5.5 3.9 0.00013 0.0432 0.3 0.26 Response to tocilizumab in rheumatoid arthritis; chr12:32378286 chr12:31877079~31887203:- CESC cis rs733592 0.507 rs3825403 ENSG00000257735.1 RP11-370I10.6 -3.9 0.00013 0.0432 -0.28 -0.26 Plateletcrit; chr12:48063376 chr12:48350945~48442411:+ CESC cis rs704 0.584 rs6505081 ENSG00000263266.2 RPS7P1 -3.9 0.00013 0.0432 -0.19 -0.26 Osteoprotegerin levels; chr17:28410870 chr17:28467822~28468406:+ CESC cis rs17772222 0.917 rs61984683 ENSG00000258983.2 RP11-507K2.2 3.9 0.00013 0.0432 0.33 0.26 Coronary artery calcification; chr14:88553162 chr14:88499334~88515502:+ CESC cis rs11971779 0.523 rs10234578 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139353242 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs7784192 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139354903 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs3924296 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139357181 chr7:139359032~139359566:- CESC cis rs11971779 0.527 rs4379397 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139358639 chr7:139359032~139359566:- CESC cis rs11971779 0.774 rs6467838 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139358755 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6961812 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139359062 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs6962366 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139359121 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs3924445 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139359426 chr7:139359032~139359566:- CESC cis rs11971779 0.585 rs3922848 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139361464 chr7:139359032~139359566:- CESC cis rs11971779 0.59 rs6944104 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139366374 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs6944244 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139366440 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs7799598 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139367087 chr7:139359032~139359566:- CESC cis rs11971779 0.553 rs7799742 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139367132 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs10274480 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139367682 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs10229249 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139367764 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs11772026 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139367843 chr7:139359032~139359566:- CESC cis rs11971779 0.68 rs1133067 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139368323 chr7:139359032~139359566:- CESC cis rs11971779 0.616 rs1133068 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139368397 chr7:139359032~139359566:- CESC cis rs11971779 0.666 rs6467847 ENSG00000273391.1 RP11-634H22.1 3.9 0.00013 0.0432 0.24 0.26 Diisocyanate-induced asthma; chr7:139394690 chr7:139359032~139359566:- CESC cis rs673078 0.562 rs56347775 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118438002 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943451 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118438929 chr12:118428281~118428870:+ CESC cis rs673078 0.518 rs61943452 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118438990 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943454 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118439140 chr12:118428281~118428870:+ CESC cis rs673078 0.517 rs61943455 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118439414 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs73207566 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118439471 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs2393416 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118439968 chr12:118428281~118428870:+ CESC cis rs673078 0.56 rs4406856 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118440094 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs4457791 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118440144 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61943456 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118440326 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs17513006 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118440383 chr12:118428281~118428870:+ CESC cis rs673078 0.56 rs61943457 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118440487 chr12:118428281~118428870:+ CESC cis rs673078 0.562 rs55883417 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118440801 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs55842338 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118441259 chr12:118428281~118428870:+ CESC cis rs673078 0.518 rs17441251 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118441361 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs17513013 ENSG00000275759.1 RP11-131L12.3 -3.9 0.00013 0.0432 -0.49 -0.26 Glucose homeostasis traits; chr12:118442070 chr12:118428281~118428870:+ CESC cis rs10129255 1 rs8012033 ENSG00000211970.3 IGHV4-61 -3.9 0.00013 0.0432 -0.2 -0.26 Kawasaki disease; chr14:106678854 chr14:106639119~106639657:- CESC cis rs10129255 0.912 rs8011090 ENSG00000211970.3 IGHV4-61 -3.9 0.00013 0.0432 -0.2 -0.26 Kawasaki disease; chr14:106678896 chr14:106639119~106639657:- CESC cis rs875971 0.545 rs73142265 ENSG00000222364.1 RNU6-96P -3.9 0.00013 0.0433 -0.35 -0.26 Aortic root size; chr7:66234510 chr7:66395191~66395286:+ CESC cis rs57502260 0.704 rs2186937 ENSG00000212093.1 AP000807.1 3.9 0.00013 0.0433 0.41 0.26 Total body bone mineral density (age 45-60); chr11:68489379 chr11:68506083~68506166:- CESC cis rs2836950 0.501 rs2836980 ENSG00000232608.1 TIMM9P2 3.9 0.00013 0.0433 0.28 0.26 Menarche (age at onset); chr21:39315692 chr21:39216624~39217506:+ CESC cis rs9322193 0.923 rs9800686 ENSG00000216906.2 RP11-350J20.9 3.9 0.00013 0.0433 0.28 0.26 Lung cancer; chr6:149634464 chr6:149904243~149906418:+ CESC cis rs9322193 0.923 rs57938011 ENSG00000216906.2 RP11-350J20.9 3.9 0.00013 0.0433 0.28 0.26 Lung cancer; chr6:149642969 chr6:149904243~149906418:+ CESC cis rs12745968 0.652 rs7546197 ENSG00000223787.2 RP4-593M8.1 -3.9 0.000131 0.0433 -0.34 -0.26 Bipolar disorder and schizophrenia; chr1:92690382 chr1:92580476~92580821:- CESC cis rs2916733 0.607 rs2166006 ENSG00000246089.3 RP11-115C21.2 -3.9 0.000131 0.0433 -0.31 -0.26 Epirubicin-induced leukopenia; chr8:6446827 chr8:6403551~6407142:- CESC cis rs12942207 1 rs12942207 ENSG00000264920.1 RP11-6N17.4 -3.9 0.000131 0.0433 -0.32 -0.26 Birth weight; chr17:47890928 chr17:47891255~47895812:- CESC cis rs9309473 0.898 rs9807961 ENSG00000163016.8 ALMS1P 3.9 0.000131 0.0433 0.33 0.26 Metabolite levels; chr2:73466916 chr2:73644919~73685576:+ CESC cis rs9309473 1 rs2140195 ENSG00000163016.8 ALMS1P 3.9 0.000131 0.0433 0.33 0.26 Metabolite levels; chr2:73475217 chr2:73644919~73685576:+ CESC cis rs10170310 0.515 rs4954715 ENSG00000241772.2 AC092620.2 3.89 0.000131 0.0433 0.42 0.26 Response to antipsychotic treatment; chr2:138552198 chr2:138569090~138574458:+ CESC cis rs9532669 0.926 rs9532647 ENSG00000176268.5 CYCSP34 3.89 0.000131 0.0433 0.26 0.26 Cervical cancer; chr13:40881799 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs9525420 ENSG00000176268.5 CYCSP34 3.89 0.000131 0.0433 0.26 0.26 Cervical cancer; chr13:40882628 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs7324383 ENSG00000176268.5 CYCSP34 3.89 0.000131 0.0433 0.26 0.26 Cervical cancer; chr13:40882754 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532648 ENSG00000176268.5 CYCSP34 3.89 0.000131 0.0433 0.26 0.26 Cervical cancer; chr13:40882795 chr13:40863599~40863902:- CESC cis rs11089937 0.512 rs13054756 ENSG00000211638.2 IGLV8-61 -3.89 0.000131 0.0433 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22130948 chr22:22098700~22099212:+ CESC cis rs11089937 0.597 rs4821768 ENSG00000211638.2 IGLV8-61 -3.89 0.000131 0.0433 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22131047 chr22:22098700~22099212:+ CESC cis rs2439831 0.85 rs8042868 ENSG00000275601.1 AC011330.13 -3.89 0.000131 0.0433 -0.43 -0.26 Lung cancer in ever smokers; chr15:43647444 chr15:43642389~43643023:- CESC cis rs34097030 1 rs34097030 ENSG00000207217.1 SNORA42 -3.89 0.000131 0.0434 -0.31 -0.26 Reticulocyte fraction of red cells; chr7:6014758 chr7:6016877~6017011:+ CESC cis rs9465539 0.597 rs9465523 ENSG00000228412.5 RP4-625H18.2 -3.89 0.000131 0.0434 -0.32 -0.26 Neuroticism; chr6:19780725 chr6:19802164~19804752:- CESC cis rs62025270 0.632 rs13379832 ENSG00000202081.1 RNU6-1280P -3.89 0.000131 0.0434 -0.35 -0.26 Idiopathic pulmonary fibrosis; chr15:85572669 chr15:85651522~85651628:- CESC cis rs9660180 0.62 rs3817856 ENSG00000231050.1 RP1-140A9.1 -3.89 0.000131 0.0434 -0.3 -0.26 Body mass index; chr1:1732392 chr1:1891471~1892658:+ CESC cis rs7160336 0.628 rs12893501 ENSG00000259065.1 RP5-1021I20.1 3.89 0.000131 0.0434 0.33 0.26 Blood protein levels; chr14:73990459 chr14:73787360~73803270:+ CESC cis rs9322193 0.884 rs2064521 ENSG00000216906.2 RP11-350J20.9 -3.89 0.000131 0.0434 -0.29 -0.26 Lung cancer; chr6:149625336 chr6:149904243~149906418:+ CESC cis rs7688540 0.771 rs6599318 ENSG00000211553.1 AC253576.2 -3.89 0.000131 0.0434 -0.4 -0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:250179 chr4:136461~136568:+ CESC cis rs11089937 0.553 rs35336247 ENSG00000211638.2 IGLV8-61 -3.89 0.000131 0.0434 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22131593 chr22:22098700~22099212:+ CESC cis rs11089937 0.553 rs34088081 ENSG00000211638.2 IGLV8-61 -3.89 0.000131 0.0434 -0.24 -0.26 Periodontitis (PAL4Q3); chr22:22131601 chr22:22098700~22099212:+ CESC cis rs6928977 0.66 rs2757647 ENSG00000234084.1 RP3-388E23.2 3.89 0.000131 0.0434 0.22 0.26 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135446416 chr6:135301568~135307158:+ CESC cis rs875971 0.571 rs160641 ENSG00000226824.5 RP4-756H11.3 3.89 0.000131 0.0434 0.36 0.26 Aortic root size; chr7:66112359 chr7:66654538~66669855:+ CESC cis rs919433 0.68 rs2565163 ENSG00000222017.1 AC011997.1 3.89 0.000131 0.0434 0.33 0.26 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197489690 chr2:197693106~197774823:+ CESC cis rs11608355 0.538 rs11611957 ENSG00000257221.1 RP11-689B22.2 -3.89 0.000131 0.0435 -0.23 -0.26 Neuroticism; chr12:109363998 chr12:108628687~108641318:+ CESC cis rs5758659 0.652 rs133301 ENSG00000273366.1 CTA-989H11.1 -3.89 0.000131 0.0435 -0.32 -0.26 Cognitive function; chr22:41994089 chr22:42278188~42278846:+ CESC cis rs658191 0.661 rs12080113 ENSG00000237624.1 OXCT2P1 -3.89 0.000131 0.0435 -0.72 -0.25 Colorectal cancer; chr1:39510894 chr1:39514956~39516490:+ CESC cis rs2337406 0.866 rs7153964 ENSG00000274576.2 IGHV2-70 -3.89 0.000131 0.0435 -0.35 -0.25 Alzheimer's disease (late onset); chr14:106790480 chr14:106770577~106771020:- CESC cis rs2337406 0.866 rs2301536 ENSG00000274576.2 IGHV2-70 -3.89 0.000131 0.0435 -0.35 -0.25 Alzheimer's disease (late onset); chr14:106790636 chr14:106770577~106771020:- CESC cis rs13177784 0.621 rs4557383 ENSG00000249664.1 CTD-2227C6.2 -3.89 0.000131 0.0435 -0.29 -0.25 Cerebrospinal fluid biomarker levels; chr5:83926740 chr5:83012285~83013109:- CESC cis rs3925075 0.531 rs56392848 ENSG00000260911.2 RP11-196G11.2 -3.89 0.000131 0.0435 -0.27 -0.25 IgA nephropathy; chr16:31349571 chr16:31043150~31049868:+ CESC cis rs853679 0.546 rs71537572 ENSG00000219392.1 RP1-265C24.5 -3.89 0.000131 0.0435 -0.55 -0.25 Depression; chr6:28002937 chr6:28115628~28116551:+ CESC cis rs7551222 0.646 rs7556371 ENSG00000240219.1 RP11-430C7.5 -3.89 0.000131 0.0435 -0.29 -0.25 Schizophrenia; chr1:204488208 chr1:204626775~204629712:+ CESC cis rs11098499 0.644 rs10050092 ENSG00000248280.1 RP11-33B1.2 3.89 0.000131 0.0435 0.28 0.25 Corneal astigmatism; chr4:119610930 chr4:119440561~119450157:- CESC cis rs12186641 0.786 rs76586675 ENSG00000259663.2 CTD-2314G24.2 3.89 0.000131 0.0435 0.61 0.25 Congenital heart disease; chr5:51878223 chr5:51372736~51383332:- CESC cis rs2933343 0.7 rs1683787 ENSG00000231305.3 RP11-723O4.2 -3.89 0.000132 0.0435 -0.24 -0.25 IgG glycosylation; chr3:128908178 chr3:128861313~128871540:- CESC cis rs6844153 1 rs7655686 ENSG00000240005.4 RP11-293A21.1 -3.89 0.000132 0.0435 -0.37 -0.25 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26897955 chr4:26859806~26860599:- CESC cis rs17301013 0.507 rs60409344 ENSG00000227373.4 RP11-160H22.5 3.89 0.000132 0.0435 0.35 0.25 Systemic lupus erythematosus; chr1:174438724 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs72713584 ENSG00000227373.4 RP11-160H22.5 3.89 0.000132 0.0435 0.35 0.25 Systemic lupus erythematosus; chr1:174439129 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12077381 ENSG00000227373.4 RP11-160H22.5 3.89 0.000132 0.0435 0.35 0.25 Systemic lupus erythematosus; chr1:174439566 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs74126805 ENSG00000227373.4 RP11-160H22.5 3.89 0.000132 0.0435 0.35 0.25 Systemic lupus erythematosus; chr1:174440226 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12078960 ENSG00000227373.4 RP11-160H22.5 3.89 0.000132 0.0435 0.35 0.25 Systemic lupus erythematosus; chr1:174440891 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12080407 ENSG00000227373.4 RP11-160H22.5 3.89 0.000132 0.0435 0.35 0.25 Systemic lupus erythematosus; chr1:174441964 chr1:174115300~174160004:- CESC cis rs2286503 0.901 rs10950922 ENSG00000228649.7 AC005682.5 3.89 0.000132 0.0436 0.22 0.25 Fibrinogen; chr7:22814387 chr7:22854178~22861579:+ CESC cis rs6693388 0.881 rs16833668 ENSG00000229021.2 AL591893.1 -3.89 0.000132 0.0436 -0.3 -0.25 Blood metabolite ratios; chr1:151945688 chr1:151994531~152042774:+ CESC cis rs79243044 1 rs7944109 ENSG00000224295.2 AC087380.14 -3.89 0.000132 0.0436 -0.28 -0.25 QRS duration in Tripanosoma cruzi seropositivity; chr11:5543689 chr11:5518441~5524955:- CESC cis rs17301013 0.507 rs12079011 ENSG00000227373.4 RP11-160H22.5 3.89 0.000132 0.0436 0.35 0.25 Systemic lupus erythematosus; chr1:174441055 chr1:174115300~174160004:- CESC cis rs2836974 0.604 rs2854727 ENSG00000232608.1 TIMM9P2 -3.89 0.000132 0.0436 -0.3 -0.25 Cognitive function; chr21:39341861 chr21:39216624~39217506:+ CESC cis rs7829975 0.846 rs6601724 ENSG00000253893.2 FAM85B 3.89 0.000132 0.0436 0.31 0.25 Mood instability; chr8:8687362 chr8:8167819~8226614:- CESC cis rs748404 0.65 rs518234 ENSG00000205771.5 CATSPER2P1 -3.89 0.000132 0.0436 -0.3 -0.25 Lung cancer; chr15:43281223 chr15:43726918~43747094:- CESC cis rs748404 0.65 rs518261 ENSG00000205771.5 CATSPER2P1 -3.89 0.000132 0.0436 -0.3 -0.25 Lung cancer; chr15:43281231 chr15:43726918~43747094:- CESC cis rs7829975 0.564 rs2921060 ENSG00000173295.6 FAM86B3P -3.89 0.000132 0.0436 -0.32 -0.25 Mood instability; chr8:8460307 chr8:8228595~8244865:+ CESC cis rs17507216 0.671 rs4779035 ENSG00000255769.6 GOLGA2P10 -3.89 0.000132 0.0436 -0.39 -0.25 Excessive daytime sleepiness; chr15:82591686 chr15:82472993~82513950:- CESC cis rs7614311 0.681 rs60505027 ENSG00000271843.1 RP11-245J9.5 -3.89 0.000132 0.0436 -0.36 -0.25 Lung function (FVC);Lung function (FEV1); chr3:63859290 chr3:64008082~64008692:- CESC cis rs42490 0.664 rs453266 ENSG00000251136.7 RP11-37B2.1 -3.89 0.000132 0.0436 -0.26 -0.25 Leprosy; chr8:89823789 chr8:89609409~89757727:- CESC cis rs62344088 0.59 rs62346174 ENSG00000250848.1 CTD-2083E4.5 -3.89 0.000132 0.0436 -0.57 -0.25 Asthma (childhood onset); chr5:296193 chr5:288833~290321:- CESC cis rs42490 0.664 rs368812 ENSG00000251136.7 RP11-37B2.1 -3.89 0.000132 0.0436 -0.27 -0.25 Leprosy; chr8:89822269 chr8:89609409~89757727:- CESC cis rs17666538 0.642 rs7821983 ENSG00000254207.1 RP11-43A14.1 3.89 0.000132 0.0436 0.48 0.25 IgG glycosylation; chr8:693696 chr8:725188~725877:- CESC cis rs1484194 0.906 rs7170955 ENSG00000275709.1 RP11-96O20.5 3.89 0.000132 0.0436 0.3 0.25 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr15:46365394 chr15:45585757~45586304:- CESC cis rs17507216 0.628 rs4627310 ENSG00000276710.3 CSPG4P8 -3.89 0.000132 0.0436 -0.36 -0.25 Excessive daytime sleepiness; chr15:82708330 chr15:82459472~82477258:+ CESC cis rs17507216 0.628 rs4513065 ENSG00000276710.3 CSPG4P8 -3.89 0.000132 0.0436 -0.36 -0.25 Excessive daytime sleepiness; chr15:82712096 chr15:82459472~82477258:+ CESC cis rs17507216 0.628 rs28371837 ENSG00000276710.3 CSPG4P8 -3.89 0.000132 0.0436 -0.36 -0.25 Excessive daytime sleepiness; chr15:82714435 chr15:82459472~82477258:+ CESC cis rs6546537 0.503 rs7576953 ENSG00000231024.1 AC092431.3 -3.89 0.000132 0.0437 -0.3 -0.25 Serum thyroid-stimulating hormone levels; chr2:69684784 chr2:69700192~69713847:- CESC cis rs7560272 0.564 rs10496190 ENSG00000163016.8 ALMS1P -3.89 0.000132 0.0437 -0.29 -0.25 Schizophrenia; chr2:73411695 chr2:73644919~73685576:+ CESC cis rs2243480 1 rs383402 ENSG00000275400.1 RP4-756H11.5 -3.89 0.000132 0.0437 -0.4 -0.25 Diabetic kidney disease; chr7:66121666 chr7:66553805~66554199:- CESC cis rs10129255 0.789 rs61997796 ENSG00000211974.3 IGHV2-70 3.89 0.000132 0.0437 0.28 0.25 Kawasaki disease; chr14:106813798 chr14:106723574~106724093:- CESC cis rs875971 1 rs11971949 ENSG00000232559.3 GS1-124K5.12 -3.89 0.000132 0.0437 -0.27 -0.25 Aortic root size; chr7:66161027 chr7:66554588~66576923:- CESC cis rs7927592 0.956 rs2155730 ENSG00000212093.1 AP000807.1 3.89 0.000132 0.0437 0.29 0.25 Total body bone mineral density; chr11:68562006 chr11:68506083~68506166:- CESC cis rs9494145 0.648 rs7758845 ENSG00000232876.1 CTA-212D2.2 -3.89 0.000132 0.0437 -0.31 -0.25 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135107399 chr6:135055033~135060550:+ CESC cis rs10129255 1 rs9324091 ENSG00000224373.3 IGHV4-59 3.89 0.000132 0.0437 0.18 0.25 Kawasaki disease; chr14:106676625 chr14:106627249~106627825:- CESC cis rs17152411 0.652 rs1036676 ENSG00000232334.1 RP11-47G11.2 3.89 0.000132 0.0437 0.28 0.25 Height; chr10:124965615 chr10:124004304~124004828:- CESC cis rs673078 0.607 rs17441214 ENSG00000275759.1 RP11-131L12.3 -3.89 0.000132 0.0437 -0.54 -0.25 Glucose homeostasis traits; chr12:118436721 chr12:118428281~118428870:+ CESC cis rs11089937 0.568 rs11089919 ENSG00000211638.2 IGLV8-61 -3.89 0.000132 0.0437 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22131648 chr22:22098700~22099212:+ CESC cis rs8080784 1 rs74257535 ENSG00000266701.1 AC005702.4 3.89 0.000132 0.0437 0.38 0.25 Coronary artery disease; chr17:60946115 chr17:60042546~60042627:- CESC cis rs3781913 0.642 rs341052 ENSG00000256633.1 RP11-169D4.2 3.89 0.000132 0.0437 0.26 0.25 Rheumatoid arthritis; chr11:72633497 chr11:72584572~72587979:+ CESC cis rs9640161 0.659 rs17837498 ENSG00000261305.1 RP4-584D14.7 3.89 0.000132 0.0437 0.36 0.25 Blood protein levels;Circulating chemerin levels; chr7:150312590 chr7:150341771~150342607:+ CESC cis rs9640161 0.659 rs11974980 ENSG00000261305.1 RP4-584D14.7 3.89 0.000132 0.0437 0.36 0.25 Blood protein levels;Circulating chemerin levels; chr7:150312749 chr7:150341771~150342607:+ CESC cis rs9640161 0.659 rs11975886 ENSG00000261305.1 RP4-584D14.7 3.89 0.000132 0.0437 0.36 0.25 Blood protein levels;Circulating chemerin levels; chr7:150313273 chr7:150341771~150342607:+ CESC cis rs853679 0.517 rs868987 ENSG00000280107.1 AL022393.9 3.89 0.000132 0.0438 0.35 0.25 Depression; chr6:28142370 chr6:28170845~28172521:+ CESC cis rs5742933 0.817 rs6942 ENSG00000273240.1 RP11-455J20.3 3.89 0.000132 0.0438 0.28 0.25 Ferritin levels; chr2:189771685 chr2:189763859~189764456:- CESC cis rs3738443 0.868 rs35229190 ENSG00000259865.1 RP11-488L18.10 3.89 0.000132 0.0438 0.28 0.25 Alcohol dependence; chr1:247202339 chr1:247187281~247188526:- CESC cis rs6844153 0.887 rs62302533 ENSG00000240005.4 RP11-293A21.1 -3.89 0.000133 0.0438 -0.35 -0.25 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26955309 chr4:26859806~26860599:- CESC cis rs1345301 1 rs1345301 ENSG00000234389.1 AC007278.3 -3.89 0.000133 0.0438 -0.25 -0.25 Waist circumference; chr2:102259127 chr2:102438713~102440475:+ CESC cis rs1345301 1 rs11686567 ENSG00000234389.1 AC007278.3 -3.89 0.000133 0.0438 -0.25 -0.25 Waist circumference; chr2:102260149 chr2:102438713~102440475:+ CESC cis rs1345301 0.935 rs11691721 ENSG00000234389.1 AC007278.3 -3.89 0.000133 0.0438 -0.25 -0.25 Waist circumference; chr2:102260219 chr2:102438713~102440475:+ CESC cis rs523522 0.962 rs3893104 ENSG00000278344.1 RP11-18C24.8 3.89 0.000133 0.0438 0.32 0.25 High light scatter reticulocyte count; chr12:120466133 chr12:120500735~120501090:- CESC cis rs11157436 0.918 rs3811285 ENSG00000211812.1 TRAV26-2 -3.89 0.000133 0.0439 -0.26 -0.25 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22155322 chr14:22202583~22203368:+ CESC cis rs42490 0.664 rs376110 ENSG00000251136.7 RP11-37B2.1 -3.89 0.000133 0.0439 -0.26 -0.25 Leprosy; chr8:89819362 chr8:89609409~89757727:- CESC cis rs2115630 0.645 rs4842978 ENSG00000259295.5 CSPG4P12 -3.89 0.000133 0.0439 -0.27 -0.25 P wave terminal force; chr15:84654022 chr15:85191438~85213905:+ CESC cis rs8080784 1 rs7218029 ENSG00000266992.1 DHX40P1 3.89 0.000133 0.0439 0.33 0.25 Coronary artery disease; chr17:60896791 chr17:59976009~60002384:- CESC cis rs6504622 1 rs4968286 ENSG00000263142.4 LRRC37A17P -3.89 0.000133 0.0439 -0.21 -0.25 Orofacial clefts; chr17:46940279 chr17:46978481~47054569:+ CESC cis rs35740288 0.731 rs11638407 ENSG00000202081.1 RNU6-1280P 3.89 0.000133 0.0439 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85551424 chr15:85651522~85651628:- CESC cis rs4650376 0.789 rs1751513 ENSG00000235613.2 NSRP1P1 -3.89 0.000133 0.0439 -0.47 -0.25 IgG glycosylation; chr1:78727192 chr1:77847110~77848802:+ CESC cis rs11157436 0.958 rs17183301 ENSG00000211812.1 TRAV26-2 -3.89 0.000133 0.0439 -0.29 -0.25 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22190003 chr14:22202583~22203368:+ CESC cis rs1775715 0.737 rs2808090 ENSG00000231245.2 C1DP1 -3.89 0.000133 0.0439 -0.32 -0.25 Bipolar disorder with mood-incongruent psychosis; chr10:31854280 chr10:32511336~32511737:- CESC cis rs988913 0.697 rs9475159 ENSG00000224984.1 RP11-524H19.2 -3.89 0.000133 0.0439 -0.25 -0.25 Menarche (age at onset); chr6:55130719 chr6:54840118~54840855:- CESC cis rs12681963 0.688 rs6994064 ENSG00000272375.1 RP11-51J9.6 -3.89 0.000133 0.0439 -0.46 -0.25 Migraine; chr8:30199673 chr8:30197404~30198048:+ CESC cis rs10492681 0.649 rs6563808 ENSG00000278390.3 RP11-74J13.8 -3.89 0.000133 0.0439 -0.31 -0.25 Select biomarker traits; chr13:40192525 chr13:41132939~41236686:+ CESC cis rs12745968 0.652 rs4294422 ENSG00000223787.2 RP4-593M8.1 3.89 0.000133 0.0439 0.34 0.25 Bipolar disorder and schizophrenia; chr1:92639098 chr1:92580476~92580821:- CESC cis rs9322193 0.884 rs7744105 ENSG00000223701.3 RAET1E-AS1 3.89 0.000133 0.0439 0.3 0.25 Lung cancer; chr6:149849308 chr6:149884431~149919508:+ CESC cis rs2412819 0.559 rs8040336 ENSG00000205771.5 CATSPER2P1 -3.89 0.000133 0.0439 -0.31 -0.25 Lung cancer; chr15:43761419 chr15:43726918~43747094:- CESC cis rs6452524 0.935 rs10043698 ENSG00000249664.1 CTD-2227C6.2 3.89 0.000133 0.0439 0.31 0.25 Hypertension (SNP x SNP interaction); chr5:83169100 chr5:83012285~83013109:- CESC cis rs6439153 0.933 rs900381 ENSG00000261159.1 RP11-723O4.9 3.89 0.000133 0.0439 0.27 0.25 Pneumococcal bacteremia; chr3:128994612 chr3:128859716~128860526:- CESC cis rs10129255 0.957 rs10132367 ENSG00000211970.3 IGHV4-61 -3.89 0.000133 0.044 -0.2 -0.25 Kawasaki disease; chr14:106690981 chr14:106639119~106639657:- CESC cis rs1320333 0.772 rs2867136 ENSG00000233296.1 AC092159.2 -3.89 0.000133 0.044 -0.42 -0.25 Obesity-related traits; chr2:701455 chr2:677186~697371:+ CESC cis rs4272720 0.51 rs4445564 ENSG00000229870.1 RP11-507K13.6 -3.89 0.000133 0.044 -0.31 -0.25 Platelet count;Plateletcrit; chr10:49088577 chr10:49815096~49815562:+ CESC cis rs453301 0.653 rs2956244 ENSG00000253893.2 FAM85B -3.89 0.000133 0.044 -0.31 -0.25 Joint mobility (Beighton score); chr8:9027656 chr8:8167819~8226614:- CESC cis rs17711722 0.503 rs453835 ENSG00000226824.5 RP4-756H11.3 3.89 0.000133 0.044 0.32 0.25 Calcium levels; chr7:66046172 chr7:66654538~66669855:+ CESC cis rs490234 0.776 rs10115455 ENSG00000232630.1 PRPS1P2 -3.89 0.000133 0.044 -0.22 -0.25 Mean arterial pressure; chr9:125696571 chr9:125150653~125151589:+ CESC cis rs853679 0.546 rs35016036 ENSG00000219392.1 RP1-265C24.5 -3.89 0.000133 0.044 -0.54 -0.25 Depression; chr6:28347103 chr6:28115628~28116551:+ CESC cis rs11089937 0.512 rs34963809 ENSG00000211638.2 IGLV8-61 -3.89 0.000133 0.044 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22130737 chr22:22098700~22099212:+ CESC cis rs11089937 0.568 rs35626600 ENSG00000211638.2 IGLV8-61 -3.89 0.000133 0.044 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22130811 chr22:22098700~22099212:+ CESC cis rs11089937 0.539 rs34228957 ENSG00000211638.2 IGLV8-61 -3.89 0.000133 0.044 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22130838 chr22:22098700~22099212:+ CESC cis rs9309473 0.95 rs6546854 ENSG00000163016.8 ALMS1P 3.89 0.000133 0.044 0.34 0.25 Metabolite levels; chr2:73606907 chr2:73644919~73685576:+ CESC cis rs57502260 0.704 rs60538784 ENSG00000212093.1 AP000807.1 3.89 0.000133 0.044 0.4 0.25 Total body bone mineral density (age 45-60); chr11:68619267 chr11:68506083~68506166:- CESC cis rs561341 0.941 rs8066156 ENSG00000265798.5 RP11-271K11.5 3.89 0.000133 0.044 0.38 0.25 Hip circumference adjusted for BMI; chr17:32034610 chr17:31038575~31059121:- CESC cis rs9309473 1 rs1881245 ENSG00000163016.8 ALMS1P 3.89 0.000133 0.044 0.32 0.25 Metabolite levels; chr2:73422800 chr2:73644919~73685576:+ CESC cis rs2299587 0.527 rs7843715 ENSG00000253671.1 RP11-806O11.1 -3.89 0.000133 0.044 -0.26 -0.25 Economic and political preferences; chr8:17876017 chr8:17808941~17820868:+ CESC cis rs9908102 0.756 rs7210890 ENSG00000263648.1 RP11-471L13.3 -3.89 0.000133 0.044 -0.38 -0.25 Schizophrenia; chr17:13013817 chr17:12115547~12115885:+ CESC cis rs9908102 0.71 rs7211164 ENSG00000263648.1 RP11-471L13.3 -3.89 0.000133 0.044 -0.38 -0.25 Schizophrenia; chr17:13013895 chr17:12115547~12115885:+ CESC cis rs9908102 0.74 rs7211210 ENSG00000263648.1 RP11-471L13.3 -3.89 0.000133 0.044 -0.38 -0.25 Schizophrenia; chr17:13014035 chr17:12115547~12115885:+ CESC cis rs9908102 0.74 rs7211501 ENSG00000263648.1 RP11-471L13.3 -3.89 0.000133 0.044 -0.38 -0.25 Schizophrenia; chr17:13014162 chr17:12115547~12115885:+ CESC cis rs67311347 1 rs2887995 ENSG00000223797.4 ENTPD3-AS1 3.89 0.000133 0.044 0.25 0.25 Renal cell carcinoma; chr3:40367538 chr3:40313802~40453329:- CESC cis rs763567 0.933 rs623752 ENSG00000271811.1 RP1-79C4.4 3.89 0.000133 0.044 0.3 0.25 Tonsillectomy; chr1:170649150 chr1:170667381~170669425:+ CESC cis rs783540 0.656 rs783524 ENSG00000278202.1 RP11-152F13.8 3.89 0.000134 0.044 0.22 0.25 Schizophrenia; chr15:82615393 chr15:82418651~82434235:+ CESC cis rs783540 0.592 rs2567632 ENSG00000278202.1 RP11-152F13.8 3.89 0.000134 0.044 0.22 0.25 Schizophrenia; chr15:82616053 chr15:82418651~82434235:+ CESC cis rs1124769 0.748 rs2289304 ENSG00000259378.1 DCAF13P3 3.89 0.000134 0.044 0.34 0.25 Cognitive performance; chr15:50997198 chr15:50944663~50945996:+ CESC cis rs76878669 0.561 rs4930362 ENSG00000255468.5 RP11-867G23.8 -3.89 0.000134 0.044 -0.28 -0.25 Educational attainment (years of education); chr11:66386889 chr11:66347950~66364804:+ CESC cis rs76878669 0.561 rs4930179 ENSG00000255468.5 RP11-867G23.8 -3.89 0.000134 0.044 -0.28 -0.25 Educational attainment (years of education); chr11:66389961 chr11:66347950~66364804:+ CESC cis rs7829975 0.572 rs28446104 ENSG00000253893.2 FAM85B 3.89 0.000134 0.044 0.32 0.25 Mood instability; chr8:8938391 chr8:8167819~8226614:- CESC cis rs2252187 0.615 rs2252412 ENSG00000226332.2 RP11-157P1.4 -3.89 0.000134 0.044 -0.29 -0.25 Multiple system atrophy; chr20:61569296 chr20:62305432~62306325:- CESC cis rs17695224 0.545 rs7252805 ENSG00000268095.1 ZNF649-AS1 3.89 0.000134 0.0441 0.31 0.25 HDL cholesterol;HDL cholesterol levels; chr19:51840169 chr19:51888025~51900463:+ CESC cis rs6674176 0.551 rs72683973 ENSG00000234093.3 RPS15AP11 -3.89 0.000134 0.0441 -0.44 -0.25 Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr1:43987353 chr1:44780331~44780715:- CESC cis rs988913 0.723 rs4715515 ENSG00000224984.1 RP11-524H19.2 3.89 0.000134 0.0441 0.25 0.25 Menarche (age at onset); chr6:55103646 chr6:54840118~54840855:- CESC cis rs9322193 0.962 rs6899661 ENSG00000223701.3 RAET1E-AS1 3.89 0.000134 0.0441 0.29 0.25 Lung cancer; chr6:149818093 chr6:149884431~149919508:+ CESC cis rs9532669 0.89 rs2324738 ENSG00000239827.7 SUGT1P3 -3.89 0.000134 0.0441 -0.27 -0.25 Cervical cancer; chr13:40925242 chr13:40908159~40921774:- CESC cis rs9532669 0.963 rs2324739 ENSG00000239827.7 SUGT1P3 -3.89 0.000134 0.0441 -0.27 -0.25 Cervical cancer; chr13:40925479 chr13:40908159~40921774:- CESC cis rs523522 0.962 rs509445 ENSG00000278344.1 RP11-18C24.8 3.89 0.000134 0.0441 0.31 0.25 High light scatter reticulocyte count; chr12:120579440 chr12:120500735~120501090:- CESC cis rs7617773 0.817 rs3937 ENSG00000228638.1 FCF1P2 -3.89 0.000134 0.0441 -0.28 -0.25 Coronary artery disease; chr3:48270912 chr3:48290793~48291375:- CESC cis rs2261181 0.809 rs2261070 ENSG00000276853.1 RP11-305O6.4 -3.89 0.000134 0.0441 -0.53 -0.25 Type 2 diabetes; chr12:65781398 chr12:65171262~65171917:+ CESC cis rs875971 0.522 rs9530 ENSG00000222364.1 RNU6-96P -3.89 0.000134 0.0441 -0.31 -0.25 Aortic root size; chr7:65960907 chr7:66395191~66395286:+ CESC cis rs17711722 0.51 rs11767457 ENSG00000226824.5 RP4-756H11.3 -3.89 0.000134 0.0441 -0.32 -0.25 Calcium levels; chr7:65825628 chr7:66654538~66669855:+ CESC cis rs4699052 0.537 rs1580278 ENSG00000246560.2 RP11-10L12.4 -3.89 0.000134 0.0441 -0.31 -0.25 Testicular germ cell tumor; chr4:103219691 chr4:102828055~102844075:+ CESC cis rs4842666 0.915 rs17249754 ENSG00000258302.2 RP11-981P6.1 -3.89 0.000134 0.0442 -0.34 -0.25 Blood pressure; chr12:89666809 chr12:89561129~89594878:+ CESC cis rs2243480 1 rs34970380 ENSG00000164669.11 INTS4P1 3.89 0.000134 0.0442 0.52 0.25 Diabetic kidney disease; chr7:65966506 chr7:65141225~65234216:+ CESC cis rs2404602 0.598 rs11855999 ENSG00000196274.5 Metazoa_SRP -3.89 0.000134 0.0442 -0.33 -0.25 Blood metabolite levels; chr15:76334992 chr15:76230048~76230390:- CESC cis rs1707322 1 rs785480 ENSG00000281133.1 AL355480.3 -3.89 0.000134 0.0442 -0.3 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46026492 chr1:45580892~45580996:- CESC cis rs2439831 0.717 rs2470132 ENSG00000205771.5 CATSPER2P1 -3.89 0.000134 0.0442 -0.37 -0.25 Lung cancer in ever smokers; chr15:43543283 chr15:43726918~43747094:- CESC cis rs2439831 0.867 rs2255051 ENSG00000205771.5 CATSPER2P1 -3.89 0.000134 0.0442 -0.37 -0.25 Lung cancer in ever smokers; chr15:43553963 chr15:43726918~43747094:- CESC cis rs227932 0.764 rs76349338 ENSG00000234286.1 AC006026.13 -3.89 0.000134 0.0442 -0.35 -0.25 Schizophrenia; chr7:23709138 chr7:23680195~23680786:- CESC cis rs2404602 0.692 rs2117369 ENSG00000280730.1 AC090181.1 3.89 0.000134 0.0442 0.2 0.25 Blood metabolite levels; chr15:76456520 chr15:77056895~77057021:+ CESC cis rs2404602 0.716 rs2164101 ENSG00000280730.1 AC090181.1 3.89 0.000134 0.0442 0.2 0.25 Blood metabolite levels; chr15:76456776 chr15:77056895~77057021:+ CESC cis rs2404602 0.716 rs67888330 ENSG00000280730.1 AC090181.1 3.89 0.000134 0.0442 0.2 0.25 Blood metabolite levels; chr15:76460142 chr15:77056895~77057021:+ CESC cis rs2404602 0.716 rs1588961 ENSG00000280730.1 AC090181.1 3.89 0.000134 0.0442 0.2 0.25 Blood metabolite levels; chr15:76460357 chr15:77056895~77057021:+ CESC cis rs2404602 0.716 rs12592171 ENSG00000280730.1 AC090181.1 3.89 0.000134 0.0442 0.2 0.25 Blood metabolite levels; chr15:76462792 chr15:77056895~77057021:+ CESC cis rs2404602 0.679 rs12899871 ENSG00000280730.1 AC090181.1 3.89 0.000134 0.0442 0.2 0.25 Blood metabolite levels; chr15:76465006 chr15:77056895~77057021:+ CESC cis rs13113518 0.812 rs11932712 ENSG00000273257.1 RP11-177J6.1 3.89 0.000134 0.0442 0.33 0.25 Height; chr4:55436423 chr4:55387949~55388271:+ CESC cis rs13113518 0.812 rs12501746 ENSG00000273257.1 RP11-177J6.1 3.89 0.000134 0.0442 0.33 0.25 Height; chr4:55437438 chr4:55387949~55388271:+ CESC cis rs1823913 0.599 rs1378155 ENSG00000227542.1 AC092614.2 3.89 0.000134 0.0443 0.27 0.25 Obesity-related traits; chr2:191266610 chr2:191229165~191246172:- CESC cis rs7005380 0.58 rs1467044 ENSG00000279347.1 RP11-85I17.2 -3.89 0.000134 0.0443 -0.24 -0.25 Interstitial lung disease; chr8:119874801 chr8:119838736~119840385:- CESC cis rs12908161 0.683 rs12903256 ENSG00000259728.4 LINC00933 3.89 0.000134 0.0443 0.29 0.25 Schizophrenia; chr15:84764910 chr15:84570649~84580175:+ CESC cis rs6141600 0.627 rs873925 ENSG00000260032.1 LINC00657 -3.89 0.000135 0.0443 -0.37 -0.25 Height;Hip circumference; chr20:36099528 chr20:36045622~36050960:- CESC cis rs7243790 0.905 rs1523871 ENSG00000277324.1 RP11-850A17.1 -3.89 0.000135 0.0443 -0.29 -0.25 Diastolic blood pressure; chr18:54424507 chr18:54268346~54270028:- CESC cis rs950880 0.796 rs12987977 ENSG00000234389.1 AC007278.3 -3.89 0.000135 0.0443 -0.28 -0.25 Serum protein levels (sST2); chr2:102358876 chr2:102438713~102440475:+ CESC cis rs7665090 0.806 rs434644 ENSG00000246560.2 RP11-10L12.4 -3.89 0.000135 0.0443 -0.32 -0.25 Primary biliary cholangitis; chr4:102662032 chr4:102828055~102844075:+ CESC cis rs172166 0.694 rs203884 ENSG00000219392.1 RP1-265C24.5 -3.89 0.000135 0.0443 -0.31 -0.25 Cardiac Troponin-T levels; chr6:28109596 chr6:28115628~28116551:+ CESC cis rs2299587 0.698 rs403894 ENSG00000253671.1 RP11-806O11.1 -3.89 0.000135 0.0444 -0.26 -0.25 Economic and political preferences; chr8:17937859 chr8:17808941~17820868:+ CESC cis rs3738443 0.83 rs6684181 ENSG00000259865.1 RP11-488L18.10 3.89 0.000135 0.0444 0.3 0.25 Alcohol dependence; chr1:247184669 chr1:247187281~247188526:- CESC cis rs703842 0.964 rs2014886 ENSG00000270039.1 RP11-571M6.17 -3.89 0.000135 0.0444 -0.31 -0.25 Multiple sclerosis; chr12:57783654 chr12:57803838~57804415:+ CESC cis rs703842 1 rs1599932 ENSG00000270039.1 RP11-571M6.17 -3.89 0.000135 0.0444 -0.31 -0.25 Multiple sclerosis; chr12:57784160 chr12:57803838~57804415:+ CESC cis rs12144049 0.662 rs1951523 ENSG00000227045.1 RP11-98D18.1 -3.89 0.000135 0.0444 -0.39 -0.25 Inflammatory skin disease;Atopic dermatitis; chr1:152435985 chr1:151701026~151708386:+ CESC cis rs12144049 0.662 rs2146118 ENSG00000227045.1 RP11-98D18.1 -3.89 0.000135 0.0444 -0.39 -0.25 Inflammatory skin disease;Atopic dermatitis; chr1:152439720 chr1:151701026~151708386:+ CESC cis rs801193 0.569 rs2659908 ENSG00000275400.1 RP4-756H11.5 3.89 0.000135 0.0444 0.27 0.25 Aortic root size; chr7:66695835 chr7:66553805~66554199:- CESC cis rs801193 0.527 rs2707837 ENSG00000275400.1 RP4-756H11.5 3.89 0.000135 0.0444 0.27 0.25 Aortic root size; chr7:66716086 chr7:66553805~66554199:- CESC cis rs801193 0.569 rs2707824 ENSG00000275400.1 RP4-756H11.5 3.89 0.000135 0.0444 0.27 0.25 Aortic root size; chr7:66724256 chr7:66553805~66554199:- CESC cis rs801193 0.569 rs2659893 ENSG00000275400.1 RP4-756H11.5 3.89 0.000135 0.0444 0.27 0.25 Aortic root size; chr7:66735006 chr7:66553805~66554199:- CESC cis rs801193 0.569 rs2659892 ENSG00000275400.1 RP4-756H11.5 3.89 0.000135 0.0444 0.27 0.25 Aortic root size; chr7:66735318 chr7:66553805~66554199:- CESC cis rs801193 0.569 rs2707847 ENSG00000275400.1 RP4-756H11.5 3.89 0.000135 0.0444 0.27 0.25 Aortic root size; chr7:66737884 chr7:66553805~66554199:- CESC cis rs7873102 0.654 rs7043870 ENSG00000230188.1 RP11-405L18.4 -3.89 0.000135 0.0444 -0.34 -0.25 Brain structure; chr9:37956376 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10733491 ENSG00000230188.1 RP11-405L18.4 -3.89 0.000135 0.0444 -0.34 -0.25 Brain structure; chr9:37956727 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10732212 ENSG00000230188.1 RP11-405L18.4 -3.89 0.000135 0.0444 -0.34 -0.25 Brain structure; chr9:37957601 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs7038759 ENSG00000230188.1 RP11-405L18.4 -3.89 0.000135 0.0444 -0.34 -0.25 Brain structure; chr9:37958732 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs3922775 ENSG00000230188.1 RP11-405L18.4 -3.89 0.000135 0.0444 -0.34 -0.25 Brain structure; chr9:37959400 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs10114319 ENSG00000230188.1 RP11-405L18.4 -3.89 0.000135 0.0444 -0.34 -0.25 Brain structure; chr9:37960396 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs7043495 ENSG00000230188.1 RP11-405L18.4 -3.89 0.000135 0.0444 -0.34 -0.25 Brain structure; chr9:37961925 chr9:37490421~37490893:- CESC cis rs6740322 0.857 rs11690012 ENSG00000234936.1 AC010883.5 3.89 0.000135 0.0444 0.26 0.25 Coronary artery disease; chr2:43315341 chr2:43229573~43233394:+ CESC cis rs875971 0.862 rs778734 ENSG00000179406.6 LINC00174 -3.89 0.000135 0.0444 -0.27 -0.25 Aortic root size; chr7:66349862 chr7:66376044~66401338:- CESC cis rs950776 0.518 rs2869544 ENSG00000279373.1 RP11-650L12.4 -3.89 0.000135 0.0444 -0.3 -0.25 Sudden cardiac arrest; chr15:78547058 chr15:78537681~78538946:+ CESC cis rs658191 0.661 rs74778290 ENSG00000237624.1 OXCT2P1 -3.89 0.000135 0.0444 -0.72 -0.25 Colorectal cancer; chr1:39499498 chr1:39514956~39516490:+ CESC cis rs2412819 0.571 rs528764 ENSG00000249839.1 AC011330.5 3.89 0.000135 0.0444 0.33 0.25 Lung cancer; chr15:43838650 chr15:43663654~43684339:- CESC cis rs17301013 0.632 rs10912782 ENSG00000227373.4 RP11-160H22.5 3.89 0.000135 0.0444 0.31 0.25 Systemic lupus erythematosus; chr1:174418758 chr1:174115300~174160004:- CESC cis rs2243480 1 rs7456042 ENSG00000275400.1 RP4-756H11.5 3.89 0.000135 0.0445 0.41 0.25 Diabetic kidney disease; chr7:65834791 chr7:66553805~66554199:- CESC cis rs9650657 0.571 rs11783247 ENSG00000269918.1 AF131215.9 -3.89 0.000135 0.0445 -0.3 -0.25 Neuroticism; chr8:10931365 chr8:11104691~11106704:- CESC cis rs7951870 1 rs7127529 ENSG00000247675.5 LRP4-AS1 -3.89 0.000135 0.0445 -0.33 -0.25 Schizophrenia; chr11:46560522 chr11:46846412~46874396:+ CESC cis rs3892630 0.878 rs66788054 ENSG00000267475.1 CTD-2538C1.2 -3.89 0.000135 0.0445 -0.37 -0.25 Red blood cell traits; chr19:32699240 chr19:32687089~32691750:- CESC cis rs3892630 0.878 rs2903759 ENSG00000267475.1 CTD-2538C1.2 -3.89 0.000135 0.0445 -0.37 -0.25 Red blood cell traits; chr19:32705041 chr19:32687089~32691750:- CESC cis rs7873102 0.702 rs943938 ENSG00000230188.1 RP11-405L18.4 -3.89 0.000135 0.0445 -0.32 -0.25 Brain structure; chr9:37983773 chr9:37490421~37490893:- CESC cis rs1580019 0.587 rs6968990 ENSG00000231952.3 DPY19L1P2 3.89 0.000135 0.0445 0.35 0.25 Cognitive ability; chr7:32512547 chr7:32812757~32838570:+ CESC cis rs10129255 0.5 rs1974468 ENSG00000280411.1 IGHV1-69-2 -3.89 0.000135 0.0445 -0.17 -0.25 Kawasaki disease; chr14:106686149 chr14:106762092~106762588:- CESC cis rs12460587 0.547 rs56244227 ENSG00000275055.1 CTC-471J1.11 -3.89 0.000135 0.0445 -0.29 -0.25 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52080439 chr19:52049007~52049754:+ CESC cis rs256277 0.544 rs26560 ENSG00000270067.1 CTC-487M23.5 -3.89 0.000135 0.0445 -0.28 -0.25 Coronary artery disease; chr5:112002769 chr5:112893333~112894001:+ CESC cis rs748404 0.589 rs3862138 ENSG00000249839.1 AC011330.5 -3.89 0.000135 0.0445 -0.37 -0.25 Lung cancer; chr15:43523801 chr15:43663654~43684339:- CESC cis rs2522056 1 rs62385693 ENSG00000233006.5 AC034220.3 -3.89 0.000135 0.0445 -0.33 -0.25 Fibrinogen;Lymphocyte counts; chr5:132437982 chr5:132311285~132369916:- CESC cis rs516805 0.52 rs553889 ENSG00000218180.2 SLC25A5P7 3.89 0.000135 0.0445 0.3 0.25 Lymphocyte counts; chr6:122407734 chr6:121653795~121654690:+ CESC cis rs516805 0.52 rs535316 ENSG00000218180.2 SLC25A5P7 3.89 0.000135 0.0445 0.3 0.25 Lymphocyte counts; chr6:122410673 chr6:121653795~121654690:+ CESC cis rs62025270 0.688 rs79083718 ENSG00000202081.1 RNU6-1280P -3.89 0.000135 0.0445 -0.35 -0.25 Idiopathic pulmonary fibrosis; chr15:85720298 chr15:85651522~85651628:- CESC cis rs12144049 0.549 rs476589 ENSG00000227045.1 RP11-98D18.1 -3.89 0.000135 0.0445 -0.32 -0.25 Inflammatory skin disease;Atopic dermatitis; chr1:152481193 chr1:151701026~151708386:+ CESC cis rs1440410 0.835 rs9992189 ENSG00000250326.1 RP11-284M14.1 -3.89 0.000135 0.0445 -0.27 -0.25 Ischemic stroke; chr4:143139575 chr4:142933195~143184861:- CESC cis rs950169 0.58 rs1061737 ENSG00000259728.4 LINC00933 3.89 0.000135 0.0445 0.32 0.25 Schizophrenia; chr15:84640559 chr15:84570649~84580175:+ CESC cis rs11992162 1 rs7460395 ENSG00000255310.2 AF131215.2 3.89 0.000135 0.0445 0.3 0.25 Monocyte count; chr8:11977866 chr8:11107788~11109726:- CESC cis rs2299587 1 rs17514360 ENSG00000253671.1 RP11-806O11.1 -3.89 0.000135 0.0445 -0.27 -0.25 Economic and political preferences; chr8:17955068 chr8:17808941~17820868:+ CESC cis rs6657613 0.503 rs9435739 ENSG00000186715.9 MST1L 3.89 0.000135 0.0445 0.32 0.25 Hip circumference adjusted for BMI; chr1:17016429 chr1:16754910~16770237:- CESC cis rs875971 1 rs709597 ENSG00000179406.6 LINC00174 3.89 0.000136 0.0445 0.27 0.25 Aortic root size; chr7:66360996 chr7:66376044~66401338:- CESC cis rs2337406 1 rs79452530 ENSG00000254174.1 IGHV1-12 3.89 0.000136 0.0445 0.26 0.25 Alzheimer's disease (late onset); chr14:106699992 chr14:106122420~106122709:- CESC cis rs875971 0.522 rs4718286 ENSG00000222364.1 RNU6-96P -3.89 0.000136 0.0445 -0.31 -0.25 Aortic root size; chr7:65827777 chr7:66395191~66395286:+ CESC cis rs17711722 0.585 rs6942660 ENSG00000222364.1 RNU6-96P -3.89 0.000136 0.0445 -0.31 -0.25 Calcium levels; chr7:65837419 chr7:66395191~66395286:+ CESC cis rs7712401 0.623 rs26372 ENSG00000263432.2 RN7SL689P -3.89 0.000136 0.0445 -0.3 -0.25 Mean platelet volume; chr5:122870752 chr5:123022487~123022783:- CESC cis rs5022942 0.632 rs56323044 ENSG00000251331.5 RP11-689K5.3 3.89 0.000136 0.0446 0.33 0.25 Myopia; chr4:81063743 chr4:81602797~82044244:- CESC cis rs5022942 0.667 rs1495643 ENSG00000251331.5 RP11-689K5.3 3.89 0.000136 0.0446 0.33 0.25 Myopia; chr4:81064385 chr4:81602797~82044244:- CESC cis rs2136613 0.703 rs10761675 ENSG00000238280.1 RP11-436D10.3 -3.89 0.000136 0.0446 -0.3 -0.25 Selective IgA deficiency; chr10:62863436 chr10:62793562~62805887:- CESC cis rs11221522 0.881 rs11221563 ENSG00000281097.1 LINC01395 3.89 0.000136 0.0446 0.28 0.25 Metabolite levels (5-HIAA); chr11:129097583 chr11:129612116~129617269:- CESC cis rs11221522 0.92 rs12794250 ENSG00000281097.1 LINC01395 3.89 0.000136 0.0446 0.28 0.25 Metabolite levels (5-HIAA); chr11:129098072 chr11:129612116~129617269:- CESC cis rs12107539 0.846 rs7644001 ENSG00000240137.4 ERICH6-AS1 -3.89 0.000136 0.0446 -0.23 -0.25 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151336110 chr3:150703564~150720146:+ CESC cis rs1707322 1 rs10789486 ENSG00000281133.1 AL355480.3 -3.88 0.000136 0.0446 -0.3 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45942995 chr1:45580892~45580996:- CESC cis rs453301 0.624 rs2979265 ENSG00000254340.1 RP11-10A14.3 3.88 0.000136 0.0446 0.3 0.25 Joint mobility (Beighton score); chr8:9001207 chr8:9141424~9145435:+ CESC cis rs17301013 0.606 rs332764 ENSG00000227373.4 RP11-160H22.5 3.88 0.000136 0.0446 0.32 0.25 Systemic lupus erythematosus; chr1:174693056 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs332763 ENSG00000227373.4 RP11-160H22.5 3.88 0.000136 0.0446 0.32 0.25 Systemic lupus erythematosus; chr1:174693482 chr1:174115300~174160004:- CESC cis rs17301013 0.581 rs332772 ENSG00000227373.4 RP11-160H22.5 3.88 0.000136 0.0446 0.32 0.25 Systemic lupus erythematosus; chr1:174695740 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs333471 ENSG00000227373.4 RP11-160H22.5 3.88 0.000136 0.0446 0.32 0.25 Systemic lupus erythematosus; chr1:174705062 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs332784 ENSG00000227373.4 RP11-160H22.5 3.88 0.000136 0.0446 0.32 0.25 Systemic lupus erythematosus; chr1:174719927 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs332798 ENSG00000227373.4 RP11-160H22.5 3.88 0.000136 0.0446 0.32 0.25 Systemic lupus erythematosus; chr1:174729096 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs459078 ENSG00000227373.4 RP11-160H22.5 3.88 0.000136 0.0446 0.32 0.25 Systemic lupus erythematosus; chr1:174733772 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs162815 ENSG00000227373.4 RP11-160H22.5 3.88 0.000136 0.0446 0.32 0.25 Systemic lupus erythematosus; chr1:174738792 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs1793307 ENSG00000227373.4 RP11-160H22.5 -3.88 0.000136 0.0446 -0.32 -0.25 Systemic lupus erythematosus; chr1:174758716 chr1:174115300~174160004:- CESC cis rs17301013 0.632 rs1653636 ENSG00000227373.4 RP11-160H22.5 -3.88 0.000136 0.0446 -0.32 -0.25 Systemic lupus erythematosus; chr1:174767739 chr1:174115300~174160004:- CESC cis rs17301013 0.62 rs1793310 ENSG00000227373.4 RP11-160H22.5 -3.88 0.000136 0.0446 -0.32 -0.25 Systemic lupus erythematosus; chr1:174770786 chr1:174115300~174160004:- CESC cis rs17301013 0.606 rs1754360 ENSG00000227373.4 RP11-160H22.5 -3.88 0.000136 0.0446 -0.32 -0.25 Systemic lupus erythematosus; chr1:174775825 chr1:174115300~174160004:- CESC cis rs8020095 0.571 rs10136026 ENSG00000258561.1 RP11-72M17.1 -3.88 0.000136 0.0446 -0.37 -0.25 Depression (quantitative trait); chr14:66943390 chr14:66212810~66509394:- CESC cis rs8020095 0.571 rs12588821 ENSG00000258561.1 RP11-72M17.1 -3.88 0.000136 0.0446 -0.37 -0.25 Depression (quantitative trait); chr14:66957783 chr14:66212810~66509394:- CESC cis rs4819052 0.851 rs2838834 ENSG00000215447.6 BX322557.10 -3.88 0.000136 0.0446 -0.22 -0.25 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45245293 chr21:45288052~45291738:+ CESC cis rs761746 0.96 rs14034 ENSG00000236132.1 CTA-440B3.1 -3.88 0.000136 0.0446 -0.32 -0.25 Intelligence; chr22:31619420 chr22:31816379~31817491:- CESC cis rs1012068 0.624 rs4820997 ENSG00000236132.1 CTA-440B3.1 -3.88 0.000136 0.0446 -0.3 -0.25 Chronic hepatitis C infection; chr22:31928154 chr22:31816379~31817491:- CESC cis rs875971 0.928 rs2036263 ENSG00000179406.6 LINC00174 3.88 0.000136 0.0446 0.27 0.25 Aortic root size; chr7:66335210 chr7:66376044~66401338:- CESC cis rs875971 0.862 rs10240949 ENSG00000179406.6 LINC00174 3.88 0.000136 0.0446 0.27 0.25 Aortic root size; chr7:66339430 chr7:66376044~66401338:- CESC cis rs875971 0.862 rs7782704 ENSG00000179406.6 LINC00174 3.88 0.000136 0.0446 0.27 0.25 Aortic root size; chr7:66340379 chr7:66376044~66401338:- CESC cis rs875971 0.862 rs6959268 ENSG00000179406.6 LINC00174 3.88 0.000136 0.0446 0.27 0.25 Aortic root size; chr7:66347979 chr7:66376044~66401338:- CESC cis rs4650376 0.789 rs1034004 ENSG00000235613.2 NSRP1P1 -3.88 0.000136 0.0446 -0.47 -0.25 IgG glycosylation; chr1:78722295 chr1:77847110~77848802:+ CESC cis rs75422866 0.85 rs73111212 ENSG00000257433.4 RP1-197B17.3 3.88 0.000136 0.0446 0.69 0.25 Pneumonia; chr12:47577638 chr12:47706085~47742294:+ CESC cis rs75422866 0.85 rs73111216 ENSG00000257433.4 RP1-197B17.3 3.88 0.000136 0.0446 0.69 0.25 Pneumonia; chr12:47577671 chr12:47706085~47742294:+ CESC cis rs75422866 0.85 rs73111217 ENSG00000257433.4 RP1-197B17.3 3.88 0.000136 0.0446 0.69 0.25 Pneumonia; chr12:47577693 chr12:47706085~47742294:+ CESC cis rs3748682 0.861 rs72661832 ENSG00000212541.1 RNU6-510P -3.88 0.000136 0.0447 -0.36 -0.25 Hypothyroidism; chr1:37795061 chr1:37991462~37991569:+ CESC cis rs35883536 1 rs1832121 ENSG00000235795.1 RP11-421L21.2 3.88 0.000136 0.0447 0.31 0.25 Monocyte count; chr1:100693920 chr1:100995473~100996260:+ CESC cis rs2235544 0.565 rs681660 ENSG00000225183.1 RP4-758J24.4 3.88 0.000136 0.0447 0.28 0.25 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54005516 chr1:54089856~54090093:+ CESC cis rs9903692 0.954 rs6847 ENSG00000263412.1 RP5-890E16.2 3.88 0.000136 0.0447 0.25 0.25 Pulse pressure; chr17:48070445 chr17:48045141~48048073:- CESC cis rs7560272 0.589 rs34874205 ENSG00000273245.1 RP11-434P11.2 -3.88 0.000136 0.0447 -0.32 -0.25 Schizophrenia; chr2:73648331 chr2:73750256~73750786:- CESC cis rs1670685 0.702 rs1945828 ENSG00000247137.7 RP11-727A23.5 3.88 0.000136 0.0447 0.4 0.25 Urate levels in overweight individuals; chr11:84124727 chr11:83184491~83193794:- CESC cis rs919433 0.647 rs2045242 ENSG00000222017.1 AC011997.1 3.88 0.000136 0.0447 0.32 0.25 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197642925 chr2:197693106~197774823:+ CESC cis rs4713118 0.621 rs9295755 ENSG00000219392.1 RP1-265C24.5 3.88 0.000136 0.0448 0.33 0.25 Parkinson's disease; chr6:28065396 chr6:28115628~28116551:+ CESC cis rs2933343 0.951 rs7648327 ENSG00000261159.1 RP11-723O4.9 3.88 0.000136 0.0448 0.28 0.25 IgG glycosylation; chr3:128851865 chr3:128859716~128860526:- CESC cis rs950776 0.745 rs36045869 ENSG00000261762.1 RP11-650L12.2 3.88 0.000137 0.0448 0.38 0.25 Sudden cardiac arrest; chr15:78637156 chr15:78589123~78591276:- CESC cis rs13113518 0.812 rs2035692 ENSG00000273257.1 RP11-177J6.1 3.88 0.000137 0.0448 0.34 0.25 Height; chr4:55528801 chr4:55387949~55388271:+ CESC cis rs13113518 0.812 rs4507426 ENSG00000273257.1 RP11-177J6.1 3.88 0.000137 0.0448 0.34 0.25 Height; chr4:55529387 chr4:55387949~55388271:+ CESC cis rs13113518 0.812 rs2035691 ENSG00000273257.1 RP11-177J6.1 3.88 0.000137 0.0448 0.34 0.25 Height; chr4:55529786 chr4:55387949~55388271:+ CESC cis rs13113518 0.756 rs11939652 ENSG00000273257.1 RP11-177J6.1 3.88 0.000137 0.0448 0.34 0.25 Height; chr4:55532542 chr4:55387949~55388271:+ CESC cis rs13028485 0.5 rs480525 ENSG00000271151.1 RP11-394I13.2 3.88 0.000137 0.0448 0.35 0.25 Multiple myeloma (IgH translocation); chr2:173666736 chr2:173968351~173969418:+ CESC cis rs9532669 0.926 rs4600337 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40879564 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs4555012 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40879997 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs12871420 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40880034 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs12871735 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40880169 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs12871895 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40880189 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532640 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40880628 chr13:40863599~40863902:- CESC cis rs9532669 0.89 rs9532641 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40880648 chr13:40863599~40863902:- CESC cis rs9532669 0.963 rs9532644 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40880860 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9532645 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40880898 chr13:40863599~40863902:- CESC cis rs9532669 0.926 rs9525419 ENSG00000176268.5 CYCSP34 3.88 0.000137 0.0448 0.26 0.25 Cervical cancer; chr13:40881047 chr13:40863599~40863902:- CESC cis rs853679 0.55 rs1237875 ENSG00000219392.1 RP1-265C24.5 3.88 0.000137 0.0448 0.32 0.25 Depression; chr6:28205232 chr6:28115628~28116551:+ CESC cis rs13113518 1 rs4865013 ENSG00000273257.1 RP11-177J6.1 3.88 0.000137 0.0448 0.33 0.25 Height; chr4:55559957 chr4:55387949~55388271:+ CESC cis rs9481169 0.557 rs33980500 ENSG00000255389.1 C6orf3 -3.88 0.000137 0.0448 -0.49 -0.25 Inflammatory skin disease; chr6:111592059 chr6:111599875~111602295:+ CESC cis rs9813712 0.571 rs9846596 ENSG00000228252.7 COL6A4P2 -3.88 0.000137 0.0448 -0.31 -0.25 Response to amphetamines; chr3:130288318 chr3:130212823~130273806:+ CESC cis rs9813712 0.595 rs1453239 ENSG00000228252.7 COL6A4P2 -3.88 0.000137 0.0448 -0.31 -0.25 Response to amphetamines; chr3:130288915 chr3:130212823~130273806:+ CESC cis rs9813712 0.523 rs9866942 ENSG00000228252.7 COL6A4P2 -3.88 0.000137 0.0448 -0.31 -0.25 Response to amphetamines; chr3:130297796 chr3:130212823~130273806:+ CESC cis rs9322193 0.962 rs7740784 ENSG00000223701.3 RAET1E-AS1 3.88 0.000137 0.0448 0.3 0.25 Lung cancer; chr6:149833364 chr6:149884431~149919508:+ CESC cis rs972578 0.668 rs9611930 ENSG00000274717.1 RP1-47A17.1 -3.88 0.000137 0.0448 -0.3 -0.25 Mean platelet volume; chr22:42839972 chr22:42791814~42794313:- CESC cis rs860295 0.65 rs28662267 ENSG00000232093.1 RP11-307C12.11 3.88 0.000137 0.0448 0.25 0.25 Body mass index; chr1:155710658 chr1:155045191~155046118:- CESC cis rs172642 0.935 rs218693 ENSG00000276384.1 RP11-186B7.7 3.88 0.000137 0.0448 0.29 0.25 Metabolite levels (small molecules and protein measures); chr17:6688433 chr17:7557820~7558245:- CESC cis rs12130219 1 rs34428306 ENSG00000237975.5 FLG-AS1 3.88 0.000137 0.0448 0.35 0.25 Inflammatory skin disease; chr1:152211840 chr1:152168125~152445456:+ CESC cis rs11633886 0.51 rs939423 ENSG00000273972.1 CTD-2306A12.1 3.88 0.000137 0.0448 0.28 0.25 Diisocyanate-induced asthma; chr15:45776743 chr15:45702640~45703183:+ CESC cis rs2179367 0.919 rs577001 ENSG00000231760.4 RP11-350J20.5 3.88 0.000137 0.0448 0.32 0.25 Dupuytren's disease; chr6:149325172 chr6:149796151~149826294:- CESC cis rs783540 0.869 rs783533 ENSG00000255769.6 GOLGA2P10 3.88 0.000137 0.0448 0.28 0.25 Schizophrenia; chr15:82581437 chr15:82472993~82513950:- CESC cis rs658191 0.661 rs11206163 ENSG00000237624.1 OXCT2P1 -3.88 0.000137 0.0449 -0.72 -0.25 Colorectal cancer; chr1:39478816 chr1:39514956~39516490:+ CESC cis rs853679 0.55 rs1233707 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000137 0.0449 -0.31 -0.25 Depression; chr6:28205175 chr6:28115628~28116551:+ CESC cis rs76878669 0.561 rs10896111 ENSG00000255468.5 RP11-867G23.8 3.88 0.000137 0.0449 0.29 0.25 Educational attainment (years of education); chr11:66348219 chr11:66347950~66364804:+ CESC cis rs76878669 0.519 rs10791869 ENSG00000255468.5 RP11-867G23.8 3.88 0.000137 0.0449 0.29 0.25 Educational attainment (years of education); chr11:66349642 chr11:66347950~66364804:+ CESC cis rs76878669 0.561 rs7110944 ENSG00000255468.5 RP11-867G23.8 3.88 0.000137 0.0449 0.29 0.25 Educational attainment (years of education); chr11:66350746 chr11:66347950~66364804:+ CESC cis rs7282265 0.941 rs9980685 ENSG00000260583.1 AP000223.42 -3.88 0.000137 0.0449 -0.33 -0.25 Chronic sinus infection; chr21:25391202 chr21:25582770~25583326:- CESC cis rs453301 0.522 rs1964356 ENSG00000173295.6 FAM86B3P 3.88 0.000137 0.0449 0.3 0.25 Joint mobility (Beighton score); chr8:8995760 chr8:8228595~8244865:+ CESC cis rs875971 0.965 rs7794930 ENSG00000237310.1 GS1-124K5.4 -3.88 0.000137 0.0449 -0.24 -0.25 Aortic root size; chr7:66313559 chr7:66493706~66495474:+ CESC cis rs72627123 0.867 rs73303113 ENSG00000270140.1 RP5-1021I20.6 -3.88 0.000137 0.0449 -0.6 -0.25 Morning vs. evening chronotype; chr14:74014365 chr14:73905267~73905636:+ CESC cis rs7826238 0.535 rs2979179 ENSG00000253893.2 FAM85B -3.88 0.000137 0.0449 -0.3 -0.25 Systolic blood pressure; chr8:8462519 chr8:8167819~8226614:- CESC cis rs9650657 0.655 rs10093774 ENSG00000255020.1 AF131216.5 3.88 0.000137 0.045 0.28 0.25 Neuroticism; chr8:10845783 chr8:11345748~11347502:- CESC cis rs34286592 1 rs13331733 ENSG00000214725.6 CDIPT-AS1 -3.88 0.000137 0.045 -0.44 -0.25 Multiple sclerosis; chr16:29837096 chr16:29863593~29868053:+ CESC cis rs703842 1 rs10877014 ENSG00000270039.1 RP11-571M6.17 -3.88 0.000137 0.045 -0.31 -0.25 Multiple sclerosis; chr12:57773878 chr12:57803838~57804415:+ CESC cis rs2058059 0.551 rs2960924 ENSG00000205578.5 POM121B -3.88 0.000137 0.045 -0.32 -0.25 Subcutaneous adipose tissue; chr7:72622795 chr7:73293497~73301161:+ CESC cis rs2554380 0.628 rs2401130 ENSG00000230373.7 GOLGA6L5P -3.88 0.000137 0.045 -0.32 -0.25 Height; chr15:83801983 chr15:84507885~84516814:- CESC cis rs2554380 0.628 rs2401131 ENSG00000230373.7 GOLGA6L5P -3.88 0.000137 0.045 -0.32 -0.25 Height; chr15:83802144 chr15:84507885~84516814:- CESC cis rs10971721 0.643 rs7040130 ENSG00000260947.1 RP11-384P7.7 3.88 0.000137 0.045 0.51 0.25 Body mass index; chr9:33785075 chr9:33697459~33700986:+ CESC cis rs8080784 1 rs9915606 ENSG00000266701.1 AC005702.4 -3.88 0.000137 0.045 -0.35 -0.25 Coronary artery disease; chr17:60923837 chr17:60042546~60042627:- CESC cis rs9393777 0.513 rs7740197 ENSG00000241549.7 GUSBP2 -3.88 0.000137 0.045 -0.34 -0.25 Intelligence (multi-trait analysis); chr6:26663250 chr6:26871484~26956554:- CESC cis rs6539288 0.63 rs10778520 ENSG00000260329.1 RP11-412D9.4 3.88 0.000137 0.045 0.23 0.25 Total body bone mineral density; chr12:106971095 chr12:106954029~106955497:- CESC cis rs6715284 1 rs13398075 ENSG00000201499.1 RNU6-312P 3.88 0.000137 0.045 0.45 0.25 Rheumatoid arthritis; chr2:201511546 chr2:200881715~200881821:- CESC cis rs897984 0.806 rs10782002 ENSG00000275263.1 RP11-1072A3.4 3.88 0.000138 0.045 0.33 0.25 Dementia with Lewy bodies; chr16:30935185 chr16:30956872~30957199:- CESC cis rs6740322 0.696 rs10188539 ENSG00000234936.1 AC010883.5 3.88 0.000138 0.045 0.26 0.25 Coronary artery disease; chr2:43257536 chr2:43229573~43233394:+ CESC cis rs950880 0.767 rs12999364 ENSG00000234389.1 AC007278.3 -3.88 0.000138 0.045 -0.28 -0.25 Serum protein levels (sST2); chr2:102357669 chr2:102438713~102440475:+ CESC cis rs950880 0.767 rs12998521 ENSG00000234389.1 AC007278.3 -3.88 0.000138 0.045 -0.28 -0.25 Serum protein levels (sST2); chr2:102357957 chr2:102438713~102440475:+ CESC cis rs2058059 0.551 rs2960920 ENSG00000205578.5 POM121B 3.88 0.000138 0.045 0.32 0.25 Subcutaneous adipose tissue; chr7:72618762 chr7:73293497~73301161:+ CESC cis rs7558911 0.711 rs6435069 ENSG00000273209.1 RP11-107N15.1 -3.88 0.000138 0.045 -0.27 -0.25 Chronic lymphocytic leukemia; chr2:201213771 chr2:202032770~202033537:- CESC cis rs876084 0.505 rs12680859 ENSG00000279347.1 RP11-85I17.2 -3.88 0.000138 0.045 -0.24 -0.25 Neurocognitive impairment in HIV-1 infection (dichotomous); chr8:120106729 chr8:119838736~119840385:- CESC cis rs2337406 1 rs74090714 ENSG00000211974.3 IGHV2-70 -3.88 0.000138 0.045 -0.35 -0.25 Alzheimer's disease (late onset); chr14:106691225 chr14:106723574~106724093:- CESC cis rs916888 0.773 rs199443 ENSG00000232300.1 FAM215B 3.88 0.000138 0.045 0.4 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46558830~46562795:- CESC cis rs875971 0.54 rs4717275 ENSG00000222364.1 RNU6-96P 3.88 0.000138 0.045 0.31 0.25 Aortic root size; chr7:65800193 chr7:66395191~66395286:+ CESC cis rs7216064 1 rs7223813 ENSG00000278730.1 RP11-147L13.11 -3.88 0.000138 0.0451 -0.31 -0.25 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67949724 chr17:68126666~68129586:+ CESC cis rs2361710 0.668 rs4889830 ENSG00000279259.1 RP11-334C17.3 3.88 0.000138 0.0451 0.29 0.25 High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes; chr17:80140729 chr17:80147250~80148596:+ CESC cis rs72946119 0.5 rs2052440 ENSG00000229267.2 AC072062.1 -3.88 0.000138 0.0451 -0.27 -0.25 Post bronchodilator FEV1/FVC ratio in COPD; chr2:214242832 chr2:214810229~214963274:+ CESC cis rs6504622 0.537 rs1662594 ENSG00000263142.4 LRRC37A17P 3.88 0.000138 0.0451 0.2 0.25 Orofacial clefts; chr17:46915371 chr17:46978481~47054569:+ CESC cis rs755249 0.567 rs1537817 ENSG00000228060.1 RP11-69E11.8 3.88 0.000138 0.0451 0.28 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39173981 chr1:39565160~39573203:+ CESC cis rs10129255 0.912 rs67410411 ENSG00000211970.3 IGHV4-61 -3.88 0.000138 0.0451 -0.2 -0.25 Kawasaki disease; chr14:106680324 chr14:106639119~106639657:- CESC cis rs1707322 1 rs12077974 ENSG00000281133.1 AL355480.3 -3.88 0.000138 0.0451 -0.3 -0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45918469 chr1:45580892~45580996:- CESC cis rs2243480 0.522 rs73150635 ENSG00000067601.7 PMS2P4 3.88 0.000138 0.0451 0.56 0.25 Diabetic kidney disease; chr7:66507503 chr7:67295608~67302907:- CESC cis rs13113518 0.812 rs13140590 ENSG00000273257.1 RP11-177J6.1 3.88 0.000138 0.0451 0.33 0.25 Height; chr4:55548666 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs55699500 ENSG00000273257.1 RP11-177J6.1 3.88 0.000138 0.0451 0.33 0.25 Height; chr4:55540912 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs56362210 ENSG00000273257.1 RP11-177J6.1 3.88 0.000138 0.0451 0.33 0.25 Height; chr4:55540972 chr4:55387949~55388271:+ CESC cis rs2271404 0.506 rs10197366 ENSG00000227992.1 AC108463.2 3.88 0.000138 0.0451 0.31 0.25 Atopic dermatitis; chr2:111239208 chr2:111203964~111206215:- CESC cis rs11169552 0.51 rs11169507 ENSG00000242041.1 RP11-70F11.2 -3.88 0.000138 0.0452 -0.32 -0.25 Colorectal cancer; chr12:50621726 chr12:49863173~49863503:+ CESC cis rs35883536 0.967 rs9434126 ENSG00000235795.1 RP11-421L21.2 -3.88 0.000138 0.0452 -0.3 -0.25 Monocyte count; chr1:100641425 chr1:100995473~100996260:+ CESC cis rs12681963 0.688 rs73242331 ENSG00000272375.1 RP11-51J9.6 3.88 0.000138 0.0452 0.48 0.25 Migraine; chr8:30198328 chr8:30197404~30198048:+ CESC cis rs916888 0.773 rs199445 ENSG00000232300.1 FAM215B 3.88 0.000138 0.0452 0.41 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46558830~46562795:- CESC cis rs748404 0.666 rs35326382 ENSG00000249839.1 AC011330.5 -3.88 0.000138 0.0452 -0.37 -0.25 Lung cancer; chr15:43338686 chr15:43663654~43684339:- CESC cis rs919433 0.617 rs700645 ENSG00000222017.1 AC011997.1 3.88 0.000138 0.0452 0.32 0.25 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197740790 chr2:197693106~197774823:+ CESC cis rs34014631 1 rs78142636 ENSG00000228657.1 RP11-170J3.2 -3.88 0.000138 0.0452 -0.62 -0.25 Coronary artery calcification; chr10:101841970 chr10:102572757~102573225:- CESC cis rs924712 0.522 rs12194012 ENSG00000224984.1 RP11-524H19.2 3.88 0.000138 0.0452 0.26 0.25 Breast cancer; chr6:54845053 chr6:54840118~54840855:- CESC cis rs9987353 0.522 rs2929466 ENSG00000253893.2 FAM85B 3.88 0.000138 0.0452 0.33 0.25 Recombination measurement; chr8:9206389 chr8:8167819~8226614:- CESC cis rs7246657 0.551 rs10419174 ENSG00000276846.1 CTD-3220F14.3 3.88 0.000138 0.0452 0.39 0.25 Coronary artery calcification; chr19:37114439 chr19:37314868~37315620:- CESC cis rs7246657 0.509 rs10426093 ENSG00000276846.1 CTD-3220F14.3 3.88 0.000138 0.0452 0.39 0.25 Coronary artery calcification; chr19:37124727 chr19:37314868~37315620:- CESC cis rs7246657 0.551 rs4806413 ENSG00000276846.1 CTD-3220F14.3 3.88 0.000138 0.0452 0.39 0.25 Coronary artery calcification; chr19:37126814 chr19:37314868~37315620:- CESC cis rs2638953 0.853 rs11049519 ENSG00000247934.4 RP11-967K21.1 -3.88 0.000138 0.0453 -0.38 -0.25 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28307285 chr12:28163298~28190738:- CESC cis rs1400816 0.85 rs77465418 ENSG00000225205.4 AC093818.1 -3.88 0.000139 0.0453 -0.44 -0.25 Amyotrophic lateral sclerosis (sporadic); chr2:171983081 chr2:172480840~172556596:- CESC cis rs6142102 0.961 rs2235596 ENSG00000275784.1 RP5-1125A11.6 3.88 0.000139 0.0453 0.26 0.25 Skin pigmentation; chr20:34096503 chr20:33989480~33991818:- CESC cis rs2131877 0.913 rs1874101 ENSG00000230266.1 XXYLT1-AS2 3.88 0.000139 0.0453 0.35 0.25 Non-small cell lung cancer; chr3:195128328 chr3:195147871~195152790:+ CESC cis rs703842 1 rs11172342 ENSG00000270039.1 RP11-571M6.17 -3.88 0.000139 0.0453 -0.31 -0.25 Multiple sclerosis; chr12:57793975 chr12:57803838~57804415:+ CESC cis rs703842 1 rs11172343 ENSG00000270039.1 RP11-571M6.17 -3.88 0.000139 0.0453 -0.31 -0.25 Multiple sclerosis; chr12:57794374 chr12:57803838~57804415:+ CESC cis rs703842 1 rs1875124 ENSG00000270039.1 RP11-571M6.17 -3.88 0.000139 0.0453 -0.31 -0.25 Multiple sclerosis; chr12:57803019 chr12:57803838~57804415:+ CESC cis rs1432089 0.773 rs62344308 ENSG00000181359.5 HSP90AA6P 3.88 0.000139 0.0453 0.48 0.25 Endometriosis; chr4:170868346 chr4:170581470~170605450:- CESC cis rs17772222 0.958 rs1816372 ENSG00000258983.2 RP11-507K2.2 3.88 0.000139 0.0453 0.32 0.25 Coronary artery calcification; chr14:88507033 chr14:88499334~88515502:+ CESC cis rs703842 1 rs4646536 ENSG00000270039.1 RP11-571M6.17 -3.88 0.000139 0.0453 -0.31 -0.25 Multiple sclerosis; chr12:57764205 chr12:57803838~57804415:+ CESC cis rs42490 0.664 rs39515 ENSG00000251136.7 RP11-37B2.1 -3.88 0.000139 0.0453 -0.25 -0.25 Leprosy; chr8:89816761 chr8:89609409~89757727:- CESC cis rs4319547 0.695 rs1973463 ENSG00000275265.1 RP11-15J22.8 -3.88 0.000139 0.0453 -0.35 -0.25 Body mass index; chr12:122453456 chr12:122501187~122501641:+ CESC cis rs2337406 0.925 rs76288499 ENSG00000254174.1 IGHV1-12 3.88 0.000139 0.0453 0.27 0.25 Alzheimer's disease (late onset); chr14:106686309 chr14:106122420~106122709:- CESC cis rs783540 0.5 rs1313494 ENSG00000278202.1 RP11-152F13.8 3.88 0.000139 0.0453 0.23 0.25 Schizophrenia; chr15:82605530 chr15:82418651~82434235:+ CESC cis rs2439831 0.85 rs3742982 ENSG00000249839.1 AC011330.5 -3.88 0.000139 0.0454 -0.37 -0.25 Lung cancer in ever smokers; chr15:43884483 chr15:43663654~43684339:- CESC cis rs17301013 0.507 rs2281010 ENSG00000227373.4 RP11-160H22.5 3.88 0.000139 0.0454 0.38 0.25 Systemic lupus erythematosus; chr1:174509917 chr1:174115300~174160004:- CESC cis rs11089937 0.857 rs5750580 ENSG00000211639.2 IGLV4-60 3.88 0.000139 0.0454 0.22 0.25 Periodontitis (PAL4Q3); chr22:22137471 chr22:22162199~22162681:+ CESC cis rs10510102 0.872 rs56108883 ENSG00000276742.1 RP11-500G22.4 3.88 0.000139 0.0454 0.41 0.25 Breast cancer; chr10:121825567 chr10:121956782~121957098:+ CESC cis rs7580658 0.724 rs7568261 ENSG00000236682.1 AC068282.3 -3.88 0.000139 0.0454 -0.3 -0.25 Protein C levels; chr2:127359748 chr2:127389130~127400580:+ CESC cis rs7614311 0.681 rs57766205 ENSG00000271843.1 RP11-245J9.5 -3.88 0.000139 0.0454 -0.37 -0.25 Lung function (FVC);Lung function (FEV1); chr3:63909627 chr3:64008082~64008692:- CESC cis rs6475606 0.532 rs10738604 ENSG00000215221.2 UBA52P6 3.88 0.000139 0.0454 0.32 0.25 Intracranial aneurysm; chr9:22025494 chr9:22012155~22012536:+ CESC cis rs9300255 0.602 rs1790095 ENSG00000235423.7 RP11-282O18.3 3.88 0.000139 0.0454 0.33 0.25 Neutrophil percentage of white cells; chr12:123196675 chr12:123252030~123261483:- CESC cis rs2337406 0.587 rs10150642 ENSG00000254174.1 IGHV1-12 -3.88 0.000139 0.0454 -0.22 -0.25 Alzheimer's disease (late onset); chr14:106647269 chr14:106122420~106122709:- CESC cis rs673078 0.607 rs61944661 ENSG00000275759.1 RP11-131L12.3 -3.88 0.000139 0.0454 -0.49 -0.25 Glucose homeostasis traits; chr12:118445514 chr12:118428281~118428870:+ CESC cis rs10129255 1 rs11627342 ENSG00000224373.3 IGHV4-59 3.88 0.000139 0.0454 0.18 0.25 Kawasaki disease; chr14:106675823 chr14:106627249~106627825:- CESC cis rs6452524 0.904 rs10473867 ENSG00000249664.1 CTD-2227C6.2 3.88 0.000139 0.0454 0.31 0.25 Hypertension (SNP x SNP interaction); chr5:83141613 chr5:83012285~83013109:- CESC cis rs9400467 0.506 rs76110409 ENSG00000272356.1 RP5-1112D6.8 -3.88 0.000139 0.0454 -0.32 -0.25 Amino acid levels;Blood metabolite levels; chr6:111281929 chr6:111309203~111313517:+ CESC cis rs9400467 0.506 rs10457237 ENSG00000272356.1 RP5-1112D6.8 -3.88 0.000139 0.0454 -0.32 -0.25 Amino acid levels;Blood metabolite levels; chr6:111284923 chr6:111309203~111313517:+ CESC cis rs2115630 0.905 rs1975277 ENSG00000225151.9 GOLGA2P7 3.88 0.000139 0.0454 0.28 0.25 P wave terminal force; chr15:84786327 chr15:84199311~84230136:- CESC cis rs227932 0.681 rs7776862 ENSG00000234286.1 AC006026.13 3.88 0.000139 0.0455 0.34 0.25 Schizophrenia; chr7:23736607 chr7:23680195~23680786:- CESC cis rs516805 0.961 rs510283 ENSG00000279453.1 RP3-425C14.4 -3.88 0.000139 0.0455 -0.29 -0.25 Lymphocyte counts; chr6:122451547 chr6:122436789~122439223:- CESC cis rs2439831 0.85 rs3825783 ENSG00000275601.1 AC011330.13 -3.88 0.000139 0.0455 -0.39 -0.25 Lung cancer in ever smokers; chr15:43810111 chr15:43642389~43643023:- CESC cis rs9860250 0.945 rs9824648 ENSG00000175841.8 FAM172BP 3.88 0.000139 0.0455 0.41 0.25 Optic disc area; chr3:100936970 chr3:101521891~101522979:+ CESC cis rs67311347 0.544 rs13098483 ENSG00000223797.4 ENTPD3-AS1 3.88 0.000139 0.0455 0.24 0.25 Renal cell carcinoma; chr3:40301252 chr3:40313802~40453329:- CESC cis rs67311347 0.544 rs9864601 ENSG00000223797.4 ENTPD3-AS1 3.88 0.000139 0.0455 0.24 0.25 Renal cell carcinoma; chr3:40303827 chr3:40313802~40453329:- CESC cis rs67311347 0.544 rs9868700 ENSG00000223797.4 ENTPD3-AS1 3.88 0.000139 0.0455 0.24 0.25 Renal cell carcinoma; chr3:40303917 chr3:40313802~40453329:- CESC cis rs9908102 0.74 rs58809197 ENSG00000263648.1 RP11-471L13.3 -3.88 0.000139 0.0455 -0.39 -0.25 Schizophrenia; chr17:13016943 chr17:12115547~12115885:+ CESC cis rs10829156 0.629 rs7069955 ENSG00000240291.1 RP11-499P20.2 3.88 0.000139 0.0455 0.31 0.25 Sudden cardiac arrest; chr10:18688210 chr10:18513115~18545651:- CESC cis rs10170310 0.515 rs35628318 ENSG00000241772.2 AC092620.2 3.88 0.000139 0.0455 0.42 0.25 Response to antipsychotic treatment; chr2:138561405 chr2:138569090~138574458:+ CESC cis rs881375 0.967 rs2109896 ENSG00000226752.6 PSMD5-AS1 -3.88 0.00014 0.0456 -0.27 -0.25 Rheumatoid arthritis; chr9:120920828 chr9:120824828~120854385:+ CESC cis rs11096990 0.593 rs35552004 ENSG00000249685.1 RP11-360F5.3 3.88 0.00014 0.0456 0.3 0.25 Cognitive function; chr4:39170914 chr4:39133913~39135608:+ CESC cis rs11096990 0.552 rs7655170 ENSG00000249685.1 RP11-360F5.3 3.88 0.00014 0.0456 0.3 0.25 Cognitive function; chr4:39171984 chr4:39133913~39135608:+ CESC cis rs5769765 0.908 rs4074304 ENSG00000229409.1 RP11-494O16.3 3.88 0.00014 0.0456 0.37 0.25 Schizophrenia; chr22:49915798 chr22:49845929~49846090:+ CESC cis rs5769765 0.908 rs9616376 ENSG00000229409.1 RP11-494O16.3 3.88 0.00014 0.0456 0.37 0.25 Schizophrenia; chr22:49917181 chr22:49845929~49846090:+ CESC cis rs5769765 0.819 rs9616379 ENSG00000229409.1 RP11-494O16.3 3.88 0.00014 0.0456 0.37 0.25 Schizophrenia; chr22:49918387 chr22:49845929~49846090:+ CESC cis rs5769765 0.862 rs9616380 ENSG00000229409.1 RP11-494O16.3 3.88 0.00014 0.0456 0.37 0.25 Schizophrenia; chr22:49918577 chr22:49845929~49846090:+ CESC cis rs5769765 0.862 rs9616381 ENSG00000229409.1 RP11-494O16.3 3.88 0.00014 0.0456 0.37 0.25 Schizophrenia; chr22:49918734 chr22:49845929~49846090:+ CESC cis rs5769765 0.773 rs58375955 ENSG00000229409.1 RP11-494O16.3 3.88 0.00014 0.0456 0.37 0.25 Schizophrenia; chr22:49918982 chr22:49845929~49846090:+ CESC cis rs6687821 0.515 rs496588 ENSG00000267734.1 RP4-604K5.3 3.88 0.00014 0.0456 0.28 0.25 Yeast infection; chr1:86858728 chr1:86932199~86934891:- CESC cis rs2276314 0.947 rs16967319 ENSG00000278986.1 RP11-723J4.3 -3.88 0.00014 0.0456 -0.29 -0.25 Endometriosis;Drug-induced torsades de pointes; chr18:35993562 chr18:35972151~35973916:+ CESC cis rs9437689 0.69 rs9437810 ENSG00000226026.4 RP11-57H12.3 3.88 0.00014 0.0456 0.27 0.25 Phospholipid levels (plasma); chr1:95071067 chr1:95163219~95233982:- CESC cis rs2404602 0.716 rs67204011 ENSG00000280730.1 AC090181.1 3.88 0.00014 0.0456 0.2 0.25 Blood metabolite levels; chr15:76554214 chr15:77056895~77057021:+ CESC cis rs9517320 1 rs9584857 ENSG00000231194.1 FARP1-AS1 3.88 0.00014 0.0456 0.3 0.25 Longevity; chr13:98476318 chr13:98435405~98435840:- CESC cis rs2439831 0.681 rs3742971 ENSG00000275601.1 AC011330.13 3.88 0.00014 0.0456 0.33 0.25 Lung cancer in ever smokers; chr15:43330718 chr15:43642389~43643023:- CESC cis rs12107539 0.915 rs1388617 ENSG00000240137.4 ERICH6-AS1 -3.88 0.00014 0.0456 -0.25 -0.25 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151305381 chr3:150703564~150720146:+ CESC cis rs11168351 0.864 rs10875743 ENSG00000258273.1 RP11-370I10.4 3.88 0.00014 0.0456 0.29 0.25 Bipolar disorder and schizophrenia; chr12:48104630 chr12:48333755~48333901:- CESC cis rs116095464 1 rs3777237 ENSG00000250848.1 CTD-2083E4.5 -3.88 0.00014 0.0456 -0.57 -0.25 Breast cancer; chr5:307526 chr5:288833~290321:- CESC cis rs62025270 0.632 rs111906684 ENSG00000202081.1 RNU6-1280P -3.88 0.00014 0.0456 -0.34 -0.25 Idiopathic pulmonary fibrosis; chr15:85678705 chr15:85651522~85651628:- CESC cis rs10129255 0.5 rs10143242 ENSG00000280411.1 IGHV1-69-2 -3.88 0.00014 0.0456 -0.17 -0.25 Kawasaki disease; chr14:106681814 chr14:106762092~106762588:- CESC cis rs2841307 0.639 rs761710 ENSG00000279170.1 RP1-199J3.6 -3.88 0.00014 0.0457 -0.34 -0.25 Bipolar disorder and schizophrenia; chr6:100248029 chr6:99587611~99589898:+ CESC cis rs67311347 1 rs12638199 ENSG00000223797.4 ENTPD3-AS1 3.88 0.00014 0.0457 0.25 0.25 Renal cell carcinoma; chr3:40433794 chr3:40313802~40453329:- CESC cis rs67311347 1 rs34762643 ENSG00000223797.4 ENTPD3-AS1 3.88 0.00014 0.0457 0.25 0.25 Renal cell carcinoma; chr3:40433942 chr3:40313802~40453329:- CESC cis rs67311347 1 rs9841335 ENSG00000223797.4 ENTPD3-AS1 3.88 0.00014 0.0457 0.25 0.25 Renal cell carcinoma; chr3:40434367 chr3:40313802~40453329:- CESC cis rs62355900 0.627 rs16886449 ENSG00000271828.1 CTD-2310F14.1 3.88 0.00014 0.0458 0.4 0.25 Endometriosis; chr5:56880479 chr5:56927874~56929573:+ CESC cis rs62355900 0.627 rs895380 ENSG00000271828.1 CTD-2310F14.1 3.88 0.00014 0.0458 0.4 0.25 Endometriosis; chr5:56881321 chr5:56927874~56929573:+ CESC cis rs6142102 0.812 rs6059574 ENSG00000275784.1 RP5-1125A11.6 3.88 0.00014 0.0458 0.26 0.25 Skin pigmentation; chr20:33935366 chr20:33989480~33991818:- CESC cis rs3925075 0.525 rs2011491 ENSG00000260911.2 RP11-196G11.2 -3.88 0.000141 0.0458 -0.27 -0.25 IgA nephropathy; chr16:31268934 chr16:31043150~31049868:+ CESC cis rs3925075 0.525 rs929868 ENSG00000260911.2 RP11-196G11.2 -3.88 0.000141 0.0458 -0.27 -0.25 IgA nephropathy; chr16:31268961 chr16:31043150~31049868:+ CESC cis rs9650657 0.562 rs10090444 ENSG00000269918.1 AF131215.9 3.88 0.000141 0.0458 0.31 0.25 Neuroticism; chr8:10887959 chr8:11104691~11106704:- CESC cis rs11637445 0.627 rs4776988 ENSG00000270964.1 RP11-502I4.3 3.88 0.000141 0.0458 0.26 0.25 Posterior cortical atrophy and Alzheimer's disease; chr15:67831813 chr15:67541072~67542604:- CESC cis rs2721195 0.967 rs748195 ENSG00000255182.2 CTD-2517M22.14 3.88 0.000141 0.0458 0.23 0.25 Age at first birth; chr8:144457131 chr8:144495458~144505444:- CESC cis rs2255336 0.938 rs4548707 ENSG00000245648.1 RP11-277P12.20 -3.88 0.000141 0.0458 -0.38 -0.25 Blood protein levels; chr12:10467634 chr12:10363769~10398506:+ CESC cis rs9309473 1 rs11903916 ENSG00000163016.8 ALMS1P 3.88 0.000141 0.0458 0.32 0.25 Metabolite levels; chr2:73588201 chr2:73644919~73685576:+ CESC cis rs7712401 0.601 rs30027 ENSG00000263432.2 RN7SL689P 3.88 0.000141 0.0458 0.31 0.25 Mean platelet volume; chr5:122947695 chr5:123022487~123022783:- CESC cis rs9650657 0.571 rs11783247 ENSG00000255046.1 RP11-297N6.4 3.88 0.000141 0.0459 0.27 0.25 Neuroticism; chr8:10931365 chr8:11797928~11802568:- CESC cis rs6110809 0.711 rs175816 ENSG00000273998.1 RP4-777L9.2 3.88 0.000141 0.0459 0.45 0.25 Thyroid-associated orbitopathy in graves' disease; chr20:15843226 chr20:16576068~16579615:+ CESC cis rs6110809 0.711 rs175815 ENSG00000273998.1 RP4-777L9.2 3.88 0.000141 0.0459 0.45 0.25 Thyroid-associated orbitopathy in graves' disease; chr20:15843274 chr20:16576068~16579615:+ CESC cis rs6110809 0.711 rs175814 ENSG00000273998.1 RP4-777L9.2 3.88 0.000141 0.0459 0.45 0.25 Thyroid-associated orbitopathy in graves' disease; chr20:15843325 chr20:16576068~16579615:+ CESC cis rs875971 1 rs937495 ENSG00000237310.1 GS1-124K5.4 -3.88 0.000141 0.0459 -0.23 -0.25 Aortic root size; chr7:66314811 chr7:66493706~66495474:+ CESC cis rs4713118 0.824 rs742046 ENSG00000216901.1 AL022393.7 3.88 0.000141 0.0459 0.3 0.25 Parkinson's disease; chr6:27771475 chr6:28176188~28176674:+ CESC cis rs9943753 0.508 rs5013021 ENSG00000257221.1 RP11-689B22.2 -3.88 0.000141 0.0459 -0.22 -0.25 HDL cholesterol; chr12:109352947 chr12:108628687~108641318:+ CESC cis rs6556937 0.562 rs31250 ENSG00000251314.2 CTD-2337A12.1 3.88 0.000141 0.0459 0.34 0.25 Blood protein levels; chr5:96677737 chr5:95962001~96631085:+ CESC cis rs919433 0.617 rs700642 ENSG00000222017.1 AC011997.1 -3.88 0.000141 0.0459 -0.32 -0.25 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197736006 chr2:197693106~197774823:+ CESC cis rs8127691 1 rs8127691 ENSG00000225331.1 AP001055.6 3.87 0.000141 0.046 0.31 0.25 Inflammatory bowel disease; chr21:44194977 chr21:44158740~44160076:- CESC cis rs2898681 0.618 rs116241740 ENSG00000248375.1 RP11-177B4.1 -3.87 0.000141 0.046 -0.48 -0.25 Optic nerve measurement (cup area); chr4:52867356 chr4:52720081~52720831:- CESC cis rs7551222 0.716 rs12041075 ENSG00000240219.1 RP11-430C7.5 3.87 0.000141 0.046 0.28 0.25 Schizophrenia; chr1:204523025 chr1:204626775~204629712:+ CESC cis rs67311347 1 rs9829800 ENSG00000223797.4 ENTPD3-AS1 3.87 0.000141 0.046 0.25 0.25 Renal cell carcinoma; chr3:40402436 chr3:40313802~40453329:- CESC cis rs453301 0.538 rs7830804 ENSG00000254340.1 RP11-10A14.3 -3.87 0.000141 0.046 -0.31 -0.25 Joint mobility (Beighton score); chr8:9113252 chr8:9141424~9145435:+ CESC cis rs7508 0.512 rs6981130 ENSG00000253671.1 RP11-806O11.1 -3.87 0.000141 0.046 -0.26 -0.25 Atrial fibrillation; chr8:18035009 chr8:17808941~17820868:+ CESC cis rs62355902 1 rs62355902 ENSG00000271828.1 CTD-2310F14.1 3.87 0.000141 0.046 0.34 0.25 Breast cancer;Breast cancer (estrogen-receptor negative); chr5:56757896 chr5:56927874~56929573:+ CESC cis rs2836950 0.501 rs62223052 ENSG00000232608.1 TIMM9P2 3.87 0.000141 0.046 0.29 0.25 Menarche (age at onset); chr21:39336776 chr21:39216624~39217506:+ CESC cis rs1707322 0.964 rs785508 ENSG00000281133.1 AL355480.3 3.87 0.000141 0.046 0.3 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46061487 chr1:45580892~45580996:- CESC cis rs1707322 0.964 rs785509 ENSG00000281133.1 AL355480.3 3.87 0.000141 0.046 0.3 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46061628 chr1:45580892~45580996:- CESC cis rs526231 0.783 rs28158 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103260191 chr5:103032376~103033031:+ CESC cis rs526231 0.819 rs26232 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103261019 chr5:103032376~103033031:+ CESC cis rs526231 0.819 rs26234 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103261455 chr5:103032376~103033031:+ CESC cis rs526231 0.747 rs39984 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103261591 chr5:103032376~103033031:+ CESC cis rs526231 0.819 rs2569018 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103262042 chr5:103032376~103033031:+ CESC cis rs526231 0.819 rs2561482 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103262097 chr5:103032376~103033031:+ CESC cis rs526231 0.747 rs434830 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103263605 chr5:103032376~103033031:+ CESC cis rs526231 0.747 rs375637 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103263877 chr5:103032376~103033031:+ CESC cis rs526231 0.747 rs434294 ENSG00000175749.11 EIF3KP1 3.87 0.000141 0.046 0.31 0.25 Primary biliary cholangitis; chr5:103263925 chr5:103032376~103033031:+ CESC cis rs11976180 0.517 rs6949375 ENSG00000228960.5 OR2A9P -3.87 0.000141 0.046 -0.46 -0.25 Obesity-related traits; chr7:144076758 chr7:144294480~144300934:+ CESC cis rs7811142 0.83 rs7792525 ENSG00000242294.5 STAG3L5P 3.87 0.000141 0.046 0.27 0.25 Platelet count; chr7:100374499 chr7:100336079~100351900:+ CESC cis rs7200543 1 rs6498541 ENSG00000260735.1 RP11-72I8.1 -3.87 0.000142 0.0461 -0.3 -0.25 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15046800 chr16:15094411~15109197:+ CESC cis rs6556937 0.627 rs7705824 ENSG00000251314.2 CTD-2337A12.1 3.87 0.000142 0.0461 0.32 0.25 Blood protein levels; chr5:96669913 chr5:95962001~96631085:+ CESC cis rs2439831 0.85 rs28564774 ENSG00000275601.1 AC011330.13 -3.87 0.000142 0.0461 -0.4 -0.25 Lung cancer in ever smokers; chr15:43833277 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28513374 ENSG00000275601.1 AC011330.13 -3.87 0.000142 0.0461 -0.4 -0.25 Lung cancer in ever smokers; chr15:43833297 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs7169322 ENSG00000275601.1 AC011330.13 -3.87 0.000142 0.0461 -0.4 -0.25 Lung cancer in ever smokers; chr15:43838816 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28707214 ENSG00000275601.1 AC011330.13 -3.87 0.000142 0.0461 -0.4 -0.25 Lung cancer in ever smokers; chr15:43839425 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs28413704 ENSG00000275601.1 AC011330.13 -3.87 0.000142 0.0461 -0.4 -0.25 Lung cancer in ever smokers; chr15:43856229 chr15:43642389~43643023:- CESC cis rs2439831 0.702 rs9989313 ENSG00000275601.1 AC011330.13 -3.87 0.000142 0.0461 -0.4 -0.25 Lung cancer in ever smokers; chr15:43860619 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs61390361 ENSG00000275601.1 AC011330.13 -3.87 0.000142 0.0461 -0.4 -0.25 Lung cancer in ever smokers; chr15:43867644 chr15:43642389~43643023:- CESC cis rs2439831 0.85 rs11856795 ENSG00000275601.1 AC011330.13 -3.87 0.000142 0.0461 -0.4 -0.25 Lung cancer in ever smokers; chr15:43868384 chr15:43642389~43643023:- CESC cis rs2688608 0.901 rs2459446 ENSG00000242288.9 RP11-464F9.1 -3.87 0.000142 0.0461 -0.28 -0.25 Inflammatory bowel disease; chr10:73841838 chr10:73674295~73730466:- CESC cis rs669446 0.591 rs586339 ENSG00000236200.4 KDM4A-AS1 -3.87 0.000142 0.0461 -0.33 -0.25 Amyotrophic lateral sclerosis (age of onset); chr1:43671586 chr1:43699765~43708138:- CESC cis rs7829975 0.573 rs7842359 ENSG00000253893.2 FAM85B 3.87 0.000142 0.0461 0.32 0.25 Mood instability; chr8:8939568 chr8:8167819~8226614:- CESC cis rs12107539 1 rs3773621 ENSG00000240137.4 ERICH6-AS1 -3.87 0.000142 0.0461 -0.25 -0.25 Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity); chr3:151278646 chr3:150703564~150720146:+ CESC cis rs11685222 0.589 rs6754531 ENSG00000229326.3 AC069154.4 3.87 0.000142 0.0461 0.35 0.25 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119673698 chr2:119698623~119700151:+ CESC cis rs2404602 0.716 rs17363713 ENSG00000280730.1 AC090181.1 3.87 0.000142 0.0461 0.19 0.25 Blood metabolite levels; chr15:76453787 chr15:77056895~77057021:+ CESC cis rs9487094 0.644 rs3757230 ENSG00000260273.1 RP11-425D10.10 3.87 0.000142 0.0461 0.31 0.25 Height; chr6:109383239 chr6:109382795~109383666:+ CESC cis rs9487094 0.644 rs3757231 ENSG00000260273.1 RP11-425D10.10 3.87 0.000142 0.0461 0.31 0.25 Height; chr6:109383248 chr6:109382795~109383666:+ CESC cis rs9487094 0.666 rs2211288 ENSG00000260273.1 RP11-425D10.10 3.87 0.000142 0.0461 0.31 0.25 Height; chr6:109383848 chr6:109382795~109383666:+ CESC cis rs9487094 0.666 rs4946970 ENSG00000260273.1 RP11-425D10.10 3.87 0.000142 0.0461 0.31 0.25 Height; chr6:109384807 chr6:109382795~109383666:+ CESC cis rs6921919 0.583 rs7764722 ENSG00000204709.4 LINC01556 3.87 0.000142 0.0461 0.28 0.25 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28943877~28944537:+ CESC cis rs867371 1 rs8041924 ENSG00000255769.6 GOLGA2P10 -3.87 0.000142 0.0461 -0.29 -0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82181320 chr15:82472993~82513950:- CESC cis rs867371 1 rs2088858 ENSG00000255769.6 GOLGA2P10 -3.87 0.000142 0.0461 -0.29 -0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82182408 chr15:82472993~82513950:- CESC cis rs867371 1 rs4778982 ENSG00000255769.6 GOLGA2P10 -3.87 0.000142 0.0461 -0.29 -0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82182931 chr15:82472993~82513950:- CESC cis rs867371 1 rs2867579 ENSG00000255769.6 GOLGA2P10 -3.87 0.000142 0.0461 -0.29 -0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82183043 chr15:82472993~82513950:- CESC cis rs867371 1 rs881308 ENSG00000255769.6 GOLGA2P10 -3.87 0.000142 0.0461 -0.29 -0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82183456 chr15:82472993~82513950:- CESC cis rs10129255 0.536 rs3944157 ENSG00000224373.3 IGHV4-59 3.87 0.000142 0.0461 0.16 0.25 Kawasaki disease; chr14:106682286 chr14:106627249~106627825:- CESC cis rs875971 0.964 rs1643388 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0461 -0.28 -0.25 Aortic root size; chr7:66379575 chr7:66376044~66401338:- CESC cis rs875971 1 rs778722 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0461 -0.28 -0.25 Aortic root size; chr7:66379841 chr7:66376044~66401338:- CESC cis rs875971 0.964 rs778721 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0461 -0.28 -0.25 Aortic root size; chr7:66380410 chr7:66376044~66401338:- CESC cis rs2019137 0.868 rs3748916 ENSG00000189223.12 PAX8-AS1 3.87 0.000142 0.0461 0.32 0.25 Lymphocyte counts; chr2:113226456 chr2:113211522~113276581:+ CESC cis rs10504130 0.74 rs78779687 ENSG00000253475.1 RP11-110G21.2 -3.87 0.000142 0.0461 -0.52 -0.25 Venous thromboembolism (SNP x SNP interaction); chr8:51699832 chr8:51895957~51896374:- CESC cis rs2115630 1 rs11854291 ENSG00000225151.9 GOLGA2P7 3.87 0.000142 0.0461 0.28 0.25 P wave terminal force; chr15:84820477 chr15:84199311~84230136:- CESC cis rs10129255 0.5 rs10142931 ENSG00000224373.3 IGHV4-59 3.87 0.000142 0.0462 0.16 0.25 Kawasaki disease; chr14:106782288 chr14:106627249~106627825:- CESC cis rs2235544 0.565 rs637590 ENSG00000225183.1 RP4-758J24.4 3.87 0.000142 0.0462 0.29 0.25 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:53996030 chr1:54089856~54090093:+ CESC cis rs5760092 0.755 rs4585126 ENSG00000228039.3 KB-1125A3.10 -3.87 0.000142 0.0462 -0.34 -0.25 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23963780~23964374:+ CESC cis rs13108904 0.518 rs4974602 ENSG00000254094.1 AC078852.1 -3.87 0.000142 0.0462 -0.32 -0.25 Obesity-related traits; chr4:1348603 chr4:1356581~1358075:+ CESC cis rs12468226 0.938 rs12464254 ENSG00000273456.1 RP11-686O6.2 3.87 0.000142 0.0462 0.35 0.25 Urate levels; chr2:202301641 chr2:202374932~202375604:- CESC cis rs911555 0.755 rs11620897 ENSG00000244691.1 RPL10AP1 -3.87 0.000142 0.0462 -0.35 -0.25 Intelligence (multi-trait analysis); chr14:103478524 chr14:103412119~103412761:- CESC cis rs911555 0.755 rs4143998 ENSG00000244691.1 RPL10AP1 -3.87 0.000142 0.0462 -0.35 -0.25 Intelligence (multi-trait analysis); chr14:103488910 chr14:103412119~103412761:- CESC cis rs911555 0.755 rs1138400 ENSG00000244691.1 RPL10AP1 -3.87 0.000142 0.0462 -0.35 -0.25 Intelligence (multi-trait analysis); chr14:103490496 chr14:103412119~103412761:- CESC cis rs9309473 0.5 rs2421668 ENSG00000273245.1 RP11-434P11.2 -3.87 0.000142 0.0462 -0.32 -0.25 Metabolite levels; chr2:73657969 chr2:73750256~73750786:- CESC cis rs11096990 0.891 rs61691409 ENSG00000249207.1 RP11-360F5.1 3.87 0.000142 0.0462 0.31 0.25 Cognitive function; chr4:39243801 chr4:39112677~39126818:- CESC cis rs11096990 0.964 rs35494908 ENSG00000249207.1 RP11-360F5.1 3.87 0.000142 0.0462 0.31 0.25 Cognitive function; chr4:39252574 chr4:39112677~39126818:- CESC cis rs7924176 0.601 rs10824073 ENSG00000213731.2 RAB5CP1 -3.87 0.000142 0.0462 -0.27 -0.25 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development; chr10:74115458 chr10:74423435~74424014:- CESC cis rs55665837 1 rs10832254 ENSG00000251991.1 RNU7-49P 3.87 0.000142 0.0462 0.28 0.25 Vitamin D levels; chr11:14413152 chr11:14478892~14478953:+ CESC cis rs55665837 1 rs11023214 ENSG00000251991.1 RNU7-49P 3.87 0.000142 0.0462 0.28 0.25 Vitamin D levels; chr11:14414713 chr11:14478892~14478953:+ CESC cis rs76878669 0.561 rs11227465 ENSG00000255468.5 RP11-867G23.8 3.87 0.000142 0.0462 0.3 0.25 Educational attainment (years of education); chr11:66348408 chr11:66347950~66364804:+ CESC cis rs34014631 1 rs79515366 ENSG00000228657.1 RP11-170J3.2 -3.87 0.000142 0.0462 -0.61 -0.25 Coronary artery calcification; chr10:101822816 chr10:102572757~102573225:- CESC cis rs6951245 1 rs79443843 ENSG00000229043.2 AC091729.9 -3.87 0.000142 0.0462 -0.4 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1035609 chr7:1160374~1165267:+ CESC cis rs2271404 1 rs2271404 ENSG00000227992.1 AC108463.2 3.87 0.000142 0.0462 0.39 0.25 Atopic dermatitis; chr2:111246290 chr2:111203964~111206215:- CESC cis rs875971 1 rs778706 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0462 -0.28 -0.25 Aortic root size; chr7:66395437 chr7:66376044~66401338:- CESC cis rs875971 0.895 rs778700 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0462 -0.28 -0.25 Aortic root size; chr7:66401463 chr7:66376044~66401338:- CESC cis rs875971 1 rs778699 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0462 -0.28 -0.25 Aortic root size; chr7:66403303 chr7:66376044~66401338:- CESC cis rs875971 0.929 rs778692 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0462 -0.28 -0.25 Aortic root size; chr7:66407462 chr7:66376044~66401338:- CESC cis rs875971 1 rs4718343 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0462 -0.28 -0.25 Aortic root size; chr7:66409301 chr7:66376044~66401338:- CESC cis rs875971 1 rs1968225 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0462 -0.28 -0.25 Aortic root size; chr7:66409786 chr7:66376044~66401338:- CESC cis rs875971 1 rs6460295 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0462 -0.28 -0.25 Aortic root size; chr7:66417741 chr7:66376044~66401338:- CESC cis rs875971 0.964 rs6978721 ENSG00000179406.6 LINC00174 -3.87 0.000142 0.0462 -0.28 -0.25 Aortic root size; chr7:66418217 chr7:66376044~66401338:- CESC cis rs2243480 0.708 rs13242216 ENSG00000067601.7 PMS2P4 3.87 0.000142 0.0462 0.49 0.25 Diabetic kidney disease; chr7:66433290 chr7:67295608~67302907:- CESC cis rs2243480 1 rs67536397 ENSG00000067601.7 PMS2P4 3.87 0.000142 0.0462 0.49 0.25 Diabetic kidney disease; chr7:66482930 chr7:67295608~67302907:- CESC cis rs2243480 1 rs58669269 ENSG00000067601.7 PMS2P4 3.87 0.000142 0.0462 0.49 0.25 Diabetic kidney disease; chr7:66486966 chr7:67295608~67302907:- CESC cis rs72634258 0.842 rs4908727 ENSG00000238249.2 HMGN2P17 -3.87 0.000142 0.0463 -0.28 -0.25 Inflammatory bowel disease; chr1:8103062 chr1:8893409~8894151:+ CESC cis rs11992162 0.967 rs7461062 ENSG00000255020.1 AF131216.5 3.87 0.000142 0.0463 0.3 0.25 Monocyte count; chr8:11974439 chr8:11345748~11347502:- CESC cis rs9322193 0.81 rs62439811 ENSG00000216906.2 RP11-350J20.9 3.87 0.000143 0.0463 0.28 0.25 Lung cancer; chr6:149640416 chr6:149904243~149906418:+ CESC cis rs516805 0.52 rs6926219 ENSG00000218180.2 SLC25A5P7 3.87 0.000143 0.0463 0.3 0.25 Lymphocyte counts; chr6:122399661 chr6:121653795~121654690:+ CESC cis rs9487094 0.62 rs7768973 ENSG00000260273.1 RP11-425D10.10 3.87 0.000143 0.0463 0.31 0.25 Height; chr6:109424122 chr6:109382795~109383666:+ CESC cis rs35934224 0.628 rs2073750 ENSG00000217261.4 POM121L4P 3.87 0.000143 0.0463 0.33 0.25 Glaucoma (primary open-angle); chr22:19885834 chr22:20689929~20698938:+ CESC cis rs1667255 1 rs1375446 ENSG00000266521.1 RP11-650P15.1 3.87 0.000143 0.0464 0.29 0.25 Retinol levels; chr18:31577372 chr18:31496645~31497195:- CESC cis rs6740462 0.568 rs74183104 ENSG00000273763.1 RP11-420C9.1 -3.87 0.000143 0.0464 -0.43 -0.25 Inflammatory bowel disease;Crohn's disease; chr2:65448696 chr2:65203571~65203813:- CESC cis rs6740462 0.568 rs62141117 ENSG00000273763.1 RP11-420C9.1 -3.87 0.000143 0.0464 -0.43 -0.25 Inflammatory bowel disease;Crohn's disease; chr2:65448800 chr2:65203571~65203813:- CESC cis rs1387259 0.57 rs12368659 ENSG00000258273.1 RP11-370I10.4 -3.87 0.000143 0.0464 -0.29 -0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48168516 chr12:48333755~48333901:- CESC cis rs950169 0.526 rs698620 ENSG00000259295.5 CSPG4P12 -3.87 0.000143 0.0464 -0.26 -0.25 Schizophrenia; chr15:84633977 chr15:85191438~85213905:+ CESC cis rs9487094 0.626 rs3799845 ENSG00000260273.1 RP11-425D10.10 3.87 0.000143 0.0465 0.33 0.25 Height; chr6:109706514 chr6:109382795~109383666:+ CESC cis rs17694108 0.887 rs11669923 ENSG00000242325.1 RPS12P31 -3.87 0.000143 0.0465 -0.37 -0.25 Crohn's disease;Ulcerative colitis;Inflammatory bowel disease; chr19:33240473 chr19:32636078~32636475:+ CESC cis rs972578 0.715 rs4820491 ENSG00000274717.1 RP1-47A17.1 -3.87 0.000143 0.0465 -0.3 -0.25 Mean platelet volume; chr22:42865059 chr22:42791814~42794313:- CESC cis rs7246657 0.525 rs1667357 ENSG00000276846.1 CTD-3220F14.3 3.87 0.000143 0.0465 0.33 0.25 Coronary artery calcification; chr19:36993450 chr19:37314868~37315620:- CESC cis rs7246657 0.525 rs1667359 ENSG00000276846.1 CTD-3220F14.3 3.87 0.000143 0.0465 0.33 0.25 Coronary artery calcification; chr19:36995270 chr19:37314868~37315620:- CESC cis rs853679 0.882 rs9468300 ENSG00000219392.1 RP1-265C24.5 -3.87 0.000143 0.0465 -0.44 -0.25 Depression; chr6:28159062 chr6:28115628~28116551:+ CESC cis rs924712 0.513 rs9464151 ENSG00000224984.1 RP11-524H19.2 -3.87 0.000143 0.0465 -0.25 -0.25 Breast cancer; chr6:54853338 chr6:54840118~54840855:- CESC cis rs924712 0.548 rs7770409 ENSG00000224984.1 RP11-524H19.2 -3.87 0.000143 0.0465 -0.25 -0.25 Breast cancer; chr6:54853891 chr6:54840118~54840855:- CESC cis rs919433 0.68 rs1961558 ENSG00000222017.1 AC011997.1 3.87 0.000143 0.0465 0.32 0.25 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197622554 chr2:197693106~197774823:+ CESC cis rs2281636 0.798 rs3184991 ENSG00000233690.1 EBAG9P1 -3.87 0.000143 0.0465 -0.27 -0.25 Obesity-related traits; chr10:99755559 chr10:99697407~99697949:- CESC cis rs7873102 0.654 rs10115992 ENSG00000230188.1 RP11-405L18.4 -3.87 0.000144 0.0466 -0.34 -0.25 Brain structure; chr9:37962586 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs7047276 ENSG00000230188.1 RP11-405L18.4 -3.87 0.000144 0.0466 -0.34 -0.25 Brain structure; chr9:37962595 chr9:37490421~37490893:- CESC cis rs2274273 0.624 rs10141396 ENSG00000258413.1 RP11-665C16.6 -3.87 0.000144 0.0466 -0.34 -0.25 Protein biomarker; chr14:55350207 chr14:55262767~55272075:- CESC cis rs7617773 0.744 rs2125482 ENSG00000228638.1 FCF1P2 -3.87 0.000144 0.0466 -0.27 -0.25 Coronary artery disease; chr3:48281643 chr3:48290793~48291375:- CESC cis rs6747380 0.935 rs10200604 ENSG00000272606.1 RP11-554J4.1 -3.87 0.000144 0.0466 -0.27 -0.25 Menarche (age at onset); chr2:56347885 chr2:55617909~55618373:+ CESC cis rs2439831 0.867 rs3213991 ENSG00000205771.5 CATSPER2P1 -3.87 0.000144 0.0466 -0.35 -0.25 Lung cancer in ever smokers; chr15:43378082 chr15:43726918~43747094:- CESC cis rs2439831 0.85 rs7163245 ENSG00000205771.5 CATSPER2P1 -3.87 0.000144 0.0466 -0.35 -0.25 Lung cancer in ever smokers; chr15:43379096 chr15:43726918~43747094:- CESC cis rs2404602 0.692 rs55864032 ENSG00000280730.1 AC090181.1 3.87 0.000144 0.0466 0.2 0.25 Blood metabolite levels; chr15:76830207 chr15:77056895~77057021:+ CESC cis rs6001482 0.964 rs5750797 ENSG00000236850.4 BMS1P20 -3.87 0.000144 0.0466 -0.28 -0.25 Diastolic blood pressure; chr22:22242651 chr22:22303224~22322847:+ CESC cis rs1124769 0.719 rs7176498 ENSG00000259378.1 DCAF13P3 3.87 0.000144 0.0466 0.34 0.25 Cognitive performance; chr15:50944641 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs3784304 ENSG00000259378.1 DCAF13P3 3.87 0.000144 0.0466 0.34 0.25 Cognitive performance; chr15:50945863 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs1955 ENSG00000259378.1 DCAF13P3 3.87 0.000144 0.0466 0.34 0.25 Cognitive performance; chr15:50945898 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs1876784 ENSG00000259378.1 DCAF13P3 3.87 0.000144 0.0466 0.34 0.25 Cognitive performance; chr15:50946758 chr15:50944663~50945996:+ CESC cis rs6693388 0.918 rs16833728 ENSG00000229021.2 AL591893.1 3.87 0.000144 0.0466 0.3 0.25 Blood metabolite ratios; chr1:151973303 chr1:151994531~152042774:+ CESC cis rs516805 0.748 rs510471 ENSG00000279453.1 RP3-425C14.4 -3.87 0.000144 0.0466 -0.31 -0.25 Lymphocyte counts; chr6:122391714 chr6:122436789~122439223:- CESC cis rs55794721 0.509 rs873308 ENSG00000224183.1 SDHDP6 3.87 0.000144 0.0467 0.27 0.25 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25294164~25294643:- CESC cis rs7980687 0.574 rs10744149 ENSG00000235423.7 RP11-282O18.3 3.87 0.000144 0.0467 0.33 0.25 Head circumference (infant);Educational attainment;Height; chr12:123223943 chr12:123252030~123261483:- CESC cis rs1862618 0.671 rs28397234 ENSG00000271828.1 CTD-2310F14.1 -3.87 0.000144 0.0467 -0.31 -0.25 Initial pursuit acceleration; chr5:56952601 chr5:56927874~56929573:+ CESC cis rs748404 0.697 rs574065 ENSG00000249839.1 AC011330.5 3.87 0.000144 0.0467 0.27 0.25 Lung cancer; chr15:43258457 chr15:43663654~43684339:- CESC cis rs5742933 0.857 rs1437891 ENSG00000253559.1 OSGEPL1-AS1 -3.87 0.000144 0.0467 -0.31 -0.25 Ferritin levels; chr2:189697982 chr2:189762704~189765556:+ CESC cis rs9925964 0.748 rs4889603 ENSG00000260911.2 RP11-196G11.2 3.87 0.000144 0.0467 0.28 0.25 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:30970904 chr16:31043150~31049868:+ CESC cis rs224278 0.509 rs1571918 ENSG00000238280.1 RP11-436D10.3 3.87 0.000144 0.0467 0.39 0.25 Ewing sarcoma; chr10:62961764 chr10:62793562~62805887:- CESC cis rs6142102 0.923 rs6059635 ENSG00000275784.1 RP5-1125A11.6 -3.87 0.000144 0.0467 -0.26 -0.25 Skin pigmentation; chr20:34025687 chr20:33989480~33991818:- CESC cis rs783540 1 rs1267657 ENSG00000255769.6 GOLGA2P10 3.87 0.000144 0.0468 0.29 0.25 Schizophrenia; chr15:82546501 chr15:82472993~82513950:- CESC cis rs12468226 0.606 rs79092351 ENSG00000226261.1 AC064836.3 3.87 0.000144 0.0468 0.43 0.25 Urate levels; chr2:202204388 chr2:202336024~202336727:- CESC cis rs6142102 0.651 rs6059692 ENSG00000275784.1 RP5-1125A11.6 3.87 0.000144 0.0468 0.27 0.25 Skin pigmentation; chr20:34158397 chr20:33989480~33991818:- CESC cis rs8072100 0.544 rs7214993 ENSG00000228782.6 CTD-2026D20.3 3.87 0.000144 0.0468 0.31 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309431 chr17:47450568~47492492:- CESC cis rs11695541 0.677 rs75997515 ENSG00000270820.4 RP11-355B11.2 3.87 0.000145 0.0468 0.55 0.25 Methadone dose in opioid dependence; chr2:60656097 chr2:61471188~61484130:+ CESC cis rs9908102 0.74 rs56375019 ENSG00000263648.1 RP11-471L13.3 -3.87 0.000145 0.0468 -0.37 -0.25 Schizophrenia; chr17:13006473 chr17:12115547~12115885:+ CESC cis rs9908102 0.74 rs58985615 ENSG00000263648.1 RP11-471L13.3 -3.87 0.000145 0.0468 -0.37 -0.25 Schizophrenia; chr17:13006671 chr17:12115547~12115885:+ CESC cis rs17695224 0.545 rs11666614 ENSG00000268095.1 ZNF649-AS1 3.87 0.000145 0.0468 0.31 0.25 HDL cholesterol;HDL cholesterol levels; chr19:51842833 chr19:51888025~51900463:+ CESC cis rs924712 0.574 rs9370328 ENSG00000224984.1 RP11-524H19.2 -3.87 0.000145 0.0468 -0.26 -0.25 Breast cancer; chr6:54815888 chr6:54840118~54840855:- CESC cis rs10995356 0.646 rs10761677 ENSG00000238280.1 RP11-436D10.3 -3.87 0.000145 0.0468 -0.31 -0.25 Temperament; chr10:62892846 chr10:62793562~62805887:- CESC cis rs875971 0.545 rs73376394 ENSG00000222364.1 RNU6-96P -3.87 0.000145 0.0468 -0.34 -0.25 Aortic root size; chr7:66172694 chr7:66395191~66395286:+ CESC cis rs17711722 0.51 rs11767457 ENSG00000236529.1 RP13-254B10.1 3.87 0.000145 0.0468 0.28 0.25 Calcium levels; chr7:65825628 chr7:65840212~65840596:+ CESC cis rs11971779 0.752 rs4732371 ENSG00000273391.1 RP11-634H22.1 3.87 0.000145 0.0468 0.26 0.25 Diisocyanate-induced asthma; chr7:139392571 chr7:139359032~139359566:- CESC cis rs10129255 0.536 rs17113249 ENSG00000211970.3 IGHV4-61 -3.87 0.000145 0.0468 -0.17 -0.25 Kawasaki disease; chr14:106678273 chr14:106639119~106639657:- CESC cis rs867371 1 rs8042464 ENSG00000255769.6 GOLGA2P10 -3.87 0.000145 0.0469 -0.27 -0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82173195 chr15:82472993~82513950:- CESC cis rs2439831 0.717 rs10518820 ENSG00000249839.1 AC011330.5 -3.87 0.000145 0.0469 -0.39 -0.25 Lung cancer in ever smokers; chr15:43596778 chr15:43663654~43684339:- CESC cis rs7578199 0.814 rs10205490 ENSG00000235151.1 AC114730.2 3.87 0.000145 0.0469 0.4 0.25 Chronic lymphocytic leukemia; chr2:241285854 chr2:241844380~241845036:+ CESC cis rs875971 1 rs4718307 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000145 0.0469 -0.27 -0.25 Aortic root size; chr7:66146001 chr7:66554588~66576923:- CESC cis rs875971 1 rs7801282 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000145 0.0469 -0.27 -0.25 Aortic root size; chr7:66148700 chr7:66554588~66576923:- CESC cis rs12681963 0.686 rs16876487 ENSG00000279041.1 CTD-2373N4.3 -3.87 0.000145 0.0469 -0.45 -0.25 Migraine; chr8:30111905 chr8:30552345~30553766:+ CESC cis rs2439831 0.681 rs11858152 ENSG00000275601.1 AC011330.13 -3.87 0.000145 0.0469 -0.33 -0.25 Lung cancer in ever smokers; chr15:43341998 chr15:43642389~43643023:- CESC cis rs9640161 0.742 rs11767726 ENSG00000261305.1 RP4-584D14.7 -3.87 0.000145 0.0469 -0.34 -0.25 Blood protein levels;Circulating chemerin levels; chr7:150321007 chr7:150341771~150342607:+ CESC cis rs4742903 0.967 rs10820605 ENSG00000270332.1 SMC2-AS1 3.87 0.000145 0.0469 0.25 0.25 Breast cancer;High-grade serous ovarian cancer; chr9:104119121 chr9:104080024~104093073:- CESC cis rs4974559 0.948 rs3856982 ENSG00000272783.1 RP13-1016M1.2 -3.87 0.000145 0.0469 -0.35 -0.25 Systolic blood pressure; chr4:1335075 chr4:1550284~1550572:+ CESC cis rs6674970 0.518 rs15740 ENSG00000261168.1 RP11-68I18.10 -3.87 0.000145 0.0469 -0.31 -0.25 Childhood ear infection; chr1:151067959 chr1:151130075~151131610:- CESC cis rs453301 0.653 rs1562211 ENSG00000254340.1 RP11-10A14.3 -3.87 0.000145 0.0469 -0.29 -0.25 Joint mobility (Beighton score); chr8:9044914 chr8:9141424~9145435:+ CESC cis rs10043775 0.872 rs9325097 ENSG00000251330.3 CTD-2283N19.1 -3.87 0.000145 0.0469 -0.33 -0.25 Periodontal microbiota; chr5:148440782 chr5:148430159~148430807:- CESC cis rs7429990 0.965 rs777015 ENSG00000229759.1 MRPS18AP1 3.87 0.000145 0.0469 0.25 0.25 Educational attainment (years of education); chr3:47895582 chr3:48256350~48256938:- CESC cis rs988913 0.957 rs6908170 ENSG00000224984.1 RP11-524H19.2 3.87 0.000145 0.047 0.27 0.25 Menarche (age at onset); chr6:54956354 chr6:54840118~54840855:- CESC cis rs7688540 0.771 rs11729365 ENSG00000211553.1 AC253576.2 -3.87 0.000145 0.047 -0.39 -0.25 Facial morphology (factor 6, height of vermillion lower lip); chr4:278735 chr4:136461~136568:+ CESC cis rs7551222 0.752 rs11240758 ENSG00000240219.1 RP11-430C7.5 3.87 0.000145 0.047 0.28 0.25 Schizophrenia; chr1:204559523 chr1:204626775~204629712:+ CESC cis rs1823913 0.599 rs13035132 ENSG00000227542.1 AC092614.2 3.87 0.000145 0.047 0.26 0.25 Obesity-related traits; chr2:191265275 chr2:191229165~191246172:- CESC cis rs9532669 0.926 rs4942007 ENSG00000176268.5 CYCSP34 3.87 0.000145 0.047 0.26 0.25 Cervical cancer; chr13:40871887 chr13:40863599~40863902:- CESC cis rs5742933 0.817 rs6738042 ENSG00000253559.1 OSGEPL1-AS1 3.87 0.000145 0.047 0.3 0.25 Ferritin levels; chr2:189776958 chr2:189762704~189765556:+ CESC cis rs4319547 0.737 rs7964138 ENSG00000275265.1 RP11-15J22.8 -3.87 0.000145 0.047 -0.33 -0.25 Body mass index; chr12:122465828 chr12:122501187~122501641:+ CESC cis rs9532669 0.926 rs9562254 ENSG00000239827.7 SUGT1P3 3.87 0.000146 0.047 0.3 0.25 Cervical cancer; chr13:40960902 chr13:40908159~40921774:- CESC cis rs7829975 0.777 rs560544 ENSG00000253893.2 FAM85B 3.87 0.000146 0.0471 0.32 0.25 Mood instability; chr8:8779919 chr8:8167819~8226614:- CESC cis rs7617773 0.817 rs9847953 ENSG00000228638.1 FCF1P2 -3.87 0.000146 0.0471 -0.26 -0.25 Coronary artery disease; chr3:48241205 chr3:48290793~48291375:- CESC cis rs2221593 0.502 rs2501852 ENSG00000198468.6 FLVCR1-AS1 -3.87 0.000146 0.0471 -0.37 -0.25 Leprosy; chr1:212674541 chr1:212852108~212858088:- CESC cis rs12908161 0.96 rs62019463 ENSG00000259728.4 LINC00933 3.87 0.000146 0.0471 0.33 0.25 Schizophrenia; chr15:84744856 chr15:84570649~84580175:+ CESC cis rs12908161 1 rs62019464 ENSG00000259728.4 LINC00933 3.87 0.000146 0.0471 0.33 0.25 Schizophrenia; chr15:84751238 chr15:84570649~84580175:+ CESC cis rs12908161 1 rs11637142 ENSG00000259728.4 LINC00933 3.87 0.000146 0.0471 0.33 0.25 Schizophrenia; chr15:84752696 chr15:84570649~84580175:+ CESC cis rs12908161 1 rs12910012 ENSG00000259728.4 LINC00933 3.87 0.000146 0.0471 0.33 0.25 Schizophrenia; chr15:84755431 chr15:84570649~84580175:+ CESC cis rs12908161 1 rs12899981 ENSG00000259728.4 LINC00933 3.87 0.000146 0.0471 0.33 0.25 Schizophrenia; chr15:84759142 chr15:84570649~84580175:+ CESC cis rs7551222 0.613 rs10900592 ENSG00000240219.1 RP11-430C7.5 3.87 0.000146 0.0471 0.29 0.25 Schizophrenia; chr1:204491553 chr1:204626775~204629712:+ CESC cis rs10392 0.543 rs3752292 ENSG00000274825.1 RP4-616B8.5 -3.87 0.000146 0.0471 -0.26 -0.25 Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis; chr20:38941832 chr20:38955910~38956547:+ CESC cis rs6452524 0.869 rs10051155 ENSG00000249664.1 CTD-2227C6.2 3.87 0.000146 0.0471 0.3 0.25 Hypertension (SNP x SNP interaction); chr5:83160851 chr5:83012285~83013109:- CESC cis rs2548724 0.755 rs1376907 ENSG00000250682.4 LINC00491 3.87 0.000146 0.0471 0.3 0.25 Type 2 diabetes; chr5:102443332 chr5:102609156~102671559:- CESC cis rs6662572 1 rs72688460 ENSG00000280836.1 AL355480.1 3.87 0.000146 0.0472 0.35 0.25 Blood protein levels; chr1:45645422 chr1:45581219~45581321:- CESC cis rs801193 1 rs2707856 ENSG00000230358.3 RP11-166O4.1 -3.87 0.000146 0.0472 -0.35 -0.25 Aortic root size; chr7:66746023 chr7:67279778~67286230:+ CESC cis rs2243480 1 rs35542501 ENSG00000275400.1 RP4-756H11.5 3.87 0.000146 0.0472 0.41 0.25 Diabetic kidney disease; chr7:65966228 chr7:66553805~66554199:- CESC cis rs2243480 0.708 rs781141 ENSG00000275400.1 RP4-756H11.5 3.87 0.000146 0.0472 0.41 0.25 Diabetic kidney disease; chr7:65973566 chr7:66553805~66554199:- CESC cis rs2299587 0.841 rs17514812 ENSG00000253671.1 RP11-806O11.1 -3.87 0.000146 0.0472 -0.26 -0.25 Economic and political preferences; chr8:18023360 chr8:17808941~17820868:+ CESC cis rs11685222 0.589 rs2272053 ENSG00000229326.3 AC069154.4 3.87 0.000146 0.0472 0.37 0.25 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab); chr2:119679197 chr2:119698623~119700151:+ CESC cis rs17711722 0.701 rs781145 ENSG00000222364.1 RNU6-96P -3.87 0.000146 0.0472 -0.31 -0.25 Calcium levels; chr7:65975383 chr7:66395191~66395286:+ CESC cis rs11676348 0.741 rs12694425 ENSG00000261338.2 RP11-378A13.1 3.87 0.000146 0.0472 0.3 0.25 Ulcerative colitis; chr2:218077590 chr2:218255319~218257366:+ CESC cis rs13108904 0.775 rs2279282 ENSG00000253399.1 AC078852.2 -3.87 0.000146 0.0472 -0.31 -0.25 Obesity-related traits; chr4:1222245 chr4:1358479~1359461:+ CESC cis rs62344088 1 rs6898413 ENSG00000250848.1 CTD-2083E4.5 -3.87 0.000146 0.0473 -0.55 -0.25 Asthma (childhood onset); chr5:173812 chr5:288833~290321:- CESC cis rs10129255 0.518 rs7143784 ENSG00000224373.3 IGHV4-59 3.87 0.000147 0.0473 0.16 0.25 Kawasaki disease; chr14:106687277 chr14:106627249~106627825:- CESC cis rs2404602 0.631 rs9646213 ENSG00000280730.1 AC090181.1 3.87 0.000147 0.0473 0.2 0.25 Blood metabolite levels; chr15:76515331 chr15:77056895~77057021:+ CESC cis rs10129255 0.957 rs10138532 ENSG00000211974.3 IGHV2-70 3.87 0.000147 0.0473 0.29 0.25 Kawasaki disease; chr14:106803901 chr14:106723574~106724093:- CESC cis rs2008905 1 rs2008905 ENSG00000272034.1 SNORD14A 3.87 0.000147 0.0473 0.28 0.25 Schizophrenia; chr11:17163076 chr11:17074654~17074744:- CESC cis rs11089937 0.568 rs12160318 ENSG00000211638.2 IGLV8-61 -3.86 0.000147 0.0473 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22131627 chr22:22098700~22099212:+ CESC cis rs763567 0.933 rs531007 ENSG00000271811.1 RP1-79C4.4 3.86 0.000147 0.0473 0.29 0.25 Tonsillectomy; chr1:170649241 chr1:170667381~170669425:+ CESC cis rs67311347 0.955 rs60554147 ENSG00000223797.4 ENTPD3-AS1 3.86 0.000147 0.0473 0.25 0.25 Renal cell carcinoma; chr3:40431012 chr3:40313802~40453329:- CESC cis rs7572733 0.555 rs1837495 ENSG00000222017.1 AC011997.1 -3.86 0.000147 0.0473 -0.32 -0.25 Dermatomyositis; chr2:198056477 chr2:197693106~197774823:+ CESC cis rs13113518 0.902 rs11133386 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55461320 chr4:55387949~55388271:+ CESC cis rs13113518 0.967 rs4340844 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55462689 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs1522112 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55463606 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs4864997 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55466010 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs960152 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55467308 chr4:55387949~55388271:+ CESC cis rs13113518 0.967 rs12644948 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55470266 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs3805151 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55470874 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs13118237 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55474259 chr4:55387949~55388271:+ CESC cis rs13113518 0.966 rs11133387 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55475130 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs4864999 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55476736 chr4:55387949~55388271:+ CESC cis rs13113518 0.966 rs10517344 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55477545 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs12501636 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55482317 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs6858803 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55484534 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs13114841 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55485974 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs939823 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55487368 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs6838882 ENSG00000273257.1 RP11-177J6.1 3.86 0.000147 0.0473 0.33 0.25 Height; chr4:55489310 chr4:55387949~55388271:+ CESC cis rs7524102 0.561 rs12733602 ENSG00000218510.5 LINC00339 -3.86 0.000147 0.0473 -0.34 -0.25 Bone mineral density;Ulcerative colitis;Bone mineral density (spine);Dupuytren's disease;Bone mineral density (hip); chr1:22406665 chr1:22025188~22031223:+ CESC cis rs2439831 0.867 rs2412778 ENSG00000205771.5 CATSPER2P1 -3.86 0.000147 0.0473 -0.35 -0.25 Lung cancer in ever smokers; chr15:43368784 chr15:43726918~43747094:- CESC cis rs2072438 0.503 rs2146838 ENSG00000226752.6 PSMD5-AS1 3.86 0.000147 0.0473 0.25 0.25 Rheumatoid arthritis; chr9:121114027 chr9:120824828~120854385:+ CESC cis rs7216064 1 rs8079754 ENSG00000278730.1 RP11-147L13.11 -3.86 0.000147 0.0473 -0.31 -0.25 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67891780 chr17:68126666~68129586:+ CESC cis rs6844153 0.887 rs3792685 ENSG00000240005.4 RP11-293A21.1 -3.86 0.000147 0.0473 -0.35 -0.25 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26957585 chr4:26859806~26860599:- CESC cis rs1598856 0.873 rs230510 ENSG00000246560.2 RP11-10L12.4 -3.86 0.000147 0.0473 -0.31 -0.25 Primary biliary cholangitis; chr4:102555009 chr4:102828055~102844075:+ CESC cis rs7923609 0.756 rs12768534 ENSG00000232075.1 MRPL35P2 -3.86 0.000147 0.0474 -0.3 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63581137 chr10:63634317~63634827:- CESC cis rs9532669 0.926 rs9525418 ENSG00000176268.5 CYCSP34 -3.86 0.000147 0.0474 -0.27 -0.25 Cervical cancer; chr13:40879081 chr13:40863599~40863902:- CESC cis rs2836950 0.565 rs2150414 ENSG00000255568.3 BRWD1-AS2 -3.86 0.000147 0.0474 -0.21 -0.25 Menarche (age at onset); chr21:39243062 chr21:39313935~39314962:+ CESC cis rs10028773 0.515 rs9994488 ENSG00000281731.1 RP11-384K6.8 3.86 0.000147 0.0474 0.32 0.25 Educational attainment; chr4:119666626 chr4:118664087~118685341:- CESC cis rs1976403 0.659 rs10799701 ENSG00000227001.3 NBPF2P 3.86 0.000147 0.0474 0.27 0.25 Liver enzyme levels (alkaline phosphatase); chr1:21494497 chr1:21424625~21427967:- CESC cis rs11690935 0.595 rs788170 ENSG00000228389.1 AC068039.4 -3.86 0.000147 0.0474 -0.3 -0.25 Schizophrenia; chr2:172055230 chr2:171773482~171775844:+ CESC cis rs62344088 0.744 rs76038312 ENSG00000250848.1 CTD-2083E4.5 -3.86 0.000147 0.0474 -0.56 -0.25 Asthma (childhood onset); chr5:228890 chr5:288833~290321:- CESC cis rs9309473 0.5 rs6546862 ENSG00000273245.1 RP11-434P11.2 -3.86 0.000147 0.0474 -0.32 -0.25 Metabolite levels; chr2:73633221 chr2:73750256~73750786:- CESC cis rs17301013 0.507 rs10912791 ENSG00000227373.4 RP11-160H22.5 3.86 0.000147 0.0474 0.35 0.25 Systemic lupus erythematosus; chr1:174479298 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs12079334 ENSG00000227373.4 RP11-160H22.5 3.86 0.000147 0.0474 0.35 0.25 Systemic lupus erythematosus; chr1:174480815 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs4652494 ENSG00000227373.4 RP11-160H22.5 3.86 0.000147 0.0474 0.35 0.25 Systemic lupus erythematosus; chr1:174495861 chr1:174115300~174160004:- CESC cis rs17301013 0.507 rs7537823 ENSG00000227373.4 RP11-160H22.5 3.86 0.000147 0.0474 0.35 0.25 Systemic lupus erythematosus; chr1:174502222 chr1:174115300~174160004:- CESC cis rs7714584 1 rs59531858 ENSG00000197083.10 ZNF300P1 3.86 0.000147 0.0474 0.45 0.25 Crohn's disease; chr5:150867501 chr5:150930645~150946289:- CESC cis rs7714584 1 rs12656538 ENSG00000197083.10 ZNF300P1 3.86 0.000147 0.0474 0.45 0.25 Crohn's disease; chr5:150871818 chr5:150930645~150946289:- CESC cis rs8040855 0.627 rs1532776 ENSG00000259295.5 CSPG4P12 3.86 0.000147 0.0475 0.31 0.25 Bulimia nervosa; chr15:85081383 chr15:85191438~85213905:+ CESC cis rs867371 1 rs13380317 ENSG00000255769.6 GOLGA2P10 3.86 0.000147 0.0475 0.28 0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214449 chr15:82472993~82513950:- CESC cis rs1387259 0.57 rs12368659 ENSG00000226413.2 OR8T1P 3.86 0.000147 0.0475 0.33 0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48168516 chr12:48442030~48442947:- CESC cis rs343092 0.63 rs971780 ENSG00000276853.1 RP11-305O6.4 3.86 0.000147 0.0475 0.48 0.25 Type 2 diabetes; chr12:65788633 chr12:65171262~65171917:+ CESC cis rs875971 0.545 rs4441996 ENSG00000226824.5 RP4-756H11.3 3.86 0.000147 0.0475 0.35 0.25 Aortic root size; chr7:66123233 chr7:66654538~66669855:+ CESC cis rs748404 0.65 rs556851 ENSG00000205771.5 CATSPER2P1 -3.86 0.000148 0.0475 -0.3 -0.25 Lung cancer; chr15:43279021 chr15:43726918~43747094:- CESC cis rs748404 0.697 rs567357 ENSG00000205771.5 CATSPER2P1 -3.86 0.000148 0.0475 -0.3 -0.25 Lung cancer; chr15:43279192 chr15:43726918~43747094:- CESC cis rs748404 0.556 rs10851414 ENSG00000205771.5 CATSPER2P1 3.86 0.000148 0.0475 0.31 0.25 Lung cancer; chr15:43141734 chr15:43726918~43747094:- CESC cis rs10958369 0.836 rs2376145 ENSG00000253369.1 RP11-1081M5.1 3.86 0.000148 0.0475 0.28 0.25 Response to antineoplastic agents; chr8:53486783 chr8:53395211~53395946:- CESC cis rs10958369 0.871 rs10958370 ENSG00000253369.1 RP11-1081M5.1 3.86 0.000148 0.0475 0.29 0.25 Response to antineoplastic agents; chr8:53505150 chr8:53395211~53395946:- CESC cis rs10028773 0.6 rs4001390 ENSG00000248280.1 RP11-33B1.2 3.86 0.000148 0.0475 0.29 0.25 Educational attainment; chr4:119344628 chr4:119440561~119450157:- CESC cis rs11098499 0.691 rs2136911 ENSG00000248280.1 RP11-33B1.2 3.86 0.000148 0.0475 0.29 0.25 Corneal astigmatism; chr4:119344704 chr4:119440561~119450157:- CESC cis rs11098499 0.554 rs2175381 ENSG00000248280.1 RP11-33B1.2 3.86 0.000148 0.0475 0.29 0.25 Corneal astigmatism; chr4:119344812 chr4:119440561~119450157:- CESC cis rs11098499 0.599 rs3864142 ENSG00000248280.1 RP11-33B1.2 3.86 0.000148 0.0475 0.29 0.25 Corneal astigmatism; chr4:119345036 chr4:119440561~119450157:- CESC cis rs11098499 0.605 rs6833140 ENSG00000248280.1 RP11-33B1.2 3.86 0.000148 0.0475 0.29 0.25 Corneal astigmatism; chr4:119345667 chr4:119440561~119450157:- CESC cis rs11098499 0.779 rs6815934 ENSG00000248280.1 RP11-33B1.2 3.86 0.000148 0.0475 0.29 0.25 Corneal astigmatism; chr4:119346155 chr4:119440561~119450157:- CESC cis rs10028773 0.568 rs6838457 ENSG00000248280.1 RP11-33B1.2 3.86 0.000148 0.0475 0.29 0.25 Educational attainment; chr4:119346212 chr4:119440561~119450157:- CESC cis rs11098499 0.535 rs10005542 ENSG00000248280.1 RP11-33B1.2 3.86 0.000148 0.0475 0.29 0.25 Corneal astigmatism; chr4:119347147 chr4:119440561~119450157:- CESC cis rs2933343 0.7 rs789233 ENSG00000231305.3 RP11-723O4.2 3.86 0.000148 0.0476 0.24 0.25 IgG glycosylation; chr3:128884307 chr3:128861313~128871540:- CESC cis rs9907295 0.685 rs9909050 ENSG00000271013.1 AC015849.15 -3.86 0.000148 0.0476 -0.35 -0.25 Fibroblast growth factor basic levels; chr17:35887129 chr17:35912635~35918010:- CESC cis rs9907295 0.901 rs59338510 ENSG00000271013.1 AC015849.15 -3.86 0.000148 0.0476 -0.35 -0.25 Fibroblast growth factor basic levels; chr17:35888098 chr17:35912635~35918010:- CESC cis rs6504663 0.596 rs7208018 ENSG00000262006.1 RP11-700H6.4 -3.86 0.000148 0.0476 -0.32 -0.25 Visceral fat; chr17:50480502 chr17:50909637~50910232:- CESC cis rs9907295 0.901 rs28550999 ENSG00000271013.1 AC015849.15 -3.86 0.000148 0.0476 -0.35 -0.25 Fibroblast growth factor basic levels; chr17:35902887 chr17:35912635~35918010:- CESC cis rs9907295 0.901 rs74780070 ENSG00000271013.1 AC015849.15 -3.86 0.000148 0.0476 -0.35 -0.25 Fibroblast growth factor basic levels; chr17:35903521 chr17:35912635~35918010:- CESC cis rs9907295 0.786 rs56344830 ENSG00000271013.1 AC015849.15 -3.86 0.000148 0.0476 -0.35 -0.25 Fibroblast growth factor basic levels; chr17:35903951 chr17:35912635~35918010:- CESC cis rs3738814 0.529 rs761422 ENSG00000186715.9 MST1L -3.86 0.000148 0.0476 -0.31 -0.25 Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Height; chr1:16975285 chr1:16754910~16770237:- CESC cis rs9860250 0.945 rs7355920 ENSG00000175841.8 FAM172BP -3.86 0.000148 0.0476 -0.4 -0.25 Optic disc area; chr3:100944699 chr3:101521891~101522979:+ CESC cis rs11264799 0.813 rs6694875 ENSG00000224520.2 KRT8P45 3.86 0.000148 0.0476 0.35 0.25 IgA nephropathy; chr1:157739338 chr1:157073257~157074703:+ CESC cis rs2933343 0.649 rs1683786 ENSG00000231305.3 RP11-723O4.2 3.86 0.000148 0.0476 0.24 0.25 IgG glycosylation; chr3:128908109 chr3:128861313~128871540:- CESC cis rs2933343 0.7 rs876754 ENSG00000231305.3 RP11-723O4.2 3.86 0.000148 0.0476 0.24 0.25 IgG glycosylation; chr3:128908910 chr3:128861313~128871540:- CESC cis rs10129255 0.518 rs2006284 ENSG00000211970.3 IGHV4-61 -3.86 0.000148 0.0476 -0.17 -0.25 Kawasaki disease; chr14:106676185 chr14:106639119~106639657:- CESC cis rs10129255 0.556 rs8010005 ENSG00000280411.1 IGHV1-69-2 -3.86 0.000148 0.0476 -0.17 -0.25 Kawasaki disease; chr14:106777987 chr14:106762092~106762588:- CESC cis rs10129255 0.556 rs6576224 ENSG00000280411.1 IGHV1-69-2 -3.86 0.000148 0.0476 -0.17 -0.25 Kawasaki disease; chr14:106777997 chr14:106762092~106762588:- CESC cis rs10129255 0.518 rs8010020 ENSG00000280411.1 IGHV1-69-2 -3.86 0.000148 0.0476 -0.17 -0.25 Kawasaki disease; chr14:106778016 chr14:106762092~106762588:- CESC cis rs9402743 0.671 rs6901733 ENSG00000234084.1 RP3-388E23.2 -3.86 0.000148 0.0476 -0.22 -0.25 Systemic lupus erythematosus; chr6:135619407 chr6:135301568~135307158:+ CESC cis rs116139393 0.561 rs62439737 ENSG00000187953.9 PMS2CL -3.86 0.000148 0.0476 -0.34 -0.25 Alzheimer's disease (APOE e4 interaction); chr7:6740179 chr7:6710128~6753862:+ CESC cis rs11971779 0.68 rs2355787 ENSG00000273391.1 RP11-634H22.1 -3.86 0.000148 0.0476 -0.24 -0.25 Diisocyanate-induced asthma; chr7:139405182 chr7:139359032~139359566:- CESC cis rs11168618 0.967 rs1895996 ENSG00000257735.1 RP11-370I10.6 3.86 0.000148 0.0477 0.28 0.25 Adiponectin levels; chr12:48561788 chr12:48350945~48442411:+ CESC cis rs2288884 0.515 rs2869602 ENSG00000275055.1 CTC-471J1.11 -3.86 0.000148 0.0477 -0.28 -0.25 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52072324 chr19:52049007~52049754:+ CESC cis rs755249 0.567 rs1126313 ENSG00000228060.1 RP11-69E11.8 3.86 0.000148 0.0477 0.28 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39174072 chr1:39565160~39573203:+ CESC cis rs4489787 0.568 rs2705135 ENSG00000206612.1 SNORA2A 3.86 0.000148 0.0477 0.29 0.25 Prostate cancer (SNP x SNP interaction); chr12:48496773 chr12:48656648~48656782:- CESC cis rs35740288 0.731 rs35085180 ENSG00000202081.1 RNU6-1280P 3.86 0.000148 0.0477 0.31 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85559381 chr15:85651522~85651628:- CESC cis rs2179367 0.959 rs540538 ENSG00000231760.4 RP11-350J20.5 3.86 0.000149 0.0478 0.32 0.25 Dupuytren's disease; chr6:149326808 chr6:149796151~149826294:- CESC cis rs7674212 0.541 rs2720448 ENSG00000246560.2 RP11-10L12.4 3.86 0.000149 0.0478 0.31 0.25 Type 2 diabetes; chr4:103109432 chr4:102828055~102844075:+ CESC cis rs7674212 0.541 rs2623064 ENSG00000246560.2 RP11-10L12.4 3.86 0.000149 0.0478 0.31 0.25 Type 2 diabetes; chr4:103109635 chr4:102828055~102844075:+ CESC cis rs6044834 0.887 rs13042787 ENSG00000218902.3 PTMAP3 3.86 0.000149 0.0478 0.48 0.25 Obesity-related traits; chr20:17455926 chr20:18011955~18012284:+ CESC cis rs2115630 0.967 rs11073731 ENSG00000225151.9 GOLGA2P7 3.86 0.000149 0.0478 0.28 0.25 P wave terminal force; chr15:84811882 chr15:84199311~84230136:- CESC cis rs2115630 1 rs8037423 ENSG00000225151.9 GOLGA2P7 3.86 0.000149 0.0478 0.28 0.25 P wave terminal force; chr15:84812263 chr15:84199311~84230136:- CESC cis rs2436845 0.627 rs1019976 ENSG00000253320.4 KB-1507C5.2 3.86 0.000149 0.0478 0.32 0.25 Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts; chr8:102852043 chr8:102864300~102977876:+ CESC cis rs11096990 0.855 rs57488936 ENSG00000249207.1 RP11-360F5.1 3.86 0.000149 0.0478 0.3 0.25 Cognitive function; chr4:39220626 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs11730771 ENSG00000249207.1 RP11-360F5.1 3.86 0.000149 0.0478 0.3 0.25 Cognitive function; chr4:39220787 chr4:39112677~39126818:- CESC cis rs7200543 1 rs4985124 ENSG00000260735.1 RP11-72I8.1 -3.86 0.000149 0.0478 -0.3 -0.25 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15031584 chr16:15094411~15109197:+ CESC cis rs1044826 0.642 rs4683464 ENSG00000178631.7 ACTG1P1 3.86 0.000149 0.0478 0.31 0.25 Obesity-related traits; chr3:139478119 chr3:139493809~139494937:+ CESC cis rs9976876 0.5 rs2222958 ENSG00000189089.5 RIMKLBP1 -3.86 0.000149 0.0478 -0.28 -0.25 Total body bone mineral density; chr21:35620853 chr21:36050214~36051377:+ CESC cis rs9976876 0.5 rs2222957 ENSG00000189089.5 RIMKLBP1 -3.86 0.000149 0.0478 -0.28 -0.25 Total body bone mineral density; chr21:35620860 chr21:36050214~36051377:+ CESC cis rs9976876 0.5 rs2835043 ENSG00000189089.5 RIMKLBP1 -3.86 0.000149 0.0478 -0.28 -0.25 Total body bone mineral density; chr21:35624988 chr21:36050214~36051377:+ CESC cis rs453301 0.606 rs6601279 ENSG00000254340.1 RP11-10A14.3 -3.86 0.000149 0.0478 -0.32 -0.25 Joint mobility (Beighton score); chr8:9050721 chr8:9141424~9145435:+ CESC cis rs453301 0.606 rs6981060 ENSG00000254340.1 RP11-10A14.3 -3.86 0.000149 0.0478 -0.32 -0.25 Joint mobility (Beighton score); chr8:9050725 chr8:9141424~9145435:+ CESC cis rs78905543 0.967 rs4242388 ENSG00000253616.4 RP11-875O11.3 3.86 0.000149 0.0478 0.33 0.25 Mean corpuscular volume; chr8:23075198 chr8:23071377~23074488:- CESC cis rs1501911 0.588 rs709386 ENSG00000248489.1 CTD-2007H13.3 3.86 0.000149 0.0478 0.33 0.25 Lung function (FEV1/FVC); chr5:98994346 chr5:98929171~98995013:+ CESC cis rs55665837 1 rs11023216 ENSG00000251991.1 RNU7-49P 3.86 0.000149 0.0478 0.28 0.25 Vitamin D levels; chr11:14415607 chr11:14478892~14478953:+ CESC cis rs694739 0.595 rs11542299 ENSG00000236935.1 AP003774.1 3.86 0.000149 0.0478 0.26 0.25 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64371333 chr11:64325050~64329504:- CESC cis rs12745968 0.652 rs4970703 ENSG00000223787.2 RP4-593M8.1 -3.86 0.000149 0.0478 -0.34 -0.25 Bipolar disorder and schizophrenia; chr1:92492298 chr1:92580476~92580821:- CESC cis rs12745968 0.62 rs7520630 ENSG00000223787.2 RP4-593M8.1 -3.86 0.000149 0.0478 -0.34 -0.25 Bipolar disorder and schizophrenia; chr1:92493404 chr1:92580476~92580821:- CESC cis rs2337406 0.704 rs1858679 ENSG00000254174.1 IGHV1-12 3.86 0.000149 0.0478 0.29 0.25 Alzheimer's disease (late onset); chr14:106706726 chr14:106122420~106122709:- CESC cis rs820077 0.736 rs6913286 ENSG00000232909.1 RP3-510O8.4 -3.86 0.000149 0.0478 -0.42 -0.25 Systemic lupus erythematosus; chr6:35084642 chr6:35733867~35736947:- CESC cis rs1075265 0.749 rs805434 ENSG00000233266.1 HMGB1P31 3.86 0.000149 0.0479 0.32 0.25 Chronotype;Morning vs. evening chronotype; chr2:53836196 chr2:54051334~54051760:+ CESC cis rs4423214 0.559 rs10898203 ENSG00000254682.1 RP11-660L16.2 -3.86 0.000149 0.0479 -0.39 -0.25 Vitamin D levels; chr11:71492390 chr11:71448674~71452157:+ CESC cis rs8062405 0.508 rs9929088 ENSG00000261067.5 RP11-264B17.3 -3.86 0.000149 0.0479 -0.26 -0.25 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28990139 chr16:28974804~28990783:+ CESC cis rs3913363 1 rs6787381 ENSG00000223387.5 RP11-408H1.3 -3.86 0.000149 0.0479 -0.26 -0.25 Response to angiotensin II receptor blocker therapy; chr3:171941090 chr3:172560888~172595607:- CESC cis rs10510102 0.935 rs11200201 ENSG00000276742.1 RP11-500G22.4 3.86 0.000149 0.0479 0.4 0.25 Breast cancer; chr10:121864790 chr10:121956782~121957098:+ CESC cis rs3768617 0.706 rs10797801 ENSG00000224468.3 RP11-181K3.4 -3.86 0.000149 0.0479 -0.25 -0.25 Fuchs's corneal dystrophy; chr1:183002830 chr1:183138402~183141282:- CESC cis rs7809950 1 rs4727684 ENSG00000238832.1 snoU109 -3.86 0.000149 0.0479 -0.31 -0.25 Coronary artery disease; chr7:107586025 chr7:107603363~107603507:+ CESC cis rs9309473 0.5 rs4852308 ENSG00000273245.1 RP11-434P11.2 -3.86 0.000149 0.0479 -0.31 -0.25 Metabolite levels; chr2:73606908 chr2:73750256~73750786:- CESC cis rs897984 0.762 rs7204459 ENSG00000275263.1 RP11-1072A3.4 3.86 0.000149 0.0479 0.33 0.25 Dementia with Lewy bodies; chr16:30972891 chr16:30956872~30957199:- CESC cis rs1124769 0.719 rs12440387 ENSG00000259378.1 DCAF13P3 3.86 0.000149 0.0479 0.34 0.25 Cognitive performance; chr15:50966473 chr15:50944663~50945996:+ CESC cis rs1124769 0.692 rs67889301 ENSG00000259378.1 DCAF13P3 3.86 0.000149 0.0479 0.34 0.25 Cognitive performance; chr15:50973842 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs12909839 ENSG00000259378.1 DCAF13P3 3.86 0.000149 0.0479 0.34 0.25 Cognitive performance; chr15:50991923 chr15:50944663~50945996:+ CESC cis rs1124769 0.719 rs17646917 ENSG00000259378.1 DCAF13P3 3.86 0.000149 0.0479 0.34 0.25 Cognitive performance; chr15:50993929 chr15:50944663~50945996:+ CESC cis rs875971 0.862 rs7803416 ENSG00000232559.3 GS1-124K5.12 3.86 0.000149 0.0479 0.28 0.25 Aortic root size; chr7:66489212 chr7:66554588~66576923:- CESC cis rs875971 0.862 rs1981799 ENSG00000232559.3 GS1-124K5.12 3.86 0.000149 0.0479 0.28 0.25 Aortic root size; chr7:66490572 chr7:66554588~66576923:- CESC cis rs875971 0.964 rs2277911 ENSG00000232559.3 GS1-124K5.12 3.86 0.000149 0.0479 0.28 0.25 Aortic root size; chr7:66493638 chr7:66554588~66576923:- CESC cis rs17301013 0.507 rs72715204 ENSG00000227373.4 RP11-160H22.5 3.86 0.000149 0.048 0.39 0.25 Systemic lupus erythematosus; chr1:174492787 chr1:174115300~174160004:- CESC cis rs7951870 1 rs61882746 ENSG00000247675.5 LRP4-AS1 -3.86 0.000149 0.048 -0.33 -0.25 Schizophrenia; chr11:46545925 chr11:46846412~46874396:+ CESC cis rs10129255 0.5 rs2027903 ENSG00000211970.3 IGHV4-61 -3.86 0.000149 0.048 -0.18 -0.25 Kawasaki disease; chr14:106807047 chr14:106639119~106639657:- CESC cis rs9322193 0.962 rs3805752 ENSG00000216906.2 RP11-350J20.9 3.86 0.000149 0.048 0.29 0.25 Lung cancer; chr6:149795490 chr6:149904243~149906418:+ CESC cis rs4742903 0.967 rs2417485 ENSG00000270332.1 SMC2-AS1 3.86 0.00015 0.048 0.25 0.25 Breast cancer;High-grade serous ovarian cancer; chr9:104104825 chr9:104080024~104093073:- CESC cis rs7560272 0.501 rs2421676 ENSG00000163016.8 ALMS1P -3.86 0.00015 0.048 -0.31 -0.25 Schizophrenia; chr2:73738960 chr2:73644919~73685576:+ CESC cis rs801193 0.548 rs6975044 ENSG00000275400.1 RP4-756H11.5 3.86 0.00015 0.048 0.28 0.25 Aortic root size; chr7:66762495 chr7:66553805~66554199:- CESC cis rs3124314 1 rs1496036 ENSG00000229021.2 AL591893.1 -3.86 0.00015 0.048 -0.27 -0.25 Hair morphology; chr1:152167540 chr1:151994531~152042774:+ CESC cis rs875971 1 rs1981798 ENSG00000232559.3 GS1-124K5.12 3.86 0.00015 0.048 0.28 0.25 Aortic root size; chr7:66489916 chr7:66554588~66576923:- CESC cis rs9925964 0.869 rs2288004 ENSG00000260911.2 RP11-196G11.2 -3.86 0.00015 0.048 -0.27 -0.25 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31042719 chr16:31043150~31049868:+ CESC cis rs6740462 0.568 rs11888514 ENSG00000273763.1 RP11-420C9.1 -3.86 0.00015 0.048 -0.42 -0.25 Inflammatory bowel disease;Crohn's disease; chr2:65450947 chr2:65203571~65203813:- CESC cis rs763121 0.853 rs2267395 ENSG00000228274.3 RP3-508I15.9 -3.86 0.00015 0.0481 -0.24 -0.25 Menopause (age at onset); chr22:38717898 chr22:38667585~38681820:- CESC cis rs67311347 1 rs28434528 ENSG00000223797.4 ENTPD3-AS1 3.86 0.00015 0.0481 0.25 0.25 Renal cell carcinoma; chr3:40443402 chr3:40313802~40453329:- CESC cis rs67311347 1 rs11716675 ENSG00000223797.4 ENTPD3-AS1 3.86 0.00015 0.0481 0.25 0.25 Renal cell carcinoma; chr3:40443789 chr3:40313802~40453329:- CESC cis rs13113518 0.812 rs12505880 ENSG00000273257.1 RP11-177J6.1 3.86 0.00015 0.0481 0.33 0.25 Height; chr4:55440988 chr4:55387949~55388271:+ CESC cis rs1124769 0.719 rs7176496 ENSG00000259378.1 DCAF13P3 3.86 0.00015 0.0481 0.34 0.25 Cognitive performance; chr15:50944640 chr15:50944663~50945996:+ CESC cis rs2115630 1 rs6496441 ENSG00000225151.9 GOLGA2P7 3.86 0.00015 0.0481 0.28 0.25 P wave terminal force; chr15:84820117 chr15:84199311~84230136:- CESC cis rs5760092 0.755 rs915589 ENSG00000228039.3 KB-1125A3.10 -3.86 0.00015 0.0481 -0.36 -0.25 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23963780~23964374:+ CESC cis rs7829975 0.688 rs7817376 ENSG00000173295.6 FAM86B3P -3.86 0.00015 0.0481 -0.32 -0.25 Mood instability; chr8:8523020 chr8:8228595~8244865:+ CESC cis rs13385 0.769 rs17118739 ENSG00000202111.1 VTRNA1-2 3.86 0.00015 0.0481 0.34 0.25 Atrial fibrillation; chr5:140218325 chr5:140718925~140719013:+ CESC cis rs13385 0.769 rs10079286 ENSG00000202111.1 VTRNA1-2 3.86 0.00015 0.0481 0.34 0.25 Atrial fibrillation; chr5:140219549 chr5:140718925~140719013:+ CESC cis rs7824557 0.507 rs7010590 ENSG00000255046.1 RP11-297N6.4 -3.86 0.00015 0.0481 -0.27 -0.25 Retinal vascular caliber; chr8:11205373 chr8:11797928~11802568:- CESC cis rs9925964 0.933 rs9929899 ENSG00000260911.2 RP11-196G11.2 -3.86 0.00015 0.0482 -0.27 -0.25 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31051380 chr16:31043150~31049868:+ CESC cis rs957448 0.698 rs116348949 ENSG00000253704.1 RP11-267M23.4 3.86 0.00015 0.0482 0.27 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94557488 chr8:94553722~94569745:+ CESC cis rs2299587 0.762 rs406329 ENSG00000253671.1 RP11-806O11.1 -3.86 0.00015 0.0482 -0.26 -0.25 Economic and political preferences; chr8:17936433 chr8:17808941~17820868:+ CESC cis rs867371 1 rs11855089 ENSG00000255769.6 GOLGA2P10 -3.86 0.00015 0.0482 -0.28 -0.25 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82154924 chr15:82472993~82513950:- CESC cis rs12681963 0.688 rs6997926 ENSG00000272375.1 RP11-51J9.6 3.86 0.00015 0.0482 0.49 0.25 Migraine; chr8:30197384 chr8:30197404~30198048:+ CESC cis rs11089937 0.626 rs4820337 ENSG00000211638.2 IGLV8-61 3.86 0.00015 0.0482 0.25 0.25 Periodontitis (PAL4Q3); chr22:22164374 chr22:22098700~22099212:+ CESC cis rs2235544 0.579 rs1537322 ENSG00000225183.1 RP4-758J24.4 -3.86 0.00015 0.0482 -0.28 -0.25 Thyroid hormone levels;Multiple myeloma (hyperdiploidy); chr1:54016633 chr1:54089856~54090093:+ CESC cis rs7208859 0.623 rs11651857 ENSG00000266490.1 CTD-2349P21.9 3.86 0.00015 0.0482 0.41 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30599344 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs216439 ENSG00000266490.1 CTD-2349P21.9 3.86 0.00015 0.0482 0.41 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30600866 chr17:30792372~30792833:+ CESC cis rs7208859 0.573 rs216442 ENSG00000266490.1 CTD-2349P21.9 3.86 0.00015 0.0482 0.41 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604179 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs216445 ENSG00000266490.1 CTD-2349P21.9 3.86 0.00015 0.0482 0.41 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606558 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs216446 ENSG00000266490.1 CTD-2349P21.9 3.86 0.00015 0.0482 0.41 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606700 chr17:30792372~30792833:+ CESC cis rs673078 0.66 rs17619932 ENSG00000275409.1 RP11-131L12.4 -3.86 0.00015 0.0482 -0.39 -0.25 Glucose homeostasis traits; chr12:118352228 chr12:118430147~118430699:+ CESC cis rs9322193 0.886 rs4870055 ENSG00000223701.3 RAET1E-AS1 3.86 0.00015 0.0483 0.31 0.25 Lung cancer; chr6:149848433 chr6:149884431~149919508:+ CESC cis rs4648045 0.565 rs62327181 ENSG00000246560.2 RP11-10L12.4 3.86 0.000151 0.0483 0.34 0.25 Lymphocyte percentage of white cells; chr4:102624981 chr4:102828055~102844075:+ CESC cis rs6504622 0.934 rs3760377 ENSG00000262879.4 RP11-156P1.3 -3.86 0.000151 0.0483 -0.28 -0.25 Orofacial clefts; chr17:46964713 chr17:46984045~47100323:- CESC cis rs6504622 1 rs11079745 ENSG00000262879.4 RP11-156P1.3 -3.86 0.000151 0.0483 -0.28 -0.25 Orofacial clefts; chr17:46966781 chr17:46984045~47100323:- CESC cis rs875971 0.895 rs1974769 ENSG00000232559.3 GS1-124K5.12 3.86 0.000151 0.0483 0.28 0.25 Aortic root size; chr7:66485627 chr7:66554588~66576923:- CESC cis rs875971 0.895 rs6460300 ENSG00000232559.3 GS1-124K5.12 3.86 0.000151 0.0483 0.28 0.25 Aortic root size; chr7:66487937 chr7:66554588~66576923:- CESC cis rs12468226 1 rs2350809 ENSG00000273456.1 RP11-686O6.2 3.86 0.000151 0.0483 0.33 0.25 Urate levels; chr2:202464210 chr2:202374932~202375604:- CESC cis rs8067354 0.872 rs2645483 ENSG00000266992.1 DHX40P1 3.86 0.000151 0.0483 0.28 0.25 Hemoglobin concentration; chr17:59770823 chr17:59976009~60002384:- CESC cis rs10129255 0.957 rs4387509 ENSG00000224373.3 IGHV4-59 3.86 0.000151 0.0483 0.19 0.25 Kawasaki disease; chr14:106704386 chr14:106627249~106627825:- CESC cis rs78773383 0.505 rs13123782 ENSG00000249207.1 RP11-360F5.1 3.86 0.000151 0.0483 0.28 0.25 Mean corpuscular volume;Mean corpuscular hemoglobin; chr4:39375785 chr4:39112677~39126818:- CESC cis rs7200543 0.961 rs3803573 ENSG00000260735.1 RP11-72I8.1 -3.86 0.000151 0.0484 -0.3 -0.25 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15044556 chr16:15094411~15109197:+ CESC cis rs10129255 0.957 rs8005468 ENSG00000280411.1 IGHV1-69-2 -3.86 0.000151 0.0484 -0.19 -0.25 Kawasaki disease; chr14:106686431 chr14:106762092~106762588:- CESC cis rs769267 0.899 rs67720221 ENSG00000269131.1 AC004447.2 3.86 0.000151 0.0484 0.21 0.25 Tonsillectomy; chr19:19330055 chr19:18990893~18993610:+ CESC cis rs11638352 1 rs8038096 ENSG00000275601.1 AC011330.13 3.86 0.000151 0.0484 0.37 0.25 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:44075092 chr15:43642389~43643023:- CESC cis rs62355900 0.627 rs726501 ENSG00000271828.1 CTD-2310F14.1 3.86 0.000151 0.0484 0.4 0.25 Endometriosis; chr5:56832039 chr5:56927874~56929573:+ CESC cis rs7432375 0.61 rs4420814 ENSG00000239213.4 NCK1-AS1 3.86 0.000151 0.0484 0.29 0.25 Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia; chr3:136794440 chr3:136841726~136862054:- CESC cis rs5742933 0.75 rs10197331 ENSG00000253559.1 OSGEPL1-AS1 3.86 0.000151 0.0484 0.3 0.25 Ferritin levels; chr2:189768112 chr2:189762704~189765556:+ CESC cis rs7246657 0.722 rs12979640 ENSG00000276846.1 CTD-3220F14.3 -3.86 0.000151 0.0484 -0.31 -0.25 Coronary artery calcification; chr19:37688255 chr19:37314868~37315620:- CESC cis rs1124769 0.748 rs11070834 ENSG00000259378.1 DCAF13P3 3.86 0.000151 0.0484 0.35 0.25 Cognitive performance; chr15:51087339 chr15:50944663~50945996:+ CESC cis rs6693388 0.56 rs7523082 ENSG00000229021.2 AL591893.1 3.86 0.000151 0.0484 0.29 0.25 Blood metabolite ratios; chr1:151875650 chr1:151994531~152042774:+ CESC cis rs4877691 0.522 rs34030580 ENSG00000267559.4 RP11-383M4.6 3.86 0.000151 0.0484 0.35 0.25 Airway imaging phenotypes; chr9:82480222 chr9:81930226~81977089:- CESC cis rs4877691 0.522 rs12551339 ENSG00000267559.4 RP11-383M4.6 3.86 0.000151 0.0484 0.35 0.25 Airway imaging phenotypes; chr9:82480758 chr9:81930226~81977089:- CESC cis rs1823913 0.599 rs13399251 ENSG00000227542.1 AC092614.2 3.86 0.000151 0.0484 0.26 0.25 Obesity-related traits; chr2:191268758 chr2:191229165~191246172:- CESC cis rs2255336 0.817 rs7310643 ENSG00000245648.1 RP11-277P12.20 3.86 0.000151 0.0485 0.39 0.25 Blood protein levels; chr12:10365501 chr12:10363769~10398506:+ CESC cis rs3768617 1 rs12026314 ENSG00000224468.3 RP11-181K3.4 -3.86 0.000151 0.0485 -0.24 -0.25 Fuchs's corneal dystrophy; chr1:183135392 chr1:183138402~183141282:- CESC cis rs13113518 1 rs13133579 ENSG00000273257.1 RP11-177J6.1 3.86 0.000151 0.0485 0.33 0.25 Height; chr4:55459921 chr4:55387949~55388271:+ CESC cis rs5758659 0.652 rs6519301 ENSG00000273366.1 CTA-989H11.1 -3.86 0.000151 0.0485 -0.32 -0.25 Cognitive function; chr22:41989963 chr22:42278188~42278846:+ CESC cis rs1113500 0.933 rs10881498 ENSG00000226822.1 RP11-356N1.2 3.86 0.000151 0.0485 0.32 0.25 Growth-regulated protein alpha levels; chr1:108092362 chr1:108071482~108074519:+ CESC cis rs1707322 1 rs785507 ENSG00000281133.1 AL355480.3 3.86 0.000151 0.0485 0.31 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46075886 chr1:45580892~45580996:- CESC cis rs17818399 0.645 rs35870739 ENSG00000279254.1 RP11-536C12.1 -3.86 0.000151 0.0485 -0.33 -0.25 Height; chr2:46557092 chr2:46668870~46670778:+ CESC cis rs17818399 0.749 rs13000560 ENSG00000279254.1 RP11-536C12.1 -3.86 0.000151 0.0485 -0.33 -0.25 Height; chr2:46563858 chr2:46668870~46670778:+ CESC cis rs9322193 0.847 rs4870054 ENSG00000216906.2 RP11-350J20.9 3.86 0.000151 0.0485 0.28 0.25 Lung cancer; chr6:149848402 chr6:149904243~149906418:+ CESC cis rs11096990 0.855 rs2711989 ENSG00000249207.1 RP11-360F5.1 3.86 0.000151 0.0485 0.33 0.25 Cognitive function; chr4:39150416 chr4:39112677~39126818:- CESC cis rs11096990 0.855 rs2566169 ENSG00000249207.1 RP11-360F5.1 3.86 0.000151 0.0485 0.33 0.25 Cognitive function; chr4:39150420 chr4:39112677~39126818:- CESC cis rs13113518 0.812 rs6830409 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0485 0.33 0.25 Height; chr4:55522229 chr4:55387949~55388271:+ CESC cis rs1432089 0.731 rs62344311 ENSG00000181359.5 HSP90AA6P 3.86 0.000152 0.0485 0.48 0.25 Endometriosis; chr4:170872065 chr4:170581470~170605450:- CESC cis rs875971 0.862 rs4149461 ENSG00000179406.6 LINC00174 3.86 0.000152 0.0485 0.26 0.25 Aortic root size; chr7:66279745 chr7:66376044~66401338:- CESC cis rs875971 0.862 rs10261398 ENSG00000179406.6 LINC00174 3.86 0.000152 0.0485 0.26 0.25 Aortic root size; chr7:66285177 chr7:66376044~66401338:- CESC cis rs875971 0.862 rs10224872 ENSG00000179406.6 LINC00174 3.86 0.000152 0.0485 0.26 0.25 Aortic root size; chr7:66294786 chr7:66376044~66401338:- CESC cis rs9595066 0.627 rs4942287 ENSG00000227258.4 SMIM2-AS1 -3.86 0.000152 0.0486 -0.37 -0.25 Schizophrenia; chr13:44160560 chr13:44110451~44240517:+ CESC cis rs6951245 1 rs77868187 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054332 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs75016635 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054485 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs113066613 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054492 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs11763793 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054706 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs11763835 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1054877 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs78861357 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1055782 chr7:1160374~1165267:+ CESC cis rs6951245 0.872 rs76713558 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056230 chr7:1160374~1165267:+ CESC cis rs6951245 0.748 rs79658522 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056241 chr7:1160374~1165267:+ CESC cis rs6951245 0.935 rs76525951 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056377 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs79683221 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056503 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs78185801 ENSG00000229043.2 AC091729.9 -3.86 0.000152 0.0486 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1056731 chr7:1160374~1165267:+ CESC cis rs1044826 0.597 rs1017468 ENSG00000178631.7 ACTG1P1 3.86 0.000152 0.0486 0.31 0.25 Obesity-related traits; chr3:139426936 chr3:139493809~139494937:+ CESC cis rs13113518 0.966 rs7677952 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55425312 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs1047354 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55429416 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs1056547 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55430596 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs1056545 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55430730 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs5863 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55430740 chr4:55387949~55388271:+ CESC cis rs13113518 0.966 rs6828570 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55431595 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs3749474 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55434518 chr4:55387949~55388271:+ CESC cis rs13113518 0.966 rs1474271 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55435912 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs11937487 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55436576 chr4:55387949~55388271:+ CESC cis rs13113518 1 rs3805146 ENSG00000273257.1 RP11-177J6.1 3.86 0.000152 0.0486 0.33 0.25 Height; chr4:55436985 chr4:55387949~55388271:+ CESC cis rs6782228 0.606 rs4634140 ENSG00000242551.2 POU5F1P6 3.86 0.000152 0.0486 0.27 0.25 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128705613 chr3:128674735~128677005:- CESC cis rs11098499 0.661 rs10015965 ENSG00000248280.1 RP11-33B1.2 3.86 0.000152 0.0486 0.29 0.25 Corneal astigmatism; chr4:119347082 chr4:119440561~119450157:- CESC cis rs12819124 0.502 rs10875718 ENSG00000240399.1 RP1-228P16.1 3.86 0.000152 0.0486 0.29 0.25 Glycated hemoglobin levels; chr12:48017319 chr12:48054813~48055591:- CESC cis rs1707322 0.896 rs809774 ENSG00000281133.1 AL355480.3 3.86 0.000152 0.0486 0.3 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46094572 chr1:45580892~45580996:- CESC cis rs1707322 1 rs785498 ENSG00000281133.1 AL355480.3 3.86 0.000152 0.0486 0.3 0.25 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126742 chr1:45580892~45580996:- CESC cis rs6504663 0.558 rs11871603 ENSG00000262006.1 RP11-700H6.4 3.86 0.000152 0.0487 0.31 0.25 Visceral fat; chr17:50481676 chr17:50909637~50910232:- CESC cis rs7216064 1 rs7209675 ENSG00000278730.1 RP11-147L13.11 -3.86 0.000152 0.0487 -0.29 -0.25 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67835142 chr17:68126666~68129586:+ CESC cis rs6920372 0.799 rs9480947 ENSG00000260273.1 RP11-425D10.10 3.86 0.000152 0.0487 0.31 0.25 Height; chr6:109397362 chr6:109382795~109383666:+ CESC cis rs1020064 0.636 rs2679876 ENSG00000235319.1 AC012360.4 -3.85 0.000152 0.0487 -0.29 -0.25 AIDS; chr2:105321650 chr2:105324210~105330529:+ CESC cis rs2439831 0.702 rs2788 ENSG00000249839.1 AC011330.5 -3.85 0.000152 0.0487 -0.36 -0.25 Lung cancer in ever smokers; chr15:43772688 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs28891769 ENSG00000249839.1 AC011330.5 -3.85 0.000152 0.0487 -0.36 -0.25 Lung cancer in ever smokers; chr15:43780662 chr15:43663654~43684339:- CESC cis rs2439831 0.85 rs28578398 ENSG00000249839.1 AC011330.5 -3.85 0.000152 0.0487 -0.36 -0.25 Lung cancer in ever smokers; chr15:43782848 chr15:43663654~43684339:- CESC cis rs703842 1 rs11172351 ENSG00000270039.1 RP11-571M6.17 -3.85 0.000152 0.0487 -0.31 -0.25 Multiple sclerosis; chr12:57819702 chr12:57803838~57804415:+ CESC cis rs6951245 1 rs78896566 ENSG00000229043.2 AC091729.9 -3.85 0.000152 0.0487 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040546 chr7:1160374~1165267:+ CESC cis rs6951245 1 rs79422648 ENSG00000229043.2 AC091729.9 -3.85 0.000152 0.0487 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040605 chr7:1160374~1165267:+ CESC cis rs6951245 0.872 rs113119264 ENSG00000229043.2 AC091729.9 -3.85 0.000152 0.0487 -0.39 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040928 chr7:1160374~1165267:+ CESC cis rs6928977 0.66 rs2614263 ENSG00000234084.1 RP3-388E23.2 3.85 0.000152 0.0487 0.21 0.25 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135459579 chr6:135301568~135307158:+ CESC cis rs1823913 0.599 rs7598639 ENSG00000227542.1 AC092614.2 3.85 0.000152 0.0487 0.26 0.25 Obesity-related traits; chr2:191267958 chr2:191229165~191246172:- CESC cis rs6928977 0.66 rs2614267 ENSG00000234084.1 RP3-388E23.2 3.85 0.000153 0.0487 0.21 0.25 Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma; chr6:135455340 chr6:135301568~135307158:+ CESC cis rs9517320 1 rs912337 ENSG00000231194.1 FARP1-AS1 -3.85 0.000153 0.0487 -0.29 -0.25 Longevity; chr13:98489018 chr13:98435405~98435840:- CESC cis rs12435908 1 rs60936033 ENSG00000259078.2 PTBP1P 3.85 0.000153 0.0487 0.4 0.25 Ischemic stroke; chr14:65390265 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs10146374 ENSG00000259078.2 PTBP1P 3.85 0.000153 0.0487 0.4 0.25 Ischemic stroke; chr14:65390694 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs11844348 ENSG00000259078.2 PTBP1P 3.85 0.000153 0.0487 0.4 0.25 Ischemic stroke; chr14:65392762 chr14:65279267~65281166:+ CESC cis rs9487094 0.643 rs35146243 ENSG00000260273.1 RP11-425D10.10 3.85 0.000153 0.0488 0.32 0.25 Height; chr6:109477209 chr6:109382795~109383666:+ CESC cis rs5753618 0.583 rs71324184 ENSG00000236132.1 CTA-440B3.1 -3.85 0.000153 0.0488 -0.29 -0.25 Colorectal cancer; chr22:31356075 chr22:31816379~31817491:- CESC cis rs1976403 0.659 rs10799699 ENSG00000227001.3 NBPF2P 3.85 0.000153 0.0488 0.27 0.25 Liver enzyme levels (alkaline phosphatase); chr1:21494468 chr1:21424625~21427967:- CESC cis rs75422866 0.558 rs73104190 ENSG00000280054.1 RP1-197B17.7 3.85 0.000153 0.0488 0.63 0.25 Pneumonia; chr12:47716040 chr12:47728151~47730598:- CESC cis rs10043775 0.718 rs10056586 ENSG00000251330.3 CTD-2283N19.1 -3.85 0.000153 0.0488 -0.33 -0.25 Periodontal microbiota; chr5:148440140 chr5:148430159~148430807:- CESC cis rs7560272 0.538 rs17434634 ENSG00000163016.8 ALMS1P -3.85 0.000153 0.0488 -0.32 -0.25 Schizophrenia; chr2:73695799 chr2:73644919~73685576:+ CESC cis rs35883536 0.967 rs2783689 ENSG00000235795.1 RP11-421L21.2 -3.85 0.000153 0.0488 -0.3 -0.25 Monocyte count; chr1:100626855 chr1:100995473~100996260:+ CESC cis rs9640161 0.659 rs77354576 ENSG00000261305.1 RP4-584D14.7 3.85 0.000153 0.0488 0.35 0.25 Blood protein levels;Circulating chemerin levels; chr7:150316211 chr7:150341771~150342607:+ CESC cis rs7560272 0.512 rs2421677 ENSG00000163016.8 ALMS1P -3.85 0.000153 0.0489 -0.31 -0.25 Schizophrenia; chr2:73738790 chr2:73644919~73685576:+ CESC cis rs853679 0.517 rs4713150 ENSG00000280107.1 AL022393.9 -3.85 0.000153 0.0489 -0.34 -0.25 Depression; chr6:28168434 chr6:28170845~28172521:+ CESC cis rs4713118 0.527 rs4713151 ENSG00000280107.1 AL022393.9 -3.85 0.000153 0.0489 -0.34 -0.25 Parkinson's disease; chr6:28168578 chr6:28170845~28172521:+ CESC cis rs853679 0.517 rs9393901 ENSG00000280107.1 AL022393.9 -3.85 0.000153 0.0489 -0.34 -0.25 Depression; chr6:28169019 chr6:28170845~28172521:+ CESC cis rs853679 0.517 rs3173443 ENSG00000280107.1 AL022393.9 -3.85 0.000153 0.0489 -0.34 -0.25 Depression; chr6:28169249 chr6:28170845~28172521:+ CESC cis rs853679 0.517 rs4713152 ENSG00000280107.1 AL022393.9 -3.85 0.000153 0.0489 -0.34 -0.25 Depression; chr6:28169676 chr6:28170845~28172521:+ CESC cis rs853679 0.517 rs9348797 ENSG00000280107.1 AL022393.9 -3.85 0.000153 0.0489 -0.34 -0.25 Depression; chr6:28169755 chr6:28170845~28172521:+ CESC cis rs853679 0.517 rs9380062 ENSG00000280107.1 AL022393.9 -3.85 0.000153 0.0489 -0.34 -0.25 Depression; chr6:28169791 chr6:28170845~28172521:+ CESC cis rs853679 0.542 rs9380063 ENSG00000280107.1 AL022393.9 -3.85 0.000153 0.0489 -0.34 -0.25 Depression; chr6:28170075 chr6:28170845~28172521:+ CESC cis rs2933343 0.7 rs2624910 ENSG00000231305.3 RP11-723O4.2 3.85 0.000153 0.0489 0.24 0.25 IgG glycosylation; chr3:128931432 chr3:128861313~128871540:- CESC cis rs7560272 0.512 rs4530394 ENSG00000163016.8 ALMS1P -3.85 0.000153 0.0489 -0.32 -0.25 Schizophrenia; chr2:73702523 chr2:73644919~73685576:+ CESC cis rs11231017 0.514 rs953169 ENSG00000254454.2 RCC2P6 3.85 0.000153 0.0489 0.25 0.25 HIV-1 viral setpoint; chr11:62316070 chr11:62371146~62373168:+ CESC cis rs10779751 0.734 rs2748878 ENSG00000230337.1 RP4-635E18.6 3.85 0.000153 0.0489 0.36 0.25 Body mass index; chr1:11069377 chr1:11099675~11102100:+ CESC cis rs10779751 0.734 rs2748877 ENSG00000230337.1 RP4-635E18.6 3.85 0.000153 0.0489 0.36 0.25 Body mass index; chr1:11069380 chr1:11099675~11102100:+ CESC cis rs10779751 0.69 rs910661 ENSG00000230337.1 RP4-635E18.6 3.85 0.000153 0.0489 0.36 0.25 Body mass index; chr1:11070059 chr1:11099675~11102100:+ CESC cis rs10779751 0.649 rs1318348 ENSG00000230337.1 RP4-635E18.6 3.85 0.000153 0.0489 0.36 0.25 Body mass index; chr1:11070361 chr1:11099675~11102100:+ CESC cis rs2276314 0.857 rs7237599 ENSG00000278986.1 RP11-723J4.3 -3.85 0.000153 0.0489 -0.27 -0.25 Endometriosis;Drug-induced torsades de pointes; chr18:36059433 chr18:35972151~35973916:+ CESC cis rs2439831 0.85 rs8032649 ENSG00000275601.1 AC011330.13 3.85 0.000153 0.0489 0.39 0.25 Lung cancer in ever smokers; chr15:43842724 chr15:43642389~43643023:- CESC cis rs5742933 0.681 rs4525728 ENSG00000253559.1 OSGEPL1-AS1 3.85 0.000153 0.0489 0.3 0.25 Ferritin levels; chr2:189780324 chr2:189762704~189765556:+ CESC cis rs9487094 0.666 rs3757235 ENSG00000260273.1 RP11-425D10.10 3.85 0.000153 0.0489 0.31 0.25 Height; chr6:109390638 chr6:109382795~109383666:+ CESC cis rs440932 1 rs378974 ENSG00000254340.1 RP11-10A14.3 3.85 0.000153 0.0489 0.31 0.25 High light scatter reticulocyte percentage of red cells; chr8:9169129 chr8:9141424~9145435:+ CESC cis rs875971 1 rs778726 ENSG00000179406.6 LINC00174 -3.85 0.000153 0.0489 -0.28 -0.25 Aortic root size; chr7:66363744 chr7:66376044~66401338:- CESC cis rs875971 0.767 rs1695815 ENSG00000179406.6 LINC00174 -3.85 0.000153 0.0489 -0.28 -0.25 Aortic root size; chr7:66366357 chr7:66376044~66401338:- CESC cis rs875971 1 rs778685 ENSG00000179406.6 LINC00174 -3.85 0.000153 0.0489 -0.28 -0.25 Aortic root size; chr7:66371189 chr7:66376044~66401338:- CESC cis rs875971 0.929 rs778682 ENSG00000179406.6 LINC00174 -3.85 0.000153 0.0489 -0.28 -0.25 Aortic root size; chr7:66372947 chr7:66376044~66401338:- CESC cis rs875971 0.964 rs11765965 ENSG00000179406.6 LINC00174 -3.85 0.000153 0.0489 -0.28 -0.25 Aortic root size; chr7:66377234 chr7:66376044~66401338:- CESC cis rs10419113 0.641 rs12983947 ENSG00000269867.1 CTD-2583A14.8 3.85 0.000153 0.0489 0.26 0.25 Pediatric bone mineral density (spine); chr19:57763541 chr19:57867038~57868172:- CESC cis rs700651 0.789 rs1147169 ENSG00000222017.1 AC011997.1 -3.85 0.000153 0.0489 -0.33 -0.25 Intracranial aneurysm; chr2:198036671 chr2:197693106~197774823:+ CESC cis rs2439831 0.85 rs60883262 ENSG00000249839.1 AC011330.5 -3.85 0.000153 0.0489 -0.36 -0.25 Lung cancer in ever smokers; chr15:43784305 chr15:43663654~43684339:- CESC cis rs7873102 0.654 rs7033326 ENSG00000230188.1 RP11-405L18.4 -3.85 0.000153 0.0489 -0.33 -0.25 Brain structure; chr9:37962802 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs7033327 ENSG00000230188.1 RP11-405L18.4 -3.85 0.000153 0.0489 -0.33 -0.25 Brain structure; chr9:37962804 chr9:37490421~37490893:- CESC cis rs7873102 0.654 rs6476666 ENSG00000230188.1 RP11-405L18.4 -3.85 0.000153 0.0489 -0.33 -0.25 Brain structure; chr9:37963050 chr9:37490421~37490893:- CESC cis rs11846409 1 rs11846409 ENSG00000211974.3 IGHV2-70 -3.85 0.000154 0.049 -0.34 -0.25 Rheumatic heart disease; chr14:106645692 chr14:106723574~106724093:- CESC cis rs783540 0.609 rs803686 ENSG00000278202.1 RP11-152F13.8 3.85 0.000154 0.049 0.23 0.25 Schizophrenia; chr15:82550590 chr15:82418651~82434235:+ CESC cis rs761746 0.96 rs5753686 ENSG00000236132.1 CTA-440B3.1 -3.85 0.000154 0.049 -0.32 -0.25 Intelligence; chr22:31551962 chr22:31816379~31817491:- CESC cis rs761746 0.96 rs9621279 ENSG00000236132.1 CTA-440B3.1 -3.85 0.000154 0.049 -0.32 -0.25 Intelligence; chr22:31553814 chr22:31816379~31817491:- CESC cis rs1345301 0.905 rs2310243 ENSG00000234389.1 AC007278.3 -3.85 0.000154 0.049 -0.25 -0.25 Waist circumference; chr2:102261100 chr2:102438713~102440475:+ CESC cis rs9309473 1 rs6755217 ENSG00000163016.8 ALMS1P 3.85 0.000154 0.049 0.34 0.25 Metabolite levels; chr2:73414157 chr2:73644919~73685576:+ CESC cis rs703842 0.892 rs1021469 ENSG00000270039.1 RP11-571M6.17 -3.85 0.000154 0.049 -0.31 -0.25 Multiple sclerosis; chr12:57814381 chr12:57803838~57804415:+ CESC cis rs6504622 1 rs4968285 ENSG00000263142.4 LRRC37A17P -3.85 0.000154 0.049 -0.2 -0.25 Orofacial clefts; chr17:46938266 chr17:46978481~47054569:+ CESC cis rs224278 0.789 rs224295 ENSG00000238280.1 RP11-436D10.3 3.85 0.000154 0.049 0.3 0.25 Ewing sarcoma; chr10:62830498 chr10:62793562~62805887:- CESC cis rs224278 0.789 rs224299 ENSG00000238280.1 RP11-436D10.3 3.85 0.000154 0.049 0.3 0.25 Ewing sarcoma; chr10:62831059 chr10:62793562~62805887:- CESC cis rs924712 1 rs924712 ENSG00000224984.1 RP11-524H19.2 -3.85 0.000154 0.049 -0.24 -0.25 Breast cancer; chr6:54862053 chr6:54840118~54840855:- CESC cis rs9487094 0.689 rs1046943 ENSG00000260273.1 RP11-425D10.10 3.85 0.000154 0.049 0.32 0.25 Height; chr6:109462738 chr6:109382795~109383666:+ CESC cis rs9487094 0.689 rs6939548 ENSG00000260273.1 RP11-425D10.10 3.85 0.000154 0.049 0.32 0.25 Height; chr6:109464011 chr6:109382795~109383666:+ CESC cis rs9487094 0.666 rs3734652 ENSG00000260273.1 RP11-425D10.10 3.85 0.000154 0.049 0.32 0.25 Height; chr6:109465777 chr6:109382795~109383666:+ CESC cis rs67311347 1 rs1466237 ENSG00000223797.4 ENTPD3-AS1 3.85 0.000154 0.049 0.25 0.25 Renal cell carcinoma; chr3:40420535 chr3:40313802~40453329:- CESC cis rs3845817 0.843 rs3911862 ENSG00000281920.1 RP11-418H16.1 3.85 0.000154 0.049 0.31 0.25 Bipolar disorder; chr2:65532537 chr2:65623272~65628424:+ CESC cis rs8059260 0.668 rs7198089 ENSG00000274038.1 RP11-66H6.4 -3.85 0.000154 0.049 -0.4 -0.25 Alcohol consumption over the past year; chr16:11027199 chr16:11056556~11057034:+ CESC cis rs2439831 0.867 rs2242068 ENSG00000205771.5 CATSPER2P1 -3.85 0.000154 0.049 -0.37 -0.25 Lung cancer in ever smokers; chr15:43407106 chr15:43726918~43747094:- CESC cis rs7688540 0.547 rs11728864 ENSG00000211553.1 AC253576.2 -3.85 0.000154 0.049 -0.4 -0.25 Facial morphology (factor 6, height of vermillion lower lip); chr4:197518 chr4:136461~136568:+ CESC cis rs526231 0.819 rs568999 ENSG00000175749.11 EIF3KP1 3.85 0.000154 0.049 0.3 0.25 Primary biliary cholangitis; chr5:103265657 chr5:103032376~103033031:+ CESC cis rs526231 0.819 rs411648 ENSG00000175749.11 EIF3KP1 3.85 0.000154 0.049 0.3 0.25 Primary biliary cholangitis; chr5:103267201 chr5:103032376~103033031:+ CESC cis rs526231 0.819 rs2569016 ENSG00000175749.11 EIF3KP1 3.85 0.000154 0.049 0.3 0.25 Primary biliary cholangitis; chr5:103267431 chr5:103032376~103033031:+ CESC cis rs526231 0.853 rs377192 ENSG00000175749.11 EIF3KP1 3.85 0.000154 0.049 0.3 0.25 Primary biliary cholangitis; chr5:103267853 chr5:103032376~103033031:+ CESC cis rs526231 0.819 rs366437 ENSG00000175749.11 EIF3KP1 3.85 0.000154 0.049 0.3 0.25 Primary biliary cholangitis; chr5:103269900 chr5:103032376~103033031:+ CESC cis rs7811142 0.83 rs6948685 ENSG00000242294.5 STAG3L5P 3.85 0.000154 0.049 0.27 0.25 Platelet count; chr7:100372565 chr7:100336079~100351900:+ CESC cis rs7811142 0.83 rs6945952 ENSG00000242294.5 STAG3L5P 3.85 0.000154 0.049 0.27 0.25 Platelet count; chr7:100384152 chr7:100336079~100351900:+ CESC cis rs7811142 0.83 rs73401450 ENSG00000242294.5 STAG3L5P 3.85 0.000154 0.049 0.27 0.25 Platelet count; chr7:100384236 chr7:100336079~100351900:+ CESC cis rs8127691 0.967 rs2838520 ENSG00000225331.1 AP001055.6 3.85 0.000154 0.0491 0.31 0.25 Inflammatory bowel disease; chr21:44196013 chr21:44158740~44160076:- CESC cis rs7567389 0.704 rs4662714 ENSG00000236682.1 AC068282.3 3.85 0.000154 0.0491 0.33 0.25 Self-rated health; chr2:127237637 chr2:127389130~127400580:+ CESC cis rs2439831 0.764 rs12324584 ENSG00000205771.5 CATSPER2P1 -3.85 0.000154 0.0491 -0.35 -0.25 Lung cancer in ever smokers; chr15:43391248 chr15:43726918~43747094:- CESC cis rs7508 0.512 rs2237851 ENSG00000253671.1 RP11-806O11.1 -3.85 0.000154 0.0491 -0.26 -0.25 Atrial fibrillation; chr8:18020240 chr8:17808941~17820868:+ CESC cis rs11089937 0.626 rs737840 ENSG00000211638.2 IGLV8-61 -3.85 0.000154 0.0491 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22162743 chr22:22098700~22099212:+ CESC cis rs11089937 0.626 rs737841 ENSG00000211638.2 IGLV8-61 -3.85 0.000154 0.0491 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22162769 chr22:22098700~22099212:+ CESC cis rs957448 1 rs56716157 ENSG00000253704.1 RP11-267M23.4 3.85 0.000154 0.0491 0.31 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94530644 chr8:94553722~94569745:+ CESC cis rs7951870 1 rs12575519 ENSG00000247675.5 LRP4-AS1 -3.85 0.000154 0.0492 -0.31 -0.25 Schizophrenia; chr11:46370052 chr11:46846412~46874396:+ CESC cis rs1930961 1 rs6004672 ENSG00000272942.1 CTA-246H3.12 -3.85 0.000154 0.0492 -0.37 -0.25 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25434324~25435070:- CESC cis rs12908161 0.959 rs2175567 ENSG00000259728.4 LINC00933 3.85 0.000154 0.0492 0.32 0.25 Schizophrenia; chr15:84657715 chr15:84570649~84580175:+ CESC cis rs17772222 0.958 rs2297128 ENSG00000258983.2 RP11-507K2.2 3.85 0.000154 0.0492 0.31 0.25 Coronary artery calcification; chr14:88469910 chr14:88499334~88515502:+ CESC cis rs11763147 1 rs11763147 ENSG00000222364.1 RNU6-96P 3.85 0.000154 0.0492 0.31 0.25 Corneal structure; chr7:65861834 chr7:66395191~66395286:+ CESC cis rs1799949 1 rs8077486 ENSG00000267681.1 CTD-3199J23.6 -3.85 0.000155 0.0492 -0.31 -0.25 Menopause (age at onset); chr17:43060788 chr17:43144956~43145255:+ CESC cis rs2002030 0.915 rs56255555 ENSG00000254866.2 DEFB109P3 -3.85 0.000155 0.0492 -0.55 -0.25 Cognitive performance; chr8:11414775 chr8:12150895~12151134:- CESC cis rs9326248 0.53 rs1351452 ENSG00000280143.1 AP000892.6 -3.85 0.000155 0.0492 -0.44 -0.25 Blood protein levels; chr11:117072638 chr11:117204967~117210292:+ CESC cis rs7819412 0.645 rs10156356 ENSG00000255046.1 RP11-297N6.4 3.85 0.000155 0.0492 0.29 0.25 Triglycerides; chr8:11188700 chr8:11797928~11802568:- CESC cis rs669446 0.562 rs6429636 ENSG00000236200.4 KDM4A-AS1 -3.85 0.000155 0.0492 -0.31 -0.25 Amyotrophic lateral sclerosis (age of onset); chr1:43717869 chr1:43699765~43708138:- CESC cis rs9813712 0.595 rs16825656 ENSG00000228252.7 COL6A4P2 -3.85 0.000155 0.0492 -0.31 -0.25 Response to amphetamines; chr3:130286225 chr3:130212823~130273806:+ CESC cis rs561341 1 rs546748 ENSG00000265798.5 RP11-271K11.5 3.85 0.000155 0.0493 0.36 0.25 Hip circumference adjusted for BMI; chr17:31997274 chr17:31038575~31059121:- CESC cis rs10463554 0.784 rs187424 ENSG00000175749.11 EIF3KP1 3.85 0.000155 0.0493 0.27 0.25 Parkinson's disease; chr5:103251882 chr5:103032376~103033031:+ CESC cis rs1061377 0.748 rs35904472 ENSG00000249685.1 RP11-360F5.3 3.85 0.000155 0.0493 0.32 0.25 Uric acid levels; chr4:39094901 chr4:39133913~39135608:+ CESC cis rs8042680 0.592 rs11073960 ENSG00000214432.8 AC068831.10 -3.85 0.000155 0.0493 -0.3 -0.25 Type 2 diabetes; chr15:90940027 chr15:91022619~91036611:+ CESC cis rs62025270 0.848 rs2554 ENSG00000202081.1 RNU6-1280P -3.85 0.000155 0.0493 -0.35 -0.25 Idiopathic pulmonary fibrosis; chr15:85759412 chr15:85651522~85651628:- CESC cis rs875971 0.965 rs6971509 ENSG00000179406.6 LINC00174 3.85 0.000155 0.0493 0.26 0.25 Aortic root size; chr7:66249983 chr7:66376044~66401338:- CESC cis rs10958369 0.588 rs1904072 ENSG00000253369.1 RP11-1081M5.1 3.85 0.000155 0.0493 0.29 0.25 Response to antineoplastic agents; chr8:53527342 chr8:53395211~53395946:- CESC cis rs2733201 1 rs11635948 ENSG00000275601.1 AC011330.13 3.85 0.000155 0.0493 0.46 0.25 Lipoprotein phospholipase A2 activity in cardiovascular disease; chr15:43993896 chr15:43642389~43643023:- CESC cis rs35740288 0.77 rs11630968 ENSG00000202081.1 RNU6-1280P 3.85 0.000155 0.0494 0.3 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85574770 chr15:85651522~85651628:- CESC cis rs35740288 0.77 rs11630112 ENSG00000202081.1 RNU6-1280P 3.85 0.000155 0.0494 0.3 0.25 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr15:85577015 chr15:85651522~85651628:- CESC cis rs6701713 0.959 rs4844610 ENSG00000274245.1 RP11-357P18.2 -3.85 0.000155 0.0494 -0.42 -0.25 Alzheimer's disease (late onset); chr1:207629207 chr1:207372559~207373252:+ CESC cis rs875971 0.862 rs6952182 ENSG00000236529.1 RP13-254B10.1 -3.85 0.000155 0.0494 -0.27 -0.25 Aortic root size; chr7:66218330 chr7:65840212~65840596:+ CESC cis rs875971 0.862 rs6964437 ENSG00000236529.1 RP13-254B10.1 -3.85 0.000155 0.0494 -0.27 -0.25 Aortic root size; chr7:66221457 chr7:65840212~65840596:+ CESC cis rs11157436 0.918 rs1983518 ENSG00000211813.2 TRAV34 3.85 0.000155 0.0494 0.26 0.25 Neurocognitive impairment in HIV-1 infection (continuous); chr14:22149336 chr14:22207522~22208129:+ CESC cis rs6504622 0.537 rs1052504 ENSG00000263142.4 LRRC37A17P 3.85 0.000155 0.0494 0.2 0.25 Orofacial clefts; chr17:46916462 chr17:46978481~47054569:+ CESC cis rs1838105 0.78 rs1623402 ENSG00000263142.4 LRRC37A17P 3.85 0.000155 0.0494 0.2 0.25 Nonsyndromic cleft lip with cleft palate; chr17:46916914 chr17:46978481~47054569:+ CESC cis rs6504622 0.537 rs1662597 ENSG00000263142.4 LRRC37A17P 3.85 0.000155 0.0494 0.2 0.25 Orofacial clefts; chr17:46917489 chr17:46978481~47054569:+ CESC cis rs8080784 0.866 rs7210906 ENSG00000266701.1 AC005702.4 3.85 0.000155 0.0494 0.37 0.25 Coronary artery disease; chr17:60839217 chr17:60042546~60042627:- CESC cis rs8080784 1 rs7210641 ENSG00000266701.1 AC005702.4 3.85 0.000155 0.0494 0.37 0.25 Coronary artery disease; chr17:60839259 chr17:60042546~60042627:- CESC cis rs2115630 1 rs4633690 ENSG00000225151.9 GOLGA2P7 3.85 0.000155 0.0494 0.28 0.25 P wave terminal force; chr15:84818729 chr15:84199311~84230136:- CESC cis rs9584850 0.609 rs7983408 ENSG00000231194.1 FARP1-AS1 3.85 0.000155 0.0494 0.34 0.25 Neuroticism; chr13:98503339 chr13:98435405~98435840:- CESC cis rs673078 0.607 rs7958551 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118442585 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs7958652 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118442630 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs111607725 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118442957 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs73207573 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118444664 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs76809232 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118444979 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61944660 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118445326 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61944662 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118445520 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs4254101 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118445877 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs4622305 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118445912 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs2393418 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118445995 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs73207575 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118446711 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61944663 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118446886 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs73207577 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118447012 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs73207579 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118447123 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61944664 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118447145 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs7969871 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118447331 chr12:118428281~118428870:+ CESC cis rs673078 0.56 rs7970361 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118447723 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61944669 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118448530 chr12:118428281~118428870:+ CESC cis rs673078 0.607 rs61944670 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000155 0.0494 -0.49 -0.25 Glucose homeostasis traits; chr12:118448697 chr12:118428281~118428870:+ CESC cis rs2288884 0.559 rs12611043 ENSG00000275055.1 CTC-471J1.11 -3.85 0.000155 0.0494 -0.29 -0.25 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52084372 chr19:52049007~52049754:+ CESC cis rs9438901 0.592 rs1293259 ENSG00000224183.1 SDHDP6 3.85 0.000155 0.0494 0.34 0.25 Red cell distribution width; chr1:25369344 chr1:25294164~25294643:- CESC cis rs2283792 0.73 rs2083565 ENSG00000224086.5 LL22NC03-86G7.1 -3.85 0.000155 0.0494 -0.29 -0.25 Multiple sclerosis; chr22:21929985 chr22:21938293~21977632:+ CESC cis rs6662572 0.737 rs7532388 ENSG00000281133.1 AL355480.3 3.85 0.000156 0.0494 0.34 0.25 Blood protein levels; chr1:46007062 chr1:45580892~45580996:- CESC cis rs1387259 0.698 rs4579969 ENSG00000240399.1 RP1-228P16.1 -3.85 0.000156 0.0495 -0.26 -0.25 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48385779 chr12:48054813~48055591:- CESC cis rs7712401 0.601 rs30048 ENSG00000263432.2 RN7SL689P 3.85 0.000156 0.0495 0.3 0.25 Mean platelet volume; chr5:122934698 chr5:123022487~123022783:- CESC cis rs9925964 0.933 rs56314408 ENSG00000260911.2 RP11-196G11.2 3.85 0.000156 0.0495 0.27 0.25 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31106068 chr16:31043150~31049868:+ CESC cis rs657075 0.653 rs9895 ENSG00000235253.1 AC010240.2 -3.85 0.000156 0.0495 -0.38 -0.25 Rheumatoid arthritis; chr5:132272249 chr5:132942932~132945050:+ CESC cis rs7432375 0.641 rs835649 ENSG00000239213.4 NCK1-AS1 3.85 0.000156 0.0495 0.29 0.25 Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia; chr3:136953048 chr3:136841726~136862054:- CESC cis rs1023500 0.596 rs133352 ENSG00000273366.1 CTA-989H11.1 -3.85 0.000156 0.0495 -0.34 -0.25 Schizophrenia; chr22:42038018 chr22:42278188~42278846:+ CESC cis rs11105468 0.601 rs4842499 ENSG00000271327.1 RP11-1109F11.3 3.85 0.000156 0.0495 0.26 0.25 Febrile seizures (MMR vaccine-unrelated);Febrile seizures;Febrile seizures (MMR vaccine-related); chr12:89715544 chr12:89367807~89369301:+ CESC cis rs7508 0.585 rs478420 ENSG00000253671.1 RP11-806O11.1 -3.85 0.000156 0.0495 -0.26 -0.25 Atrial fibrillation; chr8:17935344 chr8:17808941~17820868:+ CESC cis rs7208859 0.623 rs170051 ENSG00000266490.1 CTD-2349P21.9 3.85 0.000156 0.0495 0.42 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587135 chr17:30792372~30792833:+ CESC cis rs7208859 0.51 rs216402 ENSG00000266490.1 CTD-2349P21.9 3.85 0.000156 0.0495 0.42 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30590108 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs216434 ENSG00000266490.1 CTD-2349P21.9 3.85 0.000156 0.0495 0.42 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595317 chr17:30792372~30792833:+ CESC cis rs7208859 0.623 rs216436 ENSG00000266490.1 CTD-2349P21.9 3.85 0.000156 0.0495 0.42 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595882 chr17:30792372~30792833:+ CESC cis rs7829975 0.593 rs2921077 ENSG00000253893.2 FAM85B -3.85 0.000156 0.0495 -0.3 -0.25 Mood instability; chr8:8446992 chr8:8167819~8226614:- CESC cis rs2281636 0.723 rs11190245 ENSG00000233690.1 EBAG9P1 3.85 0.000156 0.0495 0.27 0.25 Obesity-related traits; chr10:99691502 chr10:99697407~99697949:- CESC cis rs9400467 0.506 rs12214933 ENSG00000272356.1 RP5-1112D6.8 -3.85 0.000156 0.0496 -0.33 -0.25 Amino acid levels;Blood metabolite levels; chr6:111236803 chr6:111309203~111313517:+ CESC cis rs56156301 1 rs72671371 ENSG00000253633.1 KB-1980E6.3 3.85 0.000156 0.0496 0.52 0.25 Pelvic organ prolapse; chr8:103154182 chr8:102528740~102538668:+ CESC cis rs6775745 0.901 rs9834334 ENSG00000240854.1 RP11-64K7.1 -3.85 0.000156 0.0496 -0.37 -0.25 Neutrophil count; chr3:132078248 chr3:132175402~132176711:+ CESC cis rs172166 0.637 rs1225592 ENSG00000216901.1 AL022393.7 3.85 0.000156 0.0496 0.27 0.25 Cardiac Troponin-T levels; chr6:28182464 chr6:28176188~28176674:+ CESC cis rs172166 0.637 rs1225595 ENSG00000216901.1 AL022393.7 3.85 0.000156 0.0496 0.27 0.25 Cardiac Troponin-T levels; chr6:28183562 chr6:28176188~28176674:+ CESC cis rs9309473 0.687 rs6710659 ENSG00000163016.8 ALMS1P 3.85 0.000156 0.0496 0.31 0.25 Metabolite levels; chr2:73380382 chr2:73644919~73685576:+ CESC cis rs2408955 0.522 rs3997 ENSG00000226413.2 OR8T1P -3.85 0.000156 0.0496 -0.33 -0.25 Glycated hemoglobin levels; chr12:48087804 chr12:48442030~48442947:- CESC cis rs10510102 0.935 rs10510101 ENSG00000276742.1 RP11-500G22.4 3.85 0.000156 0.0496 0.4 0.25 Breast cancer; chr10:121898614 chr10:121956782~121957098:+ CESC cis rs11770686 0.935 rs2240139 ENSG00000214243.3 AC004980.10 3.85 0.000156 0.0496 0.22 0.25 Essential tremor; chr7:75713135 chr7:76650401~76650897:- CESC cis rs4927850 0.958 rs1975582 ENSG00000273009.1 RP11-352G9.1 -3.85 0.000156 0.0496 -0.35 -0.25 Pancreatic cancer; chr3:196024568 chr3:195913078~195913683:- CESC cis rs11089937 0.597 rs11089925 ENSG00000211638.2 IGLV8-61 -3.85 0.000156 0.0496 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22137267 chr22:22098700~22099212:+ CESC cis rs11089937 0.597 rs5757024 ENSG00000211638.2 IGLV8-61 -3.85 0.000156 0.0496 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22137415 chr22:22098700~22099212:+ CESC cis rs11089937 0.597 rs5757026 ENSG00000211638.2 IGLV8-61 -3.85 0.000156 0.0496 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22137556 chr22:22098700~22099212:+ CESC cis rs6844153 0.887 rs62302532 ENSG00000240005.4 RP11-293A21.1 -3.85 0.000156 0.0496 -0.35 -0.25 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26947150 chr4:26859806~26860599:- CESC cis rs6844153 0.887 rs6448488 ENSG00000240005.4 RP11-293A21.1 -3.85 0.000156 0.0496 -0.35 -0.25 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26949365 chr4:26859806~26860599:- CESC cis rs919433 0.617 rs700643 ENSG00000222017.1 AC011997.1 3.85 0.000156 0.0497 0.32 0.25 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197736646 chr2:197693106~197774823:+ CESC cis rs919433 0.653 rs700651 ENSG00000222017.1 AC011997.1 3.85 0.000156 0.0497 0.32 0.25 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197766990 chr2:197693106~197774823:+ CESC cis rs10392 0.543 rs6028200 ENSG00000274825.1 RP4-616B8.5 -3.85 0.000156 0.0497 -0.27 -0.25 Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis; chr20:38911972 chr20:38955910~38956547:+ CESC cis rs6662572 1 rs1053941 ENSG00000280836.1 AL355480.1 3.85 0.000156 0.0497 0.35 0.25 Blood protein levels; chr1:45618711 chr1:45581219~45581321:- CESC cis rs2836950 0.565 rs2836945 ENSG00000255568.3 BRWD1-AS2 -3.85 0.000156 0.0497 -0.21 -0.25 Menarche (age at onset); chr21:39224831 chr21:39313935~39314962:+ CESC cis rs7015630 0.603 rs2189025 ENSG00000251136.7 RP11-37B2.1 -3.85 0.000157 0.0497 -0.31 -0.25 Inflammatory bowel disease;Crohn's disease; chr8:89836956 chr8:89609409~89757727:- CESC cis rs2297363 1 rs13207901 ENSG00000213073.4 RP11-288H12.3 -3.85 0.000157 0.0497 -0.3 -0.25 Total cholesterol levels;Blood protein levels; chr6:160081428 chr6:160093082~160096212:+ CESC cis rs9300255 0.62 rs1716173 ENSG00000235423.7 RP11-282O18.3 3.85 0.000157 0.0497 0.33 0.25 Neutrophil percentage of white cells; chr12:123176174 chr12:123252030~123261483:- CESC cis rs9300255 0.602 rs1727306 ENSG00000235423.7 RP11-282O18.3 3.85 0.000157 0.0497 0.33 0.25 Neutrophil percentage of white cells; chr12:123181148 chr12:123252030~123261483:- CESC cis rs9300255 0.512 rs2851436 ENSG00000235423.7 RP11-282O18.3 3.85 0.000157 0.0497 0.33 0.25 Neutrophil percentage of white cells; chr12:123182807 chr12:123252030~123261483:- CESC cis rs9300255 0.544 rs1716157 ENSG00000235423.7 RP11-282O18.3 3.85 0.000157 0.0497 0.33 0.25 Neutrophil percentage of white cells; chr12:123185926 chr12:123252030~123261483:- CESC cis rs9300255 0.544 rs10772995 ENSG00000235423.7 RP11-282O18.3 3.85 0.000157 0.0497 0.33 0.25 Neutrophil percentage of white cells; chr12:123187214 chr12:123252030~123261483:- CESC cis rs13113518 0.783 rs6843722 ENSG00000273257.1 RP11-177J6.1 3.85 0.000157 0.0497 0.33 0.25 Height; chr4:55465165 chr4:55387949~55388271:+ CESC cis rs12220238 0.915 rs12217890 ENSG00000213731.2 RAB5CP1 -3.85 0.000157 0.0497 -0.4 -0.25 Soluble interleukin-2 receptor subunit alpha; chr10:74264738 chr10:74423435~74424014:- CESC cis rs2019137 0.56 rs11123172 ENSG00000274877.1 RP11-65I12.1 3.85 0.000157 0.0497 0.32 0.25 Lymphocyte counts; chr2:113226726 chr2:113237595~113240825:+ CESC cis rs6001482 0.638 rs5757569 ENSG00000236850.4 BMS1P20 -3.85 0.000157 0.0497 -0.25 -0.25 Diastolic blood pressure; chr22:22230282 chr22:22303224~22322847:+ CESC cis rs4968361 0.892 rs11653976 ENSG00000266992.1 DHX40P1 -3.85 0.000157 0.0498 -0.41 -0.25 Schizophrenia; chr17:59439633 chr17:59976009~60002384:- CESC cis rs5742933 1 rs7557519 ENSG00000253559.1 OSGEPL1-AS1 -3.85 0.000157 0.0498 -0.35 -0.25 Ferritin levels; chr2:189718461 chr2:189762704~189765556:+ CESC cis rs11089937 0.597 rs9622919 ENSG00000211638.2 IGLV8-61 -3.85 0.000157 0.0498 -0.24 -0.25 Periodontitis (PAL4Q3); chr22:22132863 chr22:22098700~22099212:+ CESC cis rs12908161 0.959 rs11637728 ENSG00000259728.4 LINC00933 3.85 0.000157 0.0498 0.33 0.25 Schizophrenia; chr15:84660161 chr15:84570649~84580175:+ CESC cis rs62355900 0.627 rs16886383 ENSG00000271828.1 CTD-2310F14.1 3.85 0.000157 0.0498 0.4 0.25 Endometriosis; chr5:56829869 chr5:56927874~56929573:+ CESC cis rs9650657 0.589 rs6985109 ENSG00000255310.2 AF131215.2 3.85 0.000157 0.0498 0.29 0.25 Neuroticism; chr8:10904075 chr8:11107788~11109726:- CESC cis rs17152411 0.6 rs10901841 ENSG00000232334.1 RP11-47G11.2 3.85 0.000157 0.0498 0.28 0.25 Height; chr10:124943817 chr10:124004304~124004828:- CESC cis rs10256972 0.9 rs4388364 ENSG00000225146.1 AC073957.15 3.85 0.000157 0.0498 0.29 0.25 Endometriosis;Longevity; chr7:993409 chr7:1029025~1043891:+ CESC cis rs42490 0.664 rs394108 ENSG00000251136.7 RP11-37B2.1 -3.85 0.000157 0.0498 -0.25 -0.25 Leprosy; chr8:89812991 chr8:89609409~89757727:- CESC cis rs6964587 0.967 rs10279210 ENSG00000188693.7 CYP51A1-AS1 -3.85 0.000157 0.0498 -0.27 -0.25 Breast cancer; chr7:91987577 chr7:92134604~92180725:+ CESC cis rs6964587 1 rs6465343 ENSG00000188693.7 CYP51A1-AS1 -3.85 0.000157 0.0498 -0.27 -0.25 Breast cancer; chr7:91988894 chr7:92134604~92180725:+ CESC cis rs2980879 0.736 rs4336630 ENSG00000255080.1 RP11-1082L8.3 3.85 0.000157 0.0499 0.26 0.25 Adiponectin levels; chr8:125472034 chr8:124834884~124857516:- CESC cis rs62355900 0.627 rs72758096 ENSG00000271828.1 CTD-2310F14.1 3.85 0.000157 0.0499 0.39 0.25 Endometriosis; chr5:56870367 chr5:56927874~56929573:+ CESC cis rs12435908 1 rs73282223 ENSG00000259078.2 PTBP1P 3.85 0.000157 0.0499 0.4 0.25 Ischemic stroke; chr14:65387837 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs10136947 ENSG00000259078.2 PTBP1P 3.85 0.000157 0.0499 0.4 0.25 Ischemic stroke; chr14:65387893 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs10136953 ENSG00000259078.2 PTBP1P 3.85 0.000157 0.0499 0.4 0.25 Ischemic stroke; chr14:65387958 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs8017202 ENSG00000259078.2 PTBP1P 3.85 0.000157 0.0499 0.4 0.25 Ischemic stroke; chr14:65388240 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs73282230 ENSG00000259078.2 PTBP1P 3.85 0.000157 0.0499 0.4 0.25 Ischemic stroke; chr14:65389297 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs73282232 ENSG00000259078.2 PTBP1P 3.85 0.000157 0.0499 0.4 0.25 Ischemic stroke; chr14:65389359 chr14:65279267~65281166:+ CESC cis rs12435908 1 rs80068722 ENSG00000259078.2 PTBP1P 3.85 0.000157 0.0499 0.4 0.25 Ischemic stroke; chr14:65389393 chr14:65279267~65281166:+ CESC cis rs7692995 0.764 rs16895884 ENSG00000235413.3 KRT18P63 -3.85 0.000157 0.0499 -0.39 -0.25 Height; chr4:17852103 chr4:17911674~17912976:+ CESC cis rs2252187 0.615 rs2252164 ENSG00000226332.2 RP11-157P1.4 -3.85 0.000157 0.0499 -0.28 -0.25 Multiple system atrophy; chr20:61567399 chr20:62305432~62306325:- CESC cis rs4977575 0.505 rs10811641 ENSG00000277653.1 CDKN2B-AS 3.85 0.000157 0.0499 0.26 0.25 Pulse pressure; chr9:22014138 chr9:22117665~22117814:+ CESC cis rs256277 0.544 rs255928 ENSG00000270067.1 CTC-487M23.5 3.85 0.000157 0.0499 0.28 0.25 Coronary artery disease; chr5:112006636 chr5:112893333~112894001:+ CESC cis rs2836950 0.501 rs11088470 ENSG00000232608.1 TIMM9P2 3.85 0.000157 0.0499 0.28 0.25 Menarche (age at onset); chr21:39317236 chr21:39216624~39217506:+ CESC cis rs2836950 0.501 rs2836983 ENSG00000232608.1 TIMM9P2 3.85 0.000157 0.0499 0.28 0.25 Menarche (age at onset); chr21:39317410 chr21:39216624~39217506:+ CESC cis rs11089937 0.857 rs5750578 ENSG00000211639.2 IGLV4-60 3.85 0.000157 0.0499 0.22 0.25 Periodontitis (PAL4Q3); chr22:22136444 chr22:22162199~22162681:+ CESC cis rs10043775 1 rs10068216 ENSG00000251330.3 CTD-2283N19.1 3.85 0.000157 0.0499 0.32 0.25 Periodontal microbiota; chr5:148393755 chr5:148430159~148430807:- CESC cis rs10129255 0.957 rs10136781 ENSG00000211974.3 IGHV2-70 3.85 0.000158 0.0499 0.25 0.25 Kawasaki disease; chr14:106780451 chr14:106723574~106724093:- CESC cis rs10129255 0.957 rs8022165 ENSG00000211974.3 IGHV2-70 3.85 0.000158 0.0499 0.25 0.25 Kawasaki disease; chr14:106781682 chr14:106723574~106724093:- CESC cis rs10129255 0.917 rs8022493 ENSG00000211974.3 IGHV2-70 3.85 0.000158 0.0499 0.25 0.25 Kawasaki disease; chr14:106781820 chr14:106723574~106724093:- CESC cis rs1440410 0.835 rs7684847 ENSG00000250326.1 RP11-284M14.1 -3.85 0.000158 0.0499 -0.26 -0.25 Ischemic stroke; chr4:143133414 chr4:142933195~143184861:- CESC cis rs561341 0.941 rs2428341 ENSG00000265798.5 RP11-271K11.5 3.85 0.000158 0.0499 0.36 0.25 Hip circumference adjusted for BMI; chr17:31990276 chr17:31038575~31059121:- CESC cis rs11168618 1 rs3961921 ENSG00000257735.1 RP11-370I10.6 3.85 0.000158 0.05 0.27 0.25 Adiponectin levels; chr12:48549716 chr12:48350945~48442411:+ CESC cis rs11168351 0.864 rs12228750 ENSG00000258273.1 RP11-370I10.4 3.85 0.000158 0.05 0.29 0.25 Bipolar disorder and schizophrenia; chr12:48103214 chr12:48333755~48333901:- CESC cis rs72627123 0.53 rs79371463 ENSG00000270140.1 RP5-1021I20.6 -3.85 0.000158 0.05 -0.59 -0.25 Morning vs. evening chronotype; chr14:74008153 chr14:73905267~73905636:+ CESC cis rs72627123 0.867 rs73303107 ENSG00000270140.1 RP5-1021I20.6 -3.85 0.000158 0.05 -0.59 -0.25 Morning vs. evening chronotype; chr14:74010581 chr14:73905267~73905636:+ CESC trans rs6477998 0.58 rs2296073 ENSG00000238072.1 RP11-305M3.2 22.97 4.03e-60 1.53e-50 1.1 0.84 Hematology traits; chr9:113299348 chr7:129410113~129410370:- CESC trans rs941207 0.724 rs4788 ENSG00000121089.4 NACA3P 22.88 7.01e-60 2.19e-50 1.03 0.84 Platelet count; chr12:56712876 chr4:164943290~164943937:+ CESC trans rs6477998 0.58 rs7027833 ENSG00000238072.1 RP11-305M3.2 22.75 1.73e-59 3.65e-50 1.09 0.84 Hematology traits; chr9:113301377 chr7:129410113~129410370:- CESC trans rs6477998 0.58 rs9299214 ENSG00000238072.1 RP11-305M3.2 22.59 4.95e-59 6.55e-50 1.12 0.84 Hematology traits; chr9:113273416 chr7:129410113~129410370:- CESC trans rs6477998 0.535 rs3750535 ENSG00000238072.1 RP11-305M3.2 22.53 7.74e-59 6.55e-50 1.1 0.84 Hematology traits; chr9:113297453 chr7:129410113~129410370:- CESC trans rs7949030 0.626 rs7943191 ENSG00000186676.3 EEF1GP1 22.46 1.21e-58 8.34e-50 1.2 0.84 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561079 chr7:125033453~125035301:+ CESC trans rs7949030 0.626 rs11231144 ENSG00000186676.3 EEF1GP1 22.31 3.4e-58 1.74e-49 1.21 0.83 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62560566 chr7:125033453~125035301:+ CESC trans rs7949030 0.626 rs1061093 ENSG00000186676.3 EEF1GP1 22.04 2.19e-57 1.03e-48 1.2 0.83 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62567436 chr7:125033453~125035301:+ CESC trans rs7949030 0.626 rs11231141 ENSG00000186676.3 EEF1GP1 21.93 4.65e-57 2.09e-48 1.2 0.83 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62558793 chr7:125033453~125035301:+ CESC trans rs941207 0.756 rs2926743 ENSG00000121089.4 NACA3P 21.7 2.16e-56 9.01e-48 1.04 0.83 Platelet count; chr12:56720316 chr4:164943290~164943937:+ CESC trans rs6477998 0.603 rs10117451 ENSG00000238072.1 RP11-305M3.2 21.47 1.12e-55 3.81e-47 1.09 0.82 Hematology traits; chr9:113273610 chr7:129410113~129410370:- CESC trans rs7949030 0.626 rs71490390 ENSG00000186676.3 EEF1GP1 21.38 1.98e-55 6.32e-47 1.19 0.82 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561713 chr7:125033453~125035301:+ CESC trans rs1816752 0.905 rs7400631 ENSG00000237917.1 PARP4P1 21.36 2.38e-55 7.4e-47 0.95 0.82 Obesity-related traits; chr13:24415927 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs8002215 ENSG00000237917.1 PARP4P1 21.36 2.38e-55 7.4e-47 0.95 0.82 Obesity-related traits; chr13:24416229 chrY:26594851~26634652:- CESC trans rs941207 0.756 rs2958153 ENSG00000121089.4 NACA3P 21.3 3.52e-55 1.07e-46 1.01 0.82 Platelet count; chr12:56687733 chr4:164943290~164943937:+ CESC trans rs941207 0.724 rs1979325 ENSG00000121089.4 NACA3P 21.29 3.7e-55 1.12e-46 1.03 0.82 Platelet count; chr12:56728152 chr4:164943290~164943937:+ CESC trans rs941207 0.756 rs2958149 ENSG00000121089.4 NACA3P 21.25 5e-55 1.5e-46 1.03 0.82 Platelet count; chr12:56716008 chr4:164943290~164943937:+ CESC trans rs7949030 0.626 rs61296092 ENSG00000186676.3 EEF1GP1 21.17 8.92e-55 2.66e-46 1.19 0.82 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62553366 chr7:125033453~125035301:+ CESC trans rs941207 0.756 rs7315472 ENSG00000121089.4 NACA3P -21.14 1.05e-54 3.05e-46 -1 -0.82 Platelet count; chr12:56648276 chr4:164943290~164943937:+ CESC trans rs941207 0.756 rs67046307 ENSG00000121089.4 NACA3P -21.14 1.05e-54 3.05e-46 -1 -0.82 Platelet count; chr12:56651152 chr4:164943290~164943937:+ CESC trans rs941207 0.756 rs10876915 ENSG00000121089.4 NACA3P -21.14 1.05e-54 3.05e-46 -1 -0.82 Platelet count; chr12:56655280 chr4:164943290~164943937:+ CESC trans rs928391 0.681 rs12145743 ENSG00000227183.3 HDGFP1 21.13 1.11e-54 3.12e-46 1.18 0.82 Platelet count; chr1:156730859 chrX:131646639~131646890:+ CESC trans rs941207 0.756 rs7978685 ENSG00000121089.4 NACA3P 21.11 1.35e-54 3.77e-46 1.03 0.82 Platelet count; chr12:56709370 chr4:164943290~164943937:+ CESC trans rs7949030 0.626 rs11231145 ENSG00000186676.3 EEF1GP1 21.08 1.65e-54 4.59e-46 1.18 0.82 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561382 chr7:125033453~125035301:+ CESC trans rs7949030 0.626 rs72927213 ENSG00000186676.3 EEF1GP1 20.97 3.51e-54 9.55e-46 1.19 0.82 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62583726 chr7:125033453~125035301:+ CESC trans rs1816752 0.905 rs7995492 ENSG00000237917.1 PARP4P1 20.87 7.05e-54 1.91e-45 0.94 0.82 Obesity-related traits; chr13:24438885 chrY:26594851~26634652:- CESC trans rs7949030 0.591 rs12049914 ENSG00000186676.3 EEF1GP1 20.83 8.96e-54 2.41e-45 1.2 0.82 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62601964 chr7:125033453~125035301:+ CESC trans rs941207 0.789 rs2958145 ENSG00000121089.4 NACA3P -20.83 9.1e-54 2.43e-45 -1.01 -0.82 Platelet count; chr12:56662290 chr4:164943290~164943937:+ CESC trans rs13177918 0.677 rs3797622 ENSG00000213058.3 RP4-765C7.2 20.82 1.01e-53 2.66e-45 1.1 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:178411616~178411972:+ CESC trans rs928391 0.681 rs11264534 ENSG00000227183.3 HDGFP1 20.8 1.18e-53 3.06e-45 1.23 0.82 Platelet count; chr1:156750758 chrX:131646639~131646890:+ CESC trans rs928391 0.652 rs12030654 ENSG00000227183.3 HDGFP1 20.8 1.18e-53 3.06e-45 1.23 0.82 Platelet count; chr1:156751240 chrX:131646639~131646890:+ CESC trans rs6477998 0.58 rs3750532 ENSG00000238072.1 RP11-305M3.2 20.71 2.16e-53 5.53e-45 1.1 0.81 Hematology traits; chr9:113298207 chr7:129410113~129410370:- CESC trans rs7949030 0.626 rs7124057 ENSG00000186676.3 EEF1GP1 20.7 2.27e-53 5.74e-45 1.19 0.81 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62566624 chr7:125033453~125035301:+ CESC trans rs7949030 0.626 rs11231154 ENSG00000186676.3 EEF1GP1 20.68 2.65e-53 6.67e-45 1.19 0.81 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62594821 chr7:125033453~125035301:+ CESC trans rs13177918 0.677 rs3797622 ENSG00000239528.1 RPS14P8 20.61 4.22e-53 1.03e-44 1.11 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr5:116562562~116562930:+ CESC trans rs1816752 0.905 rs7571 ENSG00000237917.1 PARP4P1 20.59 5.14e-53 1.24e-44 0.95 0.81 Obesity-related traits; chr13:24426479 chrY:26594851~26634652:- CESC trans rs7949030 0.591 rs11231156 ENSG00000186676.3 EEF1GP1 20.58 5.21e-53 1.25e-44 1.19 0.81 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598982 chr7:125033453~125035301:+ CESC trans rs1816752 0.87 rs7320102 ENSG00000237917.1 PARP4P1 20.58 5.29e-53 1.25e-44 0.94 0.81 Obesity-related traits; chr13:24437435 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs7339140 ENSG00000237917.1 PARP4P1 20.58 5.29e-53 1.25e-44 0.94 0.81 Obesity-related traits; chr13:24437764 chrY:26594851~26634652:- CESC trans rs1816752 0.87 rs9511261 ENSG00000237917.1 PARP4P1 20.58 5.29e-53 1.25e-44 0.94 0.81 Obesity-related traits; chr13:24437880 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs9511262 ENSG00000237917.1 PARP4P1 20.58 5.29e-53 1.25e-44 0.94 0.81 Obesity-related traits; chr13:24437885 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs4770666 ENSG00000237917.1 PARP4P1 20.57 5.75e-53 1.35e-44 0.94 0.81 Obesity-related traits; chr13:24414891 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs13428 ENSG00000237917.1 PARP4P1 20.53 7.78e-53 1.77e-44 0.94 0.81 Obesity-related traits; chr13:24435303 chrY:26594851~26634652:- CESC trans rs1816752 0.875 rs1050110 ENSG00000237917.1 PARP4P1 20.53 7.78e-53 1.77e-44 0.94 0.81 Obesity-related traits; chr13:24435347 chrY:26594851~26634652:- CESC trans rs1816752 0.87 rs2033955 ENSG00000237917.1 PARP4P1 20.53 7.78e-53 1.77e-44 0.94 0.81 Obesity-related traits; chr13:24436406 chrY:26594851~26634652:- CESC trans rs1816752 0.87 rs2033954 ENSG00000237917.1 PARP4P1 20.53 7.78e-53 1.77e-44 0.94 0.81 Obesity-related traits; chr13:24436429 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs9511260 ENSG00000237917.1 PARP4P1 20.53 7.78e-53 1.77e-44 0.94 0.81 Obesity-related traits; chr13:24437038 chrY:26594851~26634652:- CESC trans rs13177918 0.677 rs3797622 ENSG00000224114.1 RP11-343H5.4 20.51 8.79e-53 1.97e-44 1.1 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:206695837~206696269:- CESC trans rs1816752 0.774 rs55888616 ENSG00000237917.1 PARP4P1 20.51 8.99e-53 2e-44 0.94 0.81 Obesity-related traits; chr13:24441954 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs9511266 ENSG00000237917.1 PARP4P1 20.48 1.08e-52 2.39e-44 0.95 0.81 Obesity-related traits; chr13:24438366 chrY:26594851~26634652:- CESC trans rs7949030 0.591 rs35156678 ENSG00000186676.3 EEF1GP1 20.47 1.16e-52 2.52e-44 1.21 0.81 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602409 chr7:125033453~125035301:+ CESC trans rs1816752 0.905 rs11839006 ENSG00000237917.1 PARP4P1 20.47 1.16e-52 2.52e-44 0.94 0.81 Obesity-related traits; chr13:24435893 chrY:26594851~26634652:- CESC trans rs1816752 0.817 rs7985394 ENSG00000237917.1 PARP4P1 20.46 1.23e-52 2.6e-44 0.94 0.81 Obesity-related traits; chr13:24438714 chrY:26594851~26634652:- CESC trans rs1816752 0.789 rs7986037 ENSG00000237917.1 PARP4P1 20.46 1.23e-52 2.6e-44 0.94 0.81 Obesity-related traits; chr13:24438715 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs7995909 ENSG00000237917.1 PARP4P1 20.46 1.23e-52 2.6e-44 0.94 0.81 Obesity-related traits; chr13:24439159 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs6490927 ENSG00000237917.1 PARP4P1 20.46 1.23e-52 2.6e-44 0.94 0.81 Obesity-related traits; chr13:24439802 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs6490928 ENSG00000237917.1 PARP4P1 20.46 1.23e-52 2.6e-44 0.94 0.81 Obesity-related traits; chr13:24439921 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs6490929 ENSG00000237917.1 PARP4P1 20.46 1.23e-52 2.6e-44 0.94 0.81 Obesity-related traits; chr13:24440114 chrY:26594851~26634652:- CESC trans rs1816752 0.87 rs3825449 ENSG00000237917.1 PARP4P1 20.43 1.56e-52 3.15e-44 0.94 0.81 Obesity-related traits; chr13:24440303 chrY:26594851~26634652:- CESC trans rs1816752 0.87 rs7998797 ENSG00000237917.1 PARP4P1 20.43 1.56e-52 3.15e-44 0.94 0.81 Obesity-related traits; chr13:24440850 chrY:26594851~26634652:- CESC trans rs1816752 0.87 rs7981337 ENSG00000237917.1 PARP4P1 20.43 1.56e-52 3.15e-44 0.94 0.81 Obesity-related traits; chr13:24440915 chrY:26594851~26634652:- CESC trans rs1816752 0.87 rs7981480 ENSG00000237917.1 PARP4P1 20.43 1.56e-52 3.15e-44 0.94 0.81 Obesity-related traits; chr13:24440966 chrY:26594851~26634652:- CESC trans rs1816752 0.837 rs4769355 ENSG00000237917.1 PARP4P1 20.43 1.56e-52 3.15e-44 0.94 0.81 Obesity-related traits; chr13:24441059 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs4770680 ENSG00000237917.1 PARP4P1 20.43 1.56e-52 3.15e-44 0.94 0.81 Obesity-related traits; chr13:24441110 chrY:26594851~26634652:- CESC trans rs6477998 0.557 rs3750534 ENSG00000238072.1 RP11-305M3.2 20.42 1.61e-52 3.25e-44 1.09 0.81 Hematology traits; chr9:113297844 chr7:129410113~129410370:- CESC trans rs1816752 0.805 rs61614647 ENSG00000237917.1 PARP4P1 20.4 1.94e-52 3.89e-44 0.94 0.81 Obesity-related traits; chr13:24441829 chrY:26594851~26634652:- CESC trans rs12291225 0.637 rs8570 ENSG00000236360.2 RP11-334A14.2 20.38 2.12e-52 4.23e-44 1.08 0.81 Sense of smell; chr11:14279213 chr1:52993201~52993702:- CESC trans rs1816752 0.905 rs1050112 ENSG00000237917.1 PARP4P1 20.37 2.36e-52 4.71e-44 0.95 0.81 Obesity-related traits; chr13:24435159 chrY:26594851~26634652:- CESC trans rs7949030 0.596 rs11231138 ENSG00000186676.3 EEF1GP1 20.36 2.53e-52 5.02e-44 1.19 0.81 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62548723 chr7:125033453~125035301:+ CESC trans rs1816752 0.905 rs9581026 ENSG00000237917.1 PARP4P1 20.33 3.08e-52 6.05e-44 0.94 0.81 Obesity-related traits; chr13:24423788 chrY:26594851~26634652:- CESC trans rs12291225 0.679 rs34238445 ENSG00000236360.2 RP11-334A14.2 20.3 3.91e-52 7.66e-44 1.09 0.81 Sense of smell; chr11:14294369 chr1:52993201~52993702:- CESC trans rs12291225 0.679 rs11238 ENSG00000236360.2 RP11-334A14.2 -20.27 4.57e-52 8.91e-44 -1.08 -0.81 Sense of smell; chr11:14266582 chr1:52993201~52993702:- CESC trans rs12291225 0.753 rs1431374 ENSG00000236360.2 RP11-334A14.2 20.27 4.85e-52 9.42e-44 1.09 0.81 Sense of smell; chr11:14282429 chr1:52993201~52993702:- CESC trans rs12291225 0.679 rs10832240 ENSG00000236360.2 RP11-334A14.2 20.24 5.93e-52 1.14e-43 1.09 0.81 Sense of smell; chr11:14283198 chr1:52993201~52993702:- CESC trans rs12291225 0.679 rs7934671 ENSG00000236360.2 RP11-334A14.2 20.24 5.93e-52 1.14e-43 1.09 0.81 Sense of smell; chr11:14283555 chr1:52993201~52993702:- CESC trans rs12291225 0.679 rs11023178 ENSG00000236360.2 RP11-334A14.2 20.24 5.93e-52 1.14e-43 1.09 0.81 Sense of smell; chr11:14288736 chr1:52993201~52993702:- CESC trans rs7949030 0.591 rs35880596 ENSG00000186676.3 EEF1GP1 20.24 6.01e-52 1.15e-43 1.2 0.81 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602412 chr7:125033453~125035301:+ CESC trans rs7949030 0.596 rs71490394 ENSG00000186676.3 EEF1GP1 20.21 7.15e-52 1.36e-43 1.2 0.81 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602683 chr7:125033453~125035301:+ CESC trans rs1816752 0.776 rs7998843 ENSG00000237917.1 PARP4P1 20.2 7.69e-52 1.46e-43 0.94 0.81 Obesity-related traits; chr13:24443147 chrY:26594851~26634652:- CESC trans rs13253073 0.723 rs4510829 ENSG00000260318.1 COX6CP1 20.19 8.02e-52 1.5e-43 1.24 0.81 Glucose homeostasis traits; chr8:99878982 chr16:11903923~11904137:- CESC trans rs13253073 0.723 rs7812991 ENSG00000260318.1 COX6CP1 20.19 8.02e-52 1.5e-43 1.24 0.81 Glucose homeostasis traits; chr8:99884095 chr16:11903923~11904137:- CESC trans rs13253073 0.723 rs12548840 ENSG00000260318.1 COX6CP1 20.19 8.02e-52 1.5e-43 1.24 0.81 Glucose homeostasis traits; chr8:99885580 chr16:11903923~11904137:- CESC trans rs1816752 0.837 rs7139748 ENSG00000237917.1 PARP4P1 20.17 9.49e-52 1.75e-43 0.95 0.81 Obesity-related traits; chr13:24411531 chrY:26594851~26634652:- CESC trans rs1816752 0.806 rs3816218 ENSG00000237917.1 PARP4P1 20.15 1.07e-51 1.97e-43 0.94 0.81 Obesity-related traits; chr13:24443033 chrY:26594851~26634652:- CESC trans rs1816752 0.666 rs7994022 ENSG00000237917.1 PARP4P1 20.15 1.07e-51 1.97e-43 0.94 0.81 Obesity-related traits; chr13:24443092 chrY:26594851~26634652:- CESC trans rs1816752 0.712 rs6490932 ENSG00000237917.1 PARP4P1 20.14 1.19e-51 2.13e-43 0.94 0.81 Obesity-related traits; chr13:24443313 chrY:26594851~26634652:- CESC trans rs1816752 0.713 rs7336357 ENSG00000237917.1 PARP4P1 20.14 1.19e-51 2.13e-43 0.94 0.81 Obesity-related traits; chr13:24443452 chrY:26594851~26634652:- CESC trans rs1816752 0.683 rs7330532 ENSG00000237917.1 PARP4P1 20.14 1.19e-51 2.13e-43 0.94 0.81 Obesity-related traits; chr13:24443453 chrY:26594851~26634652:- CESC trans rs1816752 0.59 rs61947036 ENSG00000237917.1 PARP4P1 20.14 1.19e-51 2.13e-43 0.94 0.81 Obesity-related traits; chr13:24443544 chrY:26594851~26634652:- CESC trans rs1816752 0.746 rs9511270 ENSG00000237917.1 PARP4P1 20.14 1.19e-51 2.13e-43 0.94 0.81 Obesity-related traits; chr13:24444542 chrY:26594851~26634652:- CESC trans rs6477998 0.58 rs3750533 ENSG00000238072.1 RP11-305M3.2 20.12 1.33e-51 2.36e-43 1.09 0.81 Hematology traits; chr9:113297941 chr7:129410113~129410370:- CESC trans rs928391 0.681 rs12161427 ENSG00000227183.3 HDGFP1 20.12 1.35e-51 2.37e-43 1.18 0.81 Platelet count; chr1:156736030 chrX:131646639~131646890:+ CESC trans rs13253073 0.723 rs4626565 ENSG00000260318.1 COX6CP1 20.12 1.36e-51 2.37e-43 1.24 0.81 Glucose homeostasis traits; chr8:99878314 chr16:11903923~11904137:- CESC trans rs13253073 0.723 rs7828241 ENSG00000260318.1 COX6CP1 20.12 1.36e-51 2.37e-43 1.24 0.81 Glucose homeostasis traits; chr8:99880417 chr16:11903923~11904137:- CESC trans rs1816752 0.905 rs7317850 ENSG00000237917.1 PARP4P1 20.11 1.47e-51 2.55e-43 0.94 0.81 Obesity-related traits; chr13:24419899 chrY:26594851~26634652:- CESC trans rs7949030 0.59 rs12225213 ENSG00000186676.3 EEF1GP1 20.07 1.96e-51 3.38e-43 1.19 0.81 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62582776 chr7:125033453~125035301:+ CESC trans rs12291225 0.679 rs11605531 ENSG00000236360.2 RP11-334A14.2 20.06 2.06e-51 3.54e-43 1.08 0.81 Sense of smell; chr11:14270048 chr1:52993201~52993702:- CESC trans rs12291225 0.639 rs61883858 ENSG00000236360.2 RP11-334A14.2 20.06 2.06e-51 3.54e-43 1.08 0.81 Sense of smell; chr11:14273162 chr1:52993201~52993702:- CESC trans rs13177918 0.559 rs10447224 ENSG00000213058.3 RP4-765C7.2 20.02 2.68e-51 4.55e-43 1.05 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:178411616~178411972:+ CESC trans rs13177918 0.559 rs10447225 ENSG00000213058.3 RP4-765C7.2 20.02 2.68e-51 4.55e-43 1.05 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:178411616~178411972:+ CESC trans rs12291225 0.679 rs4757245 ENSG00000236360.2 RP11-334A14.2 20.02 2.69e-51 4.57e-43 1.08 0.8 Sense of smell; chr11:14276326 chr1:52993201~52993702:- CESC trans rs1816752 0.87 rs8000215 ENSG00000237917.1 PARP4P1 19.99 3.31e-51 5.57e-43 0.94 0.8 Obesity-related traits; chr13:24435648 chrY:26594851~26634652:- CESC trans rs928391 0.681 rs11264535 ENSG00000227183.3 HDGFP1 19.99 3.43e-51 5.73e-43 1.2 0.8 Platelet count; chr1:156752632 chrX:131646639~131646890:+ CESC trans rs12291225 0.679 rs11369 ENSG00000236360.2 RP11-334A14.2 19.95 4.37e-51 7.29e-43 1.07 0.8 Sense of smell; chr11:14266550 chr1:52993201~52993702:- CESC trans rs1816752 0.638 rs9578730 ENSG00000237917.1 PARP4P1 19.94 4.85e-51 8.03e-43 0.94 0.8 Obesity-related traits; chr13:24425545 chrY:26594851~26634652:- CESC trans rs13253073 0.723 rs7844439 ENSG00000260318.1 COX6CP1 19.93 5.27e-51 8.71e-43 1.24 0.8 Glucose homeostasis traits; chr8:99878567 chr16:11903923~11904137:- CESC trans rs941207 0.756 rs2950394 ENSG00000121089.4 NACA3P -19.93 5.34e-51 8.8e-43 -0.99 -0.8 Platelet count; chr12:56644548 chr4:164943290~164943937:+ CESC trans rs13253073 0.723 rs1135382 ENSG00000260318.1 COX6CP1 19.92 5.41e-51 8.82e-43 1.24 0.8 Glucose homeostasis traits; chr8:99879402 chr16:11903923~11904137:- CESC trans rs1816752 0.719 rs11841989 ENSG00000237917.1 PARP4P1 19.92 5.42e-51 8.82e-43 0.94 0.8 Obesity-related traits; chr13:24423560 chrY:26594851~26634652:- CESC trans rs13253073 0.723 rs35429753 ENSG00000260318.1 COX6CP1 19.92 5.57e-51 8.89e-43 1.26 0.8 Glucose homeostasis traits; chr8:99891015 chr16:11903923~11904137:- CESC trans rs13253073 0.723 rs1130474 ENSG00000260318.1 COX6CP1 19.92 5.57e-51 8.89e-43 1.26 0.8 Glucose homeostasis traits; chr8:99892049 chr16:11903923~11904137:- CESC trans rs928391 0.681 rs11264533 ENSG00000227183.3 HDGFP1 19.91 5.87e-51 9.36e-43 1.19 0.8 Platelet count; chr1:156748656 chrX:131646639~131646890:+ CESC trans rs941207 0.756 rs1465081 ENSG00000121089.4 NACA3P -19.9 6.26e-51 9.89e-43 -1.01 -0.8 Platelet count; chr12:56656390 chr4:164943290~164943937:+ CESC trans rs12291225 0.679 rs11023170 ENSG00000236360.2 RP11-334A14.2 19.87 7.66e-51 1.2e-42 1.07 0.8 Sense of smell; chr11:14273363 chr1:52993201~52993702:- CESC trans rs12291225 0.679 rs11023172 ENSG00000236360.2 RP11-334A14.2 19.87 7.66e-51 1.2e-42 1.07 0.8 Sense of smell; chr11:14273821 chr1:52993201~52993702:- CESC trans rs13177918 0.559 rs12109637 ENSG00000213058.3 RP4-765C7.2 19.86 8.68e-51 1.36e-42 1.04 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr1:178411616~178411972:+ CESC trans rs13253073 0.723 rs7813557 ENSG00000260318.1 COX6CP1 19.86 8.76e-51 1.37e-42 1.24 0.8 Glucose homeostasis traits; chr8:99878665 chr16:11903923~11904137:- CESC trans rs13253073 0.76 rs62534633 ENSG00000260318.1 COX6CP1 19.84 9.91e-51 1.54e-42 1.26 0.8 Glucose homeostasis traits; chr8:99884533 chr16:11903923~11904137:- CESC trans rs12291225 0.679 rs4756786 ENSG00000236360.2 RP11-334A14.2 19.84 9.98e-51 1.54e-42 1.08 0.8 Sense of smell; chr11:14264354 chr1:52993201~52993702:- CESC trans rs1816752 0.837 rs7324645 ENSG00000237917.1 PARP4P1 19.78 1.47e-50 2.26e-42 0.94 0.8 Obesity-related traits; chr13:24426717 chrY:26594851~26634652:- CESC trans rs7949030 0.626 rs7930896 ENSG00000186676.3 EEF1GP1 19.75 1.85e-50 2.81e-42 1.16 0.8 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62557800 chr7:125033453~125035301:+ CESC trans rs6477998 0.58 rs10981715 ENSG00000238072.1 RP11-305M3.2 19.74 1.94e-50 2.94e-42 1.08 0.8 Hematology traits; chr9:113287218 chr7:129410113~129410370:- CESC trans rs13177918 0.677 rs13161417 ENSG00000213058.3 RP4-765C7.2 19.69 2.8e-50 4.1e-42 1.06 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs13161156 ENSG00000213058.3 RP4-765C7.2 19.69 2.8e-50 4.1e-42 1.06 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs13181401 ENSG00000213058.3 RP4-765C7.2 19.69 2.8e-50 4.1e-42 1.06 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs4541646 ENSG00000213058.3 RP4-765C7.2 19.69 2.8e-50 4.1e-42 1.06 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs3900644 ENSG00000213058.3 RP4-765C7.2 19.69 2.8e-50 4.1e-42 1.06 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs2070844 ENSG00000213058.3 RP4-765C7.2 19.69 2.8e-50 4.1e-42 1.06 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs2073472 ENSG00000213058.3 RP4-765C7.2 19.69 2.8e-50 4.1e-42 1.06 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:178411616~178411972:+ CESC trans rs13177918 0.629 rs2070842 ENSG00000213058.3 RP4-765C7.2 19.69 2.8e-50 4.1e-42 1.06 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs13171800 ENSG00000213058.3 RP4-765C7.2 19.69 2.87e-50 4.15e-42 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs2070841 ENSG00000213058.3 RP4-765C7.2 19.69 2.87e-50 4.15e-42 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs13177951 ENSG00000213058.3 RP4-765C7.2 19.69 2.87e-50 4.15e-42 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs13177970 ENSG00000213058.3 RP4-765C7.2 19.69 2.87e-50 4.15e-42 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:178411616~178411972:+ CESC trans rs1816752 0.905 rs7991450 ENSG00000237917.1 PARP4P1 19.68 2.96e-50 4.2e-42 0.94 0.8 Obesity-related traits; chr13:24425898 chrY:26594851~26634652:- CESC trans rs1816752 0.774 rs7986162 ENSG00000237917.1 PARP4P1 19.68 2.96e-50 4.2e-42 0.94 0.8 Obesity-related traits; chr13:24425941 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs4769352 ENSG00000237917.1 PARP4P1 19.68 2.96e-50 4.2e-42 0.94 0.8 Obesity-related traits; chr13:24426237 chrY:26594851~26634652:- CESC trans rs1816752 0.805 rs4769353 ENSG00000237917.1 PARP4P1 19.68 2.96e-50 4.2e-42 0.94 0.8 Obesity-related traits; chr13:24426318 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs9511264 ENSG00000237917.1 PARP4P1 -19.64 4.12e-50 5.8e-42 -0.94 -0.8 Obesity-related traits; chr13:24438079 chrY:26594851~26634652:- CESC trans rs941207 0.756 rs2950388 ENSG00000121089.4 NACA3P -19.64 4.12e-50 5.8e-42 -0.98 -0.8 Platelet count; chr12:56639569 chr4:164943290~164943937:+ CESC trans rs1816752 0.905 rs9511242 ENSG00000237917.1 PARP4P1 19.63 4.37e-50 6.13e-42 0.93 0.8 Obesity-related traits; chr13:24419261 chrY:26594851~26634652:- CESC trans rs13253073 0.723 rs7157 ENSG00000260318.1 COX6CP1 19.62 4.76e-50 6.66e-42 1.26 0.8 Glucose homeostasis traits; chr8:99877449 chr16:11903923~11904137:- CESC trans rs13177918 0.686 rs12654827 ENSG00000213058.3 RP4-765C7.2 19.59 5.8e-50 8.01e-42 1.07 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs13160685 ENSG00000213058.3 RP4-765C7.2 19.59 5.8e-50 8.01e-42 1.07 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:178411616~178411972:+ CESC trans rs1816752 0.87 rs9581025 ENSG00000237917.1 PARP4P1 19.59 5.8e-50 8.01e-42 0.95 0.8 Obesity-related traits; chr13:24423687 chrY:26594851~26634652:- CESC trans rs1816752 0.87 rs9581027 ENSG00000237917.1 PARP4P1 19.59 5.8e-50 8.01e-42 0.95 0.8 Obesity-related traits; chr13:24423790 chrY:26594851~26634652:- CESC trans rs12291225 0.645 rs3763950 ENSG00000236360.2 RP11-334A14.2 19.56 7.29e-50 1e-41 1.08 0.8 Sense of smell; chr11:14256503 chr1:52993201~52993702:- CESC trans rs13177918 0.677 rs13171800 ENSG00000239528.1 RPS14P8 19.53 8.89e-50 1.21e-41 1.09 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs2070841 ENSG00000239528.1 RPS14P8 19.53 8.89e-50 1.21e-41 1.09 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs13177951 ENSG00000239528.1 RPS14P8 19.53 8.89e-50 1.21e-41 1.09 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs13177970 ENSG00000239528.1 RPS14P8 19.53 8.89e-50 1.21e-41 1.09 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr5:116562562~116562930:+ CESC trans rs1816752 0.87 rs9318529 ENSG00000237917.1 PARP4P1 19.52 9.27e-50 1.25e-41 0.94 0.8 Obesity-related traits; chr13:24424190 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs9511249 ENSG00000237917.1 PARP4P1 19.5 1.12e-49 1.47e-41 0.94 0.8 Obesity-related traits; chr13:24425457 chrY:26594851~26634652:- CESC trans rs13177918 0.677 rs13161417 ENSG00000239528.1 RPS14P8 19.5 1.13e-49 1.47e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs13161156 ENSG00000239528.1 RPS14P8 19.5 1.13e-49 1.47e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs13181401 ENSG00000239528.1 RPS14P8 19.5 1.13e-49 1.47e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs4541646 ENSG00000239528.1 RPS14P8 19.5 1.13e-49 1.47e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs3900644 ENSG00000239528.1 RPS14P8 19.5 1.13e-49 1.47e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs2070844 ENSG00000239528.1 RPS14P8 19.5 1.13e-49 1.47e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs2073472 ENSG00000239528.1 RPS14P8 19.5 1.13e-49 1.47e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr5:116562562~116562930:+ CESC trans rs13177918 0.629 rs2070842 ENSG00000239528.1 RPS14P8 19.5 1.13e-49 1.47e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs13164105 ENSG00000213058.3 RP4-765C7.2 19.49 1.17e-49 1.53e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:178411616~178411972:+ CESC trans rs928391 0.681 rs3806417 ENSG00000227183.3 HDGFP1 19.45 1.57e-49 2.03e-41 1.17 0.8 Platelet count; chr1:156741831 chrX:131646639~131646890:+ CESC trans rs928391 0.624 rs4399146 ENSG00000227183.3 HDGFP1 19.45 1.57e-49 2.03e-41 1.17 0.8 Platelet count; chr1:156743766 chrX:131646639~131646890:+ CESC trans rs13253073 0.723 rs12548542 ENSG00000260318.1 COX6CP1 19.44 1.68e-49 2.16e-41 1.28 0.8 Glucose homeostasis traits; chr8:99890167 chr16:11903923~11904137:- CESC trans rs941207 0.756 rs7313074 ENSG00000121089.4 NACA3P -19.43 1.81e-49 2.33e-41 -0.99 -0.8 Platelet count; chr12:56760705 chr4:164943290~164943937:+ CESC trans rs13177918 0.677 rs13164105 ENSG00000239528.1 RPS14P8 19.42 1.95e-49 2.5e-41 1.09 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr5:116562562~116562930:+ CESC trans rs13177918 0.686 rs12654827 ENSG00000239528.1 RPS14P8 19.42 2e-49 2.54e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs13160685 ENSG00000239528.1 RPS14P8 19.42 2e-49 2.54e-41 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr5:116562562~116562930:+ CESC trans rs6477998 0.58 rs11552582 ENSG00000238072.1 RP11-305M3.2 19.39 2.46e-49 3.12e-41 1.07 0.8 Hematology traits; chr9:113282718 chr7:129410113~129410370:- CESC trans rs13177918 0.677 rs13161099 ENSG00000213058.3 RP4-765C7.2 19.35 3.14e-49 3.96e-41 1.07 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:178411616~178411972:+ CESC trans rs13177918 0.629 rs13161261 ENSG00000213058.3 RP4-765C7.2 19.35 3.14e-49 3.96e-41 1.07 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs57890152 ENSG00000213058.3 RP4-765C7.2 19.25 6.55e-49 8.21e-41 1.07 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:178411616~178411972:+ CESC trans rs13177918 0.626 rs3819332 ENSG00000213058.3 RP4-765C7.2 19.23 7.76e-49 9.66e-41 1.06 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:178411616~178411972:+ CESC trans rs13177918 0.626 rs13170300 ENSG00000213058.3 RP4-765C7.2 19.23 7.76e-49 9.66e-41 1.06 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:178411616~178411972:+ CESC trans rs13177918 0.677 rs13161099 ENSG00000239528.1 RPS14P8 19.19 9.94e-49 1.23e-40 1.08 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr5:116562562~116562930:+ CESC trans rs13177918 0.629 rs13161261 ENSG00000239528.1 RPS14P8 19.19 9.94e-49 1.23e-40 1.08 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr5:116562562~116562930:+ CESC trans rs1816752 0.87 rs73469543 ENSG00000237917.1 PARP4P1 19.18 1.11e-48 1.37e-40 0.94 0.79 Obesity-related traits; chr13:24424832 chrY:26594851~26634652:- CESC trans rs13177918 0.677 rs57890152 ENSG00000239528.1 RPS14P8 19.12 1.67e-48 2.05e-40 1.08 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr5:116562562~116562930:+ CESC trans rs13177918 0.677 rs13171800 ENSG00000224114.1 RP11-343H5.4 19.1 1.86e-48 2.25e-40 1.07 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs2070841 ENSG00000224114.1 RP11-343H5.4 19.1 1.86e-48 2.25e-40 1.07 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs13177951 ENSG00000224114.1 RP11-343H5.4 19.1 1.86e-48 2.25e-40 1.07 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs13177970 ENSG00000224114.1 RP11-343H5.4 19.1 1.86e-48 2.25e-40 1.07 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs13164105 ENSG00000224114.1 RP11-343H5.4 18.96 5.07e-48 6.07e-40 1.07 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:206695837~206696269:- CESC trans rs13253073 0.723 rs1130569 ENSG00000260318.1 COX6CP1 18.94 6.1e-48 7.28e-40 1.2 0.79 Glucose homeostasis traits; chr8:99887565 chr16:11903923~11904137:- CESC trans rs6477998 0.58 rs10759638 ENSG00000238072.1 RP11-305M3.2 -18.92 6.99e-48 8.31e-40 -1.05 -0.79 Hematology traits; chr9:113280212 chr7:129410113~129410370:- CESC trans rs13253073 0.657 rs35135010 ENSG00000260318.1 COX6CP1 18.91 7.71e-48 9.15e-40 1.23 0.79 Glucose homeostasis traits; chr8:99864209 chr16:11903923~11904137:- CESC trans rs1816752 0.87 rs9581029 ENSG00000237917.1 PARP4P1 18.85 1.12e-47 1.32e-39 0.93 0.79 Obesity-related traits; chr13:24425147 chrY:26594851~26634652:- CESC trans rs928391 0.681 rs4501833 ENSG00000227183.3 HDGFP1 18.85 1.13e-47 1.33e-39 1.16 0.79 Platelet count; chr1:156746806 chrX:131646639~131646890:+ CESC trans rs1816752 0.905 rs2000153 ENSG00000237917.1 PARP4P1 18.76 2.19e-47 2.56e-39 0.92 0.79 Obesity-related traits; chr13:24405752 chrY:26594851~26634652:- CESC trans rs1816752 0.905 rs1348110 ENSG00000237917.1 PARP4P1 18.76 2.19e-47 2.56e-39 0.92 0.79 Obesity-related traits; chr13:24406537 chrY:26594851~26634652:- CESC trans rs13253073 0.723 rs12546882 ENSG00000260318.1 COX6CP1 18.7 3.27e-47 3.8e-39 1.23 0.78 Glucose homeostasis traits; chr8:99869919 chr16:11903923~11904137:- CESC trans rs13177918 0.677 rs3857421 ENSG00000213058.3 RP4-765C7.2 -18.69 3.61e-47 4.19e-39 -1.06 -0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:178411616~178411972:+ CESC trans rs1816752 0.905 rs8002309 ENSG00000237917.1 PARP4P1 18.66 4.36e-47 5.02e-39 0.94 0.78 Obesity-related traits; chr13:24402217 chrY:26594851~26634652:- CESC trans rs13177918 0.677 rs13161417 ENSG00000224114.1 RP11-343H5.4 18.64 5.07e-47 5.66e-39 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs13161156 ENSG00000224114.1 RP11-343H5.4 18.64 5.07e-47 5.66e-39 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs13181401 ENSG00000224114.1 RP11-343H5.4 18.64 5.07e-47 5.66e-39 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs4541646 ENSG00000224114.1 RP11-343H5.4 18.64 5.07e-47 5.66e-39 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs3900644 ENSG00000224114.1 RP11-343H5.4 18.64 5.07e-47 5.66e-39 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs2070844 ENSG00000224114.1 RP11-343H5.4 18.64 5.07e-47 5.66e-39 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs2073472 ENSG00000224114.1 RP11-343H5.4 18.64 5.07e-47 5.66e-39 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:206695837~206696269:- CESC trans rs13177918 0.629 rs2070842 ENSG00000224114.1 RP11-343H5.4 18.64 5.07e-47 5.66e-39 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:206695837~206696269:- CESC trans rs1816752 1 rs7326932 ENSG00000237917.1 PARP4P1 18.61 6.4e-47 7.13e-39 0.92 0.78 Obesity-related traits; chr13:24430355 chrY:26594851~26634652:- CESC trans rs6477998 0.58 rs4979231 ENSG00000238072.1 RP11-305M3.2 18.6 6.91e-47 7.68e-39 1.07 0.78 Hematology traits; chr9:113286475 chr7:129410113~129410370:- CESC trans rs13177918 0.686 rs12654827 ENSG00000224114.1 RP11-343H5.4 18.55 1e-46 1.11e-38 1.05 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:206695837~206696269:- CESC trans rs13177918 0.677 rs13160685 ENSG00000224114.1 RP11-343H5.4 18.55 1e-46 1.11e-38 1.05 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:206695837~206696269:- CESC trans rs1816752 0.633 rs9578729 ENSG00000237917.1 PARP4P1 18.51 1.3e-46 1.42e-38 0.93 0.78 Obesity-related traits; chr13:24425106 chrY:26594851~26634652:- CESC trans rs941207 0.756 rs9634246 ENSG00000121089.4 NACA3P -18.5 1.48e-46 1.62e-38 -0.98 -0.78 Platelet count; chr12:56640604 chr4:164943290~164943937:+ CESC trans rs13253073 0.723 rs34830464 ENSG00000260318.1 COX6CP1 18.46 1.93e-46 2.1e-38 1.21 0.78 Glucose homeostasis traits; chr8:99866638 chr16:11903923~11904137:- CESC trans rs13177918 0.677 rs3857421 ENSG00000239528.1 RPS14P8 -18.45 2.05e-46 2.23e-38 -1.06 -0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr5:116562562~116562930:+ CESC trans rs6477998 0.58 rs4979233 ENSG00000238072.1 RP11-305M3.2 18.44 2.14e-46 2.31e-38 1.08 0.78 Hematology traits; chr9:113295501 chr7:129410113~129410370:- CESC trans rs13177918 0.557 rs12520101 ENSG00000213058.3 RP4-765C7.2 18.41 2.69e-46 2.9e-38 1.05 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:178411616~178411972:+ CESC trans rs1816752 0.819 rs4770665 ENSG00000237917.1 PARP4P1 18.38 3.34e-46 3.57e-38 0.89 0.78 Obesity-related traits; chr13:24414810 chrY:26594851~26634652:- CESC trans rs1816752 0.749 rs77832754 ENSG00000237917.1 PARP4P1 18.38 3.34e-46 3.57e-38 0.89 0.78 Obesity-related traits; chr13:24416016 chrY:26594851~26634652:- CESC trans rs1816752 0.633 rs8002387 ENSG00000237917.1 PARP4P1 18.38 3.34e-46 3.57e-38 0.89 0.78 Obesity-related traits; chr13:24416306 chrY:26594851~26634652:- CESC trans rs13177918 0.677 rs13161099 ENSG00000224114.1 RP11-343H5.4 18.36 3.83e-46 4.08e-38 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:206695837~206696269:- CESC trans rs13177918 0.629 rs13161261 ENSG00000224114.1 RP11-343H5.4 18.36 3.83e-46 4.08e-38 1.04 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:206695837~206696269:- CESC trans rs13177918 0.626 rs12186649 ENSG00000213058.3 RP4-765C7.2 18.35 4.34e-46 4.61e-38 1.1 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr1:178411616~178411972:+ CESC trans rs941207 0.855 rs2256341 ENSG00000121089.4 NACA3P -18.34 4.71e-46 4.97e-38 -1.03 -0.78 Platelet count; chr12:56599930 chr4:164943290~164943937:+ CESC trans rs941207 0.805 rs2958139 ENSG00000121089.4 NACA3P -18.34 4.71e-46 4.97e-38 -1.03 -0.78 Platelet count; chr12:56610884 chr4:164943290~164943937:+ CESC trans rs1816752 1 rs9507341 ENSG00000237917.1 PARP4P1 -18.33 4.85e-46 5.1e-38 -0.92 -0.78 Obesity-related traits; chr13:24432440 chrY:26594851~26634652:- CESC trans rs6477998 0.557 rs11789755 ENSG00000238072.1 RP11-305M3.2 18.32 5.19e-46 5.45e-38 1.08 0.78 Hematology traits; chr9:113292796 chr7:129410113~129410370:- CESC trans rs1816752 0.935 rs4770676 ENSG00000237917.1 PARP4P1 18.28 7.08e-46 7.38e-38 0.92 0.78 Obesity-related traits; chr13:24429745 chrY:26594851~26634652:- CESC trans rs13177918 0.677 rs57890152 ENSG00000224114.1 RP11-343H5.4 18.22 1.11e-45 1.15e-37 1.05 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:206695837~206696269:- CESC trans rs13177918 0.651 rs13184111 ENSG00000213058.3 RP4-765C7.2 18.19 1.39e-45 1.44e-37 1.09 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr1:178411616~178411972:+ CESC trans rs13253073 0.723 rs7840626 ENSG00000260318.1 COX6CP1 18.13 2.06e-45 2.12e-37 1.24 0.78 Glucose homeostasis traits; chr8:99867598 chr16:11903923~11904137:- CESC trans rs1816752 0.783 rs7317439 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24410939 chrY:26594851~26634652:- CESC trans rs1816752 0.819 rs7317504 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24411287 chrY:26594851~26634652:- CESC trans rs1816752 0.783 rs7317712 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24411365 chrY:26594851~26634652:- CESC trans rs1816752 0.783 rs7139527 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24411374 chrY:26594851~26634652:- CESC trans rs1816752 0.819 rs9511240 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24411768 chrY:26594851~26634652:- CESC trans rs1816752 0.819 rs7988388 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24412675 chrY:26594851~26634652:- CESC trans rs1816752 0.875 rs7993132 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24412903 chrY:26594851~26634652:- CESC trans rs1816752 0.792 rs7330956 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24413174 chrY:26594851~26634652:- CESC trans rs1816752 0.777 rs6490915 ENSG00000237917.1 PARP4P1 18.11 2.37e-45 2.38e-37 0.91 0.78 Obesity-related traits; chr13:24413724 chrY:26594851~26634652:- CESC trans rs13177918 0.677 rs3857421 ENSG00000224114.1 RP11-343H5.4 -18.09 2.84e-45 2.84e-37 -1.04 -0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:206695837~206696269:- CESC trans rs941207 1 rs941207 ENSG00000121089.4 NACA3P -18.04 4.1e-45 4.08e-37 -1.02 -0.77 Platelet count; chr12:56629500 chr4:164943290~164943937:+ CESC trans rs1816752 0.819 rs4770664 ENSG00000237917.1 PARP4P1 18.03 4.33e-45 4.3e-37 0.91 0.77 Obesity-related traits; chr13:24414695 chrY:26594851~26634652:- CESC trans rs1816752 0.819 rs7400583 ENSG00000237917.1 PARP4P1 18.03 4.39e-45 4.35e-37 0.87 0.77 Obesity-related traits; chr13:24415916 chrY:26594851~26634652:- CESC trans rs1816752 0.819 rs7985478 ENSG00000237917.1 PARP4P1 18.03 4.42e-45 4.36e-37 0.89 0.77 Obesity-related traits; chr13:24417135 chrY:26594851~26634652:- CESC trans rs13177918 0.557 rs12520101 ENSG00000239528.1 RPS14P8 17.88 1.24e-44 1.21e-36 1.05 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr5:116562562~116562930:+ CESC trans rs1816752 1 rs9511265 ENSG00000237917.1 PARP4P1 17.84 1.72e-44 1.67e-36 0.91 0.77 Obesity-related traits; chr13:24438221 chrY:26594851~26634652:- CESC trans rs1816752 1 rs7999554 ENSG00000237917.1 PARP4P1 17.82 2e-44 1.93e-36 0.9 0.77 Obesity-related traits; chr13:24435631 chrY:26594851~26634652:- CESC trans rs7949030 0.688 rs11231155 ENSG00000186676.3 EEF1GP1 17.81 2.17e-44 2.09e-36 1.11 0.77 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598147 chr7:125033453~125035301:+ CESC trans rs13177918 0.626 rs12186649 ENSG00000239528.1 RPS14P8 17.79 2.41e-44 2.32e-36 1.1 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr5:116562562~116562930:+ CESC trans rs13253073 0.723 rs7009713 ENSG00000260318.1 COX6CP1 17.69 5.25e-44 5.01e-36 1.18 0.77 Glucose homeostasis traits; chr8:99869626 chr16:11903923~11904137:- CESC trans rs13177918 0.651 rs13184111 ENSG00000239528.1 RPS14P8 17.67 5.84e-44 5.56e-36 1.1 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr5:116562562~116562930:+ CESC trans rs13253073 0.723 rs6468695 ENSG00000260318.1 COX6CP1 17.64 7.21e-44 6.83e-36 1.23 0.77 Glucose homeostasis traits; chr8:99857123 chr16:11903923~11904137:- CESC trans rs13253073 0.723 rs6468696 ENSG00000260318.1 COX6CP1 17.64 7.21e-44 6.83e-36 1.23 0.77 Glucose homeostasis traits; chr8:99857130 chr16:11903923~11904137:- CESC trans rs1816752 0.721 rs7399656 ENSG00000237917.1 PARP4P1 17.61 9.08e-44 8.58e-36 0.89 0.77 Obesity-related traits; chr13:24415708 chrY:26594851~26634652:- CESC trans rs1816752 0.712 rs2862898 ENSG00000237917.1 PARP4P1 17.56 1.28e-43 1.2e-35 0.91 0.77 Obesity-related traits; chr13:24414323 chrY:26594851~26634652:- CESC trans rs1816752 0.652 rs2902356 ENSG00000237917.1 PARP4P1 17.56 1.28e-43 1.2e-35 0.91 0.77 Obesity-related traits; chr13:24414333 chrY:26594851~26634652:- CESC trans rs13253073 0.723 rs12548344 ENSG00000260318.1 COX6CP1 17.49 2.23e-43 2.07e-35 1.19 0.76 Glucose homeostasis traits; chr8:99868676 chr16:11903923~11904137:- CESC trans rs1816752 1 rs7988810 ENSG00000237917.1 PARP4P1 17.44 3.24e-43 2.99e-35 0.91 0.76 Obesity-related traits; chr13:24444958 chrY:26594851~26634652:- CESC trans rs1816752 0.935 rs3816219 ENSG00000237917.1 PARP4P1 17.43 3.29e-43 3.03e-35 0.91 0.76 Obesity-related traits; chr13:24442995 chrY:26594851~26634652:- CESC trans rs13253073 0.723 rs62534626 ENSG00000260318.1 COX6CP1 17.38 4.85e-43 4.46e-35 1.26 0.76 Glucose homeostasis traits; chr8:99866119 chr16:11903923~11904137:- CESC trans rs13177918 0.626 rs3819332 ENSG00000224114.1 RP11-343H5.4 17.38 4.91e-43 4.5e-35 1.02 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:206695837~206696269:- CESC trans rs13177918 0.626 rs13170300 ENSG00000224114.1 RP11-343H5.4 17.38 4.91e-43 4.5e-35 1.02 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:206695837~206696269:- CESC trans rs1816752 0.819 rs6490917 ENSG00000237917.1 PARP4P1 17.35 6.32e-43 5.78e-35 0.9 0.76 Obesity-related traits; chr13:24423119 chrY:26594851~26634652:- CESC trans rs1816752 0.819 rs7316961 ENSG00000237917.1 PARP4P1 17.3 8.56e-43 7.82e-35 0.9 0.76 Obesity-related traits; chr13:24411039 chrY:26594851~26634652:- CESC trans rs6477998 0.58 rs12343629 ENSG00000238072.1 RP11-305M3.2 17.3 8.68e-43 7.91e-35 1.07 0.76 Hematology traits; chr9:113279301 chr7:129410113~129410370:- CESC trans rs13253073 0.723 rs7831963 ENSG00000260318.1 COX6CP1 17.29 9.59e-43 8.69e-35 1.22 0.76 Glucose homeostasis traits; chr8:99853014 chr16:11903923~11904137:- CESC trans rs13253073 0.723 rs7832488 ENSG00000260318.1 COX6CP1 17.29 9.59e-43 8.69e-35 1.22 0.76 Glucose homeostasis traits; chr8:99853185 chr16:11903923~11904137:- CESC trans rs7949030 0.653 rs17773169 ENSG00000186676.3 EEF1GP1 17.18 2.06e-42 1.85e-34 1.07 0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62551058 chr7:125033453~125035301:+ CESC trans rs8010715 0.816 rs6573573 ENSG00000248988.1 RP11-815N9.2 17.18 2.11e-42 1.89e-34 0.89 0.76 IgG glycosylation; chr14:24130048 chr4:159007119~159007835:+ CESC trans rs13253073 0.662 rs4434590 ENSG00000260318.1 COX6CP1 17.17 2.2e-42 1.96e-34 1.2 0.76 Glucose homeostasis traits; chr8:99848429 chr16:11903923~11904137:- CESC trans rs12291225 0.585 rs34171876 ENSG00000236360.2 RP11-334A14.2 17.14 2.9e-42 2.59e-34 1 0.76 Sense of smell; chr11:14332411 chr1:52993201~52993702:- CESC trans rs1816752 0.819 rs1981276 ENSG00000237917.1 PARP4P1 17.12 3.2e-42 2.83e-34 0.89 0.76 Obesity-related traits; chr13:24409361 chrY:26594851~26634652:- CESC trans rs1816752 0.837 rs57052031 ENSG00000237917.1 PARP4P1 17.12 3.2e-42 2.83e-34 0.89 0.76 Obesity-related traits; chr13:24409730 chrY:26594851~26634652:- CESC trans rs8010715 0.816 rs1134340 ENSG00000248988.1 RP11-815N9.2 17.12 3.29e-42 2.9e-34 0.89 0.76 IgG glycosylation; chr14:24125004 chr4:159007119~159007835:+ CESC trans rs13177918 0.559 rs10447224 ENSG00000239528.1 RPS14P8 17.12 3.37e-42 2.96e-34 1 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr5:116562562~116562930:+ CESC trans rs13177918 0.559 rs10447225 ENSG00000239528.1 RPS14P8 17.12 3.37e-42 2.96e-34 1 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr5:116562562~116562930:+ CESC trans rs7949030 0.62 rs2428551 ENSG00000186676.3 EEF1GP1 17.1 3.77e-42 3.3e-34 1.07 0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62562286 chr7:125033453~125035301:+ CESC trans rs12291225 0.679 rs1043237 ENSG00000236360.2 RP11-334A14.2 17.09 4.02e-42 3.52e-34 0.98 0.76 Sense of smell; chr11:14267507 chr1:52993201~52993702:- CESC trans rs13177918 0.559 rs12109637 ENSG00000239528.1 RPS14P8 17.08 4.39e-42 3.83e-34 0.99 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr5:116562562~116562930:+ CESC trans rs1816752 0.837 rs9318530 ENSG00000237917.1 PARP4P1 -17.06 5.2e-42 4.53e-34 -0.87 -0.76 Obesity-related traits; chr13:24424419 chrY:26594851~26634652:- CESC trans rs13177918 0.626 rs3819332 ENSG00000239528.1 RPS14P8 17.03 6.24e-42 5.41e-34 1.03 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr5:116562562~116562930:+ CESC trans rs13177918 0.626 rs13170300 ENSG00000239528.1 RPS14P8 17.03 6.24e-42 5.41e-34 1.03 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr5:116562562~116562930:+ CESC trans rs13177918 0.559 rs12109637 ENSG00000224114.1 RP11-343H5.4 17.03 6.5e-42 5.61e-34 0.98 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr1:206695837~206696269:- CESC trans rs13253073 0.662 rs34513504 ENSG00000260318.1 COX6CP1 17.02 6.8e-42 5.86e-34 1.22 0.76 Glucose homeostasis traits; chr8:99848918 chr16:11903923~11904137:- CESC trans rs13177918 0.557 rs12520101 ENSG00000224114.1 RP11-343H5.4 16.93 1.33e-41 1.14e-33 1.02 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:206695837~206696269:- CESC trans rs13177918 0.626 rs12186649 ENSG00000224114.1 RP11-343H5.4 16.92 1.47e-41 1.25e-33 1.06 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr1:206695837~206696269:- CESC trans rs12291225 0.546 rs12795545 ENSG00000236360.2 RP11-334A14.2 16.91 1.52e-41 1.29e-33 0.99 0.75 Sense of smell; chr11:14334018 chr1:52993201~52993702:- CESC trans rs12291225 0.585 rs11023194 ENSG00000236360.2 RP11-334A14.2 16.82 2.88e-41 2.42e-33 0.98 0.75 Sense of smell; chr11:14348223 chr1:52993201~52993702:- CESC trans rs13177918 0.559 rs10447224 ENSG00000224114.1 RP11-343H5.4 16.82 2.89e-41 2.42e-33 0.98 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:206695837~206696269:- CESC trans rs13177918 0.559 rs10447225 ENSG00000224114.1 RP11-343H5.4 16.82 2.89e-41 2.42e-33 0.98 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:206695837~206696269:- CESC trans rs12291225 0.546 rs12291662 ENSG00000236360.2 RP11-334A14.2 16.77 4.22e-41 3.51e-33 0.99 0.75 Sense of smell; chr11:14321403 chr1:52993201~52993702:- CESC trans rs12291225 0.545 rs11023187 ENSG00000236360.2 RP11-334A14.2 16.77 4.22e-41 3.51e-33 0.99 0.75 Sense of smell; chr11:14324013 chr1:52993201~52993702:- CESC trans rs13177918 0.651 rs13184111 ENSG00000224114.1 RP11-343H5.4 16.75 4.85e-41 4.02e-33 1.06 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr1:206695837~206696269:- CESC trans rs12291225 0.585 rs10832242 ENSG00000236360.2 RP11-334A14.2 -16.72 6.26e-41 5.16e-33 -0.99 -0.75 Sense of smell; chr11:14318958 chr1:52993201~52993702:- CESC trans rs7949030 0.653 rs2516634 ENSG00000186676.3 EEF1GP1 -16.72 6.29e-41 5.18e-33 -1.07 -0.75 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62599714 chr7:125033453~125035301:+ CESC trans rs1816752 0.905 rs3818938 ENSG00000237917.1 PARP4P1 16.6 1.48e-40 1.21e-32 0.89 0.75 Obesity-related traits; chr13:24454945 chrY:26594851~26634652:- CESC trans rs7949030 0.688 rs2849031 ENSG00000186676.3 EEF1GP1 -16.53 2.56e-40 2.07e-32 -1.07 -0.75 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598193 chr7:125033453~125035301:+ CESC trans rs928391 0.681 rs9427242 ENSG00000227183.3 HDGFP1 -16.53 2.59e-40 2.1e-32 -1.07 -0.75 Platelet count; chr1:156755209 chrX:131646639~131646890:+ CESC trans rs7949030 0.653 rs2849030 ENSG00000186676.3 EEF1GP1 -16.47 3.87e-40 3.09e-32 -1.07 -0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62599514 chr7:125033453~125035301:+ CESC trans rs7949030 0.588 rs2512562 ENSG00000186676.3 EEF1GP1 16.45 4.55e-40 3.62e-32 1.06 0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62544684 chr7:125033453~125035301:+ CESC trans rs7949030 0.588 rs2509982 ENSG00000186676.3 EEF1GP1 16.45 4.55e-40 3.62e-32 1.06 0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62544846 chr7:125033453~125035301:+ CESC trans rs61990749 0.597 rs11624101 ENSG00000235400.1 RP4-641G12.4 -16.44 5.01e-40 3.97e-32 -1.11 -0.74 Fibroblast growth factor basic levels; chr14:77671716 chr1:78749073~78750659:+ CESC trans rs1816752 0.748 rs6490912 ENSG00000237917.1 PARP4P1 16.43 5.31e-40 4.2e-32 0.89 0.74 Obesity-related traits; chr13:24408941 chrY:26594851~26634652:- CESC trans rs12291225 0.585 rs12270374 ENSG00000236360.2 RP11-334A14.2 16.41 6.11e-40 4.81e-32 0.99 0.74 Sense of smell; chr11:14353533 chr1:52993201~52993702:- CESC trans rs12291225 0.585 rs10832246 ENSG00000236360.2 RP11-334A14.2 16.41 6.11e-40 4.81e-32 0.99 0.74 Sense of smell; chr11:14359282 chr1:52993201~52993702:- CESC trans rs13253073 0.8 rs7015733 ENSG00000260318.1 COX6CP1 16.38 7.33e-40 5.74e-32 1.14 0.74 Glucose homeostasis traits; chr8:99899353 chr16:11903923~11904137:- CESC trans rs7949030 0.588 rs2509961 ENSG00000186676.3 EEF1GP1 16.38 7.59e-40 5.91e-32 1.06 0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62543437 chr7:125033453~125035301:+ CESC trans rs7949030 0.588 rs2512563 ENSG00000186676.3 EEF1GP1 16.38 7.59e-40 5.91e-32 1.06 0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62543777 chr7:125033453~125035301:+ CESC trans rs7949030 0.588 rs2428548 ENSG00000186676.3 EEF1GP1 16.38 7.59e-40 5.91e-32 1.06 0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62543990 chr7:125033453~125035301:+ CESC trans rs1816752 0.755 rs1981277 ENSG00000237917.1 PARP4P1 16.29 1.43e-39 1.1e-31 0.89 0.74 Obesity-related traits; chr13:24409375 chrY:26594851~26634652:- CESC trans rs1816752 0.712 rs9507335 ENSG00000237917.1 PARP4P1 16.29 1.43e-39 1.1e-31 0.89 0.74 Obesity-related traits; chr13:24409766 chrY:26594851~26634652:- CESC trans rs1816752 0.811 rs9507337 ENSG00000237917.1 PARP4P1 16.29 1.43e-39 1.1e-31 0.89 0.74 Obesity-related traits; chr13:24410807 chrY:26594851~26634652:- CESC trans rs12291225 0.585 rs11023197 ENSG00000236360.2 RP11-334A14.2 16.28 1.61e-39 1.23e-31 0.99 0.74 Sense of smell; chr11:14359452 chr1:52993201~52993702:- CESC trans rs13253073 0.723 rs13274441 ENSG00000260318.1 COX6CP1 16.23 2.29e-39 1.73e-31 1.23 0.74 Glucose homeostasis traits; chr8:99861038 chr16:11903923~11904137:- CESC trans rs61990749 0.597 rs72685264 ENSG00000235400.1 RP4-641G12.4 -16.2 2.88e-39 2.16e-31 -1.08 -0.74 Fibroblast growth factor basic levels; chr14:77686655 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs176946 ENSG00000235400.1 RP4-641G12.4 16.09 6.28e-39 4.44e-31 1.07 0.74 Fibroblast growth factor basic levels; chr14:77712096 chr1:78749073~78750659:+ CESC trans rs12291225 0.585 rs4517475 ENSG00000236360.2 RP11-334A14.2 16.09 6.31e-39 4.46e-31 0.99 0.74 Sense of smell; chr11:14364599 chr1:52993201~52993702:- CESC trans rs61990749 0.597 rs10148373 ENSG00000235400.1 RP4-641G12.4 16.08 7.16e-39 5.02e-31 1.12 0.74 Fibroblast growth factor basic levels; chr14:77813856 chr1:78749073~78750659:+ CESC trans rs8081395 0.741 rs1292055 ENSG00000187870.7 RNFT1P3 16.07 7.57e-39 5.29e-31 0.89 0.74 White blood cell count; chr17:59881707 chr17:20743333~20754501:- CESC trans rs8081395 0.805 rs2645485 ENSG00000187870.7 RNFT1P3 16.06 7.75e-39 5.4e-31 0.89 0.74 White blood cell count; chr17:59866920 chr17:20743333~20754501:- CESC trans rs8081395 0.775 rs2645482 ENSG00000187870.7 RNFT1P3 16.05 8.45e-39 5.84e-31 0.89 0.74 White blood cell count; chr17:59865754 chr17:20743333~20754501:- CESC trans rs7949030 0.588 rs2428549 ENSG00000186676.3 EEF1GP1 16.01 1.17e-38 7.93e-31 1.04 0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62544922 chr7:125033453~125035301:+ CESC trans rs8010715 0.816 rs7153156 ENSG00000248988.1 RP11-815N9.2 16.01 1.2e-38 8.04e-31 0.87 0.74 IgG glycosylation; chr14:24129637 chr4:159007119~159007835:+ CESC trans rs8010715 0.816 rs6573572 ENSG00000248988.1 RP11-815N9.2 16.01 1.2e-38 8.04e-31 0.87 0.74 IgG glycosylation; chr14:24130021 chr4:159007119~159007835:+ CESC trans rs8010715 0.816 rs8015168 ENSG00000248988.1 RP11-815N9.2 16.01 1.2e-38 8.04e-31 0.87 0.74 IgG glycosylation; chr14:24130663 chr4:159007119~159007835:+ CESC trans rs8010715 0.816 rs762093 ENSG00000248988.1 RP11-815N9.2 15.99 1.3e-38 8.74e-31 0.87 0.73 IgG glycosylation; chr14:24122709 chr4:159007119~159007835:+ CESC trans rs7949030 0.626 rs35587183 ENSG00000186676.3 EEF1GP1 15.99 1.35e-38 9.02e-31 1.06 0.73 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62551184 chr7:125033453~125035301:+ CESC trans rs7943191 0.805 rs12226821 ENSG00000186676.3 EEF1GP1 15.98 1.47e-38 9.79e-31 1.07 0.73 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62601546 chr7:125033453~125035301:+ CESC trans rs12291225 0.546 rs11023199 ENSG00000236360.2 RP11-334A14.2 15.93 2.17e-38 1.4e-30 0.99 0.73 Sense of smell; chr11:14372712 chr1:52993201~52993702:- CESC trans rs8010715 0.816 rs6573565 ENSG00000248988.1 RP11-815N9.2 -15.92 2.29e-38 1.48e-30 -0.87 -0.73 IgG glycosylation; chr14:24125524 chr4:159007119~159007835:+ CESC trans rs8010715 0.785 rs2877611 ENSG00000248988.1 RP11-815N9.2 15.92 2.3e-38 1.48e-30 0.87 0.73 IgG glycosylation; chr14:24126221 chr4:159007119~159007835:+ CESC trans rs7943191 0.81 rs7942154 ENSG00000186676.3 EEF1GP1 15.89 2.88e-38 1.83e-30 1.07 0.73 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62569691 chr7:125033453~125035301:+ CESC trans rs61990749 0.597 rs6574402 ENSG00000235400.1 RP4-641G12.4 15.88 2.94e-38 1.86e-30 1.1 0.73 Fibroblast growth factor basic levels; chr14:77801607 chr1:78749073~78750659:+ CESC trans rs7949030 0.523 rs12223627 ENSG00000186676.3 EEF1GP1 15.85 3.69e-38 2.32e-30 1.07 0.73 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62601085 chr7:125033453~125035301:+ CESC trans rs13253073 0.525 rs35509895 ENSG00000260318.1 COX6CP1 15.85 3.89e-38 2.44e-30 1.19 0.73 Glucose homeostasis traits; chr8:99872093 chr16:11903923~11904137:- CESC trans rs61990749 0.597 rs176943 ENSG00000235400.1 RP4-641G12.4 -15.82 4.65e-38 2.88e-30 -1.07 -0.73 Fibroblast growth factor basic levels; chr14:77709454 chr1:78749073~78750659:+ CESC trans rs61990749 0.544 rs8003979 ENSG00000235400.1 RP4-641G12.4 15.82 4.65e-38 2.88e-30 1.07 0.73 Fibroblast growth factor basic levels; chr14:77744947 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs8016416 ENSG00000235400.1 RP4-641G12.4 15.82 4.65e-38 2.88e-30 1.07 0.73 Fibroblast growth factor basic levels; chr14:77746757 chr1:78749073~78750659:+ CESC trans rs8081395 0.741 rs2645462 ENSG00000187870.7 RNFT1P3 15.8 5.38e-38 3.27e-30 0.88 0.73 White blood cell count; chr17:59906198 chr17:20743333~20754501:- CESC trans rs8081395 0.711 rs1292034 ENSG00000187870.7 RNFT1P3 15.8 5.38e-38 3.27e-30 0.88 0.73 White blood cell count; chr17:59912499 chr17:20743333~20754501:- CESC trans rs8081395 0.741 rs180532 ENSG00000187870.7 RNFT1P3 15.8 5.38e-38 3.27e-30 0.88 0.73 White blood cell count; chr17:59925936 chr17:20743333~20754501:- CESC trans rs8081395 0.741 rs180530 ENSG00000187870.7 RNFT1P3 15.8 5.38e-38 3.27e-30 0.88 0.73 White blood cell count; chr17:59926233 chr17:20743333~20754501:- CESC trans rs8081395 0.741 rs180519 ENSG00000187870.7 RNFT1P3 15.8 5.38e-38 3.27e-30 0.88 0.73 White blood cell count; chr17:59938910 chr17:20743333~20754501:- CESC trans rs61990749 0.597 rs117131659 ENSG00000235400.1 RP4-641G12.4 -15.71 1.04e-37 6.13e-30 -1.07 -0.73 Fibroblast growth factor basic levels; chr14:77664783 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs2112136 ENSG00000235400.1 RP4-641G12.4 15.66 1.55e-37 9.09e-30 1.06 0.73 Fibroblast growth factor basic levels; chr14:77782609 chr1:78749073~78750659:+ CESC trans rs7949030 0.596 rs11231137 ENSG00000186676.3 EEF1GP1 15.59 2.64e-37 1.52e-29 1.08 0.73 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62548227 chr7:125033453~125035301:+ CESC trans rs1816752 0.774 rs2862895 ENSG00000237917.1 PARP4P1 15.57 2.99e-37 1.72e-29 0.86 0.73 Obesity-related traits; chr13:24410328 chrY:26594851~26634652:- CESC trans rs1816752 0.875 rs8001187 ENSG00000237917.1 PARP4P1 15.56 3.21e-37 1.83e-29 0.88 0.73 Obesity-related traits; chr13:24402276 chrY:26594851~26634652:- CESC trans rs1816752 0.783 rs9507333 ENSG00000237917.1 PARP4P1 15.56 3.21e-37 1.83e-29 0.88 0.73 Obesity-related traits; chr13:24404172 chrY:26594851~26634652:- CESC trans rs61990749 0.597 rs1048147 ENSG00000235400.1 RP4-641G12.4 -15.55 3.42e-37 1.93e-29 -1.08 -0.73 Fibroblast growth factor basic levels; chr14:77673645 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs2267758 ENSG00000235400.1 RP4-641G12.4 -15.55 3.42e-37 1.93e-29 -1.08 -0.73 Fibroblast growth factor basic levels; chr14:77681086 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs7142390 ENSG00000235400.1 RP4-641G12.4 15.54 3.78e-37 2.13e-29 1.07 0.72 Fibroblast growth factor basic levels; chr14:77766537 chr1:78749073~78750659:+ CESC trans rs8081395 0.711 rs11368 ENSG00000187870.7 RNFT1P3 15.48 5.84e-37 3.23e-29 0.88 0.72 White blood cell count; chr17:59954051 chr17:20743333~20754501:- CESC trans rs8081395 0.737 rs4968401 ENSG00000187870.7 RNFT1P3 -15.48 5.89e-37 3.25e-29 -0.88 -0.72 White blood cell count; chr17:59963369 chr17:20743333~20754501:- CESC trans rs7943191 0.81 rs7942991 ENSG00000186676.3 EEF1GP1 -15.45 7.44e-37 4.07e-29 -1.03 -0.72 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62569731 chr7:125033453~125035301:+ CESC trans rs7943191 0.768 rs34065644 ENSG00000186676.3 EEF1GP1 15.43 8.37e-37 4.54e-29 1.08 0.72 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62604466 chr7:125033453~125035301:+ CESC trans rs61990749 0.597 rs8016447 ENSG00000235400.1 RP4-641G12.4 15.43 8.46e-37 4.58e-29 1.06 0.72 Fibroblast growth factor basic levels; chr14:77755725 chr1:78749073~78750659:+ CESC trans rs8081395 0.741 rs1292051 ENSG00000187870.7 RNFT1P3 15.42 9.12e-37 4.89e-29 0.87 0.72 White blood cell count; chr17:59886562 chr17:20743333~20754501:- CESC trans rs61990749 0.597 rs2267761 ENSG00000235400.1 RP4-641G12.4 -15.37 1.33e-36 6.95e-29 -1.05 -0.72 Fibroblast growth factor basic levels; chr14:77681506 chr1:78749073~78750659:+ CESC trans rs61990749 0.544 rs7151211 ENSG00000235400.1 RP4-641G12.4 -15.37 1.33e-36 6.95e-29 -1.05 -0.72 Fibroblast growth factor basic levels; chr14:77685558 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs7147516 ENSG00000235400.1 RP4-641G12.4 -15.37 1.33e-36 6.95e-29 -1.05 -0.72 Fibroblast growth factor basic levels; chr14:77687637 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs4903643 ENSG00000235400.1 RP4-641G12.4 15.34 1.6e-36 8.29e-29 1.08 0.72 Fibroblast growth factor basic levels; chr14:77788448 chr1:78749073~78750659:+ CESC trans rs61990749 0.544 rs176962 ENSG00000235400.1 RP4-641G12.4 15.33 1.75e-36 8.91e-29 1.05 0.72 Fibroblast growth factor basic levels; chr14:77719167 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs176971 ENSG00000235400.1 RP4-641G12.4 15.33 1.75e-36 8.91e-29 1.05 0.72 Fibroblast growth factor basic levels; chr14:77725256 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs6574391 ENSG00000235400.1 RP4-641G12.4 15.33 1.75e-36 8.91e-29 1.05 0.72 Fibroblast growth factor basic levels; chr14:77741778 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs2032781 ENSG00000235400.1 RP4-641G12.4 15.33 1.75e-36 8.91e-29 1.05 0.72 Fibroblast growth factor basic levels; chr14:77748532 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs3783980 ENSG00000235400.1 RP4-641G12.4 15.33 1.75e-36 8.91e-29 1.05 0.72 Fibroblast growth factor basic levels; chr14:77753464 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs1477262 ENSG00000235400.1 RP4-641G12.4 15.33 1.75e-36 8.91e-29 1.05 0.72 Fibroblast growth factor basic levels; chr14:77760310 chr1:78749073~78750659:+ CESC trans rs8081395 0.741 rs1292056 ENSG00000187870.7 RNFT1P3 15.31 2.04e-36 1.03e-28 0.87 0.72 White blood cell count; chr17:59881686 chr17:20743333~20754501:- CESC trans rs61990749 0.597 rs9788540 ENSG00000235400.1 RP4-641G12.4 -15.01 1.93e-35 9.31e-28 -1.04 -0.71 Fibroblast growth factor basic levels; chr14:77665829 chr1:78749073~78750659:+ CESC trans rs2950393 0.509 rs10459247 ENSG00000121089.4 NACA3P -15.01 1.95e-35 9.4e-28 -0.9 -0.71 Platelet distribution width; chr12:56777732 chr4:164943290~164943937:+ CESC trans rs8081395 0.801 rs12938273 ENSG00000187870.7 RNFT1P3 -14.97 2.61e-35 1.25e-27 -0.84 -0.71 White blood cell count; chr17:59824291 chr17:20743333~20754501:- CESC trans rs8081395 0.836 rs1292061 ENSG00000187870.7 RNFT1P3 -14.97 2.61e-35 1.25e-27 -0.84 -0.71 White blood cell count; chr17:59833869 chr17:20743333~20754501:- CESC trans rs8081395 0.741 rs180520 ENSG00000187870.7 RNFT1P3 14.95 2.93e-35 1.39e-27 0.86 0.71 White blood cell count; chr17:59937788 chr17:20743333~20754501:- CESC trans rs61990749 0.597 rs10142722 ENSG00000235400.1 RP4-641G12.4 14.91 3.87e-35 1.83e-27 1.08 0.71 Fibroblast growth factor basic levels; chr14:77809206 chr1:78749073~78750659:+ CESC trans rs8081395 0.707 rs1024637 ENSG00000187870.7 RNFT1P3 -14.91 4.06e-35 1.91e-27 -0.86 -0.71 White blood cell count; chr17:59961532 chr17:20743333~20754501:- CESC trans rs11332131 1 rs11332131 ENSG00000187870.7 RNFT1P3 14.9 4.19e-35 1.97e-27 0.84 0.71 Platelet distribution width; chr17:59849031 chr17:20743333~20754501:- CESC trans rs13177918 1 rs13177918 ENSG00000213058.3 RP4-765C7.2 14.9 4.24e-35 2e-27 1.04 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr1:178411616~178411972:+ CESC trans rs12709013 0.569 rs30837 ENSG00000230849.2 GOT2P2 14.9 4.36e-35 2.04e-27 0.85 0.71 Blood metabolite ratios; chr16:58711942 chr1:173141100~173142350:- CESC trans rs13177918 1 rs13161334 ENSG00000213058.3 RP4-765C7.2 14.79 9.4e-35 4.35e-27 1.03 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr1:178411616~178411972:+ CESC trans rs8081395 0.836 rs1295926 ENSG00000187870.7 RNFT1P3 -14.79 9.53e-35 4.4e-27 -0.84 -0.71 White blood cell count; chr17:59832012 chr17:20743333~20754501:- CESC trans rs13177918 1 rs35007082 ENSG00000213058.3 RP4-765C7.2 14.79 9.7e-35 4.46e-27 1.05 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr1:178411616~178411972:+ CESC trans rs12709013 0.591 rs30841 ENSG00000230849.2 GOT2P2 14.77 1.13e-34 5.16e-27 0.85 0.71 Blood metabolite ratios; chr16:58709819 chr1:173141100~173142350:- CESC trans rs13177918 0.906 rs12652032 ENSG00000213058.3 RP4-765C7.2 14.75 1.35e-34 6.17e-27 1.03 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr1:178411616~178411972:+ CESC trans rs12709013 0.591 rs30840 ENSG00000230849.2 GOT2P2 14.74 1.42e-34 6.52e-27 0.85 0.71 Blood metabolite ratios; chr16:58710165 chr1:173141100~173142350:- CESC trans rs8081395 0.801 rs2665404 ENSG00000187870.7 RNFT1P3 14.73 1.47e-34 6.69e-27 0.81 0.71 White blood cell count; chr17:59798035 chr17:20743333~20754501:- CESC trans rs8081395 0.801 rs2645479 ENSG00000187870.7 RNFT1P3 14.72 1.69e-34 7.7e-27 0.84 0.71 White blood cell count; chr17:59843171 chr17:20743333~20754501:- CESC trans rs8010715 1 rs3742500 ENSG00000248988.1 RP11-815N9.2 14.71 1.71e-34 7.78e-27 0.9 0.71 IgG glycosylation; chr14:24142769 chr4:159007119~159007835:+ CESC trans rs8081395 0.769 rs12449331 ENSG00000187870.7 RNFT1P3 -14.71 1.72e-34 7.83e-27 -0.82 -0.71 White blood cell count; chr17:59806285 chr17:20743333~20754501:- CESC trans rs13177918 1 rs13161334 ENSG00000239528.1 RPS14P8 14.7 1.88e-34 8.55e-27 1.04 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr5:116562562~116562930:+ CESC trans rs61990749 0.597 rs59848135 ENSG00000235400.1 RP4-641G12.4 -14.7 1.92e-34 8.7e-27 -1.07 -0.71 Fibroblast growth factor basic levels; chr14:77662657 chr1:78749073~78750659:+ CESC trans rs8081395 0.836 rs2150879 ENSG00000187870.7 RNFT1P3 -14.69 2e-34 9.06e-27 -0.82 -0.71 White blood cell count; chr17:59781849 chr17:20743333~20754501:- CESC trans rs13253073 1 rs4409375 ENSG00000260318.1 COX6CP1 14.69 2e-34 9.06e-27 1.22 0.71 Glucose homeostasis traits; chr8:99877759 chr16:11903923~11904137:- CESC trans rs9467773 0.62 rs2504567 ENSG00000242375.1 RP11-498P14.3 14.66 2.62e-34 1.18e-26 0.83 0.7 Intelligence (multi-trait analysis); chr6:26662692 chr9:97195351~97197687:- CESC trans rs13253073 0.545 rs35769167 ENSG00000260318.1 COX6CP1 14.65 2.78e-34 1.25e-26 1.2 0.7 Glucose homeostasis traits; chr8:99872095 chr16:11903923~11904137:- CESC trans rs13177918 1 rs13177918 ENSG00000239528.1 RPS14P8 14.62 3.5e-34 1.57e-26 1.04 0.7 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr5:116562562~116562930:+ CESC trans rs13177918 0.906 rs12652032 ENSG00000239528.1 RPS14P8 14.62 3.5e-34 1.57e-26 1.04 0.7 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr5:116562562~116562930:+ CESC trans rs8081395 0.801 rs2777895 ENSG00000187870.7 RNFT1P3 -14.61 3.6e-34 1.6e-26 -0.81 -0.7 White blood cell count; chr17:59802249 chr17:20743333~20754501:- CESC trans rs13177918 1 rs35007082 ENSG00000239528.1 RPS14P8 14.59 4.38e-34 1.95e-26 1.06 0.7 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr5:116562562~116562930:+ CESC trans rs941207 0.526 rs2950393 ENSG00000121089.4 NACA3P -14.51 7.48e-34 3.31e-26 -0.78 -0.7 Platelet count; chr12:56642239 chr4:164943290~164943937:+ CESC trans rs8010715 0.816 rs11574503 ENSG00000248988.1 RP11-815N9.2 -14.51 7.83e-34 3.46e-26 -0.83 -0.7 IgG glycosylation; chr14:24132109 chr4:159007119~159007835:+ CESC trans rs2950393 0.804 rs1466382 ENSG00000121089.4 NACA3P -14.48 9.39e-34 4.14e-26 -0.73 -0.7 Platelet distribution width; chr12:56723050 chr4:164943290~164943937:+ CESC trans rs2950393 0.927 rs11171914 ENSG00000121089.4 NACA3P -14.46 1.13e-33 4.96e-26 -0.78 -0.7 Platelet distribution width; chr12:56649462 chr4:164943290~164943937:+ CESC trans rs9467773 0.595 rs7767847 ENSG00000242375.1 RP11-498P14.3 14.44 1.26e-33 5.54e-26 0.83 0.7 Intelligence (multi-trait analysis); chr6:26597665 chr9:97195351~97197687:- CESC trans rs9467773 0.62 rs9467810 ENSG00000242375.1 RP11-498P14.3 14.44 1.26e-33 5.54e-26 0.83 0.7 Intelligence (multi-trait analysis); chr6:26608033 chr9:97195351~97197687:- CESC trans rs9467773 0.62 rs3800303 ENSG00000242375.1 RP11-498P14.3 14.44 1.28e-33 5.63e-26 0.83 0.7 Intelligence (multi-trait analysis); chr6:26597960 chr9:97195351~97197687:- CESC trans rs12709013 0.591 rs30834 ENSG00000230849.2 GOT2P2 14.42 1.54e-33 6.74e-26 0.85 0.7 Blood metabolite ratios; chr16:58715394 chr1:173141100~173142350:- CESC trans rs8081395 0.836 rs2063353 ENSG00000187870.7 RNFT1P3 -14.41 1.58e-33 6.89e-26 -0.82 -0.7 White blood cell count; chr17:59811831 chr17:20743333~20754501:- CESC trans rs8081395 0.899 rs2777898 ENSG00000187870.7 RNFT1P3 -14.39 1.85e-33 7.99e-26 -0.83 -0.7 White blood cell count; chr17:59738247 chr17:20743333~20754501:- CESC trans rs8081395 0.834 rs2665397 ENSG00000187870.7 RNFT1P3 -14.39 1.85e-33 7.99e-26 -0.83 -0.7 White blood cell count; chr17:59749370 chr17:20743333~20754501:- CESC trans rs8081395 0.804 rs2777884 ENSG00000187870.7 RNFT1P3 -14.39 1.85e-33 7.99e-26 -0.83 -0.7 White blood cell count; chr17:59753065 chr17:20743333~20754501:- CESC trans rs8081395 0.932 rs2777885 ENSG00000187870.7 RNFT1P3 -14.39 1.85e-33 7.99e-26 -0.83 -0.7 White blood cell count; chr17:59753112 chr17:20743333~20754501:- CESC trans rs8081395 0.866 rs2777899 ENSG00000187870.7 RNFT1P3 -14.39 1.85e-33 7.99e-26 -0.83 -0.7 White blood cell count; chr17:59755030 chr17:20743333~20754501:- CESC trans rs8081395 0.899 rs2645477 ENSG00000187870.7 RNFT1P3 -14.39 1.95e-33 8.43e-26 -0.83 -0.7 White blood cell count; chr17:59768263 chr17:20743333~20754501:- CESC trans rs941207 0.526 rs7303216 ENSG00000121089.4 NACA3P 14.38 2e-33 8.58e-26 0.76 0.7 Platelet count; chr12:56680909 chr4:164943290~164943937:+ CESC trans rs941207 0.507 rs7297289 ENSG00000121089.4 NACA3P 14.38 2e-33 8.58e-26 0.76 0.7 Platelet count; chr12:56682703 chr4:164943290~164943937:+ CESC trans rs941207 0.526 rs4759028 ENSG00000121089.4 NACA3P 14.38 2e-33 8.58e-26 0.76 0.7 Platelet count; chr12:56686399 chr4:164943290~164943937:+ CESC trans rs12709013 0.591 rs30842 ENSG00000230849.2 GOT2P2 -14.36 2.37e-33 1.01e-25 -0.82 -0.7 Blood metabolite ratios; chr16:58709550 chr1:173141100~173142350:- CESC trans rs2950393 0.857 rs1563896 ENSG00000121089.4 NACA3P 14.35 2.62e-33 1.12e-25 0.76 0.7 Platelet distribution width; chr12:56699312 chr4:164943290~164943937:+ CESC trans rs8081395 0.805 rs1295927 ENSG00000187870.7 RNFT1P3 14.29 3.82e-33 1.62e-25 0.8 0.7 White blood cell count; chr17:59852174 chr17:20743333~20754501:- CESC trans rs8081395 0.834 rs11650106 ENSG00000187870.7 RNFT1P3 -14.29 4.07e-33 1.72e-25 -0.82 -0.7 White blood cell count; chr17:59772890 chr17:20743333~20754501:- CESC trans rs2950393 0.895 rs2926740 ENSG00000121089.4 NACA3P 14.28 4.39e-33 1.85e-25 0.76 0.7 Platelet distribution width; chr12:56666751 chr4:164943290~164943937:+ CESC trans rs61990749 0.544 rs11628888 ENSG00000235400.1 RP4-641G12.4 -14.25 5.37e-33 2.23e-25 -1.04 -0.69 Fibroblast growth factor basic levels; chr14:77695163 chr1:78749073~78750659:+ CESC trans rs13177918 1 rs13177918 ENSG00000224114.1 RP11-343H5.4 14.24 5.62e-33 2.32e-25 1.01 0.69 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr1:206695837~206696269:- CESC trans rs8081395 0.801 rs2665405 ENSG00000187870.7 RNFT1P3 -14.23 6e-33 2.47e-25 -0.81 -0.69 White blood cell count; chr17:59797931 chr17:20743333~20754501:- CESC trans rs7554547 0.63 rs4845889 ENSG00000261819.1 RP11-680G24.4 14.21 7.13e-33 2.93e-25 0.88 0.69 Nonsyndromic cleft lip with cleft palate; chr1:11911288 chr16:14988259~14990160:- CESC trans rs61990749 0.597 rs2299930 ENSG00000235400.1 RP4-641G12.4 -14.17 9.68e-33 3.95e-25 -1 -0.69 Fibroblast growth factor basic levels; chr14:77697379 chr1:78749073~78750659:+ CESC trans rs8010715 0.848 rs2277483 ENSG00000248988.1 RP11-815N9.2 14.16 1.07e-32 4.35e-25 0.86 0.69 IgG glycosylation; chr14:24122683 chr4:159007119~159007835:+ CESC trans rs8010715 0.771 rs2277481 ENSG00000248988.1 RP11-815N9.2 14.14 1.17e-32 4.75e-25 0.84 0.69 IgG glycosylation; chr14:24118336 chr4:159007119~159007835:+ CESC trans rs941207 0.526 rs2950390 ENSG00000121089.4 NACA3P 14.12 1.37e-32 5.53e-25 0.75 0.69 Platelet count; chr12:56661507 chr4:164943290~164943937:+ CESC trans rs12709013 0.574 rs839418 ENSG00000230849.2 GOT2P2 14.1 1.63e-32 6.58e-25 0.83 0.69 Blood metabolite ratios; chr16:58705426 chr1:173141100~173142350:- CESC trans rs8010715 0.848 rs8009511 ENSG00000248988.1 RP11-815N9.2 14.04 2.5e-32 9.98e-25 0.85 0.69 IgG glycosylation; chr14:24124771 chr4:159007119~159007835:+ CESC trans rs8010715 0.804 rs1134334 ENSG00000248988.1 RP11-815N9.2 14.04 2.5e-32 9.98e-25 0.85 0.69 IgG glycosylation; chr14:24124905 chr4:159007119~159007835:+ CESC trans rs13177918 1 rs35007082 ENSG00000224114.1 RP11-343H5.4 14.03 2.73e-32 1.09e-24 1.02 0.69 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr1:206695837~206696269:- CESC trans rs941207 0.526 rs11171916 ENSG00000121089.4 NACA3P -14.01 3.14e-32 1.25e-24 -0.78 -0.69 Platelet count; chr12:56653236 chr4:164943290~164943937:+ CESC trans rs8010715 0.848 rs927494 ENSG00000248988.1 RP11-815N9.2 13.95 4.95e-32 1.95e-24 0.85 0.69 IgG glycosylation; chr14:24131181 chr4:159007119~159007835:+ CESC trans rs13177918 1 rs13161334 ENSG00000224114.1 RP11-343H5.4 13.92 5.99e-32 2.34e-24 1 0.69 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr1:206695837~206696269:- CESC trans rs1816752 0.875 rs59686377 ENSG00000237917.1 PARP4P1 13.9 7.19e-32 2.79e-24 0.82 0.69 Obesity-related traits; chr13:24475869 chrY:26594851~26634652:- CESC trans rs941207 0.547 rs56183434 ENSG00000121089.4 NACA3P 13.89 7.53e-32 2.92e-24 0.74 0.69 Platelet count; chr12:56676145 chr4:164943290~164943937:+ CESC trans rs13177918 0.906 rs12652032 ENSG00000224114.1 RP11-343H5.4 13.85 1.06e-31 4.1e-24 1 0.68 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr1:206695837~206696269:- CESC trans rs13177918 0.626 rs2748240 ENSG00000213058.3 RP4-765C7.2 13.82 1.26e-31 4.83e-24 0.84 0.68 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr1:178411616~178411972:+ CESC trans rs1816752 0.875 rs17384871 ENSG00000237917.1 PARP4P1 13.8 1.55e-31 5.9e-24 0.82 0.68 Obesity-related traits; chr13:24484959 chrY:26594851~26634652:- CESC trans rs7554547 0.667 rs4846072 ENSG00000261819.1 RP11-680G24.4 13.7 3.05e-31 1.14e-23 0.83 0.68 Nonsyndromic cleft lip with cleft palate; chr1:11890334 chr16:14988259~14990160:- CESC trans rs8010715 1 rs8010715 ENSG00000248988.1 RP11-815N9.2 13.6 6.65e-31 2.43e-23 0.87 0.68 IgG glycosylation; chr14:24139938 chr4:159007119~159007835:+ CESC trans rs12291225 0.535 rs10832248 ENSG00000236360.2 RP11-334A14.2 13.52 1.19e-30 4.27e-23 0.91 0.68 Sense of smell; chr11:14391541 chr1:52993201~52993702:- CESC trans rs12709013 0.591 rs30838 ENSG00000230849.2 GOT2P2 13.51 1.32e-30 4.75e-23 0.82 0.67 Blood metabolite ratios; chr16:58711513 chr1:173141100~173142350:- CESC trans rs8010715 1 rs2236352 ENSG00000248988.1 RP11-815N9.2 13.47 1.7e-30 6.06e-23 0.87 0.67 IgG glycosylation; chr14:24141524 chr4:159007119~159007835:+ CESC trans rs13253073 1 rs13252579 ENSG00000260318.1 COX6CP1 13.43 2.39e-30 8.46e-23 1.2 0.67 Glucose homeostasis traits; chr8:99885073 chr16:11903923~11904137:- CESC trans rs13253073 1 rs13253073 ENSG00000260318.1 COX6CP1 13.43 2.39e-30 8.46e-23 1.2 0.67 Glucose homeostasis traits; chr8:99885155 chr16:11903923~11904137:- CESC trans rs13253073 1 rs13259066 ENSG00000260318.1 COX6CP1 13.43 2.39e-30 8.46e-23 1.2 0.67 Glucose homeostasis traits; chr8:99889455 chr16:11903923~11904137:- CESC trans rs9611565 0.649 rs202657 ENSG00000268568.1 AC007228.9 13.41 2.58e-30 9.1e-23 1 0.67 Vitiligo; chr22:41448782 chr19:56672574~56673901:- CESC trans rs8081395 0.775 rs2526355 ENSG00000187870.7 RNFT1P3 13.4 2.8e-30 9.79e-23 0.8 0.67 White blood cell count; chr17:59875872 chr17:20743333~20754501:- CESC trans rs1292048 1 rs1292048 ENSG00000187870.7 RNFT1P3 13.4 2.8e-30 9.79e-23 0.8 0.67 Red cell distribution width; chr17:59877710 chr17:20743333~20754501:- CESC trans rs941207 0.526 rs12229457 ENSG00000121089.4 NACA3P -13.4 2.82e-30 9.87e-23 -0.77 -0.67 Platelet count; chr12:56639896 chr4:164943290~164943937:+ CESC trans rs13253073 1 rs35935983 ENSG00000260318.1 COX6CP1 13.38 3.23e-30 1.13e-22 1.14 0.67 Glucose homeostasis traits; chr8:99888966 chr16:11903923~11904137:- CESC trans rs9467773 1 rs9467791 ENSG00000242375.1 RP11-498P14.3 -13.38 3.27e-30 1.14e-22 -0.78 -0.67 Intelligence (multi-trait analysis); chr6:26562258 chr9:97195351~97197687:- CESC trans rs55665837 0.524 rs2882128 ENSG00000236360.2 RP11-334A14.2 13.36 3.89e-30 1.34e-22 0.91 0.67 Vitamin D levels; chr11:14393088 chr1:52993201~52993702:- CESC trans rs8010715 0.52 rs12435994 ENSG00000248988.1 RP11-815N9.2 13.33 4.85e-30 1.66e-22 0.84 0.67 IgG glycosylation; chr14:24120252 chr4:159007119~159007835:+ CESC trans rs8010715 0.596 rs12435995 ENSG00000248988.1 RP11-815N9.2 13.33 4.85e-30 1.66e-22 0.84 0.67 IgG glycosylation; chr14:24120255 chr4:159007119~159007835:+ CESC trans rs61990749 0.597 rs176955 ENSG00000235400.1 RP4-641G12.4 13.32 5.08e-30 1.74e-22 0.96 0.67 Fibroblast growth factor basic levels; chr14:77714877 chr1:78749073~78750659:+ CESC trans rs61990749 0.686 rs11159288 ENSG00000235400.1 RP4-641G12.4 13.32 5.08e-30 1.74e-22 0.96 0.67 Fibroblast growth factor basic levels; chr14:77750629 chr1:78749073~78750659:+ CESC trans rs13253073 1 rs10955222 ENSG00000260318.1 COX6CP1 -13.31 5.5e-30 1.88e-22 -1.21 -0.67 Glucose homeostasis traits; chr8:99875122 chr16:11903923~11904137:- CESC trans rs55665837 0.583 rs78843135 ENSG00000236360.2 RP11-334A14.2 13.3 6.2e-30 2.11e-22 0.9 0.67 Vitamin D levels; chr11:14389708 chr1:52993201~52993702:- CESC trans rs12291225 0.535 rs11023203 ENSG00000236360.2 RP11-334A14.2 13.27 7.42e-30 2.52e-22 0.9 0.67 Sense of smell; chr11:14388269 chr1:52993201~52993702:- CESC trans rs1816752 0.74 rs6490924 ENSG00000237917.1 PARP4P1 -13.24 9.17e-30 3.1e-22 -0.78 -0.67 Obesity-related traits; chr13:24432914 chrY:26594851~26634652:- CESC trans rs2950393 0.929 rs7980835 ENSG00000121089.4 NACA3P 13.22 1.05e-29 3.52e-22 0.7 0.67 Platelet distribution width; chr12:56676847 chr4:164943290~164943937:+ CESC trans rs2950393 0.929 rs10747769 ENSG00000121089.4 NACA3P 13.22 1.05e-29 3.52e-22 0.7 0.67 Platelet distribution width; chr12:56677056 chr4:164943290~164943937:+ CESC trans rs2950393 0.929 rs10876916 ENSG00000121089.4 NACA3P 13.22 1.12e-29 3.75e-22 0.7 0.67 Platelet distribution width; chr12:56692728 chr4:164943290~164943937:+ CESC trans rs2950393 0.794 rs1563897 ENSG00000121089.4 NACA3P 13.22 1.12e-29 3.75e-22 0.7 0.67 Platelet distribution width; chr12:56699316 chr4:164943290~164943937:+ CESC trans rs61990749 0.597 rs176980 ENSG00000235400.1 RP4-641G12.4 -13.17 1.58e-29 5.25e-22 -0.92 -0.67 Fibroblast growth factor basic levels; chr14:77732106 chr1:78749073~78750659:+ CESC trans rs13253073 0.55 rs6468697 ENSG00000260318.1 COX6CP1 13.16 1.72e-29 5.68e-22 1 0.67 Glucose homeostasis traits; chr8:99858154 chr16:11903923~11904137:- CESC trans rs9611565 0.694 rs106860 ENSG00000268568.1 AC007228.9 -13.16 1.75e-29 5.77e-22 -1 -0.67 Vitiligo; chr22:41444403 chr19:56672574~56673901:- CESC trans rs941207 0.507 rs73337030 ENSG00000121089.4 NACA3P -13.12 2.21e-29 7.25e-22 -0.7 -0.66 Platelet count; chr12:56652410 chr4:164943290~164943937:+ CESC trans rs2950393 0.895 rs2958154 ENSG00000121089.4 NACA3P -13.08 3.07e-29 9.93e-22 -0.71 -0.66 Platelet distribution width; chr12:56671929 chr4:164943290~164943937:+ CESC trans rs9611565 0.694 rs202622 ENSG00000268568.1 AC007228.9 13.08 3.1e-29 9.96e-22 1 0.66 Vitiligo; chr22:41429338 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs202625 ENSG00000268568.1 AC007228.9 13.08 3.1e-29 9.96e-22 1 0.66 Vitiligo; chr22:41431078 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs7285041 ENSG00000268568.1 AC007228.9 13.08 3.1e-29 9.96e-22 1 0.66 Vitiligo; chr22:41433145 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs202656 ENSG00000268568.1 AC007228.9 13.08 3.1e-29 9.96e-22 1 0.66 Vitiligo; chr22:41446199 chr19:56672574~56673901:- CESC trans rs941207 0.542 rs11171978 ENSG00000121089.4 NACA3P 13.08 3.13e-29 1e-21 0.79 0.66 Platelet count; chr12:56800015 chr4:164943290~164943937:+ CESC trans rs12291225 0.877 rs2303974 ENSG00000236360.2 RP11-334A14.2 13.05 3.95e-29 1.26e-21 0.93 0.66 Sense of smell; chr11:14243433 chr1:52993201~52993702:- CESC trans rs1816752 0.583 rs6490918 ENSG00000237917.1 PARP4P1 -13.04 4.1e-29 1.31e-21 -0.78 -0.66 Obesity-related traits; chr13:24427977 chrY:26594851~26634652:- CESC trans rs13253073 1 rs4480092 ENSG00000260318.1 COX6CP1 13.03 4.56e-29 1.45e-21 1.21 0.66 Glucose homeostasis traits; chr8:99873372 chr16:11903923~11904137:- CESC trans rs55665837 0.524 rs61884009 ENSG00000236360.2 RP11-334A14.2 13.03 4.57e-29 1.45e-21 0.9 0.66 Vitamin D levels; chr11:14404916 chr1:52993201~52993702:- CESC trans rs61990749 0.597 rs11623088 ENSG00000235400.1 RP4-641G12.4 -13.02 4.67e-29 1.48e-21 -0.96 -0.66 Fibroblast growth factor basic levels; chr14:77671392 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs13379065 ENSG00000235400.1 RP4-641G12.4 -13.02 4.67e-29 1.48e-21 -0.96 -0.66 Fibroblast growth factor basic levels; chr14:77674952 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs17106157 ENSG00000235400.1 RP4-641G12.4 -13.02 4.67e-29 1.48e-21 -0.96 -0.66 Fibroblast growth factor basic levels; chr14:77680535 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs2267759 ENSG00000235400.1 RP4-641G12.4 -13.02 4.67e-29 1.48e-21 -0.96 -0.66 Fibroblast growth factor basic levels; chr14:77681272 chr1:78749073~78750659:+ CESC trans rs5758343 1 rs5758343 ENSG00000268568.1 AC007228.9 13.02 4.84e-29 1.52e-21 1 0.66 Allergic disease (asthma, hay fever or eczema); chr22:41420648 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs5758344 ENSG00000268568.1 AC007228.9 13.02 4.84e-29 1.52e-21 1 0.66 Vitiligo; chr22:41421681 chr19:56672574~56673901:- CESC trans rs7121616 0.563 rs4936770 ENSG00000234176.1 HSPA8P1 13.01 5.05e-29 1.58e-21 0.86 0.66 Breast cancer; chr11:123058167 chrX:121203182~121205014:- CESC trans rs6477998 0.535 rs10981712 ENSG00000238072.1 RP11-305M3.2 13.01 5.18e-29 1.62e-21 0.96 0.66 Hematology traits; chr9:113283846 chr7:129410113~129410370:- CESC trans rs9467773 0.549 rs9461273 ENSG00000242375.1 RP11-498P14.3 -13 5.46e-29 1.71e-21 -0.78 -0.66 Intelligence (multi-trait analysis); chr6:26584298 chr9:97195351~97197687:- CESC trans rs9611565 0.694 rs5758347 ENSG00000268568.1 AC007228.9 12.99 5.76e-29 1.79e-21 1 0.66 Vitiligo; chr22:41425015 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs202613 ENSG00000268568.1 AC007228.9 12.99 5.76e-29 1.79e-21 1 0.66 Vitiligo; chr22:41425989 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs202614 ENSG00000268568.1 AC007228.9 12.99 5.76e-29 1.79e-21 1 0.66 Vitiligo; chr22:41426146 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs202616 ENSG00000268568.1 AC007228.9 12.99 5.76e-29 1.79e-21 1 0.66 Vitiligo; chr22:41426217 chr19:56672574~56673901:- CESC trans rs9611565 0.569 rs188057 ENSG00000268568.1 AC007228.9 12.99 5.76e-29 1.79e-21 1 0.66 Vitiligo; chr22:41426301 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs202618 ENSG00000268568.1 AC007228.9 12.99 5.76e-29 1.79e-21 1 0.66 Vitiligo; chr22:41426852 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs5751107 ENSG00000268568.1 AC007228.9 12.99 5.76e-29 1.79e-21 1 0.66 Vitiligo; chr22:41461808 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs5751108 ENSG00000268568.1 AC007228.9 12.99 5.76e-29 1.79e-21 1 0.66 Vitiligo; chr22:41462031 chr19:56672574~56673901:- CESC trans rs12291225 0.535 rs16930126 ENSG00000236360.2 RP11-334A14.2 -12.99 5.87e-29 1.82e-21 -0.87 -0.66 Sense of smell; chr11:14383437 chr1:52993201~52993702:- CESC trans rs13177918 0.603 rs2343806 ENSG00000213058.3 RP4-765C7.2 12.99 5.96e-29 1.85e-21 0.79 0.66 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr1:178411616~178411972:+ CESC trans rs13253073 1 rs12544943 ENSG00000260318.1 COX6CP1 12.99 6.07e-29 1.88e-21 1.19 0.66 Glucose homeostasis traits; chr8:99891662 chr16:11903923~11904137:- CESC trans rs61990749 0.597 rs12887282 ENSG00000235400.1 RP4-641G12.4 12.98 6.31e-29 1.94e-21 0.93 0.66 Fibroblast growth factor basic levels; chr14:77734242 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs12887606 ENSG00000235400.1 RP4-641G12.4 12.98 6.31e-29 1.94e-21 0.93 0.66 Fibroblast growth factor basic levels; chr14:77734277 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs8003691 ENSG00000235400.1 RP4-641G12.4 12.98 6.31e-29 1.94e-21 0.93 0.66 Fibroblast growth factor basic levels; chr14:77744882 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs2267768 ENSG00000235400.1 RP4-641G12.4 12.98 6.31e-29 1.94e-21 0.93 0.66 Fibroblast growth factor basic levels; chr14:77749671 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs1549119 ENSG00000235400.1 RP4-641G12.4 12.98 6.31e-29 1.94e-21 0.93 0.66 Fibroblast growth factor basic levels; chr14:77753469 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs1978416 ENSG00000235400.1 RP4-641G12.4 12.98 6.31e-29 1.94e-21 0.93 0.66 Fibroblast growth factor basic levels; chr14:77761558 chr1:78749073~78750659:+ CESC trans rs61990749 0.544 rs3759728 ENSG00000235400.1 RP4-641G12.4 12.98 6.31e-29 1.94e-21 0.93 0.66 Fibroblast growth factor basic levels; chr14:77763816 chr1:78749073~78750659:+ CESC trans rs61990749 0.5 rs8011337 ENSG00000235400.1 RP4-641G12.4 12.98 6.47e-29 1.99e-21 0.98 0.66 Fibroblast growth factor basic levels; chr14:77806283 chr1:78749073~78750659:+ CESC trans rs7121616 0.595 rs7949414 ENSG00000234176.1 HSPA8P1 12.98 6.6e-29 2.03e-21 0.91 0.66 Breast cancer; chr11:123072787 chrX:121203182~121205014:- CESC trans rs9611565 0.694 rs2142505 ENSG00000268568.1 AC007228.9 12.96 7.55e-29 2.32e-21 1 0.66 Vitiligo; chr22:41424537 chr19:56672574~56673901:- CESC trans rs12291225 0.877 rs11023160 ENSG00000236360.2 RP11-334A14.2 12.94 8.64e-29 2.64e-21 0.93 0.66 Sense of smell; chr11:14242679 chr1:52993201~52993702:- CESC trans rs61990749 0.597 rs2364584 ENSG00000235400.1 RP4-641G12.4 -12.94 8.68e-29 2.65e-21 -0.94 -0.66 Fibroblast growth factor basic levels; chr14:77685943 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs10136053 ENSG00000235400.1 RP4-641G12.4 -12.94 8.68e-29 2.65e-21 -0.94 -0.66 Fibroblast growth factor basic levels; chr14:77688862 chr1:78749073~78750659:+ CESC trans rs7121616 0.576 rs4802 ENSG00000234176.1 HSPA8P1 12.93 9.16e-29 2.79e-21 0.83 0.66 Breast cancer; chr11:123057914 chrX:121203182~121205014:- CESC trans rs928391 1 rs2777929 ENSG00000227183.3 HDGFP1 12.91 1.05e-28 3.2e-21 1.07 0.66 Platelet count; chr1:156797879 chrX:131646639~131646890:+ CESC trans rs928391 1 rs2768767 ENSG00000227183.3 HDGFP1 12.91 1.05e-28 3.2e-21 1.07 0.66 Platelet count; chr1:156797933 chrX:131646639~131646890:+ CESC trans rs1816752 0.716 rs9553289 ENSG00000237917.1 PARP4P1 -12.91 1.06e-28 3.22e-21 -0.77 -0.66 Obesity-related traits; chr13:24400640 chrY:26594851~26634652:- CESC trans rs9899728 0.764 rs7219493 ENSG00000234925.2 ATP5HP4 12.89 1.23e-28 3.72e-21 1.07 0.66 Alzheimer's disease or small vessel stroke; chr17:75048093 chr12:68642519~68642993:- CESC trans rs7554547 0.667 rs2336377 ENSG00000261819.1 RP11-680G24.4 -12.87 1.46e-28 4.41e-21 -0.79 -0.66 Nonsyndromic cleft lip with cleft palate; chr1:11889913 chr16:14988259~14990160:- CESC trans rs13253073 1 rs34029308 ENSG00000260318.1 COX6CP1 12.86 1.57e-28 4.74e-21 1.21 0.66 Glucose homeostasis traits; chr8:99892425 chr16:11903923~11904137:- CESC trans rs13253073 1 rs12541837 ENSG00000260318.1 COX6CP1 -12.84 1.76e-28 5.29e-21 -1.2 -0.66 Glucose homeostasis traits; chr8:99869645 chr16:11903923~11904137:- CESC trans rs9611565 0.592 rs5751101 ENSG00000268568.1 AC007228.9 12.84 1.81e-28 5.44e-21 0.99 0.66 Vitiligo; chr22:41432107 chr19:56672574~56673901:- CESC trans rs7121616 0.562 rs2061602 ENSG00000234176.1 HSPA8P1 12.83 1.91e-28 5.73e-21 0.88 0.66 Breast cancer; chr11:123065079 chrX:121203182~121205014:- CESC trans rs12291225 0.535 rs12806025 ENSG00000236360.2 RP11-334A14.2 12.81 2.23e-28 6.69e-21 0.88 0.66 Sense of smell; chr11:14392271 chr1:52993201~52993702:- CESC trans rs12709013 0.613 rs1618602 ENSG00000230849.2 GOT2P2 12.81 2.27e-28 6.79e-21 0.77 0.66 Blood metabolite ratios; chr16:58756080 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs8045466 ENSG00000230849.2 GOT2P2 12.81 2.27e-28 6.79e-21 0.77 0.66 Blood metabolite ratios; chr16:58765113 chr1:173141100~173142350:- CESC trans rs1816752 0.875 rs3783076 ENSG00000237917.1 PARP4P1 12.8 2.46e-28 7.37e-21 0.79 0.65 Obesity-related traits; chr13:24490319 chrY:26594851~26634652:- CESC trans rs61990749 0.597 rs1477260 ENSG00000235400.1 RP4-641G12.4 12.74 3.6e-28 1.07e-20 0.96 0.65 Fibroblast growth factor basic levels; chr14:77790475 chr1:78749073~78750659:+ CESC trans rs6732160 0.525 rs2303907 ENSG00000236165.1 PRADC1P1 12.74 3.76e-28 1.12e-20 0.78 0.65 Intelligence (multi-trait analysis); chr2:73243369 chr3:36976316~36976840:+ CESC trans rs9467773 0.62 rs2451738 ENSG00000242375.1 RP11-498P14.3 -12.74 3.79e-28 1.12e-20 -0.77 -0.65 Intelligence (multi-trait analysis); chr6:26618231 chr9:97195351~97197687:- CESC trans rs8081395 0.576 rs1292032 ENSG00000187870.7 RNFT1P3 12.74 3.84e-28 1.14e-20 0.77 0.65 White blood cell count; chr17:59914982 chr17:20743333~20754501:- CESC trans rs928391 1 rs2644615 ENSG00000227183.3 HDGFP1 12.73 3.97e-28 1.18e-20 1.07 0.65 Platelet count; chr1:156791826 chrX:131646639~131646890:+ CESC trans rs9611565 0.694 rs202639 ENSG00000268568.1 AC007228.9 12.7 5.18e-28 1.53e-20 0.98 0.65 Vitiligo; chr22:41460133 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs5758365 ENSG00000268568.1 AC007228.9 12.7 5.18e-28 1.53e-20 0.98 0.65 Vitiligo; chr22:41462653 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs79009 ENSG00000268568.1 AC007228.9 12.7 5.18e-28 1.53e-20 0.98 0.65 Vitiligo; chr22:41464860 chr19:56672574~56673901:- CESC trans rs13253073 0.825 rs6984511 ENSG00000260318.1 COX6CP1 12.69 5.19e-28 1.53e-20 1.18 0.65 Glucose homeostasis traits; chr8:99869513 chr16:11903923~11904137:- CESC trans rs6732160 0.574 rs12465780 ENSG00000236165.1 PRADC1P1 -12.68 5.78e-28 1.7e-20 -0.78 -0.65 Intelligence (multi-trait analysis); chr2:73244884 chr3:36976316~36976840:+ CESC trans rs13253073 1 rs6468694 ENSG00000260318.1 COX6CP1 12.65 7.09e-28 2.08e-20 1.19 0.65 Glucose homeostasis traits; chr8:99853608 chr16:11903923~11904137:- CESC trans rs7121616 0.563 rs1461494 ENSG00000234176.1 HSPA8P1 12.64 7.69e-28 2.25e-20 0.83 0.65 Breast cancer; chr11:123055777 chrX:121203182~121205014:- CESC trans rs12709013 0.576 rs2432622 ENSG00000230849.2 GOT2P2 12.63 8.18e-28 2.39e-20 0.77 0.65 Blood metabolite ratios; chr16:58749681 chr1:173141100~173142350:- CESC trans rs941207 0.542 rs7311381 ENSG00000121089.4 NACA3P -12.61 9.9e-28 2.88e-20 -0.79 -0.65 Platelet count; chr12:56800286 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs6581107 ENSG00000121089.4 NACA3P -12.61 9.9e-28 2.88e-20 -0.79 -0.65 Platelet count; chr12:56801197 chr4:164943290~164943937:+ CESC trans rs8081395 0.741 rs1292053 ENSG00000187870.7 RNFT1P3 -12.6 1.01e-27 2.93e-20 -0.77 -0.65 White blood cell count; chr17:59886176 chr17:20743333~20754501:- CESC trans rs7949030 0.504 rs2516633 ENSG00000186676.3 EEF1GP1 -12.6 1.07e-27 3.1e-20 -0.94 -0.65 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62604301 chr7:125033453~125035301:+ CESC trans rs61990749 0.597 rs28534379 ENSG00000235400.1 RP4-641G12.4 -12.58 1.17e-27 3.37e-20 -0.92 -0.65 Fibroblast growth factor basic levels; chr14:77705797 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs176944 ENSG00000235400.1 RP4-641G12.4 -12.58 1.17e-27 3.37e-20 -0.92 -0.65 Fibroblast growth factor basic levels; chr14:77709868 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs176952 ENSG00000235400.1 RP4-641G12.4 12.58 1.17e-27 3.37e-20 0.92 0.65 Fibroblast growth factor basic levels; chr14:77714393 chr1:78749073~78750659:+ CESC trans rs61990749 0.544 rs2544566 ENSG00000235400.1 RP4-641G12.4 12.58 1.17e-27 3.37e-20 0.92 0.65 Fibroblast growth factor basic levels; chr14:77715395 chr1:78749073~78750659:+ CESC trans rs61990749 0.544 rs2544567 ENSG00000235400.1 RP4-641G12.4 12.58 1.17e-27 3.37e-20 0.92 0.65 Fibroblast growth factor basic levels; chr14:77715396 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs1008988 ENSG00000235400.1 RP4-641G12.4 12.58 1.22e-27 3.51e-20 0.95 0.65 Fibroblast growth factor basic levels; chr14:77794452 chr1:78749073~78750659:+ CESC trans rs6732160 0.574 rs1991612 ENSG00000236165.1 PRADC1P1 12.56 1.37e-27 3.92e-20 0.78 0.65 Intelligence (multi-trait analysis); chr2:73253373 chr3:36976316~36976840:+ CESC trans rs1045902 0.967 rs1469530 ENSG00000236165.1 PRADC1P1 12.56 1.44e-27 4.1e-20 0.8 0.65 Intelligence (multi-trait analysis); chr2:73237820 chr3:36976316~36976840:+ CESC trans rs1045902 0.967 rs10207625 ENSG00000236165.1 PRADC1P1 12.55 1.46e-27 4.16e-20 0.8 0.65 Intelligence (multi-trait analysis); chr2:73237680 chr3:36976316~36976840:+ CESC trans rs2950393 0.929 rs2958155 ENSG00000121089.4 NACA3P 12.55 1.47e-27 4.18e-20 0.69 0.65 Platelet distribution width; chr12:56670761 chr4:164943290~164943937:+ CESC trans rs61990749 0.544 rs176979 ENSG00000235400.1 RP4-641G12.4 12.55 1.47e-27 4.19e-20 0.9 0.65 Fibroblast growth factor basic levels; chr14:77731729 chr1:78749073~78750659:+ CESC trans rs13253073 1 rs13273257 ENSG00000260318.1 COX6CP1 12.54 1.64e-27 4.67e-20 1.19 0.65 Glucose homeostasis traits; chr8:99852468 chr16:11903923~11904137:- CESC trans rs2950393 0.804 rs3214051 ENSG00000121089.4 NACA3P 12.53 1.72e-27 4.89e-20 0.67 0.65 Platelet distribution width; chr12:56725452 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs1646281 ENSG00000230849.2 GOT2P2 12.53 1.79e-27 5.05e-20 0.76 0.65 Blood metabolite ratios; chr16:58750512 chr1:173141100~173142350:- CESC trans rs12709013 0.613 rs8049462 ENSG00000230849.2 GOT2P2 12.53 1.79e-27 5.05e-20 0.76 0.65 Blood metabolite ratios; chr16:58757654 chr1:173141100~173142350:- CESC trans rs12709013 0.66 rs257629 ENSG00000230849.2 GOT2P2 12.53 1.79e-27 5.05e-20 0.76 0.65 Blood metabolite ratios; chr16:58758044 chr1:173141100~173142350:- CESC trans rs2950393 0.804 rs1026565 ENSG00000121089.4 NACA3P 12.52 1.88e-27 5.31e-20 0.66 0.65 Platelet distribution width; chr12:56744044 chr4:164943290~164943937:+ CESC trans rs12709013 0.591 rs30838 ENSG00000233719.3 GOT2P3 12.51 2.06e-27 5.82e-20 0.74 0.65 Blood metabolite ratios; chr16:58711513 chr12:9641802~9643007:+ CESC trans rs2950393 0.804 rs2290894 ENSG00000121089.4 NACA3P 12.49 2.33e-27 6.56e-20 0.67 0.65 Platelet distribution width; chr12:56714911 chr4:164943290~164943937:+ CESC trans rs2950393 0.777 rs2926747 ENSG00000121089.4 NACA3P 12.49 2.33e-27 6.56e-20 0.67 0.65 Platelet distribution width; chr12:56716147 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs1646284 ENSG00000230849.2 GOT2P2 12.48 2.46e-27 6.89e-20 0.76 0.65 Blood metabolite ratios; chr16:58752093 chr1:173141100~173142350:- CESC trans rs9611565 0.649 rs202645 ENSG00000268568.1 AC007228.9 12.47 2.71e-27 7.55e-20 0.95 0.65 Vitiligo; chr22:41402516 chr19:56672574~56673901:- CESC trans rs2950393 0.804 rs2926752 ENSG00000121089.4 NACA3P 12.47 2.8e-27 7.8e-20 0.67 0.65 Platelet distribution width; chr12:56710144 chr4:164943290~164943937:+ CESC trans rs2950393 0.777 rs2958148 ENSG00000121089.4 NACA3P 12.47 2.8e-27 7.8e-20 0.67 0.65 Platelet distribution width; chr12:56710153 chr4:164943290~164943937:+ CESC trans rs55665837 0.559 rs11023209 ENSG00000236360.2 RP11-334A14.2 12.46 2.93e-27 8.15e-20 0.85 0.64 Vitamin D levels; chr11:14401054 chr1:52993201~52993702:- CESC trans rs12709013 0.591 rs4410065 ENSG00000230849.2 GOT2P2 12.45 3.03e-27 8.4e-20 0.77 0.64 Blood metabolite ratios; chr16:58800968 chr1:173141100~173142350:- CESC trans rs12709013 0.591 rs2406234 ENSG00000230849.2 GOT2P2 12.45 3.03e-27 8.4e-20 0.77 0.64 Blood metabolite ratios; chr16:58801840 chr1:173141100~173142350:- CESC trans rs12709013 0.591 rs2086206 ENSG00000230849.2 GOT2P2 12.45 3.03e-27 8.4e-20 0.77 0.64 Blood metabolite ratios; chr16:58802094 chr1:173141100~173142350:- CESC trans rs6732160 0.549 rs6744529 ENSG00000236165.1 PRADC1P1 12.45 3.24e-27 8.97e-20 0.78 0.64 Intelligence (multi-trait analysis); chr2:73253741 chr3:36976316~36976840:+ CESC trans rs61990749 0.597 rs12896026 ENSG00000235400.1 RP4-641G12.4 12.44 3.38e-27 9.33e-20 0.9 0.64 Fibroblast growth factor basic levels; chr14:77778093 chr1:78749073~78750659:+ CESC trans rs61990749 0.544 rs12435761 ENSG00000235400.1 RP4-641G12.4 12.44 3.38e-27 9.33e-20 0.9 0.64 Fibroblast growth factor basic levels; chr14:77779734 chr1:78749073~78750659:+ CESC trans rs61990749 0.597 rs4632066 ENSG00000235400.1 RP4-641G12.4 -12.44 3.38e-27 9.33e-20 -0.9 -0.64 Fibroblast growth factor basic levels; chr14:77780939 chr1:78749073~78750659:+ CESC trans rs13177918 0.603 rs2748241 ENSG00000213058.3 RP4-765C7.2 12.43 3.7e-27 1.02e-19 0.74 0.64 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr1:178411616~178411972:+ CESC trans rs941207 0.542 rs6581102 ENSG00000121089.4 NACA3P -12.43 3.7e-27 1.02e-19 -0.8 -0.64 Platelet count; chr12:56790632 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs6581103 ENSG00000121089.4 NACA3P -12.43 3.7e-27 1.02e-19 -0.8 -0.64 Platelet count; chr12:56790641 chr4:164943290~164943937:+ CESC trans rs10242455 0.702 rs3528 ENSG00000228834.1 RP11-249L21.4 12.41 4.08e-27 1.12e-19 1.48 0.64 Blood metabolite levels; chr7:99458317 chr6:108907615~108907873:- CESC trans rs61990749 0.597 rs9323650 ENSG00000235400.1 RP4-641G12.4 12.4 4.64e-27 1.27e-19 0.91 0.64 Fibroblast growth factor basic levels; chr14:77683993 chr1:78749073~78750659:+ CESC trans rs12709013 0.646 rs8046154 ENSG00000230849.2 GOT2P2 -12.4 4.65e-27 1.28e-19 -0.76 -0.64 Blood metabolite ratios; chr16:58773978 chr1:173141100~173142350:- CESC trans rs13177918 0.626 rs2748240 ENSG00000224114.1 RP11-343H5.4 12.38 5.1e-27 1.4e-19 0.79 0.64 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr1:206695837~206696269:- CESC trans rs6732160 0.574 rs7557055 ENSG00000236165.1 PRADC1P1 12.38 5.14e-27 1.41e-19 0.79 0.64 Intelligence (multi-trait analysis); chr2:73245542 chr3:36976316~36976840:+ CESC trans rs12709013 0.536 rs1646260 ENSG00000230849.2 GOT2P2 12.38 5.22e-27 1.43e-19 0.78 0.64 Blood metabolite ratios; chr16:58734951 chr1:173141100~173142350:- CESC trans rs941207 0.542 rs4277148 ENSG00000121089.4 NACA3P -12.38 5.39e-27 1.47e-19 -0.79 -0.64 Platelet count; chr12:56787071 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs12370142 ENSG00000121089.4 NACA3P -12.38 5.39e-27 1.47e-19 -0.79 -0.64 Platelet count; chr12:56790801 chr4:164943290~164943937:+ CESC trans rs12367822 0.956 rs9706160 ENSG00000121089.4 NACA3P -12.38 5.39e-27 1.47e-19 -0.79 -0.64 Platelet aggregation; chr12:56791119 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs2888095 ENSG00000121089.4 NACA3P -12.38 5.39e-27 1.47e-19 -0.79 -0.64 Platelet count; chr12:56793689 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs2888096 ENSG00000121089.4 NACA3P -12.38 5.39e-27 1.47e-19 -0.79 -0.64 Platelet count; chr12:56793851 chr4:164943290~164943937:+ CESC trans rs9611565 0.729 rs2413646 ENSG00000268568.1 AC007228.9 -12.37 5.69e-27 1.54e-19 -0.97 -0.64 Vitiligo; chr22:41510321 chr19:56672574~56673901:- CESC trans rs9611565 0.729 rs2413647 ENSG00000268568.1 AC007228.9 -12.37 5.69e-27 1.54e-19 -0.97 -0.64 Vitiligo; chr22:41511144 chr19:56672574~56673901:- CESC trans rs61990749 0.597 rs759808 ENSG00000235400.1 RP4-641G12.4 12.37 5.8e-27 1.57e-19 0.89 0.64 Fibroblast growth factor basic levels; chr14:77784502 chr1:78749073~78750659:+ CESC trans rs12709013 0.569 rs30837 ENSG00000233719.3 GOT2P3 12.36 6.05e-27 1.64e-19 0.74 0.64 Blood metabolite ratios; chr16:58711942 chr12:9641802~9643007:+ CESC trans rs916888 0.773 rs199451 ENSG00000214425.5 LRRC37A4P -12.34 6.96e-27 1.87e-19 -0.84 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45506741~45550335:- CESC trans rs13253073 1 rs6986006 ENSG00000260318.1 COX6CP1 12.33 7.34e-27 1.98e-19 1.2 0.64 Glucose homeostasis traits; chr8:99857251 chr16:11903923~11904137:- CESC trans rs9899728 0.665 rs2307008 ENSG00000234925.2 ATP5HP4 12.32 8.21e-27 2.2e-19 1.06 0.64 Alzheimer's disease or small vessel stroke; chr17:75046587 chr12:68642519~68642993:- CESC trans rs6732160 0.593 rs2288630 ENSG00000236165.1 PRADC1P1 12.31 8.44e-27 2.26e-19 0.79 0.64 Intelligence (multi-trait analysis); chr2:73230424 chr3:36976316~36976840:+ CESC trans rs941207 0.542 rs6581106 ENSG00000121089.4 NACA3P -12.31 8.86e-27 2.36e-19 -0.78 -0.64 Platelet count; chr12:56796759 chr4:164943290~164943937:+ CESC trans rs928391 1 rs12129173 ENSG00000227183.3 HDGFP1 12.31 8.96e-27 2.39e-19 1.02 0.64 Platelet count; chr1:156803833 chrX:131646639~131646890:+ CESC trans rs6477998 0.535 rs4979232 ENSG00000238072.1 RP11-305M3.2 -12.3 9.7e-27 2.58e-19 -0.96 -0.64 Hematology traits; chr9:113286594 chr7:129410113~129410370:- CESC trans rs61990749 0.597 rs1006039 ENSG00000235400.1 RP4-641G12.4 -12.28 1.06e-26 2.82e-19 -0.93 -0.64 Fibroblast growth factor basic levels; chr14:77796853 chr1:78749073~78750659:+ CESC trans rs941207 0.507 rs1107479 ENSG00000121089.4 NACA3P -12.28 1.11e-26 2.94e-19 -0.69 -0.64 Platelet count; chr12:56636902 chr4:164943290~164943937:+ CESC trans rs12709013 0.591 rs30840 ENSG00000233719.3 GOT2P3 12.28 1.11e-26 2.96e-19 0.73 0.64 Blood metabolite ratios; chr16:58710165 chr12:9641802~9643007:+ CESC trans rs55665837 0.559 rs9667144 ENSG00000236360.2 RP11-334A14.2 -12.27 1.14e-26 3.02e-19 -0.88 -0.64 Vitamin D levels; chr11:14399555 chr1:52993201~52993702:- CESC trans rs12709013 0.591 rs30834 ENSG00000233719.3 GOT2P3 12.26 1.23e-26 3.26e-19 0.74 0.64 Blood metabolite ratios; chr16:58715394 chr12:9641802~9643007:+ CESC trans rs9899728 0.764 rs9660 ENSG00000234925.2 ATP5HP4 12.26 1.24e-26 3.29e-19 1.01 0.64 Alzheimer's disease or small vessel stroke; chr17:75042651 chr12:68642519~68642993:- CESC trans rs1816752 0.669 rs9553309 ENSG00000237917.1 PARP4P1 -12.26 1.27e-26 3.35e-19 -0.75 -0.64 Obesity-related traits; chr13:24471476 chrY:26594851~26634652:- CESC trans rs6477998 0.535 rs10817475 ENSG00000238072.1 RP11-305M3.2 12.25 1.39e-26 3.64e-19 0.96 0.64 Hematology traits; chr9:113296774 chr7:129410113~129410370:- CESC trans rs9611565 0.659 rs1569516 ENSG00000268568.1 AC007228.9 -12.23 1.57e-26 4.11e-19 -0.96 -0.64 Vitiligo; chr22:41514240 chr19:56672574~56673901:- CESC trans rs55665837 0.559 rs11023210 ENSG00000236360.2 RP11-334A14.2 -12.21 1.81e-26 4.72e-19 -0.84 -0.64 Vitamin D levels; chr11:14401216 chr1:52993201~52993702:- CESC trans rs9611565 0.765 rs132907 ENSG00000268568.1 AC007228.9 12.2 1.91e-26 4.96e-19 0.94 0.64 Vitiligo; chr22:41405264 chr19:56672574~56673901:- CESC trans rs9611565 0.681 rs6002372 ENSG00000268568.1 AC007228.9 12.2 1.91e-26 4.96e-19 0.94 0.64 Vitiligo; chr22:41405295 chr19:56672574~56673901:- CESC trans rs9611565 0.765 rs132908 ENSG00000268568.1 AC007228.9 12.2 1.91e-26 4.96e-19 0.94 0.64 Vitiligo; chr22:41405791 chr19:56672574~56673901:- CESC trans rs13253073 0.941 rs13264726 ENSG00000260318.1 COX6CP1 12.2 2e-26 5.2e-19 1.18 0.64 Glucose homeostasis traits; chr8:99851139 chr16:11903923~11904137:- CESC trans rs12709013 0.591 rs30841 ENSG00000233719.3 GOT2P3 12.19 2.07e-26 5.37e-19 0.73 0.64 Blood metabolite ratios; chr16:58709819 chr12:9641802~9643007:+ CESC trans rs6732160 0.657 rs10171459 ENSG00000236165.1 PRADC1P1 12.19 2.14e-26 5.54e-19 0.77 0.64 Intelligence (multi-trait analysis); chr2:73207600 chr3:36976316~36976840:+ CESC trans rs6732160 0.691 rs7599223 ENSG00000236165.1 PRADC1P1 12.19 2.14e-26 5.55e-19 0.77 0.64 Intelligence (multi-trait analysis); chr2:73199975 chr3:36976316~36976840:+ CESC trans rs9611565 0.694 rs202637 ENSG00000268568.1 AC007228.9 12.18 2.26e-26 5.85e-19 0.98 0.64 Vitiligo; chr22:41457924 chr19:56672574~56673901:- CESC trans rs12709013 0.514 rs8062639 ENSG00000230849.2 GOT2P2 12.18 2.31e-26 5.98e-19 0.76 0.64 Blood metabolite ratios; chr16:58800264 chr1:173141100~173142350:- CESC trans rs12709013 0.536 rs9930758 ENSG00000230849.2 GOT2P2 12.18 2.31e-26 5.98e-19 0.76 0.64 Blood metabolite ratios; chr16:58803167 chr1:173141100~173142350:- CESC trans rs916888 0.773 rs199448 ENSG00000214425.5 LRRC37A4P -12.17 2.45e-26 6.31e-19 -0.8 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45506741~45550335:- CESC trans rs941207 0.542 rs11171983 ENSG00000121089.4 NACA3P -12.14 2.95e-26 7.56e-19 -0.79 -0.64 Platelet count; chr12:56814461 chr4:164943290~164943937:+ CESC trans rs1816752 0.819 rs4769349 ENSG00000237917.1 PARP4P1 -12.14 2.97e-26 7.62e-19 -0.74 -0.64 Obesity-related traits; chr13:24408694 chrY:26594851~26634652:- CESC trans rs928391 0.895 rs12042999 ENSG00000227183.3 HDGFP1 12.14 2.99e-26 7.67e-19 1.01 0.64 Platelet count; chr1:156768636 chrX:131646639~131646890:+ CESC trans rs2731664 0.792 rs465670 ENSG00000215571.5 GRK6P1 12.12 3.37e-26 8.59e-19 0.77 0.63 Intelligence (multi-trait analysis); chr5:177450623 chr13:21319156~21320866:+ CESC trans rs2731664 0.792 rs335452 ENSG00000215571.5 GRK6P1 12.12 3.37e-26 8.59e-19 0.77 0.63 Intelligence (multi-trait analysis); chr5:177452670 chr13:21319156~21320866:+ CESC trans rs12709013 0.591 rs9932967 ENSG00000230849.2 GOT2P2 12.12 3.56e-26 9.06e-19 0.76 0.63 Blood metabolite ratios; chr16:58805583 chr1:173141100~173142350:- CESC trans rs6477998 0.513 rs10981720 ENSG00000238072.1 RP11-305M3.2 12.12 3.56e-26 9.06e-19 0.97 0.63 Hematology traits; chr9:113293831 chr7:129410113~129410370:- CESC trans rs2731664 0.792 rs335466 ENSG00000215571.5 GRK6P1 12.12 3.56e-26 9.07e-19 0.77 0.63 Intelligence (multi-trait analysis); chr5:177462529 chr13:21319156~21320866:+ CESC trans rs916888 0.773 rs199457 ENSG00000214425.5 LRRC37A4P -12.11 3.65e-26 9.3e-19 -0.83 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45506741~45550335:- CESC trans rs916888 0.687 rs199456 ENSG00000214425.5 LRRC37A4P -12.11 3.65e-26 9.3e-19 -0.83 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45506741~45550335:- CESC trans rs9611565 0.643 rs202634 ENSG00000268568.1 AC007228.9 12.11 3.77e-26 9.59e-19 0.94 0.63 Vitiligo; chr22:41413619 chr19:56672574~56673901:- CESC trans rs2731664 0.792 rs385981 ENSG00000215571.5 GRK6P1 12.1 3.92e-26 9.97e-19 0.77 0.63 Intelligence (multi-trait analysis); chr5:177459538 chr13:21319156~21320866:+ CESC trans rs9611565 0.659 rs9611604 ENSG00000268568.1 AC007228.9 -12.1 4.09e-26 1.04e-18 -0.96 -0.63 Vitiligo; chr22:41519997 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs11090049 ENSG00000268568.1 AC007228.9 -12.09 4.5e-26 1.14e-18 -0.95 -0.63 Vitiligo; chr22:41519325 chr19:56672574~56673901:- CESC trans rs916888 0.773 rs1378358 ENSG00000214425.5 LRRC37A4P -12.08 4.63e-26 1.17e-18 -0.83 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45506741~45550335:- CESC trans rs916888 0.773 rs169201 ENSG00000214425.5 LRRC37A4P -12.08 4.63e-26 1.17e-18 -0.83 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45506741~45550335:- CESC trans rs12709013 0.591 rs30842 ENSG00000233719.3 GOT2P3 -12.08 4.76e-26 1.2e-18 -0.71 -0.63 Blood metabolite ratios; chr16:58709550 chr12:9641802~9643007:+ CESC trans rs9611565 0.729 rs73176686 ENSG00000268568.1 AC007228.9 -12.07 5.14e-26 1.29e-18 -0.92 -0.63 Vitiligo; chr22:41386115 chr19:56672574~56673901:- CESC trans rs9611565 0.729 rs4822027 ENSG00000268568.1 AC007228.9 -12.07 5.14e-26 1.29e-18 -0.92 -0.63 Vitiligo; chr22:41390223 chr19:56672574~56673901:- CESC trans rs928391 0.895 rs11264547 ENSG00000227183.3 HDGFP1 12.06 5.27e-26 1.32e-18 1.01 0.63 Platelet count; chr1:156776326 chrX:131646639~131646890:+ CESC trans rs2731664 0.792 rs652242 ENSG00000215571.5 GRK6P1 12.06 5.39e-26 1.35e-18 0.77 0.63 Intelligence (multi-trait analysis); chr5:177446009 chr13:21319156~21320866:+ CESC trans rs10242455 0.702 rs74416635 ENSG00000228834.1 RP11-249L21.4 12.06 5.39e-26 1.35e-18 1.48 0.63 Blood metabolite levels; chr7:99582946 chr6:108907615~108907873:- CESC trans rs10242455 0.557 rs73401516 ENSG00000228834.1 RP11-249L21.4 12.06 5.53e-26 1.38e-18 1.44 0.63 Blood metabolite levels; chr7:99470728 chr6:108907615~108907873:- CESC trans rs2731664 0.792 rs335467 ENSG00000215571.5 GRK6P1 12.04 6.34e-26 1.58e-18 0.77 0.63 Intelligence (multi-trait analysis); chr5:177463641 chr13:21319156~21320866:+ CESC trans rs6732160 0.631 rs7557285 ENSG00000236165.1 PRADC1P1 12.03 6.72e-26 1.66e-18 0.76 0.63 Intelligence (multi-trait analysis); chr2:73215684 chr3:36976316~36976840:+ CESC trans rs10242455 0.702 rs55927283 ENSG00000228834.1 RP11-249L21.4 12.03 6.78e-26 1.68e-18 1.45 0.63 Blood metabolite levels; chr7:99459568 chr6:108907615~108907873:- CESC trans rs928391 0.947 rs11264549 ENSG00000227183.3 HDGFP1 12.02 7.17e-26 1.76e-18 1.02 0.63 Platelet count; chr1:156781017 chrX:131646639~131646890:+ CESC trans rs928391 1 rs12134991 ENSG00000227183.3 HDGFP1 12.02 7.17e-26 1.76e-18 1.02 0.63 Platelet count; chr1:156781285 chrX:131646639~131646890:+ CESC trans rs928391 1 rs2274501 ENSG00000227183.3 HDGFP1 12.02 7.17e-26 1.76e-18 1.02 0.63 Platelet count; chr1:156782460 chrX:131646639~131646890:+ CESC trans rs2731664 0.792 rs163199 ENSG00000215571.5 GRK6P1 12.02 7.25e-26 1.78e-18 0.76 0.63 Intelligence (multi-trait analysis); chr5:177463066 chr13:21319156~21320866:+ CESC trans rs9611565 0.659 rs169361 ENSG00000268568.1 AC007228.9 12.01 7.77e-26 1.91e-18 0.96 0.63 Vitiligo; chr22:41481985 chr19:56672574~56673901:- CESC trans rs2950393 0.857 rs9989034 ENSG00000121089.4 NACA3P 12.01 8.05e-26 1.97e-18 0.65 0.63 Platelet distribution width; chr12:56674508 chr4:164943290~164943937:+ CESC trans rs61990749 0.597 rs717683 ENSG00000235400.1 RP4-641G12.4 12 8.29e-26 2.02e-18 0.91 0.63 Fibroblast growth factor basic levels; chr14:77789110 chr1:78749073~78750659:+ CESC trans rs61990749 0.544 rs1477259 ENSG00000235400.1 RP4-641G12.4 12 8.29e-26 2.02e-18 0.91 0.63 Fibroblast growth factor basic levels; chr14:77789795 chr1:78749073~78750659:+ CESC trans rs6732160 0.691 rs1960233 ENSG00000236165.1 PRADC1P1 12 8.39e-26 2.04e-18 0.76 0.63 Intelligence (multi-trait analysis); chr2:73194250 chr3:36976316~36976840:+ CESC trans rs6732160 0.691 rs2007191 ENSG00000236165.1 PRADC1P1 12 8.39e-26 2.04e-18 0.76 0.63 Intelligence (multi-trait analysis); chr2:73194335 chr3:36976316~36976840:+ CESC trans rs12709013 0.574 rs839418 ENSG00000233719.3 GOT2P3 12 8.58e-26 2.09e-18 0.73 0.63 Blood metabolite ratios; chr16:58705426 chr12:9641802~9643007:+ CESC trans rs10242455 0.557 rs59672032 ENSG00000228834.1 RP11-249L21.4 11.99 8.82e-26 2.15e-18 1.43 0.63 Blood metabolite levels; chr7:99461074 chr6:108907615~108907873:- CESC trans rs2950393 0.929 rs2290893 ENSG00000121089.4 NACA3P 11.99 9.01e-26 2.19e-18 0.65 0.63 Platelet distribution width; chr12:56684836 chr4:164943290~164943937:+ CESC trans rs12709013 0.536 rs1646260 ENSG00000233719.3 GOT2P3 11.97 1.03e-25 2.48e-18 0.72 0.63 Blood metabolite ratios; chr16:58734951 chr12:9641802~9643007:+ CESC trans rs1816752 0.679 rs8181826 ENSG00000237917.1 PARP4P1 -11.96 1.09e-25 2.64e-18 -0.74 -0.63 Obesity-related traits; chr13:24396570 chrY:26594851~26634652:- CESC trans rs928391 1 rs12043405 ENSG00000227183.3 HDGFP1 11.96 1.12e-25 2.7e-18 1.02 0.63 Platelet count; chr1:156784508 chrX:131646639~131646890:+ CESC trans rs12709013 0.613 rs4238801 ENSG00000230849.2 GOT2P2 11.96 1.13e-25 2.72e-18 0.75 0.63 Blood metabolite ratios; chr16:58738275 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs4575523 ENSG00000230849.2 GOT2P2 11.96 1.13e-25 2.72e-18 0.75 0.63 Blood metabolite ratios; chr16:58738559 chr1:173141100~173142350:- CESC trans rs2731664 0.756 rs2545796 ENSG00000215571.5 GRK6P1 11.96 1.15e-25 2.76e-18 0.78 0.63 Intelligence (multi-trait analysis); chr5:177437268 chr13:21319156~21320866:+ CESC trans rs9611565 0.659 rs17367716 ENSG00000268568.1 AC007228.9 -11.95 1.23e-25 2.95e-18 -0.94 -0.63 Vitiligo; chr22:41517840 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs9611602 ENSG00000268568.1 AC007228.9 -11.94 1.27e-25 3.06e-18 -0.92 -0.63 Vitiligo; chr22:41512401 chr19:56672574~56673901:- CESC trans rs12709013 0.591 rs899375 ENSG00000230849.2 GOT2P2 11.94 1.31e-25 3.15e-18 0.76 0.63 Blood metabolite ratios; chr16:58792325 chr1:173141100~173142350:- CESC trans rs9611565 0.685 rs169363 ENSG00000268568.1 AC007228.9 11.94 1.34e-25 3.21e-18 0.92 0.63 Vitiligo; chr22:41457113 chr19:56672574~56673901:- CESC trans rs12709013 0.574 rs9302706 ENSG00000230849.2 GOT2P2 11.93 1.36e-25 3.27e-18 0.76 0.63 Blood metabolite ratios; chr16:58812060 chr1:173141100~173142350:- CESC trans rs9611565 0.579 rs73178621 ENSG00000268568.1 AC007228.9 -11.93 1.37e-25 3.29e-18 -0.95 -0.63 Vitiligo; chr22:41525661 chr19:56672574~56673901:- CESC trans rs2950393 0.895 rs2958123 ENSG00000121089.4 NACA3P 11.93 1.43e-25 3.43e-18 0.65 0.63 Platelet distribution width; chr12:56668441 chr4:164943290~164943937:+ CESC trans rs10242455 0.702 rs112475236 ENSG00000228834.1 RP11-249L21.4 11.93 1.44e-25 3.43e-18 1.51 0.63 Blood metabolite levels; chr7:99447056 chr6:108907615~108907873:- CESC trans rs9611565 0.694 rs202617 ENSG00000268568.1 AC007228.9 11.92 1.44e-25 3.44e-18 0.95 0.63 Vitiligo; chr22:41426789 chr19:56672574~56673901:- CESC trans rs12709013 0.591 rs6499980 ENSG00000230849.2 GOT2P2 11.92 1.45e-25 3.46e-18 0.76 0.63 Blood metabolite ratios; chr16:58787972 chr1:173141100~173142350:- CESC trans rs928391 1 rs61816272 ENSG00000227183.3 HDGFP1 11.92 1.45e-25 3.47e-18 1 0.63 Platelet count; chr1:156778073 chrX:131646639~131646890:+ CESC trans rs2731664 0.756 rs4976695 ENSG00000215571.5 GRK6P1 11.91 1.6e-25 3.8e-18 0.78 0.63 Intelligence (multi-trait analysis); chr5:177435962 chr13:21319156~21320866:+ CESC trans rs13177918 0.581 rs2748244 ENSG00000213058.3 RP4-765C7.2 11.89 1.81e-25 4.29e-18 0.75 0.63 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150436487 chr1:178411616~178411972:+ CESC trans rs13253073 0.941 rs12548827 ENSG00000260318.1 COX6CP1 11.89 1.88e-25 4.42e-18 1.15 0.63 Glucose homeostasis traits; chr8:99841495 chr16:11903923~11904137:- CESC trans rs6732160 0.65 rs7560224 ENSG00000236165.1 PRADC1P1 11.88 1.98e-25 4.67e-18 0.76 0.63 Intelligence (multi-trait analysis); chr2:73179054 chr3:36976316~36976840:+ CESC trans rs12709013 0.613 rs6499984 ENSG00000230849.2 GOT2P2 11.88 2.03e-25 4.78e-18 0.76 0.63 Blood metabolite ratios; chr16:58810209 chr1:173141100~173142350:- CESC trans rs13177918 0.626 rs2748240 ENSG00000239528.1 RPS14P8 11.86 2.24e-25 5.24e-18 0.78 0.63 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr5:116562562~116562930:+ CESC trans rs941207 0.542 rs2126068 ENSG00000121089.4 NACA3P -11.86 2.28e-25 5.34e-18 -0.78 -0.63 Platelet count; chr12:56804716 chr4:164943290~164943937:+ CESC trans rs12709013 0.591 rs4784986 ENSG00000230849.2 GOT2P2 11.84 2.68e-25 6.23e-18 0.73 0.63 Blood metabolite ratios; chr16:58803007 chr1:173141100~173142350:- CESC trans rs9611565 0.694 rs79008 ENSG00000268568.1 AC007228.9 -11.84 2.69e-25 6.23e-18 -0.91 -0.63 Vitiligo; chr22:41454496 chr19:56672574~56673901:- CESC trans rs13253073 0.941 rs4076509 ENSG00000260318.1 COX6CP1 11.84 2.76e-25 6.38e-18 1.15 0.63 Glucose homeostasis traits; chr8:99842928 chr16:11903923~11904137:- CESC trans rs6732160 0.691 rs13432787 ENSG00000236165.1 PRADC1P1 11.83 2.84e-25 6.57e-18 0.76 0.63 Intelligence (multi-trait analysis); chr2:73203106 chr3:36976316~36976840:+ CESC trans rs6732160 0.691 rs6728147 ENSG00000236165.1 PRADC1P1 -11.83 2.93e-25 6.77e-18 -0.74 -0.63 Intelligence (multi-trait analysis); chr2:73196362 chr3:36976316~36976840:+ CESC trans rs6732160 0.691 rs11886257 ENSG00000236165.1 PRADC1P1 11.82 3.07e-25 7.09e-18 0.76 0.62 Intelligence (multi-trait analysis); chr2:73189745 chr3:36976316~36976840:+ CESC trans rs12709013 0.576 rs2432622 ENSG00000233719.3 GOT2P3 11.81 3.23e-25 7.45e-18 0.7 0.62 Blood metabolite ratios; chr16:58749681 chr12:9641802~9643007:+ CESC trans rs10242455 0.85 rs57367781 ENSG00000228834.1 RP11-249L21.4 11.81 3.28e-25 7.56e-18 1.48 0.62 Blood metabolite levels; chr7:99519196 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs6974831 ENSG00000228834.1 RP11-249L21.4 11.81 3.28e-25 7.56e-18 1.48 0.62 Blood metabolite levels; chr7:99533982 chr6:108907615~108907873:- CESC trans rs9611565 0.802 rs73176692 ENSG00000268568.1 AC007228.9 -11.81 3.43e-25 7.88e-18 -0.91 -0.62 Vitiligo; chr22:41389731 chr19:56672574~56673901:- CESC trans rs9611565 0.765 rs28604950 ENSG00000268568.1 AC007228.9 -11.81 3.43e-25 7.88e-18 -0.91 -0.62 Vitiligo; chr22:41389808 chr19:56672574~56673901:- CESC trans rs9611565 0.802 rs73176694 ENSG00000268568.1 AC007228.9 -11.81 3.43e-25 7.88e-18 -0.91 -0.62 Vitiligo; chr22:41390784 chr19:56672574~56673901:- CESC trans rs941207 0.542 rs1813109 ENSG00000121089.4 NACA3P -11.81 3.44e-25 7.88e-18 -0.78 -0.62 Platelet count; chr12:56798079 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs7315786 ENSG00000121089.4 NACA3P -11.81 3.44e-25 7.88e-18 -0.78 -0.62 Platelet count; chr12:56801595 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs67808059 ENSG00000121089.4 NACA3P -11.8 3.54e-25 8.08e-18 -0.78 -0.62 Platelet count; chr12:56805228 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs1870674 ENSG00000121089.4 NACA3P -11.8 3.54e-25 8.08e-18 -0.78 -0.62 Platelet count; chr12:56805721 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs11171980 ENSG00000121089.4 NACA3P -11.8 3.54e-25 8.08e-18 -0.78 -0.62 Platelet count; chr12:56806397 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs12367339 ENSG00000121089.4 NACA3P -11.8 3.54e-25 8.08e-18 -0.78 -0.62 Platelet count; chr12:56809521 chr4:164943290~164943937:+ CESC trans rs2731664 0.792 rs337374 ENSG00000215571.5 GRK6P1 -11.8 3.65e-25 8.32e-18 -0.75 -0.62 Intelligence (multi-trait analysis); chr5:177463415 chr13:21319156~21320866:+ CESC trans rs10242455 0.702 rs45461000 ENSG00000228834.1 RP11-249L21.4 11.8 3.67e-25 8.38e-18 1.48 0.62 Blood metabolite levels; chr7:99455087 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs73403290 ENSG00000228834.1 RP11-249L21.4 11.79 3.85e-25 8.77e-18 1.47 0.62 Blood metabolite levels; chr7:99560205 chr6:108907615~108907873:- CESC trans rs13177918 0.603 rs2748241 ENSG00000224114.1 RP11-343H5.4 11.78 4.23e-25 9.61e-18 0.72 0.62 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr1:206695837~206696269:- CESC trans rs9611565 0.765 rs767593 ENSG00000268568.1 AC007228.9 -11.77 4.47e-25 1.02e-17 -0.91 -0.62 Vitiligo; chr22:41383967 chr19:56672574~56673901:- CESC trans rs1816752 0.624 rs9553312 ENSG00000237917.1 PARP4P1 -11.76 4.64e-25 1.05e-17 -0.74 -0.62 Obesity-related traits; chr13:24474055 chrY:26594851~26634652:- CESC trans rs941207 0.542 rs12366897 ENSG00000121089.4 NACA3P -11.76 4.86e-25 1.1e-17 -0.78 -0.62 Platelet count; chr12:56808329 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs12367312 ENSG00000121089.4 NACA3P -11.76 4.86e-25 1.1e-17 -0.78 -0.62 Platelet count; chr12:56809369 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs12367822 ENSG00000121089.4 NACA3P -11.76 4.86e-25 1.1e-17 -0.78 -0.62 Platelet count; chr12:56810376 chr4:164943290~164943937:+ CESC trans rs9611565 0.694 rs202664 ENSG00000268568.1 AC007228.9 11.76 4.87e-25 1.1e-17 0.91 0.62 Vitiligo; chr22:41417882 chr19:56672574~56673901:- CESC trans rs2950393 0.777 rs7966391 ENSG00000121089.4 NACA3P 11.76 4.88e-25 1.1e-17 0.66 0.62 Platelet distribution width; chr12:56745272 chr4:164943290~164943937:+ CESC trans rs10242455 0.557 rs77997620 ENSG00000228834.1 RP11-249L21.4 11.75 5.15e-25 1.16e-17 1.46 0.62 Blood metabolite levels; chr7:99472792 chr6:108907615~108907873:- CESC trans rs2657294 0.62 rs2395136 ENSG00000172974.11 AC007318.5 11.75 5.15e-25 1.16e-17 0.64 0.62 Pneumonia; chr10:75088213 chr2:65205108~65205988:+ CESC trans rs1816752 0.646 rs3783073 ENSG00000237917.1 PARP4P1 -11.74 5.38e-25 1.21e-17 -0.73 -0.62 Obesity-related traits; chr13:24493222 chrY:26594851~26634652:- CESC trans rs12709013 0.613 rs1618602 ENSG00000233719.3 GOT2P3 11.73 5.74e-25 1.29e-17 0.7 0.62 Blood metabolite ratios; chr16:58756080 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs8045466 ENSG00000233719.3 GOT2P3 11.73 5.74e-25 1.29e-17 0.7 0.62 Blood metabolite ratios; chr16:58765113 chr12:9641802~9643007:+ CESC trans rs10716881 1 rs10716881 ENSG00000121089.4 NACA3P -11.73 5.76e-25 1.29e-17 -0.65 -0.62 High light scatter reticulocyte count; chr12:56644387 chr4:164943290~164943937:+ CESC trans rs1816752 0.583 rs9511284 ENSG00000237917.1 PARP4P1 -11.73 5.91e-25 1.32e-17 -0.74 -0.62 Obesity-related traits; chr13:24463660 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511295 ENSG00000237917.1 PARP4P1 -11.73 5.91e-25 1.32e-17 -0.74 -0.62 Obesity-related traits; chr13:24467794 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs4770692 ENSG00000237917.1 PARP4P1 -11.73 5.91e-25 1.32e-17 -0.74 -0.62 Obesity-related traits; chr13:24468689 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs4770694 ENSG00000237917.1 PARP4P1 -11.73 5.91e-25 1.32e-17 -0.74 -0.62 Obesity-related traits; chr13:24468891 chrY:26594851~26634652:- CESC trans rs1816752 0.624 rs9507354 ENSG00000237917.1 PARP4P1 -11.73 5.91e-25 1.32e-17 -0.74 -0.62 Obesity-related traits; chr13:24469227 chrY:26594851~26634652:- CESC trans rs12709013 0.636 rs1646281 ENSG00000233719.3 GOT2P3 11.73 5.99e-25 1.34e-17 0.7 0.62 Blood metabolite ratios; chr16:58750512 chr12:9641802~9643007:+ CESC trans rs12709013 0.613 rs8049462 ENSG00000233719.3 GOT2P3 11.73 5.99e-25 1.34e-17 0.7 0.62 Blood metabolite ratios; chr16:58757654 chr12:9641802~9643007:+ CESC trans rs12709013 0.66 rs257629 ENSG00000233719.3 GOT2P3 11.73 5.99e-25 1.34e-17 0.7 0.62 Blood metabolite ratios; chr16:58758044 chr12:9641802~9643007:+ CESC trans rs6477998 1 rs4560868 ENSG00000238072.1 RP11-305M3.2 -11.73 6.01e-25 1.34e-17 -0.82 -0.62 Hematology traits; chr9:113223219 chr7:129410113~129410370:- CESC trans rs2731664 0.792 rs335468 ENSG00000215571.5 GRK6P1 -11.73 6.02e-25 1.35e-17 -0.74 -0.62 Intelligence (multi-trait analysis); chr5:177465348 chr13:21319156~21320866:+ CESC trans rs10242455 0.702 rs59240302 ENSG00000228834.1 RP11-249L21.4 11.73 6.11e-25 1.36e-17 1.46 0.62 Blood metabolite levels; chr7:99475368 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs73403247 ENSG00000228834.1 RP11-249L21.4 11.73 6.11e-25 1.36e-17 1.46 0.62 Blood metabolite levels; chr7:99491107 chr6:108907615~108907873:- CESC trans rs12709013 0.591 rs7184377 ENSG00000230849.2 GOT2P2 11.72 6.34e-25 1.41e-17 0.75 0.62 Blood metabolite ratios; chr16:58808765 chr1:173141100~173142350:- CESC trans rs7121616 0.562 rs7131452 ENSG00000234176.1 HSPA8P1 11.71 6.85e-25 1.52e-17 0.82 0.62 Breast cancer; chr11:123065314 chrX:121203182~121205014:- CESC trans rs12709013 0.636 rs1646284 ENSG00000233719.3 GOT2P3 11.7 7.5e-25 1.67e-17 0.7 0.62 Blood metabolite ratios; chr16:58752093 chr12:9641802~9643007:+ CESC trans rs1816752 0.646 rs7995190 ENSG00000237917.1 PARP4P1 -11.69 7.77e-25 1.72e-17 -0.74 -0.62 Obesity-related traits; chr13:24475709 chrY:26594851~26634652:- CESC trans rs9611565 0.659 rs9611603 ENSG00000268568.1 AC007228.9 -11.69 8.18e-25 1.81e-17 -0.91 -0.62 Vitiligo; chr22:41516746 chr19:56672574~56673901:- CESC trans rs941207 0.762 rs10450 ENSG00000121089.4 NACA3P 11.68 8.38e-25 1.85e-17 0.72 0.62 Platelet count; chr12:56590822 chr4:164943290~164943937:+ CESC trans rs2731664 0.819 rs449351 ENSG00000215571.5 GRK6P1 11.67 9.31e-25 2.04e-17 0.76 0.62 Intelligence (multi-trait analysis); chr5:177445590 chr13:21319156~21320866:+ CESC trans rs10242455 0.702 rs73401510 ENSG00000228834.1 RP11-249L21.4 11.67 9.46e-25 2.07e-17 1.44 0.62 Blood metabolite levels; chr7:99468189 chr6:108907615~108907873:- CESC trans rs916888 0.773 rs199439 ENSG00000214425.5 LRRC37A4P -11.66 9.9e-25 2.16e-17 -0.81 -0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45506741~45550335:- CESC trans rs941207 0.514 rs6581105 ENSG00000121089.4 NACA3P -11.66 9.93e-25 2.17e-17 -0.78 -0.62 Platelet count; chr12:56792184 chr4:164943290~164943937:+ CESC trans rs10242455 0.702 rs73403286 ENSG00000228834.1 RP11-249L21.4 11.65 1.04e-24 2.26e-17 1.57 0.62 Blood metabolite levels; chr7:99557242 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs73405247 ENSG00000228834.1 RP11-249L21.4 11.65 1.04e-24 2.26e-17 1.57 0.62 Blood metabolite levels; chr7:99561551 chr6:108907615~108907873:- CESC trans rs12709013 0.636 rs967852 ENSG00000230849.2 GOT2P2 11.65 1.07e-24 2.33e-17 0.75 0.62 Blood metabolite ratios; chr16:58807313 chr1:173141100~173142350:- CESC trans rs9611565 0.694 rs202665 ENSG00000268568.1 AC007228.9 11.64 1.1e-24 2.4e-17 0.91 0.62 Vitiligo; chr22:41418397 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs202666 ENSG00000268568.1 AC007228.9 11.64 1.1e-24 2.4e-17 0.91 0.62 Vitiligo; chr22:41418715 chr19:56672574~56673901:- CESC trans rs2731664 0.792 rs466256 ENSG00000215571.5 GRK6P1 11.63 1.21e-24 2.61e-17 0.76 0.62 Intelligence (multi-trait analysis); chr5:177448955 chr13:21319156~21320866:+ CESC trans rs916888 0.773 rs538628 ENSG00000214425.5 LRRC37A4P -11.63 1.23e-24 2.67e-17 -0.8 -0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45506741~45550335:- CESC trans rs9611565 0.659 rs17367849 ENSG00000268568.1 AC007228.9 -11.63 1.25e-24 2.7e-17 -0.91 -0.62 Vitiligo; chr22:41527640 chr19:56672574~56673901:- CESC trans rs10242455 0.702 rs73711293 ENSG00000228834.1 RP11-249L21.4 11.62 1.3e-24 2.81e-17 1.55 0.62 Blood metabolite levels; chr7:99483972 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs73711294 ENSG00000228834.1 RP11-249L21.4 11.62 1.3e-24 2.81e-17 1.55 0.62 Blood metabolite levels; chr7:99491091 chr6:108907615~108907873:- CESC trans rs1816752 0.583 rs9553311 ENSG00000237917.1 PARP4P1 -11.61 1.45e-24 3.12e-17 -0.73 -0.62 Obesity-related traits; chr13:24474016 chrY:26594851~26634652:- CESC trans rs10242455 0.557 rs2404487 ENSG00000228834.1 RP11-249L21.4 11.59 1.59e-24 3.41e-17 1.48 0.62 Blood metabolite levels; chr7:99440434 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs73711280 ENSG00000228834.1 RP11-249L21.4 11.59 1.59e-24 3.41e-17 1.48 0.62 Blood metabolite levels; chr7:99441981 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs45448997 ENSG00000228834.1 RP11-249L21.4 11.59 1.59e-24 3.41e-17 1.48 0.62 Blood metabolite levels; chr7:99443975 chr6:108907615~108907873:- CESC trans rs10242455 0.557 rs73403272 ENSG00000228834.1 RP11-249L21.4 11.58 1.71e-24 3.64e-17 1.41 0.62 Blood metabolite levels; chr7:99536585 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs7794068 ENSG00000228834.1 RP11-249L21.4 11.58 1.71e-24 3.64e-17 1.41 0.62 Blood metabolite levels; chr7:99549250 chr6:108907615~108907873:- CESC trans rs9611565 0.729 rs73176689 ENSG00000268568.1 AC007228.9 -11.58 1.75e-24 3.73e-17 -0.89 -0.62 Vitiligo; chr22:41386629 chr19:56672574~56673901:- CESC trans rs2731664 0.792 rs1130857 ENSG00000215571.5 GRK6P1 11.58 1.76e-24 3.74e-17 0.77 0.62 Intelligence (multi-trait analysis); chr5:177436518 chr13:21319156~21320866:+ CESC trans rs1816752 0.609 rs7998198 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24462979 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs7998203 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24462989 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs2862902 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24461965 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs734715 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24462041 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs730030 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24462509 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs7992667 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24462821 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs7995958 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24462895 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs8002741 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24462918 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs7998600 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24463222 chrY:26594851~26634652:- CESC trans rs1816752 0.624 rs9511282 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24463597 chrY:26594851~26634652:- CESC trans rs1816752 0.583 rs9511283 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24463656 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9507351 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24465118 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs4770688 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24466007 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs4770689 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24466008 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs12431171 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24466380 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs12854523 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24466460 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9578740 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24466692 chrY:26594851~26634652:- CESC trans rs1816752 0.631 rs4769358 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24466940 chrY:26594851~26634652:- CESC trans rs1816752 0.608 rs4769359 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24466966 chrY:26594851~26634652:- CESC trans rs1816752 0.608 rs4769360 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24467016 chrY:26594851~26634652:- CESC trans rs1816752 0.608 rs9511290 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24467189 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511291 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24467609 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511292 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24467623 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511293 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24467747 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511294 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24467773 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511296 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24467962 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9634401 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24468072 chrY:26594851~26634652:- CESC trans rs1816752 0.624 rs9634402 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24468119 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9634403 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24468211 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9581064 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24468251 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs4769361 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24468834 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs4770693 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24468835 chrY:26594851~26634652:- CESC trans rs1816752 0.609 rs4770695 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24468895 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs7337981 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24469245 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs7328391 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24470325 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs4480642 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24471358 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9551108 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24471434 chrY:26594851~26634652:- CESC trans rs1816752 0.603 rs4238178 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24472344 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs2862903 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24473169 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs7319207 ENSG00000237917.1 PARP4P1 -11.57 1.83e-24 3.79e-17 -0.73 -0.62 Obesity-related traits; chr13:24473220 chrY:26594851~26634652:- CESC trans rs2731664 0.721 rs2450333 ENSG00000215571.5 GRK6P1 11.57 1.86e-24 3.86e-17 0.74 0.62 Intelligence (multi-trait analysis); chr5:177472545 chr13:21319156~21320866:+ CESC trans rs1816752 0.608 rs7326664 ENSG00000237917.1 PARP4P1 -11.56 2.06e-24 4.26e-17 -0.74 -0.62 Obesity-related traits; chr13:24475868 chrY:26594851~26634652:- CESC trans rs9611565 0.659 rs28530678 ENSG00000268568.1 AC007228.9 -11.56 2.09e-24 4.33e-17 -0.96 -0.62 Vitiligo; chr22:41538957 chr19:56672574~56673901:- CESC trans rs12709013 0.636 rs1646256 ENSG00000230849.2 GOT2P2 11.55 2.14e-24 4.43e-17 0.72 0.62 Blood metabolite ratios; chr16:58712114 chr1:173141100~173142350:- CESC trans rs9611565 0.659 rs12484694 ENSG00000268568.1 AC007228.9 -11.55 2.23e-24 4.61e-17 -0.9 -0.62 Vitiligo; chr22:41523326 chr19:56672574~56673901:- CESC trans rs9611565 0.84 rs3788584 ENSG00000268568.1 AC007228.9 -11.55 2.24e-24 4.63e-17 -0.89 -0.62 Vitiligo; chr22:41383069 chr19:56672574~56673901:- CESC trans rs10242455 0.557 rs45529541 ENSG00000228834.1 RP11-249L21.4 11.54 2.29e-24 4.72e-17 1.49 0.62 Blood metabolite levels; chr7:99450520 chr6:108907615~108907873:- CESC trans rs2731664 0.756 rs335433 ENSG00000215571.5 GRK6P1 11.54 2.38e-24 4.91e-17 0.76 0.62 Intelligence (multi-trait analysis); chr5:177440206 chr13:21319156~21320866:+ CESC trans rs1816752 0.524 rs7996445 ENSG00000237917.1 PARP4P1 -11.54 2.39e-24 4.91e-17 -0.73 -0.62 Obesity-related traits; chr13:24475329 chrY:26594851~26634652:- CESC trans rs2731664 0.792 rs335432 ENSG00000215571.5 GRK6P1 11.51 2.84e-24 5.84e-17 0.76 0.61 Intelligence (multi-trait analysis); chr5:177439257 chr13:21319156~21320866:+ CESC trans rs2950393 0.804 rs2926748 ENSG00000121089.4 NACA3P 11.51 3e-24 6.14e-17 0.64 0.61 Platelet distribution width; chr12:56715628 chr4:164943290~164943937:+ CESC trans rs9611565 0.765 rs132909 ENSG00000268568.1 AC007228.9 11.5 3.09e-24 6.3e-17 0.9 0.61 Vitiligo; chr22:41406027 chr19:56672574~56673901:- CESC trans rs9611565 0.681 rs5751094 ENSG00000268568.1 AC007228.9 11.5 3.09e-24 6.3e-17 0.9 0.61 Vitiligo; chr22:41407275 chr19:56672574~56673901:- CESC trans rs9611565 0.765 rs132914 ENSG00000268568.1 AC007228.9 11.5 3.09e-24 6.3e-17 0.9 0.61 Vitiligo; chr22:41409745 chr19:56672574~56673901:- CESC trans rs9611565 0.765 rs132915 ENSG00000268568.1 AC007228.9 11.5 3.09e-24 6.3e-17 0.9 0.61 Vitiligo; chr22:41409778 chr19:56672574~56673901:- CESC trans rs9611565 0.722 rs202635 ENSG00000268568.1 AC007228.9 11.5 3.09e-24 6.3e-17 0.9 0.61 Vitiligo; chr22:41413633 chr19:56672574~56673901:- CESC trans rs9611565 0.765 rs132920 ENSG00000268568.1 AC007228.9 11.5 3.09e-24 6.3e-17 0.9 0.61 Vitiligo; chr22:41414166 chr19:56672574~56673901:- CESC trans rs9611565 0.765 rs202659 ENSG00000268568.1 AC007228.9 11.5 3.09e-24 6.3e-17 0.9 0.61 Vitiligo; chr22:41415616 chr19:56672574~56673901:- CESC trans rs2950393 0.929 rs7973157 ENSG00000121089.4 NACA3P -11.5 3.1e-24 6.32e-17 -0.64 -0.61 Platelet distribution width; chr12:56655409 chr4:164943290~164943937:+ CESC trans rs7121616 0.531 rs10892958 ENSG00000234176.1 HSPA8P1 11.49 3.26e-24 6.63e-17 0.87 0.61 Breast cancer; chr11:123061415 chrX:121203182~121205014:- CESC trans rs9611565 0.765 rs132905 ENSG00000268568.1 AC007228.9 11.49 3.41e-24 6.93e-17 0.89 0.61 Vitiligo; chr22:41403102 chr19:56672574~56673901:- CESC trans rs6732160 0.691 rs4536673 ENSG00000236165.1 PRADC1P1 11.48 3.49e-24 7.07e-17 0.75 0.61 Intelligence (multi-trait analysis); chr2:73186334 chr3:36976316~36976840:+ CESC trans rs6732160 0.691 rs13402225 ENSG00000236165.1 PRADC1P1 11.48 3.49e-24 7.07e-17 0.75 0.61 Intelligence (multi-trait analysis); chr2:73189778 chr3:36976316~36976840:+ CESC trans rs6732160 0.691 rs10197935 ENSG00000236165.1 PRADC1P1 11.48 3.67e-24 7.4e-17 0.74 0.61 Intelligence (multi-trait analysis); chr2:73185234 chr3:36976316~36976840:+ CESC trans rs12709013 0.613 rs4238801 ENSG00000233719.3 GOT2P3 11.47 3.85e-24 7.74e-17 0.7 0.61 Blood metabolite ratios; chr16:58738275 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs4575523 ENSG00000233719.3 GOT2P3 11.47 3.85e-24 7.74e-17 0.7 0.61 Blood metabolite ratios; chr16:58738559 chr12:9641802~9643007:+ CESC trans rs9611565 0.84 rs4822025 ENSG00000268568.1 AC007228.9 -11.47 3.87e-24 7.77e-17 -0.88 -0.61 Vitiligo; chr22:41380642 chr19:56672574~56673901:- CESC trans rs7121616 0.531 rs11218941 ENSG00000234176.1 HSPA8P1 11.46 4.03e-24 8.07e-17 0.87 0.61 Breast cancer; chr11:123061701 chrX:121203182~121205014:- CESC trans rs9611565 0.765 rs202663 ENSG00000268568.1 AC007228.9 11.46 4.29e-24 8.57e-17 0.9 0.61 Vitiligo; chr22:41416815 chr19:56672574~56673901:- CESC trans rs1816752 0.646 rs9511279 ENSG00000237917.1 PARP4P1 -11.45 4.5e-24 8.94e-17 -0.73 -0.61 Obesity-related traits; chr13:24463348 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511280 ENSG00000237917.1 PARP4P1 -11.45 4.5e-24 8.94e-17 -0.73 -0.61 Obesity-related traits; chr13:24463364 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511281 ENSG00000237917.1 PARP4P1 -11.45 4.5e-24 8.94e-17 -0.73 -0.61 Obesity-related traits; chr13:24463441 chrY:26594851~26634652:- CESC trans rs12709013 0.636 rs10852565 ENSG00000230849.2 GOT2P2 11.45 4.56e-24 9.05e-17 0.7 0.61 Blood metabolite ratios; chr16:58771277 chr1:173141100~173142350:- CESC trans rs9611565 0.765 rs9607800 ENSG00000268568.1 AC007228.9 -11.44 4.73e-24 9.38e-17 -0.89 -0.61 Vitiligo; chr22:41388558 chr19:56672574~56673901:- CESC trans rs941207 0.542 rs11171986 ENSG00000121089.4 NACA3P -11.41 5.91e-24 1.17e-16 -0.8 -0.61 Platelet count; chr12:56819043 chr4:164943290~164943937:+ CESC trans rs1816752 0.624 rs2096093 ENSG00000237917.1 PARP4P1 -11.41 5.99e-24 1.18e-16 -0.72 -0.61 Obesity-related traits; chr13:24472753 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs6490937 ENSG00000237917.1 PARP4P1 -11.41 6.14e-24 1.21e-16 -0.73 -0.61 Obesity-related traits; chr13:24475834 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs2862905 ENSG00000237917.1 PARP4P1 -11.4 6.32e-24 1.24e-16 -0.73 -0.61 Obesity-related traits; chr13:24485142 chrY:26594851~26634652:- CESC trans rs9611565 0.527 rs2234053 ENSG00000268568.1 AC007228.9 -11.4 6.39e-24 1.26e-16 -0.88 -0.61 Vitiligo; chr22:41381311 chr19:56672574~56673901:- CESC trans rs9611565 0.802 rs2234058 ENSG00000268568.1 AC007228.9 -11.4 6.39e-24 1.26e-16 -0.88 -0.61 Vitiligo; chr22:41381879 chr19:56672574~56673901:- CESC trans rs9611565 0.84 rs2234059 ENSG00000268568.1 AC007228.9 -11.4 6.39e-24 1.26e-16 -0.88 -0.61 Vitiligo; chr22:41381909 chr19:56672574~56673901:- CESC trans rs1816752 0.646 rs9511301 ENSG00000237917.1 PARP4P1 -11.4 6.51e-24 1.27e-16 -0.73 -0.61 Obesity-related traits; chr13:24477034 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs7332220 ENSG00000237917.1 PARP4P1 -11.4 6.51e-24 1.27e-16 -0.73 -0.61 Obesity-related traits; chr13:24477081 chrY:26594851~26634652:- CESC trans rs1816752 0.624 rs11149109 ENSG00000237917.1 PARP4P1 -11.4 6.51e-24 1.27e-16 -0.73 -0.61 Obesity-related traits; chr13:24477290 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs9511302 ENSG00000237917.1 PARP4P1 -11.4 6.51e-24 1.27e-16 -0.73 -0.61 Obesity-related traits; chr13:24477580 chrY:26594851~26634652:- CESC trans rs1816752 0.646 rs8002599 ENSG00000237917.1 PARP4P1 -11.4 6.51e-24 1.27e-16 -0.73 -0.61 Obesity-related traits; chr13:24478486 chrY:26594851~26634652:- CESC trans rs12709013 0.597 rs8051078 ENSG00000230849.2 GOT2P2 11.39 6.8e-24 1.33e-16 0.7 0.61 Blood metabolite ratios; chr16:58774200 chr1:173141100~173142350:- CESC trans rs9611565 0.659 rs4822035 ENSG00000268568.1 AC007228.9 11.39 7.07e-24 1.38e-16 0.9 0.61 Vitiligo; chr22:41539908 chr19:56672574~56673901:- CESC trans rs13177918 0.603 rs2343806 ENSG00000224114.1 RP11-343H5.4 11.38 7.53e-24 1.46e-16 0.73 0.61 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr1:206695837~206696269:- CESC trans rs9611565 0.659 rs1810461 ENSG00000268568.1 AC007228.9 -11.37 7.82e-24 1.51e-16 -0.91 -0.61 Vitiligo; chr22:41531816 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs73178626 ENSG00000268568.1 AC007228.9 -11.37 7.82e-24 1.51e-16 -0.91 -0.61 Vitiligo; chr22:41532367 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs132765 ENSG00000268568.1 AC007228.9 11.35 8.93e-24 1.72e-16 0.93 0.61 Vitiligo; chr22:41612064 chr19:56672574~56673901:- CESC trans rs727563 0.593 rs132770 ENSG00000268568.1 AC007228.9 11.35 8.96e-24 1.73e-16 0.94 0.61 Crohn's disease;Inflammatory bowel disease; chr22:41621260 chr19:56672574~56673901:- CESC trans rs10242455 0.702 rs73397499 ENSG00000228834.1 RP11-249L21.4 11.35 9e-24 1.73e-16 1.52 0.61 Blood metabolite levels; chr7:99442004 chr6:108907615~108907873:- CESC trans rs2657294 0.62 rs7903537 ENSG00000172974.11 AC007318.5 11.34 9.87e-24 1.89e-16 0.63 0.61 Pneumonia; chr10:75087732 chr2:65205108~65205988:+ CESC trans rs2731664 0.792 rs2731662 ENSG00000215571.5 GRK6P1 -11.33 1.08e-23 2.07e-16 -0.74 -0.61 Intelligence (multi-trait analysis); chr5:177445493 chr13:21319156~21320866:+ CESC trans rs6477998 0.874 rs10739390 ENSG00000238072.1 RP11-305M3.2 11.33 1.08e-23 2.07e-16 0.79 0.61 Hematology traits; chr9:113226209 chr7:129410113~129410370:- CESC trans rs916888 0.773 rs199447 ENSG00000214425.5 LRRC37A4P -11.33 1.09e-23 2.08e-16 -0.8 -0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45506741~45550335:- CESC trans rs928391 1 rs2644606 ENSG00000227183.3 HDGFP1 11.32 1.15e-23 2.21e-16 0.96 0.61 Platelet count; chr1:156808053 chrX:131646639~131646890:+ CESC trans rs2731664 0.792 rs2630765 ENSG00000215571.5 GRK6P1 11.32 1.16e-23 2.22e-16 0.75 0.61 Intelligence (multi-trait analysis); chr5:177449824 chr13:21319156~21320866:+ CESC trans rs916888 0.773 rs199534 ENSG00000214425.5 LRRC37A4P -11.32 1.16e-23 2.22e-16 -0.79 -0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45506741~45550335:- CESC trans rs12709013 0.636 rs1646268 ENSG00000230849.2 GOT2P2 11.31 1.2e-23 2.3e-16 0.71 0.61 Blood metabolite ratios; chr16:58743292 chr1:173141100~173142350:- CESC trans rs10242455 0.571 rs11972210 ENSG00000228834.1 RP11-249L21.4 11.3 1.31e-23 2.49e-16 1.41 0.61 Blood metabolite levels; chr7:99609320 chr6:108907615~108907873:- CESC trans rs1816752 0.646 rs750390 ENSG00000237917.1 PARP4P1 -11.28 1.49e-23 2.82e-16 -0.72 -0.61 Obesity-related traits; chr13:24461603 chrY:26594851~26634652:- CESC trans rs2731664 0.792 rs2544809 ENSG00000215571.5 GRK6P1 11.28 1.57e-23 2.96e-16 0.74 0.61 Intelligence (multi-trait analysis); chr5:177458498 chr13:21319156~21320866:+ CESC trans rs916888 0.773 rs199533 ENSG00000214425.5 LRRC37A4P -11.27 1.6e-23 3.01e-16 -0.79 -0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45506741~45550335:- CESC trans rs6477998 0.9 rs7850357 ENSG00000238072.1 RP11-305M3.2 11.25 1.85e-23 3.47e-16 0.79 0.61 Hematology traits; chr9:113222319 chr7:129410113~129410370:- CESC trans rs2731664 0.792 rs335420 ENSG00000215571.5 GRK6P1 -11.25 1.86e-23 3.49e-16 -0.71 -0.61 Intelligence (multi-trait analysis); chr5:177471618 chr13:21319156~21320866:+ CESC trans rs9611565 0.659 rs1810460 ENSG00000268568.1 AC007228.9 -11.25 1.87e-23 3.51e-16 -0.88 -0.61 Vitiligo; chr22:41531696 chr19:56672574~56673901:- CESC trans rs1816752 0.669 rs3783072 ENSG00000237917.1 PARP4P1 -11.25 1.88e-23 3.52e-16 -0.71 -0.61 Obesity-related traits; chr13:24493258 chrY:26594851~26634652:- CESC trans rs941207 0.542 rs1903370 ENSG00000121089.4 NACA3P -11.25 1.89e-23 3.53e-16 -0.78 -0.61 Platelet count; chr12:56812900 chr4:164943290~164943937:+ CESC trans rs941207 0.542 rs11171979 ENSG00000121089.4 NACA3P -11.24 1.97e-23 3.69e-16 -0.72 -0.61 Platelet count; chr12:56802199 chr4:164943290~164943937:+ CESC trans rs9611565 0.802 rs9611577 ENSG00000268568.1 AC007228.9 -11.24 2.05e-23 3.83e-16 -0.87 -0.61 Vitiligo; chr22:41397086 chr19:56672574~56673901:- CESC trans rs1816752 0.608 rs4770690 ENSG00000237917.1 PARP4P1 -11.24 2.1e-23 3.91e-16 -0.71 -0.61 Obesity-related traits; chr13:24467049 chrY:26594851~26634652:- CESC trans rs10242455 0.702 rs74347626 ENSG00000228834.1 RP11-249L21.4 11.22 2.3e-23 4.24e-16 1.62 0.61 Blood metabolite levels; chr7:99608398 chr6:108907615~108907873:- CESC trans rs1816752 0.716 rs9553330 ENSG00000237917.1 PARP4P1 -11.21 2.44e-23 4.49e-16 -0.7 -0.6 Obesity-related traits; chr13:24516018 chrY:26594851~26634652:- CESC trans rs9611565 0.527 rs73178638 ENSG00000268568.1 AC007228.9 -11.21 2.53e-23 4.64e-16 -0.94 -0.6 Vitiligo; chr22:41546900 chr19:56672574~56673901:- CESC trans rs12709013 0.646 rs8046154 ENSG00000233719.3 GOT2P3 -11.21 2.54e-23 4.65e-16 -0.68 -0.6 Blood metabolite ratios; chr16:58773978 chr12:9641802~9643007:+ CESC trans rs6477998 1 rs7038769 ENSG00000238072.1 RP11-305M3.2 11.21 2.57e-23 4.7e-16 0.79 0.6 Hematology traits; chr9:113245303 chr7:129410113~129410370:- CESC trans rs6477998 1 rs7022397 ENSG00000238072.1 RP11-305M3.2 11.21 2.57e-23 4.7e-16 0.79 0.6 Hematology traits; chr9:113245397 chr7:129410113~129410370:- CESC trans rs10242455 0.571 rs7805661 ENSG00000228834.1 RP11-249L21.4 11.21 2.59e-23 4.74e-16 1.35 0.6 Blood metabolite levels; chr7:99573899 chr6:108907615~108907873:- CESC trans rs9467773 1 rs9295695 ENSG00000242375.1 RP11-498P14.3 -11.2 2.63e-23 4.81e-16 -0.7 -0.6 Intelligence (multi-trait analysis); chr6:26528022 chr9:97195351~97197687:- CESC trans rs10242455 0.702 rs73713507 ENSG00000228834.1 RP11-249L21.4 11.2 2.64e-23 4.83e-16 1.51 0.6 Blood metabolite levels; chr7:99540980 chr6:108907615~108907873:- CESC trans rs10242455 0.557 rs45492501 ENSG00000228834.1 RP11-249L21.4 11.2 2.65e-23 4.84e-16 1.46 0.6 Blood metabolite levels; chr7:99449407 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs17854665 ENSG00000228834.1 RP11-249L21.4 11.2 2.65e-23 4.84e-16 1.46 0.6 Blood metabolite levels; chr7:99452416 chr6:108907615~108907873:- CESC trans rs9611565 0.659 rs12483998 ENSG00000268568.1 AC007228.9 -11.2 2.73e-23 4.98e-16 -0.92 -0.6 Vitiligo; chr22:41539358 chr19:56672574~56673901:- CESC trans rs6477998 1 rs10759636 ENSG00000238072.1 RP11-305M3.2 11.2 2.75e-23 5.02e-16 0.79 0.6 Hematology traits; chr9:113256497 chr7:129410113~129410370:- CESC trans rs6477998 0.932 rs4129395 ENSG00000238072.1 RP11-305M3.2 11.19 2.97e-23 5.39e-16 0.79 0.6 Hematology traits; chr9:113213109 chr7:129410113~129410370:- CESC trans rs6477998 0.966 rs7859354 ENSG00000238072.1 RP11-305M3.2 11.19 2.97e-23 5.39e-16 0.79 0.6 Hematology traits; chr9:113214165 chr7:129410113~129410370:- CESC trans rs6477998 1 rs10739388 ENSG00000238072.1 RP11-305M3.2 11.19 2.97e-23 5.39e-16 0.79 0.6 Hematology traits; chr9:113214895 chr7:129410113~129410370:- CESC trans rs10242455 0.702 rs78218664 ENSG00000228834.1 RP11-249L21.4 11.18 3.13e-23 5.65e-16 1.51 0.6 Blood metabolite levels; chr7:99556758 chr6:108907615~108907873:- CESC trans rs9611565 0.512 rs9611667 ENSG00000268568.1 AC007228.9 -11.18 3.21e-23 5.81e-16 -0.94 -0.6 Vitiligo; chr22:41791011 chr19:56672574~56673901:- CESC trans rs916888 0.779 rs199528 ENSG00000214425.5 LRRC37A4P -11.17 3.27e-23 5.91e-16 -0.79 -0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45506741~45550335:- CESC trans rs916888 0.821 rs199525 ENSG00000214425.5 LRRC37A4P -11.17 3.27e-23 5.91e-16 -0.79 -0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45506741~45550335:- CESC trans rs1816752 0.646 rs2902359 ENSG00000237917.1 PARP4P1 -11.17 3.33e-23 6.01e-16 -0.71 -0.6 Obesity-related traits; chr13:24461783 chrY:26594851~26634652:- CESC trans rs2950393 0.804 rs10783796 ENSG00000121089.4 NACA3P 11.17 3.4e-23 6.13e-16 0.62 0.6 Platelet distribution width; chr12:56733387 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs1646256 ENSG00000233719.3 GOT2P3 11.16 3.66e-23 6.59e-16 0.67 0.6 Blood metabolite ratios; chr16:58712114 chr12:9641802~9643007:+ CESC trans rs2731664 0.765 rs2630766 ENSG00000215571.5 GRK6P1 11.16 3.67e-23 6.62e-16 0.73 0.6 Intelligence (multi-trait analysis); chr5:177447940 chr13:21319156~21320866:+ CESC trans rs1816752 0.646 rs1361578 ENSG00000237917.1 PARP4P1 -11.14 4.03e-23 7.22e-16 -0.73 -0.6 Obesity-related traits; chr13:24491117 chrY:26594851~26634652:- CESC trans rs9611565 0.659 rs56319767 ENSG00000268568.1 AC007228.9 -11.14 4.15e-23 7.42e-16 -0.91 -0.6 Vitiligo; chr22:41537833 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs73178632 ENSG00000268568.1 AC007228.9 -11.14 4.15e-23 7.42e-16 -0.91 -0.6 Vitiligo; chr22:41538569 chr19:56672574~56673901:- CESC trans rs13253073 0.883 rs12545602 ENSG00000260318.1 COX6CP1 11.14 4.29e-23 7.67e-16 1.14 0.6 Glucose homeostasis traits; chr8:99834612 chr16:11903923~11904137:- CESC trans rs2950393 0.804 rs2035081 ENSG00000121089.4 NACA3P 11.13 4.34e-23 7.74e-16 0.62 0.6 Platelet distribution width; chr12:56732095 chr4:164943290~164943937:+ CESC trans rs1816752 0.624 rs7330766 ENSG00000237917.1 PARP4P1 -11.13 4.45e-23 7.94e-16 -0.72 -0.6 Obesity-related traits; chr13:24495579 chrY:26594851~26634652:- CESC trans rs9467773 1 rs9467779 ENSG00000242375.1 RP11-498P14.3 -11.12 4.86e-23 8.62e-16 -0.69 -0.6 Intelligence (multi-trait analysis); chr6:26536459 chr9:97195351~97197687:- CESC trans rs13177918 0.798 rs12514700 ENSG00000213058.3 RP4-765C7.2 11.12 4.93e-23 8.73e-16 0.83 0.6 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr1:178411616~178411972:+ CESC trans rs12709013 0.636 rs10852565 ENSG00000233719.3 GOT2P3 11.11 4.99e-23 8.82e-16 0.65 0.6 Blood metabolite ratios; chr16:58771277 chr12:9641802~9643007:+ CESC trans rs12709013 0.601 rs2432621 ENSG00000230849.2 GOT2P2 11.11 5.03e-23 8.88e-16 0.69 0.6 Blood metabolite ratios; chr16:58749676 chr1:173141100~173142350:- CESC trans rs9611565 0.512 rs964899 ENSG00000268568.1 AC007228.9 11.11 5.14e-23 9.06e-16 0.93 0.6 Vitiligo; chr22:41746382 chr19:56672574~56673901:- CESC trans rs2950393 0.804 rs898609 ENSG00000121089.4 NACA3P 11.1 5.41e-23 9.51e-16 0.62 0.6 Platelet distribution width; chr12:56713026 chr4:164943290~164943937:+ CESC trans rs2950393 0.804 rs4902 ENSG00000121089.4 NACA3P 11.1 5.41e-23 9.51e-16 0.62 0.6 Platelet distribution width; chr12:56714419 chr4:164943290~164943937:+ CESC trans rs9611565 0.625 rs73178625 ENSG00000268568.1 AC007228.9 -11.1 5.66e-23 9.94e-16 -0.87 -0.6 Vitiligo; chr22:41532316 chr19:56672574~56673901:- CESC trans rs2950393 0.777 rs12828563 ENSG00000121089.4 NACA3P 11.09 5.81e-23 1.02e-15 0.62 0.6 Platelet distribution width; chr12:56709378 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs6499976 ENSG00000230849.2 GOT2P2 11.09 5.95e-23 1.04e-15 0.68 0.6 Blood metabolite ratios; chr16:58770330 chr1:173141100~173142350:- CESC trans rs1816752 0.646 rs750388 ENSG00000237917.1 PARP4P1 -11.08 6.34e-23 1.11e-15 -0.7 -0.6 Obesity-related traits; chr13:24461690 chrY:26594851~26634652:- CESC trans rs12709013 0.561 rs1657174 ENSG00000230849.2 GOT2P2 11.08 6.53e-23 1.14e-15 0.69 0.6 Blood metabolite ratios; chr16:58755139 chr1:173141100~173142350:- CESC trans rs6477998 0.966 rs10759637 ENSG00000238072.1 RP11-305M3.2 11.08 6.56e-23 1.14e-15 0.78 0.6 Hematology traits; chr9:113262744 chr7:129410113~129410370:- CESC trans rs3749237 0.615 rs6792911 ENSG00000197582.5 GPX1P1 11.07 6.86e-23 1.19e-15 0.77 0.6 Resting heart rate; chr3:49392423 chrX:13378735~13379340:- CESC trans rs9611565 0.729 rs132902 ENSG00000268568.1 AC007228.9 -11.06 7.29e-23 1.27e-15 -0.83 -0.6 Vitiligo; chr22:41401754 chr19:56672574~56673901:- CESC trans rs6477998 0.676 rs10817470 ENSG00000238072.1 RP11-305M3.2 11.06 7.49e-23 1.3e-15 0.85 0.6 Hematology traits; chr9:113252129 chr7:129410113~129410370:- CESC trans rs1816752 0.646 rs7322323 ENSG00000237917.1 PARP4P1 -11.06 7.5e-23 1.3e-15 -0.73 -0.6 Obesity-related traits; chr13:24479189 chrY:26594851~26634652:- CESC trans rs10242455 0.702 rs58348977 ENSG00000228834.1 RP11-249L21.4 11.06 7.55e-23 1.31e-15 1.37 0.6 Blood metabolite levels; chr7:99590391 chr6:108907615~108907873:- CESC trans rs9611565 0.681 rs132918 ENSG00000268568.1 AC007228.9 11.06 7.55e-23 1.31e-15 0.84 0.6 Vitiligo; chr22:41412346 chr19:56672574~56673901:- CESC trans rs9611565 0.765 rs132921 ENSG00000268568.1 AC007228.9 11.06 7.55e-23 1.31e-15 0.84 0.6 Vitiligo; chr22:41416040 chr19:56672574~56673901:- CESC trans rs2950393 0.804 rs2958127 ENSG00000121089.4 NACA3P 11.05 7.66e-23 1.32e-15 0.62 0.6 Platelet distribution width; chr12:56720523 chr4:164943290~164943937:+ CESC trans rs9611565 0.694 rs202631 ENSG00000268568.1 AC007228.9 11.05 7.74e-23 1.34e-15 0.83 0.6 Vitiligo; chr22:41467419 chr19:56672574~56673901:- CESC trans rs12709013 0.636 rs1646268 ENSG00000233719.3 GOT2P3 11.05 7.8e-23 1.35e-15 0.66 0.6 Blood metabolite ratios; chr16:58743292 chr12:9641802~9643007:+ CESC trans rs9611565 0.802 rs9611571 ENSG00000268568.1 AC007228.9 -11.05 7.89e-23 1.36e-15 -0.84 -0.6 Vitiligo; chr22:41388863 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs12483786 ENSG00000268568.1 AC007228.9 -11.05 7.98e-23 1.37e-15 -0.91 -0.6 Vitiligo; chr22:41542532 chr19:56672574~56673901:- CESC trans rs12291225 0.883 rs1864658 ENSG00000236360.2 RP11-334A14.2 -11.04 8.33e-23 1.43e-15 -0.8 -0.6 Sense of smell; chr11:14234898 chr1:52993201~52993702:- CESC trans rs9611565 0.545 rs5758432 ENSG00000268568.1 AC007228.9 11.04 8.48e-23 1.46e-15 0.92 0.6 Vitiligo; chr22:41715689 chr19:56672574~56673901:- CESC trans rs12709013 0.574 rs35321124 ENSG00000230849.2 GOT2P2 11.04 8.66e-23 1.48e-15 0.72 0.6 Blood metabolite ratios; chr16:58786561 chr1:173141100~173142350:- CESC trans rs10242455 0.702 rs73713521 ENSG00000228834.1 RP11-249L21.4 11.03 8.91e-23 1.53e-15 1.57 0.6 Blood metabolite levels; chr7:99591026 chr6:108907615~108907873:- CESC trans rs1816752 0.624 rs4770701 ENSG00000237917.1 PARP4P1 -11.03 9.04e-23 1.55e-15 -0.73 -0.6 Obesity-related traits; chr13:24508806 chrY:26594851~26634652:- CESC trans rs3749237 0.555 rs2117939 ENSG00000197582.5 GPX1P1 11.02 9.58e-23 1.64e-15 0.77 0.6 Resting heart rate; chr3:49377746 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs6797765 ENSG00000197582.5 GPX1P1 11.02 9.58e-23 1.64e-15 0.77 0.6 Resting heart rate; chr3:49386543 chrX:13378735~13379340:- CESC trans rs12709013 0.613 rs1657178 ENSG00000233719.3 GOT2P3 11.02 9.67e-23 1.65e-15 0.67 0.6 Blood metabolite ratios; chr16:58735300 chr12:9641802~9643007:+ CESC trans rs12709013 0.591 rs4410065 ENSG00000233719.3 GOT2P3 11.02 9.79e-23 1.67e-15 0.68 0.6 Blood metabolite ratios; chr16:58800968 chr12:9641802~9643007:+ CESC trans rs12709013 0.591 rs2406234 ENSG00000233719.3 GOT2P3 11.02 9.79e-23 1.67e-15 0.68 0.6 Blood metabolite ratios; chr16:58801840 chr12:9641802~9643007:+ CESC trans rs12709013 0.591 rs2086206 ENSG00000233719.3 GOT2P3 11.02 9.79e-23 1.67e-15 0.68 0.6 Blood metabolite ratios; chr16:58802094 chr12:9641802~9643007:+ CESC trans rs2950393 0.804 rs7295862 ENSG00000121089.4 NACA3P -11.02 9.81e-23 1.67e-15 -0.63 -0.6 Platelet distribution width; chr12:56775374 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs1657164 ENSG00000230849.2 GOT2P2 11.02 9.97e-23 1.69e-15 0.69 0.6 Blood metabolite ratios; chr16:58747949 chr1:173141100~173142350:- CESC trans rs12709013 0.537 rs1657167 ENSG00000230849.2 GOT2P2 11.02 9.97e-23 1.69e-15 0.69 0.6 Blood metabolite ratios; chr16:58748955 chr1:173141100~173142350:- CESC trans rs9611565 0.559 rs132761 ENSG00000268568.1 AC007228.9 11.01 1.02e-22 1.74e-15 0.9 0.6 Vitiligo; chr22:41608367 chr19:56672574~56673901:- CESC trans rs12709013 0.514 rs8062639 ENSG00000233719.3 GOT2P3 11.01 1.03e-22 1.75e-15 0.68 0.6 Blood metabolite ratios; chr16:58800264 chr12:9641802~9643007:+ CESC trans rs12709013 0.536 rs9930758 ENSG00000233719.3 GOT2P3 11.01 1.03e-22 1.75e-15 0.68 0.6 Blood metabolite ratios; chr16:58803167 chr12:9641802~9643007:+ CESC trans rs9611565 0.512 rs5751145 ENSG00000268568.1 AC007228.9 11.01 1.05e-22 1.79e-15 0.92 0.6 Vitiligo; chr22:41737548 chr19:56672574~56673901:- CESC trans rs12709013 0.636 rs8054414 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58749772 chr1:173141100~173142350:- CESC trans rs12709013 0.597 rs11076259 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58749860 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs12325516 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58749899 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs11076260 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58749942 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1646278 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58750084 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1646279 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58750235 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1646280 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58750420 chr1:173141100~173142350:- CESC trans rs12709013 0.597 rs1646286 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58752651 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1624301 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58753491 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1626006 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58753691 chr1:173141100~173142350:- CESC trans rs12709013 0.684 rs1646287 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58753774 chr1:173141100~173142350:- CESC trans rs12709013 0.671 rs1369933 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58753927 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1369934 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58754124 chr1:173141100~173142350:- CESC trans rs12709013 0.613 rs1646288 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58755576 chr1:173141100~173142350:- CESC trans rs12709013 0.561 rs727484 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58756568 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs191783 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58759994 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs257624 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58760994 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs8060717 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58765574 chr1:173141100~173142350:- CESC trans rs12709013 0.559 rs8060721 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58765581 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs8044542 ENSG00000230849.2 GOT2P2 11.01 1.08e-22 1.82e-15 0.69 0.6 Blood metabolite ratios; chr16:58765620 chr1:173141100~173142350:- CESC trans rs12709013 0.597 rs1657171 ENSG00000230849.2 GOT2P2 11 1.11e-22 1.86e-15 0.69 0.6 Blood metabolite ratios; chr16:58752083 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1646285 ENSG00000230849.2 GOT2P2 11 1.11e-22 1.86e-15 0.69 0.6 Blood metabolite ratios; chr16:58752102 chr1:173141100~173142350:- CESC trans rs13177918 0.603 rs2343806 ENSG00000239528.1 RPS14P8 11 1.11e-22 1.86e-15 0.73 0.6 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr5:116562562~116562930:+ CESC trans rs9611565 0.512 rs2899347 ENSG00000268568.1 AC007228.9 11 1.12e-22 1.88e-15 0.92 0.6 Vitiligo; chr22:41762200 chr19:56672574~56673901:- CESC trans rs4822044 0.56 rs7284839 ENSG00000268568.1 AC007228.9 11 1.14e-22 1.91e-15 0.89 0.6 Cannabis dependence symptom count; chr22:41614898 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs132768 ENSG00000268568.1 AC007228.9 11 1.14e-22 1.91e-15 0.89 0.6 Vitiligo; chr22:41617519 chr19:56672574~56673901:- CESC trans rs13177918 0.603 rs2748241 ENSG00000239528.1 RPS14P8 10.99 1.18e-22 1.98e-15 0.7 0.6 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr5:116562562~116562930:+ CESC trans rs916888 0.773 rs199535 ENSG00000214425.5 LRRC37A4P -10.99 1.24e-22 2.08e-15 -0.76 -0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45506741~45550335:- CESC trans rs941207 0.526 rs2255074 ENSG00000121089.4 NACA3P -10.98 1.26e-22 2.11e-15 -0.64 -0.6 Platelet count; chr12:56636242 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs9937713 ENSG00000230849.2 GOT2P2 10.98 1.29e-22 2.15e-15 0.68 0.6 Blood metabolite ratios; chr16:58771921 chr1:173141100~173142350:- CESC trans rs9611565 0.559 rs5758397 ENSG00000268568.1 AC007228.9 10.97 1.43e-22 2.36e-15 0.9 0.6 Vitiligo; chr22:41623247 chr19:56672574~56673901:- CESC trans rs12709013 0.597 rs1616072 ENSG00000230849.2 GOT2P2 10.96 1.46e-22 2.42e-15 0.68 0.6 Blood metabolite ratios; chr16:58747194 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs2575374 ENSG00000230849.2 GOT2P2 10.96 1.46e-22 2.42e-15 0.68 0.6 Blood metabolite ratios; chr16:58747494 chr1:173141100~173142350:- CESC trans rs10242455 0.571 rs56167514 ENSG00000228834.1 RP11-249L21.4 10.95 1.58e-22 2.61e-15 1.34 0.6 Blood metabolite levels; chr7:99563724 chr6:108907615~108907873:- CESC trans rs12709013 0.535 rs9924136 ENSG00000230849.2 GOT2P2 10.95 1.6e-22 2.64e-15 0.72 0.6 Blood metabolite ratios; chr16:58779573 chr1:173141100~173142350:- CESC trans rs6477998 0.966 rs7851395 ENSG00000238072.1 RP11-305M3.2 10.95 1.66e-22 2.73e-15 0.78 0.6 Hematology traits; chr9:113240184 chr7:129410113~129410370:- CESC trans rs2950393 0.804 rs11171951 ENSG00000121089.4 NACA3P 10.95 1.67e-22 2.75e-15 0.61 0.6 Platelet distribution width; chr12:56718853 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs4499224 ENSG00000230849.2 GOT2P2 10.94 1.68e-22 2.76e-15 0.68 0.6 Blood metabolite ratios; chr16:58770364 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1865836 ENSG00000230849.2 GOT2P2 10.94 1.73e-22 2.85e-15 0.68 0.6 Blood metabolite ratios; chr16:58768143 chr1:173141100~173142350:- CESC trans rs2731664 0.792 rs2545795 ENSG00000215571.5 GRK6P1 10.93 1.82e-22 2.99e-15 0.72 0.6 Intelligence (multi-trait analysis); chr5:177460105 chr13:21319156~21320866:+ CESC trans rs916888 0.821 rs199504 ENSG00000214425.5 LRRC37A4P 10.93 1.88e-22 3.08e-15 0.77 0.59 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45506741~45550335:- CESC trans rs12709013 0.636 rs1595180 ENSG00000230849.2 GOT2P2 10.93 1.9e-22 3.11e-15 0.68 0.59 Blood metabolite ratios; chr16:58770545 chr1:173141100~173142350:- CESC trans rs1816752 0.646 rs7322329 ENSG00000237917.1 PARP4P1 -10.93 1.9e-22 3.11e-15 -0.72 -0.59 Obesity-related traits; chr13:24479193 chrY:26594851~26634652:- CESC trans rs916888 0.773 rs199445 ENSG00000214425.5 LRRC37A4P -10.92 1.93e-22 3.16e-15 -0.77 -0.59 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45506741~45550335:- CESC trans rs2657294 0.62 rs7475340 ENSG00000172974.11 AC007318.5 10.91 2.07e-22 3.38e-15 0.6 0.59 Pneumonia; chr10:75079597 chr2:65205108~65205988:+ CESC trans rs1816752 0.692 rs2282409 ENSG00000237917.1 PARP4P1 -10.91 2.08e-22 3.4e-15 -0.72 -0.59 Obesity-related traits; chr13:24512388 chrY:26594851~26634652:- CESC trans rs12709013 0.613 rs1657178 ENSG00000230849.2 GOT2P2 10.91 2.1e-22 3.42e-15 0.7 0.59 Blood metabolite ratios; chr16:58735300 chr1:173141100~173142350:- CESC trans rs12709013 0.591 rs9932967 ENSG00000233719.3 GOT2P3 10.91 2.11e-22 3.44e-15 0.68 0.59 Blood metabolite ratios; chr16:58805583 chr12:9641802~9643007:+ CESC trans rs9467773 0.523 rs2498399 ENSG00000242375.1 RP11-498P14.3 10.91 2.11e-22 3.44e-15 0.72 0.59 Intelligence (multi-trait analysis); chr6:26795343 chr9:97195351~97197687:- CESC trans rs9611565 0.512 rs964898 ENSG00000268568.1 AC007228.9 -10.91 2.16e-22 3.53e-15 -0.91 -0.59 Vitiligo; chr22:41746302 chr19:56672574~56673901:- CESC trans rs9611565 0.546 rs739132 ENSG00000268568.1 AC007228.9 10.91 2.17e-22 3.53e-15 0.89 0.59 Vitiligo; chr22:41727095 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs5758436 ENSG00000268568.1 AC007228.9 10.91 2.17e-22 3.53e-15 0.89 0.59 Vitiligo; chr22:41728261 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs7291736 ENSG00000268568.1 AC007228.9 10.91 2.17e-22 3.53e-15 0.89 0.59 Vitiligo; chr22:41728870 chr19:56672574~56673901:- CESC trans rs10242455 0.702 rs3823813 ENSG00000228834.1 RP11-249L21.4 10.91 2.19e-22 3.56e-15 1.62 0.59 Blood metabolite levels; chr7:99451766 chr6:108907615~108907873:- CESC trans rs9611565 0.513 rs739135 ENSG00000268568.1 AC007228.9 10.9 2.25e-22 3.65e-15 0.9 0.59 Vitiligo; chr22:41694065 chr19:56672574~56673901:- CESC trans rs727563 0.636 rs2187795 ENSG00000268568.1 AC007228.9 10.9 2.25e-22 3.65e-15 0.9 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41696221 chr19:56672574~56673901:- CESC trans rs4822044 0.68 rs8138780 ENSG00000268568.1 AC007228.9 10.9 2.25e-22 3.65e-15 0.9 0.59 Cannabis dependence symptom count; chr22:41701458 chr19:56672574~56673901:- CESC trans rs727563 0.635 rs2899348 ENSG00000268568.1 AC007228.9 10.9 2.26e-22 3.66e-15 0.9 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41768512 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs2899349 ENSG00000268568.1 AC007228.9 10.9 2.26e-22 3.66e-15 0.9 0.59 Vitiligo; chr22:41768656 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs1983576 ENSG00000268568.1 AC007228.9 10.9 2.26e-22 3.66e-15 0.9 0.59 Vitiligo; chr22:41770482 chr19:56672574~56673901:- CESC trans rs9611565 0.503 rs5996062 ENSG00000268568.1 AC007228.9 10.9 2.26e-22 3.66e-15 0.9 0.59 Vitiligo; chr22:41771460 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs6002474 ENSG00000268568.1 AC007228.9 10.9 2.26e-22 3.66e-15 0.9 0.59 Vitiligo; chr22:41772177 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs5996063 ENSG00000268568.1 AC007228.9 10.9 2.26e-22 3.66e-15 0.9 0.59 Vitiligo; chr22:41772763 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs5751139 ENSG00000268568.1 AC007228.9 10.9 2.29e-22 3.69e-15 0.89 0.59 Vitiligo; chr22:41703977 chr19:56672574~56673901:- CESC trans rs9611565 0.546 rs739129 ENSG00000268568.1 AC007228.9 10.9 2.29e-22 3.69e-15 0.89 0.59 Vitiligo; chr22:41722245 chr19:56672574~56673901:- CESC trans rs916888 0.738 rs199515 ENSG00000214425.5 LRRC37A4P 10.88 2.56e-22 4.12e-15 0.75 0.59 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45506741~45550335:- CESC trans rs9611565 0.503 rs5751156 ENSG00000268568.1 AC007228.9 10.88 2.63e-22 4.23e-15 0.9 0.59 Vitiligo; chr22:41774021 chr19:56672574~56673901:- CESC trans rs3749237 0.595 rs11720264 ENSG00000197582.5 GPX1P1 10.88 2.72e-22 4.36e-15 0.76 0.59 Resting heart rate; chr3:49542914 chrX:13378735~13379340:- CESC trans rs12709013 0.601 rs2432621 ENSG00000233719.3 GOT2P3 10.87 2.79e-22 4.47e-15 0.65 0.59 Blood metabolite ratios; chr16:58749676 chr12:9641802~9643007:+ CESC trans rs7121616 0.595 rs7941144 ENSG00000234176.1 HSPA8P1 10.87 2.9e-22 4.64e-15 0.79 0.59 Breast cancer; chr11:123079805 chrX:121203182~121205014:- CESC trans rs3749237 0.595 rs11130192 ENSG00000197582.5 GPX1P1 10.86 3.09e-22 4.93e-15 0.77 0.59 Resting heart rate; chr3:49429773 chrX:13378735~13379340:- CESC trans rs12709013 0.561 rs1657174 ENSG00000233719.3 GOT2P3 10.86 3.1e-22 4.96e-15 0.65 0.59 Blood metabolite ratios; chr16:58755139 chr12:9641802~9643007:+ CESC trans rs6477998 0.676 rs4979225 ENSG00000238072.1 RP11-305M3.2 10.86 3.12e-22 4.98e-15 0.84 0.59 Hematology traits; chr9:113225130 chr7:129410113~129410370:- CESC trans rs727563 0.638 rs5996058 ENSG00000268568.1 AC007228.9 10.86 3.14e-22 5.01e-15 0.9 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41745448 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs5758450 ENSG00000268568.1 AC007228.9 10.86 3.14e-22 5.01e-15 0.9 0.59 Vitiligo; chr22:41745636 chr19:56672574~56673901:- CESC trans rs6477998 0.676 rs10981698 ENSG00000238072.1 RP11-305M3.2 10.85 3.26e-22 5.19e-15 0.84 0.59 Hematology traits; chr9:113233500 chr7:129410113~129410370:- CESC trans rs12709013 0.636 rs257628 ENSG00000230849.2 GOT2P2 10.85 3.29e-22 5.23e-15 0.69 0.59 Blood metabolite ratios; chr16:58758924 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs257627 ENSG00000230849.2 GOT2P2 10.85 3.29e-22 5.23e-15 0.69 0.59 Blood metabolite ratios; chr16:58758956 chr1:173141100~173142350:- CESC trans rs1816752 0.669 rs4770699 ENSG00000237917.1 PARP4P1 -10.85 3.3e-22 5.25e-15 -0.72 -0.59 Obesity-related traits; chr13:24488234 chrY:26594851~26634652:- CESC trans rs9611565 0.649 rs79005 ENSG00000268568.1 AC007228.9 10.84 3.51e-22 5.56e-15 0.81 0.59 Vitiligo; chr22:41439540 chr19:56672574~56673901:- CESC trans rs9611565 0.608 rs202652 ENSG00000268568.1 AC007228.9 10.84 3.51e-22 5.56e-15 0.81 0.59 Vitiligo; chr22:41442788 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs202653 ENSG00000268568.1 AC007228.9 10.84 3.51e-22 5.56e-15 0.81 0.59 Vitiligo; chr22:41444154 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs202655 ENSG00000268568.1 AC007228.9 10.84 3.51e-22 5.56e-15 0.81 0.59 Vitiligo; chr22:41445560 chr19:56672574~56673901:- CESC trans rs727563 0.58 rs202626 ENSG00000268568.1 AC007228.9 10.84 3.51e-22 5.56e-15 0.81 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41451186 chr19:56672574~56673901:- CESC trans rs9611565 0.532 rs202627 ENSG00000268568.1 AC007228.9 10.84 3.51e-22 5.56e-15 0.81 0.59 Vitiligo; chr22:41451363 chr19:56672574~56673901:- CESC trans rs6477998 0.676 rs4979224 ENSG00000238072.1 RP11-305M3.2 10.84 3.55e-22 5.63e-15 0.83 0.59 Hematology traits; chr9:113219998 chr7:129410113~129410370:- CESC trans rs9611565 0.659 rs28623192 ENSG00000268568.1 AC007228.9 -10.84 3.62e-22 5.74e-15 -0.87 -0.59 Vitiligo; chr22:41544520 chr19:56672574~56673901:- CESC trans rs9611565 0.84 rs2234052 ENSG00000268568.1 AC007228.9 -10.83 3.79e-22 5.99e-15 -0.84 -0.59 Vitiligo; chr22:41381237 chr19:56672574~56673901:- CESC trans rs9611565 0.84 rs9607799 ENSG00000268568.1 AC007228.9 -10.83 3.79e-22 5.99e-15 -0.84 -0.59 Vitiligo; chr22:41381554 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs4822034 ENSG00000268568.1 AC007228.9 -10.83 3.83e-22 6.05e-15 -0.87 -0.59 Vitiligo; chr22:41535006 chr19:56672574~56673901:- CESC trans rs9611565 0.625 rs9611606 ENSG00000268568.1 AC007228.9 -10.83 3.83e-22 6.05e-15 -0.87 -0.59 Vitiligo; chr22:41535070 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs116959331 ENSG00000268568.1 AC007228.9 -10.83 3.83e-22 6.05e-15 -0.87 -0.59 Vitiligo; chr22:41536770 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs9607841 ENSG00000268568.1 AC007228.9 -10.83 3.84e-22 6.06e-15 -0.9 -0.59 Vitiligo; chr22:41790834 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs6519289 ENSG00000268568.1 AC007228.9 10.82 4.1e-22 6.43e-15 0.9 0.59 Vitiligo; chr22:41774428 chr19:56672574~56673901:- CESC trans rs7949030 1 rs7949030 ENSG00000186676.3 EEF1GP1 10.82 4.14e-22 6.5e-15 0.77 0.59 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62627409 chr7:125033453~125035301:+ CESC trans rs916888 0.697 rs199516 ENSG00000214425.5 LRRC37A4P 10.81 4.22e-22 6.61e-15 0.76 0.59 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45506741~45550335:- CESC trans rs9611565 0.659 rs4822037 ENSG00000268568.1 AC007228.9 -10.81 4.4e-22 6.87e-15 -0.9 -0.59 Vitiligo; chr22:41549109 chr19:56672574~56673901:- CESC trans rs1816752 0.646 rs9507355 ENSG00000237917.1 PARP4P1 10.81 4.46e-22 6.96e-15 0.69 0.59 Obesity-related traits; chr13:24476819 chrY:26594851~26634652:- CESC trans rs13177918 0.798 rs13182116 ENSG00000213058.3 RP4-765C7.2 -10.8 4.52e-22 7.06e-15 -0.8 -0.59 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr1:178411616~178411972:+ CESC trans rs3749237 0.595 rs1464568 ENSG00000197582.5 GPX1P1 10.8 4.65e-22 7.25e-15 0.76 0.59 Resting heart rate; chr3:49420833 chrX:13378735~13379340:- CESC trans rs12709013 0.636 rs1657164 ENSG00000233719.3 GOT2P3 10.8 4.75e-22 7.39e-15 0.65 0.59 Blood metabolite ratios; chr16:58747949 chr12:9641802~9643007:+ CESC trans rs12709013 0.537 rs1657167 ENSG00000233719.3 GOT2P3 10.8 4.75e-22 7.39e-15 0.65 0.59 Blood metabolite ratios; chr16:58748955 chr12:9641802~9643007:+ CESC trans rs928391 1 rs928391 ENSG00000227183.3 HDGFP1 10.8 4.82e-22 7.5e-15 0.91 0.59 Platelet count; chr1:156806925 chrX:131646639~131646890:+ CESC trans rs1816752 0.646 rs750389 ENSG00000237917.1 PARP4P1 -10.79 4.93e-22 7.66e-15 -0.69 -0.59 Obesity-related traits; chr13:24461677 chrY:26594851~26634652:- CESC trans rs202629 1 rs202629 ENSG00000268568.1 AC007228.9 10.79 4.95e-22 7.69e-15 0.81 0.59 Cannabis dependence symptom count; chr22:41453971 chr19:56672574~56673901:- CESC trans rs12709013 0.597 rs1657171 ENSG00000233719.3 GOT2P3 10.79 5.12e-22 7.95e-15 0.65 0.59 Blood metabolite ratios; chr16:58752083 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1646285 ENSG00000233719.3 GOT2P3 10.79 5.12e-22 7.95e-15 0.65 0.59 Blood metabolite ratios; chr16:58752102 chr12:9641802~9643007:+ CESC trans rs2731664 0.792 rs2630764 ENSG00000215571.5 GRK6P1 10.79 5.17e-22 8.01e-15 0.72 0.59 Intelligence (multi-trait analysis); chr5:177453084 chr13:21319156~21320866:+ CESC trans rs3749237 0.595 rs10865955 ENSG00000197582.5 GPX1P1 10.78 5.22e-22 8.08e-15 0.76 0.59 Resting heart rate; chr3:49462396 chrX:13378735~13379340:- CESC trans rs12709013 0.597 rs1616072 ENSG00000233719.3 GOT2P3 10.78 5.27e-22 8.14e-15 0.65 0.59 Blood metabolite ratios; chr16:58747194 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs2575374 ENSG00000233719.3 GOT2P3 10.78 5.27e-22 8.14e-15 0.65 0.59 Blood metabolite ratios; chr16:58747494 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs8054414 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58749772 chr12:9641802~9643007:+ CESC trans rs12709013 0.597 rs11076259 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58749860 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs12325516 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58749899 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs11076260 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58749942 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1646278 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58750084 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1646279 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58750235 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1646280 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58750420 chr12:9641802~9643007:+ CESC trans rs12709013 0.597 rs1646286 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58752651 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1624301 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58753491 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1626006 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58753691 chr12:9641802~9643007:+ CESC trans rs12709013 0.684 rs1646287 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58753774 chr12:9641802~9643007:+ CESC trans rs12709013 0.671 rs1369933 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58753927 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1369934 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58754124 chr12:9641802~9643007:+ CESC trans rs12709013 0.613 rs1646288 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58755576 chr12:9641802~9643007:+ CESC trans rs12709013 0.561 rs727484 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58756568 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs191783 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58759994 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs257624 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58760994 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs8060717 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58765574 chr12:9641802~9643007:+ CESC trans rs12709013 0.559 rs8060721 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58765581 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs8044542 ENSG00000233719.3 GOT2P3 10.78 5.37e-22 8.23e-15 0.65 0.59 Blood metabolite ratios; chr16:58765620 chr12:9641802~9643007:+ CESC trans rs6477998 0.934 rs4979223 ENSG00000238072.1 RP11-305M3.2 10.78 5.41e-22 8.29e-15 0.76 0.59 Hematology traits; chr9:113219836 chr7:129410113~129410370:- CESC trans rs9611565 0.512 rs715498 ENSG00000268568.1 AC007228.9 10.78 5.42e-22 8.3e-15 0.89 0.59 Vitiligo; chr22:41752463 chr19:56672574~56673901:- CESC trans rs6477998 0.903 rs7041615 ENSG00000238072.1 RP11-305M3.2 10.78 5.5e-22 8.42e-15 0.76 0.59 Hematology traits; chr9:113244747 chr7:129410113~129410370:- CESC trans rs6477998 0.676 rs10759631 ENSG00000238072.1 RP11-305M3.2 10.78 5.54e-22 8.47e-15 0.84 0.59 Hematology traits; chr9:113233764 chr7:129410113~129410370:- CESC trans rs6477998 0.676 rs10081797 ENSG00000238072.1 RP11-305M3.2 10.78 5.54e-22 8.47e-15 0.84 0.59 Hematology traits; chr9:113237973 chr7:129410113~129410370:- CESC trans rs6477998 0.676 rs10759632 ENSG00000238072.1 RP11-305M3.2 10.78 5.54e-22 8.47e-15 0.84 0.59 Hematology traits; chr9:113238703 chr7:129410113~129410370:- CESC trans rs9611565 0.802 rs4822028 ENSG00000268568.1 AC007228.9 -10.76 6.22e-22 9.48e-15 -0.82 -0.59 Vitiligo; chr22:41393404 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs132771 ENSG00000268568.1 AC007228.9 10.76 6.27e-22 9.54e-15 0.88 0.59 Vitiligo; chr22:41629346 chr19:56672574~56673901:- CESC trans rs727563 0.52 rs132773 ENSG00000268568.1 AC007228.9 10.76 6.27e-22 9.54e-15 0.88 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41635764 chr19:56672574~56673901:- CESC trans rs941207 0.542 rs10876928 ENSG00000121089.4 NACA3P -10.76 6.4e-22 9.73e-15 -0.71 -0.59 Platelet count; chr12:56813646 chr4:164943290~164943937:+ CESC trans rs3749237 0.636 rs1568662 ENSG00000197582.5 GPX1P1 10.75 6.51e-22 9.87e-15 0.76 0.59 Resting heart rate; chr3:49483830 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs3924462 ENSG00000197582.5 GPX1P1 10.75 6.51e-22 9.87e-15 0.76 0.59 Resting heart rate; chr3:49486803 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs4855861 ENSG00000197582.5 GPX1P1 10.75 6.51e-22 9.87e-15 0.76 0.59 Resting heart rate; chr3:49488529 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs4855859 ENSG00000197582.5 GPX1P1 10.75 6.51e-22 9.87e-15 0.76 0.59 Resting heart rate; chr3:49488867 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs7643845 ENSG00000197582.5 GPX1P1 10.75 6.51e-22 9.87e-15 0.76 0.59 Resting heart rate; chr3:49493278 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs7637999 ENSG00000197582.5 GPX1P1 10.75 6.51e-22 9.87e-15 0.76 0.59 Resting heart rate; chr3:49497682 chrX:13378735~13379340:- CESC trans rs3749237 0.576 rs3877784 ENSG00000197582.5 GPX1P1 10.75 6.51e-22 9.87e-15 0.76 0.59 Resting heart rate; chr3:49501984 chrX:13378735~13379340:- CESC trans rs2950393 0.804 rs7980317 ENSG00000121089.4 NACA3P 10.75 6.65e-22 1.01e-14 0.62 0.59 Platelet distribution width; chr12:56764399 chr4:164943290~164943937:+ CESC trans rs9611565 0.659 rs4822036 ENSG00000268568.1 AC007228.9 -10.75 6.66e-22 1.01e-14 -0.87 -0.59 Vitiligo; chr22:41540015 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs12484228 ENSG00000268568.1 AC007228.9 -10.75 6.66e-22 1.01e-14 -0.87 -0.59 Vitiligo; chr22:41543735 chr19:56672574~56673901:- CESC trans rs6477998 0.676 rs10981693 ENSG00000238072.1 RP11-305M3.2 -10.75 6.84e-22 1.03e-14 -0.83 -0.59 Hematology traits; chr9:113223137 chr7:129410113~129410370:- CESC trans rs6732160 0.656 rs2043093 ENSG00000236165.1 PRADC1P1 10.74 7.23e-22 1.09e-14 0.71 0.59 Intelligence (multi-trait analysis); chr2:73180214 chr3:36976316~36976840:+ CESC trans rs916888 0.773 rs199443 ENSG00000214425.5 LRRC37A4P -10.74 7.31e-22 1.1e-14 -0.76 -0.59 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45506741~45550335:- CESC trans rs3749237 0.595 rs1050088 ENSG00000197582.5 GPX1P1 -10.74 7.35e-22 1.11e-14 -0.75 -0.59 Resting heart rate; chr3:49533449 chrX:13378735~13379340:- CESC trans rs2950393 0.804 rs898611 ENSG00000121089.4 NACA3P -10.73 7.52e-22 1.13e-14 -0.6 -0.59 Platelet distribution width; chr12:56769532 chr4:164943290~164943937:+ CESC trans rs9611565 0.512 rs2050031 ENSG00000268568.1 AC007228.9 10.73 7.55e-22 1.13e-14 0.89 0.59 Vitiligo; chr22:41756262 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs2050033 ENSG00000268568.1 AC007228.9 10.73 7.55e-22 1.13e-14 0.89 0.59 Vitiligo; chr22:41763225 chr19:56672574~56673901:- CESC trans rs727563 0.593 rs5758461 ENSG00000268568.1 AC007228.9 10.73 7.55e-22 1.13e-14 0.89 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41766185 chr19:56672574~56673901:- CESC trans rs6477998 0.651 rs10121845 ENSG00000238072.1 RP11-305M3.2 10.73 7.69e-22 1.15e-14 0.83 0.59 Hematology traits; chr9:113227443 chr7:129410113~129410370:- CESC trans rs3749237 0.595 rs4855877 ENSG00000197582.5 GPX1P1 10.73 7.81e-22 1.17e-14 0.76 0.59 Resting heart rate; chr3:49411094 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs1568661 ENSG00000197582.5 GPX1P1 10.73 7.88e-22 1.18e-14 0.77 0.59 Resting heart rate; chr3:49483525 chrX:13378735~13379340:- CESC trans rs6477998 0.627 rs10114381 ENSG00000238072.1 RP11-305M3.2 10.71 8.67e-22 1.29e-14 0.83 0.59 Hematology traits; chr9:113213692 chr7:129410113~129410370:- CESC trans rs6477998 0.651 rs10114423 ENSG00000238072.1 RP11-305M3.2 10.71 8.67e-22 1.29e-14 0.83 0.59 Hematology traits; chr9:113213751 chr7:129410113~129410370:- CESC trans rs6477998 0.676 rs10817460 ENSG00000238072.1 RP11-305M3.2 10.71 8.67e-22 1.29e-14 0.83 0.59 Hematology traits; chr9:113214118 chr7:129410113~129410370:- CESC trans rs6477998 0.603 rs7859189 ENSG00000238072.1 RP11-305M3.2 10.71 8.67e-22 1.29e-14 0.83 0.59 Hematology traits; chr9:113217389 chr7:129410113~129410370:- CESC trans rs6477998 0.676 rs6477997 ENSG00000238072.1 RP11-305M3.2 10.71 8.67e-22 1.29e-14 0.83 0.59 Hematology traits; chr9:113218833 chr7:129410113~129410370:- CESC trans rs6477998 0.627 rs3810914 ENSG00000238072.1 RP11-305M3.2 10.71 8.67e-22 1.29e-14 0.83 0.59 Hematology traits; chr9:113219441 chr7:129410113~129410370:- CESC trans rs6732160 0.684 rs2043095 ENSG00000236165.1 PRADC1P1 10.71 8.69e-22 1.29e-14 0.72 0.59 Intelligence (multi-trait analysis); chr2:73180314 chr3:36976316~36976840:+ CESC trans rs12709013 0.636 rs1646272 ENSG00000230849.2 GOT2P2 10.71 8.73e-22 1.29e-14 0.68 0.59 Blood metabolite ratios; chr16:58746508 chr1:173141100~173142350:- CESC trans rs12709013 0.66 rs1657163 ENSG00000230849.2 GOT2P2 10.71 8.73e-22 1.29e-14 0.68 0.59 Blood metabolite ratios; chr16:58746688 chr1:173141100~173142350:- CESC trans rs3749237 0.595 rs35701831 ENSG00000197582.5 GPX1P1 10.71 8.84e-22 1.31e-14 0.76 0.59 Resting heart rate; chr3:49477567 chrX:13378735~13379340:- CESC trans rs9611565 0.918 rs73176685 ENSG00000268568.1 AC007228.9 -10.7 9.46e-22 1.39e-14 -0.81 -0.59 Vitiligo; chr22:41385090 chr19:56672574~56673901:- CESC trans rs12709013 0.636 rs257628 ENSG00000233719.3 GOT2P3 10.7 9.48e-22 1.4e-14 0.65 0.59 Blood metabolite ratios; chr16:58758924 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs257627 ENSG00000233719.3 GOT2P3 10.7 9.48e-22 1.4e-14 0.65 0.59 Blood metabolite ratios; chr16:58758956 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs4499224 ENSG00000233719.3 GOT2P3 10.69 1.02e-21 1.49e-14 0.64 0.59 Blood metabolite ratios; chr16:58770364 chr12:9641802~9643007:+ CESC trans rs3749237 0.615 rs11130202 ENSG00000197582.5 GPX1P1 10.68 1.07e-21 1.56e-14 0.75 0.59 Resting heart rate; chr3:49529282 chrX:13378735~13379340:- CESC trans rs13177918 0.798 rs13182116 ENSG00000224114.1 RP11-343H5.4 -10.68 1.1e-21 1.61e-14 -0.79 -0.59 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr1:206695837~206696269:- CESC trans rs12709013 0.636 rs1865836 ENSG00000233719.3 GOT2P3 10.68 1.11e-21 1.61e-14 0.64 0.59 Blood metabolite ratios; chr16:58768143 chr12:9641802~9643007:+ CESC trans rs9611565 0.512 rs5758439 ENSG00000268568.1 AC007228.9 10.68 1.11e-21 1.61e-14 0.89 0.59 Vitiligo; chr22:41735758 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs768414 ENSG00000268568.1 AC007228.9 10.68 1.11e-21 1.61e-14 0.89 0.59 Vitiligo; chr22:41739747 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs8141103 ENSG00000268568.1 AC007228.9 10.68 1.11e-21 1.61e-14 0.89 0.59 Vitiligo; chr22:41740926 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs5751147 ENSG00000268568.1 AC007228.9 10.68 1.11e-21 1.61e-14 0.89 0.59 Vitiligo; chr22:41743050 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs5751148 ENSG00000268568.1 AC007228.9 10.68 1.11e-21 1.61e-14 0.89 0.59 Vitiligo; chr22:41743074 chr19:56672574~56673901:- CESC trans rs727563 0.635 rs5751149 ENSG00000268568.1 AC007228.9 10.68 1.11e-21 1.61e-14 0.89 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41743497 chr19:56672574~56673901:- CESC trans rs12709013 0.636 rs1595180 ENSG00000233719.3 GOT2P3 10.68 1.12e-21 1.63e-14 0.64 0.59 Blood metabolite ratios; chr16:58770545 chr12:9641802~9643007:+ CESC trans rs6477998 0.676 rs4978536 ENSG00000238072.1 RP11-305M3.2 10.67 1.15e-21 1.67e-14 0.83 0.59 Hematology traits; chr9:113220123 chr7:129410113~129410370:- CESC trans rs13177918 0.581 rs2748244 ENSG00000224114.1 RP11-343H5.4 10.67 1.16e-21 1.69e-14 0.7 0.59 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150436487 chr1:206695837~206696269:- CESC trans rs5751150 1 rs5751150 ENSG00000268568.1 AC007228.9 10.67 1.18e-21 1.71e-14 0.89 0.59 Cannabis dependence symptom count; chr22:41757288 chr19:56672574~56673901:- CESC trans rs727563 0.562 rs5758458 ENSG00000268568.1 AC007228.9 10.67 1.18e-21 1.71e-14 0.89 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41758128 chr19:56672574~56673901:- CESC trans rs727563 0.635 rs713988 ENSG00000268568.1 AC007228.9 10.67 1.18e-21 1.71e-14 0.89 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41763068 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs45500192 ENSG00000268568.1 AC007228.9 -10.66 1.26e-21 1.82e-14 -0.89 -0.59 Vitiligo; chr22:41781895 chr19:56672574~56673901:- CESC trans rs2950393 0.804 rs7967600 ENSG00000121089.4 NACA3P 10.65 1.31e-21 1.89e-14 0.62 0.59 Platelet distribution width; chr12:56768208 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs6499976 ENSG00000233719.3 GOT2P3 10.65 1.35e-21 1.94e-14 0.63 0.59 Blood metabolite ratios; chr16:58770330 chr12:9641802~9643007:+ CESC trans rs916888 0.821 rs199505 ENSG00000214425.5 LRRC37A4P 10.65 1.4e-21 2e-14 0.75 0.58 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45506741~45550335:- CESC trans rs916888 0.821 rs70602 ENSG00000214425.5 LRRC37A4P 10.65 1.4e-21 2e-14 0.75 0.58 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45506741~45550335:- CESC trans rs9611565 0.659 rs73178641 ENSG00000268568.1 AC007228.9 -10.65 1.4e-21 2e-14 -0.89 -0.58 Vitiligo; chr22:41556071 chr19:56672574~56673901:- CESC trans rs13096760 1 rs13096760 ENSG00000197582.5 GPX1P1 10.64 1.4e-21 2.01e-14 0.76 0.58 Intelligence (multi-trait analysis); chr3:49439373 chrX:13378735~13379340:- CESC trans rs9611565 0.559 rs5758428 ENSG00000268568.1 AC007228.9 10.64 1.4e-21 2.01e-14 0.88 0.58 Vitiligo; chr22:41710212 chr19:56672574~56673901:- CESC trans rs727563 0.636 rs2413653 ENSG00000268568.1 AC007228.9 10.64 1.4e-21 2.01e-14 0.88 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41710992 chr19:56672574~56673901:- CESC trans rs12709013 0.636 rs72792430 ENSG00000230849.2 GOT2P2 -10.64 1.41e-21 2.01e-14 -0.68 -0.58 Blood metabolite ratios; chr16:58746990 chr1:173141100~173142350:- CESC trans rs3749237 0.595 rs2878298 ENSG00000197582.5 GPX1P1 10.64 1.43e-21 2.03e-14 0.76 0.58 Resting heart rate; chr3:49368647 chrX:13378735~13379340:- CESC trans rs727563 0.608 rs2076200 ENSG00000268568.1 AC007228.9 -10.64 1.44e-21 2.04e-14 -0.92 -0.58 Crohn's disease;Inflammatory bowel disease; chr22:41589952 chr19:56672574~56673901:- CESC trans rs727563 0.552 rs4822045 ENSG00000268568.1 AC007228.9 -10.64 1.44e-21 2.04e-14 -0.92 -0.58 Crohn's disease;Inflammatory bowel disease; chr22:41589954 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs9611619 ENSG00000268568.1 AC007228.9 -10.64 1.44e-21 2.04e-14 -0.92 -0.58 Vitiligo; chr22:41590710 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs4822048 ENSG00000268568.1 AC007228.9 -10.64 1.44e-21 2.04e-14 -0.92 -0.58 Vitiligo; chr22:41592221 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs4822049 ENSG00000268568.1 AC007228.9 -10.64 1.44e-21 2.04e-14 -0.92 -0.58 Vitiligo; chr22:41597492 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs5758368 ENSG00000268568.1 AC007228.9 -10.64 1.44e-21 2.05e-14 -0.81 -0.58 Vitiligo; chr22:41466284 chr19:56672574~56673901:- CESC trans rs3749237 0.595 rs17595772 ENSG00000197582.5 GPX1P1 10.64 1.47e-21 2.09e-14 0.76 0.58 Resting heart rate; chr3:49372271 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs7621003 ENSG00000197582.5 GPX1P1 10.64 1.47e-21 2.09e-14 0.76 0.58 Resting heart rate; chr3:49373971 chrX:13378735~13379340:- CESC trans rs12709013 0.636 rs4538000 ENSG00000230849.2 GOT2P2 10.63 1.51e-21 2.15e-14 0.68 0.58 Blood metabolite ratios; chr16:58744506 chr1:173141100~173142350:- CESC trans rs3749237 0.595 rs4955412 ENSG00000197582.5 GPX1P1 10.63 1.6e-21 2.26e-14 0.76 0.58 Resting heart rate; chr3:49380735 chrX:13378735~13379340:- CESC trans rs3749237 0.557 rs7631908 ENSG00000197582.5 GPX1P1 10.63 1.6e-21 2.26e-14 0.76 0.58 Resting heart rate; chr3:49388274 chrX:13378735~13379340:- CESC trans rs3749237 0.615 rs55957735 ENSG00000197582.5 GPX1P1 10.63 1.6e-21 2.26e-14 0.76 0.58 Resting heart rate; chr3:49400725 chrX:13378735~13379340:- CESC trans rs12709013 0.636 rs1646272 ENSG00000233719.3 GOT2P3 10.62 1.64e-21 2.31e-14 0.65 0.58 Blood metabolite ratios; chr16:58746508 chr12:9641802~9643007:+ CESC trans rs12709013 0.66 rs1657163 ENSG00000233719.3 GOT2P3 10.62 1.64e-21 2.31e-14 0.65 0.58 Blood metabolite ratios; chr16:58746688 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1657161 ENSG00000230849.2 GOT2P2 10.62 1.67e-21 2.36e-14 0.68 0.58 Blood metabolite ratios; chr16:58743234 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1646269 ENSG00000230849.2 GOT2P2 10.62 1.67e-21 2.36e-14 0.68 0.58 Blood metabolite ratios; chr16:58743412 chr1:173141100~173142350:- CESC trans rs7811142 0.83 rs10085549 ENSG00000228546.2 CTA-313A17.3 10.62 1.68e-21 2.37e-14 0.95 0.58 Platelet count; chr7:100385512 chr7:102337316~102339115:+ CESC trans rs6477998 0.903 rs4979226 ENSG00000238072.1 RP11-305M3.2 10.62 1.68e-21 2.38e-14 0.77 0.58 Hematology traits; chr9:113239516 chr7:129410113~129410370:- CESC trans rs3749237 0.595 rs885592 ENSG00000197582.5 GPX1P1 10.61 1.79e-21 2.52e-14 0.76 0.58 Resting heart rate; chr3:49460450 chrX:13378735~13379340:- CESC trans rs12709013 0.636 rs4538000 ENSG00000233719.3 GOT2P3 10.61 1.84e-21 2.59e-14 0.65 0.58 Blood metabolite ratios; chr16:58744506 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs72792430 ENSG00000233719.3 GOT2P3 -10.6 1.89e-21 2.65e-14 -0.64 -0.58 Blood metabolite ratios; chr16:58746990 chr12:9641802~9643007:+ CESC trans rs9611565 0.592 rs8779 ENSG00000268568.1 AC007228.9 10.59 2e-21 2.8e-14 0.89 0.58 Vitiligo; chr22:41674272 chr19:56672574~56673901:- CESC trans rs727563 0.594 rs132807 ENSG00000268568.1 AC007228.9 10.59 2e-21 2.8e-14 0.89 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41675580 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs1811113 ENSG00000268568.1 AC007228.9 10.59 2e-21 2.8e-14 0.89 0.58 Vitiligo; chr22:41677130 chr19:56672574~56673901:- CESC trans rs727563 0.594 rs5758408 ENSG00000268568.1 AC007228.9 10.59 2e-21 2.8e-14 0.89 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41681733 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs5758412 ENSG00000268568.1 AC007228.9 10.59 2e-21 2.8e-14 0.89 0.58 Vitiligo; chr22:41684799 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs13056262 ENSG00000268568.1 AC007228.9 10.59 2e-21 2.8e-14 0.89 0.58 Vitiligo; chr22:41685917 chr19:56672574~56673901:- CESC trans rs2950393 0.804 rs1131514 ENSG00000121089.4 NACA3P -10.59 2.04e-21 2.85e-14 -0.59 -0.58 Platelet distribution width; chr12:56739356 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs1657161 ENSG00000233719.3 GOT2P3 10.59 2.05e-21 2.86e-14 0.64 0.58 Blood metabolite ratios; chr16:58743234 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1646269 ENSG00000233719.3 GOT2P3 10.59 2.05e-21 2.86e-14 0.64 0.58 Blood metabolite ratios; chr16:58743412 chr12:9641802~9643007:+ CESC trans rs12709013 0.621 rs6499974 ENSG00000230849.2 GOT2P2 10.59 2.12e-21 2.95e-14 0.67 0.58 Blood metabolite ratios; chr16:58769642 chr1:173141100~173142350:- CESC trans rs1816752 0.716 rs1441058 ENSG00000237917.1 PARP4P1 -10.58 2.16e-21 3e-14 -0.68 -0.58 Obesity-related traits; chr13:24516275 chrY:26594851~26634652:- CESC trans rs12709013 0.591 rs7184377 ENSG00000233719.3 GOT2P3 10.58 2.19e-21 3.05e-14 0.67 0.58 Blood metabolite ratios; chr16:58808765 chr12:9641802~9643007:+ CESC trans rs7399018 0.643 rs6580810 ENSG00000223825.5 DAZAP2P1 10.58 2.22e-21 3.08e-14 0.82 0.58 Cisplatin-induced ototoxicity; chr12:51216694 chr2:202201384~202201886:- CESC trans rs12709013 0.585 rs7188608 ENSG00000233719.3 GOT2P3 10.58 2.22e-21 3.08e-14 0.64 0.58 Blood metabolite ratios; chr16:58736236 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1657176 ENSG00000233719.3 GOT2P3 10.58 2.22e-21 3.08e-14 0.64 0.58 Blood metabolite ratios; chr16:58736833 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs1646282 ENSG00000233719.3 GOT2P3 10.58 2.22e-21 3.08e-14 0.64 0.58 Blood metabolite ratios; chr16:58741296 chr12:9641802~9643007:+ CESC trans rs12709013 0.636 rs4784977 ENSG00000233719.3 GOT2P3 10.58 2.22e-21 3.08e-14 0.64 0.58 Blood metabolite ratios; chr16:58742120 chr12:9641802~9643007:+ CESC trans rs1816752 0.716 rs9553331 ENSG00000237917.1 PARP4P1 -10.58 2.29e-21 3.18e-14 -0.68 -0.58 Obesity-related traits; chr13:24516030 chrY:26594851~26634652:- CESC trans rs9611565 0.659 rs9611609 ENSG00000268568.1 AC007228.9 -10.57 2.34e-21 3.23e-14 -0.86 -0.58 Vitiligo; chr22:41549353 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs139562 ENSG00000268568.1 AC007228.9 -10.57 2.37e-21 3.27e-14 -0.88 -0.58 Vitiligo; chr22:41800680 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs139566 ENSG00000268568.1 AC007228.9 -10.57 2.42e-21 3.34e-14 -0.88 -0.58 Vitiligo; chr22:41803273 chr19:56672574~56673901:- CESC trans rs12709013 0.585 rs7188608 ENSG00000230849.2 GOT2P2 10.57 2.44e-21 3.36e-14 0.67 0.58 Blood metabolite ratios; chr16:58736236 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1657176 ENSG00000230849.2 GOT2P2 10.57 2.44e-21 3.36e-14 0.67 0.58 Blood metabolite ratios; chr16:58736833 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs1646282 ENSG00000230849.2 GOT2P2 10.57 2.44e-21 3.36e-14 0.67 0.58 Blood metabolite ratios; chr16:58741296 chr1:173141100~173142350:- CESC trans rs12709013 0.636 rs4784977 ENSG00000230849.2 GOT2P2 10.57 2.44e-21 3.36e-14 0.67 0.58 Blood metabolite ratios; chr16:58742120 chr1:173141100~173142350:- CESC trans rs2657294 0.62 rs4746259 ENSG00000172974.11 AC007318.5 10.57 2.44e-21 3.37e-14 0.6 0.58 Pneumonia; chr10:75082310 chr2:65205108~65205988:+ CESC trans rs9611565 0.512 rs4512 ENSG00000268568.1 AC007228.9 -10.56 2.48e-21 3.42e-14 -0.92 -0.58 Vitiligo; chr22:41810080 chr19:56672574~56673901:- CESC trans rs7811142 0.83 rs7792959 ENSG00000228546.2 CTA-313A17.3 10.56 2.51e-21 3.46e-14 0.95 0.58 Platelet count; chr7:100374780 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs6975660 ENSG00000228546.2 CTA-313A17.3 10.56 2.51e-21 3.46e-14 0.95 0.58 Platelet count; chr7:100377643 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs73401443 ENSG00000228546.2 CTA-313A17.3 10.56 2.51e-21 3.46e-14 0.95 0.58 Platelet count; chr7:100379959 chr7:102337316~102339115:+ CESC trans rs928391 1 rs2768766 ENSG00000227183.3 HDGFP1 10.56 2.53e-21 3.49e-14 0.91 0.58 Platelet count; chr1:156805842 chrX:131646639~131646890:+ CESC trans rs2657294 0.62 rs9783273 ENSG00000172974.11 AC007318.5 10.56 2.55e-21 3.51e-14 0.6 0.58 Pneumonia; chr10:75081982 chr2:65205108~65205988:+ CESC trans rs2950393 0.804 rs2958130 ENSG00000121089.4 NACA3P 10.56 2.58e-21 3.54e-14 0.61 0.58 Platelet distribution width; chr12:56746722 chr4:164943290~164943937:+ CESC trans rs9611565 0.512 rs9607842 ENSG00000268568.1 AC007228.9 -10.55 2.72e-21 3.72e-14 -0.88 -0.58 Vitiligo; chr22:41796718 chr19:56672574~56673901:- CESC trans rs2950393 0.804 rs2958132 ENSG00000121089.4 NACA3P 10.55 2.72e-21 3.73e-14 0.61 0.58 Platelet distribution width; chr12:56750749 chr4:164943290~164943937:+ CESC trans rs12709013 0.636 rs9937713 ENSG00000233719.3 GOT2P3 10.55 2.73e-21 3.74e-14 0.64 0.58 Blood metabolite ratios; chr16:58771921 chr12:9641802~9643007:+ CESC trans rs6477998 0.868 rs10513189 ENSG00000238072.1 RP11-305M3.2 10.55 2.83e-21 3.87e-14 0.75 0.58 Hematology traits; chr9:113227941 chr7:129410113~129410370:- CESC trans rs9611565 0.659 rs9607812 ENSG00000268568.1 AC007228.9 -10.54 2.84e-21 3.88e-14 -0.86 -0.58 Vitiligo; chr22:41545239 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs9607813 ENSG00000268568.1 AC007228.9 -10.54 2.84e-21 3.88e-14 -0.86 -0.58 Vitiligo; chr22:41545475 chr19:56672574~56673901:- CESC trans rs3749237 0.595 rs6784820 ENSG00000197582.5 GPX1P1 -10.54 2.87e-21 3.92e-14 -0.75 -0.58 Resting heart rate; chr3:49413431 chrX:13378735~13379340:- CESC trans rs3749237 0.555 rs7637665 ENSG00000197582.5 GPX1P1 10.54 2.97e-21 4.06e-14 0.75 0.58 Resting heart rate; chr3:49514862 chrX:13378735~13379340:- CESC trans rs9611565 0.694 rs202641 ENSG00000268568.1 AC007228.9 10.53 3.22e-21 4.37e-14 0.79 0.58 Vitiligo; chr22:41437112 chr19:56672574~56673901:- CESC trans rs12709013 0.574 rs9302706 ENSG00000233719.3 GOT2P3 10.52 3.35e-21 4.55e-14 0.67 0.58 Blood metabolite ratios; chr16:58812060 chr12:9641802~9643007:+ CESC trans rs12709013 0.591 rs4784986 ENSG00000233719.3 GOT2P3 10.52 3.4e-21 4.61e-14 0.65 0.58 Blood metabolite ratios; chr16:58803007 chr12:9641802~9643007:+ CESC trans rs916888 0.773 rs199448 ENSG00000264070.1 DND1P1 10.52 3.44e-21 4.66e-14 0.84 0.58 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45585871~45586929:+ CESC trans rs9611565 0.512 rs5758465 ENSG00000268568.1 AC007228.9 10.52 3.48e-21 4.7e-14 0.89 0.58 Vitiligo; chr22:41779310 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs5751160 ENSG00000268568.1 AC007228.9 10.52 3.48e-21 4.7e-14 0.89 0.58 Vitiligo; chr22:41779691 chr19:56672574~56673901:- CESC trans rs12709013 0.636 rs967852 ENSG00000233719.3 GOT2P3 10.5 3.81e-21 5.13e-14 0.67 0.58 Blood metabolite ratios; chr16:58807313 chr12:9641802~9643007:+ CESC trans rs12709013 0.591 rs899375 ENSG00000233719.3 GOT2P3 10.5 3.99e-21 5.36e-14 0.67 0.58 Blood metabolite ratios; chr16:58792325 chr12:9641802~9643007:+ CESC trans rs9611565 0.512 rs139560 ENSG00000268568.1 AC007228.9 -10.49 4.09e-21 5.49e-14 -0.87 -0.58 Vitiligo; chr22:41798958 chr19:56672574~56673901:- CESC trans rs5022636 0.594 rs7489 ENSG00000180764.13 PIPSL 10.48 4.44e-21 5.94e-14 0.71 0.58 Gut microbiota (functional units); chr1:151266575 chr10:93958191~93961540:- CESC trans rs12709013 0.755 rs1424245 ENSG00000230849.2 GOT2P2 10.48 4.54e-21 6.06e-14 0.67 0.58 Blood metabolite ratios; chr16:58729926 chr1:173141100~173142350:- CESC trans rs4822044 0.568 rs1883370 ENSG00000268568.1 AC007228.9 10.47 4.67e-21 6.23e-14 0.89 0.58 Cannabis dependence symptom count; chr22:41747736 chr19:56672574~56673901:- CESC trans rs13177918 0.798 rs12514700 ENSG00000224114.1 RP11-343H5.4 10.46 5.2e-21 6.92e-14 0.8 0.58 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr1:206695837~206696269:- CESC trans rs7811142 0.83 rs11768967 ENSG00000228546.2 CTA-313A17.3 10.46 5.25e-21 6.98e-14 0.9 0.58 Platelet count; chr7:100370021 chr7:102337316~102339115:+ CESC trans rs916888 0.773 rs199535 ENSG00000264070.1 DND1P1 10.46 5.29e-21 7.03e-14 0.84 0.58 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45585871~45586929:+ CESC trans rs3749237 0.595 rs4855873 ENSG00000197582.5 GPX1P1 10.44 5.98e-21 7.9e-14 0.74 0.58 Resting heart rate; chr3:49421681 chrX:13378735~13379340:- CESC trans rs916888 0.773 rs199533 ENSG00000264070.1 DND1P1 10.44 6.06e-21 8e-14 0.85 0.58 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45585871~45586929:+ CESC trans rs9611565 0.694 rs202628 ENSG00000268568.1 AC007228.9 -10.43 6.5e-21 8.56e-14 -0.79 -0.58 Vitiligo; chr22:41453509 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs9607815 ENSG00000268568.1 AC007228.9 -10.42 6.65e-21 8.74e-14 -0.85 -0.58 Vitiligo; chr22:41554667 chr19:56672574~56673901:- CESC trans rs9611565 0.694 rs9607816 ENSG00000268568.1 AC007228.9 -10.42 6.65e-21 8.74e-14 -0.85 -0.58 Vitiligo; chr22:41554893 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs56364401 ENSG00000268568.1 AC007228.9 -10.42 6.65e-21 8.74e-14 -0.85 -0.58 Vitiligo; chr22:41555239 chr19:56672574~56673901:- CESC trans rs9611565 0.546 rs132793 ENSG00000268568.1 AC007228.9 10.42 6.66e-21 8.75e-14 0.9 0.58 Vitiligo; chr22:41667677 chr19:56672574~56673901:- CESC trans rs9611565 0.659 rs12484175 ENSG00000268568.1 AC007228.9 -10.42 6.78e-21 8.89e-14 -0.85 -0.58 Vitiligo; chr22:41557735 chr19:56672574~56673901:- CESC trans rs6732160 0.741 rs6546806 ENSG00000236165.1 PRADC1P1 10.41 7.19e-21 9.38e-14 0.68 0.58 Intelligence (multi-trait analysis); chr2:73159032 chr3:36976316~36976840:+ CESC trans rs2657294 0.62 rs2395132 ENSG00000172974.11 AC007318.5 10.4 8.08e-21 1.05e-13 0.59 0.58 Pneumonia; chr10:75080840 chr2:65205108~65205988:+ CESC trans rs916888 0.779 rs199528 ENSG00000264070.1 DND1P1 10.39 8.27e-21 1.08e-13 0.86 0.58 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45585871~45586929:+ CESC trans rs916888 0.821 rs199525 ENSG00000264070.1 DND1P1 10.39 8.27e-21 1.08e-13 0.86 0.58 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45585871~45586929:+ CESC trans rs10242455 0.702 rs73397481 ENSG00000228834.1 RP11-249L21.4 10.39 8.7e-21 1.13e-13 1.61 0.58 Blood metabolite levels; chr7:99432485 chr6:108907615~108907873:- CESC trans rs12709013 0.597 rs8051078 ENSG00000233719.3 GOT2P3 10.38 9.04e-21 1.17e-13 0.62 0.58 Blood metabolite ratios; chr16:58774200 chr12:9641802~9643007:+ CESC trans rs3749237 0.595 rs4855864 ENSG00000197582.5 GPX1P1 10.38 9.19e-21 1.19e-13 0.75 0.58 Resting heart rate; chr3:49484541 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs11130199 ENSG00000197582.5 GPX1P1 10.38 9.19e-21 1.19e-13 0.75 0.58 Resting heart rate; chr3:49501366 chrX:13378735~13379340:- CESC trans rs916888 0.821 rs199512 ENSG00000214425.5 LRRC37A4P 10.37 9.79e-21 1.26e-13 0.74 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45506741~45550335:- CESC trans rs916888 0.821 rs199509 ENSG00000214425.5 LRRC37A4P 10.37 9.79e-21 1.26e-13 0.74 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45506741~45550335:- CESC trans rs916888 0.821 rs199507 ENSG00000214425.5 LRRC37A4P 10.37 9.79e-21 1.26e-13 0.74 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45506741~45550335:- CESC trans rs9611565 0.512 rs1534932 ENSG00000268568.1 AC007228.9 10.36 1.04e-20 1.33e-13 0.88 0.57 Vitiligo; chr22:41754142 chr19:56672574~56673901:- CESC trans rs916888 0.821 rs199506 ENSG00000214425.5 LRRC37A4P 10.36 1.05e-20 1.35e-13 0.74 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45506741~45550335:- CESC trans rs6732160 0.845 rs6546809 ENSG00000236165.1 PRADC1P1 10.35 1.09e-20 1.39e-13 0.69 0.57 Intelligence (multi-trait analysis); chr2:73162553 chr3:36976316~36976840:+ CESC trans rs12709013 0.574 rs35321124 ENSG00000233719.3 GOT2P3 10.35 1.11e-20 1.42e-13 0.66 0.57 Blood metabolite ratios; chr16:58786561 chr12:9641802~9643007:+ CESC trans rs727563 0.635 rs5758444 ENSG00000268568.1 AC007228.9 10.35 1.13e-20 1.45e-13 0.86 0.57 Crohn's disease;Inflammatory bowel disease; chr22:41737917 chr19:56672574~56673901:- CESC trans rs2731664 0.792 rs335434 ENSG00000215571.5 GRK6P1 10.35 1.13e-20 1.45e-13 0.74 0.57 Intelligence (multi-trait analysis); chr5:177440275 chr13:21319156~21320866:+ CESC trans rs9611565 0.512 rs139571 ENSG00000268568.1 AC007228.9 -10.34 1.17e-20 1.49e-13 -0.88 -0.57 Vitiligo; chr22:41818234 chr19:56672574~56673901:- CESC trans rs3749237 0.595 rs4855839 ENSG00000197582.5 GPX1P1 10.34 1.23e-20 1.56e-13 0.75 0.57 Resting heart rate; chr3:49470414 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs3870337 ENSG00000197582.5 GPX1P1 10.33 1.25e-20 1.58e-13 0.74 0.57 Resting heart rate; chr3:49519662 chrX:13378735~13379340:- CESC trans rs916888 0.821 rs415430 ENSG00000214425.5 LRRC37A4P 10.32 1.34e-20 1.69e-13 0.74 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45506741~45550335:- CESC trans rs916888 0.779 rs430685 ENSG00000214425.5 LRRC37A4P 10.32 1.34e-20 1.69e-13 0.74 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45506741~45550335:- CESC trans rs3749237 0.595 rs3870338 ENSG00000197582.5 GPX1P1 10.32 1.35e-20 1.7e-13 0.74 0.57 Resting heart rate; chr3:49519618 chrX:13378735~13379340:- CESC trans rs12709013 0.755 rs1424245 ENSG00000233719.3 GOT2P3 10.32 1.41e-20 1.77e-13 0.63 0.57 Blood metabolite ratios; chr16:58729926 chr12:9641802~9643007:+ CESC trans rs9611565 0.592 rs4822046 ENSG00000268568.1 AC007228.9 -10.31 1.45e-20 1.82e-13 -0.88 -0.57 Vitiligo; chr22:41591539 chr19:56672574~56673901:- CESC trans rs12709013 0.621 rs6499974 ENSG00000233719.3 GOT2P3 10.31 1.45e-20 1.83e-13 0.63 0.57 Blood metabolite ratios; chr16:58769642 chr12:9641802~9643007:+ CESC trans rs6732160 0.809 rs13406142 ENSG00000236165.1 PRADC1P1 10.31 1.49e-20 1.87e-13 0.68 0.57 Intelligence (multi-trait analysis); chr2:73156970 chr3:36976316~36976840:+ CESC trans rs13177918 0.581 rs2748244 ENSG00000239528.1 RPS14P8 10.31 1.49e-20 1.87e-13 0.69 0.57 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150436487 chr5:116562562~116562930:+ CESC trans rs9611565 0.592 rs4822038 ENSG00000268568.1 AC007228.9 -10.3 1.54e-20 1.93e-13 -0.88 -0.57 Vitiligo; chr22:41562491 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs4822044 ENSG00000268568.1 AC007228.9 -10.3 1.58e-20 1.98e-13 -0.88 -0.57 Vitiligo; chr22:41583664 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs4820444 ENSG00000268568.1 AC007228.9 10.29 1.66e-20 2.07e-13 0.85 0.57 Vitiligo; chr22:41806602 chr19:56672574~56673901:- CESC trans rs12709013 0.591 rs6499980 ENSG00000233719.3 GOT2P3 10.29 1.71e-20 2.13e-13 0.66 0.57 Blood metabolite ratios; chr16:58787972 chr12:9641802~9643007:+ CESC trans rs3749237 0.595 rs1464566 ENSG00000197582.5 GPX1P1 10.29 1.71e-20 2.13e-13 0.74 0.57 Resting heart rate; chr3:49421943 chrX:13378735~13379340:- CESC trans rs916888 0.773 rs199457 ENSG00000264070.1 DND1P1 10.28 1.82e-20 2.26e-13 0.85 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45585871~45586929:+ CESC trans rs916888 0.687 rs199456 ENSG00000264070.1 DND1P1 10.28 1.82e-20 2.26e-13 0.85 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45585871~45586929:+ CESC trans rs7121616 0.92 rs7109445 ENSG00000234176.1 HSPA8P1 10.27 1.95e-20 2.42e-13 0.72 0.57 Breast cancer; chr11:123094779 chrX:121203182~121205014:- CESC trans rs6732160 0.774 rs1367291 ENSG00000236165.1 PRADC1P1 10.27 2.01e-20 2.5e-13 0.66 0.57 Intelligence (multi-trait analysis); chr2:73147737 chr3:36976316~36976840:+ CESC trans rs4822044 0.561 rs132781 ENSG00000268568.1 AC007228.9 10.27 2.02e-20 2.5e-13 0.87 0.57 Cannabis dependence symptom count; chr22:41650118 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs132784 ENSG00000268568.1 AC007228.9 10.27 2.02e-20 2.5e-13 0.87 0.57 Vitiligo; chr22:41656359 chr19:56672574~56673901:- CESC trans rs3749237 0.537 rs4459909 ENSG00000197582.5 GPX1P1 10.26 2.05e-20 2.53e-13 0.74 0.57 Resting heart rate; chr3:49431784 chrX:13378735~13379340:- CESC trans rs3749237 0.595 rs12489092 ENSG00000197582.5 GPX1P1 10.26 2.08e-20 2.58e-13 0.74 0.57 Resting heart rate; chr3:49513481 chrX:13378735~13379340:- CESC trans rs916888 0.773 rs1378358 ENSG00000264070.1 DND1P1 10.26 2.09e-20 2.58e-13 0.85 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45585871~45586929:+ CESC trans rs916888 0.773 rs169201 ENSG00000264070.1 DND1P1 10.26 2.09e-20 2.58e-13 0.85 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45585871~45586929:+ CESC trans rs9611565 0.512 rs9611672 ENSG00000268568.1 AC007228.9 -10.25 2.2e-20 2.71e-13 -0.88 -0.57 Vitiligo; chr22:41813918 chr19:56672574~56673901:- CESC trans rs3749237 0.595 rs11130196 ENSG00000197582.5 GPX1P1 10.25 2.23e-20 2.74e-13 0.74 0.57 Resting heart rate; chr3:49452716 chrX:13378735~13379340:- CESC trans rs9467773 1 rs9467783 ENSG00000242375.1 RP11-498P14.3 10.25 2.28e-20 2.81e-13 0.66 0.57 Intelligence (multi-trait analysis); chr6:26542666 chr9:97195351~97197687:- CESC trans rs12709013 0.613 rs6499984 ENSG00000233719.3 GOT2P3 10.25 2.29e-20 2.81e-13 0.66 0.57 Blood metabolite ratios; chr16:58810209 chr12:9641802~9643007:+ CESC trans rs3749237 0.576 rs4241406 ENSG00000197582.5 GPX1P1 10.22 2.74e-20 3.35e-13 0.74 0.57 Resting heart rate; chr3:49562993 chrX:13378735~13379340:- CESC trans rs5022636 0.525 rs6587559 ENSG00000180764.13 PIPSL 10.21 2.91e-20 3.55e-13 0.7 0.57 Gut microbiota (functional units); chr1:151245262 chr10:93958191~93961540:- CESC trans rs916888 0.773 rs199439 ENSG00000264070.1 DND1P1 10.2 3.12e-20 3.8e-13 0.84 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45585871~45586929:+ CESC trans rs6732160 0.845 rs6546805 ENSG00000236165.1 PRADC1P1 10.2 3.26e-20 3.97e-13 0.68 0.57 Intelligence (multi-trait analysis); chr2:73158987 chr3:36976316~36976840:+ CESC trans rs9611565 0.659 rs9611610 ENSG00000268568.1 AC007228.9 -10.19 3.31e-20 4.03e-13 -0.85 -0.57 Vitiligo; chr22:41553255 chr19:56672574~56673901:- CESC trans rs6732160 0.845 rs6752507 ENSG00000236165.1 PRADC1P1 10.19 3.38e-20 4.11e-13 0.68 0.57 Intelligence (multi-trait analysis); chr2:73158030 chr3:36976316~36976840:+ CESC trans rs916888 0.773 rs538628 ENSG00000264070.1 DND1P1 10.18 3.56e-20 4.31e-13 0.84 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45585871~45586929:+ CESC trans rs9611565 0.694 rs19573 ENSG00000268568.1 AC007228.9 10.18 3.57e-20 4.32e-13 0.78 0.57 Vitiligo; chr22:41469805 chr19:56672574~56673901:- CESC trans rs9611565 0.512 rs139573 ENSG00000268568.1 AC007228.9 -10.18 3.71e-20 4.48e-13 -0.86 -0.57 Vitiligo; chr22:41818781 chr19:56672574~56673901:- CESC trans rs7399018 0.739 rs6580811 ENSG00000223825.5 DAZAP2P1 10.18 3.74e-20 4.52e-13 0.8 0.57 Cisplatin-induced ototoxicity; chr12:51218717 chr2:202201384~202201886:- CESC trans rs7121616 0.576 rs7123232 ENSG00000234176.1 HSPA8P1 10.17 3.82e-20 4.61e-13 0.84 0.57 Breast cancer; chr11:123056237 chrX:121203182~121205014:- CESC trans rs6732160 0.845 rs13413175 ENSG00000236165.1 PRADC1P1 10.17 3.93e-20 4.73e-13 0.69 0.57 Intelligence (multi-trait analysis); chr2:73162788 chr3:36976316~36976840:+ CESC trans rs6732160 0.845 rs72807999 ENSG00000236165.1 PRADC1P1 10.17 3.93e-20 4.73e-13 0.69 0.57 Intelligence (multi-trait analysis); chr2:73164567 chr3:36976316~36976840:+ CESC trans rs61990749 0.571 rs2364841 ENSG00000235400.1 RP4-641G12.4 10.17 4.05e-20 4.82e-13 0.99 0.57 Fibroblast growth factor basic levels; chr14:77817693 chr1:78749073~78750659:+ CESC trans rs6732160 0.774 rs11890053 ENSG00000236165.1 PRADC1P1 10.16 4.11e-20 4.89e-13 0.66 0.57 Intelligence (multi-trait analysis); chr2:73146320 chr3:36976316~36976840:+ CESC trans rs8081395 0.651 rs1292067 ENSG00000187870.7 RNFT1P3 -10.16 4.33e-20 5.13e-13 -0.67 -0.57 White blood cell count; chr17:59853285 chr17:20743333~20754501:- CESC trans rs916888 0.821 rs70600 ENSG00000214425.5 LRRC37A4P -10.16 4.33e-20 5.14e-13 -0.76 -0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45506741~45550335:- CESC trans rs5022636 0.594 rs12048670 ENSG00000180764.13 PIPSL 10.16 4.34e-20 5.14e-13 0.71 0.57 Gut microbiota (functional units); chr1:151272510 chr10:93958191~93961540:- CESC trans rs9611565 0.559 rs1006407 ENSG00000268568.1 AC007228.9 -10.14 4.84e-20 5.73e-13 -0.89 -0.57 Vitiligo; chr22:41576028 chr19:56672574~56673901:- CESC trans rs916888 0.773 rs199451 ENSG00000264070.1 DND1P1 10.14 4.94e-20 5.84e-13 0.84 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45585871~45586929:+ CESC trans rs6732160 0.838 rs13411380 ENSG00000236165.1 PRADC1P1 10.14 5e-20 5.9e-13 0.67 0.57 Intelligence (multi-trait analysis); chr2:73155718 chr3:36976316~36976840:+ CESC trans rs6732160 0.845 rs6718690 ENSG00000236165.1 PRADC1P1 -10.13 5.12e-20 6.03e-13 -0.67 -0.57 Intelligence (multi-trait analysis); chr2:73160034 chr3:36976316~36976840:+ CESC trans rs9611565 0.694 rs79011 ENSG00000268568.1 AC007228.9 10.13 5.33e-20 6.28e-13 0.78 0.57 Vitiligo; chr22:41470934 chr19:56672574~56673901:- CESC trans rs7811142 0.83 rs6979910 ENSG00000228546.2 CTA-313A17.3 10.12 5.48e-20 6.45e-13 0.9 0.57 Platelet count; chr7:100343007 chr7:102337316~102339115:+ CESC trans rs2950393 0.726 rs10459246 ENSG00000121089.4 NACA3P -10.12 5.74e-20 6.74e-13 -0.58 -0.57 Platelet distribution width; chr12:56776034 chr4:164943290~164943937:+ CESC trans rs112721625 1 rs112721625 ENSG00000187870.7 RNFT1P3 10.1 6.33e-20 7.38e-13 0.68 0.56 Monocyte count; chr17:59850066 chr17:20743333~20754501:- CESC trans rs55665837 0.778 rs11023212 ENSG00000236360.2 RP11-334A14.2 10.09 6.81e-20 7.94e-13 0.75 0.56 Vitamin D levels; chr11:14410163 chr1:52993201~52993702:- CESC trans rs7811142 0.667 rs3873746 ENSG00000228546.2 CTA-313A17.3 10.09 6.82e-20 7.94e-13 0.9 0.56 Platelet count; chr7:100337474 chr7:102337316~102339115:+ CESC trans rs1816752 0.716 rs7995304 ENSG00000237917.1 PARP4P1 -10.09 7.02e-20 8.17e-13 -0.67 -0.56 Obesity-related traits; chr13:24514284 chrY:26594851~26634652:- CESC trans rs9611565 0.559 rs739136 ENSG00000268568.1 AC007228.9 -10.08 7.2e-20 8.37e-13 -0.84 -0.56 Vitiligo; chr22:41704271 chr19:56672574~56673901:- CESC trans rs916888 0.773 rs199445 ENSG00000264070.1 DND1P1 10.08 7.35e-20 8.53e-13 0.83 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45585871~45586929:+ CESC trans rs916888 0.773 rs9896243 ENSG00000264070.1 DND1P1 10.07 8.06e-20 9.33e-13 0.79 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45585871~45586929:+ CESC trans rs1816752 0.692 rs6490944 ENSG00000237917.1 PARP4P1 -10.06 8.22e-20 9.5e-13 -0.66 -0.56 Obesity-related traits; chr13:24513866 chrY:26594851~26634652:- CESC trans rs7811142 0.775 rs1059129 ENSG00000228546.2 CTA-313A17.3 10.06 8.44e-20 9.75e-13 0.9 0.56 Platelet count; chr7:100328899 chr7:102337316~102339115:+ CESC trans rs7811142 0.562 rs7786844 ENSG00000228546.2 CTA-313A17.3 10.06 8.44e-20 9.75e-13 0.9 0.56 Platelet count; chr7:100336385 chr7:102337316~102339115:+ CESC trans rs916888 0.773 rs199443 ENSG00000264070.1 DND1P1 10.03 1.03e-19 1.17e-12 0.83 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45585871~45586929:+ CESC trans rs7399018 0.739 rs10747608 ENSG00000223825.5 DAZAP2P1 10.02 1.09e-19 1.24e-12 0.69 0.56 Cisplatin-induced ototoxicity; chr12:51222798 chr2:202201384~202201886:- CESC trans rs727563 0.638 rs4820443 ENSG00000268568.1 AC007228.9 -10.02 1.12e-19 1.27e-12 -0.84 -0.56 Crohn's disease;Inflammatory bowel disease; chr22:41797909 chr19:56672574~56673901:- CESC trans rs8010715 0.636 rs2277480 ENSG00000248988.1 RP11-815N9.2 10.02 1.13e-19 1.28e-12 0.73 0.56 IgG glycosylation; chr14:24118306 chr4:159007119~159007835:+ CESC trans rs6732160 0.809 rs6728959 ENSG00000236165.1 PRADC1P1 10.01 1.17e-19 1.32e-12 0.66 0.56 Intelligence (multi-trait analysis); chr2:73156199 chr3:36976316~36976840:+ CESC trans rs13177918 0.798 rs12514700 ENSG00000239528.1 RPS14P8 9.99 1.4e-19 1.57e-12 0.78 0.56 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr5:116562562~116562930:+ CESC trans rs8010715 0.636 rs2277482 ENSG00000248988.1 RP11-815N9.2 9.98 1.49e-19 1.66e-12 0.72 0.56 IgG glycosylation; chr14:24118586 chr4:159007119~159007835:+ CESC trans rs13177918 0.798 rs13182116 ENSG00000239528.1 RPS14P8 -9.97 1.57e-19 1.75e-12 -0.77 -0.56 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr5:116562562~116562930:+ CESC trans rs7121616 0.531 rs41361350 ENSG00000234176.1 HSPA8P1 9.96 1.65e-19 1.84e-12 0.89 0.56 Breast cancer; chr11:123060917 chrX:121203182~121205014:- CESC trans rs6732160 0.706 rs1430348 ENSG00000236165.1 PRADC1P1 9.95 1.75e-19 1.94e-12 0.66 0.56 Intelligence (multi-trait analysis); chr2:73139930 chr3:36976316~36976840:+ CESC trans rs6732160 0.774 rs7606271 ENSG00000236165.1 PRADC1P1 9.95 1.75e-19 1.94e-12 0.66 0.56 Intelligence (multi-trait analysis); chr2:73140570 chr3:36976316~36976840:+ CESC trans rs9611565 0.546 rs2092274 ENSG00000268568.1 AC007228.9 9.94 1.88e-19 2.08e-12 0.82 0.56 Vitiligo; chr22:41727733 chr19:56672574~56673901:- CESC trans rs116095464 0.558 rs10076655 ENSG00000185986.11 SDHAP3 9.94 1.9e-19 2.1e-12 0.88 0.56 Breast cancer; chr5:239349 chr5:1572222~1594620:- CESC trans rs6732160 0.845 rs11894833 ENSG00000236165.1 PRADC1P1 -9.94 2e-19 2.2e-12 -0.66 -0.56 Intelligence (multi-trait analysis); chr2:73161290 chr3:36976316~36976840:+ CESC trans rs12709013 0.535 rs9924136 ENSG00000233719.3 GOT2P3 9.92 2.15e-19 2.36e-12 0.64 0.56 Blood metabolite ratios; chr16:58779573 chr12:9641802~9643007:+ CESC trans rs2657294 0.796 rs1259501 ENSG00000172974.11 AC007318.5 9.92 2.29e-19 2.51e-12 0.55 0.56 Pneumonia; chr10:75230427 chr2:65205108~65205988:+ CESC trans rs9611565 0.592 rs5758427 ENSG00000268568.1 AC007228.9 9.91 2.37e-19 2.59e-12 0.82 0.56 Vitiligo; chr22:41703684 chr19:56672574~56673901:- CESC trans rs9611565 0.546 rs5758430 ENSG00000268568.1 AC007228.9 9.91 2.37e-19 2.59e-12 0.82 0.56 Vitiligo; chr22:41713840 chr19:56672574~56673901:- CESC trans rs9611565 0.546 rs5758431 ENSG00000268568.1 AC007228.9 9.91 2.37e-19 2.59e-12 0.82 0.56 Vitiligo; chr22:41713913 chr19:56672574~56673901:- CESC trans rs6732160 0.706 rs1430347 ENSG00000236165.1 PRADC1P1 9.91 2.44e-19 2.66e-12 0.66 0.56 Intelligence (multi-trait analysis); chr2:73139931 chr3:36976316~36976840:+ CESC trans rs8010715 0.816 rs6573573 ENSG00000238000.1 RP11-274E7.2 9.89 2.69e-19 2.92e-12 0.53 0.56 IgG glycosylation; chr14:24130048 chr5:98213402~98214121:+ CESC trans rs7121616 0.961 rs11218976 ENSG00000234176.1 HSPA8P1 9.88 2.9e-19 3.14e-12 0.71 0.56 Breast cancer; chr11:123090950 chrX:121203182~121205014:- CESC trans rs7121616 0.576 rs7949127 ENSG00000234176.1 HSPA8P1 9.86 3.39e-19 3.66e-12 0.88 0.56 Breast cancer; chr11:123057408 chrX:121203182~121205014:- CESC trans rs7121616 0.576 rs7949220 ENSG00000234176.1 HSPA8P1 9.86 3.39e-19 3.66e-12 0.88 0.56 Breast cancer; chr11:123057418 chrX:121203182~121205014:- CESC trans rs7811142 0.666 rs28401739 ENSG00000228546.2 CTA-313A17.3 9.84 3.84e-19 4.12e-12 0.94 0.55 Platelet count; chr7:100308061 chr7:102337316~102339115:+ CESC trans rs928391 1 rs928392 ENSG00000227183.3 HDGFP1 9.84 3.85e-19 4.13e-12 0.81 0.55 Platelet count; chr1:156801024 chrX:131646639~131646890:+ CESC trans rs727563 0.569 rs73178647 ENSG00000268568.1 AC007228.9 -9.84 3.89e-19 4.17e-12 -0.86 -0.55 Crohn's disease;Inflammatory bowel disease; chr22:41568164 chr19:56672574~56673901:- CESC trans rs727563 0.648 rs6002406 ENSG00000268568.1 AC007228.9 -9.84 3.89e-19 4.17e-12 -0.86 -0.55 Crohn's disease;Inflammatory bowel disease; chr22:41569233 chr19:56672574~56673901:- CESC trans rs8010715 0.636 rs3825584 ENSG00000248988.1 RP11-815N9.2 9.84 3.97e-19 4.24e-12 0.71 0.55 IgG glycosylation; chr14:24118430 chr4:159007119~159007835:+ CESC trans rs8081395 0.603 rs1292047 ENSG00000187870.7 RNFT1P3 9.83 4.05e-19 4.33e-12 0.68 0.55 White blood cell count; chr17:59877805 chr17:20743333~20754501:- CESC trans rs7121616 0.576 rs7111590 ENSG00000234176.1 HSPA8P1 9.83 4.19e-19 4.48e-12 0.89 0.55 Breast cancer; chr11:123055419 chrX:121203182~121205014:- CESC trans rs116095464 0.542 rs28650039 ENSG00000185986.11 SDHAP3 9.83 4.26e-19 4.55e-12 0.89 0.55 Breast cancer; chr5:273839 chr5:1572222~1594620:- CESC trans rs8010715 0.816 rs7153156 ENSG00000238000.1 RP11-274E7.2 9.82 4.36e-19 4.65e-12 0.54 0.55 IgG glycosylation; chr14:24129637 chr5:98213402~98214121:+ CESC trans rs8010715 0.816 rs6573572 ENSG00000238000.1 RP11-274E7.2 9.82 4.36e-19 4.65e-12 0.54 0.55 IgG glycosylation; chr14:24130021 chr5:98213402~98214121:+ CESC trans rs8010715 0.816 rs8015168 ENSG00000238000.1 RP11-274E7.2 9.82 4.36e-19 4.65e-12 0.54 0.55 IgG glycosylation; chr14:24130663 chr5:98213402~98214121:+ CESC trans rs9611565 0.512 rs139561 ENSG00000268568.1 AC007228.9 9.82 4.47e-19 4.76e-12 0.83 0.55 Vitiligo; chr22:41799406 chr19:56672574~56673901:- CESC trans rs7121616 0.576 rs7102045 ENSG00000234176.1 HSPA8P1 9.82 4.5e-19 4.79e-12 0.9 0.55 Breast cancer; chr11:123052713 chrX:121203182~121205014:- CESC trans rs7121616 0.545 rs7109348 ENSG00000234176.1 HSPA8P1 9.82 4.57e-19 4.86e-12 0.88 0.55 Breast cancer; chr11:123056555 chrX:121203182~121205014:- CESC trans rs7121616 0.545 rs7109336 ENSG00000234176.1 HSPA8P1 9.8 4.95e-19 5.26e-12 0.87 0.55 Breast cancer; chr11:123056530 chrX:121203182~121205014:- CESC trans rs928391 1 rs10157555 ENSG00000227183.3 HDGFP1 -9.8 5.03e-19 5.34e-12 -0.81 -0.55 Platelet count; chr1:156802060 chrX:131646639~131646890:+ CESC trans rs5022636 0.631 rs6587562 ENSG00000180764.13 PIPSL -9.8 5.09e-19 5.4e-12 -0.69 -0.55 Gut microbiota (functional units); chr1:151273765 chr10:93958191~93961540:- CESC trans rs13253073 0.883 rs2305290 ENSG00000260318.1 COX6CP1 9.79 5.51e-19 5.81e-12 1.01 0.55 Glucose homeostasis traits; chr8:99819066 chr16:11903923~11904137:- CESC trans rs7121616 0.576 rs1064585 ENSG00000234176.1 HSPA8P1 9.78 5.66e-19 5.95e-12 0.88 0.55 Breast cancer; chr11:123058699 chrX:121203182~121205014:- CESC trans rs1816752 0.646 rs9511309 ENSG00000237917.1 PARP4P1 -9.78 5.86e-19 6.16e-12 -0.65 -0.55 Obesity-related traits; chr13:24515435 chrY:26594851~26634652:- CESC trans rs7121616 0.531 rs1461497 ENSG00000234176.1 HSPA8P1 9.78 5.87e-19 6.16e-12 0.88 0.55 Breast cancer; chr11:123060505 chrX:121203182~121205014:- CESC trans rs916888 0.773 rs199534 ENSG00000264070.1 DND1P1 9.78 5.89e-19 6.19e-12 0.82 0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45585871~45586929:+ CESC trans rs7121616 0.576 rs7948948 ENSG00000234176.1 HSPA8P1 9.78 5.93e-19 6.22e-12 0.87 0.55 Breast cancer; chr11:123057467 chrX:121203182~121205014:- CESC trans rs9611565 0.512 rs4820446 ENSG00000268568.1 AC007228.9 -9.77 6.07e-19 6.37e-12 -0.84 -0.55 Vitiligo; chr22:41819680 chr19:56672574~56673901:- CESC trans rs6732160 1 rs6732160 ENSG00000236165.1 PRADC1P1 9.77 6.37e-19 6.68e-12 0.69 0.55 Intelligence (multi-trait analysis); chr2:73160100 chr3:36976316~36976840:+ CESC trans rs8010715 0.816 rs1134340 ENSG00000238000.1 RP11-274E7.2 9.77 6.4e-19 6.7e-12 0.53 0.55 IgG glycosylation; chr14:24125004 chr5:98213402~98214121:+ CESC trans rs116095464 0.558 rs7725227 ENSG00000185986.11 SDHAP3 9.75 6.95e-19 7.24e-12 0.86 0.55 Breast cancer; chr5:233402 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7708182 ENSG00000185986.11 SDHAP3 9.75 6.95e-19 7.24e-12 0.86 0.55 Breast cancer; chr5:234673 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10058428 ENSG00000185986.11 SDHAP3 9.75 6.95e-19 7.24e-12 0.86 0.55 Breast cancer; chr5:235493 chr5:1572222~1594620:- CESC trans rs7973618 1 rs7973618 ENSG00000121089.4 NACA3P -9.75 7.08e-19 7.38e-12 -0.6 -0.55 Mean platelet volume; chr12:56625659 chr4:164943290~164943937:+ CESC trans rs12291225 0.839 rs4757244 ENSG00000236360.2 RP11-334A14.2 -9.74 7.61e-19 7.91e-12 -0.71 -0.55 Sense of smell; chr11:14237109 chr1:52993201~52993702:- CESC trans rs116095464 0.558 rs10036253 ENSG00000185986.11 SDHAP3 9.74 7.66e-19 7.94e-12 0.86 0.55 Breast cancer; chr5:238404 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10057492 ENSG00000185986.11 SDHAP3 9.74 7.66e-19 7.94e-12 0.86 0.55 Breast cancer; chr5:239388 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs28418643 ENSG00000185986.11 SDHAP3 9.74 7.66e-19 7.94e-12 0.86 0.55 Breast cancer; chr5:240744 chr5:1572222~1594620:- CESC trans rs10242455 0.702 rs17161726 ENSG00000228834.1 RP11-249L21.4 9.73 8.26e-19 8.55e-12 1.52 0.55 Blood metabolite levels; chr7:99410772 chr6:108907615~108907873:- CESC trans rs7811142 0.83 rs6955367 ENSG00000228546.2 CTA-313A17.3 9.72 8.63e-19 8.94e-12 0.83 0.55 Platelet count; chr7:100363571 chr7:102337316~102339115:+ CESC trans rs116095464 0.51 rs10057501 ENSG00000185986.11 SDHAP3 9.71 9.15e-19 9.46e-12 0.87 0.55 Breast cancer; chr5:239430 chr5:1572222~1594620:- CESC trans rs916888 0.821 rs70600 ENSG00000264070.1 DND1P1 9.71 9.23e-19 9.54e-12 0.84 0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45585871~45586929:+ CESC trans rs10242455 0.702 rs2293256 ENSG00000228834.1 RP11-249L21.4 -9.7 9.88e-19 1.02e-11 -1.18 -0.55 Blood metabolite levels; chr7:99460078 chr6:108907615~108907873:- CESC trans rs2657294 0.796 rs1259499 ENSG00000172974.11 AC007318.5 9.7 1.04e-18 1.07e-11 0.53 0.55 Pneumonia; chr10:75228308 chr2:65205108~65205988:+ CESC trans rs116095464 0.558 rs13354585 ENSG00000185986.11 SDHAP3 9.69 1.08e-18 1.11e-11 0.86 0.55 Breast cancer; chr5:242148 chr5:1572222~1594620:- CESC trans rs8010715 0.816 rs762093 ENSG00000238000.1 RP11-274E7.2 9.68 1.12e-18 1.14e-11 0.53 0.55 IgG glycosylation; chr14:24122709 chr5:98213402~98214121:+ CESC trans rs8010715 0.785 rs2877611 ENSG00000238000.1 RP11-274E7.2 9.68 1.12e-18 1.14e-11 0.53 0.55 IgG glycosylation; chr14:24126221 chr5:98213402~98214121:+ CESC trans rs916888 0.821 rs199514 ENSG00000214425.5 LRRC37A4P 9.68 1.14e-18 1.16e-11 0.73 0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45506741~45550335:- CESC trans rs8010715 0.816 rs6573565 ENSG00000238000.1 RP11-274E7.2 -9.68 1.16e-18 1.18e-11 -0.53 -0.55 IgG glycosylation; chr14:24125524 chr5:98213402~98214121:+ CESC trans rs7811142 0.83 rs7792525 ENSG00000228546.2 CTA-313A17.3 9.68 1.16e-18 1.18e-11 0.94 0.55 Platelet count; chr7:100374499 chr7:102337316~102339115:+ CESC trans rs116095464 0.51 rs73016876 ENSG00000185986.11 SDHAP3 9.68 1.17e-18 1.19e-11 0.87 0.55 Breast cancer; chr5:244360 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7710005 ENSG00000185986.11 SDHAP3 9.67 1.23e-18 1.25e-11 0.86 0.55 Breast cancer; chr5:233457 chr5:1572222~1594620:- CESC trans rs6732160 0.619 rs12105975 ENSG00000236165.1 PRADC1P1 9.67 1.23e-18 1.25e-11 0.68 0.55 Intelligence (multi-trait analysis); chr2:73178921 chr3:36976316~36976840:+ CESC trans rs116095464 0.681 rs10060016 ENSG00000185986.11 SDHAP3 9.66 1.34e-18 1.36e-11 0.86 0.55 Breast cancer; chr5:240985 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10057299 ENSG00000185986.11 SDHAP3 9.66 1.34e-18 1.36e-11 0.86 0.55 Breast cancer; chr5:242020 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs13356367 ENSG00000185986.11 SDHAP3 9.66 1.34e-18 1.36e-11 0.86 0.55 Breast cancer; chr5:242280 chr5:1572222~1594620:- CESC trans rs116095464 0.85 rs10055295 ENSG00000185986.11 SDHAP3 9.66 1.34e-18 1.36e-11 0.86 0.55 Breast cancer; chr5:243634 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10055354 ENSG00000185986.11 SDHAP3 9.66 1.34e-18 1.36e-11 0.86 0.55 Breast cancer; chr5:243679 chr5:1572222~1594620:- CESC trans rs116095464 0.614 rs62344292 ENSG00000185986.11 SDHAP3 9.66 1.34e-18 1.36e-11 0.86 0.55 Breast cancer; chr5:244515 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs60251075 ENSG00000185986.11 SDHAP3 9.66 1.34e-18 1.36e-11 0.86 0.55 Breast cancer; chr5:245177 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs62344300 ENSG00000185986.11 SDHAP3 9.66 1.34e-18 1.36e-11 0.86 0.55 Breast cancer; chr5:246221 chr5:1572222~1594620:- CESC trans rs55665837 1 rs7121171 ENSG00000236360.2 RP11-334A14.2 9.65 1.44e-18 1.45e-11 0.69 0.55 Vitamin D levels; chr11:14424874 chr1:52993201~52993702:- CESC trans rs116095464 0.558 rs10462754 ENSG00000185986.11 SDHAP3 9.63 1.65e-18 1.65e-11 0.86 0.55 Breast cancer; chr5:246554 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10462755 ENSG00000185986.11 SDHAP3 9.63 1.65e-18 1.65e-11 0.86 0.55 Breast cancer; chr5:246633 chr5:1572222~1594620:- CESC trans rs6732160 0.932 rs768851 ENSG00000236165.1 PRADC1P1 9.63 1.67e-18 1.67e-11 0.67 0.55 Intelligence (multi-trait analysis); chr2:73151113 chr3:36976316~36976840:+ CESC trans rs116095464 0.558 rs1541822 ENSG00000185986.11 SDHAP3 -9.62 1.69e-18 1.69e-11 -0.86 -0.55 Breast cancer; chr5:269119 chr5:1572222~1594620:- CESC trans rs916888 0.821 rs199513 ENSG00000214425.5 LRRC37A4P 9.62 1.7e-18 1.7e-11 0.7 0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45506741~45550335:- CESC trans rs6732160 0.809 rs13387480 ENSG00000236165.1 PRADC1P1 9.62 1.72e-18 1.71e-11 0.64 0.55 Intelligence (multi-trait analysis); chr2:73143879 chr3:36976316~36976840:+ CESC trans rs116095464 0.558 rs13357299 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.85 0.55 Breast cancer; chr5:242096 chr5:1572222~1594620:- CESC trans rs116095464 0.614 rs10061564 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:271214 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs55776650 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:273711 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs28635197 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:278956 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs59113266 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:279850 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs11959126 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:283765 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7356696 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:284136 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7356561 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:284266 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs59284383 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:284410 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7731089 ENSG00000185986.11 SDHAP3 9.62 1.72e-18 1.71e-11 0.87 0.55 Breast cancer; chr5:290307 chr5:1572222~1594620:- CESC trans rs877636 0.692 rs11171739 ENSG00000223416.3 RPS26P15 9.61 1.87e-18 1.85e-11 0.54 0.55 Cognitive function; chr12:56076841 chr1:58056133~58056480:- CESC trans rs9611565 0.512 rs132767 ENSG00000268568.1 AC007228.9 -9.61 1.89e-18 1.87e-11 -0.8 -0.55 Vitiligo; chr22:41613516 chr19:56672574~56673901:- CESC trans rs7811142 0.83 rs73401451 ENSG00000228546.2 CTA-313A17.3 9.6 2.05e-18 2.03e-11 0.93 0.54 Platelet count; chr7:100384272 chr7:102337316~102339115:+ CESC trans rs916888 0.773 rs199447 ENSG00000264070.1 DND1P1 9.58 2.23e-18 2.2e-11 0.81 0.54 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45585871~45586929:+ CESC trans rs116095464 0.558 rs55664502 ENSG00000185986.11 SDHAP3 9.58 2.26e-18 2.23e-11 0.86 0.54 Breast cancer; chr5:270370 chr5:1572222~1594620:- CESC trans rs116095464 0.51 rs7723883 ENSG00000185986.11 SDHAP3 9.58 2.26e-18 2.23e-11 0.86 0.54 Breast cancer; chr5:270683 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs28558836 ENSG00000185986.11 SDHAP3 9.58 2.26e-18 2.23e-11 0.86 0.54 Breast cancer; chr5:285633 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs12173244 ENSG00000185986.11 SDHAP3 9.58 2.29e-18 2.26e-11 0.87 0.54 Breast cancer; chr5:269409 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs56127718 ENSG00000185986.11 SDHAP3 9.58 2.29e-18 2.26e-11 0.87 0.54 Breast cancer; chr5:270158 chr5:1572222~1594620:- CESC trans rs116095464 0.614 rs78905930 ENSG00000185986.11 SDHAP3 9.58 2.31e-18 2.27e-11 0.87 0.54 Breast cancer; chr5:246445 chr5:1572222~1594620:- CESC trans rs8081395 0.627 rs12952730 ENSG00000187870.7 RNFT1P3 9.58 2.36e-18 2.33e-11 0.67 0.54 White blood cell count; chr17:59901475 chr17:20743333~20754501:- CESC trans rs7121616 0.576 rs7111598 ENSG00000234176.1 HSPA8P1 9.57 2.46e-18 2.42e-11 0.9 0.54 Breast cancer; chr11:123055438 chrX:121203182~121205014:- CESC trans rs5022636 0.559 rs41302131 ENSG00000180764.13 PIPSL 9.57 2.5e-18 2.46e-11 0.66 0.54 Gut microbiota (functional units); chr1:151267532 chr10:93958191~93961540:- CESC trans rs116095464 0.558 rs7703803 ENSG00000185986.11 SDHAP3 9.56 2.58e-18 2.53e-11 0.87 0.54 Breast cancer; chr5:292196 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs9654452 ENSG00000185986.11 SDHAP3 9.56 2.58e-18 2.53e-11 0.87 0.54 Breast cancer; chr5:299446 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6555055 ENSG00000185986.11 SDHAP3 9.55 2.74e-18 2.68e-11 0.84 0.54 Breast cancer; chr5:226045 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6555056 ENSG00000185986.11 SDHAP3 9.55 2.74e-18 2.68e-11 0.84 0.54 Breast cancer; chr5:226107 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10075018 ENSG00000185986.11 SDHAP3 9.55 2.75e-18 2.69e-11 0.86 0.54 Breast cancer; chr5:239060 chr5:1572222~1594620:- CESC trans rs8081395 0.627 rs180536 ENSG00000187870.7 RNFT1P3 9.55 2.82e-18 2.75e-11 0.66 0.54 White blood cell count; chr17:59919445 chr17:20743333~20754501:- CESC trans rs7811142 0.83 rs6948685 ENSG00000228546.2 CTA-313A17.3 9.55 2.83e-18 2.76e-11 0.92 0.54 Platelet count; chr7:100372565 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs6945952 ENSG00000228546.2 CTA-313A17.3 9.55 2.83e-18 2.76e-11 0.92 0.54 Platelet count; chr7:100384152 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs73401450 ENSG00000228546.2 CTA-313A17.3 9.55 2.83e-18 2.76e-11 0.92 0.54 Platelet count; chr7:100384236 chr7:102337316~102339115:+ CESC trans rs8067354 0.872 rs2645466 ENSG00000187870.7 RNFT1P3 9.55 2.87e-18 2.8e-11 0.67 0.54 Hemoglobin concentration; chr17:59775853 chr17:20743333~20754501:- CESC trans rs1045902 0.583 rs36106493 ENSG00000236165.1 PRADC1P1 9.55 2.87e-18 2.8e-11 0.68 0.54 Intelligence (multi-trait analysis); chr2:73215211 chr3:36976316~36976840:+ CESC trans rs116095464 0.614 rs4371799 ENSG00000185986.11 SDHAP3 9.54 3.03e-18 2.94e-11 0.86 0.54 Breast cancer; chr5:268077 chr5:1572222~1594620:- CESC trans rs6732160 0.932 rs6546802 ENSG00000236165.1 PRADC1P1 9.51 3.6e-18 3.48e-11 0.67 0.54 Intelligence (multi-trait analysis); chr2:73152436 chr3:36976316~36976840:+ CESC trans rs6732160 0.932 rs13417029 ENSG00000236165.1 PRADC1P1 9.51 3.6e-18 3.48e-11 0.67 0.54 Intelligence (multi-trait analysis); chr2:73153295 chr3:36976316~36976840:+ CESC trans rs6732160 0.932 rs6546803 ENSG00000236165.1 PRADC1P1 9.51 3.6e-18 3.48e-11 0.67 0.54 Intelligence (multi-trait analysis); chr2:73154187 chr3:36976316~36976840:+ CESC trans rs116095464 0.558 rs3213838 ENSG00000185986.11 SDHAP3 9.51 3.62e-18 3.48e-11 0.83 0.54 Breast cancer; chr5:223775 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6555052 ENSG00000185986.11 SDHAP3 9.51 3.62e-18 3.48e-11 0.83 0.54 Breast cancer; chr5:224153 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs61689490 ENSG00000185986.11 SDHAP3 9.51 3.62e-18 3.48e-11 0.83 0.54 Breast cancer; chr5:224789 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs61492827 ENSG00000185986.11 SDHAP3 9.51 3.62e-18 3.48e-11 0.83 0.54 Breast cancer; chr5:225659 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs56342538 ENSG00000185986.11 SDHAP3 9.51 3.62e-18 3.48e-11 0.83 0.54 Breast cancer; chr5:225681 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10052012 ENSG00000185986.11 SDHAP3 9.51 3.64e-18 3.51e-11 0.86 0.54 Breast cancer; chr5:231793 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10077076 ENSG00000185986.11 SDHAP3 9.51 3.64e-18 3.51e-11 0.86 0.54 Breast cancer; chr5:231825 chr5:1572222~1594620:- CESC trans rs4276421 0.774 rs6884716 ENSG00000231752.4 EMBP1 9.5 3.84e-18 3.69e-11 0.68 0.54 P wave duration; chr5:46115267 chr1:121519112~121571892:+ CESC trans rs7121616 1 rs7121616 ENSG00000234176.1 HSPA8P1 9.5 4.04e-18 3.87e-11 0.69 0.54 Breast cancer; chr11:123095918 chrX:121203182~121205014:- CESC trans rs727563 0.635 rs5751141 ENSG00000268568.1 AC007228.9 9.49 4.21e-18 4.03e-11 0.82 0.54 Crohn's disease;Inflammatory bowel disease; chr22:41711741 chr19:56672574~56673901:- CESC trans rs5022636 0.564 rs2275900 ENSG00000180764.13 PIPSL 9.48 4.42e-18 4.23e-11 0.66 0.54 Gut microbiota (functional units); chr1:151265746 chr10:93958191~93961540:- CESC trans rs5022636 0.594 rs10888408 ENSG00000180764.13 PIPSL 9.48 4.42e-18 4.23e-11 0.66 0.54 Gut microbiota (functional units); chr1:151267094 chr10:93958191~93961540:- CESC trans rs9611565 0.546 rs739134 ENSG00000268568.1 AC007228.9 9.48 4.44e-18 4.25e-11 0.79 0.54 Vitiligo; chr22:41693619 chr19:56672574~56673901:- CESC trans rs7554547 0.871 rs6661289 ENSG00000261819.1 RP11-680G24.4 9.48 4.54e-18 4.34e-11 0.63 0.54 Nonsyndromic cleft lip with cleft palate; chr1:11882724 chr16:14988259~14990160:- CESC trans rs7121616 0.576 rs1841580 ENSG00000234176.1 HSPA8P1 9.48 4.56e-18 4.36e-11 0.86 0.54 Breast cancer; chr11:123055956 chrX:121203182~121205014:- CESC trans rs2657294 0.726 rs4746275 ENSG00000172974.11 AC007318.5 9.48 4.66e-18 4.45e-11 0.53 0.54 Pneumonia; chr10:75214940 chr2:65205108~65205988:+ CESC trans rs10242455 0.571 rs45532337 ENSG00000228834.1 RP11-249L21.4 9.47 4.72e-18 4.5e-11 1.12 0.54 Blood metabolite levels; chr7:99712696 chr6:108907615~108907873:- CESC trans rs5022636 0.594 rs11204791 ENSG00000180764.13 PIPSL 9.47 4.76e-18 4.55e-11 0.66 0.54 Gut microbiota (functional units); chr1:151268066 chr10:93958191~93961540:- CESC trans rs928391 1 rs3765787 ENSG00000227183.3 HDGFP1 -9.46 5.12e-18 4.86e-11 -0.79 -0.54 Platelet count; chr1:156784673 chrX:131646639~131646890:+ CESC trans rs116095464 0.51 rs60844864 ENSG00000185986.11 SDHAP3 9.46 5.15e-18 4.88e-11 0.87 0.54 Breast cancer; chr5:266885 chr5:1572222~1594620:- CESC trans rs6732160 0.934 rs2421390 ENSG00000236165.1 PRADC1P1 9.46 5.24e-18 4.97e-11 0.67 0.54 Intelligence (multi-trait analysis); chr2:73151975 chr3:36976316~36976840:+ CESC trans rs7811142 0.83 rs11765869 ENSG00000228546.2 CTA-313A17.3 9.45 5.5e-18 5.2e-11 0.95 0.54 Platelet count; chr7:100367166 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs705866 ENSG00000228546.2 CTA-313A17.3 9.45 5.5e-18 5.2e-11 0.95 0.54 Platelet count; chr7:100367662 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs6965458 ENSG00000228546.2 CTA-313A17.3 9.45 5.5e-18 5.2e-11 0.95 0.54 Platelet count; chr7:100375779 chr7:102337316~102339115:+ CESC trans rs9611565 0.512 rs4822052 ENSG00000268568.1 AC007228.9 -9.45 5.69e-18 5.37e-11 -0.8 -0.54 Vitiligo; chr22:41797737 chr19:56672574~56673901:- CESC trans rs916888 0.697 rs199516 ENSG00000264070.1 DND1P1 -9.45 5.71e-18 5.4e-11 -0.79 -0.54 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45585871~45586929:+ CESC trans rs867371 0.762 rs12905578 ENSG00000235370.6 DNM1P51 9.44 5.77e-18 5.45e-11 0.71 0.54 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82288923 chr15:84398316~84411701:- CESC trans rs116095464 0.558 rs10080225 ENSG00000185986.11 SDHAP3 9.44 5.84e-18 5.5e-11 0.86 0.54 Breast cancer; chr5:232060 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10475136 ENSG00000185986.11 SDHAP3 9.44 5.84e-18 5.5e-11 0.86 0.54 Breast cancer; chr5:232681 chr5:1572222~1594620:- CESC trans rs7121616 0.96 rs7122306 ENSG00000234176.1 HSPA8P1 9.44 6.01e-18 5.66e-11 0.69 0.54 Breast cancer; chr11:123096254 chrX:121203182~121205014:- CESC trans rs116095464 0.558 rs2162870 ENSG00000185986.11 SDHAP3 9.43 6.51e-18 6.06e-11 0.84 0.54 Breast cancer; chr5:228014 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs28729548 ENSG00000185986.11 SDHAP3 9.43 6.51e-18 6.06e-11 0.84 0.54 Breast cancer; chr5:228910 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs9688136 ENSG00000185986.11 SDHAP3 9.43 6.51e-18 6.06e-11 0.84 0.54 Breast cancer; chr5:229233 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs62347683 ENSG00000185986.11 SDHAP3 9.43 6.51e-18 6.06e-11 0.84 0.54 Breast cancer; chr5:230216 chr5:1572222~1594620:- CESC trans rs116095464 0.51 rs55750776 ENSG00000185986.11 SDHAP3 9.43 6.51e-18 6.06e-11 0.84 0.54 Breast cancer; chr5:230352 chr5:1572222~1594620:- CESC trans rs116095464 0.764 rs10069197 ENSG00000185986.11 SDHAP3 9.43 6.51e-18 6.06e-11 0.84 0.54 Breast cancer; chr5:230707 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7713524 ENSG00000185986.11 SDHAP3 -9.42 6.58e-18 6.12e-11 -0.84 -0.54 Breast cancer; chr5:276085 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs2288459 ENSG00000185986.11 SDHAP3 9.42 6.67e-18 6.21e-11 0.86 0.54 Breast cancer; chr5:231028 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs2288458 ENSG00000185986.11 SDHAP3 9.42 6.67e-18 6.21e-11 0.86 0.54 Breast cancer; chr5:231145 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs2288457 ENSG00000185986.11 SDHAP3 9.42 6.67e-18 6.21e-11 0.86 0.54 Breast cancer; chr5:231155 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7736600 ENSG00000185986.11 SDHAP3 9.42 6.67e-18 6.21e-11 0.86 0.54 Breast cancer; chr5:231222 chr5:1572222~1594620:- CESC trans rs2657294 0.796 rs2657290 ENSG00000172974.11 AC007318.5 9.42 6.92e-18 6.43e-11 0.53 0.54 Pneumonia; chr10:75207404 chr2:65205108~65205988:+ CESC trans rs2657294 0.765 rs2804533 ENSG00000172974.11 AC007318.5 9.42 6.92e-18 6.43e-11 0.53 0.54 Pneumonia; chr10:75207723 chr2:65205108~65205988:+ CESC trans rs1816752 0.603 rs9551099 ENSG00000237917.1 PARP4P1 -9.41 7.31e-18 6.79e-11 -0.65 -0.54 Obesity-related traits; chr13:24410978 chrY:26594851~26634652:- CESC trans rs7937890 0.9 rs7118682 ENSG00000236360.2 RP11-334A14.2 -9.41 7.36e-18 6.83e-11 -0.62 -0.54 Mitochondrial DNA levels; chr11:14253004 chr1:52993201~52993702:- CESC trans rs116095464 0.558 rs57335027 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:262792 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6869925 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:263921 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6875291 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:264077 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6866776 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:264380 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6874745 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:264412 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7715108 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:264546 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7730700 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:264598 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10057674 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:266698 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs1812843 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:267543 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs1971229 ENSG00000185986.11 SDHAP3 9.41 7.45e-18 6.9e-11 0.86 0.54 Breast cancer; chr5:268072 chr5:1572222~1594620:- CESC trans rs5022636 0.525 rs6681163 ENSG00000180764.13 PIPSL 9.4 7.76e-18 7.17e-11 0.66 0.54 Gut microbiota (functional units); chr1:151259161 chr10:93958191~93961540:- CESC trans rs11098499 0.954 rs12505469 ENSG00000275858.1 RP11-291L22.8 9.4 7.94e-18 7.33e-11 0.61 0.54 Corneal astigmatism; chr4:119328430 chr10:38450738~38451069:- CESC trans rs116095464 0.619 rs2303741 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:218241 chr5:1572222~1594620:- CESC trans rs116095464 0.614 rs10067482 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:219213 chr5:1572222~1594620:- CESC trans rs116095464 0.614 rs56299325 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:220479 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs62346526 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:220499 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs56043030 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:220802 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10067021 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:221375 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs9312977 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:221801 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6881920 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:222296 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6878061 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:222957 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs6882584 ENSG00000185986.11 SDHAP3 9.39 8.27e-18 7.58e-11 0.82 0.54 Breast cancer; chr5:223296 chr5:1572222~1594620:- CESC trans rs7121616 0.576 rs73610509 ENSG00000234176.1 HSPA8P1 9.39 8.29e-18 7.61e-11 0.85 0.54 Breast cancer; chr11:123048564 chrX:121203182~121205014:- CESC trans rs7121616 0.545 rs11600517 ENSG00000234176.1 HSPA8P1 9.39 8.35e-18 7.65e-11 0.84 0.54 Breast cancer; chr11:123047247 chrX:121203182~121205014:- CESC trans rs7121616 0.576 rs7942164 ENSG00000234176.1 HSPA8P1 9.39 8.52e-18 7.8e-11 0.85 0.54 Breast cancer; chr11:123050459 chrX:121203182~121205014:- CESC trans rs7121616 0.576 rs56131320 ENSG00000234176.1 HSPA8P1 9.39 8.52e-18 7.8e-11 0.85 0.54 Breast cancer; chr11:123053058 chrX:121203182~121205014:- CESC trans rs7121616 0.576 rs7929869 ENSG00000234176.1 HSPA8P1 9.39 8.52e-18 7.8e-11 0.85 0.54 Breast cancer; chr11:123054435 chrX:121203182~121205014:- CESC trans rs4276421 0.774 rs7720482 ENSG00000231752.4 EMBP1 -9.38 8.91e-18 8.14e-11 -0.67 -0.54 P wave duration; chr5:46106061 chr1:121519112~121571892:+ CESC trans rs8081395 0.58 rs180515 ENSG00000187870.7 RNFT1P3 9.38 9.11e-18 8.31e-11 0.65 0.54 White blood cell count; chr17:59946914 chr17:20743333~20754501:- CESC trans rs6732160 0.967 rs6760964 ENSG00000236165.1 PRADC1P1 9.38 9.17e-18 8.37e-11 0.66 0.54 Intelligence (multi-trait analysis); chr2:73160258 chr3:36976316~36976840:+ CESC trans rs10242455 0.702 rs76840929 ENSG00000228834.1 RP11-249L21.4 9.37 9.62e-18 8.75e-11 1.37 0.54 Blood metabolite levels; chr7:99348235 chr6:108907615~108907873:- CESC trans rs116095464 0.558 rs6878087 ENSG00000185986.11 SDHAP3 -9.37 9.76e-18 8.87e-11 -0.79 -0.54 Breast cancer; chr5:223002 chr5:1572222~1594620:- CESC trans rs4276421 0.695 rs4498260 ENSG00000231752.4 EMBP1 -9.36 9.9e-18 8.98e-11 -0.66 -0.54 P wave duration; chr5:46079235 chr1:121519112~121571892:+ CESC trans rs2657294 0.796 rs4746272 ENSG00000172974.11 AC007318.5 9.36 9.91e-18 9e-11 0.53 0.54 Pneumonia; chr10:75203869 chr2:65205108~65205988:+ CESC trans rs61990749 0.511 rs7146020 ENSG00000235400.1 RP4-641G12.4 9.35 1.07e-17 9.74e-11 0.85 0.54 Fibroblast growth factor basic levels; chr14:77891976 chr1:78749073~78750659:+ CESC trans rs116095464 0.867 rs10074958 ENSG00000185986.11 SDHAP3 9.34 1.13e-17 1.02e-10 0.85 0.53 Breast cancer; chr5:230713 chr5:1572222~1594620:- CESC trans rs7811142 1 rs1000215 ENSG00000228546.2 CTA-313A17.3 9.34 1.13e-17 1.02e-10 0.83 0.53 Platelet count; chr7:100406920 chr7:102337316~102339115:+ CESC trans rs2657294 0.796 rs2804534 ENSG00000172974.11 AC007318.5 -9.34 1.15e-17 1.04e-10 -0.51 -0.53 Pneumonia; chr10:75208023 chr2:65205108~65205988:+ CESC trans rs116095464 0.558 rs10079760 ENSG00000185986.11 SDHAP3 9.34 1.16e-17 1.05e-10 0.83 0.53 Breast cancer; chr5:230663 chr5:1572222~1594620:- CESC trans rs9425766 0.679 rs7552939 ENSG00000213331.4 RP11-713C19.2 9.34 1.2e-17 1.08e-10 0.61 0.53 Life satisfaction; chr1:173798305 chr4:187970273~187971284:+ CESC trans rs116095464 0.558 rs6872854 ENSG00000185986.11 SDHAP3 9.33 1.28e-17 1.15e-10 0.81 0.53 Breast cancer; chr5:208923 chr5:1572222~1594620:- CESC trans rs8067354 0.789 rs4622571 ENSG00000187870.7 RNFT1P3 9.32 1.38e-17 1.24e-10 0.65 0.53 Hemoglobin concentration; chr17:59807036 chr17:20743333~20754501:- CESC trans rs7811142 0.72 rs112622797 ENSG00000228546.2 CTA-313A17.3 9.31 1.38e-17 1.24e-10 1.03 0.53 Platelet count; chr7:100319793 chr7:102337316~102339115:+ CESC trans rs116095464 0.614 rs62344339 ENSG00000185986.11 SDHAP3 9.31 1.41e-17 1.26e-10 0.86 0.53 Breast cancer; chr5:252880 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs9687898 ENSG00000185986.11 SDHAP3 9.31 1.41e-17 1.26e-10 0.86 0.53 Breast cancer; chr5:253837 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs9688045 ENSG00000185986.11 SDHAP3 9.31 1.41e-17 1.26e-10 0.86 0.53 Breast cancer; chr5:253920 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs112343653 ENSG00000185986.11 SDHAP3 9.31 1.41e-17 1.26e-10 0.86 0.53 Breast cancer; chr5:257059 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs73024831 ENSG00000185986.11 SDHAP3 9.31 1.41e-17 1.26e-10 0.86 0.53 Breast cancer; chr5:257077 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs62344345 ENSG00000185986.11 SDHAP3 9.31 1.41e-17 1.26e-10 0.86 0.53 Breast cancer; chr5:257305 chr5:1572222~1594620:- CESC trans rs4276421 0.714 rs8185016 ENSG00000231752.4 EMBP1 9.31 1.46e-17 1.3e-10 0.66 0.53 P wave duration; chr5:46121704 chr1:121519112~121571892:+ CESC trans rs4276421 0.745 rs13354272 ENSG00000231752.4 EMBP1 -9.31 1.47e-17 1.31e-10 -0.66 -0.53 P wave duration; chr5:46078020 chr1:121519112~121571892:+ CESC trans rs928391 0.592 rs6689750 ENSG00000227183.3 HDGFP1 -9.3 1.48e-17 1.32e-10 -0.89 -0.53 Platelet count; chr1:156828933 chrX:131646639~131646890:+ CESC trans rs10940346 0.936 rs7705285 ENSG00000231752.4 EMBP1 9.3 1.49e-17 1.33e-10 0.66 0.53 Schizophrenia; chr5:50325579 chr1:121519112~121571892:+ CESC trans rs9611565 0.918 rs7290404 ENSG00000268568.1 AC007228.9 -9.3 1.55e-17 1.38e-10 -0.77 -0.53 Vitiligo; chr22:41353792 chr19:56672574~56673901:- CESC trans rs4276421 0.774 rs13361118 ENSG00000231752.4 EMBP1 -9.3 1.56e-17 1.39e-10 -0.66 -0.53 P wave duration; chr5:46078308 chr1:121519112~121571892:+ CESC trans rs4276421 0.662 rs4367307 ENSG00000231752.4 EMBP1 -9.29 1.61e-17 1.44e-10 -0.66 -0.53 P wave duration; chr5:46065857 chr1:121519112~121571892:+ CESC trans rs4276421 0.774 rs10050829 ENSG00000231752.4 EMBP1 -9.29 1.63e-17 1.45e-10 -0.66 -0.53 P wave duration; chr5:46072628 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs10067655 ENSG00000231752.4 EMBP1 -9.29 1.63e-17 1.45e-10 -0.66 -0.53 P wave duration; chr5:46072803 chr1:121519112~121571892:+ CESC trans rs4276421 0.661 rs10059426 ENSG00000231752.4 EMBP1 -9.29 1.63e-17 1.45e-10 -0.66 -0.53 P wave duration; chr5:46090412 chr1:121519112~121571892:+ CESC trans rs4276421 0.774 rs10066479 ENSG00000231752.4 EMBP1 -9.29 1.63e-17 1.45e-10 -0.66 -0.53 P wave duration; chr5:46097385 chr1:121519112~121571892:+ CESC trans rs4276421 0.774 rs12515804 ENSG00000231752.4 EMBP1 -9.29 1.63e-17 1.45e-10 -0.66 -0.53 P wave duration; chr5:46098504 chr1:121519112~121571892:+ CESC trans rs4276421 0.774 rs8188064 ENSG00000231752.4 EMBP1 9.28 1.74e-17 1.54e-10 0.66 0.53 P wave duration; chr5:46045249 chr1:121519112~121571892:+ CESC trans rs4276421 0.744 rs4431354 ENSG00000231752.4 EMBP1 9.28 1.74e-17 1.54e-10 0.66 0.53 P wave duration; chr5:46051284 chr1:121519112~121571892:+ CESC trans rs2657294 0.965 rs4746264 ENSG00000172974.11 AC007318.5 9.28 1.8e-17 1.6e-10 0.52 0.53 Pneumonia; chr10:75114194 chr2:65205108~65205988:+ CESC trans rs7811142 1 rs68116612 ENSG00000228546.2 CTA-313A17.3 9.27 1.81e-17 1.61e-10 0.87 0.53 Platelet count; chr7:100408870 chr7:102337316~102339115:+ CESC trans rs867371 0.717 rs3858954 ENSG00000235370.6 DNM1P51 -9.27 1.92e-17 1.7e-10 -0.7 -0.53 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82265693 chr15:84398316~84411701:- CESC trans rs7121616 0.576 rs11600486 ENSG00000234176.1 HSPA8P1 9.26 1.99e-17 1.76e-10 0.85 0.53 Breast cancer; chr11:123047060 chrX:121203182~121205014:- CESC trans rs727563 0.555 rs5751136 ENSG00000268568.1 AC007228.9 9.26 1.99e-17 1.76e-10 0.78 0.53 Crohn's disease;Inflammatory bowel disease; chr22:41679577 chr19:56672574~56673901:- CESC trans rs867371 0.762 rs1846910 ENSG00000235370.6 DNM1P51 -9.25 2.11e-17 1.86e-10 -0.7 -0.53 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82279439 chr15:84398316~84411701:- CESC trans rs4276421 0.713 rs8188193 ENSG00000231752.4 EMBP1 9.25 2.13e-17 1.87e-10 0.66 0.53 P wave duration; chr5:46122428 chr1:121519112~121571892:+ CESC trans rs7121616 0.576 rs73610510 ENSG00000234176.1 HSPA8P1 9.25 2.18e-17 1.91e-10 0.84 0.53 Breast cancer; chr11:123049365 chrX:121203182~121205014:- CESC trans rs5022636 0.525 rs4971021 ENSG00000180764.13 PIPSL 9.24 2.25e-17 1.98e-10 0.65 0.53 Gut microbiota (functional units); chr1:151246152 chr10:93958191~93961540:- CESC trans rs55665837 1 rs10832276 ENSG00000236360.2 RP11-334A14.2 9.24 2.34e-17 2.05e-10 0.66 0.53 Vitamin D levels; chr11:14461728 chr1:52993201~52993702:- CESC trans rs116095464 0.558 rs10043002 ENSG00000185986.11 SDHAP3 9.24 2.35e-17 2.05e-10 0.83 0.53 Breast cancer; chr5:226638 chr5:1572222~1594620:- CESC trans rs7811142 0.779 rs111312383 ENSG00000228546.2 CTA-313A17.3 9.23 2.36e-17 2.07e-10 0.95 0.53 Platelet count; chr7:100307702 chr7:102337316~102339115:+ CESC trans rs7811142 0.779 rs28680963 ENSG00000228546.2 CTA-313A17.3 9.23 2.36e-17 2.07e-10 0.95 0.53 Platelet count; chr7:100307852 chr7:102337316~102339115:+ CESC trans rs55665837 0.922 rs12287212 ENSG00000236360.2 RP11-334A14.2 9.23 2.46e-17 2.15e-10 0.67 0.53 Vitamin D levels; chr11:14428315 chr1:52993201~52993702:- CESC trans rs55665837 1 rs12276938 ENSG00000236360.2 RP11-334A14.2 9.23 2.46e-17 2.15e-10 0.67 0.53 Vitamin D levels; chr11:14441942 chr1:52993201~52993702:- CESC trans rs116095464 0.867 rs7726582 ENSG00000185986.11 SDHAP3 9.23 2.48e-17 2.16e-10 0.82 0.53 Breast cancer; chr5:215234 chr5:1572222~1594620:- CESC trans rs928391 0.948 rs2735657 ENSG00000227183.3 HDGFP1 9.23 2.52e-17 2.2e-10 0.77 0.53 Platelet count; chr1:156810514 chrX:131646639~131646890:+ CESC trans rs867371 0.722 rs8033050 ENSG00000235370.6 DNM1P51 -9.22 2.55e-17 2.22e-10 -0.7 -0.53 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82269648 chr15:84398316~84411701:- CESC trans rs4276421 0.774 rs4370277 ENSG00000231752.4 EMBP1 9.22 2.59e-17 2.26e-10 0.66 0.53 P wave duration; chr5:46048566 chr1:121519112~121571892:+ CESC trans rs4276421 0.683 rs4484447 ENSG00000231752.4 EMBP1 9.22 2.59e-17 2.26e-10 0.66 0.53 P wave duration; chr5:46048757 chr1:121519112~121571892:+ CESC trans rs11098499 0.954 rs878373 ENSG00000275858.1 RP11-291L22.8 9.22 2.64e-17 2.3e-10 0.6 0.53 Corneal astigmatism; chr4:119316329 chr10:38450738~38451069:- CESC trans rs7121616 0.576 rs60405069 ENSG00000234176.1 HSPA8P1 9.22 2.69e-17 2.33e-10 0.85 0.53 Breast cancer; chr11:123043616 chrX:121203182~121205014:- CESC trans rs116095464 0.681 rs9687745 ENSG00000185986.11 SDHAP3 9.21 2.74e-17 2.38e-10 0.83 0.53 Breast cancer; chr5:229194 chr5:1572222~1594620:- CESC trans rs916888 0.821 rs415430 ENSG00000264070.1 DND1P1 -9.21 2.75e-17 2.39e-10 -0.78 -0.53 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45585871~45586929:+ CESC trans rs916888 0.779 rs430685 ENSG00000264070.1 DND1P1 -9.21 2.75e-17 2.39e-10 -0.78 -0.53 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45585871~45586929:+ CESC trans rs116095464 0.558 rs7708515 ENSG00000185986.11 SDHAP3 9.21 2.8e-17 2.42e-10 0.83 0.53 Breast cancer; chr5:234874 chr5:1572222~1594620:- CESC trans rs11098499 0.954 rs10006706 ENSG00000275858.1 RP11-291L22.8 9.2 2.96e-17 2.57e-10 0.6 0.53 Corneal astigmatism; chr4:119487997 chr10:38450738~38451069:- CESC trans rs2657294 0.796 rs2804535 ENSG00000172974.11 AC007318.5 -9.2 2.98e-17 2.58e-10 -0.53 -0.53 Pneumonia; chr10:75212086 chr2:65205108~65205988:+ CESC trans rs4276421 0.774 rs4499842 ENSG00000231752.4 EMBP1 9.2 3.02e-17 2.61e-10 0.66 0.53 P wave duration; chr5:46034390 chr1:121519112~121571892:+ CESC trans rs2657294 0.965 rs9299525 ENSG00000172974.11 AC007318.5 9.19 3.13e-17 2.7e-10 0.51 0.53 Pneumonia; chr10:75118267 chr2:65205108~65205988:+ CESC trans rs2657294 0.965 rs10762658 ENSG00000172974.11 AC007318.5 9.19 3.13e-17 2.7e-10 0.51 0.53 Pneumonia; chr10:75119804 chr2:65205108~65205988:+ CESC trans rs55665837 1 rs12288873 ENSG00000236360.2 RP11-334A14.2 9.19 3.15e-17 2.72e-10 0.67 0.53 Vitamin D levels; chr11:14428919 chr1:52993201~52993702:- CESC trans rs55665837 1 rs11023227 ENSG00000236360.2 RP11-334A14.2 9.19 3.15e-17 2.72e-10 0.67 0.53 Vitamin D levels; chr11:14437541 chr1:52993201~52993702:- CESC trans rs55665837 1 rs11023229 ENSG00000236360.2 RP11-334A14.2 9.19 3.15e-17 2.72e-10 0.67 0.53 Vitamin D levels; chr11:14439455 chr1:52993201~52993702:- CESC trans rs7121616 0.576 rs1461495 ENSG00000234176.1 HSPA8P1 -9.19 3.17e-17 2.73e-10 -0.82 -0.53 Breast cancer; chr11:123056136 chrX:121203182~121205014:- CESC trans rs916888 0.821 rs199512 ENSG00000264070.1 DND1P1 -9.19 3.18e-17 2.74e-10 -0.78 -0.53 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45585871~45586929:+ CESC trans rs916888 0.821 rs199509 ENSG00000264070.1 DND1P1 -9.19 3.18e-17 2.74e-10 -0.78 -0.53 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45585871~45586929:+ CESC trans rs916888 0.821 rs199507 ENSG00000264070.1 DND1P1 -9.19 3.18e-17 2.74e-10 -0.78 -0.53 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45585871~45586929:+ CESC trans rs7811142 0.83 rs77861211 ENSG00000228546.2 CTA-313A17.3 9.19 3.19e-17 2.74e-10 0.87 0.53 Platelet count; chr7:100364473 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs11769057 ENSG00000228546.2 CTA-313A17.3 9.19 3.19e-17 2.74e-10 0.87 0.53 Platelet count; chr7:100367038 chr7:102337316~102339115:+ CESC trans rs61990749 0.571 rs4448861 ENSG00000235400.1 RP4-641G12.4 9.19 3.2e-17 2.75e-10 0.87 0.53 Fibroblast growth factor basic levels; chr14:77841392 chr1:78749073~78750659:+ CESC trans rs4276421 0.712 rs4389698 ENSG00000231752.4 EMBP1 9.19 3.23e-17 2.78e-10 0.65 0.53 P wave duration; chr5:46051566 chr1:121519112~121571892:+ CESC trans rs4276421 0.6 rs4426925 ENSG00000231752.4 EMBP1 9.19 3.23e-17 2.78e-10 0.65 0.53 P wave duration; chr5:46055499 chr1:121519112~121571892:+ CESC trans rs3749237 0.595 rs1464567 ENSG00000197582.5 GPX1P1 -9.19 3.27e-17 2.82e-10 -0.69 -0.53 Resting heart rate; chr3:49421819 chrX:13378735~13379340:- CESC trans rs9611565 0.918 rs9538 ENSG00000268568.1 AC007228.9 -9.18 3.34e-17 2.87e-10 -0.77 -0.53 Vitiligo; chr22:41359853 chr19:56672574~56673901:- CESC trans rs116095464 0.558 rs62347677 ENSG00000185986.11 SDHAP3 9.18 3.46e-17 2.96e-10 0.83 0.53 Breast cancer; chr5:227338 chr5:1572222~1594620:- CESC trans rs916888 0.821 rs199506 ENSG00000264070.1 DND1P1 -9.18 3.48e-17 2.97e-10 -0.78 -0.53 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45585871~45586929:+ CESC trans rs4276421 0.774 rs8188072 ENSG00000231752.4 EMBP1 9.18 3.49e-17 2.97e-10 0.65 0.53 P wave duration; chr5:46061883 chr1:121519112~121571892:+ CESC trans rs55665837 1 rs12295723 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14428655 chr1:52993201~52993702:- CESC trans rs55665837 1 rs12295888 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14428985 chr1:52993201~52993702:- CESC trans rs55665837 1 rs34382046 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14429772 chr1:52993201~52993702:- CESC trans rs55665837 1 rs7945167 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14430274 chr1:52993201~52993702:- CESC trans rs55665837 0.961 rs60622588 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14435452 chr1:52993201~52993702:- CESC trans rs55665837 1 rs11023223 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14435566 chr1:52993201~52993702:- CESC trans rs55665837 1 rs11023224 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14436193 chr1:52993201~52993702:- CESC trans rs55665837 0.961 rs11023226 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14437271 chr1:52993201~52993702:- CESC trans rs55665837 1 rs10832264 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14438436 chr1:52993201~52993702:- CESC trans rs55665837 1 rs10832268 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14443522 chr1:52993201~52993702:- CESC trans rs55665837 1 rs10832269 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14443523 chr1:52993201~52993702:- CESC trans rs55665837 1 rs10832271 ENSG00000236360.2 RP11-334A14.2 9.18 3.49e-17 2.97e-10 0.67 0.53 Vitamin D levels; chr11:14445373 chr1:52993201~52993702:- CESC trans rs116095464 0.558 rs62347678 ENSG00000185986.11 SDHAP3 9.17 3.57e-17 3.04e-10 0.82 0.53 Breast cancer; chr5:227381 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs73031482 ENSG00000185986.11 SDHAP3 9.17 3.57e-17 3.04e-10 0.82 0.53 Breast cancer; chr5:227479 chr5:1572222~1594620:- CESC trans rs11098499 0.954 rs6848389 ENSG00000275858.1 RP11-291L22.8 9.17 3.66e-17 3.11e-10 0.61 0.53 Corneal astigmatism; chr4:119481467 chr10:38450738~38451069:- CESC trans rs10242455 0.702 rs76702117 ENSG00000228834.1 RP11-249L21.4 9.16 3.83e-17 3.24e-10 1.36 0.53 Blood metabolite levels; chr7:99319156 chr6:108907615~108907873:- CESC trans rs8067354 0.789 rs1292068 ENSG00000187870.7 RNFT1P3 9.16 3.88e-17 3.28e-10 0.65 0.53 Hemoglobin concentration; chr17:59851958 chr17:20743333~20754501:- CESC trans rs11098499 0.954 rs3733519 ENSG00000275858.1 RP11-291L22.8 9.15 4.12e-17 3.49e-10 0.6 0.53 Corneal astigmatism; chr4:119502293 chr10:38450738~38451069:- CESC trans rs55665837 1 rs10832257 ENSG00000236360.2 RP11-334A14.2 9.14 4.39e-17 3.7e-10 0.67 0.53 Vitamin D levels; chr11:14421770 chr1:52993201~52993702:- CESC trans rs4606360 1 rs4606360 ENSG00000213331.4 RP11-713C19.2 9.13 4.62e-17 3.9e-10 0.61 0.53 Subjective well-being; chr1:173729868 chr4:187970273~187971284:+ CESC trans rs9425766 0.511 rs10912676 ENSG00000213331.4 RP11-713C19.2 9.13 4.62e-17 3.9e-10 0.61 0.53 Life satisfaction; chr1:173740477 chr4:187970273~187971284:+ CESC trans rs9611565 0.918 rs9611561 ENSG00000268568.1 AC007228.9 -9.13 4.63e-17 3.9e-10 -0.77 -0.53 Vitiligo; chr22:41361230 chr19:56672574~56673901:- CESC trans rs9611565 0.918 rs9611562 ENSG00000268568.1 AC007228.9 -9.13 4.63e-17 3.9e-10 -0.77 -0.53 Vitiligo; chr22:41364168 chr19:56672574~56673901:- CESC trans rs9611565 0.605 rs202638 ENSG00000268568.1 AC007228.9 9.13 4.68e-17 3.94e-10 0.7 0.53 Vitiligo; chr22:41459454 chr19:56672574~56673901:- CESC trans rs55665837 1 rs3923294 ENSG00000236360.2 RP11-334A14.2 9.13 4.85e-17 4.08e-10 0.67 0.53 Vitamin D levels; chr11:14419856 chr1:52993201~52993702:- CESC trans rs55665837 1 rs12283797 ENSG00000236360.2 RP11-334A14.2 9.13 4.85e-17 4.08e-10 0.67 0.53 Vitamin D levels; chr11:14420716 chr1:52993201~52993702:- CESC trans rs55665837 1 rs10832256 ENSG00000236360.2 RP11-334A14.2 9.13 4.85e-17 4.08e-10 0.67 0.53 Vitamin D levels; chr11:14421329 chr1:52993201~52993702:- CESC trans rs55665837 0.961 rs12795972 ENSG00000236360.2 RP11-334A14.2 9.13 4.85e-17 4.08e-10 0.67 0.53 Vitamin D levels; chr11:14422229 chr1:52993201~52993702:- CESC trans rs55665837 1 rs12287715 ENSG00000236360.2 RP11-334A14.2 9.13 4.85e-17 4.08e-10 0.67 0.53 Vitamin D levels; chr11:14423029 chr1:52993201~52993702:- CESC trans rs4276421 0.805 rs13168838 ENSG00000231752.4 EMBP1 9.13 4.92e-17 4.13e-10 0.65 0.53 P wave duration; chr5:46016815 chr1:121519112~121571892:+ CESC trans rs4276421 0.774 rs4302598 ENSG00000231752.4 EMBP1 9.13 4.92e-17 4.13e-10 0.65 0.53 P wave duration; chr5:46019065 chr1:121519112~121571892:+ CESC trans rs4276421 0.623 rs12654375 ENSG00000231752.4 EMBP1 9.13 4.92e-17 4.13e-10 0.65 0.53 P wave duration; chr5:46036452 chr1:121519112~121571892:+ CESC trans rs4276421 0.623 rs4409106 ENSG00000231752.4 EMBP1 9.13 4.92e-17 4.13e-10 0.65 0.53 P wave duration; chr5:46038004 chr1:121519112~121571892:+ CESC trans rs4276421 0.682 rs10054419 ENSG00000231752.4 EMBP1 9.12 5.03e-17 4.21e-10 0.65 0.53 P wave duration; chr5:46036863 chr1:121519112~121571892:+ CESC trans rs11098499 0.954 rs12502423 ENSG00000275858.1 RP11-291L22.8 9.12 5.09e-17 4.26e-10 0.6 0.53 Corneal astigmatism; chr4:119503017 chr10:38450738~38451069:- CESC trans rs877636 0.692 rs2271194 ENSG00000223416.3 RPS26P15 -9.12 5.1e-17 4.26e-10 -0.52 -0.53 Cognitive function; chr12:56083910 chr1:58056133~58056480:- CESC trans rs7811142 0.83 rs75636500 ENSG00000228546.2 CTA-313A17.3 9.12 5.21e-17 4.36e-10 0.95 0.53 Platelet count; chr7:100350034 chr7:102337316~102339115:+ CESC trans rs9611565 0.5 rs10775759 ENSG00000268568.1 AC007228.9 9.1 5.71e-17 4.74e-10 0.77 0.52 Vitiligo; chr22:41692154 chr19:56672574~56673901:- CESC trans rs61990749 0.511 rs2052444 ENSG00000235400.1 RP4-641G12.4 9.1 5.75e-17 4.78e-10 0.87 0.52 Fibroblast growth factor basic levels; chr14:77846575 chr1:78749073~78750659:+ CESC trans rs10940346 0.936 rs10940171 ENSG00000231752.4 EMBP1 9.1 5.82e-17 4.84e-10 0.64 0.52 Schizophrenia; chr5:50324613 chr1:121519112~121571892:+ CESC trans rs9611565 0.592 rs5758405 ENSG00000268568.1 AC007228.9 9.1 5.9e-17 4.9e-10 0.77 0.52 Vitiligo; chr22:41680377 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs5758406 ENSG00000268568.1 AC007228.9 9.1 5.9e-17 4.9e-10 0.77 0.52 Vitiligo; chr22:41680637 chr19:56672574~56673901:- CESC trans rs2657294 0.965 rs10824286 ENSG00000172974.11 AC007318.5 9.1 5.95e-17 4.94e-10 0.5 0.52 Pneumonia; chr10:75172251 chr2:65205108~65205988:+ CESC trans rs8067354 0.872 rs2645488 ENSG00000187870.7 RNFT1P3 9.09 6.08e-17 5.04e-10 0.64 0.52 Hemoglobin concentration; chr17:59812044 chr17:20743333~20754501:- CESC trans rs61990749 0.571 rs4903655 ENSG00000235400.1 RP4-641G12.4 9.09 6.24e-17 5.16e-10 0.89 0.52 Fibroblast growth factor basic levels; chr14:77839983 chr1:78749073~78750659:+ CESC trans rs55665837 1 rs11023216 ENSG00000236360.2 RP11-334A14.2 9.09 6.38e-17 5.28e-10 0.65 0.52 Vitamin D levels; chr11:14415607 chr1:52993201~52993702:- CESC trans rs9425766 0.639 rs10798295 ENSG00000213331.4 RP11-713C19.2 9.08 6.46e-17 5.33e-10 0.61 0.52 Life satisfaction; chr1:173714815 chr4:187970273~187971284:+ CESC trans rs55665837 1 rs10047429 ENSG00000236360.2 RP11-334A14.2 9.08 6.5e-17 5.37e-10 0.67 0.52 Vitamin D levels; chr11:14417486 chr1:52993201~52993702:- CESC trans rs55665837 1 rs10047457 ENSG00000236360.2 RP11-334A14.2 9.08 6.5e-17 5.37e-10 0.67 0.52 Vitamin D levels; chr11:14417913 chr1:52993201~52993702:- CESC trans rs916888 0.821 rs199505 ENSG00000264070.1 DND1P1 -9.08 6.83e-17 5.63e-10 -0.77 -0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45585871~45586929:+ CESC trans rs916888 0.821 rs70602 ENSG00000264070.1 DND1P1 -9.08 6.83e-17 5.63e-10 -0.77 -0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45585871~45586929:+ CESC trans rs7258465 1 rs7251653 ENSG00000267533.1 RP11-815J4.7 9.08 6.86e-17 5.65e-10 0.67 0.52 Breast cancer; chr19:18497473 chr18:12067173~12068417:- CESC trans rs7200543 0.961 rs1741 ENSG00000250569.1 NTAN1P2 9.07 7.06e-17 5.81e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15036494 chr8:86481754~86483002:- CESC trans rs11098499 0.909 rs1546504 ENSG00000275858.1 RP11-291L22.8 9.07 7.27e-17 5.98e-10 0.6 0.52 Corneal astigmatism; chr4:119320024 chr10:38450738~38451069:- CESC trans rs4276421 0.704 rs57407363 ENSG00000231752.4 EMBP1 -9.07 7.3e-17 6e-10 -0.64 -0.52 P wave duration; chr5:46073845 chr1:121519112~121571892:+ CESC trans rs4276421 0.807 rs12520938 ENSG00000231752.4 EMBP1 -9.07 7.3e-17 6e-10 -0.64 -0.52 P wave duration; chr5:46098683 chr1:121519112~121571892:+ CESC trans rs4276421 0.807 rs10941740 ENSG00000231752.4 EMBP1 -9.07 7.3e-17 6e-10 -0.64 -0.52 P wave duration; chr5:46100208 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs10068272 ENSG00000231752.4 EMBP1 -9.06 7.41e-17 6.08e-10 -0.64 -0.52 Schizophrenia; chr5:50313688 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs10940129 ENSG00000231752.4 EMBP1 -9.06 7.41e-17 6.08e-10 -0.64 -0.52 Schizophrenia; chr5:50315257 chr1:121519112~121571892:+ CESC trans rs8010715 0.816 rs11574503 ENSG00000238000.1 RP11-274E7.2 -9.06 7.42e-17 6.09e-10 -0.51 -0.52 IgG glycosylation; chr14:24132109 chr5:98213402~98214121:+ CESC trans rs11098499 0.954 rs6822679 ENSG00000275858.1 RP11-291L22.8 9.06 7.47e-17 6.13e-10 0.6 0.52 Corneal astigmatism; chr4:119481547 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs4577559 ENSG00000275858.1 RP11-291L22.8 9.06 7.47e-17 6.13e-10 0.6 0.52 Corneal astigmatism; chr4:119482888 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs7656252 ENSG00000275858.1 RP11-291L22.8 9.06 7.47e-17 6.13e-10 0.6 0.52 Corneal astigmatism; chr4:119483113 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs28845498 ENSG00000275858.1 RP11-291L22.8 9.06 7.47e-17 6.13e-10 0.6 0.52 Corneal astigmatism; chr4:119484031 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs28753180 ENSG00000275858.1 RP11-291L22.8 9.06 7.47e-17 6.13e-10 0.6 0.52 Corneal astigmatism; chr4:119484212 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs56270433 ENSG00000275858.1 RP11-291L22.8 9.06 7.47e-17 6.13e-10 0.6 0.52 Corneal astigmatism; chr4:119484875 chr10:38450738~38451069:- CESC trans rs7258465 0.931 rs7249020 ENSG00000267533.1 RP11-815J4.7 9.06 7.5e-17 6.15e-10 0.67 0.52 Breast cancer; chr19:18497337 chr18:12067173~12068417:- CESC trans rs916888 0.738 rs199515 ENSG00000264070.1 DND1P1 -9.06 7.64e-17 6.26e-10 -0.75 -0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45585871~45586929:+ CESC trans rs2657294 0.895 rs4746262 ENSG00000172974.11 AC007318.5 9.06 7.72e-17 6.32e-10 0.52 0.52 Pneumonia; chr10:75093631 chr2:65205108~65205988:+ CESC trans rs2657294 0.895 rs3088142 ENSG00000172974.11 AC007318.5 9.06 7.72e-17 6.32e-10 0.52 0.52 Pneumonia; chr10:75094806 chr2:65205108~65205988:+ CESC trans rs7200543 1 rs16966952 ENSG00000250569.1 NTAN1P2 9.06 7.73e-17 6.33e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15042086 chr8:86481754~86483002:- CESC trans rs7937890 0.904 rs67623158 ENSG00000236360.2 RP11-334A14.2 -9.06 7.74e-17 6.33e-10 -0.61 -0.52 Mitochondrial DNA levels; chr11:14273650 chr1:52993201~52993702:- CESC trans rs7121616 0.576 rs73608699 ENSG00000234176.1 HSPA8P1 9.06 7.75e-17 6.34e-10 0.85 0.52 Breast cancer; chr11:123044718 chrX:121203182~121205014:- CESC trans rs116095464 0.51 rs7714944 ENSG00000185986.11 SDHAP3 9.05 7.98e-17 6.52e-10 0.83 0.52 Breast cancer; chr5:231650 chr5:1572222~1594620:- CESC trans rs11098499 0.954 rs11722872 ENSG00000275858.1 RP11-291L22.8 9.05 8.02e-17 6.56e-10 0.6 0.52 Corneal astigmatism; chr4:119311875 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs1546502 ENSG00000275858.1 RP11-291L22.8 9.05 8.02e-17 6.56e-10 0.6 0.52 Corneal astigmatism; chr4:119314743 chr10:38450738~38451069:- CESC trans rs877636 0.692 rs11171739 ENSG00000196933.5 RPS26P11 9.05 8.16e-17 6.66e-10 0.57 0.52 Cognitive function; chr12:56076841 chrX:72044545~72044892:+ CESC trans rs8067354 0.83 rs2453913 ENSG00000187870.7 RNFT1P3 9.05 8.21e-17 6.7e-10 0.63 0.52 Hemoglobin concentration; chr17:59782789 chr17:20743333~20754501:- CESC trans rs7200543 1 rs1135999 ENSG00000250569.1 NTAN1P2 9.05 8.23e-17 6.71e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15038105 chr8:86481754~86483002:- CESC trans rs7200543 1 rs1136001 ENSG00000250569.1 NTAN1P2 9.05 8.23e-17 6.71e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15038117 chr8:86481754~86483002:- CESC trans rs7200543 1 rs2740 ENSG00000250569.1 NTAN1P2 9.05 8.23e-17 6.71e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15038251 chr8:86481754~86483002:- CESC trans rs7200543 1 rs34614532 ENSG00000250569.1 NTAN1P2 9.05 8.23e-17 6.71e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15039051 chr8:86481754~86483002:- CESC trans rs8067354 0.831 rs2333617 ENSG00000187870.7 RNFT1P3 -9.04 8.52e-17 6.93e-10 -0.66 -0.52 Hemoglobin concentration; chr17:59818859 chr17:20743333~20754501:- CESC trans rs8067354 0.872 rs7224006 ENSG00000187870.7 RNFT1P3 -9.04 8.52e-17 6.93e-10 -0.66 -0.52 Hemoglobin concentration; chr17:59818977 chr17:20743333~20754501:- CESC trans rs8067354 0.872 rs1295925 ENSG00000187870.7 RNFT1P3 -9.04 8.52e-17 6.93e-10 -0.66 -0.52 Hemoglobin concentration; chr17:59832902 chr17:20743333~20754501:- CESC trans rs7554547 0.871 rs11588551 ENSG00000261819.1 RP11-680G24.4 -9.04 8.7e-17 7.07e-10 -0.61 -0.52 Nonsyndromic cleft lip with cleft palate; chr1:11881879 chr16:14988259~14990160:- CESC trans rs7258465 0.931 rs875396 ENSG00000267533.1 RP11-815J4.7 9.04 8.72e-17 7.09e-10 0.67 0.52 Breast cancer; chr19:18500337 chr18:12067173~12068417:- CESC trans rs10940346 1 rs6874697 ENSG00000231752.4 EMBP1 9.04 8.77e-17 7.13e-10 0.64 0.52 Schizophrenia; chr5:50344307 chr1:121519112~121571892:+ CESC trans rs55665837 1 rs12792120 ENSG00000236360.2 RP11-334A14.2 9.03 9.25e-17 7.5e-10 0.66 0.52 Vitamin D levels; chr11:14447897 chr1:52993201~52993702:- CESC trans rs55665837 0.961 rs12576926 ENSG00000236360.2 RP11-334A14.2 9.03 9.25e-17 7.5e-10 0.66 0.52 Vitamin D levels; chr11:14458746 chr1:52993201~52993702:- CESC trans rs7258465 1 rs4808133 ENSG00000267533.1 RP11-815J4.7 9.03 9.26e-17 7.5e-10 0.67 0.52 Breast cancer; chr19:18497708 chr18:12067173~12068417:- CESC trans rs55665837 1 rs10832275 ENSG00000236360.2 RP11-334A14.2 9.03 9.32e-17 7.55e-10 0.67 0.52 Vitamin D levels; chr11:14456678 chr1:52993201~52993702:- CESC trans rs7258465 1 rs4808134 ENSG00000267533.1 RP11-815J4.7 9.02 9.64e-17 7.8e-10 0.67 0.52 Breast cancer; chr19:18497769 chr18:12067173~12068417:- CESC trans rs10242455 0.702 rs116671616 ENSG00000228834.1 RP11-249L21.4 9.02 9.7e-17 7.85e-10 1.32 0.52 Blood metabolite levels; chr7:99356935 chr6:108907615~108907873:- CESC trans rs7200543 1 rs14347 ENSG00000250569.1 NTAN1P2 9.02 9.8e-17 7.92e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15040032 chr8:86481754~86483002:- CESC trans rs10940346 1 rs10040323 ENSG00000231752.4 EMBP1 9.02 9.83e-17 7.94e-10 0.64 0.52 Schizophrenia; chr5:50336779 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs2055909 ENSG00000231752.4 EMBP1 9.02 9.83e-17 7.94e-10 0.64 0.52 Schizophrenia; chr5:50337474 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs35250488 ENSG00000231752.4 EMBP1 9.02 1.02e-16 8.23e-10 0.64 0.52 Schizophrenia; chr5:50331004 chr1:121519112~121571892:+ CESC trans rs2657294 0.929 rs6480771 ENSG00000172974.11 AC007318.5 9.01 1.06e-16 8.57e-10 0.51 0.52 Pneumonia; chr10:75101922 chr2:65205108~65205988:+ CESC trans rs11098499 0.866 rs6847778 ENSG00000275858.1 RP11-291L22.8 9.01 1.07e-16 8.65e-10 0.6 0.52 Corneal astigmatism; chr4:119372427 chr10:38450738~38451069:- CESC trans rs2657294 0.895 rs2395137 ENSG00000172974.11 AC007318.5 9.01 1.07e-16 8.65e-10 0.51 0.52 Pneumonia; chr10:75088235 chr2:65205108~65205988:+ CESC trans rs2657294 0.895 rs2002023 ENSG00000172974.11 AC007318.5 9.01 1.07e-16 8.65e-10 0.51 0.52 Pneumonia; chr10:75088766 chr2:65205108~65205988:+ CESC trans rs7258465 1 rs34256197 ENSG00000267533.1 RP11-815J4.7 9.01 1.1e-16 8.82e-10 0.66 0.52 Breast cancer; chr19:18495662 chr18:12067173~12068417:- CESC trans rs55665837 1 rs11023215 ENSG00000236360.2 RP11-334A14.2 9 1.12e-16 8.98e-10 0.67 0.52 Vitamin D levels; chr11:14415424 chr1:52993201~52993702:- CESC trans rs13177918 0.717 rs6874318 ENSG00000213058.3 RP4-765C7.2 -9 1.14e-16 9.14e-10 -0.67 -0.52 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr1:178411616~178411972:+ CESC trans rs8010715 0.771 rs2277481 ENSG00000238000.1 RP11-274E7.2 9 1.15e-16 9.27e-10 0.52 0.52 IgG glycosylation; chr14:24118336 chr5:98213402~98214121:+ CESC trans rs4276421 0.745 rs10941722 ENSG00000231752.4 EMBP1 -9 1.16e-16 9.28e-10 -0.64 -0.52 P wave duration; chr5:46067527 chr1:121519112~121571892:+ CESC trans rs7811142 0.72 rs7795656 ENSG00000228546.2 CTA-313A17.3 8.99 1.18e-16 9.46e-10 0.88 0.52 Platelet count; chr7:100352674 chr7:102337316~102339115:+ CESC trans rs116095464 0.614 rs28736753 ENSG00000185986.11 SDHAP3 8.99 1.18e-16 9.49e-10 0.85 0.52 Breast cancer; chr5:273966 chr5:1572222~1594620:- CESC trans rs7200543 1 rs1121 ENSG00000250569.1 NTAN1P2 8.99 1.2e-16 9.62e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15037219 chr8:86481754~86483002:- CESC trans rs7200543 1 rs4985154 ENSG00000250569.1 NTAN1P2 8.99 1.2e-16 9.62e-10 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15037785 chr8:86481754~86483002:- CESC trans rs11098499 0.73 rs78971550 ENSG00000275858.1 RP11-291L22.8 8.99 1.22e-16 9.73e-10 0.62 0.52 Corneal astigmatism; chr4:119359886 chr10:38450738~38451069:- CESC trans rs11098499 0.645 rs78422072 ENSG00000275858.1 RP11-291L22.8 8.99 1.22e-16 9.73e-10 0.62 0.52 Corneal astigmatism; chr4:119359887 chr10:38450738~38451069:- CESC trans rs7811142 0.83 rs7341507 ENSG00000228546.2 CTA-313A17.3 8.99 1.22e-16 9.76e-10 0.87 0.52 Platelet count; chr7:100353692 chr7:102337316~102339115:+ CESC trans rs4276421 0.745 rs4441886 ENSG00000231752.4 EMBP1 -8.99 1.22e-16 9.77e-10 -0.64 -0.52 P wave duration; chr5:46063034 chr1:121519112~121571892:+ CESC trans rs928391 0.592 rs7522395 ENSG00000227183.3 HDGFP1 -8.98 1.27e-16 1.01e-09 -0.86 -0.52 Platelet count; chr1:156826905 chrX:131646639~131646890:+ CESC trans rs11098499 0.731 rs6846966 ENSG00000275858.1 RP11-291L22.8 8.98 1.31e-16 1.05e-09 0.59 0.52 Corneal astigmatism; chr4:119372053 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs17006190 ENSG00000275858.1 RP11-291L22.8 8.98 1.32e-16 1.05e-09 0.59 0.52 Corneal astigmatism; chr4:119497683 chr10:38450738~38451069:- CESC trans rs10940346 1 rs1328253 ENSG00000231752.4 EMBP1 -8.98 1.32e-16 1.05e-09 -0.63 -0.52 Schizophrenia; chr5:50286916 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs6449782 ENSG00000231752.4 EMBP1 -8.98 1.32e-16 1.05e-09 -0.63 -0.52 Schizophrenia; chr5:50291694 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs492337 ENSG00000231752.4 EMBP1 -8.98 1.33e-16 1.06e-09 -0.63 -0.52 Schizophrenia; chr5:50274706 chr1:121519112~121571892:+ CESC trans rs12709013 0.636 rs30835 ENSG00000230849.2 GOT2P2 8.97 1.34e-16 1.07e-09 0.59 0.52 Blood metabolite ratios; chr16:58714117 chr1:173141100~173142350:- CESC trans rs916888 0.821 rs199504 ENSG00000264070.1 DND1P1 -8.97 1.34e-16 1.07e-09 -0.77 -0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45585871~45586929:+ CESC trans rs7200543 1 rs16966953 ENSG00000250569.1 NTAN1P2 8.97 1.35e-16 1.07e-09 0.65 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15041997 chr8:86481754~86483002:- CESC trans rs10940346 1 rs2036901 ENSG00000231752.4 EMBP1 8.97 1.35e-16 1.08e-09 0.63 0.52 Schizophrenia; chr5:50401306 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs12508173 ENSG00000275858.1 RP11-291L22.8 8.97 1.37e-16 1.09e-09 0.59 0.52 Corneal astigmatism; chr4:119397371 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs12504149 ENSG00000275858.1 RP11-291L22.8 8.97 1.37e-16 1.09e-09 0.59 0.52 Corneal astigmatism; chr4:119397422 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10008392 ENSG00000275858.1 RP11-291L22.8 8.97 1.39e-16 1.1e-09 0.59 0.52 Corneal astigmatism; chr4:119397684 chr10:38450738~38451069:- CESC trans rs2657294 0.796 rs7082123 ENSG00000172974.11 AC007318.5 8.97 1.39e-16 1.1e-09 0.51 0.52 Pneumonia; chr10:75091101 chr2:65205108~65205988:+ CESC trans rs2657294 0.965 rs7079694 ENSG00000172974.11 AC007318.5 8.97 1.4e-16 1.11e-09 0.51 0.52 Pneumonia; chr10:75136804 chr2:65205108~65205988:+ CESC trans rs877636 0.692 rs11171739 ENSG00000234513.1 AC073072.7 8.97 1.4e-16 1.11e-09 0.54 0.52 Cognitive function; chr12:56076841 chr7:22773646~22773993:- CESC trans rs2657294 0.965 rs7088974 ENSG00000172974.11 AC007318.5 8.97 1.4e-16 1.11e-09 0.5 0.52 Pneumonia; chr10:75131338 chr2:65205108~65205988:+ CESC trans rs928391 0.592 rs1888861 ENSG00000227183.3 HDGFP1 -8.97 1.41e-16 1.12e-09 -0.86 -0.52 Platelet count; chr1:156828169 chrX:131646639~131646890:+ CESC trans rs928391 0.592 rs7516856 ENSG00000227183.3 HDGFP1 -8.97 1.41e-16 1.12e-09 -0.86 -0.52 Platelet count; chr1:156828324 chrX:131646639~131646890:+ CESC trans rs9611565 0.625 rs9607819 ENSG00000268568.1 AC007228.9 -8.96 1.43e-16 1.13e-09 -0.72 -0.52 Vitiligo; chr22:41562858 chr19:56672574~56673901:- CESC trans rs10940346 1 rs7712749 ENSG00000231752.4 EMBP1 8.96 1.43e-16 1.13e-09 0.63 0.52 Schizophrenia; chr5:50400441 chr1:121519112~121571892:+ CESC trans rs10940346 0.875 rs10076490 ENSG00000231752.4 EMBP1 8.96 1.43e-16 1.13e-09 0.63 0.52 Schizophrenia; chr5:50389037 chr1:121519112~121571892:+ CESC trans rs4276421 0.695 rs4421114 ENSG00000231752.4 EMBP1 -8.96 1.44e-16 1.14e-09 -0.64 -0.52 P wave duration; chr5:46069241 chr1:121519112~121571892:+ CESC trans rs2657294 0.861 rs6480769 ENSG00000172974.11 AC007318.5 8.96 1.44e-16 1.14e-09 0.51 0.52 Pneumonia; chr10:75091745 chr2:65205108~65205988:+ CESC trans rs4276421 0.774 rs72755668 ENSG00000231752.4 EMBP1 -8.96 1.45e-16 1.15e-09 -0.65 -0.52 P wave duration; chr5:46102658 chr1:121519112~121571892:+ CESC trans rs4276421 0.774 rs10042199 ENSG00000231752.4 EMBP1 -8.96 1.45e-16 1.15e-09 -0.65 -0.52 P wave duration; chr5:46103946 chr1:121519112~121571892:+ CESC trans rs12709013 0.729 rs1657179 ENSG00000230849.2 GOT2P2 8.96 1.49e-16 1.18e-09 0.57 0.52 Blood metabolite ratios; chr16:58735115 chr1:173141100~173142350:- CESC trans rs11098499 0.908 rs2017057 ENSG00000275858.1 RP11-291L22.8 8.95 1.55e-16 1.22e-09 0.58 0.52 Corneal astigmatism; chr4:119336556 chr10:38450738~38451069:- CESC trans rs11098499 0.779 rs10857066 ENSG00000275858.1 RP11-291L22.8 8.95 1.57e-16 1.23e-09 0.59 0.52 Corneal astigmatism; chr4:119365441 chr10:38450738~38451069:- CESC trans rs916888 0.773 rs9896243 ENSG00000214425.5 LRRC37A4P -8.95 1.57e-16 1.24e-09 -0.64 -0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45506741~45550335:- CESC trans rs928391 0.592 rs6427332 ENSG00000227183.3 HDGFP1 -8.94 1.65e-16 1.29e-09 -0.86 -0.52 Platelet count; chr1:156827052 chrX:131646639~131646890:+ CESC trans rs10940346 1 rs555458 ENSG00000231752.4 EMBP1 -8.94 1.68e-16 1.32e-09 -0.63 -0.52 Schizophrenia; chr5:50262772 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs510897 ENSG00000231752.4 EMBP1 -8.94 1.68e-16 1.32e-09 -0.63 -0.52 Schizophrenia; chr5:50263017 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs507396 ENSG00000231752.4 EMBP1 -8.94 1.68e-16 1.32e-09 -0.63 -0.52 Schizophrenia; chr5:50263374 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs11960661 ENSG00000231752.4 EMBP1 -8.94 1.68e-16 1.32e-09 -0.63 -0.52 Schizophrenia; chr5:50266528 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs489407 ENSG00000231752.4 EMBP1 -8.94 1.68e-16 1.32e-09 -0.63 -0.52 Schizophrenia; chr5:50266701 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs491470 ENSG00000231752.4 EMBP1 -8.94 1.68e-16 1.32e-09 -0.63 -0.52 Schizophrenia; chr5:50266988 chr1:121519112~121571892:+ CESC trans rs7121616 1 rs7123187 ENSG00000234176.1 HSPA8P1 8.94 1.7e-16 1.33e-09 0.67 0.52 Breast cancer; chr11:123090915 chrX:121203182~121205014:- CESC trans rs11098499 0.954 rs10006877 ENSG00000275858.1 RP11-291L22.8 8.94 1.72e-16 1.34e-09 0.59 0.52 Corneal astigmatism; chr4:119321638 chr10:38450738~38451069:- CESC trans rs55665837 1 rs55665837 ENSG00000236360.2 RP11-334A14.2 8.94 1.72e-16 1.35e-09 0.67 0.52 Vitamin D levels; chr11:14473503 chr1:52993201~52993702:- CESC trans rs55665837 1 rs10832254 ENSG00000236360.2 RP11-334A14.2 8.94 1.73e-16 1.35e-09 0.65 0.52 Vitamin D levels; chr11:14413152 chr1:52993201~52993702:- CESC trans rs55665837 1 rs11023214 ENSG00000236360.2 RP11-334A14.2 8.94 1.73e-16 1.35e-09 0.65 0.52 Vitamin D levels; chr11:14414713 chr1:52993201~52993702:- CESC trans rs7258465 0.897 rs1043327 ENSG00000267533.1 RP11-815J4.7 8.93 1.74e-16 1.36e-09 0.66 0.52 Breast cancer; chr19:18444162 chr18:12067173~12068417:- CESC trans rs11098499 0.863 rs1480940 ENSG00000275858.1 RP11-291L22.8 8.93 1.78e-16 1.39e-09 0.6 0.52 Corneal astigmatism; chr4:119536527 chr10:38450738~38451069:- CESC trans rs4276421 0.745 rs11957047 ENSG00000231752.4 EMBP1 -8.93 1.81e-16 1.41e-09 -0.64 -0.52 P wave duration; chr5:46080090 chr1:121519112~121571892:+ CESC trans rs4276421 0.694 rs10941732 ENSG00000231752.4 EMBP1 -8.93 1.81e-16 1.41e-09 -0.64 -0.52 P wave duration; chr5:46080260 chr1:121519112~121571892:+ CESC trans rs4276421 0.661 rs4455569 ENSG00000231752.4 EMBP1 -8.93 1.81e-16 1.41e-09 -0.64 -0.52 P wave duration; chr5:46081782 chr1:121519112~121571892:+ CESC trans rs4276421 0.743 rs4455568 ENSG00000231752.4 EMBP1 8.93 1.81e-16 1.41e-09 0.64 0.52 P wave duration; chr5:46079755 chr1:121519112~121571892:+ CESC trans rs116095464 0.558 rs6555058 ENSG00000185986.11 SDHAP3 -8.93 1.85e-16 1.44e-09 -0.79 -0.52 Breast cancer; chr5:226261 chr5:1572222~1594620:- CESC trans rs11098499 0.909 rs10014719 ENSG00000275858.1 RP11-291L22.8 8.92 1.88e-16 1.46e-09 0.59 0.52 Corneal astigmatism; chr4:119399560 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10017543 ENSG00000275858.1 RP11-291L22.8 8.92 1.88e-16 1.46e-09 0.59 0.52 Corneal astigmatism; chr4:119400265 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs7695996 ENSG00000275858.1 RP11-291L22.8 8.92 1.88e-16 1.46e-09 0.59 0.52 Corneal astigmatism; chr4:119400878 chr10:38450738~38451069:- CESC trans rs10940346 1 rs4643959 ENSG00000231752.4 EMBP1 8.92 1.91e-16 1.49e-09 0.63 0.52 Schizophrenia; chr5:50391631 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs7699064 ENSG00000275858.1 RP11-291L22.8 -8.92 1.94e-16 1.51e-09 -0.59 -0.52 Corneal astigmatism; chr4:119507154 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs67265404 ENSG00000275858.1 RP11-291L22.8 8.92 1.97e-16 1.53e-09 0.59 0.52 Corneal astigmatism; chr4:119438115 chr10:38450738~38451069:- CESC trans rs916888 0.61 rs199529 ENSG00000264070.1 DND1P1 8.92 1.97e-16 1.53e-09 0.68 0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45585871~45586929:+ CESC trans rs116095464 0.558 rs113796397 ENSG00000185986.11 SDHAP3 8.91 2.01e-16 1.56e-09 0.86 0.52 Breast cancer; chr5:246388 chr5:1572222~1594620:- CESC trans rs11098499 0.564 rs11098507 ENSG00000275858.1 RP11-291L22.8 8.91 2.02e-16 1.56e-09 0.59 0.52 Corneal astigmatism; chr4:119367131 chr10:38450738~38451069:- CESC trans rs10940346 0.902 rs4865727 ENSG00000231752.4 EMBP1 -8.91 2.02e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50145945 chr1:121519112~121571892:+ CESC trans rs10940346 0.714 rs12523073 ENSG00000231752.4 EMBP1 -8.91 2.02e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50153697 chr1:121519112~121571892:+ CESC trans rs10940346 0.934 rs2353222 ENSG00000231752.4 EMBP1 -8.91 2.02e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50174249 chr1:121519112~121571892:+ CESC trans rs10940346 0.537 rs8188099 ENSG00000231752.4 EMBP1 -8.91 2.03e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50183445 chr1:121519112~121571892:+ CESC trans rs10940346 0.716 rs8188088 ENSG00000231752.4 EMBP1 -8.91 2.03e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50215591 chr1:121519112~121571892:+ CESC trans rs10940346 0.818 rs472278 ENSG00000231752.4 EMBP1 -8.91 2.03e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50215972 chr1:121519112~121571892:+ CESC trans rs10940346 0.653 rs4371800 ENSG00000231752.4 EMBP1 -8.91 2.03e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50225349 chr1:121519112~121571892:+ CESC trans rs10940346 0.584 rs496108 ENSG00000231752.4 EMBP1 -8.91 2.03e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50236794 chr1:121519112~121571892:+ CESC trans rs10940346 0.744 rs498951 ENSG00000231752.4 EMBP1 -8.91 2.03e-16 1.57e-09 -0.63 -0.52 Schizophrenia; chr5:50238681 chr1:121519112~121571892:+ CESC trans rs7258465 1 rs10427083 ENSG00000267533.1 RP11-815J4.7 8.91 2.04e-16 1.57e-09 0.66 0.52 Breast cancer; chr19:18439466 chr18:12067173~12068417:- CESC trans rs4276421 0.714 rs4259174 ENSG00000231752.4 EMBP1 -8.91 2.07e-16 1.59e-09 -0.64 -0.52 P wave duration; chr5:46074351 chr1:121519112~121571892:+ CESC trans rs4276421 0.657 rs4975885 ENSG00000231752.4 EMBP1 -8.91 2.07e-16 1.59e-09 -0.64 -0.52 P wave duration; chr5:46083476 chr1:121519112~121571892:+ CESC trans rs4276421 0.774 rs11949490 ENSG00000231752.4 EMBP1 -8.91 2.07e-16 1.59e-09 -0.64 -0.52 P wave duration; chr5:46085951 chr1:121519112~121571892:+ CESC trans rs11098499 0.954 rs28572238 ENSG00000275858.1 RP11-291L22.8 8.91 2.07e-16 1.59e-09 0.6 0.52 Corneal astigmatism; chr4:119395531 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs28714195 ENSG00000275858.1 RP11-291L22.8 8.91 2.07e-16 1.59e-09 0.6 0.52 Corneal astigmatism; chr4:119395795 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs2306455 ENSG00000275858.1 RP11-291L22.8 8.91 2.07e-16 1.59e-09 0.59 0.52 Corneal astigmatism; chr4:119500814 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10031483 ENSG00000275858.1 RP11-291L22.8 8.91 2.07e-16 1.59e-09 0.59 0.52 Corneal astigmatism; chr4:119501481 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10031665 ENSG00000275858.1 RP11-291L22.8 8.91 2.07e-16 1.59e-09 0.59 0.52 Corneal astigmatism; chr4:119501697 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs3733523 ENSG00000275858.1 RP11-291L22.8 8.91 2.07e-16 1.59e-09 0.59 0.52 Corneal astigmatism; chr4:119502564 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10518328 ENSG00000275858.1 RP11-291L22.8 8.91 2.1e-16 1.61e-09 0.59 0.52 Corneal astigmatism; chr4:119480624 chr10:38450738~38451069:- CESC trans rs7258465 1 rs10164323 ENSG00000267533.1 RP11-815J4.7 8.9 2.15e-16 1.65e-09 0.65 0.52 Breast cancer; chr19:18458682 chr18:12067173~12068417:- CESC trans rs7200543 1 rs6498540 ENSG00000250569.1 NTAN1P2 8.9 2.17e-16 1.66e-09 0.64 0.52 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15036737 chr8:86481754~86483002:- CESC trans rs10940346 1 rs4865522 ENSG00000231752.4 EMBP1 -8.9 2.2e-16 1.69e-09 -0.63 -0.52 Schizophrenia; chr5:50303674 chr1:121519112~121571892:+ CESC trans rs2657294 0.761 rs1259498 ENSG00000172974.11 AC007318.5 8.9 2.25e-16 1.73e-09 0.51 0.52 Pneumonia; chr10:75226983 chr2:65205108~65205988:+ CESC trans rs11098499 0.78 rs10013652 ENSG00000275858.1 RP11-291L22.8 8.9 2.25e-16 1.73e-09 0.59 0.52 Corneal astigmatism; chr4:119371101 chr10:38450738~38451069:- CESC trans rs928391 0.541 rs1888863 ENSG00000227183.3 HDGFP1 -8.9 2.27e-16 1.74e-09 -0.85 -0.52 Platelet count; chr1:156828046 chrX:131646639~131646890:+ CESC trans rs7258465 1 rs4808801 ENSG00000267533.1 RP11-815J4.7 8.89 2.31e-16 1.77e-09 0.65 0.52 Breast cancer; chr19:18460331 chr18:12067173~12068417:- CESC trans rs7258465 1 rs34171762 ENSG00000267533.1 RP11-815J4.7 8.89 2.34e-16 1.79e-09 0.65 0.52 Breast cancer; chr19:18448600 chr18:12067173~12068417:- CESC trans rs11098499 0.863 rs34868248 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119521275 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs10013305 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119529269 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3775849 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119529753 chr10:38450738~38451069:- CESC trans rs11098499 0.818 rs7688802 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119530513 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs7695620 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119531621 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs12502389 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119533036 chr10:38450738~38451069:- CESC trans rs11098499 0.821 rs3775852 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119533401 chr10:38450738~38451069:- CESC trans rs11098499 0.82 rs6534140 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119534156 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs7657849 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119534339 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs10034450 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119534494 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs1480939 ENSG00000275858.1 RP11-291L22.8 8.89 2.37e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119535772 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs3733524 ENSG00000275858.1 RP11-291L22.8 8.89 2.38e-16 1.81e-09 0.59 0.52 Corneal astigmatism; chr4:119502574 chr10:38450738~38451069:- CESC trans rs10940346 1 rs34044167 ENSG00000231752.4 EMBP1 8.89 2.4e-16 1.83e-09 0.63 0.52 Schizophrenia; chr5:50410136 chr1:121519112~121571892:+ CESC trans rs11098499 0.697 rs4560394 ENSG00000275858.1 RP11-291L22.8 8.88 2.48e-16 1.88e-09 0.59 0.52 Corneal astigmatism; chr4:119392280 chr10:38450738~38451069:- CESC trans rs12709013 0.66 rs30839 ENSG00000230849.2 GOT2P2 8.88 2.48e-16 1.88e-09 0.6 0.52 Blood metabolite ratios; chr16:58711437 chr1:173141100~173142350:- CESC trans rs2950393 0.572 rs10783794 ENSG00000121089.4 NACA3P -8.88 2.49e-16 1.88e-09 -0.55 -0.52 Platelet distribution width; chr12:56593395 chr4:164943290~164943937:+ CESC trans rs10940346 1 rs2137132 ENSG00000231752.4 EMBP1 8.88 2.51e-16 1.9e-09 0.63 0.52 Schizophrenia; chr5:50353988 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs1995795 ENSG00000231752.4 EMBP1 8.88 2.51e-16 1.9e-09 0.63 0.52 Schizophrenia; chr5:50356233 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs6874829 ENSG00000231752.4 EMBP1 8.88 2.51e-16 1.9e-09 0.63 0.52 Schizophrenia; chr5:50357573 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs7721808 ENSG00000231752.4 EMBP1 8.88 2.51e-16 1.9e-09 0.63 0.52 Schizophrenia; chr5:50363136 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs1812994 ENSG00000231752.4 EMBP1 8.88 2.51e-16 1.9e-09 0.63 0.52 Schizophrenia; chr5:50364397 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs13185587 ENSG00000231752.4 EMBP1 8.88 2.51e-16 1.9e-09 0.63 0.52 Schizophrenia; chr5:50365409 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs3849670 ENSG00000231752.4 EMBP1 8.88 2.51e-16 1.9e-09 0.63 0.52 Schizophrenia; chr5:50365641 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs4030572 ENSG00000231752.4 EMBP1 8.88 2.51e-16 1.9e-09 0.63 0.52 Schizophrenia; chr5:50375897 chr1:121519112~121571892:+ CESC trans rs11098499 0.954 rs1022145 ENSG00000275858.1 RP11-291L22.8 8.88 2.52e-16 1.91e-09 0.59 0.52 Corneal astigmatism; chr4:119309824 chr10:38450738~38451069:- CESC trans rs61990749 0.511 rs724263 ENSG00000235400.1 RP4-641G12.4 8.88 2.52e-16 1.91e-09 0.85 0.52 Fibroblast growth factor basic levels; chr14:77855531 chr1:78749073~78750659:+ CESC trans rs10940346 0.905 rs4030569 ENSG00000231752.4 EMBP1 8.88 2.53e-16 1.91e-09 0.63 0.52 Schizophrenia; chr5:50371779 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs4030570 ENSG00000231752.4 EMBP1 8.88 2.53e-16 1.91e-09 0.63 0.52 Schizophrenia; chr5:50371829 chr1:121519112~121571892:+ CESC trans rs2657294 0.965 rs10824285 ENSG00000172974.11 AC007318.5 8.88 2.56e-16 1.93e-09 0.5 0.52 Pneumonia; chr10:75153271 chr2:65205108~65205988:+ CESC trans rs2657294 0.965 rs2395140 ENSG00000172974.11 AC007318.5 8.88 2.56e-16 1.93e-09 0.5 0.52 Pneumonia; chr10:75139253 chr2:65205108~65205988:+ CESC trans rs2657294 0.965 rs2997754 ENSG00000172974.11 AC007318.5 8.88 2.56e-16 1.93e-09 0.5 0.52 Pneumonia; chr10:75144379 chr2:65205108~65205988:+ CESC trans rs13190036 1 rs6889220 ENSG00000217325.2 PRELID1P1 8.88 2.56e-16 1.93e-09 0.82 0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177266887 chr6:126643488~126644390:+ CESC trans rs11098499 0.954 rs10017371 ENSG00000275858.1 RP11-291L22.8 8.88 2.57e-16 1.94e-09 0.59 0.52 Corneal astigmatism; chr4:119372621 chr10:38450738~38451069:- CESC trans rs10242455 0.702 rs73713531 ENSG00000228834.1 RP11-249L21.4 8.88 2.59e-16 1.95e-09 1.31 0.52 Blood metabolite levels; chr7:99624756 chr6:108907615~108907873:- CESC trans rs11098499 0.863 rs6534139 ENSG00000275858.1 RP11-291L22.8 -8.87 2.62e-16 1.97e-09 -0.61 -0.52 Corneal astigmatism; chr4:119528301 chr10:38450738~38451069:- CESC trans rs11098499 0.738 rs28687057 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119359657 chr10:38450738~38451069:- CESC trans rs11098499 0.775 rs67281037 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119360002 chr10:38450738~38451069:- CESC trans rs10028773 0.506 rs12374346 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Educational attainment; chr4:119360550 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs12374244 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119360817 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs12374352 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119360822 chr10:38450738~38451069:- CESC trans rs11098499 0.775 rs10021601 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119361408 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs6857892 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119361541 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs28581362 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119362393 chr10:38450738~38451069:- CESC trans rs11098499 0.82 rs12503082 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119363162 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs12499602 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119363232 chr10:38450738~38451069:- CESC trans rs11098499 0.774 rs11098505 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119363472 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs13105020 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119364533 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs6824111 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119364813 chr10:38450738~38451069:- CESC trans rs11098499 0.775 rs10029303 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119365600 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs9995136 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119365690 chr10:38450738~38451069:- CESC trans rs11098499 0.687 rs71610270 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119366281 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs13125526 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119366864 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs12513310 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119366884 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs12510451 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119367988 chr10:38450738~38451069:- CESC trans rs11098499 0.774 rs73842616 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119369528 chr10:38450738~38451069:- CESC trans rs11098499 0.645 rs72676059 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119369673 chr10:38450738~38451069:- CESC trans rs11098499 0.569 rs55845118 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119369758 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs7677068 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119370549 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs9991221 ENSG00000275858.1 RP11-291L22.8 8.87 2.64e-16 1.98e-09 0.58 0.52 Corneal astigmatism; chr4:119370952 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs7681544 ENSG00000275858.1 RP11-291L22.8 8.87 2.66e-16 1.98e-09 0.59 0.52 Corneal astigmatism; chr4:119490100 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs11940028 ENSG00000275858.1 RP11-291L22.8 8.87 2.66e-16 1.98e-09 0.59 0.52 Corneal astigmatism; chr4:119490752 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs11935596 ENSG00000275858.1 RP11-291L22.8 8.87 2.66e-16 1.98e-09 0.59 0.52 Corneal astigmatism; chr4:119491302 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs12507964 ENSG00000275858.1 RP11-291L22.8 8.87 2.66e-16 1.98e-09 0.59 0.52 Corneal astigmatism; chr4:119491906 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs11098530 ENSG00000275858.1 RP11-291L22.8 8.87 2.66e-16 1.98e-09 0.59 0.52 Corneal astigmatism; chr4:119491999 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs6834796 ENSG00000275858.1 RP11-291L22.8 8.87 2.66e-16 1.98e-09 0.59 0.52 Corneal astigmatism; chr4:119493538 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs11729521 ENSG00000275858.1 RP11-291L22.8 8.87 2.66e-16 1.98e-09 0.59 0.52 Corneal astigmatism; chr4:119495633 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs11734241 ENSG00000275858.1 RP11-291L22.8 8.87 2.66e-16 1.98e-09 0.59 0.52 Corneal astigmatism; chr4:119495717 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs9998585 ENSG00000275858.1 RP11-291L22.8 8.87 2.77e-16 2.06e-09 0.58 0.51 Corneal astigmatism; chr4:119475647 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs6842762 ENSG00000275858.1 RP11-291L22.8 8.87 2.77e-16 2.06e-09 0.58 0.51 Corneal astigmatism; chr4:119477081 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs59866101 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119375436 chr10:38450738~38451069:- CESC trans rs11098499 0.618 rs6858383 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119375617 chr10:38450738~38451069:- CESC trans rs11098499 0.697 rs6832410 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119375645 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs1112817 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119376645 chr10:38450738~38451069:- CESC trans rs11098499 0.779 rs10016060 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119377257 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10005644 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119377322 chr10:38450738~38451069:- CESC trans rs11098499 0.697 rs10016448 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119377690 chr10:38450738~38451069:- CESC trans rs11098499 0.657 rs9996569 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119377849 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs11723757 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119378514 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs11723839 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119378518 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs11729050 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119378911 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs28429722 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119378938 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10014845 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119379922 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs12506546 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119380463 chr10:38450738~38451069:- CESC trans rs11098499 0.779 rs7674500 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119382438 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs28884220 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119386056 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs28793658 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119386059 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs4507344 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119386330 chr10:38450738~38451069:- CESC trans rs11098499 0.697 rs4373140 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119386543 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs13113483 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119387884 chr10:38450738~38451069:- CESC trans rs11098499 0.542 rs10440343 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119388632 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs28668716 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119388720 chr10:38450738~38451069:- CESC trans rs11098499 0.779 rs10011097 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119389204 chr10:38450738~38451069:- CESC trans rs11098499 0.542 rs7677836 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119389483 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs10002083 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119389997 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10024844 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119390373 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs7437420 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119391748 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs4345162 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119391804 chr10:38450738~38451069:- CESC trans rs11098499 0.657 rs4463052 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119392103 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs13151285 ENSG00000275858.1 RP11-291L22.8 8.86 2.84e-16 2.1e-09 0.59 0.51 Corneal astigmatism; chr4:119393586 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs7696649 ENSG00000275858.1 RP11-291L22.8 8.86 2.87e-16 2.12e-09 0.58 0.51 Corneal astigmatism; chr4:119401022 chr10:38450738~38451069:- CESC trans rs7811142 0.83 rs11771936 ENSG00000228546.2 CTA-313A17.3 8.86 2.87e-16 2.12e-09 0.87 0.51 Platelet count; chr7:100345660 chr7:102337316~102339115:+ CESC trans rs7811142 0.779 rs77370288 ENSG00000228546.2 CTA-313A17.3 8.86 2.87e-16 2.12e-09 0.87 0.51 Platelet count; chr7:100350274 chr7:102337316~102339115:+ CESC trans rs7258465 0.965 rs8100767 ENSG00000267533.1 RP11-815J4.7 8.86 2.9e-16 2.13e-09 0.65 0.51 Breast cancer; chr19:18478278 chr18:12067173~12068417:- CESC trans rs7258465 1 rs10409483 ENSG00000267533.1 RP11-815J4.7 8.86 2.9e-16 2.13e-09 0.65 0.51 Breast cancer; chr19:18479413 chr18:12067173~12068417:- CESC trans rs7258465 1 rs10409505 ENSG00000267533.1 RP11-815J4.7 8.86 2.9e-16 2.13e-09 0.65 0.51 Breast cancer; chr19:18479441 chr18:12067173~12068417:- CESC trans rs7811142 0.943 rs111757992 ENSG00000228546.2 CTA-313A17.3 8.86 2.92e-16 2.15e-09 0.84 0.51 Platelet count; chr7:100418731 chr7:102337316~102339115:+ CESC trans rs916888 0.821 rs199514 ENSG00000264070.1 DND1P1 -8.86 2.95e-16 2.17e-09 -0.78 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45585871~45586929:+ CESC trans rs11098499 0.954 rs10006525 ENSG00000275858.1 RP11-291L22.8 8.85 2.97e-16 2.18e-09 0.58 0.51 Corneal astigmatism; chr4:119487776 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs6849171 ENSG00000275858.1 RP11-291L22.8 8.85 2.97e-16 2.18e-09 0.58 0.51 Corneal astigmatism; chr4:119488394 chr10:38450738~38451069:- CESC trans rs11098499 0.657 rs10434028 ENSG00000275858.1 RP11-291L22.8 8.85 3.05e-16 2.24e-09 0.59 0.51 Corneal astigmatism; chr4:119373309 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3733525 ENSG00000275858.1 RP11-291L22.8 8.85 3.14e-16 2.3e-09 0.59 0.51 Corneal astigmatism; chr4:119525893 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3775847 ENSG00000275858.1 RP11-291L22.8 8.85 3.14e-16 2.3e-09 0.59 0.51 Corneal astigmatism; chr4:119526487 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3775848 ENSG00000275858.1 RP11-291L22.8 8.85 3.14e-16 2.3e-09 0.59 0.51 Corneal astigmatism; chr4:119526569 chr10:38450738~38451069:- CESC trans rs7258465 1 rs10403249 ENSG00000267533.1 RP11-815J4.7 8.84 3.17e-16 2.32e-09 0.65 0.51 Breast cancer; chr19:18494132 chr18:12067173~12068417:- CESC trans rs7258465 1 rs10411009 ENSG00000267533.1 RP11-815J4.7 8.84 3.17e-16 2.32e-09 0.65 0.51 Breast cancer; chr19:18495456 chr18:12067173~12068417:- CESC trans rs13190036 0.892 rs71601339 ENSG00000217325.2 PRELID1P1 -8.84 3.19e-16 2.33e-09 -0.83 -0.51 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117495 chr6:126643488~126644390:+ CESC trans rs11098499 0.954 rs3890049 ENSG00000275858.1 RP11-291L22.8 8.84 3.25e-16 2.37e-09 0.59 0.51 Corneal astigmatism; chr4:119405128 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs9759478 ENSG00000275858.1 RP11-291L22.8 8.84 3.25e-16 2.37e-09 0.59 0.51 Corneal astigmatism; chr4:119446843 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs71629403 ENSG00000275858.1 RP11-291L22.8 8.84 3.25e-16 2.37e-09 0.59 0.51 Corneal astigmatism; chr4:119451412 chr10:38450738~38451069:- CESC trans rs7811142 0.83 rs76798830 ENSG00000228546.2 CTA-313A17.3 8.84 3.31e-16 2.41e-09 0.93 0.51 Platelet count; chr7:100355205 chr7:102337316~102339115:+ CESC trans rs7811142 0.775 rs6946768 ENSG00000228546.2 CTA-313A17.3 8.84 3.31e-16 2.41e-09 0.93 0.51 Platelet count; chr7:100356770 chr7:102337316~102339115:+ CESC trans rs7200543 0.961 rs3803573 ENSG00000250569.1 NTAN1P2 8.83 3.4e-16 2.47e-09 0.64 0.51 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15044556 chr8:86481754~86483002:- CESC trans rs9611565 0.729 rs137831 ENSG00000268568.1 AC007228.9 -8.83 3.46e-16 2.51e-09 -0.65 -0.51 Vitiligo; chr22:41507809 chr19:56672574~56673901:- CESC trans rs11098499 0.909 rs10020034 ENSG00000275858.1 RP11-291L22.8 8.83 3.49e-16 2.53e-09 0.59 0.51 Corneal astigmatism; chr4:119373176 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs59394118 ENSG00000275858.1 RP11-291L22.8 8.83 3.49e-16 2.53e-09 0.59 0.51 Corneal astigmatism; chr4:119374396 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs9996417 ENSG00000275858.1 RP11-291L22.8 8.83 3.49e-16 2.53e-09 0.59 0.51 Corneal astigmatism; chr4:119374707 chr10:38450738~38451069:- CESC trans rs61990749 0.511 rs10130790 ENSG00000235400.1 RP4-641G12.4 8.83 3.51e-16 2.55e-09 0.85 0.51 Fibroblast growth factor basic levels; chr14:77857849 chr1:78749073~78750659:+ CESC trans rs61990749 0.511 rs10146144 ENSG00000235400.1 RP4-641G12.4 8.83 3.51e-16 2.55e-09 0.85 0.51 Fibroblast growth factor basic levels; chr14:77858957 chr1:78749073~78750659:+ CESC trans rs4276421 0.587 rs4975957 ENSG00000231752.4 EMBP1 -8.83 3.55e-16 2.57e-09 -0.64 -0.51 P wave duration; chr5:46265200 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs7669520 ENSG00000275858.1 RP11-291L22.8 8.83 3.55e-16 2.57e-09 0.58 0.51 Corneal astigmatism; chr4:119594123 chr10:38450738~38451069:- CESC trans rs7258465 0.965 rs7254249 ENSG00000267533.1 RP11-815J4.7 8.83 3.55e-16 2.57e-09 0.66 0.51 Breast cancer; chr19:18480935 chr18:12067173~12068417:- CESC trans rs7258465 0.965 rs7253990 ENSG00000267533.1 RP11-815J4.7 8.83 3.55e-16 2.57e-09 0.66 0.51 Breast cancer; chr19:18493275 chr18:12067173~12068417:- CESC trans rs4276421 0.657 rs10941759 ENSG00000231752.4 EMBP1 -8.83 3.59e-16 2.6e-09 -0.64 -0.51 P wave duration; chr5:46266862 chr1:121519112~121571892:+ CESC trans rs4276421 0.657 rs10941760 ENSG00000231752.4 EMBP1 -8.83 3.59e-16 2.6e-09 -0.64 -0.51 P wave duration; chr5:46267360 chr1:121519112~121571892:+ CESC trans rs11098499 0.954 rs4309825 ENSG00000275858.1 RP11-291L22.8 -8.83 3.6e-16 2.61e-09 -0.57 -0.51 Corneal astigmatism; chr4:119393726 chr10:38450738~38451069:- CESC trans rs7258465 0.965 rs748609 ENSG00000267533.1 RP11-815J4.7 8.82 3.64e-16 2.63e-09 0.65 0.51 Breast cancer; chr19:18449472 chr18:12067173~12068417:- CESC trans rs4276421 0.745 rs10041478 ENSG00000231752.4 EMBP1 -8.82 3.7e-16 2.68e-09 -0.65 -0.51 P wave duration; chr5:46103187 chr1:121519112~121571892:+ CESC trans rs7258465 1 rs8111708 ENSG00000267533.1 RP11-815J4.7 8.82 3.74e-16 2.71e-09 0.68 0.51 Breast cancer; chr19:18448066 chr18:12067173~12068417:- CESC trans rs4276421 0.744 rs4541667 ENSG00000231752.4 EMBP1 8.81 3.89e-16 2.81e-09 0.64 0.51 P wave duration; chr5:46060767 chr1:121519112~121571892:+ CESC trans rs13358908 0.599 rs34899679 ENSG00000231752.4 EMBP1 -8.81 3.9e-16 2.82e-09 -0.64 -0.51 Schizophrenia; chr5:46372360 chr1:121519112~121571892:+ CESC trans rs11098499 0.618 rs35265692 ENSG00000275858.1 RP11-291L22.8 8.81 3.91e-16 2.82e-09 0.59 0.51 Corneal astigmatism; chr4:119403980 chr10:38450738~38451069:- CESC trans rs7811142 0.83 rs1063945 ENSG00000228546.2 CTA-313A17.3 8.81 3.93e-16 2.84e-09 0.87 0.51 Platelet count; chr7:100332824 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs11761253 ENSG00000228546.2 CTA-313A17.3 8.81 3.93e-16 2.84e-09 0.87 0.51 Platelet count; chr7:100341698 chr7:102337316~102339115:+ CESC trans rs11098499 0.909 rs28571712 ENSG00000275858.1 RP11-291L22.8 8.81 3.97e-16 2.86e-09 0.59 0.51 Corneal astigmatism; chr4:119454825 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs7687843 ENSG00000275858.1 RP11-291L22.8 8.81 3.98e-16 2.87e-09 0.59 0.51 Corneal astigmatism; chr4:119500056 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs1002152 ENSG00000275858.1 RP11-291L22.8 8.81 4.04e-16 2.9e-09 0.59 0.51 Corneal astigmatism; chr4:119352232 chr10:38450738~38451069:- CESC trans rs10940346 1 rs1328254 ENSG00000231752.4 EMBP1 -8.81 4.04e-16 2.91e-09 -0.62 -0.51 Schizophrenia; chr5:50265025 chr1:121519112~121571892:+ CESC trans rs11098499 0.82 rs11737395 ENSG00000275858.1 RP11-291L22.8 8.81 4.06e-16 2.92e-09 0.59 0.51 Corneal astigmatism; chr4:119599549 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs11722183 ENSG00000275858.1 RP11-291L22.8 8.81 4.1e-16 2.94e-09 0.59 0.51 Corneal astigmatism; chr4:119359442 chr10:38450738~38451069:- CESC trans rs8067354 0.872 rs1292060 ENSG00000187870.7 RNFT1P3 8.81 4.1e-16 2.95e-09 0.62 0.51 Hemoglobin concentration; chr17:59836488 chr17:20743333~20754501:- CESC trans rs11098499 0.954 rs6849561 ENSG00000275858.1 RP11-291L22.8 -8.8 4.2e-16 3e-09 -0.58 -0.51 Corneal astigmatism; chr4:119488539 chr10:38450738~38451069:- CESC trans rs11098499 0.82 rs28535956 ENSG00000275858.1 RP11-291L22.8 -8.8 4.22e-16 3.02e-09 -0.57 -0.51 Corneal astigmatism; chr4:119615703 chr10:38450738~38451069:- CESC trans rs9611565 0.918 rs12484074 ENSG00000268568.1 AC007228.9 -8.8 4.26e-16 3.05e-09 -0.76 -0.51 Vitiligo; chr22:41356743 chr19:56672574~56673901:- CESC trans rs13190036 1 rs17078781 ENSG00000217325.2 PRELID1P1 -8.79 4.41e-16 3.15e-09 -0.83 -0.51 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117227 chr6:126643488~126644390:+ CESC trans rs6477998 0.58 rs7851623 ENSG00000238072.1 RP11-305M3.2 8.79 4.55e-16 3.25e-09 0.82 0.51 Hematology traits; chr9:113240285 chr7:129410113~129410370:- CESC trans rs11098499 0.954 rs12510138 ENSG00000275858.1 RP11-291L22.8 8.79 4.58e-16 3.26e-09 0.57 0.51 Corneal astigmatism; chr4:119502780 chr10:38450738~38451069:- CESC trans rs10242455 0.571 rs6955162 ENSG00000228834.1 RP11-249L21.4 8.79 4.58e-16 3.27e-09 1.48 0.51 Blood metabolite levels; chr7:99586777 chr6:108907615~108907873:- CESC trans rs4276421 0.904 rs10067132 ENSG00000231752.4 EMBP1 8.79 4.65e-16 3.32e-09 0.63 0.51 P wave duration; chr5:46027600 chr1:121519112~121571892:+ CESC trans rs13358908 0.596 rs9717195 ENSG00000231752.4 EMBP1 -8.79 4.68e-16 3.34e-09 -0.64 -0.51 Schizophrenia; chr5:46302679 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs1383532 ENSG00000275858.1 RP11-291L22.8 -8.78 4.72e-16 3.36e-09 -0.57 -0.51 Corneal astigmatism; chr4:119513249 chr10:38450738~38451069:- CESC trans rs116095464 0.558 rs6866632 ENSG00000185986.11 SDHAP3 8.78 4.74e-16 3.37e-09 0.88 0.51 Breast cancer; chr5:264314 chr5:1572222~1594620:- CESC trans rs11098499 0.58 rs12509234 ENSG00000275858.1 RP11-291L22.8 8.78 4.76e-16 3.38e-09 0.58 0.51 Corneal astigmatism; chr4:119398279 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs6835635 ENSG00000275858.1 RP11-291L22.8 8.78 4.84e-16 3.43e-09 0.58 0.51 Corneal astigmatism; chr4:119537712 chr10:38450738~38451069:- CESC trans rs2657294 1 rs2657294 ENSG00000172974.11 AC007318.5 8.78 4.95e-16 3.51e-09 0.5 0.51 Pneumonia; chr10:75193267 chr2:65205108~65205988:+ CESC trans rs11098499 0.909 rs10026736 ENSG00000275858.1 RP11-291L22.8 8.77 5.06e-16 3.58e-09 0.58 0.51 Corneal astigmatism; chr4:119463167 chr10:38450738~38451069:- CESC trans rs9467773 1 rs1321479 ENSG00000242375.1 RP11-498P14.3 -8.77 5.08e-16 3.59e-09 -0.59 -0.51 Intelligence (multi-trait analysis); chr6:26501669 chr9:97195351~97197687:- CESC trans rs7258465 1 rs34010330 ENSG00000267533.1 RP11-815J4.7 8.77 5.1e-16 3.61e-09 0.68 0.51 Breast cancer; chr19:18448847 chr18:12067173~12068417:- CESC trans rs11098499 0.954 rs12499324 ENSG00000275858.1 RP11-291L22.8 8.77 5.11e-16 3.61e-09 0.57 0.51 Corneal astigmatism; chr4:119472631 chr10:38450738~38451069:- CESC trans rs11098499 0.818 rs10008791 ENSG00000275858.1 RP11-291L22.8 8.77 5.17e-16 3.65e-09 0.59 0.51 Corneal astigmatism; chr4:119510314 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs11736416 ENSG00000275858.1 RP11-291L22.8 8.77 5.17e-16 3.65e-09 0.59 0.51 Corneal astigmatism; chr4:119510506 chr10:38450738~38451069:- CESC trans rs10940346 1 rs2883164 ENSG00000231752.4 EMBP1 8.77 5.2e-16 3.67e-09 0.62 0.51 Schizophrenia; chr5:50397624 chr1:121519112~121571892:+ CESC trans rs11098499 0.82 rs28394116 ENSG00000275858.1 RP11-291L22.8 8.77 5.26e-16 3.71e-09 0.57 0.51 Corneal astigmatism; chr4:119603128 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs3756156 ENSG00000275858.1 RP11-291L22.8 8.77 5.26e-16 3.71e-09 0.57 0.51 Corneal astigmatism; chr4:119603686 chr10:38450738~38451069:- CESC trans rs55665837 1 rs12804549 ENSG00000236360.2 RP11-334A14.2 8.76 5.46e-16 3.84e-09 0.64 0.51 Vitamin D levels; chr11:14416212 chr1:52993201~52993702:- CESC trans rs12709013 0.792 rs1473206 ENSG00000230849.2 GOT2P2 8.76 5.53e-16 3.89e-09 0.56 0.51 Blood metabolite ratios; chr16:58737529 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs1473205 ENSG00000230849.2 GOT2P2 8.76 5.53e-16 3.89e-09 0.56 0.51 Blood metabolite ratios; chr16:58737547 chr1:173141100~173142350:- CESC trans rs12709013 0.694 rs1616798 ENSG00000230849.2 GOT2P2 8.76 5.53e-16 3.89e-09 0.56 0.51 Blood metabolite ratios; chr16:58739433 chr1:173141100~173142350:- CESC trans rs8067354 0.872 rs2645483 ENSG00000187870.7 RNFT1P3 8.76 5.54e-16 3.9e-09 0.62 0.51 Hemoglobin concentration; chr17:59770823 chr17:20743333~20754501:- CESC trans rs11098499 0.863 rs1383533 ENSG00000275858.1 RP11-291L22.8 8.76 5.57e-16 3.91e-09 0.59 0.51 Corneal astigmatism; chr4:119513421 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs2291185 ENSG00000275858.1 RP11-291L22.8 8.76 5.57e-16 3.91e-09 0.59 0.51 Corneal astigmatism; chr4:119513678 chr10:38450738~38451069:- CESC trans rs2657294 0.965 rs2657286 ENSG00000172974.11 AC007318.5 -8.76 5.64e-16 3.97e-09 -0.49 -0.51 Pneumonia; chr10:75145940 chr2:65205108~65205988:+ CESC trans rs11098499 0.954 rs2389803 ENSG00000275858.1 RP11-291L22.8 -8.75 5.78e-16 4.05e-09 -0.57 -0.51 Corneal astigmatism; chr4:119472356 chr10:38450738~38451069:- CESC trans rs7258465 1 rs2303695 ENSG00000267533.1 RP11-815J4.7 8.75 5.78e-16 4.06e-09 0.65 0.51 Breast cancer; chr19:18451814 chr18:12067173~12068417:- CESC trans rs7811142 0.83 rs28495773 ENSG00000228546.2 CTA-313A17.3 8.75 5.92e-16 4.15e-09 0.87 0.51 Platelet count; chr7:100345960 chr7:102337316~102339115:+ CESC trans rs7258465 0.965 rs271628 ENSG00000267533.1 RP11-815J4.7 8.75 5.95e-16 4.16e-09 0.65 0.51 Breast cancer; chr19:18513523 chr18:12067173~12068417:- CESC trans rs7200543 1 rs3803575 ENSG00000250569.1 NTAN1P2 8.75 5.98e-16 4.18e-09 0.64 0.51 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15044590 chr8:86481754~86483002:- CESC trans rs13358908 0.595 rs4975942 ENSG00000231752.4 EMBP1 -8.75 6e-16 4.19e-09 -0.64 -0.51 Schizophrenia; chr5:46371833 chr1:121519112~121571892:+ CESC trans rs13358908 0.632 rs35088345 ENSG00000231752.4 EMBP1 -8.75 6e-16 4.19e-09 -0.64 -0.51 Schizophrenia; chr5:46372364 chr1:121519112~121571892:+ CESC trans rs13358908 0.712 rs28873151 ENSG00000231752.4 EMBP1 -8.75 6e-16 4.19e-09 -0.64 -0.51 Schizophrenia; chr5:46378558 chr1:121519112~121571892:+ CESC trans rs13358908 0.621 rs28847123 ENSG00000231752.4 EMBP1 -8.75 6e-16 4.19e-09 -0.64 -0.51 Schizophrenia; chr5:46378829 chr1:121519112~121571892:+ CESC trans rs13358908 0.593 rs28855077 ENSG00000231752.4 EMBP1 -8.75 6e-16 4.19e-09 -0.64 -0.51 Schizophrenia; chr5:46378855 chr1:121519112~121571892:+ CESC trans rs7258465 0.965 rs2561043 ENSG00000267533.1 RP11-815J4.7 8.74 6.29e-16 4.38e-09 0.65 0.51 Breast cancer; chr19:18511873 chr18:12067173~12068417:- CESC trans rs2657294 0.62 rs4746261 ENSG00000172974.11 AC007318.5 -8.74 6.48e-16 4.49e-09 -0.51 -0.51 Pneumonia; chr10:75085874 chr2:65205108~65205988:+ CESC trans rs7200543 1 rs4985124 ENSG00000250569.1 NTAN1P2 8.73 6.58e-16 4.55e-09 0.63 0.51 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15031584 chr8:86481754~86483002:- CESC trans rs11098499 0.863 rs3822192 ENSG00000275858.1 RP11-291L22.8 8.73 6.59e-16 4.56e-09 0.59 0.51 Corneal astigmatism; chr4:119524565 chr10:38450738~38451069:- CESC trans rs10242455 0.702 rs6977165 ENSG00000228834.1 RP11-249L21.4 8.73 6.6e-16 4.57e-09 1.3 0.51 Blood metabolite levels; chr7:99671774 chr6:108907615~108907873:- CESC trans rs12709013 0.729 rs1657179 ENSG00000233719.3 GOT2P3 8.73 6.62e-16 4.58e-09 0.54 0.51 Blood metabolite ratios; chr16:58735115 chr12:9641802~9643007:+ CESC trans rs7258465 0.931 rs271629 ENSG00000267533.1 RP11-815J4.7 8.73 6.71e-16 4.64e-09 0.65 0.51 Breast cancer; chr19:18512388 chr18:12067173~12068417:- CESC trans rs8067354 0.958 rs2777889 ENSG00000187870.7 RNFT1P3 8.73 6.82e-16 4.71e-09 0.62 0.51 Hemoglobin concentration; chr17:59770645 chr17:20743333~20754501:- CESC trans rs11098499 0.954 rs28685688 ENSG00000275858.1 RP11-291L22.8 8.73 6.83e-16 4.72e-09 0.58 0.51 Corneal astigmatism; chr4:119499179 chr10:38450738~38451069:- CESC trans rs13190036 1 rs13167431 ENSG00000217325.2 PRELID1P1 -8.73 6.86e-16 4.74e-09 -0.82 -0.51 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr6:126643488~126644390:+ CESC trans rs13190036 1 rs28580074 ENSG00000217325.2 PRELID1P1 8.73 6.94e-16 4.79e-09 0.83 0.51 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177294197 chr6:126643488~126644390:+ CESC trans rs10940346 0.967 rs62365887 ENSG00000231752.4 EMBP1 8.72 6.97e-16 4.81e-09 0.62 0.51 Schizophrenia; chr5:50408254 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs6450108 ENSG00000231752.4 EMBP1 8.72 6.98e-16 4.81e-09 0.62 0.51 Schizophrenia; chr5:50434427 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs28445612 ENSG00000231752.4 EMBP1 8.72 6.98e-16 4.81e-09 0.62 0.51 Schizophrenia; chr5:50439676 chr1:121519112~121571892:+ CESC trans rs2657294 0.965 rs4746270 ENSG00000172974.11 AC007318.5 8.72 6.98e-16 4.81e-09 0.49 0.51 Pneumonia; chr10:75185189 chr2:65205108~65205988:+ CESC trans rs10940346 0.967 rs13173678 ENSG00000231752.4 EMBP1 8.72 6.98e-16 4.82e-09 0.62 0.51 Schizophrenia; chr5:50422314 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs3775845 ENSG00000275858.1 RP11-291L22.8 8.72 6.99e-16 4.82e-09 0.59 0.51 Corneal astigmatism; chr4:119511292 chr10:38450738~38451069:- CESC trans rs7258465 1 rs28572537 ENSG00000267533.1 RP11-815J4.7 8.72 7.07e-16 4.87e-09 0.65 0.51 Breast cancer; chr19:18441398 chr18:12067173~12068417:- CESC trans rs7811142 0.943 rs67196635 ENSG00000228546.2 CTA-313A17.3 8.72 7.1e-16 4.89e-09 0.84 0.51 Platelet count; chr7:100427941 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs6962151 ENSG00000228546.2 CTA-313A17.3 8.72 7.1e-16 4.89e-09 0.84 0.51 Platelet count; chr7:100430861 chr7:102337316~102339115:+ CESC trans rs7811142 0.943 rs67483801 ENSG00000228546.2 CTA-313A17.3 8.72 7.1e-16 4.89e-09 0.84 0.51 Platelet count; chr7:100434135 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs11761784 ENSG00000228546.2 CTA-313A17.3 8.72 7.1e-16 4.89e-09 0.84 0.51 Platelet count; chr7:100442347 chr7:102337316~102339115:+ CESC trans rs10940346 0.875 rs13159506 ENSG00000231752.4 EMBP1 8.72 7.17e-16 4.94e-09 0.62 0.51 Schizophrenia; chr5:50415061 chr1:121519112~121571892:+ CESC trans rs11098499 0.618 rs28491261 ENSG00000275858.1 RP11-291L22.8 8.72 7.19e-16 4.94e-09 0.59 0.51 Corneal astigmatism; chr4:119373745 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs79026312 ENSG00000275858.1 RP11-291L22.8 8.72 7.38e-16 5.07e-09 0.58 0.51 Corneal astigmatism; chr4:119519522 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs35111518 ENSG00000275858.1 RP11-291L22.8 8.72 7.38e-16 5.07e-09 0.58 0.51 Corneal astigmatism; chr4:119519527 chr10:38450738~38451069:- CESC trans rs7258465 1 rs10164319 ENSG00000267533.1 RP11-815J4.7 8.71 7.43e-16 5.1e-09 0.64 0.51 Breast cancer; chr19:18459023 chr18:12067173~12068417:- CESC trans rs7258465 0.965 rs1560118 ENSG00000267533.1 RP11-815J4.7 8.71 7.43e-16 5.1e-09 0.64 0.51 Breast cancer; chr19:18459225 chr18:12067173~12068417:- CESC trans rs7258465 1 rs8107367 ENSG00000267533.1 RP11-815J4.7 8.71 7.49e-16 5.14e-09 0.65 0.51 Breast cancer; chr19:18453895 chr18:12067173~12068417:- CESC trans rs7258465 1 rs2007981 ENSG00000267533.1 RP11-815J4.7 8.71 7.49e-16 5.14e-09 0.65 0.51 Breast cancer; chr19:18456745 chr18:12067173~12068417:- CESC trans rs13190036 0.901 rs28563911 ENSG00000217325.2 PRELID1P1 8.71 7.63e-16 5.24e-09 0.82 0.51 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177287942 chr6:126643488~126644390:+ CESC trans rs116095464 0.558 rs7714335 ENSG00000185986.11 SDHAP3 8.71 7.64e-16 5.24e-09 0.87 0.51 Breast cancer; chr5:263398 chr5:1572222~1594620:- CESC trans rs7811142 1 rs28490152 ENSG00000228546.2 CTA-313A17.3 8.7 7.92e-16 5.41e-09 0.83 0.51 Platelet count; chr7:100423359 chr7:102337316~102339115:+ CESC trans rs916888 0.61 rs199529 ENSG00000214425.5 LRRC37A4P -8.7 7.96e-16 5.43e-09 -0.58 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45506741~45550335:- CESC trans rs7258465 1 rs2278238 ENSG00000267533.1 RP11-815J4.7 8.7 7.97e-16 5.44e-09 0.64 0.51 Breast cancer; chr19:18465674 chr18:12067173~12068417:- CESC trans rs7258465 1 rs10425982 ENSG00000267533.1 RP11-815J4.7 8.7 7.97e-16 5.44e-09 0.64 0.51 Breast cancer; chr19:18475709 chr18:12067173~12068417:- CESC trans rs11098499 0.865 rs11098513 ENSG00000275858.1 RP11-291L22.8 8.7 8.11e-16 5.53e-09 0.58 0.51 Corneal astigmatism; chr4:119394920 chr10:38450738~38451069:- CESC trans rs7258465 0.931 rs11673604 ENSG00000267533.1 RP11-815J4.7 8.7 8.13e-16 5.54e-09 0.64 0.51 Breast cancer; chr19:18430178 chr18:12067173~12068417:- CESC trans rs10940346 0.653 rs72768421 ENSG00000231752.4 EMBP1 -8.7 8.21e-16 5.59e-09 -0.62 -0.51 Schizophrenia; chr5:50246898 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs13140391 ENSG00000275858.1 RP11-291L22.8 8.7 8.23e-16 5.6e-09 0.59 0.51 Corneal astigmatism; chr4:119582282 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs13140409 ENSG00000275858.1 RP11-291L22.8 8.7 8.23e-16 5.6e-09 0.59 0.51 Corneal astigmatism; chr4:119582305 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs6833334 ENSG00000275858.1 RP11-291L22.8 8.7 8.23e-16 5.6e-09 0.59 0.51 Corneal astigmatism; chr4:119583072 chr10:38450738~38451069:- CESC trans rs13190036 0.901 rs55741473 ENSG00000217325.2 PRELID1P1 -8.69 8.57e-16 5.8e-09 -0.82 -0.51 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr6:126643488~126644390:+ CESC trans rs7258465 0.931 rs8107347 ENSG00000267533.1 RP11-815J4.7 8.69 8.62e-16 5.84e-09 0.66 0.51 Breast cancer; chr19:18501938 chr18:12067173~12068417:- CESC trans rs7258465 0.931 rs8107351 ENSG00000267533.1 RP11-815J4.7 8.69 8.62e-16 5.84e-09 0.66 0.51 Breast cancer; chr19:18501948 chr18:12067173~12068417:- CESC trans rs7811142 1 rs112317829 ENSG00000228546.2 CTA-313A17.3 8.69 8.63e-16 5.84e-09 0.84 0.51 Platelet count; chr7:100445550 chr7:102337316~102339115:+ CESC trans rs4276421 0.7 rs10070274 ENSG00000231752.4 EMBP1 8.69 8.78e-16 5.95e-09 0.64 0.51 P wave duration; chr5:46030675 chr1:121519112~121571892:+ CESC trans rs9611565 0.918 rs9611566 ENSG00000268568.1 AC007228.9 8.69 8.81e-16 5.96e-09 0.73 0.51 Vitiligo; chr22:41372621 chr19:56672574~56673901:- CESC trans rs7258465 1 rs8109573 ENSG00000267533.1 RP11-815J4.7 8.69 8.84e-16 5.98e-09 0.66 0.51 Breast cancer; chr19:18506341 chr18:12067173~12068417:- CESC trans rs9611565 0.802 rs132916 ENSG00000268568.1 AC007228.9 8.69 8.87e-16 6e-09 0.66 0.51 Vitiligo; chr22:41410764 chr19:56672574~56673901:- CESC trans rs10940346 1 rs4865674 ENSG00000231752.4 EMBP1 -8.69 8.88e-16 6.01e-09 -0.62 -0.51 Schizophrenia; chr5:50277531 chr1:121519112~121571892:+ CESC trans rs7258465 1 rs7252707 ENSG00000267533.1 RP11-815J4.7 8.68 9.15e-16 6.18e-09 0.67 0.51 Breast cancer; chr19:18501447 chr18:12067173~12068417:- CESC trans rs7554547 0.838 rs885770 ENSG00000261819.1 RP11-680G24.4 8.68 9.23e-16 6.23e-09 0.58 0.51 Nonsyndromic cleft lip with cleft palate; chr1:11878699 chr16:14988259~14990160:- CESC trans rs11098499 0.954 rs17005535 ENSG00000275858.1 RP11-291L22.8 8.68 9.51e-16 6.41e-09 0.57 0.51 Corneal astigmatism; chr4:119490407 chr10:38450738~38451069:- CESC trans rs7258465 0.931 rs34053595 ENSG00000267533.1 RP11-815J4.7 8.67 9.74e-16 6.55e-09 0.68 0.51 Breast cancer; chr19:18445939 chr18:12067173~12068417:- CESC trans rs11098499 0.863 rs10004484 ENSG00000275858.1 RP11-291L22.8 8.67 1.01e-15 6.8e-09 0.58 0.51 Corneal astigmatism; chr4:119521273 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs1155576 ENSG00000275858.1 RP11-291L22.8 8.67 1.01e-15 6.8e-09 0.58 0.51 Corneal astigmatism; chr4:119529004 chr10:38450738~38451069:- CESC trans rs7811142 1 rs4472444 ENSG00000228546.2 CTA-313A17.3 8.67 1.02e-15 6.85e-09 0.82 0.51 Platelet count; chr7:100473135 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs7809801 ENSG00000228546.2 CTA-313A17.3 8.67 1.02e-15 6.85e-09 0.82 0.51 Platelet count; chr7:100474408 chr7:102337316~102339115:+ CESC trans rs11098499 0.82 rs6829903 ENSG00000275858.1 RP11-291L22.8 8.66 1.04e-15 6.96e-09 0.58 0.51 Corneal astigmatism; chr4:119585729 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs11098527 ENSG00000275858.1 RP11-291L22.8 8.66 1.06e-15 7.1e-09 0.58 0.51 Corneal astigmatism; chr4:119478751 chr10:38450738~38451069:- CESC trans rs877636 0.692 rs11171739 ENSG00000225071.1 GS1-184P14.2 8.66 1.06e-15 7.1e-09 0.5 0.51 Cognitive function; chr12:56076841 chrX:24429573~24429920:- CESC trans rs4276421 0.688 rs10040808 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46123599 chr1:121519112~121571892:+ CESC trans rs4276421 0.684 rs8175395 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46125498 chr1:121519112~121571892:+ CESC trans rs4276421 0.716 rs13156708 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46128924 chr1:121519112~121571892:+ CESC trans rs4276421 0.744 rs13157345 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46129304 chr1:121519112~121571892:+ CESC trans rs4276421 0.805 rs7293302 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46131077 chr1:121519112~121571892:+ CESC trans rs4276421 0.657 rs13186103 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46131553 chr1:121519112~121571892:+ CESC trans rs4276421 0.652 rs8185226 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46160685 chr1:121519112~121571892:+ CESC trans rs4276421 0.656 rs8185376 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46165191 chr1:121519112~121571892:+ CESC trans rs4276421 0.625 rs61187820 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46199336 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs8188050 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46201372 chr1:121519112~121571892:+ CESC trans rs4276421 0.656 rs13188786 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46201856 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs10064792 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46202002 chr1:121519112~121571892:+ CESC trans rs4276421 0.597 rs10072776 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46202178 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs13168431 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46205598 chr1:121519112~121571892:+ CESC trans rs4276421 0.537 rs13166566 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46210486 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs8185185 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46214358 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs12697543 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.1e-09 0.63 0.51 P wave duration; chr5:46235824 chr1:121519112~121571892:+ CESC trans rs8067354 0.958 rs8081468 ENSG00000187870.7 RNFT1P3 8.66 1.06e-15 7.11e-09 0.62 0.51 Hemoglobin concentration; chr17:59759563 chr17:20743333~20754501:- CESC trans rs8067354 0.958 rs2333563 ENSG00000187870.7 RNFT1P3 8.66 1.06e-15 7.11e-09 0.62 0.51 Hemoglobin concentration; chr17:59762207 chr17:20743333~20754501:- CESC trans rs4276421 0.716 rs12656601 ENSG00000231752.4 EMBP1 8.66 1.06e-15 7.11e-09 0.63 0.51 P wave duration; chr5:46124483 chr1:121519112~121571892:+ CESC trans rs4276421 0.684 rs10072945 ENSG00000231752.4 EMBP1 8.66 1.07e-15 7.11e-09 0.63 0.51 P wave duration; chr5:46151307 chr1:121519112~121571892:+ CESC trans rs4276421 0.716 rs13155082 ENSG00000231752.4 EMBP1 8.66 1.07e-15 7.11e-09 0.63 0.51 P wave duration; chr5:46155135 chr1:121519112~121571892:+ CESC trans rs4276421 0.656 rs11960110 ENSG00000231752.4 EMBP1 8.66 1.07e-15 7.11e-09 0.63 0.51 P wave duration; chr5:46210055 chr1:121519112~121571892:+ CESC trans rs4276421 0.656 rs13172097 ENSG00000231752.4 EMBP1 8.66 1.07e-15 7.11e-09 0.63 0.51 P wave duration; chr5:46211694 chr1:121519112~121571892:+ CESC trans rs4276421 0.656 rs7293337 ENSG00000231752.4 EMBP1 8.66 1.07e-15 7.13e-09 0.63 0.51 P wave duration; chr5:46203395 chr1:121519112~121571892:+ CESC trans rs877636 0.692 rs11171739 ENSG00000235459.5 RPS26P31 8.66 1.08e-15 7.23e-09 0.51 0.51 Cognitive function; chr12:56076841 chr7:122681315~122681662:+ CESC trans rs11098499 0.863 rs10030660 ENSG00000275858.1 RP11-291L22.8 8.66 1.09e-15 7.29e-09 0.59 0.51 Corneal astigmatism; chr4:119515549 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs13149407 ENSG00000275858.1 RP11-291L22.8 8.66 1.09e-15 7.29e-09 0.59 0.51 Corneal astigmatism; chr4:119516670 chr10:38450738~38451069:- CESC trans rs12709013 0.635 rs6993 ENSG00000233719.3 GOT2P3 8.66 1.1e-15 7.31e-09 0.57 0.51 Blood metabolite ratios; chr16:58707463 chr12:9641802~9643007:+ CESC trans rs11098499 0.863 rs7664986 ENSG00000275858.1 RP11-291L22.8 8.66 1.1e-15 7.31e-09 0.59 0.51 Corneal astigmatism; chr4:119508797 chr10:38450738~38451069:- CESC trans rs11098499 0.697 rs28655325 ENSG00000275858.1 RP11-291L22.8 8.65 1.11e-15 7.41e-09 0.57 0.51 Corneal astigmatism; chr4:119451844 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3775843 ENSG00000275858.1 RP11-291L22.8 8.65 1.13e-15 7.49e-09 0.59 0.51 Corneal astigmatism; chr4:119506689 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3775844 ENSG00000275858.1 RP11-291L22.8 8.65 1.13e-15 7.49e-09 0.59 0.51 Corneal astigmatism; chr4:119506878 chr10:38450738~38451069:- CESC trans rs4276421 0.657 rs8188010 ENSG00000231752.4 EMBP1 8.65 1.13e-15 7.51e-09 0.64 0.51 P wave duration; chr5:46194057 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs1849200 ENSG00000231752.4 EMBP1 8.65 1.15e-15 7.61e-09 0.62 0.51 Schizophrenia; chr5:50448053 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs6899048 ENSG00000231752.4 EMBP1 8.65 1.15e-15 7.61e-09 0.62 0.51 Schizophrenia; chr5:50451256 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs2353437 ENSG00000231752.4 EMBP1 8.65 1.15e-15 7.61e-09 0.62 0.51 Schizophrenia; chr5:50452078 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs2102454 ENSG00000231752.4 EMBP1 8.65 1.15e-15 7.61e-09 0.62 0.51 Schizophrenia; chr5:50452446 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs10074196 ENSG00000231752.4 EMBP1 8.65 1.15e-15 7.61e-09 0.62 0.51 Schizophrenia; chr5:50464713 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs13186891 ENSG00000231752.4 EMBP1 8.65 1.15e-15 7.61e-09 0.62 0.51 Schizophrenia; chr5:50467244 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs7380816 ENSG00000231752.4 EMBP1 -8.65 1.15e-15 7.61e-09 -0.62 -0.51 Schizophrenia; chr5:50472059 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs6450134 ENSG00000231752.4 EMBP1 -8.65 1.15e-15 7.61e-09 -0.62 -0.51 Schizophrenia; chr5:50471121 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs2353436 ENSG00000231752.4 EMBP1 8.65 1.15e-15 7.61e-09 0.62 0.51 Schizophrenia; chr5:50445695 chr1:121519112~121571892:+ CESC trans rs7811142 0.943 rs28578163 ENSG00000228546.2 CTA-313A17.3 8.65 1.16e-15 7.73e-09 0.83 0.51 Platelet count; chr7:100447131 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs67239991 ENSG00000228546.2 CTA-313A17.3 8.65 1.16e-15 7.73e-09 0.83 0.51 Platelet count; chr7:100448881 chr7:102337316~102339115:+ CESC trans rs10940346 0.967 rs13154223 ENSG00000231752.4 EMBP1 8.65 1.17e-15 7.74e-09 0.61 0.51 Schizophrenia; chr5:50403152 chr1:121519112~121571892:+ CESC trans rs7937890 0.904 rs11023169 ENSG00000236360.2 RP11-334A14.2 -8.64 1.22e-15 8.1e-09 -0.59 -0.5 Mitochondrial DNA levels; chr11:14269439 chr1:52993201~52993702:- CESC trans rs11098499 0.865 rs9994730 ENSG00000275858.1 RP11-291L22.8 8.64 1.23e-15 8.13e-09 0.58 0.5 Corneal astigmatism; chr4:119460409 chr10:38450738~38451069:- CESC trans rs7811142 0.943 rs111493473 ENSG00000228546.2 CTA-313A17.3 8.64 1.23e-15 8.16e-09 0.83 0.5 Platelet count; chr7:100452119 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs11766752 ENSG00000228546.2 CTA-313A17.3 8.64 1.23e-15 8.16e-09 0.83 0.5 Platelet count; chr7:100475669 chr7:102337316~102339115:+ CESC trans rs4276421 0.688 rs10061101 ENSG00000231752.4 EMBP1 8.64 1.24e-15 8.19e-09 0.63 0.5 P wave duration; chr5:46217831 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs8188054 ENSG00000231752.4 EMBP1 8.64 1.24e-15 8.21e-09 0.63 0.5 P wave duration; chr5:46215556 chr1:121519112~121571892:+ CESC trans rs4276421 0.777 rs8185098 ENSG00000231752.4 EMBP1 8.63 1.27e-15 8.36e-09 0.62 0.5 P wave duration; chr5:46125388 chr1:121519112~121571892:+ CESC trans rs7258465 0.931 rs1560119 ENSG00000267533.1 RP11-815J4.7 8.63 1.27e-15 8.38e-09 0.65 0.5 Breast cancer; chr19:18462865 chr18:12067173~12068417:- CESC trans rs7258465 0.965 rs7256534 ENSG00000267533.1 RP11-815J4.7 8.63 1.27e-15 8.38e-09 0.65 0.5 Breast cancer; chr19:18475981 chr18:12067173~12068417:- CESC trans rs7811142 0.83 rs78256546 ENSG00000228546.2 CTA-313A17.3 8.63 1.28e-15 8.45e-09 0.86 0.5 Platelet count; chr7:100355347 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs41280971 ENSG00000228546.2 CTA-313A17.3 8.63 1.28e-15 8.45e-09 0.86 0.5 Platelet count; chr7:100356834 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs3087502 ENSG00000228546.2 CTA-313A17.3 8.63 1.28e-15 8.45e-09 0.86 0.5 Platelet count; chr7:100357741 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs61735533 ENSG00000228546.2 CTA-313A17.3 8.63 1.28e-15 8.45e-09 0.86 0.5 Platelet count; chr7:100358243 chr7:102337316~102339115:+ CESC trans rs7811142 0.83 rs11761426 ENSG00000228546.2 CTA-313A17.3 8.63 1.28e-15 8.45e-09 0.86 0.5 Platelet count; chr7:100359270 chr7:102337316~102339115:+ CESC trans rs11098499 0.954 rs3733520 ENSG00000275858.1 RP11-291L22.8 8.63 1.29e-15 8.49e-09 0.57 0.5 Corneal astigmatism; chr4:119502325 chr10:38450738~38451069:- CESC trans rs7121616 0.774 rs74693612 ENSG00000234176.1 HSPA8P1 8.63 1.29e-15 8.52e-09 0.65 0.5 Breast cancer; chr11:123092310 chrX:121203182~121205014:- CESC trans rs13190036 0.901 rs4631 ENSG00000217325.2 PRELID1P1 8.63 1.31e-15 8.61e-09 0.85 0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177306115 chr6:126643488~126644390:+ CESC trans rs4276421 0.745 rs10079238 ENSG00000231752.4 EMBP1 -8.63 1.32e-15 8.67e-09 -0.62 -0.5 P wave duration; chr5:46066531 chr1:121519112~121571892:+ CESC trans rs7258465 1 rs4808136 ENSG00000267533.1 RP11-815J4.7 -8.63 1.32e-15 8.69e-09 -0.66 -0.5 Breast cancer; chr19:18508057 chr18:12067173~12068417:- CESC trans rs11098499 0.954 rs11098526 ENSG00000275858.1 RP11-291L22.8 8.63 1.33e-15 8.72e-09 0.57 0.5 Corneal astigmatism; chr4:119469204 chr10:38450738~38451069:- CESC trans rs13358908 0.631 rs6882540 ENSG00000231752.4 EMBP1 -8.62 1.37e-15 8.99e-09 -0.63 -0.5 Schizophrenia; chr5:46345971 chr1:121519112~121571892:+ CESC trans rs1707322 0.721 rs10430124 ENSG00000255397.1 AC022182.2 -8.61 1.44e-15 9.45e-09 -0.65 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755945 chr8:60937705~60939871:- CESC trans rs7937890 1 rs2970334 ENSG00000236360.2 RP11-334A14.2 -8.61 1.45e-15 9.47e-09 -0.6 -0.5 Mitochondrial DNA levels; chr11:14307809 chr1:52993201~52993702:- CESC trans rs10940346 1 rs13360100 ENSG00000231752.4 EMBP1 -8.61 1.45e-15 9.51e-09 -0.62 -0.5 Schizophrenia; chr5:50323389 chr1:121519112~121571892:+ CESC trans rs10940346 0.967 rs2271236 ENSG00000231752.4 EMBP1 8.61 1.47e-15 9.64e-09 0.61 0.5 Schizophrenia; chr5:50405921 chr1:121519112~121571892:+ CESC trans rs1816752 0.603 rs9511278 ENSG00000237917.1 PARP4P1 -8.61 1.48e-15 9.66e-09 -0.62 -0.5 Obesity-related traits; chr13:24455766 chrY:26594851~26634652:- CESC trans rs9611565 0.57 rs12159188 ENSG00000268568.1 AC007228.9 8.61 1.49e-15 9.74e-09 0.7 0.5 Vitiligo; chr22:41725121 chr19:56672574~56673901:- CESC trans rs10940346 0.846 rs8188203 ENSG00000231752.4 EMBP1 -8.61 1.49e-15 9.74e-09 -0.62 -0.5 Schizophrenia; chr5:50161448 chr1:121519112~121571892:+ CESC trans rs10940346 0.905 rs10053631 ENSG00000231752.4 EMBP1 -8.61 1.49e-15 9.74e-09 -0.62 -0.5 Schizophrenia; chr5:50164086 chr1:121519112~121571892:+ CESC trans rs10940346 0.728 rs10053639 ENSG00000231752.4 EMBP1 -8.61 1.49e-15 9.74e-09 -0.62 -0.5 Schizophrenia; chr5:50164113 chr1:121519112~121571892:+ CESC trans rs12709013 0.66 rs30839 ENSG00000233719.3 GOT2P3 8.61 1.5e-15 9.82e-09 0.56 0.5 Blood metabolite ratios; chr16:58711437 chr12:9641802~9643007:+ CESC trans rs11098499 0.863 rs13134665 ENSG00000275858.1 RP11-291L22.8 8.61 1.51e-15 9.83e-09 0.59 0.5 Corneal astigmatism; chr4:119505275 chr10:38450738~38451069:- CESC trans rs12709013 0.635 rs6993 ENSG00000230849.2 GOT2P2 8.61 1.52e-15 9.9e-09 0.6 0.5 Blood metabolite ratios; chr16:58707463 chr1:173141100~173142350:- CESC trans rs55665837 1 rs10766182 ENSG00000236360.2 RP11-334A14.2 8.6 1.53e-15 9.95e-09 0.65 0.5 Vitamin D levels; chr11:14477990 chr1:52993201~52993702:- CESC trans rs55665837 1 rs12364959 ENSG00000236360.2 RP11-334A14.2 8.6 1.53e-15 9.95e-09 0.65 0.5 Vitamin D levels; chr11:14485889 chr1:52993201~52993702:- CESC trans rs7258465 1 rs4808804 ENSG00000267533.1 RP11-815J4.7 8.6 1.53e-15 9.99e-09 0.64 0.5 Breast cancer; chr19:18474515 chr18:12067173~12068417:- CESC trans rs7937890 0.967 rs963212 ENSG00000236360.2 RP11-334A14.2 -8.6 1.56e-15 1.01e-08 -0.59 -0.5 Mitochondrial DNA levels; chr11:14303186 chr1:52993201~52993702:- CESC trans rs1707322 0.686 rs1547924 ENSG00000255397.1 AC022182.2 -8.6 1.57e-15 1.02e-08 -0.65 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619440 chr8:60937705~60939871:- CESC trans rs11098499 0.866 rs11098506 ENSG00000275858.1 RP11-291L22.8 8.6 1.58e-15 1.03e-08 0.58 0.5 Corneal astigmatism; chr4:119363816 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs6857105 ENSG00000275858.1 RP11-291L22.8 8.6 1.58e-15 1.03e-08 0.57 0.5 Corneal astigmatism; chr4:119301143 chr10:38450738~38451069:- CESC trans rs7258465 0.896 rs8103660 ENSG00000267533.1 RP11-815J4.7 8.6 1.61e-15 1.05e-08 0.64 0.5 Breast cancer; chr19:18455585 chr18:12067173~12068417:- CESC trans rs867371 1 rs11855089 ENSG00000235370.6 DNM1P51 -8.6 1.61e-15 1.05e-08 -0.64 -0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82154924 chr15:84398316~84411701:- CESC trans rs55665837 1 rs34980103 ENSG00000236360.2 RP11-334A14.2 8.6 1.62e-15 1.05e-08 0.65 0.5 Vitamin D levels; chr11:14491339 chr1:52993201~52993702:- CESC trans rs11098499 0.954 rs1480931 ENSG00000275858.1 RP11-291L22.8 8.59 1.62e-15 1.06e-08 0.56 0.5 Corneal astigmatism; chr4:119474654 chr10:38450738~38451069:- CESC trans rs13253073 0.544 rs10955223 ENSG00000260318.1 COX6CP1 8.59 1.63e-15 1.06e-08 0.97 0.5 Glucose homeostasis traits; chr8:99903454 chr16:11903923~11904137:- CESC trans rs7258465 1 rs10442 ENSG00000267533.1 RP11-815J4.7 8.59 1.68e-15 1.09e-08 0.64 0.5 Breast cancer; chr19:18434531 chr18:12067173~12068417:- CESC trans rs7258465 1 rs2303697 ENSG00000267533.1 RP11-815J4.7 8.59 1.68e-15 1.09e-08 0.64 0.5 Breast cancer; chr19:18435868 chr18:12067173~12068417:- CESC trans rs7258465 1 rs4595905 ENSG00000267533.1 RP11-815J4.7 8.59 1.68e-15 1.09e-08 0.64 0.5 Breast cancer; chr19:18436495 chr18:12067173~12068417:- CESC trans rs11098499 0.863 rs3775841 ENSG00000275858.1 RP11-291L22.8 8.59 1.7e-15 1.11e-08 0.58 0.5 Corneal astigmatism; chr4:119504622 chr10:38450738~38451069:- CESC trans rs10242455 0.571 rs13438288 ENSG00000228834.1 RP11-249L21.4 8.59 1.73e-15 1.12e-08 1.29 0.5 Blood metabolite levels; chr7:99318791 chr6:108907615~108907873:- CESC trans rs11098499 0.865 rs28634456 ENSG00000275858.1 RP11-291L22.8 8.58 1.75e-15 1.14e-08 0.56 0.5 Corneal astigmatism; chr4:119454623 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs78332141 ENSG00000275858.1 RP11-291L22.8 8.58 1.75e-15 1.14e-08 0.56 0.5 Corneal astigmatism; chr4:119454627 chr10:38450738~38451069:- CESC trans rs11098499 0.866 rs12501602 ENSG00000275858.1 RP11-291L22.8 8.58 1.81e-15 1.17e-08 0.57 0.5 Corneal astigmatism; chr4:119366780 chr10:38450738~38451069:- CESC trans rs7258465 1 rs10413237 ENSG00000267533.1 RP11-815J4.7 8.58 1.81e-15 1.17e-08 0.64 0.5 Breast cancer; chr19:18437439 chr18:12067173~12068417:- CESC trans rs11098499 0.779 rs7699346 ENSG00000275858.1 RP11-291L22.8 8.57 1.87e-15 1.21e-08 0.58 0.5 Corneal astigmatism; chr4:119389387 chr10:38450738~38451069:- CESC trans rs13190036 1 rs13185316 ENSG00000217325.2 PRELID1P1 -8.57 1.93e-15 1.25e-08 -0.79 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177213339 chr6:126643488~126644390:+ CESC trans rs6477998 0.702 rs7861707 ENSG00000238072.1 RP11-305M3.2 8.57 1.94e-15 1.25e-08 0.68 0.5 Hematology traits; chr9:113251428 chr7:129410113~129410370:- CESC trans rs10940346 0.875 rs13172257 ENSG00000231752.4 EMBP1 8.57 1.94e-15 1.25e-08 0.61 0.5 Schizophrenia; chr5:50462916 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs13136462 ENSG00000275858.1 RP11-291L22.8 8.57 1.94e-15 1.26e-08 0.56 0.5 Corneal astigmatism; chr4:119622018 chr10:38450738~38451069:- CESC trans rs2657294 0.931 rs2804522 ENSG00000172974.11 AC007318.5 8.57 1.94e-15 1.26e-08 0.48 0.5 Pneumonia; chr10:75159132 chr2:65205108~65205988:+ CESC trans rs7811142 0.943 rs28660238 ENSG00000228546.2 CTA-313A17.3 8.56 1.97e-15 1.27e-08 0.81 0.5 Platelet count; chr7:100425685 chr7:102337316~102339115:+ CESC trans rs11098499 0.863 rs3822190 ENSG00000275858.1 RP11-291L22.8 8.56 1.99e-15 1.29e-08 0.58 0.5 Corneal astigmatism; chr4:119506943 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3822191 ENSG00000275858.1 RP11-291L22.8 8.56 1.99e-15 1.29e-08 0.58 0.5 Corneal astigmatism; chr4:119506946 chr10:38450738~38451069:- CESC trans rs13358908 0.715 rs12522625 ENSG00000231752.4 EMBP1 -8.56 2.01e-15 1.3e-08 -0.63 -0.5 Schizophrenia; chr5:46389266 chr1:121519112~121571892:+ CESC trans rs13358908 0.712 rs10941823 ENSG00000231752.4 EMBP1 -8.56 2.01e-15 1.3e-08 -0.63 -0.5 Schizophrenia; chr5:46389481 chr1:121519112~121571892:+ CESC trans rs13358908 0.622 rs12652607 ENSG00000231752.4 EMBP1 -8.56 2.01e-15 1.3e-08 -0.63 -0.5 Schizophrenia; chr5:46392338 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs10019674 ENSG00000275858.1 RP11-291L22.8 -8.56 2.07e-15 1.33e-08 -0.56 -0.5 Corneal astigmatism; chr4:119522334 chr10:38450738~38451069:- CESC trans rs867371 1 rs9944197 ENSG00000235370.6 DNM1P51 -8.56 2.08e-15 1.34e-08 -0.64 -0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82158261 chr15:84398316~84411701:- CESC trans rs55665837 0.961 rs11023237 ENSG00000236360.2 RP11-334A14.2 8.56 2.08e-15 1.34e-08 0.64 0.5 Vitamin D levels; chr11:14478788 chr1:52993201~52993702:- CESC trans rs55665837 1 rs10466412 ENSG00000236360.2 RP11-334A14.2 8.56 2.08e-15 1.34e-08 0.64 0.5 Vitamin D levels; chr11:14483643 chr1:52993201~52993702:- CESC trans rs7811142 0.775 rs1636980 ENSG00000228546.2 CTA-313A17.3 -8.56 2.1e-15 1.35e-08 -0.82 -0.5 Platelet count; chr7:100341241 chr7:102337316~102339115:+ CESC trans rs55665837 1 rs10832278 ENSG00000236360.2 RP11-334A14.2 8.56 2.1e-15 1.35e-08 0.65 0.5 Vitamin D levels; chr11:14475073 chr1:52993201~52993702:- CESC trans rs867371 1 rs7181655 ENSG00000235370.6 DNM1P51 -8.55 2.12e-15 1.37e-08 -0.66 -0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163275 chr15:84398316~84411701:- CESC trans rs867371 1 rs7180584 ENSG00000235370.6 DNM1P51 -8.55 2.12e-15 1.37e-08 -0.66 -0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163493 chr15:84398316~84411701:- CESC trans rs4276421 0.656 rs10064681 ENSG00000231752.4 EMBP1 8.55 2.14e-15 1.37e-08 0.62 0.5 P wave duration; chr5:46222829 chr1:121519112~121571892:+ CESC trans rs4276421 0.623 rs12109835 ENSG00000231752.4 EMBP1 8.55 2.14e-15 1.37e-08 0.62 0.5 P wave duration; chr5:46222967 chr1:121519112~121571892:+ CESC trans rs1707322 0.721 rs10789468 ENSG00000255397.1 AC022182.2 -8.55 2.16e-15 1.39e-08 -0.64 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658886 chr8:60937705~60939871:- CESC trans rs6477998 0.58 rs10817467 ENSG00000238072.1 RP11-305M3.2 8.55 2.17e-15 1.39e-08 0.79 0.5 Hematology traits; chr9:113246803 chr7:129410113~129410370:- CESC trans rs11098499 0.866 rs72676074 ENSG00000275858.1 RP11-291L22.8 8.55 2.18e-15 1.4e-08 0.56 0.5 Corneal astigmatism; chr4:119438686 chr10:38450738~38451069:- CESC trans rs867371 0.892 rs4344697 ENSG00000235370.6 DNM1P51 -8.55 2.19e-15 1.41e-08 -0.67 -0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82252873 chr15:84398316~84411701:- CESC trans rs10940346 1 rs12514818 ENSG00000231752.4 EMBP1 -8.55 2.24e-15 1.43e-08 -0.62 -0.5 Schizophrenia; chr5:50349925 chr1:121519112~121571892:+ CESC trans rs10242455 0.571 rs73713595 ENSG00000228834.1 RP11-249L21.4 8.54 2.33e-15 1.49e-08 1.13 0.5 Blood metabolite levels; chr7:99729036 chr6:108907615~108907873:- CESC trans rs7554511 0.894 rs404339 ENSG00000244144.1 RP11-757F18.3 -8.54 2.36e-15 1.51e-08 -0.54 -0.5 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200917763 chr3:112185480~112185998:- CESC trans rs7811142 1 rs11771419 ENSG00000228546.2 CTA-313A17.3 8.54 2.36e-15 1.51e-08 0.86 0.5 Platelet count; chr7:100390780 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs11771241 ENSG00000228546.2 CTA-313A17.3 8.54 2.36e-15 1.51e-08 0.86 0.5 Platelet count; chr7:100397162 chr7:102337316~102339115:+ CESC trans rs7811142 0.943 rs10241492 ENSG00000228546.2 CTA-313A17.3 8.54 2.36e-15 1.51e-08 0.86 0.5 Platelet count; chr7:100397190 chr7:102337316~102339115:+ CESC trans rs55665837 1 rs2305306 ENSG00000236360.2 RP11-334A14.2 8.54 2.38e-15 1.52e-08 0.66 0.5 Vitamin D levels; chr11:14513453 chr1:52993201~52993702:- CESC trans rs867371 1 rs1392976 ENSG00000235370.6 DNM1P51 8.53 2.42e-15 1.54e-08 0.64 0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82153834 chr15:84398316~84411701:- CESC trans rs4276421 0.935 rs35163964 ENSG00000231752.4 EMBP1 8.53 2.42e-15 1.55e-08 0.61 0.5 P wave duration; chr5:45904860 chr1:121519112~121571892:+ CESC trans rs4276421 0.684 rs8185217 ENSG00000231752.4 EMBP1 8.53 2.43e-15 1.55e-08 0.62 0.5 P wave duration; chr5:46169215 chr1:121519112~121571892:+ CESC trans rs7258465 1 rs3810429 ENSG00000267533.1 RP11-815J4.7 8.53 2.43e-15 1.55e-08 0.64 0.5 Breast cancer; chr19:18432460 chr18:12067173~12068417:- CESC trans rs116095464 0.558 rs6879656 ENSG00000185986.11 SDHAP3 8.53 2.44e-15 1.56e-08 0.87 0.5 Breast cancer; chr5:264313 chr5:1572222~1594620:- CESC trans rs7121616 1 rs7113273 ENSG00000234176.1 HSPA8P1 -8.53 2.46e-15 1.57e-08 -0.65 -0.5 Breast cancer; chr11:123092192 chrX:121203182~121205014:- CESC trans rs1707322 0.721 rs6429574 ENSG00000255397.1 AC022182.2 -8.53 2.49e-15 1.59e-08 -0.64 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668382 chr8:60937705~60939871:- CESC trans rs9611565 0.918 rs4822024 ENSG00000268568.1 AC007228.9 -8.53 2.53e-15 1.61e-08 -0.71 -0.5 Vitiligo; chr22:41361643 chr19:56672574~56673901:- CESC trans rs12709013 0.636 rs30835 ENSG00000233719.3 GOT2P3 8.52 2.63e-15 1.67e-08 0.54 0.5 Blood metabolite ratios; chr16:58714117 chr12:9641802~9643007:+ CESC trans rs11098499 0.863 rs1480936 ENSG00000275858.1 RP11-291L22.8 8.52 2.65e-15 1.68e-08 0.57 0.5 Corneal astigmatism; chr4:119541706 chr10:38450738~38451069:- CESC trans rs7811142 1 rs11763511 ENSG00000228546.2 CTA-313A17.3 8.52 2.67e-15 1.7e-08 0.82 0.5 Platelet count; chr7:100484321 chr7:102337316~102339115:+ CESC trans rs7258465 1 rs7252848 ENSG00000267533.1 RP11-815J4.7 8.52 2.71e-15 1.72e-08 0.65 0.5 Breast cancer; chr19:18501541 chr18:12067173~12068417:- CESC trans rs4276421 0.904 rs4489075 ENSG00000231752.4 EMBP1 8.51 2.78e-15 1.76e-08 0.61 0.5 P wave duration; chr5:46018903 chr1:121519112~121571892:+ CESC trans rs4276421 0.659 rs8188026 ENSG00000231752.4 EMBP1 8.51 2.78e-15 1.76e-08 0.61 0.5 P wave duration; chr5:46053462 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs35535623 ENSG00000217325.2 PRELID1P1 -8.51 2.79e-15 1.77e-08 -0.79 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr6:126643488~126644390:+ CESC trans rs13190036 1 rs71601343 ENSG00000217325.2 PRELID1P1 -8.51 2.79e-15 1.77e-08 -0.79 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr6:126643488~126644390:+ CESC trans rs13190036 1 rs71601344 ENSG00000217325.2 PRELID1P1 -8.51 2.79e-15 1.77e-08 -0.79 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr6:126643488~126644390:+ CESC trans rs13190036 1 rs3733875 ENSG00000217325.2 PRELID1P1 -8.51 2.79e-15 1.77e-08 -0.79 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr6:126643488~126644390:+ CESC trans rs11098499 0.863 rs7678400 ENSG00000275858.1 RP11-291L22.8 8.51 2.8e-15 1.77e-08 0.57 0.5 Corneal astigmatism; chr4:119540802 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs6858592 ENSG00000275858.1 RP11-291L22.8 8.51 2.81e-15 1.78e-08 0.57 0.5 Corneal astigmatism; chr4:119537537 chr10:38450738~38451069:- CESC trans rs7200543 1 rs6498541 ENSG00000250569.1 NTAN1P2 8.51 2.84e-15 1.8e-08 0.63 0.5 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15046800 chr8:86481754~86483002:- CESC trans rs7258465 1 rs76194 ENSG00000267533.1 RP11-815J4.7 8.51 2.86e-15 1.81e-08 0.64 0.5 Breast cancer; chr19:18519770 chr18:12067173~12068417:- CESC trans rs7258465 1 rs271621 ENSG00000267533.1 RP11-815J4.7 8.51 2.86e-15 1.81e-08 0.64 0.5 Breast cancer; chr19:18520522 chr18:12067173~12068417:- CESC trans rs1707322 0.717 rs3014237 ENSG00000255397.1 AC022182.2 8.5 2.94e-15 1.86e-08 0.66 0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624580 chr8:60937705~60939871:- CESC trans rs10940346 0.557 rs2168922 ENSG00000231752.4 EMBP1 -8.5 3.04e-15 1.92e-08 -0.61 -0.5 Schizophrenia; chr5:50151950 chr1:121519112~121571892:+ CESC trans rs11098499 0.909 rs71614422 ENSG00000275858.1 RP11-291L22.8 8.5 3.07e-15 1.93e-08 0.56 0.5 Corneal astigmatism; chr4:119438185 chr10:38450738~38451069:- CESC trans rs4276421 0.904 rs4569880 ENSG00000231752.4 EMBP1 8.5 3.07e-15 1.94e-08 0.61 0.5 P wave duration; chr5:46011373 chr1:121519112~121571892:+ CESC trans rs4276421 0.874 rs4569881 ENSG00000231752.4 EMBP1 8.5 3.07e-15 1.94e-08 0.61 0.5 P wave duration; chr5:46011667 chr1:121519112~121571892:+ CESC trans rs4276421 0.816 rs13362078 ENSG00000231752.4 EMBP1 8.5 3.07e-15 1.94e-08 0.61 0.5 P wave duration; chr5:46013351 chr1:121519112~121571892:+ CESC trans rs7811142 1 rs2406253 ENSG00000228546.2 CTA-313A17.3 8.49 3.25e-15 2.05e-08 0.82 0.5 Platelet count; chr7:100479650 chr7:102337316~102339115:+ CESC trans rs867371 1 rs13380317 ENSG00000235370.6 DNM1P51 8.49 3.25e-15 2.05e-08 0.63 0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214449 chr15:84398316~84411701:- CESC trans rs10242455 0.702 rs59574285 ENSG00000228834.1 RP11-249L21.4 8.48 3.33e-15 2.09e-08 1.3 0.5 Blood metabolite levels; chr7:99638528 chr6:108907615~108907873:- CESC trans rs11098499 0.863 rs1552095 ENSG00000275858.1 RP11-291L22.8 8.48 3.34e-15 2.1e-08 0.59 0.5 Corneal astigmatism; chr4:119539151 chr10:38450738~38451069:- CESC trans rs4276421 0.623 rs8188231 ENSG00000231752.4 EMBP1 8.48 3.37e-15 2.12e-08 0.63 0.5 P wave duration; chr5:46186924 chr1:121519112~121571892:+ CESC trans rs4276421 0.684 rs8188258 ENSG00000231752.4 EMBP1 8.48 3.37e-15 2.12e-08 0.63 0.5 P wave duration; chr5:46187284 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs10065920 ENSG00000231752.4 EMBP1 8.48 3.37e-15 2.12e-08 0.63 0.5 P wave duration; chr5:46190593 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs8188292 ENSG00000231752.4 EMBP1 8.48 3.37e-15 2.12e-08 0.63 0.5 P wave duration; chr5:46191402 chr1:121519112~121571892:+ CESC trans rs4276421 0.657 rs8175415 ENSG00000231752.4 EMBP1 8.48 3.37e-15 2.12e-08 0.63 0.5 P wave duration; chr5:46193360 chr1:121519112~121571892:+ CESC trans rs4276421 0.633 rs62370770 ENSG00000231752.4 EMBP1 8.48 3.37e-15 2.12e-08 0.63 0.5 P wave duration; chr5:46195784 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs13157667 ENSG00000217325.2 PRELID1P1 -8.48 3.42e-15 2.15e-08 -0.82 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr6:126643488~126644390:+ CESC trans rs11098499 0.954 rs13145352 ENSG00000275858.1 RP11-291L22.8 -8.48 3.44e-15 2.16e-08 -0.59 -0.5 Corneal astigmatism; chr4:119488808 chr10:38450738~38451069:- CESC trans rs5877 0.568 rs1951627 ENSG00000213331.4 RP11-713C19.2 8.48 3.46e-15 2.17e-08 0.62 0.5 Subjective well-being (multi-trait analysis); chr1:173922679 chr4:187970273~187971284:+ CESC trans rs7811142 1 rs76913697 ENSG00000228546.2 CTA-313A17.3 8.48 3.46e-15 2.17e-08 0.84 0.5 Platelet count; chr7:100405149 chr7:102337316~102339115:+ CESC trans rs867371 1 rs1174543 ENSG00000235370.6 DNM1P51 8.48 3.47e-15 2.18e-08 0.64 0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82155732 chr15:84398316~84411701:- CESC trans rs9611565 0.729 rs203319 ENSG00000268568.1 AC007228.9 -8.48 3.51e-15 2.2e-08 -0.62 -0.5 Vitiligo; chr22:41518589 chr19:56672574~56673901:- CESC trans rs11098499 0.909 rs73842633 ENSG00000275858.1 RP11-291L22.8 8.48 3.52e-15 2.2e-08 0.59 0.5 Corneal astigmatism; chr4:119454309 chr10:38450738~38451069:- CESC trans rs13190036 0.901 rs28684504 ENSG00000217325.2 PRELID1P1 8.47 3.56e-15 2.23e-08 0.81 0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177300437 chr6:126643488~126644390:+ CESC trans rs4276421 0.688 rs10038249 ENSG00000231752.4 EMBP1 8.47 3.59e-15 2.25e-08 0.61 0.5 P wave duration; chr5:46160595 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs10941746 ENSG00000231752.4 EMBP1 8.47 3.59e-15 2.25e-08 0.61 0.5 P wave duration; chr5:46202737 chr1:121519112~121571892:+ CESC trans rs4276421 0.695 rs8185255 ENSG00000231752.4 EMBP1 -8.47 3.62e-15 2.26e-08 -0.61 -0.5 P wave duration; chr5:46263336 chr1:121519112~121571892:+ CESC trans rs13190036 0.901 rs28715668 ENSG00000217325.2 PRELID1P1 8.47 3.63e-15 2.27e-08 0.81 0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177272267 chr6:126643488~126644390:+ CESC trans rs12709013 0.792 rs1473206 ENSG00000233719.3 GOT2P3 8.47 3.63e-15 2.27e-08 0.52 0.5 Blood metabolite ratios; chr16:58737529 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs1473205 ENSG00000233719.3 GOT2P3 8.47 3.63e-15 2.27e-08 0.52 0.5 Blood metabolite ratios; chr16:58737547 chr12:9641802~9643007:+ CESC trans rs12709013 0.694 rs1616798 ENSG00000233719.3 GOT2P3 8.47 3.63e-15 2.27e-08 0.52 0.5 Blood metabolite ratios; chr16:58739433 chr12:9641802~9643007:+ CESC trans rs1707322 0.686 rs2275085 ENSG00000255397.1 AC022182.2 8.47 3.71e-15 2.32e-08 0.64 0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620180 chr8:60937705~60939871:- CESC trans rs2731664 0.74 rs2731670 ENSG00000215571.5 GRK6P1 -8.47 3.71e-15 2.32e-08 -0.62 -0.5 Intelligence (multi-trait analysis); chr5:177421018 chr13:21319156~21320866:+ CESC trans rs7811142 1 rs60844404 ENSG00000228546.2 CTA-313A17.3 8.46 3.94e-15 2.46e-08 0.81 0.5 Platelet count; chr7:100482851 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs113738841 ENSG00000228546.2 CTA-313A17.3 8.46 3.94e-15 2.46e-08 0.81 0.5 Platelet count; chr7:100483683 chr7:102337316~102339115:+ CESC trans rs11098499 0.69 rs34818745 ENSG00000275858.1 RP11-291L22.8 8.46 3.95e-15 2.46e-08 0.56 0.5 Corneal astigmatism; chr4:119335900 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs4001305 ENSG00000275858.1 RP11-291L22.8 8.46 3.95e-15 2.46e-08 0.55 0.5 Corneal astigmatism; chr4:119438081 chr10:38450738~38451069:- CESC trans rs4276421 0.837 rs6451829 ENSG00000231752.4 EMBP1 8.45 4.09e-15 2.55e-08 0.61 0.5 P wave duration; chr5:45893260 chr1:121519112~121571892:+ CESC trans rs4276421 0.904 rs7716296 ENSG00000231752.4 EMBP1 8.45 4.09e-15 2.55e-08 0.61 0.5 P wave duration; chr5:45895783 chr1:121519112~121571892:+ CESC trans rs4276421 0.935 rs6882139 ENSG00000231752.4 EMBP1 8.45 4.09e-15 2.55e-08 0.61 0.5 P wave duration; chr5:45897149 chr1:121519112~121571892:+ CESC trans rs11098499 0.954 rs1546505 ENSG00000275858.1 RP11-291L22.8 8.45 4.17e-15 2.59e-08 0.57 0.5 Corneal astigmatism; chr4:119320069 chr10:38450738~38451069:- CESC trans rs10242455 0.702 rs6956305 ENSG00000228834.1 RP11-249L21.4 8.45 4.2e-15 2.61e-08 1.29 0.5 Blood metabolite levels; chr7:99643687 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs73713580 ENSG00000228834.1 RP11-249L21.4 8.45 4.2e-15 2.61e-08 1.29 0.5 Blood metabolite levels; chr7:99643987 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs6976017 ENSG00000228834.1 RP11-249L21.4 8.45 4.2e-15 2.61e-08 1.29 0.5 Blood metabolite levels; chr7:99652376 chr6:108907615~108907873:- CESC trans rs13190036 1 rs4976682 ENSG00000217325.2 PRELID1P1 8.44 4.29e-15 2.67e-08 0.79 0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177299001 chr6:126643488~126644390:+ CESC trans rs867371 1 rs6495642 ENSG00000235370.6 DNM1P51 -8.44 4.42e-15 2.74e-08 -0.66 -0.5 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82165156 chr15:84398316~84411701:- CESC trans rs1707322 0.752 rs10430105 ENSG00000255397.1 AC022182.2 -8.44 4.44e-15 2.75e-08 -0.64 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45673204 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs10890341 ENSG00000255397.1 AC022182.2 -8.44 4.44e-15 2.75e-08 -0.64 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45681568 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs11211161 ENSG00000255397.1 AC022182.2 -8.44 4.44e-15 2.75e-08 -0.64 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45682466 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs61784793 ENSG00000255397.1 AC022182.2 -8.44 4.44e-15 2.75e-08 -0.64 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45683613 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs4586014 ENSG00000255397.1 AC022182.2 -8.44 4.44e-15 2.75e-08 -0.64 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684771 chr8:60937705~60939871:- CESC trans rs1707322 0.648 rs4439382 ENSG00000255397.1 AC022182.2 -8.44 4.44e-15 2.75e-08 -0.64 -0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45685133 chr8:60937705~60939871:- CESC trans rs928391 0.592 rs1888862 ENSG00000227183.3 HDGFP1 -8.43 4.59e-15 2.84e-08 -0.8 -0.5 Platelet count; chr1:156828113 chrX:131646639~131646890:+ CESC trans rs55665837 1 rs4412729 ENSG00000236360.2 RP11-334A14.2 8.43 4.66e-15 2.89e-08 0.67 0.5 Vitamin D levels; chr11:14417454 chr1:52993201~52993702:- CESC trans rs7811142 1 rs11559117 ENSG00000228546.2 CTA-313A17.3 8.43 4.79e-15 2.97e-08 0.82 0.5 Platelet count; chr7:100478991 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs4463351 ENSG00000228546.2 CTA-313A17.3 8.43 4.79e-15 2.97e-08 0.82 0.5 Platelet count; chr7:100480603 chr7:102337316~102339115:+ CESC trans rs4276421 0.967 rs4866979 ENSG00000231752.4 EMBP1 -8.43 4.83e-15 2.99e-08 -0.61 -0.5 P wave duration; chr5:45804745 chr1:121519112~121571892:+ CESC trans rs7200543 0.848 rs62039480 ENSG00000250569.1 NTAN1P2 8.43 4.86e-15 3e-08 0.61 0.5 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15043593 chr8:86481754~86483002:- CESC trans rs877636 0.692 rs2271194 ENSG00000235459.5 RPS26P31 -8.42 4.88e-15 3.02e-08 -0.51 -0.5 Cognitive function; chr12:56083910 chr7:122681315~122681662:+ CESC trans rs8067354 1 rs8067354 ENSG00000187870.7 RNFT1P3 8.42 4.89e-15 3.02e-08 0.61 0.5 Hemoglobin concentration; chr17:59744069 chr17:20743333~20754501:- CESC trans rs8067354 0.957 rs9896742 ENSG00000187870.7 RNFT1P3 8.42 4.89e-15 3.02e-08 0.61 0.5 Hemoglobin concentration; chr17:59749169 chr17:20743333~20754501:- CESC trans rs11098499 0.909 rs2127821 ENSG00000275858.1 RP11-291L22.8 8.42 5.01e-15 3.09e-08 0.54 0.5 Corneal astigmatism; chr4:119473380 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10034623 ENSG00000275858.1 RP11-291L22.8 8.42 5.01e-15 3.09e-08 0.54 0.5 Corneal astigmatism; chr4:119476674 chr10:38450738~38451069:- CESC trans rs10242455 0.717 rs2741872 ENSG00000228834.1 RP11-249L21.4 -8.42 5.02e-15 3.1e-08 -0.86 -0.5 Blood metabolite levels; chr7:99742153 chr6:108907615~108907873:- CESC trans rs4276421 0.904 rs57299032 ENSG00000231752.4 EMBP1 8.42 5.03e-15 3.1e-08 0.62 0.5 P wave duration; chr5:45998162 chr1:121519112~121571892:+ CESC trans rs1707322 0.656 rs3014210 ENSG00000255397.1 AC022182.2 8.42 5.05e-15 3.11e-08 0.64 0.5 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45600936 chr8:60937705~60939871:- CESC trans rs55665837 1 rs11023246 ENSG00000236360.2 RP11-334A14.2 8.42 5.06e-15 3.12e-08 0.64 0.5 Vitamin D levels; chr11:14515410 chr1:52993201~52993702:- CESC trans rs11098499 0.954 rs10518331 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119402440 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs13133522 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119403269 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs35091806 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119404374 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs35165976 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119404475 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs2389802 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119404577 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs6846442 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119405168 chr10:38450738~38451069:- CESC trans rs11098499 0.738 rs34566984 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119440115 chr10:38450738~38451069:- CESC trans rs11098499 0.738 rs34965784 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119440431 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs17009122 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119441248 chr10:38450738~38451069:- CESC trans rs11098499 0.505 rs75122014 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119441271 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs9685777 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119444810 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs71614438 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119450097 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs66506550 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119450290 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs7659501 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119450397 chr10:38450738~38451069:- CESC trans rs11098499 0.779 rs28495013 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119454676 chr10:38450738~38451069:- CESC trans rs11098499 0.738 rs28408407 ENSG00000275858.1 RP11-291L22.8 8.42 5.17e-15 3.16e-08 0.55 0.5 Corneal astigmatism; chr4:119454875 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs12508504 ENSG00000275858.1 RP11-291L22.8 8.42 5.2e-15 3.18e-08 0.54 0.5 Corneal astigmatism; chr4:119489452 chr10:38450738~38451069:- CESC trans rs1707322 0.717 rs3014245 ENSG00000255397.1 AC022182.2 8.41 5.33e-15 3.26e-08 0.65 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621241 chr8:60937705~60939871:- CESC trans rs7258465 1 rs8103622 ENSG00000267533.1 RP11-815J4.7 8.41 5.39e-15 3.29e-08 0.64 0.49 Breast cancer; chr19:18462024 chr18:12067173~12068417:- CESC trans rs877636 0.692 rs2271194 ENSG00000243403.1 RP11-330L19.1 -8.41 5.41e-15 3.31e-08 -0.47 -0.49 Cognitive function; chr12:56083910 chr15:64592979~64593326:+ CESC trans rs4276421 0.904 rs4274988 ENSG00000231752.4 EMBP1 8.41 5.53e-15 3.37e-08 0.6 0.49 P wave duration; chr5:45926339 chr1:121519112~121571892:+ CESC trans rs4276421 0.935 rs7725537 ENSG00000231752.4 EMBP1 8.41 5.53e-15 3.37e-08 0.6 0.49 P wave duration; chr5:45927191 chr1:121519112~121571892:+ CESC trans rs4276421 0.935 rs35730142 ENSG00000231752.4 EMBP1 8.41 5.53e-15 3.37e-08 0.6 0.49 P wave duration; chr5:45927453 chr1:121519112~121571892:+ CESC trans rs4276421 0.635 rs12186454 ENSG00000231752.4 EMBP1 -8.41 5.54e-15 3.38e-08 -0.62 -0.49 P wave duration; chr5:46067621 chr1:121519112~121571892:+ CESC trans rs1707322 0.752 rs8179402 ENSG00000255397.1 AC022182.2 -8.4 5.59e-15 3.41e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45676794 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs8179296 ENSG00000255397.1 AC022182.2 -8.4 5.59e-15 3.41e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45678119 chr8:60937705~60939871:- CESC trans rs877636 0.692 rs2271194 ENSG00000234513.1 AC073072.7 -8.4 5.76e-15 3.51e-08 -0.52 -0.49 Cognitive function; chr12:56083910 chr7:22773646~22773993:- CESC trans rs116095464 0.558 rs56081398 ENSG00000185986.11 SDHAP3 8.39 5.92e-15 3.6e-08 0.87 0.49 Breast cancer; chr5:247203 chr5:1572222~1594620:- CESC trans rs7811142 1 rs7803454 ENSG00000228546.2 CTA-313A17.3 8.39 6.02e-15 3.66e-08 0.88 0.49 Platelet count; chr7:100393925 chr7:102337316~102339115:+ CESC trans rs7811142 0.943 rs11769886 ENSG00000228546.2 CTA-313A17.3 8.39 6.02e-15 3.66e-08 0.88 0.49 Platelet count; chr7:100400984 chr7:102337316~102339115:+ CESC trans rs11098499 0.863 rs11098531 ENSG00000275858.1 RP11-291L22.8 8.39 6.04e-15 3.67e-08 0.55 0.49 Corneal astigmatism; chr4:119543846 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs28718422 ENSG00000275858.1 RP11-291L22.8 8.39 6.04e-15 3.67e-08 0.55 0.49 Corneal astigmatism; chr4:119545149 chr10:38450738~38451069:- CESC trans rs11098499 0.818 rs12498599 ENSG00000275858.1 RP11-291L22.8 8.39 6.04e-15 3.67e-08 0.55 0.49 Corneal astigmatism; chr4:119547348 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs10009626 ENSG00000275858.1 RP11-291L22.8 8.39 6.04e-15 3.67e-08 0.55 0.49 Corneal astigmatism; chr4:119548850 chr10:38450738~38451069:- CESC trans rs7258465 1 rs10405636 ENSG00000267533.1 RP11-815J4.7 8.39 6.1e-15 3.71e-08 0.63 0.49 Breast cancer; chr19:18427932 chr18:12067173~12068417:- CESC trans rs4276421 0.904 rs7444405 ENSG00000231752.4 EMBP1 8.39 6.13e-15 3.73e-08 0.6 0.49 P wave duration; chr5:45915373 chr1:121519112~121571892:+ CESC trans rs116095464 0.558 rs6962 ENSG00000185986.11 SDHAP3 8.39 6.17e-15 3.75e-08 0.85 0.49 Breast cancer; chr5:256394 chr5:1572222~1594620:- CESC trans rs7811142 1 rs6972167 ENSG00000228546.2 CTA-313A17.3 8.39 6.26e-15 3.8e-08 0.81 0.49 Platelet count; chr7:100482390 chr7:102337316~102339115:+ CESC trans rs7258465 1 rs271623 ENSG00000267533.1 RP11-815J4.7 8.38 6.34e-15 3.85e-08 0.64 0.49 Breast cancer; chr19:18518137 chr18:12067173~12068417:- CESC trans rs7258465 0.965 rs271622 ENSG00000267533.1 RP11-815J4.7 8.38 6.34e-15 3.85e-08 0.64 0.49 Breast cancer; chr19:18518467 chr18:12067173~12068417:- CESC trans rs4276421 0.574 rs80150384 ENSG00000231752.4 EMBP1 -8.38 6.35e-15 3.85e-08 -0.62 -0.49 P wave duration; chr5:46296183 chr1:121519112~121571892:+ CESC trans rs7811142 1 rs7783550 ENSG00000228546.2 CTA-313A17.3 -8.38 6.39e-15 3.87e-08 -0.81 -0.49 Platelet count; chr7:100390182 chr7:102337316~102339115:+ CESC trans rs4276421 0.904 rs7293482 ENSG00000231752.4 EMBP1 8.38 6.42e-15 3.89e-08 0.61 0.49 P wave duration; chr5:46003984 chr1:121519112~121571892:+ CESC trans rs4276421 0.967 rs10069793 ENSG00000231752.4 EMBP1 8.38 6.63e-15 4.02e-08 0.61 0.49 P wave duration; chr5:45803049 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs1010740 ENSG00000275858.1 RP11-291L22.8 -8.38 6.66e-15 4.04e-08 -0.57 -0.49 Corneal astigmatism; chr4:119542254 chr10:38450738~38451069:- CESC trans rs10940346 0.846 rs13356208 ENSG00000231752.4 EMBP1 -8.38 6.69e-15 4.05e-08 -0.6 -0.49 Schizophrenia; chr5:50197970 chr1:121519112~121571892:+ CESC trans rs10940346 0.721 rs60147402 ENSG00000231752.4 EMBP1 -8.38 6.69e-15 4.05e-08 -0.6 -0.49 Schizophrenia; chr5:50230794 chr1:121519112~121571892:+ CESC trans rs77688320 0.535 rs6435084 ENSG00000235105.1 RP11-329A14.1 8.37 6.76e-15 4.09e-08 0.55 0.49 Breast cancer; chr2:201461274 chr1:48435967~48437223:+ CESC trans rs11098499 0.779 rs80242894 ENSG00000275858.1 RP11-291L22.8 8.37 6.92e-15 4.19e-08 0.55 0.49 Corneal astigmatism; chr4:119454597 chr10:38450738~38451069:- CESC trans rs7937890 1 rs7937890 ENSG00000236360.2 RP11-334A14.2 8.37 6.94e-15 4.2e-08 0.58 0.49 Mitochondrial DNA levels; chr11:14374939 chr1:52993201~52993702:- CESC trans rs7200543 1 rs7200543 ENSG00000250569.1 NTAN1P2 -8.37 6.98e-15 4.22e-08 -0.6 -0.49 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15036113 chr8:86481754~86483002:- CESC trans rs55665837 1 rs2305305 ENSG00000236360.2 RP11-334A14.2 8.37 7.08e-15 4.28e-08 0.63 0.49 Vitamin D levels; chr11:14519396 chr1:52993201~52993702:- CESC trans rs116095464 0.558 rs10056628 ENSG00000185986.11 SDHAP3 8.36 7.32e-15 4.42e-08 0.89 0.49 Breast cancer; chr5:279397 chr5:1572222~1594620:- CESC trans rs7554547 0.791 rs2064614 ENSG00000261819.1 RP11-680G24.4 8.36 7.38e-15 4.45e-08 0.57 0.49 Nonsyndromic cleft lip with cleft palate; chr1:11893883 chr16:14988259~14990160:- CESC trans rs1707322 0.752 rs6662164 ENSG00000255397.1 AC022182.2 -8.36 7.39e-15 4.46e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680558 chr8:60937705~60939871:- CESC trans rs4276421 0.688 rs13155792 ENSG00000231752.4 EMBP1 8.36 7.44e-15 4.49e-08 0.62 0.49 P wave duration; chr5:46176452 chr1:121519112~121571892:+ CESC trans rs4276421 0.684 rs11958686 ENSG00000231752.4 EMBP1 8.36 7.45e-15 4.49e-08 0.62 0.49 P wave duration; chr5:46173456 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs11950077 ENSG00000231752.4 EMBP1 8.36 7.45e-15 4.49e-08 0.62 0.49 P wave duration; chr5:46179798 chr1:121519112~121571892:+ CESC trans rs4276421 0.654 rs8185114 ENSG00000231752.4 EMBP1 8.36 7.45e-15 4.49e-08 0.62 0.49 P wave duration; chr5:46181843 chr1:121519112~121571892:+ CESC trans rs4276421 0.652 rs8188276 ENSG00000231752.4 EMBP1 8.36 7.45e-15 4.49e-08 0.62 0.49 P wave duration; chr5:46182731 chr1:121519112~121571892:+ CESC trans rs4276421 0.656 rs13188002 ENSG00000231752.4 EMBP1 8.36 7.45e-15 4.49e-08 0.62 0.49 P wave duration; chr5:46184203 chr1:121519112~121571892:+ CESC trans rs1707322 0.752 rs11211152 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648485 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs4607935 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651489 chr8:60937705~60939871:- CESC trans rs1707322 0.681 rs12048866 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651820 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs3811436 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660208 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs12024590 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45661824 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs12027622 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664580 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs4415615 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45666437 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs7529699 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668962 chr8:60937705~60939871:- CESC trans rs1707322 0.716 rs6699444 ENSG00000255397.1 AC022182.2 -8.36 7.62e-15 4.58e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669448 chr8:60937705~60939871:- CESC trans rs11098499 0.78 rs7680914 ENSG00000275858.1 RP11-291L22.8 8.36 7.64e-15 4.59e-08 0.55 0.49 Corneal astigmatism; chr4:119641898 chr10:38450738~38451069:- CESC trans rs10940346 1 rs11948752 ENSG00000231752.4 EMBP1 -8.35 8.08e-15 4.85e-08 -0.61 -0.49 Schizophrenia; chr5:50504082 chr1:121519112~121571892:+ CESC trans rs10242455 0.571 rs55830753 ENSG00000228834.1 RP11-249L21.4 8.35 8.08e-15 4.85e-08 1.16 0.49 Blood metabolite levels; chr7:99694599 chr6:108907615~108907873:- CESC trans rs11098499 0.78 rs12504773 ENSG00000275858.1 RP11-291L22.8 8.34 8.27e-15 4.96e-08 0.55 0.49 Corneal astigmatism; chr4:119640994 chr10:38450738~38451069:- CESC trans rs10940346 0.846 rs8175378 ENSG00000231752.4 EMBP1 -8.34 8.27e-15 4.96e-08 -0.61 -0.49 Schizophrenia; chr5:50182876 chr1:121519112~121571892:+ CESC trans rs4276421 0.684 rs10064829 ENSG00000231752.4 EMBP1 8.34 8.28e-15 4.96e-08 0.62 0.49 P wave duration; chr5:46192959 chr1:121519112~121571892:+ CESC trans rs77688320 0.517 rs2270315 ENSG00000235105.1 RP11-329A14.1 8.34 8.32e-15 4.99e-08 0.56 0.49 Breast cancer; chr2:201452542 chr1:48435967~48437223:+ CESC trans rs77688320 0.517 rs2287054 ENSG00000235105.1 RP11-329A14.1 8.34 8.32e-15 4.99e-08 0.56 0.49 Breast cancer; chr2:201454315 chr1:48435967~48437223:+ CESC trans rs77688320 0.5 rs10931948 ENSG00000235105.1 RP11-329A14.1 8.34 8.32e-15 4.99e-08 0.56 0.49 Breast cancer; chr2:201459199 chr1:48435967~48437223:+ CESC trans rs7811142 0.887 rs35111986 ENSG00000228546.2 CTA-313A17.3 8.34 8.34e-15 5e-08 0.85 0.49 Platelet count; chr7:100402651 chr7:102337316~102339115:+ CESC trans rs9611565 0.512 rs139572 ENSG00000268568.1 AC007228.9 -8.34 8.34e-15 5e-08 -0.78 -0.49 Vitiligo; chr22:41818528 chr19:56672574~56673901:- CESC trans rs11098499 0.954 rs13107475 ENSG00000275858.1 RP11-291L22.8 8.34 8.35e-15 5e-08 0.54 0.49 Corneal astigmatism; chr4:119471856 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs7436506 ENSG00000275858.1 RP11-291L22.8 8.34 8.35e-15 5e-08 0.54 0.49 Corneal astigmatism; chr4:119472614 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs10008459 ENSG00000275858.1 RP11-291L22.8 8.34 8.35e-15 5e-08 0.54 0.49 Corneal astigmatism; chr4:119473076 chr10:38450738~38451069:- CESC trans rs10242455 0.571 rs117370443 ENSG00000228834.1 RP11-249L21.4 8.34 8.35e-15 5e-08 1.34 0.49 Blood metabolite levels; chr7:99377635 chr6:108907615~108907873:- CESC trans rs11098499 0.738 rs72918577 ENSG00000275858.1 RP11-291L22.8 8.34 8.45e-15 5.06e-08 0.55 0.49 Corneal astigmatism; chr4:119405546 chr10:38450738~38451069:- CESC trans rs6732160 0.588 rs1430345 ENSG00000236165.1 PRADC1P1 8.34 8.66e-15 5.18e-08 0.65 0.49 Intelligence (multi-trait analysis); chr2:73143554 chr3:36976316~36976840:+ CESC trans rs7258465 0.965 rs2385088 ENSG00000267533.1 RP11-815J4.7 8.33 8.71e-15 5.21e-08 0.63 0.49 Breast cancer; chr19:18434730 chr18:12067173~12068417:- CESC trans rs1707322 0.717 rs2253862 ENSG00000255397.1 AC022182.2 8.33 8.9e-15 5.32e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616288 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs2991988 ENSG00000255397.1 AC022182.2 8.33 8.9e-15 5.32e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616759 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs2991989 ENSG00000255397.1 AC022182.2 8.33 8.9e-15 5.32e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45617293 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs2275086 ENSG00000255397.1 AC022182.2 8.33 8.9e-15 5.32e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620207 chr8:60937705~60939871:- CESC trans rs1707322 0.655 rs3014240 ENSG00000255397.1 AC022182.2 8.33 8.9e-15 5.32e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45623553 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs3014235 ENSG00000255397.1 AC022182.2 8.33 8.9e-15 5.32e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625840 chr8:60937705~60939871:- CESC trans rs1707322 0.656 rs9429172 ENSG00000255397.1 AC022182.2 8.33 8.9e-15 5.32e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45626804 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs1135850 ENSG00000255397.1 AC022182.2 -8.33 8.9e-15 5.32e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628020 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs3014242 ENSG00000255397.1 AC022182.2 8.33 8.99e-15 5.36e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621905 chr8:60937705~60939871:- CESC trans rs6477998 0.647 rs10981704 ENSG00000238072.1 RP11-305M3.2 -8.33 9.03e-15 5.39e-08 -0.63 -0.49 Hematology traits; chr9:113253989 chr7:129410113~129410370:- CESC trans rs1707322 0.721 rs10890343 ENSG00000255397.1 AC022182.2 -8.33 9.1e-15 5.43e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692250 chr8:60937705~60939871:- CESC trans rs10242455 0.717 rs2687134 ENSG00000228834.1 RP11-249L21.4 -8.33 9.15e-15 5.46e-08 -0.84 -0.49 Blood metabolite levels; chr7:99733419 chr6:108907615~108907873:- CESC trans rs10242455 0.717 rs2687133 ENSG00000228834.1 RP11-249L21.4 -8.33 9.15e-15 5.46e-08 -0.84 -0.49 Blood metabolite levels; chr7:99734460 chr6:108907615~108907873:- CESC trans rs10242455 0.571 rs11734 ENSG00000228834.1 RP11-249L21.4 -8.33 9.23e-15 5.51e-08 -1.11 -0.49 Blood metabolite levels; chr7:99632145 chr6:108907615~108907873:- CESC trans rs13190036 1 rs34446750 ENSG00000217325.2 PRELID1P1 -8.32 9.29e-15 5.54e-08 -0.81 -0.49 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177168079 chr6:126643488~126644390:+ CESC trans rs916888 0.821 rs199513 ENSG00000264070.1 DND1P1 -8.32 9.31e-15 5.55e-08 -0.72 -0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45585871~45586929:+ CESC trans rs8010715 0.848 rs927494 ENSG00000238000.1 RP11-274E7.2 8.32 9.46e-15 5.64e-08 0.5 0.49 IgG glycosylation; chr14:24131181 chr5:98213402~98214121:+ CESC trans rs1707322 0.721 rs12045096 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648756 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs4609469 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651513 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs12049027 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45652512 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs10789467 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45653073 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs10890337 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658855 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs3811435 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660118 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs9793568 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664701 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs11211157 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667172 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs11211158 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667178 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs6429575 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668544 chr8:60937705~60939871:- CESC trans rs1707322 0.685 rs6690926 ENSG00000255397.1 AC022182.2 -8.32 9.66e-15 5.74e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669306 chr8:60937705~60939871:- CESC trans rs7554511 0.894 rs296543 ENSG00000244144.1 RP11-757F18.3 8.32 9.69e-15 5.75e-08 0.55 0.49 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200920705 chr3:112185480~112185998:- CESC trans rs1707322 0.752 rs28719889 ENSG00000255397.1 AC022182.2 -8.31 9.96e-15 5.91e-08 -0.64 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736611 chr8:60937705~60939871:- CESC trans rs116095464 0.614 rs10059220 ENSG00000185986.11 SDHAP3 8.31 9.97e-15 5.91e-08 0.87 0.49 Breast cancer; chr5:242698 chr5:1572222~1594620:- CESC trans rs11098499 0.863 rs59732491 ENSG00000275858.1 RP11-291L22.8 8.31 1e-14 5.94e-08 0.56 0.49 Corneal astigmatism; chr4:119568433 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs11723090 ENSG00000275858.1 RP11-291L22.8 8.31 1e-14 5.94e-08 0.56 0.49 Corneal astigmatism; chr4:119569437 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs12498539 ENSG00000275858.1 RP11-291L22.8 8.31 1e-14 5.94e-08 0.55 0.49 Corneal astigmatism; chr4:119547215 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3822194 ENSG00000275858.1 RP11-291L22.8 8.31 1e-14 5.94e-08 0.55 0.49 Corneal astigmatism; chr4:119550493 chr10:38450738~38451069:- CESC trans rs7554511 0.894 rs11589638 ENSG00000244144.1 RP11-757F18.3 -8.31 1.03e-14 6.08e-08 -0.55 -0.49 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200925807 chr3:112185480~112185998:- CESC trans rs1707322 0.682 rs3014241 ENSG00000255397.1 AC022182.2 8.3 1.06e-14 6.29e-08 0.64 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45622207 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs61784800 ENSG00000255397.1 AC022182.2 8.3 1.09e-14 6.46e-08 0.62 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712440 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs6665808 ENSG00000255397.1 AC022182.2 -8.3 1.09e-14 6.46e-08 -0.62 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45696611 chr8:60937705~60939871:- CESC trans rs1707322 0.682 rs28508523 ENSG00000255397.1 AC022182.2 -8.3 1.09e-14 6.46e-08 -0.62 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723953 chr8:60937705~60939871:- CESC trans rs116095464 0.558 rs56298907 ENSG00000185986.11 SDHAP3 8.3 1.11e-14 6.55e-08 0.89 0.49 Breast cancer; chr5:283165 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs7356535 ENSG00000185986.11 SDHAP3 8.3 1.11e-14 6.55e-08 0.89 0.49 Breast cancer; chr5:284002 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs55833259 ENSG00000185986.11 SDHAP3 8.3 1.11e-14 6.55e-08 0.89 0.49 Breast cancer; chr5:286613 chr5:1572222~1594620:- CESC trans rs4276421 0.63 rs10054134 ENSG00000231752.4 EMBP1 -8.3 1.11e-14 6.55e-08 -0.61 -0.49 P wave duration; chr5:46292175 chr1:121519112~121571892:+ CESC trans rs1707322 0.686 rs1250 ENSG00000255397.1 AC022182.2 -8.29 1.15e-14 6.76e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628355 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs2991987 ENSG00000255397.1 AC022182.2 8.29 1.16e-14 6.81e-08 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615750 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs3014239 ENSG00000255397.1 AC022182.2 8.29 1.16e-14 6.81e-08 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624129 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs3014236 ENSG00000255397.1 AC022182.2 8.29 1.16e-14 6.81e-08 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625633 chr8:60937705~60939871:- CESC trans rs4276421 0.638 rs4551075 ENSG00000231752.4 EMBP1 8.29 1.17e-14 6.86e-08 0.59 0.49 P wave duration; chr5:46011710 chr1:121519112~121571892:+ CESC trans rs8010715 0.848 rs2277483 ENSG00000238000.1 RP11-274E7.2 8.29 1.17e-14 6.88e-08 0.5 0.49 IgG glycosylation; chr14:24122683 chr5:98213402~98214121:+ CESC trans rs10940346 1 rs2016360 ENSG00000231752.4 EMBP1 -8.29 1.17e-14 6.88e-08 -0.6 -0.49 Schizophrenia; chr5:50491064 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs7378983 ENSG00000231752.4 EMBP1 -8.29 1.17e-14 6.88e-08 -0.6 -0.49 Schizophrenia; chr5:50491889 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs6450164 ENSG00000231752.4 EMBP1 -8.29 1.17e-14 6.88e-08 -0.6 -0.49 Schizophrenia; chr5:50502814 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs1962832 ENSG00000231752.4 EMBP1 -8.29 1.17e-14 6.88e-08 -0.6 -0.49 Schizophrenia; chr5:50502962 chr1:121519112~121571892:+ CESC trans rs1707322 0.686 rs1541131 ENSG00000255397.1 AC022182.2 8.29 1.18e-14 6.93e-08 0.62 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619262 chr8:60937705~60939871:- CESC trans rs11098499 0.863 rs2306456 ENSG00000275858.1 RP11-291L22.8 8.29 1.18e-14 6.96e-08 0.55 0.49 Corneal astigmatism; chr4:119551267 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs11947234 ENSG00000275858.1 RP11-291L22.8 8.29 1.18e-14 6.96e-08 0.55 0.49 Corneal astigmatism; chr4:119553704 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs11933966 ENSG00000275858.1 RP11-291L22.8 8.29 1.18e-14 6.96e-08 0.55 0.49 Corneal astigmatism; chr4:119555560 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs36040693 ENSG00000275858.1 RP11-291L22.8 8.29 1.18e-14 6.96e-08 0.55 0.49 Corneal astigmatism; chr4:119556461 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs1552092 ENSG00000275858.1 RP11-291L22.8 8.29 1.18e-14 6.96e-08 0.55 0.49 Corneal astigmatism; chr4:119567341 chr10:38450738~38451069:- CESC trans rs1707322 0.682 rs12037459 ENSG00000255397.1 AC022182.2 -8.28 1.2e-14 7.05e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629287 chr8:60937705~60939871:- CESC trans rs3779195 0.86 rs12704986 ENSG00000225169.1 BRI3P1 8.28 1.21e-14 7.11e-08 0.75 0.49 Sex hormone-binding globulin levels; chr7:98357118 chr1:100213293~100213670:+ CESC trans rs3779195 0.858 rs3779196 ENSG00000225169.1 BRI3P1 8.28 1.21e-14 7.11e-08 0.75 0.49 Sex hormone-binding globulin levels; chr7:98360794 chr1:100213293~100213670:+ CESC trans rs3779195 0.789 rs6965424 ENSG00000225169.1 BRI3P1 8.28 1.21e-14 7.11e-08 0.75 0.49 Sex hormone-binding globulin levels; chr7:98361813 chr1:100213293~100213670:+ CESC trans rs8010715 0.848 rs8009511 ENSG00000238000.1 RP11-274E7.2 8.28 1.22e-14 7.13e-08 0.5 0.49 IgG glycosylation; chr14:24124771 chr5:98213402~98214121:+ CESC trans rs8010715 0.804 rs1134334 ENSG00000238000.1 RP11-274E7.2 8.28 1.22e-14 7.13e-08 0.5 0.49 IgG glycosylation; chr14:24124905 chr5:98213402~98214121:+ CESC trans rs7258465 0.965 rs10408290 ENSG00000267533.1 RP11-815J4.7 8.28 1.24e-14 7.27e-08 0.63 0.49 Breast cancer; chr19:18431891 chr18:12067173~12068417:- CESC trans rs7258465 0.965 rs10409003 ENSG00000267533.1 RP11-815J4.7 8.28 1.24e-14 7.27e-08 0.63 0.49 Breast cancer; chr19:18432244 chr18:12067173~12068417:- CESC trans rs1707322 0.691 rs11211175 ENSG00000255397.1 AC022182.2 -8.28 1.24e-14 7.28e-08 -0.62 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755212 chr8:60937705~60939871:- CESC trans rs1707322 0.691 rs61784799 ENSG00000255397.1 AC022182.2 8.28 1.25e-14 7.3e-08 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45712076 chr8:60937705~60939871:- CESC trans rs1707322 0.716 rs10890342 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45691415 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs6658700 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45694588 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs12047629 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697130 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs11211169 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701037 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs11211171 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45702970 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs28623463 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45705086 chr8:60937705~60939871:- CESC trans rs1707322 0.716 rs28370457 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706390 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs28890893 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720904 chr8:60937705~60939871:- CESC trans rs1707322 0.716 rs28375469 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45729703 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs28545085 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45736278 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs28812624 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45738064 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs28507722 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45740868 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs28568986 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45742071 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs28396194 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747555 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs28752166 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747637 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs10890345 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45748255 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs10789471 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45749947 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs11211173 ENSG00000255397.1 AC022182.2 -8.28 1.25e-14 7.3e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45753704 chr8:60937705~60939871:- CESC trans rs916888 0.61 rs199436 ENSG00000264070.1 DND1P1 -8.28 1.27e-14 7.4e-08 -0.6 -0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45585871~45586929:+ CESC trans rs4276421 0.716 rs34186279 ENSG00000231752.4 EMBP1 8.27 1.28e-14 7.46e-08 0.61 0.49 P wave duration; chr5:46221966 chr1:121519112~121571892:+ CESC trans rs1707322 0.721 rs6699418 ENSG00000255397.1 AC022182.2 -8.27 1.28e-14 7.46e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634509 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs4431884 ENSG00000255397.1 AC022182.2 -8.27 1.28e-14 7.46e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45635651 chr8:60937705~60939871:- CESC trans rs1707322 0.65 rs4660879 ENSG00000255397.1 AC022182.2 -8.27 1.28e-14 7.46e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45639729 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs11211146 ENSG00000255397.1 AC022182.2 -8.27 1.33e-14 7.73e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644122 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs11211147 ENSG00000255397.1 AC022182.2 -8.27 1.33e-14 7.73e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644422 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs11211149 ENSG00000255397.1 AC022182.2 -8.27 1.33e-14 7.73e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45646546 chr8:60937705~60939871:- CESC trans rs11098499 0.863 rs58452170 ENSG00000275858.1 RP11-291L22.8 8.26 1.37e-14 7.94e-08 0.56 0.49 Corneal astigmatism; chr4:119538519 chr10:38450738~38451069:- CESC trans rs10242455 0.571 rs45593341 ENSG00000228834.1 RP11-249L21.4 8.26 1.37e-14 7.96e-08 1.14 0.49 Blood metabolite levels; chr7:99707288 chr6:108907615~108907873:- CESC trans rs1707322 0.717 rs3014246 ENSG00000255397.1 AC022182.2 8.26 1.37e-14 7.97e-08 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620405 chr8:60937705~60939871:- CESC trans rs4276421 0.656 rs8185101 ENSG00000231752.4 EMBP1 8.26 1.41e-14 8.19e-08 0.62 0.49 P wave duration; chr5:46183248 chr1:121519112~121571892:+ CESC trans rs1707322 0.717 rs1547925 ENSG00000255397.1 AC022182.2 8.26 1.42e-14 8.25e-08 0.62 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619684 chr8:60937705~60939871:- CESC trans rs11098499 0.863 rs3822195 ENSG00000275858.1 RP11-291L22.8 8.26 1.44e-14 8.36e-08 0.55 0.49 Corneal astigmatism; chr4:119550505 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3775854 ENSG00000275858.1 RP11-291L22.8 8.26 1.44e-14 8.36e-08 0.55 0.49 Corneal astigmatism; chr4:119550816 chr10:38450738~38451069:- CESC trans rs2657294 0.674 rs10824268 ENSG00000172974.11 AC007318.5 8.25 1.46e-14 8.44e-08 0.49 0.49 Pneumonia; chr10:75085937 chr2:65205108~65205988:+ CESC trans rs916888 0.531 rs183211 ENSG00000264070.1 DND1P1 8.25 1.46e-14 8.46e-08 0.6 0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45585871~45586929:+ CESC trans rs7258465 1 rs7258465 ENSG00000267533.1 RP11-815J4.7 8.25 1.47e-14 8.51e-08 0.61 0.49 Breast cancer; chr19:18422832 chr18:12067173~12068417:- CESC trans rs11098499 0.954 rs6847248 ENSG00000275858.1 RP11-291L22.8 8.25 1.49e-14 8.62e-08 0.58 0.49 Corneal astigmatism; chr4:119304800 chr10:38450738~38451069:- CESC trans rs7937890 1 rs2970335 ENSG00000236360.2 RP11-334A14.2 8.25 1.52e-14 8.78e-08 0.58 0.49 Mitochondrial DNA levels; chr11:14303855 chr1:52993201~52993702:- CESC trans rs9611565 0.921 rs6002333 ENSG00000268568.1 AC007228.9 -8.25 1.53e-14 8.8e-08 -0.7 -0.49 Vitiligo; chr22:41323465 chr19:56672574~56673901:- CESC trans rs11098499 0.754 rs9999724 ENSG00000275858.1 RP11-291L22.8 8.25 1.53e-14 8.83e-08 0.54 0.49 Corneal astigmatism; chr4:119318789 chr10:38450738~38451069:- CESC trans rs13253073 0.544 rs13280341 ENSG00000260318.1 COX6CP1 8.25 1.53e-14 8.84e-08 0.98 0.49 Glucose homeostasis traits; chr8:99908840 chr16:11903923~11904137:- CESC trans rs11098499 0.954 rs11098525 ENSG00000275858.1 RP11-291L22.8 8.25 1.54e-14 8.85e-08 0.54 0.49 Corneal astigmatism; chr4:119468997 chr10:38450738~38451069:- CESC trans rs7937890 1 rs6486190 ENSG00000236360.2 RP11-334A14.2 8.25 1.54e-14 8.9e-08 0.58 0.49 Mitochondrial DNA levels; chr11:14379670 chr1:52993201~52993702:- CESC trans rs11098499 0.82 rs13128602 ENSG00000275858.1 RP11-291L22.8 -8.24 1.56e-14 8.98e-08 -0.55 -0.49 Corneal astigmatism; chr4:119538211 chr10:38450738~38451069:- CESC trans rs1707322 0.691 rs61784803 ENSG00000255397.1 AC022182.2 8.24 1.59e-14 9.1e-08 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45713599 chr8:60937705~60939871:- CESC trans rs1707322 0.663 rs3935296 ENSG00000255397.1 AC022182.2 8.24 1.59e-14 9.1e-08 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45714798 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs11211163 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45687876 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs12037803 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690820 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs10789470 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692659 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs61784796 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697584 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs10749856 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45699174 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs10890344 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45700418 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs4564187 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701189 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs28438704 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45704872 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs28442079 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45706329 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs28817701 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45720378 chr8:60937705~60939871:- CESC trans rs1707322 0.691 rs28495425 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45721648 chr8:60937705~60939871:- CESC trans rs1707322 0.685 rs28617418 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723854 chr8:60937705~60939871:- CESC trans rs1707322 0.682 rs28490344 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45732276 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs28501477 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45733412 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs28641748 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45747164 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs6697821 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751050 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs4330955 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45751813 chr8:60937705~60939871:- CESC trans rs1707322 0.691 rs11211174 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755144 chr8:60937705~60939871:- CESC trans rs1707322 0.691 rs12031182 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755327 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs10430123 ENSG00000255397.1 AC022182.2 -8.24 1.59e-14 9.1e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45755768 chr8:60937705~60939871:- CESC trans rs11098499 0.863 rs2306457 ENSG00000275858.1 RP11-291L22.8 8.24 1.6e-14 9.14e-08 0.55 0.49 Corneal astigmatism; chr4:119551684 chr10:38450738~38451069:- CESC trans rs11098499 0.82 rs13122709 ENSG00000275858.1 RP11-291L22.8 8.24 1.6e-14 9.16e-08 0.54 0.49 Corneal astigmatism; chr4:119634201 chr10:38450738~38451069:- CESC trans rs11098499 0.73 rs12505735 ENSG00000275858.1 RP11-291L22.8 8.24 1.6e-14 9.16e-08 0.54 0.49 Corneal astigmatism; chr4:119611801 chr10:38450738~38451069:- CESC trans rs1707322 0.686 rs2050376 ENSG00000255397.1 AC022182.2 -8.24 1.62e-14 9.25e-08 -0.62 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45612958 chr8:60937705~60939871:- CESC trans rs10242455 0.571 rs45527841 ENSG00000228834.1 RP11-249L21.4 8.24 1.63e-14 9.31e-08 1.08 0.49 Blood metabolite levels; chr7:99713342 chr6:108907615~108907873:- CESC trans rs10242455 0.571 rs73713594 ENSG00000228834.1 RP11-249L21.4 8.24 1.63e-14 9.31e-08 1.08 0.49 Blood metabolite levels; chr7:99728875 chr6:108907615~108907873:- CESC trans rs11098499 0.818 rs55825515 ENSG00000275858.1 RP11-291L22.8 8.24 1.64e-14 9.38e-08 0.55 0.49 Corneal astigmatism; chr4:119565247 chr10:38450738~38451069:- CESC trans rs916888 0.61 rs199444 ENSG00000264070.1 DND1P1 8.23 1.67e-14 9.55e-08 0.59 0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45585871~45586929:+ CESC trans rs1707322 0.721 rs10890336 ENSG00000255397.1 AC022182.2 -8.23 1.68e-14 9.59e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645384 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs11211151 ENSG00000255397.1 AC022182.2 -8.23 1.68e-14 9.59e-08 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45647080 chr8:60937705~60939871:- CESC trans rs916888 0.647 rs199449 ENSG00000264070.1 DND1P1 8.23 1.75e-14 1e-07 0.59 0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45585871~45586929:+ CESC trans rs916888 0.61 rs199438 ENSG00000264070.1 DND1P1 8.22 1.76e-14 1.01e-07 0.6 0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45585871~45586929:+ CESC trans rs1707322 0.662 rs11211160 ENSG00000255397.1 AC022182.2 -8.22 1.77e-14 1.01e-07 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680557 chr8:60937705~60939871:- CESC trans rs916888 0.61 rs199442 ENSG00000264070.1 DND1P1 8.22 1.8e-14 1.03e-07 0.59 0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45585871~45586929:+ CESC trans rs1707322 0.686 rs3014251 ENSG00000255397.1 AC022182.2 8.22 1.8e-14 1.03e-07 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45611756 chr8:60937705~60939871:- CESC trans rs10940346 0.846 rs2663076 ENSG00000231752.4 EMBP1 8.22 1.81e-14 1.03e-07 0.59 0.49 Schizophrenia; chr5:50430593 chr1:121519112~121571892:+ CESC trans rs10940346 0.936 rs303219 ENSG00000231752.4 EMBP1 8.22 1.83e-14 1.04e-07 0.59 0.49 Schizophrenia; chr5:50407795 chr1:121519112~121571892:+ CESC trans rs11098499 1 rs35643470 ENSG00000275858.1 RP11-291L22.8 8.22 1.86e-14 1.06e-07 0.56 0.49 Corneal astigmatism; chr4:119263793 chr10:38450738~38451069:- CESC trans rs4276421 0.684 rs8185055 ENSG00000231752.4 EMBP1 -8.22 1.86e-14 1.06e-07 -0.61 -0.49 P wave duration; chr5:46262149 chr1:121519112~121571892:+ CESC trans rs10242455 0.702 rs57832867 ENSG00000228834.1 RP11-249L21.4 8.21 1.89e-14 1.08e-07 1.32 0.49 Blood metabolite levels; chr7:99368773 chr6:108907615~108907873:- CESC trans rs6477998 0.603 rs12338803 ENSG00000238072.1 RP11-305M3.2 8.21 1.94e-14 1.1e-07 0.78 0.49 Hematology traits; chr9:113263148 chr7:129410113~129410370:- CESC trans rs11098499 0.863 rs6853998 ENSG00000275858.1 RP11-291L22.8 8.21 1.96e-14 1.11e-07 0.54 0.49 Corneal astigmatism; chr4:119554705 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs6858777 ENSG00000275858.1 RP11-291L22.8 8.21 1.96e-14 1.11e-07 0.54 0.49 Corneal astigmatism; chr4:119554811 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs11731756 ENSG00000275858.1 RP11-291L22.8 8.21 1.96e-14 1.11e-07 0.54 0.49 Corneal astigmatism; chr4:119557541 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs34308924 ENSG00000275858.1 RP11-291L22.8 8.21 1.96e-14 1.11e-07 0.54 0.49 Corneal astigmatism; chr4:119560276 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs2170276 ENSG00000275858.1 RP11-291L22.8 8.21 1.96e-14 1.11e-07 0.54 0.49 Corneal astigmatism; chr4:119564669 chr10:38450738~38451069:- CESC trans rs7554511 0.894 rs296545 ENSG00000244144.1 RP11-757F18.3 8.2 2e-14 1.13e-07 0.55 0.49 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200921564 chr3:112185480~112185998:- CESC trans rs7554511 0.894 rs296546 ENSG00000244144.1 RP11-757F18.3 8.2 2e-14 1.13e-07 0.55 0.49 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200921963 chr3:112185480~112185998:- CESC trans rs11098499 0.863 rs9997631 ENSG00000275858.1 RP11-291L22.8 8.2 2.01e-14 1.14e-07 0.54 0.49 Corneal astigmatism; chr4:119548840 chr10:38450738~38451069:- CESC trans rs877636 0.692 rs11171739 ENSG00000243403.1 RP11-330L19.1 8.2 2.04e-14 1.16e-07 0.46 0.49 Cognitive function; chr12:56076841 chr15:64592979~64593326:+ CESC trans rs11098499 0.909 rs7681214 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119464165 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs28559989 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119465472 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs28499576 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119465522 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs28632018 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119465575 chr10:38450738~38451069:- CESC trans rs11098499 0.908 rs71614449 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119465900 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs35063680 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119465947 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs34858317 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119465955 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs17046116 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119466104 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs17046118 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119466341 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs7654587 ENSG00000275858.1 RP11-291L22.8 8.2 2.06e-14 1.16e-07 0.54 0.49 Corneal astigmatism; chr4:119467251 chr10:38450738~38451069:- CESC trans rs7811142 0.83 rs118119933 ENSG00000228546.2 CTA-313A17.3 8.2 2.06e-14 1.16e-07 0.88 0.49 Platelet count; chr7:100341427 chr7:102337316~102339115:+ CESC trans rs116095464 0.558 rs9654453 ENSG00000185986.11 SDHAP3 8.2 2.09e-14 1.18e-07 0.88 0.49 Breast cancer; chr5:299506 chr5:1572222~1594620:- CESC trans rs1707322 0.65 rs4553239 ENSG00000255397.1 AC022182.2 -8.2 2.1e-14 1.19e-07 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684814 chr8:60937705~60939871:- CESC trans rs1707322 0.506 rs2991983 ENSG00000255397.1 AC022182.2 8.2 2.11e-14 1.19e-07 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613719 chr8:60937705~60939871:- CESC trans rs11098499 0.821 rs10032151 ENSG00000275858.1 RP11-291L22.8 8.2 2.11e-14 1.19e-07 0.54 0.49 Corneal astigmatism; chr4:119470473 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs10032158 ENSG00000275858.1 RP11-291L22.8 8.2 2.11e-14 1.19e-07 0.54 0.49 Corneal astigmatism; chr4:119470477 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs6838814 ENSG00000275858.1 RP11-291L22.8 8.2 2.11e-14 1.19e-07 0.54 0.49 Corneal astigmatism; chr4:119471288 chr10:38450738~38451069:- CESC trans rs1707322 0.686 rs2991977 ENSG00000255397.1 AC022182.2 8.19 2.14e-14 1.21e-07 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45588011 chr8:60937705~60939871:- CESC trans rs1707322 0.656 rs2991981 ENSG00000255397.1 AC022182.2 8.19 2.14e-14 1.21e-07 0.63 0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45591472 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs11211165 ENSG00000255397.1 AC022182.2 -8.19 2.14e-14 1.21e-07 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692234 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs11211166 ENSG00000255397.1 AC022182.2 -8.19 2.14e-14 1.21e-07 -0.63 -0.49 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692270 chr8:60937705~60939871:- CESC trans rs4276421 1 rs11748089 ENSG00000231752.4 EMBP1 -8.19 2.15e-14 1.22e-07 -0.59 -0.49 P wave duration; chr5:45810733 chr1:121519112~121571892:+ CESC trans rs4276421 1 rs10037766 ENSG00000231752.4 EMBP1 -8.19 2.15e-14 1.22e-07 -0.59 -0.49 P wave duration; chr5:45813215 chr1:121519112~121571892:+ CESC trans rs4276421 0.967 rs10755272 ENSG00000231752.4 EMBP1 -8.19 2.15e-14 1.22e-07 -0.59 -0.49 P wave duration; chr5:45815434 chr1:121519112~121571892:+ CESC trans rs4276421 1 rs4866982 ENSG00000231752.4 EMBP1 -8.19 2.15e-14 1.22e-07 -0.59 -0.49 P wave duration; chr5:45816754 chr1:121519112~121571892:+ CESC trans rs4276421 0.901 rs10056175 ENSG00000231752.4 EMBP1 8.19 2.17e-14 1.22e-07 0.59 0.49 P wave duration; chr5:45934503 chr1:121519112~121571892:+ CESC trans rs4276421 0.934 rs6451838 ENSG00000231752.4 EMBP1 8.19 2.17e-14 1.22e-07 0.59 0.49 P wave duration; chr5:45935060 chr1:121519112~121571892:+ CESC trans rs4276421 0.934 rs6451840 ENSG00000231752.4 EMBP1 8.19 2.17e-14 1.22e-07 0.59 0.49 P wave duration; chr5:45935584 chr1:121519112~121571892:+ CESC trans rs4276421 0.87 rs6451842 ENSG00000231752.4 EMBP1 8.19 2.17e-14 1.22e-07 0.59 0.49 P wave duration; chr5:45936431 chr1:121519112~121571892:+ CESC trans rs11098499 0.909 rs1809406 ENSG00000275858.1 RP11-291L22.8 8.19 2.18e-14 1.23e-07 0.54 0.49 Corneal astigmatism; chr4:119455967 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs2389809 ENSG00000275858.1 RP11-291L22.8 8.19 2.18e-14 1.23e-07 0.54 0.49 Corneal astigmatism; chr4:119456244 chr10:38450738~38451069:- CESC trans rs11098499 0.657 rs71614442 ENSG00000275858.1 RP11-291L22.8 8.19 2.18e-14 1.23e-07 0.54 0.49 Corneal astigmatism; chr4:119458191 chr10:38450738~38451069:- CESC trans rs11098499 0.954 rs2892848 ENSG00000275858.1 RP11-291L22.8 8.19 2.18e-14 1.23e-07 0.54 0.49 Corneal astigmatism; chr4:119460186 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs9994810 ENSG00000275858.1 RP11-291L22.8 8.19 2.18e-14 1.23e-07 0.54 0.49 Corneal astigmatism; chr4:119460435 chr10:38450738~38451069:- CESC trans rs11098499 0.697 rs10020027 ENSG00000275858.1 RP11-291L22.8 8.19 2.18e-14 1.23e-07 0.54 0.49 Corneal astigmatism; chr4:119460724 chr10:38450738~38451069:- CESC trans rs11098499 0.779 rs7356491 ENSG00000275858.1 RP11-291L22.8 8.19 2.18e-14 1.23e-07 0.54 0.49 Corneal astigmatism; chr4:119460819 chr10:38450738~38451069:- CESC trans rs867371 1 rs13380319 ENSG00000235370.6 DNM1P51 -8.19 2.22e-14 1.25e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214526 chr15:84398316~84411701:- CESC trans rs9611565 0.921 rs3927 ENSG00000268568.1 AC007228.9 -8.19 2.23e-14 1.25e-07 -0.69 -0.48 Vitiligo; chr22:41326860 chr19:56672574~56673901:- CESC trans rs4276421 0.715 rs10043248 ENSG00000231752.4 EMBP1 8.19 2.25e-14 1.27e-07 0.6 0.48 P wave duration; chr5:46025930 chr1:121519112~121571892:+ CESC trans rs4276421 0.874 rs6451830 ENSG00000231752.4 EMBP1 8.18 2.37e-14 1.33e-07 0.59 0.48 P wave duration; chr5:45893354 chr1:121519112~121571892:+ CESC trans rs11098499 0.697 rs11941899 ENSG00000275858.1 RP11-291L22.8 8.18 2.39e-14 1.34e-07 0.54 0.48 Corneal astigmatism; chr4:119461603 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs7681978 ENSG00000275858.1 RP11-291L22.8 8.18 2.39e-14 1.34e-07 0.54 0.48 Corneal astigmatism; chr4:119462620 chr10:38450738~38451069:- CESC trans rs11098499 0.821 rs28665282 ENSG00000275858.1 RP11-291L22.8 8.18 2.39e-14 1.34e-07 0.54 0.48 Corneal astigmatism; chr4:119463031 chr10:38450738~38451069:- CESC trans rs11098499 0.738 rs10026493 ENSG00000275858.1 RP11-291L22.8 8.18 2.39e-14 1.34e-07 0.54 0.48 Corneal astigmatism; chr4:119463039 chr10:38450738~38451069:- CESC trans rs4276421 0.609 rs4975911 ENSG00000231752.4 EMBP1 -8.17 2.42e-14 1.35e-07 -0.61 -0.48 P wave duration; chr5:46297143 chr1:121519112~121571892:+ CESC trans rs13358908 0.715 rs8185301 ENSG00000231752.4 EMBP1 -8.17 2.42e-14 1.35e-07 -0.61 -0.48 Schizophrenia; chr5:46312149 chr1:121519112~121571892:+ CESC trans rs13358908 0.652 rs7293494 ENSG00000231752.4 EMBP1 -8.17 2.42e-14 1.35e-07 -0.61 -0.48 Schizophrenia; chr5:46313550 chr1:121519112~121571892:+ CESC trans rs4276421 0.578 rs8185314 ENSG00000231752.4 EMBP1 -8.17 2.44e-14 1.36e-07 -0.61 -0.48 P wave duration; chr5:46299648 chr1:121519112~121571892:+ CESC trans rs11098499 0.954 rs9993199 ENSG00000275858.1 RP11-291L22.8 -8.17 2.47e-14 1.38e-07 -0.54 -0.48 Corneal astigmatism; chr4:119471718 chr10:38450738~38451069:- CESC trans rs9611565 0.838 rs4239894 ENSG00000268568.1 AC007228.9 -8.17 2.48e-14 1.39e-07 -0.7 -0.48 Vitiligo; chr22:41349544 chr19:56672574~56673901:- CESC trans rs4276421 0.904 rs34462057 ENSG00000231752.4 EMBP1 8.17 2.51e-14 1.4e-07 0.59 0.48 P wave duration; chr5:45900215 chr1:121519112~121571892:+ CESC trans rs12709013 0.59 rs982848 ENSG00000230849.2 GOT2P2 8.17 2.55e-14 1.42e-07 0.57 0.48 Blood metabolite ratios; chr16:58704294 chr1:173141100~173142350:- CESC trans rs1707322 0.752 rs4660880 ENSG00000255397.1 AC022182.2 -8.16 2.6e-14 1.45e-07 -0.63 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645368 chr8:60937705~60939871:- CESC trans rs4276421 0.816 rs6451835 ENSG00000231752.4 EMBP1 8.16 2.64e-14 1.47e-07 0.59 0.48 P wave duration; chr5:45928735 chr1:121519112~121571892:+ CESC trans rs116095464 0.558 rs9312957 ENSG00000185986.11 SDHAP3 8.16 2.64e-14 1.47e-07 0.81 0.48 Breast cancer; chr5:202079 chr5:1572222~1594620:- CESC trans rs11098499 0.82 rs28578366 ENSG00000275858.1 RP11-291L22.8 -8.16 2.67e-14 1.49e-07 -0.55 -0.48 Corneal astigmatism; chr4:119615750 chr10:38450738~38451069:- CESC trans rs4276421 0.55 rs34812524 ENSG00000231752.4 EMBP1 8.16 2.67e-14 1.49e-07 0.59 0.48 P wave duration; chr5:46054030 chr1:121519112~121571892:+ CESC trans rs13358908 0.652 rs8185385 ENSG00000231752.4 EMBP1 -8.16 2.67e-14 1.49e-07 -0.61 -0.48 Schizophrenia; chr5:46318532 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs2127823 ENSG00000275858.1 RP11-291L22.8 8.16 2.74e-14 1.53e-07 0.55 0.48 Corneal astigmatism; chr4:119564515 chr10:38450738~38451069:- CESC trans rs4276421 0.967 rs6865429 ENSG00000231752.4 EMBP1 -8.15 2.8e-14 1.56e-07 -0.6 -0.48 P wave duration; chr5:45830406 chr1:121519112~121571892:+ CESC trans rs877636 0.669 rs7297175 ENSG00000243403.1 RP11-330L19.1 -8.15 2.81e-14 1.56e-07 -0.47 -0.48 Cognitive function; chr12:56080024 chr15:64592979~64593326:+ CESC trans rs12709013 0.686 rs151817 ENSG00000230849.2 GOT2P2 -8.15 2.83e-14 1.58e-07 -0.58 -0.48 Blood metabolite ratios; chr16:58704014 chr1:173141100~173142350:- CESC trans rs7258465 1 rs34746918 ENSG00000267533.1 RP11-815J4.7 8.15 2.84e-14 1.58e-07 0.62 0.48 Breast cancer; chr19:18428934 chr18:12067173~12068417:- CESC trans rs7554547 0.905 rs4993564 ENSG00000261819.1 RP11-680G24.4 8.15 2.85e-14 1.59e-07 0.57 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11909934 chr16:14988259~14990160:- CESC trans rs12709013 0.686 rs244919 ENSG00000230849.2 GOT2P2 -8.15 2.85e-14 1.59e-07 -0.58 -0.48 Blood metabolite ratios; chr16:58704146 chr1:173141100~173142350:- CESC trans rs116095464 0.558 rs10065239 ENSG00000185986.11 SDHAP3 8.15 2.87e-14 1.6e-07 0.87 0.48 Breast cancer; chr5:275173 chr5:1572222~1594620:- CESC trans rs11098499 0.863 rs6534141 ENSG00000275858.1 RP11-291L22.8 8.15 2.91e-14 1.62e-07 0.54 0.48 Corneal astigmatism; chr4:119564068 chr10:38450738~38451069:- CESC trans rs11098499 0.863 rs3775858 ENSG00000275858.1 RP11-291L22.8 8.15 2.91e-14 1.62e-07 0.54 0.48 Corneal astigmatism; chr4:119564873 chr10:38450738~38451069:- CESC trans rs13190036 1 rs13177748 ENSG00000217325.2 PRELID1P1 -8.15 2.92e-14 1.62e-07 -0.78 -0.48 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177216953 chr6:126643488~126644390:+ CESC trans rs10940346 0.934 rs303231 ENSG00000231752.4 EMBP1 8.14 2.98e-14 1.65e-07 0.59 0.48 Schizophrenia; chr5:50447369 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs34832871 ENSG00000217325.2 PRELID1P1 -8.14 2.98e-14 1.66e-07 -0.79 -0.48 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228928 chr6:126643488~126644390:+ CESC trans rs1707322 0.717 rs1135812 ENSG00000255397.1 AC022182.2 -8.14 3e-14 1.67e-07 -0.63 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629600 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs6703748 ENSG00000255397.1 AC022182.2 -8.14 3e-14 1.67e-07 -0.63 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45630304 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs11211168 ENSG00000255397.1 AC022182.2 -8.14 3.02e-14 1.68e-07 -0.63 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45697975 chr8:60937705~60939871:- CESC trans rs10940346 0.935 rs2353959 ENSG00000231752.4 EMBP1 -8.14 3.03e-14 1.68e-07 -0.59 -0.48 Schizophrenia; chr5:50473217 chr1:121519112~121571892:+ CESC trans rs9611565 0.592 rs5996037 ENSG00000268568.1 AC007228.9 -8.14 3.06e-14 1.69e-07 -0.67 -0.48 Vitiligo; chr22:41569288 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs5996038 ENSG00000268568.1 AC007228.9 -8.14 3.06e-14 1.69e-07 -0.67 -0.48 Vitiligo; chr22:41569296 chr19:56672574~56673901:- CESC trans rs877636 0.692 rs2271194 ENSG00000196933.5 RPS26P11 -8.14 3.06e-14 1.7e-07 -0.53 -0.48 Cognitive function; chr12:56083910 chrX:72044545~72044892:+ CESC trans rs2657294 0.704 rs10824266 ENSG00000172974.11 AC007318.5 8.14 3.11e-14 1.72e-07 0.5 0.48 Pneumonia; chr10:75083476 chr2:65205108~65205988:+ CESC trans rs916888 0.61 rs199453 ENSG00000264070.1 DND1P1 8.13 3.11e-14 1.72e-07 0.59 0.48 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45585871~45586929:+ CESC trans rs4276421 0.967 rs7725171 ENSG00000231752.4 EMBP1 8.13 3.14e-14 1.74e-07 0.58 0.48 P wave duration; chr5:45923684 chr1:121519112~121571892:+ CESC trans rs1707322 0.752 rs12062535 ENSG00000255397.1 AC022182.2 -8.13 3.17e-14 1.75e-07 -0.63 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45757208 chr8:60937705~60939871:- CESC trans rs916888 0.61 rs199452 ENSG00000264070.1 DND1P1 8.13 3.22e-14 1.78e-07 0.58 0.48 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45585871~45586929:+ CESC trans rs4276421 0.874 rs34501453 ENSG00000231752.4 EMBP1 8.13 3.27e-14 1.8e-07 0.59 0.48 P wave duration; chr5:45947338 chr1:121519112~121571892:+ CESC trans rs4276421 0.845 rs4492122 ENSG00000231752.4 EMBP1 8.13 3.27e-14 1.8e-07 0.59 0.48 P wave duration; chr5:45982952 chr1:121519112~121571892:+ CESC trans rs7554547 0.791 rs34117126 ENSG00000261819.1 RP11-680G24.4 8.12 3.35e-14 1.85e-07 0.55 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11892138 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs17037520 ENSG00000261819.1 RP11-680G24.4 8.12 3.35e-14 1.85e-07 0.55 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11892349 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs12749498 ENSG00000261819.1 RP11-680G24.4 8.12 3.35e-14 1.85e-07 0.55 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11892570 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs12036266 ENSG00000261819.1 RP11-680G24.4 8.12 3.35e-14 1.85e-07 0.55 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11893257 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs2065611 ENSG00000261819.1 RP11-680G24.4 8.12 3.35e-14 1.85e-07 0.55 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11893469 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs4492637 ENSG00000261819.1 RP11-680G24.4 8.12 3.35e-14 1.85e-07 0.55 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11895787 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs4846074 ENSG00000261819.1 RP11-680G24.4 8.12 3.35e-14 1.85e-07 0.55 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11896172 chr16:14988259~14990160:- CESC trans rs4276421 0.736 rs7445572 ENSG00000231752.4 EMBP1 8.12 3.42e-14 1.88e-07 0.58 0.48 P wave duration; chr5:45920315 chr1:121519112~121571892:+ CESC trans rs6732160 0.613 rs58317144 ENSG00000236165.1 PRADC1P1 8.12 3.48e-14 1.92e-07 0.66 0.48 Intelligence (multi-trait analysis); chr2:73161025 chr3:36976316~36976840:+ CESC trans rs4276421 0.904 rs6862657 ENSG00000231752.4 EMBP1 -8.12 3.5e-14 1.93e-07 -0.6 -0.48 P wave duration; chr5:45905895 chr1:121519112~121571892:+ CESC trans rs867371 1 rs7166570 ENSG00000235370.6 DNM1P51 -8.11 3.72e-14 2.05e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82173880 chr15:84398316~84411701:- CESC trans rs867371 1 rs7173339 ENSG00000235370.6 DNM1P51 -8.11 3.72e-14 2.05e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82175253 chr15:84398316~84411701:- CESC trans rs116095464 0.558 rs10065584 ENSG00000185986.11 SDHAP3 8.11 3.73e-14 2.06e-07 0.88 0.48 Breast cancer; chr5:253882 chr5:1572222~1594620:- CESC trans rs13358908 0.715 rs10053628 ENSG00000231752.4 EMBP1 -8.11 3.73e-14 2.06e-07 -0.59 -0.48 Schizophrenia; chr5:46383233 chr1:121519112~121571892:+ CESC trans rs1707322 0.627 rs3014213 ENSG00000255397.1 AC022182.2 8.11 3.74e-14 2.06e-07 0.63 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45579850 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs2152078 ENSG00000255397.1 AC022182.2 8.11 3.74e-14 2.06e-07 0.63 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45589928 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs2991979 ENSG00000255397.1 AC022182.2 8.11 3.74e-14 2.06e-07 0.63 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45590186 chr8:60937705~60939871:- CESC trans rs1707322 0.647 rs6686944 ENSG00000255397.1 AC022182.2 -8.1 3.82e-14 2.1e-07 -0.63 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690636 chr8:60937705~60939871:- CESC trans rs11098499 0.863 rs10018280 ENSG00000275858.1 RP11-291L22.8 8.1 3.92e-14 2.16e-07 0.54 0.48 Corneal astigmatism; chr4:119556984 chr10:38450738~38451069:- CESC trans rs13190036 1 rs34832871 ENSG00000226986.4 RP11-543B16.2 -8.1 3.94e-14 2.16e-07 -0.63 -0.48 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228928 chr1:211207239~211207897:+ CESC trans rs1707322 0.752 rs28550303 ENSG00000255397.1 AC022182.2 -8.1 3.95e-14 2.17e-07 -0.63 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45723242 chr8:60937705~60939871:- CESC trans rs116095464 0.558 rs9687621 ENSG00000185986.11 SDHAP3 8.1 3.96e-14 2.18e-07 0.87 0.48 Breast cancer; chr5:229079 chr5:1572222~1594620:- CESC trans rs867371 1 rs8041924 ENSG00000235370.6 DNM1P51 -8.09 4.02e-14 2.2e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82181320 chr15:84398316~84411701:- CESC trans rs867371 1 rs2088858 ENSG00000235370.6 DNM1P51 -8.09 4.02e-14 2.2e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82182408 chr15:84398316~84411701:- CESC trans rs867371 1 rs4778982 ENSG00000235370.6 DNM1P51 -8.09 4.02e-14 2.2e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82182931 chr15:84398316~84411701:- CESC trans rs867371 1 rs2867579 ENSG00000235370.6 DNM1P51 -8.09 4.02e-14 2.2e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82183043 chr15:84398316~84411701:- CESC trans rs867371 1 rs881308 ENSG00000235370.6 DNM1P51 -8.09 4.02e-14 2.2e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82183456 chr15:84398316~84411701:- CESC trans rs3779195 0.929 rs4268041 ENSG00000225169.1 BRI3P1 -8.09 4.05e-14 2.22e-07 -0.73 -0.48 Sex hormone-binding globulin levels; chr7:98376226 chr1:100213293~100213670:+ CESC trans rs4276421 1 rs28657933 ENSG00000231752.4 EMBP1 8.09 4.07e-14 2.23e-07 0.58 0.48 P wave duration; chr5:45863597 chr1:121519112~121571892:+ CESC trans rs4276421 1 rs10039283 ENSG00000231752.4 EMBP1 8.09 4.07e-14 2.23e-07 0.58 0.48 P wave duration; chr5:45864741 chr1:121519112~121571892:+ CESC trans rs4276421 0.967 rs4282324 ENSG00000231752.4 EMBP1 8.09 4.07e-14 2.23e-07 0.58 0.48 P wave duration; chr5:45865330 chr1:121519112~121571892:+ CESC trans rs4276421 1 rs6895191 ENSG00000231752.4 EMBP1 8.09 4.07e-14 2.23e-07 0.58 0.48 P wave duration; chr5:45877572 chr1:121519112~121571892:+ CESC trans rs4276421 0.935 rs12109652 ENSG00000231752.4 EMBP1 8.09 4.07e-14 2.23e-07 0.58 0.48 P wave duration; chr5:45878206 chr1:121519112~121571892:+ CESC trans rs4276421 0.935 rs6451827 ENSG00000231752.4 EMBP1 8.09 4.07e-14 2.23e-07 0.58 0.48 P wave duration; chr5:45879496 chr1:121519112~121571892:+ CESC trans rs7811142 0.943 rs3900792 ENSG00000228546.2 CTA-313A17.3 8.09 4.1e-14 2.25e-07 0.81 0.48 Platelet count; chr7:100406954 chr7:102337316~102339115:+ CESC trans rs4276421 0.874 rs7727331 ENSG00000231752.4 EMBP1 8.09 4.22e-14 2.31e-07 0.58 0.48 P wave duration; chr5:45945199 chr1:121519112~121571892:+ CESC trans rs616147 0.627 rs9871799 ENSG00000183298.5 RP11-556K13.1 8.08 4.3e-14 2.36e-07 0.6 0.48 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39442829 chr1:101786340~101787219:- CESC trans rs1707322 0.686 rs2230658 ENSG00000255397.1 AC022182.2 8.08 4.4e-14 2.41e-07 0.62 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613182 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs2230659 ENSG00000255397.1 AC022182.2 8.08 4.4e-14 2.41e-07 0.62 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613212 chr8:60937705~60939871:- CESC trans rs867371 1 rs8037224 ENSG00000235370.6 DNM1P51 -8.08 4.51e-14 2.47e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82172189 chr15:84398316~84411701:- CESC trans rs867371 1 rs1501372 ENSG00000235370.6 DNM1P51 -8.08 4.51e-14 2.47e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82176114 chr15:84398316~84411701:- CESC trans rs3779195 0.697 rs1688606 ENSG00000225169.1 BRI3P1 8.07 4.62e-14 2.52e-07 0.75 0.48 Sex hormone-binding globulin levels; chr7:98345539 chr1:100213293~100213670:+ CESC trans rs11098499 0.662 rs13108589 ENSG00000275858.1 RP11-291L22.8 8.07 4.79e-14 2.61e-07 0.54 0.48 Corneal astigmatism; chr4:119346947 chr10:38450738~38451069:- CESC trans rs1707322 0.717 rs3014249 ENSG00000255397.1 AC022182.2 8.06 4.84e-14 2.64e-07 0.62 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613821 chr8:60937705~60939871:- CESC trans rs7121616 0.531 rs11218941 ENSG00000229091.2 HSPA8P8 8.06 4.9e-14 2.67e-07 0.61 0.48 Breast cancer; chr11:123061701 chr7:10451311~10452526:+ CESC trans rs11098499 0.908 rs9995234 ENSG00000275858.1 RP11-291L22.8 8.06 4.91e-14 2.68e-07 0.56 0.48 Corneal astigmatism; chr4:119400672 chr10:38450738~38451069:- CESC trans rs4276421 0.935 rs6451834 ENSG00000231752.4 EMBP1 8.06 4.93e-14 2.69e-07 0.58 0.48 P wave duration; chr5:45927208 chr1:121519112~121571892:+ CESC trans rs4276421 0.657 rs8188296 ENSG00000231752.4 EMBP1 8.06 4.93e-14 2.69e-07 0.6 0.48 P wave duration; chr5:46221948 chr1:121519112~121571892:+ CESC trans rs11098499 0.863 rs11098532 ENSG00000275858.1 RP11-291L22.8 8.06 4.95e-14 2.69e-07 0.54 0.48 Corneal astigmatism; chr4:119569571 chr10:38450738~38451069:- CESC trans rs9611565 0.592 rs80477 ENSG00000268568.1 AC007228.9 8.06 4.96e-14 2.7e-07 0.66 0.48 Vitiligo; chr22:41605179 chr19:56672574~56673901:- CESC trans rs867371 0.929 rs7176075 ENSG00000235370.6 DNM1P51 -8.06 5.07e-14 2.76e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82178998 chr15:84398316~84411701:- CESC trans rs867371 1 rs8041868 ENSG00000235370.6 DNM1P51 -8.06 5.07e-14 2.76e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82179985 chr15:84398316~84411701:- CESC trans rs867371 1 rs6495643 ENSG00000235370.6 DNM1P51 -8.06 5.07e-14 2.76e-07 -0.62 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82186913 chr15:84398316~84411701:- CESC trans rs13190036 1 rs13177748 ENSG00000226986.4 RP11-543B16.2 -8.06 5.12e-14 2.79e-07 -0.62 -0.48 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177216953 chr1:211207239~211207897:+ CESC trans rs1707322 0.682 rs10890334 ENSG00000255397.1 AC022182.2 -8.05 5.16e-14 2.81e-07 -0.62 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634706 chr8:60937705~60939871:- CESC trans rs1707322 0.682 rs10890335 ENSG00000255397.1 AC022182.2 -8.05 5.16e-14 2.81e-07 -0.62 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634722 chr8:60937705~60939871:- CESC trans rs1707322 0.716 rs6694889 ENSG00000255397.1 AC022182.2 -8.05 5.16e-14 2.81e-07 -0.62 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45636134 chr8:60937705~60939871:- CESC trans rs1707322 0.682 rs12041197 ENSG00000255397.1 AC022182.2 -8.05 5.16e-14 2.81e-07 -0.62 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638792 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs12023439 ENSG00000255397.1 AC022182.2 -8.05 5.16e-14 2.81e-07 -0.62 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638964 chr8:60937705~60939871:- CESC trans rs4276421 0.967 rs6878425 ENSG00000231752.4 EMBP1 8.05 5.31e-14 2.88e-07 0.58 0.48 P wave duration; chr5:45843153 chr1:121519112~121571892:+ CESC trans rs4276421 1 rs13175559 ENSG00000231752.4 EMBP1 8.05 5.31e-14 2.88e-07 0.58 0.48 P wave duration; chr5:45854525 chr1:121519112~121571892:+ CESC trans rs4276421 0.967 rs4541666 ENSG00000231752.4 EMBP1 8.05 5.31e-14 2.88e-07 0.58 0.48 P wave duration; chr5:45857027 chr1:121519112~121571892:+ CESC trans rs4276421 1 rs4331911 ENSG00000231752.4 EMBP1 8.05 5.31e-14 2.88e-07 0.58 0.48 P wave duration; chr5:45859273 chr1:121519112~121571892:+ CESC trans rs4276421 0.935 rs6898824 ENSG00000231752.4 EMBP1 -8.05 5.31e-14 2.88e-07 -0.58 -0.48 P wave duration; chr5:45842058 chr1:121519112~121571892:+ CESC trans rs4276421 0.688 rs7713759 ENSG00000231752.4 EMBP1 8.05 5.36e-14 2.91e-07 0.61 0.48 P wave duration; chr5:46143447 chr1:121519112~121571892:+ CESC trans rs10242455 0.702 rs74552228 ENSG00000228834.1 RP11-249L21.4 8.05 5.36e-14 2.91e-07 1.38 0.48 Blood metabolite levels; chr7:99379423 chr6:108907615~108907873:- CESC trans rs10242455 0.702 rs17161700 ENSG00000228834.1 RP11-249L21.4 8.05 5.36e-14 2.91e-07 1.38 0.48 Blood metabolite levels; chr7:99379444 chr6:108907615~108907873:- CESC trans rs1707322 0.686 rs2991986 ENSG00000255397.1 AC022182.2 8.05 5.39e-14 2.92e-07 0.62 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615610 chr8:60937705~60939871:- CESC trans rs1707322 0.752 rs11488313 ENSG00000255397.1 AC022182.2 -8.05 5.48e-14 2.97e-07 -0.61 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45759108 chr8:60937705~60939871:- CESC trans rs11098499 0.863 rs9884402 ENSG00000275858.1 RP11-291L22.8 8.04 5.64e-14 3.05e-07 0.54 0.48 Corneal astigmatism; chr4:119568827 chr10:38450738~38451069:- CESC trans rs11098499 0.731 rs9995026 ENSG00000275858.1 RP11-291L22.8 8.04 5.64e-14 3.05e-07 0.54 0.48 Corneal astigmatism; chr4:119569344 chr10:38450738~38451069:- CESC trans rs4276421 0.935 rs4502836 ENSG00000231752.4 EMBP1 8.04 5.73e-14 3.1e-07 0.59 0.48 P wave duration; chr5:45956617 chr1:121519112~121571892:+ CESC trans rs4276421 0.934 rs7443410 ENSG00000231752.4 EMBP1 8.04 5.73e-14 3.1e-07 0.59 0.48 P wave duration; chr5:45960831 chr1:121519112~121571892:+ CESC trans rs10242455 0.571 rs79694709 ENSG00000228834.1 RP11-249L21.4 8.04 5.75e-14 3.11e-07 1.38 0.48 Blood metabolite levels; chr7:99617088 chr6:108907615~108907873:- CESC trans rs3779195 0.929 rs10953259 ENSG00000225169.1 BRI3P1 -8.04 5.76e-14 3.11e-07 -0.77 -0.48 Sex hormone-binding globulin levels; chr7:98383795 chr1:100213293~100213670:+ CESC trans rs6732160 0.588 rs10192654 ENSG00000236165.1 PRADC1P1 -8.03 5.89e-14 3.18e-07 -0.63 -0.48 Intelligence (multi-trait analysis); chr2:73143754 chr3:36976316~36976840:+ CESC trans rs6732160 0.588 rs13407363 ENSG00000236165.1 PRADC1P1 8.03 5.89e-14 3.18e-07 0.63 0.48 Intelligence (multi-trait analysis); chr2:73145430 chr3:36976316~36976840:+ CESC trans rs77688320 0.535 rs2540441 ENSG00000235105.1 RP11-329A14.1 -8.03 5.9e-14 3.19e-07 -0.55 -0.48 Breast cancer; chr2:201481946 chr1:48435967~48437223:+ CESC trans rs1707322 0.686 rs1084086 ENSG00000255397.1 AC022182.2 8.03 5.92e-14 3.19e-07 0.62 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45575428 chr8:60937705~60939871:- CESC trans rs4276421 0.967 rs4541665 ENSG00000231752.4 EMBP1 -8.03 5.93e-14 3.2e-07 -0.59 -0.48 P wave duration; chr5:45796444 chr1:121519112~121571892:+ CESC trans rs7200543 1 rs4500751 ENSG00000250569.1 NTAN1P2 8.03 6.11e-14 3.3e-07 0.59 0.48 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15046354 chr8:86481754~86483002:- CESC trans rs9611565 0.592 rs5751129 ENSG00000268568.1 AC007228.9 8.03 6.17e-14 3.32e-07 0.65 0.48 Vitiligo; chr22:41619761 chr19:56672574~56673901:- CESC trans rs4276421 1 rs4276421 ENSG00000231752.4 EMBP1 -8.02 6.23e-14 3.35e-07 -0.58 -0.48 P wave duration; chr5:45801977 chr1:121519112~121571892:+ CESC trans rs9611565 0.559 rs12483860 ENSG00000268568.1 AC007228.9 -8.02 6.33e-14 3.4e-07 -0.66 -0.48 Vitiligo; chr22:41565912 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs12484254 ENSG00000268568.1 AC007228.9 -8.02 6.33e-14 3.4e-07 -0.66 -0.48 Vitiligo; chr22:41565999 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs4822040 ENSG00000268568.1 AC007228.9 -8.02 6.33e-14 3.4e-07 -0.66 -0.48 Vitiligo; chr22:41567549 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs7290990 ENSG00000268568.1 AC007228.9 -8.02 6.33e-14 3.4e-07 -0.66 -0.48 Vitiligo; chr22:41568353 chr19:56672574~56673901:- CESC trans rs9611565 0.559 rs7290991 ENSG00000268568.1 AC007228.9 -8.02 6.33e-14 3.4e-07 -0.66 -0.48 Vitiligo; chr22:41568357 chr19:56672574~56673901:- CESC trans rs1707322 0.752 rs11211145 ENSG00000255397.1 AC022182.2 -8.02 6.47e-14 3.47e-07 -0.66 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642819 chr8:60937705~60939871:- CESC trans rs867371 1 rs1846911 ENSG00000235370.6 DNM1P51 -8.02 6.49e-14 3.48e-07 -0.61 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82176309 chr15:84398316~84411701:- CESC trans rs867371 0.964 rs7169961 ENSG00000235370.6 DNM1P51 -8.02 6.49e-14 3.48e-07 -0.61 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82186588 chr15:84398316~84411701:- CESC trans rs1707322 0.721 rs12043945 ENSG00000255397.1 AC022182.2 -8.02 6.55e-14 3.51e-07 -0.62 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45641250 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs12091503 ENSG00000255397.1 AC022182.2 -8.02 6.55e-14 3.51e-07 -0.62 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642196 chr8:60937705~60939871:- CESC trans rs7937890 0.904 rs7484197 ENSG00000236360.2 RP11-334A14.2 8.02 6.57e-14 3.52e-07 0.55 0.48 Mitochondrial DNA levels; chr11:14262108 chr1:52993201~52993702:- CESC trans rs12709013 0.686 rs151817 ENSG00000233719.3 GOT2P3 -8.01 6.86e-14 3.67e-07 -0.54 -0.48 Blood metabolite ratios; chr16:58704014 chr12:9641802~9643007:+ CESC trans rs867371 0.896 rs6495647 ENSG00000235370.6 DNM1P51 -8.01 6.89e-14 3.68e-07 -0.61 -0.48 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82244708 chr15:84398316~84411701:- CESC trans rs1707322 0.685 rs56177313 ENSG00000255397.1 AC022182.2 -8.01 6.89e-14 3.68e-07 -0.61 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760134 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs11211178 ENSG00000255397.1 AC022182.2 -8.01 6.89e-14 3.68e-07 -0.61 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45761894 chr8:60937705~60939871:- CESC trans rs9611565 0.625 rs12483991 ENSG00000268568.1 AC007228.9 -8.01 7.04e-14 3.76e-07 -0.63 -0.48 Vitiligo; chr22:41539281 chr19:56672574~56673901:- CESC trans rs1707322 0.752 rs4660313 ENSG00000255397.1 AC022182.2 8 7.16e-14 3.82e-07 0.62 0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645169 chr8:60937705~60939871:- CESC trans rs877636 0.669 rs7297175 ENSG00000223416.3 RPS26P15 -8 7.31e-14 3.9e-07 -0.48 -0.48 Cognitive function; chr12:56080024 chr1:58056133~58056480:- CESC trans rs7258465 0.931 rs271626 ENSG00000267533.1 RP11-815J4.7 -7.99 7.54e-14 4.02e-07 -0.62 -0.48 Breast cancer; chr19:18516257 chr18:12067173~12068417:- CESC trans rs4276421 0.556 rs10213679 ENSG00000231752.4 EMBP1 7.99 7.62e-14 4.06e-07 0.59 0.48 P wave duration; chr5:45954206 chr1:121519112~121571892:+ CESC trans rs4276421 0.904 rs4289566 ENSG00000231752.4 EMBP1 7.99 7.62e-14 4.06e-07 0.59 0.48 P wave duration; chr5:45955499 chr1:121519112~121571892:+ CESC trans rs1707322 0.721 rs4559551 ENSG00000255397.1 AC022182.2 -7.99 7.75e-14 4.13e-07 -0.62 -0.48 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701861 chr8:60937705~60939871:- CESC trans rs8010715 0.52 rs12435994 ENSG00000238000.1 RP11-274E7.2 7.99 7.9e-14 4.21e-07 0.49 0.48 IgG glycosylation; chr14:24120252 chr5:98213402~98214121:+ CESC trans rs8010715 0.596 rs12435995 ENSG00000238000.1 RP11-274E7.2 7.99 7.9e-14 4.21e-07 0.49 0.48 IgG glycosylation; chr14:24120255 chr5:98213402~98214121:+ CESC trans rs11098499 0.754 rs714899 ENSG00000275858.1 RP11-291L22.8 7.99 7.92e-14 4.21e-07 0.53 0.48 Corneal astigmatism; chr4:119321880 chr10:38450738~38451069:- CESC trans rs13177918 0.717 rs6874318 ENSG00000239528.1 RPS14P8 -7.99 8e-14 4.26e-07 -0.62 -0.48 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr5:116562562~116562930:+ CESC trans rs13190036 1 rs13185316 ENSG00000226986.4 RP11-543B16.2 -7.98 8.08e-14 4.3e-07 -0.6 -0.48 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177213339 chr1:211207239~211207897:+ CESC trans rs4276421 0.682 rs12657581 ENSG00000231752.4 EMBP1 7.98 8.32e-14 4.42e-07 0.59 0.48 P wave duration; chr5:46080471 chr1:121519112~121571892:+ CESC trans rs11098499 1 rs11098499 ENSG00000275858.1 RP11-291L22.8 7.98 8.48e-14 4.51e-07 0.54 0.48 Corneal astigmatism; chr4:119266456 chr10:38450738~38451069:- CESC trans rs11098499 1 rs7659194 ENSG00000275858.1 RP11-291L22.8 7.98 8.48e-14 4.51e-07 0.54 0.48 Corneal astigmatism; chr4:119285992 chr10:38450738~38451069:- CESC trans rs9611565 0.592 rs9611612 ENSG00000268568.1 AC007228.9 -7.98 8.5e-14 4.51e-07 -0.66 -0.48 Vitiligo; chr22:41565185 chr19:56672574~56673901:- CESC trans rs3779195 0.697 rs13232861 ENSG00000225169.1 BRI3P1 7.98 8.5e-14 4.51e-07 0.75 0.48 Sex hormone-binding globulin levels; chr7:98299769 chr1:100213293~100213670:+ CESC trans rs916888 0.647 rs199449 ENSG00000214425.5 LRRC37A4P -7.97 8.52e-14 4.52e-07 -0.5 -0.48 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45506741~45550335:- CESC trans rs9611565 0.592 rs9611613 ENSG00000268568.1 AC007228.9 -7.97 8.53e-14 4.53e-07 -0.66 -0.48 Vitiligo; chr22:41565827 chr19:56672574~56673901:- CESC trans rs877636 0.692 rs11171739 ENSG00000196656.7 AC004057.1 7.97 8.7e-14 4.61e-07 0.48 0.48 Cognitive function; chr12:56076841 chr4:113214046~113217170:- CESC trans rs12709013 0.686 rs244919 ENSG00000233719.3 GOT2P3 -7.97 8.85e-14 4.69e-07 -0.54 -0.47 Blood metabolite ratios; chr16:58704146 chr12:9641802~9643007:+ CESC trans rs9611565 0.918 rs4820438 ENSG00000268568.1 AC007228.9 -7.97 9e-14 4.77e-07 -0.65 -0.47 Vitiligo; chr22:41371131 chr19:56672574~56673901:- CESC trans rs6732160 0.564 rs1430346 ENSG00000236165.1 PRADC1P1 7.96 9.37e-14 4.95e-07 0.66 0.47 Intelligence (multi-trait analysis); chr2:73140117 chr3:36976316~36976840:+ CESC trans rs11098499 1 rs13116504 ENSG00000275858.1 RP11-291L22.8 7.96 9.4e-14 4.97e-07 0.54 0.47 Corneal astigmatism; chr4:119288257 chr10:38450738~38451069:- CESC trans rs4276421 0.774 rs4601053 ENSG00000231752.4 EMBP1 7.95 9.94e-14 5.24e-07 0.59 0.47 P wave duration; chr5:46101734 chr1:121519112~121571892:+ CESC trans rs7811142 1 rs67315960 ENSG00000228546.2 CTA-313A17.3 7.95 1.01e-13 5.32e-07 0.83 0.47 Platelet count; chr7:100417501 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs11763414 ENSG00000228546.2 CTA-313A17.3 7.95 1.01e-13 5.32e-07 0.83 0.47 Platelet count; chr7:100419221 chr7:102337316~102339115:+ CESC trans rs1707322 0.721 rs10890346 ENSG00000255397.1 AC022182.2 7.95 1.01e-13 5.32e-07 0.6 0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758220 chr8:60937705~60939871:- CESC trans rs8010715 1 rs3742500 ENSG00000238000.1 RP11-274E7.2 7.95 1.02e-13 5.35e-07 0.49 0.47 IgG glycosylation; chr14:24142769 chr5:98213402~98214121:+ CESC trans rs1707322 0.752 rs6678444 ENSG00000255397.1 AC022182.2 -7.94 1.05e-13 5.54e-07 -0.61 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764175 chr8:60937705~60939871:- CESC trans rs116095464 0.558 rs10059907 ENSG00000185986.11 SDHAP3 7.94 1.05e-13 5.55e-07 0.83 0.47 Breast cancer; chr5:205245 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10060089 ENSG00000185986.11 SDHAP3 7.94 1.05e-13 5.55e-07 0.83 0.47 Breast cancer; chr5:205450 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs10068203 ENSG00000185986.11 SDHAP3 7.94 1.05e-13 5.55e-07 0.83 0.47 Breast cancer; chr5:206503 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs73029475 ENSG00000185986.11 SDHAP3 7.94 1.05e-13 5.55e-07 0.83 0.47 Breast cancer; chr5:206854 chr5:1572222~1594620:- CESC trans rs7312770 0.637 rs705700 ENSG00000234513.1 AC073072.7 7.94 1.07e-13 5.64e-07 0.5 0.47 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr7:22773646~22773993:- CESC trans rs7554511 1 rs7554511 ENSG00000244144.1 RP11-757F18.3 7.93 1.1e-13 5.78e-07 0.54 0.47 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200908434 chr3:112185480~112185998:- CESC trans rs13190036 1 rs628506 ENSG00000217325.2 PRELID1P1 -7.93 1.11e-13 5.82e-07 -0.72 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107422 chr6:126643488~126644390:+ CESC trans rs11098499 0.863 rs3736115 ENSG00000275858.1 RP11-291L22.8 -7.93 1.11e-13 5.84e-07 -0.54 -0.47 Corneal astigmatism; chr4:119567548 chr10:38450738~38451069:- CESC trans rs8010715 1 rs8010715 ENSG00000238000.1 RP11-274E7.2 7.93 1.11e-13 5.85e-07 0.5 0.47 IgG glycosylation; chr14:24139938 chr5:98213402~98214121:+ CESC trans rs1707322 0.685 rs11211177 ENSG00000255397.1 AC022182.2 -7.93 1.12e-13 5.87e-07 -0.59 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760677 chr8:60937705~60939871:- CESC trans rs2657294 0.734 rs2894244 ENSG00000172974.11 AC007318.5 7.93 1.12e-13 5.87e-07 0.48 0.47 Pneumonia; chr10:75087112 chr2:65205108~65205988:+ CESC trans rs7554547 0.791 rs4846076 ENSG00000261819.1 RP11-680G24.4 7.93 1.13e-13 5.93e-07 0.55 0.47 Nonsyndromic cleft lip with cleft palate; chr1:11896708 chr16:14988259~14990160:- CESC trans rs1707322 0.752 rs7541962 ENSG00000255397.1 AC022182.2 -7.93 1.14e-13 5.98e-07 -0.61 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769445 chr8:60937705~60939871:- CESC trans rs11098499 0.754 rs66900435 ENSG00000275858.1 RP11-291L22.8 7.93 1.15e-13 6.03e-07 0.52 0.47 Corneal astigmatism; chr4:119328270 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs17595608 ENSG00000275858.1 RP11-291L22.8 7.93 1.15e-13 6.03e-07 0.52 0.47 Corneal astigmatism; chr4:119329351 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs1980027 ENSG00000275858.1 RP11-291L22.8 7.93 1.15e-13 6.03e-07 0.52 0.47 Corneal astigmatism; chr4:119330422 chr10:38450738~38451069:- CESC trans rs4276421 0.839 rs7719401 ENSG00000231752.4 EMBP1 7.93 1.16e-13 6.09e-07 0.57 0.47 P wave duration; chr5:45938713 chr1:121519112~121571892:+ CESC trans rs4276421 0.967 rs35648163 ENSG00000231752.4 EMBP1 7.93 1.16e-13 6.09e-07 0.57 0.47 P wave duration; chr5:45945778 chr1:121519112~121571892:+ CESC trans rs4276421 0.904 rs6451843 ENSG00000231752.4 EMBP1 7.93 1.16e-13 6.09e-07 0.57 0.47 P wave duration; chr5:45946683 chr1:121519112~121571892:+ CESC trans rs10940346 1 rs2668024 ENSG00000231752.4 EMBP1 -7.92 1.17e-13 6.13e-07 -0.58 -0.47 Schizophrenia; chr5:50414421 chr1:121519112~121571892:+ CESC trans rs916888 0.61 rs199444 ENSG00000214425.5 LRRC37A4P -7.92 1.19e-13 6.26e-07 -0.5 -0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45506741~45550335:- CESC trans rs10242455 0.702 rs75156180 ENSG00000228834.1 RP11-249L21.4 7.92 1.22e-13 6.4e-07 1.28 0.47 Blood metabolite levels; chr7:99366477 chr6:108907615~108907873:- CESC trans rs4276421 0.874 rs4501347 ENSG00000231752.4 EMBP1 7.92 1.24e-13 6.46e-07 0.58 0.47 P wave duration; chr5:45974779 chr1:121519112~121571892:+ CESC trans rs4276421 0.845 rs62372987 ENSG00000231752.4 EMBP1 7.92 1.24e-13 6.46e-07 0.58 0.47 P wave duration; chr5:45979889 chr1:121519112~121571892:+ CESC trans rs116095464 1 rs28416084 ENSG00000185986.11 SDHAP3 7.91 1.24e-13 6.48e-07 0.83 0.47 Breast cancer; chr5:217525 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs9312978 ENSG00000185986.11 SDHAP3 7.91 1.24e-13 6.48e-07 0.83 0.47 Breast cancer; chr5:221815 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs9312979 ENSG00000185986.11 SDHAP3 7.91 1.24e-13 6.48e-07 0.83 0.47 Breast cancer; chr5:221942 chr5:1572222~1594620:- CESC trans rs13190036 0.591 rs78523677 ENSG00000217325.2 PRELID1P1 -7.91 1.24e-13 6.48e-07 -0.72 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177124102 chr6:126643488~126644390:+ CESC trans rs7200543 1 rs55727637 ENSG00000250569.1 NTAN1P2 7.91 1.25e-13 6.52e-07 0.61 0.47 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15051395 chr8:86481754~86483002:- CESC trans rs13190036 0.551 rs4976639 ENSG00000217325.2 PRELID1P1 7.91 1.26e-13 6.55e-07 0.7 0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177123300 chr6:126643488~126644390:+ CESC trans rs916888 0.61 rs142167 ENSG00000264070.1 DND1P1 -7.91 1.28e-13 6.67e-07 -0.58 -0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:45585871~45586929:+ CESC trans rs13190036 1 rs35535623 ENSG00000226986.4 RP11-543B16.2 -7.91 1.31e-13 6.83e-07 -0.6 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr1:211207239~211207897:+ CESC trans rs13190036 1 rs71601343 ENSG00000226986.4 RP11-543B16.2 -7.91 1.31e-13 6.83e-07 -0.6 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr1:211207239~211207897:+ CESC trans rs13190036 1 rs71601344 ENSG00000226986.4 RP11-543B16.2 -7.91 1.31e-13 6.83e-07 -0.6 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr1:211207239~211207897:+ CESC trans rs13190036 1 rs3733875 ENSG00000226986.4 RP11-543B16.2 -7.91 1.31e-13 6.83e-07 -0.6 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr1:211207239~211207897:+ CESC trans rs1707322 0.721 rs4660314 ENSG00000255397.1 AC022182.2 -7.9 1.32e-13 6.86e-07 -0.61 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764213 chr8:60937705~60939871:- CESC trans rs9611565 0.559 rs8139993 ENSG00000268568.1 AC007228.9 -7.9 1.33e-13 6.89e-07 -0.64 -0.47 Vitiligo; chr22:41599331 chr19:56672574~56673901:- CESC trans rs11098499 0.722 rs17595727 ENSG00000275858.1 RP11-291L22.8 -7.9 1.33e-13 6.92e-07 -0.52 -0.47 Corneal astigmatism; chr4:119340919 chr10:38450738~38451069:- CESC trans rs8010715 1 rs2236352 ENSG00000238000.1 RP11-274E7.2 7.9 1.34e-13 6.93e-07 0.5 0.47 IgG glycosylation; chr14:24141524 chr5:98213402~98214121:+ CESC trans rs3779195 0.929 rs2906184 ENSG00000225169.1 BRI3P1 -7.9 1.34e-13 6.94e-07 -0.76 -0.47 Sex hormone-binding globulin levels; chr7:98310675 chr1:100213293~100213670:+ CESC trans rs9899728 0.572 rs4365317 ENSG00000234925.2 ATP5HP4 7.9 1.34e-13 6.97e-07 0.69 0.47 Alzheimer's disease or small vessel stroke; chr17:75063725 chr12:68642519~68642993:- CESC trans rs1707322 0.721 rs10890333 ENSG00000255397.1 AC022182.2 -7.9 1.35e-13 7.01e-07 -0.62 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634650 chr8:60937705~60939871:- CESC trans rs116095464 0.558 rs34629844 ENSG00000185986.11 SDHAP3 7.9 1.36e-13 7.03e-07 0.8 0.47 Breast cancer; chr5:200714 chr5:1572222~1594620:- CESC trans rs9611565 0.921 rs761366 ENSG00000268568.1 AC007228.9 -7.9 1.37e-13 7.11e-07 -0.68 -0.47 Vitiligo; chr22:41348018 chr19:56672574~56673901:- CESC trans rs61990749 0.571 rs11628049 ENSG00000235400.1 RP4-641G12.4 -7.9 1.39e-13 7.18e-07 -0.77 -0.47 Fibroblast growth factor basic levels; chr14:77842108 chr1:78749073~78750659:+ CESC trans rs11098499 1 rs58601355 ENSG00000275858.1 RP11-291L22.8 7.89 1.42e-13 7.33e-07 0.55 0.47 Corneal astigmatism; chr4:119265212 chr10:38450738~38451069:- CESC trans rs13190036 1 rs6889220 ENSG00000226986.4 RP11-543B16.2 7.89 1.43e-13 7.38e-07 0.6 0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177266887 chr1:211207239~211207897:+ CESC trans rs11098499 0.863 rs17050695 ENSG00000275858.1 RP11-291L22.8 7.89 1.44e-13 7.43e-07 0.54 0.47 Corneal astigmatism; chr4:119568372 chr10:38450738~38451069:- CESC trans rs1707322 0.721 rs7519900 ENSG00000255397.1 AC022182.2 -7.89 1.44e-13 7.46e-07 -0.61 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769275 chr8:60937705~60939871:- CESC trans rs4276421 0.845 rs4371763 ENSG00000231752.4 EMBP1 7.89 1.46e-13 7.53e-07 0.58 0.47 P wave duration; chr5:45983120 chr1:121519112~121571892:+ CESC trans rs9467773 0.901 rs1407045 ENSG00000242375.1 RP11-498P14.3 7.89 1.49e-13 7.67e-07 0.56 0.47 Intelligence (multi-trait analysis); chr6:26475927 chr9:97195351~97197687:- CESC trans rs7200543 1 rs35574015 ENSG00000250569.1 NTAN1P2 7.88 1.5e-13 7.73e-07 0.61 0.47 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15052204 chr8:86481754~86483002:- CESC trans rs13190036 1 rs13167431 ENSG00000226986.4 RP11-543B16.2 -7.88 1.51e-13 7.78e-07 -0.61 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr1:211207239~211207897:+ CESC trans rs1707322 0.721 rs12069121 ENSG00000255397.1 AC022182.2 -7.88 1.52e-13 7.82e-07 -0.61 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45766312 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs61784833 ENSG00000255397.1 AC022182.2 -7.88 1.52e-13 7.82e-07 -0.61 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45768100 chr8:60937705~60939871:- CESC trans rs116095464 0.558 rs62346508 ENSG00000185986.11 SDHAP3 7.88 1.53e-13 7.89e-07 0.82 0.47 Breast cancer; chr5:203553 chr5:1572222~1594620:- CESC trans rs916888 0.61 rs199442 ENSG00000214425.5 LRRC37A4P -7.88 1.57e-13 8.09e-07 -0.5 -0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45506741~45550335:- CESC trans rs9425766 0.927 rs9425757 ENSG00000213331.4 RP11-713C19.2 7.87 1.6e-13 8.23e-07 0.56 0.47 Life satisfaction; chr1:173855675 chr4:187970273~187971284:+ CESC trans rs7121616 0.531 rs10892958 ENSG00000229091.2 HSPA8P8 7.87 1.61e-13 8.27e-07 0.6 0.47 Breast cancer; chr11:123061415 chr7:10451311~10452526:+ CESC trans rs13190036 0.551 rs28932178 ENSG00000217325.2 PRELID1P1 -7.87 1.63e-13 8.37e-07 -0.72 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210575 chr6:126643488~126644390:+ CESC trans rs7811142 1 rs67471932 ENSG00000228546.2 CTA-313A17.3 7.87 1.64e-13 8.44e-07 0.82 0.47 Platelet count; chr7:100412362 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs73161759 ENSG00000228546.2 CTA-313A17.3 7.87 1.64e-13 8.44e-07 0.82 0.47 Platelet count; chr7:100412371 chr7:102337316~102339115:+ CESC trans rs10242455 0.702 rs41385645 ENSG00000228834.1 RP11-249L21.4 7.87 1.65e-13 8.46e-07 1.23 0.47 Blood metabolite levels; chr7:99376415 chr6:108907615~108907873:- CESC trans rs916888 0.61 rs199453 ENSG00000214425.5 LRRC37A4P -7.87 1.66e-13 8.52e-07 -0.5 -0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45506741~45550335:- CESC trans rs10242455 0.557 rs57830676 ENSG00000228834.1 RP11-249L21.4 7.87 1.68e-13 8.61e-07 1.12 0.47 Blood metabolite levels; chr7:99683740 chr6:108907615~108907873:- CESC trans rs11098499 0.754 rs10213554 ENSG00000275858.1 RP11-291L22.8 -7.86 1.73e-13 8.86e-07 -0.52 -0.47 Corneal astigmatism; chr4:119339630 chr10:38450738~38451069:- CESC trans rs7200543 0.583 rs4985149 ENSG00000250569.1 NTAN1P2 7.86 1.73e-13 8.86e-07 0.6 0.47 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15053481 chr8:86481754~86483002:- CESC trans rs116095464 0.558 rs10055993 ENSG00000185986.11 SDHAP3 7.86 1.73e-13 8.9e-07 0.86 0.47 Breast cancer; chr5:264181 chr5:1572222~1594620:- CESC trans rs877636 0.692 rs2271194 ENSG00000225071.1 GS1-184P14.2 -7.86 1.76e-13 9.02e-07 -0.47 -0.47 Cognitive function; chr12:56083910 chrX:24429573~24429920:- CESC trans rs9425766 0.85 rs1322770 ENSG00000213331.4 RP11-713C19.2 7.86 1.78e-13 9.15e-07 0.56 0.47 Life satisfaction; chr1:173863198 chr4:187970273~187971284:+ CESC trans rs13190036 1 rs59737888 ENSG00000217325.2 PRELID1P1 -7.85 1.83e-13 9.35e-07 -0.78 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177160374 chr6:126643488~126644390:+ CESC trans rs116095464 0.558 rs62346506 ENSG00000185986.11 SDHAP3 7.85 1.88e-13 9.63e-07 0.8 0.47 Breast cancer; chr5:201479 chr5:1572222~1594620:- CESC trans rs116095464 0.558 rs9312956 ENSG00000185986.11 SDHAP3 7.85 1.88e-13 9.63e-07 0.8 0.47 Breast cancer; chr5:201697 chr5:1572222~1594620:- CESC trans rs11098499 1 rs11098500 ENSG00000275858.1 RP11-291L22.8 7.85 1.89e-13 9.67e-07 0.54 0.47 Corneal astigmatism; chr4:119298084 chr10:38450738~38451069:- CESC trans rs867371 1 rs8042464 ENSG00000235370.6 DNM1P51 -7.85 1.9e-13 9.72e-07 -0.58 -0.47 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82173195 chr15:84398316~84411701:- CESC trans rs116095464 0.558 rs28636067 ENSG00000185986.11 SDHAP3 7.84 1.94e-13 9.9e-07 0.82 0.47 Breast cancer; chr5:199300 chr5:1572222~1594620:- CESC trans rs7554547 0.791 rs6665662 ENSG00000261819.1 RP11-680G24.4 7.84 1.96e-13 9.99e-07 0.54 0.47 Nonsyndromic cleft lip with cleft palate; chr1:11891804 chr16:14988259~14990160:- CESC trans rs12709013 0.59 rs982848 ENSG00000233719.3 GOT2P3 7.84 1.98e-13 1.01e-06 0.53 0.47 Blood metabolite ratios; chr16:58704294 chr12:9641802~9643007:+ CESC trans rs11098499 1 rs6849889 ENSG00000275858.1 RP11-291L22.8 7.84 2e-13 1.02e-06 0.55 0.47 Corneal astigmatism; chr4:119265193 chr10:38450738~38451069:- CESC trans rs2657294 0.965 rs2657291 ENSG00000172974.11 AC007318.5 7.84 2e-13 1.02e-06 0.45 0.47 Pneumonia; chr10:75166945 chr2:65205108~65205988:+ CESC trans rs4276421 0.805 rs13165481 ENSG00000231752.4 EMBP1 7.83 2.05e-13 1.04e-06 0.58 0.47 P wave duration; chr5:46034214 chr1:121519112~121571892:+ CESC trans rs916888 0.61 rs199452 ENSG00000214425.5 LRRC37A4P -7.83 2.11e-13 1.07e-06 -0.5 -0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45506741~45550335:- CESC trans rs7200543 1 rs72774845 ENSG00000250569.1 NTAN1P2 7.83 2.14e-13 1.09e-06 0.6 0.47 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15054097 chr8:86481754~86483002:- CESC trans rs4276421 0.762 rs10043270 ENSG00000231752.4 EMBP1 7.82 2.18e-13 1.11e-06 0.58 0.47 P wave duration; chr5:45967846 chr1:121519112~121571892:+ CESC trans rs11098499 1 rs12506395 ENSG00000275858.1 RP11-291L22.8 7.82 2.18e-13 1.11e-06 0.55 0.47 Corneal astigmatism; chr4:119263939 chr10:38450738~38451069:- CESC trans rs9899728 0.572 rs9915968 ENSG00000234925.2 ATP5HP4 7.82 2.2e-13 1.12e-06 0.69 0.47 Alzheimer's disease or small vessel stroke; chr17:75063521 chr12:68642519~68642993:- CESC trans rs10865397 0.506 rs6546807 ENSG00000236165.1 PRADC1P1 7.82 2.26e-13 1.15e-06 0.59 0.47 Intelligence (multi-trait analysis); chr2:73159084 chr3:36976316~36976840:+ CESC trans rs5022636 0.964 rs7518924 ENSG00000180764.13 PIPSL 7.81 2.32e-13 1.18e-06 0.57 0.47 Gut microbiota (functional units); chr1:151319225 chr10:93958191~93961540:- CESC trans rs7258465 0.931 rs76195 ENSG00000267533.1 RP11-815J4.7 7.81 2.32e-13 1.18e-06 0.58 0.47 Breast cancer; chr19:18519020 chr18:12067173~12068417:- CESC trans rs10940346 0.934 rs2353960 ENSG00000231752.4 EMBP1 -7.81 2.37e-13 1.2e-06 -0.57 -0.47 Schizophrenia; chr5:50481153 chr1:121519112~121571892:+ CESC trans rs10940346 0.935 rs4971258 ENSG00000231752.4 EMBP1 -7.81 2.37e-13 1.2e-06 -0.57 -0.47 Schizophrenia; chr5:50498560 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs7714695 ENSG00000217325.2 PRELID1P1 -7.81 2.38e-13 1.21e-06 -0.78 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177130444 chr6:126643488~126644390:+ CESC trans rs12709013 0.792 rs12598527 ENSG00000230849.2 GOT2P2 7.81 2.42e-13 1.22e-06 0.54 0.47 Blood metabolite ratios; chr16:58772987 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs12600201 ENSG00000230849.2 GOT2P2 7.81 2.42e-13 1.22e-06 0.54 0.47 Blood metabolite ratios; chr16:58773132 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs12600206 ENSG00000230849.2 GOT2P2 7.81 2.42e-13 1.22e-06 0.54 0.47 Blood metabolite ratios; chr16:58773169 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs11076263 ENSG00000230849.2 GOT2P2 7.81 2.42e-13 1.22e-06 0.54 0.47 Blood metabolite ratios; chr16:58773295 chr1:173141100~173142350:- CESC trans rs13177918 0.717 rs6874318 ENSG00000224114.1 RP11-343H5.4 -7.8 2.51e-13 1.27e-06 -0.6 -0.47 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr1:206695837~206696269:- CESC trans rs4276421 0.774 rs4428422 ENSG00000231752.4 EMBP1 7.8 2.51e-13 1.27e-06 0.58 0.47 P wave duration; chr5:46017216 chr1:121519112~121571892:+ CESC trans rs12709013 0.792 rs1646289 ENSG00000230849.2 GOT2P2 7.8 2.58e-13 1.3e-06 0.55 0.47 Blood metabolite ratios; chr16:58755689 chr1:173141100~173142350:- CESC trans rs13190036 1 rs655623 ENSG00000217325.2 PRELID1P1 7.8 2.6e-13 1.31e-06 0.72 0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107515 chr6:126643488~126644390:+ CESC trans rs4276421 0.743 rs10060199 ENSG00000231752.4 EMBP1 7.79 2.62e-13 1.32e-06 0.58 0.47 P wave duration; chr5:46064524 chr1:121519112~121571892:+ CESC trans rs9425766 0.85 rs9425755 ENSG00000213331.4 RP11-713C19.2 7.79 2.67e-13 1.35e-06 0.55 0.47 Life satisfaction; chr1:173843501 chr4:187970273~187971284:+ CESC trans rs13190036 0.786 rs10068127 ENSG00000217325.2 PRELID1P1 -7.78 2.79e-13 1.4e-06 -0.75 -0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177204786 chr6:126643488~126644390:+ CESC trans rs11098499 0.909 rs28555550 ENSG00000275858.1 RP11-291L22.8 7.78 2.82e-13 1.42e-06 0.53 0.47 Corneal astigmatism; chr4:119289885 chr10:38450738~38451069:- CESC trans rs11098499 1 rs28419773 ENSG00000275858.1 RP11-291L22.8 7.78 2.82e-13 1.42e-06 0.53 0.47 Corneal astigmatism; chr4:119289906 chr10:38450738~38451069:- CESC trans rs11098499 1 rs11726229 ENSG00000275858.1 RP11-291L22.8 7.78 2.82e-13 1.42e-06 0.53 0.47 Corneal astigmatism; chr4:119290425 chr10:38450738~38451069:- CESC trans rs4276421 0.81 rs10213756 ENSG00000231752.4 EMBP1 7.78 2.86e-13 1.44e-06 0.58 0.47 P wave duration; chr5:45952498 chr1:121519112~121571892:+ CESC trans rs1707322 0.789 rs7540578 ENSG00000255397.1 AC022182.2 -7.78 2.92e-13 1.46e-06 -0.6 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45786472 chr8:60937705~60939871:- CESC trans rs1707322 0.717 rs1972410 ENSG00000255397.1 AC022182.2 -7.77 2.96e-13 1.49e-06 -0.6 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615275 chr8:60937705~60939871:- CESC trans rs9611565 0.592 rs4481089 ENSG00000268568.1 AC007228.9 -7.77 3.1e-13 1.56e-06 -0.63 -0.47 Vitiligo; chr22:41584888 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs5996039 ENSG00000268568.1 AC007228.9 -7.77 3.1e-13 1.56e-06 -0.63 -0.47 Vitiligo; chr22:41585953 chr19:56672574~56673901:- CESC trans rs9611565 0.592 rs57102627 ENSG00000268568.1 AC007228.9 -7.77 3.1e-13 1.56e-06 -0.63 -0.47 Vitiligo; chr22:41591623 chr19:56672574~56673901:- CESC trans rs5022636 0.927 rs943637 ENSG00000180764.13 PIPSL 7.76 3.16e-13 1.58e-06 0.56 0.47 Gut microbiota (functional units); chr1:151310543 chr10:93958191~93961540:- CESC trans rs1707322 0.721 rs11211181 ENSG00000255397.1 AC022182.2 -7.76 3.19e-13 1.6e-06 -0.59 -0.47 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45771128 chr8:60937705~60939871:- CESC trans rs5022636 0.896 rs4971032 ENSG00000180764.13 PIPSL 7.76 3.25e-13 1.63e-06 0.57 0.47 Gut microbiota (functional units); chr1:151317948 chr10:93958191~93961540:- CESC trans rs5022636 1 rs4970948 ENSG00000180764.13 PIPSL 7.76 3.25e-13 1.63e-06 0.57 0.47 Gut microbiota (functional units); chr1:151318767 chr10:93958191~93961540:- CESC trans rs11098499 0.754 rs4107728 ENSG00000275858.1 RP11-291L22.8 7.75 3.51e-13 1.75e-06 0.52 0.46 Corneal astigmatism; chr4:119332755 chr10:38450738~38451069:- CESC trans rs867371 0.929 rs1045508 ENSG00000235370.6 DNM1P51 7.74 3.56e-13 1.78e-06 0.59 0.46 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82157565 chr15:84398316~84411701:- CESC trans rs7554511 1 rs55838263 ENSG00000244144.1 RP11-757F18.3 -7.74 3.59e-13 1.79e-06 -0.55 -0.46 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200905600 chr3:112185480~112185998:- CESC trans rs10865397 0.506 rs6546810 ENSG00000236165.1 PRADC1P1 7.74 3.7e-13 1.84e-06 0.61 0.46 Intelligence (multi-trait analysis); chr2:73162588 chr3:36976316~36976840:+ CESC trans rs2589161 1 rs2589161 ENSG00000231752.4 EMBP1 7.73 3.94e-13 1.95e-06 0.56 0.46 Breast cancer; chr5:45653810 chr1:121519112~121571892:+ CESC trans rs4276421 0.869 rs1405918 ENSG00000231752.4 EMBP1 7.73 3.94e-13 1.95e-06 0.56 0.46 P wave duration; chr5:45654968 chr1:121519112~121571892:+ CESC trans rs4276421 0.869 rs1527831 ENSG00000231752.4 EMBP1 7.73 3.94e-13 1.95e-06 0.56 0.46 P wave duration; chr5:45656821 chr1:121519112~121571892:+ CESC trans rs7554511 1 rs35730213 ENSG00000244144.1 RP11-757F18.3 -7.72 4.06e-13 2.01e-06 -0.55 -0.46 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200905101 chr3:112185480~112185998:- CESC trans rs7554511 1 rs12132298 ENSG00000244144.1 RP11-757F18.3 -7.72 4.06e-13 2.01e-06 -0.55 -0.46 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200905967 chr3:112185480~112185998:- CESC trans rs7554511 1 rs12132349 ENSG00000244144.1 RP11-757F18.3 -7.72 4.06e-13 2.01e-06 -0.55 -0.46 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200906114 chr3:112185480~112185998:- CESC trans rs7554511 0.964 rs59655222 ENSG00000244144.1 RP11-757F18.3 -7.72 4.06e-13 2.01e-06 -0.55 -0.46 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200906769 chr3:112185480~112185998:- CESC trans rs7554511 1 rs41299637 ENSG00000244144.1 RP11-757F18.3 -7.72 4.06e-13 2.01e-06 -0.55 -0.46 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200908722 chr3:112185480~112185998:- CESC trans rs3779195 1 rs3779195 ENSG00000225169.1 BRI3P1 -7.72 4.17e-13 2.06e-06 -0.75 -0.46 Sex hormone-binding globulin levels; chr7:98364050 chr1:100213293~100213670:+ CESC trans rs7811142 1 rs74460138 ENSG00000228546.2 CTA-313A17.3 7.72 4.2e-13 2.07e-06 0.81 0.46 Platelet count; chr7:100429716 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs6975729 ENSG00000228546.2 CTA-313A17.3 7.72 4.2e-13 2.07e-06 0.81 0.46 Platelet count; chr7:100430564 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs1073 ENSG00000228546.2 CTA-313A17.3 7.72 4.2e-13 2.07e-06 0.81 0.46 Platelet count; chr7:100433989 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs4989959 ENSG00000228546.2 CTA-313A17.3 7.72 4.2e-13 2.07e-06 0.81 0.46 Platelet count; chr7:100434665 chr7:102337316~102339115:+ CESC trans rs7811142 0.887 rs4074838 ENSG00000228546.2 CTA-313A17.3 7.72 4.2e-13 2.07e-06 0.81 0.46 Platelet count; chr7:100435042 chr7:102337316~102339115:+ CESC trans rs13190036 0.901 rs28563911 ENSG00000226986.4 RP11-543B16.2 7.71 4.31e-13 2.13e-06 0.6 0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177287942 chr1:211207239~211207897:+ CESC trans rs4276421 0.869 rs7736561 ENSG00000231752.4 EMBP1 7.71 4.34e-13 2.14e-06 0.55 0.46 P wave duration; chr5:45716294 chr1:121519112~121571892:+ CESC trans rs7811142 1 rs66632384 ENSG00000228546.2 CTA-313A17.3 7.71 4.34e-13 2.14e-06 0.81 0.46 Platelet count; chr7:100421281 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs67163493 ENSG00000228546.2 CTA-313A17.3 7.71 4.34e-13 2.14e-06 0.81 0.46 Platelet count; chr7:100426215 chr7:102337316~102339115:+ CESC trans rs7811142 0.943 rs73403312 ENSG00000228546.2 CTA-313A17.3 7.71 4.34e-13 2.14e-06 0.81 0.46 Platelet count; chr7:100426530 chr7:102337316~102339115:+ CESC trans rs9611565 0.559 rs6002408 ENSG00000268568.1 AC007228.9 -7.71 4.37e-13 2.15e-06 -0.65 -0.46 Vitiligo; chr22:41571866 chr19:56672574~56673901:- CESC trans rs4276421 1 rs13340341 ENSG00000231752.4 EMBP1 7.71 4.38e-13 2.16e-06 0.55 0.46 P wave duration; chr5:45860834 chr1:121519112~121571892:+ CESC trans rs7554511 1 rs12131796 ENSG00000244144.1 RP11-757F18.3 -7.71 4.39e-13 2.16e-06 -0.55 -0.46 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200909599 chr3:112185480~112185998:- CESC trans rs4276421 0.682 rs10067983 ENSG00000231752.4 EMBP1 7.71 4.42e-13 2.18e-06 0.57 0.46 P wave duration; chr5:46064294 chr1:121519112~121571892:+ CESC trans rs11098499 0.954 rs6820115 ENSG00000275858.1 RP11-291L22.8 7.71 4.43e-13 2.18e-06 0.51 0.46 Corneal astigmatism; chr4:119477027 chr10:38450738~38451069:- CESC trans rs7811142 0.945 rs6955362 ENSG00000228546.2 CTA-313A17.3 7.71 4.46e-13 2.2e-06 0.81 0.46 Platelet count; chr7:100458543 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs6975514 ENSG00000228546.2 CTA-313A17.3 7.71 4.46e-13 2.2e-06 0.81 0.46 Platelet count; chr7:100458597 chr7:102337316~102339115:+ CESC trans rs7811142 1 rs11773661 ENSG00000228546.2 CTA-313A17.3 7.71 4.46e-13 2.2e-06 0.81 0.46 Platelet count; chr7:100475446 chr7:102337316~102339115:+ CESC trans rs7811142 0.943 rs66958101 ENSG00000228546.2 CTA-313A17.3 7.71 4.46e-13 2.2e-06 0.81 0.46 Platelet count; chr7:100476397 chr7:102337316~102339115:+ CESC trans rs13358908 0.602 rs4975977 ENSG00000231752.4 EMBP1 -7.71 4.54e-13 2.23e-06 -0.58 -0.46 Schizophrenia; chr5:46307988 chr1:121519112~121571892:+ CESC trans rs7811142 0.887 rs111972532 ENSG00000228546.2 CTA-313A17.3 7.7 4.62e-13 2.27e-06 0.82 0.46 Platelet count; chr7:100471465 chr7:102337316~102339115:+ CESC trans rs11098499 0.955 rs6815725 ENSG00000275858.1 RP11-291L22.8 7.7 4.75e-13 2.33e-06 0.54 0.46 Corneal astigmatism; chr4:119237255 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs1551 ENSG00000275858.1 RP11-291L22.8 7.7 4.75e-13 2.33e-06 0.54 0.46 Corneal astigmatism; chr4:119237345 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs11931312 ENSG00000275858.1 RP11-291L22.8 7.7 4.75e-13 2.33e-06 0.54 0.46 Corneal astigmatism; chr4:119237868 chr10:38450738~38451069:- CESC trans rs10242455 0.571 rs80045298 ENSG00000228834.1 RP11-249L21.4 7.7 4.76e-13 2.34e-06 1.18 0.46 Blood metabolite levels; chr7:99709830 chr6:108907615~108907873:- CESC trans rs10242455 0.571 rs41279866 ENSG00000228834.1 RP11-249L21.4 7.7 4.76e-13 2.34e-06 1.18 0.46 Blood metabolite levels; chr7:99717653 chr6:108907615~108907873:- CESC trans rs7811142 1 rs11764818 ENSG00000228546.2 CTA-313A17.3 7.7 4.82e-13 2.36e-06 0.81 0.46 Platelet count; chr7:100445432 chr7:102337316~102339115:+ CESC trans rs9876781 1 rs13069724 ENSG00000235912.1 RP1-159A19.3 -7.69 4.88e-13 2.39e-06 -0.44 -0.46 Longevity; chr3:48436629 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs9838618 ENSG00000235912.1 RP1-159A19.3 -7.69 5.01e-13 2.46e-06 -0.44 -0.46 Longevity; chr3:48445949 chr1:27649419~27649610:+ CESC trans rs11098499 0.644 rs10050092 ENSG00000275858.1 RP11-291L22.8 7.69 5.03e-13 2.46e-06 0.5 0.46 Corneal astigmatism; chr4:119610930 chr10:38450738~38451069:- CESC trans rs7811142 1 rs60257855 ENSG00000228546.2 CTA-313A17.3 7.69 5.05e-13 2.47e-06 0.8 0.46 Platelet count; chr7:100429157 chr7:102337316~102339115:+ CESC trans rs13190036 0.901 rs55741473 ENSG00000226986.4 RP11-543B16.2 -7.69 5.07e-13 2.48e-06 -0.6 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr1:211207239~211207897:+ CESC trans rs7811142 1 rs7811142 ENSG00000228546.2 CTA-313A17.3 7.69 5.1e-13 2.5e-06 0.81 0.46 Platelet count; chr7:100467820 chr7:102337316~102339115:+ CESC trans rs11098499 0.644 rs17517414 ENSG00000275858.1 RP11-291L22.8 7.68 5.16e-13 2.52e-06 0.51 0.46 Corneal astigmatism; chr4:119340946 chr10:38450738~38451069:- CESC trans rs7200543 0.666 rs34955778 ENSG00000250569.1 NTAN1P2 7.68 5.2e-13 2.54e-06 0.55 0.46 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15045737 chr8:86481754~86483002:- CESC trans rs9611565 0.592 rs28750375 ENSG00000268568.1 AC007228.9 -7.68 5.21e-13 2.55e-06 -0.63 -0.46 Vitiligo; chr22:41594640 chr19:56672574~56673901:- CESC trans rs7200543 0.883 rs4985148 ENSG00000250569.1 NTAN1P2 7.67 5.59e-13 2.73e-06 0.59 0.46 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15053931 chr8:86481754~86483002:- CESC trans rs12200782 0.505 rs7765920 ENSG00000242375.1 RP11-498P14.3 7.67 5.69e-13 2.78e-06 0.7 0.46 Small cell lung carcinoma; chr6:26514543 chr9:97195351~97197687:- CESC trans rs13190036 1 rs28580074 ENSG00000226986.4 RP11-543B16.2 7.67 5.72e-13 2.79e-06 0.6 0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177294197 chr1:211207239~211207897:+ CESC trans rs11098499 0.644 rs7693919 ENSG00000275858.1 RP11-291L22.8 7.67 5.82e-13 2.84e-06 0.51 0.46 Corneal astigmatism; chr4:119619416 chr10:38450738~38451069:- CESC trans rs9611565 0.729 rs169362 ENSG00000268568.1 AC007228.9 7.66 5.89e-13 2.87e-06 0.56 0.46 Vitiligo; chr22:41431585 chr19:56672574~56673901:- CESC trans rs9611565 0.729 rs202654 ENSG00000268568.1 AC007228.9 7.66 5.89e-13 2.87e-06 0.56 0.46 Vitiligo; chr22:41445030 chr19:56672574~56673901:- CESC trans rs4276421 0.869 rs10036065 ENSG00000231752.4 EMBP1 -7.66 5.94e-13 2.89e-06 -0.56 -0.46 P wave duration; chr5:45701926 chr1:121519112~121571892:+ CESC trans rs1707322 0.721 rs56255771 ENSG00000255397.1 AC022182.2 -7.66 5.95e-13 2.9e-06 -0.58 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758647 chr8:60937705~60939871:- CESC trans rs1707322 0.686 rs11211179 ENSG00000255397.1 AC022182.2 -7.66 5.95e-13 2.9e-06 -0.58 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45762410 chr8:60937705~60939871:- CESC trans rs1707322 0.721 rs10157795 ENSG00000255397.1 AC022182.2 -7.66 5.95e-13 2.9e-06 -0.58 -0.46 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45762520 chr8:60937705~60939871:- CESC trans rs10865397 0.506 rs13414160 ENSG00000236165.1 PRADC1P1 7.66 6e-13 2.92e-06 0.59 0.46 Intelligence (multi-trait analysis); chr2:73156133 chr3:36976316~36976840:+ CESC trans rs6732160 0.51 rs57825971 ENSG00000236165.1 PRADC1P1 7.66 6e-13 2.92e-06 0.59 0.46 Intelligence (multi-trait analysis); chr2:73157668 chr3:36976316~36976840:+ CESC trans rs10865397 0.506 rs60764301 ENSG00000236165.1 PRADC1P1 7.66 6e-13 2.92e-06 0.59 0.46 Intelligence (multi-trait analysis); chr2:73157722 chr3:36976316~36976840:+ CESC trans rs4276421 0.874 rs71618219 ENSG00000231752.4 EMBP1 7.66 6.14e-13 2.98e-06 0.57 0.46 P wave duration; chr5:45950598 chr1:121519112~121571892:+ CESC trans rs916888 0.61 rs199446 ENSG00000214425.5 LRRC37A4P 7.66 6.16e-13 2.99e-06 0.48 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45506741~45550335:- CESC trans rs12709013 0.792 rs11646756 ENSG00000230849.2 GOT2P2 7.65 6.23e-13 3.02e-06 0.53 0.46 Blood metabolite ratios; chr16:58773598 chr1:173141100~173142350:- CESC trans rs10028773 0.666 rs12498657 ENSG00000275858.1 RP11-291L22.8 7.65 6.23e-13 3.02e-06 0.52 0.46 Educational attainment; chr4:119341711 chr10:38450738~38451069:- CESC trans rs9611565 0.729 rs12165508 ENSG00000268568.1 AC007228.9 7.65 6.23e-13 3.02e-06 0.56 0.46 Vitiligo; chr22:41423956 chr19:56672574~56673901:- CESC trans rs11098499 0.955 rs1511019 ENSG00000275858.1 RP11-291L22.8 7.65 6.25e-13 3.03e-06 0.54 0.46 Corneal astigmatism; chr4:119244852 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs35434465 ENSG00000275858.1 RP11-291L22.8 7.65 6.25e-13 3.03e-06 0.54 0.46 Corneal astigmatism; chr4:119248223 chr10:38450738~38451069:- CESC trans rs9611519 0.78 rs9611546 ENSG00000268568.1 AC007228.9 -7.65 6.39e-13 3.1e-06 -0.63 -0.46 Neuroticism; chr22:41302538 chr19:56672574~56673901:- CESC trans rs77688320 0.5 rs7603584 ENSG00000235105.1 RP11-329A14.1 7.65 6.4e-13 3.1e-06 0.49 0.46 Breast cancer; chr2:201440422 chr1:48435967~48437223:+ CESC trans rs4276421 0.837 rs2696013 ENSG00000231752.4 EMBP1 7.65 6.46e-13 3.13e-06 0.56 0.46 P wave duration; chr5:45603104 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs2337483 ENSG00000231752.4 EMBP1 7.65 6.46e-13 3.13e-06 0.56 0.46 P wave duration; chr5:45608220 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs6893773 ENSG00000231752.4 EMBP1 7.65 6.46e-13 3.13e-06 0.56 0.46 P wave duration; chr5:45622394 chr1:121519112~121571892:+ CESC trans rs4276421 0.805 rs6451810 ENSG00000231752.4 EMBP1 7.65 6.46e-13 3.13e-06 0.56 0.46 P wave duration; chr5:45633898 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs2580260 ENSG00000231752.4 EMBP1 7.65 6.46e-13 3.13e-06 0.56 0.46 P wave duration; chr5:45638527 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs6451807 ENSG00000231752.4 EMBP1 7.65 6.48e-13 3.14e-06 0.56 0.46 P wave duration; chr5:45534321 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs1384732 ENSG00000231752.4 EMBP1 7.65 6.48e-13 3.14e-06 0.56 0.46 P wave duration; chr5:45553285 chr1:121519112~121571892:+ CESC trans rs12709013 0.716 rs4784987 ENSG00000230849.2 GOT2P2 7.64 6.59e-13 3.19e-06 0.51 0.46 Blood metabolite ratios; chr16:58824135 chr1:173141100~173142350:- CESC trans rs11098499 0.78 rs7692994 ENSG00000275858.1 RP11-291L22.8 7.64 6.6e-13 3.19e-06 0.53 0.46 Corneal astigmatism; chr4:119506334 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs878376 ENSG00000275858.1 RP11-291L22.8 7.64 6.62e-13 3.2e-06 0.52 0.46 Corneal astigmatism; chr4:119316547 chr10:38450738~38451069:- CESC trans rs4276421 0.935 rs4473777 ENSG00000231752.4 EMBP1 7.64 6.9e-13 3.33e-06 0.56 0.46 P wave duration; chr5:45968760 chr1:121519112~121571892:+ CESC trans rs11098499 0.955 rs35197422 ENSG00000275858.1 RP11-291L22.8 7.64 6.95e-13 3.36e-06 0.53 0.46 Corneal astigmatism; chr4:119248159 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs1511015 ENSG00000275858.1 RP11-291L22.8 7.64 6.95e-13 3.36e-06 0.53 0.46 Corneal astigmatism; chr4:119249318 chr10:38450738~38451069:- CESC trans rs4276421 0.901 rs12110137 ENSG00000231752.4 EMBP1 7.64 6.98e-13 3.36e-06 0.56 0.46 P wave duration; chr5:45727764 chr1:121519112~121571892:+ CESC trans rs12709013 0.792 rs12935488 ENSG00000230849.2 GOT2P2 7.63 7.01e-13 3.38e-06 0.54 0.46 Blood metabolite ratios; chr16:58766320 chr1:173141100~173142350:- CESC trans rs11098499 0.955 rs13129661 ENSG00000275858.1 RP11-291L22.8 7.63 7.22e-13 3.48e-06 0.53 0.46 Corneal astigmatism; chr4:119231754 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs56386062 ENSG00000275858.1 RP11-291L22.8 7.63 7.22e-13 3.48e-06 0.53 0.46 Corneal astigmatism; chr4:119233980 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs4145951 ENSG00000275858.1 RP11-291L22.8 7.63 7.22e-13 3.48e-06 0.53 0.46 Corneal astigmatism; chr4:119234662 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs35916640 ENSG00000275858.1 RP11-291L22.8 7.63 7.22e-13 3.48e-06 0.53 0.46 Corneal astigmatism; chr4:119234697 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs13114751 ENSG00000275858.1 RP11-291L22.8 7.63 7.22e-13 3.48e-06 0.53 0.46 Corneal astigmatism; chr4:119235462 chr10:38450738~38451069:- CESC trans rs11098499 0.913 rs35271032 ENSG00000275858.1 RP11-291L22.8 7.63 7.22e-13 3.48e-06 0.53 0.46 Corneal astigmatism; chr4:119235504 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs1511018 ENSG00000275858.1 RP11-291L22.8 7.63 7.25e-13 3.49e-06 0.53 0.46 Corneal astigmatism; chr4:119240425 chr10:38450738~38451069:- CESC trans rs11098499 1 rs6837898 ENSG00000275858.1 RP11-291L22.8 7.63 7.25e-13 3.49e-06 0.53 0.46 Corneal astigmatism; chr4:119257999 chr10:38450738~38451069:- CESC trans rs11098499 0.57 rs6832740 ENSG00000275858.1 RP11-291L22.8 7.63 7.25e-13 3.49e-06 0.51 0.46 Corneal astigmatism; chr4:119624981 chr10:38450738~38451069:- CESC trans rs11098499 0.644 rs6855918 ENSG00000275858.1 RP11-291L22.8 7.63 7.25e-13 3.49e-06 0.51 0.46 Corneal astigmatism; chr4:119625144 chr10:38450738~38451069:- CESC trans rs4646450 0.636 rs2003499 ENSG00000228834.1 RP11-249L21.4 7.63 7.3e-13 3.51e-06 0.83 0.46 Blood metabolite levels; chr7:99417361 chr6:108907615~108907873:- CESC trans rs4276421 0.869 rs2589162 ENSG00000231752.4 EMBP1 -7.63 7.32e-13 3.52e-06 -0.55 -0.46 P wave duration; chr5:45655791 chr1:121519112~121571892:+ CESC trans rs9611565 0.525 rs9611548 ENSG00000268568.1 AC007228.9 -7.62 7.48e-13 3.59e-06 -0.64 -0.46 Vitiligo; chr22:41308139 chr19:56672574~56673901:- CESC trans rs11098499 0.913 rs11098496 ENSG00000275858.1 RP11-291L22.8 7.62 7.69e-13 3.69e-06 0.53 0.46 Corneal astigmatism; chr4:119246311 chr10:38450738~38451069:- CESC trans rs10242455 0.717 rs58649180 ENSG00000228834.1 RP11-249L21.4 7.62 7.7e-13 3.69e-06 0.94 0.46 Blood metabolite levels; chr7:99738422 chr6:108907615~108907873:- CESC trans rs10242455 0.717 rs72494455 ENSG00000228834.1 RP11-249L21.4 7.62 7.7e-13 3.69e-06 0.94 0.46 Blood metabolite levels; chr7:99739154 chr6:108907615~108907873:- CESC trans rs11098499 0.722 rs10006192 ENSG00000275858.1 RP11-291L22.8 7.62 7.75e-13 3.72e-06 0.52 0.46 Corneal astigmatism; chr4:119341867 chr10:38450738~38451069:- CESC trans rs11098499 0.615 rs28551750 ENSG00000275858.1 RP11-291L22.8 7.62 7.75e-13 3.72e-06 0.52 0.46 Corneal astigmatism; chr4:119343746 chr10:38450738~38451069:- CESC trans rs11098499 0.691 rs9995716 ENSG00000275858.1 RP11-291L22.8 7.62 7.75e-13 3.72e-06 0.52 0.46 Corneal astigmatism; chr4:119343841 chr10:38450738~38451069:- CESC trans rs916888 0.61 rs199536 ENSG00000214425.5 LRRC37A4P 7.62 7.89e-13 3.78e-06 0.48 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45506741~45550335:- CESC trans rs9611565 0.694 rs9611591 ENSG00000268568.1 AC007228.9 7.61 8.05e-13 3.85e-06 0.55 0.46 Vitiligo; chr22:41434208 chr19:56672574~56673901:- CESC trans rs11098499 0.955 rs1397608 ENSG00000275858.1 RP11-291L22.8 7.61 8.06e-13 3.86e-06 0.53 0.46 Corneal astigmatism; chr4:119240589 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs7685268 ENSG00000275858.1 RP11-291L22.8 7.61 8.06e-13 3.86e-06 0.53 0.46 Corneal astigmatism; chr4:119241033 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs7684942 ENSG00000275858.1 RP11-291L22.8 7.61 8.06e-13 3.86e-06 0.53 0.46 Corneal astigmatism; chr4:119241046 chr10:38450738~38451069:- CESC trans rs11098499 1 rs10029750 ENSG00000275858.1 RP11-291L22.8 7.61 8.06e-13 3.86e-06 0.53 0.46 Corneal astigmatism; chr4:119251388 chr10:38450738~38451069:- CESC trans rs13190036 1 rs13157667 ENSG00000226986.4 RP11-543B16.2 -7.61 8.06e-13 3.86e-06 -0.61 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr1:211207239~211207897:+ CESC trans rs4276421 0.753 rs7443976 ENSG00000231752.4 EMBP1 7.61 8.1e-13 3.87e-06 0.56 0.46 P wave duration; chr5:45936323 chr1:121519112~121571892:+ CESC trans rs9876781 0.872 rs11797 ENSG00000235912.1 RP1-159A19.3 -7.61 8.11e-13 3.88e-06 -0.45 -0.46 Longevity; chr3:48467186 chr1:27649419~27649610:+ CESC trans rs11098499 0.913 rs10010696 ENSG00000275858.1 RP11-291L22.8 7.61 8.16e-13 3.9e-06 0.53 0.46 Corneal astigmatism; chr4:119243148 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs938056 ENSG00000275858.1 RP11-291L22.8 7.61 8.17e-13 3.9e-06 0.51 0.46 Corneal astigmatism; chr4:119316298 chr10:38450738~38451069:- CESC trans rs12709013 0.693 rs1627257 ENSG00000230849.2 GOT2P2 7.61 8.19e-13 3.91e-06 0.54 0.46 Blood metabolite ratios; chr16:58763764 chr1:173141100~173142350:- CESC trans rs12709013 0.755 rs1628029 ENSG00000230849.2 GOT2P2 7.61 8.19e-13 3.91e-06 0.54 0.46 Blood metabolite ratios; chr16:58763846 chr1:173141100~173142350:- CESC trans rs3779195 0.524 rs80195155 ENSG00000225169.1 BRI3P1 -7.61 8.25e-13 3.94e-06 -0.71 -0.46 Sex hormone-binding globulin levels; chr7:98248841 chr1:100213293~100213670:+ CESC trans rs11098499 0.863 rs1010739 ENSG00000275858.1 RP11-291L22.8 7.61 8.37e-13 3.99e-06 0.51 0.46 Corneal astigmatism; chr4:119542316 chr10:38450738~38451069:- CESC trans rs9611565 0.694 rs5758389 ENSG00000268568.1 AC007228.9 -7.6 8.43e-13 4.02e-06 -0.58 -0.46 Vitiligo; chr22:41545745 chr19:56672574~56673901:- CESC trans rs13190036 1 rs17078781 ENSG00000226986.4 RP11-543B16.2 -7.6 8.55e-13 4.08e-06 -0.59 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117227 chr1:211207239~211207897:+ CESC trans rs12709013 0.792 rs62066815 ENSG00000230849.2 GOT2P2 7.6 8.57e-13 4.08e-06 0.54 0.46 Blood metabolite ratios; chr16:58751577 chr1:173141100~173142350:- CESC trans rs12709013 0.766 rs1657175 ENSG00000230849.2 GOT2P2 7.6 8.57e-13 4.08e-06 0.54 0.46 Blood metabolite ratios; chr16:58755527 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs1646290 ENSG00000230849.2 GOT2P2 7.6 8.57e-13 4.08e-06 0.54 0.46 Blood metabolite ratios; chr16:58755807 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs1364346 ENSG00000230849.2 GOT2P2 7.6 8.57e-13 4.08e-06 0.54 0.46 Blood metabolite ratios; chr16:58756420 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs257626 ENSG00000230849.2 GOT2P2 7.6 8.57e-13 4.08e-06 0.54 0.46 Blood metabolite ratios; chr16:58759574 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs257625 ENSG00000230849.2 GOT2P2 7.6 8.57e-13 4.08e-06 0.54 0.46 Blood metabolite ratios; chr16:58759978 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs1646262 ENSG00000230849.2 GOT2P2 7.6 8.57e-13 4.08e-06 0.54 0.46 Blood metabolite ratios; chr16:58760593 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs257623 ENSG00000230849.2 GOT2P2 7.6 8.57e-13 4.08e-06 0.54 0.46 Blood metabolite ratios; chr16:58761247 chr1:173141100~173142350:- CESC trans rs4276421 0.845 rs10434580 ENSG00000231752.4 EMBP1 7.6 8.58e-13 4.08e-06 0.56 0.46 P wave duration; chr5:46010910 chr1:121519112~121571892:+ CESC trans rs12709013 0.792 rs1657170 ENSG00000230849.2 GOT2P2 7.6 8.94e-13 4.25e-06 0.54 0.46 Blood metabolite ratios; chr16:58752082 chr1:173141100~173142350:- CESC trans rs12709013 0.716 rs6416775 ENSG00000230849.2 GOT2P2 7.59 9.15e-13 4.35e-06 0.51 0.46 Blood metabolite ratios; chr16:58830410 chr1:173141100~173142350:- CESC trans rs7554511 1 rs7522462 ENSG00000244144.1 RP11-757F18.3 7.59 9.37e-13 4.45e-06 0.52 0.46 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200912467 chr3:112185480~112185998:- CESC trans rs13190036 0.901 rs28715668 ENSG00000226986.4 RP11-543B16.2 7.58 9.78e-13 4.64e-06 0.6 0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177272267 chr1:211207239~211207897:+ CESC trans rs13190036 0.892 rs71601339 ENSG00000226986.4 RP11-543B16.2 -7.58 9.99e-13 4.73e-06 -0.59 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117495 chr1:211207239~211207897:+ CESC trans rs916888 0.61 rs199454 ENSG00000264070.1 DND1P1 -7.58 1e-12 4.74e-06 -0.56 -0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45585871~45586929:+ CESC trans rs916888 0.779 rs199498 ENSG00000264070.1 DND1P1 7.58 1e-12 4.75e-06 0.6 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:45585871~45586929:+ CESC trans rs11098499 1 rs28374891 ENSG00000275858.1 RP11-291L22.8 7.57 1.01e-12 4.8e-06 0.53 0.46 Corneal astigmatism; chr4:119262395 chr10:38450738~38451069:- CESC trans rs7554547 0.765 rs4845886 ENSG00000261819.1 RP11-680G24.4 7.57 1.01e-12 4.8e-06 0.53 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11888603 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs4846069 ENSG00000261819.1 RP11-680G24.4 7.57 1.01e-12 4.8e-06 0.53 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11888974 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs11121837 ENSG00000261819.1 RP11-680G24.4 7.57 1.01e-12 4.8e-06 0.53 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11889414 chr16:14988259~14990160:- CESC trans rs7554547 0.765 rs4846070 ENSG00000261819.1 RP11-680G24.4 7.57 1.01e-12 4.8e-06 0.53 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11889464 chr16:14988259~14990160:- CESC trans rs7554547 0.739 rs61527718 ENSG00000261819.1 RP11-680G24.4 7.57 1.01e-12 4.8e-06 0.53 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11889583 chr16:14988259~14990160:- CESC trans rs9611565 0.729 rs505533 ENSG00000268568.1 AC007228.9 7.57 1.02e-12 4.8e-06 0.55 0.46 Vitiligo; chr22:41468212 chr19:56672574~56673901:- CESC trans rs10242455 0.571 rs41258334 ENSG00000228834.1 RP11-249L21.4 7.57 1.02e-12 4.84e-06 1.25 0.46 Blood metabolite levels; chr7:99674185 chr6:108907615~108907873:- CESC trans rs10242455 0.571 rs28365067 ENSG00000228834.1 RP11-249L21.4 7.57 1.02e-12 4.84e-06 1.25 0.46 Blood metabolite levels; chr7:99674687 chr6:108907615~108907873:- CESC trans rs3779195 0.585 rs56694862 ENSG00000225169.1 BRI3P1 -7.57 1.05e-12 4.97e-06 -0.76 -0.46 Sex hormone-binding globulin levels; chr7:98267808 chr1:100213293~100213670:+ CESC trans rs877636 1 rs2292239 ENSG00000223416.3 RPS26P15 7.57 1.06e-12 5e-06 0.48 0.46 Cognitive function; chr12:56088396 chr1:58056133~58056480:- CESC trans rs877636 1 rs2292239 ENSG00000243403.1 RP11-330L19.1 7.57 1.06e-12 5.02e-06 0.46 0.46 Cognitive function; chr12:56088396 chr15:64592979~64593326:+ CESC trans rs7811142 1 rs11761725 ENSG00000228546.2 CTA-313A17.3 7.57 1.07e-12 5.04e-06 0.82 0.46 Platelet count; chr7:100442192 chr7:102337316~102339115:+ CESC trans rs941207 0.756 rs7313074 ENSG00000257210.1 NACAP3 -7.56 1.11e-12 5.23e-06 -0.6 -0.46 Platelet count; chr12:56760705 chr12:93124063~93124543:- CESC trans rs7554547 0.714 rs4846071 ENSG00000261819.1 RP11-680G24.4 7.56 1.11e-12 5.23e-06 0.53 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11889612 chr16:14988259~14990160:- CESC trans rs4276421 0.837 rs10078625 ENSG00000231752.4 EMBP1 7.56 1.11e-12 5.23e-06 0.55 0.46 P wave duration; chr5:45707015 chr1:121519112~121571892:+ CESC trans rs4276421 0.869 rs13187565 ENSG00000231752.4 EMBP1 7.56 1.11e-12 5.23e-06 0.55 0.46 P wave duration; chr5:45707436 chr1:121519112~121571892:+ CESC trans rs4276421 0.776 rs10473392 ENSG00000231752.4 EMBP1 7.56 1.11e-12 5.23e-06 0.55 0.46 P wave duration; chr5:45709959 chr1:121519112~121571892:+ CESC trans rs4276421 0.869 rs7705696 ENSG00000231752.4 EMBP1 7.56 1.11e-12 5.23e-06 0.55 0.46 P wave duration; chr5:45712387 chr1:121519112~121571892:+ CESC trans rs9611565 0.571 rs2050032 ENSG00000268568.1 AC007228.9 7.56 1.13e-12 5.3e-06 0.58 0.46 Vitiligo; chr22:41756425 chr19:56672574~56673901:- CESC trans rs13190036 1 rs625882 ENSG00000217325.2 PRELID1P1 -7.55 1.15e-12 5.43e-06 -0.72 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177108030 chr6:126643488~126644390:+ CESC trans rs11098499 1 rs1011054 ENSG00000275858.1 RP11-291L22.8 -7.55 1.18e-12 5.54e-06 -0.52 -0.46 Corneal astigmatism; chr4:119281232 chr10:38450738~38451069:- CESC trans rs11098499 0.722 rs1814814 ENSG00000275858.1 RP11-291L22.8 7.55 1.18e-12 5.55e-06 0.5 0.46 Corneal astigmatism; chr4:119336969 chr10:38450738~38451069:- CESC trans rs7811142 1 rs2406255 ENSG00000228546.2 CTA-313A17.3 7.55 1.19e-12 5.58e-06 0.83 0.46 Platelet count; chr7:100456067 chr7:102337316~102339115:+ CESC trans rs3779195 0.524 rs76976120 ENSG00000225169.1 BRI3P1 -7.55 1.19e-12 5.59e-06 -0.75 -0.46 Sex hormone-binding globulin levels; chr7:98264860 chr1:100213293~100213670:+ CESC trans rs11098499 0.535 rs7671759 ENSG00000275858.1 RP11-291L22.8 7.55 1.19e-12 5.6e-06 0.51 0.46 Corneal astigmatism; chr4:119326939 chr10:38450738~38451069:- CESC trans rs11098499 0.955 rs13113112 ENSG00000275858.1 RP11-291L22.8 7.55 1.21e-12 5.69e-06 0.53 0.46 Corneal astigmatism; chr4:119234885 chr10:38450738~38451069:- CESC trans rs13190036 0.901 rs6898107 ENSG00000226986.4 RP11-543B16.2 7.54 1.23e-12 5.76e-06 0.54 0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177252694 chr1:211207239~211207897:+ CESC trans rs11098499 0.604 rs2389886 ENSG00000275858.1 RP11-291L22.8 7.54 1.23e-12 5.78e-06 0.52 0.45 Corneal astigmatism; chr4:119649267 chr10:38450738~38451069:- CESC trans rs1707322 0.721 rs7520123 ENSG00000255397.1 AC022182.2 -7.54 1.23e-12 5.8e-06 -0.57 -0.45 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769547 chr8:60937705~60939871:- CESC trans rs77688320 0.517 rs10497868 ENSG00000235105.1 RP11-329A14.1 -7.54 1.24e-12 5.8e-06 -0.49 -0.45 Breast cancer; chr2:201439317 chr1:48435967~48437223:+ CESC trans rs74781061 0.932 rs7161903 ENSG00000227288.3 RP5-837I24.1 7.54 1.24e-12 5.82e-06 0.55 0.45 Endometriosis; chr15:74647929 chr1:81501794~81503468:+ CESC trans rs4276421 0.901 rs9687260 ENSG00000231752.4 EMBP1 7.54 1.24e-12 5.83e-06 0.55 0.45 P wave duration; chr5:45759774 chr1:121519112~121571892:+ CESC trans rs4276421 0.901 rs4455566 ENSG00000231752.4 EMBP1 7.54 1.24e-12 5.84e-06 0.55 0.45 P wave duration; chr5:45752760 chr1:121519112~121571892:+ CESC trans rs10028773 0.6 rs4001390 ENSG00000275858.1 RP11-291L22.8 7.54 1.25e-12 5.85e-06 0.52 0.45 Educational attainment; chr4:119344628 chr10:38450738~38451069:- CESC trans rs11098499 0.691 rs2136911 ENSG00000275858.1 RP11-291L22.8 7.54 1.25e-12 5.85e-06 0.52 0.45 Corneal astigmatism; chr4:119344704 chr10:38450738~38451069:- CESC trans rs11098499 0.554 rs2175381 ENSG00000275858.1 RP11-291L22.8 7.54 1.25e-12 5.85e-06 0.52 0.45 Corneal astigmatism; chr4:119344812 chr10:38450738~38451069:- CESC trans rs11098499 0.599 rs3864142 ENSG00000275858.1 RP11-291L22.8 7.54 1.25e-12 5.85e-06 0.52 0.45 Corneal astigmatism; chr4:119345036 chr10:38450738~38451069:- CESC trans rs11098499 0.605 rs6833140 ENSG00000275858.1 RP11-291L22.8 7.54 1.25e-12 5.85e-06 0.52 0.45 Corneal astigmatism; chr4:119345667 chr10:38450738~38451069:- CESC trans rs11098499 0.779 rs6815934 ENSG00000275858.1 RP11-291L22.8 7.54 1.25e-12 5.85e-06 0.52 0.45 Corneal astigmatism; chr4:119346155 chr10:38450738~38451069:- CESC trans rs10028773 0.568 rs6838457 ENSG00000275858.1 RP11-291L22.8 7.54 1.25e-12 5.85e-06 0.52 0.45 Educational attainment; chr4:119346212 chr10:38450738~38451069:- CESC trans rs11098499 0.535 rs10005542 ENSG00000275858.1 RP11-291L22.8 7.54 1.25e-12 5.85e-06 0.52 0.45 Corneal astigmatism; chr4:119347147 chr10:38450738~38451069:- CESC trans rs10242455 0.717 rs4646461 ENSG00000228834.1 RP11-249L21.4 7.54 1.26e-12 5.92e-06 0.9 0.45 Blood metabolite levels; chr7:99733850 chr6:108907615~108907873:- CESC trans rs10028773 0.7 rs7690338 ENSG00000275858.1 RP11-291L22.8 7.54 1.29e-12 6.03e-06 0.51 0.45 Educational attainment; chr4:119335313 chr10:38450738~38451069:- CESC trans rs11098499 0.865 rs3956464 ENSG00000275858.1 RP11-291L22.8 7.54 1.29e-12 6.03e-06 0.51 0.45 Corneal astigmatism; chr4:119335609 chr10:38450738~38451069:- CESC trans rs11098499 0.619 rs28502463 ENSG00000275858.1 RP11-291L22.8 7.54 1.29e-12 6.03e-06 0.51 0.45 Corneal astigmatism; chr4:119335868 chr10:38450738~38451069:- CESC trans rs11098499 0.648 rs2002047 ENSG00000275858.1 RP11-291L22.8 7.54 1.29e-12 6.03e-06 0.51 0.45 Corneal astigmatism; chr4:119336073 chr10:38450738~38451069:- CESC trans rs11098499 0.691 rs12510133 ENSG00000275858.1 RP11-291L22.8 7.53 1.3e-12 6.08e-06 0.51 0.45 Corneal astigmatism; chr4:119350189 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs12506487 ENSG00000275858.1 RP11-291L22.8 7.53 1.3e-12 6.08e-06 0.51 0.45 Corneal astigmatism; chr4:119350206 chr10:38450738~38451069:- CESC trans rs11098499 0.691 rs12502524 ENSG00000275858.1 RP11-291L22.8 7.53 1.3e-12 6.08e-06 0.51 0.45 Corneal astigmatism; chr4:119350259 chr10:38450738~38451069:- CESC trans rs11098499 0.691 rs28396837 ENSG00000275858.1 RP11-291L22.8 7.53 1.3e-12 6.08e-06 0.51 0.45 Corneal astigmatism; chr4:119350386 chr10:38450738~38451069:- CESC trans rs11098499 0.629 rs28369518 ENSG00000275858.1 RP11-291L22.8 7.53 1.3e-12 6.08e-06 0.51 0.45 Corneal astigmatism; chr4:119350475 chr10:38450738~38451069:- CESC trans rs11098499 0.722 rs10025925 ENSG00000275858.1 RP11-291L22.8 7.53 1.3e-12 6.08e-06 0.51 0.45 Corneal astigmatism; chr4:119350589 chr10:38450738~38451069:- CESC trans rs3779195 0.585 rs73709460 ENSG00000225169.1 BRI3P1 -7.53 1.3e-12 6.1e-06 -0.75 -0.45 Sex hormone-binding globulin levels; chr7:98265942 chr1:100213293~100213670:+ CESC trans rs4276421 0.806 rs2337412 ENSG00000231752.4 EMBP1 7.53 1.34e-12 6.25e-06 0.56 0.45 P wave duration; chr5:45483410 chr1:121519112~121571892:+ CESC trans rs4276421 0.967 rs10062508 ENSG00000231752.4 EMBP1 7.53 1.34e-12 6.26e-06 0.56 0.45 P wave duration; chr5:45961764 chr1:121519112~121571892:+ CESC trans rs4276421 0.806 rs6451804 ENSG00000231752.4 EMBP1 7.53 1.34e-12 6.26e-06 0.56 0.45 P wave duration; chr5:45492103 chr1:121519112~121571892:+ CESC trans rs7554547 0.765 rs34175640 ENSG00000261819.1 RP11-680G24.4 -7.53 1.35e-12 6.3e-06 -0.53 -0.45 Nonsyndromic cleft lip with cleft palate; chr1:11892155 chr16:14988259~14990160:- CESC trans rs11098499 1 rs13435802 ENSG00000275858.1 RP11-291L22.8 -7.53 1.35e-12 6.32e-06 -0.52 -0.45 Corneal astigmatism; chr4:119256805 chr10:38450738~38451069:- CESC trans rs7312770 1 rs7312770 ENSG00000223416.3 RPS26P15 -7.52 1.37e-12 6.4e-06 -0.45 -0.45 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr1:58056133~58056480:- CESC trans rs12709013 0.792 rs1615326 ENSG00000230849.2 GOT2P2 7.52 1.38e-12 6.46e-06 0.53 0.45 Blood metabolite ratios; chr16:58747148 chr1:173141100~173142350:- CESC trans rs877636 0.669 rs7297175 ENSG00000235459.5 RPS26P31 -7.52 1.39e-12 6.48e-06 -0.48 -0.45 Cognitive function; chr12:56080024 chr7:122681315~122681662:+ CESC trans rs7554547 0.69 rs7516708 ENSG00000261819.1 RP11-680G24.4 7.52 1.39e-12 6.48e-06 0.53 0.45 Nonsyndromic cleft lip with cleft palate; chr1:11890148 chr16:14988259~14990160:- CESC trans rs7811142 1 rs7794485 ENSG00000228546.2 CTA-313A17.3 7.52 1.39e-12 6.51e-06 0.82 0.45 Platelet count; chr7:100471313 chr7:102337316~102339115:+ CESC trans rs4276421 0.87 rs7706116 ENSG00000231752.4 EMBP1 7.52 1.41e-12 6.56e-06 0.54 0.45 P wave duration; chr5:45742522 chr1:121519112~121571892:+ CESC trans rs12709013 0.792 rs12926512 ENSG00000230849.2 GOT2P2 7.52 1.41e-12 6.57e-06 0.53 0.45 Blood metabolite ratios; chr16:58768317 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs12595974 ENSG00000230849.2 GOT2P2 7.52 1.41e-12 6.57e-06 0.53 0.45 Blood metabolite ratios; chr16:58769132 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs1836877 ENSG00000230849.2 GOT2P2 7.52 1.41e-12 6.57e-06 0.53 0.45 Blood metabolite ratios; chr16:58769821 chr1:173141100~173142350:- CESC trans rs10865397 0.539 rs13414338 ENSG00000236165.1 PRADC1P1 7.52 1.41e-12 6.58e-06 0.58 0.45 Intelligence (multi-trait analysis); chr2:73156247 chr3:36976316~36976840:+ CESC trans rs4276421 0.901 rs7447717 ENSG00000231752.4 EMBP1 -7.52 1.44e-12 6.69e-06 -0.54 -0.45 P wave duration; chr5:45770150 chr1:121519112~121571892:+ CESC trans rs7312770 1 rs7312770 ENSG00000235459.5 RPS26P31 -7.51 1.46e-12 6.79e-06 -0.47 -0.45 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr7:122681315~122681662:+ CESC trans rs5022636 0.927 rs4522000 ENSG00000180764.13 PIPSL 7.51 1.46e-12 6.81e-06 0.56 0.45 Gut microbiota (functional units); chr1:151283612 chr10:93958191~93961540:- CESC trans rs11098499 0.82 rs2389885 ENSG00000275858.1 RP11-291L22.8 7.51 1.49e-12 6.93e-06 0.54 0.45 Corneal astigmatism; chr4:119612776 chr10:38450738~38451069:- CESC trans rs9876781 1 rs1109227 ENSG00000235912.1 RP1-159A19.3 -7.51 1.51e-12 7.04e-06 -0.43 -0.45 Longevity; chr3:48437797 chr1:27649419~27649610:+ CESC trans rs9876781 0.967 rs9876891 ENSG00000235912.1 RP1-159A19.3 -7.51 1.51e-12 7.04e-06 -0.43 -0.45 Longevity; chr3:48440024 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs3774808 ENSG00000235912.1 RP1-159A19.3 -7.51 1.51e-12 7.04e-06 -0.43 -0.45 Longevity; chr3:48440237 chr1:27649419~27649610:+ CESC trans rs1045902 0.583 rs2303904 ENSG00000236165.1 PRADC1P1 -7.51 1.52e-12 7.07e-06 -0.57 -0.45 Intelligence (multi-trait analysis); chr2:73220647 chr3:36976316~36976840:+ CESC trans rs4276421 0.837 rs1483303 ENSG00000231752.4 EMBP1 7.51 1.52e-12 7.07e-06 0.55 0.45 P wave duration; chr5:45571997 chr1:121519112~121571892:+ CESC trans rs11098499 0.754 rs9991959 ENSG00000275858.1 RP11-291L22.8 -7.51 1.53e-12 7.13e-06 -0.5 -0.45 Corneal astigmatism; chr4:119332618 chr10:38450738~38451069:- CESC trans rs7554547 0.778 rs2008113 ENSG00000261819.1 RP11-680G24.4 -7.5 1.56e-12 7.26e-06 -0.51 -0.45 Nonsyndromic cleft lip with cleft palate; chr1:11878809 chr16:14988259~14990160:- CESC trans rs77688320 0.517 rs6717641 ENSG00000235105.1 RP11-329A14.1 7.5 1.57e-12 7.27e-06 0.48 0.45 Breast cancer; chr2:201450484 chr1:48435967~48437223:+ CESC trans rs11098499 0.661 rs10015965 ENSG00000275858.1 RP11-291L22.8 7.5 1.58e-12 7.33e-06 0.51 0.45 Corneal astigmatism; chr4:119347082 chr10:38450738~38451069:- CESC trans rs11098499 0.722 rs7673476 ENSG00000275858.1 RP11-291L22.8 7.5 1.6e-12 7.43e-06 0.49 0.45 Corneal astigmatism; chr4:119327528 chr10:38450738~38451069:- CESC trans rs9611519 0.78 rs9611542 ENSG00000268568.1 AC007228.9 -7.5 1.61e-12 7.45e-06 -0.62 -0.45 Neuroticism; chr22:41281313 chr19:56672574~56673901:- CESC trans rs9876781 1 rs9881491 ENSG00000235912.1 RP1-159A19.3 -7.5 1.64e-12 7.6e-06 -0.43 -0.45 Longevity; chr3:48446507 chr1:27649419~27649610:+ CESC trans rs9611565 0.568 rs2413656 ENSG00000268568.1 AC007228.9 7.5 1.64e-12 7.61e-06 0.57 0.45 Vitiligo; chr22:41733353 chr19:56672574~56673901:- CESC trans rs11098499 0.754 rs2036857 ENSG00000275858.1 RP11-291L22.8 7.49 1.67e-12 7.74e-06 0.5 0.45 Corneal astigmatism; chr4:119328085 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs2036856 ENSG00000275858.1 RP11-291L22.8 7.49 1.67e-12 7.74e-06 0.5 0.45 Corneal astigmatism; chr4:119328133 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs4443261 ENSG00000275858.1 RP11-291L22.8 7.49 1.67e-12 7.74e-06 0.5 0.45 Corneal astigmatism; chr4:119328146 chr10:38450738~38451069:- CESC trans rs7312770 0.637 rs705700 ENSG00000196656.7 AC004057.1 7.49 1.68e-12 7.76e-06 0.46 0.45 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr4:113214046~113217170:- CESC trans rs4276421 0.806 rs6892594 ENSG00000231752.4 EMBP1 7.49 1.7e-12 7.85e-06 0.55 0.45 P wave duration; chr5:45427071 chr1:121519112~121571892:+ CESC trans rs11098499 0.754 rs28643450 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119324087 chr10:38450738~38451069:- CESC trans rs10028773 0.7 rs7671797 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Educational attainment; chr4:119327002 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs7672372 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119327251 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs7672594 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119327388 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs7672778 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119327430 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs2036860 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119327779 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs12513083 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119328457 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs12509621 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119328505 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs1511017 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119329650 chr10:38450738~38451069:- CESC trans rs11098499 0.789 rs12498994 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119329663 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs12507565 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119329966 chr10:38450738~38451069:- CESC trans rs11098499 0.826 rs12511640 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119330093 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs1980026 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119330488 chr10:38450738~38451069:- CESC trans rs11098499 0.722 rs28713555 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119330840 chr10:38450738~38451069:- CESC trans rs11098499 0.743 rs11098501 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119330862 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs11098502 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119330908 chr10:38450738~38451069:- CESC trans rs11098499 0.708 rs11732686 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119331175 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs11724409 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119331206 chr10:38450738~38451069:- CESC trans rs11098499 0.789 rs1980024 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119331892 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs34425882 ENSG00000275858.1 RP11-291L22.8 7.49 1.71e-12 7.88e-06 0.5 0.45 Corneal astigmatism; chr4:119332022 chr10:38450738~38451069:- CESC trans rs4276421 0.869 rs2337951 ENSG00000231752.4 EMBP1 7.49 1.74e-12 8.02e-06 0.55 0.45 P wave duration; chr5:45717834 chr1:121519112~121571892:+ CESC trans rs4276421 0.869 rs7718785 ENSG00000231752.4 EMBP1 7.49 1.74e-12 8.02e-06 0.55 0.45 P wave duration; chr5:45725495 chr1:121519112~121571892:+ CESC trans rs9467773 0.869 rs1796520 ENSG00000242375.1 RP11-498P14.3 -7.48 1.77e-12 8.17e-06 -0.53 -0.45 Intelligence (multi-trait analysis); chr6:26410572 chr9:97195351~97197687:- CESC trans rs9611565 0.729 rs203320 ENSG00000268568.1 AC007228.9 -7.48 1.81e-12 8.32e-06 -0.55 -0.45 Vitiligo; chr22:41517473 chr19:56672574~56673901:- CESC trans rs4276421 0.806 rs6892290 ENSG00000231752.4 EMBP1 7.48 1.82e-12 8.38e-06 0.55 0.45 P wave duration; chr5:45427035 chr1:121519112~121571892:+ CESC trans rs7312770 0.637 rs705700 ENSG00000196933.5 RPS26P11 7.48 1.82e-12 8.39e-06 0.5 0.45 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chrX:72044545~72044892:+ CESC trans rs9876781 1 rs13091785 ENSG00000235912.1 RP1-159A19.3 -7.48 1.83e-12 8.42e-06 -0.43 -0.45 Longevity; chr3:48452692 chr1:27649419~27649610:+ CESC trans rs12709013 0.792 rs7185513 ENSG00000230849.2 GOT2P2 7.48 1.83e-12 8.42e-06 0.52 0.45 Blood metabolite ratios; chr16:58794889 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs12325054 ENSG00000230849.2 GOT2P2 7.48 1.83e-12 8.43e-06 0.52 0.45 Blood metabolite ratios; chr16:58749804 chr1:173141100~173142350:- CESC trans rs9611565 0.765 rs132906 ENSG00000268568.1 AC007228.9 7.48 1.83e-12 8.44e-06 0.55 0.45 Vitiligo; chr22:41403763 chr19:56672574~56673901:- CESC trans rs12709013 0.766 rs11648511 ENSG00000230849.2 GOT2P2 7.48 1.85e-12 8.51e-06 0.53 0.45 Blood metabolite ratios; chr16:58798171 chr1:173141100~173142350:- CESC trans rs12709013 0.716 rs11647582 ENSG00000230849.2 GOT2P2 7.48 1.85e-12 8.51e-06 0.53 0.45 Blood metabolite ratios; chr16:58801474 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs35684307 ENSG00000230849.2 GOT2P2 7.48 1.85e-12 8.51e-06 0.53 0.45 Blood metabolite ratios; chr16:58801651 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs11649387 ENSG00000230849.2 GOT2P2 7.48 1.85e-12 8.51e-06 0.53 0.45 Blood metabolite ratios; chr16:58803176 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs11649133 ENSG00000230849.2 GOT2P2 7.48 1.85e-12 8.51e-06 0.53 0.45 Blood metabolite ratios; chr16:58803275 chr1:173141100~173142350:- CESC trans rs12709013 0.766 rs12599331 ENSG00000230849.2 GOT2P2 7.48 1.85e-12 8.51e-06 0.53 0.45 Blood metabolite ratios; chr16:58805307 chr1:173141100~173142350:- CESC trans rs6732160 0.588 rs1430344 ENSG00000236165.1 PRADC1P1 7.47 1.86e-12 8.55e-06 0.61 0.45 Intelligence (multi-trait analysis); chr2:73146216 chr3:36976316~36976840:+ CESC trans rs4276421 0.806 rs6860200 ENSG00000231752.4 EMBP1 7.47 1.91e-12 8.78e-06 0.55 0.45 P wave duration; chr5:45440241 chr1:121519112~121571892:+ CESC trans rs4276421 0.806 rs6451801 ENSG00000231752.4 EMBP1 7.47 1.92e-12 8.8e-06 0.55 0.45 P wave duration; chr5:45439331 chr1:121519112~121571892:+ CESC trans rs4276421 0.806 rs13169726 ENSG00000231752.4 EMBP1 7.47 1.92e-12 8.81e-06 0.55 0.45 P wave duration; chr5:45444967 chr1:121519112~121571892:+ CESC trans rs4276421 0.806 rs34666220 ENSG00000231752.4 EMBP1 7.47 1.92e-12 8.82e-06 0.55 0.45 P wave duration; chr5:45435884 chr1:121519112~121571892:+ CESC trans rs11098499 0.775 rs2002049 ENSG00000275858.1 RP11-291L22.8 7.47 1.94e-12 8.9e-06 0.5 0.45 Corneal astigmatism; chr4:119336262 chr10:38450738~38451069:- CESC trans rs12709013 0.792 rs1646276 ENSG00000230849.2 GOT2P2 7.47 1.95e-12 8.92e-06 0.52 0.45 Blood metabolite ratios; chr16:58749654 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs1646277 ENSG00000230849.2 GOT2P2 7.47 1.95e-12 8.92e-06 0.52 0.45 Blood metabolite ratios; chr16:58750037 chr1:173141100~173142350:- CESC trans rs4276421 0.967 rs7443384 ENSG00000231752.4 EMBP1 7.46 1.98e-12 9.07e-06 0.58 0.45 P wave duration; chr5:45960791 chr1:121519112~121571892:+ CESC trans rs4276421 0.776 rs7723380 ENSG00000231752.4 EMBP1 7.46 2.05e-12 9.39e-06 0.55 0.45 P wave duration; chr5:45428433 chr1:121519112~121571892:+ CESC trans rs4276421 0.806 rs12520124 ENSG00000231752.4 EMBP1 7.46 2.05e-12 9.39e-06 0.55 0.45 P wave duration; chr5:45434917 chr1:121519112~121571892:+ CESC trans rs7811142 1 rs73161762 ENSG00000228546.2 CTA-313A17.3 7.46 2.06e-12 9.4e-06 0.83 0.45 Platelet count; chr7:100417223 chr7:102337316~102339115:+ CESC trans rs13190036 1 rs59737888 ENSG00000226986.4 RP11-543B16.2 -7.46 2.06e-12 9.4e-06 -0.6 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177160374 chr1:211207239~211207897:+ CESC trans rs12709013 0.792 rs1657165 ENSG00000230849.2 GOT2P2 7.46 2.07e-12 9.45e-06 0.52 0.45 Blood metabolite ratios; chr16:58747980 chr1:173141100~173142350:- CESC trans rs12709013 0.818 rs1646273 ENSG00000230849.2 GOT2P2 7.46 2.07e-12 9.45e-06 0.52 0.45 Blood metabolite ratios; chr16:58748318 chr1:173141100~173142350:- CESC trans rs4276421 0.967 rs10941703 ENSG00000231752.4 EMBP1 -7.46 2.09e-12 9.55e-06 -0.54 -0.45 P wave duration; chr5:45781770 chr1:121519112~121571892:+ CESC trans rs916888 0.61 rs199446 ENSG00000264070.1 DND1P1 -7.46 2.09e-12 9.56e-06 -0.54 -0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45585871~45586929:+ CESC trans rs11098499 0.697 rs35280960 ENSG00000275858.1 RP11-291L22.8 7.45 2.09e-12 9.56e-06 0.51 0.45 Corneal astigmatism; chr4:119335904 chr10:38450738~38451069:- CESC trans rs9611565 0.921 rs8137373 ENSG00000268568.1 AC007228.9 7.45 2.1e-12 9.57e-06 0.62 0.45 Vitiligo; chr22:41333212 chr19:56672574~56673901:- CESC trans rs77688320 0.535 rs10460403 ENSG00000235105.1 RP11-329A14.1 7.45 2.18e-12 9.95e-06 0.48 0.45 Breast cancer; chr2:201478014 chr1:48435967~48437223:+ CESC trans rs4276421 0.805 rs13354798 ENSG00000231752.4 EMBP1 7.45 2.19e-12 9.99e-06 0.55 0.45 P wave duration; chr5:45456975 chr1:121519112~121571892:+ CESC trans rs4276421 0.869 rs6451814 ENSG00000231752.4 EMBP1 7.45 2.19e-12 9.99e-06 0.54 0.45 P wave duration; chr5:45734981 chr1:121519112~121571892:+ CESC trans rs7192380 0.639 rs7186296 ENSG00000257513.6 NPIPB1P -7.45 2.2e-12 1e-05 -0.53 -0.45 Sjögren's syndrome; chr16:69775095 chr18:11619509~11639699:- CESC trans rs9876781 1 rs6776700 ENSG00000235912.1 RP1-159A19.3 -7.44 2.26e-12 1.03e-05 -0.44 -0.45 Longevity; chr3:48455358 chr1:27649419~27649610:+ CESC trans rs77688320 0.5 rs4129010 ENSG00000235105.1 RP11-329A14.1 7.44 2.28e-12 1.04e-05 0.48 0.45 Breast cancer; chr2:201443602 chr1:48435967~48437223:+ CESC trans rs77688320 0.5 rs4129011 ENSG00000235105.1 RP11-329A14.1 7.44 2.28e-12 1.04e-05 0.48 0.45 Breast cancer; chr2:201443863 chr1:48435967~48437223:+ CESC trans rs77688320 0.517 rs7573536 ENSG00000235105.1 RP11-329A14.1 7.44 2.31e-12 1.05e-05 0.47 0.45 Breast cancer; chr2:201469676 chr1:48435967~48437223:+ CESC trans rs867371 0.656 rs2665103 ENSG00000235370.6 DNM1P51 7.44 2.32e-12 1.05e-05 0.59 0.45 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82140374 chr15:84398316~84411701:- CESC trans rs6732160 0.588 rs13394018 ENSG00000236165.1 PRADC1P1 7.44 2.33e-12 1.06e-05 0.59 0.45 Intelligence (multi-trait analysis); chr2:73145477 chr3:36976316~36976840:+ CESC trans rs9611565 0.921 rs4822021 ENSG00000268568.1 AC007228.9 -7.44 2.34e-12 1.06e-05 -0.62 -0.45 Vitiligo; chr22:41330049 chr19:56672574~56673901:- CESC trans rs4276421 0.806 rs13162651 ENSG00000231752.4 EMBP1 7.44 2.35e-12 1.07e-05 0.55 0.45 P wave duration; chr5:45409798 chr1:121519112~121571892:+ CESC trans rs4276421 0.776 rs13175193 ENSG00000231752.4 EMBP1 7.44 2.35e-12 1.07e-05 0.55 0.45 P wave duration; chr5:45408894 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs7714695 ENSG00000226986.4 RP11-543B16.2 -7.43 2.37e-12 1.08e-05 -0.6 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177130444 chr1:211207239~211207897:+ CESC trans rs6732160 0.588 rs13403748 ENSG00000236165.1 PRADC1P1 7.43 2.46e-12 1.12e-05 0.61 0.45 Intelligence (multi-trait analysis); chr2:73144347 chr3:36976316~36976840:+ CESC trans rs6732160 0.588 rs72841902 ENSG00000236165.1 PRADC1P1 7.43 2.46e-12 1.12e-05 0.61 0.45 Intelligence (multi-trait analysis); chr2:73145084 chr3:36976316~36976840:+ CESC trans rs916888 0.61 rs199438 ENSG00000214425.5 LRRC37A4P -7.43 2.5e-12 1.14e-05 -0.49 -0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45506741~45550335:- CESC trans rs916888 0.61 rs199536 ENSG00000264070.1 DND1P1 -7.42 2.52e-12 1.14e-05 -0.54 -0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45585871~45586929:+ CESC trans rs6732160 0.588 rs62151795 ENSG00000236165.1 PRADC1P1 7.42 2.55e-12 1.16e-05 0.61 0.45 Intelligence (multi-trait analysis); chr2:73149712 chr3:36976316~36976840:+ CESC trans rs6732160 0.613 rs10179063 ENSG00000236165.1 PRADC1P1 7.42 2.56e-12 1.16e-05 0.62 0.45 Intelligence (multi-trait analysis); chr2:73157983 chr3:36976316~36976840:+ CESC trans rs6732160 0.613 rs6546804 ENSG00000236165.1 PRADC1P1 7.42 2.56e-12 1.16e-05 0.62 0.45 Intelligence (multi-trait analysis); chr2:73158791 chr3:36976316~36976840:+ CESC trans rs877636 1 rs2292239 ENSG00000234513.1 AC073072.7 7.42 2.58e-12 1.17e-05 0.5 0.45 Cognitive function; chr12:56088396 chr7:22773646~22773993:- CESC trans rs13190036 0.901 rs28684504 ENSG00000226986.4 RP11-543B16.2 7.42 2.61e-12 1.18e-05 0.58 0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177300437 chr1:211207239~211207897:+ CESC trans rs916888 0.61 rs199436 ENSG00000214425.5 LRRC37A4P 7.42 2.62e-12 1.19e-05 0.49 0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45506741~45550335:- CESC trans rs11098499 0.826 rs4472123 ENSG00000275858.1 RP11-291L22.8 7.41 2.7e-12 1.22e-05 0.5 0.45 Corneal astigmatism; chr4:119315475 chr10:38450738~38451069:- CESC trans rs4276421 0.869 rs6451812 ENSG00000231752.4 EMBP1 7.41 2.72e-12 1.23e-05 0.55 0.45 P wave duration; chr5:45692206 chr1:121519112~121571892:+ CESC trans rs9876781 1 rs9883759 ENSG00000235912.1 RP1-159A19.3 -7.41 2.76e-12 1.25e-05 -0.43 -0.45 Longevity; chr3:48422209 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs6442120 ENSG00000235912.1 RP1-159A19.3 -7.41 2.76e-12 1.25e-05 -0.43 -0.45 Longevity; chr3:48423094 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs2279077 ENSG00000235912.1 RP1-159A19.3 -7.41 2.76e-12 1.25e-05 -0.43 -0.45 Longevity; chr3:48432839 chr1:27649419~27649610:+ CESC trans rs9611565 0.649 rs2413659 ENSG00000268568.1 AC007228.9 7.41 2.8e-12 1.26e-05 0.57 0.45 Vitiligo; chr22:41768858 chr19:56672574~56673901:- CESC trans rs9611565 0.546 rs5758426 ENSG00000268568.1 AC007228.9 7.41 2.8e-12 1.27e-05 0.58 0.45 Vitiligo; chr22:41702759 chr19:56672574~56673901:- CESC trans rs11098499 1 rs3749591 ENSG00000275858.1 RP11-291L22.8 7.41 2.82e-12 1.27e-05 0.52 0.45 Corneal astigmatism; chr4:119292875 chr10:38450738~38451069:- CESC trans rs6732160 0.588 rs3891890 ENSG00000236165.1 PRADC1P1 7.4 2.86e-12 1.29e-05 0.6 0.45 Intelligence (multi-trait analysis); chr2:73150921 chr3:36976316~36976840:+ CESC trans rs877636 0.859 rs3741499 ENSG00000223416.3 RPS26P15 -7.4 2.87e-12 1.3e-05 -0.46 -0.45 Cognitive function; chr12:56080595 chr1:58056133~58056480:- CESC trans rs7554547 0.739 rs4846073 ENSG00000261819.1 RP11-680G24.4 7.4 2.96e-12 1.33e-05 0.52 0.45 Nonsyndromic cleft lip with cleft palate; chr1:11890521 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs57678332 ENSG00000261819.1 RP11-680G24.4 7.4 2.96e-12 1.33e-05 0.52 0.45 Nonsyndromic cleft lip with cleft palate; chr1:11890834 chr16:14988259~14990160:- CESC trans rs7554547 0.765 rs57176983 ENSG00000261819.1 RP11-680G24.4 7.4 2.96e-12 1.33e-05 0.52 0.45 Nonsyndromic cleft lip with cleft palate; chr1:11891041 chr16:14988259~14990160:- CESC trans rs7554547 0.791 rs1321072 ENSG00000261819.1 RP11-680G24.4 7.4 2.96e-12 1.33e-05 0.52 0.45 Nonsyndromic cleft lip with cleft palate; chr1:11891261 chr16:14988259~14990160:- CESC trans rs12709013 0.792 rs12325510 ENSG00000230849.2 GOT2P2 7.39 3.04e-12 1.37e-05 0.53 0.45 Blood metabolite ratios; chr16:58749707 chr1:173141100~173142350:- CESC trans rs77688320 0.5 rs6755428 ENSG00000235105.1 RP11-329A14.1 7.39 3.05e-12 1.37e-05 0.47 0.45 Breast cancer; chr2:201431043 chr1:48435967~48437223:+ CESC trans rs12709013 0.792 rs1646270 ENSG00000230849.2 GOT2P2 7.39 3.12e-12 1.4e-05 0.52 0.45 Blood metabolite ratios; chr16:58745823 chr1:173141100~173142350:- CESC trans rs6732160 0.588 rs13390460 ENSG00000236165.1 PRADC1P1 7.39 3.18e-12 1.43e-05 0.61 0.45 Intelligence (multi-trait analysis); chr2:73144348 chr3:36976316~36976840:+ CESC trans rs9876781 0.9 rs1037773 ENSG00000235912.1 RP1-159A19.3 -7.38 3.24e-12 1.46e-05 -0.42 -0.45 Longevity; chr3:48426493 chr1:27649419~27649610:+ CESC trans rs9611565 1 rs5751086 ENSG00000268568.1 AC007228.9 -7.38 3.25e-12 1.46e-05 -0.54 -0.45 Vitiligo; chr22:41372858 chr19:56672574~56673901:- CESC trans rs4276421 0.869 rs6892627 ENSG00000231752.4 EMBP1 7.38 3.27e-12 1.47e-05 0.56 0.45 P wave duration; chr5:45722892 chr1:121519112~121571892:+ CESC trans rs74781061 1 rs4887166 ENSG00000227288.3 RP5-837I24.1 7.38 3.36e-12 1.5e-05 0.58 0.45 Endometriosis; chr15:74605257 chr1:81501794~81503468:+ CESC trans rs74781061 1 rs6495117 ENSG00000227288.3 RP5-837I24.1 7.38 3.36e-12 1.5e-05 0.58 0.45 Endometriosis; chr15:74607159 chr1:81501794~81503468:+ CESC trans rs4276421 0.901 rs10044479 ENSG00000231752.4 EMBP1 7.38 3.38e-12 1.51e-05 0.54 0.45 P wave duration; chr5:45751434 chr1:121519112~121571892:+ CESC trans rs13190036 0.901 rs10072499 ENSG00000226986.4 RP11-543B16.2 -7.38 3.39e-12 1.52e-05 -0.52 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228236 chr1:211207239~211207897:+ CESC trans rs4276421 0.806 rs7732970 ENSG00000231752.4 EMBP1 7.37 3.41e-12 1.53e-05 0.55 0.45 P wave duration; chr5:45452044 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs34446750 ENSG00000226986.4 RP11-543B16.2 -7.37 3.46e-12 1.55e-05 -0.59 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177168079 chr1:211207239~211207897:+ CESC trans rs6732160 0.588 rs28626211 ENSG00000236165.1 PRADC1P1 7.37 3.54e-12 1.59e-05 0.6 0.45 Intelligence (multi-trait analysis); chr2:73151394 chr3:36976316~36976840:+ CESC trans rs11098499 0.789 rs10212719 ENSG00000275858.1 RP11-291L22.8 7.37 3.58e-12 1.6e-05 0.5 0.45 Corneal astigmatism; chr4:119333282 chr10:38450738~38451069:- CESC trans rs6732160 0.613 rs62151837 ENSG00000236165.1 PRADC1P1 7.36 3.61e-12 1.62e-05 0.62 0.45 Intelligence (multi-trait analysis); chr2:73163268 chr3:36976316~36976840:+ CESC trans rs11098499 0.754 rs17049949 ENSG00000275858.1 RP11-291L22.8 7.36 3.63e-12 1.62e-05 0.5 0.45 Corneal astigmatism; chr4:119334135 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs7689729 ENSG00000275858.1 RP11-291L22.8 7.36 3.63e-12 1.62e-05 0.5 0.45 Corneal astigmatism; chr4:119335037 chr10:38450738~38451069:- CESC trans rs11098499 0.691 rs10010355 ENSG00000275858.1 RP11-291L22.8 7.36 3.64e-12 1.63e-05 0.49 0.45 Corneal astigmatism; chr4:119339888 chr10:38450738~38451069:- CESC trans rs11098499 0.691 rs9307471 ENSG00000275858.1 RP11-291L22.8 7.36 3.64e-12 1.63e-05 0.49 0.45 Corneal astigmatism; chr4:119340107 chr10:38450738~38451069:- CESC trans rs11098499 0.913 rs10006304 ENSG00000275858.1 RP11-291L22.8 7.36 3.68e-12 1.64e-05 0.52 0.45 Corneal astigmatism; chr4:119203150 chr10:38450738~38451069:- CESC trans rs12709013 0.792 rs12928733 ENSG00000230849.2 GOT2P2 7.36 3.69e-12 1.65e-05 0.52 0.45 Blood metabolite ratios; chr16:58807216 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs62066381 ENSG00000230849.2 GOT2P2 7.36 3.69e-12 1.65e-05 0.52 0.45 Blood metabolite ratios; chr16:58807981 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs36098613 ENSG00000230849.2 GOT2P2 7.36 3.69e-12 1.65e-05 0.52 0.45 Blood metabolite ratios; chr16:58810562 chr1:173141100~173142350:- CESC trans rs11098499 0.604 rs2389882 ENSG00000275858.1 RP11-291L22.8 7.36 3.81e-12 1.7e-05 0.5 0.45 Corneal astigmatism; chr4:119645578 chr10:38450738~38451069:- CESC trans rs11098499 0.913 rs56122576 ENSG00000275858.1 RP11-291L22.8 7.35 3.99e-12 1.77e-05 0.51 0.45 Corneal astigmatism; chr4:119208181 chr10:38450738~38451069:- CESC trans rs11098499 0.913 rs68128210 ENSG00000275858.1 RP11-291L22.8 7.35 3.99e-12 1.77e-05 0.51 0.45 Corneal astigmatism; chr4:119216664 chr10:38450738~38451069:- CESC trans rs11098499 0.913 rs13126596 ENSG00000275858.1 RP11-291L22.8 7.35 3.99e-12 1.77e-05 0.51 0.45 Corneal astigmatism; chr4:119219574 chr10:38450738~38451069:- CESC trans rs6732160 0.564 rs2043096 ENSG00000236165.1 PRADC1P1 7.35 4.04e-12 1.8e-05 0.6 0.45 Intelligence (multi-trait analysis); chr2:73148595 chr3:36976316~36976840:+ CESC trans rs12709013 0.729 rs34324769 ENSG00000230849.2 GOT2P2 7.35 4.04e-12 1.8e-05 0.51 0.45 Blood metabolite ratios; chr16:58778131 chr1:173141100~173142350:- CESC trans rs4276421 0.869 rs2337952 ENSG00000231752.4 EMBP1 7.35 4.05e-12 1.8e-05 0.54 0.45 P wave duration; chr5:45722022 chr1:121519112~121571892:+ CESC trans rs77688320 0.517 rs10931949 ENSG00000235105.1 RP11-329A14.1 7.34 4.1e-12 1.82e-05 0.47 0.45 Breast cancer; chr2:201459730 chr1:48435967~48437223:+ CESC trans rs11638815 0.626 rs11635624 ENSG00000235370.6 DNM1P51 -7.34 4.1e-12 1.82e-05 -0.58 -0.45 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82646980 chr15:84398316~84411701:- CESC trans rs4276421 0.839 rs28885449 ENSG00000231752.4 EMBP1 7.34 4.11e-12 1.82e-05 0.55 0.45 P wave duration; chr5:45994103 chr1:121519112~121571892:+ CESC trans rs11098499 0.865 rs10213221 ENSG00000275858.1 RP11-291L22.8 7.34 4.12e-12 1.83e-05 0.5 0.45 Corneal astigmatism; chr4:119334771 chr10:38450738~38451069:- CESC trans rs6732160 0.588 rs2043100 ENSG00000236165.1 PRADC1P1 7.34 4.19e-12 1.86e-05 0.6 0.45 Intelligence (multi-trait analysis); chr2:73146968 chr3:36976316~36976840:+ CESC trans rs6732160 0.588 rs2043099 ENSG00000236165.1 PRADC1P1 7.34 4.19e-12 1.86e-05 0.6 0.45 Intelligence (multi-trait analysis); chr2:73147028 chr3:36976316~36976840:+ CESC trans rs6732160 0.588 rs11126392 ENSG00000236165.1 PRADC1P1 7.34 4.19e-12 1.86e-05 0.6 0.45 Intelligence (multi-trait analysis); chr2:73147326 chr3:36976316~36976840:+ CESC trans rs6732160 0.588 rs7578991 ENSG00000236165.1 PRADC1P1 7.34 4.19e-12 1.86e-05 0.6 0.45 Intelligence (multi-trait analysis); chr2:73149043 chr3:36976316~36976840:+ CESC trans rs6732160 0.564 rs7605716 ENSG00000236165.1 PRADC1P1 7.34 4.19e-12 1.86e-05 0.6 0.45 Intelligence (multi-trait analysis); chr2:73149122 chr3:36976316~36976840:+ CESC trans rs12709013 0.792 rs11644344 ENSG00000230849.2 GOT2P2 7.34 4.19e-12 1.86e-05 0.52 0.45 Blood metabolite ratios; chr16:58803080 chr1:173141100~173142350:- CESC trans rs11098499 0.913 rs67073020 ENSG00000275858.1 RP11-291L22.8 7.34 4.22e-12 1.87e-05 0.52 0.45 Corneal astigmatism; chr4:119231402 chr10:38450738~38451069:- CESC trans rs13190036 0.792 rs6874206 ENSG00000226986.4 RP11-543B16.2 -7.34 4.22e-12 1.87e-05 -0.52 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177223970 chr1:211207239~211207897:+ CESC trans rs4276421 0.869 rs2580258 ENSG00000231752.4 EMBP1 7.34 4.24e-12 1.88e-05 0.54 0.45 P wave duration; chr5:45586815 chr1:121519112~121571892:+ CESC trans rs13190036 0.551 rs1052432 ENSG00000217325.2 PRELID1P1 -7.33 4.33e-12 1.92e-05 -0.7 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177137188 chr6:126643488~126644390:+ CESC trans rs4276421 0.904 rs10070596 ENSG00000231752.4 EMBP1 7.33 4.38e-12 1.94e-05 0.55 0.44 P wave duration; chr5:46004129 chr1:121519112~121571892:+ CESC trans rs116095464 0.558 rs12173015 ENSG00000185986.11 SDHAP3 -7.33 4.51e-12 1.99e-05 -0.67 -0.44 Breast cancer; chr5:269852 chr5:1572222~1594620:- CESC trans rs3779195 0.585 rs7777991 ENSG00000225169.1 BRI3P1 -7.33 4.57e-12 2.02e-05 -0.7 -0.44 Sex hormone-binding globulin levels; chr7:98236445 chr1:100213293~100213670:+ CESC trans rs9425766 0.962 rs2065171 ENSG00000213331.4 RP11-713C19.2 7.32 4.76e-12 2.1e-05 0.53 0.44 Life satisfaction; chr1:173876972 chr4:187970273~187971284:+ CESC trans rs9611565 0.5 rs2011053 ENSG00000268568.1 AC007228.9 7.31 4.96e-12 2.18e-05 0.56 0.44 Vitiligo; chr22:41725274 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs738422 ENSG00000268568.1 AC007228.9 7.31 4.96e-12 2.18e-05 0.56 0.44 Vitiligo; chr22:41727395 chr19:56672574~56673901:- CESC trans rs916888 0.531 rs183211 ENSG00000214425.5 LRRC37A4P -7.31 4.97e-12 2.18e-05 -0.48 -0.44 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45506741~45550335:- CESC trans rs9425766 0.924 rs9286895 ENSG00000213331.4 RP11-713C19.2 7.31 4.97e-12 2.19e-05 0.53 0.44 Life satisfaction; chr1:173873329 chr4:187970273~187971284:+ CESC trans rs9425766 0.886 rs9661233 ENSG00000213331.4 RP11-713C19.2 7.31 4.97e-12 2.19e-05 0.53 0.44 Life satisfaction; chr1:173874913 chr4:187970273~187971284:+ CESC trans rs9425766 0.962 rs4652229 ENSG00000213331.4 RP11-713C19.2 7.31 4.97e-12 2.19e-05 0.53 0.44 Life satisfaction; chr1:173877452 chr4:187970273~187971284:+ CESC trans rs9425766 0.927 rs9425765 ENSG00000213331.4 RP11-713C19.2 7.31 4.97e-12 2.19e-05 0.53 0.44 Life satisfaction; chr1:173878871 chr4:187970273~187971284:+ CESC trans rs11098499 0.644 rs3986377 ENSG00000275858.1 RP11-291L22.8 7.31 4.98e-12 2.19e-05 0.49 0.44 Corneal astigmatism; chr4:119339115 chr10:38450738~38451069:- CESC trans rs10028773 0.556 rs4473640 ENSG00000275858.1 RP11-291L22.8 7.31 4.98e-12 2.19e-05 0.49 0.44 Educational attainment; chr4:119339282 chr10:38450738~38451069:- CESC trans rs11098499 0.731 rs10015579 ENSG00000275858.1 RP11-291L22.8 7.31 5e-12 2.19e-05 0.5 0.44 Corneal astigmatism; chr4:119350647 chr10:38450738~38451069:- CESC trans rs1707322 0.827 rs6683274 ENSG00000255397.1 AC022182.2 -7.31 5e-12 2.2e-05 -0.59 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45775966 chr8:60937705~60939871:- CESC trans rs12709013 0.792 rs62064901 ENSG00000230849.2 GOT2P2 7.31 5.06e-12 2.22e-05 0.51 0.44 Blood metabolite ratios; chr16:58776758 chr1:173141100~173142350:- CESC trans rs4276421 0.901 rs35381866 ENSG00000231752.4 EMBP1 7.3 5.31e-12 2.32e-05 0.54 0.44 P wave duration; chr5:45690085 chr1:121519112~121571892:+ CESC trans rs7258465 1 rs8105994 ENSG00000267533.1 RP11-815J4.7 7.3 5.39e-12 2.36e-05 0.55 0.44 Breast cancer; chr19:18482743 chr18:12067173~12068417:- CESC trans rs11098499 0.789 rs9991166 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119316696 chr10:38450738~38451069:- CESC trans rs11098499 0.708 rs10005237 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119316742 chr10:38450738~38451069:- CESC trans rs11098499 0.575 rs907204 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119317499 chr10:38450738~38451069:- CESC trans rs11098499 0.575 rs907205 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119317509 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs878372 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119317625 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs10213267 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119317919 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs10212775 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119318089 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs2964 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119318976 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs1511025 ENSG00000275858.1 RP11-291L22.8 7.3 5.39e-12 2.36e-05 0.49 0.44 Corneal astigmatism; chr4:119319083 chr10:38450738~38451069:- CESC trans rs74781061 0.858 rs58473469 ENSG00000227288.3 RP5-837I24.1 7.3 5.4e-12 2.36e-05 0.58 0.44 Endometriosis; chr15:74592722 chr1:81501794~81503468:+ CESC trans rs9611565 0.694 rs4822032 ENSG00000268568.1 AC007228.9 -7.3 5.4e-12 2.36e-05 -0.54 -0.44 Vitiligo; chr22:41529531 chr19:56672574~56673901:- CESC trans rs11098499 0.691 rs10028773 ENSG00000275858.1 RP11-291L22.8 -7.3 5.42e-12 2.37e-05 -0.51 -0.44 Corneal astigmatism; chr4:119344104 chr10:38450738~38451069:- CESC trans rs77688320 0.553 rs12473387 ENSG00000235105.1 RP11-329A14.1 7.29 5.56e-12 2.43e-05 0.5 0.44 Breast cancer; chr2:201415778 chr1:48435967~48437223:+ CESC trans rs77688320 0.553 rs4507084 ENSG00000235105.1 RP11-329A14.1 7.29 5.56e-12 2.43e-05 0.5 0.44 Breast cancer; chr2:201420377 chr1:48435967~48437223:+ CESC trans rs9611565 0.506 rs1984839 ENSG00000268568.1 AC007228.9 -7.29 5.56e-12 2.43e-05 -0.6 -0.44 Vitiligo; chr22:41289933 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs9623450 ENSG00000268568.1 AC007228.9 7.29 5.59e-12 2.44e-05 0.57 0.44 Vitiligo; chr22:41779227 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs5758466 ENSG00000268568.1 AC007228.9 7.29 5.59e-12 2.44e-05 0.57 0.44 Vitiligo; chr22:41780055 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs126092 ENSG00000268568.1 AC007228.9 7.29 5.7e-12 2.48e-05 0.6 0.44 Vitiligo; chr22:41782437 chr19:56672574~56673901:- CESC trans rs9611565 0.568 rs5751159 ENSG00000268568.1 AC007228.9 7.29 5.72e-12 2.49e-05 0.57 0.44 Vitiligo; chr22:41779361 chr19:56672574~56673901:- CESC trans rs877636 0.669 rs7297175 ENSG00000225071.1 GS1-184P14.2 -7.29 5.72e-12 2.49e-05 -0.45 -0.44 Cognitive function; chr12:56080024 chrX:24429573~24429920:- CESC trans rs4276421 0.87 rs4257782 ENSG00000231752.4 EMBP1 7.29 5.74e-12 2.5e-05 0.53 0.44 P wave duration; chr5:45750292 chr1:121519112~121571892:+ CESC trans rs11638815 0.603 rs2678448 ENSG00000235370.6 DNM1P51 -7.28 5.83e-12 2.54e-05 -0.58 -0.44 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82594655 chr15:84398316~84411701:- CESC trans rs9876781 1 rs9812647 ENSG00000235912.1 RP1-159A19.3 7.28 5.86e-12 2.55e-05 0.43 0.44 Longevity; chr3:48407507 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs11712561 ENSG00000235912.1 RP1-159A19.3 -7.28 5.92e-12 2.57e-05 -0.42 -0.44 Longevity; chr3:48393807 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs7651407 ENSG00000235912.1 RP1-159A19.3 -7.28 5.92e-12 2.57e-05 -0.42 -0.44 Longevity; chr3:48402409 chr1:27649419~27649610:+ CESC trans rs1667255 0.83 rs2034404 ENSG00000237032.1 RP11-398C13.2 7.28 6.08e-12 2.64e-05 0.51 0.44 Retinol levels; chr18:31576339 chr10:14723171~14724055:- CESC trans rs9611565 0.512 rs5758464 ENSG00000268568.1 AC007228.9 7.28 6.13e-12 2.66e-05 0.74 0.44 Vitiligo; chr22:41775296 chr19:56672574~56673901:- CESC trans rs7113874 0.659 rs67320655 ENSG00000266891.1 RP11-692N5.2 7.28 6.16e-12 2.67e-05 0.59 0.44 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8497662 chr18:9734882~9735602:- CESC trans rs7113874 0.625 rs35760680 ENSG00000266891.1 RP11-692N5.2 7.28 6.16e-12 2.67e-05 0.59 0.44 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8500525 chr18:9734882~9735602:- CESC trans rs7113874 0.659 rs2121313 ENSG00000266891.1 RP11-692N5.2 7.28 6.16e-12 2.67e-05 0.59 0.44 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8501495 chr18:9734882~9735602:- CESC trans rs11098499 0.698 rs4422403 ENSG00000275858.1 RP11-291L22.8 7.28 6.17e-12 2.67e-05 0.49 0.44 Corneal astigmatism; chr4:119337039 chr10:38450738~38451069:- CESC trans rs11098499 0.569 rs10023641 ENSG00000275858.1 RP11-291L22.8 7.28 6.17e-12 2.67e-05 0.49 0.44 Corneal astigmatism; chr4:119337255 chr10:38450738~38451069:- CESC trans rs9611565 0.573 rs9306355 ENSG00000268568.1 AC007228.9 7.27 6.18e-12 2.68e-05 0.56 0.44 Vitiligo; chr22:41715892 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs5758434 ENSG00000268568.1 AC007228.9 7.27 6.18e-12 2.68e-05 0.56 0.44 Vitiligo; chr22:41720159 chr19:56672574~56673901:- CESC trans rs916888 0.61 rs199454 ENSG00000214425.5 LRRC37A4P 7.27 6.27e-12 2.71e-05 0.48 0.44 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45506741~45550335:- CESC trans rs1707322 0.827 rs10890347 ENSG00000255397.1 AC022182.2 7.27 6.29e-12 2.72e-05 0.58 0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776660 chr8:60937705~60939871:- CESC trans rs9611565 0.649 rs139540 ENSG00000268568.1 AC007228.9 -7.27 6.37e-12 2.76e-05 -0.57 -0.44 Vitiligo; chr22:41782036 chr19:56672574~56673901:- CESC trans rs877636 0.669 rs7297175 ENSG00000234513.1 AC073072.7 -7.26 6.64e-12 2.87e-05 -0.47 -0.44 Cognitive function; chr12:56080024 chr7:22773646~22773993:- CESC trans rs4276421 0.81 rs13190242 ENSG00000231752.4 EMBP1 7.26 6.73e-12 2.9e-05 0.55 0.44 P wave duration; chr5:46054443 chr1:121519112~121571892:+ CESC trans rs11098499 0.754 rs11732087 ENSG00000275858.1 RP11-291L22.8 7.26 6.77e-12 2.92e-05 0.49 0.44 Corneal astigmatism; chr4:119318676 chr10:38450738~38451069:- CESC trans rs714543 0.61 rs4724320 ENSG00000226038.5 PPIAP21 -7.26 6.85e-12 2.95e-05 -0.48 -0.44 Plateletcrit; chr7:44775735 chr20:43230760~43231260:+ CESC trans rs2209875 0.549 rs3211707 ENSG00000234819.1 RP11-336N8.4 7.26 6.87e-12 2.96e-05 0.54 0.44 Pelvic organ prolapse (moderate/severe); chr9:89318219 chr9:78219120~78219357:+ CESC trans rs2209875 0.573 rs74703137 ENSG00000234819.1 RP11-336N8.4 7.26 6.87e-12 2.96e-05 0.54 0.44 Pelvic organ prolapse (moderate/severe); chr9:89336429 chr9:78219120~78219357:+ CESC trans rs7554547 0.765 rs2050270 ENSG00000261819.1 RP11-680G24.4 7.26 6.89e-12 2.97e-05 0.51 0.44 Nonsyndromic cleft lip with cleft palate; chr1:11886399 chr16:14988259~14990160:- CESC trans rs7554547 0.739 rs2050269 ENSG00000261819.1 RP11-680G24.4 7.26 6.89e-12 2.97e-05 0.51 0.44 Nonsyndromic cleft lip with cleft palate; chr1:11886432 chr16:14988259~14990160:- CESC trans rs7554547 0.765 rs2050268 ENSG00000261819.1 RP11-680G24.4 7.26 6.89e-12 2.97e-05 0.51 0.44 Nonsyndromic cleft lip with cleft palate; chr1:11886487 chr16:14988259~14990160:- CESC trans rs7554547 0.765 rs2050267 ENSG00000261819.1 RP11-680G24.4 7.26 6.89e-12 2.97e-05 0.51 0.44 Nonsyndromic cleft lip with cleft palate; chr1:11886516 chr16:14988259~14990160:- CESC trans rs9876781 1 rs11130170 ENSG00000235912.1 RP1-159A19.3 -7.26 6.89e-12 2.97e-05 -0.42 -0.44 Longevity; chr3:48408490 chr1:27649419~27649610:+ CESC trans rs10242455 0.867 rs73410654 ENSG00000228834.1 RP11-249L21.4 7.25 7.06e-12 3.04e-05 0.77 0.44 Blood metabolite levels; chr7:99729040 chr6:108907615~108907873:- CESC trans rs6132905 0.52 rs2422823 ENSG00000257956.1 NOP56P3 -7.25 7.18e-12 3.08e-05 -0.62 -0.44 Mumps; chr20:2665687 chr12:79558782~79559166:+ CESC trans rs697003 0.966 rs701929 ENSG00000230450.1 NEK2P4 -7.25 7.25e-12 3.11e-05 -0.46 -0.44 Red cell distribution width; chr1:211673534 chr2:131177618~131178946:- CESC trans rs4276421 0.837 rs755048 ENSG00000231752.4 EMBP1 -7.25 7.26e-12 3.11e-05 -0.53 -0.44 P wave duration; chr5:45596256 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs10069510 ENSG00000231752.4 EMBP1 -7.25 7.26e-12 3.11e-05 -0.53 -0.44 P wave duration; chr5:45596937 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs2049656 ENSG00000231752.4 EMBP1 -7.24 7.45e-12 3.19e-05 -0.54 -0.44 P wave duration; chr5:45579590 chr1:121519112~121571892:+ CESC trans rs4276421 0.736 rs8188290 ENSG00000231752.4 EMBP1 7.24 7.73e-12 3.3e-05 0.54 0.44 P wave duration; chr5:46047215 chr1:121519112~121571892:+ CESC trans rs4276421 0.776 rs7717787 ENSG00000231752.4 EMBP1 7.24 7.82e-12 3.34e-05 0.54 0.44 P wave duration; chr5:45466514 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs7706140 ENSG00000231752.4 EMBP1 7.24 7.82e-12 3.34e-05 0.54 0.44 P wave duration; chr5:45474712 chr1:121519112~121571892:+ CESC trans rs4276421 0.837 rs7727890 ENSG00000231752.4 EMBP1 7.24 7.82e-12 3.34e-05 0.54 0.44 P wave duration; chr5:45478669 chr1:121519112~121571892:+ CESC trans rs877636 1 rs2292239 ENSG00000225071.1 GS1-184P14.2 7.23 7.84e-12 3.35e-05 0.46 0.44 Cognitive function; chr12:56088396 chrX:24429573~24429920:- CESC trans rs7312770 0.637 rs705700 ENSG00000225071.1 GS1-184P14.2 7.23 7.92e-12 3.38e-05 0.44 0.44 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chrX:24429573~24429920:- CESC trans rs9899728 0.539 rs56267297 ENSG00000234925.2 ATP5HP4 7.23 7.94e-12 3.39e-05 0.79 0.44 Alzheimer's disease or small vessel stroke; chr17:75050901 chr12:68642519~68642993:- CESC trans rs877636 0.692 rs2271194 ENSG00000196656.7 AC004057.1 -7.23 7.96e-12 3.4e-05 -0.45 -0.44 Cognitive function; chr12:56083910 chr4:113214046~113217170:- CESC trans rs9611565 0.506 rs2024566 ENSG00000268568.1 AC007228.9 -7.23 8e-12 3.41e-05 -0.59 -0.44 Vitiligo; chr22:41301334 chr19:56672574~56673901:- CESC trans rs9611519 0.732 rs1883826 ENSG00000268568.1 AC007228.9 -7.23 8e-12 3.41e-05 -0.59 -0.44 Neuroticism; chr22:41307424 chr19:56672574~56673901:- CESC trans rs9611565 0.525 rs9611549 ENSG00000268568.1 AC007228.9 -7.23 8e-12 3.41e-05 -0.59 -0.44 Vitiligo; chr22:41309905 chr19:56672574~56673901:- CESC trans rs6732160 0.564 rs60796597 ENSG00000236165.1 PRADC1P1 7.23 8.04e-12 3.43e-05 0.61 0.44 Intelligence (multi-trait analysis); chr2:73155786 chr3:36976316~36976840:+ CESC trans rs9899728 0.539 rs12938889 ENSG00000234925.2 ATP5HP4 -7.23 8.15e-12 3.48e-05 -0.82 -0.44 Alzheimer's disease or small vessel stroke; chr17:75043834 chr12:68642519~68642993:- CESC trans rs7113874 0.511 rs35091649 ENSG00000266891.1 RP11-692N5.2 7.23 8.16e-12 3.48e-05 0.58 0.44 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8526636 chr18:9734882~9735602:- CESC trans rs7113874 0.578 rs35807094 ENSG00000266891.1 RP11-692N5.2 7.23 8.16e-12 3.48e-05 0.58 0.44 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8528798 chr18:9734882~9735602:- CESC trans rs4929947 0.515 rs67191473 ENSG00000266891.1 RP11-692N5.2 7.23 8.16e-12 3.48e-05 0.58 0.44 Menarche (age at onset); chr11:8530643 chr18:9734882~9735602:- CESC trans rs12709013 0.792 rs62064940 ENSG00000230849.2 GOT2P2 7.23 8.22e-12 3.51e-05 0.51 0.44 Blood metabolite ratios; chr16:58796560 chr1:173141100~173142350:- CESC trans rs12709013 0.792 rs8049572 ENSG00000230849.2 GOT2P2 7.23 8.22e-12 3.51e-05 0.51 0.44 Blood metabolite ratios; chr16:58809672 chr1:173141100~173142350:- CESC trans rs4276421 0.776 rs56908114 ENSG00000231752.4 EMBP1 7.23 8.27e-12 3.53e-05 0.53 0.44 P wave duration; chr5:45416692 chr1:121519112~121571892:+ CESC trans rs1707322 0.963 rs10890373 ENSG00000255397.1 AC022182.2 -7.23 8.29e-12 3.53e-05 -0.57 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45928083 chr8:60937705~60939871:- CESC trans rs12709013 0.766 rs34438483 ENSG00000230849.2 GOT2P2 7.22 8.32e-12 3.55e-05 0.51 0.44 Blood metabolite ratios; chr16:58810530 chr1:173141100~173142350:- CESC trans rs697003 1 rs697003 ENSG00000230450.1 NEK2P4 7.22 8.5e-12 3.62e-05 0.49 0.44 Red cell distribution width; chr1:211669734 chr2:131177618~131178946:- CESC trans rs9611565 0.506 rs2024567 ENSG00000268568.1 AC007228.9 -7.22 8.51e-12 3.62e-05 -0.59 -0.44 Vitiligo; chr22:41303202 chr19:56672574~56673901:- CESC trans rs9611565 0.506 rs4822020 ENSG00000268568.1 AC007228.9 -7.22 8.51e-12 3.62e-05 -0.59 -0.44 Vitiligo; chr22:41304199 chr19:56672574~56673901:- CESC trans rs11098499 0.644 rs7676296 ENSG00000275858.1 RP11-291L22.8 7.22 8.57e-12 3.65e-05 0.48 0.44 Corneal astigmatism; chr4:119634532 chr10:38450738~38451069:- CESC trans rs5022636 0.927 rs10888409 ENSG00000180764.13 PIPSL 7.22 8.59e-12 3.66e-05 0.53 0.44 Gut microbiota (functional units); chr1:151299306 chr10:93958191~93961540:- CESC trans rs867371 0.896 rs8033831 ENSG00000235370.6 DNM1P51 -7.21 8.93e-12 3.8e-05 -0.56 -0.44 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82220953 chr15:84398316~84411701:- CESC trans rs10940346 0.644 rs62365309 ENSG00000231752.4 EMBP1 -7.21 9.04e-12 3.84e-05 -0.54 -0.44 Schizophrenia; chr5:50568902 chr1:121519112~121571892:+ CESC trans rs10940346 0.807 rs4865843 ENSG00000231752.4 EMBP1 -7.21 9.04e-12 3.84e-05 -0.54 -0.44 Schizophrenia; chr5:50569681 chr1:121519112~121571892:+ CESC trans rs4276421 0.869 rs1351720 ENSG00000231752.4 EMBP1 7.21 9.2e-12 3.91e-05 0.53 0.44 P wave duration; chr5:45561801 chr1:121519112~121571892:+ CESC trans rs1707322 0.821 rs11211182 ENSG00000255397.1 AC022182.2 -7.21 9.34e-12 3.97e-05 -0.58 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45774498 chr8:60937705~60939871:- CESC trans rs10940346 0.777 rs11744698 ENSG00000231752.4 EMBP1 -7.2 9.51e-12 4.04e-05 -0.53 -0.44 Schizophrenia; chr5:50586024 chr1:121519112~121571892:+ CESC trans rs5022636 0.74 rs11204795 ENSG00000180764.13 PIPSL 7.2 9.64e-12 4.09e-05 0.54 0.44 Gut microbiota (functional units); chr1:151275522 chr10:93958191~93961540:- CESC trans rs12709013 0.792 rs12596434 ENSG00000230849.2 GOT2P2 7.2 9.67e-12 4.1e-05 0.51 0.44 Blood metabolite ratios; chr16:58792309 chr1:173141100~173142350:- CESC trans rs6732160 0.613 rs59979991 ENSG00000236165.1 PRADC1P1 7.2 9.8e-12 4.15e-05 0.61 0.44 Intelligence (multi-trait analysis); chr2:73157294 chr3:36976316~36976840:+ CESC trans rs916888 0.647 rs199523 ENSG00000264070.1 DND1P1 -7.2 9.85e-12 4.18e-05 -0.54 -0.44 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45585871~45586929:+ CESC trans rs4276421 0.869 rs2879074 ENSG00000231752.4 EMBP1 7.19 9.93e-12 4.21e-05 0.54 0.44 P wave duration; chr5:45716107 chr1:121519112~121571892:+ CESC trans rs11098499 0.675 rs11098534 ENSG00000275858.1 RP11-291L22.8 7.19 1.02e-11 4.3e-05 0.48 0.44 Corneal astigmatism; chr4:119635617 chr10:38450738~38451069:- CESC trans rs10940346 1 rs10940346 ENSG00000231752.4 EMBP1 -7.19 1.05e-11 4.42e-05 -0.53 -0.44 Schizophrenia; chr5:50510208 chr1:121519112~121571892:+ CESC trans rs9611565 0.649 rs5751144 ENSG00000268568.1 AC007228.9 -7.18 1.08e-11 4.56e-05 -0.56 -0.44 Vitiligo; chr22:41732093 chr19:56672574~56673901:- CESC trans rs11098499 0.955 rs11944880 ENSG00000275858.1 RP11-291L22.8 -7.18 1.09e-11 4.61e-05 -0.51 -0.44 Corneal astigmatism; chr4:119238179 chr10:38450738~38451069:- CESC trans rs9611565 0.649 rs139553 ENSG00000268568.1 AC007228.9 7.18 1.1e-11 4.63e-05 0.55 0.44 Vitiligo; chr22:41791195 chr19:56672574~56673901:- CESC trans rs877636 1 rs4759229 ENSG00000223416.3 RPS26P15 -7.18 1.11e-11 4.68e-05 -0.45 -0.44 Cognitive function; chr12:56080696 chr1:58056133~58056480:- CESC trans rs1707322 0.721 rs4660883 ENSG00000255397.1 AC022182.2 -7.17 1.15e-11 4.82e-05 -0.57 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45770426 chr8:60937705~60939871:- CESC trans rs916888 0.647 rs199524 ENSG00000264070.1 DND1P1 -7.17 1.15e-11 4.85e-05 -0.54 -0.44 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45585871~45586929:+ CESC trans rs7937890 0.732 rs7946902 ENSG00000236360.2 RP11-334A14.2 -7.17 1.17e-11 4.91e-05 -0.54 -0.44 Mitochondrial DNA levels; chr11:14251762 chr1:52993201~52993702:- CESC trans rs3779195 0.585 rs58699591 ENSG00000225169.1 BRI3P1 -7.16 1.19e-11 4.98e-05 -0.66 -0.44 Sex hormone-binding globulin levels; chr7:98247392 chr1:100213293~100213670:+ CESC trans rs941207 0.756 rs2926743 ENSG00000257210.1 NACAP3 7.16 1.21e-11 5.08e-05 0.58 0.44 Platelet count; chr12:56720316 chr12:93124063~93124543:- CESC trans rs9467773 0.869 rs742090 ENSG00000242375.1 RP11-498P14.3 -7.16 1.23e-11 5.15e-05 -0.52 -0.44 Intelligence (multi-trait analysis); chr6:26415409 chr9:97195351~97197687:- CESC trans rs4276421 0.776 rs4133429 ENSG00000231752.4 EMBP1 7.16 1.24e-11 5.21e-05 0.53 0.44 P wave duration; chr5:45403633 chr1:121519112~121571892:+ CESC trans rs7647973 0.506 rs11920251 ENSG00000197582.5 GPX1P1 7.15 1.29e-11 5.39e-05 0.55 0.44 Menarche (age at onset); chr3:49319238 chrX:13378735~13379340:- CESC trans rs1707322 1 rs1622208 ENSG00000255397.1 AC022182.2 7.15 1.3e-11 5.43e-05 0.57 0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46032703 chr8:60937705~60939871:- CESC trans rs4240897 0.935 rs3766744 ENSG00000261819.1 RP11-680G24.4 7.15 1.32e-11 5.53e-05 0.5 0.44 Tuberculosis; chr1:11983660 chr16:14988259~14990160:- CESC trans rs9611565 0.504 rs5758452 ENSG00000268568.1 AC007228.9 7.15 1.33e-11 5.55e-05 0.55 0.44 Vitiligo; chr22:41748923 chr19:56672574~56673901:- CESC trans rs4276421 0.845 rs34040576 ENSG00000231752.4 EMBP1 7.15 1.33e-11 5.57e-05 0.54 0.44 P wave duration; chr5:46005596 chr1:121519112~121571892:+ CESC trans rs4276421 0.904 rs13360955 ENSG00000231752.4 EMBP1 7.15 1.33e-11 5.57e-05 0.54 0.44 P wave duration; chr5:46005842 chr1:121519112~121571892:+ CESC trans rs1707322 0.821 rs10749857 ENSG00000255397.1 AC022182.2 -7.14 1.34e-11 5.61e-05 -0.56 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45782471 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4074225 ENSG00000255397.1 AC022182.2 -7.14 1.36e-11 5.67e-05 -0.56 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45926692 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4134387 ENSG00000255397.1 AC022182.2 -7.14 1.36e-11 5.67e-05 -0.56 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45929486 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4660332 ENSG00000255397.1 AC022182.2 -7.14 1.36e-11 5.67e-05 -0.56 -0.44 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45995746 chr8:60937705~60939871:- CESC trans rs74781061 0.929 rs8029099 ENSG00000227288.3 RP5-837I24.1 7.14 1.36e-11 5.69e-05 0.55 0.44 Endometriosis; chr15:74474429 chr1:81501794~81503468:+ CESC trans rs7312770 0.637 rs705700 ENSG00000223416.3 RPS26P15 7.14 1.37e-11 5.72e-05 0.44 0.44 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr1:58056133~58056480:- CESC trans rs9876781 1 rs9864371 ENSG00000235912.1 RP1-159A19.3 -7.13 1.43e-11 5.95e-05 -0.41 -0.44 Longevity; chr3:48385276 chr1:27649419~27649610:+ CESC trans rs941207 0.756 rs7978685 ENSG00000257210.1 NACAP3 7.13 1.43e-11 5.96e-05 0.58 0.43 Platelet count; chr12:56709370 chr12:93124063~93124543:- CESC trans rs7312770 1 rs7312770 ENSG00000243403.1 RP11-330L19.1 -7.13 1.46e-11 6.07e-05 -0.41 -0.43 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr15:64592979~64593326:+ CESC trans rs11098499 0.754 rs1546503 ENSG00000275858.1 RP11-291L22.8 7.13 1.47e-11 6.13e-05 0.49 0.43 Corneal astigmatism; chr4:119320012 chr10:38450738~38451069:- CESC trans rs9425766 0.962 rs9425430 ENSG00000213331.4 RP11-713C19.2 7.12 1.5e-11 6.24e-05 0.52 0.43 Life satisfaction; chr1:173888145 chr4:187970273~187971284:+ CESC trans rs9611565 0.607 rs132792 ENSG00000268568.1 AC007228.9 7.12 1.52e-11 6.31e-05 0.56 0.43 Vitiligo; chr22:41666818 chr19:56672574~56673901:- CESC trans rs877636 0.692 rs11171739 ENSG00000212994.5 RPS26P6 7.12 1.52e-11 6.32e-05 0.5 0.43 Cognitive function; chr12:56076841 chr8:100895771~100896118:+ CESC trans rs9425766 0.886 rs1322775 ENSG00000213331.4 RP11-713C19.2 7.12 1.53e-11 6.37e-05 0.52 0.43 Life satisfaction; chr1:173886160 chr4:187970273~187971284:+ CESC trans rs74781061 1 rs6495116 ENSG00000227288.3 RP5-837I24.1 7.12 1.55e-11 6.42e-05 0.56 0.43 Endometriosis; chr15:74593607 chr1:81501794~81503468:+ CESC trans rs1707322 1 rs12124847 ENSG00000255397.1 AC022182.2 -7.11 1.61e-11 6.65e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45915178 chr8:60937705~60939871:- CESC trans rs9876781 1 rs7630741 ENSG00000235912.1 RP1-159A19.3 -7.11 1.64e-11 6.79e-05 -0.41 -0.43 Longevity; chr3:48378233 chr1:27649419~27649610:+ CESC trans rs11098499 0.874 rs13139045 ENSG00000275858.1 RP11-291L22.8 7.11 1.65e-11 6.82e-05 0.5 0.43 Corneal astigmatism; chr4:119247433 chr10:38450738~38451069:- CESC trans rs1707322 0.827 rs12125508 ENSG00000255397.1 AC022182.2 -7.11 1.67e-11 6.92e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45780338 chr8:60937705~60939871:- CESC trans rs1707322 0.789 rs10789473 ENSG00000255397.1 AC022182.2 -7.11 1.67e-11 6.92e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45782459 chr8:60937705~60939871:- CESC trans rs4240897 0.935 rs1474868 ENSG00000261819.1 RP11-680G24.4 -7.1 1.7e-11 7.02e-05 -0.5 -0.43 Tuberculosis; chr1:11984107 chr16:14988259~14990160:- CESC trans rs9425766 0.962 rs1322777 ENSG00000213331.4 RP11-713C19.2 7.1 1.7e-11 7.02e-05 0.52 0.43 Life satisfaction; chr1:173889962 chr4:187970273~187971284:+ CESC trans rs7554547 0.791 rs1321073 ENSG00000261819.1 RP11-680G24.4 7.1 1.71e-11 7.05e-05 0.51 0.43 Nonsyndromic cleft lip with cleft palate; chr1:11891569 chr16:14988259~14990160:- CESC trans rs9611519 0.78 rs1535048 ENSG00000268568.1 AC007228.9 -7.1 1.74e-11 7.17e-05 -0.58 -0.43 Neuroticism; chr22:41288089 chr19:56672574~56673901:- CESC trans rs9611565 0.918 rs2281333 ENSG00000268568.1 AC007228.9 -7.1 1.74e-11 7.17e-05 -0.54 -0.43 Vitiligo; chr22:41353626 chr19:56672574~56673901:- CESC trans rs697003 0.705 rs701926 ENSG00000230450.1 NEK2P4 7.1 1.75e-11 7.22e-05 0.5 0.43 Red cell distribution width; chr1:211678277 chr2:131177618~131178946:- CESC trans rs10242455 0.867 rs45624139 ENSG00000228834.1 RP11-249L21.4 7.1 1.78e-11 7.32e-05 0.76 0.43 Blood metabolite levels; chr7:99721872 chr6:108907615~108907873:- CESC trans rs9425766 0.85 rs7349095 ENSG00000213331.4 RP11-713C19.2 7.09 1.81e-11 7.43e-05 0.52 0.43 Life satisfaction; chr1:173887899 chr4:187970273~187971284:+ CESC trans rs9611565 0.532 rs4401299 ENSG00000268568.1 AC007228.9 7.09 1.82e-11 7.49e-05 0.55 0.43 Vitiligo; chr22:41760513 chr19:56672574~56673901:- CESC trans rs9899728 0.539 rs113775187 ENSG00000234925.2 ATP5HP4 7.09 1.82e-11 7.5e-05 0.78 0.43 Alzheimer's disease or small vessel stroke; chr17:75051195 chr12:68642519~68642993:- CESC trans rs1707322 0.785 rs10890348 ENSG00000255397.1 AC022182.2 -7.09 1.83e-11 7.53e-05 -0.57 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45776751 chr8:60937705~60939871:- CESC trans rs9611519 0.754 rs4820435 ENSG00000268568.1 AC007228.9 -7.08 1.92e-11 7.88e-05 -0.59 -0.43 Neuroticism; chr22:41256842 chr19:56672574~56673901:- CESC trans rs7937890 0.874 rs6486191 ENSG00000236360.2 RP11-334A14.2 7.08 1.93e-11 7.91e-05 0.51 0.43 Mitochondrial DNA levels; chr11:14382193 chr1:52993201~52993702:- CESC trans rs11098499 0.644 rs28787668 ENSG00000275858.1 RP11-291L22.8 7.08 1.93e-11 7.92e-05 0.47 0.43 Corneal astigmatism; chr4:119633532 chr10:38450738~38451069:- CESC trans rs11098499 0.909 rs10017335 ENSG00000275858.1 RP11-291L22.8 -7.08 1.93e-11 7.93e-05 -0.48 -0.43 Corneal astigmatism; chr4:119460368 chr10:38450738~38451069:- CESC trans rs4822044 0.617 rs13054514 ENSG00000268568.1 AC007228.9 7.08 1.95e-11 8.01e-05 0.55 0.43 Cannabis dependence symptom count; chr22:41734379 chr19:56672574~56673901:- CESC trans rs9611565 0.568 rs5758441 ENSG00000268568.1 AC007228.9 7.08 1.95e-11 8.01e-05 0.55 0.43 Vitiligo; chr22:41736884 chr19:56672574~56673901:- CESC trans rs9611565 0.649 rs5758442 ENSG00000268568.1 AC007228.9 7.08 1.95e-11 8.01e-05 0.55 0.43 Vitiligo; chr22:41737056 chr19:56672574~56673901:- CESC trans rs9611565 0.58 rs5758449 ENSG00000268568.1 AC007228.9 7.08 1.95e-11 8.01e-05 0.55 0.43 Vitiligo; chr22:41744156 chr19:56672574~56673901:- CESC trans rs12709013 0.792 rs1646289 ENSG00000233719.3 GOT2P3 7.08 2.01e-11 8.22e-05 0.48 0.43 Blood metabolite ratios; chr16:58755689 chr12:9641802~9643007:+ CESC trans rs3779195 0.52 rs17169479 ENSG00000225169.1 BRI3P1 7.07 2.04e-11 8.36e-05 0.67 0.43 Sex hormone-binding globulin levels; chr7:98238721 chr1:100213293~100213670:+ CESC trans rs941207 0.724 rs4788 ENSG00000257210.1 NACAP3 7.07 2.06e-11 8.41e-05 0.57 0.43 Platelet count; chr12:56712876 chr12:93124063~93124543:- CESC trans rs5022636 0.896 rs744536 ENSG00000180764.13 PIPSL 7.07 2.06e-11 8.44e-05 0.51 0.43 Gut microbiota (functional units); chr1:151356318 chr10:93958191~93961540:- CESC trans rs7113874 0.545 rs12791925 ENSG00000266891.1 RP11-692N5.2 7.07 2.07e-11 8.45e-05 0.57 0.43 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8530038 chr18:9734882~9735602:- CESC trans rs13190036 0.786 rs10068127 ENSG00000226986.4 RP11-543B16.2 -7.07 2.1e-11 8.57e-05 -0.56 -0.43 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177204786 chr1:211207239~211207897:+ CESC trans rs916888 0.61 rs199530 ENSG00000264070.1 DND1P1 -7.07 2.11e-11 8.64e-05 -0.52 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:45585871~45586929:+ CESC trans rs959695 1 rs959695 ENSG00000260318.1 COX6CP1 7.06 2.15e-11 8.8e-05 0.58 0.43 Hippocampal atrophy; chr8:99822954 chr16:11903923~11904137:- CESC trans rs4276421 0.806 rs6414906 ENSG00000231752.4 EMBP1 7.06 2.16e-11 8.81e-05 0.53 0.43 P wave duration; chr5:45406219 chr1:121519112~121571892:+ CESC trans rs7312770 0.612 rs1873914 ENSG00000234513.1 AC073072.7 7.06 2.24e-11 9.13e-05 0.45 0.43 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr7:22773646~22773993:- CESC trans rs1707322 0.963 rs6429581 ENSG00000255397.1 AC022182.2 -7.06 2.26e-11 9.19e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853424 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs12145287 ENSG00000255397.1 AC022182.2 -7.06 2.26e-11 9.19e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45859330 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10789479 ENSG00000255397.1 AC022182.2 -7.06 2.26e-11 9.19e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45886828 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs7512395 ENSG00000255397.1 AC022182.2 -7.06 2.26e-11 9.19e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45895505 chr8:60937705~60939871:- CESC trans rs13190036 1 rs4976682 ENSG00000226986.4 RP11-543B16.2 7.05 2.26e-11 9.23e-05 0.55 0.43 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177299001 chr1:211207239~211207897:+ CESC trans rs11098499 0.708 rs1546506 ENSG00000275858.1 RP11-291L22.8 7.05 2.27e-11 9.27e-05 0.48 0.43 Corneal astigmatism; chr4:119320085 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs12506610 ENSG00000275858.1 RP11-291L22.8 7.05 2.27e-11 9.27e-05 0.48 0.43 Corneal astigmatism; chr4:119320504 chr10:38450738~38451069:- CESC trans rs11098499 0.743 rs10003567 ENSG00000275858.1 RP11-291L22.8 7.05 2.27e-11 9.27e-05 0.48 0.43 Corneal astigmatism; chr4:119320519 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs10006259 ENSG00000275858.1 RP11-291L22.8 7.05 2.27e-11 9.27e-05 0.48 0.43 Corneal astigmatism; chr4:119320990 chr10:38450738~38451069:- CESC trans rs11098499 0.754 rs28652763 ENSG00000275858.1 RP11-291L22.8 7.05 2.27e-11 9.27e-05 0.48 0.43 Corneal astigmatism; chr4:119321157 chr10:38450738~38451069:- CESC trans rs9611565 0.649 rs139559 ENSG00000268568.1 AC007228.9 -7.05 2.31e-11 9.43e-05 -0.55 -0.43 Vitiligo; chr22:41795632 chr19:56672574~56673901:- CESC trans rs877636 0.669 rs7297175 ENSG00000196933.5 RPS26P11 -7.05 2.33e-11 9.48e-05 -0.48 -0.43 Cognitive function; chr12:56080024 chrX:72044545~72044892:+ CESC trans rs74781061 0.929 rs8028430 ENSG00000227288.3 RP5-837I24.1 7.05 2.33e-11 9.5e-05 0.54 0.43 Endometriosis; chr15:74553404 chr1:81501794~81503468:+ CESC trans rs9876781 1 rs9815103 ENSG00000235912.1 RP1-159A19.3 -7.05 2.37e-11 9.63e-05 -0.41 -0.43 Longevity; chr3:48372725 chr1:27649419~27649610:+ CESC trans rs11638815 0.626 rs11633829 ENSG00000235370.6 DNM1P51 7.05 2.38e-11 9.67e-05 0.57 0.43 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82658186 chr15:84398316~84411701:- CESC trans rs5022636 0.896 rs10788804 ENSG00000180764.13 PIPSL 7.05 2.38e-11 9.67e-05 0.49 0.43 Gut microbiota (functional units); chr1:151365312 chr10:93958191~93961540:- CESC trans rs867371 0.929 rs7173852 ENSG00000235370.6 DNM1P51 -7.05 2.39e-11 9.71e-05 -0.55 -0.43 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82169512 chr15:84398316~84411701:- CESC trans rs1707322 0.927 rs6690386 ENSG00000255397.1 AC022182.2 -7.04 2.41e-11 9.79e-05 -0.55 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45787339 chr8:60937705~60939871:- CESC trans rs1707322 0.827 rs6694302 ENSG00000255397.1 AC022182.2 -7.04 2.42e-11 9.83e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45779973 chr8:60937705~60939871:- CESC trans rs1707322 0.826 rs10890349 ENSG00000255397.1 AC022182.2 -7.04 2.42e-11 9.83e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45784283 chr8:60937705~60939871:- CESC trans rs1707322 0.758 rs10789474 ENSG00000255397.1 AC022182.2 -7.04 2.42e-11 9.83e-05 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45784368 chr8:60937705~60939871:- CESC trans rs7554511 0.861 rs11583546 ENSG00000244144.1 RP11-757F18.3 -7.04 2.42e-11 9.83e-05 -0.53 -0.43 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200933479 chr3:112185480~112185998:- CESC trans rs74781061 1 rs11072488 ENSG00000227288.3 RP5-837I24.1 7.04 2.44e-11 9.91e-05 0.54 0.43 Endometriosis; chr15:74494017 chr1:81501794~81503468:+ CESC trans rs9876781 1 rs11130171 ENSG00000235912.1 RP1-159A19.3 -7.04 2.45e-11 9.94e-05 -0.41 -0.43 Longevity; chr3:48421052 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs9883927 ENSG00000235912.1 RP1-159A19.3 -7.04 2.45e-11 9.94e-05 -0.41 -0.43 Longevity; chr3:48422302 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs9817615 ENSG00000235912.1 RP1-159A19.3 -7.04 2.45e-11 9.94e-05 -0.41 -0.43 Longevity; chr3:48429347 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs2290822 ENSG00000235912.1 RP1-159A19.3 -7.04 2.45e-11 9.94e-05 -0.41 -0.43 Longevity; chr3:48431794 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs13076076 ENSG00000235912.1 RP1-159A19.3 -7.04 2.45e-11 9.94e-05 -0.41 -0.43 Longevity; chr3:48437629 chr1:27649419~27649610:+ CESC trans rs9611565 0.694 rs5758411 ENSG00000268568.1 AC007228.9 7.04 2.48e-11 0.000101 0.56 0.43 Vitiligo; chr22:41683730 chr19:56672574~56673901:- CESC trans rs7113874 0.613 rs35225809 ENSG00000266891.1 RP11-692N5.2 7.04 2.51e-11 0.000102 0.57 0.43 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8512038 chr18:9734882~9735602:- CESC trans rs7554511 0.893 rs11589573 ENSG00000244144.1 RP11-757F18.3 -7.04 2.51e-11 0.000102 -0.53 -0.43 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201005987 chr3:112185480~112185998:- CESC trans rs9876781 1 rs725310 ENSG00000235912.1 RP1-159A19.3 7.04 2.53e-11 0.000103 0.41 0.43 Longevity; chr3:48377081 chr1:27649419~27649610:+ CESC trans rs11098499 0.604 rs17051352 ENSG00000275858.1 RP11-291L22.8 7.03 2.56e-11 0.000104 0.49 0.43 Corneal astigmatism; chr4:119660272 chr10:38450738~38451069:- CESC trans rs916888 0.61 rs142167 ENSG00000214425.5 LRRC37A4P 7.03 2.56e-11 0.000104 0.46 0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:45506741~45550335:- CESC trans rs7200543 1 rs16966947 ENSG00000250569.1 NTAN1P2 7.03 2.58e-11 0.000104 0.54 0.43 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15047188 chr8:86481754~86483002:- CESC trans rs10242455 0.867 rs2687077 ENSG00000228834.1 RP11-249L21.4 -7.03 2.58e-11 0.000105 -0.68 -0.43 Blood metabolite levels; chr7:99708943 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2257401 ENSG00000228834.1 RP11-249L21.4 -7.03 2.58e-11 0.000105 -0.68 -0.43 Blood metabolite levels; chr7:99709062 chr6:108907615~108907873:- CESC trans rs1707322 0.964 rs6675259 ENSG00000255397.1 AC022182.2 7.03 2.61e-11 0.000106 0.57 0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46036623 chr8:60937705~60939871:- CESC trans rs11098499 0.754 rs1980025 ENSG00000275858.1 RP11-291L22.8 -7.03 2.65e-11 0.000107 -0.47 -0.43 Corneal astigmatism; chr4:119331651 chr10:38450738~38451069:- CESC trans rs9611565 0.572 rs139569 ENSG00000268568.1 AC007228.9 -7.03 2.66e-11 0.000108 -0.54 -0.43 Vitiligo; chr22:41815137 chr19:56672574~56673901:- CESC trans rs7113874 0.578 rs67067089 ENSG00000266891.1 RP11-692N5.2 7.02 2.7e-11 0.000109 0.56 0.43 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8508480 chr18:9734882~9735602:- CESC trans rs7113874 0.578 rs34059271 ENSG00000266891.1 RP11-692N5.2 7.02 2.72e-11 0.00011 0.57 0.43 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8546311 chr18:9734882~9735602:- CESC trans rs7113874 0.578 rs1026021 ENSG00000266891.1 RP11-692N5.2 -7.02 2.72e-11 0.00011 -0.56 -0.43 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8543231 chr18:9734882~9735602:- CESC trans rs74781061 0.858 rs8023865 ENSG00000227288.3 RP5-837I24.1 7.02 2.73e-11 0.00011 0.55 0.43 Endometriosis; chr15:74561263 chr1:81501794~81503468:+ CESC trans rs77688320 0.553 rs10804114 ENSG00000235105.1 RP11-329A14.1 7.02 2.73e-11 0.00011 0.49 0.43 Breast cancer; chr2:201402139 chr1:48435967~48437223:+ CESC trans rs74781061 0.929 rs6495118 ENSG00000227288.3 RP5-837I24.1 7.02 2.73e-11 0.000111 0.55 0.43 Endometriosis; chr15:74619671 chr1:81501794~81503468:+ CESC trans rs7554511 0.858 rs12140420 ENSG00000244144.1 RP11-757F18.3 -7.02 2.75e-11 0.000111 -0.53 -0.43 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200993159 chr3:112185480~112185998:- CESC trans rs1707322 1 rs4660335 ENSG00000255397.1 AC022182.2 -7.02 2.75e-11 0.000111 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46009046 chr8:60937705~60939871:- CESC trans rs9876781 1 rs9849509 ENSG00000235912.1 RP1-159A19.3 -7.02 2.77e-11 0.000112 -0.41 -0.43 Longevity; chr3:48442021 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs60512868 ENSG00000235912.1 RP1-159A19.3 -7.02 2.77e-11 0.000112 -0.41 -0.43 Longevity; chr3:48442035 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs7636044 ENSG00000235912.1 RP1-159A19.3 -7.02 2.77e-11 0.000112 -0.41 -0.43 Longevity; chr3:48443151 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs4490383 ENSG00000235912.1 RP1-159A19.3 -7.02 2.77e-11 0.000112 -0.41 -0.43 Longevity; chr3:48443275 chr1:27649419~27649610:+ CESC trans rs11098499 0.754 rs12510269 ENSG00000275858.1 RP11-291L22.8 7.02 2.79e-11 0.000113 0.48 0.43 Corneal astigmatism; chr4:119320491 chr10:38450738~38451069:- CESC trans rs877636 0.692 rs11171739 ENSG00000234354.3 RPS26P47 7.02 2.83e-11 0.000114 0.47 0.43 Cognitive function; chr12:56076841 chr13:100539901~100540248:- CESC trans rs7312770 0.612 rs1873914 ENSG00000243403.1 RP11-330L19.1 7.02 2.84e-11 0.000115 0.41 0.43 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr15:64592979~64593326:+ CESC trans rs7113874 0.578 rs12787407 ENSG00000266891.1 RP11-692N5.2 7.01 2.91e-11 0.000117 0.57 0.43 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8532605 chr18:9734882~9735602:- CESC trans rs877636 0.692 rs11171739 ENSG00000227887.1 RPS26P13 7.01 2.92e-11 0.000118 0.45 0.43 Cognitive function; chr12:56076841 chr1:208697369~208697698:- CESC trans rs11098499 0.604 rs2389887 ENSG00000275858.1 RP11-291L22.8 7.01 2.98e-11 0.00012 0.48 0.43 Corneal astigmatism; chr4:119649489 chr10:38450738~38451069:- CESC trans rs11098499 0.604 rs34278750 ENSG00000275858.1 RP11-291L22.8 7.01 2.98e-11 0.00012 0.48 0.43 Corneal astigmatism; chr4:119649981 chr10:38450738~38451069:- CESC trans rs11098499 0.604 rs10022185 ENSG00000275858.1 RP11-291L22.8 7.01 2.98e-11 0.00012 0.48 0.43 Corneal astigmatism; chr4:119650610 chr10:38450738~38451069:- CESC trans rs11098499 0.644 rs10009566 ENSG00000275858.1 RP11-291L22.8 7.01 2.98e-11 0.00012 0.46 0.43 Corneal astigmatism; chr4:119637453 chr10:38450738~38451069:- CESC trans rs5022636 0.927 rs10788803 ENSG00000180764.13 PIPSL 7.01 2.99e-11 0.00012 0.52 0.43 Gut microbiota (functional units); chr1:151291306 chr10:93958191~93961540:- CESC trans rs13190036 0.901 rs10056655 ENSG00000226986.4 RP11-543B16.2 7.01 3e-11 0.000121 0.51 0.43 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177249350 chr1:211207239~211207897:+ CESC trans rs11098499 0.691 rs9996644 ENSG00000275858.1 RP11-291L22.8 7.01 3.02e-11 0.000122 0.48 0.43 Corneal astigmatism; chr4:119317722 chr10:38450738~38451069:- CESC trans rs11098499 0.691 rs9996494 ENSG00000275858.1 RP11-291L22.8 7.01 3.02e-11 0.000122 0.48 0.43 Corneal astigmatism; chr4:119317725 chr10:38450738~38451069:- CESC trans rs74781061 0.929 rs4324083 ENSG00000227288.3 RP5-837I24.1 7 3.04e-11 0.000122 0.54 0.43 Endometriosis; chr15:74479139 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs117379081 ENSG00000227288.3 RP5-837I24.1 7 3.04e-11 0.000122 0.54 0.43 Endometriosis; chr15:74480106 chr1:81501794~81503468:+ CESC trans rs7554511 0.858 rs7539693 ENSG00000244144.1 RP11-757F18.3 -7 3.05e-11 0.000123 -0.53 -0.43 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200986438 chr3:112185480~112185998:- CESC trans rs616147 0.627 rs816510 ENSG00000183298.5 RP11-556K13.1 -7 3.1e-11 0.000124 -0.52 -0.43 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39430804 chr1:101786340~101787219:- CESC trans rs4276421 0.845 rs4426926 ENSG00000231752.4 EMBP1 7 3.18e-11 0.000128 0.54 0.43 P wave duration; chr5:45994241 chr1:121519112~121571892:+ CESC trans rs11098499 0.644 rs34835603 ENSG00000275858.1 RP11-291L22.8 7 3.19e-11 0.000128 0.47 0.43 Corneal astigmatism; chr4:119632273 chr10:38450738~38451069:- CESC trans rs11098499 0.615 rs28850368 ENSG00000275858.1 RP11-291L22.8 7 3.19e-11 0.000128 0.47 0.43 Corneal astigmatism; chr4:119633158 chr10:38450738~38451069:- CESC trans rs6732160 0.613 rs57208378 ENSG00000236165.1 PRADC1P1 7 3.2e-11 0.000129 0.59 0.43 Intelligence (multi-trait analysis); chr2:73162871 chr3:36976316~36976840:+ CESC trans rs1707322 1 rs10890376 ENSG00000255397.1 AC022182.2 -6.99 3.21e-11 0.000129 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940910 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10890381 ENSG00000255397.1 AC022182.2 -6.99 3.21e-11 0.000129 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45986099 chr8:60937705~60939871:- CESC trans rs10242455 0.867 rs2687145 ENSG00000228834.1 RP11-249L21.4 6.99 3.22e-11 0.000129 0.67 0.43 Blood metabolite levels; chr7:99721021 chr6:108907615~108907873:- CESC trans rs11098499 0.691 rs17009144 ENSG00000275858.1 RP11-291L22.8 -6.99 3.26e-11 0.000131 -0.47 -0.43 Corneal astigmatism; chr4:119349640 chr10:38450738~38451069:- CESC trans rs11098499 0.644 rs10012252 ENSG00000275858.1 RP11-291L22.8 6.99 3.31e-11 0.000133 0.47 0.43 Corneal astigmatism; chr4:119637984 chr10:38450738~38451069:- CESC trans rs5022636 0.927 rs10888410 ENSG00000180764.13 PIPSL 6.99 3.32e-11 0.000133 0.5 0.43 Gut microbiota (functional units); chr1:151299975 chr10:93958191~93961540:- CESC trans rs3779195 0.591 rs77968419 ENSG00000225169.1 BRI3P1 -6.99 3.33e-11 0.000134 -0.68 -0.43 Sex hormone-binding globulin levels; chr7:98237168 chr1:100213293~100213670:+ CESC trans rs11098499 0.754 rs1814813 ENSG00000275858.1 RP11-291L22.8 -6.99 3.35e-11 0.000134 -0.46 -0.43 Corneal astigmatism; chr4:119337052 chr10:38450738~38451069:- CESC trans rs4240897 0.935 rs2236055 ENSG00000261819.1 RP11-680G24.4 6.98 3.42e-11 0.000137 0.49 0.43 Tuberculosis; chr1:11982204 chr16:14988259~14990160:- CESC trans rs7113874 0.534 rs2311392 ENSG00000266891.1 RP11-692N5.2 6.98 3.45e-11 0.000138 0.59 0.43 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8468889 chr18:9734882~9735602:- CESC trans rs74781061 0.929 rs79600239 ENSG00000227288.3 RP5-837I24.1 6.98 3.49e-11 0.00014 0.54 0.43 Endometriosis; chr15:74481987 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs16969247 ENSG00000227288.3 RP5-837I24.1 6.98 3.49e-11 0.00014 0.54 0.43 Endometriosis; chr15:74486541 chr1:81501794~81503468:+ CESC trans rs941207 0.724 rs1979325 ENSG00000257210.1 NACAP3 6.98 3.5e-11 0.00014 0.57 0.43 Platelet count; chr12:56728152 chr12:93124063~93124543:- CESC trans rs1707322 1 rs6675222 ENSG00000255397.1 AC022182.2 -6.98 3.53e-11 0.000141 -0.54 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45860904 chr8:60937705~60939871:- CESC trans rs877636 0.859 rs3741499 ENSG00000243403.1 RP11-330L19.1 -6.98 3.56e-11 0.000142 -0.42 -0.43 Cognitive function; chr12:56080595 chr15:64592979~64593326:+ CESC trans rs1707322 1 rs1707317 ENSG00000255397.1 AC022182.2 6.97 3.62e-11 0.000144 0.56 0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46044970 chr8:60937705~60939871:- CESC trans rs7554511 0.858 rs12118735 ENSG00000244144.1 RP11-757F18.3 -6.97 3.64e-11 0.000146 -0.53 -0.43 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200981832 chr3:112185480~112185998:- CESC trans rs6732160 0.588 rs2043101 ENSG00000236165.1 PRADC1P1 6.97 3.67e-11 0.000146 0.57 0.43 Intelligence (multi-trait analysis); chr2:73146922 chr3:36976316~36976840:+ CESC trans rs7554511 0.893 rs72749166 ENSG00000244144.1 RP11-757F18.3 -6.97 3.74e-11 0.000149 -0.54 -0.43 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201031177 chr3:112185480~112185998:- CESC trans rs1707322 0.963 rs10789478 ENSG00000255397.1 AC022182.2 -6.97 3.75e-11 0.000149 -0.56 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45884834 chr8:60937705~60939871:- CESC trans rs1707322 1 rs3922887 ENSG00000255397.1 AC022182.2 -6.96 3.83e-11 0.000153 -0.55 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46008130 chr8:60937705~60939871:- CESC trans rs1707322 1 rs3922886 ENSG00000255397.1 AC022182.2 -6.96 3.83e-11 0.000153 -0.55 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46008230 chr8:60937705~60939871:- CESC trans rs10940346 0.807 rs6898102 ENSG00000231752.4 EMBP1 -6.96 3.83e-11 0.000153 -0.51 -0.43 Schizophrenia; chr5:50578496 chr1:121519112~121571892:+ CESC trans rs1707322 1 rs11211223 ENSG00000255397.1 AC022182.2 -6.96 3.97e-11 0.000158 -0.54 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45914933 chr8:60937705~60939871:- CESC trans rs4276421 0.837 rs10073636 ENSG00000231752.4 EMBP1 -6.96 4.05e-11 0.000161 -0.51 -0.43 P wave duration; chr5:45537197 chr1:121519112~121571892:+ CESC trans rs877636 1 rs4759229 ENSG00000243403.1 RP11-330L19.1 -6.95 4.07e-11 0.000162 -0.42 -0.43 Cognitive function; chr12:56080696 chr15:64592979~64593326:+ CESC trans rs2209875 0.588 rs7469084 ENSG00000234819.1 RP11-336N8.4 6.95 4.16e-11 0.000165 0.54 0.43 Pelvic organ prolapse (moderate/severe); chr9:89366248 chr9:78219120~78219357:+ CESC trans rs12709013 0.716 rs4784987 ENSG00000233719.3 GOT2P3 6.94 4.29e-11 0.00017 0.45 0.43 Blood metabolite ratios; chr16:58824135 chr12:9641802~9643007:+ CESC trans rs11098499 0.644 rs3806808 ENSG00000275858.1 RP11-291L22.8 6.94 4.34e-11 0.000172 0.46 0.43 Corneal astigmatism; chr4:119629930 chr10:38450738~38451069:- CESC trans rs7554511 0.858 rs11583328 ENSG00000244144.1 RP11-757F18.3 6.94 4.35e-11 0.000173 0.52 0.43 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201033045 chr3:112185480~112185998:- CESC trans rs1707322 1 rs6429588 ENSG00000255397.1 AC022182.2 -6.94 4.4e-11 0.000174 -0.54 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45988386 chr8:60937705~60939871:- CESC trans rs1707322 1 rs12097799 ENSG00000255397.1 AC022182.2 -6.94 4.4e-11 0.000174 -0.54 -0.43 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45994214 chr8:60937705~60939871:- CESC trans rs11098499 0.954 rs11098524 ENSG00000275858.1 RP11-291L22.8 6.93 4.61e-11 0.000182 0.51 0.43 Corneal astigmatism; chr4:119468877 chr10:38450738~38451069:- CESC trans rs7113874 0.512 rs7952429 ENSG00000266891.1 RP11-692N5.2 6.93 4.78e-11 0.000189 0.56 0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8516370 chr18:9734882~9735602:- CESC trans rs7113874 0.592 rs10840057 ENSG00000266891.1 RP11-692N5.2 6.93 4.8e-11 0.00019 0.58 0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8476681 chr18:9734882~9735602:- CESC trans rs7113874 0.659 rs12295855 ENSG00000266891.1 RP11-692N5.2 6.92 4.84e-11 0.000191 0.54 0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8505871 chr18:9734882~9735602:- CESC trans rs9876781 1 rs6442123 ENSG00000235912.1 RP1-159A19.3 -6.92 4.91e-11 0.000194 -0.41 -0.42 Longevity; chr3:48458887 chr1:27649419~27649610:+ CESC trans rs1707322 1 rs34444543 ENSG00000255397.1 AC022182.2 -6.92 4.96e-11 0.000196 -0.55 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893190 chr8:60937705~60939871:- CESC trans rs11098499 0.566 rs7664440 ENSG00000275858.1 RP11-291L22.8 6.92 5.01e-11 0.000198 0.48 0.42 Corneal astigmatism; chr4:119657385 chr10:38450738~38451069:- CESC trans rs13190036 0.901 rs6556309 ENSG00000217325.2 PRELID1P1 6.92 5.02e-11 0.000198 0.63 0.42 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177266834 chr6:126643488~126644390:+ CESC trans rs13190036 0.901 rs6556309 ENSG00000226986.4 RP11-543B16.2 6.92 5.02e-11 0.000198 0.5 0.42 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177266834 chr1:211207239~211207897:+ CESC trans rs9876781 1 rs6794875 ENSG00000235912.1 RP1-159A19.3 -6.92 5.06e-11 0.000199 -0.4 -0.42 Longevity; chr3:48414217 chr1:27649419~27649610:+ CESC trans rs9876781 0.967 rs7618883 ENSG00000235912.1 RP1-159A19.3 -6.92 5.08e-11 2e-04 -0.41 -0.42 Longevity; chr3:48457056 chr1:27649419~27649610:+ CESC trans rs7312770 0.637 rs705700 ENSG00000235459.5 RPS26P31 6.91 5.18e-11 0.000204 0.44 0.42 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr7:122681315~122681662:+ CESC trans rs1707322 0.964 rs12067716 ENSG00000255397.1 AC022182.2 -6.91 5.37e-11 0.000211 -0.55 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45968756 chr8:60937705~60939871:- CESC trans rs941207 0.756 rs2958149 ENSG00000257210.1 NACAP3 6.91 5.39e-11 0.000212 0.57 0.42 Platelet count; chr12:56716008 chr12:93124063~93124543:- CESC trans rs7937890 0.81 rs10734224 ENSG00000236360.2 RP11-334A14.2 6.91 5.4e-11 0.000212 0.51 0.42 Mitochondrial DNA levels; chr11:14402578 chr1:52993201~52993702:- CESC trans rs9425766 0.962 rs1322780 ENSG00000213331.4 RP11-713C19.2 6.91 5.41e-11 0.000213 0.5 0.42 Life satisfaction; chr1:173896448 chr4:187970273~187971284:+ CESC trans rs10242455 0.867 rs2687076 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99709645 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2037498 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99713927 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2037499 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99715030 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687075 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99717363 chr6:108907615~108907873:- CESC trans rs10242455 0.764 rs2037497 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99718281 chr6:108907615~108907873:- CESC trans rs10242455 0.614 rs2687072 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99719303 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687144 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99721185 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2740562 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99721534 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687143 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99722846 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687142 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99722947 chr6:108907615~108907873:- CESC trans rs10242455 0.764 rs2740561 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99723818 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687141 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99723856 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2404770 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99723989 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2404769 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99724093 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687139 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99725451 chr6:108907615~108907873:- CESC trans rs10242455 0.681 rs2740559 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99726892 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687136 ENSG00000228834.1 RP11-249L21.4 -6.9 5.46e-11 0.000214 -0.68 -0.42 Blood metabolite levels; chr7:99728259 chr6:108907615~108907873:- CESC trans rs77688320 0.517 rs7605375 ENSG00000235105.1 RP11-329A14.1 6.9 5.46e-11 0.000214 0.44 0.42 Breast cancer; chr2:201465907 chr1:48435967~48437223:+ CESC trans rs7554511 0.893 rs11580823 ENSG00000244144.1 RP11-757F18.3 -6.9 5.5e-11 0.000216 -0.52 -0.42 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201014361 chr3:112185480~112185998:- CESC trans rs74781061 0.929 rs59946128 ENSG00000227288.3 RP5-837I24.1 6.9 5.57e-11 0.000218 0.55 0.42 Endometriosis; chr15:74493006 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs60777494 ENSG00000227288.3 RP5-837I24.1 6.9 5.57e-11 0.000218 0.55 0.42 Endometriosis; chr15:74493007 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs57271230 ENSG00000227288.3 RP5-837I24.1 6.9 5.57e-11 0.000218 0.55 0.42 Endometriosis; chr15:74493018 chr1:81501794~81503468:+ CESC trans rs9611565 0.649 rs2064189 ENSG00000268568.1 AC007228.9 6.9 5.59e-11 0.000219 0.54 0.42 Vitiligo; chr22:41731995 chr19:56672574~56673901:- CESC trans rs1707322 1 rs7547189 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853842 chr8:60937705~60939871:- CESC trans rs1707322 1 rs7547284 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853893 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211205 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45856202 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4660895 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45864067 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4660318 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45869204 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10890360 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45872772 chr8:60937705~60939871:- CESC trans rs1707322 1 rs6682683 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45876665 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211217 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45882557 chr8:60937705~60939871:- CESC trans rs1707322 1 rs7553924 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45886952 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4641257 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45887917 chr8:60937705~60939871:- CESC trans rs1707322 1 rs6693336 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45888923 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4539075 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45892338 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211219 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893806 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211222 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45902085 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4524994 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45904591 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs9787412 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45905924 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4660896 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45906744 chr8:60937705~60939871:- CESC trans rs1707322 0.928 rs10732844 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45907016 chr8:60937705~60939871:- CESC trans rs1707322 1 rs12133129 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45907676 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs4553121 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45909581 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs6690652 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45911020 chr8:60937705~60939871:- CESC trans rs1707322 1 rs6695421 ENSG00000255397.1 AC022182.2 -6.9 5.64e-11 0.00022 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45914535 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs10890358 ENSG00000255397.1 AC022182.2 -6.9 5.68e-11 0.000222 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45853353 chr8:60937705~60939871:- CESC trans rs1707322 1 rs7531911 ENSG00000255397.1 AC022182.2 -6.9 5.72e-11 0.000224 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45864751 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10890359 ENSG00000255397.1 AC022182.2 -6.9 5.72e-11 0.000224 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45870963 chr8:60937705~60939871:- CESC trans rs1707322 0.928 rs7527244 ENSG00000255397.1 AC022182.2 -6.9 5.72e-11 0.000224 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45903100 chr8:60937705~60939871:- CESC trans rs616147 0.548 rs2370965 ENSG00000183298.5 RP11-556K13.1 -6.89 5.78e-11 0.000226 -0.51 -0.42 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39448996 chr1:101786340~101787219:- CESC trans rs9611565 0.879 rs5758307 ENSG00000268568.1 AC007228.9 -6.89 6e-11 0.000234 -0.52 -0.42 Vitiligo; chr22:41354215 chr19:56672574~56673901:- CESC trans rs9425766 0.962 rs9425435 ENSG00000213331.4 RP11-713C19.2 6.88 6.08e-11 0.000237 0.5 0.42 Life satisfaction; chr1:173896936 chr4:187970273~187971284:+ CESC trans rs11098499 0.754 rs10212714 ENSG00000275858.1 RP11-291L22.8 6.88 6.14e-11 0.000239 0.48 0.42 Corneal astigmatism; chr4:119333147 chr10:38450738~38451069:- CESC trans rs1707322 1 rs4660331 ENSG00000255397.1 AC022182.2 -6.88 6.17e-11 0.00024 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45993111 chr8:60937705~60939871:- CESC trans rs9876781 1 rs73074358 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48385757 chr1:27649419~27649610:+ CESC trans rs9876781 0.967 rs34761139 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48386489 chr1:27649419~27649610:+ CESC trans rs9876781 0.868 rs9875280 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48387420 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs6796491 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48388977 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs6804774 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48389129 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs9826195 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48392157 chr1:27649419~27649610:+ CESC trans rs9876781 0.967 rs9864815 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48392588 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs9809843 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48392923 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs1563736 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48395329 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs13071337 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48396724 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs6442118 ENSG00000235912.1 RP1-159A19.3 -6.88 6.25e-11 0.000243 -0.4 -0.42 Longevity; chr3:48398582 chr1:27649419~27649610:+ CESC trans rs2665103 0.715 rs16973457 ENSG00000235370.6 DNM1P51 -6.88 6.29e-11 0.000244 -0.53 -0.42 Intelligence (multi-trait analysis); chr15:82271650 chr15:84398316~84411701:- CESC trans rs12138950 0.681 rs10917472 ENSG00000224237.1 MINOS1P3 6.88 6.42e-11 0.000249 0.59 0.42 Hypothyroidism;Thyroid volume; chr1:19524218 chr3:27214816~27215018:- CESC trans rs9876781 0.933 rs6442124 ENSG00000235912.1 RP1-159A19.3 -6.88 6.43e-11 0.000249 -0.41 -0.42 Longevity; chr3:48463903 chr1:27649419~27649610:+ CESC trans rs11098499 0.754 rs1849457 ENSG00000275858.1 RP11-291L22.8 6.87 6.51e-11 0.000252 0.48 0.42 Corneal astigmatism; chr4:119333200 chr10:38450738~38451069:- CESC trans rs1707322 1 rs10158032 ENSG00000255397.1 AC022182.2 -6.87 6.54e-11 0.000253 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45867029 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10890370 ENSG00000255397.1 AC022182.2 -6.87 6.56e-11 0.000254 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45923545 chr8:60937705~60939871:- CESC trans rs11098499 0.644 rs2389880 ENSG00000275858.1 RP11-291L22.8 6.87 6.65e-11 0.000257 0.46 0.42 Corneal astigmatism; chr4:119638715 chr10:38450738~38451069:- CESC trans rs5022636 0.896 rs7531495 ENSG00000180764.13 PIPSL 6.87 6.67e-11 0.000258 0.5 0.42 Gut microbiota (functional units); chr1:151352996 chr10:93958191~93961540:- CESC trans rs7113874 0.659 rs7931834 ENSG00000266891.1 RP11-692N5.2 6.87 6.68e-11 0.000258 0.53 0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8503746 chr18:9734882~9735602:- CESC trans rs7113874 0.659 rs57757082 ENSG00000266891.1 RP11-692N5.2 6.87 6.68e-11 0.000258 0.53 0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8507106 chr18:9734882~9735602:- CESC trans rs1707322 1 rs10789485 ENSG00000255397.1 AC022182.2 -6.87 6.75e-11 0.000261 -0.55 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45941636 chr8:60937705~60939871:- CESC trans rs1707322 1 rs34694458 ENSG00000255397.1 AC022182.2 -6.87 6.77e-11 0.000262 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45867024 chr8:60937705~60939871:- CESC trans rs7192380 0.639 rs12448486 ENSG00000257513.6 NPIPB1P -6.86 6.83e-11 0.000264 -0.49 -0.42 Sjögren's syndrome; chr16:69768975 chr18:11619509~11639699:- CESC trans rs7647973 0.58 rs4955432 ENSG00000197582.5 GPX1P1 6.86 6.86e-11 0.000265 0.53 0.42 Menarche (age at onset); chr3:49229339 chrX:13378735~13379340:- CESC trans rs11098499 0.866 rs10518329 ENSG00000275858.1 RP11-291L22.8 6.86 6.86e-11 0.000265 0.45 0.42 Corneal astigmatism; chr4:119480680 chr10:38450738~38451069:- CESC trans rs12709013 0.693 rs1627257 ENSG00000233719.3 GOT2P3 6.86 6.98e-11 0.000269 0.47 0.42 Blood metabolite ratios; chr16:58763764 chr12:9641802~9643007:+ CESC trans rs12709013 0.755 rs1628029 ENSG00000233719.3 GOT2P3 6.86 6.98e-11 0.000269 0.47 0.42 Blood metabolite ratios; chr16:58763846 chr12:9641802~9643007:+ CESC trans rs12709013 0.716 rs6416775 ENSG00000233719.3 GOT2P3 6.86 6.98e-11 0.000269 0.44 0.42 Blood metabolite ratios; chr16:58830410 chr12:9641802~9643007:+ CESC trans rs1707322 1 rs785478 ENSG00000255397.1 AC022182.2 6.86 7e-11 0.00027 0.53 0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46025963 chr8:60937705~60939871:- CESC trans rs9876781 1 rs2242150 ENSG00000235912.1 RP1-159A19.3 6.86 7.03e-11 0.000271 0.41 0.42 Longevity; chr3:48464565 chr1:27649419~27649610:+ CESC trans rs12709013 0.792 rs1657170 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58752082 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs62066815 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58751577 chr12:9641802~9643007:+ CESC trans rs12709013 0.766 rs1657175 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58755527 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs1646290 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58755807 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs1364346 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58756420 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs257626 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58759574 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs257625 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58759978 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs1646262 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58760593 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs257623 ENSG00000233719.3 GOT2P3 6.86 7.04e-11 0.000271 0.47 0.42 Blood metabolite ratios; chr16:58761247 chr12:9641802~9643007:+ CESC trans rs7312770 0.612 rs1873914 ENSG00000225071.1 GS1-184P14.2 6.86 7.05e-11 0.000272 0.42 0.42 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chrX:24429573~24429920:- CESC trans rs4276421 0.806 rs10079739 ENSG00000231752.4 EMBP1 -6.86 7.07e-11 0.000272 -0.53 -0.42 P wave duration; chr5:45607597 chr1:121519112~121571892:+ CESC trans rs13358908 0.507 rs12521357 ENSG00000231752.4 EMBP1 -6.86 7.17e-11 0.000276 -0.51 -0.42 Schizophrenia; chr5:46403146 chr1:121519112~121571892:+ CESC trans rs8175379 0.506 rs10035927 ENSG00000231752.4 EMBP1 -6.86 7.17e-11 0.000276 -0.51 -0.42 Interleukin-7 levels; chr5:46404107 chr1:121519112~121571892:+ CESC trans rs77688320 0.517 rs12991600 ENSG00000235105.1 RP11-329A14.1 6.86 7.19e-11 0.000277 0.44 0.42 Breast cancer; chr2:201472513 chr1:48435967~48437223:+ CESC trans rs13190036 1 rs6880798 ENSG00000217325.2 PRELID1P1 6.86 7.2e-11 0.000277 0.63 0.42 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177277456 chr6:126643488~126644390:+ CESC trans rs7554511 0.825 rs11576681 ENSG00000244144.1 RP11-757F18.3 -6.85 7.23e-11 0.000278 -0.53 -0.42 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201034923 chr3:112185480~112185998:- CESC trans rs7113874 0.613 rs10840066 ENSG00000266891.1 RP11-692N5.2 6.85 7.28e-11 0.00028 0.53 0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8510456 chr18:9734882~9735602:- CESC trans rs7113874 0.625 rs16938253 ENSG00000266891.1 RP11-692N5.2 6.85 7.32e-11 0.000281 0.56 0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8478833 chr18:9734882~9735602:- CESC trans rs1045902 0.574 rs1474298 ENSG00000236165.1 PRADC1P1 6.85 7.39e-11 0.000284 0.59 0.42 Intelligence (multi-trait analysis); chr2:73239464 chr3:36976316~36976840:+ CESC trans rs9876781 1 rs10470686 ENSG00000235912.1 RP1-159A19.3 -6.85 7.53e-11 0.000289 -0.39 -0.42 Longevity; chr3:48408549 chr1:27649419~27649610:+ CESC trans rs1707322 1 rs4660334 ENSG00000255397.1 AC022182.2 -6.84 7.66e-11 0.000294 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45996454 chr8:60937705~60939871:- CESC trans rs11098499 0.663 rs9996501 ENSG00000275858.1 RP11-291L22.8 6.84 7.89e-11 0.000302 0.47 0.42 Corneal astigmatism; chr4:119317763 chr10:38450738~38451069:- CESC trans rs11098499 0.697 rs28458294 ENSG00000275858.1 RP11-291L22.8 6.84 7.89e-11 0.000302 0.47 0.42 Corneal astigmatism; chr4:119317769 chr10:38450738~38451069:- CESC trans rs11098499 0.663 rs28369503 ENSG00000275858.1 RP11-291L22.8 6.84 7.89e-11 0.000302 0.47 0.42 Corneal astigmatism; chr4:119317770 chr10:38450738~38451069:- CESC trans rs1707322 1 rs1707322 ENSG00000255397.1 AC022182.2 -6.84 7.9e-11 0.000303 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46039475 chr8:60937705~60939871:- CESC trans rs13358908 0.51 rs4975991 ENSG00000231752.4 EMBP1 -6.84 7.92e-11 0.000303 -0.51 -0.42 Schizophrenia; chr5:46328545 chr1:121519112~121571892:+ CESC trans rs9899728 0.52 rs12936866 ENSG00000234925.2 ATP5HP4 6.84 7.92e-11 0.000303 0.77 0.42 Alzheimer's disease or small vessel stroke; chr17:75055955 chr12:68642519~68642993:- CESC trans rs9899728 0.539 rs57813751 ENSG00000234925.2 ATP5HP4 6.84 7.92e-11 0.000303 0.77 0.42 Alzheimer's disease or small vessel stroke; chr17:75057417 chr12:68642519~68642993:- CESC trans rs9899728 0.539 rs12940199 ENSG00000234925.2 ATP5HP4 6.84 7.92e-11 0.000303 0.77 0.42 Alzheimer's disease or small vessel stroke; chr17:75058664 chr12:68642519~68642993:- CESC trans rs9876781 1 rs9876781 ENSG00000235912.1 RP1-159A19.3 -6.84 7.93e-11 0.000303 -0.4 -0.42 Longevity; chr3:48445934 chr1:27649419~27649610:+ CESC trans rs12709013 0.792 rs12935488 ENSG00000233719.3 GOT2P3 6.84 7.94e-11 0.000304 0.47 0.42 Blood metabolite ratios; chr16:58766320 chr12:9641802~9643007:+ CESC trans rs7113874 0.659 rs2166470 ENSG00000266891.1 RP11-692N5.2 -6.84 7.97e-11 0.000305 -0.53 -0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8501625 chr18:9734882~9735602:- CESC trans rs11098499 0.874 rs12502503 ENSG00000275858.1 RP11-291L22.8 6.84 8.03e-11 0.000307 0.49 0.42 Corneal astigmatism; chr4:119195100 chr10:38450738~38451069:- CESC trans rs7312770 0.612 rs1873914 ENSG00000196656.7 AC004057.1 6.83 8.13e-11 0.000311 0.43 0.42 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr4:113214046~113217170:- CESC trans rs7554511 0.929 rs55757739 ENSG00000244144.1 RP11-757F18.3 -6.83 8.16e-11 0.000312 -0.5 -0.42 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200997848 chr3:112185480~112185998:- CESC trans rs9876781 1 rs3214041 ENSG00000235912.1 RP1-159A19.3 -6.83 8.27e-11 0.000316 -0.39 -0.42 Longevity; chr3:48413059 chr1:27649419~27649610:+ CESC trans rs7811142 1 rs7783159 ENSG00000228546.2 CTA-313A17.3 6.83 8.3e-11 0.000317 0.69 0.42 Platelet count; chr7:100419831 chr7:102337316~102339115:+ CESC trans rs74781061 0.929 rs9635320 ENSG00000227288.3 RP5-837I24.1 6.83 8.37e-11 0.00032 0.55 0.42 Endometriosis; chr15:74592750 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs11072494 ENSG00000227288.3 RP5-837I24.1 6.83 8.37e-11 0.00032 0.55 0.42 Endometriosis; chr15:74596822 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs11072495 ENSG00000227288.3 RP5-837I24.1 6.83 8.37e-11 0.00032 0.55 0.42 Endometriosis; chr15:74598790 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs4887159 ENSG00000227288.3 RP5-837I24.1 6.83 8.39e-11 0.00032 0.54 0.42 Endometriosis; chr15:74573541 chr1:81501794~81503468:+ CESC trans rs1045902 0.516 rs7851 ENSG00000236165.1 PRADC1P1 6.83 8.41e-11 0.000321 0.58 0.42 Intelligence (multi-trait analysis); chr2:73251333 chr3:36976316~36976840:+ CESC trans rs9611565 0.614 rs4822053 ENSG00000268568.1 AC007228.9 -6.83 8.58e-11 0.000327 -0.53 -0.42 Vitiligo; chr22:41816932 chr19:56672574~56673901:- CESC trans rs5022636 0.927 rs4971030 ENSG00000180764.13 PIPSL -6.82 8.62e-11 0.000329 -0.49 -0.42 Gut microbiota (functional units); chr1:151308519 chr10:93958191~93961540:- CESC trans rs10242455 0.867 rs1357319 ENSG00000228834.1 RP11-249L21.4 6.82 8.65e-11 0.00033 0.67 0.42 Blood metabolite levels; chr7:99712558 chr6:108907615~108907873:- CESC trans rs1045902 0.532 rs2288631 ENSG00000236165.1 PRADC1P1 6.82 8.65e-11 0.00033 0.6 0.42 Intelligence (multi-trait analysis); chr2:73228619 chr3:36976316~36976840:+ CESC trans rs9425766 1 rs9425766 ENSG00000213331.4 RP11-713C19.2 6.82 8.67e-11 0.00033 0.48 0.42 Life satisfaction; chr1:173883989 chr4:187970273~187971284:+ CESC trans rs1707322 1 rs11211232 ENSG00000255397.1 AC022182.2 -6.82 8.68e-11 0.000331 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45945474 chr8:60937705~60939871:- CESC trans rs1707322 1 rs12097761 ENSG00000255397.1 AC022182.2 -6.82 8.68e-11 0.000331 -0.55 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45825490 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4606257 ENSG00000255397.1 AC022182.2 -6.82 8.69e-11 0.000331 -0.55 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45841596 chr8:60937705~60939871:- CESC trans rs10940346 0.601 rs7712849 ENSG00000231752.4 EMBP1 6.82 8.72e-11 0.000332 0.5 0.42 Schizophrenia; chr5:50407774 chr1:121519112~121571892:+ CESC trans rs7312770 0.637 rs705700 ENSG00000243403.1 RP11-330L19.1 6.82 8.74e-11 0.000333 0.4 0.42 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr15:64592979~64593326:+ CESC trans rs1707322 1 rs11211248 ENSG00000255397.1 AC022182.2 -6.82 8.78e-11 0.000334 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46011172 chr8:60937705~60939871:- CESC trans rs4276421 0.869 rs11741075 ENSG00000231752.4 EMBP1 -6.82 8.81e-11 0.000336 -0.51 -0.42 P wave duration; chr5:45556276 chr1:121519112~121571892:+ CESC trans rs74781061 0.79 rs6495105 ENSG00000227288.3 RP5-837I24.1 6.82 8.89e-11 0.000338 0.54 0.42 Endometriosis; chr15:74480512 chr1:81501794~81503468:+ CESC trans rs9611565 0.649 rs6002480 ENSG00000268568.1 AC007228.9 -6.82 8.9e-11 0.000339 -0.53 -0.42 Vitiligo; chr22:41780913 chr19:56672574~56673901:- CESC trans rs7554511 0.893 rs17419032 ENSG00000244144.1 RP11-757F18.3 6.82 8.92e-11 0.00034 0.51 0.42 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201029403 chr3:112185480~112185998:- CESC trans rs5022636 0.964 rs1056847 ENSG00000180764.13 PIPSL 6.82 8.94e-11 0.00034 0.49 0.42 Gut microbiota (functional units); chr1:151315696 chr10:93958191~93961540:- CESC trans rs11098499 0.874 rs6822498 ENSG00000275858.1 RP11-291L22.8 6.82 9.01e-11 0.000343 0.48 0.42 Corneal astigmatism; chr4:119199028 chr10:38450738~38451069:- CESC trans rs1707322 1 rs10890382 ENSG00000255397.1 AC022182.2 -6.82 9.06e-11 0.000345 -0.55 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46004002 chr8:60937705~60939871:- CESC trans rs7554547 0.667 rs12065911 ENSG00000261819.1 RP11-680G24.4 6.81 9.12e-11 0.000347 0.51 0.42 Nonsyndromic cleft lip with cleft palate; chr1:11908323 chr16:14988259~14990160:- CESC trans rs7647973 0.6 rs12631989 ENSG00000197582.5 GPX1P1 6.81 9.21e-11 0.00035 0.52 0.42 Menarche (age at onset); chr3:49236563 chrX:13378735~13379340:- CESC trans rs7647973 0.6 rs13064780 ENSG00000197582.5 GPX1P1 6.81 9.21e-11 0.00035 0.52 0.42 Menarche (age at onset); chr3:49237393 chrX:13378735~13379340:- CESC trans rs13190036 0.901 rs4631 ENSG00000226986.4 RP11-543B16.2 6.81 9.22e-11 0.00035 0.57 0.42 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177306115 chr1:211207239~211207897:+ CESC trans rs11638815 0.581 rs783537 ENSG00000235370.6 DNM1P51 -6.81 9.32e-11 0.000354 -0.55 -0.42 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82584058 chr15:84398316~84411701:- CESC trans rs916888 0.61 rs199530 ENSG00000214425.5 LRRC37A4P 6.81 9.33e-11 0.000354 0.44 0.42 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:45506741~45550335:- CESC trans rs11098499 0.874 rs6832670 ENSG00000275858.1 RP11-291L22.8 6.8 9.76e-11 0.00037 0.48 0.42 Corneal astigmatism; chr4:119197637 chr10:38450738~38451069:- CESC trans rs7554511 0.893 rs10494828 ENSG00000244144.1 RP11-757F18.3 -6.8 9.97e-11 0.000377 -0.5 -0.42 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200987904 chr3:112185480~112185998:- CESC trans rs74781061 0.929 rs7176095 ENSG00000227288.3 RP5-837I24.1 6.8 9.97e-11 0.000377 0.55 0.42 Endometriosis; chr15:74594070 chr1:81501794~81503468:+ CESC trans rs1707322 1 rs4660905 ENSG00000255397.1 AC022182.2 6.8 1e-10 0.000379 0.53 0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45995915 chr8:60937705~60939871:- CESC trans rs1707322 1 rs6657720 ENSG00000255397.1 AC022182.2 -6.8 1e-10 0.000379 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45920597 chr8:60937705~60939871:- CESC trans rs1707322 1 rs7519181 ENSG00000255397.1 AC022182.2 -6.8 1e-10 0.000379 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45922157 chr8:60937705~60939871:- CESC trans rs1707322 1 rs7526369 ENSG00000255397.1 AC022182.2 -6.8 1e-10 0.000379 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45924888 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs10890371 ENSG00000255397.1 AC022182.2 -6.8 1e-10 0.000379 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45925225 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10890372 ENSG00000255397.1 AC022182.2 -6.8 1e-10 0.000379 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45925348 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211243 ENSG00000255397.1 AC022182.2 -6.8 1e-10 0.000379 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45989761 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211244 ENSG00000255397.1 AC022182.2 -6.8 1e-10 0.000379 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45991001 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4660903 ENSG00000255397.1 AC022182.2 -6.8 1e-10 0.000379 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45991929 chr8:60937705~60939871:- CESC trans rs7554547 0.714 rs4845890 ENSG00000261819.1 RP11-680G24.4 6.79 1.02e-10 0.000386 0.51 0.42 Nonsyndromic cleft lip with cleft palate; chr1:11912612 chr16:14988259~14990160:- CESC trans rs74781061 0.858 rs12592906 ENSG00000227288.3 RP5-837I24.1 6.79 1.03e-10 0.000387 0.54 0.42 Endometriosis; chr15:74481811 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs4886599 ENSG00000227288.3 RP5-837I24.1 6.79 1.03e-10 0.000387 0.54 0.42 Endometriosis; chr15:74484442 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs11855521 ENSG00000227288.3 RP5-837I24.1 6.79 1.03e-10 0.000387 0.54 0.42 Endometriosis; chr15:74488038 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs55662551 ENSG00000227288.3 RP5-837I24.1 6.79 1.03e-10 0.000387 0.54 0.42 Endometriosis; chr15:74488745 chr1:81501794~81503468:+ CESC trans rs74781061 0.858 rs79923136 ENSG00000227288.3 RP5-837I24.1 6.79 1.03e-10 0.000387 0.54 0.42 Endometriosis; chr15:74492219 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs12439505 ENSG00000227288.3 RP5-837I24.1 6.79 1.03e-10 0.000387 0.54 0.42 Endometriosis; chr15:74494021 chr1:81501794~81503468:+ CESC trans rs74781061 0.858 rs35752918 ENSG00000227288.3 RP5-837I24.1 6.79 1.03e-10 0.000387 0.54 0.42 Endometriosis; chr15:74494240 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs79534854 ENSG00000227288.3 RP5-837I24.1 6.79 1.03e-10 0.000387 0.54 0.42 Endometriosis; chr15:74494257 chr1:81501794~81503468:+ CESC trans rs9611565 0.918 rs6002351 ENSG00000268568.1 AC007228.9 -6.79 1.03e-10 0.000387 -0.51 -0.42 Vitiligo; chr22:41361219 chr19:56672574~56673901:- CESC trans rs6132905 0.52 rs2422823 ENSG00000235559.1 NOP56P1 -6.79 1.03e-10 0.000389 -0.56 -0.42 Mumps; chr20:2665687 chr6:28783633~28784004:- CESC trans rs877636 1 rs2292239 ENSG00000235459.5 RPS26P31 6.79 1.05e-10 0.000397 0.45 0.42 Cognitive function; chr12:56088396 chr7:122681315~122681662:+ CESC trans rs1707322 1 rs10890380 ENSG00000255397.1 AC022182.2 -6.79 1.07e-10 0.000404 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45983797 chr8:60937705~60939871:- CESC trans rs9899728 0.539 rs11077772 ENSG00000234925.2 ATP5HP4 6.79 1.08e-10 0.000405 0.79 0.42 Alzheimer's disease or small vessel stroke; chr17:75039603 chr12:68642519~68642993:- CESC trans rs7554511 0.858 rs6701496 ENSG00000244144.1 RP11-757F18.3 -6.78 1.08e-10 0.000407 -0.53 -0.42 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201038700 chr3:112185480~112185998:- CESC trans rs1707322 1 rs6687301 ENSG00000255397.1 AC022182.2 -6.78 1.08e-10 0.000408 -0.53 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45917180 chr8:60937705~60939871:- CESC trans rs8175379 0.506 rs8188256 ENSG00000231752.4 EMBP1 -6.78 1.1e-10 0.000412 -0.51 -0.42 Interleukin-7 levels; chr5:46372404 chr1:121519112~121571892:+ CESC trans rs11098499 0.874 rs12509054 ENSG00000275858.1 RP11-291L22.8 6.78 1.11e-10 0.000417 0.48 0.42 Corneal astigmatism; chr4:119193920 chr10:38450738~38451069:- CESC trans rs11098499 0.874 rs10022508 ENSG00000275858.1 RP11-291L22.8 6.78 1.11e-10 0.000417 0.48 0.42 Corneal astigmatism; chr4:119194073 chr10:38450738~38451069:- CESC trans rs11098499 0.874 rs6851169 ENSG00000275858.1 RP11-291L22.8 6.78 1.11e-10 0.000417 0.48 0.42 Corneal astigmatism; chr4:119196355 chr10:38450738~38451069:- CESC trans rs1045902 0.537 rs1018342 ENSG00000236165.1 PRADC1P1 6.77 1.16e-10 0.000436 0.57 0.42 Intelligence (multi-trait analysis); chr2:73244525 chr3:36976316~36976840:+ CESC trans rs12709013 0.792 rs12325054 ENSG00000233719.3 GOT2P3 6.77 1.16e-10 0.000436 0.46 0.42 Blood metabolite ratios; chr16:58749804 chr12:9641802~9643007:+ CESC trans rs74781061 0.929 rs16969612 ENSG00000227288.3 RP5-837I24.1 -6.77 1.17e-10 0.000437 -0.55 -0.42 Endometriosis; chr15:74514096 chr1:81501794~81503468:+ CESC trans rs12709013 0.935 rs8046667 ENSG00000230849.2 GOT2P2 6.77 1.18e-10 0.000443 0.49 0.42 Blood metabolite ratios; chr16:58790935 chr1:173141100~173142350:- CESC trans rs8175379 0.575 rs8185283 ENSG00000231752.4 EMBP1 -6.77 1.19e-10 0.000445 -0.51 -0.42 Interleukin-7 levels; chr5:46337706 chr1:121519112~121571892:+ CESC trans rs13358908 0.511 rs34101830 ENSG00000231752.4 EMBP1 -6.77 1.19e-10 0.000445 -0.51 -0.42 Schizophrenia; chr5:46349001 chr1:121519112~121571892:+ CESC trans rs12709013 1 rs8046998 ENSG00000230849.2 GOT2P2 6.77 1.19e-10 0.000445 0.49 0.42 Blood metabolite ratios; chr16:58791109 chr1:173141100~173142350:- CESC trans rs11638815 0.52 rs4779032 ENSG00000235370.6 DNM1P51 -6.77 1.19e-10 0.000446 -0.53 -0.42 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82576576 chr15:84398316~84411701:- CESC trans rs12497850 0.627 rs4974078 ENSG00000197582.5 GPX1P1 6.77 1.2e-10 0.000447 0.54 0.42 Parkinson's disease; chr3:48971953 chrX:13378735~13379340:- CESC trans rs877636 1 rs705696 ENSG00000223416.3 RPS26P15 6.77 1.21e-10 0.000452 0.44 0.42 Cognitive function; chr12:56086864 chr1:58056133~58056480:- CESC trans rs1707322 1 rs6661500 ENSG00000255397.1 AC022182.2 -6.77 1.21e-10 0.000452 -0.54 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45999990 chr8:60937705~60939871:- CESC trans rs916888 0.779 rs199498 ENSG00000214425.5 LRRC37A4P -6.76 1.22e-10 0.000454 -0.48 -0.42 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:45506741~45550335:- CESC trans rs7647973 0.6 rs11920267 ENSG00000197582.5 GPX1P1 6.76 1.22e-10 0.000456 0.52 0.42 Menarche (age at onset); chr3:49238531 chrX:13378735~13379340:- CESC trans rs74781061 0.929 rs76160708 ENSG00000227288.3 RP5-837I24.1 6.76 1.23e-10 0.000459 0.54 0.42 Endometriosis; chr15:74636901 chr1:81501794~81503468:+ CESC trans rs7647973 0.58 rs35218722 ENSG00000197582.5 GPX1P1 6.76 1.23e-10 0.00046 0.52 0.42 Menarche (age at onset); chr3:49238372 chrX:13378735~13379340:- CESC trans rs7113874 0.659 rs12574009 ENSG00000266891.1 RP11-692N5.2 6.76 1.24e-10 0.000463 0.52 0.42 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8498406 chr18:9734882~9735602:- CESC trans rs7554511 0.893 rs55862304 ENSG00000244144.1 RP11-757F18.3 -6.76 1.25e-10 0.000466 -0.51 -0.42 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201020647 chr3:112185480~112185998:- CESC trans rs74781061 0.929 rs12442097 ENSG00000227288.3 RP5-837I24.1 6.76 1.26e-10 0.000469 0.53 0.42 Endometriosis; chr15:74554792 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs8029215 ENSG00000227288.3 RP5-837I24.1 6.76 1.26e-10 0.000469 0.53 0.42 Endometriosis; chr15:74561147 chr1:81501794~81503468:+ CESC trans rs7647973 0.6 rs35174559 ENSG00000197582.5 GPX1P1 6.76 1.26e-10 0.000471 0.52 0.42 Menarche (age at onset); chr3:49250326 chrX:13378735~13379340:- CESC trans rs74781061 0.929 rs4887153 ENSG00000227288.3 RP5-837I24.1 6.75 1.29e-10 0.000479 0.53 0.42 Endometriosis; chr15:74484701 chr1:81501794~81503468:+ CESC trans rs9611565 0.879 rs4820437 ENSG00000268568.1 AC007228.9 -6.75 1.29e-10 0.00048 -0.51 -0.42 Vitiligo; chr22:41365286 chr19:56672574~56673901:- CESC trans rs7937890 0.587 rs11023204 ENSG00000236360.2 RP11-334A14.2 6.75 1.31e-10 0.000486 0.5 0.42 Mitochondrial DNA levels; chr11:14389677 chr1:52993201~52993702:- CESC trans rs8175379 0.515 rs8185067 ENSG00000231752.4 EMBP1 -6.75 1.31e-10 0.000486 -0.51 -0.42 Interleukin-7 levels; chr5:46337722 chr1:121519112~121571892:+ CESC trans rs13358908 0.503 rs10073687 ENSG00000231752.4 EMBP1 -6.75 1.31e-10 0.000486 -0.51 -0.42 Schizophrenia; chr5:46352187 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs13175695 ENSG00000226986.4 RP11-543B16.2 6.75 1.31e-10 0.000486 0.5 0.42 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177272810 chr1:211207239~211207897:+ CESC trans rs7554547 0.667 rs11121839 ENSG00000261819.1 RP11-680G24.4 6.74 1.36e-10 0.000503 0.51 0.42 Nonsyndromic cleft lip with cleft palate; chr1:11908280 chr16:14988259~14990160:- CESC trans rs877636 0.692 rs2271194 ENSG00000242970.2 AC068522.4 -6.74 1.36e-10 0.000505 -0.45 -0.42 Cognitive function; chr12:56083910 chr8:58588420~58588764:- CESC trans rs1707322 1 rs10890355 ENSG00000255397.1 AC022182.2 -6.74 1.37e-10 0.000508 -0.52 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45851676 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211204 ENSG00000255397.1 AC022182.2 -6.74 1.37e-10 0.000508 -0.52 -0.42 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45852192 chr8:60937705~60939871:- CESC trans rs1045902 0.532 rs10185579 ENSG00000236165.1 PRADC1P1 6.74 1.38e-10 0.000512 0.59 0.42 Intelligence (multi-trait analysis); chr2:73229214 chr3:36976316~36976840:+ CESC trans rs11098499 0.754 rs12711071 ENSG00000275858.1 RP11-291L22.8 6.74 1.39e-10 0.000514 0.46 0.42 Corneal astigmatism; chr4:119319779 chr10:38450738~38451069:- CESC trans rs74781061 0.86 rs8033841 ENSG00000227288.3 RP5-837I24.1 6.74 1.4e-10 0.000518 0.52 0.42 Endometriosis; chr15:74471540 chr1:81501794~81503468:+ CESC trans rs9876781 1 rs28824259 ENSG00000235912.1 RP1-159A19.3 -6.74 1.41e-10 0.00052 -0.39 -0.42 Longevity; chr3:48384185 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs12487542 ENSG00000235912.1 RP1-159A19.3 -6.74 1.41e-10 0.00052 -0.39 -0.42 Longevity; chr3:48384586 chr1:27649419~27649610:+ CESC trans rs74781061 0.932 rs11857328 ENSG00000227288.3 RP5-837I24.1 6.74 1.43e-10 0.000527 0.52 0.42 Endometriosis; chr15:74510550 chr1:81501794~81503468:+ CESC trans rs12709013 0.792 rs1646276 ENSG00000233719.3 GOT2P3 6.73 1.44e-10 0.00053 0.46 0.42 Blood metabolite ratios; chr16:58749654 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs1646277 ENSG00000233719.3 GOT2P3 6.73 1.44e-10 0.00053 0.46 0.42 Blood metabolite ratios; chr16:58750037 chr12:9641802~9643007:+ CESC trans rs9876781 0.967 rs2885509 ENSG00000235912.1 RP1-159A19.3 6.73 1.46e-10 0.000539 0.39 0.41 Longevity; chr3:48376729 chr1:27649419~27649610:+ CESC trans rs7312770 1 rs7312770 ENSG00000225071.1 GS1-184P14.2 -6.73 1.46e-10 0.00054 -0.41 -0.41 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chrX:24429573~24429920:- CESC trans rs1707322 0.963 rs4630155 ENSG00000255397.1 AC022182.2 -6.73 1.47e-10 0.000543 -0.54 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45791438 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs4508055 ENSG00000255397.1 AC022182.2 -6.73 1.47e-10 0.000543 -0.54 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45792059 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs12076580 ENSG00000255397.1 AC022182.2 -6.73 1.47e-10 0.000543 -0.54 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45792487 chr8:60937705~60939871:- CESC trans rs7554511 0.825 rs12122809 ENSG00000244144.1 RP11-757F18.3 -6.73 1.48e-10 0.000544 -0.53 -0.41 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201045838 chr3:112185480~112185998:- CESC trans rs1707322 1 rs7532204 ENSG00000255397.1 AC022182.2 6.73 1.48e-10 0.000544 0.52 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46019403 chr8:60937705~60939871:- CESC trans rs1707322 0.835 rs946525 ENSG00000255397.1 AC022182.2 6.73 1.48e-10 0.000544 0.52 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46021605 chr8:60937705~60939871:- CESC trans rs1707322 1 rs946524 ENSG00000255397.1 AC022182.2 6.73 1.48e-10 0.000544 0.52 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46021888 chr8:60937705~60939871:- CESC trans rs7554511 0.858 rs3208703 ENSG00000244144.1 RP11-757F18.3 -6.73 1.49e-10 0.000548 -0.49 -0.41 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200970514 chr3:112185480~112185998:- CESC trans rs9876781 1 rs13314659 ENSG00000235912.1 RP1-159A19.3 6.73 1.49e-10 0.000549 0.39 0.41 Longevity; chr3:48407742 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs7653691 ENSG00000235912.1 RP1-159A19.3 6.73 1.52e-10 0.000558 0.39 0.41 Longevity; chr3:48378199 chr1:27649419~27649610:+ CESC trans rs12709013 0.792 rs1615326 ENSG00000233719.3 GOT2P3 6.72 1.52e-10 0.000561 0.46 0.41 Blood metabolite ratios; chr16:58747148 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs1657165 ENSG00000233719.3 GOT2P3 6.72 1.54e-10 0.000565 0.46 0.41 Blood metabolite ratios; chr16:58747980 chr12:9641802~9643007:+ CESC trans rs12709013 0.818 rs1646273 ENSG00000233719.3 GOT2P3 6.72 1.54e-10 0.000565 0.46 0.41 Blood metabolite ratios; chr16:58748318 chr12:9641802~9643007:+ CESC trans rs8175379 0.521 rs10037109 ENSG00000231752.4 EMBP1 6.72 1.55e-10 0.000571 0.5 0.41 Interleukin-7 levels; chr5:46328343 chr1:121519112~121571892:+ CESC trans rs9876781 1 rs2885510 ENSG00000235912.1 RP1-159A19.3 6.72 1.56e-10 0.000574 0.39 0.41 Longevity; chr3:48376736 chr1:27649419~27649610:+ CESC trans rs4276421 0.571 rs59968174 ENSG00000231752.4 EMBP1 6.72 1.57e-10 0.000578 0.51 0.41 P wave duration; chr5:46027939 chr1:121519112~121571892:+ CESC trans rs2665103 0.687 rs11633000 ENSG00000235370.6 DNM1P51 -6.72 1.58e-10 0.000579 -0.52 -0.41 Intelligence (multi-trait analysis); chr15:82269320 chr15:84398316~84411701:- CESC trans rs12709013 0.792 rs12926512 ENSG00000233719.3 GOT2P3 6.72 1.58e-10 0.00058 0.46 0.41 Blood metabolite ratios; chr16:58768317 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs12595974 ENSG00000233719.3 GOT2P3 6.72 1.58e-10 0.00058 0.46 0.41 Blood metabolite ratios; chr16:58769132 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs1836877 ENSG00000233719.3 GOT2P3 6.72 1.58e-10 0.00058 0.46 0.41 Blood metabolite ratios; chr16:58769821 chr12:9641802~9643007:+ CESC trans rs11098499 0.866 rs7665125 ENSG00000275858.1 RP11-291L22.8 6.71 1.61e-10 0.000591 0.45 0.41 Corneal astigmatism; chr4:119480924 chr10:38450738~38451069:- CESC trans rs1707322 1 rs4298677 ENSG00000255397.1 AC022182.2 -6.71 1.65e-10 0.000604 -0.53 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45840947 chr8:60937705~60939871:- CESC trans rs9876781 1 rs725309 ENSG00000235912.1 RP1-159A19.3 6.71 1.65e-10 0.000607 0.39 0.41 Longevity; chr3:48377218 chr1:27649419~27649610:+ CESC trans rs7113874 0.659 rs12577287 ENSG00000266891.1 RP11-692N5.2 6.71 1.68e-10 0.000617 0.52 0.41 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8498370 chr18:9734882~9735602:- CESC trans rs7113874 0.659 rs12274454 ENSG00000266891.1 RP11-692N5.2 6.71 1.68e-10 0.000617 0.52 0.41 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8500419 chr18:9734882~9735602:- CESC trans rs11638815 0.626 rs4779039 ENSG00000235370.6 DNM1P51 6.7 1.71e-10 0.000626 0.55 0.41 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82649016 chr15:84398316~84411701:- CESC trans rs9611565 0.879 rs5758311 ENSG00000268568.1 AC007228.9 -6.7 1.72e-10 0.000629 -0.51 -0.41 Vitiligo; chr22:41363371 chr19:56672574~56673901:- CESC trans rs1707322 1 rs785467 ENSG00000255397.1 AC022182.2 6.7 1.76e-10 0.000644 0.54 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055887 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4660906 ENSG00000255397.1 AC022182.2 -6.7 1.77e-10 0.000649 -0.53 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46005188 chr8:60937705~60939871:- CESC trans rs7554511 0.858 rs12142704 ENSG00000244144.1 RP11-757F18.3 -6.7 1.78e-10 0.00065 -0.5 -0.41 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200988569 chr3:112185480~112185998:- CESC trans rs1707322 1 rs7539800 ENSG00000255397.1 AC022182.2 6.7 1.78e-10 0.000652 0.54 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45796457 chr8:60937705~60939871:- CESC trans rs1707322 1 rs6672115 ENSG00000255397.1 AC022182.2 -6.7 1.78e-10 0.000652 -0.54 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45807207 chr8:60937705~60939871:- CESC trans rs7032940 0.626 rs4314718 ENSG00000228236.2 TXNP5 6.7 1.79e-10 0.000652 0.5 0.41 Height; chr9:110211368 chr2:149068596~149068910:- CESC trans rs5022636 0.865 rs12069445 ENSG00000180764.13 PIPSL 6.69 1.81e-10 0.00066 0.48 0.41 Gut microbiota (functional units); chr1:151362964 chr10:93958191~93961540:- CESC trans rs11638815 0.603 rs7171180 ENSG00000235370.6 DNM1P51 6.69 1.84e-10 0.00067 0.52 0.41 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82640357 chr15:84398316~84411701:- CESC trans rs9876781 1 rs9838618 ENSG00000225528.1 RP3-370M22.8 -6.69 1.84e-10 0.000671 -0.4 -0.41 Longevity; chr3:48445949 chr22:39960397~39964683:+ CESC trans rs12138950 0.625 rs12041608 ENSG00000224237.1 MINOS1P3 -6.69 1.84e-10 0.000671 -0.53 -0.41 Hypothyroidism;Thyroid volume; chr1:19515431 chr3:27214816~27215018:- CESC trans rs74781061 0.929 rs79600165 ENSG00000227288.3 RP5-837I24.1 6.69 1.85e-10 0.000674 0.54 0.41 Endometriosis; chr15:74648650 chr1:81501794~81503468:+ CESC trans rs9611565 0.921 rs2143695 ENSG00000268568.1 AC007228.9 -6.69 1.89e-10 0.000689 -0.52 -0.41 Vitiligo; chr22:41332616 chr19:56672574~56673901:- CESC trans rs9876781 1 rs1459242 ENSG00000235912.1 RP1-159A19.3 6.69 1.9e-10 0.00069 0.39 0.41 Longevity; chr3:48372047 chr1:27649419~27649610:+ CESC trans rs1707322 1 rs7538978 ENSG00000255397.1 AC022182.2 6.69 1.9e-10 0.000693 0.52 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46039382 chr8:60937705~60939871:- CESC trans rs1707322 0.896 rs946528 ENSG00000255397.1 AC022182.2 6.68 1.94e-10 0.000705 0.52 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46019890 chr8:60937705~60939871:- CESC trans rs11098499 0.604 rs12642411 ENSG00000275858.1 RP11-291L22.8 6.68 1.96e-10 0.000712 0.47 0.41 Corneal astigmatism; chr4:119659370 chr10:38450738~38451069:- CESC trans rs1707322 1 rs12403666 ENSG00000255397.1 AC022182.2 -6.68 1.97e-10 0.000714 -0.53 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45965949 chr8:60937705~60939871:- CESC trans rs12709013 0.792 rs11646756 ENSG00000233719.3 GOT2P3 6.68 1.97e-10 0.000716 0.45 0.41 Blood metabolite ratios; chr16:58773598 chr12:9641802~9643007:+ CESC trans rs12709013 1 rs11641836 ENSG00000230849.2 GOT2P2 6.68 1.98e-10 0.000718 0.48 0.41 Blood metabolite ratios; chr16:58798143 chr1:173141100~173142350:- CESC trans rs13358908 0.526 rs4975974 ENSG00000231752.4 EMBP1 -6.68 1.98e-10 0.000718 -0.5 -0.41 Schizophrenia; chr5:46307464 chr1:121519112~121571892:+ CESC trans rs13358908 0.556 rs55638678 ENSG00000231752.4 EMBP1 -6.68 1.98e-10 0.000718 -0.5 -0.41 Schizophrenia; chr5:46332618 chr1:121519112~121571892:+ CESC trans rs8175379 0.509 rs4128583 ENSG00000231752.4 EMBP1 6.68 1.98e-10 0.000718 0.5 0.41 Interleukin-7 levels; chr5:46251985 chr1:121519112~121571892:+ CESC trans rs714543 0.585 rs9655458 ENSG00000226038.5 PPIAP21 6.68 1.99e-10 0.000719 0.44 0.41 Plateletcrit; chr7:44771386 chr20:43230760~43231260:+ CESC trans rs74781061 0.929 rs7171838 ENSG00000227288.3 RP5-837I24.1 6.67 2.03e-10 0.000733 0.54 0.41 Endometriosis; chr15:74571778 chr1:81501794~81503468:+ CESC trans rs10242455 0.614 rs2014764 ENSG00000228834.1 RP11-249L21.4 -6.67 2.06e-10 0.00074 -0.65 -0.41 Blood metabolite levels; chr7:99749883 chr6:108907615~108907873:- CESC trans rs2665103 0.715 rs11639440 ENSG00000235370.6 DNM1P51 -6.67 2.1e-10 0.000755 -0.52 -0.41 Intelligence (multi-trait analysis); chr15:82278705 chr15:84398316~84411701:- CESC trans rs1707322 1 rs10890365 ENSG00000255397.1 AC022182.2 -6.67 2.11e-10 0.000759 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45893676 chr8:60937705~60939871:- CESC trans rs10819083 0.823 rs10987054 ENSG00000203588.3 IGBP1-AS1 -6.67 2.11e-10 0.000759 -0.37 -0.41 Squamous cell lung carcinoma; chr9:125942948 chrX:70163842~70165206:- CESC trans rs7192380 0.756 rs12596945 ENSG00000257513.6 NPIPB1P -6.67 2.11e-10 0.00076 -0.48 -0.41 Sjögren's syndrome; chr16:69746916 chr18:11619509~11639699:- CESC trans rs1079467 1 rs1079467 ENSG00000233426.3 EIF3FP3 -6.67 2.13e-10 0.000766 -0.62 -0.41 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7948164 chr2:58251440~58252525:+ CESC trans rs10242455 0.867 rs2740560 ENSG00000228834.1 RP11-249L21.4 -6.66 2.14e-10 0.000769 -0.66 -0.41 Blood metabolite levels; chr7:99724697 chr6:108907615~108907873:- CESC trans rs10242455 0.681 rs2687140 ENSG00000228834.1 RP11-249L21.4 -6.66 2.14e-10 0.000769 -0.66 -0.41 Blood metabolite levels; chr7:99724719 chr6:108907615~108907873:- CESC trans rs11638815 0.581 rs28808991 ENSG00000235370.6 DNM1P51 -6.66 2.14e-10 0.00077 -0.53 -0.41 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82592229 chr15:84398316~84411701:- CESC trans rs7554547 0.69 rs12087996 ENSG00000261819.1 RP11-680G24.4 6.66 2.2e-10 0.000788 0.49 0.41 Nonsyndromic cleft lip with cleft palate; chr1:11897152 chr16:14988259~14990160:- CESC trans rs4276421 0.571 rs6414908 ENSG00000231752.4 EMBP1 6.66 2.24e-10 8e-04 0.51 0.41 P wave duration; chr5:45879332 chr1:121519112~121571892:+ CESC trans rs74781061 0.929 rs8027066 ENSG00000227288.3 RP5-837I24.1 6.66 2.26e-10 0.000807 0.52 0.41 Endometriosis; chr15:74535682 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs2415242 ENSG00000227288.3 RP5-837I24.1 6.66 2.26e-10 0.000807 0.52 0.41 Endometriosis; chr15:74546765 chr1:81501794~81503468:+ CESC trans rs727563 0.565 rs132774 ENSG00000268568.1 AC007228.9 -6.65 2.31e-10 0.000821 -0.54 -0.41 Crohn's disease;Inflammatory bowel disease; chr22:41635949 chr19:56672574~56673901:- CESC trans rs1707322 1 rs4660889 ENSG00000255397.1 AC022182.2 -6.65 2.34e-10 0.000833 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45831659 chr8:60937705~60939871:- CESC trans rs9876781 1 rs6442119 ENSG00000235912.1 RP1-159A19.3 -6.65 2.35e-10 0.000835 -0.39 -0.41 Longevity; chr3:48398713 chr1:27649419~27649610:+ CESC trans rs74781061 0.929 rs8025976 ENSG00000227288.3 RP5-837I24.1 6.65 2.36e-10 0.000838 0.54 0.41 Endometriosis; chr15:74577697 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs6495115 ENSG00000227288.3 RP5-837I24.1 6.65 2.36e-10 0.000838 0.54 0.41 Endometriosis; chr15:74578122 chr1:81501794~81503468:+ CESC trans rs74781061 0.858 rs4887162 ENSG00000227288.3 RP5-837I24.1 6.65 2.36e-10 0.000838 0.54 0.41 Endometriosis; chr15:74580159 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs4887163 ENSG00000227288.3 RP5-837I24.1 6.65 2.36e-10 0.000838 0.54 0.41 Endometriosis; chr15:74580405 chr1:81501794~81503468:+ CESC trans rs1707322 1 rs1707337 ENSG00000255397.1 AC022182.2 6.64 2.41e-10 0.000858 0.52 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46043097 chr8:60937705~60939871:- CESC trans rs1707322 1 rs1768807 ENSG00000255397.1 AC022182.2 6.64 2.41e-10 0.000858 0.52 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46044898 chr8:60937705~60939871:- CESC trans rs1707322 0.928 rs6681068 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45932710 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211228 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45934168 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs11211229 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45934845 chr8:60937705~60939871:- CESC trans rs1707322 1 rs9803784 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45936235 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs12022335 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45937060 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10890375 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940909 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10890377 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45940922 chr8:60937705~60939871:- CESC trans rs1707322 1 rs6671754 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45968318 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs6666763 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45970779 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4489497 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45973026 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211235 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45974703 chr8:60937705~60939871:- CESC trans rs1707322 0.893 rs9919275 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45975688 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211236 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45978095 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4660328 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45979159 chr8:60937705~60939871:- CESC trans rs1707322 0.928 rs61785614 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45980375 chr8:60937705~60939871:- CESC trans rs1707322 1 rs9793167 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45981128 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211237 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45981657 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs11211238 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45983743 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4460583 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45984246 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs4459051 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45985531 chr8:60937705~60939871:- CESC trans rs1707322 1 rs11211239 ENSG00000255397.1 AC022182.2 -6.64 2.42e-10 0.000858 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45986275 chr8:60937705~60939871:- CESC trans rs9876781 1 rs9311423 ENSG00000235912.1 RP1-159A19.3 -6.64 2.43e-10 0.000862 -0.38 -0.41 Longevity; chr3:48378818 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs7634377 ENSG00000235912.1 RP1-159A19.3 -6.64 2.43e-10 0.000862 -0.38 -0.41 Longevity; chr3:48379768 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs6442117 ENSG00000235912.1 RP1-159A19.3 6.64 2.43e-10 0.000862 0.38 0.41 Longevity; chr3:48378407 chr1:27649419~27649610:+ CESC trans rs1707322 0.963 rs34907901 ENSG00000255397.1 AC022182.2 -6.64 2.44e-10 0.000867 -0.53 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45939542 chr8:60937705~60939871:- CESC trans rs10819083 0.861 rs2058850 ENSG00000203588.3 IGBP1-AS1 -6.64 2.47e-10 0.000874 -0.36 -0.41 Squamous cell lung carcinoma; chr9:125969539 chrX:70163842~70165206:- CESC trans rs12709013 0.792 rs1646270 ENSG00000233719.3 GOT2P3 6.64 2.51e-10 0.000888 0.46 0.41 Blood metabolite ratios; chr16:58745823 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs12325510 ENSG00000233719.3 GOT2P3 6.64 2.51e-10 0.00089 0.46 0.41 Blood metabolite ratios; chr16:58749707 chr12:9641802~9643007:+ CESC trans rs1707322 1 rs785480 ENSG00000255397.1 AC022182.2 -6.64 2.52e-10 0.00089 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46026492 chr8:60937705~60939871:- CESC trans rs877636 0.692 rs11171739 ENSG00000243538.1 CTB-55B8.1 6.63 2.54e-10 0.000898 0.4 0.41 Cognitive function; chr12:56076841 chr5:16902294~16902641:- CESC trans rs916888 0.647 rs199523 ENSG00000214425.5 LRRC37A4P 6.63 2.54e-10 0.000901 0.44 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45506741~45550335:- CESC trans rs1355223 0.506 rs7130678 ENSG00000225531.1 RP11-196I18.3 6.63 2.59e-10 0.000914 0.5 0.41 Systemic lupus erythematosus and Systemic sclerosis; chr11:34847634 chr9:107116829~107117557:+ CESC trans rs11638815 0.626 rs1367841 ENSG00000235370.6 DNM1P51 6.63 2.6e-10 0.000919 0.54 0.41 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82641874 chr15:84398316~84411701:- CESC trans rs3806843 0.735 rs702394 ENSG00000231043.3 AC007238.1 6.63 2.66e-10 0.000938 0.46 0.41 Depressive symptoms (multi-trait analysis); chr5:140707201 chr2:58460292~58462032:- CESC trans rs1707322 1 rs785510 ENSG00000255397.1 AC022182.2 6.62 2.73e-10 0.000965 0.54 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46062946 chr8:60937705~60939871:- CESC trans rs9611565 0.506 rs7364221 ENSG00000268568.1 AC007228.9 -6.62 2.76e-10 0.000972 -0.56 -0.41 Vitiligo; chr22:41254186 chr19:56672574~56673901:- CESC trans rs3806843 0.735 rs6849 ENSG00000231043.3 AC007238.1 6.61 2.86e-10 0.00101 0.46 0.41 Depressive symptoms (multi-trait analysis); chr5:140706606 chr2:58460292~58462032:- CESC trans rs13190036 0.551 rs28932178 ENSG00000226986.4 RP11-543B16.2 -6.61 2.98e-10 0.00105 -0.5 -0.41 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210575 chr1:211207239~211207897:+ CESC trans rs3806843 0.735 rs809635 ENSG00000231043.3 AC007238.1 6.61 2.99e-10 0.00105 0.46 0.41 Depressive symptoms (multi-trait analysis); chr5:140702206 chr2:58460292~58462032:- CESC trans rs3806843 0.648 rs2530233 ENSG00000231043.3 AC007238.1 6.61 2.99e-10 0.00105 0.46 0.41 Depressive symptoms (multi-trait analysis); chr5:140703291 chr2:58460292~58462032:- CESC trans rs877636 0.692 rs2271194 ENSG00000212994.5 RPS26P6 -6.6 3.02e-10 0.00106 -0.47 -0.41 Cognitive function; chr12:56083910 chr8:100895771~100896118:+ CESC trans rs11098499 0.874 rs17839089 ENSG00000275858.1 RP11-291L22.8 6.6 3.04e-10 0.00107 0.46 0.41 Corneal astigmatism; chr4:119189914 chr10:38450738~38451069:- CESC trans rs11098499 0.874 rs6826823 ENSG00000275858.1 RP11-291L22.8 6.6 3.04e-10 0.00107 0.46 0.41 Corneal astigmatism; chr4:119190943 chr10:38450738~38451069:- CESC trans rs4240897 1 rs4240897 ENSG00000261819.1 RP11-680G24.4 -6.6 3.08e-10 0.00108 -0.48 -0.41 Tuberculosis; chr1:11982698 chr16:14988259~14990160:- CESC trans rs10819083 0.861 rs10760405 ENSG00000203588.3 IGBP1-AS1 -6.6 3.09e-10 0.00108 -0.36 -0.41 Squamous cell lung carcinoma; chr9:125949176 chrX:70163842~70165206:- CESC trans rs9876781 1 rs6810060 ENSG00000235912.1 RP1-159A19.3 -6.6 3.1e-10 0.00109 -0.38 -0.41 Longevity; chr3:48393284 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs6770470 ENSG00000235912.1 RP1-159A19.3 -6.6 3.1e-10 0.00109 -0.38 -0.41 Longevity; chr3:48393659 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs6784322 ENSG00000235912.1 RP1-159A19.3 -6.6 3.1e-10 0.00109 -0.38 -0.41 Longevity; chr3:48380745 chr1:27649419~27649610:+ CESC trans rs9611565 0.921 rs5758297 ENSG00000268568.1 AC007228.9 -6.59 3.21e-10 0.00113 -0.49 -0.41 Vitiligo; chr22:41324693 chr19:56672574~56673901:- CESC trans rs9611565 0.921 rs5751077 ENSG00000268568.1 AC007228.9 -6.59 3.21e-10 0.00113 -0.49 -0.41 Vitiligo; chr22:41324724 chr19:56672574~56673901:- CESC trans rs8067354 0.609 rs1292066 ENSG00000187870.7 RNFT1P3 6.59 3.23e-10 0.00113 0.55 0.41 Hemoglobin concentration; chr17:59854953 chr17:20743333~20754501:- CESC trans rs9898641 1 rs9898641 ENSG00000187870.7 RNFT1P3 6.59 3.34e-10 0.00117 0.49 0.41 Interleukin-1-beta levels; chr17:59493672 chr17:20743333~20754501:- CESC trans rs616147 0.671 rs674192 ENSG00000183298.5 RP11-556K13.1 -6.58 3.37e-10 0.00118 -0.5 -0.41 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39458653 chr1:101786340~101787219:- CESC trans rs1707322 1 rs11211200 ENSG00000255397.1 AC022182.2 -6.58 3.38e-10 0.00118 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45822680 chr8:60937705~60939871:- CESC trans rs11638815 0.581 rs783535 ENSG00000235370.6 DNM1P51 -6.58 3.4e-10 0.00119 -0.53 -0.41 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82581676 chr15:84398316~84411701:- CESC trans rs74781061 0.929 rs8043082 ENSG00000227288.3 RP5-837I24.1 6.58 3.41e-10 0.00119 0.53 0.41 Endometriosis; chr15:74564896 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs8026923 ENSG00000227288.3 RP5-837I24.1 6.58 3.41e-10 0.00119 0.53 0.41 Endometriosis; chr15:74565721 chr1:81501794~81503468:+ CESC trans rs11098499 0.566 rs17051356 ENSG00000275858.1 RP11-291L22.8 6.58 3.46e-10 0.00121 0.46 0.41 Corneal astigmatism; chr4:119664153 chr10:38450738~38451069:- CESC trans rs1707322 0.963 rs11211202 ENSG00000255397.1 AC022182.2 -6.57 3.64e-10 0.00127 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45826710 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4390216 ENSG00000255397.1 AC022182.2 -6.57 3.65e-10 0.00127 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45800784 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs10437063 ENSG00000255397.1 AC022182.2 -6.57 3.65e-10 0.00127 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45807994 chr8:60937705~60939871:- CESC trans rs1707322 1 rs6676982 ENSG00000255397.1 AC022182.2 -6.57 3.65e-10 0.00127 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45809729 chr8:60937705~60939871:- CESC trans rs1707322 0.927 rs11211194 ENSG00000255397.1 AC022182.2 -6.57 3.65e-10 0.00127 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45816412 chr8:60937705~60939871:- CESC trans rs2665103 0.715 rs7403041 ENSG00000235370.6 DNM1P51 6.57 3.66e-10 0.00127 0.51 0.41 Intelligence (multi-trait analysis); chr15:82287841 chr15:84398316~84411701:- CESC trans rs1707322 1 rs10890350 ENSG00000255397.1 AC022182.2 -6.57 3.69e-10 0.00128 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45796706 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4073847 ENSG00000255397.1 AC022182.2 6.57 3.71e-10 0.00129 0.52 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45997340 chr8:60937705~60939871:- CESC trans rs3806843 0.735 rs801167 ENSG00000231043.3 AC007238.1 -6.57 3.72e-10 0.00129 -0.46 -0.41 Depressive symptoms (multi-trait analysis); chr5:140701838 chr2:58460292~58462032:- CESC trans rs3812762 0.871 rs11042068 ENSG00000266891.1 RP11-692N5.2 6.56 3.85e-10 0.00134 0.51 0.41 Hypospadias; chr11:8794052 chr18:9734882~9735602:- CESC trans rs12709013 1 rs12599931 ENSG00000230849.2 GOT2P2 6.56 3.95e-10 0.00137 0.47 0.41 Blood metabolite ratios; chr16:58792627 chr1:173141100~173142350:- CESC trans rs11638815 0.626 rs1313492 ENSG00000235370.6 DNM1P51 -6.55 4.02e-10 0.00139 -0.54 -0.41 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82604206 chr15:84398316~84411701:- CESC trans rs7554511 0.893 rs11586763 ENSG00000244144.1 RP11-757F18.3 -6.55 4.02e-10 0.00139 -0.51 -0.41 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201020316 chr3:112185480~112185998:- CESC trans rs1707322 1 rs11211190 ENSG00000255397.1 AC022182.2 -6.55 4.06e-10 0.0014 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45800583 chr8:60937705~60939871:- CESC trans rs1707322 1 rs6429580 ENSG00000255397.1 AC022182.2 -6.55 4.06e-10 0.0014 -0.52 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45809976 chr8:60937705~60939871:- CESC trans rs74781061 0.929 rs2068982 ENSG00000227288.3 RP5-837I24.1 -6.55 4.1e-10 0.00142 -0.52 -0.41 Endometriosis; chr15:74623547 chr1:81501794~81503468:+ CESC trans rs12709013 0.792 rs12598527 ENSG00000233719.3 GOT2P3 6.55 4.16e-10 0.00144 0.44 0.41 Blood metabolite ratios; chr16:58772987 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs12600201 ENSG00000233719.3 GOT2P3 6.55 4.16e-10 0.00144 0.44 0.41 Blood metabolite ratios; chr16:58773132 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs12600206 ENSG00000233719.3 GOT2P3 6.55 4.16e-10 0.00144 0.44 0.41 Blood metabolite ratios; chr16:58773169 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs11076263 ENSG00000233719.3 GOT2P3 6.55 4.16e-10 0.00144 0.44 0.41 Blood metabolite ratios; chr16:58773295 chr12:9641802~9643007:+ CESC trans rs1707322 1 rs10890378 ENSG00000255397.1 AC022182.2 6.54 4.24e-10 0.00146 0.51 0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45944985 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs10789484 ENSG00000255397.1 AC022182.2 -6.54 4.24e-10 0.00146 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45941306 chr8:60937705~60939871:- CESC trans rs1707322 1 rs7527079 ENSG00000255397.1 AC022182.2 -6.54 4.24e-10 0.00146 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45947778 chr8:60937705~60939871:- CESC trans rs1707322 1 rs34446427 ENSG00000255397.1 AC022182.2 -6.54 4.24e-10 0.00146 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45951983 chr8:60937705~60939871:- CESC trans rs1707322 0.963 rs4660900 ENSG00000255397.1 AC022182.2 -6.54 4.24e-10 0.00146 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45953933 chr8:60937705~60939871:- CESC trans rs1707322 1 rs4454479 ENSG00000255397.1 AC022182.2 -6.54 4.24e-10 0.00146 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45957883 chr8:60937705~60939871:- CESC trans rs1707322 1 rs7517560 ENSG00000255397.1 AC022182.2 -6.54 4.24e-10 0.00146 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45960271 chr8:60937705~60939871:- CESC trans rs1707322 1 rs12077546 ENSG00000255397.1 AC022182.2 -6.54 4.24e-10 0.00146 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45966134 chr8:60937705~60939871:- CESC trans rs1707322 1 rs12124291 ENSG00000255397.1 AC022182.2 -6.54 4.24e-10 0.00146 -0.51 -0.41 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45966460 chr8:60937705~60939871:- CESC trans rs77688320 0.535 rs7561048 ENSG00000235105.1 RP11-329A14.1 6.54 4.29e-10 0.00148 0.43 0.41 Breast cancer; chr2:201388316 chr1:48435967~48437223:+ CESC trans rs10819083 0.861 rs7026855 ENSG00000203588.3 IGBP1-AS1 -6.54 4.3e-10 0.00148 -0.36 -0.41 Squamous cell lung carcinoma; chr9:125962552 chrX:70163842~70165206:- CESC trans rs10940346 0.601 rs13175165 ENSG00000231752.4 EMBP1 -6.54 4.34e-10 0.0015 -0.5 -0.4 Schizophrenia; chr5:50151463 chr1:121519112~121571892:+ CESC trans rs11638815 0.581 rs2870965 ENSG00000235370.6 DNM1P51 -6.53 4.44e-10 0.00153 -0.53 -0.4 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82632278 chr15:84398316~84411701:- CESC trans rs9425766 0.962 rs6663875 ENSG00000213331.4 RP11-713C19.2 6.53 4.53e-10 0.00156 0.47 0.4 Life satisfaction; chr1:173894071 chr4:187970273~187971284:+ CESC trans rs877636 0.692 rs2271194 ENSG00000234354.3 RPS26P47 -6.53 4.61e-10 0.00159 -0.44 -0.4 Cognitive function; chr12:56083910 chr13:100539901~100540248:- CESC trans rs916888 0.647 rs199524 ENSG00000214425.5 LRRC37A4P 6.53 4.62e-10 0.00159 0.44 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45506741~45550335:- CESC trans rs959695 1 rs2442756 ENSG00000260318.1 COX6CP1 6.53 4.63e-10 0.00159 0.54 0.4 Hippocampal atrophy; chr8:99816910 chr16:11903923~11904137:- CESC trans rs7113874 0.592 rs10500703 ENSG00000266891.1 RP11-692N5.2 6.53 4.63e-10 0.00159 0.57 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8412317 chr18:9734882~9735602:- CESC trans rs877636 1 rs2292239 ENSG00000196933.5 RPS26P11 6.53 4.68e-10 0.00161 0.47 0.4 Cognitive function; chr12:56088396 chrX:72044545~72044892:+ CESC trans rs11638815 0.603 rs783520 ENSG00000235370.6 DNM1P51 -6.53 4.68e-10 0.00161 -0.53 -0.4 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82610755 chr15:84398316~84411701:- CESC trans rs867371 0.826 rs2047678 ENSG00000235370.6 DNM1P51 -6.52 4.69e-10 0.00161 -0.53 -0.4 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82205857 chr15:84398316~84411701:- CESC trans rs9611565 0.877 rs3817999 ENSG00000268568.1 AC007228.9 6.52 4.78e-10 0.00164 0.5 0.4 Vitiligo; chr22:41351713 chr19:56672574~56673901:- CESC trans rs7113874 0.659 rs1867810 ENSG00000266891.1 RP11-692N5.2 6.52 4.79e-10 0.00164 0.51 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8483981 chr18:9734882~9735602:- CESC trans rs77688320 0.553 rs3795966 ENSG00000235105.1 RP11-329A14.1 6.52 4.8e-10 0.00165 0.43 0.4 Breast cancer; chr2:201380521 chr1:48435967~48437223:+ CESC trans rs77688320 0.517 rs12623282 ENSG00000235105.1 RP11-329A14.1 6.52 4.8e-10 0.00165 0.43 0.4 Breast cancer; chr2:201382734 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs7579853 ENSG00000235105.1 RP11-329A14.1 6.52 4.8e-10 0.00165 0.43 0.4 Breast cancer; chr2:201384256 chr1:48435967~48437223:+ CESC trans rs74781061 0.929 rs4886601 ENSG00000227288.3 RP5-837I24.1 6.52 4.88e-10 0.00167 0.53 0.4 Endometriosis; chr15:74591510 chr1:81501794~81503468:+ CESC trans rs7554547 0.667 rs12567187 ENSG00000261819.1 RP11-680G24.4 6.52 4.92e-10 0.00168 0.49 0.4 Nonsyndromic cleft lip with cleft palate; chr1:11896095 chr16:14988259~14990160:- CESC trans rs11638815 0.626 rs4779041 ENSG00000235370.6 DNM1P51 6.52 4.95e-10 0.00169 0.53 0.4 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82668307 chr15:84398316~84411701:- CESC trans rs74781061 0.929 rs8025915 ENSG00000227288.3 RP5-837I24.1 6.51 4.96e-10 0.0017 0.53 0.4 Endometriosis; chr15:74578188 chr1:81501794~81503468:+ CESC trans rs1326895 1 rs1326895 ENSG00000280389.1 RP11-512M8.11 6.51 4.96e-10 0.0017 0.73 0.4 Pursuit maintenance gain; chr9:110915816 chr12:122255119~122260274:- CESC trans rs12709013 0.804 rs8051459 ENSG00000230849.2 GOT2P2 6.51 5.04e-10 0.00172 0.48 0.4 Blood metabolite ratios; chr16:58783436 chr1:173141100~173142350:- CESC trans rs7113874 0.612 rs11517715 ENSG00000266891.1 RP11-692N5.2 6.51 5.05e-10 0.00173 0.51 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8490341 chr18:9734882~9735602:- CESC trans rs877636 1 rs705696 ENSG00000243403.1 RP11-330L19.1 6.51 5.08e-10 0.00174 0.41 0.4 Cognitive function; chr12:56086864 chr15:64592979~64593326:+ CESC trans rs1355223 0.525 rs10836316 ENSG00000225531.1 RP11-196I18.3 6.51 5.13e-10 0.00175 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34852748 chr9:107116829~107117557:+ CESC trans rs1355223 0.545 rs7123029 ENSG00000225531.1 RP11-196I18.3 6.51 5.13e-10 0.00175 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34853268 chr9:107116829~107117557:+ CESC trans rs1355223 0.545 rs7111695 ENSG00000225531.1 RP11-196I18.3 6.51 5.13e-10 0.00175 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34853359 chr9:107116829~107117557:+ CESC trans rs1355223 0.507 rs11032903 ENSG00000225531.1 RP11-196I18.3 6.51 5.13e-10 0.00175 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34854629 chr9:107116829~107117557:+ CESC trans rs1355223 0.545 rs12278318 ENSG00000225531.1 RP11-196I18.3 6.51 5.13e-10 0.00175 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34854960 chr9:107116829~107117557:+ CESC trans rs7312770 0.612 rs1873914 ENSG00000196933.5 RPS26P11 6.51 5.13e-10 0.00175 0.44 0.4 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chrX:72044545~72044892:+ CESC trans rs13190036 1 rs13175695 ENSG00000217325.2 PRELID1P1 6.51 5.18e-10 0.00177 0.61 0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177272810 chr6:126643488~126644390:+ CESC trans rs7113874 0.559 rs34378489 ENSG00000266891.1 RP11-692N5.2 6.51 5.23e-10 0.00179 0.57 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8407803 chr18:9734882~9735602:- CESC trans rs8175379 0.542 rs12657764 ENSG00000231752.4 EMBP1 -6.51 5.24e-10 0.00179 -0.49 -0.4 Interleukin-7 levels; chr5:46281165 chr1:121519112~121571892:+ CESC trans rs10940346 0.623 rs7736990 ENSG00000231752.4 EMBP1 -6.5 5.25e-10 0.00179 -0.48 -0.4 Schizophrenia; chr5:50300008 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10079897 ENSG00000231752.4 EMBP1 -6.5 5.25e-10 0.00179 -0.48 -0.4 Schizophrenia; chr5:50300032 chr1:121519112~121571892:+ CESC trans rs877636 1 rs4759229 ENSG00000234513.1 AC073072.7 -6.5 5.31e-10 0.00181 -0.44 -0.4 Cognitive function; chr12:56080696 chr7:22773646~22773993:- CESC trans rs1355223 0.525 rs7129533 ENSG00000225531.1 RP11-196I18.3 6.5 5.34e-10 0.00182 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34850745 chr9:107116829~107117557:+ CESC trans rs1355223 0.525 rs55796371 ENSG00000225531.1 RP11-196I18.3 6.5 5.34e-10 0.00182 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34851222 chr9:107116829~107117557:+ CESC trans rs1355223 0.525 rs12280958 ENSG00000225531.1 RP11-196I18.3 6.5 5.34e-10 0.00182 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34851252 chr9:107116829~107117557:+ CESC trans rs7113874 0.613 rs4326784 ENSG00000266891.1 RP11-692N5.2 6.5 5.36e-10 0.00183 0.51 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8511602 chr18:9734882~9735602:- CESC trans rs7113874 0.545 rs2084187 ENSG00000266891.1 RP11-692N5.2 6.5 5.36e-10 0.00183 0.51 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8515394 chr18:9734882~9735602:- CESC trans rs7113874 0.613 rs2100067 ENSG00000266891.1 RP11-692N5.2 6.5 5.36e-10 0.00183 0.51 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8515503 chr18:9734882~9735602:- CESC trans rs7113874 0.578 rs7924477 ENSG00000266891.1 RP11-692N5.2 6.5 5.36e-10 0.00183 0.51 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8516700 chr18:9734882~9735602:- CESC trans rs1707322 1 rs946527 ENSG00000255397.1 AC022182.2 -6.5 5.44e-10 0.00185 -0.51 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46020298 chr8:60937705~60939871:- CESC trans rs9876781 1 rs4858817 ENSG00000235912.1 RP1-159A19.3 6.5 5.47e-10 0.00186 0.38 0.4 Longevity; chr3:48375266 chr1:27649419~27649610:+ CESC trans rs10819083 0.861 rs7871599 ENSG00000203588.3 IGBP1-AS1 -6.5 5.49e-10 0.00187 -0.36 -0.4 Squamous cell lung carcinoma; chr9:125959549 chrX:70163842~70165206:- CESC trans rs1707322 0.89 rs2297883 ENSG00000255397.1 AC022182.2 6.49 5.57e-10 0.00189 0.51 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46045815 chr8:60937705~60939871:- CESC trans rs1707322 1 rs1707338 ENSG00000255397.1 AC022182.2 6.49 5.57e-10 0.00189 0.51 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46046309 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs1707339 ENSG00000255397.1 AC022182.2 6.49 5.57e-10 0.00189 0.51 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46047507 chr8:60937705~60939871:- CESC trans rs1707322 1 rs1768818 ENSG00000255397.1 AC022182.2 6.49 5.57e-10 0.00189 0.51 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46048614 chr8:60937705~60939871:- CESC trans rs1707322 1 rs1768817 ENSG00000255397.1 AC022182.2 6.49 5.57e-10 0.00189 0.51 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46048862 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785470 ENSG00000255397.1 AC022182.2 6.49 5.57e-10 0.00189 0.51 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46053950 chr8:60937705~60939871:- CESC trans rs4276421 0.509 rs4504391 ENSG00000231752.4 EMBP1 6.49 5.62e-10 0.00191 0.5 0.4 P wave duration; chr5:46035678 chr1:121519112~121571892:+ CESC trans rs9876781 1 rs898225 ENSG00000235912.1 RP1-159A19.3 6.49 5.64e-10 0.00191 0.38 0.4 Longevity; chr3:48371689 chr1:27649419~27649610:+ CESC trans rs13190036 0.901 rs6898107 ENSG00000217325.2 PRELID1P1 6.49 5.73e-10 0.00194 0.59 0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177252694 chr6:126643488~126644390:+ CESC trans rs1707322 0.964 rs7546237 ENSG00000255397.1 AC022182.2 -6.49 5.74e-10 0.00195 -0.51 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45819938 chr8:60937705~60939871:- CESC trans rs2275565 0.748 rs4659736 ENSG00000271576.1 RP11-486G15.2 6.49 5.78e-10 0.00196 0.61 0.4 Homocysteine levels; chr1:236871484 chr1:84076331~84077931:- CESC trans rs877636 1 rs705696 ENSG00000225071.1 GS1-184P14.2 6.49 5.83e-10 0.00197 0.42 0.4 Cognitive function; chr12:56086864 chrX:24429573~24429920:- CESC trans rs17137734 1 rs1551419 ENSG00000278472.1 RP11-74D7.3 -6.48 5.9e-10 0.002 -0.82 -0.4 Corneal curvature; chr15:27277213 chr15:33972059~33972515:- CESC trans rs74781061 0.929 rs8038730 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74501003 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs7178219 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74502552 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs6495109 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74504720 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs8037436 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74506167 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs4887155 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74512119 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs11072490 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74515169 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs1821847 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74516873 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs7173006 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74517792 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs78796673 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74520186 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs4261483 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74520993 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs8041030 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74525726 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs8028163 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74530360 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs11072492 ENSG00000227288.3 RP5-837I24.1 6.48 5.93e-10 0.002 0.52 0.4 Endometriosis; chr15:74531782 chr1:81501794~81503468:+ CESC trans rs1355223 0.545 rs7106831 ENSG00000225531.1 RP11-196I18.3 6.48 6.05e-10 0.00204 0.5 0.4 Systemic lupus erythematosus and Systemic sclerosis; chr11:34857995 chr9:107116829~107117557:+ CESC trans rs74781061 0.929 rs8043032 ENSG00000227288.3 RP5-837I24.1 6.48 6.16e-10 0.00208 0.52 0.4 Endometriosis; chr15:74543975 chr1:81501794~81503468:+ CESC trans rs1707322 1 rs785507 ENSG00000255397.1 AC022182.2 6.47 6.28e-10 0.00212 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46075886 chr8:60937705~60939871:- CESC trans rs12709013 0.792 rs62064901 ENSG00000233719.3 GOT2P3 6.47 6.29e-10 0.00212 0.44 0.4 Blood metabolite ratios; chr16:58776758 chr12:9641802~9643007:+ CESC trans rs2950393 0.804 rs11171951 ENSG00000257210.1 NACAP3 6.47 6.34e-10 0.00214 0.44 0.4 Platelet distribution width; chr12:56718853 chr12:93124063~93124543:- CESC trans rs10028773 0.632 rs34481394 ENSG00000275858.1 RP11-291L22.8 6.47 6.36e-10 0.00214 0.46 0.4 Educational attainment; chr4:119327219 chr10:38450738~38451069:- CESC trans rs10028773 0.666 rs35231872 ENSG00000275858.1 RP11-291L22.8 6.47 6.36e-10 0.00214 0.46 0.4 Educational attainment; chr4:119327221 chr10:38450738~38451069:- CESC trans rs10028773 0.7 rs35653026 ENSG00000275858.1 RP11-291L22.8 6.47 6.36e-10 0.00214 0.46 0.4 Educational attainment; chr4:119327223 chr10:38450738~38451069:- CESC trans rs7554511 0.823 rs67602696 ENSG00000244144.1 RP11-757F18.3 -6.47 6.38e-10 0.00215 -0.52 -0.4 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201043809 chr3:112185480~112185998:- CESC trans rs11098499 0.874 rs13123591 ENSG00000275858.1 RP11-291L22.8 6.47 6.42e-10 0.00216 0.46 0.4 Corneal astigmatism; chr4:119184835 chr10:38450738~38451069:- CESC trans rs11098499 0.874 rs7661020 ENSG00000275858.1 RP11-291L22.8 6.47 6.42e-10 0.00216 0.46 0.4 Corneal astigmatism; chr4:119185827 chr10:38450738~38451069:- CESC trans rs11098499 0.874 rs9995277 ENSG00000275858.1 RP11-291L22.8 6.47 6.42e-10 0.00216 0.46 0.4 Corneal astigmatism; chr4:119187448 chr10:38450738~38451069:- CESC trans rs13190036 0.901 rs28563911 ENSG00000228305.2 AC016734.2 6.47 6.47e-10 0.00218 0.54 0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177287942 chr2:63622178~63622831:- CESC trans rs10940346 0.601 rs2353221 ENSG00000231752.4 EMBP1 -6.47 6.49e-10 0.00218 -0.48 -0.4 Schizophrenia; chr5:50299085 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7724645 ENSG00000231752.4 EMBP1 -6.47 6.49e-10 0.00218 -0.48 -0.4 Schizophrenia; chr5:50299846 chr1:121519112~121571892:+ CESC trans rs4276421 0.509 rs10042628 ENSG00000231752.4 EMBP1 6.47 6.49e-10 0.00218 0.52 0.4 P wave duration; chr5:46004627 chr1:121519112~121571892:+ CESC trans rs10819083 0.861 rs1999200 ENSG00000203588.3 IGBP1-AS1 -6.47 6.54e-10 0.0022 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125948750 chrX:70163842~70165206:- CESC trans rs877636 0.692 rs2271194 ENSG00000227887.1 RPS26P13 -6.46 6.64e-10 0.00223 -0.42 -0.4 Cognitive function; chr12:56083910 chr1:208697369~208697698:- CESC trans rs7113874 0.545 rs72855149 ENSG00000266891.1 RP11-692N5.2 6.46 6.68e-10 0.00225 0.55 0.4 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8586160 chr18:9734882~9735602:- CESC trans rs10940346 0.562 rs6449961 ENSG00000231752.4 EMBP1 6.46 6.7e-10 0.00225 0.48 0.4 Schizophrenia; chr5:50320867 chr1:121519112~121571892:+ CESC trans rs10819083 0.861 rs7862061 ENSG00000203588.3 IGBP1-AS1 -6.46 6.72e-10 0.00226 -0.36 -0.4 Squamous cell lung carcinoma; chr9:125969651 chrX:70163842~70165206:- CESC trans rs74781061 0.929 rs8041807 ENSG00000227288.3 RP5-837I24.1 6.46 6.73e-10 0.00226 0.52 0.4 Endometriosis; chr15:74534590 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs12594447 ENSG00000227288.3 RP5-837I24.1 6.46 6.73e-10 0.00226 0.52 0.4 Endometriosis; chr15:74536392 chr1:81501794~81503468:+ CESC trans rs74781061 0.929 rs1821848 ENSG00000227288.3 RP5-837I24.1 6.46 6.73e-10 0.00226 0.52 0.4 Endometriosis; chr15:74541443 chr1:81501794~81503468:+ CESC trans rs74781061 0.858 rs4278699 ENSG00000227288.3 RP5-837I24.1 6.46 6.75e-10 0.00227 0.52 0.4 Endometriosis; chr15:74500057 chr1:81501794~81503468:+ CESC trans rs77688320 0.535 rs10804115 ENSG00000235105.1 RP11-329A14.1 6.46 6.79e-10 0.00228 0.42 0.4 Breast cancer; chr2:201415510 chr1:48435967~48437223:+ CESC trans rs13190036 0.901 rs28715668 ENSG00000228305.2 AC016734.2 6.46 6.85e-10 0.0023 0.55 0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177272267 chr2:63622178~63622831:- CESC trans rs74781061 0.929 rs7177407 ENSG00000227288.3 RP5-837I24.1 6.45 6.95e-10 0.00233 0.52 0.4 Endometriosis; chr15:74551444 chr1:81501794~81503468:+ CESC trans rs877636 0.702 rs773109 ENSG00000234513.1 AC073072.7 6.45 7.01e-10 0.00235 0.44 0.4 Cognitive function; chr12:55980911 chr7:22773646~22773993:- CESC trans rs7312770 0.637 rs705700 ENSG00000212994.5 RPS26P6 6.45 7.07e-10 0.00237 0.47 0.4 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr8:100895771~100896118:+ CESC trans rs3812762 0.912 rs4929936 ENSG00000266891.1 RP11-692N5.2 6.45 7.09e-10 0.00238 0.48 0.4 Hypospadias; chr11:8771075 chr18:9734882~9735602:- CESC trans rs17672135 0.614 rs61829191 ENSG00000280206.1 CTB-193M12.5 6.45 7.12e-10 0.00238 1.02 0.4 Coronary heart disease; chr1:240270924 chr16:15701237~15702118:+ CESC trans rs10819083 0.861 rs1105727 ENSG00000203588.3 IGBP1-AS1 -6.45 7.12e-10 0.00239 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125963264 chrX:70163842~70165206:- CESC trans rs10486715 1 rs10486715 ENSG00000274487.1 CH17-431G21.1 -6.45 7.15e-10 0.00239 -0.69 -0.4 Quantitative traits; chr7:41439010 chr17:38195740~38257152:- CESC trans rs4276421 0.593 rs7448901 ENSG00000231752.4 EMBP1 6.45 7.19e-10 0.00241 0.49 0.4 P wave duration; chr5:45941482 chr1:121519112~121571892:+ CESC trans rs4276421 0.615 rs7445658 ENSG00000231752.4 EMBP1 6.45 7.19e-10 0.00241 0.49 0.4 P wave duration; chr5:45941513 chr1:121519112~121571892:+ CESC trans rs4276421 0.593 rs10076636 ENSG00000231752.4 EMBP1 6.45 7.19e-10 0.00241 0.49 0.4 P wave duration; chr5:45942052 chr1:121519112~121571892:+ CESC trans rs9876781 1 rs1109227 ENSG00000225528.1 RP3-370M22.8 -6.45 7.25e-10 0.00242 -0.39 -0.4 Longevity; chr3:48437797 chr22:39960397~39964683:+ CESC trans rs9876781 0.967 rs9876891 ENSG00000225528.1 RP3-370M22.8 -6.45 7.25e-10 0.00242 -0.39 -0.4 Longevity; chr3:48440024 chr22:39960397~39964683:+ CESC trans rs9876781 1 rs3774808 ENSG00000225528.1 RP3-370M22.8 -6.45 7.25e-10 0.00242 -0.39 -0.4 Longevity; chr3:48440237 chr22:39960397~39964683:+ CESC trans rs3806843 0.705 rs2530230 ENSG00000231043.3 AC007238.1 6.45 7.28e-10 0.00243 0.44 0.4 Depressive symptoms (multi-trait analysis); chr5:140708546 chr2:58460292~58462032:- CESC trans rs877636 1 rs705696 ENSG00000234513.1 AC073072.7 6.45 7.29e-10 0.00244 0.45 0.4 Cognitive function; chr12:56086864 chr7:22773646~22773993:- CESC trans rs10819083 0.861 rs2111359 ENSG00000203588.3 IGBP1-AS1 -6.44 7.37e-10 0.00246 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125954113 chrX:70163842~70165206:- CESC trans rs7647973 0.516 rs4308307 ENSG00000197582.5 GPX1P1 6.44 7.42e-10 0.00248 0.51 0.4 Menarche (age at onset); chr3:49155783 chrX:13378735~13379340:- CESC trans rs7312770 1 rs7312770 ENSG00000196656.7 AC004057.1 -6.44 7.47e-10 0.00249 -0.4 -0.4 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr4:113214046~113217170:- CESC trans rs10242455 0.867 rs3735453 ENSG00000228834.1 RP11-249L21.4 -6.44 7.48e-10 0.0025 -0.64 -0.4 Blood metabolite levels; chr7:99631812 chr6:108907615~108907873:- CESC trans rs9611565 1 rs1109151 ENSG00000268568.1 AC007228.9 -6.44 7.53e-10 0.00251 -0.49 -0.4 Vitiligo; chr22:41356940 chr19:56672574~56673901:- CESC trans rs1568889 1 rs12797155 ENSG00000174912.7 METTL15P1 6.44 7.66e-10 0.00256 0.49 0.4 Bipolar disorder; chr11:28269319 chr3:156713884~156714928:- CESC trans rs77688320 0.553 rs2080320 ENSG00000235105.1 RP11-329A14.1 6.43 7.87e-10 0.00262 0.46 0.4 Breast cancer; chr2:201514450 chr1:48435967~48437223:+ CESC trans rs74781061 0.932 rs11629749 ENSG00000227288.3 RP5-837I24.1 6.43 7.99e-10 0.00266 0.47 0.4 Endometriosis; chr15:74627252 chr1:81501794~81503468:+ CESC trans rs7312770 0.612 rs1873914 ENSG00000235459.5 RPS26P31 6.43 8.16e-10 0.00272 0.41 0.4 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr7:122681315~122681662:+ CESC trans rs12709013 0.875 rs9924389 ENSG00000230849.2 GOT2P2 6.42 8.17e-10 0.00272 0.46 0.4 Blood metabolite ratios; chr16:58779849 chr1:173141100~173142350:- CESC trans rs10940346 0.537 rs7293378 ENSG00000231752.4 EMBP1 -6.42 8.31e-10 0.00276 -0.49 -0.4 Schizophrenia; chr5:50192402 chr1:121519112~121571892:+ CESC trans rs4276421 0.638 rs6895453 ENSG00000231752.4 EMBP1 6.42 8.43e-10 0.0028 0.49 0.4 P wave duration; chr5:45850134 chr1:121519112~121571892:+ CESC trans rs1707322 1 rs12077974 ENSG00000255397.1 AC022182.2 -6.42 8.43e-10 0.0028 -0.51 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45918469 chr8:60937705~60939871:- CESC trans rs10940346 0.58 rs10940533 ENSG00000231752.4 EMBP1 -6.42 8.44e-10 0.0028 -0.49 -0.4 Schizophrenia; chr5:50146552 chr1:121519112~121571892:+ CESC trans rs10940346 0.541 rs4865914 ENSG00000231752.4 EMBP1 -6.42 8.44e-10 0.0028 -0.49 -0.4 Schizophrenia; chr5:50173322 chr1:121519112~121571892:+ CESC trans rs9425766 0.924 rs5877 ENSG00000213331.4 RP11-713C19.2 6.42 8.49e-10 0.00282 0.48 0.4 Life satisfaction; chr1:173909724 chr4:187970273~187971284:+ CESC trans rs9425766 0.962 rs941989 ENSG00000213331.4 RP11-713C19.2 -6.42 8.58e-10 0.00284 -0.47 -0.4 Life satisfaction; chr1:173912733 chr4:187970273~187971284:+ CESC trans rs1568889 0.877 rs7933326 ENSG00000174912.7 METTL15P1 6.41 8.67e-10 0.00287 0.48 0.4 Bipolar disorder; chr11:28266869 chr3:156713884~156714928:- CESC trans rs10940346 0.584 rs7293449 ENSG00000231752.4 EMBP1 -6.41 8.72e-10 0.00289 -0.48 -0.4 Schizophrenia; chr5:50259959 chr1:121519112~121571892:+ CESC trans rs10940346 0.524 rs1458763 ENSG00000231752.4 EMBP1 -6.41 8.72e-10 0.00289 -0.48 -0.4 Schizophrenia; chr5:50265531 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs1458765 ENSG00000231752.4 EMBP1 -6.41 8.72e-10 0.00289 -0.48 -0.4 Schizophrenia; chr5:50266141 chr1:121519112~121571892:+ CESC trans rs7312770 1 rs7312770 ENSG00000196933.5 RPS26P11 -6.41 8.85e-10 0.00293 -0.43 -0.4 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chrX:72044545~72044892:+ CESC trans rs9611565 0.879 rs2235845 ENSG00000268568.1 AC007228.9 -6.41 8.88e-10 0.00294 -0.49 -0.4 Vitiligo; chr22:41333290 chr19:56672574~56673901:- CESC trans rs3812762 0.912 rs11042058 ENSG00000266891.1 RP11-692N5.2 6.41 8.92e-10 0.00295 0.5 0.4 Hypospadias; chr11:8742268 chr18:9734882~9735602:- CESC trans rs9611565 0.569 rs6002328 ENSG00000268568.1 AC007228.9 -6.41 9.05e-10 0.00299 -0.51 -0.4 Vitiligo; chr22:41314030 chr19:56672574~56673901:- CESC trans rs4276421 0.638 rs4282323 ENSG00000231752.4 EMBP1 6.41 9.07e-10 0.003 0.48 0.4 P wave duration; chr5:45865241 chr1:121519112~121571892:+ CESC trans rs10940346 0.562 rs559096 ENSG00000231752.4 EMBP1 -6.41 9.09e-10 0.003 -0.49 -0.4 Schizophrenia; chr5:50226512 chr1:121519112~121571892:+ CESC trans rs6741148 0.881 rs17021858 ENSG00000224224.1 HAUS1P2 6.4 9.15e-10 0.00302 0.84 0.4 Erectile dysfunction and prostate cancer treatment; chr2:38022202 chrX:18865771~18866554:+ CESC trans rs6132905 0.52 rs2422824 ENSG00000235559.1 NOP56P1 6.4 9.26e-10 0.00305 0.53 0.4 Mumps; chr20:2666724 chr6:28783633~28784004:- CESC trans rs1707322 1 rs1612419 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46081273 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs785516 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46099086 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785517 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46101863 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785484 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46108343 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785490 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46111452 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785493 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46119187 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs785496 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46122334 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785497 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126231 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs785499 ENSG00000255397.1 AC022182.2 6.4 9.27e-10 0.00305 0.53 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126748 chr8:60937705~60939871:- CESC trans rs61041336 0.534 rs2280399 ENSG00000233719.3 GOT2P3 -6.4 9.4e-10 0.00309 -0.64 -0.4 Neuritic plaque; chr16:58677628 chr12:9641802~9643007:+ CESC trans rs10819083 0.861 rs10760406 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125958409 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs7867968 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125959016 chrX:70163842~70165206:- CESC trans rs10819083 0.788 rs7868182 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125959032 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs7857456 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125959279 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs872525 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125961280 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs872524 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125961540 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs2111358 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125962404 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs10987060 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125962667 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs3829098 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125964756 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs7853588 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125967424 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs7853604 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125967451 chrX:70163842~70165206:- CESC trans rs10819083 0.823 rs7868811 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125967467 chrX:70163842~70165206:- CESC trans rs10819083 0.828 rs10739665 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125967698 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs9644951 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125968952 chrX:70163842~70165206:- CESC trans rs10819083 0.788 rs12345427 ENSG00000203588.3 IGBP1-AS1 -6.4 9.42e-10 0.00309 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125970196 chrX:70163842~70165206:- CESC trans rs877636 0.692 rs11171739 ENSG00000242970.2 AC068522.4 6.4 9.51e-10 0.00312 0.43 0.4 Cognitive function; chr12:56076841 chr8:58588420~58588764:- CESC trans rs10940346 0.562 rs4379243 ENSG00000231752.4 EMBP1 -6.4 9.56e-10 0.00314 -0.49 -0.4 Schizophrenia; chr5:50149933 chr1:121519112~121571892:+ CESC trans rs9611565 0.571 rs7364123 ENSG00000268568.1 AC007228.9 -6.4 9.58e-10 0.00314 -0.5 -0.4 Vitiligo; chr22:41820322 chr19:56672574~56673901:- CESC trans rs4455778 0.519 rs34062689 ENSG00000238249.2 HMGN2P17 -6.39 9.65e-10 0.00316 -0.38 -0.4 Lung cancer in never smokers; chr7:48995426 chr1:8893409~8894151:+ CESC trans rs9693444 0.651 rs4073220 ENSG00000278626.1 RP11-467L19.16 6.39 9.69e-10 0.00317 0.6 0.4 Breast cancer; chr8:29645393 chr15:20642799~20643448:- CESC trans rs867371 0.82 rs7164362 ENSG00000235370.6 DNM1P51 -6.39 9.82e-10 0.00321 -0.52 -0.4 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82194401 chr15:84398316~84411701:- CESC trans rs10940346 0.562 rs549751 ENSG00000231752.4 EMBP1 -6.39 9.82e-10 0.00321 -0.48 -0.4 Schizophrenia; chr5:50262114 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs1841103 ENSG00000231752.4 EMBP1 -6.39 9.82e-10 0.00321 -0.48 -0.4 Schizophrenia; chr5:50263913 chr1:121519112~121571892:+ CESC trans rs10940346 0.562 rs504773 ENSG00000231752.4 EMBP1 -6.39 9.82e-10 0.00321 -0.48 -0.4 Schizophrenia; chr5:50264656 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs514195 ENSG00000231752.4 EMBP1 -6.39 9.82e-10 0.00321 -0.48 -0.4 Schizophrenia; chr5:50267123 chr1:121519112~121571892:+ CESC trans rs2950393 0.804 rs2035081 ENSG00000257210.1 NACAP3 6.39 9.89e-10 0.00323 0.44 0.4 Platelet distribution width; chr12:56732095 chr12:93124063~93124543:- CESC trans rs9611565 0.506 rs1883825 ENSG00000268568.1 AC007228.9 -6.39 9.9e-10 0.00323 -0.52 -0.4 Vitiligo; chr22:41307404 chr19:56672574~56673901:- CESC trans rs9611565 0.525 rs1883827 ENSG00000268568.1 AC007228.9 -6.39 9.9e-10 0.00323 -0.52 -0.4 Vitiligo; chr22:41307575 chr19:56672574~56673901:- CESC trans rs1707322 1 rs4660336 ENSG00000255397.1 AC022182.2 6.39 9.93e-10 0.00324 0.51 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46022304 chr8:60937705~60939871:- CESC trans rs877636 0.702 rs773109 ENSG00000225071.1 GS1-184P14.2 6.39 9.94e-10 0.00325 0.41 0.4 Cognitive function; chr12:55980911 chrX:24429573~24429920:- CESC trans rs4276421 0.638 rs10061699 ENSG00000231752.4 EMBP1 6.39 9.95e-10 0.00325 0.48 0.4 P wave duration; chr5:45864788 chr1:121519112~121571892:+ CESC trans rs1707322 1 rs785469 ENSG00000255397.1 AC022182.2 6.39 9.95e-10 0.00325 0.5 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055419 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785468 ENSG00000255397.1 AC022182.2 6.39 9.95e-10 0.00325 0.5 0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46055845 chr8:60937705~60939871:- CESC trans rs2991971 0.933 rs666720 ENSG00000255397.1 AC022182.2 6.39 9.97e-10 0.00325 0.5 0.4 High light scatter reticulocyte count; chr1:45555123 chr8:60937705~60939871:- CESC trans rs10940346 0.54 rs2199089 ENSG00000231752.4 EMBP1 -6.38 1.03e-09 0.00335 -0.49 -0.4 Schizophrenia; chr5:50199332 chr1:121519112~121571892:+ CESC trans rs10940346 0.52 rs7293339 ENSG00000231752.4 EMBP1 -6.38 1.03e-09 0.00335 -0.49 -0.4 Schizophrenia; chr5:50207465 chr1:121519112~121571892:+ CESC trans rs10940346 0.607 rs8188210 ENSG00000231752.4 EMBP1 -6.38 1.03e-09 0.00335 -0.49 -0.4 Schizophrenia; chr5:50211664 chr1:121519112~121571892:+ CESC trans rs10940346 0.562 rs1674514 ENSG00000231752.4 EMBP1 -6.38 1.04e-09 0.00338 -0.48 -0.4 Schizophrenia; chr5:50269291 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs6889220 ENSG00000228305.2 AC016734.2 6.38 1.04e-09 0.00339 0.53 0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177266887 chr2:63622178~63622831:- CESC trans rs1707322 1 rs785465 ENSG00000255397.1 AC022182.2 -6.38 1.06e-09 0.00343 -0.51 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46056905 chr8:60937705~60939871:- CESC trans rs10940346 0.601 rs1458766 ENSG00000231752.4 EMBP1 -6.37 1.08e-09 0.0035 -0.48 -0.4 Schizophrenia; chr5:50266457 chr1:121519112~121571892:+ CESC trans rs77688320 0.535 rs11691118 ENSG00000235105.1 RP11-329A14.1 6.37 1.08e-09 0.00351 0.43 0.4 Breast cancer; chr2:201405121 chr1:48435967~48437223:+ CESC trans rs58106596 0.95 rs11695646 ENSG00000259020.3 RP11-529H20.3 -6.37 1.1e-09 0.00356 -0.5 -0.4 Lymphocyte counts;White blood cell count; chr2:231720097 chr14:92026566~92026887:+ CESC trans rs10940346 0.542 rs2219452 ENSG00000231752.4 EMBP1 -6.37 1.11e-09 0.00358 -0.49 -0.4 Schizophrenia; chr5:50209813 chr1:121519112~121571892:+ CESC trans rs2950393 0.804 rs10783796 ENSG00000257210.1 NACAP3 6.37 1.11e-09 0.0036 0.43 0.4 Platelet distribution width; chr12:56733387 chr12:93124063~93124543:- CESC trans rs877636 0.859 rs3741499 ENSG00000234513.1 AC073072.7 -6.37 1.12e-09 0.00362 -0.43 -0.4 Cognitive function; chr12:56080595 chr7:22773646~22773993:- CESC trans rs877636 0.702 rs61937249 ENSG00000234513.1 AC073072.7 6.37 1.13e-09 0.00365 0.43 0.4 Cognitive function; chr12:55988132 chr7:22773646~22773993:- CESC trans rs2950393 0.804 rs898609 ENSG00000257210.1 NACAP3 6.37 1.13e-09 0.00366 0.43 0.4 Platelet distribution width; chr12:56713026 chr12:93124063~93124543:- CESC trans rs2950393 0.804 rs4902 ENSG00000257210.1 NACAP3 6.37 1.13e-09 0.00366 0.43 0.4 Platelet distribution width; chr12:56714419 chr12:93124063~93124543:- CESC trans rs10242455 0.867 rs2687135 ENSG00000228834.1 RP11-249L21.4 -6.37 1.14e-09 0.00367 -0.62 -0.4 Blood metabolite levels; chr7:99728686 chr6:108907615~108907873:- CESC trans rs1045902 0.574 rs1053329 ENSG00000236165.1 PRADC1P1 6.36 1.15e-09 0.00371 0.57 0.4 Intelligence (multi-trait analysis); chr2:73234355 chr3:36976316~36976840:+ CESC trans rs9876781 1 rs9883759 ENSG00000225528.1 RP3-370M22.8 -6.36 1.15e-09 0.00371 -0.38 -0.4 Longevity; chr3:48422209 chr22:39960397~39964683:+ CESC trans rs9876781 1 rs6442120 ENSG00000225528.1 RP3-370M22.8 -6.36 1.15e-09 0.00371 -0.38 -0.4 Longevity; chr3:48423094 chr22:39960397~39964683:+ CESC trans rs9876781 1 rs2279077 ENSG00000225528.1 RP3-370M22.8 -6.36 1.15e-09 0.00371 -0.38 -0.4 Longevity; chr3:48432839 chr22:39960397~39964683:+ CESC trans rs2991971 0.81 rs12738318 ENSG00000255397.1 AC022182.2 -6.36 1.15e-09 0.00372 -0.47 -0.4 High light scatter reticulocyte count; chr1:45463917 chr8:60937705~60939871:- CESC trans rs10940346 0.601 rs552892 ENSG00000231752.4 EMBP1 -6.36 1.17e-09 0.00378 -0.48 -0.4 Schizophrenia; chr5:50269093 chr1:121519112~121571892:+ CESC trans rs61041336 0.534 rs59234479 ENSG00000233719.3 GOT2P3 -6.36 1.18e-09 0.00381 -0.64 -0.4 Neuritic plaque; chr16:58673724 chr12:9641802~9643007:+ CESC trans rs9876781 0.9 rs1037773 ENSG00000225528.1 RP3-370M22.8 -6.36 1.19e-09 0.00384 -0.38 -0.4 Longevity; chr3:48426493 chr22:39960397~39964683:+ CESC trans rs10819083 0.861 rs1420767 ENSG00000203588.3 IGBP1-AS1 -6.36 1.2e-09 0.00386 -0.35 -0.4 Squamous cell lung carcinoma; chr9:125956877 chrX:70163842~70165206:- CESC trans rs714543 1 rs8840 ENSG00000226038.5 PPIAP21 6.35 1.21e-09 0.00389 0.52 0.4 Plateletcrit; chr7:44877441 chr20:43230760~43231260:+ CESC trans rs9876781 1 rs9881491 ENSG00000225528.1 RP3-370M22.8 -6.35 1.22e-09 0.00393 -0.38 -0.4 Longevity; chr3:48446507 chr22:39960397~39964683:+ CESC trans rs1707322 0.964 rs6697830 ENSG00000255397.1 AC022182.2 -6.35 1.23e-09 0.00395 -0.5 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45824805 chr8:60937705~60939871:- CESC trans rs1707322 1 rs12060274 ENSG00000255397.1 AC022182.2 -6.35 1.23e-09 0.00395 -0.5 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45825390 chr8:60937705~60939871:- CESC trans rs1707322 1 rs10890353 ENSG00000255397.1 AC022182.2 -6.35 1.23e-09 0.00395 -0.5 -0.4 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45832711 chr8:60937705~60939871:- CESC trans rs11638815 0.603 rs10162807 ENSG00000235370.6 DNM1P51 -6.35 1.23e-09 0.00396 -0.53 -0.4 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; chr15:82620430 chr15:84398316~84411701:- CESC trans rs2950393 0.777 rs12828563 ENSG00000257210.1 NACAP3 6.35 1.23e-09 0.00396 0.43 0.4 Platelet distribution width; chr12:56709378 chr12:93124063~93124543:- CESC trans rs877636 1 rs4759229 ENSG00000225071.1 GS1-184P14.2 -6.35 1.23e-09 0.00397 -0.41 -0.4 Cognitive function; chr12:56080696 chrX:24429573~24429920:- CESC trans rs714543 0.967 rs12536807 ENSG00000226038.5 PPIAP21 -6.35 1.24e-09 0.00398 -0.51 -0.4 Plateletcrit; chr7:44838675 chr20:43230760~43231260:+ CESC trans rs714543 0.967 rs10951776 ENSG00000226038.5 PPIAP21 -6.35 1.24e-09 0.00398 -0.51 -0.4 Plateletcrit; chr7:44858152 chr20:43230760~43231260:+ CESC trans rs10940346 0.519 rs10940514 ENSG00000231752.4 EMBP1 -6.35 1.24e-09 0.00399 -0.49 -0.4 Schizophrenia; chr5:50146166 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs9688065 ENSG00000231752.4 EMBP1 -6.35 1.24e-09 0.00399 -0.49 -0.4 Schizophrenia; chr5:50147444 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs4865675 ENSG00000231752.4 EMBP1 -6.35 1.26e-09 0.00405 -0.48 -0.39 Schizophrenia; chr5:50279300 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs506919 ENSG00000231752.4 EMBP1 -6.35 1.26e-09 0.00405 -0.48 -0.39 Schizophrenia; chr5:50279635 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs1858343 ENSG00000231752.4 EMBP1 -6.35 1.26e-09 0.00405 -0.48 -0.39 Schizophrenia; chr5:50290180 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs1858344 ENSG00000231752.4 EMBP1 -6.35 1.26e-09 0.00405 -0.48 -0.39 Schizophrenia; chr5:50290345 chr1:121519112~121571892:+ CESC trans rs10940346 0.623 rs4865519 ENSG00000231752.4 EMBP1 -6.35 1.26e-09 0.00405 -0.48 -0.39 Schizophrenia; chr5:50293002 chr1:121519112~121571892:+ CESC trans rs11098499 0.615 rs59867181 ENSG00000275858.1 RP11-291L22.8 -6.34 1.3e-09 0.00416 -0.42 -0.39 Corneal astigmatism; chr4:119635312 chr10:38450738~38451069:- CESC trans rs74781061 0.929 rs8029116 ENSG00000227288.3 RP5-837I24.1 6.34 1.3e-09 0.00418 0.52 0.39 Endometriosis; chr15:74530753 chr1:81501794~81503468:+ CESC trans rs8175379 0.522 rs8185256 ENSG00000231752.4 EMBP1 -6.34 1.32e-09 0.00422 -0.48 -0.39 Interleukin-7 levels; chr5:46298301 chr1:121519112~121571892:+ CESC trans rs8175379 0.501 rs12514178 ENSG00000231752.4 EMBP1 -6.34 1.32e-09 0.00422 -0.48 -0.39 Interleukin-7 levels; chr5:46309072 chr1:121519112~121571892:+ CESC trans rs8175379 0.501 rs8185192 ENSG00000231752.4 EMBP1 -6.34 1.32e-09 0.00422 -0.48 -0.39 Interleukin-7 levels; chr5:46309722 chr1:121519112~121571892:+ CESC trans rs8175379 0.509 rs7293427 ENSG00000231752.4 EMBP1 6.34 1.32e-09 0.00422 0.48 0.39 Interleukin-7 levels; chr5:46253335 chr1:121519112~121571892:+ CESC trans rs877636 0.702 rs773112 ENSG00000234513.1 AC073072.7 6.34 1.32e-09 0.00422 0.43 0.39 Cognitive function; chr12:55982097 chr7:22773646~22773993:- CESC trans rs2950393 0.804 rs7967600 ENSG00000257210.1 NACAP3 6.34 1.34e-09 0.00427 0.44 0.39 Platelet distribution width; chr12:56768208 chr12:93124063~93124543:- CESC trans rs13190036 1 rs28580074 ENSG00000228305.2 AC016734.2 6.33 1.35e-09 0.00429 0.53 0.39 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177294197 chr2:63622178~63622831:- CESC trans rs3812762 0.871 rs3862352 ENSG00000266891.1 RP11-692N5.2 6.33 1.36e-09 0.00432 0.48 0.39 Hypospadias; chr11:8796473 chr18:9734882~9735602:- CESC trans rs4276421 0.638 rs4283798 ENSG00000231752.4 EMBP1 6.33 1.36e-09 0.00433 0.48 0.39 P wave duration; chr5:45866041 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs524184 ENSG00000231752.4 EMBP1 -6.33 1.37e-09 0.00435 -0.48 -0.39 Schizophrenia; chr5:50276256 chr1:121519112~121571892:+ CESC trans rs8175379 0.584 rs8185180 ENSG00000231752.4 EMBP1 -6.33 1.38e-09 0.00438 -0.48 -0.39 Interleukin-7 levels; chr5:46300291 chr1:121519112~121571892:+ CESC trans rs10940346 0.562 rs555704 ENSG00000231752.4 EMBP1 -6.33 1.38e-09 0.0044 -0.48 -0.39 Schizophrenia; chr5:50277066 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs9291925 ENSG00000231752.4 EMBP1 6.33 1.39e-09 0.00441 0.47 0.39 Schizophrenia; chr5:50320129 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7722742 ENSG00000231752.4 EMBP1 6.33 1.39e-09 0.00441 0.47 0.39 Schizophrenia; chr5:50320312 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs6876902 ENSG00000231752.4 EMBP1 6.33 1.39e-09 0.00441 0.47 0.39 Schizophrenia; chr5:50320934 chr1:121519112~121571892:+ CESC trans rs877636 1 rs2292239 ENSG00000212994.5 RPS26P6 6.33 1.39e-09 0.00443 0.48 0.39 Cognitive function; chr12:56088396 chr8:100895771~100896118:+ CESC trans rs9876781 1 rs6776700 ENSG00000225528.1 RP3-370M22.8 -6.33 1.4e-09 0.00445 -0.39 -0.39 Longevity; chr3:48455358 chr22:39960397~39964683:+ CESC trans rs12709013 0.729 rs34324769 ENSG00000233719.3 GOT2P3 6.33 1.4e-09 0.00446 0.43 0.39 Blood metabolite ratios; chr16:58778131 chr12:9641802~9643007:+ CESC trans rs877636 1 rs4759229 ENSG00000235459.5 RPS26P31 -6.33 1.4e-09 0.00446 -0.42 -0.39 Cognitive function; chr12:56080696 chr7:122681315~122681662:+ CESC trans rs8175379 0.53 rs12516847 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.5 -0.39 Interleukin-7 levels; chr5:46300736 chr1:121519112~121571892:+ CESC trans rs10940346 0.562 rs563750 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.48 -0.39 Schizophrenia; chr5:50278004 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs507761 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.48 -0.39 Schizophrenia; chr5:50279558 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs494540 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.48 -0.39 Schizophrenia; chr5:50280228 chr1:121519112~121571892:+ CESC trans rs10940346 0.51 rs10038023 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.48 -0.39 Schizophrenia; chr5:50280387 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs471455 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.48 -0.39 Schizophrenia; chr5:50280427 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs13360551 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.48 -0.39 Schizophrenia; chr5:50287350 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs4865685 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.48 -0.39 Schizophrenia; chr5:50290682 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs6449779 ENSG00000231752.4 EMBP1 -6.32 1.42e-09 0.0045 -0.48 -0.39 Schizophrenia; chr5:50290876 chr1:121519112~121571892:+ CESC trans rs7647973 0.58 rs2334958 ENSG00000197582.5 GPX1P1 6.32 1.43e-09 0.00452 0.49 0.39 Menarche (age at onset); chr3:49214931 chrX:13378735~13379340:- CESC trans rs2950393 0.804 rs2926748 ENSG00000257210.1 NACAP3 6.32 1.45e-09 0.00457 0.43 0.39 Platelet distribution width; chr12:56715628 chr12:93124063~93124543:- CESC trans rs9876781 1 rs13091785 ENSG00000225528.1 RP3-370M22.8 -6.32 1.46e-09 0.00462 -0.39 -0.39 Longevity; chr3:48452692 chr22:39960397~39964683:+ CESC trans rs7520050 0.807 rs3013594 ENSG00000255397.1 AC022182.2 -6.32 1.48e-09 0.00466 -0.49 -0.39 Reticulocyte count;Red blood cell count; chr1:45672328 chr8:60937705~60939871:- CESC trans rs12709013 1 rs6499983 ENSG00000230849.2 GOT2P2 6.32 1.48e-09 0.00467 0.46 0.39 Blood metabolite ratios; chr16:58810005 chr1:173141100~173142350:- CESC trans rs10940346 0.601 rs6449802 ENSG00000231752.4 EMBP1 -6.32 1.49e-09 0.00469 -0.47 -0.39 Schizophrenia; chr5:50299390 chr1:121519112~121571892:+ CESC trans rs10940346 0.524 rs35601537 ENSG00000231752.4 EMBP1 -6.32 1.49e-09 0.00471 -0.48 -0.39 Schizophrenia; chr5:50509460 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs2005573 ENSG00000231752.4 EMBP1 -6.32 1.49e-09 0.00471 -0.47 -0.39 Schizophrenia; chr5:50301614 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs2011540 ENSG00000231752.4 EMBP1 -6.32 1.49e-09 0.00471 -0.47 -0.39 Schizophrenia; chr5:50301634 chr1:121519112~121571892:+ CESC trans rs714543 1 rs2898 ENSG00000226038.5 PPIAP21 -6.32 1.49e-09 0.00471 -0.51 -0.39 Plateletcrit; chr7:44827034 chr20:43230760~43231260:+ CESC trans rs714543 1 rs10267576 ENSG00000226038.5 PPIAP21 -6.32 1.49e-09 0.00471 -0.51 -0.39 Plateletcrit; chr7:44831334 chr20:43230760~43231260:+ CESC trans rs714543 1 rs714543 ENSG00000226038.5 PPIAP21 -6.32 1.49e-09 0.00471 -0.51 -0.39 Plateletcrit; chr7:44847477 chr20:43230760~43231260:+ CESC trans rs714543 1 rs757693 ENSG00000226038.5 PPIAP21 -6.32 1.49e-09 0.00471 -0.51 -0.39 Plateletcrit; chr7:44848430 chr20:43230760~43231260:+ CESC trans rs714543 0.967 rs11762008 ENSG00000226038.5 PPIAP21 -6.32 1.49e-09 0.00471 -0.51 -0.39 Plateletcrit; chr7:44864065 chr20:43230760~43231260:+ CESC trans rs7113874 0.527 rs12790154 ENSG00000266891.1 RP11-692N5.2 6.31 1.5e-09 0.00473 0.55 0.39 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8383601 chr18:9734882~9735602:- CESC trans rs6749447 0.959 rs6714609 ENSG00000275208.1 MIR6745 6.31 1.5e-09 0.00474 0.43 0.39 Blood pressure; chr2:168153740 chr11:47179611~47179737:- CESC trans rs7554511 0.893 rs12122721 ENSG00000244144.1 RP11-757F18.3 6.31 1.51e-09 0.00475 0.45 0.39 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201015352 chr3:112185480~112185998:- CESC trans rs941207 0.756 rs7315472 ENSG00000257210.1 NACAP3 -6.31 1.51e-09 0.00477 -0.51 -0.39 Platelet count; chr12:56648276 chr12:93124063~93124543:- CESC trans rs941207 0.756 rs67046307 ENSG00000257210.1 NACAP3 -6.31 1.51e-09 0.00477 -0.51 -0.39 Platelet count; chr12:56651152 chr12:93124063~93124543:- CESC trans rs941207 0.756 rs10876915 ENSG00000257210.1 NACAP3 -6.31 1.51e-09 0.00477 -0.51 -0.39 Platelet count; chr12:56655280 chr12:93124063~93124543:- CESC trans rs877636 0.702 rs773112 ENSG00000225071.1 GS1-184P14.2 6.31 1.52e-09 0.00479 0.41 0.39 Cognitive function; chr12:55982097 chrX:24429573~24429920:- CESC trans rs877636 0.702 rs773110 ENSG00000234513.1 AC073072.7 6.31 1.53e-09 0.00481 0.43 0.39 Cognitive function; chr12:55981353 chr7:22773646~22773993:- CESC trans rs10940346 0.601 rs496230 ENSG00000231752.4 EMBP1 -6.31 1.54e-09 0.00484 -0.48 -0.39 Schizophrenia; chr5:50275179 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs526329 ENSG00000231752.4 EMBP1 -6.31 1.54e-09 0.00484 -0.48 -0.39 Schizophrenia; chr5:50276141 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs6868713 ENSG00000231752.4 EMBP1 -6.31 1.54e-09 0.00484 -0.48 -0.39 Schizophrenia; chr5:50276741 chr1:121519112~121571892:+ CESC trans rs928391 0.744 rs3765783 ENSG00000227183.3 HDGFP1 -6.31 1.54e-09 0.00486 -0.51 -0.39 Platelet count; chr1:156796181 chrX:131646639~131646890:+ CESC trans rs77688320 0.535 rs11680694 ENSG00000235105.1 RP11-329A14.1 6.31 1.57e-09 0.00494 0.42 0.39 Breast cancer; chr2:201393498 chr1:48435967~48437223:+ CESC trans rs72615157 0.612 rs7786505 ENSG00000228546.2 CTA-313A17.3 6.3 1.58e-09 0.00496 0.58 0.39 Lung function (FEV1/FVC); chr7:100219962 chr7:102337316~102339115:+ CESC trans rs3806843 0.741 rs2563293 ENSG00000231043.3 AC007238.1 6.3 1.61e-09 0.00504 0.43 0.39 Depressive symptoms (multi-trait analysis); chr5:140730951 chr2:58460292~58462032:- CESC trans rs3806843 0.771 rs801174 ENSG00000231043.3 AC007238.1 6.3 1.61e-09 0.00504 0.43 0.39 Depressive symptoms (multi-trait analysis); chr5:140733127 chr2:58460292~58462032:- CESC trans rs10940346 0.601 rs7717982 ENSG00000231752.4 EMBP1 6.3 1.61e-09 0.00505 0.47 0.39 Schizophrenia; chr5:50401488 chr1:121519112~121571892:+ CESC trans rs877636 0.702 rs773111 ENSG00000234513.1 AC073072.7 6.3 1.62e-09 0.00508 0.43 0.39 Cognitive function; chr12:55981956 chr7:22773646~22773993:- CESC trans rs13190036 0.901 rs10072499 ENSG00000217325.2 PRELID1P1 -6.3 1.62e-09 0.00508 -0.57 -0.39 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228236 chr6:126643488~126644390:+ CESC trans rs2991971 0.869 rs2453404 ENSG00000255397.1 AC022182.2 6.3 1.64e-09 0.00514 0.49 0.39 High light scatter reticulocyte count; chr1:45549063 chr8:60937705~60939871:- CESC trans rs2991971 1 rs622798 ENSG00000255397.1 AC022182.2 6.3 1.64e-09 0.00514 0.49 0.39 High light scatter reticulocyte count; chr1:45549599 chr8:60937705~60939871:- CESC trans rs2991971 1 rs667626 ENSG00000255397.1 AC022182.2 6.3 1.64e-09 0.00514 0.49 0.39 High light scatter reticulocyte count; chr1:45554879 chr8:60937705~60939871:- CESC trans rs13190036 0.901 rs4631 ENSG00000228305.2 AC016734.2 6.3 1.65e-09 0.00516 0.55 0.39 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177306115 chr2:63622178~63622831:- CESC trans rs2950393 0.804 rs2958127 ENSG00000257210.1 NACAP3 6.3 1.66e-09 0.00519 0.43 0.39 Platelet distribution width; chr12:56720523 chr12:93124063~93124543:- CESC trans rs13190036 0.792 rs6874206 ENSG00000217325.2 PRELID1P1 -6.3 1.66e-09 0.00521 -0.57 -0.39 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177223970 chr6:126643488~126644390:+ CESC trans rs11098499 0.874 rs28452522 ENSG00000275858.1 RP11-291L22.8 6.29 1.67e-09 0.00523 0.45 0.39 Corneal astigmatism; chr4:119189629 chr10:38450738~38451069:- CESC trans rs1568889 1 rs7934085 ENSG00000174912.7 METTL15P1 6.29 1.67e-09 0.00524 0.48 0.39 Bipolar disorder; chr11:28348113 chr3:156713884~156714928:- CESC trans rs1568889 1 rs7937117 ENSG00000174912.7 METTL15P1 6.29 1.67e-09 0.00524 0.48 0.39 Bipolar disorder; chr11:28348491 chr3:156713884~156714928:- CESC trans rs4791051 0.696 rs4082895 ENSG00000260196.1 RP1-239B22.5 -6.29 1.68e-09 0.00525 -0.46 -0.39 Heschl's gyrus morphology; chr17:66452153 chr11:17380649~17383531:+ CESC trans rs2991971 0.903 rs2991973 ENSG00000255397.1 AC022182.2 6.29 1.69e-09 0.00528 0.49 0.39 High light scatter reticulocyte count; chr1:45554960 chr8:60937705~60939871:- CESC trans rs77688320 0.573 rs59674665 ENSG00000235105.1 RP11-329A14.1 -6.29 1.69e-09 0.0053 -0.45 -0.39 Breast cancer; chr2:201514881 chr1:48435967~48437223:+ CESC trans rs12709013 0.967 rs56107162 ENSG00000230849.2 GOT2P2 6.29 1.71e-09 0.00534 0.46 0.39 Blood metabolite ratios; chr16:58804358 chr1:173141100~173142350:- CESC trans rs10940346 0.601 rs7446951 ENSG00000231752.4 EMBP1 -6.29 1.71e-09 0.00534 -0.47 -0.39 Schizophrenia; chr5:50314949 chr1:121519112~121571892:+ CESC trans rs58106596 0.848 rs2241742 ENSG00000259020.3 RP11-529H20.3 6.29 1.72e-09 0.00536 0.58 0.39 Lymphocyte counts;White blood cell count; chr2:231710097 chr14:92026566~92026887:+ CESC trans rs877636 0.692 rs2271194 ENSG00000243538.1 CTB-55B8.1 -6.29 1.72e-09 0.00537 -0.38 -0.39 Cognitive function; chr12:56083910 chr5:16902294~16902641:- CESC trans rs13014235 0.592 rs55860809 ENSG00000235105.1 RP11-329A14.1 6.29 1.73e-09 0.00539 0.42 0.39 Basal cell carcinoma; chr2:201394347 chr1:48435967~48437223:+ CESC trans rs12709013 0.792 rs11644344 ENSG00000233719.3 GOT2P3 6.29 1.74e-09 0.00541 0.44 0.39 Blood metabolite ratios; chr16:58803080 chr12:9641802~9643007:+ CESC trans rs7647973 0.58 rs2117938 ENSG00000197582.5 GPX1P1 -6.29 1.74e-09 0.00541 -0.48 -0.39 Menarche (age at onset); chr3:49226417 chrX:13378735~13379340:- CESC trans rs12709013 1 rs8057892 ENSG00000230849.2 GOT2P2 6.29 1.74e-09 0.00542 0.46 0.39 Blood metabolite ratios; chr16:58798855 chr1:173141100~173142350:- CESC trans rs12709013 1 rs11644891 ENSG00000230849.2 GOT2P2 6.29 1.74e-09 0.00542 0.46 0.39 Blood metabolite ratios; chr16:58799921 chr1:173141100~173142350:- CESC trans rs12709013 1 rs11641566 ENSG00000230849.2 GOT2P2 6.29 1.74e-09 0.00542 0.46 0.39 Blood metabolite ratios; chr16:58801276 chr1:173141100~173142350:- CESC trans rs10940346 0.562 rs34601168 ENSG00000231752.4 EMBP1 6.29 1.74e-09 0.00542 0.47 0.39 Schizophrenia; chr5:50330561 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs35740733 ENSG00000231752.4 EMBP1 6.29 1.74e-09 0.00542 0.47 0.39 Schizophrenia; chr5:50330771 chr1:121519112~121571892:+ CESC trans rs10940346 0.502 rs77189370 ENSG00000231752.4 EMBP1 6.29 1.74e-09 0.00542 0.47 0.39 Schizophrenia; chr5:50334920 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs6861461 ENSG00000231752.4 EMBP1 6.29 1.74e-09 0.00542 0.47 0.39 Schizophrenia; chr5:50348493 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs12332500 ENSG00000231752.4 EMBP1 6.29 1.74e-09 0.00542 0.47 0.39 Schizophrenia; chr5:50349021 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7710841 ENSG00000231752.4 EMBP1 6.29 1.74e-09 0.00542 0.47 0.39 Schizophrenia; chr5:50349986 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7722623 ENSG00000231752.4 EMBP1 6.29 1.74e-09 0.00542 0.47 0.39 Schizophrenia; chr5:50350496 chr1:121519112~121571892:+ CESC trans rs11098499 0.562 rs2389879 ENSG00000275858.1 RP11-291L22.8 -6.29 1.74e-09 0.00542 -0.42 -0.39 Corneal astigmatism; chr4:119636529 chr10:38450738~38451069:- CESC trans rs877636 0.669 rs7297175 ENSG00000196656.7 AC004057.1 -6.29 1.75e-09 0.00544 -0.4 -0.39 Cognitive function; chr12:56080024 chr4:113214046~113217170:- CESC trans rs1326895 0.736 rs72748157 ENSG00000280389.1 RP11-512M8.11 6.29 1.75e-09 0.00546 0.73 0.39 Pursuit maintenance gain; chr9:110917337 chr12:122255119~122260274:- CESC trans rs1707322 0.963 rs1768815 ENSG00000255397.1 AC022182.2 6.28 1.77e-09 0.0055 0.5 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46062931 chr8:60937705~60939871:- CESC trans rs7520050 0.553 rs2993263 ENSG00000255397.1 AC022182.2 -6.28 1.78e-09 0.00552 -0.48 -0.39 Reticulocyte count;Red blood cell count; chr1:45555958 chr8:60937705~60939871:- CESC trans rs877636 0.859 rs3741499 ENSG00000225071.1 GS1-184P14.2 -6.28 1.78e-09 0.00552 -0.4 -0.39 Cognitive function; chr12:56080595 chrX:24429573~24429920:- CESC trans rs941207 0.756 rs2958153 ENSG00000257210.1 NACAP3 6.28 1.79e-09 0.00556 0.51 0.39 Platelet count; chr12:56687733 chr12:93124063~93124543:- CESC trans rs10940346 0.54 rs10039622 ENSG00000231752.4 EMBP1 6.28 1.8e-09 0.00559 0.47 0.39 Schizophrenia; chr5:50336720 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10064702 ENSG00000231752.4 EMBP1 6.28 1.8e-09 0.00559 0.47 0.39 Schizophrenia; chr5:50336928 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs13160697 ENSG00000231752.4 EMBP1 6.28 1.8e-09 0.00559 0.47 0.39 Schizophrenia; chr5:50339822 chr1:121519112~121571892:+ CESC trans rs77688320 0.535 rs2241118 ENSG00000235105.1 RP11-329A14.1 6.28 1.81e-09 0.00562 0.42 0.39 Breast cancer; chr2:201388993 chr1:48435967~48437223:+ CESC trans rs3806843 0.657 rs2563283 ENSG00000231043.3 AC007238.1 6.28 1.81e-09 0.00563 0.44 0.39 Depressive symptoms (multi-trait analysis); chr5:140726393 chr2:58460292~58462032:- CESC trans rs3806843 0.771 rs2563336 ENSG00000231043.3 AC007238.1 6.28 1.81e-09 0.00563 0.44 0.39 Depressive symptoms (multi-trait analysis); chr5:140727614 chr2:58460292~58462032:- CESC trans rs7554511 0.707 rs3861928 ENSG00000244144.1 RP11-757F18.3 -6.28 1.83e-09 0.00569 -0.45 -0.39 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201051446 chr3:112185480~112185998:- CESC trans rs10940346 0.58 rs7705284 ENSG00000231752.4 EMBP1 6.28 1.84e-09 0.00571 0.47 0.39 Schizophrenia; chr5:50325574 chr1:121519112~121571892:+ CESC trans rs877636 0.702 rs773110 ENSG00000225071.1 GS1-184P14.2 6.28 1.85e-09 0.00573 0.4 0.39 Cognitive function; chr12:55981353 chrX:24429573~24429920:- CESC trans rs7554511 0.792 rs12126806 ENSG00000244144.1 RP11-757F18.3 -6.28 1.85e-09 0.00575 -0.43 -0.39 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200994697 chr3:112185480~112185998:- CESC trans rs77688320 0.535 rs13027669 ENSG00000235105.1 RP11-329A14.1 6.27 1.86e-09 0.00577 0.41 0.39 Breast cancer; chr2:201382596 chr1:48435967~48437223:+ CESC trans rs3740713 0.669 rs78098319 ENSG00000235847.2 LDHAP7 6.27 1.87e-09 0.00578 0.72 0.39 Amyotrophic lateral sclerosis (sporadic); chr11:18382752 chr2:84777259~84778223:- CESC trans rs616147 1 rs616147 ENSG00000183298.5 RP11-556K13.1 -6.27 1.88e-09 0.00581 -0.5 -0.39 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39492990 chr1:101786340~101787219:- CESC trans rs3806843 0.735 rs801180 ENSG00000231043.3 AC007238.1 6.27 1.88e-09 0.00582 0.43 0.39 Depressive symptoms (multi-trait analysis); chr5:140713318 chr2:58460292~58462032:- CESC trans rs1707322 0.929 rs785513 ENSG00000255397.1 AC022182.2 6.27 1.88e-09 0.00583 0.51 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46072648 chr8:60937705~60939871:- CESC trans rs6132905 0.52 rs2422824 ENSG00000257956.1 NOP56P3 6.27 1.9e-09 0.00587 0.55 0.39 Mumps; chr20:2666724 chr12:79558782~79559166:+ CESC trans rs877636 0.702 rs773111 ENSG00000225071.1 GS1-184P14.2 6.27 1.92e-09 0.00593 0.4 0.39 Cognitive function; chr12:55981956 chrX:24429573~24429920:- CESC trans rs55665837 0.701 rs12286408 ENSG00000236360.2 RP11-334A14.2 6.27 1.92e-09 0.00593 0.49 0.39 Vitamin D levels; chr11:14557830 chr1:52993201~52993702:- CESC trans rs77688320 0.573 rs2080327 ENSG00000235105.1 RP11-329A14.1 -6.27 1.92e-09 0.00594 -0.45 -0.39 Breast cancer; chr2:201461495 chr1:48435967~48437223:+ CESC trans rs10242455 0.717 rs776745 ENSG00000228834.1 RP11-249L21.4 6.27 1.93e-09 0.00597 0.63 0.39 Blood metabolite levels; chr7:99693714 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs776742 ENSG00000228834.1 RP11-249L21.4 6.27 1.93e-09 0.00597 0.63 0.39 Blood metabolite levels; chr7:99695132 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs1879859 ENSG00000228834.1 RP11-249L21.4 -6.27 1.93e-09 0.00597 -0.63 -0.39 Blood metabolite levels; chr7:99697139 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687086 ENSG00000228834.1 RP11-249L21.4 -6.27 1.93e-09 0.00597 -0.63 -0.39 Blood metabolite levels; chr7:99697827 chr6:108907615~108907873:- CESC trans rs10242455 0.764 rs2740564 ENSG00000228834.1 RP11-249L21.4 -6.27 1.93e-09 0.00597 -0.63 -0.39 Blood metabolite levels; chr7:99698070 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs1818797 ENSG00000228834.1 RP11-249L21.4 -6.27 1.93e-09 0.00597 -0.63 -0.39 Blood metabolite levels; chr7:99698572 chr6:108907615~108907873:- CESC trans rs10242455 0.681 rs1851425 ENSG00000228834.1 RP11-249L21.4 -6.27 1.93e-09 0.00597 -0.63 -0.39 Blood metabolite levels; chr7:99702608 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687081 ENSG00000228834.1 RP11-249L21.4 -6.27 1.93e-09 0.00597 -0.63 -0.39 Blood metabolite levels; chr7:99703135 chr6:108907615~108907873:- CESC trans rs1568889 1 rs7951681 ENSG00000174912.7 METTL15P1 6.27 1.94e-09 0.00598 0.48 0.39 Bipolar disorder; chr11:28252347 chr3:156713884~156714928:- CESC trans rs13190036 1 rs625882 ENSG00000226986.4 RP11-543B16.2 -6.26 1.97e-09 0.00609 -0.49 -0.39 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177108030 chr1:211207239~211207897:+ CESC trans rs877636 0.74 rs705698 ENSG00000225071.1 GS1-184P14.2 6.26 1.99e-09 0.00614 0.4 0.39 Cognitive function; chr12:55990903 chrX:24429573~24429920:- CESC trans rs1707322 1 rs6677777 ENSG00000255397.1 AC022182.2 -6.26 2e-09 0.00616 -0.52 -0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46010164 chr8:60937705~60939871:- CESC trans rs2950393 0.804 rs2958130 ENSG00000257210.1 NACAP3 6.26 2e-09 0.00617 0.43 0.39 Platelet distribution width; chr12:56746722 chr12:93124063~93124543:- CESC trans rs77688320 0.535 rs7579617 ENSG00000235105.1 RP11-329A14.1 6.26 2e-09 0.00618 0.41 0.39 Breast cancer; chr2:201384065 chr1:48435967~48437223:+ CESC trans rs13190036 0.901 rs28684504 ENSG00000228305.2 AC016734.2 6.26 2.01e-09 0.00621 0.53 0.39 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177300437 chr2:63622178~63622831:- CESC trans rs1326895 1 rs1547664 ENSG00000280389.1 RP11-512M8.11 6.26 2.02e-09 0.00623 0.74 0.39 Pursuit maintenance gain; chr9:110921863 chr12:122255119~122260274:- CESC trans rs7647973 0.58 rs11130184 ENSG00000197582.5 GPX1P1 6.26 2.03e-09 0.00626 0.49 0.39 Menarche (age at onset); chr3:49192497 chrX:13378735~13379340:- CESC trans rs10819083 0.861 rs10513456 ENSG00000203588.3 IGBP1-AS1 6.26 2.05e-09 0.0063 0.35 0.39 Squamous cell lung carcinoma; chr9:125957570 chrX:70163842~70165206:- CESC trans rs4276421 0.615 rs4626346 ENSG00000231752.4 EMBP1 6.26 2.05e-09 0.00632 0.5 0.39 P wave duration; chr5:45857435 chr1:121519112~121571892:+ CESC trans rs10940346 0.56 rs10039233 ENSG00000231752.4 EMBP1 6.26 2.06e-09 0.00633 0.47 0.39 Schizophrenia; chr5:50351630 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs35815956 ENSG00000231752.4 EMBP1 6.26 2.06e-09 0.00634 0.47 0.39 Schizophrenia; chr5:50350905 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10940242 ENSG00000231752.4 EMBP1 6.26 2.06e-09 0.00634 0.47 0.39 Schizophrenia; chr5:50351018 chr1:121519112~121571892:+ CESC trans rs77688320 0.553 rs2540339 ENSG00000235105.1 RP11-329A14.1 -6.25 2.08e-09 0.00638 -0.44 -0.39 Breast cancer; chr2:201415725 chr1:48435967~48437223:+ CESC trans rs77688320 0.553 rs2540340 ENSG00000235105.1 RP11-329A14.1 -6.25 2.08e-09 0.00638 -0.44 -0.39 Breast cancer; chr2:201416477 chr1:48435967~48437223:+ CESC trans rs77688320 0.553 rs7582946 ENSG00000235105.1 RP11-329A14.1 6.25 2.08e-09 0.00638 0.44 0.39 Breast cancer; chr2:201423969 chr1:48435967~48437223:+ CESC trans rs2991971 0.81 rs781058 ENSG00000255397.1 AC022182.2 -6.25 2.09e-09 0.00643 -0.46 -0.39 High light scatter reticulocyte count; chr1:45469384 chr8:60937705~60939871:- CESC trans rs1326895 0.709 rs10465128 ENSG00000280389.1 RP11-512M8.11 6.25 2.09e-09 0.00643 0.67 0.39 Pursuit maintenance gain; chr9:110971480 chr12:122255119~122260274:- CESC trans rs4276421 0.615 rs10064278 ENSG00000231752.4 EMBP1 -6.25 2.15e-09 0.00659 -0.48 -0.39 P wave duration; chr5:45786496 chr1:121519112~121571892:+ CESC trans rs10819083 0.861 rs888230 ENSG00000203588.3 IGBP1-AS1 6.25 2.16e-09 0.00664 0.35 0.39 Squamous cell lung carcinoma; chr9:125962025 chrX:70163842~70165206:- CESC trans rs6741148 0.881 rs77762745 ENSG00000224224.1 HAUS1P2 6.25 2.16e-09 0.00664 0.81 0.39 Erectile dysfunction and prostate cancer treatment; chr2:38017683 chrX:18865771~18866554:+ CESC trans rs6990917 0.59 rs6999075 ENSG00000274487.1 CH17-431G21.1 6.25 2.19e-09 0.00671 0.86 0.39 Adverse response to lamotrigine and phenytoin; chr8:67879835 chr17:38195740~38257152:- CESC trans rs877636 0.702 rs61937249 ENSG00000225071.1 GS1-184P14.2 6.25 2.19e-09 0.00671 0.4 0.39 Cognitive function; chr12:55988132 chrX:24429573~24429920:- CESC trans rs10940346 0.601 rs4865698 ENSG00000231752.4 EMBP1 -6.24 2.21e-09 0.00676 -0.47 -0.39 Schizophrenia; chr5:50303332 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs4865699 ENSG00000231752.4 EMBP1 -6.24 2.21e-09 0.00676 -0.47 -0.39 Schizophrenia; chr5:50303347 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs4865700 ENSG00000231752.4 EMBP1 -6.24 2.21e-09 0.00676 -0.47 -0.39 Schizophrenia; chr5:50303862 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs13178993 ENSG00000231752.4 EMBP1 -6.24 2.21e-09 0.00676 -0.47 -0.39 Schizophrenia; chr5:50305256 chr1:121519112~121571892:+ CESC trans rs1355223 0.506 rs11032898 ENSG00000225531.1 RP11-196I18.3 6.24 2.22e-09 0.0068 0.48 0.39 Systemic lupus erythematosus and Systemic sclerosis; chr11:34848564 chr9:107116829~107117557:+ CESC trans rs1355223 0.506 rs11032899 ENSG00000225531.1 RP11-196I18.3 6.24 2.22e-09 0.0068 0.48 0.39 Systemic lupus erythematosus and Systemic sclerosis; chr11:34848687 chr9:107116829~107117557:+ CESC trans rs1355223 0.506 rs1828299 ENSG00000225531.1 RP11-196I18.3 6.24 2.22e-09 0.0068 0.48 0.39 Systemic lupus erythematosus and Systemic sclerosis; chr11:34848871 chr9:107116829~107117557:+ CESC trans rs3806843 0.706 rs2563302 ENSG00000231043.3 AC007238.1 6.24 2.24e-09 0.00684 0.44 0.39 Depressive symptoms (multi-trait analysis); chr5:140699466 chr2:58460292~58462032:- CESC trans rs2950393 0.804 rs7980317 ENSG00000257210.1 NACAP3 6.24 2.27e-09 0.00695 0.44 0.39 Platelet distribution width; chr12:56764399 chr12:93124063~93124543:- CESC trans rs10940346 0.56 rs2137134 ENSG00000231752.4 EMBP1 6.24 2.3e-09 0.00703 0.47 0.39 Schizophrenia; chr5:50354188 chr1:121519112~121571892:+ CESC trans rs10940346 0.54 rs57137858 ENSG00000231752.4 EMBP1 6.24 2.3e-09 0.00703 0.47 0.39 Schizophrenia; chr5:50369737 chr1:121519112~121571892:+ CESC trans rs7520050 0.751 rs592214 ENSG00000255397.1 AC022182.2 6.24 2.31e-09 0.00704 0.49 0.39 Reticulocyte count;Red blood cell count; chr1:45558833 chr8:60937705~60939871:- CESC trans rs2209875 0.574 rs2274576 ENSG00000234819.1 RP11-336N8.4 6.23 2.31e-09 0.00706 0.47 0.39 Pelvic organ prolapse (moderate/severe); chr9:89311531 chr9:78219120~78219357:+ CESC trans rs77688320 0.553 rs2243791 ENSG00000235105.1 RP11-329A14.1 -6.23 2.32e-09 0.00707 -0.45 -0.39 Breast cancer; chr2:201478079 chr1:48435967~48437223:+ CESC trans rs1568889 1 rs9783281 ENSG00000174912.7 METTL15P1 6.23 2.34e-09 0.00714 0.48 0.39 Bipolar disorder; chr11:28012239 chr3:156713884~156714928:- CESC trans rs10940346 0.601 rs1511738 ENSG00000231752.4 EMBP1 -6.23 2.35e-09 0.00716 -0.47 -0.39 Schizophrenia; chr5:50313444 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10062032 ENSG00000231752.4 EMBP1 -6.23 2.35e-09 0.00716 -0.47 -0.39 Schizophrenia; chr5:50316138 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10074359 ENSG00000231752.4 EMBP1 -6.23 2.35e-09 0.00716 -0.47 -0.39 Schizophrenia; chr5:50316423 chr1:121519112~121571892:+ CESC trans rs12709013 0.967 rs8054482 ENSG00000230849.2 GOT2P2 6.23 2.35e-09 0.00717 0.46 0.39 Blood metabolite ratios; chr16:58810532 chr1:173141100~173142350:- CESC trans rs11098499 0.588 rs2389874 ENSG00000275858.1 RP11-291L22.8 -6.23 2.35e-09 0.00717 -0.42 -0.39 Corneal astigmatism; chr4:119633836 chr10:38450738~38451069:- CESC trans rs10940346 0.58 rs7447926 ENSG00000231752.4 EMBP1 -6.23 2.39e-09 0.00729 -0.47 -0.39 Schizophrenia; chr5:50310902 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs1511737 ENSG00000231752.4 EMBP1 -6.23 2.39e-09 0.00729 -0.47 -0.39 Schizophrenia; chr5:50312308 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs2036902 ENSG00000231752.4 EMBP1 6.23 2.41e-09 0.00732 0.47 0.39 Schizophrenia; chr5:50401098 chr1:121519112~121571892:+ CESC trans rs1355223 0.506 rs12294339 ENSG00000225531.1 RP11-196I18.3 6.22 2.47e-09 0.00749 0.47 0.39 Systemic lupus erythematosus and Systemic sclerosis; chr11:34838652 chr9:107116829~107117557:+ CESC trans rs7554547 0.69 rs6667637 ENSG00000261819.1 RP11-680G24.4 6.22 2.48e-09 0.00753 0.46 0.39 Nonsyndromic cleft lip with cleft palate; chr1:11887900 chr16:14988259~14990160:- CESC trans rs77688320 0.535 rs10186894 ENSG00000235105.1 RP11-329A14.1 6.22 2.55e-09 0.00771 0.44 0.39 Breast cancer; chr2:201440909 chr1:48435967~48437223:+ CESC trans rs877636 0.859 rs3741499 ENSG00000235459.5 RPS26P31 -6.21 2.61e-09 0.00787 -0.41 -0.39 Cognitive function; chr12:56080595 chr7:122681315~122681662:+ CESC trans rs11098499 0.588 rs6534149 ENSG00000275858.1 RP11-291L22.8 -6.21 2.62e-09 0.0079 -0.42 -0.39 Corneal astigmatism; chr4:119638137 chr10:38450738~38451069:- CESC trans rs77688320 0.553 rs2540449 ENSG00000235105.1 RP11-329A14.1 -6.21 2.63e-09 0.00793 -0.45 -0.39 Breast cancer; chr2:201451036 chr1:48435967~48437223:+ CESC trans rs2950393 0.929 rs10876916 ENSG00000257210.1 NACAP3 6.21 2.63e-09 0.00793 0.43 0.39 Platelet distribution width; chr12:56692728 chr12:93124063~93124543:- CESC trans rs2950393 0.794 rs1563897 ENSG00000257210.1 NACAP3 6.21 2.63e-09 0.00793 0.43 0.39 Platelet distribution width; chr12:56699316 chr12:93124063~93124543:- CESC trans rs10819083 0.861 rs11789188 ENSG00000203588.3 IGBP1-AS1 -6.21 2.63e-09 0.00793 -0.34 -0.39 Squamous cell lung carcinoma; chr9:125942733 chrX:70163842~70165206:- CESC trans rs10819083 0.788 rs11791242 ENSG00000203588.3 IGBP1-AS1 -6.21 2.63e-09 0.00793 -0.34 -0.39 Squamous cell lung carcinoma; chr9:125942910 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs7024493 ENSG00000203588.3 IGBP1-AS1 -6.21 2.63e-09 0.00793 -0.34 -0.39 Squamous cell lung carcinoma; chr9:125949963 chrX:70163842~70165206:- CESC trans rs10819083 0.788 rs12351249 ENSG00000203588.3 IGBP1-AS1 -6.21 2.63e-09 0.00793 -0.34 -0.39 Squamous cell lung carcinoma; chr9:125953417 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs7868801 ENSG00000203588.3 IGBP1-AS1 -6.21 2.63e-09 0.00793 -0.34 -0.39 Squamous cell lung carcinoma; chr9:125953697 chrX:70163842~70165206:- CESC trans rs10940346 0.56 rs6892613 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50353678 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs6450056 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50356692 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10073591 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50359010 chr1:121519112~121571892:+ CESC trans rs10940346 0.521 rs7730857 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50361516 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs10071725 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50361986 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7732000 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50364779 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs11959569 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50369429 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs6450063 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50374147 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10042504 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50386329 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs4398636 ENSG00000231752.4 EMBP1 6.21 2.63e-09 0.00793 0.46 0.39 Schizophrenia; chr5:50391957 chr1:121519112~121571892:+ CESC trans rs6732160 0.624 rs10865397 ENSG00000236165.1 PRADC1P1 6.21 2.65e-09 0.00797 0.46 0.39 Intelligence (multi-trait analysis); chr2:73131164 chr3:36976316~36976840:+ CESC trans rs72615157 0.561 rs113844570 ENSG00000228546.2 CTA-313A17.3 6.21 2.65e-09 0.00798 0.65 0.39 Lung function (FEV1/FVC); chr7:100276155 chr7:102337316~102339115:+ CESC trans rs11098499 0.739 rs951570 ENSG00000275858.1 RP11-291L22.8 -6.21 2.65e-09 0.008 -0.44 -0.39 Corneal astigmatism; chr4:119229312 chr10:38450738~38451069:- CESC trans rs12709013 0.792 rs7185513 ENSG00000233719.3 GOT2P3 6.21 2.66e-09 0.00801 0.43 0.39 Blood metabolite ratios; chr16:58794889 chr12:9641802~9643007:+ CESC trans rs8010715 0.636 rs2277480 ENSG00000238000.1 RP11-274E7.2 6.21 2.67e-09 0.00804 0.41 0.39 IgG glycosylation; chr14:24118306 chr5:98213402~98214121:+ CESC trans rs13190036 0.901 rs10056655 ENSG00000217325.2 PRELID1P1 6.21 2.68e-09 0.00806 0.58 0.39 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177249350 chr6:126643488~126644390:+ CESC trans rs959695 0.834 rs6468693 ENSG00000260318.1 COX6CP1 -6.21 2.69e-09 0.00808 -0.51 -0.39 Hippocampal atrophy; chr8:99839040 chr16:11903923~11904137:- CESC trans rs7312770 0.612 rs1873914 ENSG00000223416.3 RPS26P15 6.21 2.71e-09 0.00814 0.39 0.39 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr1:58056133~58056480:- CESC trans rs941207 0.756 rs1465081 ENSG00000257210.1 NACAP3 -6.21 2.71e-09 0.00814 -0.52 -0.39 Platelet count; chr12:56656390 chr12:93124063~93124543:- CESC trans rs9611519 0.78 rs3171692 ENSG00000268568.1 AC007228.9 -6.21 2.71e-09 0.00815 -0.55 -0.39 Neuroticism; chr22:41246208 chr19:56672574~56673901:- CESC trans rs74781061 0.929 rs9672559 ENSG00000227288.3 RP5-837I24.1 6.2 2.72e-09 0.00819 0.51 0.39 Endometriosis; chr15:74698995 chr1:81501794~81503468:+ CESC trans rs10242455 0.867 rs2687087 ENSG00000228834.1 RP11-249L21.4 -6.2 2.73e-09 0.0082 -0.63 -0.39 Blood metabolite levels; chr7:99696849 chr6:108907615~108907873:- CESC trans rs1707322 1 rs2458400 ENSG00000255397.1 AC022182.2 6.2 2.76e-09 0.00829 0.5 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46065126 chr8:60937705~60939871:- CESC trans rs1707322 0.896 rs785512 ENSG00000255397.1 AC022182.2 6.2 2.76e-09 0.00829 0.5 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46068871 chr8:60937705~60939871:- CESC trans rs1707322 1 rs9429186 ENSG00000255397.1 AC022182.2 6.2 2.76e-09 0.00829 0.5 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46074015 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785506 ENSG00000255397.1 AC022182.2 6.2 2.76e-09 0.00829 0.5 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46074980 chr8:60937705~60939871:- CESC trans rs10940346 0.601 rs1606224 ENSG00000231752.4 EMBP1 -6.2 2.77e-09 0.0083 -0.46 -0.39 Schizophrenia; chr5:50317405 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7341010 ENSG00000231752.4 EMBP1 -6.2 2.77e-09 0.0083 -0.46 -0.39 Schizophrenia; chr5:50317811 chr1:121519112~121571892:+ CESC trans rs1568889 0.877 rs57202579 ENSG00000174912.7 METTL15P1 6.2 2.78e-09 0.00835 0.47 0.39 Bipolar disorder; chr11:28200130 chr3:156713884~156714928:- CESC trans rs10940346 0.601 rs1674512 ENSG00000231752.4 EMBP1 6.2 2.8e-09 0.00839 0.46 0.39 Schizophrenia; chr5:50268794 chr1:121519112~121571892:+ CESC trans rs941207 0.756 rs2950394 ENSG00000257210.1 NACAP3 -6.2 2.8e-09 0.0084 -0.51 -0.39 Platelet count; chr12:56644548 chr12:93124063~93124543:- CESC trans rs928391 0.744 rs11264555 ENSG00000227183.3 HDGFP1 -6.2 2.8e-09 0.0084 -0.51 -0.39 Platelet count; chr1:156794246 chrX:131646639~131646890:+ CESC trans rs9899728 0.539 rs35928207 ENSG00000234925.2 ATP5HP4 6.2 2.83e-09 0.00848 0.74 0.39 Alzheimer's disease or small vessel stroke; chr17:75037534 chr12:68642519~68642993:- CESC trans rs1707322 0.964 rs785508 ENSG00000255397.1 AC022182.2 6.2 2.85e-09 0.00854 0.5 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46061487 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs785509 ENSG00000255397.1 AC022182.2 6.2 2.85e-09 0.00854 0.5 0.39 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46061628 chr8:60937705~60939871:- CESC trans rs4276421 0.615 rs7733616 ENSG00000231752.4 EMBP1 -6.2 2.87e-09 0.0086 -0.48 -0.39 P wave duration; chr5:45798621 chr1:121519112~121571892:+ CESC trans rs941207 0.789 rs2958145 ENSG00000257210.1 NACAP3 -6.19 2.94e-09 0.0088 -0.51 -0.39 Platelet count; chr12:56662290 chr12:93124063~93124543:- CESC trans rs1568889 0.838 rs4572130 ENSG00000174912.7 METTL15P1 6.19 2.98e-09 0.00889 0.41 0.39 Bipolar disorder; chr11:28350247 chr3:156713884~156714928:- CESC trans rs877636 0.74 rs705702 ENSG00000225071.1 GS1-184P14.2 -6.19 3e-09 0.00896 -0.4 -0.39 Cognitive function; chr12:55996852 chrX:24429573~24429920:- CESC trans rs7554511 0.894 rs11579874 ENSG00000244144.1 RP11-757F18.3 6.19 3.01e-09 0.00898 0.45 0.39 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200951234 chr3:112185480~112185998:- CESC trans rs4276421 0.904 rs4388219 ENSG00000231752.4 EMBP1 6.19 3.01e-09 0.00898 0.51 0.39 P wave duration; chr5:45780648 chr1:121519112~121571892:+ CESC trans rs4948102 0.655 rs4947533 ENSG00000215006.4 CHCHD2P2 -6.18 3.04e-09 0.00908 -0.5 -0.39 Plasma homocysteine levels (post-methionine load test); chr7:56003589 chr5:69333929~69334249:+ CESC trans rs1936166 0.744 rs6920118 ENSG00000237973.1 RP5-857K21.6 -6.18 3.05e-09 0.0091 -0.65 -0.39 Parasitemia in Tripanosoma cruzi seropositivity; chr6:77385440 chr1:631074~632616:+ CESC trans rs66887589 0.616 rs11098497 ENSG00000275858.1 RP11-291L22.8 6.18 3.05e-09 0.0091 0.41 0.39 Diastolic blood pressure; chr4:119265913 chr10:38450738~38451069:- CESC trans rs66887589 0.616 rs7659403 ENSG00000275858.1 RP11-291L22.8 6.18 3.05e-09 0.0091 0.41 0.39 Diastolic blood pressure; chr4:119286099 chr10:38450738~38451069:- CESC trans rs10242455 0.571 rs12334072 ENSG00000228834.1 RP11-249L21.4 6.18 3.06e-09 0.00913 0.62 0.39 Blood metabolite levels; chr7:99654084 chr6:108907615~108907873:- CESC trans rs2699783 0.901 rs2627847 ENSG00000258230.2 RP11-511H9.3 -6.18 3.07e-09 0.00915 -0.71 -0.39 Bipolar disorder (body mass index interaction); chr2:66030537 chr12:101773114~101773755:- CESC trans rs2950393 0.804 rs2958132 ENSG00000257210.1 NACAP3 6.18 3.08e-09 0.00919 0.43 0.39 Platelet distribution width; chr12:56750749 chr12:93124063~93124543:- CESC trans rs13190036 1 rs13167431 ENSG00000228305.2 AC016734.2 -6.18 3.08e-09 0.00919 -0.52 -0.39 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr2:63622178~63622831:- CESC trans rs9611519 0.78 rs9611527 ENSG00000268568.1 AC007228.9 -6.18 3.09e-09 0.00922 -0.52 -0.39 Neuroticism; chr22:41248424 chr19:56672574~56673901:- CESC trans rs877636 0.74 rs705698 ENSG00000234513.1 AC073072.7 6.18 3.1e-09 0.00923 0.42 0.39 Cognitive function; chr12:55990903 chr7:22773646~22773993:- CESC trans rs4276421 0.577 rs10054424 ENSG00000231752.4 EMBP1 6.18 3.14e-09 0.00935 0.47 0.39 P wave duration; chr5:45748769 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10054503 ENSG00000231752.4 EMBP1 6.18 3.15e-09 0.00936 0.46 0.39 Schizophrenia; chr5:50326746 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs1344339 ENSG00000231752.4 EMBP1 -6.18 3.15e-09 0.00938 -0.47 -0.39 Schizophrenia; chr5:50327987 chr1:121519112~121571892:+ CESC trans rs10242455 0.867 rs2687135 ENSG00000226278.1 PSPHP1 -6.18 3.17e-09 0.00942 -0.52 -0.39 Blood metabolite levels; chr7:99728686 chr7:55764797~55773288:+ CESC trans rs7312770 1 rs7312770 ENSG00000234513.1 AC073072.7 -6.17 3.21e-09 0.00954 -0.4 -0.39 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr7:22773646~22773993:- CESC trans rs1355223 0.506 rs1509660 ENSG00000225531.1 RP11-196I18.3 6.17 3.21e-09 0.00955 0.47 0.39 Systemic lupus erythematosus and Systemic sclerosis; chr11:34843470 chr9:107116829~107117557:+ CESC trans rs1355223 0.506 rs1509659 ENSG00000225531.1 RP11-196I18.3 6.17 3.21e-09 0.00955 0.47 0.39 Systemic lupus erythematosus and Systemic sclerosis; chr11:34843586 chr9:107116829~107117557:+ CESC trans rs1355223 0.506 rs11032894 ENSG00000225531.1 RP11-196I18.3 6.17 3.21e-09 0.00955 0.47 0.39 Systemic lupus erythematosus and Systemic sclerosis; chr11:34843997 chr9:107116829~107117557:+ CESC trans rs1355223 0.506 rs7947848 ENSG00000225531.1 RP11-196I18.3 6.17 3.21e-09 0.00955 0.47 0.39 Systemic lupus erythematosus and Systemic sclerosis; chr11:34844673 chr9:107116829~107117557:+ CESC trans rs4455778 0.501 rs35433930 ENSG00000238249.2 HMGN2P17 -6.17 3.22e-09 0.00956 -0.37 -0.39 Lung cancer in never smokers; chr7:49019456 chr1:8893409~8894151:+ CESC trans rs622217 0.871 rs675162 ENSG00000235701.1 PCBP2P1 6.17 3.24e-09 0.00962 0.44 0.39 Type 2 diabetes; chr6:160355293 chr21:39171130~39172106:- CESC trans rs7520050 0.751 rs2230657 ENSG00000255397.1 AC022182.2 6.17 3.25e-09 0.00966 0.48 0.39 Reticulocyte count;Red blood cell count; chr1:45607817 chr8:60937705~60939871:- CESC trans rs9611565 0.921 rs5751081 ENSG00000268568.1 AC007228.9 -6.17 3.27e-09 0.00969 -0.48 -0.39 Vitiligo; chr22:41346784 chr19:56672574~56673901:- CESC trans rs9611565 0.921 rs2281332 ENSG00000268568.1 AC007228.9 -6.17 3.27e-09 0.00969 -0.48 -0.39 Vitiligo; chr22:41350208 chr19:56672574~56673901:- CESC trans rs2896526 0.736 rs78950598 ENSG00000235847.2 LDHAP7 6.17 3.28e-09 0.00972 0.72 0.39 Amyloid A serum levels; chr11:18375599 chr2:84777259~84778223:- CESC trans rs4455778 0.519 rs6583488 ENSG00000238249.2 HMGN2P17 -6.17 3.35e-09 0.00992 -0.37 -0.39 Lung cancer in never smokers; chr7:49000343 chr1:8893409~8894151:+ CESC trans rs4455778 0.5 rs10224270 ENSG00000238249.2 HMGN2P17 -6.17 3.35e-09 0.00992 -0.37 -0.39 Lung cancer in never smokers; chr7:49001758 chr1:8893409~8894151:+ CESC trans rs4455778 0.501 rs10227306 ENSG00000238249.2 HMGN2P17 -6.17 3.35e-09 0.00992 -0.37 -0.39 Lung cancer in never smokers; chr7:49008430 chr1:8893409~8894151:+ CESC trans rs4455778 0.519 rs10227532 ENSG00000238249.2 HMGN2P17 -6.17 3.35e-09 0.00992 -0.37 -0.39 Lung cancer in never smokers; chr7:49008612 chr1:8893409~8894151:+ CESC trans rs77688320 0.573 rs2714480 ENSG00000235105.1 RP11-329A14.1 -6.17 3.37e-09 0.00997 -0.43 -0.39 Breast cancer; chr2:201486286 chr1:48435967~48437223:+ CESC trans rs9425766 0.927 rs5878 ENSG00000213331.4 RP11-713C19.2 6.16 3.38e-09 0.00999 0.46 0.39 Life satisfaction; chr1:173909694 chr4:187970273~187971284:+ CESC trans rs10940346 0.601 rs2137129 ENSG00000231752.4 EMBP1 -6.16 3.4e-09 0.01 -0.46 -0.39 Schizophrenia; chr5:50300962 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs12513730 ENSG00000231752.4 EMBP1 -6.16 3.4e-09 0.01 -0.46 -0.39 Schizophrenia; chr5:50302800 chr1:121519112~121571892:+ CESC trans rs9611565 0.921 rs5751080 ENSG00000268568.1 AC007228.9 -6.16 3.41e-09 0.0101 -0.48 -0.39 Vitiligo; chr22:41340263 chr19:56672574~56673901:- CESC trans rs8175379 0.551 rs4975969 ENSG00000231752.4 EMBP1 -6.16 3.41e-09 0.0101 -0.48 -0.39 Interleukin-7 levels; chr5:46295887 chr1:121519112~121571892:+ CESC trans rs8175379 0.502 rs8185361 ENSG00000231752.4 EMBP1 -6.16 3.42e-09 0.0101 -0.47 -0.39 Interleukin-7 levels; chr5:46300238 chr1:121519112~121571892:+ CESC trans rs4948102 0.924 rs13240915 ENSG00000215006.4 CHCHD2P2 -6.16 3.44e-09 0.0102 -0.48 -0.39 Plasma homocysteine levels (post-methionine load test); chr7:56023059 chr5:69333929~69334249:+ CESC trans rs4791051 0.786 rs7212766 ENSG00000260196.1 RP1-239B22.5 -6.16 3.52e-09 0.0104 -0.47 -0.38 Heschl's gyrus morphology; chr17:66482183 chr11:17380649~17383531:+ CESC trans rs7312770 1 rs7312770 ENSG00000212994.5 RPS26P6 -6.16 3.53e-09 0.0104 -0.44 -0.38 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr8:100895771~100896118:+ CESC trans rs2950393 0.726 rs10459246 ENSG00000257210.1 NACAP3 -6.16 3.54e-09 0.0104 -0.42 -0.38 Platelet distribution width; chr12:56776034 chr12:93124063~93124543:- CESC trans rs3812762 0.826 rs2292045 ENSG00000266891.1 RP11-692N5.2 6.15 3.59e-09 0.0106 0.47 0.38 Hypospadias; chr11:8785162 chr18:9734882~9735602:- CESC trans rs7520050 0.751 rs2991975 ENSG00000255397.1 AC022182.2 6.15 3.59e-09 0.0106 0.47 0.38 Reticulocyte count;Red blood cell count; chr1:45558854 chr8:60937705~60939871:- CESC trans rs10940346 0.601 rs4637546 ENSG00000231752.4 EMBP1 6.15 3.6e-09 0.0106 0.46 0.38 Schizophrenia; chr5:50358359 chr1:121519112~121571892:+ CESC trans rs77688320 0.529 rs2540438 ENSG00000235105.1 RP11-329A14.1 -6.15 3.6e-09 0.0106 -0.43 -0.38 Breast cancer; chr2:201485833 chr1:48435967~48437223:+ CESC trans rs10940346 0.601 rs1833900 ENSG00000231752.4 EMBP1 -6.15 3.65e-09 0.0107 -0.47 -0.38 Schizophrenia; chr5:50504668 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7723480 ENSG00000231752.4 EMBP1 6.15 3.65e-09 0.0107 0.47 0.38 Schizophrenia; chr5:50350324 chr1:121519112~121571892:+ CESC trans rs13190036 0.551 rs4976639 ENSG00000226986.4 RP11-543B16.2 6.15 3.67e-09 0.0108 0.46 0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177123300 chr1:211207239~211207897:+ CESC trans rs877636 0.74 rs705702 ENSG00000234513.1 AC073072.7 -6.14 3.76e-09 0.011 -0.42 -0.38 Cognitive function; chr12:55996852 chr7:22773646~22773993:- CESC trans rs12709013 0.766 rs11648511 ENSG00000233719.3 GOT2P3 6.14 3.76e-09 0.011 0.43 0.38 Blood metabolite ratios; chr16:58798171 chr12:9641802~9643007:+ CESC trans rs12709013 0.716 rs11647582 ENSG00000233719.3 GOT2P3 6.14 3.76e-09 0.011 0.43 0.38 Blood metabolite ratios; chr16:58801474 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs35684307 ENSG00000233719.3 GOT2P3 6.14 3.76e-09 0.011 0.43 0.38 Blood metabolite ratios; chr16:58801651 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs11649387 ENSG00000233719.3 GOT2P3 6.14 3.76e-09 0.011 0.43 0.38 Blood metabolite ratios; chr16:58803176 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs11649133 ENSG00000233719.3 GOT2P3 6.14 3.76e-09 0.011 0.43 0.38 Blood metabolite ratios; chr16:58803275 chr12:9641802~9643007:+ CESC trans rs12709013 0.766 rs12599331 ENSG00000233719.3 GOT2P3 6.14 3.76e-09 0.011 0.43 0.38 Blood metabolite ratios; chr16:58805307 chr12:9641802~9643007:+ CESC trans rs2991971 0.934 rs2991974 ENSG00000255397.1 AC022182.2 6.14 3.79e-09 0.0111 0.48 0.38 High light scatter reticulocyte count; chr1:45554982 chr8:60937705~60939871:- CESC trans rs62140779 0.887 rs57901007 ENSG00000253347.1 CTD-2026D20.2 6.14 3.79e-09 0.0111 0.61 0.38 Neuroticism; chr2:58478169 chr17:47409322~47423526:- CESC trans rs877636 0.74 rs772920 ENSG00000234513.1 AC073072.7 6.14 3.8e-09 0.0111 0.43 0.38 Cognitive function; chr12:55996580 chr7:22773646~22773993:- CESC trans rs7554511 0.858 rs11584383 ENSG00000244144.1 RP11-757F18.3 6.14 3.81e-09 0.0112 0.43 0.38 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200966738 chr3:112185480~112185998:- CESC trans rs10940346 0.58 rs4865801 ENSG00000231752.4 EMBP1 -6.14 3.81e-09 0.0112 -0.47 -0.38 Schizophrenia; chr5:50163364 chr1:121519112~121571892:+ CESC trans rs10819083 0.861 rs13292724 ENSG00000203588.3 IGBP1-AS1 -6.14 3.84e-09 0.0112 -0.34 -0.38 Squamous cell lung carcinoma; chr9:125971041 chrX:70163842~70165206:- CESC trans rs10940346 0.601 rs1016620 ENSG00000231752.4 EMBP1 -6.14 3.84e-09 0.0112 -0.47 -0.38 Schizophrenia; chr5:50490763 chr1:121519112~121571892:+ CESC trans rs12709013 0.967 rs2118019 ENSG00000230849.2 GOT2P2 -6.14 3.87e-09 0.0113 -0.45 -0.38 Blood metabolite ratios; chr16:58797825 chr1:173141100~173142350:- CESC trans rs9876781 0.872 rs11797 ENSG00000225528.1 RP3-370M22.8 -6.14 3.9e-09 0.0114 -0.38 -0.38 Longevity; chr3:48467186 chr22:39960397~39964683:+ CESC trans rs8010715 0.636 rs2277482 ENSG00000238000.1 RP11-274E7.2 6.14 3.93e-09 0.0115 0.41 0.38 IgG glycosylation; chr14:24118586 chr5:98213402~98214121:+ CESC trans rs12497850 0.931 rs3774628 ENSG00000197582.5 GPX1P1 6.14 3.94e-09 0.0115 0.5 0.38 Parkinson's disease; chr3:48764407 chrX:13378735~13379340:- CESC trans rs10940346 0.562 rs10940336 ENSG00000231752.4 EMBP1 -6.14 3.96e-09 0.0116 -0.47 -0.38 Schizophrenia; chr5:50505020 chr1:121519112~121571892:+ CESC trans rs10940346 0.623 rs6863840 ENSG00000231752.4 EMBP1 6.13 3.98e-09 0.0116 0.46 0.38 Schizophrenia; chr5:50328070 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs6871761 ENSG00000231752.4 EMBP1 6.13 3.98e-09 0.0116 0.46 0.38 Schizophrenia; chr5:50328134 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs6877713 ENSG00000231752.4 EMBP1 6.13 3.98e-09 0.0116 0.46 0.38 Schizophrenia; chr5:50329254 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs4337857 ENSG00000231752.4 EMBP1 6.13 3.98e-09 0.0116 0.46 0.38 Schizophrenia; chr5:50329735 chr1:121519112~121571892:+ CESC trans rs12709013 1 rs11648514 ENSG00000230849.2 GOT2P2 6.13 3.99e-09 0.0116 0.45 0.38 Blood metabolite ratios; chr16:58798176 chr1:173141100~173142350:- CESC trans rs877636 0.692 rs11171739 ENSG00000204652.6 RPS26P8 6.13 4.01e-09 0.0117 0.41 0.38 Cognitive function; chr12:56076841 chr17:45608571~45608918:+ CESC trans rs8175379 0.509 rs8185010 ENSG00000231752.4 EMBP1 -6.13 4.03e-09 0.0118 -0.49 -0.38 Interleukin-7 levels; chr5:46306373 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs628506 ENSG00000226986.4 RP11-543B16.2 -6.13 4.06e-09 0.0118 -0.47 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107422 chr1:211207239~211207897:+ CESC trans rs72615157 0.613 rs56089143 ENSG00000228546.2 CTA-313A17.3 6.13 4.08e-09 0.0119 0.57 0.38 Lung function (FEV1/FVC); chr7:100222221 chr7:102337316~102339115:+ CESC trans rs72615157 0.664 rs6953580 ENSG00000228546.2 CTA-313A17.3 6.13 4.08e-09 0.0119 0.57 0.38 Lung function (FEV1/FVC); chr7:100227652 chr7:102337316~102339115:+ CESC trans rs61041336 0.534 rs2280398 ENSG00000233719.3 GOT2P3 -6.13 4.09e-09 0.0119 -0.61 -0.38 Neuritic plaque; chr16:58678226 chr12:9641802~9643007:+ CESC trans rs9611519 0.78 rs9611528 ENSG00000268568.1 AC007228.9 -6.13 4.17e-09 0.0121 -0.48 -0.38 Neuroticism; chr22:41252498 chr19:56672574~56673901:- CESC trans rs7032940 0.784 rs10980253 ENSG00000228236.2 TXNP5 6.13 4.17e-09 0.0121 0.49 0.38 Height; chr9:110205555 chr2:149068596~149068910:- CESC trans rs7554547 0.714 rs926269 ENSG00000261819.1 RP11-680G24.4 6.12 4.21e-09 0.0122 0.48 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11909691 chr16:14988259~14990160:- CESC trans rs7554547 0.714 rs2878679 ENSG00000261819.1 RP11-680G24.4 6.12 4.21e-09 0.0122 0.48 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11915586 chr16:14988259~14990160:- CESC trans rs4276421 0.837 rs7446182 ENSG00000231752.4 EMBP1 -6.12 4.24e-09 0.0123 -0.47 -0.38 P wave duration; chr5:45401715 chr1:121519112~121571892:+ CESC trans rs169082 0.867 rs192358 ENSG00000269473.1 CTD-2619J13.19 -6.12 4.25e-09 0.0123 -0.42 -0.38 Protein quantitative trait loci; chr5:169646056 chr19:58440448~58445849:+ CESC trans rs10940346 0.56 rs7293410 ENSG00000231752.4 EMBP1 -6.12 4.3e-09 0.0125 -0.47 -0.38 Schizophrenia; chr5:50163036 chr1:121519112~121571892:+ CESC trans rs3740713 0.669 rs113003553 ENSG00000235847.2 LDHAP7 6.12 4.31e-09 0.0125 0.64 0.38 Amyotrophic lateral sclerosis (sporadic); chr11:18389314 chr2:84777259~84778223:- CESC trans rs4444359 0.679 rs6498195 ENSG00000206633.1 SNORA80B -6.12 4.32e-09 0.0125 -0.52 -0.38 Facial morphology (factor 17, height of vermillion upper lip); chr16:11452519 chr2:10446714~10446849:- CESC trans rs3812762 0.833 rs35670750 ENSG00000266891.1 RP11-692N5.2 6.12 4.32e-09 0.0125 0.47 0.38 Hypospadias; chr11:8760897 chr18:9734882~9735602:- CESC trans rs12709013 0.792 rs62064940 ENSG00000233719.3 GOT2P3 6.12 4.36e-09 0.0126 0.43 0.38 Blood metabolite ratios; chr16:58796560 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs8049572 ENSG00000233719.3 GOT2P3 6.12 4.36e-09 0.0126 0.43 0.38 Blood metabolite ratios; chr16:58809672 chr12:9641802~9643007:+ CESC trans rs12709013 0.766 rs34438483 ENSG00000233719.3 GOT2P3 6.12 4.38e-09 0.0127 0.43 0.38 Blood metabolite ratios; chr16:58810530 chr12:9641802~9643007:+ CESC trans rs4948102 0.731 rs4948099 ENSG00000215006.4 CHCHD2P2 6.12 4.4e-09 0.0127 0.48 0.38 Plasma homocysteine levels (post-methionine load test); chr7:56004557 chr5:69333929~69334249:+ CESC trans rs4276421 0.571 rs4368738 ENSG00000231752.4 EMBP1 6.11 4.41e-09 0.0128 0.48 0.38 P wave duration; chr5:45892686 chr1:121519112~121571892:+ CESC trans rs4276421 0.593 rs10223123 ENSG00000231752.4 EMBP1 6.11 4.41e-09 0.0128 0.48 0.38 P wave duration; chr5:45893554 chr1:121519112~121571892:+ CESC trans rs4276421 0.593 rs9292929 ENSG00000231752.4 EMBP1 6.11 4.41e-09 0.0128 0.48 0.38 P wave duration; chr5:45894168 chr1:121519112~121571892:+ CESC trans rs7520050 0.778 rs2991985 ENSG00000255397.1 AC022182.2 6.11 4.45e-09 0.0129 0.47 0.38 Reticulocyte count;Red blood cell count; chr1:45614858 chr8:60937705~60939871:- CESC trans rs7113874 0.592 rs12808779 ENSG00000266891.1 RP11-692N5.2 6.11 4.46e-09 0.0129 0.53 0.38 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8416280 chr18:9734882~9735602:- CESC trans rs714543 0.783 rs7806283 ENSG00000226038.5 PPIAP21 -6.11 4.47e-09 0.0129 -0.45 -0.38 Plateletcrit; chr7:44779104 chr20:43230760~43231260:+ CESC trans rs55665837 0.701 rs10766188 ENSG00000236360.2 RP11-334A14.2 6.11 4.48e-09 0.0129 0.49 0.38 Vitamin D levels; chr11:14639280 chr1:52993201~52993702:- CESC trans rs3806843 0.801 rs2531358 ENSG00000231043.3 AC007238.1 6.11 4.51e-09 0.013 0.43 0.38 Depressive symptoms (multi-trait analysis); chr5:140737852 chr2:58460292~58462032:- CESC trans rs1568889 0.838 rs10835283 ENSG00000174912.7 METTL15P1 6.11 4.51e-09 0.013 0.4 0.38 Bipolar disorder; chr11:28193438 chr3:156713884~156714928:- CESC trans rs3812762 0.871 rs3844100 ENSG00000266891.1 RP11-692N5.2 -6.11 4.54e-09 0.0131 -0.44 -0.38 Hypospadias; chr11:8796261 chr18:9734882~9735602:- CESC trans rs77688320 0.535 rs34625194 ENSG00000235105.1 RP11-329A14.1 6.11 4.55e-09 0.0131 0.41 0.38 Breast cancer; chr2:201406815 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs11691859 ENSG00000235105.1 RP11-329A14.1 6.11 4.55e-09 0.0131 0.41 0.38 Breast cancer; chr2:201407268 chr1:48435967~48437223:+ CESC trans rs77688320 0.517 rs11691865 ENSG00000235105.1 RP11-329A14.1 6.11 4.55e-09 0.0131 0.41 0.38 Breast cancer; chr2:201407309 chr1:48435967~48437223:+ CESC trans rs877636 0.74 rs772920 ENSG00000225071.1 GS1-184P14.2 6.11 4.56e-09 0.0131 0.4 0.38 Cognitive function; chr12:55996580 chrX:24429573~24429920:- CESC trans rs2950393 0.857 rs1563896 ENSG00000257210.1 NACAP3 6.11 4.59e-09 0.0132 0.44 0.38 Platelet distribution width; chr12:56699312 chr12:93124063~93124543:- CESC trans rs7520050 0.667 rs11211176 ENSG00000255397.1 AC022182.2 6.11 4.63e-09 0.0133 0.47 0.38 Reticulocyte count;Red blood cell count; chr1:45757414 chr8:60937705~60939871:- CESC trans rs3806843 0.741 rs4912597 ENSG00000231043.3 AC007238.1 6.11 4.63e-09 0.0133 0.42 0.38 Depressive symptoms (multi-trait analysis); chr5:140727272 chr2:58460292~58462032:- CESC trans rs3806843 0.771 rs2563334 ENSG00000231043.3 AC007238.1 6.11 4.63e-09 0.0133 0.42 0.38 Depressive symptoms (multi-trait analysis); chr5:140727480 chr2:58460292~58462032:- CESC trans rs10819083 0.861 rs2041943 ENSG00000203588.3 IGBP1-AS1 -6.1 4.66e-09 0.0134 -0.33 -0.38 Squamous cell lung carcinoma; chr9:125954852 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs10987059 ENSG00000203588.3 IGBP1-AS1 -6.1 4.66e-09 0.0134 -0.33 -0.38 Squamous cell lung carcinoma; chr9:125956392 chrX:70163842~70165206:- CESC trans rs4455778 0.58 rs34005483 ENSG00000238249.2 HMGN2P17 -6.1 4.66e-09 0.0134 -0.36 -0.38 Lung cancer in never smokers; chr7:49054711 chr1:8893409~8894151:+ CESC trans rs10940346 0.54 rs34645496 ENSG00000231752.4 EMBP1 6.1 4.69e-09 0.0135 0.48 0.38 Schizophrenia; chr5:50322419 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs35330444 ENSG00000231752.4 EMBP1 6.1 4.69e-09 0.0135 0.48 0.38 Schizophrenia; chr5:50322606 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs6875734 ENSG00000231752.4 EMBP1 6.1 4.69e-09 0.0135 0.48 0.38 Schizophrenia; chr5:50323203 chr1:121519112~121571892:+ CESC trans rs10242455 0.764 rs4646465 ENSG00000226278.1 PSPHP1 -6.1 4.74e-09 0.0136 -0.52 -0.38 Blood metabolite levels; chr7:99706901 chr7:55764797~55773288:+ CESC trans rs10242455 0.867 rs2687078 ENSG00000226278.1 PSPHP1 -6.1 4.74e-09 0.0136 -0.52 -0.38 Blood metabolite levels; chr7:99707089 chr7:55764797~55773288:+ CESC trans rs1707322 1 rs10789486 ENSG00000255397.1 AC022182.2 -6.1 4.79e-09 0.0138 -0.49 -0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45942995 chr8:60937705~60939871:- CESC trans rs10940346 0.519 rs7293422 ENSG00000231752.4 EMBP1 -6.1 4.86e-09 0.014 -0.48 -0.38 Schizophrenia; chr5:50146010 chr1:121519112~121571892:+ CESC trans rs9611519 0.761 rs35445172 ENSG00000268568.1 AC007228.9 -6.09 4.94e-09 0.0142 -0.48 -0.38 Neuroticism; chr22:41264297 chr19:56672574~56673901:- CESC trans rs9425766 0.888 rs1799876 ENSG00000213331.4 RP11-713C19.2 6.09 4.94e-09 0.0142 0.45 0.38 Life satisfaction; chr1:173909333 chr4:187970273~187971284:+ CESC trans rs2991971 1 rs9147 ENSG00000255397.1 AC022182.2 6.09 4.96e-09 0.0142 0.48 0.38 High light scatter reticulocyte count; chr1:45551015 chr8:60937705~60939871:- CESC trans rs2991971 1 rs2934859 ENSG00000255397.1 AC022182.2 6.09 4.96e-09 0.0142 0.48 0.38 High light scatter reticulocyte count; chr1:45552164 chr8:60937705~60939871:- CESC trans rs928391 0.744 rs6700964 ENSG00000227183.3 HDGFP1 -6.09 5.04e-09 0.0144 -0.49 -0.38 Platelet count; chr1:156790244 chrX:131646639~131646890:+ CESC trans rs12709013 1 rs12709013 ENSG00000230849.2 GOT2P2 -6.09 5.04e-09 0.0144 -0.45 -0.38 Blood metabolite ratios; chr16:58795886 chr1:173141100~173142350:- CESC trans rs2991971 0.81 rs6657237 ENSG00000255397.1 AC022182.2 -6.09 5.14e-09 0.0147 -0.45 -0.38 High light scatter reticulocyte count; chr1:45454436 chr8:60937705~60939871:- CESC trans rs8067354 0.645 rs2645467 ENSG00000187870.7 RNFT1P3 6.09 5.18e-09 0.0148 0.5 0.38 Hemoglobin concentration; chr17:59777422 chr17:20743333~20754501:- CESC trans rs2950393 0.804 rs3214051 ENSG00000257210.1 NACAP3 6.08 5.19e-09 0.0148 0.42 0.38 Platelet distribution width; chr12:56725452 chr12:93124063~93124543:- CESC trans rs66887589 0.592 rs28580295 ENSG00000275858.1 RP11-291L22.8 6.08 5.26e-09 0.015 0.4 0.38 Diastolic blood pressure; chr4:119357718 chr10:38450738~38451069:- CESC trans rs10940346 0.58 rs34185098 ENSG00000231752.4 EMBP1 6.08 5.26e-09 0.015 0.48 0.38 Schizophrenia; chr5:50330100 chr1:121519112~121571892:+ CESC trans rs13190036 1 rs13157667 ENSG00000228305.2 AC016734.2 -6.08 5.27e-09 0.015 -0.53 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr2:63622178~63622831:- CESC trans rs13190036 0.551 rs9313751 ENSG00000226986.4 RP11-543B16.2 -6.08 5.32e-09 0.0152 -0.42 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177217174 chr1:211207239~211207897:+ CESC trans rs12709013 0.792 rs12596434 ENSG00000233719.3 GOT2P3 6.08 5.33e-09 0.0152 0.42 0.38 Blood metabolite ratios; chr16:58792309 chr12:9641802~9643007:+ CESC trans rs714543 1 rs13245012 ENSG00000226038.5 PPIAP21 -6.08 5.33e-09 0.0152 -0.49 -0.38 Plateletcrit; chr7:44826120 chr20:43230760~43231260:+ CESC trans rs10940346 0.601 rs13172932 ENSG00000231752.4 EMBP1 6.08 5.34e-09 0.0152 0.48 0.38 Schizophrenia; chr5:50345364 chr1:121519112~121571892:+ CESC trans rs77688320 0.553 rs2540331 ENSG00000235105.1 RP11-329A14.1 -6.08 5.37e-09 0.0153 -0.44 -0.38 Breast cancer; chr2:201388150 chr1:48435967~48437223:+ CESC trans rs10940346 0.601 rs7448495 ENSG00000231752.4 EMBP1 -6.08 5.39e-09 0.0153 -0.45 -0.38 Schizophrenia; chr5:50300238 chr1:121519112~121571892:+ CESC trans rs2895526 0.58 rs7091892 ENSG00000228158.2 TLE1P1 6.08 5.43e-09 0.0154 0.4 0.38 Headache; chr10:12654508 chrX:65408084~65408672:+ CESC trans rs10940346 0.601 rs62365901 ENSG00000231752.4 EMBP1 6.08 5.43e-09 0.0154 0.46 0.38 Schizophrenia; chr5:50434497 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs62365902 ENSG00000231752.4 EMBP1 6.08 5.43e-09 0.0154 0.46 0.38 Schizophrenia; chr5:50434594 chr1:121519112~121571892:+ CESC trans rs11012350 0.85 rs11012386 ENSG00000279123.1 RP11-424M24.3 -6.08 5.46e-09 0.0155 -1 -0.38 Peripheral arterial disease (traffic-related air pollution interaction); chr10:18053406 chr16:70778433~70779145:+ CESC trans rs11012350 0.85 rs11012397 ENSG00000279123.1 RP11-424M24.3 -6.08 5.46e-09 0.0155 -1 -0.38 Peripheral arterial disease (traffic-related air pollution interaction); chr10:18055083 chr16:70778433~70779145:+ CESC trans rs11012350 0.85 rs11012398 ENSG00000279123.1 RP11-424M24.3 -6.08 5.46e-09 0.0155 -1 -0.38 Peripheral arterial disease (traffic-related air pollution interaction); chr10:18055118 chr16:70778433~70779145:+ CESC trans rs12339966 0.638 rs2821206 ENSG00000260947.1 RP11-384P7.7 -6.07 5.49e-09 0.0156 -0.51 -0.38 Systolic blood pressure; chr9:11682918 chr9:33697459~33700986:+ CESC trans rs11098499 0.739 rs9996382 ENSG00000275858.1 RP11-291L22.8 6.07 5.52e-09 0.0157 0.42 0.38 Corneal astigmatism; chr4:119229857 chr10:38450738~38451069:- CESC trans rs13190036 0.591 rs78523677 ENSG00000226986.4 RP11-543B16.2 -6.07 5.54e-09 0.0157 -0.46 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177124102 chr1:211207239~211207897:+ CESC trans rs77688320 0.553 rs2080322 ENSG00000235105.1 RP11-329A14.1 -6.07 5.58e-09 0.0158 -0.44 -0.38 Breast cancer; chr2:201514317 chr1:48435967~48437223:+ CESC trans rs4791051 0.723 rs4082896 ENSG00000260196.1 RP1-239B22.5 -6.07 5.59e-09 0.0159 -0.45 -0.38 Heschl's gyrus morphology; chr17:66452125 chr11:17380649~17383531:+ CESC trans rs4276421 0.571 rs62371969 ENSG00000231752.4 EMBP1 6.07 5.64e-09 0.016 0.51 0.38 P wave duration; chr5:45904700 chr1:121519112~121571892:+ CESC trans rs62045849 0.546 rs71395385 ENSG00000215030.5 RPL13P12 6.07 5.65e-09 0.016 0.83 0.38 Red blood cell count; chr16:89129871 chr17:17383377~17384012:- CESC trans rs58106596 0.66 rs62197212 ENSG00000259020.3 RP11-529H20.3 6.07 5.65e-09 0.016 0.58 0.38 Lymphocyte counts;White blood cell count; chr2:231698017 chr14:92026566~92026887:+ CESC trans rs877636 0.669 rs7297175 ENSG00000212994.5 RPS26P6 -6.07 5.66e-09 0.016 -0.45 -0.38 Cognitive function; chr12:56080024 chr8:100895771~100896118:+ CESC trans rs1326895 0.8 rs10980625 ENSG00000280389.1 RP11-512M8.11 6.07 5.67e-09 0.016 0.67 0.38 Pursuit maintenance gain; chr9:110902738 chr12:122255119~122260274:- CESC trans rs1326895 0.709 rs34860245 ENSG00000280389.1 RP11-512M8.11 6.07 5.67e-09 0.016 0.68 0.38 Pursuit maintenance gain; chr9:110947604 chr12:122255119~122260274:- CESC trans rs74781061 0.929 rs12439113 ENSG00000227288.3 RP5-837I24.1 6.07 5.67e-09 0.016 0.5 0.38 Endometriosis; chr15:74563806 chr1:81501794~81503468:+ CESC trans rs9876781 0.967 rs1870444 ENSG00000235912.1 RP1-159A19.3 -6.07 5.71e-09 0.0161 -0.36 -0.38 Longevity; chr3:48445369 chr1:27649419~27649610:+ CESC trans rs1051424 0.651 rs1292063 ENSG00000187870.7 RNFT1P3 -6.07 5.73e-09 0.0162 -0.51 -0.38 Obesity-related traits; chr17:59830407 chr17:20743333~20754501:- CESC trans rs8067354 0.645 rs2645489 ENSG00000187870.7 RNFT1P3 6.07 5.73e-09 0.0162 0.51 0.38 Hemoglobin concentration; chr17:59806010 chr17:20743333~20754501:- CESC trans rs8067354 0.645 rs2645486 ENSG00000187870.7 RNFT1P3 6.07 5.73e-09 0.0162 0.51 0.38 Hemoglobin concentration; chr17:59808540 chr17:20743333~20754501:- CESC trans rs8067354 0.645 rs2645487 ENSG00000187870.7 RNFT1P3 6.07 5.73e-09 0.0162 0.51 0.38 Hemoglobin concentration; chr17:59808764 chr17:20743333~20754501:- CESC trans rs1051424 0.642 rs115869798 ENSG00000187870.7 RNFT1P3 6.07 5.73e-09 0.0162 0.51 0.38 Obesity-related traits; chr17:59815468 chr17:20743333~20754501:- CESC trans rs10940346 0.562 rs7380318 ENSG00000231752.4 EMBP1 -6.06 5.77e-09 0.0163 -0.47 -0.38 Schizophrenia; chr5:50510557 chr1:121519112~121571892:+ CESC trans rs1707322 0.964 rs1768802 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46082196 chr8:60937705~60939871:- CESC trans rs1707322 1 rs1588663 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083153 chr8:60937705~60939871:- CESC trans rs1707322 1 rs1768801 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083465 chr8:60937705~60939871:- CESC trans rs1707322 1 rs1768800 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46083516 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs785483 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46093499 chr8:60937705~60939871:- CESC trans rs1707322 0.964 rs796773 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46098803 chr8:60937705~60939871:- CESC trans rs1707322 0.896 rs785518 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46102750 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785519 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46102890 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785486 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46109476 chr8:60937705~60939871:- CESC trans rs1707322 0.865 rs785501 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46113939 chr8:60937705~60939871:- CESC trans rs1707322 0.929 rs785500 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46127372 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785504 ENSG00000255397.1 AC022182.2 6.06 5.81e-09 0.0164 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46130024 chr8:60937705~60939871:- CESC trans rs13190036 1 rs35535623 ENSG00000228305.2 AC016734.2 -6.06 5.89e-09 0.0166 -0.5 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr2:63622178~63622831:- CESC trans rs13190036 1 rs71601343 ENSG00000228305.2 AC016734.2 -6.06 5.89e-09 0.0166 -0.5 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr2:63622178~63622831:- CESC trans rs13190036 1 rs71601344 ENSG00000228305.2 AC016734.2 -6.06 5.89e-09 0.0166 -0.5 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr2:63622178~63622831:- CESC trans rs13190036 1 rs3733875 ENSG00000228305.2 AC016734.2 -6.06 5.89e-09 0.0166 -0.5 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr2:63622178~63622831:- CESC trans rs7647973 1 rs11928090 ENSG00000197582.5 GPX1P1 6.06 5.93e-09 0.0167 0.51 0.38 Menarche (age at onset); chr3:49567471 chrX:13378735~13379340:- CESC trans rs1568889 1 rs12287732 ENSG00000174912.7 METTL15P1 6.06 5.99e-09 0.0169 0.43 0.38 Bipolar disorder; chr11:28099298 chr3:156713884~156714928:- CESC trans rs2969180 0.744 rs1974700 ENSG00000248206.1 RP11-739P1.2 -6.06 6.04e-09 0.017 -0.42 -0.38 Refractive error; chr17:11492073 chr4:183987678~183988750:+ CESC trans rs2950393 0.804 rs2290894 ENSG00000257210.1 NACAP3 6.06 6.05e-09 0.017 0.42 0.38 Platelet distribution width; chr12:56714911 chr12:93124063~93124543:- CESC trans rs2950393 0.777 rs2926747 ENSG00000257210.1 NACAP3 6.06 6.05e-09 0.017 0.42 0.38 Platelet distribution width; chr12:56716147 chr12:93124063~93124543:- CESC trans rs9650315 1 rs13271434 ENSG00000243802.2 RP11-390K5.1 6.05 6.11e-09 0.0171 0.6 0.38 Height; chr8:56246262 chr11:47191181~47191542:- CESC trans rs2950393 0.804 rs2926752 ENSG00000257210.1 NACAP3 6.05 6.11e-09 0.0172 0.42 0.38 Platelet distribution width; chr12:56710144 chr12:93124063~93124543:- CESC trans rs2950393 0.777 rs2958148 ENSG00000257210.1 NACAP3 6.05 6.11e-09 0.0172 0.42 0.38 Platelet distribution width; chr12:56710153 chr12:93124063~93124543:- CESC trans rs3749237 1 rs3749237 ENSG00000197582.5 GPX1P1 6.05 6.18e-09 0.0173 0.54 0.38 Resting heart rate; chr3:49732599 chrX:13378735~13379340:- CESC trans rs10940346 0.601 rs4145844 ENSG00000231752.4 EMBP1 -6.05 6.19e-09 0.0173 -0.47 -0.38 Schizophrenia; chr5:50478019 chr1:121519112~121571892:+ CESC trans rs9487051 1 rs1546723 ENSG00000228502.1 EEF1A1P11 6.05 6.19e-09 0.0173 0.34 0.38 Reticulocyte fraction of red cells; chr6:109304676 chr1:96446930~96448318:+ CESC trans rs4911253 0.527 rs853859 ENSG00000253915.1 MAPRE1P1 6.05 6.19e-09 0.0174 0.48 0.38 Lymphocyte counts; chr20:32814463 chr8:135625185~135625981:- CESC trans rs7647973 0.58 rs11716334 ENSG00000197582.5 GPX1P1 6.05 6.21e-09 0.0174 0.47 0.38 Menarche (age at onset); chr3:49192663 chrX:13378735~13379340:- CESC trans rs4276421 0.615 rs12109205 ENSG00000231752.4 EMBP1 6.05 6.24e-09 0.0175 0.48 0.38 P wave duration; chr5:45876576 chr1:121519112~121571892:+ CESC trans rs77688320 0.535 rs7575721 ENSG00000235105.1 RP11-329A14.1 6.05 6.25e-09 0.0175 0.4 0.38 Breast cancer; chr2:201392055 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs3815515 ENSG00000235105.1 RP11-329A14.1 6.05 6.25e-09 0.0175 0.4 0.38 Breast cancer; chr2:201393207 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs7597850 ENSG00000235105.1 RP11-329A14.1 6.05 6.25e-09 0.0175 0.4 0.38 Breast cancer; chr2:201396679 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs10931944 ENSG00000235105.1 RP11-329A14.1 6.05 6.25e-09 0.0175 0.4 0.38 Breast cancer; chr2:201398875 chr1:48435967~48437223:+ CESC trans rs77688320 0.553 rs11681526 ENSG00000235105.1 RP11-329A14.1 6.05 6.25e-09 0.0175 0.4 0.38 Breast cancer; chr2:201399037 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs13022344 ENSG00000235105.1 RP11-329A14.1 6.05 6.25e-09 0.0175 0.4 0.38 Breast cancer; chr2:201399433 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs6732993 ENSG00000235105.1 RP11-329A14.1 6.05 6.25e-09 0.0175 0.4 0.38 Breast cancer; chr2:201399593 chr1:48435967~48437223:+ CESC trans rs10940346 0.601 rs6450098 ENSG00000231752.4 EMBP1 6.05 6.26e-09 0.0175 0.46 0.38 Schizophrenia; chr5:50420076 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs62365896 ENSG00000231752.4 EMBP1 6.05 6.26e-09 0.0175 0.46 0.38 Schizophrenia; chr5:50422243 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs9292005 ENSG00000231752.4 EMBP1 6.05 6.26e-09 0.0175 0.46 0.38 Schizophrenia; chr5:50430521 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs58756661 ENSG00000231752.4 EMBP1 6.05 6.26e-09 0.0175 0.46 0.38 Schizophrenia; chr5:50436837 chr1:121519112~121571892:+ CESC trans rs12652364 0.614 rs6871551 ENSG00000269097.1 AC003682.17 -6.05 6.29e-09 0.0176 -0.66 -0.38 Response to methotrexate in juvenile idiopathic arthritis; chr5:30834616 chr19:57664280~57665039:+ CESC trans rs10940346 0.58 rs12188257 ENSG00000231752.4 EMBP1 -6.05 6.3e-09 0.0176 -0.48 -0.38 Schizophrenia; chr5:50147242 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs5011669 ENSG00000231752.4 EMBP1 -6.05 6.3e-09 0.0176 -0.49 -0.38 Schizophrenia; chr5:50311788 chr1:121519112~121571892:+ CESC trans rs7647973 0.621 rs3774800 ENSG00000197582.5 GPX1P1 -6.05 6.32e-09 0.0177 -0.51 -0.38 Menarche (age at onset); chr3:49297335 chrX:13378735~13379340:- CESC trans rs1355223 0.506 rs7131229 ENSG00000225531.1 RP11-196I18.3 -6.05 6.33e-09 0.0177 -0.47 -0.38 Systemic lupus erythematosus and Systemic sclerosis; chr11:34847781 chr9:107116829~107117557:+ CESC trans rs3806843 0.735 rs801183 ENSG00000231043.3 AC007238.1 -6.05 6.33e-09 0.0177 -0.42 -0.38 Depressive symptoms (multi-trait analysis); chr5:140711530 chr2:58460292~58462032:- CESC trans rs9611565 0.921 rs2235846 ENSG00000268568.1 AC007228.9 -6.05 6.34e-09 0.0177 -0.47 -0.38 Vitiligo; chr22:41345038 chr19:56672574~56673901:- CESC trans rs10819083 0.823 rs10987049 ENSG00000203588.3 IGBP1-AS1 -6.05 6.36e-09 0.0178 -0.33 -0.38 Squamous cell lung carcinoma; chr9:125936910 chrX:70163842~70165206:- CESC trans rs941207 0.756 rs2950388 ENSG00000257210.1 NACAP3 -6.05 6.36e-09 0.0178 -0.5 -0.38 Platelet count; chr12:56639569 chr12:93124063~93124543:- CESC trans rs10028773 0.515 rs9994651 ENSG00000275858.1 RP11-291L22.8 6.05 6.36e-09 0.0178 0.42 0.38 Educational attainment; chr4:119666648 chr10:38450738~38451069:- CESC trans rs7399018 1 rs7399018 ENSG00000223825.5 DAZAP2P1 -6.05 6.37e-09 0.0178 -0.51 -0.38 Cisplatin-induced ototoxicity; chr12:51216581 chr2:202201384~202201886:- CESC trans rs2991971 0.81 rs12119202 ENSG00000255397.1 AC022182.2 -6.04 6.43e-09 0.018 -0.45 -0.38 High light scatter reticulocyte count; chr1:45460259 chr8:60937705~60939871:- CESC trans rs10940346 0.58 rs13357429 ENSG00000231752.4 EMBP1 6.04 6.45e-09 0.018 0.46 0.38 Schizophrenia; chr5:50413616 chr1:121519112~121571892:+ CESC trans rs2991971 0.716 rs7532573 ENSG00000255397.1 AC022182.2 -6.04 6.51e-09 0.0182 -0.45 -0.38 High light scatter reticulocyte count; chr1:45450220 chr8:60937705~60939871:- CESC trans rs77688320 0.553 rs2244438 ENSG00000235105.1 RP11-329A14.1 -6.04 6.52e-09 0.0182 -0.44 -0.38 Breast cancer; chr2:201387816 chr1:48435967~48437223:+ CESC trans rs77688320 0.553 rs2540330 ENSG00000235105.1 RP11-329A14.1 -6.04 6.52e-09 0.0182 -0.44 -0.38 Breast cancer; chr2:201388133 chr1:48435967~48437223:+ CESC trans rs169082 1 rs169082 ENSG00000269473.1 CTD-2619J13.19 -6.04 6.53e-09 0.0182 -0.42 -0.38 Protein quantitative trait loci; chr5:169647052 chr19:58440448~58445849:+ CESC trans rs2991971 0.81 rs998199 ENSG00000255397.1 AC022182.2 -6.04 6.54e-09 0.0182 -0.45 -0.38 High light scatter reticulocyte count; chr1:45447226 chr8:60937705~60939871:- CESC trans rs2991971 0.81 rs2356413 ENSG00000255397.1 AC022182.2 -6.04 6.54e-09 0.0182 -0.45 -0.38 High light scatter reticulocyte count; chr1:45448376 chr8:60937705~60939871:- CESC trans rs2991971 0.776 rs12139364 ENSG00000255397.1 AC022182.2 6.04 6.55e-09 0.0183 0.45 0.38 High light scatter reticulocyte count; chr1:45424483 chr8:60937705~60939871:- CESC trans rs4455778 0.538 rs4288325 ENSG00000238249.2 HMGN2P17 -6.04 6.61e-09 0.0184 -0.36 -0.38 Lung cancer in never smokers; chr7:49090643 chr1:8893409~8894151:+ CESC trans rs7503168 0.643 rs71381467 ENSG00000234130.2 RP13-88F20.1 6.04 6.67e-09 0.0186 0.82 0.38 Plateletcrit; chr17:35693030 chrX:93222220~93225015:- CESC trans rs2991971 0.81 rs2036021 ENSG00000255397.1 AC022182.2 6.04 6.68e-09 0.0186 0.44 0.38 High light scatter reticulocyte count; chr1:45435698 chr8:60937705~60939871:- CESC trans rs13190036 1 rs6880798 ENSG00000226986.4 RP11-543B16.2 6.04 6.69e-09 0.0186 0.45 0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177277456 chr1:211207239~211207897:+ CESC trans rs10940346 0.601 rs12651834 ENSG00000231752.4 EMBP1 6.04 6.71e-09 0.0187 0.47 0.38 Schizophrenia; chr5:50351199 chr1:121519112~121571892:+ CESC trans rs1707322 0.896 rs809774 ENSG00000255397.1 AC022182.2 6.04 6.72e-09 0.0187 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46094572 chr8:60937705~60939871:- CESC trans rs1707322 1 rs785498 ENSG00000255397.1 AC022182.2 6.04 6.72e-09 0.0187 0.49 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46126742 chr8:60937705~60939871:- CESC trans rs13190036 0.551 rs11957608 ENSG00000226986.4 RP11-543B16.2 -6.03 6.76e-09 0.0188 -0.42 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228344 chr1:211207239~211207897:+ CESC trans rs3740713 0.592 rs73434674 ENSG00000235847.2 LDHAP7 6.03 6.77e-09 0.0188 0.63 0.38 Amyotrophic lateral sclerosis (sporadic); chr11:18389950 chr2:84777259~84778223:- CESC trans rs169082 0.967 rs264877 ENSG00000269473.1 CTD-2619J13.19 -6.03 6.81e-09 0.0189 -0.42 -0.38 Protein quantitative trait loci; chr5:169649846 chr19:58440448~58445849:+ CESC trans rs877636 0.702 rs61937249 ENSG00000243403.1 RP11-330L19.1 6.03 6.82e-09 0.019 0.37 0.38 Cognitive function; chr12:55988132 chr15:64592979~64593326:+ CESC trans rs169082 0.933 rs264878 ENSG00000269473.1 CTD-2619J13.19 -6.03 6.83e-09 0.019 -0.41 -0.38 Protein quantitative trait loci; chr5:169650494 chr19:58440448~58445849:+ CESC trans rs3806843 0.568 rs2530232 ENSG00000231043.3 AC007238.1 6.03 6.88e-09 0.0191 0.43 0.38 Depressive symptoms (multi-trait analysis); chr5:140703293 chr2:58460292~58462032:- CESC trans rs7554511 0.861 rs10753888 ENSG00000244144.1 RP11-757F18.3 -6.03 6.89e-09 0.0191 -0.44 -0.38 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201037057 chr3:112185480~112185998:- CESC trans rs3806843 0.735 rs801168 ENSG00000231043.3 AC007238.1 6.03 6.9e-09 0.0191 0.42 0.38 Depressive symptoms (multi-trait analysis); chr5:140700713 chr2:58460292~58462032:- CESC trans rs4455778 0.538 rs6977073 ENSG00000238249.2 HMGN2P17 -6.03 6.92e-09 0.0192 -0.36 -0.38 Lung cancer in never smokers; chr7:49075744 chr1:8893409~8894151:+ CESC trans rs13190036 0.551 rs7732930 ENSG00000217325.2 PRELID1P1 -6.03 6.97e-09 0.0193 -0.53 -0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177121593 chr6:126643488~126644390:+ CESC trans rs12652364 0.614 rs12655339 ENSG00000269097.1 AC003682.17 -6.03 6.98e-09 0.0194 -0.62 -0.38 Response to methotrexate in juvenile idiopathic arthritis; chr5:30833924 chr19:57664280~57665039:+ CESC trans rs9611519 0.808 rs5751074 ENSG00000268568.1 AC007228.9 -6.03 6.99e-09 0.0194 -0.48 -0.38 Neuroticism; chr22:41269718 chr19:56672574~56673901:- CESC trans rs7503168 0.558 rs12940422 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35620400 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs12949877 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35621517 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs11650621 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35631827 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs12947274 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35635146 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs12936693 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35639391 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs71381465 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35647713 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs12943224 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35650519 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs11651380 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35654677 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs11654542 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35662289 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs34874930 ENSG00000234130.2 RP13-88F20.1 6.03 7e-09 0.0194 0.82 0.38 Plateletcrit; chr17:35667961 chrX:93222220~93225015:- CESC trans rs616147 0.962 rs1708104 ENSG00000183298.5 RP11-556K13.1 -6.03 7.04e-09 0.0195 -0.48 -0.38 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39493251 chr1:101786340~101787219:- CESC trans rs4455778 0.58 rs7455537 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49036980 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs9942682 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49038403 chr1:8893409~8894151:+ CESC trans rs4455778 0.6 rs4404870 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49039363 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4273799 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49040213 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs7783777 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49042964 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4598208 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49044988 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs7780178 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49045544 chr1:8893409~8894151:+ CESC trans rs4455778 0.6 rs4461853 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49051305 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs10257863 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49052804 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs10215945 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49056827 chr1:8893409~8894151:+ CESC trans rs4455778 0.538 rs13236051 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49058233 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs12718320 ENSG00000238249.2 HMGN2P17 -6.03 7.05e-09 0.0195 -0.36 -0.38 Lung cancer in never smokers; chr7:49069851 chr1:8893409~8894151:+ CESC trans rs7503168 0.558 rs17670584 ENSG00000234130.2 RP13-88F20.1 6.03 7.06e-09 0.0195 0.82 0.38 Plateletcrit; chr17:35671885 chrX:93222220~93225015:- CESC trans rs714543 1 rs10278679 ENSG00000226038.5 PPIAP21 -6.03 7.09e-09 0.0196 -0.49 -0.38 Plateletcrit; chr7:44825465 chr20:43230760~43231260:+ CESC trans rs2950393 0.804 rs1466382 ENSG00000257210.1 NACAP3 -6.03 7.09e-09 0.0196 -0.42 -0.38 Platelet distribution width; chr12:56723050 chr12:93124063~93124543:- CESC trans rs1707322 0.638 rs9429095 ENSG00000255397.1 AC022182.2 6.02 7.14e-09 0.0197 0.51 0.38 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46137676 chr8:60937705~60939871:- CESC trans rs10940346 0.601 rs4495185 ENSG00000231752.4 EMBP1 6.02 7.16e-09 0.0198 0.46 0.38 Schizophrenia; chr5:50415453 chr1:121519112~121571892:+ CESC trans rs10940346 0.56 rs6450107 ENSG00000231752.4 EMBP1 6.02 7.16e-09 0.0198 0.46 0.38 Schizophrenia; chr5:50430069 chr1:121519112~121571892:+ CESC trans rs10242455 0.764 rs4646465 ENSG00000228834.1 RP11-249L21.4 -6.02 7.18e-09 0.0198 -0.59 -0.38 Blood metabolite levels; chr7:99706901 chr6:108907615~108907873:- CESC trans rs10242455 0.867 rs2687078 ENSG00000228834.1 RP11-249L21.4 -6.02 7.18e-09 0.0198 -0.59 -0.38 Blood metabolite levels; chr7:99707089 chr6:108907615~108907873:- CESC trans rs7503168 0.558 rs12945102 ENSG00000234130.2 RP13-88F20.1 6.02 7.23e-09 0.0199 0.82 0.38 Plateletcrit; chr17:35601894 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs71381463 ENSG00000234130.2 RP13-88F20.1 6.02 7.23e-09 0.0199 0.82 0.38 Plateletcrit; chr17:35610247 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs12936539 ENSG00000234130.2 RP13-88F20.1 6.02 7.23e-09 0.0199 0.82 0.38 Plateletcrit; chr17:35611677 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs34063751 ENSG00000234130.2 RP13-88F20.1 6.02 7.23e-09 0.0199 0.82 0.38 Plateletcrit; chr17:35611893 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs11650225 ENSG00000234130.2 RP13-88F20.1 6.02 7.23e-09 0.0199 0.82 0.38 Plateletcrit; chr17:35613947 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs17669281 ENSG00000234130.2 RP13-88F20.1 6.02 7.23e-09 0.0199 0.82 0.38 Plateletcrit; chr17:35616776 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs17606150 ENSG00000234130.2 RP13-88F20.1 6.02 7.23e-09 0.0199 0.82 0.38 Plateletcrit; chr17:35616789 chrX:93222220~93225015:- CESC trans rs12138950 0.681 rs10917468 ENSG00000224237.1 MINOS1P3 -6.02 7.24e-09 0.02 -0.5 -0.38 Hypothyroidism;Thyroid volume; chr1:19516860 chr3:27214816~27215018:- CESC trans rs10940346 0.601 rs11960276 ENSG00000231752.4 EMBP1 -6.02 7.28e-09 0.0201 -0.46 -0.38 Schizophrenia; chr5:50265194 chr1:121519112~121571892:+ CESC trans rs4455778 0.538 rs7779474 ENSG00000238249.2 HMGN2P17 -6.02 7.32e-09 0.0202 -0.36 -0.38 Lung cancer in never smokers; chr7:49067941 chr1:8893409~8894151:+ CESC trans rs1568889 1 rs7933332 ENSG00000174912.7 METTL15P1 6.02 7.35e-09 0.0203 0.44 0.38 Bipolar disorder; chr11:28014845 chr3:156713884~156714928:- CESC trans rs1568889 1 rs6484346 ENSG00000174912.7 METTL15P1 6.02 7.35e-09 0.0203 0.44 0.38 Bipolar disorder; chr11:28019220 chr3:156713884~156714928:- CESC trans rs3812762 0.783 rs34524863 ENSG00000266891.1 RP11-692N5.2 6.02 7.39e-09 0.0203 0.46 0.38 Hypospadias; chr11:8755861 chr18:9734882~9735602:- CESC trans rs9611519 0.78 rs2235850 ENSG00000268568.1 AC007228.9 -6.02 7.39e-09 0.0204 -0.47 -0.38 Neuroticism; chr22:41261622 chr19:56672574~56673901:- CESC trans rs7647973 0.961 rs6778080 ENSG00000197582.5 GPX1P1 -6.02 7.41e-09 0.0204 -0.48 -0.38 Menarche (age at onset); chr3:49279905 chrX:13378735~13379340:- CESC trans rs877636 0.74 rs705702 ENSG00000243403.1 RP11-330L19.1 -6.02 7.43e-09 0.0204 -0.37 -0.38 Cognitive function; chr12:55996852 chr15:64592979~64593326:+ CESC trans rs12652364 0.614 rs6875809 ENSG00000269097.1 AC003682.17 -6.02 7.48e-09 0.0206 -0.66 -0.38 Response to methotrexate in juvenile idiopathic arthritis; chr5:30834721 chr19:57664280~57665039:+ CESC trans rs2991971 0.729 rs10890328 ENSG00000255397.1 AC022182.2 -6.02 7.5e-09 0.0206 -0.44 -0.38 High light scatter reticulocyte count; chr1:45439711 chr8:60937705~60939871:- CESC trans rs9611519 0.78 rs2235852 ENSG00000268568.1 AC007228.9 -6.01 7.52e-09 0.0207 -0.48 -0.38 Neuroticism; chr22:41265150 chr19:56672574~56673901:- CESC trans rs77688320 0.535 rs13001194 ENSG00000235105.1 RP11-329A14.1 6.01 7.56e-09 0.0208 0.4 0.38 Breast cancer; chr2:201396452 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs7571761 ENSG00000235105.1 RP11-329A14.1 6.01 7.56e-09 0.0208 0.4 0.38 Breast cancer; chr2:201396837 chr1:48435967~48437223:+ CESC trans rs8067354 0.645 rs2102507 ENSG00000187870.7 RNFT1P3 6.01 7.67e-09 0.0211 0.5 0.38 Hemoglobin concentration; chr17:59798546 chr17:20743333~20754501:- CESC trans rs8067354 0.645 rs2645491 ENSG00000187870.7 RNFT1P3 6.01 7.67e-09 0.0211 0.5 0.38 Hemoglobin concentration; chr17:59799688 chr17:20743333~20754501:- CESC trans rs8067354 0.645 rs2665400 ENSG00000187870.7 RNFT1P3 6.01 7.67e-09 0.0211 0.5 0.38 Hemoglobin concentration; chr17:59802840 chr17:20743333~20754501:- CESC trans rs10028773 0.515 rs9994488 ENSG00000275858.1 RP11-291L22.8 6.01 7.69e-09 0.0211 0.43 0.38 Educational attainment; chr4:119666626 chr10:38450738~38451069:- CESC trans rs4455778 0.58 rs4291221 ENSG00000238249.2 HMGN2P17 6.01 7.73e-09 0.0212 0.36 0.38 Lung cancer in never smokers; chr7:49074869 chr1:8893409~8894151:+ CESC trans rs673253 0.593 rs3791134 ENSG00000250362.1 AC008592.5 6.01 7.74e-09 0.0212 0.53 0.38 Intelligence (multi-trait analysis); chr1:43583485 chr5:95861786~95874519:+ CESC trans rs4455778 0.58 rs4492325 ENSG00000238249.2 HMGN2P17 -6.01 7.76e-09 0.0213 -0.36 -0.38 Lung cancer in never smokers; chr7:49056558 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4543492 ENSG00000238249.2 HMGN2P17 -6.01 7.76e-09 0.0213 -0.36 -0.38 Lung cancer in never smokers; chr7:49057409 chr1:8893409~8894151:+ CESC trans rs2950393 0.804 rs898611 ENSG00000257210.1 NACAP3 -6.01 7.79e-09 0.0214 -0.41 -0.38 Platelet distribution width; chr12:56769532 chr12:93124063~93124543:- CESC trans rs77688320 0.535 rs6751543 ENSG00000235105.1 RP11-329A14.1 6.01 7.82e-09 0.0214 0.4 0.38 Breast cancer; chr2:201400210 chr1:48435967~48437223:+ CESC trans rs877636 1 rs705696 ENSG00000235459.5 RPS26P31 6.01 7.85e-09 0.0215 0.41 0.38 Cognitive function; chr12:56086864 chr7:122681315~122681662:+ CESC trans rs7554511 0.763 rs3913893 ENSG00000244144.1 RP11-757F18.3 -6.01 7.89e-09 0.0216 -0.45 -0.38 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201046655 chr3:112185480~112185998:- CESC trans rs10940346 0.562 rs10051529 ENSG00000231752.4 EMBP1 -6 7.94e-09 0.0217 -0.47 -0.38 Schizophrenia; chr5:50303103 chr1:121519112~121571892:+ CESC trans rs9876781 1 rs2362450 ENSG00000235912.1 RP1-159A19.3 -6 7.95e-09 0.0217 -0.35 -0.38 Longevity; chr3:48419904 chr1:27649419~27649610:+ CESC trans rs9876781 0.967 rs1459249 ENSG00000235912.1 RP1-159A19.3 -6 7.95e-09 0.0217 -0.35 -0.38 Longevity; chr3:48438208 chr1:27649419~27649610:+ CESC trans rs13014235 0.667 rs2540328 ENSG00000235105.1 RP11-329A14.1 -6 7.96e-09 0.0218 -0.43 -0.38 Basal cell carcinoma; chr2:201384337 chr1:48435967~48437223:+ CESC trans rs77688320 0.509 rs2714487 ENSG00000235105.1 RP11-329A14.1 -6 7.96e-09 0.0218 -0.43 -0.38 Breast cancer; chr2:201384837 chr1:48435967~48437223:+ CESC trans rs4455778 0.58 rs4524741 ENSG00000238249.2 HMGN2P17 -6 7.99e-09 0.0218 -0.36 -0.38 Lung cancer in never smokers; chr7:49065542 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4275185 ENSG00000238249.2 HMGN2P17 -6 8e-09 0.0219 -0.35 -0.38 Lung cancer in never smokers; chr7:49075019 chr1:8893409~8894151:+ CESC trans rs4276421 0.593 rs10062641 ENSG00000231752.4 EMBP1 6 8.01e-09 0.0219 0.51 0.38 P wave duration; chr5:45930240 chr1:121519112~121571892:+ CESC trans rs10242455 1 rs2301889 ENSG00000228834.1 RP11-249L21.4 6 8.22e-09 0.0224 0.74 0.38 Blood metabolite levels; chr7:99333482 chr6:108907615~108907873:- CESC trans rs10940346 0.562 rs7736775 ENSG00000231752.4 EMBP1 -6 8.27e-09 0.0225 -0.46 -0.38 Schizophrenia; chr5:50472463 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs13157992 ENSG00000231752.4 EMBP1 6 8.27e-09 0.0225 0.46 0.38 Schizophrenia; chr5:50444074 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs57300567 ENSG00000231752.4 EMBP1 6 8.27e-09 0.0225 0.46 0.38 Schizophrenia; chr5:50467359 chr1:121519112~121571892:+ CESC trans rs2250402 0.51 rs2898984 ENSG00000234106.3 RP11-288E14.2 6 8.29e-09 0.0226 0.69 0.38 Corneal curvature; chr15:40031874 chr11:93535468~93535816:+ CESC trans rs2950393 0.804 rs1131514 ENSG00000257210.1 NACAP3 -6 8.31e-09 0.0226 -0.41 -0.38 Platelet distribution width; chr12:56739356 chr12:93124063~93124543:- CESC trans rs7554511 0.707 rs6702590 ENSG00000244144.1 RP11-757F18.3 6 8.32e-09 0.0227 0.43 0.38 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:201050977 chr3:112185480~112185998:- CESC trans rs2950393 0.857 rs9989034 ENSG00000257210.1 NACAP3 6 8.32e-09 0.0227 0.41 0.38 Platelet distribution width; chr12:56674508 chr12:93124063~93124543:- CESC trans rs4455778 0.561 rs13243449 ENSG00000238249.2 HMGN2P17 -6 8.35e-09 0.0227 -0.35 -0.38 Lung cancer in never smokers; chr7:49090169 chr1:8893409~8894151:+ CESC trans rs62140779 0.83 rs17049548 ENSG00000253347.1 CTD-2026D20.2 5.99 8.35e-09 0.0227 0.59 0.38 Neuroticism; chr2:58555598 chr17:47409322~47423526:- CESC trans rs7647973 0.58 rs12629759 ENSG00000197582.5 GPX1P1 5.99 8.36e-09 0.0227 0.47 0.38 Menarche (age at onset); chr3:49199961 chrX:13378735~13379340:- CESC trans rs4455778 0.6 rs4255086 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49070202 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs10229899 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49070767 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4917032 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49071909 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4270911 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49072535 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4270912 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49072739 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4270913 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49072793 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4551289 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49072841 chr1:8893409~8894151:+ CESC trans rs4455778 0.538 rs9642332 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49073581 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs6944916 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49074136 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4917034 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49074192 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs6951015 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49075543 chr1:8893409~8894151:+ CESC trans rs4455778 0.6 rs4282517 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49075854 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs5004391 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49076033 chr1:8893409~8894151:+ CESC trans rs4455778 0.538 rs34820160 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49076352 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs5009336 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49076703 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs6952050 ENSG00000238249.2 HMGN2P17 -5.99 8.38e-09 0.0228 -0.35 -0.38 Lung cancer in never smokers; chr7:49076758 chr1:8893409~8894151:+ CESC trans rs55665837 0.701 rs11023265 ENSG00000236360.2 RP11-334A14.2 5.99 8.39e-09 0.0228 0.47 0.38 Vitamin D levels; chr11:14594492 chr1:52993201~52993702:- CESC trans rs7192380 0.639 rs2917666 ENSG00000257513.6 NPIPB1P -5.99 8.41e-09 0.0228 -0.43 -0.38 Sjögren's syndrome; chr16:69730057 chr18:11619509~11639699:- CESC trans rs1030877 0.96 rs3792049 ENSG00000146521.8 LINC01558 -5.99 8.41e-09 0.0228 -0.44 -0.38 Obesity-related traits; chr2:105285451 chr6:167784537~167796859:- CESC trans rs7520050 0.778 rs2088102 ENSG00000255397.1 AC022182.2 5.99 8.57e-09 0.0232 0.46 0.38 Reticulocyte count;Red blood cell count; chr1:45567302 chr8:60937705~60939871:- CESC trans rs10242455 1 rs73395557 ENSG00000228834.1 RP11-249L21.4 5.99 8.59e-09 0.0233 0.74 0.38 Blood metabolite levels; chr7:99336801 chr6:108907615~108907873:- CESC trans rs12339966 0.689 rs2821208 ENSG00000260947.1 RP11-384P7.7 -5.99 8.6e-09 0.0233 -0.51 -0.38 Systolic blood pressure; chr9:11682019 chr9:33697459~33700986:+ CESC trans rs3740713 0.719 rs78515595 ENSG00000235847.2 LDHAP7 5.99 8.61e-09 0.0233 0.69 0.38 Amyotrophic lateral sclerosis (sporadic); chr11:18409830 chr2:84777259~84778223:- CESC trans rs12652364 0.614 rs1921097 ENSG00000269097.1 AC003682.17 -5.99 8.67e-09 0.0234 -0.65 -0.38 Response to methotrexate in juvenile idiopathic arthritis; chr5:30833591 chr19:57664280~57665039:+ CESC trans rs12652364 0.614 rs59544605 ENSG00000269097.1 AC003682.17 -5.99 8.67e-09 0.0234 -0.65 -0.38 Response to methotrexate in juvenile idiopathic arthritis; chr5:30834035 chr19:57664280~57665039:+ CESC trans rs11012350 0.85 rs11012396 ENSG00000279123.1 RP11-424M24.3 -5.99 8.71e-09 0.0235 -0.98 -0.38 Peripheral arterial disease (traffic-related air pollution interaction); chr10:18054867 chr16:70778433~70779145:+ CESC trans rs72615157 0.561 rs113401658 ENSG00000228546.2 CTA-313A17.3 5.99 8.73e-09 0.0236 0.63 0.38 Lung function (FEV1/FVC); chr7:100260882 chr7:102337316~102339115:+ CESC trans rs4948102 0.655 rs4947533 ENSG00000186940.6 CHCHD2P9 -5.99 8.75e-09 0.0236 -0.51 -0.38 Plasma homocysteine levels (post-methionine load test); chr7:56003589 chr9:79391304~79391759:+ CESC trans rs11098499 0.739 rs4833612 ENSG00000275858.1 RP11-291L22.8 -5.99 8.78e-09 0.0237 -0.42 -0.38 Corneal astigmatism; chr4:119226441 chr10:38450738~38451069:- CESC trans rs11098499 0.739 rs10013032 ENSG00000275858.1 RP11-291L22.8 -5.99 8.78e-09 0.0237 -0.42 -0.38 Corneal astigmatism; chr4:119228264 chr10:38450738~38451069:- CESC trans rs7520050 0.743 rs61789988 ENSG00000255397.1 AC022182.2 5.98 8.81e-09 0.0238 0.46 0.38 Reticulocyte count;Red blood cell count; chr1:45619570 chr8:60937705~60939871:- CESC trans rs877636 0.702 rs773111 ENSG00000243403.1 RP11-330L19.1 5.98 8.9e-09 0.024 0.37 0.38 Cognitive function; chr12:55981956 chr15:64592979~64593326:+ CESC trans rs4948102 0.924 rs13241866 ENSG00000215006.4 CHCHD2P2 -5.98 8.9e-09 0.024 -0.46 -0.38 Plasma homocysteine levels (post-methionine load test); chr7:56023185 chr5:69333929~69334249:+ CESC trans rs3806843 0.735 rs2563306 ENSG00000231043.3 AC007238.1 5.98 8.99e-09 0.0242 0.42 0.38 Depressive symptoms (multi-trait analysis); chr5:140690432 chr2:58460292~58462032:- CESC trans rs3806843 0.735 rs813897 ENSG00000231043.3 AC007238.1 5.98 8.99e-09 0.0242 0.42 0.38 Depressive symptoms (multi-trait analysis); chr5:140690444 chr2:58460292~58462032:- CESC trans rs1030877 0.889 rs2576746 ENSG00000146521.8 LINC01558 5.98 9.02e-09 0.0243 0.43 0.38 Obesity-related traits; chr2:105293102 chr6:167784537~167796859:- CESC trans rs77688320 0.535 rs12468504 ENSG00000235105.1 RP11-329A14.1 -5.98 9.09e-09 0.0245 -0.4 -0.38 Breast cancer; chr2:201393746 chr1:48435967~48437223:+ CESC trans rs10037055 1 rs10037055 ENSG00000217325.2 PRELID1P1 -5.98 9.12e-09 0.0246 -0.49 -0.38 Migraine without aura; chr5:177264278 chr6:126643488~126644390:+ CESC trans rs10940346 0.601 rs28500170 ENSG00000231752.4 EMBP1 5.98 9.15e-09 0.0246 0.46 0.38 Schizophrenia; chr5:50441594 chr1:121519112~121571892:+ CESC trans rs12709013 0.792 rs12928733 ENSG00000233719.3 GOT2P3 5.98 9.26e-09 0.0249 0.42 0.38 Blood metabolite ratios; chr16:58807216 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs62066381 ENSG00000233719.3 GOT2P3 5.98 9.26e-09 0.0249 0.42 0.38 Blood metabolite ratios; chr16:58807981 chr12:9641802~9643007:+ CESC trans rs12709013 0.792 rs36098613 ENSG00000233719.3 GOT2P3 5.98 9.26e-09 0.0249 0.42 0.38 Blood metabolite ratios; chr16:58810562 chr12:9641802~9643007:+ CESC trans rs13190036 1 rs655623 ENSG00000226986.4 RP11-543B16.2 5.98 9.26e-09 0.0249 0.46 0.38 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107515 chr1:211207239~211207897:+ CESC trans rs7520050 0.778 rs3014238 ENSG00000255397.1 AC022182.2 5.98 9.27e-09 0.0249 0.46 0.38 Reticulocyte count;Red blood cell count; chr1:45624542 chr8:60937705~60939871:- CESC trans rs10242455 0.867 rs2222411 ENSG00000228834.1 RP11-249L21.4 -5.97 9.29e-09 0.025 -0.6 -0.38 Blood metabolite levels; chr7:99712708 chr6:108907615~108907873:- CESC trans rs3749237 0.964 rs11717463 ENSG00000197582.5 GPX1P1 5.97 9.3e-09 0.025 0.6 0.38 Resting heart rate; chr3:49771548 chrX:13378735~13379340:- CESC trans rs55665837 0.701 rs11023272 ENSG00000236360.2 RP11-334A14.2 5.97 9.33e-09 0.025 0.47 0.38 Vitamin D levels; chr11:14608824 chr1:52993201~52993702:- CESC trans rs55665837 0.665 rs11023273 ENSG00000236360.2 RP11-334A14.2 5.97 9.33e-09 0.025 0.47 0.38 Vitamin D levels; chr11:14609273 chr1:52993201~52993702:- CESC trans rs4276421 0.593 rs13176359 ENSG00000231752.4 EMBP1 -5.97 9.33e-09 0.0251 -0.51 -0.38 P wave duration; chr5:45814173 chr1:121519112~121571892:+ CESC trans rs66887589 0.616 rs11731675 ENSG00000275858.1 RP11-291L22.8 5.97 9.41e-09 0.0252 0.4 0.37 Diastolic blood pressure; chr4:119291359 chr10:38450738~38451069:- CESC trans rs4455778 0.538 rs7795732 ENSG00000238249.2 HMGN2P17 -5.97 9.41e-09 0.0252 -0.35 -0.37 Lung cancer in never smokers; chr7:49087897 chr1:8893409~8894151:+ CESC trans rs877636 0.669 rs7297175 ENSG00000233778.3 RP11-777J24.1 -5.97 9.46e-09 0.0254 -0.39 -0.37 Cognitive function; chr12:56080024 chr8:92144088~92144435:- CESC trans rs2980976 0.611 rs2957141 ENSG00000259078.2 PTBP1P -5.97 9.47e-09 0.0254 -0.64 -0.37 Response to antipsychotic treatment; chr18:62402649 chr14:65279267~65281166:+ CESC trans rs714543 0.875 rs35585318 ENSG00000226038.5 PPIAP21 -5.97 9.49e-09 0.0254 -0.49 -0.37 Plateletcrit; chr7:44852220 chr20:43230760~43231260:+ CESC trans rs3740713 0.748 rs35292478 ENSG00000235847.2 LDHAP7 5.97 9.51e-09 0.0255 0.62 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18408444 chr2:84777259~84778223:- CESC trans rs4455778 0.58 rs10261034 ENSG00000238249.2 HMGN2P17 -5.97 9.52e-09 0.0255 -0.35 -0.37 Lung cancer in never smokers; chr7:49052958 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs6952911 ENSG00000238249.2 HMGN2P17 -5.97 9.52e-09 0.0255 -0.35 -0.37 Lung cancer in never smokers; chr7:49053198 chr1:8893409~8894151:+ CESC trans rs10940346 0.601 rs7378969 ENSG00000231752.4 EMBP1 -5.97 9.55e-09 0.0255 -0.45 -0.37 Schizophrenia; chr5:50471925 chr1:121519112~121571892:+ CESC trans rs10940346 0.525 rs7728419 ENSG00000231752.4 EMBP1 -5.97 9.55e-09 0.0255 -0.45 -0.37 Schizophrenia; chr5:50474238 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs4029989 ENSG00000231752.4 EMBP1 -5.97 9.55e-09 0.0255 -0.45 -0.37 Schizophrenia; chr5:50474501 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7720960 ENSG00000231752.4 EMBP1 5.97 9.55e-09 0.0255 0.45 0.37 Schizophrenia; chr5:50450489 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs6863108 ENSG00000231752.4 EMBP1 5.97 9.55e-09 0.0255 0.45 0.37 Schizophrenia; chr5:50451450 chr1:121519112~121571892:+ CESC trans rs10940346 0.56 rs13180267 ENSG00000231752.4 EMBP1 5.97 9.55e-09 0.0255 0.45 0.37 Schizophrenia; chr5:50452300 chr1:121519112~121571892:+ CESC trans rs10940346 0.541 rs10041893 ENSG00000231752.4 EMBP1 5.97 9.55e-09 0.0255 0.45 0.37 Schizophrenia; chr5:50460740 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs10044979 ENSG00000231752.4 EMBP1 5.97 9.55e-09 0.0255 0.45 0.37 Schizophrenia; chr5:50464074 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10045034 ENSG00000231752.4 EMBP1 5.97 9.55e-09 0.0255 0.45 0.37 Schizophrenia; chr5:50464323 chr1:121519112~121571892:+ CESC trans rs10940346 0.54 rs59940663 ENSG00000231752.4 EMBP1 5.97 9.55e-09 0.0255 0.45 0.37 Schizophrenia; chr5:50467345 chr1:121519112~121571892:+ CESC trans rs10940346 0.58 rs34586987 ENSG00000231752.4 EMBP1 5.97 9.55e-09 0.0255 0.45 0.37 Schizophrenia; chr5:50467574 chr1:121519112~121571892:+ CESC trans rs941207 0.542 rs7311381 ENSG00000257210.1 NACAP3 -5.97 9.59e-09 0.0256 -0.49 -0.37 Platelet count; chr12:56800286 chr12:93124063~93124543:- CESC trans rs941207 0.542 rs6581107 ENSG00000257210.1 NACAP3 -5.97 9.59e-09 0.0256 -0.49 -0.37 Platelet count; chr12:56801197 chr12:93124063~93124543:- CESC trans rs2950393 0.777 rs7966391 ENSG00000257210.1 NACAP3 5.97 9.62e-09 0.0257 0.43 0.37 Platelet distribution width; chr12:56745272 chr12:93124063~93124543:- CESC trans rs7809799 0.85 rs6956645 ENSG00000239830.1 RPS4XP22 5.97 9.63e-09 0.0257 0.7 0.37 Ulcerative colitis; chr7:99166398 chr19:9683294~9684073:- CESC trans rs62140779 0.887 rs72813942 ENSG00000253347.1 CTD-2026D20.2 5.97 9.66e-09 0.0258 0.57 0.37 Neuroticism; chr2:58490919 chr17:47409322~47423526:- CESC trans rs77688320 0.553 rs6761777 ENSG00000235105.1 RP11-329A14.1 5.97 9.67e-09 0.0258 0.4 0.37 Breast cancer; chr2:201399879 chr1:48435967~48437223:+ CESC trans rs877636 0.702 rs773110 ENSG00000243403.1 RP11-330L19.1 5.97 9.68e-09 0.0258 0.37 0.37 Cognitive function; chr12:55981353 chr15:64592979~64593326:+ CESC trans rs7520050 0.778 rs3013597 ENSG00000255397.1 AC022182.2 -5.97 9.71e-09 0.0259 -0.46 -0.37 Reticulocyte count;Red blood cell count; chr1:45662684 chr8:60937705~60939871:- CESC trans rs4455778 0.6 rs56070219 ENSG00000238249.2 HMGN2P17 -5.97 9.72e-09 0.0259 -0.35 -0.37 Lung cancer in never smokers; chr7:49088641 chr1:8893409~8894151:+ CESC trans rs12497850 0.931 rs7616815 ENSG00000197582.5 GPX1P1 5.97 9.72e-09 0.0259 0.49 0.37 Parkinson's disease; chr3:48742282 chrX:13378735~13379340:- CESC trans rs7520050 0.771 rs4660882 ENSG00000255397.1 AC022182.2 -5.97 9.75e-09 0.026 -0.46 -0.37 Reticulocyte count;Red blood cell count; chr1:45650620 chr8:60937705~60939871:- CESC trans rs13190036 0.515 rs2878686 ENSG00000226986.4 RP11-543B16.2 -5.97 9.77e-09 0.0261 -0.41 -0.37 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206748 chr1:211207239~211207897:+ CESC trans rs4453827 1 rs10510765 ENSG00000249834.3 PGBD4P3 -5.96 9.78e-09 0.0261 -0.52 -0.37 Blood protein levels; chr3:53712179 chr5:148307298~148308258:+ CESC trans rs877636 0.74 rs772920 ENSG00000243403.1 RP11-330L19.1 5.96 9.8e-09 0.0261 0.38 0.37 Cognitive function; chr12:55996580 chr15:64592979~64593326:+ CESC trans rs740160 0.558 rs17161662 ENSG00000228834.1 RP11-249L21.4 5.96 9.83e-09 0.0262 0.69 0.37 Dehydroepiandrosterone sulphate levels; chr7:99309773 chr6:108907615~108907873:- CESC trans rs62140779 0.887 rs2019198 ENSG00000253347.1 CTD-2026D20.2 5.96 9.86e-09 0.0263 0.57 0.37 Neuroticism; chr2:58499738 chr17:47409322~47423526:- CESC trans rs77688320 0.553 rs2714488 ENSG00000235105.1 RP11-329A14.1 -5.96 9.97e-09 0.0265 -0.43 -0.37 Breast cancer; chr2:201405050 chr1:48435967~48437223:+ CESC trans rs77688320 0.553 rs2249868 ENSG00000235105.1 RP11-329A14.1 -5.96 9.97e-09 0.0265 -0.43 -0.37 Breast cancer; chr2:201412503 chr1:48435967~48437223:+ CESC trans rs10940346 0.54 rs12521033 ENSG00000231752.4 EMBP1 -5.96 1e-08 0.0266 -0.47 -0.37 Schizophrenia; chr5:50145974 chr1:121519112~121571892:+ CESC trans rs77688320 0.553 rs2540432 ENSG00000235105.1 RP11-329A14.1 -5.96 1e-08 0.0267 -0.43 -0.37 Breast cancer; chr2:201500171 chr1:48435967~48437223:+ CESC trans rs4455778 0.58 rs4560745 ENSG00000238249.2 HMGN2P17 -5.96 1.01e-08 0.0268 -0.35 -0.37 Lung cancer in never smokers; chr7:49075816 chr1:8893409~8894151:+ CESC trans rs3806843 0.838 rs2563289 ENSG00000231043.3 AC007238.1 5.96 1.01e-08 0.0269 0.41 0.37 Depressive symptoms (multi-trait analysis); chr5:140743181 chr2:58460292~58462032:- CESC trans rs77688320 0.553 rs2908763 ENSG00000235105.1 RP11-329A14.1 -5.96 1.01e-08 0.0269 -0.43 -0.37 Breast cancer; chr2:201503860 chr1:48435967~48437223:+ CESC trans rs77688320 0.535 rs60148247 ENSG00000235105.1 RP11-329A14.1 -5.96 1.01e-08 0.0269 -0.43 -0.37 Breast cancer; chr2:201513770 chr1:48435967~48437223:+ CESC trans rs77688320 0.553 rs2080324 ENSG00000235105.1 RP11-329A14.1 -5.96 1.01e-08 0.0269 -0.43 -0.37 Breast cancer; chr2:201514089 chr1:48435967~48437223:+ CESC trans rs77688320 0.553 rs2080323 ENSG00000235105.1 RP11-329A14.1 -5.96 1.01e-08 0.0269 -0.43 -0.37 Breast cancer; chr2:201514126 chr1:48435967~48437223:+ CESC trans rs1355223 0.506 rs6484738 ENSG00000225531.1 RP11-196I18.3 5.96 1.02e-08 0.027 0.44 0.37 Systemic lupus erythematosus and Systemic sclerosis; chr11:34839311 chr9:107116829~107117557:+ CESC trans rs3812762 0.871 rs11603335 ENSG00000266891.1 RP11-692N5.2 -5.96 1.02e-08 0.027 -0.42 -0.37 Hypospadias; chr11:8788297 chr18:9734882~9735602:- CESC trans rs2250402 0.51 rs2291619 ENSG00000234106.3 RP11-288E14.2 -5.96 1.02e-08 0.0272 -0.68 -0.37 Corneal curvature; chr15:40036832 chr11:93535468~93535816:+ CESC trans rs10940346 0.601 rs579279 ENSG00000231752.4 EMBP1 -5.96 1.03e-08 0.0273 -0.45 -0.37 Schizophrenia; chr5:50277308 chr1:121519112~121571892:+ CESC trans rs10503709 0.542 rs2035358 ENSG00000251013.1 GAPDHP62 5.95 1.04e-08 0.0275 0.47 0.37 Blood protein levels; chr8:21587577 chr8:100550724~100551713:- CESC trans rs10503709 0.542 rs12682357 ENSG00000251013.1 GAPDHP62 5.95 1.04e-08 0.0275 0.47 0.37 Blood protein levels; chr8:21587743 chr8:100550724~100551713:- CESC trans rs10940346 0.601 rs10042601 ENSG00000231752.4 EMBP1 -5.95 1.04e-08 0.0275 -0.46 -0.37 Schizophrenia; chr5:50315248 chr1:121519112~121571892:+ CESC trans rs2950393 0.929 rs2290893 ENSG00000257210.1 NACAP3 5.95 1.04e-08 0.0275 0.41 0.37 Platelet distribution width; chr12:56684836 chr12:93124063~93124543:- CESC trans rs9611519 0.78 rs5751071 ENSG00000268568.1 AC007228.9 -5.95 1.04e-08 0.0275 -0.47 -0.37 Neuroticism; chr22:41260328 chr19:56672574~56673901:- CESC trans rs1568889 0.838 rs6484359 ENSG00000174912.7 METTL15P1 5.95 1.04e-08 0.0276 0.38 0.37 Bipolar disorder; chr11:28240781 chr3:156713884~156714928:- CESC trans rs13190036 1 rs13185316 ENSG00000228305.2 AC016734.2 -5.95 1.04e-08 0.0277 -0.49 -0.37 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177213339 chr2:63622178~63622831:- CESC trans rs877636 0.702 rs773112 ENSG00000243403.1 RP11-330L19.1 5.95 1.05e-08 0.0279 0.37 0.37 Cognitive function; chr12:55982097 chr15:64592979~64593326:+ CESC trans rs7520050 0.807 rs5021934 ENSG00000255397.1 AC022182.2 5.95 1.05e-08 0.0279 0.45 0.37 Reticulocyte count;Red blood cell count; chr1:45643632 chr8:60937705~60939871:- CESC trans rs912593 1 rs730737 ENSG00000259570.1 RP11-671M22.4 -5.95 1.06e-08 0.028 -0.5 -0.37 Cancer; chr13:34458243 chr15:84394512~84395514:+ CESC trans rs10940346 0.56 rs16879094 ENSG00000231752.4 EMBP1 5.95 1.06e-08 0.028 0.45 0.37 Schizophrenia; chr5:50442603 chr1:121519112~121571892:+ CESC trans rs3755021 1 rs12479308 ENSG00000253632.1 RP11-486M23.1 5.95 1.06e-08 0.0281 0.45 0.37 Monocyte-lymphocyte ratio; chr2:181483615 chr8:29527312~29530323:+ CESC trans rs8067354 0.645 rs28516945 ENSG00000187870.7 RNFT1P3 5.95 1.07e-08 0.0282 0.52 0.37 Hemoglobin concentration; chr17:59739217 chr17:20743333~20754501:- CESC trans rs10940346 0.601 rs10940075 ENSG00000231752.4 EMBP1 -5.95 1.07e-08 0.0282 -0.45 -0.37 Schizophrenia; chr5:50304547 chr1:121519112~121571892:+ CESC trans rs1568889 1 rs12796293 ENSG00000174912.7 METTL15P1 -5.95 1.07e-08 0.0284 -0.45 -0.37 Bipolar disorder; chr11:28156176 chr3:156713884~156714928:- CESC trans rs7520050 0.807 rs6656279 ENSG00000255397.1 AC022182.2 -5.95 1.08e-08 0.0285 -0.45 -0.37 Reticulocyte count;Red blood cell count; chr1:45658416 chr8:60937705~60939871:- CESC trans rs7520050 0.807 rs6671802 ENSG00000255397.1 AC022182.2 -5.95 1.08e-08 0.0285 -0.45 -0.37 Reticulocyte count;Red blood cell count; chr1:45658991 chr8:60937705~60939871:- CESC trans rs62140779 0.887 rs58749016 ENSG00000253347.1 CTD-2026D20.2 5.94 1.09e-08 0.0287 0.57 0.37 Neuroticism; chr2:58505696 chr17:47409322~47423526:- CESC trans rs7520050 0.807 rs4660312 ENSG00000255397.1 AC022182.2 -5.94 1.09e-08 0.0288 -0.45 -0.37 Reticulocyte count;Red blood cell count; chr1:45644900 chr8:60937705~60939871:- CESC trans rs7520050 0.807 rs4468203 ENSG00000255397.1 AC022182.2 -5.94 1.09e-08 0.0288 -0.45 -0.37 Reticulocyte count;Red blood cell count; chr1:45647600 chr8:60937705~60939871:- CESC trans rs4455778 0.58 rs6974104 ENSG00000238249.2 HMGN2P17 -5.94 1.09e-08 0.0288 -0.35 -0.37 Lung cancer in never smokers; chr7:49087181 chr1:8893409~8894151:+ CESC trans rs17137734 1 rs73361581 ENSG00000278472.1 RP11-74D7.3 -5.94 1.09e-08 0.0288 -0.9 -0.37 Corneal curvature; chr15:27272360 chr15:33972059~33972515:- CESC trans rs17137734 1 rs7177867 ENSG00000278472.1 RP11-74D7.3 -5.94 1.09e-08 0.0288 -0.9 -0.37 Corneal curvature; chr15:27273282 chr15:33972059~33972515:- CESC trans rs877636 0.702 rs773109 ENSG00000243403.1 RP11-330L19.1 5.94 1.09e-08 0.0289 0.37 0.37 Cognitive function; chr12:55980911 chr15:64592979~64593326:+ CESC trans rs1326895 0.709 rs12380171 ENSG00000280389.1 RP11-512M8.11 5.94 1.1e-08 0.0289 0.66 0.37 Pursuit maintenance gain; chr9:110934370 chr12:122255119~122260274:- CESC trans rs10940346 0.601 rs12697055 ENSG00000231752.4 EMBP1 5.94 1.1e-08 0.0289 0.45 0.37 Schizophrenia; chr5:50317827 chr1:121519112~121571892:+ CESC trans rs3806843 0.676 rs2563304 ENSG00000231043.3 AC007238.1 5.94 1.1e-08 0.029 0.42 0.37 Depressive symptoms (multi-trait analysis); chr5:140692472 chr2:58460292~58462032:- CESC trans rs3806843 0.735 rs3776129 ENSG00000231043.3 AC007238.1 5.94 1.1e-08 0.029 0.42 0.37 Depressive symptoms (multi-trait analysis); chr5:140692707 chr2:58460292~58462032:- CESC trans rs31771 0.564 rs1496294 ENSG00000224287.2 MSL3P1 -5.94 1.1e-08 0.029 -0.49 -0.37 Intelligence (multi-trait analysis); chr5:166091646 chr2:233865437~233868444:- CESC trans rs3806843 0.735 rs2563314 ENSG00000231043.3 AC007238.1 5.94 1.11e-08 0.0293 0.42 0.37 Depressive symptoms (multi-trait analysis); chr5:140667704 chr2:58460292~58462032:- CESC trans rs3806843 0.735 rs2530240 ENSG00000231043.3 AC007238.1 5.94 1.11e-08 0.0293 0.42 0.37 Depressive symptoms (multi-trait analysis); chr5:140680962 chr2:58460292~58462032:- CESC trans rs3806843 0.735 rs801189 ENSG00000231043.3 AC007238.1 5.94 1.11e-08 0.0293 0.42 0.37 Depressive symptoms (multi-trait analysis); chr5:140683506 chr2:58460292~58462032:- CESC trans rs3806843 0.706 rs1089305 ENSG00000231043.3 AC007238.1 5.94 1.11e-08 0.0293 0.42 0.37 Depressive symptoms (multi-trait analysis); chr5:140686721 chr2:58460292~58462032:- CESC trans rs3806843 0.735 rs801185 ENSG00000231043.3 AC007238.1 5.94 1.11e-08 0.0293 0.42 0.37 Depressive symptoms (multi-trait analysis); chr5:140689284 chr2:58460292~58462032:- CESC trans rs10940346 0.601 rs4865676 ENSG00000231752.4 EMBP1 5.94 1.11e-08 0.0293 0.45 0.37 Schizophrenia; chr5:50279343 chr1:121519112~121571892:+ CESC trans rs877636 0.859 rs3741499 ENSG00000196933.5 RPS26P11 -5.94 1.11e-08 0.0293 -0.42 -0.37 Cognitive function; chr12:56080595 chrX:72044545~72044892:+ CESC trans rs4455778 0.579 rs4563839 ENSG00000238249.2 HMGN2P17 -5.94 1.11e-08 0.0293 -0.35 -0.37 Lung cancer in never smokers; chr7:49036748 chr1:8893409~8894151:+ CESC trans rs4455778 0.561 rs56235551 ENSG00000238249.2 HMGN2P17 -5.94 1.12e-08 0.0294 -0.35 -0.37 Lung cancer in never smokers; chr7:49088536 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs56191832 ENSG00000238249.2 HMGN2P17 -5.94 1.12e-08 0.0294 -0.35 -0.37 Lung cancer in never smokers; chr7:49088627 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs59806378 ENSG00000238249.2 HMGN2P17 -5.94 1.12e-08 0.0294 -0.35 -0.37 Lung cancer in never smokers; chr7:49090338 chr1:8893409~8894151:+ CESC trans rs66887589 0.616 rs6843509 ENSG00000275858.1 RP11-291L22.8 5.94 1.12e-08 0.0295 0.39 0.37 Diastolic blood pressure; chr4:119299041 chr10:38450738~38451069:- CESC trans rs877636 0.669 rs7297175 ENSG00000227887.1 RPS26P13 -5.94 1.12e-08 0.0296 -0.4 -0.37 Cognitive function; chr12:56080024 chr1:208697369~208697698:- CESC trans rs8010715 0.636 rs3825584 ENSG00000238000.1 RP11-274E7.2 5.94 1.13e-08 0.0297 0.39 0.37 IgG glycosylation; chr14:24118430 chr5:98213402~98214121:+ CESC trans rs4455778 0.579 rs6969891 ENSG00000238249.2 HMGN2P17 -5.94 1.13e-08 0.0297 -0.35 -0.37 Lung cancer in never smokers; chr7:49084002 chr1:8893409~8894151:+ CESC trans rs10940346 0.601 rs13174293 ENSG00000231752.4 EMBP1 5.94 1.14e-08 0.03 0.45 0.37 Schizophrenia; chr5:50352191 chr1:121519112~121571892:+ CESC trans rs9650315 1 rs56261906 ENSG00000243802.2 RP11-390K5.1 5.93 1.15e-08 0.0302 0.59 0.37 Height; chr8:56245920 chr11:47191181~47191542:- CESC trans rs7113874 0.659 rs7935453 ENSG00000266891.1 RP11-692N5.2 5.93 1.15e-08 0.0303 0.44 0.37 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8625216 chr18:9734882~9735602:- CESC trans rs76419734 0.51 rs28391170 ENSG00000233432.2 RP11-344P13.3 -5.93 1.16e-08 0.0304 -0.56 -0.37 Post bronchodilator FEV1; chr4:105708089 chr1:121502344~121503891:+ CESC trans rs10940346 0.601 rs34616519 ENSG00000231752.4 EMBP1 5.93 1.16e-08 0.0304 0.47 0.37 Schizophrenia; chr5:50353638 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs1039798 ENSG00000231752.4 EMBP1 5.93 1.16e-08 0.0304 0.47 0.37 Schizophrenia; chr5:50355909 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10072182 ENSG00000231752.4 EMBP1 5.93 1.16e-08 0.0304 0.47 0.37 Schizophrenia; chr5:50356818 chr1:121519112~121571892:+ CESC trans rs10940346 0.54 rs12109228 ENSG00000231752.4 EMBP1 5.93 1.16e-08 0.0304 0.47 0.37 Schizophrenia; chr5:50383135 chr1:121519112~121571892:+ CESC trans rs9876781 1 rs11130170 ENSG00000225528.1 RP3-370M22.8 -5.93 1.16e-08 0.0305 -0.36 -0.37 Longevity; chr3:48408490 chr22:39960397~39964683:+ CESC trans rs941207 0.756 rs9634246 ENSG00000257210.1 NACAP3 -5.93 1.17e-08 0.0306 -0.5 -0.37 Platelet count; chr12:56640604 chr12:93124063~93124543:- CESC trans rs7647973 1 rs9862534 ENSG00000197582.5 GPX1P1 5.93 1.17e-08 0.0306 0.5 0.37 Menarche (age at onset); chr3:49560631 chrX:13378735~13379340:- CESC trans rs877636 1 rs4759229 ENSG00000196933.5 RPS26P11 -5.93 1.17e-08 0.0307 -0.42 -0.37 Cognitive function; chr12:56080696 chrX:72044545~72044892:+ CESC trans rs7520050 0.778 rs2934857 ENSG00000255397.1 AC022182.2 -5.93 1.17e-08 0.0307 -0.45 -0.37 Reticulocyte count;Red blood cell count; chr1:45573940 chr8:60937705~60939871:- CESC trans rs9326248 0.861 rs1871757 ENSG00000260012.1 RP11-329J18.4 -5.93 1.18e-08 0.0309 -0.48 -0.37 Blood protein levels; chr11:117159865 chr16:47262741~47263500:+ CESC trans rs2980976 0.551 rs3017352 ENSG00000259078.2 PTBP1P -5.92 1.21e-08 0.0316 -0.61 -0.37 Response to antipsychotic treatment; chr18:62406372 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs116304114 ENSG00000259078.2 PTBP1P -5.92 1.21e-08 0.0316 -0.61 -0.37 Response to antipsychotic treatment; chr18:62407221 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs3018352 ENSG00000259078.2 PTBP1P -5.92 1.21e-08 0.0316 -0.61 -0.37 Response to antipsychotic treatment; chr18:62407632 chr14:65279267~65281166:+ CESC trans rs7503168 0.558 rs12945980 ENSG00000234130.2 RP13-88F20.1 5.92 1.21e-08 0.0316 0.78 0.37 Plateletcrit; chr17:35603002 chrX:93222220~93225015:- CESC trans rs9876781 1 rs922075 ENSG00000235912.1 RP1-159A19.3 5.92 1.21e-08 0.0316 0.35 0.37 Longevity; chr3:48447994 chr1:27649419~27649610:+ CESC trans rs9876781 1 rs2045554 ENSG00000235912.1 RP1-159A19.3 5.92 1.21e-08 0.0316 0.35 0.37 Longevity; chr3:48453142 chr1:27649419~27649610:+ CESC trans rs4805834 0.697 rs73036823 ENSG00000212663.2 RP1-122K4.3 5.92 1.21e-08 0.0316 0.58 0.37 Creatinine levels; chr19:32855140 chrX:13980066~13988820:- CESC trans rs2950393 0.929 rs7973157 ENSG00000257210.1 NACAP3 -5.92 1.21e-08 0.0316 -0.41 -0.37 Platelet distribution width; chr12:56655409 chr12:93124063~93124543:- CESC trans rs4455778 0.501 rs10250970 ENSG00000238249.2 HMGN2P17 -5.92 1.21e-08 0.0316 -0.36 -0.37 Lung cancer in never smokers; chr7:49012895 chr1:8893409~8894151:+ CESC trans rs4455778 0.5 rs7783586 ENSG00000238249.2 HMGN2P17 -5.92 1.21e-08 0.0316 -0.36 -0.37 Lung cancer in never smokers; chr7:49017648 chr1:8893409~8894151:+ CESC trans rs12155039 1 rs12155039 ENSG00000226038.5 PPIAP21 -5.92 1.21e-08 0.0316 -0.49 -0.37 Mean platelet volume; chr7:44833526 chr20:43230760~43231260:+ CESC trans rs2478333 0.636 rs1172416 ENSG00000255345.1 CTD-2337I7.1 5.92 1.22e-08 0.0317 0.45 0.37 QT interval; chr13:47647608 chr11:79092848~79098003:+ CESC trans rs17137734 0.59 rs11263716 ENSG00000278472.1 RP11-74D7.3 -5.92 1.22e-08 0.0318 -0.89 -0.37 Corneal curvature; chr15:27270230 chr15:33972059~33972515:- CESC trans rs17137734 1 rs28625958 ENSG00000278472.1 RP11-74D7.3 -5.92 1.22e-08 0.0318 -0.89 -0.37 Corneal curvature; chr15:27271048 chr15:33972059~33972515:- CESC trans rs17137734 1 rs11857324 ENSG00000278472.1 RP11-74D7.3 -5.92 1.22e-08 0.0318 -0.89 -0.37 Corneal curvature; chr15:27271370 chr15:33972059~33972515:- CESC trans rs4444359 0.722 rs6498196 ENSG00000206633.1 SNORA80B 5.92 1.23e-08 0.032 0.5 0.37 Facial morphology (factor 17, height of vermillion upper lip); chr16:11454429 chr2:10446714~10446849:- CESC trans rs4455778 0.58 rs4917197 ENSG00000238249.2 HMGN2P17 -5.92 1.23e-08 0.032 -0.35 -0.37 Lung cancer in never smokers; chr7:49036298 chr1:8893409~8894151:+ CESC trans rs66887589 0.592 rs2175383 ENSG00000275858.1 RP11-291L22.8 5.92 1.23e-08 0.032 0.39 0.37 Diastolic blood pressure; chr4:119294681 chr10:38450738~38451069:- CESC trans rs4455778 0.58 rs62454353 ENSG00000238249.2 HMGN2P17 -5.92 1.23e-08 0.0321 -0.35 -0.37 Lung cancer in never smokers; chr7:49048304 chr1:8893409~8894151:+ CESC trans rs66887589 0.616 rs1052633 ENSG00000275858.1 RP11-291L22.8 5.92 1.24e-08 0.0322 0.39 0.37 Diastolic blood pressure; chr4:119294159 chr10:38450738~38451069:- CESC trans rs62140779 0.887 rs11894830 ENSG00000253347.1 CTD-2026D20.2 5.92 1.24e-08 0.0323 0.59 0.37 Neuroticism; chr2:58486295 chr17:47409322~47423526:- CESC trans rs2980976 0.551 rs2957143 ENSG00000259078.2 PTBP1P -5.92 1.24e-08 0.0323 -0.63 -0.37 Response to antipsychotic treatment; chr18:62404405 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs2980970 ENSG00000259078.2 PTBP1P -5.92 1.24e-08 0.0323 -0.63 -0.37 Response to antipsychotic treatment; chr18:62404912 chr14:65279267~65281166:+ CESC trans rs12339966 0.689 rs10809553 ENSG00000260947.1 RP11-384P7.7 -5.92 1.25e-08 0.0325 -0.49 -0.37 Systolic blood pressure; chr9:11681043 chr9:33697459~33700986:+ CESC trans rs12339966 0.689 rs10809554 ENSG00000260947.1 RP11-384P7.7 -5.92 1.25e-08 0.0325 -0.49 -0.37 Systolic blood pressure; chr9:11681116 chr9:33697459~33700986:+ CESC trans rs77688320 0.553 rs6722889 ENSG00000235105.1 RP11-329A14.1 -5.92 1.26e-08 0.0327 -0.44 -0.37 Breast cancer; chr2:201439359 chr1:48435967~48437223:+ CESC trans rs941207 0.855 rs2256341 ENSG00000257210.1 NACAP3 -5.92 1.26e-08 0.0328 -0.52 -0.37 Platelet count; chr12:56599930 chr12:93124063~93124543:- CESC trans rs941207 0.805 rs2958139 ENSG00000257210.1 NACAP3 -5.92 1.26e-08 0.0328 -0.52 -0.37 Platelet count; chr12:56610884 chr12:93124063~93124543:- CESC trans rs2950393 0.895 rs2958123 ENSG00000257210.1 NACAP3 5.92 1.26e-08 0.0328 0.41 0.37 Platelet distribution width; chr12:56668441 chr12:93124063~93124543:- CESC trans rs7520050 0.807 rs72688483 ENSG00000255397.1 AC022182.2 -5.92 1.26e-08 0.0329 -0.45 -0.37 Reticulocyte count;Red blood cell count; chr1:45683537 chr8:60937705~60939871:- CESC trans rs2991971 0.782 rs10789463 ENSG00000255397.1 AC022182.2 -5.91 1.27e-08 0.033 -0.44 -0.37 High light scatter reticulocyte count; chr1:45462176 chr8:60937705~60939871:- CESC trans rs4948102 0.731 rs7800001 ENSG00000215006.4 CHCHD2P2 -5.91 1.27e-08 0.033 -0.48 -0.37 Plasma homocysteine levels (post-methionine load test); chr7:56004317 chr5:69333929~69334249:+ CESC trans rs2980976 0.551 rs3017340 ENSG00000259078.2 PTBP1P -5.91 1.28e-08 0.0331 -0.63 -0.37 Response to antipsychotic treatment; chr18:62404320 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs3017357 ENSG00000259078.2 PTBP1P -5.91 1.28e-08 0.0331 -0.63 -0.37 Response to antipsychotic treatment; chr18:62404742 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs3017356 ENSG00000259078.2 PTBP1P -5.91 1.28e-08 0.0331 -0.63 -0.37 Response to antipsychotic treatment; chr18:62404896 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs2957144 ENSG00000259078.2 PTBP1P -5.91 1.28e-08 0.0331 -0.63 -0.37 Response to antipsychotic treatment; chr18:62404946 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs3018351 ENSG00000259078.2 PTBP1P -5.91 1.28e-08 0.0331 -0.63 -0.37 Response to antipsychotic treatment; chr18:62405432 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs3017355 ENSG00000259078.2 PTBP1P -5.91 1.28e-08 0.0331 -0.63 -0.37 Response to antipsychotic treatment; chr18:62405569 chr14:65279267~65281166:+ CESC trans rs2980976 0.551 rs3017354 ENSG00000259078.2 PTBP1P -5.91 1.28e-08 0.0331 -0.63 -0.37 Response to antipsychotic treatment; chr18:62405583 chr14:65279267~65281166:+ CESC trans rs2250402 0.51 rs2291621 ENSG00000234106.3 RP11-288E14.2 5.91 1.29e-08 0.0335 0.68 0.37 Corneal curvature; chr15:40032636 chr11:93535468~93535816:+ CESC trans rs10819083 0.788 rs12353435 ENSG00000203588.3 IGBP1-AS1 -5.91 1.3e-08 0.0335 -0.32 -0.37 Squamous cell lung carcinoma; chr9:125946974 chrX:70163842~70165206:- CESC trans rs10819083 0.861 rs13293109 ENSG00000203588.3 IGBP1-AS1 -5.91 1.3e-08 0.0335 -0.32 -0.37 Squamous cell lung carcinoma; chr9:125948653 chrX:70163842~70165206:- CESC trans rs10819083 0.823 rs1999199 ENSG00000203588.3 IGBP1-AS1 -5.91 1.3e-08 0.0335 -0.32 -0.37 Squamous cell lung carcinoma; chr9:125948835 chrX:70163842~70165206:- CESC trans rs9487051 1 rs9374080 ENSG00000228502.1 EEF1A1P11 -5.91 1.3e-08 0.0336 -0.33 -0.37 Reticulocyte fraction of red cells; chr6:109295217 chr1:96446930~96448318:+ CESC trans rs12439619 0.508 rs8042665 ENSG00000259295.5 CSPG4P12 -5.91 1.3e-08 0.0336 -0.4 -0.37 Intelligence (multi-trait analysis); chr15:82189008 chr15:85191438~85213905:+ CESC trans rs12549025 0.891 rs13266950 ENSG00000275966.1 RP11-1055B8.9 5.91 1.3e-08 0.0337 0.55 0.37 Reticulocyte fraction of red cells; chr8:23537427 chr17:81345476~81345966:- CESC trans rs2250402 0.51 rs8031319 ENSG00000234106.3 RP11-288E14.2 5.91 1.3e-08 0.0337 0.72 0.37 Corneal curvature; chr15:40031491 chr11:93535468~93535816:+ CESC trans rs9611519 0.78 rs1983631 ENSG00000268568.1 AC007228.9 -5.91 1.32e-08 0.034 -0.49 -0.37 Neuroticism; chr22:41248070 chr19:56672574~56673901:- CESC trans rs12709013 0.967 rs62064905 ENSG00000230849.2 GOT2P2 5.91 1.32e-08 0.034 0.43 0.37 Blood metabolite ratios; chr16:58778839 chr1:173141100~173142350:- CESC trans rs12709013 0.935 rs34657766 ENSG00000230849.2 GOT2P2 5.91 1.32e-08 0.034 0.43 0.37 Blood metabolite ratios; chr16:58779468 chr1:173141100~173142350:- CESC trans rs12709013 0.729 rs71400031 ENSG00000230849.2 GOT2P2 5.91 1.32e-08 0.034 0.43 0.37 Blood metabolite ratios; chr16:58779554 chr1:173141100~173142350:- CESC trans rs31771 0.525 rs2644735 ENSG00000224287.2 MSL3P1 -5.91 1.32e-08 0.0341 -0.53 -0.37 Intelligence (multi-trait analysis); chr5:166088838 chr2:233865437~233868444:- CESC trans rs1707322 1 rs1707303 ENSG00000255397.1 AC022182.2 5.91 1.33e-08 0.0342 0.49 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:46132601 chr8:60937705~60939871:- CESC trans rs4276421 0.53 rs10078485 ENSG00000231752.4 EMBP1 5.91 1.33e-08 0.0342 0.5 0.37 P wave duration; chr5:45879307 chr1:121519112~121571892:+ CESC trans rs12439619 0.53 rs28883606 ENSG00000259295.5 CSPG4P12 -5.91 1.33e-08 0.0343 -0.39 -0.37 Intelligence (multi-trait analysis); chr15:82216713 chr15:85191438~85213905:+ CESC trans rs12439619 0.693 rs28665836 ENSG00000259295.5 CSPG4P12 -5.91 1.33e-08 0.0343 -0.39 -0.37 Intelligence (multi-trait analysis); chr15:82218955 chr15:85191438~85213905:+ CESC trans rs10819083 0.861 rs1411354 ENSG00000203588.3 IGBP1-AS1 -5.91 1.33e-08 0.0343 -0.33 -0.37 Squamous cell lung carcinoma; chr9:125936485 chrX:70163842~70165206:- CESC trans rs55665837 0.701 rs10160597 ENSG00000236360.2 RP11-334A14.2 5.91 1.33e-08 0.0344 0.47 0.37 Vitamin D levels; chr11:14582446 chr1:52993201~52993702:- CESC trans rs10940346 0.601 rs6868380 ENSG00000231752.4 EMBP1 5.91 1.34e-08 0.0345 0.46 0.37 Schizophrenia; chr5:50328473 chr1:121519112~121571892:+ CESC trans rs941207 0.542 rs6581106 ENSG00000257210.1 NACAP3 -5.91 1.34e-08 0.0345 -0.48 -0.37 Platelet count; chr12:56796759 chr12:93124063~93124543:- CESC trans rs66887589 0.592 rs11731571 ENSG00000275858.1 RP11-291L22.8 5.9 1.34e-08 0.0345 0.4 0.37 Diastolic blood pressure; chr4:119300030 chr10:38450738~38451069:- CESC trans rs58694847 0.577 rs78311138 ENSG00000255176.1 AP002954.3 5.9 1.34e-08 0.0345 0.45 0.37 Educational attainment (years of education);Educational attainment (college completion); chr14:84473195 chr11:118636620~118638097:+ CESC trans rs4455778 0.58 rs4336559 ENSG00000238249.2 HMGN2P17 -5.9 1.34e-08 0.0345 -0.35 -0.37 Lung cancer in never smokers; chr7:49085617 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs10259971 ENSG00000238249.2 HMGN2P17 -5.9 1.34e-08 0.0346 -0.35 -0.37 Lung cancer in never smokers; chr7:49046156 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs7808387 ENSG00000238249.2 HMGN2P17 -5.9 1.34e-08 0.0346 -0.35 -0.37 Lung cancer in never smokers; chr7:49085526 chr1:8893409~8894151:+ CESC trans rs31771 0.564 rs2644731 ENSG00000224287.2 MSL3P1 -5.9 1.34e-08 0.0346 -0.52 -0.37 Intelligence (multi-trait analysis); chr5:166091932 chr2:233865437~233868444:- CESC trans rs31771 0.564 rs2545518 ENSG00000224287.2 MSL3P1 -5.9 1.34e-08 0.0346 -0.52 -0.37 Intelligence (multi-trait analysis); chr5:166091994 chr2:233865437~233868444:- CESC trans rs31771 0.564 rs2545517 ENSG00000224287.2 MSL3P1 -5.9 1.34e-08 0.0346 -0.52 -0.37 Intelligence (multi-trait analysis); chr5:166092005 chr2:233865437~233868444:- CESC trans rs66887589 0.616 rs11098498 ENSG00000275858.1 RP11-291L22.8 5.9 1.35e-08 0.0348 0.39 0.37 Diastolic blood pressure; chr4:119265964 chr10:38450738~38451069:- CESC trans rs9487051 1 rs1341271 ENSG00000228502.1 EEF1A1P11 5.9 1.35e-08 0.0349 0.32 0.37 Reticulocyte fraction of red cells; chr6:109296339 chr1:96446930~96448318:+ CESC trans rs896322 0.858 rs7536902 ENSG00000230658.1 KLHL7-AS1 -5.9 1.36e-08 0.0349 -0.62 -0.37 Mean platelet volume; chr1:205090154 chr7:23101228~23105703:- CESC trans rs4455778 0.58 rs4244231 ENSG00000238249.2 HMGN2P17 -5.9 1.38e-08 0.0353 -0.35 -0.37 Lung cancer in never smokers; chr7:49063810 chr1:8893409~8894151:+ CESC trans rs11012350 0.85 rs72780046 ENSG00000279123.1 RP11-424M24.3 -5.9 1.38e-08 0.0353 -0.97 -0.37 Peripheral arterial disease (traffic-related air pollution interaction); chr10:18050703 chr16:70778433~70779145:+ CESC trans rs11012350 0.51 rs77131414 ENSG00000279123.1 RP11-424M24.3 -5.9 1.38e-08 0.0353 -0.97 -0.37 Peripheral arterial disease (traffic-related air pollution interaction); chr10:18053005 chr16:70778433~70779145:+ CESC trans rs12138950 0.596 rs10917471 ENSG00000224237.1 MINOS1P3 5.9 1.38e-08 0.0354 0.5 0.37 Hypothyroidism;Thyroid volume; chr1:19521118 chr3:27214816~27215018:- CESC trans rs7554511 0.861 rs296563 ENSG00000244144.1 RP11-757F18.3 5.9 1.4e-08 0.0358 0.42 0.37 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr1:200975712 chr3:112185480~112185998:- CESC trans rs9790314 0.718 rs9847866 ENSG00000245281.5 CTD-2547L16.1 -5.89 1.41e-08 0.0362 -0.48 -0.37 Morning vs. evening chronotype; chr3:161040487 chr8:18084868~18096394:+ CESC trans rs10940346 1 rs6874016 ENSG00000231752.4 EMBP1 -5.89 1.43e-08 0.0365 -0.46 -0.37 Schizophrenia; chr5:50549640 chr1:121519112~121571892:+ CESC trans rs714543 0.566 rs13231886 ENSG00000226038.5 PPIAP21 -5.89 1.44e-08 0.0368 -0.44 -0.37 Plateletcrit; chr7:44774573 chr20:43230760~43231260:+ CESC trans rs16852193 0.748 rs6766475 ENSG00000258048.1 RP11-530C5.1 -5.89 1.44e-08 0.0368 -0.41 -0.37 Glomerular filtration rate (creatinine); chr3:168445124 chr12:79690144~79778451:+ CESC trans rs9650315 0.929 rs35093016 ENSG00000243802.2 RP11-390K5.1 5.89 1.44e-08 0.0369 0.57 0.37 Height; chr8:56248853 chr11:47191181~47191542:- CESC trans rs169082 0.837 rs264879 ENSG00000269473.1 CTD-2619J13.19 -5.89 1.45e-08 0.037 -0.41 -0.37 Protein quantitative trait loci; chr5:169651930 chr19:58440448~58445849:+ CESC trans rs169082 0.837 rs264880 ENSG00000269473.1 CTD-2619J13.19 -5.89 1.45e-08 0.037 -0.41 -0.37 Protein quantitative trait loci; chr5:169652253 chr19:58440448~58445849:+ CESC trans rs7647973 0.925 rs9881860 ENSG00000197582.5 GPX1P1 5.89 1.45e-08 0.0371 0.5 0.37 Menarche (age at onset); chr3:49315089 chrX:13378735~13379340:- CESC trans rs10503709 0.542 rs10112641 ENSG00000251013.1 GAPDHP62 5.89 1.46e-08 0.0372 0.46 0.37 Blood protein levels; chr8:21588367 chr8:100550724~100551713:- CESC trans rs7312770 1 rs7312770 ENSG00000233778.3 RP11-777J24.1 -5.89 1.47e-08 0.0375 -0.38 -0.37 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr8:92144088~92144435:- CESC trans rs31771 0.525 rs2132523 ENSG00000224287.2 MSL3P1 -5.89 1.48e-08 0.0378 -0.51 -0.37 Intelligence (multi-trait analysis); chr5:166091266 chr2:233865437~233868444:- CESC trans rs6127471 0.934 rs6123474 ENSG00000280123.1 RP11-267M23.1 -5.89 1.48e-08 0.0378 -0.48 -0.37 Heart rate; chr20:38214380 chr8:94427712~94429888:- CESC trans rs36051895 0.632 rs11788164 ENSG00000228021.6 RP11-383C5.3 -5.89 1.49e-08 0.0379 -0.37 -0.37 Pediatric autoimmune diseases; chr9:5129395 chr10:125683229~125709677:+ CESC trans rs12822507 0.732 rs4763855 ENSG00000225761.1 RP11-417O11.5 5.88 1.49e-08 0.0379 0.46 0.37 Systemic lupus erythematosus; chr12:12614824 chr10:74005137~74027915:+ CESC trans rs3740713 0.669 rs34740438 ENSG00000235847.2 LDHAP7 5.88 1.49e-08 0.038 0.66 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18393783 chr2:84777259~84778223:- CESC trans rs6127471 1 rs1534967 ENSG00000280123.1 RP11-267M23.1 -5.88 1.5e-08 0.0382 -0.46 -0.37 Heart rate; chr20:38213354 chr8:94427712~94429888:- CESC trans rs3749237 1 rs2307021 ENSG00000197582.5 GPX1P1 5.88 1.5e-08 0.0383 0.55 0.37 Resting heart rate; chr3:49728050 chrX:13378735~13379340:- CESC trans rs12652364 0.614 rs5022037 ENSG00000269097.1 AC003682.17 -5.88 1.5e-08 0.0383 -0.62 -0.37 Response to methotrexate in juvenile idiopathic arthritis; chr5:30835046 chr19:57664280~57665039:+ CESC trans rs10940346 0.56 rs10073530 ENSG00000231752.4 EMBP1 5.88 1.5e-08 0.0383 0.46 0.37 Schizophrenia; chr5:50358823 chr1:121519112~121571892:+ CESC trans rs4455778 0.58 rs6583501 ENSG00000238249.2 HMGN2P17 -5.88 1.51e-08 0.0384 -0.35 -0.37 Lung cancer in never smokers; chr7:49038040 chr1:8893409~8894151:+ CESC trans rs4455778 0.561 rs10243463 ENSG00000238249.2 HMGN2P17 -5.88 1.51e-08 0.0384 -0.35 -0.37 Lung cancer in never smokers; chr7:49041589 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs56068416 ENSG00000238249.2 HMGN2P17 -5.88 1.51e-08 0.0384 -0.35 -0.37 Lung cancer in never smokers; chr7:49043630 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs7777309 ENSG00000238249.2 HMGN2P17 -5.88 1.51e-08 0.0384 -0.35 -0.37 Lung cancer in never smokers; chr7:49045928 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs10242641 ENSG00000238249.2 HMGN2P17 -5.88 1.51e-08 0.0384 -0.35 -0.37 Lung cancer in never smokers; chr7:49046152 chr1:8893409~8894151:+ CESC trans rs4455778 0.538 rs67216951 ENSG00000238249.2 HMGN2P17 -5.88 1.51e-08 0.0384 -0.35 -0.37 Lung cancer in never smokers; chr7:49048432 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4357241 ENSG00000238249.2 HMGN2P17 -5.88 1.51e-08 0.0384 -0.35 -0.37 Lung cancer in never smokers; chr7:49049872 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4437600 ENSG00000238249.2 HMGN2P17 -5.88 1.51e-08 0.0384 -0.35 -0.37 Lung cancer in never smokers; chr7:49050678 chr1:8893409~8894151:+ CESC trans rs3112530 0.786 rs294708 ENSG00000262902.1 RP11-750B16.1 -5.88 1.52e-08 0.0386 -0.69 -0.37 Aging (time to event); chr5:153138476 chr17:53105734~53106358:+ CESC trans rs3112530 0.786 rs294699 ENSG00000262902.1 RP11-750B16.1 -5.88 1.52e-08 0.0386 -0.69 -0.37 Aging (time to event); chr5:153141377 chr17:53105734~53106358:+ CESC trans rs7044246 0.924 rs7025683 ENSG00000279901.1 CTD-2270P14.2 5.88 1.53e-08 0.0388 0.45 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr9:131990428 chr16:2683106~2684764:+ CESC trans rs7554547 0.622 rs72864769 ENSG00000261819.1 RP11-680G24.4 5.88 1.55e-08 0.0392 0.45 0.37 Nonsyndromic cleft lip with cleft palate; chr1:11881264 chr16:14988259~14990160:- CESC trans rs7554547 0.69 rs6669571 ENSG00000261819.1 RP11-680G24.4 5.88 1.55e-08 0.0394 0.44 0.37 Nonsyndromic cleft lip with cleft palate; chr1:11887253 chr16:14988259~14990160:- CESC trans rs7554547 0.69 rs1474576 ENSG00000261819.1 RP11-680G24.4 5.88 1.55e-08 0.0394 0.44 0.37 Nonsyndromic cleft lip with cleft palate; chr1:11887572 chr16:14988259~14990160:- CESC trans rs7554547 0.69 rs1474577 ENSG00000261819.1 RP11-680G24.4 5.88 1.55e-08 0.0394 0.44 0.37 Nonsyndromic cleft lip with cleft palate; chr1:11887712 chr16:14988259~14990160:- CESC trans rs11098499 0.71 rs4145952 ENSG00000275858.1 RP11-291L22.8 5.88 1.55e-08 0.0394 0.42 0.37 Corneal astigmatism; chr4:119234651 chr10:38450738~38451069:- CESC trans rs66887589 0.592 rs62320740 ENSG00000275858.1 RP11-291L22.8 5.88 1.55e-08 0.0394 0.39 0.37 Diastolic blood pressure; chr4:119358331 chr10:38450738~38451069:- CESC trans rs10940346 0.601 rs7442762 ENSG00000231752.4 EMBP1 5.88 1.56e-08 0.0395 0.46 0.37 Schizophrenia; chr5:50358137 chr1:121519112~121571892:+ CESC trans rs12652364 0.614 rs12652382 ENSG00000269097.1 AC003682.17 -5.87 1.57e-08 0.0397 -0.65 -0.37 Response to methotrexate in juvenile idiopathic arthritis; chr5:30836194 chr19:57664280~57665039:+ CESC trans rs13190036 0.901 rs55741473 ENSG00000228305.2 AC016734.2 -5.87 1.57e-08 0.0397 -0.5 -0.37 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr2:63622178~63622831:- CESC trans rs31771 0.525 rs2644733 ENSG00000224287.2 MSL3P1 -5.87 1.57e-08 0.0397 -0.51 -0.37 Intelligence (multi-trait analysis); chr5:166089342 chr2:233865437~233868444:- CESC trans rs31771 0.525 rs2545519 ENSG00000224287.2 MSL3P1 -5.87 1.57e-08 0.0397 -0.51 -0.37 Intelligence (multi-trait analysis); chr5:166089412 chr2:233865437~233868444:- CESC trans rs2991971 0.967 rs2356551 ENSG00000255397.1 AC022182.2 5.87 1.58e-08 0.0399 0.46 0.37 High light scatter reticulocyte count; chr1:45543646 chr8:60937705~60939871:- CESC trans rs12138950 0.681 rs9783019 ENSG00000224237.1 MINOS1P3 5.87 1.58e-08 0.0399 0.49 0.37 Hypothyroidism;Thyroid volume; chr1:19523162 chr3:27214816~27215018:- CESC trans rs61041336 0.534 rs2280399 ENSG00000230849.2 GOT2P2 -5.87 1.58e-08 0.04 -0.62 -0.37 Neuritic plaque; chr16:58677628 chr1:173141100~173142350:- CESC trans rs941207 0.542 rs11171978 ENSG00000257210.1 NACAP3 5.87 1.58e-08 0.04 0.47 0.37 Platelet count; chr12:56800015 chr12:93124063~93124543:- CESC trans rs9876781 1 rs11130171 ENSG00000225528.1 RP3-370M22.8 -5.87 1.59e-08 0.0403 -0.36 -0.37 Longevity; chr3:48421052 chr22:39960397~39964683:+ CESC trans rs9876781 1 rs9883927 ENSG00000225528.1 RP3-370M22.8 -5.87 1.59e-08 0.0403 -0.36 -0.37 Longevity; chr3:48422302 chr22:39960397~39964683:+ CESC trans rs9876781 1 rs9817615 ENSG00000225528.1 RP3-370M22.8 -5.87 1.59e-08 0.0403 -0.36 -0.37 Longevity; chr3:48429347 chr22:39960397~39964683:+ CESC trans rs9876781 1 rs2290822 ENSG00000225528.1 RP3-370M22.8 -5.87 1.59e-08 0.0403 -0.36 -0.37 Longevity; chr3:48431794 chr22:39960397~39964683:+ CESC trans rs9876781 1 rs13076076 ENSG00000225528.1 RP3-370M22.8 -5.87 1.59e-08 0.0403 -0.36 -0.37 Longevity; chr3:48437629 chr22:39960397~39964683:+ CESC trans rs7113874 0.625 rs10743073 ENSG00000266891.1 RP11-692N5.2 -5.87 1.6e-08 0.0404 -0.46 -0.37 Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:8483072 chr18:9734882~9735602:- CESC trans rs5877 0.512 rs56753505 ENSG00000213331.4 RP11-713C19.2 5.87 1.6e-08 0.0405 0.47 0.37 Subjective well-being (multi-trait analysis); chr1:173898114 chr4:187970273~187971284:+ CESC trans rs7192380 0.63 rs2965749 ENSG00000257513.6 NPIPB1P -5.87 1.61e-08 0.0405 -0.42 -0.37 Sjögren's syndrome; chr16:69738011 chr18:11619509~11639699:- CESC trans rs4455778 0.557 rs4289754 ENSG00000238249.2 HMGN2P17 -5.87 1.61e-08 0.0406 -0.35 -0.37 Lung cancer in never smokers; chr7:49077134 chr1:8893409~8894151:+ CESC trans rs4455778 0.58 rs4304291 ENSG00000238249.2 HMGN2P17 -5.87 1.61e-08 0.0406 -0.35 -0.37 Lung cancer in never smokers; chr7:49077387 chr1:8893409~8894151:+ CESC trans rs1326895 0.643 rs10980654 ENSG00000280389.1 RP11-512M8.11 5.87 1.61e-08 0.0407 0.65 0.37 Pursuit maintenance gain; chr9:110947767 chr12:122255119~122260274:- CESC trans rs2835345 0.962 rs2835344 ENSG00000259514.1 RP11-685G9.2 5.87 1.62e-08 0.0407 0.49 0.37 Pulmonary function; chr21:36429047 chr15:76339609~76342063:- CESC trans rs10242455 1 rs776746 ENSG00000228834.1 RP11-249L21.4 -5.87 1.62e-08 0.0409 -0.59 -0.37 Blood metabolite levels; chr7:99672916 chr6:108907615~108907873:- CESC trans rs10819083 0.861 rs10987043 ENSG00000203588.3 IGBP1-AS1 -5.87 1.63e-08 0.041 -0.32 -0.37 Squamous cell lung carcinoma; chr9:125927461 chrX:70163842~70165206:- CESC trans rs616147 0.627 rs9871799 ENSG00000214263.2 RPSAP53 5.87 1.63e-08 0.0411 0.47 0.37 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39442829 chr13:67266845~67267706:- CESC trans rs3749237 0.964 rs34522271 ENSG00000197582.5 GPX1P1 5.87 1.64e-08 0.0413 0.55 0.37 Resting heart rate; chr3:49771084 chrX:13378735~13379340:- CESC trans rs7846314 0.536 rs6471900 ENSG00000235272.1 FAM103A2P 5.87 1.64e-08 0.0413 0.6 0.37 Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Myeloid white cell count;Neutrophil percentage of granulocytes;Granulocyte count;Sum basophil neutrophil counts;Granulocyte percentage of myeloid white cells;Neutrophil count;White blood cell count; chr8:60780593 chr6:166586124~166586477:- CESC trans rs10716881 1 rs10716881 ENSG00000257210.1 NACAP3 -5.87 1.64e-08 0.0413 -0.41 -0.37 High light scatter reticulocyte count; chr12:56644387 chr12:93124063~93124543:- CESC trans rs912593 1 rs912593 ENSG00000259570.1 RP11-671M22.4 5.87 1.65e-08 0.0414 0.5 0.37 Cancer; chr13:34458354 chr15:84394512~84395514:+ CESC trans rs4947019 1 rs4947019 ENSG00000233347.1 ERP29P1 5.87 1.65e-08 0.0414 0.71 0.37 Hematological parameters; chr6:109768846 chr20:52110344~52111049:- CESC trans rs55665837 0.701 rs1522633 ENSG00000236360.2 RP11-334A14.2 5.86 1.66e-08 0.0418 0.48 0.37 Vitamin D levels; chr11:14623692 chr1:52993201~52993702:- CESC trans rs2950393 0.804 rs1026565 ENSG00000257210.1 NACAP3 5.86 1.67e-08 0.042 0.4 0.37 Platelet distribution width; chr12:56744044 chr12:93124063~93124543:- CESC trans rs12497850 0.864 rs4513485 ENSG00000197582.5 GPX1P1 5.86 1.67e-08 0.042 0.5 0.37 Parkinson's disease; chr3:49102533 chrX:13378735~13379340:- CESC trans rs17507216 1 rs3850610 ENSG00000259295.5 CSPG4P12 5.86 1.68e-08 0.0421 0.48 0.37 Excessive daytime sleepiness; chr15:82552642 chr15:85191438~85213905:+ CESC trans rs3749237 1 rs6804655 ENSG00000197582.5 GPX1P1 5.86 1.68e-08 0.0422 0.56 0.37 Resting heart rate; chr3:49701512 chrX:13378735~13379340:- CESC trans rs4455778 0.58 rs7803736 ENSG00000238249.2 HMGN2P17 -5.86 1.68e-08 0.0422 -0.35 -0.37 Lung cancer in never smokers; chr7:49085415 chr1:8893409~8894151:+ CESC trans rs11099942 0.826 rs4392497 ENSG00000204652.6 RPS26P8 -5.86 1.69e-08 0.0424 -0.67 -0.37 Type 2 diabetes (age of onset); chr4:154209509 chr17:45608571~45608918:+ CESC trans rs4455778 0.6 rs4478520 ENSG00000238249.2 HMGN2P17 -5.86 1.69e-08 0.0424 -0.35 -0.37 Lung cancer in never smokers; chr7:49040192 chr1:8893409~8894151:+ CESC trans rs4948102 0.731 rs6593292 ENSG00000215006.4 CHCHD2P2 -5.86 1.69e-08 0.0424 -0.48 -0.37 Plasma homocysteine levels (post-methionine load test); chr7:55975344 chr5:69333929~69334249:+ CESC trans rs4948102 0.731 rs4543497 ENSG00000215006.4 CHCHD2P2 -5.86 1.69e-08 0.0424 -0.48 -0.37 Plasma homocysteine levels (post-methionine load test); chr7:55979522 chr5:69333929~69334249:+ CESC trans rs4948102 0.767 rs4948096 ENSG00000215006.4 CHCHD2P2 -5.86 1.69e-08 0.0424 -0.48 -0.37 Plasma homocysteine levels (post-methionine load test); chr7:55985425 chr5:69333929~69334249:+ CESC trans rs4948102 0.691 rs10435504 ENSG00000215006.4 CHCHD2P2 -5.86 1.69e-08 0.0424 -0.48 -0.37 Plasma homocysteine levels (post-methionine load test); chr7:55991898 chr5:69333929~69334249:+ CESC trans rs7503168 0.558 rs17670614 ENSG00000234130.2 RP13-88F20.1 5.86 1.69e-08 0.0425 0.79 0.37 Plateletcrit; chr17:35672348 chrX:93222220~93225015:- CESC trans rs9341835 0.51 rs7745873 ENSG00000257809.1 RP11-603J24.14 5.86 1.69e-08 0.0425 0.38 0.37 Schizophrenia; chr6:63455948 chr12:56150796~56158220:- CESC trans rs6127471 1 rs6069232 ENSG00000280123.1 RP11-267M23.1 -5.86 1.7e-08 0.0426 -0.48 -0.37 Heart rate; chr20:38214854 chr8:94427712~94429888:- CESC trans rs2991971 1 rs518365 ENSG00000255397.1 AC022182.2 5.86 1.71e-08 0.0428 0.47 0.37 High light scatter reticulocyte count; chr1:45544980 chr8:60937705~60939871:- CESC trans rs36350 0.609 rs2190864 ENSG00000252061.1 RNU6-415P -5.86 1.73e-08 0.0432 -0.47 -0.37 Autism spectrum disorder or schizophrenia; chr14:71949502 chr15:78898840~78898936:- CESC trans rs9611519 0.78 rs2284079 ENSG00000268568.1 AC007228.9 -5.86 1.73e-08 0.0433 -0.46 -0.37 Neuroticism; chr22:41262628 chr19:56672574~56673901:- CESC trans rs7124681 0.584 rs11039448 ENSG00000250906.1 RP11-632F7.3 -5.86 1.73e-08 0.0434 -0.4 -0.37 Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals; chr11:47896864 chr4:40812779~40826151:+ CESC trans rs4455778 0.58 rs4541847 ENSG00000238249.2 HMGN2P17 5.86 1.73e-08 0.0434 0.35 0.37 Lung cancer in never smokers; chr7:49070228 chr1:8893409~8894151:+ CESC trans rs76169311 0.901 rs10922302 ENSG00000233942.1 AC004012.1 -5.86 1.74e-08 0.0435 -0.8 -0.37 Luteinizing hormone levels in polycystic ovary syndrome; chr1:197845961 chr7:95471835~95473998:+ CESC trans rs61041336 0.534 rs59234479 ENSG00000230849.2 GOT2P2 -5.86 1.74e-08 0.0435 -0.62 -0.37 Neuritic plaque; chr16:58673724 chr1:173141100~173142350:- CESC trans rs3112530 0.786 rs2546331 ENSG00000225972.1 MTND1P23 5.85 1.74e-08 0.0436 0.77 0.37 Aging (time to event); chr5:153194405 chr1:629062~629433:+ CESC trans rs928391 0.572 rs11264548 ENSG00000227183.3 HDGFP1 -5.85 1.74e-08 0.0437 -0.48 -0.37 Platelet count; chr1:156779339 chrX:131646639~131646890:+ CESC trans rs12709013 1 rs12926993 ENSG00000230849.2 GOT2P2 5.85 1.75e-08 0.0437 0.43 0.37 Blood metabolite ratios; chr16:58789218 chr1:173141100~173142350:- CESC trans rs7674118 1 rs7681412 ENSG00000264599.2 AC124074.1 5.85 1.75e-08 0.0438 0.64 0.37 Glomerular filtration rate in chronic kidney disease; chr4:165928808 chr8:17303945~17304035:+ CESC trans rs969962 1 rs1931089 ENSG00000231607.7 DLEU2 -5.85 1.75e-08 0.0438 -0.58 -0.37 Cognitive performance; chr13:88111493 chr13:49982552~50125720:- CESC trans rs2991971 0.967 rs12133294 ENSG00000255397.1 AC022182.2 5.85 1.76e-08 0.0439 0.46 0.37 High light scatter reticulocyte count; chr1:45523092 chr8:60937705~60939871:- CESC trans rs616147 1 rs1768208 ENSG00000183298.5 RP11-556K13.1 -5.85 1.76e-08 0.0439 -0.49 -0.37 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39481512 chr1:101786340~101787219:- CESC trans rs11088226 0.692 rs8127603 ENSG00000271032.1 CTD-2527I21.14 -5.85 1.76e-08 0.044 -0.33 -0.37 Gastritis; chr21:32514348 chr19:35014961~35025335:- CESC trans rs12822507 0.732 rs10845586 ENSG00000225761.1 RP11-417O11.5 -5.85 1.76e-08 0.044 -0.45 -0.37 Systemic lupus erythematosus; chr12:12598728 chr10:74005137~74027915:+ CESC trans rs9584154 0.809 rs8000099 ENSG00000275476.1 RP11-996F15.4 5.85 1.76e-08 0.044 0.41 0.37 Schizophrenia; chr13:93756294 chr12:29277397~29277882:- CESC trans rs9457247 0.534 rs1130033 ENSG00000268583.1 CTC-453G23.8 -5.85 1.76e-08 0.044 -0.41 -0.37 Crohn's disease; chr6:166972135 chr19:48204083~48213154:+ CESC trans rs7312770 0.612 rs1873914 ENSG00000212994.5 RPS26P6 5.85 1.77e-08 0.0441 0.43 0.37 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr8:100895771~100896118:+ CESC trans rs9487051 1 rs1008084 ENSG00000228502.1 EEF1A1P11 5.85 1.77e-08 0.0442 0.32 0.37 Reticulocyte fraction of red cells; chr6:109305762 chr1:96446930~96448318:+ CESC trans rs2991971 0.934 rs11211129 ENSG00000255397.1 AC022182.2 5.85 1.78e-08 0.0444 0.46 0.37 High light scatter reticulocyte count; chr1:45517408 chr8:60937705~60939871:- CESC trans rs169082 0.758 rs264881 ENSG00000269473.1 CTD-2619J13.19 5.85 1.78e-08 0.0444 0.41 0.37 Protein quantitative trait loci; chr5:169652532 chr19:58440448~58445849:+ CESC trans rs7647973 1 rs10865956 ENSG00000197582.5 GPX1P1 5.85 1.78e-08 0.0444 0.48 0.37 Menarche (age at onset); chr3:49544126 chrX:13378735~13379340:- CESC trans rs73990293 0.737 rs12951703 ENSG00000234130.2 RP13-88F20.1 5.85 1.79e-08 0.0445 0.81 0.37 Clopidogrel active metabolite levels; chr17:35586035 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs79468963 ENSG00000234130.2 RP13-88F20.1 5.85 1.79e-08 0.0445 0.81 0.37 Plateletcrit; chr17:35590408 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs71381461 ENSG00000234130.2 RP13-88F20.1 5.85 1.79e-08 0.0445 0.81 0.37 Plateletcrit; chr17:35593601 chrX:93222220~93225015:- CESC trans rs7503168 0.558 rs34937989 ENSG00000234130.2 RP13-88F20.1 5.85 1.79e-08 0.0445 0.81 0.37 Plateletcrit; chr17:35594744 chrX:93222220~93225015:- CESC trans rs2250402 0.51 rs7535 ENSG00000234106.3 RP11-288E14.2 5.85 1.79e-08 0.0446 0.69 0.37 Corneal curvature; chr15:40036374 chr11:93535468~93535816:+ CESC trans rs4455778 0.543 rs4132419 ENSG00000238249.2 HMGN2P17 -5.85 1.8e-08 0.0448 -0.35 -0.37 Lung cancer in never smokers; chr7:49027037 chr1:8893409~8894151:+ CESC trans rs3749237 0.964 rs35210174 ENSG00000197582.5 GPX1P1 5.85 1.8e-08 0.0448 0.55 0.37 Resting heart rate; chr3:49775173 chrX:13378735~13379340:- CESC trans rs7647973 0.58 rs7652746 ENSG00000197582.5 GPX1P1 -5.85 1.81e-08 0.045 -0.47 -0.37 Menarche (age at onset); chr3:49224874 chrX:13378735~13379340:- CESC trans rs673253 0.662 rs61769642 ENSG00000250362.1 AC008592.5 5.85 1.81e-08 0.045 0.51 0.37 Intelligence (multi-trait analysis); chr1:43585959 chr5:95861786~95874519:+ CESC trans rs673253 0.686 rs3791139 ENSG00000250362.1 AC008592.5 5.85 1.81e-08 0.045 0.51 0.37 Intelligence (multi-trait analysis); chr1:43586100 chr5:95861786~95874519:+ CESC trans rs9341835 0.51 rs2622284 ENSG00000257809.1 RP11-603J24.14 -5.85 1.81e-08 0.045 -0.38 -0.37 Schizophrenia; chr6:63483667 chr12:56150796~56158220:- CESC trans rs4455778 0.58 rs4285433 ENSG00000238249.2 HMGN2P17 -5.85 1.82e-08 0.0452 -0.35 -0.37 Lung cancer in never smokers; chr7:49074589 chr1:8893409~8894151:+ CESC trans rs12652364 0.614 rs60242440 ENSG00000269097.1 AC003682.17 -5.85 1.82e-08 0.0452 -0.67 -0.37 Response to methotrexate in juvenile idiopathic arthritis; chr5:30837154 chr19:57664280~57665039:+ CESC trans rs10940346 0.601 rs2353961 ENSG00000231752.4 EMBP1 -5.85 1.82e-08 0.0452 -0.45 -0.37 Schizophrenia; chr5:50491604 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7379514 ENSG00000231752.4 EMBP1 -5.85 1.82e-08 0.0452 -0.45 -0.37 Schizophrenia; chr5:50492052 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs34371354 ENSG00000231752.4 EMBP1 -5.85 1.82e-08 0.0452 -0.45 -0.37 Schizophrenia; chr5:50494203 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs55843201 ENSG00000231752.4 EMBP1 -5.85 1.82e-08 0.0452 -0.45 -0.37 Schizophrenia; chr5:50494254 chr1:121519112~121571892:+ CESC trans rs10940346 0.645 rs6450162 ENSG00000231752.4 EMBP1 -5.85 1.82e-08 0.0452 -0.45 -0.37 Schizophrenia; chr5:50498547 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs7706105 ENSG00000231752.4 EMBP1 -5.85 1.82e-08 0.0452 -0.45 -0.37 Schizophrenia; chr5:50501745 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs11948302 ENSG00000231752.4 EMBP1 -5.85 1.82e-08 0.0452 -0.45 -0.37 Schizophrenia; chr5:50502317 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10940335 ENSG00000231752.4 EMBP1 -5.85 1.82e-08 0.0452 -0.45 -0.37 Schizophrenia; chr5:50502595 chr1:121519112~121571892:+ CESC trans rs10917477 0.624 rs1320978 ENSG00000224237.1 MINOS1P3 5.84 1.84e-08 0.0455 0.48 0.37 Thyroid function; chr1:19621479 chr3:27214816~27215018:- CESC trans rs9584154 0.782 rs7995215 ENSG00000275476.1 RP11-996F15.4 5.84 1.85e-08 0.0459 0.41 0.37 Schizophrenia; chr13:93756253 chr12:29277397~29277882:- CESC trans rs3812762 0.917 rs11042066 ENSG00000266891.1 RP11-692N5.2 -5.84 1.86e-08 0.0459 -0.42 -0.37 Hypospadias; chr11:8788013 chr18:9734882~9735602:- CESC trans rs17137734 0.793 rs10908270 ENSG00000278472.1 RP11-74D7.3 -5.84 1.86e-08 0.046 -0.86 -0.37 Corneal curvature; chr15:27269062 chr15:33972059~33972515:- CESC trans rs7699519 0.857 rs4560439 ENSG00000206828.1 U1 -5.84 1.86e-08 0.046 -0.47 -0.37 Common carotid intima-media thickness in HIV infection; chr4:78690690 chr1:149636766~149636929:+ CESC trans rs785830 0.729 rs560608 ENSG00000265975.1 CTB-41I6.2 5.84 1.86e-08 0.046 0.36 0.37 Platelet distribution width; chr9:270216 chr17:8967523~8976995:+ CESC trans rs10819083 0.861 rs10819089 ENSG00000203588.3 IGBP1-AS1 -5.84 1.86e-08 0.046 -0.32 -0.37 Squamous cell lung carcinoma; chr9:125958010 chrX:70163842~70165206:- CESC trans rs10819083 0.823 rs10819090 ENSG00000203588.3 IGBP1-AS1 -5.84 1.86e-08 0.046 -0.32 -0.37 Squamous cell lung carcinoma; chr9:125958445 chrX:70163842~70165206:- CESC trans rs10819083 0.571 rs3962617 ENSG00000203588.3 IGBP1-AS1 -5.84 1.86e-08 0.046 -0.32 -0.37 Squamous cell lung carcinoma; chr9:125960952 chrX:70163842~70165206:- CESC trans rs1059312 1 rs9738216 ENSG00000265683.1 RP11-173M1.5 -5.84 1.87e-08 0.0461 -0.37 -0.37 Systemic lupus erythematosus; chr12:128797243 chr17:27351858~27352584:- CESC trans rs4276421 0.638 rs62371967 ENSG00000231752.4 EMBP1 5.84 1.87e-08 0.0461 0.47 0.37 P wave duration; chr5:45897706 chr1:121519112~121571892:+ CESC trans rs714543 0.66 rs13224222 ENSG00000226038.5 PPIAP21 5.84 1.87e-08 0.0462 0.43 0.37 Plateletcrit; chr7:44772739 chr20:43230760~43231260:+ CESC trans rs877636 0.74 rs705702 ENSG00000223416.3 RPS26P15 -5.84 1.87e-08 0.0462 -0.38 -0.37 Cognitive function; chr12:55996852 chr1:58056133~58056480:- CESC trans rs10940346 0.584 rs10061339 ENSG00000231752.4 EMBP1 -5.84 1.88e-08 0.0463 -0.45 -0.37 Schizophrenia; chr5:50475952 chr1:121519112~121571892:+ CESC trans rs10940346 0.562 rs34950042 ENSG00000231752.4 EMBP1 -5.84 1.88e-08 0.0463 -0.45 -0.37 Schizophrenia; chr5:50479299 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs3845167 ENSG00000231752.4 EMBP1 -5.84 1.88e-08 0.0463 -0.45 -0.37 Schizophrenia; chr5:50480297 chr1:121519112~121571892:+ CESC trans rs10940346 0.601 rs10755228 ENSG00000231752.4 EMBP1 -5.84 1.88e-08 0.0463 -0.45 -0.37 Schizophrenia; chr5:50493498 chr1:121519112~121571892:+ CESC trans rs10940346 0.562 rs56251178 ENSG00000231752.4 EMBP1 -5.84 1.88e-08 0.0463 -0.45 -0.37 Schizophrenia; chr5:50494837 chr1:121519112~121571892:+ CESC trans rs2980976 1 rs2980976 ENSG00000259078.2 PTBP1P -5.84 1.88e-08 0.0463 -0.5 -0.37 Response to antipsychotic treatment; chr18:62412879 chr14:65279267~65281166:+ CESC trans rs928391 0.744 rs2274503 ENSG00000227183.3 HDGFP1 -5.84 1.88e-08 0.0463 -0.48 -0.37 Platelet count; chr1:156782256 chrX:131646639~131646890:+ CESC trans rs11098499 0.739 rs10031033 ENSG00000275858.1 RP11-291L22.8 5.84 1.88e-08 0.0464 0.41 0.37 Corneal astigmatism; chr4:119230297 chr10:38450738~38451069:- CESC trans rs3749237 0.964 rs11714957 ENSG00000197582.5 GPX1P1 5.84 1.89e-08 0.0465 0.55 0.37 Resting heart rate; chr3:49738745 chrX:13378735~13379340:- CESC trans rs77688320 0.553 rs1558637 ENSG00000235105.1 RP11-329A14.1 -5.84 1.89e-08 0.0465 -0.42 -0.37 Breast cancer; chr2:201398651 chr1:48435967~48437223:+ CESC trans rs11098499 0.564 rs11098507 ENSG00000253326.2 RP11-261C10.7 5.84 1.89e-08 0.0465 0.49 0.37 Corneal astigmatism; chr4:119367131 chr1:243054861~243056394:- CESC trans rs12709013 1 rs34319345 ENSG00000230849.2 GOT2P2 5.84 1.89e-08 0.0466 0.43 0.37 Blood metabolite ratios; chr16:58786688 chr1:173141100~173142350:- CESC trans rs10940346 0.562 rs13182357 ENSG00000231752.4 EMBP1 5.84 1.9e-08 0.0467 0.46 0.37 Schizophrenia; chr5:50404060 chr1:121519112~121571892:+ CESC trans rs200810 0.964 rs12528912 ENSG00000227123.1 RPL12P44 5.84 1.9e-08 0.0468 0.37 0.37 Body mass index; chr6:97387451 chr3:44937673~44938482:+ CESC trans rs7520050 0.778 rs3014218 ENSG00000255397.1 AC022182.2 5.84 1.91e-08 0.0469 0.45 0.37 Reticulocyte count;Red blood cell count; chr1:45560656 chr8:60937705~60939871:- CESC trans rs1040555 0.516 rs242547 ENSG00000253915.1 MAPRE1P1 5.84 1.91e-08 0.047 0.46 0.37 Lymphocyte percentage of white cells; chr20:32830775 chr8:135625185~135625981:- CESC trans rs4948102 0.731 rs4948099 ENSG00000186940.6 CHCHD2P9 5.84 1.92e-08 0.0472 0.48 0.37 Plasma homocysteine levels (post-methionine load test); chr7:56004557 chr9:79391304~79391759:+ CESC trans rs2991971 0.967 rs60608374 ENSG00000255397.1 AC022182.2 5.84 1.92e-08 0.0472 0.46 0.37 High light scatter reticulocyte count; chr1:45543241 chr8:60937705~60939871:- CESC trans rs6087990 0.568 rs853854 ENSG00000253915.1 MAPRE1P1 5.84 1.92e-08 0.0472 0.46 0.37 Ulcerative colitis; chr20:32832951 chr8:135625185~135625981:- CESC trans rs7520050 0.645 rs1768809 ENSG00000255397.1 AC022182.2 5.84 1.92e-08 0.0472 0.45 0.37 Reticulocyte count;Red blood cell count; chr1:46037164 chr8:60937705~60939871:- CESC trans rs12339966 0.552 rs2821205 ENSG00000260947.1 RP11-384P7.7 -5.84 1.92e-08 0.0472 -0.5 -0.37 Systolic blood pressure; chr9:11683392 chr9:33697459~33700986:+ CESC trans rs12339966 0.643 rs2821204 ENSG00000260947.1 RP11-384P7.7 -5.84 1.92e-08 0.0472 -0.5 -0.37 Systolic blood pressure; chr9:11683901 chr9:33697459~33700986:+ CESC trans rs3812762 0.879 rs3844099 ENSG00000266891.1 RP11-692N5.2 -5.83 1.93e-08 0.0474 -0.42 -0.37 Hypospadias; chr11:8786705 chr18:9734882~9735602:- CESC trans rs4791051 0.723 rs3859214 ENSG00000260196.1 RP1-239B22.5 -5.83 1.94e-08 0.0475 -0.44 -0.37 Heschl's gyrus morphology; chr17:66464690 chr11:17380649~17383531:+ CESC trans rs13014235 0.532 rs6729982 ENSG00000235105.1 RP11-329A14.1 5.83 1.94e-08 0.0476 0.39 0.37 Basal cell carcinoma; chr2:201416413 chr1:48435967~48437223:+ CESC trans rs13014235 0.532 rs10497867 ENSG00000235105.1 RP11-329A14.1 5.83 1.94e-08 0.0476 0.39 0.37 Basal cell carcinoma; chr2:201420144 chr1:48435967~48437223:+ CESC trans rs912593 1 rs73471574 ENSG00000259570.1 RP11-671M22.4 5.83 1.96e-08 0.0481 0.5 0.37 Cancer; chr13:34457667 chr15:84394512~84395514:+ CESC trans rs867371 0.82 rs12443224 ENSG00000235370.6 DNM1P51 -5.83 1.96e-08 0.0481 -0.47 -0.37 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82203269 chr15:84398316~84411701:- CESC trans rs9876781 1 rs13069724 ENSG00000225528.1 RP3-370M22.8 -5.83 1.97e-08 0.0482 -0.36 -0.37 Longevity; chr3:48436629 chr22:39960397~39964683:+ CESC trans rs4276421 0.593 rs72750046 ENSG00000231752.4 EMBP1 5.83 2e-08 0.0488 0.5 0.37 P wave duration; chr5:45930775 chr1:121519112~121571892:+ CESC trans rs1430128 0.685 rs1430129 ENSG00000248557.1 RP11-390G14.1 -5.83 2.01e-08 0.0491 -0.73 -0.37 Congenital heart disease (inherited effect); chr2:217633871 chr3:126624792~126626061:+ CESC trans rs62140779 0.775 rs66930669 ENSG00000253347.1 CTD-2026D20.2 5.82 2.03e-08 0.0496 0.55 0.37 Neuroticism; chr2:58487400 chr17:47409322~47423526:- CESC trans rs2950393 0.509 rs10459247 ENSG00000257210.1 NACAP3 -5.82 2.05e-08 0.05 -0.49 -0.37 Platelet distribution width; chr12:56777732 chr12:93124063~93124543:-